<SEC-DOCUMENT>0001682852-22-000012.txt : 20220225
<SEC-HEADER>0001682852-22-000012.hdr.sgml : 20220225
<ACCEPTANCE-DATETIME>20220225080715
ACCESSION NUMBER:		0001682852-22-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		135
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220225
DATE AS OF CHANGE:		20220225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moderna, Inc.
		CENTRAL INDEX KEY:			0001682852
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				813467528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38753
		FILM NUMBER:		22674508

	BUSINESS ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6177146500

	MAIL ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Moderna Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160822
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mrna-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:61dc7ba0-21f1-4a58-a37b-1270ec5a6c14,g:27805b16-b8d5-4e89-9c63-161f1adf5057,d:7a7cdf3fe3c348059a6b0a57c2f167fe--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:mrna="http://www.modernatx.com/20211231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrna-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV80L2ZyYWc6ODRlZWUwM2VmYzkxNGUwZmI4Y2Y4NmY0NWFlNTBkNDgvdGFibGU6OGU5MmM5OTYwZDFhNDY1MWIzNGVlYmJkYTVhODJkMGMvdGFibGVyYW5nZTo4ZTkyYzk5NjBkMWE0NjUxYjM0ZWViYmRhNWE4MmQwY18wLTEtMS0xLTc2MDQ2_5e7ed86a-88b9-45f7-b942-665c4689f098">false</ix:nonNumeric><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV80L2ZyYWc6ODRlZWUwM2VmYzkxNGUwZmI4Y2Y4NmY0NWFlNTBkNDgvdGFibGU6OGU5MmM5OTYwZDFhNDY1MWIzNGVlYmJkYTVhODJkMGMvdGFibGVyYW5nZTo4ZTkyYzk5NjBkMWE0NjUxYjM0ZWViYmRhNWE4MmQwY18xLTEtMS0xLTc2MDQ2_cf380c2a-670e-4ab4-82b5-95ebc7aca54f">2021</ix:nonNumeric><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV80L2ZyYWc6ODRlZWUwM2VmYzkxNGUwZmI4Y2Y4NmY0NWFlNTBkNDgvdGFibGU6OGU5MmM5OTYwZDFhNDY1MWIzNGVlYmJkYTVhODJkMGMvdGFibGVyYW5nZTo4ZTkyYzk5NjBkMWE0NjUxYjM0ZWViYmRhNWE4MmQwY18yLTEtMS0xLTc2MDQ2_00e09377-9dc6-466b-b301-2574cc76954e">FY</ix:nonNumeric><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV80L2ZyYWc6ODRlZWUwM2VmYzkxNGUwZmI4Y2Y4NmY0NWFlNTBkNDgvdGFibGU6OGU5MmM5OTYwZDFhNDY1MWIzNGVlYmJkYTVhODJkMGMvdGFibGVyYW5nZTo4ZTkyYzk5NjBkMWE0NjUxYjM0ZWViYmRhNWE4MmQwY18zLTEtMS0xLTc2MDQ2_f89cec5b-e8f4-4433-afea-0c941cd42e31">0001682852</ix:nonNumeric><ix:nonNumeric contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_6434c373-a6c6-4f7b-8ef6-3d80253a9ae7">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_762aa615-9010-420a-8e46-65bbadd6aae4">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_51501eb6-f175-4107-9a50-9a2a310ec651">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_b87ed32e-1ce9-4db8-a202-ed428939aa44">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_7ec179f5-0fc3-4708-bddf-316daed00725">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_859dcb73-429c-4521-9717-2a4efe10e6f1">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8c119cd5946c40fabe6b12e425327e13_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzIvZnJhZzpjMDRmZTAzN2VjNGE0MjVmOGI1OTEzODVjNjdmMzA4Yi90YWJsZTo2NmExY2ZiYWY4YjE0YjQ5OTFkYmUxNGIwZDA3Yzg4Mi90YWJsZXJhbmdlOjY2YTFjZmJhZjhiMTRiNDk5MWRiZTE0YjBkMDdjODgyXzItMS0xLTEtNzYwNDY_a0109e09-2a71-45f2-8c45-1076da558304">36</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrna-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb99458155744556b3d39993ad822db4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i58b4bf6524f44a5e8970d9daad47a515_I20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia2fcd0a4e20a4fb395dd61a92d63adc0_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e412a5cb73413dbf99d215bfabc116_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0613309ccd7f4770b391e463a962e99b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd2fff3411a4c769c4f81842918e9c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdba65dc5ee84630ac91c06737b61940_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1806b5a0029947c1aabb49f5e058cb28_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1eabe79fc2e4e4a9fdc7c2be2e9f0e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5db090169624207a4311b8780bb82f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e182cbaac1c44c8aaf481c02d369892_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2fa812bb582446faced9f5539691f0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice96c3b711e145be81cba0afd205ad43_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87fe7c36a950471bb3212e6877b0baf9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8485f63a4c2345fea4cdae33f5552050_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6916c32254f544d89e2f4ba8db2520a6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4183a6aba7e43f68918a5fb12e3d83f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f00be47b1194ea3be883db45fca7c1c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i291937679b0b473abab40f676c567dbd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea71826e0b2c464293613200c787a5f4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70d890a8a1c24221b1111740ec40546f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237e52dede034cd091787b93f9589ae5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfa777b5307245f09b6cb5f6a8fb3e1d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98fce2df066140b8974dbf5aa3059a90_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5f8052aaadc419c8d711ef7686bd436_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0bee1a0804143529b5cc7f5e167104e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ffaed07b9974d019abd45bea1588ec0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i552c6e3acac14be0baea5ae64fe4cc51_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6b33ad00e44689ad7ca663971c003f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifefe594e140042af8fa2b3baed41f390_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i086f0b86dda64ff9bdc13c547806422e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2468b82d059745f5b51fb3d31a544305_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if106b707e879407f837eee91cc731c8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieedc85414f004154b55307b19cb69ea1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64213a08436349b8bd211c3b69b414ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0408d062671a45018b3df546433745af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c70cb037668465995ce9826bb1978ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98451536c6d841db91683a82eeb89b2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcf6e685c17f4ba283b01bf8845d7cb9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i370d0735ddb64285bf22708bccdfe17a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d72e1d1f6454024a0fc769ec600c4bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb0e392c689f48b180f2315c3d508b62_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67c37cfaa8142fcac96ee487bf8fa91_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e92a0d0e8fd40c489ab3417b2dc0a47_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ff2eb538054269a37b8f1364796f48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1036f115c63f4c049064c7ba1929828a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f7e4e88f50c4deb96b15cbfbbd78d6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mrna:segment</xbrli:measure></xbrli:unit><xbrli:context id="i0271cb85b4e64ced8426ff3ab6956a89_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:EuropeanCommissionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i190252c1c7b34ddb97008b71eb4c1da9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:EuropeanCommissionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32d168477d7e4f278aa0d019fbd3fd1e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:EuropeanCommissionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7764e7b08664708b5f88fa9d5a5452d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:USGovermentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70772d46e8714f2c92cd4f05b0dae511_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:USGovermentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d8d4f2bcb249ba98ac3836f5f2f91a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9755a9f76aff4d95bd5013ac656d28eb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8df385fcd90456f89a7177c79f6f8cb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2df5a00c226e425faf323112dc3cd5c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b3cd2c6a9d148c18fec7f61ae871222_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i386857641ae64cb5840ff87d45bd2b39_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:VertexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a5edb63270a4e4587e56c35991f8f28_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:SouthKoreaGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e47c41e4cb14080aa2c9a58ea80fb94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:UnitedKingdomGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc4ca4b110a4b4ca9bc75f54db9aac8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d684fd2732b4d3aaa2c0b4c1f42cf46_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d0432cf13b142938df0d7a6e783162d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d57ca59f3dd4b58a6220848d155086a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3639b96d68064d6db852f369b410789c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb718f636d5f48ac8eb2603a3bc1c433_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i005acc5f3f5d4d808e86e28a3fb8cc6f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7f5f39ede7c4ec9b47dbe1215f0665e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aa7c4e4065b4b87a2e53619bd7fd077_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95dda1d0dbf24991852d96215768bee0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b6bf470232b486d96417def1a8e1533_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a99e8b38ce644c6b026bd53416491e6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i984222694dbe434b9c06eac34351906d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39641a4b815d4d1d9b3bc66b8889165f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide168116c3df4c06bf76ee1ab5cc8665_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eda8070f7034a6fab76518656331315_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b2a73dc0a34434fbf4adfd2bd2d0152_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if853b7ba8fdd405c9c2517b31b9bb54b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b48f865221543f19c484fbac76b65da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f1f522be3c649ccac04b63ff9e91b55_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i346fef81e10f4f86a929d87bf0cb041b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if49f6e27f6284519912ffac03c002a55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i185b16a527d64878943a25c180d19f14_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90618f5224194ab98e88f99e1cfb81b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7a70d15770e4fc5a0c8d58cdebd7aef_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5f923d3e90448fbd2a1d5a8d4e3398_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="participant"><xbrli:measure>mrna:participant</xbrli:measure></xbrli:unit><xbrli:context id="i0f13771d8cb942efb65d2bfc498700a6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47c1a858a9f9495fbac7df0e36419070_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f0f64452bc4d5da91f20c29eeecbca_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb9732dce6924b498098b6518f64703e_D20210701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida3d15a8c031486d90647c53dad031ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i115458dd79814652822c63535a915899_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i987f997b0acc4a2695f9a05d82e96f37_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae7b1ae1b03416dbb9b8f48d0bc6426_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="contract_option"><xbrli:measure>mrna:contract_option</xbrli:measure></xbrli:unit><xbrli:context id="ief33f0f4bb514efdae5a1b468c9c9c90_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3127eb355e744a881aa98a34f6d97fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf94941a6a404dd8b05524603b3a3b2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialProjectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa5a2552f63d48b5b1e01ac4535c5a2f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ef76c094447459c821c04b2de3eb206_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3802fa1330a343298542de37e4105a0c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cd3ec1f9ac141d284f0a5db5793f3c9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1d68b45e78b406482a02388fbb53604_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c202e8e92ed4514824b43cb3531dc9e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if55e1500f5544b66aa8a071e51806268_D20130301-20130331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-03-01</xbrli:startDate><xbrli:endDate>2013-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ede9f3ba9d44d22a375d16ea04e18cc_D20130301-20130331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-03-01</xbrli:startDate><xbrli:endDate>2013-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id946b8dd31834000b8e6b41766b9dedd_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d09409e8868491499e290b8a4d12cdc_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia84a8bd1c3aa4ac9b1a164b251799095_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60fc10736ee64261bd7f04a73acfaafa_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MRNAVertex2020AgreementMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d6ad74836b24c83809a74ce8d566449_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb0688f24fb7444ba43fe54c1d8443f2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70d782312fcd4253a167cb2d7ae3760e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia24b3bc3329043adb9ea279c5b254064_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b18d163a5204d569c9797b913f2d8f6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e25bd1849804ba7b479c2eced67e891_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i618406f3ce9d406aaa081c4408973067_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79a9ba91798641049354e39e4852bc1e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic63027741efa4c50b4babaada70fbc9b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia49291312e364cb4a88c0ff31026909a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i119f28ec664d4518be468660ee954b91_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4219337e58d4f1db6c745955c72cd8e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d88c4aeb3e94e9b959ea25fc2661d2c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3df9734dc9af496f9780bd6c5c379234_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17abcb6e78134f4690ee2419e8619e02_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie710a95ab39e49cdb735c3bc7fc8c4b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa328a08859144588130d892ad20192d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf669fdc68ee4630b54c9802a1b0a558_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0292df9b654d482db1060f9005959794_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia45359f849f44c0998e347e23469e818_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4712a1c564814f3abe808e0a6b9e64a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e02fcbb9afe410ab3a681bc9b64d879_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42f5d9b242cc4780b3309e0961fa5eb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5734f4fe23fc43dd969bd66b5e557046_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2364f83219a4bfc9d8ee9260dacc1b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4042eb496ee543f2a5872be11b2cf7ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b5cfdaf6a9c475fab2b7dfb72468094_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9284186e600b48258879f874e838c77a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic428ae6809614abaac1249c8d3bb020c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i709ee66b601a4d2ebd30bdd6893ba771_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6344e2313ce84b3291ddab39f4bcddfb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf656a3fa7e84852a422e94e706d2b6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec10e88bcd6c4d8181a5ca274d5cc8f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieafc1c887e174d9bbbde6dd62d64e2ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44bf012463a94b6a88a9422b0030dda0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9235e93735dc44b285d2bfdc769bb996_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id07b5918438d431a8e9c74d8ff4d2551_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1075514a7e14bb585b04979d8e91df8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33223bcc0e1b4b51acbe5ccd606713ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i959b3e4a89ca4e1392ee007bf48a9ce3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0458e4ead71746a5af5b29ed89c9ef21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a6b3fe35432446aa1c5e179c4701d65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9905b040c345c9800468da2693c514_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2565e09c4ee4bdcbd387be8850d72df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3997280202440c4b1242ce5b6a23810_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d566855dd54261b4fe635c234b2484_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id087a0a88efd4af88be84f1c3b08e19f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ef75bce2954276bae1f44362fbb2cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41a1843d0dcd4702b157723e8cc7e665_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53dd51cc137b4b4aa2f56b6bab4db8f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e93700d2ebf423091417132b7c40ab4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied3d5ab7308d4c59b813d58e2e04c6e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eeaea94154e4fe49fa61fba009f8be3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa1fb4bfb734981a51e6771d628fcc8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab996b74800b4e25a035225c3e839436_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e1fc05718e842d8a85da2e69c5bf695_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa93ec4582e34e7fbf2e3ab8bce77f21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia63eadf881ec473799e8621ff399a7de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5df7f55fdc4eb49e20e64d8f73b402_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9935ee028dc4668889878caf93655c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib074b324fc8a45e8b60ce57c228ef8bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8da0e76f2e4c59a02abce9c64913ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i342e75080ebe4c45b4605822f2cb05d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib732575815f0493f8a45f987de9435dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb052b50079e46858cb5714c483963ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19e0d73c72e24eca8ca94e49eb15e6a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2926456ed6654d0a91dee92754e33edf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3af41c88515492095e14241259a0e07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e9646a432a9439688c513fb0ec0887f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ca3868ec35146878138ef39c9381dab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4fe368718ae402a88feb1ddaf1fdc8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e686917771642979115acea50d66bd1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a2bda740e174d91b71bb62076e623b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d743eab86de4393a005da034dc6076d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib08aa8be8be24796b00714b57780c548_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cfc4e8bb05c4fae962fb281635face7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7c01916db3408ab5ad64668966705b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01fbfe4a2aeb4f52a6e5832316a78b96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b71762f59d402fb8c3f8db8d6a2794_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i173e555f8608496f9662755df4a4507f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7aa28c6c4754b4cac1648572278cb7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33a1bd3236264470831ed902e1ec14fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc3a736dedb0468eb2b96e05d6a5b5cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01cb8657700e404391363a5b93c94298_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f7bfa072504774a46de61549ed1358_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a410f63e2a34faeb71837e163488553_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id11c2636a9e849b199e50f122b90bfb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08a786fc7c8548f99e9260ccc849d096_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib091b3d4b2c54a35b6370a090b778180_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82fff40b8cf5418684879ad0b808d851_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf5ed5b20a464aa69fffcc07449d6b65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4435c73f09eb44d4992e01d4922d5bc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa3443efd7954041a7b94f68574c1294_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bab6b5e239439c88900de725d422b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d3fc18fdc324f1aa20d24c095339419_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9147f3587c94165889e686e4d2ea8b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76d4434bc6c044c7b3f4e94fb304ff0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id626af309354471c938a13ee987efb1f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia847fc5aaa414970962b3e66c726b6d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60349844b567496a8c96cb156669e486_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4e351d2d1764d1e970af57129ac281f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabdcd1636c89453094af591ed45cb1ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib52d1393c6a94df1a1ed227bb14cad8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87eab6cd7a7f48e0b5a9796ab31c2d6e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1e243dab0bc4efaa8d7f2b398dcdab5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294dcfa26a8843f783242f2540ba31cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80e7eff5bd6c4c9b84f96355143d2190_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12d89d325c9641979afcb1133eb38c92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62a0a9d758df464cb7896474951b0ac5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic39fb570a4f842229f0fb89db305d537_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6600cb5746c3408c9cb209436ced4bd4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56c3185ed7d04fccbb21599da90453cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b05b51f2234fc58d69e6a80fa771ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3992f82ad0c4b249387e250c043245a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6d422efa75e467d98852994a450a9ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf2f9fe6eb684be982187b0507723e2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e6dc104953e4bb395df7081eca0082a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2b92fa7550f4911b44a79ebc01be5fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5931b912876541d6882f7bd7117de3f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77eee50ddfaa4eb0bc9f201ff1631518_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4dca9b9d97e4b8f946f52de263fa1d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c3187a0bb484bae8f0a6c5412316823_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i752522e455054df9a2d4aa0487c93c8a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40de3a67fca0427cba0abb81a8d5a822_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e772279375842a09317b961798ebf1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bd10a6d680840d5be716e5efb005792_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2897c9b7abc74af58f8fb9170b4279dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2277cdd9a1184c06a13b5d2759fc2d43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b99b4a3a3f74767a37af24660286fb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabac96aed6194cfe8293e8e6b78f7add_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98d6bacd287f4b1593818f823e5f7584_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie04bbbe54baa412abc405e89a1039ed6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if546ef6f1b4b42b7a555f52ec50a3fb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71f80f04049942b6a29f789ba29f2842_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c346ed8a6f4ad482321e52eccd7724_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c2998e0814472496ed510917d7a471_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcda5455344c4505b3c57aa248aa98ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a2e86586b9a43d89a4d752842cfa050_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d2b742992e44e86ba5d409dbd33d210_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic39bcf7b2bd641cbbe600df4d3b15b80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id85722b295e94fcc9a11009c7e8f8554_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b0ad1b467146e3b5880e21ed60e03c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofcampuses"><xbrli:measure>mrna:numberOfCampuses</xbrli:measure></xbrli:unit><xbrli:context id="i055ce861cca24357869370abf095c083_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i7645640582764d538a26db2e1fb80bd0_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:TwoHundredTechnologySquareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32ea0d8664c84fe1a0db2e016c5ba70b_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:FiveHundredTechnologySquareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7589e8c5201244e4985147f06c09e73a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofbuilding"><xbrli:measure>mrna:numberOfBuilding</xbrli:measure></xbrli:unit><xbrli:context id="i1927cdc0d1694e40a55dd6d90f64c6d1_I20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofextensionperiod"><xbrli:measure>mrna:numberOfExtensionPeriod</xbrli:measure></xbrli:unit><xbrli:context id="i2855b96dce1e43fb93b06fb655b72372_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8db7171778ef4c6f97f7530182111044_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a0fc37d8e2145f98d23f3d4b7ed48a7_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCEastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d4877c3015e41fcb264f294807448d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i637c86f9cdcd4c4696566a2667590b81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f976ec484ae4420800a7fe5ea5fc4eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb8aaeb04f94a9091ac85eb8f851b96_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76f6a7263a5e4d65a40dd2d77b9fe3d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8894beaec40b4471a73954ee11728b2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>mrna:claim</xbrli:measure></xbrli:unit><xbrli:context id="i56f7cbe6568c4de9ac2033f8024b12fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8002ec753b4dc689c48b5e0785b43d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:SupplyAndManufacturingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab85f119dfbd439fab288fd3b899104e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c5a2128addc490e9ec198b28f43e879_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0c48f0326424b03a643d8d35796a371_I20170626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i702c1ca981884658b2caf34f2b288da1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:ModernaScienceCentreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a37b17b04c0478ca390d371241ee5bd_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:ModernaScienceCentreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="numberofoption"><xbrli:measure>mrna:numberOfOption</xbrli:measure></xbrli:unit><xbrli:context id="ib474a3e36bd94fa88daf43e69617dc76_D20200214-20200214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-14</xbrli:startDate><xbrli:endDate>2020-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac2c5503ed074a74bea898aac8577dab_I20200214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bba9fe2096647189405dc333c365807_D20200214-20200214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-14</xbrli:startDate><xbrli:endDate>2020-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b3e6c8e3e284a9b9957554efffd342a_D20200521-20200521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-21</xbrli:startDate><xbrli:endDate>2020-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafab97ea8a1846b8ae7fd38f70f3ec7a_I20200521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29fd9baa1fce4c82bab97fdcf69983b9_D20181130-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-30</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e3a57dbc43247cdbe91ca5c7ee5a665_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7adfa26ae60741ce90e3942463436967_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c119cd5946c40fabe6b12e425327e13_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>mrna:installment</xbrli:measure></xbrli:unit><xbrli:context id="i6cdf60b6c2d84337b9adeb0d5572d319_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndGrantPlan2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4c1fa50b9414740995b3595ceb68c2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66e84b53db4044d0b673a4ca8b8e75e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c500d4ffa344d5a5b3ceec87c24f6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic31e779ca3ac441093747539d1c451db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a97483f7a5746248dc20f25d9484066_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2310d5f67f14a5da16abed435202898_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dbb9beedbe644dc8350ed2167afbe18_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i728418fd03a840ca854699e0501666c2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e548fb17de479e8f1eaedbedd14aeb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17b699d019b5406ebafef856b284da2b_D20181205-20181205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-05</xbrli:startDate><xbrli:endDate>2018-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="offering"><xbrli:measure>mrna:offering</xbrli:measure></xbrli:unit><xbrli:unit id="purchase_period"><xbrli:measure>mrna:purchase_period</xbrli:measure></xbrli:unit><xbrli:context id="ia96eb4bd96214dbfb1546494df278d66_I20181205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccabe9fdd0d4459f83f43bcfe311abbb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia86a82d3b3da4738b05c1a1dc2acb3c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b4231be4ae495b8c891156606a39ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic846063843c2457783476d4cac1401a9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7050aa6851454a26bb85c8a452709530_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15360143cb64fe7abcc9084d6b9d587_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebede0396f23431fa71d2b7f1a74378c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4ee683b92644214b4cd05e7d4e55ba3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe01185da2fb461cb3ee25ad154cce2d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibad04de7079b4f4a8ea7cd1f6b9a483d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ea5c2eff4b47408d5e76fe3acde946_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a646f2a3a5433fbecbadedd7364094_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia91fb56fbec344488aef5885f842fbb0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b651cc1ef0d4fb4ac26faca60c2f102_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e527ebcd83c41c986d1270c6919f13b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04ce50e969794bcb9eefacd61a166e35_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie043af078137474da5fa9c415b806cb8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd88039ef4d41a6bd7804df805f06b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1210d8b31f44fae92d529b8b20e6c6f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cde0a9204374ab1965f099a3fc5f68b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i504dedceb6a94befbf403be7db0318ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6742a09761af484083c605c79d1094c1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d8078008d7a4681abf45cdb733f1f74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66608dd5e63640a89af4850f55816d09_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf35565bf91f430595f440c4dd64ae51_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4d55b1dda34b6b93a8469f51c7e48c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1eef6d9e8284f3dab7d5832831951df_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca45b1141c54e74bc0ba86735723e3e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79431f5fc70f4c91917d4630bbc89811_I20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibab18ae9cd9244de9112a38fb79ecf41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i835e45064363481fb77ce7bd45f5a1d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanFundingStatusAxis">us-gaap:UnfundedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a9f0c6c3c2848ffb9debae33d695d1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39bdbfea26834ede996b4fab64370074_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d35d0ab562b4b489462b57aefdefce5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a86bae6409420b83a8aed6d25de2dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd9dd4b271d421b9fca8617b75a1093_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89adc3cd6fc14bed9598b281787d3975_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaef07bcc885424dbeed30c7d98e5bf7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d38bfda565e475e8f176749260180c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f9128fb34343858d7d0963244403bc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea1da9382db47b78b24b7770c2bce16_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3370d17a262545d3a21778bdbfd9e0bd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i711d783999b541ed9d40041b1a32a2bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec2fad44150e4a03b5a8be3e02ae7631_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a80bb18be6a4ef784a0986226d8e915_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7621872360e6456f9070400abc857bfd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i608a92f69c204f27bf261e6252469cc3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97e6326dca0f4ec6947a65af86c71656_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0ed2515d854ec9b5a77c4457a02d73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90163def30db4815a2baf938575b19d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacd7ab752d5b4882a879732a1889bbb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i258d02d7ce92442dbbad9a730c0f0475_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35471f100ca04369aaa8cd79328e4486_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dce8093560b49b995bb23f3c3c63255_I20220222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2022RepurchaseProgramPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9fcc9f307dd449cbd9ff284355911be_D20220101-20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="dose"><xbrli:measure>mrna:dose</xbrli:measure></xbrli:unit><xbrli:context id="i5a40581afbae47acaae291b96f6752cd_I20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-25</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:3.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:0.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:0.35pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="margin-top:0.35pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.968%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6NGYwZDU0YWY3ZWUyNDg4YzlhZTc0NjVjOWFlM2RkYTIvdGFibGVyYW5nZTo0ZjBkNTRhZjdlZTI0ODhjOWFlNzQ2NWM5YWUzZGRhMl8wLTEtMS0xLTc2MDQ2_823845ca-c109-48b3-b06b-39f056cbd702">10-K</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3.5pt;margin-top:1.55pt;padding-right:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTk2_d04ce65b-2f99-4017-a045-403391b52311">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:0.7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18yMTk5MDIzMjU5MTc1_83287b25-e486-497d-930e-d28359539445"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18yMTk5MDIzMjU5MTc1_325cbbb1-b86f-452f-b4f8-11ed651e9786">December 31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="margin-top:3.4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNjA1_c281a242-cb7a-4d0d-9feb-14f0e3fbf8f7">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from _ to _ </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTk4_16b3c81e-0ed7-42f3-a313-3e91a9ee0c9b">001-38753</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="mrna-20211231_g1.jpg" alt="mrna-20211231_g1.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:212px"/></div><div style="margin-top:1.35pt;text-align:center"><span><br/></span></div><div style="margin-top:1.35pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTky_d6755cfc-3fe8-4cbb-b0bb-8b51aa734b60">Moderna, Inc.</ix:nonNumeric></span></div><div style="margin-top:0.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:0.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.831%"><tr><td style="width:1.0%"></td><td style="width:32.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8wLTAtMS0xLTc2MDQ2_2c72aa6d-ce8e-4ae7-8e14-962954f525c8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8wLTItMS0xLTc2MDQ2_691eaaf3-fad7-4a47-8863-39d8a04ea3cc">81-3467528</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8zLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246OTY1MGIzYmU4ZWU1NDA0NTliNzBjYTg5ZGI2ZTM0MmVfNA_7709d20d-2c03-43ac-bdcb-78b4a10c049a">200 Technology Square</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8zLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246OTY1MGIzYmU4ZWU1NDA0NTliNzBjYTg5ZGI2ZTM0MmVfNw_3566540e-e15c-4db2-ad71-d7d6d2ada9e2">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8zLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246OTY1MGIzYmU4ZWU1NDA0NTliNzBjYTg5ZGI2ZTM0MmVfMTE_86f0a26d-ee4d-4cb9-9ef9-784bd6fae00a">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8zLTItMS0xLTc2MDQ2_cab471df-3f3a-42f2-bc15-c1d272018726">02139</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTkz_42f8e2f5-8258-4e8c-a398-1e11a21a1e0b">617</ix:nonNumeric>) <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTk0_cc132b07-9616-4a0d-8d88-0c7e6da05069">714-6500</ix:nonNumeric></span></div><div style="margin-top:0.8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:0.8pt;text-align:center"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:10.12pt;padding-right:10.12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:34.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.679%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6YTI0NTM2YTkyYWJiNDJjY2E2MjBlMjU5NTE4NDgyZDcvdGFibGVyYW5nZTphMjQ1MzZhOTJhYmI0MmNjYTYyMGUyNTk1MTg0ODJkN18xLTAtMS0xLTc2MDQ2_42a27eef-81d5-4380-b617-8b8d124d6ddf">Common stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6YTI0NTM2YTkyYWJiNDJjY2E2MjBlMjU5NTE4NDgyZDcvdGFibGVyYW5nZTphMjQ1MzZhOTJhYmI0MmNjYTYyMGUyNTk1MTg0ODJkN18xLTEtMS0xLTc2MDQ2_2e93d2b5-a36a-4941-b170-33b7c8a37e70">MRNA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6YTI0NTM2YTkyYWJiNDJjY2E2MjBlMjU5NTE4NDgyZDcvdGFibGVyYW5nZTphMjQ1MzZhOTJhYmI0MmNjYTYyMGUyNTk1MTg0ODJkN18xLTItMS0xLTc2MDQ2_b2781f3a-dbff-49a4-b866-aa5912a2625e">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNjAx_4e849a3a-3378-4f4f-9487-de573fa4bd8f">Yes</ix:nonNumeric>  &#9745;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yes  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNjAy_bc69c1f7-7fc4-4fc7-9885-69a9aec2a6f7">No</ix:nonNumeric>  &#9745;</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNjAz_128f9531-3ed7-42a7-b465-2c743a85d517">Yes</ix:nonNumeric>  &#9745;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNjA0_482d5009-a334-4aa9-b1ce-0338591bbc42">Yes</ix:nonNumeric>  &#9745;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:1.2pt;padding-left:9pt;padding-right:33.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6ZTcxMjU2MDA4ZWRmNDNjYzk5YWQ3NDgyNDQyNmU1MjgvdGFibGVyYW5nZTplNzEyNTYwMDhlZGY0M2NjOTlhZDc0ODI0NDI2ZTUyOF8wLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246NDNiNTlkYWI4MTFkNGQ1ZmExMDQ2OTY4NzI4NTM5N2JfNQ_3375484d-3369-46c6-8787-e8b80fcd0ef5">Large accelerated filer</ix:nonNumeric> &#9745;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6ZTcxMjU2MDA4ZWRmNDNjYzk5YWQ3NDgyNDQyNmU1MjgvdGFibGVyYW5nZTplNzEyNTYwMDhlZGY0M2NjOTlhZDc0ODI0NDI2ZTUyOF8wLTYtMS0xLTc2MDQ2L3RleHRyZWdpb246Mjc3MDM2YmNlNTEyNGQyOGEwOWJiM2Q1OGRlNTA5ZWRfMzE_9e66e361-73b1-4b95-8aff-4d74de403e90">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6ZTcxMjU2MDA4ZWRmNDNjYzk5YWQ3NDgyNDQyNmU1MjgvdGFibGVyYW5nZTplNzEyNTYwMDhlZGY0M2NjOTlhZDc0ODI0NDI2ZTUyOF8xLTYtMS0xLTc2MDQ2L3RleHRyZWdpb246YmFlMDkzYzM5MGJjNDM3MWFlMzliOWQ1MTc1MzYxMTZfMjk_1e4b41b2-1609-443a-9891-b0185175aca4">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.5pt;padding-left:9pt;padding-right:33.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yes <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTkx_5a3873f5-fca2-4075-9a41-34673a1b5699">&#9745;</ix:nonNumeric>   No  &#9744;</span></div><div style="padding-left:20.25pt"><span><br/></span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Yes  <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18xNjQ5MjY3NDQ2Nzkw_c001be0e-70ec-42fe-b554-951d0835abad">&#9744;</ix:nonNumeric> No  &#9745;<br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the aggregate market value of voting and non-voting common equity held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="idb99458155744556b3d39993ad822db4_I20210630" decimals="-7" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18yMTk5MDIzMjYxMDQ1_bf15d1cf-b6ad-4717-b312-067c2cf73ce6">80.8</ix:nonFraction>&#160;billion based on the closing sale price on that date of $234.98. Shares of common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the Registrant have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span><br/></span></div><div style="margin-top:0.05pt;padding-left:9pt;padding-right:24.75pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of February&#160;18, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i58b4bf6524f44a5e8970d9daad47a515_I20220218" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zMjM5_6471c5e6-55c7-4e7d-b081-18e8158935c1">402,872,986</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding. </span></div><div style="margin-top:1.5pt;padding-left:9pt;padding-right:9pt;text-align:center"><span><br/></span></div><div style="margin-top:1.5pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTk1_72ef9338-a4aa-4563-a8ae-7e0d3eb9571a" continuedAt="i580f6f0884164059af1fb313cc45af4d" escape="true">DOCUMENTS INCORPORATED BY REFERENCE</ix:nonNumeric></span></div><div style="margin-top:1.5pt;padding-left:9pt;padding-right:27pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i580f6f0884164059af1fb313cc45af4d">Portions of the registrant&#8217;s Definitive Proxy Statement relating to its 2022 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</ix:continuation></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1.5pt;padding-left:9pt;padding-right:27pt;text-indent:11.25pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.095%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.15pt"><span><br/></span></div><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">PART I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_2201">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk Factors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_2385">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unresolved Staff Comments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_70">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_73">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal Proceedings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_76">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_79">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">PART II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 5.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_85">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">[Reserved]</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_88">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_91">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures about Market Risk</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_97">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial Statements and Supplementary Data</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_100">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_190">151</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Controls and Procedures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_193">151</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_196">153</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_2705">153</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">PART III</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 10.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Directors, Executive Officers and Corporate Governance</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_202">154</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Executive Compensation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_205">154</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_208">154</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain Relationships and Related Transactions, and Director Independence</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_211">154</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal Accountant Fees and Services</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_214">154</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">PART IV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 15.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibits, Financial Statement Schedules</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_220">155</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Form 10-K Summary</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_223">158</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Signatures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_226">159</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:0.1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled &#8220;Risk Factors.&#8221; These risks include, but are not limited to, the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties producing, shipping or successfully commercializing our COVID-19 vaccine consistent with our existing or potential contractual obligations, including due to delays or difficulties experienced by our commercial partners;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The pharmaceutical market is intensely competitive. We may be unsuccessful in competing effectively in the market for existing products, new treatment methods, and new technologies, including for COVID-19 vaccines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be delayed or prevented from receiving full regulatory approval of our COVID-19 vaccine in certain jurisdictions or for certain demographics;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unsuccessful in developing future versions of our COVID-19 vaccine to protect against variants of the SARS-CoV-2 virus, or booster doses of our vaccine may not protect against such variants, and a market for vaccines and boosters against these variants may not develop;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preclinical development is lengthy and uncertain, especially for a new class of medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to the clinic, any of which may have a material adverse impact on our platform or our business;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical development is lengthy and uncertain, especially with a new class of medicines such as mRNA medicines. Clinical trials of our investigational medicines may be delayed and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which could have a material adverse impact on our platform or our business;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA drug development has substantial clinical development and regulatory risks due to the novel nature of this new class of medicines, and the negative perception of the efficacy, safety, or tolerability profile of any investigational medicines that we or others develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our mRNA products, including our COVID-19 vaccine, development candidates and investigational medicines are based on novel technologies and are complex and difficult to manufacture. We or our third-party manufacturers may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping for any of our medicines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As our drug development pipeline increases and matures, the increased demand for clinical and commercial supplies from our facilities and third parties may impact our ability to operate. We rely on many service providers, all of whom have inherent risks in their operations that may adversely impact our operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to significant regulatory oversight with respect to manufacturing our COVID-19 vaccine and our mRNA investigational medicines. Our manufacturing facilities or the manufacturing facilities of our third-party manufacturers or suppliers may not meet regulatory requirements. Failure to meet cGMP requirements set forth in regulations promulgated by the FDA, EMA, and other global health authorities could result in significant delays in any approval of and costs of our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have in the past entered into, and in the future may enter into, strategic alliances with third parties for the development and commercialization of our and their products, development candidates and investigational medicines. If these strategic alliances are not successful, our business could be adversely affected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may seek to establish additional strategic alliances and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. Certain of our strategic alliance agreements may restrict our ability to develop certain products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are not able to obtain and enforce patent protection for our discoveries, or protect the confidentiality of our trade secrets, our ability to effectively compete using our development candidates will be harmed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our reliance on government funding and collaboration from governmental and quasi-governmental entities for certain of our programs adds uncertainty to our research and development efforts with respect to those programs and may impose requirements that increase the costs of development, commercialization and production of any programs developed under those government-funded programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited sales, distribution, and marketing experience, and have only recently invested significant financial and management resources to establish these capabilities. If we cannot effectively establish such capabilities or enter into agreements with third parties to market and sell our products or to help ensure compliance with local regulatory requirements, our ability to generate revenues may be adversely affected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Certain of our customers for our COVID-19 vaccine prepay us for a portion of the product payment for the vaccine doses that they expect to receive from us, and under the terms of certain of our supply agreements, we may be required to refund some or all of those prepayments if a customer reduces its purchase commitment or if we fail to deliver the purchased volume;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited history of recognizing revenue from product sales and may not be able to achieve or maintain long-term sustainable profitability;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing the development and expansion of our company, which could disrupt our operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our internal computer systems and physical premises, or those of third parties with which we share sensitive data or information, may fail or suffer security breaches, which could materially disrupt our product development programs and manufacturing operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to various and evolving laws and regulations governing the privacy and security of personal data, and our failure to comply could adversely affect our business, result in fines and/or criminal penalties, and damage our reputation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our common stock has been volatile and fluctuates substantially, which could result in substantial losses for stockholders; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable U.S. or global economic conditions could adversely affect our business, financial condition, or results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should consider carefully the risks and uncertainties described below, in the section entitled &#8220;Risk Factors&#8221; and the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, before you decide whether to purchase our common stock. The risks described above are not the only risks that we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied forward-looking statements within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our activities with respect to our COVID-19 vaccine, and our plans and expectations regarding future generations of our COVID-19 vaccine that we may develop in response to variants of the SARS-CoV-2 virus, ongoing clinical development, manufacturing and supply, pricing, commercialization, if approved, regulatory matters and third-party and governmental arrangements and potential arrangements;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to contract with third-party suppliers, distributors and manufacturers and their ability to perform adequately, particularly with respect to the timely production and delivery of our COVID-19 vaccine, including any variant booster vaccine candidates, if authorized;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the ability of third parties with whom we contract to successfully manufacture our commercial products at scale, as well as drug substances, delivery vehicles, development candidates, and investigational medicines for preclinical and clinical use;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our commercial products, investigational medicines and technology;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to the direct or indirect impact of the COVID-19 pandemic or any future large-scale adverse health event, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays in diagnoses, initiation or continuation of treatment for diseases that may be addressed by our development candidates and investigational medicines, or in patient enrollment in clinical trials, potential clinical trials, regulatory review or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps taken by us to mitigate the impact of the pandemic, and our ability to execute business continuity plans to address disruptions caused by the COVID-19 pandemic or future large-scale adverse health event;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated next steps for our development candidates and investigational medicines that may be slowed down due to the impact of the COVID-19 pandemic, including our resources being significantly diverted towards our COVID-19 vaccine efforts, particularly if the federal government seeks to require us to divert such resources;<br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop development candidates and investigational medicines, including by applying learnings from one program to our other programs and from one modality to our other modalities;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our investigational medicines;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize our products, if approved;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our medicines, if approved;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model, and strategic plans for our business, investigational medicines, and technology;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our investigational medicines and technology;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory, and commercialization expertise;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future agreements with third parties in connection with the commercialization of our investigational medicines, if approved;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for our investigational medicines, and our ability to serve those markets;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of our investigational medicines;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legal and regulatory developments in the United States and foreign countries;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to produce our products or investigational medicines with advantages in turnaround times or manufacturing cost;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel; and<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, forward-looking statements can be identified by terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on forward-looking statements. Factors that may cause actual results or events to differ materially from current expectations include, among other things, those listed under the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a guarantee of future performance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties. Industry publications and third-party research, surveys, and studies </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We have not independently verified the information contained in such sources.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY REFERENCES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, the terms &#8220;Moderna,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; in this Annual Report on Form 10-K refer to Moderna, Inc. and its consolidated subsidiaries. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRADEMARKS</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2201"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1. Business</span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2204"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna is pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed, manufactured and administered.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our founding in 2010, we have transformed from a research-stage company advancing programs in the field of mRNA to a commercial enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle (LNP) formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna has established relationships with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of our manufacturing capabilities. Most recently, Moderna&#8217;s capabilities have come together to allow the authorization and approval of one of the earliest and most-effective vaccines against the COVID-19 pandemic.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2020, mRNA technology emerged as a new class of medicine. In under a year, we designed our vaccine against COVID-19 (mRNA-1273) using mRNA-based technology, conducted clinical trials, which demonstrated that the vaccine was highly effective at preventing COVID-19, and obtained an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and authorizations from other regulators around the world. During 2021, we shipped more than 800 million doses of our COVID-19 vaccine to countries around the globe to help fight the pandemic, with approximately 25% of those doses going to low- and middle-income countries. In January 2022, the FDA approved the Biologics License Application (BLA) for our COVID-19 vaccine, Spikevax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for individuals 18 years of age and older in the United States.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2360"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE mRNA OPPORTUNITY</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">mRNA, the software of life</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA transfers the information stored in our genes to the cellular machinery that makes all the proteins required for life. Our genes are stored as sequences of DNA which contain the instructions to make specific proteins. DNA serves as a hard drive, safely storing these instructions in the nucleus until they are needed by the cell.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a cell needs to produce a protein, the instructions to make that protein are copied from the DNA to mRNA, which serves as the template for protein production. Each mRNA molecule contains the instructions to produce a specific protein with a distinct function in the body. mRNA transmits those instructions to cellular machinery, called ribosomes, that make copies of the required protein.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We see mRNA functioning as the &#8220;software of life.&#8221; Every cell uses mRNA to provide real time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. This was codified as the central dogma of molecular biology over 50 years ago, and is exemplified in the schematic below.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><img src="mrna-20211231_g2.jpg" alt="mrna-20211231_g2.jpg" style="height:205px;margin-bottom:5pt;vertical-align:text-bottom;width:506px"/></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The structure of mRNA </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Messenger RNA is a linear polymer comprising four monomers called nucleotides: adenosine (A), guanosine (G), cytosine (C), and uridine (U). Within the region of the molecule that codes for a protein, or the coding region, the sequence of these four nucleotides forms a language made up of three-letter words called codons. The first codon, or start codon (AUG), signals where the ribosome should start protein synthesis. To know what protein to make, the ribosome then progresses along the mRNA one codon at a time, appending the appropriate amino acid to the growing protein. To end protein synthesis, three different codons (UAA, UAG, and UGA) </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">serve as stop signals, telling the ribosome where to terminate protein synthesis. In total, there are 64 potential codons, but only 20 amino acids that are used to build proteins; therefore, multiple codons can encode for the same amino acid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of protein production is called translation because the ribosome is reading in one language (a sequence of codons) and outputting in another language (a sequence of amino acids). The coding region is analogous to a sentence in English. Much like a start codon, a capitalized word can indicate the start of a sentence. Codons within the coding region resemble groups of letters representing words. The end of the sentence is signaled by a period in English, or a stop codon for mRNA.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><img src="mrna-20211231_g3.jpg" alt="mrna-20211231_g3.jpg" style="height:296px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In every cell, hundreds of thousands of mRNAs make hundreds of millions of proteins every day. A typical protein contains 200-600 amino acids; therefore, a typical mRNA coding region ranges from 600-1,800 nucleotides. In addition to the coding region, mRNAs contain four other key features: (1) the 5&#8217; untranslated region or 5&#8217;-UTR; (2) the 3&#8217; untranslated region or 3&#8217;-UTR; (3) the 5&#8217; cap; and (4) a 3&#8217; polyadenosine, or poly-A, tail. The sequence of nucleotides in the 5&#8217;-UTR influences how efficiently the ribosome initiates protein synthesis, whereas the sequence of nucleotides in the 3&#8217;-UTR contains information about which cell types should translate that mRNA and how long the mRNA should last. The 5&#8217; cap and 3&#8217; poly-A tail enhance ribosome engagement and protect the mRNA from attack by intracellular enzymes that digest mRNA from its ends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The intrinsic advantages of using mRNA as a medicine</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA possesses inherent characteristics that we believe provide it with a strong foundation as a new class of medicines. These characteristics include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">mRNA is used by every cell to produce all proteins:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA is used to make every type of protein, including secreted, membrane, and intracellular proteins, in varying quantities over time, in different locations, and in various combinations. Given the universal role of mRNA in protein production, we believe that mRNA medicines could have broad applicability across human disease.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Making proteins inside one&#8217;s own cells mimics human biology: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using a person&#8217;s own cells to produce protein therapeutics or vaccine antigens provides certain advantages over existing technologies such as recombinant proteins, which are manufactured using processes that are foreign to the human body.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">mRNA has a simple and flexible chemical structure:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Each mRNA molecule comprises four chemically similar nucleotides to encode proteins made</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from up to 20 chemically different amino acids. To make the full diversity of possible proteins, only simple sequence changes are required in mRNA.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">mRNA has classic pharmacologic features: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA possesses many of the attractive pharmacologic features of most modern medicines, including reproducible activity, predictable potency, and well-behaved dose dependency; mRNA also provides the ability to adjust dosing based on an individual patient&#8217;s needs, including stopping or lowering the dose, to seek to ensure safety and tolerability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">mRNA as a new class of medicines</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike traditional approaches to medicine, where a protein or chemical is introduced to the body, we send tailored mRNA into cells to instruct them to produce specific proteins. Instead of starting from scratch for each new vaccine or therapy, our mRNA approach </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leverages the technology and fundamental components that we have been researching and developing since our founding. Our success in developing, manufacturing and commercializing the Moderna COVID-19 vaccine further supports our belief that mRNA-based medicines as a class have the potential to help patients in far-reaching ways that could exceed the impact of traditional approaches to medicine. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed four core beliefs about the value drivers of mRNA as a new class of medicines: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">mRNA has the potential to create an unprecedented abundance and diversity of medicines.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA&#8217;s breadth of applicability has the potential to create an extraordinary number of new mRNA-based medicines that are currently beyond the reach of recombinant protein technology.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Advances in the development of our mRNA medicines reduce risks across our portfolio. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA medicines share fundamental features that can</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be used to learn quickly across a portfolio. We believe that once safety and proof of protein production has been established in one program, the technology and biology risks of related programs that use similar mRNA technologies, delivery technologies, and manufacturing processes will decrease significantly.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">mRNA technology can accelerate discovery and development. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The software-like features of mRNA enable rapid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">design and the use of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">automated high-throughput synthesis processes that permit discovery to proceed in parallel rather than sequentially. We believe these mRNA features can also accelerate drug development by allowing the use of shared manufacturing processes and infrastructure.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">The ability to leverage shared processes and infrastructure can drive significant capital efficiency over time. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements of different mRNA medicines are similar and that at commercial scale, a portfolio of mRNA medicines will benefit from shared capital expenditures.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2207"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR STRATEGY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the development of mRNA as a new class of medicines, as evidenced by the development of mRNA-based vaccines during 2020, represents a significant breakthrough for patients and our industry. Our success in developing a highly effective vaccine against COVID-19, going from sequence selection, conducting clinical trials and to receipt of regulatory authorization for emergency use, all in less than a year, provides a visible example of the promise of mRNA-based medicine. The Moderna COVID-19 Vaccine/Spikevax has been</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> authorized for use or approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in over 70 countries. In January 2022, the FDA approved the BLA for Spikevax for individuals 18 years of age and older in the United States. From the beginning of the pandemic through December 31, 2021, we delivered 824 million doses of our vaccine, helping to vaccinate millions of people worldwide and combat the pandemic. We believe our success in developing this vaccine has positive implications beyond infectious disease vaccines and across our entire pipeline. We currently have 44 programs in development, and our pipeline spans five therapeutic areas: infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to deliver on the full scope of the mRNA opportunity and maximize long-term value for patients and investors, we have developed four pillars underlying our product strategy that guide our near-term and long-term goals: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Continue to advance our COVID-19 program and bring to market a pan-respiratory annual booster vaccine. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term vision is to develop, and seek regulatory approval for, a convenient, annual, single-dose booster against as many respiratory viruses as possible. mRNA vaccines have the ability to combine multiple different antigens into one vaccine. We believe a single-dose booster would provide significant value to patients and healthcare systems, as compliance and convenience would increase and there would be a reduction in vaccine administration costs. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This vision includes a single-dose booster vaccine against COVID-19, seasonal flu and respiratory syncytial virus (RSV). We are developing vaccines against each of these diseases individually, while also pursuing parallel development of combination vaccines. We are committed to bringing COVID-19 booster shots (variant-specific, if needed) to the market until the pandemic is under control. We have announced positive Phase 1 data for both our flu vaccine (mRNA-1010) and RSV vaccine (mRNA-1345). mRNA-1010 is preparing for a Phase 3 trial to start in 2022 and mRNA-1345 has started the Phase 3 portion of a pivotal Phase 2/3 study. We are also exploring agreements with governments around the world to establish local manufacturing capabilities in their countries, which would provide those governments with access to these annual vaccines, as well as future pandemic preparedness capabilities.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Bring to market first-in-class vaccines against latent viruses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Latent viruses, such as cytomegalovirus (CMV), Epstein-Barr virus (EBV) and human immunodeficiency virus (HIV), cause acute infections and significant long-term effects, or sequelae. CMV infection is the leading infectious cause of birth defects in children in the U.S. and is a major driver of immune dysfunction with aging, including cardiovascular diseases, cancer and cognitive impairment. EBV infection is a </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">major cause of infectious mononucleosis (IM), has been tied to increased risk of developing multiple sclerosis, and is associated with certain lymphoproliferative disorders, higher risk of developing cancer/autoimmune diseases and long-COVID. Untreated HIV infection causes impairment of the immune system, leading to acquired immunodeficiency syndrome (AIDS). </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our CMV vaccine (mRNA-1647) is in an ongoing pivotal Phase 3 study to evaluate the safety and efficacy of mRNA-1647 against primary CMV infection in women ages 16-40 years. Our prophylactic EBV vaccine (mRNA-1189) is in an ongoing Phase 1 study. We have two partnered HIV programs, one that is in an ongoing Phase 1 study (mRNA-1644) and another that is preparing to enter the clinic (mRNA-1547)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In February 2022, we announced two new development candidates against herpes simplex virus (HSV) and varicella-zoster virus (VZV). Both of these candidates are in preclinical development.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Bring to market therapeutics based on mRNA-encoded proteins. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that mRNA medicines have the potential to provide patients with any therapeutic protein, including those targeting intracellular or membrane proteins. Across our therapeutics pipeline, we have 15 development programs across four therapeutic areas: oncology, cardiovascular, rare disease and autoimmune diseases. </span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have had positive, early signals in clinical studies in oncology, cardiovascular and rare diseases, demonstrating early proof-of-concept. However, we are still waiting to advance these programs through full clinical development and regulatory review, as we have done with our COVID-19 vaccine. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Expand our portfolio through strategic investments that leverage or enhance our platform. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance our existing technologies in mRNA and LNP delivery as well as our biology expertise, we believe we can expand our portfolio through collaborations. This strategy includes bringing forward novel nucleic acid editing capabilities through Moderna Genomics (MGX), which is our effort to expand the use of our platform to create more innovative drugs to help patients through complex gene editing. We are committed to advancing this research responsibly and are working toward identifying the right combinations of technologies that can leverage our platform and lead to further breakthroughs in this area.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced a collaboration with Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation gene editing tools, focused on advancing new gene editing systems for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human therapeutic applications. In January 2022, we announced a collaboration with Carisma Therapeutics, Inc. to discover, develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strategic principles that guide our approach are: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We seek to discover and develop a large pipeline in parallel. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to address or prevent as many human diseases as our technology, talent,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital, and other resources permit. We do so as rapidly as we can, understanding both the urgency for patients and the need to be disciplined in our approach.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We undertake sustained, long-term investment in technology creation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aim to improve the performance of mRNA medicines in our current</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modalities, and to unlock new modalities, through investments within basic and applied science. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We focus on the pace and scale of our learning. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to accelerate our progress by solving numerous</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technical problems in parallel rather than in sequence. We make significant investments in digital assets and research infrastructure to accelerate the pace and scale of our learning.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We integrate across the most critical parts of our value chain. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA is a complex multicomponent system and we believe it demands integration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we must be directly engaged in research, drug discovery, drug development, process and analytical development, and manufacturing to accelerate our learning, reduce our risk, and protect our critical know-how. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">We forward invest in core enabling capabilities and infrastructure. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute across a broad pipeline, we need to invest at risk before we have all</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the answers. Our forward investments focus on areas where lead times are long and where early investments can reduce execution risk and accelerate future progress. We proactively invested in a dedicated manufacturing facility, the Moderna Technology Center (MTC), in Norwood, Massachusetts, to support the anticipated growth of our pipeline, and this early investment greatly facilitated our ability to respond to the COVID-19 pandemic by allowing us to begin production of our vaccine even before we received regulatory authorization for its distribution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2210"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR PLATFORM </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of our platform</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mRNA &#8220;platform&#8221; refers to our accumulated knowledge and capabilities in basic and applied sciences. There are three key components to our platform: mRNA, delivery, and the manufacturing process. Our platform incorporates advances across all three of these areas as we advance our medicines. It is the integration of these components that allows us to make our medicines and we combine different versions of mRNA delivery and process into each of our medicines. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are common features between groups of medicines, which we call &#8220;modalities.&#8221; These modalities are the application of our platform &#8211; the groupings have common features in mRNA or delivery technology or in the process by which they are made. This strategy allows us to manage risk across development programs as well as to understand, in cases of success, where we can rapidly expand and build on success with similar programs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary goal of our platform is to identify new modalities and to expand the utility of our existing modalities. Programs within a modality often have correlated technology risk, but because they pursue diverse diseases, they often have uncorrelated biology risk. Each time we add a modality and a new medicine to our portfolio, we create a network effect because each incremental program can help us gain additional insight into the other the programs in our pipeline. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have created seven modalities to date:</span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prophylactic vaccines</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Systemic secreted and cell surface therapeutics</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cancer vaccines</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intratumoral immuno-oncology</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Localized regenerative therapeutics </span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Systemic intracellular therapeutics</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inhaled pulmonary therapeutics</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our platform: mRNA science advancements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to invest in both basic and applied research, seeking to advance both the state of our technology and the state of the scientific community&#8217;s understanding of mRNA. Examples of advances in mRNA science that combine nucleotide chemistry, sequence engineering, and targeting elements are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">mRNA chemistry: Modified nucleotides to mitigate immune system activation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The innate immune system has evolved to protect cells from foreign RNA, such as viral RNA, by inducing inflammation and suppressing mRNA translation once detected. Many cells surveil their environment through sensors called toll-like-receptors (TLRs). These include types that are activated by the presence of double-stranded RNA (TLR3) or uridine containing RNA fragments (TLR7, TLR8). Additionally, all cells have cytosolic double-stranded RNA, sensors, including retinoic acid inducible gene-I (RIG-I) that are sensitive to foreign RNA inside the cell.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The immune and cellular response to mRNA is complex, context specific, and often linked to the sensing of uridine. To minimize undesired immune responses to our potential mRNA medicines, our platform employs chemically-modified uridine nucleotides to minimize recognition by both immune cell sensors such as TLR3/7/8, and broadly-distributed cytosolic receptors such as RIG-I. </span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">mRNA sequence engineering: Maximizing protein expression: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA exists transiently in the cytoplasm, during which time it can be translated into thousands of proteins before eventually being degraded. Our platform applies bioinformatic, biochemical, and biological screening capabilities, most of which have been invented internally that aim to optimize the amount of protein produced per mRNA. We have identified proprietary sequences for the 5&#8217;-UTR that have been observed to increase the likelihood that a ribosome bound to the 5&#8217;-end of the mRNA transcript will find the desired start codon and reliably initiate translation of the coding region.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We additionally design the nucleotide sequence of the coding region to maximize its successful translation into protein. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Targeting elements: Enabling tissue-targeted translation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All nucleated cells in the body are capable of translating mRNA, resulting in pharmacologic activity in any cell in which mRNA is delivered and translated. To minimize or prevent potential off-target effects, our platform employs technologies that regulate mRNA translation in select cell types. Cells often contain short RNA sequences, called microRNAs or miRNAs, that bind to mRNA to regulate protein translation at the mRNA level. Different cell types have different concentrations of specific microRNAs, in effect giving cells a microRNA signature. microRNA binding directly to mRNA effectively silences or reduces mRNA translation and promotes mRNA degradation. We design microRNA binding sites into the 3&#8217;-UTR of our potential mRNA medicines so that if our mRNA is delivered to cells with such microRNAs, it will be minimally translated and rapidly degraded.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our platform: Delivery science</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mRNA can, in specific instances, such as our VEGF therapeutic, be delivered by direct injection to a tissue in a simple saline formulation without LNPs to locally produce small amounts of pharmacologically active protein. However, the blood and interstitial fluids in humans contain significant RNA degrading enzymes that rapidly degrade any extracellular mRNA and prevent broader distribution without LNPs. Additionally, cell membranes tend to act as a significant barrier to entry of large, negatively-charged molecules such as mRNA. We have therefore invested heavily in delivery science and have developed LNP technologies to enable delivery of larger quantities of mRNA to target tissues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LNPs are generally composed of four components: an amino lipid, a phospholipid, cholesterol, and a pegylated-lipid (PEG-lipid). Each component, as well as the overall composition, or mix of components, contributes to the properties of each LNP system. LNPs containing mRNA injected into the body rapidly bind proteins that can drive uptake of LNPs into cells. Once internalized in endosomes within cells, the LNPs are designed to escape the endosome and release their mRNA cargo into the cell cytoplasm, where the mRNA can be translated to make a protein and have the desired therapeutic effect. Any mRNA and LNP components that do not escape the endosome are typically delivered to lysosomes where they are degraded by the natural process of cellular digestion.  Examples of tools we developed by using our platform include proprietary LNP formulations that address the steps of mRNA delivery, including cell uptake, endosomal escape, and subsequent lipid metabolism, and for avoidance of counterproductive interactions with the immune system. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chemistry: Novel lipid chemistry to potentially improve safety and tolerability: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initially used LNP formulations that were based on known lipid systems, which we refer to as &#8220;legacy LNPs.&#8221; A recognized limitation of these legacy LNPs is the potential for inflammatory reactions upon single and repeat administration that can impact tolerability and therapeutic index. Our later-developed, proprietary LNP systems are therefore designed to be highly tolerated and minimize any LNP vehicle-related toxicities with repeat administration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The changes we made have included engineering amino lipids to avoid the immune system and to be rapidly biodegradable relative to prior lipids. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Composition: Proprietary LNPs enhance delivery efficiency: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platform includes extensive in-house expertise in medicinal chemistry, which we have applied to design large libraries of novel lipids. Using these libraries in combination with our discovery biology capabilities, we have conducted high throughput screens for desired LNP properties and believe that we have made fundamental discoveries in preclinical studies about the relationships between structural motifs of lipids and LNP performance for protein expression. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Surface properties: Novel LNP design to avoid immune recognition: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designed our proprietary LNP systems for sustained pharmacology upon repeat dosing by eliminating or altering features that activate the immune system. These are based on insights into the surface properties of LNPs. Upon repeated dosing, surface features on traditional LNPs such as amino lipids, phospholipids, and PEG-lipids, can be recognized by the immune system, leading to rapid clearance from the bloodstream, a decrease in potency upon repeat dosing, and an increase in inflammation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our insights into these mechanisms, we have engineered our LNP systems to reduce or eliminate undesirable surface features. In preclinical studies in non-human primates for our systemic therapeutic development candidates that use our novel LNP systems, we have been able to repeat dose with negligible or undetectable loss in potency, liver damage, and immune system activation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our platform: Manufacturing process science</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest significantly in manufacturing process science to impart more potent features to our mRNA and LNPs, and to invent the technological capabilities necessary to manufacture our mRNA medicines at scales ranging from micrograms to kilograms, as well as achieve pharmaceutical properties such as solubility and shelf life. We view developing these goals of manufacturing and pharmaceutical properties as appropriate for each program, based on its stage of development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">mRNA manufacturing process: Improving pharmacology: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platform creates mRNA using a cell-free approach called </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transcription in which an RNA polymerase enzyme binds to and transcribes a DNA template, adding the nucleotides encoded by the DNA to the growing RNA strand. Following transcription, we employ proprietary purification techniques to ensure that our mRNA is free from undesired synthesis components and impurities that could activate the immune system in an indiscriminate manner. Applying our understanding of the basic science underlying each step in the manufacturing process, we have designed proprietary manufacturing processes to impart desirable pharmacologic features, for example increasing potency in a vaccine. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LNP manufacturing process: Improving pharmacology:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our platform technology includes synthetic processes to produce LNPs. Traditionally LNPs are assembled by dissolving the four molecular components, amino lipid, phospholipid, cholesterol, and PEG-lipid, in ethanol and then mixing this with mRNA in an aqueous buffer. The resulting mixture is then purified to isolate LNPs from impurities. Such impurities include molecular components that have not been incorporated into particles, un-encapsulated mRNA that could activate the immune system, and particles outside of the desired size range.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Going beyond optimization of traditional manufacturing processes, we have invested in understanding and measuring the various biochemical and physical interactions during LNP assembly and purification. We have additionally developed state-of-the-art analytical techniques necessary to characterize our LNPs and biological systems to analyze their </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performance. With these insights, we have identified manufacturing process parameters that drive LNP performance, for example, the potency in a secreted therapeutic setting. These insights have allowed us to make significant improvements in the efficiency of our processing and the potency of our LNPs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing facilities and scale: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the key aspects of our mRNA platform is that a single manufacturing facility can be used to manufacture any of our mRNA medicines. In 2016, following positive Phase 1 data, we decided to build our clinical manufacturing site in Norwood, Massachusetts. This facility produces not only mRNA medicines for all of our preclinical experiments and clinical trials, but has also produced millions of doses of our COVID-19 vaccine for commercial use. We have also partnered with Lonza and additional contract manufacturing organizations (CMOs) to scale up our manufacturing capabilities globally in an effort to combat the COVID-19 pandemic. We are currently working with governments in different geographies to build additional manufacturing facilities, with a view toward being able to combat future pandemics.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Demonstrations of our platform </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our founding in 2010, we have made considerable advancements across our platform. Several examples are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dose-dependent protein expression in the clinic: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have demonstrated in the clinic the ability to generate consistent dose dependent levels of protein (antibodies) as well as the ability to safely repeat dose. For example, we demonstrated the ability to safely repeat dosing in the Phase 1 study of our Chikungunya Antibody program (mRNA-1944), which demonstrated dose-dependent increases in levels of antibodies against chikungunya. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reproducible pharmacology, including upon repeated dosing: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By combining advances in mRNA, delivery, and manufacturing process science, we have demonstrated in preclinical studies sustained and reproducible pharmacology. An example is seen in a mouse model that recapitulates metabolic defects in propionic acidemia (PA). In this rare disease, a defect in one or both of two different subunits (PCCA and PCCB) of the mitochondrial enzyme propionyl-CoA carboxylase results in accumulation of toxic metabolites such as 2-methylcitrate (2MC). In mice hypomorphic for the PCCA subunit, monthly intravenous (IV) administration of mRNAs encoding PCCA and PCCB formulated in our proprietary LNP (mRNA-3927) resulted in a significant and sustained lowering of 2MC throughout the duration of the 6-month study compared to control (luciferase) mRNA (1 mg/kg, n=6/group). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Decreased immune activation upon repeat dosing in non-human primates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have observed decreased immune activation which enables repeat dosing in non-human primates. Published data indicates serum concentration of human erythropoietin (hEPO) with repeat dosing of mRNA encoding hEPO in our proprietary LNPs with weekly IV administration at 0.2 mg/kg in non-human primates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmacologic activity in the target tissue and cell: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While some of our modalities, such as systemic secreted therapeutics, can leverage many different cell types to make therapeutic proteins, others such as systemic intracellular therapeutics, may require delivery of our mRNA into specific tissues and cell types, for instance hepatocytes in certain liver metabolic diseases. Combining our proprietary mRNA, delivery, and manufacturing process technologies we have observed on-target pharmacologic activity in hepatocytes in non-human primates. The on-target potency of this approach contrasts with traditional delivery technologies. In published data, we have shown one of our proprietary LNPs with increased hepatocyte transfecting properties result in protein expression in liver hepatocytes in non-human primates (demonstrated with a reporter protein detected by immunohistochemistry at 6 hours after IV infusion at 2 mg/kg).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, this LNP results in extended expression of a secreted reporter protein in non-human primates as compared to one of our other proprietary LNPs after IV delivery at 0.1mg/kg.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our platform&#8217;s future: Improving and expanding our modalities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to sustaining investment in our platform, both in basic science to elucidate new mechanistic insights, and in applied science to discover new technologies that harness these insights. Our platform investments have enabled seven modalities to date, most of which have already led to multiple development candidates and investigational medicines in our pipeline. We believe that sustaining our investment in platform research and development will enable further improvements in the current modalities and will lead to the creation of new modalities, both of which will benefit our clinical pipeline in the years ahead.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2431"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR MODALITIES</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our approach to developing modalities</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our platform, we develop technologies that enable the development of mRNA medicines for diverse applications. When we identify technologies that we believe could enable a new group of potential mRNA medicines with shared product features, we call that group a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">modality</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; While the programs within a modality may target diverse diseases, they share similar mRNA technologies, delivery technologies, and manufacturing processes to achieve shared product features. The programs within a modality will also generally share similar pharmacology profiles, including the desired dose response, the expected dosing regimen, the target tissue for protein expression, safety and tolerability goals, as well as pharmaceutical properties. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Illustrating our approach: From our first modality to today</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We started with prophylactic vaccines as our first modality because we believed this modality faced lower technical hurdles, relative to other areas. Our early formulations of mRNA tended to stimulate the immune system, which would present a challenge to therapeutics but was a desired feature for vaccines. In addition, many potential prophylactic vaccine antigens are well-characterized, allowing us to reduce biology risk. Lastly, the dosing regimens for vaccines require as few as one or two administrations, and generally involve relatively low doses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our first programs in this modality we chose our H10N8 and H7N9 pandemic influenza vaccines, each requiring expression of a single membrane protein. We chose to pursue two programs in separate, but parallel, clinical trials to establish the flexibility of our platform.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When both programs met our goals for safety, tolerability, and pharmacology, we accelerated and expanded our vaccine pipeline to include multiple commercially meaningful and increasingly complex vaccines. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These included a combination vaccine, designed to protect against two unrelated respiratory viruses, human metapneumovirus (hMPV) and human parainfluenza 3 (PIV3), and a vaccine that combines six different mRNAs, our CMV vaccine, to express a complex pentameric antigen. We also sought strategic alliances with the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research Development Authority (BARDA) and Merck &amp; Co. (Merck), to allow us to rapidly expand our pipeline and complement our capabilities with their expertise. This early work in the prophylactic vaccines modality led to the ability to introduce our COVID-19 vaccine during 2020 in response to the ongoing pandemic.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over time, we have taken on more challenging applications and technological hurdles with each successive modality, but we have also tried to build upon our prior experiences to manage risk. For example, in our cancer vaccines modality, we are now applying our technology to elicit T cell responses to potentially recognize and eradicate cancer as a logical extension of our prophylactic vaccines modality. Having demonstrated local expression of protein in our vaccines, we expanded into local therapeutic applications. For example, in our intra-tumoral immuno-oncology modality, we are seeking to use local expression to drive anti-cancer T cell responses by transforming tumor microenvironments. We can also use local expression to drive regenerative processes as in our Vascular Endothelial Growth Factor A (VEGF-A) program. We expanded into two new modalities that use systemic delivery of mRNA to encode secreted and cell surface or intracellular proteins. Most recently, following a breakthrough in pulmonary delivery stemming from our partnership with Vertex Pharmaceuticals (Vertex), we expanded into the inhaled pulmonary therapeutics modality with our cystic fibrosis (CF) program. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expanding within our designated core modalities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we designated the prophylactic vaccines and systemic secreted and cell surface therapeutics modalities as &#8220;core modalities&#8221; following positive Phase 1 data from our CMV vaccine and chikungunya antibody program, respectively. We believed that this data reduced the risk of these modalities, and our strategy is to invest in additional development candidates within these modalities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our portfolio of modalities&#8212;each with distinct technological and biological risk profiles&#8212;allows us to maximize long-term value for patients and investors. We see our seven current modalities as seven distinct product pipelines that represent different risk profiles and benefit from common infrastructure and a shared platform technology. We believe the high technology correlation within a modality allows us to rapidly accelerate the expansion of the pipeline in that modality based on learnings from the initial programs. We believe the lower technology correlation between modalities allows us to compartmentalize the technology risks. We believe our ongoing investments in our platform will lead to the identification of additional new modalities in the future, and will expand the diversity of our pipeline.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modality descriptions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have seven modalities, described in more detail below: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Prophylactic vaccines</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The goal of any vaccine is to safely pre-expose the immune system to a small quantity of a protein from a pathogen, called an antigen, so that the immune system is prepared to fight the pathogen if exposed in the future, and prevent infection or disease. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe mRNA vaccines have several advantages: (1) ability to mimic many aspects of natural viral infections, (2) multiplexing of mRNA for more compelling product profiles, (3) rapid discovery and advancement of mRNA programs into the clinic, and (4) capital efficiency and speed from shared manufacturing processes and infrastructure. </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Cancer vaccines:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The goal of a cancer vaccine is to safely expose the patient&#8217;s immune system to tumor related antigens, known as neoantigens, to enable the immune system to elicit a more effective antitumor response. Our cancer vaccines modality is focused on the use of mRNA to express neoantigens found in a particular tumor in order to elicit an immune response via T cells that recognize those neoantigens, and therefore the tumor. These neoantigens can either be unique to a patient or can be related to a driver oncogene found across subsets of patients. Recent breakthroughs in cancer immunotherapy, such as checkpoint inhibitors and chimeric antigen receptor T cell therapies, have demonstrated that powerful antitumor responses can be achieved by activating antigen specific T cells. We believe one approach to improve the efficacy of checkpoint inhibitors is to develop vaccines that increase both the number and antitumor activity of a patient&#8217;s T cells that recognize tumor neoantigens. </span></div><div><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that mRNA technology is an attractive approach for cancer vaccines: (1) mRNA vaccines can deliver multiple neoantigens concatenated in a single mRNA molecule, (2) mRNA encoding for neoantigens is translated and processed by patients&#8217; endogenous cellular mechanisms for presentation to the immune system, and (3) mRNA vaccines can be efficiently personalized. </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Intratumoral immuno-oncology:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The goal of this modality is to treat or cure cancer by transforming the tumor microenvironment to drive anti-cancer T cell responses against tumors. The outlook for any patients with advanced cancer remains poor, especially in tumors that have little immune system engagement (sometimes termed immunologically &#8220;cold&#8221;). In conjunction with a checkpoint inhibitor, we aim to activate the immune system against these otherwise immunologically cold tumors. Intratumoral administration allows for localized effect of these therapeutics that could be toxic if administered systemically. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our approach to immuno-oncology using mRNA medicines could complement checkpoint inhibitors and has several advantages over recombinant protein-based drugs: (1) mRNA focuses and limits exposure of immune stimulatory proteins, (2) mRNA can produce membrane associated immune stimulatory proteins, (3) multiplexing of mRNA allows access to multiple immune stimulatory pathways, (4) mRNA sequences can be engineered to reduce off-target effects, and (5) local administration of mRNA can create a concentration gradient for encoded proteins. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Localized regenerative therapeutics:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The goal of this modality is to develop mRNA medicines to address injured or diseased tissues by locally producing proteins that provide a therapeutic benefit in the targeted tissue. There are multiple applications for tissue regeneration and our initial focus is on cardiovascular diseases. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our approach to localized regenerative therapeutics using mRNA has several advantages over alternative approaches: (1) mRNA can be administered locally to produce the desired protein for an extended duration, (2) local administration of mRNA allows for focused activity, and (3) mRNA allows for dose-dependent and repeated production of the encoded protein. </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Systemic secreted and cell surface therapeutics:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The goal of this modality is to provide secreted proteins, such as antibodies or enzyme replacement therapies across a wide range of diseases, such as heart failure, infectious diseases, and rare genetic diseases. Our mRNA medicines instruct various cells of the human body to secrete proteins for therapeutic effect. Systemically delivered, secreted and cell surface therapeutics, we believe, would allow us to target areas of biology that cannot be addressed using recombinant proteins.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential advantages in this area include: (1) mRNA can produce hard-to-make or complex secreted proteins, (2) mRNA can produce membrane associated proteins, (3) native post-translational modifications are possible through intracellular protein production using mRNA, (4) mRNA can sustain production of proteins, which can increase exposure to proteins with short half-lives, and (5) mRNA allows for desirable pharmacology in rare genetic diseases currently addressed by enzyme replacement therapies. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Systemic intracellular therapeutics:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The goal of this modality is to provide intracellular proteins, such as intracellular enzymes and organelle-specific proteins, as safe, tolerable, and efficacious therapies. Our mRNA medicines aim to increase levels of intracellular proteins to achieve a therapeutic effect in one or more tissues or cell types and our initial focus is on rare genetic diseases. Intracellular therapeutics are not currently addressable with recombinant proteins, which are typically administered systematically and cannot reach inside of the cell. </span></div><div style="padding-left:45pt"><span><br/></span></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential advantages in these areas include: (1) using mRNA to encode for intracellular and organelle-specific proteins; mRNA can produce hard-to-make or complex proteins, (2) native post-translational modifications are possible through intracellular protein production using mRNA, (3) mRNA can sustain production of proteins, which can increase exposure to proteins with short half-lives, and (4) mRNA allows for desirable pharmacology in complex metabolic diseases. </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Inhaled pulmonary therapeutics: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goal of this modality is to develop mRNA medicines that can be delivered to the lung as safe, tolerable and efficacious therapies. We are developing nebulized NLP formulations that can transfect airway epithelial cells to deliver mRNA into the lungs of patients in order to express proteins coded in the mRNA. We aim to leverage our technology for pulmonary diseases in patients for whom there are no existing effective therapies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="padding-left:45pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential advantages in these areas include: (1) mRNA can produce hard-to-make or complex proteins, (2) mRNA can replace defective genes, and (3) LNP delivery allows for repeat dosing. </span></div><div style="padding-left:45pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2451"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR PIPELINE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we nominated our first program in late 2014, we and our strategic collaborators have advanced in parallel a diverse development pipeline which currently consists of 44 development program across our 41 development candidates, with 25 having entered the clinic and one development candidate subject to an open investigational new drug application (IND). In the third quarter of 2021, we refined the way we track our development programs and now separately track each indication of our COVID-19 and RSV vaccine candidates, which resulted in an increase in the number of our development programs. We have entered seven other development candidates into the clinic that are no longer being pursued for further clinical development. Aspects of our pipeline have been supported through strategic alliances, including with AstraZeneca, Merck, and Vertex, and government-sponsored organizations and private foundations focused on global health initiatives, including BARDA, DARPA, the National Institutes of Health (NIH), and the Bill &amp; Melinda Gates Foundation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selection process for advancing new development candidates reflects both program-specific considerations as well as portfolio-wide considerations. Program-specific criteria include, among other relevant factors, the severity of the unmet medical need, the biology risk of our chosen target or disease, the feasibility of clinical development, the costs of development, and the commercial opportunity. Portfolio-wide considerations include the ability to demonstrate technical success for our platform components within a modality, thereby increasing the probability of success and learnings for subsequent programs in the modality and in some cases in other modalities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The breadth of biology addressable using mRNA technology is reflected in our current development pipeline of 44 programs. The diversity of proteins made from mRNA within our development pipeline is shown in the figure below.</span></div><div style="text-align:center"><img src="mrna-20211231_g4.jpg" alt="mrna-20211231_g4.jpg" style="height:282px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"/></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our full pipeline, grouped by modalities, is shown in the figure below: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><img src="mrna-20211231_g5.jpg" alt="mrna-20211231_g5.jpg" style="height:720px;margin-bottom:5pt;vertical-align:text-bottom;width:720px"/></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2216"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPHYLACTIC VACCINES MODALITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 29 different prophylactic vaccine programs, of which 17 have entered the clinic. We separate our prophylactic vaccines modality into three categories: (1) vaccines against respiratory viruses, (2) vaccines against latent viruses, and (3) other vaccines (such as public health programs).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prophylactic vaccines: Vaccines against respiratory viruses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 vaccine (mRNA-1273) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Moderna&#8217;s COVID-19 Vaccine/Spikevax is approved or authorized for use in more than 70 countries</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Moderna COVID-19 Vaccine, which is also marketed under the brand name Spikevax, is our first commercial product. From the beginning of the COVID-19 pandemic through December 31, 2021, we delivered approximately 824 million doses of our vaccine globally, with approximately 807 million of those doses shipped in 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coronaviruses are a large family of viruses that can cause illness in animals or humans. In humans there are several known coronaviruses that cause respiratory infections. These coronaviruses range from the common cold to more severe diseases such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19. SARS-CoV-2 is the novel coronavirus first identified in humans in December 2019 and is the cause of COVID-19. COVID-19 is the most severe global pandemic since the influenza pandemic of 1918. According to the Johns Hopkins Coronavirus Resource Center, since the identification of SARS-CoV-2 in 2020, there have been over 430 million confirmed cases and over 5.9 million global deaths from COVID-19. The risk of mortality increases with age and the risk of severe disease and mortality increase for persons with pre-existing diseases or comorbid conditions (e.g. cardiovascular disease, diabetes, chronic lung disease, obesity). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vaccine against COVID-19, mRNA-1273, was designed, subject to Phase 1, Phase 2 and Phase 3 clinical trials, delivered clinical trial results, and received emergency use and other conditional authorizations in less than a year, and has been and continues to be a key tool in fighting the global COVID-19 pandemic. The SARS-CoV-2 virus continues to evolve, and certain variants of the virus have proven to be more transmissible and to cause more severe cases of COVID-19 than the ancestral strain that first emerged in Wuhan, China. As part of our strategy to combat the COVID-19 pandemic, we have continued to develop and assess variant-specific versions of our COVID-19 vaccine, including versions aimed at targeting the Beta, Delta and Omicron variants of the virus.  Forward-looking references to our COVID-19 vaccine in this Annual Report on Form 10-K may include future modifications to mRNA-1273 or other development candidates that are designed to provide protection against variants of the SARS-CoV-2 virus.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to study the use of our COVID-19 vaccine (mRNA-1273) in adolescent and pediatric populations, and for boosting and other indications. In addition to our original COVID-19 vaccine, we have advanced multiple other variant-specific vaccines into the clinic as part of effort to fight the global COVID-19 pandemic. As of the date of this Annual Report on Form 10-K, these programs include: </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spikevax/mRNA-1273 Programs </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Moderna COVID-19 vaccine/Spikevax: Approved/authorized in individuals 18 years and older in more than 70 countries (100 &#181;g dose).</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">In January 2022, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. FDA approved the Biologics License Application (BLA) for Spikevax (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 18 years of age and older. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adolescent COVID-19 vaccine/Spikevax: Authorized in individuals 12-17 years in the European Union, UK, Australia, Canada, Switzerland and other countries (100 &#181;g dose); authorization by the U.S. FDA is pending. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The&#160;U.S.&#160;FDA notified us that it will require additional time to complete its assessment of our EUA request for the use of mRNA-1273 at the 100 &#181;g dose level in adolescents 12 to 17 years of age. In early December 2021, we also decided to evaluate the potential of a lower 50 &#181;g dose for primary vaccination. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Pediatric COVID-19 vaccine/Spikevax: In clinical trials in children from 6 months to 11 years old; authorized in individuals 6-11 years in Australia, and subject to a positive recommendation from the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use in individuals from 6-11 years (50 &#181;g dose).</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The Phase 2 study of mRNA-1273 in pediatric populations is ongoing. We selected the 50 &#181;g dose for expanded enrollment in the 6 to 11 years old cohort, which is now fully enrolled (N=4,000). Dose selection studies are underway for 2 years to 5 years old and 6 months to &lt;2 years old groups. In early December 2021, we also decided to evaluate the potential of a lower dose of 25 &#181;g to meet regulatory guidance for immunogenicity in children 6-11 years of age. We expect to report data in children 2-5 years of age in March 2022.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Booster dose of COVID-19 vaccine/Spikevax: Authorized in individuals 18 years and older in the United States, the European Union, Switzerland and other countries (50 &#181;g dose).</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">For immunocompromised individuals, a booster dose of 100 &#181;g is authorized.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other COVID-19 Vaccine Programs</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Next-generation COVID-19 vaccine (mRNA-1283) is in an ongoing Phase 2 trial. </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">mRNA-1283 is a next-generation COVID-19 vaccine candidate that encodes for the portions of the SARS-CoV-2 spike protein critical for neutralization, specifically the Receptor Binding Domain (RBD) and Nterminal Domain (NTD). The encoded mRNA-1283 antigen is shorter than mRNA-1273 and is being developed as a potential refrigerator-stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Variant-specific or multi-valent COVID-19 vaccines: As SARS-CoV-2 has continued to evolve, we have proactively made new mRNA candidates in the case they are needed for an escape variant. In the event that mRNA-1273 proves ineffective at protecting against these variants, we have developed the variant vaccines listed below, which may be utilized to the extent necessary as the virus continues to evolve: </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">mRNA-1273.351: Vaccine against the Beta variant. Phase 2 clinical trial ongoing.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">mRNA-1273.617: Vaccine against the Delta variant. Phase 2 clinical trial ongoing.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">mRNA-1273.529: Vaccine against the Omicron variant. Phase 2 clinical trial ongoing.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">mRNA-1273.211: Vaccine against the Beta variant and wild-type. Phase 2 clinical trial ongoing.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">mRNA-1273.213: Vaccine against the Beta variant and Delta variant. Phase 2 clinical trial ongoing.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">mRNA-1273.214: Vaccine against the Omicron variant and wild-type.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna COVID-19 Vaccine Clinical Trials</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final analysis of adjudicated cases from the Phase 3 clinical trial for mRNA-1273, which we refer to as the COVE Study, demonstrated efficacy of 93% through six months after the second dose of the vaccine. The final analysis also demonstrated greater than 98% efficacy against severe cases of COVID-19 and 100% efficacy against death caused by COVID-19 in the per protocol cohort. The final analysis also demonstrated consistency in our subgroup analysis, including analyses by gender, by race and by preexisting medical conditions. The safety profile for mRNA-1273 continues to be consistent with the Phase 3 data over the longer period of safety follow up and across population subgroups.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variant-specific and multivalent vaccines and Omicron update</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are continuously advancing booster candidates to address emerging variants of concern (VOCs). The strategy involves evaluating the prototype vaccine (mRNA-1273) at the authorized booster dose (50 &#181;g), an Omicron-specific booster candidate (mRNA-1273.529), and a bivalent booster candidate (mRNA-1273.214) combining mRNA-1273.529 and mRNA-1273. Booster candidates are being evaluated in ongoing Phase 2/3 studies of approximately 300-600 participants per arm. In December 2021, we announced that at day 29 post-boost, the authorized 50 &#181;g booster of mRNA-1273 increased neutralizing geometric mean titers (GMT) against Omicron approximately 37-fold higher than pre-boost levels. At day 29 post-boost, the 100 &#181;g dose booster of mRNA-1273 increased neutralizing GMTs approximately 83-fold higher than pre-boost levels. Multivalent candidates (mRNA-1273.211 and mRNA-1273.213) boosted Omicron specific neutralizing antibody levels to similarly high levels at both the 50 &#181;g and 100 &#181;g levels. Based on the strength of neutralizing titers generated by mRNA-1273, the rapid pace of Omicron expansion, and the increased complexity of deploying a new vaccine, we are focusing our near-term efforts to address Omicron on the mRNA-1273 booster.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, given the long-term threat demonstrated by Omicron&#8217;s immune escape, we are also developing an Omicron containing variant vaccine (mRNA-1273.529) and a bivalent vaccine that is tailored to Omicron and the wild-type virus (mRNA-1273.214). The first participant was dosed in the mRNA-1273.529 trial in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 2022 and this trial is ongoing.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Commercial, Manufacturing and Supply Updates </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial sales of our COVID-19 vaccine accounted for $17.7 billion in revenues for the year ended December 31, 2021, based upon the delivery of approximately 807 million doses of the vaccine, accounting for all of our commercial revenues. We anticipate that sales of our COVID-19 vaccine in 2022 will similarly provide all of our commercial revenues for the coming year. These sales, both for 2021 and 2022, have been and will primarily be made to governments and international organizations engaged in the purchase of vaccines to combat the COVID-19 pandemic. We are preparing for the fall 2022 booster season and, if marketing approval is received for boosters of our COVID-19 vaccine, we expect to initiate sales in the U.S. private market. As the COVID-19 pandemic evolves into an endemic phase, we anticipate greater seasonality for sales, with greater demand in the fall/winter season in each hemisphere as countries seek to boost their populations. For further information on the sales and manufacturing of our COVID-19 vaccine, see &#8220;Manufacturing&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonal influenza vaccine (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030) </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are developing five influenza vaccines. mRNA-1010 has reported positive Phase 1 data and is ongoing in a Phase 2 study and a Phase 3 study is planned to start soon.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seasonal influenza viruses are estimated by the World Health Organization (WHO) to cause 3 to 5 million cases of severe illness and up to 650,000 deaths each year, resulting in a severe challenge to public health. Currently licensed seasonal influenza virus vaccines rarely exceed 60% overall effectiveness and can provide low effectiveness during years when the circulating viruses do not match the strains selected for the vaccine antigens. Our mRNA seasonal influenza vaccine program has three different approaches. Our first approach &#8211; Quadrivalent Vaccine &#8211; is developing a quadrivalent seasonal flu vaccine (mRNA-1010) targeting WHO recommendations, including A H1N1, H3N2 and influenza B Yamagata and Victoria lineages. Our second approach &#8211; Expanded Coverage &#8211; is to provide an enhanced antigen selection opportunity to public health authorities with the potential for regional variation. Our third approach &#8211; Immunologic Breadth &#8211; is to provide immunity by targeting more conserved antigens to provide the broadest coverage. We also aim to work with the WHO and other regulators to make vaccines closer to the flu season and potentially choose strains closer to the ones circulating in the hemisphere.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1010 is a single investigational vaccine consisting of four distinct mRNA sequences that encode the A H1N1, H3N2 and influenza B Yamagata and Victoria lineages in our proprietary LNP. mRNA-1011 and mRNA-1012 are investigational vaccines that will include the four WHO recommended strains and aim to add additional Hemagglutinin (HA) antigens (e.g. H3N2, H1N1). mRNA-1020 and mRNA-1030 are investigational vaccines that will aim to add Neuraminidase (NA) antigens.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1010 is ongoing in a Phase 2 study and a Phase 3 efficacy study is planned to start in 2022. In December 2021, we announced positive Phase 1 data, and that mRNA-1010 successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults. In the Phase 1 study, mRNA-1010 was evaluated at 50 &#181;g, 100 &#181;g and 200 &#181;g dose levels in younger adult (age 18-49) and older adult (age 50+) cohorts. No significant safety findings were observed through day 29. Adverse reactions (ARs) were generally reported more frequently in younger adults compared to older adults, and at higher dose levels. Minimal differences in dose response was observed between the 50 &#181;g, 100 &#181;g and 200 &#181;g dose levels, suggesting the potential to explore even lower doses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expanded coverage influenza vaccines (mRNA-1011 &amp; mRNA-1012) and immunologic breadth influenza vaccines (mRNA-1020 &amp; mRNA-1030) are in preclinical studies.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSV vaccine (mRNA-1345)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are developing an RSV vaccine for children and older adults. In older adults, mRNA-1345 is ongoing in a pivotal Phase 3 study; in pediatrics, mRNA-1345 is ongoing in a Phase 1 study. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Respiratory syncytial virus (RSV) is one of the most common causes of respiratory disease in children under the age of five and also in older adults. Most children are infected at least once by two years of age. In the United States, it is estimated that over two million children younger than five years of age receive medical attention and more than 86,000 are hospitalized due to RSV infection annually. RSV also causes a substantial burden of respiratory illness in older adults. RSV infection causes an estimated 177,00 hospitalizations and 14,000 deaths per year in adults aged &gt;65 years in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1345 encodes an engineered form of the RSV F protein stabilized in the prefusion conformation and is formulated in our proprietary LNP. We believe that neutralizing antibodies elicited by mRNA-1345 may lead to an efficacious RSV vaccine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 1 study of mRNA-1345 to evaluate the tolerability, reactogenicity and immunogenicity of mRNA-1345 in younger adults, older adults, older adults of Japanese descent, women of child-bearing age and children with serologic evidence of prior RSV exposure is ongoing. The age range of children in this de-escalation Phase 1 study is 12-59 months. Enrollment in the pediatric and older adult Japanese descent cohorts are ongoing, whereas the other cohorts are fully enrolled. Phase 1 interim data from the older adult cohort showed that a single mRNA-1345 vaccination at 50 &#181;g, 100 &#181;g or 200 &#181;g boosted neutralizing antibody titers against RSV-A by approximately 14-fold and against RSV-B by approximately 10-fold. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 3 portion of the pivotal global Phase 2/3 study of mRNA-1345 with approximately 34,000 participants and testing the 50 &#181;g is currently enrolling. The FDA has granted Fast Track designation for mRNA-1345 in adults older than 60 years of age.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">hMPV/PIV3 vaccine (mRNA-1653)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are developing a combination vaccine to address two viruses that are leading causes of respiratory infection</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human metapneumovirus (hMPV) and human parainfluenza virus 3 (PIV3) are significant causes of respiratory tract infections in children. hMPV has been detected in 4% to 15% of patients with acute respiratory infections. hMPV causes disease primarily in young children but can also infect adults, the elderly, and immunocompromised individuals. Infections from parainfluenza virus (PIV) account for up to 7% of acute respiratory infections among children younger than 5 years. Of the four PIV types identified, PIV3 most frequently results in infections and leads to the more serious lower respiratory tract infections compared to the other three PIV types.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1653 is a single investigational vaccine consisting of two distinct mRNA sequences that encode the membrane F proteins of hMPV and PIV3, co-formulated in our proprietary LNP.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A first-in-human dose-ranging study, mRNA-1653-P101, in healthy adults (N=124) was completed in January 2020. This study evaluated the safety, reactogenicity, and immunogenicity of a range of dose levels (25, 75, 150 or 300 &#181;g) administered on a 1-dose or 2-dose vaccination schedule (approximately 28 days apart) compared with a placebo control in healthy adult subjects (18 through 49 years of age) with a 13 month follow-up period. The mRNA-1653 vaccine was generally well-tolerated at all dose levels. A single dose of mRNA-1653 boosted serum neutralization titers against hMPV and PIV3, and the magnitude of the boost was similar at all dose levels. The Month 1 to baseline geometric mean ratio (GMR) for the pooled mRNA-1653 treatment groups was approximately 6 for hMPV and 3 for PIV3. A second vaccination did not impact the magnitude of hMPV or PIV3 neutralization titers measured at Month 2. The hMPV neutralizing antibody titers remained above baseline at all dose levels through Month 13, and the PIV3 neutralizing antibody titers remained above baseline at all dose levels through Month 7.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a Phase 1b trial to evaluate mRNA-1653 in healthy adults and children aged 12-59 months. The Phase 1b trial is a randomized, observer-blinded, placebo-controlled, dose-ranging trial to evaluate the safety and immunogenicity of two dose levels of mRNA-1653 in healthy adults (18-49 years of age) and two dose levels in children (12-59 months of age) with serologic evidence of prior hMPV and PIV3 exposure. The study is fully enrolled. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Combination vaccines (mRNA-1073 &amp; mRNA-1365)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our vision is to develop a pan-respiratory annual booster vaccine (mRNA-1073) and a pediatric combination vaccine (mRNA-1365) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we announced two development candidates that build upon our combination strategy. mRNA-1073 is our COVID-19 and seasonal flu combination vaccine. mRNA-1073 encodes for the COVID-19 spike protein and the flu HA glycoproteins. mRNA-1365 is our pediatric RSV and hMPV combination vaccine. mRNA-1365 encodes for the RSV prefusion F glycoprotein and the hMPV F protein. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prophylactic vaccines: Vaccines against latent viruses</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CMV vaccine (mRNA-1647)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our CMV program targets prevention of CMV infections, which could reduce the risk of birth defects</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human CMV is a common human pathogen and member of the herpes virus family. Congenital CMV results from infected mothers transmitting the virus to their unborn child and it is the leading infectious cause of birth defects in the United States, with approximately 25,000 newborns in the U.S. infected annually. There is currently no available vaccine for CMV and a vaccine that leads to durable immunity in women of child-bearing age would address a critical unmet need in the prevention of congenital CMV infection. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CMV vaccine, mRNA-1647, combines six mRNAs in one vaccine, which encode for two proteins located on the surface of CMV: five mRNAs encoding the subunits that form the membrane-bound pentamer complex and one mRNA encoding the full-length membrane-bound glycoprotein B (gB). Both the pentamer and gB are essential for CMV to infect barrier epithelial surfaces and gain access to the body, which is the first step in CMV infection. mRNA-1647 is designed to produce an immune response against both the pentamer and gB for the prevention of CMV infection.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1 and 2 studies of mRNA-1647 demonstrated functional antigen-specific responses that support the vaccine candidate&#8217;s potential to prevent CMV infection. Interim, seven-month data from the Phase 2 study of mRNA-1647 at the 50 &#956;g, 100 &#956;g and 150 &#956;g dose levels showed that mRNA-1647 was generally well tolerated. In CMV-seronegative participants in mRNA-1647 treatment groups after the third vaccination, neutralizing antibody GMTs against epithelial cell infection were at least 20-fold higher than the baseline GMT of the CMV seropositive group, and neutralizing antibody GMTs against fibroblast infection approximated the baseline </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GMT of the CMV-seropositive group. In CMV positive participants in mRNA-1647 treatment groups after the third vaccination, neutralizing antibody GMTs against epithelial cell infection increased to at least 6.8-fold over baseline, and neutralizing antibody GMTs against fibroblast infection increased to approximately 2-fold over baseline.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the interim analysis of the Phase 2 study, the 100 &#956;g dose was chosen for the Phase 3 study. The first participant in the Phase 3 study, known as CMVictory, was dosed in October 2021. The study is evaluating the safety and efficacy of mRNA-1647 against primary CMV infection in women ages 16-40 years and seeks to enroll 6,900 women of child-bearing age. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EBV vaccine (mRNA-1189 &amp; mRNA-1195)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are developing two EBV vaccines &#8211; a vaccine to prevent infectious mononucleosis and another vaccine to prevent the longer term sequelae of EBV infection</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Epstein-Barr virus (EBV) a member of the herpesvirus family that includes CMV, infects approximately 90% of people by adulthood, with primary infection typically occurring during childhood or late adolescence (approximately 50% and 89% seropositivity, respectively) in the U.S. EBV is the major cause of infectious mononucleosis in the U.S., accounting for over 90% of the approximately 1-2 million cases of infectious mononucleosis in the U.S. each year. Infectious mononucleosis can debilitate patients for weeks to months and, in some cases, can lead to hospitalization and splenic rupture. EBV infection is associated with the development and progression of certain lymphoproliferative disorders, cancers, and autoimmune diseases. In particular, EBV infection and infectious mononucleosis are associated with increased risk of developing multiple sclerosis, an autoimmune disease of the central nervous system. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to our CMV vaccine (mRNA-1647) product concept, we believe that an effective EBV vaccine must generate an immune response to antigens that are required for viral entry in most of the susceptible cell types. We have thus designed our EBV vaccine, mRNA-1189, to elicit an immune response to EBV envelope glycoproteins gp220 as well as gp42, and the gH/gL complex, which are required for infection of both epithelial and B cells. mRNA-1189 contains four mRNAs encoding for these proteins encapsulated in our proprietary LNPs. mRNA-1195 encodes for additional antigens and the first indication it will focus on is post-transplant lymphoproliferative diseases (80% of PTLD can be attributed to EBV).</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are conducting a Phase 1, randomized, observer-blind, placebo-controlled study of mRNA-1189. The primary purpose of the Phase 1 study is to assess safety, tolerability and immunogenicity of mRNA-1189 in healthy adults ages 18 to 30. We announced the dosing of the first participant in January 2022 and we expect to enroll approximately 270 participants. Our EBV therapeutic vaccine, mRNA-1195, is in preclinical studies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HSV vaccine (mRNA-1608)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are developing a herpes simplex virus (HSV) vaccine candidate against HSV-2 disease</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Herpes simplex viruses (commonly known as herpes) are categorized into two types: HSV-1 infects the mouth, face and genitals, and HSV-2 primarily infects the genitals. Both viruses establish life-long latent infections within nearby sensory neurons from which they can reactivate and re-infect the skin. There is a significant burden of disease from HSV genital infections. Diagnosed, symptomatic genital herpes causes a reduction in quality of life, which antivirals (current standard of care) only partially restore. In the United States, approximately 18.6 million adults ages 18 to 49 years are living with HSV-2. Globally, approximately 5% of the population in the 18-to-49-year age range is HSV-2 seropositive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that an HSV vaccine could deliver similar efficacy as suppressive antiviral treatments and could improve compliance and quality of life. We aim to induce a strong antibody response with neutralizing and effector functionality combined with cell-mediated immunity. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our HSV vaccine (mRNA-1608) is currently in preclinical studies. In a preclinical study in mice, we demonstrated robust neutralizing response induced by an mRNA vaccine containing HSV-2 antigens against both HSV-2 infection, and cross-neutralization against HSV-1 infection. In addition, the sera also demonstrated high antibody-dependent cellular cytotoxicity (ADCC) activity. The immune responses induced by the HSV-2 mRNA vaccine are higher than the average observed in 80 randomly selected seropositive human sera. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VZV vaccine (mRNA-1468)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are developing a varicella-zoster virus (VZV) vaccine candidate to reduce the rate of herpes zoster (shingles)</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Herpes zoster occurs in one of three adults in their lifetime and incidence dramatically increases at approximately 50 years of age. Declining immunity in older adults decreases cell-mediated immunity against VZV, allowing reactivation of the virus from latently infected neurons, causing painful and itchy lesions. Serious herpes zoster complications include postherpetic neuralgia (10-13% of herpes zoster cases), bacterial coinfections, and cranial and peripheral palsies; 1-4% of individuals with herpes zoster cases are hospitalized for complications. Severity of disease and likelihood of complications, including postherpetic neuralgia (PHN) also increases with age. Immunocompromised patients, autoimmune disease patients using immunosuppressive therapies, HIV-infected patients, hematopoietic stem cell (HSCT) and organ transplant recipients have an increased risk of developing herpes zoster. The incidence of herpes zoster has been increasing throughout the world, from 0.76 per 1,000 person years from 1945 to 1949, to 7.2 per 1,000 person years in 2016. The current standard of care is Shingrix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, an FDA-approved vaccine for the prevention of shingles (herpes zoster) in adults 50 years and older. It is more than 90% effective against herpes zoster in adults aged 50-70 with only a slight reduction in efficacy for adults over age 70.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our VZV vaccine (mRNA-1468) is designed to express VZV glycoprotein E (gE) to reduce the rate of herpes zoster.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Latest data and next steps </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In partnership with Merck, we previously published preclinical data in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> showing that an LNP formulated (Merck&#8217;s proprietary LNP) mRNA encoding VZV gE antigen is highly immunogenic in non-human primates. Our VZV vaccine (mRNA-1468) using our proprietary LNP is currently in preclinical studies.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HIV vaccine (mRNA-1644 &amp; mRNA-1574)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are developing two HIV vaccines &#8211; one approach is to test a novel HIV vaccine strategy in humans for eliciting broadly neutralizing HIV-1 antibodies (bnAbs) and the second approach is to test novel HIV trimer designs in humans. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIV is the virus responsible for acquired immunodeficiency syndrome (AIDS), a lifelong, progressive illness with no effective cure. Approximately 38 million people worldwide are currently living with HIV, with 1.2 million in the U.S. Approximately 1.5 million new infections of HIV are acquired worldwide every year and approximately 680,000 people die annually due to complications from HIV/AIDS. The primary routes of transmission are sexual intercourse and IV drug use, putting young adults at the highest risk of infection. From 2000 to 2015, a total of $562.6 billion globally was spent on care, treatment and prevention of HIV, representing a significant economic burden.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with the International AIDS Vaccine Initiative (IAVI) and the Bill &amp; Melinda Gates Foundation, mRNA-1644 is testing a novel HIV vaccine strategy in humans as delivered by mRNA to elicit broadly neutralizing HIV-1 antibodies (bnAbs) through sequential vaccination of novel prime and boost antigens that induce specific B-cell responses. In collaboration with IAVI and the HIV Vaccine Trials Network, mRNA-1574 is testing multiple native-like HIV trimer mRNAs in humans to improve our understanding of how to make stable and immunogenic native-HIV trimers. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1644 is in an ongoing Phase 1 clinical trial and mRNA-1574 is in preclinical studies. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prophylactic vaccines: Public health vaccines</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zika vaccine (mRNA-1893)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In partnership with BARDA, we are in a Phase 2 clinical trial for our Zika vaccine </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zika virus is a single stranded RNA virus of the flaviviridae family. Seroepidemiology data suggest that it is endemic to regions of Africa and Asia where the Aedes mosquito vectors are found. Zika virus is predominantly spread by mosquitos from the Aedes genus, but it can also be transmitted congenitally, sexually, and through blood donation. Zika infection is usually asymptomatic or mild in adults, leading to fever, rash, and conjunctivitis. However, infection of women during pregnancy can result in devastating microcephaly in newborns. Microcephaly is a birth defect characterized by an abnormally small head and brain, associated with lifelong neurodevelopmental delay, seizures, intellectual disability, balance problems, and dwarfism / short stature, resulting in significant disability and requiring lifelong support. In 2007, a Zika infection outbreak progressed across the Pacific islands. An outbreak observed in Brazil in 2015 soon spread across the Americas. This led to the WHO declaring it a public health emergency of international concern in 2016. During the period, there were tens of thousands of cases of microcephaly and congenital Zika syndrome reported in infants and of resulting neurological sequelae such as Guillain-Barr&#233; syndrome reported in adults.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Zika vaccine, mRNA-1893, encodes for the prME structural protein encapsulated in our proprietary LNP. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we announced positive data from our Phase 1 clinical trial, which enrolled four cohorts (10, 30, 100 and 250 &#181;g). mRNA-1893 was safe and well tolerated at the 10 and 30 &#181;g dose level. In the flavivirus-seronegative group, seroconversion rates after the second vaccination reached 94.4% at the 10 &#181;g dose level and 100% in the 30 &#181;g dose level (PRNT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). In the flavivirus-seropositive group, the percentage of participants achieving a 4-fold boost in pre-existing PRNT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> titers after the second vaccination reached 50% in the 10 &#181;g dose level and 75% in the 30 &#181;g dose level (PRNT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). We are currently enrolling mRNA-1893 in a Phase 2 clinical study in the United States and Puerto Rico with approximately 800 participants. The randomized, placebo-controlled study aims to evaluate the safety, tolerability and reactogenicity of mRNA-1893 compared to placebo. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nipah vaccine (mRNA-1215)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In collaboration with the NIH-VRC, we are preparing to start a Phase 1 study for our Nipah vaccine </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nipah virus (NiV) is a zoonotic virus transmitted to humans from animals, contaminated food, or through direct human-to-human transmission and causes a range of illnesses including fatal encephalitis. Severe respiratory and neurologic complications from NiV have no treatment other than intensive supportive care. The case fatality rate among those infected is estimated at 40-75%. NiV outbreaks cause significant economic burden to impacted regions due to loss of human life and interventions to prevent further spread, such as the slaughter of infected animals. NiV has been identified as the cause of isolated outbreaks in India, Bangladesh, Malaysia, and Singapore since 2000 and is included on the WHO R&amp;D Blueprint list of epidemic threats needing urgent R&amp;D action. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-1215, our vaccine candidate against the Nipah virus (NiV), was co-developed along with the NIH&#8217;s Vaccine Research Center. The Phase 1 clinical testing will be focused on pandemic preparedness. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SYSTEMIC SECRETED AND CELL SURFACE THERAPEUTICS MODALITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our systemic secreted and cell surface therapeutics modality currently has three active development programs, of which one has entered the clinic. We previously announced positive data from our Chikungunya Antibody program (mRNA-1944) within this modality. However, we do not expect to advance our Chikungunya Antibody program without outside funding, and we are not currently pursuing further development of it at this time. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IL-2 Mutein (mRNA-6231)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IL-2 is a critical cytokine for Treg activation and expansion and our product utilizes subcutaneous mRNA administration to produce a modified version of IL-2 in order to treat autoimmune diseases</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IL-2-based therapeutics are being clinically evaluated for a wide range of immune-mediated disorders, including rheumatoid arthritis, systemic lupus erythematosus, graft versus host disease, inflammatory bowel diseases, and autoimmune hepatitis. IL-2 is a cytokine, which are potent modulators of the immune system, directing function and homeostasis. IL-2 is critically important to T cell survival and function. IL-2 acts through a receptor complex that can be dimeric, IL-2R&#223; (CD122) plus the common &#947; chain (CD132), or trimeric, which is formed through the addition of IL-2R&#945; (CD25) to the dimeric form. The trimeric form has 10-fold to 100-fold greater affinity for IL-2. Under low or homeostatic IL-2 conditions, those cells which preferentially express the trimeric receptor, or IL-2R, such as Tregs and very recently activated effector T cells, are activated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our platform can be exploited to produce a modified IL-2 for the treatment of autoimmune conditions. Our modified IL-2 is engineered with mutations that selectively decrease binding to the dimeric IL-2 receptor present on CD4+ and CD8+ T effector cells and NK cells, and increase reliance upon CD25 of the trimeric IL-2 receptor complex to trigger the signaling cascade in regulatory T cells. Our modified IL-2 is also expressed as a fusion protein to extend its half-life in the serum. It is also the first demonstration of subcutaneous administration of the delivery technology that was also used our chikungunya antibody therapeutic, mRNA-1944.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-6231 is ongoing in a Phase 1 clinical study. The trial is a Phase 1, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-6231 in healthy adult participants (between 18-50 years of age), following subcutaneous administration of mRNA-6231. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PD-L1 (mRNA-6981)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PD-L1 is a co-inhibitory receptor that can induce anergy in programmed cell death protein 1 (PD-1)-expressing T cells and we intend to induce expression of PD-L1 on myeloid cells to send a tolerizing signal to immune cells in their environment in order to treat autoimmune diseases</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PD-L1/PD-1 pathway has a critical function in immune regulation and promotes development and function of Tregs. PD-L1 is a transmembrane protein expressed on antigen presenting cells, such as dendritic cells and macrophages, activated T cells, B cells, and monocytes as well as peripheral tissues. Its cognate receptor, PD-1, is a co-inhibitory transmembrane protein expressed on T cells, B cells, natural killer cells and thymocytes. Preclinical mouse models deficient in PD-1 spontaneously develop a variety of autoimmune diseases such as arthritis, myocarditis, lupus-like glomerulonephritis and type 1 diabetes, demonstrating the critical role of the PD-L1/PD-1 interaction in maintaining tolerance to self-antigens. Additionally, treatment of cancer patients with PD-1 or PD-L1 inhibitors sometimes results in immune-related adverse events, including the development of hepatitis, dermatitis and colitis, demonstrating the role of PD-1/PD-L1 in human autoimmune reactions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our PD-L1 therapy may augment PD-L1 expression on cell types similar to those that endogenously express it, and by reducing immune activation, potentially reduce the clinical manifestations of a variety of autoimmune diseases. Our intent is to use our platform to influence myeloid cells, including dendritic cells, to provide additional co-inhibitory signals by augmenting endogenous expression of PD-L1. We believe that this tolerizing signal to lymphocytes may limit autoreactivity in the context of ongoing autoimmune pathology without severe and global suppression of the immune system. Given that our platform allows us to modify myeloid cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in situ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our approach to the creation of a tolerogenic environment may provide unique benefits in treating autoimmune diseases by seeking to restore immune homeostasis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have investigated mRNA-6981 in a range of preclinical models of autoimmune and related diseases, including arthritis, type 1 diabetes, colitis and graft-versus-host disease, and observed disease-modifying activity. We are currently in preclinical studies for mRNA-6981. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relaxin (mRNA-0184) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relaxin is a vasoactive peptide associated with cardiovascular remodeling and we intend to encode for a relaxin fusion protein to treat decompensated heart failure </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relaxin is a naturally occurring hormone, present in both men and women, that has been shown to promote vasodilation and angiogenesis, regulate extracellular matrix turnover, and suppress arrhythmias post myocardial infarction. Subsequent studies have implicated relaxin&#8217;s role beyond pregnancy, through vasodilatory, antifibrotic, anti-inflammatory and protective effects on multiple organs. Relaxin activates a variety of pathways, contributing to the reduction of oxidative stress, fibrosis, and inflammation. There is a large body of evidence to support relaxin&#8217;s clinical potential in several therapeutic areas, with its impact on cardiovascular diseases having been studied in both preclinical and clinical settings. Though prior studies have failed to demonstrate long-term benefit in clinical studies, we believe a novel approach can overcome potential flaws of previous approaches.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-0184 is being developed to treat decompensated heart failure. Acute heart failure (AHF) is defined as the new onset or worsening of symptoms and signs of heart failure (HF). In developed countries, HF has become a substantial public health problem, affecting 2% of the adult population and AHF is the most frequent cause of unplanned hospital admission in patients of &gt;65 years of age. mRNA-0184 encodes for the relaxin fusion protein. The mRNA sequence of mRNA-0184 is engineered to increase protein expression and prolong half-life.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, we have shown preliminary protein expression data in nonhuman primates that supports the hypothesis of extended pharmacology relative to historical efforts with recombinant protein. We are planning for a Phase 1 study in participants with chronic heart failure. We expect that mRNA-0814 will be administered after heart failure decompensation to bridge patients through the vulnerable period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CANCER VACCINES MODALITY </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our cancer vaccines modality currently has three development programs, two of which have entered the clinic. We have regained all rights to our KRAS vaccine (mRNA-5671) from Merck and we are evaluating next steps for the program.  </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Personalized Cancer Vaccine (PCV) (mRNA-4157)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PCV encodes for up to 34 neoantigens designed against an individual&#8217;s patient tumor mutations and is ongoing in a Phase 1 and Phase 2 trial across a variety of indications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As tumors grow, they acquire mutations, some of which create new protein sequences, or neoantigens, that can be presented on human leukocyte antigen (HLA) molecules in the tumor and recognized as non-self by T cells. These neoantigens can be shared or are completely unique to an individual patient&#8217;s tumor. In addition to the neoantigens being unique and patient specific, the presentation of those neoantigens is also dependent on a patient&#8217;s specific HLA type. Identification of patient-specific HLA type and tumor neoantigens through next generation sequencing paired with our proprietary, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in silico</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> design of each patient&#8217;s mRNA vaccine and rapid manufacturing for a specific patient allows us to rapidly deliver a completely unique and personalized medicine to patients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our personalized cancer vaccine program, mRNA-4157, consists of an mRNA that encodes up to 34 neoantigens, predicted to elicit both class I (CD8) and class II (CD4) responses, designed against each individual patient&#8217;s tumor mutations and specific to their HLA type. The neoantigens are encoded in a single mRNA sequence and formulated in our proprietary LNPs designed for intramuscular injection. The mRNA sequence is then manufactured using an automated workflow to enable a rapid turnaround time. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 1 trial is an open-label, multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with the checkpoint inhibitor, pembrolizumab (marketed in the United States as KEYTRUDA&#174;), in subjects with resected and unresected solid tumors. mRNA-4157 is administered on the first day of each 21-day cycle for a maximum of nine doses. mRNA-4157 is administered as monotherapy (Part A) or in combination with pembrolizumab (Parts, B, C, and D) in the United States. Studies have shown mRNA-4157 to be well tolerated at all dose levels. The majority of adverse events from mRNA-4157 have been low grade and reversible. Encouraging data emerging from an expansion arm in patients with head and neck cancer has recently caused us to increase the size of that cohort, which continues to recruit trial participants. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The randomized, placebo-controlled Phase 2 study is investigating a 1 mg dose of mRNA-4157 in combination with Merck&#8217;s pembrolizumab (KEYTRUDA&#174;), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma. This study was fully enrolled (N=150) in September 2021 and the primary endpoint of the Phase 2 study is recurrence-free survival at 12 months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KRAS Vaccine (mRNA-5671)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Phase 1 study, led by Merck, is ongoing; we have retained all rights to our KRAS vaccine (mRNA-5671) from Merck and we are evaluating next steps for the program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncogenic driver mutations that encode targetable T cell neoantigens have considerable potential therapeutic implications: (1) driver mutations are subject to positive selection, as they confer survival advantages for the tumor, and (2) such neoantigens could be shared between patients, enabling an easier approach to developing and manufacturing such therapeutic or curative interventions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KRAS is a frequently mutated oncogene in epithelial cancers, primarily lung, colorectal cancer (CRC) and pancreatic cancers. The four most prevalent KRAS mutations associated with these malignancies are G12D, G12V, G13D, and G12C, which constitute 80% to 90% of KRAS mutations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 1 open-label, multi-center study to evaluate the safety and tolerability of mRNA-5671 both as a monotherapy and in combination with pembrolizumab, led by Merck, is ongoing. We have retained all rights to our KRAS vaccine (mRNA-5671) from Merck and we are evaluating next steps for the program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Checkpoint cancer vaccine (mRNA-4359)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are developing a checkpoint cancer vaccine that encodes antigens for Indoleamine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2,3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1) antigens </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our checkpoint vaccine aims to stimulate effector T cells that target and kill suppressive immune and tumor cells that express IDO and PD-L1 antigens. Following vaccine-mediated activation, IDO- and PD-L1-specific T cells kill immunosuppressive (regulatory) immune cells and cancer cells. Cancer cell killing and the reduction of regulatory immune cells tip the balance towards productively </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">inflammatory immune cells with signaling molecules &#8220;heating up&#8221; the tumor microenvironment, which leads to additional tumor killing by vaccine-activated T cells. T cell priming leads to recognition of additional tumor-associated antigens and to more tumor killing by tumor-specific cytotoxic T cells. Systemic PD-1/PD-L1 blockade may further amplify the effect, leading to further immune activation and superior disease control. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our initial indications for our checkpoint vaccine are advanced or metastatic cutaneous melanoma and non-small cell lung carcinoma (NSCLC). Melanoma is the fifth most common cancer diagnosis in the U.S. It accounts for approximately 5% of all new cancer diagnoses and 1.5% of all cancer-related deaths. Cutaneous melanoma is a cancer that starts in the melanocytes (pigment-producing cells) of the skin. If diagnosed at the local stage, the 5-year survival rate is approximately 95%. However, for regional or metastatic disease (stage IIIB+), 5-year survival rates decline to approximately 30 to 60%. Approximately 18,000 new patients are diagnosed with stage IIIB+ cutaneous melanoma in the U.S. Advanced melanoma, a rare and serious type of skin cancer, is responsible for most skin cancer-related deaths, despite representing only 1% of skin cancer cases. Current standard of care pembrolizumab, nivolumab or the combination of nivolumab + ipilimumab.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NSCLC frequently goes undetected, remaining asymptomatic until it has progressed to later stages. Approximately 115,000 people are diagnosed with metastatic NSCLC or progress to metastatic disease annually in the United States. The current approach to treatment of metastatic NSCLC treatment is dependent on the presence of PD-L1 expression. If tumor PD-L1 expression is greater than 50% pembrolizumab or atezolizumab monotherapy are preferred, while a combination of chemotherapy and pembrolizumab is preferred for patients with PD-L1 expression less than 50%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our checkpoint vaccine is currently in preclinical studies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRATUMORAL IMMUNO-ONCOLOGY MODALITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intratumoral immuno-oncology modality currently has two development programs, both of which are in the clinic. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OX40L/IL-23/IL-36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#947;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (Triplet) (mRNA-2752)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Triplet includes three mRNAs encoding human OX40L, interleukin 23 (IL-23) and interleukin 36 gamma (IL-36&#947;), that are encapsulated in our proprietary LNP and administered intratumorally </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite recent advances in immune-mediated therapies for cancer, the outlook for many patients with advanced cancer is poor. We are developing Triplet (mRNA-2752) and other programs to drive anti-cancer T cell responses by transforming cold tumor microenvironments into productive, &#8220;hotter&#8221; immune landscapes with local intratumoral therapies. Triplet (mRNA-2752) utilizes the intrinsic advantage of mRNA to multiplex and to produce membrane and secreted proteins with mRNA in a single investigational medicine. Triplet (mRNA-2752) includes three mRNAs encoding human OX40L, IL-23 and IL-36&#947; that are encapsulated in our proprietary LNP and administered intratumorally. OX40L is a membrane protein, whereas IL-23 and IL-36&#947; are secreted cytokines. We believe our approach has the advantage of localized high concentration gradients of IL-23 and IL-36&#947; compared to recombinant proteins administered systemically or intratumorally. Additionally, the mRNA for OX40L encodes for the wild type membrane protein, which we believe recombinant protein technologies cannot enable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing Triplet (mRNA-2752) for the treatment of advanced or metastatic solid tumor malignancies or lymphoma as a single agent or in combination with checkpoint inhibitors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA-2752 is ongoing in a Phase 1 open-label, multicenter, dose-escalation study. This study is evaluating the safety and tolerability of escalating intratumoral injections of mRNA-2752 alone and in combination with PD-L1 inhibitor (durvalumab) to define the maximum tolerated dose (MTD) or a recommended dose for expansion (RDE). The study consists of dose escalation and dose confirmation parts, which will occur in Arm A and Arm B, followed by a dose expansion part, which will occur in Arm B, and a Dose Exploration in Arm C as a neoadjuvant therapy for cutaneous melanoma. Enrollment in the dose expansion part of Arm B and Arm C is currently ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously announced the interim results of Part A in 2020. In 2021, we announced that the Phase 1 study demonstrates that Triplet given in combination with AstraZeneca&#8217;s durvalumab (IMFINZI&#174;) was tolerated at all dose levels tested and elicited evidence of anti-tumor activity. The recommended dose for expansion (RDE) is up to of 4mg mRNA-2752 + durvalumab. The study also demonstrated evidence of immunomodulation and expected pharmacodynamics in the tumor immune microenvironment (TME) of both injected and un-injected lesions, in both monotherapy and combination cases, as indicated by increases in proliferating (activated) </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T cells, PD-L1 levels (marker of interferon signaling), and T cell-inflamed (GEP) and DC transcriptional signature score, with greatest changes observed in patients with clinical benefit.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IL-12 (MEDI1191)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In collaboration with AstraZeneca, we are developing a mRNA that encodes for IL-12 encapsulated in our proprietary LNP delivered intratumorally</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another strategy for cancer patients with immunologically cold tumors is to transform the tumor microenvironment by introducing pro-inflammatory cytokines directly into tumors or draining lymph nodes. In collaboration with AstraZeneca, we are developing MEDI1191, which is an mRNA for IL-12 encapsulated in our proprietary LNP to be delivered intratumorally. Systemic administration of recombinant IL-12 protein was poorly tolerated in early clinical trials and exhibited generally low response rates. MEDI1191 can enhance the immune response by positively impacting both antigen presenting cells and T cells, and local, intratumoral expression of IL-12 can potentially improve tolerability compared to systemic protein treatments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MEDI1191 is being developed for the treatment of advanced or metastatic solid tumors in combination with a checkpoint inhibitor. MEDI1191 consists of our proprietary LNP encapsulating an mRNA for human IL-12B (p40) and IL-12A (p35) subunits. The mRNA produces a single-chain fusion protein of the IL-12B and IL-12A subunits, with a linker between the subunits. The mRNA sequence has been engineered to enhance protein production and is designed to decrease the amount of protein that might be made in hepatocytes for better tolerability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, treatment with IL-12 transformed the tumor microenvironment, with notable activation of natural killer and dendritic cells, and an increase in cytotoxic lymphocytes. AstraZeneca is leading the early clinical development and an open-label multicenter Phase 1 clinical trial of intratumoral injections of MEDI1191 alone and in combination with the checkpoint inhibitor, durvalumab, is ongoing. In 2021, we presented IL-12 data that show evidence of antitumor activity in injected and non-injected lesions as well as pharmacodynamic effects such as increased IL-12, Interferon gamma (IFN&#947;) and 12, and inflammatory transcriptome.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGENERATIVE THERAPEUTICS MODALITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our regenerative therapeutics modality currently has one development program, which is in the clinic. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VEGF-A (AZD8601) </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In collaboration with AstraZeneca, VEGF-A is a localized therapeutic encoding for the VEGF-A protein and addressing ischemic heart failure </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Heart disease is the leading cause of death in the United States, accounting for one in every four deaths, and is often due to the inability of adults to regenerate heart tissue. Current approved therapies do not specifically address heart regeneration. Previous attempts at cardiac regeneration have included stem cell grafting and gene therapy, but have faced challenges with safety or efficacy. Several treatments are available for patients with ischemic heart failure. Current treatments include revascularization of the coronary arteries to relieve symptoms and improve cardiac function and therapies that reduce blood pressure or potentially help eliminate excess fluids in congested tissues, including: beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II inhibitors, and aldosterone receptor blockers as diuretics. However, adult humans are unable to regenerate myocardium tissue following injury and the treatment options described above cannot compensate for this. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vascular Endothelial Growth Factor A (VEGF-A) is a potent angiogenic factor that promotes growth of blood vessels and acts as a powerful promoter of blood vessel growth. Systemic injection of VEGF-A protein increases VEGF-A exposure throughout the body, which can lead to side effects, but is very short-lived in circulation. Therefore, any therapy involving VEGF-A needs to be localized to elevate local protein concentration and drive revascularization while minimizing systemic side effects. AstraZeneca has opted to pursue the localized application of VEGF-A mRNA in a simple saline formulation in the heart muscle to elevate local protein concentration for longer periods due to increased local protein production. This potentially allows for an extended pharmacodynamic effect at the specific site of injection compared to systemic or local administration of a recombinant protein version of VEGF-A.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies have been conducted at AstraZeneca in models of ischemic heart failure. In mouse, rat, and pig models of myocardial infarction, direct injection in the heart muscle (myocardium) of VEGF-A mRNA led to elevated cardiac VEGF-A protein levels and improved cardiac function. The Phase 1a/b study was a randomized, double-blind, placebo-controlled study in men with type 2 diabetes mellitus conducted in Europe. VEGF-A mRNA was administered by intradermal injection into the forearm skin in single ascending doses. Administration of AZD8601 demonstrated protein production and changes in local blood flow in diabetic patients. Tolerability of our mRNA injected intradermally was demonstrated for all dose levels. The only causally treatment-related adverse events were mild injection-site reactions, occurring in 32 of 33 participants receiving VEGF-A mRNA across both parts of the study design. All adverse events of injection-site reaction were of mild intensity. No deaths, serious adverse events, or adverse events leading to discontinuation occurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AstraZeneca has also progressed VEGF-A (AZD8601) to a randomized, placebo-controlled, double-blind, multicenter, 6-month, Phase 2a clinical trial of the safety, tolerability, and exploratory efficacy of epicardial injections of AZD8601 in patients with stable coronary artery disease and moderately decreased left ventricular ejection fraction (LVEF) who are undergoing coronary artery bypass graft surgery. Exploratory efficacy endpoints included LVEF, NT-proBNP (a biomarker which measures the level of a hormone which is elevated in patients with heart failure), and functional patient reported outcomes. In 2021, the Phase 2 study met the primary endpoint of safety and tolerability of AZD8601 for the 3 mg dose. In the study of 11 patients, seven were treated with AZD8601 VEGF-A mRNA and four received placebo injections. Numerical trends were observed in endpoints in the heart failure efficacy domains compared with placebo, including increase in LVEF and patient reported outcomes. In addition, all seven patients treated with AZD8601 had NT-proBNP levels below heart failure (HF) limit at 6 months follow-up compared to one of four patients treated with placebo. AstraZeneca has announced that they intend to move AZD8601 into further studies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SYSTEMIC INTRACELLULAR THERAPEUTICS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our systemic intracellular therapeutics modality currently has five development programs, two of which are in the clinic. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Propionic acidemia (PA) (mRNA-3927)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PA is an inherited metabolism disorder with significant morbidity and mortality and our mRNA therapy is ongoing in a Phase 1 trial, aiming to produce an intracellular, mitochondrial enzyme complex to treat the disorder</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PA is a serious inborn error of metabolism disorder with significant morbidity and mortality. There are approximately 325-2,000 PA patients in the United States based on estimated birth prevalence (0.2-1.2:100,000 newborns) and mortality rates. The vast majority of patients present with life-threatening metabolic crises during the first few days or weeks of life, with mortality rates ranging from 13-53% during the neonatal period. The cardinal feature of the disorder is the occurrence of life-threatening acute metabolic decompensations that are more frequent in the first few years of life. Longer term sequelae include cardiac complications (cardiomyopathy, arrhythmias) and severe neurologic complications. The disorder is caused by a defect or deficiency in PCC, an enzyme that is one step upstream in the same metabolic pathway as the MUT enzyme that is deficient in MMA, as further described below. PCC is a complex hetero-dodecamer enzyme composed of six alpha subunits (PCCA) and six beta subunits (PCCB). The disorder is autosomal recessive, with PA patients generally having loss-of-function mutations in either PCCA or PCCB (and in rare instances, mutations in both PCCA and PCCB). The disorder is biochemically characterized by the accumulation of toxic metabolites such as 3-hydroxypropionic acid and 2-methylcitrate, among others, and these metabolites may be used as biomarkers of disease. There is no approved therapy for PA to treat the underlying defect, including no enzyme replacement therapy, due to the complexity of PCC and mitochondrial localization. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing an IV-administered combination mRNA approach, which contains two mRNAs, one for each of the subunits of PCC (PCCA and PCCB) encapsulated in our proprietary LNP (the same LNP formulation as mRNA-1944). The intent is to potentially treat the entire PA population, regardless of whether an individual has a defect or deficiency in the PCC alpha or beta subunit. The mRNA sequences have been engineered to improve protein translation and encode enzymatically-active PCC with the proper subcellular localization in the mitochondria.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have demonstrated activity in a PA mouse model in a long-term repeat dose study. In the 6-month repeat dose study in PA mice, a significant and sustained lowering of additional disease biomarkers (e.g., 2-methylcitrate, or 2MC) was observed throughout the duration of the 6-month study. mRNA-3927 is ongoing in a Phase 1/2 study, the Paramount Study, and the first cohort is fully enrolled, and cohort 2 enrollment is ongoing. The study&#8217;s objective is to evaluate the safety and pharmacology of mRNA-3927 in patients 1 year of age and older with PA. The primary endpoints are safety and pharmacokinetics and pharmacodynamics. Secondary endpoints include incidence and severity of adverse events (AEs) and change in plasma biomarkers: methylcitric acid (2-MC) and 3-Hydroxypropionic acid (3-HP). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Designation from the FDA and Orphan Drug Designation from the European Commission for the PA program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Methylmalonic acidemia (MMA) (mRNA-3705)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MMA is an inherited metabolism disorder with significant morbidity and mortality and our mRNA therapy is ongoing in a Phase 1 trial, aiming to produce an intracellular, mitochondrial enzyme complex to treat the disorder</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are an estimated 500-2,000 MMA MUT deficiency patients in the United States based on estimated birth prevalence (0.3-1.2:100,000 newborns) and mortality rates. Mortality is significant, with mortality rates of 50% for MMA patients with complete MUT deficiency (mut </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) (median age of death 2 years) and 40% for MMA patients with partial MUT deficiency (mut </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) (median age of death 4.5 years) reported in a large European study. MMA mainly affects the pediatric population and usually presents in the first few days or weeks of life. The occurrence of acute metabolic decompensations is the hallmark of the disorder and decompensations are typically more frequent in the first few years of life. Each decompensation is life-threatening and often requires hospitalization and management at an intensive care unit. Surviving patients often suffer from numerous complications including chronic renal failure and neurologic complications such as movement disorders, developmental delays, and seizures. Consequently, the health-related quality of life for MMA patients and their families is significantly impaired.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disorder is autosomal recessive and primarily caused by loss-of-function mutations in the gene encoding MUT, a mitochondrial enzyme that metabolizes certain proteins and fats, resulting in complete (mut </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) or partial (mut </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) enzyme deficiency. There are currently no approved therapies that address the underlying defect for MMA. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing an mRNA encoding human MUT encapsulated in our proprietary LNPs for IV administration for the treatment of isolated MMA associated with MUT deficiency. The sequence has been engineered to improve protein translation. To function, the mRNA-encoded MUT protein is translocated to its site of action in the mitochondria. mRNA-3705 is our second generation MMA development candidate.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously demonstrated, in a series of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pharmacology studies, that human MUT mRNA effectively directs the biosynthesis of active MUT protein with physiologically correct mitochondrial localization in vitro, and improves survival and corrects biochemical abnormalities in two different mouse models of MMA representing the spectrum of MUT deficiency (mut0 and mut-). Technology and process improvements enabled the development of an updated drug product, mRNA-3705, which shows greater potency and better pharmacology compared to our prior candidate, mRNA-3704. mRNA-3705 is currently ongoing in a Phase 1/2 study, the Landmark Study. The study is an adaptive, open-label study is designed to evaluate the safety and tolerability of up to five different dosing regimens of mRNA-3705 administered via intravenous infusion in patients one year and older with isolated methylmalonic acidemia due to methylmalonyl-CoA mutase (hMUT). Upon establishment of an optimized dose based on safety and pharmacological data, additional patients may be enrolled in an optional expansion cohort. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Glycogen storage disease type 1a (GSD1a) (mRNA-3745)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GSD1a is an inherited metabolism disease and our approach is to use an mRNA encoding for intracellular human glucose 6-phosphatase </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GSD1a is an inherited metabolic disorder caused by a deficiency in the catalytic activity of G6Pase. G6Pase catalyzes the hydrolysis of glucose-6-phosphate to glucose and inorganic phosphate, the final step of glycogenolysis and gluconeogenesis that mainly takes place in the liver and kidneys. GSD1a patients suffer from severe fasting hypoglycemia, hepatomegaly, nephromegaly, lactic acidemia, hypertriglyceridemia, hyperuricemia, hypercholesterolemia, hepatic steatosis, and growth retardation. In addition, hepatocellular adenomas occur in 70% to 80% of GSD1a patients by their third decade of life and carries risk of transformation into hepatocellular carcinomas. Proteinuria has been observed in over half of patients above 25 years of age. GSD1a occurs in approximately 1:100,000 live births in the United States and European Union but is more common in Ashkenazi Jews where the incidence is reported to be 1:20,000 live births. There are an estimated 2,500 people in the United States and over 4,000 people in the European Union with GSD1a. Although strict diet therapy, including frequent feeding with uncooked cornstarch, allows GSD1a patients to live into adulthood by preventing hypoglycemia, the underlying pathological processes remain uncorrected resulting in the development of many long-term complications including liver adenomas and hepatocellular carcinoma.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our program, mRNA-3745, consists of an mRNA encoding for modified human G6Pase encapsulated in our proprietary LNPs. The human G6Pase sequence is modified for improved protein production and G6Pase activity. mRNA-3745 is designed to be administered intravenously and encodes G6Pase protein to restore this deficient or defective enzyme.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted several </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pharmacology studies to demonstrate preclinical proof-of-concept for GSD1a therapy. mRNA encoding for G6Pase introduced in human cells resulted in robust production of active G6Pase with subcellular localization into endoplasmic reticulum. mRNA-3745 has been granted Orphan Drug Designation by the U.S. FDA as well as the European Medicines Agency (EMA) and has an open IND. The Phase 1 study will evaluate the safety and pharmacology of mRNA-3745 in patients 18 years of age and older with GSD1a. The Phase 1 study, the Balance Study, is a single dose escalation study in adult participants diagnosed with GSD1a. The primary objective is to determine the safety and tolerability following a single dose of mRNA-3745. Secondary objectives are to evaluate pharmacokinetics and pharmacodynamics of mRNA-3745 in adult GSD1a patients. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phenylketonuria (PKU) (mRNA-3283)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PKU is a rare inherited metabolic disease is and our approach is to use an mRNA encoding for intracellular phenylalanine hydroxylase (PAH) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phenylketonuria (PKU) is a rare inherited metabolic disease resulting from a deficiency in the metabolism of phenylalanine (PHE) due to mutations within the enzyme phenylalanine hydroxylase (PAH). The most effective treatment is a restrictive diet of low protein, which controls PHE intake. Approximately 20-56% of PKU patients respond to sapropterin dihydrochloride (marketed as Kuvan in the United States), a synthetic BH4 cofactor for PAH which improves PHE metabolism, but does not fully cure patients. In addition, in May 2018, Biomarin received approval for pegylated phenylalanine lyase (PAL), marketed as Palynziq. Palynziq is a pegylated recombinant bacterial enzyme which metabolizes PHE in the blood. We believe the immune risk is, at least in part, driven by bacterial PAL. PKU occurs in approximately 1:10,000-15,000 live births in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on current population estimates that would translate into approximately 21,000-32,000 PKU patients in the United States. Affected individuals have a deficiency in the enzyme PAH, resulting in a reduced or complete inability to metabolize the essential amino acid phenylalanine into tyrosine. Thus, PKU patients suffer from a phenylalanine intoxication and a subsequent deprivation of tyrosine, leading to severe mental disability if left untreated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our program mRNA-3283 consists of an mRNA encoding human PAH encapsulated in our proprietary LNPs. The mRNA sequence is optimized for protein synthesis and contains a microRNA binding site to reduce or potentially eliminate synthesis of protein outside of the target tissues. mRNA-3283 is designed to be administered intravenously to encode enzymatically-active PAH protein in liver to restore this deficient or defective enzyme.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted several </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pharmacology studies to demonstrate preclinical proof-of-concept for PAH therapy. A PKU mouse model demonstrated a significant reduction of blood PHE levels post dose. mRNA-3283 is ongoing in preclinical studies. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Crigler-Najjar Syndrome Type 1 (CN-1) (mRNA-3351)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CN-1 is a severe condition caused by the mutations in the UGT1A1 gene and our approach, in collaboration with the Institute of Life Changing Medicines (ILCM), is to encode for the human UGTA1A1 protein </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Crigler-Najjar syndrome is a severe condition characterized by high levels of a toxic substance called bilirubin in the blood (hyperbilirubinemia). It is caused by the mutations in the UGT1A1 gene in which bilirubin, a substance made by the liver, cannot be broken down. Without this enzyme, bilirubin can build up in the body and lead to jaundice and damage to the brain, muscles and nerves. The symptoms become apparent shortly after birth and can be life-threatening. It is estimated that there are only approximately 70-100 known cases of CN-1 in the world. Affected individuals rely on current standard of care, phototherapy treatments of up to 12 hours a day, throughout life. The only definitive treatment is liver transplant that is associated with its own set of side effects and risk of death.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our program, mRNA-3351, consists of an mRNA encoding human UGTA1 encapsulated in our proprietary LNPs. It is designed to restore the missing or dysfunctional proteins that causes CN-1. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed mRNA-3351 to ILCM with no upfront fees and without any downstream payments. The goal of the collaboration is to make an mRNA therapy for the treatment of CN-1 available at no cost to patients. ILCM will be responsible for the clinical development of mRNA-3351.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INHALED PULMONARY THERAPEUTICS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inhaled pulmonary therapeutics modality currently has one development candidate. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cystic Fibrosis (CF) (VXc-522)</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CF is a multi-system disease caused by the mutations in the CFTR gene and our approach, in collaboration with Vertex, is to deliver mRNA to the lungs to provide functional CFTR protein expression that translates to transformative clinical benefit </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CF is a rare genetic disease, which is progressive from birth and leads to multi-organ damage and early death due to lung dysfunction. It is caused by the mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in the loss of CFTR chloride ion channel function. This decreased function of CFTR at the cell surface leads to thick, sticky mucus in multiple organ systems but most pathologically the lungs. It is estimated that there are ~75,000 patients with cystic fibrosis in the world, with ~10% of these patients not addressable with the approved CFTR modulators. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our program is designed to treat the underlying cause of CF by enabling cells in the lungs to produce functional CFTR protein for the treatment of the 10% of patients who do not produce any modulator-responsive CFTR protein. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Latest data and next steps</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are collaborating with Vertex on our CF candidate, VXc-522. Pre-clinical studies are ongoing and Vertex expects to submit an IND in 2022. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2471"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing plays a critical role in our value chain and our ability to develop a new class of medicines. Our manufacturing capabilities support every stage of the development of our products, from new product ideas to commercialization. During the research stage of product development, manufacturing provides mRNA drug substance and drug product for platform research and therapeutic area drug discovery. During early development of our investigational medicines, we manufacture mRNA and drug product for IND-enabling GLP toxicology studies and initial human clinical studies. For late clinical development, we produce mRNA and drug product for phase 3 studies. At the commercial stage of development, we manufacture drug substance and drug product in collaboration with our contract manufacturing organizations (CMOs), both in the U.S. and internationally. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to date has been to proactively invest and build manufacturing capacity internally and externally with our network of strategic partners in anticipation of demand. This capacity was immediately leveraged and expanded during our COVID-19 vaccine ramp-up into a commercial product in response to the ongoing pandemic. Our ability to rapidly accelerate our manufacturing capabilities in response to COVID-19 allowed us to ship 807 million doses of our COVID-19 vaccine globally in 2021, compared to 17 million doses in December 2020. We are committed to further increase our manufacturing capacity substantially in 2022.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of our manufacturing operating model</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing activities generally focus on the following:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Commercial Production:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Our manufacturing expertise includes state-of-the-art technologies for mRNA and drug product manufacturing, as well as quality control testing to attain a robust and consistent supply that matches target product profiles. Our manufacturing technology is built to scale-up and support industrialization of products for commercial approval.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Research and Development Support:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product supply enables platform research and drug discovery in our therapeutic and vaccine areas, in addition to activities related to clinical studies of our investigational medicines.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our expectations for significant ongoing pipeline expansion and the long lead time required to build manufacturing infrastructure, we built a dedicated in-house manufacturing facility in Norwood, MA, the Moderna Technology Center (MTC), which we have since expanded to a multi-building campus. The MTC provides supply for our preclinical research, IND-enabling GLP toxicology study supplies, our Phase 1 and Phase 2 pipeline activities, later-stage clinical development activities (e.g., Phase 3 CMV vaccine clinical trials), as well as COVID-19 vaccine drug substance production.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The MTC campus has been designed with a high level of automation and state-of-the-art digital integration to handle manufacturing execution, product testing and release, and regulatory filings. In addition, substantial manufacturing capabilities are realized via CMO relationships in the United States and abroad, providing drug substance and fill-finish capacity for the COVID-19 vaccine. Much of the production for our COVID-19 vaccine supply for the U.S. market is completed at the MTC campus, with additional production by Lonza Ltd. (Lonza). We have also partnered with Lonza to complete production in Switzerland of our COVID-19 vaccine for markets outside the United States, as well as with National Resilience, Inc. to manufacture drug substance at its facility in Ontario, Canada for distribution worldwide. Fill-finish services for our COVID-19 vaccine are provided by Catalent Inc., Thermo Fisher Scientific, Sanofi and Baxter BioPharma Solutions in the United States, and by ROVI (in Spain), Recipharm (in France) and Samsung Biologics (in South Korea) outside the United States. We have also partnered with other CMOs for the production of and fill-finish services of our COVID-19 vaccine, and expect that we will enter into additional collaborations as we continue to scale. In April 2021, we announced additional investments in manufacturing to increase supply at our owned and partnered manufacturing facilities, with the goal of increasing our global 2022 capacity for COVID-19 vaccine production. In May 2021, we announced the planned expansion of the MTC, which we expect to more than double the space at the MTC and allow us to continue to optimize our mRNA products as we explore new pharmaceutical delivery forms such as prefilled syringes and lyophilized products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, in February 2022, we announced new collaborations with ROVI and Thermo Fisher Scientific (Thermo Fisher) for manufacturing capabilities. With ROVI, we agreed to a ten-year collaboration to increase manufacturing capacity at ROVI&#8217;s facilities in Spain. In addition to producing our COVID-19 vaccine, we expect that ROVI's platform may be utilized to service other vaccine candidates in the future. With Thermo Fisher, we agreed to a fifteen-year collaboration to enable dedicated large-scale manufacturing in the United States of our COVID-19 vaccine and other investigational mRNA medicines in our pipeline.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during 2021 we announced agreements in principle with the governments of Canada and Australia to establish mRNA manufacturing facilities in those countries. These agreements are subject to final negotiation, but we envision entering into long-term supply agreements with these countries for the supply of mRNA vaccines. By establishing manufacturing facilities locally, we will also provide these governments with direct access to rapid pandemic response capabilities. We are in active discussions with other governments to provide similar manufacturing capabilities in other geographies.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have further committed to building a state-of-the-art mRNA facility in Africa to provide a local source of mRNA medicines for the continent, in part to prepare for future pandemics. We expect to invest up to $500 million in this facility and anticipate that once fully operational, it will be capable of producing up to 500 million doses of vaccines annually at the 50 &#181;g dose level.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing technology development</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To support our broad pipeline of products, which span multiple therapeutic areas and routes of administration (e.g., intramuscular, intratumoral, and intravenous), there is close collaboration between our platform research and technical development teams to facilitate rapid and seamless clinical translation of scientific breakthroughs. This, in turn, enables us to develop potential vaccines and therapies to serve a widening patient population.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technical development encompasses the design and optimization of robust and consistent manufacturing processes, product characterization, fit-for-purpose formulations, and product presentations. For instance, our novel hardware platforms&#8217; automation and robotics, coupled with the flexibility of our in-house digital development systems, allows for thousands of experiments and process parameters across our projects, thus supporting our drug product pharmaceutical readiness. Moreover, our recent technical manufacturing advances have enabled internalization of new key capabilities, including DNA plasmids and small molecules.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In parallel, we have refined existing processes, resulting in increased manufacturing scale and more robust stability of our mRNA and drug product. These improvements allow us significant control over our supply chain, resulting in larger production yields and longer shelf life of our products. Furthermore, formulation development advancements have added new drug product images, including lyophilization, giving us a path from frozen to refrigerated storage conditions.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our substantial investments in recent years in technical development has enabled the breadth and depth of our pipeline, and laid the foundation to help meet the needs and requirements associated with late stage development and the commercialization of the COVID-19 vaccine.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply of mRNA for All Stages of Product Development and Commercialization </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply for Research</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">High-throughput automation and custom engineered equipment allow us to produce and deliver high quality mRNA and formulated constructs in a short period of time: our proprietary platform is capable of producing up to 1,000 lots of mRNA sequences and formulations per month with a turnaround time of a few weeks from sequence to final product. The typical scale of mRNA manufactured by this team is 1&#8211;1,000 mg. This has been possible, in part, thanks to the ability of researchers in the Moderna ecosystem to order constructs through an integrated digital portal that tracks materials end-to-end in less than 45 days. In addition, multiple integrated algorithms that leverage artificial intelligence and machine learning optimize manufacturability, reduce failures, and increase quality of mRNA sequences.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply for Early Development</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established manufacturing capabilities that support the early development stage of product development in three key areas: GLP Tox, Clinical Studies, and Personalized Cancer Vaccines. We supply mRNA and formulated product to conduct IND-enabling GLP toxicology studies. In addition, human clinical studies rely on supply to meet required cGMP standards. This is achieved via internal manufacturing at the MTC and external manufacturing at well-established CMOs. We select specialized CMOs to support our portfolio. We will continue to selectively partner with CMOs to complement our capacity and provide supply contingency where needed. Our MTC facility is also suited to enable rapid technology development and scale-up for future needs. Our manufacturing also produces cGMP PCVs. Due to the specialized nature of personalized medicine (i.e., where a batch is specifically designed and manufactured for a single patient), the manufacturing Personalized Vaccine Unit (PVU) has unique requirements. We digitally integrate patient-specific data from sequencing tumor samples to automatically design PCVs for patients. We have developed proprietary bioinformatics designed algorithms linked to an automated manufacturing process for rapid production of formulated mRNA, with a typical turnaround time of a few weeks. We have operationalized PCV manufacturing at the MTC campus to meet our Phase 1 and 2 pipeline supply needs by using single-use systems with fast &#8220;needle-to-needle&#8221; turnaround times. Unlike traditional process development, each PCV batch is manufactured for a single patient and thus scaled-out (in parallel) with extensive use of automation and robotics to account for the larger number of patients involved in later phases of development and commercialization. We have shown consistent quality in our production of over 160 patient batches, each with unique mRNA sequences.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These capabilities have allowed us to build our broad pipeline of 44 development programs, including the output required to supply related toxicological and human clinical studies. While the technology that underpins these programs is the same, each program typically requires customization based on target product profiles. These custom features range from varying molecular architecture to different routes of administration, often requiring multivalent products. For example, our CMV vaccine (mRNA-1647) requires six different mRNA sequences to be manufactured for inclusion in an intramuscular mRNA medicine, whereas our COVID-19 vaccine (mRNA-1273) requires a single mRNA sequence for inclusion in an intramuscular mRNA medicine. All programs, with the exception of PCV, require that we progressively scale up supply to meet clinical demand requirements across development phases, in addition to </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the necessary preparation for regulatory approval and commercial production, which demand larger batch sizes. In contrast, the PCV program seeks to develop a cancer vaccine that is designed and manufactured for a specific patient, thus increasing the number of unique batches. As we scale manufacturing output for each program, we plan to continuously improve yield, purity, and the pharmaceutical properties of our development candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply for Late-Stage Development and Commercialization</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to manufacture our COVID-19 vaccine, our development pipeline continues to advance to later-stage development and towards commercialization. Our platform approach allows us to continue to evolve our manufacturing suites and other capabilities at our MTC campus. Building expansions and enhancements have continued throughout scale-up of our COVID-19 vaccine manufacturing capabilities. The modular nature of the MTC suites permits us to manufacture multiple products in parallel. For instance, we can produce drug substance and drug product for our phase 3 CMV clinical trial while manufacturing COVID-19 drug substance in the same facilities.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quality Unit</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality is core to the way we operate. We seek to ensure quality at Moderna through a combination of a robust Quality Management System (QMS), our quality culture, and our people. In accordance with applicable regulations, we have established, documented, and implemented a QMS to assure continued compliance with the requirements therein. The QMS facilitates cGMP compliance by implementing practices that identify the various required processes, their application throughout the organization, and the sequence of interaction of these processes.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary mode of documenting these key practices is through policies, standard operating procedures (SOPs), forms, and other quality records, which include an overarching Quality Policy and Quality Manual. We have implemented measurement tools and metrics to monitor, measure, and analyze these practices to support cGMP operations, achieve planned results, and support continuous improvement. We monitor these quality metrics through formal governance processes, including Quality Management Review (QMR), to enable continuous improvement. We have also established an independent Quality Unit that fulfills quality assurance and quality control responsibilities.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Quality Unit grew into an international organization with the introduction of COVID-19 vaccine manufacturing. Quality drives our quality culture and ensures it is applied consistently and thoughtfully across the globe.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Quality Unit is ultimately accountable and responsible for quality, this is a shared responsibility. All cGMP personnel are empowered to ensure quality systems are appropriately maintained and executed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a culture that encourages transparency, accountability, and ownership of quality at all levels in the organization. As we scale the quality organization, we have focused on hiring the best talent with the required experience, training, and education.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply Chain Unit</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established an international supply chain to enable supply of the raw materials used to produce our mRNAs and the components of our formulations, securing supply for COVID-19 vaccine alongside clinical and preclinical demands. We have worked with our supply chain vendors to characterize critical raw materials and to understand their impact on the quality of mRNA drug substance and formulated drug product. We also assess the quality system and performance of our supply chain vendors and work with them to comply with regulatory requirements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2492"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIGITAL INFRASTRUCTURE</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that digital technologies, such as robotics, automation, artificial intelligence (AI) and cloud computing, are critical to operationalize our strategy, accelerate our pace of learning and execute at scale. We aspire to digitize our operations wherever possible, with the goal of using the power of digital technology to maximize our impact on patients. Since our inception, we have invested heavily in our digital technologies, robotics/automation, analytics, data science and AI. To facilitate our growth, we will continue to invest in our digital infrastructure. Construction has begun on our new Moderna Science Center in Cambridge, which is designed to integrate digital-first scientific research and development labs. Our approach to bring these digital technologies into our workflows and processes has involved the following:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">utilization of a consistent set of digital building blocks;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">application of digital technologies in multiple business processes; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rapid iterations for maximum optimization.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have seen several benefits from our investments in digitization, most importantly through the depth of our platform technology and breadth of our pipeline. Other benefits include:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quality: Reduction in human errors by enabling automation, repeatability, and seamless integration;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Scalability: Growth in our pipeline to 44 development programs;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Speed: Rapid manufacture of cGMP product, as exhibited by our first COVID-19 vaccine batch, and research-grade mRNA; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost efficiencies: Digital infrastructure utilized across our platform, drug discovery, clinical development, and manufacturing to maximize efficiencies.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our digital building blocks</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize six building blocks for our digital infrastructure:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cloud enablement&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a critical component of our digital infrastructure. We are at the forefront of mRNA technology. We generate complex data</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sets, and our scientists need computational power and agility to operate without being limited by traditional computing technology. Maintaining digital infrastructure in the cloud provides the benefits of lower costs by simplifying provisioning and administration, flexibility, scalability, ease of maintenance, disaster recovery, and information security.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Integration of business processes&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enables us to streamline processes and bring data together in a consistent manner, avoiding caches of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information and manual intervention. This efficient flow of data between systems enables the automation of our business processes.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Internet of things&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allows for smart interconnected devices that provide real-time synchronization of operations. The data from equipment</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provides real-time guidance to our scientists and engineers and helps us in supply chain and manufacturing with compliance and traceability, including tracking material, controlling inventory and optimizing instrument usage.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Automation&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allows us to scale our operations reliably and reproducibly. With the help of custom hardware solutions and state-of-the-art robotics,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we can continue to increase our operating efficiency, reduce errors, and improve our quality and compliance.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Advanced analytics&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enable us to draw insights from our data. We are constantly generating large data sets that can provide important insights if</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mined appropriately and regularly.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">AI</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is enabling key breakthroughs in predictive modeling. It will allow us to improve our mRNA design algorithms</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on machine learning, and will provide us with critical insights into research, supply chain, manufacturing, and other processes.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Digital technologies to enable our drug discovery efforts</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have deployed multiple digital technologies to drive a rapid pace of learning, enable efficient workflows and business processes, and draw insights from vast amounts of data. Our aim is to provide our platform and discovery scientists with access to an environment that helps them through each step of their research cycle.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug Design Studio:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary in-house digital application suite contains a Sequence Designer module to tailor an entire mRNA, with ever-improving</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rule sets that contain our accumulated learning about mRNA design. Drug Design Studio utilizes cloud-based computational capacity to run various algorithms we have developed to design each mRNA sequence. The utility of cloud-based capacity allows us to provide flexible computational capacity on demand, allowing us to power parallel intake and design of multiple mRNA sequences. Once a sequence is designed, it can be ordered digitally using an internal order form application within Drug Design Studio.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacture of research-grade mRNA:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an order is optimized, the mRNA production process is triggered. We have developed proprietary interfaces</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that allow the manufacturing team to track production orders at every stage. We have automated several manufacturing steps using both off-the-shelf and custom automation. The equipment used in the manufacture of research-grade </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA is integrated with the digital interfaces to capture, extract, and interpret the data generated at each step of the manufacturing process, building digital traceability on each mRNA order. We have also embedded real-time algorithms and analytics tools to allow for automated decision-making at some stages, accelerate the quality control workflows, and provide for continuous improvement of manufacturing processes.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dispatching and shipping mRNA:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we produce large quantities of research-grade mRNA, we require digital tools to track their shipment to our</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scientists and to external contract research organizations (CROs) conducting&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;studies. Our dispatching and shipping application automatically generates bar-coded labels, allowing for traceability of product.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and registry:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Material used in research and created in production, including mRNA, cell lines, chemicals, and reagents, is tracked in our Inventory</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application. This application supports numerous workflow tools such as consumption, aliquoting, material transfer, and stock alerts. Critical material types are assigned unique registry identification by our Registry application.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Study design:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our Drug Design Studio, our scientists can design their</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">studies using our proprietary Study Design application. This application</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">captures&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;study protocol design parameters, including dose amount, number of doses, frequency, samples, and assays for each sample. This application serves two purposes. It allows our scientists to maintain and track their&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;study designs and associated research grade mRNA. Our Study Design application also allows our&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;pharmacology teams to track the various ongoing studies and leverage external CROs to manage the&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;demand as needed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Experiment management:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have deployed Electronic Lab Notebooks for experiment management, allowing our scientists to streamline documentation of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their experiments and track it in a standardized, searchable repository. We have also integrated Electronic Lab Notebooks further with our other research tools to connect inventory,&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;studies, and instrument data.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advanced analytics and AI to accelerate the pace of learning:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize AI to enable various parts of our platform and drug discovery. Examples include:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Neural networks for protein engineering</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: One way to optimize the efficacy of the proteins encoded by our mRNA is to engineer the sequence of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the protein itself. We use neural networks to analyze and model protein sequences. We train these models by inputting orthologous sequences from thousands of organisms, from which we can generate potential protein sequences optimized for specific attributes.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Neural networks for mRNA engineering</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The redundancy in the genetic code allows for a large number of mRNA sequences that encode the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">same protein. mRNA sequence may impact translation, thereby impacting the amount of protein produced in circulation. We are developing AI tools to predict mRNA sequences that can enhance protein expression.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Automated Sanger sequencing analysis</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Sanger sequencing is used repeatedly to quality check (QC) our DNA templates and final mRNA; while the data contain every nucleotide in a sequence, it is very complex to analyze. A fully automated data pipeline starts processing raw data the moment it is saved to the cloud by the sequencers. The pipeline spawns numerous AWS computer servers to run an analysis algorithm and then shuts the servers down, minimizing costs. The results are viewable in a powerful, dynamic visualization tool. We have run over three million Sanger data files through this system. We have further improved our Sanger analysis with a convolutional neural network (CNN) to better analyze the tail sections of mRNA as well.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Digital technologies to enable our clinical trials</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have deployed multiple digital technologies to drive the rapid pace of advancement, in parallel, of our development candidates into the clinic.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Digital systems for cGMP manufacture:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to having integrated systems connected with robotics to drive our manufacturing in a paperless</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">environment, and have designed and deployed automation to drive efficient manufacturing operations. We have also deployed digital tools within manufacturing process development that give us the ability to track, analyze, and rapidly deploy manufacturing process improvements. Additionally, we have implemented several digital systems across manufacturing process development, quality, supply chain, and operations, including:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enterprise Quality Management System (QMS) to electronically manage deviations, investigation, and correction and preventive actions;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Laboratory Information Management System (LIMS) to manage our analytical development data and automate our manufacturing quality control;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computerized maintenance management system to manage equipment maintenance and calibration; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SAP/S4 Hana system for enterprise resource planning (ERP), manufacturing execution system, and manufacturing control system to manage inventories, track raw material consumption, digitally integrate equipment with manufacturing recipes in batch records, and control automated equipment.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Digital systems for clinical development and clinical operations:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to track the timelines of various development candidates, we have created a set of integrated applications. Workflows include timelines for regulatory filings, planning for IND-enabling GLP toxicology studies, scheduling for cGMP manufacturing, and clinical operations management. Below is a summary of our applications:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our portfolio application is a digital interface that maintains and tracks the timelines across multiple workstreams for each of our development candidates.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The supply application manages the manufacturing schedule of IND-enabling GLP toxicology supplies and cGMP manufacture of clinical supplies to support our programs. This application helps us see how the manufacturing schedule changes over time, identifies supply/demand mismatches, and enables resource planning with real-time alerts should we have any issues.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The GLP toxicology application tracks the planned and ongoing IND-enabling GLP toxicology studies and allows us to manage timelines with our external vendors.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory application tracks timelines related to regulatory affairs including, pre-IND meetings, IND/CTA submission dates, and other planned regulatory interactions.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical operations application allows us to track our ongoing trials by accessing clinical operations information in real-time from our CROs. It also has multiple tools and analytics to draw key insights, including, for example, enrollment by trial and enrollment by site to maintain our program timelines.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Digital systems for PCV:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PCV program aims to design, manufacture, and deliver a drug product that includes an mRNA sequence encoding for each</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patient&#8217;s specific neoantigens. The personalized nature of the PCV program adds additional steps and complexity in the overall patient treatment process. We have addressed those additional steps and complexity by digitizing and automating steps within the process, as described below.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each patient is provided a unique identifier. We track the entire workflow using a single integrated tracker based on this unique identifier. This is one of many ways we ensure that each patient receives the specific drug product lot manufactured for them.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use neural networks to design the mRNA sequences for the PCV program. Our proprietary vaccine design algorithm selects the top twenty neoantigens to be used and determines their amino acid sequences to trigger the desired immune response.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We utilize Monte Carlo simulations of PCV supply/demand to manage our capacity. Since each drug product lot is personalized to a patient, there is a need to manage supply and demand to avoid bottlenecks at any stage of the workflow.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Digital systems for commercialization:&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment in our digital capabilities prepared us to rapidly scale our production of our COVID-19 vaccine in 2021 and 2022. We are continuing to build out our commercial capabilities to establish medical affairs engagements with doctors, support our sales and marketing capabilities and deliver a world-class patient experience. In addition to a patient- and doctor-centric view, our commercial capabilities will strengthen our supply chain demand forecasting and our compliance. We are looking at building a robust serialization process for regulatory requirements as well as anti-counterfeiting technologies to ensure safe, efficacious medicines to patients.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Digital technologies to support our business processes</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have deployed several digital systems across finance, manufacturing, and human resources to automate our business processes and drive efficiencies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the SAP S4/Hana system for ERP.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented various cloud-based solutions to improve business processes and drive efficiencies. For example, we have implemented the Workday system for human resource planning and management and integrated various applications across payroll, 401(k) services, equity plan management and expense reporting. Our class-leading integration platform, Dell Boomi, allows us to have a highly interconnected environment, moving us from simple cloud-to-cloud integrations to an evolving use of the integration platform for master data management, systems account management, and ultimately for cost savings and improved user experience.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMERCIAL</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have grown our U.S. and international commercial sales organization beginning in early 2020 as we prepared for the commercialization of our COVID-19 vaccine. We have active commercial subsidiaries in 11 countries, including the U.S., Canada, many European countries and the Asia Pacific region, providing us with local commercial teams in key markets around the world. This commercial presence is supported by the Moderna International Business Service center in Warsaw, Poland. Our commercial teams also work in conjunction with third-party distributors and other partners in countries where we do not have a presence. In February 2022, we announced our intention to establish a commercial presence in six additional markets in Europe and four additional markets in Asia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our COVID-19 vaccine has been sold to government customers and international purchasing organizations, such as Gavi, on behalf of the COVAX Facility, and the African Union. We anticipate that most of our COVID-19 vaccine sales in 2022 will continue </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be pursuant to government contracts and these international purchasing organizations. We expect future sales to private customers if and as we gain marketing approval in various jurisdictions.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, during 2021, we announced agreements in principle with the Canadian and Australian governments to establish mRNA manufacturing facilities in those countries, pursuant to which we would enter into long-term supply agreements for mRNA vaccines. See &#8220;Manufacturing&#8221; above for further detail. </span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2513"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THIRD-PARTY STRATEGIC ALLIANCES</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic alliances</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To accelerate the discovery and advancement of potential mRNA medicines across therapeutic areas, we have entered into, and intend to seek other opportunities to form, alliances with a diverse group of strategic collaborators. We have forged productive strategic alliances with pharmaceutical and biotechnology companies, government agencies, academic laboratories, foundations and research institutes with therapeutic area expertise and resources. Through our collaborations, we seek to advance our discovery and development programs, while leveraging our platform and our research and early development capabilities. We also seek to partner with and invest in companies developing other types of therapeutics, such as gene editing and cell-therapy, where we believe we can leverage our core mRNA and LNP capabilities to expand the reach of our technology.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through certain of our strategic alliances, we share the rewards and risks of developing a new mRNA modality or program, where we may have early research data and desire a strategic collaborator to join us in advancing early development candidates within such modality into the clinic. Representative relationships and associated programs include those with:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">AstraZeneca</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the VEGF-A program (AZD8601) in the localized regenerative therapeutics modality, and the IL-12 program (MEDI1191) in the intratumoral immuno-oncology modality;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Merck</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the personalized cancer vaccine program (mRNA-4157) in the cancer vaccines modality; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vertex</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the cystic fibrosis (CF) program (VXc-522) in the inhaled pulmonary therapeutics modality.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We view strategic alliances as important drivers for accelerating execution of our goal of rapidly developing mRNA medicines to treat patients across a wide range of medical and disease challenges. To maintain the integrity of our platform, the terms of our agreements with our strategic collaborators generally provide that either we receive rights to develop and commercialize potential mRNA medicines that we design and manufacture or our strategic collaborators receive rights to develop and commercialize potential mRNA medicines that we design and manufacture, as opposed to granting rights to our strategic collaborators to use our platform to generate new mRNA technologies, and that we generally own mRNA-related intellectual property arising from research activities performed under the strategic alliance. We plan to continue to identify potential strategic collaborators who can contribute meaningful technology and insights to our programs and allow us to more rapidly expand our impact to broader patient populations.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below are brief descriptions of certain of our collaborations. For additional information on these relationships, including their ongoing financial and accounting impact on our business, please see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Collaboration Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in this Annual Report on Form 10-K. </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca (Nasdaq: AZN)&#8212;Strategic Alliances in Cardiovascular and Oncology</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two ongoing strategic alliances with AstraZeneca. Pursuant to the first collaboration, which was established in 2013 and amended and restated in 2018, we granted AstraZeneca certain exclusive rights and licenses to research, develop and commercialize potential mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. Our localized VEGF-A program (AZD8601) is being developed by AstraZeneca pursuant to this alliance.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our second strategic alliance with AstraZeneca, which was established in 2016, we agreed to collaborate to discover, develop and commercialize potential mRNA medicines in a range of cancers. We and AstraZeneca have agreed to work together on an immune-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL-12 protein, and our IL-12 program (MEDI1191) is being developed in collaboration with AstraZeneca pursuant to this alliance.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merck (NYSE: MRK)&#8212;Strategic Alliances in Infectious Diseases and Cancer Vaccines</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a multi-faceted relationship with Merck Sharp &amp; Dohme Corp. (Merck) that includes distinct strategic alliances directed to the research, development, and commercialization of mRNA medicines for the prevention and treatment of viral infections and for the treatment of cancer. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2016 Cancer Vaccine Strategic Alliance&#8212;Personalized mRNA Cancer Vaccines with Merck</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into a personalized mRNA cancer vaccines (PCV) Collaboration and License Agreement with Merck (PCV Agreement) to develop and commercialize PCVs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient&#8217;s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique mRNA cancer vaccine designed to specifically activate the patient&#8217;s immune system against her or his own cancer cells.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the PCV Agreement, we are responsible for designing and researching PCVs, providing manufacturing capacity and manufacturing PCVs, and conducting Phase 1 and Phase 2 clinical trials for PCVs, alone and in combination with KEYTRUDA (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Expansion of the Cancer Vaccine Strategic Alliance with Merck&#8212;Shared Neoepitope Cancer Vaccines</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2018, we and Merck agreed to expand our cancer vaccine strategic alliance to include the development and commercialization of our KRAS vaccine development candidate, mRNA-5671, and potentially other shared neoantigen mRNA cancer vaccines (SAVs). We preclinically developed mRNA-5671 prior to its inclusion in the cancer vaccine strategic alliance and it is comprised of a novel mRNA construct designed by us and encapsulated in one of our proprietary LNPs. The PCV Agreement was amended and restated to include the new SAV strategic alliance (PCV/SAV Agreement). We have regained all rights to our KRAS vaccine (mRNA-5671) from Merck and we are evaluating next steps for the program. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vertex (Nasdaq: VRTX)&#8212;2016 Strategic Alliance in Cystic Fibrosis</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement) with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited (together, Vertex). The Vertex Agreement is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vertex &#8212;2020 Strategic Alliance in Cystic Fibrosis</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a new Strategic Collaboration and License Agreement with Vertex (Vertex 2020 Agreement). The Vertex 2020 Agreement is aimed at the discovery and development of potential medicines to treat CF by delivering gene-editing therapies to lung cells to facilitate production of functional CFTR proteins.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-year research period of the Vertex 2020 Agreement will initially focus on the identification and optimization of novel LNPs and mRNAs that can deliver gene-editing therapies to cells in the lungs. Following the initial three-year period, Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Vertex is also obligated to pay us for research services in connection with our performance of certain activities in accordance with a jointly agreed research plan. Subject to customary &#8220;back-up&#8221; supply rights granted to Vertex, under the agreement, we are the exclusive manufacturer of related mRNA and LNPs for preclinical, clinical, and commercialization purposes.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Collaborations</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Chiesi&#8212;2020 Collaboration and License Agreement with Chiesi</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a Collaboration and License Agreement (Chiesi Agreement) with Chiesi Farmaceutici S.P.A. (Chiesi). The Chiesi Agreement is aimed at the discovery and development of potential mRNA medicines for the treatment of pulmonary arterial hypertension (PAH), a rare disease characterized by high blood pressure in the arteries of the lungs. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Metagenomi&#8212;2021 Collaboration for Next-Generation In Vivo Gene Editing Therapeutics</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we entered into a strategic research and development collaboration with Metagenomi, Inc. (Metagenomi) focused on advancing new gene editing systems for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> human therapeutic applications. The collaboration intends to utilize Metagenomi&#8217;s novel gene editing tools and leverage our mRNA platform, as well as LNP delivery technologies, with the goal of developing curative therapies for patients with serious genetic diseases. Under the terms of the collaboration, we and Metagenomi have agreed to advance a series of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene editing therapeutics against undisclosed targets. We agreed to pay Metagenomi an up-front cash payment and make an equity investment in Metagenomi in the form of a convertible note. Metagenomi is eligible to receive certain target option exercise fees as well as certain milestone payments, plus tiered royalties on net sales of any products that are commercialized by&#160;us under the agreement.&#160;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Carisma Therapeutics&#8212;2022 Collaboration For In Vivo CAR-M Therapeutics</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into a new strategic collaboration agreement with Carisma Therapeutics, Inc. (Carisma) to discover, develop and commercialize </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer, including solid tumors. Under the terms of the agreement, we agreed to pay Carisma an up-front cash payment and make an equity investment in Carisma in the form of a convertible note. Carisma will receive research funding and is eligible to receive certain milestone payments, plus tiered royalties on net sales of any products that are commercialized by us under the agreement. Carisma will be responsible for the discovery and optimization of development candidates while we will lead the clinical development and commercialization of therapeutics resulting from the agreement. We have the option to nominate up to twelve targets for development and commercialization.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic alliances with government organizations and foundations</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Defense Advanced Research Projects Agency (DARPA)</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, DARPA awarded us up to approximately $25 million under Agreement No. W911NF-13-1-0417 to research and develop potential mRNA medicines as a part of DARPA&#8217;s Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program, which is focused on assisting with the development of technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. As of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $20 m</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">illion of the award amount has been funded. This award followed an initial award from DARPA given in March 2013 under Agreement No. W31P4Q-13-1-0007. The DARPA awards have been deployed primarily in support of our vaccine and antibody programs to protect against Chikungunya infection. Although our antibody against Chikungunya virus (mRNA-1944) had positive Phase 1 readouts, we do not have plans to advance to a Phase 2 study.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement with DARPA for an award of up to $56 million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of December 31, 2021, the committed funding, net of revenue earned was $2 million, with an additional $42 million available under Agreement No. HR0011-20-9-0118 if DARPA exercises additional contract options.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Biomedical Advanced Research and Development Authority (BARDA)</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we received an award of up to approximately $126 million under Agreement No. HHSO100201600029C from BARDA, a component of the Office of the Assistant Secretary for Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), to help fund our Zika vaccine program. Under the terms of the agreement with BARDA, an initial base award of approximately $8 million supported toxicology studies, a Phase 1 clinical trial, and associated manufacturing activities. Additionally, four contract options were awarded under the agreement with BARDA. Three out of four of these options have been exercised, bringing the total current award to approximately $</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million to support an additional Phase 1 study of an improved Zika vaccine candidate, Phase 2 and Phase 3 clinical studies, as well as large-scale manufacturing for the Zika vaccine.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with BARDA for an award of up to $483 million to accelerate development of mRNA-1273, our COVID-19 vaccine. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $472 million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $63 million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. In April 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $236 million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. In June 2021, the agreement was further amended to award additional funding of $144 million to support pediatric clinical trials for mRNA-1273. The maximum award from BARDA, inclusive of the 2020 and 2021 amendments, is $</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of December 31, 2021, the remaining available funding net of revenue earned was $189&#160;million.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Institute for Life Changing Medicines (ILCM)</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into a collaboration agreement with the ILCM to develop a new mRNA therapeutic (mRNA-3351) for CN-1. Under the terms of the agreement, we agreed to license mRNA-3351 to ILCM with no upfront fees, and without any downstream payments. ILCM will be responsible for the clinical development of mRNA-3351.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Bill &amp; Melinda Gates Foundation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Bill &amp; Melinda Gates Foundation to advance mRNA-based development projects for various infectious diseases. The Bill &amp; Melinda Gates Foundation has committed up to $20 million in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase 1 clinical trial of a potential mRNA medicine to help prevent HIV infections. Follow-on projects, which could bring total potential funding under the framework agreement up to $100 million (including the HIV antibody project) to support the development of additional mRNA-based projects for various infectious diseases, can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Bill &amp; Melinda Gates Foundation certain non-exclusive licenses.</span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2534"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>We rely on a combination of intellectual property laws, including patent, trademark, copyright and trade secret, as well as confidentiality and license agreements, to protect our intellectual property and proprietary rights. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Protecting our platform, modality, and program investments: Building an expansive, multi-layered IP estate</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built a substantial IP estate that includes numerous patents and patent applications related to the development and commercialization of mRNA vaccine and therapeutic development candidates, including related platform technologies. Our platform IP protects advances in mRNA design and engineering, proprietary LNP components, delivery systems, processes for the manufacture and purification of drug substances and products, and analytical methods. A significant portion of our platform IP estate further provides multi-layered protection for our modalities and programs.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our IP estate, our solely-owned patent portfolio consists of more than 170 issued or allowed U.S. patents or patent applications and more than 110 granted or allowed patents in jurisdictions outside of the U.S. (including granted European patents that have been validated in numerous European countries) covering certain of our proprietary platform technology, inventions, and improvements, and covering key aspects of our clinical and most advanced development candidates. We have over 430 additional pending patent applications that, in many cases, are counterparts to the foregoing U.S. and foreign patents.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the patents and applications (if issued) in our portfolio will not expire until 2033 at the earliest. Any patent that may issue from our most recently filed patent applications is projected to expire between 2042 and 2043, at the earliest. We file additional U.S. and foreign patent applications as necessary to protect our evolving intellectual property position.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trademarks, copyright, trade secrets, and know-how relating to our proprietary technology and programs, continuing innovation, and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of mRNA therapeutic and vaccine technologies. We take additional steps, such as entering into confidentiality and license agreements, to protect our intellectually property and proprietary rights. We additionally plan to rely on data exclusivity, market exclusivity, and patent term extensions when available, and plan to seek and rely on regulatory protection afforded through orphan drug designations. We also possess substantial proprietary know-how associated with related manufacturing processes and expertise.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IP protecting our platform</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a broad IP estate covering key aspects of our platform. This estate provides multiple layers of protection covering the making and use of the mRNA drug substance and delivery technologies.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our platform, we have a portfolio that includes U.S. and foreign patents or patent applications covering platform innovations that are directly related to the design, formulation and manufacturing of mRNA medicines. For example, these patents and patent applications include claims directed to:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mRNA chemistry imparting improved properties for vaccine and therapeutic uses;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods for mRNA sequence optimization to enhance the levels and fidelity of proteins expressed from our mRNA medicines;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods for identifying epitopes having superior suitability in cancer vaccine contexts;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engineering elements tailored to enhance stability and the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;performance of mRNA medicines;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LNP delivery systems, including novel lipid components designed for optimal expression of both therapeutic and vaccine mRNAs, in particular, prophylactic infectious disease and cancer vaccine mRNAs, intratumoral immuno-oncology therapeutics, local regenerative therapeutics, systemic therapeutics, and inhaled pulmonary therapeutics; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IP protection for modalities</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our IP estate provides protection for the multiple programs within our modalities both at the product-specific level and at various broader levels. For example, we have patent coverage for LNP-encapsulated mRNAs having specific chemical modification suited for vaccine and therapeutic mRNA use. Our estate also includes IP covering certain LNP-encapsulated mRNAs coding for infectious disease antigens for use in prophylactic vaccination. Our mRNA chemistry, formulation and manufacturing patent applications and related know-how and trade secrets may also provide us with additional IP protection relating to our development candidates.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prophylactic vaccines</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For programs within our prophylactic vaccines modality, we typically pursue patent protection featuring composition of matter and method of use claims. Our global patent protection strategy may vary based on the unique geographic prevalence of various infectious diseases.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have filed several patent applications covering our COVID-19 vaccine program. Claims covering mRNA-1273, which is a LNP-encapsulated mRNA encoding prefusion-stabilized Spike protein antigen, and claims to methods of vaccinating subjects against SARS-CoV-2 infection using our vaccine are featured in several patent families that includes four pending PCT applications, a pending U.S. patent application, and foreign patent applications filed in Argentina and Taiwan. Priority dates for these applications span a period from late January through late May 2020. The U.S. government has rights in certain of the foregoing patent applications. A further pending PCT application includes claims covering our variant-specific COVID-19 vaccines. Protection for mRNA-1283 can be found in a PCT application and three pending U.S. provisional patent applications. Two additional U.S. provisional patent applications include claims covering our COVID-19 and seasonal flu combination vaccine.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Issued U.S. Patent No. 10,702,600 includes claims to LNP-encapsulated mRNA encoding betacoronavirus spike protein. Issued U.S. patent 10,933,127 includes claims to methods of using such compositions to elicit an immune response in subjects. Corresponding vaccine composition and method of use claims are also featured in a pending European patent application. These patents and applications enjoy an October 2015 priority date.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further coverage for our COVID-19 vaccine and many of our other prophylactic vaccines is found in a broad, infectious disease vaccine patent family featuring claims to LNP-encapsulated mRNAs encoding infectious disease antigens and methods using such compositions for vaccination. This patent family includes two issued U.S. patents, two pending U.S. patent applications and pending patent applications in Europe, Canada, Australia, Brazil, China, Hong Kong, India, Japan, Russia, and Singapore. Issued U.S. Patent Nos. 10,022,435 and 10,709,779 feature claims directed to methods of vaccinating subjects against infection with LNP-encapsulated mRNAs encoding infectious disease antigens.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent coverage for our human CMV vaccine, which includes mRNAs encoding several surface glycoproteins of the CMV virus, can be found in pending applications in Australia, Canada, Europe and in both a granted patent and pending patent application in Japan. In the United States, our CMV vaccine is covered in a pending U.S. patent application and in issued U.S. Patent Nos. 10,064,935, 10,383,937 and 10,716,846. Two pending PCT applications and a pending U.S. patent application feature claims to clinical formulations of our CMV vaccine and methods of use.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patent applications directed to our hMPV/PIV3 vaccine are pending in the United States, Europe and Hong Kong. Five U.S. patents have issued featuring hMPV/PIV3 vaccines with U.S. Patent No. 10,064,934 having claims covering LNP-encapsulated mRNA vaccines that encode the PIV3 and hMPV fusion proteins, U.S. Patent No. 10,272,150 having claims covering administration methods for these LNP-encapsulated mRNA vaccines, U.S. Patent No. 10,543,269 having claims covering vaccines that include HMPV-encoding mRNA formulated in LNPs, U.S. Patent No. 10,702,599 having claims covering vaccines that include PIV3-encoding mRNA formulated in LNPs, and U.S. Patent 11,103,578 having claims covering specific HMPV- and PIV3-encoding mRNAs for use as vaccines. A pending provisional patent application features claims to clinical aspects of our hMPV/PIV3 vaccine. A pending U.S. patent application features claims covering our hMPV/RSV vaccine.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Zika mRNA vaccine is covered in a series of patent families directed to mosquito-borne viruses. These patent families include four issued U.S. Patents that cover our Zika vaccines, U.S. Patent Nos. 10,449,244, 10,653,767, 11,007,260 and 11,207,398, and several pending U.S., European and Hong Kong patent applications, one of which is recently allowed and soon to be issued as a U.S. patent, and one of which is recently allowed and soon to be granted as a European patent.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We filed patent applications in several jurisdictions covering RSV vaccines. At least two U.S. and two European patent applications are pending, as are applications in Canada, Australia and several Asian jurisdictions. Also pending are two provisional applications featuring our pediatric RSV vaccine.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A pending PCT patent application and a pending U.S. provisional patent application includes claims covering our vaccine program for the prevention of human infection with seasonal influenza virus. The program also is protected by the broad, infectious disease </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">vaccine patent family described above, in particular, issued U.S. Patent No. 9,872,900 and granted European Patent EP 3134131, having claims to HA-encoding mRNA vaccine compositions.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pending patent applications in the United States, Australia, Canada, Europe, and Japan include claims covering our EBV vaccines and methods of use.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have pending patent applications in the United States and Europe that include claims covering our Nipah vaccine and methods of use, and pending applications in the United States and Europe that include claims covering our HIV vaccine and methods of use.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cancer vaccines</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Composition of matter and method claims also protect programs within our cancer vaccines modality. Proprietary methods around the making and therapeutic use of our personalized cancer vaccines (PCVs) and resulting vaccine compositions are described and claimed in six pending U.S. patent applications, five pending European patent applications, four pending patent applications in each of Australia, Canada, China and Japan, and several pending patent applications in New Zealand, South Africa, as well as other European, Asian and South American countries. Of these patent applications, a U.S. patent application and a Chinese patent application are allowed and soon to be issued. These applications also relate to various vaccine design formats, in particular, polyepitopic vaccine formats, and methods of treating cancer with such personalized cancer vaccines. We also possess substantial know-how and trade secrets relating to the development and commercialization of our cancer vaccine programs, including related manufacturing process and technology.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Likewise, our KRAS antigen cancer vaccine and methods of treating cancer featuring such vaccines are covered in issued U.S. Patent No. 10,881,730, which includes claims to LNP-encapsulated mRNA encoding mutant KRAS antigens, and in a pending U.S. patent application and pending applications in Australia, Canada, Europe, and Japan, as well as in several other European, South American, Asian and Middle Eastern jurisdictions.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intratumoral immuno-oncology</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To protect programs within our intratumoral immuno-oncology modality, we have filed numerous patent applications featuring claims to mRNAs encoding immune-stimulatory proteins and methods of treating cancer using such compositions.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Two of our immuno-oncology programs are designed to be administered intratumorally to alter the tumor microenvironment in favor of mounting an immune response against tumors. Our mRNA program that includes mRNAs that encode OX40L, IL-23 and IL-36&#947; are covered by a granted European Patent, EP 3394093, by eleven issued U.S. patents, U.S. Patent Nos. 10,143,723, 10,172,808, 10,285,950, 10,322,090, 10,322,091, 10,379,767, 10,383,951, 10,406,113, 11,003,366, 11,071,716 and 11,185,510, by several pending U.S. and European patent applications, two of which are allowed and soon to issue, and by several pending patent applications in foreign jurisdictions including Asian, South American and other jurisdictions. These applications feature claims to the mRNA therapeutics as compositions of matter, formulations that include such mRNAs and methods of reducing tumors and treating cancer featuring these development candidates. Similar claims cover our IL-12 development candidate which can be found in issued U.S. Patent No. 10,646,549, issued U.S. Patent No. 11,000,573, and in pending patent applications in the United States and Europe, two of which are allowed and soon to be issued, and in Australia, Canada, China and Japan, as well as several other jurisdictions in Asia, South America and the Middle East.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Localized regenerative therapeutics</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our localized regenerative therapeutics modality is focused on regenerative therapeutics. Our sole program, VEGF-A, is being developed in collaboration with AstraZeneca and is covered by a granted European patent EP 3464338, granted Japanese patent JP 6859369 and granted Russian patent RU 2756313, and by pending U.S. and European patent applications and by several national phase patent applications filed in South American, Asian and Middle Eastern jurisdictions. The VEGF patent applications are solely-owned by Moderna.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Systemic intracellular therapeutics</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our systemic intracellular therapeutics modality, we have four programs featuring expression of intracellular enzymes for the treatment of rare diseases. For our rare disease programs, we generally pursue patent protection featuring composition of matter and method of use claims, for example, pharmaceutical composition and method of treatment claims. Our most advanced rare disease development candidate, MMA, is covered by a patent family that includes issued U.S. Patent No. 10,406,112, two pending U.S. patent applications, foreign patent applications filed in Australia, Canada, Japan, Europe and the Middle East, and two pending U.S. Provisional patent applications.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our PA development candidate, we have patent applications pending in the United States, Canada, Europe, and Japan which cover mRNA encoding the alpha and beta subunits of the enzyme propionyl-CoA carboxylase (PCCA and PCCB, respectively), for the treatment of PA.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our PKU development candidate, we have a pending PCT and pending patent applications in the U.S., Europe and Japan covering mRNA encoding phenylalanine hydroxylase (PAH) for the treatment of PKU.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our Glycogen Storage Disorder, Type 1a (GSD1a) development candidate, we have pending U.S and European patent applications, as well as applications pending in Australia, Canada, China, Japan, Israel and several Middle Eastern jurisdictions, and a pending PCT and pending provisional patent applications covering mRNA encoding glucose 6-phosphatase (G6Pase) for the treatment of this disorder.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For our Crigler-Najjar Syndrome Type 1 (CN-1) development candidate, we have patent applications pending in the U.S., Europe, Australia, Canada and Japan.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any U.S. and foreign patents that may issue from these patent families would be expected to expire in 2036 for the earliest of the MMA patents and 2038-2042 for the remaining MMA, PA, PKU, GSD1a and CN-1 patents, excluding any patent term adjustments and any patent term extensions.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As further described below, we have filed or intend to file patent applications on these and other aspects of our technology and development candidates, and as we continue the development of our intended products, we plan to identify additional means of obtaining patent protection that would potentially enhance commercial success, including protection for additional methods of use, formulation, or manufacture.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Systemic secreted and cell-surface therapeutics</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our systemic secreted and cell-surface therapeutics modality features programs directed to expression of secreted or cell-surface proteins including antibodies, circulating modulation factors, secreted enzymes and transmembrane proteins. Our mRNA-encoded antibody against Chikungunya virus reported positive interim Phase 1 results in clinical trials and utilizes the same LNP formulation being advanced for our MMA program and other rare disease programs. Patent protection for mRNA-encoded antibody against Chikungunya virus is being sought by way of a pending U.S. and European patent applications, in which we share joint ownership rights.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Relaxin development candidate is covered by several pending foreign patent applications outside the United States, for example, in several Asian, European, Middle Eastern, South American and other jurisdictions, and by a pending U.S. application and by issued U.S. Patent No. 10,730,924.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our PD-L1 and IL-2 development candidates are each covered in pending PCT patent applications.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inhaled pulmonary therapeutics</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our inhaled pulmonary therapeutics modality currently has one development candidate directed to expression of therapeutic protein in the lungs. This Cystic Fibrosis (CF) development candidate is covered by pending U.S., European and PCT patent applications.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our trademark portfolio currently contains at least 200 trademark registrations, including at least 12 registrations in the United States and the remaining in Canada, the European Union, the United Kingdom, Israel, China, Japan, Australia, and elsewhere. In addition, we have at least 375 pending trademark applications in more than 75 jurisdictions, including in the aforementioned locations and additional countries throughout Africa, Asia, and South America.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-licensed intellectual property</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we develop and manufacture our potential mRNA medicines using our internally created mRNA technology platform, we also seek out and evaluate third party technologies and IP that may be complementary to our platform.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent sublicense agreements with Cellscript and mRNA RiboTherapeutics</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trustees of the University of Pennsylvania owns several issued U.S. patents, granted European patents and pending U.S. patent applications directed, in part, to nucleoside-modified mRNAs and their uses, or the Penn Modified mRNA Patents. mRNA </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RiboTherapeutics, Inc. (MRT) obtained an exclusive license to the Penn Modified mRNA Patents and granted its affiliate, Cellscript, LLC (Cellscript), a sublicense to the Penn Modified mRNA Patents in certain fields of use.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, we entered into two sublicense agreements, one with Cellscript, and one with MRT, which agreements we collectively refer to as the Cellscript-MRT Agreements. Together, the Cellscript-MRT Agreements grant us a worldwide, sublicensable sublicense to the Penn Modified mRNA Patents to research, develop, make, and commercialize products covered by the Penn Modified mRNA Patents, or licensed products, for all</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;uses in humans and animals, including therapeutic, prophylactic, and diagnostic applications. The Cellscript-MRT Agreements are non-exclusive, although Cellscript and MRT are subject to certain time restrictions on granting additional sublicenses for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;uses in humans under the Penn Modified mRNA Patents.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid Cellscript and MRT aggregate sublicense grant fees of $28 million upon entering into the Cellscript-MRT Agreements, $25&#160;million in early 2018, and $22 million in early 2019. Cellscript and MRT are collectively eligible to receive, on a licensed product-by-licensed product basis, milestone payments totaling up to $0.5&#160;million upon the achievement of certain regulatory-based events for diagnostic products, and milestone payments totaling up to $1.5&#160;million upon the achievement of certain development and regulatory-based events for either therapeutic or prophylactic products, and up to $24&#160;million upon the achievement of certain commercial-based events for either therapeutic or prophylactic products. The Cellscript-MRT Agreements require us to pay royalties based on annual net sales of licensed products at rates in the low single digits for therapeutic, prophylactic, and diagnostic uses, and royalties based on annual net sales of licensed products sold for research uses at rates in the mid-single digits, subject to certain reductions, with an aggregate minimum floor. Following the first commercial sale of licensed products under a Cellscript-MRT Agreement, we are required to pay Cellscript or MRT, as applicable, minimum annual royalties ranging from $10,000 to $400,000 depending on the use of such licensed product, with all such payments creditable against earned royalties on net sales. In 2021, we paid $641 million in royalties and milestone payments to Cellscript in connection with sales of our COVID-19 vaccine.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cellscript-MRT Agreements will terminate upon the expiration or abandonment of the last to expire or become abandoned of the Penn Modified mRNA Patents. Cellscript or MRT, as applicable, may terminate its respective Cellscript-MRT Agreement if we fail to make required payments or otherwise materially breach the applicable agreement, subject to specified notice and cure provisions. Cellscript or MRT, as applicable, may also terminate the applicable Cellscript-MRT Agreement upon written notice in the event of our bankruptcy or insolvency or if we challenge the validity or enforceability of the Penn Modified mRNA Patents. We have the right to terminate each Cellscript-MRT Agreement at will upon 60 days&#8217; prior notice to Cellscript or MRT, as applicable, provided that we cease all development and commercialization of licensed products upon such termination. If rights to MRT or Cellscript under the Penn Modified mRNA Patents are terminated (e.g., due to bankruptcy of MRT or Cellscript), the terminated party will assign its interest in the respective Cellscript-MRT Agreement to the licensor from which it received rights under the Penn Modified mRNA Patents and our rights will continue under the new licensor.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Formulation technology in-licenses</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development candidates use internally developed formulation technology that we own. We do, however, have rights to use and exploit multiple issued and pending patents covering formulation technologies under licenses from other entities.&#160;If in the future we elect to use or to grant our strategic collaborators sublicenses to use these in-licensed formulation technologies, we or our strategic collaborators may be liable for milestone and royalty payment obligations arising from such use. We consider the commercial terms of these licenses and their provisions regarding diligence, insurance, indemnification and other similar matters, to be reasonable and customary for our industry.</span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2554"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HUMAN CAPITAL</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately 2,700 full-time employees as of December 31, 2021, representing a more than doubling of our workforce from 1,300 full-time employees as of the end of the prior year. We have undertaken significant hiring of employees to facilitate manufacturing of our COVID-19 vaccine, in addition to building out our commercial and regulatory organizations, as well as other functions, to support this continued roll-out. We also increased our hiring outside the United States during 2021, and at year-end we had employees in 12 countries around the world, with a presence in North America, Europe and the Asia-Pacific region. Much of this hiring has been of talent with experience at other pharmaceutical companies as we continue to build out our commercial and regulatory capabilities, particularly as we fill roles to facilitate our operations and commercial activities in markets around the globe. We have also continued to hire talent to support our research and clinical capabilities across the rest of our pipeline, unrelated to our COVID-19 vaccine.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment for human capital, particularly as we seek to attract and retain talent with experience in the biotechnology and pharmaceutical sectors. Our workforce is highly educated, and as of December 31, 2021, 47% of our employees hold Ph.D., Doctorate, M.D., J.D., or Master&#8217;s degrees. Among our employees, as of December 31, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">% are female. Among our leadership (which we define as employees at the vice president level and above), as of December 31, 2021, approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">% are female, an increase from 37% in the prior year. 40% of our U.S. employees identify as racially or ethnically diverse as of </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021, an increase from 35% in the prior year. In 2021, we continued to act on our commitment to belonging, inclusion &amp; diversity by, among other things:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engaging all members of our Executive Committee, vice presidents and managers in our Conscious Inclusion education series;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducting diversity-related events, celebrations and learning opportunities for all employees throughout the year, including Pride Month, Hispanic Heritage Month and Asian &amp; Pacific Islander Month;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hosting a company-wide event on Neurodiversity in line with the CEO Action of Diversity &amp; Inclusion&#8217;s #DayofUnderstanding;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased our monitoring and reporting program regarding company-wide gender and ethnicity data;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">doubling the number of our Employee Resource Groups; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">joining the Disability:IN Inclusion Works Program, an initiative that assists employers in all aspects of disability inclusion at work.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help promote alignment between our employees and our shareholders, all employees participate in our equity programs through the receipt of equity grants, and the percentage of equity as a component of overall pay mix increases with seniority. We believe that in addition to incentivizing growth that leads to shareholder value, broad eligibility for our equity programs helps promote employee retention as these awards generally vest over a four-year period.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the COVID-19 pandemic, we have implemented various initiatives to promote the safety of our workforce and continuity of our operations. We created a Coronavirus Response Team that is responsible for implementing various safety measures at our global sites. Our protocols include regular COVID-19 testing and the provision personal protective equipment (PPE). Throughout the pandemic, much of our workforce has worked remotely, wherever possible and when local conditions recommend social distancing. We also implemented remote hiring and onboarding programs to facilitate significant hiring during 2021 in a remote work environment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since October 2021, we have required all of our employees in the United States to be vaccinated against COVID-19, including having received a booster dose, absent an approved medical or religious accommodation.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2020, following the receipt of an Emergency Use Authorization from the FDA for our COVID-19 vaccine, we made the vaccine available to our employees and adult members of their households to help ensure continuity of our operations due to the critical nature of our production of the vaccine. In December 2021 and early 2022, as the Omicron variant drove a surge in COVID-19 cases globally, we made booster doses of our vaccine available to our U.S.-based employees and adult members of their households, as well as to employees of our Swiss subsidiary.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our employees are represented by a labor union, and none of our employees have entered into a collective bargaining agreement with us, other than a small number of employees in France, Italy and Spain who are covered by collective bargaining agreements governing certain benefits and working conditions. We consider our employee relations to be good.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our employees are highly engaged, and we and our employees have been recognized by surveys conducted by external groups.&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Science</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;magazine ranked us as a top employer for each of the last seven years. Additionally, in 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biospace</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ranked us the number one employer in its 2022 Best Places to Work in Biopharma report and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> named us the number one company on its 2021 Best Workplaces for Innovators list. We measure employee engagement through a vendor-supplied engagement software, using validated external benchmarks to track quarter-over-quarter employee engagement factors.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our approach to attracting and retaining talent </span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to ensuring that our employees find that their careers at Moderna are filled with purpose, growth and fulfillment. We believe that a career at Moderna provides opportunity for:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Impact</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our people will have the opportunity to do work that is unparalleled in terms of its innovation and scope of impact on people&#8217;s lives.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Growth</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We provide incredible opportunities for growth and we obsess over learning (as demonstrated, in part, by our Mindsets (see below)). We invest in the development of our people as scientists and as leaders. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Well-being</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We are committed to the health and well-being of our employees and their families by providing family-friendly benefits and opportunities to be healthy, including annual allowances for personal enrichment and monthly allowances for fitness and nutrition.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Inclusive environment</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We believe in the benefits of bringing together a diverse set of perspectives and backgrounds, and creating an environment where differences are celebrated and leveraged.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Compelling rewards</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: To attract and retain the best talent, we provide competitive rewards that help to drive groundbreaking work and allow employees to share in the value we will create together, including through our equity programs.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our approach to training our employees</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a structured training curriculum for our employees called Moderna University and have a full-time team dedicated to developing the curriculum and conducting activities for Moderna University. The objective of Moderna University is for every employee to be deeply familiar with our core technology and able to learn about technologies that might further enable our science. In addition, Moderna University is also focused on creating strong leaders through management and leadership training. There are four core areas within Moderna University including:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Professional development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Includes on-site training programs for our employees including those focused on leadership and project management, as well as tools to improve interpersonal communication.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Digital learning library</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We have built an online library of videos of a variety of scientific material that our employees can access flexibly. This content includes:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Presentations by external speakers to scientific seminars conducted in-house;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Scientific courses at external universities; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Peer-to-peer video series in which in-house experts provide an introductory view of complex topics they tackle within their teams.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Learning management system</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We have deployed a digital system to track and administer training programs for each of our employees. Training content is developed digitally and offered to our employees.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">New hire orientation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: This program is designed to onboard all new employees. During this training program, new employees meet with members of the management team and senior functional leaders to learn about the Company and functional activities.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced the launch of our Artificial Intelligence (AI) Academy in partnership with Carnegie Mellon University. The AI Academy is intended to educate and empower our workforce to identify and integrate AI and machine learning solutions into our systems and processes.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, with the continued rapid growth of our company, we articulated the Moderna Mindsets in late 2021. The Moderna Mindsets are a set of leadership behaviors we use to make decisions and lead the company. We consider the Mindsets to be key as our company continues to scale, and we are working to integrate them into all of our HR processes, including performance management. Our employees participate in the Mindsets Workshops, which is an interactive, full-immersion learning experience designed to provide the opportunity to engage with, better understand and learn how to apply the Mindsets in the workplace.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further develop and retain our workforce, we conduct periodic talent reviews that identify key talent within the organization. We use that data to inform specific development opportunities for key current and potential future leaders, and to support our periodic succession planning activities for key roles. These steps together ensure we have a robust understanding of our workforce and a talent pipeline to grow future leaders.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2574"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE SOCIAL RESPONSIBILITY </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In pursuit of our mission to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, we have scaled our operations, invested in research and building out our manufacturing and commercial capabilities, and hired top-tier talent. As we continue to mature, we believe it is important to develop long-term programs that underscore our commitment to corporate social responsibility. Please refer to the &#8220;Responsibility&#8221; section of our website, which can be found at www.modernatx.com, as well as our proxy statement related to our 2022 Annual Meeting of Stockholders that we will file with the SEC, for a description of some of the measures we have taken to support our commitment to corporate social responsibility.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2594"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITION</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition. There is also a strong emphasis on defense of intellectual property and proprietary products.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">mRNA Medicines and Our COVID-19 Vaccine</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development, and manufacturing provide us with a competitive advantage. However, we face competition from others developing mRNA vaccines and therapeutics, as well as other medicines that compete or could compete with our mRNA products, development candidates and investigational medicines. We face competition from various sources, including large pharmaceutical companies, biotechnology companies, academic institutions, government agencies, and public and private research institutions. For any products that we eventually commercialize, we will not only compete with existing medicines but also compete with medicines that may become available in the future. We also face competition when entering into strategic alliances to advance and grow our pipeline.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We face significant competition in the market for our COVID-19 vaccine, particularly from established pharmaceutical companies with longer operating histories and significant experience in producing and marketing pharmaceutical products. In the United States, the U.S. FDA has granted a BLA to the Pfizer/BioNTech COVID-19 vaccine for the prevention of COVID-19 in individuals 16 years of age and older. The Pfizer/BioNTech COVID-19 vaccine has also been authorized under an EUA as a two-dose primary series for individuals five years of age and older, as a third primary series dose for individuals five years of age and older who have been determined to have certain kinds of immunocompromise, and as a single booster dose for individuals 12 years of age and older at least five months after completing a primary series of the vaccine. The Pfizer/BioNTech COVID-19 vaccine has also been authorized for use as a single booster dose for individuals 18 years of age and older following completion of primary vaccination with a different available COVID-19 vaccine. The CDC has recommended that individuals starting their COVID-19 vaccine series or receiving a booster dose receive either our COVID-19 vaccine or the Pfizer/BioNTech COVID-19 vaccine. The Johnson &amp; Johnson/Janssen viral vector COVID-19 vaccine is also authorized under an EUA. Outside the United States, our COVID-19 vaccine has been authorized for use or approved in more than </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">70</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> countries, in addition to receiving authorization from the World Health Organization. In many of these jurisdictions, our vaccine is authorized for use in adolescents (ages 12-17). Internationally, our COVID-19 vaccine competes against over two dozen vaccines that have been authorized in various jurisdictions, and many other vaccine candidates remain in development, including other mRNA vaccines.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, competitors have developed treatments for COVID-19, and additional treatments may be developed in the future. For example, Pfizer and Merck have developed antiviral pills for the treatment of mild-to-moderate COVID-19 disease for certain adults who have tested positive for COVID-19. To the extent that these or other treatments are viewed as an alternative to vaccination against COVID-19, our competitive position could be harmed.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition for the sale of our COVID-19 vaccine can be impacted by a number of factors, including: the efficacy of our vaccine in preventing COVID-19 (particularly in the prevention of severe cases of COVID-19); the ability of our vaccine, or future iterations of the vaccine, and boosters to protect effectively against variants of the SARS-CoV-2 virus; perceptions of the efficacy of our vaccine; concerns about potential side effects from the vaccine, its safety or tolerability; the novelty of mRNA-based technology; storage and handling conditions for our vaccine and the ease or difficulty with which it can be distributed; the timing and scope of regulatory approvals; reimbursement coverage; our costs to produce and distribute our vaccine; and our ability to scale our manufacturing and distribution effectively as we continue to expand shipments internationally. The competitiveness of our COVID-19 vaccine in the future may also depend upon whether we are successful in efforts to combine the vaccine with other vaccines, like seasonal flu and RSV, and whether our competitors are successful in similar efforts. Additionally, standalone vaccines we may develop for respiratory diseases, such as seasonal flu vaccines, will face competition from existing vaccines and treatments, as well as future medicines developed by competitors. Our competitive positioning may also be affected by the fact that we do not have as long a history of producing pharmaceutical products or existing commercial relationships compared to certain of our competitors.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are additional companies that are working on mRNA medicines, some of which have reached commercialization. Companies with mRNA programs include BioNTech and Pfizer (alone and in partnership with BioNTech and others). Other competitors include Sanofi (through the acquisition of Translate Bio), CureVac and GlaxoSmithKline, Arcturus Therapeutics, eTheRNA Immunotherapies Ethris, Genevant Sciences, Stemirna Therapeutics and Abogen Biosciences, which is developing a COVID-19 mRNA vaccine in collaboration with Walvax Biotechnology and the PLA Academy of Military Science. We also compete against other pharmaceutical companies in the market for COVID-19 vaccines that do not utilize mRNA-based technologies, including AstraZeneca and Johnson &amp; Johnson, among others.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Beyond mRNA</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our strategic collaborators face competition from companies developing therapies in various areas, other than the development of mRNA medicines, related to our collaborations. For example, there are a growing number of pharmaceutical, biotechnology and academic institutions researching and developing autologous and allogeneic CAR-T therapies in both the solid and liquid tumor setting. These CAR-T cell therapies are at various stages of development and approval and could compete against any CAR-T therapeutics we discover, develop and commercialize in collaboration with Carisma Therapeutics.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, there are many companies and institutions researching and developing CRISPR and other gene editing systems, which could compete against any therapies for genetic diseases we develop and commercialize in collaboration with Metagenomi or other collaborators.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2614"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, manufacture and marketing of our products and product candidates. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained and submitted for review and approved by the regulatory authority.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. drug and biological product development</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations and biologics under the FDCA, the Public Health Service Act (PHSA), and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations. Failure to comply with applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, voluntary or mandatory product recalls, market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of our investigational medicines must be approved by the FDA through a BLA or new drug application, NDA, process before they may be legally marketed in the United States. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our current or future investigational medicines will be granted on a timely basis, or at all.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preclinical studies</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before any of our product candidates may be tested in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;in vitro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Unless the FDA raises concerns, an IND automatically becomes effective 30 days after receipt by the FDA. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical trials</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators and in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to clinical trial subjects and monitors the clinical trial until completed. Further, progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and more frequently in other situations, including the occurrence of serious adverse events. Information about certain clinical trials must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the U.S. National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (the NIH Guidelines), supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (IBC), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. While the NIH Guidelines are only mandatory for research being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign studies conducted under an IND must meet the same requirements that apply to studies being conducted in the United States. Data from a foreign study not conducted under an IND may be submitted in support of a BLA if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials generally are conducted in three sequential phases, which may overlap:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients to assess the metabolism, pharmacologic action, side effect tolerability, and safety of the product candidate.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2 clinical trials generally involve studies in disease-affected patients to evaluate proof of concept and/or determine the dosing regimen(s) for subsequent investigations. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product, and provide an adequate basis for product labeling.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also require post-approval Phase 4 non-registrational studies to explore scientific questions to further characterize safety and efficacy during commercial use of a drug.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, and purity of the final product. </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FDA review process</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following completion of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of a BLA or NDA, along with proposed labeling, chemistry, and manufacturing information to ensure product quality and other relevant data. A BLA is a request for approval to market a biologic for one or more specified indications and must contain proof of the biologic&#8217;s safety, purity, and potency. An NDA for a new drug must contain proof of the drug&#8217;s safety and efficacy. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA or NDA must be obtained before a biologic or drug may be marketed in the United States. </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA or NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel products or products which present difficult questions of safety or efficacy to an advisory committee of expert advisors for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The committee makes a recommendation to the FDA that is not binding but is generally followed. </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates a BLA or NDA, it will grant marketing approval, request additional information or issue a complete response letter (CRL), outlining the deficiencies in the submission. The CRL may require additional testing or information, including additional preclinical or clinical data, for the FDA to reconsider the application. Even if such additional information and data are submitted, the FDA may decide that the BLA or NDA still does not meet the standards for approval. If the FDA grants approval, it issues an approval letter that authorizes commercial marketing of the product with specific prescribing information for specific indications.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Orphan drug designation</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in very limited circumstances, such if the latter product is shown to be clinically superior to the orphan product. Orphan drug exclusivity, however, also could block the approval of our products for seven years if a competitor first obtains approval of the same product as defined by the FDA or if our drug candidate is determined to be contained within the competitor&#8217;s product for the same indication or disease. </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expedited development and review programs</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may employ one of several tools to facilitate and expedite the development and review of a drug, including fast track designation, breakthrough therapy designation, accelerated approval and priority review designation.&#160;Fast track designation is designed to facilitate the development and review of a drug that treats a serious condition and fills an unmet medical need. Breakthrough therapy designation is designed to expedite the development and review of a drug that treats a serious condition and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preliminary clinical evidence demonstrates substantial improvement over available therapies. Priority review designation means the FDA&#8217;s goal is to take action on an application within six months of filing. The FDA may grant priority review designation to a drug that would provide significant improvement in the safety or effectiveness of a treatment, diagnosis or prevention of a serious condition.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product may also be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM) that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions, as it deems necessary to assure safe use of the product. If the FDA determines that the conditions of approval are not being met, the FDA can withdraw its accelerated approval for such drug or biologic.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review, accelerated approval, and breakthrough therapy designation do not change the standards for approval.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emergency Use Authorization (EUA)</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Secretary of Health and Human Services (HHS) may authorize unapproved medical products to be marketed in the context of an actual or potential emergency that has been designated by the U.S. government. The COVID-19 pandemic has been designated as such an emergency. After an emergency has been announced, the Secretary of HHS may authorize the issuance of and the FDA Commissioner may issue EUAs for the use of specific products based on certain criteria, including that the product may be effective in diagnosing, treating, or preventing serious or life-threatening diseases when there are no adequate, approved, and available alternatives. From December 18, 2020, our COVID-19 vaccine was available under an EUA for active immunization to prevent COVID-19 in individuals 18 years of age and older. In January 2022, the FDA approved the BLA for our COVID-19 vaccine, Spikevax, to prevent COVID-19 in individuals 18 years of age and older in the United States. A booster dose of our COVID-19 vaccine at the 50 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#181;g dose level is authorized for use under an EUA for adults 18 years and older. A third dose of our COVID-19 vaccine at the 100 &#181;g dose level is authorized for use under an EUA in immunocompromised individuals 18 years of age or older in the United States who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise</span><span style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> An EUA terminates when the emergency determination underlying the EUA terminates. An EUA is not a long-term alternative to obtaining FDA approval, licensure, or clearance for a product. The FDA may revoke an EUA for a variety of reasons, including if the underlying health emergency no longer exists or warrants such authorization.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Public Readiness and Emergency Preparedness Act, the PREP Act, provides immunity for manufacturers from all claims under state or federal law for &#8220;loss&#8221; arising out of the administration or use of a &#8220;covered countermeasure.&#8221; However, injured persons may still bring a suit for &#8220;willful misconduct&#8221; against the manufacturer under some circumstances. &#8220;Covered countermeasures&#8221; include &#8220;qualified pandemic or epidemic products,&#8221; including products intended to diagnose or treat pandemic or epidemic disease, such as pandemic vaccines. For these immunities to apply, the Secretary of HHS must issue a declaration in cases of public health emergency or &#8220;credible risk&#8221; of a future public health emergency. On March 17, 2020, the Secretary of HHS issued a declaration under the PREP Act and has issued subsequent amendments thereto since then to provide liability immunity for activities related to certain countermeasures against the ongoing COVID-19 pandemic. While we believe our products would be covered under the provisions of the PREP Act, this cannot be assured.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pediatric information</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, all marketing applications for new active ingredients, indications, dosage forms, dosing regimens or routes of administration must contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred or inapplicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Best Pharmaceuticals for Children Act, a product may be eligible for pediatric exclusivity, which adds six months to existing exclusivity periods and patent terms. This exclusivity may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued written request for such a study.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Post-approval requirements</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping activities, reporting of adverse experiences, complying with promotion and advertising requirements, and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. Prescription drug and biologic promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or NDA or BLA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy (REMS) to assure the benefits of the product outweigh the risks. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. Newly discovered or developed safety or effectiveness data may require changes to a drug&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures, including a REMS or the conduct of post-marketing studies to assess a newly discovered safety issue. Product approvals may be withdrawn for non-compliance with regulatory standards, or if problems occur following initial marketing.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP regulations. We and our third-party manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation, and the obligation to investigate and correct any deviations from cGMP. Entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections for compliance with cGMP requirements and other laws. The discovery of violations could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA or NDA, including recall.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. patent term restoration and marketing exclusivity</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch Waxman Amendments. The Hatch Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one half the time between the effective date of an IND and the submission date of a BLA or NDA, plus the time between the submission date of a BLA or NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for such an extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a drug product that contains an active ingredient not previously approved, the product is typically entitled to five years of non-patent regulatory exclusivity. Other products may be entitled to three years of exclusivity if approval was based on the FDA&#8217;s reliance on new clinical studies essential to approval submitted by the NDA applicant. If the NDA applicant studies the product for use by children, the FDA may grant pediatric exclusivity, which extends by 180 days each existing exclusivity (patent and regulatory) related to the product. </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009 (the BPCI Act). Biosimilarity requires a showing that the product is &#8220;highly similar&#8221; to the reference product notwithstanding minor differences in clinically inactive components and that there are no clinically meaningful differences between the product and the reference product in terms of safety, purity, and potency. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product. A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. </span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">European Union drug development</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicinal products can be marketed in the EU only if a marketing authorization from the competent regulatory agencies has been obtained. Similar to the United States, the various phases of preclinical and clinical research in the EU are subject to significant regulatory controls. Effective January 2022, the European Commission adopted a new Clinical Trials Regulation to streamline and harmonize the procedures for assessment and governance of clinical trials throughout the EU and to require that information on the authorization, conduct and results of each clinical trial conducted in the EU be publicly available.   </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pediatric investigation plan</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An application for marketing authorization of a medicinal product for human use that is not yet authorized in the EU must include a Pediatric Investigational Plan (PIP), unless a waiver applies. A scientific committee assesses the content of any PIP, waivers, and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deferrals for a medicinal product submitted to it in accordance with the regulation on medicinal products for pediatric use and formulates an opinion thereon.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">European drug review and approval</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Economic Area (EEA), which is comprised of the 27 Member States of the EU and Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a marketing authorization. A company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders, or diabetes, and optional for those medicines that are highly innovative, provides for the grant of a single marketing authorization that is valid for all EU Member States. In addition to the centralized procedure, the EEA also has a nationalized procedure, which requires a separate application to and approval determination by each country; a decentralized procedure, whereby applicants submit identical applications to several countries and receive simultaneous approval; and a mutual recognition procedure, where applicants submit an application to one country for review and other countries may accept or reject the initial decision.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">European exclusivity</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EEA, new innovative products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon the grant of a marketing authorization. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic or biosimilar application. There is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to be an innovative medicinal product, and products may not qualify for data exclusivity.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">European orphan designation and exclusivity</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation is available in the EEA to promote the development of products that are intended for the diagnosis, prevention, or treatment of life threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in the EU community, or where it is unlikely that the development of the medicine would generate sufficient return to justify the necessary investment in its development, and in each case for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or, if a method exists, the product would be a significant benefit to those affected). Medicinal products that receive and maintain orphan drug designation are entitled to 10 years of market exclusivity following approval. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">European data collection</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Data Protection Directive and the General Data Protection Regulation (GDPR) governs the collection and use of personal data in the EU. The GDPR imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU, provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20.0 million or 4.0% of the annual global revenues of the infringer, whichever is greater.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The UK has incorporated the GDPR (as it existed on December 31, 2020, but subject to certain UK specific amendments) into UK law (the UK GDPR). The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Although the UK is regarded as a third country under the EU&#8217;s GDPR, the European Commission has issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EU drug marketing</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like the Anti-Kickback Statute prohibition in the United States discussed below, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the EU. Infringement of relevant EU laws could result in substantial fines and imprisonment. Payments may be made to physicians in limited circumstances, and in certain EU Member States such payments must be publicly disclosed. Moreover, agreements with physicians for the provision of services often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rest of the world regulation</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States and the EU, the requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. If we fail to comply with such requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, or criminal prosecution.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other healthcare laws</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians, and third-party payors, including governmental payors such as Medicare and Medicaid will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Any arrangements with these parties may expose us to certain fraud and abuse and other healthcare laws and regulations. In the United States, these laws include, among others:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Anti-Kickback Statute, which makes it illegal for any person to knowingly and willfully solicit, receive, offer, or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug or any other good or service, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money to the federal government.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for, among other things, knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, or falsifying, concealing, or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and their respective implementing regulations, which impose, among other things, requirements on covered entities and their business associates relating to the privacy and security of individually identifiable health information. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, the ACA, which requires certain pharmaceutical manufacturers with products reimbursed under certain government programs to disclose annually to the federal government (for re-disclosure to the public) certain payments and other transfers of value provided to physicians, teaching hospitals and certain non-physician practitioners. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous state fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply regardless of payor. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain state and foreign laws also govern the privacy and security of health information. Such data privacy and security laws may differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts. For example, the California Consumer Protection Act (CCPA) established a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. Further, the California Privacy Rights Act (CPRA), which is scheduled to take effect on January 1, 2023 (with certain provisions having retroactive effect to January 1, 2022), will create additional obligations with respect to processing and storing personal information. While clinical trial data and information governed by HIPAA are currently exempt from the current versions of the CCPA and CPRA, other personal information may be applicable and possible changes to the CCPA and CPRA may broaden its scope.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. If our operations are found to be in violation of any of these laws or other related governmental regulations, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight, and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to similar actions, penalties, and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current and future healthcare reform legislation</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our investigational medicines, restrict or regulate post-approval activities, and affect our ability to profitably sell any approved products. The ACA, for example, contains provisions that subject biological products to potential competition by lower-cost biosimilars and may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and, annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any strategic collaborators, may receive for any approved products.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the United States, it is unclear whether the ACA will be overturned or further amended. We cannot predict what effect further changes to the ACA would have on our business. Additionally, other federal health reform measures have been proposed and adopted in the United States since the ACA was enacted, including the Budget Control Act of 2011, which includes provisions to reduce the federal deficit. The Budget Control Act, as amended, resulted in the imposition of 2% reductions in Medicare payments to providers, which began in April 2013 and will remain in effect through 2030 unless additional Congressional action is taken. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act), as well as subsequent legislation, these reductions have been suspended from May 1, 2020 through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 31, 2022 due to the COVID-19 pandemic. Then, a 1% payment reduction will occur beginning April 1, 2022 through June 30, 2022, and the 2% payment reduction will resume on July 1, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. In addition, the federal government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs, including price-controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs to limit the growth of government paid health care costs. For example, the federal government has passed legislation requiring pharmaceutical manufacturers to provide rebates and discounts to certain entities and governmental payors to participate in federal healthcare programs. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environment</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been adopted in foreign countries that impose similar obligations.</span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2634"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE INFORMATION</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware on July 22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Moderna LLC was the successor in interest to Moderna Therapeutics, Inc., a Delaware corporation incorporated in 2009 as Newco LS18, Inc. by Flagship Pioneering. In August 2018, we changed our name from Moderna Therapeutics, Inc. to Moderna, Inc. Our principal corporate office is located at 200 Technology Square, Cambridge, MA 02139, and our telephone number is (617) 714-6500.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our&#160;website, www.modernatx.com including the Investor Relations section, www.investors.modernatx.com; and corporate blog www.modernatx.com/moderna-blog; as well as our social media channels: Facebook, www.facebook.com/modernatx; Twitter, www.twitter.com/modernatx; and LinkedIn, www.linkedin.com/company/modernatx; contain a significant amount of information about us, including financial and other information for investors. We encourage investors to visit these websites and social media channels as information is frequently updated and new information is shared. The information on our website and that we disclose through social media channels is not incorporated by reference in this Annual Report on Form 10-K or in any other filings we make with the Securities and Exchange Commission (the SEC).</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC in accordance with the Exchange Act. These include our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q, and our </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC also maintains a website that contains reports, proxy and information statements, and other information regarding us and other issuers that file electronically with the SEC. The SEC&#8217;s Internet website address is http://www.sec.gov.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2385"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risks and uncertainties, together with all other information in this Annual Report on Form 10-K. Any of the risk factors we describe below could adversely affect our business, financial condition or results of operations, and the market price of our common stock. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to COVID-19, mRNA-1273 and our other vaccine candidates against the SARS-CoV-2 virus </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties producing, shipping or successfully commercializing our COVID-19 vaccine consistent with our existing or potential contractual obligations including due to delays or difficulties experienced by our commercial partners. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the global COVID-19 pandemic, we are continuing to pursue the rapid manufacture, distribution and clinical testing of our COVID-19 vaccine (mRNA-1273), which is our only commercial product and source of product revenues. We may encounter difficulties producing the vaccine on the timelines and in the quantities set forth in our existing or future supply agreements. We may also be unsuccessful in entering into contracts for future sales of COVID-19 vaccines. Our ability to commercialize an effective vaccine depends on our manufacturing capability, both at our own manufacturing facility and those of our manufacturing partners, which we rapidly scaled in response to the pandemic. We are committing substantial financial resources and personnel to the development, manufacture and distribution of our COVID-19 vaccine, including to support the scale-up of manufacturing to enable our pandemic response, which may cause delays in or otherwise negatively impact our other development programs. We may need to, or the U.S. government may require us to, divert resources and capital from our other programs to the production of COVID-19 vaccines. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have sufficient internal manufacturing infrastructure to support the global roll-out of our COVID-19 vaccine on our own. We have entered into strategic collaborations for the production, as well as for commercial fill-finish manufacturing, of our COVID-19 vaccine to supply markets both in and outside the United States. We may need to engage additional collaborators in the future, including contract manufacturing organizations (CMOs), government and non-government organizations, and other manufacturing partners, to assist in meeting our capacity needs. If we cannot enter into such arrangements on favorable terms, or at all, our ability to develop, manufacture and distribute our COVID-19 vaccine would be adversely affected. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, we had not ramped up our organization for a commercial launch of any product, and doing so during a pandemic with an urgent, critical global need poses additional challenges, such as setting up distribution channels, building global teams with specialized skills, and managing potential intellectual property disputes or challenges. We may also face challenges sourcing a sufficient amount of raw materials to support the demand for our COVID-19 vaccine. We may be unable to effectively create a supply chain for the vaccine to adequately support demand as we rely on our third-party collaborators being able to fulfill demand. For example, we have in the past and may in the future experience international shipping delays as our supply chain expands and grows more complex. Any capacity or production issues or delays experienced by our collaborators may cause us to fail to meet certain product volume or delivery timing obligations under our COVID-19 supply agreements. Furthermore, we will require significant additional investment, whether from our own capital resources or other sources of funding, as we continue to expand our commercial launch efforts. We cannot guarantee that any of these challenges and requirements will be met in a timely manner or at all. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The pharmaceutical market is intensely competitive. We may be unsuccessful in competing effectively in the market for existing products, new treatment methods, and new technologies, including for COVID-19 vaccines. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical market is intensely competitive and rapidly changing. Many pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research organizations are pursuing the development of products for the same diseases that we are targeting or expect to target, including COVID-19 vaccines, and these institutions and competitors may have: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater financial, technical, manufacturing, and human resources than we have at every stage of the discovery, development, manufacture, and commercialization of products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">more extensive experience in preclinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing, and selling products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple products that have been approved or are in late stages of development; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborative arrangements in our target markets with leading companies and research institutions. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face intense competition with respect to our COVID-19 vaccine from other vaccines and treatments, and our vaccine may not continue to compete favorably with existing or future products. Over two dozen COVID-19 vaccines have been authorized in various jurisdictions, including those produced by AstraZeneca, Johnson &amp; Johnson, and Pfizer/BioNTech, and many more remain in development. These vaccines or other treatments, such as antiviral pills produced by Pfizer and Merck, may prove to be safer, more </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective, more convenient, have fewer side effects, be easier to ship or distribute, or able to be developed at a lower cost than our vaccine. These factors, or the perception of these factors, among others, could lead to a competitor&#8217;s vaccine or other treatment to become the standard of care for COVID-19, have broader market acceptance, or be more successfully commercialized. The actual or perceived success or failure of other entities may adversely impact our ability to commercialize our COVID-19 vaccine. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also will face competition from products that have already been approved and accepted by the medical community for the treatment of conditions we target. For example, we are developing a seasonal flu vaccine, for which there is a well-developed market, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and we may be unsuccessful in developing a product or achieving market share. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may compete with products that are under development for the treatment of conditions we target, which other products may be more effective, safer, less expensive, or marketed and sold more effectively.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we successfully develop and obtain approval for investigational medicines, we will face competition based on many factors, including the safety and effectiveness of our products relative to any alternative therapies; the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration; the timing and scope of regulatory approvals; the availability and cost of manufacturing, marketing, and sales capabilities; the price of any approved medicine; reimbursement coverage; and patent position. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may commercialize products with significant advantages over any products we develop, and may benefit from strategic alliances with or funding from larger pharmaceutical or biotechnology companies. If our competitors are more successful in commercializing their products than we are, our competitive position and business would be adversely affected. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses of developing and commercializing our products, if approved. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be delayed or prevented from receiving full regulatory approval of our COVID-19 vaccine in certain jurisdictions or for certain demographics. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efficacy, effectiveness, safety, and immunogenicity data with respect to our COVID-19 vaccine, as well as real-world evidence, continue to accumulate. Further results from clinical trials, as well as the experience of vaccinated individuals, could show diminished protection compared to the results released to date, as efficacy and antibody persistence wane over time. Additionally, we may observe new, more frequent or adverse events of greater severity in subjects participating in ongoing clinical trials or among those individuals vaccinated with our COVID-19 vaccine. For example, some studies have suggested that our vaccine may be associated with higher rates of myocarditis and pericarditis in young males compared to other COVID-19 vaccines. Unexpected safety issues could significantly damage our reputation and that of our mRNA platform, and lead to other issues, including delays in our other programs, the need to re-design our clinical trials and the need for significant additional financial resources. In addition, the interpretation of the data from our clinical trials of our COVID-19 vaccine by the FDA and other regulators may differ from our interpretation and such agencies may require us to conduct additional studies or analyses, which may lead to delays in obtaining authorization for these medicines. For example, in October 2021, the FDA requested that we explore a lower dosage for our COVID-19 vaccine in adolescents, which extended the length of clinical trials in this population, delaying potential authorization in the U.S. These factors could delay or prevent us from receiving regulatory approval of our COVID-19 vaccine in certain jurisdictions or for certain demographics. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assays used to estimate the effectiveness of COVID-19 vaccines have only recently been developed and continue to evolve. Validation reports for these assays have been submitted for review to regulatory agencies. Results obtained in clinical studies of mRNA-1273 with later versions of these assays may be less positive than the results we have obtained to date. Moreover, blood samples from people who have recovered from COVID-19, used to benchmark the level of antibodies produced by subjects receiving mRNA-1273 in clinical studies, have been taken from a small number of people and may not be representative of the antibody levels in a broader population of people who have recovered from COVID-19, particularly as variant strains continue to emerge. The future results in clinical studies of mRNA-1273 may not be as positive when compared to the antibody levels in other blood samples.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unsuccessful in developing future versions of our COVID-19 vaccine to protect against variants of the SARS-CoV-2 virus, or booster doses of our vaccine may not protect against such variants, and a market for vaccines and boosters against these variants may not develop. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our original COVID-19 vaccine, mRNA-1273, was developed based upon the genetic sequence of the SARS-CoV-2 virus that was first detected in Wuhan, China. As the SARS-CoV-2 virus continues to evolve, new strains of the virus, or those that are already in circulation, may prove more transmissible or cause more severe forms of COVID-19 disease than the predominant strains to date. For example, the Omicron and Delta variants have been observed to be more transmissible, or contagious, than previous variants. There is a risk that mRNA-1273 will not be as effective in protecting against these or other future variant strains. For example, a standard two-dose inoculation of mRNA-1273 appears to be less effective at neutralizing the Omicron variant, which emerged in November 2021, than against the ancestral strain of SARS-CoV-2. Additionally, administration of booster doses of our vaccine may prove to be </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ineffective, or less effective than desired, against certain variants. We have several development candidates against variants of concern, and may develop others in the future. If these efforts are unsuccessful, we are slower to develop variant-specific vaccines than competitors, or these vaccine candidates prove less effective than competitors&#8217; vaccines, these shortcomings may lead to reputational harm, loss of market share, and adverse financial results. It is also possible that we may expend significant resources adapting our COVID-19 vaccine or conducting clinical trials to protect against variants of the SARS-CoV-2 virus, but that a market for this adapted vaccine does not develop or demand does not align with our projections or cost expenditures. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory pathway for COVID-19 vaccines is continually evolving, and may result in unexpected or unforeseen challenges. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine has moved rapidly through the regulatory review and authorization and approval processes in the U.S. and other jurisdictions. The speed at which COVID-19 vaccines and therapeutics are being created and tested is atypical, and evolving or changing plans or priorities within the FDA or other regulatory authorities, including changes based on new knowledge of COVID-19 and how the disease, and new variants of the virus, affect the human body, may significantly affect the regulatory timeline for further authorizations or approvals for our COVID-19 vaccine, including variant-specific versions of the vaccine. We cannot anticipate or predict with certainty the timelines or regulatory processes that may be required for the authorization or approval of updated versions of our COVID-19 vaccine, or vaccines that may be developed to fight against variants of the SARS-CoV-2 virus. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we currently operate under an EUA provided by the FDA for mRNA-1273 for as a booster dose for adults 18 years and older at least five months after completing a primary series of the vaccine, and as a third dose in immunocompromised individuals 18 years of age or older who have undergone solid organ transplantation, the FDA may revoke such authorization if it determines that the underlying health emergency no longer exists or warrants such authorization, and we cannot predict how long the EUA will remain in place. Such revocation could adversely impact our business in a variety of ways.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EMA has made a positive recommendation for the administration of Spikevax for children ages 6 to 11, in addition to the existing conditional marketing authorization from the EMA for Spikevax in adults and adolescents ages 12 and older. Although a conditional marketing authorization is a formal marketing authorization and covers all batches produced for the EU, we are obliged to provide certain additional information and data by specified timelines as conditions of the authorization, and the EMA can take regulatory action if we fail to comply. Conditional marketing authorizations are valid for one year and can be renewed annually; however, the EMA may decide not to renew. If new data emerges that shows the benefits of our vaccine do not continue to outweigh its risks, the EMA can suspend or revoke our authorization. Similar temporary, emergency authorizations that we have received for mRNA-1273 could be revoked if the conditions for granting the authorization no longer apply. Any such revocation of the temporary authorization to distribute mRNA-1273, without receiving final approval to distribute the vaccine, could adversely impact our ability to realize the full financial benefit of our existing or future supply agreements.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to deliver our vaccine to customers may be curtailed by one or more government actions or interventions, which may be more likely during a global health crisis, such as the COVID-19 pandemic. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that one or more government entities may take actions that directly or indirectly diminish our rights or opportunities with respect to our COVID-19 vaccine, limiting our economic prospects. In the United States, the Defense Production Act of 1950, as amended (the Defense Production Act), gives the U.S. government rights and authorities that may directly or indirectly diminish such rights or economic opportunities. Our current and potential third-party service providers may be impacted by government entities potentially invoking the Defense Production Act or other potential restrictions to all or a portion of services they might otherwise offer.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government entities imposing restrictions or limitations on our third-party service providers may require us to obtain alternative service sources for our COVID-19 vaccine or our vaccine candidates. If we are unable to timely enter into alternative arrangements on satisfactory terms, we will experience delays in the development or production of our COVID-19 vaccine and our vaccine candidates, increased expenses, and delays in distribution or commercialization of our COVID-19 vaccine, or, when and if approved, our vaccine candidates. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our supply contracts with the U.S. government for our COVID-19 vaccine restrict our ability to export vaccine that is produced from our U.S.-dedicated supply chain to markets outside the United States prior to satisfying our delivery obligations to the U.S. government. Furthermore, governments have threatened to block or limit the export of COVID-19 vaccines manufactured in their territories in instances where manufacturers have been delayed or have not fully satisfied their delivery obligations to those governments. Governments of the jurisdictions in which we or our contract manufacturing partners produce our COVID-19 vaccine may impose export restrictions, prohibiting us from delivering our COVID-19 vaccine to customers in other jurisdictions. The imposition of export controls could severely and adversely impact our manufacturing activities, commercial activities and financial results. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during a global health crisis, such as the COVID-19 pandemic, where the spread of a disease needs to be controlled, closed or heavily regulated, national borders create challenges and potential delays in our development and production activities and may necessitate that we pursue strategies to develop and produce our vaccines and vaccine candidates within self-contained national or international borders, at potentially much greater expense and with longer timeframes for public distribution.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our pipeline, product development and regulatory review</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical development is lengthy and uncertain, especially for a new class of medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to the clinic, any of which may have a material adverse impact on our platform or our business. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of our pipeline is in preclinical development, and these programs could be delayed or not advance into the clinic. Before we can initiate clinical trials for a development candidate, we must complete extensive preclinical studies, including IND-enabling good laboratory practice (GLP) toxicology testing, to support our planned INDs in the United States, or similar applications in other jurisdictions. We must also complete extensive work on Chemistry, Manufacturing, and Controls (CMC) activities (including yield, purity and stability data) to be included in an IND submission. CMC activities for a new class of medicines such as mRNA require extensive manufacturing processes and analytical development, which is uncertain and lengthy. For instance, batch failures as we scale up our manufacturing have occurred and may continue to occur. In addition, we have in the past and may in the future have difficulty identifying appropriate buffers and storage conditions to enable sufficient shelf life of batches of our development candidates. If we must produce new batches, preclinical studies or clinical trials could be delayed. We cannot be certain of the timely completion or outcome of our preclinical testing and studies, whether the FDA or other regulators will accept the results, or if the outcome of our preclinical testing, studies, and CMC activities will ultimately support the further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulators allowing clinical trials to begin. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development is lengthy and uncertain, especially with a new class of medicines such as mRNA medicines. Clinical trials of our investigational medicines may be delayed and certain programs may never advance in the clinic or may be more costly to conduct than we anticipate, any of which could have a material adverse impact on our platform or our business. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, complex and lengthy, and its outcome is inherently uncertain. There is a high rate of attrition for product candidates proceeding through clinical trials and most investigational medicines that commence clinical trials are never approved as products. We may not be able to initiate, may experience delays in, or may have to discontinue clinical trials for our investigational medicines. We and our strategic collaborators also may experience unforeseen events during, or as a result of, any clinical trials that we or they conduct that could delay or prevent us or them from successfully developing our investigational medicines and gaining approval from regulators. Delays or other events that might prevent us from proceeding with clinical trials include: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, Institutional Review Boards (IRBs), or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on favorable terms with prospective trial sites and prospective contract research organizations (CROs); </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to the scale and site of our manufacturing could lead to significant delays or changes in our clinical trial designs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of our preclinical studies and our early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to establish or achieve clinically meaningful endpoints for our studies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we make changes to our investigational medicines after clinical trials have commenced (which we have done in the past), we may be required to repeat earlier stages or delay later stages of clinical testing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of any investigational medicines may fail to show safety or efficacy, or produce negative or inconclusive results, and we may decide, or regulators may require us to conduct additional nonclinical studies or clinical trials, or we may decide to abandon product development programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical and clinical data are often susceptible to varying interpretations and analyses, and many investigational medicines believed to have performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our investigational medicines, or other medicines in the same class as ours, may have undesirable side effects, such as the immunogenicity of the LNPs or their components, the immunogenicity of the protein made by the mRNA, or degradation products, any of which could lead to serious adverse events, or other effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">administration of our LNPs could lead to systemic side effects related to the components of the LNPs and could contribute, in whole or in part, to one or more of the following: immune reactions, infusion reactions, complement reactions, opsonization reactions, antibody reactions, or reactions to PEG;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant adverse events or other side effects could be observed in our trials, including those involving dosing of young, human subjects with an investigational medicine;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or withdraw from the trial, which may require that we add new clinical trial sites; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may impose a complete or partial clinical hold on a trial, or we or our investigators, IRBs, or ethics committees may elect to suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to an unacceptable benefit-risk ratio; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may impose a complete or partial clinical hold on clinical trials of other companies working on mRNA medicines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of preclinical or nonclinical testing and studies and clinical trials of any investigational medicines may be greater than we anticipate; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our investigational medicines or other materials necessary to conduct clinical trials may be insufficient or inadequate; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and efficacy concerns regarding one or more of our investigational medicines will be considered by us and by the FDA and other global regulators as we pursue clinical trials of new investigational medicines, develop effective informed consent documentation and work with IRBs and scientific review committees (SRCs); </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety or efficacy concerns could arise from nonclinical or clinical testing of other therapies targeting a similar disease state or other therapies, such as gene therapy, that are perceived as similar to ours; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse side effects could be observed in future clinical trials where our investigational medicines are administered in combination with other therapies (such as the co-administration of our PCV investigational medicine, mRNA-4157</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a lack of adequate funding to continue a particular clinical trial.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has indicated that, prior to commencing later-stage clinical trials for our programs, we will need to develop assays to measure and predict the potency of a given dose of our investigational medicines. Any delay in developing assays that are acceptable to the FDA or other regulators could delay the start of future clinical trials. Additionally, we have conducted and may conduct in the future clinical trials that utilize an &#8220;open-label&#8221; trial design, where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an approved drug or placebo. The results from an open-label trial may not be predictive of future clinical trial results from a controlled environment with a placebo or active control. Further, the FDA or other regulators may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. Significant preclinical or nonclinical testing and studies or clinical trial delays for our investigational medicines could allow our competitors to bring products to market before we do. Any delays in the development of our investigational medicines may harm our business, financial condition, and prospects significantly. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are risks that are unique to each of our programs and modalities and risks that are applicable across programs and modalities. These risks may impair our ability to advance one or more of our programs in clinical development, obtain regulatory approval, or ultimately commercialize our products, or cause us to experience significant delays in doing so, any of which may materially harm our business. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a large pipeline of development candidates and investigational medicines, of which many are in clinical trials or have an open IND. Certain features in our development candidates and investigational medicines, including those related to mRNA, chemical modifications, surface chemistries, LNPs, and their components, may result in risks that apply to some or all of our programs and modalities. As our development candidates and investigational medicines progress, we or others may determine that: certain of our risk allocation decisions were incorrect or insufficient; we made platform-level technology mistakes; individual programs or our mRNA science in general has technology or biology risks that were unknown or under-appreciated; our choices on how to develop our infrastructure to support our scale will result in an inability to manufacture our investigational medicines for clinical trials or otherwise impair our manufacturing; or we have allocated resources in such a way that we cannot recover large investments or rapidly re-direct capital. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize earlier programs in a modality to understand the technology risks within the modality, including manufacturing and pharmaceutical properties. Even if our earlier programs in a modality are successful in any phase of development, any program may fail at a later phase of development, and other programs within the same modality may fail at any phase of development, including at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">phases where earlier programs in that modality were successful. This may be a result of technical challenges unique to that program or due to biology risk, which is unique to every program. The biology risk across the majority of our pipeline represents targets and pathways not clinically validated by one or more approved drugs, and the risk that the targets or pathways that we have selected may not be effective will continue to apply across the majority of our current and future programs.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we progress our programs through clinical development, new technical challenges may arise that cause an entire modality to fail. Additionally, any portfolio spanning risks, whether known or unknown, if realized in any one of our programs, would have a material and adverse effect on our other programs and on our business as a whole. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also specific additional risks to certain of our modalities and our programs as a whole. For example, prophylactic vaccines typically require clinical testing in up to tens of thousands of healthy volunteers to define an approvable benefit-risk profile. The need to show a high degree of safety and tolerability when dosing healthy individuals could result in rare and even spurious safety findings, negatively impacting a program prior to or after commercial launch. Even if we observe positive safety, tolerability, and levels of immunogenicity in early clinical trials, there can be no assurance that we will observe acceptable safety or efficacy profiles in later-stage trials required for approval of these programs. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For neoantigen cancer vaccines, to date, no molecular (non-cell-based) therapeutic protein vaccine has been shown to be effective against cancer and there are many clinical and manufacturing challenges to personalized medicines, including cell-based therapies and vaccines. These risks include: a rapid production turn-around time that is measured in weeks in order to supply patients in our clinical trials before further progression and mutation of their tumors, the significant costs incurred in making individualized vaccines, and potential lack of immune responses due to the biology of the tumor or immune status of the patient. These risks apply to our personalized cancer vaccine (PCV) and other neoepitope investigational medicine programs. Additionally, there may be challenges in delivering an adequate quantity of active pharmaceutical ingredient (API) required to drive efficacy due to the limitation in volume of API that can be delivered to a specific location, like a tumor or injured tissue. Our investigational therapies for local injections often require specialized skills for conducting a clinical trial that could delay trials or slow or impair commercialization of an approved investigational medicine due to the poor adoption of injected local therapeutics or intratumoral therapies. In addition, the uncertain translatability of target selection from preclinical animal models, including mouse and non-human primate models, to successful clinical trial results may be impossible, particularly for immuno-oncology and systemic therapies, and cancer vaccines. In general, several biological steps are required for delivery of mRNA to translate into therapeutically active medicines. These processing steps may differ between individuals or tissues, potentially leading to variable levels of therapeutic protein, variable activity, immunogenicity, or variable distribution to tissues for a therapeutic effect. Gene therapies and mRNA-based medicines may activate one or more immune responses against any and all components of the drug product (e.g., the mRNA or the delivery vehicle, such as an LNP) as well as against the encoded protein, giving rise to potential immune reaction related adverse events. Eliciting an immune response against the encoded protein may impede our ability to achieve a pharmacologic effect upon repeat administration or a side effect. These risks apply to all of our programs, including our systemic secreted therapeutics and systemic intracellular therapeutics modalities.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience delays in identifying and enrolling participants in our clinical trials, which would delay the progress of our investigational medicines and result in increased expenses.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying trial participants for our clinical trials of our investigational medicines is critical to our success. Difficulties or delays in enrollment may result in increased costs or may affect the timing or outcome of our planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our investigational medicines and obtain regulatory approval of potential products.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to identify, recruit, and enroll a sufficient number of trial participants, or those with required or desired characteristics to achieve diversity in a trial, to complete our clinical trials in a timely manner. As we did in our Phase 3 clinical study of mRNA-1273, we may slow enrollment in a trial to focus on achieving greater diversity in the subject population. Patient and subject enrollment is affected by factors including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">severity of the disease under investigation; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexity and design of the study protocol; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">size of the patient population; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eligibility criteria for the study in question, including age-based eligibility criteria limiting subject enrollment to adolescent or pediatric populations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proximity and availability of clinical study sites for prospective trial participants; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of competing therapies and clinical trials, including by third parties or our own clinical trials;  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient referral practices of physicians; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to monitor trial participants adequately during and after treatment; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinicians&#8217; and trial participants&#8217; perceptions as to the potential advantages and side effects of the investigational medicine being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results or other adverse safety signals in our trials or related to other investigational medicines, and the resulting negative publicity, which could discourage potential trial participants and their doctors from participating in our trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the case of our PCV, the need to wait for the manufacture of the personalized drug product; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain participant informed consent. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have entered into strategic alliances under which our strategic collaborators control the development of certain of our investigational medicines, which may provide us limited or no ability to influence the enrollment rate of our clinical trials. Even if we or our strategic collaborators are able to enroll trial participants, there is no guarantee that they will ultimately be dosed as part of, or complete, a clinical trial. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mRNA drug development has substantial clinical development and regulatory risks due to the novel nature of this new class of medicines, and the negative perception of the efficacy, safety, or tolerability profile of any investigational medicines that we or others develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No mRNA medicine has been granted full or conditional approval by the FDA or other regulators, other than COVID-19 vaccines. Successful discovery and development of mRNA medicines by us or our strategic collaborators is highly uncertain and depends on numerous factors, many of which are beyond our or their control. We constantly make business decisions and take calculated risks to advance our development efforts and pipeline, including those related to mRNA technology, delivery technology, and manufacturing processes, which ultimately may be unsuccessful. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mRNA investigational medicines that appear promising in the early phases of development may fail to advance, experience delays in the clinic, experience clinical holds, or fail to reach the market for many reasons, including: </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nonclinical or preclinical study, or clinical trial, results may show potential mRNA medicines to be less effective than desired or to have harmful or problematic side effects or toxicities;  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse results in our clinical trials, or in those of others developing similar products, or adverse effects relating to mRNA, or our LNPs, may lead to negative publicity or delays in or termination of one or more of our programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse events related to products that are perceived to be similar to mRNA medicines, such as those related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the insufficient ability of our translational models to reduce risk or predict outcomes in humans, particularly given that each component of our investigational medicines and development candidates may have a dependent or independent effect on safety, tolerability, and efficacy, which may, among other things, be species-dependent; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing failures or insufficient supply of cGMP materials for clinical trials, or higher than expected cost could delay or set back clinical trials, or make mRNA-based medicines commercially unattractive; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes that we make to optimize our manufacturing, testing or formulating of cGMP materials could impact the safety, tolerability, and efficacy profile of our investigational medicines and development candidates; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing or reimbursement issues or other factors that delay clinical trials or make any mRNA medicine uneconomical or noncompetitive with other therapies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our large pipeline of development candidates and investigational medicines could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to timely advance our programs or a failure or delay in receiving necessary regulatory approvals due to, among other factors, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, preparation of a BLA, or the equivalent application, discussions with the FDA or EMA, a regulatory request for additional nonclinical or clinical data, or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new legislation or regulations passed by U.S., state, or foreign governments in response to negative public perception of mRNA medicines; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proprietary rights of others and their competing products and technologies that may prevent our mRNA medicines from being commercialized. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are developing some of our development candidates or investigational medicines for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we currently attempt to address or may address in the future. For instance, for both MMA and PA, few clinical trials have been attempted, and there are no approved drugs to treat these diseases. As a result, the design and conduct of clinical trials of investigational medicines for the treatment of these disorders and other disorders may take longer, be more costly, or be less effective due to the novelty of development in these diseases. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators conduct. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and may view the efficacy results in the context of safety as not being supportive of licensure. Regulators in other countries may make similar findings with respect to these endpoints. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our investigational medicines are classified as gene therapies by the FDA and the EMA. The association of our medicines with gene therapies could result in increased regulatory burdens, impair the reputation of our investigational medicines, or negatively impact our platform or our business. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been few approved gene therapy products in the United States or foreign jurisdictions, and there have been well-reported significant adverse events associated with their testing and use. Regulatory requirements governing gene and cell therapy products have evolved and may continue to change in the future, and the implications for mRNA-based therapies are unknown. For example, the FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research (CBER) to consolidate the review of gene therapy and related products, and convenes the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In the EU, mRNA has been characterized as a gene therapy medicinal product, which falls within a broader category known as Advanced Therapy Medicinal Products (ATMPs), which are subject to additional regulatory requirements. In certain countries, mRNA therapies have not yet been classified or any such classification is not known to us; for example, in Japan, the Pharmaceuticals and Medical Devices Agency has not taken a position on the regulatory classification. Notwithstanding the differences between mRNA medicines and gene therapies, the classification of some of our mRNA investigational medicines as gene therapies in the United States, the EU, and potentially other countries could adversely impact our ability to develop our investigational medicines, negatively impacting our platform and our business. For instance, a clinical hold on gene therapy products may apply to our mRNA investigational medicines irrespective of the differences between gene therapies and mRNA. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events reported with respect to gene therapies could adversely impact one or more of our programs. Although our mRNA development candidates and investigational medicines are generally designed not to make any permanent changes to cell DNA, regulatory agencies or others could believe that adverse effects of gene therapies caused by introducing new DNA and irreversibly changing the DNA in a cell could also be a risk for our mRNA investigational therapies, and as a result may delay one or more of our trials or impose additional testing for long-term side effects. Any new requirements and guidelines promulgated by regulatory review agencies may negatively affect our business by lengthening the regulatory review process, requiring us to perform additional or larger studies, or increasing our development costs, any of which could lead to changes in regulatory positions and interpretations, delay or prevent advancement or approval and commercialization of our investigational medicines, or lead to significant post-approval studies, limitations, or restrictions. As we advance our investigational medicines, we will be required to consult with these regulatory agencies and advisory committees and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of some or all of our investigational medicines.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have established Moderna Genomics (MGX) with the vision of becoming a leader in large, complex genomic editing. In November 2021, we announced a multi-year research collaboration with Metagenomi to leverage Metagenomi&#8217;s discovery platform and expertise to develop next-generation </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene editing therapies. Our work in genomic editing is subject to all risks associated with gene therapies. Although there have been significant advances in recent years in fields of gene therapy and genome editing, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRISPR-based genome editing technologies are relatively new and their therapeutic utility is largely unproven. Public perception and related media coverage of potential therapy-related efficacy or safety issues, as well as ethical concerns related specifically to genome editing, may adversely influence the willingness of subjects to participate in clinical trials. In addition, any review conducted by an institutional biosafety committee may result in delay or prevent initiation of a gene therapy clinical trial. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if any such therapeutic is approved, physicians and patients may be slow or fail to accept these novel and personalized treatments. Physicians, health care providers and third-party payors often are slow to adopt new products, technologies and treatment practices, particularly those that may also require additional upfront costs and training. Physicians may not be willing to undergo training to adopt these novel and potentially personalized therapies, may decide the particular therapy is too complex or potentially risky to adopt without appropriate training, and may choose not to administer the therapy. Further, due to health conditions, genetic profile or other reasons, certain patients may not be candidates for the therapies. In addition, responses by federal and state agencies, congressional committees and foreign governments to negative public perception, ethical concerns or financial considerations may result in new legislation, regulations, or medical standards that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. Based on these and other factors, health care providers and payors may decide that the benefits of these new therapies do not or will not outweigh their costs.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakthrough therapy designation or fast track designation, or accelerated approval, by the FDA or comparable pathways in other jurisdictions for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have received Fast Track Designation for some of our investigational medicines and may seek Fast Track Designation or breakthrough therapy designation for others. The FDA has broad discretion whether or not to grant either designation, and the receipt of either designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures. Even if one or more of our investigational medicines qualify for Fast Track Designation or as breakthrough therapies, the FDA may later decide that the investigational medicine no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened. Additionally, even if we obtain accelerated approval in the United States or under comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, the FDA generally requires pre-approval of promotional materials for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of the product. Further, </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may not receive ultimate approval or we may be approved only for a limited indication, we may not successfully complete required post-approval trials, such trials may not confirm the clinical benefit of our drug, or approval of the drug may be withdrawn.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to obtain and maintain orphan drug designations for our investigational medicines. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may file for orphan drug designation where available for our investigational medicines. We may never receive such designation for any particular medicine. Although we have received orphan drug designation from both the FDA and the European Commission for PA (mRNA-3927) and GSD1a (mRNA-3745), orphan drug designation neither shortens the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval process. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication, or may be lost if the FDA later determines that the request for designation was materially defective. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may be approved for the same condition, and only the first applicant to receive approval will receive the benefits of marketing exclusivity. Even after an orphan-designated product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior if it is shown to be safer, more effective, or makes a major contribution to patient care. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investigational medicines may face competition from biosimilars approved through an abbreviated regulatory pathway. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 12-year period of exclusivity provided by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologics Price Competition and Innovation Act of 2009, or BPCI Act</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, another company may still market a competing version of a product if the FDA approves a BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials demonstrate the safety, purity, and potency of the other company&#8217;s product. The BPCI Act is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that any exclusivity we receive for an investigational medicine could be shortened due to Congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCI Act, some of which may impact the BPCI Act&#8217;s exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot obtain, or are delayed in obtaining, required regulatory approvals, we will be unable to commercialize, or will be delayed in commercializing, investigational medicines we may develop. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any mRNA medicine we may develop and the activities associated with its development and commercialization, including design, testing, manufacture, record-keeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and comparable foreign regulators. To obtain required regulatory approvals to commercialize any of our investigational medicines, we and our strategic collaborators must demonstrate through extensive preclinical studies and clinical trials that our products are safe, pure, and potent in humans, including the target population. Successful completion of clinical trials is a prerequisite to submitting a BLA to the FDA, a marketing authorization application (MAA) to the EMA, and similar marketing applications to comparable global regulatory authorities, for each investigational medicine and, consequently, the ultimate approval and commercial marketing of any investigational medicines. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not received approval to market any investigational medicine, other than our COVID-19 vaccine, in any jurisdiction, and our current or future development candidates or investigational medicines may never obtain regulatory approval</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have limited experience in filing and supporting the necessary applications for marketing approvals and may need to rely on third-party CROs or </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory consultants to assist us in this process. Although we expect to submit BLAs for our mRNA-based investigational medicines in the United States, other jurisdictions may consider our mRNA-based investigational medicines to be new drugs, not biologics, and require different marketing applications. Preclinical studies and clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and approval in one country does not guarantee regulatory approval in another. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any investigational medicines we develop may be ineffective, only moderately effective, or have undesirable or unintended side effects, toxicities, or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the process of obtaining marketing approvals, both in the United States and abroad, is expensive, time-consuming, and uncertain, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the investigational medicines involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may delay the review of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of an investigational medicine. Additional delays or non-approval may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulators review the CMC section of regulatory filings. Any aspects found unsatisfactory by regulatory agencies may result in delays in clinical trials and commercialization. In addition, the regulatory agencies conduct pre-approval inspections at the time of a BLA. Any findings by regulatory agencies and failure to comply with requirements may lead to delay in approval and failure to commercialize the potential investigational medicine. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of any investigational medicines we may develop, the commercial prospects for those investigational medicines will be harmed, and our ability to generate revenues will be materially impaired. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products are, and any future products will be, subject to regulatory scrutiny. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval in a jurisdiction, the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our investigational medicines.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, our contract manufacturers or other strategic collaborators fail to comply with applicable regulatory requirements following approval of any of our investigational medicines, a regulatory agency may:  issue a warning letter asserting that we are in violation of the law; seek an injunction or impose civil or criminal penalties or monetary fines; suspend or withdraw regulatory approval or revoke a license; suspend any ongoing clinical trials; refuse to approve a pending BLA or supplements to a BLA submitted by us; seize or recall investigational medicines or products; or refuse to allow us to enter into supply contracts, including government contracts. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any approved products and generate revenues.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA or other regulators could require us to adopt a Risk Evaluation and Mitigation Strategy for any approved investigational medicine to ensure that the benefits of treatment outweigh the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. Furthermore, if we or others later identify undesirable side effects caused by any product that we develop, several potentially significant negative consequences could result, including the suspension or withdrawal of approvals and licenses; the addition of warning labels; changes to the way a product is administered; the requirement to conduct further clinical trials; lawsuits or increased liability for harm to patients and their children; and reputational harm. Any of these events could prevent us from achieving or maintaining market acceptance of any products we develop and could have a material adverse impact on our business, financial condition, results of operations, and prospects. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even though the Moderna COVID-19 Vaccine/Spikevax has been approved by the FDA for individuals 18 years of age and older in the United States, it remains the subject of regulatory scrutiny. For example, we are required to conduct post-marketing studies to further assess the risks of myocarditis and pericarditis following vaccination with Spikevax. Additionally, we have committed to conducting additional post-marketing safety studies, including conducting a pregnancy registry study to evaluate pregnancy and infant outcomes after receipt of Spikevax during pregnancy. We or others could identify previously unknown side effects, or known side effects could be observed as being more frequent or severe than in clinical studies or earlier post-marketing periods, in which case: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of mRNA-1273 may be more modest than originally anticipated; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA and other regulatory agencies may revoke authorizations for the vaccine; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may decide, or be required, to conduct recalls or send field alerts to physicians, pharmacists and hospitals; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional nonclinical or clinical studies, changes in labeling, or changes to manufacturing processes, specifications and/or facilities may be required; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government investigations or lawsuits, including class-action lawsuits, may be brought against us. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above occurrences could reduce or prevent sales of our COVID-19 vaccine, increase our expenses and impair our ability to successfully commercialize the vaccine.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to the manufacturing of our commercial products, development candidates, investigational medicines and our future pipeline </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our mRNA products, including our COVID-19 vaccine, development candidates and investigational medicines are based on novel technologies and are complex and difficult to manufacture. We or our third-party manufacturers may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping for any of our medicines.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing processes for our medicines, including our COVID-19 vaccine, are novel and complex. No mRNA medicine, other than COVID-19 vaccines, has been commercialized to date. Due to the novel nature of mRNA technology and our limited experience at larger scale production, we and our collaborators have experienced and may continue to encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping. These issues could be due to many reasons, including complexities of producing batches at larger scale, equipment failure, human error, choice and quality of raw materials and excipients, analytical testing technology, and product instability. Further, mRNA medicines encapsulated in LNPs must be developed and manufactured under well-controlled conditions, or pharmacological activity can be adversely impacted.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to optimize product features, we have in the past and may in the future make changes to our development candidates or investigational medicines in their manufacturing and stability formulation and conditions. This has in the past and may in the future result in our having to resupply batches for preclinical or clinical activities when there is insufficient product stability during storage and insufficient supply. Insufficient stability or shelf life of our development candidates and investigational medicines could materially delay our or our strategic collaborators&#8217; ability to continue the clinical trial for that development candidate or investigational medicine or require us to begin a new clinical trial with a newly formulated drug product, due to the need to manufacture additional preclinical or clinical supply.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our rate of innovation is high, which has resulted in and will continue to cause a high degree of technology change that can negatively impact product comparability during and after clinical development. Furthermore, technology changes may drive the need for changes in, modification to, or the sourcing of new manufacturing infrastructure or may adversely affect third-party relationships. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many cases, we may need to utilize multiple batches of drug substance and drug product to meet the clinical supply requirement of a single clinical trial. Failure in our ability to scale up batch size or failure in any batch may lead to a substantial delay in our clinical trials or in the commercialization of any approved product. For example, the changes we make as we continue developing new manufacturing processes for our drug substance and drug product may impact specification and stability of the drug product, and may lead to failure of batches, resulting in a substantial delay in delivery of commercial product or conduct of our clinical trials. Our mRNA investigational medicines may prove to have a stability profile that leads to a lower than desired shelf life of the final approved mRNA medicine. This poses risk in supply requirements, wasted stock, and higher cost of goods. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on a number of equipment providers who are also implementing novel technology. Further, we have developed our own custom manufacturing equipment for certain of our medicines. If we encounter unexpected performance issues with such equipment, we could encounter delays or interruptions to clinical and commercial supply. Due to the number of different programs, we may have cross contamination of investigational medicines inside of our factories, CROs, suppliers, or in the clinic that affect the integrity of our investigational medicines. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we scale the manufacturing output for commercial production and particular programs, we plan to continuously improve yield, purity, and the pharmaceutical properties of our commercial products, development candidates and investigational medicines from </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IND-enabling studies through commercial launch, including shelf life stability, and solubility properties of drug product and drug substance. Because of continuous improvement in manufacturing processes, we may switch processes for a particular program during development. However, after a change in process, more time will be required for pharmaceutical property testing, such as 6 or 12 month stability testing. That may require resupplying clinical material or making additional cGMP batches to keep up with clinical trial demand before such pharmaceutical property testing is completed. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are utilizing a number of raw materials and excipients that have a single source of supply, are new to the pharmaceutical industry, and are being employed in a novel manner. Some of these raw materials and excipients have not been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures, or supply shortages. Such issues with raw materials and excipients could cause delays or interruptions to clinical and commercial supply of our investigational medicines. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a number of analytical assays, and may have to establish several more, to assess the quality of our mRNA investigational medicines. We may identify gaps in our analytical testing strategy that might prevent release of product or could require product withdrawal or recall. For example, we may discover new impurities that have an impact on product safety, efficacy, or stability. This may lead to an inability to release mRNA investigational medicines until the manufacturing or testing process is rectified. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As our drug development pipeline increases and matures, the increased demand for clinical and commercial supplies from our facilities and third parties may impact our ability to operate. We rely on many service providers, all of whom have inherent risks in their operations that may adversely impact our operations. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completion of our clinical trials and commercialization of our vaccine candidates require access to, or development of, facilities to manufacture our vaccine candidates at sufficient yields and at commercial-scale. We have limited experience manufacturing any of our vaccine candidates in the volumes that are necessary to support large-scale clinical trials or commercial sales. Efforts to establish these capabilities may not meet initial expectations as to scheduling, scale-up, reproducibility, yield, purity, cost, potency or quality. If we are unable to institute necessary controls related to product development, manufacturing and quality, our operations may be adversely impacted. In addition, other companies, many with substantial resources, compete with us for access to the materials needed to manufacture our vaccines. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently utilize, and expect to continue to utilize, third parties to, among other things, manufacture raw materials, components, parts, and consumables, and to perform quality testing. If the field of mRNA and other nucleic acid medicines continues to expand, we may encounter increasing competition for these materials and services. Demand for third-party manufacturing or testing facilities may grow at a faster rate than their existing capacity, which could disrupt our ability to find and retain third-party manufacturers capable of producing sufficient quantities of such raw materials, components, parts, and consumables required to manufacture our mRNA investigational medicines. The use of service providers and suppliers could expose us to risks, including, but not limited to: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or non-renewal of supply and service agreements with third parties in a manner or at a time that is costly or damaging to us; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to the operations of these suppliers and service providers caused by conditions unrelated to our business or operations, including the bankruptcy of the supplier or service provider; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspections of third-party facilities by regulatory authorities that could have a negative outcome and result in delays to or termination of their ability to supply our requirements. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third-party manufacturers may adversely affect our operations or result in unforeseen delays or other problems beyond our control. Because of contractual restraints and the limited number of third-party manufacturers with the expertise, required regulatory approvals and facilities to manufacture our bulk vaccines on a commercial scale, replacement of a manufacturer may be expensive and time-consuming and may cause interruptions in the production of our vaccine. A third-party manufacturer may also encounter difficulties in production, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties with production costs, scale up and yields; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of raw materials and supplies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality control and assurance; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shortages of qualified personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with strictly enforced regulations that vary in each country where products might be sold; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of capital funding. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or interruption could adversely affect our business, financial condition, or results of operations. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to operational risks associated with the physical and digital infrastructure at both our internal manufacturing facilities and at those of our external service providers. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our MTC facility in Norwood, Massachusetts incorporates a significant level of automation of equipment with integration of several digital systems to improve efficiency of operations. Our high level of digitalization may pose risk of process equipment malfunction and even overall manufacturing system failure or shutdown due to internal or external factors including, but not limited to, design issues, system compatibility, or potential cybersecurity breaches. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities or those of our contract manufacturers may also be subject to intentional attacks or acts of sabotage by outside actors, contractors or employees. Any disruption in our or our contract manufacturers&#8217; manufacturing capabilities could cause delays in production capacity for our drug substances or products or a shutdown of facilities, could impose additional costs, or may require us to identify, qualify, and establish an alternative manufacturing site, the occurrence of which could adversely affect our business, financial condition, results of operations, and prospects. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our development and commercial capacities, we have and expect that we will continue to establish additional manufacturing capabilities inside the MTC footprint and that we will expand to other locations and geographies, such as Africa, Australia and Canada. This expansion may lead to regulatory delays or prove more costly than anticipated. If we fail to select a suitable location, complete construction in an efficient manner, engage effectively with local regulators, recruit the required personnel, and generally manage our growth effectively, the development and production of commercial products or our investigational medicines could be delayed or curtailed. We expect that we will continue to make additional investments in our manufacturing processes as we expand the MTC and our other manufacturing infrastructure. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products and investigational medicines are sensitive to shipping and storage conditions, which, in some cases, requires cold-chain logistics and subjects our investigational medicines to risk of loss or damage. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine and our investigational medicines are sensitive to temperature, storage, and handling conditions, and we could lose medicines if the product or product intermediates are not stored or handled properly. Shelf life for our products and investigational medicines is expected to be variable, and our investigational medicines may expire prior to use. Cold-chain logistics are required for certain of our investigational medicines and our COVID-19 vaccine. If we or third-party distributors do not maintain effective cold-chain supply logistics, then we may experience an unusual number of returned or out of date products and critical batches of products may be rendered unusable. This has in the past and could in the future lead to additional manufacturing costs and delays in our ability to supply required quantities for clinical trials, commercial sale, or otherwise. In addition, the cost associated with such transportation services and the limited pool of vendors could cause supply disruptions.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to significant regulatory oversight with respect to manufacturing our COVID-19 vaccine and our mRNA investigational medicines. Our manufacturing facilities or the manufacturing facilities of our third-party manufacturers or suppliers may not meet regulatory requirements. Failure to meet cGMP requirements set forth in regulations promulgated by the FDA, EMA, and other global health authorities could result in significant delays in any approval of and costs of our products. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing of medicines for clinical trials or commercial sale is subject to extensive regulation, and components of such products must be manufactured in accordance with cGMP requirements, which are enforced, in the case of the FDA, in part through its facilities inspection program. The regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of products and materials used in clinical trials. Poor control of the cGMP production processes can lead to product quality failures that can impact our ability to supply product, resulting in cost overruns and delays to clinical timelines, which could be extensive. Such production process issues include but are not limited to: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">critical deviations in the manufacturing process; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility and equipment failures; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contamination of the product due to an ineffective quality control strategy; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility contamination as assessed by the facility and utility environmental monitoring program; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raw material failures due to ineffective supplier qualification or regulatory compliance issues at critical suppliers; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffective product stability; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ineffective corrective actions or preventative actions taken to correct or avoid critical deviations due to our developing understanding of the manufacturing process as we scale; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failed or defective components or consumables. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities typically require representative manufacturing site inspections to assess adequate compliance with cGMP and manufacturing controls. If we or one of our third-party manufacturing sites fails to provide sufficient quality assurance or control, the product approval to commercialize may not be granted. Inspections by regulatory authorities may occur at any time during the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development or commercialization phase of products. The inspections may be product specific or facility specific for broader cGMP inspections, or as a follow up to market or development issues that the regulatory agency may identify. Deficient inspection outcomes may negatively impact the ability of our third-party manufacturers or suppliers to fulfill their supply obligations, impacting or delaying supply or delaying programs. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for our COVID-19 vaccine, and for any other products that we may develop, is subject to the FDA and foreign regulatory authority approval process. If we or our third-party manufacturers are unable to reliably produce products or investigational medicines to specifications acceptable to the FDA or other regulatory authorities, we or our strategic collaborators may not obtain or maintain the approvals needed to commercialize such products. Even if regulatory approval is obtained for any of our mRNA medicines, there is no assurance that either we or our CMOs will be able to manufacture the approved medicine to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our investigational medicines, impair commercialization efforts, or increase our cost of goods, which, in turn, could have an adverse effect on our business, financial condition, results of operations, and prospects. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may not have direct control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance, and qualified personnel. Our contract manufacturers supply or manufacture materials or products for other companies, and their failure to meet applicable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory requirements may generally affect the regulatory status of their facilities. In addition, to the extent that we rely on foreign contract manufacturers, including for our COVID-19 vaccine, we are subject to additional risks, including the need to comply with import and export regulations. Additionally, our potential future dependence on others to manufacture our investigational medicines and raw materials may adversely affect our future profit margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, the EMA, and other foreign regulatory authorities may require us to submit product samples of any lot of any approved product, together with the protocols showing the results of applicable tests, at any time. In some cases, regulators may prohibit us from distributing a lot or lots until it authorizes release. Deviations in the manufacturing process, including those affecting quality attributes and stability, may cause unacceptable changes in the product, resulting in lot failures or product recalls. Our third-party contract manufacturers have experienced lot failures and one has experienced a product recall related to our COVID-19 vaccine. Lot failures have in the past caused, and lot failures or product recalls in the future with respect to product produced by either our own or our third-party manufacturers&#8217; facilities could cause, us and our strategic collaborators to delay clinical trials or product launches, which could harm our business, financial condition, results of operations, and prospects. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our manufacturing partners also may encounter problems hiring and retaining the experienced scientific, quality control, and manufacturing personnel needed to operate our manufacturing processes and operations or those of our manufacturing partners, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Additionally, we may not be able to control for or ultimately detect intentional sabotage or negligence by any employee or contractor. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our PCV investigational medicine is uniquely manufactured for each patient using a novel, complex manufacturing process and we may encounter difficulties in production. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We custom design and manufacture PCVs that are unique and tailored specifically for each patient. Manufacturing unique lots of PCVs is susceptible to product loss or failure due to issues with: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">logistics associated with the collection of a patient&#8217;s tumor, blood, or other tissue sample; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shipping such samples to a facility for genetic sequencing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">next generation sequencing of the tumor mRNA; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of appropriate tumor-specific mutations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the use of a software program, including proprietary and open source components, which is hosted in the cloud and a part of our investigational medicine, to assist with the design of the patient-specific mRNA, which software must be maintained and secured; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effective design of the patient-specific mRNA that encodes for the required neoantigens; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">batch specific manufacturing failures or issues that arise due to the uniqueness of each patient-specific batch; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality control testing failures; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected failures of batches placed on stability; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shortages or quality control issues with single-use assemblies, consumables, or critical parts sourced from third-party vendors that must be changed out for each patient-specific batch; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs associated with individualized manufacturing that may adversely affect our ability to continue development; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful and timely manufacture and release of the patient-specific batch; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">shipment issues encountered during transport of the batch to the patient site of care; and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to define a consistent safety profile at a given dose when each participant receives a unique vaccine. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built and installed custom manufacturing equipment for PCVs that has been incorporated into a personalized vaccine unit in the MTC. This equipment may not function as designed, resulting in deviations in the drug product produced, which could lead to increased batch failure and the inability to supply patients enrolled in the clinical trial. If our clinical development plans are expanded, due to the custom nature of the equipment and single-use assemblies, we may require significant investments. In addition, it would take considerable time to scale up our facilities or build new facilities to meet any commercial demand if our PCV product is approved. This expansion or addition of new facilities could also lead to product comparability issues, which could further delay introduction of new capacity.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our PCVs are manufactured for each individual patient, we are required to maintain a chain of identity with respect to each patient&#8217;s tissue sample, sequence data derived from such tissue sample, results of analysis of such patient&#8217;s genomic analysis, and the custom manufactured product for each patient. Maintaining such a chain of identity is difficult and complex, and failure to do so has in the past and may in the future result in product mix up, adverse patient outcomes, loss of product, or regulatory action including withdrawal of any approved products from the market. Further, as our PCV is developed through early-stage clinical trials to later-stage clinical trials towards approval and commercialization, we expect that multiple aspects of the complicated collection, analysis, manufacture, and delivery process will be modified in an effort to optimize processes and results. These changes may not achieve the intended objectives, and any of these changes could cause our PCVs to perform differently than we expect, potentially affecting the results of clinical trials. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our reliance on third parties </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our products, development candidates and investigational medicines. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop and commercialize, our COVID-19 vaccine, development candidates and investigational medicines. We cannot ensure that these suppliers will remain in business, have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that will cease working with us. Our use of single-source suppliers exposes us to several risks, including disruptions in supply, price increases, or late deliveries. Any disruption in supply from any single-source supplier could lead to supply delays or interruptions that would damage our business, financial condition, results of operations, and prospects. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are, in general, relatively few alternative sources of supply for substitute components. If we have to switch to a replacement supplier, the manufacture and delivery of our products, development candidates or investigational medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our products or investigational medicines, if required, may not be accomplished quickly, if at all. Any replacement supplier would need to be qualified and may require additional regulatory authority approval, resulting in further delay. Any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our investigational medicines. Additionally, as part of the FDA&#8217;s approval of our investigational medicines, the FDA will review the individual components of our process, which include the manufacturing processes and facilities of our single-source suppliers.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have in the past entered into, and in the future may enter into, strategic alliances with third parties for the development and commercialization of our and their products, development candidates and investigational medicines. If these strategic alliances are not successful, our business could be adversely affected. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into strategic alliances under which our strategic collaborators have provided, and may in the future provide, funding and other resources for developing, manufacturing and commercializing our investigational medicines. Additionally, as we have begun to generate revenue, we have begun to enter into strategic alliances where we agree to provide funding and other resources to third parties. We expect to enter into additional strategic alliances in the future. Our existing strategic alliances, and any future strategic alliances we enter into, may pose a number of risks, including the following: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not perform their obligations as expected; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical trials conducted as part of such strategic alliance may not be successful; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not pursue development and commercialization of any investigational medicines that achieve regulatory approval or may elect not to continue or renew development or commercialization of programs based on clinical trial results, changes in the strategic collaborators&#8217; focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial, abandon an investigational medicine, repeat or conduct new clinical trials, or require a new formulation of an investigational medicine for clinical testing; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators could develop, independently or with third parties, products that compete directly or indirectly with our products or investigational medicines if such collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">products or investigational medicines developed in strategic alliances with us may be viewed by our strategic collaborators as competitive with their own investigational medicines or products, which may cause strategic collaborators to cease to devote resources to the development or commercialization of our investigational medicines; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a strategic collaborator with marketing and distribution rights to one or more of our products or investigational medicines that achieve regulatory approval may commit insufficient resources to the marketing and distribution of any such product; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with strategic collaborators, including over proprietary rights, contract interpretation, or the course of development of any investigational medicines, may cause delays or termination of the research, development, or commercialization of such investigational medicines, lead to additional responsibilities for us with respect to such investigational medicines, or result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may not properly maintain or defend our IP rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our IP or proprietary information; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of IP developed pursuant to our strategic alliances; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic collaborators may infringe the IP rights of third parties, exposing us to potential litigation and liability; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could face significant competition in seeking appropriate strategic collaborators and the negotiation process is time-consuming and complex; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our international operations through any future collaborations, acquisitions, or joint ventures may expose us to certain operating, legal, and other risks not encountered in the United States. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic collaborators generally may materially amend or terminate their agreements with us for convenience, which has happened in the past. If any collaboration agreement is terminated, we may not receive future research funding or milestone, earn-out royalty or other contingent payments, and the development of our investigational medicines may be delayed. It may also be difficult to attract new strategic collaborators to continue development or commercialization of the applicable investigational medicine, and the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval, and commercialization described in this Annual Report on Form 10-K apply to the activities of our strategic collaborators.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek to establish additional strategic alliances and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. Certain of our strategic alliance agreements may restrict our ability to develop certain products. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development programs and the potential commercialization of our development candidates and investigational medicines will require substantial additional cash to fund expenses. We may collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of some of our investigational medicines, and we face significant competition in seeking appropriate strategic collaborators. Our ability to establish additional strategic alliances will depend, among other things, on our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed strategic alliance, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject investigational medicine, the costs and complexities of manufacturing and delivering such investigational medicine to trial participants, the potential of competing drugs, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. Any potential strategic collaborator may ultimately collaborate on alternative investigational medicines or technologies for similar indications rather than collaborate with us.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also restricted under our existing strategic alliance agreements from entering into agreements on certain terms with potential strategic collaborators to pursue other targets on our own. These restrictions on working with targets, polypeptides, routes of administration, and fields could limit our ability to enter into strategic collaborations with other collaborators or to pursue certain potentially valuable development candidates or investigational medicines. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Strategic alliances are complex and time-consuming to negotiate and document. If we cannot negotiate and enter into new strategic alliances on a timely basis, on favorable terms, or at all, we may need to curtail the development of the investigational medicine for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">undertake development or commercialization activities at our own expense. We may need to obtain additional capital to fund these efforts, and the inability to obtain such funding on favorable terms may prevent us from further developing our investigational medicines or bringing them to market and generating product revenue.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on and expect to continue to rely on third parties to conduct aspects of our research, preclinical studies, protocol development, and clinical trials for our development candidates and investigational medicines. If these third parties do not perform satisfactorily, comply with regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our investigational medicines and our business could be substantially harmed. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties such as CROs to help manage certain preclinical work and our clinical trials, and on medical institutions, clinical investigators and CROs to assist in the design and review of, and to conduct, our clinical trials, including enrolling qualified patients. In addition, we engage third-party contractors and collaborators to support numerous other research, commercial and administrative activities, which reduces our control over these activities but does not relieve us of our responsibilities, such as ensuring that each of our clinical trials is conducted in accordance with its general investigational plan and protocols. Moreover, the FDA requires us to comply with GLPs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and good clinical practices for conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that in the case of clinical trials the rights, integrity and confidentiality of trial participants are protected. Such standards will evolve and subject us and third parties to new or changing requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If third parties do not successfully carry out their contractual duties or meet expected deadlines, we may need to replace them, which could cause a delay of the affected clinical trial, drug development program or applicable activity. If clinical trials are not conducted in accordance with our contractual expectations or regulatory requirements, action by regulatory authorities may significantly and adversely affect the conduct or progress of such trials or even require a clinical trial to be redone. Accordingly, our efforts to obtain regulatory approvals for and commercialize our drug candidates could be delayed. In addition, failure of any third-party contractor to conduct activities in accordance with our expectations could adversely affect the relevant research, development, commercial or administrative activity.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our intellectual property</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain and enforce patent protection for our discoveries, or protect the confidentiality of our trade secrets, our ability to effectively compete using our development candidates will be harmed. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends, in part, on our ability to protect proprietary methods and technologies that we develop under the patent and other IP laws of the United States and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. Because certain U.S. patent applications are confidential until the patents issue, such as applications filed prior to November 29, 2000, or applications filed after such date which will not be filed in foreign countries, third parties may have filed patent applications for technology covered by our pending patent applications without our being aware of those applications, and our patent applications may not have priority over those applications. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions, including our COVID-19 vaccine. For this and other reasons, we may be unable to secure desired patent rights, thereby losing exclusivity. Further, we may be required to obtain licenses under third-party patents to market our proposed products or conduct our research and development or other activities. If licenses are not available to us on favorable terms, we may not be able to market the affected products or conduct the desired activities. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining patent protection is expensive and time-consuming and our pending patent applications may not result in issued patents. Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent applications may fail to result in valid enforceable patents, or our patent protection could be reduced or eliminated, for non-compliance with these requirements. If we or our present or future strategic collaborators fail to file and prosecute all necessary and desirable patent applications at a reasonable cost and in a timely manner, our business may be adversely affected. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our and our strategic collaborators&#8217; efforts to protect our proprietary rights, unauthorized parties may obtain and use information that we regard as proprietary. While issued patents are presumed valid, they may not survive a validity challenge and could be held unenforceable. Any patents we have obtained, or obtain in the future, may be challenged, invalidated, adjudged unenforceable, or circumvented by parties seeking to design around our IP. Also, third parties or the USPTO may commence interference proceedings involving our patents or patent applications. Any challenge to, finding of unenforceability or invalidation, or circumvention of, our patents or patent applications, would be costly, would require significant time and attention of our management, could reduce or eliminate royalty payments to us from third-party licensors, and could have a material adverse impact on our business. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly, the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and foreign countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices, courts, and lawmakers. For example, the America Invents Act, which took effect in March 2013, included a number of changes to the patent laws of the United States. If any of the enacted changes prevent us from adequately protecting our discoveries, including our ability to pursue infringers of our patents to obtain injunctive relief or for substantial damages, our business could be adversely affected. One major provision of the America Invents Act changed U.S. patent practice from a first-to-invent to a first-to-file system. If we fail to file an invention before a competitor files on the same invention, we no longer have the ability to provide proof that we were in possession of the invention prior to the competitor&#8217;s filing date, and thus would not be able to obtain patent protection for our invention. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. In certain countries, for example, methods for the medical treatment of humans are not patentable. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. We also rely to a certain extent on trade secrets, know-how, and technology, which are not protected by patents, to maintain our competitive position. We also rely on non-disclosure agreements and invention assignment agreements entered into with our employees, consultants, and third parties. If any trade secret, know-how, or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain and maintain all available regulatory exclusivities and broad patent scope and to maximize patent term restoration or extension on patents covering our products may lead to loss of exclusivity and early biosimilar entry resulting in a loss of market share and/or revenue. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may choose not to enforce our IP rights in certain circumstances or for certain periods of time. For example, in October 2020 we announced that while the COVID-19 pandemic continues, we will not enforce our COVID-19-related patents against those making vaccines intended to combat the pandemic. We also noted that to eliminate any perceived IP barriers to vaccine development during the pandemic period, upon request we are also willing to license our IP for COVID-19 vaccines to others for the post-pandemic period. However, we may never enter into such licenses of our IP for the post-pandemic period, and our business may be otherwise adversely impacted by our decision not to enforce this IP.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty over IP in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes, which is inherently costly and unpredictable, and can have adverse financial and freedom-to-operate consequences.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA medicines are a relatively new scientific field and, as the field continues to mature, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. It is likely that there will be significant litigation and other proceedings, such as patent infringement lawsuits, interference, reexamination, and opposition proceedings, as well as inter-partes and post-grant-review proceedings introduced by provisions of the America Invents Act, in various patent offices relating to patent rights in the mRNA field. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued patents and pending patent applications in the United States and in key markets around the world that claim many different methods, compositions, and processes relating to the discovery, development, manufacture, and commercialization of mRNA medicines and our delivery technology, including LNPs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An opposition has been filed against one of our European platform patents covering uridine-modified mRNAs and we expect that further oppositions will be filed in the European Patent Office (EPO) and elsewhere relating to patents and patent applications in our portfolio.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In many cases, the possibility of appeal exists for either us or our opponents, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. We cannot be certain that such patent will survive or that the claims will remain in the current form. Even if our rights are not directly challenged, disputes could lead to the weakening of our IP rights. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many issued and pending third-party patents that claim aspects of oligonucleotide and delivery technologies that we may need for our mRNA therapeutic and vaccine candidates or marketed products, including our COVID-19 vaccine. There are also many issued third-party patents that claim targeting genes or portions of genes that may be relevant for mRNA medicines we wish to develop. For example, there are issued and pending patent applications that may be asserted against us in a court proceeding or otherwise based upon the asserting party&#8217;s belief that we may need such patents for our mRNA therapeutic candidates. Thus, it is possible that one or more organizations hold patent rights to which we may need a license or which could be asserted against us. If those organizations refuse to license such patent rights on reasonable terms or a court rules that we need such patent rights that have </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">been asserted against us and we are not able to obtain a license on reasonable terms, we may owe damages to such party, and further may be unable to market products, including our COVID-19 vaccine, covered by such patents. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain instances, we have instituted and may in the future institute inter partes review proceedings against issued U.S. patents and opposition proceedings against European patents owned by third parties in the field of mRNA medicines. We have a number of these proceedings ongoing against third-party patents related to RNA vaccinations and mRNA delivery. If </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we are unsuccessful in invalidating such third-party patents, those third parties may attempt to assert those patents against investigational medicines that obtain regulatory approval, including our COVID-19 vaccine. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our development candidates may be subject to claims</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of infringement of the patent rights of third parties.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages, or be required to stop our product development and commercialization efforts. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our investigational medicines, and third parties may assert that we are employing their proprietary technology without authorization. In addition, third parties may obtain patents in the future and claim that our technologies infringe upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our investigational medicines, any molecules formed during the manufacturing process, or any final product itself, the holders of any such patents may obtain injunctive or other equitable relief, which could effectively block our ability to commercialize such investigational medicine unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture, or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable investigational medicine unless we obtained a license or until such patent expires.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defense of infringement and other claims, regardless of their merit, would involve substantial litigation expense and divert employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may not be made available on commercially favorable terms, if at all, or may require substantial time and expense. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and products, which could limit our ability to generate revenues or achieve profitability, which could jeopardize our ability to sustain our operations. Moreover, we expect that a number of our collaborations will provide that royalties payable to us for licenses to our IP may be offset by amounts paid by our collaborators to third parties who have competing or superior IP positions in the relevant fields, which could result in significant reductions in our revenues from products developed through collaborations. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with certain license and strategic alliance agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to IP rights or the subject matter of the agreements. The cost to us of any litigation or other proceeding relating to IP rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation could delay our research, development and commercialization efforts and limit our ability to continue our operations. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party owners of any patent rights that we license do not properly or successfully obtain, maintain, or enforce the patents underlying such licenses, our competitive position and business prospects may be harmed. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become a party to licenses that give us rights to third-party IP that is necessary or useful for our business. In such a case, our success may depend in part on the ability of our licensors to obtain, maintain, and enforce patent protection for our licensed IP. Our licensors may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the IP we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we sublicense our rights under various third-party licenses to our strategic collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our strategic alliance agreements or result in termination of an agreement by one or more of our strategic collaborators. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license IP rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We license IP, which involves complex legal, business, and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. We are a party to certain IP license agreements and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty, and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license and may be subject to additional liabilities. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our strategic collaborators. Disputes may arise regarding IP subject to a licensing agreement, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether our technology and processes that are not subject to the licensing agreement infringe on IP of the licensor; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the joint creation or use of IP by our licensors and us and our strategic collaborators; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over IP that we have licensed prevent or impair our ability to maintain our current licensing arrangements on favorable terms, we may be unable to successfully develop and commercialize the affected development candidates or investigational medicines. We are generally also subject to all of the same risks with respect to protection of IP that we license as we are for IP that we own. If we or our licensors fail to adequately protect this IP, our ability to commercialize products could suffer. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. From time to time, we are subject to claims that we or our employees, consultants, or independent contractors, have inadvertently or otherwise used or disclosed IP, including trade secrets or other proprietary information, of third parties, including our employees&#8217; former employers. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable IP rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other IP. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and have been </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patents or other IP. Ownership disputes may arise, for example, from conflicting obligations of consultants or others who are involved in developing our development candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable IP rights, including exclusive ownership of, or right to use, valuable IP. Such an outcome could have a material adverse impact on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distract management and other employees, and could impact or patenting strategy. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent and regulatory law could impair our ability to protect our products. <br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is heavily dependent on IP, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and the process is costly, time-consuming and inherently uncertain. In addition, the United States has enacted and is implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. These rulings have increased uncertainty with regard to our ability to obtain patents in the future, as well as with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. See &#8220;&#8212;Risks related to the research, development, regulatory review, and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval of our existing and future pipeline&#8212;Our investigational medicines may face competition from biosimilars approved through an abbreviated regulatory pathway.&#8221; </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our IP rights throughout the world. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, and defending patents on development candidates and investigational medicines in every country would be prohibitively expensive, and our foreign IP rights can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect IP rights to the same extent as U.S. federal and state laws. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies to develop their own products in jurisdictions where we have not obtained patent protection or may export infringing products to territories where we have patent protection, but enforcement is not as strong as in the United States. These products may compete with our products. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending IP rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other IP protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our IP rights around the world may be inadequate to obtain a significant commercial advantage from the IP that we develop or license. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. As a result, in response to the COVID-19 pandemic, it is possible that certain countries may take steps to facilitate compulsory licenses that permit the distribution of a COVID-19 vaccine in those countries. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the relevant patent rights. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on government funding and collaboration from governmental and quasi-governmental entities for certain of our programs adds uncertainty to our research and development efforts with respect to those programs and may impose requirements that increase the costs of development, commercialization and production of any programs developed under those government-funded programs. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of our Zika vaccine (mRNA-1893) is funded by BARDA and our COVID-19 vaccine was developed in collaboration with NIAID. BARDA has agreed to fund the advancement of our COVID-19 vaccine to FDA licensure. Contracts and grants funded by the U.S. government and its agencies, including our agreements funded by BARDA and DARPA and our collaboration with NIAID, include provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminate agreements, in whole or in part, for any reason or no reason; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce or modify the government&#8217;s obligations under such agreements without the consent of the other party; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claim rights, including IP rights, in products and data developed under such agreements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">audit contract-related costs and fees, including allocated indirect costs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend the contractor or grantee from receiving new contracts pending resolution of alleged violations of procurement laws or regulations; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or debar the contractor or grantee from doing future business with the government; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">control and potentially prohibit the export of products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue criminal or civil remedies under the False Claims Act, False Statements Act, and similar remedy provisions specific to government agreements; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the government&#8217;s financial liability to amounts appropriated by the U.S. Congress on a fiscal-year basis, thereby leaving some uncertainty about the future availability of funding for a program even after it has been funded for an initial period. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have the right to prohibit the U.S. government from using certain technologies developed by us, and we may not be able to prohibit third-party companies, including our competitors, from using those technologies in providing products and services to the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government. The U.S. government generally takes the position that it has the right to royalty-free use of technologies that are developed under U.S. government contracts. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government contracts and grants, and subcontracts and subawards awarded in the performance of those contracts and grants, normally contain additional requirements that may increase our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specialized accounting systems unique to government contracts and grants; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public disclosures of certain contract and grant information, which may enable competitors to gain insights into our research program; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination, and affirmative action programs, and environmental compliance requirements. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under these agreements we are subject to the obligations to and the rights of the U.S. government set forth in the Bayh-Dole Act of 1980 (Bayh-Dole Act). As a result, the U.S. government may have rights in certain inventions developed under these government-funded programs, including a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or nonexclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as &#8220;march-in rights.&#8221; Any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations, and prospects. If the U.S. government exercises such march-in rights, we may receive compensation that is deemed reasonable by the U.S. government in its sole discretion, which may be less than what we might be able to obtain in the open market. IP generated under a government-funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. government requires that any products embodying any invention generated through the use of U.S. government-funding be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the IP can show that it made reasonable but unsuccessful efforts to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. manufacturers for products covered by such IP. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an organization, we are relatively new to government contracting and the related regulatory compliance obligations. If we fail to maintain compliance with those obligations, we may be subject to potential liability and to termination of our contracts. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a U.S. government contractor, we are subject to financial audits and other reviews by the U.S. government of our costs and performance on their contracts, as well as our accounting and general business practices related to these contracts. Based on the results of its audits, the government may adjust our contract-related costs and fees, including allocated indirect costs. We cannot assure you that future audits and reviews will not have a material adverse impact on our financial condition or results of operations.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to the commercialization of our pipeline </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sales, distribution, and marketing experience, and have only recently invested significant financial and management resources to establish these capabilities. If we cannot effectively establish such capabilities or enter into agreements with third parties to market and sell our products or to help ensure compliance with local regulatory requirements, our ability to generate revenues may be adversely affected. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our COVID-19 vaccine is our only commercial product, and we are investing in the development of sales, marketing, distribution, managerial and other non-technical capabilities in and out of the United States, both on our own and with others. We may seek to enter into strategic alliances with other entities to utilize their marketing and distribution capabilities, but may be unable to enter into agreements on favorable terms, if at all. If we rely on third parties to commercialize any approved product, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of such third parties. If our collaborators do not commit sufficient resources to commercialize our products, and we are unable to develop the necessary marketing capabilities on our own, we may be unable to generate sufficient product revenue to sustain our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization and distribution of our COVID-19 vaccine also subjects us to pharmacovigilance obligations under various regulatory regimes in the jurisdictions where our vaccine is distributed. These regulations generally require us to collect, process, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">analyze and monitor safety data and to identify and evaluate adverse reactions to our vaccine as it is administered in those jurisdictions. We partner with third-party organizations to assist us in collecting and processing this safety data as it is reported from healthcare providers, vaccine recipients and others. If we or these third parties cannot comply with relevant regulations, including with respect to the timely processing of safety data, we may be subject to sanctions, increased costs, and reputational harm, or our authorizations to distribute our vaccine in the relevant jurisdiction may be revoked or curtailed. There are a limited number of third-party service providers who are qualified and capable of providing pharmacovigilance services on a global basis, and our inability to identify or contract with them may impede our commercial activities. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete with many companies that currently have extensive and well-funded marketing, sales and pharmacovigilance operations, and we must also compete with such companies to recruit, hire, train and retain marketing and sales personnel. We also incur expenses associated with hiring third-party contractors to assist in conducting local pharmacovigilance services. Without a significant internal team or the support of a third party to perform these functions, we may be unable to compete successfully against these more established companies. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of certain of our supply agreements may require us to refund certain prepayments from customers of our COVID-19 vaccine if they reduce purchase commitments or if we fail to deliver the purchased volume. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some customers for our COVID-19 vaccine prepay us for a portion of the product payment for the vaccine doses that they expect to receive from us. Such prepayments can be substantial. We are generally not required by our contracts to retain these prepayments in cash or otherwise and we generally use them to make capital expenditures and fund the manufacturing scale-up and commercialization of our vaccine. Under certain supply agreements, if we fail to deliver a portion or all of the committed number of doses by a certain date, or if we are unable to successfully obtain regulatory authorization or approval for the commercialization of the vaccine in the relevant jurisdiction, a customer may reduce the volume of vaccine doses that it commits to purchase or terminate the contract. Upon termination, we would generally be required to refund a portion of that customer&#8217;s prepayment. We may not have the cash or other available resources to satisfy that repayment obligation. In this situation, our business, financial condition, results of operations, and reputation could be materially and adversely affected. Furthermore, if customers do not prepay us for our services in the future, we may have to find other sources of funding, which may not be available when needed or on acceptable terms. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of any current or future investigational medicine, if approved, will depend on the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ethical, social, and legal concerns about genetic research could result in additional regulations restricting or prohibiting the products and processes we may use, including new areas of research such as in gene editing. Additionally, the commercial success of our products will depend in part on the medical community, patients, and third-party or governmental payors accepting mRNA medicines, and our products in particular, as medically useful, cost-effective, and safe. The degree of market acceptance of our investigational medicines, if approved for commercial sale, will depend on numerous factors, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential efficacy and potential advantages over alternative treatments; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to offer our products, if approved, at competitive prices; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects, including any limitations, restrictions (including for use together with other medicines) or warnings contained in a product&#8217;s approved labeling; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects resulting from checkpoint inhibitors or other products or therapies with which our products are co-administered; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try, and physicians to prescribe, new therapies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support and timing of market introduction of competitive products; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity concerning our products or competing products and treatments; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficient third-party insurance coverage or reimbursement, and patients&#8217; willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will be unknown until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the products may require significant resources, especially due to the complexity and uniqueness of our programs, and may never be successful.  </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the risks of doing business outside of the United States. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we market our COVID-19 vaccine, and plan to market other products, if approved, and to conduct manufacturing activities outside of the United States, our business is subject to risks associated with doing business outside of the United States. We have limited experience as a company operating outside the United States. We are not permitted to market or promote any of our developmental candidates or investigational medicines before we receive regulatory approval or other authorization from an applicable authority, and we may never receive such approval for any of our developmental candidates or investigational medicines. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, manufacturing, commercial sales, pricing and distribution of our developmental candidates and investigational medicines, and we cannot predict success in these jurisdictions. We are rapidly expanding our global operations, establishing commercial subsidiaries, and entering into arrangements to support the worldwide manufacture and distribution of our COVID-19 vaccine and other medicines, including with third parties, which is a complex task that we are undertaking on an accelerated timeline. Accordingly, our business and financial results may be adversely affected due to a variety of factors associated with our expanding global business, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efforts to develop an international commercial sales, marketing, and supply chain and distribution organization, including efforts to mitigate longer accounts receivable collection times, longer lead times for shipping, and potential language barriers; for example, in the second half of 2021, we felt the impact of longer delivery lead times for international shipments and exports, which shifted certain anticipated deliveries of our COVID-19 vaccine from 2021 to 2022;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our customers&#8217; ability to obtain reimbursement for our products in foreign markets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to directly control commercial activities because we are relying on third parties; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in a specific country&#8217;s or region&#8217;s political and cultural climate or economic condition, including as a result of the COVID-19 pandemic; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increased legal and compliance burden to establish, maintain and operate legal entities in foreign countries; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements, including the European General Data Protection Regulation 2016/679 (GDPR); </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute, and the difficulty of effective enforcement of contractual provisions in local jurisdictions, and the existence of potentially relevant third-party IP rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate IP protection in foreign countries, and the existence of potentially relevant third-party IP rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trade-protection measures including trade restrictions, import or export licensing requirements such as Export Administration Regulations promulgated by the U.S. Department of Commerce and fines, penalties, or suspension or revocation of export privileges, the imposition of government controls, and changes in tariffs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of applicable foreign tax structures and potentially adverse tax consequences; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant adverse changes in foreign currency exchange rates. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to extensive federal, state and foreign anti-bribery regulations, including the U.S. Foreign Corrupt Practices Act (FCPA), the U.K. Bribery Act, and similar laws in other countries. Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. Various laws, regulations and executive orders also restrict the use and dissemination outside the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. As we expand our presence outside the United States, we will need to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside the United States, which could limit our growth potential and increase our development costs. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that we, or our employees, consultants, or third-party contractors, are or will be in compliance with all federal, state, and foreign regulations regarding bribery and corruption. Moreover, our strategic collaborators and third-party contractors outside the United States may have inadequate compliance programs or fail to respect the laws and guidance of the territories in which they operate, which may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Even if we are not determined to have violated these laws, government investigations typically require the expenditure of significant resources and generate negative publicity, which could adversely affect our business, financial condition, and results of operations. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of pharmaceutical products depends on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Third-party payor coverage and reimbursement for our COVID-19 vaccine is not currently available and there is no guarantee payors will provide coverage and reimbursement for the vaccine in the future. Even if coverage is provided, we may not be able to establish or maintain pricing sufficient to realize a sufficient return on our investment. While coverage is expected to be provided under Medicare Part B, it is unclear to what extent other payors, including certain federal entitlement programs, such as the Vaccines for Children Program, will provide coverage for the product. Additionally, it is uncertain whether any combination respiratory vaccine we develop, if approved, would qualify for coverage under Medicare Part B.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, sales of pharmaceutical products in general depends, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors. When a new product is approved, the availability and extent of government and private reimbursement, and the pricing, for that product may be uncertain. Pricing and reimbursement for any product we develop may be adversely affected by a number of factors, including:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pressure by employers on private health insurance plans to reduce costs; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for any product we develop will vary significantly from country to country. Our inability to obtain and maintain adequate prices in a particular country may limit the revenues from our products within that country and adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in many countries. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. Competition may negatively impact our ability to maintain pricing and our market share. New products marketed by competitors could cause our revenues to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of competing versions of our products or products approved under abbreviated regulatory pathways may reduce the price that we are able to charge for our products and lower our sales volume.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> use of commercial manufacturer co-pay payment assistance programs. Significant consolidation in the health insurance industry </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is: a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; and neither experimental nor investigational.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, target patient populations for some of our investigational medicines, including for rare genetic diseases, may be small, and some of our investigational medicines, like PCV, require individual customization. The pricing and reimbursement of our medicines, if approved, must be adequate to support commercial infrastructure. If we cannot obtain adequate levels of reimbursement, we may be unable to successfully market and sell our investigational medicines. The manner and level at which reimbursement is provided for services related to our investigational medicines (e.g., for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our products. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent federal legislation and actions by federal, state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face competition in the United States for our development candidates and investigational medicines, if approved, from therapies sourced from foreign countries with price controls on pharmaceutical products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in October 2020, the FDA published a final rule that would allow for the importation of certain prescription drugs from Canada, where there are government price controls. Since the issuance of the final rule, several industry groups filed federal lawsuits requesting injunctive relief to prevent the rule from taking effect and challenging multiple aspects of the final rule. This litigation has not progressed and the market implications are currently unknown, but legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products we may develop and adversely affect our future revenues and potential profitability. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform discourse and potential or enacted measures may have a material adverse impact on our business and results of operations and legislative or political discussions surrounding the desire for and implementation of pricing reforms may adversely impact our business. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products, if approved, are prescribed and purchased. For example, provisions of the ACA have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the PHSA. See the section titled "Business&#8212;Government Regulation&#8212;Current and future healthcare reform legislation." </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. There is no assurance that the ACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increasing public attention on the costs of prescription drugs and there have been, and are expected to continue to be, legislative proposals to address prescription drug pricing, which could have significant effects on our business. These actions and the uncertainty about the future of the ACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, including as a result of the COVID-19 pandemic, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the United States and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products, if approved.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures may adversely affect our revenues and results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our programs, development candidates or investigational medicines are smaller than we believe they are, or we are unable to successfully identify clinical trial participants, our revenue may be adversely affected and our business may suffer. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus certain of our research and product development activities on treatments for severe rare genetic diseases, where the patient populations are difficult to ascertain or small. Additionally, we expect to initially seek approval of our PCV and intratumoral immuno-oncology investigational medicines for use by patients with relapsed or refractory advanced disease, i.e., the populations the FDA often approves new therapies for initially. If any such medicines prove to be sufficiently beneficial, we would expect to seek approval in earlier lines of treatment and potentially as a first line therapy. There is no guarantee that our investigational medicines, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of both the number of people who have these diseases, as well as the subset of those who have the potential to benefit from treatment with our investigational medicines, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of trial participants, both in and outside the United States, may be lower than expected and potential clinical trial participants or patients may not be otherwise amenable to treatment with our investigational medicines or products, or new clinical trial participants or patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Even if we obtain significant market share for our products, if approved, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of counterfeit or stolen versions of mRNA products, or the unauthorized donation or re-sale of mRNA products, could have a negative impact on our financial performance or reputation. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties could illegally distribute and sell, especially online, counterfeit versions of mRNA products that do not meet the rigorous cGMP manufacturing and testing standards. Counterfeit products are frequently unsafe or ineffective, and could be life-threatening. Counterfeit medicines may contain harmful substances or the wrong dose. However, to distributors and users, counterfeit products may be visually indistinguishable from the authentic version. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Reports of adverse reactions to counterfeit products, increased levels of counterfeiting, or unsafe mRNA products could materially affect patient confidence in our mRNA products. It is possible that adverse events caused by unsafe counterfeit or other non-mRNA products will mistakenly be attributed to our mRNA products. In addition, thefts of inventory at warehouses, plants or while in-transit, which are not properly stored and which are sold through unauthorized channels could adversely impact patient safety, our reputation, and our business. Public loss of confidence in the integrity in mRNA products as a result of counterfeiting, theft, or improper manufacturing processes could have a material adverse effect on our business, results of operations, and financial condition. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the unauthorized donation or resale of our product could adversely affect our ability to sell in a particular territory, and have other adverse effects on our business, results of operations, and financial condition.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our finances</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited history of recognizing revenue from product sales and may not be able to achieve or maintain long-term sustainable profitability. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before the year ended December 31, 2021, we incurred net losses in each year since our inception. Other than for our COVID-19 vaccine, we have not completed pivotal clinical trials for any of our programs, and it may be years for most of our investigational medicines, if ever, before we or our strategic collaborators have a product ready for commercialization. Our ability to generate revenue and maintain profitability depends on our ability, alone or with strategic collaborators, to successfully complete the development of and obtain the regulatory approvals necessary to commercialize our products and investigational medicines, including commercializing our COVID-19 vaccine, which is subject to numerous risks.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred, and expect to continue to incur, significant costs associated with the commercialization of our COVID-19 vaccine and our clinical and preclinical development activities. We may not be able to achieve or maintain long-term sustainable profitability and may need to obtain additional funding to continue operations. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our expenses will increase substantially if and as we:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue or expand our research or development of our programs in preclinical development; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate additional preclinical, clinical, or other studies for our development candidates and investigational medicines, including under our strategic alliance agreements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to invest in our platform to conduct research to identify novel mRNA technology improvements, including to identify methods of mRNA delivery, such as improvements to our LNPs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">change or add to internal manufacturing capacity or capability, or additional manufacturers or suppliers;  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add additional infrastructure to our quality control and quality assurance groups to support our operations as we progress our investigational medicines toward commercialization; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain skilled personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create additional infrastructure to support our product development and planned future commercialization efforts, including new sites in the United States and abroad; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals and reimbursement for our investigational medicines; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing, and distribution infrastructure to commercialize any products;   </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other development candidates, investigational medicines, and technologies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make milestone or other payments under any in-license agreements; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience any delays or encounter issues with any of the above. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual operating results may fluctuate. As a result, we may fail to meet or exceed the expectations of research analysts or investors, which could cause our stock price to decline and negatively impact our financing or funding ability as well as negatively impact our ability to exist as a standalone company. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition and operating results have varied in the past and will continue to fluctuate from quarter-to-quarter and year-to-year due to a variety of factors, many of which are beyond our control. As such, a period-to-period comparison of our operating results may not be a good indication of our future performance. In any particular quarter, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described in these </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and elsewhere in this Annual Report on Form 10-K: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture and deliver supply of our COVID-19 vaccine; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results, development timelines or recommendations by securities analysts, or those of companies that are perceived to be similar to us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or failures in advancement of existing or future development candidates into the clinic or investigational medicines in clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the feasibility of developing, manufacturing, and commercializing our programs;  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of research programs, clinical trials (including any adverse safety events), or other product development or approval processes conducted by us and our strategic collaborators; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of disclosure of any milestones related to any of our programs that are managed by our strategic collaborators or competitors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to consistently manufacture our development candidates and investigational medicines;  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to accurately report our financial results in a timely manner; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, protect, and enforce our IP rights, as well as our know-how and technologies. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The investment of our cash, cash equivalents, and investments is subject to risks which may cause losses and affect the liquidity of these investments. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had approximately $17.6 billion in cash, cash equivalents, and investments, which are subject to general credit, liquidity, market, inflation and interest rate risks. We may realize losses in the fair value of these investments. In addition, if our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. These and other market risks associated with our investment portfolio may adversely affect our results of operations, liquidity, and financial condition.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our business and operations </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing the development and expansion of our company, which could disrupt our operations. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had approximately 2,700 full-time employees and, in connection with the growth and advancement of our pipeline and commercialization of our company, we expect to increase the number of employees and the scope of our operations. To manage such development and expansion, including internationally, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and recruit and train qualified personnel. Our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these development activities. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing development candidates and investigational medicines in many therapeutic areas and across a wide range of diseases. Successfully developing products for and fully understanding the regulatory and manufacturing pathways to all of these therapeutic areas and diseases requires significant depth of talent, resources, and corporate processes in order to allow simultaneous execution across multiple areas. We may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. The physical expansion of our operations, including the construction of the Moderna Science Center in Cambridge, the expansion of our Norwood campus and the construction of manufacturing facilities overseas, may lead to significant costs and may divert financial resources from other projects, such as the development of our investigational medicines. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize our COVID-19 vaccine, or our other investigational medicines, if approved, and compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to upgrade and maintain our enterprise resource planning system (ERP) could adversely impact our business and results of operations.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are working to upgrade our global ERP system to support our anticipated future growth and expansion as a commercial operation. We expect to incur substantial costs in implementing our ERP system, and a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ny disruptions or difficulties in implementing or using our ERP system could adversely affect our controls, resulting in harm to our business, including our ability to forecast or make sales and collect our receivables. S</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ignificant delays in documenting, reviewing and testing our internal control could cause us to fail to comply with our SEC reporting obligations related to our management</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">s assessment of our internal control over financial reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Moreover, such disruptions or difficulties could result in unanticipated costs and diversion of management attention.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to retain key employees, consultants, and advisors and to attract, retain, and motivate qualified personnel. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends on our ability to attract and retain highly qualified managerial, scientific, technical, quality-control, manufacturing, medical and commercial personnel. We are highly dependent on members of our management and scientific teams. Each of our executive officers and employees, including key scientists and clinicians, are employed &#8220;at will,&#8221; meaning we or each officer or employee may terminate the employment relationship at any time. The loss of any of these persons&#8217; services may adversely impact the achievement of our research, development, financing, and commercialization objectives. We do not have &#8220;key person&#8221; insurance on any of our employees. Several of our key employees, including members of our executive team, have been with us for a long period of time, and have valuable, fully vested stock options or other long-term equity incentives. We may not be able to retain these employees due to the competitive environment in the biotechnology industry, particularly in Cambridge, Massachusetts. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants, contractors, and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory approval, manufacturing and commercialization strategies. These individuals may be employed by other employers and may have commitments under contracts with others that may limit their availability to us. The loss of the services of one or more of our current employees or advisors might impede the achievement of our research, development, regulatory approval, manufacturing and commercialization objectives. In addition, we have flexibly grown our workforce through the use of contractors and part time workers. If we cannot retain the services of such personnel, we could experience delays in the operation of our business. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition for skilled personnel, including in mRNA and LNP research, clinical operations, regulatory affairs, therapeutic area management, and manufacturing, is intense and the turnover rate is high. We may be unable to attract and retain personnel on favorable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for individuals with similar skill sets. In some instances, failure to attract and retain personnel could result in delays in production or difficulties in maintaining compliance with regulatory requirements. In addition, adverse publicity, failure to succeed in preclinical or clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. We may also be unable to attract and retain highly qualified sales and marketing professionals to support our COVID-19 vaccine and any future products. The inability to recruit, or loss of services of certain executives, key employees, consultants, or advisors, may impede the progress of our research, development and global commercialization objectives and adversely impact our business, financial condition, results of operations, and prospects.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot maintain our corporate culture, we could lose the innovation, teamwork and passion that we believe contribute to our success, and our business may be harmed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest substantial time and resources in building and maintaining our culture and developing our personnel; however, as we continue to expand, it may be increasingly difficult to maintain our culture. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the COVID-19 pandemic, much of our workforce has worked remotely and we implemented remote hiring and onboarding programs to facilitate significant hiring during 2021 in a remote work environment. The dramatic growth of our workforce, coupled with shifts in workplace and workstyle, increase the risk of our ability to maintain culture. Any failure to preserve our culture could negatively affect our future success, including our ability to retain and recruit personnel and to effectively pursue our strategic plans.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems and physical premises, or those of third parties with which we share sensitive data or information, may fail or suffer security breaches, which could materially disrupt our product development programs and manufacturing operations. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of our current and any future strategic collaborators, vendors, contractors, consultants or regulatory authorities with whom we share sensitive data or information are vulnerable to damage from computer viruses, unauthorized access, natural disasters (which may become more frequent in the future as a result of climate change), terrorism, cybersecurity threats, war, and telecommunication and electrical failures. We have experienced, and may experience in the future, cyber-attacks on our information technology systems by threat actors of all types (including nation states, criminal enterprises, individual actors and/or advanced persistent threat groups). In addition, we may experience intrusions on our physical premises by any of these threat actors. If any such cyber-attack or physical intrusion were to cause interruptions in our operations, such as a material disruption of our development programs or our manufacturing operations, or due to a loss of any of our proprietary information, it would have a material and adverse effect on us. For example, the loss of clinical trial data from one or more clinical trials could cause delays in our regulatory approval efforts and increase our costs to recover or reproduce the data. In addition, because we run multiple clinical trials in parallel, any breach of our computer systems or physical premises may result in a loss of data or compromised data integrity across many of our programs in many stages of development. Our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cybersecurity liability insurance may not cover all damages we would sustain based on any breach of our computer security protocols or cybersecurity attack.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any data breach, security incident loss, or compromise of personal information, including any clinical trial participant personal data may also subject us to civil fines and penalties, or claims for damages either under the GDPR and relevant member state law in the EU, other foreign laws, and the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), and other relevant state and federal privacy laws in the United States including the California Consumer Privacy Act (the CCPA). We have from time to time received information that companies working on vaccine research and development may be a particular focus for those planning cyberattacks. For example, on May 13, 2020, the Federal Bureau of Investigation (FBI) and Cybersecurity and Infrastructure Security Agency (CISA), announced that the FBI was investigating the targeting and compromise of U.S. organizations conducting COVID-19-related research by People&#8217;s Republic of China, or PRC-affiliated cyber actors. Furthermore, on July 16, 2020, the National Security Agency and other U.S. and foreign agencies released a joint cybersecurity advisory regarding the Russian Intelligence Services&#8217; targeting of COVID-19 research and vaccine development. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, including but not limited to information related to the research and manufacturing of our COVID-19 vaccine and/or other vaccines, we could incur liability, our competitive and reputational position could be harmed, and the further development and commercialization of our investigational medicines could be delayed. With respect to potential liability for breaches involving personal information, the CCPA is of particular concern since it provides for a private right of actions for certain personal information breaches. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use our financial and human resources to pursue a particular research program or investigational medicine and fail to capitalize on programs or investigational medicines that may be more profitable or for which there is a greater likelihood of success. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue and fund the development of selected research programs or investigational medicines and may choose to forego or delay pursuit of opportunities with other programs or investigational medicines that could later prove to have greater commercial potential. For example, we have focused a significant amount of resources on our COVID-19 vaccine since the commencement of the COVID-19 pandemic. Our resource allocation decisions, or our contractual commitments to provide resources to our strategic collaborators, may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for investigational medicines may not yield commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular investigational medicine, we may relinquish valuable rights to that investigational medicine through a strategic alliance, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such investigational medicine, or we may allocate internal resources to an investigational medicine in a therapeutic area in which it would have been more advantageous to enter into a strategic alliance. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not successful in discovering, developing, and commercializing additional products beyond our current portfolio, our ability to expand our business and achieve our strategic objectives would be impaired. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to discover, develop, and potentially commercialize additional products beyond our current portfolio to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our own drug discovery efforts, exploring potential strategic alliances for the development of new products, and in-licensing technologies. Identifying new investigational medicines requires substantial technical, financial, and human resources. We may fail to identify promising investigational medicines and, even if we do identify such medicines, we may fail to successfully develop and commercialize products for many reasons, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitors may develop alternatives that render our investigational medicines obsolete; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investigational medicines we develop may be covered by third parties&#8217; patents or other exclusive rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an investigational medicine may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be incapable of producing an investigational medicine in commercial quantities at an acceptable cost, or at all; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an approved product may not be accepted as safe and effective by patients, the medical community or third-party payors. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in identifying and developing additional products, our potential for growth may be impaired. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be harmed if we suffer damage to our reputation, including as a result of a product recall. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar foreign governmental authorities have the authority to require the recall of certain commercialized products. In the case of the FDA, the authority to require a recall of a biologic product must be based on an FDA finding that a batch, lot of other quantity of the biologic product presents an imminent or substantial hazard to the public health. In addition, foreign governmental bodies have the authority to require the recall of any investigational medicine in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found. A government-mandated or voluntary recall by us or our strategic collaborators could occur as a result of manufacturing errors, design or labeling defects or other deficiencies and issues, as occurred with the recall of certain batches of our COVID-19 vaccine shipped to Japan that were found to contain foreign particulate. Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. A recall announcement could harm our reputation with customers and negatively affect our sales. Our reputation could be further impacted by public discourse regarding our business and the perception of our business strategy.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any product or investigational medicine that we may develop, such as our COVID-19 vaccine. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to product liability risk related to the development, testing, manufacturing and marketing of our COVID-19 vaccine and our investigational medicines in clinical trials. Product liability claims and related cross-claims and claims for indemnification may be brought against us by patients, healthcare providers or others using, prescribing, selling or otherwise coming into contact with our COVID-19 vaccine or investigational medicines. For example, we may be sued if the COVID-19 vaccine or any investigational medicine allegedly causes injury or is found to be otherwise unsuitable during clinical trials, manufacturing, or, if approved, marketing, sale or commercial use. If we cannot successfully defend ourselves against such claims, we could incur substantial liabilities. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also face product liability claims relating to the worsening of a patient&#8217;s condition, injury or death alleged to have been caused by one of our COVID-19 vaccine or investigational medicines. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result of interactions with alcohol or other drugs, knowledge of risks, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. Such claims might not be fully covered by product liability insurance. If we succeed in marketing products, including our COVID-19 vaccine, product liability claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs, and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used, suspension or withdrawal of approvals or license revocation. Regardless of the merits or eventual outcome, liability claims may result in decreased demand for our products, injury to our reputation and significant negative media attention, costs to defend the related litigation, withdrawal of clinical trial participants, loss of revenue, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants, patients or their family members, payments to indemnify clinical trial sites and other clinical trial partners, and a decline in our stock price. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also exposed to liabilities that are unique to developing and commercializing an mRNA vaccine during an ongoing global pandemic. Although the U.S. and certain foreign governments have contractually agreed to indemnify us or make statutory immunity available to us, such indemnification or statutory immunity may not be available to cover potential claims or liabilities resulting from the research, development, manufacture, distribution or commercialization of our COVID-19 vaccine. Additionally, other foreign government that we contract with in the future may not provide us with similar contractual indemnity or statutory immunity. Substantial claims arising from the vaccine outside the scope of or in excess of U.S. or foreign government indemnity or statutory immunity could harm our financial condition and operating results. Moreover, any adverse event or injury for which we are liable, even if fully covered under an indemnity or immunity, could negatively affect our reputation. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to maintain our product liability insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. While our current insurance program includes coverage for the sale of commercial products for when we obtain marketing approval for our medicines, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amoun</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ts. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On occasion, large judgments have been awarded in individual, mass tort and class-action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and could adversely affect our results of operations and business. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the costs of maintaining adequate insurance coverage increase significantly in the future, our operating results could be materially adversely affected. Likewise, if insurance coverage should become unavailable to us or become economically impractical, we would be required to operate our business without indemnity from commercial insurance providers. Additionally, even if we maintain insurance coverage for a type of liability, a particular claim may not be covered if it is subject to a coverage exclusion or we do not otherwise meet the conditions for coverage. If we operate our business with inadequate insurance, we could be responsible for paying claims or judgments against us, which could adversely affect our results of operations or financial condition. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws and false claims laws. If we cannot comply, or have not fully complied, with such laws, we could face substantial penalties. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. In particular, the promotion, sales and marketing of healthcare items and services, as well as a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. See the section entitled </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Business&#8212;Government Regulation&#8212;Other healthcare laws.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, is time- and resource-consuming and can divert a company&#8217;s attention from the business. If our operations are found to violate any of these laws or any other regulations that apply to us, we may be subject to significant sanctions, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance. Furthermore, if any physician or other healthcare provider or entity with whom we do business is found to be not in compliance with applicable laws, they may be subject to similar penalties. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. In addition, the approval and commercialization of any product candidate we develop outside the United States will subject us to foreign healthcare laws. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU and the U.K. The provision of benefits or advantages to induce or reward improper performance generally is also governed by the national anti-bribery laws of EU Member States, and the U.K. Bribery Act 2010 in the U.K. Infringement of these laws could result in substantial fines and imprisonment. The EU Directive </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2001/83/EC, as amended)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> governing medicinal products for human use provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the U.K. despite its departure from the EU. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often are the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization, or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to various and evolving laws and regulations governing the privacy and security of personal data, and our failure to comply could adversely affect our business, result in fines and/or criminal penalties, and damage our reputation.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privacy and data security have become significant issues in the United States, Europe and in many other jurisdictions in which we operate and/or collect personal information. We are subject to&#160;data privacy&#160;and security laws and regulations in various jurisdictions that apply to the collection, storage, use, sharing and security of personal data, including health information, and impose significant compliance obligations. In addition, numerous other federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure and security of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, the GDPR has imposed stringent obligations on us with respect to our processing personal data and the cross-border transfer of such data, including higher standards of obtaining consent, more robust transparency requirements, data breach notification requirements, requirements for contractual language with our data processors, and stronger individual data rights. Different EEA Member States have interpreted the GDPR differently and many have imposed additional requirements, adding to the complexity of processing personal data in the EEA. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA that are not considered to provide </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;adequate&#8221; protection to personal data</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, including the United States, and permits data protection authorities to impose large penalties for violations. Compliance with the GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices. Despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with any activities falling within the scope of the GDPR.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, California has passed the California Consumer Privacy Act and several other states and the federal government are actively considering proposed legislation governing the protection of personal data. Additionally, Brazil passed the General Data Protection Law, which went into effect in August 2020. Data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges. Each law is also subject to various interpretations by courts and regulatory agencies, creating additional uncertainty, and our efforts to comply with the evolving data protection rules may be unsuccessful.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must devote significant resources to understanding and complying with the changing landscape in this area. Failure to comply with data protection laws may expose us to risk of enforcement actions taken by authorities, private rights of action in some jurisdictions, and potential significant penalties if we are found to be non-compliant. Failure to comply with the GDPR and applicable national data protection laws of EEA member states could lead to substantial fines. Some of these laws and regulations also carry the possibility of criminal sanctions. For example, we could be subject to penalties, including criminal penalties, if we knowingly obtain or disclose individually identifiable health information from a HIPAA-covered health care provider or research institution that has not complied with HIPAA&#8217;s requirements for disclosing such information. Furthermore, the number of government investigations related to data security incidents and privacy violations continues to increase and government investigations typically require significant resources and generate negative publicity, which could harm our business and our reputation.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has added further complexity to the processing of personal data. For example, safety measures intended to protect our employees, contractors, and other visitors to our sites may require the collection of certain personal data. Our efforts to protect personal data may be unsuccessful and we could unintentionally be subject to unauthorized access or disclosure of such personal data.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Clinical Trials Regulation (EU) No. 536/2014 (the Clinical Trial Regulation) and the EMA policy on publication of clinical data for medicinal products for human use both permit the EMA to publish clinical information submitted in MAAs. The ability of third parties to review and/or analyze data from our clinical trials may increase the risk of commercial confidentiality breaches and result in enhanced scrutiny of our clinical trial results. Such scrutiny could result in public misconceptions regarding our drugs and drug candidates. These publications could also result in the disclosure of information to our competitors that we might otherwise deem confidential, which could harm our business. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain aspects of our business may be adversely affected by the ongoing COVID-19 pandemic. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our clinical trials have been adversely affected by the ongoing COVID-19 pandemic, resulting in paused enrollment or delayed site initiations. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed (or continue to be paused or delayed) due to changes in hospital or university policies, federal, state or local regulations or restrictions, prioritization of hospital resources toward pandemic efforts, travel restrictions, concerns for patient safety in a pandemic environment, or other pandemic-related reasons. As the pandemic persists, some participants and clinical investigators may be unable to comply with clinical trial protocols. For example, many countries have implemented quarantines or travel limitations (whether voluntary or required), which may impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct our clinical trials. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has disrupted and may continue to disrupt the United States&#8217; healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay the review and/or approval by the FDA and other regulatory agencies with respect to, our clinical trials or product approvals, which could materially delay our clinical trials for development candidates or our commercial efforts. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize third parties to, among other things, manufacture raw materials, components, parts, and consumables, perform quality testing and ship our products. We also manufacture our development candidates and investigational medicines and perform various services at our manufacturing facility. Certain of our third-party manufacturers and suppliers may encounter delays in providing their services in response to the COVID-19 pandemic. If either we or any third-party manufacturers or third parties in the supply chain for materials used in the production of our COVID-19 vaccine, development candidates or investigational medicines are adversely </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impacted by restrictions resulting from the COVID-19 pandemic, our supply chain may be disrupted, limiting our ability to manufacture our COVID-19 vaccine, as well as investigational medicines for our clinical trials, research and development operations and commercialization. In addition, delays and disruptions experienced by our strategic collaborators due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect the clinical development or regulatory approvals of development candidates and investigational medicines under joint control. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we engage in acquisitions, joint ventures, or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may complete acquisitions and collaborations, including licensing or acquiring complementary products, IP rights, technologies, or businesses. Any such acquisition, joint venture, or collaboration may entail numerous risks, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased operating expenses and cash requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assimilation of operations, IP, and products, including difficulties associated with integrating new personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of management&#8217;s attention from our existing product programs and initiatives; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the loss of key personnel and uncertainties in our ability to maintain key business relationships; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or investigational medicines and regulatory approvals; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to generate revenue from acquired technology or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undertake acquisitions, we may utilize our cash, issue dilutive securities, assume or incur debt obligations, incur large one-time expenses, and acquire intangible assets that could result in significant future amortization expense. Moreover, if we cannot locate suitable acquisition or strategic collaboration opportunities, our ability to grow or obtain access to technology or products that may be important to the development of our business may be impaired. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to ownership of our common stock </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been volatile and fluctuates substantially, which could result in substantial losses for stockholders. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been, and is expected to continue to be, subject to substantial volatility. From December 7, 2018, our first day of trading on the Nasdaq Global Select Market, through December 31, 2021, our stock has traded within a range of a high price of $497.49 and a low price of $11.54 per share. Since we began our development efforts with respect to our COVID-19 vaccine in early 2020, our stock has experienced pronounced and extended periods of volatility. As a result of the volatility in our stock price, our stockholders could incur substantial losses. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public statements by us, government agencies, the media, competitors, financial analysts, or others relating to the COVID-19 pandemic and efforts to combat it have in the past resulted, and may in the future result, in significant fluctuations in our stock price. Given the global focus on the COVID-19 pandemic, information in the public arena on this topic, whether or not accurate, has had and will likely continue to have an outsized impact (positive or negative) on our stock price. Information related to our clinical trials, manufacturing, regulatory and commercialization efforts with respect to our COVID-19 vaccine, or information regarding such efforts by competitors, or the evolution of the pandemic, may meaningfully impact our stock price. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general, and the market for biopharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above your initial purchase price. The market price for our common stock may be influenced by many factors, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our COVID-19 vaccine sales and anticipated product revenue; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials of our investigational medicines or those of our competitors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies, particularly vaccines or treatments for COVID-19; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence or decline of new or existing variants of the SARS-CoV-2 virus;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement or termination of strategic alliances; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents, or other proprietary rights; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to any of our products, investigational medicines or clinical development programs; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to discover, develop, acquire, or in-license additional investigational medicines; </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates of financial results, development timelines, or recommendations by securities analysts; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry, and market conditions; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the numerous programs in our pipeline, the development of which could each generate news or significant adverse events that could impact financial results or recommendations by securities analysts; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public announcements by us or our strategic collaborators regarding the progress of our development candidates or investigational medicines or similar public announcements by our competitors.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management&#8217;s attention and resources, which could seriously harm our business, financial condition, and results of operations, and prospects.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 18, 2022, our executive officers, directors, and affiliated stockholders beneficially owned approximately 14% of our outstanding common stock. In addition, non-affiliated five percent or greater stockholders beneficially owned approximately 25% of our outstanding common stock. These stockholders will have the ability to influence us through their ownership positions. For example, if these stockholders were to act together, they could exert significant influence over matters such as elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our amended and restated certificate of incorporation and by-laws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation, by-laws, and Delaware law contain provisions that may have the effect of delaying or preventing a hostile takeover or change in control of us or changes in our management. Our amended and restated certificate of incorporation and amended and restated by-laws include provisions that: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize &#8220;blank check&#8221; preferred stock, which could be authorized for issuance by our board of directors without stockholder approval and may contain voting, liquidation, dividend, and other rights superior to our common stock; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create a classified board of directors whose members serve staggered three-year terms; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that special meetings of our stockholders can be called only by our board of directors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit stockholder action by written consent; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that our directors may be removed only for cause; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that no stockholder is permitted to cumulate votes at any election of directors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expressly authorize our board of directors to modify, alter, or repeal our amended and restated by-laws; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated by-laws.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Any provision of our amended and restated certificate of incorporation or amended and restated by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently intend to declare or pay cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business or to return cash to shareholders through share repurchases. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated by-laws designate the Court of Chancery of the State of Delaware or the United States District Court for the District of Massachusetts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our amended and restated by-laws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders, (3) any action asserting a claim against us or any of our current or former directors, officers, employees, or stockholders arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated by-laws, or (4) any action asserting a claim governed by the internal affairs doctrine (the Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated by-laws further provide that the United States District Court for the District of Massachusetts is the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the Federal Forum Provision). Our amended and restated by-laws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts, as applicable. Additionally, the forum selection clauses in our amended and restated by-laws may limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees, which may discourage the filing of lawsuits against us and our directors, officers, and employees, even though an action, if successful, might benefit our stockholders. While the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is unenforceable or invalid, and if the Federal Forum Provision is found to be unenforceable, we may incur additional costs in resolving such matters. The Court of Chancery of the State of Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General risk factors </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators leading our clinical trials, and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions; provide accurate information to the FDA, the EMA, and other regulatory authorities; comply with healthcare fraud and abuse laws and regulations in the United States and abroad; or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and serious harm to our reputation. Sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. It is not always possible to identify and deter employee misconduct, and the precautions we take may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable U.S. or global economic conditions could adversely affect our business, financial condition, or results of operations.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and financial markets, including by the COVID-19 pandemic, or any other health epidemic. The most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the most recent global financial crisis, could result in a variety of risks to our business, including weakened demand for our investigational medicines and our ability to raise additional capital when needed on favorable terms, if at all. A weak or declining economy could strain our suppliers, possibly resulting in supply disruption, or cause delays in payments for our services by third-party payors or our collaborators. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee litigation and unfavorable publicity could negatively affect our future business. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile workplace, discrimination, wage and hour disputes, sexual harassment, or other employment issues. In recent years, there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. Any employment-related claim could negatively affect our business. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous and flammable materials and wastes, including chemicals and biological materials. We generally contract with third parties for the disposal of these hazardous materials and waste products, and we cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from any use by us of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs to comply with current or future environmental, health, and safety laws and regulations. These laws and regulations may impair our research, development, or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to evolving and complex tax laws in the jurisdictions in which we operate. The rules dealing with U.S. federal, state, and local and non-U.S. income taxation are constantly under review by legislative and tax authorities. Changes to tax laws (which changes may have retroactive application) could adversely affect us and our stockholders. In recent years, such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases our development candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This uncertainty creates risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, subjects may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, we may fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business. </span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_70"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B - Unresolved Staff Comments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_73"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two campuses in Massachusetts. We occupy a multi-building campus in Cambridge, Massachusetts (Cambridge campus), consisting of a mix of offices and research laboratory space totaling approximately 261,000 square feet. The Cambridge campus is the location of our corporate headquarters, platform, drug discovery and clinical development. The Cambridge campus is leased with the majority of the space being leased through 2029.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Moderna Technology Center (MTC campus) is located in Norwood, Massachusetts and is comprised of three buildings (MTC South, MTC North and MTC East). MTC South is approximately 200,000 square feet. MTC North is approximately 200,000 square feet and provides lab and office space, directly supporting improvement in our manufacturing capabilities. MTC East is approximately 240,000 square feet for expansion of our commercial and clinical activities. The MTC campus is leased through 2042 and we have the option to extend it for three five-year terms. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also lease other office and lab spaces globally for our business operations.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_76"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_79"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_82"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_85"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market for Our Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock began trading on the Nasdaq Global Select Market under the symbol &#8220;MRNA&#8221; on December 7, 2018. Prior to that time, there was no public market for our common stock. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of the Exchange Act or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any filing of Moderna, Inc. under the Securities Act or the Exchange Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following graph shows a comparison from December 7, 2018, the date on which our common stock first began trading on the Nasdaq Global Select Market, through December 31, 2021 of the cumulative total return for our common stock, the Nasdaq Composite Total Return Index and the Nasdaq Biotechnology Index, each of which assumes an initial investment of $100 and reinvestment of all dividends. Such returns are based on historical results and are not intended to suggest future performance. In 2021, we became part of the Standard &amp; Poor&#8217;s 500 Stock Index</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(the &#8220;S&amp;P 500&#8221;). As a result, this year we are including the cumulative total return of that index in addition to the broad equity market indices that we included in our Annual Report on Form-10-K for the year ended December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock. </span></div><div><span><br/></span></div><div style="text-align:center"><img src="mrna-20211231_g6.jpg" alt="mrna-20211231_g6.jpg" style="height:401px;margin-bottom:5pt;vertical-align:text-bottom;width:700px"/></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We had approximately 85 stockholders of record as of February&#160;18, 2022. Because many of our outstanding shares are held in accounts with brokers and other institutions, the number of beneficial owners is significantly greater than the number of record holders. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.<br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock and do not expect to pay dividends on our common stock for the foreseeable future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information about our equity compensation plans in Item 12 of Part III of this Annual Report on Form 10-K is incorporated herein by reference. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to the shares of common stock repurchased by us during the three months ended December 31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid per Share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 - October 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940,000,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 - November 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,003,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 - December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,488,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,751,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,488,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average price paid per share includes related expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br/>On August 2, 2021, our Board of Directors authorized a Share Repurchase Program (2021 Repurchase Program) of our common stock, with an expiration date no later than August 2, 2023. Pursuant to the 2021 Repurchase Program, we may repurchase up to $1.0 billion of our outstanding common stock. Since inception of the 2021 Repurchase Program through December 31, 2021, we repurchased a total of <ix:nonFraction unitRef="shares" contextRef="ia2fcd0a4e20a4fb395dd61a92d63adc0_D20211001-20211231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV84NS9mcmFnOjY0YjAxZTA2YWY1NDQ3MmViZmVlZDIzNmJkMjY4ZjZmL3RleHRyZWdpb246NjRiMDFlMDZhZjU0NDcyZWJmZWVkMjM2YmQyNjhmNmZfMjc0ODc3OTA4MTk2OQ_27d7dfe2-b701-4edf-ac77-0277ecff34bd">3.5</ix:nonFraction>&#160;million shares of our common stock for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ia2fcd0a4e20a4fb395dd61a92d63adc0_D20211001-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV84NS9mcmFnOjY0YjAxZTA2YWY1NDQ3MmViZmVlZDIzNmJkMjY4ZjZmL3RleHRyZWdpb246NjRiMDFlMDZhZjU0NDcyZWJmZWVkMjM2YmQyNjhmNmZfMjc0ODc3OTA4MTk4NA_ff1dc583-3363-4f55-8a77-8dce5b3a607e">857</ix:nonFraction>&#160;million. Subsequent to December 31, 2021, the remaining amounts authorized under the 2021 Repurchase Program have been fully utilized.</span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_88"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_91"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes and other financial information appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in &#8220;Part I, Item 1A - Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases, independently and with our strategic collaborators. In January 2022, the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for our COVID-19 vaccine, Spikevax, for individuals 18 years of age and older in the United States. Spikevax is our first product to achieve licensure in the United States, and it has been authorized for use or approved by regulators in more than 70 countries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our platform, we develop technologies that enable the development of mRNA medicines for diverse applications. When we identify technologies that we believe could enable a new group of potential mRNA medicines with shared product features, we call that group a &#8220;modality.&#8221; While the programs within a modality may target diverse diseases, they share similar mRNA technologies, delivery technologies, and manufacturing processes to achieve shared product features. The programs within a modality will also generally share similar pharmacology profiles, including the desired dose response, the expected dosing regimen, the target tissue for protein expression, safety and tolerability goals, and pharmaceutical properties. Programs within a modality often have correlated technology risk, but because they pursue diverse diseases they often have uncorrelated biology risk. We have created seven modalities to date:</span></div><div><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">prophylactic vaccines;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">systemic secreted and cell surface therapeutics;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">cancer vaccines;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">intratumoral immuno-oncology;</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">localized regenerative therapeutics; </span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">systemic intracellular therapeutics; and</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inhaled pulmonary therapeutics.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have designated our prophylactic vaccines and systemic secreted and cell surface therapeutics modalities as our &#8220;core modalities.&#8221; In these core modalities, our strategy is to invest in additional development candidates using our accumulated innovations in technology, our process insights and our preclinical and clinical experience. Our exploratory modalities continue to be a critical part of advancing our strategy to maximize the application of our potential mRNA medicines.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our founding in 2010, we have transformed from a research-stage company advancing programs in the field of mRNA to a commercial enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. We have established relationships with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of our manufacturing capabilities. Most recently, our capabilities have come together to allow the authorization and approval of one of the earliest and most-effective vaccines against the COVID-19 pandemic. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Business Highlights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Moderna COVID-19 Vaccine</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2020, we received an Emergency Use Authorization (EUA) from the FDA for the emergency use of the Moderna COVID-19 Vaccine (also referred to as mRNA-1273 and marketed under the brand name Spikevax) in individuals 18 years of age or </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">older. Subsequently, we have also received authorization for our COVID-19 vaccine from health agencies in more than 70 countries and from the World Health Organization (WHO). Additional authorizations are currently under review in other countries. In addition, we have received authorization for our COVID-19 vaccine for use in adolescents in the European Union, the United Kingdom, Australia, Canada, Switzerland and other countries, and have pending applications for authorization to administer the vaccine to adolescents with regulatory agencies in the United States and other countries. In January 2022, we received full FDA approval for Spikevax to prevent COVID-19 in individuals 18 years of age and older in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A booster dose of our COVID-19 vaccine at the 50 &#181;g dose level is authorized for use under an EUA for adults 18 years and older. A third dose of our COVID-19 vaccine at the 100 &#181;g dose level is authorized for use under an EUA in immunocompromised individuals 18 years of age or older in the United States who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. The European Medicines Agency (EMA) has also authorized a third dose of the Moderna COVID-19 vaccine given at least 28 days after the second dose to severely immunocompromised individuals 12 years of age or older, as well as the administration of 50 &#181;g booster doses for individuals 18 years of age and older.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Scaling</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we rapidly scaled our manufacturing capabilities for our COVID-19 vaccine. By June, we had delivered 200 million doses of the Moderna COVID-19 Vaccine to the U.S. government. By end of September, we and our partners ramped up our capacity worldwide and supplied more than 500 million doses of our COVID-19 vaccine globally. We took measures to scale capacity at a significant pace, including the expansion of our Moderna Technology Center (MTC) in Norwood, Massachusetts. By the end of 2021, we had shipped approximately 800 million doses of our COVID-19 vaccine worldwide. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we announced new funding commitments to increase supply at our owned and partnered manufacturing facilities. We expect these investments will allow for a doubling of drug substance manufacturing at Lonza&#8217;s Switzerland-based facility, a more than doubling of formulation, fill and finish and drug substance manufacturing at Rovi&#8217;s Spain-based facility, as well as a 50 percent increase of drug substance at Moderna&#8217;s facilities in the U.S. When completed, the investments are also expected to result in an increase in safety stock of raw materials and finished product used to deliver committed volumes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Access Expansion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that vaccine availability continues to be a challenge in many parts of the world, and we remain focused on ensuring that low-income countries have access to our vaccine. In April, we announced additional investments to increase global supply of our COVID-19 vaccine and in May we announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of our vaccine at our lowest tiered price, in line with our global access commitments. This agreement has subsequently been revised to provide up to 650 million doses to be delivered across 2021 and 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in October, we announced that Moderna will build a state-of-the-art mRNA facility in Africa with the goal of producing up to 500 million doses of vaccines each year at the 50 &#181;g dose level. We also announced the first step in our long-term partnership with the African Union with a Memorandum of Understanding to supply up to 110 million doses of our COVID-19 vaccine to address the needs of low-income countries in Africa. In January 2022, African Union informed us that it will not exercise its option for 60 million doses in the second quarter of 2022, due to its expectation that existing supplies will be sufficient to meet its vaccination targets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Program Development</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the year, we continued to build a diverse clinical portfolio of vaccines and therapeutics across our seven modalities. Our longstanding approach to portfolio development, pursuing programs that have shared technology or biology, has helped us reduce risk as our pipeline has grown to 40 programs in development, including 23 in clinical studies as of December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond our COVID-19 vaccine, in 2021 we launched the second pivotal trial in our company&#8217;s history with CMVictory, a Phase 3 study of our vaccine to prevent congenital cytomegalovirus (CMV), which is the number one cause of birth defects in the U.S. This milestone takes us one step closer to potentially bringing another important vaccine to millions of people.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are making other significant advances across our programs. Our seasonal influenza vaccine showed positive interim Phase 1 data, and our respiratory syncytial virus (RSV) vaccine moved to a Phase 2/3 trial of 34,000 participants in the fourth quarter of 2022. In oncology, our Personalized Cancer Vaccine Phase 2 trial is now fully enrolled, and we expect a readout as early as the fourth quarter of 2022. We also saw early positive data from the Phase 2 study of our mRNA VEGF-A therapeutic with AstraZeneca moving it to the next stage of clinical development.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), and the African Union for the supply of our COVID-19 vaccine. The agreements are generally subject to receipt of authorization or approval for the use and distribution of the vaccine from the relevant regulatory authority in each jurisdiction. Under these agreements, we are entitled to upfront deposits for our COVID-19 vaccine supply, which is initially recorded as deferred revenue. As of December 31, 2021, we had approximately $6.7&#160;billion in deferred revenue in connection with the supply agreements with the U.S. Government and other customers, which will be recognized as revenue when revenue recognition criteria have been met. For the year ended December 31, 2021, we delivered approximately 332 million doses of our COVID-19 vaccine to the U.S. Government and approximately 475 million doses to other governments, and we recognized $17.7&#160;billion in product sales. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had cash, cash equivalents and investments of approximately $17.6&#160;billion. We are using this capital to fund operations and investing activities for technology creation, drug discovery and clinical development programs, infrastructure and capabilities to enable our research and early development activities (which includes our MTC), our digital infrastructure, creation of our portfolio of intellectual property, acquisition of key raw materials and supplies to support our commercial production quantities, development of a commercial team, expansion into global markets, funding our strategic collaborations and administrative support. We also use this capital to fund our Share Repurchase Program, designed to return value to our stockholders and minimize dilution from stock issuances. <br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Business Updates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we announced an expansion of our MTC. The MTC has been core to our long-term strategy and has enabled us to provide the scale and flexibility to support the development of our mRNA medicines and vaccines, including our COVID-19 vaccine. This investment will more than double the space at the MTC to approximately 650,000 square feet and allow us to continue to optimize our mRNA products as we explore new pharmaceutical delivery forms such as prefilled syringes and lyophilized products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also investing in a new Moderna Science Center (MSC) in Cambridge, Massachusetts, to create a purpose-built space to support our next chapter of discovery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and serve as our principal executive offices. The MSC will integrate digital-first scientific research and development labs along with space for innovation and co-creation with our people and our partners around the world. As part of our ongoing commitment to sustainability, the high-performance building is designed to be the most sustainable commercial lab building in Cambridge.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our owned facilities in the U.S., we have expanded our footprint across the globe, with active subsidiaries in more than 12 countries, including the U.S., Canada, many European countries and the Asia Pacific region. As Moderna expands internationally, we also announced in 2021 preliminary agreements with the governments of Canada and Australia to bring state-of-the-art mRNA manufacturing facilities to those countries to provide direct access to rapid pandemic response capabilities as well as domestically manufactured mRNA vaccines against other diseases. </span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:47.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began to record product sales for our COVID-19 vaccine subsequent to its authorization for emergency use by the FDA and Health Canada in December 2020. For the years ended December 31, 2021 and 2020, we recognized $17.7&#160;billion and $200&#160;million, respectively, of product sales from sales of our COVID-19 vaccine. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than product sales, our revenue in 2021 and 2020 was derived from government-sponsored and private organizations including BARDA, DARPA and the Bill &amp; Melinda Gates Foundation and from strategic alliances with AstraZeneca, Merck and Vertex to discover, develop, and commercialize potential mRNA medicines.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes collaboration revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:47.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had signed supply agreements of approximately $20.6&#160;billion for the future supply of our COVID-19 vaccine to be delivered in 2022 and 2023 and had deferred revenue of $6.7 billion associated with customer deposits received or billable under these agreements. Additional supply agreements have been agreed upon since December 31, 2021, and others are under discussion for 2022 and 2023 deliveries. We believe that the SARS-CoV-2 virus will evolve to an endemic phase in 2022 and as a result, we expect our product sales to be larger in the second half of 2022 than in the first half. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we expect to continue to receive funding from our contract with BARDA. As of December 31, 2021, the remaining available funding, net of revenue earned was $189&#160;million under the BARDA contract. To the extent that existing or potential future products generate revenue, our revenue may vary due to many uncertainties in future product demand, the development of our mRNA medicines and other factors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes raw materials, personnel and facility and other costs associated with manufacturing our commercial product. These costs include production materials, production costs at our manufacturing facilities, third-party manufacturing costs, and final formulation and packaging costs. Cost of sales also includes shipping costs, royalties payable to third parties based on sales of our products, and charges for inventory valuation reserves. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of our business and primary focus of our activities generate a significant amount of research and development costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses represent costs incurred by us for the following:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cost to develop our platform;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">discovery efforts leading to development candidates;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">preclinical, nonclinical, and clinical development costs for our programs;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cost to develop our manufacturing technology and infrastructure; and</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">digital infrastructure costs related to our drug discovery efforts and clinical trials.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs above comprise the following categories:</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">personnel-related expenses, including salaries, benefits, and stock-based compensation expense;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses incurred under agreements with third parties, such as consultants, investigative sites, contract research organizations, or CROs, that conduct our preclinical studies and clinical trials, and in-licensing arrangements;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses associated with developing manufacturing capabilities and acquiring materials for preclinical studies, clinical trials and pre-launch inventory, including both internal manufacturing and third-party contract manufacturing organizations, or CMOs;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses incurred for the procurement of materials, laboratory supplies, and non-capital equipment used in the research and development process; and</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">facilities, depreciation, and amortization, and other direct and allocated expenses incurred as a result of research and development activities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our employee and infrastructure resources for the advancement of our platform, and for discovering and developing programs. Due to the number of ongoing programs and our ability to use resources across several projects, indirect or shared operating costs incurred for our research and development programs are generally not recorded or maintained on a program- or modality-specific basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our research and development expenses, including direct program specific expenses summarized by modality and indirect or shared operating costs summarized under other research and development expenses during the years ended December 31, 2021, 2020, and 2019 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.280%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Program expenses by modality:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prophylactic vaccines</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic secreted and cell surface therapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancer vaccines</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intratumoral immuno-oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Localized regenerative therapeutics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Systemic intracellular therapeutics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inhaled pulmonary therapeutics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total program-specific expenses by modality</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,196&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discovery programs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform research</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technical development and unallocated manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shared discovery and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes a total of 37 development candidates at December 31, 2021 and 21 development candidates at each of December 31, 2020 and 2019. Program-specific expenses include external costs and allocated manufacturing costs of pre-launch inventory, mRNA supply and consumables, and are reflected as of the beginning of the period in which the program was internally advanced to development or removed if development was ceased.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8220;modality&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> refers to a group of programs with common product features and the associated combination of enabling mRNA technologies, delivery technologies, and manufacturing processes. The program-specific expenses by modality summarized in the table above include expenses we directly attribute to our programs, which consist primarily of external costs, such as fees paid to outside consultants, central laboratories, investigative sites, and CROs in connection with our preclinical studies and clinical trials, CMOs, and allocated manufacturing costs of pre-launch inventory, mRNA supply and consumables. Costs to acquire and manufacture pre-launch inventory, mRNA supply for preclinical studies and clinical trials are recognized and included in unallocated manufacturing expenses when incurred, and subsequently allocated to program-specific manufacturing costs after completion of the program-specific production. The timing of allocating manufacturing costs to the specific program varies depending on the program development and production schedule. We generally do not allocate personnel-related costs, including stock-based compensation, costs associated with our general platform research, technical development, and other shared costs on a program-specific basis. These costs were therefore excluded from the summary of program-specific expenses by modality. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery program expenses are costs associated with research activities for our programs in the preclinical discovery stage, and primarily consist of external costs for CROs and lab services, and allocated manufacturing cost of preclinical mRNA supply and consumables.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform research expenses are mainly costs to develop technical advances in mRNA science, delivery science, and manufacturing process design. These costs include personnel-related costs, computer equipment, facilities, preclinical mRNA supply and consumables, and other administrative costs to support our platform research. Technology development and unallocated manufacturing expenses are primarily related to non-program-specific manufacturing process development and manufacturing costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shared discovery and development expenses are research and development costs such as personnel-related costs and other costs, which are not otherwise included in development programs, discovery programs, platform research, technical development and unallocated manufacturing expenses, stock-based compensation, and other expenses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The largest component of our total operating expenses has historically been our investment in research and development activities, including development of our platform, mRNA technologies, and manufacturing technologies. We expense research and development costs as incurred and cannot reasonably estimate the nature, timing, and estimated costs required to complete the development of the development candidates and investigational medicines we are currently developing or may develop in the future. There are numerous risks and uncertainties associated with the research and development of such development candidates and investigational medicines, including, but not limited to:</span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scope, progress, and expense of developing ongoing and future development candidates and investigational medicines;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry in and completion of related preclinical studies;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enrollment in and completion of subsequent clinical trials;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and efficacy of investigational medicines resulting from these clinical trials;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations relevant to the investigational medicines in development;</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of the required regulatory approvals; and</span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialization, including establishing manufacturing and marketing capabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to pursue our indication expansion of mRNA-1273 during the current pandemic, and continue to develop variant-specific COVID-19 vaccine candidates and our next-generation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 vaccine candidate (mRNA-1283), we expect to continue to incur significant additional expenses. At this time, the magnitude of these potential expenditures is not known. In connection with the BARDA agreement to accelerate development of mRNA-1273, grant revenue and expenses within the committed funding scope are expected to continue in 2022. BARDA&#8217;s funding is expected to offset those expenses that are covered under the BARDA agreement, subject to our obtaining reimbursement from BARDA. As of December 31, 2021, the remaining available funding from BARDA, net of revenue earned was $189&#160;million. Please refer to Note 4 to our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Changes in expectations or outcomes of any of the known or unknown risks and uncertainties may materially impact our expected research and development expenditures. Continued research and development is central to the ongoing activities of our business. Investigational medicines in later stages of clinical development, such as our CMV vaccine (mRNA-1647) and our COVID-19 vaccine, generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development costs to continue to increase for the foreseeable future as our investigational medicines progress through the development phases and as we identify and develop additional programs. There are numerous factors associated with the successful commercialization of any of our investigational medicines, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time due to the early stage of development of our investigational medicines. Moreover, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We started to incur sales and marketing expenses in the fourth quarter of 2020 to prepare for commercial operations in connection with the sale of our COVID-19 vaccine, and these expenses increased throughout the course of 2021. Selling, general and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for executives, finance, legal, human resources, business development and other administrative and operational functions, professional fees, accounting and legal services, information technology and facility-related costs, and expenses associated with obtaining and maintaining intellectual property, or IP. These costs relate to the operation of the business, unrelated to the research and development function, or any individual program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We anticipate selling, general and administrative expenses will increase as we continue to expand the number of programs in development and prepare for the establishment of commercial activities both within and outside the United States. We have already incurred additional expenses related to building out a regulatory, sales and marketing team to support the sale, marketing and distribution of our COVID-19 vaccine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and the expansion of our footprint across the globe, with active subsidiaries in more than 12 countries. If we obtain regulatory approval for additional investigational medicines, and do not enter into one or more third-party </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">commercialization collaboration and manufacturing arrangements, we will incur significant additional expenses related to building out these functions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a broad IP portfolio covering our development and commercialization of mRNA vaccine and therapeutic programs, including those related to mRNA design, formulation, and manufacturing platform technologies. We regularly file patent applications to protect innovations arising from our research and development. We also hold trademarks and trademark applications in the United States and foreign jurisdictions. Costs to secure and defend our IP are expensed as incurred, and are classified as selling, general and administrative expenses. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest generated from our investments in cash and cash equivalents, money market funds, and high-quality fixed income securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other expense, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of interest expense, gains (losses) from the sale of investments in marketable securities, and other income and expense unrelated to our core operations. Interest expense is primarily derived from our finance leases related to our Moderna Technology Center and certain contract manufacturing service agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies and significant judgments and estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, are reflected in the consolidated financial statements prospectively from the date of change in estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies used in the preparation of our </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements require the most significant judgments and estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. We determine our deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made. As of December 31, 2021, we maintained a valuation allowance against a portion of the state deferred tax assets based on management&#8217;s evaluation of all available evidence. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax audits and adjustments by tax authorities. The nature of uncertain tax positions is subject to significant judgment by management and subject to change, which may be substantial. We develop our assessment of uncertain tax positions and as additional information becomes available, estimates are revised and refined. We record reserves for potential tax payments to various tax authorities related to uncertain tax positions. These reserves are based on a determination of whether and how much of a tax benefit taken by us in our tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Differences between estimates and final settlement may occur resulting in additional tax expense.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our financial statements or do not otherwise apply to our operations.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion regarding our results of operations for the year ended December 31, 2021 compared to 2020 is presented below. A discussion regarding our results of operations for the year ended December 31, 2020 compared to 2019 can be found under Part II -Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our consolidated statements of operations for the periods presented (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change 2021 vs. 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(744)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,949&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change 2020 vs. 2019</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(763)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(744)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $17.7 billion in 2021, primarily due to increases in product sales. Product sales increased by $17.5 billion in 2021 from sales of our COVID-19 vaccine to domestic and international </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government customers and international purchasing organizations, such as Gavi (on behalf of the COVAX Facility) and the African Union,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsequent to the authorization by the FDA and Health Canada for emergency use in December 2020. Grant revenue increased by $206 million, or 39%, in 2021, mainly due to an increase in grant revenue from BARDA related to our COVID-19 vaccine development in 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began capitalizing our COVID-19 vaccine inventory costs in December 2020, in connection with an Emergency Use Authorization from the FDA and an Interim Order from Health Canada for use of our COVID-19 vaccine, and based upon our expectation that these costs would be recoverable through commercialization of mRNA-1273. Prior to the capitalization of our COVID-19 vaccine inventory costs, costs related to our pre-launch inventory were recorded as research and development expenses in the period incurred. We expensed $242 million of pre-launch inventory costs in 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of sales was $2.6&#160;billion, or 15% of our product sales, in 2021, including third-party royalties of $641 million. A portion of the inventory costs associated with our product sales for the year ended 2021 was expensed previously. If inventory sold for the year ended 2021 was valued at cost, including what was expensed as pre-launch inventory, our cost of sales for the period would have been $2.8&#160;billion, or 16% of our product sales. We utilized all of our pre-launch inventory during 2021. We expect that our cost of sales as a percentage of product sales will increase in 2022 due to higher manufacturing costs and lower average selling price per dose, driven by the expected increase in deliveries to low income countries. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $621 million, or 45%, in 2021. The increase was primarily attributable to an increase&#160;in clinical trial expenses of&#160;$721 million, an&#160;increase&#160;in personnel-related costs of&#160;$79 million, and an&#160;increase in consulting and outside services of&#160;$59 million, partially offset by a decrease in manufacturing expenses of $251 million, attributable to pre-launch inventory expensed in 2020 prior to FDA authorization. The increase in 2021 was largely attributable to the continued clinical development of mRNA-1273. The increase in personnel-related costs was primarily driven by an increase in the number of employees supporting our mRNA-1273 development activities as well as other research and development programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that research and development expenses will increase in 2022 as we continue to progress our indication expansion of mRNA-1273, and continue to develop our pipeline and advance our product candidates into later-stage development. In addition, we also expect to incur significant costs related to the development of variant-specific COVID-19 candidates and our next-generation COVID-19 vaccine candidate (mRNA-1283).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $379 million, or 202%, in 2021. The increase was mainly due to an increase in consulting and outside services of $97 million, an increase in personnel-related costs of $73 million, an increase in marketing expense of $67 million, an increase in distributor fees of $64 million, and an increase in legal, licensing and insurance expenses of $42 million. The increases in personnel-related costs and consulting and outside services were primarily attributable to mRNA-1273 commercialization-related activities and increased headcount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that selling, general and administrative expenses will increase in 2022, as we continue to build out our global commercial, regulatory, sales and marketing infrastructure to support the commercialization of our COVID-19 vaccine, and continue to expand the number of programs and our business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income generated from our investments in marketable securities decreased by&#160;$7 million, or&#160;28%, in 2021, mainly attributable to an overall lower interest rate.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other expense, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other expense, net for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:58.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change 2021 vs. 2020</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net increased by $23 million, or 383%, in 2021. The increase was primarily due to losses related to remeasurements and our balance sheet hedging activities, partially offset by gains on foreign currency transactions. Our interest expense is primarily related to our finance leases. The increase in interest expense was driven by new finance leases that commenced in 2021. Please refer to Note 11 to our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for income taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes increased by $1.1&#160;billion in 2021, primarily due to an increase in pre-tax income. Our effective tax rate for the year ended December 31, 2021 was 8.1%, which included tax benefits related to the release of the valuation allowance on most of our deferred tax assets, foreign-derived intangible income deduction, and stock-based compensation. Provision for income taxes was immaterial for the year ended December 31, 2020. We expect that our effective tax rate will increase in 2022 as the valuation allowance against our deferred tax assets was mostly released in 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and capital resources</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the commercialization of our COVID-19 vaccine, we have historically funded our operations primarily from the sale of equity instruments and from proceeds from certain strategic alliance arrangements and grant agreements. Starting in August 2020, we entered into supply agreements with the U.S. Government, other international governments, Gavi, and the African Union for the supply of our COVID-19 vaccine. Under these agreements, we are entitled to upfront deposits for our COVID-19 vaccine supply, which are initially recorded as deferred revenue and will be recognized as revenue when revenue recognition criteria have been met. As of December 31, 2021, we had $6.7 billion in deferred revenue related to customer deposits received or billable. In addition, we expect to continue to receive funding from our contract with BARDA related to our mRNA-1273 program. As of December 31, 2021, the remaining available funding, net of revenue earned was $189&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2021, we had cash, cash equivalents and investments of $17.6 billion. Cash, cash equivalents and investments are invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Investments, consisting primarily of government and corporate debt securities are stated at fair value. As of December 31, 2021, we had current and non-current investments of approximately $3.9 billion and $6.8&#160;billion, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective January 1, 2022, research and development expenses are required to be capitalized and amortized for U.S. tax purposes. Unless modified or repealed, and based on current assumptions, the mandatory capitalization would increase our cash tax liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work toward the large-scale technical development, manufacturing scale-up in several countries and larger scale deployment of our COVID-19 vaccine. To support the scale-up, we have expended and will need to continue to expend significant resources and capital.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flow</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the primary sources and uses of cash for the periods presented (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(459)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive cash flows from operations primarily from cash collected from customer deposits related to our COVID-19 vaccine supply agreements as well as certain government-sponsored and private organizations and strategic alliances. Our cash flows from operating activities are significantly affected by our use of cash for operating expenses and working capital to support the business. Prior to 2020, we experienced negative cash flows from operating activities as we invested in our mRNA technologies, development pipeline, digital infrastructure, manufacturing technology, and infrastructure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities in 2021 was $13.6 billion and consisted of net income of $12.2 billion and non-cash adjustments of $110 million, plus a net change in assets and liabilities of $1.3 billion. Non-cash items primarily included depreciation and amortization of $232 million, stock-based compensation of $142 million, deferred income taxes of $318 million, and amortization of investment premiums and discounts of $54 million. The net change in assets and liabilities was primarily due to an increase in deferred revenue of $2.8 billion, an increase in accrued liabilities of $989 million, an increase in income taxes payable of $876 million, and an increase in accounts payable of $204 million, partially offset by an increase in accounts receivable of $1.8 billion, an increase in inventory of $1.4 billion, and an increase in prepaid expenses and other assets of $489 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by operating activities in 2020 was $2.0 billion and consisted of net loss of $747 million less non-cash adjustments of $196 million, plus a net change in assets and liabilities of $2.6 billion. Non-cash items primarily included stock-based compensation of $93 million, leased assets expensed of $62 million, depreciation and amortization of $31 million, and amortization of investment premiums and discounts of $10 million. The net change in assets and liabilities was primarily due to an increase in deferred revenue of $3.8 billion, an increase in accrued liabilities of $388 million, an increase in accounts payable of $12 million, and an increase in operating lease liabilities of $12 million, partially offset by an increase in accounts receivable of $1.4 billion, an increase in prepaid expenses and other assets of $241 million, an increase of inventory of $47 million, and an increase in operating lease right-of-use assets of $11 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities in 2019 was $459 million and consisted of net loss of $514 million less non-cash adjustments of $108 million, plus a net change in assets and liabilities of $53 million. Non-cash items primarily included stock-based compensation of $81 million, and depreciation and amortization of $31 million. The net change in assets and liabilities was primarily due to a decrease in deferred revenue of $44 million, and a decrease in accounts payable of $24 million, partially offset by an increase in operating lease liabilities, non-current of $13 million, and a decrease in prepaid expenses and other assets of $10 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary investing activities consist of purchases, sales, and maturities of our investments and capital expenditures for manufacturing, laboratory, computer equipment, and software.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities in 2021 was $8.5 billion, which included purchases of marketable securities of $12.7 billion, purchases of property and equipment of $284 million, and investment in convertible notes of $30 million, partially offset by proceeds from sales of marketable securities of $3.1 billion and proceeds from maturities of marketable securities of $1.3 billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities in 2020 was $1.7 billion, which included purchases of marketable securities of $3.0 billion and purchases of property and equipment of $68 million, partially offset by proceeds from maturities of marketable securities of $1.1 billion and proceeds from sales of marketable securities of $215 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities in 2019 was $15 million, which included purchases of marketable securities of $1.1 billion and purchases of property and equipment of $32 million, partially offset by proceeds from maturities of marketable securities of $993 million and proceeds from sales of marketable securities of $169 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities in 2021 was $873 million, primarily from repurchases of common stock of $857 million and changes in financing lease liabilities of $140 million, partially offset by net proceeds from the issuance of common stock in connection with the exercise of stock options and employee stock purchases under our equity plans of $124 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by financing activities in 2020 was $2.0 billion, primarily from net proceeds from equity offerings of $1.9 billion and net proceeds from the issuance of common stock in connection with the exercise of stock options and employee stock purchases under our equity plans of $186 million.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by financing activities in 2019 was $52 million, primarily from net proceeds from the issuance of common stock in connection with the exercise of stock options and employee stock purchases under our equity plans of $51 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operation and funding requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From our inception to the end of 2020, we incurred significant losses from operations due to our significant research and development expenses. We generated net income for the year ended 2021 in connection with product sales following the authorization of our first commercial product. We have retained earnings of $10.0 billion as of December 31, 2021. We have significant future capital requirements including expected operating expenses to conduct research and development activities, operate our organization, meet capital expenditure needs, and fund our share repurchase program. We expect our expenses to increase in connection with our ongoing activities as we continue research and development of our development candidates and clinical activities for our investigational medicines. We also expect our expenses to increase associated with manufacturing costs, including our arrangements with our international supply and manufacturing partners. Our ongoing work on mRNA-1273, including development of any new generations of boosters and vaccines against variants of SARS-CoV-2, and buildout of global commercial, regulatory, sales and marketing infrastructure to support the commercialization of our COVID-19 vaccine will require significant cash outflows during 2022, most of which may not be reimbursed or otherwise paid for by our partners or collaborators. In addition, we have substantial facility, lease and purchase obligations. We have entered into certain collaboration agreements with third parties that include the funding of certain research and development activities and potential future milestone and royalty payments by us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents, and investments as of December 31, 2021, will be sufficient to enable us to fund our projected operations, capital expenditures and share repurchases through at least the next 12 months from the issuance of the financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this Annual Report on Form 10-K. We are subject to all the risks related to the development and commercialization of novel medicines, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors including expenses related to the ongoing COVID-19 pandemic, which may adversely affect our business. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to sustain profitability on a continuing basis, we may be required to finance future cash needs through a combination of public or private equity offerings, structured financings and debt financings, government funding arrangements, potential future strategic alliances from which we receive upfront fees, milestone payments, and other forms of consideration, and marketing, manufacturing, distribution and licensing arrangements. If we are required to finance future cash needs, additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back, or discontinue the development or commercialization of one or more of our investigational medicines, or slow down or cease work on one or more of our programs. If we raise additional funds through the issuance of additional equity or debt securities, it could result in dilution to our existing stockholders or increased fixed payment obligations, and any such securities may have rights senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise funds through strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or investigational medicines or grant licenses on terms that may not be favorable to us. Any of these events could significantly harm our business, financial condition, and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual obligations and commitments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations as of December 31, 2021 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less&#160;than&#160;1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">year</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1&#160;-&#160;3&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3&#160;-&#160;5&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">More&#160;than&#160;5</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSC lease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual cash obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The amounts in the table include a total payment of $637 million associated with our MTC leases for the optional lease extension periods. For accounting purpose, a lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. Please refer to Note 11 to our consolidated financial statements. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">We entered into a lease agreement for approximately 462,000 square feet in Cambridge, Massachusetts (Moderna Science Center) and will undergo an approximately two-year building project. Following the building project, the lease term is 15 years, subject to our right to extend the lease for up to two additional seven-year terms. The rent will commence on the Initial Phase Commencement date defined in the lease agreement that is currently estimated to be in July 2023. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The amounts represent non-cancelable fixed payment obligations related to purchases of raw materials, contract manufacturing services, clinical services and other goods or services in the normal course of business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements with certain vendors for various services, including services related to clinical operations, and support and contract manufacturing, which we are not contractually able to terminate for convenience. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly to reimburse them for their unrecoverable outlays incurred prior to cancellation. The exact amounts of such obligations are dependent on the timing of termination, and the exact terms of the relevant agreement and cannot be reasonably estimated. At December 31, 2021, we had cancelable open purchase orders of $2.4 billion in total under such agreements for our clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December 31, 2021, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the cancelable open purchase order amounts of $2.4 billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above obligations, we enter into a variety of agreements and financial commitments in the normal course of business. The terms generally allow us the option to cancel, reschedule, and adjust our requirements based on our business needs, prior to the delivery of goods or performance of services. It is not possible to predict the maximum potential amount of future payments under these agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement.</span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_97"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, we had cash, cash equivalents, restricted cash, and investments in marketable securities of $17.6 billion and $5.2 billion, respectively. Our investment portfolio comprises money market funds and marketable debt securities (including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities, and commercial paper), which are classified as available-for-sale securities. Our primary investment objectives are the preservation of capital and the maintenance of liquidity, and our investment policy defines allowable investments based on quality of the institutions and financial instruments designed to minimize risk exposure. Our exposure to interest rate sensitivity is affected by changes in the general level of U.S. interest rates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable securities are subject to interest rate risk and will fall in value if market interest rates increase. Due to the short-term maturities and low risk profiles of our investments, we do not anticipate a significant exposure to interest rate risk. If market interest rates were to increase immediately and uniformly by one percentage point from levels at December 31, 2021, the net fair value of our marketable securities would decrease by approximately $146 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue generating activities and operations have been primarily denominated in U.S. dollars. Our significant foreign currency revenue exposure for the year ended December 31, 2021 was the equivalent of $5.9 billion in Euros. As we expand internationally our results of operations and cash flows become increasingly subject to fluctuations due to changes in foreign currency exchange rates. To help manage the exposure to foreign currency exchange rate fluctuations, we have implemented cash flow hedging and balance sheet hedging programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedging Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge foreign currency product sales denominated in Euros, including the use of foreign exchange forward contracts or purchased options. We hedge our cash flow exposures to reduce the risk that our earnings and cash flows will be adversely affected by changes in exchange rates. These transactions are designated and qualify as cash flow hedges. Our foreign exchange contracts as of December 31, 2021, carried at fair value, had maturities of up to 9 months. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Hedging Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use foreign currency forward contracts to mitigate foreign currency exchange risk associated with foreign currency-denominated monetary assets and liabilities. These contracts reduce the impact of currency exchange rate movements on our assets and liabilities. As of December 31, 2021, our outstanding balance sheet hedging derivatives, carried at fair value, had maturities of less than three months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into these foreign exchange contracts to hedge our forecasted revenue and monetary assets and liabilities denominated in foreign currency in the normal course of business and accordingly, they are not speculative in nature. We believe the counterparties to our foreign currency forward contracts are creditworthy multinational commercial banks. While we believe the risk of counterparty nonperformance is not material, a sustained decline in the financial stability of financial institutions as a result of disruption in the financial markets could affect our ability to secure creditworthy counterparties for our foreign currency hedging programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Notwithstanding our efforts to mitigate some foreign currency exchange risks, there can be no assurance that our hedging activities will adequately protect us against the risks associated with foreign currency fluctuations. As of December 31, 2021, a hypothetical adverse movement of 10 percent in foreign currency exchange rates compared to the U.S. dollars across all maturities would have resulted in potential declines in the fair value on our foreign currency forward contracts used in cash flow hedging of approximately $54 million. As of December 31, 2021, a hypothetical adverse movement of 10 percent in foreign currency exchange rates compared to the U.S. dollars across all maturities would have resulted in potential declines in the fair value on our foreign currency forward contracts used in balance sheet hedging of approximately $115 million. We expect that any increase or decrease in the fair value of the portfolio would be substantially offset by increases or decreases in the underlying exposures being hedged. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_100"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_103">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_103">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_106">Consolidated Balance Sheets as of December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_106">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_109">Consolidated Statements of Operations for the years ended December 31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_109">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_112">Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_112">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_115">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_115">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_118">Consolidated Statements of Cash Flows for the years ended December 31, 2021, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_118">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_121">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7a7cdf3fe3c348059a6b0a57c2f167fe_121">122</a></span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_103"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Moderna, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Moderna, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;25, 2022 expressed an unqualified opinion thereon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:12.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.188%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product Sales Revenue Recognition</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed in Note 2 to the consolidated financial statements, the Company has entered into supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX facility), and the African Union. Under the supply agreements, the Company is entitled to upfront deposits for COVID-19 vaccine supply, which are initially recorded as deferred revenue. Revenue is recognized pursuant to Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, based on the fixed price per dose when control of the product has transferred and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. The Company must evaluate the contractual terms and conditions in its supply agreements to determine the timing of revenue recognition. For the year ended December 31, 2021, product sales revenue totaled $17.7 billion and related deferred revenue totaled $6.7 billion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing the Company's revenue recognition was especially challenging due to the volume of executed supply agreements, the varying contractual terms within the agreements, and because the amounts are material to the consolidated financial statements and related disclosures.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of the Company's internal controls over the recognition of revenue related to product sales. This included testing controls over the Company's process to evaluate the contractual terms of the supply agreements and determine the appropriate revenue recognition. We also tested the Company&#8217;s controls over evaluating transfer of control and customer acceptance, as applicable, and controls over the Company&#8217;s IT systems that are important to the initiation, processing and recording of revenue transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To test the recognition of revenue associated with supply agreements, our audit procedures included, among others, evaluating the contractual terms of supply agreements, testing the transfer of control, and assessing the timing of revenue recognition. For example, we performed procedures to test the completeness and accuracy of the underlying data in the Company&#8217;s revenue and deferred revenue calculations, including testing the mathematical accuracy of the Company&#8217;s calculations, and testing the accuracy of revenue recognized by tracing key terms to the supply agreements and agreeing a sample of revenue transactions to supporting documentation, including evidence of control transfer. We also assessed the appropriateness of the related disclosures in the consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDMvZnJhZzpmNWFmYWZjMDE4Mzc0NmY3OTk3ZmQzZDVhNTM3YjMwYi90ZXh0cmVnaW9uOmY1YWZhZmMwMTgzNzQ2Zjc5OTdmZDNkNWE1MzdiMzBiXzE5MjQxNDUzNDkwMDkx_5e06d58e-407d-4aa2-9a46-93634d7b8fc1">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2014.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDMvZnJhZzpmNWFmYWZjMDE4Mzc0NmY3OTk3ZmQzZDVhNTM3YjMwYi90ZXh0cmVnaW9uOmY1YWZhZmMwMTgzNzQ2Zjc5OTdmZDNkNWE1MzdiMzBiXzE5MjQxNDUzNDkwMDky_ab7b9f38-f406-454d-871a-96b88e15adea">Boston, Massachusetts</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2022</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_106"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzQtMS0xLTEtNzYwNDY_fd8a6426-4709-4c0f-bb5e-4aba36544bfd">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzQtMy0xLTEtNzYwNDY_eabde0ea-9976-450a-8926-20355d31d8c7">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzUtMS0xLTEtNzYwNDY_9d9a1aca-2b0c-45d6-92d6-440add351548">3,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzUtMy0xLTEtNzYwNDY_dfdc0339-d91b-4b69-a91a-63cf7534d3fe">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzYtMS0xLTEtNzYwNDY_2e4c4f4c-84bb-49a9-bbb4-cd51a7a1e60e">3,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzYtMy0xLTEtNzYwNDY_596b26cd-c70c-420d-83aa-20552172c5c6">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzctMS0xLTEtNzYwNDY_b245ed45-c99f-4058-8e81-364973741425">1,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzctMy0xLTEtNzYwNDY_391c1051-6fab-4ca8-a594-edc029bc26f0">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzgtMS0xLTEtNzYwNDY_fcbeba05-4dba-4d2c-8ee2-45b1c69ea9c5">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzgtMy0xLTEtNzYwNDY_2aff91c4-5f64-4ec1-927f-8ed2a85a050f">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEwLTEtMS0xLTc2MDQ2_5f614f4a-1807-45a0-aee8-7039a0b33ece">16,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEwLTMtMS0xLTc2MDQ2_48abc217-d885-40f1-a943-c6ac91a54408">6,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, non-current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzExLTEtMS0xLTc2MDQ2_5fd5bacb-8206-4656-99e0-5d2f2c4b6a7c">6,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzExLTMtMS0xLTc2MDQ2_108d03bc-a663-4932-bd34-d985155c5b1b">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEyLTEtMS0xLTc2MDQ2_6973ff7a-0397-4c52-8666-20a9d2a27781">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEyLTMtMS0xLTc2MDQ2_b8436be5-7210-466f-9e51-f96459bd655c">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEzLTEtMS0xLTc2MDQ2_6d905a73-ba10-40ad-981f-a48a36143f49">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEzLTMtMS0xLTc2MDQ2_8ca53cdd-1c18-4268-b612-d504f74def93">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE0LTEtMS0xLTc2MDQ2_a50a2cd1-ca8f-4266-9cc0-d3a9e80a1a81">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE0LTMtMS0xLTc2MDQ2_8f420ab1-8a05-44c6-bd1a-fcb295b2d8d9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE1LTEtMS0xLTc2NTE5_9d35c685-d800-403f-bc96-c717053847df">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE1LTMtMS0xLTc2NTE5_07899c19-d2a2-481b-ba8a-d861d607a484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE1LTEtMS0xLTc2MDQ2_ca45e19d-767d-4895-9fc3-e88288525fa8">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE1LTMtMS0xLTc2MDQ2_d1a9f3fc-f3b1-457d-bba2-ed5653f6deb0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE2LTEtMS0xLTc2MDQ2_d0e24902-d25d-4fab-9696-4bd9c93bd2c0">24,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE2LTMtMS0xLTc2MDQ2_5fe02baf-c908-4d4e-913d-a46aa9ebaeb1">7,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE5LTEtMS0xLTc2MDQ2_256dd288-d398-4b63-8465-1351726c108f">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE5LTMtMS0xLTc2MDQ2_1afbe9c2-7a02-454a-b45e-219c7c77b426">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIwLTEtMS0xLTc2MDQ2_6251f37c-6ae4-4aa7-8045-01611dcb6adf">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIwLTMtMS0xLTc2MDQ2_c70a831a-6fd6-40a9-95b2-266fd1406813">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIxLTEtMS0xLTc2MDQ2_ac2245d9-6ce6-4146-b6c4-5988decf33bc">6,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIxLTMtMS0xLTc2MDQ2_e6659308-4929-4d79-b346-58c0f5402826">3,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIzLTEtMS0xLTc2NTU4_e7d107ba-b99d-4eb8-aea2-5687a7127601">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:TaxesPayableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIzLTMtMS0xLTc2NTU4_1a511f6d-f839-444a-a5c0-b6ab60a2266b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIyLTEtMS0xLTc2MDQ2_2a161676-6d7c-400c-96d3-7d17cb28b78d">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIyLTMtMS0xLTc2MDQ2_374deb1f-5b7b-4df3-a34b-cf8560d01173">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIzLTEtMS0xLTc2MDQ2_eb5a222a-a294-4ff9-8db0-7d78f14341dc">9,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIzLTMtMS0xLTc2MDQ2_1c8a26ff-e975-4988-a841-5176ae087fd4">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI0LTEtMS0xLTc2MDQ2_3fb9fc8d-7c3e-4baf-bb00-535971cbd9c4">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI0LTMtMS0xLTc2MDQ2_fcd13bf7-4a75-41a0-a112-6837cccd8310">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI1LTEtMS0xLTc2MDQ2_4f183c78-d5f1-40b7-9bcc-57c365fd2038">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI1LTMtMS0xLTc2MDQ2_be7808db-b818-41cc-b3b4-2fd63556510c">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI2LTEtMS0xLTc2MDQ2_d11388a3-a6a0-473c-b02e-d6b432216b8d">599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI2LTMtMS0xLTc2MDQ2_4d5928ee-ec89-431e-b71b-cfd604e8c376">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI3LTEtMS0xLTc2MDQ2_07620de2-2f1d-45df-bed0-7e28d088a804">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI3LTMtMS0xLTc2MDQ2_73c106ec-acd7-4908-bafb-0ba69f15956e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI4LTEtMS0xLTc2MDQ2_533b3ead-022d-4323-9dcd-c3058bc1c1e3">10,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI4LTMtMS0xLTc2MDQ2_dccf7ff6-9592-49a7-ab81-24be0b7e8b02">4,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI5LTEtMS0xLTc2MDQ2_e7f57708-854c-4a4d-a9ae-e1fae911aad7"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI5LTMtMS0xLTc2MDQ2_ee3abf3d-3482-4f89-bc3e-aa211dbfc455"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTY5OQ_6c277de7-7ee5-472f-8d6a-deddb669f7b4"><ix:nonFraction unitRef="usdPerShare" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTY5OQ_ca5e5ca5-e8d0-40c0-b320-3f650a120ee0">0.0001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTcwNA_214aa800-a1e2-43c0-b8ea-ae73b6dc7909"><ix:nonFraction unitRef="shares" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTcwNA_5bbf34b2-e8c9-4758-98db-2038481c0544">162</ix:nonFraction></ix:nonFraction>&#160;shares authorized as of December 31, 2021 and 2020; <ix:nonFraction unitRef="shares" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTc0NQ_09eda4b2-eafa-4886-aaaa-fa0d2d3b3e49"><ix:nonFraction unitRef="shares" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTc0NQ_79b8c678-747d-4e76-89f2-303c6ba1a0c4"><ix:nonFraction unitRef="shares" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTc0NQ_ac3f1442-67df-4f2e-8c03-de2c994ac899"><ix:nonFraction unitRef="shares" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTc0NQ_e3ae2225-7823-4e4d-9dee-b71a2fadd1d6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at December 31, 2021 and 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTEtMS0xLTc2MDQ2_34ff790a-87f2-446d-afe8-2fd9dfe24448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTMtMS0xLTc2MDQ2_fe265bbc-16b8-44d5-87a0-8e527d0c8c2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTczMQ_aa17d503-2754-4420-941c-3c7070c2a8dd"><ix:nonFraction unitRef="usdPerShare" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTczMQ_e97e41d0-c704-4f2d-81e3-11d3655ba3cb">0.0001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTczNg_1b3db7ef-14c8-4940-9425-e749ecb23401"><ix:nonFraction unitRef="shares" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTczNg_53d201e7-3fdc-4c8d-b8ab-d9fe8c4cd84a">1,600</ix:nonFraction></ix:nonFraction> shares authorized as of December 31, 2021 and 2020; <ix:nonFraction unitRef="shares" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTc3Nw_0c965cb3-7450-44fe-9c73-1c866dad0ffc"><ix:nonFraction unitRef="shares" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTc3Nw_efbc16cf-bfc3-4cda-aef6-d4af2bf0a08b">403</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTc4NQ_07f3948a-ca2b-4d34-9d32-eeefbaea2bcf"><ix:nonFraction unitRef="shares" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTc4NQ_f6dafa7c-553b-4387-9b2f-e7c8b613d8a0">399</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTEtMS0xLTc2MDQ2_94042ce0-f884-42e0-8c4d-d4d4cc2ffa5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTMtMS0xLTc2MDQ2_45182cf0-d726-4231-b65d-511ad14ed27d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMzLTEtMS0xLTc2MDQ2_f1c92bbb-68e4-4be2-803a-4ea1d3f33d4f">4,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMzLTMtMS0xLTc2MDQ2_a9329ccc-ee71-46ef-8bb7-319b05030961">4,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM0LTEtMS0xLTc2MDQ2_20a7069f-06bf-4584-8145-22e250797ddc">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM0LTMtMS0xLTc2MDQ2_5092e532-2dbf-4b11-8daf-21f48ac844f8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM1LTEtMS0xLTc2MDQ2_8e25463c-22ab-4e60-9f6e-674daca50944">9,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM1LTMtMS0xLTc2MDQ2_8ea8c516-3f91-42cb-944b-2fff64eac235">2,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM2LTEtMS0xLTc2MDQ2_da02f098-00b9-4866-905e-13d6df510ee3">14,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM2LTMtMS0xLTc2MDQ2_dd070541-457b-473c-882a-3bf43e1696be">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM3LTEtMS0xLTc2MDQ2_815c9ac7-7e6e-4c0d-8080-19675817a2aa">24,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM3LTMtMS0xLTc2MDQ2_76567ea3-8bca-4379-b51b-cd22df3045d1">7,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_109"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0613309ccd7f4770b391e463a962e99b_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzMtMS0xLTEtNzYwNDY_3ce794ca-9b85-4e88-8abb-1205375f70eb">17,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd2fff3411a4c769c4f81842918e9c3_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzMtMy0xLTEtNzYwNDY_1a8f1bcc-6a22-4fd9-ba23-9295c588fb81">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdba65dc5ee84630ac91c06737b61940_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzMtNS0xLTEtNzYwNDY_8edc3849-b06c-4701-824b-3058804843cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1806b5a0029947c1aabb49f5e058cb28_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzQtMS0xLTEtNzYwNDY_376e9161-39d8-4571-8ce5-bba8039c8371">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1eabe79fc2e4e4a9fdc7c2be2e9f0e7_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzQtMy0xLTEtNzYwNDY_d50c0619-af1f-4214-894e-c8247839ab04">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5db090169624207a4311b8780bb82f3_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzQtNS0xLTEtNzYwNDY_097b94d6-ebfa-4be1-8aa8-0ac7c7348331">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e182cbaac1c44c8aaf481c02d369892_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzUtMS0xLTEtNzYwNDY_5b18a0cd-6551-4400-8d76-784ea746d71f">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2fa812bb582446faced9f5539691f0a_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzUtMy0xLTEtNzYwNDY_20ba0c2d-af98-4d21-86ac-69b8d061b71d">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice96c3b711e145be81cba0afd205ad43_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzUtNS0xLTEtNzYwNDY_2ba29ab9-759a-4ed5-b385-aaa4a3c6543e">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:47.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzYtMS0xLTEtNzYwNDY_f0360d09-397b-4742-aef0-a8996d38ddc8">18,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzYtMy0xLTEtNzYwNDY_659325fc-d403-46ab-bf8c-3369f138c927">803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzYtNS0xLTEtNzYwNDY_2f99dba6-6bc9-42e7-a4bc-11250ff7d7bc">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzgtMS0xLTEtNzYwNDY_0f8b90c6-ae26-414e-b945-ae9ee7514aa0">2,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzgtMy0xLTEtNzYwNDY_7051e068-6521-484a-a775-0a0d311929a9">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzgtNS0xLTEtNzYwNDY_80761c15-c884-4aa9-8cab-912851dfd981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzktMS0xLTEtNzYwNDY_96fad5c9-becc-4fe5-83b6-ed4838e6c54b">1,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzktMy0xLTEtNzYwNDY_9f36390e-1ce3-48fe-abae-1f280257d071">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzktNS0xLTEtNzYwNDY_7d518e11-724b-4de2-882f-0cb8bc62cbf3">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEwLTEtMS0xLTc2MDQ2_eb26c2ff-78ff-43b1-872b-5e3a37b2f007">567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEwLTMtMS0xLTc2MDQ2_7ef5096b-280a-4b8e-b0f6-d8672596d712">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEwLTUtMS0xLTc2MDQ2_dff64cb5-f60d-4d3f-82c7-6d7931d56eb6">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:47.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzExLTEtMS0xLTc2MDQ2_0d02b5ca-47de-4f86-9f75-e72ff222a81b">5,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzExLTMtMS0xLTc2MDQ2_f1517b01-89ff-487f-9c08-88d5fcc146eb">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzExLTUtMS0xLTc2MDQ2_fd47b445-1967-44a8-b229-5ed4992f4623">606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEyLTEtMS0xLTc2MDQ2_6a433760-9c2d-4bfa-848d-18b47cd1b8b6">13,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEyLTMtMS0xLTc2MDQ2_07fdaea9-41d4-40e6-8369-45d2c36e0841">763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEyLTUtMS0xLTc2MDQ2_f51850ff-4624-4d16-908e-5376df6a6c95">546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEzLTEtMS0xLTc2MDQ2_518d4f93-8e4b-4ce4-bcc5-6ddbe32abc3a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEzLTMtMS0xLTc2MDQ2_4e69f000-f773-4d85-ae0a-6d4fc80c9e29">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEzLTUtMS0xLTc2MDQ2_669f8c34-6e8d-4f8e-b749-820d988f0a5d">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE0LTEtMS0xLTc2MDQ2_04f959e1-21b4-4d4c-8718-1a1a40b74e2f">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE0LTMtMS0xLTc2MDQ2_a26c9924-b295-4099-8128-51017067b28e">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE0LTUtMS0xLTc2MDQ2_458cd4ad-db66-44dd-844d-118876860113">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE1LTEtMS0xLTc2MDQ2_80a25e88-0cd2-4783-aaf6-57db2f6054e7">13,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE1LTMtMS0xLTc2MDQ2_51fa9747-46bb-457e-b45d-f4f5d6b91217">744</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE1LTUtMS0xLTc2MDQ2_21509e15-36cf-4454-b508-1acf5886ea83">515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE2LTEtMS0xLTc2MDQ2_1840730b-9348-40de-a750-276f29546dcc">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE2LTMtMS0xLTc2MDQ2_137b9642-dbf3-416b-9756-f5ac0dec362b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE2LTUtMS0xLTc2MDQ2_8fee44fd-b546-4fd6-8115-e70c131fc979">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE3LTEtMS0xLTc2MDQ2_4994cb43-77dd-4145-887e-e90183a6132d">12,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE3LTMtMS0xLTc2MDQ2_0ad2cf3a-ea57-4b1f-9d7c-dd60688b38db">747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE3LTUtMS0xLTc2MDQ2_b9030251-39d2-4079-bdc3-1c3aec44496b">514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIwLTEtMS0xLTc5NjE1_8d83c79c-53a4-4c0f-8934-e73db8453962">30.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIwLTMtMS0xLTc5NjE1_da048eee-3ec3-49a4-bbf5-d6a0c4baad8c">1.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIwLTUtMS0xLTc5NjIy_b3874f34-7a69-439a-ba5f-389d0962444c">1.55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIxLTEtMS0xLTc5NjE1_dce71a61-e376-4be3-8086-23427b3527f1">28.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIxLTMtMS0xLTc5NjE1_c85d7b29-02f2-419f-ac87-173f5a003516">1.96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIxLTUtMS0xLTc5NjIy_d7ad475e-c61b-43af-9cfd-482ac2082a65">1.55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of earnings (loss) per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI0LTEtMS0xLTc5NjE1_af1dcc53-0768-498d-b721-f2fc8d27e181">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI0LTMtMS0xLTc5NjE1_ee2aef7c-a929-42e0-b4d1-6eb31ff11479">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI0LTUtMS0xLTc5NjM4_d1a07224-e520-4d7d-a408-61e0ebfd95e8">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI1LTEtMS0xLTc5NjE1_3cc90e5e-e81e-47f8-a2af-15f39b333667">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI1LTMtMS0xLTc5NjE1_6f906e91-8e0c-45c7-84e6-b37ee21cbde6">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI1LTUtMS0xLTc5NjM4_75515733-f198-4157-906e-2eafcf489864">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_112"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.027%"><tr><td style="width:1.0%"></td><td style="width:61.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzItMS0xLTEtNzYwNDY_f0c7f50d-9467-4781-8529-e0a3318c31bb">12,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzItMy0xLTEtNzYwNDY_94ad9a47-eb4f-4ace-b04e-4e3ac0a523b5">747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzItNS0xLTEtNzYwNDY_95e09a05-9563-4766-a5ca-0b2fc3453bd7">514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sales securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (losses) gains on available-for-sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtMS0xLTEtNzY4MTQ_e785994f-f72b-48a1-9deb-0720d8300292">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtMy0xLTEtNzY4MTQ_1fb7a303-66f4-4ca5-b3e4-7320f2fc6074">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtNS0xLTEtNzY4NTQ_e390fc08-8b81-454f-8faf-980b12d5d9f3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net realized (gains) on available-for-sale securities reclassified to net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtMS0xLTEtNzY4MTQ_b6b0fe4a-1826-4094-83ca-451508ad62ae">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtMy0xLTEtNzY4MTQ_e158088a-9066-45c9-b2fb-e7705920662c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtNS0xLTEtNzY4NTQ_f8615b67-dcbf-4e43-b91e-da6fed847bfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase from available-for-sale debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctMS0xLTEtNzY4MTQ_68436199-12e6-476a-988c-8461b3736d39">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctMy0xLTEtNzY4MTQ_03e1a7ff-b69c-4533-a81d-ac24e6697050">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctNS0xLTEtNzY4NTQ_ca80fb98-d44d-45cf-a196-01b2b8762990">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on derivative instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzktMS0xLTEtNzY4MTQ_50619b46-429c-4891-9255-49953c3a6fe2">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzktMy0xLTEtNzY4MTQ_98db51c2-593a-43c8-8e3a-3b4205bb6f0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzktNS0xLTEtNzY4NTQ_1501b6e0-44a6-4428-b342-7734cfeb7baa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net realized (gains) on derivative instruments reclassified to net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzQtMS0xLTEtNzYwNDY_59112009-617d-41f7-9493-510172e460e6">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzQtMy0xLTEtNzYwNDY_02a660fc-4de5-4991-bfea-e4a7bb659f66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzQtNS0xLTEtNzYwNDY_66078327-356a-44a4-a129-fd310f1e089c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase from derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtMS0xLTEtNzYwNDY_7309cf03-7bc6-4e4d-800e-7b4b33534fb4">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtMy0xLTEtNzYwNDY_3b152803-0697-423b-ace3-2877b1a177a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtNS0xLTEtNzYwNDY_ddfdac6f-7f32-430e-af42-9055a738845c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtMS0xLTEtNzYwNDY_c3dd79f2-7d16-466a-9b5c-2e813af77e42">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtMy0xLTEtNzYwNDY_11f017f0-57a2-4011-b6cb-7c54537e5495">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtNS0xLTEtNzYwNDY_0d93801e-710a-4c3b-8a5f-25cfae35a161">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctMS0xLTEtNzYwNDY_ed6a46aa-e806-4483-abe9-b5e5e92a37c3">12,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctMy0xLTEtNzYwNDY_7b699449-31dd-4306-ab82-4c5915100fa4">746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctNS0xLTEtNzYwNDY_f840917c-c45f-44ad-8fa9-71dea9169376">511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_115"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.095%"></td><td style="width:0.1%"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>&#160;(Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87fe7c36a950471bb3212e6877b0baf9_I20181231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItNy0xLTEtNzYwNDY_2db70a33-2050-4f3f-93e3-74c2f510f483">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87fe7c36a950471bb3212e6877b0baf9_I20181231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItOS0xLTEtNzYwNDY_4cbb9ebf-6d0d-4f7c-b2af-5a077c511d1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8485f63a4c2345fea4cdae33f5552050_I20181231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItMTEtMS0xLTc2MDQ2_3232b890-8f18-46fc-a0dd-9915d5ccdd61">2,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6916c32254f544d89e2f4ba8db2520a6_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItMTMtMS0xLTc2MDQ2_b854c33b-8066-4aa8-bba1-1e0460fba7b7">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4183a6aba7e43f68918a5fb12e3d83f_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItMTUtMS0xLTc2MDQ2_012cbb4e-0dbd-4732-af5c-6da3e97557f7">1,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f00be47b1194ea3be883db45fca7c1c_I20181231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItMTctMS0xLTc2MDQ2_a763ee91-c4d9-405a-8b62-238b0d80b675">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vesting of restricted common stock and restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i291937679b0b473abab40f676c567dbd_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzMtNy0xLTEtNzYwNDY_7ffa6d98-9806-4db4-99f5-f12c9d71227c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i291937679b0b473abab40f676c567dbd_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzgtNy0xLTEtNzYwNDY_05bea3ec-3e9e-47a6-8a03-17e0996721c1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea71826e0b2c464293613200c787a5f4_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzgtMTEtMS0xLTc2MDQ2_c21ca3fc-7d5c-4098-88fd-d3518270c03d">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzgtMTctMS0xLTc2MDQ2_ff3e4af6-68fb-46e8-93dc-a1f144807a2b">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of common stock under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea71826e0b2c464293613200c787a5f4_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEwLTExLTEtMS03Njk5MQ_7a2c6490-950c-4cbf-b963-1cc3dd2359cc">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEwLTE3LTEtMS03Njk5MQ_4e41bfae-9109-4b1e-943e-bdb61fded4b1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transition adjustment from adoption of ASC 606</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d890a8a1c24221b1111740ec40546f_I20181231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEzLTE1LTEtMS03Njk5OA_93e37e13-8b05-4cfb-8c9f-a419464383b6">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237e52dede034cd091787b93f9589ae5_I20181231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEzLTE3LTEtMS03Njk5OA_4708f77c-efd9-4503-b7bf-7b4c96644738">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transition adjustment from adoption of ASC 842</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfa777b5307245f09b6cb5f6a8fb3e1d_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTE1LTEtMS03Njk5OA_7126e4aa-ace4-4a85-b653-3aefa48b6458">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98fce2df066140b8974dbf5aa3059a90_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTE3LTEtMS03Njk5OA_642bb561-48be-40b9-bef7-5136d0b70a59">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea71826e0b2c464293613200c787a5f4_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzExLTExLTEtMS03NjA0Ng_3edf83fe-eb05-482d-a2b5-30e7490a2ac4">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzExLTE3LTEtMS03NjA0Ng_1d467392-7ad1-4489-b286-2694bb3ba400">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5f8052aaadc419c8d711ef7686bd436_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEyLTEzLTEtMS03NjA0Ng_21e948fc-9e67-4060-a029-25869d020b62">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEyLTE3LTEtMS03NjA0Ng_e22629c2-235d-4e84-b649-98818538a7f3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0bee1a0804143529b5cc7f5e167104e_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEzLTE1LTEtMS03NjA0Ng_ddc84e16-5adb-40cc-833b-c16e319ee555">514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEzLTE3LTEtMS03NjA0Ng_258d7eb4-1b93-4726-935c-316a2cd0bd72">514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ffaed07b9974d019abd45bea1588ec0_I20191231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTctMS0xLTc2MDQ2_56c48af8-b150-4194-8c40-fe9e3390053d">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ffaed07b9974d019abd45bea1588ec0_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTktMS0xLTc2MDQ2_3afa3f98-e6e2-45f4-bae4-4dd70733f2c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552c6e3acac14be0baea5ae64fe4cc51_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTExLTEtMS03NjA0Ng_c89ee137-5e59-4b46-9306-d7ecbad48250">2,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6b33ad00e44689ad7ca663971c003f_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTEzLTEtMS03NjA0Ng_3030d723-b8cf-4d9d-9a57-afc062be48c5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifefe594e140042af8fa2b3baed41f390_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTE1LTEtMS03NjA0Ng_5b50e349-61fd-49e6-b8ba-96ea753bf129">1,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTE3LTEtMS03NjA0Ng_3dc52a94-ac4c-4f3a-a446-7ae7a431ab5c">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.095%"></td><td style="width:0.1%"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Income </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ffaed07b9974d019abd45bea1588ec0_I20191231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItNy0xLTEtNzYwNDY_9a14edd2-3087-40f8-a0ea-7d7528558e63">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ffaed07b9974d019abd45bea1588ec0_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItOS0xLTEtNzYwNDY_54f354de-a696-4489-843a-a6ba855d4066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552c6e3acac14be0baea5ae64fe4cc51_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItMTEtMS0xLTc2MDQ2_0b92b95a-0e0a-4c46-84e5-69129b0de702">2,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6b33ad00e44689ad7ca663971c003f_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItMTMtMS0xLTc2MDQ2_bd1cece8-15e6-4eca-8e33-bb19c8c14b56">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifefe594e140042af8fa2b3baed41f390_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItMTUtMS0xLTc2MDQ2_f432686a-5987-4d52-83e1-d42603e7ba19">1,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItMTctMS0xLTc2MDQ2_97b36bd1-0e41-4301-8fc9-e0178fc9b7b9">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzMtMC0xLTEtNzcxMTMvdGV4dHJlZ2lvbjo5NzFmNDU4NGU5Nzg0ZGQzYmIyMzliODg2MjA5NmU4Y18yMTk5MDIzMjU1NjMy_2378790c-9924-473d-8e9f-e9a3433f3ca0">2</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2468b82d059745f5b51fb3d31a544305_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzMtNy0xLTEtNzcwODI_805a4383-22d5-45d9-8aa5-75c41614bd70">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if106b707e879407f837eee91cc731c8b_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzMtMTEtMS0xLTc3MDgy_75ff1451-21dd-4050-963d-204b844b2d13">1,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzMtMTctMS0xLTc3MDgy_16046451-5a70-40f4-8c6e-cbe2264aac6b">1,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2468b82d059745f5b51fb3d31a544305_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzQtNy0xLTEtNzYwNDY_ca84fff2-57a3-4104-a2a4-4155aa9655e0">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if106b707e879407f837eee91cc731c8b_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzQtMTEtMS0xLTc2MDQ2_349e7438-c4eb-4b6b-adfa-ff3d74160bf0">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzQtMTctMS0xLTc2MDQ2_af62eb2c-d1d2-4bb9-89d0-f3b0f09e90c5">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of common stock under employee stock purchase plan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if106b707e879407f837eee91cc731c8b_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzUtMTEtMS0xLTc2MDQ2_3d01d2c9-3cf1-4e3f-81e5-42a35925f41b">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzUtMTctMS0xLTc2MDQ2_e8f51671-1ca4-47d6-a1b7-0fbbed39d64b">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if106b707e879407f837eee91cc731c8b_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzgtMTEtMS0xLTc2MDQ2_31431d9f-0239-4963-aaea-70124c317ca9">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzgtMTctMS0xLTc2MDQ2_4fa09f49-d22c-4129-a349-59a02c46ac3e">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedc85414f004154b55307b19cb69ea1_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzktMTMtMS0xLTc2MDQ2_8cde6772-dbbb-4aa1-b285-c7b6c99848b5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzktMTctMS0xLTc2MDQ2_bc6a7274-6c60-489d-a22e-61919a52e951">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64213a08436349b8bd211c3b69b414ad_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzEwLTE1LTEtMS03NjA0Ng_cf8b4bd6-3047-40b6-830f-3df9e0860c2f">747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzEwLTE3LTEtMS03NjA0Ng_8f752d39-aee9-4de3-a0f7-34a24587a138">747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0408d062671a45018b3df546433745af_I20201231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTctMS0xLTc2MDQ2_39b870de-ad86-4e76-9586-fca75ffe0e79">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0408d062671a45018b3df546433745af_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTktMS0xLTc2MDQ2_78ab966f-bf25-42e2-9108-6710324d3a4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c70cb037668465995ce9826bb1978ee_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTExLTEtMS03NjA0Ng_ef9a13a9-0e38-4100-832c-0ee52d59eec5">4,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98451536c6d841db91683a82eeb89b2e_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTEzLTEtMS03NjA0Ng_05748f04-198b-4832-a57a-36026effccf6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcf6e685c17f4ba283b01bf8845d7cb9_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTE1LTEtMS03NjA0Ng_fd76387a-e625-43e5-8656-fdb9126ab8e0">2,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTE3LTEtMS03NjA0Ng_ce73610e-0769-4aa2-9a90-71dd9fdac250">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.886%"></td><td style="width:0.1%"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Retained Earnings (Accumulated<br/>Deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0408d062671a45018b3df546433745af_I20201231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItNy0xLTEtNzYwNDY_af8a67f3-55b9-460c-b95b-cc621dce9405">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0408d062671a45018b3df546433745af_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItOS0xLTEtNzYwNDY_9854e708-866d-41e9-8af9-5d0b188719f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c70cb037668465995ce9826bb1978ee_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItMTEtMS0xLTc2MDQ2_7a189df7-f432-4f20-b0ef-0dc850a3f720">4,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98451536c6d841db91683a82eeb89b2e_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItMTMtMS0xLTc2MDQ2_cd9ae8c9-fb99-4441-a560-61a4b7025e76">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcf6e685c17f4ba283b01bf8845d7cb9_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItMTUtMS0xLTc2MDQ2_c8a3d690-8d73-4be8-9e35-8c589f52bf40">2,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItMTctMS0xLTc2MDQ2_7e5d9f52-aefc-47c5-9c3c-909a5ae46a08">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i370d0735ddb64285bf22708bccdfe17a_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzUtNy0xLTEtNzYwNDY_1ccd19fe-e5b3-41de-88f2-57e03f8f1cb1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d72e1d1f6454024a0fc769ec600c4bf_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzUtMTEtMS0xLTc2MDQ2_63b72a4b-2e71-4782-84f3-038124fee3f9">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzUtMTctMS0xLTc2MDQ2_01096fcb-f613-40db-ad23-bcbe209c6983">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchase of common stock under employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d72e1d1f6454024a0fc769ec600c4bf_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzYtMTEtMS0xLTc2MDQ2_3365d743-44d6-42a5-b3fd-b9ac79be8e6c">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzYtMTctMS0xLTc2MDQ2_473760c4-cea3-441d-9983-f71e504be4e5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d72e1d1f6454024a0fc769ec600c4bf_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzctMTEtMS0xLTc2MDQ2_a5ca91be-87c9-41f8-a458-5470e589feca">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzctMTctMS0xLTc2MDQ2_ebdd90ec-2b46-4084-a1d9-dd3a7389c12a">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb0e392c689f48b180f2315c3d508b62_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzgtMTMtMS0xLTc2MDQ2_6d4f7113-675a-4022-8889-2ccad467ff48">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzgtMTctMS0xLTc2MDQ2_1f6a0996-6dd2-4d84-a137-c6a7ffcd1a20">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Repurchase of common stock </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i370d0735ddb64285bf22708bccdfe17a_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTctMS0xLTEwNDA2MA_42ab97a5-59ce-4c8e-bc1a-8f4c8bfef4a1">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d72e1d1f6454024a0fc769ec600c4bf_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTExLTEtMS0xMDQwNjA_38caa161-1308-4c76-80e5-f7a7fa6dbf9e">857</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTE3LTEtMS0xMDQwNjA_dc9aea59-d2fb-4614-be7a-515bc873d7db">857</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67c37cfaa8142fcac96ee487bf8fa91_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzktMTUtMS0xLTc2MDQ2_1258adfd-ef7d-4ee5-b3df-c381900b6961">12,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzktMTctMS0xLTc2MDQ2_aa0de545-95f1-4ce4-b767-4e57e827deae">12,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-2.25pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e92a0d0e8fd40c489ab3417b2dc0a47_I20211231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTctMS0xLTc2MDQ2_d6089cb3-afaa-4892-8485-00f01d5b3f60">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e92a0d0e8fd40c489ab3417b2dc0a47_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTktMS0xLTc2MDQ2_0f021f3a-3663-43a2-929e-7a983420d120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ff2eb538054269a37b8f1364796f48_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTExLTEtMS03NjA0Ng_ca141dd1-2d9d-491c-b414-4bf8bc4bbd27">4,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1036f115c63f4c049064c7ba1929828a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTEzLTEtMS03NjA0Ng_7ba73044-2926-4ad8-8e7f-78750fdf9c65">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f7e4e88f50c4deb96b15cbfbbd78d6d_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTE1LTEtMS03NjA0Ng_9d4bb092-69d8-41ca-ba6c-c7623d579f26">9,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTE3LTEtMS03NjA0Ng_105cdf94-ec4e-416a-9550-14981b9f86df">14,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMtMS0xLTEtNzYwNDY_4edbeb71-6905-4681-baf2-8a0024efa98f">12,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMtMy0xLTEtNzYwNDY_8d38f6c1-7285-4cc4-9eba-54c574b4107c">747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMtNS0xLTEtNzYwNDY_d7ba1e24-c6e1-4335-a9b6-7121eae81b50">514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzUtMS0xLTEtNzYwNDY_ffd86527-cf26-4b3d-8764-abd377871505">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzUtMy0xLTEtNzYwNDY_e0e14849-fd37-443d-84b0-13fe298b02ae">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzUtNS0xLTEtNzYwNDY_0e3d019b-2f4e-4292-b80b-cc076b07d5dd">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzYtMS0xLTEtNzYwNDY_221843dd-3527-4848-9f50-b07ce165f338">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzYtMy0xLTEtNzYwNDY_8111b2b2-d5e8-4306-8ba3-ddbdebd89fe4">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzYtNS0xLTEtNzYwNDY_e65ece00-15ca-47e5-a853-4234cdd93369">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased assets expensed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzctMS0xLTEtNzYwNDY_48e43685-1d7a-46f9-b4b3-7ff433d44754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzctMy0xLTEtNzYwNDY_a1b725d6-011e-4a86-8ffd-5c225b3f8365">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzctNS0xLTEtNzYwNDY_50fa7f66-9349-48fd-b81e-6e7e9ab12be4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization/accretion of investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzgtMS0xLTEtNzYwNDY_eb0cec40-bb1d-469f-ae82-aa9a28a1247e">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzgtMy0xLTEtNzYwNDY_cb636050-0366-4734-a365-c2a64f3b957f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzgtNS0xLTEtNzYwNDY_070cbac2-5786-4a11-9ca1-14e72f281450">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="mrna:DeferredIncomeTaxExpenseBenefitNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEwLTEtMS0xLTc3NDY2_f834f6d4-983e-4085-b376-9ecec1b9b27c">318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="mrna:DeferredIncomeTaxExpenseBenefitNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEwLTMtMS0xLTc3NDY2_a71c67f7-32ec-492d-973e-ecdf0d3e4559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="mrna:DeferredIncomeTaxExpenseBenefitNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEwLTUtMS0xLTc3NDY5_2150e4bc-cf50-4c43-b224-be13acb19e1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzExLTEtMS0xLTc2MDQ2_4de028ac-2f85-4505-b6c6-e5eac76dce28">1,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzExLTMtMS0xLTc2MDQ2_807a9385-e0bf-4c6a-95a9-1bfa0bfcdd0d">1,385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzExLTUtMS0xLTc2MDQ2_091bc41a-737e-4b0a-98f3-2ac43fc23b8a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEzLTEtMS0xLTg2Nzk5_f115ac16-29ca-4071-994f-ad60761ae7dc">489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEzLTMtMS0xLTg2Nzk5_a8adc8c7-bd03-4443-9db7-e757f4b9308f">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEzLTUtMS0xLTg2Nzk5_6c1089f2-21fd-4533-868a-ea3d8c1cc9d6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-27pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEyLTEtMS0xLTc2MDQ2_f228c700-c3a8-40b8-90a9-23ea7c04418f">1,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEyLTMtMS0xLTc2MDQ2_721a7fc4-b5b7-453f-b9b0-ca404ba74486">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEyLTUtMS0xLTc2MDQ2_1ca38784-ece9-4386-ba3c-9f5d97307656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right-of-use assets, operating leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="mrna:IncreaseDecreaseInOperatingLeasesRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE0LTEtMS0xLTc2MDQ2_38575a54-83f8-438e-a02a-66151c9d35fc">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="mrna:IncreaseDecreaseInOperatingLeasesRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE0LTMtMS0xLTc2MDQ2_22916be9-0a98-49fa-8e14-3ccb476cf723">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="mrna:IncreaseDecreaseInOperatingLeasesRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE0LTUtMS0xLTc2MDQ2_615d4ee0-bc4f-4fef-aae3-e2c73a8a42d3">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE1LTEtMS0xLTc2MDQ2_0c743bb7-3d5f-4997-8140-26247b0facdb">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE1LTMtMS0xLTc2MDQ2_b5f8b8b8-14bd-4beb-8661-af9ad906066b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE1LTUtMS0xLTc2MDQ2_b477db45-4e65-4e78-b821-bc61bdc50d9f">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE2LTEtMS0xLTc2MDQ2_e23eb83b-eba0-4816-acfc-68481c0e3ae4">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE2LTMtMS0xLTc2MDQ2_77b5fcf0-8f87-45d5-ad09-cc00409c8fb0">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE2LTUtMS0xLTc2MDQ2_af69d948-9c9b-439d-b268-d208e06662dc">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE3LTEtMS0xLTc2MDQ2_0253df2a-3a7d-461f-8b60-23c43362d421">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE3LTMtMS0xLTc2MDQ2_3f599192-3b0a-4b60-9ee0-227d496bc305">3,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE3LTUtMS0xLTc2MDQ2_371f30ce-023a-4ef7-bc29-b208c2b321b4">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTEtMS0xLTc3NTMx_d5970cc1-94a3-4bd6-ac0f-2e27028b851d">876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTMtMS0xLTc3NTMx_a90b68f3-4daa-4add-bf2a-7efc32ded8be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTUtMS0xLTc3NTU1_26b918f6-1320-4538-b375-0a8800c2ca35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTEtMS0xLTc2MDQ2_eac44879-3b5e-4fe4-a174-191b3602a6f3">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTMtMS0xLTc2MDQ2_071977e6-48e3-4e61-9ffa-49f7e75540ae">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTUtMS0xLTc2MDQ2_90d65cbe-ff2a-4473-8721-f378b46b100c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIwLTEtMS0xLTc2MDQ2_ee1edca5-7986-4bee-9c88-96efac5fb652">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIwLTMtMS0xLTc2MDQ2_17bffe36-5f42-412b-9ee5-9fc94410d92e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIwLTUtMS0xLTc2MDQ2_430a23e2-483e-4ec7-aced-25071f327d6d">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIxLTEtMS0xLTc2MDQ2_8b0bff5a-5495-47bc-a103-9d5f3cbbb4cf">13,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIxLTMtMS0xLTc2MDQ2_65b9b312-73c4-4981-8347-52f297f56772">2,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIxLTUtMS0xLTc2MDQ2_4469b32e-7f3d-4e08-a464-46bd6310e9b4">459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIzLTEtMS0xLTc2MDQ2_f02ecfbc-4bcf-4726-815a-493d937404f4">12,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIzLTMtMS0xLTc2MDQ2_bc371ca9-f167-4c25-bff1-5ad4ee9ba9aa">2,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIzLTUtMS0xLTc2MDQ2_72f730d6-dfdc-45eb-ba84-27a3406be13a">1,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI0LTEtMS0xLTc2MDQ2_46ce056f-8f42-45e8-bb87-5ddce961050d">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI0LTMtMS0xLTc2MDQ2_e9550e2f-699c-48f4-b943-08a794d66c60">1,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI0LTUtMS0xLTc2MDQ2_e65fbddd-9ecf-4678-9444-03b20046839a">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI1LTEtMS0xLTc2MDQ2_2cb7bdb4-83fb-4828-a488-c3d241a0b14e">3,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI1LTMtMS0xLTc2MDQ2_704467e2-825b-4d10-994a-827b817ad377">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI1LTUtMS0xLTc2MDQ2_2d14e849-e596-43bc-aeb4-c7d9929765ac">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI2LTEtMS0xLTc2MDQ2_de15242d-2787-46bc-a1e4-34cd6757002c">284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI2LTMtMS0xLTc2MDQ2_5653aa37-a854-4b6f-a962-7812cc9e45b0">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI2LTUtMS0xLTc2MDQ2_1e6c3a54-e8b2-4bab-a17a-c39fb76802ca">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in convertible notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI4LTEtMS0xLTEwNzQ5Mg_881e3aa4-2792-491d-8d4e-e666409d500c">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI4LTMtMS0xLTEwNzQ5Mg_0653f1fc-9571-41fe-b4fc-6d17390970a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI4LTUtMS0xLTEwNzUwMA_142f069a-fd3e-4183-afab-481b9ba5f17e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI3LTEtMS0xLTc2MDQ2_d9c276b7-65fc-43cd-a4e4-e227d466085e">8,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI3LTMtMS0xLTc2MDQ2_2f176ee1-1a21-4dbf-a6fa-926d5b9eb0ea">1,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI3LTUtMS0xLTc2MDQ2_cdae187d-8f8a-45f7-a825-32c49370c150">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from offerings of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMwLTEtMS0xLTc2MDQ2_9c24c570-be59-4334-b125-8c30f96069a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMwLTMtMS0xLTc2MDQ2_02388de0-3a31-443a-896c-8cb35ac49556">1,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMwLTUtMS0xLTc2MDQ2_12969763-b5b1-424e-8060-3ecb88a00982">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock through equity plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMyLTEtMS0xLTc2MDQ2_bf66b8e1-c2a1-492d-96f4-b2871069c25b">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMyLTMtMS0xLTc2MDQ2_0cbb43f4-8f9c-48f6-be08-f94911308287">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMyLTUtMS0xLTc2MDQ2_17e7179c-e44a-430f-a7a4-41264e12cc9a">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM1LTEtMS0xLTk0NTAw_018b0de4-3820-4efa-a694-d0bc23c2a081">857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM1LTMtMS0xLTk0NTAw_7f7f26d2-ff6f-4488-bf99-fc7a05a6df88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM1LTUtMS0xLTk0NTA2_2fcd0907-1e58-42f4-a8fd-36b9d618ab55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="mrna:ChargesToFinancingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM0LTEtMS0xLTc2MDQ2_3d279436-1915-4fa6-aa97-967b776896d5">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="mrna:ChargesToFinancingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM0LTMtMS0xLTc2MDQ2_4816c6dc-7346-4513-ba7e-3d0de53782c6">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="mrna:ChargesToFinancingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM0LTUtMS0xLTc2MDQ2_ad0f10f3-a320-4675-a979-bbaa2b0aeb08">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM3LTEtMS0xLTc2MDQ2_c38a002d-1688-4759-8e56-aebf08493e39">873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM3LTMtMS0xLTc2MDQ2_36e13b2a-b82d-430a-85da-37b97f4b8202">2,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM3LTUtMS0xLTc2MDQ2_75104a5d-b521-405c-a21b-df33d5b34bc3">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM4LTEtMS0xLTc2MDQ2_741b3922-1107-4779-8a8f-c02b972d66fc">4,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM4LTMtMS0xLTc2MDQ2_dd2d7953-3d71-4700-a06f-a109ba3baf22">2,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM4LTUtMS0xLTc2MDQ2_7b9ad937-85da-47c0-a09e-3cf92a889fb8">422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of year</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM5LTEtMS0xLTc2MDQ2_d0325c8e-7040-487c-81b3-928d06fcef68">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM5LTMtMS0xLTc2MDQ2_01aee8ec-1a2c-47db-b1d0-5f2510e96f34">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f00be47b1194ea3be883db45fca7c1c_I20181231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM5LTUtMS0xLTc2MDQ2_b11efd55-f643-4a8a-b485-acc3c0ae3fcf">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of year</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQwLTEtMS0xLTc2MDQ2_5aedec30-e23a-4fa8-ab32-6f3f4223052b">6,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQwLTMtMS0xLTc2MDQ2_cc359186-ae78-4553-8d14-81f937c20adb">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQwLTUtMS0xLTc2MDQ2_8b41d066-6cb4-4a6d-b5fa-5f2b8c6dc320">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental cash flow information</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQyLTEtMS0xLTc2MDQ2_f49ff72b-a7f4-4865-b7c9-9ce1c2165cba">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQyLTMtMS0xLTc2MDQ2_d7f4db79-772c-434a-b430-beb2ae71fa16">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQyLTUtMS0xLTc2MDQ2_97670988-80b7-4292-98a7-87bf215e1e54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQzLTEtMS0xLTc2MDQ2_2ebed6be-4047-4a81-a77d-1f0c0e9a7f54">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQzLTMtMS0xLTc2MDQ2_1b3b5096-94b2-4dbc-8821-41a4d26599b3">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQzLTUtMS0xLTc2MDQ2_10824436-e93e-4212-a795-36fb7df087b7">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQ2LTEtMS0xLTc2MDQ2_667d6efd-4777-4f66-ab10-550fb3767906">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQ2LTMtMS0xLTc2MDQ2_0cfb79fc-74ab-4584-9874-c79a98df9323">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQ2LTUtMS0xLTc2MDQ2_c8ae52fe-d035-4119-a892-8437601efc98">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_121"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MODERNA, INC.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_124"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjQvZnJhZzo0Nzg0YjNjMzk3YzY0MjMxYTEyMDY3NWMxNWViZDFjYS90ZXh0cmVnaW9uOjQ3ODRiM2MzOTdjNjQyMzFhMTIwNjc1YzE1ZWJkMWNhXzM4Njc_086f22b6-5e56-4205-8370-e1faa8814f5f" continuedAt="i739c8f55572746d3bb81bca75f2b0deb" escape="true">Description of Business</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i739c8f55572746d3bb81bca75f2b0deb" continuedAt="id337ac90219b4a0b935f73af7a81ae9e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company pioneering messenger RNA (mRNA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutics and vaccines to create a new generation of transformative medicines to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases, independently and with our strategic collaborators.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="id337ac90219b4a0b935f73af7a81ae9e">On December 18, 2020, we received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the emergency use of the Moderna COVID-19 Vaccine (also referred to as mRNA-1273 and marketed under the brand name Spikevax) in individuals 18 years of age or older. We have also received authorization for our COVID-19 vaccine from health agencies in more than 70 countries and from the World Health Organization (WHO). Additional authorizations are currently under review in other countries. In addition, we have received authorization for our COVID-19 vaccine for use in adolescents in the United Kingdom, European Union, Japan, Canada, Switzerland, Taiwan, Saudi Arabia, Australia, and the Philippines, and have pending applications for authorization to administer the vaccine to adolescents with regulatory agencies in the United States and other countries. In January 2022, we received full FDA approval for Spikevax to prevent COVID-19 in individuals 18 years of age and older in the United States. In February 2022, we received approval for the administration of Spikevax to children ages 6-11 in Australia and a positive recommendation from the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use for the administration of Spikevax in children ages 6-11 years.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_127"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjI2_78b083a3-5507-46ff-bf1c-990cb509bbb1" continuedAt="i0b8534c9fea348478a58fceebabe8f91" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0b8534c9fea348478a58fceebabe8f91" continuedAt="i4c38509276fc46369d1799190757c1ba"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjE2_8f37b5b6-9073-41a9-b8a8-d19d221f6777" continuedAt="id256e62a51ba4f9bb5cc986ce48a9edf" escape="true">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Updates (ASU) of the&#160;Financial Accounting Standards Board (FASB).</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id256e62a51ba4f9bb5cc986ce48a9edf">The consolidated financial statements include the Company and its subsidiaries.</ix:continuation> <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjMy_36ebd1e2-f3bd-47b5-845e-802d758fa49e" escape="true">All intercompany transactions and balances have been eliminated in consolidation.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjEz_a8941340-0722-47dd-872e-dba6a9d0e7a6" escape="true">We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, revenue recognition, research and development expense, leases, fair value of financial instruments, derivative financial instruments, inventory, useful lives of property and equipment, stock-based compensation, income taxes, and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjI4_9ee65c08-a4cc-4231-b477-5fb3462a3aad" escape="true">We have determined that our chief executive officer is the chief operating decision maker (CODM). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, we have concluded that we operate as <ix:nonFraction unitRef="segment" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzIzODU_f731a219-4b94-455a-b4be-b9a0cb386fbe">one</ix:nonFraction> segment.</ix:nonNumeric> </span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i4c38509276fc46369d1799190757c1ba" continuedAt="i070852d1ba834dc196c67315ba530d67"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjE3_54a416d3-e25a-4e9c-8912-5157c2923239" continuedAt="ie684f87c56934ea8be36cad6507b8f1d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted ASC 606&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is primarily generated through product sales. We also generate grant revenue from government-sponsored and private organizations, and collaboration revenue through collaboration arrangements. </span></div><div><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Sales </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are associated with our COVID-19 vaccine supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), and the African Union. These agreements generally do not include variable consideration, such as discounts, rebates or returns. Under these agreements, we are entitled to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. We recognize revenue from product sales, using the five-step model under ASC 606, based on the fixed price per dose according to the contracts when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay distribution fees to certain customers in connection with the sales of our product. We record distribution fees paid to our customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and we can reasonably estimate the fair value of the goods or services received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale. Such distribution fees were immaterial for the year ended December 31, 2021. We did not have any distribution fees for the years ended December 31, 2020 and 2019.</span></div><div style="padding-right:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Grant Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contracts with Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); the U.S. government&#8217;s Defense Advanced Research Projects Agency (DARPA); the Bill &amp; Melinda Gates Foundation (Gates Foundation) and other government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaboration Revenue</span></div></ix:nonNumeric><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie684f87c56934ea8be36cad6507b8f1d">We have entered into several strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer.</ix:continuation> </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjI5_e576ca2e-ef0d-48b6-b25f-b5f5f9189586" escape="true">We consider all highly liquid investments with an original maturity of 90&#160;days or less from the date of purchase to be cash equivalents.</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i070852d1ba834dc196c67315ba530d67" continuedAt="i2f278e2a9d274b4d8e888699e73c4199"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTg3_22971df0-43a9-41df-8896-764f0289767c" escape="true">Restricted cash is composed of amounts held on deposit related to our lease arrangements. The funds are maintained in money market accounts and are recorded at fair value. We classify our restricted cash as either current or non-current based on the terms of the underlying lease arrangement.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash shown in the Consolidated Statements of Cash Flows</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTk4_f89f1b54-d31a-4a1b-9110-8bcde5a2ab49" escape="true"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTk4_faab2400-c73b-4764-9fd9-bcb2f1a2653b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzItMi0xLTEtNzYwNDY_2d40d758-cfa3-4fbc-8a95-5e9988577f37">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzItNC0xLTEtNzYwNDY_e1eb4a02-c92f-4766-a16c-04b1d3078e47">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzItNi0xLTEtMTE0NDI1_94ef800c-34d3-46f9-adbc-74eab258d030">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzMtMi0xLTEtNzYwNDY_054c0b8f-46c9-4330-8e7f-05766374c321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzMtNC0xLTEtNzYwNDY_7241380e-5ad6-4cd9-bbe6-bd2073ed141f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzMtNi0xLTEtMTE0NDI1_18c26ddf-aa4c-4ab9-a071-ada455b0e074">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzQtMi0xLTEtNzYwNDY_304a6b29-0216-40c1-8313-aa22a495541b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzQtNC0xLTEtNzYwNDY_a6e88462-ced1-485c-81cb-043f56126082">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzQtNi0xLTEtMTE0NDI1_922de38d-7d06-4e05-b62a-caddf0d2bc4a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzUtMi0xLTEtNzYwNDY_7e1654de-7cb1-4c47-998b-51c05ba5d09d">6,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzUtNC0xLTEtNzYwNDY_0bd09e85-cb14-49db-a737-8853c93395ae">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzUtNi0xLTEtMTE0NDI1_03af204a-baeb-4945-96dd-8d728fb19f39">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in prepaid expenses and other current assets in the consolidated balance sheets.</span></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjMz_ac2964d0-9fce-4b2d-beab-125569c979d0" continuedAt="i05bfcd34d197429eb00765fef555fb47" escape="true">We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report available-for-sale investments at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive (loss) income, a component of stockholders&#8217; equity. Realized gains and losses are determined using the specific-identification method, and are included in other expense, net in our consolidated statements of operations. We classify our available-for-sale marketable securities as current or non-current based on each instrument&#8217;s underlying effective maturity date and for which we have the intent and ability to hold the investment for a period of greater than 12 months. Marketable securities with maturities of less than 12&#160;months are classified as current and are included in investments in the consolidated balance sheets. Marketable securities with maturities greater than 12&#160;months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i05bfcd34d197429eb00765fef555fb47">We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive (loss) income, net of applicable taxes.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjM3_9691196b-6a85-449b-b715-647182f9f5cb" escape="true">We have accounts receivable amounts due from our product sales and related vaccine supply agreements and our grant agreements. We also have accounts receivable amounts due from strategic collaborators as a result of manufacturing and research and development services provided under collaboration arrangements, or milestones achieved, but not yet paid. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for doubtful accounts, we make judgments about the creditworthiness of our customers based on ongoing credit evaluation and historical experience.</ix:nonNumeric> There was <ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzE2Njk3_22c13ad3-9287-425f-bb31-a7e52370b78b"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzE2Njk3_c30bc62a-2861-407d-be58-0a0462c78394">no</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts at December 31, 2021 or 2020. There was <ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzE2NzU3_18d862e8-f208-46af-ab66-38bb6bc6db71"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzE2NzU3_5b294251-72e6-4c70-b895-e3ee73abdf8f"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="INF" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzE2NzU3_e5b835f1-d610-4821-bd7d-2b7955347b70">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> bad debt expense for the years ended December 31, 2021, 2020 or 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjMw_4dd4cd2f-bf4c-4716-8ccc-0114d633a793" escape="true">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable securities, and accounts receivable. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits.</ix:nonNumeric></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i2f278e2a9d274b4d8e888699e73c4199" continuedAt="i8f1c8aba44184bcb80007239192ceb76"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:MajorCustomersPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTkz_15bb8d2c-285c-4382-8d49-68e36532309d" escape="true">Our accounts receivable are generally unsecured and are from customers in different countries. We generated revenue from product sales to the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), the African Union. grants made by government-sponsored and private organizations, and to a lesser extent, strategic alliances in 2021 and 2020. Historically, we generated revenue primarily from strategic alliances.</ix:nonNumeric> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjM4_1a4c063f-2ee2-4c0b-b803-4ffd8c814a2c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:50.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;Revenue</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended&#160;December&#160;31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;<br/>Accounts&#160;Receivable<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0271cb85b4e64ced8426ff3ab6956a89_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzItMS0xLTEtMTE4MDc1_b480f893-541c-4629-b51f-cc00094524d3">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i190252c1c7b34ddb97008b71eb4c1da9_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzItNy0xLTEtMTE4MDc1_5aeb81a1-b2cb-40d1-97ed-da66916064f6">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32d168477d7e4f278aa0d019fbd3fd1e_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzItOS0xLTEtMTE4MDc1_15df5e9c-01a4-440c-8ab4-af51b4dd1946">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government (excluding BARDA)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib7764e7b08664708b5f88fa9d5a5452d_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzMtMS0xLTEtMTE4MDg1_07236b8f-67a4-43f8-8e98-edd06ac6bdd3">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70772d46e8714f2c92cd4f05b0dae511_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzMtMy0xLTEtMTE4MDg1_e65705af-87c8-46b5-9806-ae20d77d6f8f">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia2d8d4f2bcb249ba98ac3836f5f2f91a_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzQtMy0xLTEtMTE4MTEy_2dd8c819-da4b-43ec-8f97-bbe479ecb264">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9755a9f76aff4d95bd5013ac656d28eb_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzQtNS0xLTEtMTE4MTEy_fc93e46b-80da-4a7c-b839-b644dd887aa0">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8df385fcd90456f89a7177c79f6f8cb_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzQtNy0xLTEtMTE4MTEy_10b88ca8-e7be-4679-a2a2-d78a5ae934ad">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2df5a00c226e425faf323112dc3cd5c6_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzQtOS0xLTEtMTE4MTEy_f3afd01c-08fb-48f1-b351-7be3b34f839f">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b3cd2c6a9d148c18fec7f61ae871222_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzItNS0xLTEtNzYwNDY_80cbcf16-1839-4f21-853f-4a1c341c1385">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i386857641ae64cb5840ff87d45bd2b39_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzQtNS0xLTEtNzYwNDY_c58f5b61-226a-477f-8ece-6380b29292f2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom Government</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a5edb63270a4e4587e56c35991f8f28_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzgtOS0xLTEtODU5NDg_b898bef0-357c-4088-bf47-98da97fb6c5f">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea Government</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e47c41e4cb14080aa2c9a58ea80fb94_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzktOS0xLTEtODU5NDg_f09a26b6-5f77-4d49-90f4-a4059898d50d">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">* - Represents an amount of less than 10%</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTgy_e1830786-6476-4879-9ca7-9198f37ce88c" continuedAt="i0c1ab16e0a70434ca0aecf491e5faf59" escape="true">We record all derivatives on our consolidated balance sheets at fair value. The accounting for changes in the fair value of a derivative depends on whether the derivative has been designated and qualifies for hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. </ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i0c1ab16e0a70434ca0aecf491e5faf59">The gains or losses resulting from changes in the fair value of cash flow hedges are initially recorded as a component of accumulated other comprehensive (loss) income (AOCI) in stockholders&#8217; equity and subsequently reclassified to product sales in the period during which the hedged transaction affects earnings. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to other expense, net, in our consolidated statements of operations. We may enter into derivative contracts that are intended to economically hedge certain risk, even though hedge accounting does not apply or we elect not to apply hedge accounting. Gains or losses associated with foreign currency derivatives that are not designated as hedging instruments for accounting purposes are recorded within other expense, net, in our consolidated statements of operations.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTk1_e83f0993-cfc2-4d6e-824a-6e7378d9aed1" continuedAt="i4e62c366518742c6aa2c4f9e0a20ea99" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC&#160;820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i8f1c8aba44184bcb80007239192ceb76" continuedAt="i414e72fe9c4d4039958562af045d9a0a"><ix:continuation id="i4e62c366518742c6aa2c4f9e0a20ea99"><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash equivalents and marketable securities are reported at fair value determined using Level&#160;1 and Level&#160;2 inputs (Note&#160;6). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk (Note 7). We do not have any non-financial assets or liabilities that should be recognized or disclosed at fair value on a recurring basis at December 31, 2021, 2020, and 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintained letters of credit of $<ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:LinesOfCreditFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzMyOTg1MzQ5ODQ4MDY_1fab72b0-a445-4c7c-8e4c-e2070d3da970"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:LinesOfCreditFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzMyOTg1MzQ5ODQ4MDY_3886e35a-9b96-405a-8e02-0620783d8dc3">12</ix:nonFraction></ix:nonFraction> million as of December 31, 2021 and 2020, related to our lease arrangements, which are secured by money market accounts in accordance with certain of our lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in our consolidated balance sheets.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjE4_1e741f92-6659-4fc6-9efe-92d5cdc3cd99" continuedAt="i7b1cbc7a3e704a8d8d194b11cbd9cf84" escape="true">Inventory is recorded at the lower of cost or net realizable value, with cost determined using first-in, first-out and average cost methods for different components of inventory. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b1cbc7a3e704a8d8d194b11cbd9cf84">Prior to an initial regulatory approval for our investigational medicines, we expense costs relating to raw materials and production of inventory as research and development expense in our consolidated statements of operations, in the period incurred. Upon the authorization of distribution and use of our COVID-19 vaccine under an EUA in December 2020, we began to capitalize inventory costs associated with our COVID-19 vaccine, as it was determined that inventory costs incurred subsequent to the EUA had a probable future economic benefit.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjIy_e62387fa-d0d8-4731-865e-c0ac168a325f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjEx_139df5fc-6bd3-404c-82af-5c2c43b101ce" continuedAt="i1d161277e39c4ae7b363bbb3bdac8d17" escape="true">The estimated useful lives of property and equipment are described below:</ix:nonNumeric></span></div><div><ix:continuation id="i1d161277e39c4ae7b363bbb3bdac8d17" continuedAt="i89826479fdb74e769a847621a01725ed"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:48.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idfc4ca4b110a4b4ca9bc75f54db9aac8_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTpmZTYzMzI0YWRjOGE0OGI4OWNkNTAwZjcyNmNkNDBiNy90YWJsZXJhbmdlOmZlNjMzMjRhZGM4YTQ4Yjg5Y2Q1MDBmNzI2Y2Q0MGI3XzEtMi0xLTEtNzYwNDY_68b5034f-1568-4ae3-a047-ae52879baa94">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement<br/>or&#160;remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d684fd2732b4d3aaa2c0b4c1f42cf46_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTpmZTYzMzI0YWRjOGE0OGI4OWNkNTAwZjcyNmNkNDBiNy90YWJsZXJhbmdlOmZlNjMzMjRhZGM4YTQ4Yjg5Y2Q1MDBmNzI2Y2Q0MGI3XzMtMi0xLTEtNzYwNDY_de19662b-0bb1-425d-90bd-3a7b4d75549c">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6d0432cf13b142938df0d7a6e783162d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTpmZTYzMzI0YWRjOGE0OGI4OWNkNTAwZjcyNmNkNDBiNy90YWJsZXJhbmdlOmZlNjMzMjRhZGM4YTQ4Yjg5Y2Q1MDBmNzI2Y2Q0MGI3XzQtMi0xLTEtNzYwNDY_0702002b-104d-4d94-81f9-185ccf9ca7a3">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d57ca59f3dd4b58a6220848d155086a_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTpmZTYzMzI0YWRjOGE0OGI4OWNkNTAwZjcyNmNkNDBiNy90YWJsZXJhbmdlOmZlNjMzMjRhZGM4YTQ4Yjg5Y2Q1MDBmNzI2Y2Q0MGI3XzUtMi0xLTEtNzYwNDY_48436317-27b2-45b6-95a2-9520e872d0ab">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress includes direct costs related to the construction of various property and equipment, including leasehold improvements, and is stated at original cost. Construction in progress includes costs incurred under construction contracts including project management services, engineering services, design services and development, construction services and other construction-related fees and services. Such costs are not depreciated until the asset is completed and placed into service. Once the asset is placed into service, these capitalized costs will be allocated to certain property and equipment categories and will be depreciated over the estimated useful life of the underlying assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for maintenance and repairs are charged to expense as incurred. Upon retirement or sale, the cost of the assets disposed of, and the related accumulated depreciation, are removed from the accounts, and any resulting gain or loss is recorded to other expense, net in our consolidated statements of operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i414e72fe9c4d4039958562af045d9a0a" continuedAt="i43a41f39a4bd42f89b840ba78170443c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjE1_bd44c2da-ff0d-4ed3-9d5d-66737f11457b" escape="true">We evaluate our long-lived assets, which consist of property and equipment, to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals.</ix:nonNumeric> Impairment expenses for the years ended December 31, 2021, 2020 and 2019 were <ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzkzNDU4NDg5MDg3MTc_553165d2-56bf-427e-9de1-40934517ebe7"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzkzNDU4NDg5MDg3MTc_b2ec7c58-5ccf-4055-b6d6-b6d4cd839976"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzkzNDU4NDg5MDg3MTc_bce8c4e3-f0ea-4441-b57b-ec25e7802ff4">immaterial</ix:nonFraction></ix:nonFraction></ix:nonFraction>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTgw_c5b973ee-c2ce-4bc2-be2d-87ab04eead56" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in profit or loss on a straight-line basis over the lease term.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTk2_76794aa3-a267-4d18-a73b-4bea93a36939" escape="true">Cost of sales includes cost of raw materials, production, transportation, freight and indirect overhead costs associated with our product sales during the period and third-party royalties on net sales of our product. Cost of sales also includes adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjA5_6410c558-2d43-482c-8a74-e7529cd29416" continuedAt="i524b8ea9ec5348aa8755b3ebaae2e88f" escape="true">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. </ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i524b8ea9ec5348aa8755b3ebaae2e88f">Equipment or facilities that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, should be capitalized and depreciated as tangible assets. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project and that have no alternative future uses and therefore no separate economic values are considered research and development costs and are expensed when incurred.</ix:continuation> </span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i43a41f39a4bd42f89b840ba78170443c" continuedAt="i92f2827b16284e69b18bddaa0701c558"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjIw_6f451303-1bee-48d8-a691-63c72d826f3e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Compensation&#8212;Stock Compensation)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.</span></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjEy_7d27d722-d49b-4755-bcf5-44cbde9dc44a" escape="true">We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#8220;more likely than not&#8221; criterion. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTkw_eae93fba-8c5b-4062-b951-183e3e98748e" escape="true">We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted common stock and stock options that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTg5_609227a6-36f3-4ca9-aac5-2f27c1b155c6" escape="true">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjQx_a8a0a2ba-22ec-4978-b621-30485483a241" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive (loss) income for the years ended December 31, 2021 and 2020 were as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized&#160;Gain (Loss) on Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Unrealized Gains on Derivatives Designated As Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3639b96d68064d6db852f369b410789c_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzEtMS0xLTEtNzYwNDY_8039b7f8-d426-451b-bc6b-57ab55ec389d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb718f636d5f48ac8eb2603a3bc1c433_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzEtMy0xLTEtNzgxMjI_0856e11c-a4d9-4757-b1ef-b5e517f8469b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c6b33ad00e44689ad7ca663971c003f_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzEtNS0xLTEtNzgxMjI_f7ef6804-a169-4534-a686-aad12845b907">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i005acc5f3f5d4d808e86e28a3fb8cc6f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzItMS0xLTEtNzYwNDY_edb1a179-d232-4f7b-ae9e-ec784e6e2516">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7f5f39ede7c4ec9b47dbe1215f0665e_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzItMy0xLTEtNzgxMjI_3c6ac5f7-f324-4d10-9ed9-de18ca0514f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedc85414f004154b55307b19cb69ea1_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzItNS0xLTEtNzgxMjI_b1f6adb6-35e6-4866-a6c5-4b31910e83af">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aa7c4e4065b4b87a2e53619bd7fd077_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzMtMS0xLTEtNzYwNDY_d86841db-3d16-48b2-81a6-b469fa81d788">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95dda1d0dbf24991852d96215768bee0_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzMtMy0xLTEtNzgxMjI_7336e04f-305b-4ccc-9760-ed165608d99b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98451536c6d841db91683a82eeb89b2e_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzMtNS0xLTEtNzgxMjI_8bec8d50-72eb-4c81-8b2e-899dab64bd5c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b6bf470232b486d96417def1a8e1533_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzQtMS0xLTEtNzYwNDY_86ce7d2f-0560-4e77-b983-24f67f0f6973">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a99e8b38ce644c6b026bd53416491e6_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzQtMy0xLTEtNzgxMzE_e6086a7b-d1cf-448b-a977-d9d52f2bf22b">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb0e392c689f48b180f2315c3d508b62_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzQtNS0xLTEtNzgxMzE_246ecc5e-0dd1-40ee-9153-246d989ed82f">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i984222694dbe434b9c06eac34351906d_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzUtMS0xLTEtNzYwNDY_ea8d8a74-4d73-4d1d-9f21-b1379310b565">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39641a4b815d4d1d9b3bc66b8889165f_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzUtMy0xLTEtNzgyNTI_006d2ac7-e232-40b7-9add-18d7d3a54d28">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1036f115c63f4c049064c7ba1929828a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzUtNS0xLTEtNzgyNTI_04ed6c03-f54c-4eec-9af4-9cb1fe8d4165">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i92f2827b16284e69b18bddaa0701c558"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjM2_1dda6069-1e91-4f71-8124-cc3c525d0383" escape="true">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_133"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzEwMjY_cb82882c-d2ac-4303-bab8-5fcd7162057f" continuedAt="ib2cdcce86eae472f80962cb74a51319a" escape="true">Product Sales</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib2cdcce86eae472f80962cb74a51319a" continuedAt="i9a5c6f71387747fb81b8fb6db2f7a6e5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily associated with our COVID-19 vaccine supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), and the African Union. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzEwMjc_f783c0a5-0214-4ecd-a3c6-dfbdd4430747" continuedAt="i49e742dcad1048fbb865edd6a941206a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide168116c3df4c06bf76ee1ab5cc8665_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzEtMi0xLTEtNzYwNDY_65a087ca-23f7-4f86-8013-5629889d6db6">5,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eda8070f7034a6fab76518656331315_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzItNC0xLTEtNzgzOTQ_0749038e-a6fb-4fe7-9b8f-2eae0a25e937">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2a73dc0a34434fbf4adfd2bd2d0152_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzMtMi0xLTEtMTA5ODAx_473537eb-bcc3-4e52-b577-28d358d93faf">6,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if853b7ba8fdd405c9c2517b31b9bb54b_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzMtNC0xLTEtMTA5ODAx_0e626c33-d628-4089-ae1c-23f7ebe28944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b48f865221543f19c484fbac76b65da_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzItMi0xLTEtNzYwNDY_16a786e2-2b6a-4017-b5c1-a329323ee927">5,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f1f522be3c649ccac04b63ff9e91b55_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzMtNC0xLTEtNzgzOTQ_9e6fe50c-c175-4714-ac18-cb4a4f8029a1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0613309ccd7f4770b391e463a962e99b_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzMtMi0xLTEtNzYwNDY_ccaf47a1-c02a-41e5-87fe-1e3e7c254312">17,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd2fff3411a4c769c4f81842918e9c3_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzQtNC0xLTEtNzgzOTQ_99702a3a-35a1-478c-ac6e-98ee4ae41fc9">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div></ix:nonNumeric><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="ifdba65dc5ee84630ac91c06737b61940_D20190101-20191231" decimals="INF" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzE5MjQxNDUzNDkwNTM4_e073d7f8-a24c-484b-a83d-a48364d51cb8">no</ix:nonFraction> product sales in 2019. As of December 31, 2021 and 2020, our COVID-19 vaccine was our only commercial product authorized for use. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, we had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i346fef81e10f4f86a929d87bf0cb041b_I20211231" decimals="-8" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzIxOTkwMjMyNTcwMTA_27091d4a-3618-4999-a591-7e9e0e48c39b">6.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="if49f6e27f6284519912ffac03c002a55_I20201231" decimals="-8" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzIxOTkwMjMyNTY5OTc_f0ac975e-477c-4045-a247-b069f05e393e">3.8</ix:nonFraction>&#160;billion, respectively, related to customer deposits. We expect $<ix:nonFraction unitRef="usd" contextRef="i346fef81e10f4f86a929d87bf0cb041b_I20211231" decimals="-8" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzIxOTkwMjMyNTc1NTQ_2a4a546e-227c-4439-89c1-e6798419fefc">6.2</ix:nonFraction>&#160;billion of our deferred revenue related to customer deposits as of December 31, 2021 to be realized in less than one year. Timing of product manufacturing, delivery and receipt of marketing approval will determine the period in which revenue is recognized.</span></div></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_130"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:continuation id="i9a5c6f71387747fb81b8fb6db2f7a6e5" continuedAt="i6da865cd32ae4fd9805e2325a87e4371">Grant Revenue</ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="i6da865cd32ae4fd9805e2325a87e4371" continuedAt="id375aa4605f14ed5b869bc0a5946884b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement with the DARPA for an award of up to $<ix:nonFraction unitRef="usd" contextRef="i185b16a527d64878943a25c180d19f14_D20200901-20200930" decimals="-6" name="mrna:RevenueFromGrantsMaximumAward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzE1Mg_dab77746-efbe-49bb-844a-adc25663a14a">56</ix:nonFraction>&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of December 31, 2021, the committed funding, net of revenue earned was $<ix:nonFraction unitRef="usd" contextRef="i90618f5224194ab98e88f99e1cfb81b1_I20211231" decimals="-6" name="mrna:RevenueFromGrantsCurrentFundingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzM4Mw_f7b250e7-561a-465c-b52d-e8cc75171cf8">2</ix:nonFraction>&#160;million. An additional $<ix:nonFraction unitRef="usd" contextRef="i90618f5224194ab98e88f99e1cfb81b1_I20211231" decimals="-6" name="mrna:RevenueFromGrantsRemainingFundingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzQwNg_34e411a7-4ae2-4570-85c1-a3421cd82882">42</ix:nonFraction>&#160;million of funding will be available if DARPA exercises additional contract options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with BARDA for an award of up to $<ix:nonFraction unitRef="usd" contextRef="ie7a70d15770e4fc5a0c8d58cdebd7aef_D20200401-20200430" decimals="-6" name="mrna:RevenueFromGrantsMaximumAward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzU0NQ_b06ae95c-68ef-4270-9460-ad651ccc672f">483</ix:nonFraction>&#160;million to accelerate development of mRNA-1273, our vaccine candidate against COVID-19. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $<ix:nonFraction unitRef="usd" contextRef="ieb5f923d3e90448fbd2a1d5a8d4e3398_I20200731" decimals="-6" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzcyNw_40d34e9c-8659-4a66-8d20-b1a92eab031e">472</ix:nonFraction>&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a <ix:nonFraction unitRef="participant" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="INF" name="mrna:NumberOfParticipants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzE5NzkxMjA5MzAzODIy_fc2f7fe7-38fb-4b4d-a9a3-789983ff8e80">30,000</ix:nonFraction> participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $<ix:nonFraction unitRef="usd" contextRef="i0f13771d8cb942efb65d2bfc498700a6_I20210331" decimals="-6" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzIxOTkwMjMyNTg2MzI_de9d2a55-d7ce-4512-bb18-d0c62438c305">63</ix:nonFraction>&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. In April 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $<ix:nonFraction unitRef="usd" contextRef="i47c1a858a9f9495fbac7df0e36419070_D20210401-20210430" decimals="-6" name="mrna:RevenueFromGrantsPotentialReimbursement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzIxOTkwMjMyNTg2NDU_683f3612-0afd-48f0-9364-bc9261aa2022">236</ix:nonFraction>&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. In June 2021, the agreement with BARDA was further amended to award additional funding of $<ix:nonFraction unitRef="usd" contextRef="i88f0f64452bc4d5da91f20c29eeecbca_I20210630" decimals="-6" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzIxOTkwMjMyNTg2NTk_7aee7af1-2f88-4538-b968-549a70cdd771">144</ix:nonFraction>&#160;million to support pediatric clinical trials for mRNA-1273. The maximum award from BARDA, inclusive of the 2020 and 2021 amendments, was $<ix:nonFraction unitRef="usd" contextRef="idb9732dce6924b498098b6518f64703e_D20210701-20211231" decimals="-8" name="mrna:RevenueFromGrantsMaximumAward" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzkyNQ_10b6984d-fdc6-4f4d-a513-00f41ac211ab">1.4</ix:nonFraction>&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of December 31, 2021, the remaining available funding, net of revenue earned was $<ix:nonFraction unitRef="usd" contextRef="ida3d15a8c031486d90647c53dad031ea_I20211231" decimals="-6" name="mrna:RevenueFromGrantsCurrentFundingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzExMzY_1166ce81-1f04-4fcf-867a-58c076530444">189</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we received from BARDA an award of up to $<ix:nonFraction unitRef="usd" contextRef="i115458dd79814652822c63535a915899_D20160901-20160930" decimals="-6" name="mrna:RevenueFromGrantsMaximumAward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzExOTA_763d89b6-59af-445f-aee9-dedbfaa7e3e6">126</ix:nonFraction>&#160;million, subsequently adjusted to $<ix:nonFraction unitRef="usd" contextRef="i987f997b0acc4a2695f9a05d82e96f37_D20210101-20211231" decimals="-6" name="mrna:RevenueFromGrantsMaximumAward" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzIxOTkwMjMyNTkyNTA_18eb8e2b-fd86-4af1-b351-86b164bb71e1">117</ix:nonFraction>&#160;million in 2021, to help fund our Zika vaccine program. <ix:nonFraction unitRef="contract_option" contextRef="ieae7b1ae1b03416dbb9b8f48d0bc6426_I20160930" decimals="INF" name="mrna:RevenueFromGrantsNumberOfContractOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzEyNDQ_19d7354b-7d9e-4a9f-bb8a-7090756201ad">Three</ix:nonFraction> of the <ix:nonFraction unitRef="contract_option" contextRef="ief33f0f4bb514efdae5a1b468c9c9c90_I20160930" decimals="INF" name="mrna:RevenueFromGrantsNumberOfContractOptionsExercised" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzEyNTQ_de4e933e-2d5e-4f98-a560-b1d0dedfe21b">four</ix:nonFraction> contract options have been exercised. As of December 31, 2021, the remaining available funding, net of revenue earned was $<ix:nonFraction unitRef="usd" contextRef="ia3127eb355e744a881aa98a34f6d97fa_I20211231" decimals="-6" name="mrna:RevenueFromGrantsCurrentFundingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzEzNjM_2ca924b8-28d3-446e-bc92-9d465c64deda">48</ix:nonFraction>&#160;million, with an additional $<ix:nonFraction unitRef="usd" contextRef="ia3127eb355e744a881aa98a34f6d97fa_I20211231" decimals="-6" name="mrna:RevenueFromGrantsRemainingFundingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzEzODY_eab1b0de-fb22-409c-a796-9f2caccecbbf">8</ix:nonFraction>&#160;million available if the final contract option is exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of December 31, 2021, the </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="id375aa4605f14ed5b869bc0a5946884b" continuedAt="iabbb821ccf4d45108f674a9aef95f57f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available funding, net of revenue earned was $<ix:nonFraction unitRef="usd" contextRef="icf94941a6a404dd8b05524603b3a3b2c_I20211231" decimals="-6" name="mrna:RevenueFromGrantsRemainingFundingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzE3MjE_daa8352a-9c73-4c5d-a10e-1ff6d96a3daf">7</ix:nonFraction>&#160;million, with up to an additional $<ix:nonFraction unitRef="usd" contextRef="icf94941a6a404dd8b05524603b3a3b2c_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzE3NTA_9ec44b84-96b2-4061-b7d2-b72abc2a3b6b">80</ix:nonFraction>&#160;million available if additional follow-on projects are approved.</span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzE5NDI_44b44182-daf0-4600-bc09-b4b84a5f0be8" continuedAt="iebc948fad2b64f2390f493e3eb3a8ad2" escape="true"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5a2552f63d48b5b1e01ac4535c5a2f_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzItMS0xLTEtNzYwNDY_25919aec-1116-4b3e-8f18-92011611a4ab">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ef76c094447459c821c04b2de3eb206_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzItMy0xLTEtNzYwNDY_a9885f63-d106-4b55-901c-cf109466d124">522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3802fa1330a343298542de37e4105a0c_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzItNS0xLTEtNzYwNDY_bdbfeff7-245c-4a47-ad42-b17e404ac09d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd3ec1f9ac141d284f0a5db5793f3c9_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzMtMS0xLTEtNzYwNDY_6ab377ce-57d3-4d80-a014-f8229bfb9c47">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d68b45e78b406482a02388fbb53604_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzMtMy0xLTEtNzYwNDY_04878dee-d06f-45de-93ec-6e07f6124656">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c202e8e92ed4514824b43cb3531dc9e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzMtNS0xLTEtNzYwNDY_1cc7a8b2-bcc3-49a3-8633-a7f67fec4c37">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1806b5a0029947c1aabb49f5e058cb28_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzQtMS0xLTEtNzYwNDY_2c162920-80be-49cb-86d8-7babacdefc11">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1eabe79fc2e4e4a9fdc7c2be2e9f0e7_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzQtMy0xLTEtNzYwNDY_6396e60e-03ae-43ed-acda-f82cc8ef5359">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5db090169624207a4311b8780bb82f3_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzQtNS0xLTEtNzYwNDY_3e42347c-dd11-4994-b4db-700317671e26">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_136"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2Xzc5MDcy_21837400-fcd8-449c-8634-3ff20b2b1718" continuedAt="i774ca3c676314428a9463199b41a9ffb" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i774ca3c676314428a9463199b41a9ffb" continuedAt="iad09f67fea3f4a0d99ab8e6bb19ac1d5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca &#8211; Strategic Alliances in Cardiovascular and Oncology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Option Agreement and Services and Collaboration Agreement, amended and restated in 2018</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2013, we entered into an Option Agreement, the AZ Option Agreement, and a related Services and Collaboration Agreement (2013 AZ Agreements), the AZ Services Agreement, with AstraZeneca, which were amended and restated in June 2018 (2018 A&amp;R Agreements). Under the 2018 A&amp;R Agreements, we granted AstraZeneca certain exclusive rights and licenses, and options to obtain exclusive rights to develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. The activities to be performed by the parties under the 2018 A&amp;R Agreements are limited to defined biological targets in the cardiovascular and cardiometabolic fields and one defined target in the cancer field. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the effective date of the 2013 AZ Agreements, AstraZeneca made upfront cash payments to us totaling $<ix:nonFraction unitRef="usd" contextRef="if55e1500f5544b66aa8a071e51806268_D20130301-20130331" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjI4NDQ4_e4d62b62-102d-4a25-9edf-7f6cac125a46">240</ix:nonFraction> million in exchange for the acquired options and our performance of certain research-related services, each as described above. Under the 2018 A&amp;R Agreements, we are entitled to receive, on a product-by-product basis, payments for achievement of certain development, regulatory and commercial milestones, as well as earn-out payments on worldwide net sales of products ranging from a high-single digit percentage to <ix:nonFraction unitRef="number" contextRef="i8ede9f3ba9d44d22a375d16ea04e18cc_D20130301-20130331" decimals="INF" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjI5NDY1_27b4d728-59c2-41ee-b5af-d3ffb2e536ff">12</ix:nonFraction>%, subject to certain reductions, with an aggregate minimum floor.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, AstraZeneca exercised a product option under the 2013 AZ Agreements to obtain exclusive rights to develop and commercialize with respect to AstraZeneca's VEGF-A product (AZD8601). It is currently being developed in a Phase 2 clinical trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2016 Strategic Alliance with AstraZeneca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> IL-12</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered into a Strategic Drug Development Collaboration and License Agreement (2016 AZ Agreement) with AstraZeneca to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers. Under the terms of the 2016 AZ Agreement, we and AstraZeneca have agreed to work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL-12 protein.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During a limited period of time, each party had an opportunity to propose additional discovery programs to be conducted under the 2016 AZ Agreement. We are responsible for conducting and funding all discovery and preclinical development activities under the 2016 AZ Agreement in accordance with an agreed upon discovery program plan for the IL-12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck &#8211; Strategic Alliances in Infectious Diseases and Cancer Vaccines</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2016 Cancer Vaccine Strategic Alliance-Personalized mRNA Cancer Vaccines</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into a personalized mRNA cancer vaccines (PCV) Collaboration and License Agreement with Merck (PCV Agreement), to develop and commercialize PCVs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient&#8217;s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique mRNA cancer vaccine designed to specifically activate the patient&#8217;s immune system against her or his own cancer cells.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the PCV Agreement, we are responsible for designing and researching PCVs, providing manufacturing capacity and manufacturing PCVs, and conducting Phase&#160;1 and Phase&#160;2 clinical trials for PCVs, alone and in combination with KEYTRUDA (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget and under the </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="iad09f67fea3f4a0d99ab8e6bb19ac1d5" continuedAt="i9ad713011edf4b2e8b1b045cbce383b8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oversight of a committee comprised of equal representatives of each party. The parties have entered into a clinical quality agreement with respect to Moderna&#8217;s manufacture and supply activities. We received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="id946b8dd31834000b8e6b41766b9dedd_D20160601-20160630" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjM1MDE2_18ea8115-8796-478d-be66-0f0acede8b25">200</ix:nonFraction> million from Merck. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Expansion of the Cancer Vaccine Strategic Alliance-Shared Neoepitope Cancer Vaccines</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, we and Merck agreed to expand our cancer vaccine strategic alliance to include the development and commercialization of our KRAS vaccine development candidate, mRNA-5671 or V941, and potentially other shared neoantigen mRNA cancer vaccines (SAVs). We preclinically developed mRNA-5671 prior to its inclusion in the cancer vaccine strategic alliance and it is comprised of a novel mRNA construct designed by us and encapsulated in one of our proprietary LNPs. The PCV Agreement was amended and restated to include the new SAV strategic alliance (PCV/SAV Agreement).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted Merck certain licenses and we and Merck have agreed to certain exclusivity obligations with respect to SAVs and particular SAV programs, which obligations are subject to termination or expiration upon certain triggering events. Under the PCV/SAV Agreement, Merck will be responsible for conducting Phase 1 and Phase 2 clinical trials for mRNA-5671 and for all costs associated with such activities, in accordance with a jointly agreed development plan and budget, and we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials and for all costs and expenses associated with such manufacture and supply. Under the PCV/SAV Agreement, our budgeted commitment for PCV increased to $<ix:nonFraction unitRef="usd" contextRef="i3d09409e8868491499e290b8a4d12cdc_I20180430" decimals="-6" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjM2NTk1_e1e536d1-786e-46f9-a242-7c659ff67aae">243</ix:nonFraction> million. Until the expiration of a defined period of time following the completion of Phase 1 and Phase 2 clinical trials for mRNA-5671 under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of mRNA-5671 by making a participation payment to us. In connection with the amendment of the PCV Agreement to include the development and commercialization of mRNA-5671 and potentially other SAVs, Merck made a contemporaneous equity investment in our Series H redeemable convertible preferred stock, resulting in gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia84a8bd1c3aa4ac9b1a164b251799095_D20180401-20180430" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjM3MjMy_220f204e-7dcc-4ac8-8f1c-166dca10f4de">125</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="ia84a8bd1c3aa4ac9b1a164b251799095_D20180401-20180430" decimals="-6" name="us-gaap:RedemptionPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjM3MjQ2_9d58c780-0a23-4056-a43c-33c3876a9fdd">13</ix:nonFraction> million was determined to be a premium and recorded to deferred revenue. In December 2021, Merck elected to terminate the Merck participation election with respect to the joint SAV program.</span></div><div><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vertex &#8211; Strategic Alliance in Cystic Fibrosis</span></div><div style="padding-right:11.25pt"><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2016 Strategic Alliance in Cystic Fibrosis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement), with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex. The Vertex Agreement, which was amended in July 2019 (2019 Vertex Amendment), is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins. Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period that currently extends until August 2022, leveraging our Platform technology and mRNA delivery expertise along with Vertex&#8217;s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary &#8220;back-up&#8221; supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. </span></div><div><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Strategic Alliance in Cystic Fibrosis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a new Strategic Collaboration and License Agreement with Vertex (Vertex 2020 Agreement). The Vertex 2020 Agreement is aimed at the discovery and development of potential medicines to treat CF by delivering gene-editing therapies to lung cells to facilitate production of functional CFTR proteins. The <ix:nonNumeric contextRef="i60fc10736ee64261bd7f04a73acfaafa_D20200901-20200930" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE5NzkxMjA5NjU5ODYy_75392d27-1c94-4920-baae-9fc81d080a19">three-year</ix:nonNumeric> research period of the Vertex 2020 Agreement will initially focus on the identification and optimization of novel LNPs and mRNAs that can deliver gene-editing therapies to cells in the lungs. Following the initial <ix:nonNumeric contextRef="i60fc10736ee64261bd7f04a73acfaafa_D20200901-20200930" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE5NzkxMjA5NjU5ODYz_7a12feb0-1c84-4fba-b1a1-d56bd38196a8">three-year</ix:nonNumeric> period, Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Vertex is also obligated to pay us for research services in connection with our performance of certain activities in accordance with a jointly agreed research plan. Subject to customary &#8220;back-up&#8221; supply rights granted to Vertex, under the agreement, we are the exclusive manufacturer of related mRNA and LNPs for preclinical, clinical, and commercialization purposes.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i9ad713011edf4b2e8b1b045cbce383b8" continuedAt="i7773ee79169a4f45b5bcb58870841fba"><ix:continuation id="iebc948fad2b64f2390f493e3eb3a8ad2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d6ad74836b24c83809a74ce8d566449_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzItMi0xLTEtNzYwNDY_da930ce9-14ee-4840-81f0-75dd9472b9ff">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0688f24fb7444ba43fe54c1d8443f2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzItNC0xLTEtNzYwNDY_872c4e8e-be81-4b82-8217-b3ecf26f3763">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70d782312fcd4253a167cb2d7ae3760e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzItNi0xLTEtNzYwNDY_cd251897-8844-435c-b765-b0c1dfe6c2c2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24b3bc3329043adb9ea279c5b254064_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzMtMi0xLTEtOTQ0MDc_825871a5-0770-4324-bd41-fa0930df7a77">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b18d163a5204d569c9797b913f2d8f6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzMtNC0xLTEtOTQ0MDc_a5074c55-a5b3-4e1c-bc5a-3bd06c4c029a">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e25bd1849804ba7b479c2eced67e891_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzMtNi0xLTEtOTQ0MDc_407eb87a-6677-4f96-a027-a326c2f520df">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i618406f3ce9d406aaa081c4408973067_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzQtMi0xLTEtNzYwNDY_85e3094a-63ae-45bd-a1a4-7049d709695a">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a9ba91798641049354e39e4852bc1e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzQtNC0xLTEtNzYwNDY_dce8e7cd-6836-4361-b774-aa6bd71aca04">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63027741efa4c50b4babaada70fbc9b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzQtNi0xLTEtNzYwNDY_0f51e8ff-c05d-45e2-a45a-6a4e0c750be9">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia49291312e364cb4a88c0ff31026909a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzUtMi0xLTEtNzYwNDY_d1ea8dac-88b9-419a-9c33-2774759de4e1">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119f28ec664d4518be468660ee954b91_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzUtNC0xLTEtNzYwNDY_8ab4897e-1bf9-4564-b283-86020f78428c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4219337e58d4f1db6c745955c72cd8e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzUtNi0xLTEtNzYwNDY_fdaa493e-04a6-4978-b469-3e650b01da0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzYtMi0xLTEtNzYwNDY_3ec985ea-f5ba-4ba8-b7be-de02145436d6">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d88c4aeb3e94e9b959ea25fc2661d2c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzYtNC0xLTEtNzYwNDY_8760af81-ab49-4b08-a8ec-17349c0d9049">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df9734dc9af496f9780bd6c5c379234_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzYtNi0xLTEtNzYwNDY_57ec665d-7ce9-4626-b030-ff84fdc3f22a">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2Xzc5MDkz_64c388a6-c282-4367-add9-782f9b39e122" continuedAt="i193791964a034a62976f43008ab2831e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the year ended December 31, 2021 (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17abcb6e78134f4690ee2419e8619e02_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzItMi0xLTEtNzYwNDY_233d919f-bde3-46e6-ba51-ee6e1c06e981">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetPurchase" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzItNC0xLTEtNzYwNDY_50d10a07-a64d-4d56-a434-6085cccc7ae4">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231" decimals="-6" name="mrna:ContractWithCustomerAssetDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzItNi0xLTEtNzYwNDY_527e6737-83a7-4581-b3ae-7156f7e94f85">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie710a95ab39e49cdb735c3bc7fc8c4b0_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzItOC0xLTEtNzYwNDY_09686150-ba3a-44e7-9b44-56c3ed9f87b3">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17abcb6e78134f4690ee2419e8619e02_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzQtMi0xLTEtNzYwNDY_896b1260-dee8-4bb5-989c-9b975c615cbf">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzQtNC0xLTEtNzYwNDY_9e7d318c-e139-4aab-ac18-7686daf991e1">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzQtNi0xLTEtNzYwNDY_c40ca1fa-ae24-465b-8b89-d454d713e308">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie710a95ab39e49cdb735c3bc7fc8c4b0_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzQtOC0xLTEtNzYwNDY_3574f456-7906-4f94-9cc7-e8f1f1cfaae3">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $<ix:nonFraction unitRef="usd" contextRef="ie710a95ab39e49cdb735c3bc7fc8c4b0_I20211231" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzkzNDU4NDkxOTUyOTE_37b79067-9cf9-4e0f-986c-c6209a36a90d">286</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7773ee79169a4f45b5bcb58870841fba">In addition to the collaborative arrangements mentioned above, we have other collaborative and licensing arrangements that we do not consider to be individually significant to our business at this time. Pursuant to these agreements, we may be required to make upfront payments and payments upon achievement of various development, regulatory and commercial milestones, which in the aggregate could be significant. Future milestone payments, if any, will be reflected in our consolidated financial statements when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_142"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzIwOTA_db80a1b3-097a-4e25-b7dc-eefdd788ae79" continuedAt="ib7c6593ce14f4d7eb976afe2ad4ca1df" escape="true">Financial Instruments and Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ib7c6593ce14f4d7eb976afe2ad4ca1df" continuedAt="i5af95179279345a880fa9012d754c28a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzIwOTI_d0b0718e-75bc-4a67-99f7-154c4f7a7356" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash and available-for-sale securities by significant investment category at December 31, 2021 and 2020 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa328a08859144588130d892ad20192d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItMi0xLTEtNzYwNDY_0e936f7b-cc6e-4ae7-840a-91213cec75e0">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa328a08859144588130d892ad20192d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItNC0xLTEtNzYwNDY_70c343de-31a4-4fc7-80c7-6a7bd60a688e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa328a08859144588130d892ad20192d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItNi0xLTEtNzYwNDY_909bf5ed-472f-462a-89f8-b58f7e7d81c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa328a08859144588130d892ad20192d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItOC0xLTEtNzYwNDY_d10143f0-60c1-462e-9232-dc7ca6a49d76">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf669fdc68ee4630b54c9802a1b0a558_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItMTAtMS0xLTc2MDQ2_df2dcacb-80ff-4078-aa18-41db7a586613">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0292df9b654d482db1060f9005959794_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItMTItMS0xLTc2MDQ2_cb417299-0ee9-4e05-b767-20632297fe12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45359f849f44c0998e347e23469e818_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItMTQtMS0xLTc2MDQ2_ac2650d6-e93e-4b41-a06f-6facbac06ab7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4712a1c564814f3abe808e0a6b9e64a0_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtMi0xLTEtNzYwNDY_c1ef275f-db3c-4b2a-8038-13ca6f5841c8">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4712a1c564814f3abe808e0a6b9e64a0_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtNC0xLTEtNzYwNDY_b427c5e9-c2c8-443e-bc68-6acd6d2ab834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4712a1c564814f3abe808e0a6b9e64a0_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtNi0xLTEtNzYwNDY_ffea1d57-7271-4c22-9486-274e3b4ac55f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4712a1c564814f3abe808e0a6b9e64a0_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtOC0xLTEtNzYwNDY_d3aff6eb-6cca-4fd6-ae67-78adf2f390b9">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e02fcbb9afe410ab3a681bc9b64d879_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtMTAtMS0xLTc2MDQ2_b78f459a-d612-4c1d-bbcf-b364de6f31ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f5d9b242cc4780b3309e0961fa5eb7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtMTItMS0xLTc2MDQ2_dbe3af77-de3d-42e9-adac-d2515f9c8871">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5734f4fe23fc43dd969bd66b5e557046_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtMTQtMS0xLTc2MDQ2_80b7e368-d89c-46a4-bbe6-8ad1dacc4bfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2364f83219a4bfc9d8ee9260dacc1b7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtMi0xLTEtNzYwNDY_30ac1041-0536-43ab-ab23-24feede387bb">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2364f83219a4bfc9d8ee9260dacc1b7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtNC0xLTEtNzYwNDY_9e4644a2-c422-4e38-b2af-84e7d33f4315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2364f83219a4bfc9d8ee9260dacc1b7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtNi0xLTEtNzYwNDY_f10ec9a0-cc88-4ffd-bf17-b4d30f3c103d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2364f83219a4bfc9d8ee9260dacc1b7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtOC0xLTEtNzYwNDY_24ea7c0b-9bf5-4a74-a4ff-05ab068caff3">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4042eb496ee543f2a5872be11b2cf7ca_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtMTAtMS0xLTc2MDQ2_67c62c3f-b51c-4a29-8b35-80d4765dabe2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5cfdaf6a9c475fab2b7dfb72468094_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtMTItMS0xLTc2MDQ2_8bb544ed-8ace-451f-9a17-7303a7e40b8c">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9284186e600b48258879f874e838c77a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtMTQtMS0xLTc2MDQ2_62cde42c-1b52-47fc-b11f-fa566d746a5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic428ae6809614abaac1249c8d3bb020c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMi0xLTEtNzg0NDM_ef09aaae-022c-4a08-bb00-32dc3437b87c">6,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic428ae6809614abaac1249c8d3bb020c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtNC0xLTEtNzg0NDM_d018e453-0cbe-4c5b-9abf-179b725abca7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic428ae6809614abaac1249c8d3bb020c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtNi0xLTEtNzg0NDM_9388c629-aeb0-4e94-805b-f2ec073cfe5e">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic428ae6809614abaac1249c8d3bb020c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtOC0xLTEtNzg0NDM_53a352dc-e3d9-46aa-a50c-493504faddf0">6,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709ee66b601a4d2ebd30bdd6893ba771_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTAtMS0xLTc4NDQz_36654334-61cc-41c8-9c96-d411504601bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6344e2313ce84b3291ddab39f4bcddfb_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTItMS0xLTc4NDQz_f59bae21-9158-41d4-95db-f5002e2097cf">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf656a3fa7e84852a422e94e706d2b6f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTQtMS0xLTc4NDQz_ae651613-2bbe-48ca-9223-1705ccdafc06">4,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec10e88bcd6c4d8181a5ca274d5cc8f7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMi0xLTEtNzg0NDM_8f98f314-fbcc-4e6b-90e8-a81104b5072c">3,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec10e88bcd6c4d8181a5ca274d5cc8f7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctNC0xLTEtNzg0NDM_32352106-406d-4789-9b0c-c26ffdedbaa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec10e88bcd6c4d8181a5ca274d5cc8f7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctNi0xLTEtNzg0NDM_f40af4f6-f2c5-4a43-82e8-e7abb90050a2">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec10e88bcd6c4d8181a5ca274d5cc8f7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctOC0xLTEtNzg0NDM_0cd1991f-6062-40b9-88aa-5f623ad32d3f">3,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafc1c887e174d9bbbde6dd62d64e2ab_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTAtMS0xLTc4NDQz_15cab3fd-55d0-4f21-93ea-018969fff5c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44bf012463a94b6a88a9422b0030dda0_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTItMS0xLTc4NDQz_dc7ffc67-2ba3-43c2-aa99-57439d01b5a9">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9235e93735dc44b285d2bfdc769bb996_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTQtMS0xLTc4NDQz_30e60f08-c781-4504-896b-84ccccdfbcc3">2,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07b5918438d431a8e9c74d8ff4d2551_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMi0xLTEtNzYwNDY_2698baa4-6a54-4c45-9a09-7ac1b4a7b62b">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07b5918438d431a8e9c74d8ff4d2551_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtNC0xLTEtNzYwNDY_dd627f4a-2dcf-4d53-808b-daf09650489c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id07b5918438d431a8e9c74d8ff4d2551_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtNi0xLTEtNzYwNDY_393da9ae-c739-4e2e-b90a-ba9b951eaadc">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07b5918438d431a8e9c74d8ff4d2551_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtOC0xLTEtNzYwNDY_ab5673e8-a9cf-4076-b72a-00fa1432b801">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1075514a7e14bb585b04979d8e91df8_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTAtMS0xLTc2MDQ2_364dd5ff-922e-4b3e-8318-83eca6846e85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33223bcc0e1b4b51acbe5ccd606713ff_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTItMS0xLTc2MDQ2_fa39655a-347d-427b-a46c-477a198706f3">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959b3e4a89ca4e1392ee007bf48a9ce3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTQtMS0xLTc2MDQ2_a55da9eb-2d25-4a94-b136-25156573bf98">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0458e4ead71746a5af5b29ed89c9ef21_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMi0xLTEtNzYwNDY_618d42ca-83d4-457c-af22-ea7892339be5">17,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0458e4ead71746a5af5b29ed89c9ef21_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctNC0xLTEtNzYwNDY_d0cf42f1-f505-4b43-8ce0-1cce9774b648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0458e4ead71746a5af5b29ed89c9ef21_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctNi0xLTEtNzYwNDY_b13e6518-e8fb-4730-9647-4e3123fc277a">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0458e4ead71746a5af5b29ed89c9ef21_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctOC0xLTEtNzYwNDY_26997091-d1b3-45be-875c-becdb4f7c4d0">17,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a6b3fe35432446aa1c5e179c4701d65_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTAtMS0xLTc2MDQ2_643cd6f3-0f34-46fa-9c73-355af6dbd44d">6,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9905b040c345c9800468da2693c514_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTItMS0xLTc2MDQ2_ce5f2751-066f-4c6c-b4f1-7228de7485a4">3,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2565e09c4ee4bdcbd387be8850d72df_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTQtMS0xLTc2MDQ2_ef5d5684-7419-4ca2-a9aa-acc3473e0473">6,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="45" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3997280202440c4b1242ce5b6a23810_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTItMS0xLTc2MDQ2_76880023-d144-4328-ba3f-a0c77921e71a">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3997280202440c4b1242ce5b6a23810_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTQtMS0xLTc2MDQ2_e2cadd2b-dcc4-44bf-b5a7-28ce99f89d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3997280202440c4b1242ce5b6a23810_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTYtMS0xLTc2MDQ2_ad0ec0e3-a4db-4837-ab52-e47abc3166b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3997280202440c4b1242ce5b6a23810_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTgtMS0xLTc2MDQ2_de3c92a2-cceb-4ba5-87fe-425cab2706d6">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3d566855dd54261b4fe635c234b2484_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTEwLTEtMS03NjA0Ng_b3996e7b-a6bd-4004-a5b5-cf0c3c0a5dd5">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id087a0a88efd4af88be84f1c3b08e19f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTEyLTEtMS03NjA0Ng_beb3d104-9403-44ec-8b1c-760cd6a0494d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ef75bce2954276bae1f44362fbb2cd_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTE0LTEtMS03NjA0Ng_a293cf81-f703-4928-a20e-46a4e27a8e04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a1843d0dcd4702b157723e8cc7e665_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTItMS0xLTc2MDQ2_83fa29bf-521b-4581-8812-7c9c51f5b56a">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a1843d0dcd4702b157723e8cc7e665_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTQtMS0xLTc2MDQ2_299039f5-17f1-43c8-9f08-0dc2c28d3f14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a1843d0dcd4702b157723e8cc7e665_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTYtMS0xLTc2MDQ2_2ef93e38-6a0d-42ce-8aa9-887ef35f8880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a1843d0dcd4702b157723e8cc7e665_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTgtMS0xLTc2MDQ2_b5bc8197-def0-4f36-ab69-2227e0dcce11">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53dd51cc137b4b4aa2f56b6bab4db8f4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTEwLTEtMS03NjA0Ng_4e2c9e41-aed5-4555-a2e0-7e740c1ce2ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e93700d2ebf423091417132b7c40ab4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTEyLTEtMS03NjA0Ng_17d0f010-7114-4cd6-a572-5cad4315ddd9">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3d5ab7308d4c59b813d58e2e04c6e5_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTE0LTEtMS03NjA0Ng_417a865c-bf12-44e5-914b-e77b2c65cb7f">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eeaea94154e4fe49fa61fba009f8be3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTItMS0xLTc2MDQ2_5ba06626-ce38-43ba-b413-d7cba2bf3e5e">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eeaea94154e4fe49fa61fba009f8be3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTQtMS0xLTc2MDQ2_f340cea3-50b7-4b01-ae16-e54b4e69f5b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eeaea94154e4fe49fa61fba009f8be3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTYtMS0xLTc2MDQ2_10cadb44-301b-4a4e-ac01-4527d94ba820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eeaea94154e4fe49fa61fba009f8be3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTgtMS0xLTc2MDQ2_eca99a20-d799-41ed-8c33-ec07bd49e74d">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa1fb4bfb734981a51e6771d628fcc8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTEwLTEtMS03NjA0Ng_d81b2695-a5ec-4fc8-a346-8d29fee1afc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab996b74800b4e25a035225c3e839436_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTEyLTEtMS03NjA0Ng_cd67547f-dc64-41e3-9349-3771cca64f26">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1fc05718e842d8a85da2e69c5bf695_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTE0LTEtMS03NjA0Ng_c549a58a-abe8-4cfd-b7ef-f5d65122f9b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa93ec4582e34e7fbf2e3ab8bce77f21_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTItMS0xLTc4NDc5_58b20444-8ba9-4573-970b-ce74fe0ecf06">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa93ec4582e34e7fbf2e3ab8bce77f21_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTQtMS0xLTc4NDc5_5e28fc69-33ce-494b-aec7-2f6c062d9d94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa93ec4582e34e7fbf2e3ab8bce77f21_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTYtMS0xLTc4NDc5_8d75b020-f99c-465a-9b41-6066884dbf2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa93ec4582e34e7fbf2e3ab8bce77f21_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTgtMS0xLTc4NDc5_0d909780-21f0-41f4-859f-77de69928515">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63eadf881ec473799e8621ff399a7de_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTEwLTEtMS03ODQ3OQ_1ca4711f-eb7e-4df1-8d57-e415535c30c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5df7f55fdc4eb49e20e64d8f73b402_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTEyLTEtMS03ODQ3OQ_710ccb50-f6c7-4539-8ec6-16d4fe19ab90">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9935ee028dc4668889878caf93655c1_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTE0LTEtMS03ODQ3OQ_81de6cb5-1bc7-46b1-a07d-cef2b193cba7">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib074b324fc8a45e8b60ce57c228ef8bb_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTItMS0xLTc4NDc5_d7983ccc-9792-44b6-9fbc-9385f12c9bec">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib074b324fc8a45e8b60ce57c228ef8bb_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTQtMS0xLTc4NDc5_bf3bcd3a-6440-43c6-8714-eaf1a9bffc89">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib074b324fc8a45e8b60ce57c228ef8bb_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTYtMS0xLTc4NDc5_db1d3c85-62cd-433a-899a-52644183d384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib074b324fc8a45e8b60ce57c228ef8bb_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTgtMS0xLTc4NDc5_aeffe0d0-31c2-4992-8343-70176cc8c307">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee8da0e76f2e4c59a02abce9c64913ea_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTEwLTEtMS03ODQ3OQ_83967042-3006-47fc-b451-1e0986d4e282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342e75080ebe4c45b4605822f2cb05d2_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTEyLTEtMS03ODQ3OQ_c9d9e6c3-9be9-420b-a67b-0388e2ecbd88">1,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib732575815f0493f8a45f987de9435dc_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTE0LTEtMS03ODQ3OQ_277b030a-bc76-4b3c-8ebb-b55e683a0c36">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb052b50079e46858cb5714c483963ff_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTItMS0xLTc2MDQ2_4da17bb7-1f84-46bb-b259-f743de91b725">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb052b50079e46858cb5714c483963ff_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTQtMS0xLTc2MDQ2_825c9ef5-79c4-491f-aee5-aad29d755969">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb052b50079e46858cb5714c483963ff_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTYtMS0xLTc2MDQ2_fe74302e-24f0-4da8-bf99-d74deb46f9e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb052b50079e46858cb5714c483963ff_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTgtMS0xLTc2MDQ2_515ae4c8-984a-4083-9832-57a62de1414f">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19e0d73c72e24eca8ca94e49eb15e6a5_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTEwLTEtMS03NjA0Ng_1e003259-f1fa-491a-932e-0e2de2732357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2926456ed6654d0a91dee92754e33edf_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTEyLTEtMS03NjA0Ng_8d97496b-ded8-402f-80b9-66a17e59c98a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3af41c88515492095e14241259a0e07_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTE0LTEtMS03NjA0Ng_d2ea17c0-c33a-40f4-944b-4ff2a5659783">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9646a432a9439688c513fb0ec0887f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTItMS0xLTc2MDQ2_631576ea-f745-4b3d-816e-8a87da693f4c">5,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9646a432a9439688c513fb0ec0887f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTQtMS0xLTc2MDQ2_6351db57-b73a-4a42-9265-24304bc41d7d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9646a432a9439688c513fb0ec0887f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTYtMS0xLTc2MDQ2_ac0ec1b3-66be-412d-8559-45904bd83ce3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9646a432a9439688c513fb0ec0887f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTgtMS0xLTc2MDQ2_34d2328b-ad57-44b5-a986-df76388175c1">5,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ca3868ec35146878138ef39c9381dab_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTEwLTEtMS03NjA0Ng_eb132296-1f99-42bc-a729-15da4ca08ed9">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4fe368718ae402a88feb1ddaf1fdc8d_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTEyLTEtMS03NjA0Ng_eba45a0d-e4d4-4dc7-92a4-e500e2c6b2dc">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e686917771642979115acea50d66bd1_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTE0LTEtMS03NjA0Ng_fa263398-dfcf-4654-85ad-e13174c65f2b">639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i5af95179279345a880fa9012d754c28a" continuedAt="i51c94c4b61704043b00fbdb588a8de45"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzIwOTM_a24981e2-5d29-41ff-a195-83d4724ffd5a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable securities, by contractual maturity at December 31, 2021 and 2020 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzItMi0xLTEtNzYwNDY_e92465d5-e694-4910-ac65-9c00078f6cbf">3,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzItNC0xLTEtNzYwNDY_11b6c51a-7c70-465b-b372-64af08de7678">3,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzMtMi0xLTEtNzYwNDY_c057da75-b97b-4599-a8ce-e75dcd0d22d2">6,892</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzMtNC0xLTEtNzYwNDY_170142e1-3513-40b6-9820-9de1ec06b3db">6,843</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzQtMi0xLTEtNzYwNDY_2906997d-fe95-4fa9-a618-2d9ffb4497a6">10,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzQtNC0xLTEtNzYwNDY_d7a7da50-e0d5-4fa2-95d4-d733faf221a3">10,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzctMi0xLTEtNzYwNDY_1f646944-5943-417a-a540-0103b958d55f">1,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzctNC0xLTEtNzYwNDY_f821f85f-6eb3-4118-80c6-4b0c506d3bde">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzgtMi0xLTEtNzYwNDY_88580956-a2c3-4646-a689-e23717fc4e85">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzgtNC0xLTEtNzYwNDY_94c0f02c-8c5d-425e-b52d-1cab17042784">639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzktMi0xLTEtNzYwNDY_71866e61-d1c6-4205-aa44-ffbfaeaa94d4">2,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzktNC0xLTEtNzYwNDY_3bd55c71-cec2-478a-b4e6-0a97a6de8bd7">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. We did <ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzY2Ng_13c9e1f8-f4d2-4c92-866f-293dcb815ed1"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzY2Ng_91aa8dd7-5e3a-4539-bc9a-eb259eba6494"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzY2Ng_f00cf999-5aa0-4a68-95ce-3fb265d196fc">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t record any impairment charges related to our available-for-sale securities during the&#160;years ended December 31, 2021, 2020, and 2019. We did <ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzkzNDU4NDg4Mzg1NzY_867a1a24-296b-46fd-9958-54053908306c"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzkzNDU4NDg4Mzg1NzY_d2cf9b75-81ea-4833-8b0a-c9fa6ab7e8ed">not</ix:nonFraction></ix:nonFraction> recognize any credit-related allowance to available-for-sale securities as of the years ended December 31, 2021 and 2020. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzIwOTY_27144506-2402-4c92-ba33-0d8a9f6995fa" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2021 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or More</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2021:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMi0xLTEtMTA3OTcx_14576402-868a-4d5c-b7b3-5fce5c63fd07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNC0xLTEtMTA3OTcx_869973cb-5e94-4803-a0d1-0a5b2bae356e">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNi0xLTEtMTA3OTcx_53ab4d57-221c-4e32-8c1b-2c210bed3272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtOC0xLTEtMTA3OTcx_a5b451ad-4b29-49a3-a088-e4540d2912ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTAtMS0xLTEwNzk3MQ_71686217-ebc3-45f9-9b61-5827c3159dc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTItMS0xLTEwNzk3MQ_30ffa4e1-8851-4ddb-9479-7d46b6b3a288">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d743eab86de4393a005da034dc6076d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMi0xLTEtODMyODI_19e10327-e183-4219-bfa8-317e2d5558b3">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d743eab86de4393a005da034dc6076d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNC0xLTEtODMyODI_d5815cda-e162-4733-9643-e69495dfc208">6,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d743eab86de4393a005da034dc6076d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNi0xLTEtODMyODI_02786126-3222-4fec-a47b-96cc7b425b50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d743eab86de4393a005da034dc6076d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtOC0xLTEtODMyODI_c3df409c-4d15-4952-a88a-02104d583067">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d743eab86de4393a005da034dc6076d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTAtMS0xLTgzMjgy_86d6d1fa-0cba-4c6e-8750-1f7129d224aa">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d743eab86de4393a005da034dc6076d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTItMS0xLTgzMjgy_e3de3703-1ccd-470c-aa70-03a6f30a8ec2">6,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib08aa8be8be24796b00714b57780c548_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMi0xLTEtODk4NDM_aaa89d24-9ecb-4312-a993-148f2ce67239">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib08aa8be8be24796b00714b57780c548_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtNC0xLTEtODk4NDM_2cc91cd6-a50c-445b-821f-c8ed636f7a8b">2,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib08aa8be8be24796b00714b57780c548_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtNi0xLTEtODk4NDM_4d33b62d-f647-4675-b4c7-f2f1c6f7b98f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib08aa8be8be24796b00714b57780c548_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtOC0xLTEtODk4NDM_c08ea786-3b04-4cc8-b624-2de87a0df1a6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib08aa8be8be24796b00714b57780c548_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMTAtMS0xLTg5ODQz_289da113-59a9-4932-8300-81f02323e963">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib08aa8be8be24796b00714b57780c548_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMTItMS0xLTg5ODQz_46a240ee-1d61-475f-87e5-df2174e2817c">2,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMi0xLTEtNzYwNDY_3099f6cd-aff6-4b2f-b64a-adc90ba40ff3">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNC0xLTEtNzYwNDY_2e130b1d-9afc-444e-952c-d140dbe1ba27">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNi0xLTEtNzYwNDY_9f3fa592-c15a-4392-8a86-6af78bb92bd3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtOC0xLTEtNzYwNDY_afa3ca43-89d9-43f2-b7a1-ffe2d225b42f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTAtMS0xLTc2MDQ2_1344e268-9ac2-4cea-ac8b-52980f80fad2">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTItMS0xLTc2MDQ2_68e523cb-33a9-44bb-80b3-3a4f872fe102">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMi0xLTEtNzYwNDY_4a2a51e3-643c-4c50-b3b9-2947f95af7d6">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtNC0xLTEtNzYwNDY_51717f96-a53f-4f38-a512-34f406157fb5">9,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtNi0xLTEtNzYwNDY_8bf52613-a596-4062-bd71-a367e874fead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtOC0xLTEtNzYwNDY_b483815a-d467-41dc-844e-ef8409ec56c5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMTAtMS0xLTc2MDQ2_fe409754-e6e9-4290-b021-86363ad729c5">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMTItMS0xLTc2MDQ2_640ffa22-3478-462b-96d2-70065f03af6a">9,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we did not have material gross unrealized losses. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i51c94c4b61704043b00fbdb588a8de45"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzIwOTc_688d8abb-d4d3-43cb-ba44-a125f2f49cbb" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7c01916db3408ab5ad64668966705b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzMtMi0xLTEtNzYwNDY_8c454fac-5bb3-4d19-8b4a-2552199d093b">2,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01fbfe4a2aeb4f52a6e5832316a78b96_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzMtNC0xLTEtNzYwNDY_9b0b154c-db25-47a1-b160-f1f4d9dd5472">2,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3b71762f59d402fb8c3f8db8d6a2794_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzMtNi0xLTEtNzYwNDY_d841df81-febf-4478-a8f0-cbdf7a61a7df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173e555f8608496f9662755df4a4507f_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzQtMi0xLTEtNzYwNDY_2ef90a47-f34e-41b7-9988-4be2fea9791a">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7aa28c6c4754b4cac1648572278cb7c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzQtNC0xLTEtNzYwNDY_93bc3fba-66cc-4945-9575-50942e5cbf44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a1bd3236264470831ed902e1ec14fc_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzQtNi0xLTEtNzYwNDY_77d72811-0027-43ba-8c84-7d702b3be23c">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3a736dedb0468eb2b96e05d6a5b5cb_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzUtMi0xLTEtNzYwNDY_e681b16a-4e87-4302-a2df-b8b96b3d33d9">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cb8657700e404391363a5b93c94298_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzUtNC0xLTEtNzYwNDY_bdea4562-b30d-4fe6-b444-6fa323abf709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f7bfa072504774a46de61549ed1358_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzUtNi0xLTEtNzYwNDY_0ab0995d-9ff9-46da-99a3-b5bac63c8880">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a410f63e2a34faeb71837e163488553_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtMi0xLTEtNzg2MjU_0adad64e-16b0-4761-a0ec-a5d4ded0dfe5">6,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id11c2636a9e849b199e50f122b90bfb4_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtNC0xLTEtNzg2MjU_0da44687-3a81-4a48-813f-3beb297cd316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a786fc7c8548f99e9260ccc849d096_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtNi0xLTEtNzg2MjU_13aca6c3-65b3-46eb-a152-41f59310da0e">6,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib091b3d4b2c54a35b6370a090b778180_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctMi0xLTEtNzg2MjU_cbd0e815-29c4-4c3c-ac25-68593896369c">3,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82fff40b8cf5418684879ad0b808d851_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctNC0xLTEtNzg2MjU_2a57c032-7c69-4f13-a112-f06fbe89d684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf5ed5b20a464aa69fffcc07449d6b65_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctNi0xLTEtNzg2MjU_bb336ea4-22d4-465c-9510-aced9ec604a2">3,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4435c73f09eb44d4992e01d4922d5bc6_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtMi0xLTEtNzYwNDY_27054d26-c8a5-42d6-9082-a6149f8b23b9">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa3443efd7954041a7b94f68574c1294_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtNC0xLTEtNzYwNDY_e928f6e9-1224-4e65-ad4a-edb300a0f279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bab6b5e239439c88900de725d422b6_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtNi0xLTEtNzYwNDY_37f61f28-a982-4dd8-81d9-4076203a500e">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3fc18fdc324f1aa20d24c095339419_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctMi0xLTEtNzYwNDY_0911ab1b-6151-4c8b-a37c-4ec6e12de058">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9147f3587c94165889e686e4d2ea8b9_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctNC0xLTEtNzYwNDY_cfecfa98-5511-4705-8c8c-b6fd7a84c193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d4434bc6c044c7b3f4e94fb304ff0b_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctNi0xLTEtNzYwNDY_8eadde83-ce91-46db-8ae4-9d36967519d6">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3fc18fdc324f1aa20d24c095339419_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzgtMi0xLTEtNzYwNDY_c97aa368-c88a-4e89-b9b8-1a8d2ec99b18">13,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9147f3587c94165889e686e4d2ea8b9_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzgtNC0xLTEtNzYwNDY_acc84199-c112-49e3-8423-99b12f1dc5b6">2,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d4434bc6c044c7b3f4e94fb304ff0b_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzgtNi0xLTEtNzYwNDY_0186af4e-fa41-428f-becc-fa371a124a81">10,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3fc18fdc324f1aa20d24c095339419_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzEyLTItMS0xLTc4NjI1_db9e7eda-feb8-4ed2-a7a3-a2967f883f6d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9147f3587c94165889e686e4d2ea8b9_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzEyLTQtMS0xLTc4NjI1_01a11172-09c6-4076-9bba-be64d9e0f315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76d4434bc6c044c7b3f4e94fb304ff0b_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzEyLTYtMS0xLTc4NjI1_ca262bde-ebed-4e1b-bd1f-437aa5d33d75">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id626af309354471c938a13ee987efb1f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtMi0xLTEtNzg1OTg_cb665562-a40a-4225-8efa-1db0de0cfa42">660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia847fc5aaa414970962b3e66c726b6d1_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtNC0xLTEtNzg1OTg_13b455f4-5ab9-4097-9245-718514882b2b">660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60349844b567496a8c96cb156669e486_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtNi0xLTEtNzg1OTg_a9399c89-ebae-4da3-ab93-21816997f3d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4e351d2d1764d1e970af57129ac281f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtMi0xLTEtNzYwNDY_b2c8351a-07bb-47f8-b746-61e9396c1eb1">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabdcd1636c89453094af591ed45cb1ab_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtNC0xLTEtNzYwNDY_a08d639a-df91-477e-9468-4a655822c5ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52d1393c6a94df1a1ed227bb14cad8a_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtNi0xLTEtNzYwNDY_ee4014d0-5427-4796-a333-87657b69bd03">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87eab6cd7a7f48e0b5a9796ab31c2d6e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzQtMi0xLTEtNzYwNDY_6b5d42d8-7de8-4972-95ec-30a842c4dd1d">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1e243dab0bc4efaa8d7f2b398dcdab5_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzQtNC0xLTEtNzYwNDY_f9855ef8-13fd-40a4-8590-7d5f9e28d22c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294dcfa26a8843f783242f2540ba31cd_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzQtNi0xLTEtNzYwNDY_4c9cf990-0e24-4ecf-94f9-26d18177c462">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e7eff5bd6c4c9b84f96355143d2190_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtMi0xLTEtNzg1OTg_c5358176-d6c5-4be6-9b1a-947bf3c2e9fd">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12d89d325c9641979afcb1133eb38c92_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtNC0xLTEtNzg1OTg_a534a070-1454-47ee-8412-f9c6f9b49cc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62a0a9d758df464cb7896474951b0ac5_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtNi0xLTEtNzg1OTg_b0ee1d29-4951-40c2-87d1-5224fec592fc">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39fb570a4f842229f0fb89db305d537_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzctMi0xLTEtNzg1OTg_6f9f8e9b-9175-4ab5-a503-34e7c5ae4f87">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6600cb5746c3408c9cb209436ced4bd4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzctNC0xLTEtNzg1OTg_6c81e2ba-6c0d-495e-acd2-5b0fb391b22a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c3185ed7d04fccbb21599da90453cd_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzctNi0xLTEtNzg1OTg_a7582823-c552-4f12-8bd7-3570a53afb44">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b05b51f2234fc58d69e6a80fa771ca_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzUtMi0xLTEtNzYwNDY_2fdf5a68-9d0c-458a-ab04-98786684cce8">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3992f82ad0c4b249387e250c043245a_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzUtNC0xLTEtNzYwNDY_236e495e-1ed4-479f-a4cb-092b59791543">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d422efa75e467d98852994a450a9ae_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzUtNi0xLTEtNzYwNDY_96b232cf-964c-4b95-bf90-1d0f08864de2">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2f9fe6eb684be982187b0507723e2b_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtMi0xLTEtNzYwNDY_b011808b-933b-439c-8b9c-a1be9e98e613">3,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e6dc104953e4bb395df7081eca0082a_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtNC0xLTEtNzYwNDY_deacbe0e-8d7f-42c8-8dbe-b17289fd5bcd">660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2b92fa7550f4911b44a79ebc01be5fd_I20201231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtNi0xLTEtNzYwNDY_24a241e3-3c68-4388-8bf7-a0620a972c3b">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.</span></div></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90ZXh0cmVnaW9uOmM2MzY0ZmM0OTM4ZDRiYjJhMTdiZmRhNjM2ZTRiMjJkXzIzMjk_e90afae3-dd93-4203-aa6e-ecca6882de76" continuedAt="id8242d64599343379fdc67edd70241df" escape="true">Derivative Financial Instruments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id8242d64599343379fdc67edd70241df" continuedAt="icd91ce91c51140a69f79c28879817d6b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies and have international sales and expenses denominated in foreign currencies. Therefore, we are exposed to certain risks arising from both our business operations and economic conditions. Our risk management strategy includes the use of derivative financial instruments to hedge foreign currency exchange rate fluctuations on monetary assets or liabilities denominated in foreign currencies. We do not enter into derivative financial contracts for speculative or trading purposes. We do not believe that we are exposed to more than a nominal amount of credit risk in our foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. We classify cash flows from our derivative transactions as cash flows from operating activities in our consolidated statements of cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate the foreign exchange risk arising from the fluctuations in foreign currency denominated product sales in Euro through a foreign currency cash flow hedging program, using forward contracts and foreign currency options that do not exceed 15 months in duration. We hedge these cash flow exposures to reduce the risk that our earnings and cash flows will be adversely affected by changes in exchange rates. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The derivative assets or liabilities associated with our hedging activities are recorded at fair value in other current assets or other current liabilities, respectively, in our consolidated balance sheets. The gains or losses resulting from changes in the fair value of these hedges are initially recorded as a component of AOCI in stockholders&#8217; equity and subsequently reclassified to product sales in the period during which the hedged transaction affects earnings. In the event the underlying forecasted transaction does not occur, or it becomes </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="icd91ce91c51140a69f79c28879817d6b" continuedAt="id911e0f5ee774c25a778c68614cad378"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to other expense, net, in our consolidated statements of operations. We evaluate hedge effectiveness at the inception of the hedge prospectively, and on an on-going basis both retrospectively and prospectively. If we do not elect hedge accounting, or the contract does not qualify for hedge accounting treatment, the changes in fair value from period to period are recorded as a component of other expense, net, in our consolidated statements of operations. As of December 31, 2021, we had net deferred gains of $<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90ZXh0cmVnaW9uOmM2MzY0ZmM0OTM4ZDRiYjJhMTdiZmRhNjM2ZTRiMjJkXzIxOTkwMjMyNjI4Mzg_6083b3c8-6db5-4c24-90c2-2af468b4fef9">21</ix:nonFraction>&#160;million on our foreign currency forward contracts included in AOCI that are expected to be recognized into product sales within the next 12 months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We enter into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily accounts receivable, accounts payable, and lease liabilities in Euro and Swiss Franc, that are not designated for hedge accounting treatment. Therefore, these forward contracts are accounted for as derivatives whereby the fair value of the contracts are reported as other current assets or other current liabilities on our consolidated balance sheets, and gains and losses resulting from changes in the fair value are recorded as a component of other expense, net, in our consolidated statements of operations. The gains and losses on these foreign currency forward contracts generally offset the gains and losses in the underlying foreign currency denominated assets and liabilities, which are also recorded to other expense, net, in our consolidated statements of operations. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90ZXh0cmVnaW9uOmM2MzY0ZmM0OTM4ZDRiYjJhMTdiZmRhNjM2ZTRiMjJkXzIzMjc_0457b12a-29a0-4761-891b-12693adc9b45" continuedAt="i8ad71e51abcf46f0b3e5e0f6aa8eb023" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross notional amount and fair value for foreign currency derivatives were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5931b912876541d6882f7bd7117de3f7_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzQtMi0xLTEtNzg2NTA_fdb52f03-75fe-4533-b310-5e2ee58c29b5">565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5931b912876541d6882f7bd7117de3f7_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzQtNC0xLTEtNzg2NTA_80f86a39-581d-4657-bf26-210b020d08c0">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5931b912876541d6882f7bd7117de3f7_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzQtNi0xLTEtNzg2NTA_6783a94c-c7bd-4b33-8ef2-4e762bb19e36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77eee50ddfaa4eb0bc9f201ff1631518_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzctMi0xLTEtNzg2NTA_a9767111-2f19-4cb5-882e-830785d1e7b6">1,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77eee50ddfaa4eb0bc9f201ff1631518_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzctNC0xLTEtNzg2NTA_9ba48f7a-e4e4-470e-8238-e29a6bf3954a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77eee50ddfaa4eb0bc9f201ff1631518_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzctNi0xLTEtNzg2NTA_2461d7b2-27c9-495b-9785-8576e7812dbe">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzgtMi0xLTEtNzg2NTA_c704f808-10fe-4b6a-9044-9744b8fffe5a">1,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzgtNC0xLTEtNzg2NTA_d9dff89f-9093-4b45-8e19-afa95559786a">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzgtNi0xLTEtNzg2NTA_0b4c4568-4398-4795-b9fb-c61a12bfd058">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dca9b9d97e4b8f946f52de263fa1d1_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzQtMi0xLTEtNzYwNDY_3f64885c-b461-4739-9ce0-1bb09bf0e176">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dca9b9d97e4b8f946f52de263fa1d1_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzQtNC0xLTEtNzYwNDY_7848ab89-cd35-4327-a41f-79097c8533f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dca9b9d97e4b8f946f52de263fa1d1_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzQtNi0xLTEtNzYwNDY_56e9a3fa-1a95-4453-ab82-bf0ad91b6e43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3187a0bb484bae8f0a6c5412316823_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzUtMi0xLTEtNzYwNDY_07a8b394-b9a7-4a68-9943-2cc3f249534c">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3187a0bb484bae8f0a6c5412316823_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzUtNC0xLTEtNzYwNDY_5af0d1ee-f973-40c1-977a-1d371529a5cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3187a0bb484bae8f0a6c5412316823_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzUtNi0xLTEtNzYwNDY_d22c070c-7aee-4cb5-ba58-d61117f09c0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the consolidated balance sheet within prepaid expenses and other current assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the consolidated balance sheets within other current liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gains on our foreign currency derivatives, net of tax, recognized in our consolidated statements of comprehensive income (loss) for the year ended December 31, 2021 was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3MGE3OGVkMzYxNTQ0N2JjODcwOWM5ZDU1YjdiZTBlMy90YWJsZXJhbmdlOjcwYTc4ZWQzNjE1NDQ3YmM4NzA5YzlkNTViN2JlMGUzXzItNC0xLTEtOTE1MTc_50619b46-429c-4891-9255-49953c3a6fe2">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="id911e0f5ee774c25a778c68614cad378"><ix:continuation id="i8ad71e51abcf46f0b3e5e0f6aa8eb023"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effect of derivative instruments in our consolidated statements of operations for the year ended December 31, 2021 was as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.318%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains reclassified from AOCI into income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752522e455054df9a2d4aa0487c93c8a_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo1NmQzZThlMzI4YTg0ZTE5YmYyYWVmNGE2ZTZlNmQ0YS90YWJsZXJhbmdlOjU2ZDNlOGUzMjhhODRlMTliZjJhZWY0YTZlNmU2ZDRhXzMtNC0xLTEtNzg2NjM_a2190ef5-9d49-4cff-8531-25f6e294f0f8">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40de3a67fca0427cba0abb81a8d5a822_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo1NmQzZThlMzI4YTg0ZTE5YmYyYWVmNGE2ZTZlNmQ0YS90YWJsZXJhbmdlOjU2ZDNlOGUzMjhhODRlMTliZjJhZWY0YTZlNmU2ZDRhXzctNC0xLTEtNzg2NjM_4cd07dea-5ebb-45ec-b6c3-c6e1e8b1b25f">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were immaterial hedging gains and losses for the year ended December 31, 2020 and no hedging gains or losses for the year ended December 31, 2019.</span></div></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90ZXh0cmVnaW9uOjA2M2E3MDViYzM4ODQxMzc5MmM3MTljNDU0MTE1ZjBhXzEzNg_2164e1fb-8fde-40f8-80bc-b792712ebc1e" continuedAt="iad2d8939f102443184bd09f7277380c7" escape="true">Inventory</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iad2d8939f102443184bd09f7277380c7"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90ZXh0cmVnaW9uOjA2M2E3MDViYzM4ODQxMzc5MmM3MTljNDU0MTE1ZjBhXzEzNw_c0ec1902-a6b4-415f-b32c-3d37dd8cc2e9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of December 31, 2021 and 2020 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzItMi0xLTEtNzYwNDY_af4b8ac1-1548-4987-b8b6-3929ad0e7e58">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzItNC0xLTEtNzg3MTI_f0962d7f-692c-4904-a283-a8e6edf6176e">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzMtMi0xLTEtNzYwNDY_c9bbdbd5-f612-4260-99ce-7f2f1db3cac5">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzMtNC0xLTEtNzg3MTI_e1d1f1fa-813b-452f-83be-d7375c79322f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzQtMi0xLTEtNzYwNDY_69f4bbee-ec70-41ff-9aaa-f6047d2f11f3">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzQtNC0xLTEtNzg3MTI_a18d4b97-bf86-468d-b466-8b1ca9fec474">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzUtMi0xLTEtNzYwNDY_a095f4b9-d2bc-4234-a8f7-927b770b0bc9">1,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzUtNC0xLTEtNzg3MTI_ad3d4a53-92f4-48b8-bfca-391b05b081a1">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90ZXh0cmVnaW9uOmQyYmRiMGYxM2NiNzRmNjQ5NmZhNjRlOGM4MjE1OTk4XzIyMw_df5d5876-2724-4d02-b23c-ca3831a69a85" continuedAt="i98db907822e14337a8f5b9b8464302e5" escape="true">Property and Equipment</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i98db907822e14337a8f5b9b8464302e5"><div><ix:continuation id="i89826479fdb74e769a847621a01725ed"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e772279375842a09317b961798ebf1a_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzItMi0xLTEtNzYwNDY_b3a9157d-9357-48f0-b851-8dbc0159dc53">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bd10a6d680840d5be716e5efb005792_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzItNC0xLTEtNzYwNDY_725c8908-f563-471b-bad4-4433e075c3f6">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2897c9b7abc74af58f8fb9170b4279dc_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzMtMi0xLTEtNzYwNDY_04e96cbe-ca0d-461e-9bcb-9d6b1ec84e60">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2277cdd9a1184c06a13b5d2759fc2d43_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzMtNC0xLTEtNzYwNDY_c1e3e840-46c7-452c-bdf4-bcc8d55abf31">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b99b4a3a3f74767a37af24660286fb0_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzQtMi0xLTEtNzYwNDY_7f26ddd9-7047-4b1f-8553-4e3af163399c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabac96aed6194cfe8293e8e6b78f7add_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzQtNC0xLTEtNzYwNDY_9c1256d4-cba1-4e27-b783-a255cedaaa7c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d6bacd287f4b1593818f823e5f7584_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzUtMi0xLTEtNzYwNDY_a607ae73-dc7c-4b48-8bab-9c159714f51d">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie04bbbe54baa412abc405e89a1039ed6_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzUtNC0xLTEtNzYwNDY_0422b21f-e5e9-42ef-bb9b-ab9e33da9744">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if546ef6f1b4b42b7a555f52ec50a3fb8_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzYtMi0xLTEtNzYwNDY_934c8c42-b9f7-4e4a-b9e4-0f99bc90c2fa">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f80f04049942b6a29f789ba29f2842_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzYtNC0xLTEtNzYwNDY_ec165e4c-9ae8-4a1d-9fa3-821c0065f2a0">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c346ed8a6f4ad482321e52eccd7724_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzctMi0xLTEtNzYwNDY_5ce18b10-455f-415d-b90f-fe363f52404f">857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c2998e0814472496ed510917d7a471_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzctNC0xLTEtNzYwNDY_49df3b6c-b10d-4e84-bc64-d879ee99bb58">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcda5455344c4505b3c57aa248aa98ba_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzgtMi0xLTEtNzYwNDY_6f6161d9-c047-429f-ab84-f13b68506c5a">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2e86586b9a43d89a4d752842cfa050_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzgtNC0xLTEtNzYwNDY_d4398793-4c8d-4989-b2f7-cf2a21499b47">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzktMi0xLTEtNzYwNDY_83777a69-ccd4-4220-93ed-2c33cac1bbdb">1,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzktNC0xLTEtNzYwNDY_0f360837-22cc-43b4-9e88-417e25594ed3">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzEwLTItMS0xLTc2MDQ2_e3a0018f-6e69-4b7e-8123-834749cae9db">352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzEwLTQtMS0xLTc2MDQ2_1bf45f71-ee61-4d0f-a776-219958ce9045">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzExLTItMS0xLTc2MDQ2_b83b4c4a-ca54-4b62-9780-e47123e341bc">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzExLTQtMS0xLTc2MDQ2_b4194bba-5c9f-4bf7-a4d5-f99268aac134">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the&#160;years ended December 31, 2021, 2020, and 2019 was $<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90ZXh0cmVnaW9uOmQyYmRiMGYxM2NiNzRmNjQ5NmZhNjRlOGM4MjE1OTk4XzIxOTkwMjMyNTU5NjI_221843dd-3527-4848-9f50-b07ce165f338">232</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90ZXh0cmVnaW9uOmQyYmRiMGYxM2NiNzRmNjQ5NmZhNjRlOGM4MjE1OTk4XzIxOTkwMjMyNTU5NjY_8111b2b2-d5e8-4306-8ba3-ddbdebd89fe4">31</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90ZXh0cmVnaW9uOmQyYmRiMGYxM2NiNzRmNjQ5NmZhNjRlOGM4MjE1OTk4XzIxOTkwMjMyNTU5NzA_e65ece00-15ca-47e5-a853-4234cdd93369">31</ix:nonFraction> million, respectively.</span></div></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_154"></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90ZXh0cmVnaW9uOmQ0MjVjYmRlODBkMDRkODM4ZTQxZDkwMzZmNmFiZjIyXzUzNg_c7918c58-d1a8-40be-b116-5bae1e0a73b9" continuedAt="i9a1c07a8972c4d4d96a1311d9236489a" escape="true">Other Balance Sheet Components</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9a1c07a8972c4d4d96a1311d9236489a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90ZXh0cmVnaW9uOmQ0MjVjYmRlODBkMDRkODM4ZTQxZDkwMzZmNmFiZjIyXzU0MQ_5cce76d4-cac4-472b-bcd6-3215bd6c07b0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments to manufacturing vendors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:OtherPrepaidExpenseManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzItMi0xLTEtNzYwNDY_7adf0077-4982-4f74-b74a-25432e9dceb5">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:OtherPrepaidExpenseManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzItNC0xLTEtNzYwNDY_3fa2d032-390d-42bd-b0c0-62092b5c2d4c">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzMtMi0xLTEtNzYwNDY_b395be33-eaf3-43fd-9cae-687100c474d9">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OtherPrepaidExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzMtNC0xLTEtNzYwNDY_3b6760e8-b09b-44da-95e1-284a5eb372d2">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value added tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzQtMi0xLTEtNzg4MDA_115edf67-bdd0-4105-8c24-608200b2ded0">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzQtNC0xLTEtNzg4MDA_6ed4adbc-ebc3-48bf-a947-7ec1cf66864f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzQtMi0xLTEtNzYwNDY_345aed79-3b29-44e9-b3b0-e135330e28a7">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzQtNC0xLTEtNzYwNDY_5cbde837-c369-45d7-839f-ce8911a3480f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:TenantImprovementAllowanceReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzYtMi0xLTEtMTA5OTkx_c075c513-6976-4bf6-be01-bd37a40b8e91">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:TenantImprovementAllowanceReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzYtNC0xLTEtMTA5OTkx_27ebc16a-f937-4aa7-aca0-3ca3d7b6457f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzUtMi0xLTEtNzYwNDY_f578cd3a-c730-4548-adb8-714150b4e9ff">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzUtNC0xLTEtNzYwNDY_7a340153-5761-43ad-ba76-4c802f849a6d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzYtMi0xLTEtNzYwNDY_7243e552-ce20-481e-ae75-4ea0508a2685">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzYtNC0xLTEtNzYwNDY_82e26f7e-fc83-4c50-80c0-3187b987f0ec">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90ZXh0cmVnaW9uOmQ0MjVjYmRlODBkMDRkODM4ZTQxZDkwMzZmNmFiZjIyXzUzOA_868d2c76-c3c7-45ed-ab02-ade6e6fa1577" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:AccruedClinicalTrials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzItMi0xLTEtNzYwNDY_3791a353-1b7a-46d4-a71e-1617c19a01f1">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:AccruedClinicalTrials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzItNC0xLTEtNzYwNDY_79293e28-a47c-4251-bc25-5e571e70c930">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:RawMaterialsAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzMtMi0xLTEtNzYwNDY_e61bc314-dc8c-4600-a873-9f30e37ea393">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:RawMaterialsAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzMtNC0xLTEtNzYwNDY_a72744ca-7ca1-408f-9189-571c93ee3cd8">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzQtMi0xLTEtNzYwNDY_fb439a38-57de-4226-b64f-4b23a0f84d19">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzQtNC0xLTEtNzYwNDY_f2854525-21a3-4f4c-a898-c1adf9976369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:AccruedDevelopmentOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzUtMi0xLTEtNzYwNDY_c9ad902c-5ca5-419a-b6e3-0d0d2d6c8034">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:AccruedDevelopmentOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzUtNC0xLTEtNzYwNDY_223a963a-e7f7-423a-adc8-93c0a88e7d90">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:AccruedManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzYtMi0xLTEtNzYwNDY_26372f09-dd06-429a-89dd-a56a00437bb5">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:AccruedManufacturing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzYtNC0xLTEtNzYwNDY_5a0e0a76-5f75-45a0-b76b-01d4fc46c69f">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:AccruedOtherExternalGoodsAndServicesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzctMi0xLTEtNzYwNDY_7a367b28-0747-4164-8e38-a27006787159">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:AccruedOtherExternalGoodsAndServicesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzctNC0xLTEtNzYwNDY_8d3087d7-17a8-4668-a5c1-d2a6c35c15ce">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzgtMi0xLTEtNzYwNDY_19e58f78-b174-42e2-b1ed-7b763e500d3a">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzgtNC0xLTEtNzYwNDY_79f7970d-d9b3-42b8-8810-2798086ce733">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzktMi0xLTEtNzYwNDY_37a94ee8-ee5b-4751-a499-8be7113640dc">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzktNC0xLTEtNzYwNDY_050163c2-90fa-460f-a781-517d110d9207">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzEwLTItMS0xLTc2MDQ2_e792301a-990f-46e0-a4bd-55f2ad700976">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzEwLTQtMS0xLTc2MDQ2_12e04fc6-b1d0-4a01-a1ae-a26c3631f456">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90ZXh0cmVnaW9uOmQ0MjVjYmRlODBkMDRkODM4ZTQxZDkwMzZmNmFiZjIyXzU0MA_f4f02264-6711-44e8-af40-a76efc0d78c0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"></td><td style="width:73.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - financing (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzItMi0xLTEtNzYwNDY_6ee362ba-ae17-4b79-94c9-5045a7d84798">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzItNC0xLTEtNzYwNDY_b1c0ce9f-c51b-42cc-820f-59c5ddf0b607">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - operating (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzMtMi0xLTEtNzYwNDY_0276b1e0-2027-47f7-8d41-88678d64e756">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzMtNC0xLTEtNzYwNDY_a98817ad-7358-487f-b760-110de2a7f4c9">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzQtMi0xLTEtNzYwNDY_f53caaeb-e2f9-4be9-8773-e361617b3eec">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzQtNC0xLTEtNzYwNDY_5115c5aa-0a43-4454-99f3-76b28bb9ff46">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzUtMi0xLTEtNzYwNDY_3b018cc6-c380-4da0-9f2f-932ba91b109f">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzUtNC0xLTEtNzYwNDY_3d32e46c-f8a1-482d-bcd3-9406a129ac04">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div></ix:nonNumeric><div><span><br/></span></div><ix:continuation id="i193791964a034a62976f43008ab2831e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue during the year ended December 31, 2021 (in millions): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49f6e27f6284519912ffac03c002a55_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzEtMi0xLTEtNzYwNDY_2264c611-ce8e-4176-b9d0-03207ac93413">3,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0613309ccd7f4770b391e463a962e99b_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzEtNC0xLTEtNzYwNDY_d4bfc64b-03e3-46f0-899c-ce2e32ee6179">11,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0613309ccd7f4770b391e463a962e99b_D20210101-20211231" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzEtNi0xLTEtNzYwNDY_7d70bee0-9e9a-4f3f-8a07-396087d3d30e">8,798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346fef81e10f4f86a929d87bf0cb041b_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzEtOC0xLTEtNzYwNDY_99ce9969-2556-4b74-86eb-e79a946e9a5f">6,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2b742992e44e86ba5d409dbd33d210_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzItMi0xLTEtNzYwNDY_7a55c3cc-df20-4d35-9462-024b35c8f03e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1806b5a0029947c1aabb49f5e058cb28_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzItNC0xLTEtNzYwNDY_45d8d729-767e-4593-bdd5-9eca2e78d3c2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1806b5a0029947c1aabb49f5e058cb28_D20210101-20211231" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzItNi0xLTEtNzYwNDY_e459906a-f9d4-4524-822f-016c321053ba">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39bcf7b2bd641cbbe600df4d3b15b80_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzItOC0xLTEtNzYwNDY_d504d1c6-f7e7-4131-a103-f96a1d3c5662">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id85722b295e94fcc9a11009c7e8f8554_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzMtMi0xLTEtNzYwNDY_6a741c74-d84d-4f1f-afc5-5030e78bd890">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e182cbaac1c44c8aaf481c02d369892_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzMtNC0xLTEtNzYwNDY_794e385f-245c-4a38-b832-3394e95153c5">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e182cbaac1c44c8aaf481c02d369892_D20210101-20211231" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzMtNi0xLTEtNzYwNDY_ccda6433-0a47-4a1a-bda9-2655e825e44d">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b0ad1b467146e3b5880e21ed60e03c_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzMtOC0xLTEtNzYwNDY_cd54521a-70a8-4b04-936d-abacd44adc15">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzQtMi0xLTEtNzYwNDY_95bb3f52-ba87-4c9d-ac4c-24fe6e87603c">4,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzQtNC0xLTEtNzYwNDY_ed9cff79-24f4-4a35-a568-a6014f3ed019">11,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzQtNi0xLTEtNzYwNDY_d07c473d-7d21-4623-83a4-5ac63f3802df">8,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzQtOC0xLTEtNzYwNDY_ed86a6e1-e5fc-4b40-94f6-3eb822993ee5">6,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_157"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNDU_0672f515-5e5a-4fc5-b60b-a3f716dda77a" continuedAt="i17c20e32d12640058a1cbde7f7f511e2" escape="true"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNDc_b2e007c9-30ae-4d69-9374-d309e4eac19a" continuedAt="i4a8004cf442e4775a45139b475d42b49" escape="true">Leases </ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i17c20e32d12640058a1cbde7f7f511e2" continuedAt="i7fc1f36eaec549a291e5fca0ef9e5fa5"><ix:continuation id="i4a8004cf442e4775a45139b475d42b49" continuedAt="ib9c637dfbc0d4287afffaf9dff6b66b4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2042. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have <ix:nonFraction unitRef="numberofcampuses" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="INF" name="mrna:OperatingLeaseNumberOfProperties" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzM3Mg_47fb6a1f-129a-4021-a216-eb3c4870932b">two</ix:nonFraction> campuses in Massachusetts, our Cambridge campus and our Moderna Technology Center (MTC), located in Norwood. We also lease other office and lab spaces globally for our business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cambridge Campus</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy a multi-building campus at Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately <ix:nonFraction unitRef="sqft" contextRef="i055ce861cca24357869370abf095c083_I20211231" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzY4Mw_ca31ab3e-7fab-4dbe-a885-0af45b63ee9f">261,000</ix:nonFraction> square feet. Our Cambridge campus leases have expiry ranges from 2024 to 2029.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we entered into an amendment to our lease agreements to consolidate our Technology Square space in Cambridge, Massachusetts. This included entering into a forward-starting lease agreement starting in January 2020 to acquire approximately <ix:nonFraction unitRef="sqft" contextRef="i7645640582764d538a26db2e1fb80bd0_I20190831" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEwMjI_c5e25e75-6f47-4eae-95b3-e920c68da523">50,000</ix:nonFraction> square feet of additional space at 200 Technology Square. In addition, our existing 200 Technology Square lease was extended for <ix:nonNumeric contextRef="i7645640582764d538a26db2e1fb80bd0_I20190831" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzExNTg_dd77363e-58eb-41c9-8d03-1d4280f4ce61">two years</ix:nonNumeric> to 2029. As part of the lease amendment, we completely exited our leased space of approximately <ix:nonFraction unitRef="sqft" contextRef="i32ea0d8664c84fe1a0db2e016c5ba70b_I20190831" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEyNTc_a43c87d6-9c3d-4a54-ab32-aceccdf6b3da">60,000</ix:nonFraction> square feet at 500 Technology Square by May 2020. We are also investing in a new Moderna Science Center (MSC) in Cambridge, to create a purpose-built space to support our next chapter of discovery (see Note 12). In connection with our MSC investment, in September 2021, we entered into an amendment to our lease agreements to allow for an option for early termination of the leases, either in part or full. Notification of the intent to exercise the option must be provided by August 2023. We have not elected to exercise this option. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record operating lease cost for each of our operating leases on a straight-line basis from lease commencement date through the end of the lease term. Operating lease cost is recorded in operating expenses in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an industrial technology center in Norwood, Massachusetts, our Moderna Technology Center (MTC), which comprises <ix:nonFraction unitRef="numberofbuilding" contextRef="i7589e8c5201244e4985147f06c09e73a_I20211231" decimals="INF" name="mrna:FinanceLeaseNumberOfProperties" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEzNzQzODk1MzYzOTky_01f36754-d8fa-4b32-aa43-a09ebe9bef2d">three</ix:nonFraction> buildings, MTC South, MTC North, and MTC East.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2016, we entered into a lease agreement for approximately&#160;<ix:nonFraction unitRef="sqft" contextRef="i1927cdc0d1694e40a55dd6d90f64c6d1_I20160831" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzI5MjA_bd2e1cee-dd8f-46cd-810a-805261d38830">200,000</ix:nonFraction>&#160;square feet of office, laboratory, and light manufacturing space (MTC South). The lease had an initial expiration of September&#160;2032 with the option to extend the term for&#160;<ix:nonFraction unitRef="numberofextensionperiod" contextRef="i1927cdc0d1694e40a55dd6d90f64c6d1_I20160831" decimals="INF" name="mrna:LesseeOperatingLeaseNumberOfExtension" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzMxMTA_ce19fe4d-7cf3-45a0-99c7-18f88a2a191d">two</ix:nonFraction>&#160;extension periods of&#160;<ix:nonNumeric contextRef="i1927cdc0d1694e40a55dd6d90f64c6d1_I20160831" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzMxMzQ_6960405c-91a6-4ea6-8f3a-5519cf5ebd7f">ten years</ix:nonNumeric>&#160;each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into a lease agreement for office and laboratory space of approximately <ix:nonFraction unitRef="sqft" contextRef="i2855b96dce1e43fb93b06fb655b72372_I20190228" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzE0MjkzNjUxMTcxMzE5_d00c5d7c-1fdc-4965-9f12-1caf4ae63b34">200,000</ix:nonFraction> square feet (MTC North). The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031 with the option to extend the lease for up to <ix:nonFraction unitRef="numberofextensionperiod" contextRef="i2855b96dce1e43fb93b06fb655b72372_I20190228" decimals="INF" name="mrna:LesseeOperatingLeaseNumberOfExtension" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzE0MjkzNjUxMTcxNTI1_a67420fe-b6a9-4936-9cef-607fa282d302">four</ix:nonFraction> additional <ix:nonNumeric contextRef="i2855b96dce1e43fb93b06fb655b72372_I20190228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzMyOTg1MzQ5MDAxMzI_b422570a-402a-4c02-b502-795e64963c1d">five-year</ix:nonNumeric> terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $<ix:nonFraction unitRef="usd" contextRef="i8db7171778ef4c6f97f7530182111044_I20200531" decimals="-6" name="mrna:AllowanceForTenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEzNzQzODk1MzYzOTQ5_0b009a62-e361-489f-be7c-d4dbd27ad248">22</ix:nonFraction>&#160;million to be paid back over the term of the lease with interest and extend the term of the lease to 2035.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into a lease agreement for a <ix:nonFraction unitRef="sqft" contextRef="i9a0fc37d8e2145f98d23f3d4b7ed48a7_I20210430" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzE0MjkzNjUxMTczOTcw_0b0e65e1-de30-4379-9fe4-729cbceb6e91">240,000</ix:nonFraction> square foot building for expansion of our commercial and clinical activities (MTC East). The lease had an initial expiration date of February 2034 with the option to extend the term for <ix:nonFraction unitRef="numberofextensionperiod" contextRef="i9a0fc37d8e2145f98d23f3d4b7ed48a7_I20210430" decimals="INF" name="mrna:LesseeOperatingLeaseNumberOfExtension" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzE0MjkzNjUxMTc0MTcy_da7734fc-2ce4-49ec-8b56-338934dd803c">two</ix:nonFraction> extension periods of <ix:nonNumeric contextRef="i9a0fc37d8e2145f98d23f3d4b7ed48a7_I20210430" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzE0MjkzNjUxMTc0MTk3_c736a429-99a2-48b1-936b-06a1ef737ab0">five years</ix:nonNumeric> each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into an omnibus amendment to extend the lease terms of our <ix:nonFraction unitRef="numberofbuilding" contextRef="i7589e8c5201244e4985147f06c09e73a_I20211231" decimals="INF" name="mrna:FinanceLeaseNumberOfProperties" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzMyOTg1MzQ5MDAxMzM_20bc9517-1ddd-4439-863d-b596abdbf182">three</ix:nonFraction> MTC leases to 2042. We have the option to extend the term for <ix:nonFraction unitRef="numberofextensionperiod" contextRef="i7589e8c5201244e4985147f06c09e73a_I20211231" decimals="INF" name="mrna:LesseeOperatingLeaseNumberOfExtension" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEzNzQzODk1MzYzOTYx_a10601fa-7bec-4493-9ba4-76d89773c65c">three</ix:nonFraction> extension periods of <ix:nonNumeric contextRef="i7589e8c5201244e4985147f06c09e73a_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEzNzQzODk1MzYzOTc1_43f1a471-e379-40f4-8fbf-90bdf0e95a1d">five years</ix:nonNumeric>. The base rent is subject to increases over the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Embedded Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of December 31, 2021 and 2020, we had lease liabilities of $<ix:nonFraction unitRef="usd" contextRef="i3d4877c3015e41fcb264f294807448d8_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzIxOTkwMjMyNjM4NjA_6d915d27-1436-4d9a-8355-0da61e844d47">166</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i637c86f9cdcd4c4696566a2667590b81_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzM0Mzg_4eaeec10-926c-4ad4-b2b2-cdf873b9eac5">24</ix:nonFraction> million, respectively, related to the embedded leases. Certain embedded leases dedicated to our COVID-19 vaccine program prior to the EUA from the FDA were deemed to have no alternative use. The related right-of-use assets of $<ix:nonFraction unitRef="usd" contextRef="i637c86f9cdcd4c4696566a2667590b81_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzM2NDQ_2f40c260-ae11-4cd7-ad91-4784faf17c6e">62</ix:nonFraction> million were charged to research and development expense for the year ended December 31, 2020.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i7fc1f36eaec549a291e5fca0ef9e5fa5" continuedAt="ia9302165d5f543b9b11cba83cc736f69"><ix:continuation id="ib9c637dfbc0d4287afffaf9dff6b66b4" continuedAt="i5503dfc072a94a598abcda6041dff68d"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNDY_5e3ac407-395a-4b7c-8592-e107a592a96d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2021 and 2020 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzMtMi0xLTEtNzYwNDY_dfbab9c8-06ff-4e81-96f8-526e3ed80a1c">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzMtNC0xLTEtNzYwNDY_71549f95-f8c6-4594-938b-353c135bc35d">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_6434c373-a6c6-4f7b-8ef6-3d80253a9ae7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_762aa615-9010-420a-8e46-65bbadd6aae4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMi0xLTEtNzYwNDY_bcaecf54-f29b-4141-a349-29e99f49c06c">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtNC0xLTEtNzYwNDY_1b9eab71-8220-44ec-abbc-1e5f9e2b43f7">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:OperatingAndFinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzUtMi0xLTEtNzYwNDY_fa0b7ee9-79dd-4da9-b184-b2f83a77ee0f">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzUtNC0xLTEtNzYwNDY_826b53a9-cf2e-477e-b820-4ad533224d77">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_51501eb6-f175-4107-9a50-9a2a310ec651"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_b87ed32e-1ce9-4db8-a202-ed428939aa44"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMi0xLTEtNzYwNDY_98a7912c-c0c7-4161-89ab-31833bdd9677">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktNC0xLTEtNzYwNDY_84e70952-a5fe-4ff8-ac38-41cc2ebda204">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_7ec179f5-0fc3-4708-bddf-316daed00725"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_859dcb73-429c-4521-9717-2a4efe10e6f1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTItMS0xLTc2MDQ2_2cd2a922-dfbd-4157-8619-ed17c4fb4046">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTQtMS0xLTc2MDQ2_b7f20ebe-219a-433d-8c41-549826577a24">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzExLTItMS0xLTc2MDQ2_dd5e3362-e179-4378-a6f9-1910812c13bb">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzExLTQtMS0xLTc2MDQ2_f8fe7219-3a6e-425c-90b3-bb0c34e04d3f">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEzLTItMS0xLTc2MDQ2_acf00b0e-318d-4f95-821f-2ac90a8900a3">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEzLTQtMS0xLTc2MDQ2_85714587-1c5c-46c9-8c23-5df22959e405">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE0LTItMS0xLTc2MDQ2_a1fe9de3-2a02-4d28-b0c9-bd9eb2365f8d">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE0LTQtMS0xLTc2MDQ2_aeaf4abd-603b-48d0-b2fb-75161a0e8d56">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE1LTItMS0xLTc2MDQ2_bbe00b5f-24d4-45a5-8f26-91dc73393e35">705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE1LTQtMS0xLTc2MDQ2_d8afdffe-e034-4962-b873-b702f3e48a11">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE2LTItMS0xLTc2MDQ2_b3ea3abe-eaa5-47f1-ba9b-0f6774289dc6">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:OperatingAndFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE2LTQtMS0xLTc2MDQ2_2bd2ed0a-3b2c-4f22-b3e1-5c50cd701f5d">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated amortization. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the consolidated balance sheets.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNTQ_fc08dba2-99b3-444b-8c6e-a40dffbc8e30" continuedAt="i385ecc900d8541e8b0c5ea5565383263" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease costs for the years ended December 31, 2021 and 2020 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzItMi0xLTEtNzYwNDY_6a8b5bee-5451-4afa-98dc-2b273b125715">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzItNC0xLTEtNzYwNDY_3a74efd1-c003-4d4e-9c14-132e79d229c8">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzQtMi0xLTEtNzYwNDY_c332ce07-78d5-4b9e-8061-076c689a20c1">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzQtNC0xLTEtNzYwNDY_88732e29-48e8-4034-bc7b-e67047f359b7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzUtMi0xLTEtNzYwNDY_0d68093f-f9ee-4e0b-9e1e-bbb29ad7cb05">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzUtNC0xLTEtNzYwNDY_4bd6b113-8597-4456-9d05-6fd9004deb82">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="mrna:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzYtMi0xLTEtNzYwNDY_139b5735-ee33-454b-94aa-c806f758f389">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="mrna:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzYtNC0xLTEtNzYwNDY_82c061e7-23f8-4d25-b50d-ce8072a788e9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzctMi0xLTEtNzYwNDY_50d8ff5d-2b03-493d-b11a-bae2a60d1322">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:ShortTermLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzctNC0xLTEtNzYwNDY_4b3b9bab-3dc8-456f-9f49-0725a96c7749">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzgtMi0xLTEtNzYwNDY_8dc2c4ae-3155-4200-ae46-93e366904821">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzgtNC0xLTEtNzYwNDY_8394afc8-35ad-48e2-ac60-40c4422dbe04">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ia9302165d5f543b9b11cba83cc736f69" continuedAt="i186ccb38ff7b4bb0959ccc8b681893bf"><ix:continuation id="i5503dfc072a94a598abcda6041dff68d" continuedAt="i8d431c993ba349bb864f03b052f38f9d"><ix:continuation id="i385ecc900d8541e8b0c5ea5565383263"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information relating to our leases for the years ended December 31, 2021 and 2020 was as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzMtMi0xLTEtNzYwNDY_3586dff5-182a-4cbb-aed9-08e750f37b0e">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzMtNC0xLTEtNzYwNDY_39d6739d-687b-4a2b-a770-ba97b0549c3a">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzQtMi0xLTEtNzYwNDY_3df2ab18-30cf-4d98-9417-24d8a6c317a1">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzQtNC0xLTEtNzYwNDY_75e964ba-ef03-4ae3-b605-874d626249f6">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Financing cash flows used in financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzUtMi0xLTEtNzYwNDY_56e945bf-3bf8-48a3-aa8e-1a0b2bad45d6">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzUtNC0xLTEtNzYwNDY_9c7e6074-aaf1-4c52-a7e8-7241d0ae482a">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzgtMi0xLTEtNzYwNDY_3b30d0d1-b3b3-4e01-a0e4-47c1cfc6b96e">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzgtNC0xLTEtNzYwNDY_e945e392-c8d2-4109-a6d7-48e16d890489">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzktMi0xLTEtNzYwNDY_abf12e6f-7bd9-4ab3-ac2c-d3164eb36686">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzktNC0xLTEtNzYwNDY_496f0e14-2961-436e-8d35-71690e754e3f">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEyLTItMS0xLTc2MDQ2_15ad9bfe-46ef-4bcd-bef5-2a26c4a42a37">674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEyLTQtMS0xLTc2MDQ2_2a58d46b-38a4-44ee-83d5-9ad5f3f5fa69">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEzLTItMS0xLTk0NzMx_db4e8ad0-f8b6-49e9-b40f-978ec9a25b43">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEzLTQtMS0xLTk0NzMx_31394e4b-0e52-4bfb-a4a2-88f9cf25676a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="mrna:LesseeFinanceLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEzLTItMS0xLTc2MDQ2_9e348b5d-3d52-4fda-9dfe-c6f7c6ecdfb0">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="mrna:LesseeFinanceLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEzLTQtMS0xLTc2MDQ2_6d1e4ba0-1c25-40ad-ab8c-067b64eff089">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates as of December 31, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo5ZThlNTY0NTUyYTg0N2QyYTY5ZjRhZDllZGFmMDQwOC90YWJsZXJhbmdlOjllOGU1NjQ1NTJhODQ3ZDJhNjlmNGFkOWVkYWYwNDA4XzMtMi0xLTEtNzYwNDY_6f631c49-ffc5-4db8-af2b-3d4aeccad8f6">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo5ZThlNTY0NTUyYTg0N2QyYTY5ZjRhZDllZGFmMDQwOC90YWJsZXJhbmdlOjllOGU1NjQ1NTJhODQ3ZDJhNjlmNGFkOWVkYWYwNDA4XzQtMi0xLTEtNzYwNDY_df79d454-1924-417c-8fbe-bc23166e8604">28</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo5ZThlNTY0NTUyYTg0N2QyYTY5ZjRhZDllZGFmMDQwOC90YWJsZXJhbmdlOjllOGU1NjQ1NTJhODQ3ZDJhNjlmNGFkOWVkYWYwNDA4XzYtMi0xLTEtNzYwNDY_86253a60-582e-445c-8016-1807e1a00195">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo5ZThlNTY0NTUyYTg0N2QyYTY5ZjRhZDllZGFmMDQwOC90YWJsZXJhbmdlOjllOGU1NjQ1NTJhODQ3ZDJhNjlmNGFkOWVkYWYwNDA4XzctMi0xLTEtNzYwNDY_8357e99a-21d0-4ca0-8fe5-6be8107b8a3a">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNDk_8c107cff-6e69-4f73-a8a2-18d9a4f687ba" continuedAt="iadc8593cc0544cf0ba179883839705ff" escape="true"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNTA_c51a718c-1024-4c42-84b4-8b7cf23a46a4" continuedAt="ib63f90680ad742cc83f45f69108d4964" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2021, were as follows (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzEtMi0xLTEtNzYwNDY_3097a728-7e1e-4c36-9e4f-bc88932f7c0c">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzEtNC0xLTEtNzYwNDY_c801bb2b-6148-4ec1-94c2-c6b32b30936d">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzItMi0xLTEtNzYwNDY_59ffeac8-b049-4cda-b78e-504e9fafcea9">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzItNC0xLTEtNzYwNDY_bb82db8d-a7b5-45fd-8970-0962db64d563">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzMtMi0xLTEtNzYwNDY_ef136a34-9447-4933-94b3-25cc2bce4798">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzMtNC0xLTEtNzYwNDY_bd4e6709-56d4-46db-a783-2385db227d76">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzQtMi0xLTEtNzYwNDY_093fe3c7-69ec-4a44-8db8-d28076abe676">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzQtNC0xLTEtNzYwNDY_03e28979-a8ee-427b-9e83-9e7cc0a9b2e1">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzUtMi0xLTEtNzYwNDY_f9ffd4ae-ddd3-44f9-a67a-4df9a24b7336">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzUtNC0xLTEtNzYwNDY_f3665cec-9ca2-4ec4-94a6-ddbc28e329e8">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzYtMi0xLTEtNzYwNDY_9a4acf40-dae0-488c-b977-a8b2b9075536">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzYtNC0xLTEtNzYwNDY_d5b3bc30-fc52-4a64-9aee-515e5aa41da6">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzctMi0xLTEtNzYwNDY_7342f11c-6f4b-482f-b09a-34bd48dd9c50">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzctNC0xLTEtNzYwNDY_48a99da1-1390-4d76-944f-7dd36863abb2">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzgtMi0xLTEtNzYwNDY_dd240443-64c5-4b6b-932a-6822fa45ec59">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzgtNC0xLTEtNzYwNDY_8b04c0e7-48a9-4c2c-aaa6-63008948655e">559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzktMi0xLTEtNzYwNDY_e61c259d-b579-4e39-88f8-d15837cf7f01">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzktNC0xLTEtNzYwNDY_450f42fc-d420-4e72-b39a-44fcdb2d28a4">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i186ccb38ff7b4bb0959ccc8b681893bf" continuedAt="i8ac9983fb8bb42528960a8df408727d0"><ix:continuation id="i8d431c993ba349bb864f03b052f38f9d" continuedAt="i19c6945e7ae74eb0b22847a384e5743f"><ix:continuation id="iadc8593cc0544cf0ba179883839705ff" continuedAt="ib71bc0d6dd204dffab39e9607bfc0c07"><ix:continuation id="ib63f90680ad742cc83f45f69108d4964" continuedAt="ief715d67cc534e68b32cf561031eab55">(1)  </ix:continuation></ix:continuation></ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8ac9983fb8bb42528960a8df408727d0"><ix:continuation id="i19c6945e7ae74eb0b22847a384e5743f"><ix:continuation id="ib71bc0d6dd204dffab39e9607bfc0c07"><ix:continuation id="ief715d67cc534e68b32cf561031eab55">Include the optional extensions in the MTC lease terms which represent a total of $<ix:nonFraction unitRef="usd" contextRef="i5f976ec484ae4420800a7fe5ea5fc4eb_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzQ5NjQ_b3e3dacc-4c2e-4f9f-98a7-686fe5a7bec0">637</ix:nonFraction> million undiscounted future lease payments.</ix:continuation></ix:continuation></ix:continuation></ix:continuation> </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_163"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzYxOTg_33536f83-6175-4261-a597-cdb9c8b63cd2" continuedAt="i8a0b2794f1e146d38909d935167ae5d4" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8a0b2794f1e146d38909d935167ae5d4" continuedAt="ie859e3207703401da2833d751f5da1b5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2021 and 2020, we had <ix:nonFraction unitRef="usd" contextRef="iffb8aaeb04f94a9091ac85eb8f851b96_D20210101-20211231" decimals="INF" name="us-gaap:LossContingencyLossInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzE4MTY_12614902-5569-479e-b40e-49c33bf131b6"><ix:nonFraction unitRef="usd" contextRef="i76f6a7263a5e4d65a40dd2d77b9fe3d2_D20200101-20201231" decimals="INF" name="us-gaap:LossContingencyLossInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzE4MTY_d7eb1dbf-f7c9-4702-8ebb-470d2387d7c0">no</ix:nonFraction></ix:nonFraction>t experienced any losses related to these indemnification obligations, and <ix:nonFraction unitRef="claim" contextRef="i8894beaec40b4471a73954ee11728b2a_I20201231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzE4OTM_192cbf29-0f6a-4a27-83ff-c9d57c0b8759"><ix:nonFraction unitRef="claim" contextRef="i56f7cbe6568c4de9ac2033f8024b12fd_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzE4OTM_415f22c6-0221-4e78-8d6a-b6856960cabc">no</ix:nonFraction></ix:nonFraction> material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and <ix:nonFraction unitRef="usd" contextRef="i56f7cbe6568c4de9ac2033f8024b12fd_I20211231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxMDA_125b77ad-06bf-45ad-a3ad-0f6fabe546a0"><ix:nonFraction unitRef="usd" contextRef="i8894beaec40b4471a73954ee11728b2a_I20201231" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxMDA_d7f70723-e4a8-4740-b215-c1669f9eaf38">no</ix:nonFraction></ix:nonFraction> related reserves were established.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments and Purchase Orders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of December 31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i9a8002ec753b4dc689c48b5e0785b43d_I20211231" decimals="-7" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzMwODk_f5f5a3cb-a3ac-4de5-97f6-7c4c709ba10d">2.5</ix:nonFraction>&#160;billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2025. As of December 31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="iab85f119dfbd439fab288fd3b899104e_I20211231" decimals="-6" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzMyNzg_b2997604-42e9-467e-af87-98688121d299">89</ix:nonFraction>&#160;million of non-cancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2026. These amounts represent our minimum contractual obligations, including termination fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At December 31, 2021, we had cancelable open purchase orders of $<ix:nonFraction unitRef="usd" contextRef="i9c5a2128addc490e9ec198b28f43e879_I20211231" decimals="-6" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzQxNDY_985e851e-c91a-4fc7-83c1-68b731c38a2e">2.4</ix:nonFraction> billion in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December 31, 2021, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licenses to Patented Technology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;26, 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments, up to $<ix:nonFraction unitRef="usd" contextRef="ie0c48f0326424b03a643d8d35796a371_I20170626" decimals="-6" name="mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzU0Mzc_fc2e9610-2e28-4cc6-ba72-1adf7972d7b7">24</ix:nonFraction>&#160;million, and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related product sales in the period in which the corresponding sales occur. In 2021 and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxOTkwMjMyNjI3MTg_f97f9666-3683-488e-b09e-82fc3beb3f76">641</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzU4NTI_22fdb4c2-e1b3-4903-abd7-0bacaf18ab58">7</ix:nonFraction>&#160;million, respectively, of royalties and commercial milestone payments associated with our product sales, which was recorded to cost of sales in our consolidated statements of operations. We did not recognize any such royalties and payments in 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones was not deemed probable as of December 31, 2021. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="ie859e3207703401da2833d751f5da1b5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Moderna Science Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we announced an investment in the development of the MSC in Cambridge, Massachusetts. The MSC is expected to integrate scientific and non-scientific spaces, including our principal executive offices, and will be built to support our growth as we continue to advance our pipeline of mRNA medicines. In relation to the investment, we entered into a lease agreement for approximately <ix:nonFraction unitRef="sqft" contextRef="i702c1ca981884658b2caf34f2b288da1_I20210930" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxOTkwMjMyNjI3ODM_4e2a2fe8-1393-46df-86ef-19f73e087f1f">462,000</ix:nonFraction> square feet and will undergo an approximately <ix:nonNumeric contextRef="i5a37b17b04c0478ca390d371241ee5bd_D20210901-20210930" name="mrna:LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzMyOTg1MzQ4OTA4NzE_59f1cbfc-b264-43f4-9cdd-d22382a33fe5">two-year</ix:nonNumeric> building project. Following completion of the building project, the lease term is <ix:nonNumeric contextRef="i702c1ca981884658b2caf34f2b288da1_I20210930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxOTkwMjMyNjI4MDY_02c5df10-0111-409f-964d-6c6b2d6b9bfd">15</ix:nonNumeric> years, subject to our right to extend the lease for up to <ix:nonFraction unitRef="numberofoption" contextRef="i702c1ca981884658b2caf34f2b288da1_I20210930" decimals="INF" name="mrna:LesseeOperatingLeaseNumberOfExtensionPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxOTkwMjMyNjI4MTM_f6f1c484-5e0d-42cf-a826-e858a4a81c82">two</ix:nonFraction> additional <ix:nonNumeric contextRef="i702c1ca981884658b2caf34f2b288da1_I20210930" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzkzNDU4NDg4NDM0ODA_5b857117-597b-483e-823f-d1f32018e1c0">seven-year</ix:nonNumeric> terms. Pursuant to this lease agreement, we are committed to approximately $<ix:nonFraction unitRef="usd" contextRef="i702c1ca981884658b2caf34f2b288da1_I20210930" decimals="-8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxOTkwMjMyNjI4MzU_cabea788-f0a9-4c37-a9cc-db35d43b1b7b">1.1</ix:nonFraction>&#160;billion non-cancellable rent payments for the initial lease term. We expect to begin a phased move-in process in 2023.</span></div></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE3ODI_a716fe69-21f2-4bae-913e-a840ae1c0759" continuedAt="i3ef52b570dd648889472dae906506d79" escape="true">Stockholders' Equity </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3ef52b570dd648889472dae906506d79"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2020, we sold <ix:nonFraction unitRef="shares" contextRef="ib474a3e36bd94fa88daf43e69617dc76_D20200214-20200214" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzExMzQ_15113e36-ce40-4e66-b25c-6898621e7b93">26,315,790</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iac2c5503ed074a74bea898aac8577dab_I20200214" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzExNzQ_cd3124f6-3508-4f7a-a732-5f97abcda92f">19.00</ix:nonFraction> per share through a public equity offering. The aggregate net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="ib474a3e36bd94fa88daf43e69617dc76_D20200214-20200214" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzEyNzE_8f411328-5b0d-4260-8445-e2f3f6d846b0">478</ix:nonFraction> million, net of underwriting discounts, commissions and offering expenses. In addition, the underwriters exercised their options to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i5bba9fe2096647189405dc333c365807_D20200214-20200214" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE0MjE_245b00bf-8b7d-4111-bcf4-a3e45f388092">3,947,368</ix:nonFraction> shares of common stock at the public offering price less underwriting discounts, resulting in additional net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5bba9fe2096647189405dc333c365807_D20200214-20200214" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE1NDU_10249678-4f14-4801-8bdb-03c9986419b8">72</ix:nonFraction> million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2020, we sold <ix:nonFraction unitRef="shares" contextRef="i3b3e6c8e3e284a9b9957554efffd342a_D20200521-20200521" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE1NzU_d6e6c051-07fa-4bf7-b246-cf2c61ca7883">17,600,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iafab97ea8a1846b8ae7fd38f70f3ec7a_I20200521" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE2MTU_35103348-9b89-4ad9-adb8-9d92fd8df4c6">76.00</ix:nonFraction> per share through a public equity offering. The aggregate net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="i3b3e6c8e3e284a9b9957554efffd342a_D20200521-20200521" decimals="-8" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE3MTI_60d8c189-1511-4747-b6ed-fc1e6165ca5e">1.3</ix:nonFraction>&#160;billion, net of underwriting discounts, commissions and offering expenses.</span></div></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNDc_1570d4d0-1bdc-4a0a-b22b-a0f56c6fa4f5" continuedAt="idcf24398310b4cffb9621827e87d8e1b" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idcf24398310b4cffb9621827e87d8e1b" continuedAt="ic19617e29c84487ab525fe669fd1a0a1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2016, we adopted the 2016 Stock Option and Grant Plan (the 2016 Equity Plan), which replaced the 2013 Option Plan and the 2013 Incentive Plan. The 2016 Equity Plan and provided for the grant of incentive stock options, non-qualified stock options, restricted stock, unrestricted stock, and restricted stock units to our employees, officers, directors, consultants, and other key persons.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with our initial public offering (IPO), we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Plan. The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. The 2018 Equity Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2019, by <ix:nonFraction unitRef="number" contextRef="i29fd9baa1fce4c82bab97fdcf69983b9_D20181130-20181130" decimals="INF" name="mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzE2MjU_5fe1647f-aa6a-4bd6-b26c-2f084859f6b8">4</ix:nonFraction>% of the outstanding number of shares of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Compensation and Talent Committee of our Board of Directors. The Compensation and Talent Committee chose not to increase the number of shares available under the 2018 Plan on January 1, 2021 or January 1, 2022. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a <ix:nonNumeric contextRef="i4e3a57dbc43247cdbe91ca5c7ee5a665_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNTA_f73c6656-ab49-4f9b-aa7a-76cb22b81178">four-year</ix:nonNumeric> period, with the first <ix:nonFraction unitRef="number" contextRef="i7adfa26ae60741ce90e3942463436967_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI2MzU_5b0c3b2a-6eab-4967-a4fd-67969c86fb09">25</ix:nonFraction>% of such awards vesting following <ix:nonNumeric contextRef="i7adfa26ae60741ce90e3942463436967_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI2NzE_00114cd7-32df-46e5-8353-5935f02e7ec5">twelve months</ix:nonNumeric> of continued employment or service. The remaining awards vests in <ix:nonFraction unitRef="installment" contextRef="i8c119cd5946c40fabe6b12e425327e13_D20210101-20211231" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI3NDA_8134a7c4-ffe3-43f1-8e23-9827d88c6552">twelve</ix:nonFraction> quarterly installments over the following twelve quarters. Stock options granted under the 2018 Equity Plan and the 2016 Equity Plan expire <ix:nonNumeric contextRef="i6cdf60b6c2d84337b9adeb0d5572d319_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI4NTg_893a5e8b-026c-475e-bd7b-7e4c5a5e577a">ten years</ix:nonNumeric> from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December 31, 2021, we had a total of&#160;<ix:nonFraction unitRef="shares" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzMwMTk_7bb6078c-eeb5-4e81-9781-c48e234907c8">57</ix:nonFraction> million shares reserved for future issuance under our Equity Plans, of which <ix:nonFraction unitRef="shares" contextRef="ic4c1fa50b9414740995b3595ceb68c2d_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzMwOTE_40e736a0-20a2-448e-a704-2ad6f481bdca">30</ix:nonFraction> million shares were reserved for equity awards previously granted, and&#160;<ix:nonFraction unitRef="shares" contextRef="i66e84b53db4044d0b673a4ca8b8e75e9_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzMxNTc_cea84d51-5217-49b9-8c7d-f94e7c6a06aa">27</ix:nonFraction> million shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ic19617e29c84487ab525fe669fd1a0a1" continuedAt="i18c983cf82fe49d2bf5232f1e80859f2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNDk_a42113a7-3cdb-4fe2-a11c-99bcf809c981" continuedAt="idfdff637e51043dc84e6a627a7a987d6" escape="true">The following table summarizes our option activity as of December 31, 2021 and 2020:</ix:nonNumeric></span><ix:continuation id="idfdff637e51043dc84e6a627a7a987d6" continuedAt="i69c8c557cf6d4f9287091ab6ada02938"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzEtMi0xLTEtNzYwNDY_e505eead-18e5-47b6-bb1b-96d8d372a018">34.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzEtNC0xLTEtNzYwNDY_553bbbc7-9324-4eb7-9ec7-582aeb40f6d5">17.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzEtOC0xLTEtNzYwNDY_039241e7-7765-412b-b6ad-ceaf6717b62c">6.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzEtMTAtMS0xLTc2MDQ2_29c988df-d5e6-4d43-af83-25f5b35ade24">2,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzItMi0xLTEtNzYwNDY_704a4db2-3f26-4c94-8f32-d2243fd22956">1.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzItNC0xLTEtNzYwNDY_397787e2-8945-4cab-8e14-1d1741e2fdfb">209.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzMtMi0xLTEtNzYwNDY_2654efab-37af-4b4e-8971-47194db5aa54">7.07</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzMtNC0xLTEtNzYwNDY_a6b7334d-ae2e-4fe3-ab39-79edf215c363">15.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzQtMi0xLTEtNzYwNDY_b179a7e2-275b-4595-8c4a-cc629c9d693e">1.06</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzQtNC0xLTEtNzYwNDY_b5b25985-5b44-4389-9c03-9b38b53ce812">37.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzUtMi0xLTEtNzYwNDY_5aed8834-4081-4d88-a7d4-8fe30eae0468">27.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzUtNC0xLTEtNzYwNDY_46023f82-1203-4de4-83ec-918596db7e22">27.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzUtOC0xLTEtNzYwNDY_2777de27-ddb7-4a67-99af-19f13bbf5726">5.8</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzUtMTAtMS0xLTc2MDQ2_d73465c8-6aca-4e42-b1bd-543714ca1d2c">6,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzYtMi0xLTEtNzYwNDY_df10b1f8-2072-4b01-974e-fd5ecc62f2a9">17.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzYtNC0xLTEtNzYwNDY_9b141b7d-3436-4c10-8e17-37d42a8bd949">13.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzYtOC0xLTEtNzYwNDY_71d60f60-b4e0-428b-943a-64ede6147da5">4.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzYtMTAtMS0xLTc2MDQ2_9e712d97-9ae6-4776-8247-e599ac8a80a7">4,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzctMi0xLTEtNzYwNDY_88546c64-b809-4fc2-9580-754d44ce272c">10.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzctNC0xLTEtNzYwNDY_3e8c3bb1-6500-4578-a894-ee1f0c73d6e9">50.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzctOC0xLTEtNzYwNDY_e6cac3d6-07c0-42fb-8119-549058ccc5fd">7.5</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzctMTAtMS0xLTc2MDQ2_2a0a1ae2-e16c-4b82-b75a-09219528248b">2,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><ix:continuation id="i69c8c557cf6d4f9287091ab6ada02938"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2021.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzM3NjQ_00329048-9005-47c6-a551-aa32aac87393">1.6</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzM3Njg_79c6ad4f-3c2e-47b2-9590-aeb040ff96d8">786</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzM3NzU_6290e716-aa6c-4eda-ae75-e801d688c44c">76</ix:nonFraction> million for the&#160;years ended December 31, 2021, 2020, and 2019, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The excess tax benefits realized from tax deductions from option exercises were $<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTk1MDY_1e9c6a8e-e89a-48c3-968c-4471124187bf">325</ix:nonFraction>&#160;million during the year ended December 31, 2021. For the years ended December 31, 2020 and 2019, there were <ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTk1MTk_771da7d8-80e7-43a3-a84e-9352691387dc"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTk1MTk_df725322-6714-4328-91a6-6b8e440a9fbf">no</ix:nonFraction></ix:nonFraction> excess tax benefits realized from tax deductions from option exercises due to cumulative losses and valuation allowances. The total consideration recorded as a result of stock option exercises&#160;was approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQxMDI_38ea6d47-005e-4b2d-8423-2593412098b5">112</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzE2NDkyNjc0NjA0OTQ_9263eb77-9530-4cbf-9256-51e25515b086">179</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzE2NDkyNjc0NjA1MjM_d25adbd2-5a57-4667-b292-458ad8f74a78">48</ix:nonFraction>&#160;million&#160;for&#160;the years ended December 31, 2021, 2020, and 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted RSUs and PSUs generally through the 2018 Equity Plan. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNTE_f3fa030e-45e1-4fb0-8824-c8f4a426622c" continuedAt="icd657a06f5b74ddbbfdad2f6f8f244b3" escape="true">The following table summarizes our RSU and PSU activity during the year ended December 31, 2021:</ix:nonNumeric></span><ix:continuation id="icd657a06f5b74ddbbfdad2f6f8f244b3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:72.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.836%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value per Unit</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0c500d4ffa344d5a5b3ceec87c24f6f_I20201231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzEtMS0xLTEtNzYwNDY_c9356543-ea14-4612-966a-5ad81b07a9b6">2.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if0c500d4ffa344d5a5b3ceec87c24f6f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzEtMy0xLTEtNzYwNDY_87c34461-6736-45d2-9c54-08824912a799">30.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzItMS0xLTEtNzYwNDY_5da29b57-e8f1-436a-a222-f47a0f2553e7">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzItMy0xLTEtNzYwNDY_c0afe0c4-78e5-4069-a05a-cd0ce0522c2c">210.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzMtMS0xLTEtNzYwNDY_6e58ec09-4527-4862-9bb7-f59da4aa90e2">0.60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzMtMy0xLTEtNzYwNDY_4b920bbd-fbde-48e7-9c13-429ab53a6083">29.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzQtMS0xLTEtNzYwNDY_310f0947-1408-4169-a97e-ad3434787911">0.16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzQtMy0xLTEtNzYwNDY_ab0e6af4-c084-40fc-ac7a-803d3d6124e9">63.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic31e779ca3ac441093747539d1c451db_I20211231" decimals="-4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzUtMS0xLTEtNzYwNDY_620a1d8b-ee60-4a9a-b840-8c032ae04f90">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic31e779ca3ac441093747539d1c451db_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzUtMy0xLTEtNzYwNDY_84d395d2-19ec-442e-8945-628dd4aa774b">88.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs and PSUs vested during the years ended December 31, 2021, 2020, and 2019, was $<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:RestrictedStockExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQ0NTc_8a085e5b-170e-4c4e-a2e5-2247af47b95a">18</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:RestrictedStockExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQ0NjE_b8e091c3-3a13-4d2c-b2ed-dea23f5cb7c8">5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:RestrictedStockExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzIxOTkwMjMyNjMyNTg_b8f9434c-5381-4cf0-9476-7a5dcc41163d">5</ix:nonFraction> million, respectively. The total intrinsic value of RSUs and PSUs vested during the years ended December 31, 2021, 2020, and 2019, was $<ix:nonFraction unitRef="usd" contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTM3NzY_7f6b037c-330e-408e-8929-5fa635d3f894">141</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i1a97483f7a5746248dc20f25d9484066_D20200101-20201231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTM3OTA_fdae9401-7291-406a-858c-1e9f2a67a6c4">14</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if2310d5f67f14a5da16abed435202898_D20190101-20191231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTM4MDM_ca3ad001-2d43-4611-9e9f-07f95d3560c4">12</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, we granted an immaterial amount of PSUs to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally <ix:nonNumeric contextRef="i0dbb9beedbe644dc8350ed2167afbe18_D20210101-20210331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzEzNzQzODk1MzY0Mjgz_ba50bd5e-a899-4012-a532-7ec4502a8b69">three years</ix:nonNumeric>. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from <ix:nonFraction unitRef="number" contextRef="i728418fd03a840ca854699e0501666c2_I20210331" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NDY4OTE_5b3b4cb8-d1e4-4e61-9e48-f624d28cf326">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i85e548fb17de479e8f1eaedbedd14aeb_I20210331" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NDY4OTU_1b664930-df71-45ef-a39d-a09420a2e031">200</ix:nonFraction>%. The estimated fair value of PSUs is based on the grant date fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we adopted the 2018 Employee Stock Purchase Plan (ESPP), which became effective on December 5, 2018. We will make <ix:nonFraction unitRef="offering" contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQ3ODk_358ea4f8-f477-4068-902e-193bfe5cab62">one</ix:nonFraction> or more offerings, consisting of <ix:nonFraction unitRef="purchase_period" contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205" decimals="INF" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQ4MjU_f74e479d-ed00-4dd6-b6ff-cee1f5bc8972">one</ix:nonFraction> or more purchase periods, each year to our eligible employees to purchase shares under the ESPP. Offerings will usually begin every <ix:nonNumeric contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQ5NTE_3ac294ef-e7ee-4208-b269-827bf28d13c5">six months</ix:nonNumeric> and will continue for <ix:nonNumeric contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNTY_297d7aab-a9ab-44b6-a355-e230456c55d2">six-month</ix:nonNumeric> periods, referred to as offering periods. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i18c983cf82fe49d2bf5232f1e80859f2" continuedAt="i9527bea0d68d4b94b6429a4d75a22b34"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price at which shares are sold under the ESPP will be equal to <ix:nonFraction unitRef="number" contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzUxMDM_0de7f8a6-affe-4478-8763-39a776e03dfa">85</ix:nonFraction>% of the lower of the fair market value of the shares on the first business day of the offering period or the last business day of the purchase period. Employees are generally eligible to participate through payroll deductions of between <ix:nonFraction unitRef="number" contextRef="ia96eb4bd96214dbfb1546494df278d66_I20181205" decimals="INF" name="mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzUzNDI_4b0f7a23-de6a-4974-9695-3d54215cb463">1</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia96eb4bd96214dbfb1546494df278d66_I20181205" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzUzNDg_3ba7855b-9c97-4bc3-ba83-16b8b1d45d7b">50</ix:nonFraction>% of their compensation and may not purchase more than <ix:nonFraction unitRef="shares" contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzU0MDQ_f0af4e8b-b9b6-4298-ba83-291d48cf9492">3,000</ix:nonFraction> shares of common stock during each purchase period or&#160;$<ix:nonFraction unitRef="usd" contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205" decimals="-3" name="mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzU0NjE_14ab25e0-f4b9-42c8-bcfb-3fc8daef33a1">25,000</ix:nonFraction>&#160;worth of shares of common stock in any calendar year.&#160;We began our first ESPP offering on June 1, 2019. There were <ix:nonFraction unitRef="shares" contextRef="iccabe9fdd0d4459f83f43bcfe311abbb_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTMwMjM_6beaf403-3e10-4a92-9905-4ec62aed6c36">81,423</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="ia86a82d3b3da4738b05c1a1dc2acb3c6_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzU1Nzk_080f2a80-456e-4b93-bc77-e199f7479e92">251,752</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i90b4231be4ae495b8c891156606a39ab_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI3NDg3NzkwODgzMTU_a72eff4b-6102-478b-88fa-7ae59eefe755">171,343</ix:nonFraction> shares of common stock sold at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic846063843c2457783476d4cac1401a9_I20211231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTMwMjQ_7cee686a-276d-403f-99ee-950b6fb6c609">145.90</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7050aa6851454a26bb85c8a452709530_I20201231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzU2NDE_9771966f-6a7d-406f-b266-258725a9f501">27.97</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="ib15360143cb64fe7abcc9084d6b9d587_I20191231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI3NDg3NzkwODgzMjQ_185451f9-7e16-4272-9f48-37dbd6e307f5">16.87</ix:nonFraction> per share under the ESPP during the years ended December 31, 2021, 2020, and 2019, respectively. As of&#160;December 31, 2021,&#160;<ix:nonFraction unitRef="shares" contextRef="iebede0396f23431fa71d2b7f1a74378c_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzU3MzU_90433378-a136-4f56-a9be-701d06e7e0b8">4</ix:nonFraction> million&#160;shares were available for future issuance under the ESPP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation and Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for options granted under our Equity Plans and share purchases under our ESPP is determined using the Black-Scholes option pricing model. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNTQ_596026e3-d1fe-4ab2-b744-d3be9b3f9616" continuedAt="if280aaf95b894ee08beee04a3837510d" escape="true">The weighted-average assumptions used to estimate the fair value of options granted and ESPP for the&#160;years ended December 31, 2021, 2020, and 2019 were as follows:</ix:nonNumeric></span><ix:continuation id="if280aaf95b894ee08beee04a3837510d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzQtMi0xLTEtNzYwNDY_6a38ba3b-1b5c-4341-b8a4-2dd6ca495e68">0.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzQtNC0xLTEtNzYwNDY_c3727dc6-c7fe-4e83-8e80-45e9b91495ee">0.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzQtNi0xLTEtNzYwNDY_1dbd562f-7587-4e6c-aa37-e21723d78aa3">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzUtMi0xLTEtNzYwNDY_64b150c3-bc2b-4cc1-9bab-862b48e82470">6.10</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzUtNC0xLTEtNzYwNDY_47597d2d-0cff-47ee-98be-7b9f2d1757cf">6.11</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzUtNi0xLTEtNzYwNDY_7c7036cb-d172-46c2-a814-c57472a49352">6.07</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzYtMi0xLTEtNzYwNDY_784a46f2-c541-43f2-a34c-5686eb0b1060">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzYtNC0xLTEtNzYwNDY_9d3728e1-c975-4197-a0c0-bd2506692241">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzYtNi0xLTEtNzYwNDY_90fb1b48-6d43-4fe9-a862-4b9ea588345e">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected dividends</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzctMi0xLTEtNzYwNDY_347e8cd1-ee3d-41f5-a8a2-a18917bb662f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzctNC0xLTEtNzYwNDY_2ea3719c-d8cd-4683-9006-7821dfd0c1f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzctNi0xLTEtNzYwNDY_d2ee6c5e-5a37-4da4-bfab-b6e45293538f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Weighted average fair value per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4ee683b92644214b4cd05e7d4e55ba3_I20211231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzgtMi0xLTEtNzYwNDY_bc481d0d-f5b5-402e-8233-3e7d7f77e578">91.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe01185da2fb461cb3ee25ad154cce2d_I20201231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzgtNC0xLTEtNzYwNDY_7f298586-dae2-4eff-80a1-71269eb39f72">19.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibad04de7079b4f4a8ea7cd1f6b9a483d_I20191231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzgtNi0xLTEtNzYwNDY_f63f37a8-fa9a-48e1-9dbd-5fdb907ccdc4">11.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzExLTItMS0xLTc2MDQ2_311ddd4b-5cd4-47f9-bc8b-749a9df5a2a6">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzExLTQtMS0xLTc2MDQ2_4d4ea490-5aea-4fd7-b86d-45ebfd95a6ca">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzExLTYtMS0xLTc2MDQ2_33e17e1f-dc44-4eed-b65d-5aad8870989d">1.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEyLTItMS0xLTc2MDQ2_6c2bc4e0-302a-40a7-92a6-d6930d6f918d">0.50</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEyLTQtMS0xLTc2MDQ2_3f86113e-4272-45ce-bcfa-45131fcb875b">0.50</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEyLTYtMS0xLTc2MDQ2_682454e3-d2a4-4407-a7ad-bc66dfd972f8">0.50</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEzLTItMS0xLTc2MDQ2_43e5213a-8bd2-4118-8e17-c6bff08418b0">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEzLTQtMS0xLTc2MDQ2_e9ea9b1b-d584-4c95-ba36-208aec5a3103">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEzLTYtMS0xLTc2MDQ2_b4c864cb-bf76-4e0c-91cd-efbedfb6a365">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE0LTItMS0xLTc2MDQ2_a1fadcdb-feb0-4dc2-881c-4511c29b9236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE0LTQtMS0xLTc2MDQ2_74232810-0bf0-4a36-957a-0b8f47a26ef7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE0LTYtMS0xLTc2MDQ2_a8a183c3-20e4-4960-b671-3137e601740c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05ea5c2eff4b47408d5e76fe3acde946_I20211231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE1LTItMS0xLTc2MDQ2_3f60c764-528e-4f5c-a798-f1fde688ff0f">64.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74a646f2a3a5433fbecbadedd7364094_I20201231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE1LTQtMS0xLTc2MDQ2_f2bae005-b0fa-4137-b177-e2642d7267c7">32.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia91fb56fbec344488aef5885f842fbb0_I20191231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE1LTYtMS0xLTc2MDQ2_6eabf753-3271-49bf-8d4d-63e7659f14e4">5.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNTU_186556e9-717b-4d92-90fe-2405b34f1cfd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the&#160;years ended December 31, 2021, 2020, and 2019 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzItMS0xLTEtNzYwNDY_6099ee8a-3376-4946-aa8e-92c3796319b8">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzItMy0xLTEtNzYwNDY_dfc90cc2-9d33-4289-9d64-73bb2090e0da">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzItNS0xLTEtNzYwNDY_99953636-e558-4606-85f0-e1b424f8f359">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b651cc1ef0d4fb4ac26faca60c2f102_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzMtMS0xLTEtNzYwNDY_3b260722-dae8-4ae7-8df4-6e9177220f7b">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e527ebcd83c41c986d1270c6919f13b_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzMtMy0xLTEtNzYwNDY_8d251eb5-b620-4df3-86cc-e966f4e7fecc">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ce50e969794bcb9eefacd61a166e35_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzMtNS0xLTEtNzYwNDY_34dd354b-29d3-4dda-a428-51dd91281b4b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzQtMS0xLTEtNzYwNDY_537d1686-b93e-43d8-b2cf-ff8189c1c893">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzQtMy0xLTEtNzYwNDY_61de47a8-ccd8-42b4-997c-eb90375acd46">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzQtNS0xLTEtNzYwNDY_72678e82-1559-4103-b26e-d887d5d15ab4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzUtMS0xLTEtNzYwNDY_d251a3ef-1c40-4d57-b4b3-8bbb23b5bc83">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzUtMy0xLTEtNzYwNDY_33c7fa90-c878-4e9f-9fbe-18cf45af5b8c">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzUtNS0xLTEtNzYwNDY_06e0805a-9d6c-4f84-948b-7ca793badf2e">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie043af078137474da5fa9c415b806cb8_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctMS0xLTEtNzkyMjA_97a70b25-c375-4b69-b7c2-4ebbff296577">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd88039ef4d41a6bd7804df805f06b7_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctMy0xLTEtNzkyMjA_5f56b4b2-55b4-4c78-ab02-fb2de47e9f45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1210d8b31f44fae92d529b8b20e6c6f_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctNS0xLTEtNzkyNjE_74a73b07-7828-4747-8657-49fde77f67bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cde0a9204374ab1965f099a3fc5f68b_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzYtMS0xLTEtNzYwNDY_c35006bb-5bc5-4953-9e5c-046369782dc4">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504dedceb6a94befbf403be7db0318ee_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzYtMy0xLTEtNzYwNDY_5850db0b-3d4e-4790-a826-b7062a4ab37c">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6742a09761af484083c605c79d1094c1_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzYtNS0xLTEtNzYwNDY_cba37d9e-33da-4e8b-b6f6-ac9613522dc5">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d8078008d7a4681abf45cdb733f1f74_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctMS0xLTEtNzYwNDY_f6951923-9da2-4726-97b6-bee06923dcba">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66608dd5e63640a89af4850f55816d09_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctMy0xLTEtNzYwNDY_08330c9f-3e51-439a-96be-90b77c16e8b4">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf35565bf91f430595f440c4dd64ae51_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctNS0xLTEtNzYwNDY_2836c096-f346-4f1e-884d-8f87d1937a4a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzgtMS0xLTEtNzYwNDY_407b5b03-856e-45f9-98e3-9bea89a9a791">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzgtMy0xLTEtNzYwNDY_b7181f89-699a-45e6-b3b6-2b421afe8191">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzgtNS0xLTEtNzYwNDY_58f45968-af00-45c2-a3f7-dcf60d7659c8">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020, and 2019, we recognized stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="ide4d55b1dda34b6b93a8469f51c7e48c_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzY0Njc_01850e6f-b395-481b-911a-58b2dbf4a556">16</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ic1eef6d9e8284f3dab7d5832831951df_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzY0NzE_3ce4d0e0-05b3-4487-a870-2af250f0aee0">10</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i1ca45b1141c54e74bc0ba86735723e3e_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzY0Nzg_7422b30f-4f97-4925-bba4-37f5e2bd9de7">10</ix:nonFraction>&#160;million, respectively, related to performance-based awards, including awards with vesting or commencement contingent upon our IPO. Stock-based compensation expenses related to non-employee awards were immaterial for the years ended December 31, 2021, 2020, and 2019.</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i9527bea0d68d4b94b6429a4d75a22b34"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, there were $<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzY4MjE_9792b748-738f-408a-828c-aea0722ef22c">349</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwMzg_a6ad699f-b002-4482-bc95-c0e78b0f9f10">2.9</ix:nonNumeric> years at December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, our Board of Directors authorized a Share Repurchase Program (2021 Repurchase Program) of our common stock, with an expiration date no later than August 2, 2023. Pursuant to the 2021 Repurchase Program, we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i79431f5fc70f4c91917d4630bbc89811_I20210802" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTI5Njg_e04332a6-272a-4073-ab7f-83fca09b4205">1.0</ix:nonFraction>&#160;billion of our outstanding common stock. The timing and actual number of shares repurchased depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Exchange Act).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we repurchased <ix:nonFraction unitRef="shares" contextRef="ia2fcd0a4e20a4fb395dd61a92d63adc0_D20211001-20211231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTI5ODI_27d7dfe2-b701-4edf-ac77-0277ecff34bd">3.5</ix:nonFraction>&#160;million shares of our common stock under the 2021 Repurchase Program for an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ia2fcd0a4e20a4fb395dd61a92d63adc0_D20211001-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTMwMTA_ff1dc583-3363-4f55-8a77-8dce5b3a607e">857</ix:nonFraction>&#160;million, including commissions and fees. As of December 31, 2021, there was a total of $<ix:nonFraction unitRef="usd" contextRef="ibab18ae9cd9244de9112a38fb79ecf41_I20211231" decimals="-6" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTI5OTY_b66d6aff-2cd2-4241-8407-f61ed7a56eb7">143</ix:nonFraction>&#160;million remaining for repurchases of our common stock under the 2021 Repurchase Program.</span></div></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzU1NQ_d05448e3-e788-4860-81ce-cf0e81a2e02e" continuedAt="icb05465d199d44ec8936d5d52e9e70ae" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="icb05465d199d44ec8936d5d52e9e70ae"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide a retirement savings option to our eligible U.S. employees through the Moderna, Inc. 401(k)&#160;Plan (the 401(k) Plan), subject to certain limitations. As allowed under Section&#160;401(k) of the Internal Revenue Code, the 401(k) Plan allows tax deferred salary deductions for eligible employees. We match <ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzM0MA_a53ee7e8-8abe-4209-aace-fc161fc12b28">50</ix:nonFraction>% up to the first <ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzM1OQ_2faa2361-6d29-4690-8529-1f60d09a21e6">6</ix:nonFraction>% contributed by a participant. All matching contributions are immediately vested. Total matching contributions to the 401(k) Plan were $<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzQ5Ng_46782823-cdeb-4d6b-a1f1-722af5e4b708">18</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzUwMA_5a1b6590-8a54-4bda-9629-36639d363102">5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzUwNA_b5a28520-def0-4ad2-8dbf-adf92e9093fc">4</ix:nonFraction> million for the&#160;years ended December 31, 2021, 2020, and 2019, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain various defined benefit plans to provide termination and postretirement benefits to certain eligible employees outside of the U.S. The unfunded benefit plan obligations were $<ix:nonFraction unitRef="usd" contextRef="i835e45064363481fb77ce7bd45f5a1d7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzkzNDU4NDg4Mzc3MTE_92460a3a-0b41-4ba1-98db-1b76c8322c94">9</ix:nonFraction>&#160;million as of December 31, 2021, which is recognized in other long-term liabilities in our consolidated balance sheets.</span></div></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NTI_b1e4683e-a6cc-4e82-9ad6-d485f5b84c10" continuedAt="idff854d21cf6402cb2209ff2c16ec53a" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idff854d21cf6402cb2209ff2c16ec53a" continuedAt="iacba292e1bdf4262900c768c35311923"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NTc_4c2d501b-59a3-475e-a13a-5818a070e429" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income (loss) before income taxes for the years ended December 31, 2021, 2020, and 2019 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzItMS0xLTEtNzYwNDY_36c86504-b070-4212-9c1c-298db9c645c2">13,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzItMy0xLTEtNzYwNDY_839c5ea6-25c7-4935-9db7-fdc9779b313e">745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzItNS0xLTEtNzYwNDY_c7d8d86c-b36f-4241-a4ea-a6906a378605">509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzMtMS0xLTEtNzYwNDY_3dfcd91c-013c-4295-afea-4ff7ccd209b0">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzMtMy0xLTEtNzYwNDY_142d7040-978a-4cff-bb26-7750e22ba8c0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzMtNS0xLTEtNzYwNDY_cf955872-5115-4a8a-954b-d6a352039264">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income (loss) before income taxes </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzQtMS0xLTEtNzYwNDY_7eebe411-9d49-48f9-a00f-72ae27a08da8">13,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzQtMy0xLTEtNzYwNDY_7aa85ecd-245f-465f-a1bb-74fcc299ac22">744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzQtNS0xLTEtNzYwNDY_f16c5460-6b53-4be0-8bce-ea42457187f4">515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NTY_5ae82697-84e9-4c62-9b80-73d8ad265dd9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes for the years ended December 31, 2021, 2020, and 2019 consisted of the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzMtMS0xLTEtNzYwNDY_cd96b7b3-c22e-4d1d-a3c4-c8cc14dcff08">1,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzMtMy0xLTEtNzYwNDY_c4556962-8fa8-448e-bb3b-ca82725ce056">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzMtNS0xLTEtNzYwNDY_17a9a93b-1a52-48a7-ae4a-88be186a582c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzQtMS0xLTEtNzYwNDY_655c087b-1243-43f6-bbad-130a239bc8e2">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzQtMy0xLTEtNzYwNDY_0793d762-79fa-4626-8419-d884965810ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzQtNS0xLTEtNzYwNDY_95445544-c07b-4b13-b121-c878e600a9e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzUtMS0xLTEtNzYwNDY_18a6c8ba-fa98-43db-ade3-13d3676a2276">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzUtMy0xLTEtNzYwNDY_1661b064-882b-498b-acec-230fe4716e7c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzUtNS0xLTEtNzYwNDY_3a2d62d1-990c-4ede-8950-72e50d2e2307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzYtMS0xLTEtNzYwNDY_6ea7280b-e5b8-4d4a-8345-c3dae8b766c7">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzYtMy0xLTEtNzYwNDY_c311a733-2d6c-41c6-a5c5-d0b96b8a96a9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzYtNS0xLTEtNzYwNDY_95698782-41eb-4925-b6fe-32230929cbec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzgtMS0xLTEtNzYwNDY_8e561983-d4ab-40d4-8f08-57f788cf793f">288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzgtMy0xLTEtNzYwNDY_9283938d-f013-4ba0-a4e3-32d8b2b55dc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzgtNS0xLTEtNzYwNDY_cf0e67ff-52cc-4960-b0a8-faf3fd384603">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktMS0xLTEtMTEwOTY2_5e58db10-1a7f-47e2-8b0b-fac7bba13a76">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktMy0xLTEtMTEwOTY2_db80ce8b-563d-4e76-8470-9cc6b3b9024b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktNS0xLTEtMTEwOTY2_5db10b0c-9b4d-47c5-aecd-f43302f6493c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTEtMS0xLTExMDk2Ng_c51b59c9-194a-45c5-adf9-72cdd6727484">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTMtMS0xLTExMDk2Ng_72d3ac1c-e34a-4d64-8b7e-eb71b053c403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTUtMS0xLTExMDk2Ng_01dc9620-0728-4424-a6a6-48f0fb45c854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktMS0xLTEtNzYwNDY_c0fdb2bc-59e0-4914-9d19-1ee920319102">296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktMy0xLTEtNzYwNDY_e7a8c0ed-77d1-462a-bd30-7a06bc64d68a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktNS0xLTEtNzYwNDY_ccfb1bb6-202e-4c10-8b3f-0e3fcdab7af8">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTEtMS0xLTc2MDQ2_fc37a9d8-346f-4a00-8d50-b144b51b6683">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTMtMS0xLTc2MDQ2_9d2daaea-37b0-427d-bf59-ec4429e12cc3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTUtMS0xLTc2MDQ2_01c41da0-9245-49bc-850f-6da8ab87cafe">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="iacba292e1bdf4262900c768c35311923" continuedAt="ic5e5cb5e511d48bf88258bfbf802a681"><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NDk_39b1cbb1-5925-42d0-b7cb-e161f8a47a6e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2021, 2020, and 2019 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzItMS0xLTEtNzYwNDY_cdc6198c-9a0d-43b3-8d2c-7b7fa1d224e2">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzItMy0xLTEtNzYwNDY_e4ec4df6-17e5-433e-9c12-6521b9fe2c61">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzItNS0xLTEtNzYwNDY_bbb0a574-e6e9-4419-9538-7846cd2e701b">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtMS0xLTEtMTEwNzI3_8735b6d1-2c55-45a3-b224-7b589d7aa7dc">5.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtMy0xLTEtMTEwNzI3_8ba80ff6-8127-47a7-a15d-835724daf75b">47.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtNS0xLTEtMTEwNzI3_b55567f2-3a75-4ccc-8691-5d379e0941b8">33.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="3" sign="-" name="mrna:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtMS0xLTEtMTEwOTg2_96c8171e-fb02-4496-9425-84c9cbddfaa9">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="3" name="mrna:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtMy0xLTEtMTEwOTg2_72687790-a245-4f0f-973d-ba370a0e58e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="3" sign="-" name="mrna:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtNS0xLTEtMTEwOTg2_0f82cf6d-3e56-4526-a6cb-a8cfc040501a">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzUtMS0xLTEtMTEwNzM4_e31f23b3-2352-41e2-836b-b44547356f19">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzUtMy0xLTEtMTEwNzM4_8ed0691b-a19b-4a9a-b43a-6e8c4a44fdfa">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzUtNS0xLTEtMTEwNzM4_f5ea7306-86c9-4a23-b359-f7800b127e50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzYtMS0xLTEtMTEwNzcw_24a0547a-7e94-4a4e-84fb-68a15c22dc13">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzYtMy0xLTEtMTEwNzcw_b87362b9-a408-491b-9ebd-982e76df5fd4">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzYtNS0xLTEtMTEwNzcw_ddc765fa-5e98-4643-9887-338300e7d8c9">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtMS0xLTEtNzYwNDY_f7a2fc66-7c11-471d-b895-2dfd0be65292">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtMy0xLTEtNzYwNDY_bf6453ee-84cd-4656-889f-636576d829cf">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtNS0xLTEtNzYwNDY_8cdb4e46-677b-4b64-a5c6-fba582f674f6">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtMS0xLTEtNzYwNDY_88962ed8-9a17-421a-bdaa-a4651e74b73a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtMy0xLTEtNzYwNDY_3ce67e2e-25c0-4b49-959f-cba5deb6fdbe">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtNS0xLTEtNzYwNDY_50699140-ea79-4954-9a37-cd09fdff678a">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzktMS0xLTEtNzYwNDY_fad5d901-d765-4f37-b700-f14b36b48003">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzktMy0xLTEtNzYwNDY_fecad684-fe31-4e7d-9a68-d980c8766c8e">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzktNS0xLTEtNzYwNDY_50db4770-46ac-4da2-8155-3f614fcec696">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzEwLTEtMS0xLTc2MDQ2_e81a8c81-a1ba-426e-9189-6f6b0e95e98b">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzEwLTMtMS0xLTc2MDQ2_c23091da-67a8-4219-9cce-3be59076b774">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzEwLTUtMS0xLTc2MDQ2_ba955aa6-4681-42a4-b973-f53daa75c004">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the year ended December 31, 2021 was <ix:nonFraction unitRef="number" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzM4NDgyOTA3MTc5NTU_e81a8c81-a1ba-426e-9189-6f6b0e95e98b">8.1</ix:nonFraction>% and was lower than the federal statutory tax rate primarily due to the tax benefits related to the release of the valuation allowance on most of our deferred tax assets, foreign-derived intangible income deduction and stock-based compensation. Our effective tax rate for the years ended December 31, 2020 and December 31, 2019 was lower than the federal statutory tax rate primarily due to the valuation allowance on our deferred tax assets.</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes, tax credit carryforwards and the tax effect of net operating loss carryforwards. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NTA_8f9b68bf-fe04-479a-a48b-9deaa3498422" continuedAt="i8c023d58cccd4e69b5c5edfcf77ad61a" escape="true">Significant components of our deferred tax assets and tax liabilities as of December 31, 2021 and 2020 were as follows (in millions):</ix:nonNumeric></span><ix:continuation id="i8c023d58cccd4e69b5c5edfcf77ad61a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:77.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzMtMS0xLTEtNzYwNDY_8fc13c0e-b845-4b30-9a64-c18a52068918">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzMtMy0xLTEtNzYwNDY_a831faf5-8054-448a-be2b-7a1b4b308c59">587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzQtMS0xLTEtNzYwNDY_2599cfb6-256b-4f93-bf3f-5e2d7f2b3d1d">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzQtMy0xLTEtNzYwNDY_fdc9b4a2-1441-4a21-be0e-6c240341951c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized licenses, research and development and start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzUtMS0xLTEtNzYwNDY_e72b0b47-9237-4a88-99e6-8ccd6bfc70a8">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzUtMy0xLTEtNzYwNDY_8e164f86-10de-4a95-9a3e-aed27471bfaa">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzYtMS0xLTEtNzYwNDY_8bfd56a2-a0ff-4c2c-8435-57c273effb3e">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzYtMy0xLTEtNzYwNDY_94d40a68-9568-4318-a896-5efae51c4f60">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzgtMS0xLTEtNzYwNDY_b7afdeb6-b19d-4acb-991c-425d54b35602">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzgtMy0xLTEtNzYwNDY_88c4d9b0-ed94-4521-b202-47370cda5696">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzktMS0xLTEtNzYwNDY_a7198c69-12f6-4860-ba5e-e6a765626ebf">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzktMy0xLTEtNzYwNDY_16c56d80-8837-4c6c-ac8f-85e5d5d423fd">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:DeferredTaxAssetsFinancingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEwLTEtMS0xLTc2MDQ2_246e5217-0fa8-4498-b794-32e93d25fe7d">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:DeferredTaxAssetsFinancingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEwLTMtMS0xLTc2MDQ2_56f8cd07-22a2-4e12-842e-7564098286e1">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEyLTEtMS0xLTc2MDQ2_e4d45e3c-7453-4b8f-9137-fcd682fd553b">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEyLTMtMS0xLTc2MDQ2_b153553c-c3b7-473d-85fe-5104c4df671d">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEzLTEtMS0xLTc2MDQ2_51005587-aa36-4316-9571-f52d99b7d777">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEzLTMtMS0xLTc2MDQ2_e445e50b-9606-4d75-98db-35473e1194a2">874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE0LTEtMS0xLTc2MDQ2_b93faaf1-6be6-4d81-907f-75c401d65c89">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE0LTMtMS0xLTc2MDQ2_0c419d86-d3cf-4ef9-a6e2-016e480244ef">823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE1LTEtMS0xLTc2MDQ2_69eb15c3-7308-4f84-a66b-98ea3f756431">526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE1LTMtMS0xLTc2MDQ2_e5ce3811-3b86-4fe0-881f-c9249470204a">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE3LTEtMS0xLTc2MDQ2_6e46a966-f20e-4935-ae02-b75e7b082f02">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE3LTMtMS0xLTc2MDQ2_e2d5cd9e-96e8-41c6-b436-53e399f96bdc">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE4LTEtMS0xLTc2MDQ2_5fef2d14-15b8-4721-91fc-327e43902621">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE4LTMtMS0xLTc2MDQ2_e5965624-5572-4877-b849-1b1e34d63cc6">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE5LTEtMS0xLTc2MDQ2_c44958db-5fd7-4712-ae08-a5b765b7d7b8">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE5LTMtMS0xLTc2MDQ2_9ac2b8d3-a8da-4862-b9df-b87ee1ed1a97">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIwLTEtMS0xLTc2MDQ2_953cba73-efa2-45da-8462-e75ceaad3f8c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIwLTMtMS0xLTc2MDQ2_b4d66df8-1dd8-42d3-914c-17cb473d626b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIxLTEtMS0xLTc2MDQ2_896a193f-7478-425b-82ce-9169b5ea7a45">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIxLTMtMS0xLTc2MDQ2_43559da2-5c1c-4589-b01f-89d1c77ec5b4">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIyLTEtMS0xLTc2MDQ2_333cf894-e447-47bd-bcdc-2d2f2f4ea16b">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIyLTMtMS0xLTc2MDQ2_aaedb43d-70b7-4cd1-b828-cceacef12f69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, we reassess the valuation allowance on our deferred tax assets, weighing positive and negative evidence to assess the realizability of the deferred tax assets. In the first quarter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ic5e5cb5e511d48bf88258bfbf802a681" continuedAt="ia06d2a017994485bb7be633d18e7e1cd"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we will realize the majority of our deferred tax assets, and we released the valuation allowance on the majority of our deferred tax assets, accordingly. We continue to maintain a valuation allowance on certain state deferred tax assets. </span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzkzNDU4NDg4NjUzMDk_7cf5c6c4-b9f5-4bd9-bb54-eefc4415afff" escape="true"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance for deferred tax assets during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily related to the release of the valuation allowance on deferred tax assets. The changes during the years ended December 31, 2020 and 2019 primarily related to the increase in valuation allowance on net operating loss carryforwards and research and development tax credit carryforwards. The changes were as follows (in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">millions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzItMS0xLTEtMTE0MjQw_0dfdef5f-0675-42b3-814f-a308fdcf4a23">823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzItMy0xLTEtMTE0MjQw_9cc1d4b9-56e7-41cb-951b-7107ecde8b63">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f00be47b1194ea3be883db45fca7c1c_I20181231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzItNS0xLTEtMTE0MjQw_dcbd0ba3-0664-473b-8537-107dfb101263">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases recorded as benefit to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="mrna:ValuationAllowanceDeferredTaxAssetDecreaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzMtMS0xLTEtMTE0MjQw_3ed01d80-4ee1-4090-a986-de4e7c461418">722</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="mrna:ValuationAllowanceDeferredTaxAssetDecreaseAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzMtMy0xLTEtMTE0MjQw_7959a9c9-e244-4fc4-9753-c5d2df84894b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="mrna:ValuationAllowanceDeferredTaxAssetDecreaseAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzMtNS0xLTEtMTE0MjQw_ebaef70d-4e7f-48a3-aa88-f4047063f93b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzQtMS0xLTEtMTE0MjQw_23925106-a381-4de6-84a4-06c028bdf6f5">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzQtMy0xLTEtMTE0MjQw_98f782fc-8cef-4232-a3e5-adc9e0764e37">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzQtNS0xLTEtMTE0MjQw_d982a072-5e6a-4670-a956-4e9a2ba82ffa">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzUtMS0xLTEtMTE0MjQw_d51c86e5-8e6a-43b3-b830-632018fbf25d">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzUtMy0xLTEtMTE0MjQw_63a93765-4199-46bc-84a1-82e81d8782c5">823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzUtNS0xLTEtMTE0MjQw_7d64a113-a3a5-4c0c-8312-31258e530b71">471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i5a9f0c6c3c2848ffb9debae33d695d1b_I20211231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzIxOTkwMjMyNzE3NzQ_94a79a2a-5e54-4044-b891-22b7c903cb13">1.0</ix:nonFraction> billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> state net operating loss carryforwards, which begin to expire in 2032. At December 31, 2021, we also had state tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i39bdbfea26834ede996b4fab64370074_I20211231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzIxOTkwMjMyNzE4MjQ_db484690-1eb9-4774-a586-e19067c4f14e">102</ix:nonFraction> million, the majority of which will begin to expire in 2030. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. All tax years since date of incorporation remain open to examination by the major taxing jurisdictions (federal and state) to which we are subject, as carryforward attributes generated in past years may still be adjusted upon examination by the Internal Revenue Service or the state authorities if they have or will be used in a future period. There are no open tax examinations at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NTU_0f337278-dc09-4e80-ae76-f7c8a6f0d9c5" continuedAt="i82dc6227540c4a708749a0c7fe094045" escape="true">A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2021, 2020, and 2019 were as follows (in&#160;millions):</ix:nonNumeric></span></div><div><ix:continuation id="i82dc6227540c4a708749a0c7fe094045"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"></td><td style="width:67.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzMtMS0xLTEtMTEwNjgy_cab09dd6-3ac7-431f-b5ec-1b8963b0a77e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzMtMy0xLTEtMTEwNjgy_0493640f-ad5e-454e-b6c2-fba88c2b87c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f00be47b1194ea3be883db45fca7c1c_I20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzMtNS0xLTEtMTEwNjgy_abf8f5e5-0a14-4233-85e8-42a95db573d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzgtMS0xLTEtMTEwODcz_d39df918-9302-44c2-b164-7f0d3ee25406">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzgtMy0xLTEtMTEwODY3_aeeb1f1d-bb9c-4099-8a1a-6c6470809225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzgtNS0xLTEtMTEwODY3_fa1f2fb5-4a2a-466e-9c97-8649d0d60de4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzktMS0xLTEtMTEwODcz_fe6787e7-5e61-402c-b034-e7bb6b640274">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzktMy0xLTEtMTEwODY3_13a4d9ce-4cce-4775-ab91-de2f7cbd8adc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzktNS0xLTEtMTEwODY3_cd05d811-8959-4c21-a4d1-c01825c92804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of the period </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzEwLTEtMS0xLTExMDg3OQ_24f261d2-bf2e-423d-b9bd-c840b5ba9078">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzEwLTMtMS0xLTExMDg2Nw_75ddc818-e4d4-40dd-a2bc-45e2eeb18baa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzEwLTUtMS0xLTExMDg2Nw_bbf682f1-eaae-4bdc-b946-119dd92f684c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia06d2a017994485bb7be633d18e7e1cd">As of December 31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="mrna:UnrecognizedTaxBenefitsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzM4NDgyOTA3MTgwMDI_8c408c91-ab7b-46a9-ad6f-ec19a62e7b89">43</ix:nonFraction> million of net unrecognized tax benefits, which would affect our tax rate if recognized. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our consolidated operating results. We recognize interest and penalties, if applicable, related to uncertain tax positions as a component of income tax expense; however, there has been no interest or penalties accrued to date.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_181"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90ZXh0cmVnaW9uOjVlZTA1Y2Q0YmNmZjQzNDViMzhiMDNjZDkwYTMzZDY0XzU1OA_7925dafe-5c79-484c-b17a-99ae5c07fa89" continuedAt="i56598ae54f9b407689cc9a96c57c3c52" escape="true">Earnings (Loss) per Share </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i56598ae54f9b407689cc9a96c57c3c52"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90ZXh0cmVnaW9uOjVlZTA1Y2Q0YmNmZjQzNDViMzhiMDNjZDkwYTMzZDY0XzU1NA_66c4582f-e9c3-4380-ac46-539a65ebba93" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the years ended December 31, 2021, 2020 and 2019 were calculated as follows (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:61.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzMtMS0xLTEtNzYwNDY_56b54826-6a73-4caf-83eb-8d82824f7bcc">12,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzMtMy0xLTEtNzYwNDY_56f06bc7-24c8-4332-b9ec-b84c90da6ae3">747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzMtNS0xLTEtNzYwNDY_e111ef31-f24e-477f-a554-d2751b1a5fa6">514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtMS0xLTEtNzkzOTM_9f63f9e9-6aa9-4de0-8f04-9982ed7f5550">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtMy0xLTEtNzkzOTM_f8a81793-60dd-4832-a34b-bab4e773d808">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtNS0xLTEtNzkzOTk_12812fe4-eaed-4d54-9392-4850dcd96453">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktMS0xLTEtNzkzOTM_45c8dbb7-06e5-4dc3-b2b5-9a36b5e2c293">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktMy0xLTEtNzkzOTM_1ba011c8-404a-43ec-823d-80fb3cc8c3ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktNS0xLTEtNzkzOTk_9a33388d-5dc3-4b2f-a439-6e2a9ef1864a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtMS0xLTEtNzYwNDY_8fd3c832-66be-4c1a-9fd9-c8421df1509b">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtMy0xLTEtNzYwNDY_bf2f49a8-742c-48e8-a8b8-9ee23995e2d8">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtNS0xLTEtNzYwNDY_50dc45e3-bd69-44be-ad48-260a52a52f6e">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzExLTEtMS0xLTc5NDEy_105252e0-ebdf-4707-9802-921c436837a5">30.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzExLTMtMS0xLTc5NDEy_ce0fe67d-7c2a-4aec-869e-685c8befd8f7">1.96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzExLTUtMS0xLTc5NDE3_bbe48a6d-7e45-4cff-be73-93b54140e7e3">1.55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktMS0xLTEtNzYwNDY_02a62a91-d801-4460-a40c-6f99c8472b7c">28.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktMy0xLTEtNzYwNDY_46556ecd-60b0-4bef-b74b-59adfd0d2083">1.96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktNS0xLTEtNzYwNDY_310e1385-7546-4f14-aec0-d459ff8ca1c5">1.55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90ZXh0cmVnaW9uOjVlZTA1Y2Q0YmNmZjQzNDViMzhiMDNjZDkwYTMzZDY0XzU1Ng_c9d81ccf-064e-47a1-8d7d-d97d83d91dec" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of December 31, 2021, 2020 and 2019, were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d35d0ab562b4b489462b57aefdefce5_D20210101-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzItMS0xLTEtNzYwNDY_692be7ed-bbf4-491d-912e-1271ff430d4e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9a86bae6409420b83a8aed6d25de2dd_D20200101-20201231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzItMy0xLTEtNzYwNDY_d8239f17-9086-453e-a71e-d96a2323191d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cd9dd4b271d421b9fca8617b75a1093_D20190101-20191231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzItNS0xLTEtNzYwNDY_761570fa-7c9a-4349-8c1e-849cc2d7b7a4">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89adc3cd6fc14bed9598b281787d3975_D20210101-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzQtMS0xLTEtNzYwNDY_03e7ac84-74c0-4de2-a719-6aae70a209c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaef07bcc885424dbeed30c7d98e5bf7_D20200101-20201231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzQtMy0xLTEtNzYwNDY_c28d2268-0a09-4075-806c-5756186daf8c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d38bfda565e475e8f176749260180c0_D20190101-20191231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzQtNS0xLTEtNzYwNDY_31d60bf8-ef52-4390-b82c-c8ed1e7d0e4e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzUtMS0xLTEtNzYwNDY_1d6a7022-2576-4d0d-8221-554b09f2f2da">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzUtMy0xLTEtNzYwNDY_ed663351-3d47-4523-aae7-c9a0e9e3124d">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzUtNS0xLTEtNzYwNDY_fd3521b9-839c-4514-9963-b53f33b1ea18">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:continuation id="iabbb821ccf4d45108f674a9aef95f57f" continuedAt="i79248d8b12ef4c0d9e54375b60a91147">Geographic Information </ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="i79248d8b12ef4c0d9e54375b60a91147" continuedAt="ie95c5564989945ac855d890c34399254"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90ZXh0cmVnaW9uOjgyNDc5ZDJmM2NkMDRhMmQ4ZjVkYTc4ZDkwYzM5YmYyXzY4_81283167-c0fb-4443-b942-928db317cb5b">one</ix:nonFraction> reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.</span></div><div><span><br/></span></div><ix:continuation id="i49e742dcad1048fbb865edd6a941206a" continuedAt="i8b5a39d918e642e6aaecf54afba42373"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic area of our customers and collaboration partners was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f9128fb34343858d7d0963244403bc_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzItMi0xLTEtNzYwNDY_2ed6e861-696f-4821-b84c-6502573e4562">6,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea1da9382db47b78b24b7770c2bce16_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzItNC0xLTEtNzYwNDY_357001ed-36ea-4f91-aa5a-daf557a25ed9">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3370d17a262545d3a21778bdbfd9e0bd_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzItNi0xLTEtNzYwNDY_f3caf82b-e54c-497f-bbab-14392d4c134c">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711d783999b541ed9d40041b1a32a2bf_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtMi0xLTEtMTA5Nzc2_eaed4813-829c-4d5c-8107-00aaaf01aabe">6,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2fad44150e4a03b5a8be3e02ae7631_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtNC0xLTEtMTA5Nzc2_449cb6c2-e88c-4891-a5af-6d8e4e85b981">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a80bb18be6a4ef784a0986226d8e915_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtNi0xLTEtMTA5Nzc2_da63c8ff-a682-4675-962a-b289e94a2451">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7621872360e6456f9070400abc857bfd_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtMi0xLTEtNzYwNDY_074cfa18-de74-4b76-984f-ddf1eb3776aa">5,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608a92f69c204f27bf261e6252469cc3_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtNC0xLTEtNzYwNDY_e15ad1af-64ff-49da-abe4-b9847787b174">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e6326dca0f4ec6947a65af86c71656_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtNi0xLTEtNzYwNDY_5d89228c-caad-4b4e-ab86-7d34c7b40e34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzQtMi0xLTEtNzYwNDY_c90add22-73ec-4da2-b77f-bd4a0b938ddb">18,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzQtNC0xLTEtNzYwNDY_70134810-6e9c-4e84-82fb-fe7e94e88995">803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzQtNi0xLTEtNzYwNDY_f68f1472-3f06-4d13-80ea-6ac72603d851">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi (on behalf of the COVAX Facility) as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ie95c5564989945ac855d890c34399254"><ix:continuation id="i8b5a39d918e642e6aaecf54afba42373"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0ed2515d854ec9b5a77c4457a02d73_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZToyODcyMWNiMGU4YjU0NDRhYWQ5ZDNjNmFiYTY2NzEzYS90YWJsZXJhbmdlOjI4NzIxY2IwZThiNTQ0NGFhZDlkM2M2YWJhNjY3MTNhXzItMi0xLTEtMTA5NjE5_995747dc-9141-412b-94e7-143ee4106bca">1,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90163def30db4815a2baf938575b19d7_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZToyODcyMWNiMGU4YjU0NDRhYWQ5ZDNjNmFiYTY2NzEzYS90YWJsZXJhbmdlOjI4NzIxY2IwZThiNTQ0NGFhZDlkM2M2YWJhNjY3MTNhXzMtMi0xLTEtMTA5NzQ1_051ee972-11c6-4e28-8de3-0be701b2b9ea">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacd7ab752d5b4882a879732a1889bbb8_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZToyODcyMWNiMGU4YjU0NDRhYWQ5ZDNjNmFiYTY2NzEzYS90YWJsZXJhbmdlOjI4NzIxY2IwZThiNTQ0NGFhZDlkM2M2YWJhNjY3MTNhXzMtMi0xLTEtMTA5NjE5_a67751e3-d15b-44f7-89b0-7c301136459d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZToyODcyMWNiMGU4YjU0NDRhYWQ5ZDNjNmFiYTY2NzEzYS90YWJsZXJhbmdlOjI4NzIxY2IwZThiNTQ0NGFhZDlkM2M2YWJhNjY3MTNhXzQtMi0xLTEtMTA5NjE5_95c95254-558c-4084-a9d6-08be1e224e14">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property and equipment, including financing right-of-use assets, was principally located within the United States as of December 31, 2020.</span></div></ix:continuation><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1Xzk0NA_496b620d-24ac-477e-b85d-dae782958456" continuedAt="if0785f939147428ab07ab445fbee3332" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if0785f939147428ab07ab445fbee3332"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we repurchased an additional <ix:nonFraction unitRef="shares" contextRef="i258d02d7ce92442dbbad9a730c0f0475_D20220101-20220131" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4NDE3OTI_42d7e0ec-a15f-43b2-94ce-743dfa44adc3">0.6</ix:nonFraction>&#160;million shares of our common stock under the 2021 Repurchase Program for an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i258d02d7ce92442dbbad9a730c0f0475_D20220101-20220131" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4NDE3NjQ_35650e0c-a62b-4770-aac8-cd346ea18bb4">143</ix:nonFraction>&#160;million including commissions and fees. We have repurchased the entire $<ix:nonFraction unitRef="usd" contextRef="i35471f100ca04369aaa8cd79328e4486_I20220131" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4NDE3Nzg_634d31d5-51fc-4b41-831e-7cb647c961c7">1.0</ix:nonFraction>&#160;billion of common stock that was authorized under the 2021 Repurchase Program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2022, our Board of Directors authorized a new Share Repurchase Program (2022 Repurchase Program) of our common stock, with no expiration date. Pursuant to the 2022 Repurchase Program, we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i2dce8093560b49b995bb23f3c3c63255_I20220222" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4Mzk4MzM_4a28572e-8167-484b-89ab-fddbfa200979">3.0</ix:nonFraction>&#160;billion of our outstanding common stock. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2021, we have entered into several supply agreements with customers to provide our COVID-19 vaccine, up to <ix:nonFraction unitRef="dose" contextRef="ic9fcc9f307dd449cbd9ff284355911be_D20220101-20220225" decimals="-5" name="mrna:NumberOfDosesOfVaccineCandidate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzE0OA_a3cd13dd-e0c4-4c8d-8de3-31c7590b0327">66</ix:nonFraction> million doses, and have received upfront deposits of $<ix:nonFraction unitRef="usd" contextRef="i5a40581afbae47acaae291b96f6752cd_I20220225" decimals="-5" name="us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzE5Ng_84521565-c5fb-4d07-977c-a3fa6a78028a">210</ix:nonFraction> million, based on the initial confirmed volume, subject to modifications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2021, we have entered binding purchase commitments with third-party contractual manufacturing organizations for dedicated facilities and fill &amp; finish services for our COVID-19 vaccine. We are currently committed to minimum non-cancelable purchase obligations of $<ix:nonFraction unitRef="usd" contextRef="i5a40581afbae47acaae291b96f6752cd_I20220225" decimals="-8" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4NDQ5NDU_f3634c8c-3ab6-4bcf-af2f-0756c05574e0">1.9</ix:nonFraction>&#160;billion related to these agreements, of which $<ix:nonFraction unitRef="usd" contextRef="i5a40581afbae47acaae291b96f6752cd_I20220225" decimals="-6" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4NDQwODY_f97f1cb8-1911-4d11-9276-f0bb18fc0b4e">213</ix:nonFraction>&#160;million is expected to be paid within 2022 and the remaining is expected to be paid through 2029.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_190"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_193"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of&#160;December 31, 2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of&#160;December 31, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Exchange Act Rule 13a-15(f)) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Management assessed our internal control over financial reporting as of&#160;December 31, 2021. Management based its assessment on criteria established in&#160;Internal Control - Integrated Framework&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).&#160;Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of&#160;December 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of&#160;December 31, 2021&#160;has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report included in this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Controls over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December 31, 2021, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on the Effectiveness of Controls</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, believe that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by the collusion of two or more people or by a management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Moderna, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Moderna, Inc.&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Moderna, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and December 31, 2020, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated February&#160;25, 2022 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2022</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_196"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_2705"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None Applicable.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_199"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_202"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2022 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_205"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2022 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_208"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2022 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_211"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2022 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_214"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our independent public accounting firm is Ernst &amp; Young LLP, Boston, Massachusetts, PCAOB Auditor ID 000<ix:nonNumeric contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8yMTQvZnJhZzphYTYyYmU5NjRhMzY0NmE5ODdiNDRiYWZlMjg3MjlkMC90ZXh0cmVnaW9uOmFhNjJiZTk2NGEzNjQ2YTk4N2I0NGJhZmUyODcyOWQwXzMyOTg1MzQ4ODQwMjM_4e25f905-b87d-4c80-baec-53e31a4ada7d">42</ix:nonNumeric>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the 2022 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_217"></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_220"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits, Financial Statement Schedules</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(a) Documents filed as part of this report.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a list of the consolidated financial statements included herein, see &#8220;Index to Consolidated Financial Statements&#8221; under Part I, Item 8 of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(2) Schedules.</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No financial statement schedules have been submitted because they are not required or are not applicable or because the information required is included in the consolidated financial statements or the notes thereto.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(3) Exhibits.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Index</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518349938/d677222dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518349938/d677222dex31.htm">2</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518349938/d677222dex31.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518349938/d677222dex32.htm">Amended and Restated&#160;By-laws of the Registrant. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518349938/d677222dex32.htm">2</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518349938/d677222dex32.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex41.htm">Specimen Common Stock Certificate. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex42.htm">Second Amended and Restated Investors&#8217; Rights Agreement by and among the Registrant and certain of its stockholders, dated May&#160;7, 2018. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit4312312020.htm">Description of Capital Stock</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit4312312020.htm">.</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit4312312020.htm"> </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex101.htm">2016 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex102.htm">2018 Stock Option and Incentive Plan and forms of award agreements thereunder. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex103.htm">Form of Indemnification Agreement between the Registrant and each of its directors. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex104.htm">Master Collaboration and License Agreement, by and between Moderna Therapeutics, Inc. and Merck Sharp &amp; Dohme Corp., dated as of January&#160;12, 2015, as amended by Amendment No.&#160;1 dated as of January 8, 2016, Amendment No.&#160;2 dated as of June&#160;28, 2016, Amendment No.&#160;3 dated as of June&#160;28, 2016 and Amendment No.&#160;</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex104.htm">4 dated as of June&#160;28, 2016. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex105.htm">Amended and Restated mRNA Cancer Vaccine Collaboration and License Agreement, by and between ModernaTX, Inc. and Merck Sharp &amp; Dohme Corp., dated as of April&#160;17, 2018. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex106.htm">Amended and Restated Option Agreement by and between ModernaTX, Inc. and AstraZeneca AB, dated as of June&#160;15, 2018. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex107.htm">Amended and Restated Services and Collaboration Agreement by and between ModernaTX, Inc. and AstraZeneca AB, dated as of June&#160;15, 2018. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex108.htm">Patent Sublicense Agreement, by and among ModernaTX, Inc. and Cellscript, LLC and mRNA RiboTherapeutics, Inc. (solely with respect to certain provisions), dated as of June&#160;26, 2017. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex109.htm">Lease Agreement, by and between Moderna Therapeutics, Inc. and ARE-Tech Square, LLC, dated as of May 26, 2016, as amended by Amendment No. 1 dated as of August 31, 2016, Amendment No. 2 dated as of December 31, 2016,</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex109.htm"> </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex109.htm">Amendment No. 3 dated as of April 24, 2017, Amendment No. 4 dated as of April 13, 2018. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000168285219000036/a101fifthamendmentto200tec.htm">Fifth Amendment to Lease Agreement, by and between ModernaTX, Inc. and ARE-Tech Square, LLC, dated as of August 28, 2019. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000168285219000036/a101fifthamendmentto200tec.htm">3</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000168285219000036/a101fifthamendmentto200tec.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1010.htm">Net Lease by and between Moderna Therapeutics, Inc. and Campanelli-TriGate Norwood Upland, LLC, dated as of August&#160;29, 2016, as amended by Amendment No.&#160;1 dated as of April&#160;10, 2017 and Amendment No.&#160;2 dated as of March&#160;16, 2018. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-norwoodleaseam.htm">Third </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-norwoodleaseam.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-norwoodleaseam.htm">m</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-norwoodleaseam.htm">endment</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-norwoodleaseam.htm">, dated September 11, 2018</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-norwoodleaseam.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-norwoodleaseam.htm"> Fourth Amendment, dated March 28, 2019</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-norwoodleaseam.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-norwoodleaseam.htm"> and Omnibus Amendment, dated December 30, 2021, to</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-norwoodleaseam.htm"> Net Lease</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1012-norwoodleaseam.htm">, dated as of August 29, 2016, as amended.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1011.htm">Amended and Restated Executive Severance Plan and Form of Participation Letter, as amended on November&#160;4, 2018. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1015.htm">Letter Agreement by and between the Company and St&#233;phane Bancel, dated as of June</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1015.htm"> 13, 2018, as amended by Amendment No. 1 dated as of November&#160;4, 2018. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1016.htm">Letter Agreement by and between the Company and Stephen Hoge, dated as of October&#160;17, 2017. (1)</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1016-legoffcorinneo.htm">Offer Letter by and between ModernaTX, Inc. and Corin</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1016-legoffcorinneo.htm">ne Le Goff, dated as of </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1016-legoffcorinneo.htm">December 28</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1016-legoffcorinneo.htm">, 2020</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1016-legoffcorinneo.htm">.</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1017-executivesepar.htm">Executive Separation and Transitional Services Agreement</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1017-executivesepar.htm"> by and betwe</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1017-executivesepar.htm">en ModernaTX</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1017-executivesepar.htm">, Inc. and Corinne Le Goff,</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1017-executivesepar.htm"> dated as of November 11, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1018-consultingagre.htm">Consulting Agreement by and between ModernaTX, Inc. and Corinne Le Goff</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1018-consultingagre.htm">, effective as of Decem</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1018-consultingagre.htm">ber 17, 2021</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1018-consultingagre.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1019-offerlettersha.htm">Employment Letter Agreement between ModernaTX, Inc. and Shannon Klinger, dated as of March 4, 2021.</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1017.htm">Senior Executive Cash Incentive Bonus Plan. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000168285219000023/exhibit101amendedandrestat.htm">Amended and Restated Non-Employee Director Compensation Policy. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000168285219000023/exhibit101amendedandrestat.htm">4</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000168285219000023/exhibit101amendedandrestat.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1019.htm">Form of Indemnification Agreement between the Registrant and each of its officers. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473dex1020.htm">2018 Employee Stock Purchase Plan. (1)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1024-modernarsuagre.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1024-modernarsuagre.htm">Employee</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1024-modernarsuagre.htm"> Restricted Stock </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1024-modernarsuagre.htm">Unit </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1024-modernarsuagre.htm">Award Agreement.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1025-nqsoagreementf.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1025-nqsoagreementf.htm">Employee</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1025-nqsoagreementf.htm"> Non-Qualified Stock Option Agreement. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1026-modernarsuagre.htm">Form of Non-Employee Director Restricted Stock Unit Award Agreement.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27#*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1027-nqsoagreementf.htm">Form of Non-Employee Director Non-Qualified Stock Option Agreement.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.28#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit103formofpsuagreeme.htm">Form of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Stock Option and Incentive Plan. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit103formofpsuagreeme.htm">4</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit103formofpsuagreeme.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285220000023/exhibit101.htm">Agreement No. HHSO100201600029C, by and between the Company and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020, as amended on May 24, 2020, June 16, 2020, July 25, 2020, August 31, 2020 and September 15, 2020. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285220000023/exhibit101.htm">5</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285220000023/exhibit101.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit101amendmentno6toba.htm">Amendment No. 6, dated February 16, 2021, to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit101amendmentno6toba.htm">4</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit101amendmentno6toba.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit102amendmentno7toba.htm">Amendment No. 7, dated March 12, 2021, to </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit102amendmentno7toba.htm">Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020,</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit102amendmentno7toba.htm"> (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit102amendmentno7toba.htm">4</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000017/exhibit102amendmentno7toba.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit102amendmentnos8and.htm">Amendment Nos. 8 and 9 to</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit102amendmentnos8and.htm"> </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit102amendmentnos8and.htm">Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit102amendmentnos8and.htm">. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit102amendmentnos8and.htm">8</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit102amendmentnos8and.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit102amendmentno10bar.htm">Amendment No. 10 to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit102amendmentno10bar.htm">9</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit102amendmentno10bar.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="exhibit1034-bardaamenmdent.htm">Amendment No. 11 to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of November 4, 2021.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285220000023/lonzamodernagltafullye.htm">Global Long Term Agreement, by and among ModernaTX Inc., Lonza Sales Ltd., and Lonza Ltd., dated September 4, 2020. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285220000023/lonzamodernagltafullye.htm">6</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285220000023/lonzamodernagltafullye.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285220000023/exhibit103.htm">Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated August 9, 2020, as amended September 8, 2020, and September 11, 2020. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285220000023/exhibit103.htm">6</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285220000023/exhibit103.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit1027supplycontrac.htm">Amendment No. P00003 to </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit1027supplycontrac.htm">Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit1027supplycontrac.htm">dated </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit1027supplycontrac.htm">December</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit1027supplycontrac.htm"> </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit1027supplycontrac.htm">11, 2020</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit1027supplycontrac.htm">. </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit1027supplycontrac.htm">(</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit1027supplycontrac.htm">7</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000006/exhibit1027supplycontrac.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit101amendmentsnos4to.htm">Amendment Nos. P00004, P00005, P00006, P00007, P00008, P00009, P00010, P00011 and P00012 to Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit101amendmentsnos4to.htm">Au</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit101amendmentsnos4to.htm">gust 9, 2020</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit101amendmentsnos4to.htm">. (</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit101amendmentsnos4to.htm">8</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000022/exhibit101amendmentsnos4to.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit101amendmentsnos12t.htm">Amendment Nos. P00012, P00013, P00014, P00015, P00016</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit101amendmentsnos12t.htm"> and P00017 to </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit101amendmentsnos12t.htm">Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit101amendmentsnos12t.htm">August </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit101amendmentsnos12t.htm">9, 2020</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit101amendmentsnos12t.htm">.</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit101amendmentsnos12t.htm"> </a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit101amendmentsnos12t.htm">(</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit101amendmentsnos12t.htm">9</a><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1682852/000168285221000027/exhibit101amendmentsnos12t.htm">)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40&#8224;*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1040-dodamendments.htm">Amendment Nos. P00018, P00019, P00020, and P00021 to Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1040-dodamendments.htm">August 9, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1040-dodamendments.htm">. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211subsidiaries.htm">Subsidiaries of the Registrant.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit23112312021.htm">Consent of Ernst&#160;&amp; Young LLP, Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31112312021.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31212312021.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32112312021.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32212312021.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Link Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:2.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to 17 C.F.R. &#167;&#167;230.406 and 230.83, the confidential portions of this exhibit have been omitted and are marked accordingly.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or any compensatory plan, contract or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/><br/><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Registration Statement on Form S-1 (File No. 333-228300) filed with the Securities and Exchange Commission on November 9, 2018.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Current Report on Form 8-K (File No. 001-38753) filed with the Securities and Exchange Commission on December 14, 2018.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38753) filed with the Securities and Exchange Commission on November 6, 2019. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38753) filed with the Securities and Exchange Commission on May 6, 2021.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38753) filed with the Securities and Exchange Commission on August 6, 2020.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38753) filed with the Securities and Exchange Commission on October 30, 2020. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Annual Report on Form 10-K (File No. 001-38753) filed with the Securities and Exchange Commission on February 26, 2021.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38753) filed with the Securities and Exchange Commission on August 5, 2021.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Quarterly Report on Form 10-Q (File No. 001-38753) filed with the Securities and Exchange Commission on November 4, 2021.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Incorporated by reference to the Annual Report on Form 10-K (File No. 001-38752) filed with the Securities and Exchange Commission on February 27, 2020.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157</span></div></div></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_223"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i7a7cdf3fe3c348059a6b0a57c2f167fe_226"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MODERNA, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ St&#233;phane Bancel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY AND SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each individual whose signature appears below hereby constitutes and appoints each of St&#233;phane Bancel and David Meline and as such person&#8217;s true and lawful&#160;attorney-in-fact&#160;and agent with full power of substitution and resubstitution, for such person in such person&#8217;s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said&#160;attorney-in-fact&#160;and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said&#160;attorney-in-fact&#160;and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:36.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.331%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ St&#233;phane Bancel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Meline</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Meline</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Noubar B. Afeyan, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noubar B. Afeyan, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Stephen Berenson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stephen Berenson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sandra Horning, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Horning M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert Langer, Sc.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Langer, Sc.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Francois Nader, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Francois Nader M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Elizabeth Nabel, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elizabeth Nabel, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Paul Sagan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul Sagan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Elizabeth Tallett</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elizabeth Tallett</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>exhibit1012-norwoodleaseam.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i299a2cea044346ee871f7568643f601e_1"></div><div style="min-height:74.88pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:4.7pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.12</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">THIRD AMENDMENT TO LEASE</font></div><div style="margin-top:7.55pt;text-indent:34.65pt"><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:109%">THIS THIRD AMENDMENT TO LEASE (this </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:109%">&#34;Third Amendment&#34;) </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:109%">is made as of September 11, 2018, by and between </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:109%">ARE-MA REGION NO. 64, LLC, </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:109%">a Delaware limited liability company </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:109%">(&#34;Landlord&#34;), </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:109%">and </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:109%">MODERNA, INC., </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:109%">a Delaware corporation </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:109%">(&#34;Tenant&#34;).</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="text-align:center"><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="text-align:justify;text-indent:35.3pt"><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A.</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:26.71pt">Tenant and Landlord are now parties to that certain Net Lease dated as of August 29, 2016 </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(&#34;Original Lease&#34;), </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as amended by that certain First Amendment to Lease dated as of April 10, 2017, and as further amended by that certain Second Amendment to Lease dated as March 16, 2018 (as amended, the </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#34;Lease&#34;)</font><font style="color:#383638;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">. </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Lease, Tenant leases certain premises known as 100 Tech Drive, Norwood, Massachusetts (the </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#34;Premises&#34;</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">).</font><font style="color:#383638;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Premises are more particularly described in the Lease. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="text-align:justify;text-indent:34.85pt"><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:118%">B.</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:118%;padding-left:27.16pt">At Tenant's request, Landlord and Tenant have agreed to amend the Lease as more particularly set forth in this Third Amendment.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;text-align:justify;text-indent:34.75pt"><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:118%">NOW, THEREFORE, </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:118%">in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows&#58;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:41.15pt;padding-right:8.4pt;text-align:justify;text-indent:-34.35pt"><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1.</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:26.02pt;text-decoration:underline">Use of Initial Tenant Work Allowance</font><font style="color:#383638;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">. </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 3.1(f) of the Original Lease is hereby amended to provide that the Initial Tenant Work Allowance shall not be available for any work completed (or reimbursement requested) after March 31, 2019.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:40.7pt;padding-right:8.25pt;text-align:justify;text-indent:-34.15pt"><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">2.</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:25.82pt;text-decoration:underline">Brokers</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">. </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">&#34;Broker&#34;) </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">in connection with the transaction reflected in this Third Amendment and that no Broker brought about this transaction. Landlord shall only pay commissions to Broker pursuant to a separate written agreement between Landlord and Broker. Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Third Amendment.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:40pt;padding-right:8.4pt;text-align:justify;text-indent:-33.55pt"><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">3.</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%;padding-left:25.22pt;text-decoration:underline">OFAC</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">. </font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#8220;</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">OFAC</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">&#8221;) of the U</font><font style="color:#383638;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">.</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%">S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#8220;OFAC Rules&#34;), (b) not listed on, and shall not during the term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List or the Sectoral Sanctions Identifications List, which are all maintained by OFAC and&#47;or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:40.05pt;text-align:justify;text-indent:-34.35pt"><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:26.02pt;text-decoration:underline">Miscellaneous</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:39.8pt;padding-right:8.5pt;text-align:justify;text-indent:0.05pt"><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:118%">a.</font><font style="color:#151313;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:118%;padding-left:23.82pt">This Third Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. This Third Amendment may be amended only by an agreement in writing, signed by the parties hereto</font><font style="color:#383638;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:118%">.</font></div><div style="padding-left:3.8pt;padding-right:8.5pt;text-align:justify;text-indent:18.05pt"><font><br></font></div><div style="padding-left:3.8pt;padding-right:8.5pt;text-align:justify;text-indent:18.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.537%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.65pt"><font style="color:#151313;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729682814.3</font></div></td></tr></table></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:80%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:44.85pt;padding-right:6.15pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:17.98pt">This Third Amendment is binding upon and shall inure to the benefit of the parties hereto, and their respective successors and assigns.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:44.15pt;padding-right:5.8pt;text-align:justify;text-indent:0.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:118%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:118%;padding-left:19.27pt">This Third Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Third Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:43.6pt;padding-right:5.95pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:117%;padding-left:19.23pt">Except as amended and&#47;or modified by this Third Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Third Amendment. In the event of any conflict between the provisions of this Third Amendment and the provisions of the Lease, the provisions of this Third Amendment shall prevail. Whether or not specifically amended by this Third Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Third Amendment.</font></div><div><font><br></font></div><div style="padding-left:96.42pt;padding-right:96.42pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;Signatures are on the next page.&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:49.783%"><div><font><br></font></div></div><div style="display:inline-block;max-width:0.433%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:49.784%"><div><font><br></font></div></div></div><div style="margin-top:0.3pt;padding-right:8.5pt;text-align:justify;text-indent:18.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.537%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.65pt"><font style="color:#151313;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729682814.3</font></div></td></tr></table></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:80%">2</font></div></div></div><div id="i299a2cea044346ee871f7568643f601e_4"></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-right:4.45pt;text-indent:36pt"><font style="color:#181616;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF, </font><font style="color:#181616;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the parties hereto have executed this Third Amendment as of the day and year first above written.</font></div><div style="padding-right:4.45pt"><font><br></font></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LANDLORD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARE-MA REGION NO. 64, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;a Delaware limited partnership, </font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">managing member</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;ARE-QRS CORP.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Maryland corporation,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;general partner</font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">            </font><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jackie Clem</font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">            By&#58; Jackie Clem </font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">            Senior Vice President, RE Legal Affairs</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div id="i299a2cea044346ee871f7568643f601e_7"></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TENANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div><font><br></font></div><div style="margin-bottom:24pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MODERNATX, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="margin-top:0.25pt;padding-left:180pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Steve Harbin </font></div><div style="margin-top:0.25pt;padding-left:180pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Its&#58; Norwood Site Head</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-right:8.5pt;text-align:justify;text-indent:18.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:11.537%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.65pt"><font style="color:#151313;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729682814.3</font></div></td></tr></table></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:80%">3</font></div></div></div><div id="i299a2cea044346ee871f7568643f601e_10"></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:4.75pt;padding-left:153.12pt;padding-right:153.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">FOURTH AMENDMENT TO LEASE</font></div><div style="margin-top:8.65pt;padding-left:8.45pt;padding-right:4.6pt;text-indent:34.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">THIS FOURTH AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">Fourth Amendment&#8221;)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%"> is made as of March 28,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">2019, by and between </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">ARE-MA REGION NO. 64, LLC, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">a Delaware limited liability company </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">(&#34;Landlord&#34;), </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">MODERNA, INC., </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">a Delaware corporation </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">(&#34;Tenant&#34;).</font></div><div><font><br></font></div><div style="padding-left:152.72pt;padding-right:152.72pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:8.2pt;padding-right:5.05pt;text-align:justify;text-indent:34.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">A.         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Tenant and Landlord are now parties to that certain Net Lease dated as of August 29, 2016 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">(&#34;Original Lease&#34;), </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">as amended by that certain First Amendment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">Lease dated as of April 10, 2017, as further amended by that certain Second Amendment to Lease dated as of March 16, 2018, and as further amended by that certain Third Amendment to Lease dated as of September 11, 2018 (as amended, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">Lease&#8221;)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">. Pursuant to the Lease, Tenant leases certain premises known as 100 Tech Drive, Norwood, Massachusetts (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">&#34;Premises&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">The Premises are more particularly described in the Lease. Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:7.9pt;padding-right:5.25pt;text-align:justify;text-indent:34.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At Tenant's request, Landlord and Tenant have agreed to amend the Lease as more particularly set forth in this Fourth Amendment.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:7.55pt;padding-right:5.85pt;text-align:justify;text-indent:34.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:118%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:118%">in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:41.8pt;padding-right:5.8pt;text-align:justify;text-indent:-34.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;padding-left:25.97pt;text-decoration:underline">Use of Initial Tenant Work Allowance.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">of the Original Lease is hereby amended to provide that the Initial Tenant Work Allowance shall not be available for any work completed (or reimbursement requested) after September 30, 2019.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41.25pt;padding-right:6.15pt;text-align:justify;text-indent:-34.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:115%;padding-left:25.92pt;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:115%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:115%">Broker&#8221;) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">in connection with the transaction reflected in this Fourth Amendment and that no Broker brought about this transaction. Landlord shall only pay commissions to Broker pursuant to a separate written agreement between Landlord and Broker. Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and &#183;against any claims by any Broker, claiming a commission or other form of compensation by</font></div><div style="margin-top:0.8pt;padding-left:41.2pt;padding-right:6.55pt;text-align:justify;text-indent:0.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:105%">virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Fourth Amendment.&#160;&#160;&#160;&#160;&#183;&#160;&#160;&#160;&#160;&#183; &#183;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:40.65pt;padding-right:6.4pt;text-align:justify;text-indent:-33.7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:117%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:117%;padding-left:25.37pt;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:117%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:117%">Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of the Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:117%">OFAC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:117%">&#34;)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:117%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:117%">of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#34;OFAC Rules&#34;), (b) not listed on, and shall not during the term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List or the Sectoral Sanctions Identifications List, which are all maintained by OFAC and&#47;or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-35.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;padding-left:27.22pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">.</font></div><div style="margin-top:10.3pt;padding-left:40.5pt;padding-right:7.2pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;padding-left:23.64pt">This Fourth Amendment is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:80%"><br><br><br></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.530%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.65pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">731832169.1</font></div></td></tr></table></div><div style="height:43.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:80%">1</font></div></div></div><div id="i299a2cea044346ee871f7568643f601e_13"></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:10.3pt;padding-left:40.5pt;padding-right:7.2pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">agreements and discussions. This Fourth Amendment may be amended only by an agreement in writing, signed by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> parties hereto.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:10.3pt;padding-left:40.5pt;padding-right:7.2pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.12pt">This Fourth A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">mendment is binding upon and shall inure to the benefit of the parties hereto, and their respective successors and assigns.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:10.3pt;padding-left:40.5pt;padding-right:7.2pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.64pt">This Fourth Amendment may be executed in 2 or more counterparts, each of which-shall be deemed an original, but all of which together shall constitute one and the same instrument. Coun</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">terparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Fourth Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:10.3pt;padding-left:40.5pt;padding-right:7.2pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.12pt">Except as amended and&#47;or modified by this Fourth Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and uncha</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">nged by this Fourth Amendment. In the event of any conflict between the provisions of this Fourth Amendment and the provisions of the Lease, the provisions of this Fourth Amendment shall prevail. Whether or not specifically amended by this Fourth Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Fourth Amendment.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:64.47pt;padding-right:64.47pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#91;Signatures are on the next page.&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:10.481%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.65pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">731832169.1</font></div></td></tr></table></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:80%">2</font></div></div></div><div id="i299a2cea044346ee871f7568643f601e_16"></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:4.7pt;text-indent:36pt"><font style="color:#181613;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:118%">IN WITNESS WHEREOF, </font><font style="color:#181613;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:118%">the parties hereto have executed this Fourth Amendment as of the day and year first above written.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LANDLORD</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ARE-MA REGION NO. 64, LLC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;a Delaware limited partnership, </font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">managing member</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;ARE-QRS CORP.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Maryland corporation,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;general partner</font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#181613;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jackie Clem</font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">             By&#58; Jackie Clem </font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">             Senior Vice President, RE Legal Affairs</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TENANT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#58;</font></div><div><font><br></font></div><div style="margin-bottom:24pt;padding-left:180pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">MODERNATX, INC.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="margin-top:0.25pt;padding-left:144pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#181613;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Juan Andres</font></div><div style="margin-top:0.25pt;padding-left:144pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">             By&#58; Juan Andres </font></div><div style="margin-top:0.25pt;padding-left:144pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">             Its&#58; Chief Tecnical Operations and Quality Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:80%">3</font></div></div></div><div id="i299a2cea044346ee871f7568643f601e_19"></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OMNIBUS AMENDMENT TO THREE MODERNA LEASE AGREEMENTS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS OMNIBUS AMENDMENT TO THREE MODERNA LEASE AGREEMENTS (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made as of December 30, 2021, by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARE-MA REGION NO. 92, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware limited liability company and owner of the property commonly known as One Investors Way, Norwood, Massachusetts (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">One Investors Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARE-MA REGION NO. 64, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware limited liability company and owner of the property commonly known as 100 Tech Drive, Norwood, Massachusetts (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">100 Tech Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARE-MA REGION NO. 83, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware limited liability company and owner of the property commonly known as One Upland Road, Norwood, Massachusetts (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">One Upland Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlords</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MODERNATX, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">One Investors Landlord and Tenant are parties to that certain Lease Agreement dated as of April 16, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">One Investors Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), with respect to the real property and improvements thereon located at 1 Investors Way, Norwood, Massachusetts, as more particularly described in the One Investors Lease.</font></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">100 Tech Landlord (as successor-in-interest to Campanelli-TriGate Norwood Upland, LLC) and Tenant are parties to that certain Net Lease dated as of August 29, 2016, as amended by that certain First Amendment to Lease dated as of April 10, 2017, as further amended by that certain Second Amendment to Lease dated as of March 16, 2018, as further amended by that certain Third Amendment to Lease dated as of September 11, 2018, as further amended by that certain Fourth Amendment to Lease dated as of March 28, 2019 (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">100 Tech Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), with respect to the real property and improvements thereon located at 100 Tech Drive, Norwood, Massachusetts, as more particularly described in the 100 Tech Lease. </font></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">One Upland Landlord (as successor-in-interest to BR Norwood Owner, LLC) and Tenant are parties to that certain Lease Agreement dated as of October 10, 2007, as amended by that certain First Amendment to Lease dated as of February 15, 2019, as further amended by that certain Second Amendment to Lease dated as of February 15, 2019, as further amended by that certain First Amendment to Lease Guaranty dated April 30, 2019, and as further amended by that certain Third Amendment to Lease Agreement dated as of May 21, 2020 (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">One Upland Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Collectively, the One Investors Landlord, 100 Tech Landlord, and One Upland Landlord shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlords</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, and the One Investors Lease, 100 Tech Lease, and One Upland Lease shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Leases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;. </font></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">Landlords and Tenant desire to extend the terms of the Leases and otherwise amend the Leases upon the terms and conditions contained herein. All capitalized terms not defined herein shall have the same meaning ascribed to such terms in the Leases.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual promises and agreements hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlords and Tenant hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The terms of the Leases are extended to and including September 30, 2042. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ACTIVEUS 191091489v.3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The base rent schedules for each of the Leases is hereby modified as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;padding-right:8.4pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt;text-decoration:underline">One Investors Lease&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The definition of &#8220;Base Rent&#8221; set forth on page 1 of the One Investors Lease is hereby deleted in its entirety and replaced with the following&#58;    </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Beginning on the Rent Commencement Date, annual Base Rent shall be $6,466,500.00, subject to annual increases on the Adjustment Date as set forth herein.</font></div><div style="padding-left:0.29pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Year</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Base Rent</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Monthly Base Rent</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Rent&#47;RSF</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 17, 2022 &#8211; February 28, 2023</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,466,500.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$538,875.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$26.94</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2023 &#8211; February 29, 2024</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,660,495.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$555,041.25</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$27.75</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2024 &#8211; February 28, 2025</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,860,310.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$571,692.50</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$28.58</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2025 &#8211; February 28, 2026</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7,066,119.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$588,843.25</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$29.44</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2026 &#8211; February 28, 2027</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7,278,103.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$606,508.58</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$30.33</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2027 &#8211; February 29, 2028</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7,496,446.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$624,703.83</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$31.24</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2028 &#8211; February 28, 2029</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7,721,339.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$643,444.92</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$32.17</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2029 &#8211; February 28, 2030</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7,952,979.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$662,748.25</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$33.14</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2030 &#8211; February 28, 2031</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$8,191,569.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$682,630.75</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$34.13</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2031 &#8211; February 29, 2032</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$8,437,316.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$703,109.67</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$35.16</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2032 &#8211; February 28, 2033</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$8,690,435.00</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$724,202.92</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$36.21</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div></div><div style="padding-left:0.29pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2033 &#8211; February 28, 2034</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$8,951,148.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$745,929.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$37.30</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2034 &#8211; February 28, 2035</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$9,847,200.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$820,600.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$41.03</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2035 &#8211; February 29, 2036</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$10,142,400.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$845,200.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$42.26</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2036 &#8211; February 28, 2037</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$10,447,200.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$870,600.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$43.53</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2037 &#8211; February 28, 2038</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$10,761,600.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$896,800.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$44.84</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2038 &#8211; February 28, 2039</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$11,085,600.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$923,800.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$46.19</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2039 &#8211; February 29, 2040</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$11,419,200.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$951,600.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$47.58</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2040 &#8211; February 28, 2041</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$11,762,400.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$980,200.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$49.01</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2041 &#8211; September 30, 2042</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$12,115,272.00</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$1,009,606.00</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$50.48</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:90pt;padding-right:8.4pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">100 Tech Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Schedule I of the 100 Tech Lease is hereby deleted in its entirety and replaced with the Fixed Rent set forth below. </font></div><div style="padding-left:4.42pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:32.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 7.95pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lease Year</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:31.37pt;padding-right:31.37pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Fixed Rent</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:42.55pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Monthly Fixed Rent</font></div></td></tr><tr><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 7.95pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2017 &#8211; September 30, 2018</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:31.37pt;padding-right:31.37pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,193,317.90</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:42.55pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$516,109.83</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 7.45pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2018 &#8211; September 30, 2019</font></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:31.37pt;padding-right:31.37pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,348,150.85</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-right:42.8pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$529,012.57</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 7.2pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2019 &#8211; September 30, 2020</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.45pt;padding-left:39.55pt;padding-right:39.55pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,506,854.62</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:42.8pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$542,237.89</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 7.2pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2020 &#8211; September 30, 2021</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:39.55pt;padding-right:39.55pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,669,525.98</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-right:43.05pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$555,793.83</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.95pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2021 &#8211; September 30, 2022</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:39.55pt;padding-right:39.55pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,836,264.13</font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:43.05pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$569,688.68</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.42pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:32.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.95pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2022 &#8211; September 30, 2023</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:39.32pt;padding-right:39.32pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7,007,170.74</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-right:41.6pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$583,930</font><font style="color:#5e5e5e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">90</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.95pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2023 &#8211; September 30, 2024</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.55pt;padding-right:38.55pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7,182</font><font style="color:#444444;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">350</font><font style="color:#5e5e5e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">01</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:43.3pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$598,529.17</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2024 &#8211; September 30, 2025</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.45pt;padding-left:39.32pt;padding-right:39.32pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7,361,908.76</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.45pt;padding-right:43.3pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$613,492.40</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2025 &#8211; September 30, 2026</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:39.1pt;padding-right:39.1pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7,545,956.48</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:43.55pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$628,829.71</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2026 &#8211; September 30, 2027</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:39.42pt;padding-right:39.42pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7,734,605.39</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:43.55pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$644,550.45</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2027 &#8211; September 30, 2028</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:39.1pt;padding-right:39.1pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$7,927,970.53</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:43.75pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$660,664.21</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2028 &#8211; September 30, 2029</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:39.17pt;padding-right:39.17pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$8,126,169.79</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:43.75pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$677,180.82</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.75pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2029 &#8211; September 30, 2030</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$8,329,324.03</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-right:42.55pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$694,110</font><font style="color:#5e5e5e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.75pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2030 &#8211; September 30, 2031</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.52pt;padding-right:38.52pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$8,537,557.13</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:43.4pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$711,463.09</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.55pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2031 &#8211; September 30, 2032</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$8,750,996.06</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:44pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$729,249.67</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.55pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2032 &#8211; September 30, 2033</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$9,626,095.68</font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:44pt;text-align:right"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$802,174.64</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.55pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2033 &#8211; September 30, 2034</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$9,914,878.56 </font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:44pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">826,239.88</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.55pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2034 &#8211; September 30, 2035</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$10,212,324.96 </font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:44pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$851,027.08</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.55pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2035 &#8211; September 30, 2036</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$10,518,694.68 </font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:44pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$876,557.89</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.55pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2036 &#8211; September 30, 2037</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$10,834,255.56 </font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:44pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$902,854.63</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.55pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2037 &#8211; September 30, 2038</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$11,159,283.24 </font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:44pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$929,940.27</font></div></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.55pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2038 &#8211; September 30, 2039</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$11,494,061.76 </font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:44pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$957,838.48</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.55pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2039 &#8211; September 30, 2040</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$11,838,883.56 </font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:44pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$986,573.63</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.42pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:32.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.55pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2040 &#8211; September 30, 2041</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$12,194,050.08 </font></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:44pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$1,016,170.84</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.55pt;text-align:left;vertical-align:top"><font style="color:#282828;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 1, 2041 &#8211; September 30, 2042</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:38.67pt;padding-right:38.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$12,559,871.64 </font></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-right:44pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$1,046,655.97 </font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt;text-decoration:underline">One Upland Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Article I of the One Upland Lease is hereby amended by modifying the following subsections as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">1.04 Term and Possession</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; The Initial Term of the Lease is hereby extended for a period expiring on September 30, 2042 (the &#8220;Expiration Date&#8221;). The Lease is hereby amended so that all references to the &#8220;Lease Term&#8221; and the &#8220;Initial Term&#8221; in the Lease shall refer to the Initial Term as extended hereunder, and the new Expiration Date as modified herein.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) From August 1, 2020, Base Rent for the Premises shall be paid as follows and all references to the &#8220;Base Rent&#8221; in the Lease shall be deemed to refer to the Base Rent set forth in the table below&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div></div><div style="padding-left:22.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:31.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.6pt;padding-right:1.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:97%;text-decoration:underline">Period</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:14.8pt;padding-right:14.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:99%;text-decoration:underline">Annual Base Rent</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Monthly Base Rent</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;1&#47;2020-7&#47;31&#47;2021</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2.3pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5,700,024.47</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$475,002.04</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.2pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;l&#47;2021-7&#47;31&#47;2022</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5.7pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5,794,593.41</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$482,882.78</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:3.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;l &#47;2022-7&#47;31&#47;2023</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5.7pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5,794,593.41</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$482,882.78</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;l&#47;2023-7&#47;31&#47;2024</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5.7pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5,891,999.42</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$490,999.95</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;l&#47;2024-7&#47;31&#47;2025</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5.7pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5,891,999.42</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$490,999.95</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;l&#47;2025-7&#47;31&#47;2026</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5.7pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5,992,327.61</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$499,360.63</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;1&#47;2026-7&#47;31&#47;2027</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2.85pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$5,992,327.61</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$499,360.63</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;l&#47;2027-7&#47;31&#47;2028</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2.85pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,095,665.65</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$507,972.14</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;1&#47;2028-7&#47;31&#47;2029</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2.75pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,095,665.65</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$507,972.14</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;1&#47;2029-7&#47;31&#47;2030</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2.75pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,202,103.82</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$516,841.99</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;l&#47;2030-7&#47;31&#47;2031</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2.75pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,202,103.82</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$516,841.99</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;l&#47;2031-7&#47;31&#47;2032</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5.7pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,311,735.15</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$525,977.93</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;l&#47;2032-7&#47;31&#47;2033</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5.7pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,311,735.15</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$525,977.93</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:2.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;l &#47;2033-7&#47;31&#47;2034</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5.7pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,424,655.41</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 29.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$535,387.95</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;1&#47;2034-7&#47;31&#47;2035</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$6,424,655.41</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 28.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$535,387.95</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8&#47;1&#47;2035-9&#47;30&#47;2035</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">2 month period</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$545,080.27</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10&#47;1&#47;2035-9&#47;30&#47;2036</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:36pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">$7,195,227.20</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.15pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$599,602.27</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10&#47;1&#47;2036-9&#47;30&#47;2037</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:41.45pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">$7,411,084.02</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$617,590.34</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10&#47;1&#47;2037-9&#47;30&#47;2038</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:41.45pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">$7,633,416.54</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$636,118.05</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10&#47;1&#47;2038-9&#47;30&#47;2039</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:41.45pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">$7,862,419.04</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$655,201.59</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10&#47;1&#47;2039-9&#47;30&#47;2040</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:41.45pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">$8,098,291.61</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$674,857.63</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10&#47;1&#47;2040-9&#47;30&#47;2041</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:41.45pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">$8,341,240.36</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$695,103.36</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10&#47;1&#47;2041-9&#47;30&#47;2042</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.7pt;padding-left:41.45pt;padding-right:29.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:94%">$8,591,477.57</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 30.15pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$715,956.46</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Extension Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In lieu of any existing extension rights in the Leases, Tenant is hereby granted three (3) consecutive extension rights for each of the three Leases. Accordingly, the Leases are hereby amended as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt;text-decoration:underline">One Investors Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Section 41(a) of the One Investors Lease is hereby amended by deleting &#8220;two (2) consecutive rights&#8221; and replacing it with &#8220;three (3) consecutive rights&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">100 Tech Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Section 10.2 of the 100 Tech Lease is hereby amended by deleting the first sentence in its entirety and replacing it with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Tenant shall have three (3) consecutive rights to extend the term of this Lease for five (5) years each (each, an &#8220;Extension Term&#8221;), provided that Tenant shall give Landlord notice of Tenant's exercise of such option no sooner than twenty-four </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(24) months and no later than eighteen (18) months prior to the expiration of the then current Term, and provided further that Tenant shall not be in default   at the time of giving such notice under this Lease beyond applicable notice and cure periods.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt;text-decoration:underline">One Upland Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; Section 1.04 of the One Upland Lease is hereby amended by deleting &#8220;four options to extend&#8221; and replacing it with &#8220;three options to extend&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Alterations and Restoration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For ease of administration and consistency, Landlords and Tenant agree that the process for approval by Landlords of Tenant&#8217;s proposed Tenant Improvements (as defined below), and the restoration obligations associated therewith, shall be governed by the One Investors Lease, notwithstanding any contrary provisions of the 100 Tech Lease or One Upland Road Lease. The Landlords acknowledge and agree that the Tenant Improvements will be designed and performed in furtherance of a master planning effort undertaken by Tenant and reviewed by the Landlords, the effect of which will be to treat the three Premises as a unified whole, without regard to property line and Premises boundaries. Each Landlord agrees to be reasonable in reviewing and approving applicable Tenant Improvements on its Premises, regardless of the location of such Tenant Improvements within the overall project. Notwithstanding anything to the contrary contained in the One Investors Lease regarding restoration of Installations (as defined in the One Investors Lease), Tenant shall have no obligation to remove and restore at the end of the Term any new buildings or expansions of existing buildings, landscaping, planted areas, walks, roadways, parking, and other new installations and improvements on the Premises outside of the existing buildings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant Improvement Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of the three Landlords agrees to provide an additional tenant improvement allowance of $60.00 per rentable square foot of the applicable Premises, for an aggregate total of $41,010,780.00 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2021 Tenant Improvement Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2021 TIA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), broken down as follows&#58; $14,400,000.00 under the One Investors Lease, $12,025,860.00 under the 100 Tech Lease, and $14,584,920.00 under the One Upland Lease. Notwithstanding that the 2021 TIA has been allocated to each of the separate Landlords, Tenant is not bound by such allocation, and the Landlords acknowledge and agree that Tenant may apply any amount of the 2021 TIA to Tenant Improvements across the three Premises as Tenant sees fit, without regard to each Landlord&#8217;s portion of the total. Notwithstanding contrary provisions of the Leases governing disbursement of tenant allowance funds, the 2021 Tenant Improvement Allowance shall be disbursed and used as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt">Tenant shall have no right to any portion of the 2021 TIA that is not disbursed before the second anniversary of the date hereof. </font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The 2021 TIA shall be used solely for the payment of design (including A&#38;E drawings), permits and construction, and construction management costs in connection with the construction of tenant improvements, site work, new structures and other hard construction costs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) at the properties covered by the three Leases (collectively, the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TI Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;). The 2021 TIA shall not be used to purchase any furniture, personal property or other non-building system materials or equipment, including, but not be limited to, non-ducted biological safety cabinets and other scientific equipment not incorporated into the Tenant Improvements&#59; provided, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however, the 2021 TIA may be used for Tenant&#8217;s voice and data cabling, special electrical power distribution, telephone and security systems. </font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Landlord shall have no obligation to bear any portion of the cost of any of the Tenant Improvements except to the extent of the 2021 TIA and except to the extent that any remaining contributions or allowances remain under each of the existing Leases as of the date hereof.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt;text-decoration:underline">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the course of construction of the Tenant Improvements, Landlord shall reimburse Tenant for TI Costs once a month (such reimbursement not to exceed, in the aggregate, the amount of the 2021 TIA) against a draw request in Landlord&#8217;s standard form, containing evidence of payment of such TI Costs by Tenant and such certifications, lien waivers (including a conditional lien release for each progress payment and unconditional lien releases for the prior month&#8217;s progress payments), inspection reports and other matters as Landlord customarily obtains, to the extent of Landlord&#8217;s approval thereof for payment, no later than the last day of the calendar month immediately following the calendar month in which the draw request was made. Upon completion of the Tenant Improvements (and prior to any final disbursement of the 2021 TIA), Tenant shall deliver to Landlord&#58; (i) sworn statements setting forth the names of all contractors and first tier subcontractors who did the work and final, unconditional lien waivers from all such contractors and first tier subcontractors&#59; (ii) as-built plans (one copy in print format and two copies in electronic CAD format) for such Tenant Improvements&#59; (iii) a certification of substantial completion in Form AIA G704, (iv) a certificate of occupancy for the premises covered by each Lease, to the extent not already delivered&#59; and (v) copies of all operation and maintenance manuals and warranties affecting the premises covered by each Lease.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt;text-decoration:underline">Nonpayment&#59; Offset Right&#59; Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any Landlord fails timely to pay any portion of the 2021 TIA when such portion is properly due to Tenant and as to which Tenant has satisfied each of the foregoing requisition conditions, and such failure shall continue for 30 days after written notice from Tenant to such Landlord (which such notice shall describe in detail the basis on which Tenant asserts that such Landlord has wrongfully failed to disburse such amount), then Tenant, provided no Default has occurred and is continuing, may deliver a second notice to such Landlord that includes in at least 14 point-type and all capitals (with the rest of the notice in standard font and type-size) the phrase &#8220;FAILURE TO IMMEDIATELY RESPOND COULD RESULT IN THE FORFEITURE OF RIGHTS&#8221; (an &#8220;Offset Notice&#8221;), which notice shall specify the portion of the TI Allowance that has not been timely paid and the date upon which request for payment was first sent to such Landlord, and, if such Landlord fails to disburse the amount expressly referenced in the Offset Notice within 10 business days, then Tenant shall have the right to have such unpaid amount credited against the next installment(s) of Base Rent thereafter due under the applicable Lease, until such sums due Tenant have been fully paid by such Landlord or fully credited and accounted for&#59; provided however, that the amount so offset by Tenant in any calendar month shall not exceed 20% of the amount of the monthly installment of Base Rent payable by Tenant to Landlord under the applicable Lease with respect to such calendar month. If, however, Landlord notifies Tenant prior to the expiration of such 10 business day period that Landlord disputes that Landlord has wrongfully </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">failed to disburse the amount claimed by Tenant, and if Landlord and Tenant are not able to reach agreement with respect to such dispute (with Landlord disbursing any undisputed amounts which Landlord is required to disburse under this Work Letter) within 10 business days after Tenant&#8217;s receipt of a such notice from Landlord, then the parties shall submit such dispute to arbitration conducted by the American Arbitration Association in Boston, Massachusetts in accordance with the &#8220;Expedited Procedures&#8221; of its Commercial Arbitration Rules, in which case Base Rent shall not be offset by such disputed amount unless and until Tenant prevails in such arbitration and the arbitrator concludes that Tenant has the right to such offset right and determines the amount owed to Tenant by Landlord, if any, that is to be offset against Base Rent. All costs associated with arbitration shall be awarded to the prevailing party as determined by the arbitrator.</font></div><div style="margin-bottom:12pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.68pt;text-decoration:underline">Tenant Improvement Progress Reports.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">On or before the 10th day of each calendar month during the course of design and construction of the Tenant Improvements, Tenant shall deliver to Landlords a Tenant Improvement progress report in a form provided by Landlords</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">completed to provide all of the most up-to-date information regarding Tenant&#8217;s progress with respect the design and construction of the Tenant Improvements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cross-Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant agrees that a &#8220;Default&#8221; under the One Investors Lease or &#8220;Event of Default&#8221; under the 100 Tech Lease and One Upland Lease shall automatically constitute a Default or Event of Default, as applicable, under all three Leases.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Landlords represent and warrant to Tenant that they have the right, power and authority to execute and deliver this Amendment and to perform their obligations hereunder, and this Amendment is a valid and binding obligation of Landlords enforceable against Landlords in accordance with the terms hereof. Tenant represents and warrants to Landlords that it has the right, power and authority to execute and deliver this Amendment and to perform its obligations hereunder, and this Amendment is a valid and binding obligation of Tenant enforceable against Tenant in accordance with the terms hereof. Tenant acknowledges and agrees that Landlords are in full compliance with the terms of the Leases and no event exists or has occurred that constitutes or could ripen into a Landlord default under the Leases.</font></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Brokerage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Landlords and Tenant each hereby represents that, other than Newmark Grubb Knight Frank and Jones Lang LaSalle (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), it has not dealt with any broker, agent or other person entitled to a commission, compensation, or fee with respect to the transactions contemplated by this Amendment. Landlords and Tenant each hereby agree to defend, indemnify, and hold harmless the other, and its successors and assigns, against and from all claims, losses, liabilities, and expenses, including, without limitation, reasonable attorneys&#8217; fees, arising out of any claim by any broker, agent, or other person or entity, other than the Brokers, claiming a commission or other form of compensation based upon alleged dealings with the indemnifying party with respect to this Amendment. Landlords shall be responsible to pay the commission due to the Brokers pursuant to a separate agreement.</font></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Ratification&#59; Conflict&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as amended herein, the Leases shall remain in full force and effect and the parties hereto ratify and reconfirm the Leases. On and after the date hereof, each reference in the Leases to &#8220;this Lease,&#8221; &#8220;the Lease,&#8221; &#8220;hereunder,&#8221; &#8220;hereof,&#8221; or words of like import, and each reference to the Lease in any other agreements, documents, or instruments executed and delivered pursuant to, or in connection with, the Leases, will mean and be a reference to the Leases as amended by this Amendment. In the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.16pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">event of any conflict between this Amendment and the Leases, the provisions of this Amendment shall control. No amendment or modification of this Amendment, and no further amendment or modification of the Leases, will be effective unless it is in writing and signed by Landlords and Tenant.</font></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment shall be governed by the laws of the Commonwealth of Massachusetts without regard to its conflict of law provisions.</font></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment may be executed in as many counterparts as the parties hereto may deem necessary or convenient, and each such counterpart shall be deemed an original but all of which, together, shall constitute but one and the same document. Counterparts may be delivered via electronic mail (including PDF or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Electronic signatures shall be deemed original signatures for purposes of this Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their successors and permitted assigns.</font></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event of a dispute between the parties, the prevailing party shall be entitled to have its reasonable attorneys&#8217; fees and costs paid by the other party.</font></div><div style="margin-bottom:12pt;padding-right:8.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Tenant and Landlords each acknowledge that it has read the provisions of this Amendment, understands them, and is bound by them. Time is of the essence in this Amendment.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i299a2cea044346ee871f7568643f601e_22"></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Amendment under seal as of the day and year first above written.</font></div><div style="margin-top:24pt;padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">LANDLORDS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARE-MA REGION NO. 92, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;a Delaware limited partnership, </font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">managing member</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;ARE-QRS CORP.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Maryland corporation,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;general partner</font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Mark Hikin</font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">            By&#58; Mark Hikin </font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">            Its&#58; Vice President, RE Legal Affairs</font></div><div style="margin-bottom:6pt;padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARE-MA REGION NO. 64, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;a Delaware limited partnership, </font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">managing member</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;ARE-QRS CORP.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Maryland corporation,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;general partner</font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Mark Hikin</font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">            By&#58; Mark Hikin </font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">            Its&#58; Vice President, RE Legal Affairs</font></div><div style="padding-right:5.5pt"><font><br></font></div><div style="padding-right:5.5pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:89.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARE-MA REGION NO. 83, LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;ALEXANDRIA REAL ESTATE EQUITIES, L.P.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;a Delaware limited partnership, </font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">managing member</font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;ARE-QRS CORP.,</font></div><div style="padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a Maryland corporation,</font></div><div style="margin-bottom:18pt;padding-left:180pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;general partner</font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Mark Hikin</font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">            By&#58; Mark Hikin </font></div><div style="margin-top:0.25pt;padding-left:216.85pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">            Its&#58; Vice President, RE Legal Affairs</font></div><div style="padding-right:5.5pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TENANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:24pt;padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MODERNATX, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="margin-top:0.25pt;padding-left:180pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David Meline</font></div><div style="margin-top:0.25pt;padding-left:180pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; David Meline </font></div><div style="margin-top:0.25pt;padding-left:180pt;padding-right:5.5pt"><font style="color:#181613;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Its&#58; Chief Financial Officer</font></div><div style="padding-left:303.75pt"><font><br></font></div><div style="height:89.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>3
<FILENAME>exhibit1016-legoffcorinneo.htm
<DESCRIPTION>EX-10.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i038955b1943244ab99b618d229c63d33_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:7.7pt;padding-right:5.15pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.16</font></div><div style="margin-top:7.7pt;padding-right:5.15pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:197px"></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:5.9pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 28, 2020</font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>Corinne Le Goff, Pharm. D., MBA<br>&#91;***&#93;</font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#91;***&#93;</font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Re&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Offer of Employment by ModernaTX, Inc.</font></div><div style="padding-left:4.5pt;padding-right:270.15pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:270.15pt"><font><br></font></div><div style="padding-left:4.5pt;padding-right:270.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dear Corinne,</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5.85pt;padding-right:19.55pt;text-align:justify;text-indent:36.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%">ModernaTX, Inc. (together with its affiliates, the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">&#34;Company&#34;)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%"> is pleased to confirm, contingent on receiving appropriate references and the successful completion of a background check&#47;drug screen, its offer to employ you as Chief Commercial Officer, reporting to the Chief Executive Officer. Your effective date of hire will be on or before January 19, 2021 (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">&#34;Start Date&#34;),</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%"> and you will perform services for the Company as a regular, full-time employee. The initial terms of your employment, should you accept this offer, are set forth below.</font></div><div><font><br></font></div><div style="padding-left:6.5pt;padding-right:22.55pt;text-indent:35.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This a full-time, exempt level position. Your base salary will be at the rate of $625,000.00 (USD) per year. All wages will be paid in accordance with the Company's normal biweekly pay schedule for salaried employees, and is subject to change by the Company. Your base salary will be subject to periodic review and adjustment at the Company's discretion.</font></div><div style="margin-top:11.25pt;padding-left:6pt;padding-right:17pt;text-indent:36.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to the foregoing, upon your commencement of employment with the Company, you will be paid a one-time signing bonus of $300,000.00 less applicable taxes (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#34;Signing Bonus&#34;).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> You acknowledge and agree that you will repay the Signing Bonus to the Company within 10 days of your last day of employment if you voluntarily terminate your employment with the Company or your employment is terminated for cause (as determined by the Company) during the first 24 months of your employment. That amount may be collected by the Company, either directly or indirectly, from any (i) payment of any kind due to you from the Company or any affiliate thereof including, without limitation, accrued wages, vacation, final wages, and expense reimbursements to the fullest extent permitted by applicable law&#59; and&#47;or (ii) the forfeiture or cancellation of any equity interest owned by you in the Company or any subsidiary or affiliate thereof, whether now existing or hereafter formed, and regardless of the form such equity interest (e.g., common units, incentive units (also referred to as profits interests), options to acquire common units or otherwise).</font></div><div><font><br></font></div><div style="padding-left:6.3pt;padding-right:18.8pt;text-align:justify;text-indent:36.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">You will be eligible to earn an annual performance bonus. The Company will initially target the bonus at up to 75% of your annual salary rate (pro-rated based on your Start Date, provided that your Start Date is on or before the first Monday of October of the applicable calendar year). If your Start Date is after the first Monday of October, you will not be eligible for a bonus for the calendar year in which you were hired. The actual bonus percentage is discretionary and will be subject to the Company's assessment of your performance, as well as business conditions at the Company. The bonus also will be subject to approval by and adjustment at the discretion of the Company and the terms of any applicable bonus plan. The bonus, if any, will be paid no later than March 15 of the calendar year following the calendar year to which such bonus relates. You must be employed on the date a bonus is paid to receive that bonus.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6.55pt;padding-right:19.5pt;text-align:justify;text-indent:35.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%">Subject to the commencement of your employment with the Company, the Company will recommend to the Board of Directors (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">&#34;Board&#34;)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%"> of the Company's parent entity </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">(&#8220;Parent''),</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%"> that you be eligible to participate in Moderna's equity incentive program and be granted, at such time as the Board so determines, an equity award equivalent to a total value of $8,000,000.00 as of the grant date (such equity award is referred to as the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">&#34;New Hire Equity Award&#34;).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%"> Subject to the Board's approval of the New Hire</font></div><div style="margin-top:10.1pt;padding-left:8.3pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i038955b1943244ab99b618d229c63d33_4"></div><hr style="page-break-after:always"><div style="min-height:61.92pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.35pt;padding-left:10.35pt;padding-right:5.4pt;text-align:justify;text-indent:0.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Award, the New Hire Equity Award will vest according to the following schedule&#58; 25% of the New Hire Equity Award will vest on the first anniversary of the date of grant, and the remaining 75% of the New Hire Equity Award will vest in equal calendar quarterly installments over the next three (3) years, provided that, in each case, you continue to provide continuous services to the Company as of each such vesting date. The New Hire Equity Award is subject to our &#34;Your Equity Selection&#34; (YES) program. You may choose to have your award delivered to you in one of the following mixes of Non-Qualified Stock Options and&#47;or Restricted Stock Units&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:46.75pt;text-indent:-18.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.8pt">100% of the value delivered in the form of Non-Qualified Stock Options.</font></div><div style="margin-top:7.65pt;padding-left:46.7pt;padding-right:7.2pt;text-indent:-18.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%;padding-left:14.7pt">75% of the value delivered in the form of Non-Qualified Stock Options and 25% in value delivered in the form of Restricted Stock Units. This is the default choice if no selection is made.</font></div><div style="margin-top:7.7pt;padding-left:46.7pt;padding-right:7.4pt;text-indent:-18.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%;padding-left:14.7pt">50% of the value delivered in the form of Non-Qualified Stock Options and 50% in value delivered in the form of Restricted Stock Units.</font></div><div style="margin-top:6.5pt;padding-left:10.45pt;padding-right:5.3pt;text-align:justify;text-indent:0.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">You will receive an email from the Compensation Team at the Company to register your selection prior to your grant date. In the event of a stock split, stock consolidation or similar event prior to the grant of the New Hire Equity Award, the number of shares subject thereto shall be adjusted proportionately.   The grant price of the New Hire Equity Award will be equal to the closing price on the day of grant. The grant of the New Hire Equity Award will be conditioned upon, among other things, your execution of all necessary documentation relating to the New Hire Equity Award as determined by the Company (all such documentation is collectively referred to as the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#34;New Hire Equity Award Documentation&#34;)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The New Hire Equity Award will be subject to the terms and conditions set forth in the New Hire Equity Award Documentation.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9.9pt;padding-right:5.45pt;text-align:justify;text-indent:36.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, subject to the Board's approval, and provided your start date is on or before the first Monday of October of the applicable calendar year, you will be eligible to receive an annual equity award related to your performance for the eligible performance period (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#34;Annual Equity Award&#34;)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Annual Equity Awards typically will be issued in the first quarter of the year following the performance period. Your annual grants will be based on a combination of market data and performance. You will receive an annual grant that will be a mix of stock options, RSU's, and potentially PSU's subject to the current executive pay policies in place. The current range is between </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">$2M-$4M.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Your first Annual Equity Award, if any, will be pro-rated based upon your start date. Targets may be modified up or down based on your individual performance. Annual equity guidelines are subject to change and may be updated based on market conditions.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.45pt;padding-right:6.05pt;text-align:justify;text-indent:36.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You may be required to relocate to the Greater Boston area, as applicable, by December 31, 2021, or as mutually agreed upon by both parties. The Company will pay reasonable costs associated with your relocation (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#34;Relocation Expenses&#34;)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> in accordance with the Employee Relocation Guidelines that are in effect at the time of the initiation of your relocation case. The Company will determine in its reasonable judgment what portion, if any, of your Relocation Expenses are for nondeductible expenses in accordance with applicable law and will comply with associated withholding and tax reporting obligations. You acknowledge and agree that you will repay the Relocation Expenses to the Company within 10 days of your last day of employment if you voluntarily terminate your employment with the Company or your employment is terminated for cause (as determined by the Company) within 24 months of the initiation of your relocation case.   That amount may be collected by the Company, either directly or indirectly, from any (i) payment of any kind due to you from the Company or any affiliate thereof including, without limitation, accrued wages, vacation, final wages, and expense reimbursements to the fullest extent permitted by applicable law&#59; and&#47;or (ii) the forfeiture or cancellation of any equity interest owned by you in the Company or any subsidiary or affiliate thereof, whether now existing or hereafter formed, and regardless of the form such equity interest (e.g., common units, incentive units (also referred to as profits interests), options to acquire common units or otherwise).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.3pt;padding-right:6.4pt;text-align:justify;text-indent:36.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to your compensation, you may take advantage of various benefits offered by the Company from time to time, subject to any eligibility requirements. Currently the Company provides group medical and dental insurance, short term disability coverage, group life insurance and a 401(k)</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i038955b1943244ab99b618d229c63d33_7"></div><hr style="page-break-after:always"><div style="min-height:61.2pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.85pt;padding-left:10.45pt;padding-right:5.15pt;text-align:justify;text-indent:0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">plan. These benefits, of course, may be modified, changed or eliminated from time to time at the sole discretion of the Company, and the provision of such benefits to you in no way changes or impacts your status as an at-will employee. Where a particular benefit is subject to a formal plan (for example, medical insurance or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document. Should you ever have any questions about Company benefits, you should ask for a copy of the applicable plan document. You will also be eligible for vacation pursuant to the Company's policies in effect from time to time.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:10.4pt;padding-right:6.1pt;text-align:justify;text-indent:36.45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All forms of compensation referred to in this offer letter are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:9.95pt;padding-right:5.45pt;text-align:justify;text-indent:36.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You acknowledge and agree that employment with the Company is &#34;at will.&#34; You are not being offered employment for a definite period of time, and either you or the Company may terminate the employment relationship at any time and for any reason without prior notice and without additional compensation to you. Similarly, this offer letter sets forth the initial terms and conditions of your employment, which are subject to change at any time at the Company's discretion. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company's personnel policies and procedures, may change from time to time, the &#34;at-will&#34; nature of your employment may only be changed by a written agreement signed by you and the Chief Executive Officer, which expressly states the intention to modify the at-will nature of your employment.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9.8pt;padding-right:6.1pt;text-align:justify;text-indent:37pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You are being hired as a Massachusetts employee and you must live and work in Massachusetts as a material condition of your employment. However, due to factors that affect your ability to relocate immediately, including the COVID-19 pandemic, you will be permitted to commence employment by working remotely from your home in California until your full relocation to Cambridge, Massachusetts by August 1, 2021. You will be taxed in your home state until you relocate. It is understood that the Company may change your normal place of work according to the Company's future needs.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:9.6pt;padding-right:5.95pt;text-align:justify;text-indent:36.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a condition of the commencement of your employment, you are required to enter into an Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#34;Restrictive</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Covenants Agreement&#34;,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> a copy of which is enclosed with this offer letter. This offer is conditioned on your representation that you are not subject to any confidentiality, non-competition agreement or any other similar type of restriction that may affect your ability to devote full time and attention to your work at the Company. If you have entered into any agreement that may restrict your activities on behalf of the Company, please provide me with a copy of the agreement as soon as possible. You further represent that you have not used and will not use or disclose any trade secret or other proprietary right of any previous employer or any other party.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9.45pt;padding-right:6.25pt;text-align:justify;text-indent:36.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Immigration Reform and Control Act requires employers to verify the employment eligibility and identity of new employees. You will receive a Form 1-9 that you will be required to complete. Please bring the appropriate documents listed on that form with you when you report for work. We will not be able to employ you if you fail to comply with this requirement.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.3pt;padding-right:6.35pt;text-align:justify;text-indent:36.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">This offer letter and the enclosed Restrictive Covenants Agreement constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:8.95pt;padding-right:6.35pt;text-align:justify;text-indent:36.65pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Please indicate your acceptance of this offer by signing and dating this offer letter and the enclosed Restrictive Covenants Agreement (PDF by email) and returning it by January 1, 2021.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:9.3pt;padding-right:7.45pt;text-align:justify;text-indent:35.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:111%">Corinne, we look forward to your joining the Company and are pleased that you will be working with us to build a transformative company for patients.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i038955b1943244ab99b618d229c63d33_10"></div><hr style="page-break-after:always"><div style="min-height:74.88pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:228.3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:228.2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ModernaTX, Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.45pt;padding-left:228.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By&#58; April Eldred</font></div><div><font><br></font></div><div style="padding-left:228.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Title&#58; Vice President, Talent Acquisition</font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; April Eldred</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.75pt;padding-left:11.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Accepted and Agreed&#58;</font></div><div><font><br></font></div><div style="margin-top:6.9pt;padding-left:11.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Corinne Le Goff, Pharm. D, MBA</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Corinne Le Goff</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">12&#47;29&#47;2020</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    Date</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>4
<FILENAME>exhibit1017-executivesepar.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i365d1980ef694c52b1986e305c75eaf8_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.17</font></div><div><font><br></font></div><div><img alt="image_01.jpg" src="image_01.jpg" style="height:36px;margin-bottom:5pt;vertical-align:text-bottom;width:159px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 Technology Square   &#8226;  Cambridge, MA 02139</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">phone 617-714-6500  &#8226;  fax 617-583-1998</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><img alt="image_1.jpg" src="image_1.jpg" style="height:5px;margin-bottom:5pt;vertical-align:text-bottom;width:425px"></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Personal and Confidential</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">November 11, 2021</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corinne Le Goff</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;<br>&#91;***&#93;<br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Re&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Executive Separation and Transitional Services Agreement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dear Corinne&#58; </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with the Amended and Restated Executive Severance Plan (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Moderna Inc. (individually, and together with any direct and indirect parents, subsidiaries, and affiliates, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), this executive separation and transitional services agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) sets forth the terms of your continued employment with the Company through the earliest of (i) the close of business on December 17, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Anticipated Separation Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or (ii) such earlier date when your employment is terminated (a) by the Company with Cause, (b) due to your death or Disability, or (c) by you (such actual last day of employment, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Separation Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  For purposes of this Agreement, the time period between the date first set forth above and the Separation Date shall be referred to as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Transition Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;  During the Transition Period you will continue to receive your salary and benefits (subject to eligibility under any applicable benefits plans) and continue to vest in your outstanding equity, but you will not be expected to come into the office or work remotely unless otherwise directed by the Company&#8217;s Chief Executive Officer (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CEO</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  For the avoidance of doubt, as of the date of this Agreement, the Company characterizes your termination as a termination without Cause.  In the event that the Company should seek to terminate your employment for Cause following the date of this Agreement, it will promptly notify you in writing.  Any such termination for Cause shall become effective within three (3) business days of delivery of the notice, unless the circumstances giving rise to the for Cause termination are cured within such three (3) business days.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regardless of whether you enter into the Agreement, the following bulleted terms and obligations (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall apply&#58;  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">You will continue to participate in the Company&#8217;s Severance Plan and will be entitled to any benefits and payments thereunder in the event of a Qualified Termination Event (as defined in the Severance Plan), subject to the terms and conditions of the Severance Plan.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">On the Separation Date, the Company shall pay you for all salary plus any accrued but unused vacation to which you are entitled through the Separation Date.  </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;&#8220;Cause&#8221; is defined by the Company&#8217;s Amended and Restated Executive Severance Plan effective as of November 4, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Severance Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  &#8220;Disability&#8221; is defined as your inability to perform the essential functions of your employment with the Company, with or without a reasonable accommodation, for more than 120 consecutive days, unless a longer period is required by federal or applicable state law, in which case that longer period would apply.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Separation Agreement &#8211; Page 2</font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Your eligibility to participate in the Company&#8217;s health, dental and vision plans will cease on the last day of the month in which the Separation Date occurs.  You may elect to continue your health, dental and vision benefits in accordance with and subject to the law known as COBRA.  You will be notified by separate memoranda of your rights under COBRA including payment obligations.&#160; You will participate under COBRA in accordance with the provisions of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Your eligibility to participate in the Company&#8217;s other employee benefit plans and programs will cease on the Separation Date in accordance with the terms and conditions of each of those benefit plans and programs.  Your rights to benefits, if any, are governed by the terms and conditions of those benefit plans and programs.  If you are currently participating in the Company&#8217;s 401(k) plan, deductions for the 401(k) Plan will end with your December 17, 2021 paycheck, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> this date is the Separation Date.  You will receive information by mail concerning 401(k) plan rollover procedures should you be a participant in this program.  Without limiting the generality of the foregoing and for the avoidance of doubt, you are not eligible to receive any bonus or other forms of incentive compensation with respect to you working for the Company during fiscal year 2021 or thereafter, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> you meet the conditions set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">If applicable, you shall also have the right to retain any and all vested restricted stock units and to exercise any and all vested options that you hold to purchase equity of the Company, and any such exercise shall be made in accordance with, and shall be subject to, the terms of any and all applicable unit option and grant plans, equity incentive plans and all other equity award plans and all agreements relating to any of the foregoing (all of the foregoing are collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Documents</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), including without limitation the time limits on exercise.&#160; Pursuant to the terms of the Equity Documents, all unvested restricted stock units and stock options you may hold will expire and be null and void as of the Separation Date. If you have any questions about your equity interests, please contact the Company&#8217;s Chief Legal Officer.  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">You are obligated, to the maximum extent permitted by applicable law, to comply with each of the obligations set forth in your Employee Confidentiality, Assignment, Noncompetition</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and Nonsolicitation Agreement dated as of December 29, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Covenants Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), a copy of which is being provided to you with this Agreement as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.    </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as noted above, the payments and other terms set forth above will not be affected by whether or not you agree to the terms set forth below.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the above-described non-contingent terms, you will be entitled to the Severance Benefits (described in Section 3 below) if you meet the Conditions (as defined in Section 2 below).  If you enter into this Agreement, you acknowledge that you are doing so voluntarily.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With those understandings, you and the Company agree as follows&#58;  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.66pt;text-decoration:underline">Matters Relating to the Transition Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If you enter into, do not revoke, and comply with this Agreement (including, without limitation the Conditions set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below), your employment with the Company will end on the Anticipated Separation Date, unless your employment is terminated on an earlier date in accordance with this Agreement (a) by the Company, with or without Cause, (b) due to your death or Disability, or (c) by you.  During the Transition Period, you will not report to the Company&#8217;s offices or perform any duties for or on behalf of the Company unless specifically requested by the Company&#8217;s CEO.  Notwithstanding the foregoing, you will make yourself available to answer any questions from the CEO or any other Company executive related to the Company or to transitioning </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Separation Agreement &#8211; Page 3</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">matters to other employees.  Any change to your duties as set forth herein shall not (a) constitute Good Reason as defined in and for purposes of the Severance Plan, and you hereby waive the application of Good Reason to your employment from the date of this Agreement to the Separation Date, or (b) alter any of your obligations under the Restrictive Covenants Agreement. On the earliest of (i) the Separation Date or (ii) a request by the Company, you will be deemed to have resigned from all officer positions that you hold with the Company or any of its respective subsidiaries and affiliates.  You shall execute any documents in reasonable form as may be requested by the Company to confirm or effectuate any such resignations.  With respect to compensation, you will continue to receive your current annual base salary and you will be eligible for employee benefits throughout the Transition Period (subject to your continued eligibility under the Company&#8217;s benefits plans)&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, you will not be entitled to any other compensation, incentive compensation, or bonuses during the Transition Period or with respect to any period prior to the Transition Period, except as set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> you meet the conditions set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In addition, you will continue to vest in your restricted stock units and stock options pursuant to the Equity Documents during the Transition Period.  You may exercise any vested options consistent with the terms of the Equity Documents.  All unvested restricted stock units and stock options will expire on the Separation Date and be of no further effect, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as otherwise set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below and provided you meet the conditions set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.66pt;text-decoration:underline">Conditions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Subject to the terms of this Agreement, you will be entitled to continue to be employed at the Company during the Transition Period and receive the Severance Benefits (as defined below) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> you satisfy each of the following (collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Conditions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;  (i)&#160; you enter into this Agreement during the Consideration Period (defined in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below), do not revoke it, and comply with it&#59; (ii)&#160;your employment is not terminated by the Company for Cause, due to death or Disability or as a result of your voluntary resignation prior to the Anticipated Separation Date&#59; (iii) you work cooperatively and in good faith with the Company during the Transition Period and perform the duties described in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> above to the Company&#8217;s satisfaction&#59; and (iv)&#160;you comply with the Restrictive Covenants Agreement.  For the avoidance of doubt, if you resign your employment or the Company terminates your employment for Cause before the Anticipated Separation Date, you will be paid only through the Separation Date, even if that date occurs prior to the Anticipated Separation Date, and you shall not be entitled to any payments from the Company from and after the Separation Date.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.66pt;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If you satisfy each of the Conditions, the Company will provide you with the following post-employment benefits (collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:24.08pt;text-decoration:underline">Separation Pay</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In accordance with the Severance Plan, the Company shall pay you $625,000, which amount equals twelve (12) months of your current annual base salary, less applicable deductions and withholdings (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Separation Pay</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Company shall pay you the Separation Pay in biweekly payments, beginning on the first regular payroll date following the later of the Separation Date and the Agreement Effective Date (as defined in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">).  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.57pt;text-decoration:underline">Bonus Payment. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  In accordance with the Severance Plan, you will receive a prorated portion, based on your Anticipated Separation Date, of your 2021 annual bonus at 100% of the target amount, which the parties agree to be a total of $450,721.15 before applicable deductions and withholdings (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus Payment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  The Company shall pay you the Bonus Payment in biweekly payments, beginning on the first regular payroll date following the later of the Separation Date and the Agreement Effective Date (as defined in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 22</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">).  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Post-Employment Consulting Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Provided that you satisfy the Conditions, then upon the Separation Date, and with no break in your service relationship for purposes of vesting in your </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Separation Agreement &#8211; Page 4</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">unvested stock options and restricted stock units, the consulting agreement attached hereto as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consulting Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) will become effective and shall, together with this Agreement, govern the post-employment relationship between you and the Company, pursuant to which you will provide consulting services to the Company related to Commercial operational and strategic matters on an as-needed basis through February 3, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consulting Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  For the avoidance of doubt, if this Agreement does not become effective, or if you fail to comply with the Agreement or satisfy all of the Conditions, the Consulting Agreement will be deemed void ab initio and be of no force or effect.  As described in greater detail in the Consulting Agreement, during the Consulting Period, you will no longer be an employee of the Company, but instead will be retained as a consultant.  For the avoidance of doubt, if the Consulting Agreement does not become effective, then your unvested stock options and restricted stock units will cease vesting on the Separation Date.  You will not receive any new equity awards during the Consulting Period.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.57pt;text-decoration:underline">COBRA Premium Assistance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Regardless of whether you enter into the Agreement, if you elect and remain eligible for COBRA, you may continue to participate in the medical, dental and&#47;or vision care plans which you currently participate in by electing COBRA continuation coverage.  If you remain covered under COBRA through at least twelve (12) months following the Separation Date, and in accordance with the Severance Plan, the Company will pay through that date the same portion of the COBRA premium that the Company would pay as its share of the cost of coverage if you were an active employee.  However, you will not be entitled to this employer subsidy if, prior to the twelve (12) month anniversary of the Separation date, you become eligible to be covered under other group health care coverage, through a new employer or otherwise.  During this Company subsidy period, you will be required to continue paying the employee share of premium payments to secure continued coverage.  Thereafter, medical insurance coverage shall be continued only to the extent required by COBRA and only to the extent you timely pay the full premium payments yourself.    </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.87pt;text-decoration:underline">Non-Competition and Non-Solicitation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.71pt">The non-competition obligation as set forth in Section 9(c) of the Restrictive Covenants Agreement is hereby modified as follows&#58; </font></div><div style="margin-bottom:12pt;padding-left:108.7pt;text-indent:-9.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:0.45pt">The defined term &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Nucleic Acid-Based Technology</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; is replaced with the defined term &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">mRNA-Based Technology</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, which shall mean &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">technology regarding the research, development, manufacture, use or commercialization of mRNA-based constructs for therapeutic, prophylactic, or diagnostic purposes, including sequence and chemical moieties, sequence engineering, biology, manufacturing, and characterization of any mRNA-based constructs or component thereof</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:108.7pt;text-indent:-9.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:0.45pt">The defined term &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Delivery Technology</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; is amended and restated as follows&#58; &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Delivery Technology shall mean technology regarding the research, development, manufacture, use or commercialization of delivery vehicles for mRNA-based cargo.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.19pt">The non-solicitation obligation set forth in Section 9(a) of the Restrictive Covenants Agreement is hereby amended and restated in its entirety, as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;I shall not, directly or indirectly, in any manner, contact, solicit or transact any business with any of the customers of the Company or with any of its vendors in any way that interferes with the Company&#8217;s relationship with such customers or vendors.  For </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Separation Agreement &#8211; Page 5</font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">purposes of this Agreement, (i) customers shall include then current customers to which the Company provided products or services during the twelve (12) months prior to the Last Day of Employment (the &#8220;One Year Lookback&#8221;) that I had significant contact with or learned confidential information about in the course of employment and customer prospects that the Company solicited during the One Year Lookback and that I had significant contact with or learned confidential information about in the course of employment, and (ii) vendors shall include then current vendors and vendors that provided services to or in connection with the Company during the One Year Lookback that I had significant contact with or learned confidential information about in the course of employment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except with respect to the amendments as set forth above in this Section 3(e), the terms and conditions of the Restrictive Covenants Agreement remain unchanged and in effect.  You acknowledge and reaffirm your post-employment restrictive covenants in the Restrictive Covenants Agreement and that, in exchange for the Severance Benefits (including the narrowing of the non-competition and non-solicitation obligations as set forth in this Section 3(e)), you shall not, directly or indirectly, whether as principal, owner, partner, shareholder, member, director, manager, officer, consultant, agent, employee, co-venturer or otherwise, anywhere in the world, (i) provide any of the types of services that you provided to the Company since December 28, 2020 in connection with any Competitive Business (as defined in the Restrictive Covenants Agreement) or (ii) engage or otherwise participate in any Competitive Business.  You expressly agree that your receipt of the Severance Benefits constitutes adequate consideration for the foregoing restrictions and you further acknowledge and agree that if you violate any of the provisions of this section (including but not limited to the covenants set forth in your Restrictive Covenants Agreement, which are expressly reaffirmed and incorporated by reference), the running of the restricted periods will be extended by the time during which you engage in such violation(s), and the Company will not be obligated to provide any further Separation Benefits to you.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.66pt;text-decoration:underline">Early Separation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If your employment ends prior to the Anticipated Separation Date in accordance with this Agreement, the following terms shall apply&#58;  if the Company terminates your employment for Cause, you resign or your employment ends due to death or Disability, you will receive the Accrued Benefits, cease vesting in your stock options and restricted stock units as of the Separation Date and will not be eligible for any severance pay or benefits, other than as is stated in this Agreement.  For purposes of clarity, termination for Cause, resignation, death or Disability are the only reasons your employment can end before the Anticipated Separation Date. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.66pt;text-decoration:underline">General Release of Claims</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In consideration for, among other terms, the opportunity to remain employed through the Transition Period and the Severance Benefits, to which you acknowledge and agree that you would otherwise not be entitled, you voluntarily release and forever discharge the Company, its affiliated and related entities (including, without limitation, direct and indirect parent companies (including, without limitation, Moderna, Inc.), and direct and indirect subsidiaries and direct and indirect affiliates), its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the past, present and future officers, directors, stockholders, members, managers, employees, attorneys, accountants, agents and representatives of each of the foregoing in their official and personal capacities (collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Releasees</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) generally from all claims, demands, debts, damages and liabilities of every name and nature, known or unknown (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Claims</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that, as of the date when you sign this Agreement, you have, ever had, now claim to have or ever claimed to have had against any or all of the Releasees, to the maximum extent permitted by applicable law.  This release includes, without limitation, all Claims&#58; relating to your employment by and termination of employment with the Company&#59; of wrongful discharge&#59; of breach of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Separation Agreement &#8211; Page 6</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">contract&#59; of discrimination or retaliation under federal, state or local law (including, without limitation, Claims of discrimination or retaliation under the Americans with Disabilities Act, the Age Discrimination in Employment Act, Title VII of the Civil Rights Act of 1964 or Massachusetts General Laws ch. 151B)&#59; under the&#160;California&#160;Fair Employment and Housing Act (FEHA), the&#160;California&#160;Labor Code, the&#160;California&#160;Constitution, and the&#160;California&#160;Family Rights Act (CFRA)&#59; under any other federal or state statute&#59; of defamation or other torts&#59; of violation of public policy&#59; for wages, bonuses, incentive compensation, including without limitation Claims pursuant to the Massachusetts Wage Act, the Massachusetts Overtime Law, and the Massachusetts Payment of Wages Law, vacation pay or any other compensation or benefits&#59; for stock, stock options, unit options, units, profit interests, incentive units, restricted stock units or any other equity interests or rights to acquire equity interests in the Company or any other Releasee&#59; and for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney&#8217;s fees.  You further represent that you have not filed any Claim against the Releasees in any forum, and you agree not to accept damages of any nature, other equitable or legal remedies for your own benefit or attorney&#8217;s fees or costs from any of the Releasees with respect to any Claim released by this Agreement.  Notwithstanding the foregoing, this general release does not release any Claim&#58; (a) that arises after the Agreement Revocation period has expired, including any rights that may arise under the Equity Documents&#59; (b) for unemployment or workers&#8217; compensation benefits&#59; (c) for vested rights under ERISA-covered employee benefit plans as applicable on the date you sign this Agreement&#59; (d) to be covered under the Officer Indemnification Agreement between the Executive and the Company dated December 29, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and under applicable directors and officers liability insurance for acts or omissions while serving as an officer of the Company&#59; (e) under this Agreement or the Consulting Agreement or (f) that by law cannot be waived.   You agree not to accept damages of any nature, other equitable or legal remedies for your own benefit or attorney&#8217;s fees or costs from any of the Releasees with respect to any Claim released by this Agreement.  As a material inducement to the Company to enter into the Agreement, you represent that you have not assigned any Claim to any third party, and that you have not filed any complaints, charges, applications, lawsuits, or arbitrations against the Company or any of the Releasees. To the extent that you have knowledge concerning a potential violation of any federal, state or local law, you represent that you have fully disclosed such information to the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.66pt;text-decoration:underline">Continuing Obligations&#59; Cooperation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  You understand and agree that you have been employed in a position of confidence and trust and have had access to information concerning the Company that the Company treats as confidential and the disclosure of which could negatively affect the Company&#8217;s interests (collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  You further agree that you will continue to be bound and will abide by the Restrictive Covenants Agreement, which is hereby incorporated by reference.  You hereby agree that to the maximum extent permitted by applicable law, you have not and shall not in any way voluntarily assist, aid or participate in the pursuit of any claims or actions brought by another against the Company or Releasees. In the event that your assistance is requested or required in the pursuit of any claims brought against the Company or Releasees, you must provide written notice to the Company within five (5) business days of such request, unless requested by a governmental authority to the contrary.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Without additional compensation, you agree to cooperate reasonably with the Company and Releasees (including its and their outside counsel) in investigating, defending, prosecuting, litigating, filing, initiating, or asserting any actual or potential claims or other matters involving the Company and Releasees to the extent that the Company believes you may have relevant knowledge or information.  You agree to make yourself available during and outside of regular business hours for such cooperation&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that the Company shall not utilize this Section to require you to make yourself available to an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Separation Agreement &#8211; Page 7</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">extent that would unreasonably interfere with your search for employment or any subsequent professional responsibilities that you may have.  You agree to appear without the necessity of a subpoena to testify truthfully in any legal proceedings in which the Company calls you as a witness.  In connection with fulfilling your obligations under this Section, your pre-approved, out of pocket and reasonable expenses will be reimbursed by the Company, which shall not include any attorneys&#8217; fees except as provided by the Company&#8217;s by-laws and&#47;or any applicable liability insurance policies.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.66pt;text-decoration:underline">Return of Company Property</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  You shall not dispose of any property of the Company including, without limitation, information or documents (including, without limitation, computerized data and any copies made of any computerized data or software) (all of the foregoing are collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Documents</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) without the prior written authorization of the Company.  On or before the Separation Date, as requested by the Company, you shall return to the Company all property of the Company, including, without limitation, computer equipment, electronic devices, iPads, iPhones, cellular phones and other mobile devices, software, keys and access cards, credit cards, files and any Documents containing information concerning the Company, its business or business relationships (in the latter two cases, actual or prospective).  After returning all Documents and property of the Company, you shall delete and purge any duplicates of files or documents that may contain Company information from any non-Company computer or other device that remains your property.  In the event that you discover that you continue to retain any such property, you shall return it to the Company or destroy it (in the case of computerized data and software already in the possession of the Company) immediately.  For the avoidance of doubt, you may maintain copies of your own personnel records, to the extent applicable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.66pt;text-decoration:underline">Non-disparagement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.   </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:24.08pt">Subject to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, you agree not to make any disparaging, critical or detrimental statements concerning the Company or any of its affiliates&#59; its or their products or services provided or to be provided&#59; its or their current or former officers, directors, stockholders, members, employees, managers or agents&#59; and its or their business affairs or financial condition.  You further agree not to take any actions or conduct yourself in any way that would reasonably be expected to affect adversely the reputation or goodwill of the Company or its affiliates&#59; or its or their products or services provided or to be provided&#59; or its or their current or former officers, directors, stockholders, members, employees, managers or agents.  This non-disparagement obligation shall not in any way affect your obligation to testify truthfully in any legal proceeding.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.57pt">The Company will instruct each of the members of the Company&#8217;s Executive Committee not to make any disparaging or detrimental statements concerning your employment with the Company or take any actions or conduct themselves in any way that would reasonably be expected to affect adversely your professional or personal reputation.  This non-disparagement obligation shall not in any way affect any executive officer&#8217;s obligation to testify truthfully in any legal proceeding.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.66pt;text-decoration:underline">Protected Disclosures</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Nothing contained in this Agreement or the Other Agreements (including, without limitation, the Restrictive Covenants Agreement) limits your ability to file a charge or complaint with any federal, state or local governmental agency or commission (a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Government Agency</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  In addition, nothing contained in this Agreement limits your ability to communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, nor does anything contained in this Agreement apply to truthful testimony in litigation.  If you file any charge or complaint with any Government Agency and if the Government Agency pursues any claim on your behalf, or if any other third party pursues any claim on your behalf, you waive any right to monetary or other individualized relief (either individually or as part of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Separation Agreement &#8211; Page 8</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">collective or class action)&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that nothing in this Agreement limits any right you may have to receive a whistleblower award or bounty for information provided to the Securities and Exchange Commission.  Nothing in this Agreement or the Other Agreements (including, without limitation, the Restrictive Covenants Agreement) is intended to conflict with 18 U.S.C. &#167; 1833(b), which provides that&#58; &#8220;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney&#59; and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Communications Regarding Separation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  You agree that you will not (without the prior written approval of the Company) communicate about your transition or separation with anyone until after the Company has made a formal written announcement about your transition and separation (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Company Announcement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that you may communicate with your tax advisors, attorneys, and family members about your transition and separation before the Company Announcement&#59; provided further that you first advise such persons not to reveal information about your transition and separation and each such person agrees. Once the Company has announced your transition and separation, you agree to limit any communications regarding your transition and separation departure to statements that are consistent with the Company Announcement.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Section 409A.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:24.08pt">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), you are a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred compensation otherwise subject to the twenty percent (20%) additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death.  If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.57pt">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement.  All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses).  Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:24.69pt">To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits shall be payable only upon your &#8220;separation from service.&#8221;  The determination of whether and when a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Separation Agreement &#8211; Page 9</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.57pt">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code.  To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with, or are exempt from, Section 409A of the Code.  Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).  The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with, or be exempt from, Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.87pt">The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Tax Treatment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Company shall undertake to make deductions, withholdings and tax reports with respect to payments and benefits under this Agreement to the extent that it reasonably and in good faith determines that it is required to make such deductions, withholdings and tax reports.  Payments under this Agreement are stated in gross amounts and shall be paid in amounts net of any such deductions or withholdings.  Nothing in this Agreement shall be construed to require the Company to make any payments to compensate you for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Effect of Breach</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event that you fail to comply with any of your obligations under this Agreement (including the obligations under the Other Agreements and the Restrictive Covenants Agreement), in addition to any other legal or equitable remedies it may have for such breach, including for damages and equitable relief, the Company shall have the right to (i) if you are still employed, end your employment for Cause, (ii) terminate its payments to you under the Agreement&#59; and&#47;or (iii) seek recovery of any payments made to you or for your benefit pursuant to this Agreement.  Any such consequences of a breach by you will not affect the release or your continuing obligations under this Agreement, under the Other Agreements, under the Consulting Agreement or under the Restrictive Covenants Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Non-admission</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement shall not be construed as an admission of any liability by the Company or you of any act of wrongdoing.  Each of the Company and you specifically disclaims that the Company or any of its representatives has engaged in any wrongdoing or has taken any action that would be the basis for any finding of liability.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Legally Binding</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  You are advised to consult with an attorney before executing this Agreement.  Once effective, this Agreement is a legally binding document and your signature will commit you to its terms.  You acknowledge that you have been advised to discuss all aspects of this Agreement with your attorney, that you have carefully read and fully understand all of the provisions of this Agreement, and that you are voluntarily entering into this Agreement.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Absence of Reliance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In signing this Agreement, you are not relying upon any promises or representations made by anyone at or on behalf of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Separation Agreement &#8211; Page 10</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Except for the General Release of Claims in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, if any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement, or of the Restrictive Covenants Agreement or the Consulting Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.  If the General Release of Claims in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is found to be invalid or unenforceable in whole or in part, the Company will have the option in its sole discretion either to sever the invalid or unenforceable portion and enforce the rest of the Agreement, or to cancel the entire Agreement.  In the event the Company exercises such option to cancel the entire Agreement, the Agreement shall be null and void and none of the benefits set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be owing, paid, or provided, and if such amounts or benefits have been paid or provided, you shall repay to the Company the total gross amount or value of any such benefits already paid or provided, and the total gross amount of the amounts otherwise being waived in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Waiver&#59; Amendment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  No waiver of any provision of this Agreement shall be effective unless made in writing and signed by the waiving party.  The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.  This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Forum&#59; Equitable Relief</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">You and the Company hereby agree that the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts shall have the exclusive jurisdiction to consider any matters related to this Agreement, including without limitation any claim for violation of this Agreement.  With respect to any such court action, you (i)&#160;submit to the jurisdiction of such courts, (ii)&#160;consent to service of process, and (iii)&#160;waive any other requirement (whether imposed by statute, rule of court or otherwise) with respect to personal jurisdiction or venue.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;You agree that it would be difficult to measure any harm caused to the Company that might result from any breach by you of your promises set forth in this Agreement and that in any event money damages would be an inadequate remedy for any such breach.  Accordingly, you agree that if you breach, or propose to breach, any portion of your obligations under this Agreement, the Company shall be entitled, in addition to all other remedies it may have, to an injunction or other appropriate equitable relief to restrain any such breach, without showing or proving any actual damage to the Company and without the necessity of posting a bond.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Governing Law&#59; Construction of Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement shall be construed and governed in accordance with the substantive laws of the Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision or rule (whether of the Commonwealth of Massachusetts or any other jurisdiction) that would cause the application of laws of any jurisdictions other than those of the Commonwealth of Massachusetts.  The parties acknowledge and agree that this Agreement shall not be construed more strictly against one party than another party merely by virtue of the fact that it, or any part of it, may have been prepared by counsel for one of the parties, it being recognized that it is the result of arms-length negotiations between the parties and all parties have contributed substantially and materially to the preparation of this Agreement.  The headings contained in this Agreement are for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Separation Agreement &#8211; Page 11</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.  References to agreements and other documents shall be deemed to include all subsequent amendments and other modifications thereto.  References to statutes shall include all regulations promulgated thereunder and references to statutes or regulations shall be construed as including all statutory and regulatory provisions consolidating, amending or replacing the statute or regulation.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement constitutes the entire agreement between you and the Company and supersedes any previous agreements or understandings between you and the Company, including that certain offer letter by and between the Company and you dated as of December 28, 2020, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Severance Plan, Indemnification Agreement, Restrictive Covenants Agreement, Other Agreements and Equity Documents shall remain in full force and effect and further provided that, if you meet the Conditions set forth in Section 2 of this Agreement and the parties enter into the Consulting Agreement, then this Agreement and the Consulting Agreement together will supersede any previous agreements or understandings between you and the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Time for Consideration&#59; Agreement Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  You understand and acknowledge that you have been given the opportunity to consider this Agreement for 21 calendar days from your receipt of this Agreement before signing it (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement Consideration Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Any changes to this Agreement, material or otherwise, will not restart the running of the Agreement Consideration Period.  In signing this Agreement, you acknowledge that you have knowingly and voluntarily entered into this Agreement without any duress or undue influence on the part or behalf of the parties hereto or any affiliate thereof.  You acknowledge that your release of Claims is knowing and voluntary, including without implication of limitation your release of claims of age discrimination under the Age Discrimination in Employment Act, 29 U.S.C. &#167; 621 et seq. To accept this Agreement, you must return a signed, unmodified original or PDF copy of this Agreement so that it is received by the undersigned at or before the expiration of the Agreement Consideration Period.  If you sign this Agreement before the end of the Agreement Consideration Period, you acknowledge by signing this Agreement that such decision was entirely voluntary and that you had the opportunity to consider this Agreement for the entire Agreement Consideration Period.  You have seven (7) business days following your execution of this Agreement to revoke the Agreement by written notice to the undersigned (such seven (7) business day period, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement Revocation Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  For such a revocation to be effective, it must be delivered so that it is received by the Company at or before the expiration of the Agreement Revocation Period.  This Agreement shall not become effective or enforceable during the Agreement Revocation Period.  This Agreement shall become effective as of the first (1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) day after the expiration of the Agreement Revocation Period, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Company has also executed this Agreement by that date (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;) For the avoidance of doubt, if you do not enter into this Agreement, your employment will end but you will not be entitled to any of the Severance Benefits set forth in this Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.09pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Agreement may be executed in counterparts, each of which shall be considered an original and all of which shall constitute one agreement.  The signature of each party may be delivered by facsimile or by scanned image (e.g., .pdf or .tiff file extension name) as an attachment to electronic mail (e-mail), and such facsimile or scanned signature shall be treated in all respects as having the same effect as an original inked signature.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i365d1980ef694c52b1986e305c75eaf8_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please indicate your agreement to the terms of this Agreement by signing and returning this letter to me within the time period set forth above.  </font></div><div style="margin-bottom:6pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Very truly yours,</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Tracey Franklin</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tracey Franklin</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Human Resources Officer</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">The foregoing is agreed to and accepted by&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Corinne Le Goff     </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Signature &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;        &#160;&#160;&#160;&#160;        </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Corinne Le Goff</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Name</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">11&#47;11&#47;2021</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restrictive Covenants Agreement</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Consulting Agreement</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#123;00036908.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>5
<FILENAME>exhibit1018-consultingagre.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9d9a680eb4504c629afe430ba98f9aa5_1"></div><div style="min-height:49.68pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.18</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSULTING AGREEMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:27.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THIS CONSULTING AGREEMENT</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (together with the attached </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), is made by and between ModernaTX, Inc., a Delaware corporation having a place of business at 200 Technology Square, Cambridge, MA 02139, USA (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Moderna</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and Corinne Le Goff, an individual residing at &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consultant</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  This Agreement shall become effective on the last day of Consultant&#8217;s employment with the Company (such actual last day of employment, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and as agreed to in the Executive Separation and Transitional Services Agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Executive Separation Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to which this Agreement is attached as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; provided that this Agreement shall be </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">void ab initio</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> if Consultant does not enter into the Executive Separation Agreement or satisfy each of the Conditions (as defined in the Executive Separation Agreement). Moderna desires to have the benefit of Consultant&#8217;s knowledge and experience, and Consultant desires to provide services to Moderna, all as provided in this Agreement.  Moderna and Consultant may be referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.1pt">Services.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  During the Term (as defined below), Moderna or its Affiliates (as defined below) may from time to time request, and Consultant agrees to provide, consulting and advisory services related to Commercial operations and strategy (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Services</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and certain deliverables (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Deliverables</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to Moderna and its Affiliates in accordance with the terms attached hereto as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is hereby incorporated herein by reference. Consultant will deliver all Deliverables to Moderna in the form specified, and on the schedule set forth, in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Any changes to the Services or Deliverables must be agreed to in writing between Consultant and Moderna prior to implementation of the changes.  Subject to compliance with Consultant&#8217;s obligations in this Agreement, Consultant shall retain the sole control and discretion to determine the methods by which Consultant performs the Services.  As used herein, &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, with respect to an entity, any other entity that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such first entity, with &#8220;control&#8221; meaning the power to direct the management or policies of an entity, whether through ownership of voting securities or by contract relating to voting rights or corporate governance, resolution, regulation or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.1pt">Performance.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Consultant agrees to provide the Services in accordance with all applicable laws and regulations, prevailing high-level professional standards and the additional applicable terms and policies set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Consultant will provide Services not to exceed twenty percent (20%) of the average level of services provided by Consultant as an employee of the Company prior to the Separation Date (as defined in the Executive Separation Agreement).</font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.1pt">Independent Contractor Relationship.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Parties understand and agree that Consultant is an independent contractor and not an agent or employee of Moderna or its Affiliates.  Consultant has no authority to obligate Moderna or its Affiliates by contract or otherwise.  Consultant will not be eligible for any employee benefits of Moderna or its Affiliates and expressly waives any rights to any employee benefits. &#160;Consultant will bear sole responsibility for paying and reporting Consultant&#8217;s own applicable federal and state income taxes, social security taxes, unemployment insurance, workers&#8217; compensation, health or disability insurance, retirement benefits, and other welfare or pension benefits, if any, and Consultant indemnifies and holds Moderna harmless from and against any liability with respect to such taxes, benefits and other matters.</font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.1pt">Compensation.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  As full consideration for the performance of the Services and delivery of the Deliverables, Consultant shall continue to vest during the Term (as defined in Section 8 hereof) in (a) the non-qualified stock option to purchase 58,563 shares of the Company&#8217;s common stock that he was granted on February 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Option</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; and (b) the award of 25,400 restricted units granted on February 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2021 RSUs</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and subject in each case ((a) through (b)) to </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#123;00036909.1&#125;&#160;&#160;&#160;&#160;1 </font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the terms of (i) the Moderna, Inc. 2018 Stock Option and Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; (ii) the applicable Non-Qualified Stock Option Grant Notice&#59; (iii) the applicable Non-Qualified Stock Option Agreement&#59; and (iv) the applicable Restricted Stock Unit Award Agreement ((i) through (iv) collectively, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Documents</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  Consultant shall cease vesting in the 2021 Option and the 2021 RSUs on the last day of the Term and may exercise any vested portion of the 2021 Option in accordance with the terms of the Equity Documents and subject to the time limits on exercisability.  Moderna also agrees to reimburse Consultant the expenses as expressly set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.1pt">Restrictive Covenants.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Consultant acknowledges and agrees that the terms of the Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement by and between Consultant and the Company, dated as of December 29, 2020, a copy of which is attached hereto as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (as amended by the Executive Separation Agreement, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Covenants Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), shall apply during the Term and thereafter in accordance with its terms.  The non-competition and non-solicitation restrictions contained in the Restrictive Covenants Agreement apply &#8220;&#91;d&#93;uring the period in which you perform services for or at the request of the Company &#91;ModernaTX, Inc., or any present or future direct or indirect parent, subsidiary or affiliate thereof&#93; and for one (1) year following the termination of your provision of services to the Company for any reason or for no reason.&#8221; Accordingly, for the avoidance of doubt, the non-competition and non-solicitation restrictions shall apply during the Term and for the one (1) year period following the last day of the Term.  The other obligations in the Restrictive Covenants Agreement shall apply during the Term and thereafter, in accordance with their terms.</font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.1pt">Compliance with Obligations to Third Parties.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Consultant represents and warrants to Moderna that the terms of this Agreement, Consultant&#8217;s performance of the Services under the Agreement and Consultant&#8217;s acceptance of related compensation do not and will not conflict with any of Consultant&#8217;s obligations to any third parties.  Consultant agrees not to use any trade secrets or other confidential information of any other person, firm, corporation, institution or other third party in connection with any of the Services.  If Consultant is an employee of or consultant or advisor to another company or institution or an affiliate of any foreign, federal or state government, facility, university or institution, Consultant represents and warrants that Consultant is not prohibited by any applicable laws, regulations, policies (including policies concerning professional consulting, non-competition, and additional workload), procedures, or ethical guidelines from fulfilling any of Consultant's obligations or responsibilities pursuant to this Agreement or from accepting compensation under this Agreement.  Consultant agrees not to make any use of any funds, space, personnel, facilities, equipment or other resources of a third party in performing the Services and agrees not to take any other action that would result in a third party asserting ownership of, or other rights in, any Inventions (as defined in the Restrictive Covenants Agreement), unless agreed upon in writing in advance by Moderna.</font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.1pt">Publicity.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Consultant shall not use the name or any trademark (or adaptation thereof) of Moderna or any of its Affiliates for any marketing purposes or other uses without Moderna&#8217;s prior written consent.</font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.1pt">Expiration&#47;Termination.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The term of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) will commence on the Effective Date and expire on February 3, 2022, unless sooner terminated pursuant to the provisions of this Section 8.  Moderna may terminate this Agreement at any time for Cause (as defined below) upon at least three (3) days&#8217; written notice to Consultant.  Any such termination for Cause shall become effective within three (3) business days of delivery of the notice, unless the circumstances giving rise to the for Cause termination are cured within such three (3) business days.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (i) Consultant&#8217;s refusal to perform requested Services under this Agreement, or (ii) a material breach by Consultant of this </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#123;00036909.1&#125;&#160;&#160;&#160;&#160;2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Agreement, the Restrictive Covenants Agreement or the Executive Separation Agreement.  Consultant may terminate this Agreement for any reason upon not less than fourteen (14) days&#8217; prior written notice to Moderna.  Any expiration or termination of this Agreement shall be without prejudice to any obligation of either Party that has accrued prior to the effective date of expiration or termination.  Upon expiration or termination of this Agreement, neither Consultant nor Moderna will have any further obligations under this Agreement, except that (a) Consultant will terminate all Services in progress in an orderly manner as soon as practicable and in accordance with a schedule agreed to by Moderna, unless Moderna specifies in the notice of termination that Services in progress should not be completed&#59; (b) Consultant will deliver to Moderna all Deliverables made through expiration or termination&#59; (c)  Consultant will immediately return to Moderna all Moderna property and other Confidential Information (as defined in the Restrictive Covenants Agreement) and copies thereof provided to Consultant under this Agreement&#59; and (d) the terms, conditions and obligations under Sections 3, 5 through 8, 10, and relevant portions of Section 12 will survive expiration or termination of this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.1pt">Warranties and Additional Covenants.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consultant represents, warrants and covenants that&#58; (a) Consultant has the full power and authority to enter into and perform the Services pursuant to this Agreement, without  the need for any consents or approvals not yet obtained&#59; (b) Consultant has the right to grant the rights and assignments granted herein, without the need for any assignments, releases, consents, approvals or other rights not yet obtained&#59; (c) the Services, including any Deliverables required hereunder, shall be free from material errors or other defects&#59; (d) the execution of this Agreement by Consultant and Consultant&#8217;s performance hereunder will not violate or be a breach of any agreement or obligation with any other person or entity.  </font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.6pt">Indemnification</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.   Moderna shall indemnify and hold harmless, and at Consultant&#8217;s request, defend, Consultant from and against any and all third party claims, losses, liabilities, damages, settlements, expenses and costs (including attorneys&#8217; fees and costs) which arise out of or relate to (a) any breach (or claim or threat thereof that, if true, would be a breach) of this Agreement by Moderna, and (b) Moderna&#8217;s products, including for claims arising out of the negligence or intentional wrongdoing of Moderna.</font></div><div style="margin-bottom:12pt;padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.6pt">Miscellaneous.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:3.6pt">Use of Name.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consultant consents to the use by Moderna of Consultant&#8217;s name on its website, in press releases, company brochures, offering documents, presentations, reports or other documents in printed or electronic form, and in any documents filed with or submitted to any governmental or regulatory agency or any securities exchange or listing entity.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:3.09pt">Defend Trade Secrets Act.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  18 U.S.C. &#167; 1833(b) provides&#58; &#8220;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney&#59; and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.&#8221;  Nothing in this Agreement is intended to conflict with 18 U.S.C. &#167; 1833(b) or create liability for disclosures of trade secrets that are expressly permitted by 18 U.S.C. &#167; 1833(b).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:4.21pt">Protected Disclosures.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nothing contained in this Agreement limits Consultant&#8217;s ability to communicate with any federal, state or local governmental agency or commission, including to provide documents or other information, without notice to the Company.  </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#123;00036909.1&#125;&#160;&#160;&#160;&#160;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:3.09pt">Entire Agreement&#59; Counterparts.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  This Agreement, together with </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix B, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, contains the entire agreement of the Parties with regard to its subject matter, and supersedes all prior or contemporaneous written or oral representations, agreements and understandings between the Parties relating to that subject matter&#59; provided however, that the Executive Separation Agreement, the Indemnification Agreement as defined in the Executive Separation Agreement, the Equity Documents and the Restrictive Covenants Agreement shall remain in full force and effect. For the avoidance of doubt, the Indemnification Agreement between Consultant and the Company dated December 29, 2020, shall remain in full force and effect in accordance with its terms.  This Agreement may be changed only by a writing signed by Consultant and an authorized representative of Moderna.  This Agreement may be executed in any number of counterparts, each of which will be deemed an original.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:3.39pt">Assignment and Binding Effect.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The Services to be provided by Consultant are personal in nature.  Consultant may not assign or transfer this Agreement or any of Consultant&#8217;s rights or obligations hereunder without Moderna&#8217;s prior written consent.  In no event will Consultant assign or delegate responsibility for actual performance of the Services to any third party.  Moderna may transfer or assign this Agreement without the prior written consent of Consultant.  Any purported assignment or transfer in violation of this Section is void.  This Agreement will be binding upon and inure to the benefit of the Parties and their respective legal representatives, heirs, successors and permitted assigns.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:5.51pt">Notices.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  All notices required or permitted under this Agreement must be in writing and must be given by directing the notice to the address for the receiving Party set forth in this Agreement or at such other address as the receiving Party may specify in writing under this procedure.  Notices to Moderna will be marked &#8220;Attention&#58; Chief Legal Officer (&#8220;CLO&#8221;).&#8221;  All notices must be given (i) by personal delivery, with receipt acknowledged, (ii) by prepaid certified or registered mail, return receipt requested, (iii) by prepaid recognized next business day delivery service or 2-day international delivery service&#59; or (iv) by email to Consultant&#8217;s Moderna email address or, in the case of Moderna, to the CLO&#8217;s email address.  Notices will be effective upon receipt or at a later date stated in the notice.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:3.69pt">Governing Law.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  This Agreement and any disputes relating to or arising out of this Agreement will be governed by, construed, and interpreted in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to any choice of law principle that would require the application of the law of another jurisdiction.  The Parties agree to submit to the exclusive jurisdiction of the state and federal courts located in Massachusetts and waive any defense of inconvenient forum to the maintenance of any action or proceeding in such courts.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:3.09pt">Severability&#59; Reformation&#59; Waiver.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Each provision in this Agreement is independent and severable from the others, and no provision will be rendered unenforceable because any other provision is found by a proper authority to be invalid or unenforceable in whole or in part.  If any provision of this Agreement is found by such an authority to be invalid or unenforceable in whole or in part, such provision shall be changed and interpreted so as to best accomplish the objectives of such unenforceable or invalid provision and the intent of the Parties, within the limits of applicable law.  Any delay in enforcing a Party&#8217;s rights under this Agreement, or any waiver as to a particular default or other matter, will not constitute a waiver of such Party&#8217;s rights to the future enforcement of its rights under this Agreement, except with respect to an express written waiver relating to a particular matter for a particular period of time signed by Consultant and an authorized representative of the waiving Party, as applicable</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#123;00036909.1&#125;&#160;&#160;&#160;&#160;4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:6.34pt">Remedies.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Consultant agrees that (i) Moderna may be irreparably injured by a breach of this Agreement by Consultant&#59; (ii) money damages would not be an adequate remedy for any such breach&#59; (iii) as a remedy for any such breach Moderna will be entitled to seek equitable relief, including injunctive relief and specific performance, without being required by Consultant to prove actual damages or post bond&#59; and (iv) such remedy will not be the exclusive remedy for any breach of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:6.23pt">Further Assurances.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:3.86pt">Extension to Affiliates</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Moderna shall have the right to extend the rights, licenses, immunities and obligations granted or imposed in this Agreement to one or more of its Affiliates.&#160; All applicable terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to Moderna.&#160; Moderna shall remain fully liable for any acts or omissions, including financial liabilities, of such Affiliates.&#160; To the extent that this Agreement imposes obligations on any Affiliates of Moderna, Moderna agrees to cause its Affiliates to perform such obligations.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:6.34pt">Electronic Transmissions.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement may be transmitted in electronic format and shall not be denied legal effect solely because it was formed or transmitted, in whole or in part, by electronic record&#59; however, this Agreement must then remain capable of being retained and accurately reproduced, from time to time, by electronic record by the Parties to this Agreement and all other persons or entities required by law.  An electronically transmitted signature to this Agreement will be deemed an acceptable original for purposes of consummating this Agreement and binding the Party providing such electronic signature.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.08pt">Construction.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Whenever any provision of this Agreement uses the term &#8220;including&#8221; (or &#8220;includes&#8221;), such term will be deemed to mean &#8220;including without limitation&#8221; (or &#8220;includes without limitations&#8221;).  &#8220;Herein,&#8221; &#8220;hereby,&#8221; &#8220;hereunder,&#8221; &#8220;hereof&#8221; and other equivalent words refer to this Agreement as an entirety and not solely to the particular portion of this Agreement in which any such word is used.  Except where the context otherwise requires, whenever used, the singular will include the plural and the plural the singular.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#91;Signature page follows&#93;</font></div><div id="i9d9a680eb4504c629afe430ba98f9aa5_4"></div><div><font><br></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#123;00036909.1&#125;&#160;&#160;&#160;&#160;5</font></div></div></div><div id="i9d9a680eb4504c629afe430ba98f9aa5_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Parties have executed this Consulting Agreement as of the Effective Date.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">       </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ModernaTX, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CONSULTANT</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Tracey Franklin </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Corinne Le Goff</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Tracey Franklin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Corinne Le Goff</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Chief Human Resources Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Consultant</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div id="i9d9a680eb4504c629afe430ba98f9aa5_10"></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#123;00036909.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Appendix A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">To the Consulting Agreement between</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ModernaTX, Inc. and Corinne Le Goff</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.1pt">Services&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Consultant will provide Services with respect to commercial operations and strategy, on a schedule and at a location or locations indicated above or as otherwise mutually agreed between Consultant and Moderna (or its Affiliate, if applicable).  In addition, Consultant will be available for a reasonable number of telephone and&#47;or written consultations.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.1pt">Deliverables&#58; </font></div><div style="padding-left:27.35pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Deliverables will relate to commercial operations and strategy and will be determined by the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27.35pt;text-align:justify;text-indent:-27.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:19.1pt">Compensation&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Equity Vesting</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  As explained in Section 4 above, Consultant shall continue to vest in the 2021 Option and the 2021 RSUs during the Term.</font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Moderna will reimburse Consultant for any pre-approved expenses actually incurred by Consultant in connection with the provision of Services.  Requests for reimbursement will be in a form reasonably acceptable to Moderna, will include supporting documentation and will accompany Consultant&#8217;s invoices.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#123;00036909.1&#125;&#160;&#160;&#160;&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:17.307%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACTIVE&#47;105561984.6  </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:27pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Appendix B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Applicable Terms and Policies </font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font><br></font></div><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.87pt">Code of Business Ethics and Conduct of Moderna, Inc. (available at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">www.modernatx.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.25pt">Insider Trading Policy of Moderna, Inc., a copy of which has been provided to Consultant. </font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#123;00036909.1&#125;&#160;&#160;&#160;&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:17.307%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACTIVE&#47;105561984.6  </font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i9d9a680eb4504c629afe430ba98f9aa5_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Appendix C</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Restrictive Covenants Agreement</font></div><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font><br></font></div><div style="padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#123;00036909.1&#125;&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>6
<FILENAME>exhibit1019-offerlettersha.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id843a400ebda4ecdbeb321818da303b6_1"></div><div style="min-height:25.2pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.109%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="padding-left:340.2pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.19</font></div><div style="padding-left:340.2pt"><font><br></font></div><div style="padding-left:340.2pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:197px"></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2021</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:380.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shannon Thyme Klinger &#91;***&#93;</font></div><div style="padding-right:380.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  &#91;***&#93;</font></div><div style="margin-top:0.05pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.2pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Letter Agreement Between ModernaTX, Inc. and Shannon Klinger</font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dear Shannon,</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:19.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ModernaTX, Inc. (together with its affiliates, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is pleased to enter into this Employment Letter Agreement (&#8220;Agreement&#8221;) regarding your employment as Chief Legal Officer, reporting to the Chief Executive Officer. You shall have all duties and authorities customary for such position. Your effective date of hire will be on or before June 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Start Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), or another Start Date mutually agreed upon by you and the Company, and you will perform services for the Company as a regular, full- time employee. The initial terms of your employment are set forth below.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:17.6pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You agree to devote your full business time to the performance of your duties, and not engage in any other business activity without the approval of the CEO. Notwithstanding the foregoing, you will be permitted to manage your personal investments, engage in civic and charitable activities, and serve on boards and engage in other activities as are approved by the CEO from time to time, which approval shall not be unreasonably withheld or delayed, provided that such activities do not interfere with the performance of your duties, create a conflict of interest or violate any agreement with the Company.</font></div><div><font><br></font></div><div style="margin-top:7.9pt;padding-left:6pt;padding-right:23.4pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Your initial base salary will be at the rate of $650,000.00 (USD) per year. All wages will be paid in accordance with the Company&#8217;s normal biweekly pay schedule for salaried employees. Your base salary will be subject to periodic review for potential adjustment at the Company&#8217;s discretion, and any such adjustments shall thereafter constitute your Base Salary for all purposes under this Agreement and related agreements or plans. Downward adjustments in your Base Salary, if any, will only be made in a manner that is consistent with the rest of the executive team and at the direction of the Board of Directors (and shall otherwise be subject to your rights under the Amended and Restated Executive Severance Plan (&#8220;ESP&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:19.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to the foregoing, upon your commencement of employment with the Company, you will be paid a one-time signing bonus of $250,000.00 less applicable taxes (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Signing Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). You acknowledge and agree that you will repay a pro-rated portion of the Signing Bonus to the Company within 10 days of your last day of employment if you voluntarily terminate your employment with the Company not following the occurrence of Good Reason or your employment is terminated for Cause by the Company (as such terms are defined and otherwise pursuant to the terms of, the ESP in effect as of the date of this Agreement) during the first 24 months of your employment. That amount may be collected by the Company, unless prohibited by applicable law, either directly or indirectly, from any (i) payment of any kind due to you from the Company or any affiliate thereof including, without limitation, accrued wages, vacation, final wages, and expense reimbursements to the fullest extent permitted by applicable law&#59; and&#47;or (ii) the forfeiture or cancellation of any equity interest owned by you in the Company or any subsidiary or affiliate thereof, whether now existing or hereafter formed, and regardless of the form such equity interest (e.g., common units, incentive units (also referred to as profits interests), options to acquire common units or otherwise)</font><font style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id843a400ebda4ecdbeb321818da303b6_4"></div><hr style="page-break-after:always"><div style="min-height:25.2pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.109%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:19.6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You will be eligible to earn an annual performance bonus. The Company will initially target the bonus at 60% of your Base Salary (pro-rated based on your Start Date, provided that your Start Date is on or before the first Monday of October of the applicable calendar year). If your Start Date is after the first Monday of October, you will not be eligible for a bonus for the calendar year in which you were hired. The actual bonus percentage earned will be subject to the Company&#8217;s assessment of individual and Company performance based upon established criteria, and otherwise pursuant to the Senior Executive Cash Incentive Bonus Plan. The bonus, if any, will be paid no later than March 15 of the calendar year following the calendar year to which such bonus relates. Except as otherwise provided herein, including under the terms of the ESP, you must be employed on the date a bonus is paid to receive that bonus.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:19.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within thirty (30) days of your Start Date , you shall be granted, pursuant to Moderna&#8217;s equity incentive program an equity award equivalent to a total value of $8,000,000.00 as of the grant date (such equity award is referred to as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">New Hire Equity Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). The New Hire Equity Award will vest according to the following schedule&#58; 25% of the New Hire Equity Award will vest on the first anniversary of the date that the equity is granted to you which is set as the first Monday of each month on a consistent basis for all new employees at Moderna (the Grant Date), and the remaining 75% of the New Hire Equity Award will vest in equal calendar quarterly installments over the next three (3) years, provided that, in each case, except as otherwise provided herein, you continue to provide continuous services to the Company as of each such vesting date. The New Hire Equity Award is subject to our &#8220;Your Equity Selection&#8221; (YES) program. You may choose to have your award delivered to you in one of the following mixes of Non- Qualified Stock Options and&#47;or Restricted Stock Units&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:42pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.55pt">100% of the value delivered in the form of Non-Qualified Stock Options.</font></div><div style="margin-top:5.95pt;padding-left:42pt;padding-right:21.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">75% of the value delivered in the form of Non-Qualified Stock Options and 25% in value delivered in the form of Restricted Stock Units. This is the default choice if no selection is made.</font></div><div style="margin-top:5.9pt;padding-left:42pt;padding-right:21.35pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">50% of the value delivered in the form of Non-Qualified Stock Options and 50% in value delivered in the form of Restricted Stock Units.</font></div><div style="margin-top:5.95pt;padding-left:6pt;padding-right:19.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You will receive an email from the Compensation Team at the Company to register your selection prior to your grant date. In the event of a stock split, stock consolidation or similar event prior to the grant of the New Hire Equity Award, the number of shares subject thereto shall be adjusted proportionately. The grant price of the New Hire Equity Award will be equal to the closing price on the Grant Date. The grant of the New Hire Equity Award will be conditioned upon your execution of all necessary documentation relating to the New Hire Equity Award as determined by the Company (all such documentation is collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">New Hire Equity Award Documentation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). The New Hire Equity Award will be subject to the terms and conditions set forth in the New Hire Equity Award Documentation.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:6pt;padding-right:19.95pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to the New Hire Equity Award within thirty (30) days of your Start Date, you shall also be granted an equity award equivalent to a total value of $2,000,000.00 as of the Grant Date (such equity award is referred to as the &#8220;Special Equity Award&#8221;), which shall be delivered in the form of Restricted Stock Units. The Special Equity Award will vest on the following schedule&#58; 100% of the Special Equity Award will vest on the third anniversary of the Grant Date, provided that, except as otherwise provided herein, you continue to provide continuous services to the Company as of such vesting date.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:19.6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In the event of a stock split, stock consolidation or similar event prior to the grant of the New Hire Equity Award or the Special Equity Award (collectively, the &#8220;Initial Awards&#8221;), the number of shares subject thereto shall be adjusted proportionately. The grant price of the Initial Awards will be equal to the closing price on the day of grant. The grant of these awards will be conditioned upon, your execution of all necessary documentation relating to the awards as determined by the Company (all such documentation is collectively referred to as the &#8220;New Hire Equity Award Documentation&#8221;). The Initial Awards will be subject to the terms and conditions set forth in the New Hire Equity Award Documentation. The forms of your New Hire Equity Award Documentation are attached hereto.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:25.2pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.109%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:19.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For avoidance of doubt, all accelerated&#47;continued equity vesting and&#47;or payment provisions provided to executives generally regarding equity awards, whether pursuant to the ESP, the Moderna, Inc. 2018 Stock Option and Incentive Plan (&#8220;Incentive Plan&#8221;), or otherwise, shall apply to your Initial Awards.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:19.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further, subject to the Incentive Plan and provided your Start Date is on or before the first Monday of October of the applicable calendar year, you will be eligible to receive an additional annual equity award related to your performance for the eligible performance period (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Equity Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). Annual Equity Awards typically will be issued in the first quarter of the year following the performance period. Your annual grants will be based on a combination of market data and performance. You will receive an annual grant that will be a mix of stock options, RSU&#8217;s, and potentially PSU&#8217;s subject to the current executive pay policies in place. The target value of your Annual Equity Award is $3,500,000.00. Your first Annual Equity Award will be pro-rated based upon your Start Date. Annual equity guidelines are subject to change and may be updated based on market conditions. Your Annual Equity Awards shall contain such terms and conditions (other than amounts), including but not limited to vesting schedule and treatment incident to a Sale Event and&#47;or Termination, substantially similar to those generally provided to other members of the executive committee other than the CEO.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:19.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You may be required to relocate to the Greater Boston area, as applicable, by June 1, 2021, or as mutually agreed upon by both parties. Your principal place of employment shall be Cambridge, MA, except to the extent that remote work arrangements are necessitated by the Covid-19 pandemic. The Company will pay reasonable costs associated with your relocation (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Relocation Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) in accordance with the Employee Relocation Guidelines (&#8220;Guidelines&#8221;) that are in effect at the time of the initiation of your relocation case. Notwithstanding the foregoing and any terms or limitations in such Guidelines, however, the Company agrees to provide and pay (i) without regard to volume&#47;weight, the costs of shipping and storage (for up to six (6) months) of your household goods and personal effects&#59; (ii) the costs of temporary housing for you and your family for up to three (3) months&#59; (iii) the costs of any amounts you are required to pay incident to early termination of your current residential lease&#59; (iv) business class airfare for any travel incident to such relocation. In addition to the foregoing, you shall also receive a one-time Relocation Allowance of $25,000. The Company will determine in its reasonable judgment what portion, if any, of your Relocation Expenses are for nondeductible expenses in accordance with applicable law and will comply with associated withholding and tax reporting obligations. You acknowledge and agree that you will repay a pro-rated portion of the Relocation Expenses to the Company within 10 days of your last day of employment if you voluntarily terminate your employment with the Company not following an occurrence of Good Reason or your employment is terminated for Cause within 24 months of the initiation of your relocation case. That amount may be collected by the Company, unless prohibited by applicable law, either directly or indirectly, from any (i) payment of any kind due to you from the Company or any affiliate thereof including, without limitation, accrued wages, vacation, final wages, and expense reimbursements to the fullest extent permitted by applicable law&#59; and&#47;or (ii) the forfeiture or cancellation of any equity interest owned by you in the Company or any subsidiary or affiliate thereof, whether now existing or hereafter formed, and regardless of the form such equity interest (e.g., common units, incentive units (also referred to as profits interests), options to acquire common units or otherwise).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:19.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to your compensation, you may take advantage of various benefits offered by the Company from time to time, subject to any eligibility requirements. Currently the Company provides group medical and dental insurance, short term disability coverage, group life insurance and a 401(k) plan. These benefits, of course, may be modified, changed or eliminated from time to time at the sole discretion of the Company, and the provision of such benefits to you in no way changes or impacts your status as an at-will employee. Where a particular benefit is subject to a formal plan (for example, medical insurance or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document. Notwithstanding the foregoing, the Company agrees that you shall be entitled to a minimum of four (4) weeks annual paid vacation one of which will be the Company&#8217;s annual shutdown if the Company determines in any year to have a shutdown. Should you ever have any questions about Company benefits, you should ask for a copy of the applicable plan document. You will also be eligible for any additional vacation pursuant to the Company&#8217;s policies in effect from time to time.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:25.2pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.109%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:19.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You shall also be provided a Moderna, Inc. Officer&#8217;s Indemnification Agreement, which shall be in addition to any rights of indemnification and to receive advancement to which you may be entitled under applicable law, Moderna&#8217;s organizing documents, any agreement, a vote of stockholders or a resolution of directors, or otherwise.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:20.15pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:19.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You acknowledge and agree that employment with the Company is &#8220;at will.&#8221; You are not being offered employment for a definite period of time, and either you or the Company may terminate the employment relationship at any time and for any reason without prior notice, subject to and in accordance with the terms and conditions of the ESP and other executive plans that may be applicable to you from time to time. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company's personnel policies and procedures, may change prospectively from time to time, subject to your severance and termination rights in the ESP or any successor severance agreement or plan, the &#8220;at-will&#8221; nature of your employment may only be changed by a written agreement signed by you and the Chief Executive Officer, which expressly states the intention to modify the at-will term of your employment.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:20.4pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company acknowledges and agrees that you shall be a Participant in the current ESP upon your Start Date. A copy of the Participation Letter to the ESP is attached.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:19.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further, for the avoidance of doubt, if the Company fails to employ you on the Start Date, you shall be entitled to&#58; (i) all of the termination payments, treatment and benefits set forth in the ESP as if you were already a Participant on the day before you were notified of such failure&#59; (ii) payment of the Hiring Bonus and Relocation Expenses as set forth above.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:19.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a condition of the commencement of your employment, you are required to enter into an Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Covenants Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;, a copy of which is enclosed with this Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">You also, represent that, based on your reasonable and good faith belief, you are not subject to any confidentiality, non-competition agreement or any other similar type of restriction that may affect your ability to devote full time and attention to your work at the Company, and have disclosed any applicable agreements to the Company. You further represent that you have not used and will not use or disclose any trade secret or other proprietary right of any previous employer or any other party.</font></div><div><font><br></font></div><div style="padding-left:6pt;padding-right:19.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Immigration Reform and Control Act requires employers to verify the employment eligibility and identity of new employees. You will receive a Form I-9 that you will be required to complete. Please bring the appropriate documents listed on that form with you when you report for work. We will not be able to employ you if you fail to comply with this requirement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:19.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Agreement (including the documents references herein, e.g. the ESP, the New Hire Equity Award Documentation, the Incentive Plan, the Senior Executive Cash Incentive Bonus Plan, the Guidelines the Participation Agreement, the Indemnification Agreement and the enclosed Restrictive Covenants Agreement constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:20.3pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shannon, we look forward to your joining the Company and are pleased that you will be working with us to build a transformative company for patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:25.2pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.109%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:207.4pt;padding-right:207.4pt;text-align:center;text-indent:-5.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:237%">Very truly yours, M</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:237%">ODERNA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:237%">TX, I</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:237%">NC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:237%">.</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  &#47;s&#47; Tracey Franklin</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:222.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; Tracey Franklin</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:222.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Human Resources Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Accepted and Agreed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-bottom:0.3pt;margin-top:4.65pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shannon Thyme Klinger</font></div><div style="padding-left:5pt"><font><br></font></div><div style="padding-left:8.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:98%">&#47;s&#47; Shannon Thyme Klinger</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">   3&#47;5&#47;2021</font></div><div style="margin-top:0.4pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font><img alt="image_3a.jpg" src="image_3a.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div><div style="margin-top:0.35pt;padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>7
<FILENAME>exhibit1024-modernarsuagre.htm
<DESCRIPTION>EX-10.24
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iebeb55dd2acc4b1db3bf8eb5ec2ee476_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.24</font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">RESTRICTED STOCK UNIT AWARD AGREEMENT<br>FOR COMPANY EMPLOYEES<br>UNDER THE MODERNA, INC.<br>2018 STOCK OPTION AND INCENTIVE PLAN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Grantee&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Participant Name&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No. of Restricted Stock Units&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Number of Shares Granted&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Grant date&#93;</font></div><div style="margin-bottom:12pt;margin-top:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#8220;Plan&#8221;), Moderna, Inc. (the &#8220;Company&#8221;) hereby grants an award of the number of Restricted Stock Units listed above (an &#8220;Award&#8221;) to the Grantee named above.  Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.0001 per share (the &#8220;Stock&#8221;) of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Restrictions on Transfer of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Vesting of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The restrictions and conditions of Paragraph&#160;1 of this Agreement shall lapse on the Vesting Date or Dates specified in the vesting schedule attached as Appendix A to this Agreement so long as the Grantee continues to have a Service Relationship with the Company or a Subsidiary on such Dates.  If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph&#160;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination of Service Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Grantee&#8217;s Service Relationship with the Company or a Subsidiary terminates for any reason (other than death or permanent disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination Due to Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Grantee&#8217;s Service Relationship with the Company or a Subsidiary terminates by reason of the Grantee&#8217;s death, then any Restricted Stock Units that have not vested as of the Grantee&#8217;s death shall immediately vest in full as of the date of death.    </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination Due to Permanent Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Grantee&#8217;s Service Relationship with the Company or a Subsidiary terminates by reason of the Grantee&#8217;s permanent disability (as defined below), then any Restricted Stock Units under this Award that have not vested as of the last date of the Grantee&#8217;s Service Relationship shall immediately vest in full as of such date.  For purposes of this Award, &#8220;permanent disability&#8221; shall mean the inability of the </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grantee to continue in his or her position for the Company (or an Affiliate) by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as determined by the Company in its sole discretion.      </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Issuance of Shares of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In connection with the settlement of vested Restricted Stock Units, the Company shall issue the shares of Stock referred to in Paragraph 4 to a broker designated by the Company and acting on behalf and for the account of the Grantee with instructions to (i) sell a number of shares of such Stock sufficient to satisfy the applicable withholding taxes which arise in connection with such settlement&#59; provided, that the amount sold does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment, along with any applicable third-party commission, and (ii) remit the proceeds of such sale to the Company. In the event the sale proceeds are insufficient to fully satisfy the applicable withholding taxes, the Grantee authorizes withholding from payroll and any other amounts payable to the Grantee, in the same calendar year, and otherwise agrees to make adequate provision through the submission of cash, a check or its equivalent for any sums required to satisfy the applicable withholding taxes.  </font><font style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is the intent of the parties that this Paragraph 6 comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act, and the Agreement will be interpreted to comply with the requirements of Rule 10b5-1(c) under the Exchange Act.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the withholding tax obligations of the Company and&#47;or any Affiliate thereof are satisfied, the Company shall have no obligation to issue any shares of Stock on the Grantee&#8217;s behalf pursuant to the vesting of the Restricted Stock Units.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Section 409A of the Code.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as &#8220;short-term deferrals&#8221; as described in Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">No Obligation to Continue Service Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee&#8217;s Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee&#8217;s Service Relationship with the Company or a Subsidiary at any time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">desirable for the administration of the Plan and&#47;or this Agreement (the &#8220;Relevant Information&#8221;).  By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information&#59; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information&#59; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form&#59; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate.  The Grantee shall have access to, and the right to change, the Relevant Information.  Relevant Information will only be used in accordance with applicable law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Moderna, Inc.</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#160; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">                      Name&#58; </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">                      Title&#58; &#160; </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.  Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font></div><div><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Signed Electronically&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Acceptance Date&#58;  </font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Acceptance Date&#93;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><div id="iebeb55dd2acc4b1db3bf8eb5ec2ee476_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Appendix A&#58; Vesting Schedule</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Vesting Schedule&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>8
<FILENAME>exhibit1025-nqsoagreementf.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0eda4d85cd8e4d3581738faad10e29eb_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.25</font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">NON-QUALIFIED STOCK OPTION AGREEMENT<br>FOR COMPANY EMPLOYEES<br>UNDER THE MODERNA, INC.<br>2018 STOCK OPTION AND INCENTIVE PLAN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Optionee&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Participant Name&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No. of Option Shares&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Number of Shares Granted&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option Exercise Price per Share&#58;&#160;&#160;&#160;&#160;$</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Grant Price&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Grant date&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expiration Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Expiration Date&#93;</font></div><div style="margin-bottom:12pt;margin-top:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#8220;Plan&#8221;), Moderna, Inc. (the &#8220;Company&#8221;) hereby grants to the Optionee named above an option (the &#8220;Stock Option&#8221;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#8220;Stock&#8221;) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.  This Stock Option is not intended to be an &#8220;incentive stock option&#8221; under Section 422 of the Internal Revenue Code of 1986, as amended.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Exercisability Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No portion of this Stock Option may be exercised until such portion shall have become exercisable.  Except as set forth below in Appendix A, and subject to the discretion of the Administrator (as defined in Section&#160;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated on Appendix A to this Agreement so long as the Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Manner of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Optionee may exercise this Stock Option only in the following manner&#58;  from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice.  This notice shall specify the number of Option Shares to be purchased.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payment of the purchase price for the Option Shares may be made by one or more of the following methods&#58;  (i)&#160;in cash, by certified or bank check or other instrument acceptable to the Administrator&#59; (ii)&#160;if permitted by the Administrator, through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Administrator&#59; (iii)&#160; by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure&#59; (iv)&#160;if permitted by the Administrator, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price&#59; or (v)&#160;a combination of (i), (ii), (iii) and (iv) above.  Payment instruments will be received subject to collection.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company&#8217;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations.  In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan.  The determination of the Administrator as to such compliance shall be final and binding on the Optionee.  The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee&#8217;s name shall have been entered as the stockholder of record on the books of the Company.  Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination of Service Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination Due to Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee&#8217;s death, then any portion of this Stock Option that has not vested as of the Optionee&#8217;s death shall immediately vest in full as of the date of death.  Following any termination due to death, this Stock Option may thereafter be exercised by the Optionee&#8217;s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination Due to Permanent Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee&#8217;s permanent disability (as defined below), then any portion of this Stock Option that has not vested as of the last date of the Optionee&#8217;s Service Relationship (the &#8220;Accelerated Vesting Date&#8221;) shall immediately vest in full as of the Accelerated Vesting Date.  Following any termination due to disability, this Stock Option may thereafter be exercised by the Optionee for a period of 12 months from the Accelerated Vesting Date or until the Expiration Date, if earlier.  For purposes of this Stock Option, &#8220;permanent disability&#8221; shall mean the inability of the Optionee to continue in his or her position for the Company (or an Affiliate) by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as determined by the Company in its sole discretion.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect.  For purposes hereof, &#8220;Cause&#8221; shall mean, unless otherwise provided in an employment or other service agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company&#59; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude&#59; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee&#8217;s duties to the Company.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Other Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Optionee&#8217;s Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee&#8217;s death, the Optionee&#8217;s permanent disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier.  Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrator&#8217;s determination of the reason for termination of the Optionee&#8217;s Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution.  This Stock Option is exercisable, during the Optionee&#8217;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#8217;s legal representative or legatee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event.  The Company shall have the authority to cause the minimum required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the minimum withholding amount due. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">No Obligation to Continue Service Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee&#8217;s Service Relationship with the Company or a Subsidiary at any time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and&#47;or this Agreement (the &#8220;Relevant Information&#8221;).  By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information&#59; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information&#59; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form&#59; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate.  The Optionee shall have access to, and the right to change, the Relevant Information.  Relevant Information will only be used in accordance with applicable law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Moderna, Inc.</font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;       Name&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;       Title&#58; &#160; </font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.  Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Optionee (including through an online acceptance process) is acceptable.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Acceptance Date&#58;  </font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Acceptance Date&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Appendix A&#58; Vesting Schedule</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Vesting Schedule&#93;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>9
<FILENAME>exhibit1026-modernarsuagre.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0219efdba31d4e9e93056a67fbe37089_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.26</font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">RESTRICTED STOCK UNIT AWARD AGREEMENT<br>FOR NON-EMPLOYEE DIRECTORS<br>UNDER THE MODERNA, INC.<br>2018 STOCK OPTION AND INCENTIVE PLAN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Grantee&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Participant Name&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No. of Restricted Stock Units&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Number of Shares Granted&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Grant date&#93;</font></div><div style="margin-bottom:12pt;margin-top:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#8220;Plan&#8221;), Moderna, Inc. (the &#8220;Company&#8221;) hereby grants an award of the number of Restricted Stock Units listed above (an &#8220;Award&#8221;) to the Grantee named above.  Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.0001 per share (the &#8220;Stock&#8221;) of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Restrictions on Transfer of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Vesting of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The restrictions and conditions of Paragraph&#160;1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains in service as a member of the Board on such Dates.  If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph&#160;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in the event of a Sale Event, 100% of the then-outstanding and unvested Restricted Stock Units shall immediately be deemed vested on the date of such Sale Event&#59; provided, that the Grantee remains in service as a member of the Board until the date of such Sale Event.  The Administrator may at any time accelerate the vesting schedule specified in Appendix A.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Grantee&#8217;s service as a member of the Board terminates for any reason (other than death or permanent disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination Due to Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Grantee&#8217;s Service Relationship with the Company or a Subsidiary terminates by reason of the Grantee&#8217;s death, then any Restricted Stock Units that have not vested as of the Grantee&#8217;s death shall immediately vest in full as of the date of death.    </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination Due to Permanent Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Grantee&#8217;s service as a member of the Board terminates by reason of the Grantee&#8217;s permanent disability (as defined below), then any Restricted Stock Units under this Award that have not vested as of the last date of the Grantee&#8217;s service as a member of the Board of Directors shall immediately vest in full as </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of such date.  For purposes of this Award, &#8220;permanent disability&#8221; shall mean the inability of the Optionee to continue to perform service as a member of the Board of Directors by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as determined by the Company in its sole discretion.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Issuance of Shares of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Section 409A of the Code.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as &#8220;short-term deferrals&#8221; as described in Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">No Obligation to Continue as a Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Plan nor this Award confers upon the Grantee any rights with respect to continuance as a Director.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and&#47;or this Agreement (the &#8220;Relevant Information&#8221;).  By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information&#59; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information&#59; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form&#59; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate.  The Grantee shall have access to, and the right to change, the Relevant Information.  Relevant Information will only be used in accordance with applicable law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Moderna, Inc.</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#160; &#160;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font></div><div style="padding-left:72pt;padding-right:72pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; &#160; </font></div><div style="margin-bottom:36pt;padding-left:234pt"><font><br></font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.  Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Acceptance Date&#58;  </font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Acceptance Date&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Appendix A&#58; Vesting Schedule</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Vesting Schedule&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>10
<FILENAME>exhibit1027-nqsoagreementf.htm
<DESCRIPTION>EX-10.27
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie061411d27a043709d1227ab162cf839_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.27</font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">NON-QUALIFIED STOCK OPTION AGREEMENT<br>FOR NON-EMPLOYEE DIRECTORS<br>UNDER THE MODERNA, INC.<br>2018 STOCK OPTION AND INCENTIVE PLAN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Optionee&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Participant Name&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No. of Option Shares&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Number of Shares Granted&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option Exercise Price per Share&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Grant Price&#93;</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Grant date&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Expiration Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;        </font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Expiration Date&#93;</font></div><div style="margin-bottom:12pt;margin-top:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Pursuant to the Moderna, Inc. 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#8220;Plan&#8221;), Moderna, Inc. (the &#8220;Company&#8221;) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the &#8220;Stock Option&#8221;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#8220;Stock&#8221;), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.  This Stock Option is not intended to be an &#8220;incentive stock option&#8221; under Section 422 of the Internal Revenue Code of 1986, as amended.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Exercisability Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No portion of this Stock Option may be exercised until such portion shall have become exercisable.  Except as set forth below, and subject to the discretion of the Administrator (as defined in Section&#160;2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as the Optionee remains in service as a member of the Board on such dates&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Vesting Date and Quantity&#93;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding the foregoing, in the event of a Sale Event, 100% of the then-outstanding and unvested Option Shares shall immediately be deemed vested and exercisable on the date of such Sale Event&#59; provided, that the Optionee remains in service as a member of the Board until the date of such Sale Event. Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Manner of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The Optionee may exercise this Stock Option only in the following manner&#58;  from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice.  This notice shall specify the number of Option Shares to be purchased.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payment of the purchase price for the Option Shares may be made by one or more of the following methods&#58;  (i)&#160;in cash, by certified or bank check or other instrument acceptable to the Administrator&#59; (ii)&#160;if permitted by the Administrator, through the delivery (or attestation to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACTIVE&#47;95639488.5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator&#59; (iii)&#160;by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure&#59; (iv)&#160;if permitted by the Administrator, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price&#59; or (v)&#160;a combination of (i), (ii), (iii) and (iv) above.  Payment instruments will be received subject to collection.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company&#8217;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations.  In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan.  The determination of the Administrator as to such compliance shall be final and binding on the Optionee.  The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee&#8217;s name shall have been entered as the stockholder of record on the books of the Company.  Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination as Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Optionee&#8217;s service as a member of the Board ceases, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination Due to Death or Permanent Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Optionee&#8217;s service as a member of the Board terminates by reason of the Optionee&#8217;s death or permanent disability, then any portion of this Stock Option that has not vested as of the date of such death or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permanent disability shall immediately vest in full as of the date of death or the last day of the Optionee&#8217;s service as a member of the Board of Directors, as applicable (the &#8220;Accelerated Vesting Date&#8221;).  Following any termination due to death or permanent disability, this Stock Option may thereafter be exercised by the Optionee or the Optionee&#8217;s legal representative or legatee for a period of 12 months from the Accelerated Vesting Date or until the Expiration Date, if earlier.  For purposes of this Stock Option, &#8220;permanent disability&#8221; shall mean the inability of the Optionee to continue to perform service as a member of the Board of Directors by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as determined by the Company in its sole discretion.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Other Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Optionee&#8217;s service as a member of the Board ceases for any reason other than the Optionee&#8217;s death or permanent disability, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date the Optionee ceased to be a Director, for a period of six months from the date the Optionee ceased to be a Director or until the Expiration Date, if earlier.  Any portion of this Stock Option that is not exercisable on the date the Optionee ceases to be a Director shall terminate immediately and be of no further force or effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution.  This Stock Option is exercisable, during the Optionee&#8217;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#8217;s legal representative or legatee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">No Obligation to Continue as a Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Plan nor this Stock Option confers upon the Optionee any rights with respect to continuance as a Director.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and&#47;or this Agreement (the &#8220;Relevant Information&#8221;).  By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information&#59; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information&#59; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form&#59; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate.  The Optionee shall have access to, and the right to change, the Relevant Information.  Relevant Information will only be used in accordance with applicable law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Moderna, Inc.</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; &#160; </font></div><div style="margin-bottom:24pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.  Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Optionee (including through an online acceptance process) is acceptable.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Acceptance Date&#58;  </font><font style="color:#4f81bd;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;Acceptance Date&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:234pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>11
<FILENAME>exhibit1034-bardaamenmdent.htm
<DESCRIPTION>EX-10.34
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5dad85bd0cb44f47a54ed7a6fbdab659_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.34</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;&#91;***&#93;.&#8221; Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private or confidential.</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.015%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="15" rowspan="2" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="12" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1. CONTRACT ID CODE</font></td><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PAGE OF PAGES</font></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">P00011</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Block 16C</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Schedule</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5. PROJECT NO.(If applicable)</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6. ISSUED BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASPR-BARDA</font></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7. ADMINISTERED BY (If other than item 6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE</font></div></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASPR-BARDA02</font></td></tr><tr><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASPR-BARDA<br>200 Independence Ave., S.W. Room 640-G<br>Washington DC 20201</font></td><td colspan="24" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">US DEPT OF HEALTH &#38; HUMAN SERVICES<br>ASST SEC OF PREPAREDNESS &#38; RESPONSE ACQ MANAGEMENT, CONTRACTS, &#38; GRANTS O'NEILL HOUSE OFFICE BUILDING<br>Washington DC 20515</font></td></tr><tr style="height:27pt"><td colspan="18" rowspan="4" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MODERNATX, INC 1492235<br>Attn&#58; &#91;***&#93;<br>MODERNATX, INC.&#160;&#160;&#160;&#160;200 TECHNOLOGY<br>200 TECHNOLOGY SQ<br>CAMBRIDGE MA 021393578</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10A. MOD. OF CONTRACT&#47;ORDER NO.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75A50120C00034</font></div></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="15" rowspan="2" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10B. DATED (SEE ITEM 13)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">04&#47;03&#47;2020</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE  8PTM0</font></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FACILITY CODE</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer  </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  is extended, </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  is not extended.</font></div><div style="padding-left:15.2pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58;</font></div><div style="margin-bottom:6pt;padding-left:15.2pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a) By completing Items 8 and 15, and returning _______ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Schedule</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS&#47;ORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;THE ABOVE NUMBERED CONTRACT &#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;OTHER (Specify type of modification and authority)</font></div><div style="margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAR 43.103(a)</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">E. IMPORTANT&#58;  Contractor </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> is not, </font><font style="font-family:'Wingdings 2',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> is required to sign this document and return __</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">___ copies to the issuing office.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14. DESCRIPTION OF AMENDMENT &#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax ID Number&#58;&#160;&#160;&#160;&#160;27-0226313<br>DUNS Number&#58;&#160;&#160;&#160;&#160;069723520</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The purpose of this &#34;no cost&#34; bilateral modification is to&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- Incorporate Executive Order 14042 - FAR Deviation Clause 52.223-99, Ensuring Adequate COVID Safety Protocols for Federal Contractors into Section I of the contract.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- Update Section G.8&#160;&#160;&#160;&#160;Negotiated Indirect Rates and Ceiling</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1. The following is hereby incorporated by full text, at no additional cost to the Government, into Section I&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Continued ...</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15A. NAME AND TITLE OF SIGNER (Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shaun Ryan, SVP &#38; Deputy General Counsel</font></div></td><td colspan="27" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15B. CONTRACT OR&#47;OFFEROR</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Shaun Ryan&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Signature of person authorized to sign)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15C. DATE SIGNED</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#47;20&#47;2022</font></div></td><td colspan="21" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16B. UNITED STATES OF AMERICA</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BY  &#91;***&#93;<br>(Signature of Contracting Officer)</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16C. DATE SIGNED</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021.1.05</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Previous edition unusable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">STANDARD FORM 30 (Rev. 10-83)<br>Prescribed by GSA<br>FAR (48 CFR) 53.243</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:13.611%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><div id="i5dad85bd0cb44f47a54ed7a6fbdab659_4"></div><hr style="page-break-after:always"><div style="min-height:47.52pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTINUATION SHEET</font></td><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REFERENCE NO. OF DOCUMENT BEING CONTINUED</font></td><td colspan="6" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAGE OF</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NAME OF OFFEROR OR CONTRACTOR</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MODERNATX, INC 1492235</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ITEM NO.<br>(A)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SUPPLIES&#47;SERVICES<br>(B)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">QUANTITY (C)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UNIT<br>(D)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UNIT PRICE (E)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMOUNT (F)</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.223-99 Ensuring Adequate COVID-19 Safety Protocols for Federal Contractors.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ENSURING ADEQUATE COVID-19 SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS(OCT 2021) (DEVIATION)</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Definition. As used in this clause - United States or its outlying areas means</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The fifty States&#59;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The District of Columbia&#59;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;The commonwealths of Puerto Rico and the Northern Mariana Islands&#59;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;The territories of American Samoa, Guam, and the and United States Virgin Islands&#59; and</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;The minor outlying islands of Baker Island, Howland Island, Jarvis Island, Johnston Atoll, Kingman Reef, Midway Islands, Navassa Island, Palmyra Atoll, and Wake Atoll. </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Authority. This clause implements Executive Order 14042, Ensuring Adequate COVID Safety Protocols for Federal Contractors, dated September 9, 2021 (published in the Federal Register on September 14, 2021, 86 FR 50985).</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Compliance. The Contractor shall comply with all guidance, including guidance conveyed through Frequently Asked Questions, as amended during the performance of this contract, for contractor or subcontractor workplace locations published by the Safer Federal Workforce Task Force (Task Force Guidance) at https&#58;&#47;www.saferfederalworkforce.gov&#47;contractors&#47;.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Subcontracts. The Contractor shall include the substance  of this clause, including this paragraph (d), in subcontracts at any tier that exceed the simplified acquisition threshold, as defined in Federal Acquisition Regulation 2.101 on the date of subcontract award, and are for services, including construction, performed in whole or in part within the United States or its outlying areas.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(End of clause)</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;The total amount, scope, period of performance and all other terms and conditions of the contract remain unchanged.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;By signing this modification, MODERNATX, INC, hereby releases the Government from any and all liability under this contract for further equitable adjustments attributable to such fact or circumstance giving rise to this modification. Period of Performance&#58; 04&#47;03&#47;2020 to 08&#47;31&#47;2023 </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NSN 7540-01-152-8067</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OPTIONAL FORM 336 (4-86) Sponsored by GSA<br>FAR (48 CFR) 53.110</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:13.611%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><div id="i5dad85bd0cb44f47a54ed7a6fbdab659_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Section G.8 &#8211; Negotiated Indirect Rates and Ceiling</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below are the FY21 Provisional Indirect Rates that will be added to the contract with this modification.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#001f5f;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#001f5f;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Approved FY21 Provisional Rates</font></div></td><td colspan="3" style="background-color:#001f5f;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#001f5f;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Indirect Cost</font></td><td colspan="3" style="background-color:#001f5f;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">%</font></td><td colspan="3" style="background-color:#001f5f;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Allocation Base</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fringe</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Labor Dollars</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TechDev Overhead</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TechDev Department Direct Labor Dollars + Fringe</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research Overhead</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research Department Direct Labor Dollars + Fringe</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DevOps Overhead</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DevOps Department Direct Labor Dollars + Fringe</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G&#38;A Overhead</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G&#38;A</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cost Input</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The total amount, scope, period of performance and all other terms and conditions of the contract remain unchanged</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page 3 of 3</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.705%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>12
<FILENAME>exhibit1040-dodamendments.htm
<DESCRIPTION>EX-10.40
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic5f2b492f7e14a06a131d8226b925ac8_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.40</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;&#91;***&#93;.&#8221; Such identified information has been excluded from this exhibit because it (i) is not material and (ii) is the type of information that the registrant treats as private or confidential.</font></div><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.015%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="15" rowspan="2" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="12" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1. CONTRACT ID CODE</font></td><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PAGE OF PAGES</font></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">P00018</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5-Nov-2021</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Schedule</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5. PROJECT NO.(If applicable)</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6. ISSUED BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">W58P05</font></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7. ADMINISTERED BY (If other than item 6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE</font></div></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S2206A</font></td></tr><tr><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACC-APG - COVID RESPONSE - W58P05<br>6472 INTEGRITY COURT (BUILDING 4401)<br>ABERDEEN PROVING GROUND MD 21005-3013</font></td><td colspan="24" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DCMA BOSTON<br>495 SUMMER STREET<br>BOSTON MA 02210-2138</font></td></tr><tr style="height:12pt"><td colspan="18" rowspan="4" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MODERNA US, INC.<br>&#91;***&#93;<br>200 TECHNOLOGY SQ<br>CAMBRIDGE MA 02139-3578</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10A. MOD. OF CONTRACT&#47;ORDER NO.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">W911QY20C0100</font></div></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="15" rowspan="2" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10B. DATED (SEE ITEM 13)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">09-Aug-2020</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE  8PTM0</font></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FACILITY CODE</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer  </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  is extended, </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  is not extended.</font></div><div style="padding-left:15.2pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58;</font></div><div style="margin-bottom:6pt;padding-left:15.2pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a) By completing Items 8 and 15, and returning _______ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS&#47;ORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;THE ABOVE NUMBERED CONTRACT &#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;OTHER (Specify type of modification and authority)</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">E. IMPORTANT&#58;  Contractor </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> is not, </font><font style="font-family:'Wingdings 2',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> is required to sign this document and return __</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">___ copies to the issuing office.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14. DESCRIPTION OF AMENDMENT &#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)</font></div><div style="margin-bottom:48pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Modification Control Number&#58;  &#91;***&#93;<br>See Block 14 Continuation Page</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15A. NAME AND TITLE OF SIGNER (Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shaun Ryan, SVP &#38; Deputy General Counsel</font></div></td><td colspan="27" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TEL&#58;  &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EMAIL&#58;  &#91;***&#93;</font></div></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15B. CONTRACT OR&#47;OFFEROR</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Shaun Ryan</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Signature of person authorized to sign)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15C. DATE SIGNED</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#47;4&#47;2021</font></div></td><td colspan="21" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16B. UNITED STATES OF AMERICA</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BY  &#91;***&#93;<br>(Signature of Contracting Officer)</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16C. DATE SIGNED</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5-Nov-2021</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EXCEPTION TO SF 30<br>APPROVED BY OIRM 11-84</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-105-04</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">STANDARD FORM 30 (Rev. 10-83)<br>Prescribed by GSA<br>FAR (48 CFR) 53.243</font></td></tr></table></div><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw228)<br>Page 2 of 12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been added by full text&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">P00018</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OBLIGATION AMOUNT&#58;  $0.00</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;The purpose of this modification (P00018) is to&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Update H.19 to reflect revised term agreed on by USG and Moderna (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;The total contract value and total funded amount remain unchanged.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION H - SPECIAL CONTRACT REQUIREMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.1&#160;&#160;&#160;&#160;Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any key personnel specified in this contract are considered to be essential to work performance. At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify the proposed replacement and provide an explanation of how the replacement&#8217;s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements). If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances. The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer. The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties. The following individuals are determined to be key personnel&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.2&#160;&#160;&#160;&#160;Substitution of Key Personnel</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw228)<br>Page 3 of 12</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Contractor agrees to assign to the contract those persons whose resumes&#47;CVs were submitted with the proposal who are necessary to fill the requirements of the contract. No substitutions shall be made except in accordance with this clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution. All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced. The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.3&#160;&#160;&#160;&#160;Disclosure of Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others. Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and&#47;or guidance. The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Contractor shall comply with all applicable Government requirements for protection of non-public information. Unauthorized disclosure of nonpublic information is prohibited by the Government&#8217;s rules. Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress. Neither the Contractor nor the Contractor&#8217;s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity&#8217;s security or interrupt the continuity of its operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order&#59; for submission to any government entity&#8217; for submission to any securities exchange on which the Contractor&#8217;s (or its parent corporation&#8217;s) securities may be listed for trading&#59; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions. The exceptions identified in this paragraph apply to all disclosures under this Section&#160;H.3 except to the extent that a disclosure is otherwise prohibited by law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.4&#160;&#160;&#160;&#160;Publication and Publicity</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract. The contractor shall promptly send a copy of each submission to the COR for security review prior to submission. The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract. The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw228)<br>Page 4 of 12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.5&#160;&#160;&#160;&#160;Confidentiality of Information</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and&#47;or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential. Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract. Failure to agree will be settled pursuant to the &#8220;Disputes&#8221; clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.6&#160;&#160;&#160;&#160;Regulatory Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization. Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the &#8220;Technology&#8221;). The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologics license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology. As the Sponsor of the Regulatory Application to FDA (as the terms &#8220;sponsor&#8221; and &#8220;applicant&#8221; are defined or used in at 21 CFR &#167;&#167;3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accordingly, the Contractor and the Government agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;DoD Medical Product Priority. PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel. The contractor recognizes that only the DoD can utilize PL 115-92. As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract. The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within &#91;***&#93; of award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.     &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.7&#160;&#160;&#160;&#160;Performance Based Payment Liquidated under Termination</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw228)<br>Page 5 of 12</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Based Payments (PBPs) have been authorized as a method of financing under this contract. In the event the Moderna&#8217;s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract. Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.8&#160;&#160;&#160;&#160;Public Readiness and Emergency Preparedness (PREP) Act&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with the Public Readiness and Emergency Preparedness Act (&#8220;PREP Act&#8221;), Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. &#167; 247d-6d and 42 U.S.C. &#167; 247d-6e), as well as the Secretary of HHS&#8217;s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19, 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the &#8220;Prep Act Declaration&#8221;)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of &#8220;Covered Countermeasures&#8221; for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Contractor&#8217;s performance of this Agreement falls within the scope of the &#8220;Recommended Activities&#8221; for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Contractor is a &#8220;Covered Person&#8221; to the extent it is a person defined in Section V of the PREP Act </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Declaration.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw228)<br>Page 6 of 12</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. &#167; 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope. Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the &#8220;Disputes Clause&#8221; (52.233-1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The items and technology covered by this Contract are being developed for both civil and military applications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.9&#160;&#160;&#160;&#160;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.10&#160;&#160;&#160;&#160;Ensuring Sufficient Supply of the Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;In recognition of the Government&#8217;s significant funding for the development and manufacturing of the product in this contract and the Government&#8217;s need to provide sufficient quantities of a COVID-19 vaccine to protect the United States population, the Government shall have the remedy described in this section to ensure sufficient supply of the product to meet the needs of the public health or national security. This remedy is not available to the Government unless and until both of the following conditions ((a) and (b)) are met&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Moderna gives written notice, required to be submitted to the Government &#91;***&#93;, of&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;any formal management decision to terminate manufacturing of this product vaccine prior to delivery of any doses to USG under this contract, including all exercised options, other than as a result of clinical failure, or serious technical or safety reasons or&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;any formal management decision to discontinue sale of this product vaccine to the Government prior to delivery of any doses to USG under this contract, including all exercised options, other than as a result of clinical failure, or serious technical or safety reasons&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw228)<br>Page 7 of 12</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;any filing that anticipates Federal bankruptcy protection&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Moderna has submitted an Emergency Use Authorization application under &#167;564 of the FD&#38;C Act or a biologics license application provisions of &#167;351(a) of the Public Health Service Act (PHSA).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If both conditions listed in section 1 occur, Moderna, upon the request of the Government, shall provide the following items necessary for the Government to pursue manufacturing of this product vaccine with a third party for exclusive sale to the U.S. Government&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;a writing evidencing a non-exclusive, nontransferable, irrevocable (except for cause), royalty-free paid-up license to practice or have practiced for or on behalf of the U.S. Government any Moderna Background Patent, Copyright, other Moderna Intellectual Property, Moderna Know-How, Moderna Technical Data rights necessary to manufacture doses of the mRNA-1273 vaccine&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;necessary FDA regulatory filings or authorizations owned or controlled by Moderna related to this product vaccine and any confirmatory instrument pertaining thereto&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;any outstanding Deliverables contemplated or materials purchased under this contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;This remedy will remain available until the end of the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.11&#160;&#160;&#160;&#160;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.12&#160;&#160;&#160;&#160;Transportation to Final Destination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During the course of performance under this contract, the Government may require storage of the filled drug product (FDP) before delivery to the final government location. In these circumstances, the Government will accept FDP at the contractor facility (Origin). The contractor&#59; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract. &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.13&#160;&#160;&#160;&#160;Validation of IP&#47;Data</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties. The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.14&#160;&#160;&#160;&#160;Novation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon Moderna, US, Inc.&#8217;s registration in the System for Award Management, the Government will, at the Contractor&#8217;s request, complete a novation of this Contract to recognize Moderna US, Inc. as a counterparty instead of Moderna TX, Inc. This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.15&#160;&#160;&#160;&#160;Base &#38; Option 1 Delivery Acceleration</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In an effort to accelerate production of the mRNA-1273 vaccine, &#91;***&#93; within the Option 1 period via a Modification to the contract. If these manufacturing slots are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw228)<br>Page 8 of 12</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">successfully utilized, &#91;***&#93; above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1. However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined. The Government and Moderna agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;If the Government exercises Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Moderna will reduce the cost of Option 2 by $&#91;***&#93; for each successfully accelerated drug product fill under the Base Period (&#91;***&#93;) and $&#91;***&#93; for each successfully accelerated drug product fill under Option 1 (&#91;***&#93;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Government does not exercise Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;In the event Moderna timely cancels the manufacturing slots and&#47;or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to credit the Government $&#91;***&#93; for  &#91;***&#93; and $&#91;***&#93; for &#91;***&#93;. In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drug product manufacturing fills under the Base Period and Option 1. It is understood that Moderna will make all good-faith efforts to fill reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG. The process is outlined as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.) Moderna shall submit documentation to the USG of the following&#58;</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.) Cancellation notice to the subcontractor,</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ii.) The basis of the cancellation, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iii.) Cancellation fees incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.) Moderna shall reduce credits to the USG under paragraph 2a) of this clause, IAW agreed cancellation costs incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.) Bi-lateral agreement of the final credit shall be included in a modification to the contract. Net credit shall be deducted from final payments under the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.16&#160;&#160;&#160;&#160;Delivery Schedule, as revised 11Feb2021 via modification P00004</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw228)<br>Page 9 of 12</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.17&#160;&#160;&#160;&#160;Post-Termination Disposition of Undelivered Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted&#47;undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted&#47;undelivered supplies of mRNA-1273. The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.18&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In order to facilitate projections and invoicing, the Government shall provide or direct a third party (&#91;***&#93;) to provide to Moderna (1) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; (2) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; and (3) the number of &#91;***&#93; remaining in inventory and available for upcoming shipments. This information will be provided to Moderna at a frequency of at least twice monthly.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For each 8.0mL fill volume (1600mcg) vial of vaccine shipped with a &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Both parties acknowledge that the delivery schedule is based on an &#91;***&#93; 8.0mL fill volume (1600mcg) vial delivered. In accordance with the agreed approach for invoicing and counting doses toward Moderna&#8217;s delivery requirement, &#91;***&#93;. Specifically for purposes of adhering to the scheduled delivery dates set forth in this contract for the Base Period, Option 1 and Option 2, schedule shall be deemed to have been met once doses are released by Moderna and are available for order.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.19</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product &#91;***&#93; (as added via P00018)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specific to CLINs 3001 and 4001, Moderna will deliver to the Government &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adult Primary Series (mRNA1273 or other, as determined by EUA&#47;BLA and any related supplement or amendment thereto accepted and authorized&#47;licensed by FDA and mutually agreed upon&#59; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For avoidance of doubt, all doses delivered to the Government must be suitable for use in the United States pursuant to an active EUA or approved BLA at the time of product delivery. &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If US regulatory authorities determine there is a need for an updated vaccine containing one or more variant mRNA sequences for any reason, including improved efficacy against new or emerging virus strains, the Parties agree to work together in good faith to discuss any such situation and any potential impact on this contract. &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Both parties acknowledge that the EUA for mRNA1273 may be expanded such that doses procured under this contract may have utility beyond the currently authorized indications&#47;populations, and in the event of any such expansion, the Government will not be restricted hereunder from use of mRNA1273 in accordance with the full scope of any FDA authorization and CDC recommendation to the extent consistent with the Government&#8217;s obligations under Section H.8 and the terms of Section H.20.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government and Moderna agree that the total monthly delivery quantities for CLIN 3001 and 4001 will follow the following Delivery Schedule&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government and Moderna agree as follows&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#91;***&#93;.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:14.5pt">Sale of doses to the African Union. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government is agreeing to defer delivery of 33,000,000 doses previously scheduled for delivery in December and February to facilitate Moderna&#8217;s supply of 50,000,000 doses of mRNA1273 to the African Union (AU) at a notforprofit price.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw228)<br>Page 10 of 12</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUA Wind Down. It is anticipated that all mRNA1273 under this contract will be delivered in accordance with an active EUA. If a BLA is issued during the term of this Contract for the mRNA1273 vaccine, the Government and Moderna shall discuss an appropriate transition of mRNA1273 to BLA which will include that any doses subsequently provided to the Government under this Contract are appropriately labeled and are otherwise suitable for use in the United States under the terms of the EUA (before expiration) or the BLA.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw228)<br>Page 11 of 12</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.20&#160;&#160;&#160;&#160;Donation of Excess Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;If the Government determines that a quantity of doses of mRNA-1273 supplied to the Government under this contract is no longer needed by the Government, the Government may donate such doses to a foreign nation or non- governmental organization (NGO) facilitating donation to a foreign nation, subject to the remainder of this Clause H.20. The Government shall notify Contractor in writing prior to any proposed donation to a foreign nation or NGO, which notice will include &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Contractor must verify in writing that all of the required conditions below are met before any such donation is made, &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;The Government&#8217;s donations will be from supplies of vaccine delivered to and accepted by the Government. To the extent the Government commits to deliver doses that have not yet been physically delivered to the Government, such donation will not occur until such doses have been delivered to the Government. The Government will be responsible for delivery of the donated doses to, and coordination of delivery with, the receiving foreign nation or NGO, as applicable. The Government or the receiving foreign nation or NGO, as applicable, will (i) satisfy all customs shipping requirements for import and export of the product&#59; and (ii) as the exporter, file any required FDA export notifications. To the extent not already provided to the Government, the Contractor will provide all information necessary to complete any requirements identified in this paragraph in advance of shipment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;When the conditions above are met for any donation, the Parties will &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw228)<br>Page 12 of 12</font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;Shipment of any donated doses under this Article does not constitute a violation of the Defense Production Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(End of Summary of Changes)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_7"></div><hr style="page-break-after:always"><div style="min-height:48.24pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.015%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="15" rowspan="2" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="12" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1. CONTRACT ID CODE</font></td><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PAGE OF PAGES</font></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">P00019</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15-NOV-2021</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Schedule</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5. PROJECT NO.(If applicable)</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6. ISSUED BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">W58P05</font></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7. ADMINISTERED BY (If other than item 6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE</font></div></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S2206A</font></td></tr><tr><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACC-APG - COVID RESPONSE - W58P05<br>6472 INTEGRITY COURT (BUILDING 4401)<br>ABERDEEN PROVING GROUND MD 21005-3013</font></td><td colspan="24" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DCMA BOSTON<br>495 SUMMER STREET<br>BOSTON MA 02210-2138</font></td></tr><tr style="height:12pt"><td colspan="18" rowspan="4" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MODERNA US, INC.<br>&#91;***&#93;<br>200 TECHNOLOGY SQ<br>CAMBRIDGE MA 02139-3578</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10A. MOD. OF CONTRACT&#47;ORDER NO.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">W911QY20C0100</font></div></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="15" rowspan="2" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10B. DATED (SEE ITEM 13)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">09-Aug-2020</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE  8PTM0</font></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FACILITY CODE</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer  </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  is extended, </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  is not extended.</font></div><div style="padding-left:15.2pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58;</font></div><div style="margin-bottom:6pt;padding-left:15.2pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a) By completing Items 8 and 15, and returning _______ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS&#47;ORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;THE ABOVE NUMBERED CONTRACT &#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;OTHER (Specify type of modification and authority)</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">E. IMPORTANT&#58;  Contractor </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> is not, </font><font style="font-family:'Wingdings 2',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> is required to sign this document and return __</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">___ copies to the issuing office.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14. DESCRIPTION OF AMENDMENT &#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)</font></div><div style="margin-bottom:48pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Modification Control Number&#58;  &#91;***&#93;<br>See Block 14 Continuation Page</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15A. NAME AND TITLE OF SIGNER (Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shaun Ryan, SVP &#38; Deputy General Counsel</font></div></td><td colspan="27" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TEL&#58;  &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EMAIL&#58;  &#91;***&#93;</font></div></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15B. CONTRACT OR&#47;OFFEROR</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Shaun Ryan</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Signature of person authorized to sign)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15C. DATE SIGNED</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#47;10&#47;21</font></div></td><td colspan="21" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16B. UNITED STATES OF AMERICA</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BY  &#91;***&#93;<br>(Signature of Contracting Officer)</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16C. DATE SIGNED</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15-NOV-2021</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EXCEPTION TO SF 30<br>APPROVED BY OIRM 11-84</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-105-04</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">STANDARD FORM 30 (Rev. 10-83)<br>Prescribed by GSA<br>FAR (48 CFR) 53.243</font></td></tr></table></div><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 2 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been added by full text&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">P00019</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OBLIGATION AMOUNT&#58; $0.00</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The purpose of this modification (P00019) is to&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8208;&#160;&#160;&#160;&#160;Modify the H.20 Donation of Excess Product clause to capture clinical study donations (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8208;&#160;&#160;&#160;&#160;Add H.21 Healthcare Provider List clause (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8208;&#160;&#160;&#160;&#160;Update Exhibit B as outlined in clause H.20 with donation information for multiple recipients (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The total contract value and total funded amount remain unchanged.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION H - SPECIAL CONTRACT REQUIREMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.1&#160;&#160;&#160;&#160;Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any key personnel specified in this contract are considered to be essential to work performance. At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify the proposed replacement and provide an explanation of how the replacement&#8217;s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements). If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances. The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer. The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties. The following individuals are determined to be key personnel&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 3 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.2&#160;&#160;&#160;&#160;Substitution of Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Contractor agrees to assign to the contract those persons whose resumes&#47;CVs were submitted with the proposal who are necessary to fill the requirements of the contract. No substitutions shall be made except in accordance with this clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution. All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced. The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.3&#160;&#160;&#160;&#160;Disclosure of Information&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others. Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and&#47;or guidance. The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Contractor shall comply with all applicable Government requirements for protection of non-public information. Unauthorized disclosure of nonpublic information is prohibited by the Government&#8217;s rules. Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress. Neither the Contractor nor the Contractor&#8217;s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity&#8217;s security or interrupt the continuity of its operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order&#59; for submission to any government entity&#8217; for submission to any securities exchange on which the Contractor&#8217;s (or its parent corporation&#8217;s) securities may be listed for trading&#59; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions. The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.4&#160;&#160;&#160;&#160;Publication and Publicity</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract. The contractor shall promptly send a copy of each submission to the COR for security review prior to submission. The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 4 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract. The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.5&#160;&#160;&#160;&#160;Confidentiality of Information</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and&#47;or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential. Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract. Failure to agree will be settled pursuant to the &#8220;Disputes&#8221; clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.6&#160;&#160;&#160;&#160;Regulatory Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization. Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the &#8220;Technology&#8221;). The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologics license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology. As the Sponsor of the Regulatory Application to FDA (as the terms &#8220;sponsor&#8221; and &#8220;applicant&#8221; are defined or used in at 21 CFR &#167;&#167;3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 5 of 14</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accordingly, the Contractor and the Government agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;DoD Medical Product Priority. PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel. The contractor recognizes that only the DoD can utilize PL 115-92. As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract. The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within &#91;***&#93; of award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.7&#160;&#160;&#160;&#160;Performance Based Payment Liquidated under Termination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Based Payments (PBPs) have been authorized as a method of financing under this contract. In the event the Moderna&#8217;s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract. Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.8&#160;&#160;&#160;&#160;Public Readiness and Emergency Preparedness (PREP) Act&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with the Public Readiness and Emergency Preparedness Act (&#8220;PREP Act&#8221;), Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. &#167; 247d-6d and 42 U.S.C. &#167; 247d-6e), as well as the Secretary of HHS&#8217;s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19, 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the &#8220;Prep Act Declaration&#8221;)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of &#8220;Covered Countermeasures&#8221; for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 6 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Contractor&#8217;s performance of this Agreement falls within the scope of the &#8220;Recommended Activities&#8221; for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Contractor is a &#8220;Covered Person&#8221; to the extent it is a person defined in Section V of the PREP Act </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. &#167; 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope. Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the &#8220;Disputes Clause&#8221; (52.233-1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The items and technology covered by this Contract are being developed for both civil and military applications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.9&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.10&#160;&#160;&#160;&#160;Ensuring Sufficient Supply of the Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;In recognition of the Government&#8217;s significant funding for the development and manufacturing of the product in this contract and the Government&#8217;s need to provide sufficient quantities of a COVID-19 vaccine to protect the United States population, the Government shall have the remedy described in this section to ensure sufficient supply of the product to meet the needs of the public health or national security. This remedy is not available to the Government unless and until both of the following conditions ((a) and (b)) are met&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Moderna gives written notice, required to be submitted to the Government &#91;***&#93;, of&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 7 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;any formal management decision to terminate manufacturing of this product vaccine prior to delivery of any doses to USG under this contract, including all exercised options, other than as a result of clinical failure, or serious technical or safety reasons or&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;any formal management decision to discontinue sale of this product vaccine to the Government prior to delivery of any doses to USG under this contract, including all exercised options, other than as a result of clinical failure, or serious technical or safety reasons&#59; or</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;any filing that anticipates Federal bankruptcy protection&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Moderna has submitted an Emergency Use Authorization application under &#167;564 of the FD&#38;C Act or a biologics license application provisions of &#167;351(a) of the Public Health Service Act (PHSA).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If both conditions listed in section 1 occur, Moderna, upon the request of the Government, shall provide the following items necessary for the Government to pursue manufacturing of this product vaccine with a third party for exclusive sale to the U.S. Government&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;a writing evidencing a non-exclusive, nontransferable, irrevocable (except for cause), royalty-free paid-up license to practice or have practiced for or on behalf of the U.S. Government any Moderna Background Patent, Copyright, other Moderna Intellectual Property, Moderna Know-How, Moderna Technical Data rights necessary to manufacture doses of the mRNA-1273 vaccine&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;necessary FDA regulatory filings or authorizations owned or controlled by Moderna related to this product vaccine and any confirmatory instrument pertaining thereto&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;any outstanding Deliverables contemplated or materials purchased under this contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;This remedy will remain available until the end of the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.11&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.12&#160;&#160;&#160;&#160;Transportation to Final Destination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During the course of performance under this contract, the Government may require storage of the filled drug product (FDP) before delivery to the final government location. In these circumstances, the Government will accept FDP at the contractor facility (Origin). The contractor&#59; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract. &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.13&#160;&#160;&#160;&#160;Validation of IP&#47;Data</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties. The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.14&#160;&#160;&#160;&#160;Novation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon Moderna, US, Inc.&#8217;s registration in the System for Award Management, the Government will, at the Contractor&#8217;s request, complete a novation of this Contract to recognize Moderna US, Inc. as a counterparty instead</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 8 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of Moderna TX, Inc. This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.15&#160;&#160;&#160;&#160;Base &#38; Option 1 Delivery Acceleration</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In an effort to accelerate production of the mRNA-1273 vaccine, &#91;***&#93; within the Option 1 period via a Modification to the contract. If these manufacturing slots are successfully utilized, &#91;***&#93; above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1. However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined. The Government and Moderna agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;If the Government exercises Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Moderna will reduce the cost of Option 2 by $&#91;***&#93; for each successfully accelerated drug product fill under the Base Period (&#91;***&#93;) and $&#91;***&#93; for each successfully accelerated drug product fill under Option 1 (&#91;***&#93;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Government does not exercise Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;In the event Moderna timely cancels the manufacturing slots and&#47;or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to credit the Government $&#91;***&#93; for &#91;***&#93; and $&#91;***&#93; for &#91;***&#93;. In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drug product manufacturing fills under the Base Period and Option 1. It is understood that Moderna will make all good-faith efforts to fill reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG. The process is outlined as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.) Moderna shall submit documentation to the USG of the following&#58;</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.) Cancellation notice to the subcontractor,</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ii.) The basis of the cancellation, and</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iii.) Cancellation fees incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.) Moderna shall reduce credits to the USG under paragraph 2a) of this clause, IAW agreed cancellation costs incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.) Bi-lateral agreement of the final credit shall be included in a modification to the contract. Net credit shall be deducted from final payments under the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.16&#160;&#160;&#160;&#160;Delivery Schedule, as revised 11Feb2021 via modification P00004</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_28"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 9 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.17&#160;&#160;&#160;&#160;Post-Termination Disposition of Undelivered Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted&#47;undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted&#47;undelivered supplies of mRNA-1273. The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.18&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In order to facilitate projections and invoicing, the Government shall provide or direct a third party (&#91;***&#93;)  to provide to Moderna (1) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; (2) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; and (3) the number of &#91;***&#93; remaining in inventory and available for upcoming shipments. This information will be provided to Moderna at a frequency of at least twice monthly.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For each 8.0mL fill volume (1600mcg) vial of vaccine shipped with a &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Both parties acknowledge that the delivery schedule is based on an &#91;***&#93; 8.0mL fill volume (1600mcg) vial delivered. In accordance with the agreed approach for invoicing and counting doses toward Moderna&#8217;s delivery requirement, &#91;***&#93;. Specifically for purposes of adhering to the scheduled delivery dates set forth in this contract for the Base Period, Option 1 and Option 2, schedule shall be deemed to have been met once doses are released by Moderna and are available for order.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.19</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product &#91;***&#93; (as added via P00018)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specific to CLINs 3001 and 4001, Moderna will deliver to the Government &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adult Primary Series (mRNA&#8208;1273 or other, as determined by EUA&#47;BLA and any related supplement or amendment thereto accepted and authorized&#47;licensed by FDA and mutually agreed upon&#59; &#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_31"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 10 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For avoidance of doubt, all doses delivered to the Government must be suitable for use in the United States pursuant to an active EUA or approved BLA at the time of product delivery. &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If US regulatory authorities determine there is a need for an updated vaccine containing one or more variant mRNA sequences for any reason, including improved efficacy against new or emerging virus strains, the Parties agree to work together in good faith to discuss any such situation and any potential impact on this contract. &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Both parties acknowledge that the EUA for mRNA&#8208;1273 may be expanded such that doses procured under this contract may have utility beyond the currently authorized indications&#47;populations, and in the event of any such expansion, the Government will not be restricted hereunder from use of mRNA&#8208;1273 in accordance with the full scope of any FDA authorization and CDC recommendation to the extent consistent with the Government&#8217;s obligations under Section H.8 and the terms of Section H.20.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government and Moderna agree that the total monthly delivery quantities for CLIN 3001 and 4001 will follow the following Delivery Schedule&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government and Moderna agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:14.5pt">Sale of doses to the African Union. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government is agreeing to defer delivery of 33,000,000 doses previously scheduled for delivery in December and February to facilitate Moderna&#8217;s supply of 50,000,000 doses of mRNA&#8208;1273 to the African Union (AU) at a not&#8208;for&#8208;profit price.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUA Wind Down. It is anticipated that all mRNA&#8208;1273 under this contract will be delivered in accordance with an active EUA. If a BLA is issued during the term of this Contract for the mRNA&#8208;1273 vaccine, the Government and Moderna shall discuss an appropriate transition of mRNA&#8208;1273 to BLA which will include that any doses subsequently provided to the Government under this Contract are appropriately labeled and are otherwise suitable for use in the United States under the terms of the EUA (before expiration) or the BLA.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_34"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 11 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.20&#160;&#160;&#160;&#160;Donation of Excess Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;If the Government determines that a quantity of doses of mRNA-1273 supplied to the Government under this contract is no longer needed by the Government, the Government may donate such doses to a foreign nation or nongovernmental organization (NGO) facilitating donation to a foreign nation, subject to the remainder of this Clause H.20. The Government shall notify Contractor in writing prior to any proposed donation to a foreign nation or NGO, which notice will include &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Contractor must verify in writing that all of the required conditions below are met before any such donation is made, &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_37"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 12 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Additionally, the Government may donate product for use in the clinical study to be conducted pursuant to the Clinical Trial Agreement (as amended on October 28, 2021) between The National Institute of Allergy and Infectious Disease (&#8220;NIAID&#8221;) and the South African Medical Research Counsel (&#8220;SAMRC&#8221;) under Protocol CoVPN 3008 (the &#8220;CoVPN 3008 Study&#8221;), subject to the Government&#8217;s having a binding written agreement(s) in place with the sponsor that satisfies the conditions set forth below in this clause (c)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#91;***&#93;,</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ix)&#160;&#160;&#160;&#160;&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(x)&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_40"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 13 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;The Government&#8217;s donations will be from supplies of vaccine delivered to and accepted by the Government. To the extent the Government commits to deliver doses that have not yet been physically delivered to the Government, such donation will not occur until such doses have been delivered to the Government. The Government will be responsible for delivery of the donated doses to, and coordination of delivery with, the receiving foreign nation, clinical study sponsor, or NGO, as applicable. The Government or the receiving foreign nation, clinical study sponsor, or NGO, as applicable, will (i) satisfy all customs shipping requirements for import and export of the product&#59; and (ii) as the exporter, file any required FDA export notifications. To the extent not already provided to the Government, the Contractor will provide all information necessary to complete any requirements identified in this paragraph in advance of shipment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;When the conditions above are met for any donation, the Parties will &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;Shipment of any donated doses under this Article does not constitute a violation of the Defense Production Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.21&#160;&#160;&#160;&#160;CDC Healthcare Provider List</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To ensure timely communication is provided to health care providers, the USG has provided Moderna the mailing list for the Centers for Disease Control and Prevention (CDC) healthcare providers administering Moderna&#8217;s vaccine and boosters in order for Moderna to send information regarding boosters that were authorized by the FDA on October 20, 2021. Moderna agrees to the terms below of the handling of the CDC Healthcare Provider List.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Moderna shall use the CDC Healthcare Provider List only for the express purpose of the specific mailing regarding Moderna&#8217;s FDA-authorized booster product&#47;EUA expansion&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Moderna shall not share or provide this list to any outside parties other than those who are supporting this specific mailing&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Moderna shall delete (and require any other parties to delete) the list once they have completed the mailing.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been modified&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Document Type</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page #</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CDRLs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 February 2021</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit B</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Donation of Excess Product</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 November 2021</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0001</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supply Chain Resiliency Plan for CDRL A010</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0002</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Security Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0003</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dose Tracking Template Draft Moderna</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Excel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0004</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Data Rights</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0005</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0006</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ModernaTx, Inc. Background Intellectual Property</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0007</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance Base Payment Milestone Schedule</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0008</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance Base Payment Milestone Billing Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 September 2021</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0009</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HRPAS Moderna Letter</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 September 2020</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_43"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2210)<br>Page 14 of 14</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(End of Summary of Changes)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_46"></div><hr style="page-break-after:always"><div style="min-height:48.24pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.015%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="15" rowspan="2" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="12" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1. CONTRACT ID CODE</font></td><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PAGE OF PAGES</font></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">P00020</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 DEC 2021</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Schedule</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5. PROJECT NO.(If applicable)</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6. ISSUED BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">W58P05</font></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7. ADMINISTERED BY (If other than item 6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE</font></div></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S2206A</font></td></tr><tr><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACC-APG - COVID RESPONSE - W58P05<br>6472 INTEGRITY COURT (BUILDING 4401)<br>ABERDEEN PROVING GROUND MD 21005-3013</font></td><td colspan="24" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DCMA BOSTON<br>495 SUMMER STREET<br>BOSTON MA 02210-2138</font></td></tr><tr style="height:12pt"><td colspan="18" rowspan="4" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MODERNA US, INC.<br>&#91;***&#93;<br>200 TECHNOLOGY SQ<br>CAMBRIDGE MA 02139-3578</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10A. MOD. OF CONTRACT&#47;ORDER NO.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">W911QY20C0100</font></div></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="15" rowspan="2" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10B. DATED (SEE ITEM 13)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">09-Aug-2020</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE  8PTM0</font></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FACILITY CODE</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer  </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  is extended, </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  is not extended.</font></div><div style="padding-left:15.2pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58;</font></div><div style="margin-bottom:6pt;padding-left:15.2pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a) By completing Items 8 and 15, and returning _______ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS&#47;ORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;THE ABOVE NUMBERED CONTRACT &#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;OTHER (Specify type of modification and authority)</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">E. IMPORTANT&#58;  Contractor </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> is not, </font><font style="font-family:'Wingdings 2',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> is required to sign this document and return __</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">___ copies to the issuing office.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14. DESCRIPTION OF AMENDMENT &#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)</font></div><div style="margin-bottom:48pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Modification Control Number&#58;  &#91;***&#93;<br>See Block 14 Continuation Page</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15A. NAME AND TITLE OF SIGNER (Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shaun Ryan, SVP &#38; Deputy General Counsel</font></div></td><td colspan="27" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TEL&#58;  &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EMAIL&#58;  &#91;***&#93;</font></div></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15B. CONTRACT OR&#47;OFFEROR</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Shaun Ryan</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Signature of person authorized to sign)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15C. DATE SIGNED</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#47;21&#47;2021</font></div></td><td colspan="21" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16B. UNITED STATES OF AMERICA</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BY  &#91;***&#93;<br>(Signature of Contracting Officer)</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16C. DATE SIGNED</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 December 2021</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EXCEPTION TO SF 30<br>APPROVED BY OIRM 11-84</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-105-04</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">STANDARD FORM 30 (Rev. 10-83)<br>Prescribed by GSA<br>FAR (48 CFR) 53.243</font></td></tr></table></div><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_49"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 2 of 16</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been added by full text&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">P00020</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OBLIGATION AMOUNT&#58; $0.00</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The purpose of this modification (P00020) is to&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8208;&#160;&#160;&#160;&#160;Update Section G Contracting Officer and Government Technical Point of Contract (FAR 43.103(b)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8208;&#160;&#160;&#160;&#160;Update Moderna Contractor&#8217;s Contract Administration in Section G and Key Personnel in H.1 (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8208;&#160;&#160;&#160;&#160;Update Exhibit B as outlined in clause H.20 with donation information for multiple recipients identified (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The total contract value and total funded amount remain unchanged.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION G - CONTRACT ADMINISTRATION DATA</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">G.1&#160;&#160;&#160;&#160;GOVERNMENT CONTRACT ADMINISTRATION</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In no event shall any understanding or agreement, contract modification, change order, or other matter in deviation from the terms of this contract between the Contractor and a person other than the Contracting Officer be effective or binding upon the Government. All such actions must be formalized by a proper contractual document executed by the Contracting Officer.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Procuring Contracting Officer&#58;<br>&#91;***&#93;<br>Joint COVID-19 Response Division<br>US Army Contracting Command<br>6472 Integrity Court (Building 4401)<br>Aberdeen Proving Ground, MD 21005-3013</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Specialist&#58;<br>&#91;***&#93;<br>Joint COVID-19 Response Division<br>US Army Contracting Command</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_52"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 3 of 16</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6472 Integrity Court (Building 4401)<br>Aberdeen Proving Ground, MD 21005-3013</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Specialist&#58;<br>&#91;***&#93;<br>Joint COVID-19 Response Division<br>US Army Contracting Command<br>6472 Integrity Court (Building 4401)<br>Aberdeen Proving Ground, MD 21005-3013</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">G.2&#160;&#160;&#160;&#160;GOVERNMENT TECHNICAL POINT OF CONTACT</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;<br>Biologist&#47;Project Officer<br>200 C Street, SW<br>Washington, DC 20201</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">G.3&#160;&#160;&#160;&#160;CONTRACTOR&#8217;S CONTRACT ADMINISTRATION</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;<br>Moderna US, Inc.<br>200 Technology SQ.<br>Cambridge, MA 02139-3578</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">G.4&#160;&#160;&#160;&#160;PLACES OF PERFORMANCE</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna US, Inc.<br>200 Technology SQ.<br>Cambridge, MA 02139-3578</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">G.5&#160;&#160;&#160;&#160;NOTIFICATION OF REVISIONS AND CHANGE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notification of revision or changes to names or email addresses will be provided by official correspondence from the PCO&#47;ACO or office of the PCO&#47;ACO in lieu of a contract modification. This does not apply to any such revisions or changes in the event this contract includes a key personnel clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">G.6&#160;&#160;&#160;&#160;PERFORMANCE BASED PAYMENT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based payments (PBP) are authorized under this contract in accordance with FAR 52.232-32. The contractor shall bill for the PBP upon achievement of the completion criteria identified in Attachment 0007, Performance-based Payment Milestone Table dated 4 May 2021. Upon achievement of the completion criteria, the contractor shall bill for the PBP for the base and each option IAW the following schedule&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CLIN</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0001AA</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BASE</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$90,210,000</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0001AB</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BASE</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$132,308,000</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0001AC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BASE</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$180,420,000</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0001AD</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BASE</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$198,462,000</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TOTAL</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$601,400,000</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TOTAL</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 4 of 16</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TOTAL</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TOTAL</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TOTAL</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delivery Invoicing&#58; PBPs are a type of contract financing and are recouped by the Government through deductions of payments otherwise due to the contractor for the partial or complete delivery of contract items. The deductions are made by applying a liquidation rate to the price of delivered contract items. Attachment 0008, Performance- based Payment Milestone Billing Plan, identifies the contractor invoicing schedule for liquidation. The contractor shall submit all invoices IAW Attachment 0008.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION H - SPECIAL CONTRACT REQUIREMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.1&#160;&#160;&#160;&#160;Key Personnel</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any key personnel specified in this contract are considered to be essential to work performance. At least thirty (30) calendar days prior to the Contractor voluntarily diverting any of the specified individuals to other programs or contracts the Contractor shall notify the Contracting Officer and shall submit a justification for the diversion or replacement and a request to replace the individual. The request must identify the proposed replacement and provide an explanation of how the replacement&#8217;s skills, experience, and credentials meet or exceed the requirements of the contract (including, when applicable, Human Subjects Testing requirements). If the employee of the Contractor is terminated for cause or separates from the Contractor voluntarily with less than thirty (30) calendar-day notice, the Contractor shall provide the maximum notice practicable under the circumstances. The Contractor shall not divert, replace, or announce any such change to key personnel without the written consent of the Contracting Officer. The contract will be modified to add or delete key personnel as necessary to reflect the agreement of the parties. The following individuals are determined to be key personnel&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.2&#160;&#160;&#160;&#160;Substitution of Key Personnel</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_55"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 5 of 16</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Contractor agrees to assign to the contract those persons whose resumes&#47;CVs were submitted with the proposal who are necessary to fill the requirements of the contract. No substitutions shall be made except in accordance with this clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All requests for substitution must provide a detailed explanation of the circumstance necessitating the proposed substitution, a complete resume for the proposed substitute and any other information requested by the contracting officer to approve or disapprove the proposed substitution. All proposed substitutes must have qualifications that are equal to or higher than the qualifications of the person to be replaced. The contracting officer or authorized representative will evaluate such requests and promptly notify the contractor of his approval or disapproval thereof.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.3&#160;&#160;&#160;&#160;Disclosure of Information&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance under this contract may require the Contractor to access non-public data and information proprietary to a Government agency, another Government Contractor or of such nature that its dissemination or use other than as specified in the work statement would be adverse to the interests of the Government or others. Neither the Contractor, nor Contractor personnel, shall divulge nor release data nor information developed or obtained under performance of this contract, except authorized by Government personnel or upon written approval of the CO which the KO will provide in accordance with OWS or other Government policies and&#47;or guidance. The Contractor shall not use, disclose, or reproduce proprietary data that bears a restrictive legend, other than as specified in this contract, or any information at all regarding this agency.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Contractor shall comply with all applicable Government requirements for protection of non-public information. Unauthorized disclosure of nonpublic information is prohibited by the Government&#8217;s rules. Unauthorized disclosure may result in termination of the contract, replacement of a Contractor employee, or other appropriate redress. Neither the Contractor nor the Contractor&#8217;s employees shall disclose or cause to be disseminated, any information concerning the operations of the activity, which could result in, or increase the likelihood of, the possibility of a breach of the activity&#8217;s security or interrupt the continuity of its operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No information related to data obtained under this contract shall be released or publicized without the prior written consent of the COR, whose approval shall not be unreasonably withheld, conditioned, or delayed, provided that no such consent is required to comply with any law, rule, regulation, court ruling or similar order&#59; for submission to any government entity&#8217; for submission to any securities exchange on which the Contractor&#8217;s (or its parent corporation&#8217;s) securities may be listed for trading&#59; or to third parties relating to securing, seeking, establishing or maintaining regulatory or other legal approvals or compliance, financing and capital raising activities, or mergers, acquisitions, or other business transactions. The exceptions identified in this paragraph apply to all disclosures under this Section H.3 except to the extent that a disclosure is otherwise prohibited by law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.4&#160;&#160;&#160;&#160;Publication and Publicity</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The contractor shall not release any reports, manuscripts, press releases, or abstracts about the work being performed under this contract without written notice in advance to the Government.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Unless otherwise specified in this contract, the contractor may publish the results of its work under this contract. The contractor shall promptly send a copy of each submission to the COR for security review prior to submission. The contractor shall also inform the COR when the abstract article or other publication is published, and furnish a copy of it as finally published.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Unless authorized in writing by the CO, the contractor shall not display the DoD logo including Operating Division or Staff Division logos on any publications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;The contractor shall not reference the products(s) or services(s) awarded under this contract in commercial advertising, as defined in FAR 31.205-1, in any manner which states or implies DoD approval or endorsement of the product(s) or service(s) provided.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;The contractor shall include this clause, including this section (d) in all subcontracts where the subcontractor may propose publishing the results of its work under the subcontract. The contractor shall acknowledge the support of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority whenever publicizing the work under this contract in any media by including an acknowledgement substantially as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 6 of 16</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract Number W911QY-20-C-0100.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.5&#160;&#160;&#160;&#160;Confidentiality of Information</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Confidential information, as used in this article, means non-public information or data of a personal nature about an individual, or proprietary information or data submitted by or pertaining to an institution or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;The Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and&#47;or categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which is confidential. Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information from time to time during the performance of the contract. Failure to agree will be settled pursuant to the &#8220;Disputes&#8221; clause.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;If it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C. 552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Confidential information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual, institution, or organization.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;Whenever the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor shall obtain a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;Contracting Officer Determinations will reflect the result of internal coordination with appropriate program and legal officials.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;The provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or local laws.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALL REQUIREMENTS OF THIS SECTION H.5 MUST BE PASSED TO ALL SUB-CONTRACTOR.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.6&#160;&#160;&#160;&#160;Regulatory Rights</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This contract involves supply of a product that requires FDA pre-market approval or clearance before commercial authorization. Contractor is seeking FDA authorization or clearance for the commercialization of mRNA-1273, Moderna vaccine for SARS-CoV-2 Coronavirus (the &#8220;Technology&#8221;). The Contractor is the Sponsor of the Regulatory Application (an investigational new drug application (IND), investigational device exemption (IDE), emergency use authorization (EUA), new drug application (NDA), biologics license application (BLA), premarket approval application (PMA), or 510(k) pre-market notification filing (510(k)) or another regulatory filing submitted to FDA) for the technology. As the Sponsor of the Regulatory Application to FDA (as the terms &#8220;sponsor&#8221; and &#8220;applicant&#8221; are defined or used in at 21 CFR &#167;&#167;3.2(c), 312.5, 600.3(t), 812.2(b), 812 Subpart C, or 814.20), the Contractor has certain standing before the FDA that entitles it to exclusive communications related to the Regulatory Application.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_58"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 7 of 16</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accordingly, the Contractor and the Government agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;DoD Medical Product Priority. PL 115-92 allows the DoD to request, and FDA to provide, assistance to expedite development of products to diagnose, treat, or prevent serious or life-threatening diseases or conditions facing American military personnel. The contractor recognizes that only the DoD can utilize PL 115-92. As such, the contractor will work proactively with the Government to leverage this law to its maximum potential under this contract. The contractor shall submit Public Law 115-92 Sponsor Authorization Letter that will be delivered to the designated OWS POC(s) within &#91;***&#93; award.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.7&#160;&#160;&#160;&#160;Performance Based Payment Liquidated under Termination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Based Payments (PBPs) have been authorized as a method of financing under this contract. In the event the Moderna&#8217;s mRNA-1273 COVID Vaccine is unsuccessful in its bid to obtain EUA or FDA approval, the Government may issue a Termination for Convenience (T4C) in whole or in part, on this contract. Upon notice of a T4C, the contractor shall submit a termination settlement proposal, IAW FAR 52.249-2, Termination for Convenience of the Government (Fixed-Price).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.8&#160;&#160;&#160;&#160;Public Readiness and Emergency Preparedness (PREP) Act&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with the Public Readiness and Emergency Preparedness Act (&#8220;PREP Act&#8221;), Pub. L. No. 109-148, Division C, Section 2, as amended (codified at 42 U.S.C. &#167; 247d-6d and 42 U.S.C. &#167; 247d-6e), as well as the Secretary of HHS&#8217;s Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19, 85 Fed. Reg. 15198 (Mar. 17, 2020, effective Feb. 4, 2020), and amended on April 15, 2020, 85 Fed. Reg. 21012 (together, the &#8220;Prep Act Declaration&#8221;)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;This Agreement is being entered into for purposes of facilitating the manufacture, testing, development, distribution, administration, and use of &#8220;Covered Countermeasures&#8221; for responding to the COVID-19 public health emergency, in accordance with Section VI of the PREP Act Declaration&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Contractor&#8217;s performance of this Agreement falls within the scope of the &#8220;Recommended Activities&#8221; for responding to the COVID-19 public health emergency, to the extent it is in accordance with Section III of the PREP Act Declaration&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Contractor is a &#8220;Covered Person&#8221; to the extent it is a person defined in Section V of the PREP Act </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Declaration.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_61"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 8 of 16</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Therefore, in accordance with Sections IV and VII of the PREP Act Declaration as well as the PREP Act (42 U.S.C. &#167; 247d-6d), the Department of Defense contracting via assisted acquisition on behalf of the HHS, expressly acknowledges and agrees that the HHS Declaration cited above, specifically its language providing immunity from suit and liability is applicable to this acquisition as long as Contractors activities fall within the terms and conditions of the PREP Act and the PREP Act Declaration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government may not use, or authorize the use of, any products or materials provided under this contract, unless such use occurs in the United States (or a U.S. territory where U.S. law applies such as embassies, military and NATO installations) and is protected from liability under a declaration issued under the PREP Act, or a successor COVID-19 PREP Act Declaration of equal or greater scope. Any use where the application of the PREP Act is in question will be discussed with Moderna prior to use and, if the parties disagree on such use, the dispute will be resolved according to the &#8220;Disputes Clause&#8221; (52.233-1)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The items and technology covered by this Contract are being developed for both civil and military applications.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.9&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.10&#160;&#160;&#160;&#160;Ensuring Sufficient Supply of the Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;In recognition of the Government&#8217;s significant funding for the development and manufacturing of the product in this contract and the Government&#8217;s need to provide sufficient quantities of a COVID-19 vaccine to protect the United States population, the Government shall have the remedy described in this section to ensure sufficient supply of the product to meet the needs of the public health or national security. This remedy is not available to the Government unless and until both of the following conditions ((a) and (b)) are met&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Moderna gives written notice, required to be submitted to the Government &#91;***&#93;, of&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;any formal management decision to terminate manufacturing of this product vaccine prior to delivery of any doses to USG under this contract, including all exercised options, other than as a result of clinical failure, or serious technical or safety reasons or&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;any formal management decision to discontinue sale of this product vaccine to the Government prior to delivery of any doses to USG under this contract, including all exercised options, other than as a result of clinical failure, or serious technical or safety reasons&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_64"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 9 of 16</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;any filing that anticipates Federal bankruptcy protection&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Moderna has submitted an Emergency Use Authorization application under &#167;564 of the FD&#38;C Act or a biologics license application provisions of &#167;351(a) of the Public Health Service Act (PHSA).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If both conditions listed in section 1 occur, Moderna, upon the request of the Government, shall provide the following items necessary for the Government to pursue manufacturing of this product vaccine with a third party for exclusive sale to the U.S. Government&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;a writing evidencing a non-exclusive, nontransferable, irrevocable (except for cause), royalty-free paid-up license to practice or have practiced for or on behalf of the U.S. Government any Moderna Background Patent, Copyright, other Moderna Intellectual Property, Moderna Know-How, Moderna Technical Data rights necessary to manufacture doses of the mRNA-1273 vaccine&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;necessary FDA regulatory filings or authorizations owned or controlled by Moderna related to this product vaccine and any confirmatory instrument pertaining thereto&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;any outstanding Deliverables contemplated or materials purchased under this contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;This remedy will remain available until the end of the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.11&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.12&#160;&#160;&#160;&#160;Transportation to Final Destination</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">During the course of performance under this contract, the Government may require storage of the filled drug product (FDP) before delivery to the final government location. In these circumstances, the Government will accept FDP at the contractor facility (Origin). The contractor&#59; however, shall continue to be responsible for secure delivery of the vaccine to its final destination as identified on this contract. &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.13&#160;&#160;&#160;&#160;Validation of IP&#47;Data</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties acknowledge that background intellectual property and technical data assertions have been made and evaluated by the parties. The parties agree that, should additional information relevant to these assertions become available, the parties will reevaluate said assertions as necessary in the future.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.14&#160;&#160;&#160;&#160;Novation</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon Moderna, US, Inc.&#8217;s registration in the System for Award Management, the Government will, at the Contractor&#8217;s request, complete a novation of this Contract to recognize Moderna US, Inc. as a counterparty instead of Moderna TX, Inc. This novation will be completed through a modification executed by the Government that identifies Moderna US, Inc. as the contracting party for all purposes as if it had originally executed the Contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.15&#160;&#160;&#160;&#160;Base &#38; Option 1 Delivery Acceleration</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In an effort to accelerate production of the mRNA-1273 vaccine, &#91;***&#93; within the Option 1 period via a Modification to the contract. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_67"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 10 of 16</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If these manufacturing slots are successfully utilized, &#91;***&#93; above what was projected by Moderna and assumed within the price per dose for the doses of mRNA-1273 vaccine delivered in the Base Period and Option 1. However, because the Government is funding the additional slots within the Base and Option 1 periods in order to accelerate production, the Government is entitled to an adjustment under the conditions outlined. The Government and Moderna agree to the following&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;If the Government exercises Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Moderna will reduce the cost of Option 2 by $&#91;***&#93; for each successfully accelerated drug product fill under the Base Period (&#91;***&#93;) and $&#91;***&#93; for each successfully accelerated drug product fill under Option 1 (&#91;***&#93;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;If the Government does not exercise Option 2 (NLT 15 May)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;In the event Moderna timely cancels the manufacturing slots and&#47;or is able to otherwise fully utilize the slots originally reserved for production in the Option 2 period, Moderna agrees to credit the Government $&#91;***&#93; for &#91;***&#93; and $&#91;***&#93; for &#91;***&#93;. In no case shall the number of drug product manufacturing slots credited exceed the number of successfully accelerated drug product manufacturing fills under the Base Period and Option 1. It is understood that Moderna will make all good-faith efforts to fill reserved slots or cancel reservations in a timely manner (i.e. within the time period required by the subcontractor).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;In the event that Moderna is unable to fill those reserved slots (i.e. due to lack of demand) and cancels slots, Moderna shall be entitled to recoup those reservation cancellation costs from the USG. The process is outlined as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.) Moderna shall submit documentation to the USG of the following&#58;</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">i.) Cancellation notice to the subcontractor,</font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ii.) The basis of the cancellation, and</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iii.) Cancellation fees incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.) Moderna shall reduce credits to the USG under paragraph 2a) of this clause, IAW agreed cancellation costs incurred.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.) Bi-lateral agreement of the final credit shall be included in a modification to the contract. Net credit shall be deducted from final payments under the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.16&#160;&#160;&#160;&#160;Delivery Schedule, as revised 11Feb2021 via modification P00004</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_70"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 11 of 16</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.17&#160;&#160;&#160;&#160;Post-Termination Disposition of Undelivered Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the avoidance of doubt, if the USG elects to terminate the exercised CLINs prior to acceptance and delivery in full of the required quantities of mRNA-1273, Moderna will be free to direct any unaccepted&#47;undelivered supplies of mRNA-1273 to customers other than the USG, at its discretion, without further obligation of either party with regard to such unaccepted&#47;undelivered supplies of mRNA-1273. The contract will be bilaterally modified to decrease the quantities by the agreed upon volume.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.18&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In order to facilitate projections and invoicing, the Government shall provide or direct a third party (&#91;***&#93;) to provide to Moderna (1) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; (2) actual quantities of Moderna &#91;***&#93; with 8.0mL vials during the reporting period&#59; and (3) the number of &#91;***&#93; remaining in inventory and available for upcoming shipments. This information will be provided to Moderna at a frequency of at least twice monthly.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For each 8.0mL fill volume (1600mcg) vial of vaccine shipped with a &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Both parties acknowledge that the delivery schedule is based on an &#91;***&#93; 8.0mL fill volume (1600mcg) vial delivered. In accordance with the agreed approach for invoicing and counting doses toward Moderna&#8217;s delivery requirement, &#91;***&#93;. Specifically for purposes of adhering to the scheduled delivery dates set forth in this contract for the Base Period, Option 1 and Option 2, schedule shall be deemed to have been met once doses are released by Moderna and are available for order.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.19</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product &#91;***&#93; (as added via P00018)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specific to CLINs 3001 and 4001, Moderna will deliver to the Government &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adult Primary Series (mRNA&#8208;1273 or other, as determined by EUA&#47;BLA and any related supplement or amendment thereto accepted and authorized&#47;licensed by FDA and mutually agreed upon&#59; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For avoidance of doubt, all doses delivered to the Government must be suitable for use in the United States pursuant to an active EUA or approved BLA at the time of product delivery. &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If US regulatory authorities determine there is a need for an updated vaccine containing one or more variant mRNA sequences for any reason, including improved efficacy against new or emerging virus strains, the Parties agree to work together in good faith to discuss any such situation and any potential impact on this contract. &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Both parties acknowledge that the EUA for mRNA&#8208;1273 may be expanded such that doses procured under this contract may have utility beyond the currently authorized indications&#47;populations, and in the event of any such expansion, the Government will not be restricted hereunder from use of mRNA&#8208;1273 in accordance with the full scope of any FDA authorization and CDC recommendation to the extent consistent with the Government&#8217;s obligations under Section H.8 and the terms of Section H.20.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government and Moderna agree that the total monthly delivery quantities for CLIN 3001 and 4001 will follow the following Delivery Schedule&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government and Moderna agree as follows&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#91;***&#93;.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;padding-left:14.5pt">Sale of doses to the African Union. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Government is agreeing to defer delivery of 33,000,000 doses previously scheduled for delivery in December and February to facilitate Moderna&#8217;s supply of 50,000,000 doses of mRNA&#8208;1273 to the African Union (AU) at a not&#8208;for&#8208;profit price.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">&#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 12 of 16</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUA Wind Down. It is anticipated that all mRNA&#8208;1273 under this contract will be delivered in accordance with an active EUA. If a BLA is issued during the term of this Contract for the mRNA&#8208;1273 vaccine, the Government and Moderna shall discuss an appropriate transition of mRNA&#8208;1273 to BLA which will include that any doses subsequently provided to the Government under this Contract are appropriately labeled and are otherwise suitable for use in the United States under the terms of the EUA (before expiration) or the BLA.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_73"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 13 of 16</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.20&#160;&#160;&#160;&#160;Donation of Excess Product</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;If the Government determines that a quantity of doses of mRNA-1273 supplied to the Government under this contract is no longer needed by the Government, the Government may donate such doses to a foreign nation or nongovernmental organization (NGO) facilitating donation to a foreign nation, subject to the remainder of this Clause H.20. The Government shall notify Contractor in writing prior to any proposed donation to a foreign nation or NGO, which notice will include &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Contractor must verify in writing that all of the required conditions below are met before any such donation is made, &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Additionally, the Government may donate product for use in the clinical study to be conducted pursuant to the Clinical Trial Agreement (as amended on October 28, 2021) between The National Institute of Allergy and Infectious Disease (&#8220;NIAID&#8221;) and the South African Medical Research Counsel (&#8220;SAMRC&#8221;) under Protocol CoVPN 3008 (the &#8220;CoVPN 3008 Study&#8221;), subject to the Government&#8217;s having a binding written agreement(s) in place with the sponsor that satisfies the conditions set forth below in this clause (c)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_76"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 14 of 16</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#91;***&#93;,</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ix)&#160;&#160;&#160;&#160;&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(x)&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;The Government&#8217;s donations will be from supplies of vaccine delivered to and accepted by the Government. To the extent the Government commits to deliver doses that have not yet been physically delivered to the Government, such donation will not occur until such doses have been delivered to the Government. The Government will be responsible for delivery of the donated doses to, and coordination of delivery with, the receiving foreign nation, clinical study sponsor, or NGO, as applicable. The Government or the receiving foreign nation, clinical study sponsor, or NGO, as applicable, will (i) satisfy all customs shipping requirements for import and export of the product&#59; and (ii) as the exporter, file any required FDA export notifications. To the extent not already provided to the Government, the Contractor will provide all information necessary to complete any requirements identified in this paragraph in advance of shipment.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;When the conditions above are met for any donation, the Parties &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">f.&#160;&#160;&#160;&#160;&#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">g.&#160;&#160;&#160;&#160;Shipment of any donated doses under this Article does not constitute a violation of the Defense Production Act.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H.21&#160;&#160;&#160;&#160;CDC Healthcare Provider List</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To ensure timely communication is provided to health care providers, the USG has provided Moderna the mailing list for the Centers for Disease Control and Prevention (CDC) healthcare providers administering Moderna&#8217;s vaccine and boosters in order for Moderna to send information regarding boosters that were authorized by the FDA on October 20, 2021. Moderna agrees to the terms below of the handling of the CDC Healthcare Provider List.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Moderna shall use the CDC Healthcare Provider List only for the express purpose of the specific mailing regarding Moderna&#8217;s FDA-authorized booster product&#47;EUA expansion&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Moderna shall not share or provide this list to any outside parties other than those who are supporting this specific mailing&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Moderna shall delete (and require any other parties to delete) the list once they have completed the mailing.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been modified&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 15 of 16</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Document Type</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page #</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CDRLs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 February 2021</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exhibit B</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Donation of Excess Product</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 December 2021</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0001</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supply Chain Resiliency Plan for CDRL A010</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0002</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Security Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0003</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dose Tracking Template Draft Moderna</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Excel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0004</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Data Rights</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0005</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0006</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ModernaTx, Inc. Background Intellectual Property</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0007</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance Base Payment Milestone Schedule</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0008</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance Base Payment Milestone Billing Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 September 2021</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Attachment 0009</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HRPAS Moderna Letter</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 September 2020</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_79"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>P00020<br>Page 16 of 16</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(End of Summary of Changes)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_82"></div><hr style="page-break-after:always"><div style="min-height:48.24pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.015%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="15" rowspan="2" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AMENDMENT OF SOLICITATION&#47;MODIFICATION OF CONTRACT</font></td><td colspan="12" rowspan="2" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1. CONTRACT ID CODE</font></td><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PAGE OF PAGES</font></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2. AMENDMENT&#47;MODIFICATION NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">P00021</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3. EFFECTIVE DATE</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21-JAN-2022</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4. REQUISITION&#47;PURCHASE REQ. NO.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Schedule</font></div></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5. PROJECT NO.(If applicable)</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6. ISSUED BY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">W58P05</font></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7. ADMINISTERED BY (If other than item 6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE</font></div></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S2206A</font></td></tr><tr><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACC-APG - COVID RESPONSE - W58P05<br>6472 INTEGRITY COURT (BUILDING 4401)<br>ABERDEEN PROVING GROUND MD 21005-3013</font></td><td colspan="24" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DCMA BOSTON<br>495 SUMMER STREET<br>BOSTON MA 02210-2138</font></td></tr><tr style="height:12pt"><td colspan="18" rowspan="4" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code)</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MODERNA US, INC.<br>&#91;***&#93;<br>200 TECHNOLOGY SQ<br>CAMBRIDGE MA 02139-3578</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9A. AMENDMENT OF SOLICITATION NO.</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9B. DATED (SEE ITEM 11)</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10A. MOD. OF CONTRACT&#47;ORDER NO.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">W911QY20C0100</font></div></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="15" rowspan="2" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10B. DATED (SEE ITEM 13)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">09-Aug-2020</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODE  8PTM0</font></td><td colspan="12" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FACILITY CODE</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS</font></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offer  </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  is extended, </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  is not extended.</font></div><div style="padding-left:15.2pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Offer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods&#58;</font></div><div style="margin-bottom:6pt;padding-left:15.2pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a) By completing Items 8 and 15, and returning _______ copies of the amendment&#59; (b) By acknowledging receipt of this amendment on each copy of the offer submitted&#59; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12. ACCOUNTING AND APPROPRIATION DATA (If required)</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See Schedule</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS&#47;ORDERS.<br>IT MODIFIES THE CONTRACT&#47;ORDER NO. AS DESCRIBED IN ITEM 14.</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;THIS CHANGE ORDER IS ISSUED PURSUANT TO&#58; (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;THE ABOVE NUMBERED CONTRACT &#47;ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</font></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF&#58;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;OTHER (Specify type of modification and authority)</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">E. IMPORTANT&#58;  Contractor </font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> is not, </font><font style="font-family:'Wingdings 2',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> is required to sign this document and return __</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">___ copies to the issuing office.</font></div></td></tr><tr><td colspan="36" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:20.05pt;padding-right:2.75pt;text-indent:-17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14. DESCRIPTION OF AMENDMENT &#47;MODIFICATION (Organized by UCF section headings, including solicitation&#47;contract subject matter where feasible.)</font></div><div style="margin-bottom:48pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Modification Control Number&#58;  &#91;***&#93;<br>See Block 14 Continuation Page</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.</font></div></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15A. NAME AND TITLE OF SIGNER (Type or print)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shaun Ryan, SVP &#38; Deputy General Counsel</font></div></td><td colspan="27" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TEL&#58;  &#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EMAIL&#58;  &#91;***&#93;</font></div></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15B. CONTRACT OR&#47;OFFEROR</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Shaun Ryan</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Signature of person authorized to sign)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15C. DATE SIGNED</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#47;20&#47;2022</font></div></td><td colspan="21" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16B. UNITED STATES OF AMERICA</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BY  &#91;***&#93;<br>(Signature of Contracting Officer)</font></div></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16C. DATE SIGNED</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21-JAN-2022</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EXCEPTION TO SF 30<br>APPROVED BY OIRM 11-84</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30-105-04</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">STANDARD FORM 30 (Rev. 10-83)<br>Prescribed by GSA<br>FAR (48 CFR) 53.243</font></td></tr></table></div><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_85"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 2 of 13</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION SF 30 BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUMMARY OF CHANGES</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION SF 30 - BLOCK 14 CONTINUATION PAGE</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been added by full text&#58;<br></font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">P00021</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OBLIGATION AMOUNT&#58; $203,142.00</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;The purpose of this modification (P00021) is to&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Revise Statement of Work in sections C.3.4, C.3.5, and C.7 (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Extend and fund VMI Storage by six month from 1 January 2022 to 30 June 2022 on CLIN 0006 (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-&#160;&#160;&#160;&#160;Update Exhibit B as outlined in clause H.20 with donation information for multiple recipients (Authority FAR 43.103(a)(3), Mutual Agreement of the Parties)</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;This modification was requested by the program office to meet the Government&#8217;s mission requirements.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;The total funded amount and total contract value amount increase by $203,142.00 from $8,145,591,662.60 to $8,145,794,804.60.</font></div><div style="margin-bottom:24pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other terms and conditions remain unchanged.</font></div><div style="margin-bottom:24pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION A - SOLICITATION&#47;CONTRACT FORM</font></div><div style="margin-bottom:24pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The total cost of this contract was increased by $203,142.00 from $8,145,591,662.60 to $8,145,794,804.60.</font></div><div style="margin-bottom:24pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION B - SUPPLIES OR SERVICES AND PRICES</font></div><div style="margin-bottom:24pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CLIN 0006 is added as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_88"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 3 of 13</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:24pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ITEM NO</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SUPPLIES&#47;SERVICES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UNIT</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UNIT PRICE</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMOUNT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0006</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Months</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$33,857.00</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$203,142.00</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vendor Managed Inventory Extentions FFP</font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a. The contractor shall secure, manage and maintain storage for up to 100M doses of mRNA-1273 vaccine and deliver to the designated government facility in accordance with Section F.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FOB&#58; Destination<br>PURCHASE REQUEST NUMBER&#58; 0011737324<br>PSC CD&#58; 6505</font></div><div style="margin-bottom:12pt;padding-left:252pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET AMT&#160;&#160;&#160;&#160;$203,142.00</font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACRN AP&#160;&#160;&#160;&#160;$203,142.00</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIN&#58; GFEBS001173732400001</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION C - DESCRIPTIONS AND SPECIFICATIONS</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been modified&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STATEMENT OF WORK<br>LARGE SCALE PRODUCTION OF SARS-CoV-2 VACCINE</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.1&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SCOPE</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Department of Defense and Health and Human Services (HHS) require large scale manufacturing of vaccine doses in support of the national emergency response to the Coronavirus Disease 2019 (COVID-19) for the United States Government (USG) and the US population.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.1.1&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Background</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In December 2019, a novel coronavirus now known as SARS-CoV-2 was first detected in Wuhan, Hubei Province, People&#8217;s Republic of China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally. The Secretary of Health and Human Service declared a public health emergency on January 31, 2020, under section 319 of the Public Health Service Act (42 U.S.C. 247d), in response to COVID-19. On March 1, 2020, the President of the United States, pursuant to sections 01 and 301 of the National Emergencies Act (50 U.S.C. 1601 et seq.) and consistent with section 1135 of the Social Security Act (SSA), as amended (42 U.S.C. 1320b-5), proclaimed that the COVID-19 outbreak in the United States constitutes a national emergency.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.1.1.1&#160;&#160;&#160;&#160;Under Operation Warp Speed (OWS), the Department of Defense and HHS are leading a whole of nation effort to ensure development of promising vaccine, diagnostic and therapeutic candidates and ensure that these medical countermeasures are available in the quantities required to reduce SARS-CoV-2 transmission, identify prior and&#47;or current infection, and improve patient care, thereby mitigating the impact of COVID-19 on the nation and its people. The DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRD) is providing expertise and contracting support to HHS, in compliance with PL 115-92 Authorization Letter for DoD Medical Priorities, through an Interagency Agreement, signed April 23, 2020. As OWS products progress to clinical trials to evaluate the safety and efficacy of vaccines and therapeutics, it is critical that, in parallel, the USG supports large scale manufacturing so that vaccine doses or therapeutic treatment courses are immediately available for nationwide access as soon as a positive efficacy signal is obtained and the medical countermeasures are authorized for widespread use.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_91"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 4 of 13</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.1.2&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Objective</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58; The objective of this effort is to obtain the following&#58;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Base Period&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Option Period 1&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Option Period 2&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Option Period 3&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;Option Period 4&#58; Large scale manufacturing of 100 million vaccine doses</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Base Period is 9 months, with overlapping options for a total of 20 months if all options are exercised.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.1.3&#160;&#160;&#160;&#160;Consistent with the Updated EUA Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) dated 01 April 2021, up to 15 doses may be extracted from Moderna&#8217;s newly authorized multidose vials with 8.0mL fill volume (1600mcg). The Government and Moderna agree that 15 doses per vial are only attainable using premium low dead volume (LDV) syringes, which are in short supply globally. Utilizing initial ancillary equipment, vaccine administration personnel can reliably extract 13 doses from these vials&#59; however, the Government has identified needle&#47;syringe combinations that can be used to extract 14 doses.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.1.3.1&#160;&#160;&#160;&#160;Given the two parties&#8217; shared interest in reducing vaccine waste and accelerating the availability of Moderna&#8217;s SARS-CoV-2 vaccine doses, the Government and Moderna intend that the Moderna vaccines doses be administered with needles and syringes compatible with extraction of 14 doses when possible. Toward this end, the Government shall maintain a list of syringe and&#47;or needle combinations which will allow extraction of 14 doses per 8.0mL vial, which list shall be updated jointly by the Government and Moderna as any additional syringe and&#47;or needle combinations compatible with extraction of 14 doses&#47;vial are identified. Furthermore, the Government will, to the extent that appropriate needles and syringes are available, assemble and ship kits containing sufficient quantities of syringes and needles compatible with extraction of 14 doses per vial (Kit Moderna 140) with Moderna&#8217;s SARS-CoV-2 vaccine. The Government expects that these kits will be available beginning 01 May 2021 for a significant portion of Moderna&#8217;s remaining deliveries. If, however, appropriate syringes and needles are not available, the Government will revert to shipping the Kit Moderna 130 with Moderna&#8217;s SARS-CoV-2 vaccine.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.2&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPLICABLE DOCUMENTS</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.2.1&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Federal Documents</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.2.1.1&#160;&#160;&#160;&#160;Title 21 Code of Federal Regulations (CFR), Food and Drugs&#58; Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs&#59; General&#59; and, Part 211, Current Good Manufacturing Practice In Manufacturing, Processing, Packing, or Holding of Drugs&#59; General. (https&#58;&#47;&#47;www.ecfr.gov&#47;cgi-bin&#47;text-idx&#63;SID&#61;a95cab20f443897a400bb7e44a27cf4c&#38;mc&#61;true&#38;tpl&#61;&#47;ecfrbrowse&#47;Title21&#47;21cfrv4_02.tpl#0)</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REQUIREMENTS</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Independently, and not as an agent of the USG, in accordance with the Proposal submitted by Moderna US, Inc. in response to Solicitation Number W911QY20R0043, Titled, &#8220;Advanced Procurement of mRNA-1273 Vaccine for Prevention of SARS-CoV-2 Coronavirus (COVID-19)&#8221;), dated July 10, 2020 (and any subsequent USG-approved revisions thereto), the contractor shall provide all necessary services, qualified personnel, material, equipment and facilities (not otherwise provided by the USG under the terms of this contract) to perform the specific tasks set forth below.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Contract Line Item Number (CLIN) 0001 - Base Period&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.1&#160;&#160;&#160;&#160;The contractor shall complete all scope required for the production, release and delivery use of 100 million Final Drug Product (FDP) doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include, the following tasks and other activities reasonably contemplated by such task&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.1.1&#160;&#160;&#160;&#160;Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 5 of 13</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.1.2&#160;&#160;&#160;&#160;cGMP manufacturing of 100 million doses fully compliant with 21 CFR 210 and 211.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.1.3&#160;&#160;&#160;&#160;Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.1.4&#160;&#160;&#160;&#160;Coordinating with FDA to establish an approved commercial vial label, carton and packaging insert (printed or electronic).</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.1.5&#160;&#160;&#160;&#160;Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA, including &#8220;Exemption from Certain Product Tracing and Product Identification Requirements Under Section 582 of the FD&#38;C Act&#8221; (April 2020).</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.1.6&#160;&#160;&#160;&#160;In coordination with the USG, the contractor shall conduct a demonstration of the vaccine shipping process prior to the first delivery of FDP doses at a time mutually agreed to by the contractor and the USG. Moderna shall provide specifications and details associated with the shipping process and containers (IAW CDRL A005) to enable the USG to adequately plan and prepare for potential distribution of the vaccine.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.1.7&#160;&#160;&#160;&#160;Following release of product the contractor shall, promptly deliver product to the designated delivery site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. In the unforeseen event that a designated delivery site cannot receive product and the contractor provides storage beyond 20 days of product release, the contract will be subject to modification for acceptance purposes.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.2&#160;&#160;&#160;&#160;Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.2.1&#160;&#160;&#160;&#160;BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.2.2&#160;&#160;&#160;&#160;FDA Audits. The Contractor shall notify the Contracting Officer and Contracting Officer&#8217;s Representative (COR) within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A002. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.1.2.3&#160;&#160;&#160;&#160;FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.2&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CLIN 1001 - Option Period 1&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_94"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 6 of 13</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.2.1&#160;&#160;&#160;&#160;The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.2.1.1&#160;&#160;&#160;&#160;Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.2.1.2&#160;&#160;&#160;&#160;cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.2.1.3&#160;&#160;&#160;&#160;Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.2.1.4&#160;&#160;&#160;&#160;Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.2.1.5&#160;&#160;&#160;&#160;Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.2.2&#160;&#160;&#160;&#160;Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.2.2.1&#160;&#160;&#160;&#160;BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.2.2.2&#160;&#160;&#160;&#160;FDA Audits. The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.2.2.3&#160;&#160;&#160;&#160;FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.3&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CLIN 2001 - Option Period 2&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.3.1&#160;&#160;&#160;&#160;The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.3.1.1  Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract for a period of 12 months. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf-life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 7 of 13</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.3.1.2  cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.3.1.3  Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated as appropriate.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.3.1.4  Ensuring that the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581- 585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.3.1.5  Following release the contractor shall deliver product to the nearest designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.3.2&#160;&#160;&#160;&#160;Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.3.2.1  BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.3.2.2  FDA Audits. The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A002. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.3.2.3  FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.4&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CLIN 3001 - Option Period 3&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.4.1&#160;&#160;&#160;&#160;The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.4.1.1  Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract per C.7. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf- life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_97"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 8 of 13</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.4.1.2&#160;&#160;&#160;&#160;cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.4.1.3&#160;&#160;&#160;&#160;Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.4.1.4&#160;&#160;&#160;&#160;Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.4.1.5&#160;&#160;&#160;&#160;Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.4.2&#160;&#160;&#160;&#160;Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.4.2.1&#160;&#160;&#160;&#160;BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.4.2.2&#160;&#160;&#160;&#160;FDA Audits. The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.4.2.3&#160;&#160;&#160;&#160;FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding mRNA-1273 for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.5&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CLIN 4001 - Option Period 4&#58; Large Scale Manufacturing of 100 Million Vaccine Doses</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.5.1&#160;&#160;&#160;&#160;The contractor shall complete all scope required for the production, release and delivery use of 100 million FDP doses of a SARS-CoV-2 mRNA-1273 vaccine. This shall include the following tasks and other activities reasonably contemplated by such tasks&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.5.1.1&#160;&#160;&#160;&#160;Storage of FDP doses prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations. Storage and maintenance of the vaccine prior to delivery shall be under conditions and at temperatures necessary to retain stability for use as prescribed in this contract per C.7. (Based on FDP stability data that supports a 12-month shelf-life, subject to FDA confirmation of the assigned shelf- life.) Ensure requirements of 21CFR207, Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution are met prior to distribution to the CDC. Documents shall be provided under CDRL A002, FDA Interactions and Inspections Documentation.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.5.1.2&#160;&#160;&#160;&#160;cGMP manufacturing of 100 million doses, subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.5.1.3&#160;&#160;&#160;&#160;Ensuring that vial labeling and packaging is consistent with FDA guidance for use in target populations and that labeling is updated.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.5.1.4&#160;&#160;&#160;&#160;Ensuring the product complies with the Drug Supply Chain Security Act (DSCSA), Sections 581-585 of PL 113-54 (Nov. 27, 2013), including product verification, serialization, traceability and detection and response requirements subject to any exceptions established by or the enforcement discretion of the FDA.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 9 of 13</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.5.1.5&#160;&#160;&#160;&#160;Following release of the product the contractor shall deliver the product to the designated distribution site via a qualified distribution vendor in accordance with Section F and paragraph C.7 below. To the extent a natural disaster or other emergency affecting a designated delivery site restricts such site&#8217;s ability to receive product, the Contractor and the USG will promptly agree on an alternate USG delivery location, or storage as Vendor Managed Inventory (VMI) at the contractor site.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.5.2&#160;&#160;&#160;&#160;Site Visits and Audits. The contractor shall accommodate periodic or ad hoc site visits by BARDA and FDA representatives for required site visits and audits at facilities used to support this contract throughout the period of performance of the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.5.2.1&#160;&#160;&#160;&#160;BARDA Audits. If issues are identified during an audit, the contractor shall submit a report detailing the finding and corrective action(s) in accordance with CDRL A001.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.5.2.2&#160;&#160;&#160;&#160;FDA Audits. The Contractor shall notify the Contracting Officer and COR within &#91;***&#93; of a scheduled FDA audit or within &#91;***&#93; of an ad hoc site visit or audit if the FDA does not provide advance notice. The contractor shall provide copies of any FDA Audit Report received from subcontractors that occur as a result of this contract or for this product within &#91;***&#93; of receiving correspondence from the FDA or third party in accordance with CDRL A015. The Contractor shall provide the Contracting Officer with a plan for addressing areas of nonconformance, if any are identified, within &#91;***&#93; of submittal of the audit report in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.3.5.2.3&#160;&#160;&#160;&#160;FDA Interactions. The contractor shall provide copies of the plan and processes that will ensure the USG has visibility and input on all FDA communications regarding the drugs and biologics for the following, but not limited to&#58; FDA interactions, FDA meetings, communications, submissions, inspections, and enforcement documentation in accordance with CDRL A002.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CLIN 0002&#58; Data Deliverables</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The contractor shall provide the following in accordance with the Contract Data Requirements List (CDRL), DD Forms 1423, provided at Appendix A.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.1&#160;&#160;&#160;&#160;Monthly Inventory Report (CDRL A003), detailing at a minimum, raw materials, formulated LNPs, and the fill, finish, and released product.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.2&#160;&#160;&#160;&#160;Quality Management Plan. The contractor shall provide a Quality Management Plan, in accordance with CDRL A004, describing the quality policy and objectives, management review, competencies and training, process document control, feedback, evaluation, corrective action and preventive action, process improvement, measurement, and data analysis processes. The framework is normally divided into infrastructure, senior management responsibility, resource management, lifecycle management, and quality management system evaluation.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.3&#160;&#160;&#160;&#160;Shipping Documentation (CDRL A005) for all Finished Drug Product (FDP) transferring from the contractor&#8217;s fill&#47;finish facility to a USG facility. The contractor shall obtain concurrence on planned shipment protocols prior to transport.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.4&#160;&#160;&#160;&#160;Expiring Items Report (CDRL A006) for all FDP in the USG&#8217;s possession.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.5&#160;&#160;&#160;&#160;Key Personnel Listing (CDRL A007).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_100"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 10 of 13</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.6&#160;&#160;&#160;&#160;Monthly Technical Progress Report (CDRL A008), to include an Integrated Master Schedule, identifying key activities and contract status.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.7&#160;&#160;&#160;&#160;Final Technical Report (CDRL A009), documenting the work performed and results obtained for the entire contract period of performance.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.8&#160;&#160;&#160;&#160;Supply Chain Resiliency Plan (SCRP). The contractor shall provide, in accordance with CDRL A010 and CDRL Attachment 0001, a comprehensive SCRP that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods, and key equipment suppliers and their locations, including addresses, points of contact, and work performed per location, to include subcontractors.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.9&#160;&#160;&#160;&#160;Risk Management Plan (RMP). The Contractor shall provide an RMP in accordance with CDRL A011 that outlines the impacts of each risk in relation to the cost, schedule, and performance objectives. The plan shall include risk mitigation strategies. Each risk mitigation strategy shall capture how the corrective action will reduce impacts on cost, schedule and performance. The following RMP information shall be included in the Monthly Technical Progress Report (CDRL A008).</font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Register content&#58;</font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Manuf&#47;FF -risks or possible delays. If none N&#47;A</font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Supply chain &#8211; same as above</font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Distribution challenges &#8211; same as above</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;Regulatory &#8211; same as above</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.10&#160;&#160;&#160;&#160;Manufacturing Reports and Dose Tracking. The Contractor shall provide, in accordance with CDRL A013, manufacturing reports and manufacturing dose tracking projections and actuals utilizing the USG-provided &#8220;COVID-19 Dose Tracking Template&#8221; (CDRL Attachment 0003).</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.11&#160;&#160;&#160;&#160;Product Acceptance Report (for each lot of Drug Product). The contractor shall provide, in accordance with CDRL A014, pictures of the drug product with lot number, drug product lot tree, list of associated deviations (from drug substance and product), and a Certificate of Analysis.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.12&#160;&#160;&#160;&#160;Incident Report. The contractor shall communicate to BARDA and document all critical programmatic concerns, issues, or probable risks that have or are likely to significantly impact project schedule and&#47;or cost and&#47;or performance in accordance with CDRL A016. &#8220;Significant&#8221; is frequently defined as a 10% or greater cost or schedule variance within a control account, but should be confirmed in consultation with the COR. Incidents that present liability to the project even without cost&#47;schedule impact, such as breach of GCP during a clinical study, shall also be reported.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.13&#160;&#160;&#160;&#160;FDA Correspondence. The contractor shall provide any correspondence between Contractor and FDA relevant to the scope of this contract and submit in accordance with CDRL A017.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.14&#160;&#160;&#160;&#160;Press Releases. The contractor shall accurately and factually represent the work conducted under this contract in all press releases. The contractor shall provide an advance copy of any press release in accordance with CDRL A018.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.4.15&#160;&#160;&#160;&#160;Manufacturing Development Plan. The contractor shall provide a Manufacturing Development Plan, in accordance with CDRL A025, describing the manufacturing process for the drug&#47;biologic product to ensure conformity with &#167;501(a)(2)(B) of the Food, Drug, and Cosmetics Act (FD&#38;C Act, Title 21 United States Code (USC) &#167;351 (a)(2)(B)), regarding good manufacturing practices (GMP).</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.5&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Administration</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.5.1&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Post Award Teleconference</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The contractor shall host a Post Award Teleconference within 15 calendar days after contract award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_103"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 11 of 13</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.5.1.1&#160;&#160;&#160;&#160;The contractor shall provide an Agenda, IAW CDRL A020, detailing the planned activities for the subsequent 30 calendar days and shall discuss agenda items for the Post Award Kickoff Meeting.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.5.1.2&#160;&#160;&#160;&#160;The contractor shall provide Meeting Minutes IAW CDRL A021.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.5.2&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Post Award Kickoff Meeting</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The contracting officer may request the contractor host a contract Kick-Off Meeting within 30 calendar days after contract award via teleconference. The contracting officer shall establish the date and time of the conference and prepare the agenda to include discussion on contract activities and schedule.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.5.3&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Bi-Weekly Teleconference</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The contractor shall participate in bi-weekly teleconferences (or more frequent meetings required by the USG if warranted based on contract activities) to discuss performance on the contract.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.5.4&#160;&#160;&#160;&#160;The contractor shall provide an Agenda, IAW CDRL A020&#59; Meeting Minutes in accordance with CDRL A021&#59; and, Presentation Material in accordance with CDRL A022 for each of the aforementioned teleconferences or meetings throughout the contract period of performance.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.5.5&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Daily &#8220;Check-In&#8221;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The contractor shall participate in a daily &#8220;check-in&#8221; (via teleconference or email) to address key cost, schedule and technical updates. Daily updates may be shared with senior USG leaders during the COVID- 19 response and should be provided on a non-confidential basis, unless the update includes confidential information in which case, the contractor shall provide the update in both confidential and non-confidential formats. Daily check-ins may occur on weekdays, excluding federal holidays. Upon request of the USG, check-ins may also occur on weekends and on federal holidays, provided at least 24 hours&#8217; notice.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.6&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Security</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.6.1&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Access and General Protection&#47;Security Policy and Procedures</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The contractor shall provide all information required for background checks necessary to access critical information related to OWS, and to meet USG installation access requirements to be accomplished by the installation Director of Emergency Services or Security Office. The contractor employees shall comply with all personnel identity verification requirements as directed by the USG and&#47;or local policy. In addition to the changes otherwise authorized by the changes clause of this contract, should the security status of OWS change the USG may require changes in the contractor&#8217;s security matters or processes. In addition to the industry standards for employment background checks, the contractor shall be willing to have key individuals, in exceptionally sensitive positions, identified for additional vetting by the United States USG.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.6.2&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Security Program and Plan</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The contractor shall implement a comprehensive security program that provides overall protection of personnel, information, data, and facilities associated with fulfilling the USG&#8217;s requirement. The contractor&#8217;s security practices and procedures shall be detailed in a Security Plan, in accordance with CDRL A019, and shall demonstrate how the contractor shall meet and adhere to the security requirements outlined in CDRL Attachment 0002. This plan shall be delivered to the USG within 45 days of award, and the USG will review in detail and submit comments within ten (10) business days to the Contracting Officer (CO) to be forwarded to the Contractor. The Contractor shall review the Security Plan comments, and, submit a final Security Plan to the U.S. USG within thirty (30) calendar days after receipt of the comments. The Security Plan shall include a timeline for compliance of all the required security measures outlined in CDRL Attachment 0002.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.6.3&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Operational Security (OPSEC)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The contractor shall develop and submit an OPSEC Standard Operating Procedure (SOP)&#47;Plan IAW CDRL A024. The contractor shall identify in the SOP&#47;Plan critical information related to this contract, why it needs to be protected, where it is located, who is responsible for it, and how to protect it.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.7&#160;&#160;&#160;&#160;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Vendor Managed Inventory (VMI)</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The Contractor shall provide the capability to store up to 100M doses of mRNA-1273 vaccine until 30 June 2022, in support of the extension of the delivery schedule for option 3 and 4. The contractor shall, in accordance with paragraph C.3.1.1.6, ensure the product storage of FDP doses for up to 12 months, in accordance with product labeling, and prior to delivery consistent with all FDA requirements to ensure that the product remains available for use in target populations.  &#91;***&#93;.  The contractor shall store the product to insure product quality with audible alarms and contacting. The contractor shall notify the USG within &#91;***&#93; of detection of an incident with the potential to impact product quality, and implement corrective actions to mitigate the incident. BARDA&#47;JPEO-CBRND personnel may conduct Quality Audits of the storage facility, when deemed necessary. The contractor shall notify the USG of Corrective&#47;Preventive actions within &#91;***&#93; of detection of an incident with potential to impacts product quality.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 12 of 13</font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.7.1&#160;&#160;&#160;&#160;The USG will provide the contractor advance notice of the required delivery locations for the vaccine. The contractor shall ship mRNA-1273 vaccines to designated locations &#91;***&#93; in the United States. The contractor shall be responsible for shipment of all vaccine product whether acceptance is conducted at origin or destination. &#91;***&#93;.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.7.2&#160;&#160;&#160;&#160;The vaccine product shall be shipped and tracked by the distribution vendor&#8217;s shipping tracking number, to the USG-designated sites within the continental United States.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C.7.3&#160;&#160;&#160;&#160;&#91;***&#93;. Implementation of a Vendor Managed Inventory Plan&#47;SOP (CDRL A012) shall be provided to the USG. &#91;***&#93;. Notwithstanding either of the foregoing sentences, the contractor shall not be liable for loss of or damage to supplies caused by the negligence of officers, agents, or employees of the USG acting within the scope of their employment.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION E - INSPECTION AND ACCEPTANCE</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following Acceptance&#47;Inspection Schedule was added for CLIN 0006&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INSPECT AT</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INSPECT BY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACCEPT AT</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACCEPT BY</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Destination</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Destination</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION F - DELIVERIES OR PERFORMANCE</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following Delivery Schedule for CLIN 0006 has been added&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DELIVERY DATE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUANTITY</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SHIP TO ADDRESS</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DODAAC &#47; CAGE</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30-JUN-2022</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A<br>FOB&#58; Destination</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION G - CONTRACT ADMINISTRATION DATA</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting and Appropriation</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summary for the Payment Office</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As a result of this modification, the total funded amount for this document was increased by $203,142.00 from $8,145,591,662.60 to $8,145,794,804.60.</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CLIN 0006&#58;<br>Funding on CLIN 0006 is initiated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACRN&#58; AP</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CIN&#58; GFEBS001173732400001</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acctng Data&#58; 0212021202220400000665654260&#160;&#160;&#160;&#160;S.0074658.5.44&#160;&#160;&#160;&#160;6100.0152021001</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase&#58; $203,142.00</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic5f2b492f7e14a06a131d8226b925ac8_106"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">W911QY20C0100<br>(dsotowaw2239)<br>Page 13 of 13</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total&#58; $203,142.00</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Code&#58; A5XAH</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS</font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following have been modified&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Document Type</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page #</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit A</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDRLs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 February 2021</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit B</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Donation of Excess Product</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 January 2022</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attachment 0001</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supply Chain Resiliency Plan for CDRL A010</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attachment 0002</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Security Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attachment 0003</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dose Tracking Template Draft Moderna</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 July 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attachment 0004</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Data Rights</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attachment 0005</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attachment 0006</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ModernaTx, Inc. Background Intellectual Property</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 August 2020</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attachment 0007</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Base Payment Milestone Schedule</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 June 2021</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attachment 0008</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance Base Payment Milestone Billing Plan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 September 2021</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attachment 0009</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HRPAS Moderna Letter</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 September 2020</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(End of Summary of Changes)</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>13
<FILENAME>exhibit211subsidiaries.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6fe09f6212904b3180313dccd6fe70fc_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;21.1</font></div><div><font><br></font></div></div><div style="margin-top:24pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SUBSIDIARIES</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.856%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Subsidiary</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction&#160;of&#160;Incorporation</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brizo Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Australia Pty Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Austria GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biopharma Canada Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biotech Ireland Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biotech Securities, Inc. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biotech Spain, S.L.U.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Biotech UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Charitable Foundation, Inc. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna France</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Germany GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Italy S.r.l.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Japan Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Korea Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Netherlands B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Poland sp. z o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Services, Inc. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Sweden AB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna Switzerland GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ModernaTX, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moderna US, Inc. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>14
<FILENAME>exhibit23112312021.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1acbb9600c264d78b3afca93bca3a95c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Exhibit 23.1</font></div><div style="margin-bottom:10pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-228718) pertaining to the Moderna Therapeutics, Inc. 2016 Stock Option and Grant Plan and the Moderna, Inc. 2018 Employee Stock Purchase Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-230245) pertaining to the Moderna, Inc. 2018 Stock Option and Incentive Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-3 No. 333-236348) of Moderna, Inc., </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-236713) pertaining to the Moderna, Inc. 2018 Stock Option and Incentive Plan and the Moderna, Inc. 2018 Employee Stock Purchase Plan, and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:6.34pt">Registration Statement (Form S-3 No. 333-238467) of Moderna, Inc.&#59;</font></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">of our reports dated February&#160;25, 2022, with respect to the consolidated financial statements of Moderna, Inc. and the effectiveness of internal control over financial reporting of Moderna, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2021.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#47;s&#47; Ernst&#160;&#38; Young LLP</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Boston, Massachusetts</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">February&#160;25, 2022 </font></div><div style="margin-bottom:10pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>15
<FILENAME>exhibit31112312021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if04d5ca35fbe4b46a52c77dd4cc90383_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EX-31.1 Section 302 Certification of CEO</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a)&#160;UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, St&#233;phane Bancel, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form&#160;10-K of Moderna,&#160;Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:31.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February&#160;25, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>16
<FILENAME>exhibit31212312021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id5b432e4f5ab43c3891a8bbe61314682_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EX-31.2 Section 302 Certification of CFO</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a)&#160;AND 15d-14(a)&#160;UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David W. Meline, certify that&#58;</font></div><div style="margin-bottom:9pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form&#160;10-K of Moderna,&#160;Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s)&#160;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#47;s&#47; David W. Meline</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David W. Meline</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>17
<FILENAME>exhibit32112312021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ied0c3e24c2ea4a37a82c6f787525ec23_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, St&#233;phane Bancel, Chief Executive Officer of Moderna,&#160;Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:0.1%"></td><td style="width:1.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Annual Report on Form&#160;10-K of the Company for the year ended&#160;December 31, 2021&#160;(Annual Report) fully complies with the requirements of Section&#160;13(a)&#160;or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:0.1%"></td><td style="width:1.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.279%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; St&#233;phane Bancel</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">St&#233;phane Bancel</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>18
<FILENAME>exhibit32212312021.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iccbfb5b4a17948898abf04a66dce5be2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="margin-bottom:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David W. Meline, Chief Financial Officer of Moderna,&#160;Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.573%"><tr><td style="width:0.1%"></td><td style="width:1.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Annual Report on Form&#160;10-K of the Company for the year ended&#160;December 31, 2021&#160;(Annual Report) fully complies with the requirements of Section&#160;13(a)&#160;or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.596%"><tr><td style="width:0.1%"></td><td style="width:1.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.592%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; David W. Meline</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David W. Meline</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>mrna-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:61dc7ba0-21f1-4a58-a37b-1270ec5a6c14,g:27805b16-b8d5-4e89-9c63-161f1adf5057-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrna="http://www.modernatx.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.modernatx.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.modernatx.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.modernatx.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParentheticals" roleURI="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals">
        <link:definition>1402401 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.modernatx.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies - Accounting Policies Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2406403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails">
        <link:definition>2407404 - Disclosure - Summary of Significant Accounting Policies - Significant Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails">
        <link:definition>2408405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2409406 - Disclosure - Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSales" roleURI="http://www.modernatx.com/role/ProductSales">
        <link:definition>2110103 - Disclosure - Product Sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesTables" roleURI="http://www.modernatx.com/role/ProductSalesTables">
        <link:definition>2311302 - Disclosure - Product Sales (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductSalesDetails" roleURI="http://www.modernatx.com/role/ProductSalesDetails">
        <link:definition>2412407 - Disclosure - Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantRevenue" roleURI="http://www.modernatx.com/role/GrantRevenue">
        <link:definition>2113104 - Disclosure - Grant Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantRevenueTables" roleURI="http://www.modernatx.com/role/GrantRevenueTables">
        <link:definition>2314303 - Disclosure - Grant Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantRevenueDetails" roleURI="http://www.modernatx.com/role/GrantRevenueDetails">
        <link:definition>2415408 - Disclosure - Grant Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.modernatx.com/role/CollaborationAgreements">
        <link:definition>2116105 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.modernatx.com/role/CollaborationAgreementsTables">
        <link:definition>2317304 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails">
        <link:definition>2418409 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails">
        <link:definition>2419410 - Disclosure - Collaboration Agreements - Merck &#8211; Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails">
        <link:definition>2420411 - Disclosure - Collaboration Agreements - Vertex &#8211; 2020 Strategic Alliance in Cystic Fibrosis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails">
        <link:definition>2421412 - Disclosure - Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails" roleURI="http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails">
        <link:definition>2422413 - Disclosure - Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurements" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements">
        <link:definition>2123106 - Disclosure - Financial Instruments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsTables" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables">
        <link:definition>2324305 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails">
        <link:definition>2425414 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails">
        <link:definition>2426415 - Disclosure - Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails">
        <link:definition>2427416 - Disclosure - Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails">
        <link:definition>2428417 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails">
        <link:definition>2429418 - Disclosure - Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.modernatx.com/role/DerivativeFinancialInstruments">
        <link:definition>2130107 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>2331306 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsCashflowHedgesDetails" roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashflowHedgesDetails">
        <link:definition>2432419 - Disclosure - Derivative Financial Instruments - Cash flow Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails">
        <link:definition>2433420 - Disclosure - Derivative Financial Instruments - Balance Sheet Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.modernatx.com/role/Inventory">
        <link:definition>2134108 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.modernatx.com/role/InventoryTables">
        <link:definition>2335307 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.modernatx.com/role/InventoryDetails">
        <link:definition>2436421 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.modernatx.com/role/PropertyandEquipment">
        <link:definition>2137109 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.modernatx.com/role/PropertyandEquipmentTables">
        <link:definition>2338308 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.modernatx.com/role/PropertyandEquipmentDetails">
        <link:definition>2439422 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponents" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponents">
        <link:definition>2140110 - Disclosure - Other Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsTables" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables">
        <link:definition>2341309 - Disclosure - Other Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2442423 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails">
        <link:definition>2443424 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails">
        <link:definition>2444425 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetComponentsDeferredRevenueDetails" roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails">
        <link:definition>2445426 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.modernatx.com/role/Leases">
        <link:definition>2146111 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.modernatx.com/role/LeasesTables">
        <link:definition>2347310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails">
        <link:definition>2448427 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetInformationDetails" roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails">
        <link:definition>2449428 - Disclosure - Leases - Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostsDetails" roleURI="http://www.modernatx.com/role/LeasesLeaseCostsDetails">
        <link:definition>2450429 - Disclosure - Leases - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumLeasePaymentsDetails" roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails">
        <link:definition>2451430 - Disclosure - Leases - Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMinimumLeasePaymentsDetails_1" roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1">
        <link:definition>2451430 - Disclosure - Leases - Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.modernatx.com/role/CommitmentsandContingencies">
        <link:definition>2152112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesIndemnificationObligationsDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails">
        <link:definition>2453431 - Disclosure - Commitments and Contingencies - Indemnification Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails">
        <link:definition>2454432 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails">
        <link:definition>2455433 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesModernaScienceCenterDetails" roleURI="http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails">
        <link:definition>2456434 - Disclosure - Commitment and Contingencies- Moderna Science Center (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.modernatx.com/role/StockholdersEquity">
        <link:definition>2157113 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.modernatx.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2458435 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.modernatx.com/role/StockBasedCompensation">
        <link:definition>2159114 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.modernatx.com/role/StockBasedCompensationTables">
        <link:definition>2360311 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2461436 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionsActivityDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails">
        <link:definition>2462437 - Disclosure - Stock-Based Compensation - Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails">
        <link:definition>2463438 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails">
        <link:definition>2464439 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2465440 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.modernatx.com/role/EmployeeBenefitPlan">
        <link:definition>2166115 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://www.modernatx.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2467441 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.modernatx.com/role/IncomeTaxes">
        <link:definition>2168116 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.modernatx.com/role/IncomeTaxesTables">
        <link:definition>2369312 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>2470442 - Disclosure - Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>2471443 - Disclosure - Income Taxes - Provision For (Benefit From) Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails">
        <link:definition>2472444 - Disclosure - Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails">
        <link:definition>2473445 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2474446 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesValuationAllowanceDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails">
        <link:definition>2475447 - Disclosure - Income Taxes- Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" roleURI="http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>2476448 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossperShare" roleURI="http://www.modernatx.com/role/EarningsLossperShare">
        <link:definition>2177117 - Disclosure - Earnings (Loss) per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossperShareTables" roleURI="http://www.modernatx.com/role/EarningsLossperShareTables">
        <link:definition>2378313 - Disclosure - Earnings (Loss) per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" roleURI="http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails">
        <link:definition>2479449 - Disclosure - Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" roleURI="http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails">
        <link:definition>2480450 - Disclosure - Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformation" roleURI="http://www.modernatx.com/role/GeographicInformation">
        <link:definition>2181118 - Disclosure - Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationTables" roleURI="http://www.modernatx.com/role/GeographicInformationTables">
        <link:definition>2382314 - Disclosure - Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationDetails" roleURI="http://www.modernatx.com/role/GeographicInformationDetails">
        <link:definition>2483451 - Disclosure - Geographic Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.modernatx.com/role/SubsequentEvents">
        <link:definition>2184119 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.modernatx.com/role/SubsequentEventsDetails">
        <link:definition>2485452 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DeferredTaxAssetsFinancingLeaseLiability" abstract="false" name="DeferredTaxAssetsFinancingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_A2022RepurchaseProgramPlanMember" abstract="true" name="A2022RepurchaseProgramPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_AccruedOtherExternalGoodsAndServicesCurrent" abstract="false" name="AccruedOtherExternalGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_DeferredTaxValuationAllowanceRollForward" abstract="true" name="DeferredTaxValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_NumberOfDosesOfVaccineCandidate" abstract="false" name="NumberOfDosesOfVaccineCandidate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_DefenseAdvancedResearchProjectsAgencyMember" abstract="true" name="DefenseAdvancedResearchProjectsAgencyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ChangeInContractwithCustomerAssetRollForward" abstract="true" name="ChangeInContractwithCustomerAssetRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeasesRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" abstract="false" name="ContractWithCustomerLiabilityDeductionsDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" abstract="false" name="RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_USGovermentMember" abstract="true" name="USGovermentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_RevenueFromGrantsMaximumAward" abstract="false" name="RevenueFromGrantsMaximumAward" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_UnrecognizedTaxBenefitsNet" abstract="false" name="UnrecognizedTaxBenefitsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" abstract="true" name="A2013OptionAgreementAndServicesAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RawMaterialsAccountsPayable" abstract="false" name="RawMaterialsAccountsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" abstract="true" name="RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_LesseeOperatingLeaseNumberOfExtension" abstract="false" name="LesseeOperatingLeaseNumberOfExtension" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_RevenueFromGrantsNumberOfContractOptionsExercised" abstract="false" name="RevenueFromGrantsNumberOfContractOptionsExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChargesToFinancingLeaseLiabilities" abstract="false" name="ChargesToFinancingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_TheBillAndMelindaGatesFoundationMember" abstract="true" name="TheBillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_FiveHundredTechnologySquareMember" abstract="true" name="FiveHundredTechnologySquareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_OperatingLeaseNumberOfProperties" abstract="false" name="OperatingLeaseNumberOfProperties" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_MTCEastMember" abstract="true" name="MTCEastMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ProductSalesMember" abstract="true" name="ProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" abstract="true" name="PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_UnitedKingdomGovernmentMember" abstract="true" name="UnitedKingdomGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount" abstract="false" name="ValuationAllowanceDeferredTaxAssetDecreaseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityLineItems" abstract="true" name="ChangeInContractWithCustomerLiabilityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_DeferredIncomeTaxExpenseBenefitNet" abstract="false" name="DeferredIncomeTaxExpenseBenefitNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" abstract="true" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CambridgeMassachusettsMember" abstract="true" name="CambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RevenueFromGrantsCurrentFundingCapacity" abstract="false" name="RevenueFromGrantsCurrentFundingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_EmployeeStockPurchasePlan2018Member" abstract="true" name="EmployeeStockPurchasePlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_AccruedManufacturing" abstract="false" name="AccruedManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OtherPrepaidExpenseManufacturing" abstract="false" name="OtherPrepaidExpenseManufacturing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_RevenueFromGrantsPotentialReimbursement" abstract="false" name="RevenueFromGrantsPotentialReimbursement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ClinicalOperationsAndSupportCommitmentMember" abstract="true" name="ClinicalOperationsAndSupportCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" abstract="false" name="DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_EmbeddedLeasesMember" abstract="true" name="EmbeddedLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_InitialProjectMember" abstract="true" name="InitialProjectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ContractWithCustomerAssetDeductionsDuringPeriod" abstract="false" name="ContractWithCustomerAssetDeductionsDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_VertexMember" abstract="true" name="VertexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_MTCNorthMember" abstract="true" name="MTCNorthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrna_ModernaScienceCentreMember" abstract="true" name="ModernaScienceCentreMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_CurrentMarketableSecuritiesMember" abstract="true" name="CurrentMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_StockOptionAndGrantPlan2016Member" abstract="true" name="StockOptionAndGrantPlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember" abstract="true" name="RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" abstract="false" name="RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AccruedClinicalTrials" abstract="false" name="AccruedClinicalTrials" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_A2021RepurchaseProgramMember" abstract="true" name="A2021RepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_FinancingRightOfUseAssetMember" abstract="true" name="FinancingRightOfUseAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityTable" abstract="true" name="ChangeInContractWithCustomerLiabilityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrna_RevenueFromGrantsNumberOfContractOptions" abstract="false" name="RevenueFromGrantsNumberOfContractOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" abstract="false" name="LesseeOperatingLeaseNumberOfExtensionPeriods" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_AccruedDevelopmentOperation" abstract="false" name="AccruedDevelopmentOperation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiability" abstract="false" name="OperatingAndFinanceLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrna_PersonalizedMRNACancerVaccinesProductsMember" abstract="true" name="PersonalizedMRNACancerVaccinesProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_SouthKoreaGovernmentMember" abstract="true" name="SouthKoreaGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrna_PublicEquityOfferingMember" abstract="true" name="PublicEquityOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_StockOptionAndIncentivePlan2018Member" abstract="true" name="StockOptionAndIncentivePlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_EuropeanCommissionMember" abstract="true" name="EuropeanCommissionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_NumberOfParticipants" abstract="false" name="NumberOfParticipants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseRightOfUseAsset" abstract="false" name="OperatingAndFinanceLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_AllowanceForTenantImprovements" abstract="false" name="AllowanceForTenantImprovements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="CurrentAssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm" abstract="false" name="LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrna_LesseeFinanceLeaseExpense" abstract="false" name="LesseeFinanceLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityCurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_ContractOptionsMember" abstract="true" name="ContractOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" abstract="true" name="CollaborationArrangementIncludingArrangementsWithAffiliateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ClinicalServicesMember" abstract="true" name="ClinicalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_MRNAVertex2020AgreementMemberMember" abstract="true" name="MRNAVertex2020AgreementMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_TenantImprovementAllowanceReceivableCurrent" abstract="false" name="TenantImprovementAllowanceReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityNonCurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrna_NoncurrentMarketableSecuritiesMember" abstract="true" name="NoncurrentMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrna_NorwoodMassachusettsMember" abstract="true" name="NorwoodMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RestOfWorldMember" abstract="true" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_CollaborationArrangementMember" abstract="true" name="CollaborationArrangementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_TwoHundredTechnologySquareMember" abstract="true" name="TwoHundredTechnologySquareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_RevenueFromGrantsRemainingFundingCapacity" abstract="false" name="RevenueFromGrantsRemainingFundingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrna_OtherGrantRevenueMember" abstract="true" name="OtherGrantRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_FinanceLeaseNumberOfProperties" abstract="false" name="FinanceLeaseNumberOfProperties" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_ServiceBasedAwardsMember" abstract="true" name="ServiceBasedAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_OperatingAndFinanceLeaseLiabilityCurrent" abstract="false" name="OperatingAndFinanceLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrna_MerckMember" abstract="true" name="MerckMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrna_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_MTCSouthMTCNorthAndMTCEastMember" abstract="true" name="MTCSouthMTCNorthAndMTCEastMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrna_SupplyAndManufacturingAgreementsMember" abstract="true" name="SupplyAndManufacturingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>mrna-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:61dc7ba0-21f1-4a58-a37b-1270ec5a6c14,g:27805b16-b8d5-4e89-9c63-161f1adf5057-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f0021eb7-c67a-4b28-a151-ec4f62a70edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_64177acc-3494-4b07-b101-1bf28cd54260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f0021eb7-c67a-4b28-a151-ec4f62a70edd" xlink:to="loc_us-gaap_StockholdersEquity_64177acc-3494-4b07-b101-1bf28cd54260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2e5757a4-2881-4741-98bd-a57623d9c48d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f0021eb7-c67a-4b28-a151-ec4f62a70edd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2e5757a4-2881-4741-98bd-a57623d9c48d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_67864ecb-799c-4836-91ea-e781b51868cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f0021eb7-c67a-4b28-a151-ec4f62a70edd" xlink:to="loc_us-gaap_Liabilities_67864ecb-799c-4836-91ea-e781b51868cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_74a3e5be-5c88-4d6e-8424-3c03d8c6fc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b8f2c80a-9eee-43e4-b6e6-27b3d0fb4ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_74a3e5be-5c88-4d6e-8424-3c03d8c6fc9a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b8f2c80a-9eee-43e4-b6e6-27b3d0fb4ab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_51656deb-557d-472e-ae55-6f74d88ef1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_74a3e5be-5c88-4d6e-8424-3c03d8c6fc9a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_51656deb-557d-472e-ae55-6f74d88ef1ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4cc04926-d20d-450d-822d-26f870b76d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_74a3e5be-5c88-4d6e-8424-3c03d8c6fc9a" xlink:to="loc_us-gaap_InventoryNet_4cc04926-d20d-450d-822d-26f870b76d87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b09616a8-1f06-43cd-a6a4-f4e624522244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_74a3e5be-5c88-4d6e-8424-3c03d8c6fc9a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b09616a8-1f06-43cd-a6a4-f4e624522244" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fb558501-f6a6-4863-8f6d-4c351d93504c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_74a3e5be-5c88-4d6e-8424-3c03d8c6fc9a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fb558501-f6a6-4863-8f6d-4c351d93504c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6f9bfa2a-504a-4826-80e7-c220c3425892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d42502a3-f262-41a3-8fad-1989bbaa8c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6f9bfa2a-504a-4826-80e7-c220c3425892" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d42502a3-f262-41a3-8fad-1989bbaa8c7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_be955c04-ede6-47c5-bbf3-5f4f89a1add0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6f9bfa2a-504a-4826-80e7-c220c3425892" xlink:to="loc_us-gaap_AssetsCurrent_be955c04-ede6-47c5-bbf3-5f4f89a1add0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d6611948-a2b7-4eae-b3af-ec67499f489c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6f9bfa2a-504a-4826-80e7-c220c3425892" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d6611948-a2b7-4eae-b3af-ec67499f489c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_286af16d-1d23-425f-bb9a-cc0239d28337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6f9bfa2a-504a-4826-80e7-c220c3425892" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_286af16d-1d23-425f-bb9a-cc0239d28337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_02dc1752-28e7-402c-ad72-72ec94390618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6f9bfa2a-504a-4826-80e7-c220c3425892" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_02dc1752-28e7-402c-ad72-72ec94390618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_98c1f9f2-0388-4347-a731-456a15599a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6f9bfa2a-504a-4826-80e7-c220c3425892" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_98c1f9f2-0388-4347-a731-456a15599a16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_cf4ff32f-46e4-4c51-ab4f-0a5fc23e0c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6f9bfa2a-504a-4826-80e7-c220c3425892" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_cf4ff32f-46e4-4c51-ab4f-0a5fc23e0c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0c411d06-d312-4957-9ef5-fbe9cf647d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_cac60920-c90f-4710-b660-97a5c9538da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c411d06-d312-4957-9ef5-fbe9cf647d87" xlink:to="loc_us-gaap_PreferredStockValue_cac60920-c90f-4710-b660-97a5c9538da9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c8bd0925-9eea-4d22-90f8-efff96d2510c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c411d06-d312-4957-9ef5-fbe9cf647d87" xlink:to="loc_us-gaap_CommonStockValue_c8bd0925-9eea-4d22-90f8-efff96d2510c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb41bff7-c3c4-4d05-8074-4593f35db1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c411d06-d312-4957-9ef5-fbe9cf647d87" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb41bff7-c3c4-4d05-8074-4593f35db1b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4ea1d6bd-eb21-4922-a271-0aec3ce63927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c411d06-d312-4957-9ef5-fbe9cf647d87" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4ea1d6bd-eb21-4922-a271-0aec3ce63927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_11b1c4d0-de79-485b-af88-fee4698c2829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0c411d06-d312-4957-9ef5-fbe9cf647d87" xlink:to="loc_us-gaap_AdditionalPaidInCapital_11b1c4d0-de79-485b-af88-fee4698c2829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6f16581d-c9f1-4edc-874c-8474e472c22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c7022e5-cb06-4944-a72b-2c9fd442d460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f16581d-c9f1-4edc-874c-8474e472c22b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4c7022e5-cb06-4944-a72b-2c9fd442d460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_84ff62b8-ab4f-40f2-981c-8379d0672a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f16581d-c9f1-4edc-874c-8474e472c22b" xlink:to="loc_us-gaap_TaxesPayableCurrent_84ff62b8-ab4f-40f2-981c-8379d0672a72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b24824ec-988c-4147-abf1-a71933f6e35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f16581d-c9f1-4edc-874c-8474e472c22b" xlink:to="loc_us-gaap_AccountsPayableCurrent_b24824ec-988c-4147-abf1-a71933f6e35e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cf79a546-78f6-41fe-b9ab-4ad8968b9262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f16581d-c9f1-4edc-874c-8474e472c22b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cf79a546-78f6-41fe-b9ab-4ad8968b9262" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a8661d80-df4a-45e5-b194-b11a22bc0a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6f16581d-c9f1-4edc-874c-8474e472c22b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a8661d80-df4a-45e5-b194-b11a22bc0a51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a8459b4d-5f73-4c12-8d85-32e6f676a771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_edebfa8c-6ee9-460f-9410-27fb61fe8daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8459b4d-5f73-4c12-8d85-32e6f676a771" xlink:to="loc_us-gaap_LiabilitiesCurrent_edebfa8c-6ee9-460f-9410-27fb61fe8daa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c88a516c-9ea4-4175-97e0-f5aab1ae8925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8459b4d-5f73-4c12-8d85-32e6f676a771" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c88a516c-9ea4-4175-97e0-f5aab1ae8925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ff13d9bf-60d3-4d6f-a4d2-bd1ba91c9698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8459b4d-5f73-4c12-8d85-32e6f676a771" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ff13d9bf-60d3-4d6f-a4d2-bd1ba91c9698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a7935032-981a-4c2a-8b59-418f522c5dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8459b4d-5f73-4c12-8d85-32e6f676a771" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a7935032-981a-4c2a-8b59-418f522c5dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_11f73ad3-2b4b-4c91-9c39-34d7d717f745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8459b4d-5f73-4c12-8d85-32e6f676a771" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_11f73ad3-2b4b-4c91-9c39-34d7d717f745" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_36c7ae56-6d36-4984-8a8a-29b10b04c9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f179e503-4523-40b0-858b-736a84fbef1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_36c7ae56-6d36-4984-8a8a-29b10b04c9b0" xlink:to="loc_us-gaap_OperatingIncomeLoss_f179e503-4523-40b0-858b-736a84fbef1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_177b8a8e-bf98-4bff-8171-3ce1fd12e037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_36c7ae56-6d36-4984-8a8a-29b10b04c9b0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_177b8a8e-bf98-4bff-8171-3ce1fd12e037" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f3bc92b5-1e80-41b1-b879-64272355a613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_36c7ae56-6d36-4984-8a8a-29b10b04c9b0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f3bc92b5-1e80-41b1-b879-64272355a613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_43e1def1-2286-417e-8893-31605ada6522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf491295-ab9e-4e4e-ad08-7127de59540d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_43e1def1-2286-417e-8893-31605ada6522" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf491295-ab9e-4e4e-ad08-7127de59540d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3115ab04-be92-4d4a-a349-9cbdbe18ad8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_43e1def1-2286-417e-8893-31605ada6522" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3115ab04-be92-4d4a-a349-9cbdbe18ad8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_181da8ea-1bc0-4405-a2e0-7a1027f40774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5a6d7fd4-0137-43ed-bcb7-542cae7135c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_181da8ea-1bc0-4405-a2e0-7a1027f40774" xlink:to="loc_us-gaap_Revenues_5a6d7fd4-0137-43ed-bcb7-542cae7135c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_bd669c38-7485-4247-80d9-940dd2687475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_181da8ea-1bc0-4405-a2e0-7a1027f40774" xlink:to="loc_us-gaap_CostsAndExpenses_bd669c38-7485-4247-80d9-940dd2687475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1ef4f372-0809-4e73-8587-d58861fb6003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9a9c5b0e-591d-49d7-b0d2-3ad3b5e289a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1ef4f372-0809-4e73-8587-d58861fb6003" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9a9c5b0e-591d-49d7-b0d2-3ad3b5e289a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a01c89c9-a745-4b5a-acab-6fceacc230a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1ef4f372-0809-4e73-8587-d58861fb6003" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a01c89c9-a745-4b5a-acab-6fceacc230a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5eba474a-0974-41a5-8141-fe2d87e83556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1ef4f372-0809-4e73-8587-d58861fb6003" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5eba474a-0974-41a5-8141-fe2d87e83556" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9a1a8c9f-0807-4fad-82ac-e1df03c02851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_30490fe9-04fe-4b65-9c35-ac90d7d00b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9a1a8c9f-0807-4fad-82ac-e1df03c02851" xlink:to="loc_us-gaap_NetIncomeLoss_30490fe9-04fe-4b65-9c35-ac90d7d00b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_055a2ac6-3247-435b-921d-78a52a1792c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9a1a8c9f-0807-4fad-82ac-e1df03c02851" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_055a2ac6-3247-435b-921d-78a52a1792c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_687efdda-ff4b-4806-9bd2-5a6dfb36fe61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_3cca0374-e84d-4851-a46e-d8d95fb94702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_687efdda-ff4b-4806-9bd2-5a6dfb36fe61" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_3cca0374-e84d-4851-a46e-d8d95fb94702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_e9b6ef25-5949-4563-b25f-8541f2b4d5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_687efdda-ff4b-4806-9bd2-5a6dfb36fe61" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_e9b6ef25-5949-4563-b25f-8541f2b4d5e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_1b9c654f-a725-493b-9a0e-b8d1deba5eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_9f778c8a-02fc-47a0-8a3f-94450c11b820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_1b9c654f-a725-493b-9a0e-b8d1deba5eb3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_9f778c8a-02fc-47a0-8a3f-94450c11b820" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_57d72105-d981-4db0-8e4e-f3703708e304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_1b9c654f-a725-493b-9a0e-b8d1deba5eb3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_57d72105-d981-4db0-8e4e-f3703708e304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fcad622e-551c-405c-9c4f-8390c23a8268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a1e6ebad-7004-42c3-9903-6b1b256c374c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fcad622e-551c-405c-9c4f-8390c23a8268" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a1e6ebad-7004-42c3-9903-6b1b256c374c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_92ba53ad-df57-42a9-b482-9f4303f8ec5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fcad622e-551c-405c-9c4f-8390c23a8268" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_92ba53ad-df57-42a9-b482-9f4303f8ec5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a3842a3a-5409-4029-8cb6-7deafb276dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities_bca132d0-1d84-4ccf-abc0-69fbbdfd553f" xlink:href="mrna-20211231.xsd#mrna_ChargesToFinancingLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a3842a3a-5409-4029-8cb6-7deafb276dd4" xlink:to="loc_mrna_ChargesToFinancingLeaseLiabilities_bca132d0-1d84-4ccf-abc0-69fbbdfd553f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5cf3e599-ade3-4d70-b594-9b54254cf610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a3842a3a-5409-4029-8cb6-7deafb276dd4" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5cf3e599-ade3-4d70-b594-9b54254cf610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4411317c-49af-422c-9e0e-086706eba3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a3842a3a-5409-4029-8cb6-7deafb276dd4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4411317c-49af-422c-9e0e-086706eba3bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b7ef9bad-9e0f-4550-b658-981e20f2a091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a3842a3a-5409-4029-8cb6-7deafb276dd4" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b7ef9bad-9e0f-4550-b658-981e20f2a091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5059f638-18dc-4497-950b-b691a05976b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b5c3228e-b0ea-427b-9743-ece1fb30c5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5059f638-18dc-4497-950b-b691a05976b8" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b5c3228e-b0ea-427b-9743-ece1fb30c5b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_80d42b48-a2fe-4c30-9982-527535a0853c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5059f638-18dc-4497-950b-b691a05976b8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_80d42b48-a2fe-4c30-9982-527535a0853c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_247c0eab-a40c-4f39-b185-666afbe45f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5059f638-18dc-4497-950b-b691a05976b8" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_247c0eab-a40c-4f39-b185-666afbe45f4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c5bdb18d-16af-40cf-99da-7274d8553397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5059f638-18dc-4497-950b-b691a05976b8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c5bdb18d-16af-40cf-99da-7274d8553397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_47af7804-6d5a-4f8b-b280-725c5d4a02dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5059f638-18dc-4497-950b-b691a05976b8" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_47af7804-6d5a-4f8b-b280-725c5d4a02dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8c50270b-d31e-408e-9809-44db9dd7c27c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8c50270b-d31e-408e-9809-44db9dd7c27c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2001e2c9-979d-4a05-8fa4-c367a39d9086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2001e2c9-979d-4a05-8fa4-c367a39d9086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_119f4cdb-f1aa-4222-b9d7-8d7266962919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_119f4cdb-f1aa-4222-b9d7-8d7266962919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_3ca22e16-7c43-4552-b065-87d0dedf01ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_3ca22e16-7c43-4552-b065-87d0dedf01ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e8ee97ea-5410-4dd2-9e55-95213c3131d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_NetIncomeLoss_e8ee97ea-5410-4dd2-9e55-95213c3131d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7e76f9e9-b0a3-4ede-b6e6-879350396f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_ShareBasedCompensation_7e76f9e9-b0a3-4ede-b6e6-879350396f42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dd251c6b-7753-43b3-a6cf-d967cf64e085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dd251c6b-7753-43b3-a6cf-d967cf64e085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets_cbbfe2d6-f43e-4da1-a217-38e5bb51e44c" xlink:href="mrna-20211231.xsd#mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets_cbbfe2d6-f43e-4da1-a217-38e5bb51e44c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a9902ea8-a945-4c3a-8940-154e0b9d2c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a9902ea8-a945-4c3a-8940-154e0b9d2c2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_79ef11f8-f1d3-4655-becc-c20a976e98a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_79ef11f8-f1d3-4655-becc-c20a976e98a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3fbcd28b-caee-4771-b6ed-fdcb13374950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3fbcd28b-caee-4771-b6ed-fdcb13374950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cd084fed-93ff-468b-a9e0-83438ec889cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cd084fed-93ff-468b-a9e0-83438ec889cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredIncomeTaxExpenseBenefitNet_25bd1488-23d8-416a-ba6c-ff2a3f30a2fa" xlink:href="mrna-20211231.xsd#mrna_DeferredIncomeTaxExpenseBenefitNet"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_mrna_DeferredIncomeTaxExpenseBenefitNet_25bd1488-23d8-416a-ba6c-ff2a3f30a2fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_0c468476-e96d-46ac-a07c-91218ed1e07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_0c468476-e96d-46ac-a07c-91218ed1e07d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_99948638-046e-4606-8c11-f60e4f318331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_99948638-046e-4606-8c11-f60e4f318331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_e2044649-6c32-4ad3-93f4-d7b12e6ede2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9ccc4f2-9ebd-45ce-8be8-a91c2fb4b70d" xlink:to="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_e2044649-6c32-4ad3-93f4-d7b12e6ede2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_31ab9434-fa96-4c14-8d18-d1a90dae15bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_449c001d-3ef5-4e43-871e-bf422b111b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_31ab9434-fa96-4c14-8d18-d1a90dae15bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_449c001d-3ef5-4e43-871e-bf422b111b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b21b9eb9-115d-411b-b6ba-dd8e60be474d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_31ab9434-fa96-4c14-8d18-d1a90dae15bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b21b9eb9-115d-411b-b6ba-dd8e60be474d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_578b2a19-0516-4260-8578-c558decfabde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_31ab9434-fa96-4c14-8d18-d1a90dae15bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_578b2a19-0516-4260-8578-c558decfabde" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2edceb21-2092-44ee-8ac4-2986fed688ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_978baf3c-23c7-49d3-90ac-611fd164b0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2edceb21-2092-44ee-8ac4-2986fed688ff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_978baf3c-23c7-49d3-90ac-611fd164b0fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_1a7d3f63-1d81-4acb-9304-d8a86a4443db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2edceb21-2092-44ee-8ac4-2986fed688ff" xlink:to="loc_us-gaap_RestrictedCashCurrent_1a7d3f63-1d81-4acb-9304-d8a86a4443db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_8368c6a8-4d04-4c82-af03-6463e19bf413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2edceb21-2092-44ee-8ac4-2986fed688ff" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_8368c6a8-4d04-4c82-af03-6463e19bf413" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2697f9c3-1a29-408f-9f99-c9b1d891b650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3c34697a-03c6-4da7-b8b9-2b8ec1a6e624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2697f9c3-1a29-408f-9f99-c9b1d891b650" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3c34697a-03c6-4da7-b8b9-2b8ec1a6e624" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d9de477c-8ae9-4240-83ea-4b0d266eed93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2697f9c3-1a29-408f-9f99-c9b1d891b650" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d9de477c-8ae9-4240-83ea-4b0d266eed93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fff106de-56a7-438a-8071-29e24ad6c274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2697f9c3-1a29-408f-9f99-c9b1d891b650" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fff106de-56a7-438a-8071-29e24ad6c274" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_59d93f48-1deb-49b1-8a11-9601087b648e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5464b6dc-d6fb-406e-b12f-332b8f8e9325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_59d93f48-1deb-49b1-8a11-9601087b648e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5464b6dc-d6fb-406e-b12f-332b8f8e9325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1fbae272-3a1f-44ec-b4a9-de22a9ef3fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_59d93f48-1deb-49b1-8a11-9601087b648e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1fbae272-3a1f-44ec-b4a9-de22a9ef3fcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cefe38d2-cc11-41d1-b324-81dcdbac1d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_bc5036a0-124b-4703-8dd3-3db6d547db3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cefe38d2-cc11-41d1-b324-81dcdbac1d96" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_bc5036a0-124b-4703-8dd3-3db6d547db3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_825e0cfc-6698-4783-ae74-be6e92ac4628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cefe38d2-cc11-41d1-b324-81dcdbac1d96" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_825e0cfc-6698-4783-ae74-be6e92ac4628" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a6ac0e86-c974-448f-abeb-42a4a7c5f9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_6a856092-af0b-44d3-ba4d-8b13a5469419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a6ac0e86-c974-448f-abeb-42a4a7c5f9c7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_6a856092-af0b-44d3-ba4d-8b13a5469419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_084f7b05-f444-44cc-b98e-26e4bb01a57f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a6ac0e86-c974-448f-abeb-42a4a7c5f9c7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_084f7b05-f444-44cc-b98e-26e4bb01a57f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_53c51c7c-4898-430a-a199-eef67758eb65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1e3bbe1e-09d9-48a1-a427-58aab2cc71e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_53c51c7c-4898-430a-a199-eef67758eb65" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_1e3bbe1e-09d9-48a1-a427-58aab2cc71e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_431126f6-c15b-4873-a7a5-8e22c70e7ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_53c51c7c-4898-430a-a199-eef67758eb65" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_431126f6-c15b-4873-a7a5-8e22c70e7ab5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_90ce1679-7ed3-436d-a705-c7007832535b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_26d9ff35-6ae7-4b5c-b911-269b14013366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_90ce1679-7ed3-436d-a705-c7007832535b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_26d9ff35-6ae7-4b5c-b911-269b14013366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_339e0bcc-f8c6-4dd7-b9df-4685af5546a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_90ce1679-7ed3-436d-a705-c7007832535b" xlink:to="loc_us-gaap_DerivativeAssets_339e0bcc-f8c6-4dd7-b9df-4685af5546a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7095f217-2c83-4de8-8600-1eb403ab2490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a265ef8a-58b1-4fb4-bab2-88ea3b88b709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7095f217-2c83-4de8-8600-1eb403ab2490" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a265ef8a-58b1-4fb4-bab2-88ea3b88b709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_df916905-a51d-494a-b2cc-f3c0010134f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7095f217-2c83-4de8-8600-1eb403ab2490" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_df916905-a51d-494a-b2cc-f3c0010134f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_29af0c34-763d-4ab7-b2f5-fb2141938134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7095f217-2c83-4de8-8600-1eb403ab2490" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_29af0c34-763d-4ab7-b2f5-fb2141938134" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_877f6688-e88f-4888-bf69-b508c5faee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3984de95-7401-475a-b923-9a60b2a968ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_877f6688-e88f-4888-bf69-b508c5faee0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3984de95-7401-475a-b923-9a60b2a968ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_241fb503-cfc0-483b-8ca3-53a70969fccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_877f6688-e88f-4888-bf69-b508c5faee0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_241fb503-cfc0-483b-8ca3-53a70969fccd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ca15d1a-af70-454f-967d-11bcff14502e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_652e3239-7fa1-4aef-9f3f-4c2fcc8f301e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ca15d1a-af70-454f-967d-11bcff14502e" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_652e3239-7fa1-4aef-9f3f-4c2fcc8f301e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TenantImprovementAllowanceReceivableCurrent_6aa4d11a-ba67-460e-97ba-5747d8b8392d" xlink:href="mrna-20211231.xsd#mrna_TenantImprovementAllowanceReceivableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ca15d1a-af70-454f-967d-11bcff14502e" xlink:to="loc_mrna_TenantImprovementAllowanceReceivableCurrent_6aa4d11a-ba67-460e-97ba-5747d8b8392d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseManufacturing_63db556c-5192-4787-b4ba-4f06206bfc78" xlink:href="mrna-20211231.xsd#mrna_OtherPrepaidExpenseManufacturing"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ca15d1a-af70-454f-967d-11bcff14502e" xlink:to="loc_mrna_OtherPrepaidExpenseManufacturing_63db556c-5192-4787-b4ba-4f06206bfc78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_678f8542-ae49-41f9-9054-7cb87b3c70a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ca15d1a-af70-454f-967d-11bcff14502e" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_678f8542-ae49-41f9-9054-7cb87b3c70a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_49613d43-77b6-4910-97b8-ee1b4cf2e6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ca15d1a-af70-454f-967d-11bcff14502e" xlink:to="loc_us-gaap_OtherAssetsCurrent_49613d43-77b6-4910-97b8-ee1b4cf2e6a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_252b322f-7cdf-4c8b-bd3f-02f1d99e73a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ca15d1a-af70-454f-967d-11bcff14502e" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_252b322f-7cdf-4c8b-bd3f-02f1d99e73a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#OtherBalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4571ef68-e630-4226-af64-1fe39eca36ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7ca353f9-fe02-41dd-af12-1425a561de0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4571ef68-e630-4226-af64-1fe39eca36ee" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7ca353f9-fe02-41dd-af12-1425a561de0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation_22e46f19-3a68-4617-95d8-cc568dfb1997" xlink:href="mrna-20211231.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4571ef68-e630-4226-af64-1fe39eca36ee" xlink:to="loc_mrna_AccruedDevelopmentOperation_22e46f19-3a68-4617-95d8-cc568dfb1997" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing_3898dad6-d0ee-4be0-ba14-e70490846424" xlink:href="mrna-20211231.xsd#mrna_AccruedManufacturing"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4571ef68-e630-4226-af64-1fe39eca36ee" xlink:to="loc_mrna_AccruedManufacturing_3898dad6-d0ee-4be0-ba14-e70490846424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable_2bf0b230-f2e8-4de0-aaef-6a4941dc5c09" xlink:href="mrna-20211231.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4571ef68-e630-4226-af64-1fe39eca36ee" xlink:to="loc_mrna_RawMaterialsAccountsPayable_2bf0b230-f2e8-4de0-aaef-6a4941dc5c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials_18896c63-3c05-42d4-a906-6e73fdd84f9f" xlink:href="mrna-20211231.xsd#mrna_AccruedClinicalTrials"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4571ef68-e630-4226-af64-1fe39eca36ee" xlink:to="loc_mrna_AccruedClinicalTrials_18896c63-3c05-42d4-a906-6e73fdd84f9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1895bac1-fa9b-4985-bcd7-29db6e482129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4571ef68-e630-4226-af64-1fe39eca36ee" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1895bac1-fa9b-4985-bcd7-29db6e482129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e42d47e5-2fd4-4b51-96f9-432526ff438e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4571ef68-e630-4226-af64-1fe39eca36ee" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e42d47e5-2fd4-4b51-96f9-432526ff438e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_cead14be-9ce8-4224-b3c7-977f4cb6de88" xlink:href="mrna-20211231.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4571ef68-e630-4226-af64-1fe39eca36ee" xlink:to="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_cead14be-9ce8-4224-b3c7-977f4cb6de88" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2607c0ae-eb5c-4fcb-825d-11a7eb7a928f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_8b295d5a-bd16-42ba-a50a-c5ca594b4750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_2607c0ae-eb5c-4fcb-825d-11a7eb7a928f" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_8b295d5a-bd16-42ba-a50a-c5ca594b4750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_957f6e1b-1911-4465-ab00-4f66de44cf17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_2607c0ae-eb5c-4fcb-825d-11a7eb7a928f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_957f6e1b-1911-4465-ab00-4f66de44cf17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_bf33ce96-ae50-4a03-974a-9948f8062352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_2607c0ae-eb5c-4fcb-825d-11a7eb7a928f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_bf33ce96-ae50-4a03-974a-9948f8062352" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_b5f5fe4b-7771-4eec-99e6-68faa7d7d951" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9968174f-1247-46bd-ac4c-305c60f1496d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_b5f5fe4b-7771-4eec-99e6-68faa7d7d951" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9968174f-1247-46bd-ac4c-305c60f1496d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b236011d-b9d1-4992-9ada-291b8a9a66d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_b5f5fe4b-7771-4eec-99e6-68faa7d7d951" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b236011d-b9d1-4992-9ada-291b8a9a66d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_d87e9902-9776-420b-b696-a984f499a5d9" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_f6bc39f0-ff5a-4a45-af1f-ee3cf08d29db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_d87e9902-9776-420b-b696-a984f499a5d9" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_f6bc39f0-ff5a-4a45-af1f-ee3cf08d29db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3bb17cb3-2512-40e4-890f-0d985fb83822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_d87e9902-9776-420b-b696-a984f499a5d9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3bb17cb3-2512-40e4-890f-0d985fb83822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability_888a25d4-6830-4c6d-80f7-b26bdee9256d" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_7f8abe41-3054-41db-96f5-cebb79238ed4" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability_888a25d4-6830-4c6d-80f7-b26bdee9256d" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_7f8abe41-3054-41db-96f5-cebb79238ed4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_e0ca73f1-f11a-44cd-a8a4-9ba72d192f6f" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability_888a25d4-6830-4c6d-80f7-b26bdee9256d" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_e0ca73f1-f11a-44cd-a8a4-9ba72d192f6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_72430399-1f73-4851-b9f3-7b41f5078649" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5e5ae002-b1f0-4263-980c-4cd669e9f578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_72430399-1f73-4851-b9f3-7b41f5078649" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5e5ae002-b1f0-4263-980c-4cd669e9f578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_81a953ae-0996-4476-b25f-870c8bca9128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_72430399-1f73-4851-b9f3-7b41f5078649" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_81a953ae-0996-4476-b25f-870c8bca9128" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseCost_661f639e-028f-4a1d-98cb-b9268a38323c" xlink:href="mrna-20211231.xsd#mrna_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ac855740-b442-4460-acc1-84f7b35decdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_FinanceLeaseCost_661f639e-028f-4a1d-98cb-b9268a38323c" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ac855740-b442-4460-acc1-84f7b35decdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_2f34cffa-76a7-407a-99ed-b232145882ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrna_FinanceLeaseCost_661f639e-028f-4a1d-98cb-b9268a38323c" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_2f34cffa-76a7-407a-99ed-b232145882ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8197034a-70f7-41c9-889e-b4bd57aee4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_5f20a961-a66e-4465-baa7-54969346eff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8197034a-70f7-41c9-889e-b4bd57aee4be" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_5f20a961-a66e-4465-baa7-54969346eff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_fe827737-725d-4912-95d6-7bf901d1fd71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8197034a-70f7-41c9-889e-b4bd57aee4be" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_fe827737-725d-4912-95d6-7bf901d1fd71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_452e3bb3-62d3-4035-aa76-c0bea0560c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8197034a-70f7-41c9-889e-b4bd57aee4be" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_452e3bb3-62d3-4035-aa76-c0bea0560c72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_7597e467-7bd6-4da7-8227-0fcc26492d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8197034a-70f7-41c9-889e-b4bd57aee4be" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_7597e467-7bd6-4da7-8227-0fcc26492d70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_2c4a93e8-15ae-448a-8dff-413507f3f76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8197034a-70f7-41c9-889e-b4bd57aee4be" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_2c4a93e8-15ae-448a-8dff-413507f3f76b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_af839fd8-195e-4aec-beb6-bdbc69c7acf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8197034a-70f7-41c9-889e-b4bd57aee4be" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_af839fd8-195e-4aec-beb6-bdbc69c7acf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0f3ef4ac-dc2e-4189-a108-cd5b27b2c453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_15eb4f03-a07e-43a8-843e-4c96aec81856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0f3ef4ac-dc2e-4189-a108-cd5b27b2c453" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_15eb4f03-a07e-43a8-843e-4c96aec81856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_627f7b0b-c14c-452a-9d76-9ab96f187dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0f3ef4ac-dc2e-4189-a108-cd5b27b2c453" xlink:to="loc_us-gaap_FinanceLeaseLiability_627f7b0b-c14c-452a-9d76-9ab96f187dfc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f6c99bb-16bb-4caf-8355-8b65e144fc34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c77452d6-cc53-45ba-907a-d59eccc7cd65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f6c99bb-16bb-4caf-8355-8b65e144fc34" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c77452d6-cc53-45ba-907a-d59eccc7cd65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4541afd5-a4e6-4025-97ef-409efcefed89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f6c99bb-16bb-4caf-8355-8b65e144fc34" xlink:to="loc_us-gaap_OperatingLeaseLiability_4541afd5-a4e6-4025-97ef-409efcefed89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1922e290-ffff-4afd-866c-3d436b6f201f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_aafa755b-f03a-4d24-b699-66f036e4a98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1922e290-ffff-4afd-866c-3d436b6f201f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_aafa755b-f03a-4d24-b699-66f036e4a98f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_1f66acdf-b7df-4873-8eb4-2bdabf830552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1922e290-ffff-4afd-866c-3d436b6f201f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_1f66acdf-b7df-4873-8eb4-2bdabf830552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_fc6f02e0-4dfc-40c3-926c-e397fdca6b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1922e290-ffff-4afd-866c-3d436b6f201f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_fc6f02e0-4dfc-40c3-926c-e397fdca6b45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_78ef0337-6b41-4354-be05-32ac88971e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1922e290-ffff-4afd-866c-3d436b6f201f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_78ef0337-6b41-4354-be05-32ac88971e6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_bc1259bd-739f-4545-89b1-ba6a03113370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1922e290-ffff-4afd-866c-3d436b6f201f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_bc1259bd-739f-4545-89b1-ba6a03113370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_f822994b-b283-4e71-828b-e67b211b77e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1922e290-ffff-4afd-866c-3d436b6f201f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_f822994b-b283-4e71-828b-e67b211b77e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83f4a447-014b-41c5-a3d7-f10b174eaea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a097aae4-3e5c-4bc1-8599-76d7470494c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83f4a447-014b-41c5-a3d7-f10b174eaea3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a097aae4-3e5c-4bc1-8599-76d7470494c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_00e48fd3-1a02-4f23-9c56-f9ca12d558c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83f4a447-014b-41c5-a3d7-f10b174eaea3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_00e48fd3-1a02-4f23-9c56-f9ca12d558c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6f3e2487-a350-4268-8a7b-3ccc75c17b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_67646345-6dd7-469d-a4f3-3bf665b2016b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6f3e2487-a350-4268-8a7b-3ccc75c17b28" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_67646345-6dd7-469d-a4f3-3bf665b2016b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1ee09f37-2634-49ee-9720-db66e42a44ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6f3e2487-a350-4268-8a7b-3ccc75c17b28" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1ee09f37-2634-49ee-9720-db66e42a44ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_cb3e57af-eaec-4019-aa1c-76d082855ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5ae8d7dc-2754-45be-9761-0b84b499aacf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_cb3e57af-eaec-4019-aa1c-76d082855ae6" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5ae8d7dc-2754-45be-9761-0b84b499aacf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c3c61680-3446-4acd-92e2-0ae536a4ac7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_cb3e57af-eaec-4019-aa1c-76d082855ae6" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c3c61680-3446-4acd-92e2-0ae536a4ac7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0e34f704-0188-4ac0-80ce-3d8971e18ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_cb3e57af-eaec-4019-aa1c-76d082855ae6" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0e34f704-0188-4ac0-80ce-3d8971e18ff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_286d1d12-467c-4f44-b38e-8afe1a453319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f7913f89-c353-474a-b7cd-83fa44f7a5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_286d1d12-467c-4f44-b38e-8afe1a453319" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f7913f89-c353-474a-b7cd-83fa44f7a5e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_76cb37d8-db68-45de-a251-b67db5b426e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_286d1d12-467c-4f44-b38e-8afe1a453319" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_76cb37d8-db68-45de-a251-b67db5b426e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c87ef67f-f1f5-4bff-9f96-58540e8ec2be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_286d1d12-467c-4f44-b38e-8afe1a453319" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c87ef67f-f1f5-4bff-9f96-58540e8ec2be" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3821c746-7371-4eda-9dc9-aad1a0da8b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9c696330-a269-4f24-b96c-3145fee70223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3821c746-7371-4eda-9dc9-aad1a0da8b6b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9c696330-a269-4f24-b96c-3145fee70223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_7b3fdb6e-dadf-4eb4-bbb6-f6b735766c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3821c746-7371-4eda-9dc9-aad1a0da8b6b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_7b3fdb6e-dadf-4eb4-bbb6-f6b735766c96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dd597327-08bb-4220-9394-03e2e8d5c41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3821c746-7371-4eda-9dc9-aad1a0da8b6b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dd597327-08bb-4220-9394-03e2e8d5c41b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2271b593-868a-4d9e-bfc4-7cb7b5b588f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3821c746-7371-4eda-9dc9-aad1a0da8b6b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2271b593-868a-4d9e-bfc4-7cb7b5b588f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_8df1fbcf-e5e4-4ca4-8b1b-21a76c0bfdae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3821c746-7371-4eda-9dc9-aad1a0da8b6b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_8df1fbcf-e5e4-4ca4-8b1b-21a76c0bfdae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2da4f1bd-1693-4d19-bf57-233308f25380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3821c746-7371-4eda-9dc9-aad1a0da8b6b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2da4f1bd-1693-4d19-bf57-233308f25380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1cce4e65-3421-40b2-a7d4-f27745016fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3821c746-7371-4eda-9dc9-aad1a0da8b6b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1cce4e65-3421-40b2-a7d4-f27745016fff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_1adb2d0f-2962-4ce9-81c3-49f6fe6dcc22" xlink:href="mrna-20211231.xsd#mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3821c746-7371-4eda-9dc9-aad1a0da8b6b" xlink:to="loc_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_1adb2d0f-2962-4ce9-81c3-49f6fe6dcc22" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_40ae45f8-84c4-49d7-9cf2-9bdec3b1e136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_083bc338-88db-48d5-a936-f6f1f249365c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40ae45f8-84c4-49d7-9cf2-9bdec3b1e136" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_083bc338-88db-48d5-a936-f6f1f249365c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_38d35ad1-2d31-4571-bb61-da6f0b620d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40ae45f8-84c4-49d7-9cf2-9bdec3b1e136" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_38d35ad1-2d31-4571-bb61-da6f0b620d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsFinancingLeaseLiability_4e53c84e-e25f-4206-87bc-c82c43ade8d3" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxAssetsFinancingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40ae45f8-84c4-49d7-9cf2-9bdec3b1e136" xlink:to="loc_mrna_DeferredTaxAssetsFinancingLeaseLiability_4e53c84e-e25f-4206-87bc-c82c43ade8d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_2925a49a-cda6-4696-9fcf-6e63b520f6e0" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40ae45f8-84c4-49d7-9cf2-9bdec3b1e136" xlink:to="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_2925a49a-cda6-4696-9fcf-6e63b520f6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_fe48a86d-8e02-4a3f-9262-2772b650f806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40ae45f8-84c4-49d7-9cf2-9bdec3b1e136" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_fe48a86d-8e02-4a3f-9262-2772b650f806" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e6e94618-2041-40d0-a8fa-199f97f6ab23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40ae45f8-84c4-49d7-9cf2-9bdec3b1e136" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e6e94618-2041-40d0-a8fa-199f97f6ab23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ea3abc7f-c7e0-4ae1-ad27-47d57297fdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40ae45f8-84c4-49d7-9cf2-9bdec3b1e136" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ea3abc7f-c7e0-4ae1-ad27-47d57297fdc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability_c089f633-9ee3-4abc-80c8-9863537d63d2" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40ae45f8-84c4-49d7-9cf2-9bdec3b1e136" xlink:to="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability_c089f633-9ee3-4abc-80c8-9863537d63d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a25ea070-0ac8-484b-9ca4-0146ca54fc53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0eb7f546-0047-49c2-9096-4c4258e1a4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_a25ea070-0ac8-484b-9ca4-0146ca54fc53" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0eb7f546-0047-49c2-9096-4c4258e1a4fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_678ba178-708c-40ca-90bf-1dcfb8ac1566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_a25ea070-0ac8-484b-9ca4-0146ca54fc53" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_678ba178-708c-40ca-90bf-1dcfb8ac1566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9e863140-7d7a-4a16-a117-767b2028b8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1fe48919-403b-4da6-a889-a0e2db303e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9e863140-7d7a-4a16-a117-767b2028b8e0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1fe48919-403b-4da6-a889-a0e2db303e09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_b21f5ef7-f310-4d0c-b6a6-f1b8fa237343" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9e863140-7d7a-4a16-a117-767b2028b8e0" xlink:to="loc_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_b21f5ef7-f310-4d0c-b6a6-f1b8fa237343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_e41671d8-2245-414b-ac0f-6aa88fefb93c" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9e863140-7d7a-4a16-a117-767b2028b8e0" xlink:to="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_e41671d8-2245-414b-ac0f-6aa88fefb93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_f908d899-3001-4ebd-b782-22b8a29ce95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9e863140-7d7a-4a16-a117-767b2028b8e0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_f908d899-3001-4ebd-b782-22b8a29ce95c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_99abb4e3-be8c-4751-83aa-35b978174965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_73f174f9-6476-4017-8393-da01a33aad15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_99abb4e3-be8c-4751-83aa-35b978174965" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_73f174f9-6476-4017-8393-da01a33aad15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9c5ce534-5fb0-48f9-92e1-97690f9ba0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_99abb4e3-be8c-4751-83aa-35b978174965" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_9c5ce534-5fb0-48f9-92e1-97690f9ba0c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"/>
  <link:calculationLink xlink:role="http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b92e663a-ac26-4071-baa5-d902a386eb54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_eca60c5a-3ace-41f8-bec7-462ee6097232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b92e663a-ac26-4071-baa5-d902a386eb54" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_eca60c5a-3ace-41f8-bec7-462ee6097232" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e80ea2fa-2175-472d-98af-6c6bae03aace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b92e663a-ac26-4071-baa5-d902a386eb54" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e80ea2fa-2175-472d-98af-6c6bae03aace" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>mrna-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:61dc7ba0-21f1-4a58-a37b-1270ec5a6c14,g:27805b16-b8d5-4e89-9c63-161f1adf5057-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="ie43a9e4572e7400d8d1b9a0999f6743e_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_4e492d99-8f50-4953-ad3f-6b513ce4c149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_RevenuesAbstract_4e492d99-8f50-4953-ad3f-6b513ce4c149" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ce37191c-50cd-4780-84de-5a119517ed20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_4e492d99-8f50-4953-ad3f-6b513ce4c149" xlink:to="loc_us-gaap_Revenues_ce37191c-50cd-4780-84de-5a119517ed20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_37bc11bf-9ca2-4086-900b-99fea71bd04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_37bc11bf-9ca2-4086-900b-99fea71bd04e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_94fb1a50-09c7-496d-8d4d-d15ee8824031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_94fb1a50-09c7-496d-8d4d-d15ee8824031" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_63ad9c53-92d0-40f4-a5b5-2ab6a05cc6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_63ad9c53-92d0-40f4-a5b5-2ab6a05cc6ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d1e24801-5575-45d7-acc3-55bc5f8484cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:to="loc_us-gaap_CostsAndExpenses_d1e24801-5575-45d7-acc3-55bc5f8484cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_41b523aa-3f21-41e8-b9be-e8cc90383d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_OperatingIncomeLoss_41b523aa-3f21-41e8-b9be-e8cc90383d80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7fd8d203-3b0c-4f4d-b58a-cdf502eee7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7fd8d203-3b0c-4f4d-b58a-cdf502eee7ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0f1189bb-eac6-41be-a95f-413a03075500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0f1189bb-eac6-41be-a95f-413a03075500" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dda171a0-b156-44ee-b1ab-8322a2d61877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dda171a0-b156-44ee-b1ab-8322a2d61877" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_43b9dd73-1b2c-4197-9674-c2ceb52277e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_43b9dd73-1b2c-4197-9674-c2ceb52277e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_30c54aed-09cf-4357-96ee-87f4670dd0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_NetIncomeLoss_30c54aed-09cf-4357-96ee-87f4670dd0a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a27ca88c-324f-4b86-87d1-6ac70b109f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a27ca88c-324f-4b86-87d1-6ac70b109f5f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9d74c5ca-7e8d-49c9-a1b6-722b027673c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a27ca88c-324f-4b86-87d1-6ac70b109f5f" xlink:to="loc_us-gaap_EarningsPerShareBasic_9d74c5ca-7e8d-49c9-a1b6-722b027673c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5026f927-3fa6-424e-a38e-ef2cdf63fc23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a27ca88c-324f-4b86-87d1-6ac70b109f5f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5026f927-3fa6-424e-a38e-ef2cdf63fc23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6a815568-8a94-4af1-93fc-294656cb6db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6a815568-8a94-4af1-93fc-294656cb6db4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d30d9177-317c-47d8-bc1a-e440a78e6367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6a815568-8a94-4af1-93fc-294656cb6db4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d30d9177-317c-47d8-bc1a-e440a78e6367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5ec8afd6-143d-45bf-a36b-94f0911a4cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6a815568-8a94-4af1-93fc-294656cb6db4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5ec8afd6-143d-45bf-a36b-94f0911a4cd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1bcd55b3-ec16-42fb-bf75-d836c9af01fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_StatementTable_1bcd55b3-ec16-42fb-bf75-d836c9af01fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_50bfde91-0718-4e5c-b539-a66c7dbc3ffb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1bcd55b3-ec16-42fb-bf75-d836c9af01fe" xlink:to="loc_srt_ProductOrServiceAxis_50bfde91-0718-4e5c-b539-a66c7dbc3ffb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_50bfde91-0718-4e5c-b539-a66c7dbc3ffb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_50bfde91-0718-4e5c-b539-a66c7dbc3ffb" xlink:to="loc_srt_ProductsAndServicesDomain_50bfde91-0718-4e5c-b539-a66c7dbc3ffb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f91d30c5-5253-438e-90b6-40485164e5b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_50bfde91-0718-4e5c-b539-a66c7dbc3ffb" xlink:to="loc_srt_ProductsAndServicesDomain_f91d30c5-5253-438e-90b6-40485164e5b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_0bd78d9f-a2cd-45e9-aa22-e1715d543a56" xlink:href="mrna-20211231.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f91d30c5-5253-438e-90b6-40485164e5b7" xlink:to="loc_mrna_ProductSalesMember_0bd78d9f-a2cd-45e9-aa22-e1715d543a56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_a06eeb0a-c4ee-46df-8354-c219ae3326a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f91d30c5-5253-438e-90b6-40485164e5b7" xlink:to="loc_us-gaap_GrantMember_a06eeb0a-c4ee-46df-8354-c219ae3326a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_c69d0d31-6ffc-49dc-b27a-07a3ee97da71" xlink:href="mrna-20211231.xsd#mrna_CollaborationArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f91d30c5-5253-438e-90b6-40485164e5b7" xlink:to="loc_mrna_CollaborationArrangementMember_c69d0d31-6ffc-49dc-b27a-07a3ee97da71" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i29121f2c8ae546d8b9d58f1dab70b53c_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5fce354a-8fe9-48b3-8091-5d64b69520db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5fce354a-8fe9-48b3-8091-5d64b69520db" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cd777266-9298-4c68-a77f-340047088bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_SharesOutstanding_cd777266-9298-4c68-a77f-340047088bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b2d63b3-c015-4c39-ab69-835c62eb34f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockholdersEquity_6b2d63b3-c015-4c39-ab69-835c62eb34f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_e7077293-ae2f-4fd4-93c8-d5ae05838ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_e7077293-ae2f-4fd4-93c8-d5ae05838ba8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_401a4e5e-fe66-4a90-8bee-4e333a7bc4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_401a4e5e-fe66-4a90-8bee-4e333a7bc4d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66cd7ffe-728c-43b6-977f-a0b9f3e0e96a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66cd7ffe-728c-43b6-977f-a0b9f3e0e96a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e4472d8-60e5-4f6a-84eb-ae94070c3819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e4472d8-60e5-4f6a-84eb-ae94070c3819" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9ebbf289-ff55-4648-a0e0-71a766adc380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9ebbf289-ff55-4648-a0e0-71a766adc380" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d86bb521-590e-45bc-8157-40418ed6b802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d86bb521-590e-45bc-8157-40418ed6b802" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_860d8b84-c6dd-4093-9e0b-081b6800b585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_860d8b84-c6dd-4093-9e0b-081b6800b585" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f5208e29-6fcf-4a31-b2c6-71dcae516bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f5208e29-6fcf-4a31-b2c6-71dcae516bb6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_254b1231-218b-4024-999f-c295815065e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_254b1231-218b-4024-999f-c295815065e9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_1efb086c-32b4-4856-bac6-0b7850395fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_1efb086c-32b4-4856-bac6-0b7850395fc1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02729f75-00b8-44b8-b2d5-272e831ef64d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_NetIncomeLoss_02729f75-00b8-44b8-b2d5-272e831ef64d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1048c9d8-09d6-4b40-bb86-ee2b4c656082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_95a66480-b225-423f-932d-203c077624da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0201a8fc-abb5-4bc4-834d-adb2d2b249bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5fce354a-8fe9-48b3-8091-5d64b69520db" xlink:to="loc_us-gaap_StatementTable_0201a8fc-abb5-4bc4-834d-adb2d2b249bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9067a78b-a0b7-4904-a0ca-61b3e2ea1d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0201a8fc-abb5-4bc4-834d-adb2d2b249bf" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9067a78b-a0b7-4904-a0ca-61b3e2ea1d21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_9067a78b-a0b7-4904-a0ca-61b3e2ea1d21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9067a78b-a0b7-4904-a0ca-61b3e2ea1d21" xlink:to="loc_us-gaap_TypeOfAdoptionMember_9067a78b-a0b7-4904-a0ca-61b3e2ea1d21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d56feaed-c3cd-402a-a373-f32194923127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9067a78b-a0b7-4904-a0ca-61b3e2ea1d21" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d56feaed-c3cd-402a-a373-f32194923127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_3b6bd22b-d5b2-4d0f-bf79-7b1a64bd2790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d56feaed-c3cd-402a-a373-f32194923127" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_3b6bd22b-d5b2-4d0f-bf79-7b1a64bd2790" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_e9e575c2-3fbf-40a0-9bb7-d6d3635e4157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d56feaed-c3cd-402a-a373-f32194923127" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_e9e575c2-3fbf-40a0-9bb7-d6d3635e4157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1c33bafa-a8d7-4ab4-8ed2-470a161a91ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0201a8fc-abb5-4bc4-834d-adb2d2b249bf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1c33bafa-a8d7-4ab4-8ed2-470a161a91ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1c33bafa-a8d7-4ab4-8ed2-470a161a91ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1c33bafa-a8d7-4ab4-8ed2-470a161a91ea" xlink:to="loc_us-gaap_EquityComponentDomain_1c33bafa-a8d7-4ab4-8ed2-470a161a91ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1c33bafa-a8d7-4ab4-8ed2-470a161a91ea" xlink:to="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_529c2026-5eac-475b-ac2b-ca1721c03c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:to="loc_us-gaap_CommonStockMember_529c2026-5eac-475b-ac2b-ca1721c03c2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9deb2186-15e8-4c80-925e-2ce2694177a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9deb2186-15e8-4c80-925e-2ce2694177a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9e65fa63-1723-4f5f-a3e6-a12470e0c375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9e65fa63-1723-4f5f-a3e6-a12470e0c375" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c065ff6a-de93-4ea7-a9b0-0c6adf0cc512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:to="loc_us-gaap_RetainedEarningsMember_c065ff6a-de93-4ea7-a9b0-0c6adf0cc512" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_55e56120-52af-4dce-9b71-9563a3f7faec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0201a8fc-abb5-4bc4-834d-adb2d2b249bf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_55e56120-52af-4dce-9b71-9563a3f7faec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_55e56120-52af-4dce-9b71-9563a3f7faec_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_55e56120-52af-4dce-9b71-9563a3f7faec" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_55e56120-52af-4dce-9b71-9563a3f7faec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e621ed89-3a81-4789-905d-3a4004a39276" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_55e56120-52af-4dce-9b71-9563a3f7faec" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e621ed89-3a81-4789-905d-3a4004a39276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4449e196-9a01-4fe9-bbde-f75f7a96265f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e621ed89-3a81-4789-905d-3a4004a39276" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4449e196-9a01-4fe9-bbde-f75f7a96265f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" xlink:type="extended" id="i4f4f936ac26c440ea27961e62085f35e_SummaryofSignificantAccountingPoliciesSignificantCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_819db370-6f1c-4443-a3e9-4bce87ca44fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b33d151d-abe3-4b46-a3bf-c468ce6c7fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_819db370-6f1c-4443-a3e9-4bce87ca44fd" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b33d151d-abe3-4b46-a3bf-c468ce6c7fdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_5b66d64b-bd56-4d72-b5a4-9bffffb11952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_819db370-6f1c-4443-a3e9-4bce87ca44fd" xlink:to="loc_us-gaap_ConcentrationRiskTable_5b66d64b-bd56-4d72-b5a4-9bffffb11952" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51e05488-6e5f-439b-a7ff-1c48bce09208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b66d64b-bd56-4d72-b5a4-9bffffb11952" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51e05488-6e5f-439b-a7ff-1c48bce09208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_51e05488-6e5f-439b-a7ff-1c48bce09208_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51e05488-6e5f-439b-a7ff-1c48bce09208" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_51e05488-6e5f-439b-a7ff-1c48bce09208_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_577eae75-48a4-4190-afd2-eb075764b339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51e05488-6e5f-439b-a7ff-1c48bce09208" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_577eae75-48a4-4190-afd2-eb075764b339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_0cf71246-df10-4158-8342-df6bc2d6e62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_577eae75-48a4-4190-afd2-eb075764b339" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_0cf71246-df10-4158-8342-df6bc2d6e62c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_ab067bc5-445f-421c-91ba-7d6a5b11ed4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_577eae75-48a4-4190-afd2-eb075764b339" xlink:to="loc_us-gaap_AccountsReceivableMember_ab067bc5-445f-421c-91ba-7d6a5b11ed4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_232aba4d-6d82-4a34-9afe-f8d85b554a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b66d64b-bd56-4d72-b5a4-9bffffb11952" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_232aba4d-6d82-4a34-9afe-f8d85b554a30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_232aba4d-6d82-4a34-9afe-f8d85b554a30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_232aba4d-6d82-4a34-9afe-f8d85b554a30" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_232aba4d-6d82-4a34-9afe-f8d85b554a30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_23c163e7-a590-4e93-bd13-0fc1cb757c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_232aba4d-6d82-4a34-9afe-f8d85b554a30" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_23c163e7-a590-4e93-bd13-0fc1cb757c82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d683e289-9610-463b-aab0-cd397cfa3e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_23c163e7-a590-4e93-bd13-0fc1cb757c82" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d683e289-9610-463b-aab0-cd397cfa3e90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_66f3906a-bfbc-49da-ade0-79b16b99f16e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b66d64b-bd56-4d72-b5a4-9bffffb11952" xlink:to="loc_srt_MajorCustomersAxis_66f3906a-bfbc-49da-ade0-79b16b99f16e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_66f3906a-bfbc-49da-ade0-79b16b99f16e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_66f3906a-bfbc-49da-ade0-79b16b99f16e" xlink:to="loc_srt_NameOfMajorCustomerDomain_66f3906a-bfbc-49da-ade0-79b16b99f16e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_66f3906a-bfbc-49da-ade0-79b16b99f16e" xlink:to="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EuropeanCommissionMember_07dd01e6-d2b9-439e-b170-68605c30dade" xlink:href="mrna-20211231.xsd#mrna_EuropeanCommissionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_EuropeanCommissionMember_07dd01e6-d2b9-439e-b170-68605c30dade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_USGovermentMember_f9be0779-1f19-4238-b3ee-186aa909810a" xlink:href="mrna-20211231.xsd#mrna_USGovermentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_USGovermentMember_f9be0779-1f19-4238-b3ee-186aa909810a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_113f057e-16e6-44f2-a8ff-4626a79d866f" xlink:href="mrna-20211231.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_113f057e-16e6-44f2-a8ff-4626a79d866f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember_d1cc7d2f-cda6-483d-b1c3-a74c73d56bf9" xlink:href="mrna-20211231.xsd#mrna_MerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_MerckMember_d1cc7d2f-cda6-483d-b1c3-a74c73d56bf9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember_fd4fd56e-0138-42a0-9793-ab0fe33f4ad1" xlink:href="mrna-20211231.xsd#mrna_VertexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_VertexMember_fd4fd56e-0138-42a0-9793-ab0fe33f4ad1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_UnitedKingdomGovernmentMember_35de01b0-92f7-4119-b3b5-80872a2a89a6" xlink:href="mrna-20211231.xsd#mrna_UnitedKingdomGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_UnitedKingdomGovernmentMember_35de01b0-92f7-4119-b3b5-80872a2a89a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SouthKoreaGovernmentMember_62231d59-78ad-4a4d-b094-3535e3c34562" xlink:href="mrna-20211231.xsd#mrna_SouthKoreaGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_SouthKoreaGovernmentMember_62231d59-78ad-4a4d-b094-3535e3c34562" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" xlink:type="extended" id="i7fb4b60043c044d4b3211c4f79e84f34_SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fcc97e5a-1783-41a0-b858-fa7ea575b718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1bbeca0f-100c-453f-9d66-fe911e5178ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fcc97e5a-1783-41a0-b858-fa7ea575b718" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1bbeca0f-100c-453f-9d66-fe911e5178ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dc043217-f4d5-4503-99d6-2571f4f44b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fcc97e5a-1783-41a0-b858-fa7ea575b718" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dc043217-f4d5-4503-99d6-2571f4f44b08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_11dbca67-ec70-4dca-a808-71f9f34f0b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dc043217-f4d5-4503-99d6-2571f4f44b08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_11dbca67-ec70-4dca-a808-71f9f34f0b80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11dbca67-ec70-4dca-a808-71f9f34f0b80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_11dbca67-ec70-4dca-a808-71f9f34f0b80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_11dbca67-ec70-4dca-a808-71f9f34f0b80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_11dbca67-ec70-4dca-a808-71f9f34f0b80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_6d58cd58-1d08-4869-900c-e46da5f6d8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:to="loc_us-gaap_EquipmentMember_6d58cd58-1d08-4869-900c-e46da5f6d8a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2fc88f5a-a082-441c-97a6-ceb1618bd01e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:to="loc_us-gaap_ComputerEquipmentMember_2fc88f5a-a082-441c-97a6-ceb1618bd01e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_daab7892-9c1f-485f-a929-83af7936fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_daab7892-9c1f-485f-a929-83af7936fe36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_fc494f7f-e42e-4d34-a349-77d28c9db97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_fc494f7f-e42e-4d34-a349-77d28c9db97e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i54c622d617e5485c9c7b5bcede9a5f87_SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b891b59-07ea-415d-841e-a5456196dea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_dd946711-8a82-4236-99bd-189d3522b4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b891b59-07ea-415d-841e-a5456196dea4" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_dd946711-8a82-4236-99bd-189d3522b4be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4065d625-24ad-40b4-85d6-3a6186b81011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_dd946711-8a82-4236-99bd-189d3522b4be" xlink:to="loc_us-gaap_StockholdersEquity_4065d625-24ad-40b4-85d6-3a6186b81011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7ea6d148-b3f2-487b-8bdf-6b56f6bfc8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_dd946711-8a82-4236-99bd-189d3522b4be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7ea6d148-b3f2-487b-8bdf-6b56f6bfc8f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36dbb484-91af-4351-8aeb-e8895e544acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_743aa181-e4bd-4937-8fe9-a7e3a2f0f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b891b59-07ea-415d-841e-a5456196dea4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_743aa181-e4bd-4937-8fe9-a7e3a2f0f5e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0412c722-a9c7-4a39-b16c-63be0f462dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_743aa181-e4bd-4937-8fe9-a7e3a2f0f5e7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0412c722-a9c7-4a39-b16c-63be0f462dda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0412c722-a9c7-4a39-b16c-63be0f462dda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0412c722-a9c7-4a39-b16c-63be0f462dda" xlink:to="loc_us-gaap_EquityComponentDomain_0412c722-a9c7-4a39-b16c-63be0f462dda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2b19d3f1-9737-4b96-8d86-2ceb76da8a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0412c722-a9c7-4a39-b16c-63be0f462dda" xlink:to="loc_us-gaap_EquityComponentDomain_2b19d3f1-9737-4b96-8d86-2ceb76da8a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_64516165-b728-40cf-b9fe-464f1eeb5512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2b19d3f1-9737-4b96-8d86-2ceb76da8a39" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_64516165-b728-40cf-b9fe-464f1eeb5512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2098337b-cd9d-47b9-bb5f-a7c503eab465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2b19d3f1-9737-4b96-8d86-2ceb76da8a39" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2098337b-cd9d-47b9-bb5f-a7c503eab465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_863bc009-774d-49bf-bcbe-fc4e0f086f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2b19d3f1-9737-4b96-8d86-2ceb76da8a39" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_863bc009-774d-49bf-bcbe-fc4e0f086f36" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#ProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="extended" id="if15922acc1fc43839931e192038148ae_ProductSalesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_670f0cc8-57cd-4536-b11c-b922e4b030f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e0dd09f8-0843-4fa6-ad46-5de689859bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_670f0cc8-57cd-4536-b11c-b922e4b030f3" xlink:to="loc_us-gaap_Revenues_e0dd09f8-0843-4fa6-ad46-5de689859bb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8201b1d5-28d2-4df7-82d9-d919c8b8359b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_670f0cc8-57cd-4536-b11c-b922e4b030f3" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8201b1d5-28d2-4df7-82d9-d919c8b8359b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_505ebf76-7a53-4b9a-8895-f9d828358927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_670f0cc8-57cd-4536-b11c-b922e4b030f3" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_505ebf76-7a53-4b9a-8895-f9d828358927" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d3a1b16c-ef4f-43b0-a70b-cd9c15faea05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_670f0cc8-57cd-4536-b11c-b922e4b030f3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d3a1b16c-ef4f-43b0-a70b-cd9c15faea05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b3feac25-842c-410f-8e67-89b6fe1419d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d3a1b16c-ef4f-43b0-a70b-cd9c15faea05" xlink:to="loc_srt_StatementGeographicalAxis_b3feac25-842c-410f-8e67-89b6fe1419d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b3feac25-842c-410f-8e67-89b6fe1419d3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b3feac25-842c-410f-8e67-89b6fe1419d3" xlink:to="loc_srt_SegmentGeographicalDomain_b3feac25-842c-410f-8e67-89b6fe1419d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_650f6661-49c9-4ba9-94d9-0ba77a2b0400" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b3feac25-842c-410f-8e67-89b6fe1419d3" xlink:to="loc_srt_SegmentGeographicalDomain_650f6661-49c9-4ba9-94d9-0ba77a2b0400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fe6c9bf4-89ba-4ee8-b733-f82d9a1d5e5a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_650f6661-49c9-4ba9-94d9-0ba77a2b0400" xlink:to="loc_country_US_fe6c9bf4-89ba-4ee8-b733-f82d9a1d5e5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_02f70271-da50-45a9-ae60-439a71007e05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_650f6661-49c9-4ba9-94d9-0ba77a2b0400" xlink:to="loc_srt_EuropeMember_02f70271-da50-45a9-ae60-439a71007e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestOfWorldMember_a386c3c7-32c2-4bac-a43b-5ffedcc87877" xlink:href="mrna-20211231.xsd#mrna_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_650f6661-49c9-4ba9-94d9-0ba77a2b0400" xlink:to="loc_mrna_RestOfWorldMember_a386c3c7-32c2-4bac-a43b-5ffedcc87877" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ccd152eb-85b7-448e-9766-4a0d1cb1edc3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d3a1b16c-ef4f-43b0-a70b-cd9c15faea05" xlink:to="loc_srt_ProductOrServiceAxis_ccd152eb-85b7-448e-9766-4a0d1cb1edc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ccd152eb-85b7-448e-9766-4a0d1cb1edc3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ccd152eb-85b7-448e-9766-4a0d1cb1edc3" xlink:to="loc_srt_ProductsAndServicesDomain_ccd152eb-85b7-448e-9766-4a0d1cb1edc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_91d1d5a8-aada-457a-b02d-1bf5c476fef6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ccd152eb-85b7-448e-9766-4a0d1cb1edc3" xlink:to="loc_srt_ProductsAndServicesDomain_91d1d5a8-aada-457a-b02d-1bf5c476fef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_1ee34577-1506-4983-aa90-bca765a84318" xlink:href="mrna-20211231.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_91d1d5a8-aada-457a-b02d-1bf5c476fef6" xlink:to="loc_mrna_ProductSalesMember_1ee34577-1506-4983-aa90-bca765a84318" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#GrantRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="extended" id="i36ec6bd8c44146d5907d560a54ca474a_GrantRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_250fb4fa-c5f2-4a74-bd42-2131556b846a" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_250fb4fa-c5f2-4a74-bd42-2131556b846a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_422631aa-f1d1-4699-bd04-49ed88de8124" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_422631aa-f1d1-4699-bd04-49ed88de8124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_08bbc286-919b-47be-88d3-45dc249dda85" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_08bbc286-919b-47be-88d3-45dc249dda85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_4530399d-01be-4fc3-b494-f90ae3a34c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_us-gaap_OtherCommitment_4530399d-01be-4fc3-b494-f90ae3a34c6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfParticipants_47a64962-1f3f-4ea6-afb0-54f617893b21" xlink:href="mrna-20211231.xsd#mrna_NumberOfParticipants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_NumberOfParticipants_47a64962-1f3f-4ea6-afb0-54f617893b21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsPotentialReimbursement_8094dad6-74d9-4e86-97c1-66b2c75fc1fa" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsPotentialReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsPotentialReimbursement_8094dad6-74d9-4e86-97c1-66b2c75fc1fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions_84958aa3-9c5e-4486-87d5-5fc4a4b825ff" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsNumberOfContractOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptions_84958aa3-9c5e-4486-87d5-5fc4a4b825ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_f34d84da-87e8-4e2d-83e8-2b3d3f9c8444" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_f34d84da-87e8-4e2d-83e8-2b3d3f9c8444" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9b36f2b1-2039-4b67-b321-3c2d08787e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9b36f2b1-2039-4b67-b321-3c2d08787e9f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1e56bbe5-36b4-45ea-836a-b668d8062675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_us-gaap_Revenues_1e56bbe5-36b4-45ea-836a-b668d8062675" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_39dbf5ca-1574-453c-a628-94971f9c59fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_39dbf5ca-1574-453c-a628-94971f9c59fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_91774a23-bfdb-48b4-9fa5-484c66e6a1ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_39dbf5ca-1574-453c-a628-94971f9c59fd" xlink:to="loc_srt_MajorCustomersAxis_91774a23-bfdb-48b4-9fa5-484c66e6a1ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_91774a23-bfdb-48b4-9fa5-484c66e6a1ab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_91774a23-bfdb-48b4-9fa5-484c66e6a1ab" xlink:to="loc_srt_NameOfMajorCustomerDomain_91774a23-bfdb-48b4-9fa5-484c66e6a1ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_91774a23-bfdb-48b4-9fa5-484c66e6a1ab" xlink:to="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_1f780995-cd01-40d6-bef9-aa6292ce334b" xlink:href="mrna-20211231.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:to="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_1f780995-cd01-40d6-bef9-aa6292ce334b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_69db89ef-2880-4112-b4ee-8984fb8ab7ad" xlink:href="mrna-20211231.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_69db89ef-2880-4112-b4ee-8984fb8ab7ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember_6c968725-3330-454e-ad84-8ef8c9a9d654" xlink:href="mrna-20211231.xsd#mrna_TheBillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:to="loc_mrna_TheBillAndMelindaGatesFoundationMember_6c968725-3330-454e-ad84-8ef8c9a9d654" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember_9138e562-f3a7-43a8-a0ab-bc930b09e570" xlink:href="mrna-20211231.xsd#mrna_OtherGrantRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:to="loc_mrna_OtherGrantRevenueMember_9138e562-f3a7-43a8-a0ab-bc930b09e570" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_27519a3e-1864-4891-b655-e0924386da98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_39dbf5ca-1574-453c-a628-94971f9c59fd" xlink:to="loc_srt_ProductOrServiceAxis_27519a3e-1864-4891-b655-e0924386da98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_27519a3e-1864-4891-b655-e0924386da98_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_27519a3e-1864-4891-b655-e0924386da98" xlink:to="loc_srt_ProductsAndServicesDomain_27519a3e-1864-4891-b655-e0924386da98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_65bf4b46-3050-4966-830d-f855d4ab1105" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_27519a3e-1864-4891-b655-e0924386da98" xlink:to="loc_srt_ProductsAndServicesDomain_65bf4b46-3050-4966-830d-f855d4ab1105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_1ec3f065-4c02-4b8f-8f0e-af4564271b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_65bf4b46-3050-4966-830d-f855d4ab1105" xlink:to="loc_us-gaap_GrantMember_1ec3f065-4c02-4b8f-8f0e-af4564271b6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1e06cd5c-ad15-42f9-a9e4-6ea2077aadb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_39dbf5ca-1574-453c-a628-94971f9c59fd" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1e06cd5c-ad15-42f9-a9e4-6ea2077aadb8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_1e06cd5c-ad15-42f9-a9e4-6ea2077aadb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1e06cd5c-ad15-42f9-a9e4-6ea2077aadb8" xlink:to="loc_us-gaap_ProjectMember_1e06cd5c-ad15-42f9-a9e4-6ea2077aadb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_edd28d1d-00a4-4c00-aecd-8a041bd54cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1e06cd5c-ad15-42f9-a9e4-6ea2077aadb8" xlink:to="loc_us-gaap_ProjectMember_edd28d1d-00a4-4c00-aecd-8a041bd54cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractOptionsMember_ee182d28-804f-40b5-adbd-752416be9081" xlink:href="mrna-20211231.xsd#mrna_ContractOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_edd28d1d-00a4-4c00-aecd-8a041bd54cf1" xlink:to="loc_mrna_ContractOptionsMember_ee182d28-804f-40b5-adbd-752416be9081" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialProjectMember_434b03b3-9050-4fe4-9382-b4c55182d4b2" xlink:href="mrna-20211231.xsd#mrna_InitialProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_edd28d1d-00a4-4c00-aecd-8a041bd54cf1" xlink:to="loc_mrna_InitialProjectMember_434b03b3-9050-4fe4-9382-b4c55182d4b2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails" xlink:type="extended" id="i326cf3aaed3242c984f31e54935412c5_CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d9bfecdd-2a62-4928-a265-6b57a7f02764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_a2a47a64-e9a2-4dc6-b09b-b155e1e11aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d9bfecdd-2a62-4928-a265-6b57a7f02764" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_a2a47a64-e9a2-4dc6-b09b-b155e1e11aac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_dab9eb94-49b1-4c4d-9527-488890b9b013" xlink:href="mrna-20211231.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d9bfecdd-2a62-4928-a265-6b57a7f02764" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_dab9eb94-49b1-4c4d-9527-488890b9b013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_007f6dc5-07f4-451a-a8ff-45d20cf918a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d9bfecdd-2a62-4928-a265-6b57a7f02764" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_007f6dc5-07f4-451a-a8ff-45d20cf918a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2e24fe97-0554-4632-9473-dac7b18de535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_007f6dc5-07f4-451a-a8ff-45d20cf918a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2e24fe97-0554-4632-9473-dac7b18de535" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2e24fe97-0554-4632-9473-dac7b18de535_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2e24fe97-0554-4632-9473-dac7b18de535" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2e24fe97-0554-4632-9473-dac7b18de535_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_644115cb-9e7d-4724-a9e0-7060f9ffd27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2e24fe97-0554-4632-9473-dac7b18de535" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_644115cb-9e7d-4724-a9e0-7060f9ffd27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_e5c23c0c-c0bc-4543-8548-4cac9cf8840e" xlink:href="mrna-20211231.xsd#mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_644115cb-9e7d-4724-a9e0-7060f9ffd27f" xlink:to="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_e5c23c0c-c0bc-4543-8548-4cac9cf8840e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6d837697-09a2-4494-a16c-30b5aab6f4da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_007f6dc5-07f4-451a-a8ff-45d20cf918a7" xlink:to="loc_srt_RangeAxis_6d837697-09a2-4494-a16c-30b5aab6f4da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6d837697-09a2-4494-a16c-30b5aab6f4da_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6d837697-09a2-4494-a16c-30b5aab6f4da" xlink:to="loc_srt_RangeMember_6d837697-09a2-4494-a16c-30b5aab6f4da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_264da607-4632-47a5-a774-44f26614835c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6d837697-09a2-4494-a16c-30b5aab6f4da" xlink:to="loc_srt_RangeMember_264da607-4632-47a5-a774-44f26614835c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_32e5f69d-f33e-4747-b80b-4c14d5655123" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_264da607-4632-47a5-a774-44f26614835c" xlink:to="loc_srt_MaximumMember_32e5f69d-f33e-4747-b80b-4c14d5655123" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails" xlink:type="extended" id="ic4131dcc5b5e4f249aa057a28a5501d3_CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_93e57f4f-0762-40d8-bd3c-cdb9797c58be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_93e57f4f-0762-40d8-bd3c-cdb9797c58be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_6797d95e-1b78-4b52-b8e9-c97707434edb" xlink:href="mrna-20211231.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_6797d95e-1b78-4b52-b8e9-c97707434edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b98b1303-ffcc-46bd-a49d-377fe6f926dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b98b1303-ffcc-46bd-a49d-377fe6f926dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium_a5a65d4c-e926-4d19-bf63-7e9cdb4d8182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedemptionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:to="loc_us-gaap_RedemptionPremium_a5a65d4c-e926-4d19-bf63-7e9cdb4d8182" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7ed2bc3-0e52-43f8-8d21-0a875d852701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7ed2bc3-0e52-43f8-8d21-0a875d852701" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9e47678-75b2-4dff-a338-b7e5d520c34e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7ed2bc3-0e52-43f8-8d21-0a875d852701" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9e47678-75b2-4dff-a338-b7e5d520c34e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f9e47678-75b2-4dff-a338-b7e5d520c34e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9e47678-75b2-4dff-a338-b7e5d520c34e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f9e47678-75b2-4dff-a338-b7e5d520c34e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_60ac7263-9141-4eef-a588-3f9f1bc8e554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9e47678-75b2-4dff-a338-b7e5d520c34e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_60ac7263-9141-4eef-a588-3f9f1bc8e554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_7f459b90-9128-423e-9b19-38ccb7446b00" xlink:href="mrna-20211231.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_60ac7263-9141-4eef-a588-3f9f1bc8e554" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_7f459b90-9128-423e-9b19-38ccb7446b00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1b21324b-4e4e-493d-b1d2-e03c2c8df5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7ed2bc3-0e52-43f8-8d21-0a875d852701" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1b21324b-4e4e-493d-b1d2-e03c2c8df5a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_1b21324b-4e4e-493d-b1d2-e03c2c8df5a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1b21324b-4e4e-493d-b1d2-e03c2c8df5a5" xlink:to="loc_us-gaap_ProjectMember_1b21324b-4e4e-493d-b1d2-e03c2c8df5a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_57e4ea2d-e8ac-4304-81e5-2c88a71d48a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1b21324b-4e4e-493d-b1d2-e03c2c8df5a5" xlink:to="loc_us-gaap_ProjectMember_57e4ea2d-e8ac-4304-81e5-2c88a71d48a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_5eb7b674-f06c-4270-94b4-7b0e4c7844ad" xlink:href="mrna-20211231.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_57e4ea2d-e8ac-4304-81e5-2c88a71d48a0" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_5eb7b674-f06c-4270-94b4-7b0e4c7844ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2adecc59-33de-43a1-8385-a14f78939217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7ed2bc3-0e52-43f8-8d21-0a875d852701" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2adecc59-33de-43a1-8385-a14f78939217" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2adecc59-33de-43a1-8385-a14f78939217_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2adecc59-33de-43a1-8385-a14f78939217" xlink:to="loc_us-gaap_ClassOfStockDomain_2adecc59-33de-43a1-8385-a14f78939217_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_45fb4d69-9d7c-4eab-853a-3d574da349a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2adecc59-33de-43a1-8385-a14f78939217" xlink:to="loc_us-gaap_ClassOfStockDomain_45fb4d69-9d7c-4eab-853a-3d574da349a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_046ce26c-2663-497d-98e7-2cd3bd69fd16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45fb4d69-9d7c-4eab-853a-3d574da349a9" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_046ce26c-2663-497d-98e7-2cd3bd69fd16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails" xlink:type="extended" id="i6fda07348935430db73baa21a8d4a749_CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4bcb1ae4-53f1-45de-8d33-15236896915b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_f37b86fd-2efb-4227-87cd-eab0371f1eba" xlink:href="mrna-20211231.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4bcb1ae4-53f1-45de-8d33-15236896915b" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_f37b86fd-2efb-4227-87cd-eab0371f1eba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_648adfca-768a-4d26-bac3-5846a316869e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4bcb1ae4-53f1-45de-8d33-15236896915b" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_648adfca-768a-4d26-bac3-5846a316869e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_184e7369-9e73-4b0c-bcbd-9aa4fa3bbe59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_648adfca-768a-4d26-bac3-5846a316869e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_184e7369-9e73-4b0c-bcbd-9aa4fa3bbe59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_184e7369-9e73-4b0c-bcbd-9aa4fa3bbe59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_184e7369-9e73-4b0c-bcbd-9aa4fa3bbe59" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_184e7369-9e73-4b0c-bcbd-9aa4fa3bbe59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_751a948d-7d27-498e-bab5-264d06b2c8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_184e7369-9e73-4b0c-bcbd-9aa4fa3bbe59" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_751a948d-7d27-498e-bab5-264d06b2c8cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MRNAVertex2020AgreementMemberMember_91c91a9a-f350-49ff-9f4c-92719f6be525" xlink:href="mrna-20211231.xsd#mrna_MRNAVertex2020AgreementMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_751a948d-7d27-498e-bab5-264d06b2c8cc" xlink:to="loc_mrna_MRNAVertex2020AgreementMemberMember_91c91a9a-f350-49ff-9f4c-92719f6be525" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="extended" id="i0ea5050639154a31ae40ce128e0e928e_CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ec90293a-c3f0-4ad6-a8d3-6091fea30204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4f7767d4-6e4c-4af5-bea2-d9c3ec76af7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ec90293a-c3f0-4ad6-a8d3-6091fea30204" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4f7767d4-6e4c-4af5-bea2-d9c3ec76af7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ead5754-d3da-41ab-90e7-ce9f4254f89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ec90293a-c3f0-4ad6-a8d3-6091fea30204" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ead5754-d3da-41ab-90e7-ce9f4254f89c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a5c0e4e9-dbbd-4683-9ed5-cd36790d2403" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ead5754-d3da-41ab-90e7-ce9f4254f89c" xlink:to="loc_srt_ProductOrServiceAxis_a5c0e4e9-dbbd-4683-9ed5-cd36790d2403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5c0e4e9-dbbd-4683-9ed5-cd36790d2403_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a5c0e4e9-dbbd-4683-9ed5-cd36790d2403" xlink:to="loc_srt_ProductsAndServicesDomain_a5c0e4e9-dbbd-4683-9ed5-cd36790d2403_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a63a8617-9ac7-4252-a326-3107eb7722bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a5c0e4e9-dbbd-4683-9ed5-cd36790d2403" xlink:to="loc_srt_ProductsAndServicesDomain_a63a8617-9ac7-4252-a326-3107eb7722bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_d839aa7f-dd2e-49d0-a351-ad54d1cfd905" xlink:href="mrna-20211231.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a63a8617-9ac7-4252-a326-3107eb7722bb" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_d839aa7f-dd2e-49d0-a351-ad54d1cfd905" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3f1a52a5-58b5-4b9c-9033-e970c6923eaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ead5754-d3da-41ab-90e7-ce9f4254f89c" xlink:to="loc_srt_CounterpartyNameAxis_3f1a52a5-58b5-4b9c-9033-e970c6923eaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f1a52a5-58b5-4b9c-9033-e970c6923eaf_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3f1a52a5-58b5-4b9c-9033-e970c6923eaf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f1a52a5-58b5-4b9c-9033-e970c6923eaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3f1a52a5-58b5-4b9c-9033-e970c6923eaf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AstraZenecaMember_af558894-7a04-486b-902a-32abdf00ee39" xlink:href="mrna-20211231.xsd#mrna_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:to="loc_mrna_AstraZenecaMember_af558894-7a04-486b-902a-32abdf00ee39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember_4e8d354a-7ab2-402d-be11-7048e9541d84" xlink:href="mrna-20211231.xsd#mrna_MerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:to="loc_mrna_MerckMember_4e8d354a-7ab2-402d-be11-7048e9541d84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember_5ab188b2-63b2-4d06-aa91-eddbdabad06d" xlink:href="mrna-20211231.xsd#mrna_VertexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:to="loc_mrna_VertexMember_5ab188b2-63b2-4d06-aa91-eddbdabad06d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherMember_a978cb0c-8249-4ca0-9faf-cd04d73f0264" xlink:href="mrna-20211231.xsd#mrna_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:to="loc_mrna_OtherMember_a978cb0c-8249-4ca0-9faf-cd04d73f0264" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="extended" id="i56aa3740e1234299b9f4ceaee638b1e4_CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ef3b523-2532-47df-9509-1d5fa2f5b2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerAssetRollForward_e3aa41ef-e4c0-4db8-bcd4-b20e7d2d2aad" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractwithCustomerAssetRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ef3b523-2532-47df-9509-1d5fa2f5b2bb" xlink:to="loc_mrna_ChangeInContractwithCustomerAssetRollForward_e3aa41ef-e4c0-4db8-bcd4-b20e7d2d2aad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_df2dc30e-8bb3-45a7-a1be-1617259993ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_e3aa41ef-e4c0-4db8-bcd4-b20e7d2d2aad" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_df2dc30e-8bb3-45a7-a1be-1617259993ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetPurchase_9b4b1480-d1c1-4e5c-930f-f89dc96f21c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_e3aa41ef-e4c0-4db8-bcd4-b20e7d2d2aad" xlink:to="loc_us-gaap_ContractWithCustomerAssetPurchase_9b4b1480-d1c1-4e5c-930f-f89dc96f21c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_0745939c-5856-48dd-a47c-dbe97ad110b4" xlink:href="mrna-20211231.xsd#mrna_ContractWithCustomerAssetDeductionsDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_e3aa41ef-e4c0-4db8-bcd4-b20e7d2d2aad" xlink:to="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_0745939c-5856-48dd-a47c-dbe97ad110b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_a5b2f4a9-d22d-4807-8949-498264c00b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_af1e2e64-eeb5-48b9-9383-20d850eccfec" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ef3b523-2532-47df-9509-1d5fa2f5b2bb" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_af1e2e64-eeb5-48b9-9383-20d850eccfec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e3efe91b-193c-48f4-a767-502609e78349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_af1e2e64-eeb5-48b9-9383-20d850eccfec" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e3efe91b-193c-48f4-a767-502609e78349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_516715c2-4d64-4e1c-a569-f00f8582edfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_af1e2e64-eeb5-48b9-9383-20d850eccfec" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_516715c2-4d64-4e1c-a569-f00f8582edfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_27e30a9e-0aa6-4b81-8e7d-e35ff2fd0b2f" xlink:href="mrna-20211231.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_af1e2e64-eeb5-48b9-9383-20d850eccfec" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_27e30a9e-0aa6-4b81-8e7d-e35ff2fd0b2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_532c4d72-af55-496c-bd47-376149ea05e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_0a0307ac-076a-4fb0-ab49-29e778be7dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ef3b523-2532-47df-9509-1d5fa2f5b2bb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_0a0307ac-076a-4fb0-ab49-29e778be7dfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8428760c-c9b8-4b39-a633-07b788a49166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ef3b523-2532-47df-9509-1d5fa2f5b2bb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8428760c-c9b8-4b39-a633-07b788a49166" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d942ae0e-d4e5-403b-b17a-e45f19c22a7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8428760c-c9b8-4b39-a633-07b788a49166" xlink:to="loc_srt_ProductOrServiceAxis_d942ae0e-d4e5-403b-b17a-e45f19c22a7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d942ae0e-d4e5-403b-b17a-e45f19c22a7d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d942ae0e-d4e5-403b-b17a-e45f19c22a7d" xlink:to="loc_srt_ProductsAndServicesDomain_d942ae0e-d4e5-403b-b17a-e45f19c22a7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1942340-9f44-43b5-8904-e568a8ec6060" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d942ae0e-d4e5-403b-b17a-e45f19c22a7d" xlink:to="loc_srt_ProductsAndServicesDomain_c1942340-9f44-43b5-8904-e568a8ec6060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_7000c1a7-66f9-4202-8ff3-8ce99aaaa639" xlink:href="mrna-20211231.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c1942340-9f44-43b5-8904-e568a8ec6060" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_7000c1a7-66f9-4202-8ff3-8ce99aaaa639" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended" id="i6d69ced661664a7aafa68bea4f232a17_FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cebb46c7-dd15-4968-8533-ad9ebe3ab781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cebb46c7-dd15-4968-8533-ad9ebe3ab781" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fac91de9-dad5-4c3d-95e3-b27d62a832d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fac91de9-dad5-4c3d-95e3-b27d62a832d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_63374c72-e669-47fc-aa54-fcce8624173c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_63374c72-e669-47fc-aa54-fcce8624173c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c83653a2-d375-4be1-badd-c5cb118604ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c83653a2-d375-4be1-badd-c5cb118604ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a0f6c7d-bb6f-441e-86ab-1510aba9ddf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a0f6c7d-bb6f-441e-86ab-1510aba9ddf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c30e3b5e-8e05-41c0-872c-76feb0b181b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a0f6c7d-bb6f-441e-86ab-1510aba9ddf4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c30e3b5e-8e05-41c0-872c-76feb0b181b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c30e3b5e-8e05-41c0-872c-76feb0b181b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c30e3b5e-8e05-41c0-872c-76feb0b181b8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c30e3b5e-8e05-41c0-872c-76feb0b181b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c30e3b5e-8e05-41c0-872c-76feb0b181b8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_f0b3795c-f9ac-4935-bc2a-c74cc930c19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_f0b3795c-f9ac-4935-bc2a-c74cc930c19f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4b37e476-4b81-42f2-81c6-8314f42dcb90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4b37e476-4b81-42f2-81c6-8314f42dcb90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_97dd825a-c8d6-4e1d-8052-c63392f0741f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_97dd825a-c8d6-4e1d-8052-c63392f0741f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_db48388f-21ca-486e-8cfb-3d20df348b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_db48388f-21ca-486e-8cfb-3d20df348b51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0d840cd6-fbe3-49a2-ae8b-c1c3156c43bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0d840cd6-fbe3-49a2-ae8b-c1c3156c43bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_013ce546-3b86-44a6-a636-b60d743033c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_013ce546-3b86-44a6-a636-b60d743033c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_90c68bd9-96e4-45b1-a811-f5212e82dea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a0f6c7d-bb6f-441e-86ab-1510aba9ddf4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_90c68bd9-96e4-45b1-a811-f5212e82dea0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90c68bd9-96e4-45b1-a811-f5212e82dea0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_90c68bd9-96e4-45b1-a811-f5212e82dea0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_90c68bd9-96e4-45b1-a811-f5212e82dea0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf4f1d30-517c-4015-bf09-bca12109f60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_90c68bd9-96e4-45b1-a811-f5212e82dea0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf4f1d30-517c-4015-bf09-bca12109f60a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3109c22f-4825-46c4-a54c-7fcef8ec5651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf4f1d30-517c-4015-bf09-bca12109f60a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3109c22f-4825-46c4-a54c-7fcef8ec5651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4311ff6c-562c-4abe-9844-2616e15b3989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf4f1d30-517c-4015-bf09-bca12109f60a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4311ff6c-562c-4abe-9844-2616e15b3989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_95e3dbac-ca00-4330-9d9a-76db4e4d194f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a0f6c7d-bb6f-441e-86ab-1510aba9ddf4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_95e3dbac-ca00-4330-9d9a-76db4e4d194f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_95e3dbac-ca00-4330-9d9a-76db4e4d194f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_95e3dbac-ca00-4330-9d9a-76db4e4d194f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_95e3dbac-ca00-4330-9d9a-76db4e4d194f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_44629e50-a178-4c8d-8037-dcbde8c287c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_95e3dbac-ca00-4330-9d9a-76db4e4d194f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_44629e50-a178-4c8d-8037-dcbde8c287c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_cc4c3727-5eb0-4129-8c21-f1944cd26917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_44629e50-a178-4c8d-8037-dcbde8c287c7" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_cc4c3727-5eb0-4129-8c21-f1944cd26917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember_03646761-304f-4c59-9695-08d4ef88e31d" xlink:href="mrna-20211231.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_44629e50-a178-4c8d-8037-dcbde8c287c7" xlink:to="loc_mrna_CurrentMarketableSecuritiesMember_03646761-304f-4c59-9695-08d4ef88e31d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember_9cf4cdcb-d534-49cb-9500-d74d87be3eab" xlink:href="mrna-20211231.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_44629e50-a178-4c8d-8037-dcbde8c287c7" xlink:to="loc_mrna_NoncurrentMarketableSecuritiesMember_9cf4cdcb-d534-49cb-9500-d74d87be3eab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="extended" id="i19575c1e759442a0847b7c0eb8432b20_FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_6376caa4-d47e-446b-aa45-bec9d84f4d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_6376caa4-d47e-446b-aa45-bec9d84f4d64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f3ebb52-de47-430f-8dba-6d734827e8af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f3ebb52-de47-430f-8dba-6d734827e8af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2c3bc682-22cc-4ec4-b52f-36421360dd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2c3bc682-22cc-4ec4-b52f-36421360dd9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_5594a62f-3c95-4ddd-a5d3-8d79f8ff4b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_5594a62f-3c95-4ddd-a5d3-8d79f8ff4b76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_eef5281c-e6a0-4ea8-b86f-2c99977c83ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_eef5281c-e6a0-4ea8-b86f-2c99977c83ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b7ef61fd-9519-4bee-9d67-9769d2b63ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b7ef61fd-9519-4bee-9d67-9769d2b63ff5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bf7e0358-9d4b-44ba-ad5d-37d2c8080341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bf7e0358-9d4b-44ba-ad5d-37d2c8080341" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fec4b1d5-d749-4ad4-9779-fea10148f83f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bf7e0358-9d4b-44ba-ad5d-37d2c8080341" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fec4b1d5-d749-4ad4-9779-fea10148f83f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fec4b1d5-d749-4ad4-9779-fea10148f83f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fec4b1d5-d749-4ad4-9779-fea10148f83f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fec4b1d5-d749-4ad4-9779-fea10148f83f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fec4b1d5-d749-4ad4-9779-fea10148f83f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_748096bc-6099-4da0-b332-8df580ff4cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_748096bc-6099-4da0-b332-8df580ff4cd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_e9f46318-0d4f-4142-9c0c-55e571fac93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_e9f46318-0d4f-4142-9c0c-55e571fac93a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c8a512a9-29c0-43e7-aef4-21c5d767a469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c8a512a9-29c0-43e7-aef4-21c5d767a469" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_28406ae3-b29f-4345-bec3-632987d6714d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_28406ae3-b29f-4345-bec3-632987d6714d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended" id="if63827333da54d6389b47fc74e7456fb_FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f52306b-b0df-4d1f-bee0-68926de47646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f52306b-b0df-4d1f-bee0-68926de47646" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_64071bcf-e5b4-4b6d-b969-8123d7655d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:to="loc_us-gaap_DerivativeAssets_64071bcf-e5b4-4b6d-b969-8123d7655d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_45b93347-b4a5-4380-b9c6-80807836d0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_45b93347-b4a5-4380-b9c6-80807836d0c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0173ee2a-8598-4747-ae16-272658f5c55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:to="loc_us-gaap_DerivativeLiabilities_0173ee2a-8598-4747-ae16-272658f5c55e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7658c83e-03ac-4ebf-8e1c-550db44efcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7658c83e-03ac-4ebf-8e1c-550db44efcf0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca84e49c-3ed8-41bf-a71f-d5524069a9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7658c83e-03ac-4ebf-8e1c-550db44efcf0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca84e49c-3ed8-41bf-a71f-d5524069a9e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca84e49c-3ed8-41bf-a71f-d5524069a9e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca84e49c-3ed8-41bf-a71f-d5524069a9e2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca84e49c-3ed8-41bf-a71f-d5524069a9e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8fef49ce-09f3-4908-885e-9c18d1af0d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca84e49c-3ed8-41bf-a71f-d5524069a9e2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8fef49ce-09f3-4908-885e-9c18d1af0d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1cae0564-0caa-4c12-a783-5e3532903c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8fef49ce-09f3-4908-885e-9c18d1af0d2f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1cae0564-0caa-4c12-a783-5e3532903c9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_38cc3d2f-5bfc-4081-9c95-0c4ea03b9b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7658c83e-03ac-4ebf-8e1c-550db44efcf0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_38cc3d2f-5bfc-4081-9c95-0c4ea03b9b50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_38cc3d2f-5bfc-4081-9c95-0c4ea03b9b50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38cc3d2f-5bfc-4081-9c95-0c4ea03b9b50" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_38cc3d2f-5bfc-4081-9c95-0c4ea03b9b50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38cc3d2f-5bfc-4081-9c95-0c4ea03b9b50" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_29c26c62-669c-4a41-929a-2750eb8efe87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_MoneyMarketFundsMember_29c26c62-669c-4a41-929a-2750eb8efe87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7d01b6e2-27cf-4f78-a753-5123810a2448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7d01b6e2-27cf-4f78-a753-5123810a2448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_8676c2a3-87e1-43f9-a495-5b15f04a89f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_8676c2a3-87e1-43f9-a495-5b15f04a89f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_011d54d1-9688-4a96-a045-24e83b65797c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_011d54d1-9688-4a96-a045-24e83b65797c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_df3b0031-582e-43df-9c4a-29ec6dc5868d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_df3b0031-582e-43df-9c4a-29ec6dc5868d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_72b9b79e-036e-455a-b047-787cb9439927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_72b9b79e-036e-455a-b047-787cb9439927" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7bf18936-f470-41ee-b427-8ec699fe664e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7658c83e-03ac-4ebf-8e1c-550db44efcf0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7bf18936-f470-41ee-b427-8ec699fe664e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7bf18936-f470-41ee-b427-8ec699fe664e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7bf18936-f470-41ee-b427-8ec699fe664e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7bf18936-f470-41ee-b427-8ec699fe664e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ba9d157-57b8-42ac-99c6-472fbd2e9da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7bf18936-f470-41ee-b427-8ec699fe664e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ba9d157-57b8-42ac-99c6-472fbd2e9da3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6b22f351-1c1d-4dd8-a445-2c89a227f996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ba9d157-57b8-42ac-99c6-472fbd2e9da3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6b22f351-1c1d-4dd8-a445-2c89a227f996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_928c218c-4b27-459d-a4bc-77c74062f2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ba9d157-57b8-42ac-99c6-472fbd2e9da3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_928c218c-4b27-459d-a4bc-77c74062f2c5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="extended" id="ie6ae5651d6b04e23b8c70a23731d0e55_DerivativeFinancialInstrumentsBalanceSheetHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_df442d0c-9a45-4827-97cd-81b75ac2b532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_DerivativeNotionalAmount_df442d0c-9a45-4827-97cd-81b75ac2b532" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_d94cbb0b-94a4-4631-bcd4-d5727d0cb024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_DerivativeAssets_d94cbb0b-94a4-4631-bcd4-d5727d0cb024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d4d7c761-1c69-4dcd-bfd9-cdf1f706ee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_DerivativeLiabilities_d4d7c761-1c69-4dcd-bfd9-cdf1f706ee5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_4ce112a5-caae-4608-8913-b6485d110408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_4ce112a5-caae-4608-8913-b6485d110408" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_be3b2b54-7a06-4ee1-8dab-bfa8c21b3d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_be3b2b54-7a06-4ee1-8dab-bfa8c21b3d0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_1ebc7e6e-c6cd-4e69-8fd9-4bf1154c568e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_1ebc7e6e-c6cd-4e69-8fd9-4bf1154c568e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c210fba8-4345-43d4-ac32-adf326bd3fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c210fba8-4345-43d4-ac32-adf326bd3fcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c210fba8-4345-43d4-ac32-adf326bd3fcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c210fba8-4345-43d4-ac32-adf326bd3fcd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c210fba8-4345-43d4-ac32-adf326bd3fcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_50303d99-66bd-4a85-9995-ae69a31b18f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c210fba8-4345-43d4-ac32-adf326bd3fcd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_50303d99-66bd-4a85-9995-ae69a31b18f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_cc64dd65-b436-47f5-801b-b98188d6e5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_50303d99-66bd-4a85-9995-ae69a31b18f0" xlink:to="loc_us-gaap_ForeignExchangeContractMember_cc64dd65-b436-47f5-801b-b98188d6e5d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43d7dc6c-b40d-4463-b4b4-b56d7a6c8c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43d7dc6c-b40d-4463-b4b4-b56d7a6c8c93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_43d7dc6c-b40d-4463-b4b4-b56d7a6c8c93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43d7dc6c-b40d-4463-b4b4-b56d7a6c8c93" xlink:to="loc_us-gaap_HedgingRelationshipDomain_43d7dc6c-b40d-4463-b4b4-b56d7a6c8c93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7bf4a5ae-5bfe-44f1-815c-ad55182ef297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43d7dc6c-b40d-4463-b4b4-b56d7a6c8c93" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7bf4a5ae-5bfe-44f1-815c-ad55182ef297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_d96b5de9-99fd-461e-bec8-a734dc9b79fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7bf4a5ae-5bfe-44f1-815c-ad55182ef297" xlink:to="loc_us-gaap_CashFlowHedgingMember_d96b5de9-99fd-461e-bec8-a734dc9b79fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d21f266b-6b7a-4cb9-b887-11b3a3a3de2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:to="loc_us-gaap_HedgingDesignationAxis_d21f266b-6b7a-4cb9-b887-11b3a3a3de2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d21f266b-6b7a-4cb9-b887-11b3a3a3de2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_d21f266b-6b7a-4cb9-b887-11b3a3a3de2e" xlink:to="loc_us-gaap_HedgingDesignationDomain_d21f266b-6b7a-4cb9-b887-11b3a3a3de2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_74104577-79f4-4ccd-a3d4-436216cd296a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_d21f266b-6b7a-4cb9-b887-11b3a3a3de2e" xlink:to="loc_us-gaap_HedgingDesignationDomain_74104577-79f4-4ccd-a3d4-436216cd296a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_73da1fe3-7419-48f6-ad91-5cd37bed29a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_74104577-79f4-4ccd-a3d4-436216cd296a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_73da1fe3-7419-48f6-ad91-5cd37bed29a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_455dc0b7-6fe3-496c-a74e-92cea5016409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_74104577-79f4-4ccd-a3d4-436216cd296a" xlink:to="loc_us-gaap_NondesignatedMember_455dc0b7-6fe3-496c-a74e-92cea5016409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_919b3dee-63e8-4416-ac06-6c08529d3968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_919b3dee-63e8-4416-ac06-6c08529d3968" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_919b3dee-63e8-4416-ac06-6c08529d3968_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_919b3dee-63e8-4416-ac06-6c08529d3968" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_919b3dee-63e8-4416-ac06-6c08529d3968_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9896950d-7ea4-45f3-8b4e-242a361e21e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_919b3dee-63e8-4416-ac06-6c08529d3968" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9896950d-7ea4-45f3-8b4e-242a361e21e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_99586347-e8d0-46b1-95cc-f8c7f9bd9acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9896950d-7ea4-45f3-8b4e-242a361e21e0" xlink:to="loc_us-gaap_SalesMember_99586347-e8d0-46b1-95cc-f8c7f9bd9acd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_458d55f1-0cb0-45db-8b7a-854121284d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9896950d-7ea4-45f3-8b4e-242a361e21e0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_458d55f1-0cb0-45db-8b7a-854121284d2f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="icf21dffa339d4842a8ddb3976513b157_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0df7b8bd-6965-4e97-b2eb-b0d0dfced92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0df7b8bd-6965-4e97-b2eb-b0d0dfced92c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_36a06cc2-5c2e-4fa9-8a89-e70554256a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_36a06cc2-5c2e-4fa9-8a89-e70554256a4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_96bab355-f8b8-4e8b-aef9-c1731806b6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_96bab355-f8b8-4e8b-aef9-c1731806b6bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a8b7997c-2d8e-45d7-83d4-d34573888af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a8b7997c-2d8e-45d7-83d4-d34573888af8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4dbd4fa-7623-4cc2-a3fe-05c124ec0dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4dbd4fa-7623-4cc2-a3fe-05c124ec0dbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_196c6c7f-1cbf-4eba-8bbf-5234764f216f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4dbd4fa-7623-4cc2-a3fe-05c124ec0dbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_196c6c7f-1cbf-4eba-8bbf-5234764f216f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_196c6c7f-1cbf-4eba-8bbf-5234764f216f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_196c6c7f-1cbf-4eba-8bbf-5234764f216f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_196c6c7f-1cbf-4eba-8bbf-5234764f216f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_196c6c7f-1cbf-4eba-8bbf-5234764f216f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f5861220-b28e-4e8e-8f12-6c5988b30648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_EquipmentMember_f5861220-b28e-4e8e-8f12-6c5988b30648" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4865cc98-cbba-4794-b88a-94195488a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4865cc98-cbba-4794-b88a-94195488a7b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_06e1e328-428f-41cd-bb16-dbbe54263d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_06e1e328-428f-41cd-bb16-dbbe54263d9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_96017e41-857a-4e82-8d9e-a499b003e3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_ComputerEquipmentMember_96017e41-857a-4e82-8d9e-a499b003e3b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_3aad28e7-b383-4fea-9004-ff64a16b2b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_3aad28e7-b383-4fea-9004-ff64a16b2b74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember_2b527eae-4707-4f6a-a2e6-07a71bd29ebc" xlink:href="mrna-20211231.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_mrna_FinancingRightOfUseAssetMember_2b527eae-4707-4f6a-a2e6-07a71bd29ebc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ae4333ac-c378-4d48-bde7-12add5f1f7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_ConstructionInProgressMember_ae4333ac-c378-4d48-bde7-12add5f1f7e4" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#OtherBalanceSheetComponentsDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="extended" id="iaa7da5bf7dcf46b9a090fce3fc688041_OtherBalanceSheetComponentsDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_38575d37-c2da-47a9-a39d-0a3261814583" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_0f8bd9ec-fa89-4937-8ba4-bca02869043e" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_38575d37-c2da-47a9-a39d-0a3261814583" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_0f8bd9ec-fa89-4937-8ba4-bca02869043e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_50708e59-5e84-44b9-842a-948783ef44d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_0f8bd9ec-fa89-4937-8ba4-bca02869043e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_50708e59-5e84-44b9-842a-948783ef44d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_6f6acd19-7402-4616-bc03-6f037b33e9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_0f8bd9ec-fa89-4937-8ba4-bca02869043e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_6f6acd19-7402-4616-bc03-6f037b33e9c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_e26d67d8-9694-477b-90de-3b63c5fedd61" xlink:href="mrna-20211231.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_0f8bd9ec-fa89-4937-8ba4-bca02869043e" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_e26d67d8-9694-477b-90de-3b63c5fedd61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_57e96146-1352-4d42-910a-f91790e3872d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable_f1cb2efd-e14d-40a2-8b9a-875ec3ada6c5" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_38575d37-c2da-47a9-a39d-0a3261814583" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityTable_f1cb2efd-e14d-40a2-8b9a-875ec3ada6c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ee5c76c4-30dc-42ea-a17d-8f11a78cac83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_f1cb2efd-e14d-40a2-8b9a-875ec3ada6c5" xlink:to="loc_srt_ProductOrServiceAxis_ee5c76c4-30dc-42ea-a17d-8f11a78cac83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ee5c76c4-30dc-42ea-a17d-8f11a78cac83_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ee5c76c4-30dc-42ea-a17d-8f11a78cac83" xlink:to="loc_srt_ProductsAndServicesDomain_ee5c76c4-30dc-42ea-a17d-8f11a78cac83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7326ab0e-2a4e-45e4-a6fc-dd1eb68140ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ee5c76c4-30dc-42ea-a17d-8f11a78cac83" xlink:to="loc_srt_ProductsAndServicesDomain_7326ab0e-2a4e-45e4-a6fc-dd1eb68140ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_eb9ed362-e1a0-402c-a7c3-01a5e9c70715" xlink:href="mrna-20211231.xsd#mrna_ProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7326ab0e-2a4e-45e4-a6fc-dd1eb68140ec" xlink:to="loc_mrna_ProductSalesMember_eb9ed362-e1a0-402c-a7c3-01a5e9c70715" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_ba997754-a77d-4b78-9fca-6917b2123497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7326ab0e-2a4e-45e4-a6fc-dd1eb68140ec" xlink:to="loc_us-gaap_GrantMember_ba997754-a77d-4b78-9fca-6917b2123497" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_0f7a6080-b949-42e8-8f8c-67544e47c4e4" xlink:href="mrna-20211231.xsd#mrna_CollaborationArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7326ab0e-2a4e-45e4-a6fc-dd1eb68140ec" xlink:to="loc_mrna_CollaborationArrangementMember_0f7a6080-b949-42e8-8f8c-67544e47c4e4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ie7054fa0e7854d18b0d6bb6a97f34222_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties_ceaacfe3-6026-4d49-b708-dee6433aaf1a" xlink:href="mrna-20211231.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_mrna_OperatingLeaseNumberOfProperties_ceaacfe3-6026-4d49-b708-dee6433aaf1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_f12a2523-0d82-4132-bd6d-2ba0cff9cbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_f12a2523-0d82-4132-bd6d-2ba0cff9cbc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c146a157-ff9b-4184-b19c-879f1b510913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c146a157-ff9b-4184-b19c-879f1b510913" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtension_8fd02539-8cc5-487e-b7ca-f70ab1e68d41" xlink:href="mrna-20211231.xsd#mrna_LesseeOperatingLeaseNumberOfExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtension_8fd02539-8cc5-487e-b7ca-f70ab1e68d41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseNumberOfProperties_f6ef1c82-af5d-48d4-9e6e-641bdcbefda4" xlink:href="mrna-20211231.xsd#mrna_FinanceLeaseNumberOfProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_mrna_FinanceLeaseNumberOfProperties_f6ef1c82-af5d-48d4-9e6e-641bdcbefda4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AllowanceForTenantImprovements_3f47de64-25ae-4a23-a551-90779559ef75" xlink:href="mrna-20211231.xsd#mrna_AllowanceForTenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_mrna_AllowanceForTenantImprovements_3f47de64-25ae-4a23-a551-90779559ef75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_58065773-eecc-46ee-960d-5d1c7db004be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_us-gaap_OperatingLeaseLiability_58065773-eecc-46ee-960d-5d1c7db004be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cb6b7e5d-4af6-496d-9265-5e25210ddf8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cb6b7e5d-4af6-496d-9265-5e25210ddf8f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_0f418149-2840-441d-92de-a4a0d028aff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_0f418149-2840-441d-92de-a4a0d028aff1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_155187c4-2ec5-4b69-ab38-2071b7c0a9aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0f418149-2840-441d-92de-a4a0d028aff1" xlink:to="loc_srt_StatementGeographicalAxis_155187c4-2ec5-4b69-ab38-2071b7c0a9aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_155187c4-2ec5-4b69-ab38-2071b7c0a9aa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_155187c4-2ec5-4b69-ab38-2071b7c0a9aa" xlink:to="loc_srt_SegmentGeographicalDomain_155187c4-2ec5-4b69-ab38-2071b7c0a9aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b50e5771-fe3e-4586-b6aa-9829fdd7a4a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_155187c4-2ec5-4b69-ab38-2071b7c0a9aa" xlink:to="loc_srt_SegmentGeographicalDomain_b50e5771-fe3e-4586-b6aa-9829fdd7a4a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember_4d0a5d50-c3cd-4457-9e02-f7ad2810787a" xlink:href="mrna-20211231.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b50e5771-fe3e-4586-b6aa-9829fdd7a4a0" xlink:to="loc_mrna_CambridgeMassachusettsMember_4d0a5d50-c3cd-4457-9e02-f7ad2810787a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NorwoodMassachusettsMember_9f455d83-0520-4458-8efa-753451fdc83b" xlink:href="mrna-20211231.xsd#mrna_NorwoodMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b50e5771-fe3e-4586-b6aa-9829fdd7a4a0" xlink:to="loc_mrna_NorwoodMassachusettsMember_9f455d83-0520-4458-8efa-753451fdc83b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_24f10ff9-b6f9-49e1-a828-fcaffa869754" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0f418149-2840-441d-92de-a4a0d028aff1" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_24f10ff9-b6f9-49e1-a828-fcaffa869754" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_24f10ff9-b6f9-49e1-a828-fcaffa869754_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_24f10ff9-b6f9-49e1-a828-fcaffa869754" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_24f10ff9-b6f9-49e1-a828-fcaffa869754_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_24f10ff9-b6f9-49e1-a828-fcaffa869754" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TwoHundredTechnologySquareMember_01cb50e5-7d53-4df4-b23e-eba9236103ae" xlink:href="mrna-20211231.xsd#mrna_TwoHundredTechnologySquareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:to="loc_mrna_TwoHundredTechnologySquareMember_01cb50e5-7d53-4df4-b23e-eba9236103ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FiveHundredTechnologySquareMember_c007c96b-1ec0-467b-a475-5f22f1b28d70" xlink:href="mrna-20211231.xsd#mrna_FiveHundredTechnologySquareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:to="loc_mrna_FiveHundredTechnologySquareMember_c007c96b-1ec0-467b-a475-5f22f1b28d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCEastMember_6ea3185d-f14a-4b37-b97d-fe8348d64f98" xlink:href="mrna-20211231.xsd#mrna_MTCEastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:to="loc_mrna_MTCEastMember_6ea3185d-f14a-4b37-b97d-fe8348d64f98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCNorthMember_a6624d32-4668-4b1e-afea-d581b41bc2aa" xlink:href="mrna-20211231.xsd#mrna_MTCNorthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:to="loc_mrna_MTCNorthMember_a6624d32-4668-4b1e-afea-d581b41bc2aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_b38e02c0-f8f8-4151-bb1c-9056eab5b6c0" xlink:href="mrna-20211231.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:to="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_b38e02c0-f8f8-4151-bb1c-9056eab5b6c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_9d6ee3a4-580b-453e-8250-725e89f18a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0f418149-2840-441d-92de-a4a0d028aff1" xlink:to="loc_us-gaap_LeaseContractualTermAxis_9d6ee3a4-580b-453e-8250-725e89f18a11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_9d6ee3a4-580b-453e-8250-725e89f18a11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9d6ee3a4-580b-453e-8250-725e89f18a11" xlink:to="loc_us-gaap_LeaseContractualTermDomain_9d6ee3a4-580b-453e-8250-725e89f18a11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_0718836e-56a3-45da-94ed-b64245c82dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9d6ee3a4-580b-453e-8250-725e89f18a11" xlink:to="loc_us-gaap_LeaseContractualTermDomain_0718836e-56a3-45da-94ed-b64245c82dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmbeddedLeasesMember_fc04b353-cce6-4002-9952-4397d3e44994" xlink:href="mrna-20211231.xsd#mrna_EmbeddedLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_0718836e-56a3-45da-94ed-b64245c82dce" xlink:to="loc_mrna_EmbeddedLeasesMember_fc04b353-cce6-4002-9952-4397d3e44994" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended" id="if1cdf43ee9e047bdb8ca7b4a2e496d91_LeasesMinimumLeasePaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9d423ba-f613-4c80-a8c6-d1da938aaec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5edb9780-15df-4594-ba42-fd489587f597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9d423ba-f613-4c80-a8c6-d1da938aaec3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5edb9780-15df-4594-ba42-fd489587f597" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_42df3939-3522-487e-989d-61927c4179db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9d423ba-f613-4c80-a8c6-d1da938aaec3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_42df3939-3522-487e-989d-61927c4179db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c1d72439-c90d-4a89-b8f1-3868ddbd045a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_42df3939-3522-487e-989d-61927c4179db" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c1d72439-c90d-4a89-b8f1-3868ddbd045a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c1d72439-c90d-4a89-b8f1-3868ddbd045a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c1d72439-c90d-4a89-b8f1-3868ddbd045a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c1d72439-c90d-4a89-b8f1-3868ddbd045a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c5d5020e-3250-41df-bcc5-a319e3c29513" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c1d72439-c90d-4a89-b8f1-3868ddbd045a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c5d5020e-3250-41df-bcc5-a319e3c29513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_b40e6718-c02c-4fc0-b1bc-e684e9ad93e3" xlink:href="mrna-20211231.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c5d5020e-3250-41df-bcc5-a319e3c29513" xlink:to="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_b40e6718-c02c-4fc0-b1bc-e684e9ad93e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dcd4790f-f141-4722-8b88-78d4398c10c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_42df3939-3522-487e-989d-61927c4179db" xlink:to="loc_srt_StatementGeographicalAxis_dcd4790f-f141-4722-8b88-78d4398c10c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dcd4790f-f141-4722-8b88-78d4398c10c8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_dcd4790f-f141-4722-8b88-78d4398c10c8" xlink:to="loc_srt_SegmentGeographicalDomain_dcd4790f-f141-4722-8b88-78d4398c10c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e359a281-207a-4063-a2af-89008a522ed0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_dcd4790f-f141-4722-8b88-78d4398c10c8" xlink:to="loc_srt_SegmentGeographicalDomain_e359a281-207a-4063-a2af-89008a522ed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NorwoodMassachusettsMember_e8b038e4-dbf9-4c50-bbfb-35fd45e60154" xlink:href="mrna-20211231.xsd#mrna_NorwoodMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e359a281-207a-4063-a2af-89008a522ed0" xlink:to="loc_mrna_NorwoodMassachusettsMember_e8b038e4-dbf9-4c50-bbfb-35fd45e60154" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CommitmentsandContingenciesIndemnificationObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" xlink:type="extended" id="i1edac80a8a11499aa4f698eac55b112d_CommitmentsandContingenciesIndemnificationObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_0e98f767-231f-4abf-b5e8-a41bf34dab39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_a6fbe123-c54e-485b-aeda-16d1e2da9159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_0e98f767-231f-4abf-b5e8-a41bf34dab39" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_a6fbe123-c54e-485b-aeda-16d1e2da9159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_8c551dbe-d790-461a-9801-37388184522a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_0e98f767-231f-4abf-b5e8-a41bf34dab39" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_8c551dbe-d790-461a-9801-37388184522a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f7899bfd-85fd-4d62-b226-a49954c631f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_0e98f767-231f-4abf-b5e8-a41bf34dab39" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f7899bfd-85fd-4d62-b226-a49954c631f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e0b338d1-161c-4a24-bde8-80d3672c3e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_0e98f767-231f-4abf-b5e8-a41bf34dab39" xlink:to="loc_us-gaap_LossContingenciesTable_e0b338d1-161c-4a24-bde8-80d3672c3e11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_12b66995-e05a-412a-8464-991bcf16879e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e0b338d1-161c-4a24-bde8-80d3672c3e11" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_12b66995-e05a-412a-8464-991bcf16879e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_12b66995-e05a-412a-8464-991bcf16879e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_12b66995-e05a-412a-8464-991bcf16879e" xlink:to="loc_us-gaap_LossContingencyNatureDomain_12b66995-e05a-412a-8464-991bcf16879e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_57fd9313-c4b2-4c62-94b8-b734501c31fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_12b66995-e05a-412a-8464-991bcf16879e" xlink:to="loc_us-gaap_LossContingencyNatureDomain_57fd9313-c4b2-4c62-94b8-b734501c31fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_90127959-8a9b-4def-8288-97852e9724b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_57fd9313-c4b2-4c62-94b8-b734501c31fe" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_90127959-8a9b-4def-8288-97852e9724b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="extended" id="ia02ba77026f4407fba2c615af7a4c170_CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_195a71c3-1d92-4467-8f80-72b38283fe82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_4a7a5998-c1df-4da2-a3a6-468e405410fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_195a71c3-1d92-4467-8f80-72b38283fe82" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_4a7a5998-c1df-4da2-a3a6-468e405410fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ef902342-ca8b-4e92-b1c6-935622f62dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_195a71c3-1d92-4467-8f80-72b38283fe82" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ef902342-ca8b-4e92-b1c6-935622f62dc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_28e93dbf-ef05-4695-a5c1-302d761ef56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ef902342-ca8b-4e92-b1c6-935622f62dc2" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_28e93dbf-ef05-4695-a5c1-302d761ef56e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_28e93dbf-ef05-4695-a5c1-302d761ef56e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_28e93dbf-ef05-4695-a5c1-302d761ef56e" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_28e93dbf-ef05-4695-a5c1-302d761ef56e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4a38c980-2b72-40dd-bfe8-5fd3c1c3d486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_28e93dbf-ef05-4695-a5c1-302d761ef56e" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4a38c980-2b72-40dd-bfe8-5fd3c1c3d486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember_31770971-90bf-4797-ba8b-761fb8ec0351" xlink:href="mrna-20211231.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4a38c980-2b72-40dd-bfe8-5fd3c1c3d486" xlink:to="loc_mrna_SupplyAndManufacturingAgreementsMember_31770971-90bf-4797-ba8b-761fb8ec0351" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember_f2f536f7-1b9b-4f2d-a4a5-7d332aba7241" xlink:href="mrna-20211231.xsd#mrna_ClinicalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4a38c980-2b72-40dd-bfe8-5fd3c1c3d486" xlink:to="loc_mrna_ClinicalServicesMember_f2f536f7-1b9b-4f2d-a4a5-7d332aba7241" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_a7e3b10b-8ca2-47a0-a49a-2c2ece823a20" xlink:href="mrna-20211231.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4a38c980-2b72-40dd-bfe8-5fd3c1c3d486" xlink:to="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_a7e3b10b-8ca2-47a0-a49a-2c2ece823a20" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CommitmentandContingenciesModernaScienceCenterDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails" xlink:type="extended" id="i31e7542328d840bc9ef233a62985046b_CommitmentandContingenciesModernaScienceCenterDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_6d212854-3a5c-474c-b9aa-c849fe4c4ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_6d212854-3a5c-474c-b9aa-c849fe4c4ac0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm_d3ecf2a7-e6c4-45fa-811a-cf07fcdff925" xlink:href="mrna-20211231.xsd#mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm_d3ecf2a7-e6c4-45fa-811a-cf07fcdff925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_78f42c39-0fce-4d0e-a1fd-442a4fe80314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_78f42c39-0fce-4d0e-a1fd-442a4fe80314" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_c97d32a2-e01b-4f1c-9b9c-9ce15469449b" xlink:href="mrna-20211231.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_c97d32a2-e01b-4f1c-9b9c-9ce15469449b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6d0d2daa-684c-42bd-b8c4-db52d5385639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6d0d2daa-684c-42bd-b8c4-db52d5385639" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ee8c2fc4-addd-4b2e-93d1-f68ae1c80b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ee8c2fc4-addd-4b2e-93d1-f68ae1c80b71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_70abad7a-4781-469f-a661-761e74c91e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_70abad7a-4781-469f-a661-761e74c91e1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fa918b71-266a-47dd-89cd-b5321c6381cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_70abad7a-4781-469f-a661-761e74c91e1a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fa918b71-266a-47dd-89cd-b5321c6381cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_fa918b71-266a-47dd-89cd-b5321c6381cd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fa918b71-266a-47dd-89cd-b5321c6381cd" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_fa918b71-266a-47dd-89cd-b5321c6381cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_663e2483-d5bd-4a29-9c7a-1b1edbba3374" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fa918b71-266a-47dd-89cd-b5321c6381cd" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_663e2483-d5bd-4a29-9c7a-1b1edbba3374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ModernaScienceCentreMember_8218cfb0-6393-42bf-beb4-0c8139b0b0ed" xlink:href="mrna-20211231.xsd#mrna_ModernaScienceCentreMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_663e2483-d5bd-4a29-9c7a-1b1edbba3374" xlink:to="loc_mrna_ModernaScienceCentreMember_8218cfb0-6393-42bf-beb4-0c8139b0b0ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="id25a23781e0a470bbfacbffbd1aa512f_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7a20ccd7-9bab-4f45-a4f9-facbb88e848e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ef8575a7-8477-492f-bee9-da950779c9af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7a20ccd7-9bab-4f45-a4f9-facbb88e848e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ef8575a7-8477-492f-bee9-da950779c9af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2db6dcaa-be94-48e7-a780-09848bfcd3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7a20ccd7-9bab-4f45-a4f9-facbb88e848e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2db6dcaa-be94-48e7-a780-09848bfcd3cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d69d945e-9b66-4051-acef-b2a906cc6063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7a20ccd7-9bab-4f45-a4f9-facbb88e848e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d69d945e-9b66-4051-acef-b2a906cc6063" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6129ce2f-9175-4df4-95d7-41b45403b262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7a20ccd7-9bab-4f45-a4f9-facbb88e848e" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6129ce2f-9175-4df4-95d7-41b45403b262" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_aee3a2e0-b9ba-4d8a-a44a-28ab8151010e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6129ce2f-9175-4df4-95d7-41b45403b262" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_aee3a2e0-b9ba-4d8a-a44a-28ab8151010e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aee3a2e0-b9ba-4d8a-a44a-28ab8151010e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aee3a2e0-b9ba-4d8a-a44a-28ab8151010e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aee3a2e0-b9ba-4d8a-a44a-28ab8151010e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_609518cb-eb29-42fc-93c3-0657b40ae6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aee3a2e0-b9ba-4d8a-a44a-28ab8151010e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_609518cb-eb29-42fc-93c3-0657b40ae6e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PublicEquityOfferingMember_1d213ded-fd5b-49d6-b301-78f9305484fb" xlink:href="mrna-20211231.xsd#mrna_PublicEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_609518cb-eb29-42fc-93c3-0657b40ae6e2" xlink:to="loc_mrna_PublicEquityOfferingMember_1d213ded-fd5b-49d6-b301-78f9305484fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_380369a6-7775-41fe-94ac-c85cb2d9de96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_609518cb-eb29-42fc-93c3-0657b40ae6e2" xlink:to="loc_us-gaap_OverAllotmentOptionMember_380369a6-7775-41fe-94ac-c85cb2d9de96" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i54b9d94fad074e77b5c15764e4985057_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_3550fb9f-a257-4169-8fc7-cff2441d1faf" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_3550fb9f-a257-4169-8fc7-cff2441d1faf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_014c522d-305b-4e54-a5df-80870e186d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_014c522d-305b-4e54-a5df-80870e186d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f999c205-b72c-4a13-9bbe-b92ca3f81dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f999c205-b72c-4a13-9bbe-b92ca3f81dff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_70d8efa6-06db-4fc3-9fa8-cda95e112b0e" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_70d8efa6-06db-4fc3-9fa8-cda95e112b0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ee3b298c-c6a7-4445-a3e4-8623f28f2a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ee3b298c-c6a7-4445-a3e4-8623f28f2a9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3ec0930b-ce05-4a19-9139-e4f6c54f7b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3ec0930b-ce05-4a19-9139-e4f6c54f7b11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_017bfd80-5888-4edc-bad6-2da572e477b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_017bfd80-5888-4edc-bad6-2da572e477b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_26c2c69f-929e-4d68-9da5-86ea982d1dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_26c2c69f-929e-4d68-9da5-86ea982d1dfe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_7001b5f2-ad09-4583-8061-d27fe2a30f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_7001b5f2-ad09-4583-8061-d27fe2a30f96" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_655819b7-9ea7-4b6c-8ab8-fa71f0514889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_655819b7-9ea7-4b6c-8ab8-fa71f0514889" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense_4aef853e-9760-4231-8f4c-dced8c0ebc22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_RestrictedStockExpense_4aef853e-9760-4231-8f4c-dced8c0ebc22" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2dc18bd8-0532-4f6e-9240-d328fb813a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2dc18bd8-0532-4f6e-9240-d328fb813a75" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_e0814fd7-c2df-4013-84d9-5474709397a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_e0814fd7-c2df-4013-84d9-5474709397a5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_81db5fd0-828a-4b9a-bee8-3aa6b39e8dfd" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_81db5fd0-828a-4b9a-bee8-3aa6b39e8dfd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod_b6e63c9f-cee8-4fd4-a35d-6067cc62beec" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod_b6e63c9f-cee8-4fd4-a35d-6067cc62beec" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_2142d8e1-6874-4d4c-b488-be51e6367a30" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_2142d8e1-6874-4d4c-b488-be51e6367a30" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_078854ff-ee2a-40cc-aa65-16f110b77478" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_078854ff-ee2a-40cc-aa65-16f110b77478" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_7b9807bb-4e70-4910-bff7-d3de43260cde" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_7b9807bb-4e70-4910-bff7-d3de43260cde" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_560ef731-9da0-4ff2-979b-642e3598abd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_560ef731-9da0-4ff2-979b-642e3598abd1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_14f9f6fa-f300-4760-b8de-9f9b526fa874" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_14f9f6fa-f300-4760-b8de-9f9b526fa874" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_fee378a5-df16-41d5-a64d-a27d693c574a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_fee378a5-df16-41d5-a64d-a27d693c574a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_1779bad0-fde2-414c-9c51-21cb6ce7e258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_1779bad0-fde2-414c-9c51-21cb6ce7e258" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_c57b2a9d-79af-437d-a323-60932561e086" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_c57b2a9d-79af-437d-a323-60932561e086" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ce92456b-7b7b-4f45-a555-7cc17ae0b6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ce92456b-7b7b-4f45-a555-7cc17ae0b6a6" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0463c0cf-365b-4b45-85f7-15d68f6501a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_SharePrice_0463c0cf-365b-4b45-85f7-15d68f6501a0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_34eb5ecb-461d-43b0-938a-d4fc40992aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_34eb5ecb-461d-43b0-938a-d4fc40992aa9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_79ba24a8-4ccc-4d52-8cbf-919f58d34634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_79ba24a8-4ccc-4d52-8cbf-919f58d34634" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d26e86e3-1df3-431e-8996-646c83651cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d26e86e3-1df3-431e-8996-646c83651cc7" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_81d3cb20-2d58-4c20-a2fc-c8f562395946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_81d3cb20-2d58-4c20-a2fc-c8f562395946" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_58790655-1951-4894-b373-c356e132e6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_58790655-1951-4894-b373-c356e132e6b8" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_07a4dd3d-e838-4ab2-8627-4a18aa933d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_07a4dd3d-e838-4ab2-8627-4a18aa933d72" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2599e03d-657d-4da9-af51-bc11ed1f3cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_2599e03d-657d-4da9-af51-bc11ed1f3cbe" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_804b6afa-0aba-43f2-9984-74a4b065f3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_804b6afa-0aba-43f2-9984-74a4b065f3f9" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f39f2ee5-ab7a-4032-9a12-75b76f830a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:to="loc_us-gaap_PlanNameAxis_f39f2ee5-ab7a-4032-9a12-75b76f830a7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f39f2ee5-ab7a-4032-9a12-75b76f830a7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f39f2ee5-ab7a-4032-9a12-75b76f830a7e" xlink:to="loc_us-gaap_PlanNameDomain_f39f2ee5-ab7a-4032-9a12-75b76f830a7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bc3bf8c5-7113-4fff-a7e2-c53e8ed09b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f39f2ee5-ab7a-4032-9a12-75b76f830a7e" xlink:to="loc_us-gaap_PlanNameDomain_bc3bf8c5-7113-4fff-a7e2-c53e8ed09b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member_9331b728-84c1-47aa-86f4-31632199666c" xlink:href="mrna-20211231.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bc3bf8c5-7113-4fff-a7e2-c53e8ed09b31" xlink:to="loc_mrna_StockOptionAndIncentivePlan2018Member_9331b728-84c1-47aa-86f4-31632199666c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndGrantPlan2016Member_c7bdd8b7-60bf-4f77-803f-1407d9482a23" xlink:href="mrna-20211231.xsd#mrna_StockOptionAndGrantPlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bc3bf8c5-7113-4fff-a7e2-c53e8ed09b31" xlink:to="loc_mrna_StockOptionAndGrantPlan2016Member_c7bdd8b7-60bf-4f77-803f-1407d9482a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmployeeStockPurchasePlan2018Member_4cd4697f-5798-4646-a1f8-f5ae1c25bcbe" xlink:href="mrna-20211231.xsd#mrna_EmployeeStockPurchasePlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bc3bf8c5-7113-4fff-a7e2-c53e8ed09b31" xlink:to="loc_mrna_EmployeeStockPurchasePlan2018Member_4cd4697f-5798-4646-a1f8-f5ae1c25bcbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_08c4a708-66a0-46e5-9185-6921c5756178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:to="loc_us-gaap_AwardTypeAxis_08c4a708-66a0-46e5-9185-6921c5756178" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08c4a708-66a0-46e5-9185-6921c5756178_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_08c4a708-66a0-46e5-9185-6921c5756178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08c4a708-66a0-46e5-9185-6921c5756178_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_08c4a708-66a0-46e5-9185-6921c5756178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ServiceBasedAwardsMember_31be99bf-d017-4067-b1de-2361fc5ed74e" xlink:href="mrna-20211231.xsd#mrna_ServiceBasedAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:to="loc_mrna_ServiceBasedAwardsMember_31be99bf-d017-4067-b1de-2361fc5ed74e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_63c67f5b-cdc6-4bb6-8cce-0270a9c9f524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_63c67f5b-cdc6-4bb6-8cce-0270a9c9f524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6b13bb8e-c73e-48a4-83b7-f6deb6ca516b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:to="loc_us-gaap_EmployeeStockMember_6b13bb8e-c73e-48a4-83b7-f6deb6ca516b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_fbf555fb-386e-4ad9-b3b8-4a0c4458fb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:to="loc_us-gaap_PerformanceSharesMember_fbf555fb-386e-4ad9-b3b8-4a0c4458fb36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_7204a17a-494f-4651-8926-b860cb813e4b" xlink:href="mrna-20211231.xsd#mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:to="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_7204a17a-494f-4651-8926-b860cb813e4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7283cb5b-ec7b-403c-b610-24b12af1d855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:to="loc_us-gaap_VestingAxis_7283cb5b-ec7b-403c-b610-24b12af1d855" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7283cb5b-ec7b-403c-b610-24b12af1d855_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_7283cb5b-ec7b-403c-b610-24b12af1d855" xlink:to="loc_us-gaap_VestingDomain_7283cb5b-ec7b-403c-b610-24b12af1d855_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b6348b5c-8bc5-451f-a5bb-dda4af20df89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_7283cb5b-ec7b-403c-b610-24b12af1d855" xlink:to="loc_us-gaap_VestingDomain_b6348b5c-8bc5-451f-a5bb-dda4af20df89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0ea460af-e389-416f-847b-0068ac97ae32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b6348b5c-8bc5-451f-a5bb-dda4af20df89" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0ea460af-e389-416f-847b-0068ac97ae32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_691257d7-0912-4458-a2fd-293123f395c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_b6348b5c-8bc5-451f-a5bb-dda4af20df89" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_691257d7-0912-4458-a2fd-293123f395c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c5dbf948-ef30-4ee8-b405-4651afeefb50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:to="loc_srt_RangeAxis_c5dbf948-ef30-4ee8-b405-4651afeefb50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5dbf948-ef30-4ee8-b405-4651afeefb50_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c5dbf948-ef30-4ee8-b405-4651afeefb50" xlink:to="loc_srt_RangeMember_c5dbf948-ef30-4ee8-b405-4651afeefb50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6dae2bb1-fe57-4ac9-96a6-35f23aef7fb5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c5dbf948-ef30-4ee8-b405-4651afeefb50" xlink:to="loc_srt_RangeMember_6dae2bb1-fe57-4ac9-96a6-35f23aef7fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_66315c99-2e68-4eb8-93d3-b443545bc1c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6dae2bb1-fe57-4ac9-96a6-35f23aef7fb5" xlink:to="loc_srt_MinimumMember_66315c99-2e68-4eb8-93d3-b443545bc1c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_64fe7e3d-dcff-4064-bcec-351d97c615ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6dae2bb1-fe57-4ac9-96a6-35f23aef7fb5" xlink:to="loc_srt_MaximumMember_64fe7e3d-dcff-4064-bcec-351d97c615ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_17d63d53-d056-4d4b-b638-c6c1bb3d0ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_17d63d53-d056-4d4b-b638-c6c1bb3d0ae7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_17d63d53-d056-4d4b-b638-c6c1bb3d0ae7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_17d63d53-d056-4d4b-b638-c6c1bb3d0ae7" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_17d63d53-d056-4d4b-b638-c6c1bb3d0ae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9241378f-5c80-4ab6-b7c4-e62612a48625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_17d63d53-d056-4d4b-b638-c6c1bb3d0ae7" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_9241378f-5c80-4ab6-b7c4-e62612a48625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2021RepurchaseProgramMember_b920197c-dbc0-441d-b37e-8acb7f61dacd" xlink:href="mrna-20211231.xsd#mrna_A2021RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_9241378f-5c80-4ab6-b7c4-e62612a48625" xlink:to="loc_mrna_A2021RepurchaseProgramMember_b920197c-dbc0-441d-b37e-8acb7f61dacd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="extended" id="i61796cde58974c13a03b3fb62b1cc098_StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d414a316-ea11-43f5-bdd0-031918934dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d414a316-ea11-43f5-bdd0-031918934dc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_88135190-f471-4e5f-9f61-5a5d2d132638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_88135190-f471-4e5f-9f61-5a5d2d132638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_333ead9b-074a-4257-8504-d0f6dac0c27b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_333ead9b-074a-4257-8504-d0f6dac0c27b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_297fdd31-1b2f-4b05-ad6b-cdbee7f0fd19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_297fdd31-1b2f-4b05-ad6b-cdbee7f0fd19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_25c64f38-d6bc-41f7-ae93-200c5200f132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_25c64f38-d6bc-41f7-ae93-200c5200f132" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29caab40-d70a-4193-8730-d7e9fa0e55a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d414a316-ea11-43f5-bdd0-031918934dc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_09822c33-bc43-4e63-8156-23b57b3d51d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_09822c33-bc43-4e63-8156-23b57b3d51d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84de06f3-af7f-4137-b6f2-bef05fdbd9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84de06f3-af7f-4137-b6f2-bef05fdbd9d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6910a7ad-f136-4b42-bf04-fe788b97d221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6910a7ad-f136-4b42-bf04-fe788b97d221" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ba32eb8c-e0da-464b-9680-abaa26d79052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ba32eb8c-e0da-464b-9680-abaa26d79052" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f07e0b3c-8e1c-43f5-85f9-3054721923a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3797460a-7935-4f2b-8f47-e9010bf5d93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d414a316-ea11-43f5-bdd0-031918934dc5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3797460a-7935-4f2b-8f47-e9010bf5d93c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da170505-09eb-4986-8807-bf24740306e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3797460a-7935-4f2b-8f47-e9010bf5d93c" xlink:to="loc_us-gaap_AwardTypeAxis_da170505-09eb-4986-8807-bf24740306e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da170505-09eb-4986-8807-bf24740306e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_da170505-09eb-4986-8807-bf24740306e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da170505-09eb-4986-8807-bf24740306e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd893b80-4470-40a4-ae0b-4b1e1f91a902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_da170505-09eb-4986-8807-bf24740306e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd893b80-4470-40a4-ae0b-4b1e1f91a902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_dc1a2afb-6d7c-4518-8cfd-f7d461184961" xlink:href="mrna-20211231.xsd#mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd893b80-4470-40a4-ae0b-4b1e1f91a902" xlink:to="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_dc1a2afb-6d7c-4518-8cfd-f7d461184961" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" xlink:type="extended" id="ia387dd0ad1214da2b10cf8a54e788496_StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_682ad0df-9b3d-486c-8c42-8c6d96fe90b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_682ad0df-9b3d-486c-8c42-8c6d96fe90b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cfacaf83-9639-419f-b28f-83b893653454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cfacaf83-9639-419f-b28f-83b893653454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d151e7fd-476c-481f-9701-b00c9569418e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d151e7fd-476c-481f-9701-b00c9569418e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_86bb7c94-9c0e-49a8-9fc1-b3dc3da48be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_86bb7c94-9c0e-49a8-9fc1-b3dc3da48be2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7cb5fc89-2fee-4d58-ab5a-877551c8fe34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:to="loc_us-gaap_SharePrice_7cb5fc89-2fee-4d58-ab5a-877551c8fe34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f09a93-8359-4cbc-aee0-c4e7ca46619f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f09a93-8359-4cbc-aee0-c4e7ca46619f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a47a26c5-5f2d-4549-8fe4-8833d80d19e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f09a93-8359-4cbc-aee0-c4e7ca46619f" xlink:to="loc_us-gaap_AwardTypeAxis_a47a26c5-5f2d-4549-8fe4-8833d80d19e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a47a26c5-5f2d-4549-8fe4-8833d80d19e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a47a26c5-5f2d-4549-8fe4-8833d80d19e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a47a26c5-5f2d-4549-8fe4-8833d80d19e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_128925d9-0424-4313-88a9-895128f22efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a47a26c5-5f2d-4549-8fe4-8833d80d19e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_128925d9-0424-4313-88a9-895128f22efc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3c546305-ea7d-4af2-9384-3b2919487e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_128925d9-0424-4313-88a9-895128f22efc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3c546305-ea7d-4af2-9384-3b2919487e48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5623ab5f-bc49-4eef-8ead-156147a8a7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_128925d9-0424-4313-88a9-895128f22efc" xlink:to="loc_us-gaap_EmployeeStockMember_5623ab5f-bc49-4eef-8ead-156147a8a7c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9deb6c08-4076-404c-9056-bc59ce2aad4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f09a93-8359-4cbc-aee0-c4e7ca46619f" xlink:to="loc_srt_RangeAxis_9deb6c08-4076-404c-9056-bc59ce2aad4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9deb6c08-4076-404c-9056-bc59ce2aad4b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9deb6c08-4076-404c-9056-bc59ce2aad4b" xlink:to="loc_srt_RangeMember_9deb6c08-4076-404c-9056-bc59ce2aad4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac74f7e8-afaa-440e-9fb3-76cb958361a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9deb6c08-4076-404c-9056-bc59ce2aad4b" xlink:to="loc_srt_RangeMember_ac74f7e8-afaa-440e-9fb3-76cb958361a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_9f754b1e-9a20-44c7-8f22-340566dd6936" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac74f7e8-afaa-440e-9fb3-76cb958361a0" xlink:to="loc_srt_WeightedAverageMember_9f754b1e-9a20-44c7-8f22-340566dd6936" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="ib42c60ffb7644f2cbcebdf66421dee1e_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_629a426d-405f-47b9-9656-7d102f9ef262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_42d0717d-5496-4760-8e64-7c043981723b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_629a426d-405f-47b9-9656-7d102f9ef262" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_42d0717d-5496-4760-8e64-7c043981723b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6b50a278-9f7d-4725-8b2b-7e400708c1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_629a426d-405f-47b9-9656-7d102f9ef262" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6b50a278-9f7d-4725-8b2b-7e400708c1b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df14149d-fc98-4714-9f86-b4433c34240b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6b50a278-9f7d-4725-8b2b-7e400708c1b3" xlink:to="loc_us-gaap_AwardTypeAxis_df14149d-fc98-4714-9f86-b4433c34240b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df14149d-fc98-4714-9f86-b4433c34240b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_df14149d-fc98-4714-9f86-b4433c34240b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df14149d-fc98-4714-9f86-b4433c34240b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac17743e-9cc6-48f0-a4dc-cb9ad6b5fe46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_df14149d-fc98-4714-9f86-b4433c34240b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac17743e-9cc6-48f0-a4dc-cb9ad6b5fe46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_68ee2d40-39f5-4016-b4c0-d8acda561cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac17743e-9cc6-48f0-a4dc-cb9ad6b5fe46" xlink:to="loc_us-gaap_EmployeeStockOptionMember_68ee2d40-39f5-4016-b4c0-d8acda561cea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember_d31c746b-acd3-4174-bf52-8fd85db54779" xlink:href="mrna-20211231.xsd#mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac17743e-9cc6-48f0-a4dc-cb9ad6b5fe46" xlink:to="loc_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember_d31c746b-acd3-4174-bf52-8fd85db54779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c742ff62-16d2-42b7-9ac3-c6811f3b4ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac17743e-9cc6-48f0-a4dc-cb9ad6b5fe46" xlink:to="loc_us-gaap_EmployeeStockMember_c742ff62-16d2-42b7-9ac3-c6811f3b4ecf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cf16d54d-658d-4396-825f-d7e2371cf181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6b50a278-9f7d-4725-8b2b-7e400708c1b3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cf16d54d-658d-4396-825f-d7e2371cf181" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cf16d54d-658d-4396-825f-d7e2371cf181_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cf16d54d-658d-4396-825f-d7e2371cf181" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cf16d54d-658d-4396-825f-d7e2371cf181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cbac6e12-a666-465b-a0a4-745eba4d9f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cf16d54d-658d-4396-825f-d7e2371cf181" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cbac6e12-a666-465b-a0a4-745eba4d9f54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_05b5c91f-3885-4250-83d5-49b8512e9cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cbac6e12-a666-465b-a0a4-745eba4d9f54" xlink:to="loc_us-gaap_CostOfSalesMember_05b5c91f-3885-4250-83d5-49b8512e9cf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dacd55b4-49e3-4e1d-b8cf-e8ba39998561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cbac6e12-a666-465b-a0a4-745eba4d9f54" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dacd55b4-49e3-4e1d-b8cf-e8ba39998561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3fd534bc-520f-4b71-b15c-7282c4346094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cbac6e12-a666-465b-a0a4-745eba4d9f54" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3fd534bc-520f-4b71-b15c-7282c4346094" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#EmployeeBenefitPlanDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" id="i1a2e3b66d3c14998af269b1734a5990a_EmployeeBenefitPlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_206f5ad0-216a-46c1-a8c6-6f25b3d8f12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_d5d6ea99-50ef-4081-978e-8b2757b5ef62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_206f5ad0-216a-46c1-a8c6-6f25b3d8f12a" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_d5d6ea99-50ef-4081-978e-8b2757b5ef62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9380a5e8-90f5-43e0-b98a-00fb85a5060d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_206f5ad0-216a-46c1-a8c6-6f25b3d8f12a" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9380a5e8-90f5-43e0-b98a-00fb85a5060d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusAxis_4eaee679-30b0-4f2c-a566-902d7ee01050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanFundingStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9380a5e8-90f5-43e0-b98a-00fb85a5060d" xlink:to="loc_us-gaap_RetirementPlanFundingStatusAxis_4eaee679-30b0-4f2c-a566-902d7ee01050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusDomain_4eaee679-30b0-4f2c-a566-902d7ee01050_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanFundingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanFundingStatusAxis_4eaee679-30b0-4f2c-a566-902d7ee01050" xlink:to="loc_us-gaap_RetirementPlanFundingStatusDomain_4eaee679-30b0-4f2c-a566-902d7ee01050_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusDomain_f41ff20f-01fc-4d04-8e9d-21dd451df46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanFundingStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanFundingStatusAxis_4eaee679-30b0-4f2c-a566-902d7ee01050" xlink:to="loc_us-gaap_RetirementPlanFundingStatusDomain_f41ff20f-01fc-4d04-8e9d-21dd451df46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfundedPlanMember_c61c8f7e-9f23-4ad2-a689-55379137bbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfundedPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanFundingStatusDomain_f41ff20f-01fc-4d04-8e9d-21dd451df46a" xlink:to="loc_us-gaap_UnfundedPlanMember_c61c8f7e-9f23-4ad2-a689-55379137bbb1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ice3a84af9ee84447bdc78db0d7a08862_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cba6d5b7-c6d6-4ea1-8c0e-69189008a154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cba6d5b7-c6d6-4ea1-8c0e-69189008a154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f1748967-bff7-4b8c-b1f0-8b0daf4aa9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f1748967-bff7-4b8c-b1f0-8b0daf4aa9d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_997c31c2-9675-470e-b977-3fabefe2334f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_997c31c2-9675-470e-b977-3fabefe2334f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_UnrecognizedTaxBenefitsNet_5efd3d03-c7a7-40cb-8cd8-599dfeabee43" xlink:href="mrna-20211231.xsd#mrna_UnrecognizedTaxBenefitsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:to="loc_mrna_UnrecognizedTaxBenefitsNet_5efd3d03-c7a7-40cb-8cd8-599dfeabee43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_b61b680e-d3c2-4c89-9157-9a467397ac50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_b61b680e-d3c2-4c89-9157-9a467397ac50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8ca59c6e-8f41-40f7-a13a-d692d1aeb9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b61b680e-d3c2-4c89-9157-9a467397ac50" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8ca59c6e-8f41-40f7-a13a-d692d1aeb9f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8ca59c6e-8f41-40f7-a13a-d692d1aeb9f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8ca59c6e-8f41-40f7-a13a-d692d1aeb9f4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8ca59c6e-8f41-40f7-a13a-d692d1aeb9f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4c037290-5530-45f3-9308-57ec8c82288a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8ca59c6e-8f41-40f7-a13a-d692d1aeb9f4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4c037290-5530-45f3-9308-57ec8c82288a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_b28b6754-0f33-48c0-b33e-d2bd7ad55e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4c037290-5530-45f3-9308-57ec8c82288a" xlink:to="loc_us-gaap_DomesticCountryMember_b28b6754-0f33-48c0-b33e-d2bd7ad55e0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_7c055964-d99e-473f-9c4a-3e7059af2563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b61b680e-d3c2-4c89-9157-9a467397ac50" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_7c055964-d99e-473f-9c4a-3e7059af2563" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7c055964-d99e-473f-9c4a-3e7059af2563_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_7c055964-d99e-473f-9c4a-3e7059af2563" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7c055964-d99e-473f-9c4a-3e7059af2563_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_9b2e2a75-7d04-4a9c-ac5b-aead607074df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_7c055964-d99e-473f-9c4a-3e7059af2563" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_9b2e2a75-7d04-4a9c-ac5b-aead607074df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_6b2aaba6-352b-4cfb-a4f1-1b703d90dd85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_9b2e2a75-7d04-4a9c-ac5b-aead607074df" xlink:to="loc_us-gaap_ResearchMember_6b2aaba6-352b-4cfb-a4f1-1b703d90dd85" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended" id="i345d0f624b1e4c1aa30053ec6d62706a_EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_acea2bd3-5f77-4beb-9d4f-02523412abfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48ff355a-04b7-4a01-8d24-7ef5d7a165a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_acea2bd3-5f77-4beb-9d4f-02523412abfc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48ff355a-04b7-4a01-8d24-7ef5d7a165a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7c1100-eaa3-48cb-9435-572168e618ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_acea2bd3-5f77-4beb-9d4f-02523412abfc" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7c1100-eaa3-48cb-9435-572168e618ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a38429f2-058d-4d59-918d-9ed4af4a288d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7c1100-eaa3-48cb-9435-572168e618ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a38429f2-058d-4d59-918d-9ed4af4a288d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a38429f2-058d-4d59-918d-9ed4af4a288d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a38429f2-058d-4d59-918d-9ed4af4a288d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a38429f2-058d-4d59-918d-9ed4af4a288d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce2f232e-6f56-49ce-a6a7-0875260ba77f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a38429f2-058d-4d59-918d-9ed4af4a288d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce2f232e-6f56-49ce-a6a7-0875260ba77f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1be35f5a-3d88-4dc1-b021-f3dba2ddbe27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce2f232e-6f56-49ce-a6a7-0875260ba77f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1be35f5a-3d88-4dc1-b021-f3dba2ddbe27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a494e5d1-52fc-42f1-ae02-ee7ebb3470a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce2f232e-6f56-49ce-a6a7-0875260ba77f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a494e5d1-52fc-42f1-ae02-ee7ebb3470a6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GeographicInformationDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#GeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/GeographicInformationDetails" xlink:type="extended" id="ia5015ff65f944c8abc977f6383c8a0ee_GeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_39a8c936-35bf-47c7-a55a-5352687798b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4912f020-eb7b-4ba3-87a1-c1f194b7495d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_39a8c936-35bf-47c7-a55a-5352687798b7" xlink:to="loc_us-gaap_Revenues_4912f020-eb7b-4ba3-87a1-c1f194b7495d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_38097c32-9901-4a72-b41c-becc875b62de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_39a8c936-35bf-47c7-a55a-5352687798b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_38097c32-9901-4a72-b41c-becc875b62de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_fbf7dc5e-fc05-4b2b-97e9-5eceee61dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_39a8c936-35bf-47c7-a55a-5352687798b7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_fbf7dc5e-fc05-4b2b-97e9-5eceee61dd7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ff3aceb2-41b6-46d3-b061-3e36bdc42fb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fbf7dc5e-fc05-4b2b-97e9-5eceee61dd7d" xlink:to="loc_srt_StatementGeographicalAxis_ff3aceb2-41b6-46d3-b061-3e36bdc42fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ff3aceb2-41b6-46d3-b061-3e36bdc42fb2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ff3aceb2-41b6-46d3-b061-3e36bdc42fb2" xlink:to="loc_srt_SegmentGeographicalDomain_ff3aceb2-41b6-46d3-b061-3e36bdc42fb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cfc9b216-862d-4bc0-bbf1-331c8cb92f8b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ff3aceb2-41b6-46d3-b061-3e36bdc42fb2" xlink:to="loc_srt_SegmentGeographicalDomain_cfc9b216-862d-4bc0-bbf1-331c8cb92f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0ac71343-742d-4568-a0f6-9699ca7846ef" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cfc9b216-862d-4bc0-bbf1-331c8cb92f8b" xlink:to="loc_country_US_0ac71343-742d-4568-a0f6-9699ca7846ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_15c42b26-b91b-48f9-96ed-6cee1f7186c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cfc9b216-862d-4bc0-bbf1-331c8cb92f8b" xlink:to="loc_srt_EuropeMember_15c42b26-b91b-48f9-96ed-6cee1f7186c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestOfWorldMember_16850390-f6e4-4232-9cac-bebb6c62a29e" xlink:href="mrna-20211231.xsd#mrna_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_cfc9b216-862d-4bc0-bbf1-331c8cb92f8b" xlink:to="loc_mrna_RestOfWorldMember_16850390-f6e4-4232-9cac-bebb6c62a29e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="extended" id="i92d60fb8ebe64f41a01146b88db268a9_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ad29f38e-fd7d-4bad-bf44-a17fd5ad2701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ad29f38e-fd7d-4bad-bf44-a17fd5ad2701" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2ba5cf9f-68bf-4352-ae2e-8913657f9658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_2ba5cf9f-68bf-4352-ae2e-8913657f9658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_628347f8-9bf1-4a7c-8823-97f4252f1bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_628347f8-9bf1-4a7c-8823-97f4252f1bdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDosesOfVaccineCandidate_bd6c83cb-ee4a-496b-8991-c0bd300a6fb6" xlink:href="mrna-20211231.xsd#mrna_NumberOfDosesOfVaccineCandidate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_mrna_NumberOfDosesOfVaccineCandidate_bd6c83cb-ee4a-496b-8991-c0bd300a6fb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_f0570da9-36da-4d50-af68-38c5e5153226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_f0570da9-36da-4d50-af68-38c5e5153226" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_b5f4e59b-9409-4272-89a4-01fcb5c73109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_PurchaseObligation_b5f4e59b-9409-4272-89a4-01fcb5c73109" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_398db190-a5e1-4d07-a383-b7edb7495256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_398db190-a5e1-4d07-a383-b7edb7495256" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_ec2050e2-4e52-4b2d-bfae-3823f92942f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_SubsequentEventTable_ec2050e2-4e52-4b2d-bfae-3823f92942f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f9d5f328-3276-44ff-b91c-11bde1e28f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ec2050e2-4e52-4b2d-bfae-3823f92942f3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f9d5f328-3276-44ff-b91c-11bde1e28f5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f9d5f328-3276-44ff-b91c-11bde1e28f5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f9d5f328-3276-44ff-b91c-11bde1e28f5c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f9d5f328-3276-44ff-b91c-11bde1e28f5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3661cfa5-96ef-461b-b96c-6615d43558f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f9d5f328-3276-44ff-b91c-11bde1e28f5c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3661cfa5-96ef-461b-b96c-6615d43558f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_442d21ba-8348-4e48-a6c7-fc9d26105f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3661cfa5-96ef-461b-b96c-6615d43558f7" xlink:to="loc_us-gaap_SubsequentEventMember_442d21ba-8348-4e48-a6c7-fc9d26105f8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_35c317af-944e-423e-9e3a-e86ba012b2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ec2050e2-4e52-4b2d-bfae-3823f92942f3" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_35c317af-944e-423e-9e3a-e86ba012b2cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_35c317af-944e-423e-9e3a-e86ba012b2cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_35c317af-944e-423e-9e3a-e86ba012b2cf" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_35c317af-944e-423e-9e3a-e86ba012b2cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a313988b-40b6-479f-a6a9-273e61d80cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_35c317af-944e-423e-9e3a-e86ba012b2cf" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a313988b-40b6-479f-a6a9-273e61d80cc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2021RepurchaseProgramMember_3341a06b-e324-44d3-b021-d4ac2712f2d0" xlink:href="mrna-20211231.xsd#mrna_A2021RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a313988b-40b6-479f-a6a9-273e61d80cc8" xlink:to="loc_mrna_A2021RepurchaseProgramMember_3341a06b-e324-44d3-b021-d4ac2712f2d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2022RepurchaseProgramPlanMember_0748417a-10ea-453d-942a-557720db14e6" xlink:href="mrna-20211231.xsd#mrna_A2022RepurchaseProgramPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a313988b-40b6-479f-a6a9-273e61d80cc8" xlink:to="loc_mrna_A2022RepurchaseProgramPlanMember_0748417a-10ea-453d-942a-557720db14e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>mrna-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:61dc7ba0-21f1-4a58-a37b-1270ec5a6c14,g:27805b16-b8d5-4e89-9c63-161f1adf5057-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_b27bd540-e18f-421a-a6f4-ffc78e48223e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ClinicalServicesMember_267ddae1-f585-4776-88a3-a4e86739d995_terseLabel_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical services</link:label>
    <link:label id="lab_mrna_ClinicalServicesMember_label_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services [Member]</link:label>
    <link:label id="lab_mrna_ClinicalServicesMember_documentation_en-US" xlink:label="lab_mrna_ClinicalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember" xlink:href="mrna-20211231.xsd#mrna_ClinicalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ClinicalServicesMember" xlink:to="lab_mrna_ClinicalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9c469e99-8bf4-44e9-ba6f-2c285ccce96b_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_8690c191-ec6f-4e87-b647-bd327039e866_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2a077c5c-2562-41db-b5ad-d80e728ec694_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_de85e6dc-7abc-4ba7-92cb-941fa3e7e35f_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4ed861e9-01d7-42ab-9e0f-4ac71c57a726_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized&#160;Gain (Loss) on Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_VertexMember_58388288-bc91-41f3-8612-999e2196fbdb_terseLabel_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex</link:label>
    <link:label id="lab_mrna_VertexMember_label_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex [Member]</link:label>
    <link:label id="lab_mrna_VertexMember_documentation_en-US" xlink:label="lab_mrna_VertexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vertex [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember" xlink:href="mrna-20211231.xsd#mrna_VertexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_VertexMember" xlink:to="lab_mrna_VertexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6b818311-9c41-44c2-974b-be4b9a616066_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_859b213c-7cdf-4514-a458-2615422b539a_terseLabel_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PCV products</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_label_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines Products [Member]</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember_documentation_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:href="mrna-20211231.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:to="lab_mrna_PersonalizedMRNACancerVaccinesProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_9ea1b217-99bc-4081-b1be-e31b869d3c1c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_03a0cc99-f822-4942-90aa-586f0419e89b_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of installments</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ef8c18f4-4a42-4bcc-b091-9454a63fc8c6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_81cc7b8f-ac5a-4ea8-b3bd-e7b7a09b302f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_472e2647-a6c5-4e61-b39f-cebbefd1bf75_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bda81211-81ce-4d96-a9e4-8f8c979babba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_71073485-c95b-489e-a855-bfcd5b54094a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7c950bd0-c5d7-40d5-aefb-0d5789595d83_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_03140dcd-9588-415c-b326-58f8a0bdbca3_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract options exercised</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options Exercised</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:to="lab_mrna_RevenueFromGrantsNumberOfContractOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_e8549f16-5906-4931-a4b2-706ff92e6a3c_terseLabel_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Plan</link:label>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_label_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option And Incentive Plan 2018 [Member]</link:label>
    <link:label id="lab_mrna_StockOptionAndIncentivePlan2018Member_documentation_en-US" xlink:label="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option And Incentive Plan 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member" xlink:href="mrna-20211231.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StockOptionAndIncentivePlan2018Member" xlink:to="lab_mrna_StockOptionAndIncentivePlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_812043ae-e40a-42a3-9fdb-4b581c5b0587_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_bea626ea-ddfa-4a22-a6bf-4cfcde4615d3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, operating, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_EmployeeStockPurchasePlan2018Member_7fb082e8-5c48-4086-a847-e018336c595a_terseLabel_en-US" xlink:label="lab_mrna_EmployeeStockPurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_mrna_EmployeeStockPurchasePlan2018Member_label_en-US" xlink:label="lab_mrna_EmployeeStockPurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2018 [Member]</link:label>
    <link:label id="lab_mrna_EmployeeStockPurchasePlan2018Member_documentation_en-US" xlink:label="lab_mrna_EmployeeStockPurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmployeeStockPurchasePlan2018Member" xlink:href="mrna-20211231.xsd#mrna_EmployeeStockPurchasePlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_EmployeeStockPurchasePlan2018Member" xlink:to="lab_mrna_EmployeeStockPurchasePlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_4b74eacb-8b59-44ad-af5f-011ea321d854_terseLabel_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketable Securities</link:label>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_label_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketable Securities [Member]</link:label>
    <link:label id="lab_mrna_CurrentMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_mrna_CurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember" xlink:href="mrna-20211231.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CurrentMarketableSecuritiesMember" xlink:to="lab_mrna_CurrentMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_15435d48-2afe-4a2b-80ee-1a499fc832eb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_cbaa5274-1bfa-4ef6-beea-4c00834bc207_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_1e4c21d9-fc30-42bb-99d3-3cf9621686c8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5862d0fb-91ff-45ed-a6e7-726c93b6e007_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation-related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RestOfWorldMember_af25d9f5-53fe-427b-81a3-b0d170a8d346_terseLabel_en-US" xlink:label="lab_mrna_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_mrna_RestOfWorldMember_label_en-US" xlink:label="lab_mrna_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_mrna_RestOfWorldMember_documentation_en-US" xlink:label="lab_mrna_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestOfWorldMember" xlink:href="mrna-20211231.xsd#mrna_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RestOfWorldMember" xlink:to="lab_mrna_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1c394014-2705-436f-b17d-ea307845542d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetPurchase_aacd61b8-7a7d-400b-99e6-974d517dcd9d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetPurchase_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetPurchase" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetPurchase" xlink:to="lab_us-gaap_ContractWithCustomerAssetPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ad5f02fe-8178-4f5d-b16b-566b1a35c299_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_daec2858-1df0-4bb9-84c9-90fa87bae8c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_cc27783c-ce31-4978-8454-22315c933aaf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_620b4a56-2216-4dcc-90f9-e72f0aa7e7e0_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_3708b3d2-a269-4a3f-b35a-1e966652e920_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedemptionPremium_7be10d11-93c2-4a2e-93f6-874f2daffc0e_terseLabel_en-US" xlink:label="lab_us-gaap_RedemptionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium recorded to deferred revenue</link:label>
    <link:label id="lab_us-gaap_RedemptionPremium_label_en-US" xlink:label="lab_us-gaap_RedemptionPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedemptionPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedemptionPremium" xlink:to="lab_us-gaap_RedemptionPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b2b38113-39dc-4796-931c-10cb8fbcc5ef_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2a87a4ec-418c-4f6c-963c-120a3045163d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_fed49f07-9662-4aa2-a7f4-d6998215d7b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charges related to marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b8b8b43b-6a77-4c58-a2c8-92dc8ac1cbdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_3c4d8d53-9e99-4dc7-97cf-438f1fcd6033_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares to be purchased during purchase period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_26f9463e-34d1-475e-9980-8f5d2f1f7cbb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_aa65d4fd-8396-41ca-a250-40f5a87ac0ec_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Balances of Receivables and Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5eaafd61-cacb-493f-86bd-ecce1b379c58_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Activities Summary</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f9485a85-8b0d-4515-8e4d-3be1466c82bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d0884a5b-bd14-4f44-af76-c964b33eed12_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_97e89aa7-e137-4faa-97b3-279c7eb98d19_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value added tax receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_dbd7965d-bb35-46f3-8a49-bd30f718eca5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_854dc7d4-4a78-4a45-b381-638111efd726_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b0a2139-a835-465b-b44a-e4f2d17bebfe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_b4523a07-8b0d-4be2-93cd-1990bd5ff7d3_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payout percentage</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherMember_adbe0eab-fd8b-4eaa-a2ff-8680d866268e_terseLabel_en-US" xlink:label="lab_mrna_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrna_OtherMember_label_en-US" xlink:label="lab_mrna_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_mrna_OtherMember_documentation_en-US" xlink:label="lab_mrna_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherMember" xlink:href="mrna-20211231.xsd#mrna_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherMember" xlink:to="lab_mrna_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_28535731-0caa-44c4-bfe1-5b1ff881d0d8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4d8638c4-560d-4564-b0cf-397cb611207f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c396563e-62c9-47ab-a3ca-af59816d7391_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_7ced84bb-8f6b-4a97-9dfc-dc8fc6be0f29_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87db9528-28c7-4960-a4d3-1f6a5fb372ff_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c6cfc585-5ec1-4a3a-bd1e-03357e5104fb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0f5d20c5-a7a7-40cf-8ae9-e60588943afa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cf1aaa11-a0ef-4cde-874e-819c71b0ccce_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AllowanceForTenantImprovements_032c36d5-d1fc-47ab-b066-ad005bfd6290_terseLabel_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for tenant improvements</link:label>
    <link:label id="lab_mrna_AllowanceForTenantImprovements_label_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Tenant Improvements</link:label>
    <link:label id="lab_mrna_AllowanceForTenantImprovements_documentation_en-US" xlink:label="lab_mrna_AllowanceForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AllowanceForTenantImprovements" xlink:href="mrna-20211231.xsd#mrna_AllowanceForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AllowanceForTenantImprovements" xlink:to="lab_mrna_AllowanceForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2a184f0d-8baa-4c55-9d67-7b28a9236965_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4927091e-76ab-45c6-9ee2-a78d15bc5cd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_b03d2ab2-1c1e-478f-a2db-3d8c213ca421_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due in Next Rolling 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_f396ceea-5e11-4a1b-8adf-f3d3ca439da5_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_4a96e0c5-7492-41e3-8715-e8aa80680b4e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due in Rolling Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_aedb4676-81c1-49cb-a705-049c1a0aae98_terseLabel_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Current Marketable Securities</link:label>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_label_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Marketable Securities [Member]</link:label>
    <link:label id="lab_mrna_NoncurrentMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember" xlink:href="mrna-20211231.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NoncurrentMarketableSecuritiesMember" xlink:to="lab_mrna_NoncurrentMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_d5efa825-2385-4e2c-832c-33cff599c213_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_2cf031d4-203f-4618-a322-60efa55b7040_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_eed8c2a8-58fe-409f-966d-62a3ddfb4005_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due in Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_add5cbf2-003c-49f6-9959-b16480666b88_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_464d3cc3-3fb0-40b3-82df-21b0d0d834f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_2ecbec80-d16f-4347-964b-0af0bd1b678c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions for prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_5e4c0d69-552f-4d9c-ba66-4cafbb6b64b8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_5e2d2d97-6fa0-4888-8373-599ef16738b3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3dbe8616-6a58-4cd2-b457-2cfb54960874_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_593d5746-2e8b-4195-ac6c-867e1b482c82_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c241bf15-439c-491c-8ee4-ee329be33f15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_62784369-08f8-42de-ae4b-96296f7af6ce_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_cf2cd01c-bb36-45da-aafc-2bc6a0b2e171_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_441e2aeb-1c2f-4132-9260-28fcd0c9a3b3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_a6d4b40c-8ed9-4e8b-a83b-7b84292de42a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3aa6c9a2-8769-4876-b8e1-c9aeb64df828_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b3526541-3fbf-43f1-8af5-7260e4835f57_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_01412df3-cba1-4983-ae92-d681b7ae93ef_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses related to indemnification obligations</link:label>
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_label_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Loss in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLossInPeriod" xlink:to="lab_us-gaap_LossContingencyLossInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_015977c5-c623-496c-94b1-5f877ffd5bbc_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_fe7e569f-afa5-4e23-9362-a72102e01cee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0551e1c7-1008-4976-8093-f96c0f388863_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f979fc8c-6625-41ef-bddf-5f734ff271df_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (losses) gains on available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_fa0ac1bb-a716-4ff8-ace3-f4695a0414d0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realized and unrealized (losses)</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d983d91b-f133-46b6-8400-f59202fb0ecc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_80aa5e21-fbb1-458b-9d12-6ce2cebe0c61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_052cb580-71aa-4150-bb8d-16cc4601fdf2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_56e57573-76a6-4d62-9854-9fb64fa092b0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_6d809606-3785-49d3-a5eb-5bf58b444307_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f338cb98-9df4-49eb-8b43-cc12bdce0eaf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_TwoHundredTechnologySquareMember_a1dc9dbb-b0db-4834-a431-e72f9ccaafa8_terseLabel_en-US" xlink:label="lab_mrna_TwoHundredTechnologySquareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">200&#160;Technology Square</link:label>
    <link:label id="lab_mrna_TwoHundredTechnologySquareMember_label_en-US" xlink:label="lab_mrna_TwoHundredTechnologySquareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred&#160;Technology Square [Member]</link:label>
    <link:label id="lab_mrna_TwoHundredTechnologySquareMember_documentation_en-US" xlink:label="lab_mrna_TwoHundredTechnologySquareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred&#160;Technology Square</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TwoHundredTechnologySquareMember" xlink:href="mrna-20211231.xsd#mrna_TwoHundredTechnologySquareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TwoHundredTechnologySquareMember" xlink:to="lab_mrna_TwoHundredTechnologySquareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_8b12180e-ebba-4a78-b64a-c39030204f51_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_112e9265-9bfe-4eaa-9f96-12c2790eaadc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_57ff31a4-c90c-4dd4-a343-e3b02d5029d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average expected to vest (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AstraZenecaMember_7e66e11b-3e5c-4336-9b35-9d0cdb69e465_terseLabel_en-US" xlink:label="lab_mrna_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_mrna_AstraZenecaMember_label_en-US" xlink:label="lab_mrna_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_mrna_AstraZenecaMember_documentation_en-US" xlink:label="lab_mrna_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AstraZenecaMember" xlink:href="mrna-20211231.xsd#mrna_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AstraZenecaMember" xlink:to="lab_mrna_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_7f437545-0802-46bd-a298-923491d6706e_terseLabel_en-US" xlink:label="lab_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign-derived intangible income</link:label>
    <link:label id="lab_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_label_en-US" xlink:label="lab_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Derived Intangible income, Percent</link:label>
    <link:label id="lab_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_documentation_en-US" xlink:label="lab_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Derived Intangible income, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:href="mrna-20211231.xsd#mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:to="lab_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_3a50c58e-cf66-41cf-88a1-39873fa9cf32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_4f42f605-9223-491c-bd6f-5338e16311e4_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_47876f81-f822-4f04-aee6-d4f3d30b0821_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_5f9f6532-c7f7-49e7-81ec-2af8f29c92ae_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e5e21b77-d375-4909-b96a-20b7b4e89ed2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_b598eede-697d-4892-bb87-8e1d3b0036f0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_bc39e555-204f-4e21-9a0a-b812e3e9a6ea_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_0c105a8a-d1a7-4640-81aa-d9f2c309139a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001; 162&#160;shares authorized as of December 31, 2021 and 2020; no shares issued or outstanding at December 31, 2021 and 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cf178113-60e5-49e1-9718-137536d40018_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_687a50fb-4ee6-47bc-a2e6-dfd9a3189b32_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_InitialProjectMember_55d0bcde-c2e8-4d58-883f-6d14d66c6d5e_terseLabel_en-US" xlink:label="lab_mrna_InitialProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial project</link:label>
    <link:label id="lab_mrna_InitialProjectMember_label_en-US" xlink:label="lab_mrna_InitialProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Project [Member]</link:label>
    <link:label id="lab_mrna_InitialProjectMember_documentation_en-US" xlink:label="lab_mrna_InitialProjectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Project [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialProjectMember" xlink:href="mrna-20211231.xsd#mrna_InitialProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_InitialProjectMember" xlink:to="lab_mrna_InitialProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3202fb8-8420-466b-b18d-208b86526a8b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2203d486-ff2c-414e-99f2-02f86594724a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_935c7b8f-f45f-4ca2-b042-1c7dc21c24c1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_268c9244-dab1-44f7-be51-eabba05463d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_1a953146-71f4-4c90-aaad-c820b485a1e2_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office space (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_625327b3-20f6-42a5-bf24-9a31dd92ae5e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_a249ee95-f7fb-4ddb-83f7-f6c21b5eddc8_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_d1dbc158-4ec4-4a31-b487-d8aed02c7bd4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9bad92d4-ee21-4a4f-83cf-499da9e9532f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfundedPlanMember_e9ec3fec-5361-4f44-ad74-4d9315e70ef9_terseLabel_en-US" xlink:label="lab_us-gaap_UnfundedPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded benefit plan</link:label>
    <link:label id="lab_us-gaap_UnfundedPlanMember_label_en-US" xlink:label="lab_us-gaap_UnfundedPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Unfunded Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfundedPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfundedPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfundedPlanMember" xlink:to="lab_us-gaap_UnfundedPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_aee842ee-4fa7-433e-b407-94531a6c80b6_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_16bb9f14-0640-4f2b-8b92-910593e68ed7_terseLabel_en-US" xlink:label="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized licenses, research and development and start-up costs</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_label_en-US" xlink:label="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_documentation_en-US" xlink:label="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:to="lab_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_adbd6191-d16c-49d4-abe4-0013a26065e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5e705bcc-f823-4195-b1f8-7ac839984aa5_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f3f6b6aa-1c2d-48b3-b897-0f828290de9c_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_48eb19c9-f490-4cbd-83bb-f2ff47d1739a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Components of Deferred Tax Assets and Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_da04aa0d-7188-400b-ae4a-66c82fca5087_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of compensation through payroll deductions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f435efbb-415b-4971-bf09-cc475490bba3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_6ee80efa-5461-450e-bea4-9da5e6aff9bf_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9c933f7c-5c83-472a-adff-b605f6b35cfd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bd1683d9-6bd4-4d9c-9d62-ee12f88ab4ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_496a4fcb-1ed5-4c24-b9bb-fb901f7ad103_terseLabel_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge Leases</link:label>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_label_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_mrna_CambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_mrna_CambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cambridge, Massachusetts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember" xlink:href="mrna-20211231.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CambridgeMassachusettsMember" xlink:to="lab_mrna_CambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_dcdbc2cc-2c13-4be1-8fe5-75c4f35b1cea_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_62a17090-6348-43f6-86c4-aee11abe4cfc_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows used in financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CollaborationArrangementMember_a9f6ae18-b436-4511-9baf-3637755258af_terseLabel_en-US" xlink:label="lab_mrna_CollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_mrna_CollaborationArrangementMember_label_en-US" xlink:label="lab_mrna_CollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement [Member]</link:label>
    <link:label id="lab_mrna_CollaborationArrangementMember_documentation_en-US" xlink:label="lab_mrna_CollaborationArrangementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember" xlink:href="mrna-20211231.xsd#mrna_CollaborationArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborationArrangementMember" xlink:to="lab_mrna_CollaborationArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_b4a38874-d908-4b08-8285-f9663d46ef93_negatedLabel_en-US" xlink:label="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, operating</link:label>
    <link:label id="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_A2021RepurchaseProgramMember_bb453a47-fb40-4705-bbc9-6ae0571512dc_terseLabel_en-US" xlink:label="lab_mrna_A2021RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Repurchase Program</link:label>
    <link:label id="lab_mrna_A2021RepurchaseProgramMember_label_en-US" xlink:label="lab_mrna_A2021RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Repurchase Program [Member]</link:label>
    <link:label id="lab_mrna_A2021RepurchaseProgramMember_documentation_en-US" xlink:label="lab_mrna_A2021RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2021RepurchaseProgramMember" xlink:href="mrna-20211231.xsd#mrna_A2021RepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_A2021RepurchaseProgramMember" xlink:to="lab_mrna_A2021RepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_51946226-27b6-4fe8-80fa-c1e5fa4d345a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_21296ed0-a2cd-4f2a-a955-4ed3e68d6d1a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_dbafcce7-8e86-4866-9fd6-0fd4afa95138_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_cf4f0ed2-de0e-46ca-b61f-3961f08d77ce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_12925627-1d1d-4c00-b449-2b3cc7cbfb41_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8f8e8663-8862-4be5-bd47-3e556733d923_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic EPS (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_fd2058fd-9c0d-4935-ac41-09c94bf66131_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims outstanding</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_29c62341-434d-4883-8d0e-9af8034e0b24_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_e449fd81-2295-4e51-a60e-beb161cbf240_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_4297ade4-b8da-43c1-9726-26d50ccc53e2_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Information</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8f5bd26b-5766-401a-84f2-8f78cf1de26f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_31e686f4-9950-4298-91f4-7b0e50807975_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FinanceLeaseCost_c52043f7-b1ca-4d56-ab37-52ff5d08523c_totalLabel_en-US" xlink:label="lab_mrna_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financing lease costs</link:label>
    <link:label id="lab_mrna_FinanceLeaseCost_label_en-US" xlink:label="lab_mrna_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_mrna_FinanceLeaseCost_documentation_en-US" xlink:label="lab_mrna_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseCost" xlink:href="mrna-20211231.xsd#mrna_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FinanceLeaseCost" xlink:to="lab_mrna_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_44fa8004-a300-4e4a-bd24-b3a3c116c295_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_52abf2d0-35ba-44ca-9c6d-fc1b8271cfd7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_cdd7aa75-4c29-4425-995d-cbe27b95c32f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_66137354-c8db-4ca7-919f-a3e37d1940e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization/accretion of investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_17fb3d98-2d66-4029-85fb-f0a686237425_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares/Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_dacb1c45-f099-45aa-ba8d-25e24040a964_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets expensed</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Leased Assets, Net, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:to="lab_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a834bbbd-bcb4-4a0b-85fd-988cfc082c30_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c06f7a01-1d56-479e-a8a3-c4ec6195021b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_74d68bf6-ff40-4100-9e2c-b8159a1646fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate number of shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e89fb5da-6ee6-4a00-b6ef-d0b92757ad29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows used in operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_e90086dc-9d53-49e8-a263-b18d1541f8ff_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AuditInformationAbstract_label_en-US" xlink:label="lab_mrna_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_mrna_AuditInformationAbstract_documentation_en-US" xlink:label="lab_mrna_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AuditInformationAbstract" xlink:href="mrna-20211231.xsd#mrna_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AuditInformationAbstract" xlink:to="lab_mrna_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_41606922-59af-40a9-891f-81da75db5b19_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4aea5311-e312-499c-a8d8-4fbdc5ca422e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_754b14ff-bc52-4278-8717-7022e78ab003_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_56dcb1f8-0e46-4eb9-aa32-7cccb97d15f8_terseLabel_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Bill&#160;&amp; Melinda Gates Foundation</link:label>
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Bill&#160;And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_mrna_TheBillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Bill&#160;And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember" xlink:href="mrna-20211231.xsd#mrna_TheBillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TheBillAndMelindaGatesFoundationMember" xlink:to="lab_mrna_TheBillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_decdd99c-69ec-454c-9815-e7eb7fd3a3c8_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bad debt expense</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_3f5bf4c4-b3d5-4564-83ab-092d04ff4ffc_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_87ca5eb5-ac18-43a7-8932-f3b2b82d69bc_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_79c57575-948d-4bdd-b392-eaa2f75fd3ea_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, financing, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_UnitedKingdomGovernmentMember_baf9a53c-6e61-4959-a041-7c2ab624685d_terseLabel_en-US" xlink:label="lab_mrna_UnitedKingdomGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Government</link:label>
    <link:label id="lab_mrna_UnitedKingdomGovernmentMember_label_en-US" xlink:label="lab_mrna_UnitedKingdomGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Government [Member]</link:label>
    <link:label id="lab_mrna_UnitedKingdomGovernmentMember_documentation_en-US" xlink:label="lab_mrna_UnitedKingdomGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_UnitedKingdomGovernmentMember" xlink:href="mrna-20211231.xsd#mrna_UnitedKingdomGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_UnitedKingdomGovernmentMember" xlink:to="lab_mrna_UnitedKingdomGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6869c40d-854d-48d1-9bcc-60f4addf8277_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_1273207e-e689-4725-bd34-57f334dccaee_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2e06fcc3-7aef-4adb-a0c3-4aa85c3dd308_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_094dd5a6-7ea8-4d3a-b31f-9e73ca11a101_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_aa112acf-6de9-4e1c-8ee6-c34a094a6703_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_3c80e6d6-a6ae-43df-827f-0e5592b57d07_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_fe880261-b2c1-49c8-aa44-b04e9ce64995_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_e6f0632d-5340-4045-833c-fb8b1c2fd9f1_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally developed software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_30c8403a-2918-4c62-b1d3-002fb7ca05cb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_19fee042-43c0-481b-a405-57a4cb418680_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_d4dc7fee-c5e8-4cdf-a480-4ed333c9b018_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_0447328d-0abe-42a3-96c7-ef15cb5b42ca_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liabilities:</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Liability, NonCurrent [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Liability, NonCurrent [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5dda8cc9-b17d-42f9-b2b2-ba91c6e30f7c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions for current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4639b32f-e25c-4527-9ef4-90acf03e0353_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0a7f6ed9-922c-4c1b-99c7-2c102668e7dd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_05868e87-a773-49dd-b65f-fea6ad9a9c83_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a29bc43-20a8-4051-a084-86c36d4b7e49_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_73866116-fcd2-4ec1-a491-fc724c746816_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twelve months of continued employment or service</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_40a71de2-1c67-4096-a85f-501d5b91eff8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_617375c2-8556-4f25-9401-3a38c647cc02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_0dca8055-4ac9-40d6-85a1-75b0152b4ef5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_7a506c39-f0df-40e9-b567-428d8f776766_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_0883333e-ae0a-4baf-bf4c-5e1a68542fcc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit realized from option exercised</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_0e4e3672-f743-417d-bef6-075036812824_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6d595154-8ee9-4cbe-9b9d-7d9318f21c99_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_bf5a55db-5a9b-4fdf-80a2-48c367d2d9d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_7670ea41-79f1-4bd4-97fd-58b36fb85e9a_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets_863504ea-8e93-4684-98ab-58a56200799b_negatedTerseLabel_en-US" xlink:label="lab_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, operating leases</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets_label_en-US" xlink:label="lab_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Leases, Right Of Use Assets</link:label>
    <link:label id="lab_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets_documentation_en-US" xlink:label="lab_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Leases, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets" xlink:href="mrna-20211231.xsd#mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets" xlink:to="lab_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a64b3c17-2abf-407d-b864-eb77780f0011_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_6768173c-3eee-4321-9076-35cea21dcbb2_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual percentage increase of shares reserved and available for issuance</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Annual Percentage Of Additional Shares Authorized</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Annual Percentage Of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" xlink:to="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_USGovermentMember_33885c31-5974-4453-866e-ae593b344e7e_terseLabel_en-US" xlink:label="lab_mrna_USGovermentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government (excluding BARDA)</link:label>
    <link:label id="lab_mrna_USGovermentMember_label_en-US" xlink:label="lab_mrna_USGovermentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Goverment [Member]</link:label>
    <link:label id="lab_mrna_USGovermentMember_documentation_en-US" xlink:label="lab_mrna_USGovermentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Goverment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_USGovermentMember" xlink:href="mrna-20211231.xsd#mrna_USGovermentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_USGovermentMember" xlink:to="lab_mrna_USGovermentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_f4448a8b-e819-4d06-8fd8-ffadd12fdfd4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0c1c4c77-fc04-42ee-8189-53184421b2f0_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanFundingStatusAxis_c778c072-4316-46e2-ac63-271dfa8e32ec_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanFundingStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funding Status [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanFundingStatusAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanFundingStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funding Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanFundingStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanFundingStatusAxis" xlink:to="lab_us-gaap_RetirementPlanFundingStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_a25ff126-9b9d-41bb-8a93-c9b38e759871_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal research and development credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_20b29cbd-1cad-4d87-b302-e1b0edd8a209_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ca8ff845-a4d0-4487-8f5d-f1ac8062e9a2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_39df2305-9ab0-4561-8d24-23a170fe7d8d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_120060a2-b16c-4806-871e-0a49d3c4f183_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_220e6f72-6bfc-4f93-b29f-8f8422301666_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_b9c94b92-68c3-4cbb-9e08-2fe2a1c14c17_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6cfcb60c-720b-4f5a-83df-d45b7feb5e4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1bfc72f3-4f4b-45d6-8089-993194ed898c_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_4a86340d-a971-4400-9390-74b1bd2abe12_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_a0224a26-8c27-4f9d-ae52-f5c53f651925_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d4ecb4ef-3fcc-4024-85f2-87946128c038_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4e733643-6b9c-483f-9851-ade2ec439427_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_e17004d5-6aed-42af-9aec-298c86bd89b5_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_a33e6239-6378-4e14-97fa-ce312ab7b3d5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_728e8d48-75a0-4d8c-b655-8860310377f7_terseLabel_en-US" xlink:label="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 AZ Agreements</link:label>
    <link:label id="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_label_en-US" xlink:label="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Option Agreement And Services And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Option Agreement And Services And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" xlink:href="mrna-20211231.xsd#mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" xlink:to="lab_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_abf7d208-7664-4edd-9297-537458f2a5eb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_596a2cc1-662a-4363-9ee7-fecce45e237e_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_f61e0d49-7611-4e48-bfa8-9804f1cbf46e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_1d0580dd-0d64-4ab4-bf7a-ed9c8d41d0d1_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Line Items]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer Liability [Line Items]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_968b0385-cdb8-4da0-8af3-5f40949418fb_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses, 12 months or more</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_33ff3760-95e4-426c-875f-a6851b4ad580_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_f0b1e571-94c5-43b3-a7ba-5c3974572b71_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_label_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Deductions During Period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Deductions During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:href="mrna-20211231.xsd#mrna_ContractWithCustomerAssetDeductionsDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:to="lab_mrna_ContractWithCustomerAssetDeductionsDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_4d4c5f8c-281e-4c77-8ee1-39eda4f45ec7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d2fa083d-98b2-4875-9e05-5052aabd5f14_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_a4fd417a-e1b6-46bf-ab8f-a61f80917725_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_63fbffdd-40ad-4635-a527-fdd6a1c85911_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of initial public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f1c8b876-4e3c-42d7-9f42-86752a2442d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_89440e98-8433-4962-b934-f3a6483e42d5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_42f592d3-a8aa-49d3-98ef-e09146398f82_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_8ab58c14-938c-4c19-990f-d0b157204118_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2a8b1d78-6fca-4191-9137-d203aa8c3ec1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For (Benefit From) Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e6657b40-c998-4946-a934-103c821973cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average exercise price per share, exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f71a993a-4fb6-4ae1-881e-b0dc916780f8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_d056d57c-09c6-4133-94b1-c42a4852ee04_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Assets:</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_label_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Asset [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractwithCustomerAssetRollForward_documentation_en-US" xlink:label="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Asset [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractwithCustomerAssetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:to="lab_mrna_ChangeInContractwithCustomerAssetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_aadf8869-d2f2-4b7b-a5a8-5ba62fc1a8ba_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_adbe4453-4c87-4ec6-a8da-a2968c2b2f56_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_12d9c8fd-99dc-4eec-9162-229fae34e1cf_negatedTerseLabel_en-US" xlink:label="lab_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, financing</link:label>
    <link:label id="lab_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Finance Lease Right Of Use Asset</link:label>
    <link:label id="lab_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Finance Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" xlink:to="lab_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_0d541a2d-3b56-46b4-b228-33614fb07782_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_1a143333-b588-4774-a11b-0129814d7a7a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_TenantImprovementAllowanceReceivableCurrent_4f05f930-bf1b-4f3d-8483-6b947a59840b_terseLabel_en-US" xlink:label="lab_mrna_TenantImprovementAllowanceReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance receivable</link:label>
    <link:label id="lab_mrna_TenantImprovementAllowanceReceivableCurrent_label_en-US" xlink:label="lab_mrna_TenantImprovementAllowanceReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance Receivable, Current</link:label>
    <link:label id="lab_mrna_TenantImprovementAllowanceReceivableCurrent_documentation_en-US" xlink:label="lab_mrna_TenantImprovementAllowanceReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TenantImprovementAllowanceReceivableCurrent" xlink:href="mrna-20211231.xsd#mrna_TenantImprovementAllowanceReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_TenantImprovementAllowanceReceivableCurrent" xlink:to="lab_mrna_TenantImprovementAllowanceReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60a8b8ec-ec1f-47c8-a814-aa512554187a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average remaining contractual term, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_9682f062-5f35-4717-bfc1-e48dec674b35_terseLabel_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical operations and support commitments</link:label>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_label_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Operations And Support Commitment [Member]</link:label>
    <link:label id="lab_mrna_ClinicalOperationsAndSupportCommitmentMember_documentation_en-US" xlink:label="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Operations And Support Commitment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:href="mrna-20211231.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:to="lab_mrna_ClinicalOperationsAndSupportCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_44f89bdb-10b3-406c-b08d-3e32252102b1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_b9b36ba6-0fbf-4e3f-b275-b379019daf79_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4e141117-67d2-4045-9ce3-a939bef5284c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of initial public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_bdbe1e83-9cad-45db-a505-ed3fe4e38f75_terseLabel_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue by Strategic Collaborator</link:label>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_label_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Including Arrangements With Affiliate [Member]</link:label>
    <link:label id="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_documentation_en-US" xlink:label="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Including Arrangements With Affiliate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:href="mrna-20211231.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:to="lab_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_33d0c606-d269-4c25-90d3-c619132a6112_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_993cdcc4-2f4e-437f-839d-0fdfa608f654_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a916f7bd-7ab4-4f92-8478-b8e27b361ad9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_df4757f4-8443-4d57-8810-6f447199d636_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2021 and 2020; 403 and 399 shares issued and outstanding as of December 31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_90394332-41a6-4fd8-a43d-ce6d5593450d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases, discount rate</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ca1ef5c6-6d73-4b3a-aac0-536b87be43b1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_112561aa-726f-4cd3-bc0d-f215e6ba70c0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period of cost expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_d9994be9-a14a-4252-9771-3db3b5f13d83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in convertible notes</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e70bc701-60bd-47ea-b8ea-8e2c9d940aab_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at beginning of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6f031b25-11ab-4034-bd36-4c39ef99dda3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, non-vested at end of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_b2727f6b-cc4a-4ec8-9802-da7bba486734_terseLabel_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, financing</link:label>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_label_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing, Right-Of-Use Asset [Member]</link:label>
    <link:label id="lab_mrna_FinancingRightOfUseAssetMember_documentation_en-US" xlink:label="lab_mrna_FinancingRightOfUseAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing, Right-Of-Use Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember" xlink:href="mrna-20211231.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FinancingRightOfUseAssetMember" xlink:to="lab_mrna_FinancingRightOfUseAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_21dff54e-2a7b-4a49-9784-865b0372a9a9_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ab15ac89-19f2-4887-864a-ba6e150a28df_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_f99a80d6-bdbf-4cc9-8002-f90247c887de_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based awards</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ddabb519-94bd-4d4d-a516-7d772c7a629e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_d234ea20-2c55-4678-bdb9-89ba0c0e5755_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_aac50400-ffe3-4e0d-8934-e3f369f0f4ad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a9c04ecf-d55f-4885-bd8b-d61d4100ae87_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3160a597-2b4e-473d-bb57-91d65bfa17c2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_1f63e793-ad7f-4774-b8d3-f1b0f3663d70_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets, financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_069fcda4-e529-4da6-9536-8479f1b59691_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_da241a6c-230b-45e3-a8ad-97e9eba6a4e9_terseLabel_en-US" xlink:label="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in right-of-use assets related to lease modifications and reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_label_en-US" xlink:label="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_documentation_en-US" xlink:label="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:href="mrna-20211231.xsd#mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:to="lab_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_0caacad3-22b3-4fe7-a9e6-1207b4de1ccb_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e2e9c4a7-7404-44a8-acdc-6b4a85e1cc06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_742ca7cd-081b-49b4-ba30-04dfa55009c5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_95f0ca88-4e18-47ac-b143-9552d7c2233a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_603af679-31fd-452a-9564-80bae5904730_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_d52ba5c6-e771-4dba-b551-9c06c84454f2_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_ae444da2-fb9f-4757-88f5-d938d9eb8d41_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a6e617e5-5325-484d-9de5-8508d04c8620_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_d2f43a8e-f94a-4cac-86b2-2ca241b6e52e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_a29ac2dd-ee16-41e2-ba2b-69f06dfb8d1a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_617d6730-1195-489c-889f-ac2a17622c2b_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NorwoodMassachusettsMember_2e1f6622-37c9-43be-9dc1-d0ab91c262fd_terseLabel_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwood Leases</link:label>
    <link:label id="lab_mrna_NorwoodMassachusettsMember_label_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwood, Massachusetts [Member]</link:label>
    <link:label id="lab_mrna_NorwoodMassachusettsMember_documentation_en-US" xlink:label="lab_mrna_NorwoodMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwood, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NorwoodMassachusettsMember" xlink:href="mrna-20211231.xsd#mrna_NorwoodMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NorwoodMassachusettsMember" xlink:to="lab_mrna_NorwoodMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_806cecdb-a975-48a8-9c3f-8907264dcf39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_1796a73b-3ec9-4669-9dce-69773511f710_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss on Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b761a44e-5ea7-4bde-bfbd-07439c2531bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d01fd5d1-f3e2-4462-a2c1-f4aa443aa949_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a7d4160a-0711-4b09-bdb7-99c96abefd8f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_ba5d4b81-adf4-4c9f-b552-44bb9bb57af5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_beef8638-56fa-427c-bac0-e7f0c11b9653_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net proceeds from the offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_2e2c5939-2626-4601-829c-136895414826_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7b511d1d-7822-42c2-b110-daa6dc8881b8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eee7a6d3-52ea-4f8e-ae2b-e344af94dce7_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_6ddae058-537f-498e-8618-f124510d3836_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0727dec3-a0f2-4c32-adcf-bc8e95027af6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f31b29d8-9349-4dc0-9c3c-91a6cc1926c9_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f4efab4c-d235-4fd8-8a40-fb276d51bd29_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_11d35587-aa7b-424a-83c8-2b00c9414502_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_03407399-55c9-4047-ab29-56c93c4b12fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less amounts representing interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_84a8a545-e5bc-43fa-837d-be04956baa2d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_9473829d-ae0f-4096-897b-2a9e8466c881_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2fea8b99-acc4-4108-ab5f-791ac9dc04cb_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cb9328e9-091c-4bf9-a5d9-b5712544f9cd_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d5fbfbe7-2929-4361-8704-b947afbe4f1f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherPrepaidExpenseManufacturing_18c3cf8b-291c-4a54-8f2d-a78652a308c5_terseLabel_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Down payments to manufacturing vendors</link:label>
    <link:label id="lab_mrna_OtherPrepaidExpenseManufacturing_label_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Manufacturing</link:label>
    <link:label id="lab_mrna_OtherPrepaidExpenseManufacturing_documentation_en-US" xlink:label="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseManufacturing" xlink:href="mrna-20211231.xsd#mrna_OtherPrepaidExpenseManufacturing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherPrepaidExpenseManufacturing" xlink:to="lab_mrna_OtherPrepaidExpenseManufacturing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_5ac110ce-f03b-4b84-94d4-116b3d203660_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_df2eb72f-d042-45fb-a4ba-2d205d3dbac7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_6af90541-afae-4ad3-b862-346c004b0648_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_3da70500-cc95-40eb-b306-4d65393a9157_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_86f6a802-c9ae-417e-a88c-911a20f0b140_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_be2214bf-9d7b-4f4a-8911-d73a1f8b37f7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_141e6249-5c59-4ff7-a63a-adf84a2b6eca_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ccf85dad-7b71-4be7-ac97-7cee2f9cb72f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_59f0a81f-b95d-4c74-a128-8ba040abc254_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases, remaining lease term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c7895eb2-d6d5-4d51-bc5e-1f54d8a1a796_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_65bce02b-cac3-4941-817a-5309451189ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_eb78a5b3-6078-47ef-abb9-18485e679874_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_faed0a06-89ca-4ae7-aa1e-a7da78d08c9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3b0034d7-9fbf-4ff9-b9da-7333998be771_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d70485fe-fc54-489a-9b50-4d8b2766168f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_68391ea9-cebc-4d72-b584-c15f75ead605_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_457ed468-a5cd-47c4-8735-c5eceaa2c9d4_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bf4f557e-c35d-4893-aed1-5851d04430a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b2dabf00-9212-4ac0-b033-f6fba0539b85_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b6c5c2b5-cc51-4131-b27b-b5ff6d31abdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6be518d6-586d-4a97-b93d-ce2dcf713aa7_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e5bbc635-6f06-4f70-b165-81cd06ada50f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_970594f3-d474-4526-88fd-04d583b898c0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditFairValueDisclosure_1b252909-5fd3-4f7f-b4df-900b3b4e5b4a_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit, fair value</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lines of Credit, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditFairValueDisclosure" xlink:to="lab_us-gaap_LinesOfCreditFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_d2e4eb3b-2ec5-46f0-b68b-d82b127805ef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_a5f924d9-b8d8-4b88-bb60-32f90faae595_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b5cbe10d-55e8-4de0-913b-2eb08206b1a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_StockOptionAndGrantPlan2016Member_9012dadd-308d-4378-a2ec-f9fb0e749db0_terseLabel_en-US" xlink:label="lab_mrna_StockOptionAndGrantPlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Equity Plan</link:label>
    <link:label id="lab_mrna_StockOptionAndGrantPlan2016Member_label_en-US" xlink:label="lab_mrna_StockOptionAndGrantPlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option And Grant Plan 2016 [Member]</link:label>
    <link:label id="lab_mrna_StockOptionAndGrantPlan2016Member_documentation_en-US" xlink:label="lab_mrna_StockOptionAndGrantPlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option And Grant Plan 2016 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndGrantPlan2016Member" xlink:href="mrna-20211231.xsd#mrna_StockOptionAndGrantPlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_StockOptionAndGrantPlan2016Member" xlink:to="lab_mrna_StockOptionAndGrantPlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_602a5943-2fee-4a1f-87c0-388a37cb218e_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Research Period</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Research Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" xlink:href="mrna-20211231.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_fdc7553d-efe9-4b6c-9b10-6e67ff38c395_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment expenses</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_49a6c174-aa48-4ac2-b1f0-3a91277da823_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_89c482a6-908c-47e6-b14d-d939063aefae_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a134ff1b-b30b-4091-86ab-94ebaec83867_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b7ec3853-02f0-4130-a053-f30dd35387c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4b24654a-d5d7-43c0-9726-ed37464b9629_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_15fe1780-0ff0-40a4-a67e-e2f703039e12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_b25c707e-449a-470f-8458-eb4461bfc3b0_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_ccb17955-246c-419e-b2a3-ff321603e9b3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8eff54b1-e48a-4b1f-9684-2b76eaff8af1_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13b6c4c1-1096-4ec6-9a29-57a8ee9bedc9_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_87ffff62-f003-4e50-ad61-26f2b7f56826_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_fe6c4763-21a2-467d-862c-191c16319f98_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock_5db8827b-5e36-4637-9789-4bf63bd81ab3_terseLabel_en-US" xlink:label="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Lease Liabilities</link:label>
    <link:label id="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="mrna-20211231.xsd#mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_06f803fa-2312-4072-8757-b542ddd8f730_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_855ff6be-4cc2-41c6-b83a-9239ab29e0f7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesHPreferredStockMember_57e96323-f7ec-4c3d-b428-03a0ad048f0c_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesHPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;H Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesHPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesHPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series H Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesHPreferredStockMember" xlink:to="lab_us-gaap_SeriesHPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5a6d1155-b01d-4117-a7e2-3c7d9151d5cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6bfb5715-c485-4d6e-9f7c-33f04577ef52_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_68a69261-2153-415c-b9c0-4b43c54d2260_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d8a367af-fda9-43ba-adb4-130b3ade28c4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a967798b-875b-473f-8609-cfae4e403f34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_6ac954b5-9a83-47e0-bc2f-42aebb59fcaf_terseLabel_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other external goods and services</link:label>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_label_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Other External Goods And Services Current</link:label>
    <link:label id="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Other External Goods And Services Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:href="mrna-20211231.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:to="lab_mrna_AccruedOtherExternalGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1569dc3c-bc85-4372-a0b5-7c7650a9f0a4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f5bf925e-e908-4073-8906-b32ca0124f70_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_28005538-becd-4430-8f14-51dd24076bd8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1997e21d-d4d1-424e-89e3-683c96a21f89_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_789b73bc-b027-4d5d-b4b0-3fca8c8d9c90_terseLabel_en-US" xlink:label="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Common Stock Units And Performance Stock Units</link:label>
    <link:label id="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_label_en-US" xlink:label="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Common Stock Units And Performance Stock Units [Member]</link:label>
    <link:label id="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_documentation_en-US" xlink:label="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Common Stock Units And Performance Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:href="mrna-20211231.xsd#mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:to="lab_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_SouthKoreaGovernmentMember_a4f02802-1c74-403c-ba97-5b173a54d9f5_terseLabel_en-US" xlink:label="lab_mrna_SouthKoreaGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Korea Government</link:label>
    <link:label id="lab_mrna_SouthKoreaGovernmentMember_label_en-US" xlink:label="lab_mrna_SouthKoreaGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Korea Government [Member]</link:label>
    <link:label id="lab_mrna_SouthKoreaGovernmentMember_documentation_en-US" xlink:label="lab_mrna_SouthKoreaGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Korea Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SouthKoreaGovernmentMember" xlink:href="mrna-20211231.xsd#mrna_SouthKoreaGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_SouthKoreaGovernmentMember" xlink:to="lab_mrna_SouthKoreaGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_5fdcd0cc-6838-4675-8804-b78a08c64432_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_202139a5-9f46-4746-95a3-3838e0de8d08_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e2f375d6-98b9-40fd-a956-03d5d830d6fa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f5d82f1d-b955-46c3-9cdd-112955b96632_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d3958c56-8aea-4192-8a9a-f175828c3088_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_f7f6e2ec-ddf0-4e62-bb07-055b9212864e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_fe39a1e3-5fe7-43c0-b7b4-b9d7101d4ca7_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_f8c21789-5bbc-47de-9708-801f70b9e3ba_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount committed for funding</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Current Funding Capacity</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsCurrentFundingCapacity_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Current Funding Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:to="lab_mrna_RevenueFromGrantsCurrentFundingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_8cf4487a-20c7-44b3-b46f-b47ead1bff2a_terseLabel_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA</link:label>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_label_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:label id="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_documentation_en-US" xlink:label="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biomedical Advanced Research And Development Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:href="mrna-20211231.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="lab_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsPotentialReimbursement_1bc6fd55-bfcd-442b-bd67-e7daf74c5492_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from grants, potential reimbursement</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsPotentialReimbursement_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Potential Reimbursement</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsPotentialReimbursement_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Potential Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsPotentialReimbursement" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsPotentialReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsPotentialReimbursement" xlink:to="lab_mrna_RevenueFromGrantsPotentialReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5f4c790a-3a2b-47eb-b615-f33061d261e5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_98ecda49-9c30-45db-9f63-744d63059f2e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_f74495d2-d903-439c-a6cc-4f2e00d8caef_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive offering period</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Consecutive Offering Period</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Consecutive Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_b01b1e9d-f531-4678-95d0-c03270d0f70d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_a2f48c0a-73b9-4994-bee3-00e3457fcfb1_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated&#160;Useful&#160;Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e1b95b73-353e-4c98-9cc3-b97d871140f4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_4c560d1c-f070-4179-8949-eda7d176b640_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_PublicEquityOfferingMember_f43149e8-36ef-450d-bdb4-83749608608f_terseLabel_en-US" xlink:label="lab_mrna_PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Equity Offering</link:label>
    <link:label id="lab_mrna_PublicEquityOfferingMember_label_en-US" xlink:label="lab_mrna_PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Equity Offering [Member]</link:label>
    <link:label id="lab_mrna_PublicEquityOfferingMember_documentation_en-US" xlink:label="lab_mrna_PublicEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Equity Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PublicEquityOfferingMember" xlink:href="mrna-20211231.xsd#mrna_PublicEquityOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PublicEquityOfferingMember" xlink:to="lab_mrna_PublicEquityOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_fa080113-9a69-4437-ad70-7d6ef6c3922a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_c53cdc71-183b-4544-8dd6-3e606c7661ad_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:to="lab_mrna_OperatingAndFinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_3cd8eb6d-2dcc-4ad2-b39e-b8751f8324b2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase from derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_a3d6ca4c-a103-40eb-878b-8b4f9a006621_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_df905673-55b6-4576-a2b0-ba7a4b62559b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_81a378ee-fb00-4e19-a74a-5eb2676eed49_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_ce25b2d0-ac09-4c52-a597-5d8adf768c72_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4ea79543-6663-452b-8a0f-115a5eea2109_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_104830fa-2391-4cce-a8fb-6373ea9d96d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_b68ac2f2-1e96-4859-a061-52c65567a920_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_f585f585-be39-4bb2-b191-9e4b2940f465_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_be65a610-c70d-4a9f-b5f2-292e4b603c43_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_258c573a-c911-4fec-ad18-4c4ca317bef9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_160bbcb8-7324-47fc-a870-b129dd27dc86_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_87de6f0d-f3f6-4bf1-8954-8bf6eb78daad_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4993581e-1f13-4092-96f2-ce3b6ca89d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_fcd8e3f6-63e4-4d4a-b243-3f28f879d8ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5449285a-829b-4499-ad1e-9ed89bb15abd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e77f080f-7bcd-405a-9e90-719f53a9425e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted common stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_008a7ea2-1e96-4e67-a8d9-e860b3b07d46_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0ae9d53e-8293-4005-8b83-30332da626b8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6a34701d-1134-4b31-86a5-6e4bdc0cbf0f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_58a7bcd7-0268-499a-ac3c-caf5210d9083_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_47146bad-cdf4-4cd1-9c94-972fcb5288ba_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_616f1151-632a-4a1d-a747-4793ff8b0164_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_b8463a85-5a27-4e4e-ae12-0d54599e40f0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_acde21d0-e84a-4146-ad21-6bb3d092cef0_terseLabel_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARPA</link:label>
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_label_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defense Advanced Research Projects Agency [Member]</link:label>
    <link:label id="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember_documentation_en-US" xlink:label="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defense Advanced Research Projects Agency [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:href="mrna-20211231.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:to="lab_mrna_DefenseAdvancedResearchProjectsAgencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_88cc4243-8905-4658-9461-da63461b4767_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b6ac98c9-ced1-4847-a372-29a117fd4aed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Following twelve quarters</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FiveHundredTechnologySquareMember_1df11156-846c-4996-a0ac-0ed5c0f4205a_terseLabel_en-US" xlink:label="lab_mrna_FiveHundredTechnologySquareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">500&#160;Technology Square</link:label>
    <link:label id="lab_mrna_FiveHundredTechnologySquareMember_label_en-US" xlink:label="lab_mrna_FiveHundredTechnologySquareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred&#160;Technology Square [Member]</link:label>
    <link:label id="lab_mrna_FiveHundredTechnologySquareMember_documentation_en-US" xlink:label="lab_mrna_FiveHundredTechnologySquareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred&#160;Technology Square [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FiveHundredTechnologySquareMember" xlink:href="mrna-20211231.xsd#mrna_FiveHundredTechnologySquareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FiveHundredTechnologySquareMember" xlink:to="lab_mrna_FiveHundredTechnologySquareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_f8b64729-8108-4af5-a196-e2552dd83e09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_b4b4d0b6-7cf2-4ca8-a1bc-c6c5a9b1593d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_2e5933e5-74b7-42e7-aec3-20c78127c879_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_6dee6cd4-335f-4280-a69b-9bea5315f538_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available funding</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Remaining Funding Capacity</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsRemainingFundingCapacity_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Remaining Funding Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:to="lab_mrna_RevenueFromGrantsRemainingFundingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_6bd6666c-990a-452f-9925-9e2395852ada_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bc6344f5-7049-437a-a2ea-6d5542ad7350_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_c54ed099-7b26-4ead-856a-b9532dee10b9_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Current</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_de12aab7-31aa-416f-bd7c-993fea53fe79_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_6e8315ea-fa5a-4765-8d4a-8bc62c0eed91_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due in Rolling Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_50794051-f6e3-40fa-a5aa-22ba2b1ebf51_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted common stock and restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e36d7287-068c-4f31-9ff5-37b6122a8fa5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8d12b633-924f-4076-adb4-192f123f4d5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e51a4270-fa57-4d8d-993c-5a69e0bdfc51_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a635b685-b364-4e26-b337-bec4f749b694_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_69f8aa85-ac29-4130-a613-72b0b1afeb7e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_39f140f7-f8e6-4004-b61f-932d0de05e35_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_9d270572-c282-4346-8a8e-8795046cd46d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash and Available-for-Sale Securities by Significant Investment Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_1469830c-c577-4b0b-973b-54f4c4ae7a5d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c640d9e7-f50c-4ba8-8c27-903517da4e41_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_ff7d88da-ca7c-4b07-8072-e183ce8a039f_negatedTerseLabel_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_label_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deductions During Period</link:label>
    <link:label id="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_documentation_en-US" xlink:label="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Deductions During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:href="mrna-20211231.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:to="lab_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ServiceBasedAwardsMember_d41f8614-ed6b-480d-855e-5d289fb20ad6_terseLabel_en-US" xlink:label="lab_mrna_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based awards</link:label>
    <link:label id="lab_mrna_ServiceBasedAwardsMember_label_en-US" xlink:label="lab_mrna_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Awards [Member]</link:label>
    <link:label id="lab_mrna_ServiceBasedAwardsMember_documentation_en-US" xlink:label="lab_mrna_ServiceBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ServiceBasedAwardsMember" xlink:href="mrna-20211231.xsd#mrna_ServiceBasedAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ServiceBasedAwardsMember" xlink:to="lab_mrna_ServiceBasedAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_28f04bff-0484-4bd3-b6c0-e8cfa656c36f_terseLabel_en-US" xlink:label="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in right-of-use assets related to lease modifications and reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_label_en-US" xlink:label="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained through finance lease modifications and reassessments</link:label>
    <link:label id="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_documentation_en-US" xlink:label="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained through finance lease modifications and reassessments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:href="mrna-20211231.xsd#mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:to="lab_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6f2f3e7d-6c07-408e-9c64-d4b40d734817_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1c3987c0-bdda-4470-96fc-23a230c678b6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8e158f0c-5a7a-433a-920a-19b5ebddd897_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_83d4e818-20f1-4e89-aebe-b811abb54001_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Unrealized Gains on Derivatives Designated As Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b40fa0e2-6232-4e36-a3a9-2abac8e435d5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8aab0ebb-be1f-4f10-9626-ef45bc13532a_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae293766-fcb8-4aec-a4d7-c4688c6479c3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_dd169c84-bcff-40b9-b55b-29b4ebfdabdf_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5d4154e0-dab7-4cbc-83f9-8da6fadcf4d7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_d8fb7cbd-8215-4f2d-965a-cd2901f2112c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ae55a3fc-80b5-4f49-b03e-15912065eeae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_7934929d-532d-429f-9903-bb03190332fd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_90efcf5b-8821-4da9-b45e-910eaf04b838_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_74dcd95e-4065-4786-a8f8-e8bfebfd40ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net realized (gains) on derivative instruments reclassified to net income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_b2ebbd49-018b-4942-b4fe-1f6c8f6cf590_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_68b7196a-8167-4437-8b46-f7592facc5d0_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiability_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiability" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_cddf008c-8923-4243-83d3-c5e4b4cf191c_terseLabel_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development operations</link:label>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_label_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Development Operation</link:label>
    <link:label id="lab_mrna_AccruedDevelopmentOperation_documentation_en-US" xlink:label="lab_mrna_AccruedDevelopmentOperation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Development Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation" xlink:href="mrna-20211231.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedDevelopmentOperation" xlink:to="lab_mrna_AccruedDevelopmentOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_19d65560-823d-4390-8a27-5c35c9f9313d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_5ed570fb-acf6-4bb8-8254-2f7e3c9e8d1a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_9cb022eb-885b-4596-82ba-b8e00b86e6b1_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ace99731-5c83-4815-9ab9-d6aeb46af13f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_9337d54f-6776-467a-84f4-15ec63566c83_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_78761999-0289-4c14-abb9-93e1bb01b59b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_09f6d7a0-2fe4-4751-b793-7fcaec1f9115_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Period</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_34b05afb-7372-4519-a0bd-db3f46cec67b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a7e8b8b3-d7da-451c-bb04-5718c296eb73_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4eec12f3-cdee-417d-9a47-22eebaaa654e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_d9362a32-68b6-48e5-8f61-62ed04f83226_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_db397282-d8a1-49e5-8627-43d6da76d1df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_dc4102ad-7e6e-41bd-b11f-05a840c0190d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MTCEastMember_5a5aef1e-98c7-4a62-8b3c-5011b73c42e7_terseLabel_en-US" xlink:label="lab_mrna_MTCEastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC East</link:label>
    <link:label id="lab_mrna_MTCEastMember_label_en-US" xlink:label="lab_mrna_MTCEastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC East [Member]</link:label>
    <link:label id="lab_mrna_MTCEastMember_documentation_en-US" xlink:label="lab_mrna_MTCEastMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC East</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCEastMember" xlink:href="mrna-20211231.xsd#mrna_MTCEastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MTCEastMember" xlink:to="lab_mrna_MTCEastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_49f354f9-672b-4910-8b20-916495f471d9_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanFundingStatusDomain_84a79ea8-ce5e-4cf5-ab49-ae43d0f71eed_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanFundingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funding Status [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanFundingStatusDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanFundingStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funding Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanFundingStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanFundingStatusDomain" xlink:to="lab_us-gaap_RetirementPlanFundingStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_432cc50d-9f57-4fd9-b90c-e560b9df1c02_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_366d23d4-a67f-4068-b9f7-ca2aaa4a67b7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due in Rolling after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OtherGrantRevenueMember_43e87f4a-0327-4495-92a3-c56bd0ce134a_terseLabel_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Grant Revenue</link:label>
    <link:label id="lab_mrna_OtherGrantRevenueMember_label_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Grant Revenue [Member]</link:label>
    <link:label id="lab_mrna_OtherGrantRevenueMember_documentation_en-US" xlink:label="lab_mrna_OtherGrantRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Grant Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember" xlink:href="mrna-20211231.xsd#mrna_OtherGrantRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OtherGrantRevenueMember" xlink:to="lab_mrna_OtherGrantRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_11bfc934-d4b9-40ed-906c-3d49165ea2c2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_574478a2-735a-49d9-9b5a-c59739a111ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_18dfa7f7-c004-41a0-8116-e05321b454ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_df870cd8-47d1-40b8-b927-751ca2bfa5e5_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c6a749c2-1bd1-4f4e-b336-3db7191d1007_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_d5c324d1-2d5b-485f-a46b-ab36466ec093_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract options</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsNumberOfContractOptions_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Number Of Contract Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsNumberOfContractOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:to="lab_mrna_RevenueFromGrantsNumberOfContractOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a85189fc-648a-42d5-b01c-141753bffb68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_69cfab81-f61c-4d1c-abab-ff6e60f8b27d_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f333f763-e541-4a68-a873-d87aecaa5a29_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_bc68dd92-8199-4e82-a313-0d1dbb308e63_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on derivative instruments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_36b0576d-b5ec-4a83-9fa4-bad7b45afc4b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5766e4a3-6905-4b63-83f0-02f16f516107_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9b5c415b-a801-4f3e-82dc-4db531a79d53_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_3a08fe0d-ace5-443b-b410-9fdbf5291399_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_04259b6c-6f64-4397-8747-ad8bbbe766ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MTCNorthMember_f9815e13-80b8-4cbb-91da-6a3a5d05572f_terseLabel_en-US" xlink:label="lab_mrna_MTCNorthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC North</link:label>
    <link:label id="lab_mrna_MTCNorthMember_label_en-US" xlink:label="lab_mrna_MTCNorthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC North [Member]</link:label>
    <link:label id="lab_mrna_MTCNorthMember_documentation_en-US" xlink:label="lab_mrna_MTCNorthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC North</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCNorthMember" xlink:href="mrna-20211231.xsd#mrna_MTCNorthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MTCNorthMember" xlink:to="lab_mrna_MTCNorthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_be7ca6c5-7919-4b06-b4eb-2cf17f0c5b7c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue related to customer</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_34404ca0-bb85-413d-a0f1-7e3c4e703071_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_A2022RepurchaseProgramPlanMember_d9a2f5d6-aaf9-4125-8978-d9e35bc4ca2a_terseLabel_en-US" xlink:label="lab_mrna_A2022RepurchaseProgramPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Repurchase Program</link:label>
    <link:label id="lab_mrna_A2022RepurchaseProgramPlanMember_label_en-US" xlink:label="lab_mrna_A2022RepurchaseProgramPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Repurchase Program Plan [Member]</link:label>
    <link:label id="lab_mrna_A2022RepurchaseProgramPlanMember_documentation_en-US" xlink:label="lab_mrna_A2022RepurchaseProgramPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Repurchase Program Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2022RepurchaseProgramPlanMember" xlink:href="mrna-20211231.xsd#mrna_A2022RepurchaseProgramPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_A2022RepurchaseProgramPlanMember" xlink:to="lab_mrna_A2022RepurchaseProgramPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_c940bbf9-4112-41c5-9c4b-34be8c4ab1a5_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_1990eba9-3931-4b34-a866-55f105a35620_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_aa9492bd-65c4-445b-b761-9ad735f51210_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3f3caa26-8eb7-4045-b9ab-8be86376a62c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_93fe9ab1-88d4-4a36-a600-fe45f95e1147_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c3bd9026-67c0-43bf-bbd6-6e2794ec0f4c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_6a167de4-2015-4f0b-a07b-fd0ebd904163_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_5b8ec68c-4e08-4ccb-b776-9c8b3e77138a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_b91d5e94-5da5-46eb-8419-d65eeb91edc5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price at which shares are sold, percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6725cb8c-1c41-4fd2-aefc-3b070522d0d0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_0a5f2a2f-179c-4f06-9cce-762e6dd44277_terseLabel_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_label_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials, Accounts Payable</link:label>
    <link:label id="lab_mrna_RawMaterialsAccountsPayable_documentation_en-US" xlink:label="lab_mrna_RawMaterialsAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable" xlink:href="mrna-20211231.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RawMaterialsAccountsPayable" xlink:to="lab_mrna_RawMaterialsAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_35aae9a2-210d-474d-955f-e2ad95afcba3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_e1adda84-ab54-4b80-bb04-86c698be0906_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_268d5d09-9203-4be5-b574-87e5deddf23d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a7dddc77-6ea7-4e56-9a91-994ae60dccde_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7d98b1c3-04b3-4e13-979c-31469de0479e_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at beginning of the period</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_ab2a22b4-7704-430e-b8bf-b1056e97ea7e_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at December 31</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_2d385bd9-6d54-45ba-935a-6b1000d2aee8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_d5909946-c0c3-41d3-b92b-aa91efc0c0cf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_0304632d-9705-4853-a127-f6b4bdcdbd63_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_85b55f25-2b60-40d0-bd31-ddbe2039a727_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses, Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_b098c081-ab05-4769-a32d-b88ee6b10b80_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-out payments</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" xlink:href="mrna-20211231.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_529f0cac-35cc-4be0-9e70-a179af07011a_verboseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Liability, Current [Roll Forward]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract with Customer Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_37e323af-08fb-424e-a9bb-ec7b90b11f82_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_25a5f773-1cc8-4ecb-b93e-ea01ccb07d71_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_28d44d18-d877-44cf-ae6e-c82e0e0ddd31_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense for financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_33d5b240-7766-44ee-8dd6-27ddc37ec89f_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b36554db-ca5f-48f7-a907-718a966a23a3_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_943ed07f-c6c7-4c65-8c1c-b1e70ea34b49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7e896aea-05c9-4e20-a91e-0b9c52011e39_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_da1cc106-725a-4a72-a890-27a3d653a0d0_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:href="mrna-20211231.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_76513c29-e165-43e1-9c18-71774c294f39_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9576258c-68b0-4c92-b616-ad86597fd11f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_607a6cce-b1d9-482d-a91a-d53a0c6fb383_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_db75eee1-10c4-40e5-b8da-19179de625a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0e52de28-923a-4744-8be8-3f8602295329_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LesseeFinanceLeaseExpense_a28ce9ca-14a4-4d61-be45-647833b6e7b1_terseLabel_en-US" xlink:label="lab_mrna_LesseeFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in financing lease liabilities</link:label>
    <link:label id="lab_mrna_LesseeFinanceLeaseExpense_label_en-US" xlink:label="lab_mrna_LesseeFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Expense</link:label>
    <link:label id="lab_mrna_LesseeFinanceLeaseExpense_documentation_en-US" xlink:label="lab_mrna_LesseeFinanceLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeFinanceLeaseExpense" xlink:href="mrna-20211231.xsd#mrna_LesseeFinanceLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeFinanceLeaseExpense" xlink:to="lab_mrna_LesseeFinanceLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_19283f28-e15d-45b2-93db-2d72d8b698c5_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f776242a-65da-487e-8d83-f18fa2270b79_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxValuationAllowanceRollForward_d72b935d-f180-4435-b098-cdd1b21d504f_terseLabel_en-US" xlink:label="lab_mrna_DeferredTaxValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_mrna_DeferredTaxValuationAllowanceRollForward_label_en-US" xlink:label="lab_mrna_DeferredTaxValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_mrna_DeferredTaxValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_mrna_DeferredTaxValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxValuationAllowanceRollForward" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxValuationAllowanceRollForward" xlink:to="lab_mrna_DeferredTaxValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_44bb0831-baae-422b-9e8f-3d6bdf8c2528_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from offerings of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_748e35a7-98e4-4821-95c5-b3184eb20139_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ea24c120-e35a-4149-a59c-29ba214517d7_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_70c421e8-3d6f-4888-afb6-e36a5c759e95_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_17cace54-dcb8-4124-85d6-5fbeff93aaf8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_c38917ad-f318-4e9c-b088-0618df8b2e6a_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Customers</link:label>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:to="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_91ca26e1-377a-448a-885d-fabba72cbedf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_4899b74c-689b-4794-a44e-0c9f274d43fb_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_221eca47-2270-48c0-b409-2c09856920d0_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_070f6a2d-71fa-46e2-9c06-1403ba69d358_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Common Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_39e75e5b-bfe7-4ef8-a903-261333ea137a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a2ee3123-07a5-43b9-8ef8-bb7d9f09920f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_65f574b3-e94f-4bca-b4e6-a9288867e67b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_f5a6bbfa-735e-4bba-961f-3258d522f2b1_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum value of shares to be purchased during purchase period</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_a275bb07-ea0d-409b-b3fa-8ebc6b31fc39_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_6042d3a8-d791-40da-8d45-571722cc66c2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00d28fda-5f74-4f70-9620-9167b2383453_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_cb39ed61-9652-4026-843c-c7a0f65a9ae4_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_6b84382e-5489-409e-87e5-7da7a1616d3e_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_35bcc0a4-aa44-4485-b4ce-d859d598ff5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e5a71dcd-3d2e-4959-b9e8-f408e5aab479_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_d88cabbf-f5ec-456d-a822-afef4cebe714_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carry-forwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0e24651b-c76a-4e77-880b-fcdc422516a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net realized (gains) on available-for-sale securities reclassified to net income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_0b3f3082-f7e3-4051-b8aa-c2c056741874_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_5c062f81-5d4a-4ea4-826d-2a8b54a9e82b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_4d3850f5-d012-44f1-b01b-41b36db87b8c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_0574fb56-aa7f-4276-adef-6c641a2503c6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_bcb9d5bc-0098-4814-89f6-a2a844c2c953_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of compensation through payroll deductions</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Minimum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:to="lab_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfParticipants_b55310a8-27ad-48d0-b3f8-08a295727780_terseLabel_en-US" xlink:label="lab_mrna_NumberOfParticipants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of participants</link:label>
    <link:label id="lab_mrna_NumberOfParticipants_label_en-US" xlink:label="lab_mrna_NumberOfParticipants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Participants</link:label>
    <link:label id="lab_mrna_NumberOfParticipants_documentation_en-US" xlink:label="lab_mrna_NumberOfParticipants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Participants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfParticipants" xlink:href="mrna-20211231.xsd#mrna_NumberOfParticipants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfParticipants" xlink:to="lab_mrna_NumberOfParticipants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_aaf5fc4c-cbe6-4982-821d-b88f5988ed66_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_b27c08a4-747c-47f5-b4b6-a460cecc21b6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f6e39dce-bd72-43b6-a232-e96626bea923_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_33a34b9c-e2d5-4b87-9629-dd10db328f24_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_92b01958-2d49-4c1c-aa23-c612bf0e9b50_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a591b3a3-7519-4a0a-a15e-b13d9d13a021_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_fb868156-77f7-41ab-86c5-db6e161071cb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e4d55a54-ac62-440a-add2-8c90ed9b0fa9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted EPS (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_c565daeb-c6dc-46f9-9a7e-bf69c259a594_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_315d3654-7fe4-466b-bb75-ee3e04dd248a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_0aa851a0-eecb-4778-8c2b-ff99e14082a2_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_60d23bb3-3d51-4f2e-aea9-fdeedcb6803d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_6c181b9a-5c8f-4f98-a7b5-b1155cd05970_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_c9880196-45dd-4331-8133-db3cce756717_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_37203906-5515-4897-abee-96e11e1bbf06_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_b13ac2f2-b00d-4150-b89d-125bf29a0c01_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_168748e2-4e07-46e8-92fa-53bd2360ca48_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_92942aea-e3cc-4f2a-84e9-06b7d868ec36_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_23fc24f1-e1f2-46f9-8661-a241c6e05df2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_55caa46b-e0c9-4796-92dd-5948373f4414_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e1b0b250-e5c1-432d-a664-314b53313810_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_b08e88e7-b79b-4718-8423-113b90f7d6f4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_766d413f-1f4a-4828-a529-833293c39b2b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares used in calculation of earnings (loss) per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8d3e314e-52b4-4c61-92f9-5d22391d1202_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedManufacturing_5a8d468d-0b09-438c-9d6b-bfe208e82dab_terseLabel_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing</link:label>
    <link:label id="lab_mrna_AccruedManufacturing_label_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Manufacturing</link:label>
    <link:label id="lab_mrna_AccruedManufacturing_documentation_en-US" xlink:label="lab_mrna_AccruedManufacturing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing" xlink:href="mrna-20211231.xsd#mrna_AccruedManufacturing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedManufacturing" xlink:to="lab_mrna_AccruedManufacturing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3235ebed-e8ca-4acc-b0e1-e283e1d14af3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_69d2063e-1965-4d3d-a63c-ac363dfaa9bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_45ad1c9e-cdb6-4c20-a894-5712b2ac55ba_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e7a47444-38d8-43b8-a92b-17e460b7421c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_efb87392-3d0a-4010-bc5e-26b154fe65eb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_11932746-03b8-4a9d-bf24-906fdfc0b1f9_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_185cc5eb-c344-4b8b-9971-ebfc7571c5bc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f6f2e511-c00d-45bc-966c-e2da5d23026c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_7ffa1ec3-46cb-487d-9372-627bb546f09b_terseLabel_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extension</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_label_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension Periods</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_documentation_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:href="mrna-20211231.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:to="lab_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6bf67bc7-6dbd-4ba1-b295-7a2ee8672956_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_44efb68a-7e60-4775-b858-31ba0178da53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_1d82e15c-7bea-404c-9ffd-b8b9339384cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_551f7d39-6b66-4f25-a0b8-69dc2472f337_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_48a6d06b-26d6-478d-8dc7-30b86e791d59_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cbc3889-2e33-4824-bd20-883d8a3b2d03_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_2210cc8e-bbbd-4bcc-8161-93670717476d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_f30e348d-887f-44cf-abfa-b079a21da741_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_NumberOfDosesOfVaccineCandidate_7c5cd39c-a51b-4c5a-bd97-47d004d689e9_terseLabel_en-US" xlink:label="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of doses of vaccine candidate</link:label>
    <link:label id="lab_mrna_NumberOfDosesOfVaccineCandidate_label_en-US" xlink:label="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate</link:label>
    <link:label id="lab_mrna_NumberOfDosesOfVaccineCandidate_documentation_en-US" xlink:label="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Doses Of Vaccine Candidate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDosesOfVaccineCandidate" xlink:href="mrna-20211231.xsd#mrna_NumberOfDosesOfVaccineCandidate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_NumberOfDosesOfVaccineCandidate" xlink:to="lab_mrna_NumberOfDosesOfVaccineCandidate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_40849fd1-06b9-4c18-95a3-2e18b787a405_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ab9eb9f8-1993-4277-9ab8-74e33b3a1ece_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_7ba89718-13bb-4be8-a802-86c72e0ffcb0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fd0bad6b-51de-4db1-8b0c-60a8feb60285_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_f996b718-9c38-4b9a-bec9-17cd039ae4ae_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_97bff1e4-1eb7-4365-8f35-7be4d5df2919_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b55c08ca-0e50-49fe-9011-aa1a2e476ad7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_608c693e-a5a3-47c7-89aa-d90111448405_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockExpense_5b790106-a623-4d9a-a08f-4a0643b3fd4d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockExpense_label_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense" xlink:to="lab_us-gaap_RestrictedStockExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_e4c2bb59-70cb-49ad-9e9d-466c98dd9d99_totalLabel_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current lease liabilities</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="lab_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b229b8db-40ce-461a-b38d-a977e6289f3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Options (in millions)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_551c1296-8854-4a2c-aca3-6c9698273e4c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d988f17c-e328-4855-96e4-085f19558ea7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod_b4ee7b5d-cf05-429a-9e92-ba5f2e671993_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Consecutive Offering Period</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Consecutive Offering Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f1133566-aa5d-4e4f-8230-5f6aa8377cb5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_b2a9f80f-4821-456d-a2b8-d81885c6da3d_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_8e390e7e-da80-4d39-96d2-31987b026052_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a8300afd-1611-45da-b094-3aa036fca45e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_e75e37df-2fdd-4887-86d7-33704a05d15e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_18b1e5c2-0ee7-49b5-9752-218dabcfd964_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_d8c8c0ae-efde-45af-a954-69676d53d52c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments, before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_5736e8bc-f9b1-43ec-a90a-5db292496d24_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_EuropeanCommissionMember_cdc673d2-be8c-4c1d-b286-5e5f6c9a0793_terseLabel_en-US" xlink:label="lab_mrna_EuropeanCommissionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commission</link:label>
    <link:label id="lab_mrna_EuropeanCommissionMember_label_en-US" xlink:label="lab_mrna_EuropeanCommissionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commission [Member]</link:label>
    <link:label id="lab_mrna_EuropeanCommissionMember_documentation_en-US" xlink:label="lab_mrna_EuropeanCommissionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Commission</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EuropeanCommissionMember" xlink:href="mrna-20211231.xsd#mrna_EuropeanCommissionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_EuropeanCommissionMember" xlink:to="lab_mrna_EuropeanCommissionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_a771248c-b4d7-46e6-bb3b-b66b9256ba9f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_2a8a7e51-a99f-4fff-9141-b896ee05be83_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply commitment</link:label>
    <link:label id="lab_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount_b710d1ec-236e-42ab-889f-b240773dc636_negatedTerseLabel_en-US" xlink:label="lab_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases recorded as benefit to income tax provision</link:label>
    <link:label id="lab_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount_label_en-US" xlink:label="lab_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Decrease , Amount</link:label>
    <link:label id="lab_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount_documentation_en-US" xlink:label="lab_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Decrease , Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:href="mrna-20211231.xsd#mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:to="lab_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_0020bd62-dd4c-40bd-aaf6-627f9fa79933_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8f580abe-3371-4872-9267-eb9a4260119d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_bed3752a-2230-4d52-965b-4d9dceee6697_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_c7d67319-1316-4870-a09b-d9741a03e55d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_ce3d77f6-3ea5-42c3-be11-ae13f169f39a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due in Rolling Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8973fb5f-573a-4402-a45f-fba9b52ac9d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_71b5f950-c731-4f12-80e4-ab8ac708221a_terseLabel_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_label_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods</link:label>
    <link:label id="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_documentation_en-US" xlink:label="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:to="lab_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9066d694-691d-472e-863e-1e1bed4d3c0b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_76bdb8cc-25dd-4cc0-8c3c-45c89d2a3be4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_8417d4d5-a42c-4e02-ba67-2556828907e4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_e90d6356-aa2f-4dda-b36b-6c54a69077c8_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_16a98fe6-9f3b-4c17-a142-75756dab3ae9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_273206d2-9e10-4dc8-9fd2-70bb7caed3e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_ca1bcb0a-1e8b-4914-bd8a-2e0e697ed3d6_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value, Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_bcd608f1-0c60-411a-acb8-83c9666853c0_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_5d147e67-b965-40b8-ab82-db2eb8c67db5_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxAssetsFinancingLeaseLiability_4afa7661-6e75-46fb-82f9-14cb044afad8_terseLabel_en-US" xlink:label="lab_mrna_DeferredTaxAssetsFinancingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsFinancingLeaseLiability_label_en-US" xlink:label="lab_mrna_DeferredTaxAssetsFinancingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Financing Lease, Liability</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsFinancingLeaseLiability_documentation_en-US" xlink:label="lab_mrna_DeferredTaxAssetsFinancingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Financing Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsFinancingLeaseLiability" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxAssetsFinancingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxAssetsFinancingLeaseLiability" xlink:to="lab_mrna_DeferredTaxAssetsFinancingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_529f6d6e-5e60-45f2-aea6-2eb2bd089a4a_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fb7cc10d-6333-4c82-9814-04d206c04cfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_UnrecognizedTaxBenefitsNet_f7f730e8-23bb-43eb-b412-1d6a994ad4ec_terseLabel_en-US" xlink:label="lab_mrna_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, net</link:label>
    <link:label id="lab_mrna_UnrecognizedTaxBenefitsNet_label_en-US" xlink:label="lab_mrna_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net</link:label>
    <link:label id="lab_mrna_UnrecognizedTaxBenefitsNet_documentation_en-US" xlink:label="lab_mrna_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_UnrecognizedTaxBenefitsNet" xlink:href="mrna-20211231.xsd#mrna_UnrecognizedTaxBenefitsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_UnrecognizedTaxBenefitsNet" xlink:to="lab_mrna_UnrecognizedTaxBenefitsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_52998954-5206-4abb-a355-8c3a2b072b92_terseLabel_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer Liability [Table]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_label_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Table]</link:label>
    <link:label id="lab_mrna_ChangeInContractWithCustomerLiabilityTable_documentation_en-US" xlink:label="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:to="lab_mrna_ChangeInContractWithCustomerLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_0bc7c33f-b5bd-4db1-bb30-de7aa4228a45_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_f0662121-0174-4f5b-8fdd-de98c92784b2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_62564900-37e1-40b2-a2c1-a5861c262976_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves established</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fdc628e-3512-4d39-9dc0-b7397e87c083_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3e1c4230-f2de-4ade-b196-950d11a0149c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredIncomeTaxExpenseBenefitNet_dcf61975-cab1-4cfc-a78c-864aa87107f3_terseLabel_en-US" xlink:label="lab_mrna_DeferredIncomeTaxExpenseBenefitNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_mrna_DeferredIncomeTaxExpenseBenefitNet_label_en-US" xlink:label="lab_mrna_DeferredIncomeTaxExpenseBenefitNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Net</link:label>
    <link:label id="lab_mrna_DeferredIncomeTaxExpenseBenefitNet_documentation_en-US" xlink:label="lab_mrna_DeferredIncomeTaxExpenseBenefitNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredIncomeTaxExpenseBenefitNet" xlink:href="mrna-20211231.xsd#mrna_DeferredIncomeTaxExpenseBenefitNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredIncomeTaxExpenseBenefitNet" xlink:to="lab_mrna_DeferredIncomeTaxExpenseBenefitNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MTCSouthMTCNorthAndMTCEastMember_3050ea59-4222-4145-83d0-3466772d6223_terseLabel_en-US" xlink:label="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South, MTC North and MTC East</link:label>
    <link:label id="lab_mrna_MTCSouthMTCNorthAndMTCEastMember_label_en-US" xlink:label="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South, MTC North and MTC East [Member]</link:label>
    <link:label id="lab_mrna_MTCSouthMTCNorthAndMTCEastMember_documentation_en-US" xlink:label="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MTC South, MTC North and MTC East</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:href="mrna-20211231.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:to="lab_mrna_MTCSouthMTCNorthAndMTCEastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_35f8b604-e7bb-4a04-b680-41d9f42320f8_terseLabel_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated arrangement consideration</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_label_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</link:label>
    <link:label id="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_documentation_en-US" xlink:label="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:href="mrna-20211231.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:to="lab_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_ed1de547-b044-478c-b052-cd56876fea15_terseLabel_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PCV Agreement</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_label_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp&#160;And Dohme Corp [Member]</link:label>
    <link:label id="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_documentation_en-US" xlink:label="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp&#160;And Dohme Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:href="mrna-20211231.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:to="lab_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MRNAVertex2020AgreementMemberMember_f83a5471-56dd-41b8-ae53-5173a81e9ab7_terseLabel_en-US" xlink:label="lab_mrna_MRNAVertex2020AgreementMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MRNA Vertex 2020 Agreement Member</link:label>
    <link:label id="lab_mrna_MRNAVertex2020AgreementMemberMember_label_en-US" xlink:label="lab_mrna_MRNAVertex2020AgreementMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MRNA Vertex 2020 Agreement Member [Member]</link:label>
    <link:label id="lab_mrna_MRNAVertex2020AgreementMemberMember_documentation_en-US" xlink:label="lab_mrna_MRNAVertex2020AgreementMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MRNA Vertex 2020 Agreement Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MRNAVertex2020AgreementMemberMember" xlink:href="mrna-20211231.xsd#mrna_MRNAVertex2020AgreementMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MRNAVertex2020AgreementMemberMember" xlink:to="lab_mrna_MRNAVertex2020AgreementMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b4db6fd8-7259-4004-86f8-c2225c3dd6f4_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation costs</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_fa37a9e3-b71b-487c-bf4f-e0db321a0834_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_07fa2a8f-ad14-433d-b997-4abf19ce2fb6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average remaining contractual term, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_4553212c-4a39-47ec-a3ed-1a0cf16974ce_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_12e7d741-04f8-45c2-ad36-65ca2b74ec3f_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_93d58569-cbb1-4141-a6f9-47bf77efe016_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_54ecf4d5-c0e8-455c-8c08-4c50358171fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date per Share/Unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_adb48616-5d46-4d61-9673-06a25b80a2e4_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_4ee42343-380a-4f85-9b0e-f9ffd6444928_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnifications</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ProductSalesMember_e7419988-173b-452a-94e7-38b815e0b66f_terseLabel_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_mrna_ProductSalesMember_616915bf-2f62-4c42-abea-04fc0b8ab477_verboseLabel_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_mrna_ProductSalesMember_label_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales [Member]</link:label>
    <link:label id="lab_mrna_ProductSalesMember_documentation_en-US" xlink:label="lab_mrna_ProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember" xlink:href="mrna-20211231.xsd#mrna_ProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ProductSalesMember" xlink:to="lab_mrna_ProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtension_72e572f7-d1bb-497b-ac35-47d0ef00db80_terseLabel_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extension periods</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtension_label_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseNumberOfExtension_documentation_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseNumberOfExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtension" xlink:href="mrna-20211231.xsd#mrna_LesseeOperatingLeaseNumberOfExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeOperatingLeaseNumberOfExtension" xlink:to="lab_mrna_LesseeOperatingLeaseNumberOfExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_882d5249-ae58-46fc-89f3-8b3602a429fc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_FinanceLeaseNumberOfProperties_04068a5c-fc0f-4016-b8a4-93e17a690bbd_terseLabel_en-US" xlink:label="lab_mrna_FinanceLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, number of properties</link:label>
    <link:label id="lab_mrna_FinanceLeaseNumberOfProperties_label_en-US" xlink:label="lab_mrna_FinanceLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Number Of Properties</link:label>
    <link:label id="lab_mrna_FinanceLeaseNumberOfProperties_documentation_en-US" xlink:label="lab_mrna_FinanceLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Number Of Properties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseNumberOfProperties" xlink:href="mrna-20211231.xsd#mrna_FinanceLeaseNumberOfProperties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_FinanceLeaseNumberOfProperties" xlink:to="lab_mrna_FinanceLeaseNumberOfProperties" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_3383b691-fc8f-4daf-9b9e-bbdaf1ed7f3b_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_75152018-6de3-4ab6-b5b4-04f4b6fe611c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Before Provision For (Benefit From) Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_53dd9714-6530-4435-aa53-b96111866a96_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a343583d-042b-4ffb-a65d-3d3926609085_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_006e1cab-1dc4-47ad-bb3e-db9f0e1bb1ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_50a7b216-4004-48e7-b0b7-20da55a0865f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_1dd31110-b823-4973-a296-e8054031b5b6_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_437f9a25-6337-405f-8977-b8b31caf5c82_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_5bc7a9e9-1f7a-42bf-a91b-f50b04fc1801_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_MerckMember_c5053808-9e4a-456d-ba0b-7a5adb91f888_terseLabel_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_mrna_MerckMember_label_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_mrna_MerckMember_documentation_en-US" xlink:label="lab_mrna_MerckMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember" xlink:href="mrna-20211231.xsd#mrna_MerckMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_MerckMember" xlink:to="lab_mrna_MerckMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f6265afb-940c-4dbf-972d-d4d54ea9d0bf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_4568c82c-b5e6-4998-a9df-468cafd5a185_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_c3bcc6c7-c3c1-4322-98b9-f5086c4e7d92_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_b5834017-49d0-450e-8a6c-90f47ff9dbbc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_bba479fe-9d14-4023-9ca4-e6f8b9d2be55_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities that Accounted for More than 10% of Total Revenue and Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a4caf88-dc81-4ee6-aaf1-7b9517baf2bc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_551854ee-9baf-4d25-a714-a520166630af_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d05b9c5e-8985-40c6-96aa-ed75fecc5ee7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0bc0b0ed-8d87-4929-96ee-a5b3ba0a2471_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1f739c3c-4a4f-4083-8a31-f4d0e070aef0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_bbc68978-9a4b-4cf8-b98b-0e048fdb650f_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_23416d81-28f0-4e1f-8c2e-f683245bc6ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8dc8b63f-1ae6-47d6-bbdd-bcc2fa66d66e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm_5c94f189-e526-4a2d-ad7e-1599f242dad7_terseLabel_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement for building project</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm_label_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Agreement For Building Project, Term</link:label>
    <link:label id="lab_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm_documentation_en-US" xlink:label="lab_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Agreement For Building Project, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm" xlink:href="mrna-20211231.xsd#mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm" xlink:to="lab_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_fff63720-c76d-4954-9ae1-144e2b1de817_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5bf55874-40bd-4f3e-bc3d-3b3598188250_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_052f20f6-b647-4cf1-a0cd-bfc6dbb6c44c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_711ea5c0-d4bc-4c5d-a4e0-b9352ebbbdfd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_903c5b72-31ca-4a81-86ee-4df64524dc34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_459ce466-7030-47a5-8175-c41b35b59dfc_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation to be paid in 2022</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_e61b3f98-0829-4c58-99df-6f8e37c95bf3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of RSUs and PSUs vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1ae43e12-953d-4b09-a475-18a865946b3f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_33588058-7a49-4423-be0c-949ff12bed41_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fe2407e2-c1b9-42eb-81b2-e4ab9725f705_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_5e39c5b7-bd26-4d8f-87fb-4ed3a5c5f1ee_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f74ef21a-9eaf-4cd8-bd5a-1a41d3bcbac7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d95d6132-bad5-4710-9002-d9f013bc632c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f02c0690-5d65-4e7e-a267-a151f34c1356_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_b94632dd-ebd4-4189-ab00-dab8a8db5480_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_ad32c267-1a9d-448c-be93-315fcdff8148_terseLabel_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of campuses</link:label>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_label_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Number Of Properties</link:label>
    <link:label id="lab_mrna_OperatingLeaseNumberOfProperties_documentation_en-US" xlink:label="lab_mrna_OperatingLeaseNumberOfProperties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Number Of Properties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties" xlink:href="mrna-20211231.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_OperatingLeaseNumberOfProperties" xlink:to="lab_mrna_OperatingLeaseNumberOfProperties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_7a337ec4-b1ff-4fd1-b9f7-3fa8e9d10804_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_49c07cce-b046-42a6-a08c-a653ec89bcd6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c7c370d3-1aa6-43b9-9f6d-0f275e4528b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ec8dc513-6b6b-44dc-8cd4-2d392c74e627_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_2cbad702-e605-4fcd-840a-c38516369250_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_bf1b440d-05f7-4e4a-9e17-cea63dc84ecf_terseLabel_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award amount</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_label_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:label id="lab_mrna_RevenueFromGrantsMaximumAward_documentation_en-US" xlink:label="lab_mrna_RevenueFromGrantsMaximumAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Grants, Maximum Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RevenueFromGrantsMaximumAward" xlink:to="lab_mrna_RevenueFromGrantsMaximumAward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability_27973660-ed4e-4a0d-85b5-29a82359822b_terseLabel_en-US" xlink:label="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_mrna_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ModernaScienceCentreMember_31180e34-9507-49f6-b85c-89c1eba47542_terseLabel_en-US" xlink:label="lab_mrna_ModernaScienceCentreMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Moderna Science Centre</link:label>
    <link:label id="lab_mrna_ModernaScienceCentreMember_label_en-US" xlink:label="lab_mrna_ModernaScienceCentreMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Moderna Science Centre [Member]</link:label>
    <link:label id="lab_mrna_ModernaScienceCentreMember_documentation_en-US" xlink:label="lab_mrna_ModernaScienceCentreMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Moderna Science Centre</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ModernaScienceCentreMember" xlink:href="mrna-20211231.xsd#mrna_ModernaScienceCentreMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ModernaScienceCentreMember" xlink:to="lab_mrna_ModernaScienceCentreMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_49ad1879-f860-4066-b0cc-393de37a9119_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_0b393f5d-b299-4728-b0ce-93c9eb4af917_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_83ecf58a-18b8-4ccb-b89a-03dd0a7ee8b1_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_56813dfe-a1ac-4afe-86fb-9e55b144cb6a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_aaa9b11d-3c50-40de-bf6d-7d392eddd579_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f1e789a0-5d4a-49a6-90c3-3f4e3e73b918_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_114e926c-695e-4a08-8c13-18e652c82688_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_40420465-f14a-4e07-b913-73a49606788d_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase from available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_b847c315-8791-4260-8394-2511918e0bcb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7b270e8e-b34a-453d-b13b-3ebb8dcb70e4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7810fcb5-97aa-4514-be49-5a0ef2a7e5df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_e9a59b77-9e42-40d7-9726-7290e01e2324_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a1dacd00-e3e2-4d8a-b488-eb33c30761cf_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_5251b39e-2864-4382-9475-c953136f87b0_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_ec83a899-29f1-46ea-af31-700e4e4defe7_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual commitment to pay</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_5bfe5769-71ca-40d3-bc0f-b42317792aaf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d3edac59-bfa9-48ad-8999-2e762750275c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1b3d3318-2b94-4569-a690-50658a073747_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_7a79d795-7cd6-4d03-955c-7e588279e455_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_cb4db70e-b215-48e4-9227-cc323af95caa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_fc2fff22-aab2-471e-86dc-1ed708348c43_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_3f9a3ff1-6cc7-4edd-843d-1a800a5f089b_terseLabel_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in financing lease liabilities</link:label>
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_label_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges To Financing Lease Liabilities</link:label>
    <link:label id="lab_mrna_ChargesToFinancingLeaseLiabilities_documentation_en-US" xlink:label="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges To Financing Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities" xlink:href="mrna-20211231.xsd#mrna_ChargesToFinancingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ChargesToFinancingLeaseLiabilities" xlink:to="lab_mrna_ChargesToFinancingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_7f717e13-5445-40cc-8b74-fccc0a702151_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of valuation allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_625e92aa-2b6f-468d-97de-230e137c41f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows used in financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_15068bf3-3463-4d0d-bd0d-ebee475f4f6a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_021d49ea-9cb0-441e-8d9a-e96276b1161f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_fd566819-b62c-44cb-a447-89e4b07ef38f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9faefa14-89b8-4daa-bfea-7000d94846ba_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_EmbeddedLeasesMember_72d586ee-0d9b-4bcf-92b4-b28ea167438d_terseLabel_en-US" xlink:label="lab_mrna_EmbeddedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Leases</link:label>
    <link:label id="lab_mrna_EmbeddedLeasesMember_label_en-US" xlink:label="lab_mrna_EmbeddedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Leases [Member]</link:label>
    <link:label id="lab_mrna_EmbeddedLeasesMember_documentation_en-US" xlink:label="lab_mrna_EmbeddedLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmbeddedLeasesMember" xlink:href="mrna-20211231.xsd#mrna_EmbeddedLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_EmbeddedLeasesMember" xlink:to="lab_mrna_EmbeddedLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_AccruedClinicalTrials_6a586adc-1ebc-401e-b054-64699a8f4ec4_terseLabel_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_mrna_AccruedClinicalTrials_label_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials</link:label>
    <link:label id="lab_mrna_AccruedClinicalTrials_documentation_en-US" xlink:label="lab_mrna_AccruedClinicalTrials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials" xlink:href="mrna-20211231.xsd#mrna_AccruedClinicalTrials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_AccruedClinicalTrials" xlink:to="lab_mrna_AccruedClinicalTrials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_83261970-4295-45f7-9d53-e5cf19430e7a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_63be93d6-0724-4293-b9c2-25ddf348020e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock through equity plans, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f6b2005f-e80c-43f0-981d-2cd0c0b4a828_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_636f1bb4-59d9-4324-aa63-109fb963c332_terseLabel_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply and manufacturing agreements</link:label>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_label_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply And Manufacturing Agreements [Member]</link:label>
    <link:label id="lab_mrna_SupplyAndManufacturingAgreementsMember_documentation_en-US" xlink:label="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply And Manufacturing Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember" xlink:href="mrna-20211231.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_SupplyAndManufacturingAgreementsMember" xlink:to="lab_mrna_SupplyAndManufacturingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dd6426e4-7608-4d60-af1b-2a2ec37ff7bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ccf77e84-52b9-424c-bbe2-1dc369a5d04a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_abfbae2c-5f96-4060-bf41-dbade6a4d685_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d4962025-7b94-47ff-87bd-18dbdc3f3622_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost related to non-vested stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_55ddb083-416c-422b-8d83-e02c855828b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Foreign Currency Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c3f0b8cf-52f5-4bee-85cf-e3b6411190d5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_ContractOptionsMember_b99fcd3a-4138-49e5-b5d3-621c40663d88_terseLabel_en-US" xlink:label="lab_mrna_ContractOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract options</link:label>
    <link:label id="lab_mrna_ContractOptionsMember_label_en-US" xlink:label="lab_mrna_ContractOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Options [Member]</link:label>
    <link:label id="lab_mrna_ContractOptionsMember_documentation_en-US" xlink:label="lab_mrna_ContractOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractOptionsMember" xlink:href="mrna-20211231.xsd#mrna_ContractOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_ContractOptionsMember" xlink:to="lab_mrna_ContractOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_48201732-70d4-4139-84af-033a3399b8f3_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_c413d790-5cd3-4d70-8b10-0977bd4c80fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_fe0572b9-71d8-4024-b1f9-5bb12fd4f822_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_575131fb-4f0b-4634-ab43-8b087e06eb99_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_c572e5cb-3c0b-4119-86c1-ebab6d2fcfbf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_951047e4-11da-4d6a-aaee-d7c8e691d648_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_e6672bab-b5a8-40ec-84e2-c8a5b0fb0088_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_a36d6737-ed10-4d01-bb51-f4883f68e379_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember_83614cce-f33d-4c87-8757-ca87756e9f91_terseLabel_en-US" xlink:label="lab_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember_label_en-US" xlink:label="lab_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSU) And Performance Stock Unit (PSU) [Member]</link:label>
    <link:label id="lab_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember_documentation_en-US" xlink:label="lab_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSU) And Performance Stock Unit (PSU)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember" xlink:href="mrna-20211231.xsd#mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember" xlink:to="lab_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_11765ee1-1fde-4b0a-be85-434f12c99427_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_f5d0f985-9609-4dda-bb17-3ebd1103a8ae_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3a7aeab7-6c51-4425-a3fe-6b015ed32149_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a9fb556e-4269-4348-9a67-e4028de06703_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5de4e648-da59-41fd-81e4-579d6a9ccac2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_94cc86f3-2488-4eed-ac03-ec94a4add8df_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_85a0923b-f5e3-45a7-94b2-88386eeb470f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_06a781d6-db99-4af0-adb5-9f40590f780a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value, 12 months or more</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_f6db8580-ad8a-4c33-8ae4-d81fa6d7c521_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent contributed by participant</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_f8f140d3-480a-4f61-8356-5601b9e503fb_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_e74ee342-e6be-47e1-b318-c44a38cfb294_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_474c2039-38fd-48a6-a2cf-c8e05677c798_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b94a0528-47ed-4b2c-807d-f6a377e930fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average remaining contractual term expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>mrna-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:61dc7ba0-21f1-4a58-a37b-1270ec5a6c14,g:27805b16-b8d5-4e89-9c63-161f1adf5057-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.modernatx.com/role/CoverPage" xlink:type="simple" xlink:href="mrna-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e4e8d8cc-be3d-4145-8b51-ddf20626b171" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_DocumentType_e4e8d8cc-be3d-4145-8b51-ddf20626b171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_d358ed05-1188-4ffb-bd83-37d9302955b9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_DocumentAnnualReport_d358ed05-1188-4ffb-bd83-37d9302955b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9450c736-37ff-4dc5-b444-1513bca65f74" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_DocumentPeriodEndDate_9450c736-37ff-4dc5-b444-1513bca65f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4e5c5131-b48d-41d5-9fcf-586a778d0499" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_CurrentFiscalYearEndDate_4e5c5131-b48d-41d5-9fcf-586a778d0499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_af5b5787-7377-4d7e-9bdd-71507de0fc07" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_DocumentTransitionReport_af5b5787-7377-4d7e-9bdd-71507de0fc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1eeb6662-0c21-4405-82b9-77bd162a7648" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityFileNumber_1eeb6662-0c21-4405-82b9-77bd162a7648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_31ec1101-e616-4b16-92b7-3ebb119dc154" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityRegistrantName_31ec1101-e616-4b16-92b7-3ebb119dc154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fa31ec65-881c-41de-908c-42193584392a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fa31ec65-881c-41de-908c-42193584392a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a8d21a77-7fd5-4bed-ae90-2555cbc32ee4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityTaxIdentificationNumber_a8d21a77-7fd5-4bed-ae90-2555cbc32ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7c0d7a7f-b309-4292-bcca-59a2777d95c3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityAddressAddressLine1_7c0d7a7f-b309-4292-bcca-59a2777d95c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_473ef79d-8a89-4f1e-a806-95844ad3ed77" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityAddressCityOrTown_473ef79d-8a89-4f1e-a806-95844ad3ed77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_116c1b20-f7c7-4405-9793-26fad3d9714c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityAddressStateOrProvince_116c1b20-f7c7-4405-9793-26fad3d9714c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6f1a23b8-4f3d-4bdd-a394-30db2f7ab33b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityAddressPostalZipCode_6f1a23b8-4f3d-4bdd-a394-30db2f7ab33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_49b5bbb7-9fc9-4115-b288-d5f480cd0f6c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_CityAreaCode_49b5bbb7-9fc9-4115-b288-d5f480cd0f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d931f9d5-e97b-4cab-aea5-2218c209ebf0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_LocalPhoneNumber_d931f9d5-e97b-4cab-aea5-2218c209ebf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f9d90c84-0406-49ff-b052-932710b37399" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_Security12bTitle_f9d90c84-0406-49ff-b052-932710b37399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9fed26cc-ddff-4c7a-92fd-83581926e002" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_TradingSymbol_9fed26cc-ddff-4c7a-92fd-83581926e002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f9701281-5967-4c84-8200-720fb960abde" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_SecurityExchangeName_f9701281-5967-4c84-8200-720fb960abde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_ddc053ae-c018-4236-a504-c806005e45ce" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_ddc053ae-c018-4236-a504-c806005e45ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_540d8e1e-e71e-4d79-b167-92ff1321d374" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityVoluntaryFilers_540d8e1e-e71e-4d79-b167-92ff1321d374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ec81c38d-c32b-485a-af39-898359308bc4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityCurrentReportingStatus_ec81c38d-c32b-485a-af39-898359308bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b30d0b94-af2e-425e-a8a2-2c6e243f5915" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityInteractiveDataCurrent_b30d0b94-af2e-425e-a8a2-2c6e243f5915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_840cd596-7ae5-4c5d-9bcb-c679426109df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityFilerCategory_840cd596-7ae5-4c5d-9bcb-c679426109df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2eb83952-84d8-48ad-b7a0-462286a431ef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntitySmallBusiness_2eb83952-84d8-48ad-b7a0-462286a431ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_542b3935-4542-4637-8d7c-adc6134ec639" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityEmergingGrowthCompany_542b3935-4542-4637-8d7c-adc6134ec639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_18f12914-36aa-4fcf-868d-e0a5b9562e90" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityShellCompany_18f12914-36aa-4fcf-868d-e0a5b9562e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_6383803b-9797-4ffa-ac59-109117a06086" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_IcfrAuditorAttestationFlag_6383803b-9797-4ffa-ac59-109117a06086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_a2134a32-9c9f-47bb-a68d-86c4b9b86bbb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityPublicFloat_a2134a32-9c9f-47bb-a68d-86c4b9b86bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_74996ac4-37fc-4fb5-bbd6-39f8dff3c004" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_74996ac4-37fc-4fb5-bbd6-39f8dff3c004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f933e519-92ec-4221-b772-afe005bedec8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_f933e519-92ec-4221-b772-afe005bedec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fdbf1ea3-790f-474a-87be-2af78b6c8b28" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_AmendmentFlag_fdbf1ea3-790f-474a-87be-2af78b6c8b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7119e5b7-485e-4c9e-a931-cff5b75b6ba1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_DocumentFiscalYearFocus_7119e5b7-485e-4c9e-a931-cff5b75b6ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bf37649c-0815-42d6-b140-3081108d9f03" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bf37649c-0815-42d6-b140-3081108d9f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_07d55abb-a760-4126-85b2-80f0736ffdc6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0b0e60d1-12fb-4a86-bf9f-642ae42474ff" xlink:to="loc_dei_EntityCentralIndexKey_07d55abb-a760-4126-85b2-80f0736ffdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/AuditInformation" xlink:type="simple" xlink:href="mrna-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AuditInformationAbstract_879d218b-48cf-4e64-9771-6d2682ee1fe4" xlink:href="mrna-20211231.xsd#mrna_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_4e0f9c2a-7853-4f05-bbe9-61a08b458ec0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_AuditInformationAbstract_879d218b-48cf-4e64-9771-6d2682ee1fe4" xlink:to="loc_dei_AuditorName_4e0f9c2a-7853-4f05-bbe9-61a08b458ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_d785211f-f7c3-4b99-a151-abaf33d947f9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_AuditInformationAbstract_879d218b-48cf-4e64-9771-6d2682ee1fe4" xlink:to="loc_dei_AuditorLocation_d785211f-f7c3-4b99-a151-abaf33d947f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_a7db7759-21f5-4adf-8a12-bd1d64b755ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_AuditInformationAbstract_879d218b-48cf-4e64-9771-6d2682ee1fe4" xlink:to="loc_dei_AuditorFirmId_a7db7759-21f5-4adf-8a12-bd1d64b755ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_18c7a272-a992-4a66-94d6-f9997904d5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4043006b-6fae-4838-92bf-d30f63f153d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_18c7a272-a992-4a66-94d6-f9997904d5bb" xlink:to="loc_us-gaap_AssetsAbstract_4043006b-6fae-4838-92bf-d30f63f153d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_54aa881e-dfa0-4a91-82ee-5fc263b3559a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4043006b-6fae-4838-92bf-d30f63f153d5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_54aa881e-dfa0-4a91-82ee-5fc263b3559a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c42f811-7921-4a5e-bbdf-cd7ffea13dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54aa881e-dfa0-4a91-82ee-5fc263b3559a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c42f811-7921-4a5e-bbdf-cd7ffea13dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0d653d75-c094-40f0-bc0d-4aab72c46cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54aa881e-dfa0-4a91-82ee-5fc263b3559a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0d653d75-c094-40f0-bc0d-4aab72c46cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8fb4012c-2aea-4ee8-adfd-560585083ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54aa881e-dfa0-4a91-82ee-5fc263b3559a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8fb4012c-2aea-4ee8-adfd-560585083ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4eabbae6-12fb-4398-b368-7564a0caa0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54aa881e-dfa0-4a91-82ee-5fc263b3559a" xlink:to="loc_us-gaap_InventoryNet_4eabbae6-12fb-4398-b368-7564a0caa0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b7435960-ddce-4565-bc2e-1bcbcf4108a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54aa881e-dfa0-4a91-82ee-5fc263b3559a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b7435960-ddce-4565-bc2e-1bcbcf4108a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_eb65773a-d27a-4637-a644-e504861f7164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_54aa881e-dfa0-4a91-82ee-5fc263b3559a" xlink:to="loc_us-gaap_AssetsCurrent_eb65773a-d27a-4637-a644-e504861f7164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_916c476c-1b85-4d19-b345-fcc795b75cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4043006b-6fae-4838-92bf-d30f63f153d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_916c476c-1b85-4d19-b345-fcc795b75cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_f9a2fcfd-b733-4f79-a16e-e91f915b2bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4043006b-6fae-4838-92bf-d30f63f153d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_f9a2fcfd-b733-4f79-a16e-e91f915b2bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_752a6239-6e54-4002-8d8e-664ae470ce31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4043006b-6fae-4838-92bf-d30f63f153d5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_752a6239-6e54-4002-8d8e-664ae470ce31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_b2824c0a-a420-4088-b4c7-56d0c9ff883d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4043006b-6fae-4838-92bf-d30f63f153d5" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_b2824c0a-a420-4088-b4c7-56d0c9ff883d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8fc511fa-35dc-40ae-a5ac-8a6ff7c5d87b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4043006b-6fae-4838-92bf-d30f63f153d5" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8fc511fa-35dc-40ae-a5ac-8a6ff7c5d87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b201e8d3-482c-4436-8f57-52531ea77139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4043006b-6fae-4838-92bf-d30f63f153d5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b201e8d3-482c-4436-8f57-52531ea77139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_70fe5236-2321-4740-8164-3d86558620b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4043006b-6fae-4838-92bf-d30f63f153d5" xlink:to="loc_us-gaap_Assets_70fe5236-2321-4740-8164-3d86558620b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16a6184-9216-46cf-bb06-ffa55af38b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_18c7a272-a992-4a66-94d6-f9997904d5bb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16a6184-9216-46cf-bb06-ffa55af38b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_62e7c2dd-80cf-4acc-9aa8-db0cc566534d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16a6184-9216-46cf-bb06-ffa55af38b16" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_62e7c2dd-80cf-4acc-9aa8-db0cc566534d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c5bad2c-b780-483d-a277-46c89102affd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62e7c2dd-80cf-4acc-9aa8-db0cc566534d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c5bad2c-b780-483d-a277-46c89102affd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_86a5c306-e79f-4215-ae92-9987175c345b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62e7c2dd-80cf-4acc-9aa8-db0cc566534d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_86a5c306-e79f-4215-ae92-9987175c345b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6253384d-53f3-4a01-8565-dd6d004c91b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62e7c2dd-80cf-4acc-9aa8-db0cc566534d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6253384d-53f3-4a01-8565-dd6d004c91b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_7404a67d-5eb8-4e0c-8014-b9163fa6b09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62e7c2dd-80cf-4acc-9aa8-db0cc566534d" xlink:to="loc_us-gaap_TaxesPayableCurrent_7404a67d-5eb8-4e0c-8014-b9163fa6b09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e79b1dad-baed-49a6-9ef8-2b603821f485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62e7c2dd-80cf-4acc-9aa8-db0cc566534d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e79b1dad-baed-49a6-9ef8-2b603821f485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b7e469e2-74be-4053-8dfb-a628b7c9b838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_62e7c2dd-80cf-4acc-9aa8-db0cc566534d" xlink:to="loc_us-gaap_LiabilitiesCurrent_b7e469e2-74be-4053-8dfb-a628b7c9b838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c5cfee77-b400-496a-b2b0-8cf6f1b18bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16a6184-9216-46cf-bb06-ffa55af38b16" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c5cfee77-b400-496a-b2b0-8cf6f1b18bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5ab296c5-adff-4508-8a30-6bde4b478158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16a6184-9216-46cf-bb06-ffa55af38b16" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5ab296c5-adff-4508-8a30-6bde4b478158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1619cd6c-1ff2-4b3a-9bd6-87c9b8966754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16a6184-9216-46cf-bb06-ffa55af38b16" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1619cd6c-1ff2-4b3a-9bd6-87c9b8966754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bd5ce7bf-4e19-4d33-be96-121f39e85615" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16a6184-9216-46cf-bb06-ffa55af38b16" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bd5ce7bf-4e19-4d33-be96-121f39e85615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c0f0911a-dea8-4b7d-af4a-7085ef5dd409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16a6184-9216-46cf-bb06-ffa55af38b16" xlink:to="loc_us-gaap_Liabilities_c0f0911a-dea8-4b7d-af4a-7085ef5dd409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0f7cb990-2bf5-4181-ae85-bafa8559fa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16a6184-9216-46cf-bb06-ffa55af38b16" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0f7cb990-2bf5-4181-ae85-bafa8559fa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d1b67157-e86b-42d6-a4c4-8872a3fa20e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16a6184-9216-46cf-bb06-ffa55af38b16" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d1b67157-e86b-42d6-a4c4-8872a3fa20e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e972acb7-861f-4652-a75c-375d9e216d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d1b67157-e86b-42d6-a4c4-8872a3fa20e4" xlink:to="loc_us-gaap_PreferredStockValue_e972acb7-861f-4652-a75c-375d9e216d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_86ade5cf-2d4e-4f45-a421-39f0bbe85588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d1b67157-e86b-42d6-a4c4-8872a3fa20e4" xlink:to="loc_us-gaap_CommonStockValue_86ade5cf-2d4e-4f45-a421-39f0bbe85588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d8cffc2f-5f3b-4455-91a1-17d360bab3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d1b67157-e86b-42d6-a4c4-8872a3fa20e4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d8cffc2f-5f3b-4455-91a1-17d360bab3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a6b4d2cc-252e-4919-8e8a-b06aafc340bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d1b67157-e86b-42d6-a4c4-8872a3fa20e4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a6b4d2cc-252e-4919-8e8a-b06aafc340bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_013ace30-30c2-4b8d-8e0d-f65bf0a49808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d1b67157-e86b-42d6-a4c4-8872a3fa20e4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_013ace30-30c2-4b8d-8e0d-f65bf0a49808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_380965f7-9233-426a-9a8c-619e0890f24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d1b67157-e86b-42d6-a4c4-8872a3fa20e4" xlink:to="loc_us-gaap_StockholdersEquity_380965f7-9233-426a-9a8c-619e0890f24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_33e34ae8-e0e5-4b54-aa7e-9575faf0f0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b16a6184-9216-46cf-bb06-ffa55af38b16" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_33e34ae8-e0e5-4b54-aa7e-9575faf0f0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDBALANCESHEETSParentheticals"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bb26ef3a-fffd-4f9b-bd8f-8866edda698b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_35556106-2965-4309-b726-4af0024de4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bb26ef3a-fffd-4f9b-bd8f-8866edda698b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_35556106-2965-4309-b726-4af0024de4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e81ba242-1266-4c4e-9895-8ca1cb232e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bb26ef3a-fffd-4f9b-bd8f-8866edda698b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e81ba242-1266-4c4e-9895-8ca1cb232e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cb90841e-8e6b-4d02-848c-dfeaabaa9c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bb26ef3a-fffd-4f9b-bd8f-8866edda698b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cb90841e-8e6b-4d02-848c-dfeaabaa9c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_544baf9f-197a-4ccf-a518-17598ef05633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bb26ef3a-fffd-4f9b-bd8f-8866edda698b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_544baf9f-197a-4ccf-a518-17598ef05633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_52d30851-2057-44d8-b9a6-a875c0d3830c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bb26ef3a-fffd-4f9b-bd8f-8866edda698b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_52d30851-2057-44d8-b9a6-a875c0d3830c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_151275a3-e462-4fe3-9b2a-536975f930b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bb26ef3a-fffd-4f9b-bd8f-8866edda698b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_151275a3-e462-4fe3-9b2a-536975f930b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10385814-12eb-4855-8145-32c3f2c0bf97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bb26ef3a-fffd-4f9b-bd8f-8866edda698b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10385814-12eb-4855-8145-32c3f2c0bf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_af0cfb94-eca7-41b4-b358-e4cc9e2026e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bb26ef3a-fffd-4f9b-bd8f-8866edda698b" xlink:to="loc_us-gaap_CommonStockSharesIssued_af0cfb94-eca7-41b4-b358-e4cc9e2026e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8a1afc79-18f8-4031-abf9-5813549be665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1bcd55b3-ec16-42fb-bf75-d836c9af01fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8a1afc79-18f8-4031-abf9-5813549be665" xlink:to="loc_us-gaap_StatementTable_1bcd55b3-ec16-42fb-bf75-d836c9af01fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_50bfde91-0718-4e5c-b539-a66c7dbc3ffb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1bcd55b3-ec16-42fb-bf75-d836c9af01fe" xlink:to="loc_srt_ProductOrServiceAxis_50bfde91-0718-4e5c-b539-a66c7dbc3ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f91d30c5-5253-438e-90b6-40485164e5b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_50bfde91-0718-4e5c-b539-a66c7dbc3ffb" xlink:to="loc_srt_ProductsAndServicesDomain_f91d30c5-5253-438e-90b6-40485164e5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_0bd78d9f-a2cd-45e9-aa22-e1715d543a56" xlink:href="mrna-20211231.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f91d30c5-5253-438e-90b6-40485164e5b7" xlink:to="loc_mrna_ProductSalesMember_0bd78d9f-a2cd-45e9-aa22-e1715d543a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_a06eeb0a-c4ee-46df-8354-c219ae3326a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f91d30c5-5253-438e-90b6-40485164e5b7" xlink:to="loc_us-gaap_GrantMember_a06eeb0a-c4ee-46df-8354-c219ae3326a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_c69d0d31-6ffc-49dc-b27a-07a3ee97da71" xlink:href="mrna-20211231.xsd#mrna_CollaborationArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f91d30c5-5253-438e-90b6-40485164e5b7" xlink:to="loc_mrna_CollaborationArrangementMember_c69d0d31-6ffc-49dc-b27a-07a3ee97da71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1bcd55b3-ec16-42fb-bf75-d836c9af01fe" xlink:to="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_4e492d99-8f50-4953-ad3f-6b513ce4c149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_RevenuesAbstract_4e492d99-8f50-4953-ad3f-6b513ce4c149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ce37191c-50cd-4780-84de-5a119517ed20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_4e492d99-8f50-4953-ad3f-6b513ce4c149" xlink:to="loc_us-gaap_Revenues_ce37191c-50cd-4780-84de-5a119517ed20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_37bc11bf-9ca2-4086-900b-99fea71bd04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_37bc11bf-9ca2-4086-900b-99fea71bd04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_94fb1a50-09c7-496d-8d4d-d15ee8824031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_94fb1a50-09c7-496d-8d4d-d15ee8824031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_63ad9c53-92d0-40f4-a5b5-2ab6a05cc6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_63ad9c53-92d0-40f4-a5b5-2ab6a05cc6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d1e24801-5575-45d7-acc3-55bc5f8484cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_627d1a36-551e-4a0e-988e-8a3890fcb977" xlink:to="loc_us-gaap_CostsAndExpenses_d1e24801-5575-45d7-acc3-55bc5f8484cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_41b523aa-3f21-41e8-b9be-e8cc90383d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_OperatingIncomeLoss_41b523aa-3f21-41e8-b9be-e8cc90383d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7fd8d203-3b0c-4f4d-b58a-cdf502eee7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7fd8d203-3b0c-4f4d-b58a-cdf502eee7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0f1189bb-eac6-41be-a95f-413a03075500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0f1189bb-eac6-41be-a95f-413a03075500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dda171a0-b156-44ee-b1ab-8322a2d61877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dda171a0-b156-44ee-b1ab-8322a2d61877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_43b9dd73-1b2c-4197-9674-c2ceb52277e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_43b9dd73-1b2c-4197-9674-c2ceb52277e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_30c54aed-09cf-4357-96ee-87f4670dd0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_NetIncomeLoss_30c54aed-09cf-4357-96ee-87f4670dd0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a27ca88c-324f-4b86-87d1-6ac70b109f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a27ca88c-324f-4b86-87d1-6ac70b109f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9d74c5ca-7e8d-49c9-a1b6-722b027673c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a27ca88c-324f-4b86-87d1-6ac70b109f5f" xlink:to="loc_us-gaap_EarningsPerShareBasic_9d74c5ca-7e8d-49c9-a1b6-722b027673c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5026f927-3fa6-424e-a38e-ef2cdf63fc23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a27ca88c-324f-4b86-87d1-6ac70b109f5f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5026f927-3fa6-424e-a38e-ef2cdf63fc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6a815568-8a94-4af1-93fc-294656cb6db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69da43b2-0c96-4d39-bf36-68f08b9d248a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6a815568-8a94-4af1-93fc-294656cb6db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d30d9177-317c-47d8-bc1a-e440a78e6367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6a815568-8a94-4af1-93fc-294656cb6db4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d30d9177-317c-47d8-bc1a-e440a78e6367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5ec8afd6-143d-45bf-a36b-94f0911a4cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6a815568-8a94-4af1-93fc-294656cb6db4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5ec8afd6-143d-45bf-a36b-94f0911a4cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a13eeb0-6c4e-472e-8c5f-5c4451130521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_babd6089-3a38-4bf0-a3c0-14f222ba426c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a13eeb0-6c4e-472e-8c5f-5c4451130521" xlink:to="loc_us-gaap_NetIncomeLoss_babd6089-3a38-4bf0-a3c0-14f222ba426c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5d90fe76-7f39-48c1-adc0-ef9e0e92163e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a13eeb0-6c4e-472e-8c5f-5c4451130521" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5d90fe76-7f39-48c1-adc0-ef9e0e92163e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1a630593-bac0-427a-940c-65eed052ee24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5d90fe76-7f39-48c1-adc0-ef9e0e92163e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1a630593-bac0-427a-940c-65eed052ee24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b06a6119-451f-414f-872d-bce682db96c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5d90fe76-7f39-48c1-adc0-ef9e0e92163e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b06a6119-451f-414f-872d-bce682db96c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5fd2a56b-21b4-401a-94b8-c1d88b36c861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_5d90fe76-7f39-48c1-adc0-ef9e0e92163e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5fd2a56b-21b4-401a-94b8-c1d88b36c861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_fece05ac-3263-4fbc-b409-43ed8bfefb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a13eeb0-6c4e-472e-8c5f-5c4451130521" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_fece05ac-3263-4fbc-b409-43ed8bfefb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_ea67ddce-af7b-41bd-9c3f-38630e75618e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_fece05ac-3263-4fbc-b409-43ed8bfefb80" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_ea67ddce-af7b-41bd-9c3f-38630e75618e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_7bce5d9e-9f73-4a87-b76a-76058d74a919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_fece05ac-3263-4fbc-b409-43ed8bfefb80" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_7bce5d9e-9f73-4a87-b76a-76058d74a919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_4958c5f3-b24e-436b-9ad9-b015a1533a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract_fece05ac-3263-4fbc-b409-43ed8bfefb80" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_4958c5f3-b24e-436b-9ad9-b015a1533a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bda6b5ed-9872-4147-9e85-aa5c10b6c056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a13eeb0-6c4e-472e-8c5f-5c4451130521" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bda6b5ed-9872-4147-9e85-aa5c10b6c056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_172455f9-88b4-4ac8-a5b3-2a84f74cba5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3a13eeb0-6c4e-472e-8c5f-5c4451130521" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_172455f9-88b4-4ac8-a5b3-2a84f74cba5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_248a23cd-74fe-4b27-8a28-ff97c01907e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0201a8fc-abb5-4bc4-834d-adb2d2b249bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_248a23cd-74fe-4b27-8a28-ff97c01907e3" xlink:to="loc_us-gaap_StatementTable_0201a8fc-abb5-4bc4-834d-adb2d2b249bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9067a78b-a0b7-4904-a0ca-61b3e2ea1d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0201a8fc-abb5-4bc4-834d-adb2d2b249bf" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9067a78b-a0b7-4904-a0ca-61b3e2ea1d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_d56feaed-c3cd-402a-a373-f32194923127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_9067a78b-a0b7-4904-a0ca-61b3e2ea1d21" xlink:to="loc_us-gaap_TypeOfAdoptionMember_d56feaed-c3cd-402a-a373-f32194923127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_3b6bd22b-d5b2-4d0f-bf79-7b1a64bd2790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d56feaed-c3cd-402a-a373-f32194923127" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_3b6bd22b-d5b2-4d0f-bf79-7b1a64bd2790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_e9e575c2-3fbf-40a0-9bb7-d6d3635e4157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_d56feaed-c3cd-402a-a373-f32194923127" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_e9e575c2-3fbf-40a0-9bb7-d6d3635e4157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1c33bafa-a8d7-4ab4-8ed2-470a161a91ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0201a8fc-abb5-4bc4-834d-adb2d2b249bf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1c33bafa-a8d7-4ab4-8ed2-470a161a91ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1c33bafa-a8d7-4ab4-8ed2-470a161a91ea" xlink:to="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_529c2026-5eac-475b-ac2b-ca1721c03c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:to="loc_us-gaap_CommonStockMember_529c2026-5eac-475b-ac2b-ca1721c03c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9deb2186-15e8-4c80-925e-2ce2694177a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9deb2186-15e8-4c80-925e-2ce2694177a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9e65fa63-1723-4f5f-a3e6-a12470e0c375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9e65fa63-1723-4f5f-a3e6-a12470e0c375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c065ff6a-de93-4ea7-a9b0-0c6adf0cc512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_98e26398-0191-4d13-a15a-8720f10de1b6" xlink:to="loc_us-gaap_RetainedEarningsMember_c065ff6a-de93-4ea7-a9b0-0c6adf0cc512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_55e56120-52af-4dce-9b71-9563a3f7faec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0201a8fc-abb5-4bc4-834d-adb2d2b249bf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_55e56120-52af-4dce-9b71-9563a3f7faec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e621ed89-3a81-4789-905d-3a4004a39276" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_55e56120-52af-4dce-9b71-9563a3f7faec" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e621ed89-3a81-4789-905d-3a4004a39276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4449e196-9a01-4fe9-bbde-f75f7a96265f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e621ed89-3a81-4789-905d-3a4004a39276" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4449e196-9a01-4fe9-bbde-f75f7a96265f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5fce354a-8fe9-48b3-8091-5d64b69520db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0201a8fc-abb5-4bc4-834d-adb2d2b249bf" xlink:to="loc_us-gaap_StatementLineItems_5fce354a-8fe9-48b3-8091-5d64b69520db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5fce354a-8fe9-48b3-8091-5d64b69520db" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cd777266-9298-4c68-a77f-340047088bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_SharesOutstanding_cd777266-9298-4c68-a77f-340047088bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6b2d63b3-c015-4c39-ab69-835c62eb34f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockholdersEquity_6b2d63b3-c015-4c39-ab69-835c62eb34f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_e7077293-ae2f-4fd4-93c8-d5ae05838ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_e7077293-ae2f-4fd4-93c8-d5ae05838ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_401a4e5e-fe66-4a90-8bee-4e333a7bc4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_401a4e5e-fe66-4a90-8bee-4e333a7bc4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66cd7ffe-728c-43b6-977f-a0b9f3e0e96a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66cd7ffe-728c-43b6-977f-a0b9f3e0e96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e4472d8-60e5-4f6a-84eb-ae94070c3819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e4472d8-60e5-4f6a-84eb-ae94070c3819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9ebbf289-ff55-4648-a0e0-71a766adc380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9ebbf289-ff55-4648-a0e0-71a766adc380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d86bb521-590e-45bc-8157-40418ed6b802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d86bb521-590e-45bc-8157-40418ed6b802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_860d8b84-c6dd-4093-9e0b-081b6800b585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_860d8b84-c6dd-4093-9e0b-081b6800b585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f5208e29-6fcf-4a31-b2c6-71dcae516bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f5208e29-6fcf-4a31-b2c6-71dcae516bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_254b1231-218b-4024-999f-c295815065e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_254b1231-218b-4024-999f-c295815065e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_1efb086c-32b4-4856-bac6-0b7850395fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_1efb086c-32b4-4856-bac6-0b7850395fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02729f75-00b8-44b8-b2d5-272e831ef64d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_NetIncomeLoss_02729f75-00b8-44b8-b2d5-272e831ef64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1048c9d8-09d6-4b40-bb86-ee2b4c656082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_SharesOutstanding_1048c9d8-09d6-4b40-bb86-ee2b4c656082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_95a66480-b225-423f-932d-203c077624da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6d7a6aef-85a5-427c-a684-6bef62f6048a" xlink:to="loc_us-gaap_StockholdersEquity_95a66480-b225-423f-932d-203c077624da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_acc5582c-1e55-4909-b466-6b9ff05b987c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_65eb54d7-95c1-4392-bb57-527d8d88c2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_acc5582c-1e55-4909-b466-6b9ff05b987c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_65eb54d7-95c1-4392-bb57-527d8d88c2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mrna-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_66dcaf24-5bdc-4f9c-a5b0-20b9a49c0b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b21c46b5-2006-49fc-901d-98c41d26c43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66dcaf24-5bdc-4f9c-a5b0-20b9a49c0b3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b21c46b5-2006-49fc-901d-98c41d26c43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c010f62-61cf-4ac5-99e4-00a2c599b85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b21c46b5-2006-49fc-901d-98c41d26c43f" xlink:to="loc_us-gaap_NetIncomeLoss_7c010f62-61cf-4ac5-99e4-00a2c599b85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f0c93a-9792-4924-a1ef-4c753629cc93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b21c46b5-2006-49fc-901d-98c41d26c43f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f0c93a-9792-4924-a1ef-4c753629cc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_97fa15d0-abf2-4215-a735-cb4ef0184abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f0c93a-9792-4924-a1ef-4c753629cc93" xlink:to="loc_us-gaap_ShareBasedCompensation_97fa15d0-abf2-4215-a735-cb4ef0184abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_04221e53-c35f-4e17-9f4b-d922e69c9f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f0c93a-9792-4924-a1ef-4c753629cc93" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_04221e53-c35f-4e17-9f4b-d922e69c9f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_e52e62d8-6fa5-4803-9d2a-fde9ccc414ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f0c93a-9792-4924-a1ef-4c753629cc93" xlink:to="loc_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_e52e62d8-6fa5-4803-9d2a-fde9ccc414ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_ea03c4f6-5a98-4994-8157-d295c8ed01bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f0c93a-9792-4924-a1ef-4c753629cc93" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_ea03c4f6-5a98-4994-8157-d295c8ed01bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredIncomeTaxExpenseBenefitNet_4d08ba95-ff58-4956-82e1-780bf94ddf8f" xlink:href="mrna-20211231.xsd#mrna_DeferredIncomeTaxExpenseBenefitNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f0c93a-9792-4924-a1ef-4c753629cc93" xlink:to="loc_mrna_DeferredIncomeTaxExpenseBenefitNet_4d08ba95-ff58-4956-82e1-780bf94ddf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f0c93a-9792-4924-a1ef-4c753629cc93" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e4070861-b41c-41ea-aca1-af804830f02f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e4070861-b41c-41ea-aca1-af804830f02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a961623d-aeb0-4d64-94e4-d443cffaf314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a961623d-aeb0-4d64-94e4-d443cffaf314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_4c858fe0-d3cd-4ff3-9c23-5c7dd0f89986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_4c858fe0-d3cd-4ff3-9c23-5c7dd0f89986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets_6b97595e-f3a4-4355-87a3-6e6b8b8e3562" xlink:href="mrna-20211231.xsd#mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:to="loc_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets_6b97595e-f3a4-4355-87a3-6e6b8b8e3562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e9fb1701-b775-4059-95dc-c1451ac176f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e9fb1701-b775-4059-95dc-c1451ac176f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_66c3f0ab-9c58-4b49-9fc4-812162011b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_66c3f0ab-9c58-4b49-9fc4-812162011b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cd874a78-a9df-494e-a27a-8714076ffc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cd874a78-a9df-494e-a27a-8714076ffc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e419380c-7714-43c6-8ec9-ffbb1896db18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e419380c-7714-43c6-8ec9-ffbb1896db18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_dc4299be-8f08-46e1-b157-d36235bd367e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_dc4299be-8f08-46e1-b157-d36235bd367e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8cf14e47-0f6a-4aef-95ec-ab4c36b5b4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3abde134-016c-4a3c-ba41-b49d6dea56d6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8cf14e47-0f6a-4aef-95ec-ab4c36b5b4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef71a22c-1bf7-486a-a11e-77bb55669be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b21c46b5-2006-49fc-901d-98c41d26c43f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ef71a22c-1bf7-486a-a11e-77bb55669be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db5a7845-aeb1-4378-b5b4-7846f851e65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66dcaf24-5bdc-4f9c-a5b0-20b9a49c0b3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db5a7845-aeb1-4378-b5b4-7846f851e65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_da573873-efce-4bf7-9c0f-ec0a99d074a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db5a7845-aeb1-4378-b5b4-7846f851e65e" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_da573873-efce-4bf7-9c0f-ec0a99d074a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0e878cc9-1f0e-4159-bf0a-433f3eafe0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db5a7845-aeb1-4378-b5b4-7846f851e65e" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0e878cc9-1f0e-4159-bf0a-433f3eafe0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_724d1047-92c9-4383-ab53-ac2958f2c81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db5a7845-aeb1-4378-b5b4-7846f851e65e" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_724d1047-92c9-4383-ab53-ac2958f2c81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f47a7ab5-17e6-4a2c-a885-3124f9ae3a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db5a7845-aeb1-4378-b5b4-7846f851e65e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f47a7ab5-17e6-4a2c-a885-3124f9ae3a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_33f53650-ea20-42c3-ae54-ce5642a7f74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db5a7845-aeb1-4378-b5b4-7846f851e65e" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_33f53650-ea20-42c3-ae54-ce5642a7f74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69c9d884-8991-4263-8376-66555e1f9c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_db5a7845-aeb1-4378-b5b4-7846f851e65e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69c9d884-8991-4263-8376-66555e1f9c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_01c39c9c-f6d2-4e04-bac3-acd9fb4cea0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66dcaf24-5bdc-4f9c-a5b0-20b9a49c0b3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_01c39c9c-f6d2-4e04-bac3-acd9fb4cea0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_38adb727-64af-46fb-87b9-9f82845a26ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_01c39c9c-f6d2-4e04-bac3-acd9fb4cea0a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_38adb727-64af-46fb-87b9-9f82845a26ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_ff920e3c-33df-4e20-bfa8-4b0fbe6a92a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_01c39c9c-f6d2-4e04-bac3-acd9fb4cea0a" xlink:to="loc_us-gaap_ProceedsFromStockPlans_ff920e3c-33df-4e20-bfa8-4b0fbe6a92a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8d8e1cd6-bbc9-4503-af9b-1cf6d9b00b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_01c39c9c-f6d2-4e04-bac3-acd9fb4cea0a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8d8e1cd6-bbc9-4503-af9b-1cf6d9b00b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChargesToFinancingLeaseLiabilities_76ecc1fc-f1f5-4ec7-9a04-4d524da58678" xlink:href="mrna-20211231.xsd#mrna_ChargesToFinancingLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_01c39c9c-f6d2-4e04-bac3-acd9fb4cea0a" xlink:to="loc_mrna_ChargesToFinancingLeaseLiabilities_76ecc1fc-f1f5-4ec7-9a04-4d524da58678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_623b6ae5-e664-4302-bd11-616e248edae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_01c39c9c-f6d2-4e04-bac3-acd9fb4cea0a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_623b6ae5-e664-4302-bd11-616e248edae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_257bf814-2e7a-4dee-b636-40d74aadbc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66dcaf24-5bdc-4f9c-a5b0-20b9a49c0b3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_257bf814-2e7a-4dee-b636-40d74aadbc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bead7f98-eb63-4548-9692-e02791cd3013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66dcaf24-5bdc-4f9c-a5b0-20b9a49c0b3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bead7f98-eb63-4548-9692-e02791cd3013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9fbf132e-4dab-4f07-886b-4e5b0d50d13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66dcaf24-5bdc-4f9c-a5b0-20b9a49c0b3a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9fbf132e-4dab-4f07-886b-4e5b0d50d13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_bc9e6a89-9b6e-4dd1-adea-293479c59e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66dcaf24-5bdc-4f9c-a5b0-20b9a49c0b3a" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_bc9e6a89-9b6e-4dd1-adea-293479c59e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_aea3bb9c-6ece-43b5-a090-559bb1203231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_bc9e6a89-9b6e-4dd1-adea-293479c59e86" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_aea3bb9c-6ece-43b5-a090-559bb1203231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ca66c73f-8d1b-4302-9997-f0362c1074d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_bc9e6a89-9b6e-4dd1-adea-293479c59e86" xlink:to="loc_us-gaap_InterestPaidNet_ca66c73f-8d1b-4302-9997-f0362c1074d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2439a080-f268-4a7f-ae77-c155077a1072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66dcaf24-5bdc-4f9c-a5b0-20b9a49c0b3a" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2439a080-f268-4a7f-ae77-c155077a1072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38dcd735-ff2a-423b-a614-93a52f45cb33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2439a080-f268-4a7f-ae77-c155077a1072" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38dcd735-ff2a-423b-a614-93a52f45cb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="mrna-20211231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_678e9ef2-c1b1-41c7-afa4-7ca9140a9fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8fbeb7c6-2d29-49b5-88a6-f9faf6ae1d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_678e9ef2-c1b1-41c7-afa4-7ca9140a9fc7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8fbeb7c6-2d29-49b5-88a6-f9faf6ae1d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_82615aa7-1b31-4414-99a7-e47d22ebbb76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e8c78ddd-0f92-4e3d-8336-af94926fb581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82615aa7-1b31-4414-99a7-e47d22ebbb76" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e8c78ddd-0f92-4e3d-8336-af94926fb581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_aff74623-910b-4330-8f20-83fe60c8ca2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_aff74623-910b-4330-8f20-83fe60c8ca2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_a673cf34-da25-4b63-8e17-7beb823d3041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_a673cf34-da25-4b63-8e17-7beb823d3041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f3351c7a-df0e-4ef7-94f8-67cf3a8586fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_UseOfEstimates_f3351c7a-df0e-4ef7-94f8-67cf3a8586fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_dc845a4b-8dbc-402a-9186-cbeab5478e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_dc845a4b-8dbc-402a-9186-cbeab5478e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_735e2be9-0e10-4080-aaa8-3d354956856a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_735e2be9-0e10-4080-aaa8-3d354956856a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_55c745df-d22b-4735-b000-b2c47226a029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_55c745df-d22b-4735-b000-b2c47226a029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2ffcb75f-2ab7-40a0-970f-aae02f636570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2ffcb75f-2ab7-40a0-970f-aae02f636570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_283e3fa1-7ffd-4443-8a12-4c07ca78fa5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_283e3fa1-7ffd-4443-8a12-4c07ca78fa5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_a0b5a275-775b-46fc-b82e-cf8b5ce00545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_a0b5a275-775b-46fc-b82e-cf8b5ce00545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9d77f32b-d215-4021-b600-89a7e69abdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_9d77f32b-d215-4021-b600-89a7e69abdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_fa56df1b-9ef7-43a8-9253-be952188724b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_fa56df1b-9ef7-43a8-9253-be952188724b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_c4455e4e-41f9-41d4-a54a-b6e39bbcb211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_c4455e4e-41f9-41d4-a54a-b6e39bbcb211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_03960736-e95d-4dcc-bc4b-eb61c847c244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_03960736-e95d-4dcc-bc4b-eb61c847c244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_68947bec-ebdb-414e-ac38-6b378964c064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_68947bec-ebdb-414e-ac38-6b378964c064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_88107456-b350-49b3-92d8-a07628fb3f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_88107456-b350-49b3-92d8-a07628fb3f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d74e1c37-5cc3-42f0-b519-c4df70271bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d74e1c37-5cc3-42f0-b519-c4df70271bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e2d02f12-6eef-411d-8f43-6205af63bcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e2d02f12-6eef-411d-8f43-6205af63bcb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_4ef591a9-e2e6-40c2-92e1-b05822ba6e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_4ef591a9-e2e6-40c2-92e1-b05822ba6e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_79b175b9-8a52-4cad-b67e-640d392003eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_79b175b9-8a52-4cad-b67e-640d392003eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2fac7329-1c02-41f8-bb22-ef6212e5278c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2fac7329-1c02-41f8-bb22-ef6212e5278c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_fff21306-644a-4488-b19d-c954ca625211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_fff21306-644a-4488-b19d-c954ca625211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7688428a-3068-4b81-bee1-f104fdbc2df2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7688428a-3068-4b81-bee1-f104fdbc2df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_248537e2-29df-490d-a602-e6f20a476fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_248537e2-29df-490d-a602-e6f20a476fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9731e37c-e848-45a0-a3f9-89e4b274a145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e27bc85f-5bb1-4215-a7bf-10b96fd1a7e5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9731e37c-e848-45a0-a3f9-89e4b274a145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b7d4eab1-3ab2-44dd-9a3b-145607efe6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_62a909a6-2c2d-497b-af22-9da161c6def9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7d4eab1-3ab2-44dd-9a3b-145607efe6ee" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_62a909a6-2c2d-497b-af22-9da161c6def9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d57e82e9-b6aa-47a5-acb8-39b2ee4a5e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7d4eab1-3ab2-44dd-9a3b-145607efe6ee" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d57e82e9-b6aa-47a5-acb8-39b2ee4a5e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_3dcd278d-05ce-4415-b245-e049697830eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7d4eab1-3ab2-44dd-9a3b-145607efe6ee" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_3dcd278d-05ce-4415-b245-e049697830eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9ea8338d-71d2-4abe-a8a0-01293a6265ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7d4eab1-3ab2-44dd-9a3b-145607efe6ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9ea8338d-71d2-4abe-a8a0-01293a6265ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f8f0b425-2395-43b4-8416-f4f94bb6f4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b7d4eab1-3ab2-44dd-9a3b-145607efe6ee" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f8f0b425-2395-43b4-8416-f4f94bb6f4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4a689501-b147-436b-8048-aec0fe6e75e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0c199abd-33c6-4416-b782-3e5235252b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a689501-b147-436b-8048-aec0fe6e75e9" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0c199abd-33c6-4416-b782-3e5235252b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bb4e3a54-b133-4bdb-a339-b0f6c767d232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a689501-b147-436b-8048-aec0fe6e75e9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bb4e3a54-b133-4bdb-a339-b0f6c767d232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_30cc8c9e-7be8-46c6-b30e-2ed113c701ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a689501-b147-436b-8048-aec0fe6e75e9" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_30cc8c9e-7be8-46c6-b30e-2ed113c701ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditFairValueDisclosure_fc72708e-5465-494c-8fd4-e8afd368b3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LinesOfCreditFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a689501-b147-436b-8048-aec0fe6e75e9" xlink:to="loc_us-gaap_LinesOfCreditFairValueDisclosure_fc72708e-5465-494c-8fd4-e8afd368b3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_494bdbeb-b3f4-4c76-875d-bfa7619e4276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a689501-b147-436b-8048-aec0fe6e75e9" xlink:to="loc_us-gaap_AssetImpairmentCharges_494bdbeb-b3f4-4c76-875d-bfa7619e4276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d96c8ddf-c8ab-48a5-ad2c-741b0db9b0de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_105a1627-45ac-4a98-bb7f-dfca5664f513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d96c8ddf-c8ab-48a5-ad2c-741b0db9b0de" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_105a1627-45ac-4a98-bb7f-dfca5664f513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_17ddc365-acc9-4ad2-807f-3421edc15915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d96c8ddf-c8ab-48a5-ad2c-741b0db9b0de" xlink:to="loc_us-gaap_RestrictedCashCurrent_17ddc365-acc9-4ad2-807f-3421edc15915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_979d04cd-7b5a-4928-9a90-7fa68b2f863a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d96c8ddf-c8ab-48a5-ad2c-741b0db9b0de" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_979d04cd-7b5a-4928-9a90-7fa68b2f863a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86a23baf-90af-4e15-8b04-ffaf10047b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d96c8ddf-c8ab-48a5-ad2c-741b0db9b0de" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86a23baf-90af-4e15-8b04-ffaf10047b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_acf459e3-4877-47b5-a00a-b53d0bef6eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_5b66d64b-bd56-4d72-b5a4-9bffffb11952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_acf459e3-4877-47b5-a00a-b53d0bef6eca" xlink:to="loc_us-gaap_ConcentrationRiskTable_5b66d64b-bd56-4d72-b5a4-9bffffb11952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51e05488-6e5f-439b-a7ff-1c48bce09208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b66d64b-bd56-4d72-b5a4-9bffffb11952" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51e05488-6e5f-439b-a7ff-1c48bce09208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_577eae75-48a4-4190-afd2-eb075764b339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_51e05488-6e5f-439b-a7ff-1c48bce09208" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_577eae75-48a4-4190-afd2-eb075764b339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_0cf71246-df10-4158-8342-df6bc2d6e62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_577eae75-48a4-4190-afd2-eb075764b339" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_0cf71246-df10-4158-8342-df6bc2d6e62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_ab067bc5-445f-421c-91ba-7d6a5b11ed4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_577eae75-48a4-4190-afd2-eb075764b339" xlink:to="loc_us-gaap_AccountsReceivableMember_ab067bc5-445f-421c-91ba-7d6a5b11ed4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_232aba4d-6d82-4a34-9afe-f8d85b554a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b66d64b-bd56-4d72-b5a4-9bffffb11952" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_232aba4d-6d82-4a34-9afe-f8d85b554a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_23c163e7-a590-4e93-bd13-0fc1cb757c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_232aba4d-6d82-4a34-9afe-f8d85b554a30" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_23c163e7-a590-4e93-bd13-0fc1cb757c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d683e289-9610-463b-aab0-cd397cfa3e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_23c163e7-a590-4e93-bd13-0fc1cb757c82" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d683e289-9610-463b-aab0-cd397cfa3e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_66f3906a-bfbc-49da-ade0-79b16b99f16e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b66d64b-bd56-4d72-b5a4-9bffffb11952" xlink:to="loc_srt_MajorCustomersAxis_66f3906a-bfbc-49da-ade0-79b16b99f16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_66f3906a-bfbc-49da-ade0-79b16b99f16e" xlink:to="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EuropeanCommissionMember_07dd01e6-d2b9-439e-b170-68605c30dade" xlink:href="mrna-20211231.xsd#mrna_EuropeanCommissionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_EuropeanCommissionMember_07dd01e6-d2b9-439e-b170-68605c30dade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_USGovermentMember_f9be0779-1f19-4238-b3ee-186aa909810a" xlink:href="mrna-20211231.xsd#mrna_USGovermentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_USGovermentMember_f9be0779-1f19-4238-b3ee-186aa909810a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_113f057e-16e6-44f2-a8ff-4626a79d866f" xlink:href="mrna-20211231.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_113f057e-16e6-44f2-a8ff-4626a79d866f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember_d1cc7d2f-cda6-483d-b1c3-a74c73d56bf9" xlink:href="mrna-20211231.xsd#mrna_MerckMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_MerckMember_d1cc7d2f-cda6-483d-b1c3-a74c73d56bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember_fd4fd56e-0138-42a0-9793-ab0fe33f4ad1" xlink:href="mrna-20211231.xsd#mrna_VertexMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_VertexMember_fd4fd56e-0138-42a0-9793-ab0fe33f4ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_UnitedKingdomGovernmentMember_35de01b0-92f7-4119-b3b5-80872a2a89a6" xlink:href="mrna-20211231.xsd#mrna_UnitedKingdomGovernmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_UnitedKingdomGovernmentMember_35de01b0-92f7-4119-b3b5-80872a2a89a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SouthKoreaGovernmentMember_62231d59-78ad-4a4d-b094-3535e3c34562" xlink:href="mrna-20211231.xsd#mrna_SouthKoreaGovernmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14ac50e3-160c-473d-8e79-25f14ca8adc1" xlink:to="loc_mrna_SouthKoreaGovernmentMember_62231d59-78ad-4a4d-b094-3535e3c34562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_819db370-6f1c-4443-a3e9-4bce87ca44fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_5b66d64b-bd56-4d72-b5a4-9bffffb11952" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_819db370-6f1c-4443-a3e9-4bce87ca44fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b33d151d-abe3-4b46-a3bf-c468ce6c7fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_819db370-6f1c-4443-a3e9-4bce87ca44fd" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b33d151d-abe3-4b46-a3bf-c468ce6c7fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ece588f7-c977-4625-b7ba-4ae56ce27825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dc043217-f4d5-4503-99d6-2571f4f44b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ece588f7-c977-4625-b7ba-4ae56ce27825" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dc043217-f4d5-4503-99d6-2571f4f44b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_11dbca67-ec70-4dca-a808-71f9f34f0b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dc043217-f4d5-4503-99d6-2571f4f44b08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_11dbca67-ec70-4dca-a808-71f9f34f0b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_11dbca67-ec70-4dca-a808-71f9f34f0b80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_6d58cd58-1d08-4869-900c-e46da5f6d8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:to="loc_us-gaap_EquipmentMember_6d58cd58-1d08-4869-900c-e46da5f6d8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2fc88f5a-a082-441c-97a6-ceb1618bd01e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:to="loc_us-gaap_ComputerEquipmentMember_2fc88f5a-a082-441c-97a6-ceb1618bd01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_daab7892-9c1f-485f-a929-83af7936fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_daab7892-9c1f-485f-a929-83af7936fe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_fc494f7f-e42e-4d34-a349-77d28c9db97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_03957104-47f2-41b0-b77e-a19b5b41a9b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_fc494f7f-e42e-4d34-a349-77d28c9db97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fcc97e5a-1783-41a0-b858-fa7ea575b718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dc043217-f4d5-4503-99d6-2571f4f44b08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fcc97e5a-1783-41a0-b858-fa7ea575b718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1bbeca0f-100c-453f-9d66-fe911e5178ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fcc97e5a-1783-41a0-b858-fa7ea575b718" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1bbeca0f-100c-453f-9d66-fe911e5178ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_77886c9e-c0c1-4f09-81b8-a15ce27e4dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_743aa181-e4bd-4937-8fe9-a7e3a2f0f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_77886c9e-c0c1-4f09-81b8-a15ce27e4dae" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_743aa181-e4bd-4937-8fe9-a7e3a2f0f5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0412c722-a9c7-4a39-b16c-63be0f462dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_743aa181-e4bd-4937-8fe9-a7e3a2f0f5e7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0412c722-a9c7-4a39-b16c-63be0f462dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2b19d3f1-9737-4b96-8d86-2ceb76da8a39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0412c722-a9c7-4a39-b16c-63be0f462dda" xlink:to="loc_us-gaap_EquityComponentDomain_2b19d3f1-9737-4b96-8d86-2ceb76da8a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_64516165-b728-40cf-b9fe-464f1eeb5512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2b19d3f1-9737-4b96-8d86-2ceb76da8a39" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_64516165-b728-40cf-b9fe-464f1eeb5512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2098337b-cd9d-47b9-bb5f-a7c503eab465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2b19d3f1-9737-4b96-8d86-2ceb76da8a39" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2098337b-cd9d-47b9-bb5f-a7c503eab465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_863bc009-774d-49bf-bcbe-fc4e0f086f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2b19d3f1-9737-4b96-8d86-2ceb76da8a39" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_863bc009-774d-49bf-bcbe-fc4e0f086f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b891b59-07ea-415d-841e-a5456196dea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_743aa181-e4bd-4937-8fe9-a7e3a2f0f5e7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b891b59-07ea-415d-841e-a5456196dea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_dd946711-8a82-4236-99bd-189d3522b4be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0b891b59-07ea-415d-841e-a5456196dea4" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_dd946711-8a82-4236-99bd-189d3522b4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4065d625-24ad-40b4-85d6-3a6186b81011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_dd946711-8a82-4236-99bd-189d3522b4be" xlink:to="loc_us-gaap_StockholdersEquity_4065d625-24ad-40b4-85d6-3a6186b81011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7ea6d148-b3f2-487b-8bdf-6b56f6bfc8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_dd946711-8a82-4236-99bd-189d3522b4be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7ea6d148-b3f2-487b-8bdf-6b56f6bfc8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36dbb484-91af-4351-8aeb-e8895e544acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_dd946711-8a82-4236-99bd-189d3522b4be" xlink:to="loc_us-gaap_StockholdersEquity_36dbb484-91af-4351-8aeb-e8895e544acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSales" xlink:type="simple" xlink:href="mrna-20211231.xsd#ProductSales"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/ProductSales" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fc5a4127-9d65-433d-b998-b7eaa407c350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9efa3468-fd7a-4a75-82ff-8bd711768bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fc5a4127-9d65-433d-b998-b7eaa407c350" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_9efa3468-fd7a-4a75-82ff-8bd711768bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#ProductSalesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/ProductSalesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bb6597dc-0e65-4543-b8c0-44263fb01a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0eda057e-b80c-44b8-8962-438a6f2eba3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bb6597dc-0e65-4543-b8c0-44263fb01a9c" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_0eda057e-b80c-44b8-8962-438a6f2eba3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#ProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/ProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_17f8841b-2fe3-470a-b070-c943c5ffe1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d3a1b16c-ef4f-43b0-a70b-cd9c15faea05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_17f8841b-2fe3-470a-b070-c943c5ffe1b9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d3a1b16c-ef4f-43b0-a70b-cd9c15faea05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b3feac25-842c-410f-8e67-89b6fe1419d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d3a1b16c-ef4f-43b0-a70b-cd9c15faea05" xlink:to="loc_srt_StatementGeographicalAxis_b3feac25-842c-410f-8e67-89b6fe1419d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_650f6661-49c9-4ba9-94d9-0ba77a2b0400" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b3feac25-842c-410f-8e67-89b6fe1419d3" xlink:to="loc_srt_SegmentGeographicalDomain_650f6661-49c9-4ba9-94d9-0ba77a2b0400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fe6c9bf4-89ba-4ee8-b733-f82d9a1d5e5a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_650f6661-49c9-4ba9-94d9-0ba77a2b0400" xlink:to="loc_country_US_fe6c9bf4-89ba-4ee8-b733-f82d9a1d5e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_02f70271-da50-45a9-ae60-439a71007e05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_650f6661-49c9-4ba9-94d9-0ba77a2b0400" xlink:to="loc_srt_EuropeMember_02f70271-da50-45a9-ae60-439a71007e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestOfWorldMember_a386c3c7-32c2-4bac-a43b-5ffedcc87877" xlink:href="mrna-20211231.xsd#mrna_RestOfWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_650f6661-49c9-4ba9-94d9-0ba77a2b0400" xlink:to="loc_mrna_RestOfWorldMember_a386c3c7-32c2-4bac-a43b-5ffedcc87877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ccd152eb-85b7-448e-9766-4a0d1cb1edc3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d3a1b16c-ef4f-43b0-a70b-cd9c15faea05" xlink:to="loc_srt_ProductOrServiceAxis_ccd152eb-85b7-448e-9766-4a0d1cb1edc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_91d1d5a8-aada-457a-b02d-1bf5c476fef6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ccd152eb-85b7-448e-9766-4a0d1cb1edc3" xlink:to="loc_srt_ProductsAndServicesDomain_91d1d5a8-aada-457a-b02d-1bf5c476fef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_1ee34577-1506-4983-aa90-bca765a84318" xlink:href="mrna-20211231.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_91d1d5a8-aada-457a-b02d-1bf5c476fef6" xlink:to="loc_mrna_ProductSalesMember_1ee34577-1506-4983-aa90-bca765a84318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_670f0cc8-57cd-4536-b11c-b922e4b030f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d3a1b16c-ef4f-43b0-a70b-cd9c15faea05" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_670f0cc8-57cd-4536-b11c-b922e4b030f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e0dd09f8-0843-4fa6-ad46-5de689859bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_670f0cc8-57cd-4536-b11c-b922e4b030f3" xlink:to="loc_us-gaap_Revenues_e0dd09f8-0843-4fa6-ad46-5de689859bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8201b1d5-28d2-4df7-82d9-d919c8b8359b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_670f0cc8-57cd-4536-b11c-b922e4b030f3" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8201b1d5-28d2-4df7-82d9-d919c8b8359b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_505ebf76-7a53-4b9a-8895-f9d828358927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_670f0cc8-57cd-4536-b11c-b922e4b030f3" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_505ebf76-7a53-4b9a-8895-f9d828358927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenue" xlink:type="simple" xlink:href="mrna-20211231.xsd#GrantRevenue"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GrantRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a634c310-778a-4266-9baf-0c0299f68f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_e729fa2f-473e-4755-b131-dd6ee8fa871d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a634c310-778a-4266-9baf-0c0299f68f78" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_e729fa2f-473e-4755-b131-dd6ee8fa871d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#GrantRevenueTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GrantRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c08f4982-74d9-4460-a9f6-25c7ea0c1ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2606d43c-b637-42d3-9084-d8c9e6a3c41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c08f4982-74d9-4460-a9f6-25c7ea0c1ed8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_2606d43c-b637-42d3-9084-d8c9e6a3c41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#GrantRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GrantRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1ca2a9db-db9c-4659-9f3c-b5ea443d7ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_39dbf5ca-1574-453c-a628-94971f9c59fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1ca2a9db-db9c-4659-9f3c-b5ea443d7ec4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_39dbf5ca-1574-453c-a628-94971f9c59fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_91774a23-bfdb-48b4-9fa5-484c66e6a1ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_39dbf5ca-1574-453c-a628-94971f9c59fd" xlink:to="loc_srt_MajorCustomersAxis_91774a23-bfdb-48b4-9fa5-484c66e6a1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_91774a23-bfdb-48b4-9fa5-484c66e6a1ab" xlink:to="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_1f780995-cd01-40d6-bef9-aa6292ce334b" xlink:href="mrna-20211231.xsd#mrna_DefenseAdvancedResearchProjectsAgencyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:to="loc_mrna_DefenseAdvancedResearchProjectsAgencyMember_1f780995-cd01-40d6-bef9-aa6292ce334b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_69db89ef-2880-4112-b4ee-8984fb8ab7ad" xlink:href="mrna-20211231.xsd#mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:to="loc_mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_69db89ef-2880-4112-b4ee-8984fb8ab7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TheBillAndMelindaGatesFoundationMember_6c968725-3330-454e-ad84-8ef8c9a9d654" xlink:href="mrna-20211231.xsd#mrna_TheBillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:to="loc_mrna_TheBillAndMelindaGatesFoundationMember_6c968725-3330-454e-ad84-8ef8c9a9d654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherGrantRevenueMember_9138e562-f3a7-43a8-a0ab-bc930b09e570" xlink:href="mrna-20211231.xsd#mrna_OtherGrantRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_c038fef3-432f-4890-bf4e-15d3e1153ac7" xlink:to="loc_mrna_OtherGrantRevenueMember_9138e562-f3a7-43a8-a0ab-bc930b09e570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_27519a3e-1864-4891-b655-e0924386da98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_39dbf5ca-1574-453c-a628-94971f9c59fd" xlink:to="loc_srt_ProductOrServiceAxis_27519a3e-1864-4891-b655-e0924386da98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_65bf4b46-3050-4966-830d-f855d4ab1105" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_27519a3e-1864-4891-b655-e0924386da98" xlink:to="loc_srt_ProductsAndServicesDomain_65bf4b46-3050-4966-830d-f855d4ab1105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_1ec3f065-4c02-4b8f-8f0e-af4564271b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_65bf4b46-3050-4966-830d-f855d4ab1105" xlink:to="loc_us-gaap_GrantMember_1ec3f065-4c02-4b8f-8f0e-af4564271b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1e06cd5c-ad15-42f9-a9e4-6ea2077aadb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_39dbf5ca-1574-453c-a628-94971f9c59fd" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1e06cd5c-ad15-42f9-a9e4-6ea2077aadb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_edd28d1d-00a4-4c00-aecd-8a041bd54cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1e06cd5c-ad15-42f9-a9e4-6ea2077aadb8" xlink:to="loc_us-gaap_ProjectMember_edd28d1d-00a4-4c00-aecd-8a041bd54cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractOptionsMember_ee182d28-804f-40b5-adbd-752416be9081" xlink:href="mrna-20211231.xsd#mrna_ContractOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_edd28d1d-00a4-4c00-aecd-8a041bd54cf1" xlink:to="loc_mrna_ContractOptionsMember_ee182d28-804f-40b5-adbd-752416be9081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_InitialProjectMember_434b03b3-9050-4fe4-9382-b4c55182d4b2" xlink:href="mrna-20211231.xsd#mrna_InitialProjectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_edd28d1d-00a4-4c00-aecd-8a041bd54cf1" xlink:to="loc_mrna_InitialProjectMember_434b03b3-9050-4fe4-9382-b4c55182d4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_39dbf5ca-1574-453c-a628-94971f9c59fd" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsMaximumAward_250fb4fa-c5f2-4a74-bd42-2131556b846a" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsMaximumAward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsMaximumAward_250fb4fa-c5f2-4a74-bd42-2131556b846a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_422631aa-f1d1-4699-bd04-49ed88de8124" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsCurrentFundingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsCurrentFundingCapacity_422631aa-f1d1-4699-bd04-49ed88de8124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_08bbc286-919b-47be-88d3-45dc249dda85" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsRemainingFundingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsRemainingFundingCapacity_08bbc286-919b-47be-88d3-45dc249dda85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_4530399d-01be-4fc3-b494-f90ae3a34c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_us-gaap_OtherCommitment_4530399d-01be-4fc3-b494-f90ae3a34c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfParticipants_47a64962-1f3f-4ea6-afb0-54f617893b21" xlink:href="mrna-20211231.xsd#mrna_NumberOfParticipants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_NumberOfParticipants_47a64962-1f3f-4ea6-afb0-54f617893b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsPotentialReimbursement_8094dad6-74d9-4e86-97c1-66b2c75fc1fa" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsPotentialReimbursement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsPotentialReimbursement_8094dad6-74d9-4e86-97c1-66b2c75fc1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptions_84958aa3-9c5e-4486-87d5-5fc4a4b825ff" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsNumberOfContractOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptions_84958aa3-9c5e-4486-87d5-5fc4a4b825ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_f34d84da-87e8-4e2d-83e8-2b3d3f9c8444" xlink:href="mrna-20211231.xsd#mrna_RevenueFromGrantsNumberOfContractOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_mrna_RevenueFromGrantsNumberOfContractOptionsExercised_f34d84da-87e8-4e2d-83e8-2b3d3f9c8444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9b36f2b1-2039-4b67-b321-3c2d08787e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9b36f2b1-2039-4b67-b321-3c2d08787e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1e56bbe5-36b4-45ea-836a-b668d8062675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a8e2be26-e06a-4d4d-8782-767877f2b6da" xlink:to="loc_us-gaap_Revenues_1e56bbe5-36b4-45ea-836a-b668d8062675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_1d07629e-367d-4c06-a169-1e1ffd26a29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_91e96bda-c987-4ca4-a0f5-86d9a0a6af43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_1d07629e-367d-4c06-a169-1e1ffd26a29b" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_91e96bda-c987-4ca4-a0f5-86d9a0a6af43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_d65ae468-9e20-4ec3-9366-a25f701ac83a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_db0bc602-81a4-4713-bfb9-5290e58ded0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_d65ae468-9e20-4ec3-9366-a25f701ac83a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_db0bc602-81a4-4713-bfb9-5290e58ded0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_99f147f3-41e4-40d8-92d0-522533757dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_d65ae468-9e20-4ec3-9366-a25f701ac83a" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_99f147f3-41e4-40d8-92d0-522533757dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_da2eb20e-fbe2-4e21-896a-30e23fc6485d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_007f6dc5-07f4-451a-a8ff-45d20cf918a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_da2eb20e-fbe2-4e21-896a-30e23fc6485d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_007f6dc5-07f4-451a-a8ff-45d20cf918a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2e24fe97-0554-4632-9473-dac7b18de535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_007f6dc5-07f4-451a-a8ff-45d20cf918a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2e24fe97-0554-4632-9473-dac7b18de535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_644115cb-9e7d-4724-a9e0-7060f9ffd27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2e24fe97-0554-4632-9473-dac7b18de535" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_644115cb-9e7d-4724-a9e0-7060f9ffd27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_e5c23c0c-c0bc-4543-8548-4cac9cf8840e" xlink:href="mrna-20211231.xsd#mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_644115cb-9e7d-4724-a9e0-7060f9ffd27f" xlink:to="loc_mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember_e5c23c0c-c0bc-4543-8548-4cac9cf8840e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6d837697-09a2-4494-a16c-30b5aab6f4da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_007f6dc5-07f4-451a-a8ff-45d20cf918a7" xlink:to="loc_srt_RangeAxis_6d837697-09a2-4494-a16c-30b5aab6f4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_264da607-4632-47a5-a774-44f26614835c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6d837697-09a2-4494-a16c-30b5aab6f4da" xlink:to="loc_srt_RangeMember_264da607-4632-47a5-a774-44f26614835c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_32e5f69d-f33e-4747-b80b-4c14d5655123" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_264da607-4632-47a5-a774-44f26614835c" xlink:to="loc_srt_MaximumMember_32e5f69d-f33e-4747-b80b-4c14d5655123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d9bfecdd-2a62-4928-a265-6b57a7f02764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_007f6dc5-07f4-451a-a8ff-45d20cf918a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d9bfecdd-2a62-4928-a265-6b57a7f02764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_a2a47a64-e9a2-4dc6-b09b-b155e1e11aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d9bfecdd-2a62-4928-a265-6b57a7f02764" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_a2a47a64-e9a2-4dc6-b09b-b155e1e11aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_dab9eb94-49b1-4c4d-9527-488890b9b013" xlink:href="mrna-20211231.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d9bfecdd-2a62-4928-a265-6b57a7f02764" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent_dab9eb94-49b1-4c4d-9527-488890b9b013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_1567abef-0795-4525-9450-12aefb46e158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7ed2bc3-0e52-43f8-8d21-0a875d852701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_1567abef-0795-4525-9450-12aefb46e158" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7ed2bc3-0e52-43f8-8d21-0a875d852701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9e47678-75b2-4dff-a338-b7e5d520c34e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7ed2bc3-0e52-43f8-8d21-0a875d852701" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9e47678-75b2-4dff-a338-b7e5d520c34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_60ac7263-9141-4eef-a588-3f9f1bc8e554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f9e47678-75b2-4dff-a338-b7e5d520c34e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_60ac7263-9141-4eef-a588-3f9f1bc8e554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_7f459b90-9128-423e-9b19-38ccb7446b00" xlink:href="mrna-20211231.xsd#mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_60ac7263-9141-4eef-a588-3f9f1bc8e554" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember_7f459b90-9128-423e-9b19-38ccb7446b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1b21324b-4e4e-493d-b1d2-e03c2c8df5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7ed2bc3-0e52-43f8-8d21-0a875d852701" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1b21324b-4e4e-493d-b1d2-e03c2c8df5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_57e4ea2d-e8ac-4304-81e5-2c88a71d48a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1b21324b-4e4e-493d-b1d2-e03c2c8df5a5" xlink:to="loc_us-gaap_ProjectMember_57e4ea2d-e8ac-4304-81e5-2c88a71d48a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_5eb7b674-f06c-4270-94b4-7b0e4c7844ad" xlink:href="mrna-20211231.xsd#mrna_PersonalizedMRNACancerVaccinesProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_57e4ea2d-e8ac-4304-81e5-2c88a71d48a0" xlink:to="loc_mrna_PersonalizedMRNACancerVaccinesProductsMember_5eb7b674-f06c-4270-94b4-7b0e4c7844ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2adecc59-33de-43a1-8385-a14f78939217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7ed2bc3-0e52-43f8-8d21-0a875d852701" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2adecc59-33de-43a1-8385-a14f78939217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_45fb4d69-9d7c-4eab-853a-3d574da349a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2adecc59-33de-43a1-8385-a14f78939217" xlink:to="loc_us-gaap_ClassOfStockDomain_45fb4d69-9d7c-4eab-853a-3d574da349a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesHPreferredStockMember_046ce26c-2663-497d-98e7-2cd3bd69fd16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesHPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45fb4d69-9d7c-4eab-853a-3d574da349a9" xlink:to="loc_us-gaap_SeriesHPreferredStockMember_046ce26c-2663-497d-98e7-2cd3bd69fd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f7ed2bc3-0e52-43f8-8d21-0a875d852701" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_93e57f4f-0762-40d8-bd3c-cdb9797c58be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_93e57f4f-0762-40d8-bd3c-cdb9797c58be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_6797d95e-1b78-4b52-b8e9-c97707434edb" xlink:href="mrna-20211231.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount_6797d95e-1b78-4b52-b8e9-c97707434edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b98b1303-ffcc-46bd-a49d-377fe6f926dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b98b1303-ffcc-46bd-a49d-377fe6f926dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedemptionPremium_a5a65d4c-e926-4d19-bf63-7e9cdb4d8182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedemptionPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d8dbba67-fbf9-488b-96f9-19fed1f0b4de" xlink:to="loc_us-gaap_RedemptionPremium_a5a65d4c-e926-4d19-bf63-7e9cdb4d8182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_e520aa47-09ad-4008-9e38-f0271b7ab45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_648adfca-768a-4d26-bac3-5846a316869e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_e520aa47-09ad-4008-9e38-f0271b7ab45b" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_648adfca-768a-4d26-bac3-5846a316869e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_184e7369-9e73-4b0c-bcbd-9aa4fa3bbe59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_648adfca-768a-4d26-bac3-5846a316869e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_184e7369-9e73-4b0c-bcbd-9aa4fa3bbe59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_751a948d-7d27-498e-bab5-264d06b2c8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_184e7369-9e73-4b0c-bcbd-9aa4fa3bbe59" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_751a948d-7d27-498e-bab5-264d06b2c8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MRNAVertex2020AgreementMemberMember_91c91a9a-f350-49ff-9f4c-92719f6be525" xlink:href="mrna-20211231.xsd#mrna_MRNAVertex2020AgreementMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_751a948d-7d27-498e-bab5-264d06b2c8cc" xlink:to="loc_mrna_MRNAVertex2020AgreementMemberMember_91c91a9a-f350-49ff-9f4c-92719f6be525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4bcb1ae4-53f1-45de-8d33-15236896915b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_648adfca-768a-4d26-bac3-5846a316869e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4bcb1ae4-53f1-45de-8d33-15236896915b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_f37b86fd-2efb-4227-87cd-eab0371f1eba" xlink:href="mrna-20211231.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4bcb1ae4-53f1-45de-8d33-15236896915b" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod_f37b86fd-2efb-4227-87cd-eab0371f1eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_e8dce0ee-932c-47e1-926d-8c465304cd18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ead5754-d3da-41ab-90e7-ce9f4254f89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_e8dce0ee-932c-47e1-926d-8c465304cd18" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ead5754-d3da-41ab-90e7-ce9f4254f89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a5c0e4e9-dbbd-4683-9ed5-cd36790d2403" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ead5754-d3da-41ab-90e7-ce9f4254f89c" xlink:to="loc_srt_ProductOrServiceAxis_a5c0e4e9-dbbd-4683-9ed5-cd36790d2403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a63a8617-9ac7-4252-a326-3107eb7722bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a5c0e4e9-dbbd-4683-9ed5-cd36790d2403" xlink:to="loc_srt_ProductsAndServicesDomain_a63a8617-9ac7-4252-a326-3107eb7722bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_d839aa7f-dd2e-49d0-a351-ad54d1cfd905" xlink:href="mrna-20211231.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a63a8617-9ac7-4252-a326-3107eb7722bb" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_d839aa7f-dd2e-49d0-a351-ad54d1cfd905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3f1a52a5-58b5-4b9c-9033-e970c6923eaf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ead5754-d3da-41ab-90e7-ce9f4254f89c" xlink:to="loc_srt_CounterpartyNameAxis_3f1a52a5-58b5-4b9c-9033-e970c6923eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3f1a52a5-58b5-4b9c-9033-e970c6923eaf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AstraZenecaMember_af558894-7a04-486b-902a-32abdf00ee39" xlink:href="mrna-20211231.xsd#mrna_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:to="loc_mrna_AstraZenecaMember_af558894-7a04-486b-902a-32abdf00ee39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MerckMember_4e8d354a-7ab2-402d-be11-7048e9541d84" xlink:href="mrna-20211231.xsd#mrna_MerckMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:to="loc_mrna_MerckMember_4e8d354a-7ab2-402d-be11-7048e9541d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_VertexMember_5ab188b2-63b2-4d06-aa91-eddbdabad06d" xlink:href="mrna-20211231.xsd#mrna_VertexMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:to="loc_mrna_VertexMember_5ab188b2-63b2-4d06-aa91-eddbdabad06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherMember_a978cb0c-8249-4ca0-9faf-cd04d73f0264" xlink:href="mrna-20211231.xsd#mrna_OtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f727adb-d4f5-405c-b478-ad707359b3f0" xlink:to="loc_mrna_OtherMember_a978cb0c-8249-4ca0-9faf-cd04d73f0264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ec90293a-c3f0-4ad6-a8d3-6091fea30204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_3ead5754-d3da-41ab-90e7-ce9f4254f89c" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ec90293a-c3f0-4ad6-a8d3-6091fea30204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4f7767d4-6e4c-4af5-bea2-d9c3ec76af7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ec90293a-c3f0-4ad6-a8d3-6091fea30204" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4f7767d4-6e4c-4af5-bea2-d9c3ec76af7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_a2fadfc2-24be-4a2d-9322-f9296d12efe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8428760c-c9b8-4b39-a633-07b788a49166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_a2fadfc2-24be-4a2d-9322-f9296d12efe3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8428760c-c9b8-4b39-a633-07b788a49166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d942ae0e-d4e5-403b-b17a-e45f19c22a7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8428760c-c9b8-4b39-a633-07b788a49166" xlink:to="loc_srt_ProductOrServiceAxis_d942ae0e-d4e5-403b-b17a-e45f19c22a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1942340-9f44-43b5-8904-e568a8ec6060" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d942ae0e-d4e5-403b-b17a-e45f19c22a7d" xlink:to="loc_srt_ProductsAndServicesDomain_c1942340-9f44-43b5-8904-e568a8ec6060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_7000c1a7-66f9-4202-8ff3-8ce99aaaa639" xlink:href="mrna-20211231.xsd#mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c1942340-9f44-43b5-8904-e568a8ec6060" xlink:to="loc_mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember_7000c1a7-66f9-4202-8ff3-8ce99aaaa639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ef3b523-2532-47df-9509-1d5fa2f5b2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8428760c-c9b8-4b39-a633-07b788a49166" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ef3b523-2532-47df-9509-1d5fa2f5b2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractwithCustomerAssetRollForward_e3aa41ef-e4c0-4db8-bcd4-b20e7d2d2aad" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractwithCustomerAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ef3b523-2532-47df-9509-1d5fa2f5b2bb" xlink:to="loc_mrna_ChangeInContractwithCustomerAssetRollForward_e3aa41ef-e4c0-4db8-bcd4-b20e7d2d2aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_df2dc30e-8bb3-45a7-a1be-1617259993ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_e3aa41ef-e4c0-4db8-bcd4-b20e7d2d2aad" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_df2dc30e-8bb3-45a7-a1be-1617259993ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetPurchase_9b4b1480-d1c1-4e5c-930f-f89dc96f21c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetPurchase"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_e3aa41ef-e4c0-4db8-bcd4-b20e7d2d2aad" xlink:to="loc_us-gaap_ContractWithCustomerAssetPurchase_9b4b1480-d1c1-4e5c-930f-f89dc96f21c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_0745939c-5856-48dd-a47c-dbe97ad110b4" xlink:href="mrna-20211231.xsd#mrna_ContractWithCustomerAssetDeductionsDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_e3aa41ef-e4c0-4db8-bcd4-b20e7d2d2aad" xlink:to="loc_mrna_ContractWithCustomerAssetDeductionsDuringPeriod_0745939c-5856-48dd-a47c-dbe97ad110b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_a5b2f4a9-d22d-4807-8949-498264c00b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractwithCustomerAssetRollForward_e3aa41ef-e4c0-4db8-bcd4-b20e7d2d2aad" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_a5b2f4a9-d22d-4807-8949-498264c00b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_af1e2e64-eeb5-48b9-9383-20d850eccfec" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ef3b523-2532-47df-9509-1d5fa2f5b2bb" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_af1e2e64-eeb5-48b9-9383-20d850eccfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e3efe91b-193c-48f4-a767-502609e78349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_af1e2e64-eeb5-48b9-9383-20d850eccfec" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e3efe91b-193c-48f4-a767-502609e78349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_516715c2-4d64-4e1c-a569-f00f8582edfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_af1e2e64-eeb5-48b9-9383-20d850eccfec" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_516715c2-4d64-4e1c-a569-f00f8582edfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_27e30a9e-0aa6-4b81-8e7d-e35ff2fd0b2f" xlink:href="mrna-20211231.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_af1e2e64-eeb5-48b9-9383-20d850eccfec" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_27e30a9e-0aa6-4b81-8e7d-e35ff2fd0b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_532c4d72-af55-496c-bd47-376149ea05e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward_af1e2e64-eeb5-48b9-9383-20d850eccfec" xlink:to="loc_us-gaap_ContractWithCustomerLiability_532c4d72-af55-496c-bd47-376149ea05e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_0a0307ac-076a-4fb0-ab49-29e778be7dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ef3b523-2532-47df-9509-1d5fa2f5b2bb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_0a0307ac-076a-4fb0-ab49-29e778be7dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a070ab66-b3b8-4b55-9a93-4025395520f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_fc6d57ad-26a7-4155-b109-7a35379b6ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a070ab66-b3b8-4b55-9a93-4025395520f3" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_fc6d57ad-26a7-4155-b109-7a35379b6ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e028ab36-56ab-4328-b90c-a3fc367914c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_3af41700-300b-4e3a-b7c7-60997088cd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e028ab36-56ab-4328-b90c-a3fc367914c5" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_3af41700-300b-4e3a-b7c7-60997088cd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_38ad55a1-a7ae-407f-9cd7-0bd8de947e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e028ab36-56ab-4328-b90c-a3fc367914c5" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_38ad55a1-a7ae-407f-9cd7-0bd8de947e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_ea780164-9665-4908-9a19-24493c75317d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e028ab36-56ab-4328-b90c-a3fc367914c5" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_ea780164-9665-4908-9a19-24493c75317d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_740bd947-eb5a-4a09-82b6-5385609cf644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e028ab36-56ab-4328-b90c-a3fc367914c5" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_740bd947-eb5a-4a09-82b6-5385609cf644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e1fc9d9-b3f1-46f2-bec6-2ded9e2f3e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a0f6c7d-bb6f-441e-86ab-1510aba9ddf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e1fc9d9-b3f1-46f2-bec6-2ded9e2f3e02" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a0f6c7d-bb6f-441e-86ab-1510aba9ddf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c30e3b5e-8e05-41c0-872c-76feb0b181b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a0f6c7d-bb6f-441e-86ab-1510aba9ddf4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c30e3b5e-8e05-41c0-872c-76feb0b181b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c30e3b5e-8e05-41c0-872c-76feb0b181b8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_f0b3795c-f9ac-4935-bc2a-c74cc930c19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_f0b3795c-f9ac-4935-bc2a-c74cc930c19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4b37e476-4b81-42f2-81c6-8314f42dcb90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4b37e476-4b81-42f2-81c6-8314f42dcb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_97dd825a-c8d6-4e1d-8052-c63392f0741f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_97dd825a-c8d6-4e1d-8052-c63392f0741f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_db48388f-21ca-486e-8cfb-3d20df348b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_db48388f-21ca-486e-8cfb-3d20df348b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0d840cd6-fbe3-49a2-ae8b-c1c3156c43bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0d840cd6-fbe3-49a2-ae8b-c1c3156c43bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_013ce546-3b86-44a6-a636-b60d743033c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07250d96-dc33-49a3-a184-96e309cfa066" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_013ce546-3b86-44a6-a636-b60d743033c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_90c68bd9-96e4-45b1-a811-f5212e82dea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a0f6c7d-bb6f-441e-86ab-1510aba9ddf4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_90c68bd9-96e4-45b1-a811-f5212e82dea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf4f1d30-517c-4015-bf09-bca12109f60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_90c68bd9-96e4-45b1-a811-f5212e82dea0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf4f1d30-517c-4015-bf09-bca12109f60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3109c22f-4825-46c4-a54c-7fcef8ec5651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf4f1d30-517c-4015-bf09-bca12109f60a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3109c22f-4825-46c4-a54c-7fcef8ec5651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4311ff6c-562c-4abe-9844-2616e15b3989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf4f1d30-517c-4015-bf09-bca12109f60a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4311ff6c-562c-4abe-9844-2616e15b3989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_95e3dbac-ca00-4330-9d9a-76db4e4d194f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a0f6c7d-bb6f-441e-86ab-1510aba9ddf4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_95e3dbac-ca00-4330-9d9a-76db4e4d194f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_44629e50-a178-4c8d-8037-dcbde8c287c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_95e3dbac-ca00-4330-9d9a-76db4e4d194f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_44629e50-a178-4c8d-8037-dcbde8c287c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_cc4c3727-5eb0-4129-8c21-f1944cd26917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_44629e50-a178-4c8d-8037-dcbde8c287c7" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_cc4c3727-5eb0-4129-8c21-f1944cd26917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentMarketableSecuritiesMember_03646761-304f-4c59-9695-08d4ef88e31d" xlink:href="mrna-20211231.xsd#mrna_CurrentMarketableSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_44629e50-a178-4c8d-8037-dcbde8c287c7" xlink:to="loc_mrna_CurrentMarketableSecuritiesMember_03646761-304f-4c59-9695-08d4ef88e31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NoncurrentMarketableSecuritiesMember_9cf4cdcb-d534-49cb-9500-d74d87be3eab" xlink:href="mrna-20211231.xsd#mrna_NoncurrentMarketableSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_44629e50-a178-4c8d-8037-dcbde8c287c7" xlink:to="loc_mrna_NoncurrentMarketableSecuritiesMember_9cf4cdcb-d534-49cb-9500-d74d87be3eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8a0f6c7d-bb6f-441e-86ab-1510aba9ddf4" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cebb46c7-dd15-4968-8533-ad9ebe3ab781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cebb46c7-dd15-4968-8533-ad9ebe3ab781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fac91de9-dad5-4c3d-95e3-b27d62a832d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fac91de9-dad5-4c3d-95e3-b27d62a832d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_63374c72-e669-47fc-aa54-fcce8624173c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_63374c72-e669-47fc-aa54-fcce8624173c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c83653a2-d375-4be1-badd-c5cb118604ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a99329a-3b5b-4d6c-bc75-fc999114c86c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c83653a2-d375-4be1-badd-c5cb118604ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_19df09bd-9574-4ba8-ba58-747c6545328d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_68e141b6-3165-4a5e-b92c-6dd9fbe1b11a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_19df09bd-9574-4ba8-ba58-747c6545328d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_68e141b6-3165-4a5e-b92c-6dd9fbe1b11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_50a87cda-3629-44c7-8df0-07d63316ae42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_68e141b6-3165-4a5e-b92c-6dd9fbe1b11a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_50a87cda-3629-44c7-8df0-07d63316ae42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_84ac77a3-50e3-490f-a841-e9731d478144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_68e141b6-3165-4a5e-b92c-6dd9fbe1b11a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_84ac77a3-50e3-490f-a841-e9731d478144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9ee33299-4429-4e8a-aefa-e4fdc477b95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_68e141b6-3165-4a5e-b92c-6dd9fbe1b11a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9ee33299-4429-4e8a-aefa-e4fdc477b95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13721c54-baab-4725-b394-90dd3cafe909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_19df09bd-9574-4ba8-ba58-747c6545328d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13721c54-baab-4725-b394-90dd3cafe909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0a9aa702-45fa-4131-aa3b-77e8275eb69f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13721c54-baab-4725-b394-90dd3cafe909" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0a9aa702-45fa-4131-aa3b-77e8275eb69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f38d98b6-c7e9-4f9e-9b09-40e092e6c405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13721c54-baab-4725-b394-90dd3cafe909" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f38d98b6-c7e9-4f9e-9b09-40e092e6c405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_93e6f853-2de9-4581-a3e9-15695efb8a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_13721c54-baab-4725-b394-90dd3cafe909" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_93e6f853-2de9-4581-a3e9-15695efb8a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f4ee2d68-cbd9-4f22-9aea-1f211147a531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bf7e0358-9d4b-44ba-ad5d-37d2c8080341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f4ee2d68-cbd9-4f22-9aea-1f211147a531" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bf7e0358-9d4b-44ba-ad5d-37d2c8080341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fec4b1d5-d749-4ad4-9779-fea10148f83f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bf7e0358-9d4b-44ba-ad5d-37d2c8080341" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fec4b1d5-d749-4ad4-9779-fea10148f83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fec4b1d5-d749-4ad4-9779-fea10148f83f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_748096bc-6099-4da0-b332-8df580ff4cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_748096bc-6099-4da0-b332-8df580ff4cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_e9f46318-0d4f-4142-9c0c-55e571fac93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_e9f46318-0d4f-4142-9c0c-55e571fac93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c8a512a9-29c0-43e7-aef4-21c5d767a469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c8a512a9-29c0-43e7-aef4-21c5d767a469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_28406ae3-b29f-4345-bec3-632987d6714d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1bbe637c-be87-4b01-b959-acb3f1cbcaa3" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_28406ae3-b29f-4345-bec3-632987d6714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bf7e0358-9d4b-44ba-ad5d-37d2c8080341" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_6376caa4-d47e-446b-aa45-bec9d84f4d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_6376caa4-d47e-446b-aa45-bec9d84f4d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f3ebb52-de47-430f-8dba-6d734827e8af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f3ebb52-de47-430f-8dba-6d734827e8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2c3bc682-22cc-4ec4-b52f-36421360dd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2c3bc682-22cc-4ec4-b52f-36421360dd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_5594a62f-3c95-4ddd-a5d3-8d79f8ff4b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_5594a62f-3c95-4ddd-a5d3-8d79f8ff4b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_eef5281c-e6a0-4ea8-b86f-2c99977c83ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_eef5281c-e6a0-4ea8-b86f-2c99977c83ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b7ef61fd-9519-4bee-9d67-9769d2b63ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6c3ecf60-1885-4f8b-9bd4-fb1331aaa27d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b7ef61fd-9519-4bee-9d67-9769d2b63ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8618389b-de1d-48a0-8b79-1a51a137563e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_6e4142cd-001a-4a49-af0e-61827f08496c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8618389b-de1d-48a0-8b79-1a51a137563e" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_6e4142cd-001a-4a49-af0e-61827f08496c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d6858910-1f94-4cc1-9391-66efb3baef88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8618389b-de1d-48a0-8b79-1a51a137563e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d6858910-1f94-4cc1-9391-66efb3baef88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9c8012a4-2a9b-478a-b04e-60c4521c98a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7658c83e-03ac-4ebf-8e1c-550db44efcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9c8012a4-2a9b-478a-b04e-60c4521c98a6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7658c83e-03ac-4ebf-8e1c-550db44efcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca84e49c-3ed8-41bf-a71f-d5524069a9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7658c83e-03ac-4ebf-8e1c-550db44efcf0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca84e49c-3ed8-41bf-a71f-d5524069a9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8fef49ce-09f3-4908-885e-9c18d1af0d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca84e49c-3ed8-41bf-a71f-d5524069a9e2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8fef49ce-09f3-4908-885e-9c18d1af0d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1cae0564-0caa-4c12-a783-5e3532903c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8fef49ce-09f3-4908-885e-9c18d1af0d2f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1cae0564-0caa-4c12-a783-5e3532903c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_38cc3d2f-5bfc-4081-9c95-0c4ea03b9b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7658c83e-03ac-4ebf-8e1c-550db44efcf0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_38cc3d2f-5bfc-4081-9c95-0c4ea03b9b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38cc3d2f-5bfc-4081-9c95-0c4ea03b9b50" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_29c26c62-669c-4a41-929a-2750eb8efe87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_MoneyMarketFundsMember_29c26c62-669c-4a41-929a-2750eb8efe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7d01b6e2-27cf-4f78-a753-5123810a2448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7d01b6e2-27cf-4f78-a753-5123810a2448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_8676c2a3-87e1-43f9-a495-5b15f04a89f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_8676c2a3-87e1-43f9-a495-5b15f04a89f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_011d54d1-9688-4a96-a045-24e83b65797c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_011d54d1-9688-4a96-a045-24e83b65797c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_df3b0031-582e-43df-9c4a-29ec6dc5868d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_df3b0031-582e-43df-9c4a-29ec6dc5868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_72b9b79e-036e-455a-b047-787cb9439927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2cd1efae-0f3f-46bb-82e0-f62b3c0bff49" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_72b9b79e-036e-455a-b047-787cb9439927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7bf18936-f470-41ee-b427-8ec699fe664e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7658c83e-03ac-4ebf-8e1c-550db44efcf0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7bf18936-f470-41ee-b427-8ec699fe664e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ba9d157-57b8-42ac-99c6-472fbd2e9da3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7bf18936-f470-41ee-b427-8ec699fe664e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ba9d157-57b8-42ac-99c6-472fbd2e9da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6b22f351-1c1d-4dd8-a445-2c89a227f996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ba9d157-57b8-42ac-99c6-472fbd2e9da3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6b22f351-1c1d-4dd8-a445-2c89a227f996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_928c218c-4b27-459d-a4bc-77c74062f2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ba9d157-57b8-42ac-99c6-472fbd2e9da3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_928c218c-4b27-459d-a4bc-77c74062f2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7658c83e-03ac-4ebf-8e1c-550db44efcf0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f52306b-b0df-4d1f-bee0-68926de47646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2f52306b-b0df-4d1f-bee0-68926de47646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_64071bcf-e5b4-4b6d-b969-8123d7655d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:to="loc_us-gaap_DerivativeAssets_64071bcf-e5b4-4b6d-b969-8123d7655d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_45b93347-b4a5-4380-b9c6-80807836d0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_45b93347-b4a5-4380-b9c6-80807836d0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0173ee2a-8598-4747-ae16-272658f5c55e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b2fb9c57-d6e2-468a-9914-42adf6fc0b8a" xlink:to="loc_us-gaap_DerivativeLiabilities_0173ee2a-8598-4747-ae16-272658f5c55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="mrna-20211231.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0d1f04cd-d57e-4272-93c0-e30fca4ae19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_175b713d-989b-43fd-942e-5783acd346ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0d1f04cd-d57e-4272-93c0-e30fca4ae19f" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_175b713d-989b-43fd-942e-5783acd346ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_46bbacea-f330-44e0-8a47-83b140f00ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_8439d480-2f6d-46cc-b8bf-4ae8734f3445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_46bbacea-f330-44e0-8a47-83b140f00ac0" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_8439d480-2f6d-46cc-b8bf-4ae8734f3445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashflowHedgesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#DerivativeFinancialInstrumentsCashflowHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashflowHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6f8ab305-3bd0-49ab-a2ca-745b088e8859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_64a3c92a-409f-43e8-a6d5-10143b2ad610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6f8ab305-3bd0-49ab-a2ca-745b088e8859" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_64a3c92a-409f-43e8-a6d5-10143b2ad610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e7981ba6-9a34-48eb-afad-cc0da7c5d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e7981ba6-9a34-48eb-afad-cc0da7c5d7ea" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c210fba8-4345-43d4-ac32-adf326bd3fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c210fba8-4345-43d4-ac32-adf326bd3fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_50303d99-66bd-4a85-9995-ae69a31b18f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c210fba8-4345-43d4-ac32-adf326bd3fcd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_50303d99-66bd-4a85-9995-ae69a31b18f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_cc64dd65-b436-47f5-801b-b98188d6e5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_50303d99-66bd-4a85-9995-ae69a31b18f0" xlink:to="loc_us-gaap_ForeignExchangeContractMember_cc64dd65-b436-47f5-801b-b98188d6e5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43d7dc6c-b40d-4463-b4b4-b56d7a6c8c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43d7dc6c-b40d-4463-b4b4-b56d7a6c8c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7bf4a5ae-5bfe-44f1-815c-ad55182ef297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_43d7dc6c-b40d-4463-b4b4-b56d7a6c8c93" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7bf4a5ae-5bfe-44f1-815c-ad55182ef297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_d96b5de9-99fd-461e-bec8-a734dc9b79fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_7bf4a5ae-5bfe-44f1-815c-ad55182ef297" xlink:to="loc_us-gaap_CashFlowHedgingMember_d96b5de9-99fd-461e-bec8-a734dc9b79fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d21f266b-6b7a-4cb9-b887-11b3a3a3de2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:to="loc_us-gaap_HedgingDesignationAxis_d21f266b-6b7a-4cb9-b887-11b3a3a3de2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_74104577-79f4-4ccd-a3d4-436216cd296a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_d21f266b-6b7a-4cb9-b887-11b3a3a3de2e" xlink:to="loc_us-gaap_HedgingDesignationDomain_74104577-79f4-4ccd-a3d4-436216cd296a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_73da1fe3-7419-48f6-ad91-5cd37bed29a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_74104577-79f4-4ccd-a3d4-436216cd296a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_73da1fe3-7419-48f6-ad91-5cd37bed29a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_455dc0b7-6fe3-496c-a74e-92cea5016409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_74104577-79f4-4ccd-a3d4-436216cd296a" xlink:to="loc_us-gaap_NondesignatedMember_455dc0b7-6fe3-496c-a74e-92cea5016409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_919b3dee-63e8-4416-ac06-6c08529d3968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_919b3dee-63e8-4416-ac06-6c08529d3968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9896950d-7ea4-45f3-8b4e-242a361e21e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_919b3dee-63e8-4416-ac06-6c08529d3968" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9896950d-7ea4-45f3-8b4e-242a361e21e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_99586347-e8d0-46b1-95cc-f8c7f9bd9acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9896950d-7ea4-45f3-8b4e-242a361e21e0" xlink:to="loc_us-gaap_SalesMember_99586347-e8d0-46b1-95cc-f8c7f9bd9acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_458d55f1-0cb0-45db-8b7a-854121284d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9896950d-7ea4-45f3-8b4e-242a361e21e0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_458d55f1-0cb0-45db-8b7a-854121284d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_11a0cecc-46c0-4720-bfe2-d48e64ddf5df" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_df442d0c-9a45-4827-97cd-81b75ac2b532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_DerivativeNotionalAmount_df442d0c-9a45-4827-97cd-81b75ac2b532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_d94cbb0b-94a4-4631-bcd4-d5727d0cb024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_DerivativeAssets_d94cbb0b-94a4-4631-bcd4-d5727d0cb024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d4d7c761-1c69-4dcd-bfd9-cdf1f706ee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_DerivativeLiabilities_d4d7c761-1c69-4dcd-bfd9-cdf1f706ee5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_4ce112a5-caae-4608-8913-b6485d110408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_4ce112a5-caae-4608-8913-b6485d110408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_be3b2b54-7a06-4ee1-8dab-bfa8c21b3d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_be3b2b54-7a06-4ee1-8dab-bfa8c21b3d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_1ebc7e6e-c6cd-4e69-8fd9-4bf1154c568e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_91042cce-2ef2-4504-9174-892c0e4ad251" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_1ebc7e6e-c6cd-4e69-8fd9-4bf1154c568e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/Inventory" xlink:type="simple" xlink:href="mrna-20211231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9cead71a-0b54-46c7-a5b8-02ee03520ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_eb615fbe-d276-46a2-a1f3-5a53b31e8b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9cead71a-0b54-46c7-a5b8-02ee03520ac6" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_eb615fbe-d276-46a2-a1f3-5a53b31e8b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c8ccaea4-b07c-479a-829b-49fae0ed8f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1e82724e-3f7a-4169-ba0c-de203824c96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c8ccaea4-b07c-479a-829b-49fae0ed8f39" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1e82724e-3f7a-4169-ba0c-de203824c96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/InventoryDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_64f9e041-7bf5-450b-b5a7-1d80a1947352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d1238b20-26c5-4fe2-a18f-12bfedfaac11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_64f9e041-7bf5-450b-b5a7-1d80a1947352" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d1238b20-26c5-4fe2-a18f-12bfedfaac11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_22d3ebf8-a831-430c-a28f-c37e4f7855a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_64f9e041-7bf5-450b-b5a7-1d80a1947352" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_22d3ebf8-a831-430c-a28f-c37e4f7855a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_fe23091d-f7b7-44a6-80d6-66d433fe4955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_64f9e041-7bf5-450b-b5a7-1d80a1947352" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_fe23091d-f7b7-44a6-80d6-66d433fe4955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b970d6e2-f887-4241-a3bd-a6eac3920727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_64f9e041-7bf5-450b-b5a7-1d80a1947352" xlink:to="loc_us-gaap_InventoryNet_b970d6e2-f887-4241-a3bd-a6eac3920727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="mrna-20211231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_48155325-854d-4166-8281-8a542410b921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_462d3bf2-34c8-4169-bca8-d633a7ce411c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_48155325-854d-4166-8281-8a542410b921" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_462d3bf2-34c8-4169-bca8-d633a7ce411c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b4ed94cf-d21d-4116-93a1-da72320bb354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7ede2dfd-79b1-4cc3-ac84-a2b3dbdedec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b4ed94cf-d21d-4116-93a1-da72320bb354" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7ede2dfd-79b1-4cc3-ac84-a2b3dbdedec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eaccf7c9-ab19-494c-a910-ba25450998f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4dbd4fa-7623-4cc2-a3fe-05c124ec0dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eaccf7c9-ab19-494c-a910-ba25450998f5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4dbd4fa-7623-4cc2-a3fe-05c124ec0dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_196c6c7f-1cbf-4eba-8bbf-5234764f216f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4dbd4fa-7623-4cc2-a3fe-05c124ec0dbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_196c6c7f-1cbf-4eba-8bbf-5234764f216f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_196c6c7f-1cbf-4eba-8bbf-5234764f216f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f5861220-b28e-4e8e-8f12-6c5988b30648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_EquipmentMember_f5861220-b28e-4e8e-8f12-6c5988b30648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4865cc98-cbba-4794-b88a-94195488a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4865cc98-cbba-4794-b88a-94195488a7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_06e1e328-428f-41cd-bb16-dbbe54263d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_06e1e328-428f-41cd-bb16-dbbe54263d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_96017e41-857a-4e82-8d9e-a499b003e3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_ComputerEquipmentMember_96017e41-857a-4e82-8d9e-a499b003e3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_3aad28e7-b383-4fea-9004-ff64a16b2b74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_3aad28e7-b383-4fea-9004-ff64a16b2b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinancingRightOfUseAssetMember_2b527eae-4707-4f6a-a2e6-07a71bd29ebc" xlink:href="mrna-20211231.xsd#mrna_FinancingRightOfUseAssetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_mrna_FinancingRightOfUseAssetMember_2b527eae-4707-4f6a-a2e6-07a71bd29ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ae4333ac-c378-4d48-bde7-12add5f1f7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e4e7351-d330-42fd-a1b9-ba33f47a6bc9" xlink:to="loc_us-gaap_ConstructionInProgressMember_ae4333ac-c378-4d48-bde7-12add5f1f7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4dbd4fa-7623-4cc2-a3fe-05c124ec0dbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0df7b8bd-6965-4e97-b2eb-b0d0dfced92c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0df7b8bd-6965-4e97-b2eb-b0d0dfced92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_36a06cc2-5c2e-4fa9-8a89-e70554256a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_36a06cc2-5c2e-4fa9-8a89-e70554256a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_96bab355-f8b8-4e8b-aef9-c1731806b6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_96bab355-f8b8-4e8b-aef9-c1731806b6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a8b7997c-2d8e-45d7-83d4-d34573888af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_78cab1a3-300e-472e-b76a-8938accf22d2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a8b7997c-2d8e-45d7-83d4-d34573888af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="simple" xlink:href="mrna-20211231.xsd#OtherBalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35052ec2-6407-41b2-990a-35738fff13a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_8792b066-59ae-45ee-a91d-d5dd2fe629b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35052ec2-6407-41b2-990a-35738fff13a6" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_8792b066-59ae-45ee-a91d-d5dd2fe629b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#OtherBalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96976395-831a-46db-8ecb-17a0acdbfb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_d1132d67-e9d8-4094-a52a-696433081bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96976395-831a-46db-8ecb-17a0acdbfb0d" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_d1132d67-e9d8-4094-a52a-696433081bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_589381ed-26ce-4cd1-9761-1b52d0d400c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96976395-831a-46db-8ecb-17a0acdbfb0d" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_589381ed-26ce-4cd1-9761-1b52d0d400c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_0fd6a013-184c-4c4c-bbae-511d6e2cf9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96976395-831a-46db-8ecb-17a0acdbfb0d" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_0fd6a013-184c-4c4c-bbae-511d6e2cf9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8e7d17de-1185-4ca9-a116-169e5f666790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96976395-831a-46db-8ecb-17a0acdbfb0d" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8e7d17de-1185-4ca9-a116-169e5f666790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8bcaf8b-d5fb-478e-94b7-69382c93442d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OtherPrepaidExpenseManufacturing_3ff419d1-e209-4be0-bf8f-c9bd72c55570" xlink:href="mrna-20211231.xsd#mrna_OtherPrepaidExpenseManufacturing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8bcaf8b-d5fb-478e-94b7-69382c93442d" xlink:to="loc_mrna_OtherPrepaidExpenseManufacturing_3ff419d1-e209-4be0-bf8f-c9bd72c55570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_9ccee044-78c7-447e-95b8-c0341e4da1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8bcaf8b-d5fb-478e-94b7-69382c93442d" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_9ccee044-78c7-447e-95b8-c0341e4da1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_57aeaabb-3089-48fe-b835-fa9c68a0917a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8bcaf8b-d5fb-478e-94b7-69382c93442d" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_57aeaabb-3089-48fe-b835-fa9c68a0917a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_3ab0c8a1-25de-4852-8f84-2bdd561d572e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8bcaf8b-d5fb-478e-94b7-69382c93442d" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_3ab0c8a1-25de-4852-8f84-2bdd561d572e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TenantImprovementAllowanceReceivableCurrent_ad614335-6549-4d16-b410-1e4294c9eacf" xlink:href="mrna-20211231.xsd#mrna_TenantImprovementAllowanceReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8bcaf8b-d5fb-478e-94b7-69382c93442d" xlink:to="loc_mrna_TenantImprovementAllowanceReceivableCurrent_ad614335-6549-4d16-b410-1e4294c9eacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_dc51d66d-4cf5-4b0c-b46d-ca4286a68b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8bcaf8b-d5fb-478e-94b7-69382c93442d" xlink:to="loc_us-gaap_OtherAssetsCurrent_dc51d66d-4cf5-4b0c-b46d-ca4286a68b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c3e561fa-739e-4e4b-8c60-fcd507e72c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8bcaf8b-d5fb-478e-94b7-69382c93442d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c3e561fa-739e-4e4b-8c60-fcd507e72c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#OtherBalanceSheetComponentsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83cf6a8e-cc99-4fe9-b4fa-f4e1199db856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedClinicalTrials_76178a08-cd99-4fa3-a5bf-9e9805e19735" xlink:href="mrna-20211231.xsd#mrna_AccruedClinicalTrials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83cf6a8e-cc99-4fe9-b4fa-f4e1199db856" xlink:to="loc_mrna_AccruedClinicalTrials_76178a08-cd99-4fa3-a5bf-9e9805e19735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RawMaterialsAccountsPayable_e25f1356-368c-4d47-928a-f352865ce90d" xlink:href="mrna-20211231.xsd#mrna_RawMaterialsAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83cf6a8e-cc99-4fe9-b4fa-f4e1199db856" xlink:to="loc_mrna_RawMaterialsAccountsPayable_e25f1356-368c-4d47-928a-f352865ce90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_b2cdbcea-6020-4c9d-9b92-d3d37a2d6ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83cf6a8e-cc99-4fe9-b4fa-f4e1199db856" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_b2cdbcea-6020-4c9d-9b92-d3d37a2d6ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedDevelopmentOperation_2e315c68-a0b2-42f2-8a75-3ca5bc1fff1d" xlink:href="mrna-20211231.xsd#mrna_AccruedDevelopmentOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83cf6a8e-cc99-4fe9-b4fa-f4e1199db856" xlink:to="loc_mrna_AccruedDevelopmentOperation_2e315c68-a0b2-42f2-8a75-3ca5bc1fff1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedManufacturing_2fb80be0-6080-45fe-9fa3-94e9e1429b60" xlink:href="mrna-20211231.xsd#mrna_AccruedManufacturing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83cf6a8e-cc99-4fe9-b4fa-f4e1199db856" xlink:to="loc_mrna_AccruedManufacturing_2fb80be0-6080-45fe-9fa3-94e9e1429b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_610fd963-b58d-453e-89b8-617cdd319bcc" xlink:href="mrna-20211231.xsd#mrna_AccruedOtherExternalGoodsAndServicesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83cf6a8e-cc99-4fe9-b4fa-f4e1199db856" xlink:to="loc_mrna_AccruedOtherExternalGoodsAndServicesCurrent_610fd963-b58d-453e-89b8-617cdd319bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3b10326d-9318-4ca2-b001-83cac483228f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83cf6a8e-cc99-4fe9-b4fa-f4e1199db856" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3b10326d-9318-4ca2-b001-83cac483228f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d3477c27-b139-479d-b315-f75791c5ca60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83cf6a8e-cc99-4fe9-b4fa-f4e1199db856" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d3477c27-b139-479d-b315-f75791c5ca60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f6b40fa3-0cd0-41fd-8c12-65e01d4f0b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83cf6a8e-cc99-4fe9-b4fa-f4e1199db856" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f6b40fa3-0cd0-41fd-8c12-65e01d4f0b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2840525-18b9-416d-8ab7-76823cd54aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_2bcacdd4-80d8-4e37-ba95-8e7eb759429f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2840525-18b9-416d-8ab7-76823cd54aa4" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_2bcacdd4-80d8-4e37-ba95-8e7eb759429f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d996b394-ad23-4e37-934a-d94315b67dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2840525-18b9-416d-8ab7-76823cd54aa4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d996b394-ad23-4e37-934a-d94315b67dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_85a8f53d-a321-4a48-8f95-b348db5630dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2840525-18b9-416d-8ab7-76823cd54aa4" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_85a8f53d-a321-4a48-8f95-b348db5630dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a279e877-762e-4f0a-951c-73f63221e845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2840525-18b9-416d-8ab7-76823cd54aa4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a279e877-762e-4f0a-951c-73f63221e845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#OtherBalanceSheetComponentsDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a8681b7-7138-4f19-a88e-822fd0c43459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityTable_f1cb2efd-e14d-40a2-8b9a-875ec3ada6c5" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2a8681b7-7138-4f19-a88e-822fd0c43459" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityTable_f1cb2efd-e14d-40a2-8b9a-875ec3ada6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ee5c76c4-30dc-42ea-a17d-8f11a78cac83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_f1cb2efd-e14d-40a2-8b9a-875ec3ada6c5" xlink:to="loc_srt_ProductOrServiceAxis_ee5c76c4-30dc-42ea-a17d-8f11a78cac83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7326ab0e-2a4e-45e4-a6fc-dd1eb68140ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ee5c76c4-30dc-42ea-a17d-8f11a78cac83" xlink:to="loc_srt_ProductsAndServicesDomain_7326ab0e-2a4e-45e4-a6fc-dd1eb68140ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ProductSalesMember_eb9ed362-e1a0-402c-a7c3-01a5e9c70715" xlink:href="mrna-20211231.xsd#mrna_ProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7326ab0e-2a4e-45e4-a6fc-dd1eb68140ec" xlink:to="loc_mrna_ProductSalesMember_eb9ed362-e1a0-402c-a7c3-01a5e9c70715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_ba997754-a77d-4b78-9fca-6917b2123497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7326ab0e-2a4e-45e4-a6fc-dd1eb68140ec" xlink:to="loc_us-gaap_GrantMember_ba997754-a77d-4b78-9fca-6917b2123497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CollaborationArrangementMember_0f7a6080-b949-42e8-8f8c-67544e47c4e4" xlink:href="mrna-20211231.xsd#mrna_CollaborationArrangementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7326ab0e-2a4e-45e4-a6fc-dd1eb68140ec" xlink:to="loc_mrna_CollaborationArrangementMember_0f7a6080-b949-42e8-8f8c-67544e47c4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_38575d37-c2da-47a9-a39d-0a3261814583" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityTable_f1cb2efd-e14d-40a2-8b9a-875ec3ada6c5" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_38575d37-c2da-47a9-a39d-0a3261814583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_0f8bd9ec-fa89-4937-8ba4-bca02869043e" xlink:href="mrna-20211231.xsd#mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityLineItems_38575d37-c2da-47a9-a39d-0a3261814583" xlink:to="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_0f8bd9ec-fa89-4937-8ba4-bca02869043e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_50708e59-5e84-44b9-842a-948783ef44d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_0f8bd9ec-fa89-4937-8ba4-bca02869043e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_50708e59-5e84-44b9-842a-948783ef44d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_6f6acd19-7402-4616-bc03-6f037b33e9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_0f8bd9ec-fa89-4937-8ba4-bca02869043e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_6f6acd19-7402-4616-bc03-6f037b33e9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_e26d67d8-9694-477b-90de-3b63c5fedd61" xlink:href="mrna-20211231.xsd#mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_0f8bd9ec-fa89-4937-8ba4-bca02869043e" xlink:to="loc_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod_e26d67d8-9694-477b-90de-3b63c5fedd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_57e96146-1352-4d42-910a-f91790e3872d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward_0f8bd9ec-fa89-4937-8ba4-bca02869043e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_57e96146-1352-4d42-910a-f91790e3872d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/Leases" xlink:type="simple" xlink:href="mrna-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_45a4d168-5178-42d6-83ed-680ec5e0d69f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_5e151959-639e-4567-b0d8-6390ebe02f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45a4d168-5178-42d6-83ed-680ec5e0d69f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_5e151959-639e-4567-b0d8-6390ebe02f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_11d0007b-b5bb-429c-a9c6-0b83fefa5b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45a4d168-5178-42d6-83ed-680ec5e0d69f" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_11d0007b-b5bb-429c-a9c6-0b83fefa5b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b03c43e6-145b-474d-b814-e1e0bca96c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock_3e1a4823-6fce-412a-b9e9-3533fb6475e9" xlink:href="mrna-20211231.xsd#mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b03c43e6-145b-474d-b814-e1e0bca96c02" xlink:to="loc_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock_3e1a4823-6fce-412a-b9e9-3533fb6475e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_7626dd22-a990-4266-ac5a-b290d6d2a26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b03c43e6-145b-474d-b814-e1e0bca96c02" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_7626dd22-a990-4266-ac5a-b290d6d2a26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_51d1369a-764c-4e7d-9431-a4a2b3503f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b03c43e6-145b-474d-b814-e1e0bca96c02" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_51d1369a-764c-4e7d-9431-a4a2b3503f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_91823610-8720-41b8-9d49-f2937f2cbfae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b03c43e6-145b-474d-b814-e1e0bca96c02" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_91823610-8720-41b8-9d49-f2937f2cbfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dd0c0d96-6d03-42fe-bedd-7245013cbfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_0f418149-2840-441d-92de-a4a0d028aff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd0c0d96-6d03-42fe-bedd-7245013cbfdf" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_0f418149-2840-441d-92de-a4a0d028aff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_155187c4-2ec5-4b69-ab38-2071b7c0a9aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0f418149-2840-441d-92de-a4a0d028aff1" xlink:to="loc_srt_StatementGeographicalAxis_155187c4-2ec5-4b69-ab38-2071b7c0a9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b50e5771-fe3e-4586-b6aa-9829fdd7a4a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_155187c4-2ec5-4b69-ab38-2071b7c0a9aa" xlink:to="loc_srt_SegmentGeographicalDomain_b50e5771-fe3e-4586-b6aa-9829fdd7a4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_CambridgeMassachusettsMember_4d0a5d50-c3cd-4457-9e02-f7ad2810787a" xlink:href="mrna-20211231.xsd#mrna_CambridgeMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b50e5771-fe3e-4586-b6aa-9829fdd7a4a0" xlink:to="loc_mrna_CambridgeMassachusettsMember_4d0a5d50-c3cd-4457-9e02-f7ad2810787a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NorwoodMassachusettsMember_9f455d83-0520-4458-8efa-753451fdc83b" xlink:href="mrna-20211231.xsd#mrna_NorwoodMassachusettsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b50e5771-fe3e-4586-b6aa-9829fdd7a4a0" xlink:to="loc_mrna_NorwoodMassachusettsMember_9f455d83-0520-4458-8efa-753451fdc83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_24f10ff9-b6f9-49e1-a828-fcaffa869754" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0f418149-2840-441d-92de-a4a0d028aff1" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_24f10ff9-b6f9-49e1-a828-fcaffa869754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_24f10ff9-b6f9-49e1-a828-fcaffa869754" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_TwoHundredTechnologySquareMember_01cb50e5-7d53-4df4-b23e-eba9236103ae" xlink:href="mrna-20211231.xsd#mrna_TwoHundredTechnologySquareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:to="loc_mrna_TwoHundredTechnologySquareMember_01cb50e5-7d53-4df4-b23e-eba9236103ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FiveHundredTechnologySquareMember_c007c96b-1ec0-467b-a475-5f22f1b28d70" xlink:href="mrna-20211231.xsd#mrna_FiveHundredTechnologySquareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:to="loc_mrna_FiveHundredTechnologySquareMember_c007c96b-1ec0-467b-a475-5f22f1b28d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCEastMember_6ea3185d-f14a-4b37-b97d-fe8348d64f98" xlink:href="mrna-20211231.xsd#mrna_MTCEastMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:to="loc_mrna_MTCEastMember_6ea3185d-f14a-4b37-b97d-fe8348d64f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCNorthMember_a6624d32-4668-4b1e-afea-d581b41bc2aa" xlink:href="mrna-20211231.xsd#mrna_MTCNorthMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:to="loc_mrna_MTCNorthMember_a6624d32-4668-4b1e-afea-d581b41bc2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_b38e02c0-f8f8-4151-bb1c-9056eab5b6c0" xlink:href="mrna-20211231.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c51e23fb-41dc-49af-a54b-4b13010a66fe" xlink:to="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_b38e02c0-f8f8-4151-bb1c-9056eab5b6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_9d6ee3a4-580b-453e-8250-725e89f18a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0f418149-2840-441d-92de-a4a0d028aff1" xlink:to="loc_us-gaap_LeaseContractualTermAxis_9d6ee3a4-580b-453e-8250-725e89f18a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_0718836e-56a3-45da-94ed-b64245c82dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_9d6ee3a4-580b-453e-8250-725e89f18a11" xlink:to="loc_us-gaap_LeaseContractualTermDomain_0718836e-56a3-45da-94ed-b64245c82dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmbeddedLeasesMember_fc04b353-cce6-4002-9952-4397d3e44994" xlink:href="mrna-20211231.xsd#mrna_EmbeddedLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_0718836e-56a3-45da-94ed-b64245c82dce" xlink:to="loc_mrna_EmbeddedLeasesMember_fc04b353-cce6-4002-9952-4397d3e44994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0f418149-2840-441d-92de-a4a0d028aff1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingLeaseNumberOfProperties_ceaacfe3-6026-4d49-b708-dee6433aaf1a" xlink:href="mrna-20211231.xsd#mrna_OperatingLeaseNumberOfProperties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_mrna_OperatingLeaseNumberOfProperties_ceaacfe3-6026-4d49-b708-dee6433aaf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_f12a2523-0d82-4132-bd6d-2ba0cff9cbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_f12a2523-0d82-4132-bd6d-2ba0cff9cbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c146a157-ff9b-4184-b19c-879f1b510913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c146a157-ff9b-4184-b19c-879f1b510913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtension_8fd02539-8cc5-487e-b7ca-f70ab1e68d41" xlink:href="mrna-20211231.xsd#mrna_LesseeOperatingLeaseNumberOfExtension"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtension_8fd02539-8cc5-487e-b7ca-f70ab1e68d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseNumberOfProperties_f6ef1c82-af5d-48d4-9e6e-641bdcbefda4" xlink:href="mrna-20211231.xsd#mrna_FinanceLeaseNumberOfProperties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_mrna_FinanceLeaseNumberOfProperties_f6ef1c82-af5d-48d4-9e6e-641bdcbefda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_AllowanceForTenantImprovements_3f47de64-25ae-4a23-a551-90779559ef75" xlink:href="mrna-20211231.xsd#mrna_AllowanceForTenantImprovements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_mrna_AllowanceForTenantImprovements_3f47de64-25ae-4a23-a551-90779559ef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_58065773-eecc-46ee-960d-5d1c7db004be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_us-gaap_OperatingLeaseLiability_58065773-eecc-46ee-960d-5d1c7db004be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cb6b7e5d-4af6-496d-9265-5e25210ddf8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bb7b902d-3acf-43e3-946a-1fa0803a45d8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cb6b7e5d-4af6-496d-9265-5e25210ddf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ae2dbc8c-7944-432f-9fb2-461257efb019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ae2dbc8c-7944-432f-9fb2-461257efb019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_e422aac9-e638-413b-a6bc-54f95c3b5ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_e422aac9-e638-413b-a6bc-54f95c3b5ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_f563667b-e738-4a5d-91db-c2e9e2bb61cc" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_mrna_OperatingAndFinanceLeaseRightOfUseAsset_f563667b-e738-4a5d-91db-c2e9e2bb61cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_924b1f11-246f-4c03-927b-e0249181a94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_924b1f11-246f-4c03-927b-e0249181a94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_2ae1393e-300e-4406-b8ba-be64106bd408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_2ae1393e-300e-4406-b8ba-be64106bd408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_4b6fa534-587b-412d-b914-2ec27f97cae2" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityCurrent_4b6fa534-587b-412d-b914-2ec27f97cae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_767bbb23-38c7-4628-bf75-9564893ce81c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_767bbb23-38c7-4628-bf75-9564893ce81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_66ac8b7f-a1c8-43dc-aac2-ba1ebe8ed3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_66ac8b7f-a1c8-43dc-aac2-ba1ebe8ed3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_9aceffea-5551-4ef7-a337-4c61a9955478" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent_9aceffea-5551-4ef7-a337-4c61a9955478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_OperatingAndFinanceLeaseLiability_c9a53fb4-d630-4deb-bbc5-a1599c5df091" xlink:href="mrna-20211231.xsd#mrna_OperatingAndFinanceLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_mrna_OperatingAndFinanceLeaseLiability_c9a53fb4-d630-4deb-bbc5-a1599c5df091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4c814592-4f87-4107-86e7-e22a4e8b412b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_4c814592-4f87-4107-86e7-e22a4e8b412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_84b645e4-a858-487a-b749-2b7f938cbc00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_84b645e4-a858-487a-b749-2b7f938cbc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_38bd90c2-47fb-4465-93dc-9f4cd731507f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_daada3ce-9548-4c2b-ae23-3a62576f1136" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_38bd90c2-47fb-4465-93dc-9f4cd731507f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1314f0e2-8d43-4873-b777-81430d2c5c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_OperatingLeaseCost_1314f0e2-8d43-4873-b777-81430d2c5c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_5fd55c28-18ea-4336-9bd4-14b2563ae888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_5fd55c28-18ea-4336-9bd4-14b2563ae888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_1fc1a9c4-c4e1-4560-bb14-33a94d63cb76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_1fc1a9c4-c4e1-4560-bb14-33a94d63cb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_FinanceLeaseCost_314c4d61-02c9-4d0f-81a0-629859567f6c" xlink:href="mrna-20211231.xsd#mrna_FinanceLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_mrna_FinanceLeaseCost_314c4d61-02c9-4d0f-81a0-629859567f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_0d2f0fd0-c563-4116-828a-07e5635a1af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_ShortTermLeaseCost_0d2f0fd0-c563-4116-828a-07e5635a1af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_27d29701-2454-4d24-a8ca-b153793c1bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_VariableLeaseCost_27d29701-2454-4d24-a8ca-b153793c1bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_ba458398-661a-4a07-8f1d-ade3c4a949a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_OperatingLeasePayments_ba458398-661a-4a07-8f1d-ade3c4a949a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_0f1dc8b4-5986-493c-b3ed-7a50474b2468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_0f1dc8b4-5986-493c-b3ed-7a50474b2468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_fc3e5083-83b9-4f5e-b566-253ef0c6bf77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_fc3e5083-83b9-4f5e-b566-253ef0c6bf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_77819bdc-482a-447c-9bd3-56781e095425" xlink:href="mrna-20211231.xsd#mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments_77819bdc-482a-447c-9bd3-56781e095425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bc085622-fde1-4bf8-a1c9-15b5f98cbfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bc085622-fde1-4bf8-a1c9-15b5f98cbfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_1ce2f03e-e3e2-4eb7-acc1-340b585a76fb" xlink:href="mrna-20211231.xsd#mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments_1ce2f03e-e3e2-4eb7-acc1-340b585a76fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_ec4043a2-5634-4d6d-9588-0e03656ad7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_ec4043a2-5634-4d6d-9588-0e03656ad7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeFinanceLeaseExpense_70487416-4e1f-417c-9bf1-bfabf063e452" xlink:href="mrna-20211231.xsd#mrna_LesseeFinanceLeaseExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_mrna_LesseeFinanceLeaseExpense_70487416-4e1f-417c-9bf1-bfabf063e452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9b2c66d3-5bf6-4ba8-bac9-30044062220d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9b2c66d3-5bf6-4ba8-bac9-30044062220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_359ec482-63e4-4f1b-b8b3-debef0c0f9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_359ec482-63e4-4f1b-b8b3-debef0c0f9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2ab82807-275d-43f7-94a6-2fbec819fbab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2ab82807-275d-43f7-94a6-2fbec819fbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_fd10091b-8496-42f0-86b8-229a0bc35296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3c95f0-a1ed-4297-b678-25de4bb64f2e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_fd10091b-8496-42f0-86b8-229a0bc35296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_48ced487-84cf-4ba6-bd9e-f64cfb799705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_2fb0196d-0d40-406a-bfe4-96326ac71453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_48ced487-84cf-4ba6-bd9e-f64cfb799705" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_2fb0196d-0d40-406a-bfe4-96326ac71453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_b186b84f-fb7b-4e0b-9269-57dcf0f87c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_2fb0196d-0d40-406a-bfe4-96326ac71453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_b186b84f-fb7b-4e0b-9269-57dcf0f87c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_31dd448e-7682-4507-9177-81a6a6554343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_2fb0196d-0d40-406a-bfe4-96326ac71453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_31dd448e-7682-4507-9177-81a6a6554343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_546ed9fa-cb9a-4e04-9d37-56eab53b234a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_2fb0196d-0d40-406a-bfe4-96326ac71453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_546ed9fa-cb9a-4e04-9d37-56eab53b234a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_93307f1c-cad1-4935-be57-5d17a6a22a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_2fb0196d-0d40-406a-bfe4-96326ac71453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_93307f1c-cad1-4935-be57-5d17a6a22a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_7340a281-c9d9-401e-aecc-6423c390210a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_2fb0196d-0d40-406a-bfe4-96326ac71453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_7340a281-c9d9-401e-aecc-6423c390210a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_709ec6af-ac02-495b-a3e7-e158f17f207f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_2fb0196d-0d40-406a-bfe4-96326ac71453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_709ec6af-ac02-495b-a3e7-e158f17f207f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7304e728-0309-471c-b0a7-f684ac970f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_2fb0196d-0d40-406a-bfe4-96326ac71453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7304e728-0309-471c-b0a7-f684ac970f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_653ec209-cacb-44db-aca4-642483d0c326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_2fb0196d-0d40-406a-bfe4-96326ac71453" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_653ec209-cacb-44db-aca4-642483d0c326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_dbc0b7e5-29b0-4410-8ce0-a2be718a6e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_2fb0196d-0d40-406a-bfe4-96326ac71453" xlink:to="loc_us-gaap_OperatingLeaseLiability_dbc0b7e5-29b0-4410-8ce0-a2be718a6e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e65c92ce-5cf6-436b-b0e5-1786dd3c6f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_48ced487-84cf-4ba6-bd9e-f64cfb799705" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e65c92ce-5cf6-436b-b0e5-1786dd3c6f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_f21f76e5-87d9-4ed5-ac2e-bd061cc5eaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e65c92ce-5cf6-436b-b0e5-1786dd3c6f51" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_f21f76e5-87d9-4ed5-ac2e-bd061cc5eaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_f205aca9-8cec-447b-9546-6d42190942fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e65c92ce-5cf6-436b-b0e5-1786dd3c6f51" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_f205aca9-8cec-447b-9546-6d42190942fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_baa9ad5e-026e-46c1-a15a-11fe28de0f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e65c92ce-5cf6-436b-b0e5-1786dd3c6f51" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree_baa9ad5e-026e-46c1-a15a-11fe28de0f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_55835371-7825-4bf2-a719-a7bd298110af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e65c92ce-5cf6-436b-b0e5-1786dd3c6f51" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour_55835371-7825-4bf2-a719-a7bd298110af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_7baf8733-a776-4a22-a18d-667ff1d69d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e65c92ce-5cf6-436b-b0e5-1786dd3c6f51" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive_7baf8733-a776-4a22-a18d-667ff1d69d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_5211fa9a-2f26-4d62-a03c-a5ec433a14d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e65c92ce-5cf6-436b-b0e5-1786dd3c6f51" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive_5211fa9a-2f26-4d62-a03c-a5ec433a14d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3f319ed9-edae-4dbb-bfd7-ef102e3631f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e65c92ce-5cf6-436b-b0e5-1786dd3c6f51" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3f319ed9-edae-4dbb-bfd7-ef102e3631f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_742514dd-4cba-4feb-b103-d819306ab753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e65c92ce-5cf6-436b-b0e5-1786dd3c6f51" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_742514dd-4cba-4feb-b103-d819306ab753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_c5430043-0eda-450c-9aff-0a879ec6c864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract_e65c92ce-5cf6-436b-b0e5-1786dd3c6f51" xlink:to="loc_us-gaap_FinanceLeaseLiability_c5430043-0eda-450c-9aff-0a879ec6c864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_42df3939-3522-487e-989d-61927c4179db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_48ced487-84cf-4ba6-bd9e-f64cfb799705" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_42df3939-3522-487e-989d-61927c4179db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c1d72439-c90d-4a89-b8f1-3868ddbd045a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_42df3939-3522-487e-989d-61927c4179db" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c1d72439-c90d-4a89-b8f1-3868ddbd045a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c5d5020e-3250-41df-bcc5-a319e3c29513" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c1d72439-c90d-4a89-b8f1-3868ddbd045a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c5d5020e-3250-41df-bcc5-a319e3c29513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_b40e6718-c02c-4fc0-b1bc-e684e9ad93e3" xlink:href="mrna-20211231.xsd#mrna_MTCSouthMTCNorthAndMTCEastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_c5d5020e-3250-41df-bcc5-a319e3c29513" xlink:to="loc_mrna_MTCSouthMTCNorthAndMTCEastMember_b40e6718-c02c-4fc0-b1bc-e684e9ad93e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dcd4790f-f141-4722-8b88-78d4398c10c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_42df3939-3522-487e-989d-61927c4179db" xlink:to="loc_srt_StatementGeographicalAxis_dcd4790f-f141-4722-8b88-78d4398c10c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e359a281-207a-4063-a2af-89008a522ed0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_dcd4790f-f141-4722-8b88-78d4398c10c8" xlink:to="loc_srt_SegmentGeographicalDomain_e359a281-207a-4063-a2af-89008a522ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NorwoodMassachusettsMember_e8b038e4-dbf9-4c50-bbfb-35fd45e60154" xlink:href="mrna-20211231.xsd#mrna_NorwoodMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e359a281-207a-4063-a2af-89008a522ed0" xlink:to="loc_mrna_NorwoodMassachusettsMember_e8b038e4-dbf9-4c50-bbfb-35fd45e60154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9d423ba-f613-4c80-a8c6-d1da938aaec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_42df3939-3522-487e-989d-61927c4179db" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9d423ba-f613-4c80-a8c6-d1da938aaec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5edb9780-15df-4594-ba42-fd489587f597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e9d423ba-f613-4c80-a8c6-d1da938aaec3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5edb9780-15df-4594-ba42-fd489587f597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="mrna-20211231.xsd#LeasesMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mrna-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_26c4f009-d952-433a-b949-df96f85b1cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_288188a2-7fe6-45ff-b210-54b2188635f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_26c4f009-d952-433a-b949-df96f85b1cb8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_288188a2-7fe6-45ff-b210-54b2188635f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CommitmentsandContingenciesIndemnificationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b921d9d5-20f9-4edf-850d-b51f8cfaf224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e0b338d1-161c-4a24-bde8-80d3672c3e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b921d9d5-20f9-4edf-850d-b51f8cfaf224" xlink:to="loc_us-gaap_LossContingenciesTable_e0b338d1-161c-4a24-bde8-80d3672c3e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_12b66995-e05a-412a-8464-991bcf16879e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e0b338d1-161c-4a24-bde8-80d3672c3e11" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_12b66995-e05a-412a-8464-991bcf16879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_57fd9313-c4b2-4c62-94b8-b734501c31fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_12b66995-e05a-412a-8464-991bcf16879e" xlink:to="loc_us-gaap_LossContingencyNatureDomain_57fd9313-c4b2-4c62-94b8-b734501c31fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_90127959-8a9b-4def-8288-97852e9724b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_57fd9313-c4b2-4c62-94b8-b734501c31fe" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_90127959-8a9b-4def-8288-97852e9724b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_0e98f767-231f-4abf-b5e8-a41bf34dab39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e0b338d1-161c-4a24-bde8-80d3672c3e11" xlink:to="loc_us-gaap_LossContingenciesLineItems_0e98f767-231f-4abf-b5e8-a41bf34dab39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_a6fbe123-c54e-485b-aeda-16d1e2da9159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyLossInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_0e98f767-231f-4abf-b5e8-a41bf34dab39" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_a6fbe123-c54e-485b-aeda-16d1e2da9159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_8c551dbe-d790-461a-9801-37388184522a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_0e98f767-231f-4abf-b5e8-a41bf34dab39" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_8c551dbe-d790-461a-9801-37388184522a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f7899bfd-85fd-4d62-b226-a49954c631f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_0e98f767-231f-4abf-b5e8-a41bf34dab39" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f7899bfd-85fd-4d62-b226-a49954c631f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c65000f-aab6-43ae-8b74-6cf446b3f8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ef902342-ca8b-4e92-b1c6-935622f62dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2c65000f-aab6-43ae-8b74-6cf446b3f8d3" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ef902342-ca8b-4e92-b1c6-935622f62dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_28e93dbf-ef05-4695-a5c1-302d761ef56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ef902342-ca8b-4e92-b1c6-935622f62dc2" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_28e93dbf-ef05-4695-a5c1-302d761ef56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4a38c980-2b72-40dd-bfe8-5fd3c1c3d486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_28e93dbf-ef05-4695-a5c1-302d761ef56e" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4a38c980-2b72-40dd-bfe8-5fd3c1c3d486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_SupplyAndManufacturingAgreementsMember_31770971-90bf-4797-ba8b-761fb8ec0351" xlink:href="mrna-20211231.xsd#mrna_SupplyAndManufacturingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4a38c980-2b72-40dd-bfe8-5fd3c1c3d486" xlink:to="loc_mrna_SupplyAndManufacturingAgreementsMember_31770971-90bf-4797-ba8b-761fb8ec0351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalServicesMember_f2f536f7-1b9b-4f2d-a4a5-7d332aba7241" xlink:href="mrna-20211231.xsd#mrna_ClinicalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4a38c980-2b72-40dd-bfe8-5fd3c1c3d486" xlink:to="loc_mrna_ClinicalServicesMember_f2f536f7-1b9b-4f2d-a4a5-7d332aba7241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_a7e3b10b-8ca2-47a0-a49a-2c2ece823a20" xlink:href="mrna-20211231.xsd#mrna_ClinicalOperationsAndSupportCommitmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_4a38c980-2b72-40dd-bfe8-5fd3c1c3d486" xlink:to="loc_mrna_ClinicalOperationsAndSupportCommitmentMember_a7e3b10b-8ca2-47a0-a49a-2c2ece823a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_195a71c3-1d92-4467-8f80-72b38283fe82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ef902342-ca8b-4e92-b1c6-935622f62dc2" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_195a71c3-1d92-4467-8f80-72b38283fe82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_4a7a5998-c1df-4da2-a3a6-468e405410fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_195a71c3-1d92-4467-8f80-72b38283fe82" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_4a7a5998-c1df-4da2-a3a6-468e405410fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80ec313a-3e6d-4849-a00d-cf27184d7aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_603570e8-0de8-49a2-bcd7-091895e021c8" xlink:href="mrna-20211231.xsd#mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80ec313a-3e6d-4849-a00d-cf27184d7aa9" xlink:to="loc_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount_603570e8-0de8-49a2-bcd7-091895e021c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_98a47bac-e4ba-4b86-b63f-86cc2c58fe28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80ec313a-3e6d-4849-a00d-cf27184d7aa9" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_98a47bac-e4ba-4b86-b63f-86cc2c58fe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#CommitmentandContingenciesModernaScienceCenterDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f14537b1-2673-4781-8ef7-6d9a53e5ba93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_70abad7a-4781-469f-a661-761e74c91e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f14537b1-2673-4781-8ef7-6d9a53e5ba93" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_70abad7a-4781-469f-a661-761e74c91e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fa918b71-266a-47dd-89cd-b5321c6381cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_70abad7a-4781-469f-a661-761e74c91e1a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fa918b71-266a-47dd-89cd-b5321c6381cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_663e2483-d5bd-4a29-9c7a-1b1edbba3374" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_fa918b71-266a-47dd-89cd-b5321c6381cd" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_663e2483-d5bd-4a29-9c7a-1b1edbba3374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ModernaScienceCentreMember_8218cfb0-6393-42bf-beb4-0c8139b0b0ed" xlink:href="mrna-20211231.xsd#mrna_ModernaScienceCentreMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_663e2483-d5bd-4a29-9c7a-1b1edbba3374" xlink:to="loc_mrna_ModernaScienceCentreMember_8218cfb0-6393-42bf-beb4-0c8139b0b0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_70abad7a-4781-469f-a661-761e74c91e1a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_6d212854-3a5c-474c-b9aa-c849fe4c4ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_6d212854-3a5c-474c-b9aa-c849fe4c4ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm_d3ecf2a7-e6c4-45fa-811a-cf07fcdff925" xlink:href="mrna-20211231.xsd#mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm_d3ecf2a7-e6c4-45fa-811a-cf07fcdff925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_78f42c39-0fce-4d0e-a1fd-442a4fe80314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_78f42c39-0fce-4d0e-a1fd-442a4fe80314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_c97d32a2-e01b-4f1c-9b9c-9ce15469449b" xlink:href="mrna-20211231.xsd#mrna_LesseeOperatingLeaseNumberOfExtensionPeriods"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods_c97d32a2-e01b-4f1c-9b9c-9ce15469449b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6d0d2daa-684c-42bd-b8c4-db52d5385639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6d0d2daa-684c-42bd-b8c4-db52d5385639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ee8c2fc4-addd-4b2e-93d1-f68ae1c80b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_eaf38217-69ad-43eb-9441-c7f7aae57874" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ee8c2fc4-addd-4b2e-93d1-f68ae1c80b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8dc32ed1-af7e-4200-897c-62d55594e150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e5976baa-53b9-4f54-bf9b-284eebbafc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8dc32ed1-af7e-4200-897c-62d55594e150" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e5976baa-53b9-4f54-bf9b-284eebbafc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3da73e63-399e-4e36-babf-dec11eff1aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6129ce2f-9175-4df4-95d7-41b45403b262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3da73e63-399e-4e36-babf-dec11eff1aeb" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6129ce2f-9175-4df4-95d7-41b45403b262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_aee3a2e0-b9ba-4d8a-a44a-28ab8151010e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6129ce2f-9175-4df4-95d7-41b45403b262" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_aee3a2e0-b9ba-4d8a-a44a-28ab8151010e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_609518cb-eb29-42fc-93c3-0657b40ae6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aee3a2e0-b9ba-4d8a-a44a-28ab8151010e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_609518cb-eb29-42fc-93c3-0657b40ae6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_PublicEquityOfferingMember_1d213ded-fd5b-49d6-b301-78f9305484fb" xlink:href="mrna-20211231.xsd#mrna_PublicEquityOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_609518cb-eb29-42fc-93c3-0657b40ae6e2" xlink:to="loc_mrna_PublicEquityOfferingMember_1d213ded-fd5b-49d6-b301-78f9305484fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_380369a6-7775-41fe-94ac-c85cb2d9de96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_609518cb-eb29-42fc-93c3-0657b40ae6e2" xlink:to="loc_us-gaap_OverAllotmentOptionMember_380369a6-7775-41fe-94ac-c85cb2d9de96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_7a20ccd7-9bab-4f45-a4f9-facbb88e848e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6129ce2f-9175-4df4-95d7-41b45403b262" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_7a20ccd7-9bab-4f45-a4f9-facbb88e848e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ef8575a7-8477-492f-bee9-da950779c9af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7a20ccd7-9bab-4f45-a4f9-facbb88e848e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ef8575a7-8477-492f-bee9-da950779c9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2db6dcaa-be94-48e7-a780-09848bfcd3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7a20ccd7-9bab-4f45-a4f9-facbb88e848e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2db6dcaa-be94-48e7-a780-09848bfcd3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d69d945e-9b66-4051-acef-b2a906cc6063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_7a20ccd7-9bab-4f45-a4f9-facbb88e848e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d69d945e-9b66-4051-acef-b2a906cc6063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffe4d5c4-6cce-4b6d-9209-c474a100ed02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a6364088-29f2-4af7-a8d0-b80aa6c218b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffe4d5c4-6cce-4b6d-9209-c474a100ed02" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a6364088-29f2-4af7-a8d0-b80aa6c218b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_045dede8-5909-410b-a530-9e266e27213d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_f0cdc51f-8fa0-41df-a444-8d21221f3e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_045dede8-5909-410b-a530-9e266e27213d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_f0cdc51f-8fa0-41df-a444-8d21221f3e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_497ef349-5ae9-486a-8e07-d41f3e94bb86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_045dede8-5909-410b-a530-9e266e27213d" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_497ef349-5ae9-486a-8e07-d41f3e94bb86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a443d527-4228-4e8b-83d5-76bc6ae3f57d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_045dede8-5909-410b-a530-9e266e27213d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a443d527-4228-4e8b-83d5-76bc6ae3f57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_edd7d3dc-deb4-428d-ac20-35ebe2b4a8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_045dede8-5909-410b-a530-9e266e27213d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_edd7d3dc-deb4-428d-ac20-35ebe2b4a8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e21c917-4921-463b-bbad-f51238f42036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e21c917-4921-463b-bbad-f51238f42036" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f39f2ee5-ab7a-4032-9a12-75b76f830a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:to="loc_us-gaap_PlanNameAxis_f39f2ee5-ab7a-4032-9a12-75b76f830a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bc3bf8c5-7113-4fff-a7e2-c53e8ed09b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f39f2ee5-ab7a-4032-9a12-75b76f830a7e" xlink:to="loc_us-gaap_PlanNameDomain_bc3bf8c5-7113-4fff-a7e2-c53e8ed09b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndIncentivePlan2018Member_9331b728-84c1-47aa-86f4-31632199666c" xlink:href="mrna-20211231.xsd#mrna_StockOptionAndIncentivePlan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bc3bf8c5-7113-4fff-a7e2-c53e8ed09b31" xlink:to="loc_mrna_StockOptionAndIncentivePlan2018Member_9331b728-84c1-47aa-86f4-31632199666c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_StockOptionAndGrantPlan2016Member_c7bdd8b7-60bf-4f77-803f-1407d9482a23" xlink:href="mrna-20211231.xsd#mrna_StockOptionAndGrantPlan2016Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bc3bf8c5-7113-4fff-a7e2-c53e8ed09b31" xlink:to="loc_mrna_StockOptionAndGrantPlan2016Member_c7bdd8b7-60bf-4f77-803f-1407d9482a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EmployeeStockPurchasePlan2018Member_4cd4697f-5798-4646-a1f8-f5ae1c25bcbe" xlink:href="mrna-20211231.xsd#mrna_EmployeeStockPurchasePlan2018Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bc3bf8c5-7113-4fff-a7e2-c53e8ed09b31" xlink:to="loc_mrna_EmployeeStockPurchasePlan2018Member_4cd4697f-5798-4646-a1f8-f5ae1c25bcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_08c4a708-66a0-46e5-9185-6921c5756178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:to="loc_us-gaap_AwardTypeAxis_08c4a708-66a0-46e5-9185-6921c5756178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_08c4a708-66a0-46e5-9185-6921c5756178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ServiceBasedAwardsMember_31be99bf-d017-4067-b1de-2361fc5ed74e" xlink:href="mrna-20211231.xsd#mrna_ServiceBasedAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:to="loc_mrna_ServiceBasedAwardsMember_31be99bf-d017-4067-b1de-2361fc5ed74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_63c67f5b-cdc6-4bb6-8cce-0270a9c9f524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_63c67f5b-cdc6-4bb6-8cce-0270a9c9f524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6b13bb8e-c73e-48a4-83b7-f6deb6ca516b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:to="loc_us-gaap_EmployeeStockMember_6b13bb8e-c73e-48a4-83b7-f6deb6ca516b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_fbf555fb-386e-4ad9-b3b8-4a0c4458fb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:to="loc_us-gaap_PerformanceSharesMember_fbf555fb-386e-4ad9-b3b8-4a0c4458fb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_7204a17a-494f-4651-8926-b860cb813e4b" xlink:href="mrna-20211231.xsd#mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a354de4-bd41-4f4c-afb2-5788582d44c6" xlink:to="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_7204a17a-494f-4651-8926-b860cb813e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7283cb5b-ec7b-403c-b610-24b12af1d855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:to="loc_us-gaap_VestingAxis_7283cb5b-ec7b-403c-b610-24b12af1d855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_b6348b5c-8bc5-451f-a5bb-dda4af20df89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_7283cb5b-ec7b-403c-b610-24b12af1d855" xlink:to="loc_us-gaap_VestingDomain_b6348b5c-8bc5-451f-a5bb-dda4af20df89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0ea460af-e389-416f-847b-0068ac97ae32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b6348b5c-8bc5-451f-a5bb-dda4af20df89" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0ea460af-e389-416f-847b-0068ac97ae32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_691257d7-0912-4458-a2fd-293123f395c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_b6348b5c-8bc5-451f-a5bb-dda4af20df89" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_691257d7-0912-4458-a2fd-293123f395c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c5dbf948-ef30-4ee8-b405-4651afeefb50" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:to="loc_srt_RangeAxis_c5dbf948-ef30-4ee8-b405-4651afeefb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6dae2bb1-fe57-4ac9-96a6-35f23aef7fb5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c5dbf948-ef30-4ee8-b405-4651afeefb50" xlink:to="loc_srt_RangeMember_6dae2bb1-fe57-4ac9-96a6-35f23aef7fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_66315c99-2e68-4eb8-93d3-b443545bc1c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6dae2bb1-fe57-4ac9-96a6-35f23aef7fb5" xlink:to="loc_srt_MinimumMember_66315c99-2e68-4eb8-93d3-b443545bc1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_64fe7e3d-dcff-4064-bcec-351d97c615ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6dae2bb1-fe57-4ac9-96a6-35f23aef7fb5" xlink:to="loc_srt_MaximumMember_64fe7e3d-dcff-4064-bcec-351d97c615ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_17d63d53-d056-4d4b-b638-c6c1bb3d0ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_17d63d53-d056-4d4b-b638-c6c1bb3d0ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9241378f-5c80-4ab6-b7c4-e62612a48625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_17d63d53-d056-4d4b-b638-c6c1bb3d0ae7" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_9241378f-5c80-4ab6-b7c4-e62612a48625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2021RepurchaseProgramMember_b920197c-dbc0-441d-b37e-8acb7f61dacd" xlink:href="mrna-20211231.xsd#mrna_A2021RepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_9241378f-5c80-4ab6-b7c4-e62612a48625" xlink:to="loc_mrna_A2021RepurchaseProgramMember_b920197c-dbc0-441d-b37e-8acb7f61dacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4ee37ed7-5d3d-4624-bcdd-8e6e072ecb79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_3550fb9f-a257-4169-8fc7-cff2441d1faf" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized_3550fb9f-a257-4169-8fc7-cff2441d1faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_014c522d-305b-4e54-a5df-80870e186d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_014c522d-305b-4e54-a5df-80870e186d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f999c205-b72c-4a13-9bbe-b92ca3f81dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f999c205-b72c-4a13-9bbe-b92ca3f81dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_70d8efa6-06db-4fc3-9fa8-cda95e112b0e" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments_70d8efa6-06db-4fc3-9fa8-cda95e112b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ee3b298c-c6a7-4445-a3e4-8623f28f2a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ee3b298c-c6a7-4445-a3e4-8623f28f2a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3ec0930b-ce05-4a19-9139-e4f6c54f7b11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3ec0930b-ce05-4a19-9139-e4f6c54f7b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_017bfd80-5888-4edc-bad6-2da572e477b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_017bfd80-5888-4edc-bad6-2da572e477b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_26c2c69f-929e-4d68-9da5-86ea982d1dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_26c2c69f-929e-4d68-9da5-86ea982d1dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_7001b5f2-ad09-4583-8061-d27fe2a30f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_7001b5f2-ad09-4583-8061-d27fe2a30f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_655819b7-9ea7-4b6c-8ab8-fa71f0514889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_655819b7-9ea7-4b6c-8ab8-fa71f0514889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockExpense_4aef853e-9760-4231-8f4c-dced8c0ebc22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_RestrictedStockExpense_4aef853e-9760-4231-8f4c-dced8c0ebc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2dc18bd8-0532-4f6e-9240-d328fb813a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2dc18bd8-0532-4f6e-9240-d328fb813a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_e0814fd7-c2df-4013-84d9-5474709397a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_e0814fd7-c2df-4013-84d9-5474709397a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_81db5fd0-828a-4b9a-bee8-3aa6b39e8dfd" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage_81db5fd0-828a-4b9a-bee8-3aa6b39e8dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod_b6e63c9f-cee8-4fd4-a35d-6067cc62beec" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod_b6e63c9f-cee8-4fd4-a35d-6067cc62beec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_2142d8e1-6874-4d4c-b488-be51e6367a30" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_2142d8e1-6874-4d4c-b488-be51e6367a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_078854ff-ee2a-40cc-aa65-16f110b77478" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod_078854ff-ee2a-40cc-aa65-16f110b77478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_7b9807bb-4e70-4910-bff7-d3de43260cde" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_7b9807bb-4e70-4910-bff7-d3de43260cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_560ef731-9da0-4ff2-979b-642e3598abd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_560ef731-9da0-4ff2-979b-642e3598abd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_14f9f6fa-f300-4760-b8de-9f9b526fa874" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate_14f9f6fa-f300-4760-b8de-9f9b526fa874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_fee378a5-df16-41d5-a64d-a27d693c574a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_fee378a5-df16-41d5-a64d-a27d693c574a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_1779bad0-fde2-414c-9c51-21cb6ce7e258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_1779bad0-fde2-414c-9c51-21cb6ce7e258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_c57b2a9d-79af-437d-a323-60932561e086" xlink:href="mrna-20211231.xsd#mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount_c57b2a9d-79af-437d-a323-60932561e086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ce92456b-7b7b-4f45-a555-7cc17ae0b6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ce92456b-7b7b-4f45-a555-7cc17ae0b6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0463c0cf-365b-4b45-85f7-15d68f6501a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_SharePrice_0463c0cf-365b-4b45-85f7-15d68f6501a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_34eb5ecb-461d-43b0-938a-d4fc40992aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_34eb5ecb-461d-43b0-938a-d4fc40992aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_79ba24a8-4ccc-4d52-8cbf-919f58d34634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_79ba24a8-4ccc-4d52-8cbf-919f58d34634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d26e86e3-1df3-431e-8996-646c83651cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d26e86e3-1df3-431e-8996-646c83651cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_81d3cb20-2d58-4c20-a2fc-c8f562395946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_81d3cb20-2d58-4c20-a2fc-c8f562395946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_58790655-1951-4894-b373-c356e132e6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_58790655-1951-4894-b373-c356e132e6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_07a4dd3d-e838-4ab2-8627-4a18aa933d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_07a4dd3d-e838-4ab2-8627-4a18aa933d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2599e03d-657d-4da9-af51-bc11ed1f3cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_2599e03d-657d-4da9-af51-bc11ed1f3cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_804b6afa-0aba-43f2-9984-74a4b065f3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_45a04021-cb0c-4cb8-b326-9cb96b84f21e" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_804b6afa-0aba-43f2-9984-74a4b065f3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockBasedCompensationOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_689da3b5-57a9-458d-8ea8-0eaa3c766b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_648f65cf-98e9-4032-b628-d1d5a1e15dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_689da3b5-57a9-458d-8ea8-0eaa3c766b79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_648f65cf-98e9-4032-b628-d1d5a1e15dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_61885e02-04a9-49d2-aeb4-9eddb63a01ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_648f65cf-98e9-4032-b628-d1d5a1e15dfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_61885e02-04a9-49d2-aeb4-9eddb63a01ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5e6a95dc-fd50-4865-85d5-84e1442f2b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_648f65cf-98e9-4032-b628-d1d5a1e15dfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5e6a95dc-fd50-4865-85d5-84e1442f2b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62990e70-9f86-49d4-9833-5b1049058147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_648f65cf-98e9-4032-b628-d1d5a1e15dfd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_62990e70-9f86-49d4-9833-5b1049058147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5de06d6e-2575-4fd3-8066-814505bfa96e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_648f65cf-98e9-4032-b628-d1d5a1e15dfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5de06d6e-2575-4fd3-8066-814505bfa96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad04b5ac-8853-4863-b003-32e23f86e866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_648f65cf-98e9-4032-b628-d1d5a1e15dfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ad04b5ac-8853-4863-b003-32e23f86e866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b31b8df3-d21c-4e83-9b2c-f73220e870ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_689da3b5-57a9-458d-8ea8-0eaa3c766b79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b31b8df3-d21c-4e83-9b2c-f73220e870ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b632240e-c5a9-40bc-8040-7d42b0a8d0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b31b8df3-d21c-4e83-9b2c-f73220e870ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b632240e-c5a9-40bc-8040-7d42b0a8d0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7b5d7815-cb17-4a97-bf5c-a9558743e63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b31b8df3-d21c-4e83-9b2c-f73220e870ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7b5d7815-cb17-4a97-bf5c-a9558743e63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ed9f9c9d-1574-42c8-bad7-08eb2932ce57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b31b8df3-d21c-4e83-9b2c-f73220e870ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ed9f9c9d-1574-42c8-bad7-08eb2932ce57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4a5747bc-b7fd-4eaf-93cc-4a7eee2bfeac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b31b8df3-d21c-4e83-9b2c-f73220e870ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4a5747bc-b7fd-4eaf-93cc-4a7eee2bfeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0fd6ec13-431d-42c2-982c-df6e00485b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b31b8df3-d21c-4e83-9b2c-f73220e870ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0fd6ec13-431d-42c2-982c-df6e00485b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0cf5c781-fb8c-400f-a027-eb2085500fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_689da3b5-57a9-458d-8ea8-0eaa3c766b79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0cf5c781-fb8c-400f-a027-eb2085500fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_17e4f59b-94ef-4757-a454-21f87f8f3a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0cf5c781-fb8c-400f-a027-eb2085500fa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_17e4f59b-94ef-4757-a454-21f87f8f3a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8d6ea599-78d5-4555-8aa2-f79ee637e959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0cf5c781-fb8c-400f-a027-eb2085500fa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8d6ea599-78d5-4555-8aa2-f79ee637e959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_73212532-697a-45d3-9fb2-d6e8ec6c7296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0cf5c781-fb8c-400f-a027-eb2085500fa9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_73212532-697a-45d3-9fb2-d6e8ec6c7296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_733379ca-a3c7-4ab5-8b56-7eae21185a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0cf5c781-fb8c-400f-a027-eb2085500fa9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_733379ca-a3c7-4ab5-8b56-7eae21185a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6ae6453c-4d26-4a37-b8f5-60d4a1dc9f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0cf5c781-fb8c-400f-a027-eb2085500fa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6ae6453c-4d26-4a37-b8f5-60d4a1dc9f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_05b24cca-3cc6-4414-ba63-9ae70533bc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0cf5c781-fb8c-400f-a027-eb2085500fa9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_05b24cca-3cc6-4414-ba63-9ae70533bc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_6184ca9e-97fb-402b-a641-6de8b8734f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_689da3b5-57a9-458d-8ea8-0eaa3c766b79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_6184ca9e-97fb-402b-a641-6de8b8734f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8297ab2c-b29e-476b-b55c-2a623c11254a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_6184ca9e-97fb-402b-a641-6de8b8734f70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8297ab2c-b29e-476b-b55c-2a623c11254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_885fd5a3-213b-47df-b24e-11a538bb21c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_6184ca9e-97fb-402b-a641-6de8b8734f70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_885fd5a3-213b-47df-b24e-11a538bb21c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_35955e9d-54ca-467d-b54b-636509e0cec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_6184ca9e-97fb-402b-a641-6de8b8734f70" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_35955e9d-54ca-467d-b54b-636509e0cec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0353f8a0-ac5c-4f54-88b3-d944e26a9bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_6184ca9e-97fb-402b-a641-6de8b8734f70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0353f8a0-ac5c-4f54-88b3-d944e26a9bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a28910c-7341-4e61-869d-53bf9a04dd46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3797460a-7935-4f2b-8f47-e9010bf5d93c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a28910c-7341-4e61-869d-53bf9a04dd46" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3797460a-7935-4f2b-8f47-e9010bf5d93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da170505-09eb-4986-8807-bf24740306e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3797460a-7935-4f2b-8f47-e9010bf5d93c" xlink:to="loc_us-gaap_AwardTypeAxis_da170505-09eb-4986-8807-bf24740306e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd893b80-4470-40a4-ae0b-4b1e1f91a902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_da170505-09eb-4986-8807-bf24740306e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd893b80-4470-40a4-ae0b-4b1e1f91a902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_dc1a2afb-6d7c-4518-8cfd-f7d461184961" xlink:href="mrna-20211231.xsd#mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd893b80-4470-40a4-ae0b-4b1e1f91a902" xlink:to="loc_mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember_dc1a2afb-6d7c-4518-8cfd-f7d461184961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d414a316-ea11-43f5-bdd0-031918934dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3797460a-7935-4f2b-8f47-e9010bf5d93c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d414a316-ea11-43f5-bdd0-031918934dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d414a316-ea11-43f5-bdd0-031918934dc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_88135190-f471-4e5f-9f61-5a5d2d132638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_88135190-f471-4e5f-9f61-5a5d2d132638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_333ead9b-074a-4257-8504-d0f6dac0c27b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_333ead9b-074a-4257-8504-d0f6dac0c27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_297fdd31-1b2f-4b05-ad6b-cdbee7f0fd19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_297fdd31-1b2f-4b05-ad6b-cdbee7f0fd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_25c64f38-d6bc-41f7-ae93-200c5200f132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_25c64f38-d6bc-41f7-ae93-200c5200f132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29caab40-d70a-4193-8730-d7e9fa0e55a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d498715f-5c51-4893-9cec-638f27fbf500" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29caab40-d70a-4193-8730-d7e9fa0e55a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d414a316-ea11-43f5-bdd0-031918934dc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_09822c33-bc43-4e63-8156-23b57b3d51d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_09822c33-bc43-4e63-8156-23b57b3d51d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84de06f3-af7f-4137-b6f2-bef05fdbd9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84de06f3-af7f-4137-b6f2-bef05fdbd9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6910a7ad-f136-4b42-bf04-fe788b97d221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6910a7ad-f136-4b42-bf04-fe788b97d221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ba32eb8c-e0da-464b-9680-abaa26d79052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ba32eb8c-e0da-464b-9680-abaa26d79052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f07e0b3c-8e1c-43f5-85f9-3054721923a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d10187fa-8283-4e8d-a6d2-54ca509e622b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f07e0b3c-8e1c-43f5-85f9-3054721923a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5306b81-eaf4-483b-b013-bbf583a170a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f09a93-8359-4cbc-aee0-c4e7ca46619f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a5306b81-eaf4-483b-b013-bbf583a170a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f09a93-8359-4cbc-aee0-c4e7ca46619f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a47a26c5-5f2d-4549-8fe4-8833d80d19e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f09a93-8359-4cbc-aee0-c4e7ca46619f" xlink:to="loc_us-gaap_AwardTypeAxis_a47a26c5-5f2d-4549-8fe4-8833d80d19e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_128925d9-0424-4313-88a9-895128f22efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a47a26c5-5f2d-4549-8fe4-8833d80d19e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_128925d9-0424-4313-88a9-895128f22efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3c546305-ea7d-4af2-9384-3b2919487e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_128925d9-0424-4313-88a9-895128f22efc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3c546305-ea7d-4af2-9384-3b2919487e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5623ab5f-bc49-4eef-8ead-156147a8a7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_128925d9-0424-4313-88a9-895128f22efc" xlink:to="loc_us-gaap_EmployeeStockMember_5623ab5f-bc49-4eef-8ead-156147a8a7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9deb6c08-4076-404c-9056-bc59ce2aad4b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f09a93-8359-4cbc-aee0-c4e7ca46619f" xlink:to="loc_srt_RangeAxis_9deb6c08-4076-404c-9056-bc59ce2aad4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac74f7e8-afaa-440e-9fb3-76cb958361a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9deb6c08-4076-404c-9056-bc59ce2aad4b" xlink:to="loc_srt_RangeMember_ac74f7e8-afaa-440e-9fb3-76cb958361a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_9f754b1e-9a20-44c7-8f22-340566dd6936" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac74f7e8-afaa-440e-9fb3-76cb958361a0" xlink:to="loc_srt_WeightedAverageMember_9f754b1e-9a20-44c7-8f22-340566dd6936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_76f09a93-8359-4cbc-aee0-c4e7ca46619f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_682ad0df-9b3d-486c-8c42-8c6d96fe90b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_682ad0df-9b3d-486c-8c42-8c6d96fe90b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cfacaf83-9639-419f-b28f-83b893653454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cfacaf83-9639-419f-b28f-83b893653454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d151e7fd-476c-481f-9701-b00c9569418e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_d151e7fd-476c-481f-9701-b00c9569418e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_86bb7c94-9c0e-49a8-9fc1-b3dc3da48be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_86bb7c94-9c0e-49a8-9fc1-b3dc3da48be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7cb5fc89-2fee-4d58-ab5a-877551c8fe34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_702fc2ad-bbb7-4194-af0b-169c82b96890" xlink:to="loc_us-gaap_SharePrice_7cb5fc89-2fee-4d58-ab5a-877551c8fe34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87f44728-b145-491a-9921-1a13a5d824a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6b50a278-9f7d-4725-8b2b-7e400708c1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87f44728-b145-491a-9921-1a13a5d824a2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6b50a278-9f7d-4725-8b2b-7e400708c1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df14149d-fc98-4714-9f86-b4433c34240b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6b50a278-9f7d-4725-8b2b-7e400708c1b3" xlink:to="loc_us-gaap_AwardTypeAxis_df14149d-fc98-4714-9f86-b4433c34240b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac17743e-9cc6-48f0-a4dc-cb9ad6b5fe46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_df14149d-fc98-4714-9f86-b4433c34240b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac17743e-9cc6-48f0-a4dc-cb9ad6b5fe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_68ee2d40-39f5-4016-b4c0-d8acda561cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac17743e-9cc6-48f0-a4dc-cb9ad6b5fe46" xlink:to="loc_us-gaap_EmployeeStockOptionMember_68ee2d40-39f5-4016-b4c0-d8acda561cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember_d31c746b-acd3-4174-bf52-8fd85db54779" xlink:href="mrna-20211231.xsd#mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac17743e-9cc6-48f0-a4dc-cb9ad6b5fe46" xlink:to="loc_mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember_d31c746b-acd3-4174-bf52-8fd85db54779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_c742ff62-16d2-42b7-9ac3-c6811f3b4ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac17743e-9cc6-48f0-a4dc-cb9ad6b5fe46" xlink:to="loc_us-gaap_EmployeeStockMember_c742ff62-16d2-42b7-9ac3-c6811f3b4ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cf16d54d-658d-4396-825f-d7e2371cf181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6b50a278-9f7d-4725-8b2b-7e400708c1b3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cf16d54d-658d-4396-825f-d7e2371cf181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cbac6e12-a666-465b-a0a4-745eba4d9f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cf16d54d-658d-4396-825f-d7e2371cf181" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cbac6e12-a666-465b-a0a4-745eba4d9f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_05b5c91f-3885-4250-83d5-49b8512e9cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cbac6e12-a666-465b-a0a4-745eba4d9f54" xlink:to="loc_us-gaap_CostOfSalesMember_05b5c91f-3885-4250-83d5-49b8512e9cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dacd55b4-49e3-4e1d-b8cf-e8ba39998561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cbac6e12-a666-465b-a0a4-745eba4d9f54" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dacd55b4-49e3-4e1d-b8cf-e8ba39998561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3fd534bc-520f-4b71-b15c-7282c4346094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cbac6e12-a666-465b-a0a4-745eba4d9f54" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3fd534bc-520f-4b71-b15c-7282c4346094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_629a426d-405f-47b9-9656-7d102f9ef262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6b50a278-9f7d-4725-8b2b-7e400708c1b3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_629a426d-405f-47b9-9656-7d102f9ef262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_42d0717d-5496-4760-8e64-7c043981723b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_629a426d-405f-47b9-9656-7d102f9ef262" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_42d0717d-5496-4760-8e64-7c043981723b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mrna-20211231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a91e157a-c457-4410-9113-6a3b9c99b84e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c35c6f1b-1361-4c48-9e56-fe9028ea7879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a91e157a-c457-4410-9113-6a3b9c99b84e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c35c6f1b-1361-4c48-9e56-fe9028ea7879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ca0ed585-9e5b-45e6-8106-94ae5b5a8d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_8bdbae81-6b51-40d9-8c6e-5abfec010c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ca0ed585-9e5b-45e6-8106-94ae5b5a8d44" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_8bdbae81-6b51-40d9-8c6e-5abfec010c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_6aeb4819-d55a-495b-a1c6-799bfc108a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ca0ed585-9e5b-45e6-8106-94ae5b5a8d44" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_6aeb4819-d55a-495b-a1c6-799bfc108a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_97d88db5-c92e-43d8-9cfe-2f08ee26687d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ca0ed585-9e5b-45e6-8106-94ae5b5a8d44" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_97d88db5-c92e-43d8-9cfe-2f08ee26687d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9380a5e8-90f5-43e0-b98a-00fb85a5060d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ca0ed585-9e5b-45e6-8106-94ae5b5a8d44" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9380a5e8-90f5-43e0-b98a-00fb85a5060d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusAxis_4eaee679-30b0-4f2c-a566-902d7ee01050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanFundingStatusAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9380a5e8-90f5-43e0-b98a-00fb85a5060d" xlink:to="loc_us-gaap_RetirementPlanFundingStatusAxis_4eaee679-30b0-4f2c-a566-902d7ee01050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanFundingStatusDomain_f41ff20f-01fc-4d04-8e9d-21dd451df46a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanFundingStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanFundingStatusAxis_4eaee679-30b0-4f2c-a566-902d7ee01050" xlink:to="loc_us-gaap_RetirementPlanFundingStatusDomain_f41ff20f-01fc-4d04-8e9d-21dd451df46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfundedPlanMember_c61c8f7e-9f23-4ad2-a689-55379137bbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfundedPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanFundingStatusDomain_f41ff20f-01fc-4d04-8e9d-21dd451df46a" xlink:to="loc_us-gaap_UnfundedPlanMember_c61c8f7e-9f23-4ad2-a689-55379137bbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_206f5ad0-216a-46c1-a8c6-6f25b3d8f12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9380a5e8-90f5-43e0-b98a-00fb85a5060d" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_206f5ad0-216a-46c1-a8c6-6f25b3d8f12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_d5d6ea99-50ef-4081-978e-8b2757b5ef62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_206f5ad0-216a-46c1-a8c6-6f25b3d8f12a" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_d5d6ea99-50ef-4081-978e-8b2757b5ef62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_541070db-3367-4623-9cdb-11adf7ea776f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2206871e-173b-4add-8b57-8ad42685ee57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_541070db-3367-4623-9cdb-11adf7ea776f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2206871e-173b-4add-8b57-8ad42685ee57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_49476662-209a-4e5d-95fc-d8e8698894d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4ca00bd8-69b5-4e56-aa0d-22c9112f4332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49476662-209a-4e5d-95fc-d8e8698894d2" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4ca00bd8-69b5-4e56-aa0d-22c9112f4332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_04b0ed57-bc11-409c-ab54-bf382bb051cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49476662-209a-4e5d-95fc-d8e8698894d2" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_04b0ed57-bc11-409c-ab54-bf382bb051cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e3787713-767b-4695-bfc6-585bac2242c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49476662-209a-4e5d-95fc-d8e8698894d2" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e3787713-767b-4695-bfc6-585bac2242c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7557aedb-6c8c-43ba-bb24-a466baf6f30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49476662-209a-4e5d-95fc-d8e8698894d2" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7557aedb-6c8c-43ba-bb24-a466baf6f30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_afbd46fe-8835-4e76-ba4b-a0b2fc86125c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49476662-209a-4e5d-95fc-d8e8698894d2" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_afbd46fe-8835-4e76-ba4b-a0b2fc86125c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_bd078d6b-d9f7-4ee6-8842-7aded3a78892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49476662-209a-4e5d-95fc-d8e8698894d2" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_bd078d6b-d9f7-4ee6-8842-7aded3a78892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_50c2788f-d383-4d48-8116-d87c66120b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_12277585-5641-42f6-985e-50d1fcc09255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50c2788f-d383-4d48-8116-d87c66120b99" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_12277585-5641-42f6-985e-50d1fcc09255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8f939ec6-c19c-4813-b685-01243ee70583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50c2788f-d383-4d48-8116-d87c66120b99" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8f939ec6-c19c-4813-b685-01243ee70583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4c3efc34-858e-4552-9193-b4b370a13a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_50c2788f-d383-4d48-8116-d87c66120b99" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4c3efc34-858e-4552-9193-b4b370a13a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_29f036ea-d0c5-4836-993a-20e735728151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e0436d9a-f452-4cae-be06-38445a39d6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29f036ea-d0c5-4836-993a-20e735728151" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e0436d9a-f452-4cae-be06-38445a39d6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_13e12663-4ad0-4f85-b0e7-607cae1996b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e0436d9a-f452-4cae-be06-38445a39d6cd" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_13e12663-4ad0-4f85-b0e7-607cae1996b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e4f0a371-e6f5-44bc-b4d2-678079c6d820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e0436d9a-f452-4cae-be06-38445a39d6cd" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e4f0a371-e6f5-44bc-b4d2-678079c6d820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_d8f11e1e-960e-40b6-ba7c-c849437e79b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e0436d9a-f452-4cae-be06-38445a39d6cd" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_d8f11e1e-960e-40b6-ba7c-c849437e79b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27ef543b-3552-440f-8849-05a2cf8cff33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e0436d9a-f452-4cae-be06-38445a39d6cd" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_27ef543b-3552-440f-8849-05a2cf8cff33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6ed58c8c-0f97-4165-ac33-1011ee23e93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29f036ea-d0c5-4836-993a-20e735728151" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6ed58c8c-0f97-4165-ac33-1011ee23e93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0a4dfc20-3749-44a8-9b32-6366126f6424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6ed58c8c-0f97-4165-ac33-1011ee23e93a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0a4dfc20-3749-44a8-9b32-6366126f6424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c78d62c7-453a-4bd6-8546-892509bb0c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6ed58c8c-0f97-4165-ac33-1011ee23e93a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c78d62c7-453a-4bd6-8546-892509bb0c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_f49f7174-e677-4d39-bf5b-48bd769b73cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6ed58c8c-0f97-4165-ac33-1011ee23e93a" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_f49f7174-e677-4d39-bf5b-48bd769b73cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9a5e407f-924b-4dfd-8e3d-76c64fec2c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6ed58c8c-0f97-4165-ac33-1011ee23e93a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9a5e407f-924b-4dfd-8e3d-76c64fec2c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8d0400f2-c65d-4b2c-8168-fc419471a2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29f036ea-d0c5-4836-993a-20e735728151" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8d0400f2-c65d-4b2c-8168-fc419471a2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7cd709cc-bcf1-4697-ae85-cc11a67de4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9de00ce0-83bc-47d7-b5bd-c93dd7610293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7cd709cc-bcf1-4697-ae85-cc11a67de4fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9de00ce0-83bc-47d7-b5bd-c93dd7610293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fd73ff91-11f7-4c55-b0ba-5e12fb83e3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7cd709cc-bcf1-4697-ae85-cc11a67de4fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fd73ff91-11f7-4c55-b0ba-5e12fb83e3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_b48925b7-96c4-468f-bfcc-f27ed9030b23" xlink:href="mrna-20211231.xsd#mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7cd709cc-bcf1-4697-ae85-cc11a67de4fa" xlink:to="loc_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent_b48925b7-96c4-468f-bfcc-f27ed9030b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_6b8a068e-91ef-43bd-a9d0-bdadb62c4194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7cd709cc-bcf1-4697-ae85-cc11a67de4fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_6b8a068e-91ef-43bd-a9d0-bdadb62c4194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_77215e60-c584-4da5-aef2-9e447698d41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7cd709cc-bcf1-4697-ae85-cc11a67de4fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_77215e60-c584-4da5-aef2-9e447698d41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7c1e3f2a-e1d9-4d60-a323-d71596e7554b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7cd709cc-bcf1-4697-ae85-cc11a67de4fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7c1e3f2a-e1d9-4d60-a323-d71596e7554b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_cc41e38d-9fc2-47bf-ae0b-4ebb10be9f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7cd709cc-bcf1-4697-ae85-cc11a67de4fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_cc41e38d-9fc2-47bf-ae0b-4ebb10be9f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_39e5fae8-9634-4eca-bfaf-dd91c8c05b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7cd709cc-bcf1-4697-ae85-cc11a67de4fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_39e5fae8-9634-4eca-bfaf-dd91c8c05b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_352c9e66-f630-4ac2-b0ad-1bc1cae57e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7cd709cc-bcf1-4697-ae85-cc11a67de4fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_352c9e66-f630-4ac2-b0ad-1bc1cae57e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dfce50f8-a863-432d-bcee-45c14081c07a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dfce50f8-a863-432d-bcee-45c14081c07a" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f223dda1-9dca-49ff-a04b-39992d4365aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f223dda1-9dca-49ff-a04b-39992d4365aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_078d843f-1616-4aaf-8a74-0107710dac88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_078d843f-1616-4aaf-8a74-0107710dac88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_a44f3f78-ad3b-4725-b811-2eda3ce73ca3" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:to="loc_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts_a44f3f78-ad3b-4725-b811-2eda3ce73ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_989aaf7d-ac7d-4268-8ed6-339130518cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_989aaf7d-ac7d-4268-8ed6-339130518cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_39158e8a-f4a8-4ab8-b16a-8f2c74f61135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_39158e8a-f4a8-4ab8-b16a-8f2c74f61135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability_c0804cbe-5b73-49b1-9f48-d992b6d09e6b" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:to="loc_mrna_DeferredTaxAssetsOperatingLeaseLiability_c0804cbe-5b73-49b1-9f48-d992b6d09e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxAssetsFinancingLeaseLiability_4e9d417b-0dcd-407f-a0bf-3219fff3b542" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxAssetsFinancingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:to="loc_mrna_DeferredTaxAssetsFinancingLeaseLiability_4e9d417b-0dcd-407f-a0bf-3219fff3b542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_58a47e92-1532-4b75-963c-c4765ce91766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_58a47e92-1532-4b75-963c-c4765ce91766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_9d871b52-a775-40aa-8eb9-30b83c72c0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_9d871b52-a775-40aa-8eb9-30b83c72c0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_95f20bfb-b9cb-4793-8f57-26bace3d2d00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_95f20bfb-b9cb-4793-8f57-26bace3d2d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1197989b-3ff6-4fdf-a6d4-b6386753a21b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_215d00ed-4da9-484f-9b21-92b9f313b05d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1197989b-3ff6-4fdf-a6d4-b6386753a21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_adf619f8-aeaf-488d-9531-40b0ac6c53ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dfce50f8-a863-432d-bcee-45c14081c07a" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_adf619f8-aeaf-488d-9531-40b0ac6c53ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_f934c03a-973b-4f28-9334-c5e8be3070c7" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_adf619f8-aeaf-488d-9531-40b0ac6c53ae" xlink:to="loc_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset_f934c03a-973b-4f28-9334-c5e8be3070c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_61f5c418-e2be-4a0b-a898-b88e2522a0e3" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_adf619f8-aeaf-488d-9531-40b0ac6c53ae" xlink:to="loc_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_61f5c418-e2be-4a0b-a898-b88e2522a0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_68d4f1fb-4560-429b-a03d-0db0b472714e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_adf619f8-aeaf-488d-9531-40b0ac6c53ae" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_68d4f1fb-4560-429b-a03d-0db0b472714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d5826c7f-0f23-443e-ad2f-85fcd3a6dfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_adf619f8-aeaf-488d-9531-40b0ac6c53ae" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d5826c7f-0f23-443e-ad2f-85fcd3a6dfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3d4d4f83-8d47-4be0-aa8b-d137d3a4efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_adf619f8-aeaf-488d-9531-40b0ac6c53ae" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3d4d4f83-8d47-4be0-aa8b-d137d3a4efe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_17df6abd-ed43-4c80-9741-a656091931a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dfce50f8-a863-432d-bcee-45c14081c07a" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_17df6abd-ed43-4c80-9741-a656091931a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e2a963a2-072d-442d-97c3-01ea514f4907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_db0b27dd-0a69-4307-936b-b3ea0322f4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e2a963a2-072d-442d-97c3-01ea514f4907" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_db0b27dd-0a69-4307-936b-b3ea0322f4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_b61b680e-d3c2-4c89-9157-9a467397ac50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e2a963a2-072d-442d-97c3-01ea514f4907" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_b61b680e-d3c2-4c89-9157-9a467397ac50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8ca59c6e-8f41-40f7-a13a-d692d1aeb9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b61b680e-d3c2-4c89-9157-9a467397ac50" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8ca59c6e-8f41-40f7-a13a-d692d1aeb9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4c037290-5530-45f3-9308-57ec8c82288a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8ca59c6e-8f41-40f7-a13a-d692d1aeb9f4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4c037290-5530-45f3-9308-57ec8c82288a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_b28b6754-0f33-48c0-b33e-d2bd7ad55e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4c037290-5530-45f3-9308-57ec8c82288a" xlink:to="loc_us-gaap_DomesticCountryMember_b28b6754-0f33-48c0-b33e-d2bd7ad55e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_7c055964-d99e-473f-9c4a-3e7059af2563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b61b680e-d3c2-4c89-9157-9a467397ac50" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_7c055964-d99e-473f-9c4a-3e7059af2563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_9b2e2a75-7d04-4a9c-ac5b-aead607074df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_7c055964-d99e-473f-9c4a-3e7059af2563" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_9b2e2a75-7d04-4a9c-ac5b-aead607074df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_6b2aaba6-352b-4cfb-a4f1-1b703d90dd85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_9b2e2a75-7d04-4a9c-ac5b-aead607074df" xlink:to="loc_us-gaap_ResearchMember_6b2aaba6-352b-4cfb-a4f1-1b703d90dd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b61b680e-d3c2-4c89-9157-9a467397ac50" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cba6d5b7-c6d6-4ea1-8c0e-69189008a154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_cba6d5b7-c6d6-4ea1-8c0e-69189008a154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f1748967-bff7-4b8c-b1f0-8b0daf4aa9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f1748967-bff7-4b8c-b1f0-8b0daf4aa9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_997c31c2-9675-470e-b977-3fabefe2334f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_997c31c2-9675-470e-b977-3fabefe2334f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_UnrecognizedTaxBenefitsNet_5efd3d03-c7a7-40cb-8cd8-599dfeabee43" xlink:href="mrna-20211231.xsd#mrna_UnrecognizedTaxBenefitsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6469b861-18dd-4aa8-bf46-e1847b185a04" xlink:to="loc_mrna_UnrecognizedTaxBenefitsNet_5efd3d03-c7a7-40cb-8cd8-599dfeabee43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_169cde5c-03d9-4eea-947e-661d13dc75b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_DeferredTaxValuationAllowanceRollForward_c2ec5093-bef8-4001-bb42-ce173ebf4cfa" xlink:href="mrna-20211231.xsd#mrna_DeferredTaxValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_169cde5c-03d9-4eea-947e-661d13dc75b1" xlink:to="loc_mrna_DeferredTaxValuationAllowanceRollForward_c2ec5093-bef8-4001-bb42-ce173ebf4cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ce127404-54cf-43ba-96ef-ca0b82ac8734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DeferredTaxValuationAllowanceRollForward_c2ec5093-bef8-4001-bb42-ce173ebf4cfa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ce127404-54cf-43ba-96ef-ca0b82ac8734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount_dd39ab0d-14b5-422b-b0fe-ccfc07594c26" xlink:href="mrna-20211231.xsd#mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DeferredTaxValuationAllowanceRollForward_c2ec5093-bef8-4001-bb42-ce173ebf4cfa" xlink:to="loc_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount_dd39ab0d-14b5-422b-b0fe-ccfc07594c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_170a5e2d-4e37-494c-8090-1137c7292d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DeferredTaxValuationAllowanceRollForward_c2ec5093-bef8-4001-bb42-ce173ebf4cfa" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_170a5e2d-4e37-494c-8090-1137c7292d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_88f381bc-5141-47ca-bc8e-0e3df778b9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrna_DeferredTaxValuationAllowanceRollForward_c2ec5093-bef8-4001-bb42-ce173ebf4cfa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_88f381bc-5141-47ca-bc8e-0e3df778b9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d2533cc0-9a8c-40a2-92ce-ad0279fda8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3886a174-e9d9-4328-9b35-7e115f9bc3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d2533cc0-9a8c-40a2-92ce-ad0279fda8a6" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3886a174-e9d9-4328-9b35-7e115f9bc3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1770a820-d0ee-4c5e-acc9-b8d6b30861d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3886a174-e9d9-4328-9b35-7e115f9bc3c7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1770a820-d0ee-4c5e-acc9-b8d6b30861d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ff4745ce-08aa-41ad-abe9-09dddb697e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3886a174-e9d9-4328-9b35-7e115f9bc3c7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ff4745ce-08aa-41ad-abe9-09dddb697e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_525159b1-ae46-4a12-81d6-85aea7a0d442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3886a174-e9d9-4328-9b35-7e115f9bc3c7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_525159b1-ae46-4a12-81d6-85aea7a0d442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f2c5389f-0beb-4186-8bee-8a3832600718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3886a174-e9d9-4328-9b35-7e115f9bc3c7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f2c5389f-0beb-4186-8bee-8a3832600718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShare" xlink:type="simple" xlink:href="mrna-20211231.xsd#EarningsLossperShare"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_604005c6-5c0a-4f4a-8643-f9f3ad944215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_28e5dd2c-7666-45c0-acc8-678aebe185f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_604005c6-5c0a-4f4a-8643-f9f3ad944215" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_28e5dd2c-7666-45c0-acc8-678aebe185f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShareTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#EarningsLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_60dac090-6dce-4eed-9d1d-8c786183cd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e1a07a49-a238-4478-81bb-feb20ba8767b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60dac090-6dce-4eed-9d1d-8c786183cd1b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e1a07a49-a238-4478-81bb-feb20ba8767b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_725b00a8-e51b-40d3-9f11-ae8339ea53bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60dac090-6dce-4eed-9d1d-8c786183cd1b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_725b00a8-e51b-40d3-9f11-ae8339ea53bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b279af0c-c7b2-4391-8446-31c0506a9433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5cb4b106-7827-40b0-a735-b3b70be75834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b279af0c-c7b2-4391-8446-31c0506a9433" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5cb4b106-7827-40b0-a735-b3b70be75834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_426a2d50-1f3a-4a6a-a6ea-464f0300e2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5cb4b106-7827-40b0-a735-b3b70be75834" xlink:to="loc_us-gaap_NetIncomeLoss_426a2d50-1f3a-4a6a-a6ea-464f0300e2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9d75979a-4029-4bb2-b668-165d6c792156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b279af0c-c7b2-4391-8446-31c0506a9433" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_9d75979a-4029-4bb2-b668-165d6c792156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f838bd3e-8bfe-4932-b50b-b6cfa04cf8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b279af0c-c7b2-4391-8446-31c0506a9433" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f838bd3e-8bfe-4932-b50b-b6cfa04cf8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c0ff5453-83b9-44a0-9964-d4d6001c44c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b279af0c-c7b2-4391-8446-31c0506a9433" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c0ff5453-83b9-44a0-9964-d4d6001c44c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ee7a7215-6d4c-4cd3-b814-8530d8ffa49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b279af0c-c7b2-4391-8446-31c0506a9433" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ee7a7215-6d4c-4cd3-b814-8530d8ffa49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7f258642-0c83-49cf-b250-e17566be977b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b279af0c-c7b2-4391-8446-31c0506a9433" xlink:to="loc_us-gaap_EarningsPerShareBasic_7f258642-0c83-49cf-b250-e17566be977b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_797be862-3105-4770-b12d-8020b5180687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b279af0c-c7b2-4391-8446-31c0506a9433" xlink:to="loc_us-gaap_EarningsPerShareDiluted_797be862-3105-4770-b12d-8020b5180687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b15a8539-ea95-412e-a61c-4adfac111fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7c1100-eaa3-48cb-9435-572168e618ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b15a8539-ea95-412e-a61c-4adfac111fce" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7c1100-eaa3-48cb-9435-572168e618ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a38429f2-058d-4d59-918d-9ed4af4a288d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7c1100-eaa3-48cb-9435-572168e618ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a38429f2-058d-4d59-918d-9ed4af4a288d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce2f232e-6f56-49ce-a6a7-0875260ba77f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a38429f2-058d-4d59-918d-9ed4af4a288d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce2f232e-6f56-49ce-a6a7-0875260ba77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1be35f5a-3d88-4dc1-b021-f3dba2ddbe27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce2f232e-6f56-49ce-a6a7-0875260ba77f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1be35f5a-3d88-4dc1-b021-f3dba2ddbe27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a494e5d1-52fc-42f1-ae02-ee7ebb3470a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce2f232e-6f56-49ce-a6a7-0875260ba77f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a494e5d1-52fc-42f1-ae02-ee7ebb3470a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_acea2bd3-5f77-4beb-9d4f-02523412abfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7f7c1100-eaa3-48cb-9435-572168e618ad" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_acea2bd3-5f77-4beb-9d4f-02523412abfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48ff355a-04b7-4a01-8d24-7ef5d7a165a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_acea2bd3-5f77-4beb-9d4f-02523412abfc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_48ff355a-04b7-4a01-8d24-7ef5d7a165a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GeographicInformation" xlink:type="simple" xlink:href="mrna-20211231.xsd#GeographicInformation"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GeographicInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6bac22e7-c967-4f90-8f2d-698020907d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_40172715-deeb-4835-b399-74a7faca54cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6bac22e7-c967-4f90-8f2d-698020907d9a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_40172715-deeb-4835-b399-74a7faca54cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GeographicInformationTables" xlink:type="simple" xlink:href="mrna-20211231.xsd#GeographicInformationTables"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ddec1808-ebdd-4d27-9031-f4c5b9a9a5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_7d83bd64-dcee-44a5-8981-acc442cf9211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ddec1808-ebdd-4d27-9031-f4c5b9a9a5d9" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_7d83bd64-dcee-44a5-8981-acc442cf9211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/GeographicInformationDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#GeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/GeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bca19437-5201-4444-a86d-a8f1c78b7394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_01fb01c7-1134-4593-aefe-4473fda7a933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bca19437-5201-4444-a86d-a8f1c78b7394" xlink:to="loc_us-gaap_NumberOfOperatingSegments_01fb01c7-1134-4593-aefe-4473fda7a933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_fbf7dc5e-fc05-4b2b-97e9-5eceee61dd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bca19437-5201-4444-a86d-a8f1c78b7394" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_fbf7dc5e-fc05-4b2b-97e9-5eceee61dd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ff3aceb2-41b6-46d3-b061-3e36bdc42fb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fbf7dc5e-fc05-4b2b-97e9-5eceee61dd7d" xlink:to="loc_srt_StatementGeographicalAxis_ff3aceb2-41b6-46d3-b061-3e36bdc42fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cfc9b216-862d-4bc0-bbf1-331c8cb92f8b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ff3aceb2-41b6-46d3-b061-3e36bdc42fb2" xlink:to="loc_srt_SegmentGeographicalDomain_cfc9b216-862d-4bc0-bbf1-331c8cb92f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0ac71343-742d-4568-a0f6-9699ca7846ef" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cfc9b216-862d-4bc0-bbf1-331c8cb92f8b" xlink:to="loc_country_US_0ac71343-742d-4568-a0f6-9699ca7846ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_15c42b26-b91b-48f9-96ed-6cee1f7186c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cfc9b216-862d-4bc0-bbf1-331c8cb92f8b" xlink:to="loc_srt_EuropeMember_15c42b26-b91b-48f9-96ed-6cee1f7186c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_RestOfWorldMember_16850390-f6e4-4232-9cac-bebb6c62a29e" xlink:href="mrna-20211231.xsd#mrna_RestOfWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_cfc9b216-862d-4bc0-bbf1-331c8cb92f8b" xlink:to="loc_mrna_RestOfWorldMember_16850390-f6e4-4232-9cac-bebb6c62a29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_39a8c936-35bf-47c7-a55a-5352687798b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fbf7dc5e-fc05-4b2b-97e9-5eceee61dd7d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_39a8c936-35bf-47c7-a55a-5352687798b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4912f020-eb7b-4ba3-87a1-c1f194b7495d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_39a8c936-35bf-47c7-a55a-5352687798b7" xlink:to="loc_us-gaap_Revenues_4912f020-eb7b-4ba3-87a1-c1f194b7495d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_38097c32-9901-4a72-b41c-becc875b62de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_39a8c936-35bf-47c7-a55a-5352687798b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_38097c32-9901-4a72-b41c-becc875b62de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mrna-20211231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_67a61d9e-b295-4d30-960f-90b0b2c6681b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_01923c60-0e26-43fe-b9a2-ab4181a04115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_67a61d9e-b295-4d30-960f-90b0b2c6681b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_01923c60-0e26-43fe-b9a2-ab4181a04115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mrna-20211231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.modernatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_78ed608a-a5c5-4e4a-898b-9c225ff777d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_ec2050e2-4e52-4b2d-bfae-3823f92942f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_78ed608a-a5c5-4e4a-898b-9c225ff777d6" xlink:to="loc_us-gaap_SubsequentEventTable_ec2050e2-4e52-4b2d-bfae-3823f92942f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f9d5f328-3276-44ff-b91c-11bde1e28f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ec2050e2-4e52-4b2d-bfae-3823f92942f3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f9d5f328-3276-44ff-b91c-11bde1e28f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3661cfa5-96ef-461b-b96c-6615d43558f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f9d5f328-3276-44ff-b91c-11bde1e28f5c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3661cfa5-96ef-461b-b96c-6615d43558f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_442d21ba-8348-4e48-a6c7-fc9d26105f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3661cfa5-96ef-461b-b96c-6615d43558f7" xlink:to="loc_us-gaap_SubsequentEventMember_442d21ba-8348-4e48-a6c7-fc9d26105f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_35c317af-944e-423e-9e3a-e86ba012b2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ec2050e2-4e52-4b2d-bfae-3823f92942f3" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_35c317af-944e-423e-9e3a-e86ba012b2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a313988b-40b6-479f-a6a9-273e61d80cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_35c317af-944e-423e-9e3a-e86ba012b2cf" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a313988b-40b6-479f-a6a9-273e61d80cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2021RepurchaseProgramMember_3341a06b-e324-44d3-b021-d4ac2712f2d0" xlink:href="mrna-20211231.xsd#mrna_A2021RepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a313988b-40b6-479f-a6a9-273e61d80cc8" xlink:to="loc_mrna_A2021RepurchaseProgramMember_3341a06b-e324-44d3-b021-d4ac2712f2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_A2022RepurchaseProgramPlanMember_0748417a-10ea-453d-942a-557720db14e6" xlink:href="mrna-20211231.xsd#mrna_A2022RepurchaseProgramPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a313988b-40b6-479f-a6a9-273e61d80cc8" xlink:to="loc_mrna_A2022RepurchaseProgramPlanMember_0748417a-10ea-453d-942a-557720db14e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ec2050e2-4e52-4b2d-bfae-3823f92942f3" xlink:to="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ad29f38e-fd7d-4bad-bf44-a17fd5ad2701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ad29f38e-fd7d-4bad-bf44-a17fd5ad2701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_2ba5cf9f-68bf-4352-ae2e-8913657f9658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_2ba5cf9f-68bf-4352-ae2e-8913657f9658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_628347f8-9bf1-4a7c-8823-97f4252f1bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_628347f8-9bf1-4a7c-8823-97f4252f1bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrna_NumberOfDosesOfVaccineCandidate_bd6c83cb-ee4a-496b-8991-c0bd300a6fb6" xlink:href="mrna-20211231.xsd#mrna_NumberOfDosesOfVaccineCandidate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_mrna_NumberOfDosesOfVaccineCandidate_bd6c83cb-ee4a-496b-8991-c0bd300a6fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_f0570da9-36da-4d50-af68-38c5e5153226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_f0570da9-36da-4d50-af68-38c5e5153226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_b5f4e59b-9409-4272-89a4-01fcb5c73109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_PurchaseObligation_b5f4e59b-9409-4272-89a4-01fcb5c73109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_398db190-a5e1-4d07-a383-b7edb7495256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1ccde306-79c2-4fca-ad6c-4ce2d11d31d8" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_398db190-a5e1-4d07-a383-b7edb7495256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" != 9P# 2(  A$! Q$!_\0
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MKZ,;J*UH_P .)Y/$_P#R.\;_ -?)_F2T445N?-!1110 4444 %%%% !1110
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M7;W]J[X-ZA9RVEQXOM);:96BD1[2X*LK?>7_ %=?G?HGB*T^&/QJ@U?P[?\
MVG2]*U;S;:[3<OG6WF?[?]Z/Y:^LF_X)OZ*5!7QQ?X][!/\ XNC_ (=OZ/\
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MJU?IHI##GM6. C^YYV>]XG5I+-:6$7P0@N4FHHHKT#\A*R)Y4OLU?F3^VO\
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M/X,#\EXFE*EGV,E'[-6?_I9^4?P.\83? /X]64VM(;:&SN9=,U1.RJWRLW_
M6V-_P&OU/B>WO(4D1UEC9=R%3P1]:^/_ -M;]FJY\1R3?$#PU:M-?I&/[4L8
MA\TRK@),J_WU'WO5<UYG^SC^V7>_"_3X?#?BF&;5?#\?RVMU%\TUFO\ =/\
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MCBOF1[ZY!_X^)/\ OJN3+LL>81E)3Y;'=F^<K*Y0BX<W,?6N11D5\BO?W/\
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MKETJ.-C@N8^IPV>1Q&5SS/V>D>;W?0]6R:,FO@=]6NO^?B?_ +^M43ZM=?\
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MU=&6\-K,<-'$1K\O-_=_X)R9SQQ'*,;/!SP_-R_WO_M3]*AZ=AVIDDBHA)&
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M?WOTHWC^]^E?F!_:][_S^7/_ '^:F?VO>_\ /Y<_]_FKZ?\ U'E_T$?^2_\
MVQ\+_P 12A_T"?\ D_\ ]J?IW&ZR' Y3L:E4<5Y[\$HYX/A)X:2XNI+V5[4R
M>=+]X N65?\ @((4>P%=\\A#&OS2I3Y*DJ7\NA^U8&NL;AZ5=1MSQC+[T?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
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MN7RCE"\H:9%A/OT*H]L'3Q8*RUR]AT$KU_#IW/<_234/5+L;!, *NC)>QII
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-$P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" != 9P# 2(  A$! Q$!_\0
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MKZ,;J*UH_P .)Y/$_P#R.\;_ -?)_F2T445N?-!1110 4444 %%%% !1110
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M7;W]J[X-ZA9RVEQXOM);:96BD1[2X*LK?>7_ %=?G?HGB*T^&/QJ@U?P[?\
MVG2]*U;S;:[3<OG6WF?[?]Z/Y:^LF_X)OZ*5!7QQ?X][!/\ XNC_ (=OZ/\
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MJU?IHI##GM6. C^YYV>]XG5I+-:6$7P0@N4FHHHKT#\A*R)Y4OLU?F3^VO\
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M/X,#\EXFE*EGV,E'[-6?_I9^4?P.\83? /X]64VM(;:&SN9=,U1.RJWRLW_
M6V-_P&OU/B>WO(4D1UEC9=R%3P1]:^/_ -M;]FJY\1R3?$#PU:M-?I&/[4L8
MA\TRK@),J_WU'WO5<UYG^SC^V7>_"_3X?#?BF&;5?#\?RVMU%\TUFO\ =/\
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MCBOF1[ZY!_X^)/\ OJN3+LL>81E)3Y;'=F^<K*Y0BX<W,?6N11D5\BO?W/\
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MKETJ.-C@N8^IPV>1Q&5SS/V>D>;W?0]6R:,FO@=]6NO^?B?_ +^M43ZM=?\
M/Q/_ -_6KZ/_ %5G_P _O_)?_MCX_P#U^A_T#_\ D_\ ]H?? <G@C!]*,[@>
M<5\*Z!>WUQK^G1)?7$+M<Q*LB.<K\_UK[)\;V[MX/UQ(IF@E%G+MF3[RG8>1
M7AYGE+RRI3I2GS<WD?69-GTLYH5:L:/+R_WCI,GTHR?2OSW?5KK_ )^)_P#O
MZU,_M:Z_Y^)_^_K5]!_JG/\ Y_?^2_\ VQ\9_P 1$A_T"_\ D_\ ]J?H/O0G
MG@TK<#EN/I7YYG5KP?\ +U/_ -_6K[=^%<<D/P]T SSO=3-:*3*_WB37C9MD
M4LJIPE*IS<WD?4Y!Q++/JTZ:H\G+_>.P R!MIW7/-?!'CVZO+/QCKL?VV>0)
M>R<LYY&ZN<DU>['_ "]3_P#?UJ]FCPE*M2A4]OO_ '?_ +8^6K^(<,/5G2>%
M^'^__P#:GZ,J,#@8I'D5/O&OSB.KW@_Y>I_^_K5]4?LJ":7P3J$]Q<R7(^VE
M420_< 1>!7EYKD$<KP_UB5;F_P"W3V,BXRCGF+^IPH<O_;W_ -J>ZA@XR#D4
M$!N<9_&OE_\ :Y>YL=1T&XAO)XXC%*#;QMM4MNC^;Z\C\J^=I-:O?^?J?_OZ
MU=&6\-K,<-'$1K\O-_=_X)R9SQQ'*,;/!SP_-R_WO_M3]*AZ=AVIDDBHA)&
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M?WOTHWC^]^E?F!_:][_S^7/_ '^:F?VO>_\ /Y<_]_FKZ?\ U'E_T$?^2_\
MVQ\+_P 12A_T"?\ D_\ ]J?IW&ZR' Y3L:E4<5Y[\$HYX/A)X:2XNI+V5[4R
M>=+]X N65?\ @((4>P%=\\A#&OS2I3Y*DJ7\NA^U8&NL;AZ5=1MSQC+[T?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
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MBI.R:$V*HS@I*R$+@T=9,;"5JY?7<Q)+@W)-D9M41FY264(6!G%2%OS*;'E
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8<V'_#R5/.507*Z\S     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_3a.jpg
<TEXT>
begin 644 image_3a.jpg
MB5!.1PT*&@H    -24A$4@  !.(    %" (   !GZM0X    *4E$051X7NW!
M 0T   #"H/=/;0XWH                        .X,24,  8>#E4\
(245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>mrna-20211231_g1.jpg
<TEXT>
begin 644 mrna-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2764&AO=&]S:&]P(#,N,  X0DE-! 0
M     %(< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'
M' (   (  !P"!0 >36]D97)N82!,;V=O($9)3D%,(# Y,3,Q,B!#35E+.$))
M300E       0Z9NJ@=5(@;5'E,83D9_8?#A"24T$.@     !"P   !     !
M       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU
M;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +
M<')I;G1E<DYA;65415A4    % !% %  4P!/ $X ( !7 &\ <@!K $8 ;P!R
M &, 90 @ #@ -  U       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R
M &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT
M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M 0 !.$))300F       .             #^    X0DE-! T       0   !X
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-! H
M      $  #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      S4    &              #E   #XP
M       !                          $              ^,   #E
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #E
M %)G:'1L;VYG   #XP    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    Y0    !29VAT;&]N9P   ^,
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M  P    "/_         X0DE-!!$       $! #A"24T$%       !     4X
M0DE-! P     &ND    !    H    "4   '@  !%8   &LT &  !_]C_X@Q8
M24-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D
M!@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0
M  #3+4A0("
M             !%C<')T   !4    #-D97-C   !A    &QW='!T   !\
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M0S8Q.38V+3(N,0
M                    6%E:(        /-1  $    !%LQ865H@
M             %A96B        !OH@  ./4   .06%E:(        &*9  "W
MA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P
M.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:
M  !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U
M;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M    9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M     $P)5@!0    5Q_G;65A<P         !
M H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X
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M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( "4
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M:M7+^J7U=RL8X[L&FH$0VRE@KL!_>%C!N_STN*<K,0*'?])1PX,?#'-.?N2
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M3X:@8G6.E9MGIXF91?9^Y78USM/Y#3N7'XN=T/K?4\CJ77\NH8]-AJZ=@6O
M:UC?^U%E7YSKOY?_ %'H^G=ZC5]0<VG;3DXF%D-UHR<<MJ<QX^@_]%LW[?Y:
M7NDZ@QKM(^HI/(Q@1#(,W'0XI8\?'BQF7Z/^LX?TWK;+*ZJW66N#*V N>]Q
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M)')$C#D$(@0UGA]@<&$QXOGX8?/^^OU'J6#TS&=DYMK::FCN=2?W:V_2>_\
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M_1;;)GTY+]FV=GTG?NJRC&)'%?4VMSY1D]NK]&..,W^]'B>:^J5;;:^N5/\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %^34T *@    @
M# $   ,    !#Z    $!  ,    ! X8   $"  ,    #    G@$&  ,    !
M  (   $2  ,    !  $   $5  ,    !  ,   $:  4    !    I $;  4
M   !    K $H  ,    !  (   $Q  (    >    M $R  (    4    TH=I
M  0    !    Z    2  "  (  @ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP.#HS," P-SHT,#HU,0     $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   /CH , !     $
M  #E          8! P #     0 &   !&@ %     0   6X!&P %     0
M 78!*  #     0 "   " 0 $     0   7X" @ $     0
M2     $   !(     3A"24T#_0      "      !    _^$!@$U- "H    (
M  P!   #     0^@   ! 0 #     0.&   ! @ #     P   )X!!@ #
M 0 "   !$@ #     0     !%0 #     0 #   !&@ %     0   *0!&P %
M     0   *P!*  #     0 "   !,0 "    '@   +0!,@ "    %    -*'
M:0 $     0   .@   $@  @ "  (   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#@Z,S @,#<Z-# Z-3$
M!)    <    $,#(R,: !  ,    !__\  * "  0    !   #XZ #  0    !
M    Y0         & 0,  P    $ !@   1H !0    $   %N 1L !0    $
M  %V 2@  P    $  @   @$ !     $   %^ @( !     $
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M5R"-+M9\=/8&ZG0B%;+DQ@Q%0$PLSS&LJ,%TB8"]T46;EY8P3 !ZAZJ^"@%
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M'^LGB)HXQS\^(P/LU0B_XY?$?=O&Y%O#'XV+O[EQ]#;. ]A1>>?+ NT;MMT
M]WF6W))Q\7)]=+;WG\!YM6*W)9+V8V*SR$Q7TSRSG$%KD4'\I()-#=\QL?6Q
M)&/<EEFA2=UI!SP.7$B<AO!V!-\#5@[CN:V,8(7L8F26QY:EGISE'E91ZGV>
M0(H=@/40NO>X'NRL_;&UG>B/W0*7*9.KM?K?C<57HY%EIQ[SQ%9Z]6JTP\L?
M?'AV>S$:4Q;LGOX[RHZH8&;'-7,MB#LO!YXF-IRS*%VE;D)EV_RA$,GWV,KO
M8%%BSMO:P*)U):D6M1T'B75PA&39T_82CH0>3$8QD&TH)I>/3<2_U[/W+)99
M,3D'+RE3['8D)+R]BEFKRLQY>0(K/%(26959'/>$,D(\:'A<Q.SZIZP],J4,
M&T[L]?[Z,%CE1L?AIL@X6GG<0L/X*'"7YI8:\]6+F&E:GKR5.*=DQ4Z'M,76
M;^IY.,#Q-+5B:6-M+VUR[IGE.6:,0R5=X ZJLY4$)Q,AXJDU([01<-;I,M%V
MKV0DD"F=0\8_8-HL0F9 [F'7>[MRR5W?$X^1DE"K[99C+"2/O *UX&7WEE*L
MK2R+ZH&6-")"YCT?\&7A;Q.\*@ZP=3Z<4VTJ4U@[8P61"I0S4M!BMO.YA9@(
MY<'1FCE@KU9"(;UJO8DM@T:XBN\9V:<!]&TU^.R=O1LUG9S5C3),I8BJTDFR
MEV!7HBXZLAVY=%^[/,.P4%5["0(-G$<H8 =V%5Z9TQ:?'AMC&:)+&7DE@\P=
MZ4X>U)D!]?Y(E8/V,WJ6BC7O7D=\PD[D6;=;/N@,F*R%G:W0_%XJ6AC6-)MY
M9:JT]2P8 (^-MX:-Z\*TH>WL@O9#S8[*CF'&I (IYF92G!?X>$E#FB4<*R,0
ML*0)DFXO(^1"S"1P  !<JC^ROV!U>8=0@O'K(F'GU(B41+J2OLK -'V"O.A_
MV1+4_>3]9[W="?RH1]FJN5/&]XD:UT7'WS7N('[S1M[:VV:3#_8RM?%U["I\
MO<LHX^(<'UTHK<EP\-P7# LZ.[O97D2T6K'U1637N<#*%(K9J_6SN$C/&ETC
MXHC"+R#CMR8J:<PX1CH]_! 9O)K,4R1Y[(QB63V]D-LRKE<39DEKPD=[$ 30
M(2O*V40+'8JN0.\JB!>5+QCM\\7&Z9>)#ISXJ\4W1KKGMO%8G<>91H\'DJ9:
M/%Y#*"-Q!-@[%LV+>V]R1@L:4;V;-;($25$G9K*XNQF79=F9'</QC\<9M0A5
M:X&2K[;+,O!*N"._5+UUB.R)R#))V0"^*:H/D7!6;DZ:*J[3LJKMVZQSH)\G
M#VFN;KI6V01FSD)YRJMW*K2Q6'*J> 6 Y(!(!X]2.>--/KALB3IOX*=R[%EO
M)DCMC;^'Q:7TC,0N01;RQC5IVA;GRI9*[Q--$&=8IBZ1R2HJR-:]IW:PTU-!
MQ>>(KD-[D'[1K:O(3!;,]=Q]=RE9*:HZ&TRMDGCHI,,3U)RPZ7397MNFQ;6[
MCU1=NG;TM8*LS*QGF[Q8[OW%/).V%QKN "([DD'=YLTS$**<13W^T$A9@GO2
MR'R/14E634/P:^&O;<.W/U>NK5:D<3!#9R6T\9FUB&*JXS'AWL;OS$5CF*5.
M^*7Z(AL)Y,<,!RI2;S\?)#]1M'X!V-XNL1-LW>3TW;+O)((/G.,Z;-FA*G6N
M^F508J;L<>4TW999 P]+US"R,+$(. 6;-3S#8B<DX^C$[$A\E)<O)(9653['
M7=42(<?B2S*"TC@'WA"8XU;E5:5>'/*ZQ?="MSW,I<Q'1K'T<-@:SO!%NC-T
M1>S.3[&*^UT<99(H8NI(/6"*]6O7'C[)912E9JL6X+;P6>'M9X92+88BF:6Z
M%(4T9ZIY!NI)=N;ER!4I;#,V&(<'*/M<GL4Z3$?>00  #M2[*P,B%4AL0-\1
M)%;G9@>./Q9VFC/P^!C(YY/')TB,/XX?$=BKJV[&\Z>;B#<OC\OMS!-3E'/)
M1CCJ..N1J?AS!;B8#X,#R=(SW.['MS'"6O\ ";G=MV1IJRXN9R[=@M9B-A;R
MD D]=)@WJ.6Z^S.6(L%5GSE28IS**2$6\DNR@LPKTN>",\A&3PF2VM8CR-*R
M\D ?M2TBD/'W'D07(@2K1R<!>1Q#*P"E8I#$IOITLZ\=+O&%MZ]TKZG[9HXO
M=DU.2Q%C#+YE3(O!"_FYG9V1F!NXW+XY>^PU%WDMPU>^2.SDJ:Y 04Q['=W=
M1WIX#KV7:Z@E#SJ:RE<R'4@6%92IW>-;ME9./34/R4<13U!TUEX)Z8.IQ%/V
MQ'';D$'S9NR<%F(LW02TJB.9&\JU".?P4Z@$]I/J8Y%99(F]?=;M8^8C@9==
M>.C>9Z'=0LELW)R-=H,BY/;F8*!%S&!LRRI4LLJ^[';A>&6GD(!Z17*\IC[J
M\D$LBFO2*/P&[>?I7L/U06U%.H7ZQB_ZM:^7/_U<6K?_ '-C]OO4?\T,=_CF
M/6 ]AVU7)G%&=TU7-]LG:YM;VK4ZMXJKD)6UO"GFI=G&-UW<-7SNRNV3&7DR
M VGKW9U&;I\1F[@(-@D5$S!Q#1[ XBSN5XEMSR)C<7"M9/+ 'Q]1#!W=R+*X
M'FV9BKD QIV\&(1V%\0/5K:_A1BSB;#Q&/R75GJWFLIN[)W\G'YRT*4]N6."
M[D5A,,]BG5;S<?@,4L\5=IX<C?L,7$\=VBW!W#0V<;<LEP.7,28N6K]XKD%*
M0<9)/;5:+$BEZX039OI@K.PRLF@A.GC_ !<<609@UZ&4G(H]D>^0R3&H[7P^
M.M17*M>19X4=8R\\LJ@NI0R=LC,!($+H". %=O3G@C-;?GBAZU=2]KY#9^\-
MV+DL#D[]2_:JP8G%8UW]B=IH*9FQM2K(]!;'DV37F,O=/5K2%^8R'7/Z1#\F
MW!OTX*?4*TZCG4/^4\9Z\?R9-_!GU9?[FW_-.W[^8:_Y08G2Q\ J;GN)K4,*
M;(\:R;K&&W' M"@DLMV<>^O'2<B5\[>!,6-!JX:_"!XN^$S&A4CQ2;<RL>[L
MDDJAX9PYAXO03*;BCIX2N_D4*2%YV/=Y0#3/+Y]@#M,LG<W96@YX[D+AE(>2
M.TO41.E?A:S.^NNVZ*L.Z^IO4'<.0?9N*YC2Q4JM!#":>->:.7Z.AC@XGW#G
M?*:7LL18NJLGFQQ7'U8OX+NP?'D WBIK%TCE*7!$A'UHR!:["M(O%NV4JJJ4
M?7)"O0,>F8X&.DDTBR*)%$"G76, J&GM;9."@0++#/;DX]Z6:S.A)X]2$K/
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M>53ZCT9H OQ'Q^(U:G$Q4=!149"0[)O'1$-'LXJ+CVB946K".CVR;1BR;(D
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M2N/9<32^BL7DY.9+5;'>:LD<41J5I8BSB4KI_']\,;0O\DVY'^3F,/\ :O\
MV]WOU/\ [_\ &?\ @.1_XM3_ *5]FL\_\S@ZS?[K^F/]D]U?]D-']\,;0O\
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M/+D)8Y["6-+I#SZF/+YP'2ZS;?1F[WM2J?*6]C[Y('), 6NTC ?$]K13(/\
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M ?X[B9EUU!_*910QA_?$=2#:@XV_COZ6P?Z]N<ZK3XJG9_$/U89CR1NB5/\
MU8Z=.-1^A5 'Y-;TU(M5]U_#>X?R#^C7@_ _D.C4@_ D^7OFX/F^PYD;\GX4
ML>Z3FP?V9'_HJ?\ PM'])/Y?EQK9;Q^_SO6P_P ]-L^O_P"D]Q:=CQEJ-(WC
MA\9G]5(*NG=1=TB\'01*)SFCH"X0_KI<0#S[;"%=R$BN;W$0:*''R+SU.MYP
M&; V& Y->:M/]?NK*L;GT_H4D9C]0!)^&J+^"?/5L#XC=C^UR+%#F8L[@1(Y
M"J+.1PMT44Y/[JQ>BK5HP/5I)E4<\\:S?P!,J0=HVE6O%R;MN6SXMR?-N7T:
M!P\5\';NU9S$+*G3$>H47,JVLD>4X!R \8)3  F*)N;L&TDF-M5.1YM>V9>W
MY^39C0H_V\RQSK]@4<@<@:9OW0_:=_$]8L3NIHI#B]V;5H1U[)7\%])8*6:C
M>J*W''?%4DQE@J3R1;Y'H#P]C4\U031HT:X3N?R5#8>VZYLR9/ND6D=4,9V^
M3*9<P%*YDAAG36$C$^?WSF7FG$?%,T_>JZ>(I!YG#7,S-E*>)R-B0\".I,%^
M7=)(ACAC'Q]Z25TC7T_&8:GW2O;%[>?4G8VU\?%)-9S.Z,-4XC')BK>W0RWK
M3<?"*G1CL6YG_<0P2.?1=3N^CC_KEW9_P'AO^?Y)TONG@ N94#Y5*(_NEKU_
MK:TE^Z7_ +%](/W_ +T_@^V=5,::FLG-2"[J?^'SH/T_;3_Z"Q=I/Y3]O*'_
M ,[8;C_]A_'ZOAK9;I+_ *'KN+_\/>KO\/W3JOK3@UC3HT:-22>D1_*!V_?1
M!*?7:3TINH7ID*?[P;^W-(/X\?WN=;#?<VOYG?47\\J?^(ZVJOJO^MFN_P !
M1']'M]-.O_*\']1B_P#<761&5_93)?O^Y_")-?NZ]VO@U/9Z1'\G; _TTO/J
M-/Z7?4+^5<;^^)_\$NM'/N;7\TGJ!^8\/^/L?ID/#!^0%M;^C-K_ $M*ZD>U
M/VOXW^I2?PB;59/%3_/#]6/SIF_@E367N,-L%EMVN)XG)6+(L)#.&'FKX\;#
MH$*#R_49V?Q<Q4FQA,3KFHUT49RL)G,8BZYIB(22%U-MUF_,WA@7R==+M1.^
M[31E:-1R]FL>6,:\>K2Q,6DA7GWN^5 "[H0U?!?XAJ?1W=]S;.[+1K[#WI+7
M6W=<GR=O9Z$>32S,J@-Q1LPGV#*LH!CC%.X[^50DCDQ#PU.,-5Z)4H3;5O)>
MR=0D:$F6J4_*LJPE'")(N*$D>RJ62&::#B7B9>!!,8UK83-3LU&#9%M8"1KQ
M@M*2O%VUNZ*K!'CLL61(!Y=>WVN_9&O"K!90!I%\H\HDH4@( DH7L\QWMXG_
M  7Y;/YB]U0Z)5ZN:J;A8Y?,[2IV*L<AMVP;$^8VS,TD=.[2R)?VJ7'+*)TL
M2/+CS:AL)5J4$1&Y';Q/Q03D)G?#DK#BGW?6;#)E,<L2I\N?4HY2FC))<@^^
M!0Q1+[C  ZGR9;%R)YB9*BT8]2XMP=H_ICYGN_IXUG7<Z9=1\?;-"]L#>E2Z
M&[/9;&U\W%8+<\<+$]$.WV=H(/RYTO#>/QBML>W:L3$9BVVU[/&8%FJB$#7*
M3)IS-.B7RR9@1DK==(PR\(1@Q/\ &+PT*_?SSM0J;,Z$6BN>4:1_+[QQU&)T
MHRQW[A7B,1$O5C9AZ/-.ON.%YY,4+M(QX4F(-YBV0Z*^"WJIU*RM.UNO#Y+I
M_LQ)5DR&4SM1J69MP(P+U<-@[8CO/8G7W8[MVO7Q\*EIQ):>-:DRR.$IL[RE
MN4W O^(-N21DW<.ULTG<:0XGVO86R1DEXJIVK0R9KIAT4ZDF4,K"KM$T6*D\
MTB640J9G7Y%L$7VGAK&2O_3E_O:&.9ITDD'!NW"Q;S . #% Y[^]?<,R1QQ^
M['(JVF\876G:?3#IU6\.?3!ZL-R7%U<-GDQ\WFIMG;,"KW8F>9&/=F\[VA;R
M3,\ZX^:Y/<43Y&M+JJ_38UDCJ4WBZ[*\G;?\ZM]_FV]"6:0SNQ1MRO;BMHF4
M?XSR4Q<)*#<U&S=,QO@I;%DDG,LZ636:-+"M)HRZA&4ZP0!3[LPEC'7CFJ(D
M$$LRV)'B![J5P,',IX![8I7'FB1N56=G20@/$IUO\''7':G438$OAVZG/3EN
M18RUA=OQY-PE?=&V+$;K]!I+(P7Z7PZ.T=*)&2:;')5>FK3X^Q(63[)^,=MT
MW$5>&@<R6FN8+S2V:HM9N+MD@2$HED>HHD*M,5&V2BA(EFV?J\U$ZY/R3699
M+*&8M3S:*)9)Q)L-O&A=BCCR$L5"Z %<R-V59F ]9(IF/9%W$'\#*X93RJO*
M!WFL77/P5]2NFV6O9#9>)R>_=CRS/+0N8>LU[/XR!W8I2S.'J*UR66LGNMDL
M?6EHSHHGE%%W-6-FTIG7",'$FGYG,6+8J#*D"XS$CD"ILHOLB'4"@/W$LFU$
MAB^93 J(&#W<]25LGCD3S'R%)$XY[VM0*O'U]QDX_MZJS4V%OJ_<&/H[,W9<
MOEB@I5=NY>>WW@\%?9XJ;2]P/H1V<@_'2.=^_&"K,S$O]MVQE:4ROEK(AE*6
MID.J1\@YBH$9<QHY=ACXI&Y7UNMSY-11O'2\6B,%$@N2382,H\2*BV@VX-WQ
M31OCL*9)YK/X%K<22>@<E#'34 22SOSVI*J]B]P,32/QV7R\/G@RRE*Y7ZF]
M?(ZNT-F[:"YP;<S%BM%;R(I@68Y]Q<R&##X:!E62S3MN,A<[#5GK587+RJ)X
M=6+;=A/BL84Q9?FS5G=*9;;5&65BT=D?I1\LIB>T/74>+Q'[G<K,3N_".5FQ
MUFIW**HM7#EOVEU8G@(9:^Y,=7G3RY8;DD4D?<#V.D,ZLI*DJ>U@1[K%?0<$
MCUU<GQ*[LP^^O"-OC=NWI)9L)G,1B+>+GFA:O)8I+N_$P16/(?B2)+"P^=%'
M*J3+$Z":.*7NC6Y'3RU@QJ1_B2[;<N</[=U$;[MNC1PA0;)<5+@Y=-&2CF)I
M%^FS.$[=4;0U:"GVZ;D CV048+'.U;J!,2E<24:N648L]46X\9;P&63,8\,M
M>2Q[1%(J@I6LOW&6O*%X_!3=TG8I[5>*5X 04[FV(\,74[9OB)Z.7/#]U+FC
M?<.,PJX:"*:<17,[MZ@L;X?,8J:;N[LWMPPUUL(HED7V*IDG2:*>VD#L-I/%
M6VJ;H*M%GD+Y6\/Y/\,@2PXUR+/L(!=&2$"D5^"U@EC1T1;HQ=7J.R/'+%F"
M-^DTI#QR@] S;%;KQ61C033Q4;? \RO9D$:EO@?(FD[(YE)_% (E X[XUY'-
M&>L/A)ZM]*<O;6OM[*;RVKYKMC=T;:QUC(QR5>2R?2V.IBS=PUJ-.U9UM1FF
MTG/LEVR@+#:-IW!X&H\6I-7#-.*JS%)IF5%_-Y JL:W,4H=0@B=U*I]\XA]X
MD@"BAQ$"D(8P@ ]B7*XR%"\N0I1J/FUJ$?H'O\D_8.2=(_$].NH&=M+1PNR-
MVY6VS!17H;=R]J0$GCWUBJ-Y:C]TS]JJ/5B .=3H\2WB[0F9*S([6MF1IZV?
M9 43J]RR5%1<NU=3S!^N#56CXWB100G9!6PJ"2.E9I5DB1Y&K.(J&9OB20R3
M=>;EW9'?A;&8KS7BG(CGLA'5IU/^EZ\1 E*RGA79D#2*3&D;*Y?6E/A?\'%[
M964K=6>MXQ^&7;BMEL+M>Y;I2Q4+%=/-3/;GN"23'UH\:H-FI16=VBM)';O3
M5S5]EE9_PEMF%LV?;=54,D/I(N2\IR32XVBJ*2;AS#T-LFS[$-66K KI:+3G
MD6ZR[NU2C%(AW<@Y2BCKO&D"Q<J2;:.%FQ%"1[19;5UDFD@[CVP(J\1HR@E3
M8(9FG<>O)2'EA"&:JOC ZW8CK1U+67;->J=K[3JS83$Y=:D45W<$AG\R[E9K
M!B2VV/DD2.'$5+#LL-:)K:QP39"Q$N*/2*/P&[>?I7L/U06UQNH7I!BS_P"6
MM?X.+3T^YL?M]ZC_ )H8[_',>FH<./Y"6U/Z%J;_ # -2C;/[ 8K]Z)_?;52
M_$O_ #?NKGY\YS^$G6U==W2.U/GZ1#\FW!GTX'^H=ITO.H7I4Q?[\E_@[_WM
M:,?<V_YIV_?S#7_*#$Z8[PQ/D";6OHP8_P!)2>I%M3]K^._I)_X5/JLWBG_G
MANK'YUV?X-5UN_4AT@-?P?</Y!_1KP?@?R'^]HU(/P)/E[YO^AS(W]:6/M)S
M8/[-?#_4J?U^O\+2_O?_ #^>MEO'[_.];#_/3;/^2>XM5NV:MPERK=@J-FCF
M\O7+3"RE=GHIV7K:R4--,EXZ38."?LD7;)RL@H'D/0H/(0'STX)H8[$,L$RA
MXIHWBE0_!HY%*NI_*I(UCQB\G>PN3QV8Q=F2GDL5>J9+'VX3VRU;M&>.S5L1
MM\GAGB213_1*-1G6>M;@>";O,&XUR+D+=A6TKOF$,\?&70KN4L:NW@.SU28E
M&R"C6)R'5P205!7PXKLY1HWF4(YW7)=1D]34D61V=F1(BM)"2RQ2/Z17ZA(+
M1.ZCA9U 4L O=%,BRA'@95?;/%9/IUXZ>B0PF3MUL-OO$1P6+L, 23);4W/#
M#Y(R]*I+(LMS;>7[I$*>9V359I*3V(<G32>"F7;GQ'MH>Y>O1\G3\O5:LV1P
M@@,ECW(4O&TVZQ+Y1,#JL@CIAVW;SI$#<R#)5IW,1:@@'2[ XBF5EX_<N'R$
M:E+D5>4@=U:VZ03*Q^0#L$E _HH6D7ZR#Z#+CJ7X:.LG2[)6*F;V;ELGC8Y)
M!5W'MRG:S>"N0(Q5)_:J4,DE R#AA5RD-*VO/K#V\,>U9&W5;:\20SF>R+G3
M%M6CVJ!W D>W2#6DW1"!S$D9",7CJ:EW!N7)-I%Q[QTJ;V4D3F\M?78S.)J(
M9)\C310">!/&\C ?'RXHR\LA_P![&C-]0U!MM=)>IV\+L6/VUL'=F6L2R+$&
MKX/(+5B9CP&M7YH(J-*(?NIK=B"%!ZNX&IH=\V]K)G$^GW>VO:)4[$.#:2VE
M,@Y#M\H@ZB2VF.IS1S*?"*TE$@EK5%AO"'=P,1*<YFQ6$T68\<E+HQ<6DM<_
MG;.XI#2QD$QHUE>U+R"K3+ KNUB?U"Q5XT!,4;GN>4IROG>5$NH?03H7M?PJ
MX^'JAUER^-&_<Y+5VYMK"5)(KC8FSFYHJGT;BB&'TIG[WG"'(7*G%'&XT6P+
M+TWMVWZ)Z./^N7=G_ >&_P"?Y)U]73W^7,K]M6B?[K:_CZ:COW2_]B^D'[_W
MI_!]LZJ8TT]9.:6UD'A?X.R/N_A]Z,S<LIM,EPMQQW=6M?C)6J)4E22QJTK[
M.%;+L750=SAF+Q*NM#29"3Z:ZAUG(M7#0#)%2B]C:M.SF!F7LVUG%FK:\E3!
MY/?4$/EKZPF3L8PJ7]_N]YNUE].+.;=\56_=L]&;O1"EA-IS;7O87<F#ER-J
MIEVSJUMSS9":[+'/%F8J G@;)3"J6Q[1JJ1>;',0Y=DNI1JL>C1HTN?>EPS<
M);Y;C3KME*X90K<I2JTXJ\6WH<I5F#%PQ<2CB6.N^3GZC8EU'0.'!R%,@X;H
M@B4I11$_,XQO-[8J9R>*>S8M0M%#Y(6 P]I4NS]Q\R&0]W+$<@\< <#GGFRO
M0_Q1[ZZ"87-8/:>&VKDZN=RD>5MR;@J9:Q/'/%4CIK' V/S&-C6$QQAB'CD?
MO)(<+PNF&Q[-..8,H]$QSHL6C9FD=42BH9-JB1 AE!*4A1.8I $XE*4HF$>1
M0#R"1(H1%0<\(JJ.>.>%  YX '/I\@!]FJX6)FLSSV'"AYYI)G"\A0TKL[!0
M22%!8\<DGCXD_'7MZ_6O3K&>]+9!C#?+2ZC1LI6.]5N*IMH5MD:XH;^!8/W$
M@K$NX<47JD_7K$@=H#9ZJ<"(-VZW> AA6$@"0W#S>"KYR.O'8FL0BO(TB& Q
M<L64*0WFQR#CT!''!^W3MZ']=]U]!<YF<_M/&X#)V\WBDQ%J+<%?(6*\==+D
M-T20+C\CC9%F\V!%+22R)V%AY?<0P[?@7#-;V]8>H&%:A(34K6<=01*_#2-C
M78N9QVS3<N'159)>-81;%5QUN3E$S:/:IB0I?B@'F(_=C:,>,I5Z,3R21UU9
M5>7M\Q@SM(>[L5%]"Y X4>@'/)Y)@?4'>V3ZC[TW%OC,UZ-3*;ER#9&[6QD<
M\5"&9HXXBE6.U8MV%C[8E($MB5N2?>XX Z[K[M0[2Y=V?"UVH;O))U;+A69*
MBY*=E^ZLCXU<L8&>EU"D B9[,P=QTG 610H%3(9_(Q1IL6Z:;9&801(0I(WE
MMK8K+.TSH]:TWXUBJ51I#]<T;*T<A^M^U9B/=\T  :LMT?\ %?U>Z-58L1A,
MK5SVV(3^"VSNB*?(XZFI/+KBYX;-7(XQ3RS"O5N+1\UFE>G([,653(^CC1YW
MYC1.[=XWBS*")$9'"J#Q^@D(CTD,Y;908MW2A2\N:@-&93#S$$B!Y:BS=.W[
MN5RZ=I^/=CV+ <_9>X+=OIS[O)Y/ Y]+;UONF%I:X%SH]!);"\,];?$D%>1^
M![PBEVK8EA4GGW3-.0.!WD^NM=[>^!+M-Q'+QUFR7+6S/T[&JD<(QEL385_'
MQETA R2SBFQ .'DD!3![;*<L\O$."^PYC52\^?6Q^QL;599+DTN0=2#Y;*(*
MQ(]>6A5I)']?BKSO&PX#(WS374?Q^=8-Y4[.*VO4Q'3O'VD,;VL.UC(;C$;>
MCI'F[ACAJ]P]!/0Q=*Y&?>BM(?@ZMBQ91;)I&QC-K'1T>V09,&#%NDT9,F;5
M(J+9HT:H$30;-FZ)")(((D(DDD0J:92E* !-55454151% 554!550. JJ.
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M$B:(?PW8>*S]>L3<[,&TBLIT(-D%N^5,W?Z ,F?B9O!5\Y%7BL33PBO*TJ&
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M?<6'WE'CA]__ !0Y'_YWEKK+A]B'XYFP/_S,?_0M<%MP=41^+MVI_P CF/\
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M?%.LD*M7,=2#+8B0^?(9.^QYTR1>2L9B[IT=<)&W#<5H/=MVIX_B_4),^?\
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9-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>mrna-20211231_g2.jpg
<TEXT>
begin 644 mrna-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X2@\17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#$Y.C R.C S(# Y.C0W.C(U   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,W-@  DI(  @    ,W-@  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C Q.3HP,CHP,R P.3HT-#HR,P R,#$Y.C R.C S(# Y.C0T.C(S      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  %I          8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ : $  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M2?\ /W-^2?\ Q-)#(PNI;=F+[$5PQQGYBPQP/]G]: "R_P!0W_7:7_T-JL4
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MG>.]#7$A)5><+@/@$L6&22N2 .G2D\KQ )D=9F"LR[A($8A0S]<8'3;G'X4
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MP#D!AGF@"&33K.6W:W:VB\ISEE5=H/Y5)]G@W!O)CW @@[1U P#^5  +:!0
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MT]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M  0VO_QN@#T&BO/O^&>_A9_T33P?_P""&U_^-T?\,]_"S_HFG@__ ,$-K_\
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M33P?_P""&U_^-T >@T5Y]_PSW\+/^B:>#_\ P0VO_P ;H_X9[^%G_1-/!_\
MX(;7_P"-T >@T5Y]_P ,]_"S_HFG@_\ \$-K_P#&Z/\ AGOX6?\ 1-/!_P#X
M(;7_ .-T >@T5Y]_PSW\+/\ HFG@_P#\$-K_ /&Z/^&>_A9_T33P?_X(;7_X
MW0!Z#17GW_#/?PL_Z)IX/_\ !#:__&Z/^&>_A9_T33P?_P""&U_^-T >@T5Y
M]_PSW\+/^B:>#_\ P0VO_P ;H_X9[^%G_1-/!_\ X(;7_P"-T >@T5Y]_P ,
M]_"S_HFG@_\ \$-K_P#&Z/\ AGOX6?\ 1-/!_P#X(;7_ .-T >@T5Y]_PSW\
M+/\ HFG@_P#\$-K_ /&Z/^&>_A9_T33P?_X(;7_XW0!Z#17GW_#/?PL_Z)IX
M/_\ !#:__&Z/^&>_A9_T33P?_P""&U_^-T >@TE>?_\ #/?PL_Z)IX/_ /!#
M:_\ QN@_L]_"\#,?PZ\*P/VDM]&MXW'T94!'X&@#T -FEKS.\M7^#LEK?V5Y
M=3^#'F2"]T^ZE:X.GASM2>%V)<1ARH>,DJJDL@780_I>X4 +1110!Y[\35W^
M+OA7$WW)/$TNX>NW2=1<?DRJ?PKT!5*XSC-<!\2_^1T^$_\ V,T__IFU.O0:
M "BBB@ HHHH **** "BBB@ HHKF_B%\1O#WPK\+W/B+Q1J']EZ-;,BRW/DR2
M[2[!5&V-68\D=!0!TE%>'Z!^VQ\$_$NJ0:?9>.[9;B8A4-Y9W-K%D]C)+$J#
M\6KT?QI\3O#/P]GT.+Q#JBZ8^M7JZ?8>9$[++.WW4+*I"9]6('O0!U-%87C#
MQQHO@'1O[5UZ]^P:?Y\-MYWE/)^\ED$<:X0$\LP'3CJ<#FF^.O'FA?#7PO>^
M(_$M^NF:-9!3/<M&\FW<P485 68DL!@ ]: -^BJFEZI::UI]I?V,Z7-E=1+/
M!/&<I)&RAE93W!!!_&K= !1110 4444 %%%% !1110 C=#7GWQ(&SQM\*"#@
MGQ+.I]2/[&U(X/X@?D*]!KS_ .)?_(Z?"?\ [&:?_P!,VIT >@T45Y/^U-XT
MUGX>_ OQ'KWA^\_L_5K4VPAN!&DFS?<Q(WRN"IRK,.1WJ9244Y/H=>$PT\9B
M*>&I_%-J*]6[(]7I&K\J_P#ALCXP_P#0XO\ ^"^T_P#C5'_#9'QA_P"AQ?\
M\%]I_P#&JX/K]$_4_P#B&&=_S0^]_P"1^J7\)YKX_P#V[/'NM_#7Q=\,=?\
M#]VUG?VPU @_P2*3;91US\RL!R/;.17S:W[9'QA;KXQ?_P %]I_\:KBOB/\
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M::C)I4LT%E=6LKOOL]Y, ?<B[653MVC(PHP: /2J*** "BBB@ HHHH ****
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MM+&W7ZO(Q^\[M_$Q[G^F*Z4#%.HKI22T1\;5JSK3E5J.\GJV^H5Y_P#M"_\
M) ?B7_V+.I_^DLE>@5A>//#:^,O _B+P^[K&FK:=<6#.PR%$L3(2?^^J9D;8
M;-.KF/A[XF/B?PW!+<+]GU:U_P!$U*S8Y>WND $B'VR0P;^)65APPKIMPH 6
MBDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6
MBDHH 6BDHS0!Y_\ M#-M^ /Q,)Z#PSJ?_I+)7?YYQ7G_ ,;I%UGP1>^#[=@^
MJ>*X9-'@B!Y2.5"L\Y]%CB+N3ZA5ZL >_7K0 ^BBB@!&&X8KA+KX3QPW<T_A
MWQ'K/@SSV,D\&BFV:WD<G+.(;B&6-&)Y)15)/))))/>44 >?_P#"M/$7_16/
M&'_@)HW_ ,KZ/^%:>(O^BL>,/_ 31O\ Y7UZ!10!Y_\ \*T\1?\ 16/&'_@)
MHW_ROH_X5IXB_P"BL>,/_ 31O_E?7H%% 'G_ /PK3Q%_T5CQA_X":-_\KZ/^
M%:>(O^BL>,/_  $T;_Y7UZ!10!Y__P *T\1?]%8\8?\ @)HW_P KZ/\ A6GB
M+_HK'C#_ ,!-&_\ E?7H%% 'G_\ PK3Q%_T5CQA_X":-_P#*^C_A6GB+_HK'
MC#_P$T;_ .5]>@44 >?_ /"M/$7_ $5CQA_X":-_\KZ/^%:>(O\ HK'C#_P$
MT;_Y7UZ!10!Y_P#\*T\1?]%8\8?^ FC?_*^C_A6GB+_HK'C#_P !-&_^5]>@
M44 >?_\ "M/$7_16/&'_ (":-_\ *^C_ (5IXB_Z*QXP_P# 31O_ )7UZ!10
M!Y__ ,*T\1?]%8\8?^ FC?\ ROH_X5IXB_Z*QXP_\!-&_P#E?7H%% 'G_P#P
MK3Q%_P!%8\8?^ FC?_*^C_A6GB+_ **QXP_\!-&_^5]>@44 >?\ _"M/$7_1
M6/&'_@)HW_ROH_X5IXB_Z*QXP_\  31O_E?7H%% 'G__  K3Q%_T5CQA_P"
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M% 'G_P#PK3Q%_P!%8\8?^ FC?_*^C_A6GB+_ **QXP_\!-&_^5]>@44 >?\
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M FC?_*^O0** //\ _A6GB+_HK'C#_P !-&_^5](WPS\1%2/^%L>,/_ 71O\
MY7UZ#10!S?A?P%IWA6:>[1[G4M6N%VW&K:E+YUU*HY"ENBH#R$0*@))"@DYZ
M)5(QWIU% !1110 4444 %%%% !1124 +12;N]&Z@!:*3-% "T44E "T4F:,T
M +12;A1NS0 M%%% !124FX&@!U%(#FC- "T4F:6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **;N%+N% "T4F<TM !24M(: #-
M&ZFYI-WM0 _=1NIH-*&!Q@T .HHHH **2C<.* %HI-U(&#=* '4444 %%%%
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M:#/)I5WN'^NC'"L<]0RE6Y[-7 \!AW-4(W4K;]SU(9OC51>+G9PO:W5::_\
M /J19 X!'(/(I6;;7E/[/GB*:[\-WGAR\E:2[\/3"UC>0Y:2U8;K=C]%RG_;
M(UZJ>AXKYR<'3DXRW1]M2J1K052.S,3QIXTTGP%X=NM:UBX^SV4 SQRSL?NH
MH[L3T'],UXAH/[6%YXNU@Z?H_A*!YG),$=[JRP22 9/ \HC=Q]T$UY;^U'\1
MW\8^/'T2VDWZ3H3M"%4\271'[QCZ[?N#TPWK7G_ACPO]L\/>(?%4]Y+I]MH"
M1O:20@;KB^9QY40SU7 );'(&#SFG*G*%G+KJ*G6A6OR.]FU]Q]-^)?VK)?"=
MM$NH^"KN#4)I/+C'VQ#;-CJ/-"[@W'W=GXU=T?\ :*UW6-*@U6'P7;W6FRML
M$EGK*O(&'5=IC7YO8D5P/B.WL_BAX)ANE"B+5[4.&_YY3@?>XZ$,!^1K'^%>
M@'PC9Z.SW\EW8>+(9X;A9EP+74K>1@5 [ KC ZG83TQC,V/JOP/XXTSX@:(N
MIZ8\@57:&:WG79+;R+]Z-USPP_(@@@D5T5?-GP_UM_!?Q0L9')BT_7S_ &=>
M(3P+E03!(?\ :/S1D]]P]*^DMW.* %HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ I&^Z:6O/\ XY_$ _#CX;:IJD#A-1D M;'N?/?(4@=]
MHRW_  &@#Q/X_?M'ZI:^(9_#GA&]^QQ6+%+W4HU#2-*#\T:$@@!>C'&2>!@#
MG'^&/C_7?'T%_:CQIKUEKUF!)Y:SQ21R)Z@,AY]CFO 561V6.-6N)7;:J@Y:
M5R< >Y)/YFOJWQ)\*H_A#\._"&LVJK_:6BS*-7FC7_7)<,HE8^H23R]OHH-
M'>_"/XFZAK.JW/AKQ')'-K$,1N;2]C01+?0 @,=F?ED0D!@./F!'?'J^<U\M
M>+[M_#6I67B:S4F71[A=0"KU> C;/'[@H6_(5]/VMQ'>0Q3PN)(95$B.O1@1
MP1^% $]-?[M.IK_=.: /-?CA\7(/A+X76Y5$N-8O&,5C:MG:S 99VQSM4<G'
M4X'&<CY8T/X]>)KKQ!"/$?BO5K>SNIMCRV$D<7E,V ,)MQM'X?SSF_'+Q^WQ
M$^).IW\<IDTZT)LK'!^7RD/+C_>?+9]"!VKT']F#X.V/CBQ\0:UK=N)]/DAD
MTFU1A_$Z_OI%]P"%!]2WI7VD,#A\#EGUO$PO.?P_Y_J?F,\TQF;9Y]1P4^6E
M2OS/O_3T.YM_'_B3X8ZFMQJ>M7'B7PT'7[5]KC0S00MQY\;HH+!<@E3G@'%?
M0MM,EQ$DL3K+$ZAE=3D,",@@^A%?+NB-/=>&3IVI@2ZCHT\NE78/&_82H./1
M@ 1[&O4OV=]<>Z\'SZ#<2F2Z\/W)L59NKVY4/ V/38P7_MF:\'&X>,81K4]G
M^9]7EF,J5*L\-6=Y+\CU:DI:1ONUY)]&5[_4+?3;&XO+J58+6WC:6663[J(H
MR2?8 5\4?$#]ISQ1XGUZ270;Z;1-"B8K;6\&$DF4' >1\$Y.#P.!D=<9/JG[
M87CXZ3X:L?"EK)MN=6)FNPIP1;(1\I_WWP/HC"OFCX?^#9_B%XVTGP_"607D
MX$\JCF.%1ND;VPH./<B@#W3PCXUU_P 2>&;7Q#H7C?5Q(CF&YM=1\JYCCF'9
MAL&4(Y!!!QWS7O/PK^(/_"P=!DFN8%L]8L93:ZA9J<B.4 '*YYV,"&4GL<=C
M7EWC#PG9_#_XC0VUA EEH?B2P\I88QA(KJV4 8';='L^I1CWJE\/M9;PG\5M
M,F8[+374.F72]O.4,\#GWSOC'^_0!]*44@8-@BEH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "D8[1FEIDGW#0!A^,O'F@?#[17
MU;Q%JEOI-@K!/-N&^\QZ*JC)9CZ*">*X30?VJOAAX@O4M(_$T=A-(=L?]JVT
MUDDGIM>9%4Y],YKY5^,'CJ7XG?%?6-3FE,FEZ/<RZ5I,.<H@C;;-,!TW22*P
MW==J**POW=W&T<Z+/&W5)%#*?P(K]'P'"?UG"QKU9N+EJ?B>:^(;P>/EA\/2
M4H1=F^[\C[1^,'QWT/X7Z'$\31ZUKU]E--TBVE4R7##^,D9V1KU9R..@RQ /
MS[;?&?XL->?VBOB73I[G/F'1&TU%L#W,2N#YP] Y<\\E3TKS31=$TS19'?3M
M.M;%Y!AFMX@A(ZX..V>WM75:$P;4(%[$XQ7K8;AK#X2E)5O?EW/G\;QOC<PK
MP>'_ '<%T[GV)\+/'MK\3O VD^)+6%[5+R,^9;2-N>"9&*2QD]RKJRY[X]ZZ
MT5X!^R3KME#X=\4>&S=1KJ6EZ[=R-9L^)!#,PE23:>=K;VP<=0>XKWW=7Y9B
MJ2HUYP6R9^]Y=B'BL)3JR=VTKC]U>1^,/VDM#\.Z]>Z+I>C:QXLO[%_*O#H\
M,?DV\G4QM-*Z(7&1E5+$=P*]&\3ZU'X>\-ZMJDI"QV-I+<L6Z81"Q_E7Q]\,
M&ETOP-HJ2JKW<UNMU<32#<[S2_O)&)[DL['FO4RK+XXV4G/:)X>?YO/*X05+
M>7Y'L\'[3B,!Y_PZ\8P#U2"UE_\ 0;@FO/\ QQXWG^*WQ T'4H="U71='T.R
MNT#:Q"L,D]Q.T2C8@9CA4C?+'&=_%7H=9ND'R2X'IM&*+[4Y]2\OSRI*9P54
M#KCK^5?28?*J>'K*I%;>9\-BL_KXS#.C.6_D5.OT_P __6HHH/<?T_6OH-#Y
M<S]>\06?AO3Q=WKR!6<11101M)-/*?NQQHHW.Y/0"O3?@C\._$C>*6\=>+HO
M[,O6TXZ9INC>9YDMK;O(DDC3N#M,C&.+Y5R%"XR23CD/AOIMK/\ 'SP[-?Q^
M>!H=]+IV[YEBN5F@25QVW>6X /H7]:^G%7;WXKX?.,=*4OJZ6A^F<,Y5"-..
M,GJ];+L24445\J?H04444 %%%% !1110 4444 %%%(3CF@ 8@*2>!7YV?%KQ
MH?B#\1M;UE7+VLDQ@M.>!!'\B$?7EOJQK[,_:#\:'P1\*=:NH7\N^ND^PVI!
MY\R3Y<CW5=S?\!KX#BA>3RX+>,RS.RQ11J.68\* /4\4 >E^%O\ BC/@WXB\
M1G]WJ'B*8:#I[?Q+;@;KEQ[-C;GL5%97P7UP:#\0((&;%MJ,+6SKVW*-R_F-
MPK6^.DT6BZMH/@NU<26GA?3H[:3:>'NI0))W_'*?CFL3X<^![WQ1#X@U^T:3
M'A>T74U\L?ZR4.#L_&-)OR'K0![=:>1IWC[1)+Q0VGZEYV@7ZMT:&X&$'_?Q
M4'XGUJMX;\Z'PZ=)OB9+S1;J;3IMW5O+8IGZ$!3[[JK>(XWUSP[<263_ +]H
MUNK20<XD4B2-A[[E&*NZMJD=UXT75+=52Q\7:5;ZS#C.!.JK',F/480GW)KM
MP:_VF"\T>7F>F#JOR?Y'J7[.>K&3P9>:#*Y,V@WTMFF>OD-^\A/T"OM'^Y7G
M'[9GC3R[?1?"<#X\YO[1O%!_@4E8U/L6W-_P 5J?"/6#H?Q>>S<[;;Q!IY53
MGAKBW)8#Z^6[_P#?-?.OQ=\8?\)Y\2M>U='WVKW!M[7GCR8OD1A['!;ZL:^E
MRC+56SA4Y?#%\WR/B.(<[^J\.^WB_?J+E7J]'^%Q/A/X3A\;>/\ 2M/N\+I<
M+&_U!F^ZMO$"[Y]FX7_@0K(^('BRY\<>*=9\0Y9)[NZ-Q;^L:H0(5]BJJHSW
MKM/"_P#Q1_P4\4Z^3LU#Q%.N@6+'[WD@;KAQ[$97/JHKSO3M+N-<U*STRS&;
MN^GCM80/[SMM'\Z^OIRIXS%XO&U?@IIQ7W:V_KJ?G=:%7+<OR_*</I5K24Y?
M?I?^NA]":I)'\0/!"3J>-3L%<%>-LFW((^C ?E6C'K1U;6?#OB)OE7Q9H@CN
M_07]K\DA^I! _P"V=97A_06\#7VL^$3(\BZ'>&."20<M!(!+&?R8_E5=7:U\
M#^([5%S<>%=7B\06JYZVDX*3J/929&/X5\;B)+EH8Q;;/^O(_1L%3:EBLNEO
M:Z]5_2.Q^'NJ'PY\7-'E)V6^M6\FF3#MYB@RPD^_RR*/]^O:?B=XS3P%X UO
M76V^9:V[&%6Z-*WRQK^+LHKYM\574MOI']JV(\RYTV:+4[< _>,3!\_B 1^)
MK2_:[^(D&L:%X5T73IM]OJ"+K$C*>L6W$(/LQ9C_ , %8XO RQ&8PIP_Y>6_
MX)V9?FL<)D]6O4?\)/\ X'^1\RS3MMDEGD:21F:25VY+,3EB?QKTSXIQGP9X
M0\(>!5_=74,']MZLHZ_:YQA$;W2/CZ$5B?!WPM'XP^(^BV-SC^SK=_MU\S_=
M6WB&]MW^RQ 4_P"]6-XX\52^-_&&M:_)G-_<M+&K=5CZ1C\% 'X4^)H0I9@Z
M<-HI+\">!ZE2MD\:U7><I._JV>D_ W6Q=>&=6T21LFPN1<0JQSB*3.1],YKJ
M5CEDT#QKIL.6N]/:W\7:=W8O'\ET!]47'_ ZXWX=>#;KPOH>A^,)6D%KXANK
MC3/+8?*%49A;\6CF'Y>M>@Z;?1:)XZ\,ZE.H-I+.VDWH8<-#<C9@^PD\LGZ5
M\J??D'C"-M:T6XN+!]L\D27MG(/X95Q(A'ON KZ:\(>(8O%OA?2-;@&V+4+6
M.Y"_W=R@E?P)Q^%?+OA^WET6&XT.X):XT6[ETYF8\N$<^6Q^J%#]#7KG[-VK
M#_A&]5\.NQ\S1;YUB5NOV>4^;$?H"SK_ , H ]?HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!#T/>OCW]L3QE_:OC+3?#<$F;?28?/G Z>
M?*/E!]P@!_X&:^N=0U"#3=/N;RZD$-M;Q-+-(W1$498GZ#-?FQXI\23>,/$V
MJZY<[A-J-R]P5;^ ,?E7\% 'T% 'HO[,?@K_ (3#XKV4\R;K+1XS?RY'!D!
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MMKJL1TJY(X F3,D!/N1YJ_@*XRSN;72O%VE75^ =(U*.30M35N%^SW "J3Z
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M0!U*<AO5<?W.?0RW$K#UK3^%GEYU@Y8O#-TU[T=4;/[._B0S>%[GPO=29O\
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M/QL^'OQ>^)NLW%D;;3_^$;M[IY+&WM[I8Q(H)$;R[CDN!R>P).!WKZ>/-&*
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M?QR119)WG"C<58?PX/X5O^(?@QXY\1:=]@U+PM8W)C?='=VVIHJJPP!(@89
M]CCKBOK$C-(!CTKT_P"U,4G=2M_P#Q/[!P/+RN+^_ON?*_P:_93U/3O%$&M>
M,5MX[:RD$MOIT<@E,LB\JTC#C /.!U.,XZ5]3[3U[T[;S2UR8K%U\;4=6O*[
M/0P&7X;+*"P^%ARQ0TKD8KROXK?!^?Q+>#Q#X>DAM/$2QB.>&8[8+Z,?=5R
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M$D\#XW1R7<3*<=.#%S7:_#OX4^'OA?ILEIHEJR/-@SW4[>9--CH&; X&3@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEHKD/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***0T &:*:3BDW!NAH ?FBF[ORI%8=:0$E)FC<.*.],!:*** "BBB@
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M<$IJSDH^3U;M^")PN'KU7[)IJ#DNZT4;WUUU>AX#XH^*VD:;XRO/A]JWQ/\
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MYDCY''SKZB@#H**:&!QC\*=0 4444 %%%% !1110 4444 %%%% !29HKS/\
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M1ICSL+<[B<L\6TPMW^16/WQD ^D-1\2:3H]UI]K?ZG9V-UJ$AALX+F=(WN9
M,E(U8@NV.<#-:.[O7R'\8-4M_B5XZ\=S16VO27OA2SCT[PS<:;X?O]0@&IQR
M1W<KF2"%T4B2*VBY(( ?@@BOI7X;>.+3XE> =!\362^7;ZI:)<>61S&Q'SH?
M=6#*?I0!N:?K%CJT<TEC=P7J0S/;R-;RK($D0[70D'AE/!!Y!ZU:WCT-?/\
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M ][KO@[P[>Z5IWB6^FU'Q3X_U'1DOKZTM'%EMGN9)KE52% TKI$1A]R!BN$
M!0@'U5N%&\>_K7SCX^^(7C3X?-XN\,0>)#JE_:0Z+?Z;K>H6MO\ :$2ZU 6T
ML4Z1QI&X&UMI5$.'(R2-U:=POCBZ^*^K^#;?XCZK:Z;IGANWU0WQT_3WO)KB
M2XN5!)^S^6$P@! C!.Q<$'>6 />_,'/MV[U'<7D-J$,TJ0AW$:^8P7<QZ*,]
M2?2OG'P#\1/&LNC?!_Q1K'B4Z@/&=T+*^T9;."*SA#6TTB20D)YP<&%2VZ1E
M8L^%4;0O6?M!:+=:GK_PK%KKNH:-_P 50D9^Q);M\QM+DB3][$_S *5';#MD
M$A2H!ZYI^L6.K1SR6-W!>I!-);2M;RJX25&*NA(/#*P(*GD$<U:\Q?QKY5T7
M4/%?@OPQXJ\5Z?XGDCLK7Q_=6QT VD!MIH)M5\F4R.8S,),RL04D11M7Y3SF
M6^^-OBG6+;Q7X@TC4/$WV[2M4N[72_"VG>$+B\T^]CM93&8YKI;1SYDI1_G2
M95CW+D':VX ^I&D6-2S':HY)/ %5M+UBQUO3[>_TZ[@O[&X020W-K(LD<JGH
MRLI((]Q4,EQ]LT5IS%) 9+?>8IEPZ97."/4=,?6OF'X3ZAXK^&OP%^&'B?\
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M\3/%6AWQ@U/55U*S\-^+X_#^JW@MX4:]L[JWC-M/(%7"2)-<P*WE[%(#' '
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M&UO9R74'D%$8 QJ8G^5<#"N..:^J H8G//-.5=IXZ4 "KCMCZ4ZBB@ HHHH
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M_:4\/:_X(\+ZQK":AINJ:[#++;Z7!H][/+*8]AD$*K"6F"B5#O0$$;R.%;:
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M5KF6*-D@!P3F5E& 3T&:[**9)D5T8.K#<K*<@CL1[4 /HHHH **** "BBB@
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M#;LF']G'3K&XBL;2_7_A$Y/"Z>%;W2;JW,LT]NAE*2).'79)F9LDHP/8*>:
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M6,!,-W \$R'RUR'C<!D8="",BJ>K?$KPQH>I^&;"]UJWBN?$KF/2"-S1WC!
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M9H@.21N )'L"ZYI\FN/HXNHVU-+=;MK8??6)F*JY'8%E8#/4J>.#6@>_/Z4
M?-Z>%=<L/#MKK)T?4IHM#^(FI:W/IL5LYN+BS>>Y42Q1'!DP)5E4*"6"G:"Q
M -+XAZ'JOQ$U3QEXGTSP_JR:1<Q^'M-MX[S3I[>YO&@U,332BVD42*B))C<Z
M#(5R 5Y/TEI>H1:MIL%Y"EQ'!,F]5NH)()0#V:.15=3_ +P!JT% SSC/OUH
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MU%%% !2,,C%+10 T+3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$O",%A>VLMC=7_VZ6WEN;C4M3NKRYD,$@EA4SRR-)L1UW! P7);CYFR >/\
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MB,0-ND56;*LR+PI#Y8A9/V:8=5OAX^\0ZF]G<+KGB W5K<Z>K_9)X5M;>/=
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% "4FT\<TZB@!B+M^E/HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>mrna-20211231_g3.jpg
<TEXT>
begin 644 mrna-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" *G!G,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBC<* "BDWBE)
M ZT %%)N&:7.* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5H)YCPN[^!G[8'B]3)\0/V\_&NZ1<30Z'>2V<9!'*[8W52,>HQ[57/['7Q&
MX_;0^)^??7YO_CE>[44"NSQ6T^#?[:/A%O/\"_MZ^+Y&7E8_$$TE\I]L3.XQ
M^%;&G_M+?\%1_A$5EU[0?"GQ&T^'YI#:J+>Z9?H/+R?958UZE10/F,CX8?\
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MX?\ C;XL:_\ $CQ=X<\;?"^/1]!TFXMT\,ZVNH"4ZLC(3(Q3'[O:P Z\Y]J
M.V) ZT52\07DUCH-[?6S;98;21XVQG#!20?SKQ#_ ()L_'3XE?M$_LO6/Q+^
M+&MQZAK$VJW4$ES%9QP*41@%&V-57CZ4 >^4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH/(Q0!XU^WO\
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M6[=DYPR_PG##Y2:_1"UN[6^MH[VRN$FAFC5XI8V#*ZD9# CJ".]!9)11FB@
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MR9KBYE:1VZLQH)N:6I^*[[5KT23-Y<*_ZN%3T]SZFN!^,7QI\!_!CPU+XO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPQ&>O%?0U?'?_!777H_"NE?"/Q1)IMU>+IOQ,L[IK.QC#S3B,J_EQJ2-SG&
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MXY^RSXQ/['G[>>I?#;6)Q;^#_BNJSZ7*[8CAOU+;4] =S.ON)(_:@(GZ'T4
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *X?]I#XR:?\ O@7XH^+M\$9M$TF6:UAD^[-<$;88S[-
M(R*?0&NX/2OBG_@MG\0[K2/@/X?^%FF.WVCQ-X@4R1(>6CA7('N"[+^E?/\
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MF]XYWX_[^?GFOR_Q?K2I<&RBOMSA'\>;_P!M/O/#FFJG$JD_LPD_PM^ITJC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1Z/^'OG[*O\ T)_Q8_\ #0ZS_P#(] 'U+17RU_P]\_95_P"A/^+'_AH=9_\
MD>C_ (>^?LJ_]"?\6/\ PT.L_P#R/0!]2T5\M?\ #WS]E7_H3_BQ_P"&AUG_
M .1Z/^'OG[*O_0G_ !8_\-#K/_R/0!]2T5\M?\/?/V5?^A/^+'_AH=9_^1Z/
M^'OG[*O_ $)_Q8_\-#K/_P CT ?4M%?+7_#WS]E7_H3_ (L?^&AUG_Y'H_X>
M^?LJ_P#0G_%C_P -#K/_ ,CT ?4M%?+7_#WS]E7_ *$_XL?^&AUG_P"1Z/\
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M "/0!]2T5\M?\/?/V5?^A/\ BQ_X:'6?_D>C_A[Y^RK_ -"?\6/_  T.L_\
MR/0!]2T5\M?\/?/V5?\ H3_BQ_X:'6?_ )'H_P"'OG[*O_0G_%C_ ,-#K/\
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MZEHKY:_X>^?LJ_\ 0G_%C_PT.L__ "/1_P /?/V5?^A/^+'_ (:'6?\ Y'H
M^I:*^6O^'OG[*O\ T)_Q8_\ #0ZS_P#(]'_#WS]E7_H3_BQ_X:'6?_D>@#ZE
MHKY:_P"'OG[*O_0G_%C_ ,-#K/\ \CTC_P#!7_\ 92C4N_A'XKJJC+,?A%K/
M'_DO0!]345\AZ7_P6]_88UN![K19OB#>1QRM%)):_#/5)%613AD)6$X8'@CJ
M#5G_ (?1_L8?\^'Q*_\ #6ZM_P#&* /K.BODS_A]'^QA_P ^'Q*_\-;JW_QB
MC_A]'^QA_P ^'Q*_\-;JW_QB@#ZSHKY,_P"'T?[&'_/A\2O_  UNK?\ QBC_
M (?1_L8?\^'Q*_\ #6ZM_P#&* /K.BODS_A]'^QA_P ^'Q*_\-;JW_QBC_A]
M'^QA_P ^'Q*_\-;JW_QB@#ZSHKY,_P"'T?[&'_/A\2O_  UNK?\ QBC_ (?1
M_L8?\^'Q*_\ #6ZM_P#&* /K.BODS_A]'^QA_P ^'Q*_\-;JW_QBC_A]'^QA
M_P ^'Q*_\-;JW_QB@#ZSHKY,_P"'T?[&'_/A\2O_  UNK?\ QBC_ (?1_L8?
M\^'Q*_\ #6ZM_P#&* /K.BODS_A]'^QA_P ^'Q*_\-;JW_QBC_A]'^QA_P ^
M'Q*_\-;JW_QB@#ZSHKY,_P"'T?[&'_/A\2O_  UNK?\ QBC_ (?1_L8?\^'Q
M*_\ #6ZM_P#&* /K.BODS_A]'^QA_P ^'Q*_\-;JW_QBC_A]'^QA_P ^'Q*_
M\-;JW_QB@#ZSHKY,_P"'T?[&'_/A\2O_  UNK?\ QBC_ (?1_L8?\^'Q*_\
M#6ZM_P#&* /K.BODS_A]'^QA_P ^'Q*_\-;JW_QBC_A]'^QA_P ^'Q*_\-;J
MW_QB@#ZSHKY,_P"'T?[&'_/A\2O_  UNK?\ QBC_ (?1_L8?\^'Q*_\ #6ZM
M_P#&* /K.BODS_A])^Q?_P ^'Q*_\-;JW_QBJ$/_  7,_8*N;^XTJWU+QY)=
M6A NK5/AOJ9DASTWKY.5S[T ?85%?(O_  ^W_8>]?B'_ .&RU7_XS1_P^V_8
M>]?B'_X;+5?_ (S0!]=45\B_\/MOV'O7XA_^&RU7_P",T?\ #[;]A[U^(?\
MX;+5?_C- 'UU17R+_P /MOV'O7XA_P#ALM5_^,T?\/MOV'O7XA_^&RU7_P",
MT ?75%?(O_#[;]A[U^(?_ALM5_\ C-'_  ^V_8>]?B'_ .&RU7_XS0!]=45\
MB_\ #[?]A[U^(?\ X;+5?_C-'_#[;]A[U^(?_ALM5_\ C- 'UU17R+_P^V_8
M>]?B'_X;+5?_ (S3H_\ @MM^PNT@2>^\>6Z_\];CX;ZHB#ZDP\4 ?7%%>/\
M[/W[>W[)'[3^I-X?^#/QLTG4M75=TFAS.;>]4=?]1*%<X'7 .*]@S0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 9QUH!STK'^(6HWFC^ M<U?3IO+N+32+F:WDQ]UUB9E/X$5\9_L+Z1^WK^
MT9\/O!7[2VO_ +9<,>@:AK4DVH^%9/"R,\]K:ZC)!+!YX<8\Q8&^;;\N_OCD
M ^Y,^HHKPNUM/BUXB_X*$W5X^JZE;^!_#OPVC7[(K.MM=:E<77RL1]UV6))<
M]U^3UKUCXC_$3PK\)O 6K?$GQOJ/V72-#L)+N_N"N2L:#)P.Y/0#N2!0!N;J
M,\XKXE^&FL_\%#_V^K%OB_X/^+]C\%_A_?2.?"]M#H@U#4KR ,0LTH+H &QU
M#@=<*1\Q]?\ V<O '[=GPQ^(KZ!\=?C-X=\?>#9+"0V^L0Z7]BU*"X!&T.@R
M"K#/(9^1V[@'O=%8^C_$+P)XBU:;0= \:Z1?7UOG[196>I12S18Z[D5BR_B*
M35?B)X!T'4&TC6_'&CV=TNW=:W6I11R+D9&59@>0>..: -FBH[>Y@NH5N+69
M9(Y%#1R1ME6!Z$$=14E 'EO[9?[5'@S]C;]G?7_CUXRMY+M=-A6+2]*A/[W4
MKZ0[(+9/=G(R<'"AC@XK\:?$M[X^_:%^)<WQ]_:@UO\ MSQ5J#@PPSY>ST.
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M!_\ 0"A_[^M_\51_PKGP'_T H?\ OZW_ ,57SG_PM2X_Z"$G_?TT?\+4N/\
MH(2?]_31J&A]&?\ "N? ?_0"A_[^M_\ %4SX;_ 'X6^.O&W_  L#Q!X/L[R'
MPW>-#H,-QNDBCNMH$ESL8E3(N=BL1E/GVD$FOG0_%6Y'74'_ ._QKV?]B/6[
MD?LH^!=<NIG:;7M"CURX=WRS27Y-XQ)Y[SX]@,=J-1Z'T2NB:0HVBT7';YC_
M (TO]BZ3_P ^J_\ ?1_QKBO^$D?^^?\ OHT?\)(_]\_]]&@9VO\ 8ND_\^J_
M]]'_ !H_L72?^?5?^^C_ (UQ7_"2/_?/_?1H_P"$D?\ OG_OHT@.U_L72?\
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M\_\ ?1H [7^Q=)_Y]5_[Z/\ C1_8ND_\^J_]]'_&N*_X21_[Y_[Z-'_"2/\
MWS_WT: .U_L72?\ GU7_ +Z/^-']BZ3_ ,^J_P#?1_QKBO\ A)'_ +Y_[Z-'
M_"2/_?/_ 'T: .U_L72?^?5?^^C_ (T?V+I/_/JO_?1_QKBO^$D?^^?^^C1_
MPDC_ -\_]]&@#M?[%TG_ )]5_P"^C_C1_8ND_P#/JO\ WT?\:XK_ (21_P"^
M?^^C1_PDC_WS_P!]&@#M?[%TG_GU7_OH_P"-']BZ3_SZK_WT?\:XK_A)'_OG
M_OHT?\)(_P#?/_?1H [7^Q=)_P"?5?\ OH_XT?V+I/\ SZK_ -]'_&N*_P"$
MD?\ OG_OHT?\)(_]\_\ ?1H [7^Q=)_Y]5_[Z/\ C1_8ND_\^J_]]'_&N*_X
M21_[Y_[Z-'_"2/\ WS_WT: .U_L72?\ GU7_ +Z/^-']BZ3_ ,^J_P#?1_QK
MBO\ A)'_ +Y_[Z-'_"2/_?/_ 'T: .U_L72?^?5?^^C_ (TG]C:3_P ^B_\
M?1_QKQOX\_M%^&_V?_A9JWQ4\6/(]OIL(\JUB;]Y<S,=L<2_[3,0/89)X!KP
M?PAHO_!0O]H328OB1XF_:&L?AG9WZ"?2?#NDZ&+R2.%AE!,S.F&(/]YCZ@=
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MA^R:-0+7SXKAI<$#)R47KGI7T)0 4444 %%%% !1110 4444 %%%% !1110
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MM>DC_@E=\+?^$<\)^&S\:?B T/@76$O_  @6UB,_V45?>J1#R\8# $,06&
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M^3\QR:A\*Q:5X+OK^[T.::./4)O.EM3)F-'[LH[4D,^@O^%@_P#3>C_A8/\
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M?\2?LYV^NZ1')<0^&?%5CK&J6T?)EM8Q)&_'< RJY[ (3VKVKX:?%SPM\3_
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MJ&A>9_9HUO6VN$B#KA@-PS@\=^PI#./\6:S-_9/[68%PWS3Q[?FZ?)4?Q?\
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M>D_YZ_K1_;TG_/7]:\G_ .%KW/\ SX+_ -_#1_PM>Y_Y\%_[^&@#UC^WI/\
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M7_OJF![Q_P +!_Z;T?\ "P?^F]>#_P#"UKC_ )XK_P!]4?\ "UKC_GBO_?5
M'O'_  L'_IO1_P +!_Z;UX/_ ,+6N/\ GBO_ 'U1_P +6N/^>*_]]4 >\?\
M"P?^F]'_  L$_P#/:O!_^%K7'_/%?^^JJZS\99-*TJXU*6)0L,+-G?WQQ^M
M'6>%O' ^R74JS<2:I=R*<]09W-:G_"='_GK7A.@>/+S3M'M[26)=ZQYD)?\
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ME<!\.OV=_ _PQ^,'C?XU^'[B^;5O'S69UI+B8-$OV99%C\L8XXD;/)SQ7?T
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M_B, W?GC-<QJ_P %O"%R";>RDMV_Z8RG _ YK=>/G%$O^7=./_;C?_MZ,_\
MB$.01^W-_P#;R7_MK+S_ +:7Q@3K^RM9_P#A:?\ VJH'_;B^*\?WOV6+7_PL
MO_M5<Y=?"/5].YT#Q3-'C[L<P)7]/\*R[O2_B)I1(N=-AO$ _P!9">3_ "/Z
M4UXY\83^!T'ZPDG^,[?B'_$*.&X_%[5>DHO\HG92?MV_$^+EOV6+7_PL?_M5
M0R?M^_$>/A_V6[?_ ,+#_P"U5P4VO%#MU'1[F!N_[OI^>*JW&J:/.N$N,>Q0
MUK'QNXXO[U*E\H2?Y3,Y>%?"_2I4^<E_\B>@2?\ !0KQ]'][]ERW_P#"O_\
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M .,T?\*'_P""BO\ T9AX>_\ #EI_\9K]***+L#\U_P#A0_\ P45_Z,P\/?\
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MO_A:1_\ Q%'_  YV_P""DO\ T0SP[_X6D?\ \17[C447 _#G_ASM_P %)?\
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M<+LGM[B,.DB^A4\$58HH AL+"RTNRCT[3;2.WMX4"0PPQA511T  X J:BB@
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M55TK6=-URS74-(OH[B!^5DB;(_\ K5:H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 $9ZBC
M/:BB@#Y;_:Y_X)=_!_\ :"N)O'?P\N?^$-\9;O,CU+3X_P#1KF3K^^B7')_Y
MZ(0PZG=TKY/U[6OVTOV)[PZ/\?/A[<:_X;A;9'X@L<R)M['S1Q^#A3[]J_52
MH;NTM[V%[6\MDFCD4K)'(@964]B#P17YWQ%X;Y+G=5XG#MT*S^U!:-_WHZ)^
M;5F^MS[3)>.,TRNFJ%9*M27V9;K_  RW7H[I=+'YW_#O]K'X-_$Y(X=,\4PV
MET_6SOF\I\^@SU_"NXGFL[Y,[8Y5_ UZ5\;_ /@E9^R1\9;B;6+/P6WA75)L
MDWGAEA;QEO5H,>7_ -\A23U->":]_P $IOVM/A6S2_L^?M&V^I6<?,.EZYOB
MX]!D2)GZ!?K7Y/FGA_QEE][4HUX]X/7YQ=G?T3]3]"R_C#AG&6O4=&7::T_\
M"5U]]CH+C3--?GR=O^Z36==Z!9/G8S?G_P#6KSOQ'X;_ ."E/PD++XW_ &:;
MC7H$_P"7KP_&+S>O][%LTC#\5'TKEKW]K[Q?X;E^R^/_ ("^(]+F_B6>UDBQ
M^$B U^>YAEV+PK<<5AITW_>@X_FD?98/&4,0D\/7C-?W9)_DSU>_T*W4$9;_
M #^%8E[I(4D 5P1_;?\  #QYN_!VNQGHR_9T./QW"J=Y^V9X$E&++P3KTK?W
M6MU7^IKYC%9?&K\,3WL/BIT_B9VMWI2YX%9=YI6/X:YJP^-?Q<^($H@^%O[,
MWBC5W<X3[/IL\^?^_49_^M7:^&?V/?\ @I-\7-L@^'VF>"[&;E;C6+N)) O_
M %S!DD!^J+4X/@OB'-)VP>'G/S46U]Z5E\RL3Q-D^ A?$UHQ]9)/[KW9RVMC
M3=)MS=ZI>0V\2]9)I H_6O/=6^*NEW^J1^&_A_HEWK^J7#[+>WL86;S&]!@%
MF_ ?E7V#\-_^"*&F:C>Q:W^T7\;M4UR;K)9Z4#&G^[YDFYL?0#\*^L_@I^R_
M\"/V>=,_L[X1?#/3=)9EVS7RP^9=3_[\SY=OH3@=@*_3^'_ ?/,9)3S*:HQZ
MKXI?<G;[Y+T/@\X\6LIPL7# Q=27?:/WO7[D_4_/WX"?\$J/VA_CU>6WB?\
M:)U@^#_#S,';2X,-?3)_="<K%_O/DC^Z:_0;X$_LW_!S]F[PROA3X1^#+?38
M< 7%T?GN+DC^*20_,Q_0=@*[P=.E&/:OZ(X8X&X=X3IKZG2O/K.5G+Y:62\D
ME?K<_&,^XLSKB*;^LSM#I%:1^?5_._E8  .@HHHK[ ^:"BBB@ HHHH ****
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MPSX.\/66EZ?:QA+:QT^U6&*)1V"J !6@!B@ ' Q1110 4444 %%%% !1110
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M%_\ A,9-3A33!8_;6O7D C6#9O\ ,+= NWG/3% %\G'%*#ZU\3:)\7?VU_\
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M?AC\>OA;YD6@Z[>6_FV.J6,@.^TN5"ME2&<<JZLLCHRX(*@'QC^P)\(_B?\
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MG:PE3/W54';7ZE_#O3/&.C?#_0]'^(FOQ:MK]KH]M#KFJV\(CCO+Q8E$TRH
M H=PS!0  #C H _/S_@KY^R]_P $S/'GQITOXH?\%1/VDO$UWIE[HJZ;\/\
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M]K::IO)\M8D1"("GEJ<+G=$C$,1@\K\-OV>O^#DWQ_XA\/\ @;]H/]MGX/\
MA7PCI6IVS^(O$7@CPBTFM:[:Q2JSQ_.!'"TJKM9HQ"0&./0@'T=\(?\ @F3\
M+?@Y_P %%/B#_P %']%^)WC"\\3?$3P['H^I>';[4E;2[:-&A8-&@7<2/)7:
M&8A S[0-QKZ6KYA^#GP<_P""C^@?\%(_B+\7/BQ^TAHNK?L_ZMX;BM_ _@"#
M3T6YT^^#0D2EA&&7:JW 8^8PD\U?E^4%?IZ@ HHHH ****  ]*^<_P!O/X@7
M$UEHOP4T*RO+VXUB=;O5;33EW3?8XVZ >K$-CM\AS7T8W2O+?A_\$?$6G_'?
MQ)\:_'FH6MS-?1K:Z'#;EC]EMQU!R.&P%Z>K>M?(<:8',LXRR.5X2Z6(DH5)
MI74*=G*;L]W)+D2Z\Q])PQBL#EN.EC\39^QBY0CMSST45Y6OS-_W3P/XR?&&
M_N[[PCX]\&_ _P 2>';CP5*@6YN[7$/V( *8C@<#'R_1C7HO[7GB33/$_A?X
M8>,],FW6%UXPLKA9NRJR[N3] ?R->]^(=!L?$^@WGAS5H%EM;ZUDM[B-APR,
MI4C\C7D/AC]EG4+_ . =Q\"OB9K4=Q#:W\DF@ZE9DF2WCSNC)W ?,I+ CH5.
M,U\9F'"/$6'CC<)3J>W6*IJ5^6-.,:M%PY4U'1*I!*/-;>"N?38/B+):TL+B
M)P]D\/-QMS2FY4ZBES--ZMPDV[7VD['M:,&0,#U&:^>_#AEOO^"@OB9]/?+1
M^#E5G'1&Q;CG\:EL?AG^W)X7T[_A$M"^,.AWEE&OEVNI7UD&N(H\8'WD.2!_
M>W?6NT_9_P#V>T^#_P#:7B3Q#XCEUSQ-KD@;5=6F7&0#D(@/1<\GN3CH  /:
MQ5;-N*<=@:7U&K0C1JJK4E4Y$ERQDE"'+*3FVY;I))*][Z'EX>EE^083%U/K
M4*TJM-TX1AS-^]*+<I7BE%)+:[;>GF<-_P $_P"ZL[3PIXJ\+WJ^7K5IXHF;
M4(9/]9M*JJY^C*_XUU7[0WQ5^/OPN\_7_A]\-=+U3P_8Z:;G4M2OKP(\+ G<
M GFJS   \*>M5?BO^S#KFI^.6^+OP0\<-X7\22KB^_=[K>\Q_$ZX(SP,Y!![
MC/)Y[Q)\(OVU/B5HEQX+\9?%+P[9Z7>1>3?-9Z>-]Q&1@C[G&?8K7C1I\1Y'
MPV\BIX>O[2E=4JU#V3C-7;@Y<[]S=*HG'HW&6IZ<I9+FN=K-IUJ7).SJ4ZOM
M$XNR4N7D7O;/D:?9-'L/P=\97WQ#^&&A^.=2M(H+C5=.CN)H8,[$9AT&23BN
MEK!^%_@E?AO\/M(\"1WYNETJQ2W%PT>TR;1UQDX_.MZOU/*XXR.6T%BOXO)'
MGV^+E7-MIO?;3L? 8YX>6.JO#_P^:7+_ (;NV^NUMPKXQ_X(S7<.D?#+QU\.
M_$1\OQ=I'C:X_P"$DAE/[TR'Y=S9Y(W*XSZBOLZOF+]HG]@;Q=KWQ;;]I/\
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M7/\ $JZU#S-%\1+:IY<%OYJ%H_\ 5@!F02 '8=NX=, @ ^C,UPG[3'QLT/\
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MF^(!$>DWWAFXL]%NI_\ 5QW31W"*.> ?,=1[&137U#\>M?\ C/X9^&=]K'P
M\"V/B/Q/')']BTG4;Q8(95+#>2[21@87)^\/QKG_ -J_]DSX=_M:_#Y?!_C*
M6XL=0L9OM.@Z]8G%SIMP.CK_ 'E/1E/!'3#!6'AND?!/_@K?\/--7P5X6_:7
M\'Z[IL/[NRU;6])5KJ&,=,DQ$N?]\N??% '8_L0?M<_';X]_$[X@?"?X]?#/
M1?#.K^!OL:3VNCW#3?O)C+N5G\R1&P$7!4]S7TH#D9KYX_8H_8\^)?[/7BWQ
MI\5_C+\6K?Q5XH\=/;/JTMGIXABC:'S,," N<^9C 10-O%?0X&!B@ /2OBWX
MJW-KX/\ ^"R?@GQ#X_\ DT_5_ 9L_#MU<?ZL7&;@>6">-V]CQU'FJ>XK[2KR
MG]K7]DGP'^UKX!B\+^*+VXTS5--N/M/A_P 06('VC3KCCYE]5.!N7(S@8((!
M !ZL,]Z:Q_BS7Q[I'P<_X*Z^ ].7P;H'[2'@W7;&,".UUC6=+#74<>, L3'E
MR!S\^\D]S7<?"O\ 9O\ VMO WPQ^(-WX\_:-3Q;X[\9:;#;:9<74+0V.D&-9
MQF(*!MSYY)VHH!1>#0!\R^)_VM)/%_\ P4-U;X]V/P2\5>.O#?@&&;0?"J^'
M;7S8X[H96:Y+$;?F)DVXYVE#VK6_8V_:/E\$?M]Z[HVH_"[7_!/A7XO,T]CI
MGB2U\IH]6C&XNAP 0Y9U..=TB9Z5]<?L7?LU6W[*GP TGX627<5WJFZ2[U_4
M(0<75Y*VYV&>2JC:BDXRJ D9)K)_;D_9;UG]I?X?:1_P@.JVFE^+_"NO0:KX
M;U:[#;8F4XDC8J"VQEP2!U:-,]* /)_@LPLO^"QWQAANCY;7GA/2WM5;CS56
MQL@2OJ 01^!KZL^),\-M\/->N+B58XTT>Z9W8X 'E-S7@?[3/[$7C_XM>+?#
MW[1'P>^**^"?BEHFEQVUQJ4,?F6E\H'*2#:<@$L 2K J<,IP,</XI_9A_P""
MG7Q]TD_#7XV_M)^&='\+W2B/6&\-Z6JW-]%GE<A%(R.H#*I[@]* .D_X(WPS
M)^Q9:73Q,L=QXFU*2!F7AU\W;N'J,J1]0:^JJY?X,?"3PA\"?AAH_P )? =H
MT.E:):B"U$C9=SDLSL>[,Q9B?5C744 %?('P0E6U_P""NWQ:M;D^7)=>#;&2
MW1O^6BJMN"P]0#Q7U_7SE^UE^P_XH^+7Q)TK]HK]G[XJ2>"?B)H]K]F34/)W
MV][#SA)1@],D<AE(."O>@#W#XH7,%G\-/$-W=3+''%H=V\DC' 51"Q)-?&?_
M  3]^,ND?LZ?\$N==^,WB$8CTW5=4FL(W.W[5.S)'#&O^]+A<]N3VK;\5?LO
M_P#!3C]H'1V^&GQP_:4\,Z/X7N%$>KMX;TM5N;Z/NIPB]1V#*ISR#TKK/CE^
MP!<^-/AM\,_V:?AGJ=KI7PW\*ZQ#=^)K>YE<W6HHC9;E1@NY:5BW #29 P *
M /E'X#?%Z[T#]F7QE\-/B#^R'\1/$6K?$JXN;_7O$5GIH\N=Y03 R;AG:F=P
M]V;'6O4OV;/BWX\^,7_!,3XE_ .^AO(_&?@/PQ?Z3)87$92ZDL1"QC0J>=PB
M#P[<<[%'4U]\6EG;Z?:1:?86ZPPPQK'#'&N%10,  =@!7AJ?LM>,/"O[<DW[
M3/@#5M/A\/\ B3P_]A\::/-N$EQ.BXCN$ &TG"Q@Y(X#'DF@"'_@F+XD\)^(
M?V)O Z^%98F%C8M:WT<>,QW*R-O#>_(/T->_5\@^+?V /CQ\&_B7J7Q/_8-^
M.</A.WUN<W&K>#]8MA+I[RDY)C4JR@'G *AE!(#8.!#JW[-G_!3[XW1_\([\
M7_VK-#\*Z%)\E]#X.TW;<3IWPX56Y&1CS /4&@#[$HI #G.*6@#YS_X*RP3W
M/_!/[X@16\3,P72V^4?PKJEH2?P )_"O5OV;;RVOOV??!=W:3K)&_ABR*R*>
M#^Y6MKXD?#_PQ\5_ FK?#;QI8?:=*UJQDM+Z'IE'&.#V(Z@]B :^2_"?[)7_
M  4;_9IL6^'O[.'[2'A_5O!\3,-)L_%>FJT]BA.< [#T] VWN%&2* +'[9;B
M[_X*3_L\Z=:GS+B.:ZFDACY94&XEL>@"D_0&J?[.-_9>%?\ @K9\7M$\<;8=
M6US0H9/#LEQUEMP8F*(3ZH%/':,^E=]^R]^P]X^\%?&.X_:@_:B^+/\ PFWC
M^6S:VT^2" 1VFF1.NUQ$H50&*DK\JJH#-@')-;_[8'[$'A_]IJZTOQ_X6\6W
M7@_Q]X=YT/Q5IN=X4'(AE (WIDD@@Y4DXR"RD Z;]J7QK^U#X(\,:??_ ++O
MPCTGQ=J$ETXU2VU;4H[9;>$+D.I>:+)SQ@$_2OGP?M%_%K]LW_@F]\5_$VN>
M$K'2=<T\WVF-8:.SLK+"D3ORS-EOF8<'&!6E_P *G_X+"-IO_"'-^TCX%,.#
M&?$#:+']H*=,X\C&<=]F[WSS7K/[%'[)EU^RI\'K[X;^)/&<?B2ZUC5Y]1U.
MZ^Q>5&SRHBN@4D[E^7J<9ST% #/^"=WBCP;XI_8K^'<_@J6$PV?ANWLKV.$C
M,=Y$NRX##L3*';W#9[U[8,"OCW7/^"?_ .T#\!?B!JGCS]@GXZP>&M,UBY:Y
MU#P7KUN)[(2'DB+*L O89 91QO(P!/%^SG_P4T^+6L6<'QI_:IT/P_H,%U'+
M>:?X1TW9+=*K9*EPJMAAP09,?[)H ^N\T5'!$T,21 YVJ%W'OBI* /E'_@M5
M;W$__!/'QHT$+-Y<MFTFT?=7[0G)]NE>V?LDW]GJ?[*WPUU"PN5EAF\ Z.T<
MBGAE-E%6]\7?A9X-^-_PUUKX2_$+33=Z+K^GR6>H0JVUMC#[RG^%E.&![$ U
M\6>"/V*?^"IO[)6F/\+_ -E;]JCPSKG@>%G&BV7C+25:XTZ,G(4'8>GH&V9Y
M"+G%<-3VE'%>U47)-):;IIOIIW/TS)WE/$'!,<EJXRGAJ]&O*K%U>90G"I"$
M6E.,96E%P3M))-/1W5C1_;KF2]_X*N_LMZ;:/YEQ;-JL]Q"G+1Q, %<CLI*,
M,_[)KRS_ (*D_M 'XC?MS^!_@I:?"WQ%XZ\+?"NYAUWQAH'A>V\^2YO'&^&*
M0?="@"/=N_AD8#DU] ?LG?\ !/'XG_#WXT:C^U]^UA\9?^%B?%"?36M-),</
MD6&F1D'Y4 4<G.T;554#,0&+9'4_L ?L<^//V;SXZ^)7QO\ $>GZYX^^(/B:
M74M;U/3=_E+$262)-X!"@LWRXP!M Z5RRH8BO=-<O/*[V=DDK)^;:V/L\/Q-
MPIPXZ->%:.*G@,-["FHN<%4JUZM652<)-*2A2A4E%3:BW)Q<5U/BGQ-^VG>>
M'_\ @HMX+_;)A_9N\<?#G1=8MH_#7Q F\36'EV]U'(P2*8.HP&4;,Y[0J1WK
M[(_X*N_M0WW[.7[(&K3>"KEG\4>,V70?"Z6[$R^;<#:\R <EDC+%2/XV2O3/
MVQOV<-*_:N_9R\3? [4WBAEU>Q/]FW<RY6VNT.Z&3\' S[$UX#X$_8)_:1\<
M?&#X*^+OVJO&GA_6-%^#_AWRX[/3Y97;4M5C)6WNI-Z@?*BP.2>3)&>"&JG1
MQ5%3IQ=^?K:UF]'^&OJ<U+/N".(*F79KC(1H?4.:$J#G*;K4Z<74H1C*2N[S
MO2E=^[%QZ+3X]\3?$2:[_P""=NF_L::+^PE\5+/6-$:'4]/\3_V. D>L(Y=K
MK &X [G7UVM7Z0?\$[?VF[7]J_\ 9+\+?$Z68?VQ#:_V9XFMOXH-0M_W<N1V
M#X64#^[*N><U[?M.,"OF_P#9*_8V\=_LI_M'_%+7O#.OZ:_PV\=:DNK:3HB%
MUN--OF^:50N-HCW,ZK@_="9Z5I1PM;"UHM/F37*]$K6V?YKYGE9]QAD/&G#>
M*HU*"PV(IU'B*;=2=3VDJC4:T+R7NMKEJ)*R]Q[7U^DZ*!G'-%>D?CP4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Y&*^>?^"?W_  3O
M\!?\$^H_BI'X$\?ZQKW_  M7XIZEXXU/^UH8D^Q75YLWV\7E@9C78,%LMSR:
M^AJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0MCM0!D>+
M/$EMX;BAEN) OG.0NXUK1-OC5QW4&O!?V\/B*/A]H/AFX,_E_:M2E3KUPJU[
MIILOFZ?;R'^*%3^@H L4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5'>)-);2103>7(R$))MSL..#COBI*" >HH _)
M?]OO]N7X@>.+RU^!OQ5\#+I?BKP'XGNHM4O+"0_9[Z/"JDJ*WS+N #CD@A@:
M^WOV"OVJ/'W[7MEKWQ&E\)0Z%X-TN2+3- MY#YES>W"KNFF=^@508U"J,99N
M25KY/_X+=?LX75I\5_#?QS\+:6\A\3HFE:@L4?W[R/ A/'5F0A?^  5]X?LD
M?!"T_9U_9Y\+_"F&W5;BPTY7U)E_BNI/GE/O\Y(_"@#TJBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ,XZT9K\U?^#C+_@K-\=O^"=7PK\%_#W]CIK>;XJ>-+ZZO;>*31TU
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M_@W\//!UQ:KIWC;Q5]@UQ;BU#LT.Z,80G[IPQY%>_!L#F@!U%&1ZT4 %%%%
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MUI-?W]PD,%O&TDTTC;515&2Q)Z #F@"7(Z9HS7QK>?ME_M;_ +6?C/5/#?[
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M^)VB:)#X/U8ZU9S/=RP6MHDR-#%*TL6UHG&750=N02""=3]@C]C']HWX(_\
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MM\)M$_:-_:?^/OQT^$__  TAXH\.>%]'\<3QQW6GZ@\EU$H>18[2W+M_HT(
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M:BB@ P,YQ1110 8'3%&T8QBBB@ P,8Q1CVHHH -HZXH  Z444 '6C Z8HHH
M,#THV@]J** #&.E?*/\ P2R_X)W>+?\ @GU%\;(O%?Q$T[Q!_P +6^-NL>.;
M'^S[62/[#!>>7MMWW_>==G+#@YKZNHH *-HZ8HHH , '.*,>U%% !1@8QBBB
M@ VC&,4FU?2EHH ,#&,4444 %%%% !1110 4$9&"*** $V+Z4;5]*6B@!-B^
ME&U?2EHH -H]*  .@HHH **** "BBB@ P,YHZ]1110 FT#D"O'OVX?V:-9_:
MO^"7_"I]"\2VNDS_ -M6M[]JNX6==L1;*X7G)S7L5% %?2[,V&F6]B[;C#;I
M&6'?"@9JQ@9SBBB@ HHHH **** # SFBBB@ HVCTHHH ,#THHHH **** "BB
MB@ P/2C ':BB@ P.N**** "BBB@ HHHH *.G0444 &!UQ00#UHHH P_B5\/O
M#GQ5^'NM?#3Q; TFEZ]ILUC?+&VUO+D0J2I[,,Y![$5\MZ7^PO\ MP>"?"Z_
M!SX<_MX-9^!X8#:VMO=>%[9[R"V.1Y:R["_"\#$B^V*^P** //OV8/V=_"'[
M+?P<TWX/^#+RXNK>S9Y;J^O,>9=W#G=)*0.!D\!1T  R3DGT&BB@ Q1@>E%%
M   !R!1110 4444 %&!G.*** #%%%% !1110 8S1@>E%% ";5]*6BB@ QBBB
MB@ HHHH *,8HHH ,>U&!G.*** #:/2BBB@ HHHH **** "FL !PM.HH \/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_!,_P#X*_?#_P #WEW\3+-9?!?C+P-&8E,CM(L>=N$EC+Q/&1LC=&P3N!%
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M4L_['\%>+)MOB"]T:XD4)JMT69/LP:)A,(T<O&A7<CG( !^G]?G#_P %_?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3R_8I^+%K\?9_P#A,/BAXWTYE?1=>^*&M)?C2W!X>W@CBCC#CL\@D93RI7-
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MM:/X7FU7X?\ CVWN&FNH+>*!YXTN&?\ > /#%("DA9TD50'=7#G[2_X*3_\
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M?#OQ;_P1?AU3X7>(M%U32%^*VCQPW&@7D4UL&"7990T)*Y!/(]36I_Q!Q?\
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M'%YJWC+3(K'6IO%WB".^#1I+YH9=L,9#[NI).10!]@44#CBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$W_@N5_P6_\ ^"G7
M[&G_  5"T']AC]B#2/">J+XF\/:(="T?4_#(N[R\U2^N)H4A1S,@^=UC50<
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M@Y=R77]LZCI;7]NJVK&'R58J<OT!RIX^GJ*ZC/:@ HHR*,B@ HSVHKS]_CI
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M&O\ 98US0[.YN$B75M-NQ>11EF !=0H*KD\G)^E 'OU%-5U9%8'[PS3L\9H
M**,BC(]: "BC-&10 44$@=31F@ HH!STHSCK0 49H)%</^T'\<O#_P"S[\/)
MO'VNV$UZWGI;V.GVW$EU.^=J ]AP23S@#H3@4 =QFBN+^"7C?XG>/?#%QJ_Q
M3^%O_"*7BW>VWL?[0%P9(=BL')"KM.25QC^'/?%9_C/X\/X1^/?A3X(_\(K]
MH'B:SN9_[3^W;/LWE*3CR]AWYQUW+CWH ]$HHR/6@$$9% !10&!Z&C(SC- !
M12;E]:7/>@ HHS02!UH **,YZ44 %%%% !1110 4444 %%%% !1110 4444
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MC;Q!=:?-X!TWPW;M)<:)(DT;//( @-IB#S(O+?:Q,F-IP<?17BWPM\<?!?\
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MV>+SX._#GXAK<Q^$_ -Q#)#&OVB_^U1I$DBHS16T?[M9"BAO,.U5'  /.?\
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M+Q!\/_%^L:MX#^*7[.?BRZO+",?\(KXG\/6)F:8F-6!61<&,B0D$-E?ES[4
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MTGN25[ _*?6J7PN^-GCGX#_">'X%?%/X#^+IM2T6TFL+34M"TX7-K>0_,(Y
M=P*\$ CG.,]\  Z;_@FP,?LK:7_V$+K_ -&5[W7S+^S'XF\:?L^_L.KXDNOA
M;JVJ:II]]*5\/QQM#<2!YU7/*,0 #N)"G@=*^B?".N7/B;PMI_B*[T>;3Y;Z
MSCGDL;G_ %ENS*"4;W'2@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ HHHH **** "BBB@ HHHH *"!110 4$9HHH 0**-H]*6B@
MHZT44 ! -)M'4TM% "!0*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@9'Z"NI_:B^.7BKX=^*?!_PS\$7.GZ7?>,+YH)/$>J1[H;")<9(7(#.2> 2
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MM0 97TXKH/CQ*MG\$/@G\5C!_:6@^%+VTD\00VJ^;Y:M#'B1@/[I4CURX]:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%&:,]Z "BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQK-!(KHPRK*V0?QIU=F^J.8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M,:TH-0E=1;3L[6O9[.UU>VUU<=14-_?VFF6<VHZA<+#!!&TDTLAPJ(HR6)]
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M@ KY_P#^"K?_ "C/^/7_ &2?7/\ TBEKZ KY_P#^"K?_ "C/^/7_ &2?7/\
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M)/\ MX_!Y?[)GL/#_B>^M=4$0DOK#1C+!9/)C;'*X;[_ ",JFXC/->/_  ^
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MPE>_LJZIX]^&HU/5[?Q!I=U8V=]I-KN^P2-"RF2?<RF(+W."0<<5!_P3\OO
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M\"B,Y$XLY/-E8#T"_/Z$RGKBONC]GOXO:/\ '?X.^'_BMHI55U;3TDNH5/\
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M%DQ*[;6VG!(QD!<]!7M%%% !1110 4444 <YXH^%/@+QMXJT?QKXET!+G4]
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M*,2JD DJ ISU'%?J,.E=T8QIQ48JR6R6R.64I3DY2=VPHHHJB0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** .4^)/P0^$OQ=2-/B-X"T_56C7;%-<0_O$'H'&&Q[9Q6!X/\ V0OV;? V
MH)JWA_X2:4MU&VZ.:XC,Q0]B Y('Y5Z5FCWH P?'_P ,? 'Q3T7_ (1WX@^$
M[/5+,-N2&ZBSL;U4]5/T(K'^&7[.WP6^#EW)J/P\^'NGZ;=2KM>\2,M+M] [
M$D#V&,]Z[;O10!S_ ,0?A5\.?BMIJ:1\1?!UCJ]O&VZ);R')C/<JPY7\"*Q?
M '[,WP(^%OB%?%?P_P#AM8Z7J*PM$MU;M)N"-]X?,Q'-=U10!Q/Q/_9W^#'Q
MBN8]0^(OP_L=2NH4V1W4BE90O]W<I!(]CG%;'P_^&7@#X6Z)_P (_P##WPG9
MZ39EMS16L6-[>K'JQ^I-;V:* ,3P+\./!'PSL+O2_ GAV'3;>^U"2]NXH"V)
M;APH:0Y)Y(5?;BJ5A\%?A5IFBZSX=L_ UB+'Q!=/<ZU:R(72[F8Y9V#$\YYX
MQ@]*ZBB@#@?AY^R_\!OA5X@;Q3X$^&UA8Z@58+=*&9HP>H7<3M_#FN^HHH Q
M/"WPY\$>"M7U;7O"WAV&SO-=N%GU:>(MNN9%SAFR3R-QZ8ZTGA'X:^!O >I:
MOK'A'PW!8W.O7S7FL30ELW4[,S&1LD\DLQXQUK<HH YG3?@[\,=(T[6])L/!
MEFEKXCN'GUR!E++>2.,,SAB>H],5RH_8U_9K.GP::?AA:F.WF$ELS3R[X6!R
M C;LJ,]A@9KU"B@#F_$OPC^&GC/PG;^"/%?@JQU#2[556UL[J'>(<# VD\J<
M<9!S6)X(_9:_9_\ AOXBA\6^!_AAI^FZE;JPANX&DW(",'JQ'2N_HH XSXH?
ML_\ P=^,DT-Q\2/ 5CJ<]NNV&XD4K*JYZ;E(./8\5=^&GP:^%_P?L)-/^&W@
MFQTE)\&X:WC^>7'3<YRQ^A.!7344 ! (P17FGB#]C[]FSQ/XA?Q3K/PDTN2]
MDD\R9E5D61L]2JD*3^%>ET4 9-]X)\):KX/F\ 7OAZU_L6>S-I)IL<>R(PD8
M* +C QQQBK'AOPYHGA#0K7PQX:TZ.SL+&$16MK'G;&@Z 9J]10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /RS_ .#I-@OP)^%!8_\ ,Y7?_I**^[O!_P"V7^R5!X2T
MN";]I3P0KIIT"LK>)K;((C7(^_63^W/_ ,$]?@/_ ,%"?"FA>#OCQ?\ B""T
M\/:A)>V#>']0CMW,CQ["'+Q29&.P YKYI_XAH?\ @G=G/_"1?$K_ ,*6V_\
MD2@#Z^_X;0_9&_Z.7\#_ /A36W_Q='_#:'[(W_1R_@?_ ,*:V_\ BZ^0O^(:
M'_@G=_T,/Q*_\*6V_P#D2C_B&A_X)W?]##\2O_"EMO\ Y$H ^O?^&T/V1O\
MHY?P/_X4UM_\71_PVA^R-_T<OX'_ /"FMO\ XNOD+_B&A_X)W?\ 0P_$K_PI
M;;_Y$H_XAH?^"=W_ $,/Q*_\*6V_^1* /KW_ (;0_9&_Z.7\#_\ A36W_P 7
M1_PVA^R-_P!'+^!__"FMO_BZ^0O^(:'_ ()W?]##\2O_  I;;_Y$H_XAH?\
M@G=_T,/Q*_\ "EMO_D2@#PW_ (*\?%SX6_%O_@IE^S#J'PN^(>C>(8+/5+>.
MZFT?48[A87.IQ$*Q0G!(YP:_7L'-?"?PQ_X-XOV#/A-\1M#^*'A?7OB$VI>'
M]4@U"Q6[\0V[Q&:)PZAE%J"5R!D CCO7W90 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4&IVG]H:=
M/8?:)(?.A:/S8FPR9!&0?4=JGIKLB(7D8!5Y)/:@#Y!_:$_8Z^%GP'^%^J?&
M#P5\4=>TGQ5I,8N;;4[K6"9+R;</W>."2Y.!CN><C-?2WP1\0Z_XL^$7ASQ+
MXJA:/4K[1X);Q67!+E!DX]^OXUX?_P % OV;]'\4>$]2_:)L_&E]8:QX:T^*
M6&SEF1K*98GR!L*Y$AW$ Y()V@CG->T?L]>,M5^(/P0\+^--<A6.\U#1X9;A
M50*-V,$X'3.,X''- 'E/_!2*YNK7X5^&Y+6XDC8^,K,,T;E<C#<<5[EXO\=>
M#?A_I#:]XX\366DV:M@W-_<+&N?3)/)]J\)_X*4_\DH\-_\ 8Z6?\GKE?VB5
M\0>.OVZ=#\#:CX*L?$EEIOALW6C>']8U7[):W$QR7DSL<.PP?EQSLZX&" ?2
MO@/XL?#3XH6<M]\/O'&FZQ%"<3-8W2OY?^\!R/QKC=&_;%_9^U?QEJW@QOB1
MI5G)I5Q';BXO+Y(TNYFSN6+)^<*<*2.,G Z5P'@[]G_XF6O[1&E_$J#X2>'?
M"&B3:;<6'B?3M)UP7$=_$Z-L)C$48W!L \'(^E9'[)GP=^%.M_%SXK6VK_#W
M2+F/2?%B1Z:DUBC"U7#'"9'RC('2@#UOQ/\ M;_ KPA\31\+M>\>Z?:WD=FT
M]]=7-XD<%L<C;$SDX,C YVCD 9.,C/8:K\3OAYH7A*'QYK/C72[71;B)9;?5
M)KQ%@E1AE65B<$$=,=:^<;+X2?##5?\ @H1KGAG4_ >E7&G?\(?#=?8YK-&C
M\YB,R;2,;CW/6J/[0ND7&M_MC>#_ (46_P /M,UC1=)\-M/H'A?4-2^PV4TH
M#9Z(X8JJ\)CD)Z @@'TQX!^+?PS^*4$ES\._'.FZPL)Q-]ANED,?^\!R/QJK
MJGQU^#6BV&H:IJOQ-T6&WTF_:QU*234$_P!&N02#"_/#@@_+UXKQGPC\"/BM
MIO[1OA[XM:)\)?#W@K3[>WEM/$5OH^O^<M]"PRA\L0Q@,I^I(QTVUD?LH_"+
MP'X_^+GQFUOQOH-OJRV_Q&U&"WM;Z,20Q;IY2SJIX#$8!.,X&* /H'5_C9\(
M]!\(V_CW6/B-H]OHUYQ:ZE)?)Y4Q]%.?F/L.:O>"/B+X%^)6EG6_ /BRQU>U
M5MK3V%PLBJWH<=#['FO$_P!I#]EJ_?2O!VN_ 7PKI,W_  @MS<2V_A&_CS:W
ML<Q4L,$_?RAQD\YZ\8/0_LB_$#X9>-H/$">%_A>/!OB.WO(T\6:#Y6PI.H(#
MC  (QD;L GOVH ]=U35=-T2PFU76+^&UM;>,O-<7$@5(U'4DG@"N:\$?'CX-
M?$G5I-"\!_$O1]6O(@2]K9WJN^!U(&>1[C(IGQX_X5FOPLU2X^,#+_PCL,:R
MZC&S'$BJP(3 Y.3@;1USBOE_QSJ]A?\ QY^#7C/P9\$I/!FG77B.&WL;R01P
M3W]NQ08,,?*H5;C<<D-C H ^KO$7Q<^&'A'6)/#_ (H\?Z3I]]#:?:I;2[OD
MCD6'_GH5)SM]Z/ 'Q:^&?Q3MYKKX=^.--UA;=MMQ]ANE<QGW Y%> ^-_!7A;
MQW_P4BT_2?&&B6^H6L/@LW"V]U'NC,BGY6*]#C/?(SSV%7/^$8T'X=_\%$M'
ML?!.E0Z9;ZQX&EEU*ULXQ'%-(LK@.5'&["KS[4 >U>//CA\(?AC=1V'Q!^(F
MDZ3--S'#>WBH[#UVYSCWKQ?]AKQ%:>*/C-\;=8TK65OK&X\6126-Q%-YD;1L
M]T0R'I@C'2J?[&G@'PA\4-?\??%+XFZ':ZOXC?QA=64HU*$2FQA0X6%5;.T8
MX]P!Z5:_89TK3M#^-GQQT?2+&*UM;;Q?%';V\$85(T$EV H Z "@#Z.U'4K#
M2+";5-4O([>WMXVDGGF;:L: 9+$GH *XR^_:9_9]TW[%]M^,?AZ,:BNZR;^U
M(R)5SC((/3/&>E7_ (WC/P=\4G_J7[O_ -%-7@?P"^"/PHU?]@QM7U'P)ILU
M[?\ AF]N;F^DMPTS3*LNU]YR05VC&.!B@#Z@&HV)LO[2^V1_9_+\SS_,&S9C
M.[/3&.]<;IG[2OP!UGQ"/"FE_%_0)M09]BVL>I)N9O[HYP3[ U\FZYXR\43?
M\$^/ASX>EUZXMM/UKQ,NF:QJ"R'<EF)IL1D_W<*/PC Z<5[U\9?V6OV<K+X
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MV_\ BZ^0O^(:'_@G=_T,/Q*_\*6V_P#D2C_B&A_X)W?]##\2O_"EMO\ Y$H
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MBJXM9M2_X2'4H[@JT"R*FS9%'M&)6SG.>.E>^T %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_86_8)^"_P"W?\9_VE/B3^V1X>B\::Y;_$N;P_;Z[:SW%@L$EM'LE:W2&15
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>mrna-20211231_g4.jpg
<TEXT>
begin 644 mrna-20211231_g4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IA;65S($1I
M;&QO;@    60 P "    %   $*:0!  "    %   $+J2D0 "     S4W  "2
MD@ "     S4W  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M=&X^I_.DHH 7<?4_G1N/J?SI** %W'U/YT;CZG\Z2B@!=Q]3^=&X^I_.DHH
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MRD[7,T^([I[R2XDA@?S;;[,\9#;63\#G/'7-+<>);FZ^TB>WMF2YB2-T"L
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M>G("]_7BY+:W%O<0^&;56%OXKM[*;<@/[L*H%P?J40'\:0SIH/ACY.CR6/\
M:^=^D?V9O^S=/WK2>9C?_M8Q[9S5[2?A_#I7B$ZC'/:R1FX:YP^GH9][* 1Y
MQ)(3.6  !&<9(KKD18T5(U"JHPJJ, #TIU,05R>NZ-KFH^*K*]2#3[O3=/'F
MV]K/=O"?M'_/1L1.#M!(4=LYKK*X;QKKMSX1UZVU<S2O975E/;&W+DH+A1OB
M(7IN;!7- &9JOPTU+7KFX:_N;:UBN]0:ZE%O,[-&K0"/ )0;OF]< CTSBI-0
M\$>)=3NK:6[FTT>6;1B()I(D4PM\PV+'A\]5W'Y.0!WJ[X2&IV7B\:7JE_=7
M+Q:'!+,L\S./.:1BYY/7/&?0 5F6BZ]J?B#4FTQM3:6U\0E#=-?XM8K=0A:(
MQ&3G@GHG\0YXX0'IU%%%, HHHH **** .8^(ND7VO> =1TW2H//NYO*\N/>J
M[L2HQY8@= >]>&?\*C\;_P#0$_\ )N#_ .+KZ:HKII8F=*/+$YJN&A5ES2/F
M7_A4?C?_ * G_DW!_P#%T?\ "H_&_P#T!/\ R;@_^+KZ:HK;Z]5[+^OF9?4:
M?=_U\CYE_P"%1^-_^@)_Y-P?_%T?\*C\;_\ 0$_\FX/_ (NOIJBCZ]5[+^OF
M'U&GW?\ 7R/F7_A4?C?_ * G_DW!_P#%T?\ "H_&_P#T!/\ R;@_^+KZ:HH^
MO5>R_KYA]1I]W_7R/F7_ (5'XW_Z G_DW!_\77L'PE\.:KX8\)W-GKEK]EN)
M+YY53S%?*E$ .5)'537=45E5Q4ZL>5I&E+"PI2YDV%%%%<IU!1110 4444 %
M%%% !7G_ (\_Y#L/_7LO_H35Z!7G_CS_ )#L/_7LO_H35YF:?[N_5'/B/X9S
M-7;;1[Z[MQ/;P;D)(7Y@"Y R0H)RWX9JE6_IVN6EM;:<;B.8SZ<TC1J@&V7=
MR,DG*\^QXKYNC&$I6F[+^OT//@HM^\4$T+47LQ<K #$T9E4^8N2@ZD+G)Q]*
M;_8U_P#8OM7V<^5L$G##=M)P&VYW8/KC%;,7B:UVV_G12EDM)H7"J,%G.1CG
MI52XU>QN6MKR1+C[;;0QHL:A1&60_>)ZX([8'UK=TZ%M)?U]WX&CC3MHRNOA
M^^6XMTN8O)2:9(6<,K&,MC&X Y!P<X.*)/#]]YTZV\7FI%+)$K9"F4IG.U2<
MMTZ#-:1\0V$5S/-;QW#&[NXKB82*H\L(V["X/)SGDX[4H\1V+7,%S)%<"2SN
M)Y8455Q('8L QS\IR>P-7[/#[<W]7_RU_ ?+3[F3!H.HW-LL\-N#&R-(N9%4
ME1U;!.<>^*9+HU]")C+!M$$:R2$NN K?=.<\Y]JZFWU&S>QBU">YA6=+"6%H
M5D4<YX&"=V3Z8(]_7+U/44'A2QM=\;7<BJLWEN&Q&A.P'!.#\WUXHE0HQA>_
M2_\ 7S?X,'3@E>YSE;7A'_D:;3_@?_H#5BUM>$?^1IM/^!_^@-7/AOX\/5?F
M9T_C7J>F4445]J>N>3^-/^1OO?\ MG_Z+6L6&)[B>.&%=TDC!%&<9).!6UXT
M_P"1OO?^V?\ Z+6LW2G6/6+)Y&"(MPA9F. !N')KZ2D[48OR7Y'VE!M8:+7\
MJ_(AN;:6SNI+>Y39+$Q5UR#@CW%15UNRVB\=G4;R:SDL'NF8,MS')USM)4$G
M&<'IQ5^TU"TCFL1J][;W&J+Y^R[$JNL8.=FYQQUR0/X<]LU#KM):7T(>):2M
M&^G^?]/U.#JW#IEU/:"ZC1! TWD^8\JH-^W=@DD8X'7I75Z7<RQ3S3ZCK%I-
M>K#"J!;I$RNXY#R@ L5X)"MDXP2>E:*:CIL>K,4O+58SK/G9$JXVF Y;KTW'
MKZU,L1)721$\7--J,=CSEAM8@XR#C@YI*[H7JV?A_P L:A#="ZN-]Q&;Q#Y,
M ;.Q4+9R1G@#^E6KC5M-_MJT-U+;2P"],D$INEE,2[,#"A?W:9V\$YR,]LT_
MK$ND>_X#^MRZ0OOU['!RV5Q!9V]U+'MAN=WE-N!W;3@\=1U[U7KI?$UR\VBZ
M1'<WT-Y=QM/YS13+)C++MR1[?R]JYJMZ<G*-WY_F=-&;G#F?G^9ZQX+_ .10
MLO\ MI_Z,:O#*]S\%_\ (H67_;3_ -&-7AE?.5_XLO5G/E'\?$>OZR"M/2M"
MFU6WN;D7%O:V]L462:X+!07.%'R@]^_0=ZS*Z?P=J\>D23O)J<5LDI59K6YM
MFDBN8^0<E02" 3CC!]<9%8GLXB4XTFZ>_P#7J8LFD7R7*0QV\EP9'9(7@4R+
M.5/.PC[WX4@TC4FMA<+I]T8"VP2B!MN[.W&<8SGC'KQ7>6.JV4.D:UJ-I;20
M6=E<O+I;LI"EY$:,JH],_-@=,]L5F1^(=/?P6;*]NUDF2S,4*PQR0SJ^[A'(
M^22/G/)' ^Z30<BQ59[0V:3^>OX*U_F8-[X6UFRU 63V$\MP8A+L@C9_E.,]
M!S@G!QQFJL&BZI=1E[;3;R9 2"T<#, 1U&0.U=U<^)]$N+K4-EW;XO%M722:
M*?"&+&5;9ALC[PP2..2.*6#QAI3W-C+<7BJ8]5DN)MENZ+L,94/M^;J3TR3S
M09K%XKEUIZ^C[7_/0XF'P_J+W0@N+6>U=HVE7SK>7YE'7 52?QQCU-5FTV^2
MQ6]>RN%M&Z3F)A&><?>QCK7<:?XHTF*.Q^T7AWQ1WXD)C<D&5P4[<YY^G>LG
M6]4L=1LUN;35Y+0_8(;=M.CC?YF3(*D\+L'4')^E!K#$5W.TH67H^[7X[]CE
M****#TCW[PY_R*VE?]>4/_H K2K-\.?\BMI7_7E#_P"@"M*J/S.M_%EZL***
M*#(**** "BBB@ HHHH *!UHH'6@ HHHH **** "BBB@ KB?^$VUV[UK4['0_
M"?\ :":=<&"2;^TDBR>W#+_C7;5XU<:-I@\7>()O$O@[7M5\Z]9K::SMI2FS
MOR&4']: /3XO$%M;V4+>(9;31[QHO,DM9[R,F,;MN=V0",X&>F3BK4FL:;%I
MRZA+J-HED^-MRTZB-L],-G%<%'HEMK'CG0)9/#URFD0:.8D@U"U)$)5F55?=
MD;L= 23T-<_8Z#J%EI&AW&H^'[S4--T_4+OS]-%L6<J^!&PC;[P!Y]/SH ]=
M;5]-331J+ZA:K8G&+DSJ(SSC[V<=>*5=5T]]-_M%+^U:QP3]J$RF+ ."=^<=
M>*\POM(D>STC4H/!UW%HUMJ4\\^D F6657"JLAA/W>0?W8X'T)-4[GPWJ=SH
MNIZA9:#<VVESZM;W2:,8]DKPQAUD_=#IN)4[?]GCC!H ]$T[QA::GXHN]+M?
M)DMK>T6Y%]'<!T<$X(X&..><]JUK/5]-U&"2;3]0M;J*+_6203JZIQGD@\<5
MY!>:%J&KW/B:3P_X;O-'M[O3XA!!+:^1YFV1"Z@#Y5)"MP#D_C3-.\*ZQ>Z/
MKSV4.HPSRZ>(/)N-(CT])<2*V%"/\S85AG;WY/2D!Z4/&EC<>*M.TC3&M[^*
M]CE8W=O<JZQLBYVX .3C'<=:Z2O*/#MGYWQ T"\T_P )WVBVMO9R0W$DUGY0
M:38>3CKU&&."<^U>KTP*6HV'VZ%E#*CE"H9EW;?<#UKB]=^WMJ*:=-<^>\0"
M1-W#RG:,^X4$_C7H-<+%_I?CMF;D"ZE?_OW&$'ZFDQHZVSMH[6WB@A7;'$H1
M1Z #%7%'%11BIU'I2&<]H_ABY@\2W6N:Q=17-W*-L2PH0L2].,^PQ^?K6QJ>
MG?;HAY3*DR@J">C*<9'MR 0>Q JIXG\0)X<T5[PJ))6;RX8V. S'U]@ 3^%1
M^'==N]1<V^JVZ6]T$W[%!&,8R""3R,J>O(- $5[ITEAX4U66ZD66?[%*-R]
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<_KWA?\
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MNQI_VKS(-WV?[5]GWGS/*SC?TQCOUS6]I7B#3([6RNM1G)N[/[20G[PGY\D
M<$,3D\EAC/.>M9,WBB2?1TLWCF#I;"V!6Z=8BH[F,=6QQR<>U-2K.6W]:_\
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MX'B\/9 46AA9QW<CEO\ OHYJ/3O"HL[H2SW,<L?G&Y\F& QJTO9CEFR!U X
M//85T!- 'GO@34&M]5NM.N_W<EP-VP]IH_ED7\@#_P !-=M)7/Z[X.34M3_M
M'3[]M.N2P=V6/>"XZ..1AL<'L1U%;<:RQVT:7$HFF5 'D";=[8Y..V?2@#CM
M4D5/&8=CA4EM=Q^FXG]*[&VU.SN\_9Y@^" 2 >">GYUR%@JZGXU9R-\?VB20
M@C(*1IY8_P#'B:Z^/3+6*?S(H_+Z$HG"D@Y!QZ\TT)ENBBBF(**** "BBB@
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M+$SJ58TH.<WH>5^'- U>^\*V=WH.BQQR"PNHIYWG55U'?( J':X8[0&^_@<
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M-7DLH1$LUQ:J<\ 9 ;.,@#//.*V:* ,:X\/1W'B33=2>4+!ID+I;6B1@*KL
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M:K:7-W>W>J-,VH7B?)JMS&H5;F15 59   J@8 [5U51PP16Z%((TC4LSE47
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MWTJ.R6"^UR2XU'2YWANC?":WN66#S&?:SED*XR"BJ,MCIT/;U?YG]X?6:_\
M._O9U/\ PA>@?\^'_D:3_P"*H_X0O0/^?#_R-)_\56-X.EN-/\,66JZQ'>2?
M:;.!A)%?7>H/*60,6,.PB,]_ER!G&?7%;Q?=/\1O[12YO1HD=VFE&$PRK!EE
M.Z5FQL#"4JO)#8H]O5_F?WA]9K_SO[V=G_PA>@?\^'_D:3_XJC_A"] _Y\/_
M "-)_P#%5NT4_;5?YG]XOK-?^=_>R"RLK?3K-+6SC\N&/.U=Q.,G)Y//4U\[
M5](5Y+_PJO6_^?K3_P#OX_\ \16,FV[L]O)L52HNHZTK7MO\Q--\8:;:V>FB
M>.Z\ZSLYK5E2-2K;^C!BP/8<8[_F6_C.PCM8;9H)0ATM+.60P1RE75B00C'#
M+ST.*7_A5>M_\_6G_P#?Q_\ XBC_ (57K?\ S]:?_P!_'_\ B*D])U,N;;<_
MZU?ZE;5/%UMJ&CWMFPNIFENHI(S,L:YC10,-LP >.@''J>M;=OXRT>YNK6TM
M_/MH3J,,T:2QQQ0VR+C*C#<#.3G Z_C6;_PJO6_^?K3_ /OX_P#\11_PJO6_
M^?K3_P#OX_\ \103*67./*IV_I?Y$Z^,-,T74GBLHY[N)]2FN;B1E3@,I3$?
M)#=2<G&< =^*:^+;+,MK+)>/9R:=):!A:PQF-W(.Y8TP O'0L>M2_P#"J];_
M .?K3_\ OX__ ,11_P *KUO_ )^M/_[^/_\ $4#4\N6KFK]PO_%VE7L>H6ZI
M>1PW5C!;(YC1F5HV)Y&X#!SUS^%,U7Q3HVN&]M[U+Z&UFNX;F-XHT+Y6(1LI
M!; R <')^G:G_P#"J];_ .?K3_\ OX__ ,11_P *KUO_ )^M/_[^/_\ $4#C
M4R^+NJGX^G^2*^G^)]+MM!?3KN&ZNK91-Y5E/'%(BLQ.QQ(-K(P!(. >I(QV
MY&NV_P"%5ZW_ ,_6G_\ ?Q__ (BC_A5>M_\ /UI__?Q__B*#HIXS TVW&HM3
MTCPY_P BMI7_ %Y0_P#H K"^)-[=6/ANWEL;F:VD-VJEX9"A(V/QD=N!72:3
M:/8:+96DQ5I+>WCB8J>"54 X]N*Y7XI_\BO;?]?B_P#H#U1\;%J6(OTN><?\
M)%K?_08U#_P*?_&C_A(M;_Z#&H?^!3_XUFT5)Z_)'L:7_"1:W_T&-0_\"G_Q
MH_X2+6_^@QJ'_@4_^->@:UI6F7&NWMU?6*W4LNL6]IEI77:C1IGA6'/7_/%-
MLM+L)--M-'NK43VS:U<P+ND8% JM@@J1SP.N1[4'-[6%K\IP/_"1:W_T&-0_
M\"G_ ,:/^$BUO_H,:A_X%/\ XUU=AX5T_P#L.5;ZV7[6UG<W$4JR.S81L*QP
M0JCI\N&)[E>E:NJ:1IMV_P!OU%8IFAM+*)8I#+A0Q.3B(%B3T7MGKF@;J4T[
M6//_ /A(M;_Z#&H?^!3_ .-'_"1:W_T&-0_\"G_QKO-#T73-)UK3);&WDN7N
M-0GC6>82(\"HIPNWCGUW#UX';SG4/^0E=?\ 79_YF@N#A-V2+7_"1:W_ -!C
M4/\ P*?_ !KOOAAJ-[J!U/[?>7%SL\G9YTK/MSOSC)XZ"O+Z]'^$O75O^V/_
M +/31&)C%4G9?U<]'HHHIGC!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 9FMZ,FK6Z[6$5S%DPRXSC/4$=U/<5RNG:G=^'[EK*\@<P)RT ^9H1_
M>C_OI[=17<7+O':RO$-SJI*C&>:Q%\/IJ<\\^K/YS,?W+QDIY?NO&0?SI#-*
MSOX+VW6>TF6:)NC(<_\ ZOI5D25QMUX;U33+AKG3I'FSUEMR$E/^^A^5_P!#
M38O%E]:R"*^AAE<=F)MI/^^7X_(TAG6:FV[2;L>L#C]#5?P\=GA^S7T3^IK%
MN/%44MC,KV%ZI:-AE45QT]0U1:?XHB@TN!%L+QBJ]2JH.OJ6H Z\O56]O[>Q
MMVGNYDBB7JS']!ZGVKE9?%=]=OY-C%#$YXPF;F3_ +Y7@?B:?:>&M3U*X6YU
M*1X?26=@\P'^RH^6/]30!!J&HW?B&Z6RM(&$+<K;MPTH_O2?W$]NIKJ]%T>/
M2;9@6\VYEP9IL8W'L .RCL*SY=%32;FTETHF$;BLSL"^[_:8]2?KQTZ8K?B?
MS(D<C&X X/:F(?1113$%%%% !115#7;F6S\.ZE=6S[)H+262-L [6"$@X/'4
M4 7Z*\V37?$$'AC2=2FO-326\N;%'-Y'9F.192-_EB(;@,?WL'!'?.-S1?'/
M]L:AI=K_ &=Y/]H?:_F\_=Y?D/MZ;1G=U[8]Z .MKE_%.EZ/,_FZ_P"()M/L
MKDQI):RWB1P3[&W@?.,J3CG85) KJ*Y+4EDTSX@?VO>VEU<V,FF?9HGMK5YS
M%()"S*50%AN&.<8XP3TH 6'X?: UI#)!O:[^U?;AJB^6;F1R^_)DV\J<XQC&
M/SJ.+P[X<@L(+V#5S&ECJ,ERE^MS'^[DD?#Q%L;=K$A2IYZ#K6%K(U8&X_LS
M3]:TU38P'0[2RC9(XIBQWB98B8QSMXD^7;GOFG#0=6/CO^R)K1_['FOH];EN
M$C)B\T)AXMW3F4!MIYQS]0#H-4T70[?5[>Y\0ZY(T<D\DMM8ZC=1^27==K!0
MPW,,-C9N*C=TKH[*PM--M1;:=:P6D"DD101A%!/7@<5QGQ$,UW)!I%KIDW^G
MQ&*\U:/3Y+@V]ON!,:[%8EF*].@P#Z$=O %6WC";MH0!=X(.,=\\YH YGQ9X
MEN-%US1K&*^TW3H+];AI;K4$+*AC"%0/WB#G<1R?2LN?QMK"^$=(U5H+6T6[
MEE6ZOI;>62WA1=PC?:I#!9"$PQ. &[\&NJU+0['4-4L]2OBQ-C%-&(VV^6ZR
MJ ^\$<C"^H[YS6/'H>F66AVME:>)KZTM[/=Y4B7<9(C<$",AE*LH_AR"PQP:
M+-B;2W*%YX[O-+355OH[*:6/3H+W3C:EFCN#)\A&XGYAYA7!&,J:[:U\_P"Q
MP_;/+^T>6OF^6"%WXYQDGC/O7,1>"/#]_'H-Q;-,T6C "VVOQ( 00),C)PR@
MXXYKK*-5N%TU='-V%QXBU6*>YM]0TNWA6[N((XWTZ21@L4SQ@EA.N20F>@ZU
M:^R^)_\ H,:1_P""J7_Y(JXOV#0[0JTBV\,D\DF7;J\CL[?JS'V'L*?::G9W
MTKQVEPLS(,G;G!'3(/0].U/E=KBYHIVOJ4/LOB?_ *#&D?\ @JE_^2*/LOB?
M_H,:1_X*I?\ Y(K0U&]&G:=-=LN\1+G;G&?Q[5C-XN4(6%A+\@_>!G Q_NXS
MN_2M(4IS5XHRJ8BE2=INPS4Y_$VEVL5PVI:3,K75O 4&F2*<2S)'G/GGIOST
M[5I^(H9)_#]U'"A=RHP N[@,">._';OTJ:>&TUFRC7S!+")8IU,;C[R.LB_J
MHJ[41;C),TE%3BX]SP7Q')=:?=36EG:SQ/,%::6<[&(S@#'&!Z=.IKT+PSXY
M^T:HNBZMI:Z=<DJD9A;=&S;<D'T/'OZ9JYXZ\/IJ5DFI+/Y$U@C./DW>8!@A
M>HQR/?J>*\NU[4-0M;FUU")UCF21MCPKD9!(W<YQTXZU[T5#&TM=TOQ/DJCJ
MY7B/=^%M?-?Y_<>^T5YY_:.J7<1:\U&X25&9)%@8(F0>0I ''OUXZCFM;PGJ
M]_=:E/8SL]Q;PQ;Q+)RR$MPI.<L#@]NW)KRYX2<:?M+JQ[U/,:52LJ*3NS4\
M5X'AV60C)BF@E3G'SI,C+VY&X#COTR,YKEO^$LU'2M3A?4[DW232,@@140%
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M"SC )!7 9@/E//3@4 >J45YEK7CJZT>Y\/:4FN6L\PFM7U:^D,2"2.1APBX
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MG-:E'HM8W_"6Z(;&>[COEEAM[H6;F&-Y"TQQ\BJH)<_,/N@]_0TX_P!I:O&
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M[>VGNYU@M89)Y7^['&I9F[\ 58;1M3298GTZ[61D,BH8&#%1U;&.GO6M\/\
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MLY=-W7$UK$(#&<9=>,L"3P>/Q_"N-2YN7U 620L;DRF'RRR@A@<8SG'7WK/
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MX.C&,,5*_.UW[_\  (?%>GJ^GR:A$[)/$JJW=63=SD>VYCD?K1X=T.TA\-D
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M<LC\,C;@02V[@G.UNW; JQ%X;\-R7U_Y,$;SSQR1W,:W#':LO^LPF[";NY4
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M_K3_ ())%X/W^%SK)O6=,2E1#;-(GR$@!B#N7=@D$K@=R,UT/PEZZM_VQ_\
M9ZY2R\5W=A;2):VME'-(DD9N$AV/M<Y(PI"G';*G':NK^$O75O\ MC_[/31%
M?F]E+F_K4]'HHHIGD!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM;[M]F7_ '85_P *);"\N('AFG7RY%*LJH!D$8(XJWJ%_#IMC)=7!PB#\ST
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M_9-I_<_4TATBT_N?J:O4478<L>QGG1K;L"/QJ'^S;,W1MUG_ 'RH'*!N0I.
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MD9XZT :%4M5T>QUNU6VU.#SXE<2!=[+A@",Y!'8FKM% TVG='-_\*_\ #/\
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MSCM;.)8H8EVHBC@"IZ)2OHM@C&VKW$I:**DH***;)(D4;22LJ(@)9F. !ZT
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M2%!8[N 20.>Y K0TK7-)UVW>?1-3L]2AC;8\EG<)*JMC."5) .".* +U%%%
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MJS'96\>-L2\=\47BA6D]S'S#)WO+GZ84?UJ1+=S_ *G3HQ[RN6_K_2MD*HZ
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MT&69C@ 5SEM&WBC4([ZYC*:7 V;:%A@SL/XV]O04^<WHX=2O.;M%;_Y+S?\
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MBEL%%%1S3Q6T1EN)4BC7J[L !^)I#)**Y^7Q;!-*T&B6D^J3 X)A7;&I]W/
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MI4]VNZ85_A4NS1?H8[5)]!2U%=-LM)F_NHQ_2LUJ[&TG97*FAKMT6W'LQ_\
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M_+MPUS+_ '(1G]>E1^7J=Y_K9%LHS_#'\S_GVJ_#!%;IL@C6-?11BGD@ DG
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M_)?YD@>SL^(]N[T7YF-+YMU-_J8A$O\ >DZ_E38Y HQ:6C?[Q&W]:;++*/\
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M_7D/7H@?5+53A9#(WHBDTW[;<R_\>]C)CUE(2I#>65N,"6-?9.?Y4S^T@_\
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M6TDB(KKCH=_&#T[UU]%(9Y]<:9JE_P"'M7L+?P1:Z))<6V$>WN8#YK!AA3M
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M1;*/S)[B"-K>T0@E@2K2$[F(!ZA>@^M3V4+WJK*S;BTS):QD9"MM'F2GUQR
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MGI4 W2-OX<CN?NK0%QUY^O2E8C^([O0'@?E5));$-M[@H&_(!FD]3T%*_/\
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MXTX:A;CB%7D]HXS4Z6T$?W(4'OMJ2K4)+:R^0[,J?:[A_P#563G_ 'V"T?\
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M@<-<O\L*?C_%^%2V/AZ..Y%[JDS7][U$D@^6/V5>@K6BBC@B6.%%C11A548
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MZS8^G'\J:82WWW+?F:F\Z/\ YYFD\]!_ /R-+FD.S(A H[Y_ "G;!W9OQ?\
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M<\4Z@ I#GM2T4 %%%% !1110 4444 %%%% !113&ZT .I:8#@TH.: '4444
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M6H?*E'(&1_LFC=*O7>/J#5>TCU#E)LIVG;\:7KTN!^E5Q.3_ !*?KBG;R?\
MEFC?\!JE*+V8G%K<GQ)VF4_@*,3]F0_A5<NG>)?SQ2@Q?\\R/]U\TQ6_K0G_
M -(_Z9G\Z,W']U#^-0_(/^>ZT!T[7,@^M <I-OG_ .>2G_@5)YL__/O_ ./B
MF D_=NQ^(%. F/W9T;_@- K+R_$7SI?^?=O^^A1Y\G_/N_YT8NAT,1^H-)NN
MA_!&?H30%EY!]I;O;R_E1]J]8)O^^*/,N1_RP4_1Z//G'6V/X.#0%EV_$/M8
M_P">,W_?%)]L7_GE-_WQ2_:7'6VD_#FD^U^L$X_X!0/E\OQ#[:G>.7_OBC[=
M'_=D_P"^#1]M3NDH^J4?;X!U+#ZJ: Y?[HGV^+TD_P"^#1]OA])/^^#2_P!H
M6W_/3_QTTOVZV/\ RU6@.7^Z_P"OD-_M"'TD_P"^#1_:$/I)_P!\&G_;+?\
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M[>3JT#CI,K0N/7@LO\C_ -]5%;)Y*R0#I!(T8_W0?E_3%./RWEDQZ"X&?Q!
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MU53^%-,,1ZQH?^ BJN-37HUL_P!0PH\W45ZVT+_[LF/YT#L^C+)MH#UAC/\
MP 4GV2V_Y]XO^^!5?[7>K]_3V_X#*#1_:$H^_87 _P!T T#]_O\ B3?8K4];
M:'_OV*/L%IWM8/\ OV*@_M1!]^UNE^L5)_;%H/OF1/\ >C- _P!YYD_]GV?_
M #Z0?]^Q1_9]E_SZ0?\ ?L5$-8L#TN!^*D?TIXU2R/2YC_$XH"]3S'?V?9?\
M^D'_ 'Z%'V"S_P"?2#_OV*47UHW2ZA_[^"G+<0'I-&?HXH%S3[L;]@M/^?6#
M_OV*46=L.EO$/^ "I1(AZ,I_&G4"YY=R(6T Z0QC_@ IPBC'1%'X4^BF3S,0
M #H /I2T44""BBDH **6B@ HI,TM !1110 444A('4@?6@!:*B:Y@3[TT:_5
MQ43:E8K]Z\MQ]95_QI#LRU15!M:TU>M[#^#9J(^(]+'"W)<^BQL?Z4%<DGT-
M2BLD^(8#_J;6\F_W(#1_;%R_^ITB\/\ O@)0/V<C5S29K)^VZQ)_J]*2/WDN
M ?T%&S7Y.LEC /\ 95F/ZT!R/JT:XI:R/[.U63_7:R5]HX%'ZTAT'>/](U*_
ME]1YV!^0% <L>K-22>*$9EE2,>K,!5*;7]*A^_?1'_<.[^6:BC\.Z7&<_9%<
M^LC%OYFK\-G;6X_<6T4?^X@%&H>XNYG?\)'!)_QZ6E[<^\4!Q^N*3[?K-Q_Q
M[:4L([-<3#^0YK9HH#FBMD8WV+7+C_7ZG#;CNMO#G]6H_P"$;@E.;Z[O+OU6
M28[?R%;-%%@]I+IH4K;1].L\&WLX4(Z-MR?S/-7*6B@AMO<3-%(>M ZTQ#J*
M** "BBB@ HHHH **** "BF;C3Z &$'-.'2EHH **** "BBB@ HHHH **** "
MBBB@ HHHH *!U%% ZB@ HHHH :QII8BE9,G-*%]: &TH.*0CG@TF#ZT 2=:6
MD7I2T (1GOBEHI#QTH 6DHI"N30 ZBDQ2T %)2TU@30 M&<4BC%*1F@ !S2T
M@&*6@ HHHH **** $)Q0#F@C- XH 6BBB@ HHHH *YO4/$%^?[573K -;V(>
M)[OSP&200^9N\LC!4$J,YSD]".:Z2LFZ\,Z3>WTEW<VK/++]\><X1CL*;B@.
MW=M.-V,@=Z0S%L/&%W_9<OV^TMX[N"WMI5,EUA9Q*K$9VH2'.P_(BODD 9ZB
MK'X]GF-O-#I[L]PB1K:O.$02-=-!U,>X<KGG''\(-='+X7TB92&MG4[85#1S
MR(RB+/EX8,""-S<@Y.><TR'PCH<#1F*RV^4ZNG[Y\*1*91@;O[Y)Q_3BC4-#
M-B\47E[+LALVCFLUNY+FW@82&9H&""-&*C(8MG. > *+3Q3<W]I%>")+?R;^
M*UN;=)=^1(PC&0RJZ,KL.&4=#U!!K3F\,V+3B2%%C60SBYC8%UG2;F13D\98
M*?08/'- \,VD3Q"!I!&+E;F?S9'FDG=!\F9'8G"D X]ATYR:AH;!YH I:*8@
MI,TM-Q0!7BNUCBNMC@W\[&%(N\:C.&/MR6S]!4\<:Q1)&GW44*/H*=2TAW"B
MBBF(**** "BBB@ KB/$/_(>N/^ _^@BNWKG-5\/W5]J4MQ%)"$?& S'/  ]/
M:O"SS#U:^&C&E&[YE^3/6RJM3HUW*H[*WZHYBBMF3PQ>Q1,YD@8*,D*QS_*B
M+PQ>31+(DUN589'S-_A7Q_\ 9N,YN7V;N?3?7L-:_.C&KI='U2R@L+%+BX$3
MVUV974HQRI7&1@'UJM_PBE]_SUM_^^F_PH_X12^_YZV__?3?X5TX?!X_#SYX
MTOO^_OY&%;%8.M'EE4-"VUS3XFM#)+N97N0S%6^0.<AO_P!7-12:S:_V?=VX
MGBR;-(8C#$X!Y.5RQ)( /4XJI_PBE]_SUM_^^F_PH_X12^_YZV__ 'TW^%=7
M+F5K>R_#RMW\OO.?FP-[^T_J]^QH)J>FC27MXKA=TEM$BHZ.S[P>06(QCI@
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MNV)2T44Q!1110 4444 )BEHHH **** "BBB@ HHHH 2EI*6@ HHHH **2EH
M**** "BBB@!,"EHHH *3-+2$9H 6BDI: "BBB@ HI",CB@# YH 6BBB@ HHH
MH **** "@=110.HH **** "D/2EI* &4H&:=M%%  !@4M%% !124M !1110
M4AZ<4$9H P* &C.:?110 T9SS3J** "D!S2T4 %%%% !1110 4444 )2T44
M%%%% !2&@]*0=: %'%+110 4444 %%%% !1110 4444 %%%% !1110 4444
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M132: '44@.:6@!.E+3=U+0 M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 % ZBB@=10 4444 %-V\YIU% !1110 4AZ
M4M% #,&G4C=*1>M #Z**3.* %HI <]*6@ HI"<4 YZ4 +2$XZTM)0 4M%% !
M1110 4444 %%%% !1110 4F<4M% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %%(>G% SWH 6BBB@!*3=2GD4R@!]+2#@4M !1110 4444 %%%%
M!132:4&@!:*** "BBB@ HHHH **** "BBB@ HHHH **** /'I?A_XA>SE@%H
M/(N(KB6:'S4RTZM-Y/.[N)0?^ C.*FB\!:]YIS:B.*ZNV6\0RH=\ $+IT/\
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M@>*K O@K,!_>V4!9LVZ*K6M_:WJYMIE?V!Y'X59H$%%%% !29HHQB@!:***
M"BBB@ HHI : %HHHH **::!UH =1110 4444 %%%% !1110 4TG%.I",T  .
M:6D Q2T %%%% !1110 4444 %)2TE !N%+3-II] !1110 4444 %%(<]J6@
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M5NI(&YI:*6@04444 %%%% "4M%% !1110 4444 %%%% !1110 4444 %%%%
M!24'I3* )**1>E+0 4444 (QQ3=QIQ&:3;0 ZDI:* "BBB@ HHHH 0C-  %+
M10 44PL<TX'(H 6BBB@ HHHH 0G% .:1ES0JXH =1110 4444 %%%% !1110
M 4#K2'IQ3%SN&/6@!P;)IU)BEH 2C:*6B@ HHHH **** "BBB@ HHII;'2@!
MU%-#9-.H **** "BBB@ HHHH **** &[13J** "BBB@ HHHH **** "BBB@
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MS8W-]9+:6[+)*ZQR";S4$+/C) (((^GN14UKXA>8P+<Z2\#37"0 L'5=K(S
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M --?_'?_ *]']F_]-?\ QW_Z]%%%V'*@_LW_ *:_^.__ %Z/[-_Z:_\ CO\
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M_37_ ,=_^O111=ARH/[-_P"FO_CO_P!>C^S?^FO_ ([_ /7HHHNPY4']F_\
M37_QW_Z]']F_]-?_ !W_ .O111=ARH/[-_Z:_P#CO_UZ/[-_Z:_^._\ UZ**
?+L.5!_9O_37_ ,=_^O0--_Z:_P#CO_UZ**+L.5'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>mrna-20211231_g5.jpg
<TEXT>
begin 644 mrna-20211231_g5.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
MQ?$/^O?_ (#_ .@BLZM'Q#_KW_X#_P"@BLZ@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M JUI?^NC_P"NB?\ H0JK5K2_]='_ -=$_P#0A0!I^,/]<O\ US'_ *$U85;O
MC#_7+_US'_H35A4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %=/KG_'I#_VS_P#0#7,5T^N?\>D/_;/_ - - ',4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =/H?_'I-_P!M/_0!
M7,5T^A_\>DW_ &T_] %<Q0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5N^#_ /7-_P!<S_Z$M85;O@__ %S?]<S_ .A+0!A4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :?AK_CX3
M_@7_ *":/$O_ !\/_P !_P#011X:_P"/A/\ @7_H)H\2_P#'P_\ P'_T$4 9
ME%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 :/A[_7I_P+_T$T4>'O\ 7I_P+_T$T4 'B'_7
MO_P'_P!!%9U:/B'_ %[_ / ?_016=0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M *"*SJ "BBN@\"Z>+VZ564,BABP8 C&T@<'K\Q'\Z .?HKOOB3HB6J131(B
M,RML4*26&1T'.-I_.N5\,6/VZZBBX(+@D-T(7YF'?J 10!ET5Z5\0=#CAMO,
MAB12DBEBBJIVD$=L$\D<5YK0 4444 %%%% !16AX>_X^8/\ KM'_ .ABNP^*
M_P#RP_[:_P#LE 'G]%%% !117J&A_P#();_KC/\ S>@#R^BNT\%>([73()8I
M_O,2<;-V]=N O\^&P.>O)J/X7_\ 'R__ %Q;_P!#2@#CZ*Z#Q[_Q^R_\ _\
M1:US] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 445[)JEK8Z6HEFCB52< ^4#R03V4^E 'C=%>J/X>L/$2%[?:&Q@-'\I7
MDX)CXZX/4 D=#T(\ON+=K=FB<89"01UP0<'I0!'1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%=Q\,].BO/.\U
M%?;Y>-ZAL9WYQD'TH X>BMS[.O\ :'E;1L^U;=N!MQYF,8Z8QQBO1-633])V
M^?'$N_./W(.<8S]U3ZB@#Q^BO5AX?T_Q"I>$*" !F+Y&')ZIC S@\E<D=.U>
M=^(-#?193 Y!XRI'=22 <=NG(]?48) ,VBBB@ HKT#5_^)=I,4/WO-V<],;R
M9>G.<8Q^OM1\0_\ 0;:WLNN,?-T_U2!>G/7=GKQCO0!Y_1110 4444 %%%%
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MM()SM;&1@DY.0#]".O(  .1HKU#7/^02O_7&#^:5Y?0 4444 %%%% !1110
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M$H \OHHHH **** "BBB@ HHHH **** "BBB@ HKO/!/A&&:+[?<X93DJI.%
M0\LW3/3H>,=<YXWK*+3=<W0Q)&2 "0J>6V,]0<*>O7'T/6@#R6BM;Q/H?]BS
MF#)*D!E)QDJ?IZ$$=LXS@ UDT %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!T^A_P#'I-_VT_\ 0!7,5T^A_P#'I-_VT_\
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M-V?VRYBCP&!D4D'&"JG+=>.@/'>NZ\?Z!%%:F6&-$,;J254*2#E<<#U8'\*
M/,Z*FL[4W;K"N,NRJ,],L<"O4O%_A^(6LK0Q('4 Y5%4@*P+<X'\(/UZ4 >3
MT444 %%%% !1110 45ZA\4/^/9/^NR_^@/7E] !1110 4444 %%%% !1110
M4444 %%%% !16IX8OH[&YCFF'R*3GC.." <>QP?7CCFKGC?58=3N/-@Y78H+
M;=NXC//.#T('/IZ8H Y^BBB@ HHKU#7/^02O_7&#^:4 >7T444 %%>H:'_R"
M6_ZXS_S>O+Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDGQ!M+1_LZ[MJD+N11Y8 XXP<X'L.W&1BLGQMX0C:/[?:@   LJ#Y2O]]=O
MP.3V(YX(.>'N-/DMY#;LI$@.-N,G)Z8QUSVQU[5Z<MJ=&TMHI\!A%(#CGF0M
MM''NP![9[XYH Y/P)X875W:68$Q(,8R1ECVR/0<G!!R5[&NNOO&MIHC?9%4_
M)U$2KM!SR.J\^N._OFJ?PMN%:"2('YEDR1[,H _]!/Y5Y_JVDR:5(8)1AA^1
M'8@]P?\ ZQP010!ZYX;6UF4W5HH42XW <8*CH5Z C/;KG/.0:Q_!7_'S??\
M7;_V>2H_AGI,EI&\[C"S;-N>I"[N<>ASQZ]>F"9/!7_'S??]=O\ V>2@#)\:
MZ]#!$=*MP5$;*&P%*8 W$9R3G=C/?(.3US:\$^$X5A^VW2@ELL-_W0@&,D'
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M_P#HMJ &^--#31I_+C)V.H8 ]LDC&>_3COCKGJ<&NP^*'_'RG_7%?_0WKCZ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 45:CTJ:1/.6-S'@G<$8K@=3G&.,<U5H *
M*** "BBB@ HHHH **** "BK5KI4UV-\4;N <91&89],@55H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HJ:ULWNSLB5G(&<(I8X]<"FW%NUNQ
MC=2K#J&!!&>>AH CHHHH **** "BBB@ HHHH *M:7_KH_P#KHG_H0JK5K2_]
M='_UT3_T(4 :?C#_ %R_]<Q_Z$U85;OC#_7+_P!<Q_Z$U85 !7H'PH_Y;_\
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M@CC((!R_@;PN-8<RRC,,?!'S#<2#@ C'3J>?08YKK)O'MGIA\B($JN?]4JA
M<G(&2OUR,@YZU7^%MPK021 _,LF2/9E '_H)_*FZE\1'TUS#+;D$$_\ +0@$
M D;AF,9!QP: &^(= @\0PF^LR-Z[B=JD;\<D%<9W]P<9.>>""/-Z]*N/B%+;
M(LSVK!' *L7.#G..=G?&0.I'/0@UYK0 5T'@+_C]B_X'_P"BVKGZZ#P%_P ?
ML7_ _P#T6U &A\4/^/E/^N*_^AO7'UV'Q0_X^4_ZXK_Z&]<?0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !73ZY_QZ0_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@"YI.K2:5()XCAA^1'<$=P?_KC! ->@6_Q2@907C<-W"[6'YDK_ "%>9T4
M=AXH\?MJ:FW@!2-OO$GYF&.F!T'7/)R/09!X^BB@ K4\,ZHNE7"7+@E4W9"X
M)Y4CN1ZUET4 ;WC+7DUN99H@P C"_. #D,Q[$^M8-%% !1110 4444 %%%%
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ME&.F#U'3'(P/48 X^B@#TRX^*4"J2D;ENP;:H_,%OY&O/]6U:359#/*<L?R
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M9[\\5G^$?%O]@EE9 T;D9Q@.,=\]^,_*>,]".<\[10!Z1??%*(+^YC8OV\S
M4<=>"2>>W&?45YS)(9278DDDDDG))/4YIM% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 :/A[_ %Z?\"_]!-%'A[_7I_P+_P!!-% !XA_U[_\
M ?\ T$5G5H^(?]>__ ?_ $$5G4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KI]<_X](?\
MMG_Z :YBNGUS_CTA_P"V?_H!H YBBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#I]#_P"/2;_MI_Z *YBNGT/_ (])O^VG_H K
MF* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MWP?
M_KF_ZYG_ -"6L*MWP?\ ZYO^N9_]"6@#"HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH T_#7_'PG_ O_031XE_X^'_ . _^@BC
MPU_Q\)_P+_T$T>)?^/A_^ _^@B@#,HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#1\/?Z]/
M^!?^@FBCP]_KT_X%_P"@FB@ \0_Z]_\ @/\ Z"*SJT?$/^O?_@/_ *"*SJ "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** -CPOX@_L*4S[-^Y"N-VWJ0<YP?2J^OZM_:T[W.W;O
MV\9SC"A>N!Z>E9]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %6M+_P!='_UT3_T(55JUI?\ KH_^NB?^A"@#3\8?ZY?^
MN8_]":L*MWQA_KE_ZYC_ -":L*@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KI]<_P"/2'_MG_Z :YBNGUS_ (](?^V?_H!H YBB
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#I]#_
M ./2;_MI_P"@"N8KI]#_ ./2;_MI_P"@"N8H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *W?!_\ KF_ZYG_T):PJW?!_^N;_ *YG
M_P!"6@#"HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH T_#7_'PG_ O_031XE_X^'_X#_Z"*/#7_'PG_ O_ $$T>)?^/A_^ _\
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M?XT?V7/^9!_;M/\ E9:_X51_TW_\A?\ V='_  JC_IO_ .0O_LZJ_P!K3?\
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M_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\
M?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_
M .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_
MZ;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK
M_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\
M?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_
M .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_
MZ;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK
M_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\
M?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_
M .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_
MZ;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK
M_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\
M?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_
M .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_
MZ;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK
M_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\
M?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_
M .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_
MZ;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK
M_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\
M?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_
M .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK_A5'_3?_ ,A?_9T?\*H_
MZ;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\ ?;?XT?V7/^9!_;M/^5EK
M_A5'_3?_ ,A?_9T?\*H_Z;_^0O\ [.JO]K3?\]'_ .^V_P :/[6F_P">C_\
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M^SJK_:TW_/1_^^V_QH_M:;_GH_\ WVW^-']ES_F0?V[3_E9:_P"%4?\ 3?\
M\A?_ &='_"J/^F__ )"_^SJK_:TW_/1_^^V_QH_M:;_GH_\ WVW^-']ES_F0
M?V[3_E9:_P"%4?\ 3?\ \A?_ &='_"J/^F__ )"_^SJK_:TW_/1_^^V_QH_M
M:;_GH_\ WVW^-']ES_F0?V[3_E9:_P"%4?\ 3?\ \A?_ &='_"J/^F__ )"_
M^SJK_:TW_/1_^^V_QH_M:;_GH_\ WVW^-']ES_F0?V[3_E9:_P"%4?\ 3?\
M\A?_ &='_"J/^F__ )"_^SJK_:TW_/1_^^V_QH_M:;_GH_\ WVW^-']ES_F0
M?V[3_E9:_P"%4?\ 3?\ \A?_ &='_"J/^F__ )"_^SJK_:TW_/1_^^V_QH_M
M:;_GH_\ WVW^-']ES_F0?V[3_E9:_P"%4?\ 3?\ \A?_ &='_"J/^F__ )"_
M^SJK_:TW_/1_^^V_QH_M:;_GH_\ WVW^-']ES_F0?V[3_E9:_P"%4?\ 3?\
M\A?_ &='_"J/^F__ )"_^SJK_:TW_/1_^^V_QH_M:;_GH_\ WVW^-']ES_F0
M?V[3_E9:_P"%4?\ 3?\ \A?_ &='_"J/^F__ )"_^SJK_:TW_/1_^^V_QH_M
M:;_GH_\ WVW^-']ES_F0?V[3_E9:_P"%4?\ 3?\ \A?_ &='_"J/^F__ )"_
M^SJK_:TW_/1_^^V_QH_M:;_GH_\ WVW^-']ES_F0?V[3_E9:_P"%4?\ 3?\
M\A?_ &='_"J/^F__ )"_^SJ&WUR:!@^]CCLS$@^Q!-=QI.K)J2;UX(^\O<'_
M  ]#W^N17/B,'.BK[HZ\'F5/$MQ6C[,XW_A5'_3?_P A?_9T?\*H_P"F_P#Y
M"_\ LZ] HKF.X\__ .%4?]-__(7_ -G1_P *H_Z;_P#D+_[.O0** //_ /A5
M'_3?_P A?_9T?\*H_P"F_P#Y"_\ LZ] HH \_P#^%4?]-_\ R%_]G1_PJC_I
MO_Y"_P#LZ] HH \__P"%4?\ 3?\ \A?_ &='_"J/^F__ )"_^SKT"B@#S_\
MX51_TW_\A?\ V='_  JC_IO_ .0O_LZ] HH \_\ ^%4?]-__ "%_]G1_PJC_
M *;_ /D+_P"SKT"B@#S_ /X51_TW_P#(7_V='_"J/^F__D+_ .SKT"B@#S__
M (51_P!-_P#R%_\ 9T?\*H_Z;_\ D+_[.O0** //_P#A5'_3?_R%_P#9T?\
M"J/^F_\ Y"_^SKT"B@#S_P#X51_TW_\ (7_V='_"J/\ IO\ ^0O_ +.O0**
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MH \__P"%4?\ 3?\ \A?_ &='_"J/^F__ )"_^SKT"B@#S_\ X51_TW_\A?\
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M !1110 4444 %%%% !1110 5J>&O^/A/^!?^@FLNM3PU_P ?"?\  O\ T$T
M=U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA_(UQ6O?ZX_[L?\ Z M=V6?Q7Z?JCRL\_@1_Q+\F9]%%%>P?.!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %:GAK_CX3_@7_ *":RZU/#7_'PG_ O_030!W5%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB1IU]:-IHCF6,QA%^53MVXV'_6@G:0#R><<U7^"NO&.233F(VN/,3) ^88#
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MNZ6VEW,6JPY#.1DXR \6"AR<C)'1<8^0GG)K)\3:ZWCJ[M[:,%4PBX W[6D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)(4Y#8#;><9QG'/<<U-_Q,O^G;_R+0 6'B*2*46EZ@CD?.QU.8WP2,#/0],
MG)[X) /05RNHZ?J-^H1OLP*LK*P\S<K*<@C<"/;IT)'>NJH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"AKO\ J6_#_P!"%%&N_P"I;\/_ $(44 <+<_>/^>U15+<_>/\ GM45 !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&Q2Q01(, ?F3ZGW_ ,]*L5XF+Q;K.R^$^HP& CAHW>LGN_T04445RG<%%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *U/#7_'PG_ O_03676IX:_X
M^$_X%_Z": .ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV[_L_P#CW_UJ -:BLG^W?]G_ ,>_^M1_;O\ L_\ CW_UJ -:BLG^W?\ 9_\
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M*R?[=_V?_'O_ *U']N_[/_CW_P!:@#6HK)_MW_9_\>_^M1_;O^S_ ./?_6H
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M_"+7/]S_ ,>7_&C_ (1:Y_N?^/+_ (UTW_"1?['_ (]_]:C_ (2+_8_\>_\
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M_'O_ *U']IU>R_'_ ##^PZ'>7WK_ ".9_P"$6N?[G_CR_P"-'_"+7/\ <_\
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M'0[R^]?Y',_\(M<_W/\ QY?\:/\ A%KG^Y_X\O\ C73?\)%_L?\ CW_UJ/\
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MD9Q]Y1_,U+_PBUS_ '/_ !Y?\:W=/U;[&I3;G)SUQV'M5G_A(O\ 8_\ 'O\
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M_P"$B_V/_'O_ *U'_"1?['_CW_UJ/[3J]E^/^8?V'0[R^]?Y',_\(M<_W/\
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M?Y',_P#"+7/]S_QY?\:/^$6N?[G_ (\O^-=-_P )%_L?^/?_ %J/^$B_V/\
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M )A_8=#O+[U_D<S_ ,(M<_W/_'E_QH_X1:Y_N?\ CR_XUTW_  D7^Q_X]_\
M6H_X2+_8_P#'O_K4?VG5[+\?\P_L.AWE]Z_R.9_X1:Y_N?\ CR_XT?\ "+7/
M]S_QY?\ &NF_X2+_ &/_ ![_ .M1_P )%_L?^/?_ %J/[3J]E^/^8?V'0[R^
M]?Y',_\ "+7/]S_QY?\ &C_A%KG^Y_X\O^-=-_PD7^Q_X]_]:C_A(O\ 8_\
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M^/+_ (UTW_"1?['_ (]_]:C_ (2+_8_\>_\ K4?VG5[+\?\ ,/[#H=Y?>O\
M(YG_ (1:Y_N?^/+_ (T?\(M<_P!S_P >7_&NF_X2+_8_\>_^M1_PD7^Q_P"/
M?_6H_M.KV7X_YA_8=#O+[U_D<S_PBUS_ '/_ !Y?\:/^$6N?[G_CR_XUTW_"
M1?['_CW_ -:C_A(O]C_Q[_ZU']IU>R_'_,/[#H=Y?>O\CF?^$6N?[G_CR_XT
M?\(M<_W/_'E_QKIO^$B_V/\ Q[_ZU'_"1?['_CW_ -:C^TZO9?C_ )A_8=#O
M+[U_D<S_ ,(M<_W/_'E_QH_X1:Y_N?\ CR_XUTW_  D7^Q_X]_\ 6H_X2+_8
M_P#'O_K4?VG5[+\?\P_L.AWE]Z_R.9_X1:Y_N?\ CR_XT?\ "+7/]S_QY?\
M&NF_X2+_ &/_ ![_ .M1_P )%_L?^/?_ %J/[3J]E^/^8?V'0[R^]?Y',_\
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MC_Q[_P"M1_PD7^Q_X]_]:@#:HK%_X2+_ &/_ ![_ .M1_P )%_L?^/?_ %J
M-JBL7_A(O]C_ ,>_^M1_PD7^Q_X]_P#6H VJ*Q?^$B_V/_'O_K4?\)%_L?\
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M>_\ K4 ;5%8O_"1?['_CW_UJ/^$B_P!C_P >_P#K4 ;5%8O_  D7^Q_X]_\
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M?<=K_P )K#_=?\E_^*H_X36'^Z_Y+_\ %5Q5%']G4?,/[9Q/=?<=K_PFL/\
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M?<=K_P )K#_=?\E_^*H_X36'^Z_Y+_\ %5Q5%']G4?,/[9Q/=?<=K_PFL/\
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M !1110!BZG_KX_\ @/\ Z$:VJQ=3_P!?'_P'_P!"-;5 !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !69X@_U8_P!X?R-:=9GB#_5C
M_>'\C0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 4M8_P!4WX?S%&C_ .J7\?YFC6/]4WX?S%&C_P"J7\?YF@"[1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% %#7?]2WX?^A"BC7?]2WX?^A"B@#A;G[Q_SVJ*I;G[Q_SV
MJ*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K4\-?\?"?\"_]!-9
M=:GAK_CX3_@7_H)H [JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGDGA5R <9) SCC.3Q7C^@>%KKX@,][<385<)O*AB2 #M" J  #DGCD\ DL0
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MJ***V.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 8NI_Z^/\ X#_Z$:VJ
MQ=3_ -?'_P !_P#0C6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5F>(/\ 5C_>'\C6G69X@_U8_P!X?R- &G1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6IX:_X^$_X%_Z":RZU
M/#7_ !\)_P "_P#030!W5%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %07O^K?_ '6_E4]07O\ JW_W6_E0
M!3\/_P"K/^\?Y"M.LSP__JS_ +Q_D*TZ ,GQ9_QYW/\ U[S?^@-7C'P\\(GQ
M+(\3LRP( S[".6Y"#!SSRQS@X&1QNS7L_BS_ (\[G_KWF_\ 0&K@/@9_R]?]
ML?\ VI0!RGBW1V\%WJBV=AA5>-B07 .5(/R@=0>,$%3@YR174:W\)EM;22[>
M5GND1I');]V2#N?JI8G&<$GEN3@' S/C7_Q^1_\ 7NO_ *')7JOBS_CSN?\
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M& (W -PN#G (ZE<GC@<U5^*7B"^T)XY;9]L#KM.$5L."3R64XR",#/.T\<4
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M -:?]V/_ - 6NS\0?ZL?[P_D:XS6_P#6G_=C_P#0%KNRS^*_3]4>5GG\"/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRP8W%D.T9Q\PY7G(_B ]O7BL'P/(=2+7SDDK''"I8_-\JAI,^NYCD$Y/TZ4
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M/^>U15+<_>/^>U14 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:G
MAK_CX3_@7_H)K+K4\-?\?"?\"_\ 030!W5%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&^-P!()P=PRV=QP>G/MTK4HH *Q[[PA:WS>;)$-QZD%ESSG)VD9//4\UL44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9;7_ )ZC_OM*/LMK_P ]1_WVE'M,1WE^(>QPG:'W(L_\(M;?W/\ QYO\:/\
MA%K;^Y_X\W^-5OLMK_SU'_?:4?9;7_GJ/^^TH]IB.\OQ#V.$[0^Y%G_A%K;^
MY_X\W^-'_"+6W]S_ ,>;_&JWV6U_YZC_ +[2C[+:_P#/4?\ ?:4>TQ'>7XA[
M'"=H?<BS_P (M;?W/_'F_P :/^$6MO[G_CS?XU6^RVO_ #U'_?:4?9;7_GJ/
M^^TH]IB.\OQ#V.$[0^Y%G_A%K;^Y_P"/-_C1_P (M;?W/_'F_P :K?9;7_GJ
M/^^TH^RVO_/4?]]I1[3$=Y?B'L<)VA]R+/\ PBUM_<_\>;_&C_A%K;^Y_P"/
M-_C5;[+:_P#/4?\ ?:4?9;7_ )ZC_OM*/:8CO+\0]CA.T/N19_X1:V_N?^/-
M_C1_PBUM_<_\>;_&JWV6U_YZC_OM*/LMK_SU'_?:4>TQ'>7XA['"=H?<BS_P
MBUM_<_\ 'F_QH_X1:V_N?^/-_C5;[+:_\]1_WVE'V6U_YZC_ +[2CVF([R_$
M/8X3M#[D6?\ A%K;^Y_X\W^-'_"+6W]S_P >;_&JWV6U_P">H_[[2C[+:_\
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M@_9;7_GJ/^^TH^RVO_/4?]]I1[.?9A[:GW7WF]16#]EM?^>H_P"^TH^RVO\
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M?^>H_P"^TH^RVO\ SU'_ 'VE'LY]F'MJ?=?>;U%8/V6U_P">H_[[2C[+:_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5J>&O^/A/^!?\ H)K+K4\-?\?"?\"_]!-
M'=4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5!>_ZM_P#=;^53U!>_ZM_]UOY4 4_#_P#JS_O'^0K3K,\/
M_P"K/^\?Y"M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,SQ!_JQ_O#^1KC-;_P!:?]V/_P!
M6NS\0?ZL?[P_D:XS6_\ 6G_=C_\ 0%KNRS^*_3]4>5GG\"/^)?DRA1117L'S
M@4444 %%%*B%R% R3P .M "44^6)H3M8$$=B,'\C3*-P:MH%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !78>&_$GG8MYC\W16/?V/OZ'O]>O'T5E7H1K1LSHPN*GAI\T
M?FNYZK17->&_$GG8MYC\W16/?V/OZ'O]>O2UX5:C*E+E9]5AL3#$04X_\,8N
MI_Z^/_@/_H1K:K%U/_7Q_P# ?_0C6U69L%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %9GB#_5C_>'\C6G69X@_P!6/]X?R- &G111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_5-
M^'\Q1H_^J7\?YFC6/]4WX?S%&C_ZI?Q_F: +M%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M4-=_U+?A_P"A"BC7?]2WX?\ H0HH X6Y^\?\]JBJ6Y^\?\]JBH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *U/#7_'PG_ O_ $$UEUJ>&O\ CX3_
M (%_Z": .ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML04ARP.0S'LK<?-7:ZY9-?V\UNF TL3J">F64@9QGCF@#SCX&?\ +U_VQ_\
M:E8_BN%9M<". 5:>V!!&005C!!!Z@UW'PW\%3>&/.\]D;S?+QY98_=W9SE5_
MO"J.K_#RXO=3&J*T8B$L+8);?B,(#QM(S\IQS0!R5JK?#[4PKG]RV1G(),+M
M@,<+G*D9( !)4@<')]8\3S+-8W#H05:VE((.008R001U!K,^(7@P^)XE6,JL
ML394OG;AN&4XSC. <X/3'&2:-&\.W,&G2:;.R-(8Y(T96<C:RD*&+#/!)' P
M%  % ')?!&%9ENT< JPB!!&00?,!!!Z@UR_B"QD\$W4MO$<I-"R@N 2T<HP<
MX/!4CKQDKG&TX/I?PW\%3>&/.\]D;S?+QY98_=W9SE5_O"M+QSX07Q-!Y0(6
M5#N1B.^,%2<9VMWQW .#C! .-^!G_+U_VQ_]J5SGQ-UX:E?-&26AMR$ 4E>G
M^L^\" V[*[MN,!>#CGO? 7@JY\,)<;FB:255\O!<KN4/C=\JG&6'3G&:B^'O
MPW?P_*UU<E&?;B/820,_>/S*"#C !!Z%@>M '.:A\6XKZ!K)K0")DVX64# Q
M@8'E$ KP5XX(%-^#&NFWG>Q8_),I90<GYTYX[#*YR2.=H&>Q]EKSKQ)\-YI[
MX:E9F)<,DA60L!YBG).$7H< GG))8YH VO'7]H_NO[,_V_,_U7^SM_UGX]/Q
M[55\%?VMYS?VC_JO+./]3][<N/\ 5\],^WZ5VM% !7BGP4_X_)/^O=O_ $..
MO:Z\\^'GP\N/#=PUQ,T95HBH"%B<EE/=5X^6@#T.O&OB9XV_MQUTZS+-&&PV
MSD2-D;0 !D@'IV8G(!PI/HOCC1[C6+<VUJZHSL-Y8D I@Y7(5CR<9Z9&0>"0
M?.K7X/W]HPEBFB1QG#))(K#(P<$)GI0!W7P[\(?\(Y!^\'[^7!D^;(&,[5';
M@'GKR3R1BK?CKQ'_ &!:/.O^L;Y(_P#>;.#T(^4 MSP<8[US_A;PAJ6GW*3W
M-SYD2[MR^=*V<J0/E90#@D'FKOQ#\"2>)PCQR!6B! 1Q\AW$9.X#<#@>C X&
M O)(!C_!CPYY$;ZD_P!Z7*)_NJ?F/![L,<C(V\<&NS\4>*(O#<0N)@Q5G"@(
M 3D@GN5X^6KNE:8FEQ):Q#"1J .F3CJ3@ 9)Y)QR233-:T>/6(7M)L[)!@X.
M",$$$'U! /IZ@CB@#-L9;3QI )VC5T.]<2!2Z'H1D$E20 >"#C!]*\OMBOAS
M61#:']WYR1D;BPQ)M#J2",[23@'."HSDBM6/X47^FLPM+E51L<AY(F.!W5 P
MX)..3^&<5T?@KX81Z ZW<KEYU!QCA%W+@X'5CU&3@$'[H(S0!UMQJT-LZP22
M(LCXVJSJ&.3@84G)R>![UY_\;=3>&*&U4X25G+8SD^7MP.N,9;.".H![4>,?
MA;-KEXUW'(BQR;-V[=N7:H4X !#<#(Y7DXXZGL_%7AF/Q' ;60D<[E8?PL 0
M#CN.2".X/&#@@ \_E\"V1TG[<N!+Y ?S"Y/S\$IC<%R3F,#&0?5NMWX):F\T
M4UJQRD3(5SG(\S=D=< 97. .I)[UG_\ "J+_ !]D^TK]FW?=WR8V[LY\O&W/
M?&<9[]Z]#\*^&8_#D M8R3SN9C_$Q !..PX  [ <Y.20#,^*7_(.G_[9_P#H
MU*RO@I_QYR?]?#?^@1UTOC/1'UNTDLXBH>39@N2%^5U8YP">@]*I?#SPO+X;
MMVMYBI9I2P*$D8*J.X7GY: .BN[I;1&FD.$C4LQP3@*,DX'/2O(/ ]JWB_4G
MU.4?)$P?&1P>D29&T_*%SG'.W##YJ]-\6>'SX@MVLPYCWE22%#9VD'!!QQQV
M(.0.<9!I> ?"/_"-0>4^TRNQ+LO(]% )53@#L>A+8ZT =+1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &9X@_U8_P!X?R-<9K?^M/\ NQ_^
M@+79^(/]6/\ >'\C7&:W_K3_ +L?_H"UW99_%?I^J/*SS^!'_$OR90K9TW5(
MHX&M90_SMG*8_P!GU/J/2L:BO5J4U-6?J>!1K2I-M=K?>;,-_;67[R)'9QT\
MTC X/.%Z\_\ UB#67+=O*_G,3O)SGOGM],=O2HJ*(TE%WW?F.I7E-):)+HM#
M<NM4M]1Q),KK)T)BVX/ Y.[_ #CN>U+[7''*DD:E40KG)RQVG.?0$CL.*H45
M,:,8JRO;M<J>)G-W:5][V5R[K-ZM]*TRY ;'7KP .V?2K^I:M#J:AY%<3!2/
MEQM)[=3G&?QYQD\5AT4_8QM'^[L'UF=Y[/FU9N'5H;R)(IU<-%P#'CI@#^(^
MW/TX/.*35-:CNX$@C0H58''!7 !'7J3SGIZUB45*P\$T]='=:E/&5&FM-59N
MVK^85JZ#JJ6.]95W(X&1@'E3QP2!CD_I6516E2"G%Q9C2JRI34ENB[=:D99S
M<CKO##([*?E!Q[ 5HW>K6UP_VDHYDXRI(V$CCD\GCZ8..1R:P:*AT(NW2RMI
MV-(XJHN;9W=]5?7N:GB'5%U*02(" % ^;&>I/8GUH\0ZHNI2"1 0 H'S8SU)
M[$^M9=%.-&,>6W384\3.?/?[33?R-2WU18[9[4@[G8$'C'\/OGMZ5+::M$\'
MV2=6PIRI3&>I/<X[G\#TR,UC44G0B[^M_F..*J)K;1<OR-V?6H3;M:QHRY(P
M3@YP0=Q/')Q[XZ XJM;ZHL=L]J0=SL"#QC^'WSV]*RZ*%AX)6\[_ #'+%U).
M^GP\NW0U/#VJ+ILAD<$@J1\N,]0>Y'I4>AZI_9LGF$9!&#ZX)!X]^/\ /6L^
MBG*C&7-?KN3'$3CR6^R[KYES46A8@P!QG.0^,#T QD_G5.BBKC'E5C.<N:3=
MDO0****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5W2=)?4G
MV+P!]YNP'^/H._TR:-)TE]2?8O 'WF[ ?X^@[_3)KT"QL4L4$2# 'YD^I]_\
M]*Y,7BU17*OB_(]'+LN>(?-+2"_$Q9+%+&6.)!@#;]2=W4^_^>E=%6+J?^OC
M_P" _P#H1K:KQ6W)W9]-&*BDEHD%%%%(84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !69X@_P!6/]X?R-:=9GB#_5C_ 'A_(T :=%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/]4WX?S%
M&C_ZI?Q_F:-8_P!4WX?S%&C_ .J7\?YF@"[1110!A^-;'[9:2@8R@W@GML.3
MCKSM!'XXZ53TN[_MNZ6<C"V\"$*3T>==V01U&S@Y[]!WKII(Q*"C $$$$$9!
M!ZC%8_A+03HD'DL07+%FP<KDX QD ] /QS0 >+[4S6[2)@20$2H3V,?.<<@\
M9 !&,_G6?I,XU>^:["@+%;Q@;OO9E'F ],#@E3S^AXZJL?PQH']B1M#G(:1F
M'L#@*">,G !/ Y./>@"GXC"K=6;N/D#R#)&1N91L['G<./IGM7253U;28]5C
M,$HRI_,'L0>Q'_UCD$BLF.RU"S C26*4 #YIE=7],?*3GIG).22<T -^( 5K
M4H1EW=!&,9.[=VP#SM!_EWJ36?\ C]L_^WC_ -%BG6?AQY)1=W;B5T'R*%VQ
MH2<G S\V.Q// )Y Q:U#2VN+BWN01MA\W<#G)WJ ,<?GTH U*X&.,R:+A02<
M$\#/ FR3^ &3[5WU9/AW1SI]LMI+M8@.&QRI#,3CD#/!YXH T+.1)$5HL>65
M4K@8&TCCCC'':B\D2-&:7'EA6+9&1M YXYSQVK#CT&?2?ELI%\LD_NYP2JY.
M259?F]@IR.22<U'+H-UJQ"WLB"$%28X P#XR>6;!'..!D'V(!H D\#1B6QC1
M@"") 01D$%VR,5EV^I/IMM+IY):>.00QX)5B)1^Z;=D@<9(&1@* <&NB\,Z6
MVE6Z6SD%DW9*Y(Y8GN!ZU7N_#?GW:7N1L4?,F/O.H(1O0D!N">1@ => #+UG
M3UT$6ETN,6Q$;D)_"XPSG;R,')'7YF]>M[3(QJ-Y-=D B "%#CN,F3@\Y!.,
MC ()Z]:V-4L!J$3V[8PZD9(S@D<''L>1[BJ_AW1QI$"6XQD#+$=V/4YP,^@S
MS@ 4 4=9_P"/VS_[>/\ T6*C\1A5NK-W'R!Y!DC(W,HV=CSN''TSVK0U#2VN
M+BWN01MA\W<#G)WJ ,<?GTJQJVDQZK&8)1E3^8/8@]B/_K'()% %RN9^(DB+
M9L'QDL@3(S\V<\>GR@\^G'>IOL=_:?NXI(I$[&<,' Z $IPW'\1Y))K-U/P;
M/JR-)<2*TV,1J,K$F7R>@R<KQDC/KG ( +GCV#SHHAD "XCW,0&500PW,#Q@
M$C.>#T/6IO[&O?\ G\_\EX_\:VKRS2\0PR ,C#!!_P _D>H/(K!M]+O=,406
M[Q21+]WSP^]1V7*\$ =#QZ8  % $=]X?NKA1%)><,1C]RBDE?G&"&!R-N>/2
MNHKG[#P[)+*+N]<22)G8BC$:9).1GJ>F"1D=\D CH* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:
M[_J6_#_T(44:[_J6_#_T(44 <+<_>/\ GM452W/WC_GM45 !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !6IX:_P"/A/\ @7_H)K+K4\-?\?"?\"_]
M!- '=4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5!>_P"K?_=;^53U!>_ZM_\ =;^5 %/P_P#ZL_[Q_D*T
MZS/#_P#JS_O'^0K3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#,\0?ZL?[P_D:XS6_P#6G_=C
M_P#0%KL_$'^K'^\/Y&LR?PI]O(FWXW*G&W/10.N1Z5UX&K"E4;D[*W^1Y^:X
M>I7HJ,%=WO\ @SD**ZK_ (0;_II_XY_]E1_P@W_33_QS_P"RKTOKU#^;\'_D
M>+_96+_E_%?YG*T5U7_"#?\ 33_QS_[*C_A!O^FG_CG_ -E1]>H?S?@_\@_L
MK%_R_BO\SE:*ZK_A!O\ II_XY_\ 94?\(-_TT_\ '/\ [*CZ]0_F_!_Y!_96
M+_E_%?YG*T5U7_"#?]-/_'/_ +*C_A!O^FG_ (Y_]E1]>H?S?@_\@_LK%_R_
MBO\ ,Y6BNJ_X0;_II_XY_P#94?\ "#?]-/\ QS_[*CZ]0_F_!_Y!_96+_E_%
M?YG*T5U7_"#?]-/_ !S_ .RH_P"$&_Z:?^.?_94?7J'\WX/_ "#^RL7_ "_B
MO\SE:*ZK_A!O^FG_ (Y_]E1_P@W_ $T_\<_^RH^O4/YOP?\ D']E8O\ E_%?
MYG*T5U7_  @W_33_ ,<_^RH_X0;_ *:?^.?_ &5'UZA_-^#_ ,@_LK%_R_BO
M\SE:*ZK_ (0;_II_XY_]E1_P@W_33_QS_P"RH^O4/YOP?^0?V5B_Y?Q7^9RM
M%=5_P@W_ $T_\<_^RH_X0;_II_XY_P#94?7J'\WX/_(/[*Q?\OXK_,Y6BNJ_
MX0;_ *:?^.?_ &5'_"#?]-/_ !S_ .RH^O4/YOP?^0?V5B_Y?Q7^9RM%=5_P
M@W_33_QS_P"RH_X0;_II_P".?_94?7J'\WX/_(/[*Q?\OXK_ #.5HKJO^$&_
MZ:?^.?\ V5'_  @W_33_ ,<_^RH^O4/YOP?^0?V5B_Y?Q7^9RM%=5_P@W_33
M_P <_P#LJ/\ A!O^FG_CG_V5'UZA_-^#_P @_LK%_P OXK_,Y6BNJ_X0;_II
M_P".?_94?\(-_P!-/_'/_LJ/KU#^;\'_ )!_96+_ )?Q7^9RM%=5_P (-_TT
M_P#'/_LJ/^$&_P"FG_CG_P!E1]>H?S?@_P#(/[*Q?\OXK_,Y6BNJ_P"$&_Z:
M?^.?_94?\(-_TT_\<_\ LJ/KU#^;\'_D']E8O^7\5_F<K175?\(-_P!-/_'/
M_LJ/^$&_Z:?^.?\ V5'UZA_-^#_R#^RL7_+^*_S.5HKJO^$&_P"FG_CG_P!E
M1_P@W_33_P <_P#LJ/KU#^;\'_D']E8O^7\5_F<K175?\(-_TT_\<_\ LJ/^
M$&_Z:?\ CG_V5'UZA_-^#_R#^RL7_+^*_P SE:*ZK_A!O^FG_CG_ -E1_P (
M-_TT_P#'/_LJ/KU#^;\'_D']E8O^7\5_F<K175?\(-_TT_\ '/\ [*F3^"O*
M4OYGW03]ST'^]1]>H?S?@_\ (/[*Q?\ +^*_S.8HKH=/\)?;%+[\8./NY[#_
M &JL_P#"#?\ 33_QS_[*CZ]0_F_!_P"0?V5B_P"7\5_F<K175?\ "#?]-/\
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M  @W_33_ ,<_^RH^O4/YOP?^0?V5B_Y?Q7^9RM%=5_P@W_33_P <_P#LJ/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM.?_ )Y_^.M_C1_:<_\ SS_\=;_&MJB@#%_M.?\ YY_^.M_C1_:<_P#SS_\
M'6_QK:HH Q?[3G_YY_\ CK?XT?VG/_SS_P#'6_QK:HH Q?[3G_YY_P#CK?XT
M?VG/_P \_P#QUO\ &MJB@#%_M.?_ )Y_^.M_C1_:<_\ SS_\=;_&MJB@#%_M
M.?\ YY_^.M_C1_:<_P#SS_\ '6_QK:HH Q?[3G_YY_\ CK?XT?VG/_SS_P#'
M6_QK:HH Q?[3G_YY_P#CK?XT?VG/_P \_P#QUO\ &MJB@#%_M.?_ )Y_^.M_
MC1_:<_\ SS_\=;_&MJB@#%_M.?\ YY_^.M_C1_:<_P#SS_\ '6_QK:HH Q?[
M3G_YY_\ CK?XT?VG/_SS_P#'6_QK:HH Q?[3G_YY_P#CK?XT?VG/_P \_P#Q
MUO\ &MJB@#%_M.?_ )Y_^.M_C1_:<_\ SS_\=;_&MJB@#%_M.?\ YY_^.M_C
M1_:<_P#SS_\ '6_QK:HH Q?[3G_YY_\ CK?XT?VG/_SS_P#'6_QK:HH Q?[3
MG_YY_P#CK?XT?VG/_P \_P#QUO\ &MJB@#%_M.?_ )Y_^.M_C1_:<_\ SS_\
M=;_&MJB@#%_M.?\ YY_^.M_C1_:<_P#SS_\ '6_QK:HH Q?[3G_YY_\ CK?X
MT?VG/_SS_P#'6_QK:HH Q?[3G_YY_P#CK?XT?VG/_P \_P#QUO\ &MJB@#G-
M0O)9E D7 SUP1S@^M30:A,B@*F0 ,':W3'UJUX@_U8_WA_(UF3^*_L!$.S.U
M4YW8ZJ#TP?6M*5*=5VBKLRKXBG0CS3=EL7/[3G_YY_\ CK?XT?VG/_SS_P#'
M6_QK._X3G_IG_P"/_P#V-'_"<_\ 3/\ \?\ _L:V^HU_Y?Q7^9S?VKA/YOP?
M^1H_VG/_ ,\__'6_QH_M.?\ YY_^.M_C6=_PG/\ TS_\?_\ L:/^$Y_Z9_\
MC_\ ]C1]1K_R_BO\P_M7"?S?@_\ (T?[3G_YY_\ CK?XT?VG/_SS_P#'6_QK
M._X3G_IG_P"/_P#V-'_"<_\ 3/\ \?\ _L:/J-?^7\5_F']JX3^;\'_D:/\
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M.?\ IG_X_P#_ &-'_"<_],__ !__ .QH^HU_Y?Q7^8?VKA/YOP?^1H_VG/\
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MG_X__P#8T?\ "<_],_\ Q_\ ^QH^HU_Y?Q7^8?VKA/YOP?\ D:/]IS_\\_\
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MK_,/[5PG\WX/_(T?[3G_ .>?_CK?XT?VG/\ \\__ !UO\:SO^$Y_Z9_^/_\
MV-'_  G/_3/_ ,?_ /L:/J-?^7\5_F']JX3^;\'_ )&C_:<__//_ ,=;_&F3
MZA,ZD,F 0<G:W3'UJC_PG/\ TS_\?_\ L:9/XU\U2GE_>!'W_4?[M'U&O_+^
M*_S#^U<)_-^#_P BWI]Y+"I$:Y&>N"><#TJS_:<__//_ ,=;_&L73_%OV-2F
MS.3G[V.P_P!FK/\ PG/_ $S_ /'_ /[&CZC7_E_%?YA_:N$_F_!_Y&C_ &G/
M_P \_P#QUO\ &C^TY_\ GG_XZW^-9W_"<_\ 3/\ \?\ _L:/^$Y_Z9_^/_\
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MY_Z9_P#C_P#]C1_PG/\ TS_\?_\ L:/J-?\ E_%?YA_:N$_F_!_Y&C_:<_\
MSS_\=;_&C^TY_P#GG_XZW^-9W_"<_P#3/_Q__P"QH_X3G_IG_P"/_P#V-'U&
MO_+^*_S#^U<)_-^#_P C1_M.?_GG_P".M_C1_:<__//_ ,=;_&L[_A.?^F?_
M (__ /8T?\)S_P!,_P#Q_P#^QH^HU_Y?Q7^8?VKA/YOP?^1H_P!IS_\ //\
M\=;_ !H_M.?_ )Y_^.M_C6=_PG/_ $S_ /'_ /[&C_A.?^F?_C__ -C1]1K_
M ,OXK_,/[5PG\WX/_(T?[3G_ .>?_CK?XT?VG/\ \\__ !UO\:SO^$Y_Z9_^
M/_\ V-'_  G/_3/_ ,?_ /L:/J-?^7\5_F']JX3^;\'_ )&C_:<__//_ ,=;
M_&C^TY_^>?\ XZW^-9W_  G/_3/_ ,?_ /L:/^$Y_P"F?_C_ /\ 8T?4:_\
M+^*_S#^U<)_-^#_R-'^TY_\ GG_XZW^-']IS_P#//_QUO\:SO^$Y_P"F?_C_
M /\ 8T?\)S_TS_\ '_\ [&CZC7_E_%?YA_:N$_F_!_Y&C_:<_P#SS_\ '6_Q
MH_M.?_GG_P".M_C6=_PG/_3/_P ?_P#L:/\ A.?^F?\ X_\ _8T?4:_\OXK_
M ##^U<)_-^#_ ,C1_M.?_GG_ ..M_C1_:<__ #S_ /'6_P :SO\ A.?^F?\
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M7^8?VKA/YOP?^1H_VG/_ ,\__'6_QH_M.?\ YY_^.M_C6=_PG/\ TS_\?_\
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M.?\ IG_X_P#_ &-'U&O_ "_BO\P_M7"?S?@_\C1_M.?_ )Y_^.M_C1_:<_\
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M^F?_ (__ /8T?4:_\OXK_,/[5PG\WX/_ "-'^TY_^>?_ (ZW^-']IS_\\_\
MQUO\:SO^$Y_Z9_\ C_\ ]C1_PG/_ $S_ /'_ /[&CZC7_E_%?YA_:N$_F_!_
MY&C_ &G/_P \_P#QUO\ &C^TY_\ GG_XZW^-9W_"<_\ 3/\ \?\ _L:/^$Y_
MZ9_^/_\ V-'U&O\ R_BO\P_M7"?S?@_\C1_M.?\ YY_^.M_C1_:<_P#SS_\
M'6_QK._X3G_IG_X__P#8T?\ "<_],_\ Q_\ ^QH^HU_Y?Q7^8?VKA/YOP?\
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M_//_ ,=;_&MJB@#%_M.?_GG_ ..M_C1_:<__ #S_ /'6_P :VJ* ,7^TY_\
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MVG/_ ,\__'6_QH_M.?\ YY_^.M_C6U10!B_VG/\ \\__ !UO\:/[3G_YY_\
MCK?XUM44 8O]IS_\\_\ QUO\:/[3G_YY_P#CK?XUM44 8O\ :<__ #S_ /'6
M_P :/[3G_P">?_CK?XUM44 8O]IS_P#//_QUO\:/[3G_ .>?_CK?XUM44 8O
M]IS_ ///_P =;_&C^TY_^>?_ (ZW^-;5% &+_:<__//_ ,=;_&C^TY_^>?\
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MHH Q?[3G_P">?_CK?XT?VG/_ ,\__'6_QK:HH Q?[3G_ .>?_CK?XT?VG/\
M\\__ !UO\:VJ* ,7^TY_^>?_ (ZW^-']IS_\\_\ QUO\:VJ* ,7^TY_^>?\
MXZW^-']IS_\ //\ \=;_ !K:HH Q?[3G_P">?_CK?XT?VG/_ ,\__'6_QK:H
MH Q?[3G_ .>?_CK?XT?VG/\ \\__ !UO\:VJ* ,7^TY_^>?_ (ZW^-']IS_\
M\_\ QUO\:VJ* ,7^TY_^>?\ XZW^-']IS_\ //\ \=;_ !K:HH Q?[3G_P">
M?_CK?XT?VG/_ ,\__'6_QK:HH Q?[3G_ .>?_CK?XT?VG/\ \\__ !UO\:VJ
M* ,7^TY_^>?_ (ZW^-']IS_\\_\ QUO\:VJ* ,7^TY_^>?\ XZW^-']IS_\
M//\ \=;_ !K:HH Q?[3G_P">?_CK?XT?VG/_ ,\__'6_QK:HH Q?[3G_ .>?
M_CK?XT?VG/\ \\__ !UO\:VJ* ,7^TY_^>?_ (ZW^-']IS_\\_\ QUO\:VJ*
M ,7^TY_^>?\ XZW^-']IS_\ //\ \=;_ !K:HH Q?[3G_P">?_CK?XT?VG/_
M ,\__'6_QK:HH Q?[3G_ .>?_CK?XT?VG/\ \\__ !UO\:VJ* ,7^TY_^>?_
M (ZW^-']IS_\\_\ QUO\:VJ* ,7^TY_^>?\ XZW^-']IS_\ //\ \=;_ !K:
MHH Q?[3G_P">?_CK?XT?VG/_ ,\__'6_QK:HH Q?[3G_ .>?_CK?XT?VG/\
M\\__ !UO\:VJ* ,7^TY_^>?_ (ZW^-']IS_\\_\ QUO\:VJ* ,7^TY_^>?\
MXZW^-']IS_\ //\ \=;_ !K:HH Q?[3G_P">?_CK?XT?VG/_ ,\__'6_QK:H
MH Q?[3G_ .>?_CK?XT?VG/\ \\__ !UO\:VJ* .=U"^FE0JZ84XR=K#N/6BM
M/7?]2WX?^A"B@#A;G[Q_SVJ*I;G[Q_SVJ*@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K4\-?\?"?\"_]!-9=:GAK_CX3_@7_H)H [JBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#\I;T]#[^E>M.I&"NSY^E2E5=H^O;\S*HK7.B+.K&WD\QEY*["IQZC/7_/?
M.11"I&=[#J494[7Z[6::^]!114MK:M=,(T&6.<#('09[U3:2NR$G)V6Y%13Y
M8C"Q1N"I(/U'!IE&XFK:!1110 4444 %%%% !115R]LEMU1U<,7&2!C*\#@\
MGU]NE)R2:7<I0;3?8IT444R0HHHH **L)8.\9N /D4X)R.O';.>XJO233V&X
MN-KK<****8@HHHH **** "BKEE9+<*[LX4H,@'&6X/ Y'I[]:L:3I:WD<TC$
MYB7(QC'1CSP?2HE5C%-OI^IK##SFTEUNU\M_R,NBBM3P]I:ZE(8W) "D_+C/
M4#N#ZTYS4(N3V1-*E*K-06[,NBBBJ("BK%S8/;*KN,"097D'(X/8^_>J])--
M70Y1<79JS"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "KNDZL^FOO7D'[R]B/\ 'T/;Z9%4J*4HJ2:>Q4)R
MIR4D[-'IMC?)?()4.0?S!]#[_P">E6*\WTG5GTU]Z\@_>7L1_CZ'M],BO0+&
M^2^02H<@_F#Z'W_STKQ,7A'1=U\)]1@,?'$QL])+=?JC-U/_ %\?_ ?_ $(U
MM5BZG_KX_P#@/_H1K:KE.X**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *S/$'^K'^\/Y&M.LSQ!_JQ_O#^1H TZ*** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>RY#-R>V<9Z=2 8M3^+MC8N8AODQU:)05R"1C+,N>G49!!&":\\^*^CQ:7>
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MA@9Y'W2, DT ='\#/^7K_MC_ .U*[KQEKHT2TEN,X?:53H3O;A<!N#@\D<\
MG!Q7"_ S_EZ_[8_^U*K_ !AUXWLT>E1D8C(9\D*-[#Y02P  53G.[;\W.-M
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M=Z\JC\K)]!E%%%=!QA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5J>&O^/A/^!?\ H)K+K4\-
M?\?"?\"_]!- '=4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5!>_ZM_P#=;^53U!>_ZM_]UOY4 4_#_P#J
MS_O'^0K3K,\/_P"K/^\?Y"M.@#)\6?\ 'G<_]>\W_H#5P'P,_P"7K_MC_P"U
M*]5HH \4^-?_ !^1_P#7NO\ Z')7JOBS_CSN?^O>;_T!JUJ* /*O@9_R]?\
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M_H$=>@44 %>*>)?^0\O_ %\6O\HZ]KHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% %+6/]4WX?S%&C_P"J7\?YFC6/]4WX?S%&C_ZI?Q_F: +M%%%
M%?4;3[9$\&<>8C+G&<;@1G''K7-_#RW9HFNW&#+L48Z;85"*<<G.0<Y]. !7
M644 0WEJ+M&A;.'5E..N&&#7-^ K-XTDEE!60LL9'\.(%" CKGG()!(R.,5U
M5% &+XETE[L)/!@3V[;DR2 P_B3@C[V!_+(!)JO'XY@C %P'AD('R2(^?J,
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:[_ *EOP_\ 0A11KO\
MJ6_#_P!"%% '"W/WC_GM452W/WC_ )[5%0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5J>&O^/A/^!?^@FLNM3PU_P ?"?\  O\ T$T =U3)IEA4
MNY 50223@ #DDD] *?7'^*U_MN[@T8AO**F:?!VY5<JBYSD@O]X8S]T@C!(
M'IX^.I$KIUO)<;3RY(ABZ G#O_$,CY2 >IZ#ED_C>YT[Y[NRE2/:QW0NL^-N
M,[MN HQSDGMTZXZV&%85"( %4   8  X  '0"GT 4='UJ'6(_/MW#IDC(R,$
M=000"#]1TP>A%5_$/B>#P^@EN&QNSM4#+,0,X _J< $C)&:FTG0(-(W_ &>-
M4\QMS;>Y_H!V48 R< 9KFO!%O_;<LNNRC_6,4MPW5(TRN1\S %CD'IR&(X>@
M"U_PE-[/\\%@YC/0RS1POZ',9R1SG'/(P>]3:=X[BFE%E<(]O<-@!)1\K$Y!
MVN,AAD8!.-W&W)XKI:S]=T*+7(C;3C*MT(^\I[,#V(_^L<@D$ A\3:[_ &%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ J"]_U;_P"ZW\JGJ"]_U;_[K?RH I^'_P#5G_>/
M\A6G6)H]^ENA5S@[B>A/8>@J]_;$7][]#_A0!=HJE_;$7][]#_A1_;$7][]#
M_A0!=HJE_;$7][]#_A1_;$7][]#_ (4 7:*I?VQ%_>_0_P"%']L1?WOT/^%
M%VBJ7]L1?WOT/^%']L1?WOT/^% %VBJ7]L1?WOT/^%']L1?WOT/^% %VBJ7]
ML1?WOT/^%']L1?WOT/\ A0!=HJE_;$7][]#_ (4?VQ%_>_0_X4 7:*I?VQ%_
M>_0_X4?VQ%_>_0_X4 7:*I?VQ%_>_0_X4?VQ%_>_0_X4 7:*I?VQ%_>_0_X4
M?VQ%_>_0_P"% %VBJ7]L1?WOT/\ A1_;$7][]#_A0!=HJE_;$7][]#_A1_;$
M7][]#_A0!=HJE_;$7][]#_A1_;$7][]#_A0!=HJE_;$7][]#_A1_;$7][]#_
M (4 7:*I?VQ%_>_0_P"%']L1?WOT/^% %VBJ7]L1?WOT/^%']L1?WOT/^% %
MVBJ7]L1?WOT/^%']L1?WOT/^% %VBJ7]L1?WOT/^%']L1?WOT/\ A0!=HJE_
M;$7][]#_ (4?VQ%_>_0_X4 7:*I?VQ%_>_0_X4?VQ%_>_0_X4 7:*I?VQ%_>
M_0_X4?VQ%_>_0_X4 7:*I?VQ%_>_0_X4?VQ%_>_0_P"% %VBJ7]L1?WOT/\
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M*[W=:?W4_P"_?_V-&ZT_NI_W[_\ L:/[4A_*P_L*I_,C@J*[W=:?W4_[]_\
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M@J*[W=:?W4_[]_\ V-&ZT_NI_P!^_P#[&C^U(?RL/["J?S(X*BN]W6G]U/\
MOW_]C1NM/[J?]^__ +&C^U(?RL/["J?S(X*BN]W6G]U/^_?_ -C1NM/[J?\
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M@J*[W=:?W4_[]_\ V-&ZT_NI_P!^_P#[&C^U(?RL/["J?S(X*BN]W6G]U/\
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MO?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\
M"@"[15+^V(O[WZ'_  H_MB+^]^A_PH NT52_MB+^]^A_PH_MB+^]^A_PH NT
M52_MB+^]^A_PH_MB+^]^A_PH NT52_MB+^]^A_PH_MB+^]^A_P * +M9GB#_
M %8_WA_(U-_;$7][]#_A5'6+]+A J')W ]".Q]10!MT52_MB+^]^A_PH_MB+
M^]^A_P * +M%4O[8B_O?H?\ "C^V(O[WZ'_"@"[15+^V(O[WZ'_"C^V(O[WZ
M'_"@"[15+^V(O[WZ'_"C^V(O[WZ'_"@"[15+^V(O[WZ'_"C^V(O[WZ'_  H
MNT52_MB+^]^A_P */[8B_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\* +M%4O
M[8B_O?H?\*/[8B_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\ "@"[15+^V(O[
MWZ'_  H_MB+^]^A_PH NT52_MB+^]^A_PH_MB+^]^A_PH NT52_MB+^]^A_P
MH_MB+^]^A_PH NT52_MB+^]^A_PH_MB+^]^A_P * +M%4O[8B_O?H?\ "C^V
M(O[WZ'_"@"[15+^V(O[WZ'_"C^V(O[WZ'_"@"[15+^V(O[WZ'_"C^V(O[WZ'
M_"@"[15+^V(O[WZ'_"C^V(O[WZ'_  H NT52_MB+^]^A_P */[8B_O?H?\*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U/#7_'
MPG_ O_03676IX:_X^$_X%_Z": .ZKDM3+:?JD%RP'E7$#0;B<;7#&09XQEN%
M49R3GTYZVL_7="BUR(VTXRK="/O*>S ]B/\ ZQR"00#0HKC[:/5-$&SY+V,8
M"DMY,W0<DME2!@]RQ)R3U )]1U:__=Q6\5O\K9>:42\G &T(.".3\RD'OZ$
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M?WDLRR*HP?X4&<YQCAAZC'(U?#7AK^Q_,EDD:6>=@9)&&,XSM 7)"A0>!_3
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MN_J?\:NT4 4O['B_N_J?\:/['B_N_J?\:NT4 4O['B_N_J?\:/['B_N_J?\
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MJ[10!2_L>+^[^I_QH_L>+^[^I_QJ[10!2_L>+^[^I_QH_L>+^[^I_P :NT4
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MN_J?\:NT4 4O['B_N_J?\:/['B_N_J?\:NT4 4O['B_N_J?\:/['B_N_J?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K4\-?\?"?\"_]!-9=:GAK_CX3_@7_H)H [JBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+W_5O_NM
M_*IZ@O?]6_\ NM_*@"GX?_U9_P!X_P A6G69X?\ ]6?]X_R%:= !1110 444
M4 %%%>+^-]4NWU1[*">1 [PJH$CJ@+H@Z*>!DY.!0![117C6K+JW@O9=R3^8
MC-M(,C2KG[V"L@!&0#RO( (R,C/H#^(?[6TR34(@T9:WF(Y^9656!P1Z$<'@
M]#@'B@#I:*\,\"?$&>RN52YE9X92%;S6+;<_=8%F^4 GYN<;<\$@8]@\3S-#
M:7#H2&6"4@@X((0D$$="* -.BO-/@UJTVH?://D>3;Y6/,=FQG?G&2<9P*]#
MU&]6PB>X?)6)&8@=<*"3C..>* +%%?/^E_$2Y@NUO)9':,R$M'O<IM;.X*A;
M' /R@G (%?0% !1110 45R_C;2;[552*RD6)0=S/YDB.3R OR*?EYR<GDXX&
M.>*^$6N7%_=NDTLCJ(&(#NS#.]!G!)YYH ]=HJIJNIII<3W4IPD:DGIDXZ 9
M(&2> ,\D@5Y%IMSJOCB1IX93$B #Y7>*+/\ =&W<2W.3G..Y VB@#VBBO-/A
MUXVGDG;2+XYD7<%8\MNCX9"5!#< G<3G(.2V1BWXI\(:EJ%R\]M<^7$VW:OG
M2KC"@'Y54@9()XH ] HKP?Q5'J/AID2:[9FD!($<\I( P,D';@'MZX/I7H?A
M&YN-*TW[9/YMQ+)^\5,EWP^U44'+'&,,?[H)^7(Y .UHKR*VTS6_$S-<-(UN
M <!6:2 =S@*HR0,XW-R>!DX.-#X>^.;AK@Z1>Y:0%E5N"RF,'<K$?>'RGYN3
MGJ2#D 'IM%%<UX^\7?\ "-0>:FTRNP"*W(]6) 93@#N.A*YZT =+17BEO9ZQ
M- VL>>X5<R;6D8$J/F+"/[FW&2%. 0.%((SWWPX\8-XC@/FX\Z$@/@8R"/E?
MI@$X(('<9P 0* .MHKS+XDVFHQ>9J*3"*"(*H2*64,06P&( "[B6YYX&!DXR
M=7X1:C+?VCO,[.PG8 NQ8XV(<9)/'- '<45S7CK7;C2X@MG$\DLF0&1"ZH!C
M+$ 'GGY0>.I.<8/ S:+K4,)U1YV&T&4QF5@P .XYC(V  <[/3Y=N?EH ]CHK
MC_AOXS;Q)$RRC][!M#,,!6#9PV.Q^4Y'3N.N!V% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 9GB#_ %8_WA_(UQFM_P"M/^['_P"@+79^(/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EK'^J;\/YBC1_\
M5+^/\S1K'^J;\/YBC1_]4OX_S- %VBBB@ HK#2X:WOFA+'RYH0RAB<!T."J=
MON_,PY/?I6M>70M$:9LX168XZX49- $U%<SX(UB2_61)\^8K!QTP$F&]0#DG
MUX/0$#M@7O%M\UG;.8_]8^$0#.XER!\N,'=@DC'IF@#8HJ.WA\A5CR6V@#+'
M+' QDGN3WJ2@ HHHH ***Y_P%_QY1?\  _\ T8U '04444 %%<_X"_X\HO\
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M\[]O^TN,;:J^"OAO_P (Q,USYWF;HRF/+V]64YSN;^[Z4 =K7BGP4_X_)/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !70>%M:>!Q;$%D<\ <E2>_T]?3KZYP[>W:X81H,LW0"N]T/0UTQ
M<]9&ZG^@]OY_D!R8ZK3C3Y7JWLOU/0RJA5G54XNR6[_0U****\0^H"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,74_P#7Q_\  ?\ T(UM
M5BZG_KX_^ _^A&MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K,\0?ZL?[P_D:TZS/$'^K'^\/Y&@#3HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2<\XYQFB\\.MI"&;3V9"HR8B2\;XY(VG)W$  $'/&.,YK8T75TU:);A".1R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *U/#7_'PG_ O_03676IX:_X^$_X%_Z": .ZHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[H46N1&VG&5;H1]Y3V8'L1_]8Y!(.A10!S7A_P !0Z"DT4#R_P"D* 6++N7
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M%/83=]0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;_"C^S)_^>G_ (\W^%'UZO\ S?@O\@_LK"?R_B_\S._X0;_II_XY_P#94?\
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M;_"C^S)_^>G_ (\W^%'UZO\ S?@O\@_LK"?R_B_\S._X0;_II_XY_P#94?\
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M_"CZ]7_F_!?Y!_96$_E_%_YF=_P@W_33_P <_P#LJ/\ A!O^FG_CG_V5:/\
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M_P#'F_PH_LR?_GI_X\W^% &U16+_ &9/_P ]/_'F_P */[,G_P">G_CS?X4
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M;_"C^S)_^>G_ (\W^% &U16+_9D__/3_ ,>;_"C^S)_^>G_CS?X4 ;5%8O\
M9D__ #T_\>;_  H_LR?_ )Z?^/-_A0!M45B_V9/_ ,]/_'F_PH_LR?\ YZ?^
M/-_A0!M45B_V9/\ \]/_ !YO\*/[,G_YZ?\ CS?X4 ;5%8O]F3_\]/\ QYO\
M*/[,G_YZ?^/-_A0!M45B_P!F3_\ /3_QYO\ "C^S)_\ GI_X\W^% %W6/]4W
MX?S%&C_ZI?Q_F:S+RQFB0L[Y48R-S'O[T6=C-*@9'PIS@;F'?VH Z"BL7^S)
M_P#GI_X\W^%']F3_ //3_P >;_"@#:HK%_LR?_GI_P"/-_A1_9D__/3_ ,>;
M_"@#:HK%_LR?_GI_X\W^%']F3_\ /3_QYO\ "@#:HK%_LR?_ )Z?^/-_A1_9
MD_\ ST_\>;_"@#:HK%_LR?\ YZ?^/-_A1_9D_P#ST_\ 'F_PH VJ*Q?[,G_Y
MZ?\ CS?X4?V9/_ST_P#'F_PH VJ*Q?[,G_YZ?^/-_A1_9D__ #T_\>;_  H
MVJ*Q?[,G_P">G_CS?X4?V9/_ ,]/_'F_PH VJ*Q?[,G_ .>G_CS?X4?V9/\
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M>G_CS?X4?V9/_P ]/_'F_P * -JBL7^S)_\ GI_X\W^%']F3_P#/3_QYO\*
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M4?Y4']H8G^=G0?\ ":S?W4_)O_BJ/^$UF_NI^3?_ !5<_11]4H_RH/[0Q/\
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MU/R;_P"*JK!XEDA<R@+ELYR#CDY]:R:*/JE'^5!_:&)_G9T'_":S?W4_)O\
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MBBB@ HHHH **** "BBB@ HHHH **** ,74_]?'_P'_T(UM5BZG_KX_\ @/\
MZ$:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
MSQ!_JQ_O#^1K3K,\0?ZL?[P_D: -.BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"EK'^J;\/YBC1_]4OX_S-&L?ZIOP_F*-'_U
M2_C_ #- %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** *&N_P"I;\/_ $(44:[_ *EOP_\
M0A10!PMS]X_Y[5%4MS]X_P">U14 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %:GAK_CX3_@7_H)K+K4\-?\ 'PG_  +_ -!- '=4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M!>_ZM_\ =;^53U!>_P"K?_=;^5 %/P__ *L_[Q_D*TZS/#_^K/\ O'^0K3H
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M.>,$G /'3)XKUW3]0CU&-;B%@T;C((_SP1T(/(/!YH Y3QA\38?#S_9U4RS
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M]Y3W4CL1_P#7&003H5YE\#XI!%.YSY1= O/&X [^,\'!7)QSQZ<>FT %%%%
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M** "BBB@ HHHH **** "BBB@ K,\0?ZL?[P_D:TZS/$'^K'^\/Y&@#3HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"M3PU_Q\)_P+_P!!-9=:GAK_ (^$_P"!?^@F@#NJ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@O?]6_\
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M5UE7JIS_ /6X['O75_8%^U?;/^67E^;G8=N<8_/^+U]N]<?6BVNR/#]D."O
MR<[N#D<YQ[=.E17I2FTX^C]&:83$0IIJ71\R]5_F6-*LUU)I;F;[J9=@O!))
M+8Y[8![@].:U?"]Q%-(WE1;,+RV]F')''/'/]*YW3-5?3FWQ]^H/0_\ ZO\
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M?"KG'"#"\#' J*NI;'"TD] HHHH$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !73>&/#Q<BYEX P5'<^C'V]/7Z=4\-^&_.Q<3#Y>JJ>_N?;T'?Z=>PKS<;C
M;7A'YL]K+,LO:K-:=%^K"BBBO+/>"BBB@ HHHH **** "BBB@ HHHH ****
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M.&.WC@X(/(4%E;K: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH H:[_ *EOP_\ 0A11KO\ J6_#_P!"
M%% '"W/WC_GM452W/WC_ )[5%0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5J>&O^/A/^!?^@FLNM3PU_P ?"?\  O\ T$T =U1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%
M[_JW_P!UOY5/4%[_ *M_]UOY4 4_#_\ JS_O'^0K3K,\/_ZL_P"\?Y"M.@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** ,SQ!_JQ_O#^1KC-;_UI_P!V/_T!:[/Q!_JQ_O#^1KC-
M;_UI_P!V/_T!:[LL_BOT_5'E9Y_ C_B7Y,H4445[!\X%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %=+X;\-^=BXF'R]54]_<^WH._TZGA
MOPWYV+B8?+U53W]S[>@[_3KV%>;C<;:\(_-GM99EG-:K46G1?JPHHHKRSW@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q=3_ -?'
M_P !_P#0C6U6+J?^OC_X#_Z$:VJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "LSQ!_JQ_O#^1K3K,\0?ZL?[P_D: -.BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV/\ Q[_ZU'_"1?['_CW_ -:MJB@#%_X2+_8_\>_^M1_PD7^Q_P"/?_6K:HH
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M>_\ K4?\)%_L?^/?_6K._P"$Y_Z9_P#C_P#]C1_PG/\ TS_\?_\ L:/J-?\
ME_%?YA_:N$_F_!_Y&C_PD7^Q_P"/?_6H_P"$B_V/_'O_ *U9W_"<_P#3/_Q_
M_P"QH_X3G_IG_P"/_P#V-'U&O_+^*_S#^U<)_-^#_P C1_X2+_8_\>_^M1_P
MD7^Q_P"/?_6K._X3G_IG_P"/_P#V-'_"<_\ 3/\ \?\ _L:/J-?^7\5_F']J
MX3^;\'_D:/\ PD7^Q_X]_P#6H_X2+_8_\>_^M6=_PG/_ $S_ /'_ /[&C_A.
M?^F?_C__ -C1]1K_ ,OXK_,/[5PG\WX/_(T?^$B_V/\ Q[_ZU'_"1?['_CW_
M -:L[_A.?^F?_C__ -C1_P )S_TS_P#'_P#[&CZC7_E_%?YA_:N$_F_!_P"1
MH_\ "1?['_CW_P!:C_A(O]C_ ,>_^M6=_P )S_TS_P#'_P#[&C_A.?\ IG_X
M_P#_ &-'U&O_ "_BO\P_M7"?S?@_\C1_X2+_ &/_ ![_ .M1_P )%_L?^/?_
M %JSO^$Y_P"F?_C_ /\ 8T?\)S_TS_\ '_\ [&CZC7_E_%?YA_:N$_F_!_Y&
MC_PD7^Q_X]_]:C_A(O\ 8_\ 'O\ ZU9W_"<_],__ !__ .QH_P"$Y_Z9_P#C
M_P#]C1]1K_R_BO\ ,/[5PG\WX/\ R-'_ (2+_8_\>_\ K4?\)%_L?^/?_6K.
M_P"$Y_Z9_P#C_P#]C1_PG/\ TS_\?_\ L:/J-?\ E_%?YA_:N$_F_!_Y&C_P
MD7^Q_P"/?_6H_P"$B_V/_'O_ *U9W_"<_P#3/_Q__P"QH_X3G_IG_P"/_P#V
M-'U&O_+^*_S#^U<)_-^#_P C1_X2+_8_\>_^M1_PD7^Q_P"/?_6K._X3G_IG
M_P"/_P#V-'_"<_\ 3/\ \?\ _L:/J-?^7\5_F']JX3^;\'_D:/\ PD7^Q_X]
M_P#6H_X2+_8_\>_^M6=_PG/_ $S_ /'_ /[&C_A.?^F?_C__ -C1]1K_ ,OX
MK_,/[5PG\WX/_(T?^$B_V/\ Q[_ZU'_"1?['_CW_ -:M*QODOD$J'(/Y@^A]
M_P#/2K%<S3B[,[8R4DFM4S%_X2+_ &/_ ![_ .M1_P )%_L?^/?_ %JVJ*0S
M%_X2+_8_\>_^M1_PD7^Q_P"/?_6K:HH Q?\ A(O]C_Q[_P"M3)]>\U2FW[P(
M^]ZCZ5NU!>_ZM_\ =;^5 &'I^K?8U*;<Y.>N.P]JL_\ "1?['_CW_P!:I_#_
M /JS_O'^0K3H Q?^$B_V/_'O_K4?\)%_L?\ CW_UJVJ* ,7_ (2+_8_\>_\
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MB_V/_'O_ *U'_"1?['_CW_UJVJ* ,7_A(O\ 8_\ 'O\ ZU'_  D7^Q_X]_\
M6K:HH Q?^$B_V/\ Q[_ZU'_"1?['_CW_ -:MJB@#%_X2+_8_\>_^M1_PD7^Q
M_P"/?_6K:HH Q?\ A(O]C_Q[_P"M5.VU'R)&EQG=GC/J<^E=-6+IG^OD_P"!
M?^A"@ _X2+_8_P#'O_K4?\)%_L?^/?\ UJVJ* ,7_A(O]C_Q[_ZU'_"1?['_
M (]_]:MJB@#%_P"$B_V/_'O_ *U'_"1?['_CW_UJVJ* ,7_A(O\ 8_\ 'O\
MZU'_  D7^Q_X]_\ 6K:HH Q?^$B_V/\ Q[_ZU'_"1?['_CW_ -:MJB@#%_X2
M+_8_\>_^M1_PD7^Q_P"/?_6K:HH Q?\ A(O]C_Q[_P"M1_PD7^Q_X]_]:MJB
M@#%_X2+_ &/_ ![_ .M1_P )%_L?^/?_ %JVJ* ,7_A(O]C_ ,>_^M1_PD7^
MQ_X]_P#6K:HH Q?^$B_V/_'O_K4?\)%_L?\ CW_UJVJ* ,7_ (2+_8_\>_\
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M(O\ 8_\ 'O\ ZU&I_P"OC_X#_P"A&MJ@#%_X2+_8_P#'O_K4?\)%_L?^/?\
MUJVJ* ,7_A(O]C_Q[_ZU'_"1?['_ (]_]:MJB@#%_P"$B_V/_'O_ *U'_"1?
M['_CW_UJVJ* ,7_A(O\ 8_\ 'O\ ZU'_  D7^Q_X]_\ 6K:HH Q?^$B_V/\
MQ[_ZU'_"1?['_CW_ -:MJB@#%_X2+_8_\>_^M1_PD7^Q_P"/?_6K:HH Q?\
MA(O]C_Q[_P"M1_PD7^Q_X]_]:MJB@#%_X2+_ &/_ ![_ .M1_P )%_L?^/?_
M %JVJ* ,7_A(O]C_ ,>_^M1_PD7^Q_X]_P#6K:HH Q?^$B_V/_'O_K4?\)%_
ML?\ CW_UJVJ* ,7_ (2+_8_\>_\ K4?\)%_L?^/?_6K:HH Q?^$B_P!C_P >
M_P#K4?\ "1?['_CW_P!:MJB@#%_X2+_8_P#'O_K4?\)%_L?^/?\ UJVJ* ,7
M_A(O]C_Q[_ZU'_"1?['_ (]_]:MJB@#%_P"$B_V/_'O_ *U'_"1?['_CW_UJ
MVJ* ,7_A(O\ 8_\ 'O\ ZU'_  D7^Q_X]_\ 6K:HH Q?^$B_V/\ Q[_ZU'_"
M1?['_CW_ -:MJB@#%_X2+_8_\>_^M1_PD7^Q_P"/?_6K:HH Q?\ A(O]C_Q[
M_P"M1_PD7^Q_X]_]:MJB@#%_X2+_ &/_ ![_ .M1_P )%_L?^/?_ %JVJ* ,
M7_A(O]C_ ,>_^M1_PD7^Q_X]_P#6K:HH Q?^$B_V/_'O_K56U#5OMBA-N,'/
M7/8^U='69X@_U8_WA_(T 0?\)%_L?^/?_6H_X2+_ &/_ ![_ .M6U10!B_\
M"1?['_CW_P!:C_A(O]C_ ,>_^M6U10!B_P#"1?['_CW_ -:C_A(O]C_Q[_ZU
M;5% &+_PD7^Q_P"/?_6H_P"$B_V/_'O_ *U;5% &+_PD7^Q_X]_]:C_A(O\
M8_\ 'O\ ZU;5% &+_P )%_L?^/?_ %J/^$B_V/\ Q[_ZU;5% &+_ ,)%_L?^
M/?\ UJ/^$B_V/_'O_K5M44 8O_"1?['_ (]_]:C_ (2+_8_\>_\ K5M44 8O
M_"1?['_CW_UJ/^$B_P!C_P >_P#K5M44 8O_  D7^Q_X]_\ 6H_X2+_8_P#'
MO_K5M44 8O\ PD7^Q_X]_P#6H_X2+_8_\>_^M6U10!B_\)%_L?\ CW_UJ/\
MA(O]C_Q[_P"M6U10!B_\)%_L?^/?_6H_X2+_ &/_ ![_ .M6U10!B_\ "1?[
M'_CW_P!:C_A(O]C_ ,>_^M6U10!B_P#"1?['_CW_ -:C_A(O]C_Q[_ZU;5%
M&+_PD7^Q_P"/?_6H_P"$B_V/_'O_ *U;5% &+_PD7^Q_X]_]:C_A(O\ 8_\
M'O\ ZU;5% &+_P )%_L?^/?_ %J/^$B_V/\ Q[_ZU;5% &+_ ,)%_L?^/?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&(R [JIQTS@D<<5-9:C%?KOA=74'!*,&&>N,@GGF@"Q115>]U&*P7?,ZHI.
M78*,]<9)'/% %BBJ]EJ,5^N^%U=0<$HP89ZXR">>:L4 %%%% !1110 4444
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M_J6_#_T(44 <+<_>/^>U15+<_>/^>U14 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %:GAK_CX3_@7_H)K+K4\-?\?"?\"_\ 030!W5%%% !1110
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M);&252LTY#,#P0HR$4C)YY)Z C=@CB@#'^*'@R,PS:JTDK2KLVAF78 7"[0
MH( #''/7DY).;?P4_P"/.3_KX;_T".M7XI?\@Z?_ +9_^C4K*^"G_'G)_P!?
M#?\ H$= 'H%>#_$SQB==G\B,GR(20!D%68$@R<=0>B\GCD8W$5W'Q9\7_P!F
M1?8(C^]G7YLKD",Y4\GC+$8[X&>AVFN7M_"ITO1Y[R0#S+@0E>AQ'YB%><<%
MLY(R> N<$$4 =1\%/^/.3_KX;_T".O0*\_\ @I_QYR?]?#?^@1UZ!0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &9X@_U8_P!X?R-<9K?^M/\
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M)+E<8W^:_0-&T[^T)5B.0#DD@= /Y9Z9]ZO:9HT=]YQ#$"/[A) &/FP6R.G
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M_P"A"MJL73/]?)_P+_T(4 ;5%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &+J?^OC_ . _^A&MJL74_P#7Q_\  ?\ T(UM4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9GB#_ %8_
MWA_(UIUF>(/]6/\ >'\C0!IT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 4M8_U3?A_,4:/_JE_'^9HUC_ %3?A_,4:/\ ZI?Q
M_F: +M%%% '*7'_$OU6-^BWENZ87O)"=^YAP#A#M4\GMP*V/$NL#1[:6[.,Q
MH2N02"QX0$#G!8@=OJ.M87Q,C\F"+4 JL;.XBD.>&*[L%0<'&25SVXSR0!4O
MBK_B;7%OI2]-PGFSROEQG 4J<!@[\8R<8R5(H S_ (=PRZ-)-IMR<R.J7 )Y
M9C( LN6#,/E<!>3DG+<@\:?Q&F8VOV5"1)=RQPJ0< %VR=Q'.TJ"#@'KC&*B
M\:AM,EM]70@+"^R8XZQ2D DX()"'E5P?F.['!RS68_[1U6U@*J5MH9)B6YSO
M.Q<#'56 8'/OP0,@'6PPK"H1  J@  #  '   Z 5A:GX^L=,<PRS*''4*&?!
M!(()0, 01R#R/2J7CIY+U[?28V*"\=_,8'!\N-0SJ/E/+ _I@Y!-=%IFE1:6
M@A@140=E&,G &2>I. ,DY)[F@!FEZW!JJ[[>17& 3M8$C=TR.JGV(!Z^E%]K
M4-@Z12N%:4.5SG&(UW.2V,  <\D5ROCC35T+;KEJ DD3KYH4[1*CMA@1M(+%
MB/F//4\D+AGQ T9=9O+"UD^XS3ENO(14<KP01D#&<\9S0!T>A^+K;769+9RY
M09;Y'4#/3EE R>PSDX/H:S/A;_R#H/\ MI_Z->NHAA6%0B !5   &  .  !T
M KSW0=9;1M"%U']]5D"]."\S(&Y!!P3G&.<8H Z_6_%5KHF!<R*A.,+RS8.>
M=J@G'!YQC/&<T:)XJM=;R+:17(SE>5; QSM8 XY'.,9XSFJ_A7PK'H<8) :X
M<9EE/S.S-@M\Q .W(X''3)^;))XJ\*QZY&2 %N$&8I1\KJRY*_, 3MR>1SUR
M/FP0 9'P_P!4CTS2X)9FVH6==Q!*@M*X&2 0HS_$< =SS7:UP7A+1QK&BK:'
M&9$E"Y) #"5RA)'. P!_H>E;7AWQ4M[8#4')8QQ$RXV[MT:_/P#@$XR!QP0>
M,T ;<&H1W#O"C O$5#KW&Y0R\>A!X/3J.H.&:EJD>FJ))6P"RJ, LQ9C@*%4
M$L3Z $]^@KSKP?YFA7%O-,ZL-6C9W)(&),F13]T=0X7:#RS'L%%='JY;6-0A
MLP 8;0>?(<_QG(B7@<,/O $@,I)(.!D TM4M+.2ZMVG53<G?Y)(8GY!N/3CY
M<Y&[H>5YK;KE/$7_ "$=/_[>O_10IOCIY+U[?28V*"\=_,8'!\N-0SJ/E/+
M_I@Y!- %W4_'UCICF&690XZA0SX()!!*!@"".0>1Z5E>/]5BU32IIH'5T/E<
MJ<X/F(<$=0<$9!P1W%=5IFE1:6@A@140=E&,G &2>I. ,DY)[FN"^*_A6-(&
MU" "-P0)=ORAU=QU &&;?M.3CN3DA< 'I%<_J?CZQTQS#+,H<=0H9\$$@@E
MP!!'(/(]*J?$K6WTJT_=ML::18_,R1L#9);@,>BD<#(SD<@5FZ#XOT?0HQ#!
M(!P 6\J3>V,\LVSD\GV&<  <4 =;HVOP:TOF6TBN!UQPPY(&5.",X.,@9ZCB
MM"O+-;\4Z;#,FIV<I6=''F+'$R^:C.#("&55W8)(8G)(]=I7U.@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** *&N_ZEOP_]"%%&N_ZEOP_]"%% '"W/WC_GM452W/WC_GM45 !1110
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M/F!1][.,89O[IJU_PB=G_P ^\/\ WY3_ .)JW8Z3#I^?(C2/=C/EHJYQG&<
M9QDT <_\4O\ D'3_ /;/_P!&I65\%/\ CSD_Z^&_] CKNKJT2[4Q2JKH<95P
M&4X.1D'CK3;+3HK!=D**BDY(10HSTS@ <\4 <EXU^&__  D\RW/G>7MC"8\O
M=T9CG.Y?[WI7$^*?A1_8-L][Y^_R]OR^5MSN8+UWGUSTKVNH;JT2[4Q2JKH<
M95P&4X.1D'CK0!YA\%-"_P!9J6[^]%LV_P#7-]V[/X8Q^->JU7LM.BL%V0HJ
M*3DA%"C/3. !SQ5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]?)_P+_T(4 ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ@O?]6_^ZW\J *?A_P#U9_WC_(5IUD:'<+&A#, =QZD#L*T/ML?]Y?\ OH4
M3T5!]MC_ +R_]]"C[;'_ 'E_[Z% $]%0?;8_[R_]]"C[;'_>7_OH4 3T5!]M
MC_O+_P!]"C[;'_>7_OH4 3T5!]MC_O+_ -]"C[;'_>7_ +Z% $]%0?;8_P"\
MO_?0H^VQ_P!Y?^^A0!/14'VV/^\O_?0H^VQ_WE_[Z% $]%0?;8_[R_\ ?0H^
MVQ_WE_[Z% $]%0?;8_[R_P#?0H^VQ_WE_P"^A0!/14'VV/\ O+_WT*/ML?\
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MXC(P#+DJ>X]* (/#_P#JS_O'^0K3K(T.X6-"&8 [CU('85H?;8_[R_\ ?0H
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M_P!]"@">BH/ML?\ >7_OH4?;8_[R_P#?0H GK%TS_7R?\"_]"%:?VV/^\O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWO[GX_\  /0O^$?C]6_,?X4?\(_'ZM^8_P *\]HH_LO^]^'_  0_M[^Y^/\
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M2.Y ]**O:[_J6_#_ -"%% '"W/WC_GM452W/WC_GM45 !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH H:[_J6_#_T(44:[_J6_#_T(44 <+<_>/^>U15+<
M_>/^>U14 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5+;736QWH2#[?YY'M45% %^YUR:Y&QG.#Z #^0''M45[J<E[CS#G
M;G' '7KT ]*JT4 6+2^>S.Z-B#^A^HZ&IWUR9V$A<Y7IP,=".F,9P3SBJ%%
M$MS<M=,9'.6/4\#H,=JM6VN36PV*YP/4 _S!X]JH44 2W-TUR=[DD^_^>![5
M+_:<GE_9\_N_3 ]<]<9ZU5HH M0:G) AA4X5LY&!W&#R1GI3;2^>S.Z-B#^A
M^HZ&J]% %N]U66] 61L@=L #] *J444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %:GAK_CX3_@7_H)K+K4\-?\
M'PG_  +_ -!- '=4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRGTW YSBN=^!G_+U_P!L?_:E<Y\3=>&I7S1DEH;<A %)7I_K/O @-NRN[;C
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MKH+/_CPE_P"N@_FE>CB=5'_$OS/'P+M*;_N2_(9XCB%RJ7Z=)0 WLPX[_3'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF[CY \@R1D;F4;.QYW#CZ9[5TE '.PZO/ILJ6]X%9)2%CEC!&6S@!QV+=>.
M>F1DK'XMUR;3)(%@ 8RF1=IQAFPH3D\C!;/!&>A-.^( 5K4H1EW=!&,9.[=V
MP#SM!_EWJ36?^/VS_P"WC_T6* +FC6-Q;_-<S>82!\H154'OR!D^W3W'IG^"
MKA;>P25SA4$A)ZX =B>E=)7 QQF31<*"3@G@9X$V2?P R?:@#:M[J[UQ1+$1
M;Q'E2RB25AV.TX4*0<]SD<$@YHN+J[T-3+*1<1#EBJB.51W.T94J ,]CD\D
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MYD7'S$G"N!P"1C&.!ZGDCI*Y>^\/W5PHBDO.&(Q^Y122OSC!# Y&W/'I744
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!0UW_4M^'_ *$**-=_U+?A_P"A"B@#A;G[Q_SVJ*I;G[Q_
MSVJ*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K4\-?\?"?\"_\
M03676IX:_P"/A/\ @7_H)H [JBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 445TOAOPWYV+B8?+U53W]S[>@[_3
MKG6K1I1YF;8;#3Q$U"/_  P>&_#?G8N)A\O55/?W/MZ#O].O8445X5>O*M*[
M/JL+A88:'+'YON%%%%9'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 8NI_P"OC_X#_P"A&MJL74_]?'_P'_T(UM4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %9GB#_5C_>'\C6G69X@_U8_W
MA_(T :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %+6/]4WX?S%&C_P"J7\?YFC6/]4WX?S%&C_ZI?Q_F: +M%%% #9(Q*"C
M$$$$$9!!ZC%8_A+03HD'DL07+%FP<KDX QD ] /QS6U10 5C^&- _L2-H<Y#
M2,P]@<!03QDX )X')Q[UL44 4]6TF/58S!*,J?S![$'L1_\ 6.02*R8[+4+,
M"-)8I0 /FF5U?TQ\I.>F<DY))S7144 8-GX<>247=VXE=!\BA=L:$G)P,_-C
ML3SP">0,6M0TMKBXM[D$;8?-W YR=Z@#''Y]*U** "LGP[HYT^V6TEVL0'#8
MY4AF)QR!G@\\5K44 <['H,^D_+92+Y9)_=S@E5R<DJR_-[!3D<DDYJ.70;K5
MB%O9$$(*DQP!@'QD\LV".<<#(/L0#7344 9?AG2VTJW2V<@LF[)7)'+$]P/6
MJ]WX;\^[2]R-BCYDQ]YU!"-Z$@-P3R, #KQN44 5=4L!J$3V[8PZD9(S@D<'
M'L>1[BJ_AW1QI$"6XQD#+$=V/4YP,^@SS@ 5I44 9>H:6UQ<6]R"-L/F[@<Y
M.]0!CC\^E6-6TF/58S!*,J?S![$'L1_]8Y!(JY10!S_V._M/W<4D4B=C.&#@
M= "4X;C^(\DDUFZGX-GU9&DN)%:;&(U&5B3+Y/09.5XR1GUS@$=E10!#>6:7
MB&&0!D88(/\ G\CU!Y%8-OI=[IBB"W>*2)?N^>'WJ.RY7@@#H>/3   KI**
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MG169Y]S_ '%_/_[*CS[G^XOY_P#V5 &G169Y]S_<7\__ +*CS[G^XOY__94
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M1Y]S_<7\_P#[*@#3HK,\^Y_N+^?_ -E1Y]S_ '%_/_[*@#3HK,\^Y_N+^?\
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M_P#[*C^T:WD']C8;L_O.=_X0J;^\GYM_\31_PA4W]Y/S;_XFNB\^Y_N+^?\
M]E1Y]S_<7\__ +*C^T:WD']C8;L_O.=_X0J;^\GYM_\ $T?\(5-_>3\V_P#B
M:Z+S[G^XOY__ &5'GW/]Q?S_ /LJ/[1K>0?V-ANS^\YW_A"IO[R?FW_Q-'_"
M%3?WD_-O_B:Z+S[G^XOY_P#V5'GW/]Q?S_\ LJ/[1K>0?V-ANS^\YW_A"IO[
MR?FW_P 31_PA4W]Y/S;_ .)KHO/N?[B_G_\ 94>?<_W%_/\ ^RH_M&MY!_8V
M&[/[SG?^$*F_O)^;?_$T?\(5-_>3\V_^)KHO/N?[B_G_ /94>?<_W%_/_P"R
MH_M&MY!_8V&[/[SG?^$*F_O)^;?_ !-'_"%3?WD_-O\ XFNB\^Y_N+^?_P!E
M1Y]S_<7\_P#[*C^T:WD']C8;L_O.=_X0J;^\GYM_\31_PA4W]Y/S;_XFNB\^
MY_N+^?\ ]E1Y]S_<7\__ +*C^T:WD']C8;L_O.=_X0J;^\GYM_\ $T?\(5-_
M>3\V_P#B:Z+S[G^XOY__ &5'GW/]Q?S_ /LJ/[1K>0?V-ANS^\YW_A"IO[R?
MFW_Q-'_"%3?WD_-O_B:Z+S[G^XOY_P#V5'GW/]Q?S_\ LJ/[1K>0?V-ANS^\
MYW_A"IO[R?FW_P 31_PA4W]Y/S;_ .)KHO/N?[B_G_\ 94>?<_W%_/\ ^RH_
MM&MY!_8V&[/[SG?^$*F_O)^;?_$T?\(5-_>3\V_^)KHO/N?[B_G_ /94>?<_
MW%_/_P"RH_M&MY!_8V&[/[SG?^$*F_O)^;?_ !-'_"%3?WD_-O\ XFNB\^Y_
MN+^?_P!E1Y]S_<7\_P#[*C^T:WD']C8;L_O.=_X0J;^\GYM_\31_PA4W]Y/S
M;_XFNB\^Y_N+^?\ ]E1Y]S_<7\__ +*C^T:WD']C8;L_O.=_X0J;^\GYM_\
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M=G]YSO\ PA4W]Y/S;_XFC_A"IO[R?FW_ ,371>?<_P!Q?S_^RH\^Y_N+^?\
M]E1_:-;R#^QL-V?WG._\(5-_>3\V_P#B:/\ A"IO[R?FW_Q-=%Y]S_<7\_\
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MRH\^Y_N+^?\ ]E0!IT5F>?<_W%_/_P"RH\^Y_N+^?_V5 &G169Y]S_<7\_\
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M1Y]S_<7\_P#[*@#3HK,\^Y_N+^?_ -E1Y]S_ '%_/_[*@#3HK,\^Y_N+^?\
M]E1Y]S_<7\__ +*@#3HK,\^Y_N+^?_V5'GW/]Q?S_P#LJ -.BLSS[G^XOY__
M &5'GW/]Q?S_ /LJ -.BLSS[G^XOY_\ V5'GW/\ <7\__LJ -.BLSS[G^XOY
M_P#V5'GW/]Q?S_\ LJ -.BLSS[G^XOY__94>?<_W%_/_ .RH TZ*S//N?[B_
MG_\ 94>?<_W%_/\ ^RH TZ*S//N?[B_G_P#94>?<_P!Q?S_^RH TZ*S//N?[
MB_G_ /94>?<_W%_/_P"RH TZ*S//N?[B_G_]E1Y]S_<7\_\ [*@#3HK,\^Y_
MN+^?_P!E1Y]S_<7\_P#[*@#3HK,\^Y_N+^?_ -E1Y]S_ '%_/_[*@#3K,\0?
MZL?[P_D://N?[B_G_P#953U269U D4 9[>N#[F@#?HK,\^Y_N+^?_P!E1Y]S
M_<7\_P#[*@#3HK,\^Y_N+^?_ -E1Y]S_ '%_/_[*@#3HK,\^Y_N+^?\ ]E1Y
M]S_<7\__ +*@#3HK,\^Y_N+^?_V5'GW/]Q?S_P#LJ -.BLSS[G^XOY__ &5'
MGW/]Q?S_ /LJ -.BLSS[G^XOY_\ V5'GW/\ <7\__LJ -.BLSS[G^XOY_P#V
M5'GW/]Q?S_\ LJ -.BLSS[G^XOY__94>?<_W%_/_ .RH TZ*S//N?[B_G_\
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M-^'\Q1H_^J7\?YFJ-_-.R$.H"\9(^H]S1833J@"*"O."?J?<4 ;=%9GGW/\
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M &G169Y]S_<7\_\ [*CS[G^XOY__ &5 &G169Y]S_<7\_P#[*CS[G^XOY_\
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MS_?_ /'5_P */^$IN?[_ /XZO^%95%'U>E_*ON0?7*_\\OO9J_\ "4W/]_\
M\=7_  H_X2FY_O\ _CJ_X5E44?5Z7\J^Y!]<K_SR^]FK_P )3<_W_P#QU?\
M"C_A*;G^_P#^.K_A6511]7I?RK[D'URO_/+[V:O_  E-S_?_ /'5_P */^$I
MN?[_ /XZO^%95%'U>E_*ON0?7*_\\OO9J_\ "4W/]_\ \=7_  H_X2FY_O\
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ME-S_ '__ !U?\*/^$IN?[_\ XZO^%95%'U>E_*ON0?7*_P#/+[V:O_"4W/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %+6/\ 5-^'\Q1H_P#JE_'^9HUC_5-^'\Q1H_\ JE_'^9H NT44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!0UW_4M^'_H0HHUW_4M^'_H0HH X6Y^\?\]JBJ6Y
M^\?\]JBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U/#7_'PG_
MO_03676IX:_X^$_X%_Z": .ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH I:Q_JF_#^8HT?_5+^/\ ,T:Q_JF_#^8HT?\ U2_C_,T
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M3[G@8S[X'-:E9][>113PQ.N9)/,V-@';M7+<GD9'''7O5Z201 NQ  !)).
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M1110 4444 %%%% !1110 4444 %%%% !4%[_ *M_]UOY5/4%[_JW_P!UOY4
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M(*\9W')SQ>^'OA:?5;LZS<($CWM( RGYVD!8%0W\*[MP;GD#&3D@ ]=HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH S/$'^K'^\/Y&N,UO_6G_ '8__0%KL_$'^K'^\/Y&N,UO_6G_ '8__0%K
MNRS^*_3]4>5GG\"/^)?DRA1117L'S@4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=<\Y!()&1QB@";Q7&;Z6VL"<1S.[/UY$0#;>".#^AP1TKHHXQ$ B@     8
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M)  (R3C&.X)'>FV?B-+-!#':W*HHP (?_LOS/4GDUJ:_I1U*/:A"R(RO&QY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"]_U;_[K?RJ>H+W_
M %;_ .ZW\J *?A__ %9_WC_(5IUF>'_]6?\ >/\ (5IT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLF;_ )YO_P!\-_A1[2'=![&IV?W%2BK?]DS?\\W_ .^&_P */[)F_P">;_\
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M\\W_ .^&_P */[)F_P">;_\ ?#?X4>TAW0>QJ=G]Q4HJW_9,W_/-_P#OAO\
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M5**M_P!DS?\ /-_^^&_PH_LF;_GF_P#WPW^%'M(=T'L:G9_<5**M_P!DS?\
M/-_^^&_PH_LF;_GF_P#WPW^%'M(=T'L:G9_<5**M_P!DS?\ /-_^^&_PH_LF
M;_GF_P#WPW^%'M(=T'L:G9_<5**M_P!DS?\ /-_^^&_PH_LF;_GF_P#WPW^%
M'M(=T'L:G9_<5**M_P!DS?\ /-_^^&_PH_LF;_GF_P#WPW^%'M(=T'L:G9_<
M5**M_P!DS?\ /-_^^&_PH_LF;_GF_P#WPW^%'M(=T'L:G9_<5**M_P!DS?\
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M]11]A?T_44<\>X>SGV97HJQ]A?T_44?87]/U%'/'N'LY]F5ZM6=GYOS'[O\
M.G6^GDGY^!_.M$#'%9U*MM$;4:%]6 &.*6BBN<ZPHHHH **** "BBB@ HHHH
M *S/$'^K'^\/Y&M.LSQ!_JQ_O#^1H TZ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** *6L?ZIOP_F*-'_U2_C_,T:Q_JF_#^8HT
M?_5+^/\ ,T 7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH H:[_ *EOP_\ 0A11KO\ J6_#
M_P!"%% '"W/WC_GM452W/WC_ )[5%0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5J>&O^/A/^!?^@FLNM3PU_P ?"?\  O\ T$T =U1110 4444
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M_L>+^[^I_P : #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_&C^QXO[OZG_ !H
M/[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\:/['B_N_J?\ &@ _MB+^]^A_PH_M
MB+^]^A_PH_L>+^[^I_QH_L>+^[^I_P : #^V(O[WZ'_"C^V(O[WZ'_"C^QXO
M[OZG_&C^QXO[OZG_ !H /[8B_O?H?\*BNM5B=&4-R5('![CZ5+_8\7]W]3_C
M45UI42(S!>0I(Y/8?6@"MH]^ENA5S@[B>A/8>@J]_;$7][]#_A5'1[!+A"SC
M)W$=2.P]#5[^QXO[OZG_ !H /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\:/['
MB_N_J?\ &@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_QH_L>+^[^I_P : #^V
M(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_&C^QXO[OZG_ !H /[8B_O?H?\*/[8B_
MO?H?\*/['B_N_J?\:/['B_N_J?\ &@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^
MI_QH_L>+^[^I_P : #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_&C^QXO[OZG_
M !H /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\:/['B_N_J?\ &@ _MB+^]^A_
MPH_MB+^]^A_PH_L>+^[^I_QH_L>+^[^I_P : #^V(O[WZ'_"C^V(O[WZ'_"C
M^QXO[OZG_&C^QXO[OZG_ !H /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\:/['
MB_N_J?\ &@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_QH_L>+^[^I_P : #^V
M(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_&C^QXO[OZG_ !H /[8B_O?H?\*/[8B_
MO?H?\*/['B_N_J?\:/['B_N_J?\ &@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^
MI_QH_L>+^[^I_P : #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_&C^QXO[OZG_
M !H /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\:/['B_N_J?\ &@ _MB+^]^A_
MPH_MB+^]^A_PH_L>+^[^I_QH_L>+^[^I_P : #^V(O[WZ'_"C^V(O[WZ'_"C
M^QXO[OZG_&C^QXO[OZG_ !H /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\:/['
MB_N_J?\ &@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_QH_L>+^[^I_P : #^V
M(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_&C^QXO[OZG_ !H /[8B_O?H?\*S+&\2
M*9Y&/RMNP<'NV:T_['B_N_J?\:S+&S269XV'RKNP,GLV* -/^V(O[WZ'_"C^
MV(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\ "C^Q
MXO[OZG_&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A_P */['B_N_J?\:/['B_
MN_J?\: #^V(O[WZ'_"C^V(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH /[8B_O
M?H?\*/[8B_O?H?\ "C^QXO[OZG_&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A
M_P */['B_N_J?\:/['B_N_J?\: #^V(O[WZ'_"C^V(O[WZ'_  H_L>+^[^I_
MQH_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\ "C^QXO[OZG_&C^QXO[OZG_&@
M _MB+^]^A_PH_MB+^]^A_P */['B_N_J?\:/['B_N_J?\: #^V(O[WZ'_"C^
MV(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\ "C^Q
MXO[OZG_&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A_P */['B_N_J?\:/['B_
MN_J?\: #^V(O[WZ'_"C^V(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH /[8B_O
M?H?\*/[8B_O?H?\ "C^QXO[OZG_&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A
M_P */['B_N_J?\:/['B_N_J?\: #^V(O[WZ'_"C^V(O[WZ'_  H_L>+^[^I_
MQH_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\ "C^QXO[OZG_&C^QXO[OZG_&@
M _MB+^]^A_PH_MB+^]^A_P */['B_N_J?\:/['B_N_J?\: #^V(O[WZ'_"C^
MV(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\ "C^Q
MXO[OZG_&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A_P */['B_N_J?\:/['B_
MN_J?\: #^V(O[WZ'_"C^V(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH S+Z\26
M9)%/RKMR<'LV:T_[8B_O?H?\*S+ZS2*9(U'RMMR,GNV*T_['B_N_J?\ &@ _
MMB+^]^A_PH_MB+^]^A_PH_L>+^[^I_QH_L>+^[^I_P : #^V(O[WZ'_"C^V(
MO[WZ'_"C^QXO[OZG_&C^QXO[OZG_ !H /[8B_O?H?\*/[8B_O?H?\*/['B_N
M_J?\:/['B_N_J?\ &@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_QH_L>+^[^I
M_P : #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_&C^QXO[OZG_ !H /[8B_O?H
M?\*/[8B_O?H?\*/['B_N_J?\:/['B_N_J?\ &@ _MB+^]^A_PH_MB+^]^A_P
MH_L>+^[^I_QH_L>+^[^I_P : #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_&C^
MQXO[OZG_ !H /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\:/['B_N_J?\ &@ _
MMB+^]^A_PH_MB+^]^A_PH_L>+^[^I_QH_L>+^[^I_P : #^V(O[WZ'_"C^V(
MO[WZ'_"C^QXO[OZG_&C^QXO[OZG_ !H /[8B_O?H?\*/[8B_O?H?\*/['B_N
M_J?\:/['B_N_J?\ &@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_QH_L>+^[^I
M_P : #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_&C^QXO[OZG_ !H /[8B_O?H
M?\*/[8B_O?H?\*/['B_N_J?\:/['B_N_J?\ &@ _MB+^]^A_PH_MB+^]^A_P
MH_L>+^[^I_QH_L>+^[^I_P : #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_&C^
MQXO[OZG_ !H /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\:/['B_N_J?\ &@ _
MMB+^]^A_PH_MB+^]^A_PH_L>+^[^I_QH_L>+^[^I_P : #^V(O[WZ'_"C^V(
MO[WZ'_"C^QXO[OZG_&C^QXO[OZG_ !H /[8B_O?H?\*/[8B_O?H?\*/['B_N
M_J?\:/['B_N_J?\ &@ _MB+^]^A_PJCK%^EP@5#D[@>A'8^HJ]_8\7]W]3_C
M5'6+!+= R#!W =2>Q]30!>_MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_P :/['B
M_N_J?\: #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_ !H_L>+^[^I_QH /[8B_
MO?H?\*/[8B_O?H?\*/['B_N_J?\ &C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^
MA_PH_L>+^[^I_P :/['B_N_J?\: #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_
M !H_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\ &C^QXO[OZG_&
M@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_P :/['B_N_J?\: #^V(O[WZ'_"C
M^V(O[WZ'_"C^QXO[OZG_ !H_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\*/['
MB_N_J?\ &C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_P :/['B
M_N_J?\: #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_ !H_L>+^[^I_QH /[8B_
MO?H?\*/[8B_O?H?\*/['B_N_J?\ &C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^
MA_PH_L>+^[^I_P :/['B_N_J?\: #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_
M !H_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\ &C^QXO[OZG_&
M@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_P :/['B_N_J?\: #^V(O[WZ'_"C
M^V(O[WZ'_"C^QXO[OZG_ !H_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\*/['
MB_N_J?\ &C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_P :/['B
M_N_J?\: #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_ !H_L>+^[^I_QH /[8B_
MO?H?\*/[8B_O?H?\*/['B_N_J?\ &C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^
MA_PH_L>+^[^I_P :/['B_N_J?\: *VI:E'-&R*<DX['U'M1INI1PQJC'!&>Q
M]3[4:EIL<,;.HP1CN?4>]&FZ;'-&KL,DY[GU/O0!9_MB+^]^A_PH_MB+^]^A
M_P */['B_N_J?\:/['B_N_J?\: #^V(O[WZ'_"C^V(O[WZ'_  H_L>+^[^I_
MQH_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\ "C^QXO[OZG_&C^QXO[OZG_&@
M _MB+^]^A_PH_MB+^]^A_P */['B_N_J?\:/['B_N_J?\: #^V(O[WZ'_"C^
MV(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\ "C^Q
MXO[OZG_&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A_P */['B_N_J?\:/['B_
MN_J?\: #^V(O[WZ'_"C^V(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH /[8B_O
M?H?\*/[8B_O?H?\ "C^QXO[OZG_&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A
M_P */['B_N_J?\:/['B_N_J?\: #^V(O[WZ'_"C^V(O[WZ'_  H_L>+^[^I_
MQH_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\ "C^QXO[OZG_&C^QXO[OZG_&@
M _MB+^]^A_PH_MB+^]^A_P */['B_N_J?\:/['B_N_J?\: #^V(O[WZ'_"C^
MV(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\ "C^Q
MXO[OZG_&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A_P */['B_N_J?\:/['B_
MN_J?\: #^V(O[WZ'_"C^V(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH /[8B_O
M?H?\*/[8B_O?H?\ "C^QXO[OZG_&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A
M_P */['B_N_J?\:/['B_N_J?\: #^V(O[WZ'_"C^V(O[WZ'_  H_L>+^[^I_
MQH_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\ "C^QXO[OZG_&C^QXO[OZG_&@
M _MB+^]^A_PH_MB+^]^A_P */['B_N_J?\:/['B_N_J?\: #^V(O[WZ'_"C^
MV(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\ "C^Q
MXO[OZG_&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A_P */['B_N_J?\:/['B_
MN_J?\: #^V(O[WZ'_"C^V(O[WZ'_  H_L>+^[^I_QH_L>+^[^I_QH /[8B_O
M?H?\*/[8B_O?H?\ "C^QXO[OZG_&C^QXO[OZG_&@"GJVI1S1,BG)..Q]1[44
M:MIL<,3.HP1CN?4>]% ''W/WC_GM452W/WC_ )[5%0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5J>&O^/A/^!?^@FLNM3PU_P ?"?\  O\ T$T
M=U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !4%[_JW_P!UOY5/4%[_ *M_]UOY4 4_#_\ JS_O'^0K3K,\
M/_ZL_P"\?Y"M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** ,SQ!_JQ_O#^1KC-;_UI_P!V/_T!
M:[/Q!_JQ_O#^1KC-;_UI_P!V/_T!:[LL_BOT_5'E9Y_ C_B7Y,H4445[!\X%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=AX;\2>=BWF/
MS=%8]_8^_H>_UZ\?165>A&M&S.C"XJ>&GS1^:[GJM%<UX;\2>=BWF/S=%8]_
M8^_H>_UZ]+7A5J,J4N5GU6&Q,,1!3C_PP4445F;!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %07O\ JW_W6_E4]07O^K?_ '6_E0!3\/\ ^K/^
M\?Y"M.LSP_\ ZL_[Q_D*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "L73/]?)_P+_T(5M5BZ9_KY/^!?\ H0H VJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,74_\ 7Q_\!_\
M0C6U6+J?^OC_ . _^A&MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K,\0?ZL?[P_D:TZS/$'^K'^\/Y&@#3HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I:Q_JF_#^8HT?_ %2_
MC_,T:Q_JF_#^8HT?_5+^/\S0!=HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AKO^I;\/\
MT(44:[_J6_#_ -"%% '"W/WC_GM452W/WC_GM45 !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !6IX:_X^$_X%_P"@FLNM3PU_Q\)_P+_T$T =U111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M--]W'/Y:*VT 2-$N?O8"Q@DX!'+<D$#)P<=1\:)F2R4 D!IT! .,C:YP?49
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M[\<_^77_ +;?^TZ[_P )_P#'G;?]>\/_ * M &M1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F>(/]6/]X?R-
M<9K?^M/^['_Z M=GX@_U8_WA_(UQFM_ZT_[L?_H"UW99_%?I^J/*SS^!'_$O
MR90HHHKV#YP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "NP\-^)/.Q;S'YNBL>_L??T/?Z]>/HK*O0C6C9G1A<5/#3YH_-=SU6BL
MOPW/)-"&FZ]B>I7C!/\ CW'/N=2O J0Y)./8^MI5%4@I[75]0HHHJ2PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *@O?]6_^ZW\JGJ"]_P!6_P#NM_*@
M"GX?_P!6?]X_R%:=9GA__5G_ 'C_ "%:= !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6+IG^OD_X%_Z$*VJQ=,_U\G_ O_0A0!M4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8NI_
MZ^/_ (#_ .A&MJL74_\ 7Q_\!_\ 0C6U0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5F>(/]6/\ >'\C6G69X@_U8_WA_(T :=%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/\
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M4;1M8NH)!).>=IS@$FH>$6T&-KC2F:-D&XPDM)%)CEAM.Y@[   @YXVC&20
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "H+W_5O_ +K?RJ>H+W_5O_NM_*@"GX?_ -6?]X_R%:=9GA__ %9_
MWC_(5IT 9/BS_CSN?^O>;_T!JX#X&?\ +U_VQ_\ :E>FZC9+?Q/;OD+*C*2.
MN&!!QG//-8_A3P5#X8\SR&=O-VY\PJ?NYQC"K_>- 'FGQK_X_(_^O=?_ $.2
MO5?%G_'G<_\ 7O-_Z U9OBCX>6_B247$S2!E0* A4# )/=6Y^:N@U&R6_B>W
M?(65&4D=<,"#C.>>: /,O@9_R]?]L?\ VI63XE_Y#R_]?%K_ "CKTOPIX*A\
M,>9Y#.WF[<^85/W<XQA5_O&J]]\/+>]NQJC-()0\;8!79F,*!QM)Q\HSS0!Y
MYXMTP^!]0COX!^[=BZK\H YQ)&, X&&P#MX# #)7->EZOJ::IILUU$<I):RD
M=,C,9R#@D9!X(SP015KQ+X:B\11?9I]VT,&!0X8$9&1D$="1R#U]<$5]+\'Q
M:=:OIJO(T4@<9=@642+@A?E  ZGIU)/>@#B/@9_R]?\ ;'_VI6#\3/"[:!<?
M:8%*03 X*<*K,"'CX/1ADXX!!*@84UZGX4\%0^&/,\AG;S=N?,*G[N<8PJ_W
MC6AKNA1:Y$;:<95NA'WE/9@>Q'_UCD$@@'G7P,_Y>O\ MC_[4KE]:N9O&&H/
M):*9,']V#AEV1X )$@"A6/.UAC+8.2>?6/#_ ("AT%)HH'E_TA0"Q9=RX# %
M2%&"-QYYYQ3O"O@2W\-,[PEF:0 $R;20!DX!"K@'OZX'I0!Q4T/B&92C@%6!
M!!%J00>""#U!K'^'-\_AO4#9W 9/-_=LI)P&)!0X (;)X!Z8;<#CK[A7+Z_\
M/+?6IQ>LTD<JA>82J\J<AL[2=PX&<] /2@!GCKP+_P )5Y7[WR_*W_P;\[]O
M^TN,;:J^"OAO_P (Q,USYWF;HRF/+V]64YSN;^[Z5VM% !7BGP4_X_)/^O=O
M_0XZ]KKE_"_P\M_#<IN(6D+,A4ARI&"0>RKS\M %3XM:6U]8LRYS"ZR8 SD#
M*GZ !BQ/H/Q&;\+?%]O%9BUFD2-X68?O'"[@S%PPW8'4D8!.,9.,BO1:XK4_
MA%8WSF4;X\]5B8!<DDYPRMCKT&  !@"@#A-,D/BG61.GW!-O#*IQLAQL)!Y&
MX*H).,%NG:O<*R?#WAB#P^ABMUQNQN8G+,0,9)_H, $G &:UJ /%/@I_Q^2?
M]>[?^AQU[77+^%_AY;^&Y3<0M(69"I#E2,$@]E7GY:ZB@#RKXY_\NO\ VV_]
MIUW_ (3_ ./.V_Z]X?\ T!:J^*_!4/B?R_/9U\K=CRRH^]C.<JW]T5L:=9+8
M1);IDK$BJ">N%  SC'/% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#,\0?ZL?[P_D:XS6_]:?]V/\ ] 6N
MS\0?ZL?[P_D:XS6_]:?]V/\ ] 6N[+/XK]/U1Y6>?P(_XE^3*%%%%>P?.!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5TOAOPWYV
M+B8?+U53W]S[>@[_ $ZGAOPWYV+B8?+U53W]S[>@[_3KV%>;C<;:\(_-GM99
MEG-:K46G1?JPHHHKRSW@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "H+W_5O_NM_*IZ@O?]6_\ NM_*@"GX?_U9_P!X_P A6G69X?\ ]6?]X_R%
M:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+IG
M^OD_X%_Z$*VJQ=,_U\G_  +_ -"% &U1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!BZG_ *^/_@/_ *$:VJQ=3_U\?_ ?_0C6
MU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F>(/
M]6/]X?R-:=9GB#_5C_>'\C0!IT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 4M8_U3?A_,4:/_ *I?Q_F:-8_U3?A_,4:/_JE_
M'^9H NT444 8GC73/[3LIX,,28R5"<L63YU &#G)4#'4]N:Y_P !73:].^J.
M<[+>& ,  &;:))LKUR'. 0 N.F>M=W69X=\/Q:!"+6'.T$DEL;B2<Y) &3VZ
M= !VH B\7Z.=8M)K49+,F5 (&64[E&3Q@L #[=QUKG/ ETWB"YEU=SD"&&%=
MH 4$JLDRX/S?*YX)/0G!(QCNZS]%T*+1E:. ;5>1W([98] !@     #H!WR2
M <_XYF.F3V>J,,Q6\CK)C.5$RA-_"GA<?B< =>.MAF690Z$%6 ((.00>001U
M!HFA692C@%6!!!&00>""#U!KE_\ A7,$/%M+<6Z=T@G8*3_>.[<<D8'7H!0!
M7^)5V+J)=(CPT]VZ +D_*H8,9" #\HVX/MDC.TU8\1?\A'3_ /MZ_P#10K3T
M/PG;Z*S2Q*3*XP\CL7=NY))/5CR<8!/;@8L7NB)=SPWC%M]MYFT C:?,7:<\
M9Z=,$?C0!H5YII>F/J>@>1$,N5<@<DG9.7(  ))(7 '<XKTNL_0-$31($LXB
MQ2/=@N06^9BQS@ =3Z4 ,\.:]'KL"749'S ;@#G:V/F4\#D?09&"."*/$>O1
MZ% ]U(1\H.T$XW-CY5'!Y/T.!DG@&J6I^"(+QS<1EX)6^]);/Y3,"22#C(.2
M<DXR2!SQ46G> (+647<C2SRIC8UQ)YA7&>G '4YYS@\C!H A^%O_ "#H/^VG
M_HUZYJ;?I8G\.Q;AY]PBQ$Y8K#< F3:C9++&%8,P/5BQ*D<^@:!HB:) EG$6
M*1[L%R"WS,6.< #J?2F3^'89[E-18'SHD95.3C!SV]1E@/\ >.<X& #G_'.F
M?V=!!>6RG.GNA"JS ^4 %=,C/! &XGHH.3U!F\%RC5YKG5N=LCB.+<#_ *N(
M<LI8 A78Y*@## YR>G3W=JMVC0R#*2*589(R&&",CGI46E:8FEQ):Q#"1J .
MF3CJ3@ 9)Y)QR230!S_B+_D(Z?\ ]O7_ **%1>.9CID]GJC#,5O(ZR8SE1,H
M3?PIX7'XG '7CH+W1$NYX;QBV^V\S: 1M/F+M.>,].F"/QJ[-"LRE' *L"""
M,@@\$$'J#0 0S+,H=""K $$'((/(((Z@UPOQ?UZ.UM399!EG*_+GD*K!MV,'
MC*[1G&<DC.TUJS?#Z$,3;RSVZL22EO*40L>K;2#@]!Q@8  %,7X:V@ADM_G+
M3X\R5FW2MA_,^\00,D#. ,X&<D9H ;\3-/%U;)(ZEXH)XY)57.XQC*N!C'.&
MSU& "<C%0Z?\/=*U&-;B&(-&XR"))?\ XO@CH0>0>#S79UR\WP^A#$V\L]NK
M$DI;RE$+'JVT@X/0<8&  !0!E7_@_2+&:*S>(F6<G:JO,Q  )W$!^%XQGZGH
M&([VL3P_X0@T(M)&&:63.^21MTC9);D].O7 &< G)&:VZ "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M H:[_J6_#_T(44:[_J6_#_T(44 <+<_>/^>U15+<_>/^>U14 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %:GAK_CX3_@7_H)K+K4\-?\?"?\"_\
M030!W5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %07O^K?_=;^53U!>_ZM_P#=;^5 %/P__JS_ +Q_D*TZ
MS/#_ /JS_O'^0K3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#,\0?ZL?[P_D:XS6_]:?]V/\
M] 6NS\0?ZL?[P_D:J-X7BOL3,6!95Z$8X4#N#Z5U8*M&E-N78X<SPT\1248[
MWO\ @SB**[7_ (0J'^\_YK_\31_PA4/]Y_S7_P")KT/[1H^9XW]C8GLOO.*H
MKM?^$*A_O/\ FO\ \31_PA4/]Y_S7_XFC^T:/F']C8GLOO.*HKM?^$*A_O/^
M:_\ Q-'_  A4/]Y_S7_XFC^T:/F']C8GLOO.*HKM?^$*A_O/^:__ !-'_"%0
M_P!Y_P U_P#B:/[1H^8?V-B>R^\XJBNU_P"$*A_O/^:__$T?\(5#_>?\U_\
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M **** "BBB@ HHHH **** "BBB@ K%TS_7R?\"_]"%;58NF?Z^3_ (%_Z$*
M-JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%
MU/\ U\?_  '_ -"-;58NI_Z^/_@/_H1K:H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *S/$'^K'^\/Y&M.LSQ!_JQ_O#^1H TZ**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6L?ZI
MOP_F*-'_ -4OX_S-&L?ZIOP_F*-'_P!4OX_S- %VBBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** *&N_ZEOP_]"%%&N_ZEOP_]"%% '"W/WC_ )[5%4MS]X_Y[5%0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5J>&O\ CX3_ (%_Z":RZU/#7_'P
MG_ O_030!W5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %07O\ JW_W6_E4]07O^K?_ '6_E0!AZ?9RS*3&
MV!GIDCG ]*L_V9/_ ,]/_'F_PJ?P_P#ZL_[Q_D*TZ ,7^S)_^>G_ (\W^%']
MF3_\]/\ QYO\*VJ* ,7^S)_^>G_CS?X4?V9/_P ]/_'F_P *VJ* ,7^S)_\
MGI_X\W^%']F3_P#/3_QYO\*VJ* ,7^S)_P#GI_X\W^%']F3_ //3_P >;_"M
MJB@#%_LR?_GI_P"/-_A1_9D__/3_ ,>;_"MJB@#%_LR?_GI_X\W^%']F3_\
M/3_QYO\ "MJB@#%_LR?_ )Z?^/-_A1_9D_\ ST_\>;_"MJB@#%_LR?\ YZ?^
M/-_A1_9D_P#ST_\ 'F_PK:HH Q?[,G_YZ?\ CS?X4?V9/_ST_P#'F_PK:HH
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M3_\ /3_QYO\ "MJB@#%_LR?_ )Z?^/-_A1_9D_\ ST_\>;_"MJB@#%_LR?\
MYZ?^/-_A1_9D_P#ST_\ 'F_PK:HH Q?[,G_YZ?\ CS?X4?V9/_ST_P#'F_PK
M:HH Q?[,G_YZ?^/-_A1_9D__ #T_\>;_  K:HH Q?[,G_P">G_CS?X4?V9/_
M ,]/_'F_PK:HH Q?[,G_ .>G_CS?X4?V9/\ \]/_ !YO\*VJ* ,7^S)_^>G_
M (\W^%']F3_\]/\ QYO\*VJ* ,7^S)_^>G_CS?X4?V9/_P ]/_'F_P *VJ*
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M 8O]F3_\]/\ QYO\*/[,G_YZ?^/-_A6U10!B_P!F3_\ /3_QYO\ "C^S)_\
MGI_X\W^%;5% &+_9D_\ ST_\>;_"C^S)_P#GI_X\W^%;5% &+_9D_P#ST_\
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M;_"C^S)_^>G_ (\W^%;5% &+_9D__/3_ ,>;_"C^S)_^>G_CS?X5M44 8O\
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MLR?_ )Z?^/-_A1_9D_\ ST_\>;_"MJB@#%_LR?\ YZ?^/-_A1_9D_P#ST_\
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M[,G_ .>G_CS?X4?V9/\ \]/_ !YO\*VJ* ,7^S)_^>G_ (\W^%']F3_\]/\
MQYO\*VJ* ,7^S)_^>G_CS?X4?V9/_P ]/_'F_P *VJ* ,7^S)_\ GI_X\W^%
M']F3_P#/3_QYO\*VJ* ,7^S)_P#GI_X\W^%']F3_ //3_P >;_"MJB@#G[RQ
MFB0L[Y48R-S'O[T6=C-*@9'PIS@;F'?VK3UC_5-^'\Q1H_\ JE_'^9H I?V9
M/_ST_P#'F_PH_LR?_GI_X\W^%;5% &+_ &9/_P ]/_'F_P */[,G_P">G_CS
M?X5M44 8O]F3_P#/3_QYO\*/[,G_ .>G_CS?X5M44 8O]F3_ //3_P >;_"C
M^S)_^>G_ (\W^%;5% &+_9D__/3_ ,>;_"C^S)_^>G_CS?X5M44 8O\ 9D__
M #T_\>;_  H_LR?_ )Z?^/-_A6U10!B_V9/_ ,]/_'F_PH_LR?\ YZ?^/-_A
M6U10!B_V9/\ \]/_ !YO\*/[,G_YZ?\ CS?X5M44 8O]F3_\]/\ QYO\*/[,
MG_YZ?^/-_A6U10!B_P!F3_\ /3_QYO\ "C^S)_\ GI_X\W^%;5% &+_9D_\
MST_\>;_"C^S)_P#GI_X\W^%;5% &+_9D_P#ST_\ 'F_PH_LR?_GI_P"/-_A6
MU10!B_V9/_ST_P#'F_PH_LR?_GI_X\W^%;5% &+_ &9/_P ]/_'F_P */[,G
M_P">G_CS?X5M44 8O]F3_P#/3_QYO\*/[,G_ .>G_CS?X5M44 8O]F3_ //3
M_P >;_"C^S)_^>G_ (\W^%;5% &+_9D__/3_ ,>;_"C^S)_^>G_CS?X5M44
M8O\ 9D__ #T_\>;_  H_LR?_ )Z?^/-_A6U10!B_V9/_ ,]/_'F_PH_LR?\
MYZ?^/-_A6U10!B_V9/\ \]/_ !YO\*/[,G_YZ?\ CS?X5M44 8O]F3_\]/\
MQYO\*/[,G_YZ?^/-_A6U10!B_P!F3_\ /3_QYO\ "C^S)_\ GI_X\W^%;5%
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M*9-,L*EW("J"22<  <DDGH!7F^I_&V*%RD$+2(/XF?R\G)Z#:QQC!&<'U H
M]+HKG/"'CF#Q,I$>5E0 LC8SVR01]Y<\9X/3(&1F+QMX[C\+J@VB25S]S=M(
M7GYL[6XR,#.,\XZ&@#J**XKP5\2/^$GF:V\GR]L9?/F;NC*,8VK_ 'O6NUH
M**\WUCXU0VTFRWC,J #YRQCR>X"E"<#U..<\8P3TOA#QS!XF4B/*RH 61L9[
M9((^\N>,\'ID#(R ='1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#%U/_7Q_P# ?_0C6U6+J?\ KX_^ _\ H1K:H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S/$'^K'^\
M/Y&M.LSQ!_JQ_O#^1H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** *6L?ZIOP_F*-'_U2_C_ #-&L?ZIOP_F*-'_ -4OX_S-
M %VBBB@ HK)M]=\R[DT]UVLD:2(=V=ZGAC@#Y=K<8)R>H&*UJ "BL?PQXFC\
M0QO/$"%25TR>^W!##H<%2#@@$'([9-C7]9718)+M^1&N<<\D\*N0#C)(&<<9
MR>* -"BH;21I45Y%V.5!9<AMI(Y7(X.#QGO4U !1110 445B>#-;?6[2.\E"
MAY-^0@(7Y791C))Z#UH VZ*** "BL3P9K;ZW:1WDH4/)OR$!"_*[*,9)/0>M
M;= !1110 45S^L:Q=VMW!;PP;X),^9)G[OKST7:.><[\[5P1704 %%%8GC/6
MWT2TDO(@I>/9@."5^9U4YP0>A]: -NBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AKO\
MJ6_#_P!"%%&N_P"I;\/_ $(44 <+<_>/^>U15+<_>/\ GM45 !1110 4444
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MV=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN?O+6[\+O!QT2$W,P(GG R& !103A?7+<%AQV! *\@'<4444 %%%% !1110
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MGZU<KYVIR\SY=NA]E2YW!<WQ6UL%%%%26%%%% !1110 4444 %%%% !1110
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M,*N[<>2,XST'/M7044 %<_XOTN34/LWE+N\J\AD;D#"KNW'DC.,]!S[5T%%
M&9XBT-=:A,!8HV0R.OWD=3E6'H1[$'!(!&<UBPZMJEFHADM5G90 98YTC5O?
M:R@@^O &<D #%=;10!S_ (:T"6U>2]O'62YFP/D'R(BDD(F1G'<^IQG)!8]!
M110 5P^I^ C=7HE"K]EE=)I0<9\R$. H7&"K[\MG.<-D@D ]Q10 5Q]OH=WX
M8W"QVSVQ8D02-L=,]DD.1C))(;L.,L23V%% '&7=QJNL#[.L*VBL#NE:42N
M2/N;,8;&>OX,IP:M^ /#KZ!%-;N"%^TR&,DJ24PH5CM[G'L?85U%% '*3^'[
MC1Y9+NP9669M\EO*2%+<EF1\_*S=,$;><DX"@17.JZK>CRHK5(&;/[R699%4
M8/\ "@SG.,<,/48Y'844 9^AZ?)81^7-*TSEF)=E"_>.< #H!V&3CH,+@#G[
M?0[OPQN%CMGMBQ(@D;8Z9[)(<C&220W8<98DGL** ./FO=5U,B)(4M%_BD>1
M9FQE?NJO&<9^\,'U4X-:MYI,BV$EEO::4V[H&? 9F*$#/;KQR<_WB3DG;HH
MY_\ LN3^S?L6W][]C\O;D?>\K;C.<=>,YQ[UH>'K5K2V@AD&'CAC5AD'!5 "
M,CCK6A10!S_B_2Y-0^S>4N[RKR&1N0,*N[<>2,XST'/M5KQ+X?778O)9F1E8
M/&Z$AD=<[6&",XST_(@X(UJ* .2AU;5+-1#):K.R@ RQSI&K>^UE!!]> ,Y(
M &*E\/Z)=2S?VE?N/-";4BB+"- P!;//S,2.>6&0#DX7;U%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %07O^K?_
M '6_E4]07O\ JW_W6_E0!3\/_P"K/^\?Y"M.LSP__JS_ +Q_D*TZ ,_Q#:M=
MVT\,8R\D,BJ,@9+(0!D\=:X_X4>%KG0?/^TIL\SRMOS*V=N_/W2?4=:] HH
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M?Y"M.LSP_P#ZL_[Q_D*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "L73/]?)_P+_T(5M5BZ9_KY/\ @7_H0H VJ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,74_P#7Q_\  ?\
MT(UM5BZG_KX_^ _^A&MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K,\0?ZL?[P_D:TZS/$'^K'^\/Y&@#3HHHH **** "BBB@
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M&5@\;H2&1USM88(SC/3\B#@C(AU+5;!1%+;QW#8'[R*81#TP5=1\W&20 O(
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M)/844 <EIVD7FK3I>WY$20DF*")S]XEAND8'#';QP<$'D*"RMUM%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 4-=_P!2WX?^A"BC7?\ 4M^'_H0HH X6Y^\?\]JBJ6Y^\?\ /:HJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M3PU_Q\)_P+_T$UEUJ
M>&O^/A/^!?\ H)H [JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC_Q[_P"M1_PD7^Q_X]_]:@#:HK%_X2+_ &/_ ![_ .M1_P )%_L?^/?_ %J
M-JBL7_A(O]C_ ,>_^M1_PD7^Q_X]_P#6H VJ*Q?^$B_V/_'O_K4?\)%_L?\
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MX]_]:C_A(O\ 8_\ 'O\ ZU<QW&U16+_PD7^Q_P"/?_6H_P"$B_V/_'O_ *U
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M (]_]:@#:HK%_P"$B_V/_'O_ *U'_"1?['_CW_UJ -JBL7_A(O\ 8_\ 'O\
MZU'_  D7^Q_X]_\ 6H VJ*Q?^$B_V/\ Q[_ZU'_"1?['_CW_ -:@#:HK%_X2
M+_8_\>_^M1_PD7^Q_P"/?_6H VJ*Q?\ A(O]C_Q[_P"M1_PD7^Q_X]_]:@#:
MHK%_X2+_ &/_ ![_ .M1_P )%_L?^/?_ %J -JBL7_A(O]C_ ,>_^M1_PD7^
MQ_X]_P#6H VJ*Q?^$B_V/_'O_K4?\)%_L?\ CW_UJ -JBL7_ (2+_8_\>_\
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M?['_ (]_]:@#:HK%_P"$B_V/_'O_ *U'_"1?['_CW_UJ -JBL7_A(O\ 8_\
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MC_Q[_P"M1_PD7^Q_X]_]:@#:HK%_X2+_ &/_ ![_ .M1_P )%_L?^/?_ %J
M-JBL7_A(O]C_ ,>_^M1_PD7^Q_X]_P#6H VJS/$'^K'^\/Y&H/\ A(O]C_Q[
M_P"M5;4-6^V*$VXP<]<]C[4 ='16+_PD7^Q_X]_]:C_A(O\ 8_\ 'O\ ZU &
MU16+_P )%_L?^/?_ %J/^$B_V/\ Q[_ZU &U16+_ ,)%_L?^/?\ UJ/^$B_V
M/_'O_K4 ;5%8O_"1?['_ (]_]:C_ (2+_8_\>_\ K4 ;5%8O_"1?['_CW_UJ
M/^$B_P!C_P >_P#K4 ;5%8O_  D7^Q_X]_\ 6H_X2+_8_P#'O_K4 ;5%8O\
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M?['_ (]_]:@#:HK%_P"$B_V/_'O_ *U'_"1?['_CW_UJ -JBL7_A(O\ 8_\
M'O\ ZU'_  D7^Q_X]_\ 6H VJ*Q?^$B_V/\ Q[_ZU'_"1?['_CW_ -:@#:HK
M%_X2+_8_\>_^M1_PD7^Q_P"/?_6H VJ*Q?\ A(O]C_Q[_P"M1_PD7^Q_X]_]
M:@#:HK%_X2+_ &/_ ![_ .M1_P )%_L?^/?_ %J -JBL7_A(O]C_ ,>_^M1_
MPD7^Q_X]_P#6H VJ*Q?^$B_V/_'O_K4?\)%_L?\ CW_UJ -JBL7_ (2+_8_\
M>_\ K4?\)%_L?^/?_6H VJ*Q?^$B_P!C_P >_P#K4?\ "1?['_CW_P!:@#:H
MK%_X2+_8_P#'O_K4?\)%_L?^/?\ UJ -JBL7_A(O]C_Q[_ZU'_"1?['_ (]_
M]:@#:HK%_P"$B_V/_'O_ *U'_"1?['_CW_UJ -JBL7_A(O\ 8_\ 'O\ ZU'_
M  D7^Q_X]_\ 6H VJ*Q?^$B_V/\ Q[_ZU'_"1?['_CW_ -:@#:HK%_X2+_8_
M\>_^M1_PD7^Q_P"/?_6H VJ*Q?\ A(O]C_Q[_P"M1_PD7^Q_X]_]:@#:HK%_
MX2+_ &/_ ![_ .M1_P )%_L?^/?_ %J -JBL7_A(O]C_ ,>_^M1_PD7^Q_X]
M_P#6H VJ*Q?^$B_V/_'O_K4?\)%_L?\ CW_UJ +>N_ZEOP_]"%%9FH:U]I0Q
M[<9QSG/0@^E% ',7/WC_ )[5%4MS]X_Y[5%0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5J>&O\ CX3_ (%_Z":RZU/#7_'PG_ O_030!W5%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %07O\ JW_W6_E4]07O^K?_ '6_E0!3\/\ ^K/^\?Y"M.LSP_\ ZL_[
MQ_D*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH S/$'^K'^\/Y&HTUZ"U58W;#!5R-K'JH/85
M)X@_U8_WA_(UQFM_ZT_[L?\ Z M=.#H1K3<7VOH<68XJ>&I*4;7O;7T9V/\
MPE-M_?\ _'6_PH_X2FV_O_\ CK?X5Y_17?\ V92[O\/\CR?[<K]H_<_\ST#_
M (2FV_O_ /CK?X4?\)3;?W__ !UO\*\_HH_LREW?X?Y!_;E?M'[G_F>@?\)3
M;?W_ /QUO\*/^$IMO[__ (ZW^%>?T4?V92[O\/\ (/[<K]H_<_\ ,] _X2FV
M_O\ _CK?X4?\)3;?W_\ QUO\*\_HH_LREW?X?Y!_;E?M'[G_ )GH'_"4VW]_
M_P =;_"C_A*;;^__ ..M_A7G]%']F4N[_#_(/[<K]H_<_P#,] _X2FV_O_\
MCK?X4?\ "4VW]_\ \=;_  KS^BC^S*7=_A_D']N5^T?N?^9Z!_PE-M_?_P#'
M6_PH_P"$IMO[_P#XZW^%>?T4?V92[O\ #_(/[<K]H_<_\ST#_A*;;^__ ..M
M_A1_PE-M_?\ _'6_PKS^BC^S*7=_A_D']N5^T?N?^9Z!_P )3;?W_P#QUO\
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M75;Q-&B8JN45@20K/*5(W8)RJ_+CC(.[KQ0!Z?9:Y;W[;(98W8#)".K''3.
M3QS5ZO%/'/@!/"D,5Y!*YD$BJ2<#YMI8,N,%<%3QDGD<\<]F_C=TT@:F<"9D
MV#)49?<8]P&W!/!?;C& 1TYH ZJ]URWL&V32QHQ&0'=5..F<$CCBK<,RS*'0
M@JP!!!R"#R"".H->.^!/AVGB:)[Z[>4%Y"%Q@%L<LY9@V[))'U!R2>AX$U1_
M"VH/I4K-Y3R%.00-V<1R!<$C>,#@X(8$DA10![+1110 4444 %%%% !1110
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M** "BBB@ HHHH *S/$'^K'^\/Y&M.LSQ!_JQ_O#^1H TZ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6L?ZIOP_F*-'_U2_C_
M #-&L?ZIOP_F*-'_ -4OX_S- %VBBB@"-+A9&:,,"R8W $$C/(R.V>U25S\W
M^AZ@C?PW,++A>[QG=N;I_"< \GMP*TM<U+^S8)+CC**<9!(W'A1QSR2!0!<C
MD$G*D$9(X.>0<$?@1@^]$D@B!=B  "22<  =3FN5\&1R::\EC.<NP68$\L=X
M DR02/E8 >IY/0\7O&DA-O\ 9U)#W$B1J<X&6/.2.<$ @]>N,4 ;D<@E =2"
M" 00<@@]#FG4V.,1 (H     &  .@Q63?>+[6Q;RI)1N'4 ,V.<8.T'!XZ'F
M@#8HJK8:I%J W0NKC )VD$C/3(ZCZ'!HNM3CM&6.1@I<,1G.,(-S'/08'/)%
M %JJ]A?IJ"">([D;.#@CH2#P0#U%5=*\10:J2L#%BHR?D< 9Z<D ?AUZ^AJC
MX"_X\HO^!_\ HQJ .@HK/U37X-+QYSA2>@Y+<YYV@$XXZXQ1I>OP:IGR7#$=
M1R&XQSM(!QSUQB@"Q87Z:@@GB.Y&S@X(Z$@\$ ]15BN7\'WZ6-A#)*=JDL,X
M. 3(P&2!P/<X'O744 %%0PWB3,T:D%HR P[C< 1^8/7IU[@TV^OTL5#R' )"
MC@DDG@   DD^@% $=SK$-M(EN[@22?=4]_\ #/09QD\#)JY67?V]L\\)E4&<
M[O+)!_A&3TXXZC/0\CFM2@ JO?WZ:>AGE.U%QDX)ZD < $]36??>+[6Q;RI)
M1N'4 ,V.<8.T'!XZ'FL_Q?J$=_82RQ,&4^7R#_MH<'T//0\B@#J***Q[[Q?:
MV+>5)*-PZ@!FQSC!V@X/'0\T ;%%4]-UB'4UWPN& ZXZCJ.0<$9QQD<]JN4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!0UW_4M^'_ *$**-=_U+?A_P"A"B@#A;G[Q_SVJ*I;G[Q_
MSVJ*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K4\-?\?"?\"_\
M03676IX:_P"/A/\ @7_H)H [JBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1,WFDMR4^8_)NV@$ J.N <\D9/.?&O\ X_(_^O=?_0Y*]5\6?\>=S_U[S?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %8NF?Z^3_ (%_Z$*VJQ=,_P!?)_P+_P!"
M% &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!BZG_KX_^ _^A&MJL74_]?'_ ,!_]"-;5 !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR,#'I5ZB@"&ZM$NU,4JJZ'&5<!E.#D9!XZU%;Z3#;(T$<:+&^=RJBA3D8.5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6+IG^OD_P"!?^A"MJL73/\ 7R?\"_\ 0A0!M4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8NI_Z^/_@/
M_H1K:K%U/_7Q_P# ?_0C6U0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5F>(/]6/]X?R-:=9GB#_ %8_WA_(T :=%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/]4WX?S%&C_ZI
M?Q_F:-8_U3?A_,4:/_JE_'^9H NT444 %1V]NMNHC10JCH%  &>>@J2B@ IL
M<8CX4 #)/ QR3DG\2<GWIU% !56ZTJ&[.^6-'(&,NBL<>F2*M44 -CC$0"*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_?0JG_PC\?JWYC_  H_X1^/U;\Q_A0!<^VQ_P!Y?^^A1]MC_O+_ -]"J?\
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M7_OH53_X1^/U;\Q_A1_PC\?JWYC_  H N?;8_P"\O_?0H^VQ_P!Y?^^A5/\
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ML?\ >7_OH4?;8_[R_P#?0JG_ ,(_'ZM^8_PH_P"$?C]6_,?X4 7/ML?]Y?\
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M7_OH53_X1^/U;\Q_A1_PC\?JWYC_  H N?;8_P"\O_?0H^VQ_P!Y?^^A5/\
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M?^^A5/\ X1^/U;\Q_A1_PC\?JWYC_"@"Y]MC_O+_ -]"C[;'_>7_ +Z%4_\
MA'X_5OS'^%'_  C\?JWYC_"@"Y]MC_O+_P!]"C[;'_>7_OH53_X1^/U;\Q_A
M1_PC\?JWYC_"@"Y]MC_O+_WT*/ML?]Y?^^A5/_A'X_5OS'^%'_"/Q^K?F/\
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M8_[R_P#?0JG_ ,(_'ZM^8_PH_P"$?C]6_,?X4 7/ML?]Y?\ OH4?;8_[R_\
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MA0!<^VQ_WE_[Z%'VV/\ O+_WT*I_\(_'ZM^8_P */^$?C]6_,?X4 7/ML?\
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MDY)QSCT/M0!L?;8_[R_]]"C[;'_>7_OH53_X1^/U;\Q_A1_PC\?JWYC_  H
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M/\* +GVV/^\O_?0H^VQ_WE_[Z%4_^$?C]6_,?X4?\(_'ZM^8_P * +GVV/\
MO+_WT*/ML?\ >7_OH53_ .$?C]6_,?X4?\(_'ZM^8_PH 75;I'B8!@3QP"#W
M%&E72)$H+ 'G@D#N:K7^CI;H7!.1CJ1W('I18:.EP@<DY.>A'8D>E &I]MC_
M +R_]]"C[;'_ 'E_[Z%4_P#A'X_5OS'^%'_"/Q^K?F/\* +GVV/^\O\ WT*/
MML?]Y?\ OH53_P"$?C]6_,?X4?\ "/Q^K?F/\* +GVV/^\O_ 'T*/ML?]Y?^
M^A5/_A'X_5OS'^%'_"/Q^K?F/\* +GVV/^\O_?0H^VQ_WE_[Z%4_^$?C]6_,
M?X4?\(_'ZM^8_P * +GVV/\ O+_WT*/ML?\ >7_OH53_ .$?C]6_,?X4?\(_
M'ZM^8_PH N?;8_[R_P#?0H^VQ_WE_P"^A5/_ (1^/U;\Q_A1_P (_'ZM^8_P
MH N?;8_[R_\ ?0H^VQ_WE_[Z%4_^$?C]6_,?X4?\(_'ZM^8_PH N?;8_[R_]
M]"C[;'_>7_OH53_X1^/U;\Q_A1_PC\?JWYC_  H N?;8_P"\O_?0H^VQ_P!Y
M?^^A5/\ X1^/U;\Q_A1_PC\?JWYC_"@"Y]MC_O+_ -]"C[;'_>7_ +Z%4_\
MA'X_5OS'^%'_  C\?JWYC_"@"Y]MC_O+_P!]"C[;'_>7_OH53_X1^/U;\Q_A
M1_PC\?JWYC_"@"Y]MC_O+_WT*/ML?]Y?^^A5/_A'X_5OS'^%'_"/Q^K?F/\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S/$'^K'^\/Y&N,UO\
MUI_W8_\ T!:[/Q!_JQ_O#^1KC-;_ -:?]V/_ - 6N[+/XK]/U1Y6>?P(_P")
M?DRA1117L'S@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M);W#6["1#AEZ$5WNAZXNIKCI(O4?U'M_+\B?/JDM[AK=A(APR]"*Y\3AHUH^
M?1G9@<=+"R[Q>Z/4:*R]#UQ=37'21>H_J/;^7Y$ZE>'.$H2<7N?4TJL:L5*+
MNF%%%%26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!>_ZM_\
M=;^53U!>_P"K?_=;^5 %/P__ *L_[Q_D*TZS/#_^K/\ O'^0K3H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=,_P!?)_P+_P!"
M%;58NF?Z^3_@7_H0H VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,74_]?'_ ,!_]"-;58NI_P"OC_X#_P"A&MJ@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,\0?ZL?[P_D:TZ
MS/$'^K'^\/Y&@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH I:Q_JF_#^8HT?_5+^/\ ,T:Q_JF_#^8HT?\ U2_C_,T 7:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+[_+\K;\JKC=OS]T#T'6NZN[I;1&FD.$C4LQP3@*,DX'/2O,/@9_R]?]L?\
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MN"U>(6&N@197-S"3@G_EKL+\YZ-N.1TP<=.* /;:*** "BBB@ HHHH ****
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M* "BBB@ HHHH **** "BBB@#%U/_ %\?_ ?_ $(UM5BZG_KX_P#@/_H1K:H
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MX^ZI*$=2<G;DCID,1@'G0\17A>2"QC8J\L@9L-M/EH"S#(^8;L<$8S@C(YH
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MNX_Q Y )/X <!NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH *U/#7_'PG_ O_ $$UEUJ>&O\ CX3_ (%_Z":
M.ZHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1KC-;_UI_P!V/_T!:[/Q!_JQ_O#^1KC-;_UI_P!V/_T!:[LL_BOT_5'E9Y_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110 4444 %%%% !6IX:_X^$_X%_Z":RZU/#7_'PG_ O_ $$T =U1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !4%[_JW_W6_E4]07O^K?\ W6_E0!3\/_ZL_P"\?Y"M.LSP_P#ZL_[Q
M_D*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BZ9_KY/^!?^
MA"MJL73/]?)_P+_T(4 ;5%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% &+J?^OC_P" _P#H1K:K%U/_ %\?_ ?_ $(UM4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9GB#_5C_ 'A_
M(UIUF>(/]6/]X?R- &G1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:U% &3_I/^=M'^D_YVUK44 9/^D_YVT?Z3_G;6M10!D_Z3_G;1_I/^=M:U%
M&3_I/^=M'^D_YVUK44 9/^D_YVT?Z3_G;6M10!D_Z3_G;1_I/^=M:U% &3_I
M/^=M'^D_YVUK44 9/^D_YVT?Z3_G;6M10!D_Z3_G;1_I/^=M:U% &3_I/^=M
M'^D_YVUK44 9/^D_YVT?Z3_G;6M10!D_Z3_G;1_I/^=M:U% &3_I/^=M'^D_
MYVUK44 9/^D_YVT?Z3_G;6M10!D_Z3_G;1_I/^=M:U% &3_I/^=M'^D_YVUK
M44 9/^D_YVT?Z3_G;6M10!D_Z3_G;1_I/^=M:U% &3_I/^=M'^D_YVUK44 9
M/^D_YVT?Z3_G;6M10!D_Z3_G;1_I/^=M:U% &3_I/^=M'^D_YVUK44 9/^D_
MYVT?Z3_G;6M10!D_Z3_G;1_I/^=M:U% &3_I/^=M'^D_YVUK44 9/^D_YVT?
MZ3_G;6M10!D_Z3_G;1_I/^=M:U% &3_I/^=M'^D_YVUK44 9/^D_YVT?Z3_G
M;6M10!D_Z3_G;3)OM!4[ONX.?N].];-0W?W&_P!T_P J ,>P$H4^5]W/MUX]
M:L?Z3_G;4VB?</\ O'^0K0H R?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_
M $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH
MR?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_
M $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH
MR?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_
M $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH
MR?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_
M $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH
MR?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_
M $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH R?\ 2?\ .VC_ $G_ #MK6HH
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M[T=>$QU+$I\NZZ/<R?\ 2O\ .RC_ $K_ #LK:HK ZC%_TK_.RC_2O\[*VJ*
M,7_2O\[*/]*_SLK:HH Q?]*_SLH_TK_.RMJB@#%_TK_.RC_2O\[*VJ* ,7_2
MO\[*/]*_SLK:HH Q?]*_SLH_TK_.RMJB@#%_TK_.RC_2O\[*VJ* ,7_2O\[*
M/]*_SLK:HH Q?]*_SLH_TK_.RMJB@#%_TK_.RF3_ &G:=WW<'/W>F.:W:@O?
M]6_^ZW\J ,/3_.VGRONY_P!GK@>M6?\ 2O\ .RI_#_\ JS_O'^0K3H Q?]*_
MSLH_TK_.RMJB@#%_TK_.RC_2O\[*VJ* ,7_2O\[*/]*_SLK:HH Q?]*_SLH_
MTK_.RMJB@#%_TK_.RC_2O\[*VJ* ,7_2O\[*/]*_SLK:HH Q?]*_SLH_TK_.
MRMJB@#%_TK_.RC_2O\[*VJ* ,7_2O\[*/]*_SLK:HH Q?]*_SLH_TK_.RMJB
M@#%_TK_.RC_2O\[*VJ* ,7_2O\[*/]*_SLK:HH Q?]*_SLH_TK_.RMJB@#%_
MTK_.RC_2O\[*VJ* ,7_2O\[*/]*_SLK:HH Q?]*_SLH_TK_.RMJB@#%_TK_.
MRC_2O\[*VJ* ,7_2O\[*/]*_SLK:HH Q?]*_SLH_TK_.RMJB@#%_TK_.RC_2
MO\[*VJ* ,7_2O\[*/]*_SLK:HH Q?]*_SLJG;>;YC;/O\YZ>O/7CK735BZ9_
MKY/^!?\ H0H /]*_SLH_TK_.RMJB@#%_TK_.RC_2O\[*VJ* ,7_2O\[*/]*_
MSLK:HH Q?]*_SLH_TK_.RMJB@#%_TK_.RC_2O\[*VJ* ,7_2O\[*/]*_SLK:
MHH Q?]*_SLH_TK_.RMJB@#%_TK_.RC_2O\[*VJ* ,7_2O\[*/]*_SLK:HH Q
M?]*_SLH_TK_.RMJB@#%_TK_.RC_2O\[*VJ* ,7_2O\[*/]*_SLK:HH Q?]*_
MSLH_TK_.RMJB@#%_TK_.RC_2O\[*VJ* ,7_2O\[*/]*_SLK:HH Q?]*_SLH_
MTK_.RMJB@#%_TK_.RC_2O\[*VJ* ,7_2O\[*/]*_SLK:HH Q?]*_SLH_TK_.
MRMJB@#%_TK_.RC_2O\[*VJ* ,7_2O\[*/]*_SLK:HH Q?]*_SLH_TK_.RMJB
M@#F;GS?,7?\ ?XQT]>.G'6KG^E?YV4:G_KX_^ _^A&MJ@#%_TK_.RC_2O\[*
MVJ* ,7_2O\[*/]*_SLK:HH Q?]*_SLH_TK_.RMJB@#%_TK_.RC_2O\[*VJ*
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MV'W6^;KC Z^^".A]Q5:QNS9NLHZJ?S'<?B*[>?9;;[P8.8QZ#.,D?-_M9 _
M=: .;\3*OFB&)0" ,A5P26[<=>,8^M:"V,&BH&G&]VSVR.V0 >./4\]?I7.V
M]WME6=^?G#''7KDUO^*-->Z*SQC<-N/EY[Y!'KG/;TH GL/LNI.&1,,N?E*@
M CIR!E>I^N1Z5C:O8^9<F", 9*@ # &5&3QV[FK?AK2)$E$SJ55<_>&"21C&
M#SWZXQQBEN;D6U]O;ID#\T S].>: +4D=KHH$<B[W(!.5R>_// 'L.>F<]:I
MZI+:74?F)\DG8 8/'8@<8.>O\\8I?$ND2/*9D4LK8^Z,D$#&,#GMUQCG%9KZ
M',B><5(49SGJ .^.N/\ #/2@"QX?T7^T&+O]Q>ON?3/\^_YY&E_:UG&0@C!
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M44 %%%% !4-W]QO]T_RJ:H;O[C?[I_E0!5T3[A_WC_(5H5GZ)]P_[Q_D*T*
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M%% !1110 4444 %%%% !1110 4444 %%%% &+J?^OC_X#_Z$:VJQ=3_U\?\
MP'_T(UM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %9GB#_5C_>'\C6G69X@_P!6/]X?R- &G1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!2UC_5-^'\Q1H_^J7\?YFC6/]4WX?S%
M&C_ZI?Q_F: +M%%% !152WU2.YDDMD;,D&S>,$8WC*\D8.1Z$^]6Z "BJ]GJ
M$=Z&,;!MCLC8[,APRD=B/U&"."#3KNZ6T1II#A(U+,<$X"C).!STH FHJ&TN
MENT6:,Y210RG!&0PR#@\]*FH **** "BBL_0-;36X$O(@P23=@. &^5BIS@D
M=1ZT :%%%% !16?H&MIK<"7D08))NP' #?*Q4YP2.H]:T* "BBB@ HK$U3Q?
M!IEQ%82%O,GQMPN5&3M7)_VB,#&<=\#FMN@ HHK/U_6TT2![R4,4CVY" %OF
M8*,9('4^M &A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!0UW_4M^'_H0HHUW_4M^'_H0
MHH X6Y^\?\]JBJ6Y^\?\]JBH H:W!YL>[NIST[=_\?PJSX1N=R-'S\K9]L-V
M'X@U*Z!P5/0C!_&L/0IOL<^PXYRAZ^O&/Q K7#SY:B.?&4^>E)=M3N5:I5:J
MRM4BM7HM'BQD6E:I%:JRM3PU9N)O&19#UGW7AVWNV\QXQN/4@E<]\G:1D^_6
MK0>G!ZAP3-(U&MCR2O1-#T"!$BN GS[%;))/)4'."<?IQVKSNO4-(;]Q%_US
M3_T$5S4(IMG=BYN,4:!>HV:F%Z:6KK43SW,5FJ-FI&:HV:K2,I2!FK \67?E
MQ>7W<_H.3^N*VF:N-\1W!NIO+7G;A1SQD]?IZ'Z5&(ERTWYZ&F#A[2LO+4L:
M%!L3?W8_H./\:TJ;%'Y8"CH !^5.KSCV@HHHH **** "BBB@ HHHH *O2ZO)
M+$+8_=7OSDXZ \]!].PJC10 5HZ=KTM@-BD%>>&&0,_D?UQ6=10!LOXJF9@_
M  _A .#P1SSGOZXZ5G7UX;QS*V 6QTZ<#'OZ57HH U;'Q)+:+L&& Z;AG'X@
MC]?PJ/4=>EOQL8@+QPHP#C\S^N*SJ* )()VMV#H<,.A%;">+YE &%/N0<_H:
MPZ* )KN\>[;?(<G_ #V%6;O6'NHU@8#:F,8!SP,>M4** +]WK#W4:P,!M3&,
M YX&/6H]-U)M/8R( 21CYLXZ@]B/2JE% $LMR9',O1BQ;CC!)SQ6I;>*IH1M
M.&QW8'/Z$?KS6-10!:O]2>_.Z0YQG ' &?\ /UJW8^));1=@PP'3<,X_$$?K
M^%95% %O4=3?4&WOVZ =!_\ KJI110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %;O@[_7-_P!<S_Z$M85;O@[_ %S?]<S_ .A+0!V-<O\ $2[DCMA;
M0X#W<J0 D\#S,Y)X/! (]1G(Y%=17+_$2TDDMA<PX+VDJ3@$<'R\Y!Y' !)]
M3C Y- '0:?I\>G1K;PJ%C08 '^>2>I)Y)Y/-6*KZ?J$>HQK<0L&C<9!'^>".
MA!Y!X/-6* (?LB;_ #]J^9MV[L#=MSG;NZXSSCIFN2^SG7-5;S /*TY$VJ<'
M,DPW!L%>@ ]>&52.IKK?M:;_ "-R^9MW;<C=MSC=MZXSQGIFN523^Q=4<R,H
MCU"--A/!\R'">6#GN#G) R2%'(Y .PHHHH X_P /1_V-J$^FHJK!+&MP@7HI
MR(W&,?Q$9 !PH P.2 _QTYTAH=80$F!PDNW',,G!!&5+$-@H,X#')'<,\/2?
MVSJ$^I(RM!%&MNA7HQR)'.<_PDX! PP(P>"3U5W:K=HT,@RDBE6&2,AA@C(Y
MZ4 35R6A.=:OI[Q@?+M"8(LXQN'^N;&3AN@##&4.""<XR;#Q)-I.GRVSX-W:
MN+=%!&YBV!$RH5R1M.5&T[PA/<X[#PUHXT>VBM!C,: -@D@L>7()YP6)/;Z#
MI0!C^/O^7/\ ["%O_P"S4?%+_D'3_P#;/_T:E'C[_ES_ .PA;_\ LU'Q2_Y!
MT_\ VS_]&I0!U=5]0T^/48VMYE#1N,$'_/!'4$<@\CFK%0W=TMHC32'"1J68
MX)P%&2<#GI0!S7PVG<6K6LO+VDTD);<6!V'(QD @ -M ] .G0=77+_#R%FMW
MNV!4W<\LVTC[H<X SQD$ $' R#TKJ* ,G_A++/\ Y^(?^_R?_%5S7PX\0VUI
M80Q2S1(X\S*O(BL,R,1D$YZ5TO\ PB=G_P ^\/\ WY3_ .)KFOAQX>MKNPAE
MEAB=SYF6>-&8XD8#)(STH [6UNTNU$L3*Z'.&0AE.#@X(XZU-4-K:):*(HE5
M$&<*@"J,G)P!QUJ:@#S^+Q3;:#J-]]I?9YGV;;\K-G;%S]T'U'6NET3QG::V
MYAMI-[A2Q&QUX! SEE ZD5G^'?\ D(ZA_P!NO_HHUU= '*?\QG_N'_\ M>K>
MC:I)<WMY;.V8X/L^P8 QOC);D#)R?4GVJI_S&?\ N'_^UZ/#O_(1U#_MU_\
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M"W<#.,LBB.8!MJ_=R%P"<]^ 2S*.1T'B+7%T6$SE2[9"HB_>=V.%4>I/L"<
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MX(/0^M<%8?%R[OHS'%;B2YR3^[5R@0;<$J"S$Y)!Y4#Y>O(KK?BE_P @Z?\
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M**]@^<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY/\ @7_H0H VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,74_P#7Q_\  ?\ T(UM5BZG_KX_^ _^A&MJ@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,\0?ZL?[P_D:TZS/$'^K'
M^\/Y&@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRCV/4RN'N.??]#3HHHKD/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>,5V7/D[0"=P\M"ISQCKTP3^%;=% '.:YX5:>9=1M'$5THP21E)%QPC@$<<
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MZW\JGJ"]_P!6_P#NM_*@"GX?_P!6?]X_R%:=9GA__5G_ 'C_ "%:= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+IG^OD_X%_Z$
M*VJQ=,_U\G_ O_0A0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 8NI_Z^/_ (#_ .A&MJL74_\ 7Q_\!_\ 0C6U0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F>(/]6/\ >'\C
M6G69X@_U8_WA_(T :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% %+6/\ 5-^'\Q1H_P#JE_'^9HUC_5-^'\Q1H_\ JE_'^9H
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MI\]['0C4XO[Z_P#?0_QIPU2+^^O_ 'T/\:YS_A'?]O\ \=_^O1_PCO\ M_\
MCO\ ]>K^O2[&7]E1_F9THU2+^^O_ 'T/\:7^U8O[Z_\ ?0_QKF?^$=_V_P#Q
MW_Z]'_"._P"W_P"._P#UZ7UU]A_V7'^9G3?VK%_?7_OH?XT?VK%_?7_OH?XU
MS/\ PCO^W_X[_P#7H_X1W_;_ /'?_KT?77V#^S(_S,Z4ZI%_?7_OH?XTTZI%
M_?7_ +Z'^-<Y_P ([_M_^.__ %Z/^$=_V_\ QW_Z]'UV78/[+C_,SH3J<7]]
M?^^A_C3#J4?]]?\ OH?XU@_\([_M_P#CO_UZ/^$=_P!O_P =_P#KT_K\NQ+R
MF/\ ,R/7KO[5($0Y"C Q@\GTQU[5LV\/DJ$'8?3\:S[;0A$P<MG!!&!CD?G6
MI7+4FYR<GU.^C25*"@N@4445)H%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %;O@[_ %S?]<S_ .A+6%6SX5N%@E+,<#8?YB@#M:*J
M?VI'_>_0_P"%']J1_P![]#_A0!;HJI_:D?\ >_0_X4?VI'_>_0_X4 6Z*J?V
MI'_>_0_X4?VI'_>_0_X4 6Z*J?VI'_>_0_X4?VI'_>_0_P"% %NBJG]J1_WO
MT/\ A1_:D?\ >_0_X4 6Z*J?VI'_ 'OT/^%']J1_WOT/^% %NBJG]J1_WOT/
M^%']J1_WOT/^% %NBJG]J1_WOT/^%']J1_WOT/\ A0!;HJI_:D?][]#_ (4?
MVI'_ 'OT/^% %NBJG]J1_P![]#_A1_:D?][]#_A0!;HJI_:D?][]#_A1_:D?
M][]#_A0!;HJI_:D?][]#_A1_:D?][]#_ (4 6Z*J?VI'_>_0_P"%']J1_P![
M]#_A0!;HJI_:D?\ >_0_X4?VI'_>_0_X4 6Z*J?VI'_>_0_X4?VI'_>_0_X4
M 6Z*J?VI'_>_0_X4?VI'_>_0_P"% %NBJG]J1_WOT/\ A1_:D?\ >_0_X4 6
MZ*J?VI'_ 'OT/^%']J1_WOT/^% %NBJG]J1_WOT/^%']J1_WOT/^% %NBJG]
MJ1_WOT/^%']J1_WOT/\ A0!;HJI_:D?][]#_ (4?VI'_ 'OT/^% %NBJG]J1
M_P![]#_A1_:D?][]#_A0!;HJI_:D?][]#_A1_:D?][]#_A0!;HJI_:D?][]#
M_A1_:D?][]#_ (4 6Z*J?VI'_>_0_P"%']J1_P![]#_A0!;HJI_:D?\ >_0_
MX4?VI'_>_0_X4 6Z*J?VI'_>_0_X4?VI'_>_0_X4 6Z*J?VI'_>_0_X4?VI'
M_>_0_P"% %NBJG]J1_WOT/\ A1_:D?\ >_0_X4 6Z*J?VI'_ 'OT/^%']J1_
MWOT/^% %NBJG]J1_WOT/^%']J1_WOT/^% %NBJG]J1_WOT/^%']J1_WOT/\
MA0!;HJI_:D?][]#_ (4?VI'_ 'OT/^% %NBJG]J1_P![]#_A1_:D?][]#_A0
M!;HJI_:D?][]#_A1_:D?][]#_A0!;HJI_:D?][]#_A1_:D?][]#_ (4 6ZAN
M_N-_NG^51?VI'_>_0_X5'<:E&ZLH/)4]CZ?2@!-$^X?]X_R%:%9&EWJ0*58X
M.?0^@JY_:D?][]#_ (4 6Z*J?VI'_>_0_P"%']J1_P![]#_A0!;HJI_:D?\
M>_0_X4?VI'_>_0_X4 6Z*J?VI'_>_0_X4?VI'_>_0_X4 6Z*J?VI'_>_0_X4
M?VI'_>_0_P"% %NBJG]J1_WOT/\ A1_:D?\ >_0_X4 6Z*J?VI'_ 'OT/^%'
M]J1_WOT/^% %NBJG]J1_WOT/^%']J1_WOT/^% %NBJG]J1_WOT/^%']J1_WO
MT/\ A0!;HJI_:D?][]#_ (4?VI'_ 'OT/^% %NBJG]J1_P![]#_A1_:D?][]
M#_A0!;HJI_:D?][]#_A1_:D?][]#_A0!;HJI_:D?][]#_A1_:D?][]#_ (4
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M_>_0_P"%']L1?WOT/^%']J3_ )4']A4_YF<%_9,W_/-_^^&_PH_LF;_GF_\
MWPW^%=[_ &Q%_>_0_P"%']L1?WOT/^%']J3_ )4']A4_YF<%_9,W_/-_^^&_
MPH_LF;_GF_\ WPW^%=[_ &Q%_>_0_P"%']L1?WOT/^%']J3_ )4']A4_YF<%
M_9,W_/-_^^&_PH_LF;_GF_\ WPW^%=[_ &Q%_>_0_P"%']L1?WOT/^%']J3_
M )4']A4_YF<%_9,W_/-_^^&_PH_LF;_GF_\ WPW^%=[_ &Q%_>_0_P"%']L1
M?WOT/^%']J3_ )4']A4_YF<%_9,W_/-_^^&_PH_LF;_GF_\ WPW^%=[_ &Q%
M_>_0_P"%']L1?WOT/^%']J3_ )4']A4_YF<%_9,W_/-_^^&_PH_LF;_GF_\
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M_A0!=HJE_;$7][]#_A1_;$7][]#_ (4 7:*I?VQ%_>_0_P"%']L1?WOT/^%
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MWOT/^% %VBJ7]L1?WOT/^%']L1?WOT/^% %VBJ7]L1?WOT/^%']L1?WOT/\
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M_0_X4?VQ%_>_0_X4 7:*I?VQ%_>_0_X4?VQ%_>_0_P"% %VBJ7]L1?WOT/\
MA1_;$7][]#_A0!=HJE_;$7][]#_A1_;$7][]#_A0!=HJE_;$7][]#_A1_;$7
M][]#_A0!=HJE_;$7][]#_A1_;$7][]#_ (4 7:*I?VQ%_>_0_P"%']L1?WOT
M/^% %VBJ7]L1?WOT/^%']L1?WOT/^% %VBJ7]L1?WOT/^%']L1?WOT/^% %V
MBJ7]L1?WOT/^%']L1?WOT/\ A0!=HJE_;$7][]#_ (4?VQ%_>_0_X4 7:*I?
MVQ%_>_0_X4?VQ%_>_0_X4 7:*I?VQ%_>_0_X4?VQ%_>_0_X4 7:*I?VQ%_>_
M0_X4?VQ%_>_0_P"% %VBJ7]L1?WOT/\ A1_;$7][]#_A0!=HJE_;$7][]#_A
M1_;$7][]#_A0!=HJE_;$7][]#_A1_;$7][]#_A0!=HJE_;$7][]#_A1_;$7]
M[]#_ (4 7:*I?VQ%_>_0_P"%']L1?WOT/^% %VBJ7]L1?WOT/^%']L1?WOT/
M^% %VBJ7]L1?WOT/^%']L1?WOT/^% #==_U+?A_Z$**JZMJ4<T3(IR3CL?4>
MU% ''W/WC_GM452W/WC_ )[5%0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5M^$HQ)*P8 _(>HSW6L2MWP=_KF_ZYG_T): .K^R)_=7\A1]D3^ZO
MY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH A^R)_=7\A
M1]D3^ZOY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH A^
MR)_=7\A1]D3^ZOY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D
M*FHH A^R)_=7\A1]D3^ZOY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'
MV1/[J_D*FHH A^R)_=7\A1]D3^ZOY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'[(
MG]U?R%'V1/[J_D*FHH A^R)_=7\A1]D3^ZOY"IJ* (?LB?W5_(4?9$_NK^0J
M:B@"'[(G]U?R%'V1/[J_D*FHH A^R)_=7\A1]D3^ZOY"IJ* (?LB?W5_(4?9
M$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH A^R)_=7\A1]D3^ZOY"IJ* (?LB?
MW5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH A^R)_=7\A1]D3^ZOY"IJ
M* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH A^R)_=7\A1]D3
M^ZOY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH A^R)_=
M7\A1]D3^ZOY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH
M A^R)_=7\A1]D3^ZOY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[
MJ_D*FHH A^R)_=7\A45Y;(J,0HR%/8>E6Z@O?]6_^ZW\J *&APK(A+ $[CU&
M>PK0^R)_=7\A5+P__JS_ +Q_D*TZ (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R
M%'V1/[J_D*FHH A^R)_=7\A1]D3^ZOY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'
M[(G]U?R%'V1/[J_D*FHH A^R)_=7\A1]D3^ZOY"IJ* (?LB?W5_(4?9$_NK^
M0J:B@"'[(G]U?R%'V1/[J_D*FHH A^R)_=7\A1]D3^ZOY"IJ* (?LB?W5_(4
M?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH A^R)_=7\A1]D3^ZOY"IJ* (?L
MB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH A^R)_=7\A1]D3^ZOY"
MIJ* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH A^R)_=7\A1]
MD3^ZOY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH A^R)
M_=7\A1]D3^ZOY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*F
MHH A^R)_=7\A1]D3^ZOY"IJ* (?LB?W5_(4?9$_NK^0J:B@"'[(G]U?R%'V1
M/[J_D*FHH R=<A6- 5 'S#H,=C3H9;>-5#F,-M7.XJ#R >]+X@_U8_WA_(UQ
MFM_ZT_[L?_H"UT82@JTW%NVESCS#%O"TU-*^MOS.U^TVO]Z+\TH^TVO]Z+\T
MKSNBNW^RX?S,\O\ MVI_*CT3[3:_WHOS2C[3:_WHOS2O.Z*/[+A_,P_MVI_*
MCT3[3:_WHOS2C[3:_P!Z+\TKSNBC^RX?S,/[=J?RH]$^TVO]Z+\TH^TVO]Z+
M\TKSNBC^RX?S,/[=J?RH]$^TVO\ >B_-*/M-K_>B_-*\[HH_LN'\S#^W:G\J
M/1/M-K_>B_-*/M-K_>B_-*\[HH_LN'\S#^W:G\J/1/M-K_>B_-*/M-K_ 'HO
MS2O.Z*/[+A_,P_MVI_*CT3[3:_WHOS2C[3:_WHOS2O.Z*/[+A_,P_MVI_*CT
M3[3:_P!Z+\TH^TVO]Z+\TKSNBC^RX?S,/[=J?RH]$^TVO]Z+\TH^TVO]Z+\T
MKSNBC^RX?S,/[=J?RH]$^TVO]Z+\TH^TVO\ >B_-*\[HH_LN'\S#^W:G\J/1
M/M-K_>B_-*/M-K_>B_-*\[HH_LN'\S#^W:G\J/1/M-K_ 'HOS2C[3:_WHOS2
MO.Z*/[+A_,P_MVI_*CT3[3:_WHOS2C[3:_WHOS2O.Z*/[+A_,P_MVI_*CT3[
M3:_WHOS2C[3:_P!Z+\TKSNBC^RX?S,/[=J?RH]$^TVO]Z+\TH^TVO]Z+\TKS
MNBC^RX?S,/[=J?RH]$^TVO\ >B_-*/M-K_>B_-*\[HH_LN'\S#^W:G\J/1/M
M-K_>B_-*/M-K_>B_-*\[HH_LN'\S#^W:G\J/1/M-K_>B_-*/M-K_ 'HOS2O.
MZ*/[+A_,P_MVI_*CT3[3:_WHOS2C[3:_WHOS2O.Z*/[+A_,P_MVI_*CT3[3:
M_P!Z+\TH^TVO]Z+\TKSNBC^RX?S,/[=J?RH]$^TVO]Z+\TJ*ZN;;8VUH\[3C
M!7.<5P%%']EP_F8?V[4_E1VVCW,&P^8R9W'[Q7.,#UJ]]IM?[T7YI7G=%']E
MP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[T7Y
MI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%']EP_F
M8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[T7YI1]
MIM?[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%']EP_F8?V
M[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[T7YI1]IM?
M[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%']EP_F8?V[4_
ME1Z)]IM?[T7YI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7
MYI7G=%']EP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z
M)]IM?[T7YI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7
MG=%']EP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z)]I
MM?[T7YI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%
M']EP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[
MT7YI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%']E
MP_F8?V[4_E1Z)]IM?[T7YI1]IM?[T7YI7G=%']EP_F8?V[4_E1Z)]IM?[T7Y
MI698W,/G/N9-OS8R5Q][C';I7'44?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1
M?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_;M3^5'
MHGVFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE
M>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_;M3^5'HGV
MFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T
M4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_;M3^5'HGVFU_
MO1?FE'VFU_O1?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V
M7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?
MFE'VFU_O1?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V7#^
M9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'
MVFU_O1?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_
M;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU
M_O1?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_;M3
M^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1
M?FE>=T4?V7#^9A_;M3^5'HGVFU_O1?FE'VFU_O1?FE>=T4?V7#^9A_;M3^5'
M8WUS#YR;63;\N<%<?>YSVZ5I_:;7^]%^:5YW11_9</YF']NU/Y4>B?:;7^]%
M^:4?:;7^]%^:5YW11_9</YF']NU/Y4>B?:;7^]%^:4?:;7^]%^:5YW11_9</
MYF']NU/Y4>B?:;7^]%^:4?:;7^]%^:5YW11_9</YF']NU/Y4>B?:;7^]%^:4
M?:;7^]%^:5YW11_9</YF']NU/Y4>B?:;7^]%^:4?:;7^]%^:5YW11_9</YF'
M]NU/Y4>B?:;7^]%^:4?:;7^]%^:5YW11_9</YF']NU/Y4>B?:;7^]%^:4?:;
M7^]%^:5YW11_9</YF']NU/Y4>B?:;7^]%^:4?:;7^]%^:5YW11_9</YF']NU
M/Y4>B?:;7^]%^:4?:;7^]%^:5YW11_9</YF']NU/Y4>B?:;7^]%^:4Z)[>8[
M5,9)[#:3^0KSFE1RA# X(Y!'6AY7'^9C6>SOK%'IOV*/^ZO_ 'R*/L4?]U?^
M^165X>\0B_'E2<2#\F]Q[^H_$<=-RO-JTI4Y<KW/:H5X5H*<7H0?8H_[J_\
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M +J_]\BIZ* ,W5;5$B8A0#QR !W%&E6J/$I*@GGD@'N:EUC_ %3?A_,4:/\
MZI?Q_F: )OL4?]U?^^11]BC_ +J_]\BIZ* (/L4?]U?^^11]BC_NK_WR*GHH
M @^Q1_W5_P"^11]BC_NK_P!\BIZ* (/L4?\ =7_OD4?8H_[J_P#?(J>B@"#[
M%'_=7_OD4?8H_P"ZO_?(J>B@"#[%'_=7_OD4?8H_[J_]\BIZ* (/L4?]U?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6[X._US?]<S_P"A+6%6[X._US?]<S_Z$M '8T45D^)?$"Z%%YS*SLS!(T0$
ML[MG:HP#C..OY G (!K45Q]MX?O]6&^^N&A!P1%:80J<#K(02>^5RPS@AL "
MGR^%+O3QOLKN1FR"4NR)4;!'&[;N08SG:,GCD8S0!UM%8/A7Q(VKJ\4R&.Y@
M(65". 3G#*><JV,CD_4C#&E_S&?^X?\ ^UZ .KHHHH **Y3P[_R$=0_[=?\
MT4:ZN@ HHHH **** "BBB@ HHHH ***Y3Q]_RY_]A"W_ /9J .KHHHH ***Y
M3P[_ ,A'4/\ MU_]%&@#JZ*Y3P[_ ,A'4/\ MU_]%&NKH **** "BN/\91/=
MW=E9K++$DWVC<87*,=B*P]NOJ#U-/F^'[%2$O;L-@X)GR >Q( &1[9'U% '6
MT5SGA/4YI'GL+IA)-:NO[Q5"ADD7<AP.C#D$ 8'')Y-8^AVD_C"/^T)KB6&-
MV;RH[9]FU0=IW-MRQ)7Z#DC&[: #NZ*YKPE;W]FTEM>%9(DQY4N0'88Q@J.>
MG4L<[L\N#D,\*7DMO/<Z;.23$^^(LQ9C%(20 6&Y@AX+$MR=N>!D ZBBBN7O
M[R6_U"*SB)$-NAEF*L1EFR(T.T<$?>VDX9220<#(!U%%%% !1110 4444 %%
M%% !1110 4444 %%<_K'A+^TKN"_\UT^SY^1>A[\'MGH_!W+@<=:Z"@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+W_5
MO_NM_*IZ@O?]6_\ NM_*@"GX?_U9_P!X_P A6G69X?\ ]6?]X_R%:= !1110
M 4444 %%%>+^-]4NWU1[*">1 [PJH$CJ@+H@Z*>!DY.!0![117C6K+JW@O9=
MR3^8C-M(,C2KG[V"L@!&0#RO( (R,C/H#^(?[6TR34(@T9:WF(Y^9656!P1Z
M$<'@]#@'B@#I:*\,\"?$&>RN52YE9X92%;S6+;<_=8%F^4 GYN<;<\$@8]@\
M3S-#:7#H2&6"4@@X((0D$$="* -.BO-/@UJTVH?://D>3;Y6/,=FQG?G&2<9
MP*]#U&]6PB>X?)6)&8@=<*"3C..>* +%%?/^E_$2Y@NUO)9':,R$M'O<IM;.
MX*A;' /R@G (%?0% !1110 45R_C;2;[552*RD6)0=S/YDB.3R OR*?EYR<G
MDXX&.>*^$6N7%_=NDTLCJ(&(#NS#.]!G!)YYH ]=HJCK6HMIT+SI&TK*.$C&
M68D@ <9XYY.#@9.#TKS"VTS6_$S-<-(UN <!6:2 =S@*HR0,XW-R>!DX. #U
MVBO,OA[XYN&N#I%[EI 656X+*8P=RL1]X?*?FY.>I(.1Z5-,L*EW("J"22<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %9GB#_5C_ 'A_(UIUF>(/]6/]X?R- &G1110 4444 %%%% !1110
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MN<L2H7E03\H;&.#7+HTFJP0^''+"5)BDY   A@PP8<$@,"@C8J-Q')YY]0H
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M7'<7&JI;VC;&FLPC28)*)YC,S#'0_* #QR0 02"-KQ%_R$=/_P"WK_T4*/\
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M@CD]3K5B>#[*VM[=7LT:.*;]YM?=NRP R=Y)Z =#@]02#D[= !1110 4444
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M\O\ U7^SN_U?X=?P[UZ'X5UZ;0M-%W?*S(I0)L\LD1,B",XW+QDXYRW/(QR
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MM.LSQ!_JQ_O#^1H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** *6L?ZIOP_F*-'_ -4OX_S-&L?ZIOP_F*-'_P!4OX_S- %V
MBBB@#C_B WV!K34LL/L]P Y W*(Y1B0D8)Z  'WXY(J7Q_\ Z<L.ECK>3*&
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MKO\ J6_#_P!"%% '"W/WC_GM452W/WC_ )[5%0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5N^#O]<W_ %S/_H2UA5N^#O\ 7-_US/\ Z$M '8T4
M44 <U=?#ZU=C-!OMY&QEK9S$2,?=P,J < G &2,^N60_#RW9@]PTMR4(*_:9
M2X7UP!@$' R""#@5U%% #(85A4(@ 50  !@ #@  = *I?V(GVG^T,MYGD^5C
M(V[=^_.,9SGWQCM6A10!DZWX8@UG#2K^\7&V1#MD4C.TAQSP3D Y&><5D/\
M#:&X(%Q-<3HISLFF+)G! / !R,\8(_+(KK:* ,S3?#\6G2RW$>09Q$"O 11$
MNQ0H &!CZ^V*BUSPK#J[+*VY)D&%EB8I(H/4 CJ#R.0< G&,UL44 <I'\.(&
M=9;B2:XV?=6XEWJ#D'.,#TY!R".H-='J-DM_$]N^0LJ,I(ZX8$'&<\\U8HH
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M:[H46N1&VG&5;H1]Y3V8'L1_]8Y!(.A10!S7A_P%#H*310/+_I"@%BR[EP&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$#) S@#.!G)&:ZNB@ KEYOA]"&)MY9[=6))2WE*(6/5MI!P>@XP,  "NHHH
MQ/#_ (0@T(M)&&:63.^21MTC9);D].O7 &< G)&:VZ** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MH:[_ *EOP_\ 0A11KO\ J6_#_P!"%% '"W/WC_GM452W/WC_ )[5%0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5J^'+]+&0O(< H1T)YR#V!]*R
MJ5;=I_E12QZX4$G]* .W_P"$IMO[_P#XZW^%'_"4VW]__P =;_"N*_LF;_GF
M_P#WPW^%']DS?\\W_P"^&_PH [7_ (2FV_O_ /CK?X4?\)3;?W__ !UO\*XK
M^R9O^>;_ /?#?X4?V3-_SS?_ +X;_"@#M?\ A*;;^_\ ^.M_A1_PE-M_?_\
M'6_PKBO[)F_YYO\ ]\-_A1_9,W_/-_\ OAO\* .U_P"$IMO[_P#XZW^%'_"4
MVW]__P =;_"N*_LF;_GF_P#WPW^%']DS?\\W_P"^&_PH [7_ (2FV_O_ /CK
M?X4?\)3;?W__ !UO\*XK^R9O^>;_ /?#?X4?V3-_SS?_ +X;_"@#M?\ A*;;
M^_\ ^.M_A1_PE-M_?_\ '6_PKBO[)F_YYO\ ]\-_A1_9,W_/-_\ OAO\* .U
M_P"$IMO[_P#XZW^%'_"4VW]__P =;_"N*_LF;_GF_P#WPW^%']DS?\\W_P"^
M&_PH [7_ (2FV_O_ /CK?X4?\)3;?W__ !UO\*XK^R9O^>;_ /?#?X4?V3-_
MSS?_ +X;_"@#M?\ A*;;^_\ ^.M_A1_PE-M_?_\ '6_PKBO[)F_YYO\ ]\-_
MA1_9,W_/-_\ OAO\* .U_P"$IMO[_P#XZW^%'_"4VW]__P =;_"N*_LF;_GF
M_P#WPW^%']DS?\\W_P"^&_PH [7_ (2FV_O_ /CK?X4?\)3;?W__ !UO\*XK
M^R9O^>;_ /?#?X4?V3-_SS?_ +X;_"@#M?\ A*;;^_\ ^.M_A1_PE-M_?_\
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M^R9O^>;_ /?#?X4?V3-_SS?_ +X;_"@#M?\ A*;;^_\ ^.M_A1_PE-M_?_\
M'6_PKBO[)F_YYO\ ]\-_A1_9,W_/-_\ OAO\* .U_P"$IMO[_P#XZW^%'_"4
MVW]__P =;_"N*_LF;_GF_P#WPW^%']DS?\\W_P"^&_PH [7_ (2FV_O_ /CK
M?X4?\)3;?W__ !UO\*XK^R9O^>;_ /?#?X4?V3-_SS?_ +X;_"@#M?\ A*;;
M^_\ ^.M_A1_PE-M_?_\ '6_PKBO[)F_YYO\ ]\-_A1_9,W_/-_\ OAO\* .U
M_P"$IMO[_P#XZW^%'_"4VW]__P =;_"N*_LF;_GF_P#WPW^%']DS?\\W_P"^
M&_PH [7_ (2FV_O_ /CK?X4?\)3;?W__ !UO\*XK^R9O^>;_ /?#?X4?V3-_
MSS?_ +X;_"@#M?\ A*;;^_\ ^.M_A1_PE-M_?_\ '6_PKBO[)F_YYO\ ]\-_
MA1_9,W_/-_\ OAO\* .U_P"$IMO[_P#XZW^%'_"4VW]__P =;_"N*_LF;_GF
M_P#WPW^%']DS?\\W_P"^&_PH [7_ (2FV_O_ /CK?X4?\)3;?W__ !UO\*XK
M^R9O^>;_ /?#?X4?V3-_SS?_ +X;_"@#M?\ A*;;^_\ ^.M_A1_PE-M_?_\
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MF_YYO_WPW^%(VE3+R8WP/]AO\* .HT?Q!!;H5=L'<3]UCV'H*O?\)3;?W_\
MQUO\*XB/3I9.51B/92?Z4[^R9O\ GF__ 'PW^% ':_\ "4VW]_\ \=;_  H_
MX2FV_O\ _CK?X5Q7]DS?\\W_ .^&_P */[)F_P">;_\ ?#?X4 =K_P )3;?W
M_P#QUO\ "C_A*;;^_P#^.M_A7%?V3-_SS?\ [X;_  H_LF;_ )YO_P!\-_A0
M!VO_  E-M_?_ /'6_P */^$IMO[_ /XZW^%<5_9,W_/-_P#OAO\ "C^R9O\
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MMO[_ /XZW^%<5_9,W_/-_P#OAO\ "C^R9O\ GF__ 'PW^% ':_\ "4VW]_\
M\=;_  H_X2FV_O\ _CK?X5Q7]DS?\\W_ .^&_P */[)F_P">;_\ ?#?X4 =K
M_P )3;?W_P#QUO\ "C_A*;;^_P#^.M_A7%?V3-_SS?\ [X;_  H_LF;_ )YO
M_P!\-_A0!VO_  E-M_?_ /'6_P */^$IMO[_ /XZW^%<5_9,W_/-_P#OAO\
M"C^R9O\ GF__ 'PW^% ':_\ "4VW]_\ \=;_  H_X2FV_O\ _CK?X5Q7]DS?
M\\W_ .^&_P */[)F_P">;_\ ?#?X4 =K_P )3;?W_P#QUO\ "C_A*;;^_P#^
M.M_A7%?V3-_SS?\ [X;_  H_LF;_ )YO_P!\-_A0!VO_  E-M_?_ /'6_P *
M/^$IMO[_ /XZW^%<5_9,W_/-_P#OAO\ "C^R9O\ GF__ 'PW^% ':_\ "4VW
M]_\ \=;_  H_X2FV_O\ _CK?X5Q7]DS?\\W_ .^&_P */[)F_P">;_\ ?#?X
M4 =K_P )3;?W_P#QUO\ "C_A*;;^_P#^.M_A7%?V3-_SS?\ [X;_  H_LF;_
M )YO_P!\-_A0!VO_  E-M_?_ /'6_P */^$IMO[_ /XZW^%<5_9,W_/-_P#O
MAO\ "C^R9O\ GF__ 'PW^% ':_\ "4VW]_\ \=;_  H_X2FV_O\ _CK?X5Q7
M]DS?\\W_ .^&_P */[)F_P">;_\ ?#?X4 =K_P )3;?W_P#QUO\ "C_A*;;^
M_P#^.M_A7%?V3-_SS?\ [X;_  H_LF;_ )YO_P!\-_A0!VO_  E-M_?_ /'6
M_P */^$IMO[_ /XZW^%<5_9,W_/-_P#OAO\ "C^R9O\ GF__ 'PW^% ':_\
M"4VW]_\ \=;_  H_X2FV_O\ _CK?X5Q7]DS?\\W_ .^&_P */[)F_P">;_\
M?#?X4 =K_P )3;?W_P#QUO\ "C_A*;;^_P#^.M_A7%?V3-_SS?\ [X;_  H_
MLF;_ )YO_P!\-_A0!T^L>((+A J-D[@?NL.Q]163=16]VWF&;:2J@CRV.,*!
MU_"LR33I8^61@/=2/Z4JZ5,W(C?!_P!AO\*TI59TG>+LS*OAZ=>/+-76Y<_L
MZV_Y^/\ R$W^-']G6W_/Q_Y";_&JG]DS?\\W_P"^&_PH_LF;_GF__?#?X5M]
M>K_S?@O\CF_LK"?R_B_\RW_9UM_S\?\ D)O\:/[.MO\ GX_\A-_C53^R9O\
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M^;\%_D']E83^7\7_ )EO^SK;_GX_\A-_C1_9UM_S\?\ D)O\:J?V3-_SS?\
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M?^0F_P :J?V3-_SS?_OAO\*/[)F_YYO_ -\-_A1]>K_S?@O\@_LK"?R_B_\
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MS?\ /-_^^&_PH^O5_P";\%_D']E83^7\7_F6_P"SK;_GX_\ (3?XT?V=;?\
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MEO\ LZV_Y^/_ "$W^-']G6W_ #\?^0F_QJI_9,W_ #S?_OAO\*/[)F_YYO\
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MY";_ !H_LZV_Y^/_ "$W^-5/[)F_YYO_ -\-_A1_9,W_ #S?_OAO\*/KU?\
MF_!?Y!_96$_E_%_YEO\ LZV_Y^/_ "$W^-']G6W_ #\?^0F_QJI_9,W_ #S?
M_OAO\*/[)F_YYO\ ]\-_A1]>K_S?@O\ (/[*PG\OXO\ S+?]G6W_ #\?^0F_
MQH_LZV_Y^/\ R$W^-5/[)F_YYO\ ]\-_A1_9,W_/-_\ OAO\*/KU?^;\%_D'
M]E83^7\7_F6_[.MO^?C_ ,A-_C1_9UM_S\?^0F_QJI_9,W_/-_\ OAO\*/[)
MF_YYO_WPW^%'UZO_ #?@O\@_LK"?R_B_\RW_ &=;?\_'_D)O\:/[.MO^?C_R
M$W^-5/[)F_YYO_WPW^%']DS?\\W_ .^&_P */KU?^;\%_D']E83^7\7_ )EO
M^SK;_GX_\A-_C1_9UM_S\?\ D)O\:J?V3-_SS?\ [X;_  H_LF;_ )YO_P!\
M-_A1]>K_ ,WX+_(/[*PG\OXO_,M_V=;?\_'_ )";_&C^SK;_ )^/_(3?XU4_
MLF;_ )YO_P!\-_A1_9,W_/-_^^&_PH^O5_YOP7^0?V5A/Y?Q?^9;_LZV_P"?
MC_R$W^-']G6W_/Q_Y";_ !JI_9,W_/-_^^&_PH_LF;_GF_\ WPW^%'UZO_-^
M"_R#^RL)_+^+_P RW_9UM_S\?^0F_P :/[.MO^?C_P A-_C53^R9O^>;_P#?
M#?X4?V3-_P \W_[X;_"CZ]7_ )OP7^0?V5A/Y?Q?^9;_ +.MO^?C_P A-_C1
M_9UM_P _'_D)O\:J?V3-_P \W_[X;_"C^R9O^>;_ /?#?X4?7J_\WX+_ "#^
MRL)_+^+_ ,RW_9UM_P _'_D)O\:/[.MO^?C_ ,A-_C53^R9O^>;_ /?#?X4?
MV3-_SS?_ +X;_"CZ]7_F_!?Y!_96$_E_%_YEO^SK;_GX_P#(3?XT?V=;?\_'
M_D)O\:J?V3-_SS?_ +X;_"C^R9O^>;_]\-_A1]>K_P WX+_(/[*PG\OXO_,M
M_P!G6W_/Q_Y";_&C^SK;_GX_\A-_C53^R9O^>;_]\-_A1_9,W_/-_P#OAO\
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M9O\ GF__ 'PW^%'UZO\ S?@O\@_LK"?R_B_\RW_9UM_S\?\ D)O\:/[.MO\
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M;_"C^R9O^>;_ /?#?X4 =K_PE-M_?_\ '6_PH_X2FV_O_P#CK?X5Q7]DS?\
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M-_SS?_OAO\* .U_X2FV_O_\ CK?X4?\ "4VW]_\ \=;_  KBO[)F_P">;_\
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MO_\ CK?X4?\ "4VW]_\ \=;_  KBO[)F_P">;_\ ?#?X4?V3-_SS?_OAO\*
M.U_X2FV_O_\ CK?X4?\ "4VW]_\ \=;_  KBO[)F_P">;_\ ?#?X4?V3-_SS
M?_OAO\* .U_X2FV_O_\ CK?X4?\ "4VW]_\ \=;_  KBO[)F_P">;_\ ?#?X
M4?V3-_SS?_OAO\* .U_X2FV_O_\ CK?X4?\ "4VW]_\ \=;_  KBO[)F_P">
M;_\ ?#?X4?V3-_SS?_OAO\* .U_X2FV_O_\ CK?X4?\ "4VW]_\ \=;_  KB
MO[)F_P">;_\ ?#?X4?V3-_SS?_OAO\* .U_X2FV_O_\ CK?X4?\ "4VW]_\
M\=;_  KBO[)F_P">;_\ ?#?X4?V3-_SS?_OAO\* .U_X2FV_O_\ CK?X4?\
M"4VW]_\ \=;_  KBO[)F_P">;_\ ?#?X4?V3-_SS?_OAO\* .U_X2FV_O_\
MCK?X4?\ "4VW]_\ \=;_  KBO[)F_P">;_\ ?#?X4?V3-_SS?_OAO\* .U_X
M2FV_O_\ CK?X4?\ "4VW]_\ \=;_  KBO[)F_P">;_\ ?#?X4?V3-_SS?_OA
MO\* .U_X2FV_O_\ CK?X4?\ "4VW]_\ \=;_  KBO[)F_P">;_\ ?#?X4?V3
M-_SS?_OAO\* .U_X2FV_O_\ CK?X4?\ "4VW]_\ \=;_  KBO[)F_P">;_\
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MO_\ CK?X4?\ "4VW]_\ \=;_  KBO[)F_P">;_\ ?#?X4?V3-_SS?_OAO\*
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MX2FV_O\ _CK?X4?\)3;?W_\ QUO\*XK^R9O^>;_]\-_A1_9,W_/-_P#OAO\
M"@#M?^$IMO[_ /XZW^%'_"4VW]__ ,=;_"N*_LF;_GF__?#?X4?V3-_SS?\
M[X;_  H [7_A*;;^_P#^.M_A1_PE-M_?_P#'6_PKBO[)F_YYO_WPW^%']DS?
M\\W_ .^&_P * .U_X2FV_O\ _CK?X4?\)3;?W_\ QUO\*XK^R9O^>;_]\-_A
M1_9,W_/-_P#OAO\ "@#M?^$IMO[_ /XZW^%'_"4VW]__ ,=;_"N*_LF;_GF_
M_?#?X4?V3-_SS?\ [X;_  H [7_A*;;^_P#^.M_A1_PE-M_?_P#'6_PKBO[)
MF_YYO_WPW^%']DS?\\W_ .^&_P * .U_X2FV_O\ _CK?X4?\)3;?W_\ QUO\
M*XK^R9O^>;_]\-_A1_9,W_/-_P#OAO\ "@#M?^$IMO[_ /XZW^%'_"4VW]__
M ,=;_"N*_LF;_GF__?#?X4?V3-_SS?\ [X;_  H [7_A*;;^_P#^.M_A1_PE
M-M_?_P#'6_PKBO[)F_YYO_WPW^%']DS?\\W_ .^&_P * .U_X2FV_O\ _CK?
MX4?\)3;?W_\ QUO\*XK^R9O^>;_]\-_A1_9,W_/-_P#OAO\ "@#M?^$IMO[_
M /XZW^%'_"4VW]__ ,=;_"N*_LF;_GF__?#?X4?V3-_SS?\ [X;_  H [7_A
M*;;^_P#^.M_A1_PE-M_?_P#'6_PKBO[)F_YYO_WPW^%']DS?\\W_ .^&_P *
M .U_X2FV_O\ _CK?X4?\)3;?W_\ QUO\*XK^R9O^>;_]\-_A1_9,W_/-_P#O
MAO\ "@#M?^$IMO[_ /XZW^%'_"4VW]__ ,=;_"N*_LF;_GF__?#?X4?V3-_S
MS?\ [X;_  H [7_A*;;^_P#^.M_A1_PE-M_?_P#'6_PKBO[)F_YYO_WPW^%'
M]DS?\\W_ .^&_P * .U_X2FV_O\ _CK?X4?\)3;?W_\ QUO\*XK^R9O^>;_]
M\-_A1_9,W_/-_P#OAO\ "@#M?^$IMO[_ /XZW^%'_"4VW]__ ,=;_"N*_LF;
M_GF__?#?X4?V3-_SS?\ [X;_  H [7_A*;;^_P#^.M_A1_PE-M_?_P#'6_PK
MBO[)F_YYO_WPW^%']DS?\\W_ .^&_P * .U_X2FV_O\ _CK?X4?\)3;?W_\
MQUO\*XK^R9O^>;_]\-_A1_9,W_/-_P#OAO\ "@#K-2U^"[C:-&RQQ@;6'0@]
MQ17+P:=+"P9D8 =RI _,BB@!MS]X_P">U15+<_>/^>U14 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %;O@[_ %S?]<S_ .A+6%6[X._US?\ 7,_^
MA+0!V-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %07O^K?_=;^53U!>_ZM_P#=;^5 %/P__JS_ +Q_D*TZ
MS/#_ /JS_O'^0K3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]FK_ ,)3<_W_ /QU?\*/^$IN?[__ (ZO^%95%'U>E_*ON0?7*_\ /+[V:O\
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M_"C_ (2FY_O_ /CJ_P"%95%'U>E_*ON0?7*_\\OO9J_\)3<_W_\ QU?\*/\
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MV:O_  E-S_?_ /'5_P */^$IN?[_ /XZO^%95%'U>E_*ON0?7*_\\OO9J_\
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M]FK_ ,)3<_W_ /QU?\*/^$IN?[__ (ZO^%95%'U>E_*ON0?7*_\ /+[V:O\
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M"C'.2>W3KCK885A4(@ 50  !@ #@  = *?0!1T?6H=8C\^W<.F2,C(P1U!!
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M*ME!$TURZ;PBD(H4'&YG;A1UQUY !QD9 -ZBN2EGUBW&\I:R $92-I%<C(R
MSD*#CN?R/0Z7A;Q(=<1B\3PR1MM=) >"1N&&(7.00<8!&>1@@D VZ*Y>X\43
MZA));:?$&,3E'FF)6%67DJ /G<]0<8P<'E3FJEWK.JZ2/-EMXITP>+5G#@Y
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M.0H(Y9BRCH#U.>0&"ZMMK]WILJ1:BD7ESLJ1R6Y8J)&SA&5SNYQU P.,]25
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3==<Z+?07B@^7=D02XQC<?\ 4MC(RW4%CG"#  .,]5#"L*A$ "J   ,  <
M#H!6?XET<:Q;2VAQF1"%R2 &'*$D<X# '^AZ4 8LKG6M3\@@^3IZ!SG&#-*!
ML)!)R%3)4X!5@>>1GK:P?!>CR:9;@3X\^5WDE(.<NYSVX! P"%^7(XSU.]0!
MRG@#_E\_["%Q_P"RT> /^7S_ +"%Q_[+5OPAI<FG_:?-7;YMY-(O(.5;;M/!
M.,XZ'GVK$TLW^B/<)':>:DUU+*K?:(TX<C'!R>@SVZ]* .[KDM2F6_U6VA0C
M=:1322<]I0J*O&?FY!(./E(()S3+G5=5O1Y45JD#-G]Y+,LBJ,'^%!G.<8X8
M>HQR-7PUX:_L?S)9)&EGG8&21AC.,[0%R0H4'@?TP  9_P#Q.?\ IS_\CUT&
ME^=Y:_:=GF\[O*W;.IQC=STQG/?-6Z* .4_YC/\ W#__ &O75US_ /9<G]I?
M;=O[K['Y>[(^]YN[&,YZ<YQCWKH* .2\0^$+2!GU,R26QP3(\$ACW9QU&#R2
M.B@%F/.215'X>^%/+9M6F+.\_,)E.^58R/E+-DC<RXSCH!C/)4;&MZ/+KDZ0
MOE+2$AW&5/G-D%4V\_(N/FW?>)P%X##HZ "BBB@#C_!<QTN:?17&!$QD@ZX,
M,C9P"5&=I."22220.%H\'3'6[BXU<C]V<0P$Y!\M"2S8*KD,V#SD@@KQCE_C
MSPK)JVRXM@OGJ'C._@&.93&Q) R2F[<.>/FX8D ]%I6F)I<26L0PD:@#IDXZ
MDX &2>2<<DDT <UX"*R2WTA.93>2*V6);8G$8P3P!\P'TQVX["N:U3PU-%.V
MHV,BI*Z@21RAC%)C 4G!RI4=".O XRV:\NNZI,-D=DJ,2!ODN$=%Y&257#$8
M]#GV/0@$-M%&FMR%,;FL@7P<_-YB@9&>#L"\<<8/?)F\#S+<S7TK$&;[6R-S
MSLC&V+Y1T ^8 XR<').*J>%_"-QI=\;R=C*9;8^9(2,>:9 =JKP=H51CC''&
M.%&GJGAJ:*=M1L9%25U DCE#&*3& I.#E2HZ$=>!QEL@'2UG^(;IK2VGFC.'
MCAD93@'!5"0<'CK6%+KNJ3#9'9*C$@;Y+A'1>1DE5PQ&/0Y]CT.KX;TRXL58
MW<YFDD()^4*BX4 A0 ...O /7:"6) (? L4<=C;B+&WRE)P<_,>7YR>=Y.1V
M/'&,5O5Q]OH=WX8W"QVSVQ8D02-L=,]DD.1C))(;L.,L2237NJZF1$D*6B_Q
M2/(LS8ROW57C.,_>&#ZJ<&@"7XI?\@Z?_MG_ .C4H^*7_(.G_P"V?_HU*/%'
MA^>XTUK!&:>;;&-SE59BKJ2220.@[DGU)/)M^/=+DU6REMH%W2/LP,@9Q(I/
M)('0'O0!M6EJMHBPQC"1J%49)P%& ,GGI7->(O\ D(Z?_P!O7_HH5U=<_K.E
MR7-[9W*+F.#[1O.0,;XP%X)R<GT!]Z .<\J\FU2[EM/*+1)"G^D&3Y5= VU0
MAQ@L,G/?IU.=C_B<_P#3G_Y'JQXD\-RW,J:A9N$NH@%^<GRW3.2C 9XY)! S
MGWVLM677=4F&R.R5&) WR7".B\C)*KAB,>AS['H0"7P_I-[#=27ET8 LL2JP
M@#?,R-\C'>,Y"DCKTP,<#'45B>%M!?2D9IY&EGF;?(Q)V[L8PJ\    = 2 .
M@"JNW0!RGQ2_Y!T__;/_ -&I6QXGF:&TN'0D,L$I!!P00A(((Z$52\?V/VZP
MN(\XQ&7SC/\ JR),=1UVX]LYYZ5JZ3??VA#'<XV^;&CXSG&Y0<9P,XSZ4 9G
M@6*..QMQ%C;Y2DX.?F/+\Y/.\G(['CC&*WJX^WT.[\,;A8[9[8L2()&V.F>R
M2'(QDDD-V'&6))9=W&JZP/LZPK:*P.Z5I1*X!(^YLQAL9Z_@RG!H S?"Y6TL
M-1-L<)'-=^6R,3@+&-A#9STQ@Y]\UT_@6*..QMQ%C;Y2DX.?F/+\Y/.\G(['
MCC&*J^ /#KZ!%-;N"%^TR&,DJ24PH5CM[G'L?857M]#N_#&X6.V>V+$B"1MC
MIGLDAR,9))#=AQEB20#L*\Z\+E;2PU$VQPD<UWY;(Q. L8V$-G/3&#GWS6E=
MW&JZP/LZPK:*P.Z5I1*X!(^YLQAL9Z_@RG!JWX \.OH$4UNX(7[3(8R2I)3"
MA6.WN<>Q]A0!:\"Q1QV-N(L;?*4G!S\QY?G)YWDY'8\<8Q6]7&6VB7GAAF6R
M"S6A.Y89'*R*3G*HY!7;D[OF[9&-Q+,^ZEU365,*QI:*<!G:7S9,$\E-@ !
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MOUI%N&53&&.T\D9.#^'3M1[#W4M%JGHNPOK?O-MR=XM:N^YN>"O]<W_7,_\
MH2U!X:O%C+P2'"3*03D#& >YX'!/KSBLJ"X: [D8J>F5)!_2HZ<J',YWZV_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ72+=;29@YB+!6!)RF25R"/E(!QM!8  8/IL44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9/B?3Y=2@:U@95,N
M%9F[(?OX&#N)&0!E>N=P(K6HH AM+5;1%AC&$C4*HR3@*, 9//2IJ** "H+W
M_5O_ +K?RJ>H+W_5O_NM_*@"GX?_ -6?]X_R%:=9GA__ %9_WC_(5IT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!F>(/]6/\ >'\C7&:W_K3_ +L?_H"UV?B#_5C_ 'A_(URF
MK:?+-)N5&(*Q\A21]Q>X%=N6M*J[]OU1Y>=1<J$4E?WOT9D45;_LF;_GF_\
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MX;_"C^R9O^>;_P#?#?X4>TAW0>QJ=G]Q4HJW_9,W_/-_^^&_PH_LF;_GF_\
MWPW^%'M(=T'L:G9_<5**M_V3-_SS?_OAO\*/[)F_YYO_ -\-_A1[2'=![&IV
M?W%2BK?]DS?\\W_[X;_"C^R9O^>;_P#?#?X4>TAW0>QJ=G]Q4HJW_9,W_/-_
M^^&_PH_LF;_GF_\ WPW^%'M(=T'L:G9_<5**M_V3-_SS?_OAO\*/[)F_YYO_
M -\-_A1[2'=![&IV?W%2BK?]DS?\\W_[X;_"C^R9O^>;_P#?#?X4>TAW0>QJ
M=G]Q4HJW_9,W_/-_^^&_PH_LF;_GF_\ WPW^%'M(=T'L:G9_<5**M_V3-_SS
M?_OAO\*/[)F_YYO_ -\-_A1[2'=![&IV?W%2BK?]DS?\\W_[X;_"C^R9O^>;
M_P#?#?X4>TAW0>QJ=G]Q4HJW_9,W_/-_^^&_PH_LF;_GF_\ WPW^%'M(=T'L
M:G9_<5**M_V3-_SS?_OAO\*/[)F_YYO_ -\-_A1[2'=![&IV?W%2BK?]DS?\
M\W_[X;_"C^R9O^>;_P#?#?X4>TAW0>QJ=G]Q4HJW_9,W_/-_^^&_PJ-;"1SM
M",2.H"G/\J/:0[H/8U.S^X@HJW_9,W_/-_\ OAO\*/[)F_YYO_WPW^%'M(=T
M'L:G9_<5**M_V3-_SS?_ +X;_"C^R9O^>;_]\-_A1[2'=![&IV?W%2BK?]DS
M?\\W_P"^&_PH_LF;_GF__?#?X4>TAW0>QJ=G]Q4HJW_9,W_/-_\ OAO\*/[)
MF_YYO_WPW^%'M(=T'L:G9_<5**M_V3-_SS?_ +X;_"C^R9O^>;_]\-_A1[2'
M=![&IV?W%2BK?]DS?\\W_P"^&_PH_LF;_GF__?#?X4>TAW0>QJ=G]Q4HJW_9
M,W_/-_\ OAO\*/[)F_YYO_WPW^%'M(=T'L:G9_<5**M_V3-_SS?_ +X;_"C^
MR9O^>;_]\-_A1[2'=![&IV?W%2BK?]DS?\\W_P"^&_PH_LF;_GF__?#?X4>T
MAW0>QJ=G]Q4HJW_9,W_/-_\ OAO\*/[)F_YYO_WPW^%'M(=T'L:G9_<5**M_
MV3-_SS?_ +X;_"C^R9O^>;_]\-_A1[2'=![&IV?W%2BK?]DS?\\W_P"^&_PH
M_LF;_GF__?#?X4>TAW0>QJ=G]Q4HJW_9,W_/-_\ OAO\*/[)F_YYO_WPW^%'
MM(=T'L:G9_<5**M_V3-_SS?_ +X;_"C^R9O^>;_]\-_A1[2'=![&IV?W%2BK
M?]DS?\\W_P"^&_PH_LF;_GF__?#?X4>TAW0>QJ=G]Q4HJW_9,W_/-_\ OAO\
M*/[)F_YYO_WPW^%'M(=T'L:G9_<5**M_V3-_SS?_ +X;_"C^R9O^>;_]\-_A
M1[2'=![&IV?W%2BK?]DS?\\W_P"^&_PH_LF;_GF__?#?X4>TAW0>QJ=G]Q4H
MJW_9,W_/-_\ OAO\*/[)F_YYO_WPW^%'M(=T'L:G9_<5**M_V3-_SS?_ +X;
M_"C^R9O^>;_]\-_A1[2'=![&IV?W%2BK?]DS?\\W_P"^&_PH_LF;_GF__?#?
MX4>TAW0>QJ=G]Q4HJW_9,W_/-_\ OAO\*/[)F_YYO_WPW^%'M(=T'L:G9_<5
M**G:PD0[2C GH"IS_*I/[)F_YYO_ -\-_A1[2'=![&IV?W%2BK?]DS?\\W_[
MX;_"C^R9O^>;_P#?#?X4>TAW0>QJ=G]Q4HJW_9,W_/-_^^&_PH_LF;_GF_\
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M_P#CW_UJUJ* ,G^W?]G_ ,>_^M1_;O\ L_\ CW_UJUJ* ,G^W?\ 9_\ 'O\
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M]_\ 6K6HH R?[=_V?_'O_K4?V[_L_P#CW_UJUJ* ,G^W?]G_ ,>_^M1_;O\
ML_\ CW_UJUJ* ,G^W?\ 9_\ 'O\ ZU']N_[/_CW_ -:M:B@#)_MW_9_\>_\
MK4?V[_L_^/?_ %JUJ* ,G^W?]G_Q[_ZU']N_[/\ X]_]:M:B@#)_MW_9_P#'
MO_K4?V[_ +/_ (]_]:M:B@#)_MW_ &?_ ![_ .M1_;O^S_X]_P#6K6HH R?[
M=_V?_'O_ *U']N_[/_CW_P!:M:B@#)_MW_9_\>_^M1_;O^S_ ./?_6K6HH R
M?[=_V?\ Q[_ZU']N_P"S_P"/?_6K6HH R?[=_P!G_P >_P#K4?V[_L_^/?\
MUJUJ* ,G^W?]G_Q[_P"M1_;O^S_X]_\ 6K6HH R?[=_V?_'O_K4?V[_L_P#C
MW_UJUJ* ,G^W?]G_ ,>_^M1_;O\ L_\ CW_UJUJ* ,G^W?\ 9_\ 'O\ ZU']
MN_[/_CW_ -:M:B@#)_MW_9_\>_\ K4?V[_L_^/?_ %JUJ* ,G^W?]G_Q[_ZU
M']N_[/\ X]_]:M:B@#)_MW_9_P#'O_K4?V[_ +/_ (]_]:M:B@#)_MW_ &?_
M ![_ .M3)]9\U2FW[P(Z^H^E;-0W?W&_W3_*@#"T_5OL:E-N<G/7'8>U6?\
MA(O]C_Q[_P"M5K1/N'_>/\A6A0!B_P#"1?['_CW_ -:C_A(O]C_Q[_ZU;5%
M&+_PD7^Q_P"/?_6H_P"$B_V/_'O_ *U;5% &+_PD7^Q_X]_]:C_A(O\ 8_\
M'O\ ZU;5% &+_P )%_L?^/?_ %J/^$B_V/\ Q[_ZU;5% &+_ ,)%_L?^/?\
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MD7^Q_P"/?_6H_P"$B_V/_'O_ *U;5% &+_PD7^Q_X]_]:C_A(O\ 8_\ 'O\
MZU;5% &+_P )%_L?^/?_ %J/^$B_V/\ Q[_ZU;5% &+_ ,)%_L?^/?\ UJ/^
M$B_V/_'O_K5M44 8O_"1?['_ (]_]:C_ (2+_8_\>_\ K5M44 8O_"1?['_C
MW_UJ/^$B_P!C_P >_P#K5M44 8O_  D7^Q_X]_\ 6H_X2+_8_P#'O_K5M44
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M  D7^Q_X]_\ 6H_X2+_8_P#'O_K5G?\ "<_],_\ Q_\ ^QH_X3G_ *9_^/\
M_P!C1]1K_P OXK_,/[5PG\WX/_(T?^$B_P!C_P >_P#K4?\ "1?['_CW_P!:
ML[_A.?\ IG_X_P#_ &-'_"<_],__ !__ .QH^HU_Y?Q7^8?VKA/YOP?^1H_\
M)%_L?^/?_6H_X2+_ &/_ ![_ .M6=_PG/_3/_P ?_P#L:/\ A.?^F?\ X_\
M_8T?4:_\OXK_ ##^U<)_-^#_ ,C1_P"$B_V/_'O_ *U'_"1?['_CW_UJSO\
MA.?^F?\ X_\ _8T?\)S_ -,__'__ +&CZC7_ )?Q7^8?VKA/YOP?^1H_\)%_
ML?\ CW_UJ/\ A(O]C_Q[_P"M6=_PG/\ TS_\?_\ L:/^$Y_Z9_\ C_\ ]C1]
M1K_R_BO\P_M7"?S?@_\ (T?^$B_V/_'O_K4?\)%_L?\ CW_UJSO^$Y_Z9_\
MC_\ ]C1_PG/_ $S_ /'_ /[&CZC7_E_%?YA_:N$_F_!_Y&C_ ,)%_L?^/?\
MUJ/^$B_V/_'O_K5G?\)S_P!,_P#Q_P#^QH_X3G_IG_X__P#8T?4:_P#+^*_S
M#^U<)_-^#_R-'_A(O]C_ ,>_^M1_PD7^Q_X]_P#6K._X3G_IG_X__P#8T?\
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M_P"M6=_PG/\ TS_\?_\ L:/^$Y_Z9_\ C_\ ]C1]1K_R_BO\P_M7"?S?@_\
M(T?^$B_V/_'O_K4?\)%_L?\ CW_UJSO^$Y_Z9_\ C_\ ]C1_PG/_ $S_ /'_
M /[&CZC7_E_%?YA_:N$_F_!_Y&C_ ,)%_L?^/?\ UJ/^$B_V/_'O_K5G?\)S
M_P!,_P#Q_P#^QH_X3G_IG_X__P#8T?4:_P#+^*_S#^U<)_-^#_R-'_A(O]C_
M ,>_^M1_PD7^Q_X]_P#6K._X3G_IG_X__P#8T?\ "<_],_\ Q_\ ^QH^HU_Y
M?Q7^8?VKA/YOP?\ D:/_  D7^Q_X]_\ 6H_X2+_8_P#'O_K5G?\ "<_],_\
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MX3G_ *9_^/\ _P!C1]1K_P OXK_,/[5PG\WX/_(T?^$B_P!C_P >_P#K4?\
M"1?['_CW_P!:L[_A.?\ IG_X_P#_ &-'_"<_],__ !__ .QH^HU_Y?Q7^8?V
MKA/YOP?^1H_\)%_L?^/?_6H_X2+_ &/_ ![_ .M6=_PG/_3/_P ?_P#L:/\
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M_P OXK_,/[5PG\WX/_(T?^$B_P!C_P >_P#K4?\ "1?['_CW_P!:L[_A.?\
MIG_X_P#_ &-'_"<_],__ !__ .QH^HU_Y?Q7^8?VKA/YOP?^1H_\)%_L?^/?
M_6H_X2+_ &/_ ![_ .M6=_PG/_3/_P ?_P#L:/\ A.?^F?\ X_\ _8T?4:_\
MOXK_ ##^U<)_-^#_ ,C1_P"$B_V/_'O_ *U'_"1?['_CW_UJSO\ A.?^F?\
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M#_R-'_A(O]C_ ,>_^M1_PD7^Q_X]_P#6K._X3G_IG_X__P#8T?\ "<_],_\
MQ_\ ^QH^HU_Y?Q7^8?VKA/YOP?\ D:/_  D7^Q_X]_\ 6JG;:CY$C2XSNSQG
MU.?2HO\ A.?^F?\ X_\ _8U3MO%'D2-+LSNSQN]3GTH^HU_Y?Q7^8?VKA/YO
MP?\ D;O_  D7^Q_X]_\ 6H_X2+_8_P#'O_K5G?\ "<_],_\ Q_\ ^QH_X3G_
M *9_^/\ _P!C1]1K_P OXK_,/[5PG\WX/_(T?^$B_P!C_P >_P#K4?\ "1?[
M'_CW_P!:L[_A.?\ IG_X_P#_ &-'_"<_],__ !__ .QH^HU_Y?Q7^8?VKA/Y
MOP?^1H_\)%_L?^/?_6H_X2+_ &/_ ![_ .M6=_PG/_3/_P ?_P#L:/\ A.?^
MF?\ X_\ _8T?4:_\OXK_ ##^U<)_-^#_ ,C1_P"$B_V/_'O_ *U'_"1?['_C
MW_UJSO\ A.?^F?\ X_\ _8T?\)S_ -,__'__ +&CZC7_ )?Q7^8?VKA/YOP?
M^1H_\)%_L?\ CW_UJ/\ A(O]C_Q[_P"M6=_PG/\ TS_\?_\ L:/^$Y_Z9_\
MC_\ ]C1]1K_R_BO\P_M7"?S?@_\ (T?^$B_V/_'O_K4?\)%_L?\ CW_UJSO^
M$Y_Z9_\ C_\ ]C1_PG/_ $S_ /'_ /[&CZC7_E_%?YA_:N$_F_!_Y&C_ ,)%
M_L?^/?\ UJ/^$B_V/_'O_K5G?\)S_P!,_P#Q_P#^QH_X3G_IG_X__P#8T?4:
M_P#+^*_S#^U<)_-^#_R-'_A(O]C_ ,>_^M1_PD7^Q_X]_P#6K._X3G_IG_X_
M_P#8T?\ "<_],_\ Q_\ ^QH^HU_Y?Q7^8?VKA/YOP?\ D:/_  D7^Q_X]_\
M6H_X2+_8_P#'O_K5G?\ "<_],_\ Q_\ ^QH_X3G_ *9_^/\ _P!C1]1K_P O
MXK_,/[5PG\WX/_(T?^$B_P!C_P >_P#K4?\ "1?['_CW_P!:L[_A.?\ IG_X
M_P#_ &-'_"<_],__ !__ .QH^HU_Y?Q7^8?VKA/YOP?^1H_\)%_L?^/?_6H_
MX2+_ &/_ ![_ .M6=_PG/_3/_P ?_P#L:/\ A.?^F?\ X_\ _8T?4:_\OXK_
M ##^U<)_-^#_ ,C1_P"$B_V/_'O_ *U'_"1?['_CW_UJSO\ A.?^F?\ X_\
M_8T?\)S_ -,__'__ +&CZC7_ )?Q7^8?VKA/YOP?^1H_\)%_L?\ CW_UJ/\
MA(O]C_Q[_P"M6=_PG/\ TS_\?_\ L:/^$Y_Z9_\ C_\ ]C1]1K_R_BO\P_M7
M"?S?@_\ (T?^$B_V/_'O_K4?\)%_L?\ CW_UJSO^$Y_Z9_\ C_\ ]C1_PG/_
M $S_ /'_ /[&CZC7_E_%?YA_:N$_F_!_Y&C_ ,)%_L?^/?\ UJ/^$B_V/_'O
M_K5G?\)S_P!,_P#Q_P#^QH_X3G_IG_X__P#8T?4:_P#+^*_S#^U<)_-^#_R-
M'_A(O]C_ ,>_^M1_PD7^Q_X]_P#6K._X3G_IG_X__P#8T?\ "<_],_\ Q_\
M^QH^HU_Y?Q7^8?VKA/YOP?\ D:/_  D7^Q_X]_\ 6H_X2+_8_P#'O_K5G?\
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MZC7_ )?Q7^8?VKA/YOP?^1H_\)%_L?\ CW_UJ/\ A(O]C_Q[_P"M6=_PG/\
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M'_"1?['_ (]_]:MJB@#%_P"$B_V/_'O_ *U'_"1?['_CW_UJVJ* ,7_A(O\
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M (]_]:MJB@#%_P"$B_V/_'O_ *U'_"1?['_CW_UJVJ* ,7_A(O\ 8_\ 'O\
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M+_PD7^Q_X]_]:C_A(O\ 8_\ 'O\ ZU;5% &+_P )%_L?^/?_ %J/^$B_V/\
MQ[_ZU;5% &+_ ,)%_L?^/?\ UJ/^$B_V/_'O_K5M44 8O_"1?['_ (]_]:C_
M (2+_8_\>_\ K5M44 8O_"1?['_CW_UJ/^$B_P!C_P >_P#K5M44 8O_  D7
M^Q_X]_\ 6H_X2+_8_P#'O_K5M44 8O\ PD7^Q_X]_P#6H_X2+_8_\>_^M6U1
M0!B_\)%_L?\ CW_UJ/\ A(O]C_Q[_P"M6U10!B_\)%_L?^/?_6H_X2+_ &/_
M ![_ .M6U10!B_\ "1?['_CW_P!:C_A(O]C_ ,>_^M6U10!B_P#"1?['_CW_
M -:C_A(O]C_Q[_ZU;5% &+_PD7^Q_P"/?_6H_P"$B_V/_'O_ *U;5% &+_PD
M7^Q_X]_]:C_A(O\ 8_\ 'O\ ZU;5% &+_P )%_L?^/?_ %J/^$B_V/\ Q[_Z
MU;5% &+_ ,)%_L?^/?\ UJ/^$B_V/_'O_K5M44 8O_"1?['_ (]_]:C_ (2+
M_8_\>_\ K5M44 8O_"1?['_CW_UJ/^$B_P!C_P >_P#K5M44 8O_  D7^Q_X
M]_\ 6H_X2+_8_P#'O_K5M44 8O\ PD7^Q_X]_P#6H_X2+_8_\>_^M6U10!B_
M\)%_L?\ CW_UJ/\ A(O]C_Q[_P"M6U10!SNH:U]I0Q[<9QSG/0@^E%:>N_ZE
MOP_]"%% '"W/WC_GM452W/WC_GM45 !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=_<;_=/\JFJ&[^XW^Z?Y4 5=$^X?]X_R%:%9^B?</^\?Y"M"@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,SQ!_JQ_O#^1KC-;_P!:?]V/_P! 6NS\0?ZL?[P_D:XS6_\ 6G_=
MC_\ 0%KNRS^*_3]4>5GG\"/^)?DRA1117L'S@4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %7=)U9]-?>O(/WE[$?X^A[?3(JE12E%233V*A.5.2D
MG9H]-L;Y+Y!*AR#^8/H??_/2K%>;Z3JSZ:^]>0?O+V(_Q]#V^F17H%C?)?()
M4.0?S!]#[_YZ5XF+PCHNZ^$^HP&/CB8V>DENOU1FZG_KX_\ @/\ Z$:VJQ=3
M_P!?'_P'_P!"-;5<IW!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !69X@_U8_WA_(UIUF>(/\ 5C_>'\C0!IT444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4M8_U3?A_,4:/_JE_'^9H
MUC_5-^'\Q1H_^J7\?YF@"[1110 45#'=I*S1*REX\;E!!9=PR,CJ,CIGK4U
M!13(IEE&5((R1D'/*D@CZ@@@^AXHFF6%2[D!5!)).  .223T H ?13(9EF4.
MA!5@""#D$'D$$=0:?0 4444 %%%5-+U2/58UN8&W1OG!P1G!(/! /4'M0!;H
MHHH **J:7JD>JQK<P-NC?.#@C."0>" >H/:K= !1110 45GWFOP64L=I)(JR
MS?<4]3_09/ SC<>!DUH4 %%%5-4U2/2HVN9VVQIC)P3C) ' !/4CM0!;HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6K'*1,A7.<CS-V1UP!E<X ZDGO7*^//,_MAO(_UOF0;.GWMD>W[W'7'7CUH
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MJQ\:M>$<<>G*3N<^8^"1\HR%!&,$%LGKP5''(- 'G6F:[-I]RNJD$L968G
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M)])DU6[?592?W98YQC=)*#GMC !)(&,$KV->P33+"I=R J@DDG  ')))Z 4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH I:Q_JF_#^8HT?_5+^/\S1K'^J;\/YBC1_]4OX_P S0!=HHHH
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M!(P'<9VE05(/7<2>MJOI^GQZ=&MO"H6-!@ ?YY)ZDGDGD\U8H Y3P!_R^?\
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MASG 8 '=P/8@,PZ*Z\/6%HIEEAMT08RSQQJHR<#)(QUK5NK1+M3%*JNAQE7
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M34EAACVI.NV0;W.1@C&2Q(X8],5+H7A:VT'=]F39YFW=\S-G;G'WB?4]* .
M_P"$ UG_ )_/_)B?_P")K!\&/)X2U06DP!+D0MM^;_6%2C Y'!.T\\A2>,\5
M[G6)K?@RTUMQ-<Q[W"A0=[KP"3C"L!U)H B\5^"H?$_E^>SKY6['EE1][&<Y
M5O[HJOX7^'EOX;E-Q"TA9D*D.5(P2#V5>?EKJ** "O%/@I_Q^2?]>[?^AQU[
M76)HG@RTT1S-;1['*E2=[MP2#C#,1U H MZ[KL6AQ&YG.%7H!]YCV4#N3_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5V'AOPWY.+B8?-U53V]S[^@[
M?7H>&_#?DXN)A\W55/;W/OZ#M]>G2UY>-QM[PC\V>]EF6<MJM1:]%^K,74_]
M?'_P'_T(UM5BZG_KX_\ @/\ Z$:VJ\T]H**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *S/$'^K'^\/Y&M.LSQ!_JQ_O#^1H TZ***
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M+C)!]L@*2PZ6]TZ*_79,BNH.0'4,,],X(//-,L=)AT_/D1I'NQGRT5<XSC.
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MEEXXRIGD ^0#?M5 2.27P<KV'!(W8]%O=#M[]M\T4;L!@%T5CCKC)!XYI_\
M9,/E_9?+3RO[FQ=G7=]W&.O/3KS0!F>,='DU&%6@P9K>5)HPQPK-&?NGV()[
MCG&2!FHM'\>6M]'OD=89 2KQS.J.K#J,-C(]#CZX(('1U1O=#M[]M\T4;L!@
M%T5CCKC)!XYH Q8/&@U2Y6TL5$J(29Y22J*.0 IQ\S$C(QD$#@X)9.HJ&UM$
MM%$42JB#.%0!5&3DX XZU-0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% %#7?\ 4M^'_H0HHUW_ %+?
MA_Z$** .%N?O'_/:HJEN?O'_ #VJ*@ HHHH **** "BBB@ HHHH **Z?3-,M
M_LZW$P]<G+?WB!P#2R:-;Z@C-;'YESP">3V!#>O8\#ZXH Y>BBB@ HHHH **
M** "BBI+<JK*7&5R,@=<9YH CHK0UN:*63, PN!G P,^P_+L.?SK/H ****
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M_>7\Q1]K3^\OYB@":BH?M:?WE_,4?:T_O+^8H FHJ'[6G]Y?S%'VM/[R_F*
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M^A0!/14'VV/^\O\ WT*/ML?]Y?\ OH4 3T5!]MC_ +R_]]"C[;'_ 'E_[Z%
M$]%0?;8_[R_]]"C[;'_>7_OH4 3T5!]MC_O+_P!]"C[;'_>7_OH4 3T5!]MC
M_O+_ -]"C[;'_>7_ +Z% $]%0?;8_P"\O_?0H^VQ_P!Y?^^A0!/14'VV/^\O
M_?0H^VQ_WE_[Z% $]%0?;8_[R_\ ?0H^VQ_WE_[Z% $]%0?;8_[R_P#?0H^V
MQ_WE_P"^A0!/14'VV/\ O+_WT*/ML?\ >7_OH4 3T5!]MC_O+_WT*/ML?]Y?
M^^A0!/14'VV/^\O_ 'T*/ML?]Y?^^A0!/14'VV/^\O\ WT*/ML?]Y?\ OH4
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M#D%L#) P">Y ).![9/U-/H **** "BBB@ HHHH **** "BBB@ HKG_%OV_\
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M!K45YIX)^*[ZM.+2Z5%\SA&3*C=SP=S'.[H,<YP,'/'>ZY>M86\UPF"T43L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#7^8 .6HK2T^..XN% &(RW 8@].0#GU/&/PR>M=+?ZFMH3#+'^ZP,' *G
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M_P!3][<N/]7STS[?I0!VM>*?!3_C\D_Z]V_]#CKVNO%/@I_Q^2?]>[?^AQT
M>RW5HEVIBE570XRK@,IP<C(/'6N:\1^)K;P0BHL./-WE5A5$4LH7[W3&<@9
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MY65 "R-C/;)!'WESQG@],@9&;>B:+9PQN;5(S%<$EBF'1NH(ZD;1R-H^4<@
M<UY5X#B$6L%+;/DJ\X^0EE\L!MN3DY7.W!)Y..^* /;:*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,SQ!_JQ_
MO#^1KC-;_P!:?]V/_P! 6NS\0?ZL?[P_D:XS6_\ 6G_=C_\ 0%KNRS^*_3]4
M>5GG\"/^)?DRA1117L'S@4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %;WAC7&MF%NW*.0!Z@D]O;/4?B.^<)$+D*!DG@
M =:[CP]X>%@/-DYD/Y+[#W]3^ XZ\N-J4XTVI:WV1W992K3K)PTMN_+L;E%%
M%>&?5!1110 4444 %%%% !1110 4444 %%%% !1110 5BZ9_KY/^!?\ H0K:
MK%TS_7R?\"_]"% &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!BZG_KX_P#@/_H1K:K%U/\ U\?_  '_ -"-;5 !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !69X@_P!6/]X?R-:=
M9GB#_5C_ 'A_(T :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %+6/]4WX?S%&C_ZI?Q_F:-8_P!4WX?S%&C_ .J7\?YF@"[1
M110!S?BQ_L<MK>9 "3%#NZ8E&&;.1C !_GVYF\82&2-;-"0]S(J?*?F"YR[8
M')  PW08/)J;Q?:?:K29,XPF[IG[AWX_'&*S?#UT=;N/MC8Q#!&HQRF^0!W*
MG^$K]TCDXZGM0!->!='O(I -L5PGE$*,*&4CRR<#!)'RCI@ \X!H\2/]IN;2
MT! _>&4]V_=#*\9Z-R,^W'0BKWBFP-[;NJ9\Q!O0@98,GS#;CD$XP".>?PK+
M\.W1UBZ>^X"+!&@ Y&7 D8;NA*'@C'<9QW -3Q%K?]EHH0!II6"1J2!ECW.2
M.!W]R!D9R*O_  C<UW^\N+B4.>T#>6@'7 &"3@Y^8\D8STJ/Q-,+.XM+I^(U
M>1&.0,&10%SDCC@DGL!]*Z2@#EY+V?P](@GD\VVD(0,VU70\[=QXW#'WF/H3
MQT9OC&\GAFMH[8D/(95QR5Y"C<0.NW);D$#&<5-X]F!M_LHYDN'1$&0,G<#W
M(XXQGL2,]:DUG_C]L_\ MX_]%B@"YHVAG3OF:665B #YCDK[D+VS[Y(Z9ZYR
M_"5\MAIR3O\ =02$]/[[<#..3T'J:ZBN#@MVGT;:HR0&/X+,6/7T - &M9VE
MQKR"XFD:&-QE(X#AL'E6:3DG(/(  Z'@Y%%Y:7&@H;B&1IHT&7CG.6P.699.
M", < @CJ>3@5O:??+?QK.GW7 (Z?D<9Y'0^AHU"^6PC:=_NH"3T_(9QR>@]3
M0!R.EJXTI9(F*R1!W!!(^Y(Q(('!R,C!!!/7UKL+.Z%VBS+G#JK#/7##(K%\
M!?\ 'E%_P/\ ]&-6&+AM-AFTA3EO.6*,M]T+< E<D8.0-Q)P<$C&1T +WA7Q
M,U_/(LA(68;X0<?=4E".I.3MR1TR&(P#SH>(KPO)!8QL5>60,V&VGRT!9AD?
M,-V.",9P1D<U3\36O]DI;72;B+-E4_=)\M@$;@XR3@#C'4GW%C0)!J5Q/? @
MJI$,9SV7YGZ<$,Q!!Y./0<4 3:M<-'=VD88A7\_< 2 <(",COCM4WB+6_P"R
MT4( TTK!(U) RQ[G)' [^Y R,Y%76?\ C]L_^WC_ -%BH_$TPL[BTNGXC5Y$
M8Y P9% 7.2.."2>P'TH D_X1N:[_ 'EQ<2ASV@;RT ZX P2<'/S'DC&>E8/C
M,W&F6YMY&$L,I 5VXD4@A@IQPW"GG&2<DXX![ZN7^(M\L%JT1^]*5"CC^%@Q
M/T&,?4CUH V-=UE='A:X?G' 7(!)/0<_F>N "<'%9-OX>N+[]]=3R([#[D#;
M%7DG&1G=U'/7MEN#3O'<.^&-R2J1SQL[*<,J\J6'?()&, GVIT?A02@.MU<D
M$ @B;((/0YQ0!'";C0I$CD9I[>1@H8_ZR-F;"[C_ ! Y )/X <!NFKD]1\,0
MC;!/<S_OCA5>8$,1ST*_3\<#J1764 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0UW_4M^'_H0HHUW
M_4M^'_H0HH X6Y^\?\]JBJ6Y^\?\]JBH **** "BBB@"6UG\AUDQG:P./H<U
MT^NZ6=5"W$!#?+C&<9&>,9[\G.2/SKDZM6>IR6?^K8@'MU'Y'(SQUH WO#_A
M^2VD$THQMS@9!.2,=LC&">^<U7OKL6EZ96Z KGZ% ,_AG-9SZY,["0N<KTX&
M.A'3&,X)YQ56YN6NF,CG+'J>!T&.U '1:]H+W;_:(<,' [CTZCH,8 [UH>'=
M(;3U8O\ >?' .0 !Q^/)SU%<I::Q+:#:C$#TX(_#.<?A3XM<FC)<.<MC.0#T
MSCJ#@<G@4 :WA:X69'M&."^<<\D$8...HQ_];BJ?_"*3[MN!C^]GCI^?MTK(
M1RA##@CH1UJ__P )#/C9O.,8Z#/YXSGWSF@#4\4W"PHEHIR4QGGD # SQU.?
M_K<T[7/^/2'_ +9_^@&N:=RY+'DGJ3UJQ/J<DZ"%CE5Q@8'88'(&>E '6:;>
M/<6RF'&] %(;.#M'3/')&#Z=O<-CGO7!)2,8[$G)^F&/ZXKD+:Z:V.]"0?;_
M #R/:K5SKDUR-C.<'T '\@./:@"5('UJ<YP"?O$<@!<#(Y.?SY^E=)I*3C=#
M< ,N,!B0<]L8ZD$<Y(SZ]:XJ*4Q'<I(([@X-79]>GG4HS\'K@ ?J!0!;T>\2
MQN6Z",EE!SP!G(.>>.,?KFIM7\-2O(TD8W*Y)Z@$9Y/7'?..O'6N>J_;:Y-;
M#8KG ]0#_,'CVH EU#P^]B@E8CG&1GD$YX]_P_D,UM^&KLS0&*/ >//WLD<D
MD9QCW'MC/M7,7=\]X=TC$G]!]!T%112F([E)!'<'!H [&&>]D."D:^[$X_\
M'6-<UK-V]S)^] #*-I"\CC)]3SS3I?$,\@VES@^@ /Y@ UG4 =/XU_Y9_P#
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MO$'C'!SP>>W; ]<#&2:XVKT.M31*4#?*<Y# -UZ_>!ZU1H W?!W^N;_KF?\
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MHTE)QNAN &7& Q(.>V,=2".<D9]>M<5%*8CN4D$=P<&KL^O3SJ49^#UP /U
MH JWJJLCA/NAFQ@Y&,\<U#110 4444 %%%% !6[X._US?]<S_P"A+6%6[X._
MUS?]<S_Z$M '8UB>)]$?5?L_EE1Y%U%*VXD95,Y P#SSQT'O6W10 4444 <D
M?"MQHTCRZ8\:I*06@F#>4&[NI0Y4]!MQCWP% AG\+WNO,$U&6,6X*DQ6P8!\
M9/S,V& SC@$@XXVL U=G10!#]D39Y&U?+V[=N!MVXQMV],8XQTQ7,1>%[K0A
MMTV53$2?W-R&9%W$DE77YP!P IR.68DDUUM% '&3^%[W7F":C+&+<%28K8,
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MQ/<G_P"L,  #0HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *@O?]6_^ZW\JGJ"]_U;_P"ZW\J *?A__5G_ 'C_
M "%:=9GA_P#U9_WC_(5IT 4=<LFO[>:W3 :6)U!/3+*0,XSQS7,?#?P5-X8\
M[SV1O-\O'EEC]W=G.57^\*[6B@#SSXA_#RX\27"W$+1A5B"D.6!R&8]E;CYJ
M[77+)K^WFMTP&EB=03TRRD#.,\<U>HH XKX;^"IO#'G>>R-YOEX\LL?N[LYR
MJ_WA5'5_AY<7NIC5%:,1"6%L$MOQ&$!XVD9^4XYKT.B@#E/B%X,/B>)5C*K+
M$V5+YVX;AE.,XS@'.#TQQDFC1O#MS!ITFFSLC2&.2-&5G(VLI"ABPSP21P,!
M0 !75T4 <5\-_!4WACSO/9&\WR\>66/W=V<Y5?[PK2\<^$%\30>4"%E0[D8C
MOC!4G&=K=\=P#@XP>CHH X3P%X*N?#"7&YHFDE5?+P7*[E#XW?*IQEATYQFH
MOA[\-W\/RM=7)1GVXCV$D#/WC\R@@XP 0>A8'K7H%% !7G7B3X;S3WPU*S,2
MX9)"LA8#S%.2<(O0X!/.22QS7HM% !1110 5YY\//AY<>&[AKB9HRK1%0$+$
MY+*>ZKQ\M>AT4 4=:T>/6(7M)L[)!@X.",$$$'U! /IZ@CBO,H_A1?Z:S"TN
M55&QR'DB8X'=4##@DXY/X9Q7K=% '#^"OAA'H#K=RN7G4'&.$7<N#@=6/49.
M 0?N@C-=Q110!Q7Q(\%3>)_)\AD7RO,SYA8?>VXQA6_NFMI?#2W5BFF7'($,
M:,4)'* <@X[$9&1]1CBMNB@#R1OA1?V@:WM[E?(;J"\D8;( ;**&'/3J<C\J
M[/P7X"B\+AF#&25P 6*@8 ).%') /&?F.2 >*ZBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S/$'^K'^\
M/Y&N,UO_ %I_W8__ $!:[/Q!_JQ_O#^1KC-;_P!:?]V/_P! 6N[+/XK]/U1Y
M6>?P(_XE^3*%%%%>P?.!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !2HA<A0,D\ #K0B%R% R3P .M=QX>\/"P'FR<R'\E]A[^
MI_ <=<,1B(T8W>_1'5@\'/$SLMNK#P]X>%@/-DYD/Y+[#W]3^ XZ[E%%>'5J
MRJ2YGN?4T*$*,%"*T"BBBH-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *Q=,_U\G_ O_0A6U6+IG^OD_P"!?^A"@#:HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Q=3_ -?'_P !_P#0C6U6+J?^OC_X
M#_Z$:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWICBM*-:5*5XF&)PT,1%1EM>YC_\(5-_>3\V_P#B:/\ A"IO[R?FW_Q-;?\
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M7^=E'^E?YV4?VC6\@_L;#=G]YB?\(5-_>3\V_P#B:/\ A"IO[R?FW_Q-;?\
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M^)K2T_SMI\K[N?\ 9ZX'K5G_ $K_ #LH_M&MY!_8V&[/[S$_X0J;^\GYM_\
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M\31_PA4W]Y/S;_XFMO\ TK_.RC_2O\[*/[1K>0?V-ANS^\Q/^$*F_O)^;?\
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MM45B_P"E?YV4?Z5_G90!M45B_P"E?YV4?Z5_G90!M45B_P"E?YV4?Z5_G90
M:G_KX_\ @/\ Z$:VJYFY\WS%W_?XQT]>.G'6KG^E?YV4 ;5%8O\ I7^=E'^E
M?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E
M?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E
M?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E
M?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E
M?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E
M?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E
M?YV4 ;5%8O\ I7^=E'^E?YV4 ;5%8O\ I7^=E'^E?YV4 ;59GB#_ %8_WA_(
MU!_I7^=E5M0\[:/-^[G_ &>N#Z4 ='16+_I7^=E'^E?YV4 ;5%8O^E?YV4?Z
M5_G90!M45B_Z5_G91_I7^=E &U16+_I7^=E'^E?YV4 ;5%8O^E?YV4?Z5_G9
M0!M45B_Z5_G91_I7^=E &U16+_I7^=E'^E?YV4 ;5%8O^E?YV4?Z5_G90!M4
M5B_Z5_G91_I7^=E &U16+_I7^=E'^E?YV4 ;5%8O^E?YV4?Z5_G90!M45B_Z
M5_G91_I7^=E &U16+_I7^=E'^E?YV4 ;5%8O^E?YV4?Z5_G90!M45B_Z5_G9
M1_I7^=E &U16+_I7^=E'^E?YV4 ;5%8O^E?YV4?Z5_G90!M45B_Z5_G91_I7
M^=E &U16+_I7^=E'^E?YV4 ;5%8O^E?YV4?Z5_G90!M45B_Z5_G91_I7^=E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5!>_ZM_\ =;^53U!>_P"K?_=;^5 %/P__ *L_[Q_D*TZS/#_^
MK/\ O'^0K3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?VKB_P";\%_D=5_PG/\ TS_\?_\ L:/^$Y_Z9_\ C_\ ]C7*T4?4:'\OXO\
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M,44?4:'\OXO_ ##^U<7_ #?@O\CH=/\ %OV-2FS.3G[V.P_V:L_\)S_TS_\
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M$Y_Z9_\ C_\ ]C7*T4?4:'\OXO\ S#^U<7_-^"_R.J_X3G_IG_X__P#8T?\
M"<_],_\ Q_\ ^QKE:*/J-#^7\7_F']JXO^;\%_D=5_PG/_3/_P ?_P#L:/\
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MB] K%TS_ %\G_ O_ $(5M5BZ9_KY/^!?^A"H-3:HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH Q=3_ -?'_P !_P#0C6U6+J?^
MOC_X#_Z$:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "LSQ!_JQ_O#^1K3K,\0?ZL?[P_D: -.BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMK=I=J)8F5T.<,A#*<'!P1QUI\T*S*4< JP(((R"#P00>H-<KX-A6UN;Z"$
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M;=M3GRDSG! 4Y' .#M(XJ[H/AA=,>2Z<^9<3L2\A!'&>$4$L54# QD]!DX
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M0 4444 %%%% !1110 4444 9GB#_ %8_WA_(UQFM_P"M/^['_P"@+79^(/\
M5C_>'\C7&:W_ *T_[L?_ * M=V6?Q7Z?JCRL\_@1_P 2_)E"BBBO8/G HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5F>(/]6/\ >'\C6G69X@_U
M8_WA_(T :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% %+6/\ 5-^'\Q1H_P#JE_'^9HUC_5-^'\Q1H_\ JE_'^9H NT444 4X
M=4669[7!#QA6^; #!NZ\Y(!X)QP>*N5SNK2?8+V"XYQ,K0L2"0.0R 8Z%FXY
MXQZ8)JYXIOS96[LF?,<;$ .&+/\ *-N.21G( YX_&@"UIFK1ZFK/$<A'9#]5
M]#T((P01V/KQ4FH7RV$;3O\ =0$GI^0SCD]!ZFN=\/V/]@7!L<DI-$KJ3D#>
MGRN "3DM]XX/ P,8 -6/&4GGK%8\DW,JJ0 2VQ2&=@>@QQU[9X] #>MYO/59
M,%=P!PPPPR,X([$=ZDJ&\O$LT,TA"HHR2?\ /Y#J3P*Q?^$CGN?GMK9I(^S.
MZQ9]P&Y*D8(/&?3B@#H**Q]-\2K=R?99$:*8#.V0#G&<[2#\P&#SQD<C@'#?
M$'B=-$:,2 E9!)D@\C8 0,8YW$XZ@#J>* -JL_0-6_M:!+G;MW[N,YQABO7
M]/2H]&U&>]^::'REP",R!F.>VT*,8[YP1TQUQ3\!?\>47_ __1C4 =!16#)X
MI^T$I9Q-.5)RP(2,8ZC>W!/0X'!!R#1'XI^SD)>1- 6(PQ(>,YZ#>O /4X/
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MR 36U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %#7?]2WX?\ H0HHUW_4M^'_ *$** .%N?O'_/:H
MJEN?O'_/:HJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1ON) )_B4<<<XR1UP>:I?#J*>.ZOOM6/.8P,P!) WJ[!023PH(7J0,8!(YH
MTO '_+Y_V$+C_P!EJO\ #6T%U$VKR8:>[=R6P?E4,5$8))^4;<CVP#G:*L>
M/^7S_L(7'_LM4M.,O@EI(7C9[ N7CDCRYB#<LK*26V* 26&?4Y+84 [6:%9E
M*. 58$$$9!!X((/4&N'^'^C+HUY?VL?W%: KUX#J[A>22< XSGG&:MW/Q1M&
M&VUWW$K9VQQ1ON) )_B4<<<XR1UP>:I?#J*>.ZOOM6/.8P,P!) WJ[!023PH
M(7J0,8!(YH TO$7_ "$=/_[>O_10JO\ $^R6_BMK=\A9;V%21UPP<'&<\\U8
M\1?\A'3_ /MZ_P#10H\??\N?_80M_P#V:@#3\3PK#8W"( %6VE  &  (R  !
MT JOI-]_9^FQW.-WE6:/C.,[8@<9P<9QZ5:\6?\ 'G<_]>\W_H#5%X>M5N["
M"&0922UC5ADC(:, C(YZ4 5_ FEK:VRW)PTUT!+*^,%FD^?\EW8 &!U( R:W
M;JT2[4Q2JKH<95P&4X.1D'CK7&Z/JLO@^/['?JQ@C)$=R@+IL[!P"S(02%7C
M'8<+N-B;XEP7)$5BCW,K?PHK(H&5&69U&T<]<$>I&<T =1I^GQZ=&MO"H6-!
M@ ?YY)ZDGDGD\U8JII4DLL2-<*J2E1O5#N4'V/\ ^O'0%NIMT <%X!T&-[J]
MU%@#(+N:-,C[N&)8@YZMN Z9 !YPQ%=%XVM5NK&X1QD"%VZD<H-ZGCT(!_GQ
M6?X _P"7S_L(7'_LM:OBS_CSN?\ KWF_] :@"K_:DG]F_;=W[W['YF[ ^]Y6
M[.,8Z\XQCVK$T_PPTVDP11',\:K/$<#B0DRJ,$X/WBN6XYW$=J?J]ZUEH8=<
M$FTA7GTD5$/ISACCWKK=)L?[/ACML[O*C1,XQG:H&<9.,X]: *FE^(X[ZT74
MC\L9C+MU.W;G>.@)VD$<#G'%8OA[1FU6VN+J7Y9=25CV;9&4*1+P0&VJ<YPI
M.<-R*Y_6=!G-W)HR;OLU],+AFQ]U1S,N[8<$L%V\X'R _?->H4 <U\-[IKK3
MX'<Y(5EZ <([(HX]  /Y\US_ (;\,?VJ]Y+Y]Q%B^G&V"78IP0<D8///7T K
M8^&@:WMY+,D$6ES-$& QD*=V2,GDEC^&/J7> /\ E\_["%Q_[+0!8T_P';VT
MBW,ADGFC.5>XD,C+Z #A< Y(XR"<@],='110!Q_AW9H%[-I0VA)_](B P/O?
M*Z=AP5RJJ#A023Q1\GB'4OX6CTU?8YEE_,$(%_V65QWQ5CQY"UM''JD8)ELG
MWX SN1L+*O< %>2V"5 XQUJUX*TMK"V5I,^=.3+*2-IWR_,<KV(X7 P.,X&:
M -ZBBB@#E/\ A'=1_P"?_P#\E8O\:Y_P%HU[<V44D%YY49WX3[/&^,2,#\Q.
M3DY/XXKTNLGPMH7]@VR66[?Y>[YMNW.YBW3)]<=: +>EV\EM&L<\GFR#.7V!
M,Y)(^4<# P/PS5NBB@#S^+0/[7U&^_?31;/LW^HDV9S%WX.<8X],FMB'X>6[
M,'N&EN2A!7[3*7"^N , @X&000<"F>'?^0CJ'_;K_P"BC75T %<I\+?^0=!_
MVT_]&O75URGPM_Y!T'_;3_T:] $7B+9H%[#JIVA)_P#1Y2<#[WS(_8<%<,S$
MX4  <4_QU,NHM#H@(W7;@OSRL<7SL1UPQVX7*D'#9QBMW7]&76H)+1^!(N,\
M\$<JV 1G! .,\XP>*YKX?B756DU6Z#"7:L"AEVD", R'@*#NDR2,?*05![4
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MBC1B,$HBJ<=<9 ''% %ZO%/@I_Q^2?\ 7NW_ *''7M=>*?!3_C\D_P"O=O\
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MWS8;!:0A0HQD <9.>IP!W'B+P#Y^FKIL'+P;67G:&89W9SG&[<Q R "1R%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *6L?ZIOP_F*-'_U2_C_,T:Q_JF_#^8HT?_5+^/\ ,T 7
M:*** .?\<0LUL9DSO@=)%P,\J<9(P> "3^'/&:CGN%UNZAC4YAA19R1W9O\
M5@]"I .X ]1U%;UY:B[1H6SAU93CKAA@US_@/37MH3-,"))"HY!#!(U"("I
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MLQ5H+>,DA3CS)#D@;@1\HQU!^H)X9>BH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AKO^I;\/_0A1
M1KO^I;\/_0A10!PMS]X_Y[5%4MS]X_Y[5%0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5N^#O]<W_7,_^A+6%6[X._US?]<S_P"A+0!V-%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %07O^K?_ '6_E4]07O\ JW_W6_E0!3\/_P"K/^\?Y"M.LSP__JS_ +Q_
MD*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH S/$'^K'^\/Y&N,UO_6G_ '8__0%KL_$'^K'^
M\/Y&N,UO_6G_ '8__0%KNRS^*_3]4>5GG\"/^)?DRA1117L'S@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !116IH>AMJ;9Z1KU/]![_P OR!F<XPBY
M/8NE2E5DHQ5VPT/0VU-L](UZG^@]_P"7Y ][;VZVZB-!A5Z 46]NMNHC085>
M@%25X>)Q,JTO+HCZG X&.%CWD]V%8NF?Z^3_ (%_Z$*VJQ=,_P!?)_P+_P!"
M%<YV&U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!BZG_KX_\ @/\ Z$:VJQ=3_P!?'_P'_P!"-;5 !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !69X@_U8_P!X?R-:=9GB#_5C_>'\
MC0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 4M8_P!4WX?S%&C_ .J7\?YFC6/]4WX?S%&C_P"J7\?YF@"[1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %#7?]2WX?^A"BC7?]2WX?^A"B@#A;G[Q_SVJ*I;G[Q_SVJ*@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K7\,W0MI"S9^X1Q]1616
MWX2C$DK!@#\AZC/=: .C_MM/1OR'^-']MIZ-^0_QJU]D3^ZOY"C[(G]U?R%
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M?9$_NK^0H^R)_=7\A0!5_MM/1OR'^-']MIZ-^0_QJU]D3^ZOY"C[(G]U?R%
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M=7\A1]D3^ZOY"@"K_;:>C?D/\:/[;3T;\A_C5K[(G]U?R%'V1/[J_D* *O\
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M[Y%'V*/^ZO\ WR*/:3[L/8T^R^XR/M5K_P \A_WPE'VJU_YY#_OA*U_L4?\
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MOR'^-'_"01^C?D/\:N?8H_[J_P#?(H^Q1_W5_P"^10!3_P"$@C]&_(?XT?\
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M?XU<^Q1_W5_[Y%'V*/\ NK_WR* *?_"01^C?D/\ &C_A((_1OR'^-7/L4?\
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M]BC_ +J_]\B@"G_PD$?HWY#_ !H_X2"/T;\A_C5S[%'_ '5_[Y%'V*/^ZO\
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MH_[J_P#?(H^Q1_W5_P"^10!3_P"$@C]&_(?XT?\ "01^C?D/\:N?8H_[J_\
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M]BC_ +J_]\BC[%'_ '5_[Y% %/\ X2"/T;\A_C1_PD$?HWY#_&KGV*/^ZO\
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M^^10!3_X2"/T;\A_C1_PD$?HWY#_ !JY]BC_ +J_]\BC[%'_ '5_[Y% %/\
MX2"/T;\A_C1_PD$?HWY#_&KGV*/^ZO\ WR*/L4?]U?\ OD4 4_\ A((_1OR'
M^-'_  D$?HWY#_&KGV*/^ZO_ 'R*/L4?]U?^^10!3_X2"/T;\A_C1_PD$?HW
MY#_&KGV*/^ZO_?(H^Q1_W5_[Y% %/_A((_1OR'^-'_"01^C?D/\ &KGV*/\
MNK_WR*/L4?\ =7_OD4 4_P#A((_1OR'^-'_"01^C?D/\:N?8H_[J_P#?(H^Q
M1_W5_P"^10!3_P"$@C]&_(?XT?\ "01^C?D/\:N?8H_[J_\ ?(H^Q1_W5_[Y
M% %/_A((_1OR'^-'_"01^C?D/\:N?8H_[J_]\BC[%'_=7_OD4 4_^$@C]&_(
M?XT?\)!'Z-^0_P :N?8H_P"ZO_?(H^Q1_P!U?^^10!3_ .$@C]&_(?XT?\)!
M'Z-^0_QJY]BC_NK_ -\BC[%'_=7_ +Y% %/_ (2"/T;\A_C1_P )!'Z-^0_Q
MJY]BC_NK_P!\BC[%'_=7_OD4 4_^$@C]&_(?XT?\)!'Z-^0_QJY]BC_NK_WR
M*/L4?]U?^^10!3_X2"/T;\A_C1_PD$?HWY#_ !JY]BC_ +J_]\BC[%'_ '5_
M[Y% &3J>L)<1L@!R<=0.Q!]:*LZS:HD3$* >.0 .XHH XJY^\?\ /:HJEN?O
M'_/:HJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MWP=_KF_ZYG_
M -"6L*MWP=_KF_ZYG_T): .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&[^XW^Z?Y5-4-W]QO\ =/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &+J?^OC_P" _P#H1K:K%U/_
M %\?_ ?_ $(UM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %9GB#_5C_ 'A_(UIUF>(/]6/]X?R- &G1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!2UC_ %3?A_,4:/\ ZI?Q_F:-
M8_U3?A_,4:/_ *I?Q_F: +M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4-=_U+?A_Z$**-
M=_U+?A_Z$** .%N?O'_/:HJEN?O'_/:HJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%8NF?Z^3_@7_ *$*VJQ=,_U\G_ O_0A0!M4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 8NI_Z^/\ X#_Z$:VJQ=3_ -?'_P !
M_P#0C6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5F>(/\ 5C_>'\C6G69X@_U8_P!X?R- &G1110 4444 %%%% !1110 4444
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MVAN"!<37$Z*<[)IBR9P0#P <C/&"/RR*VM-\/Q:=++<1Y!G$0*\!%$2[%"@
M8&/K[8H Q_ '_+Y_V$+C_P!EJO\ #6[%K$VD286>T=P5R?F4L6$@! ^4[L#V
MP3C<*Z/2-$32O-\LL?/F>5MQ!PSXR!@#CCCJ?>H=;\,0:SAI5_>+C;(AVR*1
MG:0XYX)R <C/.* -.:985+N0%4$DDX  Y))/0"N'^'^LKK-Y?W4?W&: +UY"
M*Z!N0",@9QCC.*O/\-H;@@7$UQ.BG.R:8LF<$ \ '(SQ@C\LBMK3?#\6G2RW
M$>09Q$"O 11$NQ0H &!CZ^V* ,?Q%_R$=/\ ^WK_ -%"CQ]_RY_]A"W_ /9J
MV[W1$NYX;QBV^V\S: 1M/F+M.>,].F"/QHU?1$U7RO,+#R)DE7:0,LF< Y!X
MYYZ'WH A\6?\>=S_ ->\W_H#52TZR:_TM+=,!I;)5!/3+1 #.,\<UMZC9+?Q
M/;OD+*C*2.N&!!QG//-&G62V$26Z9*Q(J@GKA0 ,XQSQ0!A?#[65O[1(?NRV
MRB*1#G<I3Y1D$ C(&?8Y&20:W[J[2T4RRLJ(,99R%49.!DGCK65K/A"#5&\\
MAHYQTEA;RY1P ?F'7@;?F!P,@8K/C^'$#.LMQ)-<;/NK<2[U!R#G&!Z<@Y!'
M4&@#H]/U"/48UN(6#1N,@C_/!'0@\@\'FK%,AA6%0B !5   &  .  !T I]
M'*>'?^0CJ'_;K_Z*--A#>%KD19 L;IPL:@?ZJ9N=H&>$?!/ PK<849+;MEHB
M6D\UXI;?<^7N!(VCRUVC'&>G7)/X5+JNF)JD3VLHRDBD'ID9Z$9!&0>0<<$
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ML.4R1%9*CG!P&:0.JYQC)4Y'X^AP>.G.D-#K" DP.$EVXYADX((RI8AL%!G
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M:@ HHHH **** "H;O[C?[I_E4U0W?W&_W3_*@"KHGW#_ +Q_D*T*S]$^X?\
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M/):*9,']V#AEV1X )$@"A6/.UAC+8.2>?6/#_@*'04FB@>7_ $A0"Q9=RX#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO*40L>K;2#@]!Q@8  %,7X:V@ADM_G+3X\R5FW2MA_,^\00,D#. ,X&<D9H
M;\3-/%U;)(ZEXH)XY)57.XQC*N!C'.&SU& "<C%0Z?\ #W2M1C6XAB#1N,@B
M27_XO@CH0>0>#S79UR\WP^A#$V\L]NK$DI;RE$+'JVT@X/0<8&  !0!E7_@_
M2+&:*S>(F6<G:JO,Q  )W$!^%XQGZGH&([VL3P_X0@T(M)&&:63.^21MTC9)
M;D].O7 &< G)&:VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH H:[_ *EOP_\ 0A11KO\ J6_#_P!"
M%% '"W/WC_GM452W/WC_ )[5%0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5N^#O]<W_ %S/_H2UA5J^'+]+&0O(< H1T)YR#V!]* .YHK)_X2FV
M_O\ _CK?X4?\)3;?W_\ QUO\* -:BLG_ (2FV_O_ /CK?X4?\)3;?W__ !UO
M\* -:BLG_A*;;^__ ..M_A1_PE-M_?\ _'6_PH UJ*R?^$IMO[__ (ZW^%'_
M  E-M_?_ /'6_P * -:BLG_A*;;^_P#^.M_A1_PE-M_?_P#'6_PH UJ*R?\
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M;;^__P".M_A1_P )3;?W_P#QUO\ "@#6HK)_X2FV_O\ _CK?X4?\)3;?W_\
MQUO\* -:BLG_ (2FV_O_ /CK?X4?\)3;?W__ !UO\* -:BLG_A*;;^__ ..M
M_A1_PE-M_?\ _'6_PH UJ*R?^$IMO[__ (ZW^%'_  E-M_?_ /'6_P * -:B
MLG_A*;;^_P#^.M_A1_PE-M_?_P#'6_PH UJ*R?\ A*;;^_\ ^.M_A1_PE-M_
M?_\ '6_PH UJ*R?^$IMO[_\ XZW^%'_"4VW]_P#\=;_"@#6HK)_X2FV_O_\
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M /QUO\* -:BLG_A*;;^__P".M_A1_P )3;?W_P#QUO\ "@#6HK)_X2FV_O\
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M_P#'6_PH UJ*R?\ A*;;^_\ ^.M_A1_PE-M_?_\ '6_PH UJ*R?^$IMO[_\
MXZW^%'_"4VW]_P#\=;_"@#6HK)_X2FV_O_\ CK?X4?\ "4VW]_\ \=;_  H
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M)3;?W_\ QUO\*/\ A*;;^_\ ^.M_A0!K45D_\)3;?W__ !UO\*/^$IMO[_\
MXZW^% &M163_ ,)3;?W_ /QUO\*/^$IMO[__ (ZW^% &M163_P )3;?W_P#Q
MUO\ "C_A*;;^_P#^.M_A0!K45D_\)3;?W_\ QUO\*/\ A*;;^_\ ^.M_A0!K
M45D_\)3;?W__ !UO\*/^$IMO[_\ XZW^% &M163_ ,)3;?W_ /QUO\*/^$IM
MO[__ (ZW^% &M163_P )3;?W_P#QUO\ "C_A*;;^_P#^.M_A0!K45D_\)3;?
MW_\ QUO\*/\ A*;;^_\ ^.M_A0!K45D_\)3;?W__ !UO\*/^$IMO[_\ XZW^
M% &M163_ ,)3;?W_ /QUO\*/^$IMO[__ (ZW^% &M163_P )3;?W_P#QUO\
M"C_A*;;^_P#^.M_A0!K45D_\)3;?W_\ QUO\*/\ A*;;^_\ ^.M_A0!K5BZ9
M_KY/^!?^A"I/^$IMO[__ (ZW^%9ECKL,4SR,WRMNP=K=VSZ4 =3163_PE-M_
M?_\ '6_PH_X2FV_O_P#CK?X4 :U%9/\ PE-M_?\ _'6_PH_X2FV_O_\ CK?X
M4 :U%9/_  E-M_?_ /'6_P */^$IMO[_ /XZW^% &M163_PE-M_?_P#'6_PH
M_P"$IMO[_P#XZW^% &M163_PE-M_?_\ '6_PH_X2FV_O_P#CK?X4 :U%9/\
MPE-M_?\ _'6_PH_X2FV_O_\ CK?X4 :U%9/_  E-M_?_ /'6_P */^$IMO[_
M /XZW^% &M163_PE-M_?_P#'6_PH_P"$IMO[_P#XZW^% &M163_PE-M_?_\
M'6_PH_X2FV_O_P#CK?X4 :U%9/\ PE-M_?\ _'6_PH_X2FV_O_\ CK?X4 :U
M%9/_  E-M_?_ /'6_P */^$IMO[_ /XZW^% &M163_PE-M_?_P#'6_PH_P"$
MIMO[_P#XZW^% &M163_PE-M_?_\ '6_PH_X2FV_O_P#CK?X4 :U%9/\ PE-M
M_?\ _'6_PH_X2FV_O_\ CK?X4 :U%9/_  E-M_?_ /'6_P */^$IMO[_ /XZ
MW^% &M163_PE-M_?_P#'6_PH_P"$IMO[_P#XZW^% &M163_PE-M_?_\ '6_P
MH_X2FV_O_P#CK?X4 :U%9/\ PE-M_?\ _'6_PH_X2FV_O_\ CK?X4 :U%9/_
M  E-M_?_ /'6_P */^$IMO[_ /XZW^% &M163_PE-M_?_P#'6_PH_P"$IMO[
M_P#XZW^% &M163_PE-M_?_\ '6_PH_X2FV_O_P#CK?X4 :U%9/\ PE-M_?\
M_'6_PH_X2FV_O_\ CK?X4 1ZG_KX_P#@/_H1K:KEK[7899DD5OE7;D[6[-GT
MK3_X2FV_O_\ CK?X4 :U%9/_  E-M_?_ /'6_P */^$IMO[_ /XZW^% &M16
M3_PE-M_?_P#'6_PH_P"$IMO[_P#XZW^% &M163_PE-M_?_\ '6_PH_X2FV_O
M_P#CK?X4 :U%9/\ PE-M_?\ _'6_PH_X2FV_O_\ CK?X4 :U%9/_  E-M_?_
M /'6_P */^$IMO[_ /XZW^% &M163_PE-M_?_P#'6_PH_P"$IMO[_P#XZW^%
M &M163_PE-M_?_\ '6_PH_X2FV_O_P#CK?X4 :U%9/\ PE-M_?\ _'6_PH_X
M2FV_O_\ CK?X4 :U%9/_  E-M_?_ /'6_P */^$IMO[_ /XZW^% &M163_PE
M-M_?_P#'6_PH_P"$IMO[_P#XZW^% &M163_PE-M_?_\ '6_PH_X2FV_O_P#C
MK?X4 :U%9/\ PE-M_?\ _'6_PH_X2FV_O_\ CK?X4 :U%9/_  E-M_?_ /'6
M_P */^$IMO[_ /XZW^% &M163_PE-M_?_P#'6_PH_P"$IMO[_P#XZW^% &M1
M63_PE-M_?_\ '6_PH_X2FV_O_P#CK?X4 :U%9/\ PE-M_?\ _'6_PH_X2FV_
MO_\ CK?X4 :U%9/_  E-M_?_ /'6_P */^$IMO[_ /XZW^% &M163_PE-M_?
M_P#'6_PH_P"$IMO[_P#XZW^% &M163_PE-M_?_\ '6_PH_X2FV_O_P#CK?X4
M :U%9/\ PE-M_?\ _'6_PH_X2FV_O_\ CK?X4 :U%9/_  E-M_?_ /'6_P *
M/^$IMO[_ /XZW^% &M69X@_U8_WA_(TS_A*;;^__ ..M_A5'6/$$%P@5&R=P
M/W6'8^HH Z2BLG_A*;;^_P#^.M_A1_PE-M_?_P#'6_PH UJ*R?\ A*;;^_\
M^.M_A1_PE-M_?_\ '6_PH UJ*R?^$IMO[_\ XZW^%'_"4VW]_P#\=;_"@#6H
MK)_X2FV_O_\ CK?X4?\ "4VW]_\ \=;_  H UJ*R?^$IMO[_ /XZW^%'_"4V
MW]__ ,=;_"@#6HK)_P"$IMO[_P#XZW^%'_"4VW]__P =;_"@#6HK)_X2FV_O
M_P#CK?X4?\)3;?W_ /QUO\* -:BLG_A*;;^__P".M_A1_P )3;?W_P#QUO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M5MVG^5%+'KA02?TI*W?!W^N;_KF?_0EH Q?[)F_YYO\ ]\-_A1_9,W_/-_\
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M-_\ OAO\*]+HH \T_LF;_GF__?#?X4?V3-_SS?\ [X;_  KTNB@#S3^R9O\
MGF__ 'PW^%']DS?\\W_[X;_"O2Z* /-/[)F_YYO_ -\-_A1_9,W_ #S?_OAO
M\*]+HH \T_LF;_GF_P#WPW^%']DS?\\W_P"^&_PKTNB@#S3^R9O^>;_]\-_A
M1_9,W_/-_P#OAO\ "O2Z* /-/[)F_P">;_\ ?#?X4?V3-_SS?_OAO\*]+HH
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M_P#WPW^%']DS?\\W_P"^&_PKTNB@#S3^R9O^>;_]\-_A1_9,W_/-_P#OAO\
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MPK6_X36;^ZGY-_\ %4?\)K-_=3\F_P#BJ/[.K>0?VSAN[^XR?[)F_P">;_\
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M_LZMY!_;.&[O[C)_LF;_ )YO_P!\-_A1_9,W_/-_^^&_PK6_X36;^ZGY-_\
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MR;_XJC_A-9O[J?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\
MWPW^%:W_  FLW]U/R;_XJC_A-9O[J?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_
M^^&_PH_LF;_GF_\ WPW^%:W_  FLW]U/R;_XJC_A-9O[J?DW_P 51_9U;R#^
MV<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\ WPW^%:W_  FLW]U/R;_XJC_A-9O[
MJ?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\ WPW^%:W_  FL
MW]U/R;_XJC_A-9O[J?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_^^&_PH_LF;_G
MF_\ WPW^%:W_  FLW]U/R;_XJC_A-9O[J?DW_P 51_9U;R#^V<-W?W&3_9,W
M_/-_^^&_PH_LF;_GF_\ WPW^%:W_  FLW]U/R;_XJC_A-9O[J?DW_P 51_9U
M;R#^V<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\ WPW^%:W_  FLW]U/R;_XJC_A
M-9O[J?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\ WPW^%:W_
M  FLW]U/R;_XJC_A-9O[J?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_^^&_PH_L
MF;_GF_\ WPW^%:W_  FLW]U/R;_XJC_A-9O[J?DW_P 51_9U;R#^V<-W?W&3
M_9,W_/-_^^&_PH_LF;_GF_\ WPW^%:W_  FLW]U/R;_XJC_A-9O[J?DW_P 5
M1_9U;R#^V<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\ WPW^%:W_  FLW]U/R;_X
MJC_A-9O[J?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\ WPW^
M%:W_  FLW]U/R;_XJC_A-9O[J?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_^^&_
MPH_LF;_GF_\ WPW^%:W_  FLW]U/R;_XJC_A-9O[J?DW_P 51_9U;R#^V<-W
M?W&3_9,W_/-_^^&_PH_LF;_GF_\ WPW^%:W_  FLW]U/R;_XJC_A-9O[J?DW
M_P 51_9U;R#^V<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\ WPW^%:W_  FLW]U/
MR;_XJC_A-9O[J?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\
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MR;_XJC_A-9O[J?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\
MWPW^%:W_  FLW]U/R;_XJC_A-9O[J?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_
M^^&_PH_LF;_GF_\ WPW^%:W_  FLW]U/R;_XJC_A-9O[J?DW_P 51_9U;R#^
MV<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\ WPW^%:W_  FLW]U/R;_XJC_A-9O[
MJ?DW_P 51_9U;R#^V<-W?W&3_9,W_/-_^^&_PH_LF;_GF_\ WPW^%:W_  FL
MW]U/R;_XJI+?QM(&'F*NWOM!!_#)(_SVI/+ZRZ(:SC#-VN_N,7^R9O\ GF__
M 'PW^%']DS?\\W_[X;_"O1[>X6X42(<JW0BI*Y&K:'H)IJZ/-/[)F_YYO_WP
MW^%']DS?\\W_ .^&_P *]+HH&>:?V3-_SS?_ +X;_"C^R9O^>;_]\-_A7I=%
M 'FG]DS?\\W_ .^&_P */[)F_P">;_\ ?#?X5Z710!YI_9,W_/-_^^&_PH_L
MF;_GF_\ WPW^%>ET4 >:?V3-_P \W_[X;_"C^R9O^>;_ /?#?X5Z710!YI_9
M,W_/-_\ OAO\*/[)F_YYO_WPW^%>ET4 >:?V3-_SS?\ [X;_  H_LF;_ )YO
M_P!\-_A7I=% 'FG]DS?\\W_[X;_"C^R9O^>;_P#?#?X5Z710!YI_9,W_ #S?
M_OAO\*/[)F_YYO\ ]\-_A7I=% 'FG]DS?\\W_P"^&_PH_LF;_GF__?#?X5Z7
M10!YI_9,W_/-_P#OAO\ "FR:=+'RR,![J1_2O3:S/$'^K'^\/Y&@#A_[)F_Y
MYO\ ]\-_A1_9,W_/-_\ OAO\*]+HH \T_LF;_GF__?#?X4?V3-_SS?\ [X;_
M  KTNB@#S3^R9O\ GF__ 'PW^%']DS?\\W_[X;_"O2Z* /-/[)F_YYO_ -\-
M_A1_9,W_ #S?_OAO\*]+HH \T_LF;_GF_P#WPW^%']DS?\\W_P"^&_PKTNB@
M#S3^R9O^>;_]\-_A1_9,W_/-_P#OAO\ "O2Z* /-/[)F_P">;_\ ?#?X4?V3
M-_SS?_OAO\*]+HH \T_LF;_GF_\ WPW^%']DS?\ /-_^^&_PKTNB@#S3^R9O
M^>;_ /?#?X4?V3-_SS?_ +X;_"O2Z* /-/[)F_YYO_WPW^%']DS?\\W_ .^&
M_P *]+HH \T_LF;_ )YO_P!\-_A1_9,W_/-_^^&_PKTNB@#S3^R9O^>;_P#?
M#?X4?V3-_P \W_[X;_"O2Z* /-/[)F_YYO\ ]\-_A1_9,W_/-_\ OAO\*]+H
MH \T_LF;_GF__?#?X4?V3-_SS?\ [X;_  KTNB@#S3^R9O\ GF__ 'PW^%']
MDS?\\W_[X;_"O2Z* /-/[)F_YYO_ -\-_A1_9,W_ #S?_OAO\*]+HH \T_LF
M;_GF_P#WPW^%']DS?\\W_P"^&_PKTNB@#S3^R9O^>;_]\-_A1_9,W_/-_P#O
MAO\ "O2Z* /-/[)F_P">;_\ ?#?X4?V3-_SS?_OAO\*]+HH \T_LF;_GF_\
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M^^&_PKTNB@#S3^R9O^>;_P#?#?X4?V3-_P \W_[X;_"O2Z* /-/[)F_YYO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !4-W]QO]T_RJ:H;O[C?[I_E0!5T3[A_P!X_P A6A6?HGW#_O'^
M0K0H **** "BBB@ HHKS_P 4_%?^P;E[+R-_E[?F\W;G<H;IL/KCK0!Z!17F
MFF?&V*9PD\+1H?XE?S,'(ZC:IP!DG&3Z UWNHZHMK;O>)AU2)I!@\,%4L,,,
M\'UYH O45P_@_P"*,?B&;[(\9B=@2GS;PV 2PSM7!P,CL>>0< ];JU]_9\,E
MSC=Y4;OC.,[5)QG!QG'I0!;HKE/ OCK_ (2KS?W7E^5L_CWYW[O]E<8VUU=
M!17G^E_%V._NULA'B-Y"BR[R<]0AV; 1N.!R>,\]*] H **** "BN7\;>.X_
M"ZH-HDE<_<W;2%Y^;.UN,C SC/..AJEX*^)'_"3S-;>3Y>V,OGS-W1E&,;5_
MO>M ':T45C^*O$T?AR'[3*"0750!U.3SCMD*">< XQD9H V**S]"UR/6XA=0
M[MC?WE*G(ZCG@X/!()&00"<5H4 %%<%XJ^+$>B3FUCC$VP?,1)MPV3E?N-DC
MC//!.#R#6[J?BO[#8#5=F<QQ/LW8_P!85&-V#TW>G..U '045Y5_PO/_ *=O
M_(W_ -KJ[HGQ@;59X[5;8YE=5R)=V 3RV/+Z*,D^PZB@#TBBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UO[
M@_WA_(UQ6O?ZX_[L?_H"UVNM_<'^\/Y&N*U[_7'_ '8__0%KNRS^*_3]4>5G
MG\"/^)?DS/HHHKV#YP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#4T/7&TQL=8VZC^H]_Y_D1WMO<+<*)$.5;H17EU:FAZXVF-CK&W4
M?U'O_/\ (CBQF#]I[T?B_,]3+<R=!\D_A_+_ (!Z#14=O<+<*)$.5;H14E>,
MU;0^C335T%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LS
MQ!_JQ_O#^1K3K,\0?ZL?[P_D: -.BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"EK'^J;\/YBC1_\ 5+^/\S1K'^J;\/YBC1_]
M4OX_S- %VBBB@ HK/AU;?</9LNTJBNISG<IX)QCC#<<G)Z]*T* "BLW0M<36
M4:6,'"R,O/?'((Z'D$'D @\>YFUC4ETR%[ENB#./4] . <9) SVZT 7**CMW
M:159QM8@$KG."1R,CKCUJ2@ HHHH ***R_#.J-JMNERX 9]V0N0.&([D^E &
MI1110 45E^&=4;5;=+EP S[LA<@<,1W)]*U* "BBB@ HK'U+4KB"XBABBW1/
M]]_3UYZ# YY^]T'-;% !1167XFU1M*MWN4 +)MP&R1RP'8CUH U**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *&N_ZEOP_P#0A11KO^I;\/\ T(44 <+<_>/^>U15+<_>
M/^>U14 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;O@[_7-_US/_
M *$M85;O@[_7-_US/_H2T =C7'^*U_MN[@T8AO**F:?!VY5<JBYSD@O]X8S]
MT@C!(["N2U,MI^J07+ >5<0-!N)QM<,9!GC&6X51G).?3D ZJ&%85"( %4
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M\N>,M$P!#;H_OH>3GCY@V%'\/)K;KG_'.F/?6K-"/W\#++%U)#1G/  .XD9
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MLZ* ,3^VW^W_ -GX7R_LOFYP=V[S-F,YQC'MG/>LKQ+X[.A77V5DWJUN&C5
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M::?VCWLEJ5FG%_ NOGY%RBBBO-/:"BBB@ HHHH **** "BBB@ HHHH ****
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M!'MTZ$CO754 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!0UW_4M^'_ *$**-=_U+?A_P"A"B@#A;G[
MQ_SVJ*I;G[Q_SVJ*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5M^96SMWY^Z3ZCK6A\1O!/\ PD40DB"_:(OND\%EYS'G..O()X!XX#$UV%%
M'G7PS\-7?AU+EYHOG94,:[T^8H'^7() R2!D^M4? ?PXE2>2ZU*,-Q\HD*R;
MF<G<QPS9(_V@<EL]17J=% &3_P (G9_\^\/_ 'Y3_P")K@-:\!7.F:@M]I\6
MZ(,C[4=8P#GYXQN;.& [# #;0,"O5:* "BBB@ KR_P"%_@R[T2Y>:YCV(864
M'>C<ET.,*Q/0&O4** *FJZ8FJ1/:RC*2*0>F1GH1D$9!Y!QP0#7E5KX,U?PP
M[I8E623&67RN0I;;D2\@X.3C(YZG%>P44 >?_#GX<MH3&\N2IE*X51A@@8#)
M)Q][^'Y> ,\MNXZV;PQ:3,7>"(LQ)),2$DGDDDCDFM.B@#S3XD> 'OO)_L^!
M!M\S?Y8CCZ[=N<E<]#ZX_&NS\.:2=,M(X$58Y?*7=A01YFP LP4C<<CDYYQU
M[UL44 >;^ _A[/I=W)>7A#,@^1@Q;<T@.]LDAL@9!W+R6R.F:](HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,_6_N#_>'\C7%:]_KC_NQ_\ H"UVNM_<'^\/Y&N*U[_7'_=C_P#0%KNR
MS^*_3]4>5GG\"/\ B7Y,SZ***]@^<"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO"JI$0T<49)PV<@N>Y7IQP3TP,AK6IV#SW5M.HRD7G;CD<;D '&<G)]*V**
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MBL_^TG_YYM^O^%']I/\ \\V_7_"@#0HK/_M)_P#GFWZ_X4?VD_\ SS;]?\*
M-"BL_P#M)_\ GFWZ_P"%']I/_P \V_7_  H T**S_P"TG_YYM^O^%']I/_SS
M;]?\* -"BL_^TG_YYM^O^%']I/\ \\V_7_"@#0HK/_M)_P#GFWZ_X4?VD_\
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MH_M)_P#GFWZ_X4 :%%9_]I/_ ,\V_7_"C^TG_P">;?K_ (4 :%%9_P#:3_\
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MU_\ B:/[5D_YY-^O_P 31_:G]W\?^ ']@_W_ ,/^">>T5Z%_:LG_ #R;]?\
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MU_\ B:/[5D_YY-^O_P 31_:G]W\?^ ']@_W_ ,/^">>T5Z%_:LG_ #R;]?\
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MD_YY-^O_ ,31_:LG_/)OU_\ B:/[4_N_C_P _L'^_P#A_P $\]HKT+^U9/\
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MD_YY-^O_ ,31_:LG_/)OU_\ B: -.BLS^U9/^>3?K_\ $T?VK)_SR;]?_B:
M-.BLS^U9/^>3?K_\31_:LG_/)OU_^)H TZ*S/[5D_P">3?K_ /$T?VK)_P \
MF_7_ .)H TZ*S/[5D_YY-^O_ ,31_:LG_/)OU_\ B: -.BLS^U9/^>3?K_\
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MR?\ /)OU_P#B:/[5D_YY-^O_ ,30!IT5F?VK)_SR;]?_ (FC^U9/^>3?K_\
M$T :=%9G]JR?\\F_7_XFC^U9/^>3?K_\30!IT5F?VK)_SR;]?_B:/[5D_P">
M3?K_ /$T :=%9G]JR?\ /)OU_P#B:/[5D_YY-^O_ ,30!IT5F?VK)_SR;]?_
M (FC^U9/^>3?K_\ $T :=%9G]JR?\\F_7_XFC^U9/^>3?K_\30!IT5F?VK)_
MSR;]?_B:/[5D_P">3?K_ /$T :=%9G]JR?\ /)OU_P#B:/[5D_YY-^O_ ,30
M!IT5F?VK)_SR;]?_ (FC^U9/^>3?K_\ $T :=%9G]JR?\\F_7_XFC^U9/^>3
M?K_\30!IT5F?VK)_SR;]?_B:/[5D_P">3?K_ /$T :=%9G]JR?\ /)OU_P#B
M:/[5D_YY-^O_ ,30!IT5F?VK)_SR;]?_ (FC^U9/^>3?K_\ $T :=%9G]JR?
M\\F_7_XFC^U9/^>3?K_\30!IT5F?VK)_SR;]?_B:/[5D_P">3?K_ /$T :=%
M9G]JR?\ /)OU_P#B:/[5D_YY-^O_ ,30!IT5F?VK)_SR;]?_ (FC^U9/^>3?
MK_\ $T :=%9G]JR?\\F_7_XFC^U9/^>3?K_\30!IT5F?VK)_SR;]?_B:/[5D
M_P">3?K_ /$T :=%9G]JR?\ /)OU_P#B:/[5D_YY-^O_ ,30!IT5F?VK)_SR
M;]?_ (FC^U9/^>3?K_\ $T 2:[_J6_#_ -"%%4=3U!Y8V4QE0<<G/J/844 <
MG<_>/^>U15+<_>/^>U14 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %;O@[_7-_US/_H2UA5N^#O]<W_7,_\ H2T =C117G_A:+4=>MDO?MNSS-WR
M_9HFQM8KUX],]* /0**Q-$TJ[M'+W-UYR%2 ODI'@Y'S94YZ9&/?VK*UNXN[
MN_%A;3^2@M1*?W229/F%/XN>F._;IS0!V%%<9>7=[X8"W-Q,MQ;%U$I,0B>-
M6.T.NPG<,GD8)X  Y)&QXQNI[*U>YMC^\AP^"%*LJG+@[NVW)^4AN.#V(!MT
M57TZ]6_B2X3(65%8 ]<, 1G&>>:L4 %%<YX)UB76XY+Z3(CDE80KA1B-/E!X
MR=Q.=V2>1\H Z]'0 4444 %%%% !1110 4444 %%%% !117/^+='N]2\G[)/
MY.R3+\=1V/'7'/R'Y6SR>!0!T%%%% !1110 4444 %%%% !17.>&)I-3EGOV
M8F)G,<*A\ILC)5I!M."78'DC< , E33?%EVYGL[.)F5Y;C>2"54QPJ6D4XY.
MX$8&,'OB@#I:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BJ^HWJV$3W#Y*Q(S$#KA02<9QSQ63X&6464!G<O(Z;BQ8L2')=<EN<A
M2![8P.* -ZBBN?\ $FJ20SVEG VUYYB6) *F.)=TB\@D$@C&!^(H Z"BL'QM
MK$FE6KRP8\YBJ1@C)+.P&%7^)L9('/3D$9%:&B:HNJP1W2XQ*BM@'=@D<KGU
M4Y!]QT% %ZBBN7\*^*CKMS=HA!A@,:QXQS]_<V03D,1QSC:!P#G(!U%%<UXP
MNWL9+.>-F&ZZ6)ER=C+,""2HQDKC*]@>QKI: "BBB@ HHHH **** "BBB@ H
MHHH *AN_N-_NG^535#=_<;_=/\J *NB?</\ O'^0K0K/T3[A_P!X_P A6A0
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M /XZW^%>?T4?V92[O\/\@_MROVC]S_S/0/\ A*;;^_\ ^.M_A1_PE-M_?_\
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MKY/^!?\ H0K:K%TS_7R?\"_]"% &U1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!BZG_KX_P#@/_H1K:K%U/\ U\?_  '_ -"-
M;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !69X@
M_P!6/]X?R-:=9GB#_5C_ 'A_(T :=%%% !1110 4444 %%%% !1110 4444
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MR.JSQ;R& 4G:X!Z@;CA5Z *?7+:OB?6_[&@:<#=(<+&N,EI&X10N03SR0.<
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MDXXST '% '46.K0ZAGR)$DVXSY;JV,YQG!.,X-6)IEA4NY 50223@ #DDD]
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M3CDDFK=% $-W:K=HT,@RDBE6&2,AA@C(YZ5RMMX,N]/'E6M\ZQ#&U98DF8
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M10 4444 9^M_<'^\/Y&N*U[_ %Q_W8__ $!:[76_N#_>'\C7%:]_KC_NQ_\
MH"UW99_%?I^J/*SS^!'_ !+\F9]%%%>P?.!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5N>%+Z2*01(-R-]X=A_M>V/U
MZ=<5EV-B]\XB09)_(#U/M_GK7?Z3I*::FQ>2?O-W)_P]!V^N37'CJ\(0<7JW
MT_4]+*\)4J5%-.R77]"]1117BGTP4444 %%%% !1110 4444 %%%% !1110
M4444 %8NF?Z^3_@7_H0K:K%TS_7R?\"_]"% &U1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!BZG_KX_\ @/\ Z$:VJQ=3_P!?
M'_P'_P!"-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K=\'?ZYO^N9_]"6L*MWP=_KF_ZYG_ -"6@#L:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 58L;%[YQ
M$@R3^0'J?;_/6BQL7OG$2#)/Y >I]O\ /6N_TG24TU-B\D_>;N3_ (>@[?7)
MKEQ>+5%67Q'=@,!+$RN](K=_H@TG24TU-B\D_>;N3_AZ#M]<FKU%%>)*3DVW
MN?40A&G%12LD%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "L73/
M]?)_P+_T(5M5BZ9_KY/^!?\ H0H VJ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZX--M-.BL\^4BINQG8H7..F< >M6** ([>W6W41HH51T"@ #//04XQ@D/@9
M(!QS@XR,^^!^0IU% !38XQ$ B@     8  Z#%.HH C>W61ED*@LF=I(!(SP<
M'MGO4E%% %6ZTJ&[.^6-'(&,NBL<>F2*=_9T6SR-B^7_ '-HV]<_=QCKS]:L
M44 %5;K2H;L[Y8T<@8RZ*QQZ9(JU10!';VZVZB-%"J.@4  9YZ"I*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH H:[_J6_#_ -"%%&N_ZEOP_P#0A10!PMS]X_Y[5%4MS]X_Y[5%
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>0.:I?\ "TM._P">W_D.7_XBHOBM=+%8M$QQY\D:!B"54[@Y)QDX 0] 3[4
M/A?674,1:*2 2#YV1GL<$C(]B1Z&K&A^(YS-]@OXECE*LR.C9CD"M@[03D$#
M!VY)QDD+P*A_X6EIW_/;_P AR_\ Q%9^AZ@WC&[CU*-=EM9^8J[\>8[R( P(
M!(4*"/7\<G: =!;ZV_VZ33Y NWR4EB*@YVYV.&)/7=]W QCJ<UMUR7B^%;.Z
ML=0 !83^21C!(G4J#N]$Y(&.<GD5UM &)XIU]M*14A3S+B9MD4>1R<9+'D':
MHY8]N,E0<C8A#!0'(+8&2!@$]R 2<#VR?J:Y+PNK:]</K#G,(W1VH)! 4':\
MF"H*ERO?#8)4Y 6NPH **** "BBB@ HHHH **** "H;O[C?[I_E4U0W?W&_W
M3_*@"CI$ZQH0Q ^8]2!V%7OM:?WE_,5EZ=IRW*EF)ZXXQZ#VJU_8B>K?F/\
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M$]6_,?X4?V(GJWYC_"@"U]K3^\OYBC[6G]Y?S%5?[$3U;\Q_A1_8B>K?F/\
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MI_A6/_;4?]QO^_@_^(H_MJ/^XW_?P?\ Q%')C?/[T'M<K\ON?^1L?\(O:_\
M/0_]]I_A1_PB]K_ST/\ WVG^%8_]M1_W&_[^#_XBC^VH_P"XW_?P?_$4<F-\
M_O0>UROR^Y_Y&Q_PB]K_ ,]#_P!]I_A1_P (O:_\]#_WVG^%8_\ ;4?]QO\
MOX/_ (BC^VH_[C?]_!_\11R8WS^]![7*_+[G_D;'_"+VO_/0_P#?:?X4?\(O
M:_\ /0_]]I_A6/\ VU'_ '&_[^#_ .(H_MJ/^XW_ '\'_P 11R8WS^]![7*_
M+[G_ )&Q_P (O:_\]#_WVG^%'_"+VO\ ST/_ 'VG^%8_]M1_W&_[^#_XBC^V
MH_[C?]_!_P#$4<F-\_O0>UROR^Y_Y&Q_PB]K_P ]#_WVG^%'_"+VO_/0_P#?
M:?X5C_VU'_<;_OX/_B*/[:C_ +C?]_!_\11R8WS^]![7*_+[G_D;'_"+VO\
MST/_ 'VG^%'_  B]K_ST/_?:?X5C_P!M1_W&_P"_@_\ B*/[:C_N-_W\'_Q%
M')C?/[T'M<K\ON?^1L?\(O:_\]#_ -]I_A1_PB]K_P ]#_WVG^%8_P#;4?\
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M^%'_  C\?JWYC_"CZW6_F8?V?AOY$9G_  B]K_ST/_?:?X4?\(O:_P#/0_\
M?:?X5I_\(_'ZM^8_PH_X1^/U;\Q_A1];K?S,/[/PW\B,S_A%[7_GH?\ OM/\
M*/\ A%[7_GH?^^T_PK3_ .$?C]6_,?X4?\(_'ZM^8_PH^MUOYF']GX;^1&9_
MPB]K_P ]#_WVG^%'_"+VO_/0_P#?:?X5I_\ "/Q^K?F/\*/^$?C]6_,?X4?6
MZW\S#^S\-_(C,_X1>U_YZ'_OM/\ "HY_#-LBDK(20#@;UZX^E:__  C\?JWY
MC_"H[C0TC5F!;(!/4=A]*/K=;^9A_9^&_D1C:?X>@F4F1R#GIN4<8'J*M?\
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M,/[/PW\B,S_A%[7_ )Z'_OM/\*/^$7M?^>A_[[3_  K3_P"$?C]6_,?X4?\
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M_"/Q^K?F/\*/^$?C]6_,?X4 7/ML?]Y?^^A1]MC_ +R_]]"J?_"/Q^K?F/\
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M(_'ZM^8_PH N?;8_[R_]]"C[;'_>7_OH53_X1^/U;\Q_A1_PC\?JWYC_  H
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M8_[R_P#?0JG_ ,(_'ZM^8_PH_P"$?C]6_,?X4 7/ML?]Y?\ OH4?;8_[R_\
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MA0!<^VQ_WE_[Z%'VV/\ O+_WT*I_\(_'ZM^8_P */^$?C]6_,?X4 7/ML?\
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MF/\ "C_A'X_5OS'^% %S[;'_ 'E_[Z%'VV/^\O\ WT*I_P#"/Q^K?F/\*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB#_5C_>'\C6G69X@_P!6/]X?R- &G1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!2UC_5-^'\Q1H_^J7\?YFC6/]4WX?S%&C_Z
MI?Q_F: +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 4-=_U+?A_P"A"BC7?]2WX?\ H0HH
M X6Y^\?\]JBJ6Y^\?\]JBH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]K^3\VWR+B.7[N<[,_+U&,YZ\X]*UJ** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *AN_N-_NG^535#=_<;_=/\J *NB?</\ O'^0K0K/T3[A_P!X_P A6A0
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M !1110 4444 %%%% !1110 4444 %%%% &?K?W!_O#^1KBM>_P!<?]V/_P!
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M I^'_P#5G_>/\A6G69X?_P!6?]X_R%:= !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !6+IG^OD_X%_P"A"MJL73/]?)_P+_T(4 ;5
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+J?
M^OC_ . _^A&MJL74_P#7Q_\  ?\ T(UM4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %9GB#_ %8_WA_(UIUF>(/]6/\ >'\C0!IT
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4M8_
MU3?A_,4:/_JE_'^9HUC_ %3?A_,4:/\ ZI?Q_F: +M%%% '/V^J21ZC)8NVZ
M-[=)4& -F&\MEX&6W'YLD\= .];5W=+:(TTAPD:EF."<!1DG YZ5ROCJ3^SY
M['4-R@1W!C;?]W;.N&8G(QM"GVYR>!@V/B!,TT*:?&2)+R5(\J?F5,[I'VCE
ME"C#<@8;DXZ@#/ 'BM]?27SAMD23(7!!$<@WQ9. #QD @#( )'.3H>--9;1K
M.:ZC^^J@+TX+L$#<@@X)SC'.,5E7X70-0@F4;8;J/R"$4J@="#$3M!!)!V*"
M!M4'G (!XPD^V7EC8!E&9C,W=AY*EEXR,!OF&?4<="" =5:1M$BI(V]PH#-@
M+N('+8' R><=JFK!\7>)#HD:B-0\\[B.)"0,LW&3DCY1QGW(!(SD4O\ A#Y[
M[][=7<PD/\-LWDQJ.NT#!+8)/S'DC&>E '5T5Q4NHW/A.6-;J7SK.9A&KOM6
M2)N=NX\;P0/F8\\$\8PS/B#J%U;7%G%9L1)*9EQ\Q3D( S*,Y"9+<@@8S@C(
MH [BN:^'%V]W80RRLSN?,RSDLQQ(P&2>>E6O#WAHZ1EGGFF<J 3-(64'N57H
M,GUR0. >N<7P'J::7I$=U*<)&LI/3)Q*^ ,D#)/ &>20* .UHKC-/L;OQ1&M
MU<3-;Q2#='%;$*^#RC-+R22IY4 #[IP#D4:A8W?A>-KJWF:XBC&Z2*Y(9\#E
MV67@@A1PI!'WC@G H O?#B[>[L(9969W/F99R68XD8#)//2NEKS?1%E&A++
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MS8F=\)N/\2G(!8_@%X5NSH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AKO^I;\/\ T(44:[_J6_#_
M -"%% '"W/WC_GM452W/WC_GM45 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !6IX:_X^$_X%_P"@FLNM3PU_Q\)_P+_T$T =O-,L*EW("J"22<
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M]O8L&M98A+M"NH1PP1@H;'!SDX&/NJ,!:]#H R?%G_'G<_\ 7O-_Z U'A/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UO[@_P!X?R-<5KW^N/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1EP\9W#;CD,<;01R,]^E8OA&];Q!>RZGP(TMH8E"_,"9 )7&_H61CM( '49
M/7N*Q_#'AF/P]&\$1)5Y7?![;L *.IP% &222<GO@ &/XSN1I]W87LG$222H
MS9  ,R!5)R1QP23V /L#V%5]0T^/48VMYE#1N,$'_/!'4$<@\CFN:A\&W.GJ
M(;2]D2( 866-)B,<<,=N%P!A0,#D]Z &?%&Y#6GV)>9;J2-(U! ).]6SR1QQ
MC/8D9ZYJ7Q%_R$=/_P"WK_T4*MZ-X.2QE^VRN\]P5QOE((7.2VQ0,("2>.<#
M@'!.;6HZ%]LN;>]W8^S>;\NW.[S5"]<C&,9Z'/M0!K5Y?;6K77ATH@R0K-U
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6IX:_P"/A/\
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M_=/\J *NB?</^\?Y"M"L_1/N'_>/\A6A0 4444 %%%% !1110 4444 %%%%
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M7_"C^R8?^>:?]\+_ (4?VI#^5A_853^9'FM%>E?V3#_SS3_OA?\ "C^R8?\
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M "BBB@ J"]_U;_[K?RJ>H+W_ %;_ .ZW\J *?A__ %9_WC_(5IUF>'_]6?\
M>/\ (5IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %8NF?Z^3_@7_H0K:K%TS_7R?\"_]"% &U1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!BZG_KX_\ @/\ Z$:VJQ=3_P!?'_P'
M_P!"-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!69X@_U8_P!X?R-:=9GB#_5C_>'\C0!IT444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 4M8_P!4WX?S%&C_ .J7\?YFC6/]4WX?
MS%&C_P"J7\?YF@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %#7?]2WX?^A"BC7?]2WX?
M^A"B@#A;G[Q_SVJ*I;G[Q_SVJ*@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K3\/Q,\N4^\JDCI]._UK,K=\'?ZYO^N9_P#0EH V_P#2?\[:/])_
MSMK6HH R?])_SMH_TG_.VM:B@#)_TG_.VC_2?\[:UJ* ,G_2?\[:/])_SMK6
MHH R?])_SMH_TG_.VM:B@#)_TG_.VC_2?\[:UJ* ,G_2?\[:/])_SMK6HH R
M?])_SMH_TG_.VM:B@#)_TG_.VC_2?\[:UJ* ,G_2?\[:/])_SMK6HH R?])_
MSMH_TG_.VM:B@#)_TG_.VC_2?\[:UJ* ,G_2?\[:/])_SMK6HH R?])_SMH_
MTG_.VM:B@#)_TG_.VC_2?\[:UJ* ,G_2?\[:/])_SMK6HH R?])_SMH_TG_.
MVM:B@#)_TG_.VC_2?\[:UJ* ,G_2?\[:/])_SMK6HH R?])_SMH_TG_.VM:B
M@#)_TG_.VC_2?\[:UJ* ,G_2?\[:/])_SMK6HH R?])_SMH_TG_.VM:B@#)_
MTG_.VC_2?\[:UJ* ,G_2?\[:/])_SMK6HH R?])_SMH_TG_.VM:B@#)_TG_.
MVC_2?\[:UJ* ,G_2?\[:/])_SMK6HH R?])_SMH_TG_.VM:B@#)_TG_.VC_2
M?\[:UJ* ,G_2?\[:/])_SMK6HH R?])_SMH_TG_.VM:B@#)_TG_.VC_2?\[:
MUJ* ,G_2?\[:/])_SMK6HH R?])_SMH_TG_.VM:B@#)_TG_.VC_2?\[:UJ*
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M0!B_Z5_G91_I7^=E;5% &+_I7^=E,G^T[3N^[@Y^[TQS6[4%[_JW_P!UOY4
M8>G^=M/E?=S_ +/7 ]:L_P"E?YV5/X?_ -6?]X_R%:= &+_I7^=E'^E?YV5M
M44 8O^E?YV4?Z5_G96U10!B_Z5_G91_I7^=E;5% &+_I7^=E'^E?YV5M44 8
MO^E?YV4?Z5_G96U10!B_Z5_G91_I7^=E;5% &+_I7^=E'^E?YV5M44 8O^E?
MYV4?Z5_G96U10!B_Z5_G91_I7^=E;5% &+_I7^=E'^E?YV5M44 8O^E?YV4?
MZ5_G96U10!B_Z5_G91_I7^=E;5% &+_I7^=E'^E?YV5M44 8O^E?YV4?Z5_G
M96U10!B_Z5_G91_I7^=E;5% &+_I7^=E'^E?YV5M44 8O^E?YV4?Z5_G96U1
M0!B_Z5_G91_I7^=E;5% &+_I7^=E'^E?YV5M44 8O^E?YV4?Z5_G96U10!B_
MZ5_G91_I7^=E;5% &+_I7^=E4[;S?,;9]_G/3UYZ\=:Z:L73/]?)_P "_P#0
MA0 ?Z5_G91_I7^=E;5% &+_I7^=E'^E?YV5M44 8O^E?YV4?Z5_G96U10!B_
MZ5_G91_I7^=E;5% &+_I7^=E'^E?YV5M44 8O^E?YV4?Z5_G96U10!B_Z5_G
M91_I7^=E;5% &+_I7^=E'^E?YV5M44 8O^E?YV4?Z5_G96U10!B_Z5_G91_I
M7^=E;5% &+_I7^=E'^E?YV5M44 8O^E?YV4?Z5_G96U10!B_Z5_G91_I7^=E
M;5% &+_I7^=E'^E?YV5M44 8O^E?YV4?Z5_G96U10!B_Z5_G91_I7^=E;5%
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M;5% &+_I7^=E'^E?YV5M44 8O^E?YV4?Z5_G96U10!B_Z5_G91_I7^=E;5%
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M<=0H9\$$@@E P!!'(/(]*U=,U6+5$$T#JZ'NIS@X!P1U!P1D'!'<4 6Z***
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MX:5&7ET9]3@<='%1[26Z)****YSL"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *@O?]6_\ NM_*IZ@O?]6_^ZW\J *?A_\ U9_WC_(5IUF>'_\
M5G_>/\A6G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5BZ9_KY/^!?\ H0K:K%TS_7R?\"_]"% &U1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!BZG_KX_P#@/_H1K:K%U/\ U\?_
M  '_ -"-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !69X@_P!6/]X?R-:=9GB#_5C_ 'A_(T :=%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %+6/]4WX?S%&C_ZI?Q_F:-8_P!4
MWX?S%&C_ .J7\?YF@"[1110 45GV^MI//)8X99(E1OF  96_B7G) /#'& >*
MT* "BL_1==BUE6D@.Y4D=">V5/4$9!!!!!!Z$=\@2ZKJ::7$]U*<)&I)Z9..
M@&2!DG@#/)(% %NBH;2X^THLN&7>H.UQAAD9P1V([CUJ:@ HHHH ***R?"VN
M_P!O6R7NW9YF[Y=V[&UBO7 ],]* -:BBB@ HK)\+:[_;ULE[MV>9N^7=NQM8
MKUP/3/2M:@ HHHH **Y_6/%O]FW<%AY3O]HS\Z]!VX'?'5^1M7!YZ5T% !11
M63XIUW^P;9[W;O\ +V_+NVYW,%ZX/KGI0!K4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M4-=_U+?A_P"A"BC7?]2WX?\ H0HH X6Y^\?\]JBJ6Y^\?\]JBH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBI8+5Y\[%+8Z[03_*@"*BBB@ HHHH
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M-8M;J,!?M GW #'S)&V6Z]6W#/ Y&3DDT =EJ>JQ:6AFG=40=V.,G!. .I.
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M;%<YK>B0:99W9@C6/S()2VQ0N<1D#@= /0<9)/4DD T(=5BAM!>HI$*P"0*
M 0@3<% !P"!QC./>LV?Q_ @01K++))&DGE0Q[Y%5QD%@#@=1D9SR.,'-0_\
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M*SQ&-&C<%<L1NR4.UAG' P3PN #T.BBB@ HHHH **** "BBB@ HHHH ****
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M@94+$N% P"!V9N?FH T-<\(VVNLKW*%R@POSNH&>O"L!D]SC)P/05Y9\%/\
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M21H\F5QY<84X<O(=HVXY+#.X <G';K5+XEVS-9FXCW>9;21RIM /*-@D@@Y
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M3P.:YSQ%_P A'3_^WK_T4*B\9VPU"[L+*3F)Y)79< @F% R@Y!XY(([@GV(
M)?\ A+[F\_>6=F\L79Y)%@W=PRJX)*D$$-QG.,<5A>.O%T=[8S6DJM#<X0^5
M*,9Q*F2C?==<YP1R0"<8%>D5Q7Q<TQ+JQ:=A\\#*5(QGYF"$9QG!!S@8Y ]*
M .RFF6%2[D!5!)).  .223T KDH?',^IDM8VCS1#_EH[K"K'+#Y=X.X<?4="
M!W9\5"\EM';H"?/N8HV4%5+ Y8*&8$*2RCGMWXR*FAUS4(5")IX"J  !=1
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MO@[_ %S?]<S_ .A+6%6[X._US?\ 7,_^A+0!V-<IX^_Y<_\ L(6__LU=710
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M^0^$C.YV4\*6+#\ !R &;TNB@#DM8TZ?2+O^U;9#+'*@6XB4G>=@XD4%L,P
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M "BBB@ HHHH **** "BBB@ HHHH *AN_N-_NG^535#=_<;_=/\J *NB?</\
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M<!1(2<#GI6+X2\/MX[NYKBY9@@^9RA&<MPB#<6(  ..#@+MXR#7NM% 'G_\
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MHH **** "BBB@ HHHH **** "BBB@#%U/_7Q_P# ?_0C6U6+J?\ KX_^ _\
MH1K:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S
M/$'^K'^\/Y&M.LSQ!_JQ_O#^1H TZ*** "BBB@ HHHH **** "BBB@ HHHH
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M=W52, \=@N3GD\\^G(Y-<U10!N^#O]<W_7,_^A+5K0_^/N;_ +:?^ABN8HH
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MX)Y[17H7_"01^C?D/\:/^$@C]&_(?XT?VI_=_'_@!_8/]_\ #_@GGM%>A?\
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M:T/^$@C]&_(?XT :=%9G_"01^C?D/\:/^$@C]&_(?XT :=%9G_"01^C?D/\
M&C_A((_1OR'^- &G169_PD$?HWY#_&C_ (2"/T;\A_C0!IT5F?\ "01^C?D/
M\:/^$@C]&_(?XT :=%9G_"01^C?D/\:/^$@C]&_(?XT :=%9G_"01^C?D/\
M&C_A((_1OR'^- &G169_PD$?HWY#_&C_ (2"/T;\A_C0!IT5F?\ "01^C?D/
M\:/^$@C]&_(?XT :=%9G_"01^C?D/\:/^$@C]&_(?XT :=%9G_"01^C?D/\
M&C_A((_1OR'^- &G169_PD$?HWY#_&C_ (2"/T;\A_C0!IT5F?\ "01^C?D/
M\:/^$@C]&_(?XT :=%9G_"01^C?D/\:/^$@C]&_(?XT :=%9G_"01^C?D/\
M&C_A((_1OR'^- &G169_PD$?HWY#_&C_ (2"/T;\A_C0!IT5F?\ "01^C?D/
M\:/^$@C]&_(?XT :=%9G_"01^C?D/\:/^$@C]&_(?XT :=%9G_"01^C?D/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_D*/LB?W5_(5-10!#]D3^ZOY"C[(G]U?R%344 0_9$_NK^0H^R)_=7\A4U%
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M9_X2AO\ GG%_WP?\:/\ A*&_YYQ?]\'_ !K&HH^J4?Y4']H8G^=FS_PE#?\
M/.+_ +X/^-'_  E#?\\XO^^#_C6-11]4H_RH/[0Q/\[-G_A*&_YYQ?\ ?!_Q
MH_X2AO\ GG%_WP?\:QJ*/JE'^5!_:&)_G9L_\)0W_/.+_O@_XT?\)0W_ #SB
M_P"^#_C6-11]4H_RH/[0Q/\ .S9_X2AO^><7_?!_QH_X2AO^><7_ 'P?\:QJ
M*/JE'^5!_:&)_G9L_P#"4-_SSB_[X/\ C1_PE#?\\XO^^#_C6-11]4H_RH/[
M0Q/\[-G_ (2AO^><7_?!_P :/^$H;_GG%_WP?\:QJ*/JE'^5!_:&)_G9L_\
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MBC_NK_WR*/L4?]U?^^14]% $'V*/^ZO_ 'R*/L4?]U?^^14]% $'V*/^ZO\
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M8H_[J_\ ?(J>B@"#[%'_ '5_[Y%'V*/^ZO\ WR*GHH @^Q1_W5_[Y%'V*/\
MNK_WR*GHH @^Q1_W5_[Y%'V*/^ZO_?(J>B@"#[%'_=7_ +Y%'V*/^ZO_ 'R*
MGHH @^Q1_P!U?^^11]BC_NK_ -\BIZ* (/L4?]U?^^11]BC_ +J_]\BIZ* (
M/L4?]U?^^11]BC_NK_WR*GHH @^Q1_W5_P"^11]BC_NK_P!\BIZ* (/L4?\
M=7_OD4?8H_[J_P#?(J>B@"#[%'_=7_OD4?8H_P"ZO_?(J>B@"#[%'_=7_OD4
M?8H_[J_]\BIZ* (/L4?]U?\ OD4?8H_[J_\ ?(J>B@"#[%'_ '5_[Y%'V*/^
MZO\ WR*GHH PM0@5)D4  ';D #'WC6M]BC_NK_WR*S-3_P!?'_P'_P!"-;5
M$'V*/^ZO_?(H^Q1_W5_[Y%3T4 0?8H_[J_\ ?(H^Q1_W5_[Y%3T4 0?8H_[J
M_P#?(H^Q1_W5_P"^14]% $'V*/\ NK_WR*/L4?\ =7_OD5/10!!]BC_NK_WR
M*/L4?]U?^^14]% $'V*/^ZO_ 'R*/L4?]U?^^14]% $'V*/^ZO\ WR*/L4?]
MU?\ OD5/10!!]BC_ +J_]\BC[%'_ '5_[Y%3T4 0?8H_[J_]\BC[%'_=7_OD
M5/10!!]BC_NK_P!\BC[%'_=7_OD5/10!!]BC_NK_ -\BC[%'_=7_ +Y%3T4
M0?8H_P"ZO_?(H^Q1_P!U?^^14]% $'V*/^ZO_?(H^Q1_W5_[Y%3T4 0?8H_[
MJ_\ ?(H^Q1_W5_[Y%3T4 0?8H_[J_P#?(H^Q1_W5_P"^14]% $'V*/\ NK_W
MR*/L4?\ =7_OD5/10!!]BC_NK_WR*/L4?]U?^^14]% $'V*/^ZO_ 'R*/L4?
M]U?^^14]% $'V*/^ZO\ WR*/L4?]U?\ OD5/10!!]BC_ +J_]\BC[%'_ '5_
M[Y%3T4 0?8H_[J_]\BC[%'_=7_OD5/10!!]BC_NK_P!\BL_7+=8T!50#N'0
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M8H_[J_\ ?(J>B@"#[%'_ '5_[Y%'V*/^ZO\ WR*GHH @^Q1_W5_[Y%'V*/\
MNK_WR*GHH @^Q1_W5_[Y%'V*/^ZO_?(J>B@#+UFU1(F(4 \<@ =Q14NN_P"I
M;\/_ $(44 <+<_>/^>U15+<_>/\ GM45 !1110 4444 %%%% !1110 4444
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MNYVK@$'<1G=MP<XJ[HEFUE!'#(Q:144.Q9GRV/F.YN2"<X]!P !Q0!>HHHH
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MB!UPH).,XYXH L45\_Z7\1+F"[6\ED=HS(2T>]RFUL[@J%L< _*"< @5] 4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "%:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M+IG^OD_X%_Z$*VJQ=,_U\G_ O_0A0!M4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 8NI_Z^/_ (#_ .A&MJL74_\ 7Q_\!_\
M0C6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F
M>(/]6/\ >'\C6G69X@_U8_WA_(T :=%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% !1110 4444 %%%% !1110 4444 4-=_U+?A_Z$**-=_U+?A_Z$**
M.%N?O'_/:HJEN?O'_/:HJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_0A6U6+IG^OD_P"!?^A"@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH Q=3_ -?'_P !_P#0C6U6+J?^OC_X#_Z$:VJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LSQ!_JQ_O#^
M1K3K,\0?ZL?[P_D: -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQRSS 2NS'JQ9P>3U.,#.2 ,U0\=))9/;ZM&I<6;OYB@9/ER*%=A\PY4#]<G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "H;O[C?[I_E4U0W?W&_P!T_P J *NB?</^
M\?Y"M"L_1/N'_>/\A6A0!7U&R6_B>W?(65&4D=<,"#C.>>:Q_"G@J'PQYGD,
M[>;MSYA4_=SC&%7^\:Z"B@#E_%'P\M_$DHN)FD#*@4!"H& 2>ZMS\U=!J-DM
M_$]N^0LJ,I(ZX8$'&<\\U8HH Y_PIX*A\,>9Y#.WF[<^85/W<XQA5_O&J]]\
M/+>]NQJC-()0\;8!79F,*!QM)Q\HSS7444 9/B7PU%XBB^S3[MH8,"APP(R,
MC((Z$CD'KZX(KZ7X/BTZU?35>1HI XR[ LHD7!"_* !U/3J2>];U% '/^%/!
M4/ACS/(9V\W;GS"I^[G&,*O]XUH:[H46N1&VG&5;H1]Y3V8'L1_]8Y!(.A10
M!S7A_P !0Z"DT4#R_P"D* 6++N7 8 J0HP1N///.*=X5\"6_AIG>$LS2  F3
M:2 ,G (5< ]_7 ]*Z.B@ KE]?^'EOK4XO6:2.50O,)5>5.0V=I.X<#.>@'I7
M444 %%%% !7+^%_AY;^&Y3<0M(69"I#E2,$@]E7GY:ZBB@ HHHH Y?PO\/+?
MPW*;B%I"S(5(<J1@D'LJ\_+6EXA\,0>($$5PN=N=K X921C(/]#D$@9!Q6M1
M0!Q6F?"*QL7$IWR8Z+*P*Y!!SA57/3H<@@G(-=E-"LRE' *L""",@@\$$'J#
M3Z* .$NO@W8S,74RH#CY4<%1QVWJQYZ\D_E6[X9\%6WAP$P*2[#!=SER,YQV
M 'T S@9R1FMZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH S];^X/\ >'\C7%:]_KC_ +L?_H"UVNM_<'^\
M/Y&N*U[_ %Q_W8__ $!:[LL_BOT_5'E9Y_ C_B7Y,SZ***]@^<"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "K%C8O?.(D&2?R ]3[?YZT
M6-B]\XB09)_(#U/M_GK7?Z3I*::FQ>2?O-W)_P /0=OKDURXO%JBK+XCNP&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"EK'^J;\/YBC1_]4OX_S-&L?ZIOP_F*-'_U2_C_ #- %VBBB@ JII>E
MQZ5&MM NV-,X&2<9))Y))ZD]ZMT4 %5[/3X[(,(U"[W9VQW9SEF)[D_H, <
M"K%% !7.7OP[T^];>\"@@8^0M&/R0J,\]<9KHZ* *.EZ)!I2[+>-4& #M4 G
M;TR>K'W))Z^M/N-+CN9([EUS)!OV')&-XPW .#D>H/M5NB@ JII>EQZ5&MM
MNV-,X&2<9))Y))ZD]ZMT4 9.M^%;76\&YC5R,8;E6P,\;E(..3QG&><9J+1O
M!=GHS>;!$JO_ 'B6=AP1P7)(R"<XQGO6W10!4TO2X]*C6V@7;&F<#).,DD\D
MD]2>]$FE12RK=LBF5%*JY'S -U'^>F2!]XYMT4 ,FA692C@%6!!!&00>""#U
M!IEI:K:(L,8PD:A5&2<!1@#)YZ5-10!4N-+CN9([EUS)!OV')&-XPW .#D>H
M/M5NBB@#G]3\ V.IN9I85+GJ5+)DDDDD(5!))Y)Y/K4L?@NSB@:R6)1%)C<
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MIGN* .YHK)_L+_:_\=_^O1_87^U_X[_]>@#6HK)_L+_:_P#'?_KT?V%_M?\
MCO\ ]>@#6HK)_L+_ &O_ !W_ .O1_87^U_X[_P#7H UJ*R?["_VO_'?_ *]'
M]A?[7_CO_P!>@#6HK)_L+_:_\=_^O1_87^U_X[_]>@#6HK)_L+_:_P#'?_KT
M?V%_M?\ CO\ ]>@#6HK)_L+_ &O_ !W_ .O1_87^U_X[_P#7H UJ*R?["_VO
M_'?_ *]']A?[7_CO_P!>@#6HK)_L+_:_\=_^O1_87^U_X[_]>@#6HK)_L+_:
M_P#'?_KT?V%_M?\ CO\ ]>@#6HK)_L+_ &O_ !W_ .O1_87^U_X[_P#7H UJ
M*R?["_VO_'?_ *]']A?[7_CO_P!>@#6HK)_L+_:_\=_^O1_87^U_X[_]>@#6
MHK)_L+_:_P#'?_KT?V%_M?\ CO\ ]>@#6HK)_L+_ &O_ !W_ .O1_87^U_X[
M_P#7H UJ*R?["_VO_'?_ *]']A?[7_CO_P!>@#6HK)_L+_:_\=_^O1_87^U_
MX[_]>@#6HK)_L+_:_P#'?_KT?V%_M?\ CO\ ]>@#6HK)_L+_ &O_ !W_ .O1
M_87^U_X[_P#7H UJ*R?["_VO_'?_ *]']A?[7_CO_P!>@#6HK)_L+_:_\=_^
MO1_87^U_X[_]>@#6HK)_L+_:_P#'?_KT?V%_M?\ CO\ ]>@#6HK)_L+_ &O_
M !W_ .O1_87^U_X[_P#7H UJ*R?["_VO_'?_ *]']A?[7_CO_P!>@#6HK)_L
M+_:_\=_^O1_87^U_X[_]>@#6HK)_L+_:_P#'?_KT?V%_M?\ CO\ ]>@#6HK)
M_L+_ &O_ !W_ .O1_87^U_X[_P#7H UJ*R?["_VO_'?_ *]']A?[7_CO_P!>
M@#6HK)_L+_:_\=_^O1_87^U_X[_]>@#6HK)_L+_:_P#'?_KT?V%_M?\ CO\
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M_P"O1_87^U_X[_\ 7H UJ*R?["_VO_'?_KT?V%_M?^.__7H UJ*R?["_VO\
MQW_Z]']A?[7_ ([_ /7H UJ*R?["_P!K_P =_P#KT?V%_M?^._\ UZ -:BLG
M^PO]K_QW_P"O1_87^U_X[_\ 7H UJ*R?["_VO_'?_KT?V%_M?^.__7H UJ*R
M?["_VO\ QW_Z]']A?[7_ ([_ /7H UJ*R?["_P!K_P =_P#KT?V%_M?^._\
MUZ -:BLG^PO]K_QW_P"O1_87^U_X[_\ 7H UJ*R?["_VO_'?_KT?V%_M?^._
M_7H UJ*R?["_VO\ QW_Z]']A?[7_ ([_ /7H UJ*R?["_P!K_P =_P#KT?V%
M_M?^._\ UZ -:BLG^PO]K_QW_P"O1_87^U_X[_\ 7H UJ*R?["_VO_'?_KT?
MV%_M?^.__7H UJ*R?["_VO\ QW_Z]']A?[7_ ([_ /7H UJ*R?["_P!K_P =
M_P#KT?V%_M?^._\ UZ -:BLG^PO]K_QW_P"O1_87^U_X[_\ 7H UJ*R?["_V
MO_'?_KT?V%_M?^.__7H UJ*R?["_VO\ QW_Z]']A?[7_ ([_ /7H UJ*R?["
M_P!K_P =_P#KT?V%_M?^._\ UZ -:BLG^PO]K_QW_P"O1_87^U_X[_\ 7H U
MJ*R?["_VO_'?_KT?V%_M?^.__7H UJ*R?["_VO\ QW_Z]']A?[7_ ([_ /7H
M UJ*R?["_P!K_P =_P#KT?V%_M?^._\ UZ -:BLG^PO]K_QW_P"O1_87^U_X
M[_\ 7H UJ*R?["_VO_'?_KT?V%_M?^.__7H FUO[@_WA_(U:M/N+_NC^58]]
MIGV9=V<Y..F.Q]Z=#H'F*&W=0#]WU_&@#<HK%_X1W_;_ /'?_KT?\([_ +?_
M ([_ /7H VJ*Q?\ A'?]O_QW_P"O1_PCO^W_ ..__7H VJ*Q?^$=_P!O_P =
M_P#KT?\ "._[?_CO_P!>@#:HK%_X1W_;_P#'?_KT?\([_M_^._\ UZ -JBL7
M_A'?]O\ \=_^O1_PCO\ M_\ CO\ ]>@#:HK%_P"$=_V__'?_ *]'_"._[?\
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M_P!O_P =_P#KT?\ "._[?_CO_P!>@#:HK%_X1W_;_P#'?_KT?\([_M_^._\
MUZ -JBL7_A'?]O\ \=_^O1_PCO\ M_\ CO\ ]>@#:HK%_P"$=_V__'?_ *]'
M_"._[?\ X[_]>@#:HK%_X1W_ &__ !W_ .O1_P ([_M_^.__ %Z -JBL7_A'
M?]O_ ,=_^O1_PCO^W_X[_P#7H VJ*Q?^$=_V_P#QW_Z]'_"._P"W_P"._P#U
MZ -JH+W_ %;_ .ZW\JS/^$=_V_\ QW_Z],GT'RE+[ON@G[OH/K0!:\/_ .K/
M^\?Y"M.N<T_2?MBE]V,''3/8>]6?^$=_V_\ QW_Z] &U16+_ ,([_M_^._\
MUZ/^$=_V_P#QW_Z] &U16+_PCO\ M_\ CO\ ]>C_ (1W_;_\=_\ KT ;5%8O
M_"._[?\ X[_]>C_A'?\ ;_\ '?\ Z] &U16+_P ([_M_^.__ %Z/^$=_V_\
MQW_Z] &U16+_ ,([_M_^._\ UZ/^$=_V_P#QW_Z] &U16+_PCO\ M_\ CO\
M]>C_ (1W_;_\=_\ KT ;5%8O_"._[?\ X[_]>C_A'?\ ;_\ '?\ Z] &U16+
M_P ([_M_^.__ %Z/^$=_V_\ QW_Z] &U16+_ ,([_M_^._\ UZ/^$=_V_P#Q
MW_Z] &U16+_PCO\ M_\ CO\ ]>C_ (1W_;_\=_\ KT ;5%8O_"._[?\ X[_]
M>C_A'?\ ;_\ '?\ Z] &U16+_P ([_M_^.__ %Z/^$=_V_\ QW_Z] &U16+_
M ,([_M_^._\ UZ/^$=_V_P#QW_Z] &U16+_PCO\ M_\ CO\ ]>C_ (1W_;_\
M=_\ KT ;5%8O_"._[?\ X[_]>C_A'?\ ;_\ '?\ Z] &U16+_P ([_M_^.__
M %Z/^$=_V_\ QW_Z] &U16+_ ,([_M_^._\ UZ/^$=_V_P#QW_Z] &U16+_P
MCO\ M_\ CO\ ]>C_ (1W_;_\=_\ KT ;5%8O_"._[?\ X[_]>C_A'?\ ;_\
M'?\ Z] &U16+_P ([_M_^.__ %Z/^$=_V_\ QW_Z] &U16+_ ,([_M_^._\
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MB_\ "._[?_CO_P!>C_A'?]O_ ,=_^O0!M45B_P#"._[?_CO_ ->C_A'?]O\
M\=_^O0!M45B_\([_ +?_ ([_ /7H_P"$=_V__'?_ *] &U16+_PCO^W_ .._
M_7H_X1W_ &__ !W_ .O0!M45B_\ "._[?_CO_P!>C_A'?]O_ ,=_^O0!M45B
M_P#"._[?_CO_ ->C_A'?]O\ \=_^O0!M45B_\([_ +?_ ([_ /7H_P"$=_V_
M_'?_ *] &U16+_PCO^W_ ..__7H_X1W_ &__ !W_ .O0!M45B_\ "._[?_CO
M_P!>C_A'?]O_ ,=_^O0!M45B_P#"._[?_CO_ ->C_A'?]O\ \=_^O0!M45B_
M\([_ +?_ ([_ /7H_P"$=_V__'?_ *] &U16+_PCO^W_ ..__7H_X1W_ &__
M !W_ .O0!M45B_\ "._[?_CO_P!>C_A'?]O_ ,=_^O0!M45B_P#"._[?_CO_
M ->C_A'?]O\ \=_^O0 :G_KX_P#@/_H1K:KF;G3O(D6+.=V.<>IQZU<_X1W_
M &__ !W_ .O0!M45B_\ "._[?_CO_P!>C_A'?]O_ ,=_^O0!M45B_P#"._[?
M_CO_ ->C_A'?]O\ \=_^O0!M45B_\([_ +?_ ([_ /7H_P"$=_V__'?_ *]
M&U16+_PCO^W_ ..__7H_X1W_ &__ !W_ .O0!M45B_\ "._[?_CO_P!>C_A'
M?]O_ ,=_^O0!M45B_P#"._[?_CO_ ->C_A'?]O\ \=_^O0!M45B_\([_ +?_
M ([_ /7H_P"$=_V__'?_ *] &U16+_PCO^W_ ..__7H_X1W_ &__ !W_ .O0
M!M45B_\ "._[?_CO_P!>C_A'?]O_ ,=_^O0!M45B_P#"._[?_CO_ ->C_A'?
M]O\ \=_^O0!M45B_\([_ +?_ ([_ /7H_P"$=_V__'?_ *] &U16+_PCO^W_
M ..__7H_X1W_ &__ !W_ .O0!M45B_\ "._[?_CO_P!>C_A'?]O_ ,=_^O0!
MM45B_P#"._[?_CO_ ->C_A'?]O\ \=_^O0!M45B_\([_ +?_ ([_ /7H_P"$
M=_V__'?_ *] &U16+_PCO^W_ ..__7H_X1W_ &__ !W_ .O0!M45B_\ "._[
M?_CO_P!>C_A'?]O_ ,=_^O0!M45B_P#"._[?_CO_ ->C_A'?]O\ \=_^O0!M
M45B_\([_ +?_ ([_ /7H_P"$=_V__'?_ *] &U16+_PCO^W_ ..__7H_X1W_
M &__ !W_ .O0!M45B_\ "._[?_CO_P!>C_A'?]O_ ,=_^O0!M5F>(/\ 5C_>
M'\C4'_"._P"W_P"._P#UZK:AI/V-0^[.3CICL?>@#HZ*Q?\ A'?]O_QW_P"O
M1_PCO^W_ ..__7H VJ*Q?^$=_P!O_P =_P#KT?\ "._[?_CO_P!>@#:HK%_X
M1W_;_P#'?_KT?\([_M_^._\ UZ -JBL7_A'?]O\ \=_^O1_PCO\ M_\ CO\
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M@#:HK%_X1W_;_P#'?_KT?\([_M_^._\ UZ -JBL7_A'?]O\ \=_^O1_PCO\
MM_\ CO\ ]>@#:HK%_P"$=_V__'?_ *]'_"._[?\ X[_]>@#:HK%_X1W_ &__
M !W_ .O1_P ([_M_^.__ %Z -JBL7_A'?]O_ ,=_^O1_PCO^W_X[_P#7H VJ
M*Q?^$=_V_P#QW_Z]'_"._P"W_P"._P#UZ -JBL7_ (1W_;_\=_\ KT?\([_M
M_P#CO_UZ -JBL7_A'?\ ;_\ '?\ Z]'_  CO^W_X[_\ 7H NZQ_JF_#^8HT?
M_5+^/\S69>:+]F0R;LXQQC'4X]:+/1?M*"3=C.>,9Z''K0!T%%8O_"._[?\
MX[_]>C_A'?\ ;_\ '?\ Z] &U16+_P ([_M_^.__ %Z/^$=_V_\ QW_Z] &U
M16+_ ,([_M_^._\ UZ/^$=_V_P#QW_Z] &U16+_PCO\ M_\ CO\ ]>C_ (1W
M_;_\=_\ KT ;5%8O_"._[?\ X[_]>C_A'?\ ;_\ '?\ Z] &U16+_P ([_M_
M^.__ %Z/^$=_V_\ QW_Z] &U16+_ ,([_M_^._\ UZ/^$=_V_P#QW_Z] &U1
M6+_PCO\ M_\ CO\ ]>C_ (1W_;_\=_\ KT ;5%8O_"._[?\ X[_]>C_A'?\
M;_\ '?\ Z] &U16+_P ([_M_^.__ %Z/^$=_V_\ QW_Z] &U16+_ ,([_M_^
M._\ UZ/^$=_V_P#QW_Z] &U16+_PCO\ M_\ CO\ ]>C_ (1W_;_\=_\ KT ;
M5%8O_"._[?\ X[_]>C_A'?\ ;_\ '?\ Z] &U16+_P ([_M_^.__ %Z/^$=_
MV_\ QW_Z] &U16+_ ,([_M_^._\ UZ/^$=_V_P#QW_Z] &U16+_PCO\ M_\
MCO\ ]>C_ (1W_;_\=_\ KT ;5%8O_"._[?\ X[_]>C_A'?\ ;_\ '?\ Z] &
MU16+_P ([_M_^.__ %Z/^$=_V_\ QW_Z] &U16+_ ,([_M_^._\ UZ/^$=_V
M_P#QW_Z] &U16+_PCO\ M_\ CO\ ]>C_ (1W_;_\=_\ KT ;5%8O_"._[?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "MWP=_KF_ZYG_T):PJW?!W^
MN;_KF?\ T): .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J&[^XW^Z?Y5-4-W]QO]T_RH JZ)]P_[Q_D
M*T*S]$^X?]X_R%:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 9^M_<'^\/Y&K5I]Q?]T?RJKK
M?W!_O#^1JU:?<7_='\J )J*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *@O?]6_^ZW\JGJ"]_U;_P"ZW\J *?A__5G_ 'C_ "%:=9GA
M_P#U9_WC_(5IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %8NF?Z^3_@7_H0K:K%TS_7R?\  O\ T(4 ;5%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% &+J?\ KX_^ _\ H1K:K%U/
M_7Q_\!_]"-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !69X@_U8_WA_(UIUF>(/]6/]X?R- &G1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!2UC_5-^'\Q1H_\ JE_'^9HUC_5-
M^'\Q1H_^J7\?YF@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %#7?]2WX?^A"BC7?]2WX
M?^A"B@#A;G[Q_P ]JBJ6Y^\?\]JBH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *W?!W^N;_KF?\ T):PJW?!W^N;_KF?_0EH [&BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P">B?\ ?:_XT?VM#_ST3_OM?\:\UHH_LN'\S#^W:G\J/2O[6A_YZ)_WVO\
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M>E?VM#_ST3_OM?\ &C^UH?\ GHG_ 'VO^->:T4?V7#^9A_;M3^5'I7]K0_\
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M-+R22IY4 #[IP#D4:A8W?A>-KJWF:XBC&Z2*Y(9\#EV67@@A1PI!'WC@G H
MO?#B[>[L(9969W/F99R68XD8#)//2NEKS?1%E&A++ Y26$22*P8C_5RNS @<
M,"H(VL"I.,^H] TZ]6_B2X3(65%8 ]<, 1G&>>: +%%<%X'\9OJEU*DQ(2X'
MF6ZL5^XC-&P^\2&.W)4<9#L, \ZOBW46DFMM,B<K)/*&?:VT^5&"SC<IWJ6Q
MA2,9P1D#- %C6-'N[J[@N(9]D$>?,CQ][UXZ-N''.-F-RY)KH*YK7KMXK^QB
M5F"2?:=R@D*VV,$9'0X/3/2I_%WB0Z)&HC4//.XCB0D#+-QDY(^4<9]R 2,Y
M !O5S7Q'NWM+":6)F1QY>&0E6&9%!P1STJ'_ (0^>^_>W5W,)#_#;-Y,:CKM
M P2V"3\QY(QGI7+_ !%-WHUJUK*XGMIBJK(P"S(58,JMCAP50_-C).22. 0#
MU.BLGQ/XA3P_ UW(,[<!5R 68] ,_F>I !.#BL*T\)W>IC[1?74J2,!B.U<1
MHG).W(SN(R!GKQC<PP: .SHKC+<W?AB:.*5VN;29P@=@/-B9WPFX_P 2G(!8
M_@%X5NSH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"AKO^I;\/_0A11KO^I;\/_0A10!PMS]X_Y[5%
M4MS]X_Y[5%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5N^#O]<W
M_7,_^A+6%6[X._US?]<S_P"A+0!V-%%% !1110 4444 %%%% !1110 4444
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M'E9Y_ C_ (E^3,^BBBO8/G HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KL/#?B3SL6\Q^;HK'O['W]#W^O7CZ*RKT(UHV9T87
M%3PT^:/S7<]5HKFO#?B3SL6\Q^;HK'O['W]#W^O7I:\*M1E2ERL^JPV)AB(*
M<?\ A@HHHK,V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%TS_7R?\
M O\ T(5M5BZ9_KY/^!?^A"@#:HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH Q=3_U\?_ ?_0C6U6+J?^OC_P" _P#H1K:H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S/$'^K'^\/
MY&M.LSQ!_JQ_O#^1H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*Z\+)<WL6J%F#PQL@48VG.<'UX#-]>.F#D PO&5E_8,5G>Q;BNGNBM]TGRG
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M_0A10!PMS]X_Y[5%4MS]X_Y[5%0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5N^#O]<W_7,_^A+6%6[X._US?]<S_P"A+0!V-%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W?
MW&_W3_*IJAN_N-_NG^5 %71/N'_>/\A6A6?HGW#_ +Q_D*T* ,GQ9_QYW/\
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M-TK\_P!X#S%^]M^50.1G.S@98UN_"/7AJ-I]F))DMCM.23\K$E#DC@#E0,G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N\\+7TEW'F4<+PK'JWK^7KW^H-<_P"'O#QOSYLG$8_-O8>WJ?P'/3MT
M0( H& . !TKS,QKP:Y%J^_8]S)L)4B_:MVB^G<=1117F'N!1110 4444 %%%
M% !1110 4444 %%%% !1110 5BZ9_KY/^!?^A"MJL73/]?)_P+_T(4 ;5%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+J?^OC
M_P" _P#H1K:K%U/_ %\?_ ?_ $(UM4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %9GB#_5C_ 'A_(UIUF>(/]6/]X?R- &G1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_ %3?
MA_,4:/\ ZI?Q_F:-8_U3?A_,4:/_ *I?Q_F: +M%%% !1535-4CTJ-KF=ML:
M8R<$XR0!P 3U([5%HFOP:VAFMFWH&*D[67D '&& /0B@#0HHK!L/'-GJ$PLX
M90TI+  *^#M!)PVW:1@'G.#VH WJ**Q-$\9VFMN8;:3>X4L1L=> 0,Y90.I%
M &W116)K?C.TT1Q#<R;'*A@-CMP21G*J1U!H VZ*Q]7\76VCJCW#E!*"5RCY
M.,9R I((R." :TK2Z6[19HSE)%#*<$9##(.#STH FHHKG-&\<PZM((HTE"N6
M"2O&1$Y7)(5LGG"D\@="#@\4 ='1110 4444 %%%% !1110 45GZ1K::KYOE
MAAY$SQ-N &63&2,$\<\=#[5H4 %%%% !1110 45GZ1K::KYOEAAY$SQ-N &6
M3&2,$\<\=#[5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 4-=_U+?A_Z$**-=_U+?A_Z$** .%N?O'_ #VJ*I;G
M[Q_SVJ*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K=\'?ZYO^N9
M_P#0EK"K=\'?ZYO^N9_]"6@#L:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:]_KC_NQ_P#H"UW99_%?I^J/*SS^!'_$OR9GT445[!\X%%%% !1110 4444
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M*PJ$0 *H   P !P  .@%>*ZO*+_708LMBYA!P#_RRV!^,=%VG)Z8&>G->VT
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M@C'RCD??^[CU(."0* '_  TA9+")W!$DI=V+#YF+.Q#DGDDKCD]1CM3)/B/
MSM%;QS7&S[S6\6]0<D8SD>G!&01T)K"\77,UA:66E;9,S(JS"##2;(D42(H
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M_LJZNBCZ]7_F_!?Y!_96$_E_%_YG*?\ "#?]-/\ QS_[*C_A!O\ II_XY_\
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M_P!E75T4?7J_\WX+_(/[*PG\OXO_ #.4_P"$&_Z:?^.?_94?\(-_TT_\<_\
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M?N[8%+,/7)!XXQZD5=\4:/)=&*\M\&>U<LH)QO5AB2/)R 7'1B#@CMDD;U%
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M+A(@A/&>Q ^8]\E3M /0**S]#T./1(_L\.[8&8@,Q;&XYP,] .P_$Y8DG0H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN_N-_N
MG^535#=_<;_=/\J *NB?</\ O'^0K0K!LM2^RKMQG)SUQ_2K']N_[/\ X]_]
M:@#6HK)_MW_9_P#'O_K4?V[_ +/_ (]_]:@#6HK)_MW_ &?_ ![_ .M1_;O^
MS_X]_P#6H UJ*R?[=_V?_'O_ *U']N_[/_CW_P!:@#6HK)_MW_9_\>_^M1_;
MO^S_ ./?_6H UJ*R?[=_V?\ Q[_ZU']N_P"S_P"/?_6H UJ*R?[=_P!G_P >
M_P#K4?V[_L_^/?\ UJ -:BLG^W?]G_Q[_P"M1_;O^S_X]_\ 6H UJ*R?[=_V
M?_'O_K4?V[_L_P#CW_UJ -:BLG^W?]G_ ,>_^M1_;O\ L_\ CW_UJ -:BLG^
MW?\ 9_\ 'O\ ZU']N_[/_CW_ -:@#6HK)_MW_9_\>_\ K4?V[_L_^/?_ %J
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M/^$B_P!C_P >_P#K4 ;5%8O_  D7^Q_X]_\ 6H_X2+_8_P#'O_K4 ;5%8O\
MPD7^Q_X]_P#6H_X2+_8_\>_^M0!M45B_\)%_L?\ CW_UJ/\ A(O]C_Q[_P"M
M0!M45B_\)%_L?^/?_6H_X2+_ &/_ ![_ .M0!M45B_\ "1?['_CW_P!:C_A(
MO]C_ ,>_^M0!M45B_P#"1?['_CW_ -:C_A(O]C_Q[_ZU &U16+_PD7^Q_P"/
M?_6H_P"$B_V/_'O_ *U &U16+_PD7^Q_X]_]:C_A(O\ 8_\ 'O\ ZU &U6+I
MG^OD_P"!?^A"C_A(O]C_ ,>_^M5.VU'R)&EQG=GC/J<^E '345B_\)%_L?\
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MJ/\ A(O]C_Q[_P"M0!M45B_\)%_L?^/?_6H_X2+_ &/_ ![_ .M0!M45B_\
M"1?['_CW_P!:C_A(O]C_ ,>_^M0!M45B_P#"1?['_CW_ -:C_A(O]C_Q[_ZU
M &U16+_PD7^Q_P"/?_6H_P"$B_V/_'O_ *U &U16+_PD7^Q_X]_]:C_A(O\
M8_\ 'O\ ZU &U16+_P )%_L?^/?_ %J/^$B_V/\ Q[_ZU &U16+_ ,)%_L?^
M/?\ UJ/^$B_V/_'O_K4 ;5%8O_"1?['_ (]_]:C_ (2+_8_\>_\ K4 ;5%8O
M_"1?['_CW_UJ/^$B_P!C_P >_P#K4 &I_P"OC_X#_P"A&MJN9N=1\^19<8VX
MXSZ'/I5S_A(O]C_Q[_ZU &U16+_PD7^Q_P"/?_6H_P"$B_V/_'O_ *U &U16
M+_PD7^Q_X]_]:C_A(O\ 8_\ 'O\ ZU &U16+_P )%_L?^/?_ %J/^$B_V/\
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M$B_V/_'O_K4?\)%_L?\ CW_UJ -JBL7_ (2+_8_\>_\ K4?\)%_L?^/?_6H
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M_P!C_P >_P#K4?\ "1?['_CW_P!:@#:HK%_X2+_8_P#'O_K4?\)%_L?^/?\
MUJ -JBL7_A(O]C_Q[_ZU'_"1?['_ (]_]:@#:HK%_P"$B_V/_'O_ *U'_"1?
M['_CW_UJ -JBL7_A(O\ 8_\ 'O\ ZU'_  D7^Q_X]_\ 6H VJ*Q?^$B_V/\
MQ[_ZU'_"1?['_CW_ -:@#:HK%_X2+_8_\>_^M1_PD7^Q_P"/?_6H NZQ_JF_
M#^8HT?\ U2_C_,UF7FM?:4,>W&<<YST.?2BSUK[,@CVYQGG..ISZ4 =!16+_
M ,)%_L?^/?\ UJ/^$B_V/_'O_K4 ;5%8O_"1?['_ (]_]:C_ (2+_8_\>_\
MK4 ;5%8O_"1?['_CW_UJ/^$B_P!C_P >_P#K4 ;5%8O_  D7^Q_X]_\ 6H_X
M2+_8_P#'O_K4 ;5%8O\ PD7^Q_X]_P#6H_X2+_8_\>_^M0!M45B_\)%_L?\
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MJ/\ A(O]C_Q[_P"M0!M45B_\)%_L?^/?_6H_X2+_ &/_ ![_ .M0!M45B_\
M"1?['_CW_P!:C_A(O]C_ ,>_^M0!M45B_P#"1?['_CW_ -:C_A(O]C_Q[_ZU
M &U16+_PD7^Q_P"/?_6H_P"$B_V/_'O_ *U &U16+_PD7^Q_X]_]:C_A(O\
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MKH-4TN/58VMIUW1OC(R1G!!'((/4#O1JFEQZK&UM.NZ-\9&2,X((Y!!Z@=Z
M+=<IXB_Y".G_ /;U_P"BA75U4N-+CN9([EUS)!OV')&-XPW .#D>H/M0!QNK
MVUOI6H//?1*\%Z(PLLB*R1NBE=ASG 8 '=P/8@,PZ*Z\/6%HIEEAMT08RSQQ
MJHR<#)(QUK5NK1+M3%*JNAQE7 93@Y&0>.M<[#\,M.B8.(!E2",O(PX]06((
M]B,'O0 _P=<6U_YES:VZQ(&*)((T3S%&,D8 ;&X=QC@?Q959[R*Q\3PF23RY
M8HRP+YQMVD%OG!!4< D@@%<'E2,[<,*PJ$0 *H   P !P  .@%86I^ ;'4W,
MTL*ESU*EDR2222$*@DD\D\GUH K_  \F8V[Q9+10SRQPN3G?&A^5MW1AU4%<
M# P!Q744R&%85"( %4   8  X  '0"GT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %0W?W&_W3_*IJAN_N-_NG^5 %71/N'_ 'C_
M "%:%9^B?</^\?Y"M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,_6_N#_>'\C5JT^XO^Z/Y5
M5UO[@_WA_(U:M/N+_NC^5 $U%%% !1110 4444 %%%% !1110 4444 %%%%
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MP_F*-'_U2_C_ #- %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *&N_P"I;\/_ $(44:[_
M *EOP_\ 0A10!PMS]X_Y[5%4MS]X_P">U14 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %;O@[_7-_P!<S_Z$M85;GA!PLQ![H<?F#0!V5%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %0W?W&_W3_*IJAN_N-_NG^5 %71/N'_>/\A6A6?HGW#_ +Q_D*T* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH S];^X/\ >'\C65<^*_L!$.S.U5YW8ZJ#TP?6M76_N#_>
M'\C7%:]_KC_NQ_\ H"UUX&E"K4:DKJW^1Y^:XBI0HJ4'9WM^#-K_ (3G_IG_
M ./_ /V-'_"<_P#3/_Q__P"QKE:*]+ZC0_E_%_YGB_VKB_YOP7^1U7_"<_\
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MG_IG_P"/_P#V-'_"<_\ 3/\ \?\ _L:Y6BCZC0_E_%_YA_:N+_F_!?Y'5?\
M"<_],_\ Q_\ ^QH_X3G_ *9_^/\ _P!C7*T4?4:'\OXO_,/[5Q?\WX+_ ".J
M_P"$Y_Z9_P#C_P#]C1_PG/\ TS_\?_\ L:Y6BCZC0_E_%_YA_:N+_F_!?Y'5
M?\)S_P!,_P#Q_P#^QH_X3G_IG_X__P#8URM%'U&A_+^+_P P_M7%_P WX+_(
MZZW\;J[ .FU3U(;./?&!72HX<!@<@\@CI7EE;GA[Q"; ^5)S&?S7W'MZC\1S
MUYL3E\>6\%JNAV8'-Y<W+5>CZ]CN:*:CAP&!R#R".E.KRSW@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"]_U;_[K?RJ>H+W_5O_ +K?
MRH I^'_]6?\ >/\ (5IUF>'_ /5G_>/\A6G0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5BZ9_KY/^!?^A"MJL73/]?)_P "_P#0
MA0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 8NI_P"OC_X#_P"A&MJL74_]?'_P'_T(UM4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %9GB#_5C_>'\C6G69X@_U8_WA_(T :=%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/]
M4WX?S%&C_P"J7\?YFC6/]4WX?S%&C_ZI?Q_F: +M%%% &3;Z[YEW)I[KM9(T
MD0[L[U/#' 'R[6XP3D]0,5K5R7B5SIE]9WH!VREK>0C!SOP8EP3P ^6)'.!@
MYX!M>/[UK>T>*/!EN2(44]VE.TC/ !VY()(&1SZ$ M^&/$T?B&-YX@0J2NF3
MWVX(8=#@J0<$ @Y';)L:_K*Z+!)=OR(USCGDGA5R <9) SCC.3Q7-:-IB>%[
M\6D8Q%=VZ[2<9,EN,$?* !E#N8D<L>#VJQX]<WC6VE@%A=3@N. #%%AY!G((
M/0C'/!&>Q .GM)&E17D78Y4%ER&VDCE<C@X/&>]35GZ[KL6AQ&YG.%7H!]YC
MV4#N3_\ 7. "1B?VAJE_^]@BAAC/1;EG,A'4,1'PN01\IY!!SVH ZNBN7T_Q
M=)#.MA?Q"&20?NW5]T4A!P<' VD\%5.3R <$KN9XT\8OX=DMT5/,6?S05 )<
MLH7RPN#QEF /#''09Z@'5UB>#-;?6[2.\E"AY-^0@(7Y791C))Z#UH\/-?R9
M>^$*@J,+"'+ GKN)8CCIQG)[X'.;\,YEATR%W("J)223@ "1R22>@% '6T5R
M47BBZUT;M-B41 G]]<EE1MI((5%^<@\$,<#AE(!%$OBBZT(;M2B4Q$C]];%F
M1=Q  9&^< <DL,CE5 )- &EX,UM];M([R4*'DWY" A?E=E&,DGH/6MNO//#.
MJRZ1HL5W"H<Q%BRD$Y3SF#8(/RD YW$,  <CT] AF690Z$%6 ((.00>001U!
MH ?17->&/&B:[/<6R;=L##80PRZ]&; )R PX8'!#+D ];7B;6WT_R880IEN)
ME0!@6PO5Y-@(+!1UY &02?4 BUC6+NUNX+>&#?!)GS),_=]>>B[1SSG?G:N"
M*Z"L35=;>TN[6S4+LN?.W$@[AY:!ACG'7KD'\*MZ[KL6AQ&YG.%7H!]YCV4#
MN3_]<X ) !H5B>,];?1+22\B"EX]F X)7YG53G!!Z'UK/_M#5+_][!%##&>B
MW+.9".H8B/A<@CY3R"#GM7.^/O%$@LY-/O8C%.X78RG?#)LD3<5;JIZG:PR!
MC)R0* /3:*KZAJ$>G1M<3,%C09)/^>2>@ Y)X'-<I::]J6MCS[6&** @%#=%
MR[@DX;$?W1C'!'?(9@> #LZ*Y32_%LL$RV&HQK%+)GRY$.8I"&(P,Y*G&, G
M)SR%)4'JZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH H:[_J6_#_T(44:[_J6_#_T(44 <+<_>/^>U
M15+<_>/^>U14 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:GAK_C
MX3_@7_H)K+K4\-?\?"?\"_\ 030!W5%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$*VJQ=,_U\G_  +_ -"% &U1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!BZG_ *^/_@/_ *$:VJQ=3_U\?_ ?_0C6U0 4444
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M?\]JBJ6Y^\?\]JBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-+>3^;&8R OFR/ABRD'#@#H#SUYH [6O%/@I_P ?DG_7NW_H<=>UUXI\%/\
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MBBB@ HHHH *Q=,_U\G_ O_0A6U6+IG^OD_X%_P"A"@#:HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q=3_P!?'_P'_P!"-;58
MNI_Z^/\ X#_Z$:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHV6N6]^VR&6-V R0CJQQTS@$\<T 7J**HWNN6]@VR:6-&(R [JIQTS@D<<4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!B_"A7^1B3D8P&)ST'?BMWQIKO\ PEE\MJ'5;>-RBNQ4*!QYDFXL 0<97D9
M  W$Y;\2[2V@-N+25'1(?+PC(Q&PYW,4.,N7)/ R03SG@ ]UKQ3PW_Q36LFV
M_P!7&TCQ@?>^63F(9^8\G9SG(_B/6O6_#^I_VI;Q765)DC4ML^Z&(^8#D]#D
M8SD8P>:\J^+EJVEWT5_$-I=58-D',D1ZX.>@V=L'W.: /8IIEA4NY 50223@
M #DDD] *\/LD;Q]JF]\^2#N(/:)#@+C=P6R =IX9BP%=-\5_&8$$=K;L?])0
M2,1D9B8?*.1T?OR#A<$8:N@^&OA4:%;!W!$TX5I,YXZ[5P0,%0>>,[B>2,8
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M'&.,4 =W1110 4444 %%%% !1110 4444 4-=_U+?A_Z$**-=_U+?A_Z$**
M.%N?O'_/:HJEN?O'_/:HJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^R8?^>:?]\+_ (5;HH]I/NP]C3[+[BI_9,/_ #S3_OA?\*/[)A_YYI_WPO\
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M% !1110 4444 %9GB#_5C_>'\C6G69X@_P!6/]X?R- &G1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_5-^'\Q1H_^J7\?
MYFC6/]4WX?S%&C_ZI?Q_F: +M%%% 'BGQ9_XF6HI;0_-((XX\=/F9F(&3@<A
MQSG'/7K7=_$WQ8=!M]D?^MGW*IR05&/F<$=QD8Y')!YP1712Z';RR?:&BC,N
M0=Y12^5Q@[L9R,#'I1>Z';W[;YHHW8# +HK''7&2#QS0!Y;X)^%":M +NZ9U
M\SE%3"G;SR=RG.[J,<8P<G/#_&WPNM]$M7O(7D+1E<ARK AF"XX5<'G.>>F,
M<Y'K4,*PJ$0 *H   P !P  .@%$T*S*4< JP(((R"#P00>H- '#_  =U/[59
M>02N8)&  ^]M;YP2,]R6 / X]0:B^,^E_:;1+D+EH)!DYQA7X/&><ML[$_AF
MNUL=)AT_/D1I'NQGRT5<XSC. ,XR:ENK1+M3%*JNAQE7 93@Y&0>.M 'AOP_
M\/OXGNEEFPT5N(]^=O(1=L:;<'(.P \<J#DY(S[Q5>RTZ*P79"BHI.2$4*,]
M,X '/%6* /%/!'_$RUEKF'YHQ)<29Z?*VX X.#R7'&,\].M=]\4M8.FV+A<A
MIB(P0 ?O9+9SV*!AD<Y(^HW[+0[>P;?#%&C$8)1%4XZXR ..*YK7?#L^LZC!
M*P*VMJ P;*#+YW< 9;!(4'< ,*V,$@D W?"NB?V):Q6><F-?F.<C<Q+-C@<9
M)QQG&,\UY[\:M!D=H]14$QA/+? ^[AB5).>C;B.F 0.<L!7K%% 'FEK\;8?*
M!EB?S]IR$V^66'3#%L@'Z$C_ &L9.5X!\.3>)+O^V[G_ %8D+C.[YF'W0O.=
MJ''4D<!.?FQZ;-X8M)F+O!$68DDF)"23R221R36G0!XI\6?^)EJ*6T/S2"..
M/'3YF9B!DX'(<<YQSUZUH?'&Z5GMX0?G59&(P>CE0ISTY*G\OI7ILNAV\LGV
MAHHS+D'>44OE<8.[&<C QZ47NAV]^V^:*-V P"Z*QQUQD@\<T -\/6K6EM!#
M(,/'#&K#(."J $9''6O)/!'_ !,M9:YA^:,27$F>GRMN .#@\EQQC//3K7M=
M4;+0[>P;?#%&C$8)1%4XZXR ..* /*/BCH<MA>_VH$\R)O+8[DW1@IM38^#T
M.!UQG=@=#5B7XA:6(]RV*F7 ^4Q1!,\9&_!.!S@[>?0=O7:S(?#%I"P=((@R
MD$$1("".000."* ,?P28-307BV:V[C[K>6@R&!Y1@%8@J1DX .< G!KS_P $
M?\3+66N8?FC$EQ)GI\K;@#@X/)<<8SSTZU[75&RT.WL&WPQ1HQ&"415..N,@
M#CB@#"\>^+9O#BQRQ1>8A8^8QW;54%1C(X4L6X)XXZ'MY5XVU:TU^5)+&)UE
MD9O,R.79MH7"JS#).<X ))R<DU[[-"LRE' *L""",@@\$$'J#52RT.WL&WPQ
M1HQ&"415..N,@#CB@ T.*2*WA2;/FK$@?)W'<%&[)R<G/?/-6+NZ6T1II#A(
MU+,<$X"C).!STJ:F30K,I1P"K @@C((/!!!Z@T <[\-[5K73X$<8)5FZ@\.[
M.IX]00?Y\T[QSI\ES"D\*EWM9XY@@ZOY9.5!['!)Z$G& "3700PK"H1  J@
M #  '   Z 4^@#!B\=6,D?GBXCVX)P6P_&<_(</GC@8R>V<BJ7@E6OGN-696
M1;MH_+5\;MD2;5<X/\><X[8R"P(-;?\ PCUMO\_R8O,W;MWEINW9SNW8SG/.
M>N:T* .4\+?O[V_N5YC:2&,'_:ACQ(,'G@D<XP>Q-=+=W2VB--(<)&I9C@G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K4\-?\?"?\"_\ 03671YS0X9201W!P?S%
M'IU%>:?VM-_ST?\ [[;_ !H_M:;_ )Z/_P!]M_C0!Z717FG]K3?\]'_[[;_&
MC^UIO^>C_P#?;?XT >ET5YI_:TW_ #T?_OMO\:/[6F_YZ/\ ]]M_C0!Z717F
MG]K3?\]'_P"^V_QH_M:;_GH__?;?XT >ET5YI_:TW_/1_P#OMO\ &C^UIO\
MGH__ 'VW^- 'I=%>:?VM-_ST?_OMO\:/[6F_YZ/_ -]M_C0!Z717FG]K3?\
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M^^V_QH_M:;_GH_\ WVW^- 'I=%>:?VM-_P ]'_[[;_&C^UIO^>C_ /?;?XT
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M\]'_ .^V_P :/[6F_P">C_\ ?;?XT >ET5YI_:TW_/1_^^V_QH_M:;_GH_\
MWVW^- 'I=%>:?VM-_P ]'_[[;_&C^UIO^>C_ /?;?XT >ET5YI_:TW_/1_\
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M^^V_QH_M:;_GH_\ WVW^- 'I=%>:?VM-_P ]'_[[;_&C^UIO^>C_ /?;?XT
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M/[6F_P">C_\ ?;?XT?VM-_ST?_OMO\: /2Z*\T_M:;_GH_\ WVW^-']K3?\
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MV_QH ]+HKS3^UIO^>C_]]M_C1_:TW_/1_P#OMO\ &@#TNBO-/[6F_P">C_\
M?;?XT?VM-_ST?_OMO\: /2Z*\T_M:;_GH_\ WVW^-']K3?\ /1_^^V_QH ]+
MHKS3^UIO^>C_ /?;?XT?VM-_ST?_ +[;_&@#TNBO-/[6F_YZ/_WVW^-']K3?
M\]'_ .^V_P : /2Z*\T_M:;_ )Z/_P!]M_C1_:TW_/1_^^V_QH ]+HKS3^UI
MO^>C_P#?;?XT?VM-_P ]'_[[;_&@#TNBO-/[6F_YZ/\ ]]M_C1_:TW_/1_\
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MK3?\]'_[[;_&C^UIO^>C_P#?;?XT >ET5YI_:TW_ #T?_OMO\:/[6F_YZ/\
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M^^V_QH_M:;_GH_\ WVW^- 'I=%>:?VM-_P ]'_[[;_&C^UIO^>C_ /?;?XT
M>ET5YI_:TW_/1_\ OMO\:/[6F_YZ/_WVW^- 'I=%>:?VM-_ST?\ [[;_ !H_
MM:;_ )Z/_P!]M_C0!Z717FG]K3?\]'_[[;_&C^UIO^>C_P#?;?XT >ET5YI_
M:TW_ #T?_OMO\:/[6F_YZ/\ ]]M_C0!Z717FG]K3?\]'_P"^V_QH_M:;_GH_
M_?;?XT >ET5YI_:TW_/1_P#OMO\ &C^UIO\ GH__ 'VW^- '>:[_ *EOP_\
M0A17#P:C+,P5G8@]BQ(_(FB@!MS]X_Y[5%4MS]X_Y[5%0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\
M_"$P_P!Y_P U_P#B:/\ A"8?[S_FO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[
MS_FO_P 37044 <__ ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG
M_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B:/\ A"8?[S_F
MO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[S_FO_P 37044 <__ ,(3#_>?\U_^
M)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%%
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M0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\
M_"$P_P!Y_P U_P#B:/\ A"8?[S_FO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[
MS_FO_P 37044 <__ ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG
M_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B:/\ A"8?[S_F
MO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[S_FO_P 37044 <__ ,(3#_>?\U_^
M)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%%
M'/\ _"$P_P!Y_P U_P#B:/\ A"8?[S_FO_Q-=!10!S__  A,/]Y_S7_XFC_A
M"8?[S_FO_P 37044 <__ ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$
MP_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B:/\ A"8?
M[S_FO_Q-=!10!RNH^%(K90RENN.2/0_[-30>#89%#%GY /5>X_W:U-;^X/\
M>'\C5JT^XO\ NC^5 &+_ ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$
MP_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B:/\ A"8?
M[S_FO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[S_FO_P 37044 <__ ,(3#_>?
M\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$U
MT%% '/\ _"$P_P!Y_P U_P#B:/\ A"8?[S_FO_Q-=!10!S__  A,/]Y_S7_X
MFC_A"8?[S_FO_P 37044 <__ ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_
M /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B:/\
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M /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B:/\
MA"8?[S_FO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[S_FO_P 37044 <__ ,(3
M#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_
M /$UT%% '/\ _"$P_P!Y_P U_P#B:/\ A"8?[S_FO_Q-=!10!S__  A,/]Y_
MS7_XFC_A"8?[S_FO_P 37044 <__ ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%%
M '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B
M:/\ A"8?[S_FO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[S_FO_P 37044 <__
M ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_
M )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B:/\ A"8?[S_FO_Q-=!10!S__  A,
M/]Y_S7_XFC_A"8?[S_FO_P 37044 <__ ,(3#_>?\U_^)H_X0F'^\_YK_P#$
MUT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U
M_P#B:/\ A"8?[S_FO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[S_FO_P 37044
M <__ ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FL^S\,
MQS2M$2V%SC!&>#CTKL*Q=,_U\G_ O_0A0!#_ ,(3#_>?\U_^)H_X0F'^\_YK
M_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y
M_P U_P#B:/\ A"8?[S_FO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[S_FO_P 3
M7044 <__ ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC
M_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B:/\ A"8?[S_FO_Q-=!10
M!S__  A,/]Y_S7_XFC_A"8?[S_FO_P 37044 <__ ,(3#_>?\U_^)H_X0F'^
M\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P
M_P!Y_P U_P#B:/\ A"8?[S_FO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[S_FO
M_P 37044 <__ ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_
M (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B:/\ A"8?[S_FO_Q-
M=!10!S__  A,/]Y_S7_XFC_A"8?[S_FO_P 37044 <__ ,(3#_>?\U_^)H_X
M0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\
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M /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B:/\
MA"8?[S_FO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[S_FO_P 37044 <__ ,(3
M#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_
M /$UT%% '/\ _"$P_P!Y_P U_P#B:/\ A"8?[S_FO_Q-=!10!S__  A,/]Y_
MS7_XFC_A"8?[S_FO_P 37044 <__ ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%%
M '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B
M:/\ A"8?[S_FO_Q-=!10!S__  A,/]Y_S7_XFC_A"8?[S_FO_P 37044 <__
M ,(3#_>?\U_^)H_X0F'^\_YK_P#$UT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_
M )K_ /$UT%% '/\ _"$P_P!Y_P U_P#B:/\ A"8?[S_FO_Q-=!10!S__  A,
M/]Y_S7_XFC_A"8?[S_FO_P 37044 <__ ,(3#_>?\U_^)H_X0F'^\_YK_P#$
MUT%% '/_ /"$P_WG_-?_ (FC_A"8?[S_ )K_ /$UT%% '/\ _"$P_P!Y_P U
M_P#B:IZIX5BM%#*6R3CDCT/M765F>(/]6/\ >'\C0!2_X0F'^\_YK_\ $T?\
M(3#_ 'G_ #7_ .)KH** .?\ ^$)A_O/^:_\ Q-'_  A,/]Y_S7_XFN@HH Y_
M_A"8?[S_ )K_ /$T?\(3#_>?\U_^)KH** .?_P"$)A_O/^:__$T?\(3#_>?\
MU_\ B:Z"B@#G_P#A"8?[S_FO_P 31_PA,/\ >?\ -?\ XFN@HH Y_P#X0F'^
M\_YK_P#$T?\ "$P_WG_-?_B:Z"B@#G_^$)A_O/\ FO\ \31_PA,/]Y_S7_XF
MN@HH Y__ (0F'^\_YK_\31_PA,/]Y_S7_P")KH** .?_ .$)A_O/^:__ !-'
M_"$P_P!Y_P U_P#B:Z"B@#G_ /A"8?[S_FO_ ,31_P (3#_>?\U_^)KH** .
M?_X0F'^\_P":_P#Q-'_"$P_WG_-?_B:Z"B@#G_\ A"8?[S_FO_Q-'_"$P_WG
M_-?_ (FN@HH Y_\ X0F'^\_YK_\ $T?\(3#_ 'G_ #7_ .)KH** .?\ ^$)A
M_O/^:_\ Q-'_  A,/]Y_S7_XFN@HH Y__A"8?[S_ )K_ /$T?\(3#_>?\U_^
M)KH** .?_P"$)A_O/^:__$T?\(3#_>?\U_\ B:Z"B@#G_P#A"8?[S_FO_P 3
M1_PA,/\ >?\ -?\ XFN@HH Y_P#X0F'^\_YK_P#$T?\ "$P_WG_-?_B:Z"B@
M#G_^$)A_O/\ FO\ \31_PA,/]Y_S7_XFN@HH Y__ (0F'^\_YK_\31_PA,/]
MY_S7_P")KH** .?_ .$)A_O/^:__ !-'_"$P_P!Y_P U_P#B:Z"B@#G_ /A"
M8?[S_FO_ ,31_P (3#_>?\U_^)KH** .7O\ PC%;H7!?(QU([D#^[18>$8KA
M Y+Y.>A'8D?W:V]8_P!4WX?S%&C_ .J7\?YF@#,_X0F'^\_YK_\ $T?\(3#_
M 'G_ #7_ .)KH** .?\ ^$)A_O/^:_\ Q-'_  A,/]Y_S7_XFN@HH Y__A"8
M?[S_ )K_ /$T?\(3#_>?\U_^)KH** .?_P"$)A_O/^:__$T?\(3#_>?\U_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6[X._US?]<S_P"A+6%6[X._US?]<S_Z$M '8T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5#=_<;_ '3_ "J:H;O[C?[I_E0!5T3[A_WC_(5H5GZ)]P_[Q_D*T* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH S];^X/]X?R-6K3[B_[H_E576_N#_>'\C7%:]_KC_NQ
M_P#H"UOAL/[>;C>VESDQV+^JTU.U[NW;N>BT5Y5179_9?][\/^">=_;W]S\?
M^ >JT5Y511_9?][\/^"']O?W/Q_X!ZK17E5%']E_WOP_X(?V]_<_'_@'JM%>
M544?V7_>_#_@A_;W]S\?^ >JT5Y511_9?][\/^"']O?W/Q_X!ZK17E5%']E_
MWOP_X(?V]_<_'_@'JM%>544?V7_>_#_@A_;W]S\?^ >JT5Y511_9?][\/^"'
M]O?W/Q_X!ZK17E5%']E_WOP_X(?V]_<_'_@'JM%>544?V7_>_#_@A_;W]S\?
M^ >JT5Y511_9?][\/^"']O?W/Q_X!ZK17E5%']E_WOP_X(?V]_<_'_@'JM%>
M544?V7_>_#_@A_;W]S\?^ >JT5Y511_9?][\/^"']O?W/Q_X!ZK17E5%']E_
MWOP_X(?V]_<_'_@'JM%>544?V7_>_#_@A_;W]S\?^ >JT5Y511_9?][\/^"'
M]O?W/Q_X!ZK17E5%']E_WOP_X(?V]_<_'_@'JM%>544?V7_>_#_@A_;W]S\?
M^ >JT5Y511_9?][\/^"']O?W/Q_X!ZK17E5%']E_WOP_X(?V]_<_'_@'JM07
MO^K?_=;^5>8T4?V7_>_#_@A_;W]S\?\ @'H7A_\ U9_WC_(5IUY511_9?][\
M/^"']O?W/Q_X!ZK17E5%']E_WOP_X(?V]_<_'_@'JM%>544?V7_>_#_@A_;W
M]S\?^ >JT5Y511_9?][\/^"']O?W/Q_X!ZK17E5%']E_WOP_X(?V]_<_'_@'
MJM%>544?V7_>_#_@A_;W]S\?^ >JT5Y511_9?][\/^"']O?W/Q_X!ZK17E5%
M']E_WOP_X(?V]_<_'_@'JM%>544?V7_>_#_@A_;W]S\?^ >JT5Y511_9?][\
M/^"']O?W/Q_X!ZK17E5%']E_WOP_X(?V]_<_'_@'JM%>544?V7_>_#_@A_;W
M]S\?^ >JT5Y511_9?][\/^"']O?W/Q_X!ZK17E5%']E_WOP_X(?V]_<_'_@'
MJM%>544?V7_>_#_@A_;W]S\?^ >JT5Y511_9?][\/^"']O?W/Q_X!ZK17E5%
M']E_WOP_X(?V]_<_'_@'JM%>544?V7_>_#_@A_;W]S\?^ >JT5Y511_9?][\
M/^"']O?W/Q_X!ZK17E5%']E_WOP_X(?V]_<_'_@'JM%>544?V7_>_#_@A_;W
M]S\?^ >JT5Y511_9?][\/^"']O?W/Q_X!ZK6+IG^OD_X%_Z$*X2BC^R_[WX?
M\$/[>_N?C_P#U6BO*J*/[+_O?A_P0_M[^Y^/_ /5:*\JHH_LO^]^'_!#^WO[
MGX_\ ]5HKRJBC^R_[WX?\$/[>_N?C_P#U6BO*J*/[+_O?A_P0_M[^Y^/_ /5
M:*\JHH_LO^]^'_!#^WO[GX_\ ]5HKRJBC^R_[WX?\$/[>_N?C_P#U6BO*J*/
M[+_O?A_P0_M[^Y^/_ /5:*\JHH_LO^]^'_!#^WO[GX_\ ]5HKRJBC^R_[WX?
M\$/[>_N?C_P#U6BO*J*/[+_O?A_P0_M[^Y^/_ /5:*\JHH_LO^]^'_!#^WO[
MGX_\ ]5HKRJNE\-^)/)Q;S'Y>BL>WL?;T/;Z=,ZV72A&Z=_D;8;.859J,ERW
MZWO^B.PHHHK@/6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,74_\ 7Q_\!_\ 0C6U6+J?^OC_ . _^A&MJ@ HHHH **** "BBB@ HHHH
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M** "BBB@#%U/_7Q_\!_]"-;58NI_Z^/_ (#_ .A&MJ@ HHHH **** "BBB@
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MW/05TTD8E!1@""""",@@]1BL/PAH;Z0CK*06:0X;^(HH"IGKC@9 R< XZY%
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MM:W!GAWC='='+X.U3^]P3@<MQC&.%<D@[?BK7&TB'?&H::1UCB4\!G<X )[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4_\ 7Q_\!_\ 0C6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8ZM#J&?(D23;C/ENK8SG&<$XS@U;H ***KWNHQ6"[YG5%)P"[!1GKC)(YXH
ML45#:W:7:B6)E=#G#(0RG!P<$<=:FH ***Q/^$TL_/\ L'FKYV[;MPV-W]W=
MC;GMC.<_+UXH VZ*** "BBB@ HHHH **** "BJFGZI'J&_RFW>5(T;<$89<;
MAR!G&>HX]ZMT %%%% !1110 454T_5(]0W^4V[RI&C;@C#+C<.0,XSU''O5N
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AKO^I;\/\
MT(44:[_J6_#_ -"%% '"W/WC_GM452W/WC_GM45 !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2&7:3M9AA]O\(8Y.YAW; SU(SDG%F\$FT8R:?,UL6)+*%$D)SR2(WX5N@R"
M , <UU%% '))X%>]D674+AKD1D%8]BQQ9&[ED4D,>?;T.0<5K^%M"_L&V2RW
M;_+W?-MVYW,6Z9/KCK6M10 54U73$U2)[649212#TR,]",@C(/(.." :MT4
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M_N[.\>*+LDD:S[>P56<@A0  %YQC.>:?I/@.."47MT[7-R#D/)PJ\L1M0$@
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M>8#_ %C]L@ [5Z*.OJV"1N(KJ** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UO[@_WA_(UQ6O?ZX_[L?_
M * M=KK?W!_O#^1KBM>_UQ_W8_\ T!:[LL_BOT_5'E9Y_ C_ (E^3,^BBBO8
M/G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.2:.2) [QY4.NTR8+9SU 'R\9ZAA@ [#X.ZG]JLO()7,$C  ?>VM\X)&>Y+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AKO^I;\/\
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M^TG_ .>;?K_A1_:3_P#/-OU_PH T**S_ .TG_P">;?K_ (4?VD__ #S;]?\
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M;]?\*/[2?_GFWZ_X4 :%%9_]I/\ \\V_7_"C^TG_ .>;?K_A0!H45G_VD_\
MSS;]?\*/[2?_ )YM^O\ A0!H45G_ -I/_P \V_7_  H_M)_^>;?K_A0!H45G
M_P!I/_SS;]?\*/[2?_GFWZ_X4 :%%9_]I/\ \\V_7_"C^TG_ .>;?K_A0!H4
M5G_VD_\ SS;]?\*/[2?_ )YM^O\ A0 :W]P?[P_D:M6GW%_W1_*LK4KQIEP4
M*\]3GT/'05)!J;JH B8X YY]/I0!KT5F?VK)_P \F_7_ .)H_M63_GDWZ_\
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M5F?VK)_SR;]?_B:/[5D_YY-^O_Q- &G169_:LG_/)OU_^)H_M63_ )Y-^O\
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MLG_/)OU_^)H_M63_ )Y-^O\ \30!IT5F?VK)_P \F_7_ .)H_M63_GDWZ_\
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M !- &G169_:LG_/)OU_^)H_M63_GDWZ__$T :=%9G]JR?\\F_7_XFC^U9/\
MGDWZ_P#Q- &G169_:LG_ #R;]?\ XFC^U9/^>3?K_P#$T :=%9G]JR?\\F_7
M_P")H_M63_GDWZ__ !- &G169_:LG_/)OU_^)H_M63_GDWZ__$T :=%9G]JR
M?\\F_7_XFC^U9/\ GDWZ_P#Q- &G169_:LG_ #R;]?\ XFC^U9/^>3?K_P#$
MT :=%9G]JR?\\F_7_P")H_M63_GDWZ__ !- &G169_:LG_/)OU_^)H_M63_G
MDWZ__$T :=%9G]JR?\\F_7_XFC^U9/\ GDWZ_P#Q- &G169_:LG_ #R;]?\
MXFC^U9/^>3?K_P#$T :=9GB#_5C_ 'A_(T?VK)_SR;]?_B:IZI>M.H5D*C/4
MY]#QT% &_169_:LG_/)OU_\ B:/[5D_YY-^O_P 30!IT5F?VK)_SR;]?_B:/
M[5D_YY-^O_Q- &G169_:LG_/)OU_^)H_M63_ )Y-^O\ \30!IT5F?VK)_P \
MF_7_ .)H_M63_GDWZ_\ Q- &G169_:LG_/)OU_\ B:/[5D_YY-^O_P 30!IT
M5F?VK)_SR;]?_B:/[5D_YY-^O_Q- &G169_:LG_/)OU_^)H_M63_ )Y-^O\
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ME0J8RH..3GU'L*+#4'B0*(RP&>1GU/L: -NBLS^U9/\ GDWZ_P#Q-']JR?\
M/)OU_P#B: -.BLS^U9/^>3?K_P#$T?VK)_SR;]?_ (F@#3HK,_M63_GDWZ__
M !-']JR?\\F_7_XF@#3HK,_M63_GDWZ__$T?VK)_SR;]?_B: -.BLS^U9/\
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M %%%% !1110 4444 %%%% !6+IG^OD_X%_Z$*VJQ=,_U\G_ O_0A0!M4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8NI_Z^/_
M (#_ .A&MJL74_\ 7Q_\!_\ 0C6U0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5F>(/]6/\ >'\C6G69X@_U8_WA_(T :=%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/\ 5-^'
M\Q1H_P#JE_'^9HUC_5-^'\Q1H_\ JE_'^9H NT444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!0UW_4M^'_H0HHUW_4M^'_H0HH X6Y^\?\]JBJ6Y^\?\]JBH **** "BBB@
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MS/#_ /JS_O'^0K3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *Q=,_U\G_ O_0A6U6+IG^OD_P"!?^A"@#:HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q=3_ -?'_P !_P#0C6U6
M+J?^OC_X#_Z$:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "LSQ!_JQ_O#^1K3K,\0?ZL?[P_D: -.BBB@ HHHH **** "BBB@
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M'X:U"*-<)#>0",#.?WD& A)8Y V$*N"=S=1GFIO&Y:\FL]. &V:?>^X_*4@
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M/4<\$<<8Z?4G*>)=321%MD._;@ELYZ#'7N><D_Y'/44 %%%% !1110 4444
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MN]-\[[7/YV^3*<=!W//3/'R#Y5QP>30!T%%%% !1110 4444 %%%% !1110
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MO=#UQ=37'21>H_J/;^7Y$^/C,'[/WH_#^1])EN9*NN2?Q?G_ ,$U****X3U
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+W_5O_NM_*IZ@O?]
M6_\ NM_*@"GX?_U9_P!X_P A6G69X?\ ]6?]X_R%:= !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !6+IG^OD_X%_Z$*VJQ=,_U\G_
M  +_ -"% &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!BZG_ *^/_@/_ *$:VJQ=3_U\?_ ?_0C6U0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5F>(/]6/]X?R-:=9GB#_5C_>'
M\C0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 4M8_U3?A_,4:/_ *I?Q_F:-8_U3?A_,4:/_JE_'^9H NT444 <U\1],_M"
MPF4!=R+Y@+=O+.YB.#@E00/KC.":S]%OO^$DOENB,):VL;!2>5DNE#D@@#</
M+^4[L<\A>]=E-"LRE' *L""",@@\$$'J#7/^ _"[>&[;[.Y!D9V9BIRN3@#&
M0IQM4=>^>U !X_LFN+1Y8\"6V(F1CV:([B<<@G;D $$9//J,K0KE=>U-[Y5
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MI;G[Q_SVJ*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M99[&WF;<Z[F>5V)55!!P3N*Y+#E1NSM.0 37K_BS_CSN?^O>;_T!JX#X&?\
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M3D8Y]-\/^,1KNF7$$A'GPVTH(R2S*(R!)SU)Z-R>>3C<!5+X&?\ +U_VQ_\
M:E<SXWT1_"%TZVY989XV"\D@JXVO&21@X/;D@;3G=S0!TWP,_P"7K_MC_P"U
M*VOB_KIT^T%NAP]PVT]<[%Y?!''7:"#U!(QZ8OP,_P"7K_MC_P"U*Y?QKJK>
M(=08PJ9E0A$0#=N6/EL>6<E2=QR#G:>H[ $NI^"'M=+BU XW;R[#"Y"2A53Y
MMW(&T$#&1YAX&#GU/X=ZZ=9LHY'.Z1,HYYSE>A);.25*DG/4GZ#B;OQIJUVC
M0R664D4JP\B<9##!&0^>E9OPFU@Z3>-9RY03#80P Q(A^4'=@@_>7'=B!CT
M/;:*Y3QUH%YJ_E?8IO*V;]_[QTSG;M^X#G&#UZ9JKX*\,7^E3-+>3^;&8R O
MFR/ABRD'#@#H#SUYH [6O%/@I_Q^2?\ 7NW_ *''7M=>*?!3_C\D_P"O=O\
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M+7=EG\5^GZH\K//X$?\ $OR9GT445[!\X%%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!BZG_KX_P#@/_H1K:K%U/\
MU\?_  '_ -"-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !69X@_P!6/]X?R-:=9GB#_5C_ 'A_(T :=%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH Q/%/A9/$*+&S,C(V0Z8W;6&V1,GLZD@]LX)! P=B&%85"( %4   8  X
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M$GF6Y\[R]L83'E[NC,<YW+_>]*ZK5K'^T(9+;.WS8W3.,XW*1G&1G&?6K=%
M'*>!? O_  BOF_O?,\W9_!LQLW?[39SNJKJ?PW^W7XU7SL8DB?9Y>?\ 5A1C
M=N'7;Z<9[UVM% '/^,_!Z>)XA"S;'1LJX4,1V(QP<$=@1R ><8J+1O![:?8R
M:6TN\.LBJWEA=HD!XQN.<$D\GOC@"NEHH Y3P+X%_P"$5\W][YGF[/X-F-F[
M_:;.=U:?BKPS'XC@-K(2.=RL/X6 (!QW')!'<'C!P1L44 <?X0\ MX:2=(YL
MO.JA6\L#85#8;!9@W+9QQT]Z/ _P[7PN[S&3S'=0H.TIM&<L,;F!R0/ICW-=
MA10 5Q7B3X;_ -JW8U*&;R9!L/\ J_,RR=&Y8#H ,8QQ[FNUHH **** "N*\
M%?#?_A&)FN?.\S=&4QY>WJRG.=S?W?2NUHH P?&7AEO$< M1(8AO#$A=V0 ?
ME(W+QD@_4#BN(_X49_T\_P#D'_[97JM% 'G_ (6^%']@W*7OG[_+W?+Y6W.Y
M2O7>?7/2O0*** .*\%?#?_A&)FN?.\S=&4QY>WJRG.=S?W?2NMU#3X]1C:WF
M4-&XP0?\\$=01R#R.:L44 >7W7P.1F)BN&5.,!XP[=.<L&4'GV']:[7PQX0@
M\-JR0!LOC<SMEFP3C/0#&XC@#WR:VZ* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UO[@_WA_(UQ6O?ZX_
M[L?_ * M=KK?W!_O#^1KBM>_UQ_W8_\ T!:[LL_BOT_5'E9Y_ C_ (E^3,^B
MBBO8/G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK<\
M/>'C?GS9.(Q^;>P]O4_@.>D5:L:<>9[&E"A.M-0BM0\/>'C?GS9.(Q^;>P]O
M4_@.>G;H@0!0, < #I0B! % P!P .E.KP\1B)5I7>W1'U6#P<,-"RWZL****
MP.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"]_U;_P"ZW\JG
MJ"]_U;_[K?RH I^'_P#5G_>/\A6G69X?_P!6?]X_R%:= !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5N^#O]<W_7,_^A+6%6[X._US?]<S_P"A+0!V-%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %0W?W&_W3_*IJAN_N-_NG^5 %71/N'_>/\A6A6?HGW#_ +Q_D*T*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH S];^X/\ >'\C6%?>%Y;YO.4J RIU)SPH'8'TK=UO
M[@_WA_(U:M/N+_NC^5:4:TJ4KQ,,3AH8B*C+:]SD/^$*F_O)^;?_ !-'_"%3
M?WD_-O\ XFNUHKH_M&MY')_8V&[/[SBO^$*F_O)^;?\ Q-'_  A4W]Y/S;_X
MFNUHH_M&MY!_8V&[/[SBO^$*F_O)^;?_ !-'_"%3?WD_-O\ XFNUHH_M&MY!
M_8V&[/[SBO\ A"IO[R?FW_Q-'_"%3?WD_-O_ (FNUHH_M&MY!_8V&[/[SBO^
M$*F_O)^;?_$T?\(5-_>3\V_^)KM:*/[1K>0?V-ANS^\XK_A"IO[R?FW_ ,31
M_P (5-_>3\V_^)KM:*/[1K>0?V-ANS^\XK_A"IO[R?FW_P 31_PA4W]Y/S;_
M .)KM:*/[1K>0?V-ANS^\XK_ (0J;^\GYM_\31_PA4W]Y/S;_P")KM:*/[1K
M>0?V-ANS^\XK_A"IO[R?FW_Q-'_"%3?WD_-O_B:[6BC^T:WD']C8;L_O.*_X
M0J;^\GYM_P#$T?\ "%3?WD_-O_B:[6BC^T:WD']C8;L_O.2L?!;!P9BI0=E)
MR?;D# _S[CJT0( H& . !TIU%85L1.L[R9U8;"4L.FHK<****R.@**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@O?]6_^ZW\JGJ"]_P!6
M_P#NM_*@"GX?_P!6?]X_R%:=9GA__5G_ 'C_ "%:= !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !6+IG^OD_X%_Z$*VJQ=,_U\G_
MO_0A0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJD;R$]<*6:0'C/\ "0<=>V,\5POP2M6:YEF ^18=I.1U=U*C'7D*?R^E>O\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 4-=_P!2WX?^A"BC7?\
M4M^'_H0HH X6Y^\?\]JBKS[QK_Q]R?\  /\ T!:Q* /7**\CHH ]<HKR.B@#
MURBO(Z* /7**\CHH ]<HKR.B@#URBO(Z* /7**\CHH ]<HKR.B@#URBO(Z*
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M5HH ^JJ*^5:* /JJBOE6B@#ZJHKY5HH ^JJ*^5:* /JJBOE6B@#ZJHKY5HH
M^JJ*^5:* /JJBOE6B@#ZJHKY5HH ^JJ*^5:* /JJBOE6B@#ZJHKY5HH ^JJ*
M^5:* /JJBOE6B@#ZJHKY5HH ^JJ*^5:* /JJBOE6B@#Z:UO[@_WA_(U:M/N+
M_NC^5?+=% 'U517RK10!]545\JT4 ?55%?*M% 'U517RK10!]545\JT4 ?55
M%?*M% 'U517RK10!]545\JT4 ?55%?*M% 'U517RK10!]545\JT4 ?55%?*M
M% 'U517RK10!]545\JT4 ?55%?*M% 'U517RK10!]545\JT4 ?55%?*M% 'U
M517RK10!]545\JT4 ?55%?*M% 'U54%[_JW_ -UOY5\N44 ?2_A__5G_ 'C_
M "%:=?*M% 'U517RK10!]545\JT4 ?55%?*M% 'U517RK10!]545\JT4 ?55
M%?*M% 'U517RK10!]545\JT4 ?55%?*M% 'U517RK10!]545\JT4 ?55%?*M
M% 'U517RK10!]545\JT4 ?55%?*M% 'U517RK10!]545\JT4 ?55%?*M% 'U
M517RK10!]545\JT4 ?55%?*M% 'U56+IG^OD_P"!?^A"OF^B@#ZJHKY5HH ^
MJJ*^5:* /JJBOE6B@#ZJHKY5HH ^JJ*^5:* /JJBOE6B@#ZJHKY5HH ^JJ*^
M5:* /JJBOE6B@#ZJHKY5HH ^JJ*^5:* /JJBOE6B@#ZJHKY5HH ^JJ*^5:*
M/JJBOE6B@#ZJHKY5HH ^JJ*^5:* /JJBOE6B@#ZJHKY5HH ^JJ*^5:* /JJB
MOE6B@#ZJHKY5HH ^D-3_ -?'_P !_P#0C6U7RK10!]545\JT4 ?55%?*M% '
MU517RK10!]545\JT4 ?55%?*M% 'U517RK10!]545\JT4 ?55%?*M% 'U517
MRK10!]545\JT4 ?55%?*M% 'U517RK10!]545\JT4 ?55%?*M% 'U517RK10
M!]545\JT4 ?55%?*M% 'U517RK10!]545\JT4 ?55%?*M% 'U517RK10!]55
MF>(/]6/]X?R-?-%% 'U517RK10!]545\JT4 ?55%?*M% 'U517RK10!]545\
MJT4 ?55%?*M% 'U517RK10!]545\JT4 ?55%?*M% 'U517RK10!]545\JT4
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M /Q5:]% &1_PB5K_ '/_ !Y__BJ/^$2M?[G_ (\__P 56O10!D?\(E:_W/\
MQY__ (JC_A$K7^Y_X\__ ,56O10!D?\ ")6O]S_QY_\ XJC_ (1*U_N?^//_
M /%5KT4 9'_")6O]S_QY_P#XJC_A$K7^Y_X\_P#\56O10!D?\(E:_P!S_P >
M?_XJC_A$K7^Y_P"//_\ %5KT4 9'_")6O]S_ ,>?_P"*H_X1*U_N?^//_P#%
M5KT4 9'_  B5K_<_\>?_ .*H_P"$2M?[G_CS_P#Q5:]% &1_PB5K_<_\>?\
M^*H_X1*U_N?^//\ _%5KT4 9'_")6O\ <_\ 'G_^*H_X1*U_N?\ CS__ !5:
M]% &1_PB5K_<_P#'G_\ BJ/^$2M?[G_CS_\ Q5:]% &1_P (E:_W/_'G_P#B
MJ/\ A$K7^Y_X\_\ \56O10!D?\(E:_W/_'G_ /BJ/^$2M?[G_CS_ /Q5:]%
M&1_PB5K_ '/_ !Y__BJ/^$2M?[G_ (\__P 56O10!D?\(E:_W/\ QY__ (JC
M_A$K7^Y_X\__ ,56O10!D?\ ")6O]S_QY_\ XJC_ (1*U_N?^//_ /%5KT4
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M_GC_ .1)?_BZ/^%6Z=_SQ_\ (DO_ ,775T4 <I_PJW3O^>/_ )$E_P#BZ/\
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M_(DO_P 775T4 <I_PJW3O^>/_D27_P"+H_X5;IW_ #Q_\B2__%UU=% '*?\
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M7_XNC_A5NG?\\?\ R)+_ /%UU=% '*?\*MT[_GC_ .1)?_BZ/^%6Z=_SQ_\
M(DO_ ,775T4 <I_PJW3O^>/_ )$E_P#BZCN/AAIR*S"'D*?^6DOI_OUU]0W?
MW&_W3_*@#CM+^&NGSJ6:')S_ ,])/0?[=7/^%6Z=_P \?_(DO_Q=;>B?</\
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MX_\ D27_ .+KJZ* .4_X5;IW_/'_ ,B2_P#Q='_"K=._YX_^1)?_ (NNKHH
MY3_A5NG?\\?_ ")+_P#%T?\ "K=._P">/_D27_XNNKHH Y3_ (5;IW_/'_R)
M+_\ %T?\*MT[_GC_ .1)?_BZZNB@#E/^%6Z=_P \?_(DO_Q='_"K=._YX_\
MD27_ .+KJZ* .4_X5;IW_/'_ ,B2_P#Q='_"K=._YX_^1)?_ (NNKHH Y3_A
M5NG?\\?_ ")+_P#%T?\ "K=._P">/_D27_XNNKHH Y3_ (5;IW_/'_R)+_\
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M_GC_ .1)?_BZZNB@#E/^%6Z=_P \?_(DO_Q='_"K=._YX_\ D27_ .+KJZ*
M.4_X5;IW_/'_ ,B2_P#Q='_"K=._YX_^1)?_ (NNKHH Y3_A5NG?\\?_ ")+
M_P#%T?\ "K=._P">/_D27_XNNKHH Y3_ (5;IW_/'_R)+_\ %T?\*MT[_GC_
M .1)?_BZZNB@#B-4^&NGP*&6'!S_ ,])/0_[=6+?X8:<ZJQAY*C_ ):2^G^_
M6_K?W!_O#^1KE8_&LT8"A4X '1NW_ J#>AAIU[\O0O\ _"K=._YX_P#D27_X
MNC_A5NG?\\?_ ")+_P#%U2_X3B?^ZGY-_P#%4?\ "<3_ -U/R;_XJ@V_LROY
M?>7?^%6Z=_SQ_P#(DO\ \71_PJW3O^>/_D27_P"+JE_PG$_]U/R;_P"*H_X3
MB?\ NI^3?_%4!_9E?R^\N_\ "K=._P">/_D27_XNC_A5NG?\\?\ R)+_ /%U
M2_X3B?\ NI^3?_%4?\)Q/_=3\F_^*H#^S*_E]Y=_X5;IW_/'_P B2_\ Q='_
M  JW3O\ GC_Y$E_^+JE_PG$_]U/R;_XJC_A.)_[J?DW_ ,50']F5_+[R[_PJ
MW3O^>/\ Y$E_^+H_X5;IW_/'_P B2_\ Q=4O^$XG_NI^3?\ Q5'_  G$_P#=
M3\F_^*H#^S*_E]Y=_P"%6Z=_SQ_\B2__ !='_"K=._YX_P#D27_XNJ7_  G$
M_P#=3\F_^*H_X3B?^ZGY-_\ %4!_9E?R^\N_\*MT[_GC_P"1)?\ XNC_ (5;
MIW_/'_R)+_\ %U2_X3B?^ZGY-_\ %4?\)Q/_ '4_)O\ XJ@/[,K^7WEW_A5N
MG?\ /'_R)+_\71_PJW3O^>/_ )$E_P#BZI?\)Q/_ '4_)O\ XJC_ (3B?^ZG
MY-_\50']F5_+[R[_ ,*MT[_GC_Y$E_\ BZ/^%6Z=_P \?_(DO_Q=4O\ A.)_
M[J?DW_Q5'_"<3_W4_)O_ (J@/[,K^7WEW_A5NG?\\?\ R)+_ /%T?\*MT[_G
MC_Y$E_\ BZI?\)Q/_=3\F_\ BJ/^$XG_ +J?DW_Q5 ?V97\OO+O_  JW3O\
MGC_Y$E_^+H_X5;IW_/'_ ,B2_P#Q=4O^$XG_ +J?DW_Q5'_"<3_W4_)O_BJ
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M_"<3_P!U/R;_ .*H#^S*_E]Y=_X5;IW_ #Q_\B2__%T?\*MT[_GC_P"1)?\
MXNJ7_"<3_P!U/R;_ .*H_P"$XG_NI^3?_%4!_9E?R^\N_P#"K=._YX_^1)?_
M (NC_A5NG?\ /'_R)+_\75+_ (3B?^ZGY-_\51_PG$_]U/R;_P"*H#^S*_E]
MY=_X5;IW_/'_ ,B2_P#Q='_"K=._YX_^1)?_ (NJ7_"<3_W4_)O_ (JC_A.)
M_P"ZGY-_\50']F5_+[R[_P *MT[_ )X_^1)?_BZ/^%6Z=_SQ_P#(DO\ \75+
M_A.)_P"ZGY-_\51_PG$_]U/R;_XJ@/[,K^7WEW_A5NG?\\?_ ")+_P#%T?\
M"K=._P">/_D27_XNJ7_"<3_W4_)O_BJ/^$XG_NI^3?\ Q5 ?V97\OO+O_"K=
M._YX_P#D27_XNC_A5NG?\\?_ ")+_P#%U2_X3B?^ZGY-_P#%4?\ "<3_ -U/
MR;_XJ@/[,K^7WEW_ (5;IW_/'_R)+_\ %U%=?##3D1F$/(4D?O)>P_WZK_\
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M_GC_ .1)?_BZ/^%6Z=_SQ_\ (DO_ ,775T4 <I_PJW3O^>/_ )$E_P#BZ/\
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MDO\ \71_PJW3O^>/_D27_P"+KJZ* .4_X5;IW_/'_P B2_\ Q='_  JW3O\
MGC_Y$E_^+KJZ* .4_P"%6Z=_SQ_\B2__ !='_"K=._YX_P#D27_XNNKHH Y3
M_A5NG?\ /'_R)+_\71_PJW3O^>/_ )$E_P#BZZNB@#E/^%6Z=_SQ_P#(DO\
M\71_PJW3O^>/_D27_P"+KJZ* .4_X5;IW_/'_P B2_\ Q='_  JW3O\ GC_Y
M$E_^+KJZ* .4_P"%6Z=_SQ_\B2__ !='_"K=._YX_P#D27_XNNKHH Y3_A5N
MG?\ /'_R)+_\71_PJW3O^>/_ )$E_P#BZZNB@#E/^%6Z=_SQ_P#(DO\ \71_
MPJW3O^>/_D27_P"+KJZ* .4_X5;IW_/'_P B2_\ Q='_  JW3O\ GC_Y$E_^
M+KJZ* .4_P"%6Z=_SQ_\B2__ !='_"K=._YX_P#D27_XNNKHH Y3_A5NG?\
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M\?\ P'_T(UM4 <I_PJW3O^>/_D27_P"+H_X5;IW_ #Q_\B2__%UU=% '*?\
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M7_XNC_A5NG?\\?\ R)+_ /%UU=% '*?\*MT[_GC_ .1)?_BZ/^%6Z=_SQ_\
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M1_PJW3O^>/\ Y$E_^+KJZ* .4_X5;IW_ #Q_\B2__%T?\*MT[_GC_P"1)?\
MXNNKHH Y3_A5NG?\\?\ R)+_ /%T?\*MT[_GC_Y$E_\ BZZNB@#E/^%6Z=_S
MQ_\ (DO_ ,71_P *MT[_ )X_^1)?_BZZNB@#E/\ A5NG?\\?_(DO_P 71_PJ
MW3O^>/\ Y$E_^+KJZ* .4_X5;IW_ #Q_\B2__%T?\*MT[_GC_P"1)?\ XNNK
MHH Y3_A5NG?\\?\ R)+_ /%T?\*MT[_GC_Y$E_\ BZZNB@#E/^%6Z=_SQ_\
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M0XSP>"Q'0GM170:[_J6_#_T(44 <+<_>/^>U15+<_>/^>U14 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %;O@[_7-_US/_H2UA5N^#O]<W_7,_\
MH2T =C1110!RGPM_Y!T'_;3_ -&O1X _Y?/^PA<?^RT?"W_D'0?]M/\ T:]'
M@#_E\_["%Q_[+0!U$TRPJ7<@*H)))P !R22>@%9G_"66?_/Q#_W^3_XJM.:%
M9E*. 58$$$9!!X((/4&LS_A$[/\ Y]X?^_*?_$T :<,RS*'0@JP!!!R"#R""
M.H-1:AJ$>G1M<3,%C09)/^>2>@ Y)X'-,NKJ+2(C(Y6.*)1VPH X  'Y #KP
M *Q]/T^369%OKM2J(<P0-_#Z2R#O(>PZ1C_:R0 'A_3Y+J>35IU*-*BI%&WW
MTB!W?-CC<[?,0<E.F[J!T=%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWNY[FSE"[[:1<% =ICD7='G)SNQG=P!TQF@#;HJIJNIII<3W4IPD:DGIDXZ
M9(&2> ,\D@5G^#O$/_"06J71"ASD.JG(#*<?49&& /(!')ZD VZ*Q/%FMOI4
M:>2%,L\T<4>\$H&<]6P0<8!Z9.<<5MT %%%% !116?XANFM+:>:,X>.&1E.
M<%4)!P>.M &A16?X>NFN[:":0Y>2&-F. ,ED!)P..M:% !16?XANFM+:>:,X
M>.&1E. <%4)!P>.M'AZZ:[MH)I#EY(8V8X R60$G XZT :%%%% !117/_P"G
M_;_X/L/E^V[./^^MV[_@&S_:H Z"BBB@ HKG_%^J2:?]F\IMOFWD,;< Y5MV
MX<@XSCJ.?>N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** *&N_ZEOP_]"%%&N_ZEOP_
M]"%% '"W/WC_ )[5%4MS]X_Y[5%0 4444 %%%% !1110 4444 %%,FF6$;F.
M![UA7FK-=?NT! /&!R3G_/0?K0!T%%<V4ETIAD;=WT(./I_^O\ZV;+4ENN!P
MWH?Z>M VFG9ENBBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !5[2-7?3'WKR#]Y>Q'^/H>WTR*HT4"G!33B]4SU&
MPOTOT$L9R#^8/H??_/2K-<[X2T1[$&:0D%Q]ST'J??T]!GN<#HJ#YO$0A"HU
M%W04444&04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BZ
M9_KY/^!?^A"MJL73/]?)_P "_P#0A0!M4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 8NI_P"OC_X#_P"A&MJL74_]?'_P'_T(
MUM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9GB
M#_5C_>'\C6G69X@_U8_WA_(T :=%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% %+6/]4WX?S%&C_P"J7\?YFC6/]4WX?S%&C_ZI
M?Q_F: +M<E>%M.U:)P!LO8'0@''SPY?>PQACMPH.<@$] ,'K:X_XF1^3!%J
M56-G<12'/#%=V"H.#C)*Y[<9Y( H E\<_P"GM;:7VNILN#PICA&]UR.03QC&
M.G) INC3+I.H7%@2 MR%N(US_$<K+R>=S%=P R H)&.13O#?_$RO;N_/2)A;
M1YX8"/YI!@<$,Y!!.3]!Q1X__P!!6'5!ULYE+$<L8Y"$D4 \$MD=<8QP0>H
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M?8MW[K['YFW ^]YNW.<9Z<8SCVJEX(A74)+C6"!FXE*QL!UBBPBD _,"Q'S
MXR0#@<4[_F,_]P__ -KT :'B7Q+_ &/Y<4<;2SSL1'&IQG&-Q+8(4*#R?Z9(
MS_[&U.Y_>/>)$QZI%;JZ#''#2'<<]3GN2!QBHKH+'K,32#[]FRQDJ2-ZN68
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M29M/^T>?&\>[RL>8C+G&_.,@9QD5Z7110 4444 %%%% !1110 4444 %%%%
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M% WJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFZ:Y.]R2??\ SP/:HJ "BBB@ HHHH **** "BBB@ HHHH *W?!W^N;_KF?\
MT):PJW?!W^N;_KF?_0EH [&N<\9ZI+"J6-MC[3=ED0DE=JA<O)D=U'3G.3D
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MQI5XU[$DSHT;.H)1\;E)['']<'U .0&66AV]@V^&*-&(P2B*IQUQD <<5>H
M*Y*_E'AF[DU&3/V6Z1!(X!8I)&-J9"C(1E.,X;Y\9P",];10!CS>,;*)2YN(
ML*"3B16/'H 22?8#)[5R5OKS^(M5M_+C98+>.5U9P59UD79Y@#8^4G:%P,]2
M>X7LH?#%I"P=((@RD$$1("".000."*N_9$W^?M7S-NW=@;MN<[=W7&><=,T
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M4$'^?-,\00MI5U'K !:)8FBGP-Q5-V]9 HYPK??ZD+R%X)'2PPK"H1  J@
M#  '   Z 4^@#'A\8V4JAQ<188 C,BJ>?4$@@^Q&1WKC-=\4'Q%=V5M:HQ@^
MT)*)64H',7+[=V,A!G=W)X X&[N)O#%I,Q=X(BS$DDQ(22>222.2:NR6B2LL
MK*I>/.UB 67<,'!ZC(ZXZT <QXHE&A746L-DQ%#!-@%MJLVY'  X ?AB2>"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** ,74_]?'_P'_T(UM5BZG_KX_\ @/\
MZ$:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
MSQ!_JQ_O#^1K3K,\0?ZL?[P_D: -.BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"EK'^J;\/YBC1_]4OX_S-&L?ZIOP_F*-'_U
M2_C_ #- %VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** *&N_P"I;\/_ $(44:[_ *EOP_\
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M'<5E5N^#O]<W_7,_^A+0!M_V[_L_^/?_ %J/[=_V?_'O_K5K44 9/]N_[/\
MX]_]:C^W?]G_ ,>_^M6M10!D_P!N_P"S_P"/?_6H_MW_ &?_ ![_ .M6M10!
MD_V[_L_^/?\ UJ/[=_V?_'O_ *U:U% &3_;O^S_X]_\ 6H_MW_9_\>_^M6M1
M0!D_V[_L_P#CW_UJ/[=_V?\ Q[_ZU:U% &3_ &[_ +/_ (]_]:C^W?\ 9_\
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MM6M10!D_V[_L_P#CW_UJ/[=_V?\ Q[_ZU:U% &3_ &[_ +/_ (]_]:C^W?\
M9_\ 'O\ ZU:U% &3_;O^S_X]_P#6H_MW_9_\>_\ K5K44 9/]N_[/_CW_P!:
MC^W?]G_Q[_ZU:U% &3_;O^S_ ./?_6H_MW_9_P#'O_K5K44 9/\ ;O\ L_\
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M_P#CW_UJUJ* ,G^W?]G_ ,>_^M1_;O\ L_\ CW_UJUJ* ,G^W?\ 9_\ 'O\
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MJ/\ A(O]C_Q[_P"M6U10!B_\)%_L?^/?_6H_X2+_ &/_ ![_ .M6U10!B_\
M"1?['_CW_P!:C_A(O]C_ ,>_^M6U10!B_P#"1?['_CW_ -:C_A(O]C_Q[_ZU
M;5% &+_PD7^Q_P"/?_6H_P"$B_V/_'O_ *U;5% &+_PD7^Q_X]_]:C_A(O\
M8_\ 'O\ ZU;5% &+_P )%_L?^/?_ %J/^$B_V/\ Q[_ZU;5% &+_ ,)%_L?^
M/?\ UJ/^$B_V/_'O_K5M44 8O_"1?['_ (]_]:C_ (2+_8_\>_\ K5M44 8O
M_"1?['_CW_UJ/^$B_P!C_P >_P#K5M44 8O_  D7^Q_X]_\ 6H_X2+_8_P#'
MO_K5M44 8O\ PD7^Q_X]_P#6H_X2+_8_\>_^M6U10!B_\)%_L?\ CW_UJ/\
MA(O]C_Q[_P"M6U10!B_\)%_L?^/?_6H_X2+_ &/_ ![_ .M6U10!B_\ "1?[
M'_CW_P!:C_A(O]C_ ,>_^M6U10!B_P#"1?['_CW_ -:F3Z]YJE-OW@1][U'T
MK=J"]_U;_P"ZW\J ,/3]6^QJ4VYR<]<=A[59_P"$B_V/_'O_ *U3^'_]6?\
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M/^$B_P!C_P >_P#K5M44 8O_  D7^Q_X]_\ 6H_X2+_8_P#'O_K5M44 8O\
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M/^$B_P!C_P >_P#K5M44 8O_  D7^Q_X]_\ 6H_X2+_8_P#'O_K5M44 8O\
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MJ* ,7_A(O]C_ ,>_^M1_PD7^Q_X]_P#6K:HH Q?^$B_V/_'O_K4?\)%_L?\
MCW_UJVJ* ,7_ (2+_8_\>_\ K4?\)%_L?^/?_6K:HH Q?^$B_P!C_P >_P#K
M4?\ "1?['_CW_P!:MJB@#%_X2+_8_P#'O_K4?\)%_L?^/?\ UJVJ* ,7_A(O
M]C_Q[_ZU'_"1?['_ (]_]:MJB@#%_P"$B_V/_'O_ *U'_"1?['_CW_UJVJ*
M,7_A(O\ 8_\ 'O\ ZU'_  D7^Q_X]_\ 6K:HH Q?^$B_V/\ Q[_ZU'_"1?['
M_CW_ -:MJB@#%_X2+_8_\>_^M1_PD7^Q_P"/?_6K:HH Q?\ A(O]C_Q[_P"M
M1_PD7^Q_X]_]:MJB@#G[S6OM*&/;C..<YZ'/I19ZU]F01[<XSSG'4Y]*T]8_
MU3?A_,4:/_JE_'^9H I?\)%_L?\ CW_UJ/\ A(O]C_Q[_P"M6U10!B_\)%_L
M?^/?_6H_X2+_ &/_ ![_ .M6U10!B_\ "1?['_CW_P!:C_A(O]C_ ,>_^M6U
M10!B_P#"1?['_CW_ -:C_A(O]C_Q[_ZU;5% &+_PD7^Q_P"/?_6H_P"$B_V/
M_'O_ *U;5% &+_PD7^Q_X]_]:C_A(O\ 8_\ 'O\ ZU;5% &+_P )%_L?^/?_
M %J/^$B_V/\ Q[_ZU;5% &+_ ,)%_L?^/?\ UJ/^$B_V/_'O_K5M44 8O_"1
M?['_ (]_]:C_ (2+_8_\>_\ K5M44 8O_"1?['_CW_UJ/^$B_P!C_P >_P#K
M5M44 8O_  D7^Q_X]_\ 6H_X2+_8_P#'O_K5M44 8O\ PD7^Q_X]_P#6H_X2
M+_8_\>_^M6U10!B_\)%_L?\ CW_UJ/\ A(O]C_Q[_P"M6U10!B_\)%_L?^/?
M_6H_X2+_ &/_ ![_ .M6U10!B_\ "1?['_CW_P!:C_A(O]C_ ,>_^M6U10!B
M_P#"1?['_CW_ -:C_A(O]C_Q[_ZU;5% &+_PD7^Q_P"/?_6H_P"$B_V/_'O_
M *U;5% &+_PD7^Q_X]_]:C_A(O\ 8_\ 'O\ ZU;5% &+_P )%_L?^/?_ %J/
M^$B_V/\ Q[_ZU;5% &+_ ,)%_L?^/?\ UJ/^$B_V/_'O_K5M44 8O_"1?['_
M (]_]:C_ (2+_8_\>_\ K5M44 8O_"1?['_CW_UJ/^$B_P!C_P >_P#K5M44
M 8O_  D7^Q_X]_\ 6H_X2+_8_P#'O_K5M44 8O\ PD7^Q_X]_P#6H_X2+_8_
M\>_^M6U10!B_\)%_L?\ CW_UJ/\ A(O]C_Q[_P"M6U10!B_\)%_L?^/?_6H_
MX2+_ &/_ ![_ .M6U10!B_\ "1?['_CW_P!:C_A(O]C_ ,>_^M6U10!SNH:U
M]I0Q[<9QSG/0@^E%:>N_ZEOP_P#0A10!PMS]X_Y[5%4MS]X_Y[5%0!SFKQ^5
M*2>0<'!)^F/T_*NOMB&4%?ND#';CM7.Z_!N42#L<'CL??_/6M3PY/YL0'.5)
M'/YC]"*#LP$[2<>YL(*F05$E3I0=LB5!4%GK$=RYA4G</48SZXSSD=P<592N
M4\1:*UNQG7E&.3[$G^7H?P/;,S;2N5AJ5.M)PD[-[>IVR"IT6N6\,^(_.Q;S
M'YNBL>_L??T/?Z]>K04XR4E<Y<31G0GRR.*\;^/O[&;[-" 9,<D]!7&/\3;M
MQ@E2/<5GZ["VHWSQY^9Y2HS]<"LF^M#9NT+=4)!_"F<$I-LZ2'XA7%J,KM!/
MHH%7]+^*T\;CS@&0GG P:X6KL^DM#"ET<;9&('KQ0)29]!6MRMXBS)RK#(I7
M%<Y\-)C+9+G^%F KI7%!TP=RLXJ%Q5AQ4#T&\65W%0.*L/4#T&T2NXKD?$KJ
M9< #( R>^?\ ]6/\].O>N*MF-[/OYY;=ZX Y _I08XV=H*/<W;2#R$">@_7O
M^M2T44'G!1110 5V=B?L%NDD*>86 W;<9YSGH"3@G&.WX&N,KI['3KK3-I3#
M*W+)D#!],GOCN._7( R 9VLW,>HR*(%P6ZGIDMVQTR#U/?Z &MX@:*H2*-G9
ML;BH..!C).&_+MS^-+Q0RVTL4P W Y89P2%(QG]1G_"M:^N)B%DM@K*P!PV0
M>>0>2./;K_0 H75D-9C+^68YE]1C/H,D#(.,>WTZ\_H^G?VA((^@ZDCK@?YQ
M^M='<WUW;IYS+& .HR<C_P >Q^1)YK#\-WRVDN7X# KD]!G!!_3'ZT ;%UK\
M>E'R(DSMZX( S@=^<GL<\Y%9NMZI#?J&52)3@D\#'8@G^+IQ_,<BIM7\-2O(
MTD8W*Y)Z@$9Y/7'?..O'6J6H>'WL4$K$<XR,\@G/'O\ A_(9H V]-D2&T29Q
MGR]S#/\ >W,!_/\ #K67$QU^X!884 9&<X4=L\'DGZC/M5S_ )A_^?\ GI6=
MX8NQ;3#/1QM_$D8_48_&@#>FU-K$^3# S(O&0"![X^4Y^O<_F<WQ!I2E!=Q*
M5'&Y2-N.V<=CGCCKU]SK7L]W&Q$:HR]CT/T.6'/^?:LSQ#=W$:>5*$VOCE,Y
MX.>A.>W/&.: -'1]4WVYDV_ZE2,9Z[%!].,_C63I\ UR=IG7" #(SWQ@#(P>
MV?PQ4^A_\>DW_;3_ - %0>#[L1NT1ZN!CZKGC\B?RH TY=893Y0@<Q]/ND<=
M/N[>GH,_E61XDTE;;$\8PC]1C&#UZ'D9],<8^@K:EGO%;:JH5SPW(&/7&[/U
M_3-8WB.[FX@F"8SN!3//&.YSCGN![4 7-)MX]*A%W*/F/3UPW0#G&<<^N,BI
M+/7X]2=8Y$PV1M)(.".>O!'('3KTI(XQK5JL2$!X]O!/<<<\=".1[\9X-5-(
M\-2I(LD@VJA!Z@DXY'3/?&>G'2@"/QC_ *Y?^N8_]":L*MWQC_KE_P"N8_\
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M.?KW/YG"\-W(M)]K?Q97(.1DD8Z9SR,>G.:Z&]GNXV(C5&7L>A^ARPY_S[4
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MI_X2Q8K"T*_Z3&6N#GYHH\A7497!9B2H./1L ,&%CQ?I\>G1V-O"H6-+^W
M_P"!?F3U)/)/)YH [.BN*^*MP]M#;RQ#=(EY$57!.6"N5&!R<GL.:EM?AQ#=
MJ)-1+7%P<EG+N%&3G8H4J H)...Y. ,  '845RGAEFT>X?169GC2%986;!<)
MG8R,V%Z-]T '"\9X '5T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W?W&_W3_*IJAN
M_N-_NG^5 %71/N'_ 'C_ "%:%9^B?</^\?Y"M"@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML??T/?Z]0X,;@.5<\-NJ.HHHHH/,"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "H+W_5O_ +K?RJ>H+W_5O_NM_*@"GX?_ -6?]X_R%:=9
MGA__ %9_WC_(5IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %8NF?Z^3_@7_ *$*VJQ=,_U\G_ O_0A0!M4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 8NI_Z^/\ X#_Z$:VJQ=3_
M -?'_P !_P#0C6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5F>(/\ 5C_>'\C6G69X@_U8_P!X?R- &G1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_5-^'\Q1H_^J7\?YFC
M6/\ 5-^'\Q1H_P#JE_'^9H NT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7530K,I1P"K @@C((/!!!Z@UR_\ PKR.+Y8)[F&,=(XIR$7UP"&/)R3SU)H
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M%45MI1-V-Q4;<ACCDY)()'3  !Q\5C+X(9+^9P\=P<795"<.S.RRC'106VG
M QR%+, -CQ]_RY_]A"W_ /9JZB:%9E*. 58$$$9!!X((/4&L*'P9&D4-LTDK
M+;3)+&792P*9VH2%&5&>G4= 0   "IX^_P"7/_L(6_\ [-75UGZOHB:KY7F%
MAY$R2KM(&63. <@\<\]#[UH4 <I_S&?^X?\ ^UZZNL_^Q$^T_P!H9;S/)\K&
M1MV[]^<8SG/OC':M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&[^XW^Z?Y5-4-W]Q
MO]T_RH JZ)]P_P"\?Y"M"L_1/N'_ 'C_ "%:% !16)<^,[2UG%@\F)RRKMV.
M>7QM&0N.<CO]:JW7Q(T^U8QM.I(Q]Q7=>1GAD4@_@?;K0!TM%9FI^);;2XQ/
M-*JHXRISNW XY4+DL.1T!X.>E,T3Q5:ZWD6TBN1G*\JV!CG:P!QR.<8SQG-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5BZ9_KY/^!?\ H0K:K%TS_7R?\"_]"% &
MU1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!BZ
MG_KX_P#@/_H1K:K%U/\ U\?_  '_ -"-;5 !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !69X@_P!6/]X?R-:=9GB#_5C_ 'A_(T :
M=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6
M/]4WX?S%&C_ZI?Q_F:-8_P!4WX?S%&C_ .J7\?YF@"[6?I>MIJ+2Q*&5X)"C
M*X ;ID,!DG:P^Z3C/-:%<E%*-,U9XSG;?0*P)!.9(<KM4@8 "<G.><<C(! .
MJFF6%2[D!5!)).  .223T JIHNL1ZQ"EW#G9(,C(P1@D$$>H((]/0D<UB_$"
M9IH4T^,D27DJ1Y4_,J9W2/M'+*%&&Y PW)QUB\%Q#2)KG2>=L;B2+<3_ *N4
M<JH8DE488+ G+$YP>H!NZYK::-'Y\@9LLJJJ %V9C@*JDC)[XZX!K0KDO$\H
MO[VST\9(1S</M!ROE@^6<XQM9L@]^@R,C._K&M0Z/'Y]PX1,@9.3DGH  "2?
MH.@)Z T 7J*Y3_A*;V?YX+!S&>AEFCA?T.8SDCG..>1@]ZT- \6Q:RSPJKQR
MQXW1S+LDP0"&VY/'/X<9QD9 -NJFK7W]GPR7.-WE1N^,XSM4G&<'&<>E<_XE
M\>KH4_V1HV=FA#Q["2SNSE%C "G&<9SGV )P"_4+ZXO+&Z:YA$!$$H4>:)"?
MW;9/R@ #TY)Z\#C(!NZ3??VA#'<XV^;&CXSG&Y0<9P,XSZ5;K'\,3+#8V[N0
M%6VB)).  (P223T K,_X362_^;3[9YXQUD9A A_W3(,M@@AN!@COD4 =!JU]
M_9\,ESC=Y4;OC.,[5)QG!QG'I1I-]_:$,=SC;YL:/C.<;E!QG SC/I7):YXR
M4VT]I=QM;3O!*%5_FC<^6QPDJ_*QQC/3YB%&35W3M=_LFUT\,NY)U@B)#896
M>,;3MQ@C(YY!'8'I0!U=%%8_ACQ-'XAC>>($*DKID]]N"&'0X*D'! (.1VR0
M#8KG_P#A+?\ 3_[)\I_]7N\S^'IG./[O\.[/W_EQWJUJFN_8I[>S5=SW+/@E
MMJJL:[F/0DG'08P>Y%']N_Z9_9NW_EW\W?N_V]FW;C\<Y_"@#6HJCK&M0Z/'
MY]PX1,@9.3DGH  "2?H.@)Z UA?\)3>S_/!8.8ST,LT<+^AS&<D<YQSR,'O0
M!JZ_KO\ 9'D_+N\^XCB^]C&_/S=#G&.G&?6M:O//$?BJ'5VM(EW),E_;EHI5
M*2*#NP2#U!X/!. 1G&:[/7==BT.(W,YPJ] /O,>R@=R?_KG !( -"BN//B^^
M=3,E@YC&XC?,J2$*3UC*E@3CH,Y[9XSM>'_$L6NJS1;E:-BKQR#;(A!(PRY.
M,XX_$=00 #6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"AKO\ J6_#_P!"%%&N_P"I;\/_ $(4
M4 <+<_>/^>U15+<_>/\ GM45 !63K\&Y1(.QP>.Q]_\ /6M:HKN#ST*>H_7M
M^M %CPY=>?",]4^7\NGZ$5L(:X[PI=>7(8S_ !C]5_\ K9KKT-!ZE"?/33^1
M90US.NZ^TA:W3A0<$]SC@_A_GOBNC0U3M="CAD\[DG)/S'(!/?US]2?7K4S3
M>B.G#3I4Y.4E>VWJ4]"\+])I_J$(_+/^'Y]Q77*U55:I5:G&*BCFQ->=>7-(
MXK_A73&]^V;QY>_=COGKBO.O$7-S*/\ IHW\Z]]#UX%X@_X^9?\ KH?YTS@J
MQ42#4=,:P(5\?,H88]#7;Z1X4;Q!IZ*A 9)&(STKG_%@&^-C_P \EKT3X:29
MLQ_OM_2@4(WE8UO"^B_V) MN3D@DD]LFM)FH9JB9J#IC&PCFH'-/9JA=J#6*
M&.:@<U(YK)\0W?D0MZM\H_'K^F:#5OEBWV.81O[1GWGH6SR.PZ _A@5T-8_A
M^#[TGX#^9_I6Q0>2W=W"BBB@04444 %%%% !1110 4444 %%%% !15[185FF
M17^Z3WQ@X&0.?4\>]=3?ZFMH3#+'^ZP,' *G R%QC Z<<]@>G- '$45T'A-@
MT[E1@%&P,YP-R\9K)U3_ %TG_71__0C0!5HKI]<_X](?^V?_ * :NR7:6,$5
MPR[F5%"_\" SS@XX'].] &5X3T]+EG=QG9C /(YSV_"L_6+N.Z<-"NU0H&,
M<Y//%=3H&L'40V1@J?7/#$X'0= ,>]95NH\13>8R[4C4 @'.>20,\=>?R]Z
M.<HKJYO%4=J?*B3*KD<$*.IZ  \=\U<26.:VDDA&U65\C@8(7'0<#@#^?>@#
MB**W/#>DK<YGE^XGKC!(Y.?8?D?S%7?^$Q1"%6,[!@=0#C_=QCCMS^5 '+45
MH:U<13ONA7 []@?<#M_G@'KT-K;#18PPC+S,.=H)]R,C( '3CKC\@#CJ*[(Q
MC6U*RQM&XZ,5/\R!Z\C\1[<A+$8B4;@J2#]10 RBBB@ HHHH **** "BBB@
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M-M:,8I9HD<8RKR(K#(R,@G/2KL,RS*'0@JP!!!R"#R"".H- #Z*** "BBB@
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M3ZGW_P ]*#CQN-5%<J^+\B:&/RE"9)P ,DY)QW)]:?110>"W<**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J"]_U;_[K?RJ>H+W_5O_ +K?RH I
M^'_]6?\ >/\ (5IUF>'_ /5G_>/\A6G0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5BZ9_KY/^!?^A"MJL73/]?)_P "_P#0A0!M
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8NI
M_P"OC_X#_P"A&MJL74_]?'_P'_T(UM4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %9GB#_5C_>'\C6G69X@_U8_WA_(T :=%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/]4WX?
MS%&C_P"J7\?YFC6/]4WX?S%&C_ZI?Q_F: +M<?\ $!OL#6FI98?9[@!R!N41
MRC$A(P3T  /OQR1785B>-=,_M.RG@PQ)C)4)RQ9/G4 8.<E0,=3VYH S[/\
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M%%% !1110 4444 %%%% !1110!0UW_4M^'_H0HHUW_4M^'_H0HH X6Y^\?\
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M %%%% !1110 4444 %8NF?Z^3_@7_H0K:K%TS_7R?\"_]"% &U1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!BZG_KX_\ @/\
MZ$:VJQ=3_P!?'_P'_P!"-;5 !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR]-+T&RB.9JC9J:7IC-0:*)4UB[^SQ,W<C YP<GCCZ=?PK"\/P?>D_ ?S/\
M2I?%%SDK%_P(_P A_6K>FP>1&J]\9/&.3_ATH/-QL[U+=BS1110<H4444 %%
M%% !1110 445H^'HA+.BL 0=W!&1]TT 9U%;5_;JMX(P %WQ\ #'(7/%'BJW
M6"4*@"C8.%  ZGTH Q:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HKHM9M4CM8G50&.S)  )RA/6J/GP?9MF/WV[KCGKUSZ8XQZ\X[T 9=%%% !
M1110 4444 %%%% !1110 4444 %;O@[_ %S?]<S_ .A+6%6SX5N%@E+,<#8?
MYB@#M:J:AI<>H;/-7=Y4BR+R1AESM/!&<9Z'CVH_M2/^]^A_PH_M2/\ O?H?
M\* +=5-4TN/58VMIUW1OC(R1G!!'((/4#O1_:D?][]#_ (4?VI'_ 'OT/^%
M%NN?U/P#8ZFYFEA4N>I4LF22220A4$DGDGD^M:O]J1_WOT/^%']J1_WOT/\
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M[=C&<=><XS[U8FA692C@%6!!!&00>""#U!JO_:D?][]#_A1_:D?][]#_ (4
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M'_>_0_X4 6Z*J?VI'_>_0_X4?VI'_>_0_P"% %NBJG]J1_WOT/\ A1_:D?\
M>_0_X4 6Z*J?VI'_ 'OT/^%']J1_WOT/^% %NBJG]J1_WOT/^%']J1_WOT/^
M% %NBJG]J1_WOT/^%']J1_WOT/\ A0!;HJI_:D?][]#_ (4?VI'_ 'OT/^%
M%NBJG]J1_P![]#_A1_:D?][]#_A0!;HJI_:D?][]#_A1_:D?][]#_A0!;HJI
M_:D?][]#_A1_:D?][]#_ (4 6Z*J?VI'_>_0_P"%']J1_P![]#_A0!;HJI_:
MD?\ >_0_X4?VI'_>_0_X4 6Z*J?VI'_>_0_X4?VI'_>_0_X4 6Z*J?VI'_>_
M0_X4?VI'_>_0_P"% %NBJG]J1_WOT/\ A1_:D?\ >_0_X4 6Z*J?VI'_ 'OT
M/^%']J1_WOT/^% %NBJG]J1_WOT/^%']J1_WOT/^% %NBJG]J1_WOT/^%']J
M1_WOT/\ A0!;HJI_:D?][]#_ (4?VI'_ 'OT/^% %NBJG]J1_P![]#_A1_:D
M?][]#_A0!;HJI_:D?][]#_A1_:D?][]#_A0!;HJI_:D?][]#_A1_:D?][]#_
M (4 6Z*J?VI'_>_0_P"%']J1_P![]#_A0!;HJI_:D?\ >_0_X4?VI'_>_0_X
M4 1:W]P?[P_D:M6GW%_W1_*L[5;U)E 4Y(.>A]#4UOJT2*JEN0H['T^E &C1
M5+^V(O[WZ'_"C^V(O[WZ'_"@"[15+^V(O[WZ'_"C^V(O[WZ'_"@"[15+^V(O
M[WZ'_"C^V(O[WZ'_  H NT52_MB+^]^A_P */[8B_O?H?\* +M%4O[8B_O?H
M?\*/[8B_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\* +M%4O[8B_O?H?\*/[8
MB_O?H?\ "@"[15+^V(O[WZ'_  H_MB+^]^A_PH NT52_MB+^]^A_PH_MB+^]
M^A_PH NT52_MB+^]^A_PH_MB+^]^A_PH NT52_MB+^]^A_PH_MB+^]^A_P *
M +M%4O[8B_O?H?\ "C^V(O[WZ'_"@"[15+^V(O[WZ'_"C^V(O[WZ'_"@"[15
M+^V(O[WZ'_"C^V(O[WZ'_"@"[15+^V(O[WZ'_"C^V(O[WZ'_  H NT52_MB+
M^]^A_P */[8B_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\* +M%4O[8B_O?H?
M\*/[8B_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\ "@"[15+^V(O[WZ'_  H_
MMB+^]^A_PH NT52_MB+^]^A_PH_MB+^]^A_PH NU!>_ZM_\ =;^50_VQ%_>_
M0_X5%=:K$Z,H;DJ0.#W'TH 3P_\ ZL_[Q_D*TZQ-'OTMT*N<'<3T)[#T%7O[
M8B_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\ "@"[15+^V(O[WZ'_  H_MB+^
M]^A_PH NT52_MB+^]^A_PH_MB+^]^A_PH NT52_MB+^]^A_PH_MB+^]^A_PH
M NT52_MB+^]^A_PH_MB+^]^A_P * +M%4O[8B_O?H?\ "C^V(O[WZ'_"@"[1
M5+^V(O[WZ'_"C^V(O[WZ'_"@"[15+^V(O[WZ'_"C^V(O[WZ'_"@"[15+^V(O
M[WZ'_"C^V(O[WZ'_  H NT52_MB+^]^A_P */[8B_O?H?\* +M%4O[8B_O?H
M?\*/[8B_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\* +M%4O[8B_O?H?\*/[8
MB_O?H?\ "@"[15+^V(O[WZ'_  H_MB+^]^A_PH NT52_MB+^]^A_PH_MB+^]
M^A_PH NT52_MB+^]^A_PH_MB+^]^A_PH NT52_MB+^]^A_PH_MB+^]^A_P *
M +M%4O[8B_O?H?\ "C^V(O[WZ'_"@"[15+^V(O[WZ'_"C^V(O[WZ'_"@"[15
M+^V(O[WZ'_"C^V(O[WZ'_"@"[15+^V(O[WZ'_"C^V(O[WZ'_  H NUBZ9_KY
M/^!?^A"KO]L1?WOT/^%9EC>)%,\C'Y6W8.#W;- '0452_MB+^]^A_P */[8B
M_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\
M* +M%4O[8B_O?H?\*/[8B_O?H?\ "@"[15+^V(O[WZ'_  H_MB+^]^A_PH N
MT52_MB+^]^A_PH_MB+^]^A_PH NT52_MB+^]^A_PH_MB+^]^A_PH NT52_MB
M+^]^A_PH_MB+^]^A_P * +M%4O[8B_O?H?\ "C^V(O[WZ'_"@"[15+^V(O[W
MZ'_"C^V(O[WZ'_"@"[15+^V(O[WZ'_"C^V(O[WZ'_"@"[15+^V(O[WZ'_"C^
MV(O[WZ'_  H NT52_MB+^]^A_P */[8B_O?H?\* +M%4O[8B_O?H?\*/[8B_
MO?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\
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M0CL?44 ;=%4O[8B_O?H?\*/[8B_O?H?\* +M%4O[8B_O?H?\*/[8B_O?H?\
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M_4_XT?V7'_=_4_XU;HH J?V7'_=_4_XT?V7'_=_4_P"-6Z* *G]EQ_W?U/\
MC1_9<?\ =_4_XU;HH J?V7'_ '?U/^-']EQ_W?U/^-6Z* *G]EQ_W?U/^-']
MEQ_W?U/^-6Z* *G]EQ_W?U/^-']EQ_W?U/\ C5NB@"I_9<?]W]3_ (T?V7'_
M '?U/^-6Z* *G]EQ_P!W]3_C1_9<?]W]3_C5NB@"I_9<?]W]3_C1_9<?]W]3
M_C5NB@"I_9<?]W]3_C1_9<?]W]3_ (U;HH J?V7'_=_4_P"-']EQ_P!W]3_C
M5NB@"I_9<?\ =_4_XT?V7'_=_4_XU;HH J?V7'_=_4_XT?V7'_=_4_XU;HH
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MC_N_J?\ &K=% %3^RX_[OZG_ !H_LN/^[^I_QJW10!4_LN/^[^I_QH_LN/\
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M5OY7]S+7]CQ?W?U/^-']CQ?W?U/^-5?^$KMO[_\ XZ_^%'_"5VW]_P#\=?\
MPH#ZM6_E?W,M?V/%_=_4_P"-']CQ?W?U/^-5?^$KMO[_ /XZ_P#A1_PE=M_?
M_P#'7_PH#ZM6_E?W,M?V/%_=_4_XT?V/%_=_4_XT6&L17Y*Q-D@9(P0?U J[
M09RC*+LU9E+^QXO[OZG_ !H_L>+^[^I_QJ[10(I?V/%_=_4_XT?V/%_=_4_X
MU=HH I?V/%_=_4_XT?V/%_=_4_XU=HH I?V/%_=_4_XT?V/%_=_4_P"-7:*
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MW?U/^-7:* *7]CQ?W?U/^-']CQ?W?U/^-7:* *7]CQ?W?U/^-']CQ?W?U/\
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M"1#AAT/!ZC'>HJ* +$E\\C^>3\^0<X'4=..G:B\OGO#OD.2!CH!Q^&/6J]%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?K?W!_O#^1K
MS6O2M;^X/]X?R->:T'JY1]OY?J%%%%!ZH4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!);W#6S"1#AE/!%>@Z#KRZHN.DBCYE_J/;^70]B?
M.JDM[AK9A(APRG@B@YL7A(UX^?1GJU%96@Z\NJ+CI(H^9?ZCV_ET/8G5H/ J
M4Y4Y.+W"BBB@D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"]_
MU;_[K?RJ>H+W_5O_ +K?RH I^'_]6?\ >/\ (5IUF>'_ /5G_>/\A6G0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BZ9_KY/^!?
M^A"MJL73/]?)_P "_P#0A0!M4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 8NI_P"OC_X#_P"A&MJL74_]?'_P'_T(UM4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM"ISQCKTP3^%;=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W?W&_W
M3_*IJAN_N-_NG^5 %71/N'_>/\A6A6?HGW#_ +Q_D*T* *,NN6\4GV=I8Q+D
M#874/EL8&W.<G(QZTVZ\0VUHQBEFB1QC*O(BL,C(R"<]*\7^(,4DNK.D.?-9
MX0F#M.XHFW!R,'/?/%:OC3X71:%:&[B=F>,IOWD!2&.TE5"Y!W$<%C@9Y)H
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M]>\W_H#4 <!\#/\ EZ_[8_\ M2O5:\J^!G_+U_VQ_P#:E>JT %%%% !1110
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MB@ J"]_U;_[K?RJ>H+W_ %;_ .ZW\J *?A__ %9_WC_(5IUF>'_]6?\ >/\
M(5IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8N
MF?Z^3_@7_H0K:K%TS_7R?\"_]"% &U1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!BZG_KX_\ @/\ Z$:VJQ=3_P!?'_P'_P!"
M-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !69X
M@_U8_P!X?R-:=9GB#_5C_>'\C0!IT444 %%%% !1110 4444 %%%% !1110
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M;&2-HW,.HX8#![=#@D"JEWI;:CI$2QY$J6T,D949</&BL-N.0QQM!'(SWZ4
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M%% !1110 4444 %%%% !1110 4444 %;O@[_ %S?]<S_ .A+6%6[X._US?\
M7,_^A+0!V-%%% #)IEA4NY 50223@ #DDD] *Y+PIXKDU6YD20,L<T*S0(0
M5C#F,EC@'+G# ?,,'AO67Q%<MK$ZZ/%NV?*]RZD8$9SB$X((,F.<$';SAE+8
M;XSA72C:ZB@"I9RA6&/D6*4"-CM'.5^4*%Z>A'0 ZVBBN:O;M[C4X;5694AM
MY)6 )VOO;RPI7@?*?F!.?3 ZT =+117*>"G?6+.2XDD<?:Y)F7#'=$K,4"JQ
M_NXR#@ $]* )M1NWGU*WM8V95BAEEE&2%96Q&@P.I#<\C '(.>*Z6O,M+\'M
M>:A<QFZN +9(E#"7]Z1(N_!?'W00>,=P>W/6ZUK)T-(;.+=+<38CB\S+9*@!
MI)& SA0=S8Y/L,D '045R4/@RXNU#W=Y.9<#/V=A"@]L!?F.<_,0"1C@8IUK
M=3Z!/%9W,GFV\^Y8Y'7$BN,;(W?(5MR@X.-[OGC% &AXOTNXU. PVDOE2;E.
M[)&0.J[ER5]<CKC'0FM6TC:)%21M[A0&; 7<0.6P.!D\X[5@>*+MVN;*RC9D
M\V9G9E)&5@7<8R!C(?.#S@8Z&J/Q!U2X@DM+6TR)9I]V<L%Q'C*L%Y*'=EO0
M*>/0 [.BN4_X0N=_WKWMP9^N5*I%D?=_<@8QTW#/S<YZUGZ/J%[XC#69D\G[
M,S1SS1KS(P9E*QDC"_*-S-]X,5PH'4 [NBN"UW3Y_""#4X;B69(R!+%<R%PR
MNP7Y3CY6!/7'Z JV_P".=4;2[*>=,[@FT$':07(0,".Z[L_AU'6@#>HKBM)\
M+W>IPQR7EU,C>6F$@/E%?E .]B"SL< G.-K;@.#4*ZA>Z?.=%63S'D56BF=<
MF.+Y@Q? PS J N>&8Y9N=M '=T5Q]UX(GVF6*]N/M'# N_[DL#DYC P%)_AY
M '9@,'8\(ZXVN6L=XZA6<'('3*L5)&>QQG'..F3UH V**YKX?W;ZA;&]D9C]
MHFE=58EMB[BHC!/4#;D< <]*/'UV\<$=O$S(]S<0Q"1"0R;FR6&,$\+C&1UZ
MT =+17)?$[5);&TVP;O-FE2-3&2'!)+<;>23MVX'K^!9!X6N]6_TB]N98G95
M_=6C^6B8SD$Y;<3W/8Y )7& #L**Y3PY?SV5W+I-P[2!8UDAD8+N,?"$,0>2
M#QDC+$,QX(%&N:Y/>S_V78?+(FTS3,N5C4\@ 'AF8=!TQ^)0 ZNBN/'@*6-0
M4OKGS5VG<\F^/(()S&>H/H6/OGO=\&Z[+?K):W0 N;5]DF 0&!^[(,@<-@]/
M3. "!0!T=<U\0+MXK800LR2W,T44;*2NUF8')8<@84@XR>>E=+7"?$JXF:6Q
MM;<*7>X\P;@Q&Z+;@G;SM 8EN,X&<C% '=T5R4W@>:Y4M)>W'G$'YHV$<>>B
MGREZ <9 89.3D9J7P5K<UVUQ971+36LNW>4";D;.QMH/4X)X &W;R>30!U%%
M<9J.IW/B.9[&Q8PPPEEFG*Y)?!!C0''([L"".H(^7>^Y\$3VX\RTO;@2KG'G
MOYL9X(P5(QUQSAL=0"<8 .PHK$\(>(#KL F==DJ,R2)@C:Z]1\PSTP<<XS@D
MD&N5TZ_U#6;V[2W?RH%DV>8X,H0Q?+B-20N7ZL,< \G.W(!Z+17*?\((T?S1
MWEV''*EY@ZY'3*E0&&>H[CBK>@:X[2OIESS<0J&#A2J2QG $@'0')PPZ;L[2
M1D  Z"BN2N-;N=<GDL[ B** E9;ATW?.#]Q%) )'1B>,'(Q\I8E\!R(-T-[=
M"0$$&27S$X(/*87</8G'KD<$ ZVL3QKJ?]F64\^6!$9"E.&#/\BD'(Q@L#GJ
M.W-<KX<U>^O]1%C=LJFSC=F$6=LNX*H+?-@_>#CY1CIM!/#OB7X?:X,9$\H%
MW<PQ%"^80&'41\<@J#UZY_  [C2;=[:&.*4[I$C0,V2<L% 8Y/)R>YYK*\):
M/=Z;YWVN?SM\F4XZ#N>>F>/D'RKC@\FB#3O^$8AGN?-FGVQE\3R[O]6K' .W
MC/?@]O2HO#^F/?:=%#+-+OEC5S*CE91O/F !CN/ .WW'IV "RNWN]3F56;RK
M:WC1D).TR2-Y@8+T^[P2<'MR.:M>+]+N-3@,-I+Y4FY3NR1D#JNY<E?7(ZXQ
MT)KC?"?@]M0DNY6NKA2ER\64EVNPBX!=L'<<$ <#&#ZX'4>*+MVN;*RC9D\V
M9G9E)&5@7<8R!C(?.#S@8Z&@#?M(VB14D;>X4!FP%W$#EL#@9/..U35Q5LK>
M+99PT\L*VLS1+';R!&PO61S@D[B/E& %VD#)R:VO#6EW&F>9#/+YT08&)G),
MN#DLKD\'!Q@_7H,* #;HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "H;O[C?[I_E4U0W?W&_W3_*@"KHGW#_ +Q_D*T*S]$^
MX?\ >/\ (5H4 >*>)?\ D/+_ -?%K_*.O0/BE_R#I_\ MG_Z-2M"Y\&6EU.+
M]X\SAE;=O<<IC:<!L<8';ZUH:II<>JQM;3KNC?&1DC."".00>H'>@#BO@I_Q
MYR?]?#?^@1URGB7_ )#R_P#7Q:_RCKUO1- @T1##;+L0L6(W,W) &<L2>@%5
M+GP9:74XOWCS.&5MV]QRF-IP&QQ@=OK0!S7QK_X\X_\ KX7_ - DK'M_"HUW
M1870$S0"9H\9Y_>MN7 !R6 XXSN Y SGTC6] @UM!#<KO0,& W,O(!&<J0>A
M-2Z7I<>E1K;0+MC3.!DG&22>22>I/>@#A?A!XL-_&=.D^_ N4.224S@@YR!L
M) '/0@ ?*37,^)?^0\O_ %\6O\HZ]-L/ UGI\PO(8@LH+$$,^!N!!PN[:!@G
MC&!VI]SX,M+J<7[QYG#*V[>XY3&TX#8XP.WUH I?$/PJ?$5L4C ,T9W1YP,_
MWER1T8>X&X+DX%>)>$_^/RV_Z^(?_0UKZ5K!E\#6<D_VXQ#SMX?<&<?,""&V
MA@N<C)XY/)SDT <[\9=;^R6JV8'-RW)(X"QE6/?KG;V(QGH<5R_ASP!J;P)-
M;SB&.4!PHFD7[PX8A 1DC'?., X/ ]-UOP9::VXFN8][A0H.]UX!)QA6 ZDU
MMT >&>,/!&H64/VN[F$R1D#_ %KN5WD#.' X)P#CGIQ@9'H'@.]7Q)IOV=\C
M:C0,5XX"  C.[G8PY/\ %GC%=;=VJW:-#(,I(I5ADC(88(R.>E9^A>%K;0=W
MV9-GF;=WS,V=N<?>)]3TH Y7_A2EG_?F_P"^D_\ C=6_B[ICWUB6C&?)D61A
MR3M 921@'INR>@ !.>*[6B@#R?P9\0+73M/-I<8,D8E C(9A(&RP!(0J Q8K
MSGID\&J_P2TQVFEO,?NUC\O)SRS,K8'&#@+SSD9''-=W=?#?3[IC(T"@G'W&
M=%X&.%1@!^ ]^M;]K:):*(HE5$&<*@"J,G)P!QUH YKXD^)O[#M&V'$LV43!
MP1G[S<$$;1T(SABN>M<_\&/#GD1OJ3_>ERB?[JGYCP>[#'(R-O'!KT6ZM$NU
M,4JJZ'&5<!E.#D9!XZT6EJMHBPQC"1J%49)P%& ,GGI0!YU\;=,>:*&Z492)
MG#8SD>9MP>F ,KC)/4@=ZF\+_%*SMK2..8LDD,838%9BVQ0 00,?-CN1@\'C
MD^A30K,I1P"K @@C((/!!!Z@US4WPRTZ5BY@&6))P\BCGT 8 #V P.U 'GGP
MYC?6M4;4%7:BM+(V<D#S=P"YQC.6[XR 3VQ7JOBS_CSN?^O>;_T!JMZ9I46E
MH(8$5$'91C)P!DGJ3@#).2>YJ6[M5NT:&09212K#)&0PP1D<]* /,/@9_P O
M7_;'_P!J5ZK63H7A:VT'=]F39YFW=\S-G;G'WB?4]*UJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UO[@
M_P!X?R->:UZ5K?W!_O#^1KS6@]7*/M_+]0HHHH/5"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBI+>W:Y81H,LQX H!M)7"WMVN6$:#+
M,> *]!T'05TM<]9&'S-_0>W\^I[ &@Z"NEKGK(P^9OZ#V_GU/8#5H/$QN-=5
M\D?A_,****#@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@O?]
M6_\ NM_*IZ@O?]6_^ZW\J *?A_\ U9_WC_(5IUF>'_\ 5G_>/\A6G0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BZ9_KY/^!?\
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M_P#</_\ :]=710!R_BC1IUGBU6S ::(%'C+%?,C8_=R2%!4DD9'7GG:%+/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+N^5@RLC%65@"%<$=QGC.1GM0!H5Q_C"8W]W9Z=&,NLRW#GG"I%D#.%(^8Y
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M_P!)U.\D?EH([>-#TPKJ9&''7+<Y.3V!QQ75UDZ'H7]F-/*S;WN)F<L5PP7
M"QYR20@Z= ,\ 4 3>(;IK2VGFC.'CAD93@'!5"0<'CK6/HL+6&E)]F!$@M-Z
M #<=[(7X!SDESG'3MC'%:OB32&UBWDM%<QF0 ;@,X&02,9&00"#ST-:$,*PJ
M$0 *H   P !P  .@% &%X MT@L+=8SN4Q@DY!^9B6<<>C$C'48P>:J>)?],O
MK*T^\BM),ZCJ#&O[ISCD#<2!V)X.:)/!T]J[&QNFMXGY\KRUE13DD[ QP@).
M2 .OM@#0T#PLFE,]PS-+<38\R5\;CP/E4#A5R.%'3@9(48 ,WQ<ANKS3[4DB
M,RRR$#'+0(&3D@\<D$=P?7!'6UDR:%YMVNH,V1'"45"N0K,V3(#G@D?*<#)'
M?'%:U '*:-_I.IWDC\M!';QH>F%=3(PXZY;G)R>P..*PM!\)+>7-Z&FGAF%R
MQ98)-@*29>)B0IR3EN^1W []EH>A?V8T\K-O>XF9RQ7#!< +'G))"#IT SP!
M57Q!X2_M.1;R&5X+A%"ATY4J&#;60X##.>,@'/S9  H J?\ " ?]/EY_X$?_
M &-7?#'AJ+2B]Q'+),;@(2\KB3(4':0P R,'WXQBLV;P-/J9"WUV\T0_Y9HB
MPJQRI^;83N''U'4$=^HT_3X].C6WA4+&@P /\\D]23R3R>: +%<I<?Z3J\<;
M\K!9O(@Z89Y/+8\=<KQ@Y'<#/-=7639:%]GNIK]FW&98U4%>45!RH;)X8_,0
M !GU/- &M7*>"/W\E[<MS(UX\9/^S" (Q@<< GG&3W)KJZR?#.A?V) +<MYC
M[G9Y"N&=F8G<>22<8&22>* .(\!^"UN+<C[1<12I+(DJ0R[$#J<=E()V[<D$
MCW[#H)O RPJ7>]NPJ@DDW.  .222O %6-6\'-/.;ZTG>WF?;OP \;!5*C,;$
M D C'.!C(&3FJC> &U)@VHW#W"KC;&%$,>0&&2J'D_-P1@]B2.* -KP[X=30
M4:*-G?S)&D9I6#,68 $Y 'I]<YYK ^%&II?VKMG]^9G:;.,EG.0^ > 1@= ,
MJ<#C-;OB:9=.LIBA$82!PA4[-IVD(!C&#G 7'? %<_8^ ED@M[B!FM;I8(@S
M1KC)PK,)(^-QR#G.,G[VX "@#N*XS0;L:WJ4U]#@P00" ."2'8OYA*G&,+R#
MR?X2,AN+'_"(7-Y^[O+QY8NZ1QK!N[%69"25()!7C.<YXKH]/T^/3HUMX5"Q
MH, #_/)/4D\D\GF@#FOA?"MO9B# $L4LJ2@#^,.>I'#';MY!(Q@9XKK:P=8\
M+FZD^UVTK6\Y !9 &1\<#?&>'(!(4\$9[X %";P;<Z@IAN[V1XB#E8HTA)SQ
MRPW97!.5(P>#VH 9X:U./6M0NKE"K"".&)'7."I+L_?!^<<$#& ,<$DR^*?W
M][86S<QM)-(1_M0QYC.1SP2>,X/<&KOA3PE'X<65(\$2RLP^7!"\;4R22P7G
M!)[GCK5B30O-NUU!FR(X2BH5R%9FR9 <\$CY3@9([XXH H?$BZ:UT^=T."55
M>@/#NJ,.?4$C^7-;NG62V$26Z9*Q(J@GKA0 ,XQSQ5'Q%H7]LK'$6VHDR.ZE
M=RNJ'/ED9 P3CKD<=#5[4;9KJ)XD8HSHRAQU4L" PP1R.O4?6@#G/AE^]LEN
M6_UEQ)+)(?[S&1@3CH.%'  'M3;Q#=ZO$C$[;>T>1 ,?>=S&V>,D%<<9Z@>^
M=_1-+72H([5<8B15R!MR0.6QZL<D^YZFJ2^&%DGN+B4[UN8UC"D$%$"D,H;.
M<.3D@8YYY/- #-8\(QWLGVN)FAN< >;$<9QT#K]UUSC(/)  S@4_PGK;ZK&_
MG!1+!-)%)L!"%D/5<DG&".N#G/%8Z>![JT4V]M?2)"1@*\:R.HVA<"3*D#CC
M;MV]N>3T>A:%%H<0MH!A5ZD_>8]V)[D__6&    :%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5#=_<;_=/\JFJ&[^XW^Z?
MY4 5=$^X?]X_R%:%9^B?</\ O'^0K0H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UO[@_P!X
M?R->:UZ5K?W!_O#^1K*@\%0R*&+/R >J]Q_NT'?E^)A0YN;K;]3BJ*[C_A!X
M/[S_ )K_ /$T?\(/!_>?\U_^)H.[^TZ'G]QP]%=Q_P (/!_>?\U_^)H_X0>#
M^\_YK_\ $T!_:=#S^XX>BNX_X0>#^\_YK_\ $T?\(/!_>?\ -?\ XF@/[3H>
M?W'#T5W'_"#P?WG_ #7_ .)H_P"$'@_O/^:__$T!_:=#S^XX>BNX_P"$'@_O
M/^:__$T?\(/!_>?\U_\ B: _M.AY_<</17<?\(/!_>?\U_\ B:/^$'@_O/\
MFO\ \30']IT//[CAZ*[C_A!X/[S_ )K_ /$T?\(/!_>?\U_^)H#^TZ'G]QP]
M%=Q_P@\']Y_S7_XFC_A!X/[S_FO_ ,30']IT//[CAZ*[C_A!X/[S_FO_ ,31
M_P (/!_>?\U_^)H#^TZ'G]QP]%=Q_P (/!_>?\U_^)H_X0>#^\_YK_\ $T!_
M:=#S^XXNWMVN6$:#+,> *]!T'05TM<]9&'S-_0>W\^I[ 2:3H4>F9*9);NV"
M<>G ''^?2M&@X<;CG6]V/P_F%%%%!P!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !4%[_JW_W6_E4]07O^K?\ W6_E0!3\/_ZL_P"\?Y"M
M.LSP_P#ZL_[Q_D*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L73/]?)_P+_T(5M5BZ9_KY/\ @7_H0H VJ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,74_P#7Q_\  ?\ T(UM
M5BZG_KX_^ _^A&MJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K,\0?ZL?[P_D:TZS/$'^K'^\/Y&@#3HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;\Q_A1_8B>K?F/\ "@"U]K3^\OYBC[6G]Y?S%5?[$3U;\Q_A1_8B>K?F/\*
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M?^^A5/\ X1^/U;\Q_A1_PC\?JWYC_"@"Y]MC_O+_ -]"C[;'_>7_ +Z%4_\
MA'X_5OS'^%'_  C\?JWYC_"@"Y]MC_O+_P!]"C[;'_>7_OH53_X1^/U;\Q_A
M1_PC\?JWYC_"@"Y]MC_O+_WT*/ML?]Y?^^A5/_A'X_5OS'^%'_"/Q^K?F/\
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ML?\ >7_OH4?;8_[R_P#?0JG_ ,(_'ZM^8_PH_P"$?C]6_,?X4 7/ML?]Y?\
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M]MC_ +R_]]"C[;'_ 'E_[Z%4_P#A'X_5OS'^%'_"/Q^K?F/\* +GVV/^\O\
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M8_[R_P#?0JG_ ,(_'ZM^8_PH_P"$?C]6_,?X4 7/ML?]Y?\ OH4?;8_[R_\
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MA0!<^VQ_WE_[Z%'VV/\ O+_WT*I_\(_'ZM^8_P */^$?C]6_,?X4 7/ML?\
M>7_OH4?;8_[R_P#?0JG_ ,(_'ZM^8_PH_P"$?C]6_,?X4 7/ML?]Y?\ OH4?
M;8_[R_\ ?0JG_P (_'ZM^8_PH_X1^/U;\Q_A0!<^VQ_WE_[Z%'VV/^\O_?0J
MG_PC\?JWYC_"C_A'X_5OS'^% %S[;'_>7_OH4?;8_P"\O_?0JG_PC\?JWYC_
M  H_X1^/U;\Q_A0!<^VQ_P!Y?^^A1]MC_O+_ -]"J?\ PC\?JWYC_"C_ (1^
M/U;\Q_A0!<^VQ_WE_P"^A1]MC_O+_P!]"J?_  C\?JWYC_"C_A'X_5OS'^%
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M8_[R_P#?0H^VQ_WE_P"^A5/_ (1^/U;\Q_A1_P (_'ZM^8_PH N?;8_[R_\
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M8_[R_P#?0H^VQ_WE_P"^A5/_ (1^/U;\Q_A1_P (_'ZM^8_PH N?;8_[R_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6[X._US?]<S_P"A+6%6[X._US?]<S_Z$M '8T444 %%9/\ PEEG_P _$/\
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M] !R3P.:-/U"/48UN(6#1N,@C_/!'0@\@\'F@"Q1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4%[_JW_ -UOY5/4%[_JW_W6_E0!3\/_ .K/^\?Y"M.LSP__ *L_[Q_D*TZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L73/]?)
M_P "_P#0A6U6+IG^OD_X%_Z$* -JBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#%U/_7Q_\!_]"-;58NI_Z^/_ (#_ .A&MJ@
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MX."<5+_:D?G?8MW[WR_,VX/W=VW.<8Z\8SGVH MT444 %%%% !1110 4444
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MK@]0<YSG/.<YR<YS7/\ A#_0[F\T]/\ 50R1N@_N^>I=E & %!'R@ 8R<YH
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M[G'VJY(:7:?E&W(1 !QA5X[DG/S,,&N%\-^*["XE?4]0<&X=SY:,CR")%.4
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MZ5%JB&&=%=#V89P<$9!Z@X)P1@CL:I6=A#X5MG\L-Y40DDP6+$#EBJ[CP!T
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M?Y"M"L_1/N'_ 'C_ "%:% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 9^M_<'^\/Y&O(!K]RO
MFD_[^-_C7K^M_<'^\/Y&O$*ZL(D^8Y<6VN4T/^$AN?\ GM+_ -_&_P :/^$A
MN?\ GM+_ -_&_P :SZ*Z^5=CEYGW-#_A(;G_ )[2_P#?QO\ &C_A(;G_ )[2
M_P#?QO\ &L^BCE78.9]S0_X2&Y_Y[2_]_&_QH_X2&Y_Y[2_]_&_QK/HHY5V#
MF?<T/^$AN?\ GM+_ -_&_P :/^$AN?\ GM+_ -_&_P :SZ*.5=@YGW-#_A(;
MG_GM+_W\;_&C_A(;G_GM+_W\;_&L^BCE78.9]S0_X2&Y_P">TO\ W\;_ !H_
MX2&Y_P">TO\ W\;_ !K/HHY5V#F?<T/^$AN?^>TO_?QO\:/^$AN?^>TO_?QO
M\:SZ*.5=@YGW-#_A(;G_ )[2_P#?QO\ &C_A(;G_ )[2_P#?QO\ &L^BCE78
M.9]S0_X2&Y_Y[2_]_&_QH_X2&Y_Y[2_]_&_QK/HHY5V#F?<T/^$AN?\ GM+_
M -_&_P :/^$AN?\ GM+_ -_&_P :SZ*.5=@YGW-#_A(;G_GM+_W\;_&C_A(;
MG_GM+_W\;_&L^BCE78.9]S0_X2&Y_P">TO\ W\;_ !H_X2&Y_P">TO\ W\;_
M !K/HHY5V#F?<T/^$AN?^>TO_?QO\:/^$AN?^>TO_?QO\:SZ*.5=@YGW-#_A
M(;G_ )[2_P#?QO\ &C_A(;G_ )[2_P#?QO\ &L^BCE78.9]S0_X2&Y_Y[2_]
M_&_QH_X2&Y_Y[2_]_&_QK/HHY5V#F?<T/^$AN?\ GM+_ -_&_P :/^$AN?\
MGM+_ -_&_P :SZ*.5=@YGW-#_A(;G_GM+_W\;_&C_A(;G_GM+_W\;_&L^BCE
M78.9]S0_X2&Y_P">TO\ W\;_ !H_X2&Y_P">TO\ W\;_ !K/HHY5V#F?<T/^
M$AN?^>TO_?QO\:/^$AN?^>TO_?QO\:SZ*.5=@YGW-#_A(;G_ )[2_P#?QO\
M&C_A(;G_ )[2_P#?QO\ &L^BCE78.9]S0_X2&Y_Y[2_]_&_QH_X2&Y_Y[2_]
M_&_QK/HHY5V#F?<T/^$AN?\ GM+_ -_&_P :1M?N6X,TF#_TT;_&J%%'*NP<
MS[EZ/7+B/A99 /:1A_6G?\)#<_\ /:7_ +^-_C6?11RKL',^YH?\)#<_\]I?
M^_C?XT?\)#<_\]I?^_C?XUGT4<J[!S/N:'_"0W/_ #VE_P"_C?XT?\)#<_\
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MC_A(;G_GM+_W\;_&L^BCE78.9]S0_P"$AN?^>TO_ '\;_&C_ (2&Y_Y[2_\
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MFI17.V6HM9'RV'RYY!ZCZ5O6URMPN]>G^>*Q-B2BBB@ HHHH **** "BBB@
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MK1/%YUZ<K:INM8U.^9LKES@A5!&3@?>SCKGC WP_\QG_ +A__M>NHAA6%0B
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M:S8M>MM<N_M,T\:06;E8XWDC&^0 YFP?X1G$9!/(W KR#VJZ=$BN@10LI8N
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MVKY>W;MP-NW&-NWIC'&.F* ,_P )_P#'G;?]>\/_ * M97C[_ES_ .PA;_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P !_P#0C6U6+J?^OC_X#_Z$:VJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "LSQ!_JQ_O#^1K3K,\0?ZL?[P_D: -.BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5B+L;>5N4*,WW"0HPRDY8G@9.2%V[MW4_'MCIZ&4S(_HL3"1B<$XPI.,XZG
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6[X._US?]<S_P"A+6%6[X._US?]<S_Z$M '8T444 9^H:VEC)#;$,TEPS!0
MH'11EF))  4=><GL#1K>OP:(@FN6V(6"@[6;D@G&%!/0&L33O],U6XEZ?9K>
M*+'7=YI,N[MC&,8YSUR.E'C[_ES_ .PA;_\ LU !_P +2T[_ )[?^0Y?_B*Z
M6UNTNU$L3*Z'.&0AE.#@X(XZT^:%9E*. 58$$$9!!X((/4&N5\&PK:W-]!"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5#=_<;_=/\JFJ&[^XW^Z?Y4 5=$^X?]X_R%:%9^B?</\
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MQC[3N#-D@A4VY Q_>S@]L9&#GCT"LG7?"UMKVW[2F_R]VWYF7&[&?ND>@ZT
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M,JSPW$"NVT23Q;(P2"0"VXXSC\.IP 2.KH **Q-9\7P:6WD$M).>D4*^9*>
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M*** *FI:I'IJB29MJDXS@GG!/8'THTW5(]24R0MN4'&<$<X![@>M<C\3)_\
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MNKMT/WD><E6'=3A0<$<'D<5NZ/HL.CQ^1;H$3).!DY)ZDDDDGZGH .@%7J*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS]%=!_P@5[_SR_\ 'X__ (JC_A KW_GE_P"/Q_\ Q5'M8=T'LY]F<_170?\
M"!7O_/+_ ,?C_P#BJ/\ A KW_GE_X_'_ /%4>UAW0>SGV9S]%=!_P@5[_P \
MO_'X_P#XJC_A KW_ )Y?^/Q__%4>UAW0>SGV9S]%=!_P@5[_ ,\O_'X__BJ/
M^$"O?^>7_C\?_P 51[6'=![.?9G/T5T'_"!7O_/+_P ?C_\ BJ/^$"O?^>7_
M (_'_P#%4>UAW0>SGV9S]%=!_P (%>_\\O\ Q^/_ .*H_P"$"O?^>7_C\?\
M\51[6'=![.?9G/T5T'_"!7O_ #R_\?C_ /BJ/^$"O?\ GE_X_'_\51[6'=![
M.?9G/T5T'_"!7O\ SR_\?C_^*H_X0*]_YY?^/Q__ !5'M8=T'LY]F<_170?\
M(%>_\\O_ !^/_P"*H_X0*]_YY?\ C\?_ ,51[6'=![.?9G/T5T'_  @5[_SR
M_P#'X_\ XJC_ (0*]_YY?^/Q_P#Q5'M8=T'LY]F<_170?\(%>_\ /+_Q^/\
M^*H_X0*]_P">7_C\?_Q5'M8=T'LY]F<_170?\(%>_P#/+_Q^/_XJC_A KW_G
ME_X_'_\ %4>UAW0>SGV9S]%=!_P@5[_SR_\ 'X__ (JC_A KW_GE_P"/Q_\
MQ5'M8=T'LY]F<_170?\ "!7O_/+_ ,?C_P#BJ/\ A KW_GE_X_'_ /%4>UAW
M0>SGV9S]%=!_P@5[_P \O_'X_P#XJC_A KW_ )Y?^/Q__%4>UAW0>SGV9S]%
M=!_P@5[_ ,\O_'X__BJ/^$"O?^>7_C\?_P 51[6'=![.?9G/T5T'_"!7O_/+
M_P ?C_\ BJ/^$"O?^>7_ (_'_P#%4>UAW0>SGV9S]%=!_P (%>_\\O\ Q^/_
M .*H_P"$"O?^>7_C\?\ \51[6'=![.?9G/T5T'_"!7O_ #R_\?C_ /BJ/^$"
MO?\ GE_X_'_\51[6'=![.?9G/T5T'_"!7O\ SR_\?C_^*IK^!;Q 6,7 &3\Z
M=O\ @5'M8=T'LY]F8-%;=OX,N[@;DCR,X^^@_FU2_P#"!7O_ #R_\?C_ /BJ
M/:P[H/9S[,Y^BN@_X0*]_P">7_C\?_Q5'_"!7O\ SR_\?C_^*H]K#N@]G/LS
MGZ*Z#_A KW_GE_X_'_\ %4?\(%>_\\O_ !^/_P"*H]K#N@]G/LSGZ*Z#_A K
MW_GE_P"/Q_\ Q5'_  @5[_SR_P#'X_\ XJCVL.Z#V<^S.?HKH/\ A KW_GE_
MX_'_ /%4?\(%>_\ /+_Q^/\ ^*H]K#N@]G/LSGZ*Z#_A KW_ )Y?^/Q__%4?
M\(%>_P#/+_Q^/_XJCVL.Z#V<^S.?HKH/^$"O?^>7_C\?_P 51_P@5[_SR_\
M'X__ (JCVL.Z#V<^S.?HKH/^$"O?^>7_ (_'_P#%4?\ "!7O_/+_ ,?C_P#B
MJ/:P[H/9S[,Y^BN@_P"$"O?^>7_C\?\ \51_P@5[_P \O_'X_P#XJCVL.Z#V
M<^S.?HKH/^$"O?\ GE_X_'_\51_P@5[_ ,\O_'X__BJ/:P[H/9S[,Y^BN@_X
M0*]_YY?^/Q__ !5'_"!7O_/+_P ?C_\ BJ/:P[H/9S[,Y^BN@_X0*]_YY?\
MC\?_ ,51_P (%>_\\O\ Q^/_ .*H]K#N@]G/LSGZ*Z#_ (0*]_YY?^/Q_P#Q
M5'_"!7O_ #R_\?C_ /BJ/:P[H/9S[,Y^BN@_X0*]_P">7_C\?_Q5'_"!7O\
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MUM5BZG_KX_\ @/\ Z$:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "LSQ!_JQ_O#^1K3K,\0?ZL?[P_D: -.BBB@ HHHH ****
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MHABX9]O/'5AN)Z<],?3Z4 9TOA&9!D;2?0$Y_4 ?K6,Z%"5/!'4'K5VWUR:
M[@Y/!'S$L.>^#W'^>*?I0_M"X7S3G<23GO@$X^G&,>G% $MIX7FN%W\+[/D'
M\L&J5_IKV!VR#&<X(Y!Q_GZUV6HZ9)=ME92BCH%!_4AAG_/OF._L";9HY6WE
M%)#8P?E&1W//8GN/SH Y.PTI[X.R8_=C)'.3G/ P#SQ4FH:*]@H=ROS=@?FZ
M9/;MWP:U_!7_ "T_X!_[-6!>7SW9W.2>20,D@9[#/04 5Z*** "BBB@ HHHH
M **** "BBB@ HHHH *W?!W^N;_KF?_0EK"K=\'?ZYO\ KF?_ $): .QHHHH
MYJWM'L-2DD"L8KR%"7P6 DA^4+D<*"AS\W4\ ]JZ6BB@ HHHH **** "BBB@
M HHHH 9-*(E+G.%!)P"QX]  23[ 9/:L+P5:RQQ/<7 99+F9Y2CG+(&PJH3W
MPJCL,?=P,5T%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W?W&_W3_*
MIJAN_N-_NG^5 %71/N'_ 'C_ "%:%9^B?</^\?Y"M"@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,_6_N#_>'\C5JT^XO^Z/Y55UO[@_WA_(U:M/N+_NC^5 $U%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %07O^K?\ W6_E4]07O^K?
M_=;^5 %/P_\ ZL_[Q_D*TZS/#_\ JS_O'^0K3H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *Q=,_U\G_  +_ -"%;58NF?Z^3_@7
M_H0H VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** ,74_]?'_P'_T(UM5BZG_KX_\ @/\ Z$:VJ "BBB@ HHHH **** "BBB@
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M_&C^QXO[OZG_ !H /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\:/['B_N_J?\
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M_"C^QXO[OZG_ !H_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\
M&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_P :/['B_N_J?\:
M#^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_ !H_L>+^[^I_QH /[8B_O?H?\*/[
M8B_O?H?\*/['B_N_J?\ &C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A_PH_L>+
M^[^I_P :/['B_N_J?\: #^V(O[WZ'_"C^V(O[WZ'_"C^QXO[OZG_ !H_L>+^
M[^I_QH /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\ &C^QXO[OZG_&@ _MB+^]
M^A_PH_MB+^]^A_PH_L>+^[^I_P :/['B_N_J?\: #^V(O[WZ'_"C^V(O[WZ'
M_"C^QXO[OZG_ !H_L>+^[^I_QH /[8B_O?H?\*/[8B_O?H?\*/['B_N_J?\
M&C^QXO[OZG_&@ _MB+^]^A_PH_MB+^]^A_PH_L>+^[^I_P :/['B_N_J?\:
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M?&&QQSN&1GD$#TH SZ*M6&FO?G;&,XQDG@#/^?K6C+X1F09&TGT!.?U 'ZT
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M6A6?HGW#_O'^0K0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UO[@_WA_(UXA7M^M_<'^\/Y
M&O$*Z\']KY')B_L_,****ZSE"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M& >,>I'Z?EUK5\RFF2CD0<[#4[9KQ B.8R#G*YST/'!'K6(GA9HF+K,0QZD
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M1VZ#K@^_K6!J=Y]LD:7H&/'T' ]><#FM+0M:6!3;3?ZML\\\9'(X['V[_7@
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MQL> '7)/3J* -GQ';"6YC3H'" XZ\L1GZXK<U#3GN $CD\M5[*.?S!''M_\
M6QSGBBZ$DRO&P.$'*G."&)ZCO5YKJVUH+YIV2*.3POUP3D8R>!U_6@#5M],8
M1M!*_F!NY'S#/N2<XZCT_+')Z!J*V$F]_NL,$CMD@Y_3_/2K>JVUI;)MC):3
ML5;/KU/W<#T'/3ZU6T'R-Q$_<87/W>>#G'0^AZ#D]<4 ;=[;S /-;R;T?/&<
MD<_PG\_3CU.*Y"NOAN(-%1C&^_.,+N!Y_#I[GV_"N0H **** "BBB@ HHHH
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MCH0>0>#S4LTRPJ7<@*H)))P !R22>@%<KH$RZ)>2Z02!'*//@&>@8D21@<
M,"RJHX7<2<T[QK=_;&AT9&VO=M\Y!PPB0%GQC)!8#:N05/S T ='I]^FH1K/
M&24<94E67(['# '![<<CD<5CZGX^L=,<PRS*''4*&?!!(()0, 01R#R/2L_Q
MJK3&UT:$^6ETS!RA"XBB4%D "G&0>.W&T_*372Z9I46EH(8$5$'91C)P!DGJ
M3@#).2>YH SX_&EG+ UZLJF*/&X@,67<VT93&X9/3(YZ].:VZ\W^*_A6-(&U
M" "-P0)=ORAU=QU &&;?M.3CN3DA<=!XVF:[,.DH2IO78,P.,1QC?( 1_$PP
M!D$$$@XH L:GX^L=,<PRS*''4*&?!!(()0, 01R#R/2KNC^);;6!FWE5S@G:
M#AP <$E#A@,^H]/458TS2HM+00P(J(.RC&3@#)/4G &2<D]S6?-X.M9)TOPF
MR9&W;HR4W$[L[@N <ELD]3T)*Y! -NN?U/Q]8Z8YAEF4..H4,^""002@8 @C
MD'D>E5_&TS79ATE"5-Z[!F!QB.,;Y "/XF& ,@@@D'%;NF:5%I:"&!%1!V48
MR< 9)ZDX R3DGN: *^C^);;6!FWE5S@G:#AP <$E#A@,^H]/457^R6?V[?M7
M[;Y.[.&SLSLW9^[G^'/WL<?=HF\'6LDZ7X39,C;MT9*;B=V=P7 .2V2>IZ$E
M<@Y__,9_[A__ +7H Z"XU2.VDCMG;$D^_8,$YV#+<@8&!ZD>U8MU\2-/M6,;
M3J2,?<5W7D9X9%(/X'VZUC_$72FU:ZL;56*^89PQ!VG9M0N <'DID<C!S@\9
MKLK72HK6(6B(HB"E=F,K@]0<YSG/.<YR<YS0!8AF690Z$%6 ((.00>001U!J
MOJ>JQ:6AFG=40=V.,G!. .I. < 9)["N?\(?Z'<WFGI_JH9(W0?W?/4NR@#
M"@CY0 ,9.<UR\OB&SO+Z>;4W&VW=HH8F5Y$&WY7<J$*DL1QDDCH?NH: .NM?
MB1I]TPC6=03G[ZNB\#/+.H _$^W6NEKBM3\>:1JB&&>170]FBE.#@C(.S(."
M<$8([&G?#;5HYUFLXI6FCMW7RW=<?NW7*KS@DJ0PY XQC P  =G1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*;D**C AS\P)8@]!\N #R>O QGE_'EC_ &AK#6V=OFR0)G&<;DC&<9&<9]:
M/9= UE=:@CNTX$BYQSP1PRY(&<$$9QSC(XKS_7/&=W:ZLM@DF(#- NW8AX<)
MN&2N><GO]*Q_ >O-X0NY-,NB%C9\,6+!58 [7&1]U^,D@9&UB0!RSQ+_ ,AY
M?^OBU_E'0![77G_Q2\;R:'Y=M;-ME;YV. <+R ,,I!W'/0Y&WWKT"O$K(-XV
MU?S"0T*/NY&5\J(_*-KGH_&1ZL3MZB@#O?AGXM;Q! PF.9X6PQP!D-DJV H
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M10 4444 %%%% !1110 4444 4M8_U3?A_,4:/_JE_'^9HUC_ %3?A_,4:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#7?]2WX?\
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MRUGN))4C( 94? 52HX4@#[HZ=.N0.EHHH Y3XA:>YB748/\ 7V3>8O) *_\
M+13AEX(&3W(!4?>J+P7"=4FGUISD2L8X.N!#&V,@%CC<1D@@$$$CAJ["F0PK
M"H1  J@  #  '   Z 4 <UXVTV8F'4;8%Y;-V;8"/G1QB11E3\Q P.^,X!;
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MI<F58V4X9)B(G5AU4JY'(Z'&1G(!.*WJHWNAV]^V^:*-V P"Z*QQUQD@\<T
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M,X9(T5AD8."!GI6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFG;XGQ.\+(6R%*RA=I)V9V\_,,#."#@=*U=?T9=:@DM'X$BXSSP1RK8!&<$
MXSSC!XK*\#^#V\+H\)E\Q'8,!Y83:<88YW,3D ?3'N: ./\ ^$ UG_G\_P#)
MB?\ ^)KT+7/$<&AJKW+%%<X!V.PSUQE5.#Z9ZX..AK3K/UW0HM<B-M.,JW0C
M[RGLP/8C_P"L<@D$ KQ7]G%:>>IC%GL)X4"/:Q.1MQU))!7&2W&,\5YE\$K5
MFN99@/D6':3D=7=2HQUY"G\OI6K_ ,*.3?G[0WE[ON^6-VW/3=NQG'?;C/..
MU=[X?\.PZ!%]GMP0N<DDDDM@ L<]S@=,#T H \B(6[UPK?#*M<,N'4X(P5A!
M '(/R=>".6R":E^,.EV^GS1"!51VC.Y$4*N-WRMP ,D[@>3P!T[]]XP^'$'B
M-O/R8YL ;U (.,?>7C) X!!!Z9R !63H/P;@L)!-/(9MI!"[ B<9^\,MN'3C
M('&#D'% '9Z3=,+:.:Y.U_)1I"X"8.P%R1P%P<YZ8KR31/\ BNM5,\G^J3+A
M6_YYQD!%VG<.207'0Y;'6O8-5TU=3B>V<L%D4J2C%6P?0C^1R#T(()%8_@WP
M7'X76148N97SDC!"C[JGG!(R>0!G/3@4 ='63XL_X\[G_KWF_P#0&K6JIJUC
M_:$,EMG;YL;IG&<;E(SC(SC/K0!YK\#/^7K_ +8_^U*]5KE/ O@7_A%?-_>^
M9YNS^#9C9N_VFSG=75T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &?K?W!_O#^1KQ"O;];^X/\ >'\C7B%=
M>#^U\CDQ?V?F%%%%=9RA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5U7@WP:=6(GER( ?H7([#V]3^ YR0>#?!IU8B>7(@!^A<CL/;U/X#G)
M'J<<8B 10     ,  =!BN:O7Y?=6YT4*'-[SV".,1 (H     &  .@Q3J**X
MCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%TS
M_7R?\"_]"%;58NF?Z^3_ (%_Z$* -JBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[P_^@+5NWTF&V1H(XT6-\[E5%"G(P<J!@Y'!]JL0PK"H1  J@  #  '   Z
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MM6%>LB.*6/@*W_?)_P *?F?T;_OG_P"M74L1&VIS/#ROH;"R4\25B[I_1O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\O\ WTO_ ,11]:IA]6F>845Z?_PK"V_OR_\ ?2__ !%'_"L+;^_+_P!]+_\
M$4?6J8?5IGF%%>G_ /"L+;^_+_WTO_Q%'_"L+;^_+_WTO_Q%'UJF'U:9YA17
MI_\ PK"V_OR_]]+_ /$4?\*PMO[\O_?2_P#Q%'UJF'U:9YA17I__  K"V_OR
M_P#?2_\ Q%'_  K"V_OR_P#?2_\ Q%'UJF'U:9YA17I__"L+;^_+_P!]+_\
M$4?\*PMO[\O_ 'TO_P 11]:IA]6F>845Z?\ \*PMO[\O_?2__$4?\*PMO[\O
M_?2__$4?6J8?5IGF%%>G_P#"L+;^_+_WTO\ \11_PK"V_OR_]]+_ /$4?6J8
M?5IGF%%>G_\ "L+;^_+_ -]+_P#$4?\ "L+;^_+_ -]+_P#$4?6J8?5IGF%%
M>G_\*PMO[\O_ 'TO_P 11_PK"V_OR_\ ?2__ !%'UJF'U:9YA17I_P#PK"V_
MOR_]]+_\11_PK"V_OR_]]+_\11]:IA]6F>845Z?_ ,*PMO[\O_?2_P#Q%'_"
ML+;^_+_WTO\ \11]:IA]6F>845Z?_P *PMO[\O\ WTO_ ,11_P *PMO[\O\
MWTO_ ,11]:IA]6F>845Z?_PK"V_OR_\ ?2__ !%'_"L+;^_+_P!]+_\ $4?6
MJ8?5IGF%%>G_ /"L+;^_+_WTO_Q%'_"L+;^_+_WTO_Q%'UJF'U:9YA17I_\
MPK"V_OR_]]+_ /$4?\*PMO[\O_?2_P#Q%'UJF'U:9YA17I__  K"V_OR_P#?
M2_\ Q%'_  K"V_OR_P#?2_\ Q%'UJF'U:9YA17I__"L+;^_+_P!]+_\ $4?\
M*PMO[\O_ 'TO_P 11]:IA]6F>845Z?\ \*PMO[\O_?2__$5'<?#2VC5F#29
M)^\O8?[E'UJF'U:9YI17H>E_#RWNU+,TF0<<%?0?[-7/^%86W]^7_OI?_B*/
MK5,/JTSS"BO3_P#A6%M_?E_[Z7_XBC_A6%M_?E_[Z7_XBCZU3#ZM,\PHKT__
M (5A;?WY?^^E_P#B*/\ A6%M_?E_[Z7_ .(H^M4P^K3/,**]/_X5A;?WY?\
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MO>01QB(!%      P !T&*=117(=84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6+IG^OD_X%_Z$*VJQ=,_U\G_ O_0A0!M4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8NI_
MZ^/_ (#_ .A&MJL74_\ 7Q_\!_\ 0C6U0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5F>(/]6/\ >'\C6G69X@_U8_WA_(T :=%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+6/\
M5-^'\Q1H_P#JE_'^9HUC_5-^'\Q1H_\ JE_'^9H NT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!0UW_4M^'_H0HHUW_4M^'_H0HH X6Y^\?\]JBJ6Y^\?\]JBH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *U?#D+2R$(<'8>Y'<>E95;O@[_7
M-_US/_H2T ;?]GS?W_\ QYO\*/[/F_O_ /CS?X5K44 9/]GS?W__ !YO\*/[
M/F_O_P#CS?X5K44 9/\ 9\W]_P#\>;_"C^SYO[__ (\W^%:U% &3_9\W]_\
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MW_\ QYO\*/[/F_O_ /CS?X5K44 9/]GS?W__ !YO\*/[/F_O_P#CS?X5K44
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M3_*@#'LK625<HV!GU(_E5C^SYO[_ /X\W^%3:)]P_P"\?Y"M"@#)_L^;^_\
M^/-_A1_9\W]__P >;_"M:B@#)_L^;^__ ./-_A1_9\W]_P#\>;_"M:B@#)_L
M^;^__P"/-_A1_9\W]_\ \>;_  K6HH R?[/F_O\ _CS?X4?V?-_?_P#'F_PK
M6HH R?[/F_O_ /CS?X4?V?-_?_\ 'F_PK6HH R?[/F_O_P#CS?X4?V?-_?\
M_'F_PK6HH R?[/F_O_\ CS?X4?V?-_?_ /'F_P *UJ* ,G^SYO[_ /X\W^%'
M]GS?W_\ QYO\*UJ* ,G^SYO[_P#X\W^%']GS?W__ !YO\*UJ* ,G^SYO[_\
MX\W^%']GS?W_ /QYO\*UJ* ,G^SYO[__ (\W^%']GS?W_P#QYO\ "M:B@#)_
ML^;^_P#^/-_A1_9\W]__ ,>;_"M:B@#)_L^;^_\ ^/-_A1_9\W]__P >;_"M
M:B@#)_L^;^__ ./-_A1_9\W]_P#\>;_"M:B@#)_L^;^__P"/-_A1_9\W]_\
M\>;_  K6HH R?[/F_O\ _CS?X4?V?-_?_P#'F_PK6HH R?[/F_O_ /CS?X4?
MV?-_?_\ 'F_PK6HH R?[/F_O_P#CS?X4?V?-_?\ _'F_PK6HH R?[/F_O_\
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M ,]I?^_C?XT?\)#<_P#/:7_OXW^-'U-]P^MKL>J_V9/_ ,]/_'F_PH_LR?\
MYZ?^/-_A7E7_  D-S_SVE_[^-_C1_P )#<_\]I?^_C?XT?4WW#ZVNQZK_9D_
M_/3_ ,>;_"C^S)_^>G_CS?X5Y5_PD-S_ ,]I?^_C?XT?\)#<_P#/:7_OXW^-
M'U-]P^MKL>J_V9/_ ,]/_'F_PH_LR?\ YZ?^/-_A7E7_  D-S_SVE_[^-_C1
M_P )#<_\]I?^_C?XT?4WW#ZVNQZK_9D__/3_ ,>;_"C^S)_^>G_CS?X5Y5_P
MD-S_ ,]I?^_C?XT?\)#<_P#/:7_OXW^-'U-]P^MKL>J_V9/_ ,]/_'F_PH_L
MR?\ YZ?^/-_A7E7_  D-S_SVE_[^-_C1_P )#<_\]I?^_C?XT?4WW#ZVNQZK
M_9D__/3_ ,>;_"C^S)_^>G_CS?X5Y5_PD-S_ ,]I?^_C?XT?\)#<_P#/:7_O
MXW^-'U-]P^MKL>J_V9/_ ,]/_'F_PH_LR?\ YZ?^/-_A7FVD^,;BPD$I=I%[
MJ[D@C\<X/H?YC(/J^DZM'JL8GB.5/Y@]P1V(_P#KC((-95:,J9I2K1J%'^S)
M_P#GI_X\W^%']F3_ //3_P >;_"MJBLC4Q?[,G_YZ?\ CS?X4?V9/_ST_P#'
MF_PK:HH Q?[,G_YZ?^/-_A1_9D__ #T_\>;_  K:HH Q?[,G_P">G_CS?X4?
MV9/_ ,]/_'F_PK:HH Q?[,G_ .>G_CS?X4?V9/\ \]/_ !YO\*VJ* ,7^S)_
M^>G_ (\W^%']F3_\]/\ QYO\*VJ* ,7^S)_^>G_CS?X4?V9/_P ]/_'F_P *
MVJ* ,7^S)_\ GI_X\W^%']F3_P#/3_QYO\*VJ* ,7^S)_P#GI_X\W^%']F3_
M //3_P >;_"MJB@#%_LR?_GI_P"/-_A1_9D__/3_ ,>;_"MJB@#%_LR?_GI_
MX\W^%,GT^9%)9\@ Y&YNF/I6[4%[_JW_ -UOY4 8>GV<LRDQM@9Z9(YP/2K/
M]F3_ //3_P >;_"I_#_^K/\ O'^0K3H Q?[,G_YZ?^/-_A1_9D__ #T_\>;_
M  K:HH Q?[,G_P">G_CS?X4?V9/_ ,]/_'F_PK:HH Q?[,G_ .>G_CS?X4?V
M9/\ \]/_ !YO\*VJ* ,7^S)_^>G_ (\W^%']F3_\]/\ QYO\*VJ* ,7^S)_^
M>G_CS?X4?V9/_P ]/_'F_P *VJ* ,7^S)_\ GI_X\W^%']F3_P#/3_QYO\*V
MJ* ,7^S)_P#GI_X\W^%']F3_ //3_P >;_"MJB@#%_LR?_GI_P"/-_A1_9D_
M_/3_ ,>;_"MJB@#%_LR?_GI_X\W^%']F3_\ /3_QYO\ "MJB@#%_LR?_ )Z?
M^/-_A1_9D_\ ST_\>;_"MJB@#%_LR?\ YZ?^/-_A1_9D_P#ST_\ 'F_PK:HH
M Q?[,G_YZ?\ CS?X4?V9/_ST_P#'F_PK:HH Q?[,G_YZ?^/-_A1_9D__ #T_
M\>;_  K:HH Q?[,G_P">G_CS?X4?V9/_ ,]/_'F_PK:HH Q?[,G_ .>G_CS?
MX4?V9/\ \]/_ !YO\*VJ* ,7^S)_^>G_ (\W^%']F3_\]/\ QYO\*VJ* ,7^
MS)_^>G_CS?X4?V9/_P ]/_'F_P *VJ* ,7^S)_\ GI_X\W^%']F3_P#/3_QY
MO\*VJ* ,7^S)_P#GI_X\W^%']F3_ //3_P >;_"MJB@#%_LR?_GI_P"/-_A1
M_9D__/3_ ,>;_"MJB@#%_LR?_GI_X\W^%']F3_\ /3_QYO\ "MJB@#%_LR?_
M )Z?^/-_A5.VMI))&16PPSDY(S@\\]>M=-6+IG^OD_X%_P"A"@ _LR?_ )Z?
M^/-_A1_9D_\ ST_\>;_"MJB@#%_LR?\ YZ?^/-_A1_9D_P#ST_\ 'F_PK:HH
M Q?[,G_YZ?\ CS?X4?V9/_ST_P#'F_PK:HH Q?[,G_YZ?^/-_A1_9D__ #T_
M\>;_  K:HH Q?[,G_P">G_CS?X4?V9/_ ,]/_'F_PK:HH Q?[,G_ .>G_CS?
MX4?V9/\ \]/_ !YO\*VJ* ,7^S)_^>G_ (\W^%']F3_\]/\ QYO\*VJ* ,7^
MS)_^>G_CS?X4?V9/_P ]/_'F_P *VJ* ,7^S)_\ GI_X\W^%']F3_P#/3_QY
MO\*VJ* ,7^S)_P#GI_X\W^%']F3_ //3_P >;_"MJB@#%_LR?_GI_P"/-_A1
M_9D__/3_ ,>;_"MJB@#%_LR?_GI_X\W^%']F3_\ /3_QYO\ "MJB@#%_LR?_
M )Z?^/-_A1_9D_\ ST_\>;_"MJB@#%_LR?\ YZ?^/-_A1_9D_P#ST_\ 'F_P
MK:HH Q?[,G_YZ?\ CS?X4?V9/_ST_P#'F_PK:HH Q?[,G_YZ?^/-_A1_9D__
M #T_\>;_  K:HH Q?[,G_P">G_CS?X4?V9/_ ,]/_'F_PK:HH Q?[,G_ .>G
M_CS?X4?V9/\ \]/_ !YO\*VJ* ,7^S)_^>G_ (\W^%']F3_\]/\ QYO\*VJ*
M ,7^S)_^>G_CS?X4?V9/_P ]/_'F_P *VJ* ,7^S)_\ GI_X\W^%']F3_P#/
M3_QYO\*VJ* ,7^S)_P#GI_X\W^%']F3_ //3_P >;_"MJB@#F;FVDCD5&;+'
M&#DG&3QSUZU<_LR?_GI_X\W^%&I_Z^/_ (#_ .A&MJ@#%_LR?_GI_P"/-_A1
M_9D__/3_ ,>;_"MJB@#%_LR?_GI_X\W^%']F3_\ /3_QYO\ "MJB@#%_LR?_
M )Z?^/-_A1_9D_\ ST_\>;_"MJB@#%_LR?\ YZ?^/-_A1_9D_P#ST_\ 'F_P
MK:HH Q?[,G_YZ?\ CS?X4?V9/_ST_P#'F_PK:HH Q?[,G_YZ?^/-_A1_9D__
M #T_\>;_  K:HH Q?[,G_P">G_CS?X4?V9/_ ,]/_'F_PK:HH Q?[,G_ .>G
M_CS?X4?V9/\ \]/_ !YO\*VJ* ,7^S)_^>G_ (\W^%']F3_\]/\ QYO\*VJ*
M ,7^S)_^>G_CS?X4?V9/_P ]/_'F_P *VJ* ,7^S)_\ GI_X\W^%']F3_P#/
M3_QYO\*VJ* ,7^S)_P#GI_X\W^%']F3_ //3_P >;_"MJB@#%_LR?_GI_P"/
M-_A1_9D__/3_ ,>;_"MJB@#%_LR?_GI_X\W^%']F3_\ /3_QYO\ "MJB@#%_
MLR?_ )Z?^/-_A1_9D_\ ST_\>;_"MJB@#%_LR?\ YZ?^/-_A1_9D_P#ST_\
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M,G_YZ?\ CS?X5M44 8O]F3_\]/\ QYO\*/[,G_YZ?^/-_A6U10!B_P!F3_\
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M[,G_ .>G_CS?X4?V9/\ \]/_ !YO\*VJ* ,7^S)_^>G_ (\W^%']F3_\]/\
MQYO\*VJ* ,7^S)_^>G_CS?X4?V9/_P ]/_'F_P *VJ* ,7^S)_\ GI_X\W^%
M']F3_P#/3_QYO\*VJ* ,7^S)_P#GI_X\W^%']F3_ //3_P >;_"MJB@#%_LR
M?_GI_P"/-_A1_9D__/3_ ,>;_"MJB@#%_LR?_GI_X\W^%']F3_\ /3_QYO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **Q_%'BB+PW$+B8,59PH" $Y()[E>/EKE_^%UV?]R;_OE/_CE
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M* "BBB@#%U/_ %\?_ ?_ $(UM5BZG_KX_P#@/_H1K:H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *S/$'^K'^\/Y&M.LSQ!_JQ_O
M#^1H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** *6L?ZIOP_F*-'_P!4OX_S-&L?ZIOP_F*-'_U2_C_,T 7:**Q-#UM[N>YL
MY0N^VD7!0':8Y%W1YR<[L9W< =,9H VZ*J:KJ::7$]U*<)&I)Z9..@&2!DG@
M#/)(%9_@[Q#_ ,)!:I=$*'.0ZJ<@,IQ]1D88 \@$<GJ0#;HK$\6:V^E1IY(4
MRSS1Q1[P2@9SU;!!Q@'IDYQQ6W0 4444 %%%9_B&Z:TMIYHSAXX9&4X!P50D
M'!XZT :%%9_AZZ:[MH)I#EY(8V8X R60$G XZUH4 %%9_B&Z:TMIYHSAXX9&
M4X!P50D'!XZT>'KIKNV@FD.7DAC9C@#)9 2<#CK0!H4444 %%%<__I_V_P#@
M^P^7[;LX_P"^MV[_ (!L_P!J@#H**** "BN?\7ZI)I_V;RFV^;>0QMP#E6W;
MAR#C..HY]ZZ"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:[_J6_#_ -"%%&N_ZEOP
M_P#0A10!PMS]X_Y[5%4MS]X_Y[5%0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKV%B!UPH<G&<<\5ULEVD3+$S*'DSM4D!FVC)P.IP.N.E<Q\1(5F6T1P"K7\
M((R"#N!!!Z@T ,M;;4]847+3+:;L[8A"LK!<Y4LSG.['4  <#@'(&AX9UF61
MGT^\V_:8%4EEX216'#J"%/!^5L#:&Z=<#H*Y3_F,_P#</_\ :] %CQ)XDEMI
M4T^S0/=2@-\X/EHF<%V(QQP0 #G/OM5J0T358E$@O$>0;24>!5C)R-REU&['
M7D*"?]GJ,S^R9[G5+LP3BW<I"03"DC.FP E=^#M#+@XX)P#R!6Q_PCNH_P#/
M_P#^2L7^- %WPKXD;5U>*9#'<P$+*A' )SAE/.5;&1R?J1AC%K'B"=I_[/L4
M5Y50,[R,1%'D_*&"Y8LP!P.#R&Y&<-T#0)[:X>ZGNO/;RQ$RB-8P""'7(5B,
M@,<9&<-UP:K^!Y09KY'SYPNV)W [O+(_=<D<K@':,\#IP1D )="U2$;X[U78
M$'9);HB-R,@LN6 QZ#/N.HTO"VI75ZC"]A\J6-L<$%&!&05^9CP#@\D9Z'.5
M7;HH XSPAJ$>G1WUQ,P6-+^X))_X#^9/0 <D\#FM/0M2GUQA>@-%:[?D1E7S
M)"1]]NNU1_"%.6^\3MP#YY)I\GF37TBF:SM]1N#+ /P_>X_C SR#P /[K.1Z
MWI^H1ZC&MQ"P:-QD$?YX(Z$'D'@\T <?XH\77&EWPLX%,IEMAY<8 QYID(W,
MW!VA5.><<<XY86XM"U28;Y+U48DG9';HZ+R< ,V&(QZC/N>IAN98TUN,/C<U
MD0F1GYO,8G!QP=@;GCC([X/9T <UI?B6:*==.OHU25U)CDB+&*3&2P&1E2HZ
M@]>3QE<VO$OB7^Q_+BCC:6>=B(XU.,XQN);!"A0>3_3)&5X]"R2V,8&93>1L
MN%);8G,AR!P!\I/TSVX+H+'K,32#[]FRQDJ2-ZN68 XP"$SGV..XR 2_V-J=
MS^\>\2)CU2*W5T&..&D.XYZG/<D#C%/T?Q)<17']G:@BK+("T3PAC$X499?F
MR0R]3G'T'RENHKC_ !Z%DEL8P,RF\C9<*2VQ.9#D#@#Y2?IGMP :&C:I)<WM
MY;.V8X/L^P8 QOC);D#)R?4GVK'\4>+KC2[X6<"F4RVP\N, 8\TR$;F;@[0J
MG/...<<L+OAW_D(ZA_VZ_P#HHTUX5?602 2MAD$C.#YQ&1Z'!(^A(H )='U4
M#S5NXR^0?*, $74$IOY?:!D XW'U!Y&UX=UQ=:A$X4HV2KHWWD=3AE/H1[@'
M!!(&<5IURG@#_E\_["%Q_P"RT <__8U[_:7E?;/WOV/=YOV>/[OFXV;,XZ\[
MNO:O2ZY3_F,_]P__ -KUU= &3XG:>.!I;0_O8\.%QN#A>60C!)W#.-N#G'(Y
MJWI6IIJD2741RDB@CID9Z@X)&0>",\$$5;KBO#UZ/#]W<:7,RK$VZ> DA5"-
MDN@&[ "D'  ' =C@$4 :OB+5)/-AT^V;;+,VYV #%(D^\W(8 L?E4LI4G(X.
M*-?\2O:RII]K'YES*I;YB5C1>1YCD#IGL.3TR"5!S_ C-JSSZS(.+AMD((&5
MBC)'7<V-Q^\O W+NY!%&B!8M5O0XQ(\<#(2IR450KD-CINV@\\D?[)P /FT+
M5'4N+U5<@D(+=-@)YVASEMH/&2"<<D9K/L_%UV]_;Z9<*(WS-YFP QR+L+1,
MI;+ 9!SSU'/.57O:XS7Y8SJUB@QYH2<MQSM*-LYQR,AL#/'/KR :OB#Q!):2
M1V5L@DN)@Q +81%''F/C)VY/ XW8(!W8!H3:%JCJ7%ZJN02$%NFP$\[0YRVT
M'C)!..2,T:/*!JMVDF=YB@,6X'_5@?/M)& N\C(!Y;/<''6T <_X:U*]F>2"
M^A5"F"LD1_=L"2,<L3GC/T(W!3C<[Q!X@DM)([*V027$P8@%L(BCCS'QD[<G
M@<;L$ [L [U<EH\H&JW:29WF* Q;@?\ 5@?/M)& N\C(!Y;/<'  3:%JCJ7%
MZJN02$%NFP$\[0YRVT'C)!..2,U=\-:E>S/)!?0JA3!62(_NV!)&.6)SQGZ$
M;@IQNZ"B@#G_  AJDFH?:?-;=Y5Y-&O &%7;M' &<9ZGGWK"O/%UVE_<:9;J
M)'S#Y>\ 1QKL#2LQ7#$9(QSUZ<X5M+P!_P OG_80N/\ V6F^'H5.IZ@Y W 6
MP!QR 8\D9]#@9^@]* &7-AJ>F#[2MRMR(\EHF@6,LH!)"L@8[O[HQC/7(X/2
MZ5J::I$EU$<I(H(Z9&>H."1D'@C/!!%6ZX+PI"TVAE$!+-!<@ #))+2   =2
M: +$.L7OBEB]BRP6BM@3.FZ20@,"51N-N<#G!]\[D!>76H^&O])F=;NV&/,Q
M&(Y4'.655X('!.2?^ C+54\*:#>2VD+V]ZJ1F-2%6VB8*3]Y<YY(.0Q/).<\
MYK3FT/4(5+OJ "J"23:Q  #DDDG@"@#I[2Z6[19HSE)%#*<$9##(.#STJ:LS
MPWI#:/;QVC.9#&"-Q&,C)(&,G  ( YZ"M.@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&[^XW^Z?Y5-4-W]QO\
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M?WLX/;&1@YX .'\<:_)XPN&%N"T%NCLORX^50#)(2>QQQG'&T8#$@]'\#/\
MEZ_[8_\ M2L3PIJ5CI=C<;Y?]*N89$VF-OE&&"J&"D?,<$G..@(&W)T/@IJD
M=M)+;.V))]FP8)SL$A;D# P/4CVH ["[^'%HT[:G<,[_ #%V$KJ8\#G!^4':
MHZ G&  <CBO//B6UG=3Q0:>BEP,-Y"C8Q8C8HV\,W7.!W R2,#UU[ZVUY)+.
M.9'\R-@PBD1F"L-I/&?7KC&<5Y5XQ\%-X*,>HVDK8\P*N[&]25)Z@88'#9!
MXP"&!- 'J<-U)I5B)I@6E@M@S@MDEDCRP+<\DCKSZ\UY%\-]3L+'SO[0"'=Y
M>SS(C)TW;L85L=1Z9_"O4M/F7QEIZERR"X3#F,[3E6PX&=WRDJ1SG*G!ZUA6
M_P &K5(&A=F:<YQ+R,'MA-V,>N<DY."., '6Z/IUH@^T6B1 ,"-\*H,C/(W*
M.1D<^XKQ^:-;W6RE[G:;DC!7J!Q"I&TY5L*.G*G)/.:T_@EJ;K-+9Y_=M'YF
M#GAE95R.<#(;GC)P.>*ZWQWX"MM85KUV,,D:$M(J[@57DEE'+$*"!@@],Y
MH XKXQ:/;Z=+"8%5&=&W(@51A2-K;5 Y.2,GKMP.AKUK0Y9);>%YL^:T2%\C
M:=Q4;LC P<]L<5X;\-O#/]N7:[QF*'#OD9!Q]U>00=QZ@XRH;'2OH"@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\H!JZIJDC7MO80M@;7EFP!NV+\J#+ C#/P<?-Z%1S1_:DG]I?8MW[K['YFW
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MU=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 4-=_P!2WX?^A"BC7?\ 4M^'_H0HH X6Y^\?\]JB
MJ6Y^\?\ /:HJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M -6?]X_R%:=9GA__ %9_WC_(5IT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %8NF?Z^3_@7_ *$*VJQ=,_U\G_ O_0A0!M4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8NI_Z^/\
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M#_&@#0HK/_MM/1OR'^-']MIZ-^0_QH T**S_ .VT]&_(?XT?VVGHWY#_ !H
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MDY(  'J20.P]2!S0!8^R)_=7\A1]D3^ZOY"L?P/K$FL6<=W-C?(9"<# &)&
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M_(4?9$_NK^0J:B@"'[(G]U?R%'V1/[J_D*FHH A^R)_=7\A1]D3^ZOY"IJ*
M(?LB?W5_(4?9$_NK^0J:B@#+UB!40$ #YNP [&K-K9HR*2J_='8>E1:W]P?[
MP_D:S(?%/EJ%V= !][T_"LZE:%.W,[7)E-1W-S[%'_=7_OD4?8H_[J_]\BL7
M_A+/]C_Q[_[&C_A+/]C_ ,>_^QK/ZY1[_@R?;0[FU]BC_NK_ -\BC[%'_=7_
M +Y%8O\ PEG^Q_X]_P#8T?\ "6?['_CW_P!C1]<H]_P8>VAW-K[%'_=7_OD4
M?8H_[J_]\BL7_A+/]C_Q[_[&C_A+/]C_ ,>_^QH^N4>_X,/;0[FU]BC_ +J_
M]\BC[%'_ '5_[Y%8O_"6?['_ (]_]C1_PEG^Q_X]_P#8T?7*/?\ !A[:'<VO
ML4?]U?\ OD4?8H_[J_\ ?(K%_P"$L_V/_'O_ +&C_A+/]C_Q[_[&CZY1[_@P
M]M#N;7V*/^ZO_?(H^Q1_W5_[Y%8O_"6?['_CW_V-'_"6?['_ (]_]C1]<H]_
MP8>VAW-K[%'_ '5_[Y%'V*/^ZO\ WR*Q?^$L_P!C_P >_P#L:/\ A+/]C_Q[
M_P"QH^N4>_X,/;0[FU]BC_NK_P!\BC[%'_=7_OD5B_\ "6?['_CW_P!C1_PE
MG^Q_X]_]C1]<H]_P8>VAW-K[%'_=7_OD4?8H_P"ZO_?(K%_X2S_8_P#'O_L:
M/^$L_P!C_P >_P#L:/KE'O\ @P]M#N;7V*/^ZO\ WR*/L4?]U?\ OD5B_P#"
M6?['_CW_ -C1_P )9_L?^/?_ &-'URCW_!A[:'<VOL4?]U?^^11]BC_NK_WR
M*Q?^$L_V/_'O_L:/^$L_V/\ Q[_[&CZY1[_@P]M#N;7V*/\ NK_WR*/L4?\
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M ![_ .QH^N4>_P"##VT.YM?8H_[J_P#?(H^Q1_W5_P"^16+_ ,)9_L?^/?\
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M8H_[J_\ ?(H^Q1_W5_[Y%3T4 0?8H_[J_P#?(H^Q1_W5_P"^14]% $'V*/\
MNK_WR*/L4?\ =7_OD5/10!!]BC_NK_WR*/L4?]U?^^14]% $'V*/^ZO_ 'R*
M/L4?]U?^^14]% $'V*/^ZO\ WR*/L4?]U?\ OD5/10!!]BC_ +J_]\BC[%'_
M '5_[Y%3T4 0?8H_[J_]\BC[%'_=7_OD5/10!!]BC_NK_P!\BC[%'_=7_OD5
M/10!!]BC_NK_ -\BC[%'_=7_ +Y%3T4 0?8H_P"ZO_?(H^Q1_P!U?^^14]%
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MR*GHH @^Q1_W5_[Y%'V*/^ZO_?(J>B@"#[%'_=7_ +Y%'V*/^ZO_ 'R*GHH
M@^Q1_P!U?^^11]BC_NK_ -\BIZ* (/L4?]U?^^11]BC_ +J_]\BIZ* (/L4?
M]U?^^11]BC_NK_WR*GHH @^Q1_W5_P"^11]BC_NK_P!\BIZ* (/L4?\ =7_O
MD4?8H_[J_P#?(J>B@"#[%'_=7_OD4?8H_P"ZO_?(J>B@"#[%'_=7_OD4?8H_
M[J_]\BIZ* (/L4?]U?\ OD4?8H_[J_\ ?(J>B@"#[%'_ '5_[Y%'V*/^ZO\
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MBC_NK_WR*/L4?]U?^^14]% $'V*/^ZO_ 'R*/L4?]U?^^14]% $'V*/^ZO\
MWR*/L4?]U?\ OD5/10!!]BC_ +J_]\BC[%'_ '5_[Y%3T4 0?8H_[J_]\BC[
M%'_=7_OD5/10!!]BC_NK_P!\BC[%'_=7_OD5/10!FZK:HD3$* >.0 .XHTJU
M1XE)4$\\D ]S4NL?ZIOP_F*-'_U2_C_,T 3?8H_[J_\ ?(H^Q1_W5_[Y%3T4
M 0?8H_[J_P#?(H^Q1_W5_P"^14]% $'V*/\ NK_WR*/L4?\ =7_OD5/10!!]
MBC_NK_WR*/L4?]U?^^14]% $'V*/^ZO_ 'R*/L4?]U?^^14]% $'V*/^ZO\
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M<\J^4B@_,S2_)@#!)(!)P.3C\:RO'EC_ &?H[6V=WE1P)G&,[7C&<9.,X]:
M.UHHJCK>J+I4$ETV,1(S8)VY('"Y]6. /<]#0!@6A;6=3>8@&&P0HA!SF60
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &+J?\ KX_^ _\ H1K:K%U/_7Q_\!_]"-;5
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQOS\W0YQCIQGUK6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *&N_ZEOP_]"%%&N_ZE
MOP_]"%% '"W/WC_GM452W/WC_GM45 !1110 4,VWD]!4-U>+;#+'Z#N:PYKJ
M34V$2 \\!0>OU_S@4 6]0UO;\D77/WNWX5)HWA234/WLA*H<'/5FR?T^I]L
MUN:%X26R(EE.Z0'@#[H]#R,D_P"<9&:Z117/4K]$9RJ=B"TLDM%V1J%'M^63
MZGW/-60M*%IX6L;7(&A:7;4@6EVT^4=B+;2%:FVTA6GRA8@*U!=6JW*F-QE6
M'(-7"M,*U+0K' ZWX2>U)E@RR9&%&2X^GJ!^?Y9JC8ZYM^63D>O?\?\ .?K7
MI#+6!KOA5+_YTPDG/;AN_..^>_7Z\8VA7MHRXS[E%6W<CH:*Y[=+I#^6XQT)
M4XP?<$9_,?CTK:M+Y;H94\^AZ_E70G<T)Z*** "BBB@ HHHH **** "BBB@
MHHK=U73(X+>.91AFV9.3W4D\$XZT 85%%% !1171>+K5(/+V*%SNSM ']WTH
M YVBBB@ HHHH **Z+[*GV'S-HW?WL#/^LQUZ]*YV@ HHHH **** "BBB@ HH
MHH **** "BBB@ HK:\*VZSRE7 8;#PP!'4>M9VI($ED4< .V .G4T 5J***
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MD%R)"<DQK'\N!@84]01D-U!Z=!6/;>#+O3QY5K?.L0QM66))F   QN8CCC@
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M/;,S*LBE24QNP>"!N##D<=._&#S4MI:K:(L,8PD:A5&2<!1@#)YZ4 34444
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MSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5:T[46L6W+T/4
M=C_GL:JT4XR<7=;C3:=SN[2[6[42(>#^8]C4U8WA_2VM09'R"P^[_4^_\OY;
M->U1E*4$VK,[8-M784445H4%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %8NF?Z^3_ (%_Z$*VJQ=,_P!?)_P+_P!"% &U1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!BZG_KX_^ _^A&MJ
ML74_]?'_ ,!_]"-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !69X@_U8_WA_(UIUF>(/\ 5C_>'\C0!IT444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4M8_U3?A_,4:/_JE_'^9H
MUC_5-^'\Q1H_^J7\?YF@"[7)12C3-6>,YVWT"L"03F2'*[5(&  G)SGG'(R
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M5<9SC' 'ISUK&\8_ZY?^N8_]":K7C7_EG_P/_P!EH NR7:6,$5PR[F5%"_\
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M['O4UX8+N-;UQE5YZ<GG&TCOS^&>^"<\YXE_X^'_ . _^@BM/_F'_P"?^>E
M%K2]=CU$_9F0*".!]Y3CG&,#&,<?_JK"N=)_TDVJ="W'L"-W<\X'OSBCPU_Q
M\)_P+_T$U<OKL6EZ96Z KGZ% ,_AG- %ZYU.+0L01IEL#/('KU/)S[8Z'BFS
M0QZ_&94&V5?IDG'0^H/0$XZ?45%KV@O=O]HAPP<#N/3J.@Q@#O4^F6W]A1/+
M*1N;'&?0<+TZY)SU'>@"MX/B$HE1N0P4'Z'=4-[?_P!LNEI&-J!CC'0@=#C
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MS2;AM=G8&0AB<G</NDG)XZ=JB\5AM6NK;2U(V9\^<$9RD; (I!(#*[9!')!
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MR5"<L63YU &#G)4#'4]N:VZ* .?\#:8]C:JTP_?SLTLO4$M(<\@@;2!@$
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M4Z#ZKDCN/H,@9.!7DJ6;N_DA6+Y(V@$MD=1CKQCFG9!8]!\1:(GB2-;RW.7
M(7.0& )XYQ@YS@_GQ@CEM"\32Z,WDODQ@D,A'(YYQGD$'MTZ]"<UZ-HNF?V9
M EOG)4<_4G)QP.,DX]JY3XBZ6JA;L<,6VM@=>"03],8Z<YZ\"H36PO(ZT.)
M&4Y!&01R"#WIC"L7P3>&YM@#UC8KDG.0,$?3 .,>U;35SS5G8S:(FJ%JF:HF
MK&1#*&J7?V.-I?[HXSTST'3WKB= @WN7_NC]3_\ 6S70>-+ORHUB'_+0\^F%
MY_F16=HD'E1[N['/3MV_Q_&NK"QM%ON:TEI<OT445T&@4444 %%%% !1110
M5:GU.2=!"QRJXP,#L,#D#/2JM% %J#4Y($,*G"MG(P.XP>2,]*@BE,1#KP5(
M(^HIE% %B\OGO#OD.2!CH!Q^&/6G7NIR7N/,.=N<< =>O0#TJK10!:GU.2=!
M"QRJXP,#L,#D#/2H(I3$=RD@CN#@TRB@#1E\0SR#:7.#Z  _F #4$^IR3H(6
M.57&!@=A@<@9Z55HH M?VG)Y?V?/[OTP/7/7&>M012F([E)!'<'!IE% &C+X
MAGD&TN<'T !_, &J=M<M:L)$.&'0\'J,=ZBHH EN;EKIC(YRQZG@=!CM4O\
M:<GE_9\_N_3 ]<]<9ZU5HH EMKEK5A(APPZ'@]1CO1<W+73&1SECU/ Z#':H
MJ* +EIK$MH-J,0/3@C\,YQ^%1W=\]X=TC$G]!]!T%5Z* +5EJ<EEGRSC=C/
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MD [BN*UR\_X2&]@L+?E+299IW RJLF=B9R!DG((Y(_X"P%B'X<QHHB-Q=-$
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M<*/Y]<T[X@_.MK$>4DOH%=3]UE)8[2.A&0.#QQ71Z=9+81);IDK$BJ">N%
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M[I_E4U0W?W&_W3_*@"KHGW#_ +Q_D*T*S]$^X?\ >/\ (5H4 %%%% !1110
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M 'R/\*/[.B_N+_WR/\*/[/EW0?5WW.&HKN?[.B_N+_WR/\*/[.B_N+_WR/\
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M?<X:BNY_LZ+^XO\ WR/\*/[.B_N+_P!\C_"C^SY=T'U=]SAJ*[G^SHO[B_\
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M1110!BZG_KX_^ _^A&MJL74_]?'_ ,!_]"-;5 !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !69X@_U8_WA_(UIUF>(/\ 5C_>'\C0
M!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4
MM8_U3?A_,4:/_JE_'^9HUC_5-^'\Q1H_^J7\?YF@"[1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH?\ "JFE_9M*C6V@^6-,X'S'&22>3D]2>]6_[+C_ +OZG_&C^RX_[OZG_&@
M_M2/^]^A_P */[4C_O?H?\*/[+C_ +OZG_&C^RX_[OZG_&@ _M2/^]^A_P *
M/[4C_O?H?\*/[+C_ +OZG_&C^RX_[OZG_&@ _M2/^]^A_P */[4C_O?H?\*/
M[+C_ +OZG_&C^RX_[OZG_&@ _M2/^]^A_P */[4C_O?H?\*/[+C_ +OZG_&C
M^RX_[OZG_&@ _M2/^]^A_P */[4C_O?H?\*/[+C_ +OZG_&C^RX_[OZG_&@
M_M2/^]^A_P */[4C_O?H?\*/[+C_ +OZG_&C^RX_[OZG_&@ _M2/^]^A_P *
M/[4C_O?H?\*/[+C_ +OZG_&C^RX_[OZG_&@ _M2/^]^A_P */[4C_O?H?\*/
M[+C_ +OZG_&C^RX_[OZG_&@ _M2/^]^A_P */[4C_O?H?\*/[+C_ +OZG_&C
M^RX_[OZG_&@ _M2/^]^A_P */[4C_O?H?\*/[+C_ +OZG_&C^RX_[OZG_&@
M_M2/^]^A_P */[4C_O?H?\*/[+C_ +OZG_&C^RX_[OZG_&@ _M2/^]^A_P *
M/[4C_O?H?\*/[+C_ +OZG_&C^RX_[OZG_&@ _M2/^]^A_P */[4C_O?H?\*/
M[+C_ +OZG_&C^RX_[OZG_&@ _M2/^]^A_P */[4C_O?H?\*/[+C_ +OZG_&C
M^RX_[OZG_&@ _M2/^]^A_P */[4C_O?H?\*/[+C_ +OZG_&C^RX_[OZG_&@
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MLSQL/E7=@9/9L4 :?]L1?WOT/^%']L1?WOT/^%']CQ?W?U/^-']CQ?W?U/\
MC0 ?VQ%_>_0_X4?VQ%_>_0_X4?V/%_=_4_XT?V/%_=_4_P"- !_;$7][]#_A
M1_;$7][]#_A1_8\7]W]3_C1_8\7]W]3_ (T ']L1?WOT/^%']L1?WOT/^%']
MCQ?W?U/^-']CQ?W?U/\ C0 ?VQ%_>_0_X4?VQ%_>_0_X4?V/%_=_4_XT?V/%
M_=_4_P"- !_;$7][]#_A1_;$7][]#_A1_8\7]W]3_C1_8\7]W]3_ (T ']L1
M?WOT/^%']L1?WOT/^%']CQ?W?U/^-']CQ?W?U/\ C0 ?VQ%_>_0_X4?VQ%_>
M_0_X4?V/%_=_4_XT?V/%_=_4_P"- !_;$7][]#_A1_;$7][]#_A1_8\7]W]3
M_C1_8\7]W]3_ (T ']L1?WOT/^%']L1?WOT/^%']CQ?W?U/^-']CQ?W?U/\
MC0 ?VQ%_>_0_X4?VQ%_>_0_X4?V/%_=_4_XT?V/%_=_4_P"- !_;$7][]#_A
M1_;$7][]#_A1_8\7]W]3_C1_8\7]W]3_ (T ']L1?WOT/^%']L1?WOT/^%']
MCQ?W?U/^-']CQ?W?U/\ C0 ?VQ%_>_0_X4?VQ%_>_0_X4?V/%_=_4_XT?V/%
M_=_4_P"- !_;$7][]#_A1_;$7][]#_A1_8\7]W]3_C1_8\7]W]3_ (T ']L1
M?WOT/^%']L1?WOT/^%']CQ?W?U/^-']CQ?W?U/\ C0 ?VQ%_>_0_X4?VQ%_>
M_0_X4?V/%_=_4_XT?V/%_=_4_P"- !_;$7][]#_A1_;$7][]#_A1_8\7]W]3
M_C1_8\7]W]3_ (T ']L1?WOT/^%']L1?WOT/^%']CQ?W?U/^-']CQ?W?U/\
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M_C1_8\7]W]3_ (T ']L1?WOT/^%']L1?WOT/^%']CQ?W?U/^-']CQ?W?U/\
MC0 ?VQ%_>_0_X4?VQ%_>_0_X4?V/%_=_4_XT?V/%_=_4_P"- !_;$7][]#_A
M1_;$7][]#_A1_8\7]W]3_C1_8\7]W]3_ (T ']L1?WOT/^%']L1?WOT/^%']
MCQ?W?U/^-']CQ?W?U/\ C0 ?VQ%_>_0_X4?VQ%_>_0_X4?V/%_=_4_XT?V/%
M_=_4_P"- !_;$7][]#_A1_;$7][]#_A1_8\7]W]3_C1_8\7]W]3_ (T ']L1
M?WOT/^%']L1?WOT/^%']CQ?W?U/^-']CQ?W?U/\ C0 ?VQ%_>_0_X4?VQ%_>
M_0_X4?V/%_=_4_XT?V/%_=_4_P"- !_;$7][]#_A1_;$7][]#_A1_8\7]W]3
M_C1_8\7]W]3_ (T ']L1?WOT/^%']L1?WOT/^%']CQ?W?U/^-']CQ?W?U/\
MC0 ?VQ%_>_0_X4?VQ%_>_0_X4?V/%_=_4_XT?V/%_=_4_P"- !_;$7][]#_A
M1_;$7][]#_A1_8\7]W]3_C1_8\7]W]3_ (T ']L1?WOT/^%']L1?WOT/^%']
MCQ?W?U/^-']CQ?W?U/\ C0 ?VQ%_>_0_X4?VQ%_>_0_X4?V/%_=_4_XT?V/%
M_=_4_P"- !_;$7][]#_A1_;$7][]#_A1_8\7]W]3_C1_8\7]W]3_ (T ']L1
M?WOT/^%']L1?WOT/^%']CQ?W?U/^-']CQ?W?U/\ C0 ?VQ%_>_0_X4?VQ%_>
M_0_X4?V/%_=_4_XT?V/%_=_4_P"- !_;$7][]#_A1_;$7][]#_A1_8\7]W]3
M_C1_8\7]W]3_ (T ']L1?WOT/^%']L1?WOT/^%']CQ?W?U/^-']CQ?W?U/\
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M< <?Y[UO#<PGN9)!T8.1GKRP-9%WK$MV-KL2/3@#\<8S^-1V=\]F=\9P2,=
M>/QSZ4 .U3_72?\ 71__ $(UNZY_QZ0_]L__ $ US<LIE)=N2Q)/U-3SZG).
M@A8Y5<8&!V&!R!GI0!TFIVW]NQ)+$1N7/&?4<KTZY QT'>H-!T%[1_M$V%"
M]QZ=3U&,$]ZP+2^>S.Z-B#^A^HZ&I+O6);L;78D>G 'XXQG\: )-0U'S9S<)
MV8$9Z';@ ]NN*M7'BJ6=6C(7# @X!SR,>M8M% !1110 4444 %%%% !1110
M4444 %;O@[_7-_US/_H2UA5N^#O]<W_7,_\ H2T =C1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-W]QO
M]T_RJ:H;O[C?[I_E0!5T3[A_WC_(5H5GZ)]P_P"\?Y"M"@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  E,OHOY'_&C_A*9?1?R/^-'UZEYA[>!U-%<M_PE,OHOY'_&C_A*9?1?R/\
MC1]>I>8>W@=317+?\)3+Z+^1_P :/^$IE]%_(_XT?7J7F'MX'4T5RW_"4R^B
M_D?\:/\ A*9?1?R/^-'UZEYA[>!U-%<M_P )3+Z+^1_QH_X2F7T7\C_C1]>I
M>8>W@=317+?\)3+Z+^1_QH_X2F7T7\C_ (T?7J7F'MX'4T5RZ^*9,\JN/;(_
MK716EVMVHD0\'\Q[&M*6(A5=D5&I&6Q-1116Q84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6+IG^OD_P"!?^A"MJL73/\
M7R?\"_\ 0A0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 8NI_Z^/_@/_H1K:K%U/_7Q_P# ?_0C6U0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5F>(/]6/]X?R-:=9GB#_ %8_
MWA_(T :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% %+6/]4WX?S%&C_ZI?Q_F:-8_U3?A_,4:/_JE_'^9H NU#;W:7.[RV5MC
M%6VD'##JIQT([CK4U<EJ.CW>D3O>Z?M>.8@RV[D)ELJ"Z'@!F&=Q/?D[C@
MZ74-/CU&-K>90T;C!!_SP1U!'(/(YKS1;]FTO3[J4DK!=Q%V"YVI&[H"0HZ
M #U)QU)KH+VWU#Q*OV66,6D!/[TB59)'4_PKM&%'9L]01U&Y3T=UH45S;G3R
M/W1C" =2 !A2"V>5P""<\@&@#0KE/&_[^2RMEYD:\20#_9A!,AR>. 1QG)[
MU7M+C5=''V=H5NU4#;*LHB<@$_?WYRV,=/Q9CDU;\/Z'<S3?VEJ#*90FV.*/
ME(PP&X\Y^<]"03QD;B" H ^[_M;>WE?9/+W';O\ .W;<_+G'&<=<<9J_IEW-
M;(/[0:%9'DVIY18*<@;5_><EB<\#MC%:U9GB+0UUJ$P%BC9#(Z_>1U.58>A'
ML0<$@$9S0!IUR6K0K9ZI:2Q@*URDZ2D#[RQHK+GW! YZX !.!BF6VJZK9#RI
M;5)V7'[R*98U88'\+C.<YSPH]!CDW?#?AN6VE?4+QP]U*"OR$^6B9R$4'''
M))&<^^YF *O@.4))?6YR)%O97(((^63&QN1T;:2/;GH1GK:Y?Q!H=S#-_:6G
MLHE*;9(I.$D"@[3QCYQT!)'&!N !#5+NXU76!]G6%;16!W2M*)7 )'W-F,-C
M/7\&4X- %CX>?O8[BY7_ %=Q>3R1G^\I( ..HY4\$ ^U=7532M,32XDM8AA(
MU '3)QU)P ,D\DXY))JW0!RGAW_D(ZA_VZ_^BC75UR_B#0[F&;^TM/91*4VR
M12<)(%!VGC'SCH"2.,#< "&I:BVIZ^IL_(2UCD4K([R+,VTD A0G?&>HP>S*
M<&@"U\+?^0=!_P!M/_1KUU=5].LEL(DMTR5B15!/7"@ 9QCGBL?1_M_VN?[3
ML^R\>5MQGVQWZ??W?Q8V?+F@#=FA692C@%6!!!&00>""#U!KASI__"%W4/V?
M=]CNY!&\9.X)(1A&4LV?FQ\W7@'.?D F31[WPS([62K<6\TA=HY'VRJS [B)
M&X(R!RVYNV,Y8VK33[K7I%FOXUAB@D#QQ*P=BZCAV=3C"DG:!C)/S9 &X ZN
MBN?\6_;_ -S_ &?L_P!9^\WXZ=NO\/7=M^?IM[UT% !7&?#V*,2W[C'FF]E#
M<\[03LXSP,EL''//IQV=>:>&]%N&FO+^SE59!>3HT<H)B<!@03MY!7<Q!&>P
MX!;(!Z77'VI6/695C/W[-6D 8D;U<*I(S@$)C'L<]SF7^V=3N?W:6:1,>CRW
M"N@QSRL8W'/08[D$\9K0\->&O['\R621I9YV!DD88SC.T!<D*%!X'],  &;\
M/X5#7K@#<;^<$XY(&"!GT&3CZGUIGB\J]]I\4IQ&9)FP6*J715,9ZC)#' ]<
MX[X.AX0TN33_ +3YJ[?-O)I%Y!RK;=IX)QG'0\^U6O$OA]==B\EF9&5@\;H2
M&1USM88(SC/3\B#@@ UJX_XK%4L6E)VR1R1M$0Q5@X8#(P1DA2Q]NO;(?#J6
MJV"B*6WCN&P/WD4PB'I@JZCYN,D@!>0 !BBWT"ZUB>.[U JL<)#Q01,QP^<A
MI&XRR<#CY2>F!D, .\??\N?_ &$+?_V:M7Q9_P >=S_U[S?^@-57Q?I<FH?9
MO*7=Y5Y#(W(&%7=N/)&<9Z#GVK0\0VK7=M/#&,O)#(JC(&2R$ 9/'6@"'PG_
M ,>=M_U[P_\ H"UE> /^7S_L(7'_ ++6WX>M6M+:"&08>.&-6&0<%4 (R..M
M9_A#2Y-/^T^:NWS;R:1>0<JVW:>"<9QT//M0!T%8/BKPVVKJDL+F.Y@):)P>
M 3C*L.<JV,'@_0C*G>K$UV2]MW6:U5)8U5@\3'8[$D897.1QZ''&?O$C: 5=
M#\1SF;[!?Q+'*59D=&S'(%;!V@G((&#MR3C)(7@54FM5FUI'89,=CN7D\$RL
MF??AB.?7UJ73=/NM6N4O[R-8!;;Q%&K!V)D4*S,X.,?W0 #GKP/FM_V7)_:7
MVW;^Z^Q^7NR/O>;NQC.>G.<8]Z .@KE/ '_+Y_V$+C_V6NKKG_"&ER:?]I\U
M=OFWDTB\@Y5MNT\$XSCH>?:@#/\ A25>Q64'=)))(TI+%F+EB,G)."5"GWZ]
M\GL*Y2?P_<:/+)=V#*RS-ODMY20I;DLR/GY6;I@C;SDG 4"*YU75;T>5%:I
MS9_>2S+(JC!_A09SG&.&'J,<@ 9X/BCCU#41%C;O@)P<_,5<OSD\[R<CL>.,
M8J;X?PJ&O7 &XW\X)QR0,$#/H,G'U/K3/ _A230)[K>6=)?)*R.06=@K&0D
MDCYF/7GW/6M#PAI<FG_:?-7;YMY-(O(.5;;M/!.,XZ'GVH J>(O^0CI__;U_
MZ*%1>*[5;K4-.1QD!KANI'*(KJ>/0@'^?%:&LZ7)<WMG<HN8X/M&\Y QOC 7
M@G)R?0'WHUG2Y+F]L[E%S'!]HWG(&-\8"\$Y.3Z ^] '05RGAW_D(ZA_VZ_^
MBC75US^C:7);7MY<NN(Y_L^PY!SLC(;@'(P?4#VH J>"/W\E[<MS(UX\9/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH Q=3_P!?'_P'_P!"-;58NI_Z^/\ X#_Z$:VJ "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M: #XU_\ 'Y'_ ->Z_P#H<E>@?\*MT[_GC_Y$E_\ BZ\_^-?_ !^1_P#7NO\
MZ')6M_PHS_IY_P#(/_VR@#I?B/:K::5+#&,)&L*J,DX"R( ,GGI7*?"_P9::
MW;/-<Q[W$S*#O=> B'&%8#J373>/+'^S]':VSN\J.!,XQG:\8SC)QG'K53X*
M?\><G_7PW_H$= ')>*?#<O@&>.\M'8Q,1U)'*D,8W*[05;&0.,@$8^7)[7QO
MJBZKH[W2XQ*D+8!W8)D3*Y]5.0?<=!53XV3*+2-"1N,X(&>2 C@G'H,C/U'K
M6?+"T7AW# @X!P1CAKD$'Z$$$>HYH T_@I_QYR?]?#?^@1TSXF^$;:.VGU$(
M?/RAWEW/5U4\%B,8. ,8 Z8P*?\ !3_CSD_Z^&_] CK5^*7_ "#I_P#MG_Z-
M2@#*^"G_ !YR?]?#?^@1UV6L:-%K$?V><%HR02 S+G'3.TC([X/&<'J!7&_!
M3_CSD_Z^&_\ 0(Z] H \*U'2X]*UF.V@7;&EQ;8&2<9\LGDDGJ3WKW6O%/$O
M_(>7_KXM?Y1U[70!X/X.M4\7Z@SWI!WAW*DL-QZ!%.X, H.0 3A5QTZ/\:Z>
M/!NH)):?* J2*N6P.2I4G=DAMISR.&*]*Z7QWX -BTFLVDWE,-SL"Q4Y(.XJ
MX.<N2 %[DD @86N?^&6COX@O?MD[,XM]KLSL68MTC!);/&,]Q\NT\&@#V+6-
M&BUB/[/."T9() 9ESCIG:1D=\'C.#U KQC4=+CTK68[:!=L:7%M@9)QGRR>2
M2>I/>O=:\4\2_P#(>7_KXM?Y1T >UT444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9^M_<'
M^\/Y&N.KL=;^X/\ >'\C7'5Y^8_9^?Z'/B.@4445P'.%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !5K3M1:Q;<O0]1V/^>QJK13C)Q=UN--I
MW.[M+M;M1(AX/YCV-35C>']+:U!D?(+#[O\ 4^_\OY;->U1E*4$VK,[8-M78
M4445H4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8NF?Z
M^3_@7_H0K:K%TS_7R?\  O\ T(4 ;5%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &+J?\ KX_^ _\ H1K:K%U/_7Q_\!_]"-;5
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJD5NKH,<<-(=QSU.>Y('&*BN@L>LQ-(/OV;+&2I(WJY9@#C (3.?8X[C/84
M>=7GBN_TR6WT^Z"B22XA'FQ &.2,_+(/F'#9(S@#KP%&"VUXB_Y".G_]O7_H
MH57^(4L8EL$./--[$5XYV@C?SC@9*Y&>>/3BQXB_Y".G_P#;U_Z*% &?\6+*
M=[6299ML"K&&B\M3N/F#YM_4=1P/3WK;F6YTBSN))9_-E2.5U?RU3&$RHVC(
M.",\]<XJI\4O^0=/_P!L_P#T:E:OBS_CSN?^O>;_ - :@ TG5/\ 0X[V=O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTD&[ &X18VG Z<$#&3TR22:J> ]D2WEX=H22\G82' 5HU/#;^A4'=SG Y]Z
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MN_N-_NG^5 %71/N'_>/\A6A6?HGW#_O'^0K0H \4N?\ B<Z\/+XVW"YW<?\
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MAC&$C6%5&2<!9$ &3STKL** //\ X*?\><G_ %\-_P"@1UJ_%+_D'3_]L_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5TFAZ'Y6)I!\W8'M[GW_ )?7
MH:'H?E8FD'S=@>WN??\ E]>F[7H83"6]^7R1TTJ75A1117>;A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BZ9_KY/\ @7_H0K:K
M%TS_ %\G_ O_ $(4 ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% &+J?^OC_X#_Z$:VJQ=3_U\?\ P'_T(UM4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %9GB#_5C_>'\C6G69X@
M_P!6/]X?R- &G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!2UC_5-^'\Q1H_^J7\?YFC6/]4WX?S%&C_ZI?Q_F: +M9+Z0TTO
MFOC;GH,]!TZC\ZUJ*QKX>%:RELG<NG4E"]NH5GZMIOVS!7 8>OI^7^>:T**J
MM1A6@X2V8H3<)<RW,FZTZ6=$BRORCGD\XX';TJ!-(GC&T/@>@9A_2MVBN:>6
MTI2YFW>UM^QJL5-*VGW%73H'@4K(=QSUR3Q@>M6J**ZJ=-4XJ*V1C*3D[F)J
MNB/=W=K>*5V6WG;@2=Q\Q HQQCKUR1^-:>H:?'J,;6\RAHW&"#_G@CJ".0>1
MS5BBK$<?:Z!J.B*(+2:*6(9"K=*P9%!^4!HSEN#@YP!@;0!P'CPC/J\B3ZE*
MKI&2PMXD(A#= 26.YQCG##J2/NY!ZVB@ K)\6?\ 'G<_]>\W_H#5K54U:Q_M
M"&2VSM\V-TSC.-RD9QD9QGUH XWPWX7GT^VBN=/E"F6*-WAF!:%F:-06!'SH
M>I.,Y.!PHQ6A-H-_K2F"]FCCA((9;0-N<'L7DSM P.@.X$@UT6DV/]GPQVV=
MWE1HF<8SM4#.,G&<>M6Z *^GZ?'IT:V\*A8T& !_GDGJ2>2>3S7.-X2ETEFF
MTR18P[;F@E&8"2 ,C;\R=SQG)VCA0!75T4 <9=Z#J6MCR+J:** @AQ:AR[@D
M97,GW1C/(/?!5@>-/P;X:/A])H?EV/<2.@4DX0A0H)89R .>OU-=!10!R_Q)
MN4CLI(G4NTQ6.-!NR78Y7&T'D8W8Z-C;WK8T#1ET6".T3D1KC//)/+-@DXR2
M3C/&<#BJ^H^'5U&YAO)""ML'*)M_C?'S%B3P, J  0W.[M6Q0 5B>)]$?5?L
M_EE1Y%U%*VXD95,Y P#SSQT'O6W10 5R^H>$9(9VO["40R2#]XC)NBD(.1D9
M&TGD,PR>21@EMW444 <E-IVJZBIBEF@@4@_/;H[OZ8^<C YSN!W @8K=T+0H
MM#B%M ,*O4G[S'NQ/<G_ .L,  #0HH Y?XDW*1V4D3J7:8K'&@W9+L<KC:#R
M,;L=&QM[UL:!HRZ+!':)R(UQGGDGEFP2<9))QGC.!Q5?4?#JZC<PWDA!6V#E
M$V_QOCYBQ)X& 5  (;G=VK8H R?$'AJ+7559=RM&P9)(SMD0@@Y5L'&<<_@>
MH!&5]GU>V_=I);2J.CRI(CG//*Q_*,=!CL 3SFNKHH X)_A[//)#?3S"6Z2>
M%F9LJBQQ\LB*HP26YR0N>N%);/1:KHCW=W:WBE=EMYVX$G<?,0*,<8Z]<D?C
M6W10!B>,]$?6[22SB*AY-F"Y(7Y75CG )Z#TJ[KEDU_;S6Z8#2Q.H)Z992!G
M&>.:O44 9^DZ9]FMH[.4*VR%(V'53A K#D<@^XZ=JY^W\-7F@[HM.DB:!F)$
M=R'/EY[*RDD@DG@]..I+$]A10!Q\?A*XU>19M4D1TC;*00@^5G  9BV"W?Y3
MGKUVDJ>@US3Y+^/RX96A<,I#JH;[IS@@]0>XR,]#E<@Z%% ''S:!?ZV1!J#P
MBVZNEN'W.0595+.,J 1G*D'MWR.PHHH 9-"LRE' *L""",@@\$$'J#7)6_A:
M[T+<NGS(82Q*PW*L50-R<2*=W7H.F"2<MR>PHH X^X\+7>N[5U"9!"&!:&V5
M@KA>1F1CNZ]1TP 1AN1I>+O#[:K9O80;4+! H/RH CJ<?*#@8&!@5O44 %8F
MJZ(]W=VMXI79;>=N!)W'S$"C'&.O7)'XUMT4 %%%% !1110 4444 4-=_P!2
MWX?^A"BC7?\ 4M^'_H0HH X6Y^\?\]JBJ6Y^\?\ /:HJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "MWP=_KF_ZYG_T):PJW?!W^N;_KF?\ T):
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M R>Y&.:ZB&%85"( %4   8  X  '0"F?9$W^?M7S-NW=@;MN<[=W7&><=,T
M35RGP\_>QW%RO^KN+R>2,_WE) !QU'*G@@'VKJZAM;1+11%$JH@SA4 51DY.
M ..M '-?$W][9-;+_K+B2*.,?WF,BD#/0<*>20/>K'CK2Y;V!98,&6UE6=5(
M+;S&"=F%YR<\8ZGCC.1NW%HESM\Q5;8P9=P!PPZ,,]".QZU-0!@V7CBSNER9
M5C93ADF(B=6'52KD<CH<9&<@$XK%US7!XM#:5I[$Y($TP!\M$R=P#9&YFQ@
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M^K^9Y]72:'H?E8FD'S=@>WN??^7UZ;M%:T<%&$KMW*A047?<****ZS8****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%TS_7
MR?\  O\ T(5M5BZ9_KY/^!?^A"@#:HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH Q=3_U\?_ ?_0C6U6+J?^OC_P" _P#H1K:H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S/$'^K
M'^\/Y&M.LSQ!_JQ_O#^1H TZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *6L?ZIOP_F*-'_U2_C_,T:Q_JF_#^8HT?_5+^/\
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M., YQ0!U%%<_I/A^?2I1MN'EMRK;EN/WDF[C!5\ @8['('/!+97H* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"AKO^I;\/_0A11KO^I;\/_0A10!PMS]X_Y[5%4MS]X_Y[5%0 4444 %%%
M% !1110 4444 %%%4+[5EM_E'+?H/K_A_*@"_16;8ZTLORO\I]?X?_K5I4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %;O@[_7-_US/_ *$M85;O@[_7-_US/_H2T =C1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-W]
MQO\ =/\ *IJAN_N-_NG^5 %71/N'_>/\A6A6?HGW#_O'^0K0H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#/UO[@_WA_(U:M/N+_NC^55=;^X/]X?R-6K3[B_[H_E0!-1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%[_JW_P!UOY5/
M4%[_ *M_]UOY4 4_#_\ JS_O'^0K3K,\/_ZL_P"\?Y"M.@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%TS_ %\G_ O_ $(5M5BZ
M9_KY/^!?^A"@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=X^7#=5"DG"^HR<DD]\4 ;%I=+=HLT9RDBAE.",AAD'!YZ5R6@V@T34IK&'
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M^SYO[_\ X\W^%']GS?W_ /QYO\* -:BLG^SYO[__ (\W^%']GS?W_P#QYO\
M"@#6HK)_L^;^_P#^/-_A1_9\W]__ ,>;_"@#6HK)_L^;^_\ ^/-_A1_9\W]_
M_P >;_"@#6HK)_L^;^__ ./-_A1_9\W]_P#\>;_"@#6HK)_L^;^__P"/-_A1
M_9\W]_\ \>;_  H UJ*R?[/F_O\ _CS?X4?V?-_?_P#'F_PH UJ*R?[/F_O_
M /CS?X4?V?-_?_\ 'F_PH UJ*R?[/F_O_P#CS?X4?V?-_?\ _'F_PH UJ*R?
M[/F_O_\ CS?X4?V?-_?_ /'F_P * -:BLG^SYO[_ /X\W^%']GS?W_\ QYO\
M* -:BLG^SYO[_P#X\W^%']GS?W__ !YO\* -:BLG^SYO[_\ X\W^%']GS?W_
M /QYO\* -:BLG^SYO[__ (\W^%']GS?W_P#QYO\ "@#6HK)_L^;^_P#^/-_A
M1_9\W]__ ,>;_"@#6HK)_L^;^_\ ^/-_A1_9\W]__P >;_"@#6HK)_L^;^__
M ./-_A1_9\W]_P#\>;_"@#6HK)_L^;^__P"/-_A1_9\W]_\ \>;_  H UJ*R
M?[/F_O\ _CS?X4?V?-_?_P#'F_PH UJ*R?[/F_O_ /CS?X4?V?-_?_\ 'F_P
MH UJ*R?[/F_O_P#CS?X4?V?-_?\ _'F_PH UJ*R?[/F_O_\ CS?X4?V?-_?_
M /'F_P * -:BLG^SYO[_ /X\W^%']GS?W_\ QYO\* -:H;O[C?[I_E6?_9\W
M]_\ \>;_  ILUC*JDE\@ Y^8T 6-$^X?]X_R%:%8-E:R2KE&P,^I'\JL?V?-
M_?\ _'F_PH UJ*R?[/F_O_\ CS?X4?V?-_?_ /'F_P * -:BLG^SYO[_ /X\
MW^%']GS?W_\ QYO\* -:BLG^SYO[_P#X\W^%']GS?W__ !YO\* -:BLG^SYO
M[_\ X\W^%']GS?W_ /QYO\* -:BLG^SYO[__ (\W^%']GS?W_P#QYO\ "@#6
MHK)_L^;^_P#^/-_A1_9\W]__ ,>;_"@#6HK)_L^;^_\ ^/-_A1_9\W]__P >
M;_"@#6HK)_L^;^__ ./-_A1_9\W]_P#\>;_"@#6HK)_L^;^__P"/-_A1_9\W
M]_\ \>;_  H UJ*R?[/F_O\ _CS?X4?V?-_?_P#'F_PH UJ*R?[/F_O_ /CS
M?X4?V?-_?_\ 'F_PH UJ*R?[/F_O_P#CS?X4?V?-_?\ _'F_PH UJ*R?[/F_
MO_\ CS?X4?V?-_?_ /'F_P * -:BLG^SYO[_ /X\W^%']GS?W_\ QYO\* -:
MBLG^SYO[_P#X\W^%']GS?W__ !YO\* -:BLG^SYO[_\ X\W^%']GS?W_ /QY
MO\* -:BLG^SYO[__ (\W^%']GS?W_P#QYO\ "@#6HK)_L^;^_P#^/-_A1_9\
MW]__ ,>;_"@#6HK)_L^;^_\ ^/-_A1_9\W]__P >;_"@#6HK)_L^;^__ ./-
M_A1_9\W]_P#\>;_"@#6HK)_L^;^__P"/-_A1_9\W]_\ \>;_  H UJ*R?[/F
M_O\ _CS?X4?V?-_?_P#'F_PH UJ*R?[/F_O_ /CS?X4?V?-_?_\ 'F_PH UJ
M*R?[/F_O_P#CS?X4?V?-_?\ _'F_PH UJ*R?[/F_O_\ CS?X4?V?-_?_ /'F
M_P * -:BLG^SYO[_ /X\W^%']GS?W_\ QYO\* )M;^X/]X?R-6K3[B_[H_E6
M/?6LD2Y=LC/J3S@^M.ATZ=E!#X! Q\S?X4 ;E%8O]F3_ //3_P >;_"C^S)_
M^>G_ (\W^% &U16+_9D__/3_ ,>;_"C^S)_^>G_CS?X4 ;5%8O\ 9D__ #T_
M\>;_  H_LR?_ )Z?^/-_A0!M45B_V9/_ ,]/_'F_PH_LR?\ YZ?^/-_A0!M4
M5B_V9/\ \]/_ !YO\*/[,G_YZ?\ CS?X4 ;5%8O]F3_\]/\ QYO\*/[,G_YZ
M?^/-_A0!M45B_P!F3_\ /3_QYO\ "C^S)_\ GI_X\W^% &U16+_9D_\ ST_\
M>;_"C^S)_P#GI_X\W^% &U16+_9D_P#ST_\ 'F_PH_LR?_GI_P"/-_A0!M45
MB_V9/_ST_P#'F_PH_LR?_GI_X\W^% &U16+_ &9/_P ]/_'F_P */[,G_P">
MG_CS?X4 ;5%8O]F3_P#/3_QYO\*/[,G_ .>G_CS?X4 ;5%8O]F3_ //3_P >
M;_"C^S)_^>G_ (\W^% &U16+_9D__/3_ ,>;_"C^S)_^>G_CS?X4 ;5%8O\
M9D__ #T_\>;_  H_LR?_ )Z?^/-_A0!M45B_V9/_ ,]/_'F_PH_LR?\ YZ?^
M/-_A0!M45B_V9/\ \]/_ !YO\*/[,G_YZ?\ CS?X4 ;5%8O]F3_\]/\ QYO\
M*/[,G_YZ?^/-_A0!M45B_P!F3_\ /3_QYO\ "C^S)_\ GI_X\W^% &U16+_9
MD_\ ST_\>;_"C^S)_P#GI_X\W^% &U16+_9D_P#ST_\ 'F_PH_LR?_GI_P"/
M-_A0!M5!>_ZM_P#=;^59G]F3_P#/3_QYO\*9/I\R*2SY !R-S=,?2@"UX?\
M]6?]X_R%:=<YI]G+,I,;8&>F2.<#TJS_ &9/_P ]/_'F_P * -JBL7^S)_\
MGI_X\W^%']F3_P#/3_QYO\* -JBL7^S)_P#GI_X\W^%']F3_ //3_P >;_"@
M#:HK%_LR?_GI_P"/-_A1_9D__/3_ ,>;_"@#:HK%_LR?_GI_X\W^%']F3_\
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M3_\ /3_QYO\ "@#:HK%_LR?_ )Z?^/-_A1_9D_\ ST_\>;_"@#:HK%_LR?\
MYZ?^/-_A1_9D_P#ST_\ 'F_PH VJ*Q?[,G_YZ?\ CS?X4?V9/_ST_P#'F_PH
M VJ*Q?[,G_YZ?^/-_A1_9D__ #T_\>;_  H VJ*Q?[,G_P">G_CS?X4?V9/_
M ,]/_'F_PH VJQ=,_P!?)_P+_P!"%']F3_\ /3_QYO\ "J=M;222,BMAAG)R
M1G!YYZ]: .FHK%_LR?\ YZ?^/-_A1_9D_P#ST_\ 'F_PH VJ*Q?[,G_YZ?\
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MZ?\ CS?X4?V9/_ST_P#'F_PH VJ*Q?[,G_YZ?^/-_A1_9D__ #T_\>;_  H
MVJ*Q?[,G_P">G_CS?X4?V9/_ ,]/_'F_PH VJ*Q?[,G_ .>G_CS?X4?V9/\
M\]/_ !YO\* -JBL7^S)_^>G_ (\W^%']F3_\]/\ QYO\* -JBL7^S)_^>G_C
MS?X4?V9/_P ]/_'F_P * -JBL7^S)_\ GI_X\W^%']F3_P#/3_QYO\* -JBL
M7^S)_P#GI_X\W^%']F3_ //3_P >;_"@#:HK%_LR?_GI_P"/-_A1_9D__/3_
M ,>;_"@ U/\ U\?_  '_ -"-;5<S<VTD<BHS98XP<DXR>.>O6KG]F3_\]/\
MQYO\* -JBL7^S)_^>G_CS?X4?V9/_P ]/_'F_P * -JBL7^S)_\ GI_X\W^%
M']F3_P#/3_QYO\* -JBL7^S)_P#GI_X\W^%']F3_ //3_P >;_"@#:HK%_LR
M?_GI_P"/-_A1_9D__/3_ ,>;_"@#:HK%_LR?_GI_X\W^%']F3_\ /3_QYO\
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MG_YZ?^/-_A0!M45B_P!F3_\ /3_QYO\ "C^S)_\ GI_X\W^% &U16+_9D_\
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MLR?_ )Z?^/-_A1_9D_\ ST_\>;_"@#:HK%_LR?\ YZ?^/-_A1_9D_P#ST_\
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M[,G_ .>G_CS?X4?V9/\ \]/_ !YO\* -JBL7^S)_^>G_ (\W^%']F3_\]/\
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MC_F'_P"?^>E &"FFRN P1B#T(4X_E22V$D0W,C #N5('\JW=#UR:=DMU"[5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[!]6J]F;E%8?_"7Q?W7_ "'_ ,51_P )?%_=?\A_\51["IV#ZM5[,W*@O?\
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MS#_\_P#/2C_F'_Y_YZ5SOVI]OE[CM_NY..N>G3K1]J?;Y>X[?[N3CKGITZT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1K:K%U/_ %\?_ ?_ $(UM4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %9GB#_5C_ 'A_(UIUF>(/]6/]X?R- &G1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2UC_ %3?A_,4:/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,_6_N#_>'\C7"5W>M_<'^\/Y&N$KLP7VOD>AEWVOE^H4
M445V'H!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^?8I(+#/!QD>YQCI:* ,GQ3H7]O6SV6[9YFWYMN[&U@W3(],=:UJ** .:O\
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M([_ICI3QX/S_ ,M/_'?_ +*M9SK7T2M_7F>]2A@Y03E)I_UY,UE\2VX_C_\
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M9M0'!YW8&X ]#\GRLO7..>O)(VUS7B+7O[:F\QBPB!PHX)4<9.,@9/7KZ#.
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M5C0':F]R "Y&1A<]<< D#(!R*5K\.DNU#ZD[W,IR3ND<1J6.6"*I7 / ]\#
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M50!NGW<IC)QR5&.:[W1O!=GHS>;!$JO_ 'B6=AP1P7)(R"<XQGO6Q-"LRE'
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M 4444 %%%% !1110 5F>(/\ 5C_>'\C6G69X@_U8_P!X?R- &G1110 4444
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M\8XP =;16#X.UB34866?!FMY7AD*C"LT9^\/8@CL.<X &*Q=.$OC9I)GD9+
M.4CCCRAE"\,S,0&V,"05&/0X*Y8 [BN4\._\A'4/^W7_ -%&C_A7%M:_O+,O
M;RCH\;LWN%97)#+G!*\9QC-9OPZEGDNK[[5CSE,"L0" =BNH8 @<, &Z '.0
M .* .]HHKSKQ7I,FKZJEK&[(DEF!,R8W>7YC$@9_O$*O&>O(*Y! /1:*YR2S
MM?!-M-<PQA5 W$98EF^ZB[CN(!)P.PR3CK6?I_A%M>C6XU5FD9QN$(+1Q1YY
M4;1M8NH)!).>=IS@$@'9T5Q6I^#6T1#=:6SQM%\_D;G>*3 .X%"22S# &#V
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MX[4R&2RG(1#,XWQN$)5 >,JVW"@  '@8/WV^*2E_?PZ?=EEMI(6*@,Z)+*7
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M@8Z"K:?#VTC\M@&\R.993(3ND=E_O.P)(8\D# SR,5JWNB)=SPWC%M]MYFT
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M3@C)!'!!X/(JAX#B#R7UP<F1KV5"22?ECQL7D]%W$#VXZ 8ZJ&%85"( %4
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MYO\ &C_A&[?^Y_X\W^-'UR'9A_:%/L_Z^9P]%=Q_PC=O_<_\>;_&C_A&[?\
MN?\ CS?XT?7(=F']H4^S_KYG#T5W'_"-V_\ <_\ 'F_QH_X1NW_N?^/-_C1]
M<AV8?VA3[/\ KYG#T5W'_"-V_P#<_P#'F_QH_P"$;M_[G_CS?XT?7(=F']H4
M^S_KYG#T5W'_  C=O_<_\>;_ !H_X1NW_N?^/-_C1]<AV8?VA3[/^OF</17<
M?\(W;_W/_'F_QH_X1NW_ +G_ (\W^-'UR'9A_:%/L_Z^9P]%=Q_PC=O_ '/_
M !YO\:/^$;M_[G_CS?XT?7(=F']H4^S_ *^9P]%=Q_PC=O\ W/\ QYO\:/\
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M\(W;_P!S_P >;_&CZY#LP_M"GV?]?,X>BNX_X1NW_N?^/-_C1_PC=O\ W/\
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M]G_7S.'HKN/^$;M_[G_CS?XT?\(W;_W/_'F_QH^N0[,/[0I]G_7S.'HKN/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %9GB#_5C_>'\C6G69X@_P!6
M/]X?R- &G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!2UC_5-^'\Q1H_^J7\?YFC6/]4WX?S%&C_ZI?Q_F: +M<9;W8T?59DF
MP%OTB,3$D M$-GE],;CG/7^Z.K 5V=5-3TJ+5$,,Z*Z'LPS@X(R#U!P3@C!'
M8T 6ZX+4M>CO]8M;6,AOLXGW$'/S/&V5Z=5VC/)Y.#@@UH3?#F-U,0N+I8B"
M!&)_D"GC8 5/R@<8.>.M7[3P5;63P20J4^S&4JJG@F50K%BV6)P..>.!T %
M%+_F,_\ </\ _:]=76?_ &(GVG^T,MYGD^5C(V[=^_.,9SGWQCM6A0!RG@#_
M )?/^PA<?^RU7^&MV+6)M(DPL]H[@KD_,I8L) "!\IW8'M@G&X5T>D:(FE>;
MY98^?,\K;B#AGQD# ''''4^]0ZWX8@UG#2K^\7&V1#MD4C.TAQSP3D Y&><4
M :<TRPJ7<@*H)))P !R22>@%</\ #_65UF\O[J/[C- %Z\A%= W(!&0,XQQG
M%7G^&T-P0+B:XG13G9-,63." > #D9XP1^616UIOA^+3I9;B/(,XB!7@(HB7
M8H4 # Q]?;% &G7*?\QG_N'_ /M>NKK/_L1/M/\ :&6\SR?*QD;=N_?G&,YS
M[XQVH S_ !]ICZG8S01#+E00.23L8.0  220N .YQ5WPYKT>NP)=1D?,!N .
M=K8^93P.1]!D8(X(K3KG-0\!V]S(US&9()I#EGMY#&S>H(Y7!.">,DC)/7(!
MH>(]>CT*![J0CY0=H)QN;'RJ.#R?H<#)/ -4O .F/IEC#!*,.%)(Y!&]BX!!
M ((#8(['-,T_P';VTBW,ADGFC.5>XD,C+Z #A< Y(XR"<@],='0!YO<:HWAA
M)]$3/F2'_0P#M)6X8K@-S@QN2=SL"WL,5W&@:,NBP1VB<B-<9YY)Y9L$G&22
M<9XS@<5S^GS'7=2>?'[BP5HT)R,S/@2$?*,X *D$D#AA][-=A0!QGPUNQ:Q-
MI$F%GM'<%<GYE+%A( 0/E.[ ]L$XW"NPFF6%2[D!5!)).  .223T K,UOPQ!
MK.&E7]XN-LB';(I&=I#CG@G(!R,\XK(?X;0W! N)KB=%.=DTQ9,X(!X .1GC
M!'Y9% %'X?ZRNLWE_=1_<9H O7D(KH&Y (R!G&.,XK0\._\ (1U#_MU_]%&M
MC3?#\6G2RW$>09Q$"O 11$NQ0H &!CZ^V*?9:(EI/->*6WW/E[@2-H\M=HQQ
MGIUR3^% &)_S&?\ N'_^UZ/$7_(1T_\ [>O_ $4*V_[$3[3_ &AEO,\GRL9&
MW;OWYQC.<^^,=J+W1$NYX;QBV^V\S: 1M/F+M.>,].F"/QH Y?XDZ?$[VMU=
M*6M8GD64+NR/-4!&^7!VAE&><\@ $G%6X?AGIDRATB!5@"")9""#R""'Y!KJ
MIH5F4HX!5@001D$'@@@]0:Y?_A7D<7RP3W,,8Z1Q3D(OK@$,>3DGGJ30!2M?
M#.E6EXEI%&?M*#S!M:5@FT@KN.X@$]0#QTS]Y0W4:MI<&M*;2X57 VL5)PPY
M.UN"",X(R,9Y'3-0^'O#$'A]#%;KC=C<Q.68@8R3_08 ). ,U7UCP=#J,GVD
M-)#,0 9(',;LH_A/4$=.V> ,X&* ,WPS$VA7;Z1YCRQ&W66,RD%D"MY93..0
M>".@7& .23V%9/A_PU%H2LL6YFD8L\DAW2.22<LV!G&>/Q/4DG6H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:[
M_J6_#_T(44:[_J6_#_T(44 <+<_>/^>U15+<_>/^>U14 %%%% &#K\&QP_\
M>'ZC_P"MBNTTR\^UQK+_ 'ASCIGH>OO7.:Q!YL9]5Y_+K^E3^#KS<K0G^$Y'
M/8]<#T!_G6U"5I6[G1A96E;N=2K5*K565JE5JZ&CJ:+"M6/KWAA-4S(ORRXX
M/8^F[^61S]< 5J!J>&K.4;F<H)GG;6MWH#%UW*!U9>4/4#/4=^ >1GH*NIX_
MN% !"' ZE3D^_# ?E7<AJJOI<,A+&-"2<DE%))/X5G[-K9F/LFMF<@_C^X8$
M (,CJ%.1[\L16<5NM>;<=TG)&>B X&1V4< >F?K7H*:7#&0PC0$'((1001WZ
M59+4>S;W8>Q;W9Q=[X):W@+*=\H()QQP <@#N<\^X' !X/.06$D[^4JDN#R,
M<CG'/I@]<]*]5+4PM3=%,;H)D5K#]F18LYV*HSTS@8S3F:AFJ-FK9(Z8Q(YY
MA$"[<!02?H*X'3P;R8R-CJ6/USV_$UTOBJ]\B$H.KG'7!QU/U'8_6LC0(-B%
M_P"\?T'_ -?-8UWJD<V*EJHFG1116!S!1110 4444 %%%% !74^#(BH=B" V
MW!QP<;LXKEJZ[PA>&5&B.,1XQZ_,6)S0!2\*V[03%7!4^6>&!!^\/6LV^M7G
MFEV*6Q(V=H)_B/I6SH.I-J%P9' !$1'RYQ]X'N3ZT:AXH-I(8HU4HIYZ@DYR
MWICGV///- ',NA0E3P1U!ZTL41E.U023V R:Z7Q4BW$4=R.IQCIG# MS],>O
M<U9TFS:Q@$D:!Y7&>PP&Y')P< 8R/7\P <G/:O!C>I7/3<"/YTV*(RG:H))[
M 9-=K:M-=9BN8AL8=01^HW$_0CH?S&)IMG]CO!%U"EL?0H2/3G!YH R!92$%
MMK87.3M.!CKGTQ3(HC*=J@DGL!DUT7B36#$6M$ "X&XXP<M\QQ@]#GGCGFK,
MLJ^'8E50#(_7D\D#DYQT!/ XZ^N: .7DLI(B%96!;H"I!/T]:22U>,A&4ACT
M!!!.>.E='IGB@W3B*55PQ&",\'MP<YYQCICK2:Y_Q]P_]L__ $,T <\;*16$
M95MQZ#:<_E23VKP8WJ5STW C^==?KNM_V:0J*"[#J>P!X^O?OQ46F:FNN*T$
MJC<!GCGKD9&0<$9'<]: .0JQ%822C<J,0>X4D?RJ]HVE>=<>4^"(R2WH=IQC
MD<@G]*Z&[N+F-MD,2[%X&2.WL&&!Z#_]0 .(J7[*^WS-IV_WL''7'7IUKI/$
MFG^=&+HKLD&-PR#QT[9!(.,'CCKV ;_S#_\ /_/2@#FXHC*=J@DGL!DU<TRU
M<3HNTY5U)&#D#(Y/H*E\-?\ 'PG_  +_ -!-:,UX;6^.W'SE%.?0A?UH C\7
MV[-() #M"#)P<?>/>J_B&Z^T>7^[,>U<?,,>G XZ#M]>@J_XLU)HS]F &UE!
M)YS]X^_MZ4GC7_EG_P #_P#9: .;BB,IVJ"2>P&33YK*2 ;G5E'JRD#]:ZB6
M5?#L2JH!D?KR>2!R<XZ G@<=?7-4XO&!8,)4# C@#@>X.<\8_P \\ '.U--9
M20#<ZLH]64@?K6GX9D03[FP,@[>N,GM^60,_SK9U+59;/>)(PR'.TCE>>/F_
M/VR>!UR #C:*** "BBB@ HHHH **** "MWP=_KF_ZYG_ -"6L*M7PY,T4A*#
M)V'L3W'I0!W-%9/]H3?W/_'6_P :/[0F_N?^.M_C0!K45D_VA-_<_P#'6_QH
M_M";^Y_XZW^- &M3)HA*I0YPP(."5//H000?<'([5F?VA-_<_P#'6_QH_M";
M^Y_XZW^- %[3]/CTZ-;>%0L:#  _SR3U)/)/)YJQ63_:$W]S_P =;_&C^T)O
M[G_CK?XT :U%9/\ :$W]S_QUO\:/[0F_N?\ CK?XT :U%9/]H3?W/_'6_P :
M/[0F_N?^.M_C0!K45D_VA-_<_P#'6_QH_M";^Y_XZW^- &M163_:$W]S_P =
M;_&C^T)O[G_CK?XT :U%9/\ :$W]S_QUO\:/[0F_N?\ CK?XT :U%9/]H3?W
M/_'6_P :/[0F_N?^.M_C0!K45D_VA-_<_P#'6_QH_M";^Y_XZW^- &M163_:
M$W]S_P =;_&C^T)O[G_CK?XT :U%9/\ :$W]S_QUO\:/[0F_N?\ CK?XT :U
M%9/]H3?W/_'6_P :/[0F_N?^.M_C0!K45D_VA-_<_P#'6_QH_M";^Y_XZW^-
M &M163_:$W]S_P =;_&C^T)O[G_CK?XT :U%9/\ :$W]S_QUO\:/[0F_N?\
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MD_VA-_<_\=;_ !H_M";^Y_XZW^- &M163_:$W]S_ ,=;_&C^T)O[G_CK?XT
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M_&@#:J"]_P!6_P#NM_*LS^TY_P#GG_XZW^-,GU"9U(9, @Y.UNF/K0!:\/\
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MM.?_ )Y_^.M_C0!M45B_VG/_ ,\__'6_QH_M.?\ YY_^.M_C0!M45B_VG/\
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M_:<__//_ ,=;_&C^TY_^>?\ XZW^- &U16+_ &G/_P \_P#QUO\ &C^TY_\
MGG_XZW^- &U16+_:<_\ SS_\=;_&C^TY_P#GG_XZW^- &U16+_:<_P#SS_\
M'6_QH_M.?_GG_P".M_C0!M45B_VG/_SS_P#'6_QH_M.?_GG_ ..M_C0!M45B
M_P!IS_\ //\ \=;_ !H_M.?_ )Y_^.M_C0!M45B_VG/_ ,\__'6_QH_M.?\
MYY_^.M_C0!M45B_VG/\ \\__ !UO\:/[3G_YY_\ CK?XT ;5%8O]IS_\\_\
MQUO\:/[3G_YY_P#CK?XT ;5%8O\ :<__ #S_ /'6_P :/[3G_P">?_CK?XT
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MM.?_ )Y_^.M_C1_:<_\ SS_\=;_&@#:HK%_M.?\ YY_^.M_C1_:<_P#SS_\
M'6_QH VJ*Q?[3G_YY_\ CK?XT?VG/_SS_P#'6_QH VJ*Q?[3G_YY_P#CK?XT
M?VG/_P \_P#QUO\ &@#:HK%_M.?_ )Y_^.M_C1_:<_\ SS_\=;_&@#:HK%_M
M.?\ YY_^.M_C1_:<_P#SS_\ '6_QH VJ*Q?[3G_YY_\ CK?XT?VG/_SS_P#'
M6_QH VJ*Q?[3G_YY_P#CK?XT?VG/_P \_P#QUO\ &@#:HK%_M.?_ )Y_^.M_
MC1_:<_\ SS_\=;_&@#:HK%_M.?\ YY_^.M_C1_:<_P#SS_\ '6_QH VJ*Q?[
M3G_YY_\ CK?XT?VG/_SS_P#'6_QH VJ*Q?[3G_YY_P#CK?XT?VG/_P \_P#Q
MUO\ &@#:HK%_M.?_ )Y_^.M_C1_:<_\ SS_\=;_&@#:HK%_M.?\ YY_^.M_C
M1_:<_P#SS_\ '6_QH MZ[_J6_#_T(45F:A?32H5=,*<9.UAW'K10!S%S]X_Y
M[5%4MS]X_P">U14 %%%%  R[N#T-8>C2FPN AS@DJ>.N>G7WP?I6Y6#K\&QP
M_P#>'ZC_ .MBG%V=QQERM,[E6J16K/TZ\^U1K)_>'./7OU]ZMAJ[]U<]3=7+
M :GAJKAJ>&J6B7$G#TN^H ]+OI6%RDV^D+U%OHWT6#E)"U,+4PM32U-(:B.9
MJC9J0M44D@49/ 'K5)%I')>++OS91'V0?J>3^F*T[6'R55/0#IZ]ZP[5C?S^
M8<_>+=<XQT'X<#Z5T%<,Y<TFSRZDN:384445)(4444 %%%% !1110 5T_@K_
M ):?\ _]FKF*E@NG@SL8KGKM)'\J -CP=_KF_P"N9_\ 0EK,U3_72?\ 71__
M $(U##<- =R$J?520?TIKN7)8\D]2>M '2ZY_P >D/\ VS_] -6M)O&OH!'&
MX25!CL<A>!P<G!&,GU_(\G)=/( C,2HZ DD#''2F(Y0AAP1T(ZT =BMK=J&9
MYE&!D?*"/Q)48'YUC:-<-<7:NYW$[N0, X0@=A_*LN:]DG&UV9AZ,Q(_6F12
MF([E)!'<'!H T?$O_'P__ ?_ $$5M2Q+XBB5E($B=>#P2.1C/0D<'GIZYKE)
M93*=S$DGN3DT12F([E)!'<'!H Z73/"YM7$LK+A2, 9Y/;DXQSC'7/2DUS_C
M[A_[9_\ H9KGI+V24AF9B5Z$L21]/2IK.Z,DT;R,3AUY8YP V>I[4 =1KNB?
MVD0R, ZCH>X)X^G?MS4.G:<N@JUQ,P)(QQGUZ#/4GCL,8],FLWQ->AIEDB;H
M@Y1O=NXK'FN&G.YR6/JQ)/ZT :6C:KY-QYKX D)#>@W'.>3P ?TKH;NWN9&W
MPRKL;D9 [^X4Y'H?_P!9XBIH;V2 ;49E'HK$#]* -OQ$\UL/*>4.'QQM"MP<
MYX'3CUY].#5C1"NI6YLR<,,_7&[<#CTSP?Z9%<P[ER6/)/4GK0CE"&'!'0CK
M0!U6C^'38/Y\K#" XP>.A!)) X _SZY+W8N[L2KT,J8^@(&?QQFL^:]DG&UV
M9AZ,Q(_6HT<H0PX(Z$=: -OQC_KE_P"N8_\ 0FJUXU_Y9_\  _\ V6N<FN&G
M.YR6/JQ)/ZTL]T\^-[%L=-Q)_G0!U,L2^(HE92!(G7@\$CD8ST)'!YZ>N:IQ
M>#RH8RN% '!'(]R<XXQ_GCG BE,1W*2".X.#3YKV2<;79F'HS$C]: +VC:.-
M09DW !1VZGL" <<>OX#C/'2V,<EE&PNF5D'<DDX/4'(Y]NI[>E<0CE"&'!'0
MCK4DU[).-KLS#T9B1^M $-%%% !1110 4444 %%%% !6[X._US?]<S_Z$M85
M;O@[_7-_US/_ *$M '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5#=_<;_=/\JFJ&[^XW^Z?Y4 5=$^X
M?]X_R%:%9^B?</\ O'^0K0H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UO[@_P!X?R-58/$4
M<:A2&X '0=A]:M:W]P?[P_D:Y.O/S+%5*')R];_H=F"P\*W-S=+'2_\ "2Q^
MC?D/\:/^$EC]&_(?XUS5%>=_:N(\ON.W^SZ/F=+_ ,)+'Z-^0_QH_P"$EC]&
M_(?XUS5%']JXCR^X/[/H^9TO_"2Q^C?D/\:/^$EC]&_(?XUS5%']JXCR^X/[
M/H^9TO\ PDL?HWY#_&C_ (26/T;\A_C7-44?VKB/+[@_L^CYG2_\)+'Z-^0_
MQH_X26/T;\A_C7-44?VKB/+[@_L^CYG2_P#"2Q^C?D/\:/\ A)8_1OR'^-<U
M11_:N(\ON#^SZ/F=+_PDL?HWY#_&C_A)8_1OR'^-<U11_:N(\ON#^SZ/F=+_
M ,)+'Z-^0_QH_P"$EC]&_(?XUS5%']JXCR^X/[/H^9TO_"2Q^C?D/\:/^$EC
M]&_(?XUS5%']JXCR^X/[/H^9TO\ PDL?HWY#_&C_ (26/T;\A_C7-44?VKB/
M+[@_L^CYG2_\)+'Z-^0_QH_X26/T;\A_C7-44?VKB/+[@_L^CYG2_P#"2Q^C
M?D/\:/\ A)8_1OR'^-<U11_:N(\ON#^SZ/F=+_PDL?HWY#_&C_A)8_1OR'^-
M<U11_:N(\ON#^SZ/F=+_ ,)+'Z-^0_QH_P"$EC]&_(?XUS5%']JXCR^X/[/H
M^9TO_"2Q^C?D/\:/^$EC]&_(?XUS5%']JXCR^X/[/H^9TO\ PDL?HWY#_&C_
M (26/T;\A_C7-44?VKB/+[@_L^CYG2_\)+'Z-^0_QH_X26/T;\A_C7-44?VK
MB/+[@_L^CYG2_P#"2Q^C?D/\:/\ A)8_1OR'^-<U11_:N(\ON#^SZ/F=+_PD
ML?HWY#_&C_A)8_1OR'^-<U11_:N(\ON#^SZ/F=+_ ,)+'Z-^0_QH_P"$EC]&
M_(?XUS5%']JXCR^X/[/H^9TO_"2Q^C?D/\:/^$EC]&_(?XUS5%']JXCR^X/[
M/H^9TO\ PDL?HWY#_&H[CQ#'(K* V2".@[CZUSU%']JXCR^X/[/H^9M:7K*6
MBE6!R3G@#T'O5O\ X26/T;\A_C7-44?VKB/+[@_L^CYG2_\ "2Q^C?D/\:/^
M$EC]&_(?XUS5%']JXCR^X/[/H^9TO_"2Q^C?D/\ &C_A)8_1OR'^-<U11_:N
M(\ON#^SZ/F=+_P )+'Z-^0_QH_X26/T;\A_C7-44?VKB/+[@_L^CYG2_\)+'
MZ-^0_P :/^$EC]&_(?XUS5%']JXCR^X/[/H^9TO_  DL?HWY#_&C_A)8_1OR
M'^-<U11_:N(\ON#^SZ/F=+_PDL?HWY#_ !H_X26/T;\A_C7-44?VKB/+[@_L
M^CYG2_\ "2Q^C?D/\:/^$EC]&_(?XUS5%']JXCR^X/[/H^9TO_"2Q^C?D/\
M&C_A)8_1OR'^-<U11_:N(\ON#^SZ/F=,OB2(G&&'O@?XUJJP89'(-<)6II&K
MFT.Q^4/Z?_6]1^(]^G"YJW*U39]3#$9>E&\-^QU%%(K!AD<@TM>P>:%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BZ9_KY
M/^!?^A"MJL73/]?)_P "_P#0A0!M4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 8NI_P"OC_X#_P"A&MJL74_]?'_P'_T(UM4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9GB#_5C
M_>'\C6G69X@_U8_WA_(T :=%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% %+6/]4WX?S%&C_P"J7\?YFC6/]4WX?S%&C_ZI?Q_F
M: +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN<#CL/?_ #TK6J.W@$"A%Z"I*Q.<**** "BBB@ HHHH **** "BBB@ HHHH
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MPE]S>?O+.S>6+L\DBP;NX95<$E2""&XSG&.*-+\?I-,MA=1/;W#9P),%"=Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -32-7-H=C\H?
MT_\ K>H_$>_3JP89'(-<)6II&KFT.Q^4/Z?_ %O4?B/?U,OS#V=J<]NC[?\
M .#&8/G]^._5=SJ**16##(Y!I:]P\H**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "L73/]?)_P+_T(5M5BZ9_KY/^!?\ H0H VJ**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,74_\
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M3M8?=)QGFM"N2BE&F:L\9SMOH%8$@G,D.5VJ0, !.3G/..1D @'533+"I=R
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M-&SLT(>/826=V<HL8 4XSC.<^P!. 7ZA?7%Y8W37,(@(@E"CS1(3^[;)^4
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M93J0&MHU8$88'8!T8'#*>1D<$5D:9J-YX906ES \\47R1RVP5F*@#8#%D$8
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M7=& ,GH,GIGK4_B[PV=;C4QL$G@<21.0#AEYP<@_*>,^X!(.,$ WJ8\*N02
M2IR"1G!P1D>AP2/H2*Y?_A,)[']U=6DQD'\5LOG1L.FX'(*Y(/RGD#&>M&FZ
MIJ&KRK*(EM[56Y$P)F<?,/NC&SL><8.""ZY! .KKC_&=L-0N["RDYB>25V7
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MAB%H;2W1P0RP1 @C!!" $$'H16G0!RGAW_D(ZA_VZ_\ HHT?%+_D'3_]L_\
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M<D!@>F-PS@@5VOP4_P"/.3_KX;_T".N4\2_\AY?^OBU_E'0!U?QK_P"/./\
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M1II#A(U+,<$X"C).!STKQWP'8-XJU&34I =D3^9@MNPQ)\I,Y!PN,CC&$VD
M&NH^,NM_9+5;,#FY;DD<!8RK'OUSM[$8ST.*Y?PYX U-X$FMYQ#'* X432+]
MX<,0@(R1COG& <'@ $3Q#P'JP)R(&.1@G_529'(!8D(>QY8H#QD&O:IIEA4N
MY 50223@ #DDD] *\/\ &'@C4+*'[7=S"9(R!_K7<KO(&<.!P3@''/3C R/0
M/ =ZOB33?L[Y&U&@8KQP$ !&=W.QAR?XL\8H W?^$LL_^?B'_O\ )_\ %5K5
MY_\ \*4L_P"_-_WTG_QNK?Q0U:\TB*.ZM'VHK$2816/S8V'YE8  @C.1R0.<
M\ %'XGPZE-E+0,;5HE#B,*6+%B",#]X01C..,9SQFL_X*W-MB2(*1=8R6/.4
MR!A3CY0"1D=2<')'"Z>A?%RU:W#73,LZ+AE"DERH^\"H"C=Z';@\=,$\I\.8
MWUK5&U!5VHK2R-G) \W< N<8SEN^,@$]L4 :?C#P9=:3>?VO8*7!<2%4W%@Q
M(W J#N97)).WL6!  !/-7>M7/Q N8+63:O) "+@ 'EW^9LDA5SC/; &3SZE\
M2?$W]AVC;#B6;*)@X(S]YN""-HZ$9PQ7/6N?^#'ASR(WU)_O2Y1/]U3\QX/=
MACD9&WC@T =ZVB0/$EJ\:M%&%"JZAP-HVC[V>0.,]:YWQIXKA\(P?9X JRNK
M>6D84!<Y_>$8P #DXQ\QX_O$:OBSQ9%X;B\Z7EFR$0'YF/\ 0#N>WN2 ?$/[
M3'B6[\_49O+0]2%9L*.D:* V.O!/ Y8[FX8 [?X*^'V02:DV0&'EH.F1D%VY
M'(R  0>H8$5Z1JNIII<3W4IPD:DGIDXZ 9(&2> ,\D@5E>&?%-EJ&+*S?=Y4
M8PNV085<*.7 SC('7-<5\9_$WW-,C/H\N#_WPIP?^!$$?W"* ,_X5Z&VMW;Z
MI/\ ,(V+9(&&E?)SC;CY<EN,%24(XKV6L3P;H0T2TBM\8?:&?H3O;ELE>#@\
M \\ #)Q6W0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 9^M_<'^\/Y&N3KK-;^X/]X?R-<G7CYS_ ,N_G^AZ
M66?;^7ZA1117CGI!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 445J:1I!NSO?A!^O_UO4_@/;2C1G5FHQW(J5(TX\SV+WAOS-IS_ *OMGU[X
M]O7WZ=ZVJ15"C X I:^GP]'V--0O>QX5:I[2;E:UPHHHK4S"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "L73/]?)_P+_T(5M5BZ9_KY/^
M!?\ H0H VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** ,74_\ 7Q_\!_\ 0C6U6+J?^OC_ . _^A&MJ@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K,\0?ZL?[P_D:TZS/$'^K'^\/
MY&@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH I:Q_JF_#^8HT?_ %2_C_,T:Q_JF_#^8HT?_5+^/\S0!=KC_B WV!K34LL/
ML]P Y W*(Y1B0D8)Z  'WXY(KL*Q/&NF?VG93P88DQDJ$Y8LGSJ ,'.2H&.I
M[<T 9]G_ ,3G49)CS'8+Y<>.5,DHS(=PQRHPA4[L=>#3?%L0TRYMM6&0%<0R
M\D+Y<F<,QS@*C'/(Y)&2,"KO@;3'L;56F'[^=FEEZ@EI#GD$#:0, @  $'ZF
M[XET<:Q;2VAQF1"%R2 &'*$D<X# '^AZ4 87AYO[2U*[O,L5@5($.,+_ 'I5
MZ DJX]>A[@K1J%L-0U>&.3E+>U:5%P,;VDV$G(STP1Z$ COF[X!T^2TM0\ZE
M9YW>67/!+.QY(Z*=N. !CN <TWQ;X>DNFCU"T*BZML[0P&UU(P8R>O3.TY &
M3TSN !TM<?XWMA;SV5\G$HNDBR .4ER&!R,],XYXW$CDY$O_  F\D'R3V5R)
M!U$2"9/48D! /&,\<'([5%8:-<ZW=)J%^BQ);9\F$%9#N8#,C...N-H&"" >
M,9< )K59M:1V&3'8[EY/!,K)GWX8CGU]:VO%G_'G<_\ 7O-_Z U4/LC_ -K>
M?M;R_L.W=@[=WG9V[NF<<XZXK2\3PM-:7"("6:"4  9))0@  =2: ./UU#<:
M;86A)"7+V<;XQG:R9X)!P<@'/MZ9%>@0PK"H1  J@  #  '   Z 5S1\,+K6
MFQ6,P*-Y$."5^9'5!S@]".A'!P2,C-10^);O2%$-[;22L  );11(KXZDK\I0
M\CJ,,<E0 * +OCW3$U"QG60?<C:13QD-&"P(R#C.,'O@D9YJD^CG6-(2U&2S
M6D14 @9945E&3Q@L #[=QUK'\37-[XLADAB@>"W569C,O[V0HH=8UCZC+=QG
M..N04/9>&(6AM+='!#+!$"",$$( 00>A% '-:KXH;5-*69 /.O (54C +N3&
MX'/ X8J6..!GTIFE:8OA;44M8@WD7EN /N<R0#DG !'R<DX^9G)_W32O#$D&
MIO(RL+>-I9HWR/FDN5174^H&UL  $8!8D$9T_B%H[WUN)X%)N;9UDBVA2V5(
MR.0<C'.T=2J]>A (O#B'4[ZZU$D[8C]F13@8V8:3( Y!?E3G."<@<8=_S&?^
MX?\ ^UZU?"NB?V):Q6><F-?F.<C<Q+-C@<9)QQG&,\U0^R/_ &MY^UO+^P[=
MV#MW>=G;NZ9QSCKB@"IJ%L-0U>&.3E+>U:5%P,;VDV$G(STP1Z$ COGL*YSQ
M1X;DOI(KZU94NK<G:7&496X96(!;&"<8Z9.,$[A7_P"$WD@^2>RN1(.HB03)
MZC$@(!XQGC@Y':@"K\0=,1IK&\Q^\6\ACR,<JS;L'C)P5XYP,GCFJGBN2:75
M(%CA^T?9[<RK'O2,!F<H7+.#G&%P.H(!'0YI:I9WVMSVFHSQ&...YA"0J-[J
MK$,\KL!P/E P0,=P",MU7BK0YIV2_LF"W4 ( .-LB'!,;'CCC*Y. <]"=R@%
M?_A(M1_Y\/\ R:B_PJKIL-W/?I>O9K &C=)7\Y)"PP&0X4CD%0,X.0<'@#%B
M;QY)$I4V5UYJ@Y BW)N'82 G*Y_B Y'(':KOAJWO)'DO+P[/,P$@4JRHJDX)
M89RQSR0<$=?X50 Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** *&N_ZEOP_P#0A11KO^I;\/\
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M@%5+GP9:74XOWCS.&5MV]QRF-IP&QQ@=OK6W10!GZWH$&MH(;E=Z!@P&YEY
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q=3_ -?'_P !
M_P#0C6U6+J?^OC_X#_Z$:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^>C?K_C1_9K_ //1OU_QH T**S_[-?\ YZ-^O^-']FO_ ,]&_7_&@#0HK/\
M[-?_ )Z-^O\ C1_9K_\ /1OU_P : -"BL_\ LU_^>C?K_C1_9K_\]&_7_&@#
M0HK/_LU_^>C?K_C1_9K_ //1OU_QH T**S_[-?\ YZ-^O^-']FO_ ,]&_7_&
M@#0HK/\ [-?_ )Z-^O\ C1_9K_\ /1OU_P : -"BL_\ LU_^>C?K_C1_9K_\
M]&_7_&@#0HK/_LU_^>C?K_C1_9K_ //1OU_QH T**S_[-?\ YZ-^O^-']FO_
M ,]&_7_&@#0HK/\ [-?_ )Z-^O\ C1_9K_\ /1OU_P : -"BL_\ LU_^>C?K
M_C1_9K_\]&_7_&@#0HK/_LU_^>C?K_C1_9K_ //1OU_QH T**S_[-?\ YZ-^
MO^-']FO_ ,]&_7_&@#0HK/\ [-?_ )Z-^O\ C1_9K_\ /1OU_P : -"BL_\
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MV2?V'#_=_5O\:/[#A_N_JW^-1_V5)_SU;]?_ (JC^RI/^>K?K_\ %4?5:/\
M)'[D'MZO\S^]DG]AP_W?U;_&C^PX?[OZM_C4?]E2?\]6_7_XJC^RI/\ GJWZ
M_P#Q5'U6C_)'[D'MZO\ ,_O9)_8</]W]6_QH_L.'^[^K?XU'_94G_/5OU_\
MBJ/[*D_YZM^O_P 51]5H_P D?N0>WJ_S/[V2?V'#_=_5O\:/[#A_N_JW^-1_
MV5)_SU;]?_BJ/[*D_P">K?K_ /%4?5:/\D?N0>WJ_P S^]DG]AP_W?U;_&C^
MPX?[OZM_C4?]E2?\]6_7_P"*H_LJ3_GJWZ__ !5'U6C_ "1^Y![>K_,_O9)_
M8</]W]6_QH_L.'^[^K?XU'_94G_/5OU_^*H_LJ3_ )ZM^O\ \51]5H_R1^Y!
M[>K_ #/[V2?V'#_=_5O\:/[#A_N_JW^-1_V5)_SU;]?_ (JC^RI/^>K?K_\
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MG_/5OU_^*JX4H0^%)>B)E4G/=M^IIT5F?V5)_P ]6_7_ .*H_LJ3_GJWZ_\
MQ562:=%9G]E2?\]6_7_XJC^RI/\ GJWZ_P#Q5 &G169_94G_ #U;]?\ XJC^
MRI/^>K?K_P#%4 :=%9G]E2?\]6_7_P"*H_LJ3_GJWZ__ !5 &G169_94G_/5
MOU_^*H_LJ3_GJWZ__%4 :=%9G]E2?\]6_7_XJC^RI/\ GJWZ_P#Q5 &G169_
M94G_ #U;]?\ XJC^RI/^>K?K_P#%4 :=%9G]E2?\]6_7_P"*H_LJ3_GJWZ__
M !5 &G169_94G_/5OU_^*H_LJ3_GJWZ__%4 :=%9G]E2?\]6_7_XJC^RI/\
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ME2?\]6_7_P"*H_LJ3_GJWZ__ !5 &G169_94G_/5OU_^*H_LJ3_GJWZ__%4
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MOU_^*JGJEDT"AF<L,]#GT//4T ;]%9G]E2?\]6_7_P"*H_LJ3_GJWZ__ !5
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M !5 &G169_94G_/5OU_^*H_LJ3_GJWZ__%4 :=%9G]E2?\]6_7_XJC^RI/\
MGJWZ_P#Q5 &G169_94G_ #U;]?\ XJC^RI/^>K?K_P#%4 :=%9G]E2?\]6_7
M_P"*H_LJ3_GJWZ__ !5 &G169_94G_/5OU_^*H_LJ3_GJWZ__%4 3:Q_JF_#
M^8HT?_5+^/\ ,U1O]/>)"QD+ 8X.?4>YHL-/>5 PD*@YX&?4^XH VZ*S/[*D
M_P">K?K_ /%4?V5)_P ]6_7_ .*H TZ*S/[*D_YZM^O_ ,51_94G_/5OU_\
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MYG_T):PJW?!W^N;_ *YG_P!"6@#L:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN_N-_NG^535#=_<;_=
M/\J *NB?</\ O'^0K0K/T3[A_P!X_P A6A0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?K?W!
M_O#^1JU:?<7_ '1_*JNM_<'^\/Y&N:%](O =O^^C7+B\9'#<MU>YT8?#.O>S
MM8[6BN+^WR?WV_[Z/^-'V^3^^W_?1_QKD_MF'\K.C^S)=T=I17%_;Y/[[?\
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M% !69X@_U8_WA_(UIUF>(/\ 5C_>'\C0!IT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 4M8_U3?A_,4:/_JE_'^9HUC_5-^'\
MQ1H_^J7\?YF@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %#7?]2WX?\ H0HHUW_4M^'_
M *$** .%N?O'_/:HJEN?O'_/:HJ "BBB@ HHHH **** "BBB@ HHHH ****
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M=%<YX+\:1^*(V=5*21D!T)W8W9VD-@9!P>P((/&,$U?B+XR;PS%&T6TRR.0
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M1110 4444 %%%% &+J?^OC_X#_Z$:VJQ=3_U\?\ P'_T(UM4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %9GB#_5C_>'\C6G69X@
M_P!6/]X?R- &G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!2UC_5-^'\Q1H_^J7\?YFC6/]4WX?S%&C_ZI?Q_F: +M%%<UX>N
MWAO+NQD9BH9)8O,)+%9%^<+G_EFC# P,*3@DF@#I:*R?%6M_V):RWF,F-?E&
M,C<Q"KGD<9(SSG&<<U0^'VIR7MKY=P6,]O(\4A;!.Y#Z@G. 0">I()YZD Z6
MBN:\<7;A8+.)F5[FXC0F,D2B,'=(RXY&T 9." #SUKI: "BBB@ HHK)\6?\
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M<,<#MU.3570)ET2\ET@D".4>? ,] Q(DC X  8%E51PNXDYIWAW_ )".H?\
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MUZ/2K.17(WSHT:+G!.X;6/0\*#D]N@R"10!I>$_^/.V_Z]X?_0%K6K)\)_\
M'G;?]>\/_H"UK4 <II7^EZI=2MUMH88EQT*R9E)/OGIC QV)YJ+XK7&VQ: !
MF>>2.- HR=VX/C'7D*0,9.<<5+X=_P"0CJ'_ &Z_^BC3?'DH>2QMQDR->Q.
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M)7(&UMS@D D[NAXXZ55\5PK-K@1P"K3VP((R""L8((/4&O0OBE_R#I_^V?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!BZG_KX_P#@/_H1K:K%U/\ U\?_  '_ -"-;5 !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !69X@_P!6/]X?R-:=9GB#_5C_
M 'A_(T :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ$EA=3D(> #%%E(SC (/4'// ..YAUZ[&B:E#?38$$\!@+DD!&#^8"QQC#<
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M)8@@9/7CC<&#/^%964OS3J\TAZR2RR%V],D,HX& ..@%5]>NQHFI0WTV!!/
M8"Y) 1@_F L<8PW '(_B)P%Y[.@#S+Q+87.E7%G;-*TUJUW"RM*-TB.K<J7
M&0VXD9YP,  +D]%XMU2:>6/2+1MDLZEI),,3'&.-PP,98@@'(P<#@L&&;X^U
MZ-[JRTY2#(+N&1\'[N& 4$8ZMN)ZY  XPP-,\:Z7;-?PW&H+FVEA\H-EE59
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M>Y346!\Z)&53DXP<]O498#_>.<X&-.B@ K/TC1$TKS?++'SYGE;<0<,^,@8
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MM"^\+Q7MH-+8L(@D:Y!&_$94CG!&?E&>*V** "N7F^'ENK%[=I;8N26^S2E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%36MJUTP1>I_(>]5&+DTEN)M)786MJUTP1>I_(>]=986"V2[5ZGJ>YHL+!
M;)=J]3U/<U:KZ# X%4%S/XOR/'Q>+=5\J^'\PHHHKN.0**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L73/\ 7R?\"_\ 0A6U6+IG
M^OD_X%_Z$* -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#%U/_7Q_P# ?_0C6U6+J?\ KX_^ _\ H1K:H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S/$'^K'^\/Y&M.LSQ!_JQ
M_O#^1H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *&N_P"I;\/_ $(44:[_ *EOP_\ 0A10!PMS]X_Y[5%4MS]X_P">U14
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W?W&_
MW3_*IJAN_N-_NG^5 %71/N'_ 'C_ "%:%9^B?</^\?Y"M"@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** ,_6_N#_>'\C6"FBS. P7@CU7_&M[6_N#_>'\C5JT^XO^Z/Y5S8K!PQ
M%N9O3L;T,3*C>UM>YS']AS?W?U7_ !H_L.;^[^J_XUUM%<W]CT>\OP_R-O[2
MJ]E^/^9R7]AS?W?U7_&C^PYO[OZK_C76T4?V/1[R_#_(/[2J]E^/^9R7]AS?
MW?U7_&C^PYO[OZK_ (UUM%']CT>\OP_R#^TJO9?C_F<E_8<W]W]5_P :/[#F
M_N_JO^-=;11_8]'O+\/\@_M*KV7X_P"9R7]AS?W?U7_&C^PYO[OZK_C76T4?
MV/1[R_#_ "#^TJO9?C_F<E_8<W]W]5_QH_L.;^[^J_XUUM%']CT>\OP_R#^T
MJO9?C_F<E_8<W]W]5_QH_L.;^[^J_P"-=;11_8]'O+\/\@_M*KV7X_YG)?V'
M-_=_5?\ &C^PYO[OZK_C76T4?V/1[R_#_(/[2J]E^/\ F<E_8<W]W]5_QH_L
M.;^[^J_XUUM%']CT>\OP_P @_M*KV7X_YG)?V'-_=_5?\:/[#F_N_JO^-=;1
M1_8]'O+\/\@_M*KV7X_YG)?V'-_=_5?\:/[#F_N_JO\ C76T4?V/1[R_#_(/
M[2J]E^/^9R7]AS?W?U7_ !H_L.;^[^J_XUUM%']CT>\OP_R#^TJO9?C_ )G)
M?V'-_=_5?\:/[#F_N_JO^-=;11_8]'O+\/\ (/[2J]E^/^9R7]AS?W?U7_&C
M^PYO[OZK_C76T4?V/1[R_#_(/[2J]E^/^9R7]AS?W?U7_&C^PYO[OZK_ (UU
MM%']CT>\OP_R#^TJO9?C_F<E_8<W]W]5_P :/[#F_N_JO^-=;11_8]'O+\/\
M@_M*KV7X_P"9R7]AS?W?U7_&C^PYO[OZK_C76T4?V/1[R_#_ "#^TJO9?C_F
M<E_8<W]W]5_QH_L.;^[^J_XUUM%']CT>\OP_R#^TJO9?C_F<E_8<W]W]5_QH
M_L.;^[^J_P"-=;11_8]'O+\/\@_M*KV7X_YG)?V'-_=_5?\ &C^PYO[OZK_C
M76T4?V/1[R_#_(/[2J]E^/\ F<E_8<W]W]5_QH_L.;^[^J_XUUM%']CT>\OP
M_P @_M*KV7X_YG)?V'-_=_5?\:1]&E0%BO &3R.WXUUU07O^K?\ W6_E1_8]
M'O+\/\@_M*KV7X_YG*6^F27 W(N1G'4#^9J7^PYO[OZK_C6UX?\ ]6?]X_R%
M:=']CT>\OP_R#^TJO9?C_F<E_8<W]W]5_P :/[#F_N_JO^-=;11_8]'O+\/\
M@_M*KV7X_P"9R7]AS?W?U7_&C^PYO[OZK_C76T4?V/1[R_#_ "#^TJO9?C_F
M<E_8<W]W]5_QH_L.;^[^J_XUUM%']CT>\OP_R#^TJO9?C_F<E_8<W]W]5_QH
M_L.;^[^J_P"-=;11_8]'O+\/\@_M*KV7X_YG)?V'-_=_5?\ &C^PYO[OZK_C
M76T4?V/1[R_#_(/[2J]E^/\ F<E_8<W]W]5_QH_L.;^[^J_XUUM%']CT>\OP
M_P @_M*KV7X_YG)?V'-_=_5?\:/[#F_N_JO^-=;11_8]'O+\/\@_M*KV7X_Y
MG)?V'-_=_5?\:/[#F_N_JO\ C76T4?V/1[R_#_(/[2J]E^/^9R:Z#,3C;CWR
M/\:Z*PL%LEVKU/4]S5JBM\-@:5!\RNWYF5;%U*RL]O(****ZSG"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=,_U\G_ O
M_0A6U6+IG^OD_P"!?^A"@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH Q=3_ -?'_P !_P#0C6U6+J?^OC_X#_Z$:VJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LSQ!_JQ_O#^
M1K3K,\0?ZL?[P_D: -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"EK'^J;\/YBC1_P#5+^/\S1K'^J;\/YBC1_\ 5+^/\S0!
M=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"AKO^I;\/_0A11KO^I;\/_0A10!PMS]X_P">
MU15+<_>/^>U14 %%%% !114%W?+:C+'GT'7\J )V;;R>@K$OM<W?+'P/7O\
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M:HH Q?\ 2O\ .RC_ $K_ #LK:HH Q?\ 2O\ .RC_ $K_ #LK:HH Q?\ 2O\
M.RC_ $K_ #LK:HH Q?\ 2O\ .RC_ $K_ #LK:HH Q?\ 2O\ .RC_ $K_ #LK
M:HH Q?\ 2O\ .RC_ $K_ #LK:HH Q?\ 2O\ .RC_ $K_ #LK:HH Q?\ 2O\
M.RC_ $K_ #LK:HH Q?\ 2O\ .RC_ $K_ #LK:HH Q?\ 2O\ .RC_ $K_ #LK
M:HH Q?\ 2O\ .RC_ $K_ #LK:HH Q?\ 2O\ .RC_ $K_ #LK:HH Q?\ 2O\
M.RC_ $K_ #LK:HH Q?\ 2O\ .RC_ $K_ #LK:HH Q?\ 2O\ .RC_ $K_ #LK
M:HH Q?\ 2O\ .RC_ $K_ #LK:HH Q?\ 2O\ .RC_ $K_ #LK:HH Q?\ 2O\
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M_P!4WX?S%&C_ .J7\?YF@"E_I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44
M8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44
M8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44
M8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44
M8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44
M8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44
M8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44
M8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44
M8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44 8O\ I7^=E'^E?YV5M44
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ME9,[LGDYYYZ\]0?6FW-F]M@.I7/3(_'^O/IWH AHHHH **** "BBB@ HHHH
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MJT2[4Q2JKH<95P&4X.1D'CK0 ^&99E#H058 @@Y!!Y!!'4&L2\\<V=DI>24
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Q=3_ -?'_P !_P#0C6U6+J?^OC_X
M#_Z$:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"LSQ!_JQ_O#^1K3K,\0?ZL?[P_D: -.BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@"EK'^J;\/YBC1_P#5+^/\S1K'^J;\/YBC
M1_\ 5+^/\S0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@"AKO^I;\/_0A11KO^I;\/_0A
M10!PMS]X_P">U9^HZA]C'3);./3CU_.M"Y^\?\]JQ]?@WH'_ +I_0_\ U\4
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M^FW_ )#_ /LZA'A"/?F]NE\S^-=XW=/E^9SGICJO3CWJ#6- L[%?.@N?G7)
M!61BP&5P4P5Y'4\=.G>M>Y.G8JZKX$N+'+*!(N3]S);&<#*]><]LXYR:=HOC
MB:R(24^9'GG/+@<YPW?KWSTP,5TOP]U.:^C=9265"-K-DDYR2-QZXX]QGTQ5
MOQ+X1CU8&1<+-@8;G!QT!']>HXZ@8J6^C&EU1?L=0CU!?-B;<N2,C(Y'8@\C
M_)J5A7EWA[6FT*4E@=I^5UY!X/7']X>_N.,YKU)7$@#*001D$<@@]ZYZM/E9
MM3GS$3"HV%3,*C:N:2-XLA85BZUX<CU'Y_NR<?,.>GJ,C/\ /ISCBMMJC:LN
M>4'=.S-.525F>;3V\VBMAN,_BK '_/H1GMFMJRO!=KO QS@Y]:D\<70"I#W)
MW=>1@8''OG]*JZ/!Y48]6Y_/I^E>KAZDJE-29Y]:"A-I%VBBBMC,**** "BB
MB@ HHHH **** -;2/$+:>"A&Y>PSC!]C@\>W_P!?+]5\2-?KY04*IQGG).#G
MKQQT[?C6-10 ^*(RD(O)8@#ZFNF\57GD(MJ"22 23R<#IGCJ2,_A[US=M<M:
ML)$.&'0\'J,=Z6[O'NVWR')_SV% !9W;6CB5.J^O3T-;_P#PFAQC8-V.N[C/
MKC'3VS^-<U10!92^;S!</\S!@QSWP<X]OZ5-K&J?VDXDV[<*!C.>Y/H/6J%%
M &MI?B-[ "/ 9!VZ$=3P?J>^?PJS?>+GG78B[,]3G)_#@8_SC%8%% &IHNM?
MV9N^7=NQWQTS['UK+HHH U-:UK^T]OR[=N>^>N/8>E&BZU_9F[Y=V['?'3/L
M?6LNB@#4T76O[,W?+NW8[XZ9]CZUGP3M;L'0X8="*CHH Z6+QH0/F0$^H; _
M+!_G65JNM/J)^;A1T4=/J?4_Y %9]% !1110 4444 %%%% !1110 4444 %%
M%% !6[X._P!<W_7,_P#H2UA5N^#O]<W_ %S/_H2T =C4-W:K=HT,@RDBE6&2
M,AA@C(YZ5-10!P6F:Y+X+5;'4%)MU++%<KE@0/F560;F4XR!]  "H+5TL/C&
MRE4.+B+# $9D53SZ@D$'V(R.];%9/_")V?\ S[P_]^4_^)H YK4M2'CL"QM0
M_P!E\Q?/GVA5(4;PBA_F)+8R<?+P2"IYZ7Q9_P >=S_U[S?^@-6M3)H5F4HX
M!5@001D$'@@@]0: ,SPG_P >=M_U[P_^@+7(:_:SV$\FEVX_=ZJVX-E?W9_Y
M>3ALELISU7&<)R*]"AA6%0B !5   &  .  !T KDO"JMJ]W<:LQ_=C,$.""I
M1&RS@[1N#,,J03C++S@4 =5:6JVB+#&,)&H51DG 48 R>>E<5X?U#_A#BVFW
MFY8!(?L\Q&8RLA)$;,% 5@<DEN.O10I/=TR:%9E*. 58$$$9!!X((/4&@#"U
M/Q[8Z>AE,R/Z+$PD8G!.,*3C..IP,XR15BSG/B*V=98Y(1*)$VO@/M.5W8YP
M2.Q'!]1@FQ:^'K:T82Q0Q(XSADC16&1@X(&>E:% '#^%_%"Z*JZ1J+"*:$;5
M9N(W09V,'P   -OS8)('.[(&GK/Q!M+!?W;K-*W"1PG>S-D #*Y R3WY/. 2
M,5OW5HEVIBE570XRK@,IP<C(/'6HK'28=/SY$:1[L9\M%7.,XS@#.,F@#"\,
M^%WALY+>Z)\V[,K3%2O#2C!Q@8! QZC=G&1BJ7AOQ8ND!=)U#;#- JJK$D12
M(HPKASP.%P<XYX'.57LID+J5!*D@@$8R,]QD$9'N"/45Q3^(EM8Q;:Y",J>)
M3'YL#D9"D8!VN1D[2HXR?ER% !H:YXZBA58K(K<7,IVQI&P89[LQ4\*.IR1G
MU !9:GP^LEO])2W?(65)E)'7#.X.,YYYJNGB>W='AT6'?/(I&Z&$1(AP=K.S
MJHXY*@YR01QFNKT#1ET6".T3D1KC//)/+-@DXR23C/&<#B@#G/#'B==+4:5?
ME89K=%"LS8CD0?*KJS8YXY'7.>!AE6QK?CZ*+%O9%;BZDP(TC.Y<G/S,PX 7
M&2,YQUP/F'1WNG17Z[)D5U!R ZAAGIG!!YYIECI,.GY\B-(]V,^6BKG&<9P!
MG&30!8A+%07 #8&0#D ]P"0,CWP/H*Y?X6_\@Z#_ +:?^C7KJZAM;1+11%$J
MH@SA4 51DY. ..M '-?%+_D'3_\ ;/\ ]&I75U#=6B7:F*55=#C*N RG!R,@
M\=:FH J:KJ2Z9$]RX8K&I8A%+-@>@'\S@#J2 ":Y+QCK6GZQ:E=\<LKH1"%^
M>4.RY0!5!=26 !R /X6]*[BJ,6AV\4GVA8HQ+DG>$4/ELY.[&<G)SZT /TGS
M/)C\_P#UOEIOZ?>VC=]WCKGIQZ5S_P +?^0=!_VT_P#1KUU=0VMHEHHBB540
M9PJ *HR<G ''6@#BAJ'_  A=U-]HW?8[N0R)(!N"2$9=6"KGYL?+UX QGYR.
M@NO&UC:J9&N(B!C[CAVY..%3)/X#WZ5MUGVOAZVM&$L4,2.,X9(T5AD8."!G
MI0!S_A*.35[B36Y59$DC$<"-C=Y>=Q8@#^(C*\GJ>J[29? '_+Y_V$+C_P!E
MKJZAM[1+;=Y:JN]BS;0!ECU8XZD]SUH YWQMILQ,.HVP+RV;LVP$?.CC$BC*
MGYB!@=\9P"V!5JR\<6=TN3*L;*<,DQ$3JPZJ5<CD=#C(SD G%;U4;W0[>_;?
M-%&[ 8!=%8XZXR0>.: /.OB3XP75X)+6RR\<94SR ?(!OVJ@)')+X.5[#@D;
ML==XRL)5,.I6R>9+:,Y\O.-R2+M<# SNQC;^/#' .U_9,/E_9?+3RO[FQ=G7
M=]W&.O/3KS5+Q(;J)4FLP'9'&^)BJAT/!&XCAAP0<@=<AN!0!7TSQ[8Z@@E$
MR)ZK*PC8' .,,1G&>HR,YP37*>)O%/\ ;-Q;16Z[K:&^@#3?PM)DX5?4 9R>
M<\=!@MH77BS29F+W<:I.<;EN+8F4<<;OD;M@CD\8JQ;Y\2S0&.)H[&U.]2ZA
M!(Z@"+8N0P10=RG[K?=*\4 7O&5A*IAU*V3S);1G/EYQN21=K@8&=V,;?QX8
MX!GT_P <V5[&LPGC7<,[9'5''J"I/!'Y'J"1@UO5GW7AZVNV,LL,3N<99XT9
MC@8&21GI0!E:)XO.O3E;5-UK&IWS-E<N<$*H(R<#[V<=<\8&_I:9#"L*A$ "
MJ   ,  <  #H!3Z ,GQ5HG]MVLMGG!D7Y3G W*0RYX/&0,\9QG'-96A>-D51
M;7Y\BZ1?G$V$5MIV^8K8"$,>@!]<9 R>KJO>Z=%?KLF174'(#J&&>F<$'GF@
M#FO$'CN)5^RV+":[E&(Q$0P!.?G+<IA<9(/MD!26&9X:_P"0"W_7O=?SDKM;
M'28=/SY$:1[L9\M%7.,XS@#.,FGQ:=%%']G5%$6"-@4!,-G(VXQ@Y.?6@#"T
M_7(]$TZVN)MVP0VX)52V-RJ,G'0#N?P&6(!Q_&^H6NIJ@M&CEO\ ?&8#%M=P
M4<$Y89 4 DX<[>I[9'=0PK"H1  J@  #  '   Z 54LM#M[!M\,4:,1@E$53
MCKC( XXH R/&5A*IAU*V3S);1G/EYQN21=K@8&=V,;?QX8X!GT_QS97L:S">
M-=PSMD=4<>H*D\$?D>H)&#6]6?=>'K:[8RRPQ.YQEGC1F.!@9)&>E &5HGB\
MZ].5M4W6L:G?,V5RYP0J@C)P/O9QUSQ@;V>-M-F)AU&V!>6S=FV CYT<8D49
M4_,0,#OC. 6P*Z6&%85"( %4   8  X  '0"GT 8-EXXL[I<F58V4X9)B(G5
MAU4JY'(Z'&1G(!.*XKXD^,%U>"2ULLO'&5,\@'R ;]JH"1R2^#E>PX)&['HM
M[H=O?MOFBC=@, NBL<=<9(/'-/\ [)A\O[+Y:>5_<V+LZ[ONXQUYZ=>: *FI
M^)X-+E2VG;8958JSC;'\N."YXS[9^N"5SSMO+!=:G'-I^UL)*+IX@-A#@-'E
ML;2Q?NI+'!!X!QV5U:)=J8I55T.,JX#*<'(R#QUIMEIT5@NR%%12<D(H49Z9
MP .>* .4U>Y;PK=OJ+*6M;L1K*XY:-T!56P!]P@@'J<]\[5;8NO&UC:J9&N(
MB!C[CAVY..%3)/X#WZ5MUF0^&+2%@Z01!E(((B0$$<@@@<$4 5_"VM2ZRC7,
MD7EQ,W[G)^=DQ]YEZ#)Y'/(/H S;=%% &3XL_P"/.Y_Z]YO_ $!J/"?_ !YV
MW_7O#_Z M:<T*S*4< JP(((R"#P00>H-$,*PJ$0 *H   P !P  .@% '.^.+
M5HD34XAF6R8OC(&Z,C$J9/ RO.<$C&%&31X'M6E1]3E&);U@^,@[8P,1)D<'
M"\YP"<X89%5/':MJSP:-&>+AM\Q!&5BC(/3:V-Q^ZW W+MY!-=A0!P7Q%N9K
M6ZL9;92\B&=M@QEE54+J,@\E,C@$^@SBM^R\<6=TN3*L;*<,DQ$3JPZJ5<CD
M=#C(SD G%4O$7_(1T_\ [>O_ $4*W;W0[>_;?-%&[ 8!=%8XZXR0>.: .2\0
M:A_PF)73;/<T!D'VB8#$86,@F-6*D,Q.""O'3JI8B]XJ$FC7":U&AD1(C%.H
M/S"/<'#J/53G=D],=!EAU4,*PJ$0 *H   P !P  .@%/H Q/^$VL=GG?:(MN
MW=C>-V,9^Y][/^SC.>,9J+PUXE?7GDECCQ:+@1R,2&=@3N(7'W?0\$$=R2$N
MS>&+29B[P1%F)))B0DD\DDD<DUIT %%%% !4-W]QO]T_RJ:H;O[C?[I_E0!5
MT3[A_P!X_P A6A6?HGW#_O'^0K0H **X37OBDNC7AL)(OD5HPTF\\!U5BVP(
M2< ],\XK*NOCBBL1%;LR<8+R!&Z<Y4*P'/N?Z4 >H45PFK?%^TM(TDA#2O(N
M=GW=O."'/.#UP &SC/W2"9O"'Q0B\02"U9&CE;=M&=ZD*,_>P"#C)Y&,#KDX
MH W?%'BB+PW$+B8,59PH" $Y()[E>/EKE_\ A==G_<F_[Y3_ ..4?&O_ (\X
M_P#KX7_T"2L_P;_9?]GI]K^S^9MEW[MGFXWMCI\^=N-N.>F.U 'H6CZU#K$?
MGV[ATR1D9&".H((!!^HZ8/0BL#6?B;:Z/<&QF$@92H+!5*#< V?O;L 'G SZ
M UP_P2W_ &F7&[R_)^;&=N[>NW/;.-V.^,X[UC_$R%IM3F1 2S&(  9))C0
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MX('3OS[=/UHJ83D<E=-QU:\@AB.91=K)[&75Z6Q5(5GYW,V#Z=_\*HUKW/\
MQZQ_[Y_]FJ</!252_2-_Q0ZTFG"W5_HQ;315N8@^XAVSC.,9!/'3/0?UK-MX
M-[K&V1E@#Z]<&M0SF"VB=>H?/ZM1=0!I8[A/NR,I^AR,]./_ *^:Z:E"#C!I
M:I1OYI]?O,859IRN]&W;Y%.XL5CF\@9V[E'OSC_&I[NVM[5C&WF9&.FW'(S3
MKW_CZ'^^G_LM5]<_US?A_P"@BIJ1C3C4:2TG;7MJ.#E-P3;^&_Y"7NF^4HFC
M.Z,]\8(YQS_C_P#6JC6QI+;X9D/("Y ]\'G]!6/6&(A%*$UIS+;S6C-:,I7E
M%ZV>X4445SFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 :FD:N;0['Y0_I_];U'XCWZ"[8-&Q'(*'^5<75^QU0P*T1Y5@0/8D?R]
M?S^OJ9?F'L[4Y[='V_X!P8S!\_OQWZKN;7A__5G_ 'C_ "%:=9GA_P#U9_WC
M_(5IU[AY04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5BZ9_KY/^!?^A"MJL73/]?)_P "_P#0A0!M4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 8NI_P"OC_X#_P"A&MJL74_]?'_P
M'_T(UM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M444 %%%% !1110 4444 %%%% !1110 4444 4-=_U+?A_P"A"BC7?]2WX?\
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M!!_S^1Z@\BN'\#A]/N9[ Y*J">01RK !@,\;@<^_'-1))HJ.A%\1])"E+Q<
ML=C>YP2IZ>@())[#%7_ FI&Z@,3'+1''?.T\KR?Q QT '%:WBNV^TVLJYQA-
MW3/W/FQ^.,5R'PZN2LLD79D#'URI '_H1K.7O4WY%K2:\SNFJ)JE:HFKBD=,
M2-JB:I6JEJ=U]EC>7C*J2,],XX'XGBL6KNQJG97.&UZ8ZA<E!G .P<=,=>GO
MD_2ME5V\#H*Y_0H-[[^RC]3Q_C705[,(J$5'L>9*7,VPHHHJA!1110 4444
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M<<_C0!S-%=9;:1:7S!HCD#JN3SQUYPW4CGIVJA_9D?VS[/C]WZ9/]S/7.>M
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M*RC@&)0S!@V&!P>..>#T(-0?$:U:>QE:,?O(MLBD$!E,;!BP/&"%!Y'/8=:
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M6O+8:F?.B(W$#<N><\>OY=AQ6/16U.JHQ<6KI_UH9SIW:DG9HU[2P^P,)IL
M+G"\%B>V!^/X?K4FASF>=Y#_ !*3USW''X5B5HZ'=K:N6<X!4CH3W'I71AZ\
M54A%>[%.^K_-Z&-:E+DD]Y-6T)K'2&#B7(\M3NW9X('/3J/?/3FJMU?!YO/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 8NI_P"OC_X#_P"A&MJL74_]?'_P'_T(UM4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDLF-TDS;Y,  !=V!QQ^/&<X& #/_ .8S_P!P_P#]KUJ^+/\ CSN?^O>;_P!
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M"@8 & !P !VK,T75EU2)9UXSP1D$@CJ./S'M@XJAXG\6C1L1JNZ1AD \*!R
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MY4>[NQST[=O\?QJ_2(@0!1T P/PI:]0X HHHH **** "BBB@ KI]#_X])O\
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M9]\8XZT 6O"?_'G;?]>\/_H"UK54TFQ_L^&.VSN\J-$SC&=J@9QDXSCUJW0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W
M?W&_W3_*IJAN_N-_NG^5 %71/N'_ 'C_ "%:%9^B?</^\?Y"M"@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,/;TOYE]Z*%%7_[#F_N_JO\ C1_8<W]W]5_QH^JUOY)?<P]O2_F7WHH45?\
M[#F_N_JO^-']AS?W?U7_ !H^JUOY)?<P]O2_F7WHH45?_L.;^[^J_P"-']AS
M?W?U7_&CZK6_DE]S#V]+^9?>BA15_P#L.;^[^J_XT?V'-_=_5?\ &CZK6_DE
M]S#V]+^9?>BA15_^PYO[OZK_ (T?V'-_=_5?\:/JM;^27W,/;TOYE]Z*%%7_
M .PYO[OZK_C1_8<W]W]5_P :/JM;^27W,/;TOYE]Z*%%7_[#F_N_JO\ C1_8
M<W]W]5_QH^JUOY)?<P]O2_F7WHH5J:1I!NSO?A!^O_UO4_@/:2P\/LS9E&%'
M;(R?;C_/].C50HP. *[\#ESD^>:LNSZG)B\:HKE@]>X*H48' %0WO^K?_=;^
M53U!>_ZM_P#=;^5>V>64_#_^K/\ O'^0K3K,\/\ ^K/^\?Y"M.@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%TS_7R?\"_]"%;5
M8NF?Z^3_ (%_Z$* -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#%U/\ U\?_  '_ -"-;58NI_Z^/_@/_H1K:H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S/$'^K'^\/Y&M.LS
MQ!_JQ_O#^1H TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!H3?W/_'6_QH_M";^Y_P".M_C0!K45D_VA-_<_\=;_ !H_M";^Y_XZW^-
M&M163_:$W]S_ ,=;_&C^T)O[G_CK?XT :U%9/]H3?W/_ !UO\:/[0F_N?^.M
M_C0!K45D_P!H3?W/_'6_QH_M";^Y_P".M_C0!K45D_VA-_<_\=;_ !H_M";^
MY_XZW^- &M163_:$W]S_ ,=;_&C^T)O[G_CK?XT :U%9/]H3?W/_ !UO\:/[
M0F_N?^.M_C0!K45D_P!H3?W/_'6_QH_M";^Y_P".M_C0!K45D_VA-_<_\=;_
M !H_M";^Y_XZW^- &M163_:$W]S_ ,=;_&C^T)O[G_CK?XT :U%9/]H3?W/_
M !UO\:/[0F_N?^.M_C0!K5#=_<;_ '3_ "K/_M";^Y_XZW^--FOI64@I@$'/
MRF@"QHGW#_O'^0K0K!LKJ2)<(N1GT)_E5C^T)O[G_CK?XT :U%9/]H3?W/\
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MJBL7^TY_^>?_ (ZW^-']IS_\\_\ QUO\: -JBL7^TY_^>?\ XZW^-']IS_\
M//\ \=;_ !H VJ*Q?[3G_P">?_CK?XT?VG/_ ,\__'6_QH VJ*Q?[3G_ .>?
M_CK?XT?VG/\ \\__ !UO\: -JBL7^TY_^>?_ (ZW^-']IS_\\_\ QUO\: -J
MBL7^TY_^>?\ XZW^-']IS_\ //\ \=;_ !H VJ*Q?[3G_P">?_CK?XT?VG/_
M ,\__'6_QH VJ*Q?[3G_ .>?_CK?XT?VG/\ \\__ !UO\: -JBL7^TY_^>?_
M (ZW^-']IS_\\_\ QUO\: -JBL7^TY_^>?\ XZW^-']IS_\ //\ \=;_ !H
MVJ*Q?[3G_P">?_CK?XT?VG/_ ,\__'6_QH VJ*Q?[3G_ .>?_CK?XT?VG/\
M\\__ !UO\: -JBL7^TY_^>?_ (ZW^-']IS_\\_\ QUO\: -JBL7^TY_^>?\
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M_:<__//_ ,=;_&C^TY_^>?\ XZW^- &U16+_ &G/_P \_P#QUO\ &C^TY_\
MGG_XZW^- &U16+_:<_\ SS_\=;_&C^TY_P#GG_XZW^- &U16+_:<_P#SS_\
M'6_QH_M.?_GG_P".M_C0!M45B_VG/_SS_P#'6_QH_M.?_GG_ ..M_C0!M45B
M_P!IS_\ //\ \=;_ !H_M.?_ )Y_^.M_C0!M45B_VG/_ ,\__'6_QH_M.?\
MYY_^.M_C0!M45B_VG/\ \\__ !UO\:/[3G_YY_\ CK?XT ;5%8O]IS_\\_\
MQUO\:/[3G_YY_P#CK?XT ;5%8O\ :<__ #S_ /'6_P :/[3G_P">?_CK?XT
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M_P#QUO\ &C^TY_\ GG_XZW^- &U16+_:<_\ SS_\=;_&C^TY_P#GG_XZW^-
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M\:/[3G_YY_\ CK?XT ;5%8O]IS_\\_\ QUO\:/[3G_YY_P#CK?XT ;5%8O\
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MJBL7^TY_^>?_ (ZW^-']IS_\\_\ QUO\: -JBL7^TY_^>?\ XZW^-']IS_\
M//\ \=;_ !H VJ*Q?[3G_P">?_CK?XT?VG/_ ,\__'6_QH VJ*Q?[3G_ .>?
M_CK?XT?VG/\ \\__ !UO\: -JBL7^TY_^>?_ (ZW^-']IS_\\_\ QUO\: -J
MBL7^TY_^>?\ XZW^-']IS_\ //\ \=;_ !H VJ*Q?[3G_P">?_CK?XT?VG/_
M ,\__'6_QH VJ*Q?[3G_ .>?_CK?XT?VG/\ \\__ !UO\: -JBL7^TY_^>?_
M (ZW^-']IS_\\_\ QUO\: -JBL7^TY_^>?\ XZW^-']IS_\ //\ \=;_ !H
MVJ*Q?[3G_P">?_CK?XT?VG/_ ,\__'6_QH VJ*Q?[3G_ .>?_CK?XT?VG/\
M\\__ !UO\: -JBL7^TY_^>?_ (ZW^-']IS_\\_\ QUO\: -JBL7^TY_^>?\
MXZW^-']IS_\ //\ \=;_ !H VJ*Q?[3G_P">?_CK?XT?VG/_ ,\__'6_QH V
MJ*Q?[3G_ .>?_CK?XT?VG/\ \\__ !UO\: +NL?ZIOP_F*-'_P!4OX_S-9EY
M?32H5=,*<9.UAW]Z+.^FB0*B949P=K'O[4 =!16+_:<__//_ ,=;_&C^TY_^
M>?\ XZW^- &U16+_ &G/_P \_P#QUO\ &C^TY_\ GG_XZW^- &U16+_:<_\
MSS_\=;_&C^TY_P#GG_XZW^- &U16+_:<_P#SS_\ '6_QH_M.?_GG_P".M_C0
M!M45B_VG/_SS_P#'6_QH_M.?_GG_ ..M_C0!M45B_P!IS_\ //\ \=;_ !H_
MM.?_ )Y_^.M_C0!M45B_VG/_ ,\__'6_QH_M.?\ YY_^.M_C0!M45B_VG/\
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M@CK@]>W8'9UF[BM2&FCW9X#;58?3)/\ G\ZJQ:_#;+YBQ,JMW"* <9[@\]Z
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M3?A_,4:/_JE_'^9H NT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3HVN)F"QH,DG_/)/0 <D\#FN7/Q,B93,D%R\2[OWB0_NR%)!8,6'''?&.^*
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MX:#'F1,NV5<OY?W20#@D9P3C(S@G% '5T444 4=:UB/1X7NYL[(QDX&2<D
M#U)('8>I YHO]8CTZ$W=QF-%"ELC<5W$  A-V3DXXR/?'-87C#_2KFQLNFZX
M,N[K_P >ZEMN/]K.,YX]#1\4O^0=/_VS_P#1J4 '_"TM._Y[?^0Y?_B*Z#3-
M5BU1!- ZNA[J<X. <$=0<$9!P1W%6ZX_2+1+#5)8;956)K5&E6,#:) Y"9QP
MI*$G:,9'S8/6@#I;C5([:2.V=L23[]@P3G8,MR!@8'J1[5;KDO$\RPZA8.Y
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MGZW]P?[P_D:Y.NLUO[@_WA_(UR=>/G/_ "[^?Z'I99]OY?J%%%%>.>D%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %/BE,)#J<$=#3**:;
M3N)JYUVEZH+T>CCJ/ZCV_E_.]7#12F$AU.".AKJ]+U07H]''4?U'M_+^?O8#
M'JLN27Q?F>3B\)[/WH_#^1>HHHKT3B"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *@O?]6_^ZW\JGJ"]_U;_P"ZW\J *?A__5G_ 'C_ "%:=9GA
M_P#U9_WC_(5IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %8NF?Z^3_@7_H0K:K%TS_7R?\  O\ T(4 ;5%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% &+J?\ KX_^ _\ H1K:K%U/
M_7Q_\!_]"-;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3!Z$4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH H:[_J6_#_ -"%%&N_ZEOP_P#0A10!PMS]
MX_Y[5%4MS]X_Y[5%0 4444 %9,V@!V+!L GICI^HK6HH QO^$=_V_P#QW_Z]
M'_"._P"W_P"._P#UZV:* ,;_ (1W_;_\=_\ KT?\([_M_P#CO_UZV:* ,;_A
M'?\ ;_\ '?\ Z]'_  CO^W_X[_\ 7K9HH QO^$=_V_\ QW_Z]'_"._[?_CO_
M ->MFB@#&_X1W_;_ /'?_KT?\([_ +?_ ([_ /7K9HH QO\ A'?]O_QW_P"O
M4UKH8A8.6SCH,8Y_.M.B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *W?!W^N;_ *YG_P!"6L*MWP=_KF_ZYG_T): .QHHH
MH \T\!>$/[0LHI_M-S'NW_+%-M08D8<+M.,XR??-=;H_@NWTR3[4-TD^"#+,
MY>0YX[\ @?*" #MX[G-+X6_\@Z#_ +:?^C7KJZ .*^*MC_:$-O;9V^;>1)G&
M<;E<9QD9QGUKK=/T^/3HUMX5"QH, #_/)/4D\D\GFN<\??\ +G_V$+?_ -FK
MJZ .4M_]&U>2-.%GLTD<=<LDGEJ>>F%XP,#N1GFL+5=4#:J[S0RSK9I&(E@C
M,@5G ?S&^8 -V''. >"@-;O_ #&?^X?_ .UZ;K=O/H=R=4MD,L4P1;B) 3)\
MN0LB^I ."HP,<GJ64 =_PGW_ $YWG_@/_P#952\$N(KJ9(;>>&WE19,3(419
M V&"KR &!!Z\;< ;0 +<OQ2L,8C=I7) 5(XWWL20 !N"C//K].>*TO"UQ=W:
M-<7@5/,;,<0'S(N, ,>Y/7& 02<XSM4 YW3=!CO]8NKJ0!OLX@V@C/S/&N&Z
M]5VG'!Y.1@@5V]W:K=HT,@RDBE6&2,AA@C(YZ5S7AW_D(ZA_VZ_^BC75T <U
M\-[IKK3X'<Y(5EZ <([(HX]  /Y\U7\%%M,EN-(< +"^^$9ZQ2DD 9 )"'AF
MR?F.W/ R[X6_\@Z#_MI_Z->HO'^_3?*U2VV_:(V\L*<_O5EXV;5PSD-AE7.!
MAC@F@ T^8Z[J3SX_<6"M&A.1F9\"0CY1G !4@D@<,/O9J7_F,_\ </\ _:]:
MOAC1/[&@6 G=(<M(V<EI&Y=BV 3SP">< 9K*_P"8S_W#_P#VO0!R^M>)I-%O
MKV.$ 27#VB"5^(H\Q'YF///.0",<$G(7![OPSX9CT&,HI+R.=TDC??=NY)YX
MY.!GCW)).)INGQZC?:E;S*&C<6H(/_7(_D1U!'(/(YJ;3S)X0"V\[F2S)VI*
MPPT63A4D]4/ #\!3P0%*X ,GQQ>":_@MIHI)H(8C,8H4,A9BQ0%EW ;5P#G!
MZE2"&XV/^$^_Z<[S_P !_P#[*G^*M/GM94U:S4/+$A22,YS)$2&VJ><,IR1@
M9.>^ K13?%*PA4[W82*#F,QN'##JAR-H8'CKC/?'- &?HEV&U 3P6UQ$MPCB
M;S8S''N&&23 R-QP5.2.6R.2V=+XI?\ (.G_ .V?_HU*M^&M0N]3>2YF3RK<
MX6*-UQ+\I.7;GC/]W!Z#& -SU/BE_P @Z?\ [9_^C4H W=<O6L+>:X3!:*)V
M /3*J2,XQQQ61\/M&6PM$F^]+<J)9'.=S%_F&222< X]SDX!)K?N[5;M&AD&
M4D4JPR1D,,$9'/2N*T;6I/""_8+]7,,7^KN41GCV$G:'QDJ0<* ,]AC #, =
MGJ&GQZC&UO,H:-Q@@_YX(Z@CD'D<UP^BR.NEWMI(V[[)]JA5N<E40XSDGUP!
MT  ':M"Z^(J7:E--1[F4X VQN(U+'"EV8+@'D^^#DKUH3P^="TNXA=M\KPSO
M(^2=SLAR?F.>F!GC.,D DT 6/ASH,>E6<;(!OG19';&"=PW*.IX4' [=3@$F
MF>-_W$EE<KQ(MXD8/^S,")!@\<@#G&1V(K5\)_\ 'G;?]>\/_H"UE>/O^7/_
M +"%O_[-0 >/O^7/_L(6_P#[-75U@^,='DU&%6@P9K>5)HPQPK-&?NGV()[C
MG&2!FJ$/Q.LXU N2T$V!OBDCDW*?3A.0>H/<$' Z4 ._YC/_ '#_ /VO571-
M,2;5[VZ89>)8 N<8'F1#)Z9!PN,@]"1WJUX:@EU.YDU>>-H08Q#$C\/L#EF9
MU(X).,<],\$88GAW_D(ZA_VZ_P#HHT 'C[_ES_["%O\ ^S5%XYA.ISV>EL<1
M7$CM)C.6$*A]G##AL_@<$=.9?'W_ "Y_]A"W_P#9JL>,M"EOUCNK4@7-J^^/
M)(# _>C.".&P.OIC(!)H Z"&%85"( %4   8  X  '0"N%^+^@QW5J;W $L!
M7YL<E68+MSD<9;<,YQ@@8W&M+_A8]M:_N[P/;RCJDB,WL65D!#+G(#<9QG%<
MEX_\22^([9VMD9;.(AGE<%/,._RU5!_$N?F.>X&0I # 'K%%%% '*?\ ,9_[
MA_\ [7H^*7_(.G_[9_\ HU*+C_1M7CD?A9[-XT/7+))YC#CIA><G [ YXH^*
M7_(.G_[9_P#HU* #_A /^GR\_P# C_[&MC0_#=OH2LEL@0.<MR6)QTY8DX'8
M9P,GU-:=% 'GGQ0T-M<GL[-&"LXN<$],JBL <=CC&><=<'I70>$/$BWZFSD0
M0W-N KP@8  P R#NAXQC.,CD@JS5_$7_ "$=/_[>O_10K3US0VNF6[MV"740
MPK'[K+U,;@=4/YJ?F7GJ ;%<IX _Y?/^PA<?^RUL:'KBZHK J4FB.V6)OO(W
M]5/56'##D=P.:;46\&3S>=&S6=S*91*@W;'D*JX<#&%SRN.<<#<2=H!T7BS_
M (\[G_KWF_\ 0&H\)_\ 'G;?]>\/_H"US&N>+QXFC;3M,#2/, KR["L2*V=V
MXL,Y*@CIW^4EABNWM+5;1%AC&$C4*HR3@*, 9//2@#FO#O\ R$=0_P"W7_T4
M:ZNN4\'_ .E7-]>]-UP(MO7_ (]U"[L_[6<XQQZFNKH **** "BBB@ HHHH
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MZ>A?%RU:W#73,LZ+AE"DERH^\"H"C=Z';@\=,$\I\.8WUK5&U!5VHK2R-G)
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M"DD<@C>Q< @@$$!L$=CF@#H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M^ZW\J *?A_\ U9_WC_(5IUF>'_\ 5G_>/\A6G0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5BZ9_KY/^!?\ H0K:K%TS_7R?\"_]
M"% &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!BZG_KX_P#@/_H1K:K%U/\ U\?_  '_ -"-;5 !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !69X@_P!6/]X?R-:=9GB#_5C_ 'A_
M(T :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M %+6/]4WX?S%&C_ZI?Q_F:-8_P!4WX?S%&C_ .J7\?YF@"[7'^.I/[/GL=0W
M*!'<&-M_W=LZX9B<C&T*?;G)X&#V%<_X_L?MUA<1YQB,OG&?]61)CJ.NW'MG
M//2@"I_R%]3]%TZ/Z$R7"_B"H0?[)#>HIOB-#IE]:ZB"=LI^S.HP<[\M'@$<
M /RQSG & ><V/A]:LEK]ID&)+N1YV (V@RG(QUP"H!P22,\^@N^+]'.L6DUJ
M,EF3*@$#+*=RC)XP6 !]NXZT 8^C2?VCJMU.&4K;0QP@+SG>=[9.>JL"I&/;
M@@Y9KUH-;U*&QFP8((#.4()#L7\L!AG&%X(X/\0.0W%OX<PL;7[4X(DNY9)F
M!& "[8&T'G:5 (R3USG%,\6Z7-!+'J]HN^6!2LD>6!DC/.T8.,J22!@Y.#R5
M"D ZNN,\66@TR[M-3APLDLZ02#!^=9!@$X(R5QQD'G;GA0*L?\+-LHOEG9X9
M!UCEBD#KZ9 5AR,$<]"*JP13>*[J.XEB>&UM&W*DP9))), ABH. $/0\]QSN
M8* %]IB7VM1M(,^39^8HX(W"5E!.0>F[(Z$$ YXK?\6?\>=S_P!>\W_H#5E?
M\QG_ +A__M>M7Q9_QYW/_7O-_P"@-0!RNM2.VEV5I&VW[7]EA9N<A709Q@CT
MP1T()'>NXT_3X].C6WA4+&@P /\ /)/4D\D\GFN7?P^==TNWA1MDJ0P/&^2-
MKJ@P?E.>F1GG&<@$@4^'X@)IZB/4D:WFP,Y1GC8]RC)NR!D9'\).,G!- $OQ
M&T&/5;.1G WP(TB-C)&T;F'4<,!@]NAP2!52[TMM1TB)8\B5+:&2,J,N'C16
M&W'(8XV@CD9[]*RO%GBYO$5O+;Z>K&)4<RSL&1-J*'**>"6;[I! XSP5.X=E
MX3_X\[;_ *]X?_0%H R-8\6BYTS[=!GS+A B*K$/YCG854X!+(<D8'.W(P.:
MS_#&G_\ ")WHTP,3#<P*RDJV#+&,/CE@"P!=O3Y5[#-?1]&==1-B0WV>UDEN
M$RI\K]\%$:!?NKY;;RI&>0V #FMCXC6C)"FI0Y\ZR<.N QRI($BD*1\I'+'^
MZ". 2: #2 VL:A->$@PV@\B,8_C.#*W)X8?=)  92 "<'+O^8S_W#_\ VO6A
MX.T9M)M4BEYE;+R$XW%W.YLD$[B,[=V3G%9__,9_[A__ +7H KZ]:#6]2AL9
ML&"" SE""0[%_+ 89QA>".#_ ! Y#<=G7+^*-&G6>+5;,!IH@4>,L5\R-C]W
M)(4%221D=>>=H4L_X6;91?+.SPR#K'+%('7TR K#D8(YZ$4 9OC[08TNK+45
M $ANX8WP/O98%23GJNTCID@CG"@5#XXO!-?P6TT4DT$,1F,4*&0LQ8H"R[@-
MJX!S@]2I!#<9^N:S/KT]G=B-HK1;N )YF5>1G(;?M!(V@#"GW."<D+U?BK3Y
M[65-6LU#RQ(4DC.<R1$AMJGG#*<D8&3GO@*P S_A/O\ ISO/_ ?_ .RK-T2[
M#:@)X+:XB6X1Q-YL9CCW##))@9&XX*G)'+9');.A-\4K"%3O=A(H.8S&X<,.
MJ'(VA@>.N,]\<U=\-:A=ZF\ES,GE6YPL4;KB7Y2<NW/&?[N#T&, ;G .@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@"AKO^I;\/_0A11KO^I;\/_0A10!PMS]X_P">U15+<_>/
M^>U14 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;O@[_ %S?]<S_
M .A+6%6[X._US?\ 7,_^A+0!V-%%% !1110 4444 %%%% !1110 4444 %<I
MJFG2:QJ$2L&%M9J)"2&56F)^49R VT8;(! Y5OO8KJZ* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .:\76CI):ZA
M$K.UO-A@H+8CF&R1MJ_,2.,8SCDD$=.EHHH **** "BBB@ HHHH *J:K?&QB
M>=59V120B EF/91M#'D\9P<=3P*MT4 8_A'3)-,M8X)B6EP6<GD[I&+L"<G)
M!;&<\]>];%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %0W?W&_W3_*IJAN_N-_NG^5 %71/N'_>/\A6A6?HGW#_ +Q_
MD*T* ,2Y\&6EU.+]X\SAE;=O<<IC:<!L<8';ZUH:II<>JQM;3KNC?&1DC.""
M.00>H'>K=% &?HF@0:(AAMEV(6+$;F;D@#.6)/0"JESX,M+J<7[QYG#*V[>X
MY3&TX#8XP.WUK;HH S];T"#6T$-RN] P8#<R\@$9RI!Z$U+I>EQZ5&MM NV-
M,X&2<9))Y))ZD]ZMT4 8-AX&L]/F%Y#$%E!8@AGP-P(.%W;0,$\8P.U/N?!E
MI=3B_>/,X96W;W'*8VG ;'&!V^M;=% !6#+X&LY)_MQB'G;P^X,X^8$$-M#!
M<Y&3QR>3G)K>HH Q-;\&6FMN)KF/>X4*#O=> 2<85@.I-;=%% $-W:K=HT,@
MRDBE6&2,AA@C(YZ5GZ%X6MM!W?9DV>9MW?,S9VYQ]XGU/2M:B@ IDT*S*4<
MJP(((R"#P00>H-/HH Y>;X9:=*Q<P#+$DX>11SZ , ![ 8':NBM;1+11%$JH
M@SA4 51DY. ..M344 <I_P *MT[_ )X_^1)?_BZ/^%6Z=_SQ_P#(DO\ \775
MT4 5X=/CBB%J%'E*@0*?F&T#;M.<Y&..>O>N?F^&6G2L7, RQ).'D4<^@#
M>P&!VKJ** *FF:5%I:"&!%1!V48R< 9)ZDX R3DGN:J:WX5M=;P;F-7(QAN5
M; SQN4@XY/&<9YQFM:B@#$T;P79Z,WFP1*K_ -XEG8<$<%R2,@G.,9[UMT44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Q=,_U\G_ O_0A6U6+IG^OD_P"!?^A"@#:HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q=3_ -?'
M_P !_P#0C6U6+J?^OC_X#_Z$:VJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "LSQ!_JQ_O#^1K3K,\0?ZL?[P_D: -.BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EK'^J;\/YBC1
M_P#5+^/\S1K'^J;\/YBC1_\ 5+^/\S0!=HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AKO
M^I;\/_0A11KO^I;\/_0A10!PMS]X_P">U15+<_>/^>U14 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %;O@[_ %S?]<S_ .A+6%6KX<A:60A#@[#W
M([CTH [FBLG^SYO[_P#X\W^%']GS?W__ !YO\* -:BLG^SYO[_\ X\W^%']G
MS?W_ /QYO\* -:BLG^SYO[__ (\W^%']GS?W_P#QYO\ "@#6HK)_L^;^_P#^
M/-_A1_9\W]__ ,>;_"@#6HK)_L^;^_\ ^/-_A1_9\W]__P >;_"@#6HK)_L^
M;^__ ./-_A1_9\W]_P#\>;_"@#6HK)_L^;^__P"/-_A1_9\W]_\ \>;_  H
MUJ*R?[/F_O\ _CS?X4?V?-_?_P#'F_PH UJ*R?[/F_O_ /CS?X4?V?-_?_\
M'F_PH UJ*R?[/F_O_P#CS?X4?V?-_?\ _'F_PH UJ*R?[/F_O_\ CS?X4?V?
M-_?_ /'F_P * -:BLG^SYO[_ /X\W^%']GS?W_\ QYO\* -:BLG^SYO[_P#X
M\W^%']GS?W__ !YO\* -:BLG^SYO[_\ X\W^%']GS?W_ /QYO\* -:BLG^SY
MO[__ (\W^%']GS?W_P#QYO\ "@#6HK)_L^;^_P#^/-_A1_9\W]__ ,>;_"@#
M6HK)_L^;^_\ ^/-_A1_9\W]__P >;_"@#6HK)_L^;^__ ./-_A1_9\W]_P#\
M>;_"@#6HK)_L^;^__P"/-_A1_9\W]_\ \>;_  H UJ*R?[/F_O\ _CS?X4?V
M?-_?_P#'F_PH UJ*R?[/F_O_ /CS?X4?V?-_?_\ 'F_PH UJ*R?[/F_O_P#C
MS?X4?V?-_?\ _'F_PH UJ*R?[/F_O_\ CS?X4?V?-_?_ /'F_P * -:BLG^S
MYO[_ /X\W^%']GS?W_\ QYO\* -:BLG^SYO[_P#X\W^%']GS?W__ !YO\* -
M:BLG^SYO[_\ X\W^%']GS?W_ /QYO\* -:BLG^SYO[__ (\W^%']GS?W_P#Q
MYO\ "@#6HK)_L^;^_P#^/-_A1_9\W]__ ,>;_"@#6HK)_L^;^_\ ^/-_A1_9
M\W]__P >;_"@#6HK)_L^;^__ ./-_A1_9\W]_P#\>;_"@#6HK)_L^;^__P"/
M-_A1_9\W]_\ \>;_  H UJ*R?[/F_O\ _CS?X4?V?-_?_P#'F_PH UJ*R?[/
MF_O_ /CS?X4?V?-_?_\ 'F_PH UJ*R?[/F_O_P#CS?X4?V?-_?\ _'F_PH U
MJ*R?[/F_O_\ CS?X4?V?-_?_ /'F_P * -:BLG^SYO[_ /X\W^%']GS?W_\
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M^SYO[_\ X\W^%']GS?W_ /QYO\* -:BLG^SYO[__ (\W^%']GS?W_P#QYO\
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M_)'[D'MZO\S^]EO^PX?[OZM_C1_8</\ =_5O\:J?V9/_ ,]/_'F_PH_LR?\
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MG_YZ?^/-_A0!M45B_P!F3_\ /3_QYO\ "C^S)_\ GI_X\W^% &U16+_9D_\
MST_\>;_"C^S)_P#GI_X\W^% &U16+_9D_P#ST_\ 'F_PH_LR?_GI_P"/-_A0
M!M45B_V9/_ST_P#'F_PH_LR?_GI_X\W^% &U16+_ &9/_P ]/_'F_P */[,G
M_P">G_CS?X4 ;5%8O]F3_P#/3_QYO\*/[,G_ .>G_CS?X4 ;5%8O]F3_ //3
M_P >;_"C^S)_^>G_ (\W^% &U16+_9D__/3_ ,>;_"C^S)_^>G_CS?X4 ;5%
M8O\ 9D__ #T_\>;_  H_LR?_ )Z?^/-_A0!M45B_V9/_ ,]/_'F_PH_LR?\
MYZ?^/-_A0!M45B_V9/\ \]/_ !YO\*/[,G_YZ?\ CS?X4 ;5%8O]F3_\]/\
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MG_YZ?^/-_A0!M45B_P!F3_\ /3_QYO\ "C^S)_\ GI_X\W^% &U16+_9D_\
MST_\>;_"C^S)_P#GI_X\W^% &U16+_9D_P#ST_\ 'F_PH_LR?_GI_P"/-_A0
M!M45B_V9/_ST_P#'F_PH_LR?_GI_X\W^% &U16+_ &9/_P ]/_'F_P */[,G
M_P">G_CS?X4 ;5%8O]F3_P#/3_QYO\*/[,G_ .>G_CS?X4 ;5%8O]F3_ //3
M_P >;_"C^S)_^>G_ (\W^% &U16+_9D__/3_ ,>;_"C^S)_^>G_CS?X4 ;5%
M8O\ 9D__ #T_\>;_  H_LR?_ )Z?^/-_A0!M45B_V9/_ ,]/_'F_PH_LR?\
MYZ?^/-_A0!M45B_V9/\ \]/_ !YO\*/[,G_YZ?\ CS?X4 ;5%8O]F3_\]/\
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M3_\ /3_QYO\ "@#:HK%_LR?_ )Z?^/-_A1_9D_\ ST_\>;_"@#:HK%_LR?\
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M,G_YZ?\ CS?X4 ;5%8O]F3_\]/\ QYO\*/[,G_YZ?^/-_A0!M45B_P!F3_\
M/3_QYO\ "C^S)_\ GI_X\W^% &U16+_9D_\ ST_\>;_"C^S)_P#GI_X\W^%
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MU+?A_P"A"BLS4+&:)"SOE1C(W,>X]:* .8N?O'_/:HJEN?O'_/:HJ "BBB@
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MC>#59#:8>*<9_=3IL<@ '('(Z'.,YP"<8YH Z"BLS7?$$6B+&\V0LLJQ@C&
M6R=S$D848Y/;TJEH?C)-;?9#%-Y9W8E:,+$0IQD,6R<G@#&?4#!P =!5>_U"
M/3T,TS!4!4%CT&Y@HR>PR1ST'4\58KE/BE_R#I_^V?\ Z-2@#JZAN[I;1&FD
M.$C4LQP3@*,DX'/2L+0-0DL9#IEVQ,@+&!VY\V(=,MQF1/XQ@'&&Y&6J[XL_
MX\[G_KWF_P#0&H T+2Z6[19HSE)%#*<$9##(.#STJ:LGPG_QYVW_ %[P_P#H
M"U5U/QO!9N;>,//*OWH[9/-90"02<8 P1@C.02..: .@JCK6L1Z/"]W-G9&,
MG R3D@  >I) [#U('-9&G>/X+J46DBRP2OC8MQ'Y9;.>G)'48YQD\#)JU;>(
MH=3LFU#:Q@,<A9752Q5-P8%<D'.T\9P>] !_PE\'V/\ M;+>3MS]WYL[MNW'
MKN^7KC/.<<U=T76(]8A2[ASLD&1D8(P2""/4$$>GH2.:K_VA#]C^U;/]'^S[
M]FU?]7LW;=N=OW>,9QVZ5;TFX2YACEB&V-XT*K@#"E05&!P,#L.* +=%<_J?
MC>"S<V\8>>5?O1VR>:R@$@DXP!@C!&<@D<<U%IWC^"ZE%I(LL$KXV+<1^66S
MGIR1U&.<9/ R: .EHK'L?%$5[:'5%#"()(V"!OQ&6!XR1GY3CFLR#XBPWC+'
M;Q33$K&3Y2*RH9!D*S%@%([\X'(SD' !U=%%9.N^)(]&VJX=Y)-VR.)"[MMQ
MNP!QP#DY(XSC- &M16/H?BJ'5V:)=R3(,M%*I210>A(/4'@\$X!&<9JQHNMI
MJRLZ!E,<CQNK@;E9#R#@D'L<@D<]<YH T**AN[I;1&FD.$C4LQP3@*,DX'/2
MLIO%<:16]RR.%NY(T0$+N!ER5)PQ ! SP21GIG( !MT5R\WQ!A+$6\4]PJD@
MO;Q%T##JNXD9/0\9&""#6QH6NQ:Y$+F Y5NH/WE/=2.Q'_UQD$$@&A1534]5
MBTM#-.ZH@[L<9."< =2< X R3V%<_P#\+#C^_P"1<^5U\WR#Y>W_ )Z9SG;C
MG.,X[=J -N]UM+2>&S8-ON?,VD ;1Y:[CGG/3I@'\*T*XJ_U6+5+[3IH'5T/
MVKE3G!\E3@CJ#@C(.".XK5UWQQ;Z'(8)RP98?-& ,,-VP(.<EB>V,8Y) !P
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MA7G7B3Q/MU"U;R+C_1VN1@1<R93;F/GY@,9)XXP:Z^Y\1):B!I%=1=,JKN4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+_T(4 ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &+J?^OC_ . _^A&MJL74_P#7Q_\  ?\ T(UM4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %9GB#_ %8_WA_(UIUF>(/]6/\
M>'\C0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *W?!W^N;_KF?\
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M_P +#YE(R,' 8X)KK:Y+QWX9:\5[VW)$ZP21E?F(DC96RFU?XAG<GJV 0>"
M"OJ6IOIFBK/$<.+6  \@C>$0D$$$$!L@]CBNB\.:#'H4"6L8'R@;B!C<V/F8
M\GD_4X& . *S;+1EUK2XK1^!):Q#//!"*5; (S@@'&><8/%4=/\ %S:#&MOJ
MJM&R#:)@&DBDQPIW#<P=@"2",\;CC(  .@\1Z#'KL#VL@'S [21G:V/E8<CD
M?49&0>":Y+PU_P @%O\ KWNOYR58U+QQ_;JFRTH-))( IEVLD<0;=EBQPP8
M97CKT)(VFOX:_P"0"W_7O=?SDH U?^8-_P!P_P#]H55U+4WTS15GB.'%K  >
M01O"(2"""" V0>QQ5K_F#?\ </\ _:%366C+K6EQ6C\"2UB&>>"$4JV 1G!
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MH00#GBLF*\N-1U6TNYT:*)_M"Q1OD/A(SN=E/"EBP_  <@!FZ#_F,_\ </\
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MZ!#"L*A$ "J   ,  <  #H!0!PO@'08WNKW46 ,@NYHTR/NX8EB#GJVX#ID
M'G#$5WM>9>&K^YTJXO+E8FFM6NYE98CND1U;A@A(R&W ''.!DD!<'HO^%FV4
MORP,\TAZ1Q12%V]< JHX&2>>@- %?0;0:)J4UC#@03P"<( 0$8/Y9"C.,-R3
MP/X0,!><73=<"WUU?303SR1RM#&88C(D:QY4@$OPS9R0 ,9)!PY%=+X7T:=I
MY=5O %FE 1(PQ;RXU/W<@E26(!.!UYXW%14N&E\)W$DX0O8W+EY-BEGA<CYW
M/4E&QD]E[ 8 < FF\<K,I1[*[*L""#;9!!X((+<@TSX=DPB>W6*:*!9 T0N
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M$16[,G&"\@1NG.5"L!S[G^E=QX9\50>(XS- 3\IPRM@.OID G@]B"0>G4$
MV**Y+QA\1X/#C>1@R38!V*0 ,X^\W."1R  3TS@$&LG0?C)!?R"&>,P[B &W
MATYS]XX7:.G.".<G &: /0Z**\RU'XUK:RO$D =4=E#B;A@I(##"'@]>I^M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L73/\ 7R?\"_\ 0A6U6+IG^OD_X%_Z$* -JBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?2\7^'SKL!A1MDJ,KQODC:Z]#\ISTR,\XSD D"@#3T_3X].C6WA4+&@P /\
M/)/4D\D\GFN?^(V@QZK9R,X&^!&D1L9(VC<PZCA@,'MT."0*BA^(":>HCU)&
MMYL#.49XV/<HR;L@9&1_"3C)P36)XL\7-XBMY;?3U8Q*CF6=@R)M10Y13P2S
M?=(('&>"IW  [+PG_P >=M_U[P_^@+6M63X3_P"/.V_Z]X?_ $!:UJ .4_YC
M/_</_P#:]1>.83J<]GI;'$5Q([28SEA"H?9PPX;/X'!'3F7_ )C/_</_ /:]
M6/&6A2WZQW5J0+FU??'DD!@?O1G!'#8'7TQD DT =!#"L*A$ "J   ,  <
M#H!7'_$JT%K$NKQX6>T="&P?F4L%,9((^4[LGVR!C<:FA^)EM$H%V)+:4@$I
M+$^?J"%.5SD G!.#P*HZA+)XW=+:.-TL597DDD#)YH!.U$&02K#G/;@X! #
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M3_/%!@24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>/FP>2QKE[;7&US5(+QU"L\]OD#IE2BDC/8XSCG'3)ZT ?0=>)>*'/BW5Q:
M$*CB'C"MMC),C9)(R/F(]0!QGBO3_&^O'0[22Y4@28VID@?,QP" 0<E>6QCD
M ]N:\E^'7BJU\--)/.LC2N J[%4@+U/)<9)(';C'!Y(H T_A+J#:1>R:;(N&
MERIQ@D/#N.,@XQC=TSDXQQFO9:^?_&7B>'4KM-2LPZ2#:6\Q5^]'C:P^9P>
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MUA\,>=YZNWF^7CRPI^[NSG++_>%>H:!(OB[3XS=+N$JX<9(R8WQNRNW&2N[
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MBBO'/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK4TC5S:'8_*']/\ ZWJ/Q'OEUJ:1I!NSO?A!^O\ ];U/X#VZ,)[7VJY-_P"M
M_(QQ/L_9OGV.G5@PR.0:6D50HP. *6OJ$>"%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5!>_ZM_P#=;^53U!>_ZM_]UOY4 4_#_P#JS_O'^0K3
MK,\/_P"K/^\?Y"M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K%TS_7R?\  O\ T(5M5BZ9_KY/^!?^A"@#:HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q=3_U\?_ ?_0C6U6+J
M?^OC_P" _P#H1K:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *S/$'^K'^\/Y&M.LSQ!_JQ_O#^1H TZ*** "BBB@ HHHH ****
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MOCN <'&#T=% 'CEGX>UW28VLX,^5E@-KQ=^I4L0Z@]1C:03G .:ZCP#\-?\
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M_+OY_H>EEGV_E^H4445XYZ04444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-8 T;I*_G)(6& R'"D<@J!G!R#@\ 8[6@ HHHH **** "BBB@ HHHH ****
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M@Y]>M85 !1110 4444 %%%% !1110 4444 %%%% !1110 5N^#O]<W_7,_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *AN_N-_NG^535#=_<;_=/\J *NB?</\ O'^0K0K/T3[A_P!X_P A6A0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% &?K?W!_O#^1K!319G 8+P1ZK_C6]K?W!_O#^1JU:?<
M7_='\JYL5@X8BW,WIV-Z&)E1O:VO<YC^PYO[OZK_ (T?V'-_=_5?\:ZVBN;^
MQZ/>7X?Y&W]I5>R_'_,Y+^PYO[OZK_C1_8<W]W]5_P :ZVBC^QZ/>7X?Y!_:
M57LOQ_S.2_L.;^[^J_XT?V'-_=_5?\:ZVBC^QZ/>7X?Y!_:57LOQ_P SDO[#
MF_N_JO\ C1_8<W]W]5_QKK:*/['H]Y?A_D']I5>R_'_,Y+^PYO[OZK_C1_8<
MW]W]5_QKK:*/['H]Y?A_D']I5>R_'_,Y+^PYO[OZK_C1_8<W]W]5_P :ZVBC
M^QZ/>7X?Y!_:57LOQ_S.2_L.;^[^J_XT?V'-_=_5?\:ZVBC^QZ/>7X?Y!_:5
M7LOQ_P SDO[#F_N_JO\ C1_8<W]W]5_QKK:*/['H]Y?A_D']I5>R_'_,Y+^P
MYO[OZK_C1_8<W]W]5_QKK:*/['H]Y?A_D']I5>R_'_,Y+^PYO[OZK_C1_8<W
M]W]5_P :ZVBC^QZ/>7X?Y!_:57LOQ_S.;L/#[,V91A1VR,GVX_S_ $Z-5"C
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M%%%% !1110 4444 %%%% !1110 4444 %%;/B'1TTW9L).[=G<1VQZ >M8U
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M_P "H\Z?^ZO^?^!5H44 9_G3_P!U?\_\"H\Z?^ZO^?\ @5:%% &?YT_]U?\
M/_ J/.G_ +J_Y_X%6A10!G^=/_=7_/\ P*CSI_[J_P"?^!5H44 9_G3_ -U?
M\_\  J/.G_NK_G_@5:%% &?YT_\ =7_/_ J/.G_NK_G_ (%6A10!G^=/_=7_
M #_P*CSI_P"ZO^?^!5H44 9_G3_W5_S_ ,"H\Z?^ZO\ G_@5:%% &?YT_P#=
M7_/_  *CSI_[J_Y_X%6A10!G^=/_ '5_S_P*CSI_[J_Y_P"!5H44 9_G3_W5
M_P _\"H\Z?\ NK_G_@5:%% &?YT_]U?\_P# J/.G_NK_ )_X%6A10!G^=/\
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M #I_[J_Y_P"!4>=/_=7_ #_P*M"B@#/\Z?\ NK_G_@5'G3_W5_S_ ,"K0HH
MS_.G_NK_ )_X%1YT_P#=7_/_  *M"B@#/\Z?^ZO^?^!4>=/_ '5_S_P*M"B@
M#/\ .G_NK_G_ (%1YT_]U?\ /_ JT** ,_SI_P"ZO^?^!4>=/_=7_/\ P*M"
MB@#/\Z?^ZO\ G_@5'G3_ -U?\_\  JT** ,_SI_[J_Y_X%1YT_\ =7_/_ JT
M** ,_P Z?^ZO^?\ @5'G3_W5_P _\"K0HH S_.G_ +J_Y_X%1YT_]U?\_P#
MJT** ,_SI_[J_P"?^!4>=/\ W5_S_P "K0HH S_.G_NK_G_@5'G3_P!U?\_\
M"K0HH S_ #I_[J_Y_P"!4>=/_=7_ #_P*M"B@#/\Z?\ NK_G_@5'G3_W5_S_
M ,"K0HH S_.G_NK_ )_X%1YT_P#=7_/_  *M"B@#/\Z?^ZO^?^!4>=/_ '5_
MS_P*M"B@#/\ .G_NK_G_ (%1YT_]U?\ /_ JT** ,_SI_P"ZO^?^!4>=/_=7
M_/\ P*M"B@#/\Z?^ZO\ G_@5'G3_ -U?\_\  JT** ,_SI_[J_Y_X%1YT_\
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M6G10!F>?<_W%_/\ ^RH\^Y_N+^?_ -E6G10!F>?<_P!Q?S_^RH\^Y_N+^?\
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M5'GW/]Q?S_\ LJTZ* ,SS[G^XOY__94>?<_W%_/_ .RK3HH S//N?[B_G_\
M94>?<_W%_/\ ^RK3HH S//N?[B_G_P#94>?<_P!Q?S_^RK3HH S//N?[B_G_
M /94>?<_W%_/_P"RK3HH S//N?[B_G_]E1Y]S_<7\_\ [*M.B@#G+R20RJ7
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M//N?[B_G_P#95IT4 9GGW/\ <7\__LJ//N?[B_G_ /95IT4 9GGW/]Q?S_\
MLJ//N?[B_G_]E6G10!F>?<_W%_/_ .RH\^Y_N+^?_P!E6G10!F>?<_W%_/\
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MO-<_V?APX=DRP4)E<CKNSR1@<<DBFHM[#2;-'S[G^XOY_P#V5'GW/]Q?S_\
MLJTZYO7_ ![;Z))]GD#LVT$[ I SV.6!!QSCT(/>B,7)V0)-FCY]S_<7\_\
M[*CS[G^XOY__ &5:=%(1F>?<_P!Q?S_^RH\^Y_N+^?\ ]E6G10!F>?<_W%_/
M_P"RH\^Y_N+^?_V56M3O/L,4D^,^6C-C.,[03C/.,XK$\'>,?^$C\S]WL\K9
M_'NSNW?[(QC%-1;3?0=G:YH^?<_W%_/_ .RH\^Y_N+^?_P!E6G12$9GGW/\
M<7\__LJ//N?[B_G_ /95IT4 9GGW/]Q?S_\ LJ//N?[B_G_]E6G10!F>?<_W
M%_/_ .RH\^Y_N+^?_P!E6G63H&N_VOYWR[?(N)(OO9SLQ\W08SGISCUH ?Y]
MS_<7\_\ [*CS[G^XOY__ &5:=% &9Y]S_<7\_P#[*CS[G^XOY_\ V5:=% &9
MY]S_ '%_/_[*CS[G^XOY_P#V5:=% &9Y]S_<7\__ +*CS[G^XOY__95IT4 9
MGGW/]Q?S_P#LJ//N?[B_G_\ 95IT4 9GGW/]Q?S_ /LJ//N?[B_G_P#95IT4
M 9GGW/\ <7\__LJ//N?[B_G_ /95IT4 9GGW/]Q?S_\ LJ//N?[B_G_]E6G1
M0!F>?<_W%_/_ .RH\^Y_N+^?_P!E6G10!F>?<_W%_/\ ^RH\^Y_N+^?_ -E6
MG10!F>?<_P!Q?S_^RH\^Y_N+^?\ ]E6G10!F>?<_W%_/_P"RH\^Y_N+^?_V5
M:=% &9Y]S_<7\_\ [*CS[G^XOY__ &5:=% &9Y]S_<7\_P#[*CS[G^XOY_\
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M%)!D!">I'.1Z8]:UO"L;6L;RR9"<$9ST R6QZ$8Y'7%4/!W^N;_KF?\ T):
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M!QD8&#S]3FGZW)_9ENEJO!88)&<<<MSUY)_+- ',RL&)*C ).!G.!Z9IE%%
M!1110 4444 %%%% !1110 4444 %;O@[_7-_US/_ *$M85;O@[_7-_US/_H2
MT =C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !4-W]QO\ =/\ *IJAN_N-_NG^5 %71/N'_>/\A6A6?HGW
M#_O'^0K0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#/UO[@_WA_(UYM7I.M_<'^\/Y&O-J#IP
MO4****#I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +VD:
MN^F/O7D'[R]B/\?0]OID5Z%87Z7Z"6,Y!_,'T/O_ )Z5Y?5[2-7?3'WKR#]Y
M>Q'^/H>WTR*#*K2Y]5N>ET56L+]+]!+&<@_F#Z'W_P ]*LT'$U8**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@O?]6_\ NM_*IZ@O?]6_
M^ZW\J *?A_\ U9_WC_(5IUF>'_\ 5G_>/\A6G0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5BZ9_KY/^!?\ H0K:K%TS_7R?\"_]
M"% &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!BZG_KX_P#@/_H1K:K%U/\ U\?_  '_ -"-;5 !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !69X@_P!6/]X?R-:=9GB#_5C_ 'A_
M(T :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M %+6/]4WX?S%&C_ZI?Q_F:-8_P!4WX?S%&C_ .J7\?YF@"[7EGQ.M#IUU%?1
MX#. <]3OB(YP<C&"N/H<CU]3KF_B#I/]I6CX.##^\'I\@.0>#_"3CISCG%:4
M9<LT5!V9K:;JJ7L"7F0JL@8_,"%XRP+<#Y3D'ITYQ7F?AG_BI-4-TW*JS28;
MY3A,+&/EXRIV]^<')/>#3?%GV?39;+)\S?M3A?N2<M[D<-DX."RX/IU?PJTG
M[+;M=$\SMP.P$9*CMUSN[GC'O6G+[.,G\D5;E3.HUC6(](C-Q,<*.@'4GLH'
M<G_ZYP 37#R_&  D+ 2N3@F3!([9&PX/MD_6J'Q<N6:XCB)^58MP''5F()]>
M0H_*I+;Q'J%M&+9+,"(+MV^1*1@]0<MSGOGKWHA27*F];^=@C%6N=[X?\20Z
MZAEA)^4X96P&'ID G@]B#C\00,35OB(FE736<J'8@Y<-D\IO "[>I)V]<=R0
M*YGP!8W-C>AV@=(Y%=6W1N%48W  M[J ,D_GS5;Q3;+=:MY3C*O+ I'(R"J
MCCGI0J4>=KI:X*"N;>H_$!KZREE,.U78P@^8#R\;$G[H/RC''?/7BN?^'GB3
M^R9?(V;OM+Q+G=C;R1G&#G[WMTKU'Q+_ ,>L_P#UPE_] -<3\'O^7C_ME_[/
M1&4?9RT!-<KT.B\4^/(=!/DX,DN =JD #./O-S@D<@8)]< @UC:?\7(Y7"S1
M%%/\2MOQR.HVJ<8Y.,GT!KA]%OYFN#=1Q">;+/@HS8).2^U".03QV!/ SC&W
MX@U&_P!=0136A^4Y5EAE##UP23P>X(Q^(!%>QBM']]Q\B6AZK+<$QF6(!SL+
M* P ;C*@-TP?7IWKE- ^(JZE/]DFC\ECD#<Y)W@XV8*K@]>O<8ZD59^'"2Q6
M@AF0H8W8*&4J2#ALX/NQ&?:N7^*=E':31W<;;9WY8!CN^7 5QCITQU&<# R&
M-9PA%R<7\F3&*O8W]?\ B*NFS_9(8_.88!VN0=Y.-F K9/3IW..H-=;;2-(B
MLZ[6*@E<@X)'(R.#@\9[UYG\*=,AFD:X9LSQYVITP",%_?J1[=^2N/4:FK&,
M7RH4TEH5-4N)+:-I((_-D&,)O"9R0#\QX&!D_ABN*^'FHW+27$;6^(WO)VD?
MS5/EM@$IMQEL$ ;AQSGM7H%<IX _Y?/^PA<?^RUF2;&N>(H=%53,3ND.$106
M=V_NJHZD\#L,D D9%8__  E-[_K/L#^5USYT?F;>N?*Z[L?P9SGY<U%I5L+W
M5;J>3EK6.%(\@842*78],YSGG/1B.F,=A0!D^'_$L6NJS1;E:-BKQR#;(A!(
MPRY.,XX_$=00-:N/U6V%EJMK/'PUU',DF ,,(U#J>F<YQSGHH'3.>PH Q_$O
MB)="6)W *RSI&26VA0^27)(/ Q[?45CP^.9]3):QM'FB'_+1W6%6.6'R[P=P
MX^HZ$#NSXGV2W\5M;OD++>PJ2.N&#@XSGGFNPAA6%0B !5   &  .  !T H
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MP3D\+@GDX&37F_@-SJNL&[B!V;YY#G (5PP&1GKEP,#/Y<T >A>.O'B>&%"
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M%_Z$*VJQ=,_U\G_ O_0A0!M4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 8NI_Z^/_ (#_ .A&MJL74_\ 7Q_\!_\ 0C6U0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F>(/]6/\
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M@#"HHHH **** "BBB@ HHHH **** "MWP=_KF_ZYG_T):PJW?!W^N;_KF?\
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M8#DJK(%#'T!/ )X)XZUU=<OI)74-1N+D XMXHX P.48DF23M]Y3A2,\=^HP
M=11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5#=_<;_=/\JFJ&[^XW^Z?Y4 5=$^X?]X_
MR%:%9^B?</\ O'^0K0H Q/&6A#6[26WQE]I9.@.]>5P6X&3P3QP2,C->&V?B
MAK>QETO Q+*C9QV&"W.>N43'!XW9[5]&UY)JOP:FN;AY(GB6!Y"0,,&56.2
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M;^53U!>_ZM_]UOY4 4_#_P#JS_O'^0K3K,\/_P"K/^\?Y"M.@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%TS_7R?\  O\ T(5M
M5BZ9_KY/^!?^A"@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH Q=3_U\?_ ?_0C6U6+J?^OC_P" _P#H1K:H **** "BBB@
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M;FYG>QL%B+0*C2/.SA07R0@51DDC#;@2,9!YJ_H&H3W0=+J+RWB8+N5MT;\
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MB0L,9.1\S=20>JJ,D9 .5(%2YU#5]/'G/%;S(,[D@:19,8)R"_'7L 2>@'<
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M_P :WZH:)!Y4>[NQST[=O\?QJ_0><%%%% !1110 4444 %%%% !73_\ ,/\
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MTU3'$N 69CDEF+,<EBS$EB?4DGMT%6Z* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
M&[^XW^Z?Y5-4-W]QO]T_RH JZ)]P_P"\?Y"M"L_1/N'_ 'C_ "%:% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 9^M_<'^\/Y&O-J])UO[@_WA_(U@0^!O,4-YG4 _<]?^!4&]
M"<8WN<K176?\('_TU_\ '/\ [*C_ (0/_IK_ ..?_94&_MX=SDZ*ZS_A _\
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M_",'^\?^^?\ Z]'_  C!_O'_ +Y_^O110 ?\(P?[Q_[Y_P#KT?\ ",'^\?\
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MZ'^-'V^/^^O_ 'T/\:** #[?'_?7_OH?XT?;X_[Z_P#?0_QHHH /M\?]]?\
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MZ'^-'V^/^^O_ 'T/\:** #[?'_?7_OH?XT?;X_[Z_P#?0_QHHH /M\?]]?\
MOH?XT?;X_P"^O_?0_P :** #[?'_ 'U_[Z'^-'V^/^^O_?0_QHHH /M\?]]?
M^^A_C45Y?1LC .N2I_B'I110!4T.Z2-"&8 [CU('85H?;X_[Z_\ ?0_QHHH
M/M\?]]?^^A_C1]OC_OK_ -]#_&BB@ ^WQ_WU_P"^A_C1]OC_ +Z_]]#_ !HH
MH /M\?\ ?7_OH?XT?;X_[Z_]]#_&BB@ ^WQ_WU_[Z'^-'V^/^^O_ 'T/\:**
M #[?'_?7_OH?XT?;X_[Z_P#?0_QHHH /M\?]]?\ OH?XT?;X_P"^O_?0_P :
M** #[?'_ 'U_[Z'^-'V^/^^O_?0_QHHH /M\?]]?^^A_C1]OC_OK_P!]#_&B
MB@ ^WQ_WU_[Z'^-'V^/^^O\ WT/\:** #[?'_?7_ +Z'^-'V^/\ OK_WT/\
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M/\:/M\?]]?\ OH?XT44 'V^/^^O_ 'T/\:/M\?\ ?7_OH?XT44 'V^/^^O\
MWT/\:/M\?]]?^^A_C110!DZA<J\R,&! VY((Q]XUK?;X_P"^O_?0_P :** #
M[?'_ 'U_[Z'^-'V^/^^O_?0_QHHH /M\?]]?^^A_C1]OC_OK_P!]#_&BB@ ^
MWQ_WU_[Z'^-'V^/^^O\ WT/\:** #[?'_?7_ +Z'^-'V^/\ OK_WT/\ &BB@
M ^WQ_P!]?^^A_C1]OC_OK_WT/\:** #[?'_?7_OH?XT?;X_[Z_\ ?0_QHHH
M/M\?]]?^^A_C1]OC_OK_ -]#_&BB@ ^WQ_WU_P"^A_C1]OC_ +Z_]]#_ !HH
MH /M\?\ ?7_OH?XT?;X_[Z_]]#_&BB@ ^WQ_WU_[Z'^-'V^/^^O_ 'T/\:**
M #[?'_?7_OH?XT?;X_[Z_P#?0_QHHH /M\?]]?\ OH?XT?;X_P"^O_?0_P :
M** #[?'_ 'U_[Z'^-'V^/^^O_?0_QHHH /M\?]]?^^A_C1]OC_OK_P!]#_&B
MB@ ^WQ_WU_[Z'^-'V^/^^O\ WT/\:** #[?'_?7_ +Z'^-'V^/\ OK_WT/\
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MQ_WU_P"^A_C1]OC_ +Z_]]#_ !HHH /M\?\ ?7_OH?XT?;X_[Z_]]#_&BB@
M^WQ_WU_[Z'^-'V^/^^O_ 'T/\:** #[?'_?7_OH?XT?;X_[Z_P#?0_QHHH /
MM\?]]?\ OH?XT?;X_P"^O_?0_P :** #[?'_ 'U_[Z'^-'V^/^^O_?0_QHHH
M /M\?]]?^^A_C1]OC_OK_P!]#_&BB@ ^WQ_WU_[Z'^-'V^/^^O\ WT/\:**
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7QHHH I:S>))$RJRDG' ()ZBBBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>mrna-20211231_g6.jpg
<TEXT>
begin 644 mrna-20211231_g6.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$'_@]Y
M_P"36?@?_P!E U'_ -(111_P>\_\FL_ _P#[*!J/_I"** //_P#@TV_Y2F?M
M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J "BBB@ HHHH ****
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MG[47[,]_X'UCXG6/[1/@6;PUX>56U_Q#%XNLFL=,4]#<3B7RX0>V]AFOBO\
MX+F>%+3_ (*&?L$:+\,/V0O^"D_PO^'NH:YK]GX@TW6=2^)<5CIOBK28EN(7
M@6[M6=WA\YDD#(LB&2U"MC[R_E'_ ,&Q?_!,;X3_ /!4#]F[X\?"G]J+Q/XF
M'@#3=8TE](T/PWK;V.-;EM[E1J<A4%9I+:% L,<HDA!NIBT;':1]%_\ !RS^
MPC\%/^">W_! WX-?LM?!M]2U'2?!/QOMXM,UCQ#+'-J$AO++7+NY+21HB@/,
M^=B*JX1.#M!H _6K]A30;_\ 9M_X)^_#S0/CO^T[H_CF;PEX(@3Q%\4)=:5[
M"]6)26N/M<K8>%%P@FD8%EC#-@D@=;\*_P!L?]D/XZ3VMM\$OVJ?AOXQDOKY
M[*RC\*^.=/U!KBY2&2=X$%O,^^188I92@RP2)V(PI(_%S]N+X(_M.?'#_@T;
M^ 6G?LWZ7JFJ6V@Z;HNL^/\ 1=&1WGO-#@BO-[&-,M+'%<-:SN@!PL/F' B-
M;G_!&3_@IW^Q#_P5)_:K^!%]\:_AAX?^$_[3GPA2_@T#5?#FBQ0:9X^TN71;
MRQFT]"FTV[HLRW*P/O"&W;R3B61% /VF^+OQR^"G[/WA4^.OCS\8/"W@G1!,
M(CK/B[Q!;:;:^802$\VX=$W$ \9SQ2_"3XW_  6^/_A1?'GP(^+WA?QMH;2F
M)=9\(^(+;4K0N,$J)K=W3(R.,YYK\(?#'Q[\2?\ !03_ (/!]-^'_P :1_:O
M@SX.:WXATCP=X5U!?,L[)]-TJZ!N1$V5,KWJ?:?,QNRD0SB- #X@_'SQ%^P)
M_P '@TW@GX'L=)\)_%_6_#FC^-_"VGCR[*_DU/3;9/M#Q+A?-2[<7/F ;MS2
M\XD<, ?N7)^U)^S)%XT_X5O+^T7X$7Q%_:7]G?V"WB^R%[]L\SR_LWD>;YGF
M[_D\O&[=QC/%1^&/VK_V6O&_Q9O?@)X+_:4\ :OXZTWS/[1\%Z7XRL;C5K7R
M_P#6>99QRF9-O?<HQWK^?'_@OO\ #7PSXS_X.@?@CX%N%NM-M_%FJ?#ZVU>]
MT.[>RO"9]8-NTT<\1#QSB,*%E4AU**005%5/^"PGP-^#W[ W_!R#^S1IG['G
MPXTOX>V$J^"-1GT_PO;"UADN)-?NK29V5."98(423/\ K 6+;BS$@']+%4?$
MGB;PWX-T"[\5>+_$%CI6EZ? T]_J6I7:06]M$HRSR2.0J*!U)( J]7X#_P#!
MWI^U!\1_&/[7OP)_X)J66NWEEX)UNTT[Q)XIL;69HTU>:[U6:QMTEP?G6!;2
M9U7INGW')52H!^VGP6_:[_9._:2O[S2OV=OVG_AWX^NM.3=J%MX*\:V&JR6J
MY S(MM*Y09(&3CK7PK_P=!?\%+?B%^P5^P*-$_9J^+ECH'Q)\:^*K+1#+8:G
M$NKZ1I4UO>3S7T$>[S(RQM! LX7Y#,2K*X4CX_\ ^#MO4Y/V#/CY^R-^U9^R
M1967@7QGX>BU^SL-0\/VB6H-I8-I3VMHZ1A0]NHN;B,Q'Y&CG="-K$5T_P#P
M=VV/PM^+/_!*GX*?M?V?PJT.R\6^+?'?A[=XA_LF'^TTTZXT'5;P6#76SS6@
M61@WE%MFX;L9YH [S_@E7_P3L\5?M#7W[*G_  4F^ O_  4(U#1%\._##2D^
M-O@G2]3FU.X\4ZLQGN;@ZC*UV0))Q<+'(LT;,BVZ%.0I3[R_X*N_LU_&[]KK
M]F72_@!\"/B?XD\%:AKOQ#T%=;\5^$]4DL[[2]'2[5[Z:.2-E.?(5P%)PS%0
M1@FN6_X(,?"SX8?#O_@D_P# [7/A_P##C0="O?$OPUT?4/$=YH^CP6LNJWAM
M5!N+EXU4SRD<&1R6]Z^PJ /P*_X.=?V?HO\ @F3^RO\ "CQ1^R+^T%\;=%UW
M6_&,^FZ[KNH_'/Q)?3ZA EDT@#QSWS0(=XW$Q1IZ=.*]O_8<_P""8(_;V_X(
MC> _C-X>_:@^-WAKXV^*?!%W?6?CBS^.7B-X[C4TN+A(%GM)KY[80L8XT<1Q
MQMM)(8-S7(?\'NG_ ":#\%O^RDWG_IO>ON3_ (-W?^4+7[/_ /V*,W_I?=4
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M  2;_9JO_&&N:S8:G\2M=L)8?ASX(,P:>_NB"JW4R [DLXF^:20X#;?+4[V
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M$Q^=;:A)!%)@_P 0CF=<]2#S0!_1#1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!^(/_![S_R:S\#_ /LH&H_^D(HH_P"#WG_DUGX'_P#90-1_
M](110!Y__P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6#P?-J?@#0HM(M-7\&Z[=7D&I0QE]LKI<V=NT#;2H*@R D$[ATKZ*H _GG\
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MK_"R5(6\,ZC?1VJ^(-.2X%U%%'/*5CCFAG\QE$C(CK<298%5#?J510!^-O\
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M_BQ/$6A:-<>(()/$?BF4WB3/"98;DV5ML!=A+-)O=8HX=B#$H^LOV0/V2/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML:<M_H6IZ3X<AN[+4K?(5WBD6X# H^4975&!7(!5E9@#[/HK\]/C-_P<R_\
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M+).!^[LTK^MGXQ?&+X4?LX?";6_C1\9_&FG^&/"/A;36O-9UC4'V06ENF!T
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MMG:C4=5T* :4+>ZD"0W[727#*MJ5/F%R R*&WJK*R@ ^XJ*^"_A-_P '%W[
MOQ3_ &W--_8-O_"OQ4\%^+->NXK7PQJGQ!\"-H]AK,LPS:K"LTHNH_M (\HS
M6\0<LH!RR@_27[;G[>/[-/\ P3V^$"_&?]IGQM)IMA=:A'I^B:7I]F]WJ.M7
MTF?+M+.VC^>:5L'T50,LR@9H ]BHKXY^$'_!;?\ 9;^('[:D?_!/?XK_  S^
M(WP@^*][9PW.B>'?B?I%A"FK"6#SXT@N-/O;N'S&CR0CNA+*T?\ K!LK[&H
M**** "O,?VC/VT/V3OV0XM-N/VH?VA?"G@&+6&==*F\5:O'9I=,F"RHTA 8@
M$' .<5^0O_!6G_@NM\1;W_@JU\%_V"_AO\%OB+I?@OP5\7_#^L^.;8>%+F/6
M_&TL%['+;V]C8.JRRVNY!)'D W,HC90%16D[+_@ZB^-%A^T7_P $0/#WQ6M_
MA7XT\(+<_&?3%BT+XB>&)-)U6W:.WU*(N]M+EHPPR5/\2L#T- 'Z[?"KXK_#
M3XY?#W2_BQ\'?'.F>)O#.MP&?2-=T:[6>UO(PQ4O'(I(8;E89'<&N@K\5/\
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M_BA_P=+?&OXF?#?4DO?#_B+6/B#J>AWD<#Q">TN-4,L4@1U5DW(ZG:P!&<$
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MK_X*F_\ !.;XY^,+?X??!C]M#X>>*]<NF M])\/>(X;RX?+!0=D18@;F49/
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MKNG_ !TFFC^&\&A:!8W=S?F.,RLTD4=Z6MD$2O(SR[5148R%,8KZLTV[GO\
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M%'Q;\/>-?%&H#QE#JK>%OASX7?5M1ATV"Q43ZA.H9(;2UC) ,]Q+$F<@%B"
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MOA;4HY)/*2YM[J:5)I[4R?*+N.!K<_>$A3YZ /T#HKYX_P""BO\ P4P^ O\
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M_@C^QG^RV?VS/'>G:]XC^'<=O9W5SKW@FTAOU@L[HHMO=E3,A>!VEB >/?\
MZQ20%RP /;J*_.+6O^#H[_@FO;_LX2_M->"O"OQ<\7Z/8Z@;;7-.\*^ ?/N=
M#0NL<=Q?R23I:V<4LC;(O-G5Y2&V(P&:^Q?V)_VUO@#_ ,% OV<M$_:C_9N\
M2S:AX8UOS45;ZV\BZLKB)RDUM<1$GRY488(!*D%65F5E8@'?_$'XA>"?A3X-
MO_B%\1O$MKH^B:7$)=1U.^DV0VZ%@NYCV&2!GWKSO]G;]OO]BC]KCQ'?^$/V
M8?VI? _CW5-+LA>:C8>%O$,-Y+;6Y<)YKK&Q*KN95R>Y%?.6@_\ !PA^Q/\
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M::W\.+[5-9MS?Z;:+]LCGBU>VB ,9 CW0, UNV2V,#Z#_; _8!\4_P#!,?\
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M5\1O#DFOW.KZ7<Q> )-&O+6>=8ED1W_M&Y26/]T"H"(P+'+,, <!_P %O/\
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M]I=MKFAZE;WME>0)/:7EI,LD4\3J&5T=20RD$$$'!!R*\4_X*@_\HT?VB/\
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M<^DVNE>)AXB\4^+_ !#X#_MC4M<U$"X(\L1W]I!96P:ZEVVZ1L$5(40JJ$.
M?FU^V1I>F6'_  9C?!Q+'3X(0VKZ5.PAB"@ROJMZ7<X'+,6))ZDDYZUT'C#X
M@>/_  ?_ ,&1GAZ\\'WUS$^I6PTK5;N!B&CT^7QE<12(2.B.H6%AT*RE>]?8
M7Q:_X(!_&CXM?\$DO!'_  27U/\ ;R\/VN@^#M<^UOXOA^#4QN[^UCE>:VMC
M$=;V1LDLTI>4$^8HB4)&4=I/:OV0?^"1.@_!3_@EK=?\$H?VEOBO8?%'P-+I
MNHZ;;ZG8>$7T.Z2TN[N:\RX:]NU:>*XF+Q2KLV^7'E&*EF /@#_@F;^Q/^T/
M_P %5_\ @W)\)?L?>&?VGOA?X4^'^J37-E?0Q_"Z^O=<TJZLO$<E^5>Y&LQP
M,\CHDA/V9?W5R!C/SU^L?_!/;]F?Q)^QI^Q;\//V5O%?Q87QQ>> =!&C#Q,F
MG&T%U##(ZPJ(3+*8_+B\N'&]O]5VZ#\[/V'_ /@W-_;W_P"">_CO7O!_[+G_
M  63UOPE\)_$VI?:-=T33?AW9SZE<1[0O[HWCSP6MT8P(S>1(&^1&V854'ZK
M_"CX7^#O@K\.='^%?@"PEM](T2R6VM%N+EYYI,9+2S2N2\TTCEI))7)>1W9V
M)9B2 >(?\%9/^3*;_P#[*-X#_P#4PT:N'_X+6_\ !(SX8_\ !6S]E>X^'5]]
MCTGXA^&DFO?AMXMFC_X\KPJ-UK,R@L;6?:J2 9VD)( S1@'M?^"DW[''[2O[
M</PD7X(_!W]K+0?A;HLVJ:5J6HWT_P ,Y-<U&2ZT_4(K^#RI3J=M%%'YUO;%
ME,+L?+8;\.0/<_AAIGQ3T?P=;6'QE\:Z#X@UY.+K5/#?AJ;2;67@?=MIKR[9
M#G)_US=>@QR ?S+_ /!!+X_?M?\ P-_X*5?"3_@D)^T/I%Y8:7X*^..I^)(]
M!UG)N/#VIV_AC7[2X@@.2IMYQ>B8X)0LBR1_ZYV?]*_^#D_P7_P2^TWQ?\%_
MCQ^V9X@^)-_\3M U5H?A;\._A=JT,-]XI?[3!)Y,WG1.+> 3B(&X1HY!YA5/
M,8*%^M?V@/\ @E7\&OC!_P %%O@[_P %+_#4D.@^/_AM=7EOX@FAM<IXETR;
M3;JUCBFQC$\#SJR2\GR]\; @1F/PO_@M3_P;\V'_  5L^-O@#]H/PQ^U9J/P
MR\2^"]+&ERSQ>'CJ,<UJMR]S%+"%N8&@N(Y))#OW,&!3[NS) /RQ_P""O.K?
MM,ZI_P '%/[+OBO]J;0O"V@^+=0N/A_>+X;\(3S7$.A6[>))S'9RW<A_TVX0
MAB]PD<,;%MJ1X3>_V=_P<W?\$O?VO?C]\<?!?_!1O_@GUXKU#4/B1\)?"5K:
MZSX1\,ZB8]=LK*.]O+FSU.QC0[Y&,CWJ-&/GD$($8D*NH[;]K'_@U^U_]H;]
MHKX6?M4^'_\ @I=X_C\>^!(-.&N^+/'>BQ^(+S4[JRNVNK>ZMU::&&SV,VT6
MXC>'"J[!G,K3?6OQE_89_:VN?VJ_#/[6W[-'[:5MH.K^'_A?:^#]:T/QQX-_
MM:Q\8I%=37!GU 6MQ:>3*&EW));A2CO)A?+=HV /@W_@AM_P6P\9_M[>"OC5
MI7QH^&%E:_M-^ O@O/,OC32K,P'Q1I>G-<>0MQ:C"0W-O>7O(50KF[;:J %:
M\@_X,>)+'5_$_P"T]XAUBX^TZW+'X2/VJX??,\<CZRTS;CR=SK&6/<A<U^F?
M_!.C_@DE:?L@?M/?&#]N[XR?$+1O%7Q;^-%\[:W+X8\-MI6CZ-9M*LSVEI!)
M--(_F2)&\DLKEG,2< [V?Y\^$?\ P;N_'+]AS]M[Q9^TG_P3$_;UMOA7X/\
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MEO+W$L0#]*KV_L--A6XU&]AMXVFCB62>0(IDD<(B G^)G95 ZDL .37\[_\
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M]FK5#:75J2);8,EPDDR$<JR1L[AA]TKGM7RE_P &XGP1_:#_ &U_^"+7Q?\
MV0OA)\?/ACX5\-^(_%6NZ#XMM-<^'%]JFLP?VAI=I']MCGBU>VB ,9VQ;H&P
MUNV2P&!^G?\ P36_X);?$']C?]EQ/V6/VF/VKKOXQ^&;3PI>>%](\-MX8BTC
M2;31[J1GN(98(Y9'O97#>7YTSDQQ I&J;Y6E^/?V?/\ @V:_:\_8#_:6U_XD
M?\$U?^"LFI?#'P=XGD6+4=)U/X?V^L726:NS)!(EQ(;6\DC#,(YWBC==[8 R
MVX ^YO\ @C__ ,$_?%/_  3$_8NT[]CWQ-\>X_B&N@:]?W6G:M%HAT\6MO=2
M"X^R^29YL8D>63.[GSN@ZGL_^"FO_*-S]H/_ +(?XL_],]U7;_L[_ CP[^SG
M\+K/X;Z'X@U;7+A9I;O6_$OB&Z$^HZYJ$S;[B]NI  &ED<]%"HBA(XU2-$1>
M6_;F_9]^,7[5/[.'BW]G;X4_&G0/ T/C?PMJ6@:]K&L>")M;E2UO(#;NUNB:
MA:+'((WEPS^8,LIV_*0P!^(W_!CE_P E)_:,_P"P'X9_]':E6-_P6[L+'5?^
M#K[]G/2]4LH;FVN?%/PTBN;>XC#QRQMKH#(RGAE()!!X(-??G_!'+_@W[^,G
M_!'7XG^*/&OPV_;RT#QCI/C6SLK7Q)HNM?!J:WD:.VE=T:">/6SY,F)9ERR2
M+\X)4[<&M^VS_P &]'Q@_;%_X*=^'_\ @IL/V^-"\-ZUX,UW1;_PAX83X-2W
M=O;1Z5=+<VL5S*=:C:X8N/WCJL0;)VJG  !\)?\ !Q$[67_!S1^S-=VI\N1;
M?P!('7@[AXGO,'Z\#\JB_P"#OGQ1K6M_\%6OV=OACXSE9_!=EX+T^]C@G/[C
MS[O7;F*].#QDPVEJ&]@N:^\O^"A7_!O1\8/V^O\ @H5X7_X*#ZE^WQH7A?5_
M!*Z,GA?P_;?!J6ZMXETZZ:\B\^1M:1IBT\DA8@)\K!1R-Q]8_P""R_\ P1$^
M'?\ P6#^"_A72O&GQ+3PE\3/!*.=!\<Z9H9DMI/-5/M-M-:-/N-O(\:N@\XO
M"P!#N"ZR 'QU_P 'M]O;G]BGX.7!@3S$^*,R))M&Y5.FSD@'L#M7(]AZ5YO_
M ,%SO''CCPO_ ,&L/[(?AOPU=3PZ7XDT3X>V7B-H20LT$?A>6YBA?'53/!%)
MS_%"M?1O[97_  ;P_MK?\%&_@1\/OAG^VC_P51_MO6? ^H@6U]IWPY2.Q2R%
MN8F=K=+F-KN_E81%[J60!%0JD:EY&D^I]<_X(_\ PV^*W_!*ZQ_X)8_M)?%G
M5/&NA:-X?LM*\/\ B]=(M["_TM;%(TL)8DCW)OA$:KELF1"R.6#,2 ?%GA[_
M ()D?M&?\%I?^"('[.?P3OOVO?A=X:\ :7X5\-ZKH3Z!\)+^;4K6XT_2Y=.:
MUGN)-;,4KH9)XY76&/=)&2%0$K7V=^W[_P $]? _[4G_  1[U#]C_P#:&^*N
MF7M[X9^&EG-!\3M506T%MK.EV*E=9<L[^1$[QR-+\[$0SRKN.<U\S_\ !/S_
M (-_?V^OV)=-N_V>H/\ @L/X@7X$WNH2W&J>!_"G@N&SO[^.0_O(8+Z>2:72
M/-'^L>T<.26*E7;S!]??MC?L-?'[]HG1O!GPA^#W[27@SX>_"GPMJ^D7>I_#
MZ;X33:FNOVNGR1R1:5<SIJULJV#&) T$<2EE0(SLA9& /R#_ .#/O]JK1=)_
M:-\4?L0_M&SZHGC7P]X:NX/A%::_*Z+HMM]K>YUO3+>"0 PS32B"YDXW,MFP
M.T18/[]>,OB]\)OAUK>C^&?B#\4/#NA:EXAN3;Z!I^LZW!:SZG-D#R[>.5U:
M9\LHVH"?F'K7YE_M2_\ !MS\4OCC_P %.)?^"HOP;_X*!:3\+?&,>O66K:=I
M^@_!N2XB2XMHTB#SL^LJ)VEC0+-A$24,^4&]L^:_\',/_!&S5/VG]!T?]OKQ
M!^U3):>.?"?@FR\)Z9X&T;PA(\7B_79+R4V%OID37K2V<L]S=%2FZX*HH?)\
MMR0#]H*_"'_@^+_Y)7^SL?\ J8/$?_HC3Z_;3X%Z!XX\)_!+P=X6^)VL'4?$
MNF^%=/M?$.H-+O-S?1VT:3R[OXMT@=L]\U\N?\%JO^".7P__ ."Q?P&T'X::
M[\4[OP3XD\(:Q)J/A?Q+!I@OHHS+&(YX)[<R1^9'(JH<JZLK1J02-R, 6?C1
M_P J_OBS_LSJ_P#_ %%'K\KO^#7;2],/_!'?]M74#I\'VBXTC4H)Y_*&^2)?
M#]R51FQDJ"[D \ NWJ:_4OPE_P $U/VF]-_X)S>*_P!BCQQ^WL_B;Q+XL^'2
M>!F\::Q\/U_L_1]$6RELA%::5;7L ^T>3/(6NI9WDD?RRX9(HXE\6_X)X_\
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M7_@XP@@A_P"#EO\ 9JDBA16ELO 32LJ@%V_X2>\7)]3@ 9] /2OT+_X*)_\
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M?!FD0:?X7T&R^$;W[1)'<R7/F3W#ZO&)I#)(1E8XUVJHVYRQ]F_X*G_\$;?
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M&5"@'QS_ ,$/_%WCW7O^#6W]L;P]XCN)YM%T+3O&MOX<:8DK"DGAR">>&//
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M,6B:C=94)<'3[Z5XIN?+ANK:5SEK90/Z%/%/[&_QX\(_LIS_ +/?[)?[6O\
MPA?B?5TNI/$WQ7\8^#V\1ZWJ-]<@>=J0V7MG''=$_=)5XHD6*..)$B11\:_\
M%"/^#:*Z_;\^"WP0^$NJ?M7^$_!EU\&O"4NB?\)#H/P;GDN-<#LA9Y1)K?R*
M3&)"K&5S/+<2^9^^*  _52OD+_@N=\,?V&/BG_P3E\7Z1_P4/^)VM>$/ASI]
MW9ZA)K?ANY5-12^BD_T:*VC:.1;B61F*")HV!#$_+MWK[7^QG\'?CM^S_P#L
M\>'O@W^T+^T+:?%'7?#EC'80^,X?"CZ1/?6L4:I$;J)KRZ\VXPOSS!U#\$H&
MW,WE'_!8G_@E_P"'/^"MG['K_LO:U\5+OP9>6?B6UU_0M?M]/%Y'#>01SQ!9
MH/,C\V)H[B52 ZD,5?)V[2 ?A3_P64\4^.O&O_!#O]G+4/A[\,)?!GP"TKQN
MNF?"*P\9ZF=1\7Z[:QV-\!JVH2Q%+:SCDQ)Y=K&DF0RN)$0(C?HS^V)+)/\
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M3;_E*9^UW_V\?^GR>OW^K\ ?^#3;_E*9^UW_ -O'_I\GK]_J "BBB@ HHHH
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MJ\<:( K.K2<_,[8&/2J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*U"I'%:VYN+B:9DBC4R22;I"Y5=OTC110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X@_\'O/_)K/
MP/\ ^R@:C_Z0BBC_ (/>?^36?@?_ -E U'_TA%% 'G__  :;?\I3/VN_^WC_
M -/D]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!^ O_  ><_M4?MG^!#X%_9:C\1:#HOP=\
M=0W-^++0KZ=]3UV>Q:U+C4=\2)% DMPAB@B:0,8_-D;<(TC^X_VZ+C]MB?\
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M4>VW=4KB_P#@UH_;D_9Q^)?Q)_:#_9+_ ."@7BG3]3\0_M%Q03S>(/&EZ/\
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M;Q)X;U%M8TKQD_Q1\.Z!+$WGPZ()_+=PA&54VDEU?#U1P>K8H [#7M.MX/\
M@Q@@41#Y(()EXZ,_Q'4D_P#CQ_.O%;G]L_X@#_@SAA\ G6KCS'^,?_"NOM7F
M'S/[/%R=9\K=UV[!Y./^>?R=.*]>UWQ1I5Y_P8TVUO'?1"0RPV31EQN\U/B$
M'*8]=B[\>G-9-U_P3.^*H_X,\XHO^$4O/^$H3Q+_ ,+=;11 ?.^P&<P^9C&<
M?V4?M7^[QUH Z+7M.MX/^#&"!1$/D@@F7CHS_$=23_X\?SK[)_X-+OC-XA^+
M7_!&[PQH/B*]DN'\"^+]8\.VDLK;F^SK*EY&F?1%O-BCLJ*.@%?%6N^*-*O/
M^#&FVMX[Z(2&6&R:,N-WFI\0@Y3'KL7?CTYK[Y_X->/V9_%7[-/_  1X\ 1>
M-])FL-4\=:A?^+IK*XC*O'!=R!;1B#_?M(;>4>THH [[_@X!_90^,W[:/_!)
M[XI_ OX 6-Q?^*9K>PU33]$MC\^K+8WT%W):*/XI&2%BB_Q2+&O?-?D%_P $
M</\ @ZIUO]BGX=>'/V(_^"@WPBU34?"W@JW30M%\7Z%;[-6T.U@_=1VEY92;
M1.L( CW(R2HD84I*W-?N!_P4W_;?TW_@GK^S[H_[2?B=XT\.6OQ%\/Z9XMF>
M R&WTJ\O4M[F=5'):-',@ Y/EX'6O+/^"AW_  1!_P"";_\ P5M\%'XF>(_"
M6GZ7XNUK2TN= ^+O@-XDNKA'C#032F/]SJ4)4H1YH8E.(Y(\A@ >D?LOW_P4
M\>?!SXE?M<?\$S?&7@[QG)\9M=_X2>PDOM2EM='.M+IUG8/]H,$#SVY(LXY)
MHS%YOF%]P5F)'XF_\$'/VJ/^"JG[77_!5;X__'7P-XA^%WBCXD:AX1^S^))/
MB7?:E::7:6,.HQ1Q6^GI8Q2/&D;*JHC #9EF)<DGW#_@SN^%WQV^!_QL_:L^
M"FJZZ=4\!^#_ !1:Z(^I6CLVG7>NVES>0236A/!W01JSE>=AMMW\%>.?\&CG
MB#0/ O\ P4B_::UCQKKEGI%GI7@6_NM3N]2N5@BM((=8C,LLCN0$1!RS$@*.
MI% 'Z7?\%!?^"T7C+X,_M\_#3_@E+^QQX(\,>(/C+XZNK3_A(-<\7/<2:+X4
MMYD,H,L%L\<UU+Y"//Y8DBQ'Y?S$R?)3^%G_  6;^*7P9_X*LG_@DC_P4+\,
M^#8_$7B&UM;CX<_$SX?VEU8:9K#7$)DAM;BQO+BYDM9'=)8587$@,J*N '##
M\]_''P[\8_!__@]8\.Z]\4()H[+Q?XC35O#6H7.0E[:3^&9K6 QD]0D\3V_^
M]"0.U1?\%DO 7C3X\?\ !V)\"OAW\)[>:YUC3KGP1<736@)>RAM+Z34+BX;'
M016RM,3_ '5H _3O]MO_ (*V>*O '_!0SX:_\$F_V-O"WAW6OC!X\1K[7M>\
M7">;1_".FI;S73236]M)%+=W!M[>658!-"-OE9?]Z,<#_P $U?\ @M#^T1\=
MO^"FGQ8_X)2?MF?!WPU9>-OA])J,VC^,O -C>6FG:G:6LT2AI;2[GN)+?S89
MX9D?SF4AMG4JS?FO^V3\:[W_ ()N_P#!WS#^U'^T/+-8^$]4UW3[C^V[M6\G
M^P]1T!=(:Z!ZF.V9I0V,X-HP . #_0;I/Q-_9?F^)VBW/AGQ7X.N_%_CS2G?
M1KO2)+>>^UC3X(_-:42P[G>U1=O[QCY0:2-0=TB!@#\$_P#@G#_RN-_%?_L<
M/'7_ *(GK]9OA1^U'_P4-^/7[</CKX4?";PY\);GX'^!M5%E=?%>;3]2::\O
M0<SZ3:P+=>7=7-MGRIYUD6%)%92!(KP+^'G@[X*?'+]HW_@YN_:)^"W[./Q_
MN/AEXM\0:Q\0+73/%]G:"66V8VMS\BMD-#O.$:9,R1HSM'APK+]<_P#!KY_P
M4K^(_P !/BIXA_X(>?MT_:-$\6^$]9OX_AV=9D_>1W$<CR7FC%R</\V^YMV!
M(=6E4,1Y*D _=*OP(_X/F?\ D&_LQ?\ 7?QE_P"@Z)7[[U^ _P#P?,L/[._9
MB7/)F\9$#\-#H _2W]@CQ;\2?A__ ,$'/@_X_P#A"-$;Q'H/[.6B:EI</B*V
MFELIWM]*AE:*40R1N ZHR!U;Y"P;:X4HWQ3_ ,$Z?^#A7_@J-_P4[^%?Q=?]
MFW]ASX8MXK^'VEV6H6^K:SXBO+?1+6&1+MWBG4.T]S=2FW58(HS%'A9FEFCV
MHK_:W[!;*?\ @@5\,6## _9;L<G/_4!%?ES_ ,&6;*/A%^UYEAQIGA@GGI_H
M^NT ??/_  ;R?\%N/''_  6&^&/CVU^-/PQT+PUXY^'5]8?VF?"_GKIVH6EZ
M+CR)8H[B262)U:UF5U,CC[C C<57B/"7_!;K]L']OK_@IGXS_80_X)7_  V^
M%J^&OAC9WLWB[XC_ !734;F#47M;A+:1;2*PFB,:M<2".-V,N]%:7  "'XY_
MX,= [^,OVE(HY=C-I'A;:V,X/F:KSBN:_P"#/7[;\$/^"F_QZ_9P^+K'3O&L
M?@^XM+BQOFVS/=Z?JJ1W<0W<LX:3<1UPC-T4D &'^PGXE^)7B[_@\A77OC%\
M/8/"OBF7Q3XF37=!L]4%[!;7,?A.^C<PS[$,T+E?,C<HC%'7<JME1^MO[;/_
M  5M\3?#_P#X*%_#;_@DW^QQX5\/ZW\8/'8^VZ_KWBQ)IM'\(::MO-=-+-;V
M\D4MY<&VMY95@$T(QY69/WHQ^5?[+GBOPQXK_P"#UO4]=\,^(+/4+*3QQXIM
MX[NSN%DC:6+PI?0R(&4X)61'0CLRD=JPOV]=<\-?LN?\'<4WQ)_:T\6>(_#'
M@7Q1JFF,WBG1/%-]H<\.EWOAZ/38KI+ZSEBFA@AN04E97 V6TJME<@@'ZS_L
M8?\ !5[XH_$+_@H=\7/^"27[5^B>$=,^+W@"Q_M+PIXN\)Z?<PZ+XEL)+:WN
M8W-E<7,LUM.D-W!*T(N9 P\T!U\K+?,OCS_@X-_;I_9N_P""L^B?\$S?VQ?@
MO\*/!6FZMXJL["/XCV\.I3VMQI]Y_P >=]%&]R@"2L4B8L^V%_,WD^4V?L'X
M9?\ !.K_ ()=_ _]O3PE^T]X237]:^.WB72;NYT+Q'K/Q.USQ!?7NFII_P!E
MENYOM-W,K6JP/% LTH\L/) BMO:,5\-?\'<G[)^@_M;^"].\7_ ;P%/KWQ/^
M!_A.X\2_$.^TUEV:9X/FD*I%<G&7G:9)KF"+M!::A(<?*' /T9_88^/O[8?[
M3/B;Q9\2/'MK\.(/A':>);_3?AWK?A_3;X:CXMM+>5H1J8$MRT5O;-(KB-AY
MOGJGF)MC>-W^F*_/O_@VO_X*,:%^WW_P3:\,Z%JEU:1>./A-:6WA+Q=IUNBQ
MYB@A"6-XL:X"I-;HHR %\V&<* %%?H)0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'X@_\'O/_ ":S\#_^R@:C_P"D(HH_X/>?^36?
M@?\ ]E U'_TA%% 'G_\ P:;?\I3/VN_^WC_T^3U^_P!7X _\&FW_ "E,_:[_
M .WC_P!/D]?O]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'C'[;G_  3W_9 _X*+?#:T^%/[8/P;M/%NE:;??;-)=KR>TNK"<KM+P
MW%L\<L>X8#*&VO@;@V!CGHO^"4O[!MM^R)/^PGI_P5NK'X7WTZS:MX>TKQCJ
M]G+JKJBH/MEY;W:75VNQ(T*32NI6*)<;8T"_1%% 'RA\,O\ @B-_P35^#/P#
M\8_LN?"SX(>(-#^'_P 0'5_&'A:P^+'B=;;4B%"$M_Q,MR;T54DV%?-151]R
MJ .P_8B_X)>?L0_\$Y!K4/[&?PFU'P;;>(MAUC3O^$YUK4+2X=<;9?L]]>31
M+*  OFJH?;\N['%>_P!% 'PQ^T1_P;?_ /!(/]I[XW7WQ_\ B5^S T&O:Q?&
M]UZ/P]XEOM-M-3N&;<\LL%O*J*[G)=H@A<L68EB6K[&^$_PG^&GP*^&^C?"#
MX.^!]-\-^&/#UBEGHNAZ1:K#;VD*]%51ZDDDGEF)8DDDUT-% 'G?[3O[*GP(
M_;(^&L7P=_:.\"6_B;PNNM6>J7&AWCM]GNYK642Q+,H(\R/> 6C/RL!A@02#
MY!8?\$A_V5_"6C7'@CX/>,?BQ\//"%[YGVSP)X!^+VM:9HQ$A)D6&VCN,6:O
MD[EM3"IR>,DFOJ.B@#A_V=OV:_@1^R5\)].^!W[-_P +M*\(>%=*#&STC282
MJ;V.7ED=B7FE8\M+(S.QY9B:^/?VA/\ @V8_X(\_M(?%:^^,?BK]FZZT75M6
MNWNM8@\(^)+O3K.\F8DLYMXW\N(L3D^4L>3R>22?OJB@#Y?\,?\ !%S_ ():
M^#_V:]6_9(T#]BKP;%X&UTQOK%C+;22WEW+&"(YWOY'-V9DW-LE\[>FYMI7)
MSE?L#_\ !$+_ ()Q_P#!-CQ_J7Q8_9?^"<MKXIU&W>U'B#7M9GU&YL[9B"T%
MN9F(@5L89E =APS,.*^M:* /ES]KO_@C+_P3J_;T\86OCG]KWX-:_P".;_3S
M.=,35?BGXD2VT_SF5I1;6T.HI!;!RB96)%!"(,850/6/V7/V1?@9^QG\.[?X
M2_L]:3K^E^&K*VBM].T75_'&KZS!80QERD5LNHW4_P!F0;V^6+:" H((5<>E
MT4 %>;?M7_LA_LY?MQ?!B_\ V?OVIOA=9>+?"FH31SRZ=>2RQ-%/'G9/#-"R
M2P2KE@'C96PS#.&(/I-% 'Q?^S-_P0%_X)I_LH_;+'X:?#7Q3=:-?W"SWWA/
MQ!\0M5O=#NY%QAKC37N/LEV1@#_2(I ,"OLM[*SDLSISVD36[1>68#&"A3&-
MNWIC'&.E2T4 ?(L?_!#7_@G!'>#2_P#A4.KMX+7Q6?$T?PG?QGJ1\'IJY_Y>
MQHQG^RYZ_NMGD\D>7CBOK7[!8FQ_LLV47V;RO*^S^6/+\O&-FWIMQQCIBI:*
M /D6/_@AK_P3@CO!I?\ PJ'5V\%KXK/B:/X3OXSU(^#TU<_\O8T8S_9<]?W6
MSR>2/+QQ7UO!!!:P):VL*1Q1H%CCC4!54#   Z #M3Z* /._VG?V5/@1^V1\
M-8O@[^T=X$M_$WA==:L]4N-#O';[/=S6LHEB6901YD>\ M&?E8## @D'R"P_
MX)#_ +*_A+1KCP1\'O&/Q8^'GA"]\S[9X$\ _%[6M,T8B0DR+#;1W&+-7R=R
MVIA4Y/&237U'10!P_P"SM^S7\"/V2OA/IWP._9O^%VE>$/"NE!C9Z1I,)5-[
M'+RR.Q+S2L>6ED9G8\LQ->$M_P $0O\ @EV?VL+G]M9?V4M+3Q_>ZF=2O;N/
M5KY;"YO3()3<R:>)Q:/(9%$AW1%3(!(07^:OJZB@#Q7]KS_@GM^RA^W&_AO5
M?V@OAO)=Z]X,U%;_ ,&>+]$U:YTO6=!NE97$MK>VDD<T?SHC;=Q0LBL5)4$4
M?V:/^";'[)?[*GQ9\2?M"_#[P5J6J_$CQ?&(O$GQ&\:>(;O6M;O85"*L/VJ\
MD=HH@L<:^7%L4B*,$'8N/>** /G[]O3_ ()=?L/?\%+/#.F^'?VO_@G;>(IM
M$9SH>M6U[-9:AI^_&]8[B!T?RVP"8V+1D@$KD BO^PG_ ,$I?V$?^";GA[5M
M$_9'^!\'AZZUZ(1:YX@GU&XN]4O8P<B-KJ9VD2,'D1QE$##=MW<U]$T4 ?)'
MPT_X(9?\$QO@_P#M)1_M@_#GX%>(-.^)J:Q<:I)XT_X6UXHFO;B[G+&>29I=
M283B7>XD60,L@=@P8$BD^,W_  0K_P""7?[0/[2-[^U]\6/V>=6U'XEW^K6^
MIS>,+?XG^)+.ZBN[=8U@EA^S:C&MN8EBC$8B"!!&H4# KZXHH KZ5IMOHVEV
MVCV<EP\5I;I#$]W=R3RLJJ%!>65F>1L#EW8LQR22237S#^UM_P $6_\ @G)^
MW=XSM_'W[77P7U_QSJ5B9_[-_M;XJ>)5M[ 3.'E6VMXM12&V5F"Y6)%7"(,8
M50/J:B@#PSX>?\$X_P!E'X4_LW:E^R+X!\/^,K#X=ZII TJ;P[_PMCQ)*+:R
MW,3;VLTFH--9QMO966W>,.AV-E?EK@_V<_\ @B)_P33_ &1M+\7Z+^S3\#_$
M'@RU\>Z)_9/BZ'1/BOXGC&HVHW;5;.I':Z[Y LJ;9$$L@5@'8'ZOHH ^9/V+
M_P#@CI_P3M_X)Y^/;[XE_L<? W4O!6K:I9BUU0VWQ"UZ[MKV(9VK-;7=]+!*
M5+,5+H2A8E2"36!^TY_P0S_X)K_M:?M$Q?M6_%+X(WUGX])7^TM?\)>*M0T:
M75 J>7_I'V.:/>QCS&9%VR,AVER N/KJB@#Y \%_\$%_^"4'@#X[-^TGX:_9
M)TV#Q>EW!<:=>QZS?I!IIAB2*);:U2=;>%51% VQYZY)S7;_ +?'_!*K]A;_
M (*8:-I6G?M>_!*#7[S0MXT37;*_GL=0L4<@O&EQ;NK-&2,F-]R9^;;NYKZ(
MHH ^>?V&_P#@E=^PU_P3E\$:SX(_9)^#">&_^$C0)X@ULZK<SZI?J P56O))
M#,BKN8JL;(J,2R@,2QC\)?\ !*K]BOP.WQ(F\.>%/&Z3?%ZT%M\2+JZ^,WBJ
MYGUQ -H,LLVI,ZN$S$'0J_E,T6?+9E/T510!\M?L>?\ !%O_ ()N_L!?$N7X
MN_L@? C5?!6NW%H;6]FLOB1XAN(+R$\^7/;7%_)!<*#\RB1&VMAEP1FOJ6BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q!_X/>?
M^36?@?\ ]E U'_TA%%'_  >\_P#)K/P/_P"R@:C_ .D(HH \_P#^#3;_ )2F
M?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGW</]HZW/<2>9)(V[EV( X[ ?C7T!_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M0!L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M0!L45C_ /"#Z1_S\WO_
M (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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M(/I'_/S>_P#@6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M%+9P27'G7]_+;6N+C4+V?,S&5F),\HD<.NX5Z]/^VQ^U5X:_X*97'[(/CO\
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M+XX^&Y\%?%WPEH5Q;1ZE#)!-'/IVM6R7,L4=SM$7V66+S%=8RCHLA# ?9=%
M'R%^PS^QW\1[#]M3XV_\%,/V@_"1\.>*?BO'IFA^#_!EQ>07-UX<\-:?!'&B
MW4MN[P_:KJ9!<21Q22I%MC42,=V/KVBB@ HHHH \+\ _\I!/'_\ V(FE?^C&
MKW2O"_ /_*03Q_\ ]B)I7_HQJ]TH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH _$'_@]Y_P"36?@?_P!E U'_ -(111_P>\_\
MFL_ _P#[*!J/_I"** //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^
MUW_V\?\ I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#POP#_R
MD$\?_P#8B:5_Z,:O=*\+\ _\I!/'_P#V(FE?^C&KW2@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM'::>;R.(*DC2W<TL,9(+-Y;'D6Z[?TF=UC0R.V%49)/84 >9?&#]M#]E7X
M^*1X*^,?QW\.Z!JJV"W]W97M[\]A9L^Q;NZV@BTMRP*B>;9&2K#=\IQZ.NJ:
M8^F#6DU& V9@\\78F7RC%MW;]V<;<<YSC'-?F_\ \&X>OK^U]^QY\8?VR?C!
MIL.L:S\>OC/K]YK[:C&)?,TJ.*&SM--.[K;00K)&D9R%5V'<U\%WG[8_QBMO
M^#>^]_8NL/'&H_:%_:[?]GFUUO[4QNQX>+?;1%YF<[?LV;/_ *X_)TH _<SX
M1?MI?LI_'KQ9_P (-\'?CSX=\0:J]G+>65KI]\#_ &A:QN(Y+FT8@+>0(Y56
MF@,B*64%AN&>@^,GQ]^#7[/NAV?B'XS?$73?#]OJ5\MCI27LQ,^H73 LMO;0
MJ#)<2E59O+C5FVJQQ@$CX*_X.,-8M/V.?V&/A5^UA\&--AT35_@!\7_#=]X3
M73D$7DZ>5DL;C35QC_1IK>01/%]UE10>@J7X+?$34OVE/^#F#XMZ/XJF-WHW
M[._P,TS2?!EE(<Q6=]K0LKZZOHU/W9GAD^SLXY,:!: /OSX4_%[X8?'+P5;_
M !%^#_CS3/$>B74DD46I:3=K+&)8W*2Q-CE)$=61XV =&4JP!!%='7YT?LH_
M$/4_@]_P<8?M(_LE>'[@Q>%?B'\)]&^)C:4AQ!:ZS ;/3;F>-.B/<)*CRD#+
MM"I/(K]%Z "BBO$M4_:E^,MAJ=S86W[%OC>ZC@G>..YBN;;;,H8@.,MT(&1]
M: (/ /\ RD$\?_\ 8B:5_P"C&KW2OEGX!?$OQ=XP_;9\<>(==^#^LZ#=3>"]
M/232M0DC,L024A6)4XPV21_NFOH[_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6J>O_$-?
M"VAWGB;Q#H,]G8:?:R7-[=SRJJ0PHI9W8]@%!)^E.,93DHQ5VPW/@[_@N-\)
MOA9IUQX9^,T6O_9?%VIL=.DTE(@PO[2(%OM!.1L,194)P=PD0<;*^:)_^"<'
M[7=C\'KSXX:K\,Q:Z+::.FJ".34(6NIK5@K%U@1F=2J'>RN%8*IXR,5[C\(;
M+Q'_ ,%./VZK[XX^+_#5W<^ O"$L1MM,< IY",QM;1L\9D<--*.>-Z\ K7Z0
MR>(=3EC:*7P9=LC*0RL5((]"*_?,5QOFOAWEF"R6'+5K0BI5>;7D4G>-*+36
MJCNWS6NK:62]R6,JX"G"BM6M_+R/"O\ @EU^T%X#^,_[+>B^%?#5E!IVJ>"[
M*'2M9TF)ONE5^2Y&>2LP!?)_C\P<XR?H^OS"^,.@>,O^"7/[9%E\>OAWX8O(
MOA]XIN'2XTD8$8A<AI['(X#(<2PDXX '(5\_HCX+^*]A\0_"6G>.?!NC3W^E
M:M9I<V%Y!(I66-QD'V/8@\@@@\BOSSC?)\/0Q,,WP#<L+B[SBWJXR;]^G+SB
M[_+J[-G!C*48R56'PRU7KU1UE%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2U
M\*<1L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7
MO_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_
M -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A
M>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]
M]+0!L45C_P#"2ZO_ -"A>_\ ?2UH:;>3WUJ)[BPDMF+$>5*1GZ\4 6**** /
MQ!_X/>?^36?@?_V4#4?_ $A%%'_![S_R:S\#_P#LH&H_^D(HH \__P"#3;_E
M*9^UW_V\?^GR>OW^K\ ?^#3;_E*9^UW_ -O'_I\GK]_J "H-5NY;#3+F^@MS
M*\$#R)$.KD*2%_'&*GHH _++]JC]IC_@E'_P5*^'OPOUS]K+Q[X.'@^^^%'B
MNY\7>']4UF.+6/!^MD:+BV$38N(-2BE\V.)0F^8@A%D23:VC^R=_P4"D_P""
M1?\ P0[^#'BS_@IWXRO+/X@W^G7&G^$_#/B>:5-6OH3>2G3X;E0DDL*6]C):
M&=_+=K>,*A1Y=D;_ **:U\%?A5XB^*&C?&G6O UC<>*?#]E=6FD:TZ'S;>&Y
M,)F7@X;/V>+!8$KM.TKN;/44 ?FI^QC_ ,%E_P#@E%=?$NV\(_##]J63XO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7PK_P5Y_:5UR__LC]B;X0F6[U
M[Q1<6[:]!9G,AC=P+>S&.C2OAV''RJF<B0U]9?M'?'7PK^S;\&M;^,'BYPT.
MEVI-K:;]K7ERWRQ0+[LY SV&6/ -?&?_  2H^!/BKXX?%37_ -OOXWH;N]O=
M1N$\.F=/EDN6RL]P@/1(U/DQ@9 ^<#!C%?HG!."PV74*W$N.C>EAM*<7_P O
M*S^%>D?B?;1]&=^#A&G%XB>T=O-]/N/K+]CG]FK0_P!E/X#Z1\+-.$4NH!/M
M6OW\8_X^[Z0#S'SW5<!%_P!A%SSFO4J**^%QV-Q.8XRIBL1+FG-N3?=O^OD<
M4YRJ3<I;LX7]I#X!>#?VF/@]J_PB\:Q!8-0AW6=XJ!GLKI<F*=/=6ZC(W*64
M\,:^*_\ @FK\??&7[+GQMU;]@']H64V@&J.GAN:9SY<%XWS>4C'&8;A2)(SQ
M\[=,R\?H=7Q]_P %8/V.+KXP> (_VA/AA92)XQ\'0>9<"SR);ZP0ER%(Y\V$
MYD0CDC>!D[0/MN#,TP>)I5.'LSE;#XA^[)_\NJNT9KLGM+RM=I7.S"5823H5
M/AEMY/HS[!HKYX_X)Q?MD6O[6/P6CC\1WL8\8^'$CM?$<' -P,8CNU'I(%.[
M'1U88 VY^AZ^0S;*\9DN8U<%BHVJ4W9_HUY-:I]4SEJTIT:CA+=!1117G&84
M444 %%%% !1110 4444 %%%% !1110 4444 ?B#_ ,'O/_)K/P/_ .R@:C_Z
M0BBC_@]Y_P"36?@?_P!E U'_ -(110!Y_P#\&FW_ "E,_:[_ .WC_P!/D]?O
M]7X _P#!IM_RE,_:[_[>/_3Y/7[_ % !1110 4444 %%%% !1110 4444 %%
M%% !1110!X7X!_Y2">/_ /L1-*_]&-7NE>%^ ?\ E()X_P#^Q$TK_P!&-7NE
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#@9'4;A^=?1'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
M?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_
MPF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8
M^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?
M]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'
M_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )
MCX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
M?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_
MPF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8
M^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?
M]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'
M_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )
MCX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
M?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_
MPF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8
M^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?
M]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'
M_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )
MCX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
M?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_
MPF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8
M^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?
M]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'
M_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )
MCX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
M?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_
MPF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8
M^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?
M]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'
M_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )
MCX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
M?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_
MPF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8
M^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?
M]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'
M_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )
MCX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
M?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_
MPF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8
M^&/^@U!_WU1_PF/AC_H-0?\ ?5 %G6-8TOP]I%UK^N7\5K96-L]Q>74[[4AB
M12SNQ/0!023Z"OS5^%VDZM_P52_;XO?BAXGL96^''@QHS!9SJ0CVJ.WV>V8?
MWYW#2R#^Z'7/"UZ1_P %<_VL+B70--_9$^#UZU[K?BN2(ZZ+(Y=;=G AM1C^
M*9\$C^XH!R)*]_\ V*O@IX _90^ FE?#2WUBSDU61?MGB.]C/_'Q?2 ;\''*
M( (U_P!E <9)K].RK_C#>%99K+3%XM.%'O"G]NIY-[1?HU=-GHTO]DPWM?M2
MT7DNK/:U544(B@ #  '2EK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J_,3SC2
MHK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ
M_P!!J#_OJ@#2KY/_ ."J/[&,G[0GPO7XM?#W36;QIX0MVDA6W7]YJ%BI+O ,
M<ET.9(^^=Z@9<8^GO^$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJO6R/.<;D&:4L?
MA7:<'?R:ZQ?DUH_\S6C5G0J*<=T?//\ P3)_;.C_ &I/@Z/#7C+4U;QIX6B2
MWUD2-\]]!TBO .Y;&U_1QG@.HKZ8K\SOVQ/!6L_L!_M9:5^V'^SUY;^&]<OV
M.KZ5 Q6&*:3FXM' &!%,H+H<'8X. -B9_0#X7?'KX8?%_P"'^E?$GP;XEBET
M[5[19X-_#QD\-&X_A=6!5AV*FOI>,\FP</99UEB_V3$ZI?\ /NI]NF^UG=Q\
MKVT5SHQ=&"M6I_#+\'U1V-%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5?"'$:5
M%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/
M^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#
M4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]5<L;^SU* 75C<++&20'
M7IF@":BBB@#\0?\ @]Y_Y-9^!_\ V4#4?_2$44?\'O/_ ":S\#_^R@:C_P"D
M(HH \_\ ^#3;_E*9^UW_ -O'_I\GK]_J_ '_ (--O^4IG[7?_;Q_Z?)Z_?Z@
M J*]NX-/LY;^Z8K%!$TDC 9PJC)_05+3+BWANH'M;F,/'(A21&'#*1@@T ?F
M1_P4?_X)V?!W_@H#^T/\'?VJ?V.?B@_PK^*OB'X;ZWXK\&_&;PBOV:746MH]
M)?3_ +>%Q]HMVAO)$8D>8(W"DLBF)OIG_@C)^V!\6?V\/^":_P ,_P!I_P".
M>AVUEXLUVRO;;6I+*$1P7TMG?W%G]LC4<*LPMQ+A?E!<A?E"UB'_ ((M_LGZ
M7KOA_2/ ^N^/- ^'FC:'K&F7'PQT[XD:XNF30Z@]HTD,!^W;[*U/V9A):P[8
M91+@J I#?3V@?#'P'X0^&]I\(O!/AN'0/#>G:2FF:9I7AYFT]+&T1/+2*W-N
M4: *H 4QE2N!@@T ?"/_  01(/C[]N+!_P";X_&W\[:OOZ#Q/X:NO$%QX2MO
M$-C)JMI;I<76F1W:&XAB<D)(\8.Y58@@,1@X..E>2?LN_P#!/C]E;]C/Q+XI
M\7?LZ^$/$.BWOC?6[C6?%AO_ (AZYJD6J:E.=TU[+%?WLT;7#G[TNW>>YKS*
MP_X)S_#B+_@K3/\ \%$_ _PWU/PWKS>&Y[#QMXIN?$4KIXL=[*UM+6U@LA,\
M<<$,4(>61TB)FM[?RU<&5P 3?\%@M4U/QM^SKX?_ &+?"E_+#K7[1/CS3O )
M:U<B6#1IB]UKEP .2J:3:WP)X :1,GD9^H[.V\/^$M'L]&LDM=.L;6.&SL;=
M2L<<:@!(HD' '\*JH]@*Y;Q?^S[\-/'7QP\&_M">*--N+GQ'X!T_5+3PLYNW
M$%H-06%+J7RA\K2F.!8PYR51Y ,;VSB?M?\ [&O[.W[=_P &+CX!?M.^!6U_
MPW-J%O?QP0ZE<6<]M=P,6AN(9[=TDCD4DX(;D$@@@D$ ^3O^"I/['_@6?]N3
M]D_]KGX!Z!:Z)\:D^/.FZ3JNI:-$L5UKWA0VUS+K,=V$P9HX;.%\2OD()#'G
M]ZHKG?V:_!FI?!7_ (.;OVC#XL@:"+XR_ [P]XF\(W$HPEU%IJV6F742,>&=
M9(]Q0<A2&QC!K[,_9V_8J^ /[,5Q_;'P\TG7M2ULZ<-/_P"$H\;^,-2\0ZJM
MF&#?98[S4IYY8;?<J-Y$3)$2BG;D UJ?'7]EGX-?M$ZEX=\2?$+1+Z'7_"%W
M-<^$_%.@:S<Z9JND/-'Y4X@N[61)5CECPDD1)CD 7>C;5P ?#_[,_@S5_B9_
MP<W?M%_'G1(7DT#X=? ?0?!&I7J#]T=3OWLM26$-T9DB@?<H^Z67."17Z25Q
M/P'_ &=OA!^S3X0N?!7P=\)_V;;:AJD^J:Q=W-[->7NK:A,09KV\N[AWGN[A
M\+NEE=G(55SA5 [:@ K$E^&GPXGE:>?X?Z([NQ9W?2H26)ZDG;R:VZ* /G[X
M8^'?#^D_M\^/;#2M"L[:!/ VEE(;>U1$4F1LD # S@?E7O?]G:?_ ,^,/_?H
M5XCX!_Y2">/_ /L1-*_]&-7NE $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
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MI_\ SXP_]^A1_9VG_P#/C#_WZ%345\V<Y#_9VG_\^,/_ 'Z%']G:?_SXP_\
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M^,\X9]GOC\''3O5HKIYRI].K7=MV])?[;A[?;A^*_P T?I51117Y<>:%%%%
M!1110 4444 %%%% !1110!^(/_![S_R:S\#_ /LH&H_^D(HH_P"#WG_DUGX'
M_P#90-1_](110!Y__P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"W
MC_T^3U^_U !1139I4@B:>3.U%+-@$G ]AUH =17YH_LF?MO?MG_\%,9OAO\
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M;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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M0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\
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MQM2*M0I_#'\7U9C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L45^?G"8_\
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M6?@?_P!E U'_ -(111_P>\_\FL_ _P#[*!J/_I"** //_P#@TV_Y2F?M=_\
M;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J "BBB@ HHHH *;'##"7:*
M)5,C;G*KC<< 9/J< ?E3J* "BBB@ HHHH **** "BBB@#POP#_RD$\?_ /8B
M:5_Z,:O=*\+\ _\ *03Q_P#]B)I7_HQJ]TH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS03H=LB'HKJZ+ZY0 4444 >%^ ?^4@GC_P#[$32O_1C5[I7A?@'_ )2">/\
M_L1-*_\ 1C5[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**
M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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MB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU:Z^W>&+/44^:1SRM^Z'A5 P(4P   X  C-??--BBBMXE@@B5$10J(BX"@=
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MS4]-UK3;?6-'U""[M+N!)K6ZMI1)'-&P#*Z,I(92"""."#F@">BBB@ HHHH
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MBL0JS48*T([+]?4****^0.4**** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ
M%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPM+^+4OY1U_'8I_%;_@N#\(M(E;2O@G\*M:\373-LANM2D6Q@9CP"J@22/\
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M'TC_ )^;W_P+:LA&Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR*^COL7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&@#8HK'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &@#8HK'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &@#8HK&^Q>-_^@W9?^ Q_P :\1^._P#P4$^ O[/O
MG6/BKXT:7J>JPY!T3PY:_;;G</X6V-Y<3>TCK7=@,MS#-:ZHX.E*I/M%-O\
M#9>;T+A3J59<L%=GT/67XO\ &W@WX?:'+XF\=^*].T;3H/\ 6WVJ7J01)[%W
M(&?:OSSU+_@IY^VO^TOJ\W@S]CWX+3PJ6V'4TTT7EQ$#T9V8?9[<?[^X=/FJ
MWX;_ ."3/[47[0&KQ^.OVR/V@9A._P W]G17K7]U&IZQAV_<P?2,.OM7W$>
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M_"7A[Q]%%9VGD>3'#IELZC=;QN<%XV8_,QZDUQO_  V+^T=_T47_ ,I%G_\
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M\4_@K]K/POT/PQ</J1C-Y)XELYY_+\O=L\L0RQXSYC9R3T7'>NE;_@H/^V,
M%M+3X80*.JGPQJ#Y]^-07'Y5^A<&^"G'M3ANA[?B"I@/B_<1]H^3WY=:=51]
M_P"/1?:UUN?+9_XA\.T\VJ*EE2Q6W[WW%S>ZOYXW]WX=>VA>/[2W[3NH?ZOQ
MKJ;[^!Y.FQ#/TVQT?\+D_:LU#_5>(_$S[NGDV;#IZ;4K,?\ ;^_;:D)VZS\+
M8U/0#P%J+,OXG5\$^^/PJ"7]NS]MF9=I\;^ (^<[H? ER#_X]J+#'X5]/_Q
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MG_GPTO\ \&2_X5Y>/CI\:Q_S6/Q3_P"%#<__ !='_"\_C8?^:Q>*O_"AN?\
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M* /Q!_X/>?\ DUGX'_\ 90-1_P#2$44?\'O/_)K/P/\ ^R@:C_Z0BB@#S_\
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M8Y(DD>>20A2902/G'45^;'ASPAXE\6:DNE:!H\]Q,S ':AVI[LW11[FOO_\
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MS8)"J.IZ"OTI3_@E%\$(_P#5ZMMSUQHEL/Z5\?\ [<O[%&G>!_B;/X<^'E]
M);*UA*+(L<:W,;1ALD1\1N&+C! RH4\#!/U7 >)\+^'N+,-BG1Q"G>485*U6
M5:%.3A+WVK6@W'FIJITY^7[9UX?.L-44XPI0I*VK5DVKK3N];.WE?9'R,CO&
MXDC8JRG*L#@@U]E_ G_@K!XM^%?PKT;X=W3S%],@:-YFTJ.7S&:1G+;C("22
MV3D#DU\]>'/V8?B-J6I+#KT$&FVH;][.UPDC%>^U4)R?KBOT#^ __!+_ /9^
M^(7P?T/Q7XAMWCN+RU)*V]O:O\JNRJ6?82S%54MDY#$@@$8'UWC%F7AIQ34P
M>#QDZU6K#GE&KA*G(X1?(I0E55XVJ/EE[._O.GS?8-_[8P^$I/W85(W5XRM)
M7ULTGVU5UM>SW/.;?_@LCK<W^LU^&+_KIX?S_P"@DU=M_P#@KUJESPOCS3%/
MI)H,B_S%>QR?\$>/V3+A0+F/6<_Q&&XBC_E'Q4$O_!%_]C.1MP7Q6OLNN+_\
M:K\57!/A+4?O8[-X^F)@U^C,'Q%@)?\ ,+37_<.!YA#_ ,%6_$5Q_JOB)X>'
M_72S5/YFKEO_ ,%._&UU_P >WQ!\+N3V7R"?RWUW%Q_P1-_8^F!$>N>-H<]X
M]:@./^^K<UE:E_P0T_9BF!.E?$WQW;M_TWO;*4?D+93^M;1\/?"F?PYSF4?\
M523_ /29(S>=8.6U.FO^X,/\C)@_X*+_ !:NO^/7Q'H4GILMXS_)JM+^WW\=
M7&Y;O3"#T(T]?\:RM4_X(0_#>7/]C?M!:Y;^GVK1H9L?]\NE8%]_P0@UJT8R
M>'OVI8R>RS^$VCQ^*W3?RKHCX8^&<_@XBQ*\I/%?G&HC-YG1ELZ2_P"X$/\
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M@*S4=/\ ?S7T_P#LN?"'X=_&SQ==^#/&>OZC87?V;S].^Q/&!.%/[Q#O5OF
M(88[!O2OH&W_ ."=GP4B&9_$OB:0]\WMN!^D']:]?A'P_P""N#L!/"T,NP^(
MYIN?-B:%'$35U%<L9U*;:BN6ZBM$W)[MGF<19SG?$N+C7K8RM2M%1Y:-:K1B
M[-N[C3FDY:V;WLDMDC\SKCX&?M,W7$O[9.HCC_EGX6B3_P!!F%4+G]FC]HB[
MSYO[:7B 9S_JM,=/_0;D5^I]O^P#\ H3F1=:E]I-2 _]!05>M_V%_P!G.''F
M>%[V;&/]9JTPS_WRPK[BC/+<-_ R["0_PX/#+_W$?*U,F5;^+BL3+UQ6(?\
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MZ$;')_X1B->/KL%7K;]A[XAA"+;]G (N>1_8T*<_0@5^D]%9/&XR6]27WO\
MS-5@L%':E'_P%?Y'YS6_[$/Q>!0P? 4)C&S_ $:W7;Z=^*OVW[$WQZ#G[/\
M!S8<<GS[5>/J9!7Z%45DZU:6\G]YLJ-&.T5]Q\!6_P"Q3^TF(\6_POV+GI_:
MMFOZ>=5J/]B+]I-R W@.%,]2VKVO'Y25]YT5GN:;'YZ_$+]E_P"+WPL\,R^+
MO'&DV=G91R)&&_M&)V=V. JJI))ZGZ GM7GM?I1\2/A%\/OB[8VVF_$+0GU"
MWLY3+;PB^GA57(QN(B==QQP,YQDXZFN0_P"&*OV9O^B:?^5F]_\ CU 'RO\
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MSI4%UL#9?[0BRKYGS< QJN#RPQD^3?!G]C_]N;QYXQBTGXK?L_:/X$T99/\
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M/_D>@#[&HKXY_P"'E/[67_2)_P"*?_@6/_D>C_AY3^UE_P!(G_BG_P"!8_\
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ME/[67_2)_P"*?_@6/_D>C_AY3^UE_P!(G_BG_P"!8_\ D>@#[&K@_C5^S#\
MOVB8((?C-\+]-UQ[9=MM=3!XKB)<YVK-$RR*N>=H;&>U?.O_  \I_:R_Z1/_
M !3_ / L?_(]'_#RG]K+_I$_\4__  +'_P CUOAL5BL%65;#S<)K9Q;37HU9
ME1E*#O%V9]%?!7]F'X!?L[03P_!GX7Z;H;W*[;FZA#RW$JYSM::5FD9<\[2V
M,]J[ROCG_AY3^UE_TB?^*?\ X%C_ .1Z/^'E/[67_2)_XI_^!8_^1Z,3BL5C
M:SK8B;G-[N3;;]6[L)2E-WD[L^QJ*^.?^'E/[67_ $B?^*?_ (%C_P"1Z/\
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M_ L?_(]'_#RG]K+_ *1/_%/_ ,"Q_P#(] 'V-17QS_P\I_:R_P"D3_Q3_P#
ML?\ R/1_P\I_:R_Z1/\ Q3_\"Q_\CT ?8U%?'/\ P\I_:R_Z1/\ Q3_\"Q_\
MCT?\/*?VLO\ I$_\4_\ P+'_ ,CT ?8U%?'/_#RG]K+_ *1/_%/_ ,"Q_P#(
M]'_#RG]K+_I$_P#%/_P+'_R/0!]C45\<_P##RG]K+_I$_P#%/_P+'_R/1_P\
MI_:R_P"D3_Q3_P# L?\ R/0!]C45\<_\/*?VLO\ I$_\4_\ P+'_ ,CT?\/*
M?VLO^D3_ ,4__ L?_(] 'V-17QS_ ,/*?VLO^D3_ ,4__ L?_(]'_#RG]K+_
M *1/_%/_ ,"Q_P#(] 'V-17QS_P\I_:R_P"D3_Q3_P# L?\ R/1_P\I_:R_Z
M1/\ Q3_\"Q_\CT ?8U%?'/\ P\I_:R_Z1/\ Q3_\"Q_\CT?\/*?VLO\ I$_\
M4_\ P+'_ ,CT ?8U%?'/_#RG]K+_ *1/_%/_ ,"Q_P#(]'_#RG]K+_I$_P#%
M/_P+'_R/0!]C45\<_P##RG]K+_I$_P#%/_P+'_R/1_P\I_:R_P"D3_Q3_P#
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MC_Y'H ^QJ*^.?^'E/[67_2)_XI_^!8_^1Z/^'E/[67_2)_XI_P#@6/\ Y'H
M^QJ*^.?^'E/[67_2)_XI_P#@6/\ Y'H_X>4_M9?](G_BG_X%C_Y'H ^QJ*^.
M?^'E/[67_2)_XI_^!8_^1Z/^'E/[67_2)_XI_P#@6/\ Y'H ^QJ*^.?^'E/[
M67_2)_XI_P#@6/\ Y'H_X>4_M9?](G_BG_X%C_Y'H ^QJ*^.?^'E/[67_2)_
MXI_^!8_^1Z/^'E/[67_2)_XI_P#@6/\ Y'H ^QJ*^.?^'E/[67_2)_XI_P#@
M6/\ Y'H_X>4_M9?](G_BG_X%C_Y'H ^QJ*^.?^'E/[67_2)_XI_^!8_^1Z/^
M'E/[67_2)_XI_P#@6/\ Y'H ^QJ*^.?^'E/[67_2)_XI_P#@6/\ Y'H_X>4_
MM9?](G_BG_X%C_Y'H ^QJ*^.?^'E/[67_2)_XI_^!8_^1Z/^'E/[67_2)_XI
M_P#@6/\ Y'H ^QJ*^.?^'E/[67_2)_XI_P#@6/\ Y'H_X>4_M9?](G_BG_X%
MC_Y'H ^QJ*^.?^'E/[67_2)_XI_^!8_^1Z/^'E/[67_2)_XI_P#@6/\ Y'H
M^QJ*^.?^'E/[67_2)_XI_P#@6/\ Y'H_X>4_M9?](G_BG_X%C_Y'H ^QJ*^.
M?^'E/[67_2)_XI_^!8_^1Z/^'E/[67_2)_XI_P#@6/\ Y'H ^QJ*^.?^'E/[
M67_2)_XI_P#@6/\ Y'H_X>4_M9?](G_BG_X%C_Y'H ^QJ*^.?^'E/[67_2)_
MXI_^!8_^1Z/^'E/[67_2)_XI_P#@6/\ Y'H ^QJ*^.?^'E/[67_2)_XI_P#@
M6/\ Y'H_X>4_M9?](G_BG_X%C_Y'H ^QJ*^.?^'E/[67_2)_XI_^!8_^1Z/^
M'E/[67_2)_XI_P#@6/\ Y'H ^QJ*^.?^'E/[67_2)_XI_P#@6/\ Y'H_X>4_
MM9?](G_BG_X%C_Y'H ^QJ*^.?^'E/[67_2)_XI_^!8_^1Z/^'E/[67_2)_XI
M_P#@6/\ Y'H ^QJ*^.?^'E/[67_2)_XI_P#@6/\ Y'H_X>4_M9?](G_BG_X%
MC_Y'H ^QJ*^.?^'E/[67_2)_XI_^!8_^1ZR_"?\ P5;_ &C?'&FR:OX5_P""
M7GQ&U&VBNI+>2>PU19466-MKH2+?A@>".U 'VU17QS_P\I_:R_Z1/_%/_P "
MQ_\ (]'_  \I_:R_Z1/_ !3_ / L?_(] 'V-17QS_P /*?VLO^D3_P 4_P#P
M+'_R/1_P\I_:R_Z1/_%/_P "Q_\ (] 'V-17QS_P\I_:R_Z1/_%/_P "Q_\
M(]?0O[-'QB\=_'+X:#QQ\1/@5KGP[U'^T);?_A'O$$@:X\M NV;(5?E;) X_
MA- 'H-%%% 'X@_\ ![S_ ,FL_ __ +*!J/\ Z0BBC_@]Y_Y-9^!__90-1_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5
MZBOK"QU2TDT_4[**XMY5VRP3QAT<>A4\$4 8_P +O^29^'?^P%:?^B4K=IL4
M44$2P01JB(H5$08"@= !V%.H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O"_VL/^2V? __ +'N7_TF:O=*@N]+TR_G@N;[
M3H)I+63?;230JS1-C&Y21\IQW% $]%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5X7_P3W_Y(GJW_8]ZS_Z4FO=*@T_2
M],TB VVE:=!:QM(SM';PJBEB<EL #DGJ: )Z*** "BBB@ HHHH **** /Q!_
MX/>?^36?@?\ ]E U'_TA%%'_  >\_P#)K/P/_P"R@:C_ .D(HH \_P#^#3;_
M )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H **** "BBB@
MHHHH **** "BBB@ HHHH **** "OG'P)_P %+/A9\1?^"BVI_P#!-[1?AAXV
ML?$VC?#>?QE>:_X@T-M/L9[-+ZVLT6V6;$TX:2=_WGEK'^Y(5GSD?1U?GG@#
M_@ZHR!U_8-Y_\+&@#Z>_;-_;7L/V3+#0]!\+_ OQM\4_'?BIK@^&/A]\/]-2
M>]NH;<1_:+N:25DBM+6(S0*\TC ;YXE4,S 5YU_P3Z_X*W_"_P#;F^+/C/\
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M NG>'?VZ_P!C#Q!\-/%7B;X:77A?]G'Q+<:_::EINI64,LE]J)D>WRD=Y-A
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_F\CQ)_Z+AK]#* "BBB@#\0?^#WG_DUGX'_]E U'_P!(111_P>\_\FL_ _\
M[*!J/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?
M)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^!_^%-_M:'_ (.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ.JW,KW%U,N[YMGF2%$W?-Y:(#R#7T'10 4444 %%%% !1110 4444 %%%%
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M5V%1N^_P:^\*** "BBB@#\0?^#WG_DUGX'_]E U'_P!(111_P>\_\FL_ _\
M[*!J/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?
M)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q!_P"#WG_DUGX'
M_P#90-1_](111_P>\_\ )K/P/_[*!J/_ *0BB@#S_P#X--O^4IG[7?\ V\?^
MGR>OW^K\ ?\ @TV_Y2F?M=_]O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH _$'_@]Y_Y-9^!__90-1_\ 2$44?\'O/_)K/P/_ .R@:C_Z
M0BB@#S__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H
M**** "BBB@ HHHH **Y/XL_'7X0_ K3K35OB[X^L- MK^9H;.:_<J)7 W%1@
M'D#FN&_X>%_L4_\ 1QWAS_O^_P#\37I8;)LWQE)5</AZDXOK&$FOO2L:1I59
MJ\8MKT/9:*\:_P"'A?[%/_1QWAS_ +_O_P#$T?\ #PO]BG_HX[PY_P!_W_\
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M;:"-2\DKNV JJH+$G@ $U^&_['VIWW_!+;_@ISX4_:JEO)+;X2?M=?%7XB>
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M<$ C((X/-3U\B_M+?\%4]4_9X_;W\#_L'VW[&_CCQ-J?CWPYJ>J>']<TK4[
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MG_M]? >>PAGOY]4MYWB5IH!IY;RW(Y7<#@X/&>]3?\-Z_L^?]!+5?_!8W^-
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MQ<S0@*TC(#*S/(J1L] 'V]5;6M8TWP]I%SKNL7/DVEG TUS+L+;$49)PH)/
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M)O@)XN^"/P5_:>GF\,?$7XXL]GX<\.6%C/?01ZE#!#)=6SW,2%%6-YXXQ(Q
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M;\400VWB;P]8ZC';W"SP1W]HDRQRK]V10X.&'8CD4 ?E?_P<H?M8_!OXO_\
M!!SQ5KEAXA71KCQ[JFBS>"=#\1$66I:S91:["\=Y%:2E9O*EM[=KE=R!A$RE
MU1LJ/T0_9+\4_!;XF? _PO\ %#X.:WX;UJVU#PY9+-KGA^:"<3-]GB8H\L1.
M6&5)4G(R,BO3J* "OFD_\%@_^";]I\8_&G[/7B/]J/1-"\<^ ]7;3-:\)^(;
M>XL=0N;D $)8P31J^I%L_*+42E^"H(92?I:JAT#0CK \1'1+3^T!%Y8OOLR^
M<$_N[\;L>V<4 ?F;KO\ P2:\9_&'_@C+^TO^S;X7\%2>&-7^.7Q(\1?$;P)X
M*U!%MI-&\S4;>]TK3Y4)VVKR+86YDBX$#73QG_5FL;]LG]INP_;8_P""'^@_
ML=_ Z[@U'X]?%?P]X?\ !$WPP,H75]#U6&XM$UG^T+7_ %UE!9I!<M+-*BHH
M\LDXE3/ZK57ATC2;?4IM8@TNW2[N$5+BZ2!1)*J_=#,!E@.P/2@#\S_C5^RU
MI_\ P3G_ ."D?[)O[9,MWL^%GAGX,CX(>/?%$X$=OX?CAMW;2+Z[;I#;S7#>
M0\SD1Q,8PS#>*ZC0? 5K^W)_P7ST#]L3X7:E;ZS\,?V>/A#=:#'XPTZ99K#4
M?%>I2W23V5K.A,=QY%E/F9HV;RI&6-L,<#]#;BW@NX'M;J!)8I4*21R*&5U(
MP00>H([4RPL+#2K./3M,LH;:WA7;#!!&$1%] HX ^E '"?M:?$WQ)\%?V5OB
M9\9/!T,,FK^$OA]K.M:5'<1[XVN;6QFGB#*/O*7C7([BOCK]JGXV?\$/?^"I
M_P"Q9/K'[8OQ'\!6%I;Z$UQ/9^*M3@TWQ=X*O7A#-%'!)MO(+M7P!$J,MP54
M!9D<!OT#N;:WO+>2TNX$EBE0I+%(H974C!!!X(([5G:GX)\&:WK=KXEUGPCI
M=WJ5C_QY:A=6$<D]OSGY)&4LG/H10!^(WQ6^#'[6GAK_ (,SO$7PZ^/V@^()
M_$=A8:??:1I6KVLG]I67AV+Q597%L+B-LO&([-#+L;F& *IV^60/;O\ @J5\
M<O#_ ,3M=_8[_P""O7[.][J'C7X,_!#XFW?_  L/5-$TFXDCATG4[:RAEU>-
M"@,\-H(Y4=T!"2,R$@I)M_5YT21#'(H96&&4C((I(X((8%MHH46-4"K&J@*%
M P !Z8H _-W_ (*33?##_@IC^TI^R!\,OV1/B=H/CBY\&_'#3OB3XJ\0^#M6
MAU"WT#P[IT;2M)<3P,RVYNI3## K$-(X)4$1N5\K_92_;Z^$7_!'7_@H'^U3
M^RI_P4:U^[\!Z-\4OC-J?Q3^%GCK4-(NKC3M<M-3">;:K+!&Y#PK%!&!C;O2
M5"58('_6K0/#'AOPK:/8>%_#UCIL$DS2R0V%HD*-(WWG(0 %CW/4T[5O#OA_
M7VMWUW0K.]-G.)[0W=JDA@E'1TW [6'J.: /RF_X.'_VK?"/Q>_X(>^)O&WB
M"#_A$X/&GC?0Y?AUHOB7-CJ^LZ5;ZM9O]M-E-MFC\Q(Y;A8RN]+=X3(L;ED6
M3]E3]L'P'_P2!_;AG_8=^/'[1FC>)?@/\?M3U#QO\!?BUJ/B:&[EL+VYN2;W
M3-3NR[&6-IV/E7LC$,Q 9V+N(/UAHH KV6K:5J6E1:[IVIV\]C/;K/!>0S*\
M4D3+N617!P5*D$,#@@YK\F?V0OVE_P!G?5O^#I/]I&[TWXY>$I[?7/@]H&EZ
M'=Q>(;9H=2OHDTL26MO('VS3*208T)8%7&,JV/UNHH _,/\ X)E?M#? 2Z_X
M+>_\%";^W^-7A1K?59OA]/I<_P#PD%OLO(M/T*\2_DB;?B1+=N)67(C_ (L5
M\8Z!X,UG]MG_ ((B?M[_  5_94\3V7BKQ8_[77B3Q;;>%] OTN+O5]%BU'2K
MKSH88R7FC>.&1XBH(E>'8F6.*_H*HH _%C_@M!_P5C_8R_;X_P""#NN7OP2^
M+&GW_B[5Y_"USK7@"S1Y-5T">/6+)KB*\MU4M:HDBM$LTFV*1RBQNYD0-U/_
M  48^-7[.?[-7_!5[X>_\%%/VP_@5:>/?V9/BO\ !*#P8/&6N> &U2#PIK%O
MJ=Q=P7$EM/ TD4<L4V%P@>02R,@<1$-^MD/@[PC;RW$\'A734>[O$N[MTL8P
M9KA""DKD#YG4@$,>00,&K>J:5IFMZ?+I.M:=!=VMPFR>VNH5DCD7T96!!'L:
M /C']ES]L_\ X)<Z=X)\=?M;_LP_#WP)X(^#/A30@OB3XR67@9/#UIJUT)-Q
ML;3=;0RWHA"C>54JTT\,47F2"14^+OC-\2#_ ,$YOVF_!/\ P<.O)X6@^'W[
M0VH)H'Q4\"Z2;62ZTS0;Q(#INJ6LL;,;N_46L<]\D)96=O+7>J&>OVAL;"QT
MNRBTW3+**VMX(PD$$$81(U P%51P !V%2T 8GPW^)7P]^,/@;3/B;\*/&^E>
M)/#NLVPN-)UO1+Y+FUNXB2-T<D9*L,@@X/!!!Y!K;HHH **** "BBB@ HHHH
M **** "BBB@ HHHH *\!UC]@3P?K&K76K2^/]21KJY>9D6VCPI9BV/UKWZBO
MF^(N$.'.+(4X9MAU55.[C=R5KVO\+6]EN>KE>=YKDLI2P55P<K7LD[VVW3[G
MSS_P[S\&?]%#U3_P%CH_X=Y^#/\ HH>J?^ L=?0U%?+?\0;\-/\ H71_\"J?
M_)GL?Z]<6?\ 04_NC_\ (GSS_P .\_!G_10]4_\  6.OEWQ!IJ:-KU]I$4I=
M;2\EA5V'+!7*Y/Y5^E%%?(\6?1_X7SJG2CE+6"<6^9J,JG/>UE[U2-K6>V]S
MVLF\2LWP$YO&IUT[63:AR]]H.]S\RZ^HO#_[ G@_6=!L=7E\?ZDC7=G%,R+;
M1D*60-C]:^DJ*PX3^CWPYDM2K+-JBQJDERIPE3Y+7N_=JRO>ZWVL:9SXF9KC
MXP6"BZ#5[VDI\VUMX*UOU/GG_AWGX,_Z*'JG_@+'1_P[S\&?]%#U3_P%CKZ&
MHK[7_B#?AI_T+H_^!5/_ ),\'_7KBS_H*?W1_P#D3YY_X=Y^#/\ HH>J?^ L
M=>_:1IR:1I-KI,<A=;6W2%78<L%4#/Z58HKZ3AW@KA?A.=2>4X94G4LI6<G>
MU[?$WM=['E9IG^;YU&,<;5<U&]KI*U]]DNQ\A?\ !6K]H#X&_"'2_@KHWQ1^
M+WAOP_>7/[0W@RYAM=8UJ"WD-NFHY><J[ B%0CEI#\B[3DC%4_\ @K1_P36\
M._\ !3'X#Z%\2O@-X\MO#?QE^'\R>(?@C\3](NP#;7B[94@:>/.ZUG*)EANV
M,$D 8*R/]DT5]2>.?E;^QQ^UW^VE\%_^"(G[07[7_CKX#QR_'+0/'/BW4-?\
M&3Z;((8=62:&.YE>!&+-#'^\N&16PT:$*V"&KYT_:I_:E_9$^(NE?L*_M9:)
M^TAXC^)NJVW[1?A6_P#BC\3-8BOIK/29Y+=Y9K 1I&++3&#AF^P6J(X2$.ZL
M<2/^[<<,,3.\4*J9&W2%5 W-@#)]3@ ?@*KVVAZ+9V46G6FD6L5O!('@@CMU
M5(VSNW*H& <DG([F@#\M?VYO@]^PI^V?^UG\0?B1\,_VR=0_9:_:A^$^BZ8;
M/QZ/$W]COK6CW&DVNH6\NHV5R8O/MHS</;2IQ+'Y"B;*&.*O%OCQ^T9^V%;?
M"?\ X)S_ /!93]MOX:ZHNF_#G6?$$'QL.F:'(ITVUU79866O2VD:YCCEM81<
MMA%56FC1%4RHE?M=K/A7POXC,+>(?#=A?FWG$UN;RS27RI!C#KN!VL,#D<\"
MKEQ;V]W;O:W4"2Q2H4DCD4,KJ1@@@\$$=J /R9_;?_;V_9%^-/\ P6-_X)]_
M%7X*_&[3/&?AK1K_ .(L6HZ[X2AFU*UBFO=$LH8+<26Z.KS[V0/ I,L7F1F1
M4$B%LOQY^W9X&_:O\;_ME?L]?MA^-?$6F^,_ .J^(O#?PD_9^T*UOXQJ^F0Z
M>ZVNNRV]FOF:L]R_[UOM!DM;:)(9-D8/FG];M+\+>&-$CM(M%\.6%FMA \-B
MMK9I&+>)RK.D>T#8K%%) P"5&>@JRNFZ<FH/JJ6$(NI(A$]R(AYC("2%+8R0
M"2<=.30!^!^D?&B7PW_P2%_8 _;A^'_A[6_%G@G]F?XAV%Q\8;71](G8V%LR
M2P372;U5)S;?,I9"55[A S+EBOT5^WC^WI^RS^W/^UY^PAXJ_9.^)#>,]#L_
MVBXVO-?L-(NH;*"5K+*VQEGCC!N-IW-"N7C&#($WQ[_UGCL+&&R&FPV426XC
MV"W6,! O3;MZ8]J^(O\ @I?^R9^T-\9?VD/V6_%W[.'P,M+WPQ\$_BDOBKQ/
MLUFQT]7M#&(S;V4+R+OF ,CD.(DR%&\[F*@'W%7Y"_\ !+CQ=X2_X(%_'KXL
M?\$XOVU]57P1\,O&7Q$N/%OP'^+&N@PZ!JEO<PQ0R:;/?-^ZM+J**VM\I*R@
MLLIR T1E_7>WE>>WCFEMWA9T#-%(5+(2/NG:2,CIP2/0FH-9T31O$>F2Z+XA
MTBUO[.X7;/:7MNLL4@]&5@01]10!Y+8?MO\ P*^)GB.R\ _LO_$'P]\4=?NK
MN%;V'P;KT-_::+:%@9+N_NK<R1VJK'N,<;D23N D:GYF3XA_8K^(6E_\$Z_^
M"Q/[5GP;_;%\567A/2OCQX@L?'GPC\:^)+Q+33=<A2.5+O3TNIBL?VBW\Z)!
M 6W[8G8#:5+?IKX?\-^'?">F)HOA;0++3+.,DQVFGVJ0Q*3U(5  ,_2C7_#7
MASQ78#2_%&@66I6HD$@MK^U2:/>.C;7!&1V- 'Y<_"'P]X4C_:(_X*&?\%1+
MCQ9I^D?"'Q]X2T_PYX(\2WMVEO8>(9--T#[/>W\$CD)- ;H>3#,A9)F\THS=
M_)O!'QR^"\7_  9T7&C2_%GPVMZOP@O]%:R;6X!,-2:^F"V>S=N\\]1'C<1R
M!CFOVK1$C01QH%51A548 'I2T ?C=_P5\_:#^!.H?\&\7P0_L[XQ^&+EKV3X
M=BSBMM=MY'F-J+1[H*JN2QA56,@ RF#NQ7J?[9'[0?P2\$_\'!G[)WQ4\3_%
M/0K3PKK'P9\4V]CXHDU2+^SG>=F6$FY#>4JR/M17+!6=T4'+ ']/J^&OVBOV
M7OVE_B#_ ,%E?A%^V)H?P'75/AIX"^'NM^&/$,UQKVGK=7DFH!\30VLDN)($
MR@;S&1R"^$.U0X!YY\0O@_:?MY_\%O\ _A=_[/GBFVN?#'PM_9NU;PCXE^(6
MC3+/9#7]5DNDMM,CGC)6::W@N'NI%0MY6^-6VLX%87_!"#]L/X,_L8?\$[W_
M &'OVVO'VB?#'XF?L^:QK.E^+?"_BG48[2ZN[66_N;VVO;*)R&O89DN-D;0A
M_-=/E!\Q-WZ>:1HVD>']-AT;0=*MK&SMUVV]I9P+%%$O7"JH 4?05%?>%_#.
MJ:O:Z_J?AVPN+^QS]BO9[1'FM\]=CD;D_ B@#\</V;?V0/V5?@3_ ,$8OA)^
MR?\ \%;?!<WA3P_\<?C/J.H:8^KZH=*G^'U_=V]_>:5*TQ'^B3>3:K&=^U8Y
M+UHY05\Q3[Q_P2@\6_M$?LS?M4_&/]COXB_MI-\<?@%\/?!NF:UX7^+OBC4H
M9;CPW<SR.IT.]U$,8YY4@7SCN<^7&(6 B681C](;NSM+^!K6^M8YHG4J\<J!
ME8$8((/4$$C\:@T30=#\-:;'HWAS1K33[.+/E6ME;+%&F3DX50 ,DD_C0!^.
M/_!*KQ3X9^-/_!O%^UC\-OA/X@LO$/B"ZA^*R0:'I%TEQ=N;RSNC:8A0E\3!
MUV''SYXS6'\2?&]M^UA_P;L?L\^+OV3/"B_%>_\ V:;GX=^)?B)X'BT>2X@U
M)=(M6AU#2)%>,I<.@S)-"H<K$%8J1(F[]M:9!;V]K%Y-K D: DA(U &2<DX'
MJ23^- 'YQ?L9?MS_ /!%7]LCQSX(TW_@GO\ LJ>!]>^(MSJ%EJ5]I]I\&(]-
MN/!%K%*LES?7M[]C$-M)"%98O*E<RW!A6,E6,B_HOK.M:/X<TFYU_P 0ZM;6
M%A9P-->7M[.L4,$:C+.[L0JJ ,DD@ 5'I/ASP]H$ES-H6@V5D][.9KQ[2U2,
MSR'J[E0-S>YR:NT ?DE_P0B_:5_9ZU#_ (*.?M_BU^-_A,C7?C0FIZ&S>(+=
M1J5C"=2\VZMR7Q/"@7+2)N55*L2 P)V/^"&W[2G[/.F_#']N?7=3^.7A&VL_
M^&N?'_B(W-SXAMHT_LBX6S2WO\LX_P!'D<;$E^XS< D\5^JM% '\[OPMNO%F
MK_\ !MM^Q_\ M _!2T;QJO[,O[0\7CKXH>#?#\RW%[:Z?:^(-8F\R6!264JD
MT3X8#$4S2DA%+5]1_P#!7?\ X*6_L/\ [45M^Q;\2/V>OV@-)\8:5I'[87@G
M7]>FT"*:Z?1[-!<NPO$C0M:S[2S"VE"S,(Y"J,(V(_7^LW3?!WA'1HH8-'\*
MZ;:);W3W,"6UC'&(YG4J\BA0,.P9@6')#$'K0!^/OQK^-'['O[ __!9?XQ^.
M?^"IO[/^B:E\)?VB])\-Z]\*?BKXM^' U>VTRZL=*BL[G3I@]O)+;LQ0$H%W
M1A(F=0LFY?K_ .&W[?/_  3T_9U_92\8?MH_##X6^&?AU\()[R"W\&ZK8>&(
M/#D_Q"O@A"M9VLL=NTD;R.((990N[RYY3M@42M]DZYX>T#Q/8'2O$NAV>H6K
M.&:VOK9)HRP.0=K@C(/2K:(D:A$4*JC  & !0!^-W@?Q3IO_  00_P""A&A?
M%[XZ>,O MG\+/VSI6NO'4.@/!%!X$\4B>6X@DM6XDFT?9>&%IR N[S)V$0VQ
MM^Q&BZWHWB71[3Q%X=U>UU#3[^V2XL;ZRN%EAN(74,DD;J2KJRD$,"00015J
MB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?\ @]Y_Y-9^!_\ V4#4?_2$
M44?\'O/_ ":S\#_^R@:C_P"D(HH \_\ ^#3;_E*9^UW_ -O'_I\GK]_J_ '_
M (--O^4IG[7?_;Q_Z?)Z_?Z@ HHHH **** "BBB@ HKY9_X*E_\ !0+QA_P3
M^\ ^%?&'@_X?:;X@E\0:Q-9S0ZE=21+$J1;PRE.I)XYKXI_XB3?C=_T;5X5_
M\&]S_A7V&4<"\29Y@8XS!TE*G*Z3<HK9V>C=]SXW../N&<BQ\L'C*KC4C9M*
M,GNKK5*VS/U\HK\@_P#B)-^-W_1M7A7_ ,&]S_A1_P 1)OQN_P"C:O"O_@WN
M?\*]+_B%W&?_ #X7_@</\SR_^(K<%?\ /^7_ (!/_(_7;4M2T[1]/GU?5[^&
MUM+6%IKFZN90D<,:@EG9F("J "23P *^?/\ A[-_P3J_X3/_ (0/_AJG0/MW
MG>5YWD77V/=G'_'WY7V?;_M>9CWK\JOVW?\ @LW\=?VT/@]_PI.Z\#Z9X2TF
MYOTGU=M&OIG?4(T!*P.7P/+WX<CN47L,'XYKZ_(/"!U\+*>;U)0F]HP<7;S;
MM)._96]>WQW$'C(J&+C#)Z<:D$M934E?R2O%JW=W]--?ZGM.U+3M8T^#5](O
MX;JTNH5FMKJVE#QS1L 5=64D,I!!!'!!J:OPA_8C_P""S?QU_8O^#W_"D[7P
M/IGBW2;:_>?2&UF^F1]/C< M A3(\O?EP.Q=NQP/8O\ B)-^-W_1M7A7_P &
M]S_A7S.,\*>*J.*G##P4X)Z2YHJZZ.S=UYH^HP7BUPG6PD)XB<J<VO>CRRE9
M]5=*S79_D?KY17Y!_P#$2;\;O^C:O"O_ (-[G_"C_B)-^-W_ $;5X5_\&]S_
M (5S?\0NXS_Y\+_P.'^9T_\ $5N"O^?\O_ )_P"1^OE8GQ#\0>*_"WA*[UWP
M5X!N/$^HVZ;H-#M-0@M9;KU5)+AEC5O3>RCU(ZU\B?\ !+3_ (*E^/O^"@/C
M[Q5X/\8?"O1_#T7A[1X;R&;3;V65I6>7858/T '/%?:U?(9OE&.R/'2P>,CR
MU(V;2:>ZNM5IL?99/G& S[ 1QF#ES4Y72;36SL]'KN?+O_!.?_@K!\ O^"C6
MK>/_ (=^$?"WB#P1\0?A?XBGTCQO\./&BV\>JZ>\4AB:8""61)(O-22(LK':
M\9# !D+]E^T=^U_XL^ 'QH^'/P<L/V;M?\5/\4/$$^B^'=8TG6;"&W@NX=/N
M-0E%R+B5'C06UI<N&57SY) &XJ&_,GXH?\$__CEH_A[Q'_P5_P#^";%I]E^/
MWPN_:#^*(\1^'+:,F'XA^'D\9ZOYVG7$2X\Z98P0F/G=0$4^9';E/J/X:?\
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M?%.H:\VHRZ=IT=K B0:U>V\$4<:# 5(8HT!)+$+EF9B6(!N?\%._^"FFA?\
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M=Q+X6CUOP5X<\/ZU%:_\)-'(BR1"&Y=65 \;;PVUB0,!68A3W/P]U[Q%XJ\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /Q!_X/>?\ DUGX'_\ 90-1_P#2$44?\'O/_)K/P/\
M^R@:C_Z0BB@#S_\ X--O^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_
M *?)Z_?Z@ HHHH **** "BBB@#B/C=^S;\"_VD=*L=$^.GPRTSQ-::;<-/80
M:G&S+#(R[2RX(Y(XKSC_ (=9?\$]?^C3_"G_ (#R?_%U[]17H8?-LUPE)4Z%
M><(KI&4DON3L>=B,HRG%U75KX>$Y/K*$6_O:N> _\.LO^">O_1I_A3_P'D_^
M+H_X=9?\$]?^C3_"G_@/)_\ %U[]16W]OY[_ -!53_P.7^9C_J_D/_0)2_\
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M3NVFV^[;NSP'_AUE_P $]?\ HT_PI_X#R?\ Q='_  ZR_P"">O\ T:?X4_\
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MWCZRN_B[\$(?'&GF7QAI$4TLL(E=G%K(D;LCM:/*ZL^TLI$=>X^ ?@C_ ,%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$'_ (/>?^36?@?_ -E
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M\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;H ^OZ*^0/\
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M\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;H ^OZ*^0/\
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M\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;H ^OZ*^0/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784196392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 18, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Moderna, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3467528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Technology Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">714-6500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,872,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">DOCUMENTS INCORPORATED BY REFERENCEPortions of the registrant&#8217;s Definitive Proxy Statement relating to its 2022 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784103656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784637464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,848<span></span>
</td>
<td class="nump">$ 2,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">3,879<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">3,175<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,441<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">16,071<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments, non-current</a></td>
<td class="nump">6,843<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,669<span></span>
</td>
<td class="nump">7,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">6,253<span></span>
</td>
<td class="nump">3,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,128<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, non-current</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,524<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001; 162&#160;shares authorized as of December 31, 2021 and 2020; no shares issued or outstanding at December 31, 2021 and 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2021 and 2020; 403 and 399 shares issued and outstanding as of December 31, 2021 and 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">4,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="nump">9,958<span></span>
</td>
<td class="num">(2,244)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">14,145<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 24,669<span></span>
</td>
<td class="nump">$ 7,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629785016088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 18,471,000,000<span></span>
</td>
<td class="nump">$ 803,000,000<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">2,617,000,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,991,000,000<span></span>
</td>
<td class="nump">1,370,000,000<span></span>
</td>
<td class="nump">496,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">567,000,000<span></span>
</td>
<td class="nump">188,000,000<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,175,000,000<span></span>
</td>
<td class="nump">1,566,000,000<span></span>
</td>
<td class="nump">606,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">13,296,000,000<span></span>
</td>
<td class="num">(763,000,000)<span></span>
</td>
<td class="num">(546,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">39,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(29,000,000)<span></span>
</td>
<td class="num">(6,000,000)<span></span>
</td>
<td class="num">(8,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">13,285,000,000<span></span>
</td>
<td class="num">(744,000,000)<span></span>
</td>
<td class="num">(515,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="nump">1,083,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 12,202,000,000<span></span>
</td>
<td class="num">$ (747,000,000)<span></span>
</td>
<td class="num">$ (514,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (usd per share)</a></td>
<td class="nump">$ 30.31<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (usd per share)</a></td>
<td class="nump">$ 28.29<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares used in calculation of earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 17,675,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">735,000,000<span></span>
</td>
<td class="nump">529,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 61,000,000<span></span>
</td>
<td class="nump">$ 74,000,000<span></span>
</td>
<td class="nump">$ 48,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784142360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 12,202<span></span>
</td>
<td class="num">$ (747)<span></span>
</td>
<td class="num">$ (514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income, net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (losses) gains on available-for-sale debt securities</a></td>
<td class="num">(42)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: net realized (gains) on available-for-sale securities reclassified to net income (loss)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Net (decrease) increase from available-for-sale debt securities</a></td>
<td class="num">(43)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gains on derivative instruments</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Less: net realized (gains) on derivative instruments reclassified to net income (loss)</a></td>
<td class="num">(58)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Net increase from derivatives designated as hedging instruments</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 12,175<span></span>
</td>
<td class="num">$ (746)<span></span>
</td>
<td class="num">$ (511)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629786207336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2018</a></td>
<td class="nump">$ 1,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,538<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (1,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period (Accounting Standards Update 2014-09) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period (Accounting Standards Update 2016-02) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock and restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(514)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(514)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2019</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,670<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(1,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds of initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds of initial public offering, net of issuance costs</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">$ 2,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,802<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(2,244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options to purchase common stock (in shares)</a></td>
<td class="nump">7,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options to purchase common stock</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased</a></td>
<td class="num">(857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">12,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 14,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,211<span></span>
</td>
<td class="num">$ (24)<span></span>
</td>
<td class="nump">$ 9,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788806472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629789055400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 12,202<span></span>
</td>
<td class="num">$ (747)<span></span>
</td>
<td class="num">$ (514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases', window );">Leased assets expensed</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization/accretion of investments</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_DeferredIncomeTaxExpenseBenefitNet', window );">Deferred income taxes</a></td>
<td class="num">(318)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,784)<span></span>
</td>
<td class="num">(1,385)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(489)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,394)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets', window );">Right-of-use assets, operating leases</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">989<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">3,842<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">13,620<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
<td class="num">(459)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(12,652)<span></span>
</td>
<td class="num">(2,956)<span></span>
</td>
<td class="num">(1,145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">3,105<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Investment in convertible notes</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(8,523)<span></span>
</td>
<td class="num">(1,672)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offerings of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock through equity plans, net</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(857)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChargesToFinancingLeaseLiabilities', window );">Changes in financing lease liabilities</a></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(873)<span></span>
</td>
<td class="nump">2,033<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">4,224<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
<td class="num">(422)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">2,636<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">6,860<span></span>
</td>
<td class="nump">2,636<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChargesToFinancingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges To Financing Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChargesToFinancingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredIncomeTaxExpenseBenefitNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Tax Expense (Benefit), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredIncomeTaxExpenseBenefitNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Leases, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 40<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=124072958&amp;loc=SL51729484-110225<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 40<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123393937&amp;loc=d3e44908-112734<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784115512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">162,000,000<span></span>
</td>
<td class="nump">162,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">403,000,000<span></span>
</td>
<td class="nump">399,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">403,000,000<span></span>
</td>
<td class="nump">399,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788839400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company pioneering messenger RNA (mRNA)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutics and vaccines to create a new generation of transformative medicines to improve the lives of patients. mRNA medicines are designed to direct the body&#8217;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases, independently and with our strategic collaborators.</span></div>On December 18, 2020, we received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the emergency use of the Moderna COVID-19 Vaccine (also referred to as mRNA-1273 and marketed under the brand name Spikevax) in individuals 18 years of age or older. We have also received authorization for our COVID-19 vaccine from health agencies in more than 70 countries and from the World Health Organization (WHO). Additional authorizations are currently under review in other countries. In addition, we have received authorization for our COVID-19 vaccine for use in adolescents in the United Kingdom, European Union, Japan, Canada, Switzerland, Taiwan, Saudi Arabia, Australia, and the Philippines, and have pending applications for authorization to administer the vaccine to adolescents with regulatory agencies in the United States and other countries. In January 2022, we received full FDA approval for Spikevax to prevent COVID-19 in individuals 18 years of age and older in the United States. In February 2022, we received approval for the administration of Spikevax to children ages 6-11 in Australia and a positive recommendation from the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use for the administration of Spikevax in children ages 6-11 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629789217256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Updates (ASU) of the&#160;Financial Accounting Standards Board (FASB).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, revenue recognition, research and development expense, leases, fair value of financial instruments, derivative financial instruments, inventory, useful lives of property and equipment, stock-based compensation, income taxes, and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that our chief executive officer is the chief operating decision maker (CODM). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, we have concluded that we operate as one segment. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted ASC 606&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is primarily generated through product sales. We also generate grant revenue from government-sponsored and private organizations, and collaboration revenue through collaboration arrangements. </span></div><div><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Sales </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are associated with our COVID-19 vaccine supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), and the African Union. These agreements generally do not include variable consideration, such as discounts, rebates or returns. Under these agreements, we are entitled to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. We recognize revenue from product sales, using the five-step model under ASC 606, based on the fixed price per dose according to the contracts when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay distribution fees to certain customers in connection with the sales of our product. We record distribution fees paid to our customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and we can reasonably estimate the fair value of the goods or services received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale. Such distribution fees were immaterial for the year ended December 31, 2021. We did not have any distribution fees for the years ended December 31, 2020 and 2019.</span></div><div style="padding-right:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Grant Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contracts with Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); the U.S. government&#8217;s Defense Advanced Research Projects Agency (DARPA); the Bill &amp; Melinda Gates Foundation (Gates Foundation) and other government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaboration Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into several strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with an original maturity of 90&#160;days or less from the date of purchase to be cash equivalents.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash is composed of amounts held on deposit related to our lease arrangements. The funds are maintained in money market accounts and are recorded at fair value. We classify our restricted cash as either current or non-current based on the terms of the underlying lease arrangement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash shown in the Consolidated Statements of Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,860&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in prepaid expenses and other current assets in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report available-for-sale investments at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive (loss) income, a component of stockholders&#8217; equity. Realized gains and losses are determined using the specific-identification method, and are included in other expense, net in our consolidated statements of operations. We classify our available-for-sale marketable securities as current or non-current based on each instrument&#8217;s underlying effective maturity date and for which we have the intent and ability to hold the investment for a period of greater than 12 months. Marketable securities with maturities of less than 12&#160;months are classified as current and are included in investments in the consolidated balance sheets. Marketable securities with maturities greater than 12&#160;months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive (loss) income, net of applicable taxes. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accounts receivable amounts due from our product sales and related vaccine supply agreements and our grant agreements. We also have accounts receivable amounts due from strategic collaborators as a result of manufacturing and research and development services provided under collaboration arrangements, or milestones achieved, but not yet paid. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for doubtful accounts, we make judgments about the creditworthiness of our customers based on ongoing credit evaluation and historical experience. There was no allowance for doubtful accounts at December 31, 2021 or 2020. There was no bad debt expense for the years ended December 31, 2021, 2020 or 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable securities, and accounts receivable. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable are generally unsecured and are from customers in different countries. We generated revenue from product sales to the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), the African Union. grants made by government-sponsored and private organizations, and to a lesser extent, strategic alliances in 2021 and 2020. Historically, we generated revenue primarily from strategic alliances. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:50.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;Revenue</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended&#160;December&#160;31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;<br/>Accounts&#160;Receivable<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government (excluding BARDA)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom Government</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea Government</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">* - Represents an amount of less than 10%</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We record all derivatives on our consolidated balance sheets at fair value. The accounting for changes in the fair value of a derivative depends on whether the derivative has been designated and qualifies for hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The gains or losses resulting from changes in the fair value of cash flow hedges are initially recorded as a component of accumulated other comprehensive (loss) income (AOCI) in stockholders&#8217; equity and subsequently reclassified to product sales in the period during which the hedged transaction affects earnings. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to other expense, net, in our consolidated statements of operations. We may enter into derivative contracts that are intended to economically hedge certain risk, even though hedge accounting does not apply or we elect not to apply hedge accounting. Gains or losses associated with foreign currency derivatives that are not designated as hedging instruments for accounting purposes are recorded within other expense, net, in our consolidated statements of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC&#160;820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash equivalents and marketable securities are reported at fair value determined using Level&#160;1 and Level&#160;2 inputs (Note&#160;6). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk (Note 7). We do not have any non-financial assets or liabilities that should be recognized or disclosed at fair value on a recurring basis at December 31, 2021, 2020, and 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintained letters of credit of $12 million as of December 31, 2021 and 2020, related to our lease arrangements, which are secured by money market accounts in accordance with certain of our lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in our consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is recorded at the lower of cost or net realizable value, with cost determined using first-in, first-out and average cost methods for different components of inventory. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to an initial regulatory approval for our investigational medicines, we expense costs relating to raw materials and production of inventory as research and development expense in our consolidated statements of operations, in the period incurred. Upon the authorization of distribution and use of our COVID-19 vaccine under an EUA in December 2020, we began to capitalize inventory costs associated with our COVID-19 vaccine, as it was determined that inventory costs incurred subsequent to the EUA had a probable future economic benefit. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property and equipment are described below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:48.552%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.553%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement<br/>or&#160;remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress includes direct costs related to the construction of various property and equipment, including leasehold improvements, and is stated at original cost. Construction in progress includes costs incurred under construction contracts including project management services, engineering services, design services and development, construction services and other construction-related fees and services. Such costs are not depreciated until the asset is completed and placed into service. Once the asset is placed into service, these capitalized costs will be allocated to certain property and equipment categories and will be depreciated over the estimated useful life of the underlying assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for maintenance and repairs are charged to expense as incurred. Upon retirement or sale, the cost of the assets disposed of, and the related accumulated depreciation, are removed from the accounts, and any resulting gain or loss is recorded to other expense, net in our consolidated statements of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our long-lived assets, which consist of property and equipment, to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals. Impairment expenses for the years ended December 31, 2021, 2020 and 2019 were immaterial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in profit or loss on a straight-line basis over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes cost of raw materials, production, transportation, freight and indirect overhead costs associated with our product sales during the period and third-party royalties on net sales of our product. Cost of sales also includes adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment or facilities that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, should be capitalized and depreciated as tangible assets. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project and that have no alternative future uses and therefore no separate economic values are considered research and development costs and are expensed when incurred. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Compensation&#8212;Stock Compensation)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#8220;more likely than not&#8221; criterion. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted common stock and stock options that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive (loss) income for the years ended December 31, 2021 and 2020 were as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized&#160;Gain (Loss) on Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Unrealized Gains on Derivatives Designated As Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788809832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Sales</a></td>
<td class="text">Product Sales<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily associated with our COVID-19 vaccine supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), and the African Union. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no product sales in 2019. As of December 31, 2021 and 2020, our COVID-19 vaccine was our only commercial product authorized for use. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, we had deferred revenue of $6.7&#160;billion and $3.8&#160;billion, respectively, related to customer deposits. We expect $6.2&#160;billion of our deferred revenue related to customer deposits as of December 31, 2021 to be realized in less than one year. Timing of product manufacturing, delivery and receipt of marketing approval will determine the period in which revenue is recognized.</span></div>Grant Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement with the DARPA for an award of up to $56&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of December 31, 2021, the committed funding, net of revenue earned was $2&#160;million. An additional $42&#160;million of funding will be available if DARPA exercises additional contract options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with BARDA for an award of up to $483&#160;million to accelerate development of mRNA-1273, our vaccine candidate against COVID-19. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $472&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $63&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. In April 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. In June 2021, the agreement with BARDA was further amended to award additional funding of $144&#160;million to support pediatric clinical trials for mRNA-1273. The maximum award from BARDA, inclusive of the 2020 and 2021 amendments, was $1.4&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of December 31, 2021, the remaining available funding, net of revenue earned was $189&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we received from BARDA an award of up to $126&#160;million, subsequently adjusted to $117&#160;million in 2021, to help fund our Zika vaccine program. Three of the four contract options have been exercised. As of December 31, 2021, the remaining available funding, net of revenue earned was $48&#160;million, with an additional $8&#160;million available if the final contract option is exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of December 31, 2021, the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available funding, net of revenue earned was $7&#160;million, with up to an additional $80&#160;million available if additional follow-on projects are approved.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Geographic Information <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic area of our customers and collaboration partners was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,471&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi (on behalf of the COVAX Facility) as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property and equipment, including financing right-of-use assets, was principally located within the United States as of December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629785868072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Grant Revenue</a></td>
<td class="text">Product Sales<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily associated with our COVID-19 vaccine supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), and the African Union. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no product sales in 2019. As of December 31, 2021 and 2020, our COVID-19 vaccine was our only commercial product authorized for use. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, we had deferred revenue of $6.7&#160;billion and $3.8&#160;billion, respectively, related to customer deposits. We expect $6.2&#160;billion of our deferred revenue related to customer deposits as of December 31, 2021 to be realized in less than one year. Timing of product manufacturing, delivery and receipt of marketing approval will determine the period in which revenue is recognized.</span></div>Grant Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement with the DARPA for an award of up to $56&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of December 31, 2021, the committed funding, net of revenue earned was $2&#160;million. An additional $42&#160;million of funding will be available if DARPA exercises additional contract options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with BARDA for an award of up to $483&#160;million to accelerate development of mRNA-1273, our vaccine candidate against COVID-19. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $472&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $63&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. In April 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. In June 2021, the agreement with BARDA was further amended to award additional funding of $144&#160;million to support pediatric clinical trials for mRNA-1273. The maximum award from BARDA, inclusive of the 2020 and 2021 amendments, was $1.4&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of December 31, 2021, the remaining available funding, net of revenue earned was $189&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we received from BARDA an award of up to $126&#160;million, subsequently adjusted to $117&#160;million in 2021, to help fund our Zika vaccine program. Three of the four contract options have been exercised. As of December 31, 2021, the remaining available funding, net of revenue earned was $48&#160;million, with an additional $8&#160;million available if the final contract option is exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of December 31, 2021, the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available funding, net of revenue earned was $7&#160;million, with up to an additional $80&#160;million available if additional follow-on projects are approved.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Geographic Information <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic area of our customers and collaboration partners was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,471&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi (on behalf of the COVAX Facility) as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property and equipment, including financing right-of-use assets, was principally located within the United States as of December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629785806968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca &#8211; Strategic Alliances in Cardiovascular and Oncology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Option Agreement and Services and Collaboration Agreement, amended and restated in 2018</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2013, we entered into an Option Agreement, the AZ Option Agreement, and a related Services and Collaboration Agreement (2013 AZ Agreements), the AZ Services Agreement, with AstraZeneca, which were amended and restated in June 2018 (2018 A&amp;R Agreements). Under the 2018 A&amp;R Agreements, we granted AstraZeneca certain exclusive rights and licenses, and options to obtain exclusive rights to develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. The activities to be performed by the parties under the 2018 A&amp;R Agreements are limited to defined biological targets in the cardiovascular and cardiometabolic fields and one defined target in the cancer field. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the effective date of the 2013 AZ Agreements, AstraZeneca made upfront cash payments to us totaling $240 million in exchange for the acquired options and our performance of certain research-related services, each as described above. Under the 2018 A&amp;R Agreements, we are entitled to receive, on a product-by-product basis, payments for achievement of certain development, regulatory and commercial milestones, as well as earn-out payments on worldwide net sales of products ranging from a high-single digit percentage to 12%, subject to certain reductions, with an aggregate minimum floor.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, AstraZeneca exercised a product option under the 2013 AZ Agreements to obtain exclusive rights to develop and commercialize with respect to AstraZeneca's VEGF-A product (AZD8601). It is currently being developed in a Phase 2 clinical trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2016 Strategic Alliance with AstraZeneca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> IL-12</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered into a Strategic Drug Development Collaboration and License Agreement (2016 AZ Agreement) with AstraZeneca to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers. Under the terms of the 2016 AZ Agreement, we and AstraZeneca have agreed to work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL-12 protein.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During a limited period of time, each party had an opportunity to propose additional discovery programs to be conducted under the 2016 AZ Agreement. We are responsible for conducting and funding all discovery and preclinical development activities under the 2016 AZ Agreement in accordance with an agreed upon discovery program plan for the IL-12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck &#8211; Strategic Alliances in Infectious Diseases and Cancer Vaccines</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2016 Cancer Vaccine Strategic Alliance-Personalized mRNA Cancer Vaccines</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we entered into a personalized mRNA cancer vaccines (PCV) Collaboration and License Agreement with Merck (PCV Agreement), to develop and commercialize PCVs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient&#8217;s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique mRNA cancer vaccine designed to specifically activate the patient&#8217;s immune system against her or his own cancer cells.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the PCV Agreement, we are responsible for designing and researching PCVs, providing manufacturing capacity and manufacturing PCVs, and conducting Phase&#160;1 and Phase&#160;2 clinical trials for PCVs, alone and in combination with KEYTRUDA (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget and under the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oversight of a committee comprised of equal representatives of each party. The parties have entered into a clinical quality agreement with respect to Moderna&#8217;s manufacture and supply activities. We received an upfront payment of $200 million from Merck. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Expansion of the Cancer Vaccine Strategic Alliance-Shared Neoepitope Cancer Vaccines</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, we and Merck agreed to expand our cancer vaccine strategic alliance to include the development and commercialization of our KRAS vaccine development candidate, mRNA-5671 or V941, and potentially other shared neoantigen mRNA cancer vaccines (SAVs). We preclinically developed mRNA-5671 prior to its inclusion in the cancer vaccine strategic alliance and it is comprised of a novel mRNA construct designed by us and encapsulated in one of our proprietary LNPs. The PCV Agreement was amended and restated to include the new SAV strategic alliance (PCV/SAV Agreement).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted Merck certain licenses and we and Merck have agreed to certain exclusivity obligations with respect to SAVs and particular SAV programs, which obligations are subject to termination or expiration upon certain triggering events. Under the PCV/SAV Agreement, Merck will be responsible for conducting Phase 1 and Phase 2 clinical trials for mRNA-5671 and for all costs associated with such activities, in accordance with a jointly agreed development plan and budget, and we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials and for all costs and expenses associated with such manufacture and supply. Under the PCV/SAV Agreement, our budgeted commitment for PCV increased to $243 million. Until the expiration of a defined period of time following the completion of Phase 1 and Phase 2 clinical trials for mRNA-5671 under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of mRNA-5671 by making a participation payment to us. In connection with the amendment of the PCV Agreement to include the development and commercialization of mRNA-5671 and potentially other SAVs, Merck made a contemporaneous equity investment in our Series H redeemable convertible preferred stock, resulting in gross proceeds of $125 million, of which $13 million was determined to be a premium and recorded to deferred revenue. In December 2021, Merck elected to terminate the Merck participation election with respect to the joint SAV program.</span></div><div><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vertex &#8211; Strategic Alliance in Cystic Fibrosis</span></div><div style="padding-right:11.25pt"><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2016 Strategic Alliance in Cystic Fibrosis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement), with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex. The Vertex Agreement, which was amended in July 2019 (2019 Vertex Amendment), is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins. Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period that currently extends until August 2022, leveraging our Platform technology and mRNA delivery expertise along with Vertex&#8217;s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary &#8220;back-up&#8221; supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. </span></div><div><span><br/></span></div><div style="padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Strategic Alliance in Cystic Fibrosis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a new Strategic Collaboration and License Agreement with Vertex (Vertex 2020 Agreement). The Vertex 2020 Agreement is aimed at the discovery and development of potential medicines to treat CF by delivering gene-editing therapies to lung cells to facilitate production of functional CFTR proteins. The three-year research period of the Vertex 2020 Agreement will initially focus on the identification and optimization of novel LNPs and mRNAs that can deliver gene-editing therapies to cells in the lungs. Following the initial three-year period, Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Vertex is also obligated to pay us for research services in connection with our performance of certain activities in accordance with a jointly agreed research plan. Subject to customary &#8220;back-up&#8221; supply rights granted to Vertex, under the agreement, we are the exclusive manufacturer of related mRNA and LNPs for preclinical, clinical, and commercialization purposes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.262%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the year ended December 31, 2021 (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $286&#160;million.</span></div>In addition to the collaborative arrangements mentioned above, we have other collaborative and licensing arrangements that we do not consider to be individually significant to our business at this time. Pursuant to these agreements, we may be required to make upfront payments and payments upon achievement of various development, regulatory and commercial milestones, which in the aggregate could be significant. Future milestone payments, if any, will be reflected in our consolidated financial statements when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788793752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Financial Instruments and Fair Value Measurements</a></td>
<td class="text">Financial Instruments and Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash and available-for-sale securities by significant investment category at December 31, 2021 and 2020 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,622&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,843&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="45" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable securities, by contractual maturity at December 31, 2021 and 2020 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,892&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. We did not record any impairment charges related to our available-for-sale securities during the&#160;years ended December 31, 2021, 2020, and 2019. We did not recognize any credit-related allowance to available-for-sale securities as of the years ended December 31, 2021 and 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2021 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.797%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or More</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2021:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we did not have material gross unrealized losses. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2021 and 2020, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788894360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">Derivative Financial Instruments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies and have international sales and expenses denominated in foreign currencies. Therefore, we are exposed to certain risks arising from both our business operations and economic conditions. Our risk management strategy includes the use of derivative financial instruments to hedge foreign currency exchange rate fluctuations on monetary assets or liabilities denominated in foreign currencies. We do not enter into derivative financial contracts for speculative or trading purposes. We do not believe that we are exposed to more than a nominal amount of credit risk in our foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. We classify cash flows from our derivative transactions as cash flows from operating activities in our consolidated statements of cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate the foreign exchange risk arising from the fluctuations in foreign currency denominated product sales in Euro through a foreign currency cash flow hedging program, using forward contracts and foreign currency options that do not exceed 15 months in duration. We hedge these cash flow exposures to reduce the risk that our earnings and cash flows will be adversely affected by changes in exchange rates. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The derivative assets or liabilities associated with our hedging activities are recorded at fair value in other current assets or other current liabilities, respectively, in our consolidated balance sheets. The gains or losses resulting from changes in the fair value of these hedges are initially recorded as a component of AOCI in stockholders&#8217; equity and subsequently reclassified to product sales in the period during which the hedged transaction affects earnings. In the event the underlying forecasted transaction does not occur, or it becomes </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to other expense, net, in our consolidated statements of operations. We evaluate hedge effectiveness at the inception of the hedge prospectively, and on an on-going basis both retrospectively and prospectively. If we do not elect hedge accounting, or the contract does not qualify for hedge accounting treatment, the changes in fair value from period to period are recorded as a component of other expense, net, in our consolidated statements of operations. As of December 31, 2021, we had net deferred gains of $21&#160;million on our foreign currency forward contracts included in AOCI that are expected to be recognized into product sales within the next 12 months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Hedges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We enter into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily accounts receivable, accounts payable, and lease liabilities in Euro and Swiss Franc, that are not designated for hedge accounting treatment. Therefore, these forward contracts are accounted for as derivatives whereby the fair value of the contracts are reported as other current assets or other current liabilities on our consolidated balance sheets, and gains and losses resulting from changes in the fair value are recorded as a component of other expense, net, in our consolidated statements of operations. The gains and losses on these foreign currency forward contracts generally offset the gains and losses in the underlying foreign currency denominated assets and liabilities, which are also recorded to other expense, net, in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross notional amount and fair value for foreign currency derivatives were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the consolidated balance sheet within prepaid expenses and other current assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the consolidated balance sheets within other current liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gains on our foreign currency derivatives, net of tax, recognized in our consolidated statements of comprehensive income (loss) for the year ended December 31, 2021 was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effect of derivative instruments in our consolidated statements of operations for the year ended December 31, 2021 was as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.318%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains reclassified from AOCI into income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were immaterial hedging gains and losses for the year ended December 31, 2020 and no hedging gains or losses for the year ended December 31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629791539832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of December 31, 2021 and 2020 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788788568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,593&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the&#160;years ended December 31, 2021, 2020, and 2019 was $232 million, $31 million, and $31 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629789185144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Other Balance Sheet Components</a></td>
<td class="text">Other Balance Sheet Components<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments to manufacturing vendors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value added tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"/><td style="width:73.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.119%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"/><td style="width:73.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.119%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - financing (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - operating (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue during the year ended December 31, 2021 (in millions): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,798)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,872)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,868&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629791315384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2042. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge campus and our Moderna Technology Center (MTC), located in Norwood. We also lease other office and lab spaces globally for our business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cambridge Campus</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy a multi-building campus at Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 261,000 square feet. Our Cambridge campus leases have expiry ranges from 2024 to 2029.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we entered into an amendment to our lease agreements to consolidate our Technology Square space in Cambridge, Massachusetts. This included entering into a forward-starting lease agreement starting in January 2020 to acquire approximately 50,000 square feet of additional space at 200 Technology Square. In addition, our existing 200 Technology Square lease was extended for two years to 2029. As part of the lease amendment, we completely exited our leased space of approximately 60,000 square feet at 500 Technology Square by May 2020. We are also investing in a new Moderna Science Center (MSC) in Cambridge, to create a purpose-built space to support our next chapter of discovery (see Note 12). In connection with our MSC investment, in September 2021, we entered into an amendment to our lease agreements to allow for an option for early termination of the leases, either in part or full. Notification of the intent to exercise the option must be provided by August 2023. We have not elected to exercise this option. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record operating lease cost for each of our operating leases on a straight-line basis from lease commencement date through the end of the lease term. Operating lease cost is recorded in operating expenses in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an industrial technology center in Norwood, Massachusetts, our Moderna Technology Center (MTC), which comprises three buildings, MTC South, MTC North, and MTC East.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space (MTC South). The lease had an initial expiration of September&#160;2032 with the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet (MTC North). The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031 with the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22&#160;million to be paid back over the term of the lease with interest and extend the term of the lease to 2035.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into a lease agreement for a 240,000 square foot building for expansion of our commercial and clinical activities (MTC East). The lease had an initial expiration date of February 2034 with the option to extend the term for two extension periods of five years each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into an omnibus amendment to extend the lease terms of our three MTC leases to 2042. We have the option to extend the term for three extension periods of five years. The base rent is subject to increases over the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Embedded Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of December 31, 2021 and 2020, we had lease liabilities of $166&#160;million and $24 million, respectively, related to the embedded leases. Certain embedded leases dedicated to our COVID-19 vaccine program prior to the EUA from the FDA were deemed to have no alternative use. The related right-of-use assets of $62 million were charged to research and development expense for the year ended December 31, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2021 and 2020 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_6434c373-a6c6-4f7b-8ef6-3d80253a9ae7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_762aa615-9010-420a-8e46-65bbadd6aae4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_51501eb6-f175-4107-9a50-9a2a310ec651"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_b87ed32e-1ce9-4db8-a202-ed428939aa44"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_7ec179f5-0fc3-4708-bddf-316daed00725"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_859dcb73-429c-4521-9717-2a4efe10e6f1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated amortization. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease costs for the years ended December 31, 2021 and 2020 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information relating to our leases for the years ended December 31, 2021 and 2020 was as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Financing cash flows used in financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates as of December 31, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2021, were as follows (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div>(1)  Include the optional extensions in the MTC lease terms which represent a total of $637 million undiscounted future lease payments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2042. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge campus and our Moderna Technology Center (MTC), located in Norwood. We also lease other office and lab spaces globally for our business operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cambridge Campus</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occupy a multi-building campus at Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 261,000 square feet. Our Cambridge campus leases have expiry ranges from 2024 to 2029.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we entered into an amendment to our lease agreements to consolidate our Technology Square space in Cambridge, Massachusetts. This included entering into a forward-starting lease agreement starting in January 2020 to acquire approximately 50,000 square feet of additional space at 200 Technology Square. In addition, our existing 200 Technology Square lease was extended for two years to 2029. As part of the lease amendment, we completely exited our leased space of approximately 60,000 square feet at 500 Technology Square by May 2020. We are also investing in a new Moderna Science Center (MSC) in Cambridge, to create a purpose-built space to support our next chapter of discovery (see Note 12). In connection with our MSC investment, in September 2021, we entered into an amendment to our lease agreements to allow for an option for early termination of the leases, either in part or full. Notification of the intent to exercise the option must be provided by August 2023. We have not elected to exercise this option. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record operating lease cost for each of our operating leases on a straight-line basis from lease commencement date through the end of the lease term. Operating lease cost is recorded in operating expenses in our consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Technology Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an industrial technology center in Norwood, Massachusetts, our Moderna Technology Center (MTC), which comprises three buildings, MTC South, MTC North, and MTC East.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space (MTC South). The lease had an initial expiration of September&#160;2032 with the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet (MTC North). The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031 with the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22&#160;million to be paid back over the term of the lease with interest and extend the term of the lease to 2035.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into a lease agreement for a 240,000 square foot building for expansion of our commercial and clinical activities (MTC East). The lease had an initial expiration date of February 2034 with the option to extend the term for two extension periods of five years each at market-based rents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into an omnibus amendment to extend the lease terms of our three MTC leases to 2042. We have the option to extend the term for three extension periods of five years. The base rent is subject to increases over the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Embedded Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of December 31, 2021 and 2020, we had lease liabilities of $166&#160;million and $24 million, respectively, related to the embedded leases. Certain embedded leases dedicated to our COVID-19 vaccine program prior to the EUA from the FDA were deemed to have no alternative use. The related right-of-use assets of $62 million were charged to research and development expense for the year ended December 31, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2021 and 2020 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_6434c373-a6c6-4f7b-8ef6-3d80253a9ae7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_762aa615-9010-420a-8e46-65bbadd6aae4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_51501eb6-f175-4107-9a50-9a2a310ec651"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_b87ed32e-1ce9-4db8-a202-ed428939aa44"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_7ec179f5-0fc3-4708-bddf-316daed00725"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_859dcb73-429c-4521-9717-2a4efe10e6f1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated amortization. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease costs for the years ended December 31, 2021 and 2020 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information relating to our leases for the years ended December 31, 2021 and 2020 was as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Financing cash flows used in financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates as of December 31, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2021, were as follows (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div>(1)  Include the optional extensions in the MTC lease terms which represent a total of $637 million undiscounted future lease payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629785857640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2021 and 2020, we had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments and Purchase Orders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of December 31, 2021, we had $2.5&#160;billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2025. As of December 31, 2021, we had $89&#160;million of non-cancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2026. These amounts represent our minimum contractual obligations, including termination fees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At December 31, 2021, we had cancelable open purchase orders of $2.4 billion in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December 31, 2021, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licenses to Patented Technology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;26, 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments, up to $24&#160;million, and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related product sales in the period in which the corresponding sales occur. In 2021 and 2020, we recognized $641&#160;million and $7&#160;million, respectively, of royalties and commercial milestone payments associated with our product sales, which was recorded to cost of sales in our consolidated statements of operations. We did not recognize any such royalties and payments in 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones was not deemed probable as of December 31, 2021. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Moderna Science Center</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we announced an investment in the development of the MSC in Cambridge, Massachusetts. The MSC is expected to integrate scientific and non-scientific spaces, including our principal executive offices, and will be built to support our growth as we continue to advance our pipeline of mRNA medicines. In relation to the investment, we entered into a lease agreement for approximately 462,000 square feet and will undergo an approximately two-year building project. Following completion of the building project, the lease term is 15 years, subject to our right to extend the lease for up to two additional seven-year terms. Pursuant to this lease agreement, we are committed to approximately $1.1&#160;billion non-cancellable rent payments for the initial lease term. We expect to begin a phased move-in process in 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629785854472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2020, we sold 26,315,790 shares of common stock at a price of $19.00 per share through a public equity offering. The aggregate net proceeds from the offering were $478 million, net of underwriting discounts, commissions and offering expenses. In addition, the underwriters exercised their options to purchase an additional 3,947,368 shares of common stock at the public offering price less underwriting discounts, resulting in additional net proceeds of $72 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2020, we sold 17,600,000 shares of common stock at a price of $76.00 per share through a public equity offering. The aggregate net proceeds from the offering were $1.3&#160;billion, net of underwriting discounts, commissions and offering expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788897224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August&#160;2016, we adopted the 2016 Stock Option and Grant Plan (the 2016 Equity Plan), which replaced the 2013 Option Plan and the 2013 Incentive Plan. The 2016 Equity Plan and provided for the grant of incentive stock options, non-qualified stock options, restricted stock, unrestricted stock, and restricted stock units to our employees, officers, directors, consultants, and other key persons.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with our initial public offering (IPO), we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Plan. The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. The 2018 Equity Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2019, by 4% of the outstanding number of shares of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Compensation and Talent Committee of our Board of Directors. The Compensation and Talent Committee chose not to increase the number of shares available under the 2018 Plan on January 1, 2021 or January 1, 2022. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a four-year period, with the first 25% of such awards vesting following twelve months of continued employment or service. The remaining awards vests in twelve quarterly installments over the following twelve quarters. Stock options granted under the 2018 Equity Plan and the 2016 Equity Plan expire ten years from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December 31, 2021, we had a total of&#160;57 million shares reserved for future issuance under our Equity Plans, of which 30 million shares were reserved for equity awards previously granted, and&#160;27 million shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity as of December 31, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.33&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $1.6 billion, $786 million, and $76 million for the&#160;years ended December 31, 2021, 2020, and 2019, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The excess tax benefits realized from tax deductions from option exercises were $325&#160;million during the year ended December 31, 2021. For the years ended December 31, 2020 and 2019, there were no excess tax benefits realized from tax deductions from option exercises due to cumulative losses and valuation allowances. The total consideration recorded as a result of stock option exercises&#160;was approximately&#160;$112 million, $179 million, and $48&#160;million&#160;for&#160;the years ended December 31, 2021, 2020, and 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted RSUs and PSUs generally through the 2018 Equity Plan. The following table summarizes our RSU and PSU activity during the year ended December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:72.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.836%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value per Unit</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs and PSUs vested during the years ended December 31, 2021, 2020, and 2019, was $18 million, $5 million, and $5 million, respectively. The total intrinsic value of RSUs and PSUs vested during the years ended December 31, 2021, 2020, and 2019, was $141&#160;million, $14&#160;million and $12&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, we granted an immaterial amount of PSUs to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally three years. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%. The estimated fair value of PSUs is based on the grant date fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we adopted the 2018 Employee Stock Purchase Plan (ESPP), which became effective on December 5, 2018. We will make one or more offerings, consisting of one or more purchase periods, each year to our eligible employees to purchase shares under the ESPP. Offerings will usually begin every six months and will continue for six-month periods, referred to as offering periods. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price at which shares are sold under the ESPP will be equal to 85% of the lower of the fair market value of the shares on the first business day of the offering period or the last business day of the purchase period. Employees are generally eligible to participate through payroll deductions of between 1% to 50% of their compensation and may not purchase more than 3,000 shares of common stock during each purchase period or&#160;$25,000&#160;worth of shares of common stock in any calendar year.&#160;We began our first ESPP offering on June 1, 2019. There were 81,423, 251,752, and 171,343 shares of common stock sold at a weighted average price of $145.90, $27.97, and $16.87 per share under the ESPP during the years ended December 31, 2021, 2020, and 2019, respectively. As of&#160;December 31, 2021,&#160;4 million&#160;shares were available for future issuance under the ESPP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation and Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for options granted under our Equity Plans and share purchases under our ESPP is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of options granted and ESPP for the&#160;years ended December 31, 2021, 2020, and 2019 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.11 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected dividends</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Weighted average fair value per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the&#160;years ended December 31, 2021, 2020, and 2019 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021, 2020, and 2019, we recognized stock-based compensation expense of $16&#160;million, $10&#160;million, and $10&#160;million, respectively, related to performance-based awards, including awards with vesting or commencement contingent upon our IPO. Stock-based compensation expenses related to non-employee awards were immaterial for the years ended December 31, 2021, 2020, and 2019.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, there were $349 million of total unrecognized compensation cost related to non-vested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 2.9 years at December 31, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, our Board of Directors authorized a Share Repurchase Program (2021 Repurchase Program) of our common stock, with an expiration date no later than August 2, 2023. Pursuant to the 2021 Repurchase Program, we may repurchase up to $1.0&#160;billion of our outstanding common stock. The timing and actual number of shares repurchased depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Exchange Act).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we repurchased 3.5&#160;million shares of our common stock under the 2021 Repurchase Program for an aggregate of $857&#160;million, including commissions and fees. As of December 31, 2021, there was a total of $143&#160;million remaining for repurchases of our common stock under the 2021 Repurchase Program.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788904440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plans<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide a retirement savings option to our eligible U.S. employees through the Moderna, Inc. 401(k)&#160;Plan (the 401(k) Plan), subject to certain limitations. As allowed under Section&#160;401(k) of the Internal Revenue Code, the 401(k) Plan allows tax deferred salary deductions for eligible employees. We match 50% up to the first 6% contributed by a participant. All matching contributions are immediately vested. Total matching contributions to the 401(k) Plan were $18 million, $5 million, and $4 million for the&#160;years ended December 31, 2021, 2020, and 2019, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain various defined benefit plans to provide termination and postretirement benefits to certain eligible employees outside of the U.S. The unfunded benefit plan obligations were $9&#160;million as of December 31, 2021, which is recognized in other long-term liabilities in our consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629789213640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income (loss) before income taxes for the years ended December 31, 2021, 2020, and 2019 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(745)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income (loss) before income taxes </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(744)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes for the years ended December 31, 2021, 2020, and 2019 consisted of the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2021, 2020, and 2019 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the year ended December 31, 2021 was 8.1% and was lower than the federal statutory tax rate primarily due to the tax benefits related to the release of the valuation allowance on most of our deferred tax assets, foreign-derived intangible income deduction and stock-based compensation. Our effective tax rate for the years ended December 31, 2020 and December 31, 2019 was lower than the federal statutory tax rate primarily due to the valuation allowance on our deferred tax assets.</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes, tax credit carryforwards and the tax effect of net operating loss carryforwards. Significant components of our deferred tax assets and tax liabilities as of December 31, 2021 and 2020 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:77.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized licenses, research and development and start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, we reassess the valuation allowance on our deferred tax assets, weighing positive and negative evidence to assess the realizability of the deferred tax assets. In the first quarter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we will realize the majority of our deferred tax assets, and we released the valuation allowance on the majority of our deferred tax assets, accordingly. We continue to maintain a valuation allowance on certain state deferred tax assets. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance for deferred tax assets during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily related to the release of the valuation allowance on deferred tax assets. The changes during the years ended December 31, 2020 and 2019 primarily related to the increase in valuation allowance on net operating loss carryforwards and research and development tax credit carryforwards. The changes were as follows (in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">millions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases recorded as benefit to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0 billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> state net operating loss carryforwards, which begin to expire in 2032. At December 31, 2021, we also had state tax credit carryforwards of $102 million, the majority of which will begin to expire in 2030. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. All tax years since date of incorporation remain open to examination by the major taxing jurisdictions (federal and state) to which we are subject, as carryforward attributes generated in past years may still be adjusted upon examination by the Internal Revenue Service or the state authorities if they have or will be used in a future period. There are no open tax examinations at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2021, 2020, and 2019 were as follows (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of the period </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of December 31, 2021, we had $43 million of net unrecognized tax benefits, which would affect our tax rate if recognized. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our consolidated operating results. We recognize interest and penalties, if applicable, related to uncertain tax positions as a component of income tax expense; however, there has been no interest or penalties accrued to date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629785868632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text">Earnings (Loss) per Share <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the years ended December 31, 2021, 2020 and 2019 were calculated as follows (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:61.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of December 31, 2021, 2020 and 2019, were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629785809432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Geographic Information</a></td>
<td class="text">Product Sales<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are primarily associated with our COVID-19 vaccine supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), and the African Union. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no product sales in 2019. As of December 31, 2021 and 2020, our COVID-19 vaccine was our only commercial product authorized for use. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, we had deferred revenue of $6.7&#160;billion and $3.8&#160;billion, respectively, related to customer deposits. We expect $6.2&#160;billion of our deferred revenue related to customer deposits as of December 31, 2021 to be realized in less than one year. Timing of product manufacturing, delivery and receipt of marketing approval will determine the period in which revenue is recognized.</span></div>Grant Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement with the DARPA for an award of up to $56&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of December 31, 2021, the committed funding, net of revenue earned was $2&#160;million. An additional $42&#160;million of funding will be available if DARPA exercises additional contract options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an agreement with BARDA for an award of up to $483&#160;million to accelerate development of mRNA-1273, our vaccine candidate against COVID-19. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $472&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $63&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. In April 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. In June 2021, the agreement with BARDA was further amended to award additional funding of $144&#160;million to support pediatric clinical trials for mRNA-1273. The maximum award from BARDA, inclusive of the 2020 and 2021 amendments, was $1.4&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of December 31, 2021, the remaining available funding, net of revenue earned was $189&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, we received from BARDA an award of up to $126&#160;million, subsequently adjusted to $117&#160;million in 2021, to help fund our Zika vaccine program. Three of the four contract options have been exercised. As of December 31, 2021, the remaining available funding, net of revenue earned was $48&#160;million, with an additional $8&#160;million available if the final contract option is exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of December 31, 2021, the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available funding, net of revenue earned was $7&#160;million, with up to an additional $80&#160;million available if additional follow-on projects are approved.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Geographic Information <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geographic Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic area of our customers and collaboration partners was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,471&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi (on behalf of the COVAX Facility) as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property and equipment, including financing right-of-use assets, was principally located within the United States as of December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629785811400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we repurchased an additional 0.6&#160;million shares of our common stock under the 2021 Repurchase Program for an aggregate of $143&#160;million including commissions and fees. We have repurchased the entire $1.0&#160;billion of common stock that was authorized under the 2021 Repurchase Program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2022, our Board of Directors authorized a new Share Repurchase Program (2022 Repurchase Program) of our common stock, with no expiration date. Pursuant to the 2022 Repurchase Program, we may repurchase up to $3.0&#160;billion of our outstanding common stock. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2021, we have entered into several supply agreements with customers to provide our COVID-19 vaccine, up to 66 million doses, and have received upfront deposits of $210 million, based on the initial confirmed volume, subject to modifications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2021, we have entered binding purchase commitments with third-party contractual manufacturing organizations for dedicated facilities and fill &amp; finish services for our COVID-19 vaccine. We are currently committed to minimum non-cancelable purchase obligations of $1.9&#160;billion related to these agreements, of which $213&#160;million is expected to be paid within 2022 and the remaining is expected to be paid through 2029.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784671560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Updates (ASU) of the&#160;Financial Accounting Standards Board (FASB).The consolidated financial statements include the Company and its subsidiaries.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">All intercompany transactions and balances have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, revenue recognition, research and development expense, leases, fair value of financial instruments, derivative financial instruments, inventory, useful lives of property and equipment, stock-based compensation, income taxes, and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">We have determined that our chief executive officer is the chief operating decision maker (CODM). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, we have concluded that we operate as one segment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted ASC 606&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is primarily generated through product sales. We also generate grant revenue from government-sponsored and private organizations, and collaboration revenue through collaboration arrangements. </span></div><div><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Sales </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are associated with our COVID-19 vaccine supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), and the African Union. These agreements generally do not include variable consideration, such as discounts, rebates or returns. Under these agreements, we are entitled to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. We recognize revenue from product sales, using the five-step model under ASC 606, based on the fixed price per dose according to the contracts when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. </span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pay distribution fees to certain customers in connection with the sales of our product. We record distribution fees paid to our customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and we can reasonably estimate the fair value of the goods or services received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale. Such distribution fees were immaterial for the year ended December 31, 2021. We did not have any distribution fees for the years ended December 31, 2020 and 2019.</span></div><div style="padding-right:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Grant Revenue</span></div><div style="padding-right:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contracts with Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); the U.S. government&#8217;s Defense Advanced Research Projects Agency (DARPA); the Bill &amp; Melinda Gates Foundation (Gates Foundation) and other government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.</span></div><div style="padding-right:9pt"><span><br/></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaboration Revenue</span></div>We have entered into several strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text">We consider all highly liquid investments with an original maturity of 90&#160;days or less from the date of purchase to be cash equivalents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted cash is composed of amounts held on deposit related to our lease arrangements. The funds are maintained in money market accounts and are recorded at fair value. We classify our restricted cash as either current or non-current based on the terms of the underlying lease arrangement.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments</a></td>
<td class="text">We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report available-for-sale investments at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive (loss) income, a component of stockholders&#8217; equity. Realized gains and losses are determined using the specific-identification method, and are included in other expense, net in our consolidated statements of operations. We classify our available-for-sale marketable securities as current or non-current based on each instrument&#8217;s underlying effective maturity date and for which we have the intent and ability to hold the investment for a period of greater than 12 months. Marketable securities with maturities of less than 12&#160;months are classified as current and are included in investments in the consolidated balance sheets. Marketable securities with maturities greater than 12&#160;months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive (loss) income, net of applicable taxes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text">We have accounts receivable amounts due from our product sales and related vaccine supply agreements and our grant agreements. We also have accounts receivable amounts due from strategic collaborators as a result of manufacturing and research and development services provided under collaboration arrangements, or milestones achieved, but not yet paid. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for doubtful accounts, we make judgments about the creditworthiness of our customers based on ongoing credit evaluation and historical experience.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable securities, and accounts receivable. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersPolicyPolicyTextBlock', window );">Significant Customers</a></td>
<td class="text">Our accounts receivable are generally unsecured and are from customers in different countries. We generated revenue from product sales to the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), the African Union. grants made by government-sponsored and private organizations, and to a lesser extent, strategic alliances in 2021 and 2020. Historically, we generated revenue primarily from strategic alliances.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text">We record all derivatives on our consolidated balance sheets at fair value. The accounting for changes in the fair value of a derivative depends on whether the derivative has been designated and qualifies for hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The gains or losses resulting from changes in the fair value of cash flow hedges are initially recorded as a component of accumulated other comprehensive (loss) income (AOCI) in stockholders&#8217; equity and subsequently reclassified to product sales in the period during which the hedged transaction affects earnings. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to other expense, net, in our consolidated statements of operations. We may enter into derivative contracts that are intended to economically hedge certain risk, even though hedge accounting does not apply or we elect not to apply hedge accounting. Gains or losses associated with foreign currency derivatives that are not designated as hedging instruments for accounting purposes are recorded within other expense, net, in our consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC&#160;820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash equivalents and marketable securities are reported at fair value determined using Level&#160;1 and Level&#160;2 inputs (Note&#160;6). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk (Note 7). We do not have any non-financial assets or liabilities that should be recognized or disclosed at fair value on a recurring basis at December 31, 2021, 2020, and 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintained letters of credit of $12 million as of December 31, 2021 and 2020, related to our lease arrangements, which are secured by money market accounts in accordance with certain of our lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in our consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">Inventory is recorded at the lower of cost or net realizable value, with cost determined using first-in, first-out and average cost methods for different components of inventory. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.Prior to an initial regulatory approval for our investigational medicines, we expense costs relating to raw materials and production of inventory as research and development expense in our consolidated statements of operations, in the period incurred. Upon the authorization of distribution and use of our COVID-19 vaccine under an EUA in December 2020, we began to capitalize inventory costs associated with our COVID-19 vaccine, as it was determined that inventory costs incurred subsequent to the EUA had a probable future economic benefit.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property and equipment are described below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:48.552%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.553%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement<br/>or&#160;remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress includes direct costs related to the construction of various property and equipment, including leasehold improvements, and is stated at original cost. Construction in progress includes costs incurred under construction contracts including project management services, engineering services, design services and development, construction services and other construction-related fees and services. Such costs are not depreciated until the asset is completed and placed into service. Once the asset is placed into service, these capitalized costs will be allocated to certain property and equipment categories and will be depreciated over the estimated useful life of the underlying assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for maintenance and repairs are charged to expense as incurred. Upon retirement or sale, the cost of the assets disposed of, and the related accumulated depreciation, are removed from the accounts, and any resulting gain or loss is recorded to other expense, net in our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">We evaluate our long-lived assets, which consist of property and equipment, to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in profit or loss on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text">Cost of sales includes cost of raw materials, production, transportation, freight and indirect overhead costs associated with our product sales during the period and third-party royalties on net sales of our product. Cost of sales also includes adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Equipment or facilities that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, should be capitalized and depreciated as tangible assets. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project and that have no alternative future uses and therefore no separate economic values are considered research and development costs and are expensed when incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Compensation&#8212;Stock Compensation)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#8220;more likely than not&#8221; criterion. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text">We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted common stock and stock options that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629790013352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,860&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in prepaid expenses and other current assets in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Restricted Cash</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, non-current </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,860&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in prepaid expenses and other current assets in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Entities that Accounted for More than 10% of Total Revenue and Accounts Receivable</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:50.153%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;Revenue</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended&#160;December&#160;31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage&#160;of&#160;<br/>Accounts&#160;Receivable<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Commission</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government (excluding BARDA)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom Government</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea Government</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">* - Represents an amount of less than 10%</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Estimated Useful Lives of Property and Equipment</a></td>
<td class="text">The estimated useful lives of property and equipment are described below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:48.552%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.553%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement<br/>or&#160;remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,593&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of accumulated other comprehensive (loss) income for the years ended December 31, 2021 and 2020 were as follows (in millions):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;<br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized&#160;Gain (Loss) on Available-for-Sale Debt Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Unrealized Gains on Derivatives Designated As Hedging Instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income, balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788804984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic area of our customers and collaboration partners was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,471&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi (on behalf of the COVAX Facility) as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788894360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.262%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629871076024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes grant revenue for the periods presented (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BARDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.262%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Collaboration Revenue by Strategic Collaborator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Balances of Receivables and Contract Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the year ended December 31, 2021 (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $286&#160;million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue during the year ended December 31, 2021 (in millions): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,798)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,872)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,868&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784311624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash and Available-for-Sale Securities by Significant Investment Category</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash and available-for-sale securities by significant investment category at December 31, 2021 and 2020 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,622&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,570&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,848&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,843&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="45" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equivalents</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Current</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and estimated fair value of marketable securities, by contractual maturity at December 31, 2021 and 2020 were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,892&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,619&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule of Unrealized Loss on Investments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2021 (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.797%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or More</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2021:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our financial assets measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,623&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788915736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule Of Foreign Currency Derivatives</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total gross notional amount and fair value for foreign currency derivatives were as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as cash flow hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the consolidated balance sheet within prepaid expenses and other current assets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As presented in the consolidated balance sheets within other current liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gains on our foreign currency derivatives, net of tax, recognized in our consolidated statements of comprehensive income (loss) for the year ended December 31, 2021 was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effect of derivative instruments in our consolidated statements of operations for the year ended December 31, 2021 was as follows (in millions):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.318%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Statement of Operations Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives in cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains reclassified from AOCI into income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realized and unrealized (losses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788825592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of December 31, 2021 and 2020 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,441&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788904440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">The estimated useful lives of property and equipment are described below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:48.552%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.553%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;Useful&#160;Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement<br/>or&#160;remaining life of related lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease term</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset, financing</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,593&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784718424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Down payments to manufacturing vendors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value added tax receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"/><td style="width:73.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.119%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external goods and services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation-related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"><tr><td style="width:1.0%"/><td style="width:73.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.119%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - financing (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities - operating (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Deferred Revenue Activities Summary</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the year ended December 31, 2021 (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $286&#160;million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activities in deferred revenue during the year ended December 31, 2021 (in millions): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,798)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,872)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,868&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784718424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock', window );">Assets and Lease Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2021 and 2020 were as follows (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_6434c373-a6c6-4f7b-8ef6-3d80253a9ae7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_762aa615-9010-420a-8e46-65bbadd6aae4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) (4)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_51501eb6-f175-4107-9a50-9a2a310ec651"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_b87ed32e-1ce9-4db8-a202-ed428939aa44"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.51pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_7ec179f5-0fc3-4708-bddf-316daed00725"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_859dcb73-429c-4521-9717-2a4efe10e6f1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current lease liabilities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are real estate related assets, which include land, office and laboratory spaces.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net of accumulated amortization. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assets are&#160;real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in property and equipment in the consolidated balance sheets, net of accumulated depreciation.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in other current liabilities in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease costs for the years ended December 31, 2021 and 2020 were as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amortization of right-of-use assets, financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest expense for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financing lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information relating to our leases for the years ended December 31, 2021 and 2020 was as follows (in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in financing leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Financing cash flows used in financing leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in right-of-use assets related to lease modifications and reassessments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in financing lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates as of December 31, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining lease term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Finance Lease Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2021, were as follows (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div>(1)  Include the optional extensions in the MTC lease terms which represent a total of $637 million undiscounted future lease payments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Maturity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2021, were as follows (in&#160;millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______</span></div>(1)  Include the optional extensions in the MTC lease terms which represent a total of $637 million undiscounted future lease payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784055576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Options Activity</a></td>
<td class="text">The following table summarizes our option activity as of December 31, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.987%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options <br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Price per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.07)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.33&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Common Stock Units Activity</a></td>
<td class="text">The following table summarizes our RSU and PSU activity during the year ended December 31, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:72.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.836%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Units<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date Fair Value per Unit</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, non-vested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted</a></td>
<td class="text">The weighted-average assumptions used to estimate the fair value of options granted and ESPP for the&#160;years ended December 31, 2021, 2020, and 2019 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.986%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.11 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Expected dividends</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Weighted average fair value per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value per share</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense for the&#160;years ended December 31, 2021, 2020, and 2019 (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years&#160;Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629789973848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Loss Before Provision For (Benefit From) Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income (loss) before income taxes for the years ended December 31, 2021, 2020, and 2019 consisted of the following (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(745)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income (loss) before income taxes </span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,285&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(744)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision For (Benefit From) Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for (benefit from) income taxes for the years ended December 31, 2021, 2020, and 2019 consisted of the following components (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for (benefit from) income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2021, 2020, and 2019 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant Components of Deferred Tax Assets and Tax Liabilities</a></td>
<td class="text">Significant components of our deferred tax assets and tax liabilities as of December 31, 2021 and 2020 were as follows (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:77.898%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized licenses, research and development and start-up costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, financing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, operating</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of valuation allowance</a></td>
<td class="text"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the valuation allowance for deferred tax assets during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily related to the release of the valuation allowance on deferred tax assets. The changes during the years ended December 31, 2020 and 2019 primarily related to the increase in valuation allowance on net operating loss carryforwards and research and development tax credit carryforwards. The changes were as follows (in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">millions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases recorded as benefit to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at December 31</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text">A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2021, 2020, and 2019 were as follows (in&#160;millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:67.005%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at end of the period </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788146952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted EPS for the years ended December 31, 2021, 2020 and 2019 were calculated as follows (in millions, except per share data):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:61.208%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(514)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic EPS</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted EPS</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents, presented based on amounts outstanding as of December 31, 2021, 2020 and 2019, were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted common stock units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629785809432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by customer geographic location was as follows (in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.177%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic area of our customers and collaboration partners was as follows (in millions): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,471&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes product sales recognized under the agreement with Gavi (on behalf of the COVAX Facility) as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our property and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784931976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Accounting Policies Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditFairValueDisclosure', window );">Letters of credit, fair value</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629789170568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,848<span></span>
</td>
<td class="nump">$ 2,624<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, non-current</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="nump">$ 6,860<span></span>
</td>
<td class="nump">$ 2,636<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">$ 670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629786518440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Significant Customers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | European Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | U.S. Government (excluding BARDA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | Vertex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | European Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | United Kingdom Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | South Korea Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_EuropeanCommissionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_EuropeanCommissionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_USGovermentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_USGovermentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_VertexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_VertexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_UnitedKingdomGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_UnitedKingdomGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_SouthKoreaGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_SouthKoreaGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629785965496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated&#160;Useful&#160;Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated&#160;Useful&#160;Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internally developed software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated&#160;Useful&#160;Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Furniture, fixtures and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated&#160;Useful&#160;Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629786485384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">$ 2,561<span></span>
</td>
<td class="nump">$ 1,175<span></span>
</td>
<td class="nump">$ 1,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">14,145<span></span>
</td>
<td class="nump">2,561<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized&#160;Gain (Loss) on Available-for-Sale Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(43)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Net Unrealized Gains on Derivatives Designated As Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period</a></td>
<td class="num">$ (24)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629786114280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Sales (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 18,471,000,000<span></span>
</td>
<td class="nump">$ 803,000,000<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">6,868,000,000<span></span>
</td>
<td class="nump">4,044,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">17,675,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">6,658,000,000<span></span>
</td>
<td class="nump">3,799,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue related to customer</a></td>
<td class="nump">6,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">6,177,000,000<span></span>
</td>
<td class="nump">764,000,000<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">5,393,000,000<span></span>
</td>
<td class="nump">194,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">6,846,000,000<span></span>
</td>
<td class="nump">33,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">6,834,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_RestOfWorldMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">5,448,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_RestOfWorldMember', window );">Rest of world | Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 5,448,000,000<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629780420264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Revenue (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>contract_option</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>participant</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>participant</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_NumberOfParticipants', window );">Number of participants | participant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsNumberOfContractOptions', window );">Number of contract options | contract_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,868<span></span>
</td>
<td class="nump">$ 6,868<span></span>
</td>
<td class="nump">$ 4,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,471<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember', window );">DARPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember', window );">DARPA | Contract options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsRemainingFundingCapacity', window );">Available funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsMaximumAward', window );">Award amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsPotentialReimbursement', window );">Revenue from grants, potential reimbursement</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsNumberOfContractOptionsExercised', window );">Number of contract options exercised | contract_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA | Contract options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsCurrentFundingCapacity', window );">Amount committed for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsRemainingFundingCapacity', window );">Available funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA | Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">713<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember', window );">The Bill&#160;&amp; Melinda Gates Foundation | Initial project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RevenueFromGrantsRemainingFundingCapacity', window );">Available funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember', window );">Other Grant Revenue | Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfParticipants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Participants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfParticipants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsCurrentFundingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Current Funding Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsCurrentFundingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsMaximumAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Maximum Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsMaximumAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsNumberOfContractOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Number Of Contract Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsNumberOfContractOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsNumberOfContractOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Number Of Contract Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsNumberOfContractOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsPotentialReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Potential Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsPotentialReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RevenueFromGrantsRemainingFundingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Grants, Remaining Funding Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RevenueFromGrantsRemainingFundingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784232056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember', window );">2013 AZ Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember', window );">2013 AZ Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent', window );">Earn-out payments</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629783918104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Merck &#8211; Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember', window );">PCV Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember', window );">PCV Agreement | Series&#160;H Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from the offering</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedemptionPremium', window );">Premium recorded to deferred revenue</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember', window );">PCV Agreement | PCV products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount', window );">Estimated arrangement consideration</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_PersonalizedMRNACancerVaccinesProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629785906376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Vertex &#8211; 2020 Strategic Alliance in Cystic Fibrosis (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MRNAVertex2020AgreementMemberMember', window );">MRNA Vertex 2020 Agreement Member</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod', window );">Initial research period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Research Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MRNAVertex2020AgreementMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_MRNAVertex2020AgreementMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629780406584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) - Collaboration Revenue by Strategic Collaborator - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Vertex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total collaboration revenue</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_VertexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_VertexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrna_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrna_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629786126728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward', window );"><strong>Contract Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 4,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">11,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(8,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">6,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember', window );">Collaboration Revenue by Strategic Collaborator</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractwithCustomerAssetRollForward', window );"><strong>Contract Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Beginning balance</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetPurchase', window );">Additions</a></td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerAssetDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Ending balance</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward', window );"><strong>Contract Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue related to customer</a></td>
<td class="nump">$ 286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Liability, NonCurrent [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractwithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractwithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerAssetDeductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Deductions During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerAssetDeductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Deductions During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase from purchase of right to consideration in exchange for good or service transferred to customer when right is conditioned on passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629781057192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 10,774<span></span>
</td>
<td class="nump">$ 2,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">17,622<span></span>
</td>
<td class="nump">5,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(52)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">17,570<span></span>
</td>
<td class="nump">5,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">3,879<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">6,843<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Level 1 | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents | Level 1 | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills | Level 2 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills | Level 2 | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills | Level 2 | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,595<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">6,564<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Level 2 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Level 2 | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">1,984<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Level 2 | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">4,580<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,508<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">3,488<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2 | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">1,323<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2 | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,165<span></span>
</td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities | Level 2 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities | Level 2 | Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities | Level 2 | Non- Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrna_CurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrna_NoncurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629780368728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 3,882<span></span>
</td>
<td class="nump">$ 1,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">6,892<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">10,774<span></span>
</td>
<td class="nump">2,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">3,879<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">6,843<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 10,722<span></span>
</td>
<td class="nump">$ 2,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629786509464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="num">$ (52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated fair value, less than 12 months</a></td>
<td class="nump">9,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross unrealized losses, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated fair value, 12 months or more</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">9,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated fair value, less than 12 months</a></td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross unrealized losses, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated fair value, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated fair value, less than 12 months</a></td>
<td class="nump">6,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross unrealized losses, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated fair value, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">6,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated fair value, less than 12 months</a></td>
<td class="nump">2,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross unrealized losses, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated fair value, 12 months or more</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">2,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Gross unrealized losses, less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Estimated fair value, less than 12 months</a></td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Gross unrealized losses, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Estimated fair value, 12 months or more</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Gross Unrealized Losses, Total</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Estimated Fair Value, Total</a></td>
<td class="nump">$ 112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784055576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings', window );">Impairment charges related to marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629779995624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">17,570<span></span>
</td>
<td class="nump">$ 5,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury bills | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">6,564<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">3,488<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">Government debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">13,072<span></span>
</td>
<td class="nump">3,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">2,329<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">10,743<span></span>
</td>
<td class="nump">2,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,329<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">2,329<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Money market funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Certificates of deposit | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury bills | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury bills | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">6,564<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury notes | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | U.S. treasury notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">6,564<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">3,488<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Corporate debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">3,488<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Government debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Government debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring | Government debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Value</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788912152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Cash flow Hedges (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Gain on foreign currency forward contracts</a></td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629780309080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Balance Sheet Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Amount</a></td>
<td class="nump">$ 1,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gains on derivative instruments</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Net gains reclassified from AOCI into income</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency forward contracts | Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Net gains reclassified from AOCI into income</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency forward contracts | Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Net realized and unrealized (losses)</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency forward contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Amount</a></td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency forward contracts | Cash Flow Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional Amount</a></td>
<td class="nump">565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629790014680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 870<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 1,441<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629781037608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,593<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(352)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Furniture, fixtures and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internally developed software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember', window );">Right-of-use asset, financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrna_FinancingRightOfUseAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629786433912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OtherPrepaidExpenseManufacturing', window );">Down payments to manufacturing vendors</a></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">Value added tax receivable</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_TenantImprovementAllowanceReceivableCurrent', window );">Tenant improvement allowance receivable</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 728<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OtherPrepaidExpenseManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Prepaid Expense, Manufacturing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OtherPrepaidExpenseManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_TenantImprovementAllowanceReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Improvement Allowance Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_TenantImprovementAllowanceReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629783879208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedClinicalTrials', window );">Clinical trials</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RawMaterialsAccountsPayable', window );">Raw materials</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedDevelopmentOperation', window );">Development operations</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedManufacturing', window );">Manufacturing</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AccruedOtherExternalGoodsAndServicesCurrent', window );">Other external goods and services</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation-related</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedDevelopmentOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Development Operation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedDevelopmentOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedManufacturing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Manufacturing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedManufacturing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AccruedOtherExternalGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Other External Goods And Services Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AccruedOtherExternalGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RawMaterialsAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Raw Materials, Accounts Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RawMaterialsAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784880376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Components - Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease liabilities</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784034760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Components - Deferred Revenue (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward', window );"><strong>Change In Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">$ 4,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">11,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(8,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">6,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward', window );"><strong>Change In Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">3,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">11,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(8,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">6,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward', window );"><strong>Change In Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward', window );"><strong>Change In Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod', window );">Deductions</a></td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract with Customer Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Deductions During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrna_CollaborationArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629780210360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>numberOfBuilding </div>
<div>numberOfExtensionPeriod </div>
<div>numberOfCampuses</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>ft&#178; </div>
<div>numberOfExtensionPeriod</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>ft&#178; </div>
<div>numberOfExtensionPeriod</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>ft&#178; </div>
<div>numberOfExtensionPeriod</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingLeaseNumberOfProperties', window );">Number of campuses | numberOfCampuses</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities | $</a></td>
<td class="nump">$ 152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases | $</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=mrna_EmbeddedLeasesMember', window );">Embedded Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities | $</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating leases | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember', window );">MTC South, MTC North and MTC East</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtension', window );">Number of extension periods | numberOfExtensionPeriod</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_FinanceLeaseNumberOfProperties', window );">Finance lease, number of properties | numberOfBuilding</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember', window );">Cambridge Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember', window );">Cambridge Leases | 200&#160;Technology Square</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember', window );">Cambridge Leases | 500&#160;Technology Square</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember', window );">Norwood Leases | MTC East</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtension', window );">Number of extension periods | numberOfExtensionPeriod</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember', window );">Norwood Leases | MTC North</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtension', window );">Number of extension periods | numberOfExtensionPeriod</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_AllowanceForTenantImprovements', window );">Allowance for tenant improvements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_AllowanceForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance For Tenant Improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_AllowanceForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_FinanceLeaseNumberOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Number Of Properties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_FinanceLeaseNumberOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeOperatingLeaseNumberOfExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Extension</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeOperatingLeaseNumberOfExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingLeaseNumberOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Number Of Properties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingLeaseNumberOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=mrna_EmbeddedLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=mrna_EmbeddedLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_TwoHundredTechnologySquareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_TwoHundredTechnologySquareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_FiveHundredTechnologySquareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_FiveHundredTechnologySquareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCNorthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCNorthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629783870168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating, net</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right-of-use assets, financing, net</a></td>
<td class="nump">665<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseRightOfUseAsset', window );">Total</a></td>
<td class="nump">807<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease liabilities</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiabilityCurrent', window );">Total current liabilities</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, non-current</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Total non-current lease liabilities</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_OperatingAndFinanceLeaseLiability', window );">Total</a></td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization<span></span>
</td>
<td class="text">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Liabilities, Current<span></span>
</td>
<td class="text">Other Liabilities, Current<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Liabilities, Current<span></span>
</td>
<td class="text">Other Liabilities, Current<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_OperatingAndFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_OperatingAndFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629780801528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets, financing leases</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense for financing lease liabilities</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_FinanceLeaseCost', window );">Total financing lease costs</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used in operating leases</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows used in financing leases</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows used in financing leases</a></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments', window );">Changes in right-of-use assets related to lease modifications and reassessments</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments', window );">Changes in right-of-use assets related to lease modifications and reassessments</a></td>
<td class="nump">674<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for financing lease liabilities</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeFinanceLeaseExpense', window );">Changes in financing lease liabilities</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, remaining lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases, remaining lease term</a></td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, discount rate</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases, discount rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeFinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeFinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained through finance lease modifications and reassessments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629786451944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Minimum Lease Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2022</a></td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2023</a></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2024</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2025</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">2026</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">Thereafter</a></td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest</a></td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract', window );"><strong>Financing Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths', window );">2022</a></td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2023</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree', window );">2024</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour', window );">2025</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive', window );">2026</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">1,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest</a></td>
<td class="num">(559)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Undiscounted future lease payments</a></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember', window );">MTC South, MTC North and MTC East | Norwood Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest</a></td>
<td class="num">(637)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Undiscounted future lease payments</a></td>
<td class="nump">$ 637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_MTCSouthMTCNorthAndMTCEastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_NorwoodMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629787708312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Indemnification Obligations (Details) - Indemnifications<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Losses related to indemnification obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims outstanding | claim</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Reserves established</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629789896312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember', window );">Supply and manufacturing agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Contractual commitment to pay</a></td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember', window );">Clinical services</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Contractual commitment to pay</a></td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember', window );">Clinical operations and support commitments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-term Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Contractual commitment to pay</a></td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_SupplyAndManufacturingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=mrna_ClinicalOperationsAndSupportCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629791477800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Licenses to Patented Technology (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 26, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Consideration paid</a></td>
<td class="nump">$ 641<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629781488744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies- Moderna Science Center (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>numberOfOption</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_ModernaScienceCentreMember', window );">Moderna Science Centre</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm', window );">Lease agreement for building project</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods', window );">Number of extension | numberOfOption</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extension term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Agreement For Building Project, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_LesseeOperatingLeaseNumberOfExtensionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Extension Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_LesseeOperatingLeaseNumberOfExtensionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_ModernaScienceCentreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mrna_ModernaScienceCentreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629789114840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 21, 2020</div></th>
<th class="th"><div>Feb. 14, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offerings of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,853<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrna_PublicEquityOfferingMember', window );">Public Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock issued (in shares)</a></td>
<td class="nump">17,600,000<span></span>
</td>
<td class="nump">26,315,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (usd per share)</a></td>
<td class="nump">$ 76.00<span></span>
</td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offerings of common stock, net of issuance costs</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriting Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,947,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offerings of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrna_PublicEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrna_PublicEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629778843432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 05, 2018 </div>
<div>USD ($) </div>
<div>offering </div>
<div>purchase_period </div>
<div>shares</div>
</th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="nump">$ 786,000,000<span></span>
</td>
<td class="nump">$ 76,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit realized from option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Consideration for options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000,000<span></span>
</td>
<td class="nump">179,000,000<span></span>
</td>
<td class="nump">48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,000,000<span></span>
</td>
<td class="nump">93,000,000<span></span>
</td>
<td class="nump">81,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to non-vested stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of cost expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 857,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=mrna_A2021RepurchaseProgramMember', window );">2021 Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 857,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember', window );">Service-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember', window );">Service-based awards | Twelve months of continued employment or service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember', window );">Service-based awards | Following twelve quarters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments', window );">Number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate number of shares authorized for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000,000<span></span>
</td>
<td class="nump">78,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage', window );">Payout percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage', window );">Payout percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember', window );">Restricted Common Stock Units And Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Intrinsic value of RSUs and PSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,000,000<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member', window );">2018 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized', window );">Annual percentage increase of shares reserved and available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrna_StockOptionAndGrantPlan2016Member', window );">2016 Equity Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrna_EmployeeStockPurchasePlan2018Member', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share available for future issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrna_EmployeeStockPurchasePlan2018Member', window );">ESPP | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod', window );">Offering period | offering</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods', window );">Purchase period | purchase_period</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod', window );">Consecutive offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price at which shares are sold, percent</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate', window );">Minimum percentage of compensation through payroll deductions</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of compensation through payroll deductions</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum shares to be purchased during purchase period (in shares) | shares</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount', window );">Maximum value of shares to be purchased during purchase period</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under employee stock purchase plan (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,423<span></span>
</td>
<td class="nump">251,752,000,000<span></span>
</td>
<td class="nump">171,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average fair value per share (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145.90<span></span>
</td>
<td class="nump">$ 27.97<span></span>
</td>
<td class="nump">$ 16.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Consecutive Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Consecutive Offering Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Annual Percentage Of Additional Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Minimum Employee Subscription Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mrna_A2021RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mrna_A2021RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_ServiceBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrna_StockOptionAndIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrna_StockOptionAndGrantPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrna_StockOptionAndGrantPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrna_EmployeeStockPurchasePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrna_EmployeeStockPurchasePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629780197688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Options (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">34,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(7,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(1,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">27,410<span></span>
</td>
<td class="nump">34,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (usd per share)</a></td>
<td class="nump">$ 17.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">209.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">15.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (usd per share)</a></td>
<td class="nump">37.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (usd per share)</a></td>
<td class="nump">$ 27.08<span></span>
</td>
<td class="nump">$ 17.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Outstanding and Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number&#160;of options, exercisable (in shares)</a></td>
<td class="nump">17,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- average exercise price per share, exercisable (usd per share)</a></td>
<td class="nump">$ 13.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- average remaining contractual term, outstanding</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- average remaining contractual term, exercisable</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 6,247<span></span>
</td>
<td class="nump">$ 2,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 4,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Vested and expected to vest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Expected to vest (in shares)</a></td>
<td class="nump">10,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- average expected to vest (usd per share)</a></td>
<td class="nump">$ 50.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- average remaining contractual term expected to vest</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value expected to vest</a></td>
<td class="nump">$ 2,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629781645320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details) - Restricted Common Stock Units And Performance Stock Units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares/Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, non-vested at beginning of period (in shares) | shares</a></td>
<td class="nump">2,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares) | shares</a></td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled/forfeited (in shares) | shares</a></td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, non-vested at end of period (in shares) | shares</a></td>
<td class="nump">2,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date per Share/Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, non-vested at beginning of period (usd per share) | $ / shares</a></td>
<td class="nump">$ 30.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued (usd per share) | $ / shares</a></td>
<td class="nump">210.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share) | $ / shares</a></td>
<td class="nump">29.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled/forfeited (usd per share) | $ / shares</a></td>
<td class="nump">63.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, non-vested at end of period (usd per share) | $ / shares</a></td>
<td class="nump">$ 88.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629787972376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.84%<span></span>
</td>
<td class="nump">0.83%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 9 days<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average fair value per share (usd per share)</a></td>
<td class="nump">$ 91.84<span></span>
</td>
<td class="nump">$ 19.30<span></span>
</td>
<td class="nump">$ 11.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.08%<span></span>
</td>
<td class="nump">0.14%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average fair value per share (usd per share)</a></td>
<td class="nump">$ 64.25<span></span>
</td>
<td class="nump">$ 32.18<span></span>
</td>
<td class="nump">$ 5.98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629781043064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember', window );">RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation costs</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784296872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percent of match</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percent contributed by participant</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total matching contributions</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanFundingStatusAxis=us-gaap_UnfundedPlanMember', window );">Unfunded benefit plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanFundingStatusAxis=us-gaap_UnfundedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanFundingStatusAxis=us-gaap_UnfundedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629784029016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="nump">$ 13,108<span></span>
</td>
<td class="num">$ (745)<span></span>
</td>
<td class="num">$ (509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">$ 13,285<span></span>
</td>
<td class="num">$ (744)<span></span>
</td>
<td class="num">$ (515)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629786454584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision For (Benefit From) Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 1,304<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">1,379<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(288)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(296)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for (benefit from) income taxes</a></td>
<td class="nump">$ 1,083<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629780801384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(5.40%)<span></span>
</td>
<td class="num">(47.40%)<span></span>
</td>
<td class="num">(33.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent', window );">Foreign-derived intangible income</a></td>
<td class="num">(4.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="num">(2.60%)<span></span>
</td>
<td class="nump">19.80%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research and development credits</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefits</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Foreign Derived Intangible income, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629780015336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts', window );">Capitalized licenses, research and development and start-up costs</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_DeferredTaxAssetsFinancingLeaseLiability', window );">Financing lease liabilities</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(149)<span></span>
</td>
<td class="num">(823)<span></span>
</td>
<td class="num">$ (471)<span></span>
</td>
<td class="num">$ (308)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">526<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset', window );">Right-of-use assets, financing</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Right-of-use assets, operating</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxAssetsFinancingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Financing Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxAssetsFinancingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Finance Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629789076280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_UnrecognizedTaxBenefitsNet', window );">Unrecognized tax benefits, net</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry-forwards</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_UnrecognizedTaxBenefitsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_UnrecognizedTaxBenefitsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629790034168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes- Valuation Allowance (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_DeferredTaxValuationAllowanceRollForward', window );"><strong>Deferred Tax, Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at beginning of the period</a></td>
<td class="nump">$ 823<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount', window );">Decreases recorded as benefit to income tax provision</a></td>
<td class="num">(722)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at December 31</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 823<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_DeferredTaxValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_DeferredTaxValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Decrease , Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788350472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions for current year</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions for prior years</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance as of end of period</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788096568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 12,202<span></span>
</td>
<td class="num">$ (747)<span></span>
</td>
<td class="num">$ (514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic EPS (usd per share)</a></td>
<td class="nump">$ 30.31<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted EPS (usd per share)</a></td>
<td class="nump">$ 28.29<span></span>
</td>
<td class="num">$ (1.96)<span></span>
</td>
<td class="num">$ (1.55)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629788032648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">36,000,000<span></span>
</td>
<td class="nump">47,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="nump">46,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted common stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629786036440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 18,471<span></span>
</td>
<td class="nump">$ 803<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">6,177<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">6,846<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrna_RestOfWorldMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">5,448<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrna_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrna_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139629780907976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> shares in Millions, dose in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 25, 2022 </div>
<div>USD ($) </div>
<div>dose</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 22, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 02, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 857,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=mrna_A2021RepurchaseProgramMember', window );">2021 Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 857,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrna_NumberOfDosesOfVaccineCandidate', window );">Number of doses of vaccine candidate | dose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted', window );">Supply commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase obligation to be paid in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2021 Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased (in shares) | shares</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased</a></td>
<td class="nump">$ 143,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2022 Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrna_NumberOfDosesOfVaccineCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Doses Of Vaccine Candidate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrna_NumberOfDosesOfVaccineCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of disclosed arrangements (excluding long-term commitments) in which the entity must commit resources to supply goods or services to one or more customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mrna_A2021RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mrna_A2021RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mrna_A2022RepurchaseProgramPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mrna_A2022RepurchaseProgramPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>mrna-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrna="http://www.modernatx.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrna-20211231.xsd" xlink:type="simple"/>
    <context id="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb99458155744556b3d39993ad822db4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i58b4bf6524f44a5e8970d9daad47a515_I20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="ia2fcd0a4e20a4fb395dd61a92d63adc0_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20e412a5cb73413dbf99d215bfabc116_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0613309ccd7f4770b391e463a962e99b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icfd2fff3411a4c769c4f81842918e9c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifdba65dc5ee84630ac91c06737b61940_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1806b5a0029947c1aabb49f5e058cb28_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id1eabe79fc2e4e4a9fdc7c2be2e9f0e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5db090169624207a4311b8780bb82f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e182cbaac1c44c8aaf481c02d369892_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie2fa812bb582446faced9f5539691f0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice96c3b711e145be81cba0afd205ad43_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i87fe7c36a950471bb3212e6877b0baf9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8485f63a4c2345fea4cdae33f5552050_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6916c32254f544d89e2f4ba8db2520a6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id4183a6aba7e43f68918a5fb12e3d83f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3f00be47b1194ea3be883db45fca7c1c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i291937679b0b473abab40f676c567dbd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea71826e0b2c464293613200c787a5f4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i70d890a8a1c24221b1111740ec40546f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i237e52dede034cd091787b93f9589ae5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idfa777b5307245f09b6cb5f6a8fb3e1d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i98fce2df066140b8974dbf5aa3059a90_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie5f8052aaadc419c8d711ef7686bd436_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic0bee1a0804143529b5cc7f5e167104e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9ffaed07b9974d019abd45bea1588ec0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i552c6e3acac14be0baea5ae64fe4cc51_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c6b33ad00e44689ad7ca663971c003f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifefe594e140042af8fa2b3baed41f390_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i086f0b86dda64ff9bdc13c547806422e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2468b82d059745f5b51fb3d31a544305_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if106b707e879407f837eee91cc731c8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieedc85414f004154b55307b19cb69ea1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64213a08436349b8bd211c3b69b414ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0408d062671a45018b3df546433745af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c70cb037668465995ce9826bb1978ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98451536c6d841db91683a82eeb89b2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifcf6e685c17f4ba283b01bf8845d7cb9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i370d0735ddb64285bf22708bccdfe17a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d72e1d1f6454024a0fc769ec600c4bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb0e392c689f48b180f2315c3d508b62_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib67c37cfaa8142fcac96ee487bf8fa91_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e92a0d0e8fd40c489ab3417b2dc0a47_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40ff2eb538054269a37b8f1364796f48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1036f115c63f4c049064c7ba1929828a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f7e4e88f50c4deb96b15cbfbbd78d6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0271cb85b4e64ced8426ff3ab6956a89_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:EuropeanCommissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i190252c1c7b34ddb97008b71eb4c1da9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:EuropeanCommissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32d168477d7e4f278aa0d019fbd3fd1e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:EuropeanCommissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib7764e7b08664708b5f88fa9d5a5452d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:USGovermentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70772d46e8714f2c92cd4f05b0dae511_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:USGovermentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia2d8d4f2bcb249ba98ac3836f5f2f91a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9755a9f76aff4d95bd5013ac656d28eb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8df385fcd90456f89a7177c79f6f8cb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2df5a00c226e425faf323112dc3cd5c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b3cd2c6a9d148c18fec7f61ae871222_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i386857641ae64cb5840ff87d45bd2b39_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5a5edb63270a4e4587e56c35991f8f28_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:SouthKoreaGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e47c41e4cb14080aa2c9a58ea80fb94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:UnitedKingdomGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idfc4ca4b110a4b4ca9bc75f54db9aac8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d684fd2732b4d3aaa2c0b4c1f42cf46_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d0432cf13b142938df0d7a6e783162d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d57ca59f3dd4b58a6220848d155086a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3639b96d68064d6db852f369b410789c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibb718f636d5f48ac8eb2603a3bc1c433_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i005acc5f3f5d4d808e86e28a3fb8cc6f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib7f5f39ede7c4ec9b47dbe1215f0665e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1aa7c4e4065b4b87a2e53619bd7fd077_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95dda1d0dbf24991852d96215768bee0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b6bf470232b486d96417def1a8e1533_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a99e8b38ce644c6b026bd53416491e6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i984222694dbe434b9c06eac34351906d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39641a4b815d4d1d9b3bc66b8889165f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide168116c3df4c06bf76ee1ab5cc8665_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5eda8070f7034a6fab76518656331315_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b2a73dc0a34434fbf4adfd2bd2d0152_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if853b7ba8fdd405c9c2517b31b9bb54b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b48f865221543f19c484fbac76b65da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6f1f522be3c649ccac04b63ff9e91b55_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i346fef81e10f4f86a929d87bf0cb041b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if49f6e27f6284519912ffac03c002a55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:ProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i185b16a527d64878943a25c180d19f14_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i90618f5224194ab98e88f99e1cfb81b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:DefenseAdvancedResearchProjectsAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7a70d15770e4fc5a0c8d58cdebd7aef_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ieb5f923d3e90448fbd2a1d5a8d4e3398_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i0f13771d8cb942efb65d2bfc498700a6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i47c1a858a9f9495fbac7df0e36419070_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i88f0f64452bc4d5da91f20c29eeecbca_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idb9732dce6924b498098b6518f64703e_D20210701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida3d15a8c031486d90647c53dad031ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i115458dd79814652822c63535a915899_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i987f997b0acc4a2695f9a05d82e96f37_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieae7b1ae1b03416dbb9b8f48d0bc6426_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="ief33f0f4bb514efdae5a1b468c9c9c90_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="ia3127eb355e744a881aa98a34f6d97fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:ContractOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf94941a6a404dd8b05524603b3a3b2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:TheBillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:InitialProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa5a2552f63d48b5b1e01ac4535c5a2f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ef76c094447459c821c04b2de3eb206_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3802fa1330a343298542de37e4105a0c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0cd3ec1f9ac141d284f0a5db5793f3c9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if1d68b45e78b406482a02388fbb53604_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8c202e8e92ed4514824b43cb3531dc9e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrna:OtherGrantRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if55e1500f5544b66aa8a071e51806268_D20130301-20130331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="i8ede9f3ba9d44d22a375d16ea04e18cc_D20130301-20130331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:A2013OptionAgreementAndServicesAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="id946b8dd31834000b8e6b41766b9dedd_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i3d09409e8868491499e290b8a4d12cdc_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mrna:PersonalizedMRNACancerVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="ia84a8bd1c3aa4ac9b1a164b251799095_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i60fc10736ee64261bd7f04a73acfaafa_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrna:MRNAVertex2020AgreementMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6d6ad74836b24c83809a74ce8d566449_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieb0688f24fb7444ba43fe54c1d8443f2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70d782312fcd4253a167cb2d7ae3760e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia24b3bc3329043adb9ea279c5b254064_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3b18d163a5204d569c9797b913f2d8f6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e25bd1849804ba7b479c2eced67e891_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i618406f3ce9d406aaa081c4408973067_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79a9ba91798641049354e39e4852bc1e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic63027741efa4c50b4babaada70fbc9b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:VertexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia49291312e364cb4a88c0ff31026909a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i119f28ec664d4518be468660ee954b91_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib4219337e58d4f1db6c745955c72cd8e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrna:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d88c4aeb3e94e9b959ea25fc2661d2c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3df9734dc9af496f9780bd6c5c379234_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i17abcb6e78134f4690ee2419e8619e02_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie710a95ab39e49cdb735c3bc7fc8c4b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa328a08859144588130d892ad20192d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf669fdc68ee4630b54c9802a1b0a558_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0292df9b654d482db1060f9005959794_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia45359f849f44c0998e347e23469e818_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4712a1c564814f3abe808e0a6b9e64a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e02fcbb9afe410ab3a681bc9b64d879_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42f5d9b242cc4780b3309e0961fa5eb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5734f4fe23fc43dd969bd66b5e557046_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2364f83219a4bfc9d8ee9260dacc1b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4042eb496ee543f2a5872be11b2cf7ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b5cfdaf6a9c475fab2b7dfb72468094_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9284186e600b48258879f874e838c77a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic428ae6809614abaac1249c8d3bb020c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i709ee66b601a4d2ebd30bdd6893ba771_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6344e2313ce84b3291ddab39f4bcddfb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf656a3fa7e84852a422e94e706d2b6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec10e88bcd6c4d8181a5ca274d5cc8f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieafc1c887e174d9bbbde6dd62d64e2ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44bf012463a94b6a88a9422b0030dda0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9235e93735dc44b285d2bfdc769bb996_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id07b5918438d431a8e9c74d8ff4d2551_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1075514a7e14bb585b04979d8e91df8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33223bcc0e1b4b51acbe5ccd606713ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i959b3e4a89ca4e1392ee007bf48a9ce3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0458e4ead71746a5af5b29ed89c9ef21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a6b3fe35432446aa1c5e179c4701d65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c9905b040c345c9800468da2693c514_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2565e09c4ee4bdcbd387be8850d72df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3997280202440c4b1242ce5b6a23810_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3d566855dd54261b4fe635c234b2484_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id087a0a88efd4af88be84f1c3b08e19f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81ef75bce2954276bae1f44362fbb2cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41a1843d0dcd4702b157723e8cc7e665_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53dd51cc137b4b4aa2f56b6bab4db8f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e93700d2ebf423091417132b7c40ab4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied3d5ab7308d4c59b813d58e2e04c6e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8eeaea94154e4fe49fa61fba009f8be3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6aa1fb4bfb734981a51e6771d628fcc8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab996b74800b4e25a035225c3e839436_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e1fc05718e842d8a85da2e69c5bf695_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa93ec4582e34e7fbf2e3ab8bce77f21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia63eadf881ec473799e8621ff399a7de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c5df7f55fdc4eb49e20e64d8f73b402_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9935ee028dc4668889878caf93655c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib074b324fc8a45e8b60ce57c228ef8bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee8da0e76f2e4c59a02abce9c64913ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i342e75080ebe4c45b4605822f2cb05d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib732575815f0493f8a45f987de9435dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb052b50079e46858cb5714c483963ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19e0d73c72e24eca8ca94e49eb15e6a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2926456ed6654d0a91dee92754e33edf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3af41c88515492095e14241259a0e07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e9646a432a9439688c513fb0ec0887f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ca3868ec35146878138ef39c9381dab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4fe368718ae402a88feb1ddaf1fdc8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e686917771642979115acea50d66bd1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrna:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4a2bda740e174d91b71bb62076e623b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d743eab86de4393a005da034dc6076d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib08aa8be8be24796b00714b57780c548_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cfc4e8bb05c4fae962fb281635face7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b7c01916db3408ab5ad64668966705b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01fbfe4a2aeb4f52a6e5832316a78b96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib3b71762f59d402fb8c3f8db8d6a2794_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i173e555f8608496f9662755df4a4507f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7aa28c6c4754b4cac1648572278cb7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33a1bd3236264470831ed902e1ec14fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc3a736dedb0468eb2b96e05d6a5b5cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01cb8657700e404391363a5b93c94298_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37f7bfa072504774a46de61549ed1358_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a410f63e2a34faeb71837e163488553_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id11c2636a9e849b199e50f122b90bfb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08a786fc7c8548f99e9260ccc849d096_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib091b3d4b2c54a35b6370a090b778180_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82fff40b8cf5418684879ad0b808d851_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf5ed5b20a464aa69fffcc07449d6b65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4435c73f09eb44d4992e01d4922d5bc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa3443efd7954041a7b94f68574c1294_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18bab6b5e239439c88900de725d422b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d3fc18fdc324f1aa20d24c095339419_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9147f3587c94165889e686e4d2ea8b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76d4434bc6c044c7b3f4e94fb304ff0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id626af309354471c938a13ee987efb1f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia847fc5aaa414970962b3e66c726b6d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60349844b567496a8c96cb156669e486_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4e351d2d1764d1e970af57129ac281f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabdcd1636c89453094af591ed45cb1ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib52d1393c6a94df1a1ed227bb14cad8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87eab6cd7a7f48e0b5a9796ab31c2d6e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1e243dab0bc4efaa8d7f2b398dcdab5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i294dcfa26a8843f783242f2540ba31cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80e7eff5bd6c4c9b84f96355143d2190_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12d89d325c9641979afcb1133eb38c92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62a0a9d758df464cb7896474951b0ac5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic39fb570a4f842229f0fb89db305d537_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6600cb5746c3408c9cb209436ced4bd4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56c3185ed7d04fccbb21599da90453cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8b05b51f2234fc58d69e6a80fa771ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3992f82ad0c4b249387e250c043245a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id6d422efa75e467d98852994a450a9ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf2f9fe6eb684be982187b0507723e2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e6dc104953e4bb395df7081eca0082a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2b92fa7550f4911b44a79ebc01be5fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5931b912876541d6882f7bd7117de3f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77eee50ddfaa4eb0bc9f201ff1631518_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4dca9b9d97e4b8f946f52de263fa1d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c3187a0bb484bae8f0a6c5412316823_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i752522e455054df9a2d4aa0487c93c8a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40de3a67fca0427cba0abb81a8d5a822_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e772279375842a09317b961798ebf1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bd10a6d680840d5be716e5efb005792_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2897c9b7abc74af58f8fb9170b4279dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2277cdd9a1184c06a13b5d2759fc2d43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b99b4a3a3f74767a37af24660286fb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabac96aed6194cfe8293e8e6b78f7add_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98d6bacd287f4b1593818f823e5f7584_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie04bbbe54baa412abc405e89a1039ed6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if546ef6f1b4b42b7a555f52ec50a3fb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71f80f04049942b6a29f789ba29f2842_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10c346ed8a6f4ad482321e52eccd7724_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5c2998e0814472496ed510917d7a471_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrna:FinancingRightOfUseAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcda5455344c4505b3c57aa248aa98ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a2e86586b9a43d89a4d752842cfa050_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d2b742992e44e86ba5d409dbd33d210_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic39bcf7b2bd641cbbe600df4d3b15b80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id85722b295e94fcc9a11009c7e8f8554_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49b0ad1b467146e3b5880e21ed60e03c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrna:CollaborationArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i055ce861cca24357869370abf095c083_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7645640582764d538a26db2e1fb80bd0_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:TwoHundredTechnologySquareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i32ea0d8664c84fe1a0db2e016c5ba70b_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:FiveHundredTechnologySquareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i7589e8c5201244e4985147f06c09e73a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1927cdc0d1694e40a55dd6d90f64c6d1_I20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-31</instant>
        </period>
    </context>
    <context id="i2855b96dce1e43fb93b06fb655b72372_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i8db7171778ef4c6f97f7530182111044_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCNorthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i9a0fc37d8e2145f98d23f3d4b7ed48a7_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCEastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i3d4877c3015e41fcb264f294807448d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i637c86f9cdcd4c4696566a2667590b81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">mrna:EmbeddedLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f976ec484ae4420800a7fe5ea5fc4eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:MTCSouthMTCNorthAndMTCEastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:NorwoodMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffb8aaeb04f94a9091ac85eb8f851b96_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76f6a7263a5e4d65a40dd2d77b9fe3d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8894beaec40b4471a73954ee11728b2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56f7cbe6568c4de9ac2033f8024b12fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a8002ec753b4dc689c48b5e0785b43d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:SupplyAndManufacturingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab85f119dfbd439fab288fd3b899104e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c5a2128addc490e9ec198b28f43e879_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">mrna:ClinicalOperationsAndSupportCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0c48f0326424b03a643d8d35796a371_I20170626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <instant>2017-06-26</instant>
        </period>
    </context>
    <context id="i702c1ca981884658b2caf34f2b288da1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:ModernaScienceCentreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5a37b17b04c0478ca390d371241ee5bd_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">mrna:ModernaScienceCentreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib474a3e36bd94fa88daf43e69617dc76_D20200214-20200214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-14</startDate>
            <endDate>2020-02-14</endDate>
        </period>
    </context>
    <context id="iac2c5503ed074a74bea898aac8577dab_I20200214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-14</instant>
        </period>
    </context>
    <context id="i5bba9fe2096647189405dc333c365807_D20200214-20200214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-14</startDate>
            <endDate>2020-02-14</endDate>
        </period>
    </context>
    <context id="i3b3e6c8e3e284a9b9957554efffd342a_D20200521-20200521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-21</startDate>
            <endDate>2020-05-21</endDate>
        </period>
    </context>
    <context id="iafab97ea8a1846b8ae7fd38f70f3ec7a_I20200521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrna:PublicEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-21</instant>
        </period>
    </context>
    <context id="i29fd9baa1fce4c82bab97fdcf69983b9_D20181130-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-30</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i4e3a57dbc43247cdbe91ca5c7ee5a665_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7adfa26ae60741ce90e3942463436967_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c119cd5946c40fabe6b12e425327e13_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:ServiceBasedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6cdf60b6c2d84337b9adeb0d5572d319_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndGrantPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4c1fa50b9414740995b3595ceb68c2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66e84b53db4044d0b673a4ca8b8e75e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:StockOptionAndIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0c500d4ffa344d5a5b3ceec87c24f6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic31e779ca3ac441093747539d1c451db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a97483f7a5746248dc20f25d9484066_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if2310d5f67f14a5da16abed435202898_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedCommonStockUnitsAndPerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0dbb9beedbe644dc8350ed2167afbe18_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i728418fd03a840ca854699e0501666c2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i85e548fb17de479e8f1eaedbedd14aeb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i17b699d019b5406ebafef856b284da2b_D20181205-20181205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-05</startDate>
            <endDate>2018-12-05</endDate>
        </period>
    </context>
    <context id="ia96eb4bd96214dbfb1546494df278d66_I20181205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-05</instant>
        </period>
    </context>
    <context id="iccabe9fdd0d4459f83f43bcfe311abbb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia86a82d3b3da4738b05c1a1dc2acb3c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i90b4231be4ae495b8c891156606a39ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic846063843c2457783476d4cac1401a9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7050aa6851454a26bb85c8a452709530_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib15360143cb64fe7abcc9084d6b9d587_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iebede0396f23431fa71d2b7f1a74378c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrna:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie4ee683b92644214b4cd05e7d4e55ba3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe01185da2fb461cb3ee25ad154cce2d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibad04de7079b4f4a8ea7cd1f6b9a483d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i05ea5c2eff4b47408d5e76fe3acde946_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74a646f2a3a5433fbecbadedd7364094_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia91fb56fbec344488aef5885f842fbb0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7b651cc1ef0d4fb4ac26faca60c2f102_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e527ebcd83c41c986d1270c6919f13b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04ce50e969794bcb9eefacd61a166e35_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrna:RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie043af078137474da5fa9c415b806cb8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4bd88039ef4d41a6bd7804df805f06b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1210d8b31f44fae92d529b8b20e6c6f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3cde0a9204374ab1965f099a3fc5f68b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i504dedceb6a94befbf403be7db0318ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6742a09761af484083c605c79d1094c1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7d8078008d7a4681abf45cdb733f1f74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66608dd5e63640a89af4850f55816d09_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf35565bf91f430595f440c4dd64ae51_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ide4d55b1dda34b6b93a8469f51c7e48c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1eef6d9e8284f3dab7d5832831951df_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ca45b1141c54e74bc0ba86735723e3e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79431f5fc70f4c91917d4630bbc89811_I20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="ibab18ae9cd9244de9112a38fb79ecf41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i835e45064363481fb77ce7bd45f5a1d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanFundingStatusAxis">us-gaap:UnfundedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a9f0c6c3c2848ffb9debae33d695d1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39bdbfea26834ede996b4fab64370074_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d35d0ab562b4b489462b57aefdefce5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9a86bae6409420b83a8aed6d25de2dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5cd9dd4b271d421b9fca8617b75a1093_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i89adc3cd6fc14bed9598b281787d3975_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idaef07bcc885424dbeed30c7d98e5bf7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d38bfda565e475e8f176749260180c0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i05f9128fb34343858d7d0963244403bc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifea1da9382db47b78b24b7770c2bce16_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3370d17a262545d3a21778bdbfd9e0bd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i711d783999b541ed9d40041b1a32a2bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec2fad44150e4a03b5a8be3e02ae7631_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a80bb18be6a4ef784a0986226d8e915_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7621872360e6456f9070400abc857bfd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i608a92f69c204f27bf261e6252469cc3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i97e6326dca0f4ec6947a65af86c71656_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3b0ed2515d854ec9b5a77c4457a02d73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90163def30db4815a2baf938575b19d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iacd7ab752d5b4882a879732a1889bbb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrna:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i258d02d7ce92442dbbad9a730c0f0475_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2021RepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i35471f100ca04369aaa8cd79328e4486_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2021RepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i2dce8093560b49b995bb23f3c3c63255_I20220222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mrna:A2022RepurchaseProgramPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-22</instant>
        </period>
    </context>
    <context id="ic9fcc9f307dd449cbd9ff284355911be_D20220101-20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="i5a40581afbae47acaae291b96f6752cd_I20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>mrna:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="participant">
        <measure>mrna:participant</measure>
    </unit>
    <unit id="contract_option">
        <measure>mrna:contract_option</measure>
    </unit>
    <unit id="numberofcampuses">
        <measure>mrna:numberOfCampuses</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="numberofbuilding">
        <measure>mrna:numberOfBuilding</measure>
    </unit>
    <unit id="numberofextensionperiod">
        <measure>mrna:numberOfExtensionPeriod</measure>
    </unit>
    <unit id="claim">
        <measure>mrna:claim</measure>
    </unit>
    <unit id="numberofoption">
        <measure>mrna:numberOfOption</measure>
    </unit>
    <unit id="installment">
        <measure>mrna:installment</measure>
    </unit>
    <unit id="offering">
        <measure>mrna:offering</measure>
    </unit>
    <unit id="purchase_period">
        <measure>mrna:purchase_period</measure>
    </unit>
    <unit id="dose">
        <measure>mrna:dose</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV80L2ZyYWc6ODRlZWUwM2VmYzkxNGUwZmI4Y2Y4NmY0NWFlNTBkNDgvdGFibGU6OGU5MmM5OTYwZDFhNDY1MWIzNGVlYmJkYTVhODJkMGMvdGFibGVyYW5nZTo4ZTkyYzk5NjBkMWE0NjUxYjM0ZWViYmRhNWE4MmQwY18wLTEtMS0xLTc2MDQ2_5e7ed86a-88b9-45f7-b942-665c4689f098">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV80L2ZyYWc6ODRlZWUwM2VmYzkxNGUwZmI4Y2Y4NmY0NWFlNTBkNDgvdGFibGU6OGU5MmM5OTYwZDFhNDY1MWIzNGVlYmJkYTVhODJkMGMvdGFibGVyYW5nZTo4ZTkyYzk5NjBkMWE0NjUxYjM0ZWViYmRhNWE4MmQwY18xLTEtMS0xLTc2MDQ2_cf380c2a-670e-4ab4-82b5-95ebc7aca54f">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV80L2ZyYWc6ODRlZWUwM2VmYzkxNGUwZmI4Y2Y4NmY0NWFlNTBkNDgvdGFibGU6OGU5MmM5OTYwZDFhNDY1MWIzNGVlYmJkYTVhODJkMGMvdGFibGVyYW5nZTo4ZTkyYzk5NjBkMWE0NjUxYjM0ZWViYmRhNWE4MmQwY18yLTEtMS0xLTc2MDQ2_00e09377-9dc6-466b-b301-2574cc76954e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV80L2ZyYWc6ODRlZWUwM2VmYzkxNGUwZmI4Y2Y4NmY0NWFlNTBkNDgvdGFibGU6OGU5MmM5OTYwZDFhNDY1MWIzNGVlYmJkYTVhODJkMGMvdGFibGVyYW5nZTo4ZTkyYzk5NjBkMWE0NjUxYjM0ZWViYmRhNWE4MmQwY18zLTEtMS0xLTc2MDQ2_f89cec5b-e8f4-4433-afea-0c941cd42e31">0001682852</dei:EntityCentralIndexKey>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_6434c373-a6c6-4f7b-8ef6-3d80253a9ae7">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_762aa615-9010-420a-8e46-65bbadd6aae4">http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_51501eb6-f175-4107-9a50-9a2a310ec651">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_b87ed32e-1ce9-4db8-a202-ed428939aa44">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_7ec179f5-0fc3-4708-bddf-316daed00725">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_859dcb73-429c-4521-9717-2a4efe10e6f1">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8c119cd5946c40fabe6b12e425327e13_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzIvZnJhZzpjMDRmZTAzN2VjNGE0MjVmOGI1OTEzODVjNjdmMzA4Yi90YWJsZTo2NmExY2ZiYWY4YjE0YjQ5OTFkYmUxNGIwZDA3Yzg4Mi90YWJsZXJhbmdlOjY2YTFjZmJhZjhiMTRiNDk5MWRiZTE0YjBkMDdjODgyXzItMS0xLTEtNzYwNDY_a0109e09-2a71-45f2-8c45-1076da558304">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6NGYwZDU0YWY3ZWUyNDg4YzlhZTc0NjVjOWFlM2RkYTIvdGFibGVyYW5nZTo0ZjBkNTRhZjdlZTI0ODhjOWFlNzQ2NWM5YWUzZGRhMl8wLTEtMS0xLTc2MDQ2_823845ca-c109-48b3-b06b-39f056cbd702">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTk2_d04ce65b-2f99-4017-a045-403391b52311">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18yMTk5MDIzMjU5MTc1_83287b25-e486-497d-930e-d28359539445">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18yMTk5MDIzMjU5MTc1_325cbbb1-b86f-452f-b4f8-11ed651e9786">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNjA1_c281a242-cb7a-4d0d-9feb-14f0e3fbf8f7">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTk4_16b3c81e-0ed7-42f3-a313-3e91a9ee0c9b">001-38753</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTky_d6755cfc-3fe8-4cbb-b0bb-8b51aa734b60">Moderna, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8wLTAtMS0xLTc2MDQ2_2c72aa6d-ce8e-4ae7-8e14-962954f525c8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8wLTItMS0xLTc2MDQ2_691eaaf3-fad7-4a47-8863-39d8a04ea3cc">81-3467528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8zLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246OTY1MGIzYmU4ZWU1NDA0NTliNzBjYTg5ZGI2ZTM0MmVfNA_7709d20d-2c03-43ac-bdcb-78b4a10c049a">200 Technology Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8zLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246OTY1MGIzYmU4ZWU1NDA0NTliNzBjYTg5ZGI2ZTM0MmVfNw_3566540e-e15c-4db2-ad71-d7d6d2ada9e2">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8zLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246OTY1MGIzYmU4ZWU1NDA0NTliNzBjYTg5ZGI2ZTM0MmVfMTE_86f0a26d-ee4d-4cb9-9ef9-784bd6fae00a">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6OTNmODNhOGU4NjRhNDllYmIxODg5ODViZmRiMjkyNzYvdGFibGVyYW5nZTo5M2Y4M2E4ZTg2NGE0OWViYjE4ODk4NWJmZGIyOTI3Nl8zLTItMS0xLTc2MDQ2_cab471df-3f3a-42f2-bc15-c1d272018726">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTkz_42f8e2f5-8258-4e8c-a398-1e11a21a1e0b">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTk0_cc132b07-9616-4a0d-8d88-0c7e6da05069">714-6500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6YTI0NTM2YTkyYWJiNDJjY2E2MjBlMjU5NTE4NDgyZDcvdGFibGVyYW5nZTphMjQ1MzZhOTJhYmI0MmNjYTYyMGUyNTk1MTg0ODJkN18xLTAtMS0xLTc2MDQ2_42a27eef-81d5-4380-b617-8b8d124d6ddf">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6YTI0NTM2YTkyYWJiNDJjY2E2MjBlMjU5NTE4NDgyZDcvdGFibGVyYW5nZTphMjQ1MzZhOTJhYmI0MmNjYTYyMGUyNTk1MTg0ODJkN18xLTEtMS0xLTc2MDQ2_2e93d2b5-a36a-4941-b170-33b7c8a37e70">MRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6YTI0NTM2YTkyYWJiNDJjY2E2MjBlMjU5NTE4NDgyZDcvdGFibGVyYW5nZTphMjQ1MzZhOTJhYmI0MmNjYTYyMGUyNTk1MTg0ODJkN18xLTItMS0xLTc2MDQ2_b2781f3a-dbff-49a4-b866-aa5912a2625e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNjAx_4e849a3a-3378-4f4f-9487-de573fa4bd8f">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNjAy_bc69c1f7-7fc4-4fc7-9885-69a9aec2a6f7">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNjAz_128f9531-3ed7-42a7-b465-2c743a85d517">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNjA0_482d5009-a334-4aa9-b1ce-0338591bbc42">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6ZTcxMjU2MDA4ZWRmNDNjYzk5YWQ3NDgyNDQyNmU1MjgvdGFibGVyYW5nZTplNzEyNTYwMDhlZGY0M2NjOTlhZDc0ODI0NDI2ZTUyOF8wLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246NDNiNTlkYWI4MTFkNGQ1ZmExMDQ2OTY4NzI4NTM5N2JfNQ_3375484d-3369-46c6-8787-e8b80fcd0ef5">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6ZTcxMjU2MDA4ZWRmNDNjYzk5YWQ3NDgyNDQyNmU1MjgvdGFibGVyYW5nZTplNzEyNTYwMDhlZGY0M2NjOTlhZDc0ODI0NDI2ZTUyOF8wLTYtMS0xLTc2MDQ2L3RleHRyZWdpb246Mjc3MDM2YmNlNTEyNGQyOGEwOWJiM2Q1OGRlNTA5ZWRfMzE_9e66e361-73b1-4b95-8aff-4d74de403e90">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGFibGU6ZTcxMjU2MDA4ZWRmNDNjYzk5YWQ3NDgyNDQyNmU1MjgvdGFibGVyYW5nZTplNzEyNTYwMDhlZGY0M2NjOTlhZDc0ODI0NDI2ZTUyOF8xLTYtMS0xLTc2MDQ2L3RleHRyZWdpb246YmFlMDkzYzM5MGJjNDM3MWFlMzliOWQ1MTc1MzYxMTZfMjk_1e4b41b2-1609-443a-9891-b0185175aca4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTkx_5a3873f5-fca2-4075-9a41-34673a1b5699">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18xNjQ5MjY3NDQ2Nzkw_c001be0e-70ec-42fe-b554-951d0835abad">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="idb99458155744556b3d39993ad822db4_I20210630"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18yMTk5MDIzMjYxMDQ1_bf15d1cf-b6ad-4717-b312-067c2cf73ce6"
      unitRef="usd">80800000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i58b4bf6524f44a5e8970d9daad47a515_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zMjM5_6471c5e6-55c7-4e7d-b081-18e8158935c1"
      unitRef="shares">402872986</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xL2ZyYWc6NmY0YjNmNWE1ZDRhNDJkZGE4OTQxY2Q0NmFmNDdiY2MvdGV4dHJlZ2lvbjo2ZjRiM2Y1YTVkNGE0MmRkYTg5NDFjZDQ2YWY0N2JjY18zNTk1_72ef9338-a4aa-4563-a8ae-7e0d3eb9571a">DOCUMENTS INCORPORATED BY REFERENCEPortions of the registrant&#x2019;s Definitive Proxy Statement relating to its 2022 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ia2fcd0a4e20a4fb395dd61a92d63adc0_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV84NS9mcmFnOjY0YjAxZTA2YWY1NDQ3MmViZmVlZDIzNmJkMjY4ZjZmL3RleHRyZWdpb246NjRiMDFlMDZhZjU0NDcyZWJmZWVkMjM2YmQyNjhmNmZfMjc0ODc3OTA4MTk2OQ_27d7dfe2-b701-4edf-ac77-0277ecff34bd"
      unitRef="shares">3500000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia2fcd0a4e20a4fb395dd61a92d63adc0_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV84NS9mcmFnOjY0YjAxZTA2YWY1NDQ3MmViZmVlZDIzNmJkMjY4ZjZmL3RleHRyZWdpb246NjRiMDFlMDZhZjU0NDcyZWJmZWVkMjM2YmQyNjhmNmZfMjc0ODc3OTA4MTk4NA_ff1dc583-3363-4f55-8a77-8dce5b3a607e"
      unitRef="usd">857000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <dei:AuditorName
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDMvZnJhZzpmNWFmYWZjMDE4Mzc0NmY3OTk3ZmQzZDVhNTM3YjMwYi90ZXh0cmVnaW9uOmY1YWZhZmMwMTgzNzQ2Zjc5OTdmZDNkNWE1MzdiMzBiXzE5MjQxNDUzNDkwMDkx_5e06d58e-407d-4aa2-9a46-93634d7b8fc1">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDMvZnJhZzpmNWFmYWZjMDE4Mzc0NmY3OTk3ZmQzZDVhNTM3YjMwYi90ZXh0cmVnaW9uOmY1YWZhZmMwMTgzNzQ2Zjc5OTdmZDNkNWE1MzdiMzBiXzE5MjQxNDUzNDkwMDky_ab7b9f38-f406-454d-871a-96b88e15adea">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzQtMS0xLTEtNzYwNDY_fd8a6426-4709-4c0f-bb5e-4aba36544bfd"
      unitRef="usd">6848000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzQtMy0xLTEtNzYwNDY_eabde0ea-9976-450a-8926-20355d31d8c7"
      unitRef="usd">2624000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzUtMS0xLTEtNzYwNDY_9d9a1aca-2b0c-45d6-92d6-440add351548"
      unitRef="usd">3879000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzUtMy0xLTEtNzYwNDY_dfdc0339-d91b-4b69-a91a-63cf7534d3fe"
      unitRef="usd">1984000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzYtMS0xLTEtNzYwNDY_2e4c4f4c-84bb-49a9-bbb4-cd51a7a1e60e"
      unitRef="usd">3175000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzYtMy0xLTEtNzYwNDY_596b26cd-c70c-420d-83aa-20552172c5c6"
      unitRef="usd">1391000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzctMS0xLTEtNzYwNDY_b245ed45-c99f-4058-8e81-364973741425"
      unitRef="usd">1441000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzctMy0xLTEtNzYwNDY_391c1051-6fab-4ca8-a594-edc029bc26f0"
      unitRef="usd">47000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzgtMS0xLTEtNzYwNDY_fcbeba05-4dba-4d2c-8ee2-45b1c69ea9c5"
      unitRef="usd">728000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzgtMy0xLTEtNzYwNDY_2aff91c4-5f64-4ec1-927f-8ed2a85a050f"
      unitRef="usd">252000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEwLTEtMS0xLTc2MDQ2_5f614f4a-1807-45a0-aee8-7039a0b33ece"
      unitRef="usd">16071000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEwLTMtMS0xLTc2MDQ2_48abc217-d885-40f1-a943-c6ac91a54408"
      unitRef="usd">6298000000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzExLTEtMS0xLTc2MDQ2_5fd5bacb-8206-4656-99e0-5d2f2c4b6a7c"
      unitRef="usd">6843000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzExLTMtMS0xLTc2MDQ2_108d03bc-a663-4932-bd34-d985155c5b1b"
      unitRef="usd">639000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEyLTEtMS0xLTc2MDQ2_6973ff7a-0397-4c52-8666-20a9d2a27781"
      unitRef="usd">1241000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEyLTMtMS0xLTc2MDQ2_b8436be5-7210-466f-9e51-f96459bd655c"
      unitRef="usd">297000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEzLTEtMS0xLTc2MDQ2_6d905a73-ba10-40ad-981f-a48a36143f49"
      unitRef="usd">142000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzEzLTMtMS0xLTc2MDQ2_8ca53cdd-1c18-4268-b612-d504f74def93"
      unitRef="usd">90000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE0LTEtMS0xLTc2MDQ2_a50a2cd1-ca8f-4266-9cc0-d3a9e80a1a81"
      unitRef="usd">12000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE0LTMtMS0xLTc2MDQ2_8f420ab1-8a05-44c6-bd1a-fcb295b2d8d9"
      unitRef="usd">11000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE1LTEtMS0xLTc2NTE5_9d35c685-d800-403f-bc96-c717053847df"
      unitRef="usd">326000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE1LTMtMS0xLTc2NTE5_07899c19-d2a2-481b-ba8a-d861d607a484"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE1LTEtMS0xLTc2MDQ2_ca45e19d-767d-4895-9fc3-e88288525fa8"
      unitRef="usd">34000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE1LTMtMS0xLTc2MDQ2_d1a9f3fc-f3b1-457d-bba2-ed5653f6deb0"
      unitRef="usd">2000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE2LTEtMS0xLTc2MDQ2_d0e24902-d25d-4fab-9696-4bd9c93bd2c0"
      unitRef="usd">24669000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE2LTMtMS0xLTc2MDQ2_5fe02baf-c908-4d4e-913d-a46aa9ebaeb1"
      unitRef="usd">7337000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE5LTEtMS0xLTc2MDQ2_256dd288-d398-4b63-8465-1351726c108f"
      unitRef="usd">302000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzE5LTMtMS0xLTc2MDQ2_1afbe9c2-7a02-454a-b45e-219c7c77b426"
      unitRef="usd">18000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIwLTEtMS0xLTc2MDQ2_6251f37c-6ae4-4aa7-8045-01611dcb6adf"
      unitRef="usd">1472000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIwLTMtMS0xLTc2MDQ2_c70a831a-6fd6-40a9-95b2-266fd1406813"
      unitRef="usd">470000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIxLTEtMS0xLTc2MDQ2_ac2245d9-6ce6-4146-b6c4-5988decf33bc"
      unitRef="usd">6253000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIxLTMtMS0xLTc2MDQ2_e6659308-4929-4d79-b346-58c0f5402826"
      unitRef="usd">3867000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIzLTEtMS0xLTc2NTU4_e7d107ba-b99d-4eb8-aea2-5687a7127601"
      unitRef="usd">876000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIzLTMtMS0xLTc2NTU4_1a511f6d-f839-444a-a5c0-b6ab60a2266b"
      unitRef="usd">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIyLTEtMS0xLTc2MDQ2_2a161676-6d7c-400c-96d3-7d17cb28b78d"
      unitRef="usd">225000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIyLTMtMS0xLTc2MDQ2_374deb1f-5b7b-4df3-a34b-cf8560d01173"
      unitRef="usd">34000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIzLTEtMS0xLTc2MDQ2_eb5a222a-a294-4ff9-8db0-7d78f14341dc"
      unitRef="usd">9128000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzIzLTMtMS0xLTc2MDQ2_1c8a26ff-e975-4988-a841-5176ae087fd4"
      unitRef="usd">4389000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI0LTEtMS0xLTc2MDQ2_3fb9fc8d-7c3e-4baf-bb00-535971cbd9c4"
      unitRef="usd">615000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI0LTMtMS0xLTc2MDQ2_fcd13bf7-4a75-41a0-a112-6837cccd8310"
      unitRef="usd">177000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI1LTEtMS0xLTc2MDQ2_4f183c78-d5f1-40b7-9bcc-57c365fd2038"
      unitRef="usd">106000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI1LTMtMS0xLTc2MDQ2_be7808db-b818-41cc-b3b4-2fd63556510c"
      unitRef="usd">97000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI2LTEtMS0xLTc2MDQ2_d11388a3-a6a0-473c-b02e-d6b432216b8d"
      unitRef="usd">599000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI2LTMtMS0xLTc2MDQ2_4d5928ee-ec89-431e-b71b-cfd604e8c376"
      unitRef="usd">110000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI3LTEtMS0xLTc2MDQ2_07620de2-2f1d-45df-bed0-7e28d088a804"
      unitRef="usd">76000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI3LTMtMS0xLTc2MDQ2_73c106ec-acd7-4908-bafb-0ba69f15956e"
      unitRef="usd">3000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI4LTEtMS0xLTc2MDQ2_533b3ead-022d-4323-9dcd-c3058bc1c1e3"
      unitRef="usd">10524000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI4LTMtMS0xLTc2MDQ2_dccf7ff6-9592-49a7-ab81-24be0b7e8b02"
      unitRef="usd">4776000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI5LTEtMS0xLTc2MDQ2_e7f57708-854c-4a4d-a9ae-e1fae911aad7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzI5LTMtMS0xLTc2MDQ2_ee3abf3d-3482-4f89-bc3e-aa211dbfc455"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTY5OQ_6c277de7-7ee5-472f-8d6a-deddb669f7b4"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTY5OQ_ca5e5ca5-e8d0-40c0-b320-3f650a120ee0"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTcwNA_214aa800-a1e2-43c0-b8ea-ae73b6dc7909"
      unitRef="shares">162000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTcwNA_5bbf34b2-e8c9-4758-98db-2038481c0544"
      unitRef="shares">162000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTc0NQ_09eda4b2-eafa-4886-aaaa-fa0d2d3b3e49"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTc0NQ_79b8c678-747d-4e76-89f2-303c6ba1a0c4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTc0NQ_ac3f1442-67df-4f2e-8c03-de2c994ac899"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246ODE1YmIwODI4MGM4NGRkZGE2MjM5YjBmOTI1NTdmNGNfMjE5OTAyMzI1NTc0NQ_e3ae2225-7823-4e4d-9dee-b71a2fadd1d6"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTEtMS0xLTc2MDQ2_34ff790a-87f2-446d-afe8-2fd9dfe24448"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMxLTMtMS0xLTc2MDQ2_fe265bbc-16b8-44d5-87a0-8e527d0c8c2f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTczMQ_aa17d503-2754-4420-941c-3c7070c2a8dd"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTczMQ_e97e41d0-c704-4f2d-81e3-11d3655ba3cb"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTczNg_1b3db7ef-14c8-4940-9425-e749ecb23401"
      unitRef="shares">1600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTczNg_53d201e7-3fdc-4c8d-b8ab-d9fe8c4cd84a"
      unitRef="shares">1600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTc3Nw_0c965cb3-7450-44fe-9c73-1c866dad0ffc"
      unitRef="shares">403000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTc3Nw_efbc16cf-bfc3-4cda-aef6-d4af2bf0a08b"
      unitRef="shares">403000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTc4NQ_07f3948a-ca2b-4d34-9d32-eeefbaea2bcf"
      unitRef="shares">399000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTAtMS0xLTc2MDQ2L3RleHRyZWdpb246MTdkYjEyY2I4ZjE4NDRhZWI1ZDA2M2QxMDhhMmNhZmVfMjE5OTAyMzI1NTc4NQ_f6dafa7c-553b-4387-9b2f-e7c8b613d8a0"
      unitRef="shares">399000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTEtMS0xLTc2MDQ2_94042ce0-f884-42e0-8c4d-d4d4cc2ffa5c"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMyLTMtMS0xLTc2MDQ2_45182cf0-d726-4231-b65d-511ad14ed27d"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMzLTEtMS0xLTc2MDQ2_f1c92bbb-68e4-4be2-803a-4ea1d3f33d4f"
      unitRef="usd">4211000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzMzLTMtMS0xLTc2MDQ2_a9329ccc-ee71-46ef-8bb7-319b05030961"
      unitRef="usd">4802000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM0LTEtMS0xLTc2MDQ2_20a7069f-06bf-4584-8145-22e250797ddc"
      unitRef="usd">-24000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM0LTMtMS0xLTc2MDQ2_5092e532-2dbf-4b11-8daf-21f48ac844f8"
      unitRef="usd">3000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM1LTEtMS0xLTc2MDQ2_8e25463c-22ab-4e60-9f6e-674daca50944"
      unitRef="usd">9958000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM1LTMtMS0xLTc2MDQ2_8ea8c516-3f91-42cb-944b-2fff64eac235"
      unitRef="usd">-2244000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM2LTEtMS0xLTc2MDQ2_da02f098-00b9-4866-905e-13d6df510ee3"
      unitRef="usd">14145000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM2LTMtMS0xLTc2MDQ2_dd070541-457b-473c-882a-3bf43e1696be"
      unitRef="usd">2561000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM3LTEtMS0xLTc2MDQ2_815c9ac7-7e6e-4c0d-8080-19675817a2aa"
      unitRef="usd">24669000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDYvZnJhZzpkMTdiZTlmZmI3MmY0YWZlOWM2YzY1YjBhYTI0NmZlOC90YWJsZTplYmEyZWZmNzQyOTY0ZDA0YmIzNjc0Mjk3OWNjYzYyNS90YWJsZXJhbmdlOmViYTJlZmY3NDI5NjRkMDRiYjM2NzQyOTc5Y2NjNjI1XzM3LTMtMS0xLTc2MDQ2_76567ea3-8bca-4379-b51b-cd22df3045d1"
      unitRef="usd">7337000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i0613309ccd7f4770b391e463a962e99b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzMtMS0xLTEtNzYwNDY_3ce794ca-9b85-4e88-8abb-1205375f70eb"
      unitRef="usd">17675000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icfd2fff3411a4c769c4f81842918e9c3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzMtMy0xLTEtNzYwNDY_1a8f1bcc-6a22-4fd9-ba23-9295c588fb81"
      unitRef="usd">200000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdba65dc5ee84630ac91c06737b61940_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzMtNS0xLTEtNzYwNDY_8edc3849-b06c-4701-824b-3058804843cf"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1806b5a0029947c1aabb49f5e058cb28_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzQtMS0xLTEtNzYwNDY_376e9161-39d8-4571-8ce5-bba8039c8371"
      unitRef="usd">735000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1eabe79fc2e4e4a9fdc7c2be2e9f0e7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzQtMy0xLTEtNzYwNDY_d50c0619-af1f-4214-894e-c8247839ab04"
      unitRef="usd">529000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5db090169624207a4311b8780bb82f3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzQtNS0xLTEtNzYwNDY_097b94d6-ebfa-4be1-8aa8-0ac7c7348331"
      unitRef="usd">12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0e182cbaac1c44c8aaf481c02d369892_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzUtMS0xLTEtNzYwNDY_5b18a0cd-6551-4400-8d76-784ea746d71f"
      unitRef="usd">61000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie2fa812bb582446faced9f5539691f0a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzUtMy0xLTEtNzYwNDY_20ba0c2d-af98-4d21-86ac-69b8d061b71d"
      unitRef="usd">74000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice96c3b711e145be81cba0afd205ad43_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzUtNS0xLTEtNzYwNDY_2ba29ab9-759a-4ed5-b385-aaa4a3c6543e"
      unitRef="usd">48000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzYtMS0xLTEtNzYwNDY_f0360d09-397b-4742-aef0-a8996d38ddc8"
      unitRef="usd">18471000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzYtMy0xLTEtNzYwNDY_659325fc-d403-46ab-bf8c-3369f138c927"
      unitRef="usd">803000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzYtNS0xLTEtNzYwNDY_2f99dba6-6bc9-42e7-a4bc-11250ff7d7bc"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzgtMS0xLTEtNzYwNDY_0f8b90c6-ae26-414e-b945-ae9ee7514aa0"
      unitRef="usd">2617000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzgtMy0xLTEtNzYwNDY_7051e068-6521-484a-a775-0a0d311929a9"
      unitRef="usd">8000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzgtNS0xLTEtNzYwNDY_80761c15-c884-4aa9-8cab-912851dfd981"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzktMS0xLTEtNzYwNDY_96fad5c9-becc-4fe5-83b6-ed4838e6c54b"
      unitRef="usd">1991000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzktMy0xLTEtNzYwNDY_9f36390e-1ce3-48fe-abae-1f280257d071"
      unitRef="usd">1370000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzktNS0xLTEtNzYwNDY_7d518e11-724b-4de2-882f-0cb8bc62cbf3"
      unitRef="usd">496000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEwLTEtMS0xLTc2MDQ2_eb26c2ff-78ff-43b1-872b-5e3a37b2f007"
      unitRef="usd">567000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEwLTMtMS0xLTc2MDQ2_7ef5096b-280a-4b8e-b0f6-d8672596d712"
      unitRef="usd">188000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEwLTUtMS0xLTc2MDQ2_dff64cb5-f60d-4d3f-82c7-6d7931d56eb6"
      unitRef="usd">110000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzExLTEtMS0xLTc2MDQ2_0d02b5ca-47de-4f86-9f75-e72ff222a81b"
      unitRef="usd">5175000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzExLTMtMS0xLTc2MDQ2_f1517b01-89ff-487f-9c08-88d5fcc146eb"
      unitRef="usd">1566000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzExLTUtMS0xLTc2MDQ2_fd47b445-1967-44a8-b229-5ed4992f4623"
      unitRef="usd">606000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEyLTEtMS0xLTc2MDQ2_6a433760-9c2d-4bfa-848d-18b47cd1b8b6"
      unitRef="usd">13296000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEyLTMtMS0xLTc2MDQ2_07fdaea9-41d4-40e6-8369-45d2c36e0841"
      unitRef="usd">-763000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEyLTUtMS0xLTc2MDQ2_f51850ff-4624-4d16-908e-5376df6a6c95"
      unitRef="usd">-546000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEzLTEtMS0xLTc2MDQ2_518d4f93-8e4b-4ce4-bcc5-6ddbe32abc3a"
      unitRef="usd">18000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEzLTMtMS0xLTc2MDQ2_4e69f000-f773-4d85-ae0a-6d4fc80c9e29"
      unitRef="usd">25000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzEzLTUtMS0xLTc2MDQ2_669f8c34-6e8d-4f8e-b749-820d988f0a5d"
      unitRef="usd">39000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE0LTEtMS0xLTc2MDQ2_04f959e1-21b4-4d4c-8718-1a1a40b74e2f"
      unitRef="usd">-29000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE0LTMtMS0xLTc2MDQ2_a26c9924-b295-4099-8128-51017067b28e"
      unitRef="usd">-6000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE0LTUtMS0xLTc2MDQ2_458cd4ad-db66-44dd-844d-118876860113"
      unitRef="usd">-8000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE1LTEtMS0xLTc2MDQ2_80a25e88-0cd2-4783-aaf6-57db2f6054e7"
      unitRef="usd">13285000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE1LTMtMS0xLTc2MDQ2_51fa9747-46bb-457e-b45d-f4f5d6b91217"
      unitRef="usd">-744000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE1LTUtMS0xLTc2MDQ2_21509e15-36cf-4454-b508-1acf5886ea83"
      unitRef="usd">-515000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE2LTEtMS0xLTc2MDQ2_1840730b-9348-40de-a750-276f29546dcc"
      unitRef="usd">1083000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE2LTMtMS0xLTc2MDQ2_137b9642-dbf3-416b-9756-f5ac0dec362b"
      unitRef="usd">3000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE2LTUtMS0xLTc2MDQ2_8fee44fd-b546-4fd6-8115-e70c131fc979"
      unitRef="usd">-1000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE3LTEtMS0xLTc2MDQ2_4994cb43-77dd-4145-887e-e90183a6132d"
      unitRef="usd">12202000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE3LTMtMS0xLTc2MDQ2_0ad2cf3a-ea57-4b1f-9d7c-dd60688b38db"
      unitRef="usd">-747000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzE3LTUtMS0xLTc2MDQ2_b9030251-39d2-4079-bdc3-1c3aec44496b"
      unitRef="usd">-514000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIwLTEtMS0xLTc5NjE1_8d83c79c-53a4-4c0f-8934-e73db8453962"
      unitRef="usdPerShare">30.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIwLTMtMS0xLTc5NjE1_da048eee-3ec3-49a4-bbf5-d6a0c4baad8c"
      unitRef="usdPerShare">-1.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIwLTUtMS0xLTc5NjIy_b3874f34-7a69-439a-ba5f-389d0962444c"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIxLTEtMS0xLTc5NjE1_dce71a61-e376-4be3-8086-23427b3527f1"
      unitRef="usdPerShare">28.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIxLTMtMS0xLTc5NjE1_c85d7b29-02f2-419f-ac87-173f5a003516"
      unitRef="usdPerShare">-1.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzIxLTUtMS0xLTc5NjIy_d7ad475e-c61b-43af-9cfd-482ac2082a65"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI0LTEtMS0xLTc5NjE1_af1dcc53-0768-498d-b721-f2fc8d27e181"
      unitRef="shares">403000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI0LTMtMS0xLTc5NjE1_ee2aef7c-a929-42e0-b4d1-6eb31ff11479"
      unitRef="shares">381000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI0LTUtMS0xLTc5NjM4_d1a07224-e520-4d7d-a408-61e0ebfd95e8"
      unitRef="shares">331000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI1LTEtMS0xLTc5NjE1_3cc90e5e-e81e-47f8-a2af-15f39b333667"
      unitRef="shares">431000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI1LTMtMS0xLTc5NjE1_6f906e91-8e0c-45c7-84e6-b37ee21cbde6"
      unitRef="shares">381000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMDkvZnJhZzowOTY0N2I1N2E0OWI0NjhkYTk0ZGUyZDkyNTYzOTUxZC90YWJsZToyYTY3ODBlYTJjNDc0ZDViOTU0N2QwOWNjYjdlOWZkYy90YWJsZXJhbmdlOjJhNjc4MGVhMmM0NzRkNWI5NTQ3ZDA5Y2NiN2U5ZmRjXzI1LTUtMS0xLTc5NjM4_75515733-f198-4157-906e-2eafcf489864"
      unitRef="shares">331000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzItMS0xLTEtNzYwNDY_f0c7f50d-9467-4781-8529-e0a3318c31bb"
      unitRef="usd">12202000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzItMy0xLTEtNzYwNDY_94ad9a47-eb4f-4ace-b04e-4e3ac0a523b5"
      unitRef="usd">-747000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzItNS0xLTEtNzYwNDY_95e09a05-9563-4766-a5ca-0b2fc3453bd7"
      unitRef="usd">-514000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtMS0xLTEtNzY4MTQ_e785994f-f72b-48a1-9deb-0720d8300292"
      unitRef="usd">-42000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtMy0xLTEtNzY4MTQ_1fb7a303-66f4-4ca5-b3e4-7320f2fc6074"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtNS0xLTEtNzY4NTQ_e390fc08-8b81-454f-8faf-980b12d5d9f3"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtMS0xLTEtNzY4MTQ_b6b0fe4a-1826-4094-83ca-451508ad62ae"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtMy0xLTEtNzY4MTQ_e158088a-9066-45c9-b2fb-e7705920662c"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtNS0xLTEtNzY4NTQ_f8615b67-dcbf-4e43-b91e-da6fed847bfb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctMS0xLTEtNzY4MTQ_68436199-12e6-476a-988c-8461b3736d39"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctMy0xLTEtNzY4MTQ_03e1a7ff-b69c-4533-a81d-ac24e6697050"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctNS0xLTEtNzY4NTQ_ca80fb98-d44d-45cf-a196-01b2b8762990"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzktMS0xLTEtNzY4MTQ_50619b46-429c-4891-9255-49953c3a6fe2"
      unitRef="usd">74000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzktMy0xLTEtNzY4MTQ_98db51c2-593a-43c8-8e3a-3b4205bb6f0a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzktNS0xLTEtNzY4NTQ_1501b6e0-44a6-4428-b342-7734cfeb7baa"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzQtMS0xLTEtNzYwNDY_59112009-617d-41f7-9493-510172e460e6"
      unitRef="usd">58000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzQtMy0xLTEtNzYwNDY_02a660fc-4de5-4991-bfea-e4a7bb659f66"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzQtNS0xLTEtNzYwNDY_66078327-356a-44a4-a129-fd310f1e089c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtMS0xLTEtNzYwNDY_7309cf03-7bc6-4e4d-800e-7b4b33534fb4"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtMy0xLTEtNzYwNDY_3b152803-0697-423b-ace3-2877b1a177a3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzUtNS0xLTEtNzYwNDY_ddfdac6f-7f32-430e-af42-9055a738845c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtMS0xLTEtNzYwNDY_c3dd79f2-7d16-466a-9b5c-2e813af77e42"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtMy0xLTEtNzYwNDY_11f017f0-57a2-4011-b6cb-7c54537e5495"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzYtNS0xLTEtNzYwNDY_0d93801e-710a-4c3b-8a5f-25cfae35a161"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctMS0xLTEtNzYwNDY_ed6a46aa-e806-4483-abe9-b5e5e92a37c3"
      unitRef="usd">12175000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctMy0xLTEtNzYwNDY_7b699449-31dd-4306-ab82-4c5915100fa4"
      unitRef="usd">-746000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTIvZnJhZzpkYmM5MWQ4MmRiYWE0ZjBhODVjMGIxMTQzOGVhZDEzZC90YWJsZTpkMDE0OGM0Y2Q4ODA0MWRmOGJmOWRjYmY3NWE0ZjkzNy90YWJsZXJhbmdlOmQwMTQ4YzRjZDg4MDQxZGY4YmY5ZGNiZjc1YTRmOTM3XzctNS0xLTEtNzYwNDY_f840917c-c45f-44ad-8fa9-71dea9169376"
      unitRef="usd">-511000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i87fe7c36a950471bb3212e6877b0baf9_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItNy0xLTEtNzYwNDY_2db70a33-2050-4f3f-93e3-74c2f510f483"
      unitRef="shares">329000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i87fe7c36a950471bb3212e6877b0baf9_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItOS0xLTEtNzYwNDY_4cbb9ebf-6d0d-4f7c-b2af-5a077c511d1a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8485f63a4c2345fea4cdae33f5552050_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItMTEtMS0xLTc2MDQ2_3232b890-8f18-46fc-a0dd-9915d5ccdd61"
      unitRef="usd">2538000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6916c32254f544d89e2f4ba8db2520a6_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItMTMtMS0xLTc2MDQ2_b854c33b-8066-4aa8-bba1-1e0460fba7b7"
      unitRef="usd">-1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4183a6aba7e43f68918a5fb12e3d83f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItMTUtMS0xLTc2MDQ2_012cbb4e-0dbd-4732-af5c-6da3e97557f7"
      unitRef="usd">-1007000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f00be47b1194ea3be883db45fca7c1c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzItMTctMS0xLTc2MDQ2_a763ee91-c4d9-405a-8b62-238b0d80b675"
      unitRef="usd">1530000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i291937679b0b473abab40f676c567dbd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzMtNy0xLTEtNzYwNDY_7ffa6d98-9806-4db4-99f5-f12c9d71227c"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i291937679b0b473abab40f676c567dbd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzgtNy0xLTEtNzYwNDY_05bea3ec-3e9e-47a6-8a03-17e0996721c1"
      unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iea71826e0b2c464293613200c787a5f4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzgtMTEtMS0xLTc2MDQ2_c21ca3fc-7d5c-4098-88fd-d3518270c03d"
      unitRef="usd">48000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzgtMTctMS0xLTc2MDQ2_ff3e4af6-68fb-46e8-93dc-a1f144807a2b"
      unitRef="usd">48000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iea71826e0b2c464293613200c787a5f4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEwLTExLTEtMS03Njk5MQ_7a2c6490-950c-4cbf-b963-1cc3dd2359cc"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEwLTE3LTEtMS03Njk5MQ_4e41bfae-9109-4b1e-943e-bdb61fded4b1"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockholdersEquity
      contextRef="i70d890a8a1c24221b1111740ec40546f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEzLTE1LTEtMS03Njk5OA_93e37e13-8b05-4cfb-8c9f-a419464383b6"
      unitRef="usd">28000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i237e52dede034cd091787b93f9589ae5_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEzLTE3LTEtMS03Njk5OA_4708f77c-efd9-4503-b7bf-7b4c96644738"
      unitRef="usd">28000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idfa777b5307245f09b6cb5f6a8fb3e1d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTE1LTEtMS03Njk5OA_7126e4aa-ace4-4a85-b653-3aefa48b6458"
      unitRef="usd">-4000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i98fce2df066140b8974dbf5aa3059a90_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTE3LTEtMS03Njk5OA_642bb561-48be-40b9-bef7-5136d0b70a59"
      unitRef="usd">-4000000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iea71826e0b2c464293613200c787a5f4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzExLTExLTEtMS03NjA0Ng_3edf83fe-eb05-482d-a2b5-30e7490a2ac4"
      unitRef="usd">81000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzExLTE3LTEtMS03NjA0Ng_1d467392-7ad1-4489-b286-2694bb3ba400"
      unitRef="usd">81000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie5f8052aaadc419c8d711ef7686bd436_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEyLTEzLTEtMS03NjA0Ng_21e948fc-9e67-4060-a029-25869d020b62"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEyLTE3LTEtMS03NjA0Ng_e22629c2-235d-4e84-b649-98818538a7f3"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ic0bee1a0804143529b5cc7f5e167104e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEzLTE1LTEtMS03NjA0Ng_ddc84e16-5adb-40cc-833b-c16e319ee555"
      unitRef="usd">-514000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzEzLTE3LTEtMS03NjA0Ng_258d7eb4-1b93-4726-935c-316a2cd0bd72"
      unitRef="usd">-514000000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9ffaed07b9974d019abd45bea1588ec0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTctMS0xLTc2MDQ2_56c48af8-b150-4194-8c40-fe9e3390053d"
      unitRef="shares">337000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9ffaed07b9974d019abd45bea1588ec0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTktMS0xLTc2MDQ2_3afa3f98-e6e2-45f4-bae4-4dd70733f2c2"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i552c6e3acac14be0baea5ae64fe4cc51_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTExLTEtMS03NjA0Ng_c89ee137-5e59-4b46-9306-d7ecbad48250"
      unitRef="usd">2670000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c6b33ad00e44689ad7ca663971c003f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTEzLTEtMS03NjA0Ng_3030d723-b8cf-4d9d-9a57-afc062be48c5"
      unitRef="usd">2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifefe594e140042af8fa2b3baed41f390_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTE1LTEtMS03NjA0Ng_5b50e349-61fd-49e6-b8ba-96ea753bf129"
      unitRef="usd">-1497000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTpkY2U4YmU3ZjhkZTk0NGViODg4OGUxNDI5MTFjMjFkMy90YWJsZXJhbmdlOmRjZThiZTdmOGRlOTQ0ZWI4ODg4ZTE0MjkxMWMyMWQzXzE0LTE3LTEtMS03NjA0Ng_3dc52a94-ac4c-4f3a-a446-7ae7a431ab5c"
      unitRef="usd">1175000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i9ffaed07b9974d019abd45bea1588ec0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItNy0xLTEtNzYwNDY_9a14edd2-3087-40f8-a0ea-7d7528558e63"
      unitRef="shares">337000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9ffaed07b9974d019abd45bea1588ec0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItOS0xLTEtNzYwNDY_54f354de-a696-4489-843a-a6ba855d4066"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i552c6e3acac14be0baea5ae64fe4cc51_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItMTEtMS0xLTc2MDQ2_0b92b95a-0e0a-4c46-84e5-69129b0de702"
      unitRef="usd">2670000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c6b33ad00e44689ad7ca663971c003f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItMTMtMS0xLTc2MDQ2_bd1cece8-15e6-4eca-8e33-bb19c8c14b56"
      unitRef="usd">2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifefe594e140042af8fa2b3baed41f390_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItMTUtMS0xLTc2MDQ2_f432686a-5987-4d52-83e1-d42603e7ba19"
      unitRef="usd">-1497000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzItMTctMS0xLTc2MDQ2_97b36bd1-0e41-4301-8fc9-e0178fc9b7b9"
      unitRef="usd">1175000000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzMtMC0xLTEtNzcxMTMvdGV4dHJlZ2lvbjo5NzFmNDU4NGU5Nzg0ZGQzYmIyMzliODg2MjA5NmU4Y18yMTk5MDIzMjU1NjMy_2378790c-9924-473d-8e9f-e9a3433f3ca0"
      unitRef="usd">2000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2468b82d059745f5b51fb3d31a544305_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzMtNy0xLTEtNzcwODI_805a4383-22d5-45d9-8aa5-75c41614bd70"
      unitRef="shares">48000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if106b707e879407f837eee91cc731c8b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzMtMTEtMS0xLTc3MDgy_75ff1451-21dd-4050-963d-204b844b2d13"
      unitRef="usd">1853000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzMtMTctMS0xLTc3MDgy_16046451-5a70-40f4-8c6e-cbe2264aac6b"
      unitRef="usd">1853000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2468b82d059745f5b51fb3d31a544305_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzQtNy0xLTEtNzYwNDY_ca84fff2-57a3-4104-a2a4-4155aa9655e0"
      unitRef="shares">14000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if106b707e879407f837eee91cc731c8b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzQtMTEtMS0xLTc2MDQ2_349e7438-c4eb-4b6b-adfa-ff3d74160bf0"
      unitRef="usd">179000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzQtMTctMS0xLTc2MDQ2_af62eb2c-d1d2-4bb9-89d0-f3b0f09e90c5"
      unitRef="usd">179000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if106b707e879407f837eee91cc731c8b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzUtMTEtMS0xLTc2MDQ2_3d01d2c9-3cf1-4e3f-81e5-42a35925f41b"
      unitRef="usd">7000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzUtMTctMS0xLTc2MDQ2_e8f51671-1ca4-47d6-a1b7-0fbbed39d64b"
      unitRef="usd">7000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if106b707e879407f837eee91cc731c8b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzgtMTEtMS0xLTc2MDQ2_31431d9f-0239-4963-aaea-70124c317ca9"
      unitRef="usd">93000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzgtMTctMS0xLTc2MDQ2_4fa09f49-d22c-4129-a349-59a02c46ac3e"
      unitRef="usd">93000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ieedc85414f004154b55307b19cb69ea1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzktMTMtMS0xLTc2MDQ2_8cde6772-dbbb-4aa1-b285-c7b6c99848b5"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzktMTctMS0xLTc2MDQ2_bc6a7274-6c60-489d-a22e-61919a52e951"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i64213a08436349b8bd211c3b69b414ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzEwLTE1LTEtMS03NjA0Ng_cf8b4bd6-3047-40b6-830f-3df9e0860c2f"
      unitRef="usd">-747000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzEwLTE3LTEtMS03NjA0Ng_8f752d39-aee9-4de3-a0f7-34a24587a138"
      unitRef="usd">-747000000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i0408d062671a45018b3df546433745af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTctMS0xLTc2MDQ2_39b870de-ad86-4e76-9586-fca75ffe0e79"
      unitRef="shares">399000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0408d062671a45018b3df546433745af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTktMS0xLTc2MDQ2_78ab966f-bf25-42e2-9108-6710324d3a4c"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c70cb037668465995ce9826bb1978ee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTExLTEtMS03NjA0Ng_ef9a13a9-0e38-4100-832c-0ee52d59eec5"
      unitRef="usd">4802000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i98451536c6d841db91683a82eeb89b2e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTEzLTEtMS03NjA0Ng_05748f04-198b-4832-a57a-36026effccf6"
      unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifcf6e685c17f4ba283b01bf8845d7cb9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTE1LTEtMS03NjA0Ng_fd76387a-e625-43e5-8656-fdb9126ab8e0"
      unitRef="usd">-2244000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTo0N2JkMDI1NDhkM2Y0ZTZiOGRiNjM0NDM5MWMwY2E3ZC90YWJsZXJhbmdlOjQ3YmQwMjU0OGQzZjRlNmI4ZGI2MzQ0MzkxYzBjYTdkXzExLTE3LTEtMS03NjA0Ng_ce73610e-0769-4aa2-9a90-71dd9fdac250"
      unitRef="usd">2561000000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i0408d062671a45018b3df546433745af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItNy0xLTEtNzYwNDY_af8a67f3-55b9-460c-b95b-cc621dce9405"
      unitRef="shares">399000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0408d062671a45018b3df546433745af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItOS0xLTEtNzYwNDY_9854e708-866d-41e9-8af9-5d0b188719f8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4c70cb037668465995ce9826bb1978ee_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItMTEtMS0xLTc2MDQ2_7a189df7-f432-4f20-b0ef-0dc850a3f720"
      unitRef="usd">4802000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i98451536c6d841db91683a82eeb89b2e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItMTMtMS0xLTc2MDQ2_cd9ae8c9-fb99-4441-a560-61a4b7025e76"
      unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifcf6e685c17f4ba283b01bf8845d7cb9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItMTUtMS0xLTc2MDQ2_c8a3d690-8d73-4be8-9e35-8c589f52bf40"
      unitRef="usd">-2244000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzItMTctMS0xLTc2MDQ2_7e5d9f52-aefc-47c5-9c3c-909a5ae46a08"
      unitRef="usd">2561000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i370d0735ddb64285bf22708bccdfe17a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzUtNy0xLTEtNzYwNDY_1ccd19fe-e5b3-41de-88f2-57e03f8f1cb1"
      unitRef="shares">7000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4d72e1d1f6454024a0fc769ec600c4bf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzUtMTEtMS0xLTc2MDQ2_63b72a4b-2e71-4782-84f3-038124fee3f9"
      unitRef="usd">112000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzUtMTctMS0xLTc2MDQ2_01096fcb-f613-40db-ad23-bcbe209c6983"
      unitRef="usd">112000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4d72e1d1f6454024a0fc769ec600c4bf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzYtMTEtMS0xLTc2MDQ2_3365d743-44d6-42a5-b3fd-b9ac79be8e6c"
      unitRef="usd">12000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzYtMTctMS0xLTc2MDQ2_473760c4-cea3-441d-9983-f71e504be4e5"
      unitRef="usd">12000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4d72e1d1f6454024a0fc769ec600c4bf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzctMTEtMS0xLTc2MDQ2_a5ca91be-87c9-41f8-a458-5470e589feca"
      unitRef="usd">142000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzctMTctMS0xLTc2MDQ2_ebdd90ec-2b46-4084-a1d9-dd3a7389c12a"
      unitRef="usd">142000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibb0e392c689f48b180f2315c3d508b62_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzgtMTMtMS0xLTc2MDQ2_6d4f7113-675a-4022-8889-2ccad467ff48"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzgtMTctMS0xLTc2MDQ2_1f6a0996-6dd2-4d84-a137-c6a7ffcd1a20"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i370d0735ddb64285bf22708bccdfe17a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTctMS0xLTEwNDA2MA_42ab97a5-59ce-4c8e-bc1a-8f4c8bfef4a1"
      unitRef="shares">3000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i4d72e1d1f6454024a0fc769ec600c4bf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTExLTEtMS0xMDQwNjA_38caa161-1308-4c76-80e5-f7a7fa6dbf9e"
      unitRef="usd">857000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTE3LTEtMS0xMDQwNjA_dc9aea59-d2fb-4614-be7a-515bc873d7db"
      unitRef="usd">857000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="ib67c37cfaa8142fcac96ee487bf8fa91_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzktMTUtMS0xLTc2MDQ2_1258adfd-ef7d-4ee5-b3df-c381900b6961"
      unitRef="usd">12202000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzktMTctMS0xLTc2MDQ2_aa0de545-95f1-4ce4-b767-4e57e827deae"
      unitRef="usd">12202000000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i2e92a0d0e8fd40c489ab3417b2dc0a47_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTctMS0xLTc2MDQ2_d6089cb3-afaa-4892-8485-00f01d5b3f60"
      unitRef="shares">403000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2e92a0d0e8fd40c489ab3417b2dc0a47_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTktMS0xLTc2MDQ2_0f021f3a-3663-43a2-929e-7a983420d120"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40ff2eb538054269a37b8f1364796f48_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTExLTEtMS03NjA0Ng_ca141dd1-2d9d-491c-b414-4bf8bc4bbd27"
      unitRef="usd">4211000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1036f115c63f4c049064c7ba1929828a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTEzLTEtMS03NjA0Ng_7ba73044-2926-4ad8-8e7f-78750fdf9c65"
      unitRef="usd">-24000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f7e4e88f50c4deb96b15cbfbbd78d6d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTE1LTEtMS03NjA0Ng_9d4bb092-69d8-41ca-ba6c-c7623d579f26"
      unitRef="usd">9958000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTUvZnJhZzo2NmExMTZlM2RmMzQ0MmVmYmU5MGFmNTUyMjYwNDhlYy90YWJsZTplMTI3MzkxZmQ0Y2E0MzlhYmIyZDFmYWM4MmVkN2UwMy90YWJsZXJhbmdlOmUxMjczOTFmZDRjYTQzOWFiYjJkMWZhYzgyZWQ3ZTAzXzEwLTE3LTEtMS03NjA0Ng_105cdf94-ec4e-416a-9550-14981b9f86df"
      unitRef="usd">14145000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMtMS0xLTEtNzYwNDY_4edbeb71-6905-4681-baf2-8a0024efa98f"
      unitRef="usd">12202000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMtMy0xLTEtNzYwNDY_8d38f6c1-7285-4cc4-9eba-54c574b4107c"
      unitRef="usd">-747000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMtNS0xLTEtNzYwNDY_d7ba1e24-c6e1-4335-a9b6-7121eae81b50"
      unitRef="usd">-514000000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzUtMS0xLTEtNzYwNDY_ffd86527-cf26-4b3d-8764-abd377871505"
      unitRef="usd">142000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzUtMy0xLTEtNzYwNDY_e0e14849-fd37-443d-84b0-13fe298b02ae"
      unitRef="usd">93000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzUtNS0xLTEtNzYwNDY_0e3d019b-2f4e-4292-b80b-cc076b07d5dd"
      unitRef="usd">81000000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzYtMS0xLTEtNzYwNDY_221843dd-3527-4848-9f50-b07ce165f338"
      unitRef="usd">232000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzYtMy0xLTEtNzYwNDY_8111b2b2-d5e8-4306-8ba3-ddbdebd89fe4"
      unitRef="usd">31000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzYtNS0xLTEtNzYwNDY_e65ece00-15ca-47e5-a853-4234cdd93369"
      unitRef="usd">31000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzctMS0xLTEtNzYwNDY_48e43685-1d7a-46f9-b4b3-7ff433d44754"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases>
    <us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzctMy0xLTEtNzYwNDY_a1b725d6-011e-4a86-8ffd-5c225b3f8365"
      unitRef="usd">-62000000</us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases>
    <us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzctNS0xLTEtNzYwNDY_50fa7f66-9349-48fd-b81e-6e7e9ab12be4"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzgtMS0xLTEtNzYwNDY_eb0cec40-bb1d-469f-ae82-aa9a28a1247e"
      unitRef="usd">-54000000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzgtMy0xLTEtNzYwNDY_cb636050-0366-4734-a365-c2a64f3b957f"
      unitRef="usd">-10000000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzgtNS0xLTEtNzYwNDY_070cbac2-5786-4a11-9ca1-14e72f281450"
      unitRef="usd">4000000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <mrna:DeferredIncomeTaxExpenseBenefitNet
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEwLTEtMS0xLTc3NDY2_f834f6d4-983e-4085-b376-9ecec1b9b27c"
      unitRef="usd">-318000000</mrna:DeferredIncomeTaxExpenseBenefitNet>
    <mrna:DeferredIncomeTaxExpenseBenefitNet
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEwLTMtMS0xLTc3NDY2_a71c67f7-32ec-492d-973e-ecdf0d3e4559"
      unitRef="usd">0</mrna:DeferredIncomeTaxExpenseBenefitNet>
    <mrna:DeferredIncomeTaxExpenseBenefitNet
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEwLTUtMS0xLTc3NDY5_2150e4bc-cf50-4c43-b224-be13acb19e1c"
      unitRef="usd">0</mrna:DeferredIncomeTaxExpenseBenefitNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzExLTEtMS0xLTc2MDQ2_4de028ac-2f85-4505-b6c6-e5eac76dce28"
      unitRef="usd">1784000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzExLTMtMS0xLTc2MDQ2_807a9385-e0bf-4c6a-95a9-1bfa0bfcdd0d"
      unitRef="usd">1385000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzExLTUtMS0xLTc2MDQ2_091bc41a-737e-4b0a-98f3-2ac43fc23b8a"
      unitRef="usd">-7000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEzLTEtMS0xLTg2Nzk5_f115ac16-29ca-4071-994f-ad60761ae7dc"
      unitRef="usd">489000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEzLTMtMS0xLTg2Nzk5_a8adc8c7-bd03-4443-9db7-e757f4b9308f"
      unitRef="usd">241000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEzLTUtMS0xLTg2Nzk5_6c1089f2-21fd-4533-868a-ea3d8c1cc9d6"
      unitRef="usd">-10000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEyLTEtMS0xLTc2MDQ2_f228c700-c3a8-40b8-90a9-23ea7c04418f"
      unitRef="usd">1394000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEyLTMtMS0xLTc2MDQ2_721a7fc4-b5b7-453f-b9b0-ca404ba74486"
      unitRef="usd">47000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzEyLTUtMS0xLTc2MDQ2_1ca38784-ece9-4386-ba3c-9f5d97307656"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <mrna:IncreaseDecreaseInOperatingLeasesRightOfUseAssets
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE0LTEtMS0xLTc2MDQ2_38575a54-83f8-438e-a02a-66151c9d35fc"
      unitRef="usd">58000000</mrna:IncreaseDecreaseInOperatingLeasesRightOfUseAssets>
    <mrna:IncreaseDecreaseInOperatingLeasesRightOfUseAssets
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE0LTMtMS0xLTc2MDQ2_22916be9-0a98-49fa-8e14-3ccb476cf723"
      unitRef="usd">11000000</mrna:IncreaseDecreaseInOperatingLeasesRightOfUseAssets>
    <mrna:IncreaseDecreaseInOperatingLeasesRightOfUseAssets
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE0LTUtMS0xLTc2MDQ2_615d4ee0-bc4f-4fef-aae3-e2c73a8a42d3"
      unitRef="usd">6000000</mrna:IncreaseDecreaseInOperatingLeasesRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE1LTEtMS0xLTc2MDQ2_0c743bb7-3d5f-4997-8140-26247b0facdb"
      unitRef="usd">204000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE1LTMtMS0xLTc2MDQ2_b5f8b8b8-14bd-4beb-8661-af9ad906066b"
      unitRef="usd">12000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE1LTUtMS0xLTc2MDQ2_b477db45-4e65-4e78-b821-bc61bdc50d9f"
      unitRef="usd">-24000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE2LTEtMS0xLTc2MDQ2_e23eb83b-eba0-4816-acfc-68481c0e3ae4"
      unitRef="usd">989000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE2LTMtMS0xLTc2MDQ2_77b5fcf0-8f87-45d5-ad09-cc00409c8fb0"
      unitRef="usd">388000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE2LTUtMS0xLTc2MDQ2_af69d948-9c9b-439d-b268-d208e06662dc"
      unitRef="usd">-3000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE3LTEtMS0xLTc2MDQ2_0253df2a-3a7d-461f-8b60-23c43362d421"
      unitRef="usd">2824000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE3LTMtMS0xLTc2MDQ2_3f599192-3b0a-4b60-9ee0-227d496bc305"
      unitRef="usd">3842000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE3LTUtMS0xLTc2MDQ2_371f30ce-023a-4ef7-bc29-b208c2b321b4"
      unitRef="usd">-44000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTEtMS0xLTc3NTMx_d5970cc1-94a3-4bd6-ac0f-2e27028b851d"
      unitRef="usd">876000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTMtMS0xLTc3NTMx_a90b68f3-4daa-4add-bf2a-7efc32ded8be"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTUtMS0xLTc3NTU1_26b918f6-1320-4538-b375-0a8800c2ca35"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTEtMS0xLTc2MDQ2_eac44879-3b5e-4fe4-a174-191b3602a6f3"
      unitRef="usd">17000000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTMtMS0xLTc2MDQ2_071977e6-48e3-4e61-9ffa-49f7e75540ae"
      unitRef="usd">12000000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzE5LTUtMS0xLTc2MDQ2_90d65cbe-ff2a-4473-8721-f378b46b100c"
      unitRef="usd">13000000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIwLTEtMS0xLTc2MDQ2_ee1edca5-7986-4bee-9c88-96efac5fb652"
      unitRef="usd">123000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIwLTMtMS0xLTc2MDQ2_17bffe36-5f42-412b-9ee5-9fc94410d92e"
      unitRef="usd">8000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIwLTUtMS0xLTc2MDQ2_430a23e2-483e-4ec7-aced-25071f327d6d"
      unitRef="usd">-6000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIxLTEtMS0xLTc2MDQ2_8b0bff5a-5495-47bc-a103-9d5f3cbbb4cf"
      unitRef="usd">13620000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIxLTMtMS0xLTc2MDQ2_65b9b312-73c4-4981-8347-52f297f56772"
      unitRef="usd">2027000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIxLTUtMS0xLTc2MDQ2_4469b32e-7f3d-4e08-a464-46bd6310e9b4"
      unitRef="usd">-459000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIzLTEtMS0xLTc2MDQ2_f02ecfbc-4bcf-4726-815a-493d937404f4"
      unitRef="usd">12652000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIzLTMtMS0xLTc2MDQ2_bc371ca9-f167-4c25-bff1-5ad4ee9ba9aa"
      unitRef="usd">2956000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzIzLTUtMS0xLTc2MDQ2_72f730d6-dfdc-45eb-ba84-27a3406be13a"
      unitRef="usd">1145000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI0LTEtMS0xLTc2MDQ2_46ce056f-8f42-45e8-bb87-5ddce961050d"
      unitRef="usd">1338000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI0LTMtMS0xLTc2MDQ2_e9550e2f-699c-48f4-b943-08a794d66c60"
      unitRef="usd">1137000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI0LTUtMS0xLTc2MDQ2_e65fbddd-9ecf-4678-9444-03b20046839a"
      unitRef="usd">993000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI1LTEtMS0xLTc2MDQ2_2cb7bdb4-83fb-4828-a488-c3d241a0b14e"
      unitRef="usd">3105000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI1LTMtMS0xLTc2MDQ2_704467e2-825b-4d10-994a-827b817ad377"
      unitRef="usd">215000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI1LTUtMS0xLTc2MDQ2_2d14e849-e596-43bc-aeb4-c7d9929765ac"
      unitRef="usd">169000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI2LTEtMS0xLTc2MDQ2_de15242d-2787-46bc-a1e4-34cd6757002c"
      unitRef="usd">284000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI2LTMtMS0xLTc2MDQ2_5653aa37-a854-4b6f-a962-7812cc9e45b0"
      unitRef="usd">68000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI2LTUtMS0xLTc2MDQ2_1e6c3a54-e8b2-4bab-a17a-c39fb76802ca"
      unitRef="usd">32000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI4LTEtMS0xLTEwNzQ5Mg_881e3aa4-2792-491d-8d4e-e666409d500c"
      unitRef="usd">30000000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI4LTMtMS0xLTEwNzQ5Mg_0653f1fc-9571-41fe-b4fc-6d17390970a2"
      unitRef="usd">0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI4LTUtMS0xLTEwNzUwMA_142f069a-fd3e-4183-afab-481b9ba5f17e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI3LTEtMS0xLTc2MDQ2_d9c276b7-65fc-43cd-a4e4-e227d466085e"
      unitRef="usd">-8523000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI3LTMtMS0xLTc2MDQ2_2f176ee1-1a21-4dbf-a6fa-926d5b9eb0ea"
      unitRef="usd">-1672000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzI3LTUtMS0xLTc2MDQ2_cdae187d-8f8a-45f7-a825-32c49370c150"
      unitRef="usd">-15000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMwLTEtMS0xLTc2MDQ2_9c24c570-be59-4334-b125-8c30f96069a4"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMwLTMtMS0xLTc2MDQ2_02388de0-3a31-443a-896c-8cb35ac49556"
      unitRef="usd">1853000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMwLTUtMS0xLTc2MDQ2_12969763-b5b1-424e-8060-3ecb88a00982"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMyLTEtMS0xLTc2MDQ2_bf66b8e1-c2a1-492d-96f4-b2871069c25b"
      unitRef="usd">124000000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMyLTMtMS0xLTc2MDQ2_0cbb43f4-8f9c-48f6-be08-f94911308287"
      unitRef="usd">186000000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzMyLTUtMS0xLTc2MDQ2_17e7179c-e44a-430f-a7a4-41264e12cc9a"
      unitRef="usd">51000000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM1LTEtMS0xLTk0NTAw_018b0de4-3820-4efa-a694-d0bc23c2a081"
      unitRef="usd">857000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM1LTMtMS0xLTk0NTAw_7f7f26d2-ff6f-4488-bf99-fc7a05a6df88"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM1LTUtMS0xLTk0NTA2_2fcd0907-1e58-42f4-a8fd-36b9d618ab55"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <mrna:ChargesToFinancingLeaseLiabilities
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM0LTEtMS0xLTc2MDQ2_3d279436-1915-4fa6-aa97-967b776896d5"
      unitRef="usd">-140000000</mrna:ChargesToFinancingLeaseLiabilities>
    <mrna:ChargesToFinancingLeaseLiabilities
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM0LTMtMS0xLTc2MDQ2_4816c6dc-7346-4513-ba7e-3d0de53782c6"
      unitRef="usd">-6000000</mrna:ChargesToFinancingLeaseLiabilities>
    <mrna:ChargesToFinancingLeaseLiabilities
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM0LTUtMS0xLTc2MDQ2_ad0f10f3-a320-4675-a979-bbaa2b0aeb08"
      unitRef="usd">1000000</mrna:ChargesToFinancingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM3LTEtMS0xLTc2MDQ2_c38a002d-1688-4759-8e56-aebf08493e39"
      unitRef="usd">-873000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM3LTMtMS0xLTc2MDQ2_36e13b2a-b82d-430a-85da-37b97f4b8202"
      unitRef="usd">2033000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM3LTUtMS0xLTc2MDQ2_75104a5d-b521-405c-a21b-df33d5b34bc3"
      unitRef="usd">52000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM4LTEtMS0xLTc2MDQ2_741b3922-1107-4779-8a8f-c02b972d66fc"
      unitRef="usd">4224000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM4LTMtMS0xLTc2MDQ2_dd2d7953-3d71-4700-a06f-a109ba3baf22"
      unitRef="usd">2388000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM4LTUtMS0xLTc2MDQ2_7b9ad937-85da-47c0-a09e-3cf92a889fb8"
      unitRef="usd">-422000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM5LTEtMS0xLTc2MDQ2_d0325c8e-7040-487c-81b3-928d06fcef68"
      unitRef="usd">2636000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM5LTMtMS0xLTc2MDQ2_01aee8ec-1a2c-47db-b1d0-5f2510e96f34"
      unitRef="usd">248000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3f00be47b1194ea3be883db45fca7c1c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzM5LTUtMS0xLTc2MDQ2_b11efd55-f643-4a8a-b485-acc3c0ae3fcf"
      unitRef="usd">670000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQwLTEtMS0xLTc2MDQ2_5aedec30-e23a-4fa8-ab32-6f3f4223052b"
      unitRef="usd">6860000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQwLTMtMS0xLTc2MDQ2_cc359186-ae78-4553-8d14-81f937c20adb"
      unitRef="usd">2636000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQwLTUtMS0xLTc2MDQ2_8b41d066-6cb4-4a6d-b5fa-5f2b8c6dc320"
      unitRef="usd">248000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQyLTEtMS0xLTc2MDQ2_f49ff72b-a7f4-4865-b7c9-9ce1c2165cba"
      unitRef="usd">480000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQyLTMtMS0xLTc2MDQ2_d7f4db79-772c-434a-b430-beb2ae71fa16"
      unitRef="usd">1000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQyLTUtMS0xLTc2MDQ2_97670988-80b7-4292-98a7-87bf215e1e54"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQzLTEtMS0xLTc2MDQ2_2ebed6be-4047-4a81-a77d-1f0c0e9a7f54"
      unitRef="usd">14000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQzLTMtMS0xLTc2MDQ2_1b3b5096-94b2-4dbc-8821-41a4d26599b3"
      unitRef="usd">9000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQzLTUtMS0xLTc2MDQ2_10824436-e93e-4212-a795-36fb7df087b7"
      unitRef="usd">6000000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQ2LTEtMS0xLTc2MDQ2_667d6efd-4777-4f66-ab10-550fb3767906"
      unitRef="usd">111000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQ2LTMtMS0xLTc2MDQ2_0cfb79fc-74ab-4584-9874-c79a98df9323"
      unitRef="usd">18000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMTgvZnJhZzo3ZTIzOGI4NTBmZTg0NGI1YWIyZGFmMjJhOTVmYzI1MS90YWJsZTo2ZTRjN2ViYTI2NzE0YjNmOTAwM2Q3NDE0NDIwOGM5Zi90YWJsZXJhbmdlOjZlNGM3ZWJhMjY3MTRiM2Y5MDAzZDc0MTQ0MjA4YzlmXzQ2LTUtMS0xLTc2MDQ2_c8ae52fe-d035-4119-a892-8437601efc98"
      unitRef="usd">5000000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjQvZnJhZzo0Nzg0YjNjMzk3YzY0MjMxYTEyMDY3NWMxNWViZDFjYS90ZXh0cmVnaW9uOjQ3ODRiM2MzOTdjNjQyMzFhMTIwNjc1YzE1ZWJkMWNhXzM4Njc_086f22b6-5e56-4205-8370-e1faa8814f5f">Description of Business&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our or the Company) was incorporated in Delaware on July&#160;22, 2016. We are the successor in interest to Moderna LLC, a limited liability company formed under the laws of the State of Delaware in 2013. Our principal executive office is located at 200 Technology Square, Cambridge,&#160;MA. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biotechnology company pioneering messenger RNA (mRNA)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;therapeutics and vaccines to create a new generation of transformative medicines to improve the lives of patients. mRNA medicines are designed to direct the body&#x2019;s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates.&#160;We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases, independently and with our strategic collaborators.&lt;/span&gt;&lt;/div&gt;On December 18, 2020, we received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the emergency use of the Moderna COVID-19 Vaccine (also referred to as mRNA-1273 and marketed under the brand name Spikevax) in individuals 18 years of age or older. We have also received authorization for our COVID-19 vaccine from health agencies in more than 70 countries and from the World Health Organization (WHO). Additional authorizations are currently under review in other countries. In addition, we have received authorization for our COVID-19 vaccine for use in adolescents in the United Kingdom, European Union, Japan, Canada, Switzerland, Taiwan, Saudi Arabia, Australia, and the Philippines, and have pending applications for authorization to administer the vaccine to adolescents with regulatory agencies in the United States and other countries. In January 2022, we received full FDA approval for Spikevax to prevent COVID-19 in individuals 18 years of age and older in the United States. In February 2022, we received approval for the administration of Spikevax to children ages 6-11 in Australia and a positive recommendation from the European Medicines Agency&#x2019;s Committee for Medicinal Products for Human Use for the administration of Spikevax in children ages 6-11 years.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjI2_78b083a3-5507-46ff-bf1c-990cb509bbb1">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Updates (ASU) of the&#160;Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, revenue recognition, research and development expense, leases, fair value of financial instruments, derivative financial instruments, inventory, useful lives of property and equipment, stock-based compensation, income taxes, and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined that our chief executive officer is the chief operating decision maker (CODM). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, we have concluded that we operate as one segment. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2019, we adopted ASC 606&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is primarily generated through product sales. We also generate grant revenue from government-sponsored and private organizations, and collaboration revenue through collaboration arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Sales &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are associated with our COVID-19 vaccine supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), and the African Union. These agreements generally do not include variable consideration, such as discounts, rebates or returns. Under these agreements, we are entitled to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. We recognize revenue from product sales, using the five-step model under ASC 606, based on the fixed price per dose according to the contracts when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We pay distribution fees to certain customers in connection with the sales of our product. We record distribution fees paid to our customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and we can reasonably estimate the fair value of the goods or services received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale. Such distribution fees were immaterial for the year ended December 31, 2021. We did not have any distribution fees for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Grant Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have contracts with Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); the U.S. government&#x2019;s Defense Advanced Research Projects Agency (DARPA); the Bill &amp;amp; Melinda Gates Foundation (Gates Foundation) and other government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into several strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments with an original maturity of 90&#160;days or less from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash is composed of amounts held on deposit related to our lease arrangements. The funds are maintained in money market accounts and are recorded at fair value. We classify our restricted cash as either current or non-current based on the terms of the underlying lease arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in prepaid expenses and other current assets in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report available-for-sale investments at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive (loss) income, a component of stockholders&#x2019; equity. Realized gains and losses are determined using the specific-identification method, and are included in other expense, net in our consolidated statements of operations. We classify our available-for-sale marketable securities as current or non-current based on each instrument&#x2019;s underlying effective maturity date and for which we have the intent and ability to hold the investment for a period of greater than 12 months. Marketable securities with maturities of less than 12&#160;months are classified as current and are included in investments in the consolidated balance sheets. Marketable securities with maturities greater than 12&#160;months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive (loss) income, net of applicable taxes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have accounts receivable amounts due from our product sales and related vaccine supply agreements and our grant agreements. We also have accounts receivable amounts due from strategic collaborators as a result of manufacturing and research and development services provided under collaboration arrangements, or milestones achieved, but not yet paid. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for doubtful accounts, we make judgments about the creditworthiness of our customers based on ongoing credit evaluation and historical experience. There was no allowance for doubtful accounts at December 31, 2021 or 2020. There was no bad debt expense for the years ended December 31, 2021, 2020 or 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable securities, and accounts receivable. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounts receivable are generally unsecured and are from customers in different countries. We generated revenue from product sales to the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), the African Union. grants made by government-sponsored and private organizations, and to a lesser extent, strategic alliances in 2021 and 2020. Historically, we generated revenue primarily from strategic alliances. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage&#160;of&#160;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage&#160;of&#160;&lt;br/&gt;Accounts&#160;Receivable&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;European Commission&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government (excluding BARDA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BARDA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vertex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;* - Represents an amount of less than 10%&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We record all derivatives on our consolidated balance sheets at fair value. The accounting for changes in the fair value of a derivative depends on whether the derivative has been designated and qualifies for hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The gains or losses resulting from changes in the fair value of cash flow hedges are initially recorded as a component of accumulated other comprehensive (loss) income (AOCI) in stockholders&#x2019; equity and subsequently reclassified to product sales in the period during which the hedged transaction affects earnings. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to other expense, net, in our consolidated statements of operations. We may enter into derivative contracts that are intended to economically hedge certain risk, even though hedge accounting does not apply or we elect not to apply hedge accounting. Gains or losses associated with foreign currency derivatives that are not designated as hedging instruments for accounting purposes are recorded within other expense, net, in our consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC&#160;820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cash equivalents and marketable securities are reported at fair value determined using Level&#160;1 and Level&#160;2 inputs (Note&#160;6). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk (Note 7). We do not have any non-financial assets or liabilities that should be recognized or disclosed at fair value on a recurring basis at December 31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintained letters of credit of $12 million as of December 31, 2021 and 2020, related to our lease arrangements, which are secured by money market accounts in accordance with certain of our lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is recorded at the lower of cost or net realizable value, with cost determined using first-in, first-out and average cost methods for different components of inventory. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to an initial regulatory approval for our investigational medicines, we expense costs relating to raw materials and production of inventory as research and development expense in our consolidated statements of operations, in the period incurred. Upon the authorization of distribution and use of our COVID-19 vaccine under an EUA in December 2020, we began to capitalize inventory costs associated with our COVID-19 vaccine, as it was determined that inventory costs incurred subsequent to the EUA had a probable future economic benefit. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property and equipment are described below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.552%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement&lt;br/&gt;or&#160;remaining life of related lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset, financing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress includes direct costs related to the construction of various property and equipment, including leasehold improvements, and is stated at original cost. Construction in progress includes costs incurred under construction contracts including project management services, engineering services, design services and development, construction services and other construction-related fees and services. Such costs are not depreciated until the asset is completed and placed into service. Once the asset is placed into service, these capitalized costs will be allocated to certain property and equipment categories and will be depreciated over the estimated useful life of the underlying assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for maintenance and repairs are charged to expense as incurred. Upon retirement or sale, the cost of the assets disposed of, and the related accumulated depreciation, are removed from the accounts, and any resulting gain or loss is recorded to other expense, net in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our long-lived assets, which consist of property and equipment, to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals. Impairment expenses for the years ended December 31, 2021, 2020 and 2019 were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in profit or loss on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales includes cost of raw materials, production, transportation, freight and indirect overhead costs associated with our product sales during the period and third-party royalties on net sales of our product. Cost of sales also includes adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equipment or facilities that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, should be capitalized and depreciated as tangible assets. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project and that have no alternative future uses and therefore no separate economic values are considered research and development costs and are expensed when incurred. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (Compensation&#x2014;Stock Compensation)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#x201c;more likely than not&#x201d; criterion. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted common stock and stock options that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive (loss) income for the years ended December 31, 2021 and 2020 were as follows (in millions):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&#160;Gain (Loss) on Available-for-Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Unrealized Gains on Derivatives Designated As Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss, balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjE2_8f37b5b6-9073-41a9-b8a8-d19d221f6777">Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Updates (ASU) of the&#160;Financial Accounting Standards Board (FASB).The consolidated financial statements include the Company and its subsidiaries.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjMy_36ebd1e2-f3bd-47b5-845e-802d758fa49e">All intercompany transactions and balances have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjEz_a8941340-0722-47dd-872e-dba6a9d0e7a6">We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, revenue recognition, research and development expense, leases, fair value of financial instruments, derivative financial instruments, inventory, useful lives of property and equipment, stock-based compensation, income taxes, and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjI4_9ee65c08-a4cc-4231-b477-5fb3462a3aad">We have determined that our chief executive officer is the chief operating decision maker (CODM). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, we have concluded that we operate as one segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzIzODU_f731a219-4b94-455a-b4be-b9a0cb386fbe"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjE3_54a416d3-e25a-4e9c-8912-5157c2923239">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2019, we adopted ASC 606&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2019. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. To determine the appropriate amount of revenue to be recognized for arrangements that we determine are within the scope of ASC 606, we perform the following five steps (the five-step model): (i) identify the contract(s) with our customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as each performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is primarily generated through product sales. We also generate grant revenue from government-sponsored and private organizations, and collaboration revenue through collaboration arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Sales &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are associated with our COVID-19 vaccine supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), and the African Union. These agreements generally do not include variable consideration, such as discounts, rebates or returns. Under these agreements, we are entitled to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue. We recognize revenue from product sales, using the five-step model under ASC 606, based on the fixed price per dose according to the contracts when control of the product transfers to the customer and customer acceptance has occurred, unless such acceptance provisions are deemed perfunctory. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We pay distribution fees to certain customers in connection with the sales of our product. We record distribution fees paid to our customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and we can reasonably estimate the fair value of the goods or services received. If both conditions are met, we record the consideration paid to the customer as an operating expense. These costs are typically known at the time of sale, resulting in minimal adjustments subsequent to the period of sale. Such distribution fees were immaterial for the year ended December 31, 2021. We did not have any distribution fees for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Grant Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have contracts with Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); the U.S. government&#x2019;s Defense Advanced Research Projects Agency (DARPA); the Bill &amp;amp; Melinda Gates Foundation (Gates Foundation) and other government-sponsored and private organizations for research and development related activities that provide for payments for reimbursed costs, which may include overhead and general and administrative costs as well as a related profit margin. We recognize revenue from these contracts as we perform services under these arrangements when the funding is committed. Associated expenses are recognized when incurred as research and development expense. Revenues and related expenses are presented gross in the consolidated statements of operations as we have determined we are the primary obligor under the arrangements relative to the research and development services we perform as lead technical expert.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;We have entered into several strategic collaborations and other similar arrangements with third parties for research and other licenses, development and commercialization of certain products and product candidates. Such arrangements provide for various types of payments to us, including upfront fees, funding of research and development services and preclinical and clinical material, technical, development, regulatory, and commercial milestone payments, licensing fees, option exercise fees, and royalty and earnout payments on product sales. Such payments are often not commensurate with the timing of revenue recognition and therefore result in deferral of revenue recognition. We recognize revenue based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good or service to the customer.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjI5_e576ca2e-ef0d-48b6-b25f-b5f5f9189586">We consider all highly liquid investments with an original maturity of 90&#160;days or less from the date of purchase to be cash equivalents.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTg3_22971df0-43a9-41df-8896-764f0289767c">Restricted cash is composed of amounts held on deposit related to our lease arrangements. The funds are maintained in money market accounts and are recorded at fair value. We classify our restricted cash as either current or non-current based on the terms of the underlying lease arrangement.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTk4_f89f1b54-d31a-4a1b-9110-8bcde5a2ab49">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in prepaid expenses and other current assets in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTk4_faab2400-c73b-4764-9fd9-bcb2f1a2653b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash, non-current &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in prepaid expenses and other current assets in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzItMi0xLTEtNzYwNDY_2d40d758-cfa3-4fbc-8a95-5e9988577f37"
      unitRef="usd">6848000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzItNC0xLTEtNzYwNDY_e1eb4a02-c92f-4766-a16c-04b1d3078e47"
      unitRef="usd">2624000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzItNi0xLTEtMTE0NDI1_94ef800c-34d3-46f9-adbc-74eab258d030"
      unitRef="usd">236000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzMtMi0xLTEtNzYwNDY_054c0b8f-46c9-4330-8e7f-05766374c321"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzMtNC0xLTEtNzYwNDY_7241380e-5ad6-4cd9-bbe6-bd2073ed141f"
      unitRef="usd">1000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzMtNi0xLTEtMTE0NDI1_18c26ddf-aa4c-4ab9-a071-ada455b0e074"
      unitRef="usd">1000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzQtMi0xLTEtNzYwNDY_304a6b29-0216-40c1-8313-aa22a495541b"
      unitRef="usd">12000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzQtNC0xLTEtNzYwNDY_a6e88462-ced1-485c-81cb-043f56126082"
      unitRef="usd">11000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzQtNi0xLTEtMTE0NDI1_922de38d-7d06-4e05-b62a-caddf0d2bc4a"
      unitRef="usd">11000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzUtMi0xLTEtNzYwNDY_7e1654de-7cb1-4c47-998b-51c05ba5d09d"
      unitRef="usd">6860000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzUtNC0xLTEtNzYwNDY_0bd09e85-cb14-49db-a737-8853c93395ae"
      unitRef="usd">2636000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTozZTcyM2MzN2UyMDA0ZGRlYjI3Yzk5Y2IzYjFjMzIzNC90YWJsZXJhbmdlOjNlNzIzYzM3ZTIwMDRkZGViMjdjOTljYjNiMWMzMjM0XzUtNi0xLTEtMTE0NDI1_03af204a-baeb-4945-96dd-8d728fb19f39"
      unitRef="usd">248000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjMz_ac2964d0-9fce-4b2d-beab-125569c979d0">We invest our excess cash balances in marketable debt securities. We classify our investments in marketable debt securities as available-for-sale. We report available-for-sale investments at fair value at each balance sheet date, and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive (loss) income, a component of stockholders&#x2019; equity. Realized gains and losses are determined using the specific-identification method, and are included in other expense, net in our consolidated statements of operations. We classify our available-for-sale marketable securities as current or non-current based on each instrument&#x2019;s underlying effective maturity date and for which we have the intent and ability to hold the investment for a period of greater than 12 months. Marketable securities with maturities of less than 12&#160;months are classified as current and are included in investments in the consolidated balance sheets. Marketable securities with maturities greater than 12&#160;months for which we have the intent and ability to hold the investment for greater than 12 months are classified as non-current and are included in investments, non-current in the consolidated balance sheets.We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. Any impairment that is not credit- related is recognized in other comprehensive (loss) income, net of applicable taxes.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjM3_9691196b-6a85-449b-b715-647182f9f5cb">We have accounts receivable amounts due from our product sales and related vaccine supply agreements and our grant agreements. We also have accounts receivable amounts due from strategic collaborators as a result of manufacturing and research and development services provided under collaboration arrangements, or milestones achieved, but not yet paid. Amounts payable to us are recorded as accounts receivable when our right to consideration is unconditional. To estimate the allowance for doubtful accounts, we make judgments about the creditworthiness of our customers based on ongoing credit evaluation and historical experience.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzE2Njk3_22c13ad3-9287-425f-bb31-a7e52370b78b"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzE2Njk3_c30bc62a-2861-407d-be58-0a0462c78394"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzE2NzU3_18d862e8-f208-46af-ab66-38bb6bc6db71"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzE2NzU3_5b294251-72e6-4c70-b895-e3ee73abdf8f"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzE2NzU3_e5b835f1-d610-4821-bd7d-2b7955347b70"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjMw_4dd4cd2f-bf4c-4716-8ccc-0114d633a793">Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable securities, and accounts receivable. Our investment portfolio comprises money market funds and marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:MajorCustomersPolicyPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTkz_15bb8d2c-285c-4382-8d49-68e36532309d">Our accounts receivable are generally unsecured and are from customers in different countries. We generated revenue from product sales to the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), the African Union. grants made by government-sponsored and private organizations, and to a lesser extent, strategic alliances in 2021 and 2020. Historically, we generated revenue primarily from strategic alliances.</us-gaap:MajorCustomersPolicyPolicyTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjM4_1a4c063f-2ee2-4c0b-b803-4ffd8c814a2c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant portion of our revenue to date has been generated from the following entities that accounted for more than 10% of total revenue and accounts receivable for the periods presented:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.153%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage&#160;of&#160;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Percentage&#160;of&#160;&lt;br/&gt;Accounts&#160;Receivable&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;European Commission&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Government (excluding BARDA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BARDA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vertex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;* - Represents an amount of less than 10%&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0271cb85b4e64ced8426ff3ab6956a89_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzItMS0xLTEtMTE4MDc1_b480f893-541c-4629-b51f-cc00094524d3"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i190252c1c7b34ddb97008b71eb4c1da9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzItNy0xLTEtMTE4MDc1_5aeb81a1-b2cb-40d1-97ed-da66916064f6"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i32d168477d7e4f278aa0d019fbd3fd1e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzItOS0xLTEtMTE4MDc1_15df5e9c-01a4-440c-8ab4-af51b4dd1946"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib7764e7b08664708b5f88fa9d5a5452d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzMtMS0xLTEtMTE4MDg1_07236b8f-67a4-43f8-8e98-edd06ac6bdd3"
      unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i70772d46e8714f2c92cd4f05b0dae511_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzMtMy0xLTEtMTE4MDg1_e65705af-87c8-46b5-9806-ae20d77d6f8f"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia2d8d4f2bcb249ba98ac3836f5f2f91a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzQtMy0xLTEtMTE4MTEy_2dd8c819-da4b-43ec-8f97-bbe479ecb264"
      unitRef="number">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9755a9f76aff4d95bd5013ac656d28eb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzQtNS0xLTEtMTE4MTEy_fc93e46b-80da-4a7c-b839-b644dd887aa0"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if8df385fcd90456f89a7177c79f6f8cb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzQtNy0xLTEtMTE4MTEy_10b88ca8-e7be-4679-a2a2-d78a5ae934ad"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2df5a00c226e425faf323112dc3cd5c6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzQtOS0xLTEtMTE4MTEy_f3afd01c-08fb-48f1-b351-7be3b34f839f"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2b3cd2c6a9d148c18fec7f61ae871222_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzItNS0xLTEtNzYwNDY_80cbcf16-1839-4f21-853f-4a1c341c1385"
      unitRef="number">0.61</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i386857641ae64cb5840ff87d45bd2b39_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzQtNS0xLTEtNzYwNDY_c58f5b61-226a-477f-8ece-6380b29292f2"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5a5edb63270a4e4587e56c35991f8f28_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzgtOS0xLTEtODU5NDg_b898bef0-357c-4088-bf47-98da97fb6c5f"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9e47c41e4cb14080aa2c9a58ea80fb94_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTplODA2YTc4NDc0Nzc0M2RkYjBhOWE3MTEzNzM0YzYyOS90YWJsZXJhbmdlOmU4MDZhNzg0NzQ3NzQzZGRiMGE5YTcxMTM3MzRjNjI5XzktOS0xLTEtODU5NDg_f09a26b6-5f77-4d49-90f4-a4059898d50d"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTgy_e1830786-6476-4879-9ca7-9198f37ce88c">We record all derivatives on our consolidated balance sheets at fair value. The accounting for changes in the fair value of a derivative depends on whether the derivative has been designated and qualifies for hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The gains or losses resulting from changes in the fair value of cash flow hedges are initially recorded as a component of accumulated other comprehensive (loss) income (AOCI) in stockholders&#x2019; equity and subsequently reclassified to product sales in the period during which the hedged transaction affects earnings. In the event the underlying forecasted transaction does not occur, or it becomes probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to other expense, net, in our consolidated statements of operations. We may enter into derivative contracts that are intended to economically hedge certain risk, even though hedge accounting does not apply or we elect not to apply hedge accounting. Gains or losses associated with foreign currency derivatives that are not designated as hedging instruments for accounting purposes are recorded within other expense, net, in our consolidated statements of operations.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTk1_e83f0993-cfc2-4d6e-824a-6e7378d9aed1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. ASC&#160;820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from our independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e.,&#160;supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cash equivalents and marketable securities are reported at fair value determined using Level&#160;1 and Level&#160;2 inputs (Note&#160;6). The fair value of our foreign currency forward contracts is calculated using Level 2 inputs, which include currency spot rates, forward rates, interest rate curve and credit or non-performance risk (Note 7). We do not have any non-financial assets or liabilities that should be recognized or disclosed at fair value on a recurring basis at December 31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintained letters of credit of $12 million as of December 31, 2021 and 2020, related to our lease arrangements, which are secured by money market accounts in accordance with certain of our lease agreements. The amounts are recorded at fair value using Level 1 inputs and included as restricted cash in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LinesOfCreditFairValueDisclosure
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzMyOTg1MzQ5ODQ4MDY_1fab72b0-a445-4c7c-8e4c-e2070d3da970"
      unitRef="usd">12000000</us-gaap:LinesOfCreditFairValueDisclosure>
    <us-gaap:LinesOfCreditFairValueDisclosure
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzMyOTg1MzQ5ODQ4MDY_3886e35a-9b96-405a-8e02-0620783d8dc3"
      unitRef="usd">12000000</us-gaap:LinesOfCreditFairValueDisclosure>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjE4_1e741f92-6659-4fc6-9efe-92d5cdc3cd99">Inventory is recorded at the lower of cost or net realizable value, with cost determined using first-in, first-out and average cost methods for different components of inventory. We periodically review the composition of inventory in order to identify excess, obsolete, slow-moving or otherwise unsaleable items. If unsaleable items are observed and there are no alternate uses for the inventory, we will record a write-down to net realizable value in the period that the decline in value is first recognized through a charge to cost of sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.Prior to an initial regulatory approval for our investigational medicines, we expense costs relating to raw materials and production of inventory as research and development expense in our consolidated statements of operations, in the period incurred. Upon the authorization of distribution and use of our COVID-19 vaccine under an EUA in December 2020, we began to capitalize inventory costs associated with our COVID-19 vaccine, as it was determined that inventory costs incurred subsequent to the EUA had a probable future economic benefit.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjIy_e62387fa-d0d8-4731-865e-c0ac168a325f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property and equipment are described below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.552%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement&lt;br/&gt;or&#160;remaining life of related lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset, financing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress includes direct costs related to the construction of various property and equipment, including leasehold improvements, and is stated at original cost. Construction in progress includes costs incurred under construction contracts including project management services, engineering services, design services and development, construction services and other construction-related fees and services. Such costs are not depreciated until the asset is completed and placed into service. Once the asset is placed into service, these capitalized costs will be allocated to certain property and equipment categories and will be depreciated over the estimated useful life of the underlying assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for maintenance and repairs are charged to expense as incurred. Upon retirement or sale, the cost of the assets disposed of, and the related accumulated depreciation, are removed from the accounts, and any resulting gain or loss is recorded to other expense, net in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjEx_139df5fc-6bd3-404c-82af-5c2c43b101ce">The estimated useful lives of property and equipment are described below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.552%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;estimated&#160;useful&#160;life&#160;of&#160;improvement&lt;br/&gt;or&#160;remaining life of related lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset, financing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset, financing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idfc4ca4b110a4b4ca9bc75f54db9aac8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTpmZTYzMzI0YWRjOGE0OGI4OWNkNTAwZjcyNmNkNDBiNy90YWJsZXJhbmdlOmZlNjMzMjRhZGM4YTQ4Yjg5Y2Q1MDBmNzI2Y2Q0MGI3XzEtMi0xLTEtNzYwNDY_68b5034f-1568-4ae3-a047-ae52879baa94">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2d684fd2732b4d3aaa2c0b4c1f42cf46_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTpmZTYzMzI0YWRjOGE0OGI4OWNkNTAwZjcyNmNkNDBiNy90YWJsZXJhbmdlOmZlNjMzMjRhZGM4YTQ4Yjg5Y2Q1MDBmNzI2Y2Q0MGI3XzMtMi0xLTEtNzYwNDY_de19662b-0bb1-425d-90bd-3a7b4d75549c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6d0432cf13b142938df0d7a6e783162d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTpmZTYzMzI0YWRjOGE0OGI4OWNkNTAwZjcyNmNkNDBiNy90YWJsZXJhbmdlOmZlNjMzMjRhZGM4YTQ4Yjg5Y2Q1MDBmNzI2Y2Q0MGI3XzQtMi0xLTEtNzYwNDY_0702002b-104d-4d94-81f9-185ccf9ca7a3">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7d57ca59f3dd4b58a6220848d155086a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTpmZTYzMzI0YWRjOGE0OGI4OWNkNTAwZjcyNmNkNDBiNy90YWJsZXJhbmdlOmZlNjMzMjRhZGM4YTQ4Yjg5Y2Q1MDBmNzI2Y2Q0MGI3XzUtMi0xLTEtNzYwNDY_48436317-27b2-45b6-95a2-9520e872d0ab">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjE1_bd44c2da-ff0d-4ed3-9d5d-66737f11457b">We evaluate our long-lived assets, which consist of property and equipment, to determine if facts and circumstances indicate that the carrying amount of assets may not be recoverable. If such facts and circumstances exist, we assess the recoverability of the long-lived assets by comparing the projected future undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If such review indicates that such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their estimated fair values based on the expected discounted future cash flows attributable to the assets or based on appraisals.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzkzNDU4NDg5MDg3MTc_553165d2-56bf-427e-9de1-40934517ebe7"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzkzNDU4NDg5MDg3MTc_b2ec7c58-5ccf-4055-b6d6-b6d4cd839976"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzkzNDU4NDg5MDg3MTc_bce8c4e3-f0ea-4441-b57b-ec25e7802ff4"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTgw_c5b973ee-c2ce-4bc2-be2d-87ab04eead56">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases are classified at their commencement date, which is defined as the date on which the lessor makes the underlying asset available for use by the lessee, as either operating or finance leases based on the economic substance of the agreement. We recognize lease right-of-use assets and related liabilities in our consolidated balance sheets for both operating and finance leases. Lease liabilities are measured at the lease commencement date as the present value of the future lease payments using the interest rate implicit in the lease. If the rate implicit is not readily determinable, we will utilize our incremental borrowing rate as of the lease commencement date. Lease right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments less lease incentives. The lease term is the non-cancelable period of the lease and includes options to extend or terminate the lease when it is reasonably certain that an option will be exercised. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize operating lease cost in operating expenses in our consolidated statements of operations, inclusive of rent escalation provisions and rent holidays, on a straight-line basis over the respective lease term. For our finance leases, we recognize depreciation expense associated with the leased asset acquired and recognize interest expense related to the portion of the financing in our consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not separate non-lease components from lease components for all classes of underlying assets. We do not recognize right-of-use assets and lease liabilities for leases with a lease term of 12 months or less. Instead, these lease payments are recognized in profit or loss on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTk2_76794aa3-a267-4d18-a73b-4bea93a36939">Cost of sales includes cost of raw materials, production, transportation, freight and indirect overhead costs associated with our product sales during the period and third-party royalties on net sales of our product. Cost of sales also includes adjustments for excess and obsolete inventory to the extent management determines that the cost cannot be recovered based on estimates about future demand.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjA5_6410c558-2d43-482c-8a74-e7529cd29416">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services, and other outside costs. The value of goods and services received from contract research organizations and contract manufacturing organizations in the reporting period are estimated based on the level of services performed, and progress in the period in cases when we have not received an invoice from the supplier. Equipment or facilities that are acquired or constructed for research and development activities and that have alternative future uses, in research and development projects or otherwise, should be capitalized and depreciated as tangible assets. However, the costs of equipment or facilities that are acquired or constructed and intangibles that are purchased from others for a particular research and development project and that have no alternative future uses and therefore no separate economic values are considered research and development costs and are expensed when incurred.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjIw_6f451303-1bee-48d8-a691-63c72d826f3e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issue stock-based awards to employees and non-employees, generally in the form of stock options, restricted stock units (RSUs), and performance stock units (PSUs). We account for our stock-based compensation awards in accordance with ASC 718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; (Compensation&#x2014;Stock Compensation)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Most of our stock-based awards have been made to employees. We measure compensation cost for equity awards at their grant-date fair value and recognize compensation expense over the requisite service period, which is generally the vesting period, on a straight-line basis. The grant date fair value of stock options is estimated using the Black-Scholes option pricing model, which requires management to make assumptions with respect to the fair value of our common stock on the grant date, including the expected term of the award, the expected volatility of our stock, calculated based on a period of time generally commensurate with the expected term of the award, risk-free interest rates and expected dividend yields of our stock. The grant date fair value of RSUs is estimated based on the fair value of our underlying common stock. For performance-based stock awards, we recognize stock-based compensation expense over the requisite service period using the accelerated attribution method when achievement is probable. We classify stock-based compensation expense in our consolidated statements of operations in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified. We made an accounting policy election to recognize forfeitures of stock-based awards as they occur.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjEy_7d27d722-d49b-4755-bcf5-44cbde9dc44a">We account for income taxes based on an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities. These differences are measured using the enacted statutory tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided when the expected realization of deferred tax assets does not meet a &#x201c;more likely than not&#x201d; criterion. We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance could be materially impacted. Changes in these estimates may result in significant increases or decreases to our tax provision in a period in which such estimates are changed, which in turn would affect net income or loss. We recognize tax benefits from uncertain tax positions if we believe the position is more likely than not to be sustained on examination by the taxing authorities based on the technical merits of the position. We make adjustments to these tax reserves when facts and circumstances change, such as the closing of a tax audit or the refinement of an estimate. The provision for income taxes includes the effects of any reserves for uncertain tax positions, as well as the related net interest and penalties.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTkw_eae93fba-8c5b-4062-b951-183e3e98748e">We calculate diluted net earnings (loss) per share attributable to common stockholders by dividing net earnings (loss) by the weighted average number of common shares outstanding after giving consideration to the dilutive effect of restricted common stock and stock options that are outstanding during the period. For periods in which we have generated a net loss, the basic and diluted net loss per share attributable to common stockholders are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MTg5_609227a6-36f3-4ca9-aac5-2f27c1b155c6">Comprehensive income (loss) includes net income (loss) and other comprehensive income (loss) for the period. Other comprehensive income (loss) consists of unrealized gains and losses on our investments and derivatives designated as hedging instruments. Total comprehensive income (loss) for all periods presented has been disclosed in the consolidated statements of comprehensive income (loss).</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjQx_a8a0a2ba-22ec-4978-b621-30485483a241">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of accumulated other comprehensive (loss) income for the years ended December 31, 2021 and 2020 were as follows (in millions):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;br/&gt;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&#160;Gain (Loss) on Available-for-Sale Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Unrealized Gains on Derivatives Designated As Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive income, balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss, balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i3639b96d68064d6db852f369b410789c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzEtMS0xLTEtNzYwNDY_8039b7f8-d426-451b-bc6b-57ab55ec389d"
      unitRef="usd">2000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb718f636d5f48ac8eb2603a3bc1c433_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzEtMy0xLTEtNzgxMjI_0856e11c-a4d9-4757-b1ef-b5e517f8469b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c6b33ad00e44689ad7ca663971c003f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzEtNS0xLTEtNzgxMjI_f7ef6804-a169-4534-a686-aad12845b907"
      unitRef="usd">2000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i005acc5f3f5d4d808e86e28a3fb8cc6f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzItMS0xLTEtNzYwNDY_edb1a179-d232-4f7b-ae9e-ec784e6e2516"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib7f5f39ede7c4ec9b47dbe1215f0665e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzItMy0xLTEtNzgxMjI_3c6ac5f7-f324-4d10-9ed9-de18ca0514f6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ieedc85414f004154b55307b19cb69ea1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzItNS0xLTEtNzgxMjI_b1f6adb6-35e6-4866-a6c5-4b31910e83af"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i1aa7c4e4065b4b87a2e53619bd7fd077_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzMtMS0xLTEtNzYwNDY_d86841db-3d16-48b2-81a6-b469fa81d788"
      unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95dda1d0dbf24991852d96215768bee0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzMtMy0xLTEtNzgxMjI_7336e04f-305b-4ccc-9760-ed165608d99b"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i98451536c6d841db91683a82eeb89b2e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzMtNS0xLTEtNzgxMjI_8bec8d50-72eb-4c81-8b2e-899dab64bd5c"
      unitRef="usd">3000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9b6bf470232b486d96417def1a8e1533_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzQtMS0xLTEtNzYwNDY_86ce7d2f-0560-4e77-b983-24f67f0f6973"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9a99e8b38ce644c6b026bd53416491e6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzQtMy0xLTEtNzgxMzE_e6086a7b-d1cf-448b-a977-d9d52f2bf22b"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ibb0e392c689f48b180f2315c3d508b62_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzQtNS0xLTEtNzgxMzE_246ecc5e-0dd1-40ee-9153-246d989ed82f"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i984222694dbe434b9c06eac34351906d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzUtMS0xLTEtNzYwNDY_ea8d8a74-4d73-4d1d-9f21-b1379310b565"
      unitRef="usd">-40000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i39641a4b815d4d1d9b3bc66b8889165f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzUtMy0xLTEtNzgyNTI_006d2ac7-e232-40b7-9add-18d7d3a54d28"
      unitRef="usd">16000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1036f115c63f4c049064c7ba1929828a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90YWJsZTo0NmU2MTQzYWI3ZWQ0OWM1YTE4MWQ4NWY4NTU1MzZkOC90YWJsZXJhbmdlOjQ2ZTYxNDNhYjdlZDQ5YzVhMTgxZDg1Zjg1NTUzNmQ4XzUtNS0xLTEtNzgyNTI_04ed6c03-f54c-4eec-9af4-9cb1fe8d4165"
      unitRef="usd">-24000000</us-gaap:StockholdersEquity>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMjcvZnJhZzphMzJhYWM4ZTViNmM0YWNkYjZlMmNmMTNlNzQ3NWVjNy90ZXh0cmVnaW9uOmEzMmFhYzhlNWI2YzRhY2RiNmUyY2YxM2U3NDc1ZWM3XzM4MjM2_1dda6069-1e91-4f71-8124-cc3c525d0383">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzEwMjY_cb82882c-d2ac-4303-bab8-5fcd7162057f">Product Sales&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are primarily associated with our COVID-19 vaccine supply agreements with the U.S. Government, other international governments, Gavi (on behalf of the COVAX Facility), and the African Union. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales by customer geographic location was as follows (in millions): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes product sales recognized under the agreement with Gavi as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no product sales in 2019. As of December 31, 2021 and 2020, our COVID-19 vaccine was our only commercial product authorized for use. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, we had deferred revenue of $6.7&#160;billion and $3.8&#160;billion, respectively, related to customer deposits. We expect $6.2&#160;billion of our deferred revenue related to customer deposits as of December 31, 2021 to be realized in less than one year. Timing of product manufacturing, delivery and receipt of marketing approval will determine the period in which revenue is recognized.&lt;/span&gt;&lt;/div&gt;Grant Revenue&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into an agreement with the DARPA for an award of up to $56&#160;million to fund development of a mobile manufacturing prototype leveraging our existing manufacturing technology that is capable of rapidly producing vaccines and therapeutics. As of December 31, 2021, the committed funding, net of revenue earned was $2&#160;million. An additional $42&#160;million of funding will be available if DARPA exercises additional contract options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, we entered into an agreement with BARDA for an award of up to $483&#160;million to accelerate development of mRNA-1273, our vaccine candidate against COVID-19. In July 2020, we amended our agreement with BARDA to provide for an additional commitment of up to $472&#160;million to support late-stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. We further amended the agreement in March 2021 to provide for an additional commitment of $63&#160;million to further support late-stage clinical development, including Phase 2/3 mRNA-1273 pediatric studies. In April 2021, we entered into a further amendment to the BARDA agreement, increasing the amount of potential reimbursements by $236&#160;million in connection with costs associated with the Phase 3 clinical trials for mRNA-1273 and pharmacovigilance efforts. In June 2021, the agreement with BARDA was further amended to award additional funding of $144&#160;million to support pediatric clinical trials for mRNA-1273. The maximum award from BARDA, inclusive of the 2020 and 2021 amendments, was $1.4&#160;billion. Under the terms of the agreement, BARDA will fund the advancement of mRNA-1273 to FDA licensure. All contract options have been exercised. As of December 31, 2021, the remaining available funding, net of revenue earned was $189&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, we received from BARDA an award of up to $126&#160;million, subsequently adjusted to $117&#160;million in 2021, to help fund our Zika vaccine program. Three of the four contract options have been exercised. As of December 31, 2021, the remaining available funding, net of revenue earned was $48&#160;million, with an additional $8&#160;million available if the final contract option is exercised.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2016, we entered a global health project framework agreement with the Gates Foundation to advance mRNA-based development projects for various infectious diseases, including human immunodeficiency virus (HIV). As of December 31, 2021, the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;available funding, net of revenue earned was $7&#160;million, with up to an additional $80&#160;million available if additional follow-on projects are approved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes grant revenue for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BARDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Geographic Information &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Geographic Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one reporting segment that primarily focuses on the discovery, development and commercialization of mRNA medicines. Our chief executive officer manages our operations and evaluates our financial performance on a consolidated basis. Most of our principal operations, other than manufacturing, and our decision-making functions are located at our corporate headquarters in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue by geographic area of our customers and collaboration partners was as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes product sales recognized under the agreement with Gavi (on behalf of the COVAX Facility) as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our property and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our property and equipment, including financing right-of-use assets, was principally located within the United States as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzEwMjc_f783c0a5-0214-4ecd-a3c6-dfbdd4430747">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales by customer geographic location was as follows (in millions): &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes product sales recognized under the agreement with Gavi as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue by geographic area of our customers and collaboration partners was as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes product sales recognized under the agreement with Gavi (on behalf of the COVAX Facility) as Gavi facilitates a fair allocation and distribution of our COVID-19 vaccine around the world.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our property and equipment, including financing right-of-use assets, by geographic area was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="ide168116c3df4c06bf76ee1ab5cc8665_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzEtMi0xLTEtNzYwNDY_65a087ca-23f7-4f86-8013-5629889d6db6"
      unitRef="usd">5393000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5eda8070f7034a6fab76518656331315_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzItNC0xLTEtNzgzOTQ_0749038e-a6fb-4fe7-9b8f-2eae0a25e937"
      unitRef="usd">194000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b2a73dc0a34434fbf4adfd2bd2d0152_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzMtMi0xLTEtMTA5ODAx_473537eb-bcc3-4e52-b577-28d358d93faf"
      unitRef="usd">6834000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if853b7ba8fdd405c9c2517b31b9bb54b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzMtNC0xLTEtMTA5ODAx_0e626c33-d628-4089-ae1c-23f7ebe28944"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b48f865221543f19c484fbac76b65da_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzItMi0xLTEtNzYwNDY_16a786e2-2b6a-4017-b5c1-a329323ee927"
      unitRef="usd">5448000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6f1f522be3c649ccac04b63ff9e91b55_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzMtNC0xLTEtNzgzOTQ_9e6fe50c-c175-4714-ac18-cb4a4f8029a1"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0613309ccd7f4770b391e463a962e99b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzMtMi0xLTEtNzYwNDY_ccaf47a1-c02a-41e5-87fe-1e3e7c254312"
      unitRef="usd">17675000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icfd2fff3411a4c769c4f81842918e9c3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90YWJsZTpkYmY4N2E1M2ZkZTQ0ZGYwODk1NDFhYTJkZjU1MDIyOC90YWJsZXJhbmdlOmRiZjg3YTUzZmRlNDRkZjA4OTU0MWFhMmRmNTUwMjI4XzQtNC0xLTEtNzgzOTQ_99702a3a-35a1-478c-ac6e-98ee4ae41fc9"
      unitRef="usd">200000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdba65dc5ee84630ac91c06737b61940_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzE5MjQxNDUzNDkwNTM4_e073d7f8-a24c-484b-a83d-a48364d51cb8"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i346fef81e10f4f86a929d87bf0cb041b_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzIxOTkwMjMyNTcwMTA_27091d4a-3618-4999-a591-7e9e0e48c39b"
      unitRef="usd">6700000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if49f6e27f6284519912ffac03c002a55_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzIxOTkwMjMyNTY5OTc_f0ac975e-477c-4045-a247-b069f05e393e"
      unitRef="usd">3800000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i346fef81e10f4f86a929d87bf0cb041b_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzMvZnJhZzozMDQ4MjYyMGY2Mzk0NzJlOGU2YTY1ZThjMDJjYjM5Mi90ZXh0cmVnaW9uOjMwNDgyNjIwZjYzOTQ3MmU4ZTZhNjVlOGMwMmNiMzkyXzIxOTkwMjMyNTc1NTQ_2a4a546e-227c-4439-89c1-e6798419fefc"
      unitRef="usd">6200000000</us-gaap:RevenueRemainingPerformanceObligation>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="i185b16a527d64878943a25c180d19f14_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzE1Mg_dab77746-efbe-49bb-844a-adc25663a14a"
      unitRef="usd">56000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="i90618f5224194ab98e88f99e1cfb81b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzM4Mw_f7b250e7-561a-465c-b52d-e8cc75171cf8"
      unitRef="usd">2000000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:RevenueFromGrantsRemainingFundingCapacity
      contextRef="i90618f5224194ab98e88f99e1cfb81b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzQwNg_34e411a7-4ae2-4570-85c1-a3421cd82882"
      unitRef="usd">42000000</mrna:RevenueFromGrantsRemainingFundingCapacity>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="ie7a70d15770e4fc5a0c8d58cdebd7aef_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzU0NQ_b06ae95c-68ef-4270-9460-ad651ccc672f"
      unitRef="usd">483000000</mrna:RevenueFromGrantsMaximumAward>
    <us-gaap:OtherCommitment
      contextRef="ieb5f923d3e90448fbd2a1d5a8d4e3398_I20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzcyNw_40d34e9c-8659-4a66-8d20-b1a92eab031e"
      unitRef="usd">472000000</us-gaap:OtherCommitment>
    <mrna:NumberOfParticipants
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzE5NzkxMjA5MzAzODIy_fc2f7fe7-38fb-4b4d-a9a3-789983ff8e80"
      unitRef="participant">30000</mrna:NumberOfParticipants>
    <us-gaap:OtherCommitment
      contextRef="i0f13771d8cb942efb65d2bfc498700a6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzIxOTkwMjMyNTg2MzI_de9d2a55-d7ce-4512-bb18-d0c62438c305"
      unitRef="usd">63000000</us-gaap:OtherCommitment>
    <mrna:RevenueFromGrantsPotentialReimbursement
      contextRef="i47c1a858a9f9495fbac7df0e36419070_D20210401-20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzIxOTkwMjMyNTg2NDU_683f3612-0afd-48f0-9364-bc9261aa2022"
      unitRef="usd">236000000</mrna:RevenueFromGrantsPotentialReimbursement>
    <us-gaap:OtherCommitment
      contextRef="i88f0f64452bc4d5da91f20c29eeecbca_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzIxOTkwMjMyNTg2NTk_7aee7af1-2f88-4538-b968-549a70cdd771"
      unitRef="usd">144000000</us-gaap:OtherCommitment>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="idb9732dce6924b498098b6518f64703e_D20210701-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzkyNQ_10b6984d-fdc6-4f4d-a513-00f41ac211ab"
      unitRef="usd">1400000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="ida3d15a8c031486d90647c53dad031ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzExMzY_1166ce81-1f04-4fcf-867a-58c076530444"
      unitRef="usd">189000000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="i115458dd79814652822c63535a915899_D20160901-20160930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzExOTA_763d89b6-59af-445f-aee9-dedbfaa7e3e6"
      unitRef="usd">126000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsMaximumAward
      contextRef="i987f997b0acc4a2695f9a05d82e96f37_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzIxOTkwMjMyNTkyNTA_18eb8e2b-fd86-4af1-b351-86b164bb71e1"
      unitRef="usd">117000000</mrna:RevenueFromGrantsMaximumAward>
    <mrna:RevenueFromGrantsNumberOfContractOptions
      contextRef="ieae7b1ae1b03416dbb9b8f48d0bc6426_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzEyNDQ_19d7354b-7d9e-4a9f-bb8a-7090756201ad"
      unitRef="contract_option">3</mrna:RevenueFromGrantsNumberOfContractOptions>
    <mrna:RevenueFromGrantsNumberOfContractOptionsExercised
      contextRef="ief33f0f4bb514efdae5a1b468c9c9c90_I20160930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzEyNTQ_de4e933e-2d5e-4f98-a560-b1d0dedfe21b"
      unitRef="contract_option">4</mrna:RevenueFromGrantsNumberOfContractOptionsExercised>
    <mrna:RevenueFromGrantsCurrentFundingCapacity
      contextRef="ia3127eb355e744a881aa98a34f6d97fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzEzNjM_2ca924b8-28d3-446e-bc92-9d465c64deda"
      unitRef="usd">48000000</mrna:RevenueFromGrantsCurrentFundingCapacity>
    <mrna:RevenueFromGrantsRemainingFundingCapacity
      contextRef="ia3127eb355e744a881aa98a34f6d97fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzEzODY_eab1b0de-fb22-409c-a796-9f2caccecbbf"
      unitRef="usd">8000000</mrna:RevenueFromGrantsRemainingFundingCapacity>
    <mrna:RevenueFromGrantsRemainingFundingCapacity
      contextRef="icf94941a6a404dd8b05524603b3a3b2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzE3MjE_daa8352a-9c73-4c5d-a10e-1ff6d96a3daf"
      unitRef="usd">7000000</mrna:RevenueFromGrantsRemainingFundingCapacity>
    <us-gaap:ContractWithCustomerLiability
      contextRef="icf94941a6a404dd8b05524603b3a3b2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzE3NTA_9ec44b84-96b2-4061-b7d2-b72abc2a3b6b"
      unitRef="usd">80000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90ZXh0cmVnaW9uOmE2MGVkOTk4NjU0NzQ3YzA5MTM5ODNiODBhYzdiYzUwXzE5NDI_44b44182-daf0-4600-bc09-b4b84a5f0be8">&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes grant revenue for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BARDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collaboration Revenue by Strategic Collaborator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vertex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="iaa5a2552f63d48b5b1e01ac4535c5a2f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzItMS0xLTEtNzYwNDY_25919aec-1116-4b3e-8f18-92011611a4ab"
      unitRef="usd">713000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ef76c094447459c821c04b2de3eb206_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzItMy0xLTEtNzYwNDY_a9885f63-d106-4b55-901c-cf109466d124"
      unitRef="usd">522000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3802fa1330a343298542de37e4105a0c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzItNS0xLTEtNzYwNDY_bdbfeff7-245c-4a47-ad42-b17e404ac09d"
      unitRef="usd">8000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0cd3ec1f9ac141d284f0a5db5793f3c9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzMtMS0xLTEtNzYwNDY_6ab377ce-57d3-4d80-a014-f8229bfb9c47"
      unitRef="usd">22000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if1d68b45e78b406482a02388fbb53604_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzMtMy0xLTEtNzYwNDY_04878dee-d06f-45de-93ec-6e07f6124656"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c202e8e92ed4514824b43cb3531dc9e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzMtNS0xLTEtNzYwNDY_1cc7a8b2-bcc3-49a3-8633-a7f67fec4c37"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1806b5a0029947c1aabb49f5e058cb28_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzQtMS0xLTEtNzYwNDY_2c162920-80be-49cb-86d8-7babacdefc11"
      unitRef="usd">735000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1eabe79fc2e4e4a9fdc7c2be2e9f0e7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzQtMy0xLTEtNzYwNDY_6396e60e-03ae-43ed-acda-f82cc8ef5359"
      unitRef="usd">529000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5db090169624207a4311b8780bb82f3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzAvZnJhZzphNjBlZDk5ODY1NDc0N2MwOTEzOTgzYjgwYWM3YmM1MC90YWJsZTplMDQyNzc4ZmEyNmQ0NDkxOWQ3MGM0NGM5ZjlkN2M2OC90YWJsZXJhbmdlOmUwNDI3NzhmYTI2ZDQ0OTE5ZDcwYzQ0YzlmOWQ3YzY4XzQtNS0xLTEtNzYwNDY_3e42347c-dd11-4994-b4db-700317671e26"
      unitRef="usd">12000000</us-gaap:Revenues>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2Xzc5MDcy_21837400-fcd8-449c-8634-3ff20b2b1718">Collaboration Agreements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca &#x2013; Strategic Alliances in Cardiovascular and Oncology&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2013 Option Agreement and Services and Collaboration Agreement, amended and restated in 2018&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2013, we entered into an Option Agreement, the AZ Option Agreement, and a related Services and Collaboration Agreement (2013 AZ Agreements), the AZ Services Agreement, with AstraZeneca, which were amended and restated in June 2018 (2018 A&amp;amp;R Agreements). Under the 2018 A&amp;amp;R Agreements, we granted AstraZeneca certain exclusive rights and licenses, and options to obtain exclusive rights to develop and commercialize potential therapeutic mRNA medicines directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services to AstraZeneca. The activities to be performed by the parties under the 2018 A&amp;amp;R Agreements are limited to defined biological targets in the cardiovascular and cardiometabolic fields and one defined target in the cancer field. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the effective date of the 2013 AZ Agreements, AstraZeneca made upfront cash payments to us totaling $240 million in exchange for the acquired options and our performance of certain research-related services, each as described above. Under the 2018 A&amp;amp;R Agreements, we are entitled to receive, on a product-by-product basis, payments for achievement of certain development, regulatory and commercial milestones, as well as earn-out payments on worldwide net sales of products ranging from a high-single digit percentage to 12%, subject to certain reductions, with an aggregate minimum floor.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, AstraZeneca exercised a product option under the 2013 AZ Agreements to obtain exclusive rights to develop and commercialize with respect to AstraZeneca's VEGF-A product (AZD8601). It is currently being developed in a Phase 2 clinical trial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2016 Strategic Alliance with AstraZeneca&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; IL-12&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2016, we entered into a Strategic Drug Development Collaboration and License Agreement (2016 AZ Agreement) with AstraZeneca to discover, develop and commercialize potential mRNA medicines for the treatment of a range of cancers. Under the terms of the 2016 AZ Agreement, we and AstraZeneca have agreed to work together on an immuno-oncology program focused on the intratumoral delivery of a potential mRNA medicine to make the IL-12 protein.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During a limited period of time, each party had an opportunity to propose additional discovery programs to be conducted under the 2016 AZ Agreement. We are responsible for conducting and funding all discovery and preclinical development activities under the 2016 AZ Agreement in accordance with an agreed upon discovery program plan for the IL-12 program and any other discovery program the parties agree to conduct under the 2016 AZ Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merck &#x2013; Strategic Alliances in Infectious Diseases and Cancer Vaccines&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2016 Cancer Vaccine Strategic Alliance-Personalized mRNA Cancer Vaccines&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, we entered into a personalized mRNA cancer vaccines (PCV) Collaboration and License Agreement with Merck (PCV Agreement), to develop and commercialize PCVs for individual patients using our mRNA vaccine and formulation technology. Under the strategic alliance, we identify genetic mutations present in a particular patient&#x2019;s tumor cells, synthesize mRNA for these mutations, encapsulate the mRNA in one of our proprietary LNPs and administer to each patient a unique mRNA cancer vaccine designed to specifically activate the patient&#x2019;s immune system against her or his own cancer cells.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the PCV Agreement, we are responsible for designing and researching PCVs, providing manufacturing capacity and manufacturing PCVs, and conducting Phase&#160;1 and Phase&#160;2 clinical trials for PCVs, alone and in combination with KEYTRUDA (pembrolizumab), Merck&#x2019;s anti-PD-1 therapy, all in accordance with an agreed upon development plan and budget and under the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;oversight of a committee comprised of equal representatives of each party. The parties have entered into a clinical quality agreement with respect to Moderna&#x2019;s manufacture and supply activities. We received an upfront payment of $200 million from Merck. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Expansion of the Cancer Vaccine Strategic Alliance-Shared Neoepitope Cancer Vaccines&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, we and Merck agreed to expand our cancer vaccine strategic alliance to include the development and commercialization of our KRAS vaccine development candidate, mRNA-5671 or V941, and potentially other shared neoantigen mRNA cancer vaccines (SAVs). We preclinically developed mRNA-5671 prior to its inclusion in the cancer vaccine strategic alliance and it is comprised of a novel mRNA construct designed by us and encapsulated in one of our proprietary LNPs. The PCV Agreement was amended and restated to include the new SAV strategic alliance (PCV/SAV Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted Merck certain licenses and we and Merck have agreed to certain exclusivity obligations with respect to SAVs and particular SAV programs, which obligations are subject to termination or expiration upon certain triggering events. Under the PCV/SAV Agreement, Merck will be responsible for conducting Phase 1 and Phase 2 clinical trials for mRNA-5671 and for all costs associated with such activities, in accordance with a jointly agreed development plan and budget, and we will be responsible for manufacturing and supplying all mRNA-5671 required to conduct such trials and for all costs and expenses associated with such manufacture and supply. Under the PCV/SAV Agreement, our budgeted commitment for PCV increased to $243 million. Until the expiration of a defined period of time following the completion of Phase 1 and Phase 2 clinical trials for mRNA-5671 under the PCV/SAV Agreement and our delivery of an associated data package to Merck, Merck has the right to elect to participate in future development and commercialization of mRNA-5671 by making a participation payment to us. In connection with the amendment of the PCV Agreement to include the development and commercialization of mRNA-5671 and potentially other SAVs, Merck made a contemporaneous equity investment in our Series H redeemable convertible preferred stock, resulting in gross proceeds of $125 million, of which $13 million was determined to be a premium and recorded to deferred revenue. In December 2021, Merck elected to terminate the Merck participation election with respect to the joint SAV program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Vertex &#x2013; Strategic Alliance in Cystic Fibrosis&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:11.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2016 Strategic Alliance in Cystic Fibrosis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement), with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited, together, Vertex. The Vertex Agreement, which was amended in July 2019 (2019 Vertex Amendment), is aimed at the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis (CF) by enabling cells in the lungs of people with CF to produce functional cystic fibrosis transmembrane conductance regulator (CFTR) proteins. Pursuant to the Vertex Agreement, we lead discovery efforts during an initial research period that currently extends until August 2022, leveraging our Platform technology and mRNA delivery expertise along with Vertex&#x2019;s scientific experience in CF biology and the functional understanding of CFTR. Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Subject to customary &#x201c;back-up&#x201d; supply rights granted to Vertex, we exclusively manufacture (or have manufactured) mRNA for preclinical, clinical and commercialization purposes. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Strategic Alliance in Cystic Fibrosis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into a new Strategic Collaboration and License Agreement with Vertex (Vertex 2020 Agreement). The Vertex 2020 Agreement is aimed at the discovery and development of potential medicines to treat CF by delivering gene-editing therapies to lung cells to facilitate production of functional CFTR proteins. The three-year research period of the Vertex 2020 Agreement will initially focus on the identification and optimization of novel LNPs and mRNAs that can deliver gene-editing therapies to cells in the lungs. Following the initial three-year period, Vertex is responsible for conducting development and commercialization activities for candidates and products that arise from the strategic alliance, including the costs associated with such activities. Vertex is also obligated to pay us for research services in connection with our performance of certain activities in accordance with a jointly agreed research plan. Subject to customary &#x201c;back-up&#x201d; supply rights granted to Vertex, under the agreement, we are the exclusive manufacturer of related mRNA and LNPs for preclinical, clinical, and commercialization purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Collaboration Revenue by Strategic Collaborator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vertex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the year ended December 31, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $286&#160;million.&lt;/span&gt;&lt;/div&gt;In addition to the collaborative arrangements mentioned above, we have other collaborative and licensing arrangements that we do not consider to be individually significant to our business at this time. Pursuant to these agreements, we may be required to make upfront payments and payments upon achievement of various development, regulatory and commercial milestones, which in the aggregate could be significant. Future milestone payments, if any, will be reflected in our consolidated financial statements when the corresponding events become probable. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="if55e1500f5544b66aa8a071e51806268_D20130301-20130331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjI4NDQ4_e4d62b62-102d-4a25-9edf-7f6cac125a46"
      unitRef="usd">240000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent
      contextRef="i8ede9f3ba9d44d22a375d16ea04e18cc_D20130301-20130331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjI5NDY1_27b4d728-59c2-41ee-b5af-d3ffb2e536ff"
      unitRef="number">0.12</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="id946b8dd31834000b8e6b41766b9dedd_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjM1MDE2_18ea8115-8796-478d-be66-0f0acede8b25"
      unitRef="usd">200000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount
      contextRef="i3d09409e8868491499e290b8a4d12cdc_I20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjM2NTk1_e1e536d1-786e-46f9-a242-7c659ff67aae"
      unitRef="usd">243000000</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia84a8bd1c3aa4ac9b1a164b251799095_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjM3MjMy_220f204e-7dcc-4ac8-8f1c-166dca10f4de"
      unitRef="usd">125000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RedemptionPremium
      contextRef="ia84a8bd1c3aa4ac9b1a164b251799095_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE0ODQzNDA3MjM3MjQ2_9d58c780-0a23-4056-a43c-33c3876a9fdd"
      unitRef="usd">13000000</us-gaap:RedemptionPremium>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod
      contextRef="i60fc10736ee64261bd7f04a73acfaafa_D20200901-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE5NzkxMjA5NjU5ODYy_75392d27-1c94-4920-baae-9fc81d080a19">P3Y</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod
      contextRef="i60fc10736ee64261bd7f04a73acfaafa_D20200901-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzE5NzkxMjA5NjU5ODYz_7a12feb0-1c84-4fba-b1a1-d56bd38196a8">P3Y</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d6ad74836b24c83809a74ce8d566449_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzItMi0xLTEtNzYwNDY_da930ce9-14ee-4840-81f0-75dd9472b9ff"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb0688f24fb7444ba43fe54c1d8443f2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzItNC0xLTEtNzYwNDY_872c4e8e-be81-4b82-8217-b3ecf26f3763"
      unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70d782312fcd4253a167cb2d7ae3760e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzItNi0xLTEtNzYwNDY_cd251897-8844-435c-b765-b0c1dfe6c2c2"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia24b3bc3329043adb9ea279c5b254064_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzMtMi0xLTEtOTQ0MDc_825871a5-0770-4324-bd41-fa0930df7a77"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b18d163a5204d569c9797b913f2d8f6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzMtNC0xLTEtOTQ0MDc_a5074c55-a5b3-4e1c-bc5a-3bd06c4c029a"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e25bd1849804ba7b479c2eced67e891_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzMtNi0xLTEtOTQ0MDc_407eb87a-6677-4f96-a027-a326c2f520df"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i618406f3ce9d406aaa081c4408973067_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzQtMi0xLTEtNzYwNDY_85e3094a-63ae-45bd-a1a4-7049d709695a"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79a9ba91798641049354e39e4852bc1e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzQtNC0xLTEtNzYwNDY_dce8e7cd-6836-4361-b774-aa6bd71aca04"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic63027741efa4c50b4babaada70fbc9b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzQtNi0xLTEtNzYwNDY_0f51e8ff-c05d-45e2-a45a-6a4e0c750be9"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia49291312e364cb4a88c0ff31026909a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzUtMi0xLTEtNzYwNDY_d1ea8dac-88b9-419a-9c33-2774759de4e1"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i119f28ec664d4518be468660ee954b91_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzUtNC0xLTEtNzYwNDY_8ab4897e-1bf9-4564-b283-86020f78428c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4219337e58d4f1db6c745955c72cd8e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzUtNi0xLTEtNzYwNDY_fdaa493e-04a6-4978-b469-3e650b01da0f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzYtMi0xLTEtNzYwNDY_3ec985ea-f5ba-4ba8-b7be-de02145436d6"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d88c4aeb3e94e9b959ea25fc2661d2c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzYtNC0xLTEtNzYwNDY_8760af81-ab49-4b08-a8ec-17349c0d9049"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3df9734dc9af496f9780bd6c5c379234_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTpkYTA5N2YzNGU4NTg0OWM1OGU4Yzc3ZDExNjdiZjY4Mi90YWJsZXJhbmdlOmRhMDk3ZjM0ZTg1ODQ5YzU4ZThjNzdkMTE2N2JmNjgyXzYtNi0xLTEtNzYwNDY_57ec665d-7ce9-4626-b030-ff84fdc3f22a"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2Xzc5MDkz_64c388a6-c282-4367-add9-782f9b39e122">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the year ended December 31, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the aggregated amount of the transaction price allocated to performance obligations under our collaboration agreements that are unsatisfied or partially unsatisfied was $286&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities in deferred revenue during the year ended December 31, 2021 (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i17abcb6e78134f4690ee2419e8619e02_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzItMi0xLTEtNzYwNDY_233d919f-bde3-46e6-ba51-ee6e1c06e981"
      unitRef="usd">6000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetPurchase
      contextRef="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzItNC0xLTEtNzYwNDY_50d10a07-a64d-4d56-a434-6085cccc7ae4"
      unitRef="usd">26000000</us-gaap:ContractWithCustomerAssetPurchase>
    <mrna:ContractWithCustomerAssetDeductionsDuringPeriod
      contextRef="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzItNi0xLTEtNzYwNDY_527e6737-83a7-4581-b3ae-7156f7e94f85"
      unitRef="usd">23000000</mrna:ContractWithCustomerAssetDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ie710a95ab39e49cdb735c3bc7fc8c4b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzItOC0xLTEtNzYwNDY_09686150-ba3a-44e7-9b44-56c3ed9f87b3"
      unitRef="usd">9000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i17abcb6e78134f4690ee2419e8619e02_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzQtMi0xLTEtNzYwNDY_896b1260-dee8-4bb5-989c-9b975c615cbf"
      unitRef="usd">240000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzQtNC0xLTEtNzYwNDY_9e7d318c-e139-4aab-ac18-7686daf991e1"
      unitRef="usd">27000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzQtNi0xLTEtNzYwNDY_c40ca1fa-ae24-465b-8b89-d454d713e308"
      unitRef="usd">63000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie710a95ab39e49cdb735c3bc7fc8c4b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90YWJsZTphYzNmMmI2NjUyZGY0ZmRiODhiNGNjODk1NGU0YWViOS90YWJsZXJhbmdlOmFjM2YyYjY2NTJkZjRmZGI4OGI0Y2M4OTU0ZTRhZWI5XzQtOC0xLTEtNzYwNDY_3574f456-7906-4f94-9cc7-e8f1f1cfaae3"
      unitRef="usd">204000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ie710a95ab39e49cdb735c3bc7fc8c4b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xMzYvZnJhZzoyODdmYTM4NGEwNjc0MzljOWE2NDQ4Yzk3MzIxZjAwNi90ZXh0cmVnaW9uOjI4N2ZhMzg0YTA2NzQzOWM5YTY0NDhjOTczMjFmMDA2XzkzNDU4NDkxOTUyOTE_37b79067-9cf9-4e0f-986c-c6209a36a90d"
      unitRef="usd">286000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzIwOTA_db80a1b3-097a-4e25-b7dc-eefdd788ae79">Financial Instruments and Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash and available-for-sale securities by significant investment category at December 31, 2021 and 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="45" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and estimated fair value of marketable securities, by contractual maturity at December 31, 2021 and 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. We did not record any impairment charges related to our available-for-sale securities during the&#160;years ended December 31, 2021, 2020, and 2019. We did not recognize any credit-related allowance to available-for-sale securities as of the years ended December 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or More&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, we did not have material gross unrealized losses. We neither intend to sell these investments nor conclude that we are more-likely-than-not that we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our financial assets measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2021 and 2020, we did not have non-financial assets or liabilities measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzIwOTI_d0b0718e-75bc-4a67-99f7-154c4f7a7356">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash and available-for-sale securities by significant investment category at December 31, 2021 and 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.212%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="45" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Non-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifa328a08859144588130d892ad20192d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItMi0xLTEtNzYwNDY_0e936f7b-cc6e-4ae7-840a-91213cec75e0"
      unitRef="usd">6848000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifa328a08859144588130d892ad20192d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItNC0xLTEtNzYwNDY_70c343de-31a4-4fc7-80c7-6a7bd60a688e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifa328a08859144588130d892ad20192d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItNi0xLTEtNzYwNDY_909bf5ed-472f-462a-89f8-b58f7e7d81c8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa328a08859144588130d892ad20192d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItOC0xLTEtNzYwNDY_d10143f0-60c1-462e-9232-dc7ca6a49d76"
      unitRef="usd">6848000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idf669fdc68ee4630b54c9802a1b0a558_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItMTAtMS0xLTc2MDQ2_df2dcacb-80ff-4078-aa18-41db7a586613"
      unitRef="usd">6848000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0292df9b654d482db1060f9005959794_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItMTItMS0xLTc2MDQ2_cb417299-0ee9-4e05-b767-20632297fe12"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia45359f849f44c0998e347e23469e818_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzItMTQtMS0xLTc2MDQ2_ac2650d6-e93e-4b41-a06f-6facbac06ab7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4712a1c564814f3abe808e0a6b9e64a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtMi0xLTEtNzYwNDY_c1ef275f-db3c-4b2a-8038-13ca6f5841c8"
      unitRef="usd">80000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4712a1c564814f3abe808e0a6b9e64a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtNC0xLTEtNzYwNDY_b427c5e9-c2c8-443e-bc68-6acd6d2ab834"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4712a1c564814f3abe808e0a6b9e64a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtNi0xLTEtNzYwNDY_ffea1d57-7271-4c22-9486-274e3b4ac55f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4712a1c564814f3abe808e0a6b9e64a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtOC0xLTEtNzYwNDY_d3aff6eb-6cca-4fd6-ae67-78adf2f390b9"
      unitRef="usd">80000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e02fcbb9afe410ab3a681bc9b64d879_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtMTAtMS0xLTc2MDQ2_b78f459a-d612-4c1d-bbcf-b364de6f31ba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i42f5d9b242cc4780b3309e0961fa5eb7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtMTItMS0xLTc2MDQ2_dbe3af77-de3d-42e9-adac-d2515f9c8871"
      unitRef="usd">80000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5734f4fe23fc43dd969bd66b5e557046_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzQtMTQtMS0xLTc2MDQ2_80b7e368-d89c-46a4-bbe6-8ad1dacc4bfa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic2364f83219a4bfc9d8ee9260dacc1b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtMi0xLTEtNzYwNDY_30ac1041-0536-43ab-ab23-24feede387bb"
      unitRef="usd">479000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic2364f83219a4bfc9d8ee9260dacc1b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtNC0xLTEtNzYwNDY_9e4644a2-c422-4e38-b2af-84e7d33f4315"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic2364f83219a4bfc9d8ee9260dacc1b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtNi0xLTEtNzYwNDY_f10ec9a0-cc88-4ffd-bf17-b4d30f3c103d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2364f83219a4bfc9d8ee9260dacc1b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtOC0xLTEtNzYwNDY_24ea7c0b-9bf5-4a74-a4ff-05ab068caff3"
      unitRef="usd">479000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4042eb496ee543f2a5872be11b2cf7ca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtMTAtMS0xLTc2MDQ2_67c62c3f-b51c-4a29-8b35-80d4765dabe2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b5cfdaf6a9c475fab2b7dfb72468094_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtMTItMS0xLTc2MDQ2_8bb544ed-8ace-451f-9a17-7303a7e40b8c"
      unitRef="usd">479000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9284186e600b48258879f874e838c77a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzUtMTQtMS0xLTc2MDQ2_62cde42c-1b52-47fc-b11f-fa566d746a5d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic428ae6809614abaac1249c8d3bb020c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMi0xLTEtNzg0NDM_ef09aaae-022c-4a08-bb00-32dc3437b87c"
      unitRef="usd">6595000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic428ae6809614abaac1249c8d3bb020c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtNC0xLTEtNzg0NDM_d018e453-0cbe-4c5b-9abf-179b725abca7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic428ae6809614abaac1249c8d3bb020c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtNi0xLTEtNzg0NDM_9388c629-aeb0-4e94-805b-f2ec073cfe5e"
      unitRef="usd">31000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic428ae6809614abaac1249c8d3bb020c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtOC0xLTEtNzg0NDM_53a352dc-e3d9-46aa-a50c-493504faddf0"
      unitRef="usd">6564000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i709ee66b601a4d2ebd30bdd6893ba771_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTAtMS0xLTc4NDQz_36654334-61cc-41c8-9c96-d411504601bb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6344e2313ce84b3291ddab39f4bcddfb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTItMS0xLTc4NDQz_f59bae21-9158-41d4-95db-f5002e2097cf"
      unitRef="usd">1984000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idf656a3fa7e84852a422e94e706d2b6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTQtMS0xLTc4NDQz_ae651613-2bbe-48ca-9223-1705ccdafc06"
      unitRef="usd">4580000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iec10e88bcd6c4d8181a5ca274d5cc8f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMi0xLTEtNzg0NDM_8f98f314-fbcc-4e6b-90e8-a81104b5072c"
      unitRef="usd">3508000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iec10e88bcd6c4d8181a5ca274d5cc8f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctNC0xLTEtNzg0NDM_32352106-406d-4789-9b0c-c26ffdedbaa5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iec10e88bcd6c4d8181a5ca274d5cc8f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctNi0xLTEtNzg0NDM_f40af4f6-f2c5-4a43-82e8-e7abb90050a2"
      unitRef="usd">20000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec10e88bcd6c4d8181a5ca274d5cc8f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctOC0xLTEtNzg0NDM_0cd1991f-6062-40b9-88aa-5f623ad32d3f"
      unitRef="usd">3488000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieafc1c887e174d9bbbde6dd62d64e2ab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTAtMS0xLTc4NDQz_15cab3fd-55d0-4f21-93ea-018969fff5c8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i44bf012463a94b6a88a9422b0030dda0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTItMS0xLTc4NDQz_dc7ffc67-2ba3-43c2-aa99-57439d01b5a9"
      unitRef="usd">1323000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9235e93735dc44b285d2bfdc769bb996_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTQtMS0xLTc4NDQz_30e60f08-c781-4504-896b-84ccccdfbcc3"
      unitRef="usd">2165000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id07b5918438d431a8e9c74d8ff4d2551_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMi0xLTEtNzYwNDY_2698baa4-6a54-4c45-9a09-7ac1b4a7b62b"
      unitRef="usd">112000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id07b5918438d431a8e9c74d8ff4d2551_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtNC0xLTEtNzYwNDY_dd627f4a-2dcf-4d53-808b-daf09650489c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id07b5918438d431a8e9c74d8ff4d2551_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtNi0xLTEtNzYwNDY_393da9ae-c739-4e2e-b90a-ba9b951eaadc"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id07b5918438d431a8e9c74d8ff4d2551_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtOC0xLTEtNzYwNDY_ab5673e8-a9cf-4076-b72a-00fa1432b801"
      unitRef="usd">111000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic1075514a7e14bb585b04979d8e91df8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTAtMS0xLTc2MDQ2_364dd5ff-922e-4b3e-8318-83eca6846e85"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33223bcc0e1b4b51acbe5ccd606713ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTItMS0xLTc2MDQ2_fa39655a-347d-427b-a46c-477a198706f3"
      unitRef="usd">13000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i959b3e4a89ca4e1392ee007bf48a9ce3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzYtMTQtMS0xLTc2MDQ2_a55da9eb-2d25-4a94-b136-25156573bf98"
      unitRef="usd">98000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0458e4ead71746a5af5b29ed89c9ef21_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMi0xLTEtNzYwNDY_618d42ca-83d4-457c-af22-ea7892339be5"
      unitRef="usd">17622000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0458e4ead71746a5af5b29ed89c9ef21_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctNC0xLTEtNzYwNDY_d0cf42f1-f505-4b43-8ce0-1cce9774b648"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0458e4ead71746a5af5b29ed89c9ef21_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctNi0xLTEtNzYwNDY_b13e6518-e8fb-4730-9647-4e3123fc277a"
      unitRef="usd">52000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0458e4ead71746a5af5b29ed89c9ef21_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctOC0xLTEtNzYwNDY_26997091-d1b3-45be-875c-becdb4f7c4d0"
      unitRef="usd">17570000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a6b3fe35432446aa1c5e179c4701d65_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTAtMS0xLTc2MDQ2_643cd6f3-0f34-46fa-9c73-355af6dbd44d"
      unitRef="usd">6848000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3c9905b040c345c9800468da2693c514_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTItMS0xLTc2MDQ2_ce5f2751-066f-4c6c-b4f1-7228de7485a4"
      unitRef="usd">3879000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2565e09c4ee4bdcbd387be8850d72df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzctMTQtMS0xLTc2MDQ2_ef5d5684-7419-4ca2-a9aa-acc3473e0473"
      unitRef="usd">6843000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia3997280202440c4b1242ce5b6a23810_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTItMS0xLTc2MDQ2_76880023-d144-4328-ba3f-a0c77921e71a"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia3997280202440c4b1242ce5b6a23810_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTQtMS0xLTc2MDQ2_e2cadd2b-dcc4-44bf-b5a7-28ce99f89d95"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia3997280202440c4b1242ce5b6a23810_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTYtMS0xLTc2MDQ2_ad0ec0e3-a4db-4837-ab52-e47abc3166b9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia3997280202440c4b1242ce5b6a23810_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTgtMS0xLTc2MDQ2_de3c92a2-cceb-4ba5-87fe-425cab2706d6"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3d566855dd54261b4fe635c234b2484_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTEwLTEtMS03NjA0Ng_b3996e7b-a6bd-4004-a5b5-cf0c3c0a5dd5"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id087a0a88efd4af88be84f1c3b08e19f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTEyLTEtMS03NjA0Ng_beb3d104-9403-44ec-8b1c-760cd6a0494d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81ef75bce2954276bae1f44362fbb2cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzEyLTE0LTEtMS03NjA0Ng_a293cf81-f703-4928-a20e-46a4e27a8e04"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i41a1843d0dcd4702b157723e8cc7e665_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTItMS0xLTc2MDQ2_83fa29bf-521b-4581-8812-7c9c51f5b56a"
      unitRef="usd">239000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i41a1843d0dcd4702b157723e8cc7e665_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTQtMS0xLTc2MDQ2_299039f5-17f1-43c8-9f08-0dc2c28d3f14"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i41a1843d0dcd4702b157723e8cc7e665_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTYtMS0xLTc2MDQ2_2ef93e38-6a0d-42ce-8aa9-887ef35f8880"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41a1843d0dcd4702b157723e8cc7e665_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTgtMS0xLTc2MDQ2_b5bc8197-def0-4f36-ab69-2227e0dcce11"
      unitRef="usd">239000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i53dd51cc137b4b4aa2f56b6bab4db8f4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTEwLTEtMS03NjA0Ng_4e2c9e41-aed5-4555-a2e0-7e740c1ce2ee"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e93700d2ebf423091417132b7c40ab4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTEyLTEtMS03NjA0Ng_17d0f010-7114-4cd6-a572-5cad4315ddd9"
      unitRef="usd">215000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ied3d5ab7308d4c59b813d58e2e04c6e5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE0LTE0LTEtMS03NjA0Ng_417a865c-bf12-44e5-914b-e77b2c65cb7f"
      unitRef="usd">24000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8eeaea94154e4fe49fa61fba009f8be3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTItMS0xLTc2MDQ2_5ba06626-ce38-43ba-b413-d7cba2bf3e5e"
      unitRef="usd">492000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8eeaea94154e4fe49fa61fba009f8be3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTQtMS0xLTc2MDQ2_f340cea3-50b7-4b01-ae16-e54b4e69f5b7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8eeaea94154e4fe49fa61fba009f8be3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTYtMS0xLTc2MDQ2_10cadb44-301b-4a4e-ac01-4527d94ba820"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8eeaea94154e4fe49fa61fba009f8be3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTgtMS0xLTc2MDQ2_eca99a20-d799-41ed-8c33-ec07bd49e74d"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6aa1fb4bfb734981a51e6771d628fcc8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTEwLTEtMS03NjA0Ng_d81b2695-a5ec-4fc8-a346-8d29fee1afc7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab996b74800b4e25a035225c3e839436_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTEyLTEtMS03NjA0Ng_cd67547f-dc64-41e3-9349-3771cca64f26"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e1fc05718e842d8a85da2e69c5bf695_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE1LTE0LTEtMS03NjA0Ng_c549a58a-abe8-4cfd-b7ef-f5d65122f9b0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifa93ec4582e34e7fbf2e3ab8bce77f21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTItMS0xLTc4NDc5_58b20444-8ba9-4573-970b-ce74fe0ecf06"
      unitRef="usd">87000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifa93ec4582e34e7fbf2e3ab8bce77f21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTQtMS0xLTc4NDc5_5e28fc69-33ce-494b-aec7-2f6c062d9d94"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifa93ec4582e34e7fbf2e3ab8bce77f21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTYtMS0xLTc4NDc5_8d75b020-f99c-465a-9b41-6066884dbf2c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa93ec4582e34e7fbf2e3ab8bce77f21_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTgtMS0xLTc4NDc5_0d909780-21f0-41f4-859f-77de69928515"
      unitRef="usd">87000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia63eadf881ec473799e8621ff399a7de_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTEwLTEtMS03ODQ3OQ_1ca4711f-eb7e-4df1-8d57-e415535c30c0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c5df7f55fdc4eb49e20e64d8f73b402_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTEyLTEtMS03ODQ3OQ_710ccb50-f6c7-4539-8ec6-16d4fe19ab90"
      unitRef="usd">38000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id9935ee028dc4668889878caf93655c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTE0LTEtMS03ODQ3OQ_81de6cb5-1bc7-46b1-a07d-cef2b193cba7"
      unitRef="usd">49000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib074b324fc8a45e8b60ce57c228ef8bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTItMS0xLTc4NDc5_d7983ccc-9792-44b6-9fbc-9385f12c9bec"
      unitRef="usd">1788000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib074b324fc8a45e8b60ce57c228ef8bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTQtMS0xLTc4NDc5_bf3bcd3a-6440-43c6-8714-eaf1a9bffc89"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib074b324fc8a45e8b60ce57c228ef8bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTYtMS0xLTc4NDc5_db1d3c85-62cd-433a-899a-52644183d384"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib074b324fc8a45e8b60ce57c228ef8bb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTgtMS0xLTc4NDc5_aeffe0d0-31c2-4992-8343-70176cc8c307"
      unitRef="usd">1792000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee8da0e76f2e4c59a02abce9c64913ea_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTEwLTEtMS03ODQ3OQ_83967042-3006-47fc-b451-1e0986d4e282"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i342e75080ebe4c45b4605822f2cb05d2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTEyLTEtMS03ODQ3OQ_c9d9e6c3-9be9-420b-a67b-0388e2ecbd88"
      unitRef="usd">1239000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib732575815f0493f8a45f987de9435dc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE4LTE0LTEtMS03ODQ3OQ_277b030a-bc76-4b3c-8ebb-b55e683a0c36"
      unitRef="usd">553000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibb052b50079e46858cb5714c483963ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTItMS0xLTc2MDQ2_4da17bb7-1f84-46bb-b259-f743de91b725"
      unitRef="usd">13000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibb052b50079e46858cb5714c483963ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTQtMS0xLTc2MDQ2_825c9ef5-79c4-491f-aee5-aad29d755969"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibb052b50079e46858cb5714c483963ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTYtMS0xLTc2MDQ2_fe74302e-24f0-4da8-bf99-d74deb46f9e8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb052b50079e46858cb5714c483963ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTgtMS0xLTc2MDQ2_515ae4c8-984a-4083-9832-57a62de1414f"
      unitRef="usd">13000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19e0d73c72e24eca8ca94e49eb15e6a5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTEwLTEtMS03NjA0Ng_1e003259-f1fa-491a-932e-0e2de2732357"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2926456ed6654d0a91dee92754e33edf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTEyLTEtMS03NjA0Ng_8d97496b-ded8-402f-80b9-66a17e59c98a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic3af41c88515492095e14241259a0e07_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE2LTE0LTEtMS03NjA0Ng_d2ea17c0-c33a-40f4-944b-4ff2a5659783"
      unitRef="usd">13000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2e9646a432a9439688c513fb0ec0887f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTItMS0xLTc2MDQ2_631576ea-f745-4b3d-816e-8a87da693f4c"
      unitRef="usd">5243000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2e9646a432a9439688c513fb0ec0887f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTQtMS0xLTc2MDQ2_6351db57-b73a-4a42-9265-24304bc41d7d"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2e9646a432a9439688c513fb0ec0887f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTYtMS0xLTc2MDQ2_ac0ec1b3-66be-412d-8559-45904bd83ce3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e9646a432a9439688c513fb0ec0887f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTgtMS0xLTc2MDQ2_34d2328b-ad57-44b5-a986-df76388175c1"
      unitRef="usd">5247000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ca3868ec35146878138ef39c9381dab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTEwLTEtMS03NjA0Ng_eb132296-1f99-42bc-a729-15da4ca08ed9"
      unitRef="usd">2624000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib4fe368718ae402a88feb1ddaf1fdc8d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTEyLTEtMS03NjA0Ng_eba45a0d-e4d4-4dc7-92a4-e500e2c6b2dc"
      unitRef="usd">1984000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e686917771642979115acea50d66bd1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2NWM4Mjc3MDg0NGI0M2E2OTIxZjFjNWUzMTAwNDdlYi90YWJsZXJhbmdlOjY1YzgyNzcwODQ0YjQzYTY5MjFmMWM1ZTMxMDA0N2ViXzE3LTE0LTEtMS03NjA0Ng_fa263398-dfcf-4654-85ad-e13174c65f2b"
      unitRef="usd">639000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzIwOTM_a24981e2-5d29-41ff-a195-83d4724ffd5a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost and estimated fair value of marketable securities, by contractual maturity at December 31, 2021 and 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzItMi0xLTEtNzYwNDY_e92465d5-e694-4910-ac65-9c00078f6cbf"
      unitRef="usd">3882000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzItNC0xLTEtNzYwNDY_11b6c51a-7c70-465b-b372-64af08de7678"
      unitRef="usd">3879000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzMtMi0xLTEtNzYwNDY_c057da75-b97b-4599-a8ce-e75dcd0d22d2"
      unitRef="usd">6892000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzMtNC0xLTEtNzYwNDY_170142e1-3513-40b6-9820-9de1ec06b3db"
      unitRef="usd">6843000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzQtMi0xLTEtNzYwNDY_2906997d-fe95-4fa9-a618-2d9ffb4497a6"
      unitRef="usd">10774000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzQtNC0xLTEtNzYwNDY_d7a7da50-e0d5-4fa2-95d4-d733faf221a3"
      unitRef="usd">10722000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzctMi0xLTEtNzYwNDY_1f646944-5943-417a-a540-0103b958d55f"
      unitRef="usd">1981000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzctNC0xLTEtNzYwNDY_f821f85f-6eb3-4118-80c6-4b0c506d3bde"
      unitRef="usd">1984000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzgtMi0xLTEtNzYwNDY_88580956-a2c3-4646-a689-e23717fc4e85"
      unitRef="usd">638000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzgtNC0xLTEtNzYwNDY_94c0f02c-8c5d-425e-b52d-1cab17042784"
      unitRef="usd">639000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzktMi0xLTEtNzYwNDY_71866e61-d1c6-4205-aa44-ffbfaeaa94d4"
      unitRef="usd">2619000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZToxZGMxMDM2MzM0YTg0OTQ2YjQ3ZTM0MThiYjQzOGQ3Zi90YWJsZXJhbmdlOjFkYzEwMzYzMzRhODQ5NDZiNDdlMzQxOGJiNDM4ZDdmXzktNC0xLTEtNzYwNDY_3bd55c71-cec2-478a-b4e6-0a97a6de8bd7"
      unitRef="usd">2623000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzY2Ng_13c9e1f8-f4d2-4c92-866f-293dcb815ed1"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzY2Ng_91aa8dd7-5e3a-4539-bc9a-eb259eba6494"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzY2Ng_f00cf999-5aa0-4a68-95ce-3fb265d196fc"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzkzNDU4NDg4Mzg1NzY_867a1a24-296b-46fd-9958-54053908306c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzkzNDU4NDg4Mzg1NzY_d2cf9b75-81ea-4833-8b0a-c9fa6ab7e8ed"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzIwOTY_27144506-2402-4c92-ba33-0d8a9f6995fa">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by length of time the securities have been in an unrealized loss position at December 31, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or More&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMi0xLTEtMTA3OTcx_14576402-868a-4d5c-b7b3-5fce5c63fd07"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNC0xLTEtMTA3OTcx_869973cb-5e94-4803-a0d1-0a5b2bae356e"
      unitRef="usd">329000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNi0xLTEtMTA3OTcx_53ab4d57-221c-4e32-8c1b-2c210bed3272"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtOC0xLTEtMTA3OTcx_a5b451ad-4b29-49a3-a088-e4540d2912ca"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTAtMS0xLTEwNzk3MQ_71686217-ebc3-45f9-9b61-5827c3159dc6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i4a2bda740e174d91b71bb62076e623b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTItMS0xLTEwNzk3MQ_30ffa4e1-8851-4ddb-9479-7d46b6b3a288"
      unitRef="usd">329000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i6d743eab86de4393a005da034dc6076d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMi0xLTEtODMyODI_19e10327-e183-4219-bfa8-317e2d5558b3"
      unitRef="usd">31000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i6d743eab86de4393a005da034dc6076d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNC0xLTEtODMyODI_d5815cda-e162-4733-9643-e69495dfc208"
      unitRef="usd">6332000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i6d743eab86de4393a005da034dc6076d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNi0xLTEtODMyODI_02786126-3222-4fec-a47b-96cc7b425b50"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i6d743eab86de4393a005da034dc6076d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtOC0xLTEtODMyODI_c3df409c-4d15-4952-a88a-02104d583067"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i6d743eab86de4393a005da034dc6076d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTAtMS0xLTgzMjgy_86d6d1fa-0cba-4c6e-8750-1f7129d224aa"
      unitRef="usd">31000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i6d743eab86de4393a005da034dc6076d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTItMS0xLTgzMjgy_e3de3703-1ccd-470c-aa70-03a6f30a8ec2"
      unitRef="usd">6332000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib08aa8be8be24796b00714b57780c548_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMi0xLTEtODk4NDM_aaa89d24-9ecb-4312-a993-148f2ce67239"
      unitRef="usd">20000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib08aa8be8be24796b00714b57780c548_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtNC0xLTEtODk4NDM_2cc91cd6-a50c-445b-821f-c8ed636f7a8b"
      unitRef="usd">2573000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ib08aa8be8be24796b00714b57780c548_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtNi0xLTEtODk4NDM_4d33b62d-f647-4675-b4c7-f2f1c6f7b98f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ib08aa8be8be24796b00714b57780c548_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtOC0xLTEtODk4NDM_c08ea786-3b04-4cc8-b624-2de87a0df1a6"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ib08aa8be8be24796b00714b57780c548_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMTAtMS0xLTg5ODQz_289da113-59a9-4932-8300-81f02323e963"
      unitRef="usd">20000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ib08aa8be8be24796b00714b57780c548_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMTItMS0xLTg5ODQz_46a240ee-1d61-475f-87e5-df2174e2817c"
      unitRef="usd">2574000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMi0xLTEtNzYwNDY_3099f6cd-aff6-4b2f-b64a-adc90ba40ff3"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNC0xLTEtNzYwNDY_2e130b1d-9afc-444e-952c-d140dbe1ba27"
      unitRef="usd">112000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtNi0xLTEtNzYwNDY_9f3fa592-c15a-4392-8a86-6af78bb92bd3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtOC0xLTEtNzYwNDY_afa3ca43-89d9-43f2-b7a1-ffe2d225b42f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTAtMS0xLTc2MDQ2_1344e268-9ac2-4cea-ac8b-52980f80fad2"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i3cfc4e8bb05c4fae962fb281635face7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzQtMTItMS0xLTc2MDQ2_68e523cb-33a9-44bb-80b3-3a4f872fe102"
      unitRef="usd">112000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMi0xLTEtNzYwNDY_4a2a51e3-643c-4c50-b3b9-2947f95af7d6"
      unitRef="usd">52000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtNC0xLTEtNzYwNDY_51717f96-a53f-4f38-a512-34f406157fb5"
      unitRef="usd">9346000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtNi0xLTEtNzYwNDY_8bf52613-a596-4062-bd71-a367e874fead"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtOC0xLTEtNzYwNDY_b483815a-d467-41dc-844e-ef8409ec56c5"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMTAtMS0xLTc2MDQ2_fe409754-e6e9-4290-b021-86363ad729c5"
      unitRef="usd">52000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo3YjJmNTA2NDJmNzE0NDMwOWVjMGU5Njc4OTlkZWIyNy90YWJsZXJhbmdlOjdiMmY1MDY0MmY3MTQ0MzA5ZWMwZTk2Nzg5OWRlYjI3XzUtMTItMS0xLTc2MDQ2_640ffa22-3478-462b-96d2-70065f03af6a"
      unitRef="usd">9347000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90ZXh0cmVnaW9uOjYzYjFlZTA5ZGM4MDQzMWJhZGQwM2IyYjM3OTAxYmNhXzIwOTc_688d8abb-d4d3-43cb-ba44-a125f2f49cbb">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our financial assets measured at fair value on a recurring basis as of December 31, 2021 and 2020 (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments (Note 7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b7c01916db3408ab5ad64668966705b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzMtMi0xLTEtNzYwNDY_8c454fac-5bb3-4d19-8b4a-2552199d093b"
      unitRef="usd">2329000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01fbfe4a2aeb4f52a6e5832316a78b96_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzMtNC0xLTEtNzYwNDY_9b0b154c-db25-47a1-b160-f1f4d9dd5472"
      unitRef="usd">2329000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib3b71762f59d402fb8c3f8db8d6a2794_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzMtNi0xLTEtNzYwNDY_d841df81-febf-4478-a8f0-cbdf7a61a7df"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i173e555f8608496f9662755df4a4507f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzQtMi0xLTEtNzYwNDY_2ef90a47-f34e-41b7-9988-4be2fea9791a"
      unitRef="usd">80000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7aa28c6c4754b4cac1648572278cb7c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzQtNC0xLTEtNzYwNDY_93bc3fba-66cc-4945-9575-50942e5cbf44"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33a1bd3236264470831ed902e1ec14fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzQtNi0xLTEtNzYwNDY_77d72811-0027-43ba-8c84-7d702b3be23c"
      unitRef="usd">80000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc3a736dedb0468eb2b96e05d6a5b5cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzUtMi0xLTEtNzYwNDY_e681b16a-4e87-4302-a2df-b8b96b3d33d9"
      unitRef="usd">479000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01cb8657700e404391363a5b93c94298_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzUtNC0xLTEtNzYwNDY_bdea4562-b30d-4fe6-b444-6fa323abf709"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37f7bfa072504774a46de61549ed1358_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzUtNi0xLTEtNzYwNDY_0ab0995d-9ff9-46da-99a3-b5bac63c8880"
      unitRef="usd">479000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a410f63e2a34faeb71837e163488553_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtMi0xLTEtNzg2MjU_0adad64e-16b0-4761-a0ec-a5d4ded0dfe5"
      unitRef="usd">6564000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id11c2636a9e849b199e50f122b90bfb4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtNC0xLTEtNzg2MjU_0da44687-3a81-4a48-813f-3beb297cd316"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i08a786fc7c8548f99e9260ccc849d096_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtNi0xLTEtNzg2MjU_13aca6c3-65b3-46eb-a152-41f59310da0e"
      unitRef="usd">6564000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib091b3d4b2c54a35b6370a090b778180_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctMi0xLTEtNzg2MjU_cbd0e815-29c4-4c3c-ac25-68593896369c"
      unitRef="usd">3488000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i82fff40b8cf5418684879ad0b808d851_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctNC0xLTEtNzg2MjU_2a57c032-7c69-4f13-a112-f06fbe89d684"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf5ed5b20a464aa69fffcc07449d6b65_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctNi0xLTEtNzg2MjU_bb336ea4-22d4-465c-9510-aced9ec604a2"
      unitRef="usd">3488000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4435c73f09eb44d4992e01d4922d5bc6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtMi0xLTEtNzYwNDY_27054d26-c8a5-42d6-9082-a6149f8b23b9"
      unitRef="usd">111000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa3443efd7954041a7b94f68574c1294_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtNC0xLTEtNzYwNDY_e928f6e9-1224-4e65-ad4a-edb300a0f279"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18bab6b5e239439c88900de725d422b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzYtNi0xLTEtNzYwNDY_37f61f28-a982-4dd8-81d9-4076203a500e"
      unitRef="usd">111000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeAssets
      contextRef="i7d3fc18fdc324f1aa20d24c095339419_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctMi0xLTEtNzYwNDY_0911ab1b-6151-4c8b-a37c-4ec6e12de058"
      unitRef="usd">21000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if9147f3587c94165889e686e4d2ea8b9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctNC0xLTEtNzYwNDY_cfecfa98-5511-4705-8c8c-b6fd7a84c193"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i76d4434bc6c044c7b3f4e94fb304ff0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzctNi0xLTEtNzYwNDY_8eadde83-ce91-46db-8ae4-9d36967519d6"
      unitRef="usd">21000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7d3fc18fdc324f1aa20d24c095339419_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzgtMi0xLTEtNzYwNDY_c97aa368-c88a-4e89-b9b8-1a8d2ec99b18"
      unitRef="usd">13072000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if9147f3587c94165889e686e4d2ea8b9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzgtNC0xLTEtNzYwNDY_acc84199-c112-49e3-8423-99b12f1dc5b6"
      unitRef="usd">2329000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i76d4434bc6c044c7b3f4e94fb304ff0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzgtNi0xLTEtNzYwNDY_0186af4e-fa41-428f-becc-fa371a124a81"
      unitRef="usd">10743000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i7d3fc18fdc324f1aa20d24c095339419_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzEyLTItMS0xLTc4NjI1_db9e7eda-feb8-4ed2-a7a3-a2967f883f6d"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if9147f3587c94165889e686e4d2ea8b9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzEyLTQtMS0xLTc4NjI1_01a11172-09c6-4076-9bba-be64d9e0f315"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i76d4434bc6c044c7b3f4e94fb304ff0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTo2YTJjNzU5NzMyOTI0Y2U0YTczMTIyNGI5MGIyNjZjNy90YWJsZXJhbmdlOjZhMmM3NTk3MzI5MjRjZTRhNzMxMjI0YjkwYjI2NmM3XzEyLTYtMS0xLTc4NjI1_ca262bde-ebed-4e1b-bd1f-437aa5d33d75"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id626af309354471c938a13ee987efb1f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtMi0xLTEtNzg1OTg_cb665562-a40a-4225-8efa-1db0de0cfa42"
      unitRef="usd">660000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia847fc5aaa414970962b3e66c726b6d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtNC0xLTEtNzg1OTg_13b455f4-5ab9-4097-9245-718514882b2b"
      unitRef="usd">660000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60349844b567496a8c96cb156669e486_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtNi0xLTEtNzg1OTg_a9399c89-ebae-4da3-ab93-21816997f3d2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4e351d2d1764d1e970af57129ac281f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtMi0xLTEtNzYwNDY_b2c8351a-07bb-47f8-b746-61e9396c1eb1"
      unitRef="usd">239000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iabdcd1636c89453094af591ed45cb1ab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtNC0xLTEtNzYwNDY_a08d639a-df91-477e-9468-4a655822c5ff"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib52d1393c6a94df1a1ed227bb14cad8a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzMtNi0xLTEtNzYwNDY_ee4014d0-5427-4796-a333-87657b69bd03"
      unitRef="usd">239000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i87eab6cd7a7f48e0b5a9796ab31c2d6e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzQtMi0xLTEtNzYwNDY_6b5d42d8-7de8-4972-95ec-30a842c4dd1d"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia1e243dab0bc4efaa8d7f2b398dcdab5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzQtNC0xLTEtNzYwNDY_f9855ef8-13fd-40a4-8590-7d5f9e28d22c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i294dcfa26a8843f783242f2540ba31cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzQtNi0xLTEtNzYwNDY_4c9cf990-0e24-4ecf-94f9-26d18177c462"
      unitRef="usd">492000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80e7eff5bd6c4c9b84f96355143d2190_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtMi0xLTEtNzg1OTg_c5358176-d6c5-4be6-9b1a-947bf3c2e9fd"
      unitRef="usd">87000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i12d89d325c9641979afcb1133eb38c92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtNC0xLTEtNzg1OTg_a534a070-1454-47ee-8412-f9c6f9b49cc4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62a0a9d758df464cb7896474951b0ac5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtNi0xLTEtNzg1OTg_b0ee1d29-4951-40c2-87d1-5224fec592fc"
      unitRef="usd">87000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic39fb570a4f842229f0fb89db305d537_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzctMi0xLTEtNzg1OTg_6f9f8e9b-9175-4ab5-a503-34e7c5ae4f87"
      unitRef="usd">1792000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6600cb5746c3408c9cb209436ced4bd4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzctNC0xLTEtNzg1OTg_6c81e2ba-6c0d-495e-acd2-5b0fb391b22a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i56c3185ed7d04fccbb21599da90453cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzctNi0xLTEtNzg1OTg_a7582823-c552-4f12-8bd7-3570a53afb44"
      unitRef="usd">1792000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id8b05b51f2234fc58d69e6a80fa771ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzUtMi0xLTEtNzYwNDY_2fdf5a68-9d0c-458a-ab04-98786684cce8"
      unitRef="usd">13000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic3992f82ad0c4b249387e250c043245a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzUtNC0xLTEtNzYwNDY_236e495e-1ed4-479f-a4cb-092b59791543"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6d422efa75e467d98852994a450a9ae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzUtNi0xLTEtNzYwNDY_96b232cf-964c-4b95-bf90-1d0f08864de2"
      unitRef="usd">13000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibf2f9fe6eb684be982187b0507723e2b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtMi0xLTEtNzYwNDY_b011808b-933b-439c-8b9c-a1be9e98e613"
      unitRef="usd">3283000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8e6dc104953e4bb395df7081eca0082a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtNC0xLTEtNzYwNDY_deacbe0e-8d7f-42c8-8dbe-b17289fd5bcd"
      unitRef="usd">660000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie2b92fa7550f4911b44a79ebc01be5fd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDIvZnJhZzo2M2IxZWUwOWRjODA0MzFiYWRkMDNiMmIzNzkwMWJjYS90YWJsZTplMWY4MTVmMmJmYjE0MDFiOTg1M2I2MTgzYjZjMGFhYy90YWJsZXJhbmdlOmUxZjgxNWYyYmZiMTQwMWI5ODUzYjYxODNiNmMwYWFjXzYtNi0xLTEtNzYwNDY_24a241e3-3c68-4388-8bf7-a0620a972c3b"
      unitRef="usd">2623000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90ZXh0cmVnaW9uOmM2MzY0ZmM0OTM4ZDRiYjJhMTdiZmRhNjM2ZTRiMjJkXzIzMjk_e90afae3-dd93-4203-aa6e-ecca6882de76">Derivative Financial Instruments&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We transact business in various foreign currencies and have international sales and expenses denominated in foreign currencies. Therefore, we are exposed to certain risks arising from both our business operations and economic conditions. Our risk management strategy includes the use of derivative financial instruments to hedge foreign currency exchange rate fluctuations on monetary assets or liabilities denominated in foreign currencies. We do not enter into derivative financial contracts for speculative or trading purposes. We do not believe that we are exposed to more than a nominal amount of credit risk in our foreign currency hedges, as counterparties are large, global and well-capitalized financial institutions. We classify cash flows from our derivative transactions as cash flows from operating activities in our consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate the foreign exchange risk arising from the fluctuations in foreign currency denominated product sales in Euro through a foreign currency cash flow hedging program, using forward contracts and foreign currency options that do not exceed 15 months in duration. We hedge these cash flow exposures to reduce the risk that our earnings and cash flows will be adversely affected by changes in exchange rates. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The derivative assets or liabilities associated with our hedging activities are recorded at fair value in other current assets or other current liabilities, respectively, in our consolidated balance sheets. The gains or losses resulting from changes in the fair value of these hedges are initially recorded as a component of AOCI in stockholders&#x2019; equity and subsequently reclassified to product sales in the period during which the hedged transaction affects earnings. In the event the underlying forecasted transaction does not occur, or it becomes &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;probable that it will not occur, within the defined hedge period, we reclassify the gains or losses on the related cash flow hedge from AOCI to other expense, net, in our consolidated statements of operations. We evaluate hedge effectiveness at the inception of the hedge prospectively, and on an on-going basis both retrospectively and prospectively. If we do not elect hedge accounting, or the contract does not qualify for hedge accounting treatment, the changes in fair value from period to period are recorded as a component of other expense, net, in our consolidated statements of operations. As of December 31, 2021, we had net deferred gains of $21&#160;million on our foreign currency forward contracts included in AOCI that are expected to be recognized into product sales within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Balance Sheet Hedges&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We enter into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily accounts receivable, accounts payable, and lease liabilities in Euro and Swiss Franc, that are not designated for hedge accounting treatment. Therefore, these forward contracts are accounted for as derivatives whereby the fair value of the contracts are reported as other current assets or other current liabilities on our consolidated balance sheets, and gains and losses resulting from changes in the fair value are recorded as a component of other expense, net, in our consolidated statements of operations. The gains and losses on these foreign currency forward contracts generally offset the gains and losses in the underlying foreign currency denominated assets and liabilities, which are also recorded to other expense, net, in our consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross notional amount and fair value for foreign currency derivatives were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as cash flow hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;_________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the consolidated balance sheet within prepaid expenses and other current assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the consolidated balance sheets within other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gains on our foreign currency derivatives, net of tax, recognized in our consolidated statements of comprehensive income (loss) for the year ended December 31, 2021 was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives in cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effect of derivative instruments in our consolidated statements of operations for the year ended December 31, 2021 was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives in cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gains reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized and unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There were immaterial hedging gains and losses for the year ended December 31, 2020 and no hedging gains or losses for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90ZXh0cmVnaW9uOmM2MzY0ZmM0OTM4ZDRiYjJhMTdiZmRhNjM2ZTRiMjJkXzIxOTkwMjMyNjI4Mzg_6083b3c8-6db5-4c24-90c2-2af468b4fef9"
      unitRef="usd">21000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90ZXh0cmVnaW9uOmM2MzY0ZmM0OTM4ZDRiYjJhMTdiZmRhNjM2ZTRiMjJkXzIzMjc_0457b12a-29a0-4761-891b-12693adc9b45">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total gross notional amount and fair value for foreign currency derivatives were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as cash flow hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;_________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the consolidated balance sheet within prepaid expenses and other current assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As presented in the consolidated balance sheets within other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Gains on our foreign currency derivatives, net of tax, recognized in our consolidated statements of comprehensive income (loss) for the year ended December 31, 2021 was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives in cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The effect of derivative instruments in our consolidated statements of operations for the year ended December 31, 2021 was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Statement of Operations Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives in cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gains reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realized and unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5931b912876541d6882f7bd7117de3f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzQtMi0xLTEtNzg2NTA_fdb52f03-75fe-4533-b310-5e2ee58c29b5"
      unitRef="usd">565000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i5931b912876541d6882f7bd7117de3f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzQtNC0xLTEtNzg2NTA_80f86a39-581d-4657-bf26-210b020d08c0"
      unitRef="usd">20000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i5931b912876541d6882f7bd7117de3f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzQtNi0xLTEtNzg2NTA_6783a94c-c7bd-4b33-8ef2-4e762bb19e36"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i77eee50ddfaa4eb0bc9f201ff1631518_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzctMi0xLTEtNzg2NTA_a9767111-2f19-4cb5-882e-830785d1e7b6"
      unitRef="usd">1370000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i77eee50ddfaa4eb0bc9f201ff1631518_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzctNC0xLTEtNzg2NTA_9ba48f7a-e4e4-470e-8238-e29a6bf3954a"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i77eee50ddfaa4eb0bc9f201ff1631518_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzctNi0xLTEtNzg2NTA_2461d7b2-27c9-495b-9785-8576e7812dbe"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzgtMi0xLTEtNzg2NTA_c704f808-10fe-4b6a-9044-9744b8fffe5a"
      unitRef="usd">1935000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzgtNC0xLTEtNzg2NTA_d9dff89f-9093-4b45-8e19-afa95559786a"
      unitRef="usd">21000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTpiMGI4OTE1M2ZhOGM0MTgxOWY5ZjczYTQ4YzQ3ZjQxZC90YWJsZXJhbmdlOmIwYjg5MTUzZmE4YzQxODE5ZjlmNzNhNDhjNDdmNDFkXzgtNi0xLTEtNzg2NTA_0b4c4568-4398-4795-b9fb-c61a12bfd058"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if4dca9b9d97e4b8f946f52de263fa1d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzQtMi0xLTEtNzYwNDY_3f64885c-b461-4739-9ce0-1bb09bf0e176"
      unitRef="usd">368000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="if4dca9b9d97e4b8f946f52de263fa1d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzQtNC0xLTEtNzYwNDY_7848ab89-cd35-4327-a41f-79097c8533f8"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="if4dca9b9d97e4b8f946f52de263fa1d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzQtNi0xLTEtNzYwNDY_56e9a3fa-1a95-4453-ab82-bf0ad91b6e43"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5c3187a0bb484bae8f0a6c5412316823_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzUtMi0xLTEtNzYwNDY_07a8b394-b9a7-4a68-9943-2cc3f249534c"
      unitRef="usd">368000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i5c3187a0bb484bae8f0a6c5412316823_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzUtNC0xLTEtNzYwNDY_5af0d1ee-f973-40c1-977a-1d371529a5cd"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i5c3187a0bb484bae8f0a6c5412316823_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3ZmQxZGMyNWRiOGE0NDA2OGNjYjA4OWNhNjE1MTA1Ny90YWJsZXJhbmdlOjdmZDFkYzI1ZGI4YTQ0MDY4Y2NiMDg5Y2E2MTUxMDU3XzUtNi0xLTEtNzYwNDY_d22c070c-7aee-4cb5-ba58-d61117f09c0e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo3MGE3OGVkMzYxNTQ0N2JjODcwOWM5ZDU1YjdiZTBlMy90YWJsZXJhbmdlOjcwYTc4ZWQzNjE1NDQ3YmM4NzA5YzlkNTViN2JlMGUzXzItNC0xLTEtOTE1MTc_50619b46-429c-4891-9255-49953c3a6fe2"
      unitRef="usd">74000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i752522e455054df9a2d4aa0487c93c8a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo1NmQzZThlMzI4YTg0ZTE5YmYyYWVmNGE2ZTZlNmQ0YS90YWJsZXJhbmdlOjU2ZDNlOGUzMjhhODRlMTliZjJhZWY0YTZlNmU2ZDRhXzMtNC0xLTEtNzg2NjM_a2190ef5-9d49-4cff-8531-25f6e294f0f8"
      unitRef="usd">58000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i40de3a67fca0427cba0abb81a8d5a822_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDUvZnJhZzpjNjM2NGZjNDkzOGQ0YmIyYTE3YmZkYTYzNmU0YjIyZC90YWJsZTo1NmQzZThlMzI4YTg0ZTE5YmYyYWVmNGE2ZTZlNmQ0YS90YWJsZXJhbmdlOjU2ZDNlOGUzMjhhODRlMTliZjJhZWY0YTZlNmU2ZDRhXzctNC0xLTEtNzg2NjM_4cd07dea-5ebb-45ec-b6c3-c6e1e8b1b25f"
      unitRef="usd">-8000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90ZXh0cmVnaW9uOjA2M2E3MDViYzM4ODQxMzc5MmM3MTljNDU0MTE1ZjBhXzEzNg_2164e1fb-8fde-40f8-80bc-b792712ebc1e">Inventory&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory as of December 31, 2021 and 2020 consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90ZXh0cmVnaW9uOjA2M2E3MDViYzM4ODQxMzc5MmM3MTljNDU0MTE1ZjBhXzEzNw_c0ec1902-a6b4-415f-b32c-3d37dd8cc2e9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory as of December 31, 2021 and 2020 consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzItMi0xLTEtNzYwNDY_af4b8ac1-1548-4987-b8b6-3929ad0e7e58"
      unitRef="usd">870000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzItNC0xLTEtNzg3MTI_f0962d7f-692c-4904-a283-a8e6edf6176e"
      unitRef="usd">37000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzMtMi0xLTEtNzYwNDY_c9bbdbd5-f612-4260-99ce-7f2f1db3cac5"
      unitRef="usd">338000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzMtNC0xLTEtNzg3MTI_e1d1f1fa-813b-452f-83be-d7375c79322f"
      unitRef="usd">9000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzQtMi0xLTEtNzYwNDY_69f4bbee-ec70-41ff-9aaa-f6047d2f11f3"
      unitRef="usd">233000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzQtNC0xLTEtNzg3MTI_a18d4b97-bf86-468d-b466-8b1ca9fec474"
      unitRef="usd">1000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzUtMi0xLTEtNzYwNDY_a095f4b9-d2bc-4234-a8f7-927b770b0bc9"
      unitRef="usd">1441000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNDgvZnJhZzowNjNhNzA1YmMzODg0MTM3OTJjNzE5YzQ1NDExNWYwYS90YWJsZTo2YmQ1NjhlMDg2N2M0MDU5OGZkMzMwYjM1OGExYjU3YS90YWJsZXJhbmdlOjZiZDU2OGUwODY3YzQwNTk4ZmQzMzBiMzU4YTFiNTdhXzUtNC0xLTEtNzg3MTI_ad3d4a53-92f4-48b8-bfca-391b05b081a1"
      unitRef="usd">47000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90ZXh0cmVnaW9uOmQyYmRiMGYxM2NiNzRmNjQ5NmZhNjRlOGM4MjE1OTk4XzIyMw_df5d5876-2724-4d02-b23c-ca3831a69a85">Property and Equipment&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset, financing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for the&#160;years ended December 31, 2021, 2020, and 2019 was $232 million, $31 million, and $31 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i6e772279375842a09317b961798ebf1a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzItMi0xLTEtNzYwNDY_b3a9157d-9357-48f0-b851-8dbc0159dc53"
      unitRef="usd">175000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i2bd10a6d680840d5be716e5efb005792_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzItNC0xLTEtNzYwNDY_725c8908-f563-471b-bad4-4433e075c3f6"
      unitRef="usd">121000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i2897c9b7abc74af58f8fb9170b4279dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzMtMi0xLTEtNzYwNDY_04e96cbe-ca0d-461e-9bcb-9d6b1ec84e60"
      unitRef="usd">313000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i2277cdd9a1184c06a13b5d2759fc2d43_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzMtNC0xLTEtNzYwNDY_c1e3e840-46c7-452c-bdf4-bcc8d55abf31"
      unitRef="usd">180000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i7b99b4a3a3f74767a37af24660286fb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzQtMi0xLTEtNzYwNDY_7f26ddd9-7047-4b1f-8553-4e3af163399c"
      unitRef="usd">11000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="iabac96aed6194cfe8293e8e6b78f7add_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzQtNC0xLTEtNzYwNDY_9c1256d4-cba1-4e27-b783-a255cedaaa7c"
      unitRef="usd">5000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i98d6bacd287f4b1593818f823e5f7584_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzUtMi0xLTEtNzYwNDY_a607ae73-dc7c-4b48-8bab-9c159714f51d"
      unitRef="usd">16000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie04bbbe54baa412abc405e89a1039ed6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzUtNC0xLTEtNzYwNDY_0422b21f-e5e9-42ef-bb9b-ab9e33da9744"
      unitRef="usd">13000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="if546ef6f1b4b42b7a555f52ec50a3fb8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzYtMi0xLTEtNzYwNDY_934c8c42-b9f7-4e4a-b9e4-0f99bc90c2fa"
      unitRef="usd">9000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i71f80f04049942b6a29f789ba29f2842_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzYtNC0xLTEtNzYwNDY_ec165e4c-9ae8-4a1d-9fa3-821c0065f2a0"
      unitRef="usd">7000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i10c346ed8a6f4ad482321e52eccd7724_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzctMi0xLTEtNzYwNDY_5ce18b10-455f-415d-b90f-fe363f52404f"
      unitRef="usd">857000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="id5c2998e0814472496ed510917d7a471_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzctNC0xLTEtNzYwNDY_49df3b6c-b10d-4e84-bc64-d879ee99bb58"
      unitRef="usd">56000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ibcda5455344c4505b3c57aa248aa98ba_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzgtMi0xLTEtNzYwNDY_6f6161d9-c047-429f-ab84-f13b68506c5a"
      unitRef="usd">212000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i7a2e86586b9a43d89a4d752842cfa050_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzgtNC0xLTEtNzYwNDY_d4398793-4c8d-4989-b2f7-cf2a21499b47"
      unitRef="usd">35000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzktMi0xLTEtNzYwNDY_83777a69-ccd4-4220-93ed-2c33cac1bbdb"
      unitRef="usd">1593000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzktNC0xLTEtNzYwNDY_0f360837-22cc-43b4-9e88-417e25594ed3"
      unitRef="usd">417000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzEwLTItMS0xLTc2MDQ2_e3a0018f-6e69-4b7e-8123-834749cae9db"
      unitRef="usd">352000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzEwLTQtMS0xLTc2MDQ2_1bf45f71-ee61-4d0f-a776-219958ce9045"
      unitRef="usd">120000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzExLTItMS0xLTc2MDQ2_b83b4c4a-ca54-4b62-9780-e47123e341bc"
      unitRef="usd">1241000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90YWJsZTpmODQzMWVhY2RmZTk0YmQyYjRiZDdjYWQxMTgzOTcxNS90YWJsZXJhbmdlOmY4NDMxZWFjZGZlOTRiZDJiNGJkN2NhZDExODM5NzE1XzExLTQtMS0xLTc2MDQ2_b4194bba-5c9f-4bf7-a4d5-f99268aac134"
      unitRef="usd">297000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90ZXh0cmVnaW9uOmQyYmRiMGYxM2NiNzRmNjQ5NmZhNjRlOGM4MjE1OTk4XzIxOTkwMjMyNTU5NjI_221843dd-3527-4848-9f50-b07ce165f338"
      unitRef="usd">232000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90ZXh0cmVnaW9uOmQyYmRiMGYxM2NiNzRmNjQ5NmZhNjRlOGM4MjE1OTk4XzIxOTkwMjMyNTU5NjY_8111b2b2-d5e8-4306-8ba3-ddbdebd89fe4"
      unitRef="usd">31000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTEvZnJhZzpkMmJkYjBmMTNjYjc0ZjY0OTZmYTY0ZThjODIxNTk5OC90ZXh0cmVnaW9uOmQyYmRiMGYxM2NiNzRmNjQ5NmZhNjRlOGM4MjE1OTk4XzIxOTkwMjMyNTU5NzA_e65ece00-15ca-47e5-a853-4234cdd93369"
      unitRef="usd">31000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90ZXh0cmVnaW9uOmQ0MjVjYmRlODBkMDRkODM4ZTQxZDkwMzZmNmFiZjIyXzUzNg_c7918c58-d1a8-40be-b116-5bae1e0a73b9">Other Balance Sheet Components&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Down payments to manufacturing vendors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value added tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tenant improvement allowance receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - financing (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - operating (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activities in deferred revenue during the year ended December 31, 2021 (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90ZXh0cmVnaW9uOmQ0MjVjYmRlODBkMDRkODM4ZTQxZDkwMzZmNmFiZjIyXzU0MQ_5cce76d4-cac4-472b-bcd6-3215bd6c07b0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Down payments to manufacturing vendors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value added tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tenant improvement allowance receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <mrna:OtherPrepaidExpenseManufacturing
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzItMi0xLTEtNzYwNDY_7adf0077-4982-4f74-b74a-25432e9dceb5"
      unitRef="usd">405000000</mrna:OtherPrepaidExpenseManufacturing>
    <mrna:OtherPrepaidExpenseManufacturing
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzItNC0xLTEtNzYwNDY_3fa2d032-390d-42bd-b0c0-62092b5c2d4c"
      unitRef="usd">217000000</mrna:OtherPrepaidExpenseManufacturing>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzMtMi0xLTEtNzYwNDY_b395be33-eaf3-43fd-9cae-687100c474d9"
      unitRef="usd">126000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzMtNC0xLTEtNzYwNDY_3b6760e8-b09b-44da-95e1-284a5eb372d2"
      unitRef="usd">7000000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzQtMi0xLTEtNzg4MDA_115edf67-bdd0-4105-8c24-608200b2ded0"
      unitRef="usd">70000000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzQtNC0xLTEtNzg4MDA_6ed4adbc-ebc3-48bf-a947-7ec1cf66864f"
      unitRef="usd">7000000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzQtMi0xLTEtNzYwNDY_345aed79-3b29-44e9-b3b0-e135330e28a7"
      unitRef="usd">21000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzQtNC0xLTEtNzYwNDY_5cbde837-c369-45d7-839f-ce8911a3480f"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <mrna:TenantImprovementAllowanceReceivableCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzYtMi0xLTEtMTA5OTkx_c075c513-6976-4bf6-be01-bd37a40b8e91"
      unitRef="usd">51000000</mrna:TenantImprovementAllowanceReceivableCurrent>
    <mrna:TenantImprovementAllowanceReceivableCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzYtNC0xLTEtMTA5OTkx_27ebc16a-f937-4aa7-aca0-3ca3d7b6457f"
      unitRef="usd">10000000</mrna:TenantImprovementAllowanceReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzUtMi0xLTEtNzYwNDY_f578cd3a-c730-4548-adb8-714150b4e9ff"
      unitRef="usd">55000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzUtNC0xLTEtNzYwNDY_7a340153-5761-43ad-ba76-4c802f849a6d"
      unitRef="usd">11000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzYtMi0xLTEtNzYwNDY_7243e552-ce20-481e-ae75-4ea0508a2685"
      unitRef="usd">728000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpmODU3OTJmYTJkYmU0YzU2OTZhZjE2NTE4NzQwYTZkZC90YWJsZXJhbmdlOmY4NTc5MmZhMmRiZTRjNTY5NmFmMTY1MTg3NDBhNmRkXzYtNC0xLTEtNzYwNDY_82e26f7e-fc83-4c50-80c0-3187b987f0ec"
      unitRef="usd">252000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90ZXh0cmVnaW9uOmQ0MjVjYmRlODBkMDRkODM4ZTQxZDkwMzZmNmFiZjIyXzUzOA_868d2c76-c3c7-45ed-ab02-ade6e6fa1577">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other external goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation-related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <mrna:AccruedClinicalTrials
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzItMi0xLTEtNzYwNDY_3791a353-1b7a-46d4-a71e-1617c19a01f1"
      unitRef="usd">283000000</mrna:AccruedClinicalTrials>
    <mrna:AccruedClinicalTrials
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzItNC0xLTEtNzYwNDY_79293e28-a47c-4251-bc25-5e571e70c930"
      unitRef="usd">98000000</mrna:AccruedClinicalTrials>
    <mrna:RawMaterialsAccountsPayable
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzMtMi0xLTEtNzYwNDY_e61bc314-dc8c-4600-a873-9f30e37ea393"
      unitRef="usd">260000000</mrna:RawMaterialsAccountsPayable>
    <mrna:RawMaterialsAccountsPayable
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzMtNC0xLTEtNzYwNDY_a72744ca-7ca1-408f-9189-571c93ee3cd8"
      unitRef="usd">78000000</mrna:RawMaterialsAccountsPayable>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzQtMi0xLTEtNzYwNDY_fb439a38-57de-4226-b64f-4b23a0f84d19"
      unitRef="usd">241000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzQtNC0xLTEtNzYwNDY_f2854525-21a3-4f4c-a898-c1adf9976369"
      unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <mrna:AccruedDevelopmentOperation
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzUtMi0xLTEtNzYwNDY_c9ad902c-5ca5-419a-b6e3-0d0d2d6c8034"
      unitRef="usd">137000000</mrna:AccruedDevelopmentOperation>
    <mrna:AccruedDevelopmentOperation
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzUtNC0xLTEtNzYwNDY_223a963a-e7f7-423a-adc8-93c0a88e7d90"
      unitRef="usd">29000000</mrna:AccruedDevelopmentOperation>
    <mrna:AccruedManufacturing
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzYtMi0xLTEtNzYwNDY_26372f09-dd06-429a-89dd-a56a00437bb5"
      unitRef="usd">227000000</mrna:AccruedManufacturing>
    <mrna:AccruedManufacturing
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzYtNC0xLTEtNzYwNDY_5a0e0a76-5f75-45a0-b76b-01d4fc46c69f"
      unitRef="usd">53000000</mrna:AccruedManufacturing>
    <mrna:AccruedOtherExternalGoodsAndServicesCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzctMi0xLTEtNzYwNDY_7a367b28-0747-4164-8e38-a27006787159"
      unitRef="usd">79000000</mrna:AccruedOtherExternalGoodsAndServicesCurrent>
    <mrna:AccruedOtherExternalGoodsAndServicesCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzctNC0xLTEtNzYwNDY_8d3087d7-17a8-4668-a5c1-d2a6c35c15ce"
      unitRef="usd">92000000</mrna:AccruedOtherExternalGoodsAndServicesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzgtMi0xLTEtNzYwNDY_19e58f78-b174-42e2-b1ed-7b763e500d3a"
      unitRef="usd">126000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzgtNC0xLTEtNzYwNDY_79f7970d-d9b3-42b8-8810-2798086ce733"
      unitRef="usd">95000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzktMi0xLTEtNzYwNDY_37a94ee8-ee5b-4751-a499-8be7113640dc"
      unitRef="usd">119000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzktNC0xLTEtNzYwNDY_050163c2-90fa-460f-a781-517d110d9207"
      unitRef="usd">25000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzEwLTItMS0xLTc2MDQ2_e792301a-990f-46e0-a4bd-55f2ad700976"
      unitRef="usd">1472000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTo2ZWZhZjUzODEzNDY0M2EyOWYzZThlZGRhZjQ4MTk3YS90YWJsZXJhbmdlOjZlZmFmNTM4MTM0NjQzYTI5ZjNlOGVkZGFmNDgxOTdhXzEwLTQtMS0xLTc2MDQ2_12e04fc6-b1d0-4a01-a1ae-a26c3631f456"
      unitRef="usd">470000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90ZXh0cmVnaW9uOmQ0MjVjYmRlODBkMDRkODM4ZTQxZDkwMzZmNmFiZjIyXzU0MA_f4f02264-6711-44e8-af40-a76efc0d78c0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities, as of December 31, 2021 and 2020 consisted of the following (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.888%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.057%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - financing (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities - operating (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzItMi0xLTEtNzYwNDY_6ee362ba-ae17-4b79-94c9-5045a7d84798"
      unitRef="usd">165000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzItNC0xLTEtNzYwNDY_b1c0ce9f-c51b-42cc-820f-59c5ddf0b607"
      unitRef="usd">24000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzMtMi0xLTEtNzYwNDY_0276b1e0-2027-47f7-8d41-88678d64e756"
      unitRef="usd">46000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzMtNC0xLTEtNzYwNDY_a98817ad-7358-487f-b760-110de2a7f4c9"
      unitRef="usd">6000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzQtMi0xLTEtNzYwNDY_f53caaeb-e2f9-4be9-8773-e361617b3eec"
      unitRef="usd">14000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzQtNC0xLTEtNzYwNDY_5115c5aa-0a43-4454-99f3-76b28bb9ff46"
      unitRef="usd">4000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzUtMi0xLTEtNzYwNDY_3b018cc6-c380-4da0-9f2f-932ba91b109f"
      unitRef="usd">225000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTplOTExOTNhYzk2ZmE0OGU3OTc3YTgxMTE5NzIyZmIyOC90YWJsZXJhbmdlOmU5MTE5M2FjOTZmYTQ4ZTc5NzdhODExMTk3MjJmYjI4XzUtNC0xLTEtNzYwNDY_3d32e46c-f8a1-482d-bcd3-9406a129ac04"
      unitRef="usd">34000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if49f6e27f6284519912ffac03c002a55_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzEtMi0xLTEtNzYwNDY_2264c611-ce8e-4176-b9d0-03207ac93413"
      unitRef="usd">3799000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i0613309ccd7f4770b391e463a962e99b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzEtNC0xLTEtNzYwNDY_d4bfc64b-03e3-46f0-899c-ce2e32ee6179"
      unitRef="usd">11657000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="i0613309ccd7f4770b391e463a962e99b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzEtNi0xLTEtNzYwNDY_7d70bee0-9e9a-4f3f-8a07-396087d3d30e"
      unitRef="usd">8798000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i346fef81e10f4f86a929d87bf0cb041b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzEtOC0xLTEtNzYwNDY_99ce9969-2556-4b74-86eb-e79a946e9a5f"
      unitRef="usd">6658000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3d2b742992e44e86ba5d409dbd33d210_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzItMi0xLTEtNzYwNDY_7a55c3cc-df20-4d35-9462-024b35c8f03e"
      unitRef="usd">5000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i1806b5a0029947c1aabb49f5e058cb28_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzItNC0xLTEtNzYwNDY_45d8d729-767e-4593-bdd5-9eca2e78d3c2"
      unitRef="usd">12000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="i1806b5a0029947c1aabb49f5e058cb28_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzItNi0xLTEtNzYwNDY_e459906a-f9d4-4524-822f-016c321053ba"
      unitRef="usd">11000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic39bcf7b2bd641cbbe600df4d3b15b80_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzItOC0xLTEtNzYwNDY_d504d1c6-f7e7-4131-a103-f96a1d3c5662"
      unitRef="usd">6000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id85722b295e94fcc9a11009c7e8f8554_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzMtMi0xLTEtNzYwNDY_6a741c74-d84d-4f1f-afc5-5030e78bd890"
      unitRef="usd">240000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i0e182cbaac1c44c8aaf481c02d369892_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzMtNC0xLTEtNzYwNDY_794e385f-245c-4a38-b832-3394e95153c5"
      unitRef="usd">27000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="i0e182cbaac1c44c8aaf481c02d369892_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzMtNi0xLTEtNzYwNDY_ccda6433-0a47-4a1a-bda9-2655e825e44d"
      unitRef="usd">63000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i49b0ad1b467146e3b5880e21ed60e03c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzMtOC0xLTEtNzYwNDY_cd54521a-70a8-4b04-936d-abacd44adc15"
      unitRef="usd">204000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzQtMi0xLTEtNzYwNDY_95bb3f52-ba87-4c9d-ac4c-24fe6e87603c"
      unitRef="usd">4044000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzQtNC0xLTEtNzYwNDY_ed9cff79-24f4-4a35-a568-a6014f3ed019"
      unitRef="usd">11696000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzQtNi0xLTEtNzYwNDY_d07c473d-7d21-4623-83a4-5ac63f3802df"
      unitRef="usd">8872000000</mrna:ContractWithCustomerLiabilityDeductionsDuringPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTQvZnJhZzpkNDI1Y2JkZTgwZDA0ZDgzOGU0MWQ5MDM2ZjZhYmYyMi90YWJsZTpjOWFhMDVhYjUwNDU0YmYwOWU5YjcxNjUwMDY0M2NmNS90YWJsZXJhbmdlOmM5YWEwNWFiNTA0NTRiZjA5ZTliNzE2NTAwNjQzY2Y1XzQtOC0xLTEtNzYwNDY_ed86a6e1-e5fc-4b40-94f6-3eb822993ee5"
      unitRef="usd">6868000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNDU_0672f515-5e5a-4fc5-b60b-a3f716dda77a">Leases &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2042. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge campus and our Moderna Technology Center (MTC), located in Norwood. We also lease other office and lab spaces globally for our business operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cambridge Campus&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occupy a multi-building campus at Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 261,000 square feet. Our Cambridge campus leases have expiry ranges from 2024 to 2029.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, we entered into an amendment to our lease agreements to consolidate our Technology Square space in Cambridge, Massachusetts. This included entering into a forward-starting lease agreement starting in January 2020 to acquire approximately 50,000 square feet of additional space at 200 Technology Square. In addition, our existing 200 Technology Square lease was extended for two years to 2029. As part of the lease amendment, we completely exited our leased space of approximately 60,000 square feet at 500 Technology Square by May 2020. We are also investing in a new Moderna Science Center (MSC) in Cambridge, to create a purpose-built space to support our next chapter of discovery (see Note 12). In connection with our MSC investment, in September 2021, we entered into an amendment to our lease agreements to allow for an option for early termination of the leases, either in part or full. Notification of the intent to exercise the option must be provided by August 2023. We have not elected to exercise this option. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record operating lease cost for each of our operating leases on a straight-line basis from lease commencement date through the end of the lease term. Operating lease cost is recorded in operating expenses in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Technology Center&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an industrial technology center in Norwood, Massachusetts, our Moderna Technology Center (MTC), which comprises three buildings, MTC South, MTC North, and MTC East.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space (MTC South). The lease had an initial expiration of September&#160;2032 with the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet (MTC North). The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031 with the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22&#160;million to be paid back over the term of the lease with interest and extend the term of the lease to 2035.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, we entered into a lease agreement for a 240,000 square foot building for expansion of our commercial and clinical activities (MTC East). The lease had an initial expiration date of February 2034 with the option to extend the term for two extension periods of five years each at market-based rents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, we entered into an omnibus amendment to extend the lease terms of our three MTC leases to 2042. We have the option to extend the term for three extension periods of five years. The base rent is subject to increases over the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Embedded Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of December 31, 2021 and 2020, we had lease liabilities of $166&#160;million and $24 million, respectively, related to the embedded leases. Certain embedded leases dedicated to our COVID-19 vaccine program prior to the EUA from the FDA were deemed to have no alternative use. The related right-of-use assets of $62 million were charged to research and development expense for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2021 and 2020 were as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_6434c373-a6c6-4f7b-8ef6-3d80253a9ae7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_762aa615-9010-420a-8e46-65bbadd6aae4"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_51501eb6-f175-4107-9a50-9a2a310ec651"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_b87ed32e-1ce9-4db8-a202-ed428939aa44"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_7ec179f5-0fc3-4708-bddf-316daed00725"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_859dcb73-429c-4521-9717-2a4efe10e6f1"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property and equipment in the consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the lease costs for the years ended December 31, 2021 and 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amortization of right-of-use assets, financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Interest expense for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financing lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information relating to our leases for the years ended December 31, 2021 and 2020 was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Financing cash flows used in financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease terms and discount rates as of December 31, 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2021, were as follows (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;(1)  Include the optional extensions in the MTC lease terms which represent a total of $637 million undiscounted future lease payments.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNDc_b2e007c9-30ae-4d69-9374-d309e4eac19a">Leases &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into various long-term non-cancelable lease arrangements for our facilities and equipment expiring at various times through 2042. Certain of these arrangements have free rent periods or escalating rent payment provisions, which we recognize lease cost under such arrangements on a straight-line basis over the life of the leases. We have two campuses in Massachusetts, our Cambridge campus and our Moderna Technology Center (MTC), located in Norwood. We also lease other office and lab spaces globally for our business operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cambridge Campus&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occupy a multi-building campus at Technology Square in Cambridge, Massachusetts with a mix of offices and research laboratory space totaling approximately 261,000 square feet. Our Cambridge campus leases have expiry ranges from 2024 to 2029.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, we entered into an amendment to our lease agreements to consolidate our Technology Square space in Cambridge, Massachusetts. This included entering into a forward-starting lease agreement starting in January 2020 to acquire approximately 50,000 square feet of additional space at 200 Technology Square. In addition, our existing 200 Technology Square lease was extended for two years to 2029. As part of the lease amendment, we completely exited our leased space of approximately 60,000 square feet at 500 Technology Square by May 2020. We are also investing in a new Moderna Science Center (MSC) in Cambridge, to create a purpose-built space to support our next chapter of discovery (see Note 12). In connection with our MSC investment, in September 2021, we entered into an amendment to our lease agreements to allow for an option for early termination of the leases, either in part or full. Notification of the intent to exercise the option must be provided by August 2023. We have not elected to exercise this option. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record operating lease cost for each of our operating leases on a straight-line basis from lease commencement date through the end of the lease term. Operating lease cost is recorded in operating expenses in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Moderna Technology Center&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have an industrial technology center in Norwood, Massachusetts, our Moderna Technology Center (MTC), which comprises three buildings, MTC South, MTC North, and MTC East.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August&#160;2016, we entered into a lease agreement for approximately&#160;200,000&#160;square feet of office, laboratory, and light manufacturing space (MTC South). The lease had an initial expiration of September&#160;2032 with the option to extend the term for&#160;two&#160;extension periods of&#160;ten years&#160;each at market-based rents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, we entered into a lease agreement for office and laboratory space of approximately 200,000 square feet (MTC North). The lease commenced in the second quarter of 2019 and had an initial expiration date of 2031 with the option to extend the lease for up to four additional five-year terms. In May 2020, we entered into an amendment to the lease whereby we exercised an option available in the original lease to receive a tenant improvement allowance in the amount of $22&#160;million to be paid back over the term of the lease with interest and extend the term of the lease to 2035.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, we entered into a lease agreement for a 240,000 square foot building for expansion of our commercial and clinical activities (MTC East). The lease had an initial expiration date of February 2034 with the option to extend the term for two extension periods of five years each at market-based rents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, we entered into an omnibus amendment to extend the lease terms of our three MTC leases to 2042. We have the option to extend the term for three extension periods of five years. The base rent is subject to increases over the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Embedded Leases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into multiple contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. As of December 31, 2021 and 2020, we had lease liabilities of $166&#160;million and $24 million, respectively, related to the embedded leases. Certain embedded leases dedicated to our COVID-19 vaccine program prior to the EUA from the FDA were deemed to have no alternative use. The related right-of-use assets of $62 million were charged to research and development expense for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2021 and 2020 were as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_6434c373-a6c6-4f7b-8ef6-3d80253a9ae7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_762aa615-9010-420a-8e46-65bbadd6aae4"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_51501eb6-f175-4107-9a50-9a2a310ec651"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_b87ed32e-1ce9-4db8-a202-ed428939aa44"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_7ec179f5-0fc3-4708-bddf-316daed00725"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_859dcb73-429c-4521-9717-2a4efe10e6f1"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property and equipment in the consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the lease costs for the years ended December 31, 2021 and 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amortization of right-of-use assets, financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Interest expense for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financing lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information relating to our leases for the years ended December 31, 2021 and 2020 was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Financing cash flows used in financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease terms and discount rates as of December 31, 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2021, were as follows (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;(1)  Include the optional extensions in the MTC lease terms which represent a total of $637 million undiscounted future lease payments.</us-gaap:LesseeFinanceLeasesTextBlock>
    <mrna:OperatingLeaseNumberOfProperties
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzM3Mg_47fb6a1f-129a-4021-a216-eb3c4870932b"
      unitRef="numberofcampuses">2</mrna:OperatingLeaseNumberOfProperties>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i055ce861cca24357869370abf095c083_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzY4Mw_ca31ab3e-7fab-4dbe-a885-0af45b63ee9f"
      unitRef="sqft">261000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i7645640582764d538a26db2e1fb80bd0_I20190831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEwMjI_c5e25e75-6f47-4eae-95b3-e920c68da523"
      unitRef="sqft">50000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i7645640582764d538a26db2e1fb80bd0_I20190831"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzExNTg_dd77363e-58eb-41c9-8d03-1d4280f4ce61">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i32ea0d8664c84fe1a0db2e016c5ba70b_I20190831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEyNTc_a43c87d6-9c3d-4a54-ab32-aceccdf6b3da"
      unitRef="sqft">60000</us-gaap:AreaOfRealEstateProperty>
    <mrna:FinanceLeaseNumberOfProperties
      contextRef="i7589e8c5201244e4985147f06c09e73a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEzNzQzODk1MzYzOTky_01f36754-d8fa-4b32-aa43-a09ebe9bef2d"
      unitRef="numberofbuilding">3</mrna:FinanceLeaseNumberOfProperties>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i1927cdc0d1694e40a55dd6d90f64c6d1_I20160831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzI5MjA_bd2e1cee-dd8f-46cd-810a-805261d38830"
      unitRef="sqft">200000</us-gaap:AreaOfRealEstateProperty>
    <mrna:LesseeOperatingLeaseNumberOfExtension
      contextRef="i1927cdc0d1694e40a55dd6d90f64c6d1_I20160831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzMxMTA_ce19fe4d-7cf3-45a0-99c7-18f88a2a191d"
      unitRef="numberofextensionperiod">2</mrna:LesseeOperatingLeaseNumberOfExtension>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i1927cdc0d1694e40a55dd6d90f64c6d1_I20160831"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzMxMzQ_6960405c-91a6-4ea6-8f3a-5519cf5ebd7f">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i2855b96dce1e43fb93b06fb655b72372_I20190228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzE0MjkzNjUxMTcxMzE5_d00c5d7c-1fdc-4965-9f12-1caf4ae63b34"
      unitRef="sqft">200000</us-gaap:AreaOfRealEstateProperty>
    <mrna:LesseeOperatingLeaseNumberOfExtension
      contextRef="i2855b96dce1e43fb93b06fb655b72372_I20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzE0MjkzNjUxMTcxNTI1_a67420fe-b6a9-4936-9cef-607fa282d302"
      unitRef="numberofextensionperiod">4</mrna:LesseeOperatingLeaseNumberOfExtension>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i2855b96dce1e43fb93b06fb655b72372_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzMyOTg1MzQ5MDAxMzI_b422570a-402a-4c02-b502-795e64963c1d">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mrna:AllowanceForTenantImprovements
      contextRef="i8db7171778ef4c6f97f7530182111044_I20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEzNzQzODk1MzYzOTQ5_0b009a62-e361-489f-be7c-d4dbd27ad248"
      unitRef="usd">22000000</mrna:AllowanceForTenantImprovements>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i9a0fc37d8e2145f98d23f3d4b7ed48a7_I20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzE0MjkzNjUxMTczOTcw_0b0e65e1-de30-4379-9fe4-729cbceb6e91"
      unitRef="sqft">240000</us-gaap:AreaOfRealEstateProperty>
    <mrna:LesseeOperatingLeaseNumberOfExtension
      contextRef="i9a0fc37d8e2145f98d23f3d4b7ed48a7_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzE0MjkzNjUxMTc0MTcy_da7734fc-2ce4-49ec-8b56-338934dd803c"
      unitRef="numberofextensionperiod">2</mrna:LesseeOperatingLeaseNumberOfExtension>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i9a0fc37d8e2145f98d23f3d4b7ed48a7_I20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzE0MjkzNjUxMTc0MTk3_c736a429-99a2-48b1-936b-06a1ef737ab0">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mrna:FinanceLeaseNumberOfProperties
      contextRef="i7589e8c5201244e4985147f06c09e73a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzMyOTg1MzQ5MDAxMzM_20bc9517-1ddd-4439-863d-b596abdbf182"
      unitRef="numberofbuilding">3</mrna:FinanceLeaseNumberOfProperties>
    <mrna:LesseeOperatingLeaseNumberOfExtension
      contextRef="i7589e8c5201244e4985147f06c09e73a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEzNzQzODk1MzYzOTYx_a10601fa-7bec-4493-9ba4-76d89773c65c"
      unitRef="numberofextensionperiod">3</mrna:LesseeOperatingLeaseNumberOfExtension>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i7589e8c5201244e4985147f06c09e73a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzEzNzQzODk1MzYzOTc1_43f1a471-e379-40f4-8fbf-90bdf0e95a1d">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3d4877c3015e41fcb264f294807448d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzIxOTkwMjMyNjM4NjA_6d915d27-1436-4d9a-8355-0da61e844d47"
      unitRef="usd">166000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i637c86f9cdcd4c4696566a2667590b81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzM0Mzg_4eaeec10-926c-4ad4-b2b2-cdf873b9eac5"
      unitRef="usd">24000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i637c86f9cdcd4c4696566a2667590b81_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzM2NDQ_2f40c260-ae11-4cd7-ad91-4784faf17c6e"
      unitRef="usd">62000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNDY_5e3ac407-395a-4b7c-8592-e107a592a96d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and financing lease right-of-use assets and lease liabilities as of December 31, 2021 and 2020 were as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_6434c373-a6c6-4f7b-8ef6-3d80253a9ae7"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMC0xLTEtOTA1NzE_762aa615-9010-420a-8e46-65bbadd6aae4"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) (4)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_51501eb6-f175-4107-9a50-9a2a310ec651"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMC0xLTEtNzYwNDY_b87ed32e-1ce9-4db8-a202-ed428939aa44"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt;text-indent:-22.51pt"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_7ec179f5-0fc3-4708-bddf-316daed00725"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTAtMS0xLTc2MDQ2_859dcb73-429c-4521-9717-2a4efe10e6f1"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are real estate related assets, which include land, office and laboratory spaces.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net of accumulated amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These assets are&#160;real estate assets related to the MTC leases as well as assets related to contract manufacturing service agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in property and equipment in the consolidated balance sheets, net of accumulated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in other current liabilities in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzMtMi0xLTEtNzYwNDY_dfbab9c8-06ff-4e81-96f8-526e3ed80a1c"
      unitRef="usd">142000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzMtNC0xLTEtNzYwNDY_71549f95-f8c6-4594-938b-353c135bc35d"
      unitRef="usd">90000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtMi0xLTEtNzYwNDY_bcaecf54-f29b-4141-a349-29e99f49c06c"
      unitRef="usd">665000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzQtNC0xLTEtNzYwNDY_1b9eab71-8220-44ec-abbc-1e5f9e2b43f7"
      unitRef="usd">55000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <mrna:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzUtMi0xLTEtNzYwNDY_fa0b7ee9-79dd-4da9-b184-b2f83a77ee0f"
      unitRef="usd">807000000</mrna:OperatingAndFinanceLeaseRightOfUseAsset>
    <mrna:OperatingAndFinanceLeaseRightOfUseAsset
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzUtNC0xLTEtNzYwNDY_826b53a9-cf2e-477e-b820-4ad533224d77"
      unitRef="usd">145000000</mrna:OperatingAndFinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktMi0xLTEtNzYwNDY_98a7912c-c0c7-4161-89ab-31833bdd9677"
      unitRef="usd">46000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzktNC0xLTEtNzYwNDY_84e70952-a5fe-4ff8-ac38-41cc2ebda204"
      unitRef="usd">6000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTItMS0xLTc2MDQ2_2cd2a922-dfbd-4157-8619-ed17c4fb4046"
      unitRef="usd">165000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEwLTQtMS0xLTc2MDQ2_b7f20ebe-219a-433d-8c41-549826577a24"
      unitRef="usd">24000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzExLTItMS0xLTc2MDQ2_dd5e3362-e179-4378-a6f9-1910812c13bb"
      unitRef="usd">211000000</mrna:OperatingAndFinanceLeaseLiabilityCurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzExLTQtMS0xLTc2MDQ2_f8fe7219-3a6e-425c-90b3-bb0c34e04d3f"
      unitRef="usd">30000000</mrna:OperatingAndFinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEzLTItMS0xLTc2MDQ2_acf00b0e-318d-4f95-821f-2ac90a8900a3"
      unitRef="usd">106000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzEzLTQtMS0xLTc2MDQ2_85714587-1c5c-46c9-8c23-5df22959e405"
      unitRef="usd">97000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE0LTItMS0xLTc2MDQ2_a1fe9de3-2a02-4d28-b0c9-bd9eb2365f8d"
      unitRef="usd">599000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE0LTQtMS0xLTc2MDQ2_aeaf4abd-603b-48d0-b2fb-75161a0e8d56"
      unitRef="usd">110000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE1LTItMS0xLTc2MDQ2_bbe00b5f-24d4-45a5-8f26-91dc73393e35"
      unitRef="usd">705000000</mrna:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE1LTQtMS0xLTc2MDQ2_d8afdffe-e034-4962-b873-b702f3e48a11"
      unitRef="usd">207000000</mrna:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <mrna:OperatingAndFinanceLeaseLiability
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE2LTItMS0xLTc2MDQ2_b3ea3abe-eaa5-47f1-ba9b-0f6774289dc6"
      unitRef="usd">916000000</mrna:OperatingAndFinanceLeaseLiability>
    <mrna:OperatingAndFinanceLeaseLiability
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo3YjRkZmI5ZmFmNzc0NDFiOTEwNmU4N2ViYjFkYjk1OC90YWJsZXJhbmdlOjdiNGRmYjlmYWY3NzQ0MWI5MTA2ZTg3ZWJiMWRiOTU4XzE2LTQtMS0xLTc2MDQ2_2bd2ed0a-3b2c-4f22-b3e1-5c50cd701f5d"
      unitRef="usd">237000000</mrna:OperatingAndFinanceLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNTQ_fc08dba2-99b3-444b-8c6e-a40dffbc8e30">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the lease costs for the years ended December 31, 2021 and 2020 were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amortization of right-of-use assets, financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Interest expense for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financing lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information relating to our leases for the years ended December 31, 2021 and 2020 was as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Financing cash flows used in financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease non-cash items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in right-of-use assets related to lease modifications and reassessments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease terms and discount rates as of December 31, 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzItMi0xLTEtNzYwNDY_6a8b5bee-5451-4afa-98dc-2b273b125715"
      unitRef="usd">24000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzItNC0xLTEtNzYwNDY_3a74efd1-c003-4d4e-9c14-132e79d229c8"
      unitRef="usd">17000000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzQtMi0xLTEtNzYwNDY_c332ce07-78d5-4b9e-8061-076c689a20c1"
      unitRef="usd">189000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzQtNC0xLTEtNzYwNDY_88732e29-48e8-4034-bc7b-e67047f359b7"
      unitRef="usd">1000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzUtMi0xLTEtNzYwNDY_0d68093f-f9ee-4e0b-9e1e-bbb29ad7cb05"
      unitRef="usd">17000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzUtNC0xLTEtNzYwNDY_4bd6b113-8597-4456-9d05-6fd9004deb82"
      unitRef="usd">10000000</us-gaap:FinanceLeaseInterestExpense>
    <mrna:FinanceLeaseCost
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzYtMi0xLTEtNzYwNDY_139b5735-ee33-454b-94aa-c806f758f389"
      unitRef="usd">206000000</mrna:FinanceLeaseCost>
    <mrna:FinanceLeaseCost
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzYtNC0xLTEtNzYwNDY_82c061e7-23f8-4d25-b50d-ce8072a788e9"
      unitRef="usd">11000000</mrna:FinanceLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzctMi0xLTEtNzYwNDY_50d8ff5d-2b03-493d-b11a-bae2a60d1322"
      unitRef="usd">49000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzctNC0xLTEtNzYwNDY_4b3b9bab-3dc8-456f-9f49-0725a96c7749"
      unitRef="usd">13000000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzgtMi0xLTEtNzYwNDY_8dc2c4ae-3155-4200-ae46-93e366904821"
      unitRef="usd">100000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTphMjhmZGMyYmY3MDE0Mzc5YWU2MmE0NjBlNGNiMWRmYi90YWJsZXJhbmdlOmEyOGZkYzJiZjcwMTQzNzlhZTYyYTQ2MGU0Y2IxZGZiXzgtNC0xLTEtNzYwNDY_8394afc8-35ad-48e2-ac60-40c4422dbe04"
      unitRef="usd">5000000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzMtMi0xLTEtNzYwNDY_3586dff5-182a-4cbb-aed9-08e750f37b0e"
      unitRef="usd">19000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzMtNC0xLTEtNzYwNDY_39d6739d-687b-4a2b-a770-ba97b0549c3a"
      unitRef="usd">15000000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzQtMi0xLTEtNzYwNDY_3df2ab18-30cf-4d98-9417-24d8a6c317a1"
      unitRef="usd">14000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzQtNC0xLTEtNzYwNDY_75e964ba-ef03-4ae3-b605-874d626249f6"
      unitRef="usd">9000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzUtMi0xLTEtNzYwNDY_56e945bf-3bf8-48a3-aa8e-1a0b2bad45d6"
      unitRef="usd">140000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzUtNC0xLTEtNzYwNDY_9c7e6074-aaf1-4c52-a7e8-7241d0ae482a"
      unitRef="usd">8000000</us-gaap:FinanceLeasePrincipalPayments>
    <mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzgtMi0xLTEtNzYwNDY_3b30d0d1-b3b3-4e01-a0e4-47c1cfc6b96e"
      unitRef="usd">-7000000</mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments>
    <mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzgtNC0xLTEtNzYwNDY_e945e392-c8d2-4109-a6d7-48e16d890489"
      unitRef="usd">7000000</mrna:RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzktMi0xLTEtNzYwNDY_abf12e6f-7bd9-4ab3-ac2c-d3164eb36686"
      unitRef="usd">72000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzktNC0xLTEtNzYwNDY_496f0e14-2961-436e-8d35-71690e754e3f"
      unitRef="usd">17000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEyLTItMS0xLTc2MDQ2_15ad9bfe-46ef-4bcd-bef5-2a26c4a42a37"
      unitRef="usd">674000000</mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments>
    <mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEyLTQtMS0xLTc2MDQ2_2a58d46b-38a4-44ee-83d5-9ad5f3f5fa69"
      unitRef="usd">46000000</mrna:RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEzLTItMS0xLTk0NzMx_db4e8ad0-f8b6-49e9-b40f-978ec9a25b43"
      unitRef="usd">126000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEzLTQtMS0xLTk0NzMx_31394e4b-0e52-4bfb-a4a2-88f9cf25676a"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <mrna:LesseeFinanceLeaseExpense
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEzLTItMS0xLTc2MDQ2_9e348b5d-3d52-4fda-9dfe-c6f7c6ecdfb0"
      unitRef="usd">3000000</mrna:LesseeFinanceLeaseExpense>
    <mrna:LesseeFinanceLeaseExpense
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo4MjE5M2ViZTMzMjk0NWVjYWYyYWYyYTc1MDBlMmJmNC90YWJsZXJhbmdlOjgyMTkzZWJlMzMyOTQ1ZWNhZjJhZjJhNzUwMGUyYmY0XzEzLTQtMS0xLTc2MDQ2_6d1e4ba0-1c25-40ad-ab8c-067b64eff089"
      unitRef="usd">1000000</mrna:LesseeFinanceLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo5ZThlNTY0NTUyYTg0N2QyYTY5ZjRhZDllZGFmMDQwOC90YWJsZXJhbmdlOjllOGU1NjQ1NTJhODQ3ZDJhNjlmNGFkOWVkYWYwNDA4XzMtMi0xLTEtNzYwNDY_6f631c49-ffc5-4db8-af2b-3d4aeccad8f6">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo5ZThlNTY0NTUyYTg0N2QyYTY5ZjRhZDllZGFmMDQwOC90YWJsZXJhbmdlOjllOGU1NjQ1NTJhODQ3ZDJhNjlmNGFkOWVkYWYwNDA4XzQtMi0xLTEtNzYwNDY_df79d454-1924-417c-8fbe-bc23166e8604">P28Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo5ZThlNTY0NTUyYTg0N2QyYTY5ZjRhZDllZGFmMDQwOC90YWJsZXJhbmdlOjllOGU1NjQ1NTJhODQ3ZDJhNjlmNGFkOWVkYWYwNDA4XzYtMi0xLTEtNzYwNDY_86253a60-582e-445c-8016-1807e1a00195"
      unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTo5ZThlNTY0NTUyYTg0N2QyYTY5ZjRhZDllZGFmMDQwOC90YWJsZXJhbmdlOjllOGU1NjQ1NTJhODQ3ZDJhNjlmNGFkOWVkYWYwNDA4XzctMi0xLTEtNzYwNDY_8357e99a-21d0-4ca0-8fe5-6be8107b8a3a"
      unitRef="number">0.031</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNDk_8c107cff-6e69-4f73-a8a2-18d9a4f687ba">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2021, were as follows (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;(1)  Include the optional extensions in the MTC lease terms which represent a total of $637 million undiscounted future lease payments.</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzUxNTA_c51a718c-1024-4c42-84b4-8b7cf23a46a4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancelable lease agreements as of&#160;December 31, 2021, were as follows (in&#160;millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______&lt;/span&gt;&lt;/div&gt;(1)  Include the optional extensions in the MTC lease terms which represent a total of $637 million undiscounted future lease payments.</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzEtMi0xLTEtNzYwNDY_3097a728-7e1e-4c36-9e4f-bc88932f7c0c"
      unitRef="usd">54000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzEtNC0xLTEtNzYwNDY_c801bb2b-6148-4ec1-94c2-c6b32b30936d"
      unitRef="usd">184000000</us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzItMi0xLTEtNzYwNDY_59ffeac8-b049-4cda-b78e-504e9fafcea9"
      unitRef="usd">39000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzItNC0xLTEtNzYwNDY_bb82db8d-a7b5-45fd-8970-0962db64d563"
      unitRef="usd">20000000</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzMtMi0xLTEtNzYwNDY_ef136a34-9447-4933-94b3-25cc2bce4798"
      unitRef="usd">15000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzMtNC0xLTEtNzYwNDY_bd4e6709-56d4-46db-a783-2385db227d76"
      unitRef="usd">20000000</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzQtMi0xLTEtNzYwNDY_093fe3c7-69ec-4a44-8db8-d28076abe676"
      unitRef="usd">16000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzQtNC0xLTEtNzYwNDY_03e28979-a8ee-427b-9e83-9e7cc0a9b2e1"
      unitRef="usd">20000000</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzUtMi0xLTEtNzYwNDY_f9ffd4ae-ddd3-44f9-a67a-4df9a24b7336"
      unitRef="usd">16000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzUtNC0xLTEtNzYwNDY_f3665cec-9ca2-4ec4-94a6-ddbc28e329e8"
      unitRef="usd">21000000</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzYtMi0xLTEtNzYwNDY_9a4acf40-dae0-488c-b977-a8b2b9075536"
      unitRef="usd">51000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzYtNC0xLTEtNzYwNDY_d5b3bc30-fc52-4a64-9aee-515e5aa41da6"
      unitRef="usd">1058000000</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzctMi0xLTEtNzYwNDY_7342f11c-6f4b-482f-b09a-34bd48dd9c50"
      unitRef="usd">191000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzctNC0xLTEtNzYwNDY_48a99da1-1390-4d76-944f-7dd36863abb2"
      unitRef="usd">1323000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzgtMi0xLTEtNzYwNDY_dd240443-64c5-4b6b-932a-6822fa45ec59"
      unitRef="usd">39000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzgtNC0xLTEtNzYwNDY_8b04c0e7-48a9-4c2c-aaa6-63008948655e"
      unitRef="usd">559000000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzktMi0xLTEtNzYwNDY_e61c259d-b579-4e39-88f8-d15837cf7f01"
      unitRef="usd">152000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90YWJsZTpiNzQ0YTI4MmU2MGY0ZTQ4YTcwYTkzZmJhMTUwNDdiZi90YWJsZXJhbmdlOmI3NDRhMjgyZTYwZjRlNDhhNzBhOTNmYmExNTA0N2JmXzktNC0xLTEtNzYwNDY_450f42fc-d420-4e72-b39a-44fcdb2d28a4"
      unitRef="usd">764000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i5f976ec484ae4420800a7fe5ea5fc4eb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNTcvZnJhZzo4YzIwNDg5MjE4ZGI0NzUxYjU0YjdkMDkyMjNjNzk5MS90ZXh0cmVnaW9uOjhjMjA0ODkyMThkYjQ3NTFiNTRiN2QwOTIyM2M3OTkxXzQ5NjQ_b3e3dacc-4c2e-4f9f-98a7-686fe5a7bec0"
      unitRef="usd">637000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzYxOTg_33536f83-6175-4261-a597-cdb9c8b63cd2">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not currently a party to any material legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer&#x2019;s or director&#x2019;s lifetime.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December 31, 2021 and 2020, we had not experienced any losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments and Purchase Orders&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into agreements in the normal course of business with vendors and contract manufacturing organizations (CMOs) for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of December 31, 2021, we had $2.5&#160;billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2025. As of December 31, 2021, we had $89&#160;million of non-cancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2026. These amounts represent our minimum contractual obligations, including termination fees.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to purchase commitments, we have agreements with third parties for various services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. At December 31, 2021, we had cancelable open purchase orders of $2.4 billion in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December 31, 2021, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licenses to Patented Technology&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;26, 2017, we entered into sublicense agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc. to sublicense certain patent rights. Pursuant to each agreement, we are required to pay certain license fees, annual maintenance fees, minimum royalties on future net sales and milestone payments contingent on achievement of certain development, regulatory and commercial milestones for specified products, on a product-by-product basis. Commercial milestone payments, up to $24&#160;million, and royalties based on annual net sales of licensed products for therapeutic and prophylactic products are accounted for as additional expense of the related product sales in the period in which the corresponding sales occur. In 2021 and 2020, we recognized $641&#160;million and $7&#160;million, respectively, of royalties and commercial milestone payments associated with our product sales, which was recorded to cost of sales in our consolidated statements of operations. We did not recognize any such royalties and payments in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments for specified products associated with the agreements. The achievement of these milestones was not deemed probable as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Moderna Science Center&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, we announced an investment in the development of the MSC in Cambridge, Massachusetts. The MSC is expected to integrate scientific and non-scientific spaces, including our principal executive offices, and will be built to support our growth as we continue to advance our pipeline of mRNA medicines. In relation to the investment, we entered into a lease agreement for approximately 462,000 square feet and will undergo an approximately two-year building project. Following completion of the building project, the lease term is 15 years, subject to our right to extend the lease for up to two additional seven-year terms. Pursuant to this lease agreement, we are committed to approximately $1.1&#160;billion non-cancellable rent payments for the initial lease term. We expect to begin a phased move-in process in 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="iffb8aaeb04f94a9091ac85eb8f851b96_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzE4MTY_12614902-5569-479e-b40e-49c33bf131b6"
      unitRef="usd">0</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="i76f6a7263a5e4d65a40dd2d77b9fe3d2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzE4MTY_d7eb1dbf-f7c9-4702-8ebb-470d2387d7c0"
      unitRef="usd">0</us-gaap:LossContingencyLossInPeriod>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i8894beaec40b4471a73954ee11728b2a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzE4OTM_192cbf29-0f6a-4a27-83ff-c9d57c0b8759"
      unitRef="claim">0</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i56f7cbe6568c4de9ac2033f8024b12fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzE4OTM_415f22c6-0221-4e78-8d6a-b6856960cabc"
      unitRef="claim">0</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i56f7cbe6568c4de9ac2033f8024b12fd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxMDA_125b77ad-06bf-45ad-a3ad-0f6fabe546a0"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i8894beaec40b4471a73954ee11728b2a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxMDA_d7f70723-e4a8-4740-b215-c1669f9eaf38"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i9a8002ec753b4dc689c48b5e0785b43d_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzMwODk_f5f5a3cb-a3ac-4de5-97f6-7c4c709ba10d"
      unitRef="usd">2500000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="iab85f119dfbd439fab288fd3b899104e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzMyNzg_b2997604-42e9-467e-af87-98688121d299"
      unitRef="usd">89000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i9c5a2128addc490e9ec198b28f43e879_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzQxNDY_985e851e-c91a-4fc7-83c1-68b731c38a2e"
      unitRef="usd">2400000000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount
      contextRef="ie0c48f0326424b03a643d8d35796a371_I20170626"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzU0Mzc_fc2e9610-2e28-4cc6-ba72-1adf7972d7b7"
      unitRef="usd">24000000</mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxOTkwMjMyNjI3MTg_f97f9666-3683-488e-b09e-82fc3beb3f76"
      unitRef="usd">641000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzU4NTI_22fdb4c2-e1b3-4903-abd7-0bacaf18ab58"
      unitRef="usd">7000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i702c1ca981884658b2caf34f2b288da1_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxOTkwMjMyNjI3ODM_4e2a2fe8-1393-46df-86ef-19f73e087f1f"
      unitRef="sqft">462000</us-gaap:AreaOfRealEstateProperty>
    <mrna:LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm
      contextRef="i5a37b17b04c0478ca390d371241ee5bd_D20210901-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzMyOTg1MzQ4OTA4NzE_59f1cbfc-b264-43f4-9cdd-d22382a33fe5">P2Y</mrna:LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i702c1ca981884658b2caf34f2b288da1_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxOTkwMjMyNjI4MDY_02c5df10-0111-409f-964d-6c6b2d6b9bfd">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <mrna:LesseeOperatingLeaseNumberOfExtensionPeriods
      contextRef="i702c1ca981884658b2caf34f2b288da1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxOTkwMjMyNjI4MTM_f6f1c484-5e0d-42cf-a826-e858a4a81c82"
      unitRef="numberofoption">2</mrna:LesseeOperatingLeaseNumberOfExtensionPeriods>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i702c1ca981884658b2caf34f2b288da1_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzkzNDU4NDg4NDM0ODA_5b857117-597b-483e-823f-d1f32018e1c0">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i702c1ca981884658b2caf34f2b288da1_I20210930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjMvZnJhZzo5ODZjNzZiZmQ0MzI0YzljYTU0ZTY4YjBlMTJlNGFjNi90ZXh0cmVnaW9uOjk4NmM3NmJmZDQzMjRjOWNhNTRlNjhiMGUxMmU0YWM2XzIxOTkwMjMyNjI4MzU_cabea788-f0a9-4c37-a9cc-db35d43b1b7b"
      unitRef="usd">1100000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE3ODI_a716fe69-21f2-4bae-913e-a840ae1c0759">Stockholders' Equity &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 14, 2020, we sold 26,315,790 shares of common stock at a price of $19.00 per share through a public equity offering. The aggregate net proceeds from the offering were $478 million, net of underwriting discounts, commissions and offering expenses. In addition, the underwriters exercised their options to purchase an additional 3,947,368 shares of common stock at the public offering price less underwriting discounts, resulting in additional net proceeds of $72 million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 21, 2020, we sold 17,600,000 shares of common stock at a price of $76.00 per share through a public equity offering. The aggregate net proceeds from the offering were $1.3&#160;billion, net of underwriting discounts, commissions and offering expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib474a3e36bd94fa88daf43e69617dc76_D20200214-20200214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzExMzQ_15113e36-ce40-4e66-b25c-6898621e7b93"
      unitRef="shares">26315790</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iac2c5503ed074a74bea898aac8577dab_I20200214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzExNzQ_cd3124f6-3508-4f7a-a732-5f97abcda92f"
      unitRef="usdPerShare">19.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib474a3e36bd94fa88daf43e69617dc76_D20200214-20200214"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzEyNzE_8f411328-5b0d-4260-8445-e2f3f6d846b0"
      unitRef="usd">478000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5bba9fe2096647189405dc333c365807_D20200214-20200214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE0MjE_245b00bf-8b7d-4111-bcf4-a3e45f388092"
      unitRef="shares">3947368</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5bba9fe2096647189405dc333c365807_D20200214-20200214"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE1NDU_10249678-4f14-4801-8bdb-03c9986419b8"
      unitRef="usd">72000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3b3e6c8e3e284a9b9957554efffd342a_D20200521-20200521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE1NzU_d6e6c051-07fa-4bf7-b246-cf2c61ca7883"
      unitRef="shares">17600000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iafab97ea8a1846b8ae7fd38f70f3ec7a_I20200521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE2MTU_35103348-9b89-4ad9-adb8-9d92fd8df4c6"
      unitRef="usdPerShare">76.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3b3e6c8e3e284a9b9957554efffd342a_D20200521-20200521"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjYvZnJhZzplOTNhNTNhMTAzZjI0NjkzOWUzYzVlYjVmYjliNDUwZC90ZXh0cmVnaW9uOmU5M2E1M2ExMDNmMjQ2OTM5ZTNjNWViNWZiOWI0NTBkXzE3MTI_60d8c189-1511-4747-b6ed-fc1e6165ca5e"
      unitRef="usd">1300000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNDc_1570d4d0-1bdc-4a0a-b22b-a0f56c6fa4f5">Stock-Based Compensation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August&#160;2016, we adopted the 2016 Stock Option and Grant Plan (the 2016 Equity Plan), which replaced the 2013 Option Plan and the 2013 Incentive Plan. The 2016 Equity Plan and provided for the grant of incentive stock options, non-qualified stock options, restricted stock, unrestricted stock, and restricted stock units to our employees, officers, directors, consultants, and other key persons.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with our initial public offering (IPO), we adopted the 2018 Stock Option and Incentive Plan (the 2018 Equity Plan) in November 2018. The 2018 Equity Plan became effective on the date immediately prior to the effective date of the IPO and replaced our 2016 Plan. The 2018 Equity Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce. The 2018 Equity Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2019, by 4% of the outstanding number of shares of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Compensation and Talent Committee of our Board of Directors. The Compensation and Talent Committee chose not to increase the number of shares available under the 2018 Plan on January 1, 2021 or January 1, 2022. The shares of common stock underlying any awards that are forfeited, canceled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2018 Equity Plan and the 2016 Plan will be added back to the shares of common stock available for issuance under the 2018 Equity Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms and conditions of stock-based awards are defined at the sole discretion of our Board of Directors. We issue service-based awards, vesting over a defined period of service, and performance-based awards, vesting upon achievement of defined conditions. Service based awards generally vest over a four-year period, with the first 25% of such awards vesting following twelve months of continued employment or service. The remaining awards vests in twelve quarterly installments over the following twelve quarters. Stock options granted under the 2018 Equity Plan and the 2016 Equity Plan expire ten years from the date of grant and the exercise price must be at least equal to the fair market value of common stock on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;December 31, 2021, we had a total of&#160;57 million shares reserved for future issuance under our Equity Plans, of which 30 million shares were reserved for equity awards previously granted, and&#160;27 million shares were available for future grants under the 2018 Equity Plan. No additional awards will be granted under the 2016 Equity Plan as it was replaced by the 2018 Equity Plan.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted options generally through the 2018 Equity Plan and 2016 Equity Plan. The following table summarizes our option activity as of December 31, 2021 and 2020:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was $1.6 billion, $786 million, and $76 million for the&#160;years ended December 31, 2021, 2020, and 2019, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period. The excess tax benefits realized from tax deductions from option exercises were $325&#160;million during the year ended December 31, 2021. For the years ended December 31, 2020 and 2019, there were no excess tax benefits realized from tax deductions from option exercises due to cumulative losses and valuation allowances. The total consideration recorded as a result of stock option exercises&#160;was approximately&#160;$112 million, $179 million, and $48&#160;million&#160;for&#160;the years ended December 31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Common Stock Units (RSUs) and Performance Stock Units (PSUs)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have granted RSUs and PSUs generally through the 2018 Equity Plan. The following table summarizes our RSU and PSU activity during the year ended December 31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value per Unit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of RSUs and PSUs vested during the years ended December 31, 2021, 2020, and 2019, was $18 million, $5 million, and $5 million, respectively. The total intrinsic value of RSUs and PSUs vested during the years ended December 31, 2021, 2020, and 2019, was $141&#160;million, $14&#160;million and $12&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2021, we granted an immaterial amount of PSUs to certain senior executives with vesting that is contingent upon the achievement of specified preestablished goals over the performance period, generally three years. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%. The estimated fair value of PSUs is based on the grant date fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, we adopted the 2018 Employee Stock Purchase Plan (ESPP), which became effective on December 5, 2018. We will make one or more offerings, consisting of one or more purchase periods, each year to our eligible employees to purchase shares under the ESPP. Offerings will usually begin every six months and will continue for six-month periods, referred to as offering periods. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price at which shares are sold under the ESPP will be equal to 85% of the lower of the fair market value of the shares on the first business day of the offering period or the last business day of the purchase period. Employees are generally eligible to participate through payroll deductions of between 1% to 50% of their compensation and may not purchase more than 3,000 shares of common stock during each purchase period or&#160;$25,000&#160;worth of shares of common stock in any calendar year.&#160;We began our first ESPP offering on June 1, 2019. There were 81,423, 251,752, and 171,343 shares of common stock sold at a weighted average price of $145.90, $27.97, and $16.87 per share under the ESPP during the years ended December 31, 2021, 2020, and 2019, respectively. As of&#160;December 31, 2021,&#160;4 million&#160;shares were available for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation and Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for options granted under our Equity Plans and share purchases under our ESPP is determined using the Black-Scholes option pricing model. The weighted-average assumptions used to estimate the fair value of options granted and ESPP for the&#160;years ended December 31, 2021, 2020, and 2019 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.11 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected dividends&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Weighted average fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense for the&#160;years ended December 31, 2021, 2020, and 2019 (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2021, 2020, and 2019, we recognized stock-based compensation expense of $16&#160;million, $10&#160;million, and $10&#160;million, respectively, related to performance-based awards, including awards with vesting or commencement contingent upon our IPO. Stock-based compensation expenses related to non-employee awards were immaterial for the years ended December 31, 2021, 2020, and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, there were $349 million of total unrecognized compensation cost related to non-vested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 2.9 years at December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 2, 2021, our Board of Directors authorized a Share Repurchase Program (2021 Repurchase Program) of our common stock, with an expiration date no later than August 2, 2023. Pursuant to the 2021 Repurchase Program, we may repurchase up to $1.0&#160;billion of our outstanding common stock. The timing and actual number of shares repurchased depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities Exchange Act of 1934, as amended (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Exchange Act).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2021, we repurchased 3.5&#160;million shares of our common stock under the 2021 Repurchase Program for an aggregate of $857&#160;million, including commissions and fees. As of December 31, 2021, there was a total of $143&#160;million remaining for repurchases of our common stock under the 2021 Repurchase Program.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized
      contextRef="i29fd9baa1fce4c82bab97fdcf69983b9_D20181130-20181130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzE2MjU_5fe1647f-aa6a-4bd6-b26c-2f084859f6b8"
      unitRef="number">0.04</mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4e3a57dbc43247cdbe91ca5c7ee5a665_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNTA_f73c6656-ab49-4f9b-aa7a-76cb22b81178">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i7adfa26ae60741ce90e3942463436967_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI2MzU_5b0c3b2a-6eab-4967-a4fd-67969c86fb09"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7adfa26ae60741ce90e3942463436967_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI2NzE_00114cd7-32df-46e5-8353-5935f02e7ec5">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments
      contextRef="i8c119cd5946c40fabe6b12e425327e13_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI3NDA_8134a7c4-ffe3-43f1-8e23-9827d88c6552"
      unitRef="installment">12</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i6cdf60b6c2d84337b9adeb0d5572d319_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI4NTg_893a5e8b-026c-475e-bd7b-7e4c5a5e577a">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzMwMTk_7bb6078c-eeb5-4e81-9781-c48e234907c8"
      unitRef="shares">57000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic4c1fa50b9414740995b3595ceb68c2d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzMwOTE_40e736a0-20a2-448e-a704-2ad6f481bdca"
      unitRef="shares">30000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i66e84b53db4044d0b673a4ca8b8e75e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzMxNTc_cea84d51-5217-49b9-8c7d-f94e7c6a06aa"
      unitRef="shares">27000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNDk_a42113a7-3cdb-4fe2-a11c-99bcf809c981">The following table summarizes our option activity as of December 31, 2021 and 2020:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Price per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.06)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of common stock for those options in the money as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzEtMi0xLTEtNzYwNDY_e505eead-18e5-47b6-bb1b-96d8d372a018"
      unitRef="shares">34060000.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzEtNC0xLTEtNzYwNDY_553bbbc7-9324-4eb7-9ec7-582aeb40f6d5"
      unitRef="usdPerShare">17.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzEtOC0xLTEtNzYwNDY_039241e7-7765-412b-b6ad-ceaf6717b62c">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzEtMTAtMS0xLTc2MDQ2_29c988df-d5e6-4d43-af83-25f5b35ade24"
      unitRef="usd">2976000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzItMi0xLTEtNzYwNDY_704a4db2-3f26-4c94-8f32-d2243fd22956"
      unitRef="shares">1480000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzItNC0xLTEtNzYwNDY_397787e2-8945-4cab-8e14-1d1741e2fdfb"
      unitRef="usdPerShare">209.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzMtMi0xLTEtNzYwNDY_2654efab-37af-4b4e-8971-47194db5aa54"
      unitRef="shares">7070000.00</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzMtNC0xLTEtNzYwNDY_a6b7334d-ae2e-4fe3-ab39-79edf215c363"
      unitRef="usdPerShare">15.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzQtMi0xLTEtNzYwNDY_b179a7e2-275b-4595-8c4a-cc629c9d693e"
      unitRef="shares">1060000.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzQtNC0xLTEtNzYwNDY_b5b25985-5b44-4389-9c03-9b38b53ce812"
      unitRef="usdPerShare">37.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzUtMi0xLTEtNzYwNDY_5aed8834-4081-4d88-a7d4-8fe30eae0468"
      unitRef="shares">27410000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzUtNC0xLTEtNzYwNDY_46023f82-1203-4de4-83ec-918596db7e22"
      unitRef="usdPerShare">27.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzUtOC0xLTEtNzYwNDY_2777de27-ddb7-4a67-99af-19f13bbf5726">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzUtMTAtMS0xLTc2MDQ2_d73465c8-6aca-4e42-b1bd-543714ca1d2c"
      unitRef="usd">6247000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzYtMi0xLTEtNzYwNDY_df10b1f8-2072-4b01-974e-fd5ecc62f2a9"
      unitRef="shares">17330000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzYtNC0xLTEtNzYwNDY_9b141b7d-3436-4c10-8e17-37d42a8bd949"
      unitRef="usdPerShare">13.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzYtOC0xLTEtNzYwNDY_71d60f60-b4e0-428b-943a-64ede6147da5">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzYtMTAtMS0xLTc2MDQ2_9e712d97-9ae6-4776-8247-e599ac8a80a7"
      unitRef="usd">4173000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzctMi0xLTEtNzYwNDY_88546c64-b809-4fc2-9580-754d44ce272c"
      unitRef="shares">10080000.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzctNC0xLTEtNzYwNDY_3e8c3bb1-6500-4578-a894-ee1f0c73d6e9"
      unitRef="usdPerShare">50.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzctOC0xLTEtNzYwNDY_e6cac3d6-07c0-42fb-8119-549058ccc5fd">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo4NTYwNWM1NjIyNDI0Y2MyOGRhYTJiYTRkYzIzYjE2Mi90YWJsZXJhbmdlOjg1NjA1YzU2MjI0MjRjYzI4ZGFhMmJhNGRjMjNiMTYyXzctMTAtMS0xLTc2MDQ2_2a0a1ae2-e16c-4b82-b75a-09219528248b"
      unitRef="usd">2074000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzM3NjQ_00329048-9005-47c6-a551-aa32aac87393"
      unitRef="usd">1600000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzM3Njg_79c6ad4f-3c2e-47b2-9590-aeb040ff96d8"
      unitRef="usd">786000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzM3NzU_6290e716-aa6c-4eda-ae75-e801d688c44c"
      unitRef="usd">76000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTk1MDY_1e9c6a8e-e89a-48c3-968c-4471124187bf"
      unitRef="usd">325000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTk1MTk_771da7d8-80e7-43a3-a84e-9352691387dc"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTk1MTk_df725322-6714-4328-91a6-6b8e440a9fbf"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQxMDI_38ea6d47-005e-4b2d-8423-2593412098b5"
      unitRef="usd">112000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzE2NDkyNjc0NjA0OTQ_9263eb77-9530-4cbf-9256-51e25515b086"
      unitRef="usd">179000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzE2NDkyNjc0NjA1MjM_d25adbd2-5a57-4667-b292-458ad8f74a78"
      unitRef="usd">48000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNTE_f3fa030e-45e1-4fb0-8824-c8f4a426622c">The following table summarizes our RSU and PSU activity during the year ended December 31, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Units&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value per Unit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:29.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, non-vested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if0c500d4ffa344d5a5b3ceec87c24f6f_I20201231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzEtMS0xLTEtNzYwNDY_c9356543-ea14-4612-966a-5ad81b07a9b6"
      unitRef="shares">2190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if0c500d4ffa344d5a5b3ceec87c24f6f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzEtMy0xLTEtNzYwNDY_87c34461-6736-45d2-9c54-08824912a799"
      unitRef="usdPerShare">30.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzItMS0xLTEtNzYwNDY_5da29b57-e8f1-436a-a222-f47a0f2553e7"
      unitRef="shares">710000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzItMy0xLTEtNzYwNDY_c0afe0c4-78e5-4069-a05a-cd0ce0522c2c"
      unitRef="usdPerShare">210.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzMtMS0xLTEtNzYwNDY_6e58ec09-4527-4862-9bb7-f59da4aa90e2"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzMtMy0xLTEtNzYwNDY_4b920bbd-fbde-48e7-9c13-429ab53a6083"
      unitRef="usdPerShare">29.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzQtMS0xLTEtNzYwNDY_310f0947-1408-4169-a97e-ad3434787911"
      unitRef="shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzQtMy0xLTEtNzYwNDY_ab0e6af4-c084-40fc-ac7a-803d3d6124e9"
      unitRef="usdPerShare">63.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic31e779ca3ac441093747539d1c451db_I20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzUtMS0xLTEtNzYwNDY_620a1d8b-ee60-4a9a-b840-8c032ae04f90"
      unitRef="shares">2140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic31e779ca3ac441093747539d1c451db_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZToyZTE3OWY3YjU1ZTk0YWNkOTUwYzMwODMyMzc3NzkzYi90YWJsZXJhbmdlOjJlMTc5ZjdiNTVlOTRhY2Q5NTBjMzA4MzIzNzc3OTNiXzUtMy0xLTEtNzYwNDY_84d395d2-19ec-442e-8945-628dd4aa774b"
      unitRef="usdPerShare">88.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedStockExpense
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQ0NTc_8a085e5b-170e-4c4e-a2e5-2247af47b95a"
      unitRef="usd">18000000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQ0NjE_b8e091c3-3a13-4d2c-b2ed-dea23f5cb7c8"
      unitRef="usd">5000000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzIxOTkwMjMyNjMyNTg_b8f9434c-5381-4cf0-9476-7a5dcc41163d"
      unitRef="usd">5000000</us-gaap:RestrictedStockExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i671d5986ef5a44ceadff9cc6c3f38088_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTM3NzY_7f6b037c-330e-408e-8929-5fa635d3f894"
      unitRef="usd">141000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i1a97483f7a5746248dc20f25d9484066_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTM3OTA_fdae9401-7291-406a-858c-1e9f2a67a6c4"
      unitRef="usd">14000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="if2310d5f67f14a5da16abed435202898_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTM4MDM_ca3ad001-2d43-4611-9e9f-07f95d3560c4"
      unitRef="usd">12000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i0dbb9beedbe644dc8350ed2167afbe18_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzEzNzQzODk1MzY0Mjgz_ba50bd5e-a899-4012-a532-7ec4502a8b69">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="i728418fd03a840ca854699e0501666c2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NDY4OTE_5b3b4cb8-d1e4-4e61-9e48-f624d28cf326"
      unitRef="number">0</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage
      contextRef="i85e548fb17de479e8f1eaedbedd14aeb_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NDY4OTU_1b664930-df71-45ef-a39d-a09420a2e031"
      unitRef="number">2</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod
      contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQ3ODk_358ea4f8-f477-4068-902e-193bfe5cab62"
      unitRef="offering">1</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods
      contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQ4MjU_f74e479d-ed00-4dd6-b6ff-cee1f5bc8972"
      unitRef="purchase_period">1</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod
      contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzQ5NTE_3ac294ef-e7ee-4208-b269-827bf28d13c5">P6M</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNTY_297d7aab-a9ab-44b6-a355-e230456c55d2">P6M</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzUxMDM_0de7f8a6-affe-4478-8763-39a776e03dfa"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate
      contextRef="ia96eb4bd96214dbfb1546494df278d66_I20181205"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzUzNDI_4b0f7a23-de6a-4974-9695-3d54215cb463"
      unitRef="number">0.01</mrna:ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="ia96eb4bd96214dbfb1546494df278d66_I20181205"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzUzNDg_3ba7855b-9c97-4bc3-ba83-16b8b1d45d7b"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzU0MDQ_f0af4e8b-b9b6-4298-ba83-291d48cf9492"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount
      contextRef="i17b699d019b5406ebafef856b284da2b_D20181205-20181205"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzU0NjE_14ab25e0-f4b9-42c8-bcfb-3fc8daef33a1"
      unitRef="usd">25000000</mrna:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iccabe9fdd0d4459f83f43bcfe311abbb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTMwMjM_6beaf403-3e10-4a92-9905-4ec62aed6c36"
      unitRef="shares">81423</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia86a82d3b3da4738b05c1a1dc2acb3c6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzU1Nzk_080f2a80-456e-4b93-bc77-e199f7479e92"
      unitRef="shares">251752000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i90b4231be4ae495b8c891156606a39ab_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI3NDg3NzkwODgzMTU_a72eff4b-6102-478b-88fa-7ae59eefe755"
      unitRef="shares">171343</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:SharePrice
      contextRef="ic846063843c2457783476d4cac1401a9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTMwMjQ_7cee686a-276d-403f-99ee-950b6fb6c609"
      unitRef="usdPerShare">145.90</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i7050aa6851454a26bb85c8a452709530_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzU2NDE_9771966f-6a7d-406f-b266-258725a9f501"
      unitRef="usdPerShare">27.97</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="ib15360143cb64fe7abcc9084d6b9d587_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzI3NDg3NzkwODgzMjQ_185451f9-7e16-4272-9f48-37dbd6e307f5"
      unitRef="usdPerShare">16.87</us-gaap:SharePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iebede0396f23431fa71d2b7f1a74378c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzU3MzU_90433378-a136-4f56-a9be-701d06e7e0b8"
      unitRef="shares">4000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNTQ_596026e3-d1fe-4ab2-b744-d3be9b3f9616">The weighted-average assumptions used to estimate the fair value of options granted and ESPP for the&#160;years ended December 31, 2021, 2020, and 2019 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.11 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Expected dividends&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Weighted average fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzQtMi0xLTEtNzYwNDY_6a38ba3b-1b5c-4341-b8a4-2dd6ca495e68"
      unitRef="number">0.0084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzQtNC0xLTEtNzYwNDY_c3727dc6-c7fe-4e83-8e80-45e9b91495ee"
      unitRef="number">0.0083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzQtNi0xLTEtNzYwNDY_1dbd562f-7587-4e6c-aa37-e21723d78aa3"
      unitRef="number">0.0229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzUtMi0xLTEtNzYwNDY_64b150c3-bc2b-4cc1-9bab-862b48e82470">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzUtNC0xLTEtNzYwNDY_47597d2d-0cff-47ee-98be-7b9f2d1757cf">P6Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzUtNi0xLTEtNzYwNDY_7c7036cb-d172-46c2-a814-c57472a49352">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzYtMi0xLTEtNzYwNDY_784a46f2-c541-43f2-a34c-5686eb0b1060"
      unitRef="number">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzYtNC0xLTEtNzYwNDY_9d3728e1-c975-4197-a0c0-bd2506692241"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzYtNi0xLTEtNzYwNDY_90fb1b48-6d43-4fe9-a862-4b9ea588345e"
      unitRef="number">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzctMi0xLTEtNzYwNDY_347e8cd1-ee3d-41f5-a8a2-a18917bb662f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzctNC0xLTEtNzYwNDY_2ea3719c-d8cd-4683-9006-7821dfd0c1f2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzctNi0xLTEtNzYwNDY_d2ee6c5e-5a37-4da4-bfab-b6e45293538f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="ie4ee683b92644214b4cd05e7d4e55ba3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzgtMi0xLTEtNzYwNDY_bc481d0d-f5b5-402e-8233-3e7d7f77e578"
      unitRef="usdPerShare">91.84</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="ibe01185da2fb461cb3ee25ad154cce2d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzgtNC0xLTEtNzYwNDY_7f298586-dae2-4eff-80a1-71269eb39f72"
      unitRef="usdPerShare">19.30</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="ibad04de7079b4f4a8ea7cd1f6b9a483d_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzgtNi0xLTEtNzYwNDY_f63f37a8-fa9a-48e1-9dbd-5fdb907ccdc4"
      unitRef="usdPerShare">11.35</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzExLTItMS0xLTc2MDQ2_311ddd4b-5cd4-47f9-bc8b-749a9df5a2a6"
      unitRef="number">0.0008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzExLTQtMS0xLTc2MDQ2_4d4ea490-5aea-4fd7-b86d-45ebfd95a6ca"
      unitRef="number">0.0014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzExLTYtMS0xLTc2MDQ2_33e17e1f-dc44-4eed-b65d-5aad8870989d"
      unitRef="number">0.0195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEyLTItMS0xLTc2MDQ2_6c2bc4e0-302a-40a7-92a6-d6930d6f918d">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEyLTQtMS0xLTc2MDQ2_3f86113e-4272-45ce-bcfa-45131fcb875b">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEyLTYtMS0xLTc2MDQ2_682454e3-d2a4-4407-a7ad-bc66dfd972f8">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEzLTItMS0xLTc2MDQ2_43e5213a-8bd2-4118-8e17-c6bff08418b0"
      unitRef="number">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEzLTQtMS0xLTc2MDQ2_e9ea9b1b-d584-4c95-ba36-208aec5a3103"
      unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzEzLTYtMS0xLTc2MDQ2_b4c864cb-bf76-4e0c-91cd-efbedfb6a365"
      unitRef="number">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE0LTItMS0xLTc2MDQ2_a1fadcdb-feb0-4dc2-881c-4511c29b9236"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE0LTQtMS0xLTc2MDQ2_74232810-0bf0-4a36-957a-0b8f47a26ef7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE0LTYtMS0xLTc2MDQ2_a8a183c3-20e4-4960-b671-3137e601740c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="i05ea5c2eff4b47408d5e76fe3acde946_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE1LTItMS0xLTc2MDQ2_3f60c764-528e-4f5c-a798-f1fde688ff0f"
      unitRef="usdPerShare">64.25</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i74a646f2a3a5433fbecbadedd7364094_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE1LTQtMS0xLTc2MDQ2_f2bae005-b0fa-4137-b177-e2642d7267c7"
      unitRef="usdPerShare">32.18</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="ia91fb56fbec344488aef5885f842fbb0_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTpjYjQ1ZmY1YmQwNGE0NmQ2YjA5N2VjMjFjMDgwZDI2Mi90YWJsZXJhbmdlOmNiNDVmZjViZDA0YTQ2ZDZiMDk3ZWMyMWMwODBkMjYyXzE1LTYtMS0xLTc2MDQ2_6eabf753-3271-49bf-8d4d-63e7659f14e4"
      unitRef="usdPerShare">5.98</us-gaap:SharePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwNTU_186556e9-717b-4d92-90fe-2405b34f1cfd">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of stock-based compensation expense for the&#160;years ended December 31, 2021, 2020, and 2019 (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&#160;Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzItMS0xLTEtNzYwNDY_6099ee8a-3376-4946-aa8e-92c3796319b8"
      unitRef="usd">96000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8625838d4da34f98ac9fa30bd9ef9d73_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzItMy0xLTEtNzYwNDY_dfc90cc2-9d33-4289-9d64-73bb2090e0da"
      unitRef="usd">78000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8083cb4066f8460e9c21f65294d25c14_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzItNS0xLTEtNzYwNDY_99953636-e558-4606-85f0-e1b424f8f359"
      unitRef="usd">75000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7b651cc1ef0d4fb4ac26faca60c2f102_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzMtMS0xLTEtNzYwNDY_3b260722-dae8-4ae7-8df4-6e9177220f7b"
      unitRef="usd">42000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7e527ebcd83c41c986d1270c6919f13b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzMtMy0xLTEtNzYwNDY_8d251eb5-b620-4df3-86cc-e966f4e7fecc"
      unitRef="usd">12000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i04ce50e969794bcb9eefacd61a166e35_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzMtNS0xLTEtNzYwNDY_34dd354b-29d3-4dda-a428-51dd91281b4b"
      unitRef="usd">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i810ca2b86be34819afd959db0bda2b71_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzQtMS0xLTEtNzYwNDY_537d1686-b93e-43d8-b2cf-ff8189c1c893"
      unitRef="usd">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b0dcebc66a84fb0bf6787ccc6e6deb8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzQtMy0xLTEtNzYwNDY_61de47a8-ccd8-42b4-997c-eb90375acd46"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b0ea27cee374c888b530720c3234c96_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzQtNS0xLTEtNzYwNDY_72678e82-1559-4103-b26e-d887d5d15ab4"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzUtMS0xLTEtNzYwNDY_d251a3ef-1c40-4d57-b4b3-8bbb23b5bc83"
      unitRef="usd">142000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzUtMy0xLTEtNzYwNDY_33c7fa90-c878-4e9f-9fbe-18cf45af5b8c"
      unitRef="usd">93000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzUtNS0xLTEtNzYwNDY_06e0805a-9d6c-4f84-948b-7ca793badf2e"
      unitRef="usd">81000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie043af078137474da5fa9c415b806cb8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctMS0xLTEtNzkyMjA_97a70b25-c375-4b69-b7c2-4ebbff296577"
      unitRef="usd">22000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4bd88039ef4d41a6bd7804df805f06b7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctMy0xLTEtNzkyMjA_5f56b4b2-55b4-4c78-ab02-fb2de47e9f45"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1210d8b31f44fae92d529b8b20e6c6f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctNS0xLTEtNzkyNjE_74a73b07-7828-4747-8657-49fde77f67bb"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3cde0a9204374ab1965f099a3fc5f68b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzYtMS0xLTEtNzYwNDY_c35006bb-5bc5-4953-9e5c-046369782dc4"
      unitRef="usd">68000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i504dedceb6a94befbf403be7db0318ee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzYtMy0xLTEtNzYwNDY_5850db0b-3d4e-4790-a826-b7062a4ab37c"
      unitRef="usd">56000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6742a09761af484083c605c79d1094c1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzYtNS0xLTEtNzYwNDY_cba37d9e-33da-4e8b-b6f6-ac9613522dc5"
      unitRef="usd">48000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d8078008d7a4681abf45cdb733f1f74_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctMS0xLTEtNzYwNDY_f6951923-9da2-4726-97b6-bee06923dcba"
      unitRef="usd">52000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i66608dd5e63640a89af4850f55816d09_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctMy0xLTEtNzYwNDY_08330c9f-3e51-439a-96be-90b77c16e8b4"
      unitRef="usd">37000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaf35565bf91f430595f440c4dd64ae51_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzctNS0xLTEtNzYwNDY_2836c096-f346-4f1e-884d-8f87d1937a4a"
      unitRef="usd">33000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzgtMS0xLTEtNzYwNDY_407b5b03-856e-45f9-98e3-9bea89a9a791"
      unitRef="usd">142000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzgtMy0xLTEtNzYwNDY_b7181f89-699a-45e6-b3b6-2b421afe8191"
      unitRef="usd">93000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90YWJsZTo1YjIyMmUzODFjYmY0OTcwYTkxZmY3MzRmYzdhMmY2MS90YWJsZXJhbmdlOjViMjIyZTM4MWNiZjQ5NzBhOTFmZjczNGZjN2EyZjYxXzgtNS0xLTEtNzYwNDY_58f45968-af00-45c2-a3f7-dcf60d7659c8"
      unitRef="usd">81000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide4d55b1dda34b6b93a8469f51c7e48c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzY0Njc_01850e6f-b395-481b-911a-58b2dbf4a556"
      unitRef="usd">16000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1eef6d9e8284f3dab7d5832831951df_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzY0NzE_3ce4d0e0-05b3-4487-a870-2af250f0aee0"
      unitRef="usd">10000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1ca45b1141c54e74bc0ba86735723e3e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzY0Nzg_7422b30f-4f97-4925-bba4-37f5e2bd9de7"
      unitRef="usd">10000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzY4MjE_9792b748-738f-408a-828c-aea0722ef22c"
      unitRef="usd">349000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzcwMzg_a6ad699f-b002-4482-bc95-c0e78b0f9f10">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i79431f5fc70f4c91917d4630bbc89811_I20210802"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTI5Njg_e04332a6-272a-4073-ab7f-83fca09b4205"
      unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ia2fcd0a4e20a4fb395dd61a92d63adc0_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTI5ODI_27d7dfe2-b701-4edf-ac77-0277ecff34bd"
      unitRef="shares">3500000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia2fcd0a4e20a4fb395dd61a92d63adc0_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTMwMTA_ff1dc583-3363-4f55-8a77-8dce5b3a607e"
      unitRef="usd">857000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ibab18ae9cd9244de9112a38fb79ecf41_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNjkvZnJhZzpjNjI3NGNiZWMzM2Y0MzVmYmFjNWRmZjFjY2I0YjAzMC90ZXh0cmVnaW9uOmM2Mjc0Y2JlYzMzZjQzNWZiYWM1ZGZmMWNjYjRiMDMwXzkzNDU4NDg4NTI5OTY_b66d6aff-2cd2-4241-8407-f61ed7a56eb7"
      unitRef="usd">143000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzU1NQ_d05448e3-e788-4860-81ce-cf0e81a2e02e">Employee Benefit Plans&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide a retirement savings option to our eligible U.S. employees through the Moderna, Inc. 401(k)&#160;Plan (the 401(k) Plan), subject to certain limitations. As allowed under Section&#160;401(k) of the Internal Revenue Code, the 401(k) Plan allows tax deferred salary deductions for eligible employees. We match 50% up to the first 6% contributed by a participant. All matching contributions are immediately vested. Total matching contributions to the 401(k) Plan were $18 million, $5 million, and $4 million for the&#160;years ended December 31, 2021, 2020, and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain various defined benefit plans to provide termination and postretirement benefits to certain eligible employees outside of the U.S. The unfunded benefit plan obligations were $9&#160;million as of December 31, 2021, which is recognized in other long-term liabilities in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzM0MA_a53ee7e8-8abe-4209-aace-fc161fc12b28"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzM1OQ_2faa2361-6d29-4690-8529-1f60d09a21e6"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzQ5Ng_46782823-cdeb-4d6b-a1f1-722af5e4b708"
      unitRef="usd">18000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzUwMA_5a1b6590-8a54-4bda-9629-36639d363102"
      unitRef="usd">5000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzUwNA_b5a28520-def0-4ad2-8dbf-adf92e9093fc"
      unitRef="usd">4000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i835e45064363481fb77ce7bd45f5a1d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzUvZnJhZzowMWMyYzZkYWFiZTY0Njc5OWNkM2IwZjRiNmZiZTIyNy90ZXh0cmVnaW9uOjAxYzJjNmRhYWJlNjQ2Nzk5Y2QzYjBmNGI2ZmJlMjI3XzkzNDU4NDg4Mzc3MTE_92460a3a-0b41-4ba1-98db-1b76c8322c94"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NTI_b1e4683e-a6cc-4e82-9ad6-d485f5b84c10">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Income (loss) before income taxes for the years ended December 31, 2021, 2020, and 2019 consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Income (loss) before income taxes &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for (benefit from) income taxes for the years ended December 31, 2021, 2020, and 2019 consisted of the following components (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2021, 2020, and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to U.S. federal, state, and foreign income taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our effective tax rate for the year ended December 31, 2021 was 8.1% and was lower than the federal statutory tax rate primarily due to the tax benefits related to the release of the valuation allowance on most of our deferred tax assets, foreign-derived intangible income deduction and stock-based compensation. Our effective tax rate for the years ended December 31, 2020 and December 31, 2019 was lower than the federal statutory tax rate primarily due to the valuation allowance on our deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes, tax credit carryforwards and the tax effect of net operating loss carryforwards. Significant components of our deferred tax assets and tax liabilities as of December 31, 2021 and 2020 were as follows (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized licenses, research and development and start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a quarterly basis, we reassess the valuation allowance on our deferred tax assets, weighing positive and negative evidence to assess the realizability of the deferred tax assets. In the first quarter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we reassessed the valuation allowance noting the increase in positive evidence, including significant revenue growth, expectations regarding future profitability, and successful supply chain and &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;manufacturing capabilities to meet global product demand. After assessing both the positive evidence and negative evidence, we determined it was more likely than not that we will realize the majority of our deferred tax assets, and we released the valuation allowance on the majority of our deferred tax assets, accordingly. We continue to maintain a valuation allowance on certain state deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the valuation allowance for deferred tax assets during the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; primarily related to the release of the valuation allowance on deferred tax assets. The changes during the years ended December 31, 2020 and 2019 primarily related to the increase in valuation allowance on net operating loss carryforwards and research and development tax credit carryforwards. The changes were as follows (in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;millions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases recorded as benefit to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, we had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.0 billion&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; state net operating loss carryforwards, which begin to expire in 2032. At December 31, 2021, we also had state tax credit carryforwards of $102 million, the majority of which will begin to expire in 2030. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. All tax years since date of incorporation remain open to examination by the major taxing jurisdictions (federal and state) to which we are subject, as carryforward attributes generated in past years may still be adjusted upon examination by the Internal Revenue Service or the state authorities if they have or will be used in a future period. There are no open tax examinations at this time.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize, in our financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2021, 2020, and 2019 were as follows (in&#160;millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions for current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at end of the period &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of December 31, 2021, we had $43 million of net unrecognized tax benefits, which would affect our tax rate if recognized. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not anticipate a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our consolidated operating results. We recognize interest and penalties, if applicable, related to uncertain tax positions as a component of income tax expense; however, there has been no interest or penalties accrued to date.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NTc_4c2d501b-59a3-475e-a13a-5818a070e429">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Income (loss) before income taxes for the years ended December 31, 2021, 2020, and 2019 consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Income (loss) before income taxes &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzItMS0xLTEtNzYwNDY_36c86504-b070-4212-9c1c-298db9c645c2"
      unitRef="usd">13108000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzItMy0xLTEtNzYwNDY_839c5ea6-25c7-4935-9db7-fdc9779b313e"
      unitRef="usd">-745000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzItNS0xLTEtNzYwNDY_c7d8d86c-b36f-4241-a4ea-a6906a378605"
      unitRef="usd">-509000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzMtMS0xLTEtNzYwNDY_3dfcd91c-013c-4295-afea-4ff7ccd209b0"
      unitRef="usd">177000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzMtMy0xLTEtNzYwNDY_142d7040-978a-4cff-bb26-7750e22ba8c0"
      unitRef="usd">1000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzMtNS0xLTEtNzYwNDY_cf955872-5115-4a8a-954b-d6a352039264"
      unitRef="usd">-6000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzQtMS0xLTEtNzYwNDY_7eebe411-9d49-48f9-a00f-72ae27a08da8"
      unitRef="usd">13285000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzQtMy0xLTEtNzYwNDY_7aa85ecd-245f-465f-a1bb-74fcc299ac22"
      unitRef="usd">-744000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpiZmQyNTk5NTkxMmE0OTdkYTIxYTRlMWRiNzM0MGQ1YS90YWJsZXJhbmdlOmJmZDI1OTk1OTEyYTQ5N2RhMjFhNGUxZGI3MzQwZDVhXzQtNS0xLTEtNzYwNDY_f16c5460-6b53-4be0-8bce-ea42457187f4"
      unitRef="usd">-515000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NTY_5ae82697-84e9-4c62-9b80-73d8ad265dd9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for (benefit from) income taxes for the years ended December 31, 2021, 2020, and 2019 consisted of the following components (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for (benefit from) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzMtMS0xLTEtNzYwNDY_cd96b7b3-c22e-4d1d-a3c4-c8cc14dcff08"
      unitRef="usd">1304000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzMtMy0xLTEtNzYwNDY_c4556962-8fa8-448e-bb3b-ca82725ce056"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzMtNS0xLTEtNzYwNDY_17a9a93b-1a52-48a7-ae4a-88be186a582c"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzQtMS0xLTEtNzYwNDY_655c087b-1243-43f6-bbad-130a239bc8e2"
      unitRef="usd">35000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzQtMy0xLTEtNzYwNDY_0793d762-79fa-4626-8419-d884965810ea"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzQtNS0xLTEtNzYwNDY_95445544-c07b-4b13-b121-c878e600a9e9"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzUtMS0xLTEtNzYwNDY_18a6c8ba-fa98-43db-ade3-13d3676a2276"
      unitRef="usd">40000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzUtMy0xLTEtNzYwNDY_1661b064-882b-498b-acec-230fe4716e7c"
      unitRef="usd">3000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzUtNS0xLTEtNzYwNDY_3a2d62d1-990c-4ede-8950-72e50d2e2307"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzYtMS0xLTEtNzYwNDY_6ea7280b-e5b8-4d4a-8345-c3dae8b766c7"
      unitRef="usd">1379000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzYtMy0xLTEtNzYwNDY_c311a733-2d6c-41c6-a5c5-d0b96b8a96a9"
      unitRef="usd">3000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzYtNS0xLTEtNzYwNDY_95698782-41eb-4925-b6fe-32230929cbec"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzgtMS0xLTEtNzYwNDY_8e561983-d4ab-40d4-8f08-57f788cf793f"
      unitRef="usd">-288000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzgtMy0xLTEtNzYwNDY_9283938d-f013-4ba0-a4e3-32d8b2b55dc3"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzgtNS0xLTEtNzYwNDY_cf0e67ff-52cc-4960-b0a8-faf3fd384603"
      unitRef="usd">-1000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktMS0xLTEtMTEwOTY2_5e58db10-1a7f-47e2-8b0b-fac7bba13a76"
      unitRef="usd">-6000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktMy0xLTEtMTEwOTY2_db80ce8b-563d-4e76-8470-9cc6b3b9024b"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktNS0xLTEtMTEwOTY2_5db10b0c-9b4d-47c5-aecd-f43302f6493c"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTEtMS0xLTExMDk2Ng_c51b59c9-194a-45c5-adf9-72cdd6727484"
      unitRef="usd">-2000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTMtMS0xLTExMDk2Ng_72d3ac1c-e34a-4d64-8b7e-eb71b053c403"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTUtMS0xLTExMDk2Ng_01dc9620-0728-4424-a6a6-48f0fb45c854"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktMS0xLTEtNzYwNDY_c0fdb2bc-59e0-4914-9d19-1ee920319102"
      unitRef="usd">-296000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktMy0xLTEtNzYwNDY_e7a8c0ed-77d1-462a-bd30-7a06bc64d68a"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzktNS0xLTEtNzYwNDY_ccfb1bb6-202e-4c10-8b3f-0e3fcdab7af8"
      unitRef="usd">-1000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTEtMS0xLTc2MDQ2_fc37a9d8-346f-4a00-8d50-b144b51b6683"
      unitRef="usd">1083000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTMtMS0xLTc2MDQ2_9d2daaea-37b0-427d-bf59-ec4429e12cc3"
      unitRef="usd">3000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphNDlkMDJiZThjM2U0NmMwODhmOTg1OGE0ODA4ZTAxNC90YWJsZXJhbmdlOmE0OWQwMmJlOGMzZTQ2YzA4OGY5ODU4YTQ4MDhlMDE0XzEwLTUtMS0xLTc2MDQ2_01c41da0-9245-49bc-850f-6da8ab87cafe"
      unitRef="usd">-1000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NDk_39b1cbb1-5925-42d0-b7cb-e161f8a47a6e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31, 2021, 2020, and 2019 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal research and development credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzItMS0xLTEtNzYwNDY_cdc6198c-9a0d-43b3-8d2c-7b7fa1d224e2"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzItMy0xLTEtNzYwNDY_e4ec4df6-17e5-433e-9c12-6521b9fe2c61"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzItNS0xLTEtNzYwNDY_bbb0a574-e6e9-4419-9538-7846cd2e701b"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtMS0xLTEtMTEwNzI3_8735b6d1-2c55-45a3-b224-7b589d7aa7dc"
      unitRef="number">-0.054</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtMy0xLTEtMTEwNzI3_8ba80ff6-8127-47a7-a15d-835724daf75b"
      unitRef="number">-0.474</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtNS0xLTEtMTEwNzI3_b55567f2-3a75-4ccc-8691-5d379e0941b8"
      unitRef="number">-0.330</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <mrna:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtMS0xLTEtMTEwOTg2_96c8171e-fb02-4496-9425-84c9cbddfaa9"
      unitRef="number">-0.048</mrna:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent>
    <mrna:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtMy0xLTEtMTEwOTg2_72687790-a245-4f0f-973d-ba370a0e58e4"
      unitRef="number">0</mrna:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent>
    <mrna:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtNS0xLTEtMTEwOTg2_0f82cf6d-3e56-4526-a6cb-a8cfc040501a"
      unitRef="number">-0.002</mrna:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzUtMS0xLTEtMTEwNzM4_e31f23b3-2352-41e2-836b-b44547356f19"
      unitRef="number">-0.026</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzUtMy0xLTEtMTEwNzM4_8ed0691b-a19b-4a9a-b43a-6e8c4a44fdfa"
      unitRef="number">0.198</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzUtNS0xLTEtMTEwNzM4_f5ea7306-86c9-4a23-b359-f7800b127e50"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzYtMS0xLTEtMTEwNzcw_24a0547a-7e94-4a4e-84fb-68a15c22dc13"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzYtMy0xLTEtMTEwNzcw_b87362b9-a408-491b-9ebd-982e76df5fd4"
      unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzYtNS0xLTEtMTEwNzcw_ddc765fa-5e98-4643-9887-338300e7d8c9"
      unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtMS0xLTEtNzYwNDY_f7a2fc66-7c11-471d-b895-2dfd0be65292"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtMy0xLTEtNzYwNDY_bf6453ee-84cd-4656-889f-636576d829cf"
      unitRef="number">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzMtNS0xLTEtNzYwNDY_8cdb4e46-677b-4b64-a5c6-fba582f674f6"
      unitRef="number">0.079</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtMS0xLTEtNzYwNDY_88962ed8-9a17-421a-bdaa-a4651e74b73a"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtMy0xLTEtNzYwNDY_3ce67e2e-25c0-4b49-959f-cba5deb6fdbe"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzQtNS0xLTEtNzYwNDY_50699140-ea79-4954-9a37-cd09fdff678a"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzktMS0xLTEtNzYwNDY_fad5d901-d765-4f37-b700-f14b36b48003"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzktMy0xLTEtNzYwNDY_fecad684-fe31-4e7d-9a68-d980c8766c8e"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzktNS0xLTEtNzYwNDY_50db4770-46ac-4da2-8155-3f614fcec696"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzEwLTEtMS0xLTc2MDQ2_e81a8c81-a1ba-426e-9189-6f6b0e95e98b"
      unitRef="number">0.081</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzEwLTMtMS0xLTc2MDQ2_c23091da-67a8-4219-9cce-3be59076b774"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmOTIzZTlhNzFmOWU0NWQyYTQ3MjA4ZmY3ODJmNTA2Zi90YWJsZXJhbmdlOmY5MjNlOWE3MWY5ZTQ1ZDJhNDcyMDhmZjc4MmY1MDZmXzEwLTUtMS0xLTc2MDQ2_ba955aa6-4681-42a4-b973-f53daa75c004"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzM4NDgyOTA3MTc5NTU_e81a8c81-a1ba-426e-9189-6f6b0e95e98b"
      unitRef="number">0.081</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NTA_8f9b68bf-fe04-479a-a48b-9deaa3498422">Significant components of our deferred tax assets and tax liabilities as of December 31, 2021 and 2020 were as follows (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.898%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized licenses, research and development and start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, financing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzMtMS0xLTEtNzYwNDY_8fc13c0e-b845-4b30-9a64-c18a52068918"
      unitRef="usd">69000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzMtMy0xLTEtNzYwNDY_a831faf5-8054-448a-be2b-7a1b4b308c59"
      unitRef="usd">587000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzQtMS0xLTEtNzYwNDY_2599cfb6-256b-4f93-bf3f-5e2d7f2b3d1d"
      unitRef="usd">44000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzQtMy0xLTEtNzYwNDY_fdc9b4a2-1441-4a21-be0e-6c240341951c"
      unitRef="usd">33000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzUtMS0xLTEtNzYwNDY_e72b0b47-9237-4a88-99e6-8ccd6bfc70a8"
      unitRef="usd">204000000</mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts>
    <mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzUtMy0xLTEtNzYwNDY_8e164f86-10de-4a95-9a3e-aed27471bfaa"
      unitRef="usd">14000000</mrna:DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzYtMS0xLTEtNzYwNDY_8bfd56a2-a0ff-4c2c-8435-57c273effb3e"
      unitRef="usd">80000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzYtMy0xLTEtNzYwNDY_94d40a68-9568-4318-a896-5efae51c4f60"
      unitRef="usd">99000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzgtMS0xLTEtNzYwNDY_b7afdeb6-b19d-4acb-991c-425d54b35602"
      unitRef="usd">43000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzgtMy0xLTEtNzYwNDY_88c4d9b0-ed94-4521-b202-47370cda5696"
      unitRef="usd">30000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <mrna:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzktMS0xLTEtNzYwNDY_a7198c69-12f6-4860-ba5e-e6a765626ebf"
      unitRef="usd">32000000</mrna:DeferredTaxAssetsOperatingLeaseLiability>
    <mrna:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzktMy0xLTEtNzYwNDY_16c56d80-8837-4c6c-ac8f-85e5d5d423fd"
      unitRef="usd">22000000</mrna:DeferredTaxAssetsOperatingLeaseLiability>
    <mrna:DeferredTaxAssetsFinancingLeaseLiability
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEwLTEtMS0xLTc2MDQ2_246e5217-0fa8-4498-b794-32e93d25fe7d"
      unitRef="usd">136000000</mrna:DeferredTaxAssetsFinancingLeaseLiability>
    <mrna:DeferredTaxAssetsFinancingLeaseLiability
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEwLTMtMS0xLTc2MDQ2_56f8cd07-22a2-4e12-842e-7564098286e1"
      unitRef="usd">24000000</mrna:DeferredTaxAssetsFinancingLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEyLTEtMS0xLTc2MDQ2_e4d45e3c-7453-4b8f-9137-fcd682fd553b"
      unitRef="usd">67000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEyLTMtMS0xLTc2MDQ2_b153553c-c3b7-473d-85fe-5104c4df671d"
      unitRef="usd">65000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEzLTEtMS0xLTc2MDQ2_51005587-aa36-4316-9571-f52d99b7d777"
      unitRef="usd">675000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzEzLTMtMS0xLTc2MDQ2_e445e50b-9606-4d75-98db-35473e1194a2"
      unitRef="usd">874000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE0LTEtMS0xLTc2MDQ2_b93faaf1-6be6-4d81-907f-75c401d65c89"
      unitRef="usd">149000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE0LTMtMS0xLTc2MDQ2_0c419d86-d3cf-4ef9-a6e2-016e480244ef"
      unitRef="usd">823000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE1LTEtMS0xLTc2MDQ2_69eb15c3-7308-4f84-a66b-98ea3f756431"
      unitRef="usd">526000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE1LTMtMS0xLTc2MDQ2_e5ce3811-3b86-4fe0-881f-c9249470204a"
      unitRef="usd">51000000</us-gaap:DeferredTaxAssetsNet>
    <mrna:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE3LTEtMS0xLTc2MDQ2_6e46a966-f20e-4935-ae02-b75e7b082f02"
      unitRef="usd">119000000</mrna:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset>
    <mrna:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE3LTMtMS0xLTc2MDQ2_e2d5cd9e-96e8-41c6-b436-53e399f96bdc"
      unitRef="usd">12000000</mrna:DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset>
    <mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE4LTEtMS0xLTc2MDQ2_5fef2d14-15b8-4721-91fc-327e43902621"
      unitRef="usd">31000000</mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE4LTMtMS0xLTc2MDQ2_e5965624-5572-4877-b849-1b1e34d63cc6"
      unitRef="usd">20000000</mrna:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE5LTEtMS0xLTc2MDQ2_c44958db-5fd7-4712-ae08-a5b765b7d7b8"
      unitRef="usd">49000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzE5LTMtMS0xLTc2MDQ2_9ac2b8d3-a8da-4862-b9df-b87ee1ed1a97"
      unitRef="usd">18000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIwLTEtMS0xLTc2MDQ2_953cba73-efa2-45da-8462-e75ceaad3f8c"
      unitRef="usd">1000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIwLTMtMS0xLTc2MDQ2_b4d66df8-1dd8-42d3-914c-17cb473d626b"
      unitRef="usd">1000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIxLTEtMS0xLTc2MDQ2_896a193f-7478-425b-82ce-9169b5ea7a45"
      unitRef="usd">200000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIxLTMtMS0xLTc2MDQ2_43559da2-5c1c-4589-b01f-89d1c77ec5b4"
      unitRef="usd">51000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIyLTEtMS0xLTc2MDQ2_333cf894-e447-47bd-bcdc-2d2f2f4ea16b"
      unitRef="usd">326000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZToxOWRjMzllY2EwNTU0ZGFhOTM3MmE3MWIyMWExNzM3ZS90YWJsZXJhbmdlOjE5ZGMzOWVjYTA1NTRkYWE5MzcyYTcxYjIxYTE3MzdlXzIyLTMtMS0xLTc2MDQ2_aaedb43d-70b7-4cd1-b828-cceacef12f69"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzkzNDU4NDg4NjUzMDk_7cf5c6c4-b9f5-4bd9-bb54-eefc4415afff">&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the valuation allowance for deferred tax assets during the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; primarily related to the release of the valuation allowance on deferred tax assets. The changes during the years ended December 31, 2020 and 2019 primarily related to the increase in valuation allowance on net operating loss carryforwards and research and development tax credit carryforwards. The changes were as follows (in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;millions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases recorded as benefit to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at December 31&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzItMS0xLTEtMTE0MjQw_0dfdef5f-0675-42b3-814f-a308fdcf4a23"
      unitRef="usd">823000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzItMy0xLTEtMTE0MjQw_9cc1d4b9-56e7-41cb-951b-7107ecde8b63"
      unitRef="usd">471000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i3f00be47b1194ea3be883db45fca7c1c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzItNS0xLTEtMTE0MjQw_dcbd0ba3-0664-473b-8537-107dfb101263"
      unitRef="usd">308000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <mrna:ValuationAllowanceDeferredTaxAssetDecreaseAmount
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzMtMS0xLTEtMTE0MjQw_3ed01d80-4ee1-4090-a986-de4e7c461418"
      unitRef="usd">722000000</mrna:ValuationAllowanceDeferredTaxAssetDecreaseAmount>
    <mrna:ValuationAllowanceDeferredTaxAssetDecreaseAmount
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzMtMy0xLTEtMTE0MjQw_7959a9c9-e244-4fc4-9753-c5d2df84894b"
      unitRef="usd">0</mrna:ValuationAllowanceDeferredTaxAssetDecreaseAmount>
    <mrna:ValuationAllowanceDeferredTaxAssetDecreaseAmount
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzMtNS0xLTEtMTE0MjQw_ebaef70d-4e7f-48a3-aa88-f4047063f93b"
      unitRef="usd">0</mrna:ValuationAllowanceDeferredTaxAssetDecreaseAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzQtMS0xLTEtMTE0MjQw_23925106-a381-4de6-84a4-06c028bdf6f5"
      unitRef="usd">48000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzQtMy0xLTEtMTE0MjQw_98f782fc-8cef-4232-a3e5-adc9e0764e37"
      unitRef="usd">352000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzQtNS0xLTEtMTE0MjQw_d982a072-5e6a-4670-a956-4e9a2ba82ffa"
      unitRef="usd">163000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzUtMS0xLTEtMTE0MjQw_d51c86e5-8e6a-43b3-b830-632018fbf25d"
      unitRef="usd">149000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzUtMy0xLTEtMTE0MjQw_63a93765-4199-46bc-84a1-82e81d8782c5"
      unitRef="usd">823000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTphZGM3ZWM3OWNjMmU0ZmFjODgzNzBiOWZkY2E3NjNkMi90YWJsZXJhbmdlOmFkYzdlYzc5Y2MyZTRmYWM4ODM3MGI5ZmRjYTc2M2QyXzUtNS0xLTEtMTE0MjQw_7d64a113-a3a5-4c0c-8312-31258e530b71"
      unitRef="usd">471000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i5a9f0c6c3c2848ffb9debae33d695d1b_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzIxOTkwMjMyNzE3NzQ_94a79a2a-5e54-4044-b891-22b7c903cb13"
      unitRef="usd">1000000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i39bdbfea26834ede996b4fab64370074_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzIxOTkwMjMyNzE4MjQ_db484690-1eb9-4774-a586-e19067c4f14e"
      unitRef="usd">102000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzU1NTU_0f337278-dc09-4e80-ae76-f7c8a6f0d9c5">A reconciliation of the beginning and ending amounts of unrecognized tax benefits during the years ended December 31, 2021, 2020, and 2019 were as follows (in&#160;millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions for current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at end of the period &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzMtMS0xLTEtMTEwNjgy_cab09dd6-3ac7-431f-b5ec-1b8963b0a77e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzMtMy0xLTEtMTEwNjgy_0493640f-ad5e-454e-b6c2-fba88c2b87c6"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3f00be47b1194ea3be883db45fca7c1c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzMtNS0xLTEtMTEwNjgy_abf8f5e5-0a14-4233-85e8-42a95db573d7"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzgtMS0xLTEtMTEwODcz_d39df918-9302-44c2-b164-7f0d3ee25406"
      unitRef="usd">54000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzgtMy0xLTEtMTEwODY3_aeeb1f1d-bb9c-4099-8a1a-6c6470809225"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzgtNS0xLTEtMTEwODY3_fa1f2fb5-4a2a-466e-9c97-8649d0d60de4"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzktMS0xLTEtMTEwODcz_fe6787e7-5e61-402c-b034-e7bb6b640274"
      unitRef="usd">14000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzktMy0xLTEtMTEwODY3_13a4d9ce-4cce-4775-ab91-de2f7cbd8adc"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzktNS0xLTEtMTEwODY3_cd05d811-8959-4c21-a4d1-c01825c92804"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzEwLTEtMS0xLTExMDg3OQ_24f261d2-bf2e-423d-b9bd-c840b5ba9078"
      unitRef="usd">68000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzEwLTMtMS0xLTExMDg2Nw_75ddc818-e4d4-40dd-a2bc-45e2eeb18baa"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i086f0b86dda64ff9bdc13c547806422e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90YWJsZTpmNzIwYmYyNjliMTU0MmVlOGI3MjQyMWI2MDRjNjlhNi90YWJsZXJhbmdlOmY3MjBiZjI2OWIxNTQyZWU4YjcyNDIxYjYwNGM2OWE2XzEwLTUtMS0xLTExMDg2Nw_bbf682f1-eaae-4bdc-b946-119dd92f684c"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <mrna:UnrecognizedTaxBenefitsNet
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xNzgvZnJhZzozNTUwMDJjMTY3Nzc0ZjcxYTY5MjlkNjRhMTBmNjBhMi90ZXh0cmVnaW9uOjM1NTAwMmMxNjc3NzRmNzFhNjkyOWQ2NGExMGY2MGEyXzM4NDgyOTA3MTgwMDI_8c408c91-ab7b-46a9-ad6f-ec19a62e7b89"
      unitRef="usd">43000000</mrna:UnrecognizedTaxBenefitsNet>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90ZXh0cmVnaW9uOjVlZTA1Y2Q0YmNmZjQzNDViMzhiMDNjZDkwYTMzZDY0XzU1OA_7925dafe-5c79-484c-b17a-99ae5c07fa89">Earnings (Loss) per Share &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computation of basic earnings (loss) per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares outstanding during the period as determined by using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted EPS for the years ended December 31, 2021, 2020 and 2019 were calculated as follows (in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents, presented based on amounts outstanding as of December 31, 2021, 2020 and 2019, were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90ZXh0cmVnaW9uOjVlZTA1Y2Q0YmNmZjQzNDViMzhiMDNjZDkwYTMzZDY0XzU1NA_66c4582f-e9c3-4380-ac46-539a65ebba93">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted EPS for the years ended December 31, 2021, 2020 and 2019 were calculated as follows (in millions, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzMtMS0xLTEtNzYwNDY_56b54826-6a73-4caf-83eb-8d82824f7bcc"
      unitRef="usd">12202000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzMtMy0xLTEtNzYwNDY_56f06bc7-24c8-4332-b9ec-b84c90da6ae3"
      unitRef="usd">-747000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzMtNS0xLTEtNzYwNDY_e111ef31-f24e-477f-a554-d2751b1a5fa6"
      unitRef="usd">-514000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtMS0xLTEtNzkzOTM_9f63f9e9-6aa9-4de0-8f04-9982ed7f5550"
      unitRef="shares">403000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtMy0xLTEtNzkzOTM_f8a81793-60dd-4832-a34b-bab4e773d808"
      unitRef="shares">381000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtNS0xLTEtNzkzOTk_12812fe4-eaed-4d54-9392-4850dcd96453"
      unitRef="shares">331000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktMS0xLTEtNzkzOTM_45c8dbb7-06e5-4dc3-b2b5-9a36b5e2c293"
      unitRef="shares">28000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktMy0xLTEtNzkzOTM_1ba011c8-404a-43ec-823d-80fb3cc8c3ec"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktNS0xLTEtNzkzOTk_9a33388d-5dc3-4b2f-a439-6e2a9ef1864a"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtMS0xLTEtNzYwNDY_8fd3c832-66be-4c1a-9fd9-c8421df1509b"
      unitRef="shares">431000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtMy0xLTEtNzYwNDY_bf2f49a8-742c-48e8-a8b8-9ee23995e2d8"
      unitRef="shares">381000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzgtNS0xLTEtNzYwNDY_50dc45e3-bd69-44be-ad48-260a52a52f6e"
      unitRef="shares">331000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzExLTEtMS0xLTc5NDEy_105252e0-ebdf-4707-9802-921c436837a5"
      unitRef="usdPerShare">30.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzExLTMtMS0xLTc5NDEy_ce0fe67d-7c2a-4aec-869e-685c8befd8f7"
      unitRef="usdPerShare">-1.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzExLTUtMS0xLTc5NDE3_bbe48a6d-7e45-4cff-be73-93b54140e7e3"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktMS0xLTEtNzYwNDY_02a62a91-d801-4460-a40c-6f99c8472b7c"
      unitRef="usdPerShare">28.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktMy0xLTEtNzYwNDY_46556ecd-60b0-4bef-b74b-59adfd0d2083"
      unitRef="usdPerShare">-1.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTplOWU0MzQwYTQ1ZjA0NzIwODc2YmNjMmZkZTQ3NDQ2Ni90YWJsZXJhbmdlOmU5ZTQzNDBhNDVmMDQ3MjA4NzZiY2MyZmRlNDc0NDY2XzktNS0xLTEtNzYwNDY_310e1385-7546-4f14-aec0-d459ff8ca1c5"
      unitRef="usdPerShare">-1.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90ZXh0cmVnaW9uOjVlZTA1Y2Q0YmNmZjQzNDViMzhiMDNjZDkwYTMzZDY0XzU1Ng_c9d81ccf-064e-47a1-8d7d-d97d83d91dec">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents, presented based on amounts outstanding as of December 31, 2021, 2020 and 2019, were excluded from the calculation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because their inclusion would have been anti-dilutive (in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted common stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9d35d0ab562b4b489462b57aefdefce5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzItMS0xLTEtNzYwNDY_692be7ed-bbf4-491d-912e-1271ff430d4e"
      unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id9a86bae6409420b83a8aed6d25de2dd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzItMy0xLTEtNzYwNDY_d8239f17-9086-453e-a71e-d96a2323191d"
      unitRef="shares">34000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5cd9dd4b271d421b9fca8617b75a1093_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzItNS0xLTEtNzYwNDY_761570fa-7c9a-4349-8c1e-849cc2d7b7a4"
      unitRef="shares">46000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i89adc3cd6fc14bed9598b281787d3975_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzQtMS0xLTEtNzYwNDY_03e7ac84-74c0-4de2-a719-6aae70a209c0"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idaef07bcc885424dbeed30c7d98e5bf7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzQtMy0xLTEtNzYwNDY_c28d2268-0a09-4075-806c-5756186daf8c"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0d38bfda565e475e8f176749260180c0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzQtNS0xLTEtNzYwNDY_31d60bf8-ef52-4390-b82c-c8ed1e7d0e4e"
      unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzUtMS0xLTEtNzYwNDY_1d6a7022-2576-4d0d-8221-554b09f2f2da"
      unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzUtMy0xLTEtNzYwNDY_ed663351-3d47-4523-aae7-c9a0e9e3124d"
      unitRef="shares">36000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODEvZnJhZzo1ZWUwNWNkNGJjZmY0MzQ1YjM4YjAzY2Q5MGEzM2Q2NC90YWJsZTo4YzhjMGI3OTU2Zjg0ODEyOTMyZDBjZWI1ZDVjM2E3OS90YWJsZXJhbmdlOjhjOGMwYjc5NTZmODQ4MTI5MzJkMGNlYjVkNWMzYTc5XzUtNS0xLTEtNzYwNDY_fd3521b9-839c-4514-9963-b53f33b1ea18"
      unitRef="shares">47000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90ZXh0cmVnaW9uOjgyNDc5ZDJmM2NkMDRhMmQ4ZjVkYTc4ZDkwYzM5YmYyXzY4_81283167-c0fb-4443-b942-928db317cb5b"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Revenues
      contextRef="i05f9128fb34343858d7d0963244403bc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzItMi0xLTEtNzYwNDY_2ed6e861-696f-4821-b84c-6502573e4562"
      unitRef="usd">6177000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifea1da9382db47b78b24b7770c2bce16_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzItNC0xLTEtNzYwNDY_357001ed-36ea-4f91-aa5a-daf557a25ed9"
      unitRef="usd">764000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3370d17a262545d3a21778bdbfd9e0bd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzItNi0xLTEtNzYwNDY_f3caf82b-e54c-497f-bbab-14392d4c134c"
      unitRef="usd">55000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i711d783999b541ed9d40041b1a32a2bf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtMi0xLTEtMTA5Nzc2_eaed4813-829c-4d5c-8107-00aaaf01aabe"
      unitRef="usd">6846000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iec2fad44150e4a03b5a8be3e02ae7631_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtNC0xLTEtMTA5Nzc2_449cb6c2-e88c-4891-a5af-6d8e4e85b981"
      unitRef="usd">33000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a80bb18be6a4ef784a0986226d8e915_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtNi0xLTEtMTA5Nzc2_da63c8ff-a682-4675-962a-b289e94a2451"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7621872360e6456f9070400abc857bfd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtMi0xLTEtNzYwNDY_074cfa18-de74-4b76-984f-ddf1eb3776aa"
      unitRef="usd">5448000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i608a92f69c204f27bf261e6252469cc3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtNC0xLTEtNzYwNDY_e15ad1af-64ff-49da-abe4-b9847787b174"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97e6326dca0f4ec6947a65af86c71656_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzMtNi0xLTEtNzYwNDY_5d89228c-caad-4b4e-ab86-7d34c7b40e34"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzQtMi0xLTEtNzYwNDY_c90add22-73ec-4da2-b77f-bd4a0b938ddb"
      unitRef="usd">18471000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzQtNC0xLTEtNzYwNDY_70134810-6e9c-4e84-82fb-fe7e94e88995"
      unitRef="usd">803000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3bbc30492b746759ff2b77c9620ccff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZTpmODQyNmM3NDU0YzM0N2JkYjM0OTBhYWUzMWMxODY2Ni90YWJsZXJhbmdlOmY4NDI2Yzc0NTRjMzQ3YmRiMzQ5MGFhZTMxYzE4NjY2XzQtNi0xLTEtNzYwNDY_f68f1472-3f06-4d13-80ea-6ac72603d851"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i3b0ed2515d854ec9b5a77c4457a02d73_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZToyODcyMWNiMGU4YjU0NDRhYWQ5ZDNjNmFiYTY2NzEzYS90YWJsZXJhbmdlOjI4NzIxY2IwZThiNTQ0NGFhZDlkM2M2YWJhNjY3MTNhXzItMi0xLTEtMTA5NjE5_995747dc-9141-412b-94e7-143ee4106bca"
      unitRef="usd">1050000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i90163def30db4815a2baf938575b19d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZToyODcyMWNiMGU4YjU0NDRhYWQ5ZDNjNmFiYTY2NzEzYS90YWJsZXJhbmdlOjI4NzIxY2IwZThiNTQ0NGFhZDlkM2M2YWJhNjY3MTNhXzMtMi0xLTEtMTA5NzQ1_051ee972-11c6-4e28-8de3-0be701b2b9ea"
      unitRef="usd">181000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="iacd7ab752d5b4882a879732a1889bbb8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZToyODcyMWNiMGU4YjU0NDRhYWQ5ZDNjNmFiYTY2NzEzYS90YWJsZXJhbmdlOjI4NzIxY2IwZThiNTQ0NGFhZDlkM2M2YWJhNjY3MTNhXzMtMi0xLTEtMTA5NjE5_a67751e3-d15b-44f7-89b0-7c301136459d"
      unitRef="usd">10000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i20e412a5cb73413dbf99d215bfabc116_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODQvZnJhZzo4MjQ3OWQyZjNjZDA0YTJkOGY1ZGE3OGQ5MGMzOWJmMi90YWJsZToyODcyMWNiMGU4YjU0NDRhYWQ5ZDNjNmFiYTY2NzEzYS90YWJsZXJhbmdlOjI4NzIxY2IwZThiNTQ0NGFhZDlkM2M2YWJhNjY3MTNhXzQtMi0xLTEtMTA5NjE5_95c95254-558c-4084-a9d6-08be1e224e14"
      unitRef="usd">1241000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1Xzk0NA_496b620d-24ac-477e-b85d-dae782958456">Subsequent Events&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, we repurchased an additional 0.6&#160;million shares of our common stock under the 2021 Repurchase Program for an aggregate of $143&#160;million including commissions and fees. We have repurchased the entire $1.0&#160;billion of common stock that was authorized under the 2021 Repurchase Program. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 22, 2022, our Board of Directors authorized a new Share Repurchase Program (2022 Repurchase Program) of our common stock, with no expiration date. Pursuant to the 2022 Repurchase Program, we may repurchase up to $3.0&#160;billion of our outstanding common stock. The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to December 31, 2021, we have entered into several supply agreements with customers to provide our COVID-19 vaccine, up to 66 million doses, and have received upfront deposits of $210 million, based on the initial confirmed volume, subject to modifications.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to December 31, 2021, we have entered binding purchase commitments with third-party contractual manufacturing organizations for dedicated facilities and fill &amp;amp; finish services for our COVID-19 vaccine. We are currently committed to minimum non-cancelable purchase obligations of $1.9&#160;billion related to these agreements, of which $213&#160;million is expected to be paid within 2022 and the remaining is expected to be paid through 2029.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i258d02d7ce92442dbbad9a730c0f0475_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4NDE3OTI_42d7e0ec-a15f-43b2-94ce-743dfa44adc3"
      unitRef="shares">600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i258d02d7ce92442dbbad9a730c0f0475_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4NDE3NjQ_35650e0c-a62b-4770-aac8-cd346ea18bb4"
      unitRef="usd">143000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i35471f100ca04369aaa8cd79328e4486_I20220131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4NDE3Nzg_634d31d5-51fc-4b41-831e-7cb647c961c7"
      unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i2dce8093560b49b995bb23f3c3c63255_I20220222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4Mzk4MzM_4a28572e-8167-484b-89ab-fddbfa200979"
      unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <mrna:NumberOfDosesOfVaccineCandidate
      contextRef="ic9fcc9f307dd449cbd9ff284355911be_D20220101-20220225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzE0OA_a3cd13dd-e0c4-4c8d-8de3-31c7590b0327"
      unitRef="dose">66000000</mrna:NumberOfDosesOfVaccineCandidate>
    <us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted
      contextRef="i5a40581afbae47acaae291b96f6752cd_I20220225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzE5Ng_84521565-c5fb-4d07-977c-a3fa6a78028a"
      unitRef="usd">210000000</us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:PurchaseObligation
      contextRef="i5a40581afbae47acaae291b96f6752cd_I20220225"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4NDQ5NDU_f3634c8c-3ab6-4bcf-af2f-0756c05574e0"
      unitRef="usd">1900000000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="i5a40581afbae47acaae291b96f6752cd_I20220225"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8xODcvZnJhZzphZmIxZThjZmZjYjA0MTA0OWZkYWE4NmRjNWI5NTk2NS90ZXh0cmVnaW9uOmFmYjFlOGNmZmNiMDQxMDQ5ZmRhYTg2ZGM1Yjk1OTY1XzkzNDU4NDg4NDQwODY_f97f1cb8-1911-4d11-9276-f0bb18fc0b4e"
      unitRef="usd">213000000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <dei:AuditorFirmId
      contextRef="if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdhN2NkZjNmZTNjMzQ4MDU5YTZiMGE1N2MyZjE2N2ZlL3NlYzo3YTdjZGYzZmUzYzM0ODA1OWE2YjBhNTdjMmYxNjdmZV8yMTQvZnJhZzphYTYyYmU5NjRhMzY0NmE5ODdiNDRiYWZlMjg3MjlkMC90ZXh0cmVnaW9uOmFhNjJiZTk2NGEzNjQ2YTk4N2I0NGJhZmUyODcyOWQwXzMyOTg1MzQ4ODQwMjM_4e25f905-b87d-4c80-baec-53e31a4ada7d">42</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>130
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #C0%E4"2"Z37L&  #)&0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;*59:W/B-A3]W/X*#=WI[,Z$8,N\LDTR0WBT=!="(;L[::<?A"W $UMB)3DD
M_[Y7QF V8ZX]TR_@UST^NI+.N9*O=U(]Z0WGAKS$D= WM8TQVX^-AO8W/&;Z
M4FZY@#LKJ6)FX%2M&WJK. O2H#AJ4,=I-V(6BMKM=7IMIFZO96*B4/"9(CJ)
M8Z9>[W@D=S<UMW:X, _7&V,O-&ZOMVS-%]Q\V<X4G#6.*$$8<Z%#*8CBJYM:
MS_TX\#HV('WB:\AW^N28V*8LI7RR)^/@IN981CSBOK$0#/Z>>9]'D44"'M\S
MT-KQG3;P]/B /DH;#XU9,LW[,OH6!F9S4^O62,!7+(G,7.[^X%F#6A;/EY%.
M?\EN_VRS62-^HHV,LV!@$(=B_\]>LD2<!'2=,P$T"Z!O MQS;_"R *]J0#,+
M:*:9V3<ES<. &79[K>2.*/LTH-F#-)EI-#0_%+;?%T;!W1#BS&U?/G-%9M#%
MI$Z^+ ;D_;L/Y!T)!9F$400]HZ\;!MYCGV[X&>;='I.>P70IF4AA-IH,1<"#
M'P$:0/#(DAY8WE$4<<#]2^*Y%X0ZU"T@U,?#1WQY2=QN&DX+P@=X^)^)@+<[
M16__H37>,>=>BN>A.?^GM]1&P;C_%X%L'B&;*63S7(*DG\!L-.3A=<N+>@P/
M=YWZ)X1%Z\BB58U%3XB$163.MU*9(CHXCE$)1^BTCW3:U>C,N IE8$<C@4E2
MF)\2I&S\_?S33R5CH'/DUD$1^XE2EMHHU#YDZI$SA?+#T>IUE]8]C%?WR*M;
M<2 I!N*>:O/Y;L2Q5BS26#]>'3E=H3A#84+S"JF*.)DF\9*K(BXXAN.X=:_;
M:7D(']?)1=.IPFC.UZ&=PY"N*8L+^ZT$:"(#K@2[(&/A7V+43O3<K4(-\*2"
M;F.V!R_(PL"X(E*1ODR$4:_P'Q3SQ=$'0XPDS4G2*B0?V L9!S#:PE7HITR1
M_BV![$+_-MN=%NUB#'.)=KTJ#'M!H+C6%X<#\AF>(_>B.'<X))1BY('[&R$C
MN7XEB^\)4]CT<'/Q=W'Y?DNV;\^@LQ_D3A02Q>'Z+%ZJ,%BCY')/<'$Q?TON
M.!1G2CZ'PB].)8XYZ6'4<G]P<5E_2VTFM0$Q_CO<GI\?."*8@W>%<<O]P2TQ
MB)09E/+GJ>  ;;>#$<D-P<55_+.T!C7;2(&I;PE(QVW6VRW'P1CE=N#B6OX0
M&G "N2(N?;_\0!;<3Q1DJY 6CM27<0RB U6V_W1!MN#!SRQ*.'GG7#K@&&0+
M=9K>X-.4YJY!<;$'2PU"L2:+UW@IHR*Z)0"3^10;^#0W"8K+^"%E9/CB;YB
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MZ8)4N?K.GS[39D)3XR_CN:S_@J<&&XQ 5DG%B\98,RA8N?E/GIM = Q@.&"
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M$LW< /3O"Z[EM+DQWSJVW[9F_P)02P,$%     @ XT!95#26(W9<!0  "A<
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M-!KE5?,Z11YE4#'/*R G$MW=W_QN_=5_7%R<WX!558#;:17)5)8![2*?RCK
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MO.NOO>N7-FZ+=[P6\>ZJX+6)\RNO]H5.E,5T09,8Y\4O8/IY1=A7\/<U31+
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MNJ;N^CI O?&=MM1(?>NG!3T48%P"[:^TQGW@!)JG)_D#4$L#!!0    ( .-
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M6>I&'(31-';]Y<-F _ZRLH9ID,B#Y'N6KW^E8.,NH;9<MOX#:5%@_:5SEQ6
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M:RW8]+*X*A0=+3)[VLZ$AK/;-F.X7E%I F!^+H1^ZY@#O+JP]?\!4$L#!!0
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MA6&I&P)3-V(CC;D!M96.--I.H#-LRJ&X!4P::^B 1(!+0[>6KFN96(ER0)=
MF>VK<4O[!"07_!4Q)RD3YL3;C:TV!90N7UDR ]-' ME'[#\!TY)TK:Q8]CT?
M[J9L1F%HVIM1$#2V7-K&#I 'I3P H'F2NQ=T >@>"_103^=K1X$)0-0Z6K@>
M>X\P>8:YC,#7U0H<B L"/F!26W#;#I*#P+CJNVW1T9-D,A Z*J GE6L1/3V
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M/YE:F8Y8@R#HC'JMO%R7,9H3=N*/7>,1YS?";+R"XO&/J501"@X?V*5D!MQ
M<535B"/3"5HZB%/LQ)MH^9O$H*B!AYKY>&PKF(<,I!W;7"2W+1FUX(*5$8U#
MYM%0P@T+:E%\LE9#88&0A26@4PAO>J8 ?W(Q]U??E9:QGTI0=HI+>@:/X\ZH
M&\()&6CE'9LVZLF4O#P1[D"\0EJ8OG*FOP%:&-E[X+R%B]-&;^HNF)6"U\P$
MQS=8UB7KPG6H#)$*R;LWJV+9015W;6V':+N9@:E= > -H<!) 0#Y[J!.$Z-+
MW0//N%7G-% RW.W@4]+6/[;=;>L=,3H%;QKX6*C)AG4(;:16Z(@-V4-_I;<)
M]\-?)P_ 2*A#M88%"&4),K)!4/O88SO&;KV%SFC XW?DY1!S@R-?$82V2SJ3
M#[,Q/=1T:(@9MO<0$]A?.UW+'5CLC/$HEM)/K"6\5?='M"530^FE)?C6[(9?
MUC?@C1H&>'3*7B5.V:6&>>Z*HY>7[UY=0I[21H63/$W\QNZ#_W3IR*8?L)%K
M4Y$4A"V'@[S5@%8+VL5[Z*706P9QFK?OCE/;A;7!*]S/Z,'2/YNR&62#/X^D
M>&EU)<"CGW^^/GX1GXM:XE_^Z9N+\Z]?.%IJ!>*9.3!ILK\:P.:2Y']%QWQU
M^>[MI2[WTI*=^2_E=O>B^)4<9#(.2>M OK]&N$IC4=-O)# EZNO+=#2#Z:!_
M3"YZ*4$^,KDEYL V( NVVO##*@[\2G:[''MQ8AVK'+:\X5=ZW8;];4PIFU(-
MR'^7-;@$45LV\)7=0.X$$I5-LA]Z_\K"N>K7MKU/TPS*N)X:>;5@D09Y,J;Z
M,K5X66FP5*);F)4=G(>M'09(G\MH@838">1#8D3S"G1TUA1X_T/!B.!>"<7Z
M(V?K1_]V31Y1:E5&7R^)FG2KQ*M4&$P==34-1"M:B4C#R"2DQF!7!AO>F;T)
M)N_!@P4P)Z 7/X=$L*DV;8S/D=JZRBS"J6#!J25"/<#)OF'B89(Q:UOEYJ1+
MN,+9K6W*B3^C"M22A@#;6S/##O)X0_MOV2M+#R;F[994!YPO92E VVMNU<5.
M^4^,#5)^->/(J8#/]I2REH]1DKK1X)'G-1AN["*"I4"7WHR##%\$:F4-_A!6
M9&^F(F'#B.!3^0]>QRPBIC(80,VM1R($#G;E "&E1T;#@-"!W_A"(<D>(&^U
MXY K D/T#,)^QD>Y^NZ.Q*\&RLJ^17PT *!KI_X+@S)<!RUWJX%X3_U]9"!'
M]FN"V30@UKU.7> D:NAM^-X0)GQ,%XPFAF[9''CN@#3*3-?H>Q_P(2%C2=)X
M5Y,M%?8!:1L^_G' '4R\QL-^:.8T<@1*#6".OY8 [=9BPU.+;F(Q$;>63DB+
M__CQ;R/IF(8Q\$<TN3AVLK'K#1E,C:5[:HZ0>CN($0+#J[<DSH7H1C8 "$+?
MGA5U><?F'UN@P:;T4>_=2-2-X+_$+RKLP\1]<*2/;)P*8.1-)I_Y9A'IY/T8
MMKQ\;)P#=1P49,<H"&*UFCE*,W%8WZNB\/%#$E(E"U<8@,0&=]!8'\W@XW_"
M>UYAB"<U) 8PTU+5D)^+B$;'KGV^=\0&+$LH5C @JIXHOCWQ'S.Z@[!WGNQ8
MJC><:-@[B^!UL8]4M:$R>+H-3&!505>I"KK.5!#?_+KI;IT *H2") ZJ@D_4
M/&*1Y$Q'@<K;F>)6%>0$G3.Z4#-=!2?8U89QX]:3\] -9? )7;DUZLDI)60'
MO$?'\NM7?, C-OF;!EKH^/F^-2Y6-"SHR$%[I_M3\6SQS=-OZ-^+Q;.+I_CW
MR;,]\CTZ/R[8Z+QX49S3?R;7%QDYG%\4Y^?X__=\Y"\ Z]\!!-[_LS/9/^V<
M_J738+]O?*39YWUL:N $K>MWK>FOAS%+_F B5_XP*F8D=_&I@OS@_87,)]#$
M+,DD6)LE]&(%X6,U)I:Q7RJU[GV4S=6;DDP.NGA"$OA$'+H_?$)MYFJV>B8'
M\(G%?W9:EH"B*KUI#9=N;,FS;MCVW'0-FP%KDD*:/21KT6C$-;JBX(/XMF--
M_X_;422>(H-D9&\V4-ZD?8ZPTK'FIA:<8]'D WNO2&;A[:9WZA Q@0UW$,>Z
MN[U=28PD6*0Q+ 2=A_SAB49W?4Y>XOZ+($5M0E:RZ9#@:\TPFVH^9"7OXWX&
M80G^<]0_)(P9F3%6'WS&1"8;29MS=EVU(6L\CO?3NCZC(68QH(2XI1JEDB*^
M UZ!!;WLJ4O#-C'8L":*&=C$)RU,(F++Y3ZGQ:^SYV-UK9NR8I=J;"A]FA&B
M +3B^01VGD'7A+,>Y///V]K\P?XA\#NP]/ZI4P)XX.2YK/X<,!"1&LD$9W#
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MUM,18OY_;!GJFJK!-9;_6>I7"O,,,Q>MUGL7-99V',ZR^U#'_UW-PTR] VM
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M,W!#0JF#V<'I4EU.Z-Q5AOOI2?Z RH%([C.V'7-'V?K08=+5(%WS-]IF%ZM
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M_JR$<"AEEU0P_XQC,S=R]4.$/III/;T0X"^S08X(L--KEOS3 9X2_T($,UF
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MVS86_BL8K[=KSTBR)3O./3.*'6_3)JW'3M-I=_8!(B$)#4DP !E;_?7[G0.
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M/4'WB7A;B/>L;-IE(&Z5P!IE^8G*8,W&S@-1+968_K[E!NT@L4?&6SR$.W'
MTH%:J[?#9H>&0F>/6UTMNYK%E:4&_[=@>J>H/]2%\O(>\.?T.YF7SZ^[FX[$
M+UAJ>>L=S[!Z%E861+5KW$39"L JU%V2U0[P)2RAC)<\@P2%4\ZKQ[#2G(!N
MS6S[(MQ*O=?SBL3DN;*)EIG^4XG25& %/XA1*TM55_"E_/JGJ<A5JA/XIA.I
MMD!3TD/5\%9)NU"@C@3!,E;(#16;P,Q%LNE^_E*N*E@-(H FHM(%:R;DN#88
MG/23$M>E-5]TJAH'<-%\N-=1UTA\P/Z,\[K2_O8,DBE+R0OK9BOFL)26;]=?
MLXN0,'VF<UUY/H#V4 /H: H@G9"R@O2D"!!Z@+QSK;+42VO@/)&F)]32(3WX
M9T>0D71)U]5\KCB/B12:B%<W77W0<Z-<0GEU.;? 9Y!V2ZA@Y26$5#5]5O""
M8B'V)Z?'2#- $ 23]Z&E+!:JL:Y,/M>:HCCZ&\M1VZAEXIL-'[S#!LP=KMMN
M()0D*(93*9=8/2.OFIDOZJ'Q0K8ACZTR;QQXIH)B!H)R/;E,6B?5<+8:AJ^4
MO#66-J*32&!!(R0:=PU<IVUR&(#P L:LC%VMA0TI"E@ *U(,.C"59?0? A=#
M%$#M5F )Q4F6WI(7%S"SDUA).P;FG$#T+\@",%(._I<(V:'#A0RFU@M=D8(1
M[Q4J)9)V//GG )74[ ^X _UN]4WDR#(!T0"T<@'-+<A?4$#HO,[%/#/&C@BC
MH>&SOK.H.Y+.D3DB=\'8_8!9\[AO!A[F$FY2!DDZO/S+B8]O_GTYG#:,'$Q_
MOWAR=CP&JKY%L#B42-9B^VR%2"?UA7T\.DMQM02TB(E(X-T^7BVV';'86U+F
M1A)HTNO;=T,4.%#8#[*H4;T&Q6VDM0[1"ULO>F5&/U61)MYY"%]+6V<]S1YN
M,D7ZU"Y!L  J'P+I:S"^%:HENZ /7D8?UXU$R)B[#M[T>?0!6?23UU+" UH0
MI^H<_P%RR"\<I$"8/*\+,S2Q(H&9D0;AGP:E+X&,1T.H%DJK<Z@N@[P97 L6
M8)YWR$@;YO*3XN7>=J!=P45&XJ*VY"FR079$EC8I"X=^(P 3)8D59*"<#_\O
MC:WJ0N.2ST>E@=EDFFJR)7$5[-'($+-/8@KR7&S3BYZ^_D;B5P]H% >(73W+
M/.2&U<POU#L'#?Z>=7>D.^C(&A_OH%<W&]ZS/P=+DAB;ME' P,'&J\'2IH"B
MS/!(=*5&QWR+TW<!$[&M-Y=VLS!OPA#F9;U?3^_AWI^^5O2^+3A+&F2VBVYU
M<>ZSZD>(RG' ]/L7MY <7B$6R,B(J=2[V3JAMVTEN!44R@T*(<%_B10.KLX_
M'CX((=@X7@VTJ ,4@_N!%@_[T-=P(M13-5REQ$Z,WC7E&D[DS%[@RSL=TCHE
M0&*I4LFRX%CM@H-K=":#SE@)2'8(S?E*+  (7$W6E?150TEU0? [[PF^8 K\
ML'T?/T<,4= CN649\IE;H;U4CF1A)H/O03L-801OD<C2$;\^^/E);$.U%B*<
M2Q6$K]4HR."1[WZZ\KXA4TJ.KB*13(0 9@8<(O(_UVJ;Y:AZT8O"0QSE,#VG
M&$0^XLB+7*S+Q< 'Q:VP(<)E@;3I*L' :)'[@;2W1=R)I1^)J]JZ&BT";40D
M>[9O*J)U /'L1?R(U1C])G<8A-*:?J-TJ^=@VJ,CE"@3@CM:UK_E%WK_:M#)
M)]HQ7]Z>=+WOA<69"<X%R\!+9[KP_L7._>.;WSY<_W(Q%0>ERF<65?.?=2YG
M\&]V^T:)4(8>7ET,QZ%E60T8&!^ 91V 9!0C3F9U2@4X?6T1B&#+41'CLPT%
ME*XJ1;">PX<X1\V%^DRQ9%7P:DD%.B?+-I/XWB1B'J?&-8QHM$7$6//]D.^4
M2.\-^"MDHXC6/EZIKB[+Z(&,_9Q?0H',"2TV Z%")5[W)\=MZ<]5*&M[Y(OP
M-W>E]).X4 -\'39OEI+$^TD95>H*-=DVV)Q"BQEOT=00'MO:PD'1UK[)6(N]
M3=RAYW6!\C/U<==+A6N(Z#TN8,*/U].;3DRWJ[!EJJG9&G#X#Q^=/1Y3D'Y\
M>CKV4="4(%E,>,Y+7BA#+@KTVX'Y-]./-!^ ;3KI&U3:(K;=$GHR#$V:NTVN
ML'V/UND7[U$,!YLOF;NN*T4!'P_5$^(9*RD'-ZB&EKGV -D!UO0K@.J=O0=0
MXA:-T=8IRIK%"G4KH)=M(E"Z.Z)[;<ICY7$TQ?&)]Y[8#L49"6_9\Z^UZG1]
MTD(!:&:97H2$M1Z"9#IO_39Y$6NQ^HO3HRX-PN=.RT8E=<0]F!9NKD/B9Y!J
MYBMHHA:*D1=N@5S=S;P;&@D8"7Z!A+-["\J'0G;K@Z$:8)1-C*,!B7,&T42*
M9PVYFGKZ!G<&6\%8_&$TMVQ!_?? \2 :;I<\_=34@E^LDEOFK0J3BTZIR>P&
M4;<(1UY_5P8'VB;I=N#]BH$H8KQT*@T9A44/Z9&BP5+-RISN3TY/(BH3W4IG
M?A#4>@M'<1PC]7L9T,PR<TO*8)1 Y&<J+OKK]J]WB]7,@7KM6=%5&T"4:KWD
M4QAAL*,.FG!T3)@G!HSZ60@3'V"ZI%(*WC2O6=L/ O:6<\ 8VD'?]K4$Z;&8
M 7D0QB,1.$<1SHS8TCSV(N2*F7*C^OJFK-,/J\TD0@@3M<,#/"H_ '$Y6E&)
MU )8)H\&3ND"Y485^S@RP@V\ #[[/8V#P**D:,%BV*7BR$&ZF2M+P> J0T9
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MJN[FF2V93$DDT4DA0:0U7Q;BQ6R*VFD,>^5 6[%;J*K>CINI2".B<M7/Q)(
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M:?AU($,^9LA#AOQ_KN\@U*MM9CM>X(*1G"R:1V1[%;]:W(*N@.X&VS6:\7Z
MJ](;,12:-&(=EC[.-0B5EB0VH6KX(!1-C90D /MQ]I;D3\; =LM[&C"'1G!I
MX0BFDYB^V03N25Y ?)W1-15L(<NF\!DNA1(T?R746I<6TBR#!+YIQR4%[WHX
M@N0XSQ-:\PG\[=ZCO1%NT=1!J)9:VR@W3/.X.[X%9X,$7L.'A^2:FUHH"Q(K
M@L8GDU,&9A#GX#C=!4&LM2-Y!;.A]PR-#Z#S2FNW<WR"\85<O@!02P,$%
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MB,8;T/Y"4T&U$W_ _B(Z^0]02P,$%     @ XT!95%V[VC#@"P  %#X  !D
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M)H&(BKTH9",+'8X+\0.D(0051+)D?<MI'<T:*?WK7UZL5\__X<>Z^V=&;U4
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M>YA1'7-F95'\F+4/AGS/?Z]IDPW0S&]!DEC,1GW -!0HTXU!(/Y%(A ?N8.
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M<VAE971S+W-H965T,C0N>&ULI57;;MM&$/V5 >$ ":"2%"6G3B )L)P4]4,
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M=8W^CF6'+$MIU>LB_5,G;G,Q6 Q$HE:R3-W'8O>KJN29$EY<I):/8N?71M%
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MG//G #'\ZIU+.^>NTH.(UYP-:9P<4SI*DP-XXS[8<< ;?R_891<E_7NYLLZ
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;,59:V_;.!;]*X376+2
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M!A%&I\!HK6#:WT#8MQ$+.Q1<*_&/(G3 TA+*=2 DD#!LGD*Q(*U>8=." C-
MT8];Z4$5RDE3W037_K1;HK,-K=I\@(S<2&V8>9TU"E9?R;D\<;PCD[3IS9;T
MQ;,9KY$HS'>;\.7U[>M'S3==3/;M!YVAS')PA&,KYK=_N3Z+XOFDCA1M@$ *
M2'5*^^4*A2.B;!M#F-,_5[!)QZ@$,8KJ1. DDX'CUT:GJN-W7Q5DF):?EO]Y
MO,\_I43K@B!7/O,!Q:A(D(61J<P3 FD.\0RR-04-E70Q6(K)>#!&2BBE WAT
M*7'Z9HWJ44R$#U6Z);_K4BYB3E8YSK6ML(=Y 9O?2P<G;</']\K;GTT.':V^
MY3L%WI>QYCX>378J0 A)46T@H[-,6AWA+#J!LT-!F4U\)FEK6W8R\]T(D;Y5
ML,R1PEBHT@9LH(3BE,Z7E?--(8,"HA]/=J$%:H,G%$T#P(A)K.? ?%@H$?W6
M/)TB()@TGE6\$YG"0KF6*.826& %;RP2R)AA5_ -> 'P76 XB5@* @\L;ALW
MVS-FZ_]DR6@Z/879G0V>9)P3/C4..J_RYB*NA)FAQM >Z:0MX;AB:I)OM+,6
M:CZ.8-%PVN;&(0JKMI2A!.-;$GNV;,2F,):UA8A,-Z2\!YY%TKW!;J,3-'^5
MH^+ /(QI* ; [5*IHHN!Z3>"M%/4IG)B[ +I]X3K:'&Q"]A'"3&:,<HY_6[4
MOE)/!<XH[M Y@ F77GVI(#_5X^FOJ!]J'/2C:+X/XD8"*];*E+4"*1C^77^6
M74A%1$#!G).=H?76!!GM^S]J#L5R)R[C_S!8];OEP]3&K.L3F8SR]Q[/Y&Y(
M]])M=Y9HXXT4*V.7(+%&G86;H:!?J:S+H"5%HX)31<M;+K3?4+%<5]CDE35.
M:X#2!."P5FGHUOZV02-F*ZJ@,XXZ>$1]CBBF_'XP75>H4H3.\ZJP*"F1(521
M;,5&.QQX]M.[3\^_88__S KS(R/48#PVQ?BT+?;#$7=>9]C1"4T-:%UEJKJI
M:#9QU&82];@'Q:07 "@4UG)(^MH5HM0I*4_&2T]U=LU<8:^;HPZE<;2^F$?4
MR)W',7X7X@,'UL/;L#07TZ9Q.US"\<DY'[^@EBX6>YU[.S5 BD9_R"6.KHMT
MIRC^DIQ>K>I$1@7FKAO/+#H"2&WK3 \<)-0Z;P<'\*$0NVN1]&^RK2$(;B)'
M=.=Z="@^D">OM<K:4H-C-; #48$FY/"FZ6(VV<^)MD+Y7S&J:9&<JJA[,>5X
M)D'()I.3IWEKN"I+:="E<>=[6S? =!2"%53)F+T;V@D!=RY'W8ELHE2JX*S8
M?);+SZ0M #9IV -VN)4E;PVB#E4.6B4MPVO3+_!L.+/OBJ7]!G[8V+*U(I+_
MWM  M&7+>=N8^4;9!MBVM01<H!6T].WA@G]ZNL!X/!XQS ;1?$X FTT)8.=[
M<X;I3$PFXOR)(4,[ANB&#8O!=!X1PL>$]MGO.W'XYA3G?S^3^, P(WB%NJE%
M=M0/*M$&PWAR-'(]L]D9_(QJ.D7ER0D</&W;A_8\MF(T&)^/6]-%B^C(9M%X
M9Z)!/(U^'SF(Z<[G$$Y:3R&+G?*'1Z8-X^&I4>9H;V(,SUCQ7!RM,978]?"X
M^]J-WJ_KB?-N>SVW1V.")MRC'\]P=#R<G_=J@=J78$N>/R]M@!OR(SFW<K0!
MZYE%/=^\T 7=?TA<_1M02P,$%     @ XT!95.]8HH6W!   IPH  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&ULI5;;;MPV$/T58A$4+;#>B]9.X]1>
MP(X3Q 6"&':;/!1]H*19B;5(*KSLVOGZGJ$N7A>.>WO9E<B9PYDS9T8\V5EW
MZVNB(.YT8_SII ZA?3V?^Z(F+?W,MF2PL[%.RX!75\U]ZTB6R4DW\VRQ>#G7
M4IG)^B2M7;GUB8VA48:NG/!1:^GNSZFQN]/)<C(L7*NJ#KPP7Y^TLJ(;"K^V
M5PYO\Q&E5)J,5]8(1YO3R=GR]?DAVR>#3XIV?N]9<":YM;?\<EF>3A8<$#54
M!$:0^-O2&VH:!D(87WK,R7@D.^X_#^CO4N[()9>>WMCFLRI#?3IY-1$E;61L
MPK7=O:<^GR/&*VSCTZ_8=;;9\404T0>K>V=$H)7I_N5=S\.>PZO%-QRRWB%+
M<7<'I2@O9)#K$V=WPK$UT/@AI9J\$9PR7)2;X+"KX!?6-S'W]"62">+M%K_^
M9!X RYOSHH<X[R"R;T L,_'!FE![\=:45#X&F".>,:AL".H\>Q;Q@HJ96"VG
M(EMDRV?P5F.2JX2W^J=)BM_.<A\<)/'[,_"'(_QA@C_\/QS^2PAQ:<3/TD0T
M"K.03<6.T 1M=$4-$99"0M%EJ5C:LA&+V4NHHVE8Z+Z6CKRP&V&C$X75FA>#
M+6Y%1(&<"#4E9L7UB">NG*V<U )MGJ"KRE$E S',B^7A:D17IFABJ4R5D)7G
M[O1P*<6&R,_$9Q*UW#Z.E0]$4LH1L&8+D?=8P'X47JAE$#L)N!AJZ]17^/YM
MR#/QT8AWE+N.JVS:\\7)GUOI2C[F F<7P;I'T%(83(T;INLI*KYGG"<V?GB*
M6M1'A5H8*^BN54ZFD5."P)FXBLY'B<H&.^3Q%&RJL);W>\R)V++3B]5CSOAL
MS%<?P/I0B"&.F?@%1P2E>8.K HU'",1$G8-'>/?RV*_/#M@891CT( O%%UOI
M%(5[-M_(Q-MTK_"M4P5-146&'*#SZ*%FWXD D_T6GY+"FDZ;<.1EB\0=(+;D
M@V:5V[:U+D0#(^IM^L"8@ORO^G$V5K7@3]%PPK#KQUWF-OJD6+1V%VDC(4YE
M O%D8BZ_@ RUN>]E=1T;$LM%?G2PW!/:VSL@FXK$61%F8J\UX8_11(G)83RE
MLB7%PX(<3L%Q5GC:)G)\;-OF'OWDB'1J[*23;K(3] C;UMFM*BG5]<W'3Y<7
M!\MCE* H0.NTU\#+A_XNK1\HZSNM('S9T"KMQF$0<R6M5R&-@!?9<C%X3M/W
M*Y68TU1,/D)$K3;*:6QL;1,UCO0Q_P/MPN=J6ZJ-*I*>_7\@(U>=1D=)IZD1
M]J@(M7+E02L=](90TE1FQ6I,/Q9?=.R/:X<TZFL71YI2*"C'A3-@I9HDI&X.
ML9J_D[K]"8]&^1K%<%M(MO-[BN4TMG@,%-$YA-;<]W&&3C7H)J6C1GN;@T*:
M@AJ90SEC4C9O5-7'E@;F['AL6 ?C'@:LP_A!"U,VWM6JJ+E.>S/6\Q1!!3HW
M=$,K59GH4J:;'YPH%]$1W[R8H6\X#=T!K^/94Q^[^=[E 8JLTA7)(_]H0G>/
M&%?'6]A9=_EX,.^N<!^DJQ0H:&@#U\7LQZ.)<-VUJ'L)MDU7D=P&R#\]UKA)
MDF,#[&^L#<,+'S#>3==_ E!+ P04    " #C0%E4Q>Y#-!8E  "N>0  &0
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M=88T \P)0+VX(A_=IQ4O U'2PRN&0&H> ?$9M_>1>\ZNZZ$]S&?K9/(:"^G
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M*\83*K'*UWVQY4"7>E(2]UW;'O43&J6]Z95N^\2G5RR3<93")TY$EB24/]]
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M1Y(<$%ZK544T#:3I%+["-9><9K* 2JG"0)*F$,.#LDQ0\*Z'(XA/LRRF-9O
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M.IMD >C^A>@G5K6^*^?*4H_WPYH>5=3.@/8KI>QNX@B&9WKQ#U!+ P04
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M*/,W\5?8@+[M*,'WQC";M)GRE#Z:S<#WO<JHYLZA81,/[<=@;0,W\\GO()S
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MY]Q]Q]B1NZ]!5TRM!$Z(E"^1U1M,\$BJW!<6=V-D8;]J+*0Q,K/+-6>8?2+
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M#F&!J64+DAZ/>(U%P8;(C;\:FX-N25;<';?6W[K8*9:Y-'BMBD]Y9E<7@_$
M,ES(36%OU?87;.*)V5ZJ"N/^8=O(>@-(-\:JLE$F#\J\JI_R2Y.';U$(&H7
M^5TOY+Q\(ZV\/-=J"YJER1H/7*A.FYS+*]Z4.ZMI-B<]>WEG5?KY](KBRN!:
ME;371KIT'=W+>8'F^'QH:1D6'J:-R:O:9'# I!_ >U79E8&;*L/L:P-#\J]S
M,FB=O IZ+;[!5$#HGT#@!7Z/O; +.G3VPD-!KZ3&T[D+>B:?"&,6IEK+:HEN
M_/MT;JPFP/S1LUC4+1:YQ:(#BWU8<SX-3!E_N7W:E]!^"_<KA(4JB#]YM03+
M^]*0*/\;#:B-!K5^QCBM 9(^+X#RAN4<=9<[D%7& ^\,?MVX&9+ZY)!+J9@^
MHB8BPLT7U&EN$&8Z3Q'6).8RUDF>=J*WR,1GMZYIRSEE&UG />H2ILNEQJ6T
M".]H)B<:I_!1%AN$(_\8CO**X%P4G)IC^+"QQI)O;$C:%WY[$$;"&\$K\!/A
M1S 2"3RAU(:^!">39 0_T^9Q"+Z(QJ0Q$9'?A9'!42*\Y!C\6(PCN)952D4A
M&U)%6V#.6D<^63^&,!'1Z-]\\2%(V#K]>V,@BXTGHY,@2MHUW1;M5:8 PA#\
M4 0A1&+2*$<G?A*2\IIJ%?EC%3RBL0<L>&YA3TPB2$3<6 A.O"2"/^N?R_!S
M_O,N_X\N_[F!5!;III"\&$'%$L"R?+% C90;F*/=(E;N,[986#LL$%SXZX:(
MK8LG3I%JX,W(XJF%S'6S#@FGJBP)EX:K#&%8DX@B8ZU27B]"(G@0LZ*'@W''
MP;B70;>43?+?UD6./7)U#QZJW/8SL]<N=\PSLY8I7@RH)1K4CSCX%KK>WCVX
MA,WXV7(VVVBG0.J\IX!</5_F8Y>ZM?\O".S8 &]X[]_R=M2T8QZSPB["3Z!2
MU2F#C9&PCWF!\"=$L] 3XQC>&;,A04\D1  "(D'Y8ZU[Y(F1=PS!1 23O13S
MA$\4&X4B";[' 9\=B& \%G$,/4@8=4@8]2*A*V%MKJ844MG \<'4Y+LQ-B\Y
M>[P7.QFDC+?5O"DX^R#3Z\!AR&Q;SV3CF=SQ;--XAKN>?4VUEE/+IA0ROF[N
M9K.&=M@4B@.HJG?[I&D0M.5;*@9,R1K)YNPERGYS]F[VVVO PY::E)W!;6X^
MGRXTNHI$YJG":8[%X[+\FA\A/0)&T.N=8LC-9"1\KRVTPO>[H=<V@D[\45%9
MRPLF%!7SUQ"/Z6_D[UK,B&\9Y<' CS^, S_XB2;WC;J(VQW923B3R;BF^ HF
M/@= S6DB0H^?O@ACE_N^F+VQB]GGT'TQB5_$[(FXC7G_<%_,(9N+W5_X?\8\
MBD00<UT@>H[I&8O)N(^?2<?/I)>?!\^C'$EE<!_A>BU^>XUVLY6MVR$UKC5U
M)7YE2J0%L3%?Y&GM#-'-M;3F#)GN.HJUH_^1=E^=B\Z^EV,,1CXF);PE2<Q]
MQK2-ADX9 =#9O$8F1$#'$+A7ELYK!%F:(]V0_L8^)9Y@RC%*N@'P&8LG6XP\
MCZBKDGOIRJV0X2/=\-;N_#RB\\D(Z"1V1[<M5^276!&<"B<I,[K'Y'S Y@L9
MQ $=O( ZR7Y?]F%JN'/?*5$OW:V.#C5J4]GZZM-][2Z.T_J^]"Q>WSK?2[VD
MLQ$4N"!5:FS4\'5]DZM?K%J[V]-<6;J+N>&*+K^H68#F%TK9]H47Z*[3E_\
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MP]>IB/$M$6\O=>D9LU69PV*)<!J=X6.]\4(;FY+8+W2)7)A.UW8H1,L+#F$
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M7775Q,BU.\N7TL#-X(8%?!U090&PGDMI/B;V>FB^-]*_4$L#!!0    ( .-
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M"_/V 64WF/5<2MP:-D#WFIK\!E!+ P04    " #C0%E4JL^D&#$$   -$0
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MD-,HL+_H3#ZT)M$9DQ"!;[01:PX^-P4IC@WXTK_>2;1W\@$Y+>9D<0="^#-
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M#.U T(W^YGZA0B[A].F:X((P!9#WEY2*_4!-T._S3/\'4$L#!!0    ( .-
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M[O X=<@L?O7H/JE<@W0JSU'T);U9NN<C/65$?;KB*001'R_T@OI^BB1X_%V
MCLHQ4\?J]0']*IN\F,PS2>A%Y/_FN7Q[/G)&P*5KLO/Y8[2_H<6$S!1O%?E)
M]A_L<UO3'('5+N%14#@+!H$7YI_D:Q&(B@."/0ZH<$!#'7#A@(<Z&(6#T7#
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M!Z/H*2><&5#X.9M+Q9RIPU0A4I*,A@L8:J/8$PJ,&<T(Q RF/(9AGG,F8M3
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MU/+XX8;:6-3N!7J^5LH>)FZ#IC&>_@!02P,$%     @ XT!95"4V "Y? @
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M:-H@:5.@BSW0TE@B0I%>DH[3?]\AI<BV+*LYY)"+15+SGN;-HZG1>"O5@RX
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M4#8 [Z^D-,\3^X#FFV;Z"U!+ P04    " #C0%E4#C08:S\#  !'"P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6RM5F%OXC@0_2M6M!]VI6T3&QI"
M!4A0[G0G;:6JU=Y]-LD UCHV:QO8_?<[=M*$+B2MKO<%[,3SWLSDY64F1VV^
MV2V (S]*J>PTVCJWNXUCFV^AY/9:[T#AG;4V)7>X-9O8[@SP(@25,F9)DL8E
M%RJ:3<*U!S.;Z+V30L&#(79?EMS\7(#4QVE$H^<+CV*S=?Y"/)OL^ :>P'W=
M/1C<Q0U*(4I05FA%#*RGT9S>+NC8!X03_P@XVI,U\:6LM/[F-W\7TRCQ&8&$
MW'D(CG\'N ,I/1+F\;T&C1I.'WBZ?D;_,Q2/Q:RXA3LM_Q6%VTZC+"(%K/E>
MND=]_ OJ@FX\7JZE#;_D6)]-(I+OK=-E'8P9E$)5__Q'W8B3 $8[ E@=P$+>
M%5'(<LD=GTV,/A+C3R.:7X120S0F)Y1_*D_.X%V!<6Z&U4B^TH:''LTW!@![
M[BRY(G=;KC9@B5!DP257.:[UFCQ"#N+ 5Q*W7!7D3BMGL+GDB^ K(843>./C
M$AP7TGXB'WS\O9 2\>TD=IBS9X[S.K]%E1_KR(\R<H\$6TO^4 44+P%B++:I
MF#U7O&"]B$O(K\F ?B8L8?3KTY)\_/"I!W;0-'(08 >=C3QOPVT/[K#!'0;<
M80?N C9"*:$V*+[P$"[UL(*X"1#^/3S,ALEP.(D/%XAO&N*;7N)Y40C7]="J
MT/2$D-)TG%YF3!O&M)=Q"<4^[Z1,SRBOLFS$+E..&LI1+R6*ZI76CLYHTRS-
M+K-F#6O6R_KRI7N$ Z@]D-5/@H>XPP>>D_:(-CTJ&C>,X[>I<VXMN%YATJ2U
MCN3]TJPQ7C3P<O?HB6?1_R[-.O:4D'4QLI:1O4.:=? +;;)!!V=K*'3P3FW6
M *>\XP[6UF[H\'_U,=KZ">TWE+?)Y=Q9V##I**HU%MKO+/V".7<6-NI@;'V%
M]AO+*X(Y=Y6KM$LPK:O0?EMY@V"R\U*3CN\$;;V%CE^I=0W&0(%36N5D!B3:
M6$&<KD<8,!>S&9]]MECV^ZL:G\PVB+,)$YPEN=XK5XTYS=5F2IQ7LU%[O!HQ
M[[E!!5HB88VAR?4(F4TUM54;IW=A4EIIATF'Y18G73#^ -Y?:^V>-YZ@F9UG
MOP!02P,$%     @ XT!95,C)C7$D"   (3T  !D   !X;"]W;W)K<VAE971S
M+W-H965T-38N>&ULO9M1;]LV$,>_"N$-PPHT,4F)%-4E ;IT[0JT0[&@W<.P
M!\5F$J&RE$ITT@[[\*-DUR>)%"68@5Y:.SE2I[OPQ^-?NK/'HOQ<W4FIT-=-
MEE?GBSNE[E\LE]7J3FZ2ZK2XE[G^S4U1;A*EOY:WR^J^E,FZ&;3)EA1COMPD
M:;ZX.&M^]J&\."NV*DMS^:%$U7:S2<IOO\JL>#Q?D,7W'_R9WMZI^@?+B[/[
MY%9>2?7Q_D.IORT/LZS3C<RKM,A1*6_.%R_)BTN"13VB,?F4RL>J]1G5]W)=
M%)_K+V_7YPM<NR0SN5+U'(G^[T%>RBRKI]*.?-G/NCA<M![8_OQ]]M?-W>N[
MN4XJ>5ED?Z5K=7>^$ NTEC?)-E-_%H^_R_T=L7J^59%5S;_H<6^+%VBUK52Q
MV0_6'FS2?/=_\G4?B=8 $@X,H/L!=.J 8#\@:&YTYUES6Z\2E5R<E<4C*FMK
M/5O]H8E-,UK?39K7>;Q2I?YMJL>IB]=IGN2K-,G0V[Q2Y5:G2%4HR=?H=9*6
MZ%.2;25Z+Y-J6\K=[T[0U2[GJ+A!ETEUUUB_?$C2++G.Y(G^VSJY2C*)KN1J
M6Z8JE16Z_H:NTML\O4E72:[TI1YDI>KI] 1*WA9ZLI]?2:6GJ)[I"WR\>H5^
M_O$9^A&E.7J?9IE.>'6V5/I^:Z^7J_V]_;J[-SIP;Z_DZA0%Y#FBF!++\,OI
MPW%W^%)'^1!J>@@U;>8+!N>[5JV@/._%K*IC]O<[/0B]57)3_>.X9'"X9-!<
M,ARXY,M-4:KT7[E&ET6E;!'<C6?-^'K-/UP0'$7AV?*A'2C3BG(2'XPZOH4'
MWT*G;^_D@\P0==PE.\S$Y@HL/UR2>P9V-YZW QMQ2GN!-:T8#0-[8*.#;Y'3
MMX^Y!GK6./=&@]RZ<"+CNKCGF6D1VMT2![?$5+?>%54EK7X)XZHGK!\STP;;
M/8L/GL5.SVK2_?0#X?B7!G<VOV)+-EG4CYEII;,9V9TC& B-IRP4]!_0MOGP
MVY=M^J#_MC64'7_1I+43D+F6$0$F$NH;^_T,[;!R$8I>["U6E-.!OUD" "5N
M@K:"ORW+>L=ZGY2?]59UW=GA7+$ ())PM@0 .PGS3@ S0AN(*.XGP+0BL1A*
M ("6N$D+"?BCR$^.SP+0DT2S90'82-QPG)(%DWMZ&03]+%BL@H&=F@ @B9N0
M@^#1:=DEB+@*)$ =Q7/%G@+W*/'<R_<3C!#(8C5,(-JJ&MV$G+*=4Q-^_;W)
M:=)U#>!(W7"<M*7OYW#ZYC+I^@8PI>[R<L**VL\PEE;3RI%6X"YU<W?"DCIR
MQZ? 5LIG6V[ 5^HN3Z<DQBP^;8DQK1R) 113-XHG)N;(?8@"<VD\VW$1 !RX
M:\T)R=G/X%K/3I.N9T#IP$WI:6GQJA$"8'(PWU&^=99WTW9*;L99ZS3I>@:L
M#=RLO91Z ZVU'26K6A5:R_NB2M4A,ZY#?@#$#&8[Y@> R,#WH!^89WAA!-VT
MH4-560 D#?P/^L'X2=]ITG4-(!H\P6$_<)WD][Y-/NP' -; ^[@?F"=Y,Z>F
MS6!.0P!PZ ;PZ%(ZLB@( ;3A;#) "$ -O66 <+S&=9IT/0/JAF[J3DK(D1M.
MV-)*9Y,&0@!NZ"T-A.:AWU@H%AM*V$!> ,RA&\Q3\N)5#83 X7 VQ2 $PH;>
MBD$XSE>+R5 %'0)@0S=@/YY>G2)5-@^-OJ'K-,NJ2:4  TJRV70"!F!DOCH!
M,Q6 T-#);$8QM<>< 4"9OTK Q@GJ-.FZ!@1E3Z 2L/'*U6G2]0VXRKQ5 F:>
M_RU)M1@-)K7U7,L-8.=".K(08$!8-ILZP("ES%L=8.,EK=.DZQD EXV4M&/)
M.'*?8<!5-ILBP &UW%L1X.9QWUPA-J.A%<*!R=S-Y+&D>%4 '.C+9],#.'"5
M>^L!?)RJ3I.N9T!5[J9J-RMY49=H4PH #F3D\SWR;SWS]W[H;Y[S.8M9/^06
MQ6#@*3$'<')_,8"/D]-ITG4-R,F?0 S@ED?_ >E[-UD.X$!5[BT'</.HSQGO
MOR1CL1I*:P3XC=SX=2ZE(TN "/ :S:8%1 #3R%L+B,8K6:=)US,@;C12R8XE
MX\B-)@*R1K/I !' -O+6 :*1A__[G-A>)!A("E Y<E-Y+"E>)4#4>NEJ-A$@
M K)&WB) 9"(S9(9&8[,:T#(C(&LT\M9 4=X79:(D6M?!J>!]T"G%@ !&BMG4
M  %H%+YJ@# /^@'#_:>8%BL2B8%5(0"BPE\/$.,4M9@,O08(%!5/H <(LRP]
MH89WDVM7 805WHJ , _[02B,Q)I6)!HZ\0B L1AY;V!\41U9%@A KIA-&1
M6.&M#(CQ^M9ITO6L]6+KR!L#TU)RY!8D@+=B-GT@!OC&WOI ;![]24#[;Z[9
MK 8?J,7 Z7CDO8%)R?$J$F*@<CR;3A #;V-OG2 V04H)[Y];+5:,#;RL'@-P
M8S=PWQ0/LLR;9I!CRH08R!G/IAG$@,K85S.(+9T"I/_.N\UH*/) U-A?,HC'
MD>HTZ;H&2(V?0#*(+9)!7S&PV PYUVH7\.\7L#0,$,,WB]% 4@ENMPNXB3QE
M01W;3(!;W01XOG8"W.HGP/X-!7B\\'7;]+QK=1-@-XNGYN;8M]QQJ]D S]=M
M@%OM!MB_WP!;U 3C17>+T6""6MT&V,WKB0GRZT7 K68$/%\W FZU(V#_?H3]
M%.VNP-CHRK$8&8Q;MMI7Z^9A'<];O1VA3-[H0?BTEHW*73ON[HLJ[IN.UNM"
MJ6+3?+R3R5J6M8'^_4U1J.]?ZB;90U?TQ?]02P,$%     @ XT!95(2RE S5
M @  70@  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N>&ULM59;;]HP&/TK
M5M2'5NJ:&Y"D J065JT/2%59NV<3OA"KCLULI[3[]?N<I!F7P/JPO9#8/N?X
M?!?'##=2O>@<P)"W@@L]<G)CUM>NJ],<"JJOY!H$KF12%=3@4*U<O59 EQ6I
MX&[@>0.WH$PXXV$U]Z#&0UD:S@0\**++HJ#J_1:XW(P<W_F8>&2KW-@)=SQ<
MTQ7,P3RM'Q2.W%9ER0H0FDE!%&0CY\:_GB067P&>&6STUCNQD2RD?+&#^^7(
M\:PAX) :JT#Q\0H3X-P*H8V?C:;3;FF)V^\?ZG=5[!C+@FJ82/Z#+4T^<F*'
M+"&C)3>/<O,-FGCZ5B^57%>_9--@/8>DI3:R:,CHH&"B?M*W)@];!+]WA! T
MA."SA+ AA%6@M;,JK"DU=#Q4<D.41:.:?:ER4[$Q&B9L%>=&X2I#GAG?,4%%
MRB@G]T(;56*!C"94+,D=98H\4UX"F0'5I8)Z[0NY*:0R[!<LR41J4X&_:L,P
MI[!#DQF94?4"ABXXD#FDI6*&@;XDBW>D"J.PB"5N/:/&+KV3\RF"&=<7N,O3
M?$K.SR[(&6&"S!CG6'4]= T&;:V[:1/@;1U@<"3 *:17)/0O2> %?@=]\GFZ
MMTMW,=5MOH,VWT&E%Q[1V\W="<&P%0PKP=XQ@YAH3) 40-Z!*B(5X: [$U4+
M]2LA>[I?QV$<!T/W=3L=AR _B?T6M..QUWKL_=4CS0RH/S9-KF2YRDF&A[B:
MZ71<RPZVS SB9-]Q!RB,NPWW6\/]DX9/5:EVUC_8U/>BJ+=G[1 5#/RDV]N@
M]38XV4%=1^U$'T6M;/2O^B@ZB"J,HV0O]$,0]E&O._2X]1C_GSZ*._JH%^XY
M[@"%1VJ5M(:3DX:_2T-YEZ'D\)1Y4;#?V8>H8!"$>Y;<K8^_O7CQD[MB0F/U
M,J1Y5Q'R57V9U0,CU]5]L) &;Y?J-<?['Y0%X'HFI?D8V"NF_4<Q_@U02P,$
M%     @ XT!95 BN#Y55!   ?!<  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3@N>&ULO9C=CMLH%(!?!5F]:*4F-I#?*HG4F=G9':DCC9J=]F*U%R0A$U1L
MLD"2MD^_X+C&K8V7>#5SD_B/PP<^? 9F)R&_J!VE&GQ->:;FT4[K_;LX5NL=
M38GJBSW-S)VMD"G1YE0^Q6HO*=GDA5(>HR09Q2EA6;28Y=<>Y&(F#IJSC#Y(
MH YI2N2W*\K%:1[!Z,>%C^QII^V%>#';DR>ZI/IQ_R#-65Q&V;"49HJ)#$BZ
MG4?OX;NK06(+Y$]\8O2D*L? -F4EQ!=[<K>91XDEHIRNM0U!S-^17E/.;23#
M\4\1-"KKM 6KQS^BW^:--XU9$46O!?_,-GHWCR81V- M.7#]49S^H$6#AC;>
M6G"5_X)3\6P2@?5!:9$6A0U!RK+S/_E:=$2E (*> J@H@'+N<T4YY0W19#&3
MX@2D?=I$LP=Y4_/2!HYE]JTLM31WF2FG%[<L(]F:$0[N,J7EP72X5H!D&W!+
MF 2?"#]0<$^).DAZOM<#CYEY_YQ]IQOP02@%'H1B>1>_OJ&:,*[>@%> 9>">
M<6XNJUFL#:FM+UX75%=G*N2ANJ'K/L#P+4 )@H_+&_#ZU9N?H\2FG65C4=E8
ME(?%WK K#99T?9"&EZJWX/W1X)(5ISV3WSU%. 5_?3"%P)VFJ?J[I4I<5HGS
M*@>>*G^7MH<.KL>X.;=5<VJNZQW) $0@%9G>-?;3.?HPCVY'V''1&Z)9?&Q
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M[_E$BWV^O;H26HLT/]Q1LJ'2/F#N;X59C10G=L>VW'!?_ M02P,$%     @
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MMDD!Z8B;=$^01&>9;?26Y7PZRGK]?A" &AD-:@2@1GX6U$A_J!& &CD1:L0
M-8]1<GRIZ6$XQ!:H$8 :^5E0([VA1@!JY"2HW>09_X[6<?&52[3:9DOAN@*
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M7I0!ZOM5KHK;^DWY+'OS?Q?F_P-02P,$%     @ XT!95'3[^ 48 @  )00
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M/-6$'99AAZUA]_!38UAMW-S#:"^N([XNZJB,.NH:57#ZR 6W+W611Y7(X_K
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MC4=3C1;U(U1/%"_M/=YRI5\%.\SUNPW"!.C]'>?J.#%/0_M/$/\#4$L#!!0
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M4CB><Z>-(J8VW+[>>)^DBU>+F6)!1BSZBP9R<=GH-D! 0KR*Y#>VOB7Y@E*
M,Q:)]!>LL[F^BCA;"<GBW%B-8YID__@U3\260:=788!R [1CT'8J#-S<P-TQ
M0%60VKE!>]>@*H*7&W@[!K!38>#G!OZA:^CD!IU##;JY03>M;E:.M)9C+/&@
MS]D:<#U;>=,7*2%2:U5"FFCN/DJNGE)E)P=?B2J\ .?@'G..-8_ Z9A(3"-Q
M!D+Y^V^PT_T,: *>%FPE<!*()CC1XSL:18I\HM^2"H9VUIKE(8=92%01<DQF
M%\"%38 <!+\_CL'IR=DF4K**IX3_$0Y7- IH,M^,KU]E]KX\$$Y9L+D]PO%R
MI?"7@!C905PMN0+A9"!VH^]$*_$^/GR)3K[$$B_7=B]W^.T )Y.:A:[F&RBP
MMUEHB9L;NYL)F5X U'WOYO!\W1X.TO]/WEN*[P7I44%ZE(9S*TDO!"%-D)*_
M"<9$S#A=IEKZ]U<U%WR1)!;_6"*Y120WC=2NB'2?K@&P$,QRJH*?X #V#C.W
M?NI6[S\O ]1OO90@:1=(VE8D#YP(DDCP@J,5T8 BO7@043RE$94T1792!B7S
MZVU!@5X%&*\ XUG!I%OD.0O/U?(!5L602E;4?JP5*)EGT"KQ>'NI@6V#)WL]
MO3W,/:<<LE] ]JV0KU7-@H $&6F$A1N=PF/GR"SL%I&Z1ZI]=[_VOK^3Z^X^
M5=OEN>X5>'M'H\>XMP?9KV K=,PFZ5@!W3V-P*/J_!9-H"_O&9<+H#;#='2-
MA;04"6YMQ?#(A(!& 2&RTWDCJD 2'I=NXG8''G@CF-O> VA$$AZJDJ2 M4S%
M?ELNZW>9(=R73;>B]D8WH5TX)S3!R8QDK&OF:#36)=>4S-^>W<:E%%W[8'1&
M2*%=2=4>,N4TF)-Z78)&ZJ!_;"(:$80=ZP*NU(E+9Y.%(559%DNL?D]5@RF>
M0WFF,FOI68:Y[W?:X\.*G!JUA':YW,VI J&.@@J%[WQ^(K-%PB(V?P./SRO,
MB2T)1N]@[\@)1T;+D%W+/I+P2>Y[.^%>Q<:*C.XA^#$MFM0X0+5:A+9:0[NN
ME13?^S_%1T;]D'OLXALQ0W8Q^UCQ]_7+KRJ^$3!D%S"UEZX9"TRV#]A2D5$R
M=&PE0T;)T/&4;(1*E*Q=E5RC9,BN9+5OUJC&0?TNCXS((7M7]ZMV^5$>YX##
MD6M4T;6K8BD-TS[/=@HT$N<>N[5SC8*Y=@7[" ]O<M_O<NLX[SO^VYI)[W%O
M'97M76 M66]J')22-4=LMX1.+<]=H[&N76-_%<]OW'V];>]68G]*U:M@%-FU
M*_)5%+%UVO*&C*M:J/97 AJK=O>%Q.H8677RNG;W3]UH%TUKZU.E_CA^A_F<
M)D)UUZ$R<BXZRIIGWYNS@63+].OEE$G)XO1R07! N)Z@GH>,R<U ?Q MOOH/
M_@502P,$%     @ XT!95#N3I0*X P  F0X  !D   !X;"]W;W)K<VAE971S
M+W-H965T-S N>&ULS9??C]HX$,?_%2OJ0RNQFSA @ J06&AUE;8Z5&[;A^H>
M3'# JF-3VRS;^^MO[(0 2<C2U9YT+Q G,U]_9L8_AWNI?N@-I08]I5SHD;<Q
M9OO>]W6\H2G1MW)+!7Q)I$J)@:9:^WJK*%DYIY3[81!$?DJ8\,9#]VZNQD.Y
M,YP).E=([]*4J%]WE,O]R,/>X<47MMX8^\(?#[=D31?4/&SG"EI^H;)B*16:
M28$434;>!+^?XJYU<!9?&=WKDV=D0UE*^<,V/JU&7F")**>QL1($_A[IE')N
ME8#C9R[J%7U:Q]/G@_I'%SP$LR2:3B7_QE9F,_+Z'EK1A.RX^2+W?] \( <8
M2Z[=+]KGMH&'XITV,LV=@2!E(OLG3WDBKG$(<X?P6H=V[M!V@69D+JP9,60\
M5'*/E+4&-?O@<N.\(1HF;!D71L%7!GYF?$\A!QK=H#O"B8@I6KC!\TED(\1F
M^NV,&L*X?@=6#XL9>OOF'7J#F$"?&>=@H(>^ 1*KY\=YKW=9K^&%7F<TOD5M
MW$)A$.(:]^GU[L&YNP_Q%TD(BR2$3J_=G(3ODZ4V"@;6WPV:[4*S[30[%S3=
MA+B1R<U.4T2TID:W$,P^!4D5ZQ82U-3E+1/M.E$[!1_'N!,._<?3Y%1M!D%A
M<@;;*6 [OP^;, $CH@DV$XU.0**H6X*MVG2[];#= K;;"/N7-(37X70K7?6#
M7@FG:H,[%WBB@B=JY/GS4%3$[3A"G)$EX\PP6CLSH@I!)RI!5DVB>L1>@=AK
M1/QX*.5UB+UJDBIUK=J$G7K(?@'9?[ZNL.8I185Y#K%?[1[C$F+5IGUAG@P*
MQ,%+2PV31(J;G+Z.>%!-:E N?-5FT*LGQL%Q@0]>6OMGF7/IL]D[&)2@:XPP
MOI!H?+(OX2M&PPG?=4,W5SV%Z07EL5MC% :7$GW<1'#XLG4I]SM;L'&Y]#5&
M8?L2TW$3PLV[4%9\BMP.UT+%.O\ F9S8=;Z%%H88FMH$RP3E@P4R/Y>:N>W_
M^X<G8X]M2PXR3)<WQSS$9HRYLCN?^=5"<SAE0*=$K-"'GSNV=1W;UAEI+2A)
M#%5H$L>[=,>!>85F%(ZN0)L="$%DDDIEV#_N1>VQXO^.>5[FX_:-F_?OX[J4
M%_H^GR40RC2;/J]5Z&= S :"OS]=8J87EY?I*XF=)^UXC,#-YXC2W/CO4M:,
M\9LI>QVQ+&7^R;W!7MH^$[5F0L-*FX!Z<-N#SE1V#\H:1F[=56(I#5Q,W.,&
M[HY460/XGDAI#@U[.RENH^-_ 5!+ P04    " #C0%E4\Y8EY#0$   8$0
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MOZSQ!P+:.>!YJ93=&2Y!]TO*_@)02P,$%     @ XT!95$0@^:F) @  9@<
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M=,#]\8[]@_=.7E;,X$*)[[RPU2QX%T"!:[81]EIM/V+GQPO,E3#^%[9=[#"
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M[:[V6Z'ICO%7L0:0Z"V)4W$S6$NYN;8L$:PAH6+(-I"J-TO&$RK5D*\LL>%
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M971S+W-H965T.#,N>&ULC55M3]LP$/XK5K1)(&W-2U]H45N)$J8A#:F"L7U
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MBG0^57)#E+4V;';@DNG0)GPF;-GO4)E=9G XORHK+E\ R ($Y S)DE-!3F)
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M53=F#C>JPP:N!>I^PI@\GN@!RIY]\A]02P,$%     @ XT!95'7' YJM P
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M4#L#^CY0RBXFSD'UUNO^!5!+ P04    " #C0%E4W<$8$NT"  !4"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6R=5LMNVS 0_!5"R"$!DLAZ^)'
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M">-_857:-@)(EL:JK 03@XS+XI^MRSAL :+."4!< N)]0.L$H%D"FN\%M$I
MRT>FD.+C,&*6#7I:K4 [:_+F!CZ8'DWRN71I?[*:=CGA[.!!)BI#^,+6:. #
M3#!1,N&",Y\5-0.[0!CBG$O)Y1R83.%>IFYXFZFEM,;9/$M-N+GDOS!UK@@@
M<<9I<Z*$ $K0BND4SD=H&1?F@@YZ?AK!^=D%G &7\,B%H.-,+[0DR1$+DY+^
ML* ?GZ ?Q?"HI%T8QPK370<AQ:(*2+P)R#"N]3C"Y J:T27$C3@Z0NCN_?#&
M$?CHW?#H8XV:9I7>IO?7/.'O,)\G<W4)]^M$+'=R.T9-&?.9MXKV&55@"9N@
M76IIX/MVBG_44&Y5E%N><NL$Y2$33"8(S)?6M"H]FN2HN4J/54GALNU=NI?N
M=4#!?]U.VU\M1G46.TK:E9)VK9+;-.4N[,:_3"E0 BQ%+E>F7*97F^ZXUB@M
MO"'3QY051W2V6+5;>](.3?:EU5GL2.M4TCK_+RVG;&DO[.C-[AR0BO:5'9KL
M*ZNSV%'6K91U_Z'\D-Z[VL+K'A1-YWI/Q*')OH@ZBT)$N/7"9ZCGOE,:2-PU
M+=ZV:K5JQK>^!^VM#ZE)%SWUCYNBPS\R35?-@, 9N6Q<=8F/+KIF,;$J]WUD
MJBQU)3]<T(<&:F= ^S.E[&;B#J@^70:_ 5!+ P04    " #C0%E40?2DH&(#
M  "@"@  &0   'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6RM5EV/VCH0_2NC
M:!^H5,@G7RM 6LA6]TIWJU71WOML$@/6)C:UG:7]]QT[(0TD4![N"\23,\<^
M,^/)S(Y"OJL]I1I^Y!E7<V>O]>'1=56RISE1 W&@'-]LA<R)QJ7<N>H@*4FM
M4YZY@>>-W)PP[BQFUO8J%S-1Z(QQ^BI!%7E.Y,\ES<1Q[OC.R?"-[?;:&-S%
M[$!V=$WUV^%5XLJM65*64ZZ8X"#I=NX\^8^Q[QD'B_B7T:-J/(.1LA'BW2S^
M3N>.9TY$,YIH0T'P[X.N:)89)CS']XK4J?<TCLWG$_L7*Q[%;(BB*Y']QU*]
MGSL3!U*Z)46FOXGC7[02-#1\B<B4_85CA?4<2 JE15XYXPERQLM_\J,*1,/!
M'UUQ""J'X-(ANN(05@[AO0Y1Y1#9R)12;!QBHLEB)L41I$$CFWFPP;3>*)]Q
MD_>UEOB6H9]>/!/)&=\IZ/TCE/H$!RIAO2>20A^61+$$"$\A9EFA:0I?L1 -
MK@%[TEJR3:'))J.@!:Q$GF,^UUHD[WN1I50B=TPU81G2]^%M'4/OX1,\@ O*
M,"A@'-XXT^ISP_#"L@SK FT/S>7,U2C:'-U-*H'+4F!P1: ?P(O@>J_@F:<T
M/2=P,5IUR()3R);!3<:8)@,(_<\0>('?<:#5_>Y>AWM\M[L_O:$FK L@M'SA
M%;ZO14XET4(^WB"+:K+(DD77R+ ^&$]$3J&7F7KJRE=),;04IBU]8(XP%C/W
MHQG$-JH_CL;GH+@#-/2C&G2F85AK&-X,2$RYP(OVIY",:KK1S9"4E^AH^P]-
M^^0#H[VCD)37I"IX;,A*XT7#FP@]=C)W1J_<;=20''GA1>S:F'#B7X2N Q/Z
MW9$;UU+'-Z4^;[?8S4%L(37] OLY*)H4DFF&&O^@:]PZ3S"YD-6&>!>B;B'.
M)$UJ29.;DDZ-[__+WZ2=O_ B-ZLVIIV_#LRU_$UKL=,[2O7Y=0V]0J6VQULA
MG3I*JG%S?V_04M)&]?W!='2AI1,U'':K\;W?GS;OKN3=J:AB&Y^5X""87DCJ
M@'5IZH:U1+F-3S<VXIT=@1265\%U^4FJK?68]62'BPO[THQ?=B3X35/.;B]$
M[AA7D-$M4GJ#,?8_68Y#Y4*+@QT0-D+CN&$?]SA"4FD ^'XKA#XMS ;U4+KX
M!5!+ P04    " #C0%E49N=*V_0"  #7"0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Y,BYX;6S-5EUOVC 4_2M6GEII;3X+;05(!3JMTCJAHFT/TQ[<Y$*L
M.G9J.]#]^]E.,!1"Q$NE\D#\<<_)N?<XM@=K+EYD#J#06T&9''JY4N6M[\LT
MAP++2UX"TS,++@JL=%<L?5D*P)D%%=2/@J#G%Y@P;S2P8S,Q&O!*4<)@)I"L
MB@*+?V.@?#WT0F\S\$26N3(#_FA0XB7,0?TL9T+W?,>2D0*8))PA 8NA=Q?>
M3L/  &S$+P)KN=-&)I5GSE],YR$;>H%1!!1292BP?JQ@ I0:)JWCM2'UW#L-
M<+>]8?]JD]?)/&,)$TY_DTSE0^_:0QDL<$75$U]_@R:A*\.7<BKM/UHWL8&'
MTDHJ7C1@K: @K'[BMZ80.X"P=P00-8!H'Y < <0-(#X5D#2 Q%:F3L7688H5
M'@T$7R-AHC6;:=AB6K1.GS#C^UP)/4LT3HWNL6"$+24Z^\ZE/$<E"#3/L0!T
M@2:\*+0U<\73%W3_6I$5IL"41/=O*:TRR-!"\ )-,$TKBJV-?(&FA%9*S_W0
MB]9PHIFC/)N"PH3JUUP@:4;DP%<Z"2/%3QO!XUIP=$1P&*%'SE2N53 MX3V!
MK[-W)8@V)1A'G8Q32"]1''Y!41"%+8(FI\.#%OCT9'AXTY%-[ R-+5]\A.^.
M*9(9"_3GA.:05H(H @>>\:*LE//,K8*M5W^^:V+TH*"0?SMD)4Y68F4E';(N
MG"ZYU75&6+,6SML60\W:LZQF#UN-PL#^!OYJUZ/#N+C7%C@]#$SZ>X'O$KQR
M"5YU)EA_);PT)94=!>LYOMYG\K'O9/4_Q,?^B3X>QL5)JX^'@<F^X>\2O'8)
M7G<F^ 12"9*:'2RM]S]IG:T845V^WCC^F\_D:QAL#X+@0YQM:'>=V#>U)21J
M-;4E<'^9U-GY.R=> 6)I;PY2.U8Q5>_\;M3=3N[LF;PW/C:W%GN2;FGJ*\\C
M%DO")**PT)3!95]__Z*^1=0=Q4M[KCYSI4]IV\SUS0N$"=#S"\[5IF->X.YR
MH_]02P,$%     @ XT!95#\6X\*4 P  3PT  !D   !X;"]W;W)K<VAE971S
M+W-H965T.3,N>&ULM5?;;MLX$/T50NA#"Q21*.OFPC80V]W= ,TB2#:[#\4^
MT-98$BJ1+DG%+; ?OR0E2XYN#=#TQ1:IF<,S%Q\/%R?&OX@40*)O14[%TDJE
M/'ZP;;%/H2#BBAV!JC<'Q@LBU9(GMCAR(+%Q*G+;=9S +DA&K=7"[-WQU8*5
M,L\HW'$DRJ(@_/L:<G9:6M@Z;]QG22KUAKU:'$D"#R ?CW=<K>P&)<X*H")C
M%'$X+*UK_&&+Y]K!6/R=P4E</",=RHZQ+WIQ$R\M1S."'/920Q#U]00;R'.-
MI'A\K4&MYDSM>/E\1O_-!*^"V1$!&Y;_D\4R75J1A6(XD#*7]^ST!]0!^1IO
MSW)A/M&ILO5""^U+(5E1.RL&14:K;_*M3L2%@QN-.+BU@]MUP",.L]IA]E('
MKW;P3&:J4$P>MD22U8*S$^+:6J'I!Y-,XZW"SZBN^X/DZFVF_.3J=V ))\<T
MVZ,;6K61+L?;+4B2Y>(=>H,RBFZS/%?;8F%+=:;VM/<U_KK"=T?PL8MN&96I
M0!]I#/%S %N1;1B[9\9K=Q)Q"_LK-,/OD>NX^/%AB]Z^>2<@4;TH!^AM7@[F
MU& #*-L7H^#Y(,JS2&=-;68&=C8">P]/0$M !\X*M%%9Y.I7HOI#IFAC.@,X
M^GR]$V;_WXD#O>9 SQSHC1SX9UGL%"8[(*4K7'4"35"=6H'^0^-97E>X@<'5
M4O.TP@O[:8"*WU#Q)V/?9H(D"8>DZD=%Z9R-SY^4*;J14(BIF(/FH& RYK^8
M)+E2, ,^%%KE[E^&%GEA&U[59GVKR)D]M]GV;0)G.$MA0SZ<)'_'=:'D=T1H
MC.!KF1UU@=XC"H-5"OM5<KUN)'TC=QX.TXP:FM$DS4>:28C1@R02Q$3-Y@W>
M_-<V!W9:>71^KCUJ_\M\!3@,.TD=L H#K],? T:^/YQY?*'O^#5;I$9[UB..
M/]*FV&U9N),L/I::QE1%6E'$TZKX\\5OY1!/Z^&/B]_7O2#R@F[Q^U:SKC8,
MV(R5OI50[+]JZ?U^Z:,1&<>MO.)I?;T'(761U/B73_W]XU;S</B+&Z#5+3PM
M7#]N@*A?-L^+N@T0]96_6_^^R=B/KE5)/'_5^L_[_W1=#O;%I*G&C\1,[ +M
M64EE-<(UN\VMX-K,PIW]M;XMF FVA:FN&K>$)QD5*(>#@G2N0D6(5]-[M9#L
M:.;9'9-J!C*/J;KQ -<&ZOV!,7E>Z .:.]3J?U!+ P04    " #C0%E46<6X
M\NL#  #$$   &0   'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6RU6%UOHS@4
M_2L6FH=6J@(V@:2C)%+3M/.A[2IJ-;L/JWEPP E6 3.V2696^^/7!@)I TZ8
MJCP0V_B<>WWOY1AGLF/\642$2/ SB5,QM2(ILX^V+8*()%@,6$92]63->(*E
MZO*-+3).<%B DMA&CN/;"::I-9L48TL^F[!<QC0E2PY$GB28_YJ3F.VF%K3V
M X]T$TD]8,\F&=Z0)R*_94NN>G;-$M*$I(*R%'"RGEHW\.,GY&I ,>,O2G;B
MH WT4E:,/>O.EW!J.=HC$I- :@JL?K;DEL2Q9E)^_*A(K=JF!AZV]^SWQ>+5
M8E98D%L6_TU#&4VML05"LL9Y+!_9[C.I%N1IOH#%HKB#73G7]RP0Y$*RI (K
M#Q*:EK_X9Q6( P :=0!0!4"O 5T6W K@GFMA6 &&KP&P ^!5 .]<@%\!_',!
MHPHP*I)51K=(S0)+/)MPM@-<SU9LNE'DMT"KC-!4E^*3Y.HI53@Y>\I7@OS(
M22K!W5;=!;A8$(EI+"Z!B# G M 4/- X5H4CKD#(!#D<F=A2>:&Y[*"R."\M
MH@Z+$#RP5$8"W*4A"5OPMV8\.H5?F/'N*?S="?]-#M@J_'4.T#X'<V1D_(K3
M 7#A%4 .0M^>%N#BPV49^[;HF+GNR6H D/>"2^>L+4YFI@4):J_@*:_N^G.U
ML-R?LS;T8FTM+)_,+#?Y9@ <9/#E11+=^D5R"UKWS!<)_/.'F@&^2)*([P;^
M8<T_+/B'7?R2!<]*_+.<!Y'2WM;*+2F\@D)O0MO9V!LYQ36QMRW6O=JZ9[2N
M8P4>:^-@R=F&X\2P+K]F]M\E;J.:?]0O;N!"R5=9R)?@/]!9THN2%SH'T70'
M7GL<Q[4WXS=G<3'NF\7KVOIU+^L@*]-X!7 N(\;IORH\.&%Y*MO>J^LCOZ"S
MO]H=@TZS#3EFUUZ5@2'S\&!O@^]26Q U%I#1[3_S9$4X8.MB8Q2ZL<5!H*T$
M. UIB"511=:AP+<5NW\04M_O"&4C1- ]$<HLBW^!@"4)E<E1+"O+[E$R$33G
MLE$J:):JY;Z\V"JF&ZP_.5M=&!XM'EZ?J*=&KZ!9L%I\ )*!E:IY3$/]!:,W
MD5:WO);(N$:O&JV#?J\J5Z717UEA(WUP]#[UW\@9[*EGYZKKO")^(:_.H*OX
M&X6#_22N36#GL$7)AL84HT;(T DA>Y/&SBOV/B*+&CU$\#?*#_4K/]2((T+O
M4GZHD3IT0NK>%.Q[="R";E>P[8,S5D+XIC@^"Z6RBKL\;M6C]1']ICB8VLWT
M\GS_@/F&I@+$9*V@SF"D'.#ED;GL2)85)[85D^K\5S0C@D/"]03U?,V8W'>T
M@?J/B]G_4$L#!!0    ( .- 652I/L[E(0,  ! 2   -    >&PO<W1Y;&5S
M+GAM;-U8;6O;,!#^*T8=HX-1)W'KQFL2V *%P38*[8=]*THL)P)9\F2E2_KK
MI[-DYZ6ZTO7#ELTAM72/[KE'=^?*9%2;C6"W2\9,M"Z%K,=D:4SU(8[K^9*5
MM#Y3%9,6*90NJ;%3O8CK2C.:U^!4BGC0ZZ5Q2;DDDY%<E=>EJ:.Y6DDS)N>=
M*7*WS_F8]--S$CFZJ<K9F-R?OOVQ4N;J3>3N)^]/3GKW[ZX.[:<-\([$0=*+
M%Y">]7!>BV'4Z<NHGR?'Z2_WZ;V#Y6I]&\?8YW8R*I3<IC@ASF"9:<FB!RK&
M9$H%GVD.7@4MN=@X\P ,<R64CHRMK0W5!TO]Z."^FT'9/4_)I=)-;!?!_9WY
MY0= .P.!7(A.X( XPV1446.8EM=VTBQNC$^@R(_O-I55N-!TTQ]<D*U#<[-!
M9DKG3'=A^J0U34:"%2!'\\42[D95,8#&J-(.<DX72M)&0^OA!Y9VSH2XA6?B
M>[''O2YV:M:#BLEN: 7YH:-Q$^#?97/<N[2OXXTJ_J#,IY7=CFSFT&?L1K."
MKYOYNN@$8.Q]G)U6E=A\%'PA2^8V_^* DQ%M_:*ETOS11H-6F5L#TR1Z8-KP
M^:[EIZ;5'5N;MIW6!:YY\ ]J_K-Y7C#)-!6[HFWO'W.67ZW8'R)_0W/S;^50
M<5!D<GG\&OW!>>PBT^,7F63'K]&_;!R=R-@?C3OG[][IVUDC>,L9DV_POB2V
M0:/9B@O#I9\M>9XS^>00MO2&SNSK[AZ_79^S@JZ$N>O ,=F.O[*<K\JL6W4#
MB?"KMN,OL+U^VKUBV5A<YFS-\JF?ZL6L&49V8*/Z"QP.D>OF"B.8C\/""&!8
M'$P!YN.\L#C_TWZ&Z'X<AFD;!I$AZC-$?9Q7")DV'RQ.V">S5WBG698D:8IE
M=#H-*IAB>4M3^(;9,&W@@<6!2+^7:[S:>(<\WP=839_K$&RG>"=B.\5S#4@X
M;^"19>%J8W'  ZL"UCL0/QP'>BKLDR1054P;]@3C2)9A"/1BN$?3%,E."I]P
M?;"G)$FR+(P %E:0)!@"3R..8 I  X8D27,.'IQ'<7M.Q=O?@":_ %!+ P04
M    " #C0%E4EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_
MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+
MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D
M5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@
M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/
M['X 4$L#!!0    ( .- 650!@BF#G08  )D]   /    >&PO=V]R:V)O;VLN
M>&ULQ9M=<]HX%(;_BH:;32^R!(,_Z#2=(82TF4D"$YCNY8YBE*"I;5'))$U_
M_<HF:8^)>6=O3K@";&,>9$O/T='QIR=CO]\9\UW\S+/"G7969;G^V.VZ=*5R
MZ?XV:U7X/??&YK+T'^U#UZVMDDNW4JK,LVYP<A)U<ZF+SN=/K^>:V2[]8$J5
MEMH4?F.UX9M63^[/_NJC>-1.W^E,E\^GG?I]ICHBUX7.]2^U/.V<=(1;F:>O
MQNI?IBAE-D^MR;+33F^[XYNRI4[?;)Y7D MYY^HMI;R[E1[DM!.=^!/>:^O*
M^HCZ_-(S/BI_\/;3IC07.BN5/9>E^F+-9JV+A^HT_E]TR=^HV^'U==N('^W_
M:49S?Z]3=6[23:Z*<MN.5F458.%6>NTZHI"Y.NV,S:.R8B8?5/6G_*]<+K=_
ML/1DI+GL1^UWV,MES<C',]HL=2DNB^V7_5Z"%0"L@!=K/+V93Z\NST>+R;DX
M&UV-;L83,?\ZF2SF!+ / /OO"#A?^)?KR<UB+J878CJ;W!+( 8 <' QR/+V>
M$<@00(8'@YPOIF,"&0'(Z("0_P8$,@:0\>$N]VC^E4 F #(Y6,\61S-)((<
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MS@1Z9]0[$^B=4>],H'=&O3.!WAGUS@1Z9]0[$^B=4>],H'>>'/8FT#NCWIE
M[X)Z%P*]"^I="/0NJ'<AT+N@WH5 [X)ZEY_4>QB_#G6X]7RO\?D_2?5X^6Z]
M/?ZZ_+XX>7NO.+O[BN'I+U!+ P04    " #C0%E4N.0S3$8"  ",-0  $P
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M_X_CEV<ZU-WXDB^6/V'=_@102P$"% ,4    " #C0%E4!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M .- 653_XQCA[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( .- 65297)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ XT!95 D@
MNDU[!@  R1D  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( .- 651#@KXE( (  ' %   8
M  " @;\.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #C
M0%E4T-%C&%<&  #G&@  &               @($5$0  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ XT!95#26(W9<!0  "A<  !@
M         ("!HA<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( .- 650%'"R#^ ,  ,P-   8              " @30=  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #C0%E4103J[)L&  !Z(
M&               @(%B(0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ XT!95!_#!:]" @  A@0  !@              ("!,R@  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .- 653AE;-LV <
M -\C   8              " @:LJ  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " #C0%E4UQ9AK=4"  "\"0  &               @(&Y
M,@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ XT!95&5J
M!Y5L!   /PD  !D              ("!Q#4  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " #C0%E4!=@0\/HF   [>P  &0
M    @(%G.@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M .- 653.5)NB.0D  (H8   9              " @9AA  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ XT!95+\0[Z0^"0  BA@  !D
M             ("!"&L  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " #C0%E4XGBQFL0.  !#*P  &0              @(%]=   >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .- 653,F"-*>P<
M ,87   9              " @7B#  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ XT!95"SUT26F"   NAH  !D              ("!
M*HL  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #C0%E4
MVHHWG& "   M!0  &0              @($'E   >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( .- 6532M20[& ,  -,&   9
M      " @9Z6  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ XT!95!CE;[A.!   E H  !D              ("![9D  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #C0%E47;O:,. +   4/@
M&0              @(%RG@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( .- 651@^&N18 H  /T:   9              " @8FJ  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ XT!95)#3KESG
M @  , <  !D              ("!(+4  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " #C0%E43AX_Y4,/  #[+   &0
M@($^N   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .-
M650"% =AD0,  -,'   9              " @;C'  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ XT!95"<XES1W"0  'QP  !D
M         ("!@,L  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " #C0%E4$2^*"?0#  !\"0  &0              @($NU0  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .- 653:9F5P0 D  )P8
M   9              " @5G9  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ XT!95.]8HH6W!   IPH  !D              ("!T.(
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #C0%E4Q>Y#
M-!8E  "N>0  &0              @(&^YP  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( .- 652#B<R/>P8  +43   9
M  " @0L- 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
MXT!95$1J7^^D P  H@@  !D              ("!O1,! 'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " #C0%E4[Z@G)/4"  ":!@  &0
M            @(&8%P$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( .- 653,:,'C7@0   L+   9              " @<0: 0!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ XT!95&RXWO)A!@
MOA4  !D              ("!61\! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " #C0%E4?&@W/ T$   *"P  &0              @('Q
M)0$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .- 650)
M5#XC= (  $$%   9              " @34J 0!X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ XT!95! A))55 P  L@<  !D
M     ("!X"P! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .- 652>?4J$U ,  /X(   9              "
M@5Q) 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ XT!9
M5)_HU7*G P  JP@  !D              ("!9TT! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " #C0%E4@],UH^$"  !K"   &0
M        @(%%40$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( .- 651761])V@(  'L(   9              " @5U4 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ XT!95!CX&NJ\ P   A(
M !D              ("!;E<! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " #C0%E44FKK9- "  !9"0  &0              @(%A6P$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( .- 652JSZ08
M,00   T1   9              " @6A> 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ XT!95+]M&M[? P  \Q$  !D
M ("!T&(! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #C
M0%E4("2Q-, %   .'0  &0              @('F9@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( .- 650E?.P6W (  %D(   9
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M970U-2YX;6Q02P$"% ,4    " #C0%E4R,F-<20(   A/0  &0
M    @(%'?0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M .- 652$LI0,U0(  %T(   9              " @:*% 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ XT!95 BN#Y55!   ?!<  !D
M             ("!KH@! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    " #C0%E4K&)>[)$"  "$!@  &0              @($ZC0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( .- 652M$=,WR@8
M ,<P   9              " @0*0 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ XT!95'3[^ 48 @  )00  !D              ("!
M Y<! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " #C0%E4
MSI$+!%H$  ! $P  &0              @(%2F0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( .- 653U!_#[30(  !4&   9
M      " @>.= 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ XT!95(]6A_(@!   ]A$  !D              ("!9Z ! 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #C0%E4"K<T?PH#  "W"
M&0              @(&^I $ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( .- 650-VS./(P,  (T)   9              " @?^G 0!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ XT!95)MME/J"
M @  DP8  !D              ("!6:L! 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    " #C0%E4.Q=;588#  #Q#0  &0
M@($2K@$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( .-
M650[34=X%@4   $8   9              " @<^Q 0!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ XT!95#N3I0*X P  F0X  !D
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M=#<T+GAM;%!+ 0(4 Q0    ( .- 651+'G33A (  #<&   9
M  " @=_( 0!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @
MXT!95%,F&V$N P  2 D  !D              ("!FLL! 'AL+W=O<FMS:&5E
M=',O<VAE970W-BYX;6Q02P$"% ,4    " #C0%E4XCG78ST#   8"P  &0
M            @('_S@$ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4
M Q0    ( .- 653ES:N5&0D  /$Q   9              " @7/2 0!X;"]W
M;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ XT!95&FCP):Y!
ME1(  !D              ("!P]L! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX
M;6Q02P$"% ,4    " #C0%E4%'06AD4#  #5"@  &0              @(&S
MX $ >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( .- 651,
MX"02( 0  %<2   9              " @2_D 0!X;"]W;W)K<VAE971S+W-H
M965T.#$N>&UL4$L! A0#%     @ XT!95"6!Q86E P  WP\  !D
M     ("!AN@! 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .- 651_7Y%=1P0  (<0   9              "
M@:GY 0!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ XT!9
M5,P2&IDG P  ]PD  !D              ("!)_X! 'AL+W=O<FMS:&5E=',O
M<VAE970X."YX;6Q02P$"% ,4    " #C0%E4W<$8$NT"  !4"   &0
M        @(&% 0( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0
M   ( .- 653Z%HOK @,  ,8(   9              " @:D$ @!X;"]W;W)K
M<VAE971S+W-H965T.3 N>&UL4$L! A0#%     @ XT!95$'TI*!B P  H H
M !D              ("!X@<" 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q0
M2P$"% ,4    " #C0%E49N=*V_0"  #7"0  &0              @(%["P(
M>&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( .- 650_%N/"
ME ,  $\-   9              " @:8. @!X;"]W;W)K<VAE971S+W-H965T
M.3,N>&UL4$L! A0#%     @ XT!95%G%N/+K P  Q!   !D
M ("!<1(" 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q02P$"% ,4    " #C
M0%E4J3[.Y2$#   0$@  #0              @ &3%@( >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( .- 6527BKL<P    !,"   +              "  =\9
M @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .- 650!@BF#G08  )D]   /
M          "  <@: @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #C0%E4
MMO4_!K8"  !1-P  &@              @ &2(0( >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " #C0%E4N.0S3$8"  ",-0  $P
M        @ & ) ( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     9@!F  $<
(  #W)@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>361</ContextCount>
  <ElementCount>552</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>106</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>17</UnitCount>
  <MyReports>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1402401 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Product Sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/ProductSales</Role>
      <ShortName>Product Sales</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Grant Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GrantRevenue</Role>
      <ShortName>Grant Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - Financial Instruments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements</Role>
      <ShortName>Financial Instruments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134108 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2137109 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140110 - Disclosure - Other Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponents</Role>
      <ShortName>Other Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2146111 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2152112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2157113 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2159114 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2166115 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2168116 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2177117 - Disclosure - Earnings (Loss) per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsLossperShare</Role>
      <ShortName>Earnings (Loss) per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2181118 - Disclosure - Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GeographicInformation</Role>
      <ShortName>Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2184119 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Product Sales (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/ProductSalesTables</Role>
      <ShortName>Product Sales (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/ProductSales</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Grant Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GrantRevenueTables</Role>
      <ShortName>Grant Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/GrantRevenue</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/CollaborationAgreements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables</Role>
      <ShortName>Financial Instruments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/Inventory</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/PropertyandEquipment</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2341309 - Disclosure - Other Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsTables</Role>
      <ShortName>Other Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/OtherBalanceSheetComponents</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2347310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/Leases</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2360311 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/StockBasedCompensation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2369312 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2378313 - Disclosure - Earnings (Loss) per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsLossperShareTables</Role>
      <ShortName>Earnings (Loss) per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/EarningsLossperShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2382314 - Disclosure - Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GeographicInformationTables</Role>
      <ShortName>Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/GeographicInformation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies - Accounting Policies Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Accounting Policies Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Summary of Significant Accounting Policies - Significant Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Significant Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/ProductSalesDetails</Role>
      <ShortName>Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/ProductSalesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Grant Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GrantRevenueDetails</Role>
      <ShortName>Grant Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/GrantRevenueTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails</Role>
      <ShortName>Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Collaboration Agreements - Merck ??? Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails</Role>
      <ShortName>Collaboration Agreements - Merck ??? Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Collaboration Agreements - Vertex ??? 2020 Strategic Alliance in Cystic Fibrosis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails</Role>
      <ShortName>Collaboration Agreements - Vertex ??? 2020 Strategic Alliance in Cystic Fibrosis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails</Role>
      <ShortName>Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails</Role>
      <ShortName>Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2427416 - Disclosure - Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - Derivative Financial Instruments - Cash flow Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashflowHedgesDetails</Role>
      <ShortName>Derivative Financial Instruments - Cash flow Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - Derivative Financial Instruments - Balance Sheet Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails</Role>
      <ShortName>Derivative Financial Instruments - Balance Sheet Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/InventoryTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Components - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Balance Sheet Components - Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails</Role>
      <ShortName>Other Balance Sheet Components - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Leases - Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Leases - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Leases - Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2453431 - Disclosure - Commitments and Contingencies - Indemnification Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Indemnification Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2454432 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails</Role>
      <ShortName>Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2455433 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails</Role>
      <ShortName>Commitments and Contingencies - Licenses to Patented Technology (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2456434 - Disclosure - Commitment and Contingencies- Moderna Science Center (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails</Role>
      <ShortName>Commitment and Contingencies- Moderna Science Center (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2458435 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2461436 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2462437 - Disclosure - Stock-Based Compensation - Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2463438 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2464439 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2465440 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2467441 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2470442 - Disclosure - Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2471443 - Disclosure - Income Taxes - Provision For (Benefit From) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision For (Benefit From) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2472444 - Disclosure - Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2473445 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2474446 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2475447 - Disclosure - Income Taxes- Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails</Role>
      <ShortName>Income Taxes- Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2476448 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2479449 - Disclosure - Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails</Role>
      <ShortName>Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/EarningsLossperShareTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2480450 - Disclosure - Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/EarningsLossperShareTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2483451 - Disclosure - Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/GeographicInformationDetails</Role>
      <ShortName>Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/GeographicInformationTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="mrna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2485452 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.modernatx.com/role/SubsequentEvents</ParentRole>
      <Position>94</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mrna-20211231.htm">mrna-20211231.htm</File>
    <File>exhibit1012-norwoodleaseam.htm</File>
    <File>exhibit1016-legoffcorinneo.htm</File>
    <File>exhibit1017-executivesepar.htm</File>
    <File>exhibit1018-consultingagre.htm</File>
    <File>exhibit1019-offerlettersha.htm</File>
    <File>exhibit1024-modernarsuagre.htm</File>
    <File>exhibit1025-nqsoagreementf.htm</File>
    <File>exhibit1026-modernarsuagre.htm</File>
    <File>exhibit1027-nqsoagreementf.htm</File>
    <File>exhibit1034-bardaamenmdent.htm</File>
    <File>exhibit1040-dodamendments.htm</File>
    <File>exhibit211subsidiaries.htm</File>
    <File>exhibit23112312021.htm</File>
    <File>exhibit31112312021.htm</File>
    <File>exhibit31212312021.htm</File>
    <File>exhibit32112312021.htm</File>
    <File>exhibit32212312021.htm</File>
    <File>mrna-20211231.xsd</File>
    <File>mrna-20211231_cal.xml</File>
    <File>mrna-20211231_def.xml</File>
    <File>mrna-20211231_lab.xml</File>
    <File>mrna-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrna-20211231_g1.jpg</File>
    <File>mrna-20211231_g2.jpg</File>
    <File>mrna-20211231_g3.jpg</File>
    <File>mrna-20211231_g4.jpg</File>
    <File>mrna-20211231_g5.jpg</File>
    <File>mrna-20211231_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1190">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>136
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrna-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 36,
   "contextCount": 361,
   "dts": {
    "calculationLink": {
     "local": [
      "mrna-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrna-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mrna-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrna-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrna-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mrna-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 747,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 7,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 11
   },
   "keyCustom": 56,
   "keyStandard": 496,
   "memberCustom": 46,
   "memberStandard": 56,
   "nsprefix": "mrna",
   "nsuri": "http://www.modernatx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.modernatx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.modernatx.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Product Sales",
     "role": "http://www.modernatx.com/role/ProductSales",
     "shortName": "Product Sales",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Grant Revenue",
     "role": "http://www.modernatx.com/role/GrantRevenue",
     "shortName": "Grant Revenue",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Collaboration Agreements",
     "role": "http://www.modernatx.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - Financial Instruments and Fair Value Measurements",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements",
     "shortName": "Financial Instruments and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Derivative Financial Instruments",
     "role": "http://www.modernatx.com/role/DerivativeFinancialInstruments",
     "shortName": "Derivative Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134108 - Disclosure - Inventory",
     "role": "http://www.modernatx.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137109 - Disclosure - Property and Equipment",
     "role": "http://www.modernatx.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140110 - Disclosure - Other Balance Sheet Components",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponents",
     "shortName": "Other Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.modernatx.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146111 - Disclosure - Leases",
     "role": "http://www.modernatx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.modernatx.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157113 - Disclosure - Stockholders' Equity",
     "role": "http://www.modernatx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159114 - Disclosure - Stock-Based Compensation",
     "role": "http://www.modernatx.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2166115 - Disclosure - Employee Benefit Plan",
     "role": "http://www.modernatx.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168116 - Disclosure - Income Taxes",
     "role": "http://www.modernatx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2177117 - Disclosure - Earnings (Loss) per Share",
     "role": "http://www.modernatx.com/role/EarningsLossperShare",
     "shortName": "Earnings (Loss) per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2181118 - Disclosure - Geographic Information",
     "role": "http://www.modernatx.com/role/GeographicInformation",
     "shortName": "Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2184119 - Disclosure - Subsequent Events",
     "role": "http://www.modernatx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Product Sales (Tables)",
     "role": "http://www.modernatx.com/role/ProductSalesTables",
     "shortName": "Product Sales (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Grant Revenue (Tables)",
     "role": "http://www.modernatx.com/role/GrantRevenueTables",
     "shortName": "Grant Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables",
     "shortName": "Financial Instruments and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Derivative Financial Instruments (Tables)",
     "role": "http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables",
     "shortName": "Derivative Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Inventory (Tables)",
     "role": "http://www.modernatx.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.modernatx.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341309 - Disclosure - Other Balance Sheet Components (Tables)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables",
     "shortName": "Other Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347310 - Disclosure - Leases (Tables)",
     "role": "http://www.modernatx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2360311 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2369312 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.modernatx.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2378313 - Disclosure - Earnings (Loss) per Share (Tables)",
     "role": "http://www.modernatx.com/role/EarningsLossperShareTables",
     "shortName": "Earnings (Loss) per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2382314 - Disclosure - Geographic Information (Tables)",
     "role": "http://www.modernatx.com/role/GeographicInformationTables",
     "shortName": "Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies - Accounting Policies Narrative (Details)",
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Accounting Policies Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i086f0b86dda64ff9bdc13c547806422e_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i0271cb85b4e64ced8426ff3ab6956a89_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Summary of Significant Accounting Policies - Significant Customers (Details)",
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails",
     "shortName": "Summary of Significant Accounting Policies - Significant Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i0271cb85b4e64ced8426ff3ab6956a89_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "idfc4ca4b110a4b4ca9bc75f54db9aac8_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)",
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment and Software Capitalization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "idfc4ca4b110a4b4ca9bc75f54db9aac8_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Summary of Significant Accounting Policies - Components of Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i9b6bf470232b486d96417def1a8e1533_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - Product Sales (Details)",
     "role": "http://www.modernatx.com/role/ProductSalesDetails",
     "shortName": "Product Sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i346fef81e10f4f86a929d87bf0cb041b_I20211231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:NumberOfParticipants",
      "reportCount": 1,
      "unitRef": "participant",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Grant Revenue (Details)",
     "role": "http://www.modernatx.com/role/GrantRevenueDetails",
     "shortName": "Grant Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "ieae7b1ae1b03416dbb9b8f48d0bc6426_I20160930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mrna:RevenueFromGrantsNumberOfContractOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "contract_option",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails",
     "shortName": "Collaboration Agreements - AstraZeneca - Strategic Alliances in Cardiovascular and Oncology (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if55e1500f5544b66aa8a071e51806268_D20130301-20130331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Collaboration Agreements - Merck \u2013 Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails",
     "shortName": "Collaboration Agreements - Merck \u2013 Strategic Alliances in Infectious Diseases and Cancer Vaccines (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "id946b8dd31834000b8e6b41766b9dedd_D20160601-20160630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i60fc10736ee64261bd7f04a73acfaafa_D20200901-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Collaboration Agreements - Vertex \u2013 2020 Strategic Alliance in Cystic Fibrosis (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails",
     "shortName": "Collaboration Agreements - Vertex \u2013 2020 Strategic Alliance in Cystic Fibrosis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i60fc10736ee64261bd7f04a73acfaafa_D20200901-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails",
     "shortName": "Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if7642861ebea4b3bbea1f51aa82ef91f_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)",
     "role": "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails",
     "shortName": "Collaboration Agreements - Changes in Balances of Receivables and Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i17abcb6e78134f4690ee2419e8619e02_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
     "shortName": "Financial Instruments and Fair Value Measurements - Summary of Cash and Available-for-Sale Securities by Significant Investment Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i0458e4ead71746a5af5b29ed89c9ef21_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails",
     "shortName": "Financial Instruments and Fair Value Measurements - Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427416 - Disclosure - Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails",
     "shortName": "Financial Instruments and Fair Value Measurements - Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Financial Instruments and Fair Value Measurements - Narrative (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails",
     "shortName": "Financial Instruments and Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i87fe7c36a950471bb3212e6877b0baf9_I20181231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i87fe7c36a950471bb3212e6877b0baf9_I20181231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details)",
     "role": "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
     "shortName": "Financial Instruments and Fair Value Measurements - Financial Assets Measured At Fair Value On a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i7d3fc18fdc324f1aa20d24c095339419_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - Derivative Financial Instruments - Cash flow Hedges (Details)",
     "role": "http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashflowHedgesDetails",
     "shortName": "Derivative Financial Instruments - Cash flow Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - Derivative Financial Instruments - Balance Sheet Hedges (Details)",
     "role": "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
     "shortName": "Derivative Financial Instruments - Balance Sheet Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Inventory (Details)",
     "role": "http://www.modernatx.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.modernatx.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OtherPrepaidExpenseManufacturing",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Other Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OtherPrepaidExpenseManufacturing",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:AccruedClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Other Balance Sheet Components - Accrued Liabilities (Details)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails",
     "shortName": "Other Balance Sheet Components - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:AccruedClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Other Balance Sheet Components - Other Current Liabilities (Details)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails",
     "shortName": "Other Balance Sheet Components - Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherSundryLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Other Balance Sheet Components - Deferred Revenue (Details)",
     "role": "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
     "shortName": "Other Balance Sheet Components - Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i0613309ccd7f4770b391e463a962e99b_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OperatingLeaseNumberOfProperties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "numberofcampuses",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.modernatx.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrna:OperatingLeaseNumberOfProperties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "numberofcampuses",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i99112c4f1c1f49918efba7058bf95a07_D20200101-20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Leases - Balance Sheet Information (Details)",
     "role": "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
     "shortName": "Leases - Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrna:CurrentAssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Leases - Lease Costs (Details)",
     "role": "http://www.modernatx.com/role/LeasesLeaseCostsDetails",
     "shortName": "Leases - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Leases - Minimum Lease Payments (Details)",
     "role": "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
     "shortName": "Leases - Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "iffb8aaeb04f94a9091ac85eb8f851b96_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyLossInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453431 - Disclosure - Commitments and Contingencies - Indemnification Obligations (Details)",
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails",
     "shortName": "Commitments and Contingencies - Indemnification Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "iffb8aaeb04f94a9091ac85eb8f851b96_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyLossInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i9a8002ec753b4dc689c48b5e0785b43d_I20211231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454432 - Disclosure - Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)",
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails",
     "shortName": "Commitments and Contingencies - Purchase Commitments and Purchase Orders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i9a8002ec753b4dc689c48b5e0785b43d_I20211231",
      "decimals": "-7",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "ie0c48f0326424b03a643d8d35796a371_I20170626",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455433 - Disclosure - Commitments and Contingencies - Licenses to Patented Technology (Details)",
     "role": "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails",
     "shortName": "Commitments and Contingencies - Licenses to Patented Technology (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "ie0c48f0326424b03a643d8d35796a371_I20170626",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mrna:ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456434 - Disclosure - Commitment and Contingencies- Moderna Science Center (Details)",
     "role": "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails",
     "shortName": "Commitment and Contingencies- Moderna Science Center (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i702c1ca981884658b2caf34f2b288da1_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458435 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.modernatx.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i3b3e6c8e3e284a9b9957554efffd342a_D20200521-20200521",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461436 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462437 - Disclosure - Stock-Based Compensation - Options Activity (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails",
     "shortName": "Stock-Based Compensation - Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if0c500d4ffa344d5a5b3ceec87c24f6f_I20201231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463438 - Disclosure - Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Common Stock and Common Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if0c500d4ffa344d5a5b3ceec87c24f6f_I20201231",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464439 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails",
     "shortName": "Stock-Based Compensation - Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i9eca330cf2ff4b44932a76f9c4d88ba2_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465440 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "ie043af078137474da5fa9c415b806cb8_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467441 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://www.modernatx.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470442 - Disclosure - Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details)",
     "role": "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails",
     "shortName": "Income Taxes - Loss Before Provision For (Benefit From) Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471443 - Disclosure - Income Taxes - Provision For (Benefit From) Income Taxes (Details)",
     "role": "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision For (Benefit From) Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472444 - Disclosure - Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)",
     "role": "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473445 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)",
     "role": "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Tax Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474446 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mrna:UnrecognizedTaxBenefitsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475447 - Disclosure - Income Taxes- Valuation Allowance (Details)",
     "role": "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails",
     "shortName": "Income Taxes- Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mrna:ValuationAllowanceDeferredTaxAssetDecreaseAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1402401 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "role": "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i20e412a5cb73413dbf99d215bfabc116_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i7fdc6010e6c54fd7a4a4a2bb470eb659_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476448 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)",
     "role": "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails",
     "shortName": "Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i3f00be47b1194ea3be883db45fca7c1c_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2479449 - Disclosure - Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails",
     "shortName": "Earnings (Loss) per Share - Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2480450 - Disclosure - Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
     "shortName": "Earnings (Loss) per Share - Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2483451 - Disclosure - Geographic Information (Details)",
     "role": "http://www.modernatx.com/role/GeographicInformationDetails",
     "shortName": "Geographic Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "i3b0ed2515d854ec9b5a77c4457a02d73_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "if53b8e06db654f6eaae84e25e1fcb425_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485452 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.modernatx.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrna-20211231.htm",
      "contextRef": "ic9fcc9f307dd449cbd9ff284355911be_D20220101-20220225",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mrna:NumberOfDosesOfVaccineCandidate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "dose",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 106,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.modernatx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrna_A2013OptionAgreementAndServicesAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2013 Option Agreement And Services And Collaboration Agreement [Member]",
        "label": "2013 Option Agreement And Services And Collaboration Agreement [Member]",
        "terseLabel": "2013 AZ Agreements"
       }
      }
     },
     "localname": "A2013OptionAgreementAndServicesAndCollaborationAgreementMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_A2021RepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Repurchase Program",
        "label": "2021 Repurchase Program [Member]",
        "terseLabel": "2021 Repurchase Program"
       }
      }
     },
     "localname": "A2021RepurchaseProgramMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_A2022RepurchaseProgramPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Repurchase Program Plan",
        "label": "2022 Repurchase Program Plan [Member]",
        "terseLabel": "2022 Repurchase Program"
       }
      }
     },
     "localname": "A2022RepurchaseProgramPlanMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_AccruedClinicalTrials": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trials",
        "label": "Accrued Clinical Trials",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "localname": "AccruedClinicalTrials",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AccruedDevelopmentOperation": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Development Operation",
        "label": "Accrued Development Operation",
        "terseLabel": "Development operations"
       }
      }
     },
     "localname": "AccruedDevelopmentOperation",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AccruedManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Manufacturing",
        "label": "Accrued Manufacturing",
        "terseLabel": "Manufacturing"
       }
      }
     },
     "localname": "AccruedManufacturing",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AccruedOtherExternalGoodsAndServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Other External Goods And Services Current",
        "label": "Accrued Other External Goods And Services Current",
        "terseLabel": "Other external goods and services"
       }
      }
     },
     "localname": "AccruedOtherExternalGoodsAndServicesCurrent",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AllowanceForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Tenant Improvements",
        "label": "Allowance For Tenant Improvements",
        "terseLabel": "Allowance for tenant improvements"
       }
      }
     },
     "localname": "AllowanceForTenantImprovements",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.modernatx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biomedical Advanced Research And Development Authority [Member]",
        "label": "Biomedical Advanced Research And Development Authority [Member]",
        "terseLabel": "BARDA"
       }
      }
     },
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge, Massachusetts [Member]",
        "label": "Cambridge, Massachusetts [Member]",
        "terseLabel": "Cambridge Leases"
       }
      }
     },
     "localname": "CambridgeMassachusettsMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ChangeInContractWithCustomerLiabilityCurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract with Customer Liability, Current",
        "label": "Change In Contract with Customer Liability, Current [Roll Forward]",
        "verboseLabel": "Change In Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityCurrentRollForward",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChangeInContractWithCustomerLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Contract With Customer Liability",
        "label": "Change in Contract With Customer Liability [Line Items]",
        "terseLabel": "Change In Contract With Customer, Liability [Line Items]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityLineItems",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChangeInContractWithCustomerLiabilityNonCurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract with Customer Liability, NonCurrent [Roll Forward]",
        "label": "Change In Contract with Customer Liability, NonCurrent [Roll Forward]",
        "terseLabel": "Contract Liabilities:"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityNonCurrentRollForward",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChangeInContractWithCustomerLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability",
        "label": "Change In Contract With Customer, Liability [Table]",
        "terseLabel": "Change in Contract With Customer Liability [Table]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityTable",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChangeInContractwithCustomerAssetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract with Customer Asset [Roll Forward]",
        "label": "Change In Contract with Customer Asset [Roll Forward]",
        "terseLabel": "Contract Assets:"
       }
      }
     },
     "localname": "ChangeInContractwithCustomerAssetRollForward",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_ChargesToFinancingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charges To Financing Lease Liabilities",
        "label": "Charges To Financing Lease Liabilities",
        "terseLabel": "Changes in financing lease liabilities"
       }
      }
     },
     "localname": "ChargesToFinancingLeaseLiabilities",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ClinicalOperationsAndSupportCommitmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Operations And Support Commitment [Member]",
        "label": "Clinical Operations And Support Commitment [Member]",
        "terseLabel": "Clinical operations and support commitments"
       }
      }
     },
     "localname": "ClinicalOperationsAndSupportCommitmentMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ClinicalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Services",
        "label": "Clinical Services [Member]",
        "terseLabel": "Clinical services"
       }
      }
     },
     "localname": "ClinicalServicesMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CollaborationArrangementIncludingArrangementsWithAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement Including Arrangements With Affiliate [Member]",
        "label": "Collaboration Arrangement Including Arrangements With Affiliate [Member]",
        "terseLabel": "Collaboration Revenue by Strategic Collaborator"
       }
      }
     },
     "localname": "CollaborationArrangementIncludingArrangementsWithAffiliateMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_CollaborationArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement [Member]",
        "label": "Collaboration Arrangement [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationArrangementMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ContractOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Options",
        "label": "Contract Options [Member]",
        "terseLabel": "Contract options"
       }
      }
     },
     "localname": "ContractOptionsMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ContractWithCustomerAssetDeductionsDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, Deductions During Period",
        "label": "Contract With Customer, Asset, Deductions During Period",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetDeductionsDuringPeriod",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ContractWithCustomerLiabilityDeductionsDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Deductions During Period",
        "label": "Contract With Customer, Liability, Deductions During Period",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeductionsDuringPeriod",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_CurrentAssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Current Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Assets and Lease Liabilities"
       }
      }
     },
     "localname": "CurrentAssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrna_CurrentMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Marketable Securities [Member]",
        "label": "Current Marketable Securities [Member]",
        "terseLabel": "Current Marketable Securities"
       }
      }
     },
     "localname": "CurrentMarketableSecuritiesMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_DefenseAdvancedResearchProjectsAgencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defense Advanced Research Projects Agency [Member]",
        "label": "Defense Advanced Research Projects Agency [Member]",
        "terseLabel": "DARPA"
       }
      }
     },
     "localname": "DefenseAdvancedResearchProjectsAgencyMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_DeferredIncomeTaxExpenseBenefitNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Tax Expense (Benefit), Net",
        "label": "Deferred Income Tax Expense (Benefit), Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitNet",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs",
        "label": "Deferred Tax Assets, Capitalized Licenses, Research And Development, And Start-Up Costs",
        "terseLabel": "Capitalized licenses, research and development and start-up costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_DeferredTaxAssetsFinancingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Financing Lease, Liability",
        "label": "Deferred Tax Assets, Financing Lease, Liability",
        "terseLabel": "Financing lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsFinancingLeaseLiability",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Finance Lease Right Of Use Asset",
        "label": "Deferred Tax Liabilities, Finance Lease Right Of Use Asset",
        "negatedTerseLabel": "Right-of-use assets, financing"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease Right Of Use Asset",
        "label": "Deferred Tax Liabilities, Operating Lease Right Of Use Asset",
        "negatedLabel": "Right-of-use assets, operating"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_DeferredTaxValuationAllowanceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax, Valuation Allowance",
        "label": "Deferred Tax, Valuation Allowance [Roll Forward]",
        "terseLabel": "Deferred Tax, Valuation Allowance [Roll Forward]"
       }
      }
     },
     "localname": "DeferredTaxValuationAllowanceRollForward",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrna_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Foreign Derived Intangible income, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Derived Intangible income, Percent",
        "terseLabel": "Foreign-derived intangible income"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomePercent",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_EmbeddedLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Embedded Leases",
        "label": "Embedded Leases [Member]",
        "terseLabel": "Embedded Leases"
       }
      }
     },
     "localname": "EmbeddedLeasesMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_EmployeeStockPurchasePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan 2018 [Member]",
        "label": "Employee Stock Purchase Plan 2018 [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2018Member",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_EuropeanCommissionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Commission",
        "label": "European Commission [Member]",
        "terseLabel": "European Commission"
       }
      }
     },
     "localname": "EuropeanCommissionMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost",
        "label": "Finance Lease, Cost",
        "totalLabel": "Total financing lease costs"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_FinanceLeaseNumberOfProperties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Number Of Properties",
        "label": "Finance Lease, Number Of Properties",
        "terseLabel": "Finance lease, number of properties"
       }
      }
     },
     "localname": "FinanceLeaseNumberOfProperties",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_FinancingRightOfUseAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing, Right-Of-Use Asset [Member]",
        "label": "Financing, Right-Of-Use Asset [Member]",
        "terseLabel": "Right-of-use asset, financing"
       }
      }
     },
     "localname": "FinancingRightOfUseAssetMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_FiveHundredTechnologySquareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Hundred\u00a0Technology Square [Member]",
        "label": "Five Hundred\u00a0Technology Square [Member]",
        "terseLabel": "500\u00a0Technology Square"
       }
      }
     },
     "localname": "FiveHundredTechnologySquareMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_IncreaseDecreaseInOperatingLeasesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Leases, Right Of Use Assets",
        "label": "Increase (Decrease) In Operating Leases, Right Of Use Assets",
        "negatedTerseLabel": "Right-of-use assets, operating leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeasesRightOfUseAssets",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_InitialProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Project [Member]",
        "label": "Initial Project [Member]",
        "terseLabel": "Initial project"
       }
      }
     },
     "localname": "InitialProjectMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_LesseeFinanceLeaseExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance Lease, Expense",
        "label": "Lessee, Finance Lease, Expense",
        "terseLabel": "Changes in financing lease liabilities"
       }
      }
     },
     "localname": "LesseeFinanceLeaseExpense",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Agreement For Building Project, Term",
        "label": "Lessee, Operating Lease, Lease Agreement For Building Project, Term",
        "terseLabel": "Lease agreement for building project"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseAgreementForBuildingProjectTerm",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_LesseeOperatingLeaseNumberOfExtension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Extension",
        "label": "Lessee, Operating Lease, Number Of Extension",
        "terseLabel": "Number of extension periods"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfExtension",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_LesseeOperatingLeaseNumberOfExtensionPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Extension Periods",
        "label": "Lessee, Operating Lease, Number Of Extension Periods",
        "terseLabel": "Number of extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfExtensionPeriods",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_MRNAVertex2020AgreementMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MRNA Vertex 2020 Agreement Member",
        "label": "MRNA Vertex 2020 Agreement Member [Member]",
        "terseLabel": "MRNA Vertex 2020 Agreement Member"
       }
      }
     },
     "localname": "MRNAVertex2020AgreementMemberMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MTCEastMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTC East",
        "label": "MTC East [Member]",
        "terseLabel": "MTC East"
       }
      }
     },
     "localname": "MTCEastMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MTCNorthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTC North",
        "label": "MTC North [Member]",
        "terseLabel": "MTC North"
       }
      }
     },
     "localname": "MTCNorthMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MTCSouthMTCNorthAndMTCEastMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTC South, MTC North and MTC East",
        "label": "MTC South, MTC North and MTC East [Member]",
        "terseLabel": "MTC South, MTC North and MTC East"
       }
      }
     },
     "localname": "MTCSouthMTCNorthAndMTCEastMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_MerckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck [Member]",
        "label": "Merck [Member]",
        "terseLabel": "Merck"
       }
      }
     },
     "localname": "MerckMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ModernaScienceCentreMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Moderna Science Centre",
        "label": "Moderna Science Centre [Member]",
        "terseLabel": "Moderna Science Centre"
       }
      }
     },
     "localname": "ModernaScienceCentreMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_NoncurrentMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent Marketable Securities [Member]",
        "label": "Noncurrent Marketable Securities [Member]",
        "terseLabel": "Non- Current Marketable Securities"
       }
      }
     },
     "localname": "NoncurrentMarketableSecuritiesMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_NorwoodMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Norwood, Massachusetts",
        "label": "Norwood, Massachusetts [Member]",
        "terseLabel": "Norwood Leases"
       }
      }
     },
     "localname": "NorwoodMassachusettsMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_NumberOfDosesOfVaccineCandidate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Doses Of Vaccine Candidate",
        "label": "Number Of Doses Of Vaccine Candidate",
        "terseLabel": "Number of doses of vaccine candidate"
       }
      }
     },
     "localname": "NumberOfDosesOfVaccineCandidate",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_NumberOfParticipants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Participants",
        "label": "Number Of Participants",
        "terseLabel": "Number of participants"
       }
      }
     },
     "localname": "NumberOfParticipants",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_OperatingAndFinanceLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Liability",
        "label": "Operating And Finance Lease, Liability",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiability",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingAndFinanceLeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Liability, Current",
        "label": "Operating And Finance Lease, Liability, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Liability, Noncurrent",
        "label": "Operating And Finance Lease, Liability, Noncurrent",
        "totalLabel": "Total non-current lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingAndFinanceLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Right-Of-Use Asset",
        "label": "Operating And Finance Lease, Right-Of-Use Asset",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseRightOfUseAsset",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_OperatingLeaseNumberOfProperties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Number Of Properties",
        "label": "Operating Lease, Number Of Properties",
        "terseLabel": "Number of campuses"
       }
      }
     },
     "localname": "OperatingLeaseNumberOfProperties",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_OtherGrantRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Grant Revenue",
        "label": "Other Grant Revenue [Member]",
        "terseLabel": "Other Grant Revenue"
       }
      }
     },
     "localname": "OtherGrantRevenueMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_OtherPrepaidExpenseManufacturing": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Prepaid Expense, Manufacturing",
        "label": "Other Prepaid Expense, Manufacturing",
        "terseLabel": "Down payments to manufacturing vendors"
       }
      }
     },
     "localname": "OtherPrepaidExpenseManufacturing",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp\u00a0And Dohme Corp [Member]",
        "label": "Personalized MRNA Cancer Vaccines (PCV) Collaboration And License Agreement With Merck Sharp\u00a0And Dohme Corp [Member]",
        "terseLabel": "PCV Agreement"
       }
      }
     },
     "localname": "PersonalizedMRNACancerVaccinesPCVCollaborationAndLicenseAgreementWithMerckSharpAndDohmeCorpMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_PersonalizedMRNACancerVaccinesProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personalized MRNA Cancer Vaccines Products [Member]",
        "label": "Personalized MRNA Cancer Vaccines Products [Member]",
        "terseLabel": "PCV products"
       }
      }
     },
     "localname": "PersonalizedMRNACancerVaccinesProductsMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Sales",
        "label": "Product Sales [Member]",
        "terseLabel": "Product sales",
        "verboseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductSalesMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_PublicEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Equity Offering [Member]",
        "label": "Public Equity Offering [Member]",
        "terseLabel": "Public Equity Offering"
       }
      }
     },
     "localname": "PublicEquityOfferingMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RawMaterialsAccountsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Raw Materials, Accounts Payable",
        "label": "Raw Materials, Accounts Payable",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "RawMaterialsAccountsPayable",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Earnout Payment, Percent",
        "terseLabel": "Earn-out payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersEarnoutPaymentPercent",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Maximum Amount",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Maximum Amount",
        "terseLabel": "Estimated arrangement consideration"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumAmount",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contract To Perform For Others, Research Period",
        "label": "Research And Development Arrangement, Contract To Perform For Others, Research Period",
        "terseLabel": "Initial research period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersResearchPeriod",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_RestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest Of World",
        "label": "Rest Of World [Member]",
        "terseLabel": "Rest of world"
       }
      }
     },
     "localname": "RestOfWorldMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RestrictedCommonStockUnitsAndPerformanceStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Common Stock Units And Performance Stock Units",
        "label": "Restricted Common Stock Units And Performance Stock Units [Member]",
        "terseLabel": "Restricted Common Stock Units And Performance Stock Units"
       }
      }
     },
     "localname": "RestrictedCommonStockUnitsAndPerformanceStockUnitsMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units (RSU) And Performance Stock Unit (PSU)",
        "label": "Restricted Stock Units (RSU) And Performance Stock Unit (PSU) [Member]",
        "terseLabel": "RSUs and PSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUAndPerformanceStockUnitPSUMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_RevenueFromGrantsCurrentFundingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Current Funding Capacity",
        "label": "Revenue From Grants, Current Funding Capacity",
        "terseLabel": "Amount committed for funding"
       }
      }
     },
     "localname": "RevenueFromGrantsCurrentFundingCapacity",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RevenueFromGrantsMaximumAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Maximum Award",
        "label": "Revenue From Grants, Maximum Award",
        "terseLabel": "Award amount"
       }
      }
     },
     "localname": "RevenueFromGrantsMaximumAward",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RevenueFromGrantsNumberOfContractOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Number Of Contract Options",
        "label": "Revenue From Grants, Number Of Contract Options",
        "terseLabel": "Number of contract options"
       }
      }
     },
     "localname": "RevenueFromGrantsNumberOfContractOptions",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_RevenueFromGrantsNumberOfContractOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Number Of Contract Options Exercised",
        "label": "Revenue From Grants, Number Of Contract Options Exercised",
        "terseLabel": "Number of contract options exercised"
       }
      }
     },
     "localname": "RevenueFromGrantsNumberOfContractOptionsExercised",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_RevenueFromGrantsPotentialReimbursement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Potential Reimbursement",
        "label": "Revenue From Grants, Potential Reimbursement",
        "terseLabel": "Revenue from grants, potential reimbursement"
       }
      }
     },
     "localname": "RevenueFromGrantsPotentialReimbursement",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RevenueFromGrantsRemainingFundingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Grants, Remaining Funding Capacity",
        "label": "Revenue From Grants, Remaining Funding Capacity",
        "terseLabel": "Available funding"
       }
      }
     },
     "localname": "RevenueFromGrantsRemainingFundingCapacity",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets obtained through finance lease modifications and reassessments",
        "label": "Right-of-use assets obtained through finance lease modifications and reassessments",
        "terseLabel": "Changes in right-of-use assets related to lease modifications and reassessments"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments",
        "label": "Right-Of-Use Assets Reduced Through Lease Modifications And Reassessments",
        "terseLabel": "Changes in right-of-use assets related to lease modifications and reassessments"
       }
      }
     },
     "localname": "RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ServiceBasedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service-Based Awards [Member]",
        "label": "Service-Based Awards [Member]",
        "terseLabel": "Service-based awards"
       }
      }
     },
     "localname": "ServiceBasedAwardsMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period, Number Of Installments",
        "terseLabel": "Number of installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodNumberOfInstallments",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Consecutive Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Consecutive Offering Period",
        "terseLabel": "Consecutive offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveOfferingPeriod",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Employee Subscription Amount",
        "terseLabel": "Maximum value of shares to be purchased during purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Consecutive Offering Periods",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Consecutive Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutiveOfferingPeriod",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Purchase Periods",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Payout Percentage",
        "terseLabel": "Payout percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPayoutPercentage",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Annual Percentage Of Additional Shares Authorized",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Annual Percentage Of Additional Shares Authorized",
        "terseLabel": "Annual percentage increase of shares reserved and available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageOfAdditionalSharesAuthorized",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Minimum Employee Subscription Rate",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Minimum Employee Subscription Rate",
        "terseLabel": "Minimum percentage of compensation through payroll deductions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardMinimumEmployeeSubscriptionRate",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrna_SouthKoreaGovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South Korea Government",
        "label": "South Korea Government [Member]",
        "terseLabel": "South Korea Government"
       }
      }
     },
     "localname": "SouthKoreaGovernmentMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_StockOptionAndGrantPlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option And Grant Plan 2016 [Member]",
        "label": "Stock Option And Grant Plan 2016 [Member]",
        "terseLabel": "2016 Equity Plan"
       }
      }
     },
     "localname": "StockOptionAndGrantPlan2016Member",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_StockOptionAndIncentivePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option And Incentive Plan 2018 [Member]",
        "label": "Stock Option And Incentive Plan 2018 [Member]",
        "terseLabel": "2018 Equity Plan"
       }
      }
     },
     "localname": "StockOptionAndIncentivePlan2018Member",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_SupplyAndManufacturingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply And Manufacturing Agreements",
        "label": "Supply And Manufacturing Agreements [Member]",
        "terseLabel": "Supply and manufacturing agreements"
       }
      }
     },
     "localname": "SupplyAndManufacturingAgreementsMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_TenantImprovementAllowanceReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Improvement Allowance Receivable, Current",
        "label": "Tenant Improvement Allowance Receivable, Current",
        "terseLabel": "Tenant improvement allowance receivable"
       }
      }
     },
     "localname": "TenantImprovementAllowanceReceivableCurrent",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_TheBillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Bill\u00a0And Melinda Gates Foundation [Member]",
        "label": "The Bill\u00a0And Melinda Gates Foundation [Member]",
        "terseLabel": "The Bill\u00a0&amp; Melinda Gates Foundation"
       }
      }
     },
     "localname": "TheBillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_TwoHundredTechnologySquareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Hundred\u00a0Technology Square",
        "label": "Two Hundred\u00a0Technology Square [Member]",
        "terseLabel": "200\u00a0Technology Square"
       }
      }
     },
     "localname": "TwoHundredTechnologySquareMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_USGovermentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Goverment",
        "label": "US Goverment [Member]",
        "terseLabel": "U.S. Government (excluding BARDA)"
       }
      }
     },
     "localname": "USGovermentMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_UnitedKingdomGovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Kingdom Government",
        "label": "United Kingdom Government [Member]",
        "terseLabel": "United Kingdom Government"
       }
      }
     },
     "localname": "UnitedKingdomGovernmentMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrna_UnrecognizedTaxBenefitsNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net",
        "label": "Unrecognized Tax Benefits, Net",
        "terseLabel": "Unrecognized tax benefits, net"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNet",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_ValuationAllowanceDeferredTaxAssetDecreaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance, Deferred Tax Asset, Decrease , Amount",
        "label": "Valuation Allowance, Deferred Tax Asset, Decrease , Amount",
        "negatedTerseLabel": "Decreases recorded as benefit to income tax provision"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetDecreaseAmount",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrna_VertexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex [Member]",
        "label": "Vertex [Member]",
        "terseLabel": "Vertex"
       }
      }
     },
     "localname": "VertexMember",
     "nsuri": "http://www.modernatx.com/20211231",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r65",
      "r67",
      "r135",
      "r136",
      "r324",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r142",
      "r150",
      "r156",
      "r258",
      "r497",
      "r498",
      "r499",
      "r541",
      "r542",
      "r590",
      "r593",
      "r595",
      "r596",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r142",
      "r150",
      "r156",
      "r258",
      "r497",
      "r498",
      "r499",
      "r541",
      "r542",
      "r590",
      "r593",
      "r595",
      "r596",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r142",
      "r150",
      "r156",
      "r258",
      "r497",
      "r498",
      "r499",
      "r541",
      "r542",
      "r590",
      "r593",
      "r595",
      "r596",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r217",
      "r370",
      "r375",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r323",
      "r331",
      "r457",
      "r458",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r688",
      "r739",
      "r743",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r323",
      "r331",
      "r457",
      "r458",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r688",
      "r739",
      "r743",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r217",
      "r370",
      "r375",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r213",
      "r370",
      "r373",
      "r692",
      "r738",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r213",
      "r370",
      "r373",
      "r692",
      "r738",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r323",
      "r331",
      "r404",
      "r457",
      "r458",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r688",
      "r739",
      "r743",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r323",
      "r331",
      "r404",
      "r457",
      "r458",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r688",
      "r739",
      "r743",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails",
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails",
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r135",
      "r136",
      "r324",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r214",
      "r215",
      "r370",
      "r374",
      "r741",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r370",
      "r374",
      "r741",
      "r759",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r664",
      "r666",
      "r669",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Accounting Standards Update 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49",
      "r654"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r29",
      "r218",
      "r219"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r708",
      "r732"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": {
     "auth_ref": [
      "r69",
      "r76",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]",
        "terseLabel": "Net Unrealized Gains on Derivatives Designated As Hedging Instruments"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r76",
      "r86",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized\u00a0Gain (Loss) on Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r74",
      "r75",
      "r76",
      "r727",
      "r751",
      "r755"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r86",
      "r87",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r73",
      "r76",
      "r86",
      "r87",
      "r88",
      "r139",
      "r140",
      "r141",
      "r562",
      "r746",
      "r747",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r30",
      "r500",
      "r654"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r497",
      "r498",
      "r499",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r143",
      "r144",
      "r145",
      "r146",
      "r156",
      "r228",
      "r229",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r311",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r539",
      "r540",
      "r541",
      "r542",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r651",
      "r693",
      "r694",
      "r695",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r460",
      "r462",
      "r503",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r462",
      "r489",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Compensation costs"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r36",
      "r224",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of office space (in sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r115",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment expenses"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r130",
      "r196",
      "r205",
      "r211",
      "r254",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r558",
      "r563",
      "r609",
      "r652",
      "r654",
      "r703",
      "r724"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r11",
      "r13",
      "r61",
      "r130",
      "r254",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r558",
      "r563",
      "r609",
      "r652",
      "r654"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r234",
      "r269"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r239",
      "r241",
      "r717"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r239",
      "r242",
      "r718"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r239",
      "r240",
      "r716"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsAmortizedCostandEstimatedFairValueofMarketableSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r230",
      "r235",
      "r269",
      "r707"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair\u00a0Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r232",
      "r269"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r232",
      "r269"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Investments, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r463",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r573",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r120",
      "r121",
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r45",
      "r117"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r20",
      "r118",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r111",
      "r117",
      "r123"
     ],
     "calculation": {
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r111",
      "r618"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r128",
      "r130",
      "r159",
      "r160",
      "r161",
      "r163",
      "r165",
      "r174",
      "r175",
      "r176",
      "r254",
      "r312",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r329",
      "r330",
      "r334",
      "r338",
      "r609",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r55",
      "r297",
      "r709",
      "r731"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r305",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Share available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r139",
      "r140",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r654"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2021 and 2020; 403 and 399 shares issued and outstanding as of December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r81",
      "r83",
      "r84",
      "r92",
      "r712",
      "r734"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r217",
      "r606",
      "r607",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r217",
      "r606",
      "r607",
      "r757",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r217",
      "r606",
      "r607",
      "r757",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r179",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r184",
      "r185",
      "r217",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r186",
      "r606",
      "r608",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r217",
      "r606",
      "r607",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r125",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Changes in Balances of Receivables and Contract Liabilities",
        "verboseLabel": "Deferred Revenue Activities Summary"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsTables",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r348",
      "r350",
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetPurchase": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase from purchase of right to consideration in exchange for good or service transferred to customer when right is conditioned on passage of time.",
        "label": "Contract with Customer, Asset, Purchase",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetPurchase",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r348",
      "r349",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r348",
      "r349",
      "r371"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r348",
      "r349",
      "r371"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r405",
      "r453",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r97",
      "r692"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r535",
      "r545"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r535"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r535",
      "r545",
      "r547"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r535",
      "r545"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r183",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r236",
      "r269",
      "r275",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r248",
      "r273",
      "r278"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "negatedLabel": "Gross unrealized losses, 12 months or more"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r248",
      "r273"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "verboseLabel": "Estimated fair value, 12 months or more"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r248",
      "r273",
      "r278"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "negatedTerseLabel": "Gross unrealized losses, less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r248",
      "r273"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "Estimated fair value, less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r245",
      "r270",
      "r278"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "negatedTotalLabel": "Gross Unrealized Losses, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r246",
      "r271"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "totalLabel": "Estimated Fair Value, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r536",
      "r545"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r536",
      "r545"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r131",
      "r536",
      "r545",
      "r546",
      "r547"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r24",
      "r25",
      "r525",
      "r704",
      "r723"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r536",
      "r545"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r531",
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r527"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: valuation allowance",
        "periodEndLabel": "Valuation allowance at December 31",
        "periodStartLabel": "Valuation allowance at beginning of the period"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails",
      "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r533",
      "r534"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "terseLabel": "Benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Total matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Percent of match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percent contributed by participant"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r115",
      "r194"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r63",
      "r64",
      "r67",
      "r605"
     ],
     "calculation": {
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative instruments",
        "verboseLabel": "Derivative asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r67",
      "r574",
      "r575",
      "r578",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r586",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r571",
      "r574",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r577",
      "r579"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Net realized and unrealized (losses)"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r63",
      "r64",
      "r67",
      "r605"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative instruments",
        "verboseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r567",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r137",
      "r566",
      "r568",
      "r571",
      "r572",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Instruments and Hedging Activities"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsTables",
      "http://www.modernatx.com/role/GrantRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r93",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r157",
      "r159",
      "r163",
      "r164",
      "r165",
      "r169",
      "r170",
      "r596",
      "r597",
      "r713",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (usd per share)",
        "verboseLabel": "Basic EPS (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r93",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r159",
      "r163",
      "r164",
      "r165",
      "r169",
      "r170",
      "r596",
      "r597",
      "r713",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (usd per share)",
        "verboseLabel": "Diluted EPS (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r516"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r133",
      "r516",
      "r549"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r516",
      "r549"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r516",
      "r549"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r516",
      "r549"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r505",
      "r516"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r516",
      "r549"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r516",
      "r549"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Federal research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationofUSStatutoryIncomeTaxRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation-related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to non-vested stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period of cost expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Tax benefit realized from option exercised"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r86",
      "r87",
      "r88",
      "r139",
      "r140",
      "r141",
      "r144",
      "r153",
      "r155",
      "r173",
      "r258",
      "r345",
      "r346",
      "r497",
      "r498",
      "r499",
      "r541",
      "r542",
      "r595",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r746",
      "r747",
      "r748",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r325",
      "r327",
      "r328",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r453",
      "r600",
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r599",
      "r600",
      "r601",
      "r602",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r325",
      "r405",
      "r407",
      "r412",
      "r453",
      "r600",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "verboseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r325",
      "r327",
      "r328",
      "r405",
      "r407",
      "r412",
      "r453",
      "r600",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r325",
      "r327",
      "r328",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r453",
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r632",
      "r639",
      "r649"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "mrna_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense for financing lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r634",
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "negatedTerseLabel": "Operating cash flows used in financing leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due, Rolling Maturity [Abstract]",
        "terseLabel": "Financing Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r630",
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Financing lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "verboseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Finance Lease Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Financing lease liabilities, non-current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach.",
        "label": "Finance Lease, Liability, Payments, Due in Next Rolling 12 Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Finance Lease, Liability, Payments, Due in Rolling after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Finance Lease, Liability, Payments, Due in Rolling Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Finance Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Finance Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Finance Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less amounts representing interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r633",
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Financing cash flows used in financing leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r629"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Right-of-use assets, financing, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r632",
      "r639",
      "r649"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "mrna_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets, financing leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "verboseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r646",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases, discount rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r645",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases, remaining lease term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r251",
      "r252",
      "r253",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r272",
      "r274",
      "r277",
      "r278",
      "r326",
      "r343",
      "r586",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "terseLabel": "Gain on foreign currency forward contracts"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsCashflowHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r67",
      "r405",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency forward contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases": {
     "auth_ref": [
      "r285",
      "r627"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases.",
        "label": "Gain (Loss) on Sale of Leased Assets, Net, Operating Leases",
        "negatedTerseLabel": "Leased assets expensed"
       }
      }
     },
     "localname": "GainLossOnSaleOfLeasedAssetsNetOperatingLeases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r571",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r284",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r132",
      "r548"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r90",
      "r196",
      "r204",
      "r207",
      "r210",
      "r212",
      "r700",
      "r710",
      "r714",
      "r736"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r132",
      "r548"
     ],
     "calculation": {
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r290",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r133",
      "r517",
      "r523",
      "r530",
      "r543",
      "r550",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r154",
      "r155",
      "r195",
      "r515",
      "r544",
      "r551",
      "r737"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes",
        "totalLabel": "Total provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/IncomeTaxesProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r511",
      "r512",
      "r523",
      "r524",
      "r529",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r114",
      "r689"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r114",
      "r643"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "auth_ref": [
      "r306",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.",
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnifications"
       }
      }
     },
     "localname": "IndemnificationGuaranteeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r110",
      "r112",
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r37",
      "r281"
     ],
     "calculation": {
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r58",
      "r654"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r19",
      "r59",
      "r126",
      "r172",
      "r279",
      "r280",
      "r282",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r39",
      "r281"
     ],
     "calculation": {
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r38",
      "r281"
     ],
     "calculation": {
      "http://www.modernatx.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r99",
      "r193"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedTerseLabel": "Amortization/accretion of investments"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Amortized Cost and Estimated Fair Value of Marketable Securities, by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r250",
      "r701",
      "r720",
      "r758",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measurements"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails",
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails",
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total minimum lease payments",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails",
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less amounts representing interest",
        "terseLabel": "Undiscounted future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Extension term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentandContingenciesModernaScienceCenterDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r51",
      "r130",
      "r206",
      "r254",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r559",
      "r563",
      "r564",
      "r609",
      "r652",
      "r653"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r130",
      "r254",
      "r609",
      "r654",
      "r706",
      "r729"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r53",
      "r130",
      "r254",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r559",
      "r563",
      "r564",
      "r609",
      "r652",
      "r653",
      "r654"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LinesOfCreditFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time.",
        "label": "Lines of Credit, Fair Value Disclosure",
        "terseLabel": "Letters of credit, fair value"
       }
      }
     },
     "localname": "LinesOfCreditFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Reserves established"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyLossInPeriod": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.",
        "label": "Loss Contingency, Loss in Period",
        "terseLabel": "Losses related to indemnification obligations"
       }
      }
     },
     "localname": "LossContingencyLossInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of claims outstanding"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesIndemnificationObligationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MajorCustomersPolicyPolicyTextBlock": {
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.",
        "label": "Major Customers, Policy [Policy Text Block]",
        "terseLabel": "Significant Customers"
       }
      }
     },
     "localname": "MajorCustomersPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r111",
      "r113",
      "r116"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r79",
      "r82",
      "r88",
      "r91",
      "r116",
      "r130",
      "r143",
      "r148",
      "r149",
      "r150",
      "r151",
      "r154",
      "r155",
      "r162",
      "r196",
      "r204",
      "r207",
      "r210",
      "r212",
      "r254",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r597",
      "r609",
      "r711",
      "r733"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r156",
      "r169",
      "r228",
      "r229",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r311",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r539",
      "r540",
      "r541",
      "r542",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r651",
      "r693",
      "r694",
      "r695",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r196",
      "r204",
      "r207",
      "r210",
      "r212"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r640",
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesMinimumLeasePaymentsDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "verboseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseLiabilityNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r635",
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedTerseLabel": "Operating cash flows used in operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r629"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "mrna_OperatingAndFinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, operating leases",
        "verboseLabel": "Right-of-use assets, operating, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/LeasesBalanceSheetInformationDetails",
      "http://www.modernatx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r646",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases, discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r645",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases, remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r52"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r60",
      "r654"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Other Commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r556",
      "r557",
      "r561"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Net (decrease) increase from available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "totalLabel": "Net increase from derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r69",
      "r74"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized gains on derivative instruments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r74",
      "r77"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Less: net realized (gains) on derivative instruments reclassified to net income (loss)",
        "terseLabel": "Net gains reclassified from AOCI into income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments, before Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsBeforeTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r80",
      "r83",
      "r556",
      "r557",
      "r561"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other comprehensive loss",
        "verboseLabel": "Other comprehensive income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r74",
      "r77",
      "r78",
      "r249"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Less: net realized (gains) on available-for-sale securities reclassified to net income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r70",
      "r74"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (losses) gains on available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r52",
      "r654"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r283"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r52",
      "r310"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings",
        "terseLabel": "Impairment charges related to marketable securities"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriting Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r102",
      "r104",
      "r231"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "terseLabel": "Consideration paid"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesLicensestoPatentedTechnologyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Payments to Acquire Notes Receivable",
        "negatedTerseLabel": "Investment in convertible notes"
       }
      }
     },
     "localname": "PaymentsToAcquireNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r404",
      "r406",
      "r412",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r463",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r27",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETSParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r27",
      "r654"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001; 162\u00a0shares authorized as of December 31, 2021 and 2020; no shares issued or outstanding at December 31, 2021 and 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r11",
      "r43",
      "r44"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from offerings of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.modernatx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r102",
      "r103",
      "r231"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r102",
      "r103",
      "r231"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r107",
      "r492"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Consideration for options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock through equity plans, net"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r288",
      "r632",
      "r639"
     ],
     "calculation": {
      "http://www.modernatx.com/role/PropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedTerseLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r62",
      "r289",
      "r639"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/PropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r21",
      "r287",
      "r629"
     ],
     "calculation": {
      "http://www.modernatx.com/role/PropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r292",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "terseLabel": "Furniture, fixtures and other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r289",
      "r763",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r21",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Estimated Useful Lives of Property and Equipment",
        "verboseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentTables",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r21",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Estimated\u00a0Useful\u00a0Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r95",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Bad debt expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r23",
      "r705",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r23",
      "r705",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Line Items]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": {
     "auth_ref": [
      "r23",
      "r705",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.",
        "label": "Purchase Commitment, Excluding Long-term Commitment [Table]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r23",
      "r705",
      "r725"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Contractual commitment to pay"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CommitmentsandContingenciesPurchaseCommitmentsandPurchaseOrdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase obligation to be paid in 2022"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedemptionPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.",
        "label": "Redemption Premium",
        "terseLabel": "Premium recorded to deferred revenue"
       }
      }
     },
     "localname": "RedemptionPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r507",
      "r691",
      "r778"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r7",
      "r20",
      "r123"
     ],
     "calculation": {
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r14",
      "r22",
      "r123",
      "r760"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, non-current"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted Stock or Unit Expense",
        "terseLabel": "Restricted stock unit"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted common stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r346",
      "r500",
      "r654",
      "r728",
      "r750",
      "r755"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r139",
      "r140",
      "r141",
      "r144",
      "r153",
      "r155",
      "r258",
      "r497",
      "r498",
      "r499",
      "r541",
      "r542",
      "r595",
      "r746",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanFundingStatusAxis": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r434",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of funding for defined benefit plan designed to provide retirement benefits.",
        "label": "Defined Benefit Plan, Funding Status [Axis]",
        "terseLabel": "Defined Benefit Plan, Funding Status [Axis]"
       }
      }
     },
     "localname": "RetirementPlanFundingStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanFundingStatusDomain": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r434",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of funding for defined benefit plan designed to provide retirement benefits.",
        "label": "Defined Benefit Plan, Funding Status [Domain]",
        "terseLabel": "Defined Benefit Plan, Funding Status [Domain]"
       }
      }
     },
     "localname": "RetirementPlanFundingStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r191",
      "r192",
      "r203",
      "r208",
      "r209",
      "r213",
      "r214",
      "r217",
      "r369",
      "r370",
      "r692"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsSummaryofTotalConsolidatedNetRevenuesfromStrategicCollaboratorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r184",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesSignificantCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r372",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "netLabel": "Geographic Information",
        "terseLabel": "Grant Revenue",
        "verboseLabel": "Product Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformation",
      "http://www.modernatx.com/role/GrantRevenue",
      "http://www.modernatx.com/role/ProductSales"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/GeographicInformationTables",
      "http://www.modernatx.com/role/ProductSalesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Deferred revenue related to customer"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r89",
      "r130",
      "r191",
      "r192",
      "r203",
      "r208",
      "r209",
      "r213",
      "r214",
      "r217",
      "r254",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r609",
      "r714"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "verboseLabel": "Net revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/GeographicInformationDetails",
      "http://www.modernatx.com/role/GrantRevenueDetails",
      "http://www.modernatx.com/role/ProductSalesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r644",
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for financing lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r644",
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate net proceeds from the offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares of common stock issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsBalanceSheetHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r76",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Components of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of Cash and Available-for-Sale Securities by Significant Investment Category"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsChangesinBalancesofReceivablesandContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provision For (Benefit From) Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Significant Components of Deferred Tax Assets and Tax Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r437",
      "r438",
      "r441",
      "r442",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of U.S. Statutory Income Tax Rate to Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r462",
      "r488",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r462",
      "r488",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Loss Before Provision For (Benefit From) Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r19",
      "r40",
      "r41",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Restricted Common Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r577",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule Of Foreign Currency Derivatives"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r47",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsAstraZenecaStrategicAlliancesinCardiovascularandOncologyDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails",
      "http://www.modernatx.com/role/CollaborationAgreementsVertex2020StrategicAllianceinCysticFibrosisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r20",
      "r123",
      "r702",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r463",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-Average Assumptions Used to Estimate the Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Schedule of Unrealized Loss on Investments"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r522",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r186",
      "r606",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Entities that Accounted for More than 10% of Total Revenue and Accounts Receivable"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series H preferred stock or outstanding series H preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series H Preferred Stock [Member]",
        "terseLabel": "Series\u00a0H Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesHPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled/forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Issued (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, non-vested at end of period (in shares)",
        "periodStartLabel": "Outstanding, non-vested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares/Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, non-vested at end of period (usd per share)",
        "periodStartLabel": "Outstanding, non-vested at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date per Share/Unit"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum percentage of compensation through payroll deductions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum shares to be purchased during purchase period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Aggregate number of shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Outstanding and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number\u00a0of options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- average exercise price per share, exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r479"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r470",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Options (in millions)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Options Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- average expected to vest (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r461",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationRestrictedCommonStockandCommonStockUnitsActivityDetails",
      "http://www.modernatx.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled/forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Twelve months of continued employment or service"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Following twelve quarters"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r463",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Weighted average fair value per share (usd per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Intrinsic value of RSUs and PSUs vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r483",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedtoEstimatetheFairValueofOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- average remaining contractual term, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- average remaining contractual term, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- average remaining contractual term expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price at which shares are sold, percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r641",
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r124",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r55",
      "r709",
      "r730"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of disclosed arrangements (excluding long-term commitments) in which the entity must commit resources to supply goods or services to one or more customers.",
        "label": "Supply Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Supply commitment"
       }
      }
     },
     "localname": "SignificantSupplyCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Internally developed software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/PropertyandEquipmentDetails",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentandSoftwareCapitalizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r128",
      "r130",
      "r159",
      "r160",
      "r161",
      "r163",
      "r165",
      "r174",
      "r175",
      "r176",
      "r254",
      "r312",
      "r316",
      "r317",
      "r318",
      "r321",
      "r322",
      "r329",
      "r330",
      "r334",
      "r338",
      "r345",
      "r609",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CollaborationAgreementsMerckStrategicAlliancesinInfectiousDiseasesandCancerVaccinesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r57",
      "r86",
      "r87",
      "r88",
      "r139",
      "r140",
      "r141",
      "r144",
      "r153",
      "r155",
      "r173",
      "r258",
      "r345",
      "r346",
      "r497",
      "r498",
      "r499",
      "r541",
      "r542",
      "r595",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r746",
      "r747",
      "r748",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r173",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r27",
      "r28",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Purchase of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Proceeds of initial public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock and restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r28",
      "r345",
      "r346",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of options to purchase common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/StockBasedCompensationOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r27",
      "r28",
      "r345",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Purchase of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r345",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds of initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r57",
      "r345",
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options to purchase common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r27",
      "r28",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Stock repurchased (in shares)",
        "terseLabel": "Stock repurchased (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r27",
      "r28",
      "r345",
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Stock repurchased",
        "terseLabel": "Stock repurchased"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r33",
      "r34",
      "r130",
      "r226",
      "r254",
      "r609",
      "r654"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r129",
      "r330",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r626",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r626",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r626",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r626",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r655",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of valuation allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Other Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carry-forwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r251",
      "r252",
      "r253",
      "r326",
      "r343",
      "r586",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r143",
      "r144",
      "r145",
      "r146",
      "r156",
      "r228",
      "r229",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r311",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r539",
      "r540",
      "r541",
      "r542",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r651",
      "r693",
      "r694",
      "r695",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "Government debt securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. treasury bills"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. treasury notes"
       }
      }
     },
     "localname": "USTreasuryNotesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnaRecurringBasisDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsSummaryofCashandAvailableforSaleSecuritiesbySignificantInvestmentCategoryDetails",
      "http://www.modernatx.com/role/FinancialInstrumentsandFairValueMeasurementsUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfundedPlanMember": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r434",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan in which retirement benefits are payable directly from general assets of employer sponsoring plan.",
        "label": "Defined Benefit Plan, Unfunded Plan [Member]",
        "terseLabel": "Unfunded benefit plan"
       }
      }
     },
     "localname": "UnfundedPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r510",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions for current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions based on tax positions for prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountsofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r177",
      "r178",
      "r180",
      "r181",
      "r187",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/IncomeTaxesNarrativeDetails",
      "http://www.modernatx.com/role/IncomeTaxesValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "Value added tax receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/OtherBalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r642",
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r158",
      "r165"
     ],
     "calculation": {
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Diluted weighted-average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average common shares used in calculation of earnings (loss) per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r157",
      "r165"
     ],
     "calculation": {
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic weighted-average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.modernatx.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.modernatx.com/role/EarningsLossperShareBasicandDilutedNetLossperShareAttributabletoCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 17
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=124072958&loc=SL51729484-110225"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123389529&loc=d3e10037-110241"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e13051-110250"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123393937&loc=d3e44908-112734"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6806780-109447"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r780": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r781": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r782": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r783": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r784": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r785": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r786": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r787": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r788": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r789": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r790": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r791": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r792": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r793": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r794": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r795": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r796": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r797": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>137
<FILENAME>0001682852-22-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001682852-22-000012-xbrl.zip
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MG>O(KE+]-3BMZ7<?V+/Y\V$&T=2;_/V=_FZ!@A^UZ5]$S9,*B;HX"3[^=]4
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M+O*5(ZFN*IE6!UFED.5HDJ4KBYOU'635@BQ#5KM85BW(4JMB6?H&S?L#H1M
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M"'2M>S=B#6#GV96Z]RX:LTP%<"61T6TK&+)5]ZYDP[8WQ&!4AAA(.V,,)R.
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MI!-DREB\,:(Q W'<I.:SF'@H]*B%X&$\7-AG46 <&\^?!<<*;*U9+_OMTT,
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M=OZXB:AK0AGDL9PBEH&4VT%@KYF#);L #,;1 %9B2B<\*=/+A!<$E,X1>@V
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M8M'QY+_P7/^WD&+K*8SVW)R32[:Y<S(<>OX\X?D%U+%*YK^2<EZNV [W9>U
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MDTAT%+UI2HSFXG1U1D;*XRZ%^37G#4XN&% :SWO2/I7*5+FBU9GH7$]3.+1
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MW)1RY,*(]*S [U'PIAL2&T8,,6_'NSL+<HP4(BORID*7@#<SOBX).IQTZ-O
M5>"-+'5>N6P&_+Y:RGE+N4&L1H'AF*&8N$K"R<]I6H'O'JT0<TA2R9>!W8M&
M[U<3S2\\Z/3G6"_W@DU":\7EY4$\AC4QS@*8[-$"()E_5&:T[Q9:<_+0.Z(>
M@ "=[F/"'J/K7\-N!%/'19+XO)'D6585T5S=:I)/KERD@Z=6:.CEC&G!*Q&!
M F87'"EUF1(DI*J+^!/X2R9O@SB7S[J,,0_<\\MBR9)/X2H<P;S(Z$?+IHSG
M:'$REL4<GS8(1_<QR6[[!(MX6JBDSRKEW]FKG.LY"H&D_DB]:!N^E@R9OH:C
M/Q<[<F0&ZHY>9U_B;<3<YHO4G2J3U@46_HMQOXQ-3<F$=6R' [ICQZ) HQ4,
M&8XQ@]WZ4'!?-SPKI@IVKPGDD1<FN/-M.DD6&8@>?4:H8"-])H+POBFK!@4C
MR"+*:K5?=41KW^3;=Q+_;3;,2L(QM%_8G?B\3$LM<+,H;S*)PH!EZ8%D.F:S
M.#RTW5'6_M' $.@1:E(P?JQTL@WO E_#J)<9^8,8!%)QW>L0,0SL1ST#^U$@
M8(\A@*^7C<?=+_$LG8R,\"W4YW31+$ Z:@QX+3$M7@MVS]-LE$%@1. R$U"U
M\])U $0)K!02CQL31/!+&@F!>%55Z2QGM,O/X'JA-U*3M?/GSMVSW0RO?2@6
MW(3PZI@"CHT6<4'VA#*&O#]M".#TDD( )P/&_'P0184'W35XSKG"@VL0Y2&@
M4D&.ERO&86%@&QSUB::XKUC]UOGE2)4/ML.U&-94&T*$JSVAUG?6V7M W=V0
MPX]KEA>TD1 0S\:<10P1D(ZL+SZ)V_!Y'QVM*$//ZM%@^(J2OJ5X#$I)>*Z[
MN]TSR+VG:LR$G4WS$C0%('A57*83>.^\R(\XLS,CB"N^X\B!R%LPK1 (]=JB
MW-W]X(BPL0>>H4,,W08>\+7S@%L@+>MURD]=@#8 589@65JH&'-(,,J9=KX%
MGI )6<K@W]P660.V2PFS.^@U^Y55% :N22<8D+^LBJG],&$[EE!5":ZTNA\&
M<@_O-_YS ?!?8$6=/C^^L,9EOPK^28'-5%;1!\\QZRT+V9.*[FR*$0@Z::U2
MWQ:?]$B2(<ZX:QUZ!];I&:WS>JX?XU2[13D/1UM!1"X!)).[H5K3 H0VET92
M2"(LJ.S-RH7+WJFG[,*;OKBV\GAS!95WJK"@+D&BS,;J)"O)?Z14A\%P<9*B
M3C6GV/#_$6PP5]FT%2TR$XAYCW2*6$2*C9"GNZ&*Z>8=O,'/18T384NK@HB+
M]PH+]8F1$)6&YZM;E69*$C;PWG=2W.6<ZVE9, P-'D.8+@SSD+EA!NVJQRD<
MY Y<<P%F8@JOEAR']XCK>L1UW0O7=78O7-<>[(.%'+T@ZB%BH9)RIWBN\IFG
MEU@E!.DXS%=B91'%?5'9H-Y#("98LB#+T=^* N&[".*,0@/4)&G#JMTVL)>/
M5PJCP9/0=5"I1,\EQD)+ +_UGV1&[->%&:W07PCF3.[6"8%Z%_2SRFI1- 8%
MY<=M&,2$O]_BO!]' KSO(T;H ,2DGE\9C=HY4'SG(<$GD":C@&.I,3P$']"+
M<U";:T6-PFFG!CHG:6%?.*7(.26WB7/#HR]IL9<(6(#E@?4L!S\3$Y;%M?=0
MO7S@5!1QI7KJ_K-#8''3%*Z&<3'<NU%R<TI5\!L+Y(Q1 WY&WD_7>S.WML98
M,"IP_QP)#!!<[]<=!WZ;P1"@/+=A/Y6I=< 3O[_@V2]=;A-M="J9^P[45CDS
M>":7KP:6#1Z!D-WAUMZ']=@RB'HJHE@!AC+2#_4@E4#H$!#^9%,=NUAZOA#B
MHP0SOH3_+==Z.Z-(V_C+ _ )SAZ1#X_(AX?E47+)N0G:K3D1 AZ(G3.(RU::
MLIV9W*@V?$"XG]YOI?71QDJK.G"!-Z9#T:;[HGRHGP)= U*5S"@\.2^B:5.R
M-4EG]"..S<>Q.::/![ MSP[B?2/:;%;I4;O=6[L--S!]^A "TRXHNZ?U^Z6O
M8KZ'P61=!LD_Q_ K]DO 60N953::L+@'C5>T+B/EN?62A7JTQACR!S)535<!
MVL-QDASX>+(!$^'M=Q\8Y($DVP[20X&";<Q4^D)]C882%O@&'K<7B!K6=-M3
M8[]IEB#'%:5U-\V5UAQFP! 5KTE/%@7OX6526C$=2ULT,OF/GM0'A:$J"H)5
M35;;^)O),J_\P$_H56](_=BQIX>V5@->KUB2H!#$DZE[HQG&%:<*7[D3(=NJ
M._VJ> F?!@G\8<K>7D@<!3*R)DO%NE31^'CM<'H/TELG>ZTD[ ZQV(WL9P*E
M8.'JA)-;)3U6QKNY1,?--=%3YBO8DI3T#_2E2C$!F86TNIV?(%$/CI@BNHFK
M+MYY/[@XNPOE]X3)+/+')=G,7J8P,\6":XE2M@&QPS5(SQZ"0=JUO?8+B>@S
M;YRQ$%()&8H]-,A\>*!O$"V+JC[R-HYC]GP@EM(P%BBPF.ZQY0($.$+"O_$>
M/%!["#:T-N&SXY,7VS:AU6GOU5Z8\"5NV5,3WLZ<KN?R^N>+T_,1#&\D*%ZU
M*,"6PEH$E551?:<S.#(/QJ>'S&/A,<"O38J-(J;:<<!WKU!;23TVYAD18#=@
M]/7^%]AC8_JX=@5;YRL,%<W)27JG]:?,G=,CT**PSPG (K%;)KHN]:R!9<,+
ML4!;.+ #QE1$QI1KBELL.-*Y7#>6@8LN:,%-A[;(^W2R#N\7G-N[8MY'77-+
M,9\=GS_?K)A?4[W^>Y;[XSVQ*>^HF*V!;PD'T#8JR2Y'J![EHU"W$O:0%.]&
MT]UH9V(1,*J9YD-AL\>3?S&[&-SEF:Y%W8\\;B(B8#"-4B1@J."_2#@$O_WG
M9^<GH^>GX^/QN?%B'KRB#P1FT'H^&.FCFG]4\U]'S>\CV=>QOR\N-ZOY]^@D
MWC@G$:.[34:% WLM$WAOR]\,ILZXQSUN<1XUR_Y,^LAJ4,RD$U;6P@^DFY64
ML,.]YNFR@Z#$Y+XP*=&/'E'+CZCE>Z&6GPT=M6P!+"%*A3.5?9"6D<$,&$7A
MNL&INE;Q'"Y'<#$S.0SK!#,%JJ_W8L\.UWCSU/X@"J--O+[5_<-2HHQ:'2+;
M.7RFV6-3O!4&#=2]:5O54Y\X"F!GCG8]"+UZN\ V1VS5OG@E,?#1 A%HZ 0L
M)8,J#*2PT>"J61I'IHJ JZ14=91KC0<A^"^IQ3Y'/^A)V6"R[HSJ[T\?AFSM
MSZ3PG(,M2:IVYKO0E61O0F$DW+(DM:;(U]?BI C-_**T!HQ'B-,-[W>W8;L@
M@5E2)F"1X"];4,&BY+98/$J$*+82I'!7\D\29$C*'$%D][FC=M(_6,,  6[8
MN]')S1U@OTV$A!T-TAS.&N4Z:3!3$_-**+.=U"[)Q+7SM6'%:MNW\=ZGGD\M
M:HS"?IO3YW?DG+]C0<S!*O.)E:J-DWR?#-_>W9UD_^[.]J@6\R*_+_4B;19$
M^<)=H/;DY7Q))R91.4QNS?*Z0+*SH&B&WG-DJ9>V=+X!M8*EICXE]E__\NSY
M*[B1,&/'2$@@7-WV).QCG:5[3H1[&R699UP&P)LDQL,9;&.7^I17H"]@V_D<
MUN; PQX!&DG!>[(I80"FUP5<0_N[*<4CU-H^4L"  ?"R2F'W2XXN6E5'0UZ*
M>'6:KG%; [PE:#O4*6#+E%9/Q@67KYGI,2M]IXDK"SN_HAHQZA5F[^]< ;2Y
M&H?[._./2BDU6\&]1R&6H3.M&/C$1FJ5<KW4O*E-++3"J%F/^'6B6VO)Y4 S
MF,>E\*^S2)EW';EU9AUIQFL(8Q'C[5=IPSO9 )^\TK)],$GY6UJV\)NP $96
M[%EE5\(LGNOB5$38!:/47A69)\$?/899V4=XR#4L578M+9&?NPFC4'CVA?/*
M[Z+!LD2,,-T+*90)?C['+#E V9!=VAJ]J?.^+SG.WH^3?="_=XZ3%UN.DY^+
M_.C:$85%0J!U](O'H#5\M'KXVL_;J_^GMFG:\072O0.(QJ?'S\?XWIA+8*HA
MM\ZN5KE33VABY)?(+B%J<PMP#H&=4HV]*!+N&-&FQ?GBY1R?O#A^WE[1R^.S
M\V]/G[/W'7UR_.S<+*E)LB#2<)A^\\]-G.DTCJ[B-#EZ3=G+CSJ>YS"@V3Z!
M%-SN"8S!6'M%[L.?S\6'GZ^&-(\F7\RFP4*#B?=UY^V>]1ZUG21,>X*?8HPF
M<)"U*F-JH7.KLV+)CLE"Y0TBBL%4&D6(SRVH %PB7NE_6V8)6@A.QQ.S1=G$
MM6T^4:JE;L"90/.T6,Y7&9J],05;DE3-<C"284^8%(U/@5LAU0$:782LGX,A
MA+;8HD@UIN)'[GN=@\;4NB1:G$E*K^@/GS[GF]@6S';P:''VOP"_[K+(N>$R
M*/1BNL^N\/\+CHS3QR/C7BKNC>E]/0@%AP>%\KI.EJ;K9-NX&93:ZYE#7T5_
M-:UH^Y;?:C@6,N$*\U4-;-MB#W:Q7<\'[E(,P*<X.1Y?^CY%P+3L.15K/ KU
M!1Y%[P:$NV+X"<-$I48VO-:._$,K_8W7593'6U=H SL07BO&P"2F:'+SURB2
MGA"P)W.,UP@E_"B2=: J)*P[4Q1:7463IH+G595I 6@#87%3P010FB[D[S,<
M-1[1$ZQ.4I25>?@=Q6M4S13U4V2I[Q3"V3*M(%E)5Q$UD_?XTMQ?,B:/ )5'
M@,J] "KG]P:H['W+AQ1W8>8?R=_<]F"=P#Z"YO2?*;EP%]GTOK^1+5,&_",Q
M]KW-\7M9NYY\1!!8_Q&3%F^XDZD'M//S]>]R'?V&;<M^+(I/$Q5_LC (4A1O
MH[E*(BR;)$I0'#LK+DN FL&/<_9&;%.#H*<<-\B0=$],,6'J;NC&0_Z.3 F^
M,U%L5=T<AJA*>)@W!YT7$##%-QK\2(I78>F-LMVP\.82:CDB_Z:AVB7WH1QT
M@N#8<CF&-Q4M=^?AF\W!@*M!A?F^S=U&N7VT3H3[ODMW;UH7^DUA_?9'?6TS
MM]M&DFQL<J;C3$Q^T&(F?FNQLK/IA)R,X/<1>J"+*7*/C.TC9;6VC<=L%3)/
M]&<A"35-#OL80ES, Z_(55ER]E,FH!VMQ@=LL#:K3@R[,^F'H["4>;V%97+8
MBK1@CCGA;!05=V1O89J8_D'9-JQIX*P9=A(QMRQ*\IG@9"I'AF)SY %#8*_/
M:,N;U!U^>02SBAY6F"]$M;"Z0SO8+,5=468)GQ$&P>49=?5JR6>*V_\&?.QW
MXPBT(7(:>MU07D@WE!Z5@9?;7!&(PFMC6[8@_SN(S*&E,M7Y#,]P_ZW;R?AU
MSQ5!UY^7(+U59OCXS2N7C%M9UET>62N(CI<69"C!:L>:(7&.'\2(L6O]9?>*
MP=L0@$HXSMK;SAN39,-OTR(S-*4RLK"?-0EO)3/O;15$'V%ZG+CBW4JZ[=IM
M%K1E&6RU9ZF]:32:PBJ6N !KI31\'=3H#,.0HLG*1LI,IB:*8,!'G,^N'!<1
MIGX3KW4P]O:2P\>!,D0BD$,8/06>+IB*@^IPU&G!X&,&;$,F HEXN\.LC6=*
M6@E@@M5!DV,]V[O;OP,7P8TJ073<#.^5B2"@VP"1VYWU8CN/_ZA%4B"=:>:F
M?>%*B(G2T*W>A0]DY/.+%&7_FZSGQ>DI(Z2WC>,2T1JO;3OO$ -HJTEVQ1&N
M;7 GI2H>BL='=-%I8U4P@CZ0-M<.2KH&S0DRC.$?%^D)%T#"!+X+%6>JI DP
MLVP4MTRKQP<TZF444L+"0D 5YJ+NKE.,T% "J^["VG(\8(UR_A TRM^XGS?V
M@2%YA76^SE2ZV!O)2=ZU#$98.8MG7VU;7K%^*)8(K,/]LF(><48X&L8]G[JG
MGR>JWV 9A4C^#<8&4U@A6L_952UL'>L+KS<3!NMHJH6)'Q\/1FV%6<29#J'0
MI @,R;L)SG*= -T?:X<W-[HQ]K(8&?('["'::_2<76[R4P$+DJL1K$]\+!9"
MWXT[%/5]%SG:^D-Y15Z*M/39[L%0 I$%8PD<[Q%:*?)O7@/JPEAM^'F;#][K
M30NN<Q/+&-&,1P-(6MX:H5BJJL;4LJZ,ZS5MT',PKD;E_! <'.IM]E,JXZA4
MUC^IG!."3P!U!#[\"O\)1R!*!3=-G=G6;J66!U/,E<88<AD:&YG=@+3D4:52
M(P(&844%([%:JEB$Y$%VT16EI/=*Z!/-6$5F*]?3(285B:<<K'%"_YC@(B9J
M >O(JP@23N>>2)FFI%V.:&!RM!6G^E"UD!G2Y/S/@T&NQ/[.A"#&.?+,(D)8
MWTFE!D7-.C:D:0-,1&TE1M=&H)[O>/ELRPZL@\&OZ5.OE0<&X]1,82E*9/IR
MN)H<*YM?T)B6\, $C^*30.*/5;_NQ8?R_+/1Z_?2;EM/$^9/]"VT,'[;32$A
MJ1]6%91PQ$Z;S!U%]BM,<K#Z><P:/6:-[I4UNAAZ63-&V!&\984=Q;],W>XI
MJ?8,S17\D\L4IAK-TVS$WA,%Y@L$D<'6WFI)\4[>]4GD_BS@U6*JJ<'-:QTJ
M/%BN8G&5KV"RWX0W!.O 2R31E1_1)(W^\^U;FX].;U,P_G%"Z&;X^?CRXAF.
MYB<PLF#?@V]7PY?&4?A1W551/#^.QN?CU]+RQHZ5]P$N#!@I>:KX[Q]46OI#
M00WU]P+CBS-ZYL$/-W^_XCA7_PU^5!-T,\$&W7#1M8DRLM)D0V[=@%""_-<^
MN/[APU7P-JX[C:PV)?9HO?%_F]KIQT2#2-I%%"\%')/*7F'#:U0ZTDPRQ"9B
MF%WT+WK1=V@YC$R+F_5M<%RHLJ>MI4A7NQ-&N)2_XLZTDA-^]PY.0HH8_HC]
MTXTY'%YC*''@77XE<X>NO572%$R"#OWM??QPA'MW,J!'87!D1(&0\*^*X)YH
MS1,J0E=U,%%RR9J(2C FJ:ZTMZ'MQ_* 1G%,!3;=JVPA;-BJBVYI+ +'DXNO
M9DQ"*QDEEN>*4<B9TK+V5K5?:]@I+,"(E%MBY7G.P7K[29K_WN2QZ;&8ZBE[
M2^)S6+S(5-N6829L:YT.Y]F2%83N++AKY'VN6+ZL513802:) "_=+!RO+7O+
M1$B-\THI/CLG/ /&%O96ABPE2GC.5.:F;&KB=6@I&\<.%Z'O!1E"5QG67"\3
MX,;<URB*WU%L,PFCMT)C6WIHTO7B-E@CS]8;._]?GL5F'<*V:.K!,<6(FR/T
M=6?K!WU;F%W&48PY&,3<)";Q50,Q"H@XXSVQNI/NZYTK[4XUPLT].:1I;O*0
M=AF9NL&QE!D.]W2XH;&B94J (VYXP\/@Y]Y\>/O+U9$I^EOGHP=\EE(]3>;^
M&DM?GIL<]A854L9=FO"]A4\6G%YOF2V&XH%FQC8J;6="$HJ]N$3>I23RADNK
ML/:-]^K,X;S*.>L1VIF("I<S2J3%.M(KKV"20MV"MBD6:<5IO;LY*"I.R^(>
MP/O8]HLA $\D1A]:&0G8'"S-> ]O .94I[)503>@S0?&F43]J$TF]I)B=,#_
M1MUWA0P,"V2'8/!)TL1!*T^O<^3ZZG1.P:P_<3B^%QPZ,D(83YE0\GIE[)/U
MQQ41;<!91?D8<FHQTN8:F,)?L'Y5P[D1F,MRDM:E@3MXIURW-V<PE\?1QZ#N
M-AR3"Q^#MP&R2(E<!09@+0B>P#RD,W2]@[%Y[K"Z=T6>15;@ E)LTP<(A8LT
M8#30Q4/(GH""P"IM7,]W#BC#RN6ZL.0]>\JEH JBP9*=TI>[()F9X+%GDR9H
MQ=E>M<PSP%@SJ9BJRZ9B%\X%R2@TCZ+E2YHGZX%::",%:Z2:H4,_0+69DU=D
MF6/ODI6)*>62ZYGM&4*8K%YHM+/='PJ?_;4_#6_=C.Z9#\EW%MHIL';_1C@)
M)T4C,D??PA&>: -)V1$PXZH3UJ)C9%RFB,$-Z]XQV5'K #(48O27A\GW,WF*
MB&'@1$FIZVP/90HYXFEM]'HLP1\R7NB0F5"*4@*WA4QN[[GC'39OI9GUK7\
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M(PR@@^WVC? CGDRPUJ]Y<O<)^D6D#4$CK8.*H \YY2UZTV PI0B:CO*6^B?
M(UN>Z:T>]87<^$3&PFX1*@M55^8(Y';,#?%#$D$W%JX;+E5*:&(K73-XK\MM
M#S^\]UZXJ1HT]3$M3/Y-G\/N,*SFO4>M^\8P7QQGHE ?-UG%/WW.>L<FL2D\
MT.H$@0OA\W13YH!]B+[#=L [< !=$+;OP*M)I071\D%SS'=_5C<*?7=/.2B<
M=&!:X3641I30TX*:+A5E*[XE=AQ7[")N0''A1R[%J6V&O,?\X6/^\%[YP_')
MT!.(XP$0LN[@]V/%0:S%JMJ3_KEQ8!ZJE)<6<!^,0S8U#1K3?*"L8>?[80TS
M*0 LZ+,D"FM3CMM*.C?=BF(+\K(]=D1A.X5M<6 W]0@[%%=((B@2R)U@]!C<
M$<K*9C:@TN3:B&[&!PUV:6!: HI/TH]_;\JT2M+8UJSFXNHCG6-B^IMUWJ4'
ME\I8F[[9P5+/M 0KDIN(5):K0>'#L.J2T[O2G87LT*K8_E*CT#/D2 75/U';
MEI$K_C'#$NK1M0)@([^W('Z"T?0F40+H:$W"(O8V?^$NW&^GC_OT/J7BY,LV
M# B;($Z$Y[\CQ83H+#+IN4%)V#"Z1PZ)#>YQCU?J28*0KR+C0N52T\>2R<5B
M*WTKT:6U3_8E2#Z7C5)9^'UKBR!/+H@[0^*Q(*'4@7O0"N6ZEP 'KHS);*0]
M)6^Q^7ZC< 1.DO,FXZ972-U*_\C1W)0A.SR<#[L9IFB>[44T[402R'A$.:>1
MU6\,C& .&P:42"K*3]VT</_!;WW&7VQPW&YVB)CF IF=_#08W@+DM-%!MLL^
MS[#\=I]F O9]MY02$C-^6[4PT=03FAI0/@I':)D-V,,? %GQ=N/Z5Y2JDM,@
M5X@SVF.6_N>"A;STFAML-Q1L,,TT%S- 1ZQ[-PV>I.>HQ*/Q*?@-0X@8'H )
M/$.>0<F>DJ$M?M(9[ PJ?I:0"*D',#W(M'3LANOM-7D[(0GC1\A])/?3\UMG
M82U+/JE:#5_D,!1R#M9$?<,JV4[%W!XRN@0S[=V.1]+- 6 B4.R\19$P_!RC
MWU*L*=4.Q*-A9M[-.FS#.0=J,/07)0UB':0?@;8=@7<.N>Q_<P^ ^''[YOX!
M&[;SWKZQ*=D/E)(=NK+^ V"]':-@#Z><^^R8JKE_D^T3T"5TVV,BWU)#I64E
M7";NIOQF4>1W6F4U*9J?5%7!3F_ \/20!/^1I^A($0%0A82AY"K+G4SXPW[<
MN4TKN0]:(6LJ5,Z^FVMR**FA.3)- PVJM!/+]]$&W;B 1S!([>E]7J!.3N#7
MGN;8DI#'5U2N>10B$CBZ">IQX1I!!*]B-"[]NF(< O^($OR, C#(?&P]A91"
ME?!\$-J KW8LB.R;R[G#41%3SF(JE&')$9[5($<3(G YHD!K[5%:'G:A:H;U
M-WP%F#*LQ']PA:;K@M$MGI[42]W"P05'#2;OJ+I.$6$6$X_ B1DCEB3IN@!(
M]4DP%:GVMC"O$+)AP#XVZ;"ALM/EM20+S6<[,E^N+)C&#IOJI,&N^4?#;4/A
M#%_9Y+.'RD& "=4$P$;)5@%!"CV*X34&P<.>";%NH=LOGP8QMAWA2WT(GXDC
M >C"CS#[)W+>Q1J-A#@LS7]O<BNC4C2)9$K+$@%['9P1VVM8_NHW=S'O9?1&
M->=J5>.7A<U->>H[W8OR9'U+/)A X2:;%'DR8*OE]$'P?S$++4[HCX;3[;H0
M8G>122MW0X+'A- 8$!@FS>NOU"'. 3"Z:Y63[T(-_W8YJ)T<S]B)$1BKG&3Q
MO*"#IG1,ADR.YSM3)1\:]EC9R4 (\/W^^7'HHV-(@_8%I\T+XCW\7_?$HG<9
M3KN&QL,XD(NQMJ9F#91I41#D$(T:=$VD33;&Z<03Q.&9VFC^:*$QVXRZ_S8M
MZ\:.>ZIBB^T>F6DS=,3XD854<D0*PT["$B!-G$FS>S%">4ML&";!(,0FSG+R
MG3Q4N(1#A8\$#K0*-ET^@^G+]:R@OL[4F5S7=UK2#'8"!9)A_F8<!^R%,ITT
M:))9825H"EX.1AML(/I3M"6_RGK3"U=LKA5CTC?27Y>,-WW,N3_FW.^7<Q\/
M/>=.W2P)5..*!_/,K[#R,+]![P^/OJGD#L%+[&.W=K=],$^BU)X*0>,A":I7
MC2\!(L21&;8=^,*+#RD3)0S[*28$S60%0^F_NNB,07R6JDWG0[%W5SV(YG.3
MS93-)!H^W"0J^^]'X!YW@[[SN/(\2'HC^FU1KOSB1?S30Z/ASXN,F#(P\4!O
M+O,/FBY3L64/XH&$XQBR(?@@* !O6AFV81A[/B>'EP>T^\L>KZN>> T3>:$;
MKA-IC(!1W90JK-T.-7A[0\=7;;JI'QLA8R#&RC8LP04E@O4=U#5TLI+Z-'?V
MMP'6">TX16;:&W!PD'PT.GTQBDY/3D]& ^%3?Z24WS^E/,48<0CDS[S/5#Z*
MWH*\+G)["/BA@2UXFU%_61-%K/WFNB9)B[@8/!D1!!(Q#H P :8)E2.W#?AX
M1R;ZL=#:9/MMU6\0J#$9S=.^:F79>\9.)C/(H(_[,4,6U--[H]YZF[J8L6=&
M: JK,/X<?3'D<^EA5#0CBQ>5GDD,6UB7*(=JU_#&YB6Q>_8>BQ=\T#WUM=Y8
M#C"#$>>"W<$H8)/;GDH2L&\),D[$Z1@<?W U$X6%@*N* Z04.:0>$LNZ9RM)
ML82!=6,OY7JHA*]NU,&:1^^)PF_/7;.NN.E3/F.KN!V9-7YZD!L8N?I"C)AB
M=(*B!TUN"&)#-%/?:^\ RU\K:_@YQ:@%&=4JZ:"H0)>@Q;*"4"/R4MJFPSHU
MF/&?9@U7*[C0!F>]?3B_#7"0BV+",[:#*3L<Q71#[4SIRC =FK R;Q2\SZHO
M;Y4NPL"82V.U;RX5;AC+F0EP+K4L9WXU*V7D_"_A%+MQ9;)7,:S'Z66KE\D%
M[%HX]L"O.T9V(.QWOVR'RZ2Y>%/5IA^ZDJP^UHQZ. #A+(7I?/_F!VQ ONK#
M;!11P&% W64L*H/U%$,&E*R<I;37GY>I'UG:13;YN,<[KE$];+XGN]VQ*]&8
MA>L5_LCQZ($ZX:#K'=4=HJL ,F[E(ZQNFJODOIJW#XFX;D)^,YL/T99Y=/#\
MT/4D9JUMF3RYT)K+V'KA-]P0H/BD6S,W6=E^$Z!;TMAF4OS5/:"IZ1^%L*)R
M0FG@9\$'F(%X0 ?!#Z9$7]'BQ+;;ZB2H.<1,&^YHBO9D" /"^.[&O6E=Q?OL
MR\[T;"XL9MIP:S4A(X$'__7(<[_@"9V[*YMM8:+I@_&?NG;/C\?G.YF>G=AU
M72Q?'IT=O\"?P\I0*W6)N4[@6& 1K/82"SGT.,+OO?:/\0/?>P[:G62P]UC7
MDJL:GE0"/R!"]X=@'P_ [3$:D?0AI2(1>6]0FTG13%PP0"C" C>^8P"U6GDC
M+4G.#/$!4<<D['H@) 1AL.1U+]R_%;L?L(/^()B"KA%!KTLT]??5Y[H'/#O1
M;I=3[STWR)%M6,\56$$"0QI>J-R9V5X!O?\#CSB/"II;J5?'&H!,S<R)28EL
M'IRS!4#I3%5<@3O!A3YHZ,;(T@D#)W3,@3Z>'8^BXV4RQ>^/ZW0ZY0;$5)%%
M!F^N%OK04(34-3S.&(X:6Y>619[&\.@T@[L=X7\/1Y'M<Q$\WCS;C=_.3XW$
M<H*PH."@L!8HRF#;](RR9[\,R,YDFG_R[_PE$+C])$3%]KL<O_K@5PI2%A1;
M[.3,F@G.QH^P:Z+7F<H_P>5GZ]L3/N;4-^;4\9W3Y-^?I&<7Y\GX\L6)GEY<
M/HO/3R?8N$B?G9S'S\^UFK[XKV=/OE(>GB?P^^\FY?=#3W._YR &,IC$0L)7
M>CDRTY4':4KZ0H/.L^;L+(8>K)\M&2T"</K=C;RF&M[QJB;%[3WV]05*?W#>
MC"_"G?X[^$[I=/6-)_0_D8FL+K%P N>R&JU]GR&.GNC5*OK?Z&.I8KV*?@"#
MZ!-<^74/Z.=KAK/+[A_,G/:_Q'J)'J($K%GU!S'VZSF"B__>P%F$R4S8?@A
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MP"@:&9N6-EFTIB?<5*@$G8@"]E3]U!7H_MHHT'-OFG6D*<%[C4M8HXANJ\A
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MR.0R-]>92B>*U9 Q$>JQ9P>$+F!))7K<S9)TAD*9H*.M%?GXQD)7Y#/8B.$
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MN#0 "82[B)@9#F#B@IAMQ8T#3Q3G[NS657_2[Y$-AR4T /& E, /Q#U7BC\
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MD&BWOT<DP*\<L]FY!(FP>1/*8UC&W\'WI= #._,%S.E4WX;]G;W;+/O,+Z1
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M>_*4$2H_EUZU^N2K?7OZ]"N]V\NT[<#!H/N&N>=X+_?N_G%%/\5%*1,U%_\
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M+JMC9.,$]' PEL81PA(^9:FR+ !U4W'48M;3J@5\R6(1C? #-P:"/%!9!4R
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M*R9S20\JHTC+5M54<,QV/"@6:W1AF&OCW&6IP]YI8<UYON0\6XF:+UB+?^<
M6W\)'XVT&.$F#Y:N*M?KW6Y6:Q3>7SRO5[A\G;NBUC&RD!&Z8V4V2!4^I&:L
MXLC169?&?#&.MG.<M]<1T6_6!]$I',W\#U24CGFZ8BSWE46%,!9T#5$$&@(:
M"1]0R;#$Z)0?/8J&V+;57#3'_E0>_.$U"M5VI&Z%]OZD4%#7R%FLS1=]G18
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M,&G=-?8E.[O!F^W.9KBUV=D"2[#Y8:NL2 G6NPLAT!^!#P]MJXQJ*P=,C8[
M4:4S2#&=5)^V\9+][A?YL[N%SZG/N1>T@:D@EB,^$P75#//K5_L'1U[?RO*#
MB_TQPM=%.ZUHU<]Y#5_XJVU"7H)\2=,PDA]XF"\">I^0S0TZWE8#(<LGB-8Q
M]#E8F]"GB'GW=]^?5NH3B14RL'%2C-<MI@=U:!<M2@XF&GRX=G8'3RR-M''C
MH 05U1!%52-RB 1Q)Y+,.O?29"B6R0I=MR]"&_!7=ALS!*R\0UC%8U,4H:E
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M>3;P]!1O]A3A_#EV8%XB3S8$SRZ6E1N4-7F\:\>]NI->(GKR7U!+ P04
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M6MAZ2Y^#_JDT"#AI>B*'!(386U1G'U5.'%F.]92AC34C(!)>K9-29UK:.4)
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M@)AW<T:OI%!!D55.JARJM10P\0@@+RSD;0!+LU3F4\Q,4_ ]K7*%6N#[)@Z
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M3JHFY>G!<>!*HF+#(G!*FX+OH8T@?,FQ3G6Y$)_BF4JJ5*V/_&?O (4W(,V
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M%BMEXMO=@)/:PG%VLQ6YMSNFS^O^R$2T.^I"$S5(^4]UT9JJ-RT5E;"*^J:
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MGRR\%[(?8<9T[#OWG(\62WL>SFU<W/4<SS__(/)_%U22Z9D#VWDX_ZUE#U@
M=38"W1N8[F_I "&<"9AO]^(7 _N_#'O$SOG/43R:(K;CV"Z;C"X>DOJC;W?L
M$"11D'.?SJC"BDG-#;:+@&/^MD=;?C38W,K!5I@?FK8+7<_MV18.Q#8=&'H^
M85< 7@_"OAT &T^I;]XSZ##F@C>P0\(7T[7 9T/'[.*/D1WVX>.'4C8K7GS\
M4)8N?O_]=_R4+P3^4+H (^KV(>ZG9V,-V^UY_L"DWK#Q(&Z;_>@ZD86E/=\;
M+ Z@P[IF%## KRG[%+#$]4+ !G#R.' :3<J."\(^@_!AR&@2\]V$?3/DA3Z[
MLX,0:0E_$O8'@ ,8^HC9(5;R%T B+*[C=#4_?PK-CL,FB];Q?(OY&5P[QQP&
M['SRY<*R X31P[GM\B7@E2X&IG^'J-WQPM ;G.=QO>YQ->RNZ8P1@^-(7#Q#
M>D&,$3_T\7]KTO.X6.!%9Z&U7)85"G)Y;:DH2&O+-K::$R2QN/5FI;P@E]97
MW=3LYK*"_',U-PY6$N1"?NO-RH*8WWZK62&;S6V]U9)0*F:WWFI.*$H_AUN;
M>\P5MC_6O"#)VV^UC/M],APXX_S G[PP8?+(54YX161%P=!T_SB1\B?@>Z/X
M1_;D$>MR6"_$=K$:!)YC6S#9@<;E?&/=]$+H#5<6#TW+0M'B/#O\ 1*RNJ7]
M[S'S&]B6Y;!M[XJE1%NX<JO6J_A_"QHU,!HHBVDMI:4UZA\_Y(H7MXVJ5M,J
M_ &]4&G46[I2:4WWB/%:S4">_160)X0HT*<L%(N+P*76E_85;_C2<%TM;4C"
M%%B@5?%[55T+M/+NHN:;P:^I7*F$<?1I+$ N,?D7'H-U+'YL@-N6$'2'X2JM
MQ4)Y^^!Z!W@JK\+-7<3#]=QQ_ORY(*?+V,+X"75(/\<=Q /,"L7\W+-XM>.'
M;[,860&F^]GR_E5O"&O/J'L^\2:V+DF/3FZ/"?R(AZ_&% 10:S6UTM*^J%!5
M6NJAXIW!&%PZ7O<[2(7*$^@G+8F#1_Q[H67)":"K?[8U0YM*\LVV7KE6#)4*
MA$-FA8221K?/K,AA;X"1VQ)Y]N&,DQ>@J3?^@7R.$"JE]< <#AT<6<=AIT>Y
M:'=HHB" 9AAMM0J7WR;K\K+V@M7C^/A!*I"^_/'?%QE3,M L',QW36[:!R:@
M&$T]<ZGH566]4BA_I/176HTBGH"JMUI=,UJJSND=B"][89_Y9 ]RP0[9  JG
M1S;P7#:PI*4["@L_QR?$[-.RP1L>%O8+F)\Z_N>L*(+F6FS(\(_;9:#<,R$-
MAO 5SP&>A^2>$S-7].97,^CC5$//A6J%7!S$]?K ;.Z(\+^R1FT#JFJ3VU6N
M5>6F=0T?/\BE"[ANWRIU,%3]BU91#5H5Q3!:^*#"]=VZVE20<]=5PQA7T%6C
MV:CCT4VI_ E85[E22<&5GAH8C/3XS2M=J;<,:/Q65[6;&[ANM U2HM>P([AL
M:S=5K;X2#?)2/H&*/5M<MK"5YLP]+X OK[/+2]F=W]=+>&97;A$%ZE7<X*LZ
M8<></:ZA0ZKN$<V'/F,AHH87N>$#_287#W(6^3][B$^MN8/9YH/_'@#E%C=M
MO:ZT_I4&K5X!*5?.9N4\IZ@P=#]^R"-)+#CG4-%B)6&=+$(\M:56KNN-F\;5
MMPF7G3T!XT]Z6%%N+W6M>J4B88*8E>2RG"^6GI DEBPMOTH&(A'!R2M)WN^)
MAY>5.8O"8POY@A9M ]N4EMCF$0'V!@$N!:[ KT+*4%706NHM2-)*Y=8;+/L>
M ?)?KZH=> G#<R+!8K<W3$E$?H8;H# O.W#S0$/'77&C66"W9U;,*WE1RHH5
M[.6Q*_*SB72] ]/N8.;^T_P^0/GP#Q:2N&J'D]>?$G9[.F*.LS-1YA^DX$C,
M"W;*@VP?R)MTI@"E9NM6W.@/NJO$O0\PKBD5[49K?5MV(%VI-I5? &/?@1.?
M) G0NM:,F/LUZC??0&DV;S35@%9C=@ T'I\ 5SJF[N>*_,3N5OCYS6UA);_B
MRU0A^*4U?$/C$4"KS\#L>/<,W&C083ZS..2[=AA'8MD!F /2SEL4>16P$'J>
M'_;!=D$C>YR4$W@;?2_RN;;.(K5=,&3=.'@,WP:?=9F-2^KUH-'K,1]@U90/
M#;(\(B[DH$N_EPE3H-]DT@D/9%)>R.Z4(!:CZ" *0C"[WUUOY##KCLTC,8]V
MY%3!PW*'OHU('GH\8'$='=@N+UZ@+:QESLBK\P">R^+V&=*-XW@CBO,=L+#O
M60%7"B?4@"_QMYT#<LH\A<L'W&P&0X>%-$WB)@&4..RD?'H<M!I&ODNE?\7_
ML,+09L$$2-,U0."4+R#5X8W.5HUJKE\W7 %F=OO4YL.D18\O?A!UXM#9N%U<
MIU27-QVPH>G3PN*@40R@DI Y[,XW!S#JVQ0WZ_*X6.P'>\:VN%5SC!L+BT_S
MFXTE9KZ! #5%NVGK/(#D6Z.M@U+Y9[WQ]4:M7G%%+F[JE^0)65&U+WCP4?#)
MM0K-&Z6B0E4UM*LZ/Q#5&CHOX"_&EKQ&K:;J!C1UC<H:O/B:]U"O\F,4&$VU
MHM4TK'ZK?"/;7?NF!5H=OY&CW#B.B@^*MR6 UB.DO;?],&(KX/O@18"0L'T.
M@&[?=._(H#.&L>GXS+0>9K!.XU=:C?B]@?D '?JP&'4RA3)"/(9]&NG.N[>)
M<O@J+K^!E;_C0CR]#(OCCE'/#F+,N<?V%PC<&S*.D6L(_7$0\GL4K_;.]TBB
M\(M*I=&NM[3Z56RJ;#;U!A)+;"]!^E"X.Y+/_A,A0EM);9%[!XHGG)#W&I5W
M[>PFSY_=)L<V?H9#_CP? +1@,3=F:F]#($NNUAJ_3(<^Y.JKU>.@D%>'4=&U
M2^3PR-9C?5ENI2'PK8Q^\IZ$\KT$4Q0%<1TKB+NVR4<J/,](14%^*_:@K'4[
MX)A<N5;J%/W*D8XP._;=;K9UHZUP\27V;4@9?+]$62U"X=:WPX?3&'5Y?0,,
MM44R3.MZ#E%!T<E7H:K2LWD\AQF.3]\6E>0;\1&[C]@=8_?E!NQ60;EL?%&A
MWKZ]Y [*4_2;X[.(\F-67"4>KJNU&XHQX;7'SLVZPF/K)IB>XD(O'@-CN3>@
M@^+0?" )$^5DN\O2%)KB>RB#Q@(KB9MI8&%7.%U))NEY:HM[;K>N&SJI8G$7
MJ2DZY&1!$N74Y>F11HXT\FS;R>8=P&BC',.]/)4;4*YTE7\GPL /3C=:'?%R
M'D?G\7.%EN,5L7*/S"OK+=2'2$%[3"_5M?320.:LST2A21ZT@6?9R/CGM$13
M&>FI0^<>@VEN7S)/#^W@^1YT*"I*W[=-%$84RF!!0CY4L))O=D//?P_VC]C\
M\1Q3#V3W>;(351@I1@/$Z%B-:DV2E<[T]_#77V\VU)@*+=;U?,Y0SR/D=3Z]
M-9=0Z T .&?+&.N5[2"(9E+_48U\*/(R&<ACO5MS8D.9^>4OI_I)-?P[T\7F
MN4&P7:E!P+IQZE5F<JZ1'MN8"%GF31F\K>Z8Y9)9Y=]8D=*NDBEDU&<^@QXS
M [OC,&%?G>1:Y@_*25?GUC*^RZR-@BEFQ&RV($LRJ4BK[;J1I)98*!>S<OZQ
M[]W^P <9R3#RAUXP,\A]_"#G+EP/6480\N_0L1U*QFLZB[(FY>/U-IN9=WOV
M&=!<9/1#CYMHU1^L&X7V/8,&,2V0<F(N"QFN :FR^[$ZI>+P7,5Y2KDJ9\KE
M-*AN$/E$7(J%.QRU5&E\0:0SS!X+'Z#I>Z%'[)>[MM28Q0$Y$W5(@X,LW1A3
MK3:Q+$\H<U_]U#/0'G)3YV1F5T)I'1G5V9T7VCQ7N>9:*"0@(]+Q9\"E@@JS
ML?F[/86#%/L[S?PSD&R(N2*WMF?8Q[EW+W(<H(TH#6:(PB'0).*4\)P:)UO_
ME8<;HQO;GA>19Y^ID4C"=B,$A2#L8<ZF8K)3SX\N0S&()R4?>R,0,M@N+CE?
M?'\0(SV2?[SV4^>5J:0\=5"PIEYU987<&"1125/3U&+H(;MA8RVQE<9* ]/&
MQB)W_"CV6G!CI,-WNW'P+.OUV!+362]./CNAZSL-1\HK<V'-+:UUPSUVR/^&
M5#HMKLKQR7'$#?=5UC+Z9N2"_F B+AM?FN- _2H;1K@+7C%WO.]%;L"<)\*&
ML\7W>TC9M665"BM1=V+-(O^7..]"<CS><X@L!MHG9)3'%'"OQVLOA7E;?VQN
M)0_$AGZ8*+E):<5G'_"_,./03^6E>CGX+/M7O9%#L8$C,,/(YP??(?,#LI[$
MEI/_SI24JTP++YQ*_$C6:\BZ(HS]CDEJJAXF*>,\Q_&<D[#.[%.RDG1$P5<3
MA7!G:=<U\I@W6HB*QE@[JVL5Y5#Q\?(;+*<66N2>$V46:3<:W!SA/\4WW[$5
M8M<66"J\#\:*O%02)$',KQ/9S_@-;G,3CX?YF1!^"2B;RAZ%V^>*0IY'4WGQ
M!8_G/G-,4C2OO?1P0@RS*F8'<38*EZOLTV5U)4$L%+9_H5A.*,KR]N]4DX6R
MF.PRLB><S?;06ZSILWO;BP)@L1(2(C<*"&42W*GSM,OF/D,&]_UZ5=%YR-PM
MR"*D='8O@"1F2O(I<0,$7=#U[4ZLTK\R>-Y2LB&E<B6HU/13R,M"-K?B-IT5
M_.>5:5L6"I+T,Z1=+B&QK"_^J3OMUF/4)O:[#IR/[OA,>'5M[F12I^_/1G/'
M,AV?F=\S9@_/K^>F,S(?@D<RP>QZVPG[7^;<ZZ:PCQ>1RHD1X%D7,";'J^<T
M6Q!R;]KJ&AJ0MYVBZS#RQR2\HIE4?EJ]';O%&->JNO[NQA?.?+:?4%V]W^EJ
M3=75>D7E\5)XW*TV*FWNBW2IDNY_#/6Y8\.31[U]OGHP(=3&=SHFN<UQ)='O
M@$)GUT":32!Z'N$U@U<R ?.I ^XK2]?<SCA)/M'0 ?^;)?Y>,<2]D8\D49#+
MV[_X.U<6Y(1W23_OANI\8?OWB1>%K+1]J:OT(J?_DB"5DK6Z^E*/TFZ><<N)
MJ'!-MOG7C_M_2S:;#%0\B):2"9-27#E-OD<=/FAX9*>FQNDGYB\!25T>X30'
MIS\IKI6B65.5(USFX$*&-HXNU2-8'H&%LG+AB2RE;A$R>YU )QGHE%O*V 2I
M6H(K.[=YJ'B&1GQ[G;UYYM-76M1I),:Z0(R,5$X<BY'4[WSWP:+6C;;.DY-5
M5=QA6NH<,)2:BMM-4V^T&I7&C<&S_]54E/F4F[GCEI%J5%IT<YIT"JFJ^B5.
M;9;4JW/W(90R3]>YP559SW:YX4L )8 HF"3DM /HQ@% &6CC&_B<WSL5D->K
M'>)'%#H\&8OI,S.  </Q'0[$I+40XR$N=@]I+(8'3X1Y.!//;IQXU0Y"W^Z&
ML2^,$PTZMGE@ ) W J#K#0:>.V*F$_9YO$HSPEW& ]WN>N.,F0SJE >:^2[<
MFKYMNB9H@8-EAX8JN8V00G'(MW&G&2>E50;82==T<8,:>&8:KB)SD)Y"C#X7
MN<P7FZ"Q #EZZW"@E]\(O8'M(I^=\E@[!@,!\M+\SOPQ7-)P[8WHR_3W/TS_
M'EGW]*?7=P.Z$E()/<=)PS^Q,1PYZ(SUTG!K6R/S80+C--3->S,(S&GMIND,
M'GQS4IGZ^8J]Q[\%.)RUZ*Q="V62889B&V=[HDW)F2E$+5@=3/OKL;)IGLX,
MR8$-0T;1V5!.<Q$%4L.HX]A!?Y8Z>U)=9W?(GRGYLCM7CQ*?4<4TE I0TR$O
MEDOYQPG.]GGUNFM7KT))M)$#=UD<FCJ7=B7H4Q0BS[+] ",[[/.HQ+O(MNCU
M^4P"DV<4J'C/'LACON][T5T?:I3H Y$ 6U""[UCP9\0"'LF8GD]?;L6(0"LU
M9#ZN]X W-XE"GX0_ISDJ=&=#]'BZ[;D'(\__/G1,K.MX<61Z #-DH%S0V 4A
MV RCOF*5..2Q90;?H<:_IN:^7XUG=TJ!N/TP' ;C- "YXL5H-!(":JX7MS::
M-";<>?<+21408?GO \(J:RU6&;-%"=;@U3C7>9Q4.^H$(5_QV9)S+C*/9/PQ
M95"_\\UA'[!W*IU?_X 6R'1QD>WXVG>Z3Z#+6+R!!L21XGSZ9O<_D1T[4Q*F
MLJ#O.19'2(N$_9AM3/!#F7L9V4?DQ+'_64$2)?!B]L)CVW'H<X,!<V3Z5KPE
MF)0^@V;.<.OILH4L'/@^"HP1C]E.3[ _'L$(A\5#Z'A:1S_D1#AF: D.' >$
M:2H"$<$;(\7AG#JSZ],ADGCHA8A^* M&%-L?=+TAXPAB>]8X3&G**#F2(5%Y
M)%1O#!R?HF<< SX+ 3\<;)'70I4N8;#OW"DWF<]@DH9%2U=ZDIC!9PX2$^5:
M6LBV #W?&W!N,P$^;J,=VT%!"'C(W>+6Q>F_%_%3#U#RJ]A:;5K_CH(P%I/,
M$ ^.G2@NH) S2N[:H[JTZ=E^-QJ,N>2=?4]S\.U@?"_!H[D(T)RB27.&)G%F
MM>6[XJ@-L<1_RI.(HZP,*WPI#THI>GB=/:F]7SF:%XUW*.6$<N$8[W",=]@?
MCX>Z48=B/B=F1"DCY;.9DE@H'G"H0S*@-'@".N5F'.H@%R"5RY0*IV ,4;KP
M_(T1#I(D)G) .T8X\(F;W>]W>'QVK<QX<7O\WQ+W?KW0A^(60A^*/Q?WL%H*
MY5<,OWCV "GW?&=S\O9-*$K3)-[(/WXN#QM\_%#*2M(%_%KBM3>8VIH89>9X
M(W[DYHJ_;UF)5(GW>(3GN=,>38UK"48VBN\=DL:M.-O#PDF)J[Z69>Q]]D"5
MBT*NL'WW2PFED=SVFT4A)_\\=IN<M8JBU,OWMN4*GD3*?^$A;,_58RZ@^SF'
M_J1L>;RIO12/VY0'1Z%+4>AROB7NP)E"\H/O+Z[E+[M9+9_CW@[WMRC,OB%J
M3+>'BA>$21SJ7I^<G^E(]X; _/LK ' '7!7?DI,Y$SL77)H!^PE7QATB^Q<7
M#6MD94R2MF"+L(EA BNPC&/N[@!G(:]/(LI]70+="PQK<9O-C8E3@RH)_'YP
MI,G-$&/=?I7=0P-'1+<4'*GS2)TOC6M5NHF=6]V@&DM["Q0+_PLK=HHCZ2ZE
M V !,_UN_TB[1]I]/60[$N]6X(E\L#$,CJ1[)-W70K4CX6X%FE?\+@7E#2CW
M)[7;\UWLED;TF.-I+7KM6H*=@]\Q=B?G\5Z@::QH(24]:.XP"A/YEZSQ-=A%
M*_;K.P#_BI=?\<52&D^J/";XM\KE9MXQD F6\MO;__-"4<R_8_^ELXYG/>!'
M/QPXG_\?4$L#!!0    ( .- 650P/(/8@N$  '4\!P =    97AH:6)I=#$P
M-# M9&]D86UE;F1M96YT<RYH=&WL?>MWXDB6Y_?]*V*K9WOQ'*!X^)G9W>=@
MP)E,VX8!G-6U7_H(%-CJ%(B6A)W,7[_W$1$*"43:^2BC3/;L=#F1%%)$W+C/
MW[WW+_^[TV^/?Q]TQ4,\]\7@[O*ZUQ:_5'[]];=F^]=?.^..>#^^N1;'U5I=
MC$-G$7FQ%RP<_]=?N[>_B%\>XGCYYM=?GYZ>JD_-:A#>_SH>_HI#'?_J!T$D
MJV[L_O*WO^ O\+_2<?_VO_[RORL5T0FFJ[E<Q&(:2B>6KEA%WN)>_.;*Z*.H
M5-1=[6"Y#KW[AU@T:HV&^"T(/WJ/#E^/O=B7?]/C_.57_O=??J67_&42N.N_
M_<7U'H7G_O47;WHR:TR.+QJS,UD_=FJG3KU9=\\;C=/)1>/$F9[_LPX?^2O<
MSL]$\=J7?_UE[BTJ#Q+?_Z9YNHS?/GEN_/"F7JO]GU]2]\7R4UQQ?.]^\8:^
M%J[. IB;NCP-_"!\\Z<:_;^W>*4R<^:>OW[S?\?>7$;B5CZ)83!W%O^W',$*
M5R(9>C.^,?+^1\(;X>7TSR?^FC,8Q_<64G\=?U+WTX,W\6)1KU6/:W_Y%1_8
M,BGK8Z>P<#)\_M>V0L_Q<[[Q//.)QUL_L2W#V/$68AHL9IX+KX<!Q3((D:8B
M$<Q$_.!%0JJ)/#B/4DRD7(A@[L5()<["%:%<^LX4_O'DQ0_BSW^";:R]_?.?
M+NIO__,__Q/^VWQ;I1_K;\5H-7T0_)Z9!T]XBUD0SAU\&PP>\=CRT]1?N7!U
M%@;S] =,Y-1915+ GR7O2,"511 +&$#B2M#7E#R^$#]($:^7$B=AOR9^<&*Z
M&,I[+XKA!,$_D>8C 1^P#(&>8W@H3"U)]3F[9Y,:$'SXM_1#YM&__25V)K[4
M(TR"T)5A!;;9=Y:1?*/_>.MZ$2SL^HVWH'VCA][.G? >3L$DB.-@_N8$-OD1
MMM";.K[Z"OH@OIR<CVJ-ST@,'Q6[^LWJ<I4N_1J[F]<:U=/F1>[56K6>>VWG
MJ,?5>NWLFP];/ZDVS_,?W37L[FNGS2][<N?'UJO-TY-O/FRS6COY]J,VJHW&
M\3<?];QZ?M;XYJ,>5\_J7T9;N]]X?/KMO_6D6F]^^U$O0#5X'@W\2OP@U#=H
MR0!<Y1=Z$%A1M'06?_VE?O*+"(,G_D?CEPSK\N4LAG'A,1$%ON<*+:S4=6*,
MNVZ(@^76RTO'=4$+>=-8?A)U8'4;HC++_.:>Z_KR6XO[K"C=+NU;-]W;#OS?
M6/2OQ*@/:EMOW!KW^K=__M/QV=N;?J=WU6O3#WA#NW\['K;:8R,CU%XE2][X
MFB5_YHH*_&^S>G:67EP<?4.N!,OOO:[;591ZU2R6Z'7@[TXW=]$N]I<T7VW]
M!JUW7:0X_.\HM7+//OZGV655ZL>.=?M&!+K'ZUK/I<+FMU^NGX!.ZXUMQ+F/
MA)C/'FU;-:6H-V$$]0N^$/^I7L ?V*B>G5B_\7;SCZ^S&XVJ, )M4X#=]O,M
MHH)/? "CU\\SIEOVA!_H\(_:CF95=*^NNNUQ[T-7=%KC[H]*=R>5V^"QTJ@U
MZI^AO?J&,G@@ON^T)\=5,>S^]UUOU#-Z_.!NV'[?&G7Q0O5'YH,C*<5H^B#=
ME2]?@2*_E<)3! OGI"H&P_Y_ 9-#@BKU9L)9+GWXLHDOCPY*T?Z<B=.JZ(U&
M=]V.N/Q=[\OW#2QL_XX__ZE^BB[V[/]^EV]Z9B#!-LOW36DJ A/X[>1\4#O)
M=P>='$[Y'[039V#Z=&YZM[W1N#NDLRZ0)P?Q@PPQ?+007BSGXO3HP )>R@(V
M_','1>%%.EFC43MM?5XC>$43H0C+V&JW*ZW!.U$1[?Z'7@=4^=&@?PLZ?44H
M+CP)_W9Z?-80O=MQ]]VP-_X=[KP;CD7I\JYWW>G=OA/'Q[7Z$=[7NNP..]WN
M+:IP'_#*NV'_[K8C;CJB :\[J31K]68N6V\<'T[$UVQEIWW3$I?]T;A_BYMQ
M?'$B1G<W-]VA&(V'W>X8?^3+ FZL-6!+*HUZ\_PY?O#&9ACLW(K)?(>=^V,$
M,DYLST7P.9C6K9NN:,%!:G4Z<$!'=M"L/Q2EVZ!:%J,XE#(NBW:P6L1K_#>"
M-Q &\O^\)?SJ6O;3;ON\ (MR _)U>-L2=Z,R,*9V%6D[!;/!'QJUFAAWV^]O
M^]?]=[^+T7_CC^W6S>6PUWG7Y4-0;UY4FB=GGW-R;H0QOI9\:TB\O_Q!RNW/
MQ 4O6I:W/AM^3CFI\ME=H[[![@X$4!@"N*R2<[PC2J-N5_3&W1M1KV_U';W"
MMA=H(?_QAQK@WR.J^RR%8+\%7;T&_ RD7=66^>1][X.J/=SI==_OF?UV4:__
M]^^-6KL&_]XB?E]R1O/!0?M#F,4_\D58Y1_?'JC7M@FX9KYRO]_3J5U46JM[
M#/8^GPGL%2RK".<:W9%"G _&-[6=(,M]/=5%6..K5KMWS>ZQ#"ISJU^R^1TH
M]F= QM6K8OR^-V*VU[^]_EVT!H/K7G<DQOW$\!ME+;^M:,]B[L@7B+73+Y=J
MJ9W\#6[&!Z*OVL-7C,L(,7Z0PID$CU(L5O.)#*5+*S_U8LZ)\B+AS.4"<ZZ<
M2$0R%K,@C!^$MQ ]#'75CZLTQD.P"LF[YJ*;+5K**:=QP=TBE%/IP98&,]&?
MS60HQ+8I_V@K2[EI,2U=^6>9,*;<Z4D_TQ"KGU0;>Z6!,8G.5U$LG.G'1?#D
M2_=>VD1,>8=T*B@M=AEZ0.1Q0*F#>>? 6]#EU-F"IYSD>$W6(EA('E_"N?']
MX GS;.<R?@C<Z,]_.CE_^TR/]09_V[M%+CE'XG(-PF:^]&6,TT1N$HES6KOZ
M25FEC\:K<(%7_\G_#QY8>C+2BV3V !;GXJTH36C09-?PR?Q]@QV0SO0!QUSK
M$0/:_&@UX216'A?VJ32EH2.Y=$+<6/AH4 /P2BQ]>1\Z<_'TX&$&ZX(R5.$]
M\&882RZF4M-&:O-Q?LFW,/.-JN*JU;N^&U)6QN_]NZ%HM?]^V__MNMMY1PY<
M$.J7"#!L=WL?P.)IP2_ONV)PW6IW1:<[ZKV[)4OHJC^D"W3C@/R^_:NK[G D
M!L,>7NO3Y??TAML.V4]B-.BV>U<]>/RF]3M&/N^NQZ)W"W\A_DPE)]%'T5A5
MT9LAT3YZ8;R26]9W':P$K(07T@),'YS%/09@U!H[?B@==YVL=1G^Q-W@^^;.
M6DSP/Z[$EYA5AA7GM2_#N0L>/3PYM(N;=\##'V$C/K\-Z>]FTO,BIIQ'&#]U
MP(.E)(K,.>C5?*NM..I5$>R+.J8AM-O]N]LQAM8I'#@8#/M X!S; )IN$3HG
ME/]> 1&ZS\!+[O.F[+,5TK2M$&V D#4"G,9.#TG%:D>)XW9$(<O>6-V,Y@OP
MI^T.7M$:(:]K#WN7P*N 0;'+YWAK*.NUPE;-@F1Z?0_47JU:R[.F^-7> HLG
MO*G4SZK-U]) 6M4\G!Q1<OM]ZQ:3(XGHD+(9W#NX&X[N6B2(22$3I1%Q?M Z
M5J"FA5Z\/F+2I>='8M0=HS0>O[<(5;2&&&[O=/$WF\Y%0N/F[EKK^2+E0-T'
MZF;JOMQ!W5W1NNQ_Z(K;NYM+0K$:\K/X+)"\8L4=Y.'#[M4U)B'0TPH!.VQ1
MYI6F]!*I;V#0L 87H<FS=-:H*X'&YTUE&7,7P@"T*5:]4'$J"QE/JT=;CTG9
M/FW\YKOQ^SYA[D"*7+6&XKA9K=>:I<NCUSLC!5*9\L-9A_.\Y^>YO5M:C>Y
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MP481Z\EPY[0P-::'XO;$SYG^B79MT!N#2O.@;_UA61E3AD\GO'*"HAQW,UC
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MNY*PB,?\^Q'KT7JAX)-;R]#S80S]7&KH1KT&%F I#NXEVL)E.P:)4Z!/MQ9
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MTR.L.EJ6OK.X7R%YL)N4FD^0:SU>,QXA6GG<7,7W')6ZS:5@=&H_)ZU&J4G
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MH!WR&VRGZ 1/"YV_D%1 5 D,Z!<P+&*; ;+9+G:+7I^R_BFKUR&['X/'W'W
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M>8-FZUM$6/^WD5FCU!NI=J8D!D)2&&ZZ7WDNPYURX1RPJ67<:CQL#.9 7H4
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M!0S"M@@R#:2==3 %B5\IA91'GXZB8%/QK2!1B7SO,(86;U1L0)=4'Z MX\7
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M9CPZY6WYH_IL?>B9%C3J@*:W_.0B?ZOWPVQ_ 1+[XH#$MFW]TY\ B5WR\MG
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MY))IV<#9R2_\QC1NQ<Q^XBE1C;:N+KI%Z0U6,WMK+96)JY07 C<_ O.<%R2
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M&[LRHX>FIR;&E^>=&YP -ZT'?.9*/=&GPP_CV<*)(AI0#,^%<ZI8].B0+\T
M#]:E]@3X2\1=?A^8"_;TX%C(%RTWMF&))KP9GL5I4+6_>?BXOW0M@OF&-79I
M#*[OQE26\>?P;LR,[N^WPS^N^[TK<N""4+_ !,-N?_ 9+!X#OOG49Z-KH]MG
MO?YD<'5+EM#E<$P_T(4C\OL.+R_[XPD;C0?XVY!^_D1ON.V1_<0FHWYW<#F
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MN#<Q;"'XRG'C'$S!#CH!:VB( 6 ZC?,S5KDQ _A\6F5-4.'!X)_/N:BON^0
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MD"I]I8)NE%;KN'%4#-*@J7J"QI,(+""T4,6HCM%)V0E%285IE3;40>48]O(
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MLDHLI?2I1T,8!;%J)YVT8D /:>072,[EUZC3O( X2NH;>D+I1I(3FC4V\B7
M9;WM<6 ]4)+@MC2_PP=(:T<A8NKTD.6:"RJ'33P?PKE!P6_/WFB <$A[S_5
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MD2:^TW CO%B-CDEZ^,M(IL!4%=:4=4X/)MD;U)L>)]!)3_M:LW5X9-(5!ZW
M]/TS3(+CJ0BJ9F*G4DJEPVQ $=;O-G4U4D:\YS%JD<7 UMRVTK?^8T&X.-4'
M)-;IW:0*O-*JI<,>^'V2K:I.:$(-;XAS&5C^PVX23^M6CEIE&YVFM.?+ZK)D
MFA3:7H]:9%^/)5,YFJS>2M1GM6;A-[5$VJPP8U%)YB9I0HDQ\T]Y-6E3R:M4
M#%\M Z-P0)7W:!@O*-E<>CWX5V#66P=D"'I.&'*X=8&Z.*'V#XFY32:_RC5&
MSDXMFAYP]21I*!,H>;L.SF+02FYC/ZSH8>1Z8L.E])KTE"@T0!B[<E#%(6TS
MOU["P\Q\[/DJ)S6YHH6:U&"TN/*&:5Q=JZW3LJX2P"S1[V^+K#1$L!0QU^;P
MU?*36 OG]S\M_?ZH%S?J'\#Q/YA+)2/KNPQ='T<34&*!JK0#?J@:T*V3#F51
MLB>J<C63/J]9MPNY54(<76CKI+;$HC2D,W)DI6D=RJNU0;9:_:Q\!'&TD:!4
M?(NBWAK[I.P"T)O$J*&L" &1I/))*,TMU<@$ +1U7H@1#_8Z;Q!]A *;![D<
M:$-*8R- T2G"EMT\3?O?<1C)Y FM25B2\1E'>'9RQF'&*VFG$"YR+?V.-*&-
M>D85SPW58319Y?9ZRAH=T(U61:F6>CYO1.KS-/]-((0(8"2[!O+Z:Y82*9(@
MAE%H=)NBY9J!3S->4XS3*:F2>;#(SGFUER5$M/:6@]*MOB%$M8:HML]%MI3"
MV'>*L)EB;H6]V"P6T,%"WX\;KM7O:4(F;;J+V?(RHRR=]9*1/*(ZC.[3U'0<
MYQH\REB.IOEEM;FFY-C5+,.D1!(KP$X:Z\>W!=W7Y-YVFL@Z@M ;YL$KD+:$
M?XIR\$3O<.REJM/(-@B)Q=$T88M+8R2]?3_:RSX7*3',H?NL!!U$HN >K@PC
MG)5'5E>&02W,+YS,J7OX'3 /PYM")P^3,=+)":FSDV@A?Y"!&^HU*=%&CO&H
M.#5>RQ1$8 MBJ98G&732.,S,G2@"+\D/>ZVU1]!@3L>AR$3.Z)9#OW40"\#9
MP@GJFM870C4.2[:/Y/PT09=T>4H3R?@^74-!+T"\S+Q(%M'00UPUHY%F8ZNN
MH'>3*^D#P];!84B#S:0>L_<PBLVC^I74;L=#P__OK9,W5%B.UH F&SK8OD6!
MPHR=B)EJZPFPNW>^1&W4NS]V^5R84V^T3P?VV=6/67:WD!O+T%SU\'>#VT&D
MG)FADTZSU_97?6$@]]?#V=K&4<U1O#F>%0?!RZ86'0J1-3>(3*K#0B:&.GG)
M4=%)L]BFUOM:C33"3BHD]>UMK*O(D&H!I"Z<8XS08SZ>F137)^$]:BDL])R$
MR<NY3Z*18M;SNN'@NN71QOTVGD92N2;>L53-@C;;71^42,YUG>:VF$W<I!/K
M 3;N4D<VFNF'^0^-QB6?->O-!KD+,[!$SU*]?4B;SQO6LU<$LV@>S=-ZZ=$D
MCV;C77DT<PDXOV,;L/ECO7<6EHCZ85)_AOV&E'.Q, 5VE])E:C[ZCJTZK-A^
M/(N2XEH4CQQ#W6&VL$;T[5#%$=WKP6VH->ZGQ QZ(-H+2;J$XY%-K@1+8H1E
MJ^*VM()60;^Y=%/:<)LE$BO!HJ&W<>$+B+5SH'*V]8>2S1Z#1;H NU0OYI"[
MI1@HZ@=8?A)PH=>I 1?S.* ;_)DK&SU3-;08;"\BA&N#'40A\@O7F$U5278_
M<Z2,1B-7]=6B(A=M.+T&2VG;2JV%\ID?@6LN"A*SS^WDEI$UA[25W%ACXN5/
M^E)Q%>IPU-P:;.+N6-26:FMMI\HRQSE?$OTSF>#K7E>M !4^*DJJ-(ZP:00F
MKF2I3EVP&=ED9[7ZXAI5$[#YM1%.8F*UG#GM^+9(J*HT?_ +J-:S=;3FR\H^
M5>1;4A:^:.+N42HN!9*2'$STM\5+RU^0O^S!H4K@4.8;9.9V2?I+VD-H\*01
M['-*CL!Z#BPSBQB.+(E8](3&[@+PX\%='13)Y4L#\LF+XR 'D> 7@#4G]?K"
MNC^B0\)=JI :PFVI6C68!YS(MGW/%U@8LLQ+^1)5XE)XA5)SIPYTE+9,<]_6
M,.]9V"6LG[R[VYHV2GY-W4?Q..;4-U0R!]G0)1:SKU0YHTCN66N#FJQ<REF1
M]K/F89[H[6O6N^B9-L@UK3N& H$FTFVJY5J;Y*77R:NPK.8HKJ9!',UEW*RF
M(-:L1,RBQO=K^7,<6T%;*M*+H68Y)6@S:ASP-8(G3GQ0B)DK_\[5*O=\?Q?4
M[UG@?-][\V3N"]?RJK!0;="SE(9#(4P;V3$:S6BO-,X*T)=%$1SBM%";6[!R
MT0(5/JSIO)+.GBOL?[$G/.-Y?$/?DUG[L4B>YZQX2R3/F7Y@8Q7Y*' 6F&([
MX31 M((F 3+T^MFO9+P@!XNH_ZN9&5X(?*]_9Y!U<7%M)(5(JF")K SIU M$
MSUF9"$E52$R9)^+&I#$W/4_6PM$[J"LVMDJAB: 8-4QM"Z&=?:MN?C 8.2LQ
M<IM+KXA':95'^9U'^8:6R#:?%"J%0NG;F(2A5RK%823:XCA1:NB%?'NG/GV4
M,*;3B4[=<@J F   %Q-3C=(T@G162J(*'W(53VX&Y]U$+XR5G%]TTU/"10@)
MT9J7.EM1#KP'/%^,J5"6(&K\TNCV/7)3++#VZ]$,' 0O2C*P$\A.QFZ5]!#5
M D5ON^(L),PY]J7">:6F[+J.8]'01L7N":+C)\Z PZ('QY,E8J-LT8PO1KZH
MKNF( 9AJPD2JB>PQ$U/#*3G-.G1 LHF:+2E#TUDOL#*T:(I4OO6M5B_B/Q[1
MNOZ!58"8X?%U:5([;8(9W27H$A,VXF![22_=3&8<I61%^*25+]NH4?C4B]R5
M/A<$QP7+!H.DBJ3]ST(Y"%K/=9$M?FA)M,!P6P8MJ=5R@G' L>,[12$1Q\6:
M*1XI.[VO;W]+ UQ1"84Y'*KS."YB<Q0B+K?;ZU)"##4CS\1*90ML')>,K2EH
MG1NCB1++/G4_JU"IZI#]J7:6=*83#6!A0>F/S7H!L//Y/&6%I9$?8?LHX6%+
M?1*:WY$FG("5E36R-H:5IUT[-@*UVTVK0Q3CN1&W0A[ROFE>&\IF)JWBN''V
MAB%QC"2_H=Z75<0;[5H'8;&GL/KH<*4G_ATT2+!_OQ'2$]FT+FDZAZS&F(OY
M=Z"%8KW[6UH%:S3H2+5).GQM/L?2&JW4O=6JPH+P_Q-ISQ^QN9V[TES#R'+U
MB&^/6YRB-#26D,^"6+:BT6)AZZ[KM!%II[[VSBU2>1MD6<6X.Q+1&1#V\NJY
MJ&>%3Z"GS)U(E!"]*&?KHY/%CV(WAY$8]+%S?)HY.3X'G<JS?:]HO_P!1,EZ
M_I.G:A'2[H.R& ']">O,9)OALCE_<XLAD'$>P"NQO3.Z#3"8+#KO:Z%MU,TW
MJ^95K&Q]34G9<92O-8F066K/"M\%,#C*UL$V-DFNTA;^B0M]>G# <J*]RN1.
M":6D;VH8SX0%CW::'@W?Z.*<P##375Y;$CS -6?<53YG^#4MW-G/<Y,FB2:6
MCC)=*[+Q#)B!CBA)I]GE%(>\-@Z="[T@/;%5IB<2ZVI]B/3$9F[7_Y[O)>EH
M_:]4,U.8+,0=Q8&;99'**RG'\YC*V%^EBG8FVT_FUSW#I1).3YU&:-(._(3>
MSFW]0[;VQK)]RHLD[U.B\)O(P6"O'E/'$V"'RK3S%;6#OC<]Y26JW%X-C[+3
M"VUUM%N>5T66_&]NJ98_,O')%CE1@@%3_8+P_:R7@ N9@54Y\Y4^;1TGULI>
MFVE.IYB:@[DA]LXUX1YA%U4I3V3-3T:L%,U?FE]LIP&-P@Z/^(*5#L!$T5A/
M>M5J]$$.^D]J=H%JFI;X,A-@.R'UCJI^7^S_\!KZKV^G"&U'=[6V+^A^7K*A
M8K0LK3B/^^VI #PHO_VJD?0><5>[1%/23"&K5"=3"\(HME>R\2$R)U&>I<='
MJ9>5NGR*75RU4:P5;>PS,*LA,$7T^C3/:)YQ YM!1D^8OX="Z%9-BAEX(4AO
M',X%_-%P71[<BSS=@4=3DW%T0@]L LP>5-.I;P?&H*<&'"?ACHD?@Q6FG$!J
M@O.8P[T!<%&<TAMR-WG(Q+@9=Y.'"%T 5*;(AP.%BS^/*&9PQBKX[&2*:?+U
M!(&5CL=>$\-;8C8/YJ-H6#US1-L8-=0EJ;>KA#0K?NF:>FR)&E"2[0)R) 2P
MA=2R;*W+2YJ *61)DH8II'_%>J931.$,GY/2\"'#I_VN#)_O4QWR:\@/:"L?
M56TH@(C=6UTHRN&\M^V\,]IY?&_,X/%E1D0!=N1\?7]&T9Y;*@##MG=,8-BJ
MA"M72JA5%--$[K0(=[-7)#F_[#1'?L,?6&/33!;7F@F&^5ZRX8@JYY .0E3I
M*2$.\]%6Y/H!@V#YL IE0=:.--?JFG,HR6NC.49RP(3FC4SKIW8\=,-#J$U,
MSC3"7^^ +TQ,._%\5F6=&DU73CS3R5UHW52E.\SBSJ,<RYKQ;*[9I=(.JB;N
M15.?F;ZQ<!GM>:7'5P4@0!&5)MB*7'JBCCP419#X$JW23N2>.0LL817=WK_2
MQ^QP5:VD%5BGZCLM+L4JC[GC<IDG*]V&F%DH'T6.VV0"\QH2TJ15%XPA>U>H
M3AR"YL6D?:JZ8=/--IC/3!)*^X![J^S&M5$'R@Y->^M@Y-1^5(G=JNRV ,R&
MYS*;/QZXMVZ0B[ZVRJ6KLIT5M6:3E8O&=N>YD"C:3NYS=S*1B)D.#M49G!8Z
M,N ,+9>G#3LQAU>ZM$SVZ/BNUB*?LQZ?TV2Q4=IKTBA(=Z-F[L0?S&L6LP,M
MQ/B18!\!NW;" L0?I\DH;-5W% 1V[*D.3&+.5\(_Y;1KVJC\/I#%!]@KY<'4
M+D_ZF5(#4S$'$T</)HD>78XC$(2H4%Y.8L:^2T)A%%!J.T4& <A'\NW9EP,_
M78 L"R-1J[V>2Z</)YOY?D@O3#I/XYN39?HLY)15K\\4P4XF^-SD7E);GK F
M1$O5ETH12B?=^5L7SM_:EL:I:>*&<%E* GF =;K: /9=N'509//2YM39Q!W5
M8GS7=@&R;CI'$I2  ./\LF!?P2M4]<4*X=(37,<,.*QC_0C% :>J2?OT5TRF
M26HI"F*TY;=9SH(<F35\"JA6*9WAZ8CQH"KFC8/M\ =5+I/I&(1P?WKP9;O[
MI6I70@]9/X@"F8CYD^W6LLTX*8 59"UJ-AC!+.F'Y'!E]\"%HF>+*S!9-":7
M!4'Z,)>$51: NB?][G0PO&6_L6-V/9A,V?"2]8;=NYO^[7129?U_?AI<#*83
M9MSVV'#ZJ3]FQG1J=#_1[X>_O6FF-$;KP"&;3Q4AIO2QPT.=;T[I_=__7Z1@
M)L>"ZL(Q[,LUER'_N_KPJ^V$2]=<_=WQ:'ETTZ]9#.[ 7AYQDAB8VQ)F!#[Q
M<PKB6EV .8)%1;9ZL_RY1C_]3V1O^>VTUC@YS_VY7FODW[KCL9UV[>0'//:T
MUNFT7OVIC9-:L[[?8O^'X"M@#,<8@G3_/[^T?ED[:4KBKV,./P/R<VRFD%G^
M'OG+K3_+(H"_-Y=?64.51XA#MTC;W4 %?_FCB6>[1=.3W;;9=+7D"15(Z'UH
MP/#0"IQE9I)7"1;!4?_R>A AN?&^0=8SHRQE_53>P_#?5NWT- LC?/H;0"BG
M4.7K@S-S(F;\=$HK G2ZO?%U6$)FFU^A<WB,J!!P:Z0UJ.B9*KG3/MSIHJ3!
MK0KDLT4W);ATTBM9UK? K9.6T)<<ZSE@&5%D6@]DUL%[7A'CWA&,)J*[0O?!
M=#Q,D'=<AYI7CUS3$QUS0.UB1KU1+\&WS3M>LK%O 5NSQ7Z+7=*ZZB4/VY^'
M-4LBW,;#N!4'6/:+3*N$T!8(G99LJF13/X]-O:)4?$<PZF&&P#0PK2\809WR
MQ1(;<K->8,Z3N:PEX+9Z'BSNEASLVUR#)0?[%@[6+@EQ>PC'9&/\HG3$E];@
MZVFGS(COL6-*R:5>QJ5>,>[SCF"TO3-R"2'-KBGY5,FG?B*?.BFI< N,I,DW
M_5IE \^JL0NP#.\#/Z:&-Q%W<=(NCLX<!?X2EKPJ@5BJ7*\%MI.2E7T;*WM%
M3^H[@M&(!U0FAI4<8KBGN2*(W3@N#R.< :1F:)3PV^:F*;G8-X&MS7Z+ ;?*
M5(B7,;&SD@B_C8E=."[549:!QCR*?$55_R-QLA:;8$.9[TGL4L5R^?#Z0'B8
MY7?G^R-E"46]S\-X9$R2<OUK'D4\*$'YHS6\[X?;!^:<6XS9_Z$ZU'T*7@^N
M8/D%37#/RR:X5.5\\A&:X/8]FX9YQ@N:$ \?NP^F=\_#HW>#T&?-5T#H]EFM
MV=Z"T^^JY+U9.VF]?FEZLUUKU$]?OS:]4VN=Y=^ZZ[&[?SMI?=N=.Q?;J+5.
M.J_^V%:MWGG]IS9KS6;[U9]Z5CL[;;[Z4]NUT\:WX=;N-[9/7G^MG5JC]?I/
M/:_5&_OA@+3^UOAX@P8J9A3)1N<7%OA/XH_FX5:@+QS;=OEKB\ZSO8K0C9O^
M;0\[[F!WGLGP>M =3 ULVT,=KFZ&O<'EH$M?X 7=X>UT;'2GN;I[H_D]("^$
M%KX.U[S69@FPV* 'GWO]7*"='RYJOAG\1L95'S$._YUL<_X\3_XG;V9_'S!<
M"VEV'S(\6\][)@\#$?/98ZY%UX(GR&_PA?AG9HQQLW;:T;X3QRV^?)O3:-98
M(M V!=CM<-^N>87;.!G]C373;9W"2SS\6<?1JK'^Y27V/_S<9SUCVG^O>-=L
M'/]FW!XWZ\WF,\C7V- &2^S[08?2KK%Q_Q]W@\D@4>1'=^/N)V/2QQ]J[YD1
M3OB6S)J?AY'O(]"P'Z@[-38:#W\#+H<(5<&9[LE,B*-2*SH<FCBIL<%D<M?O
ML8L_U;F\A9<^KV_R#UG3?J#)V.6'IC45@0G\T3D;[2B[01=<2>4_Y21.P?;I
MW0QN!Y-I?TRTSI G:RW9G8@OV,E1R0)>R@(V''2EHO BG:S9K)\8SVL$;V@B
M% &,1K=[;(RNV#'K#C\/>J#*3T;#6]#ICYGDPK/@?T_:ITTVN)WVK\:#Z9]P
MY=UXRBH7=X/KWN#VBK7;]<817F=<],>]?O\65;C/^,O5>'AWVV,W/=:$UW6.
M6_5&?BE)LUU2Q/<<9:][8["+X60ZO,7#:)]WV.3NYJ8_9I/IN-^?XI?B9P87
M@G'=J!\W&ZVS?1SAS<TXV)D6E/D!)_=S!'*C>? B^ Q,:^.F3Q,MC%X/"'2B
M1\V&8U:Y]6M5-HD"SJ,JC5V/5OBW&8D91/_76<*W-L]/6RD<4&Y OHYO#78W
MJ0)CZM80M[,5R?!%LUYGTW[WT^WP>GCU)YO\ [_L&C<7XT'OJB^(H-$Z/VYU
M3L^>$=:OGFU>1^3]Y2<IMQ^)"YX;FKM^/?Z<<5+EL[MF8X/=E0A0& 2XJ)%W
MO,<JDWZ?#:;]&]9H;/4=O<&Q%PB0__RI!OB/".ONI1 <MJ!KU(&?@;2KZ3*?
MO.]#4+7'.[WNA[VS;([QIOA]"8WF9P<=#F(6G^2+ .7W;P\TZML$7"M?N3_L
M[=3/CXWX_CA35/(<$SBHO*PBT#6Z(QD[&TUO\AN,EY'+[X/QI=$=7 OWV%I:
MYO;*TA^ L1\A-:Y18]-/@XE@>\/;ZS^9,1I=#_H3-AVFAM]DW?+;FNY9S!/Y
M!K%V\NU2+7.2?\#%>$/X76?XAG$9QG#"JCGS'SGS8BQGY#9!WG*B9/BXN> >
M#A,W0Q9R&AT>/>#\[@&&NAKM&CWCP8\#\J[9Z&:3HX?A)ISF$'"+.TN:9#^<
MSWG V+8MOS?( N0 20ETU8^R89QHK3:]IR'6Z-2:!Z6!"11=8)\JT_KB^4\N
MM^^YCL0T79NH@FK]EX&#$]'%0/D\.G \,1Q=IRVXRTS):[9BV.U#3E%/IQXO
M>/3@V^'N4<?/\+># W+%/&(7*S5V&[>)W"1D9P2[1J?*Q$CO* X\_/5?XG]P
MPY)FH L@)6<@1IM79O30]-3$]/F\<X,3X*;U@,]<J2?Z=/AA/%LX443SI>&Y
M<$X5BQX=\J49X,&ZU)8 ?XFXR^\#<\&>'AP+^:+EQC8LT80WP[,XS1GW-P\?
M]Y>N13#?L,8NC<'UW9C*,OX<WHV9T?W]=OC'=;]W10Y<$.H7F&#8[0\^@\5C
MP#>?^FQT;73[K->?#*YNR1*Z'([I![IP1'[?X>5E?SQAH_$ ?QO2SY_H#;<]
MLI_89-3O#BX'</N-\2=&/N^NIVQP"Y]^DU/&U:+H634VF"/2/CI!%/,M\%WY
M,0-(X$QV (!%M<*P;0ECTPVX::]26%?A(YZ&N&YAKM@,_[$YOB2!,D!<P+X*
M=.<_.D@Y=(J;5\#-7^ @GC^&[+H%ZCFAP)Q'>'Z&P/TE)XS,(?1:OM7V8=2K
MPJ7U-+"FH=L=WMU.,4Q/H<71:#P$8A%Q$J /@S)] OZ?&!#:WC=V6#A0/)/;
M6VA4/C3;K:7;;LIL(QL.^+->59.)<$]2=_>$ KV#J;P8C3[@ZMO=XLR8H(3H
MC@<7P.&!K0M'67MK /"M@GVM@A3(_0BF6*_5\UB!>+4#:J(7_?VX<5IKO15[
M,&IYV86$R=U/QBW6E!+2(6:+E.C1W7AR9Y#Z0FHLJTQ(7H*N%H-RBV.TC@3J
MTOT3-NE/48>9?M(0E1EC3%+H]?$['<]9BN/)U75C?T%<8G>)W0*[+W9@=Y\9
M%\//?79[=W-!N;\)^FE\%E!>LN(>\O!Q__(:2S?H;IDW/#:H8$UA>H647C #
MA=X;HJ&X-%>H88*>[%B\BA4?@0\ZJ%!84=VL,AY9M:.M9%+5J4V\^6[Z:4B9
MBB!%+HTQ:[=JC7JK<G'T=C12($=V?A"PI.<#I^?N;FDUN0.=JX]VM7'-C*MQ
MGSXC$<,_1..#6Z AG9YT6MKBD2FES(_!R@+C8"\7!X? G,>I*A2MEN1%6?BV
M XQ?\Q(E.M)[,\@^@F^A#UKIS0B$M('M$E#Y95VX*3"MR \^0EQ A 5>$@)A
MS2)O5KF(T&$8 D8+]Z+M6S%Y15._-OO7O]YLJ8(*;6[Y 3&:O\? *@.\2FM?
M\P8 U'S\TM_JA&&<:L.E>_6]Z&88.!;^J)&*+:1YZIM]92K#X-[TX/$4*+OK
M7K*06R0B'[A)7*,J8R^(++J+GYYE29:+X89_PXUL85*(X.F!!YS-N1DZ,Y?7
M]G7KML^*)H9N=*V"!)#OLEN*.DFIM%$O@J[@"]>WOJ#S!6]QO%C<CTUOB^<
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M!J[\6^QQ\3<FWEP/;AG@U,F'A>C=DNJE^U\?G)D3L0O,AO'C")] R2Z6:\:
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M+INPI;^,77IY ?010.%#1.)=J6D7IO7E/O#AF[?%\8$'2&UQ;%!#6%-E)O,
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MJX,QMPIUJ$E 9@DTB=AK/#C31YNL2 L9,NU<S@LH1O)1:Y?Z.T% ?W9"3%M
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M)K]DAV^Z#.04XOC*0,Y/A/6/#>0,QV5LYK!B,XU.&9MY4X(K8S-E;&9OA#G
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MG7JC8AY5FD>5BZ.DM,'W[2JI-4(7Z/KA@D>84&2(8.#?_M(Z^[6+?U79U(F
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M^_"% $K2!<&2M;9@,:0:)1U_C1&!#&A7)%0BCP"7:"=!U'VRB'I'JD)?'5Q
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M2:J&FHQQK(\J0Y0X8'U^R4:#1FW.7,OT/70YUP;2&*KMBBYU)FF)4O<T<?,
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M7:E[QZ4F)Z/40])#2#D_1#D\27=-"4R)35!\WXQ(Q'NR(WYMD,H-Y(ZCR,!
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M>@?OY_[R!?X\1<_N;W\#4$L#!!0    ( .- 651$N^TA7@0  &LR   :
M97AH:6)I=#(Q,7-U8G-I9&EA<FEE<RYH=&WM6UMSXC84?N^OT'JGW9?@&^2R
MAC 3(+O+YM),@*9]Z@A+8$ULRR,)"/GUE25[0QI8,FFV;2S\@#%'1SKG^XZ.
M+EBM=[U?N\,_KDY!))(87(TZY_TNL&J.<U/O.DYOV -?AA?GH&&['A@RF'(B
M"$UA[#BGEQ:P(B&RP'$6BX6]J-N439WAM9-7U7!B2CFVD4!6NY7_(C\Q1.V?
M6N]J-="CX2S!J0 APU!@!&:<I%-P@S"_!;5:4:I+LR4CTT@ W_5]<$/9+9E#
M+1=$Q+A=UM-R]'/+48VTQA0MVRU$YH"@8XL<3+#[<7+@>_Y'MS&N>T=NW:NC
M,$12<.A.PC\]::0CBVL=+I8Q/K82DM8BG+<?'/J9:"X($E'@N>[/UJ-R M^)
M&HS)- V4M5(ZH=*W0CR&X>V4T5F*:B&-*0O>3]35+)Y<=35SE=H$)B1>!A^&
M),$<7.(%N*8)3#_L<0E]C6-&)KH@)_=8FB*M4H^+PDQ93TQ27)KM^;FMIW<1
M&1/QRWOOP&WZGNVUG%QIQ6-ML(2-M1_+GF("V53"(F@6^ W9^HKOH>0!L__.
M^<9:YP>CSJ#?ZY]<]T\'&_S^%VSUGV6K9JBT4L!QC+_91AG"++<KAAG'0?FE
MB0C/8K@,2*KJ4TK-@J4Q%8(FP;YL?(Z9("&,"ZX4;5K\$-:VJT-;R"@0J&RY
M$-M*Y CT5+8O-7UOH]BU7R;S[$.__D+-S<8V]NVC_8-G5>LH(%A9H*1*AKVE
M%"4'/(/IL56WRC(91$@FLL %GBI5MO$#BA;6;=/QL[M<:[6CQGCR)"!T+%CK
M^GH11=XS>OL_[BA'VQ*:BM#!;,P)(I M_Y:M7A7M*B+W=<8(1R3,!W&=;>A$
MW_MI2%E&&<Q%:V#=$FY%?LK'!>DNX#0F")3N? =1#<9&3%\5HNTCAL*HP\@]
M!><"V=]@>)6XJA)$F"4S!!_A\_)\]#]T\()*JE((3F9<,&D/!%=BF<?$ZX;$
MVP+E 0Q#B)>>?D[&7XSGG!C0TSN$9A%D"01=F$(D;VN&0P,#0*-A!/\"AQ'H
M,QS#%(%SDA"!C<[W!13F<#_ H9P?"X+Y'I#S81N8S/X%Y!R&T8QC(;A!,9!!
MDNZ!@7UNCUYY ?"V@%% F,/[Z&R7\JWV*,T1 &?28D23ZK/?E5,^HC=:/^4;
MOVJZMTO^[9X<^1>0X>I'P"<&TQ";S/4:!"K)]&<L5W?ITO@E?8%#]0GO"Q@O
MY4R.V;'1,SF%0_7I_@JE&Z!+[;T?L'G_MB!14%2?\3/*,-Q-V^5:C<Y$I.&H
M/NN76$28Y3M3''3LWXSNZ"M85)_X*ZIV9GEF@WM ;6HT\QJ,ZI,^P&Q.PMV.
MK%&+\L$"(YR"DX[)=&L03"";B'L]B!F_-E_!HO+$#W_7.=UDOLU)Z:/!;@3_
M#MV.^A-B\POWQ:ND1UEYNF#-R_HK6JO'%C*J#VT$^=_Y@LSQQH,,12/N@PH<
M<QK/Q%.5+2<&BD]]#$,="&G_!5!+ P04    " #C0%E4+*_12?<#  " %
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M\W4WO"3<Z]_ 7;"13.!9 FGER2) QW0,Z[5QF8R0,;Z(RB2,LP@Z@=::VXI
M6NIXSE(XF^*$XB>.5X&08V#N+8U8BUSG5:0968P)0%\!(K><<?:$W(S9*%8S
MLP@-+6ZDL6C;+.-TT=L-*XMK")N%,1O6OB20&V4VN..15WM'M>#-B<EAS*F=
MDD&-T L)O6_R^DX^ZS&NA4,'WI;#6) 7F4!(#&-IQB1&TR8@!"(%^AU)$\;*
M9) CJM J]C"E6H4BPF7#]H%*) "S=WWW:SCFR8U@+61A/XN%R>F76I"#?;%F
MCVM!Z-)KIU-274]\H-!*C))V+7X\GF35HTNR?+61UYPO-,)"M./[48495$IV
M+89W(N6P_E-%RK*OZPB#I@E^<CSZ.)Q%HOB09^;I(L2U0P% \I4\>ZM,0P&R
M<RJ-RWG,$HG30YW'BBW6&4>+F#N$<_I>H53,V8@&)9@#MA@5R\@=O$PV-#*2
M7$O:@/1%QG%@0IHR0\3O4L2X*N$8 B<[&(0CEQ-*.4(KS&).Q(9M.2-6!002
MOARM5U%\&PJ:".Z!O(B^BVM^M@@:;HV@)R?I1B ]/;V?'$^(032W%";<X$!/
MC,8-0HRZ"(H=KJ,%CH@LR8<REG9.A67;LA35#G*'YO(<N:UV>N+\FF\HS72*
M:#*N$(:ATI$SP/4C-R)!?8L15!@1*44K34&OY0,'42U31Y(('?928B?,8Z<[
MY7'F4I0<*T8C.K!/X1*SI;POB]D3*,?_W%[Q7:A $'1A?%\Q5)E]V(*GD")?
MSA;4-(T>;R[9<-&.N>@7WA.PQR.-!5X*V-&"*+P?-_&@PT5>H=W(5M!WH <J
M'RH,,TU>7^/J+5HGREA<IWL&T&5"*/HK ]5#]?X#(B.$#Q+WWNS<<+2GPIV+
MZ,CDCIK>KM?>JC$WR\)&*>_"342."YT_<IZ:X_1S*^+\D'1O?O&[7?3=(?:3
M];T'._>]S/>[[@Y!M(C+XBHGB2+68V.5GH3N#D5NHU%9FL;1K%BES;*NN M0
M.<$!V@KQ#0(<*E0N&H\D['-*]A%!X!M#?(:_U#(MPE[\E4F8[T(\2]P=4>KZ
M7V SV\(IDYH"=Y\7=M 9()0"H.0E8=E4S@2_)8[W1=FQO&LGW V,Q8ES)ZCS
M_L^?H+:D,8\@:,0RBQ\,B[P)@0BP1:]0](7&H,J8; )DX!FWF9P]MY[-7UP1
M672;+=2*D4:J%.%PX;(;D+D[/3FV14^U,IFJ>"J(;Q-^D]^PTCDAB$D:J[G
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M66^]'M^"A"H;D3@K0I_<L@!N#+B@6EZ$WH31$$X9)]QG)()A&#*?2A A7(B
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MJ763%SX,+*_99XKT@\G)/U!+ P04    " #C0%E4SENJG"V?!0!93#( $0
M &UR;F$M,C R,3$R,S$N:'1M['UI5UM)LNWW^RMXONM-:UV5<XB<W-7U%F6P
MVWT-N "7&[[4BLR,!&$-M"1LXU__(B7 !KNJ<%F@<X3:72!TYK-W1NS(C(S\
M\?]]Z/?6WM%HW!T._OY(_B >K?V_GW[\'YW.OW[>?;FV,4QG?1I,UIZ."">4
MU]YW)\=K;S*-WZZ5T;"_]F8X>MM]AYW.])BGP]/S4??H>+*FA%(W-HZ>6)F3
MBR@Z2A;9 32^@]K%CE1.4#)HDX3_.GJBG!<F2MN)/IL.D ^=D*SN2,N'82Y&
M&/=?^8E#EW+1A732P$<$M%&@<4D5:5VA>MGC"3\=/^%@_.1#'/6Z?W]T/)F<
M/GG\^/W[]S_4;WX8CHX>*R'TX^Y@/,%!HD<7^Y^-.T>(IU='%!S'Z=X7&_@H
M)3M"=K2\/&0\FGRY.W_YE5U[W<';/[B9NCGB^.IFZM;\Z>X_W]D^GFV\W+4[
M'H*2[H^>=+;'Y0%I>#:8C,ZOGWQ,Z8>CX;O'%QNG3W#U9B:CWSU[>,Q;KV[E
MP^3K.W8'_(!4&?9X,L+!N Q'?9PP ^MU1$<HIL3E2?JC 5X[2W^8B;^;?/@A
M#?O3&Y/JTXO],+X.\GM]>6OR\;^V7NZE8^ICYP;87SM"AA >?Z@$^NQQ.OQ>
MKNU\^9[^Z(FDZ0C_&?:9NE]_V;QA^CS_AJNG^8(GU^ZN;OUT=[\'BM2?W=YT
M]R<]'!S]_1$-.J_W'G$K(<P__=BG":[5,W3HWV?==W]_]'0XF'#;[^R?G_*+
M2K.__OYH0A\FCZ?OY?%/__$?__'CI#OIT4\5ILXE&#\^GGWYX^/9J>,PG__T
M8^Z^6QM/SGOT]T>Y.S[MX?F3P7! ? /=#T_JCC2:?>SF3(/I1]Z^S09HU$VS
MZW^8[%+Y^Z-N,3IZ$C9':Z!80B0/I S)DB(H\]M&O17!_SJ?"#+ ?KTT=9^L
MLTW+U:X]Z^'1H[5NYE-F_>MYW!B^>ZEVWQWHK;-\LOGN\'DXV3G)Q]MJ^^WA
MR7;_<'_[9.OC+["U\=H<[!]VMYYORFVU=7YXLJFVU6'OI=[N'7P<ZH/]?'+X
M_.#C8?_UQX./6V)G8UWNO-E4!R<_'V_SMJW^P8?MD]P__-6+E^KP_.!-LCL;
MN[W#-Z_?;ZE?^P<?WW[8?O[Z_6'_!1RH ]CN'XCM-\]ZV_L_O]W>.'J7GS_K
MQN>O[<[SUV:KOV5V]@_>'VX\.][>.)!;;UY\W'[^:^^@_\^W!_N_'N]L_//M
MUO.MBV-^Y6N9P>'^$ [WWY[S=<SVR<]OM]YLBNV3UQ\.3K;$X9M?NP?]W>/M
M-YNPU?_E_8'T[U_N;TZV]L2'E_M);6W\HGXSY"A[BQWO8^B *:X3 ZB.M2:!
M]:&(X!_]5+ WIA\?7\/Q+F&]]%;/NN.$O0/"T3/^9KP"^,\ _O %P*EH+Y+"
MCF77S*XZ0L>K:#K!4$P.$S(^CWZJ("P,WU=\_F%>(7PKA,^_0%@($D$[UPDY
MV0Y8&SM1UQ=O'*3D;## IOG9P3WBNSE@MW'^E!$>8>_%(-.'_Z;S%;9_ANW'
M+[ M/B06U+%#OD '0.L.%L*.2 %DRJ"(7_Q/@C61]<H;]2T8*T$@%9H4G0:I
M<RPA9"5-+!B3E/:W%S>AO1#,3YYU!U5SO206MKLU2M@IK\>T/A[39&_"T45M
MVCMEME>7V_=PW*T*:O,#ZXYQ-_;H97<\62P=/FSOIW>'@W\>'WX<PL''%^\9
M;K-UL@F'SU^([8\5HM?BX"2_W=IX>[YULGVRS1!N[05Q\.:?8X95'YSLOF7:
MF,/^L_[VQR2V-YYU=_8WWV_W7\.V8FA/GKT].'DK=YY>'/.O?Q['?N[Q<W6W
MG^_V#TYZ_8,W!WK[XR^"J62V]M?5X?Z1/GSSS^[6FUT^UVOXU\=?)EM/Q=2H
M[^ROR^V/F[]9T)"T8Q[8VMH+1UV>BNWH[(4R&@.2>_33GX<Z__EJ-#RET>3\
M%4O(R?H@;[)6/*W(\><_ 'B]3&BTGMA^G_5J(+E!IR-BE"O ?.1Z?SB:=#].
M__P6,KK"QHOM"=G$!B<[!/ZG8@3V6FR#PI2,8D7&9I'1685H.2P*#%T'E& =
M26 [UL2(.5MV&]!",OYUR[C#3\&7&QQ-[_9E%V.W5SWAV6C$#[/BXUSY^/:*
MC]L?#_@>#WXST@C)]J)3I#,=D()%$1K!/Q1J-B[)&GDK/NY,CFET"5^7QA<
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M.LV--"97$EOL*)I;T*&=R,VQACYJY5%X;X($,)Z;GL@^*,RU::L6K*SXK#O
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MO"(-Y$HL_ &CCXF<N\QY:S9GFT29AA;%F*-3MIHP%^\EL\9I%^JZ4$J6HD-
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M/#K?^_<9CNX@B^03#67H"#\G$:L(1?;60O)02/(?L:[A:).)Z&:KP327//.
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M2A>=(3K*X/%BKJH +9I(E#L YCX)>@^R2T!'B[D,'H!W+K$),02RI*@L%!7
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MM'(D]8I&\Z71_OOADM#HJM]D*BUZO7JW7^\T^6R';^XQL2D7*Z)-*GO0VL6
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M!3XG)8HR.8 '86V+LGF;BMOB\W@+H\8A2+&N2$"345H.G#-HPY?Q86IX9;@
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M!-$(DZR@F 0V&5RR.-3\"3AH$5'6#X/_ZG1[.P?[.\$%,D"04(4>7X25/>%
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MT 0 2OWE&GL9L#^!$X5HIH+#%-:0!"=:TT=P83)'XRR)P->JM.:AP51#[%D
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M>O>FZ4TK<M4DI3;4H*[P9+.GA@<%?;Q&<"$ZJ+-W:)MEW'<.4:\/@_9!M]M
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MQ/>ELND_'.'T]) 3G0URX@$-(GKB7V</'U2!5^RAUP]E\VNLS60BH#OB!IK
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M%_&L EZ7L@X*0N6A+5K93>!<!"ZQTN@>=/:VY5G-" P_U&*DNY$2C,IR*9/
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M"CV@<3;"HJ^PY&'LS;G+AIVA5D-M5N#M+9YTB*MG?T"NAW/7>'%1G>$S X7
MPY%Y2X3.H+K\#5'ADFQ_XY%X.'UA/ Y*$=A R>H.S,A0[QT22A;/@ZWVMI_D
MG,0825&MT:,W,--->.ZXW5)0/EN=;5MW^.RWIZ#SRWE \)4@%A/T KNO%DFP
MU=T6\F-'@<X=^+8_V5[1JV 9 "+5J_A];_6V VK*PUR.8\F@ '&JL<2*XBBN
M[2I0!3OIODO\K:QR&QWYE3KR137[^K"D9Q7MN) 8KJI(3SU*J&>1X$OJDC.2
MINID:O4-F:FBD$8I<W]UL\!J=:]DFQ4?,CLRDRYK;L2I448YK,IN$TEE%LXD
ME,)[$7.TEV.4*I2W.N8:X#Y*)@SC'B&Z+X8T>21CUF25Z>*H=E E2G*X-H@U
M>?&2RM>5S3!367BB"D5;>"_#J^,O#7.[.B:0!_*J$$,5&RMY06@(+$>['3RE
M..>+45J(YD7+,PHY LU!DMEZ$M+O!.>4/*UD2[EUB?>:$]^<>YJ[IJYPK,-/
M4X@$T3B-XT%,D]XE:52I[=E!\";;S=<BKV^Y^YEV<8IA+==Z%^6@,$\MN#%J
MK#&MCM2GP#>U75N79I"8'\>FN@+U-"..+#F1XLZF^H?DHV.@EE86>8RJ(:NG
M4CKSNDX&6!%)(^]I;.L5^QH+9VZ51-%//2FY-[7^\':><R(53"$=:G2S2N*N
MB:^\=S;,EG0!.P%5?X$&S&GIO3.X@LHQ@W,"8I<JKZ&:$2F$2Y79B>(@5/I5
MA]5704)1'7MK##))J#EN\HYI3MF(6\;=&$G+VB\X0LJ&*3-F<P75(3H?RT\]
M<"Q;&'1-=5YD,C]OXPS\(&?@F/JCZ^N'Z^,95(%>K-MP5 =;F%EN:[I+I4EC
MOY;*DW>L=5H<"U[$-)C.RB3+/C'E5NK.C?17&MB&7#+7$[P$V(LL;P14CH@-
M(15?U6,>A><KDT4?1*<CB"!HT5O8QUS2/F/ZVS32>]-G;94EB:2TPGP1H$4^
MSM+034-2M9:#2\7Q1":[KJ+#MMM"3@%9WFN:\K2P&ER&W;N*K"WVQW/2%[>4
MJL0TS45&G=M*3*6XY#&MXFQ+HM"(A_:ZFOF_N6"%:WD2H:B/9F:GH8H(8&;]
MA88&WD0/\K/:;QI+I:0:V](@5W(""!WFN)^:7#B(\MG(MWWL!?,5:2AAP=X]
M3:,86E$3(#""Q5P/O;5R(?7$,DS(8C-5461AS);RQJMT5P33(H<JY)YUK]&P
M[GJJ'&.RN4$Q,?V>1WB&GH5S(VV\$3;#H>E19QD7QWNKORT@B7IZ%KHHCTH@
MJ)K/;T%SH6EH".)$A)S?81"^N_!O+.W-EO:-56L5L(NOT];;X)I@8D%[H*&0
M6;@QF!B:W63S?Y$EI!C,%V:I2S[(&[5,;=PXO+P"@C+%U K%B+TP6>2<T4WV
MJ%9 <,2+Q)TO;N.SU);R3?V2E!(^:H9A91[%V97!'#DBC"=H0I+;Y=8W*S=9
M")I)EZI*F%0)BDS8[-MP(S4>T[W?"V5SX.2,.98%PQW%%N-&I>KY'B8_8V+?
MA?#%^^8"!YZ;@>OZP[S2^H(^WH0W/TCI7GP=8FF]%;#1C_99G#]CQR<ZSD7R
M HB3#N0R49+BMWDMDVY3$ U$,F: F'YM0Z6YYE@C'?U0Q0F5?$Q- I2E^RZ)
M/^I@U!!EA3OH;'F\&(8.F/6W//N<2I*SPG!_@G%A]I<?UID*X;E;FDM_X?GZ
M;K1\XXYOON&UO#6DP<P'S(NW1LULN%#3R&4F7//("&,)B6J<V[F6?.*:IJN?
MQ(@0ZX=MF_.4OVG5PMTSW20+6M^H]C%8WF:9-8E%BVFEJ1VC1N;O' E4W7ZQ
M/Q!NE$V3#1-^$#@X0P>>IS%\11%S8< @=&L0OKZ^=Y;0"PIP@<(HLF ;W-*X
MLS'T9XG:F,CTU:#X2_<YDEB/53)LHIQ[T<.2F:H;_$2YA]KCZF$@G"CC<-D;
M-,D-7M'3PRSU-YBE373YD([.:B[!Q^'<U/=0.&^D^CGK)<XDT:0 ^$ W;5W-
M_1RC$C74MBTT$?"*5-+("_$T6HW3(DE1JYT=T77]DGW>"%7CL7C\PU18-H$R
M&CU'*'E3E+K"X3I>*0'26U4N:WDZU$*!NNRQ&.N$/X=EB8]5DVE5I?DLC8Q7
ME!,,/$[]"5>XNI\WF+[9#Y(9ZZJH>D)>".VZC89+346W"/HO=_>HJH[4#_2*
MNC_8*^I]C5=D=J>.!743L_^@DN1-;6D/2R;\K3E2B1(Q1+2AJ:F7)S.$A"S9
MIYO,DQ!%>NQ?J1[,.$MW^N9ME6+%WMR2S8(MR\'A#/0T-JV4 N;('!3!<@N;
M-58@.57LD>"6[''D9)>9: M7XB6S!;4TR@N-O80G<.V/)B)![6!NBE^Y'G/C
M26Y:A>'VU+4S\K!9;J_6@BSCGUJX1V3'OM'^V)])B"E#&O!=HH=3N$0LTNHZ
M(ENGTRO<[??H7-R5U+'O2!T?C-D*J0[?'K\]>G-\>O08V@EYI-(UGF(>J1TM
M,_T0W346/#NM=H_A"=4F3+#1L-X$S#4QBYB1?P:&$:>6=P>AAX8WSFO.M'UO
MXFU8YU@&_9#BZ_6JOY'%>1.=>NT5+9\RW*O3QY61GDK9:?9F#=$SI2OH;!$3
MB90A/,,SR*8T+J5*;HL-:EAG]XM?P=;QZ4LS" 658IQ'V$) )-,X<J/5:=..
MYGI(\SCP6V@8KHF9//PDC<Y+C\UQ";(T&(*C9"Z_$&\_\MKH*B0>^,/S"]?"
M6]DFVO_*\!#/\1-S(EA%N6[=XMSP.;/1W,K#?&0KVG(7H.YL-<7 8+LI@5RI
M9DE,3Q&7BX3;U](Y>1??"0ZK4PNMF-'2:+YP,9L2Y7=D7>D:3AF?!9 $Z1"_
M]"=HQ5 UF/&%M2-W^PO_EYU0UR0H4\9U67^6'N/_&.%#"%Q;,+4891Z>AQ6
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M2GS[]L8!9[^>O3A[??SF_-U9\N89_?3J[.V;\Y/+>X=%J3.CZN+6.D&;\35
M%)SN#B!*8$Q^6_"3=V>_/NV31C_^[].'1[N#6V)*W[ #J8L@Y/<NZQD6@KLL
ML!EP^A4S"B29.[:>BGD##&*;)7C#[G[W<CWC$1NR5*'NIG@<@[FTE>R"F_8,
MY6ZKI21%&3=EYHIP RT;P^2$G -2$)EQ!Y)*\1DAIEC7$@V]RT8@+ZT"/9*9
MT]D?(O3&N(*>=NQ@[(#H/NE#O(0 </65H^8G\VTV!PQ\(9T)TE'T4>N4PXB!
M,>RAF4 RN%V-E7QQ@;W&?GO)<+FPS@.,$)G2<#*.5PFZ7-)BB(Y/,-81?$QK
MH>!<(*EO^$ G*C5T>,NG[SQ[?I6"1^GPP0.D;1?R3U$S[5%%V@[> CTI W.^
M[(/DS",6?O/J;*U<*TJM?-/]8&VNC=Z&155Q;PW:Q3ICF'/@)DZS8IXHESAW
M!1EASR;%,A^K-X258ZR.=(P,>@O] O,[[7,Q#9,9<*L1>C9=3G#M<(4KMV7[
M=#/+@O1S]$F0U<5_0@'XN )@H2I]4\K$WL/],7.:"Q1,4-<@70+8I9+M6PJ/
M6WRFK74)DI \HZ!1,]DQ2VTCTO(>YV*BD?]"-L80IL]0MH'A"KX3@PJN?',R
M[+=*H7?6!N2L'%?&3?%K75W3 7^:<E4I*2T1PMLBN.7PN*XR= $F\D$^<ZYG
MZI4\!&D</G\? -O7^$8*^R^5AUV3K;<L['MU^POZG" *Y QF?+2E'GP^1_^0
M?9Q7?.J55A3M][CDLP(SCC):,"%L*C$1=#E2"U4$"<V9)6H#LJP^8E1BDN?U
M2'->VM-EPG%R(-4L"967'ZJ"FZKH:,A3EBJX81;J/U Z9A^D*0HW=]'9Q$@@
M=G$8H+8J1@2@C^C83!L9VFJ%$XK]'+;"YLHI.5_6N FNQ$AX;N>.E298ZQ#\
M!7)/DJ=<!60<CIK@YLX"+!G!TRBW\"[3Q/U!QXNL5L+]QE26=Q3B[_LH@^(A
M0O&F_*1<"%:N-C>(G1*KLG+5A U@C.RQV9GK#*#QD$?:722.4*:=D">F@PM7
M]3N/67R_^=2'/_*I7W%PKSIZ$WH21Q),$"R"TXA"1&70BG&='7A>2A?K'A('
M8M7,\ZO@BYT]U'J:N@E$3I<PW?)6S'9;-A>13AD[4[&E*S5Y'!B5XQ6K4F*_
M&LE*?QX&U()I1+ XKI:TS7TP@G73+;I.+VAF)S$L0$;W7#-*@)S(%UDVP;+3
MQ\^6=05NX7""_/H0TZIYL93;3Q?1TJFK ^4,-DVNSV12;@%.-G3[I0FQ\)8>
MKPAP==AC",R: +>EQ;&ZK _$DF%:8?J=3-639R.TWL+E,9&7*%B-J 43*V3E
MHY&P8NMB+>6B5/B1_#UGR:YI\9U<HRO=#%!>MWK]1D#\VH&[%[0J1+7#'L:[
MOQ^W[H&MGH<F#T]&FQ9(*SFNBK9"9X5=(2E BU\4[6&%NC<>CXP8UT@&S;X$
ML% O*N?X6OEONYTYUBQ^3U#F3RZY<J'J&>!99YO6^&==;X78P&/T5E UNQ*&
M0NWV9ZA2V[<[PJ4>]9GJLV<,H6E'O/MVZN5,@9$(XII#SA#5>>[%8Q@CMQNY
M@CEI)%$0.],W0?7NF*5O+17"EGY"T'JR2' .ZER<H<SDQZ36P[;U_-W9TVVR
MLRMU+.DQ M]MOVUX,P<!.X<G4#!/ABP=RK.N21K)J@L0C!.\II>\> -J@"<O
M7B5;:3+,*\7WB+LRHT&3@K& $3HBLIVI[4-] -4I@"X*8:^I%!YD(M_SP*/(
MG7P>Y$N7"_3O:X(TPBHI["Q;K*60O06);+MI ;]]H]WEEWDA01\=# +^232]
M5"' PLW*NNUYD?QABGD.4T,\08#+*0].%@F.Y2RK]>32X%4FAA"G<,,"G6QA
M1[>Q=)G L.^=!:'#DW>&O9G#U!2V/NK:T;W\QIC28[$OJ^ [EW6MQ)1<6W^B
M5.T/,RBEU5:.UNA^D1PIB:^&1_K+>>3\X*C1GO"R=K]?Y[OJ=:[B<&\2WRAX
MAKB*O^,!\<J]*C6^_/OEF[.+\Y.$:XY/SIX_?_O\^'6<Y=FL>:S/[C0^]A+V
M#+Y+GF>"@,4=&K1]>P7'K\APS;F%83K*R6;+TV3KU;$5U^X_VOL6^V4=*PPL
M+^ELY,)-3EJY*O)F!D5<U6,H,B.LXEP!'8I950_S<:XJ@OZUD+/$99IF$KNP
MVIK:&;8W>B#(4TO.2AIY/,'!)1,F7U2C:06\ -!4$IZ67C4??8==+J_0,=^'
MJZJK[\S>O!Q6-6FMNJYJHQ[YO5MAC:LY*Q*3_>P=]O>8:X7>[S1!9_>*(9M;
M9$ZA6%3:K@SS6OI+,VTQ;=;6[LY>?["SA\"%D05A&LUVZVS4GG3E0XJ6Y$&;
M!C<,:Z4N%;7Y).NCYI2^R2!(6Y!1,JIS1(W'PD_MNU],:&?&Z0UC)Z^S[#T;
MH'B.@E-:PX$E[7LY#/;[A_L_A0\M,S*P0.VLO42%,@96+NRN22:0:S69W1YI
M<E =$45FK$PFY9;/?DIQG]/&%\TRCYIKEIR7K>FZ#LC<;3AY+K%8[M3-^*\B
M=?DX%R_@J^-(P[:DQ?CLID(7=9CYOGW\MM85 ^I)R[&L!14;/T'6)9R_MK20
M(JR,8[5 LV9T:&FC1QQ9>'7"/4'L.O-\<T$:("29+.?HSY[.;,I-.@O72SN^
M6U?LB[=OVD^RU_&B75P<<SV)&2<^,\2FU0Z&HZ1@*E>F&1):_3&Y("-Z=1W*
M':8E@J&<?R2[;CY-'?P.719/CG79Z*_(N,5_?+*]NE[H:]14"(; Y&5N33VQ
MX27U0%=M_EZ0F]ZO)GV75?0$XC!_<YXIQH/5QZO)01&(4BT*'"17W) O^B([
M_OPU9@3M'C+Y.1)($X3T-(7O1=?DD^P[@P3I!K@< VX)([EL"W'_#%2TWY_>
MC$E(W<PC+<SOW^O3-Z8WQ2CG&$H/V$.P>&%RFGY4=O3@P> )')+CUT@+&^>4
M2=FA>)@F(W/T!VQGR04=_NHX5B_L2!8W EX5QD'O'925'1%R!6!,LP'ETMQ!
M)E^/F$H_G#R6E9&6T[R.IJSN@S[KX(<ND_-W_2CV%V+CQ-G38ONPL0U[8[ W
MF6N@QS*!R^-0E&\1"KM3NH);\8&]$Y1]R\D5_"O,B*729J\_>'1PH(>?79Z%
MXO_#G)4_'O@5K0#N;#771_6X5W$]9KHLMI\S8:^,.DBRG[565++WCE/"HD9@
MM$ZJ= !^PZAXJW^]XA$\AIPV/*P%E#89?([3A5QNX0N5$3@X(Y:2FU8,G7\1
MGE@;=7BF?V=-T?>79'KT(\FT46[2_89Z6[>&* \1PH-3""S.?4FV2WZ'I'Z?
MS4C29A!PG+)0'@,-]6DT>?43;-\= R(.?1TY+$*^VVCG"!3KL[D=DPM;##C0
MVUO9SM5.;]4:(&FX=W$BE=HN^->"CXR7/D$4CEMGXSS\=;[JSWO6G(DE,9DZ
M4OYP*;\T_)$8Y=*G#8^*VWGUM,J9_[JGOS8B20?\=I7<KCJ]XB9"S /?W-8&
MQ# 2S"=G;! RJR#D.&"'@9?[2F+L5>$<RU?',H!V3%C;&:V^"]5K'$X*?VGE
MXX#I(3D8/\E\$?JOXM:=A]'=M&_K^$S=$,G7\72*M)D%L?;FE\0?"S,>M_;Z
M%]J)9[__K-.^W*(_O-K>Z>QW,$Q'[Z^XC6A?K^J$_^_QO_KBNBCX:^S"*^;B
MPB1/]9*<9E+^R\;&RWH.2L[3>GD5_H%7X2G\[C=DI[^/_L3.+P[3TU,QH-8]
MPWU0LKSTD9-J-LNEL,T2 J^.[U6_E@L^-C/4;T2A/_(77>SOP>[AMQ?[HPG^
M"/Y]U=9/%IX+XVN'N[L:G</^(*@1> )_2+1N_TNB=1?N%^ M\H=@33B-A#>(
MBR$*,/P6Q8#V%F_/:FM&6OK/[@/TQW?]V?V:+>(AFJ 'RD1)Z:3P8$^B@;*9
M!VMW@B$@=)>^C8WH;^!&'.P<VE:XM+!8U6CSX_6G&J#8(J2@ 8#5<COVL9VJ
M]^$$X=5IA-=<P^7-:E2X,PBN2*,H+OVY,+0&LU&3 5-K)=@ME9SQ=R#5%C=S
M#0U^6?SZ#"&>^(%<XKD2/H>VX0H9/#D'P&):@<?4AR"TD25MC)1_+E2Y 'DD
M)1D(Z"& <LF-$IBCP2Z*/+M93M":DPV?$GB#:MFTHN<^_C<BIP-&!*TML@.:
MI1>'L3MP[N*?2*+S(&U=N7>!R\)R(6M!6]I38SG_!$C)#OSGQBCZ>P9Q*!93
M!QO[GV5JR TLX:I 4-\EITGB?@!1&8MZY4+([PNDZ@ZA=?%67"-/GZRX/9Z.
MY>7*)5?U1@(4[FVGA2+U\'JOP/(Z(@&6YJ[:7Y9^D@(<(X1H:B0Y/7E/Y?%7
M5HQ<^"7Z[9XNX%=6:'I^O6$0YI(]6F0U9>(*V:R2L#-C8B+H'N<TV,-I$2!+
M_O&S*0?E6WK7+CWI)$ A*2;/@L1N=P2.C3<-''V&\..6Z#^PS0Y4Z(F$^Y(0
M&//K7-E6H]^LA)D/3P9#@%;?I*.U&8#$.=3L&0*KQ"&B)*@@Q61#!!(IH7$^
MIA=M#DO ]Q8_#A@]PRAR3^O*I 26=GZS>C2@<"M?U-77%*>\WQNX+!^^[JI$
ML6I//@/EX<6IB%GVAX232TIM1*\,\ZJY*9'XYU+Y1'.4H9@27W=ZT^01E5O-
M]3KKD^V)G9M>6&S3^&YJ$L:O92P!#"))AV6%P@_2^5)5PNU;<K@0&0?.7(I%
MR&-(T$6-R:R6<5$O9_R!5?]\5[R:Y:*/K+0QL6M0OJZX&%Q'++7LPLPN^8E0
MJC)93+*<CX74&:%>K8[I>2%M.7GPS/@&59S['LD[E<\IVL\(=LPJ,!>B/1'C
M_OD'+7VPPGA\2Q+F.3V.'=)+8]9VJ2<.:J;C="Y-' *^'_>!D-?JKFW5A8A7
M +)N3\<5$UN@/=\L"UBX>4H1\.%#GDID\T-6"MI/V;_"[ R #IR?:25FG"4P
MZPY7*[8D^.M-T3^ICMF! 5_WE,X2G9BW<XD/TIG(FVEP$% PSQ4EDL1SL<3N
M_))0*Y$ZZX5).S<+!=]8XHMWL=2:?&'#4Y)C28:MM03_Y6+I!P;!EF)_MRLG
M_QUB$#8.I_YK<3,"D0.]MZH1=+1<.1=H#M)DZ]?+TT'JDU<'WV#RBJ?XF?25
M*R*+6KI(#GW)?VHY<A-KK^(036*+7!7+$83B47^.$",9*7CR?3#=;U^FD8^3
MM?"Z+>C9"!CHFP4K'(6-T+WY]>@5@RCEO_HA:V?$<,[B1HTS7<&^7T%65[:P
M@DFMZJL42LU]I*>18B:X!B*8GR2G7Y_-9$)X2IGAMVP,2N!-HNF+]#T-B,&8
M-AFFK>4OOL_'97;3T QXF9SZ"H.^BGR>I U;:-.;>84A0.GVE-QREEVEB+Z6
MV7Q:NW\56"JOH7OX:E8OZIR_7D>_7=;Y*/@GF:5%QFPZ1? >T%LLR !# V6Q
M3)6RI49P8:Q.?%1QIN2;=IK3<8:N%(UO>_%@]R?LP\-=;H;;6@8!\>9,CU-S
MD!^<GA9(9B,XK=GSJ_-&$@/&$VEV-#V[-0;7/[H!J13;Z33[U <LPOJ]"CLU
M38M)5",@3#Y[ASYS0%+0-I&GQK9W7/4P<!E/[+\D1M?D43$SEZ"A/]%,E%B&
M,QG:TQH]09KI>S*O/^7)?V5D'G/K*27J,F@+]RS6_(_PR Q^V5L91U2L$>9O
M]WJ'OB?NVL'R,AV$[7/UHZU9L"7)RX3:[<44""F08><CY!VR *KL<QHN;S/)
M,OX%/V1)(K-ZSVC>&ACR&O!=I6YIG2+T_67L4LG-Z9=X;\62!D$%=7SB:]4*
M&P+H[XQ.]7%PZ+C_, ^%73$:311&[W!XN"^=Q[6MR^.HA+#;@B5>=XKO14;D
MY=*US7.^UP'Y=B$-<J<R)%<UG^1H=,9Z4 7]7:*<XH]%7W.Q2;Y(^F!6N<9F
ML8:E0;_ONZ>X*;0]N6'6T3E.W*WB)H W-_9,%P<%XQCLJ8RYP(+*$8%B*_Y.
M(N.;LN??6Q"2L7">;*11"L -#*[]B#G>EYBC\)J[B';$B4W"H9H@&\R$9W-)
M7(EV4T6YTR$S5;)8WP<1D2((I6& *"GY?5T-R>L*!9Z/9.J#!'ZWOLJ":=S'
M%0-B&7NP "G&<A:*26=<D0I@'NEU $^MVWJ[<[DC8%!/"QW9$Q?:+[1)CJ\D
M-'EVH35O0AC 0;?D_,5IQ$AD=$1HO?9E*&86]B&*^6%D_;7#96KDK+Q:;(LG
M:<&T]XK>SH/.C.V&= [,+ER5$7?..$^O2BX$;+_3X--MY/88%84S:ZVW+M3H
MZ2WC886+$4*KW5L4>!-$-.\$TUY999EK;,?=__+^:5;>%.^S124.Q]:KO[UU
M,9*]A_O?7HR$)BAG6VL].]U_8S/^Y^(D<UY<7"L<;BWE+#CP_.KX60=Y]@9:
M&-T'Y&X+Z!T/#AITQ5""V!2<V6C!MEX].]MV,7P'.8)8T6\K)N,SZZR5@!6I
M%)<V"Q %,I=,/#Y)8V0+Z6A\W>X!K'1234)#PV:G[\G%/HY<ZKW=_N$1!PYP
MTIQHEGXZ0KB9PB] 43#(U'BXHRGM)CA.I0G:0LIS_X9NFIT.[C:7#W&B#Q&0
M)\\.:&A*8"L%NL^,0<GR=!BQ7VUAA1U76<.,UU*2,P(PSXNV*&B"6O$4LQL\
M["5/N, $FMIJ, 3S GP?@$;9U8WX0?'.%#>Z)\]I_.%$7Z7%3?DI_Y\=]Y.2
M]+H'A?2C0ZFH]I@R8Y3RH#+9'LF(@KPNZF6]"+H<(43#@:,%R-.:A:A3]$-E
MDEK6_?Y]-/(=WM;;XBF(./0'AW>*JFR6.;KS50W1)Y9<TWQGB.ZUV(^&,:^K
M)3J/*4S'HBCQ-1SP/NPKIT=X%;LV@FXQBP8V0*W\6.N%N^26GCRZ9RV88JI\
MY=R>R6$6/4>]I"/UH,JCFD9JIA-:5L#'4($57QPA@+RID55EN/(2S1/#.87!
MV;3CVQ^- 5EZ^9+EK !9FAO99;XCC;VE%Y():KC7,+=Y8[/))T([MRR5,VM3
MH@!WC?PDSM*Y/>XCK@K$ZMWC/'&SJ;P)LLDL)37*XO$:@J#0.O]4.@GA&<-<
MV#T92<9!&:X):E'@>_;[" 'BNF@M%\RBK4CU!1#WUA2AV0G6X8NB1^QGW5(;
M3POF6<TUA/@CK+0!\_D15OH15MKXL!+$APLJ';/&"PORX]+]J!J31:3I-.$O
MADVHM)%S^ +"SAG)O0!?U=$&[O<Z^]\?2F;P R6SF>&>$R3:L[K_(OW'/](Z
MN;PIQ\C-)V\8))-LG;SH#USX9__P&VP0C1D:OR ;M=!QN33%<&@/CDRT:YS>
M_OIF<#R04J=V7*@G%4HK?</PO7,24?EB*44 SP$2.)DJOYX/&&^=/S^YV.X9
MEX685%;](,8GO?\8 S![ZCX8$JWSUMAY6[,!;;:T*3W*9#:S0PM5&KP79FA+
M8&QR07>1U\MA7D9.?[+%N!'W1Z31MW>2\T5,Q??9S<Y+C3"X)_74A9)!<%-7
M?1!;N#UKJ$2V\["NWJ-?675=[B2_Y0LE7P&Q-=NWO6#P:.$S7(((?CEW,ZG&
M$@RWWC[_2)>T7LH/,DYGB/,K?]H0;;%[VERA4;NS_F#\DJX#UQ#!%"; 3-G1
MYJ9 7&0+T+)4QPN0I>0>/ZTB4UM"#\@P F0%:S!I?^R./]CMD\Q.WI>T#O3<
M1@HCY#+*1*^KNABO<</KC,'/+C* A1^G-7,-HEZU!W34HC)VA:!GF0,H#_82
M6OJ:Z<12SG@X*IR@!KCD4HX)Z?W5(*$Z+P@ZS(N4*>R$4+%=@L3L:S3-1L*(
M8>\B7E;#!7%-]*;X-U\*E2#E\!FH1""U[N@TGR_:SJ?W$U$Q)=T2X23>-"'1
MNU6.\H;PQ6[X:&U,+=UWZ3P6Z*X &>L.#'84>LXZ(M/5G-25H*CD:ERK@ 0B
M"2)3J4[GZ<U,.XV@V+CR#1EBG2O:<Y:^]^F9D+9RI9*0Y8_OCDBGAP8U@G,
MZA4?")<Q%P6DH03RF]S:*2X<UW>KK[++']+,-^R6=QN'YR^>'3\_.TU>O7U^
M\?+%\>N_1S3OFS6#]7(J+Z<I;(+YLIA)2XO%[VCD&U17WO,,[\E-@Q31TWR(
MP"Y9FB=/R<)_]W]'_<.]O6_0OG\JQB6W=^D+Y;]+2'[&Z#MY^N;UE]GW[[*:
M%JKG@ QB(XC@$9NL6)97C3(YH2-YV*&$WV?F?/:1>YOBT6).67:C$38GCR'^
M$ B<(8UVDB\V1='=:6LX;XQE7OA<<= QV_K\8)Z<S_ &*6Q@$?&\NPR--QN8
M<8S<Y5ZX9C1OC/4/[84[VO\CN343NS6\_K-L1B9VZ>*B;/W7V17L&M($6]C/
M;3E ,AO)#+F'@D>#U0[VW:5\U?,IRZR(.I:Q*63-?1SUAGU=N;VXB7"SK-$C
MV"\/^1>C][T$4WA_0Y,;<6&=K!J T+)P<CD:S@1S=CR$%!<W_OA^UN#_?P\D
MW=EBMFJM86CH*U/6_QL(QEZ8JMW7X3LI6P(K9N=+.VH%7@.2Y;+T&]=,Y?-Y
MIY:AV\FE[?IGT\T9WDC-*O^>$7-VJ (!PVFA=0*FTP+"+W0/_.9-*^N$[>GG
M;OQJ]\T$^I!%;]B83?C>S&UF(/'*R<H11#G!;X8JHS,4U!JK_N<6YOV5YI'B
MQ$LL'"NB3R(5)87F%:(?W&")T8PXBGN[>-J/ /G= N1[ZP/D&&X^_L]_RQ^D
M#T;CR?XDVQ_M'SS</7R4'@UWT\,'H[W)X.C!)/O_]@X>#/[MNXRK?S5&VC5D
MJ<<OWCX]/GGS]O7YBU__&9GQU;EU+])R"1B9]'J9@UL-K3_JG//Z"4KO+'P#
M,&T&PR4OO;GL02[J3-&W2QK:J$C%])E9Q'LG@3:<1>\;I7-Y0LZ\$G-4B('N
M&'W+%THDV%&_I,$D6&1-3TGILFO[%5VF+&69A1*UK![E0?^(4]_4!GP3J-CR
MK[('!*_KM4:L1KUT11"Z"!\7EE;GGD%"4!\DU6#'^_<IU9RYJ!"^J7R/>WA^
MX,Z+.E S<%?FGY<?8)U=I:KYW3J3H94%@\Y\*\&5H9$D[SL;X]?GKR3:'F=P
MI28U9[B2PO=7LJ1/T4@<^=VNL B/Q\R*]6.9,SY]WS_T>&$M0G0/_3ZUGQ[.
M]G-;TNW68449ZIF"$B7:<2G'_60]@DXN7@*,R:UA+'6 ,@%9)Y*^I>Y(<?//
MF4=?732\#&'0N.#885="(?9G:I0T<AR%"H43&JL7?20T^[Q$A=6A?73_=/M
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MJ7G',M-F1FN2S*HB(Y%SWU-VYVQ;@IF@Z+DT%@(^$K?*)6D0G/N(0,["%.W
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M^WC5HD+.#'6&F)<[P9\]I^H%(J2!&SCN@TIL*_?AF&T9.$29T%<HO\::F)^
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M)"N<?O0,-UY9>/34)9/P286;YJ"]I2:E)*0JIEGZ(2\<4J5[0VPC?H[V 9$
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M7V(O&D0RV=.A5_'JEJ&[;BBF$4 IOA*V*S)M' UJIR"6;U(GM]PAY-@6A_/
M:ZR$]LE=?IK<%1ZZ8_#KE;0 T3I6MX9GRF%_4E+8_7? 7!V+!V)P,^/)TO9[
M:7F'[;M9H4Q"1.ZX)T:$IO&2XL YN!3'T=)10Q$L2ARE\P+D9 1_KW'#A,4*
M%8O+Q."#84R'/9,&UB/+<_R02 +36V5,RZ93"W"EB+/-7473- +J93Y-N89]
M9^[AQ(V_%2(:,N*^+8]V3MZ_WZ4I/*9I],OB^F-3'_)*,D!1C6&"75YYOO8I
MB#_:PFR9JQN:0+@AK_OG]B[SN$F_>SGA3 VGA[/"]M'%EH#7X^8':YEF*2DG
M:ICG8X[+NO;2\VB8.2^C<BL2]AX9\;V6G35/5#$/S622-0TK99 89E.S66-]
M.T?HQY,LA<?*R0TE!((& ]:4R=14.%IC[;R-C:L0>-WXG"&6\RW00VYGE</N
MD7O:'7*D ^$^^7R+0?' 7BWL*)!VU<YNDD 7D/M\C;>>">7HT+(Z4V$C5MLC
M:%I4._E<[KOD!EY/"SSO(%7JYWSNS?!#'P8_X;7II:WC*J,,[GV+V$WO#BD_
MF(%0E\[#FFSSM-]YL(7A7K&L=D/;SVV%,[KBR;X[_W5^15Z0L74Q OT+7 !I
M2]W.XNBI[-J.=\0N^:IB+TEG(A,?+YX<]IVVLVF^_CZ_2X9EQ>.4SSRFY(Z]
M?G<FFRV[2\0)4G<*!Y6P.TZX!HEV.BQ;JQMON]=??Z\UX*-,L4>4[V$7=&:W
MVV;74NU_@\XO;.!0YGQMQPU]FTE2@XL?KXZBM[ UNE,$0W'*&N)M.&N89LN3
M@GA,=DXO+W9;[%HR8YA0EW29KME"VB>[(!**7: R.Z,K_*GS88^(X_)P(W"=
M3)$C'-X6;$(VI="'9US1\(8JK=5H\$.Y/(J]V".#HW_?-O_C;9O_!H?''9/!
M9#"Y_,$YU.L<.I\I"4P 3T4V &H3Q-U3N$=W;L2%*MJ#F.AH9"_V]I#'&)I9
MICC!@W@WQ,5EJE+RAL89$D["7:PBQ0^<O7_5LZR5;]Y=P--_R01M:Y%']>C&
MI+-<O]-*:%ARPXX-\RSQ7O328/L=#6X"=3K!AA-)%ODOM8V4OK--)G:XLFK&
M99Z5 =*=MFZ!H(-#>NU=\""*=>L$:'2M.4<J(A-\U.NF6)D^W!;6OO[V8Y%#
MDAK^WO-!KCMH5$0[D'U:J4[PH@K-;R=%F?5-](?]).*+N9%76]5HQFM'KXT=
M/5$;4**=[$[V.4<W6""II?P"ZQG;EEQ3R[O_*$#V259/T&E3 *8.RUET2SD%
MZC' 8(=P5-^4LSRUFCTIP&VLZ]E6E+^5*+>$T)<93TG1+DJ^5#M)'F :.2?@
M\Q)J8XE5>A9 ;7M0(-9(RVHK -]( #P7J&OS[491A,05#_\KXW&25;5+Y,:8
MU^N!;$038QKVJ.!?/YY\'(#J&(*^0 1()!Z=Q_DL$N9=FRRHI :WTO!M')LN
M'S5LYO,.,[OQU/T@.H%KP(A.8$YD2BMT7-(?TD8,(VH6[-P'[$23;M ::VR>
M7\05E39O&/,]([&\<C['OE1R]PZ!PY%1&H<CD?-$LS QB<'6R_]]C<2^?MNI
M9V/=P?AW*-%>G'Q:Y] 2U1@\HMV;).,N2"[S^:DP*9KA< %T;A+N'Q B&W;4
M)5!$ 6OA[ C/J$$>.N/;\NP?GJ@&*H#F*#\[Z!^_J!V4N3 ETK==&QUH![JC
MQI(EY;*+1'WBIKWU:5KC_^AL6Z86M9.)S!<L00BZM:0B9Q[)0T08:C5T^*6D
MZ95VTQ2QBVC^;J@I_IX[@/:@.)#A45YEQ-&=2D58H.I,M)@03?*HRH;8,(#I
M@-^9X]P:Q3_+*)YBT*T2DM7*&HG))^$MLK%1I5T"DML2BG=+K"3<UA'^AT!Q
M-FG%+%A59(=N$)BMX_H4UR&+<B'#CR%>PBPM!E!P5/!0,/3:?^K*C$QV*[&I
M/6&!YLM+'^ @?04XLF#K=WU]$5O>F>)HD]HH:]D?7_<Q#8-/5W,+3A@U'K?&
MX\!UL'XO^:=R&C5WL&=S7^DRU)$QMFPQP1>?4"# 3;>P. 7V'&:IC_TNE;6;
M\;1P7Q2F;#*9%52JFH+SMYT,]XUD2CHJS[$F$ITD55[B\'5!]U/"':4GS.>$
MY7X=$[ 7767D :%:65 <J!5]ZXPP:%4^TH7 J5&:7N_NH%DT$B^].XW$1A;P
M)C>%P1 4"<D+X117DZ\Z]=_!^4:PH:E&F45*K[,KCBJ(H3^,7^>@27/B*$\$
M9\/<T+0RTP35 P>3"F1STT5]@GG.>I]\^'3VJM=_;C4;7/]@_Z!/,@0_'/B3
M I'0F6+2D@FL(QSO05)M%S1\(,0U@90-\ZR^B2;8W()AH20X3'$MA1K)6:7E
MJ*%QF'X&MDYRR7I-DNHSY3_">X31!XAQ#CN5)SB]2*PULQGPV(^SPGJ:P:GJ
M\77H"7I86ZX(36_NXI4O2$.[L*)07!.RGY[8GT,LQQ"DSHR2NE'?5:ZI@SUU
MC?.R5!INRQ">(,IU5C?8*^ DUF($6S4W85\6Z@8&S.-_T0J! ,^HA&(R[EU:
M@*"3NU,G8PSHN?N6JH>T<VRI2EVP]8_2?Q<,WQ>]Q3%8&_+*#X3BWX-)Q8X>
MZLOI*+S>S."7MB3!/;\^4&UQZ81;P$< CX@5N4OI?NLE\9"Z:VD#R$)?#2ZB
MJZ,?V\BET\N+O0U)FW3N]7=?W XAL+@)?RR4FZGM#<Q\A*"_]O.E71AQW&2$
M5Z3)W-_@\*RY\I_ S11VJ.,I) "V([(\H(.>[&DRQZQL'!WM]W<^[U(76C;"
MZ@%:#PA;\![M:Z,5+6HF^:D:FB3*Z6TPM> I)ZG?LD$62EA%XN@5&J&793G)
MXC#=S9F@Z 9V0]!ME>OP"!H-)C3"#;]&^>R:UDVVIRE[W,+GW=W.#KPM<_FF
M=76['I([R\%":RN<3T;E%"-9T)"H"I8&T^@3GM;+[B5::^IAJ?W1WNB7F<IW
M1S;$GG2?YI,/Y^>GER=G@W<;\AJKCS\\Q!T[<+_L7>VY:2^%G?#F?$!V2OTQ
M"A#:7V=\+K'3%6<UH_N\SSZ8\\PUR[ 0@BQSR+V,*0_R]1]C-JRS-$L01HJW
M[?<C$E"&E3K64;PAOE0,,6N1I$G,::[3655.35*X+VF+:C2HLR2Z2#BOA33B
MB$/E1)T<0_+8\W(4+@S3)<*C8-6('79L7,7MU2@S3R7IYGT-V]AUJIUX8,9V
MY)Z7*>X"N.[^;KQ4Q7O%RBMB0"C>^]>DJA-PW"]*4&.IJ*GV,U(1C!I1L4>_
M+'Z;%2,[!@^SA57:0Y(D3#O73 )25K5?7H4_%H8*M=X"WE%L?H?4=%$!D;QH
M.'U!"D!>FV$UPVP2QE=D"D"CPQ5&TDU+&'&-4%S\E'2O&)RD[(N?/M=EA[_P
M#G-_-J'>.C^%F[T\@^1A;G^#,"0;S__VH(3YTN^MS<G_6%+1/.X.A+% .C38
MK5WFE$>YQNH&3Z'EV6E&Y"%4$],9TN$QV;4_9R6V P#>@&F((](9-TD^5K,$
M3S#X[^@U'#KN\[)G<0RQ*"S;+X6ED #I&&53YB5#)!P:G&4!/>LJ#NL/.&"5
M4'X[N,U#=#_;(KHW[/AR/AV.6XUSJ=HGM.2A1]:DU>:!YY1.&/IHHR8:SQK.
MB.22^P"W'D^=.__96.B<48U?)]20JFDJ<+W!8A)PU;KCOT$072/)RVH(SF.5
M[OIL3?^ D>EJ:N(H93 D9A5;QBZYKHRDJH@T!SP6ANGJ:#YR5[*$NQL'L!!5
M@ADS;Z/;.4:LZ80@S#$K5'&1N-CL>4F^_%C:L#N"4*I# 7_)R^*ZA_4:FV)W
MCVXYJ43C@@1=&1-1?6/_Q;G_,/2[_@L<C'S+8_*43B,UR'FQMZB15]O:+/T_
M?\N.D^-1.CX<F\/1X=&S_2?/DZ?#_>3)\>A@W']Z/#;_[^!)__!OZR MW8'$
MQ[=GEZ]Z%X/+C_\377V\''P\?7-V$@W>O3L;O#\YO=J0Z&+9_!D,QZ^12B[G
M9.]F)Q$_+K"B6JI05H2.I8,(L2SE'I],FTB63 3*?C(U,Z1$@_@H\5I2Z/01
MA593NN&;7-*JC?DL;GA)T<*LL 4'3CG8U58NFA0+!#6%>3.:SEG;G8&UR[6'
MUT.HP(6N>2XRU4QNC?>5UN6%,I[>0X!OPZRTN67F,P(3@PK',U(XM6O$3+NC
M),617I%]$/KU&'=:<S>%-RH 67FS!GD)K;(,UI&3# VV,\KW.%&+H1>3^W %
M0E^<'=0[PRN+J1/>1ZDU^3OL]TDH/#X6RB>AO[>#7GQ>6?Q%,/>,@^2P[<*5
M5MC1Q2!-'TD"+ME0D@>LBG'\)<OK,ZNQ?/!T+':Q=8D\7QSY^"*39K8R@V/6
M>OQ9I'+0<&YH\@PNK9R2EN>?E[$2- %>X-W[B\4BV)>I>O.5WW/B)&134D'+
MX((L5".0.8)U\NMUG!<6LIND$HH?<Y=4J0AW5G^FG?+V$"O<=Z([RI3;W4L+
M&?7V!QG[6&V05%E!LWWTC)P@]O*N<X^[]%L)CSXC-X'%G]I\.Z34<@L)XHR$
MR3Y?FW HNC0<K3<4/3'L&P_<339=& :B)\IUUY'#@C?:MJE],[N]A.X/1><?
MB*%(UK*089.+GT[?O.X-+()S9_"/5\^>[O=W%:9):3L"EE1&V'&%<\MJ2"O.
M+@]Q]J[7/W 7/3]]==;O/W=7S3#B:F:3$FN*!% J>V4A[2MZN2U)Q=>7TW-3
MC3ZOMX0&Z*816H;*)JRLA*':[QWUGQQ;$0L_Z81T2Y[Q;23K$]AW\V6]16LT
MK]$+'F=#B# R'&_]>M?)U*?_'O6>'!QX2NLFR='NSO()"&0U[]:"F^V>_<K$
MH9WQ2T)<9A!"80Z$RM:5,%)KF!>2G8AK=UUB^]'8(TNS/ELKTB,$JTD:"QS2
MV"\!KR9%EL>"48@6'X;>&D0N24V-LWENL'<6(A>O;\B5<676M1]NQ(S"-=7$
M3KCPTC6V/7)) "A\\4BW(LAT 8!G/)[&*/H;'%;LB6)4,;V]]BS8RIY9'@#3
M->\<DCC@CC'HY*YZQF_P"-0[@=%US1!3.#\%R8*[YZHGA#]3R=T/ _$J2L9O
M_7H?@:7.!C^7VPBLS)(UT)9)W/L<$=<S9O/'8!?"4P@A*.6'$ $7:V+P+@!)
M4^&#T(3D5,=$+!P*"CT) L'3AKA6@J /[AN8>TNZ[/7O;DH*%"D/31,$8.$3
MK ^/9Q[J;*XS=H(UM4& ;?;57E^,-/7(25!)%4/A*B\C4'I)2M5)QCY.RZG"
MDW]GX\LDJ2"@[TEMY_O92N;RP,!Q6&5F+&T]4XN\;L6>86Z#T3=>^=-OERQU
M!$40F;4*Z)EKR61@G'8X"BB$*O^\#6418."0_X24&1(%?&6TVR/I^7'Z5O0D
MCD[\Q8H&5EE^3VQ>K*<!N;#*G"+NU%O[&L)I6SR@6#EEHPXV?U 4J!@N#6,Y
M"]S]2=3?[_V\-,.^)GY7$&5&.^^3.DW^^5,T^,?[76KI.WCA,LH#:\3AO4]P
M(%MYF]0X;* BR?P@P=>F^RZ4U\&9MF[BYI(\K+=V>]&%5]E!13_.JKH)]4*L
M)1\P=;:(Q')TL-\_Y/,-,I9*STYE2.KT \\HFT6&$7[G;YPJ(_,%)+/V+#4-
M"<U&B*1CC+Y8J?CW&/ TJQ@JA_,AY(X-CA%I7#N3:\%$';DH)/RKB8&7AT,V
M4L]+^B\IWI(AQ*@54JZ"LENDQECA@_BW8 <0>.-R#<NS$@BTH.G(O 0,_?&7
M<QIL)9'JBZG>:-GV)91\*0.Z+NT0[P7I7BVX3[G.:C?,R3RY,9K/_UTR1W3:
MUF=G 9%D?1&> 88^V8<@K%53@G!2V8:&)' ;F\L2J6R,R]',]FVV,DO2ZT%>
M?[+L.;DGZK,)$U<X-"6VQ8CE^:Q%>:0:@V\CVQNR^2+:;8THEP1VZ'^N3G^*
MSB]_OL<*G15CXB,&=_65KTA..''S21(W&[(DJRV2?^X2YM+H(3L9S_1VGB3+
M"B_DU4U23:/_3";3%]&K\F9BP/6JIGL@??CGW19? B(/X1]-I\&SRE_,VX(E
M<?CD3K!IZUS;S)QP2)<Z$]XS'[=9Q:ZS3N:0UJ8N0X/[_6@XP[\M^NSY%GVV
M;NVDW>^!UK6ES:)%72A*\L+/<M-Y:^E!3S5LM$H\*Z*_8S^Z]3U\\ 9:Z86%
M:&?R=RY./NVVXE"JIK.O[&)27YOBE]Q?=E>GP>"SK.6R A8P2RESI"E))I*P
MTT2U%"'Z33N\_7I]],N*#!*M@<T6Z<R_R:P1+(?4@W4V205_)8>\3=Y"/@]!
M$A"R,"\P38'O0@\IBA='9^J%D8=IE$QK?%[C2 XP*\+T%F6+S^#=^PO),J4X
M?(K:7Q"OX)-=6%J.CHUS<S\0E2-$&)2RHZR;FYP<OI?0%TB34X*X20C-R"^L
M(G2>,.$G=Z*WWQ0GZGX_7RDFK-BRKUY9,H<,%27N+2^MXE+4O.._493]=HP6
MZ;A0#'3PD?,7A02<4$WXRQM,3G''-_]\T!Y!I915^.6\E(/!N)MA5G@>\<^G
M__/Q\I=7@VAG:B;#"B+*?\TFR7 WYA-K!8#:D2]>]?J1A=H@;Q">AQ%2E;N@
M!\&?'$/,ILARYZ./<D&&#F<IA!6/]38VP=8\BTXQRUN+SR:8V-7&Q].0ZJS?
M4._1>U.::=9@1\A?Q!]7L/$ %%KN,C(H$VPA7/CI9<M;*JPCW,9<O\7?F&B!
M)WQ9\];/EX,K3S5V8(9BKF,\>7K<YX-H U@L<U!H7/-N.>J8)1;S:O"IWN5:
M!40"<F!=*4XL+=T*L=6,<<HT75H+4>!B6;UK0>B\$R\)0NUP3$+*\7=1PLWD
M 4%Y-152F%BC,)QCX8)Y *U=2N^Q1\Q.%NA(RG-T)N):.X55)5B7KE= 9^%'
M_)MS&+S9B 9MD*%J2ZO %>SICEW27:XRB9@5J6IQ<YOD,RZ:%A!="#69BZZ$
M6&A#3EQW4H!A "X[_>GRXW]K8H <Y ZEA"EJKLR_ELK\ABS!"H^7>CR[/5ZW
M @_Q:7=D13U?EI2X_/HB@!?7T5D!-G)*^;R4M<B2#^YP ^ NW'*2X7'9T01<
M+%_9Y=/6OC^Q"V433BTOHKQ]U;8*Y=V=&^@":("FL,S'Y/%9K-H,NZCQ)J:T
MO2$GKR4/C5.6H[&T;F(K:NO:-+UY@JY(4AAU>D@>+6<*WO_CY:[F!]??U7PD
MZ8)LK3V>!_O_'L?SRDPAN,!AZOC.76>4C,6CSJE_*/7,THKZ-L4[3^'??O>A
M6L32P % 0DQ.A>.9P1BSISAV]JD%>XX'2(X4=D=P-Q0&9B$9E'>(\#QLSG&X
ME\>6QAWWYA ].4P(,C"4J;K4W;M%K;(9-I:06T4U"5N1$ ;)D9.6<MK@\&;K
M#[)G9 -LU(S>*'=EK%J^;XM:$$$," ;1EGYY-O\%^;U4N:/ M:-*+_"[WZWU
MH#/T78=\YW&#)$#R5@D-SR*G:%E2)&0DH!'7/O:=3A<W9MC[[GFO0MT@)=B(
M:W7]I@DYF,R!)5MKJY'<UU\8KZV?W$W& '%WBX.->*_:%852<T"CC7]>)PX&
MH7O1U6SXFV$$#O>&HC,K'8!X"'JSJ?;^20.A.)E:/(8O\HO&'C0I6<@1$ FJ
MK2E[:*V*P'A2D/5[47AUO @ACMQ/W;L^G56(^MJ8H]]M]SY0,!5H];6W:8\T
M[2<W(*Z9;]D?;,3XJ^N^'G_<QC_(^^;%6/"^Y=>OG4^=15=[%WN#/?V*6/OV
M][^F]^R RDDEPP)OY@A_-)PEVKD8O-V-J49?&1]'B]WP,K@27 >D7(J&>5G2
MU-B:B/_$UO!U;=.<VIYUEY5'GIUS@^RG13GQSD^_)2ZX >^Q1/A&FF1*K'!'
MG[+;,L)?1:=BN#]ZF/%U7Z?[SM1['&LM1ZK?=:2<90_:.8-TUR)6PJUWC/$K
ME;SU-[L^X,.UWJ%_'O1G^ARN:T=YU[V@2/T XK*>+1/,+!?T#@>S_CZ2E^9O
M);=@,[I;R9##@X39?79]@ZUS$T:"UEG2> ZW[Q&68ANMA?J$&'%+#Z%-"%[S
MP6@6-+.IYVH+?>QC&B;CT,*<8M[\HIYM'VC:B^"EF/7-VU@G[9Y.Z%:L2K<"
M^\<%-A0IOU%':XCP<&!K<VY:8"@D@],<>A%B!F_GX/5FTQZ$+92EK['L.;<1
M$4'(D$60:1%#&F;O(F(YJ<F!TN(0>-QB_SU&7078][W@TW4$@GU-?R0(*/=R
MA A.BB=+1)"B<XZ1E3$!HZ]^'-89'@KSZ?+D!#C'?H&,M'95SI.<XAJX&LB[
MDM>-B0.\'<.%S'3D*S W]JSN"DSV0N+L+9+G:'^+Y%E'K^>QD15F,R9)X-@Y
M/_&@Y2=B;XGZA2>#R][Y7\HA_'M2A&R%'6G4KC8H"KA:46?'LJH[*'_;?2A"
M>6M/_[@]-<4U_)(V<W0#5T;2>RTZHUF:8GT$PLUR-&\,;!'*]FYH>%? /_V$
M'W7P,)YIN9O5RG<%)EM%Y_?;:[W" XRU?I12P+;74J.=,3H9 LNYQY9_=>,<
M+;'+X2L,%]%%BVF)=@)[&><),?T@21I>&8F?/;*3KJ'J76")0(3@T1 \K8V;
MK1>Q#4 X7VRJM*CH2!58Q9A-J2H"7A%^QFM^N?<Y-CN]V4$LQCK6XY<*> V5
M!58)I3;Z[5^9,2?Q.-!*HTL]G!=5^1M-8AH@N=8\VGDUN+P8[&[(VRXUPA]&
M3<E)F?YA'-$[10ER)_&T%SX%1#CY1:G(?SAX@OHGQQ/#*L(E*-^7<+">]_OO
M7_?ZA[U^;_^H?^RWH_D9G14D;K7 5_%(TS/9%,!@!EJOG' C2')=E+4.%3VE
M>=:P3T&?@>\11#N#5Z<7'W=]FB=L=LKJ($]4UQD/5+'Y@%9BM3W;0QNG+3!7
MD$33LI N"K1A=<0M[Z!;:2BB'61J3670(H<CFC%7,B"M_0KT/R7/#OLQ)="^
M;P?M#P?[T60M70^12S7\*,E1,B%V?4N\C';6*%LX?V1,!5 "@=GRI_P%30>?
MBVNPP(1M.R=1ID[.S@-PV+\X^B\Y /O[QYSP\LY6S9:''L9.39E6<,"JC.85
MN'$Q#&7S<>/H1PW+=.ZZ^1FRTF"=4-,5)S?9YUEQ/2OFB>NK 6'*FQO+TF<O
MU/6EVZR"(\:PM/[SHZ-=>&0$%6+<#(^NV%X0[+2<-4R_YE.38_FR]E-6Y-(K
M#!B'CF\X]\E#JD0+<0K+ +&@%")?L,.L9']X\M2J5014S!8K.@GXS$/TDD+T
M-6Y^B7R$;9Y$\T4T6?AYCR6"^\)J)A;D\%NU&3N)^'D+#17&+JM0EVJGV,XB
MR!KJKF?/-B97E K*<))F1*J'X$A$8?YPH&\?.X"VXU7XX<C^/4INDRRGQ^TZ
M?6\O]_?[_=[!?N]Y#WYXAE3*O.Z:\@K&SBJAL_B &UZ<?HDMUTQWL^C"X/:]
M\B0*;.E-240W.R\'EZ\VWYGQ#Z3 )R5P2CL.7,NKZ1\\7>G6O'U[]:&_OX]7
MAA<Y>'["IH%6+N8A"F#PU44 \?^ 4WKL<)@!N178K'%E1A6CDJG[029XT,P)
MW*%+F;T)WLK5Q>5N[(\?I@DBK_ +-B1^:R#0X[U]2V67*\6I[, 3[Q+;Q8W)
MIZQ04"O\(_N<M$G1[@^=^5#JVSHKB3.,W,JVUO2975$W?0,=&VG+1C/ [#S6
MH(0-(G&;QC)49#Z<9V"/=#Z/>2I%^VB#/%3&>;>+T:WWCD1H:PQ/(ASS]7A)
M:F.OYZRXJI8T1A:9XEJQ2*"74<?,JHK"15JF1='[GLY<OW^\EHZ<;PO5&PI-
M@HH,.1.<VG 3D0(A][HDU -Q34F'3N:</+IR2(ZA?X]'7;8(X"7;X=]J4ZS'
M4A6J'2\/\V?HJ"SS9XZ>'?J;Z-%[M]P:=C(/C@^[)Z;0;!L!Q<MC:<M&0,'F
M/Y+')J)/YYM\]$OT[OJTQP==(H? MQX/M.W,1(6/'P(1 W*[)#K<CV'[I"TS
MFZ(I4 ED$?:5_*_&4OCKRX:JR@M##OJ/>=\?GAZ&?B;?Y8$O[+^CG*4?#]T2
M1%/P/A(:<BJ'B7;/2E4G\"-X47I,Z6?DO?2RMW!O)'/7!9; +L Z52:;#&=5
M+11.0\Q7'#K+W@'>[,:+4C]E6T%X78ONE0FRR@T2L /7X)K2 .8Q?*JI17BI
MAUG]8D]B0<$L;'.I8:O;0<T,X_;UCXZZ!-4M_,JGY5ATDH#QF4W\$%<LN_1P
MW5J_A8>-\=#>OMLBI#&KO[/EVCM:3\LUY-UY2#F")9PRWF.=9=8:=> $#7;[
M-7R::9YFE<%X?C& Z?)*[@G4*H,$F.11V=!*16Y%Q-9_]IS+]"*.FV+\ND.G
M,QU]0 ?F739&_&7"KMRY34WNG+T[.?]+!4K=.GEEN97)CT[. V($CWG3 WYQ
M!NGP\ DV-L*ZGKSO]1]=IQ-BL\A>"W])#T"/4Y1@Q+ERAV 6#AKP+^B\8[TK
M+>^PA=0D$ULNV]/O+Z]BK;3W^!2_D_CRWP^[TN_"<OS;8E?61N.A)_ 2#P#S
M1IT;^$B:1&^H'/O:5O0V7=DYG$FKI3:)KO-RB$!WSJ%,N<0'_A"X.40KUZ'W
M'K!@?MJ;E 7/>6X-N.%J(BH;G>&6.9(SAQQ]X"91=<,E7"6HP3*-<WRI)\@:
M]M90>LWGZ")HSX^XXMI^+L&,E@X\H@ZA\/,Z@J+:-#S_QH73G!>F5C&.BH@]
MLX>GFK)7W7F@>SGY*,,E%&/1V[-/'IF8=K?UL -)EETK?R.:QS;DK#BE:MP]
M=)U<GJA++F2A00'9E=X)HT!\&K]F@P^PZZ]^1X71GZ?J!.BA0A-3)^"0DGM<
M<Z0LVE2'1</#Y-Q+EWVAU&%![.P)<Q\N>5,<;61[T18L=^<7W#I0]HP;[.1\
ML"QJG/< ^5;D2U$6/=>III2GCS7%#YUO=WBTQO/MSMY_/'WW[O3DXR^#=]'%
MY8>+T\N/_[/N"IDVY%<B>9U3N3T@^P%QZJ9@SY.[@#D;A]2BC$'HDQH<C0E"
M7T[GU/TH!(/P!V0^K4P3)/1 ^XRY4L]CE3SF7(_./_:KJCH\N8,9GMM5+<\(
M=U_^7G["^RC1O[O$7?""M.>PQ:VI/LI]ZG!R]4_1RUF6"[R-27/P ,?";YDG
M<S+)9Q<1,[!LPAJMIO$<POLBR1D.4\>Z#]H4^WHM0LYB-C$5JG 6:VF#II^#
MUIFV57X0)FZ!><Z/S[K!>/Y)TUNZ:0L>_(6YF.V?X/WDS-3J 9%;0(_@C8-0
MT O5A%L\/:Z05L>N4T=:M.C3<-'::V/TQUO0NLTJUT&/>,-J=JV[,&JUF$N!
M"0SMG$<L3@R$C2G6DR)B2<,+T;B#RN=C\E]8-E33>)*&K5N"+<NBW7_4H\1G
M)G./1'".Y<-[UU_TT4G&4%K<!&)#UA7BY#Z$K*#X>Q"0&ROAN+CC$GPGHGK*
M,!N+8EM27SJ\7O]X/\KJ>H8)_XKG5L"/E";7\\*M6 O'A;"[[CK]?=L7[UU(
MKP%R&DQ1QMI?C1EU\7'HAIYSIY=B+ARXOEZ(SK;+PH'G+$,&T'W1DVZ_96<&
M[T8$FF6FFF#FA']"%H_A/"9%6PA3(Z&'N0PFEHPU@USZLP&K13MDA]A87YN7
MJV[T[*9+U(,#S^)5HZ/#?=]CG9K",]'AAN#2Q*01,"\S8F^5 <@SC,JP.%);
M8GW8.2;FIZ47TDR#2D26>H//RCFNLTB6K_6#Y=K)QB+Y-%B*9,$>%LI=(> *
MK"F.H&2__F#_\%#;PW'&) A6 ]H,4=^\'R2=.-:2+LS)?U9'=4-P":*C&&>Y
MZ39!6:V!B"7 P[L/37.'TGZP?W0@]8*CPWCQ2;"PA1 F3V"6[&[K*(.5-*CY
M:996Z)N9VS*_I4$IG4Z:9LPV6%IT9JUZS=;MK3V_-PZ<7CGXGPL(?6_*.Z$.
MY\"_K51:<X/<^%V94L1K6Y2WTJC*-)T]=IO)&VQ/2Q;%$6,'#UA[D 'YFAVU
MM:#89)=L'T5F\M3Z+T$S,5Q&_9G0&?D5H?J? ^$BGCPWEY=R/R(JY9\1"S!2
M;G4T\*O_1/G<SH#2W:1ALAK4DA>-6VN:\'>>3T@3X\T7X6; W@GCP>+DHW(3
M&G/,B&2^FV4HF_M>28+U2BXSRR#G:HI&D[PG=MVT?5N%$7:L1M22[^'ZKV]%
MKUU;M7PR;1BC>';D(NJ@Z?4^M8_L_W,.<CN&6NNW?%# D_"0,,\G7N5TZ'L+
M#%N^$7K/R,M'#C03]3EAM1=F__^S=DW19+BQ(Z@.77]I/NCH_5]O&7NTS^WB
M\CN[-\YO"$//9:[5,I?:+KUU1)UA\!K*>(H$3<QN1:RH2>* _7R13WIAC 3/
M63-?DLD4]1O#\.X+EI7 =90GV208;+$X\GH[T_7W/UOW3%?F[KTQ$PCHX+CA
M#+M*I]EQ(EKLIG)I+$M1P*&NM^.=O\&&<>K#XH7 <_CGS!"=G=_!B2Y_<<,]
M'3?<<B ,+.A*Y3(W56D>T8XC#Y1)O4@C.-K;K?VV6ZM=:C1^EVG;"3-$W=0S
M(GI$-""X-,,LYV[G-I$W1@6P$]NM^P9;YZ5*(Y,+JA$"*'@BB;_E,-9VPT2!
M;@B1 4/(UIG.@)^PQ>^Y56+?^B0$S%VV'N#RL<P.EF?3+/5J"&YH .7=T9)!
MF"I625+ZX-W?+,TP$,$NY2S=0!TN6MS,<^Q &774X",WY7+Q0M[001I84[I!
MA4U 8$(S+C%>%YI 2S^F'^!5@"<(?\WIF54#Z%_@9[8R^]5E5F.C6_. PA65
MH9!=7M5+1_BJ<1/FYO&O4LC:0A$?"$4\V$(1-X,IR\N42<W4U4LW&I'XP2^*
MNH17ZV5)/V@.S';Z2RMHJWI,YDL*+:(/>CHSC>,S5B^-!8U1H@Y,$P=OK>2*
MYHPDI4()'VP'(EC\^XM>,'*'Z><U?-";4MA/Y?0R=;5X#"K$#B^+]4GM0<#/
MN )9(THVVX35V<5BG73)8XW*5!OU.DTT$5*Q/L;,85:$9IT?DCE]Z'G"E,9]
M2:QE!6G-B+GT> NN5%-YCE/LTM0U$Q(>K[ 1'I!V=6=)X7;=3\XC8X>+Q>W:
M<.WPFDCU%X][AV!BEMS"KN#0-O.I3.JBF='V /N:Q20ZS \=9"FXH;N1-#BB
MD828<@74&5EK[I3%7]#2BY<5EKXYR>TM^IH,6)6A%C+F\=K@:TUOX 40J0O>
MJ812J_#/F[J9-$%.*R-<3*^)G"-?G57O:H!U3?HGG,FVG_9:3RV54=*M#7%2
M&JM#6/PQC6GK2<H &=^NIMEGHUD[58T"'>&;XN1S22/1GHENI*S1D'')2B1S
M-;B\ZIV4GWH'#H?MC4*URK\R(I&,C6DM$&T)E9.#@L68AVTPQN3BY&.PD#$-
MA>6_>0 A_S/QO5 #WBYXH$%UC;FR(F$JJ22[PYD<%Y@APSP+\]:Y<:G!14@0
M$QT(0[E/&IZJW0A:9J5?GB?<W,QP?WIPCVX-H?TRUB,K?&Q0")+I>!6$L5E@
M6O>2N84=M82+MZK*DL)S)]JR6>-ZA&X:R^2S0T6A$S<<-P>T[\WF'WD6PDU#
MJU<+FJCKK3[>E0L DGN^U*X&=9\X?"#4/-QUF\\"</*F]_CS5$L&TM&27? R
M(;M)?S\^WC^(G^[O+P@$'/Q[-,K0-,FHK&#1F#:J]I7)7N3?4G8&;O?\\# &
MU=5U.T_/L-8@](9GLNA3!O8V:YCU@<;^5LJ<0@1:K)- 9Y:5<+%Y7$:!_5MF
M]4A!D1OF:RFG8%K /U_<Z"#7*Y!=IOBMQ$RM3\#WA,=IJFK96#EC1T;43A ^
M=%HW\9SGB@PH%4?;X? 059]5)Q3&Q%V^O;6<GBF9^^[/:M&NG6RO"AR<X-1+
M!=5%.U8PLKKU7/8(-*#7LH73@@ D^,,]=DWJX"O E[!F++(QSNE-TB2.!C/T
MW?(,?GQ9)?_*\AA9X KXY]L2KO)SB0#M,[@D_.;O"<A7'%W.ZAK_B7>[@ELE
MTQ);T3OU2DV*!?F=CPZ?T#=(SSR/CX^?ZZ'J*,\_V-%PW@5%1W]@+S?[L%UT
MA.IXE+BG[N3\DQX(ZR>JQ+562%VP>E9!( L^>SX?E;:6JY.B\7JHZ.,%$Z_B
MUY8[3\Y4]%@4)5<M.0R+J5;Q72G1^#T22B+9((AV01F&JX:;&$C=N)?G,<.W
M9D&1+SE1^FS9"M%^>@2&[$F,/Q\^.X2?CZV8]Y_&SXZ>LK.RS%]EPW#O@[2.
M"B(7%;/MY2 LMLI_9U]'L77;6%$G_^6B0['YJH/$_OSBTX\79Y\.@U!#%SGK
ME!5/'*WJVXM>8^8^Z#2@@$XDPMF3A3M*OJ;#S6*1.=*<6=L=[7:U[%4I%J+C
MRO +NB<^-#Y!Q'&=!5_$7?<_.#Z(^T_VE]T_22<@6131XZ5\Y !'.:L?L/.6
M3XX.XX.GSY?=,GPY]=/?P@OUK&*BFWC%#T[Z==\.'=DGSQ]Y.US(!]P.E]J_
M9;\?]_</XR?'SY;=SH9.]$),/+9P+Y>$A%C/A58#I_U61C>J(.HN#=$"7BZ(
MJG^;>Q10=Y!(5[R\^O37") ^*$5BT#?7-AUN_E([6Q'X,66-$P/*WK"LX")D
M-*6IOS8+WU11I S'HM'1*:_4<],F<EPX"6R?CHZ>QP='1V2?GCXYC(^?'L<H
ML_O[QW BF=@)_GD _SQ\_BR6^%?2,)Y,Q"[8"31DEY\)=K>@O)Y-2=FNDL2R
M+,-M2@:3#:TZ)=IO3P+Y<1Y[,74AZ&JM$&VS)?-7LZHMQ^7/PBXV>U2]$XJJ
MI<$9"^!#8VAA0<#XCQ5A;>T;4NJJIA"Y]1P+P44@5@.('EJ==DAD53LGB0;2
MWI6!S@L3=-;N<BY0F<_^,CIH$#B,2SS3MMNXVD+<D^8+$LVV CEU9/IP!#F:
M:,5<-EL&O\]GIOB7<(=S*E,OR"4\6^5D&GR\P_(0?@M:L*"%PRUH81U/:7>2
M"<[8J,J&:(&&Y:U90(YU1I-[T?/X&3CFS_?9)B_T%LLG3R^BP_[A41_Y^T)_
M$XS?VT'+@>U(=FYZHF-U>JLCKEN:>6#O@O('*VL#IR^=V?S+1=-:H;PG;;BP
MKK00$C('8537"K[/ILG-BH1$'.1Y_MQ[(_O2!J="'HF'. D0IQN+A"#1/+D/
MH:!%&L')4'=N%W0BA.$ZT 15+FVSJ@I&0N_<;BQL]2/9)D93D?-#)?3V?78N
M3C[5NP+YT4ED72J9&^:<V=":NU3%LR_WIOYC" R\4[S*@X_# OJ2 V\2"+;@
M)3NT)]4'G.[LCAF77!9%XQ\FR>$K<715SL!_'(S!<T\"AB8N .E+Q!(Q4+V!
MOT(#!7WJC+WH@W+S=[YRLC+%F] [=7]9:H KPE:-YL,P29KUB>JGM @7W7VA
MPJ%^@J8#7%[F<V[-<;4O]^&6&J,!B>0(L/RQ5XYUJ%72N;J+>P4TS0>:/9B"
M:/$8>AP#BU1#G7WA_"R6J&#M5?=*1?TN^VSNLEI(<7Z^'%QI):J]3O?LM@N%
M:<N=HU(9/V&UQ.GL[\?/GO7CX\/]A<+0@XO_DQE--?'?P;8@/+#&\NBJ41SH
M'Z<YO"1(6XF$JL-7*N=9FD+T<9K48&#:F8EUE[)'.@AG*YI/UOU55T>0JWV
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M(J"%A2=2H7 TKAM-!.^0,8H?0V/2OT8FW$,$X\]WV")&'6+TV18QNF9A5_^
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M#9W"M!7$#.#<Y%D]B17>)_ -+J;$?B]*T&K")TK;4#33TTJ*;BF:OY7P'#Q
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M.N4)1)6S>N01-)HT[)RI\.1 D$]2E%AR5X9&R([S"76)L0PTX2['7^Z*%4M
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MH^7AORR($6-VWFEX,[$(<P]GA%X1"<2++[P;_<,QW$^NR[^%[><&&AC_.Y3
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MJ%2&AA/4K2I%^FS8)Z\4Q3@88( OK3J4")2CM18W ]Q %#4C?LY88$R81!@
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M=D9[2OLF'RT+UX0R_1OZ2!21@*X<?$R"]T<E@/M8**[':%)9;@LB#A6+I[!
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MPZKJ0GPANLJRV?GQK-ZI\D]M<<+4T>%7.SJ='K^-4[]:6R?\(93K]L,48NE
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M6>FIO9-2PC6+9Q%AZ3^<=CP( #:>(<[>&C;&]R(_ZN7^5HD>[K U88$7.0I
MV[*3F!$V#;!G:><>,91X8029UFP>71@U"Y(O)"S@W53 62(C\!UM #ZK]S,D
M\P=A,0]F%H[!VCT$:R-^U[&R'1_'J;>4)<!_]!/&;,O("'/;%;3O8N\5#+VB
MV[C/#[XR@:#)RG---3B&P<",A:WP]8^ 8A?'.MROD_4[A&=FO3 ^<Y07V'PP
M9(Z%MS=AOTH;U46Z3)HD3,Q.Q<^8Q4BUSZ;YP!2CZ_0XE CV,-'7,8-\GVM)
MA*.<:Q+I^J:<SVQ&'.US:F:\ON+(X?%TTC3S^'>Q!AXGF[0OY^20 ;VM!W!\
M!FFMOF,590[_[0*!;M4.X99PN"(\O-X0C'@%[49KS9S"%,8^:WU7+,)]SG O
MMZ >H6W&;#L(<#10$IDDVI['!/<]Z4(D*@T.L<*U!NY.DPE%#Q[[=5!41E,_
M'])@II7N :P(M.]UH\8[9JK%;,,SM":L3T/Y'^!V,[G37,(DTYN(_XRL(X<[
M\6/D;VFI\(=M0ZT1$A R6<!2VC^+[L3N<+36][%@TR"0P@P0'H[(]4SK9+-8
M_>G-A9,OF:&/PW%.,;=&_!3: +P/H1S?KTN-ND3:2KW@<U=!*#W;JQ@;>A'9
MYSW4Y*@.<%PV]X%9 !EQY\Z9#\@?4F_T5BE0D[6514&)EE;-=A G<+JF>(4P
M:XAPOMUE87P*\9>:O>/*N1\(;KF25= 6Y78Y!%]1NGS0QFSI0VWSP1)C<S'#
M4XF%1YY/FKT<ZB(X7\W6,U4+@S3SO$U%)H[3?U^EXW\.P>^,:Z]-9YY.HRV(
MG8W[ZT>RYS&+"GE''%%AX>AI-59+]Q+5DN"V2UN<&E,MXKIEHSRK^U&4UC5>
M-_NY_,TQ7&A([&HZ<H1"+##-P#L>;5^L&$+TU$H0+3J"R=7FY>,G5$XQ;MI]
M0MB=^1;^ T1TQ^#D'O:>>'=,&H'>4%]U\#S(N7J"EFUA+*"J,T31NKE2F!03
M4U??:BO*S.*>QGI9TP[3:9.TB/A*P6FF0QSBOO)M=P/MIN6?A/ABUY0P 8XG
M#EQ+$V6%8(CRL"?R:M^5))5&_PP_+2ZQC8P!).SJ/(H1Y8OO_G*6*<4%73(,
M"Z)!WI;<742EKJ$3;FM%YLK^??7F+ /#:Z()&PPA1_KQJ0^I=]&#X@F4F$T]
M+N:62&V2'+T^\<9.U!3DXV("4:XYGIOWDL4/EZZ*R[*+<RB+ ^MGEW<==T?_
M=/K^-&,5MDQ<[8):/R^IJEIOE1O,B$VF2=:191^)RAY!=O>82F*4?M'#TM+W
M.Y=V3S4 N!?*4JSXHQ9\R\)AKY5=PKCN'1<\F4^&@">"%NN'7^W]3/C,=P7S
M_ K0W%<P'%O' ;>TN8M/'Q0@"GN'?\OM\-AY[%D9Y"G8U[YR?J.K X<[9F#1
MIT<BS&PX:8:.S]^;>(K!GA?!LUO+7-^F)12=P%(L/@BX17Q48&!VX5D F*3R
M 2YSS-W;(B?F8RKO21GIX:^:3^26K9L1?Y-K.=0V!E"/%4)##LA?!1X;K#-&
M39%K;2O!]!"80)R<L;XOMCMI&%XS09 PR\@_$]TN9J8M 3LAA $M/*AOO7G#
M:K$7P878 +:53A\RNX#VR!V+M>&XX@NG?.O)ZW7&[\ J(<I$GRV<GA1K30G<
M:C/'V?.9>\AN#,K+SG$UQL]HL "QJ8+C2:):RX)#$LH\5ESJGE:KQ]@W#AS]
MYN>!3][["&'^- CSET<(\T,T;HKAU9-BW="^*P7B)CBO2' @Y5ES_A.E!E_/
M3 X"HP^B,\9B,/@UQ8EPC$(PCP\<YAYUE-7$7-HQ;5>DGF55'A0[R^NFY[AG
ME,Q0/=H[ <IBH9P,7Q'!S>OFEH?6H<E\_Y/@KKF6)U@*)XXF93U>,"VTC,*Y
MV_6F%!B;H:Q5#^8K/+U%?);RCN>TG N"=/Y1II23-Y=0,0R^?ULBU<6K(K9G
MS5P.PCPY,X6V\0_)V.C N#FJ]@E!L+V'UB?M,C:ZM"S6)$JE$@4=96W7N.GD
ML>*+ 7N/]V!-#JG;=QQZ:PE<&1OI#\*:*#*8D";WR&2/>P$FCW;RQ][3IG<B
M%L+90J@QB3QD<#B+NL.!_"XJ-E()G]=DV.20[A(!MP\1Y:!DZ4H,AARDG$1=
MX=_\H?M1G^E]OW<^]NU*T8"<\X9+E<-+QO^J^5(8^JLW9[Q.PL\:4MQR\M#Q
MRACOT<7&V>19D,=R"'X&0)9,*\S[=>=(L^_&D$^SJ4(,"-$R-5B_$54_]J&C
MQTG^J'F6"7+'(E?9@R'LI[/E?:\AER8R_C:$W0QY5J3BH^,:[T+)YA-.M%,>
MWQFE$3A)5TGXEMI?FE4G91J<=[>O]VF"D',JH+LK:B9:)O+4Z3MQH]!U4UVG
M:KRF,R3BKHF#'YLKPCK1M"$[QZXD[D*1*#TW4JW074*8_O!NX?PINRO^[>(M
MV4#LQA\E#4AW/>/$\)KVDEQ>-+C(G)[#H\23?"<DS=WB57 (!MX'=(5WP83E
M;8ATGYQ_]^K=4^F^"%XK*_?RSH$E#K=.5@+WIS"^*^(()9X(\U:PU3\7FMI,
M'AS? -5Q?.;P&A0;[(-OMMV&0+LH!)1-),'T7'3PX(# HX"'&F;D)]:+CUT0
MD:+Q[VR+\O2A98]'1DS%O&QR8C*7P<L7R[;)*= FL;Q+>C)6!LJ[\9#O%V_L
MDA>ZCIZ<_?CFHGN:N<8$99SBJ-%$3^97+%Y0NR#L9))WC2L)RY7.NST4=>GU
MHQT6I!GP>/JQ:#66?$KR*Y&$7?<2B\068KCK?^3!/O&2O$@H[GGAX:7#"WP?
M)H2:Y\XN(<M])0<P!7<TC!H(J8BQ>]_TF4X7/S0]C3Z4]%19FHF]"[3G*;OW
M*!=&#Y,>$9G@]9-7)A?!G69W]!1,S[ Y:Y?9&DPD$PA_,W(IQEU/[D!QJ?M4
M6_+@V32KV)*<3:J3$P^G- 61IZT+-#GS-AY)#2_-<,>XE:UX1^)S'9K#RWFF
M\T=^B)Z-$;5RL(W=QEF/9KHX#E=J3Q=G%>D275[%2?E%I7DR3,+G3S1!R @5
M:][!3<1L[(JP_X%6-#Q1PR?H]X0*]TG+2R&HB9U__'K+HI( +>\G0//T9,&8
M4#8.=1*B.J?5J.G4<$=^J9;RXRVI'(CFNAJ-[[%$:9$7H+MG@?*N$3%&@FXJ
M0_7L<G:&!(Q),7$F,%V4\Z>S$\$NT%\HDJ*EN"JLKU%?GA :/NFG8!%T>L/$
M=8%Y&\HU(!C0Z]T.U:4*+R;'!PYIFP"$\]%2N#Y+*^LOJ8Q87X;WK77LIA>4
M?K-,'HN^.*C8#AN;^):-8$9:8:;13@1XZ&JEDH5*O-RS6 9#4<B"2[LY]5C1
M]1U&,\3LO0HR&^)":RA2/]\*/M;:(=E9F9$<N3L\T ?T7FMXK/[$+FYC$,5=
M^*=A,1&M)#Y0ON=/[&U5A:NE4]@0CXW6ISK'73&[*86-G%VME;I:G0X#V7E<
M(4&E'%R,P4E!@D![WI AL%32Z EM2M X*@[UJ&UT1O3ZX% \;A[S5(=(-4^]
MR_^F"=YGG9.C3.BXX%*^^=/_>1JS3]=H5J5A6A9AZEAVA]8DF'QX&V8"V/A(
MUI6NHNT6<"]_"$$1Z-!?/'OQ' ]!BL\#7-M\L:6VTI,]-56V&B'$E!S=&H_R
MIB "*[HX37(%19@0'\6/A0RK<PW#B9N",EHO6B#J -64%.=S";?ZM6K!!],E
M\[-*RDWE=?, *]?_]K^2=IMXQ+$>U$W3?EBPA+I?)A0G^+"E4I'&<3B>'M[.
M.QD'_*,0GWDW!+%44QB3<THN!##5>NP7[-77)S-AC4./:VW\:H][Z\.=OWO]
M_N*=)"K2 4[!":SL5*E30=Y*1#?T3M((\ND 7K$I O@?Z222$9C 5WPJ@4Q\
M\-T:,26)BH4LA!/]KB6&(X!*H5X.RUB$F!YBP@TQ"]2QUTWET^#]LF.>K"VN
MZ9I?GI"PT#$<OE2+/HSL$_:,C+VLF(''C73%N"<<KI84.=BU(VVC$+"5_2!'
MW[)LY!7MY![IG4S<GG#?/N961YF0QT:\\AD':KF)J0^_*LN( \@<:ZT*G7/7
MGS@O'O[(T$1:K.)<,?4*?N99SB*%8ECD=OE,]%I#4,.JXX3(,%Q0V:Y/:,%0
MW^&>*A*LMH>4$3T"TY*'.]?LC$N:+=V6M;MWY.8=]:!Q1Z;ABQ 2J:B?<^*'
MW:9M3#B2+YV7-=R&^%)>EUVV C))!*BX;.PG\?$G ^?2)>D@QO"+PZT514DH
M[-G;V"(N:<,UYN?0VG?7I=-J'Q^!SJIFZ!-657U0I=J@6+)IND)C8)7[$LR-
MW-?5(064H%.LI"OAZ6FWB8 <M[Q$D(]00&B&+UE[,J@NAC>8Q0%IPJCW1JHK
MQ1JJ?* 4I325N?_D#M:J(@ISF 0 <P#$6T&'V=2P-BB6A6.=>V49K"3Y\-16
MC7"2ED2P(&DK"4;D _-VG6+L*:(ZF#Y+922+I.$V#FNF4%F =X0.;U9'2>;M
MAKQ4K:=B4E7^\73Q'8[.1N$G$?-B<.K#-D#V?;+8!9_D*Z:R@;@D*FD2J<V&
M)T14B/\>>EA*@QQVGRWZ]*\+@OG]$03S."K39PM,0'_56IQ!QP%G, UYO<E)
M";*EKE7W%^:Z",<Y-2D"%R,[/1LUY]"IDK<8L6"AKVZ4RP(;.REOBJ@G>-[4
MAFN"*,=C%&GBJVEG4FT^,V5I-R2X>M$FI.MJP1M/2FJ_51E.K'4T&G@*V -N
M!%$.(N0(Y/J/U]U[_H*)'1%4R@NN%W^DF?X1,_V]6P,T+=VG@1CD].^*XL.A
MJQ$H\:Y5M['$=\3!H#A)]40D05I6"KRY*K".T/3(90$B<%L4)6,E_7J-_,OA
M=7?(E4V_-K<&?=/=S"ITN5U:@%FR GGUJW U84OU0!<R</LF$V=RT5<&EEX;
M5U]3FWJDHIQ)FQ^>$U&9Q,T.3PD&=S(K";P:#3,L<S<Z8 \2K->-8%/#1T7?
M*=Q(G#L\$C^>%1A;VJ9SAS@:E@@LWO"XT1/-['@[P2GXN*+*44V _C2R<<@N
M9?.=,60'L1DZ4Y]JURR;&]R8F5RP2VP+3IK>89;<4:5YN@.0AUB%DKMTP/$E
M8I9MLVUTGA)B ZM7QLZW>?ON*PR3@EOO!$$W,N'J1H;E,]3$"RO<UGQ#%P8\
M=(OI )YZ*BAQ8.+IQNR]P7^:6I3#<R.HC1H "70TT@Y6^]@L:&6 M#RB[7\<
MI4=<IO0Y;,IV*X5\R5-XVA^J(P6;E%HL+V<M+Z&=B/6#KQ?\,C%DS4[,47LW
M[0[T;DP^:S8SZO,>+JX\6N\@&1L*NO&N\P-!1S"E/DPGXQ/&12Y=4Z'#-A)6
M\.0DIJ S)BST&BXY?C-V8@X])[=[-:[SU&"40]OL"B)KI5@>@3UN?G&V> +L
MV1??OOCZ*2.NWG__/-=/O_[R]T^S@_>KQ;F04ZB3=I'H-^!$FW5A^2\;\4.R
ML)E;()N[N#.A1:_2)WI2?9(S/$I[%!]7U="E_JTTW\V>?V(2S(;A%(6_9S?B
MB7/FS7!@(,BA:_*@G>AXC8RA- +1;8A#QP'WU?]@&CQM+.)WCQW#R?+,.SOG
M@,Z0/IAY$+PE,^*<Z@"5O=IOP[PQTMO]72VO==M4+#RJ2MF:/\%:-(H.&B#I
MT%.83R_.(@I#\4,F_0F.7UE81]N<NDR7;YVCQ:XO#B#@+<NVL^9L[D/0/9BZ
M4?KI.(<2%XI[=_%.61DKKV=F6%\^R1_KQ*[(\@W+CF:1^\/X*W1<\IQS/";;
M%R_H1V-_X-W]XJ$$6S6L_:IQUR;9]-C6T0WP-5OZ?8EG)F+06EM#\@TM'#C@
M-M?&X410EVW^MT8XD\OEH)I"J@!'^:N'?SQ\YF'Z]M8PQ/Q?O^S9)I>-] CX
M!D.)0\(;Y\LE63-FD';H%7:Z'_XPWGK*?L^<!+06G[]@I( $.12>.M,BV4ZC
M/IDK@=[70T<8]$5+<.IS-Z5D:E[7=; B^.<9-T2^>/;L6^R/[R[.7].'#[*"
M2X920:<AFJG9H(?U7%7*0)V[]G, Y[0J:-8MVAM9S!TS9)B!FO2OPTQHI8<L
M&-4AFM9 'V1W/)&QL'2L^3^PAU2F$!^C(4#HVJMB(A)*+)K$W]XJ,ET)QW9#
M:U1C* "M3.$\&15[, O@*$>C,PM#*I4DI-TZ&4%N)S*8F?0&$-H?P7#A67U&
MG;9T\%B@Q8%F%G_I\CO2C3?&BAL9?O_8[<6/VDF/PJ, ,1D.&I:K-Q@WYA-'
MA^Q FD;!I3%CH@6Y\Z36Q8Q022E'>%_D.*55;QD8:[._/3_%)RHT40$+L#3$
MIIGC>LB2VB0E<16+LVC0J#;4ZJDA&X(FR&B>NJ:IU1$EVBP&&*Q/%V^QPG-.
MK^BRUS6=6?XS*LZX?(=^S3;&Q'!WG =BFE%&T1;L">LJ!7D7\#M5J>-TNG@3
M/ RJ)+*C5'SL16-;.B+<V1DF BP*YEDIPA$**02 *")Q;E-;XG!FX)'HO*'F
M<II7VK^1J-CW9NKXVATT<*J;^F0I9T3L$>FT8X+Z+%950<\,<T4/RD2H5/O+
M2:&"$'7F:>ZJG/DA_/&?$.9AN_=\'>6V>/@;_3/]*\:)K@A?V$N@PIF;5E06
M6,.2_X)BO.6,YGBK$ACL4*MP45+TS:PHNDSNX;^$.QW>WBDM\\.?E-L!,A/J
MQ?3U+*6 T(191\8P/SK+Q@)%$_2TI^OC$,H813W%7D%SO&K:]<F'HMCACU5.
M30+T7UV8[YSPJS%SBVQM#VV/+&:"2:JHD@:\==E9Q)*-CU$RI&UQ5=3(%T2L
MP;@WU:7&%0\1Y7&"M]!$::%;%NAD-2K"_6YTM[;N'&J$WPY=/W*#.-R A<7;
MC94C#BBNL_V1W+R0$;7L4L&A*GQ;DR>V]J(VX?X$[R/H^TZ&-)$)DB2P^)KC
M)R!G@!X7@]F5/;9QF#6"I3"BF;Q/H?P(4Y0A/+5:)A/D"&C?4;8MGKPY.WNJ
MOV.*-@CL\EF05$-COZ:L$IG]RZI9IOUYCH^'25Q Y'W0,P$I$(04)2_ !^$T
MZ9[N(O=T=ZEL_6,6Z1Z3L=:F:)G.6 1H+#RYY54372I:L6-MJDRI)GSU*K/-
M)-P]@ 2@9?<7,4;%Q.]A>;$'&1PB;8U)T-RG(Z\"VKK2-FJE3)#-'?DCDZW"
M8D9C3$$LHJM$;$M91("B(LKQ_-U;C/,1=62HHZ^.J*.'Z#+Y7F7NK\H%$TF=
MQ>$8'J304':Q0N&K.\Q0',\T.LUB]<UQ ]S24#O;=CR'0!*F@ABW?M+U.80U
M'?B, 0B:),LD=&&,<$SFSY^@IXN+3_0\(M"=O'X.X^N^C54(J@P ;SUI<_2L
M>%/N%NG8=# (?W5P)]'EHW;I'-X31PDN'%R98J5TT-,O>@1UIR&QEN% G$9M
M3N*>+ EY["LIL[)^3,>+GD;NHQ9NSY'ZPXI@ITRMDDD-J2JNF<UGRB+-K:6W
M!CH:!4A9)GSL:@-4?B$)E)95!M.R <X5PI5T9:N$24--N;)Z#5*/V.*:.<&P
MS+%!&64#\1.E#)BH>K":HP:',R>/[WF@UDR@@YU/!7*0QQV^)2@@648KZ3VY
M;6A(M(4JQ[,546P65#@S\L7)7B&$R%#'/8'5VQHXWE*10O(1AN>:7 ,G9$N:
MO[ XPP[YD/!W5+C"0QH0>A0^['>Q3]%RN([>[S:4%ID )FLY79S'1N&9!;)K
M2)6,$-.Q:I$@X5"YR'R[L;)"U^'!M4/5M4D0MGX0GW&,79]O6I;"MH4.$NBX
M^F)".QU[S?N$@R5/8AW'MI6&K[<;2MZV7H+801-EK8S+[^;>M<5FZ K7%(.2
MOHN_I KN@7! ["#[WXZ4EQ(HH3]OW&"[D#9;Q/\R$R*'S0@@0*LS2=R+^ZHX
M(7H<WCN48*1BA ^=TX-+^O>=*([T=6?>^,R9ILUM"6R/[U.Y/$E#VA5\XP0N
M1K,]PYAS&XGL'MF68!!)2C>Y^J@??<&AM("$'[?1]#MC+'5L@!5B*'IS3HQV
M>MCZ5"TB(^%FT S[AEZ)1':)48_-VG[LI7@6AE&#7C?3$SB?2ALMYQ%.QNZA
M[*T)7C+Z#^'B#H>JK/?\2L9L=^#QT1<TXO_?*Y^) X-Z1GJ3(4@V=7H5EQG#
M668-GH?WR:->B9P G]46CH>WWY)EPJR@Z+[$IMSAT;G<;C8&LQH85RJ[37?;
M&:M9=&*!4@KB4>N5].KCF"KJP?W( 9B8B^\W2%+^=I1#E2B$]A=GF^R/,BJ9
M3TW/:%,^_!'Z),[:B$H[%&:-\G7B==RJB!-Q#<*R,^(R34XR=AX!SRO $2A4
MW2[%ZA+@F>/N:>K+AN.^D=!(4L,%6_4\[0OWHH8_2'ZS&]KK(CPV<1[,8.")
MAXLKAWD=L424_@Z.>;.LRDL3CF^"#X]JZ%HHIB9LB;KZ5!O&HSSH"D4A>FW:
M_\X#)GX?3H<?;WTF5"$0_DIFHV;$)N0'&=E0I2E#& U>#!%@(HA+([J+Y%+1
M_XSN<6;O$"M%S5@B)29B8L&(ZQBSW0-X$7^LH3ECJ#0X2JM(L7.#$\YR-$>2
M7K\XW$*>]N16^<VTBW?>?0 GLT *&?C'+T\,=^76E9%CLE: I%;'DMR$K\I\
M)N71@X?/WWW\,@$TP$5YDGZA/EP72<S7W?0H/DB3-,\\N@D7:6ZF <&G5 /S
MR9* ]?O#8B$\FHN;G%E-JZ('=K7K"LW=LV@!!UN+Z[*I;)YY#=V\%.@SQ29_
M"Z&]-3&Q_5N5UR4K%;74$D-.0XB$JUXL6S!"K':R8;$9"+/5:RZZ<\O%H5[J
ML(&:#T#'@I"YB#]F? ?;W9&#_-('G8:OI5_1E\DD)=:'L[3X/$;9P<<EHLNN
M@.XEX/M$:7/8\7&=12_Y!_8(-*O"@\8<JR'&;%1]5==8DNR(;?7Q[X_\G*<(
MPKU6,I!8YE557(:!M^6'T#NL/2-QYD!?QO$C%H$_SA&Q\#G7A<UB9$$BB:34
MG_ \IPKT?(@U*Z[^,7<NH&::)^05C?[-L,J75)=<-M?L.I?U5;F<<@Q,J_KC
M4ZI+'TL=XL<>2T\3D/.Z-=WLW#+_1KYX1YB_$0'Q&P.-+=ZS\=T;VLL&]V"9
M'1NP0V0Y2YH0E4D<+X+06%DF+L:? G///%J.H??S@MBY\%3@\4&-1S>J(B*6
M[Y2V#7*GAX.K.( ]KDFK;*CULKLJKSW%"#-($$Z'_EQ03M6!/P2G+UZB.DG)
MW;I]UQ?;3MTB\@H*YT>0)+1:,<!PL^A77TMPX\1:N"I_(X"[?K^#V5:O(WC?
MP<5J(V,*_5*E!:Q76KH92E(?HXY?7T_P%03'"^I)/?2XLWBW Q%=E?ACWK!$
M&5 %:*Q&U/+C/#6?49T<DD[@D(Q*4@"78RT<&7!BU4<D!*8>U^3!A;^/_%W"
M+3HT=N>X9XKU2VL5$M]":!]Y/?'03@]-<C.'LN\<#6=!3Z@6;8,"#C5:Q@7H
M&+U65V6U#K;SI08;0J!/O,'A5YQ#,FH2B3YX%#4C.HA:&?.FB*"PMBC&DH5D
MDG-GIF/07"0@-;Z^R-Z;(*N&0$:>FU"=9BDMC2/.40F/9J=$-9GN"^U7/I*G
M?!J,X>LCC.'7>3@T>"/I$FD7C4#4H%)_9:C4[][OR@_%=?XQ<N;;*>O D!M8
MC/ VY7H@R_;\&V%GI-UY*3C%2MA&9R *)25C:)];83QBQ6?R74D^1 *7$<$M
MY[AC1@4*+Y)K"=]0&TA!4->E9^]VWX13DW9]IZ1MI7T00S0&DSEV4QVJ,0N#
M=NXJ@Y9_1,1ZKG(U>F!F\#-JX'C(^)^3];PD>X6L/!W=_!.XH 6[3X7[$@,&
M-CF[.9"SEG9&QQAB\[[63(G\'/"P9L37;4<Q&7*2UP:#(RL&I#7]\,OIQ[$Q
MHUF&!7W-6@S<1P/?8=,R+A)Q&YW6!?L1OC;B,FEAZ55ET8Z'D\NV&$?E=@@G
MW!]^H<E^G**HOZ;V*:&O.Q6?/7G^XNLO%$&"22;02-<+;+,M+\N:,V.Q>^4W
M)TK\:RO1'JAW3DJ2G(/Q".K(,RB@VN/<_!/GQBIR!(E0?4L]X3)_Q'%:JF/#
M2)53XD)>A(W6"KNL(Q85M=-2F3JO@M-*9:ON.'?_Q+G[!!EW.] =]">I4KA8
M;[9@0;\=E6/"A/X.)':&]AOQZO\F-;Y_S8D^E,SL6-F"8^G$:2.1H1-I+HU?
MD'E:HC,G*AP.CZ1E(T;UDA"-.=28)(%VIH,^F2MPJ#]#6 OISPPT5'4:EN@;
M)5K'5%(CQ(A<][&4I>9Q ^\0GR@9N62!4NN@RMX)=D.ZB>=[6&[K:%3DAL(2
MRAV4/!Y\9OH7X#'0ZQC'*F[9^>7YB]63EDK\R\S6$UINB&,Z3@$"T1,E5)^>
M!(4%84.;M,ND94HR+&$;$HH3>MIRK5)QKV[IQ&HY8<-SZG?OKHJ*=%"IP<]:
M,JW74HM75SE?*GRX12J<')&K<K=3_2)7O72]: ]^$=T)%3QP+L>&C5B:O6LY
ML3:[4IW+_)/$7=J#F_2UC:^"IGM5-?0&D%%V87V>+KX?*:(OZKP7Q =+!>IR
MW-O>GVD!RWN3;0J^C)4IE-W/NNB2@C@KUMA%YN4R?\VUBO(?9819+=,2$L(/
ML67A!6%B]WD8@:*7?)SM3'ULF?>KJZ(;#U>V('>,38<@;C+NE5T4;=NTY!,V
MI=  @#.4@>U4(H] %-;""5&Q%H&"J=GW"?8X3J:EJ+E20+I^2D1NU& CF<0P
M$_FN&RIA+%O\Y8<+0;\L+;UNDV@F9RV,H1->%D=S3SX AR%&FR ]Y'OT""R+
M"=5FL7XL!_<!/ E5+BG51> K O_LB#?T[Z[ 5V ?=C%5*%G2'='8ZDY)5&19
M;<^%"1.MM$]L4^6KEF-@E&"/8N%GJRWPHM@J$TK;INQ@>NY^Y@AMIJ<-+RJ2
M#_0Y=JCN&69I+69C)\<X<'/%W"),%).T">C0QG>0/*88!>V:BK_@1R"4E?_0
M?@Y3H4;&2$5_B1_ IB6AZH,0R]#>(6LOK"LIP$"MIZ<^13U/\C-Y/_^4MZT*
M1J_XBOPR/ T82TAW)KT-8YOH+U5<*$2L0UQSAL5;NZ-'VGV=X3C0O)'&S#(_
MC]MS(&<32 \T_!E[&&VA\"T%$M!VXLW"YM?88Q)Q:1 IYOAAF./+MF 1U7B(
MB_PT*V'D]8Q&>23FXDZ@9*O (45=(#)RQ:4T*M%/;BL2%:T2*V+:-TF[$Q$+
MKB,G-C4S*OJ0\#L2T=":2XU366_:8&7:@1>/] ]-B*2]8\REU&"PPG'_V(%4
MKVMV1ZAX$3FW=5M!2RL<+I#D"[Z)&=4PE-B3TL8E+H;?I@G:=[3Q$C !(,*$
ME:W&5B>L"H$1BY7W03K<Q6''3[3H!%BWB3^@M^(_^A:1/.T\TX81.)FCQIC&
M"HRSH-4Y!-8,NEI7Z(T<LQ 'BWLO4B_-K,UI('#7H#N.K22E-SJ#/5VUF54]
M9W6H'(9;IEUA"[QO#HTE:71";9%H5R;9 U:WX'RSIAC&*F461=_.B"' Y$81
M&?']=J)[!&M%[R.HS*JYT9@'*!_J$DX.8J9ZK1E"SE.;>+/BHA!.M6,:N;*>
M6=2TDTCS@,:\67W@L27;6K L#N0%FV;]V*W'SX40:1%^$ILYI2*+X<G.=(=N
MKAK\"!A^HR/$!DCS&#ZD4%\VA@MP<6Y"?!H"B68[VC@N+'(@_VGF0)JC+%0<
M:B9.*-:J,8QM)G$<O!,P;MOU,][,Y(2Y@-.:*='^V0Z[2/.3M'C&S:$.B8^J
M;10C^\%.5+C-4#,6H&VZCODPMPHB@$MPV$]'P5S&@_L(44(@AA0)<4N@^YP-
MQ),+5$_/Q )O>-F*3?DM,[NS5C(?.S/)TJ'?#;VR+XY,GMI?Q\F>3*2B+.50
M8,1#V!DP;WNJP:4THXB,..Z%N"#?"6*V,0_^&7G;.V(,@.B.8#,#FWUS!)L]
MQ WZ^H?O3PIB9$S064)1-Y%3\7DWYP*8"R&\;6%)1I?"[;#$Z3(OS!RST\5W
MPDT/'TBWM6YJ*?,=+L>*=>_"B4,8\<0-S&?LB$9924CUY^#L@ 55Z.4UA"/5
M1U5? E8&O0X3;?=-S*Z-K,S>I47I- PN[5=T4CQ_0=AO.B/-$9,ODMLDS"J:
M"] \3=)Q8YA:)H4? =I6?WIS81%(L)=$WT@A ,[E429A76QI6I8%<2GR8][Q
M,I&"N7\,C<*?XI=Q^,:XONA.W);]Y?-=_6D.RKC_A96&:<:DQE#<J*<R&EC%
MW6=6A6+P71'&MA$NU%R<O?"F-<B.A"F8X=RW/J%1^K&L-QW($MF1!GRUD&8H
MRH].'"R'XG9%".?UC4[UUA:'!$/L$LG%0/P<['P'WLFKQ$V\]17X"42\XI<Z
MB[]UATN) PNR)E49C/0Z6<:N3)%W71C#&,'B=U0#TI]:5X;DEQJ/U76%D>;.
MP--T> RE>IGO.DM03$LGG386,;<4O: !%Z3D%&L]$AW[+B;]@^_[T ;"*7@9
M:;*R@X0YMF@X<0:AXG%;NW;-"I;=%D)[%3;GE1[+.PA\DU0*069=2D;?YH[(
M/<1(937G0L?-IJP_)635PBB7C\$B?ZZ.:!<S.@D?E$(C%+>B[$=2UN&H2QMJ
MY)S;)%6-&7-1JB,O$9_BNG)5 F>O0C(KNCK2G!LWJC!>0/DUD3PDF'6Y<N+"
M&35@,O-[N*54H:XXAF5HO)6*8O=+9%^;Z.,AV+<O/ORE<*MA.T^(B><RC[.4
M//IEJ='[^,UHJU9&Y->,1%\WF9_U4<7DP&5S*F19^0J!J"!+_-%Z@B/X5J+7
M<3EP?\N[2+KA.GC>VV*68L =\"B&\P/,I6_])B",V.GB%0JG77HXL-.QRG>\
MUCW[ 3+8X;K(<+*7H!#)CM/0X5@:A#J<'N-DV%&65$KW&DN,@GA* 691+:35
M(T@34O#=C%R>BNR0(G!C( 7Q!,*EAMS->S89>L,!9*--9;)8TX)Y2A;A54V0
M-(()D-Q83 =;WW0F4A*LB(BNO*:-2U5. O64J/(P+>FYM?+8=W_8)L()36TM
M7%_)Q$'<&65\K,S95U(K#;+.F:Y@/VJ)#\K3T-2<G:;+B,/$5(NTV.0#6DJ<
M_#37R,*XUYHB)V"X0GTBZ+\>5E51KL+LENND2LWOH\WV("@7;R6F3>504R2,
MR5UQ&:\K1OZT'#IA/7P?S\!Y_-K$ET]@S6$YW)!),YUB(;?/]8@J/I9"P1=,
MQ I[QZNY!G^+O/;Q:4D$9]*\BNSS86@=+$_EW$#XC='RAEFH>T,%(9;][*E-
M6MK&6^LNEY<@:I+,F!SUQMV-C'$,KHC)@^O]./!=OB5;+(>>=<KEJ.B;?ZV^
MJ5_9"!UHX8$ZI+%H$E-CL%*%-)J[^%F70$XH :8\$8E!;Z 0Y'-X#[T5VE](
M-*D^CK3PDZ.2;_-+@>\,O[W^D0<YVV*T--7 2E#F"U@F)FYL/_-Q\T=2!*=0
M/M3.*_&]\, DN6[WE.=@F=<?Z)FB@)K>G1N2TGO_)CM0'N12\7R>F)AXCB5T
MX(>XTADRY*D3C -#6H:5:"?E*J7%0X=VZXN:?"(GW1J<#!O:I #_R+U$0+N*
MJF16BMN<AUFTTLBU9Z)=&=V!J.'#WBYJEWL4#KFV";["EI#?^\:@UX@T)A4-
M8H$9V,\/_UTZ]@X[UF.N[O#CFS@MPL4>XGBW"QPQI>MMH>QRJ#Y8N,"0!!\)
M,G(ZQ&BDD!8A2/ZY-!@R6G)^MX29/*+.,2QI]E;QJ[$ G$:\IXNS@X/"4TKH
MB,,8=H^3-RMZ=*)^=5N9S!/6MEL"Y/%T682NT0+BK,K1Y[F79MKKO*P<!&Y:
MH]%4Z7$^[F,^-+L@1PRG%KMN:.G4.T[!O;!H: F3]@/F@VHME/_IFA"Z5<=9
MN(]9 .R ?3W.HX+QCO1NR%=;14\HEDD@?Q(< 9 (JLK0#=I7C+V,BXVD9MM4
MO\V._0<YF\&M_  O.0<AQF(S@"KVD4<DU)DOS44I5$%"N]D8Y X2/(M+1CQX
M1^*[3\4B?GO$(CZ.:K\@LARCNRUW"J)1$Q^+'C.VBBAWI*B_+B]A448]2^$X
M@- 6HX%ZXMZK#NNV20&7I3<D*B425_QJDN%[Y%:+\BAO?CS7]\>1^4/3WC2D
MN/6&<$.KJQ"]]Q!P7S7MCMHC:9 2SE8&EE&68 B6PG)1L<N -:H!A;>_*N1(
M)TVI;_O&L-V%E'@XX^GM'STW>O'LUG(9!0.@_X5F$$TH7#E"134^U#:O-LJN
MCOHBT30V>*CQ\N!GBQT_U)\Z]&OJKY!F2UM7C5LM*B=_:VDG$RUN@<=E>C-4
MD'LKD7M]B\5JOZ3#9(5Z^8),%V$^?P-KT>U#D[\QP/ZL/( E@Y:)]8#*H5B/
MO._#N^&*1.V.Q9<'BT"MR4M*C?9H]U 5/+U1P^(# LLL1&HJ%@84U":M9_//
MIWW$Z7I*L!0S:,<D@V5EU0-=;@D;/EXRKDY6]Y,[94H@R3H"'CG,F1=I[DS;
MD17(ETG\([C5" \A!9(**QXYZ]'.":N<,5DIV[LO$/\2U^B_@Q_X@>T'[JAA
M.,"D WZ$89,E4GI> X^9$!;N25^SF\6X&FY9J](9!19;.C::IM^%;_62VW9W
MD><V_96J\7HSEP7A\G=7>& %R9]MB/LU6YP1/#HLM1Q?/<_K?)T+OA)7[=3
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MS!05Q;\;"0/VS*%8WYQ)PD55%1I#!8%23G8/[SQ&EI4DY_((^<AA7]AA83K
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M=XYB\D4&B_#YCA/\J0_(>8$2T?LV@!;]@XDW=PEAY,"'UVSE0E5NYE<DJ?4
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MP>*TPZX"JUWX<M]7=QWKRP*037WB'N!Y'"K_. H722" AV-/WN=<CWKVSM,
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MRY-_YW>G0TF:#DD9E!KA77]E(9U7VD,>-?6*E?%I=FW#'C2HS)@<)&O\=V8
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MK4[P;@A;=]S$?F-O:)1JAKX6IG2H""2!/H0+].J1H%<.U**SX;:3G1[HM]Q
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MUS"P'MPZ>N!0\0J9B"3KNTD_9*PIR?,5LB/*J(M@!+6R":[#GEI\%VERL+9
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MG\'$6?#CX[BEHT7]-F4?-EV_:G!9\JQTDJ=$DM KK?MAQ+?ED4]I#B<C<7H
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MOGW'&N4(3H3O[;ZRAOD'JL%CAWZ8B5=_V>6/LBQ&2+8)+I;KUV^HS+:EPN)
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MN*5S(/QY) A1TW'"">ZFG"*F_#RY-CI#6H#QPO8)_HQH/_FLR&WYS[*W\K:
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M-0*L?CQN;]SQA> 0_@['!9'E@LS^0*NP'S5K,PQ7[ G'7*&59Q! X:"3^BY
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M4D7;+;BX8*K$<:;4WDP%7*W9A@W7LG7H%T<C:5RB_Z#XCL(CF#?9<Q@:0B6
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MOA.\5!*"D#;.$:B9#'OU2+(NI?W1BC7V,)&52@B=&CW? $A2 B?(0LT]9@E
MA7:0!%_SA>R,H"T,8J(&4M^XGDN,4Q([Q!_*@C)T.H?L6DNHY?K]@S,KO"I-
MC >UO>UX;RNOX#XLS:%M^$ H:DCQ45'(X+[%U$/.'!;H=M&NOGYYIG>6TX.L
M0MT_63-,![I??79JP;_ =9R'0K#^W'@5FD:BPJ@@BP<O91ONU=NS2EFY0^?
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M[:^T]>W$?YF1WHH? W^A]/(":9[%ZM4N!49FH78['%.)B:'+X;-=3[3;&%^
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M%Z'W!+6+9*^>-B%9R3-U1)[(B\CYFN;JF?['<Q#T:1S,GD4)C9%^]+P*6=[
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M_TN#5JF1.>X2K7N@5$0[1"9TLOLLT*W [9+ '>X^,7PK<*W W4S@'E56Z8/
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M.143PS:\:_U>_W7^]E[S]J8,T'P;5GXT'5OO3_XZW"<TLJZX$#!^?*0<P10
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MN#$T2M+_N28B5C8"H$:+&E0*+S;GR[!(QN#9#@KOPP3'GL!;FL7.] 8&4Y3
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MPOA<>4<+'5BZ&/5E;FQ7?<"2]!N>Q_&<2[^RFXN$LAM81%"$VE%6N4 ZG0S
M4 W+?D6CK)R$>ERLF @=!+&PK#V&C1"WL%X%OK'2H8K:_B] G8?:<=((?EV\
M+FB)F-N69JQJ3)X:7&(/CGPHEZ!R&'4VS]2O!)M,/QV J.9>G"D *)#/N*GX
MAVHU<-B].R[B0FLD/ /+,V!>C!(K[:+J,I"I"9&8P\M\#BOHJ((5Q8M66YB9
MI\HDP%?,)Z(V@B*P,6LIU"5Q5OP60:!.=REQJ@Y,O>J=FL"TP&>:T^@QED_
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M=./L+6AE<2MGQE-F>MPYK:;++%AWAF0%8T#F)[HT#^;Y!ZUE 0]_[R!<;(]
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M<E[X BR--#:%N^@E:KH!#DOC<\CUU7FOCB:G/WY[.DS_.U6ZWU).])^.Q72
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MVQ-B.IAJ%N!]=3G&'@HX;+AR;X \Q-]S>L7.FMD8%-[,63-^%+A)$G!BNU%
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M(X]$B7")"D,G##W'2SARM#XOB6,7BM@*"Z-3T4T;$5I%)>51XB:")&Y,"?-
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M_?#U\Z\'SM&7(P_&/C@Y/:3P[H/C7X^3HR\'WLGIWLW1=_S;F7?RQ]^^<()
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M;A#[-&(VH@V-<K2AT7UMGU9R@VT'"ATWS)Y02>&&#+#']@5A :Q,Z+"8N#9
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MXOY3S^H5Y&LQ!T8=#JV'0W3.+W"%B&SE*:)"J@@+DI!PAR>$>HD;Q:[K^GX
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MA[0W"5E.#)><:>;DV@9MTGED 6B] *6P  0%>S%BQGW(/:&U<H8E([2Q412
M/B9 V0Q N<(Z*>513+F0A\ ,.>424HY[(R7GBNF& ?2Y!PPL8.9K3DN,0(D1
M*%[V(J4BI2*E(J4BI29)::&2J,DJI9Q@6%$N$C9.>B>2M#HY%DDHI9T?W9[
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MK2?<10Q@M,)&R5/DW@M2%X?VQET4^B,TO4<ATL7K(\RF\WEM8B1,(1%%;GW
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M=])$2Q96=JM]^5K3ZDF_ZK_ZP^%>'.VG _O]37^0Q[4Y&@W:;CRRKA,/^F]
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M5QI @7*S/09%3&5?+%):%8]!V1?KVQ=GO 9<,25!DT$^VKPYDH",T0PE1:+
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M!)>0E<DB0V40SD2'8Y4'*U4-GM9"#T^*'AZ]7MV-]% 88$$&F#EH\<%&HE5
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M*Y&U1B$C%>PT4AL9@)4(+[4^GB9TZT^-*]!]*.C.')%P3:27P2/%N$1<$(9
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M;3\"BRE_?I^3M.=+@K6'Y64&S/^W?2FMMQ>"RA]L]L+U-ZY<^08>MP^4.5D
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M1[;?JOV>Q7;?X-U;IS&@ >. VO6(;PFX> H"O>\EC]?W$>=K=!DBG X'GG\
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MO$:04D\/!B:-\!ER2P;+Z*[[K/J2AR5^'[V><5?G\O%+#^^\H!;USD<_[:M
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M4J69?&2G]"<Y,$XJ8_KV@<[8GL_GN$'.R,TS/&ZE0UQA\[CJONC<BND=&1"
M&4XP6:19T=_6'W[W"_3+,)&[#)"\*O-Z]HO.E:L HKMC0Y\6%+K2TB)GQI)2
M*Y 5-2N)$%R1G.H$BR&81!@?.%DD=V2&NKN#]L!FYA7DKB#WT2K7*\A]-) [
MKYXG"D#5\IP XC+"A%%$EEE).,\S+;),Y-+ZF,T?CVQ:0>X*<E>0^Q/#0G\
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M29E:3*,N$Z*XR(G-K"TSJ8SC[D8;>RN=8;6Q=[ZQ-E<\RQTEIJ )83RE1!D
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M=&HD<2XQA%F3$6%R0XJBS$I'*<M+M:0HN W)^S:DIB$-]CT-!E;5I+[Y@/S
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MK'U+D5$U;N,%F]=/:;/KH@Z">AUFB-;8T=?&@W%9:EE8T&D/&F_,AC7SSA=
MD'"8)K'[9Y .,0*V2?.44S]U$'VG>[H KJU;W9]BOUEUTW.V':V/B5V^'3XR
M]LSV^\U &UDM['@4V(,18!!<_[^(F_R-'&$.7=U[_F\@YQ=X4GK>AO9(IO.0
M(E&S-G_9D5^2E62TO??E[,!**S*G).$Z!\DH*5*B1$X)Y9G-K. EXPMV0U3,
M&A4;6 JZ.L+ALBW]]5OZJX^\.VLN<[&KI&(-%O15J?.@,B.F+'M:Q,1 1';:
M 6XP\8F*WD$>GHJOK+TS&N#+/\_[+7J'U=?%/EO1;.'G@3ZN*)?X8-AI4\FN
M"</[L&<,+BV/[KYS(?2HU<:K83 7!N[4>(V#1<+/S,\?9QWX,EJ ='"7=5;;
M!R[>;(GQND;S76O@,08 3X-?V[Y?&,#>+$NGV_59(P0 ^ZY(<\4O@J%H AU9
MX(4^)#KJE0%/'\F$'C9(LK,Z87$"D*[@='OO,#\H$I&FI2Q(5KB,8/%_(J7.
M2>K24E-%\UPO)#C-4EP4A2+FM;)01UJ-/W6K.%W^@$:=;!!H]\H[HIH1([N#
M\@2(XQ/R@S8W#('?@TYONZCH>(?^J/KJ/>9UK$_5A$8<67,8(NHQFJ%I CP<
M^\I:WY\!!IPWN!D3>N"91[(.+H!IZ_=HV?N.&? [K_IA!+MG;ZB&%9ST[:[;
MF!9+\ONYY%0B8'G?]V]])(_??SN07"8R!0DG3:TF3)2<J"*E)$L8SQG/9,KH
MH_",[AW-)%K,-3A;=M2G((%$?*TR#FT'\%# 0:(FU??%)9[#V8GMP^L7+^_'
M^9=>:R%"1X*90_9SVU;1)%E/0N#*3?M6Y>FZ2,L[[S!%L_6RN&W+J^^WPV*K
MP18/U;OKVC5' WG^](9<_CA^:H6 <##?H<4E6AA "-AH\I0) !#!_!E '37N
M?6P5AFM4F/Y5UVX'Q+;I^O7>>2%JB.UNIU+2YE1*VJA[_XI2TM942OJ-U\^+
MA[].O79QK1J_&U>P_<#OU]JL>CF>Y_-4S-/,G35G2WK77,'[(9MKEDG^C_N;
M?W?>/J7U44W\!E5]LB(32A2FX$G!#&@F/$]=5@C%:%)RH0^VEI5J(L6"7M*Q
M,+WQ@55MO9[BB2H=H2;], '%(MW>>W^Q_\]6]OF?]\GN/]MT?^\-V_[G/=OY
M9Y_M['VBVQ>?O^R^GJM)?_P^_;P'X]C<.=H_-OW/F^_S_8N_C[;W#K]]WCRD
MGX\/*=Q[L7/RGOEN=!]G:]+S!+:F=)P8EA:$Y501I0M%\E*J/+<ZX\(\>Y4N
M%.Z)DO-]T3[^>L,S<)==)588ML*P.0Q3JJ3<%5EA<L>XU-RJM$@RF2E--<NR
M'\&P*VJ1K;#MFMAVWF#;(8QYZR#A>6$IU40R(S 6IR2*6D=4;G,*F,>  Z$-
MP(<EKQ!NA7"_-\+EP/>S3)HDL8P57$A3:EF Z%92G2296TEI/PW)=C[.(IDK
MK0/AF1%)"T"R/(._"EX0*0U-.<N52,HG)*7=4?LB_^Y\/7_<.O;E?K!+K2WI
MS99B*00_:2A*DEQJG;O,Y889GG#+"YMRF3G%M2[<%26<%S'I>\ZK'3O>=3Z"
MV1?FVNA$-^P-_Y)8B6P%8#<"L*T%-=,:124M!3%IEA+F2D6D%99876(.JTUS
M6CQ[17\4P+Z#$_<E9UVW/]AO?Z95Z>! "VMLJ9G50K'2*$M3FKND*'+[\\_T
M2NVZF[,^IW9ENI" W25Q6<JPF%="8-?AZ%O*M4QRREQQ9VK7ZL0_WA-OK=$\
M9[#?2<)HSE2>9TFIJ-"J$%;2%1=_Y"=[7@U1U!72J()DN2T(XP5H((7."5,9
M*(:)Y9ETCXN+KWQXU_#AI<FM-)$[L10]:8"C4J(LPY(B5TSQ4J8VSPHJE"F=
M2<H2+2;7P;65Q>0'H6I[0>$PO.",&D4R0Q&J5$HXE051K!!.<FI*SCMMVQ^[
MQ>2NNZ6OSO5W.TCEQDAJ$J-<ZCM(Y:D1!6@J9<&5M<F/G.N5TG$WYWU.Z2BS
MK+ )<R1+,+M(:TU$623$PO'/BX0;\?OZ>E:G_GJGGK.< O_6A?&L0] "!%J>
M6JNX4*E=<?.?=KKG%0] 7<U-GI RM7BZ.27 T2WA0ABI"J9,KI\0-__M_1^8
M3?";>3^>WP2)5*$<*Y,T2Q5HV2![,%H:ZZCD%A JNZ(+'D(2!OK"7RL+RD,"
MV?O%<+M"V]*DCB0@E!!FRY(HP3.2,E>4+G&%*+-GK]@BDKU8640?Z\F^R<&6
M0EBN,JYMP9@N5)(6P+LR1@LFJ"VN<;!7Y_E!SW-7[;AX<V!!M2ADJ8BAV "5
M<46D@$-MA,E3EX+^F(+:08M'9!)='>J[9M=*)383J2ZX<$ !E"<.#FZN,Y!8
MN2K2%;M^*L=[1N^ XYVRPFJ=6Y(8@SVKK24"!#!@UR"4<6$-3]VS5UC;_#&P
MZY6S(U8R^8ZK@]Y2&8Q)O1ELC1E.,$6XF>LJ4O;.%NC780F"LS1-"\&,LBQC
M2NBDL%)G+,NI2 KC;4DWX00KH](/@ONGQ9@TR8WOS\1,F6&<BB'"I90HFI4B
MHXG*BQQTL>0'P/W.C\C3R!I8@>5O#Y8WR0Y%\Y9DBE,,]J5&J$SIHE"<<T&+
MW%V.E2N(O&N(G*JWYSM[6P<)L*I4ZI)8'[:;J)((H$%"N2E-)G-F4GX7ZNT*
M)U<X^7OBY$V$2IIDA:,TUT7FF$X8")),ETI2D0J><KD2*G\^8G8L!@$QF36%
M3C+B<J8)LU8#8CI&A%;466X81:$R9;^"4.GM#?_I+4Z7=758VB*OF=IOV 6/
MS];R^SV[X'VWO.'2%GE/J^7=!XM4UC_O;6'[,=/;F#94^8@E>WUOE)WAN+=O
MQ[T-,SP=6[.J^/H21CE=J;]&P\$0RZ[[NE2KRJ]-F<GM]( "Y1=)(0BU@F(N
M'26<IHQHG>D\S4V2\6R^S.1;WP\8NU%A$>H*X\$'0!3=5C\S"^[K-U>!?&,U
M[+<;'_]L>]7VZDC(O=J._?UJ:)K&N#*0--XX\4V 8K5G;-X5VA:%RM=HL#6^
M3O^G01\['K=M<'V=U4E=^\8*W7X'L5=]: 01*F?'LQ8'6[<'K*V4C4T0SK'*
M=_M2WQL$OP[=>]L6$^USE[1XFO8WZ51Y#86R?4E8;(-T15G76_2+]11>RE(;
MESF;Z8SQ)!>R4(G,2YTZ6I3.'M L>_83T6$YZF7KO7MO/?_5#B86:1FY"TI.
M_U3CH]>3&@0".WHTP'"Q'8%A>+&]"<\^WC_??K>?;E]\278N_JN_^^Y3NK^W
M3S_O'1UO;_[7\?[Q=KY=S0'#\?;9SB:(E,=;9Y^/]R]V]]YGVR>? & ^'^T<
M_PW/V#X#<*G@F>?_??'F#-YQH!4H =AT'E5VPK!%IY**D]QI4P+G3/+2S?>2
M5:DV($]RV _+RM3Q1!2I5B63.<VH6&A5!+!L)G!"L/AB_0-%C)=R^:L',]<(
M5X(J!/"7\;)DI5.<*NX44%CJ2EG8_"'EH&:A:ERHV#<(%+(1O E[[@QC'^^V
MO<[KW;^W-@D5O:^ R=B+T3=NAVL/1S:"3=LP\-/ZQ_7>.^R.-\!?UB(D^X8C
MH:L+H-1A^WN]UGLGOU:]Y]CMQ1[)OFL &5ZZ\=^]MZ$I^'GL5XH_;+@1MLP!
M7/:M76ZVL3\' =Y\\[/M-Z>__O/\G1T>CN3I4:4WL+7/XRI*_2"@H ]<R3,-
MS(+ BC+01[4A,M,%,0X$: 8@ 2=G_EPQ84N6&BT-31B<*,6+W!I32,& N(L%
M4'@LIPSD#1VIH7?8TD(/=C^ S)FL+R]#W1+YDRD 78AU6MZN /3W?RO+].Z+
M'Z?K)>=/:+#BV@-:8C!NJ .@T-[\RKNO_GSII>+)%>OU9V7?RE'OS6+=^9O4
M[[W+9>RX"BXSNGTORN;Q+?"R2)E;S?:W6K++\ZA_$C3<58C7@[I$0.A$T?@C
MJMG7J4B^JGVXJGWXHS$(QM*"4UKHS*!KK5"N+*RE4N5:\Z)8KIM\+Q@A:BKU
M;,+O8')"S'!,XIV/Q]MV2^TD>-M.O^R?[+.=] W=3C]_^;SW/H'WGNUN?J$[
MFV^/]O?^"\;]B6YO;ITO>-M./E2?CP]AK)]@G!_Z.YL?X-H-MKOW*=G^Y^W1
M]LF'DYV]3Z#);(4*K]5L"%>1RX276I(T<R5ACA>$)S0C>9$*S@66&B^>O<K7
M,O%D<@-7&+?"N'NJ[VJ-Y$F9N#+)F"R<5&614]#MBRRC&<UO7(YIBG$K&+L!
MC&V-=UZW00-HQ#E(2B:2C%L"NZ( QFQ)A.*.I%;:1*:Y%5GY[!45BU$#3PK$
M?K+HNSRSXE'#V)O):'AZ>5W85;K6'< @5ZDL,Z,3F3&6,:<<D\:95)G4)#2_
M3K;62M2[;XS<;D6][;V-'.;S[8"569Z5%ON3Z(PPFZ=$Y65)4FZRG!N1.2P^
M5ZSQ[(=A<I5M^7B/K^-YIDHEN3.&);D6.LUIJ3*JA%(Y4S\@Q3SVTDQ/Y.0V
MTDU[<A-;I*!99\04*2<LX8)(2[57VJRR*1>,/9V"L$_+@/<0KKDD!,'5/D#G
M;#CJM]%M=SJ0PE>^N6HD2R)+4>XEV?H2_YR2M<4'/'O5>T[GNK _5$6N7QO.
MF6+<@0Z:IC1GF:-",PXRF=1EH8K<R)4T]@@P?6O!\$8+66)+!I*J0@*DTQ*$
M,4V)S%*1I9FU(BW1\,88OR.=]1'9UE:GMSF]A:,.CJZRF2Z8T%KJA*DB<TY8
M056^,BG]=*&K,2D)6SB;)YIH6N:$E901J2DG6C')'$]2(2EH2X_^<*YL1E<=
M5]^XN'<?-J.K[OMN!M+E1L9?VKUPETOSR[")I*!9E@!_,*5C99FH3%#+BDR*
M(K5"J)60]RAXR+R0!_P<MDM2HI,4A#QJ<\)+9PFUF2UU"O(Z39^]HN5:4>9W
MI+;?Q;EY8%/="C57J'DGJ*F=26%5,D:I9* /@VKL..4L%91;H;.5</US@/']
MHG M2D#$3)(L!W1D)=<@7!>6"&XMDY91IP4&!"Z6#OI54/$.Q/(V<?QADUH/
MPO\MIM[-QOX21->7E#>06PV,'8Q?$OSFKJ'D&H;-]-:&S>?T1>]>S+'77.^M
M@>Y/##SO="9W8V3U\'  SS$ B4#./@VI37X*N4\^BTG6X;\N9"UAC&A/PJ=J
MU)/]-M4C)F:&DICXQ= M3[.2_KSYMWE+]?IBRF8WP^U6A/&HDKCWCNP(YHK_
MW,3K9I0L<J-S:SD([HG4@NJD*+-2%52P!'D1%9$7+3:)WMIY>VNW6_)$F=0/
M9&[EV\?OO^UL?KK8V?QRMK.WS0YL4F:@/'$B4RPKPIDBDF>&2,:S@IF<:L6?
MO1H,%QC.W#&K!CW<G_7>AL_*7JB.Z0\.2A-KRX\+IE#A#\-!_QQ+;\*Q\#G1
MS5OD9'PT'/EC#-O:F]3V1MF##W8JKEZ.,]L[D@ JUMG1"*8W"O2+M_W'38J=
ML<)9$.,L31S&JTJ1"L-+Y1*M$D;5)35\^/SQ698 _>]**I_)>3VU6/QV!VOK
MV^[>%Y#JML]W]O39]M[&05HF@AH&DEQ!.6%""")S04EIA4TLXSK#MD'%^F*%
MWR#)J9 _Z.GD)F3@F'"%34N'!4UR*@ Q'7"T)-,)2)9Y?DFOF149W#49[.>[
M>_K (4,K<PNR? GPFK <@;8D*BF$2W*;B<QBA8/+G%F1#-8 %;#(!0IC_7/\
M%"H5CX?3Q%1CO=Q6K_?^L3W[#:]^$ ")_/>#/9'5  NNV)&GEH&VNPID1B]'
MK2CH&D!"=T E3"63.0,=,$V1@E@F"!>:$EN4@C,J8,\T DEZ!9!$.76!S7R/
ME&*)E47N!1<KO!5T .3(P/Q]F97Q$3!84,=ZYU:.UGO 2+& "SRAX>) !1-
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ME;CV+S;R[;UM>-9.M;OYY]'^A:GV+SZ=@>9%MP\/C%0EG+^"6*= (A!*$<Y
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MPZ_,$#3?6LU'C?.BCSNSV>+G+UWT030/:32:=JY?7Z<U(<<;BIMMY**/5SF
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MU#V-9) ]6I<TH%D1O$_>T!RB"]6B6$<@+TEDFA4#FS.)5"64R,")EPH%M)=
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M++GA\EXCPTJ$E84W9_2JP*J=N\+TJH6!!1^"%!]_&;^=Q-X0_@BQU^_"CHP
MK."9L\]:;[0.XR#F+RHLM(.8[^X/X891O^%!$EBX<= >'L.CX9^,;&G0[S9
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MR+>QHW$'QD)HL]+[5L7%_NQ.J&^[K>.SYE'S?.=HFS<O#KY(K)EC7B,9G$
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M<>%*7]Z_[=Y_!GT?AP4?'X&/S1FMSQOG@@L" 112Q*G$R!@?D4HTD>"8MUX
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MY_5D?]=4@]]_:_=RH]T_HAW&CWF8N^G3,&[F'L?C;F:;WI]V3SNYS-!6/!G
M:\:%:'MAL]N'9;VH_JR/P^>!MM[8X7/2W=WZ<-'\_-?A'OT(XSO&>]GN._K8
MWM\*1WN?/WQKM@XN=EO^V\ZTPZ>[QW>VFM_V/_\&8]WO[+;R/;^W=][_?@SS
M/=S?>O=M=ZLI=B[>D;OR<QRSA@@5D&%"(:X31DX+@L#R\I@($[Q@:QM$B=4.
M92^P6&#QT0=\+A!L99 ::XZ#<%$1&45,#F.A#)W785U@L7ZP>.T''\.BHL)K
M@S5*0C+$%7'(V< 1YXQ%K(1G20(LTD5%F+SF#)\Q0.([$'):(:]/8$K%H(?]
M3FBTNR>#_M=QT[^2 /2D^*N-\L8IZ[SB-@F=='*&*.PX**O!%[5T5?%W-H$(
M\VBD=Q%YBP/BDD1DG'?(!.E(])I'B=<V&'ET0&Y)(*HQPU.E? C&$J*YQ](2
MYD2@2ICD:>"L*%RKR_#3"I<GD450JX'7O<H)2!ZYD#ARWNL@A'4)=GF#Z$?7
MB2@I2$N'@-].!\#TIX/XII':W_(OXU*X_5P*O20E/6G0E3/&<<LL2XHKJ2Q3
M-E$N):9:@B%;=*A5A=39I":5J P@/I'"'"#5D=QJ2H U&YE-1#)FC =(K7^2
M1.'W!_.[A7D;:6.0Q'"?HJ8&Q&R43NFD8.9%A5I=?I]6H8PG5,C D7>6 )=3
MA6";&;)4"!^#M58!OR_*D?]B%*C'Y$2MP&ER[OIX.LHM9BY9MM*UAOTT.K.#
M^(B#Y6+'S@G"1@<)4P]4JP1B6!BFB4Z:LBA2/F(M2M>J@O =.442*QL50\$K
M#TH7UT@[ZQ" LS"*\"1( *5+UMZ,+?S^8'Z/F#OGHN#.VIP2Z#S'(FIC"68&
M5+&B=*TNOT\K79A3ZBB85E%$@SB-"3EG'++.1,:"-8KG1/3Z^ZE7PFVU,EK7
M=H[D[-E.YQPX_&OL ",O1.<JAN^<&)P$ES')1!S(8.J4%4(D0:,7V++D=-&Y
M5A6#]V9T+L.XUYY3Y$Q28/AR"[]%CG RQGF#/4UV <7+BI^KONRN2-(X88ZY
M,<#NTE(@!6U<_I=J7F*S5IC=IU6NZ(D4D7MD;-2(6Q*0298A38G'6(I$+5[;
M6%3MY1>C<;UP/U?%D:B?T.DP-FQFRGRZF#D61EN\7$\/P01[!CI7T%8F;@/7
ME%$2L\KE@U*T>+E6%H+]C,8E?"3:$8PX:-6Y$6, C0LGE"*3#-1LD,.Y,;%8
M5)V(XN:J(<,'X:DQ.F)-. <&-\#\@F!#5"[FHDC1N5:7X:=U+FY"8DYZ!$P?
MP,32.3)+<A2T,C&"F>5R&Q]1?[=V<7,M]G"Q-QP-3L=0<:,51O%P/3W\.A^L
M /G+./=<8.&8%\I:RK6U1KN2I;FR\'LP6Y\Z22)),,A7H5S4)&0=8' B ,I:
M8.F%7=N@A-;>Z"T,_W ?EZ512Z&E,Y:SH.%G4")[MWRR6."B;ZTNPT_K6X$S
M ZH50]SKD-LF&N1H4L@G:BGA.8A7K6VP$LSU0./MF0S QV6)KS1:+:H<\K.@
MU4I465X)*#N>T5TT4TI9";J+SPG4E&)D6 R(>I;[@)'<*2Q7619F44$2M:DQ
M49"D3H6"B]Y3/["8":=*3&) #$2I]X@SQY&)6B-.5*1"&!X#6]N OU8;*HH7
M:K'%&(;#7QLW.!1@X)I%BR_J@<OZR^IH>P6=GP"=WYW]T=H>-?_,".UI<^L#
M_1*9Q9CHA&0$A8X[%9&&346:<<6-M]%D78Z)63_4/^ICDA8^?SB?+UD7*WS^
M1'S^X3:?$Y>X2(J@&"7))>03LBI7E"?&".VCP5SD\E>SU1AJQ.<O(+Z*FG4J
MZJ-H_:!V_=-%6,VIPM_=0P3_J(W(7*9S[:IG++;MT/T6J-Z";(7TU32*@^*<
M?'9)]VU&HW6:.>ZY1=X*#AJMI,@HC5'D"G8_ G&X7"3C#7V>'G#W8L=5[@17
M@+D <QT-C/L <\'>>V+OE)7A.#'<.8N$-PFP-RED>1 (9#&5VEI/&%_;H.99
MNLTM$7D7V7-NIKO<'+VWGJ%;W-V]L&YR5V53V!O\U8C?3F)OF'M<#7*OJ_&>
MGT<[&#8BF$)AME%6]1._F?3+(J9Q9H>-_W.OK-$']*?[$0S=G"'\WHFO3L-[
M1#.[;_#O6?.H>;[3^B1VCK:_4$HT9R$@)FAN5L U,DE@Y+#RD4B1&-, &&S6
M_=B8=$5[<R]R, :VV/-$/$D<_M Q.:NPT& N"(M510[XDASFD$J%'!9'#GM?
M-"'$44=1$#D1D&&9:ZTP%((+T05M4N2Y2/ /J"$CQ7THPC/G/,/<4*>XS)5H
M$_RFO)$4>Y]2I@AB)A1!3*&(9Z2(B\TO40J0"1@C(KQ%7$6!K,XE#RGCN9(P
M8]+\A"(&<7@2X<.OL7.^/N75>KK6K7QM7DE]*:,G@I1)D+0G_6$[#^C7002M
M%89^W8KQ?VY[%R>Z#[Z^Q3I0<TY'W[]EID'9\QL1E;) F)K:CAL_#P?7_M.#
MB-P@VF-DLS+_J^V<V?/AVC]O3:K;[J&;*S@]^>5,L54UZNRGQMN,.3-=OY;;
MVI?@)^_M^^?I"2!@MM)LY]^VDXVT/P]CO-':=UB?WKX?KM!N9VN;[-'?C_=;
M!V?[6YMX?PL,IO>?<//S!]'<:M+]H_W#O>[>>;,]@W:X>?37$2!>9W?KW\?-
MK8_'8##Q_=:';_M;@&PPDIWN;^W]H^WSOR\^7>P<?/$*M! O- K$@LC##FB=
M$(F$LY%$;!5S9J:WKR4>*ZN- ETF\&!R(75"@J%,<FWL=&_?W5R&N3%9_T:U
M 8U<11!LCJK'Q8)[_/YL=$]+\M43?VT#P;7]'$SPGT$\L6 4OAO;)N.ZU>,%
M>WLZ&.3JBI4?87B/9;E<FR=DK*V8(HPNO.T/1\.W]J2:[T4,D^F OE'-83ST
M.C;2?G9FP\T/7X3W454%5:WGH$U0AYP/$K%\4! DD*W#T\RSI)[28ZJ,-ZFR
MJJ;>\!.JK"HB#-^4%M.EQ?3R6TR7=M"E'71I![V2"X?O0XCW"OIY4 >X;CN$
MSA+$[IA)^V>]QHD]KWJ_-4;]!CSQ-%D_.AUD<?DU]D)_\+"F<*4[:>E.^KP1
M+=U!S_Y:60$3;7)BXC1OTG2-G(T/LPBNSSP_L=W6[]V]UN_'>]U/>._B$]UM
M[1]68VJ]XSL7'\Y@K,?[;^\X\VQYT>SN'S:[']O[K8]'.ZT] 99#M]G:(\W6
M =O9@O%V/Q[?U6Y9V9 P5BJG]%+$D^+(*6X1%9S1:(*/3JQM<%S:+1= >^6
M]MA(D )H3P%HTPE[+%D:,*.(F5P8BKJ '/8828H-=2+W:?2Y,LFBRG$^.: M
MO:GQ4E7:L2OS9,J?5/H:UUESNW3RWH%U$Y]T0;E[H=QL.V+'C'"1,11M8HBS
M%%#.=D-2*]ANSQ4/)N?#U+_^7>'3I8>F%CY=&)_.:"-.*HFC!AW$.,1YL,B(
M2!#5W(KHF**!+J T^ *Y]'5[T/ZRG=/8@*G$T!C9;XU!]+']-1\+E3; JZ!R
M5/NWF;>O9;]]O-J\ F</@;.;'7P/8/Z;7P@1,22ID L!(TZP0-I3CB36%&-'
M8=USIX-']T0O*??U9=5%:1V%51?*JM>:QYA590S<!N=1=!XL!.T2LH8KI*(G
M/DFI9:Z(7Z>F)*_;T;$%MWVM8F4GH3'%Q[$*"L?UMHUCU0I\/5;3F!A.7-@8
ME$',40.&4S3(,8=1)$PPAB/55F4W;HTLI\*C-=4TOLNC-[-84OM;#.@B#OJ%
M=Q^L>EPVXW$AYIJ)GN6B7"(HI)E)R$=M"+$YY014C____].4T'_5B(%?M^NC
M%7NV-VJTNR>#_M<JYZ%A<Z!M%71?_""KH9949\SCG=R^WLC-RWTL9M;CL.ZZ
MU6NSM2EV6\??OGBLA!>$(6F4S#4#)'(1$^0" X&%G8Z&K&V(1RLJQ2527ZY=
M2&1(X=JGX]I+#>6*:ZF*@*?2HF1 3^'6*F2]Q8AYRX)RD@N5<H9AC;CV=;M'
M=N]('BH>DCJK(K=.EXMSY.'P]6G&.9*$TCXPB[QBN>4IU\@&IY$BG CL>#0)
MT$L\.F:W.$?JRYX+#?XH[/D8]ISV?RC+.":"(:%RL6)F W(V&P=>8YHT-U8&
M4"[JY+M\I@X.5RK$RM07GC./^>EZ.LP9?UR*6C[# KT8X;&X:L,W@P9O5VTH
MTN1Q'J8K:4(YBT)0Y",%94^3B&Q4 O&8>VQJ2Z46:QN*ZL4F--2N*&5!SH*<
MRT?.Q94#+LCY5%Z^JT:/-%*95$3)Z]RX5F"D<RH8(UHYHU7",:>"W=$<:%61
M<Z;T[JVZ6,LMO'O/PE:;W@].8VC\T;:NW6F/VO$^):R>N"R</XSAM!-WTV24
M-P99E<Q[Q76J+G8WOVBI _5@\7KF%>(B!F0=ILB&**-,E@BE9NI4+:W(X26E
M=:XW<>%EJ1IWT.[SEJ@R>EUK_< *55BH)RCZ)#!=?-$GLDZ(6:'!TN]_72I4
ME0I5-5G<4J&J9A6JYO:T+L.>>@L?Y;$T1H,VV#^EX%2IS[("3LTJ"F>B#%Y2
M<*LBX!=BB??I_N=L=8..OO7N BQDW*3OSG<_P[M;AYW]]Q_A.QAOZYCM37?6
M.=KO[(/5O=-JPO=-O'/TX6*OM2U@GIW=]W\=[[^'[[8.ONVVPN%=5::8,L0R
MP1!QRB*>2]A:12(BDBA/C,4D$<!*S5:E*$M!L8)B]70P%A1;&(K-G.L;:EBD
M&EFN/.)4$.0\%4A$ 6"FL#<,KVV8!1_$U+ZR5*U5T8_VK-&U8!0\6!$M$4G/
MJ7_!?C4OMPM0#!9Q-/R//<]>KX)?]\*OV:)141+G&>$H> WX)3%&5BN&3&(X
M,A4M,PRT,/GHJ.<2-UA?+EV(?E&X='%<.JUE6$45Y]XBY2U!'.N$#-$&@8X!
M"D:,S >]MJ$>K66L</3@4A2)_KGMW#J%+*E4-50B+H]H)Q;0U:Y-8BHV>V&G
MW_,O*L#BN:!JMDA#<IP9RS1@4XA@$%&)G.2Y<S)E%B?- S&@4#R^4WU)?JPO
MQRXJ(FH^CGW1)1N>CY.GE8Y$M>"""D2)98@G[L$T,!IY8@,@L))5G](%E6RH
M7U)DK36/K?@U=OHG546&_DD<5+T*BR^CUFK(32_LC?W;O=R^ ECW JS9%$AO
M;#"8>B2\%8@38T'UB SA@ ,-TFO,^*1%;VW,I,*E-5,]"I<NF$NGU0H*=H"1
MS**HDLI-SRVRP6MDF,=6ZZB A\% ,#5BTM?@R[C5<:;X,U9%D7B)C8*>"YMF
M\^JH9(HF;% (6 (V@0:A30C("FDQYDRYW/F,TCJ5R"WL66,-HK#G8]ASIHBD
MQ1'GJ@DBY617^!,Y)1W")/#DN?32Y!HGBXH8*\Z(^]1A@@%&H/Q.XZ#?#^.J
M"/"\KVU?6G.MCCI1;>6[R4Z^SQNYV0M_3K;Q9>6@/A>,^3OZJS*I'-4(*PX6
M$)$<Z<@TLE1A+)561)BU#54G"Z@P;8V5C,*T3\"T,XGC@6&M@D)$68VXE,"O
MPA,4J)6>P6_"@_PUC\X;+VZ+^Z45];NY6D+EFD.#V+&C&(KWHL[JQN79[KON
M2:=_'N/'\:;=2)<OD/40R#J8T3.(B4(GI9$CBB-.(X7?8D *C"86!<:!V84T
M!"W>C/JRZZ)",0J[+II=9U-)DC(*!Q2,8[E+N49:$XRH,AIKZ:-B##2,1U=P
M+=Z-^WLWB@=C%52*<;VLF?([!: > E#'=V3L6L-CU"A&X1!7@B#+C4':144(
MDQP'GVO8%L?%"^;5Q=:8+KRZ(%Z=5B:PP$0R3Y'!*6?7XX2LT@0)H@(A.!B*
M<Z^\.I6#7V2K+89OU(S^OF(QZI\LB>/N*#"VQ)(H#RA/^(I*#3QZ=5X,^"\X
M$^<NW+\9S-\[[:+0'Z')HXI0N)=0>'?V1VM[U/PS"P9/FUL?Z)>H#&686&1
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MI+>'MG<0MWO-:(>G@[B;0 TX&,3AL*#F(E%SVJT<N$M><@<P&1GB,F&DC?$
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MEKV^,2&)5;)4T\ P7=M(8*+/TNR-LZ8?B>G[['L1TP\6T^>[K0,PK',.RB9
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M/%FD<]INNIPB/LFRYWST@JJ/$+K:&=TX]9AUWNJ'%#MO!%&(A! 0Y\P@+5D
M#\Y(ZX)+X*)<NS&:[>\P):5@K/G8V&B?_L$MZFK$J+*HJ_.L#GX<6H(E)LDB
MY<"8<FX8,LX"/91!&S"V7@I_K3@M;5.7$8'*IJYJF3TYY"P1RQ4!!QH< (X3
M1SJYA QV(>%HA!V%?!;;U)*O9TM:GA%M]FJ]@3N)OC [S79.KBP2W:[UJ-?&
M]"Z91_8.H"7D3+JU2B1;_FAR<<#LK!4+A<P:/+O5'[O?B[VH<;;IT-%J=D.1
M,IH]N%&R5;LX:1Q'<S.T*?D+HRT(#Y8]"\#NWV]J.MN9W0(=KH@- UJ3E;UP
M%J]BB-D7+)G+1+7L96-W0-*U4IYA(B+/-0ZHY(D:KK'B7 =]V_)$TVBS<86)
M'CUCY0?\>UX_J5_ T_"]D]U#&0P1@0)7X4PB'HQ%F@F!<+"21,UYX&IKA\CK
MBE^.XG991)81 ,F4US(9'WS@GDLCA9262JD$ )XFMZU@70G <F05UR^/#O,Y
MI>@)1H;*W (H<.2HH\B'I!5S!KRSW)9@OO!T;;C<K_)9U;.<4O\]MB[R;RT[
MS" O,J&G06=<]V 6C>#'IA]]LS@\OO_/A[>(F-IWZWW.P3[+57#M*?S;!'H[
MO/Z[S[ME6G;^Y?W;78"E;H2+ 2@65QIFMM=LJY\34_,H:X-LW[*%'(VUJ$F%
M.@D-<B05J$M_:11[&"'^E >VGS[WXFX>527*UX@RW7O[\9 FCCV5&-E(".(^
M*&0!TA!7FB>;B/(R;NW(^6V'D2B7LN./;?>H%)ZK4]@9TD($ >]<%?G(J?F%
MGY4%+[.P6GF6;M9DXIE=AJJ2V;TJF9GK*YF]G)ID"\OUW%CF9Z9<CS4,>)44
M023! >D=(=Y9S7R.Z"5IKBL+=&.9GYG["(%92!XK:@VWPFCK<K\JS$G^B@X/
M5@VK+ ,\Z&87J(#/WFX[_'M,5$LGM9COEUT=Z^!01&8]QPHQDVN>.>61%H:B
M2+"")8.5DV&NAMF3J<CX&%7&Y51$*L>'JA89\R)E;\Y1L3?X.*4]L+GH4TX-
MZ-5^ =XRM!6]7U^/-+,H5#D&UZ(RIL\]AL]Z\?7HA]]"LW?6LA>OF^WB@8HO
M_78*I@90:(C(XFRN,&8!O.7;8WS:QB5&#3LS#>\\?'N[>&NFS&?YGF+;C/-K
MW\;;Y([O<7.WJ_YLL 1O&\TV:;#B5I>]H:?6C>WNEOBHF?OH@FK/I3U_G-K&
M^J;"EX5<3RKD5-G:1YRZB;K=MRUUN]Z3FH'M-GW,;GS:%S5E>!GYNVTKOK6N
MM5X2I=>W$94[=^R\Q36N%:%E17&]!KFBAHJWEJ );V=X"90_7_H[Q46:X+2V
M^Z\1I=NB'.A32-VG><[V:GP2_E6M'?M7&Q(K'9_<%K<8X +G.B\Z8ML+*%O>
M=LD7V-KYA?Q:^X7^.N/!/6*+B!?0ZJ%JV7"/:.*&!PS+K@QPKY-/W[Z>?A!?
M3]^?[EUZO/?V?7._\>Y\[_0SWZ/_- ].WH,7_(WLOYGIRG 2FGM_?#H].&F=
M'GPY8'N7'W']RP=1;^S2KXTC]O7+G\WZET]PK<\\M_2=[=L8DK/.>(VP3 GQ
MJ DR,FDDJ(PL!HTM\5L[A%^7Z'P?65_SYC05\JS3LSU!.]D*>5:)/+.M"A41
MW"0C4-)>(BY,;B:N'6*"><*$\TR$K1US78V!IP">QW:>[DM]<UH2:OY Q\T
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M,_P/J^8O(6%JK]-&ODJ:>K2DJ4(0F=I$*OR3Q)%7M?98CIZ:$C]O@_C R0J
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M!#<W8?8^Q'AIN(C*1L6CPXY2S95EFD>A.$O7W>?F2O\S1>,5<1X'&0+%/"0
M8F8B/)-RR6./U77WN;G8_/1]8E)$!*F\%XQ'J1VC/@E),"/1.B&*HKNUVJT$
M]5:O/$#-X5OJYS4"<$?!N:L@W'5A;UZH#VW?&H18ZQ^#\WZ6OVE;-0"'V.[E
MROJU9KMXJ]YX,]'2N5<[/V[ZX_$&1<W6^D6>!_C__[,$AQ#)*!D]U]Q&#H9*
M8VQ5BB):D3Q,T -'VY_S5N7=FU9\%'LG'P\=BRQ8[W,\+B*>3$)&6X6DEK!
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M1"Y=ES. V!]%@*]U<7W:5^^_J3^;W(RI)]X:3;3F$C@A!=+!>*)YLQ*TI(Q
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M3S&092*8=R2I^N[MO:KLB%M@Q>7G0V]=M$IKE'!1[)XI9(WW*#@F F>...7
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M!O 50NYRX65N';3F+L,]\64^%KXBX_CT0?#'C^G5&Q\.)0[: T=!.1Z1"[H
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MX3NL!U_^['UM=/A>X^!\[TN=P'<O]M["^S">_3\^'1\T_FP>-#Y].[C\<'D
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M4#^"VO6S*=:K6W[66CCYPN9TJOB\?I\3DW)L]S$)AN%LE]9Q==LZ0NW26>-
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MJVE@C@7+%=,."T\L"9Y:[YB_*;[UH>7CY<4-?B([9]\.L,:)6@WB(&3NC6K
M /-*H4B,22J'6^25D0KR2HG9@,$ZSGXQP3#8@7P1%[F-W BGO3:$""FQM,!\
MW>(MQ MPK#;]@P%HY%31D]WMP[/FWJ<#JVA,L* A23!%7($AI76R2-DH3(PI
M*I$;Z"KRBO%9Y+AN':O\7W;8L(V32?LH6V?ICIUF<,(/#:CKDI,U!UEBFC-/
MN5!*,ZYDX-YZPC&Q9I'DY,I[]8)E87H1>7^@?(P2L!U1&%0$JTF"121&9 1V
M,CGI)3;9U2TVS:R!<T.*Q#43JK# UDHMX*K<4NF<%E[;7&X3YS:^BW3Y>.D3
M^HGN;+\],$H1(V5"TJH\B?";HU(B*K2BPIHD<+92U:91UV#^7>;1$<$D)J"7
M3G( #>N\-QC8C70FP)TK?\P,X)=YO 5(@V(2+;@@R2 52>:X"JR[Q#5B*K@@
M(\,J99"6FWIV3JO6=Q5,3V](W#WO[FK&WYN,_S5)F3UW7 9@(3,BNA@B9D8F
M"HL.25:10)U*Q"K.E/;S47Z.]7!I9^)W>YP#\6K#X4,<Q/Z_,?S1Z_\QRM6]
MLH61 ^^+07D-M+#FV:<#@SEC, '(DMR&)PF)K'$1*4P"EE%%[')#[6M316M9
M&)L,%2^U_]I6N]I7S $(J9J+*DJ]RH*8BFU9DU[2"T9UYC2G"_]E)8NH\LPT
M+GMO&N.\Y35YQQ_N@=;O4 ?O7G'0YCGLU>E>Y_DV]1QFG\6E;MEU#G -2A/_
MVN#R5S,\M0:@W,/8[\ #P'4&$ZSZK6WA]A_]4:^=+<_J?I55F;_0Z878?L!F
MW/,=;=4(3>HQ3^;_#8AUI_ZL=.?>>W\@C,04%B\42-XBM8XBISA'@;EH'$M&
M$CD=&I"H!G,Q96II>(Q8NP@_N66:*4%PF->=>\) T(2!V(N) +&J UXFH>H7
MNZWGVZS3$IU%MQ+05&^BUJBVT HZ!K_!N'/X8+$NWS<.PD-W^288;^(Z.F71
M-M\2;PIYZQ;7"_7COEN7[Q_VX\:;1K/RL/?TL+<3@]7W+[_VJT0\S5[GU[;L
M+N-WJ_';SUA>P_K;#.A7N4W]%T#[8PWKI7*'UY58G%-E<;V'_(=E8!=\X9<V
M<->W7R\#]Z.!RTVV;Z_!J^H3!D/W@RX79GTZ7(SYR^L;^EJLHOCJ+:ZQ,@$N
M#[GP0SY0"Y@GHQFU!3#[\T-K\ VE7*VAE=$..&6C#YQR"04JK25N'Q)JHK>,
M89]HWL_DW#!JE4S&\Z"UL_2&J)75%3X_KS]\R>.31>,/D(QW8\%X'B&B=7WB
MXZ_[7]^3+YU]LM]Y?[+SYUN\TWD/]WDC=NC?7YMP3G/[\.3+]CO:G*Y/W-EI
M[6S_#=?]N_5E^PW>WWM/OVS#.VU_8W#_T^;G7-_XMV_-K_NG5<>(UE3%<\M@
M9IE#Q F/..,$.6TYHB%(;[D14>K<448O7?%\-0TC'D.)_G,;Z[  SQ+ HR45
MFNG @V4\&6V]299A%TQ,)BAV0SA4 9[U!YZ=WZ>:)C-%5? 2>95]UU$SI&,5
M:16-,R0C3ZR 9TU:)A?@>9; @S7S+E<433DN*AI/29*"&AZH\(3?$&Y7@.<)
M ,^4Q4.""T+2A)30*M?F\LA:IE"D1%$6E(:_<H^7Y9N-/A?@*6Z=VY'7'(#@
MJTI,L=]9#Y_/#Z9@_:3N1R$'=Z*F*TK6GH?-D[G>@ZF>7Z4S;V<7B+X%1'^:
M):7<$8%SMJ.G#G'O"3+..@0TP7&P$BE7>&-+;A(\4XMC7.3S#F93T;I9K;L3
M+RM:]S2T;IJ1<26,"C0@0-F$>"Z,9'2.370FT4"44#Y56D>*UMVOUMV%E!2M
M>R):-[76*:\PD]XAT#"*N/0464TX\D)Q12T8.H)FK</J%EI7MID6M-3_[>6"
M6NW6\+1L,3V%+:;5-<G\$=#]?2X5Q>6R.,;MS]CS2G/+9:( :IP@SN W6_7+
MDEI&AQW!$NQY+HO#I0#/FFXQ%>!Y"L S36E,8(KJ2) W2B!.C$(6>XP<&-)@
M7AM*.=G8$K,-.0OP%.!9CRVF CQ/ GBF+!Z#DR..:R2K)F,I&F!UDN82(M$*
MK1D7$5C==3T37QSPE"VF!8DKO$,+'C(,'F"?Z4<H/F<>GB6*+\E;5UGL\$<X
MOCT6BQK%+V?BI];W&-!9[/<*NB^&[GZ&SS*NHO:!H!A9 +,R"4!W"Z26:$.4
M<U+2E'584T)_71;BYR/=TX/X@DIK1VH+*CUE5)HFNS1:IHCQ*  V(2XU0P9C
MB13 4$@!>Y)H0:6"2NO.> LJ/6E4FK*5 HU1>A&1R$&6L%!QY))UR,G(0228
M8+K82DO3X1>ZCWM>IF%2F.92W9GSHFWWM[.[M&]SWJ0\JAC^SS*>IS57L3O4
M9(P\E_-DSE#).25 _'W (JK HQ#.LI=7+/5AEY/#&>KM/-<DX("2< +QW()4
M4Y:+=JN@DE)1*+VQ9<C:)"P6O"EX<_L:L!$3HD6P-#DNB7<L1BIL((*#:4/#
MRZOE^]!X,TVJ5:)&"RU1L)$B#M8ETM@2I B5)CIF4FY42\PFNZYA1<&;-=+)
M@C=7\<8&S$-46!G'$[<Z6N4#D'5G+-<LO+R:TP^.-U/V39(L,64UB(BQB.?8
M%1-<0"(%9[#R/G@.>$,VV6SCP\?#FS%?G=QK(I:B0I-'3 4HU[CG:ZS(45&O
M'7C.XC'M@)COPG@,N,T%;%_?:_14N<9JKK$6P244;U*Q/AZUU1?:*CLD"^R0
M$.PM=5JZR+@FQJ9@!*SSV.5>AHJ40EM/W+!["T;=NV'S8S;N/&UNOZ<'C) 0
M G=(^, 15\D@Y[5#BAMK0A*66ID+WN"EHY&?RRY(09[5(P]W./CHO)16\P2
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M1*K3JT@EDI"..XJ$<+D[HM+(.DQ1<C3OM$>3N%BS4NT/Z>LH.+5.[[:(QX*
M712T8R1QGFPT- AJG'841^GE_7DL"DZM!*=V+EE4.U_?'BAN%7-8(:6I1F +
M*Z3!BD+<I!"52E(YMXXX]4"%?<ZYZ1,((_@0!]'V_5&5:ACBO['=.\[=6V[H
MX_#B Y^8#Q%;0X$3@C8X BPB86,L2UXDJ5TA@^L 7?LS&^J>"0RFL4/">2"#
M1C!DHO (<\FD 3P+GF]LR76J]EO"CN]'A050I9@#CZ4UW,7D$L?,114<9D3'
M6':*UT2%IW:*A18XIW<@%G@$Z\-@9#65R"DLJ04P9LIO;(E5E:EZ;!4NNCM'
M=Z7BU&*C)+&):YYKE4@LO#*!8,,]*7N@ZZ&[TWN@WEFF@HF(L6 1C]HA)Y-$
MUAM)F*"P_(J-+;Y.R^\+KD'R,;;AP\-7C</8C7W;KDB"#9U6MS48]D$Q_HVE
M,LFU90V"QDICK(.R7&IBP;X0/CC%6"))\<(0U@&B_ Q#2-((8BCP@F IF!=@
M61CEP+R($4OX/ "&@7GQ?+>+B@J?6QE2@OH&$65N"&:UR<:&P$D(363 IC"$
M-5'A*88 YB##WB3$HB"(,V.1D2XB@W.<')%@=@#)9^J9J'#1W3FZ:Q,30@J7
M#$F<86%$XAQ['H+D%L2B,(3UT-UIAD UDQX;B1+C$O%$(M*:!Z235H$8!L84
M++]L57'@3VA;X5FG)EX-.!RW'9H3<_ABX]U7/T#/!NI+<N-3@/K#&:;%L7+"
M88:TD!%QD0PR.@+Q<C';VL8J0U:2W+ARW5F/K9P"I@5,2_[D2P73*<[K%-$D
M:8.D ;K+193(,2<1A160V!0UR6"Z?/[DL\#2 J(%1$N*9@'1:>>#T(D+(S6R
M"6, 44^194FAX)/$(3<$]WH5*9IK Z(WN"XFK8'A5>./<?<I?W.FG?I%__"M
MQVZF_L.>U'_4#:,;"_6*?M4XB8W^>2_RQHUMJ7NI\3\+8%^(/ CA2,A-L9QT
MAEG-I4F">!6Y]O?&QB\'>W=''11Z0S2^[I,'QKNW6=_'.U_] 29:X"@3V(1&
M(*Z)0V#G6P1F/0TN<2N$!*I]7<S4N+7XJX4$P1, .1E,U%3SQ()U*@C-J&;$
M"!+2@V0G%4&X) AG;P^8!_7$$2,L'$.<:X6L5AA1FZC "=L8,0@"ODD0,IHL
M(@S$6PZ@0#CQ@D?%G<?.:JF84)1%%A\D!:0(PV5A.#Q0G%+'<$(\F9R]005R
MSG+$5!*1NF!"5+<1AGX<'$>?PX':I_FO=IZ7QK#7.([]:OR[/HY7&'MB^V'P
MJM'J^O8HFR_C3QHGK>%1X]\X&.;/8%V#I:@3X;R<C%")$GR>?QT=@Z#U1OW&
MN[]V-QL?;UB\!I>?!MX Q<YQNW<:X_EM8S\V6AT0$5B";3N+R^)+ZN;49@>,
M5OW$H^IA;C8?IFIH, G+_W%OT,IGOZ[> ,;VUY-6&!Y-R,BEL\;V([XXQ3HP
M%4?#ZT^9:<C]\)RJLF (%U-C=^GG4?]BI^L0!*@?[3>PS.%I7]OVB3T=;/QR
MY:4ZK2ZZ/(+3+_\XK[B7[<IL1/V>\7 FLZ;Z.24P-1H9096+%@>I W<&;"E.
MC>5!"9O5EC_F2[T9Y#>:HQB@.Z!0E58MLCQ0'#FA5GBG&"<,3!)C B7")>L\
M(?+@W>ULQ;=C]?X8^_^V?)R_-NSTNAEH8GA384"U77GY>"[OL=,;[D=XN(F9
M7!:2:Q82WOSZ]L"HRM.AD6(:5A.L+0*CSR,+XJLHC8E2O['%N)E921KC122+
MTS!/!$C))7)R!=-]+KLRA>?U1%Y/8JIE9;P^Y7-Z=2_[5XTK_?4:AWT+TA@V
M&WM'=EC?J#6H%A$_OIF[0IIZP*H;ME'K2 S(PM^ 47G!:_5"?IG_=X5'KF##
M\H$$_:_J#8!9CC_*WR-7I!\PP[\.HWY>(E^<O/N3)AA.5MH@C0$ZA3'-5C1%
MS@.Q\C@J[7 RB8 533?-M#MA;%> C,U@Y^8U3H6']CA45WS= E%I^2LK@9J[
M$E22U_@0CT=]?P0"V/BKWP-MZJS)V_QP%=OM-MZ,#D>@['2R?F7+\K<>:$NU
MOK5 Y8>]/&&CX5&O7ZF^;5SWRHV?\C7F'/@Y7RQ?.1NUO6Z-5J]J;+*5K=KJ
MUW 5 -L UQH9X[(A:J>>D&TV_AKU!R- JPQ*V5*]YIZ5FZ=C3P&US@^-CO-)
MBZS+RG!&DDA>X<2] 6*F I<,.^>UT834ZS+6F%Y>E]_M_#&-5Y6A?O&4XX=\
M<SZL;SJ]47=(;K?,FA<'.]_.=K8_\9WM0[ZS]T[L?#T\R-6H&+42444M++F*
M(>M40IHE;[&!900+L*\WKR-O[F+=S9+9&PT'0U@.,_NZ+*5Y18R-8:M34;6<
M_N&'(UBE86HR>.4B:%D;!I?$+.>1PQ(#&M0%9?G7]EMQ>)J_F6RE3)?)WS&
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M8<TF+B1.P9##V"NI/1.,Y-J'Y\FN]R6#'_U1#*-VW$WUL/P6 =OCA63"?P9
M4]]T<R0BZ$>WBJ)^V6+J#[BG06#B$( 70UP)$%C"<A87T<"+<.343(O=HQA
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M@7L4P^1AMBLFRA^5U1[#:"H52"ZH:)$+#"-EL71> @71JRNH6%#@":# >L5
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MZA_W!CEI/O]5ESNK;PU?/+'],#B_S-47J'+L:_""6[5[@\'5TS8GP#M>KE<
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M4-F$!ZH=L0.;J'H";++]/,N9+#4IR\-.#H''".=<@S>M[$5J>TT075 ?D*^
M;>:.&RJ:2G&"!ULE%P"M'5E7-1AHJ'ZH*W(\+.^G6'H7Q%;KB+R5\&5*V3Y5
M2=9)J'F'RWW0Y4>*YFM5C_4YX*=Y\-UQ0FJ#\:P+/[1T:F$YUA!L9]N"K=@6
M0<!\:Q).GD^$Y0)*[JZ*3534;UZ@,NM$858PL<*^TC7':[26A@/HIN)7*,!0
M'X$"*(8,J[9.L?N35UOU'/->U5;-!C&\E5<%->%+8_[7#REANOK2L)LW6+)&
M!5?7JCKC$C55ZVJJ=375NIKJ>A#N>:JISBH+73Q"Q^M?^^4S8L"2;OY:]Y_#
M!RYI)!5DEL.[9A2%7I),*^/ >T<S[^X@5Q0?*L^*+*-![!EL/LFR:W4,VQ1Y
MZ9Y5)O9#L@FW]#1^.T_55YZ4!ZQT(CD)/5F;<8)V7\N^.%EOGWW]@M>!Y?[9
M_'9S8.!)^]E12,#"A_=\^_'M\K/5/()[ID[6O]CPW>_F$8SIZ._.Z=%GZ_3F
M@#9_?XME]]'.>;MY%!K-HZNQ8K_-WU>W\-EWVPELZA%'=YAKZ31DD>Y9(M ]
M[A&/T,@-PG#OK4GVR8Q.8AM?+Z"&I$V"I!=/FTV8P83AIS^ 4XT_R^'/8!)_
M(L,)0E<G-/1T:EE$#WP1ZH%'0]_@S&'"VGOK4G<*?!ZD7]2X4^/.H^#."K(9
M:]QY!-QI3N@]PC1-$5FF'A$JTX\CG=DVU3EQ;3,PF1TQK(XVH^3 L^!.7=FR
M)D)-A/O7.-U^/^*1Z":R(>KC>A+7WT.WJ2/<>0>B.O>?"H>9&\]2U_15.J>B
MS&/[Y+X6ZW*@EJ4I@Y3.(AERDYV-5D6N8JV>+J6>7E?<<C]^GUV>?O<CQXI\
MX>L.8[Y.N3!T+S*H[OL>$=R-;-LV]MY28SH:?N-]<K48/V91K%J,'U6,!^-B
M''G,,UW?TAU,]:6>171FT4 /6$"%ZUK<,[R]MY9GUF*\U6*\\AI7M1@_IA@W
MQW;C']]-XIDD$E07#!13RFW8B"V?@$#;!@^Y[U#; C&VUDF,5V0B;ZXY<5QD
ML$6CT/A,A/TTQARPNL+NL]L.17S^%&0=\)M^EG> IVK<6@JW?DQ9$=0./1X$
MKFXXP@;<"BT]((&M^\QR EN0D/B 6^3!19KJ\IIK+<]/8T0L(L]K7AYC8^1\
MPLPP V:8)IZ?&Y3IU!*A[F%%-L^( BL,O1 ^6<>:FK6P;ZJI40O[DPG[I#$"
MF[=E>1[7;=S/:4 BG5'+UQU!F"\BTW/HZFJ(K5\!W<TU2 J9>:(3C@=4/=MT
M"'RJLX]Y(%A#W+U//U1PCA=Q*T1GJ>,$V"# 9+H?<1^+RQ*31Z9M^ &6 EJ5
MOV4CBB#6PK]&QDXM_(]P9J*$/X@(+!SS=)>24*>>\'3F!9[N"T$LW[<%X2L]
M,ZF%?WN$_ZG.66KA7_E)2Y$.8/"0VL+2 ^[X.J6P_3-./9TX!K,)_ ?JW"I/
M6IZ@AF<^+&A6,K8M1?L9(M+J9RSPC%7:J1+D-LI(54%XQY\NZNS=34Y9N2MC
MI2R4M5JKF?RI!.!X*()1;Y +;)#'OT:M5T*[>70\^&X:-K&),'01\$BGKN'J
MOF<0W2=F2"W'LUQFPPYI--8J&J'.F]M!$+HS;VX."CW0?"=ST^=J.%H-')V.
MPU$H#&S>RW4WQ+;C#(\>'5_HCF>'7B B[D7NWENSX3OKD4A7 U$-1 L!T0-=
M"340/380?:D"D?4]" 3UF - )*BM4U@A/1"NI?M68%.3&L+%0@)FP[;7 XA6
M&9^Y>6;FT:BRZT/.HK<-6F=-<;VA=0T-S8*W:DB]=_2H\L4:A#F$84MV#Y:"
M4L?0&35"W8E\/_2H"]MAB-&C#>*O49C)BMR(-0IM$@JMM:59X]%#HUP5'E''
MMAT1<MTQ D.G8%SJH)H'NNTS'G&#$\.S'FQJUDA4(]'6FIHU$CTT!%<AD64:
MPK0\6W=MZNBPA5"=B=#0.<6U\T)FAO:#;<U5A]X.>TD..T=66P+]J<79T_5S
M.>CF<9FQ=S%,V#O^%;;[7/#W:=(Y'#77F6[_LM.M7JZ_AS[W3  -W7!D73-F
MZAYWN<Y]EWL6]TW C:E6+T\,E,-&3:H7"W8<*D.@9:\A\9]^_!, JHLM&WNI
MR+"P/1]U36(=D)-\HAG2O):@8PUA]E5'&%$PDQ8!-\FN,F6/F(E^3=W)FM:5
M#C$LS],XZ*M^,'DR-H56TN8BS89-:U2[I0R>Q4%(Y61$R/J9P&_C%-_1[F?X
M\DHW1MG$$)L_ZL,$UFK3FE%WFJ=M20/[7-E5Y1X]:1S7?91^+'3U_5B,AN]9
M]6!7/UB_X;F+]<]971N7;>R)4]1]>YH^.*MH8+)IW4L>UB]G5WN^U,UR-JI9
M#I!N,RI<7DCE,.G)WM /+W&YBFSBA;EO*Z/M?6[9W&"![9" !M3S*?Q@NTQ$
M7$2A6#[/[H&FWX&T"[8D!C^A5[];-Z<?3JRSRR_DV\TUO.MX<'8)8SIZ=_/M
MZXGY[>COFU-R;)U=3'@W;EHW9Q].;Z]N0KMY^:US=@3SNCRQ3W__]>/T \SC
MYN\?S:^GOZ\N0_O?OT^FSGT<GP3"%5P/@HCJ%$Q&W3>)T$WBFE%$+8-3,!H?
M'%VXK AM4)&!W88%[C//"9APJ.%38@2>Q3PFN,.)S07A?.D,O!H6G@46)HY?
MN$<L/S)=W3<\1Z>V)73FFD+GOL.(!8L(0+'WUIHNF%_C0HT+B MVR'W.:0#;
M"*?$#/PH!* PW<"UF6GXUM+)>34N/ <N3!Z&N(YINT;$=#?TL?@0]74O!%SP
MJ!^&A,/R,KKWEDX?RJXI+M0-%AZW%</L&,JML5+/19:G<8@^_K%##<3&AUBM
M=;G=Q7<:SV<\M$+N1*%) \%]V_<"XIFNYW++=Y_-,-WJBEA/M0-]G@Y4M(3+
M0H_J+@T-+)9/4#.5M?.%:S!B^*&QLHI8ZY>+4HM^U?AD(C*P::GGV910'@C!
M+2-TN>\).XB6+_]2*YG/(N(3QF=(/$Z(X^D&,WR=&JZM>X83ZK9K.Z;G<!9Y
M&(M<"_=6"[?!+2^(.+,=6U#7%EYDNHY+?>(8IF>$1FU!;H1P3X?3<<<((D\7
MD4W @O0-/?!(J(>>X*9PN2%6XG!>O^2MQ8R>YY#+RR1G[46.<9_ 758$)UFP
M5CSI8ZA3.?_=]J<],(_*J,'P^<'PRY0Q UC(7(,0G=BN \:,P76/$%.W;1H8
M?D0BPMG*3]]6(&*;YX:O<>6)*FC6P/(LP#)A0@GN.)9EF[K%J:M3FU@Z^D?T
MT&>&\(5E@K6\]]9:L9^^1I8:61ZO/&>-+,^!+)/V6\0M&\]S=<_R0T 6$_N4
M.I8>V%9D68$IF.GMO:7NUB#+>#[51";5*+\*>3_N]B7S_3G#2O&>R]R01U8D
MK-"BGF'[S D,9KLAB4S'C<1WTZ-[8WE9CROV4[&J,GG']!K:?T_,4(V?!0'8
M[IB!1#EP@N%%CDN9SP3H#I'M1@H1X![!#_ DQ/4)];@7F$1$-#2X+VQJN7;@
M& S4$.KNO?T@DNN4]5IQJ)UTU0D*OFT&A:=SUN:1>^;0_SB4B:$+WPYMVZ&^
MY_O49J%GV]SS#5@WR_>)3?<>=X'D$U_'8*?'X0)+5B'CN?@I8!9+T.L)&&UV
MEMA7H24]D;)<:'%7F[_;B&O5<V:5!O))\_WD?E/6?SZ38P(8N5 OSL;.]F"R
MX>MNOW,+.)2)[AJEVWXN]Q=Z>O/9.OOZ&9Z':80'QM7E7S_./ER9WS[ _O !
M]Y?3WV=?_^J<QI,IB=>#YE%H?SN"[V"LIT?GK=/.9_H-]@C8'ZA,2?Q]:E]U
MK@;__GU%OWLF\2R +CTTHD"GE,*^X%.L5^GQP#+=,+"#O;=)5TSM#EHJ>DF*
M5-:*]=7R%LNU7@H+E *O <W#?H8M4[HRRX['69@ < _V815_BG;2DS=A\A\>
MQ8LTC$%8?@^S_#KGS0.M(W@< M]E#>VLGVIA*Q:1)GZ!,B$S[I(HBD.1:L#)
M[%IV9TD+CL0H=/EL\9.U 4>*+Z.XR[KX(DSZDTS1#87,6D3FE'L1*[(98WCG
M:9+)'I5X*TP,[NS!K:,W[&L)3 VS"$'XX%G]"*@#>D[W>E^^'.]#EL7D0;W#
M?B"UHGXW+(:7"JV=J(Q#H!Q>'"8I4!4%JB48_T^?I3EF*L:*A%] HN#:BQSG
MTW@HHE)?N)3PD''3H%X$.X-C"\X=YE,0;X=-(JH7V,SR.9J<#B4"SV_#R*8,
M[$]*+-=Z9$2].U\5/:+ DA(ZM6"@78\ %<C,RD4$C@1- 4FJ^*[=9D&B%E/K
M ;&[^-4MRS!C5>6_9A-IG=H,LF],BJ=M-J@Q_^O[)R*Z+EE]UJ35<)W[#J@>
M[)\&N]ACZQS//Z:&70D&H''<Q93U:HK[&J=ZSC"UUIO&#\WVK$YXUPA7)WQN
M4L+GLSH,QQ3,QSA@?MP<C+6CY]*UM!:?_X9ZGOL9GPP;LB,?K- HL"C\W[.Q
M(([A.Q8!:]2P@G#I<.#"@3)N]:/%K_,DUXL[U\BM?#^SOZBRA>[@0;-S:C6/
MOACXKB;YZ\?5#;SS\EWKZNN7WZ=?3^$=5S.J;%W1YM$)N?H=&LW+<YR7==4Y
MC^%?>,_[UK?+TU]7OX]I\P:K;)WDI_&X6YD([@C/,77'=R*=>L34 X^&NF,;
MQ'8M06V'[+UU]DUWQ9[EM3^2JC&NQKA)7Z=@)F>^Y1$>4#=PO8#0P'5=(R1!
M*$QGZ4/[$<;5,+84C#4/)Z(;;5#_3,%URQ%,I[ 5Z8S93.<LLFV7$5MP?^^M
MZ^Q:XFP-8C6(38"89;D&-T$F'&)3FUN,P-[N!3R(N"^,@"\='U"#V'U!;$(7
MBZR011X)=&&#!D9]-]*#@ 6Z22V?<!J:%@WWWLZH=[JF&/9$6:O/*GC'_33I
MB7O9V'52RH*(Y9HF=SW+]WWL,@,[.8='4C,PF448":+:M%P#.#L=FI:GEP=V
M\W=(O@LF./5,2_<(ABQQ.]0]TW!UPV",18;)6"#0MO0>7K>@SBE;7_$5(8D8
MI]2T#4&9804V\P)A"8,PX3J665M-3R6AI=4TE%!*_3!P0J(+SP,)]=!LLEFD
M.]P35'AVX'LF=@*OQ7-[Q=-AGA$$)HBDPZB(7 ]DU/<<0I )?-.N[8$G$\_)
M#90SQPJ]*-*9XQ$=@[EUWR%,#XCG"Y\R0FT0SP?; YN7LSE\Z7-$*@TKT& T
MTFV2MODPF&BE(W$:]@)#>=-+LAA7_74JL+;^3_$&+3K=:LR(0L+J_OB O;<O
MS)</J).SPFR.[097UR&FYQ++,81#;2?R#=> A[(@]&PWB'AMNJP%\DZ>BADN
M#2-F>D!0E^HT<!W=]VBD<QZ9(K!<UV$,@'>?4F_[NO+5TCM4C0R/^21R_) 8
M-"(@L,0QA4-L0N&ST*HMEZ>V7(9YEJ;-N(F6"@7UB/J<Z2P05 >#A;JNYP:F
M2_?>KBK-LA;.-11.WQ6.!49*R(R(BM#QJ<L<,%X])W1-QW8>8+>L?0FY#1':
MB5T5,[<(\4(]9(S#KDH%"*WGZ"ZW:.@&U! 675D)N55W=MOR<PR5>?$8YQA_
MNN_.3-/YAU1;?3J]2M)L#> _,-.PMJ6> O4_3]E2H6\ .Q*BNY; 4R!&],#%
MHVU.F1'XEL=Y@,G.^]1=5?6Q5<C-,_NG:]2L47,U:O*J"PW5-NP]@7'2AG4-
MTZ*>:>B.P.-QV,QTCT2!'@E7^/"KY_OVWEO/6-7I6XV*-2K6J/A(19)J5+PO
M*DX&03I>9%*7Z%9D8&E&#!\R!-,=%KK$,2SNX9FG8VP!*,[H&/]LE1>^J_]-
M%TP:3U=6G4!,;[(5"'ZR:JE?X/R3/.3\\W%.;1>D]TE7ED_+M%Z:\'X(O 6H
MD6FI")/K+CR' WIQH1J;L^M4"%EEY3;.6]H']C/67@"^!:+%VA&>0N-5AV=_
M'_Q;>\_"N!WG@Y=8^D)>&:E/9.T4!K_%J<;:LEX)8B36S^!QIKJL%R5;L,(&
M/.WD2#=][2<+L7*+QJ3TR#?),^^)NB4S"D4M7YRK6(."4)8#E)Q>W6'UC/\[
MWJNF$&%C= L+0&#[^?Q;IC*7GW[C4I6^J#]!S<K?K70D@]="#U+!?N@L@M&^
M9NU;-LCV7HU-JA-W]2H%)R?_3)5=9&T58*Y#W(:[^:SYSBQOLT !L)GWK7.9
MFS-9APCK#^4#5=WH/_U8UE':UV()#++"D"IR!#_)O41/(KV?@2!FF<BS_5G5
M<>ZL>+/)!6\\JV$XSO:597F&7F&/4Z)DHVI"S*WN4B_'&A>%>>(.>G79CSJ;
MM,XF_7,V:6 (3FP3E#*;BM 'K<MU0TIMEQF$N];WD\7.XCX5ZM"G-NOF!UU^
M7&I$\/-[J0B)CP*LMW,<YEGT)1,'J <=H!Y\$(;]3K^-!1B/1 ],J%CJ@7#G
M00=K6ZIBE+MPRI<,SH["P>G7)HSE"[VZ^6(TC\Y;5U\_V]^.FC#B]_'5Y15I
M_C[^?355GOJ$-G^?_+HB)[??+EMQ\_*ST41WS5'[QRDY)7!MJWD#E+ALMJIU
M1&2L^LVQ_=WW;9>Z/-1]DYHZ-4F@^U2XF+PJ!#4-)PBQI<:^83_8=?.\.?@;
MT<FUSHG=]N@WPW0L+B++X 'U3)N1@$6^Y=FN'9@^=]<)=VMH70):)_-H/YO?
M#=L4PG>);IJAHU-!/-WCPM*-0+B&&9# %PBMWCHU;UL+[-Q '7XLK^BY>\-M
M-X2RD+LL<&W";8!0CS#/]5V+,-/S?&RP4$/H=D H:J?,<5U 44OGIHT%\B-7
MAT4V=#>T#-.T'&K['"!T5:KIUB#H_;3/36RI64>>U)$G3['K$ .L8<+L,' M
M:EH\B'R?$T"EB 6A:3KKM.O4#I-5;4F?9SA,[-"WB4UUV\;:&X9'=>9S1S>\
M0)B"$"I,B@X30K<W+'H%N]EX_,SR00<;? *,Q[W#=C;MP; )#4:)S&HU@V?#
M8%I4C[\TC/G]8RC'RKJJN7M/2/DY7=7\1MGBJN@FMX(LDW%HON@'&:PG+.;Q
M3^Q;=0D/?P>+\^/9H3(LH++7^M8Y^06P=?.M\^WFZN;  %@RSKY^^W'U]9@V
M.^<WS:\G=O/R!VE>3+2FZKSO7-V\;Y]]@#%V #://O^"/_:W#L#FY37Y]N'4
MO+KY89Y=7IG__OW#:!Y\I[X3.,3@.J$,@,YUA1YX-M<Y$ZY'?-NCMC/9I"@R
M7,^.?,LWJ4N)QP(#3#5*[2@0PK(LL%T%[#\]C.%)^P ((Y)KBN;3'0-GROW"
M79;^.*!G!).3KO87@]&F Q1G L @L*U7/PU;H !PP!<-$1PG@SE^2W43);;'
M\2 G%#ZAE/ @8-QGKF6$1F105XD#*<4!?IC06^PIX<A!$,Y'HSN2?;8^P<P3
M?E&,8#/TCB<7IM_-HR^T>70-?T"?N3SY#NOA"D.$.C/M2*=60'2?AD)WJ<4C
M1BGCH;7WUFC,RX,O@H,TM?+#YEI)IX,?XD)5HA 1[;31PFF@@%ZGK(.+)3GL
M^CH5U]CR#![S?Y91B!_(85.:\5T<]C=K US4#+8 @S5O/G^W;,<VA $,YI
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MKJ-'LK!^%(+%*G##^*.;+$,C&_8#Q39@+/18/#S/D^8U*W*PTW)_GW=3:3S
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MW,$["B,Y4Z'#Q5K(YP;J#I@K[N?E*5?A\8A3:6.CK2Q"5@;@R7". AG:%61
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MC\[CJZ_?VJ<WU];I3?O'Z>%4==U6\^:O^!M6WOUP_+MY\YE<7?Z@37)B-#_
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M@(7\%^,!T25Z5XE:&P67=90D7[;BE"]IR*WUA ZV:"Z=+9I+@;-;-*-RF[K
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M5+UQ]?8RL;U,-02;$_>[5GO+=!<SV6I[^'VEJV:]^:QH\[D+$[9H\WD$L'B
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MF 8K=6$*!%PY*FB@P_G$N,\>DV=BNL7+P6) <H?359(QK@!'/GQ#95W2X:2
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MLR>B@PB#PIT'+"+@$?E,-M+^!IB!X,0J;TW89(E9\5>-4X&EB92+"R5Y+W.
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M)A*$; 58@<DKZ9GA[D$S1[LIQ^,Z^8>9Q+[":F<W::F$NO%STY*8>)=X\44
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MUNKC8$%#I^,<Z+G"^ GG6*:DDCC7@50/1/0"5%8!@E2U#FK,$;D+N5-=O5L
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MRF@(D9&"+H:TI5*I\#[W3>_&-::<5Q>BM)-*,Z9LGM3\"E$L4B;T9+11$X[
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MQ]KM6S#(T1A4@A1WZ'/<ZQY@X[..;;G24B[-R'(/@5,D;]"& EB/_BK&/83
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M>XP'-T.^\4U7)??X(M:_67P3GXPW4C)2\,;7G1U:][Z><.%*%T3+A.BS_]\
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MI#7)X!@#A4+);?(3.H#K/VA0F2^KL8/:"FF0R/(^GD.ZNL!#:2W8^5UZPKT
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M+WUM+6Z/K'1 "TR3% (HR;5(KN= P"K$XR-.&^TTN,(I_9RNIC!>W?J<ILR
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M9F45)>-9<)DQ0\F:+ "?#41)VK2N>,FT<NIN3X(M,<CM[^C!UNY8'>/N9=G
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MK3N<O1KE>BNPZ$E%WW\>CFI1SR\8IOBA3C9[7_Z8XJ*PYU69X>152O,O]:X
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M:)H?.:#.K+3[<%,G7]&NMKT; Q2B+@JUKZG"S)/G9@4M@* 6C6>C3E9RYIO
MZ#XM3P0>)PKYOMIU]VI_,\=WHU_)K?S]3[SZAO\<CV:?Z[T<>9"<O/B@D=>N
MPQ:"=!*BQ;Q('Q"ZS9:R)X%/%B"GJ^,^:LS)9]-MWI>7;Y@$TPR)921#6D51
M/:Z M($)6;SP2I0VK4,V47.N"^TVI\BIXNW[ GL;(W5&\^*:QF==I*##35@#
M2I52 [L).-G.R%&XHAMY-)L)ZJW*YV1%[T#.,0)OX>G>)VM]O;H'84T+;+:2
MUD]E32<*W V*$Z1_5GA(8W@J0=?;G@+*\$@$TBY*/]992:U=:9/R>F98["B
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M.P8WYCM-!-K8R1MAJ7W($@O: V@#IH %8 (8 V# !D !:, 3T,$?80 ""U,
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M.1>YN+ETN7RX4KD><4UQ,W,?X/;@3N2^QSW!P\BCRN/.D\C3P#,)9@*K@[W
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M0PB "(B(24C)R"DH07_L! $$A#N== "("$1(0$1 3$I"1DQ()8WMI"<DVLL
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MX=R1]3!M21XKYW3X3\P64P@"60E5@%&*!1-[4S-&4?^I$,O?*F=I-C+_!'2
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MK!)WR:+"%)LH-/)4C-0PS,R2+[RII729H"11P6#):'1L6$&*JGBOHS  BA?
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MHR">\<6I=S_?@U\)"372Y5+D$MW)GNV*$(82#'6QK:D"C:*[+PE1H"G]Y@U
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M277W$'RSJD]JIU>GE7KY;$VZ'G"4FG>:]88R0</+!'QDN3QT6A1%L?>84*K
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MUED_&I\9X*\JJO]Z^!Z9)J:V-W#>V4[/.&$X7+DVZ2R]]>?'CB9.4D:S%%9
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M@KXO&ER<U2H.->TD$E6 H=]@G]/K!I\AS[4NZ.Z-Y^VMA8Q0KYA4:-%W^1/
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M*+<2^\>=<],%!0(E2BW<#(2Z"5( ;D 1\%5676!AJTYU[''@@R(H_A&V3OV
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MKW&?R+>*8OYJOGA>49S7[J3*N"E$GF;5^=NC?K 7C_;GFA?Z;\^K3O )/(E
MS/1L4.U$/*CR<:RA35$E%8'%&'-E,T';8T,:R\.0G(C;L+)6=P?/@JU38>,-
MV%3/0&VC/S?6/6\6GNW.MT&]:[2<05(D/VP7]=.72$).D4P?T5U<\WX_(UO@
MG0-$*[N^8L9H1#WWFOR#,CS<Y;74\]M-)?X"WSU:IWB1%+.<J_UB<@^5D/W?
M2U:2OQMR1I\JRG#?+E$X(UZE91(=.D\'^"FU%;#_5*Z;0M'C3443/?).1-%9
M\L%1H_G:OU_O(;8[:%;(.;@X?UJ"3KM*^E.9_<%I!Z1Z9N?\'IHY;EB))SLO
M] UG[-X><W_&!CT\ )WK@/G1"\R9O*$7N!Y9=0<9*-C$_3[&9TD.-G^0D[QG
MWM7,$ZU,H7Z>Q<8"RWRZ(0^"3YO!_1:WF)S;O47N%'5<6.(17 ]F.WW6VE$Z
M"GK@AB.]_M,OG)P[/B]!&2\B**%C'V#ZNK-GEI59J;F=D($;,]TE+UQCZ*_$
M0F[XXUY6)*G*G/G<0Q00<[1E(N7[L!#LK0;B[31<Q>5L4U\B?Y=:&78(_;P[
MF(O +GD:R+H?F%CH(&.\GIHW1L#1^:+>G2"^-Q%Y;]W7X Y"=]RD68II8[$E
MW:X$2C66D#;SON2=KY<4*/37F'OT:\R17(K:)Z]3K:$9[N]!5_%KT('.;49Y
MAV[&_0?"]9W.[+XG)<:A1G.9OR%LHEOS52#!_NNH$@17[OJ)4<"8P>B&MJD:
M8<+=_A76CT XL9IHRA0I-F."[,G2DDJ7H3RV_3SM,HPX\8.]T8/AZ3FX#;\P
MATR!6K:CV(C&#V%1^0-R(0#PGRW> .'Y2XXAP+!WBS213EPU 9(=$N?/)"J4
MMVWN.#-&K"KH8B0LT7(%#_#V.[?:[%&8!/8TAGWI:!DQZ*"A^,HZ4UUYF80S
M1M33Y^-W6!7;<-K<D$5H1@OYU&5*<UE2,QV+ R% 4GPJCKW^Z.QD?EK(?N[V
MY7M_^0U%0LT'^(4_P:20_)-$^$+.YE3KRZ,]0+"]N"'D,BWU^>S3RGX^@5>9
M?$]UR(FW,QA -^54:NWFB6K4;RW55BVI"O 3)_LL7)CP2.G]&."(L&=Z^]K.
M)%>J;<!WGY>M>Q[W^&V+,,1X4?*% !]?C8.GC-<GAP#V^,Y"^[4XD8CYINB&
MQ\$9(I^Y*3%^>M-SYB^81:  JA9^N-.<6K/9EQ9.LDU?_[MK6B.F(YBRCQAI
M'EPWF)7&^FE0"L'M,/*. #]5]WL\4K;4-%+N3_)A9GJF' \FWO&-I(Y)!<N;
M:A8A"G<N@$MV9I(=R]TVEMYI4BT1R'9@)/SVE69R*:HD. F8CCOJ:6,\*:<;
M10%6*( &0J(/+^9Z?EPJ003ND%$YL0U[W]SP%O3 D,.>X[8^Y]0KZZ3NZL2$
MAK;5(%F2+E"U9'!YS1Z9_[W(#DPD-79L9&F91\"M[40*SD0GHM8XCNLK!2G2
MG'%ER/J]SL#H]<;FLM;<'YM>.C[?O3]R=)!#?9CNW$2\*A'$1TB--/'N3VON
M/]"^7NUG(F5?RA"$5;']XXRY]"OXX2/TIBO(7VG_TT)T6(BLDI]]P=<\-3%J
M _W*3WM5<P\P3EEWK!_6V?5\B:('CHJX?ST!ZD_E<"^T]4#ZSVF/7FJ(H,MN
M_TQZ;LP6\3/S"S3#_=H'&;S<TKQD"VU].'U0WD<R+87F]6J0OLLM1?2"[V*0
M'M-::00JAYA+C0X4W7?JF^Q# ??#%SVTE?Q1 -\GT)B9(9J-K2Q>#&DK"4AW
MF^6+\TOM9;L6:N2=L:=G*H-* SHO,/RU83&E'(,O=TM6Q_WY+9G7/;G L$5H
M*&-F4^FD"B]R3_.=_#4$]G>D#"3[6<D+H_63;2+DA[ZD$&ACZYP7$^XBA.H\
M=G]O83=\O_O+B2]QL%UMBL36L0_MY9H7DE-N\*C<&%/9?V["^BPS'!Z=^>1&
MB(\93Z$>>J1G!+:8^8Q.9"*',@\46CC0V\JJ0O1TR/>WN:":"Q$G& X]X=N$
MGJMQ^.4?*LZ/C.@,_0=:*GG'C!<^O?@:@=X134UW2)KMOX(7=W9M??$2]I&G
M'I6?YI.J3]N-][ZI=[16N&&F:Y!NGTGL>4LP-G4M>L[O89Z9G43C8Y?BN@R.
M&'N3<)-/M^.VGA.[D6"6 C[>864USC%FS B&)=I D ,2=Q@AZ AY+1,67DK=
MM7NY&MNGYOE*V";:;; ^H8&+5NXI0A#6W1'M?&>BA14>V47&];))W+6XFRML
MQZ/@06.2UYZP08*_C4@K#[9BSRMRMWXS3:PNX3.#%']>N#0X!$F]U4("8TRI
MBW\Z,966<!D]F30]J\Z&S9$<Z%C^HDLT0QWP$7EJ5DW4W:X-TP?30P*EIC61
MDV:8Z*PIGU2O'12ZT32[>A8J#_D\BU!P-VP1<Z;PUX"?[4MVS#'#XO>/4QIR
M'L]/3J7S,"3:M#S0T:2S86E-+2%-C YQDRX+#L1%N(>UM2]4F\KN=R-86FV1
M@_2'C]0O:VO]O-XT-9VQ;Y])VGI)#SB4PB;:!"DVSM>^[#Q<&!\()T'<\!K9
M:+6$8;SK2_A^;RDJV2[XUI?N+@4ZZ9T( %8> :UY^=J,4E8[ZP[,J6]!+C9L
MC^@E>O_V192SRK6@)X?\4WJ(A<*9%N7N+56IQ48_\)2S"2QV>V2.?\23X=[Q
M-(AL:OVU46BF\QN!I-G;T3PJ(KN*[#JQR4DB*3L1V\>Q(6 J6<RE6'(',/YQ
M)GY?+CQAZT+Y0AGV3)*!ORR"I^EC$TAXCM)*$I/1IKK)<1_:A92 "Y.$B<=2
M/-K*X G0&=6N;TF9,3)ZK^+)V$^H1B^*K:=>9,S7G:#L DC'4CS-I)9UO5"$
MM+>9DL%J\E_Z@_,V4B1M#AQ9&3:R$Q3FV9_"L>1I*]Q</SIV2^]";6*9(;'=
M&9BM\GQ^]L>7%(^:A@7*=BCZ8E:R7%KL'A U#"IV,U4%%RYDAM&G1,):N^9$
M,OQ41L4_$<E_G^*>C>H=NH[Y&OMV\&&4>:S_8NQS,+&X8&BC<T3IL?2.$T@/
MQH2LP*BV>?)Q8"'>V*V,$:.'COGE$&[.\)]IO1*:"/]U\'@??P[\ZQB;'[HV
M_*ON//D@0O_/C,47QR$$7F'N5BM#\HH_.V&C2;)(H)B/M-">F83S$=</7+X^
MHHX22K=.%VGQ'QOG(;6%ELY^UJY,LWD=#GR2I!^MXFFOE>2Z*.*6 D;O$R(
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M ;SK*"#$?E'PG)=9" 5\5F=  <G'ZY17)OY_9V+Y]]4S@19N^)?-V7J(?[,
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ME8Y\"MU<?>+1[S?OB7)?7\)J'.A0T)72-+6PVK/@[<7/-.")-T/%A)+<"&2
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M=->PPZ]D6 RT=S)>Q'0ZJWV[VEA(!W_D4$405AY74JP5MP@<[GO=9?W-QT)
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MAQD?FQ%AV2+\ZG$:YKXC"O49+#_6LLFL&.K"]45.E>[E\0-U-$>?KW-P]#^
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M+4,>)WMI+ANYJU=E!_1L_ /4)I\='[N-S_7I+@Z4@/8EV6L<'<_5@L[\%O6
MO9A^V!@4*%A_<89PQ BAC1W&.2)%;L+AW1>0<-L71(K,G6-,I98G""UW7UK
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MDU03=\/3W:1[T&TJE$ID 2N%T5T_";]V3$EC*V49"96>/MI6%Y5\[$C\6 ,
M(,P25*GHC9[5*]$ )B;9[430QDEX=#Z5N:"I/KXHQ%%3L/+\/'_TWNY=M#Q
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M90JQ98+'WD3GJC99?<^S%O(<;S6D9F[%CJY[ZR Y=FG0WIH*8^R I5.PMM0
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M7!58O65%\4O<\5W#?H?8G=*@&6VSPEH*YGL@T$GL<RN]O:2_0%<!+%LNS3I
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M,UYM6Y#>(8#X#RV\D]2)],#GC8@:0Z,^+X4R^U>+$^Q TP4^".TPB^T"YU\
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MANO'&4?:*S%,*ZY[5B20#:V8E'KBI+&'T1HQ!"OA!LK;HI[,?P(R(ZIQ20A
MUV;]@[$#1>3+!\F:3O/Z3@EK^/U=!J08Q$]Q!0J%[3!,XK:W3CO=D0TZ9! O
M ^1"A O</(?4:F-9H^C P$+)CVBN.TE:?B:>3>3GG8DF&^EN]I,7.HVNQE5J
M^QJ#-+)J!XK,$@ZWVC_%P=PZ8&KC,+ LPO.J!)CD>,&G8)?NDB$]KY]))\*A
M:*I-D4"/$V9@63L'"PA7(']D&-X: QFC\"($Q;EFN,-U,LQYF\Y,8[2OW]'D
MD^+U\E55 *LP<$3_5&WBH:-V[^U0O$I(RKTT4/FHST)+^C=3LX-;N[D_,][O
M1+=88A<!M)_5^P'>1'\!P9<.0)X[Q27Y="]/MU+' YQ,_G+A3KLI1/RULLM9
M (365?0"4V;>*S)W%LKY4.F^>8F:"(>"/>T=V0X:;FD[IRXS"X/()!)_B7!V
MG)03-&8Z;ZK2AE&:W#$EH@)Z6OID5FO7U\WD8T%71W=@'<V6VJ:P#<)UEV2@
M!COWT(9(&789H^J+(73)EA':BSK.P#C.^JF&<R-OJ1I%3(?YL]QC@B:&'Y0K
M"9^?8-,!#L!FCOPLOE]-]H7CA2EV<+N&\&:D]P^L9:I#Q=<4>AMNNZ<N>0HF
M']D.S78'LHCJZ:,S);)WL6O5NA,P1$;RE/B>'0]WR<]M3T0RT:'M"U<._;GF
MR#5JF]+!!:GJ:[VRF+VL2BR BOXXS$#-9[B@HD.9'3]?7;Q? :1B<N8(KK)M
M0?(#?^:Y9(WF^-YE3YA7QB>DQ;H8W?<,1Q585-T+-HW8\>@$AIAJ[H/TR3'"
MGY6U(RF$LJY.1 JZX;H:A9'.["9[$.L3JG-%31Z6!$9CWL3>F')B)79*MXA<
M$B*T8)4E1&WK+%R><1WMWB?1P5;S]<!+Q/S @$#J2]C89"NX1LSV?9<&8;@K
MAI<M"1 I&50-AC)O,6.@@_\"$!8M86F^C@PM*F&1CDR9%*GGD49;@LMCNKW?
MR.Q/<(W&IPF2X)?%N*<DM?VL>H_LC Y8NYD*F-:6Z,1D$V1<>?GO&0OTS(F1
MW@I,RXVR?Q:7T_AS5+$AH6Z:Y>*0,V\SVJ ,=+0-XI?4GH-:5J,%Y/C[9] S
MKT#XQ_9&2IB#8JE(N8%=$5S^O<3=8&O^"]\OBA- KS';(WF^Z3;9,H=YF="%
M1*_R57A1C+]Y8];SV!W>%&R2) EI*0:;*AR ZP:#37/8]M9C"67H51ZH")U-
MWPJ?J=AM27H>"^_SMT^CJZ\A8MMWD")*$L*OEES@@X.9MS;ZSL+CM]9 1BB2
M"!=/'K'A_)GBI)$30<L,;M\*FOSSWJVO53'_.108M];29W_80BYXKG-).-$'
M6UFJ=YN[8<F.CF[EEKVE#EN(AM"BCR9GX%_Q,,*4IQ6#<D%<A>&OVO\"PKZB
MC$H_.1/%=%#4-X2A\EQX=JBI5;:-!_ !>2P,,?%Z5N6M>!OR.45O9^'/8:T&
M[B*K0-]$B17S8=G=[RRR[$:?[,*TA0HX$C!8L'8FL _\V::@_%M:@L:U_P@-
M_(]60[-^JFRU4S\(ZC:1:76,GQX-.?)C!F=J) & !_2_]$589OR)#S>>M=$C
M=7HSLL):\]1*( '&,Y=<(%,VJHNOH:3<ZX5BGT;4#;ZE&#.+))$L9@;1ZI/X
M\[@MQ$__4[;Y;91VNQ_RHG\YJS'RGEL@%%SJX-/GSS!-=NIKGBH4!'RF@?T(
MAF5KOM^*_<Y;(K41KXUFSE>R!R$LS7B IJZWXX7.MBTHNT(J=PN15PDWB2O]
M%%ITE+%J9^QJG^QI6'+>O$\>OJZ6"+\*0\J-_4ASFZB4R*0?2G*R1L8Z67_0
MBC%2!<77WRA1E#M_7E'%YP9D ,Z98V_M(^X5Y5_\SK%%Z6;<,K:HQF^-<:C8
ME5<O3D'ORB_#.>=Z>6)+M$:?<@U+XK@4M!&Y.K?1YXY,KIK7FW2]D70%DK.>
M+[!NN]+2>+#$1)640U\C!\++T!][KLT:H_;[JFRFGZQ.K0LIHHUU=6U%-I,D
MJ0"V";S*CV25+Q2H2L+&-NZU"^O!2F!HPU^ ;A6[8"N]_QU&L/O)["3N'.4O
MQ[\ LC;QGY C7:1G51G#.L?,)K6D!"L#1<RQ-*'J/(L&+0N9\:\W04WVQ409
M_W>6]&NSUP#4V7+#CMD]8X9+K7P^^[Q8VAV#G;).-)JXG[^+.W>"5GP(?==[
M.SCHYV+=C-R-J\Q;&MP\47NE6?FAQT^ZJNHT0\(D5?HM0_Z3YF3GU>'0M;#!
M5G1Y3X9Q#"SG^.3CPDGJ2X@SL%-XYCI1O4[U<R$3(\4V<!N/!9&LAOJ85NV4
M,9]EY[F_[DA>"?]C95Z=PJY:]V(GD'['4X&'/<?J.58/E+RH,:)-;=.CO0.=
MZ>N;UVKY$&TX6?'GCE'F55#>BVO,<=(7B>RYSS0$W']0X@1M">(?45GC/V*8
M#A=:K:P>M+2W-4Z*%T9=!9JNA7D;QN02'N)_(JR9,+L5C5V=_@MX ;@IL*R9
M@\6'!U#(,VILC;G\QZ]</+G_MU^5GEG&."^\H\D[#_EW-/_Y%19FX/("E+I2
M>7-C^>DOQ[0T8Y_0KZZF8E^JQJ#&ZF$*JZAT>=?1H)SOI"?6JEZ7P.W[1T-"
M9^#5/AP V;]G3QM%N6]I31^D88[J(/?R7("(M;961UHP)CO#>YK 3:Q@11>?
M[0Y*M([%S".[@Z2QF?@#O,TG)[K0NP3FH6):S>)@DB2$5<JIT(8QX&;]VGG[
M+Z!:#>5#4@2 +N2AV4U=0JPQ85.%UJ8;BT["XLOP@HH&EB4KGB1%8^' TV8^
MF92SJ#WX@SY8=#.M-P#3"F)N"EN 68*4:]N2P!+JQUL.+N]C?J6]R:=]]14S
MG_MC7UL@UO91,-4K6Q;*@2=RPG&7O0X!V/>L6VLOIT_'1R[ W\) LK*5^J=[
MXV,WO4I@ODI"3F4A)C.!274:6@H,T#97BG<5E!W5D?7>^=IKP8?SI(T*19)M
M2H?W5H5QF(.DTO4?J(*=Q5TB_P)6U-1GP6(W;90E2Y%P1AF0P5[1V$0ZOJF>
M^OOSI)):?2F6',>)_9,Q]VP>=-#67P#."-N\)TGMT+RD600F+<=8>UVY]HV*
MU#*'MLP/)/X_2'J/]MV<> :AA;)7.AEGBR'[4Q:^?OK3$$#\6\-/K@(Y*MHF
MVG651J9*\[JB2,_XQ4K<E_W?@D&/S.&]CQC!4NPH;!XO3W=_X[XR;*_6DO2=
MCPY;&&R$X[_8ERM::T9*6+PDTO2LS93<"<Z";4U):XQ?]+)L_D$4=NVC_;S_
M H"(0/E/R2_G87)XVG,[DY[2F]/^G(=T\+GV]F]UJWYQIE7YY(-D9=[4U[\W
M6O5?)W6]>VLB]F#=STR^LV#0:S96G"X9_TDP'_0@;Z+1H$6GWC&I%_@\^QV6
M (81JPGNII],NYJT?+O;(T6G9TN.-@SCPCCJGKO2]/[UPKT.4TB ;[&CO]@,
MW)NU$>:5M+?HR.O",<E"^WW@W!X_]88!\$O(QSHB6S" 2F.S\F-OKQ6WC'8D
M(M.[2H!K\M0F!2&1]F2ZJ-8:1JF:@O$Q@EB#/I##%_,H YJQ_1MQ*#$[O>:\
MO.AW&?G]9S-CD-T[T=FR[1 SO$Z%?T6XGDVYP >4!55D,>MG\),@N(HJ)XK[
M/^TA$&/[S7I\>@RT0IRFAL\Y@[-R:P'3Z/"\PTY2<1U:2,X;Y&-%ALHO?Z89
M\';;3$EC<YN#N+#8=+0CA7II))>D#&'H9PPKG6DSJSRJRN)N[Z<6:MC#[4:'
M^"S?L)8*$M_._@6T890K*4Y(372: 9 N44RDX:;H%$1KN['B IR(S(7(,4I0
MC,;$HA=H?$V&_\Z3!5;S>&I9UHS$);W&D>/N7K/N:PF/A*.=X8R^EL@?KN;M
M844(/QI'K_S-,_*7[.<L@C1Z]'C"Q)9I[N^VY])]0X(57N/A_054*C)YW;UT
MI/8YZZ6/EN7E@=-NZ,_0'U^A:$T3/0F^N,.PNMY^\ 7@ Y]N/;(YT%6%H%I<
M*"2J$6/<*K,P*3'T&9"WH+^LS4!9K&I*D]YL=2BJYZV=K6*S$:%[H_SMX@LU
M%S>M%]*,?NX;R%R2S#;>+6]_QL-L(M0W'_MH.!' _'#*2OFG(VKBI]FHKSME
MSVJFN>$JY;(D#IG<;P[Z*7^_MKV<4LLC*PX42=1QFV0Y9UP:BFE&MZ4NKD?9
MAY_X6\*_4OWX5F0G/?5EIE?HA]?!3YC-& 34*]JY>V6<PTN=KJ_^14G[ECEG
MJL,KK>-UCVBZ5_38"9T<#D)-#/:T8A@7[95Q]0B7*!%0+<3%K'[&'K4;>JSC
M5S**#WH[9?MUE>+=4U8H5AMFX<D[FDV+N4=&2(@%FGW;4F)DY'9!SX76\A"U
M4LC#<*VK]A/_+^!+/0E_]$"ZUF;!LV9LNEO%:JGA<>'U3#?7U(;S,5[**'&!
M?;Q 7!WM@$H M+\*0K6/V&V,*)B!!T28-<"@HG[%YE;H<M7&:;Y\4%9Z:%!]
M8Y(1_]/SJ-^YG[M2QL?A",UXIGLEM$PJTU,45\Y#?-FH?)'X5;1XFXSSIY*8
MEW9V3S9K!WY'<X]T2IAB7.L0HI.U4>'A?];<-9KN/J:4=J5)--(S H?6E(R6
MNX2&I'>,OANT5E, 'I8.5+B6GV/,_L\VDR+"FBH ,7Z9_X^NJH7RLS!=O'C_
M28( [U*HU/2GRQ/E7N1A!SN5E_M!HY8+1TVF9IA#8S7[ETE<:3P<]7=/+CJ9
MG9870@P0S%\]7$A!('M[P?"J8SC^):VS<X79Z<V'5 Q@:-:WBO?!0WT(-;Q=
M%A(+]#"RJ./%V.:BW3F]]K1G8NFZ&M^T"KLJ_YZ*L)C-YR&F5^^4>>@_TSSC
MU9_9W/]Z_(=^C,$Q2<O>UXOR83;-N'["S1VH'<^0-'YJEU 6!73^+!3D?T:!
MT:NQU5T)?6N-J5$.B5OHE9$/9RHC6SFZ+G/S!5Z3LXLU?K"6FQ<*Q+Z0B!=-
M<,V$[G>?N"/B([.Q9L7]- WF/1F9'\G\Y.F;+@DBY)<84U9YL(!N+06B I2/
M%AJ->T0PC#_VT1UTO^6E6FI;YOA/C6[[9%8V'!>NJ23URK=]\',]_&*#OJW!
M4O15#4E-_4G1^LQH5?_1PEB%1]+*WM=W.'T-&_9&*^TZJ:-[O&#+D;L0&PZ&
M#,#-]=9Z.0JKWXH:&1X#6R,96,CFF*T"GU6?"<!'A?,G'/E"QD/YB;9(\U^-
MU2;A?!-S,D]]YUD%UW+I,U,-_[#.,<\7>M;WH/DF&S%]]2JEDF(=L2HD;;A"
M5XJ%X_KTQ [;YS@ $TA-54N5WV(Q.-HF\]4'FA$[<W#P6<-%^M.O#D6_OH97
M 9#3N]7Y"FN">TF2I9>.37<"E0+-Q/;?3MK3?EUPWJV>7A3>Z(Q>>&R^PXI$
MFQ>/=#Q'[8<+P"T__ 5H(1\;00+?G>&:Z5R1MO5A-N2_IFFY8C38[^M$"9\)
M!P)^=P"=)'T4NA48-Q8M_VTB.-]*BZ@?%LH9.T_%FAC^HBLH6)JF/*.Q=S'3
M *RFYBVV<G=B-J,W>_JA+4-4*HA*KLCPY-U4_H!N8"%C'Q5FX_V_"*#0G\T\
MZZ%E1 )W] EM75[M;D^&.A>9>O%@VY)/AB@R*RAO$0SY<T)EIVQ1 ='<-2C<
M$"_?BO*C1I9UK6>-MIYVKN .;PVVU8$G&/ZGAA=TQ.T(4"?5O7!<_P<455D1
M*)MG^B33<M8N8M@%BV9RU)4M?2E5"!=1V("KK2'^!X54C?$<8S>^HY&)2P;Q
MIWQ;MWD\I 6V'S5*29\G)^'3;)>-?TE'YO0LRU>^+UTZ^$#?2M\Z>N0-O-$>
MKAJ6) E>E!T&/E-\?/8/,@MGX=8,3ITTGM5DRZ9HESXZDC !#T&TVHFSV<YW
M1B8WB+W#-AG'U_="!<X+:V&<:NS;;/[T_N,7O\>I!(G1Y;U77BU?A,K I5^#
MJOB[CNYVUV0NKE,#]'+*+C="'^E0$LU<]:4''5]*!-(EXOG[O,CZ[&!I:9$]
M0H3X',&JAC]BZ.PCY2G0YOV/^(W(N-I"-;^M(\\@UGIO6UQAX@U>,ESB)\NX
M[DDBQ)\=L 8>V;0D^^*C%S(,( I&J/ PH&2AUGN9 [(E%LN7Y_S5K2>B?02<
M]>_ :_$*B3-R"\<+B#'E/FM"\)^3+])@J,;6\,:KV<VFYW:F[[I4_0JKK$3I
M=\B(CX/5Q#?0+CTRQE\1'?&:\#NACM;4VX.8>'9-L7"!W1_)BP#1T*> +H"!
M6#7N@0QWA'B6\\"L^:'/X#>7(E.&BC&R;ZH\K0[@$IQ [$ ,;BP $S.VOPC*
M)?@2;T9 7.L#O0*#D]NAC&=5Q95DHXR/Y9MHHO9A.^%O+CS!>#$B P8^(2$;
M]Q2SQ\X5]TIV8.XH_BJQ!\5NSP)TW8ZEI>.IC?&3>I>$8?IROJ@!1[R)0$5Z
MU;'K[K^ IX=TYHL=61QZ$GD2/^O-UG5P^HSUZ\62!H'.=:HFK<&DW\ ?K5O<
MS#I(D?+QF[ZRT6"V=?70O@$$PC<SW;E*@(.%Z)^OB"5)3/XD$.[2Q0/HXHVV
MI%W=0<51U-'YJ.K(RGLEO#B[&;XB2_V/P<M+<#V77;_OR80AH&:F#\(,&(&Y
MQ"5]+7.#O0K4D(U>(W\V%+:/18MVHES^L+= &;31F#K)7,QHPEU"K^AI%(&4
MH4UGS#._8IVOC]3)O1>_8XL#^JJV]1\74DE@FA>6]$&NMFNM7K>3],Y?4#$V
M43ID4&YD9[2@N&R[P9L[K?$"1Z*4OGR$R6(_826?^6NA\R7;#]TSA,3$$ J,
MBUOT73\SL;._0%%E=FW1RH$_1;39C$?ULR/^\M7EL98MPJHSCCR,\Y0V>*K*
M<NX.E1U=AP12!B(YN(%S*1OP["CC.-G)/3/"DU_;O.F,D\YS%'^*,?V] @3\
M]<4'18G[\G@;Y%] =PX^VMH\T[1F9E^FO;_<='7#RHE:TL"R3UW6WMO61D((
M,UV24@_NVO:6B/W*%\D57N5(UYZ=["KHX<5?3'NIV5Q0@V/Z5(E\1)]C><?;
M(0]B)?^V"R\**CTGS_(O-#X^0Z5FY4&6+_HR8N?@EP]K>XT.8J8G=@G>*/[T
M=GDSCE?'O)BCS10_DKKNU$ZP*BQ_*Q"<"O)5E]1DB3,*:_6W%7,]6;@ZW*P!
MXNJ/^"FQ7);KW>,C#<U@7ML:WV^\PG7C=< O=V$[S1PYTI]B<NQ)FJ,QV8=L
MFJ"K"\8(%X(#?^%)%YCEQQ'9!X$K48JK<WO"DNPG.\]<E3&?L#S[_!QK0)Y;
M,D9\(F)=8/*>^Z=VHS#:1JM92\XE8\EV['(P.W$(XYD6WW,;<HP466W5U6I1
M! DI"0DZH)_./U,A'LA?N;+V^_-P 3K96#+T?:9NE"B0FLU[L2 6U7*SXO]2
M E-#OM7E3@'-Q'Q"[??"MS7KY9-WS>WMLU6GSC]46).X+G92"HU5I36P\"P$
MIB6J^,WNR9 Q5-0-=8MKU@\MYM[.SN+\VH?G>\K8P2:&$WRQ7'V>J\^$+%*W
M]SX%0OX"XDX\+5^?;0\T=+Q X?QXI(F2C:5;'S3,6%^?MYUA_5$;2<,7])VP
M,"BYC"#M@X>8KY\:8@:J- L7) ?YB)]&[BP=N#F:?6MP,TVT(1I<MGJ^RM&_
MDQ['1=RJ*R#<TIY]M+47XDL2Q98QZ -)![:;7T^3P.)9E.+H=QZ60V\D;B_W
MVEH1>-URYGU6++-FH[V/C,TS52?OZS7+Q,?4= )XR!WBSN<I'> XRDG8%8'E
M-$-8?(JR)$O[ANT+\CCHIW\!NFU-G1TM4^"/&8>'JDD:E@7ZEEEU)LFK\\S'
M S5_ 3U1,]AWP'B8D[Q]>G">_XJ\>[;P@G2U$I(Z9!-)'?2'A'#EUP+5K5:,
M!(]H*1%++.8I>ZW4Q+;%#X7ZDF#^2J9Q*?&BF4*OQ#\S""WU)?DKOL/Y#8?S
M*&&;;[RP8"5LNG^$T.M/&CYH1M)U0G6Y$S:^!51^2/^,>\"?9SDP8C+\>RB8
M^J74C3'#AY8'/(2/"BICVPBEW&_W$V+?+3D%FN(%U(X2K;ZQQ:H;RK1]<]&@
MP@CZ35^-_7LAHR.\3.,]3>L4F<F?J]ATJC5;)?I2%5;U%X!N;$*WJ#X4<[<"
M#KJ^C[IEO3R?<[S,SY$R=/8(6/N0_V375(_#\%V%Y,]]]@2)']7_5$ KZSH2
MBI^/-D:H5F_R![R>RUO@F@>J_-02CS;/Y$74_BHBVRKN<XO6[VRAN5/X19UL
M;3?(]KKT]\CO7M9OP4].HDHJ';[(LTVYP&)?+\N.2=SB-30W)LO:QLZ6\PQ^
MP*<XH59KF/3(Y)<8L^3GV]*$&&E8&3W)?1%\JBG<Q5#+L<TQB7/X7_I3T6UX
M+(QE6 =MH=3ZXN.HSR'19M/<L(Y&B<XEG\*K2##+3.Y[V8I/5%:*/2., .7S
M^T&%UTPJWNMP)%8W$\N"I]^'B]<_-IR.2_2%G(Q=!Z&4E)3<D9R&J4(_\5(/
MC=.V]_]5]FHG99MQ"=I%;4Y L(BN)+Z-&?202=#*YWK$NATMK*HSO$<PM+-<
M\&A"Y@=:\><X2OL+(/(G0,>_G?$ZI$L-S]<2(W$=X]7@T$UB//\\R,X-S/[L
M.XU.[A*!Y RLDS<WU<S83+9)LULO#]4)-TG*&_341K35E-&5GZXR)(T4.&")
MKVBY,/X2I!BJ5V%Y<< 67%$2_$1.]3G67A9!K[_$++-BB&8-.JADY;"A;AD2
M8K( 5 &)J4J#<\!K+6J^O$HBO_12WJDO@(380P>XBE#Q_3XEH2<N?,X?90:#
M@,*EAU9L83RF^G[:K/R%PB.!][]M@P_!)2%P$@:ZZQSB>Q*D5^BE.>/+7JUF
M1]BE1TW4A7Y+2V,-,<"E7HFODH&!J&#T;<^N*D6BN0QW;R<QVDL?1957XBAD
M;@D)<W/_*<DG4(A?SU>A/K"*!& GJ0]S!0)MNHRRQ6;N53;OUA1>H;IAS?K9
M;&THU59'+T=W\IY?W%&4[6G#"9HUH:&D7UHQA1N=)8/M9]L$D5Y;C7V^U60@
MG]#>-=..CMNX:C<Q<K-QLQ6WR!WATH@QBLP4)7EMA 9'C@/RK.LO  ]B;E0[
MRR=VE"R1795*:GGH96QTA=%%=.7 F5(0$@3S=FJR*.U)>E$=(T\UZ(FL@6#U
MMOC%T!']PM),=Q&P^PMX5?].N<T&E&[+W%,Q@K_32<-"?D_1,2L^@3F((-)&
MF!8N"-C/L9C:?C0!_X_NSNNIR0:-XA$%2T@@($@5*8)*49 F$*(+4CY00&DA
M!(S20RA2$B""J#0I8FC2N^@'!)&.$:1&NH" A)X0J@&"BB]%7+Z+G=FKG=G9
MB]W9B_,7//,[\YR;<YP2,_W-J4R+8]&S=YPJ.XW)^';!;\ W1@HUHD;<QJIR
M4/4]A[B!-EKN5OWP?$...S.^*.B.4Z"E;?*1J3HEXR,L:AGR2T?)^#6LMTC'
MD6.55)$- 4L0:(_3KTD)<,\#AC;[?]Z.7-/>576;:QI6 \>"4PPZE_8F@F#=
M?(?.V;X^(^9T^.KIRW3\F"@]V>%8*H\XH53_TQX<YU->@#5W_XF_W:/0M3AI
MMI5ID.31>I)3QJD2DV4CRH90+'7D2_088%0I[NY,R[YRA.Z4*M]DC]?K8X^,
MX[B[%H1JO6D^*+DF^:60@4=-O(V5@ZQ[P[+#B+<8;,CY[P_^MFA6GZ!^A=#[
MR8BD4H6)=I',7+BB,WCP-YFU2!M6#S6_8:!$3<#OM31)[I8OE![%)O:**@UY
MWG*ZZWA%^ZWQ&9'IXT-SU8.>ZU(A28HC*>0?I 6;.%PTY[BHLM&FUE=P4E=7
MA0Y06#(%)#&B'A)UB7JE;COPT?37DPYV[G9QM3C"O9![(FEQI1Q@_F3)-V*N
MV$NZ47,' /858&D= S0G+:=/M!:LT]BM[L0RH^Y>@7[>VJN2P5^YC648R4#L
M!BY4BFBZD=! !(:JL?)+F5]_5M$<#%7[#L7/D<3+ZF&-E="B2&KO\9.'F#8B
M+VOP?LZS+71QOUT-,R"R463%^%5W'5Y=L<389W33_CRT ]GM/47QO)V](M*X
MZ\C3Q<@5 KZ94L;VKA>.$VYIXS2,47"7%7XAK.6+J=Z6G_8-+M3UO8YVUS.I
MQ!UX5.L,>#G8*Q[C7JQ@O0-?_ERNK!JWZF_59KJ&\B>W(H^[@P45DY+Z].@S
M3W0%V)TO:0FE&)^Q^ZA?I""%]34<YZ3PQZ=SF.='V/-U/6<PD7<T[R7R9! 1
M#(AQFAU0X+"YVN&[=[%Z]&_E+.IX47T?;5U];J]9X0E4>J*:KQ?DHO  _$'P
M $S*M=G=/H0>FSJN=))*EQ_@7QW%!Z;!JA5:"06HKCB5XX&\;PJ4QNX8J+.V
MN #L7"U;(*<VPSLIS/W>KS2AN@RC//4L^JEP6T,I)48-^N8D^VG/QGJ+!!=@
M8_7VLZ?_Q &-;\\^T<A(&?DL*/E/-/YQ0.,'&?.C<8 L#D5-E>!04./AQP[2
M5AQ.?U:JD79]W7>DCB4Q'AB4)'WTH\)-YITI Y^^='\40F25IILKD4F7. 5@
M]<?4RF4W>XS',F^..-N2D0H+&K)NIBTPM+"#DUQPP[2-P%K&Q38S"(#?AWTK
M66YVU>(LJM7"KS.]I835@V)[Q+<WA].ZM@EPK-;N;,63B]&)MFBD?6QI9DO0
MRQ6\-5[*)(8[*5Q512%<?*,3/J%2NKE7\%!TP]6V<I1RV%LM8JL!SZUQ2I E
M$2.D]JOH>7?WUF:=M3+O;;_+)-#9F=<;%1*$'CND+-LZ2B.&S-D<*UFY/YUK
MM7LZ:1X\7Q-BY/\]NWW>RU_%^(3@A<VCVQ9FPPZG-FK39W^)0.2,:@0#S5,E
M-:K>759VQ0>>S?Y"ZNTU498AW?#=H7Y=GX4'FS#""@=\(<PV!_CKSVNCT]J1
MN 6ZD'Z!ILM4TD+GG]LNBPM70-^:^; 9Y)@RHC_;TR[A]8. .4UKM*CI_J<L
MY(%GCOL:S7\@\YDC'^,"S@B<#:Q2O@B$N#)N(-ISH.^'OYN)B9H\O-V.SSDW
MYKG&\KKKAGS"UJ\CO<@Z<.M(533Y UF=,?%]YB"_H1>J CCSOOU(,U;C2C5,
MME?1KU32XP-]>7H)U*\2)#,&GYL)WX=ND ^"\Q?W.HAN#KD6YN!A\Y=#O^$9
MSTLU2(!R#3+_G+M?>,(H#VI"CXB?B0[5)"(^01O*W!L51]/_M'>8<+=[,AKF
MH5Q3D5K&5GD[6ZF=_'C$+_+,=F"N;]E2&&2-B/P-.NX871$0+]K99E"UZU"A
MK;<E,"(X\3%#<=I^.SY7I;M<UFQFVT;"?(I@8MK$ULVF@V,=+]L,YV701A=[
M?9G4\WIG:-#A7,4K9YXG\,B^=0+,YMR)"-_\VO1L)8:%5O5?-2S)7HV78Q_+
MLG:CUJ_B&B8ZE1/.'5ZLD !Z4(:9'79BT[+U@OORD3V[P8N6_[BTIO^/]'9@
M<LG!]O99=-LC&+;^W5"%[CFLHX"H!5NVIK NBAR967SMY8J*G:%'0?_Y_4$9
MWWID#Z4DIHW\&70H=<"U++1___!8SF\0:P?>OC$]J3:?VDQ+P^+$V]09.I=B
M]'VZ;YJEBY0R,W/3J_+I%8_V^=CEN],K-/_- ;5&VM2#7/.&6M07F[/W&FR+
M+'P>^V&<N2_UK;@=7AB(H$U7T2$2'T*%M0QC:]!@TPVE=&)J$_](P; ,*:CW
ME7.J=6.MBQ4OR]+:N>MNV]K8$((+U2$_BS(B8G !WJ4MJAOY3:G"7LYU2*%K
M,GU@U5!,K NKB!D.7ZXB\FP0,QP>8P1S THZ\NU^19GEWAA1^KJ&J6M])C?P
MU"HED77+ZL4C2SZ50^2TUB;8$!&63UO:.9L<')KK!?U8V"63E.IRUT2[\HKK
M762,#.FFV^&[_W(J^7](&9/G55<,T-V&KSI 0=:9;(K'Z:, GBXX:*?&#I@,
M+/>L.]OW<C7H97\@SZ5PJ')$_]>M%L<HA #E.EN$>GU,D7+>:9]W]+"JQI;6
MR@#>LS 0T@OANR#VVM"6^?PYT-(&ZP*\9\>>5;]#1 5S=E"C.B-F^\PGB[_C
M^=_W[8%/LO7M+IZWEK5*4<F?U-!TGOCF,+0/6:USA%4C^&;<3O-LC.9C M3Z
M\RL %Z3UNAV/J&2"F^DY&#K=67LAJ]0@CS][]I .@EUZJ_Y3J+ =P;NU_!4:
MJ#*MISR%FZ$3BS-:I>3ZZPE%I*OZ)0LTE(]%G++45@I[U9PM$ZR;7DA R[$C
M6/WYWGXOISVX1$T0E29,>Z.?\OS*9LK/;\,$<8P+E,1FGE#HJ@/L-RC";BS-
MFN<WZ%AM3$B)XX,<0UVGJ@>Y6,-D8<<I=1.<M/3C?LUL['7O\'WY8>(-? 7@
M?7/$*P#N0X6^#U),R UPQ=^OXU!_OXG$9 M+WXDKKS_.\5T!!'><0[3O_@9%
M#Q'(PY8;ZWO2C6E1-8BO#>5]B[0C95()>E+J[=L\Z9LD%1LL;U&*6,G34 0V
MXW0^^]CR/CC*8DB'U^*'Z/:/L"K*1J9_-B6Z'=)XW=JS5.7B"3UF-!+A\B(
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M;CHY7XV,+*>5EO84LI GQ#2FWP"O-#?G%!5J<*"L">,M7QH;>#BZRA1R$V^
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M/M@D*WOB1PFM*&R-\$&LQ&/Y1UP$VB[>4?YQ8/F)RIJ</NAC]$@O";6\/AT
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M&;E_8\^/\7GM,HMBI2=[]FO*O60#)?-6)J62,YXJ5#.?9!_F8XGZ;2/RP^4
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M$KFRJS!))X8#T*X--?=^F,+NW3QG;JE4F!5\,.OS$8Z/EN^P',P&2.!@6H$
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MRK]QKL!;D&VZ>Z#6NGI*:4J[YF.L>X,O,3G_^E/;[?RK%=6(- PP8<\F>?8
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M2G$'BT=])GS$D46H0416(C67M@P,>1#U&6=#3]>#>7W"X]152[G5AN_>.B/
M&7IO$M3XLQR$9Q;J\$/8^.%N<@3()W*(K.C-23?7#066[H$<Y4<L@E,,YL%G
M1Z.DCTR,0A0:]D!I+&G ._H#'$310"4Q;.6>,U,M1X,D>+SL\)&GA\T/2:IL
M"O>TL$-/'.T:$$%W9IA N8&O+JGREWJ"ZG^?WT[N'L@//G]^#Q1I:WZS0_Y,
MQVU8X'.*+8N/0/EC#>6"N=!R*8BV$CR]3</%9=B^^FU::-]9T67FUC+A",<D
MJPO<,-@;A$**88_"58!MRJ 990 S'U3SGM9JC+>F]Z6U9:._/Y?ED.2R?02]
MROD\;Y=$4V6B3$ZP!MTUJ*7=R#2<1!7#GHB2-ZY;'9Y:(4H5^<"_GSEZ^M$O
M#XXC@NV./^;OW(OA',9J )6/_HN#HN/@IJ0]4);M&./0 X9A6 CK@^O]^<@[
M!7I!'KTW?I5OJ)/5MM#3$S1+"ICL/R_5KDE,G4G7NC42:#*RL <Z?#N6EGZ>
MA'H5?6L^T#5M_DX<!TCA@]9<7B]0!U58 7-#YJNQG".Y':W<Y&/SL^$]9Q0;
MQG7>G-(9#2&!:LXN?9%CT/N,^R/ ?.SXAKVO,Y\) HBCL\ ?6KJM!+#9X_Q
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M$PXQS)M&JHR\WUY$*F1_</'+>_R]92MP/IIZU;BC:J"!"*X5[D4E@66+J5K
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MEFTCXT[8QC'\>%=/@YJVKW[YK2J3*X]L&#76)_5./NS[_2$SH![UXSO*67T
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M\-V8^[??=_+$_5#YM*5%>.SU2\:$E#/JGP[G=:I]U,HZDL8?K\H20 T),I'
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MU.<[ML!%=*&PNGTE[IN/D^ZYR]<(DD?D_ =_P.W^=9#C0^P;35*6 ,;H1$_
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MK6GZ\95;KEFVT9UGCH7/*8OW]WM!8>=HX_K"%FDB<EUL^8H3DSTS6AC";H*
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M/6EG!$(LXB'QVA T9*GHS PPU.FWT:( ,$T8==3^]?D>?2<R]$0KQOZ@\!3
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M3V.> 2"]B^R4\[+MI4#NPA]/7YCU,*MLTDI^WL^_Y^P$I4^(5;A'<PV#"4_
M_8MBM&$4P60W_K"IQ_P1[@AD2=C>*2XR>>I'SM^F8P;)DQFFLP*]:^2&;3#!
MOO,())).+4%3[U #CT"F$AU0.A"Z#EGAS)6CHK77:"\L67!<%![1)1L*OS>^
M<%N&&'K[F#Q0/*',0(QYDR?EOJIW^0.8(L=RM'R,KJ_0OU=:.@8[WO747'TA
M5%<_?=^!]?_03U["*272J=#9R?K- 9^@E\&#"6N?VMK^7C-DZNW6/U?[8L^#
M/VLZ\F)D=LT'R-+W(] _?=2,":VW&;*W)A-!/@*QR-'-(K6' >316XF:O4>@
M6'UA*."PR.ZS,H[0?.HN,;WO<$;3T?.[B=+S-S?J,C[)"IXP&6!9W\EY7/9[
MQJ>CL-2AGZ/R3&7(R%7E<I%(?I./H$>8@OMK-"[[>O"^BOD1Z/WW7P>:%-'S
M=,P(*R3]H[XX F'S.S0W\SHN(>0;TKJM-0,>1;C?LOK$-LHE:P2ZIA2P 4X%
MP.S]A4"JUQ!D[[_4,<ZP'TH1.U[ARN37$<A3D1NR]*:P5B!3(Y-8]^61#M5:
MG$5Y#AZWL,B9:6Q5V-A9S_?PKW;USQNWPL"4,UPT-I]25.>M(Y![WF(,6#SX
MQD6D)AQ\ TXQ\I25\@GY)?A@7.H6N[[?IR*PPM\O#UA^I[&4(D_3+=.)(9BB
M4Z"U%OV/Z3:?H&]1+6H9@=4[F9&M<)?01?U-6SS@;"?31U9_9V\*57U_P-]=
M]W'&]0'#P#& +Z-I^) M4%,"=+9J<9]42!&/(B,MR#+'VF.7.I@ *7MOJ #%
MK56;3XD]S[5QE(\%DTECSO.AY7 :,GDO[0(JNSTM\2E'(%\TVOGRK[OJ+;_:
MN,17OG6]E<QP,A>/CK[-;(O/M%^LUT?[T,V[1W>RG"T:Z&$P.J:0T35CML='
M]&EVDW5NT.<VI^[H2[";,]%<YW,<(ST8CZFJ**H3AEE* Q-N[0)RU3%D/>"@
M'RFKK_S+MUH=+=%0$[7CEN;PC_!.<>G1]32^),FP,Z]VO-=@@#2,PF=#ND]-
MHGM?^X)D,LF3^.LO<@@BJFLP8_YJO/[?Q9\O#BIEZFR2;OF8A7_E:'II2NU^
M&O_<@(H#$ZZC 6D'3M32:SJ\@1!2Z?$$Y_VWF\9YE]X@<=KWCE/4:#=J.>8A
M;+JFVYF%R-6U;:H./=.]M"VN:$\V?<3C*62L[^(;8EZ(-7I!*N*:U9M;NCLY
M@")<@\WV<0'R, HO^DNAR+ZYK1,\S[R.UD4L6/L>8]5PWR3T(%W#;'?5O3WB
MZ7_MY@'+T18.D.RUU&)]W@7*-8TCT)3_PHV9LEG>(&>+EWE-G+AV-JP)W?X/
MMZWZK4.@I^+C4$V%H5-'H+HMTN#![2VQ,+?FW5FEFZ/[0S.%2S_3JSR'G6;F
MO+[G"#0I)TIEW4K,>JS+O>6]&&3Q#'(:H5YN4@D$8M]%E2T8%5[8&#*).\^K
MG_+A5!'794"/*+=D$8G@)TKU=9P<#1ZH;(/@V&;1O(JS3S/, IZ]8C_[>@6N
M]95?^@C4A.Y<H7TMZ.ZFR74T_#IYU6R30VB0*?-K:NTW;,<12.I"7L*0.MWC
MN"(A=3G;HNE'(%7F&GJ3)X?!GVXGOIU"?J=QU-6/86\L&L796,:L/J?THLOE
M7N\7L2^"D=.+G&U<^/!=T#0<TJLOV3;J8CP![FZY4: C_D691R#X2N>RO-;O
MR:2OU"*4#XJ-H@CXOX$W=;6(TTJ#<==X/4<:GB757O_Q5^T5B.7+@]JU0.6]
MDVE0O&#,OA(S0.Y%U;MO]1)#31M^U2^[X-%L&X*G?79NG?\+L[Z2^BV-2U@W
M3C2-GA8\CT!)(1@!E*L%B&*E;3GV\#,Q.U]O3F['8?OO-;KKA.IQM8/")SNY
MT@Z5^CFT#P^,">B$H,*M?U*F-CTB[M.Y=Y=>%\V%,J19/$E:UY>$MXQ]H7&.
MZUJ%&3CHA 2#%WR3(#P&Y?46O #,GLWSK3=)TTJQY>;(K)/4I[ZPRZ ,AOV:
MB]0W;\=I,D"_$<"%'1PZ7^VPW5(Y&WJJQ#)D1R+?0?SG#!$>KU*>M6)58>3\
MMDKHTM_,E23R_&*&>WGF@W)\W2FK]]M,3\U)*<&9Y'IG'S'WZ+T?**Q$&;8F
M%2G5DCE(5!^OJ%;8BY5]TM=/^)<6%E1C3*W^B>2L<Z<]REX\Y*Z$\B)_0O@1
M1MC/:AQ6^(LY$X/@G:W5!@8V^7\F3>HYE9LBDSV[TW=Q UU_O!;$FM,4K\ZE
M?/XC=,*BXZ<%^1U&+?6BLTTF/N#S\&NINREEG.X"*UJ]%QI77G0HROGN6%OK
MX^XK Y1!-G2J[8^N2I=+]T;OO,@K0[HV3FANO0GOB#D"22HH'>ZCCT"&_"M(
M-2@PB&%A. (9#-90N?6"49RTRP@]HN:SB_ML,('?A/J0]TT:!YJF8L\_6G*N
M/#HE%KSNG3 6/ _!%6Z;/ZP!KN*WPU#Q:E^S-PXON;@'!3$X%*\ >J37-A-K
M\"T!'9;(.(FW;FOV,4GF&N-NI7*/1Z1GMQ []Y_U/O37^FP=DY1ZH;PQU[2Y
M/J?"1V8N2?R<Q8PH7J/6&^?P2K0;R?_J8;R%\84F7A[CU7URI44C2U68^E G
M.C8T!/J@\(N]9[*O<F.GQ>J5&O61X'64^V)JV$I\2JC#.E(^W?=)L.Q=%U,&
MV(N"J07#O7\6UYQ8^E(UEPYZ%)GUPNV!+([FNJ;TRIEN^UAK-ZFHQ5#)H!H=
MQ?*H.&A214+IZ9<-5\@WQOV3FU17;#*RBLK_-$_;537HU [W#@K'EQF_Q<;Y
MH:6B?:!9@1ZY;9]W?U2-K#OS$#K2EWXP@SG7[ZB%9/\[TS<J,,/Z4P794.KL
M39:Q4._OY-"P6W%W\??_J^IZ!*KVVOM =LSA-Q/-Q!+YBK\*=ZG<<3!2RW50
M;)P&*^8^W'@8>&'<7=]=V/1*J&=[V.X&WQVCL/C_G XEA.C0?X:B#OA4 8?P
MZS&F8X\_VTXMZ5R@5.PI1CDQ!2X*(+C /9BXW+7(QSF#M(FQQTUV7-?=H"\*
M'TRI,2Q!/[%L;1=1K @]J/J:_HK[1+F$-@OI'(W!<OD,49V(K?<?XE>6V=.4
M&4 ,/\)9DC"/=R.1EY/4?G4(K!._\B41AES<&O](,3XW3#E-Q$QSD3((DUTH
M#KFM(>(1Z%Y\%^TLH6W4OENC2C*.[:5F]E69)TK7(DT9<CQ/3E;!9TG-U'Q=
M%D]2J@UN(CE0X8&1>^FBS/A/TZ4G";7"^UH2>PR:?34S.MBA+T)/@A:YJ_9I
M9>\1N6[Q);/_)D.U\!<^@[@"C!Y05*EU- G@;]]'BB81'!M,3U.;.8BI:7A&
MS]5+[27!CUA)6D-/)EGH") '<,>N4?B8A_HP_+X/ZT;W:UCZ8=@J&\NS/MNK
M''_[V_^/]MXU',HP_!<=48J8G,^FHHBDR"G,5!*2IN24TU3.IR:$P3 BQS A
M%#$*43GD?,PXBT+.IY@3.4YFBO'6C+&GM?>'_W6MM?>ZUG]]6'M?>WUXYL,S
MS[SO^]S/?3_W[_?._=QWFY7+L"*V[4!H*<RO4@;%3;Z*YR!;TG"7G_.P+3V>
M=5)\*KC:*_#TL(?OZ];.GT^HAZ_)%?T242HH #L"8\P;* EB?94+2?63JM64
MP:5W)FU]E[Z57YD2?*D0VL]E>_07W"7*W_D$;9/LB!/%$%]?B&S1B=:J! ]*
M1"_'^<$<Z^U^\ 0V^KGO?XC2*_\B9VL$_ ,)@G3Q2OIMJ_IJ;+>\1 V"C[ F
M?-H?G=:;WELQS?6T,*]I^*NAL5[0O(@SQR.G>S7,BE?ZA!^AG1YPJVV\(ZH=
MYF8F52!(('M0,VG,=JAF+JDOCJ56B6IQK'%<$X?*U(A$9,R:G 9!NQ1#>AZP
M!':+(^5880YS, $33,E:CCNLMM;P_EQ_<_TP*+.?QZ-1B2!&@53Q/F5)T89[
M\$*1LJR;D[Y;>,F&I\M-.1:6;K$_J=<J!LN [UP+@%P1C_^@ RVUJ0!M\:_J
M .PI5&BA*^BM9YM8.J%'NOCI@8:FM$;3'6SFM'87!X)G>3#?1ET(A\TMMT<>
MK1^'1T/%@#&'YM&Z0^7(LHU'C3-O[.@OS0_Q;2@^*]1/O)W)S<-PEMPM98N@
M/A#KEOO"#6^@'CEIZUQX$G*$VE@?U'Y.8U\D^AF()]JTH_)?ZIL'?9* #\5K
M7P!!1.OHC0OL'[--R)G>/E+Y5.=FBK1.CT^I+TM3)W53K7(I+4GQX&]?F\_,
M%_=?&";P<E;8"D PG5=@PJT6)4 P(A9Z=D1ATJH>^\Y[UEOMTT#L_$[:G)="
M6MIP>=A/RBI"!7V.WI"*=]]\VB8"R,%Z!/3[\@7HEQ[1-D:^*S8T!Y3*F"G?
M<%D&I5_JF$LILIVX9NC)W1L$F0MI3T-E=\L?XNA=%T'<Y\)4/+)MT+]DM=G;
MU'W]I?63%T+)01%%Z6?!NI5OV0N(PRQSTO.)5@%BI:A/S@L/AV&PUU\[GP]R
M.-1@UG3,V.' N=>]L T?60SM4Z0.M*.%+9Q[KP5OMH;?.(?D08A#]11OOG_/
M,FZRMG:\AV;F0Y]SK4(/[[Z#2@ $(G6G]Q/48?K1O/I7BVN3X8BM7*_;4@EO
M,K(677B6CW\TD&%ZHW2ZG75&66 R)AZJ0FMMWGI\7J;RB->JK&U9F++*AG7J
M52XY>LYO6!3BR'GD$V<^8(GR"6'"]*O(H.2^F^RQ\DL#^ QY!U/#;>"]3@CR
M\%.6"4V?#.G&":UT$NSH[)?^;STO&%9^\9'Y(A(7^B(KK?Z9X-FV<:XMG=X]
MT.QMTDY[_^E'>6$"1K<GM6P4KG][Y("\L$;Y?N8B_T]3QB#*%R'N"E0Q'Z'V
ML9=)##RIJ6Q+IK&HAK[_?>]FWH:<=LT!QQ!*_D0=>???L41!//%-L/-9H#@4
MZ56\ML#O@Q!8LQT2/OB@ZRV)LS6<N/)TJBQFL@QM1!=\3%:?HY"Z_PHV>$3(
M1LJTWE&L:3+;]PK/\T[W/-=WM-7N1S0_C=*;CM8=09\@@\5\LNB)ZF4&>O=K
M(M),/_^6>K%?=T,C,G.4)0SL$.%8>X'>&N)R<YR/#+9FS=ZY$)P9Z*&^XWK]
ME<>K(Z:ZT+@V;\!JEA"'\4(D+O!QV)1G,$VPO!25[K"NU31:YNIT=6*Z-OQ$
ML]' :^[[^2^/RFH;>C#\:> H@W/T^)Y\A6]M4!.*6KA-3>SV"O5NO1WYV,=4
M@OL^K<#/O5R+Z7J#H'#GUZ5W5FTTO<-2OCZ<F^L=M3B?4G<+U'\_'*3:^2]=
M< %>D#678M2Y!SILX%'A&1R@X8AZ>GW4NAP%TSSEL?]YB*[8;.24-#C) ,[4
M!OJ,: &F4[\]-Y=,P.K'557-)+G?>795Z"^+?8T<Q,OA/>;@,WCCQJ>]L_*Y
M/L5>A\1+7()"90,</G^(MTG.ZTX_)"LW0]$K. CSQ,R&=-KBJRO>40AQA;<G
MJ*Q+Q?-V,P0O[9:V#H7+ ZZXP%,)ZH'1E_K$>%DBOYCMLR4=AGH&,-K0NFG;
M*-62?]"2:9YZ$A\BDV-:Q%.;\%!/E]H3ZM'QY<X9O"LL-?_LR-8?-0.M<F?O
M!GFINB"5=\AZ>+,A2*75/U.A+D**>5)Y#Q3G2T/L1KUF6W&M^.QX>?XG,L")
M_4)2%9LXVT\>6F@/]-%PA_VTJ;+LPR)LCF*92^RC6M">,MY,^9[,Z H[_]NK
MN:[[7!93YX7BGP3(ANEBV,;Q)O^<6_":IZQ;C._<4M9#:S>Q/99QQX6<EE0T
M;R7]1AK/XYQM!_ ?&UAY2M3]^0O:&7N@JU^<6TK9,XCJR6S2 7KK'DB^5?U$
M0OS76P>J1+ZR/.X^T7F!V.5XCEL(G<@O,#&3J$@9]*/=1JUY#1\YB6[YHXVM
MM T=\[J*0(4$J_"7)U(.24D-ORXMM\35Q\!]&E;]AMB0_M_70@^X\3UWD["=
M'HW7\/]1NFY<JCK[L[\^:]X4XZW.ZX-OP%-O?T"#:9-%]!6( %K37W'L"D%U
M;4S]<]'64J9(?K3>P<J''+F$L_S&H>J1P\'VR*3Y^$0#)4W/G"T-CZ^_C^G?
MFC-8>G8F<"+&]@E[$/813Q6J8$&QY.T2JEDE2N<V_1U[8J)V5^/[N^" K['3
MNHI4W\=S(6+%-$1'OOIN',RW!<*+VB&+]26<QSP5_UE9X6RT5+/6T7^3A7O9
M/_=J*3E&:_"J];T[-L_M?\S/!P&1U#:/J>47Z-RSG]<6[0RL5,P/B:G<3'8O
M'K0P(QLNBTF%FP\$/\7P^ 5.P(B%>+$@Q $T^"FI,L9UGHR$K!UZL\*@UT-\
MTI;-^G3Y+F=,?Z[[L0>J1CZIV /=1\Y6K#/N36B9N7]#>Q7,K4$AS8TK.R-7
M]G>&'3BMJ,M>N=9+QW41Y",7\/4Z"4%X;K1I,VTHD=:LNS6OY%@3'Q[1V*01
MBL;F'MLYJ\?E(M=CN5L"<\'-JI-"8E[O%LDP<B997N]9L":L=57=A-KT"Q<3
MF[3Q; .0CL:6BLQYJTPSZR"*^+@SUB)K#Q2)#U!5Z5C2-<C*%KSO_S#V^G69
M=[Q23>'VKZI?;RHW]J4I.^FIIX;,0T(%,V/HMW%Q\HJ0;2Z.(HV '0E1>"]8
M7/YY6D@,Z\8LRZ8:U3MX8LS/X33Z*VC%5%(&L=3?:Q'L?'HDMSM2?+S5H";4
M?0\$SYG[VC>_$!L(N'\R_WUY_1U0YC7>_H,O+VB I&H&33TSB"Y#[^Z!>-Y
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M9>2B[!ZH&Q*+$(Q4]7I7A#:F!:56(F4>)"*/]2?OJ'1EL@Z6(4"17PG[H.)
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M EJ[EG##>X^G-[(#T14?>RL_"E]4DV06BOT,\]CXE^Q2=3<K")Q . "[#T_
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MA9N3FUN(DUN(FX>62U"(FU.(E_\_/89 (8 1  +, $> %G@%6 (?$1];X ]
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MJJG/B-)S&0OU#1UB\LFZY5,3$,DQF1JI(DT(_'=466A,8D\"C5#EGZ@J0\Q
M4+*?5.BJ:SKZF#K4%G\G1QK-@'A^5TY W+<(V[8[Q,8 FS.+NZ:WSJ@>K[4A
MW?OB@E(9]=2 /78=V395@$V'KN8-M'_XD^TA)>1N.\%Q@T5NYD7-Q,_F;"^I
M+\=>-.,5;"+B>5:JWH7*<0H.*R?C>B*;GF LDUFL:6AIX-G@!]P+]42#DT4:
MKHAU< Y+> _52)AI8]BJUL<Q/="U#5D?'&C1"#$D$PU];KLY5R'#R6,W%G-=
MPE*0RA \K!],B"J"%#Y%%6HMEH+AC$7F@9=Z%JA<<QR;'9)4:+EJ<$*+GWZG
MRGB6V^_E'";_9((^6->6-2Z9?35WDO+( QSUMN%H.L%NH;N@G>/NO%9,%[<+
MK-/1.,I'Q6[B:L0: X4#<9$^,;X'8OO^LZ=OU\N75/2&@]:KZI\_R%;1#^\[
M(#2B:FUH.PG;!V/^,J\+7S'_WD9&884LL>C]P/)K7+ I=U"&-N%C7!.E_VV@
MC*.TSI8R=/GE??C O'40VGBY5A:[Q.S=JLNF9@K8Y,I_O_4#;'BR*0QF'KLI
M7^O"U4C:8]]CO6A1JHK]?1!7:2[OAYO ?ASIP'!EDH[NR\[PB'44*[;PE/SO
M*+9X[O@@[ F!'IY#32,EHFYO2T>VN'RG:1MJPKI@376ZA;*-:D\&HM%3=P4/
MB\T('"GVW:+6M1H1JUUQ8OV51_5LU49/>7AU3>(OA1L^PWY!>ZUXKT1DC5QM
M!<<Y;%H&%"2IN@@(@X+ZWR-10HY$]^8L\F'37DTM0UJEY]Z.CK>6AC=P@-XM
MH>R8*VY=TJR 1:_END;R:1".8S0 2;4\7;BJ@9C/&TW_.%D4<@]A 1F-!7K0
M>%PD,K=6;R&J_9CX[C[(%D37/=0:HCC;P+EG:(%1IEBCO^:QX:KGJ?INHEOE
M;:6L;1%](6F0J=HW3LD[VAM/S6H5A5M]1!FHHMG=!T/.(K"\"?2C/\0I\JBX
MDX7P5#?&,9;(]^J4Q7UB#C\^V*B=QM^6_)+P3GE?8+56=?23.M1)761=R>VI
M)O;$V]U"$7W:XX^NN"+VUO*\/NA1&LH_T2645(/#67 )VFW9FH@;JNR&TKAY
MPY5+H_PC!02)H-_>P6;B[VZEP87EB'HW#@>^B"@6B;P=(TV<T+"8Y_N:$:Y'
M:-A0=T;UQ<I#]ZI"<"M5P#D[[CUJ-/, V1$GM^=Z\X]@\;]X/PHNC-*YM:1F
MQ$E;]_349GM?-959&R.\)K?U\)I4$'A_W.T$QJEJENKM4NWW-'&T):LVPV9E
M]4G9Z9';:R^5SZPL3GQ=+/@RBB7)J()4N1BS9:Q%WR^8J93RAC,SF GXB];7
M>2GD[>+K*V3^0LQA[01*?>E&%R>C@;G-RU+E.[+L/(Q; QI<7\*GN/ZXU;S
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MZ_-)\<-Y\+&S_UOVGXEN.N>ZH70NM<)6+ B2%Y"?"1XIR4#P6 3)#<F"$?]
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MI2N=6W>[@+@>VPY[FC3;$>3L7JEV_CA87];2[4Q,BXR2Z!N+J"QYR>6"Y>&
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M<X0:E+[!U G[LI!AAI6WA1EHME2[B*NS?KY26Y.9Z#0CYMF%_&JI<\ E]#8
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M!%I5_FF>LA+IZ@L9KACH>.'<5<4)BU,]?V-V2LW7[?>#/O;)]N'-K3?GPW#
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M=+X0&&GKMKQ(E:7Z%5_;DN35! =6,<$ZH 7;^+0[Y,HK@WLO:#&6'Q>&C(9
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MW3]CD5-]5QE(FC[Y/J@$'RW 5"HK@X9+2@ZUDFOXK:QD5_?JD-SL\N+2=U!
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MH]3-$<4;C?HH..GG$XZ*:\ZBWV]\BSX$FNZ^V:$$J*FH85DE2%!&R#@+>41
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M1;F5!%,+O">,&Y)^1O^K@2QB@23BH%$D\DK;TM">VJI(F1W@65I]1NY^OCJ
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M>6 ]SA,#N]<2$D8 ^J?37Q9.#.OT(/2AJVJ?H^!$N#PTZ5^)8T85>G?,HV_
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M*MCG0ZN4WGWOY>8YIU+@>EBZZNG1J6\<TM,Q:9[PL@O5]]B > \-:C?'?#V
M!.RQ$CV=(P&/RN]:DSXGEG4"MAYC_KGZ<G20.['9:D%6[8<=@84">]U--AZ^
M_,[=-Q.LS[&H1S'M&J\$[S$.6,<N;2,L'I0?#C#)4YPMMHDSRSNOP:KU2DB
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M,-X"5 %5KU#]7#?;Q[<],#?U%NS]++#,Y42,@]D(7F7,;;[9HH\#W -/[^$
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MWY<M#(_Q(^@:&2DK8YU8U[K7TE"+?VE!BP.\,!ZY,"ZX#@P ]J^VWVQIF#N
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MMG/[CM#CUJL&O&ZZGRK$&:X_\E2(XDC3!SC8LI-/OOYGH-E&=?DIU5-K*88
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M6:D*9*BW5YWEM9MPP8+7/XU VI0U;WA=)@*+-J;'<U\1R5#B%P@B]?GF/LZ
MVUO::[W2&1K-D>T2#S;;CG:,=:%EA(R[OI -X=BGJV#77RY;1F=-YCX* 3B
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M[)Q7IS<X0'=$F?,9RTQ>62R^G"?#&0[@X5WD9>1(]JK2:MVEA3.M*E#($0
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MVL>>8J)]7+IUP=7;Y/Z&*$PZ<".OR[S5X9%>D)=1<[>ZTHBWP7!C.*FB5A=
MSWT;ZYYTVDVUU76_ZR'A9+R@A_=S\P'FV<C!3SF;V66%Q<K?"2 2=[YP@/V
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M[Y!VZW"K@BG#J4VH?7$Q-BT WY[&\4 $^SX?5<T,#X0=@DN4PB\2T4:\,UG
MXTF9$[K,(K(:(I15''E\\VFIV\#E1&&DW7*MVHE207.QG5CM?H=!GCJ?_XEW
M('CR>]SW8"V#+_A:#L ;!8<,P1VW%:QOSW'99<J#I+%R)P6O-!Q@2.A*(Y!V
M\]SK<KZ%S\_99:D(:PZ^>LQ26$8/^<-2'UMG1AQ8\H[*XR+)2=V_S)R!A_SH
MK.3ABE(4DU)!3J;F5Q!\CR3PODN_6<?09236%/@7W:GX7(Y"*5H37U[S"_N9
MPHEA>;EH7=T;'&#./+F%?D!+O!01T)F8CU3R!7WV@MZLNMF+&8^CCHP8[2M+
MT8IP5,^:(J,I"$5MM=!UO)R%_9URD6ZCD;+J^;KKYM>M6?>4J*H^-GZ(;I#X
MO&1VHU\V?I$S;_;A ,C(U+/\%!22$Z;R!0>@@37&0>$RE^.3S90502Y(4Y_$
M*2G_G?P%Q6$/T@IYFH/\K[WUVZ\H*&@(C/)\BNW.Z8XNO&F<,'-KMR74P,XW
M-*XHC<+C7L8,W>1>G_1DR9>[*<T5>J.J?Z34-=5',LXH]]%ETJ0,8GLG#JXF
MA.3NOBR?X5E$?S[1VT4^%0$Y'1IE)2(20.FA9SW9(\;EC1G=>9B& GL:VQ2=
M\)]Y'3/'8]OX6NSPMJF4,.>I:C%F]?/)Q0;HIE_*IBU\R.6GC-NB6TE"JE5^
M5V4G2A0_(*SG.B._>'3"H41VL-MZ?YTM(/TWZR%BHA*I5*%J8--!-#@KF"I1
M(M/21&.E$6!PFK]WQ'QYE3&E&GZNN=X-S)-6G))QYTE)=5.*ZK2,GR!64.7[
M31=A,;3<),;\>L8']1TCV:#4AVUB1RRIBC$]WW8WL>=_!K.-BJ>3)ZVXWR@\
M$K*7K10%?F)/$B@+JV_LN&UMPH$CGGS\>!*JMZR7N=*.OZX]Z"*D"1\94MY#
MY59MNY_-NZT62/>-O9R;/!.:MS =;%5$B.8-3J+P&78*HCMH^$*6Y"/(LPM^
MTP5+%_04H1@=(U*\L;NJO\:DQPH&P2-[MT[Z=&]HE3-],OAT:DSSA.='L-ZO
M<6XG-]9T$AS 6PP850"LLH9A@2Y6GWQSP0PXP-EV.QE93<OV*WGI7SWH 1[[
MRAGC*73B5?!J[R**7)_&8$8,'VL$.N9=&Q_!P+S=<0"ZJ6*2L\@[R,  -:-?
MS34UMS*.'X'==P-SE&!R7%UOPXJP>ALRUC_LUHL7Y_7XJ>L'M/SE'4]T+JYP
M^N!@"QQ9T@$N=((V5-W!3G;89BMMS-PJ5M=X5[_VUIQ\-<$;Z;]FK\\0>Z<[
MQMI)V::+B\Z@=0>E$]1P1"+LBB'^FJ&NN:%NN7,@'H1&PM;H$K7?C*[^HJ_F
M3$P##S%=:9_N&.EJ!:B/SNWY? .JA9[0=6O%,<1O]V(; O[8!>2#GA ;=U4^
MG!0ZU83XB%)*$@S>F&*FR!*R27& C$1\NLO-/"I0FGN!2<\G<%TZXHK /L=^
M?.6:=V=5XEPN?V)O!-WP:8H?!W CADWE*:YM>\-V+(W9A@Z[3H ;J+*V>WI;
M_WWS_WJ1 =]=XXU )\ .90?V>VOJK:IS7-XN\OHP221AA9P+5(M0.8XAU>VP
MN6!O;9'M1//ME<@!PB.QA<5$%94\T1OD!.;^YQ+B0.7G3+R<A6S;!G_U_+;[
M.$G'_L9L->DXR5RF^/M*4K<G.E^X@7VUHZ2_Y9GK$F3I /#?X*N FQ(OP.18
M\R3,QJIU0-#Y"5:67-K$!FO0^ANH/5DZ:SB+XIG]G #4PF<]0FP61K!U+'K/
M1\B_RH9P:@:3:#/%T\L>UV='%G<!-*2Z1@RU'"J4UJ6$*7DMMVXJOM/I"2Z6
M;^NCM\G!-B'0,^$YNHXBD/4MF;>4.QA!$T]NPLA3.O)2KZS"JS*BVD7XT!*Z
M%B]+$'0+HF,E0X=9\YR$9?8M=G#4-(*LG,ORS#D7 S*J4A2T."QKE,JE1PN5
M>6.- ZU4:?FG0%K<.6TB"UYBM^A6J_Q&Z&G-?K\5N_*"^BZ[;78TO3QI-'B9
MVL&P>< >&O#95P8PIWC3E4D2P3Z6KFC+F5+<"S'LUL5CBOW"21#@%2!KC3Q<
ME5T:7U:MQ0%TR5?0BEM*]5+8\C\@(E ES:K!;!HO^N%%2?<K"(KTQX(01(A"
M1^8+FSBW2B3VM.4^%IR(2,^WU9CN=]ZG+3V '<RICONQ88F-D)HR0UJYA:HI
MZDOR)-H"!$''QX\?*]8U1"F26'!UYHQ72YAR#,^9*5?XLM$D2G_Q%HJVRY]W
MT \MV E=:Z.<=_KHRYL#1)SG>HQFIYS'"T(W5EM*'DP;F3@D;A791R?MK8A5
M5;LLX0!./\OR/.(T94CMZZ&5QCRMMYGQ$;0>">T(<N8:LL=<GSKIZC'VF>VW
M>V$]O0TG5D:=\)SXYU1F7WT-/(WT)80C"@2E6%2!PA>:GHF:]>OZM$1>\N<D
MD;U\.E.UL!YO\&H]ICWE07@*60(W(_CU@8U-IX@-?/.^O:8\OI1*#$)$K*&&
M6? +^^EWZ^2D!P/T\LZ95!I\JF](]KF<GC@>%V87,*?FXY>X53D\XFX\W/0>
M-311^KD[:A(5W:UXO!+]Z\GD8C@3\:7*9?(]GS</P% N:= E.:BS,6-]\R63
M:;>Z(F5K[NKD3V?JQP2(GJ1H :$MA[0>)OX*IAK_GM#5FQ5:AX(CLV2R>'@(
MJ=5);BVO1#-^4F\;G(;0?K,1;\GA<;?EY$&)GF*,B?&!&(#W?LUUPI"Y2L?E
MSP)C<X="[KYXB'!-=))_[NH&'90N&"37@!*;THCL<X\G9RZS#!?AY#GL=PT/
M!FQDTKKOI5S0$6XG7%O_M++<E.TBHF[M=E[]-F?=6+6$C?BPS%ZV>Z8T.T"4
M%:E[9:@2\P@?>Z]ZR]?\9]XPLKVBO-[N@ZSZS._WRF*2%G11A1!3]7>>:CYZ
MFUM_QYV<\??7S+.$+(D49+K/2Q64:F"G8<_A-^=[T.%5,(>'""$U.'N; CCW
MZSYHHQLCK\]J,:!+IUV2Z5E,,LF;:3(W2_D"ZZMX0M@/CC"NF2IA?27@*/T#
M'I\ )^,FT7SWO[>622;Y?R:#:6D-_U\/A'M9&=A6;(?Z^9;G?=R-"&C;P:VJ
MNDAW7+ H3+./?RT@R0UH9/T5C,G*;A6@Z2ZJ?'<V)PI<N1REA"NJA) -+@<
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M&ABZ"XI6=Q^L1>RF-ARD"#M,?W:CHN4PK!&<J,1_)''!N-:12ER"J5>%ERF
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M&+F6%,R6DZ',RT]CGS<H_#\S/A^6DE)5[&D4!IEHJ.)27M0,#O<*(.D3N+3
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M#Z^'6VZTZ-2ME]Q8WO@>,XOG!._6"R:J^S#G\,="]@6(#A[A9!.R2HXHS>2
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MC.QF)#X2ZA_R$4;6<7JPS@-JV?ZD\L\9WA "RX3FG@1_*:K:<0];QT_5=AX
M+ ,T;0PA-Q@U@7>!6KJ:<).*;F*TAE-/Q*.=8ME?0E($>BIPF/H%B!".4@WW
M,5^1O+-^)W96)/NK4"$_< OYXFLMO>\B)\DQM)MKE\=M#VXF(<^L^QT_LR()
M#OC;1%EL[?RAF^QG+1&,#+V0K5K91>,OE L31ZG84,4:5=IUUX7M+'Q0#L&E
MRBV6:)*1&M?A>YJ/R8IU11>S@D929T !L/W+%2(OD_>T[%S!4T96_P9R+:A
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M#HPXQM>,;8RS3% F?B9E)@NFNTQ93(U,!&8P,P^S$C.6.93Y.7,S\S0+!8L
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M*^]RW@VZ2PA3#<L-IP]W#1^(D(U(OP>Y9WNOZ[[$_2?WCR(M(ML?G'N0].
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M3?&>ZSF)Z27.PD=#BMN\A]J&WPZ<,H8&A=0=ZV^$>UJFNZ9%PY '6I1SK2B
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MKYZ-AXS'CE*:/HD(R""A#'>#%_Z*/83PX<YP7KWXT[<B7WO&JMHSM\$-DGM
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M&J7Q,K45KP\(O5I9P@&+V,"]ZE-S2:41*125VWDVPD@M*=!B 0[P<=7TE>I
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M QL@]2P>;_L]\U3X/NK/..-YS.;AWWL/*YC=-$/MA&QRT*_N]>R L3]#V)
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M;O&+9%UZ\VVT=46L[HLV<JMXI/TEX>@M>!D1B"8"*SKP6EN&+;-5,P)_2:9
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M-XZ $7J)2U"V62?ZQ/*<3Z_J':RANM-40Q:]<HL:)/MAA%PE:"Z1Q_&8<=9
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M@YX"R.?-2VZIUV.X/>46!0@JM(J0*!X"&DZOD&6U4Q9D#FI<1WF>>]6K/6&
M2D(TT^]RZ_D"G7U<Y[CO.S91!'H'CQH%5'L%.AF1TT1/^IFQ5S3I8WV0NBFA
M6*-G-8#4%UI6\@5R'S^*<CIW];*BC<>I-2U/C^CM.G2QN#I*CGL/![>1CJ9J
MODB.'SF8X'Z97D]!T9W.\QR4SJM7+_JO3^'2&>/PMS7HUQ#O6NO+C9NG+6NF
M>?EH"O5.W1*:HX\7B]OGFHE&G8(U;3JL[4(0G<KMDBB*HL#KA<0>EZ<M<3PM
M[0F*[*EHD$?/LZ49@2SG]7,/QGFBZ>]:+8D:=O(U#XO+"\ESYXD!RCW/'9[7
M#^&?!>7PHU)#K>4X&^2I,V9_1KS]3X]X\TA>-+5+?HOT"F1?$,J8/X9N'A;/
MP3Z>#MBLSGV)Z5V+-OA+VHV@QJ7QMQ@ '^A)R(=-T@;U5;&CR> ?8;29;OK'
MC-AROFT8X(4;3.VX<5\1 YP[=LL^"-J(N\#/S(DFWC_1VJ:=E/@)^=\2,O#;
M$I HBWL^69/:NEZ=P0;L"])7W95E,2/C0(1:=0@1%N(9FP/C=&IT).?3ECB[
M^GILY,<^'/LO-2##4A /X1LRNAM^6O"O^:$6O^2'6JS!I]O1W%HK157;O?!Q
M8XDA,_A\&@:H["[X\C9PZ_B^4"!I@?",YM>LU)&CV/UM^->DU-\@9(P;%F(
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M?1'3&F/2HMWU%1$Z#$H1%W=8E/66#37@9)H5Q89"FAMP^5&)A<\O4#;J7VU
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M!1'H;F,* "C@V'^F+2M1)(M LE.<M-RXYF;E24$54#K=7>8[OR(H0/_>KWR
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M PAB@,U3YY9R.,&='5YP^@T*OK\,#Z#]#KDH+8Y =_5TF,_'HOG'IR6^(#'
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M"'<@WCN1."KX6VY<_1SK>)/IGFD(JH0!22B=_P-#+LEO6@SVIK3-S*_KO\,
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MWJT)/<T6^GG[TQ]X^U/D) ;8-3J9/GYIW/7]<)B\<PDE]+X[R=1X=N2J/M3
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M/C:#!"2;YXJ/-7\HZ3*K>TZ0YV+FS?R.C&7\M'/+I5((&'LG"$NR!I3C0*<
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M]%0.W9&KK(>DO3TNIN5_R-;OUP_:9KV_W/$F#$K]@Q@^B'F,#M4]65O5D@A
MAG[#7LR5O[T/]MC2T:I.M\6H4GA]U93%4'"&H7Y,SJ8AVPY)Q?,UT;R(7G!1
M+3#V@:J?35.[=+L'#-"^*PM<<WG,^SGAR7A/&#:'WJ!/9(Q;)  :H:HET\+
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M!(5YN6)\(U2P;F_$9LK>A[,/--CS?L!:"I59'O.W0[G9+P06TFO1D7H1JP*
M 0 #0)WD'H#:YZTTAY>X R?*:'9V=B('(FI2A%H7)(%.OU:2P[=F]D+Q$\OV
M'O#E6HHQJGEK$#OTX=LO]J3" 03 -$"]U:*MJ 3OY:CF)6A-8AZS*ENY/?1^
MX7W0EO_M(1&- ,$25B'@SB0+^CG[B_CC^JMA(QT;U0;30ITMPM:5":VF4#NT
M76/UBKK9B)B?F6SX)XF*&@.B,/<L9>D![+GG<B#8</T0ACLEZ]!)YK7NRT%E
MP>S.H/+4#^"_,CI3D[K?.AKL!U)6Y,O7C4? #WP^$#>.^4BS^VBPJMVS;OW
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M[ZF-+.7CUY&C'?CF@%\QM8E_8/PN!DM@S$U>,"C8A4B@82/E5S-@$B<Q<<K
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MW^!8Q-]==';V[[ZA@!S]..,IK>HABP%6'BCQ:"]#$BE%F*T<53QX8<$OM(X
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ML*9%HXZ4X;9'J;/P./HT35,U=Y[0LP>=SRWAXM0P.!VKWZ)G':TV?WI;["5
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M''!]_FV5D/SK $@?AC_%Z]<1@.@WWS^$&"<A &_C=G\*^+Z'^*[5WXFR+Y,
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MZ../XX^/_A>/NB9\L_35OF55(<?_:MQK_$)N\Z^+8OP6.V+.6R!^A0"PDA&
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M)8"R%QH&95H+7Q9 @[M-!XW6N'9?W\!,>:X6A1O3LT%.HJJ,,?#&R54YET:
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M:7O>BL<9-J2R0C]N>PP+20,I49YP35NM)>DVRRKQXO(W-1-3@%^XNJ[0Q,X
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MQ"(2>=M(CJ4).#T%6.,EF(;,D<6.5\95@-*ZY,L0X/%K*I9>&=![AJ4@H=$
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MW8A5R9R-Q'U&@_X5MO[3D>,K\?#M6;YS-^8>SG(<S""%KZ5C;/2=;<,AO+;
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M_C!=3W(ZE;EB6/DG8OB3S!]!1GNCDOFZ? )X,E5HU77%6/CQ2MH:^B]P^FX
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M04\KH:VM!0P$4#X3AYC7"$N%<JI\EUEMDY;Z5'X66%C$IQ;M0"N8XR(6SQ1
MK70"EQ(85$=/#JV_47^C[6V1V;UP)RVNR/(D8EOMS*_IY^LX,O3O+DU^\?=
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M975<)9H^E*79B6U9=G)%("Q<C1(^YQIL7U5WDM?D-*<0>AZ(7Z8+^[P9(\U
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MXWNA&MTYG_JOQHNP*58)BEPBG!C5[[UQEV^5MW9D(*C$]J5A #^-T3FINGX
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M:81*!TI0+<][++%/?Q<$=,;G?A>F^%V0^Y69]-;OPKX;$7M"B(/WFR'TWXT
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MPJ=B!45'3%20E]$9Q=70%LSG2(73V.>::;\-]V%&OX5(@9M;%8,2I+N8NZ[
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M:CD:[5O5_]8<M>\";)CGTK&Y=H3?<=I Z\%+1&[T4=AF,BDP^)UP.$!TU['
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M@ G<69V(YR"YO*OA78,V?B[W2!A[%QL(QKGJE:KF4FV_*<#,35TOG.F>O2M
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MP(9H8!B9&; DKL 8:.%= E^^>K#!S:S4W;>HQ <#0XV['FF@=^0QFW;MB$!
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M*BMY\.\9Q?Q;KDB4ZNZ^0)B/UT1!D"O/!@D 6N:P #*/HC[)/A;@-N#;@XC
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MQ/%F+!LV&RY)U/WY<'1OVQGTEK&4?9,VDE3T\E43C$&PV8,C6YB^%DA*<B0
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M;;;@\2+FC-SDE3Q<M(GMEY%.TQQ,(5.5WA+%C(]+$B.6Z !A^F8@R9,7ABZ
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M9U#*212/]K3D%#\O@ND])*K.X)Z<E\=*TB<N;@^QFRW4<*)80=7>>_CK!02
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M__UN;]N(=18\NI$ L,+V_EXFI1_E$?C?D$7%?^, SNCN7)1N:#<=&GW(AH<
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MES>S_9XI2!%=O5=H4+38C*\6Y+*42S, P #C2)" _8@-+1%Z7N1U7'^):_-
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MDIRTK F_+Y*TY:D+E75@+7K1>4\Z;<N^(0@]9B^O[#EP_Y[Z!8!.$B#R!<8
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M#"N4=)Y[Z;WH.\3CRA4F<ROC&</&:4\9&<GQ5\#,$47VFV>I58XLME=Y<=E
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M-!T#GRM$E#V$V.!3,=!P G5D5>]TS_JO&&,CRZR@,"JJ2[H4S+2ALT(A!4'
M;)GX^*/NRU8+<>DECV=E 5#L<2_5<#U$#<%5A!W4V_^(Y5-C</X4VRC>8;,'
ME^@33)_0^$AV)",$6?*M%6Y1<ZQ"X_!AA]KEVU1,9^?E'1R;'AJ#+<"(E@1"
M?2M?TY7J!OI+*?G8N)30*[)SL>,Y!&$0+UE#:4"K>VMO:[[O*\69BX2 >#O3
M-M.&$O.K/&ERT!=]5_$5@?5%X><RSV)";;^&@_%&=B[?B#W7O (X[;MKLR02
M*IV;#WU[G-#")O(L(\VZ%OG6G,& SFTJ<3>EWAVZY!QQKU9=Y#67;E@%>Q;-
M^+D.=\U1<E SO'8.A1GE-T2UX)!1J^ X1<,9<.WYX6C>X/19XP"&,%<1W^;W
M"WIQY$#C7_@IUJV3S_*_\R[PEQBHMBM?-K^TI,RHE/-Q7.*Y(C<+]3FDTX(/
MG&#XY%=4+1QC[Q:FCRL^[-]M&BUM'8LUIFPH=QQ*[C^ZOJOZ)LF*.<:1+&K?
MVV+434P'X6Y>-.U4=4EN'A-9B"U)]WQ*X^]WJ"'G")X=D#,QC%>[5HEMSIP@
MA<>DI6'YH.#)^WJN\ P-*F:0#- TEW9'&J X._IV-.4&0[-<VET39  E%!H?
MQ4<.:G/EK<Y.S-H/88J62K&C]I*+,5% 3EV247H<2S;0U/TWGK/2\K%JS:ZR
M F%G2+!##A,X4=5XXCVP'\H4&=\;FOU8M*3?V,UF5JNXGE&EV""4!VN@LH4L
MA0HJ&K*,2Q>(>= ]U_>V*8>^FIZE1I+ VS$>QH$8^FHVJ<-V2X/DWAV:, 16
M]H!U(\1@?<I.4%1B", JP4PR0I4(1A?;+O<P5[-CO1^*OMG\G"$&9MP\1RLY
M<_=1CJ]>1W(_(W\W,NL1]!OK<N4.% V\<\"'2 4!,^(?MQ6(1R6O\LH(\347
MA1%YRX<&5()G12(4/53>[&E.NFGNH)Q=@@N9E"/",O<#\VRH,ZOJ-9YQ.#U2
MQKV2E2PZ.IH]&35H/6>#'=?0*I%"8YRK&[[7^78^U,7%RC7-6<=MV)O9?I.$
MI8%RJ9_)BZ\0T^-/TRQ"+5V<7.N<=?>%)9CM-CHRVRF7NK%1%)A?'5_-^6N[
MQ:CDVU-T(<ED5*4;\,9)&P ;&N^!L%)+W86#\D21F.BOY((C:U>#KW#) %Y"
MN]BD/70-[Y,1O%L<!!Q$EZR!ZEQ5KTVZ924'^$$- %S_9P;\[]DDZKUGQT9L
M=Y4V$@E*?DTF^;BE5/2G1<S^@"-*M&NZ]V%:@;>+W"$7#ZX]8V03PR/(9_.C
M:QW,G1SQU%$#LV8& NQV*K@.J2&)_1A+=O,J'F\IS;YGVR52><6[T%:R&GO$
M3D?$8.= RW!JE/..9K..Q85'H1_!#.9DK"(1$ F/?DEIP!X-G-G"WU(P#YAQ
M%GSYXFSS"+ED;"8T@Z]]WHNP]%/OJ^.I6ES+8><M$9AG.NACFZQMMCO&.V$&
MOG-'(,X\QOO:#)9XPPS-.?:[.K$F.X*"]1VXH.Q@#Z72OD<IMDSPA=MY 7I-
M3?(7.,*DD-ZEM!^#EC$&)3[AY2WV].':2$X#+R^H6,?G"6\4DQ/N1]25Q^+6
MMM:C;W/C8?;5,32 @QR5OE<*\BB17B(9(;)9_0IG]MF;$9TGC<4NGD%,$EZ/
M;H[0D('N*RF[KH0]N!:H?Q95^T$!3O:2TE_=[@.0$C%R7C>RX7;P9[O>!7)E
M7*4C1F?XYC?BXWTEU)4B#OK*W?OT/4>'KBW:WZ",TOH1DHT,>48D\5-7U>GP
M*;>%?J$H$*_ESW:Q%N%&EH4UON7!5;@$F*SW8:;._G3GBSL>HX'\-^V\S<.;
M[.8V1\==GK+:6P0G'%;WJ4)K[:COX=.L:M)75Y(0"8?(08M$#,9#!0K7OA:G
M0._IQ-:U$8BX[@<**TST)]QVC!":/L0A!]4_%MM[+'+]HMO=ZZL$$:G+&HTP
M*C#3.)G<#FV+V=&--;ZQ)S;0<*K;X <&-#Q8BKM#M;@K'3ZNNO8EG\\' 0%=
MO=:DADA#J/);'D4L)"BR_5;U>KO?A=H.-PG_**)I(^$I'/EZY\+'+L#X%"0%
MTZ4.[35#JY'4]ZH2V*_B]C^K4$U[X@3)J._";P-]<:(#[5FA ;S-XQP7K1A+
M@&5?BSF"$ADA@VM7A!,H^,7ET3^7.N'U.^DO_3J'OB?+S.VU=P^F4,OP ZQ^
MYWM'6@L'*<WMXM[TZ]>:7F[] Z1U&L^H+Y3;DQ%&[H,6/2O:M>]D9.75<]ZY
MG&5H;+3;QB@9 6<052K<7])#1::^>?7Z0H37I@OSD2C$-N?.1<6(5P\>WI<_
M_#*2L+9%6U[,YU[V\#Y'W^.LB:/V-RT?9@)UN_ILUS#&7-1^\Y2NX)2NX'?I
M"G#N_"Z/ZQ2*;.AC97\7X?6OVIQX0ZJCV _LF[##!IOFJ "BSYCP2%_E@\Y>
M_.C&>753)J<:+"+>>+<<\0F;!";YZYN9]Q12F>!$'&$R>$N1<55/F,A@]>Q%
MF-"@G<I"=>R=BV;JF==:8W3R(._#SEC2&@.GK7H)IMZ[7E=T;B;J/>5(8R"+
MJ-T_\"&?<0S#KX*)$"Q9)!*=4XY6HB[1D:5."_I0%B%')=*!/_2$!U^39JX0
M B"H;]3J;Y!VHX$53! N3; XGXA5I(0[WY)MT61QA']>)=Z549-M -L<&XS<
M1-*QER8C8%_$Z[XDUA<<O,U_Z&OQ C>"E;LZKL818H#/@%POFF+ ^W2-!FZ3
M^:'+5YX)P1ICQ62/.QI]U:X*075?:(LI./VD.4H_W@"\TS.6<>Z1?G)VQR.3
ML>@QZT:% Z6<O]>26_#[/-ATCB0L5QH#0 .T%@WJ^7:O_?*\=GA>CM")A"-2
M:<*CZ/RF";TU4/3:\M-\6WN;N33-KO.IQ!R.T9>E-A(3GO-S5^5@;'1&Y*=O
M;EET/!UI%7=7L^4N\.>6BT2 P;LI,&A Y=("$B&?$W(2V$P8#VNC5M=$RU+>
MRB&_UD6%D;3$(D;,J>H<[HNO,Y5#"YP+9'1@3\RCJI2XOFWT*L/)YF8%5W&E
MPL#N=>2@T,GLLY]<G66JS(+[Y%YL4'1,DPG[-DZ3\,;2:(KFUKI:D\MF!!06
M41'ZTV "HFTV2@HF&L<!9+B/!\:O1'27*8D_,;]AYL]!$K'1'+@;^\$?:6)?
M[]A#7X;+7Z'S_Z#6-_30@.I8(,J/)>6WLT2B\W/?Z#>'DC-MO-;1@.A;-H#U
M0\,L5GH2MM>C118PY&;1(5,:-<*!2!& ;JV$UI=P9\H>;Z.!\L"]/NG9)\Q&
MXU.B,KSMLVS$>[+P8330 #_8[I:E8+.?^=1V51&++[W=@Q:O9Q)U@ ;&;AQ9
MUJ@_.\0HFB?Q>HXCBG1L!PVLCZ$^TZ^%H$^FZIC_MQ=1GSGK]0=54&:/4GXK
MG(;J_0UG_ONX!4^G'?H=7?C+.(&==_IC^H?S\&#ZH3RX)_Q;$HKO9"VL,&H,
M)8P&^E-^$J#GZ7O((][:]GPQ_)>2U[O?2G]O7S]&Z_"^'<+WOJ&!^Z&_-6_+
MTUG/]Y 3 _);M/\.JOG1*<1'T(H5-#!5<>PN/D&+!FPQJHL)\;L/CDK)-EZ@
M 5YH?PZJE^&F( $7MV_35L/]WH^VQ!%)$,.M(RNQ82E2+H?!*FP#X_#]OC2'
MGM>QL0EJY<&7;Q&<2521IKCR]V[]\@\=?Y8O=%?CXX2.OX]JJQT__2P+^%/R
M6_@#V>-O'2?KCH?"T8#'EOB$Q/GYMPF__B&[DPK_>DR\IXQ3PI;^_5SE.)-^
MM^(&BAQD$Y3YZ_EO<@"=4Z&G0O\(0G_-+9#^_AL%;7T:=1:+2)1H:'H7XMS-
MP\"3[&<+39D8]S!639C@EIA/SA^RH:="_R>%8FN/C?QI?]F(ONO[9F$?4D@T
M! GD#I^-$"Q\TNEY*:$60>1.?T--9[&3\6WT-,NRIUA4 5UI"J=);EK(0S-2
MH\3$T4_%-7"3+VA 9 RU9[N6<GC%=A\S@=^M@?N[5 R3PG^IKE;_I#HM_9U4
M-!!%!]^A$)\UQSF.%#C:A!].5%2'+K^LF'N-\=-G411?T<!#Z>\W_QO^! 8Y
M1?T!46=MD[X(8P_4B [*@4<BV(NZ'CWO5C/:4/IJ,XT& A-7MIO24 //#L>2
M3HA)"AA1N_/PZN)URJ8^S4%:5Y&">*IB#GUGO>1,^%]6HMM@[QR4=IQWX1?M
M__5GX/?*2ERP>*O_%\JHC#/$%O/]7.57,:!_F\A?MPMY2[_RI.+S ?U:1LZG
MNW%4-QS4O:M6Q9X#/VT<8F2QNV#CKSN^RIPD&IB8-?:?VZA3D?^MR+IN\?XF
M-(!U\B%.[S?-;\TKDWOC1GF470J!E)HAA C^&(TY%?G?B%3]L]09+7%/UXC6
M"-9]+1M%8K,OEC]&SC](<TY%_IE(J]_2DUX?&EW[YA5XQ!:2YQ6#1T&D..Y.
M.G 0! S_@5MW*O*'2-!?["ZB\8GCEF"*B5J$_<!!Z(/KH[=@QNK&/KP#!PD/
M@+[_74T_%?FO%0F,_KJ,\^WBT'/'FXWI3%-YVW0]RA!ZQ]W0_145]>\<.A3_
MDB\J?\]!43C!4AOQWH"XT1VYJUW[4Z9*(E'N\M/CWB-_>A.EU=QIM@<G"_&8
M=[4VR#W#Q4LJPC(S$O&\&A-&]1M5=FZB%E%2;Y(1EPX9X4[P2[*#YPZS]@E>
M!0&!IR).1?QU$=)N#X.04DA_T< TG1^;+ 8$$C3ZO<=>%97Q(.CX!:E>]M.>
M7?]133@5\?>(((QSH @&*4-:A0B=K\^;%@:K"R+Y>]LF$S= WQ1^_?9J_VKL
MH/N7;_@R9#[9 N=7TMI$:LZOY?=TE1<<M?6O\%=\?;9Y2ZS;ZGB^XGJN<'(I
M_,/$4>L&&BA\ &<3/?=??@]=+H+S$J\,)32'WCR\D[N;?-05FC^$!MRO?6%O
MFT\YY*1OK3ET3M](Z?R.2?DN8K.$!=42N,F%&LT\RMA2^HYA^2ZC;#5(_*1B
M\=-J_X]4&[0X.VQL;;&9/X7C&*L%DJ8?M$.9T0]_$H^B+0AUQ*V9Y3&W/ZQS
M1!)K?]YYK?]->C_-;90<;EJS_P)NTX-2=V<>LH9_OC#[W/--_V&GE^5]EY\D
MT#W]#J&W_(3:TG^E%=<INZ,K_C)P9T5I1C;Y.T3V%PE1<X]4CF.(9PV/2]7V
M5>83?H&HG%9Z6NF/2LWNCM3,B<W>J>#GT:+W0#HOZ#K],6[\M-+_(Y4:>SH2
MQ[Z^QW]47*7KN>HXG&9Y_,>X\?_12A6?KLP*J]?++_-'[A-LOE)W\.."0<-D
MM>FTZ&>-[RU_>Z>R4&$4>IB%!AX'B=71[VJA]BFB)KZ1/%N?D:_UW;"U_[8H
M3MIPIWGS05>4H,/G]@?^KIH^L??]Z/\2)$J!F_I?+Y*#( ,IJ$4T,,88FB=[
MW(L&RJ65I ')'18T4%*QVYBRK((&G.#?PM4Z)4@\@\17<X\W6 [)X:/ZA]/J
M6\K8_V:)'[=;G()!&L J+4 ;;-7W*Q/6=9#CKU)E?RV:GHQ@^"Y6Y=>Z,^<3
M\;Z+)?]>-9L["Q;QK_?Y6]WQ08#OJ<1_KT3"4<U>LBN7)$0< -JZBQIO16[=
M\G&;1GB\BOG+)$O$E3]H$T\E_ILEMO19JS :D8,;&$ C*JI+?V-%W;^(/>^_
M/7[FL#7\B=VV V(L31$YJ4_"Z7\AMKFMM0IZ$_MCJ?D#)!@YE3N-7\EPL4>+
MWGKB\/BN;7F1A605J;8A02S1!Q+Y;U$MA.,!E5@)U_PYM];+FU=E'OJH+C]5
M>2]+7; JB9RS:)H*1W9 =*0-]K1J@[.RZG@H5PTNF4K!L.<(TV.SC*&1VU!"
M2WBK.6H"#1S>1PB5G*Q487^^]NW(SXGXT D-=,J4E/Q.@GNQ$CV\)>'8CP,-
M[#P %N>_7R1" XVRRICIO/XQ^0D'Z)]?L<KZE5'TR/3<Z.C@O7<?:B,]4^S]
MF[D'@FJ&<S-$[XC9!BZK^WTN/>OK8]X(R6, A:^$;Y.#^CIUY_RV!5/=ECE?
MR/-EY7ZCD J0O^! 0X04Q 9Y-S!'WCV@345QA1Y*63TU#!XLRUA),.N%6(X,
M.]1&'1#)U:\D@DN3BW/Q=<8&\Z/[_4V><L\HA-$&</NDQ,<IT*RV<Q+=$&%U
MXRC;%7HX'7GNVY./YXW)_<) AL4^=&?(1N**QTW &<E!,]^^7:[H8?SX)/QL
M"9496ZWI:\;KPK+8GBNI$\\C)"L;(2I_-9_2\:#!KR(_9[QB4T^L/2'<G>Z(
M;G#^B+;%NT%[_A];BOA;;H*[S^ZQ#L9*QIH1K'L_UA(XO?S!O]GQXP8H)E$"
MO9QCZAXLS.'@,K9$N45$"<-\NG=DI+<$7:>T:]^[DD*?';TF\1?(83F>ZUD)
MGWT^ #(2(KD,6#P\O//$D_0KUCQWI!@ZHPM?A'B9FFI"L-U)J\:W8) @8,$B
MEW"-N99J.4>#T]0\0)6BK(^C4-S)VVQ?@GEVCMJQBL%X0$2)]X:EW;R<J8\J
M'HS!CXE$5HH%K!BTJ>2KG3\4."2R3W>G7%.DP:S>98Z*F:HR]T:/K68U<]'C
MJ*=43VCM$B.14_$L6'44FZB8=;+9,Y_*HF4M6OWR/4;>]+6-9^C0@#=\[/ H
MMG!^>2VN=6W*^LJAAGI0L_13R9'V6;D0)89KC>DS<\S,D2&X@I/EI%8Q%W9M
M(A6@&=Y/B)9KA#O,L>/=$HGUDC.6M)]9=I0M4-]JALG5WWO* *IWG8OT]8[T
M[2JK'K[==W3[BUT77Q$$="\5X0(C2&$BG')T<*6"P8#M(?;6<KJ]V8D<HG"/
MZ+#S&C9G6)&TS;6>$QL)KR/C4WW#%]1NO\]T86#SD6<&0$U,\0AE\'PN]GI@
M+>NV<("'&QTL9D:2NB0 2(A%ANB(^8+!!4KYKD9FK[I&1R*^8-^,<)!GP6>*
M3^W C:.8BBF\\/5*CPU']A4+/^ERM>M!+YZ\,PE.R:)_3;GJ)GH@?L;UAFKW
MJJK'ZP2>RZ/%CQ=T!%4AS<V@*H9-";I_)EL8]S<>TGHK^)+2=SK;A-^[.&B^
MKI^^&,HN@L*&UU9<44X.8A\0L_M7<%_\;S]^FQ^LBHA.DGJ)9,+"O.ZLBA[+
M3L(6:E13GE_RKJ+Q$>JC1(I8R;1[(1>KII@#XOI&51:?:]('EDE=:XAB)B-N
M^MQ0D7$D2RO 7I-U2WVF>5?LS2^S!HP:J%_T_T.NL<&,IRJCG]^\Z5O^,J,[
M'*@\O4(F,WRK87CUJ!57R0O'9E$@R_#<B-BM6F0M49&R?+U].SG(*&A*C-K5
MQUK%+&1.[$%)HQ %OEVY$8L@,S@6W(A-N.Z=/O7ESM:AX,5SA_W#- ;F]I:4
MG!>PR2K)9 0;VV")1#Y! 5UCRXUYIJ^-O(O;[HX;,^TR%V__QE<[(W8>X^F$
MB \MT4#*#T>ZAQFA&>;%5])1P>Z+WREGBH^-J_6'M.ST]W,2S-L;/Q-[$3_<
M\B*:J9S*_A/CF4,"><4TK?C)C@&=F1*T>O^OG+Y\8]L<>_!YJ:#?3H")7Y=U
M1/^RS.,?9K?^_^TH?$R+*JY8>HF)U*+?9[E4C2V]1A4G'.-;@/-RQ)4++@;D
M$CHX1.]DLW'B"N2_QA>D6O 1Q<-V:3?4C4$R6/-8?"KJ?=U(&,E&=_LV_BAR
MW,_V->5<)@.G!";F4>_FN_OIYCF)Q7F/S#8B4!6M9!45!-N%@J-W2)LU6E-=
M$ODQ["V/'8\2K07X11_)\(."R$L,[>3K15,XQG1&.XW"H<RBB.V6BEE,O&:'
M!HYS-;:8Z:Z4";TGY%CI:  ]1"S+D]VZ  737V.80T[$8#7\RBHYCQ4=>WG]
MHSQO8Y,!3:I]PW,>_XF7+Q##E&0$2'<:BA8]-.!O;VUUV,*SLQ$22OW1P]_4
MX0:GW:WU6&,^_8GL@4]/\Y]R?1P2]BD6YXF^R@1X;\0-T TP4_L[G_M+#P(Y
ML[9X;[JD_%!39(:+G00/8H1Q(-XU '4B1! @8LG/MZ7C';F]7( W8QQ\YMKK
M3]Z<T]Y1L$IPF -(-?5C.?T2^[NO^J.RNU2)9_K#@N:IP_ :J>IA;>SL5>6$
M[TN(C9WH;#D&_1!ESXILA/5D9IK#9&&T3VE\) 1L4!?K'HBL"+[ZZ@2QU#(*
M;KRDR_TPEQ9"V_C0Z-V=K(*L-[KR+!I1AD7R%'>YM*1-#:M@;3RX2M@.[J\.
M FM&V16#<ZX\N6K!(Q^AC[KVG1M>3)C=RI/-Y:-,"&OV3*35ZF@T$ADW'8]X
M!!.59)A&F+E>J\Q;))'V\"+\0![:HBG.*..[^X!"$0]**+D42QI7>T!KLJ>$
M$EFI6/I*?PRRTD8(PLFM>//7+35-KG;Y?+ND^E7W@=<.'IL"B4334@.U+RZ\
M^L.'F-FX^Y;$]RY'2ZTL1%#)@@'[#H+<7+W@<ZH!!P_QF!&5NA%87'"N\[!Z
M:H0@?:TBUN9@!R3:ZM7U \(=9Q^9Z,Z<<=99TWA^J0MFX\"09'.H,8)+P<F+
MI<_<<K+K7>.]-)RO4FEE13W'RR3JT0S>D?TA KA4]\7Z4SRR. 3E>,X4F3RF
M+PT 25(N#C]="@.F",]J]^?4/\V\X<F/?:[2@%,>1"G^X@R-\=E*FM!)9I ;
M@/&R!,W-^J^<W%)%3:+OG2E\(V=*0PAJD&"/6^?P;XNR-W_8E=^7[7*&_9:
M7$AV<PQ@PC\IXU99"7 JO>G'F5IQ%RCYT/W<EZ$T0+;JL,B G#0DNRB^&"#B
MJNS C7E2,0U-1P/#_:@@BM[^RY/[T<T;]1NJY\G=PF/CP0ITY\0:(/&^Q11]
M'1#6B;%]O$7ZG24TD!PLG:J=/;J33NC+RCC,3A@>UO$>"HU_C@;P;A<6QO2'
MDW245@>-KVFSK.WM4-%LB3Y-_S,^2LIRZC73Y <7Y*"3O=FOKL6A5-7<Q#WB
M9=S:9[3I6%GA<*($YWO6J?Y!B+:G5],J\6I)B#I *E4CLLQVN/V!\&EH!GPX
M%Q7$5YAE:6=URYJ30O?L._58KND5&SPH# JEFG[T!5#O*.,L@>;YCT@T)QF:
M77TBR?0ANHFJ_?8V4^Q1J?-2Z%KKG22]\O!9D3QJIVA>5IPP=C=3WA#)\1!O
M>X0@TPXYJ,YU:%+!:AB?(?1+F&<Z?MD5QXN^FW2XN$H3069Q4\^^W$L-."--
M?.[%R*=FDN#NJTDW*""'G^VD8GO'2.&-LDJ8.5#N,3DKZDI^I$+8@YT!:LC!
M+>-C$X4CW3"!>A[U-;DI&+4<3NZ9/:?\CQRU;70>,80S+M:4- PC#3.Z8>F^
M2"P81;A3FL*$X)W1B.O1']YO9G>8/H\7:6S8U*]9'6_H&K4*'QZ.NS%KX6<D
MF2=OE&I"(K2U74E[%X%/MJ#]ZD'XY1Y95D8?(1/S#!B3"1U>.S:I!*F%]K+V
MM-0L.,HF\7A&M">D%KY=+XD]X=K#_Y*C/,</QW_GMGT?JQQV+(G<C>8<XE87
M8]]H2^?J;LVBN_#>%IM0%L":;+7:1V(\JL4@MD#!L5XH6*;)=M+#I?&>RO/P
M?D(\6)O;+(+6Y5'!DVXYN_!,,Q@S2$:^<B[-L8(XFVGCXL%CM_X04Y%'JI#H
MXA:R)#=EI69JRO%^SN K6=AB- [5ZB]2IP$@@)#+L(J!BP5JE&)/$^^V30"P
M/^^OF)1UH7L#"WIXPWZ $!,=/-\"6^[?>Q'+"A!99;T[ALOH/<#GH/=FG!)9
MD_VQ5)4%:_DOB8[J+%^]^!0P5>L"S*H<ICWT850KN#Q?=QOI,'!9\8:FR*NM
M@R^I0MPCA3RM.QL%COZ^N#*C%;.7Y4;;J.=HZ]TKJ.9E/(44V.UWH7>>-<&>
M9%G3RC-Q0C(;^A L"RA2:W>^HMY[J>;4?@SY]K+QZM;4=TM\))GFXM)AV'69
MKO2'^'=6GVL+0D%(G9=3SSF7,]6BKTI6;_8G8J_27@ODF]\>(%OD$3,0 !P_
MY6VRCCN(^4*Q[:3IH/TI'8D>F7C[DD/X];,-S2F^30<TA)&5UT%M>\1J=Z[)
MA2RJ^06;,K]1O/P8%($K/TZX(4>^(E[-D2M3>#'K.G+*SN]\",MF<W"*U05E
M.:;8S?PY(-;SVFU/)8D-1BJ''(GIR \.TP"(*:P(7%SG0D?3G])OH)#1N(\8
M ;7U-;2F>S<>$"))J\A!;5\?\Y]/^-Q]V<,2EZACN3-/-[R(3$EMS XL?JDI
M>XS4ZD[R,%4(W4,<:8W##0$"+)LF[$V$_! 1;U!IYF*>I8597"^)BS$R]AQ"
M*!)AARN_S!ZWYZ.M8)&;A"5=$,_:J+8;[MB!&'D\V"Y1+)H!!$X</"!@ZHG+
MN5+9IA?!)UK-9ET)HQ*OE;'CD;Z!&1F/\YO.6_,[^]_PZ12TO"0XE+TQ3;,"
MR62*!9H0LEKIBZ2+W-FU5R\*4&'#X_'F):?IB/F(TK.KTA#FX6KVE2.5YF$P
M.E\H<R)-+)$%^,R?+8*N6]=UN7#QK<X0?_VK5JB\SRWF%ZVMW!U'B> &)D"2
M(3CW)S-G00,OVH]KT,#.9X!?WW_'1@#$\)IAOUIKTP4+_W&$EKU(9&$%Y=2%
M(]IW\AG5+6*$?1ME/!24FA;M7^EJ20<<8P%NG=YF5S!*7WSYDCT:^-"!:YV6
MXKH>/VEN^EZ6G<;BWN/1=_@N3(29]0"-;QA!U.5LO2.^H!ZW(4>^LD6BKIPZ
MZC"I(J/!^T)$PF$#=8:N E71%R27;5*^S)1RA5T(=SG;8)4Q4JR*-P?.@X8I
MKB:M[=[J3K%ZFGSF(F&$20P:>(;QNT3RXXX2U.54O<,:B!-G?J]+6I.0HC/H
M_7BL.168V4=05/&3D:M8\]#7T?M?+L+>',_VCY9>!9J^RL]#;OCVD!$ICO[W
MZ6LXWPX*T8!31922\GTTD 7?U=E7QA'_L?GJ1Y&?$H>:ULV/W$;00'_9V %8
M*VCOC'11_T4%F*E%LBFN)A F0?@VG;+-A?YY&%[3G 7%ROVK:"!4..%@]S4:
MD'@P+H8+;^D_QOC/H>>@Y@>:'X_$/V,Q-Q&D<E-J:2X2!(B8D/HXUD_X^NJ4
M0_<<7?A*%UW4+L0I?Y21$)9QX2(N LC)[%*H&G77[L"#X>O[],<>N:C R^ZY
M/Q.H(@3U_>B88C2"[C*;.?L_#W0>J95/>#X7Z9,Z'=E/ [ 'K<_4#%N=O7KC
MT5,F'"WL&1\9=0,'!P\BJ\0]*C1P37^G 0T\T%1Z"I\6J=A>MSI*2238%=K>
MK>77H;A;>:-L95_6=$2!EX9S]5D[LV^]*.?4#;TS"M%?[KX/&;)]L1[1W*HH
M3!CIW09Q["O;K"LQ7!-+HCT"[]K4]7HI0V 1W @[K@&(+0A!Q?YJZ[.^VAVU
M.Z\6H<\C^E2%3,QXP^SD&D5(X_$8$2):-5_/63N<>9H\8EJXT9R,<,$=+7*?
M!H4CY[ -(KB']A3J,)WH;OW%+WWWO79+X1F$,>D*30A/ZE2!C%!<?>@/$EF#
MH]MKI187Z"V];TERP5BKL[@N38UO&4:&@+ S*-4DJ,? XC-+J &,B=WJV&O/
M>>9*5J?4SHMKP.5U<RY^B@-)(C@DXT&#!GY(=#CH;?W*U4.G(,UC@%JFX5D.
M!<B80%)Y<U:$IN\=E!BH+S;4[.9WI23,;AJ;1?7'GU=.#"YU(/!7'1PWW!?1
MLEK[J'<Q+D)&T:1PGY(&[+U+!+$NHF(PR5Q"]E^[+G;IY2T8SET2R?.I)*X,
MOCT7&_8<'Z.H>\[&59ILPIV;Y2N-)&\@\![&@Q8"1HB$$![^%,VN2Y45:U%N
M^I\WCK+10%6%\ X:R"^J'\H:SPU  VO(V_UB+B]+>%YL[&R;"K;-HKZE <Z?
M)A-PQ*<VE YV;8^)A'9*UI5\$M;WF8\]"E&!M("''L;B21]+NZ0P4L-V<>\)
ME-=[>DM-%(T[,<]BV\^?U5N?_2SF;[U3ZJ3)MDCO)4<P2%5I*CBB[K+47=2^
M!J]]PF?AHMM$H\9ZR9?T8FQD?LZL(.52FV0[0!I&)#!!(.GTJ+MMV:;<R#L4
M8B<\[.SPQ<>!^&'AER:]T&=?N?F7CF/P+\6"657%%MI7CQU&E91BP&'UQ2]L
MM;3ZHCVN^KMUK&^8JA/SE=I5<@O.>$^;3+Y[\!6KQVOP\C(IO*6F,;C\VK=H
MM0#;I"IZ%0E*%-M:1D=V-FW5.44F2]YXL=G>*C".Y!QRE3F".]1B;;MA\!U#
M#.$PA[&PLFD(% *X,+_?SKVXWK\3NEJ1CXE#-]! +_QCZ;'^1/_:M_N!$WKN
MUF?N7'!I;@U2OM)^-?P<(UZ;P#4JV!Q'.Y0&02RX]B8N4SN_D)^E*IDPQ#E'
MAJN.OV@FH#,,9%BYRCL/)_*"\I?4MTVS/.?4"""'*?/@M7]%78OQX:U>F;.]
ML_?,V).T:%-3Q*;YEE0C_^:NY.4/0M9M[DZ-=&YK!^?[^,PKD*1D95UD-8F1
M=AI34/O16//$A^>"@)V@?X(0BE=$$O7N3^R[O#IH0/L[^^[RT>]=_0M.7AY_
M<I7[59O_DF7__P<.K%]?G?4G6V@YZ-4R/3<,A:L,Y@V+']M74;3OV=9X.7->
MH;^FH38V<NA.=+(WJ;_;/7_7.QL<VDL'])*1$VQJBBG.2NEP\0W,DRR;&OA#
MTN:*3X(]O;/YKKX_%*TDDAA)%I1A8C*(1P">>]-!,1@_M-!"%"WT]7828L+/
M/FR#BQFA!<YQC >)7A>Q>@.W'%3"I8RD8CL7?35!",'E&)%HG+GRQ1&%56+M
M[M)+,V=:QH4+ %_RY?FU<F[$8@&ZC]JU@<^3%X3N'']:PWXW/BRN*, _O\9#
MI&!N/VU-RXO\6'?V. EN:G#&6L9RA&5A)G24^R$-5F7F7$6FF@[=M<ZV/$N^
MC":SVQG8A!_BFGE<JPQ .ZM"_8+C"F_6<5I+2F.]";ER.K!\-$Q>VGG91K5C
MQ_N-AR.!AZXM>M%5QI\^ 2.C8HT;^ 20KV'C=!>@N3EV$HQ9:*"ZJ*#D>&;"
MXZF25OB@9_/;))"6X"6W>OM7SQIX:7D\1%4"C K#^VZ;LUU1?KVG5CVU#@/G
MTC[DO=I,B\=622+9R+"!!\VX#JI9))4?#U1X,>V29Z8>(7A&_#F^L!X1/D$*
MTF7<)(*@<)(COU]+DUN'6YZFK;2>YVVS]X!)B)3)FN268)WV7I0S9[(>H\CU
M71L$IU)SDB\5'G"48D-<(-?6K?DS1TWB66)B5Z'^FGW^A4 VBKBG9@R>KE0B
M88E8]@U@C)/T=8KJ?&12ZG73BK5!))(=1Q=A'R'1!FM3HACM?V7I;KSH#@DG
M:8ER@##%1<8P /A,_I6T;2Q@8Z6U9U:=V?5OOT!A(Y=P4H)$-E(LANIZR/"9
M158$*YEZ1!B'"*WMTWAE&@4HY2T9(VG>#[EP.0. 9#NU#(_<O(A@KFQ.98Q*
M^":H"!R7'?I2"1R^144)]6%9I_M,YP\>E9-M)NK /&XQ#1HZI8YQDWA0(A'[
MS:YAE8XHX\8H[ @9==.:!O;WPR$W:*RQ'7C'TEPN:GZ(V5GPC%)WK2EL)<BE
M,M#QWHCU[:84K#-ZS($&PA[1[V#"<IG/CFJV7;4HVF=VFZND1LQ7-:D1MU^K
M?+AG3%#U@N[=W2AHV!DOW/XW5@56B<TE$2\-(<Z0F*C!78GV:-!HO?HEP:OL
MQG4?@A5GA^6I+L7>N8:=&T-G]X[;)Z>&)AZ/"L*8M-[V\C@.^T)TLV-Z"<G;
M5N+G@-9MY)H$]=/YQ.EM7%N<9CZW'"<;Y\9)6"$8E7.IA=4 3\LX(I&02[!I
M'OCVTW2 K0'Y:?#A>6$=Y;-?NI=#&<(2/1>(0!,.0@=SV%AL%3^_=+D08B9D
MLN.>0EAG"WWWHDW]=I+ 6KI_PZ0=Y#YP^4\O#IT.6ZIWR>)SH1\.HS2DL'(<
MI#:14WPM1]*=Z1W9VC F\X]A;_,=3%M=#1HUUL-\+90IQ\V+'X8J!YB^O)&$
M<Q<+3Q";3A+;";=(_]G!EG/!FQ:&%D']&!%_S;.EE"*FSL@I029SRT2B9W4H
M!B%R7!.]C5(VF1?,CH62&\BMI@:J>A!V4$/^GA5%Q^:G\U9/!\[6Q?E<8XJ2
M2+,KVQ)Q 3D&O9XTB^?,CI!579<4<;B5%5?/'67''6(WN,@%$J3,>(0& DLT
M4RZ.W" YV0&5J>)('_L1PP8QY!7P-+]8Y/S"=2+MNE%-N1DOQDUZ4&>H-$XQ
MK9*JH@NSO2X%1L6WGE$E?W1]&NW@_+:L50*(JX5,N-9[I2<:"0_]T]]9DG+0
M0*9MS<FV@2H_3I4A9_YCUOC\S8V\R%4D:'K[:Y:TC*]3KTP_-,V.K95K&*UL
M1MCA5U)!Q8I-Q(DY!GU'KA=>QF/?>:G@OUU)B4U#Z(,'H^A1D2 ,H/"78@"I
M P E0 0 C[ RX4;,0_!\GJ_FD3/&4)O1PTVDN>!NO;"F/SDH,GO/Z*SY63;4
MNGW!36$35=[\0)HU10E!JCF*,#1P-JF(0?>.O1!K6].;JR^K@#508SLE=*,Q
MIR (:.U^+'X^[FHAZ315K40NB/QF*3D+8&"\M!+T3'?MG5#IU>SB*Y+^T5=8
M&7U[L(1\&Z=IL.R1?77DH&;9M4E<I^A)^1Q^S]ZB&'??,$<DL:)D(S2#KW.1
M7P%^;KA<JAF9&E)D(%GOV,YG% 3DIM_C\).W><E.QN;C/B$!AC6(:&#<'9Y-
M-MG*;=6W)32FNKAJON%AKDNZ_4?LC9/[!O&SE URD[%^^KI8E!L.2J+R.3E!
MP&RV%]V0-I.]#-7CS)08.T$SBRJP/<-ZT[@!EB)WI,ZNYE/G-ZP:>D0\.6#6
MJL9&$:?,C$0B-13%M/WC]TJ.A,:I]HI2UW) A&Z"S/&I/7T5Q-8<9+ 4PG+U
MSI8BFH_7#;R+PERGU[A S)1-.=&8N\ZP7%_D_E36?%& D@&C;7B+>--TLGQM
M\.JRT%6W73$M)?9VL?MC^W-(<QM8O6/(\5)6,H)]X??V8=/ZT$G6Y99+7G"8
M<,V.R9I.>X5R2E1H.J$ZGR61\)"#E(/YU;J";?'&+I9,YTQ.9PAO=X[\R>+8
M\7DG*K&NBW)F#& F(F-GE2/F#&CZPS5<.VZ='F5<I< COO-^[_)LS,*?B430
M=@DRQ7XT,*>:6A>59]8.8@&+[=Y4*)XH,QI>*?N22)J__RQ_#KFUX"-^L0-C
M8:V=URDZ:U(?U@LX5%';U([(7P)4_.?>R-$6,\,V'L.\]=(*(ZP\T8";]<Q
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MZ["^A( %'+,N6],")[O%><42S(8#(O!&R*]FMW_1PTTQ*5P7+9V^FM$LMQ2
M36,NLJF)B8;AU?$$@35TYF%M7VU&]OV51MNX_?6_7<SU7-OXNK/\ -F%?Z-^
M ,?9C"O1/C_V<8I(/V9<-MF+J5%Q#;KV4:G4PJ RJ0:+AX<';UYNFJZ\B+$\
M9GPO?TFK6V/:(I6(9_D,2[B=U%$BJ&=K4?X;QIX@XA-*.#<F0GD;S6T%;!Y7
MIZ_.45;G[@9;6)60:T_+#-E'V?AYSHB^H*N%;X=(,LQCQOC^P",<(I](:7 +
M*BSQ_-72&!""30J)F;"VP])=M2JC41?-715XY8 K=U(1/'9X&I6BQW:B["D8
M2YC9QCC=Z(.>R>U7<C/*9=4:;FIA@T.*$Y5M[J %O>^?W[6N3< #HU'4ST>D
MNLZ;L-V(@F+[#FHE1)<$L8 BI3ZRR@)96'A0!M\J;+K$?F*G-9MZ,\XWZA!Z
M-A@;;.7SW<W^"#C;ZGPB(9QX[]:PA*Y.XEGD!9'BA=B\93LBW LB"'8CS"B1
ML*[OD[0N'C/W,3>JE.Z>RFY>[(S.8?(GZ^NU!?X/UTNN(V4#JYK]AWWKB63O
M<Z]HSB<2D2V-CR);]6YG$(FIVZG;#[OGS>4RH31ZYX>P+[+M.W>^!??3Y$V'
M1PLR4\&:8/.P;()_:M($_FU>-L57L9W^G9VV_?<N_L6.S2PJTA3+]+#_J>#@
MCWQ0=/W.9#L]X$A@SFC2<&-;0_2XO3#QV];2@-;KX/JAM= O\7WWHAVULZ73
MI0_>)P>QMXB._SV/]UT["3SK3U1:BA]_?>N2>%;H7[$_#N9@M:)??+V&,@JF
M/U9%B;=V_@4]@<2%DQT#V'EKRNF?2?AIU\0E1B@8VS/-,2%X/![- RO:CTZ&
M9$[_\\AL&O"#LI!IYQ8Z!"& ^0>1$)Z.(_@=:[R&!@AF\5P+HB='A5//O5>%
ME[G8"$+!N1+LF""!>TL<?WC^75=M:O,4,33/Q68Z0DE3)-;@W+#WLPM_Q5WT
M^9,#FE[>R5>>8MVKO9OJ\5[79XSWO& E.',+8U[@A)XC4IRIUT]:JM@]%S@2
MFLVP(R3K)9LP%LA$Y)J1_PV0M&(I#4^+5Z^O+XIL94=NC1.EB\R=>#@.<E!"
MHL739(EH^_.L=,L7& I;ZT+L@$5/UL@]9ZI5-16#Q_/A48J*7([#/:8(-. Z
M!Z/L3D9<*OVDDV]A0B5/GD48'E:#;>+8E=R57]LUJ7 W@(P/>-34H&H'-(E$
MALA?R?X;7K!W,.G>\Q2$AC<V:9CDN ^QLN66,N2:0,W\C7.V5W<6:R.B-YY+
M-619,XQOT1@8 #C<7A>'\$P*]UN40GDTK;L*Z%L/:TEX)-J -EP'&:NLDY%U
M=L\3S\AZ)G[T;H3J5]4G=[>M4VGH?)&8YW7",%N[A@;\&#J>R5.:1=_^%B$S
M"C6)GMY:Z@?,@=CP5\/_#[EA__ESEJR)EJV\L+) ((D6?XYA!]+U(5-S-'U?
M18&N2%G^F 5<B.F:-\.':&!O">Y/O_9\& Y' [2V:SGL/]'4T0_RPML%T$ Y
M]1$+^-,IXA1QBCA%G").$?\[$;).DU8N,LI'40R/LT<\V4-03:]1;A7':V,3
M<D/J+4W!:^(#MFN)1"FRZ]CGYS6&(?;B3J&&\VR[1Y?YQ\;00(/.$?N34,5H
M10W*4%/F [6*#V:8*, 6#3P6V%.&6*$!_#N%NVA@O>^$T'."M0"%!E!"8Q.Z
M6CNWQS:_H(%O 2<_G().0:>@4] IZ!\%*;US]3GC1Q <641?4I.W31'I1/%Y
MV"W .O6MCT@!K-J[?^U=T_4%XYEPQ*ZJ>!K;@IH HT 5&C"LJ,Y/TWP4-[G<
MFC6QT!]ZM;=OIGUYR79_#PTTWD%=AYOKP-L;4%*VZV\3?G(=/YR#CJ=[Q:;7
MF:,0V^5WS!NH:T<M\,&^L<UU-!#V^L@"U5: !A)"C_S&IC1^OE^5GTBC<[50
MME7P,+BIH7C,.GQ6YR>,[(Y3X=$1?/H*&KB8^;L\T^3?J_<]9,<_JGB&!GC&
M?L*(?\RNF)M" Y<$]GJ5?@+]S$R^U(L&7J_I3],/WE6:.=+?CT8#/U"=QW'6
M:$"<?A^_HO[M7^$SI[^?>S3F@P884,W5\&N3:*"U\"=4Z(_.Y%/[*X[X8!L^
M>W1A'[*C>6X??@%E6O&// #9_BPT(#!>T2C^X7U"RU[%)@<:^ V3<B@TC/(2
MWS@'#U;_"?*S&HE]UM^OP$%)'D?YH?3KT,!+VQ\8^A^/\D'Z7],]E>U%-/!E
M[]H&\:D&G&K J0;\5PUXM7-^G(RYJ0'<;'C\H/#G7I3I>G/_MJTWZG=%Q']M
MAE"Y%<1N;0R@ ;:8'P]%]:_$V:?/X=023S7@5 -.->!?I@%\A)IA'RDL[5)@
M8CHTFPLJ/]W#&\X$:%P297@/CB!*_;]TP^[_JFXX-83_ZX9PJ@&G&O#'TX F
MTWS_NVPM4;"FC0'CA%NO?\A3L1:[*7R+BSF1S?$H$PW\[^V"4R/X#S*"K//\
M?6$PEQA7^IJ9]U2[2^$KQ[!W[;_?$ZGKGX8*!:9A,R_NYO=@;L/\GWA/J,4]
MY%SQX]-0"HKLM>TW-#"5C:*H^RO=!YP"_A< W@HU/&$HDL@8%/8^?"=,KZ+;
M\+.*/'SU*&^CL=(CD[X+(0S?NV5=48$&0@KW5/Y,PR8K?G^$0 CKGT).(:>0
M4\C?!1'ZHE!K=X>:L5R^8:TP8R?ESCH-27U&NP_O$<>B9U:X)X\Z%7<179H<
MZOF5E^S()R.ARJEHX!:P@@9^N#C9G](.@OY*[ 2LP$\!IX!3P"G@_QI@B8_#
MZTS1T/6'>?6X?;1XHG44+57I"F=P30P@#JG$K4$LH%^SM!5^R=K^GV-%^+,U
MI7<U?EIOF@\:^!>1??[3A_J%BL6QXSZ4AJBD!RH;#8S:SDB0'_V@"6I=0P,'
M'U'K**G\^7\%O\+?7CXTQT?K[J&UT?D^20W\(#XCO2@G]/<6$8V4D,;)O"J/
M\Y)]':L>)X1?E[]?8MD9":]6<SQ& T=.\.K0O5LV\!.?GKNGJ4&QZ'D_9B.W
MF [2SXZ99Y3O/$ #?Z4H^2\E3PN>%CPM^-<+AA_=L1O/],*KVM>JF+CW2&7;
M7;^Y?)I>-_=HXW PR782?Z6^YR'AW&HFRBCM)$5W[B1%=Q$-^)NJR/8NP-D.
MPSP=*C9;OIGE'ET6$#_Q!5I'+*<%3PN>%OS7%&2C_-24;,Q8V#K85+TKN/66
M_,]--NMDWMM^,N_M_>5%;/&?8C6,;:N?%CPM>%KPWU+02\_!\J[<ETU.+KO/
M(9YLMG^ 0."TX&G!_Z2"[^[NE=R-I5*<7N4"'2!![?N[E.JJK@_NZ$1YUH0(
MD)Y/$#X<7.3?/6.7?%-0<UY:_KYGTE+P&WZA^E'9;3HTT+X!_5Q8I.-/=JFY
M4(J]H78B3>:^'M76"YI']BHKETN8?H\,(<?Q_?\L&>&_9:\)S$%P\=M!])'X
MUB7IWTX NS_&6YCN*R\-55<E-+ C% %PA+PHD-Y//_D)-5SJ*W.I+/F-Y9KS
MC!;;L]AI'S3@:BS^R(=+#G!WW5N\F1-G>[F^NR7BTK-$9HSX6AXQ5="B.]$]
M\>#51]_B5YO50ZUH.TK:@XO:5HH(N-OD5[ISA 8,[ZHS A02  @!C ,0"=8M
MD*QL7U(?='-E1,@$B422]I!(,!S+WJ;STX"3[,43$R=&3^25"JL3?B3A18AG
M5F(CPU^]EN]@Z!(XCN=3XB[D_SIW !J4 9HJJ7*LJLZC@6&'EIQF\3YN!;M1
MU>O-TX];0<9A[@Z4(70(#GBUFH=X.X[OB_8;5SNK48'<L>%M]NU0R.<[Z:ZK
MK&GGM?!V=L\BR%0V\@0A5L@ *DKL*1=J!]><Z(_;HP0<#E!K&$;QQ3;B6XF-
MQ \:&,(D+JWSEQ[[@\K8BTDC7<\&$+1>@/K@8X?@*WM*6];PM"9U^+P#8=/X
M$#/X"/GJ]OOF4NM\M+)*O!U^H?#%N9Z,(2^#V@AU9.S&(!2I,BZ\LS'=;<+4
M8H2Z?VME)'9?"6F E0*.L!,X]P5PH@B=^$;*661F4;F1_+P^NU2X&7'O/2[6
M!G]< S0"Y\:4GE.^E5D$U^TN4AH)PHAOE94U)B&*>%7UPKTK8!F]\W@KY\(O
M3HEL*%T=8)IBBD2NQQ*Q8-&"]5#]F^5ZY=*UX9[+<V9B-KY4[8KV2W?S7)M7
M5V84K,2Y&5Y.<NSXW7XNABQ>\!W+U8ZII-_81P.&9T*/HT,!>,O<L1^G^(XV
M$ 2G'ED8$QU]GDG7)YSDE$!M'S=L1VX<&SF<KNMTT2N)+N7BB%15BGV8[/YX
MB!^=Y/BF)GM0WB<ZZA[_?,GHH1T!4PE)21Z'6J*W_$0C9!+S@#)1WTO>YZJ5
MYQG(@'I%8<(P'L]&NC<)TH"C-G-0>FDQ_P5^E,*3VRF[65=DUA*JN?M%#Q_-
MEFC/B/^VI8I.R;2J@BW/C02^9+L7PHJ3Z39$,D0><T% M2VUZ";/PLZ*0QY_
M7V2K7$H;J/JC.;R<.P2OT>#!U^#)3I=K S90"TZIU8%IGO=SS^UK#(A<*:<)
M5XR(07K2]L:0,'6_8 T?I&$E=15=<9-8\6BC()^(Y6:[,0U\Z4N'80AUB_05
MV]?=E,USLPN^)]OL:"H]W<9_-'!Q$4>3V_"E3@EQA6]XOG<$$?4;_@@+L'90
M0->"3:<9<H9)N=E.Y@:AKV_[K>;U\P4[=\Z^ ]W>Y;'6&X_24"F19:!HZSP2
M]A:<@M4!UIVZJ(^3G9;7!JRG+%=OK0[XL65,Q3A63]/!!,?MB^73KA[4%7U5
M[9/ :Y;I8@\/#Z-J5+8?0<DF 4L6.>(U]X6%5OH'-?C9AJ/#=4D9;WW -F$:
M)P&UWSX8GY&)+I[T-68;E#QWQV&AC#$LB)S&QMR&W*GAO@2$B@KXFES,:M['
M4;\1_0&04>4/UT4B$6U2OB%S&Z)$,?YE<DZU1NLB/#+#>DP0'YF)@$N.89+U
M(*II Q\)_OF<^U-UYQ;)Y*W3:REK9^@LG][5B(E()(YK5[9'TM"IS[[56Q+*
MB1 9M)Z,XW+]9$Y$) $AI QOFE _B "FP<9U!VGU+T&ONJ[QWVGF'X\%]Q;D
MG'$W>-3F#M8NB+B>D<NX[)#X89J_2Y8]O*IJ2G0)?'_=LK"[+<OFLR:_"EMX
M34DNE&%+A,3.E2&\KQ^Y7=C)P53VA-5UQP!VV<M<0[ *DK2=>+:$/;1PG6/V
M<XF>$"P:QP@[YG+#RY#%MR" Q$W4=?X&*&GBV.M>JM696O5B:4Z1CR^^BM;=
MR&4*<;WTWIUNF@4B*6VP%UFGD,JC4Q]@]?+)(%DLF7 >3%C=8,.3V*#6[%FV
M&1]9OO.77?E@JK[;9#Q)+Y:QB?:AW:)X$$-IXSWSVLZESAAEU9O")L'E!P)V
MLC1V=O;M>=AG@P#V<]4'PTL/=N^J@,*C:<#%441=TY%'-VDX>]E#'&-[RME[
MQ3]D7RD^^RF"?\@^EGL"5H5B%$*ZK\OZ7Z]8SI*S#EHQ"78AG"-T\W* /XD/
MI(M5QOU$T2SPS+3W95(W]!X6?U^\VA,00'.V@G>7QAAB.2/'=__;_9Y\R;G1
M&^3O 877JA,=6#P#D=\(S1'")A^\&R'FTHZHL^NLZUAW!%KR.)ENLN$U VGR
MA(X1Q*)B/F__EN3KH-X^Y@"^PEZOSED<.NF>/,X.&0UN'P<ED<T.#\V'0]NH
MH#<> \81)/AF^1S%P*KJ;1L(-(E:@JE;[.(HQY#>':IF>4]>UBHJ0I(38P&6
M67)4RG0X_S_VWCLLJBU9']XMH0&Q"8)V2]1N1<E!I)N,2!(EYRQ!E)PSDA0%
MFRPH2I2<@V20)#9-CI*1U$C.DD/_..?.G'%FSLQSO[EW[MSYKG_LYVDVM5;5
M7JNJUJH5ZLWM@,1>PE*5E6S&B9, D];[B14S4"%%5HG,_-)CF3NJ(F,\\I0-
M#TL?D@=3M-_%\H[1HXW(&9I.M4PJWZ#T6<T@J7_/G6700K2*M'TH,D7RH^6A
MFPT3*"T(ZM?'GA1G+NRH??#MU)EE=-F?)0Y926,.VZ7;A">#P]V$>Y(7J19&
MO"Z>Y];J';DBAP?L?7C_ WL(L%76,TO_F&5ITE4:>#V)F49 JJT",57$- YM
M)G3%/@2_O&3XTLS?K+#?1"LM2E3OA2/-4QXHK$45;70^*N%V9)*OLY,&RXOM
MP4(>7?'LW8OLK7Y#V;[9\BAF^F<S;.&R8ES\%Z(R#1'O1S81EZ/?R-LTMT'K
M1UJ/YL;.QZ')B9D)DMX7.G?1T,$T6DG>6KZ^/T7S5"EIQE'(+B5?<!- 8CM(
M_X8UDX!UI8S==)N>ZTESG?^$L"[M%7=#V$"-+Z((Z8VH$J1)6,34-JP^M ]<
M<K)D+YIIC^B\@HXA $/9[>-\'7CJC:$ )#]XAG-[1?X.HW<_CSQ 6%G*R0#
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M_7>LZN)7=RE38%B10 K^;XF4I> -A:0J)_H7[]H,( +G#S%(/=^*AD5 Y5.
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MI]^1(]/AVI#=9.] %XRKSR"[OD)%L^T>G3$,-MR$))X,G\:B_2G3KX\",O!
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M?-F+6 M]!=JQ$W"&&129[%(? 3VY,VW0E#71]]2'"=(Q[N^\T'*CU=#& @
M&$#,$%_6_'' (9&F#L<@=OP!#_1DZ3*RQ":75#@A>!MN$-)3WJ8F@2?3RC?O
MB-D45H0AF\RV3@TYY\H]9P:7F5'47)K%@L#$"&6S8TBMU:.]3OM*"8P='_I
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MN8]K:0=JD#IT]VB,25E[:%@8Q%\3,C;[Q;D"&A/^M5 Y,]Y%@?Q+2O*$AWB
MCWS57$2+6A&V[VN$\16Y\@^L6Y#_=CX4/8 '!A)W34Y-^$*UV.^^+>Z:KE/\
MPJCA?D2"!X*>W$N6HM$L])KJ=@L[OE]^?#KJ#:L4B.!Z=:6N9AT&6/H2W!('
M[ -.D,PS?=&14VD@[:"S]821X+[>%YR7""JA60O1"*;>RB=YJU*/1JR7RLJ%
M8@2_L'"H1,K+/,Q]O7^I*F1V%..U_&+(;XLUJ^LKO1'CN(=&Z#MG^ A1F5A-
M4.B4KQQA5#UJ^\A.?/>;><7CSCGCYG2M2!\=V;1'"K,(JC%ZIG9U>4@:86YT
M_$[W&Q-Z"Y3!?7[+\H*6=YH7!_/H8@4(,70.K.MCKL")_HT=GXTIKF,GI@XV
M:L_R"LS.P^;[30EU.E(59JI0DY)-:06*J;Y2QD_C\E+9'IR-!Q,UHPZN+W6J
M5VW<V(X=?0;Y\$ RA\14SF=T#34]HE4"10 %5T[:*18@<S-_^-J4#%;Z3M<E
MVWJESYO2;^6URK<^AIR-/^/I,J(<5N7_:8MI,-'""U2B'9$(,Y EI 9AX0'H
MF8@N>_4K_5>?6FL:@8V:*+"7"M224=?2+-TI%U5?JO@_SO VF A,_U;^OKI:
MD62"_CES1D=+IPSC_LY"IX4^!+OP]*O>N>RD9^! =K>I)[%+2PEQ:"3GUPDA
MV&L1ETA![QLL/[3=\[LVPB$YUG,F4B_2+B5\D=JRM5SPJ5X_DK->&[DAU3 ;
M8(.<$<:%BEBF?N%XK:B]^OKQ>=\L?\6)V>/*13%L_MVTR!6<$KI=S8DPDAA)
MKYHE^58N[Z+A_<^2M,M3B"^C7T0[.PPW#EM*$K=[3J<<=T[5ZMECMRC%&,OG
M9M+,*[@;\-7028U+J-M0>BHL/$_G9.#=B8?8\<[$C(+3[ K-E[*RU+X<"M.%
MUL,)17G:V:!D(2U*&6-N'_B]C#:V>ZX\B 0<[N1AK"[;J"K8<J%068J&Y!_%
MW/J__>1J#7W<>A%NFHBE4%TY\>BUEM(/Y7%XS*%[ENYBK3TU>=0^:-&[KDMG
M*?_[Y[XDK=>)B8B$.7"B[=9V'@.+W'W^6UR(XV^KBGL>D F]MR__>"5ZP_Y-
MN?9FP?,MT7><;0,,CO(S/GX9IT[D\ORS?\+>%4UIV/;]/1\>Z;"3+!^F;X\&
MQ+X(3!U]OB1VD';D$YMTMD19"G#  ]16EQ9;9=!,O&>*D\^59$G&&#F@2*L/
M'(.SK#UJ63X&O;YV5HO:BI&'?88G4#7\;D9[VI,E\V\K^M;CV>,IDLRMLFF_
M3*Z@<'A"=(<7:AWWEJ/R4.9@GXXC[@*9[Y5KDPKB!/ X\AD:  ^\T'&/'#.0
M3NIXN,1KSE0O82?7,%IBZBMQ5:8W2TLO_V.V=[+ 38VRK)+(V\\3OY%?1.VG
M(%$,E?.EP_?)VM/HS^22,*/]*0@I/0+T!GV]^*X%T 3QD*_<^.1#%0+(;IT&
M%JR50A+-X"N^;'LU.1./-^[:PR(?-AAGZ]/>,\]L(;<3<0S=$WGV"Y#I4OYG
MW =>WD*W<5+RT,J13X3FL(5]2COI.X(Q.4;O;UC/5%A1?)7B?N%AE).Y7]'"
M3(0#B*^#$FF#TU[>51B&1]YZ$<C:\ D4X<][.T9TW--4K&D]MRHT#GJ&S\%.
MVEVK/V";\(P(Q4W=^8LZ31OCBT0:2%FWI* W4UOAO0(PTTG[S:@^@LOY2X)Z
MKP7*7*]7AE*4V*((Z&9 ;BPL+-U,'L \6]N5V/?KJVKA=M(2S><<))ANDX+[
M[0TR] 8#G(A+^WH;%^SNMN97^TV-5[0F3.Z(Y0$V"STR-++A,ZUJ2F^$ KN)
MQ^CCT*Y=-RUX9-@5HDQ:38WVA:1[(<MQ:'+7+MJVD:&)O<=W*(FJ_1RH])M4
MF;N HM;B3.BR@QM(G)9V-C]EVO#[XPAKCE#A=EE$=#-*W6R2H!Y%<$+(6P+B
M^O12O;KW?:#$JXB'&C#XY50[:1D1-C'Y#?JW&HD<)74;VX\PXV<FJWF@?M$D
M*A+@4%(SE;%-MJ3U"Z^O19O1EBR5W9F("+>/A89*P),9EL14U@/&%GF^ G7F
M0HA7%X30A8%:806@Y\ S(86I.%,"UBTY1DIK49RU4N+\%A6<2/011_6W&8M*
MUSF&*N#6LO8=_A %^:@HAF"2/L)7O,AKTH24!->%8.[+"B1GRFKD4T*,1W0E
MT=BGG'( ]RPI/([X5!,E>[/=V&Y;7QHV"8^Z^;3E!@NB>M/!81CN%VYGG_ =
M)-]DN$G5=SHQ7L(#4F0O/\\:'"H&J[YHC[IUEE9E/MM$1%K6Q&\ISK6A>\"I
MDM/6:E79D9[IT5<'8@',F74%!<4DT6W+IEHF?1>NJ[$1T0&8>5E3Y\X!*!S9
MI8@-\ ?X<]![Y32V&95>-IKH= 51ZR$D#+?,T2QLNH,M.D[)6L #599.E<UR
M)M$/L/,"\(! 9,OHYI9?[VDX=G[/7'GC)@?[E%*Z\#NW,6<N_T[<"N*:?<!$
M2 9K/1T3C;'E"^;R>T\.5A&77Q):!3:6]4+&?!50,_!PUN8C!9^%+CP 'U@M
M36G.O;T396X:  83&OF3B";Y>HM(T&L*63IFS2]RO*6M'HTO#HJYQA9WW<P^
M?FA1 A[1@D*<J?T["RUCFE<S'E]\6[+@^>2.'.FUZU<<=X,>5$F#R5TV&AK
MX4G%Y;K_]S:__@F7C/X*$G5 \^GW+*>7SB6Q 6]>$AG)M9I&8^&SS/361+Z
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MDXV3VR7705'W"K-<F5G]Y5@ 4 LBP5==WMKAZX+V3,PM+8Q>3@X1?5PD!4'
M8/<7GPL^S?%=QYX=>"")WZWY4Q=)(C5V0XBWWI=O&1Z#8V[H$B[JA!#+T'T0
M9YPPR]>=*,.:A0R1AX?FVO<A"3<Z+E;-?@RP>JO5\P(+6<Q@X/.7H=<,W"N7
ML27ZFEGF E5W&PK7(XAF/DIR!J,IU2;G$)K*>4?7='7E.+]J>*9*1[38CD="
MYA;3@C!V<K.52#! ,,#66.-N<IR<RU_FLE\L'HNQKX3#,-+VB3J+M:06MC=5
M=8I:[V U4=@M 5/G>IC>)"0U8;MU;ZO]9,@6?FP;2]R9Z&GJ^627P7XP3 <H
MFE8D[IJ4DE_R])='2I;>95H#A;3#%+Y*S/@UK,R?S;]5F2KGMDB;,.+EU\?*
M( =;MH]S#(T5L6RWXEP3]F;5ZA+TK7Q0P1K*#:$%QNJIQ44"'(@M!_@Y&$68
M[K_MI5\.'3'B=5!0#D(<1,HMBP#T2N 0M_.?STTM18<745:>O;Y2LE$-%<YW
MX.;K)V@IL-L0;N,/^91,I#.B0H(BA+;\$O)M^)"X29Y0(SF]B@[W:E*8.GP=
MZQP2QOR:%<1QY -K 5[&-NPV3I5![#%]T)=4NW?,=Y]4&J04M$74*XM?K"7V
M:1L\+L(#(]'S!U\SJ]2H]6_Q4/,9Q5<RVU5NF_B*=$D:V*_SG1C4K82=].<P
M72J=HK=?:%68$S69C-A$/R,T(;S0LM2@W,S<#8Y__'9YQ+MU,94:HV%L!QB[
M1SCZ@RY7UN^[G@'?/1#]RU!U<]QUJFO8*:T>#\@&.!5T[?IN75RSWE>#2#M^
M\(OAKUX/,[@4DC$<=$W>I 07M5ET%2(["5$CCR-:)J$!C2FK<Y4^<CIRWT1X
M?@CC^>*(-H>=.L)T;<N8W95BF(D+ 0*>0^_4"1)V%(?6WEIW2F!1>]Y)U?3<
M98+-G0/;N3+C2P% <'$;8<)_D=@OV(L&#X2UB"V-UWU'SA,,;!^;.6DAJI_<
ML8QS;!%FQ1&@(XGM,0YN!4S=PAS.&Z"$G6DKUBF!:'(Y@"$9I 2 3R.826JM
M,(NJ$OE2GKO9\_;1=J>3<VF)F;P'EB/C!0',G%2:]D)P-*NM%:3>#DSWCI[<
M&4E($+QG.8U:YAR5JC!>//M^4]?R#@401_E,;=(DGYM8ITQ8=3WET&-VS>LX
MX>'$Z];QD.R+^1L+"=&=7BR]IE]L)M1?)8['H# "<M=1*VA CMF$L,#$H.%F
M&]EKAS.9B$@[@#Y2;IX(\#J<"0,7/!N_3+T?NJ@5QI[>$W>C\QL8P90N\MGC
M^5.GQT>H])-9@;&6PRZ.T&[8CB]DI6(DZ0+A'+.O.^VG/9NFO4$USW+"QGS]
M\NN'V?;4E""]<(!Y6VDLJL/3&G"G+6\\G*#DT[.@?A6%5!IZ%=$BYMR8C5L'
MUP$FG'OVT_(AHNOS'P3>^,6#V!4^42=6*0K)ZEG/T%.%2BR>7,$#CZP4EU=&
M75J^+0]70_4KNCH2/X;$S4W0?O:Z[,9A\Y:TY]E@.V7AI#788P6C7@B16XG>
M=R<'+9?\,_)^_/!V/,:']N!)YN:'KDF9(_E-,[(/Z<SN)BJ\9S.9OR^RENKV
M^@S*X ']\WC@-NV2VIYA\M;W6N1!BL*AS*'9J 24+.4Q$@!NY2N *T]'<L&T
M/#WIY2M!XEHG^I]@5O85$0T+S7,3!&G]LM5\(Y\W.S:CNB;H--$[DS/TWG8Z
M%1FWGV9!X?X4.M\:6SH[OM]MFZT<#PM.Q;VOO;9ZS/1I<^E$ZMC&D+]ALZ;@
ME5<%QEWX.Y-B8PX'.K362)JM!:L:*KC56WZD""0L7N^2)H$(;N+4#*Y\22U_
MUQI2EJMK=]&OFU%&<B'TS<H@9_3#&9+/-@592+2PB6#D.Q>%D:LY1Y0)<#R@
M:HT'?LF)KY:YS&Y2\GSEP[E]Y)T6 N:MJ#"3YGL><T$UJBRQM-5&Y,E(>E!X
M'&CA_@;3P3O;@SD\4)QF?K]<@7)D90(W>BN/]E*IA6T;=.1XY"X>N)*QT^1X
M5-SHYVU,!_6<8T%^%SX?[!*=P1*S&QF"C2,"$T:%9A3BG$[>H&B[#7R:GQIN
M=^,!@;SLY@A$2;7LMV0!]5:5#[,O+:5PI:N:)U^E$3>IK%"3G'3@C(ZEM;#6
M$(W/',+5F=+&3^PFN GI5Y KHS"6 *WM;L.C&.ZLR=<(@D$F >1WW!/C5Y-9
MK;<6EP=;0N-E=&A156P99BE51UAAQ8=%@AW0)H=,. #:@_!@*/I[W6QZ3,T3
M)"JOW&ZR<["O;UC"^%"RJMNNG.6EX+*I#R454JS+,&R085@H3BS2837Y5F&L
M(,V=+8WJZ@X=8EE2>K?SI"MO_XGA.B:49^?KR-<U+K$N2Y_).[4,ZDX)YNK&
MP5 ;)6F[YHP'S5;J-YSK>.[N*Y/[\YXG-*] +6D>L3<85[#SGB%'S\ I(A*&
M<T=SAA J69 !Y"=W]-!<=U^P0LEW6_7-'O=@%?M/?19R^B+\U5_VQ=J[W@>S
MY6XU_JLN6OY//OE_M1ZMSGKC+JM<1I%27%:+G-!-%P?#J]^+6I\SKQP$5"?O
MX@$1MO?Y;+)]C)UWN!J,,VR3QB<F]KT]7$JWODQ![V=6IRRME[*JI<'N:Q>>
MMB*?W7]WRJ;?PZ!/.B?X3]HD^4\!/LURBDT;9F..+VR.]YW]*JMPW(X$D[AD
MX78F-9J#G/U21N5=[-]T1V,1%X29F1W]FR 3R@.%M==D< T7DFBUAL>D+G>1
M:[J0!02@(RM7,.[,9*\_&V[<JBCO?9T^)3P\ZU71>28:2<ZPAU'@B4Q5(O;Y
M5&'6D_KN?B4JX@LG2/@##-!V:'CCE7]FTT%!-]RM;R^$C\ZP./F*?*7),UDD
M4&VZ"H]/DP #VQ@>9;?^6[$<M?E/B9[MW+,?N"%+&$<I*]F:3]'N:A(08\ES
M.J8LEA72JI1UM_!P=+K&O_0+S:[G1NU.^H5#RJ :M"2^1$H 8 0@ 5 W66/_
MD;=).BI0^Q5RD89OTE^",,F(!![NSA@MWZQX=6ET@:=(PFWM&S=25,\"UN^5
M$0/^WH"]5L7!=_>EO 0Y269 ,=ITDCRJ/PX4Z:#H*$[>NUW!KSYA>Z6BGL7R
MC/1J+(/:(26%X5VNTDPKABO1C27)K7/()LO*%BLC (4+GO6R3\]_5JY7"D($
M#7:0N00ICY*3C$@8-WDU)V1$7B3?\TOA_.#^P))E[&%<N<%M5I0!"9S9!#6#
M2H*$26XXEU6UQW3J);5YA2:99[ GF>[ 6AJ^\\>NEY](=/N,*AY?VNZ7)&M,
MI@2R 8 <  . (,C ,VF)(^71[46QVAQF@[B+L>$"S '^CFA'M!+8,&\O>_!.
M?66$4MP#]X<-74)JYT,ID!BWSD<]PNJ6>3A=V7QIAYH<(Y/X7% S/,Y$V)S?
ML+&6-DP234V@AVPO3HP=?D=4:PP:C:B?25?LB%2D==,0<> 5/VL7P'-75%-#
M+WK?E\5&$9Y0R72+!,#N^63+I#^VD^>SOMU9_>*JQ&,]\G 2Y<1I)$'EMVJ=
M_\?>>T<UM6W[XSL&"#4402FA:/" ($H1#"4D@#0+14$Z(D44I/<>0% QA";8
MZ+TC2A44$"0T*5*E0^B]=Y(OIWCN.?><]WZ_U^Z[[[WSQQXC(V.OSYRKS;+6
MW'..5IY)"353_#%-7^2/]6N8RN55ID$85/M&7@%T)\ON 47B1"'NM$7]T$#*
M[02,/54]FA! SY9(5R9.N<0YID0^+L#I%=K$YK[!L^+IPBE7*RYT RE^.;($
M9*&)T7LJ4JV1367J _!5R1F[C![M OFRTE>6M]B+'BRI@IG,&S*6<$F?%B$Q
M9GW\^6$Z0KE6#-\PM!*!;>'3.ZV7KU://1H&PME4>6&TF/M6,3&.1@9%<^D3
MRVNJM.H-E[ABO<L;AMK7*GN&'.-_6Y#CIK?SFO&'CU$<S"=Q1#-PX&1]4IQR
MDX>)WS58P+UC2QF$>4Z1%M&6)+Q&4@(9$^49," '"VS8R"W@GBNT>J75B9Z;
M\<[7FH:T* 1(!0:(0BF7!+,[+V86%3%4ASR6YJ]7 QJ1JM5L?+S;XC7>.BNY
M]\%6#"". +(*7XVY)2F,\)>J^XUX1T?Y4?!7P81_<>'?'+]5LJ>=L31@=OTT
M?LH\U/_M57O6C1L(-K:&">HO[=ZW4V8T'YN$0P&A2=4/A?%Z)8X>LK4( ,H/
MSNLHWA%/6Q=*U0'G(^XT@@7LE>P=PL6Z'/19)E^-A#CWW;VNUGKC74J8B-F3
MYU^4[,W)1+.7:GA%)'D]%P7GG/^]US4@!2,2<&/D$?$A?\JOOQ*A)W[.-9#U
M/?? ?UON6,&_I?^SIOYM8D",-/ODP9VTAK 3.3:LD5XWOJD%$2Q./3,Q?].J
MY=IL7X?Q#.$'<]<2A4IZ>R66:,S.T$.E+ 6\:/TCHMN 5\79UO;WKWX<5Y0+
M4)H"XC[82Q5N ?'QQ3JZ*T'I;]S4J=\Q4=V)=O+WCS$485U0D_*DSK)8659_
M:S-[+%))UO$K?6,S[6HO6R*5-WP\<!S1/WJYHQ[V\)S<,,0!]] 9'DX/>@)A
MU;Q]P=\R\JR.371+L,J$AHJRP"6EIA3_M8,7,/K;+PK<KKUB>7D%0:[+(,=&
MQD7)LTF!8;-V?6YUYDET^S3M0]%8&(P1KS_M+4=XL3"PX%H6OXKK#I4$UJA<
M84"9=+#<9K^LR7Y!\)Y/)QL[.1EA22QY1>13"H "+?<4;WQ@HCOK:E"?*0SJ
M3SQ>FJY^2W8BJK<'([!SM78^T>!,9OVHZ(2;4S-LU-R5C:W_2*>C\#%TD_@L
M):J8SP<M% /EB/6;DM7D2NIDHS;@5W-G_SY)8CM$<'0G.$=FKZ-13_TY5!7U
M'COZA@P+<3C2-#?HC>KB2W)F][P]G:WMJ(-"*0#NZ4C/2 ^^J"^ZB=";U=QK
MNR3@#DW884P8X-<\??CP/&I+?^;BX7DDRN]9A?<W=J6)V'=F#A.QEIP0KNZG
M;BOCGQ;[[Y]J;OC\8C>2-D:2#U38@Y$H1MX2$J+M?)\,77"("K"'W+"''NWA
M($<B1UREHOM>/OVW9 66CY/UX^K+O&PR7!(3H&@>&,L=G3Q?CMFM7%Y=YHB$
MCZWS#7B!!;D#Y2K]V7M@/B*C-&IW^Q'Q((,$'-<_4?+D7C)_M":%?>:QS,;&
M:IA+5N81^T0SU#8]">C?[.Y67R@[6"Y9/%Q^/KG4N%]1:L:&-W;"[G>_!Z8/
M;N<C ]+RJ@Y\C"0:WJ8],PE=<H@E@R#IL\C ^NPGL.\ORY-/OJ^(77)#>;2J
M\A9.1SIT)K*<\S1T:.J]X^<YQUS(&Y>2C(UDMHP\"<2K73?XR5R#TNC%[LBN
M+D?+!2SQG1=EH$I6<IFV(U]!LS6+B4P#M_ 89XG.Q/7T(Y_\:8QHDPHPN4L3
MFJT$FO02>>!@H!\3?2(]^6R'D8(@4 L7<*3?D$T,=Z1BL<4@?/ANW*8U&M0;
M8H@P;.JL%:3+O$K;$%3*0+U"X1"?L<R/C.[NUS\;<TM+#OLN/%O47E2=\]X?
M77:G-P>BG<DFXT<CC:W$(C;)'\/[L%P;H"=C<=[6[XN>4U(^UF?!1@N6W])N
M=NHZ.0A1HZ D8R]-G;LZ]K3BJ70RD^!+?7>+.\54=UXRE(R#C(%6L:[#24CV
M(\5@-L4F'J9S\CQ*:$KH:))</R#[;?%KKI'^F?X7:=K.B*8RV@P(G&>U!T.3
M4U1T\UQN9B";Y2DM\U'S>*D>H9)"R-/$> Y7FS1]Y"3K>2,I+ '1!@_$FVB]
M6ODSCC>_UOZ=[D?#"OQET'E,L\]9<4N#E"TV-:>4FYH;!R5H(Y%'UAF?FU[O
M:(=.RY'^YWHY&<8#XV]$-+2"\#<_L[?Z4Q1]-&JQ&G5NHY4D&PNF;*6P5_+D
M$D1=6Z'#O1B_EZ1!2#)M"Z#DP4QB>'"4$Y[M%#IAXF>Z-IZ<UQ#6._$#J"O'
MI"E.CFC&LTD60*>_DT8">&9)P&(",?3*C/CU\\A;$B5Q;DH[#8UL-62.E$CT
MLE)6&CZ[OJ<S?V:$C0V.X,')03(Y9X[]G4+5T=$^?[%LR1PWV2LJ5W6GD758
M>! <&#%'7PPXO/]0_#$Z4V:[0[#&$TYS[G%NQ/NS1H\DJTU 0]5;/&+0D/G:
MGA,A%C$<SD?+ <_^8W 6G-/ZUES'^:[/ CE)]=K5%@A)-@BNN+5VI5GM2>!C
M"JT T35A0M<)GC!38:]V\ &G@XW?E&'_0*X*:[(*_/(ZLQFO"47]V*"9_X&>
M]NS]\+^KR'=S!OSL=SV?F\.5F_=NK1ND@Z\>S^1+UU-AJW>?>G= XUE:(K%4
M#ES.:<OU.[5)$'!8/)JZ3V$L2N'G$R09RW@_5TQ"\Z>3^&@'MFEI7<&\$M)#
MZMI/KRI<7,H,K("9C\:"NF+!&%'U.X8%F(N9Q=<%6"T5G67M:,4"IQ -2+D:
M!)S,53PGW9T"?\WAHD:F0WNA90T9 ]JQFD&9S!%Y[TCE>#YX-6<\W/BB/EFB
MGGH-KL6/4R(TTG5B"3QC06(UKC%N65MLB\E7*RRT(WA#:6" 3+7#.L7H=-<V
M^54WEZB\G5N]!C7EH8;8.^6WJMLXG@7BU-GJ/>KO@4_6I5QO?TYG1]/2Q_@I
M0LG<L2ZHFEJ%#%>VQ8:@6'XB@SQ,R6BT.$;YE$>0E5JXYN%KX8Q[O%@F*$BR
M,8?]4L#"QMUUDR?:)*#RJC24<K2<U_QXK!ERWA8C["TXGKG94,TK](GV*N.N
MD9X]QR1O7+D,E^?HP3=@52<DI9W P] +%6%6F'*]VW#[&8/KA*/[K/^Z"0?[
M2)"-2R7'B^Z&>H[H![2KY2J(B=58R]B[R1V5)RU3+KTFNU)P.*[79Z],W@CG
MB26P+:-A%PZ:$Z:)OCEO5HEQ0ETTXF5#0D4=+5G8)9'IR3EZA7A)1/5$-PG8
M4<S[^.7P];M#[OW7K_<'B%MN/DN>Q.@\--LK^L>CO6;'T=4K5(:A\[$KS7TK
M/CA1*E@O:I7CL^8W@T9+-GH' =&%VR^RHYO? 8Z)IW@M^T8S$7T]WB<M<TM?
MRUQI.QS58UV!G*'D V@M$8M*":,52"07:[*VGG8T3K?P%B"ZS/L&P@FJ]YA'
M,^VH$V46J^:'N0]!UH)C=@>!B22@)&%/?#ZMJ-C@LJX9JTJ7 #8*DP*8KW]-
M_KI1MI'9TT\^P&X)YB7P1C7R;O)] )Q( (W?!"?DL(@$=!0H_^W"0;S]OJ>A
MIY:US;'%4#'_2(=(U8E(SZCAIS[GI>_SEBO612T,.ZJYTEX@&S7Q!!V-74Q4
MUH7@\TOGEAZKY%O<'XL.[CH3;"X_\)C<'8QHN[G]C*MI;E&(N5E0@*=>KT&;
M#<'&AROZHX@L[_-EN]\A[  TA2L9*\$\ ^H8%Y3H/8'VCDH]N]QS4?+XYH=C
M<<^2?=KK JKMI:?)CO9FP'UK3]N$<17RP4E:"Z5OI60"4/1NJT@ ?M+VDKV.
M>,??^TJ&!U70C5W>]1::"I[1$U3U(FO'CL,<10)')"^"+O@76'QX&Z"W/L4\
M$3N!4;DE_5;5 O1N1!+&GC9F-S(\,E@@4A1>3[^O@7]"02_#)%E/;VJ=]L<@
MEC>58#"-IL/IH,C984M@XK@@4ZJCO80-H=37"<W)^6\/O!3UUB,!7&ZHS>5+
M1$QWM3<M"7A>L&]& HH%.Y?^$/"1>TCSJ:<?NOSNAS8QV^67KZ6=PBK5LV;1
M7-JK!404G 04N!S9J1,%VK^KB*4_$B@D7GK<$/_A4Q#$JP"(P@J"NEYU5Q0;
M%-TS9U-ESJ&-"*\E,W?ZBI&I_;7VDI[LF2/!O7:$\;E@#?=!1WZEN"2P8J'Q
M7<M Q=3=UD'"\O$Y3RT=6=JB][&W*SUB14L6ER2OV2#H<,+2/O? 7XBG9Q;'
MO!HVK1_XPV-D"H]=F_2'L^I TI=\':JK\_>V]8RLK\8L(ICTFQS:R. 4AN%B
M 92MDO7*+ 6Y]][,,^Z>I.04A4*5*&?DR!A\'Z4KRUM]3!BSMI$]^?:)Q.?S
MB\WE.#?^6Q.12F@\!09![Y^PMDD"'OAMI=WU-E[)*GR]+R],=C.<@Y4U"B(#
M($S$XGUMZ@APV;0D=_T!N:$M\V]3-D/K8I:V#MM/-I$"6TD9^,SZGG7^>X,F
M@41W>.:18P5KA[S\[70\9U0G^,BKYMECU39-K]CHKF36!>#=:+:=UF%8:/SG
M]!W1SNNJ=X*165*+X79.$0$BD74XUHW/5_^4(C\80P(>@H_F/J'MX$7"C\7L
MN2EDXIFZR5.KF2;D!WSM-H.N"$O"CA>M-]QP;V-9<GF2=T3 P$&\Q6N07\/M
M_0H5XM,;3M5$RDJ=T4QO]<G=A?E)6WR,EL^"I>0MXDPV\>2.A]U8^?4ZH5-W
MY5,E;PBK(*,]=JU_3/&]JAZ0L+K+=^A52GS$Z65D>B^>MJ@#]L6&"R^@%;<T
MR 05;E'6X#\V7)'_.:G.UA*A/0,9-ON&7E(G 8:CQY0#Y^-Y[4X8Y@R6A9P;
M<[^KVUM%+=KB<*2-\4,:(LOLP_X4)0$<T</^@:#RY^&4K5J![:_J2$"0089?
M&_?!DPLDX"2:;B7L2=&$[D:%) T#I<:M:[$6?9%-%.I\;Q8@<GH))P^N;U&2
M8RVWGW-[02)8Y]L#+G%),2BM&E$\'Q44$E L#Q!Z^X.]6X-#N-QH(2?5HOZ_
M9.[P@Q-V])+H1!MYX4R&W@MJ5#7[@?"201B3O>Y&J\!(G6!S#H>"P]T!8PG:
M$7[3F^%]Y+KV*KRK&*JV@JN*@$=5(/'<IY6%*L=W9U$2GQ0"5"&,!63.<*Y'
M?'RPM*!F]W>Z!IE:V;N%Y4.M3 R5L>  U\-+#&+#'Z3FQSXF.-<K^<LA]K$S
ME;3VF=7TU5Z;>7G_PAG4SQ&?_\:G916R5TA<(2J5?;$[O$\"7%%'JN+=G_U9
M<8XHN'&H.6F94!VV\WRBB<5,_9F"@+0]2U="(L^K D7/1:.+W@L639T+5G.O
M$O=5RQ].'$OE4K)/9.PC%*88E@6O/UCUSA_Q\9B?[^0V]A@E2.9F"R(ZL![Z
M,WEKZQ(Q/SC>5.N)JDI9DSA0S!:J:[XH%!=2AH"'UVV<3NOZH;CK<9FEN:FL
M,[5NK /&$^R/W9@-E\SW#;E*SYP<9=5OF&5VAD_BJY7:5D_O4K'$@5PFWC4\
M]W9U*LOTY)B]J#)2JO.<"V+BL;XA11^'0#.V8 P7FV!<"8T.4Z2A9R'G=.YV
M._[Y2Y?+Q8I;UFDEAW2WW_4/'$PI/>_0IG9:4K?%P]8___ \.Y=_ZVN 653"
M,XS<)E>E?Q<!M_E<\6;RJW<V),#X%E,=HA&16OG<8-EKL&^?+CFR_JY@6Q-#
M\!9'&-L!2J @9R[!5B!; L_Z";I#R-H<]8M7\V%6BGYE4]+32P+\[Z@S#!K>
MT%3WNGW[P[N;M=OS5@MO24!.Q)520Q][R:VM+V+&E08O(<^)>2S:GAO@D?C4
M'A=F+]9]-=^DS2=>%RS2"OQ0Z@IVM=N%U5'*@C;KS("]^EU(1KI59<F)N=3<
M71X8O5"P^IW8U5<MR<\+MV.CK(@)$ZA<8\; $-</\1]<9MHU%5FR,/]=L;?_
MR$?GSE@5W2ZB[(7WD+:ZG=/RC+2/)Q?'RDC4TR>/OG1K;6W+$@-+>S.N&AM?
MXO#ZA)+P^G97K]FJ^,2'DW,M1G_[J-3T=Y'M7Y")_]GW!?^D=P9MJQ0O#[/L
MA/*97\)-*H@SIK(WW)%0J$,$%F<=N:--8PRW@E(V*=+>";8/Y[DE@-\Q6E,!
M@_P;?ZCH#^[I$&)69,KF:64!M-DD$6!<$>BVP==>[8"KM^K/*!E&5)#A.+BR
M[97+Y@3#=V[3&+-M4OD?/PX[![.H";BH<R9,TBE "0&/M/Z0KDA=)YP(BK2G
MD#151=U0Y>M:1\-Z0XN^/7FD64(^^<[5!A,6!S-59+NYSB L34"0OQ&H?TD8
MX)0C2S97UXY^^  *JF?%$I!*2DX!UHG9E]YS?MBW>\4_A*D^'X+G=(BD/U+<
MIPKFF@D2[-=?"C&X7&(JH&0T6#JF-?D"FP6#T3)5E,RZ/R7*2_D=?O";23*Z
M+)PKP A0)P) -6 /@!.9&X68;NGI:55Z]-<=:RXS&=UDXW3HP?Q0@%KY^.2P
M-%DHWMY<3R)VU%;OY7,9+E$*]U8QG'6[ (?!Y2)-YBN9@0@MD);YQ"A4JATB
MGN3^C46Q>'?M?(2O@P2CP?V!*4&34[2>@(]#N*C!.#UG7<Z6P8GC1DTBK(^#
M@=B#R?)KYT7EMAJHKT)CMM5"#EVOA<Q!T2ZT8IT(GO4OHGC51^IM$>S*%6QK
M'3J(5C&,&/85,$T\00(:I.CWC^1]BG'YT-W&H/E[*5S7-U;5= K1;!GD'U?N
MWJO1@"+FRD]_X/KC+*Y3QT#1@R" $ ZE8MM L.W17P&F?4_=7W2Y=S>TI-'J
MD[.,F8AY; #4O162+U9OQ0TH;:N>SQ)=C-RZ7NT4P1Y:>'9,&8S@\:X.4%WL
M[CP5=$?C,: - !0 & -P HG0V[\KQ./WKTVT8')DQQF+Z.BK^+A<]+F*8"B]
M9D0OIY454/-V]7/<UXFFPK>QHM<NJ^5*9>G (]H)<$D@5H=EE:^>)J?F3%Z,
M,:+IY01X NS;C5:9>%[3M 5CNF368><L[;4U<E&S H0Q8L%)$7BY)#-(@'GM
MY.'S9G7!_=<G+8U&W%CGV]0JVRDLL<X>XJS:B36OAK5>">.IO[#M9_0%>.$<
M(BFLA+CQ,:4=RQ$];""!U98Y7*X45D(4"94MX_'OZ.88@@X?EGYAMJTV.:EH
MABMKA.#N@4_0L]/=F+0YIW7EL6K\C2O).#2UP[H(',Y&!H52F<_]R9+IZOJ'
MGZGG)USK%"*VEAZG-XPMW7X, U_](=0N$RY>N/M<YI@'TI]NOF]%MBP1:OR[
M2UR!JX[93886CJ(00\M7 "ZDO6<J1$\,^#1J"0;+UJXM2![,R_XBF_*??N[)
M@CPOE)]V=<6@*F;1L/]?V8U9LOQDZ&FM6>L"EV%>3E$C?!&]X,XTB_;_S^^C
M##Y"CPS5D<V6(^E^55>[=.PLF6.A*:3!,]9-'UB8R?3M21B^W:*Y541<(YIB
M?DA.VM?W\_ 34>[OW&_>#0%>A3Q:O'\X>?"9VUI]^<(4_S$K >[BC.WGZ\P^
M>:C*JA>)5)E_0?S+$)DVBTP#;C'9%7WO; "+L%N(.76GGK#?-3KV!R%4+*[P
M<_M?7@2)L]#_S(+L3^@:9%U:J)]9^)E!]'%-C<.?T%)^9A"XKOA?#P%RN??<
MRC1:NYT@,"H:"\,&XO5?_2>,V"^!GC^W$)#.234W8?7I'/34()/Z?DSPMNCI
MLU#*N^ II IGD/'^ [_AV_LS&F0;6MPV8?O-),"'6G: >_LY<8\9A&2!#)@1
MC_SV$?FP$OSA) GX& 2H*\IM]9& RJKM]I3%0A+@X;><A#[>H>%3@EJ^<+C!
M_Q?B_Q[$FW_F!!;TGC]Q&:1[O,R99^OBCFEIA%89MJ2[=31U!5@V8KTRAQU\
M]3$&L4X+_WQ30ZU_9%UF+V1#_9W^4>L+C?S[X@7;I@>1%7[%IPYRCZB]R?83
ME5GZXPMABRI^@O0+ @DM8=+)'XXO]%0-/5V[(OO%^K"OBC=E_P9W4^T^=<8Z
MO'6FX/+W)M\AB%V/UMX0/V4=-*R_%^SXWN87"-2/A%%_D?V_0U9 ,,?:)K38
MK+432][JH+R5BHI^M,6B/J4,4G3M1Q9QT+_(BL,OD[<*(ZVVO^7Y59R<>.9G
MI;"KZW='BVCN,<0RDW"WF+AP.U)SR_KVTN?=,]S]X<1;W'W:J)=<;HJ>?+\T
M\7G5NU_HJ_H;^+@.XR??F_R"<)A%/WGG,.CF;L2TLT[R]R9_$?V+Z*]$HU^:
MV=#'[D=+'/0U&/HLB0RD_>TUF,L_,>-_$?V?1-3UCT==Z=D*#QX*,P9(DI%_
MT?O%5KB%P-9TA9W3KHC3E4F^:-EVR>O!GUD9AI#<NU:_/0>CT8@S-C>1 ]NJ
MP+G=>TJ_6Q88ON3$7Y UOX,D4LUD?K="OELJQSP%Z+\;(;^:*D!\2.!W@LI_
M(?XC$.?%OE<I*/_^9^ZAXY@YFL5?^I$\O1F:_7^5N?M_$U'A[\YW-:U*55:%
M::D(&+DE_J_Y$:<U=,%M9/Z#[131_U.[^!?B/Q:1W,?M\*HO]QY#<G*/;<2X
M">MQ/! XJ(F&:?_K25Y ?;/AO%M6D9S93E'A*&Q$(R'O7, %:(H-;\4T1WDC
MIY2)B>6\-FJ*F^@WG7851!PHYO>(1/DZ2G%5U2$:EZ/Z,<)%1JC%KP]1SHXC
M<CNX#RA8[U6)]!Z^QF *<V-1$'B$^VQ;;_E!*WWP^<]%M4B8S8$JZZ$2BGVF
MP+(B]'&HYO/"&=]'YR1)@&P7*&J<[NP5FK)GF03'B%+.=SB\C$-O07EI(D])
MJ5A]Q<0TCYF;\<MZ3UI"%4'[0,'-@=WCQL/^G4FQ>*CG\?C!59R5T*5KY<7:
M\3"+U>B&V:[C\9(']3ZMP*G>3?[E8XO7W_HQPLG,0C-Z,XQKY]!#'F;!_9(_
M<$1K"R,DSSBTK[CS[6YERPJA.U*Q0'BX2&RL222R&C%]8#6X=[]+R P+$]:"
M(V67)$>W^%83*6UD%+G2?=M.FZ# ?/ ]DSVS#Q;7,PZ#9QE\.D^S[)W8BX]#
MT7:'PFMOI#[E#;1*@F3R$B(ZD:OQL<[I<R>;W=S8U.3?GE=6"&Y$Y:/T@<)\
M/_P@:JN-!"B(VQET/[_&>YJXIAGIA:7+]H @I;R\NJ\[$7_\DKC$;X\M^Z,(
M"3"LVFSQF[F./CD6C#PF(ACZM;23AY"X 4Z"(WT#8MINA]UPP5VN-;?A#0R0
MG*^!^7<67#%2&]AWY8TY?>F\>UOFI*=+ ^N,=+?0G[&82%4\/U)HQ-O7VK=G
MR>D&K=SK)@%,5@EFZA=LO;L=8@DPT&R;?OUJV-[1*LTW(P'R5L6$V[N6) !,
M K[=.Z9[)PR-O4)PSMMH0,P@@1F5MMN)&096#M;E 9=K30CA/E)<4)_"=B>E
M#)O#"J:KC!S/92R['#](3= Z<\[10>2\E/<O]VE@MKGBU#6QQX<QHG>*)-P$
M&>?>%HR+"OLQ&D%+<\Z_4%$\G$CAW6;ET%J#>CIO;>=>JCCI9JH]8W'-!P1&
MX<1N[N /'4E []%@)8D#!EVKV?IYU9.$^?F^2^",[8_Q+U-7NHZU7JKT?<'C
M S$^5!VU[!Q.7@D=OFH@0?V&%XS[0(GW#IN\X9[N]X[7-<0=L.RE^;3O2>31
M@$B>2[]A5'Y.%773@(OYP]J9M<;J<+-2S<Z]L*S<*XZ2\JSVRO)2[11Y1*QO
MY\0%4*L24'TSTKW-UK<L)_Y\!=CB[8:Q"FOU0LH 6,:3T2"F5%!*B, 54>(0
MZRJ$-Z8F 7OS0>_++YTSM\UU(@$]>] N4&<MK2>9J0Y'FEVZ'%YN!B*OY'E(
M+A1?Q94Z#WL2W-"O"B%SZ@V0!&<8/WL?5[JUH'KNLJWA:H)FT\9\N$B[6[:^
M<G":Z@E5BFYY>@U5/#S=BX!$S**IQANP[Y(OG(E [\58?3A7Z.XB'S0$![<!
M\4J.'CR>4$_/=:V#ZZ@(!]B+UNZ;82G';Q4/G9M+LN4Y]='0#-'0QMKFJ^:H
M/(UF,'(/YIAIB(8NA5!039<]H'64)'0&-N22 /I9N(93Q1(?'^=ZNZ\,T2A;
M<:6H@EWI4_2"R@R%:L.HK^PNWJ,2[OU&^O*@QXL:V1097TEBW,RQB6$!7->N
MY@_:CHA3RC?; ??E5TV]!4D5IY)O<.S@ (C,QI)3UY',$#DS$I0>^EBNW*-F
M4 R[&DM(^)IC]1Y^O^R<'-V,1^O17MT^6(W5H"@I)P%<X21@ '4(=.]:X&CN
M340KD%_^%#^1#[E=4)6/R&:?/O!4( $/2, &6.DW;[>3#Z&TPPPH^-24$3)8
MYP8$J\RA#[+\$*6ZOD0+B5:2#E-C)O16J3_H3H#XY=OM3?EMG,F8+37M7UWO
M&.I=%<+/B>RT4Z3VO]9-^(&5+<*]@8S>VSL#93R]+OF1Y^NSQ(HG5W"7SG(X
M#" 6G/"<GOMQUM^6"*9P+8L%3^ZD9JA?6_%=]^"E\8MK:53%JTV6,K -/F0Y
M =8.KN0[]M #0\<C Q7KQ')]:V0C =2!AMV1BQ)%%G?;' (2G7J!<+G93=F7
MCU2_9E!M9:K1HQ&-G/3&4ELHXUJI]ROK-J4M2>:LU6W>HX0Y23PJ_1Y88%H?
M9^!20A7,.HVE=8$/'DK'^SA8R]LPJ22?Y.-0@XJUTBL<5$PGY%G^\29'G\A6
M?%*4Y<'A)_>]D(:\D5]'(Q'Z:)\1:;#./::\==JS= KUJ8@_D98$+%S>M&OQ
M"^+N>S(W\N*(^?9DC!@)*#S>725"9/8SY<OQ-3L0E \!VHAUZK<.\#N:AX_C
M\W;#5O*H^<&HOQ#_0OPG1-0<O$_%_NZ8(PA909]FI76R:F[DL(>H!0I+F[5V
M37L1&X@3F4%F3Q_ 5_=^)!Q&3P)R?KHD4L.(H<:XPWZF]0G%_1,QM1"@A00\
M]$7]1(X$4![X_D10BA\L1F3<.?RI#]^QBF82:=MVE D_=V(E#/]S+SJ3_T+^
M/X8,UOK:TZ%P5I(/1FC?UW[J0\>K;6K "^YRX[X2]?UT@2!>M9EQ>.19;)#G
MK?3YV5WB&+@:^V+A=O?]K/YMU\7!!1+P!Y)M]_+;%JJ6?;E7U*7WO?83P@[
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M^&+SRT6$9N\%_4_#U@]K[B6[ AM-67 $'J8CGF$\M[UZYI-/^+G,7-#ZNV
M2Y!91W/&L33INN.6FIR+NDP5CXOH3@55.1O<.T7I%*[.8TD>1IUJWOW!KZ[
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MT6\D@F=[P8GYOR;EW@"L/_*4E<?.OG(L>/7TI<4S[O/"S=&<4-T)QAHN_-0
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M(R/C\Q#E C]:H_7-]>2+9HP]%W''\!)!RXK*WNA&1H.6TRQ]>A7SD3""O&5
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M)Q9@P0)+7\7W64P,%L"M8<?!#H6JVPPLK7O5F^3+>H:;WB>.0K(PIQ(/S+%
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MZOK1Z7<O%3YI?[FYJNMV]*&TT4!RP;[!SDU$B/<)VDU(^^1KYO,-"&?1^PX
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MFMK.KAUN_BB@;4\7"[#.P9??8((]VM?(_!A'#18N@,+TVQE,O4;X+TAU:HQ
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MB:^Z'W;./LY6H<$^/,[\4SFY3^+&-A:XC]A),]V+QLBT8@'#T]4MHL#'M8!
MTMT/'PX=)F/LLI/<@[S1PLFUAL^F(_@>#A3O)= $-$Q2 %DV7  I@&\* ',$
M=HETGA)=A1Z5,-)4GN<3OK#@#0B^5T\]%K C&<M?9]G!A%]>QN3;S"C"Q[0Z
ME"4EC&3L:SJNJD!.K776-4\17;K(+C(Z37,?[TY@C*_@/O,C7SDYJRC_O.;)
M^HH>7A\I]MM(DNDGUXT<X/X!A.XL3BB\6TX(,/S+(@8G0BU?SU]_6-LPB2@Z
M@_\.X""!C-(?S^9J)B]N3*Q1=Q$@_B!3<Z\NC_%S2D\*&V589P3U@[L;OEH
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MH.*65-(D510;F9IKZ/ ,20LL=LE?%0@VA&6_+3 JO;ED>N_#UH-R0,1 L ;
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M)2A=OJ KJMS3'_X>[2&3O,<56'TLRW;SE.S[KB>,BV,U;GF)6>!I:V RPJM
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MS[=EHUY/Y;EM5X_8=D$^?R#W%0<],[5-_QR>-<MYX;R03BLTREW=^%L]K2.
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M091.+!"!X2TSX2\U#DX>#JMG+26;1182-W,+&+>^S.J965M]S',X*B%_.5Q
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MP^=[PQ<T%@F()? NU2X1",8S^3VOLA=:3[V:'1CDC=ZADSI:\:,TUW9KP_$
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M#$"GAOY&5GF.4\NK]UI_^NXU)5DUY/1!\@6R*R+^ <XM&&3V0BLYEM)@U+-
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M)K<T6OL-,P\>6A)Q/#ZDV,3A&7@&&<A'1CD10#41UI- DZUU.9H28H:2:5:
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M"O[+U[?DQ^X=J/MQ?F=(#__I!P[S%Z":C#_CUF3]'N?!?^CY&4)-'M_?@=<
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MUXS)1<6A/=AJM(1AM+J+B^9=ZL7Y5#H1S1!E$N ;7U*Z7BR99D&#\.D3F&3
MC @G4T(FB$['C)1CS Y2:#T^C\XHAR:92>G0$GG@+?D&Z3@)K]=,]K"VS,[^
MIM"S:9<BD]95PW?TYD4H 5K0^QN.P(47]65L(96ZS8,-#\U::45TZ7EF)_ <
MC5%-'LQ'/K_YU63E3^M;R\/^%0["%8Y7S/!N3:[&JT%J=]87M@4A5GEWT]TX
M5T+I;J"C1Y)BALFJJWG!T14[?A4B-.&*>M7N<KQWBKGVWJ"N*?O=Q@;59$OW
MOZU-P]KMRET8/STEX;?B6B(GJ(V?*\1\^Y&0SF/<4UNVG_+4,<H947M/XG-*
M?%:SZT"2MUX9LQ:%YM;)[U9;<5]W[ZV7VY, 1[_ES_O"$<T1#)ZVY]QU+4;R
MV2C44%+FBI02>O7-SMT3WCCE,F90F_JDP9Y_L?K6H.KH3%W46Q $M^B2.;X!
M<3:H/A%T(H2A''?G1K:<5X0'3Y7<P1T<P'JT>0PS(VIGN@\;3I" /3%W]Y0"
MZ]"\EFG5FT[M[:WR[A82M'D*]<O)E=RX\_P\%WMJ2UB];E:\:>R<"9L,F""/
MD$ _8)<$)0-'')&]S,YHR6GN[RV8'X?#49@CUQ":Q;Z40@(>W-JBCZ;99B0$
MZ)LE'&B88WB2B 0*J.W1;--R'MM1EF$H;4J\.0U(%S_K<@+JNI6(+]7FJ3"P
ML2,%.'/(U=EVA^_4:;7+IX/D1$^XDP.(Z!O2=,]ELN.3P8QJ6T^I;GWJ$J?L
M.W\%0#VIA,_-2Q*=W]LO?C]M^_;&$WVOX^C<4O^X*Q.(P!;I;[*;:?*(S/U3
MUXSWJX,ZNF$+K%G^]'L-HG'U0"$*<J\MWPBK>/BQS(?R:1MM3FKZ*C-C+#7U
MJOPPG@CM#>M/Q\%I^:D?R)-E 8 0@ " >?([GH$-QD,NYZ9%7I^D3+N8R:<C
M9)\7 @IV;9:7V"T&6'JTY1&^8Q0IUT\Y%HQ9A^R77-+7)>CL#U.-8+X34@D'
MRBF9+9G*Y:M9^CTFH$,OGFR>:"_I3S^J&QA_B+\5H*XRH5K9+<W87@Z"UP-$
M:2(T+/YR[W'UT'.F,-4^4"\/NUH=&+VN(8%.K% "+MZSK;#N:16)/J,'1YT*
MIFR=RW I'Z.MZ6V)M?-=8FC^%(=.P &T#J88(@X ]V;+!#&#NCRQ=:L+@EN9
MY\3:$!W\)QRKF2<X @F2KR#AC;JCUQ4/>Y+')I].5UB9P0USA0WYW>MXC[3V
M1C/_K2/;A+M#<4^F;^#+,+Z#-8N_G8].YX(FK9\I );-3#R2EHC[59H]11^?
M8,?HT6=X"Y>\)J?\ 2!M&G&\&W:T7E+)BMUD:/:$,V.?^HQ<Z=(O@ D ^AO1
MJ@J]J? )ZA_M?<73L&;*9I;CZ&CI:-G1FH0NM>%H* R&<$YRO;IF%7*C\<*R
MM>JU)E73FO)8Y#0M0;5U$<-=SIM*:7].[\,)6#.3&/61^\Y[Y/M^RSN04MQC
M?]^T\N4@LWW7@^CX.,-[>DZB6R'"N__EE:"^+"XU")EP5#(1B8]P4LE*I;MW
ML?FYC^O]]2BZ87.4DV/,W&,&3SDI@'Y/VKG#K4Q%Z0/QPZ2ZJFNQL'],M(L:
M.N6:FDQ(*CCLS:]_T;QX;YOMH'<_Q_8O6,A:Y$;'5SBW(]99TFY^_PD,^8CC
MFR2 XY[<YE?Q0]RG:4Z:_5.<#[FB5BCFT[1C:77B?)<7N@#(JD*7)'Z@<*?D
M4'H%NS3F> #*Q>W 28"@\58+";#5@@JN'5?4/#9&7L[%G*Z*.]&.B)T,Y9$P
M^KR<Y%$P8+!ST^Z.&8J7VS/=<D/-X;)OR_1H*1E(>P"8BQ;QZ@['KNUR'O@4
M'H9P>1?^'3XPQMA_X$J;,Y7<Z=*[%- ;M+"YPE,J,YL%=BUQ7UWSSFNS%TM'
MDM^-"CX#NQ[56K\B41#X5P_YIBP7"8A<)P$#387K!)S(:YD[/&$._<W?O12,
M!ID</-HGJH^U3*/!;0B6>LC$C2*[1%]OCQ29UWPGSI<_!N1&'#N37R2K36\8
M0ION0^8W6G*'<35)#G6(RYDNY502YPB>S3=XN')?<2"-L)?CYLV<RY]@V)-.
MT0K'^(^8S]E -E/IQ5?I'PPT1AJ]6P^]T29< UY/24$1G.I,-K\XJ;((/MC7
MOWNNH/112KQ0=XD7,F10X1'T:%JAG!=4N(+L]VE)0'SAGAD)*./CQ-\^SCL^
M5'30/U0,4"']@WS7 23Y<B A@P!P_VP2M-=B#/:N*V5<$I>=^,)L4<&@RVPR
MAV9214EGL]ND0"SU]99'<#FG?UQ+;%"ADW$W)#(6F/85WL29^I9)6)K6!$14
MA]9I:0 ((O)X&PS)WERU.G-=W4"_3K1.NC.KS0HEPGOJ'H,*M1#5$"Z9=T=\
MBKRZX@(4-('V7R2H=1M&PR(] ;(W[RV/E"V>!&2F[ >2@&%^J(J:-$W.61$&
M[8?*9NO\*J=@OJ\PU$X:]+K\-?#SH*7JKV'VI>RU-O>3+9=K^2]X$.7<.+7[
MTS](6]GD5P4/75UA+F)C]X30SCRF>Z%3_34HOVRYUN;JX>WE6E$!<3,YMPB%
M'R_#;=(E$H=D"#K94J.5:,2=)X14+8I1S\QZS9W]F,,WPR3@(N%-P>OK$YG[
M?FHDX/;RD<?6(L\Q<%MWK?O0"+M<<=A;J%O(MS-' @1JMXY>M^F!8B?E=C;*
M24"A)_8;>>&YG13)I>TV*]N@6;R716Q)Y<%R91=PY5DC$2KUZJ38XNWC1P:X
ME./W[1 2(']KW9CQ[-MCGXX=CK:O2S_4I&ZX\E5+ <-?&=$6-H&3Y]_I;6 -
M?L8Z8M1J&:X&9Y)^*DJHJ:MS2$"8 UXHV<PT-<>I9]*7<LNY(SK.1'8&*?>(
MN+9/B$2+;ANPU.TL3>%OC5:55"B3*8J7XFC)3^% ^NNJT\F!15TJ]JOO%&*4
M2VB$^-9K5'7P+*W4H.F-(&@1O![.#)I+),1F^4J/HD4$8_GYOFJ%H!WYJ(^D
M99YD[AK>7.%'[WG_I8V85_'-4)US;>@-U#1!;2_-_W!'[.D:W\W7"EDJF:=?
MT01=;:]C:IF+69FS;J:"PQ3?!=CUE^8+GZ^,[C_U(%R>7<2Y+PD0T403H]52
M:?XK@0Q62UBG'TD4!?RW28 A=C3BASR7W7^)J77/(J7)+R5'.F_CQ\<MIOV$
M%"7F&Z]\)_Y9@<*_"!R>"Q)\$:; =*QUW-.#<]G';'-A@"7>S'2[Z[1"-!8I
MHUFQNV1T^ O0*6=B;@.#LW=%[Z;,V4*J:QE*Y[_$&_>\.>(M[+[0OSF>0,+A
M6\V=DX</^&W_=D<ASZ;S.T63F"YBEX@D $<"YI7+<__NDN+W*:;RMQ"96^X)
M4_2;9C]J,0$VOU/,"DC]'\-CPLT.KOMQ=FH_)P$YQBV[B4#-D1<(%2<^7D\G
MK )72S_42C.)!J1.$-'X ]%!G1_!/:$/>A:(+R\5>]^]B'N!H* =N=<LHI!_
MU;1E>;4-"G<S$7?KDKT^GE:_57!O<M]RAG6M'JX_=04_::I%!=FR;$,Z4:Y8
MD\V%@8H\W5F0E$_-7[L3%"DTZ#1Z6V'22<0PAY<I]GW(A_X/45X:7EW$5R9F
M629TV*PY.YU7K \T'0;?91\9Q6@GYR]>'%-5M:!FARL5T61HKM-2P8:PJ(M,
MFG+"TX1&UT2@:JK%)RY$4U''L,31Q,D#V2%XL8^S%QI@9]NB2:CWS7K,1ZCS
M,>/I6^M;M^-ING"-DV\+N*5NR6/=THD7FG#R0CHO)YE/O2Q:<\^?V@W0-=9&
M04R<DTRBEOK,O5F!]VNZD1^=<^K(7M^5KJOE=;.<9@R@0A.P'*J&XLVLMHOW
M+D3*C9J=D9U4+$(P#L"Z[\X^S5T$-W:>WS.])5/W'CFIF+V7&NFB!H<XURV*
MFVZ5D #.<NS6&@E(;P(<56 /(5K T5\=X 8K$%?K>WKEXZ6%[<<8CJ8,/GKD
MMR[G<5C!Q\H#J/KAIX_]PQ@!3FCF:67^9'HX6+8/5#9) NA?/L9%TG:*HD-F
M3=\'C O#F[WI&S=B5!Y*RR;F, ''>3M=Z&,#!2[OUUG!%^48NX[I?O352KMT
MTJK]F4HG5T-P"]L[IQ?'%[[B_1,=BJ8:P5^V\K@J(^] S(4@<[/GVO<KVZ!K
M==/ ]=6MIP<9&8_\1):X1539'N!UUKHAX%N)X@]/S/;<%CY[3<2\6=Q!8<.)
MCL(Y$C-!B*7'U1+;!7<X#_&V37W+JM7V0F8=U7$285M#8+B"G.<)<XA9A/-[
M0/R=S[>$M&@]B"UEYXC_QG1U2K5D,!@XF+I/;F^+7KP190#0>A#?^V$CHF 3
M3BIC]=(!GL2$UV:6O<,)6I/+K;&:=UMBYEV;G62<DT6U=Q18W:,/%4*J[M>Y
M1H8)!:8B:"?\6Y&)@%C*SL&1Y"LB#DZ<>7OV7I6UVS<NI8X+6U"H*6WQ-QF%
M R%/[F=Y)*!E.>7@-7:^2&/MZN.0]C>X$]&?0X>$-U"T& 2'*L+'"HY)/6;'
M+BM%OIZNE2,%6L:G7&^YWE:@,G4RY(.I72M.&4)U83_MTQ-WP.6>R?2A!-(L
MM6Q-MY3(K:1(1]VNB$%EG2KJ36M6]AD0)&*9CBGS5)1WI+.(5.[A'!H*5.?.
M!48-.D<E 8Z>XSKVLN/34K=4=,9CU@.C#7":"@0)>.NT+CNJT=LA.@!C2$>A
M&;?WE+UMN/OZ%RD3O990MX$W>-@KBV"E*!#F6JLW9Q9/Y1S"7WOA[;F 97&I
M/ TJVF@A/3UV%4SWP"X"!WJ_F'CPV.7<9FF0A1[;)\:0)_AWGA* %5Q"YF!5
MY;Z^L&?*\D;^FU0FOIC9MZI*1PU:T,DJII+.T35]_S]&S?VS/QK\X_,?JQ$C
M8JUGP3O!8J( ,6?P1 ;VL1::O7B7.=<:CAK%[UKG)EG!Z^#-5PW2<;QC\Q[;
MRV^MGWN @6I^A'NSZH_/C4&6UP@@/0B#L@(T@%)&X<>MUUFW)V[[NXPO?(I2
MSK&XXHD8,*;MI7K:< ?/$"MO9Q742TDPMIGNBQ4*S!'K'08$+WX0Z&OBRTUK
MUJVSP$C H80REK<QQXK/,S8_8IMSR>&]'A48"X:B I?UYE.IXR2O2/KY/OPH
M,]@=%U;5[)P$2C+_%)IV\_%SG*X_A#%282* 7LOFFQ8YFSW=V*>;J#"QFQ0(
M/KY@!)X!BHH9Z.O]\BO4Y;II@70<W:1\ML;/:]> <$8L!$DBFD,BM^_/MZ$Z
M=TNE?"C&:;6?,P9HLVA($I%TF!__TQ4L?>).Z[7VXJEKA#!+T9&LH/"ZH\[
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MWDQ[M=1AH[C[.']0 L/9J"HMAN+[HS657U>\3RVYR<AWV!SKZQ3I0=4@>&?
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MD<HJ$'.$T,2! @"^%;;1?<Q._)#_YFWX):&\K^7*X>Q;2<R/K !RZ-G&:#6
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M+0J7O6YG%8<A24 RY>(/Z">Q]Q=3Q^=SD,6)$J< <H-7PY%T]<3F"1=O_U*
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M"@M+(T]C_"*(!"CW#AX?H)>  PR#LL;P;N2,ZJG*H36]T(,*NW/)3N;&C^?
M+I$=/W+:I*W@+>=) )VU\+P65YZ);ZH#TLS5;-:L;?I @P*8H ;F#OD,Q#Z5
M.CN<81MI+)9;S;F@/#M]+.V5%](*,<=B=L@XJG*()0'K>H)K!8&ZO<=U0I<M
MX&K,@;TH&<I6%'*=#H-DG<TO/3#6Y+BL[BA":^_5KQ0# T-XV'VBU18U34 G
MLB>>CNI=*$_><W/$1Y0HBQXI"R$9^:]ZLES!E16$3@;RT4[A$R@,[3US6H*"
M]H[5XEEK#I:X(04?+ZGWLA^%Z%H?"QGB H'U-TZ@B=@14.ZMV8??D[:Z8]>1
M42_<T<%G3VY?,L%2H:,BZ9VLP0Y5ZN/?WMR"/<THRXLND(R+>IU.7RYI!I5I
MG:JN;BS^P"YH6?LX^QC"N2G@'E]$0CT,'#_-H5F)T*+ -CJ.*[ D[,7?T+HT
M?7\BH\+< \HG&2"3FYMWU?72?0T?J_9=!M6/DM$73]#LI0O)/8A6;856BE7(
MD[LDWOA^.]N=W[T\&!;/3MV6H":[NX"G]>!)7%P*>W2I+\^JLNK!L/@0NLM"
M9&7HM7*E%K.]\=V8I)@FP*.LW;/B@&^EX?U;XI7U:-FM^>,N$5>8O(BR#W3Z
M4X:&!][O\<17.GR><QA.>0HG8A:21;5V(BZ]KJH)VQILT*,<Y.LRO)-R:O N
M8L9) NU.E.Z!:I_G%WGL1/T*&2!"*<V@L'C,N60A-&U1;]R"XY917H/.%<KN
MQT\?!S6#VA;E<BT']C6P"]TD /4IXMC.;74XZ_>5ZV)]#QG*+Z1GU?/F" E7
M6F'@2SAU<S)CQ()]SDU-,BOGJW6@RN@'&"VHQW!$2]K"3=:W)22 ZJQ>OQ""
M;89>H+F-P#6K4.7-A/40J5$;R:2HN36S?WS">O\\^DYPU.BK\494=VL5,5ED
M$,Q#4 R49V?)R!DZ_0[6H)RF8YY$#@/S),>*_0K&DM;HC^@$-Q+ EYA6LQ=^
MN'"H [IQ:2_D@+@?9*WG%[I-O]>R2]WSNV1>_-KS/P&<M^ K/J7)<V*#,SZ]
M:/G+_3?TCID:MF%=9;!/$?P7WIE:A20F82>[==,K2<"QG9BVIM<M,_-Y/CZ<
MCA>'%WI?%5*_H=*.3=C4-]01%IJ->.]QU&>QY+_+6^H;$J!' E8JUK,7:<8W
M'0^7L'Q YB0)V+3Z(6N;?JL0$O IY0=T2.;OD[Q@NI"R-$T"_+'SBN6Y)Z^0
M &.>?1H2H,@,*OL]"B\</10"F8=OY7;H#Q_8V1:YRVVND8 Z[#>4@<[O@P5@
M]5#N4\2/M9/YMZ(//13/?J=D$.:RB,VK.UAAY8C#;"SGK/7?UWU(I2G]G2 !
M?NW1&L#V54S^2 +C_=LO<-"?/<J<O^"E_1.1)%<']GW_M-@4Q.)O);.2@(@'
M?UJ(W#BIG'^K(=_+[!R5#.4!T?+!7CB&!XZD WBRV7-&_UX NE>OZT1<#B^P
MLB]Z*>*D(2*/ #2O2>E6_RVAC*<Q\>16IZF8?;3*:36VY=&RR&GV*F M*K!%
MHH4E_^]E:;[T_>16;<R&_;H *GYE3DIT?1/6Y;T1<;G__U)ZVW^BZ-C-PU/5
M=NHVL_A)8K#R=9R3+A442BB;/F3?"<JQM5B^0V:39*&F8X2C&/&DKFHS/($V
M-X.Z SY*+$2]<2;!;VR%**W=3T[L %Z(%DQ!BR.3EZC'R-#1GVXNFEHV5:TM
M_7#I0B7$1-G3LB&:4T"M%0Z0"<D#LS@9C]<=3>-,*]]R6UX%8$;.R*?FED3/
M9W+RXY.2:*GGWW+L=.XD<]N0Y15=@'%[3%;IP;M$ X1C>J7-J3>P;+?S@XL=
M.+E,XT8?LCMEPS%=$E,X\><[A5XOJP_>#M]U[*5<JX"8AT\'U\E@I@E*][83
M%\M>) 95W= -&J674M/E@3AYXQGK$81C7HX1K^^?#$LG= U)B'NEO341T:#.
M";KVF>=>A4)]-WM^<@1WQ',UNPN01_9.JE#,"'M1BG82PCGY <$:S%DOQS*N
MEW3+B$\PH4'$0GG%4^K)W#T%@JM_8++4J,MFWKG9RBLGPGA,Z*_D1(OBG9M\
MY^Z\;%]KN\]85VZ]S3!H8AB9)_O 0P(2V(OV/GPZ53\EPS<Y?'#78ST/%Q7M
M6[(Q809Z&Q@IWR4J?]Q7?"UOC&?C]:;2^NO77G="QD:39I[NI=><^4>4X@X_
M"FS'P,&15AN*_>"K-T"(MS13%!_A%,SJ^DBW$4"G+'M]H1(QQPSJ6L#"QF:7
M3:.T[9,5P28AU"X,18*E9N$M+T7#-F_M+N[5KQO8K-DJ^>V'UWQUH*R_9!X@
M1*%;]?6-EP3Q\SYC(;O+1ZDX9%MX80!]9R8D$JAW8(--, XG F-_NHU8JP@5
M<(N]5!*4$4O07'GA1M/MCIKE@<&EK3"M73SONA_>XT!7VGG%">4RFF@)2= ^
MKQ'G%/-F_WNL'YQ,NLVERX9SU%08\@@.')G:%IBGS$NV9.U(S6FZ5H^:A2>\
MKI4\PQ(6V.SG1 7@B?B!_(%87U<2$&^\9T\"2N?!'[Y)]==6!$^NLNI'/607
M::=J=FT1Z]K9F&+:L6)(__JL+Y).,6N:@J<6M8)WHE,E2OT# E!$:%Q^QJ+I
M^B5ZYF >:K\ERH;<4VC&E/BH;EK1 690$6>3SWNQ@>6M83._)RKAE2BT(_H"
M:*$%[<+?N_P+*.9"KIT,(IN,"VRJPG[];,)H4;SM,A+_"CJ+=A*1O>U-N_V6
MHMB>33.4I^&QLN7H^C)MY_Y*,W7@AE4:!4["R'5*=\JHP\J,J;,(X8S DP!>
MT#I+"&A=%.^VU#>Z6O%H\YSB#+*J?'W*?OAI6ZQS$-JWLY$V$BHV=YMEK<0Z
M7L2X-=FNLX!MEJJCTF7D#+O*%;JR+[<9UCHYN*^AVMMQ)Y2;?<P#9-?G\*O>
MYK1XG-N_-.[/#?7)6B8O3,63_3<L$8YFR_,^]R5==;*"6K5$- &ZLF>VPKD<
M>O;!C1H/^IX?.5+>&2PI:;?4;!@(U^/8WT#_#WOO =?DEJT/OQ @]"8(@5"4
M( BH]-Z1)DJ1+E4Z(KT730!!P= %&T(H"DB3WE1Z5XK2I$.0WGM-/CCG>(XS
MY\S<N??_G9FY<_W]R$LV),\N[][[76OMM9YEW1D W[H/Z(4$'$ZFG8NK?KJU
M.?45_US.F&QJ.)?:WWW4!.T<&6&!RK&VC,Q+\-[J@]S#3-SDWR0KPR268\'@
M)]:!%W_*D_A'0JW_OU__4$(MG,ZA^5CES%:+I4J1,E5-<[(GSA<>!R8,W[T=
MURPKT=<[\FF0[=J9.J673\83\2$<H*3XMMUYC<6]14^R-CQO N&Q':^.<AL.
M-D;Y9"<W'WIA:=:KG^6?!5B%76)76<^8UNF88['[^HBSWHV ,2X21;H*#A\S
M4PV8*+T<=\9%CJI%I#$.00$!$/P S#TN!7W-NMA!+"_M8!YU29WDC>QP$#E1
M!U\'GZ'^A >9/-$CQ]!Y&=9[US.9"/E.%5.J@BV""'K!B;@X:"+I+[Z6YA E
M&P$1+^8K":;\O(S3D"VH!RO"4R^F6"6+S=D%)6!^<1)\(;"F=8;I]:W:->\P
M\C"&!SV2&^61,!AID6M<K+16TYT6/.34=2QP3]I_973$Y -,IO[VZ-5;XDL@
MO%(B&;XII.U+P--#G_9BFON$F*515L""V!.EO ,]E><OJJ(8:T'3EIUX:T@!
M:=9Y.KW^TZZ&!=17;(P#&L4(0?S(J7-J;H3T'80M*/+)BOS[=,[>-TD+BR22
M!7BFBJ J-59)?KKY%#YV<Q#;)/O$3+R/9ZS!%;JS_'?<9,>9*QI7F5\],XUA
MZLD@8FC3N)IX91<$(XVK@4Q%<X)*4LL_2C>M-%+E]C9\=*8)]G UHLP/;A-0
M:X5E?94%+2>"8I12++TG? ;G1VW*P_DJ5?)4;&N^?K$>#Z)Q2:?:B22J09&,
MD5\<7:Z#6-MX2]L8MMJ(QB!:)3?S$MZ.7394NE=8\Y7]GNK9-Q8RO6V+-8'U
MN*B('.(XY'Z4[.=\/0RL_&I(/"U"RJ6&*M$VR0ZWD;;6AZ7)^;7)E3AJZG'?
MA/G&NY,"2O4KU/1+K5I-"F]J).=WR[3LSY5^/NM6J,%I.SBD$4_/@W9[,6]$
M?YTOD2I:0/:T4 3S\OPRR0/;+WB^&VS-HUOH-">H>\23X8ISE<33)0MEX9@F
M=ALBCD%O3ABW(Y(JIFM\L_-*<N,H3!QVBTUSHV-2-#J:_V.3NLJ>,F2'E5H@
M&N>=<7^#?UGQFV<&3V.:'X?*ZX9::;HH2W&Q["K,O#]:ZAVN4S@4_CC5E);7
MQ:MF'K?!K-+DIW]IC69DMB_7@3MLZ157-AM0=$:/]/7 1*V.C#"_NBH;0E9*
M/;QU3>:!=OVJT'"PA NM&XZ-%- Y[1>-(RJ:PZU!-#)ON437?ST=2<!6XLK
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M]C8/0Y_!O2KYRGLNM?2<MUW<XP*C*M-P'+IF01R-R6LSQPJ/Z09\EDSY'A9
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M;L<P.OHU('2>I)7^-H*1,^6^E'AB5%N5#/XN\2624/,F56/ (),>B N!1E-
M]B)5P.' _/_$8MK9AQG_2<LTUGN'*<<"52S'XSWX1[:,Y7:9\",9'5_#F54V
M#/N>@'0X9[[Y7LT_Y@*E(S_%">% @&\ 5"31**LD@,FA?'7G?@ABPVI:8>_2
MFYTM&00Z:V*%XGA"MGZXOVYV<V4>CM-LTK;N6CX*=Y/PO-.9TL[?:7LKSG1'
M<0A#,76LOOK.Y/V7)@/\E?TR+.!9':^A>=R5;/B.T9XFO@S%\=N?B!+5BR1E
M,#D_VX?%_QS"M>].@VA+#"IM]_=.:*TH461_USK___#B^^XT2/=A%A;(C\*
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MM=JS-<'[/7_C=$,CG.W\("K6'R?NZG__3/![@_*;[-^R)MN!"O*TF\?69[#
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M;7VQW-EH^P1O&\(^&7XBM=N:%0U6Y&!9*3 $M@6+)B/T-$@IILM,EW]#A(O
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M-:^FQ@\* 4_FNSFYHU6:#!]+B2.#"&N%9I)I-WV*JVK.:&;#5!IU\#7=6FL
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MKB3$89BCYBI=)*ZRJ1AZOT]U"*8M?/NDEH0"TNPY"S_I[/[6>)7VPX$&GB,
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M1K@"WWL/[\6UOUF#4]HLDEGKDEDJ)@#,:WJ\I;MGV%L[SNZZ9:RFOJ\I?DH
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MYX)N.@D6G=Z<XO(+0(P1MXF<SFA0CEK5"N?Q-;^\&+D9=N,"^CR':3E\%N@
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MKMUD,-;X@.M&V'@^%+$3D", DK3=M(V2838)]^I*Q;WNVYXU4T8QWD"HW,=
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MK +_!3&NYH]L!;^/?@M?/>-\TS?VGIX_[SJ;@Q5^IWUT$NVF_=>'8G%I,GA
MM2ITX]I?;CUW$@Y^\VT.NJS"0A7.MQG^4#,F56.L<9)@SX,BVMP^+ZZ<%&R4
M09V(?9BB<"=A,'LFCU7,>LNV<PP?EVP_O?R48W@)LKFFX]4W?:4TDQR=T>)F
MDY!^TC#,6_L>!,':IU_N_[H>4\;P0LQV9BYK?F8S;\!S56[L)*4[#)/T(KN.
M]V-JI]];$ ',CQSN)^@O3OXBTS+^I8>JM:.0=0A/I)]]!( ]X1$^^*JP7*=0
M*PTI1\V;2!%6!\=N=/]1)_O7G\^TP%TJ[F7R[$]V4K89'M(TL@RT(2; PE;9
MOYTVZZQ4L<ZU.>!;6=]>WM.RKT <5'LP1&?_[0(-36B.6WG?#1/Y9R?XT+Z!
M1IAGM?Z^<TFEB%DK=6B,"=DC&@-B^.09=P**WO/ P[_XMYI\R%TA"Y9BE_K(
ME7YN!1?2$KB!@4?XDOC9V3^[2*:N9?B0''U!,6NR=XV?8YY)&1@,[@VU!$I^
MQJN_U_5;XU7".]I-!Y+0*P4EGT)Z$.T"EZ"-TO;)VC.'I[#W=J6\1K_N)=ET
M8 ="$JH&'\PX.SLI06@F[@7B@=7(CR6BKK'%W''K.TZFR/8IW,XK9^VBT.U'
MO#IFM@ETK^T3;>[RH=$3HD4VW]@I?O5U:KTXNJ/R0\L/+CRLB@5M'?MY:70E
M9!4/$1T>2^8I9*A&;W)%JGHFT_[9 0T26DR]D;^?T DDL(%6U1;P'U+,CY2W
M< W2HM%I.U4H2TX[[.@G-[G3!&C(2P$.282K5P^9/]BN>'4(F*T^:/PTNG3=
ML;SP4&TL[E &5!06WCYE>,@) B9*)_V$_!O)B/N/W0P/$+L15EZ+?.EH,J-&
M\E63CB2PSJ" :*H (^C9A44%68VYNJ.3C,H#(!9WTI"&(1_)9!EO>\8O'O=,
MI;F47@*XSQ7GH_C<>4\''=U[%J,0T@;J!*&-0AWULO^P:J9!@\W]9COT[3Y1
MUV?EO''KVULFR/9IW,HKET(EPH<W%$.50[*GE;I*:R"'JS)*,O!U9*Y ^2X,
M7=]@UYIH(&PXE(XT:"47K=OORU 6ITVB77W$0*<N"S99*WO^[I.??9*/D3T,
MM!*I6FF!11PJT3P;8$6?>>G5TD(P=1*VUGO&PPP.TI.B!IU^E3G(7$=;*YVJ
M:IQ(2 MF2XKF/VY^NAI^'^CP0"T/G^[>5]/95J.VH<]1,T()!Q^B![O^WRC?
M?K]U7YH+[RMTN4.(M,I!4G_^I;<<E)H35[; XBS6Z8D2:R;S4KAXS6BFBSX.
M1II_=XFFXO1?QA[GHY3U83.76EJ6'][A4'Y%0YO%^BVR,/SO)M@_HXO_@]$%
M0A$=>^?T8RD$Y>W@83)QTMWM*8F)GN[L0[8B3:?=$6G2$!8!M@C8ZX>E2HC-
MK1RKB9#10\]J.IP''[O8<L#]JIU.R )FZ^NN($UP:S\[X$Z1",)H2;#-R['N
M)YF?J,)4RASYFF_D[C?NL> !]P+_SM"H$\.K]IBM,1Q)+QXHN&J0S &$$5VM
M#4"%/T'25M]W['0=+_&RR#ENNEI>Q:F?K2<<@A=5V6'N$3:<( A47UH<.%T_
M546Y="7E^GBWJI.L5R4+"T7>C",UHBV6=9570GC&A]PYEWIU]%!%NZ48#VC0
MR:[Y[GS00CXVFQ9^GCC#LANJO55%/H\:C%G3,Y&+X+]2L!S(,@V.[)PT0M+6
M3%=FC4]E6;AVW:N_'JMF, #AO>F!G4D9&((,3_N(!%O$T'!-$BK)L6(!)&MD
M)\GJ :LMHV7"J*BLT&.1%S=\2D=J'OBX)$&?@O0$&E!07P*7XD54MY)LO;'I
M14;V22?O0_^ &EK+6='SNZKFZC7#%-?&M&_/8"HT"$AI($E\I4FRC0 "%5)R
MNX]'4K$Y;QD,SJH@0BXT*^\]M.I;NJ+>=9:VD9*?)(T5RUX-%=[,I5V[W8;*
MSN0AITT:X5:8:FJ&\C0WC@\PE'4@<ZU3R(5W'P?I5A1V23#I/F-,P8+1,*I2
MC@]$/!%\25^#]-U71\CR'9VS\Q'A'\W)0"372SX"C9*/ /^CQ1E_-6\>MTQY
M[O('-W/C UZRE$>HLB-G[5SMFZO;3Y$ \[G>S!;;=_)G[LIV-)^7V$LQ3!(T
MX\]_;9EO^?BB[^?.'95$&/@X//3C)2->OARR.E-KI6F@6)3J'G=BP$7O96CI
M]>O<[_G:%13L?9#T] DUY27]]TW-DV2[?*N;PTZ\7)56*E$BLI,!/4XA\Q_?
M"39:U[D3@@<\I]GB$A1'ABJ]ZHUR>FHZ%C3+%:H(<T+XWYY^&O'J)9WFZOK;
MFU.!7Y4RL =;+>E>EGF!)U]$ U2W:%LV*&65@H,LA,F(:<$($7MEMYXZEWW1
MYS;SOEPF/.>&%38>)Z!(Y0 >.A_ #+HD?AY%LJ6C1]:MDQ6D:I9@(W<ACODU
MH!QAISL#KA(F$QHA;_A2/L&K(TL?9HSF371JIR4-U75J[E#61ZU.C#5\2+>Y
MFN.+XLY3(U435REAL^FIX/ ,]T-T*#Q<G.C:BO+[_#C$YC[X=*+-Y?>\0J31
M\ T,'=LUT'+![;PWKG ./SDV /0M&42#7Z!^1/ BNQGTKD2M;%VH)+6?2$W-
MDBY; QZ@D;O6=%M2G;TVEEZ !Q2$G!)G 8<FL,Z0W%BR=B(>IQ!&=UO#6XJ=
M'R2/DQ!U8:K]AY"38>3:117R193UK;..@9)0!3(RXHELDU\5QK!JPU$NV!JY
M;P-#XPDH2<EE*4Y6D(]P0*/H70GH08H:ZOS0]?=919D\!ATP@]R.0D*]0W"7
MPG@=&C8#ZX3D:;M%?%UWS0^INW/F0A2XD1@RW3CL)\Z"A/AW?K$]Y P10T7.
MY"P-.19MSR .#EPFCMY.P&9HDK-VH=<J3CWFI'D4(5V!F>$<YXO@YFL[74<"
ML$[0SDWC3N:]^T*SR"4A_X1\^?6P?1)W@L,Y),QLQ3B#J7@2/&I)]S<\TY?*
MG2/Z;\;,1>0S9[#E4 -\:,<&S13R:SV5GB;;!T\'3/:\2M,"BN5V[+0E?,H.
M#J<"'Y)=[IR.$1%DGCE)+2M7/:8&,8"(0\1%H]O=3NW@ :MR,8$$=ZZ^A7+^
MVM=TY1A)+-:!D)&:"_<I_5/@8$>^#(*-2X!]JW6&I4>D0)S^RJOND1>?H*VR
MJ5%8=" 4 DF*IFE\0U\8/B1T7VYGD99-B$@GC)M;1'8[Z\Q?G0#0N(H'& 6K
M=F).B67(,2BV:$7.WCI0@DC89\I8L[JT]T<\/" ZV5X3,TE*2GY7).L<[JQT
M<E7+1I_+4MG@@6/BPZ,*>]P7>XQC<,W:Q2>,3XI4"Z-;@D\9+ 9[KM3HD[=J
MTK!N<4 4B)?'>UX$BQ5DLC\E>$!RPK @O(2VIJ4C&Y#_:_%:C=XMS<)"/H7Y
MQT+YC0HGJ^GEJA%@UFV:UEW*60MUE7S.+]L]NNXW ?F;R=<E:$]'5B0]FX"3
MT6.7".;A5@+5(O75O$3 2[GGS6>,L9L/CL:25XZ[=(^^<>EDIUK^YQ+(@_G9
M2M+U]A3R^@/G#!NQ;F>W"6_U4P+AD-M\+5/Y$SD::!@&:Q8_RR_"<469E.]%
M.<-'ON,.AES)3H&XAC[$'@^0;<IT<]D:W/^8T9G)1^F0JIFY#"?-Y/6#@-'V
MP<#B?W%NYO[@H6S/<IQT00:;V$.]<[Y)6KV@W62;HOHY'&?^%S//I5NW'YEJ
M,KD-A"M-S##=\/LTRN;'USQ0\KKWT/VEY6/#)"DGD?A+"F3$S4*\9"=K:%GR
M4\B^9%IZO-76AJ8[WZ3OGV CP)*]Q,) $9XDDQ\8K?SH3AJ[\$J9KF?F$?#)
MG ^"D+HA$& 6,+C8\A[$G$T9K/4!M'P1%,9-R'Q[6=R?#9)FMD)ZW/O9&YSZ
M4D5Y[> UQ=OYDQVC&E)8LQAGP)MM*/N&/2XRJXEN/4^K\K&@89+BE5!ZATJ#
M25>P<)_$FSGEXT(^I^G<-DR$481Y^/O921,O6H7NNKX0#7?T!)\UD0Y0CHN,
M)FG0L =,E*/.(&!&:"6(Z\\)[>]U_=8)[>^27/$K%Y'W'RFKG02]5#@*F"/4
MW#E.S@J%W_E3AKIZMN@X'B@7B[XVV'\W."9$]^G!1<:]Z>2=6CP0P#C C0<Z
MKN&!#^<..4:HCUX>O!,)$6U;YD 9'T\8A'MPN_=6TWYX7N=%J(7HXL]'_LXC
M<+]&!-FDE$H/1PIC=_J+X#LE9?;!P>](V%^$U?Z6Z#_E/1Y0QP/+)>MOYO_$
MH@.D?T_;^6(6A <^)W^C3$__?2C2?VJX_(]>OT7#Q2V](7GWF>4E:_)/< QB
MK6?:]#Z1 H2I"=DDXM'GNB;0$"11,L"X/[##D1BF:C1M)V,?CI%A9;"3<KH[
MZ[+>LAT8S,<E\559?LK>OP+:7-WTZEPY_?L#VWCV$9]JKN F>OL(\N/(+F:7
M;4S2LO-4Q6OG#:34[4M#'6P.B<OS/(W<#HYUA]:KY:,WBSR;]26[HIL=WA*;
MGL+0V+FWN\^A'<,7E/XJOE&^=IDWRHXD#^['2RQ\1F+^-&"'!R#.8D5:[@0Y
M!N$^X!5KVT1*ON$88!6Q1?1BM^/5T>LN+LFIE##C&5H-[%J2PY 0U:YIA0[]
M17HQT9L6#(MF;5*Z$XAVH)W74B?K9H4*=69.$%0#%(6=-&80[(0$'HJM'NPF
MS9DDG*8I#?5V6:=P:4RP<R"K)H=E()$LHFMJBX6S;\\9LV>\G'RDE";"YP,1
M5@L&UA0)4/5M6E9QWN;UL91FZ:U#/@B$<"S,2'AS06^GX8K!7#'7.:;7S-SB
MD!7C8L?^%,/P=MG]D(,K9%]K2NJHS>L-HJ14,*7-8,SE^#XO(=&"C)K+)XJ+
M4[@?I+3-N (F>;)*K@!W-IKR)#"RFO/DZ(D539*#T;VX&19'RD\8")0-9D;;
MP3]3=;X02I_6JTI%JWAE5729-IIU)LV&Y34(G)A'LT"M!(G7/K0.:B723.X8
M=*"RC=%TJCO;#)F5/8Y8H4A]T.KD5]8*W%#9L:NR<O%53!ON2&X\S[#O#:]6
M\'[@\> K;>&SIY449^_+761EC6QA#6_A3Q=GN+1FAKNH':QS8T.6!2/LM/<L
MSC?2M]F^W;Y#ORCUOQ !>O?;G0GL)6+Y):;S!KRNB=2R#H[-!*1EZ*U:A"GP
M -45DQS#O31*7;FDY,LV !:[KFN/WNC)]M13?M>YM$CGQ2.-ECYY4PVQ@/9!
MC/L(IXUC@JX$K&RG*/)>7.]?OM/EEZ!BA-U$T-L_[Z<_K1D[?C:&9;B8PZ1Z
M[[8R00>4;E4!@A!RWZ1_[U+ M-KPDI,>_I@W3(("#L=($) 1IY"B".+XKYU[
M:EJ\++K@;LY+RZ#LHPY_ T4 ,T#B^0T\\%][A'Z?ZH-"(4^B45+E- H_91H%
MP>,@&)%">I5AM]B6C-.AX5Q<0&A<D\MG)54CE@!.'3^WB=2E*?WKG[/Y]^[*
MTSXW"4_XV#PU4!Q0F\7=@FP'6!,3(_4/_KJIJ/Z:%4Z376(N";C8$9\/]WK>
M9*=<P<;&)K+Q2;.B7.>FQ4N$;&\!C,HGC17KV/WZ]1V2CZ]@)]X2P]%^Y 1G
M//S%82MUGNI%/5@9V@M:Y?YU%8))(A*0O0V%M?;D"Q\O"7/H+9EA#/RS]HRG
M)!;MY&;E&@'6/HF_UB,2]>&^O_89';XW/BY2RD:8=V@FQE0W@R'B]31C?N-V
M07MOF=]47:K"_+#(RV: TEH#(=:4.%',>^K$:6L\4"MB7=6Q?G]#P&9DZO72
M0/M2?[MCN\=T(3LX:K5D9<5V62-N4-8(<I1A5.\/23H)FX#D\W>/_$T"M-3[
M%SHVZY\U/,]:IY#FSS?1RRU[]$S_E0QX"IE&]3XR]A:F^T%&S"50#73HTGUB
M872TP<,*3*^;8[W]',_K9UYMI*OP>W%+(>'>JLXN6#^>X>O84?8&Y[_NR%0U
MRITT%MX9:R@Y@#,,DY[50)+,P52J:R-%F>-GSU%Q"S'[[*'K7?8$K.E;1'SA
ML/L%.)K*V+/=>JV @ !O,T_/=#4"RGJZ&LW@=FB5D=]MV+,Q*1V^W.A5J-;.
MA\:23EQ\550H+T5Q,_,Q7X XC;2" C"1#=A_./\E=;7B^E.'<;%+_;4=8;ET
M4S5<XGK5DXSE?+63TX7\MH]=OCR2 @GP<0L9E1Q-N['%Z/H@9J &R$$IIW-_
M4V2+&,';@MY>C[M%^CMB@LL:[1-!B<:=(%=+?G9M*)@]GO<MKP"PX,<K0(H^
M0.\'SW@AQQ&;<3VW/Y@$NIVY^M&EL;F*0[#"3H)VF<[.-NI^^6"N9[J4=\5%
M*6<(7# 0.I=XQGW:AX=?D7Y(.X?)T)X/_(Z=/.ZCC&VD2]=P9#\EJ/&RV)A.
MB[WUA>$4L*,CIS^]Z .P;X3X,''-3&AC^=-?[>1U;A8J4]_*\$>H@E2-)[%D
M@IT$O;^RKJ[4A^HM&?NVELS^_1<XX \SELP_3F#^>1JW/YRAX(^52>P<BPJ3
ML;-#\8@S/)=R3]\N'-WHP@,KQ7C@O%C1:SR0%(H''I;L=D)>=>E;'&4+'&ZB
M#I:J&D.7+*IFTO# J#7N&FC.22,>974'#X@PX@YLU](.M&WW9O' SA J!/#0
MHYE.'NQ!=<@<Q^Q#A^:X+PDX#[&C[=$)<8;8GX _ 7\"_O,!OR\-;.3^\,(@
MM6>EO']XAG[Z3_I7N;QW;FGN:AANWA?+%OK7K=)/P)^ _[. KME'-;A5G'2V
M]L.&X\:"XM@(ZGT5&>@BILZVWQVB;H*5_1.$R;]-G7X"_EL _CE;0N/Y\0S[
MSR]X::UNBFW>%5OZANOX?<6M[YE,1ALCR2*D@.+(8O2'EX*[9W.O?7^SS(^U
M #;++W_ZL2I=WVOA(\(5O*'X0U5^J$4*N?R+RIX?JL+X$_#_$N"/9R;M?W V
MBZ<9LD%V+@1;3!C4<\##^5^I/?T$_ \'-/KQB&TNC[6DC-#3?)943L?#.3SP
M+]R8?@+^^P-^7(/LYW\+%$M1/[Q\@!]J//;\\<Y]5#;@8?UOTY!^ O[[ S[\
M*U9!?>_]Q!QN8P>14U1'YG<45&DI$0R^CW&%H+G"_XCZ_@3\"?C_&]#].^.E
M!CE1&N='FN>/19Y2BC&;IQ#]@0-)[8^42+]/#L-ON<QG/;3G%8P<Q$D4V]!;
MX%+1HN<Z'\CP@.[HUD<\,"LO?EYL]5'=T<QA'QYXDH8[$X>JQ /Q>&"-OU-9
M'(8'#IFX\8 ['N#' ^/?B TO,JZ(35<=WG&B5H*(X0'BVV)?49]0N_%B8R>#
M#CKV<O$ E1XA-:@##]12D>\D;]S#70S=E33$;>"L\$!]GX04X(@'?B+^1/R)
M^*^(F#&S^H#GC4%'-5OF-N-RG]P/"8#3FRLD4@ZOXDIT[612\(!I-NK/;RR\
M]B>>VG]V^7\B_D3\7T&\G+%[][()Z:ORB0@1\@/^:PRG Z5(M?: +?V)H\'>
MO\E+!>[_IU3\)^*_*&+&LC =J>5'Z#I(1",/#[B4W_I.CX?,OEJ;K_?&]$J8
M?0V#_V#.]ZX[YP?B/*=_X=K]1/S/0'Q[($;:="V;XDI .[>T&V(SI_;[H5KQ
M,_^RQ?Z)^!^*^' FT"A0[?'9.B,DBW"BAWK0CP6PM/Z!:/-?K>0_$?\3$2V3
MWHQI9E/SQK0@)D-O+.F9F+KY'VG^$DR*4U=]AY3Y\4]6*2]\D'C@.VK7#^6<
M94\A0_T >NW[X%].P@Y._J&*C-^+F>,7#,S@@9^ _W<!];^QD^BDVMUCH9==
M%L<MG66@"!X#1^PA9V7NR^Q8V1Y[I>IHT ;U<2.9CUW#F?KPB?W;U.TGX$_
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M ><S%"DNQ>Z@*H,1:0JU#@W-\R=/UJX=LH5)O+UW;J']2E+[-!\LYYR%2KG
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M44S/;2/'#XY BR/628 <N2>2Q5&*!9>5G]F1KP8:L&/H^]NDB$38WOT7[LW
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M-;4<+EQV"6JRI&B_JP3)ZM2_9C^Q:%3+D6_ :A:#)84WW/8RJYPW0K9)WRS
M!N-0E!<6[T<'Y<*WJ/*H!$@#1\0;&V\%CV%+XLD^L3=6'%VY,C$Q99E#*WA=
MPK?@O+JH\Q)KHQ':_H-O**@]>=M_+NM"2C1/0# 4J@"J447 & 0[B/QH9O
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M;.7Q7EX1D]CZCW>&YTMC-6ZKJ1ZW49@HY1!0+A=2$"/LR]G.QPDOH>8_6A^
M,M#;4#QPR6"S 0_<52(BK3S3+0QUGAJ6Z5H$LRTMTF4 7BI8'T$KL#^A'3=Y
M;+E)9@NHQR0R4:F\(O599X\\RI8("4'D<E![-,!I;F(-]KVD\8#^_*%=U*2?
M,=&^O78H[7)<J]:)XDDI_'"7(NHH99Y '%Z_;CE"0E+IM(YE\D$"1O0*%NW[
MKIX'<9F\;?RN*F+;;3R%<&0;.4^(W.R5KT X$1,&.Q27#CRT\0#K+*@2L?(8
M)Z2:6US,E!$@I%F*FQ483%"UFHP5@ 7CT&5T9FY7HZQJGEU(::+GKNGWCJU%
MMD/GO;L.IY)*@77 8&#;,TX!Q!&RUGLVG:M26D@XAVM_0S9[=X6D0['3B??0
M9ED+^/D:*!F4:6RM"RU\ZL;RVB=.16=H^T!%7HN/K,9(.-?!L/%FO8*4P/HH
MQ7:=19E)'17E3*TE*QR1SXKQ9A&1G1V.=44.'U'Y9H0U>+">E/MG'.:MM&[%
M\AUK8LH(RH$B#,<V)[T+9IPO@SY\BR1D,8$K<]@3MPJ@L!E2U%W0-R"T[3-C
MVB#$N-W>_^9K3U:RTS^>Z:9]FVPB07F<;"CJB@Z#5I.*,\SW14KJ NABREA
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M+^MQ!:EN%$H8)(1?HUV%,/#T4H+Z5:0?NF>U]NU;7M39HUM!YI15WHOR?]^
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MR(T;15W9'YJH5IL[E0MZ",#>6?09R<C(>2[/#_<9CW8?%T>^"EV<B0>C\"[
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MA6)AR[;$52,S/%#H01A1&YEP1^.R!P::7;;"[6+ QZG9QEH6ZBBS?(&ZV61
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MBY_&]D:DKY3="<8GDJ*(=TJZ1KT2%;LF03=&J465?WO\VEL;WN?<F;D9]PA
M$2.S=U@$7#')$&6O96-0FLL&LU*Y"8WB*Y1/JYNAC+NI*MFD3\V TN6E!9?7
M2D[65TI*<F?LW5V5NR3G72L9D3)>EQ<+;"@^WE'A2">>4CZC$A6%A"WI0T+J
MZ"L$7>,$\LI9:I[(7S:]=FV+\PD8;!4\ZD7J\)X"-+C$,[RP&\09?B;W2AH^
M_P-'*D^S$E(>SX >IVZ^+?72]6B5EN5BV3T5B8?NT^NI4:OMU=/36R\VSII=
M^33VM*7R3=!MWT,\-[SZENJ1I&ES^@'#S?U]5ZSU2*:)G8C#DP1)A_.2_BB
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M[/"YHC?XZ#CY8FQOD/#CU<V,.SV\+W,)'*)0F,'G=%?IQ,7N6-(OF[^7UL?
M>H >/JLQP#&%3-R+KK4+!^15U27+]>Y%AX/:5;J2"2'#+[ZQVM!OBAJ=2>.E
M-CN+^O \-EQ^$P<0,L^RI<X3B3CO5CRS2&>/42&PS\;+[NQLH'7)R09?P%ZP
MIDMV&[XR4NDJ&/JES7=NO/<(UN/>9GUQ+ Q5>*5.N:EKX/GU2?7W["P$@.#8
M/3PB8,YQ<J9B6\W]X:='U]?OZ#QCB0^/5&*)E&49? DXQN* !:&Z2#;.,XDR
M<Z^ATUN43D.</3*R#YU:+_[U?SD7#[/<^Y2;[<%;C02]L&CH7#PUP$SRW_H1
MN.2F8!%Z,YCH<JR)OSVE:1*IIR:DV4NS_/.D+#6K3DU <ZU0LJ@DY&#+@+(O
MOTNE@:/!G["#<5T2DGU3ZFQ3VGD@%P"( 0@ "($D:.M#<0""-:9DB]F0!8DH
M);PJ%=4.H/FCOEP6L3LZX"J(2[B\P0(^B9?DHTV&X3LD)3<,*;"FWWW/R1$7
M)JR-U'$CIJ7/8"X4^OA;/_;A#W2YZ^WM5>YQ?K!AX0W ]O-^DPSHQ4<[!'Q)
M7%RD\;I3,3:36[C+-2(!-1E "T6-[J02%]$8<!>$-E<W\-1LL\714#HLRC'T
MAG#??!3;^)CE@';XZ8L,FZNBP6F-C7MS@^6V!10K]U1S:VC-] G4 B+"W9?4
ME"&L4W:4C=9X.@9"C:(E7+:1;_1M:"3/O*'F ;U3E<!WZHNW6=-JJ7GBU!AU
M!AD-]<RH"[GT\(A]SKY#+)ZC/?-MW\K:B/='F64"D+,F; D5[CY;T/P7#^Y=
M*38JYVM;4AGYJ!SF-56_3%9RM2T/GU<$VCKOMXTS$0E7.N>+W<7.>(2^"N)!
M# >)R/%X3$;T\'A=T+!QD3MF<[M5T&P3LJHDQ,:(<9HRE7D,\$@PH\[ 'TUK
M&=E9Q([4E6N,M[ZP '-Y%K>K>B67&>BR#L=G:CC#NJJ(LR#,C!N#2)YR\:<7
M71G/A-]=M<^Q>Z:?Y!<6/4GOW@F=@XIHML6X#Q6S](32"/FK;%3++SN<V/M(
MP$&QNG1O ^R"V#\^;60/R:)S"(?0:BP"G)'UT>Z/5N_+W#N)73@O-WGQ&HN)
ME2E[AXP::NJ=MSF VBE3)A 9YRUYIO#BZ9O4J&=48?1("OE=,%NYH^;AUOYS
MC<I-C)G_.-Q IU'3)<+5 RD@INH:V-"KZA6XG+;>^HJ+CO$I7[@D.2,C6A*?
ME#"OWO0^UG=@2V!ES*_6UJG23=\\R;D;<-+M/53,,K_LV"?KP(R.UU*YG.PY
M4]70N2ISZLJ:MYP3GI22N^(,,ZUJ4225:_]@KT0[F>201,_IMORLOG?XW:.Q
MVC>"-CVNJTNH+71"[MYO<B.L[\1JU<2.G=61YXAWK)6TJ34SHW.-)! F1>(1
MDKMKJ2F=+=J5QN!OCM7E0'68(VCVGJS9Q3G&,@5)X >>";LU_.>CX]Y?GA$"
M#ZP0Y[F6)<XQQHQ.J4Y05,/!#-<:1#8B^7OXW+/K>%\+/*,\#%R@=VYY?XTF
M_DHV"^-,R7GSK*,,1CS7_#)A+X()8I4,<G\5*D4A#",I+,_ISWD((,+KXP,%
MSOOD;42:MJGKJSU98<J26._/(I+G++54EH"+SQY:9#6,:@C:Z>"A[0OV#L/K
M B<C/OVYZDJIQ.[>)F8<P9?('R"9^3B2?209 Y9E9#TQMR8H&<@-ONKI9E"+
M]44^T[D+X74\<C-A(G!S8T/":&J?U?%:\E]RO\+5$GE/3IXM4IXYTFHY]ADG
M5WZNH<C*0Y#9*(^])PI=M21!VQ[">IFJ7[?9M$6Y40!DD]M=30O 0/L/Y2>1
MN?)YF_N+;;#C+0?Z43#RJZ]#6+C95B\SE&XC0&\@@2R(F\EX 5\RVI_P&0C?
MD9#17AJ0GJH__])!]P%E1'O$FRY@_&Q %:!$NS--[D\$/Y=@AXW*Z[SB^$;G
ME:WG@V0E7EE1Q[II4U<V$2TMY7:+"/Z[N6G3;;, @4T&F"VG82$Y&A23Y_Z.
MY(II>157\L,9@[@]T]612K>'0DE(@#&27Q_[-J<Y9WS8YTE^Y37&ZQLV9MIP
M';" 0X\[;<3(F:#5P<6/U_M;.?+2VC0:S&!P* 1=3H6.(DU)N7(SS)5_)KW0
M(<D<,(?>!-G^9P+RTVJ/0K$+6(U;4FY[-">?C[/Q"I_MD1VU'YSMRS^YL,KP
MG88R[5\6YO<;IRH#>4I5]:MA,Y)#3UI/C%XHC&[6< YFIRYBA[!K&!P ;.I^
M_RI>C@-J]T\]-I'8D)U<=K(5Q"I6?)V,-?VM50CXR.BH/NP8W&E1I)N._+]T
M7>X?R9?^6.4]>Y'L.@XX+/W=Z>W\_S>U"]\WBT$W>1UX#FIRD\?G)OI<#[<7
MV5/;R1/NYGNH5OK</AV:D_^I%*(?PS-M?H3&L?HOIJO\M4+\0W#FGS ^9?\S
MDI: 7V @K!5+122Q^=]#=5-)A/X9V5BGY9HUP^*+=>S#4(835:SXAX]_!J,O
M<<GB7YB'EU:( W+LFG' ;4J57S\J0\[]/E=(_8^Y0P 55?>G$9(/"-*Y!0T7
M$FT][X#8$PA#P:.O7^1SBQ^ZTVGC "8LG5@T*:^CJUY@]](B]PPCC"V03FGH
M>-*WO#)CWU3JV=5F ;$%*/A8:5YT_Q9"\=.GC@<0L:PU7Y=T_X!WL512.E;M
MZ?U=9?U4?&=)3%LU<C0LOA?>Z* GA1>^"8:D*%T9O. O(T]GW1?#^0'+X>XI
MZU(K<1<#H<OFS6$SB>NK>R#ZQ.]YK*H'_NS;PG%)H6<0&0#K,EDC\/QJYI66
M$ ^1C4]O#WL^+W_,-QI3%F>2O&G:QJ?^N-PR-MTL=4PN][URR4"6;F K0?$C
MF;P,UOV#(&IB CK9_3#L.U[]F)DG-5*V*Y%@TN!U;/!Z#[_!4DB1R!65<B3C
M+O,5/_7FMM>U_"^*!V(Q,R*"\[XI4\>+)X^LDB_SSDQ-.\6((LB,YG9R:WS+
M'AZP3)L7.6!OTE)=N_NB5-#B=2M[-(%:N&7_^;]YD*DEG:'[*K:DEIU+<#*<
MB%K"<TCX#S.[QLM;X/>7DR5=.D2%0H ":9L_#X@"V O>,DOJ/>'_<+HK[:#;
MB%0"S,,0<Q<KTWV"*=+&:$P@S/ V+Q=(-C,.& 1%_6DJT4>+P1S6_,*N<R3[
M+'@RY^G+0#T?#2Z&6D7J=BVGOIGPEV!Y %K27_GU("5OZGU]28<>M(M\B*[5
M[,>H(X*)W;4C\?T]'* ;MC*QB]A8PY9;GZY+XB/URS@ ,W%B)5Z)^(H#VNL/
M!PJD 5,<8(L#2G% &&(G&SN& \QQ #T.6-(LIP1%G=1B>[&BI_IF'+F=I!Q[
MX8 "W7YE J6?$GY*^"GA-R2\$"B=O6;P5I+.!W'VRR\OGDV^6AF9&53U*'IB
M#C5^4>+^KZ^@V7ZYG>POMRK/3B5.^6-=AE^4'4Q'\B'^J' _XA==\W1#@,X?
M]%7Y1=<"JY\"?@KX"P$\=N7B986C)A!1IR]':FE#Q^7G*E/!:YZ^5$Y_RN2E
M#HK# 427CAA^;T/[<O5??F\MY=+ 0QS0)(UM_[U-8"EN[(I_EV.C(D%=OQZ!
M*/Z]%>& )\]/PGZGF)ZZ,L&-8Q:C9<3O#&_J"@XP^8-]#5""GO^4\[] SFNE
M(H]<-;MQ?)\UE>V"8?^]$ST<4#/1A>39/M%;ME*S=70:H@LNU_E!K-H/)&S.
M_V;-^2GGWUM.KNMP6 2S FJU%[H#WRY,_($?&?(_I D_Y?S[R7$2% I+N?(>
M9=,.W89OYZ7\>O,_#=[YMV[$3SG_;G+RK"Y7CE!>'36>*_1BL)K_ 2PHX!<Y
M#+_(R+,* 5I_D"/[BXSA="0OX@<Y*C_(J#CU^8Q^:4\_XI>F%.2R@R_]%/._
M1PS\J-MZA=UD!(5)FDOKS;SH.?0U7+82U@MO5TNY^_E/(_)2SQK]#[&1GW)^
MROF-!;DFJ'PWFG>ES:''J2]@0=KR%QI92E#3[Z/N-/X0A"=!.UO$$'.-+=S>
M7O[09/LXKZB"*9KJZ!6Q*Z;<J>:8)EI.F)9>F &Q-5@N A=_<9YV1IX6:[)]
M): 4)"S?7OW&_[6D"JMB-%T)JZ2RSA+Y:'6@_*BH#/\2:BMBE%8CNE"M19=3
MK_BEAPQ<K"5E9AX!'N$7^%2M;:6^)-^DV+VRZ-K!X:P[4\?_35SXXA;#B_3B
MM66?$S)$D6'!&5BGO/Y,R\>71)L=W^KL,&O+CXYN,D)Y.T7/.(1M"*RT$:F*
MMIHOO:G(\-Z8F_6XBSJQY[QZV/>U]O:8<CCBK#G^JQ$A.5\F?5U489]2NI_6
M=GW(YS9,#R@\V9['.C"O=(&;^)JS0X4,H^>&1'3"-E5!U_B5#TEYQ"%:5#W>
M-^/?FU9C+QIS9CI(?H8XEH8$MFH[*(L2;)BY48%#WNR ^VPH:D.FO>\NFC6
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M>VK(RTQV.*!4PT=@T.ZL$EU.>*<9G##(G 9C_R07W*91,24!@!L:CW9%?'#
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MYHNL+,#H43A)5K2(#R$/E$LQ6J'*4U7YLJ->4>$<31$L/XXFS@5K=Z-!>OO
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MT8W&]_XWZ8BKIOB&M4MYDX4=5NM5I&-=%LZ5LW1&RWR)JNC2BZ(V<(RD;D.
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M3V-UXUPY(R.7EE):N]E3?K!:17.?.Y[D3?LY2R<M=M,\\FF)R!-<!DO/'[2
M5>V?A.':+A6RDSK>#POJ"*H'36$.GP4^LE6W9:PL%+HX5\];WW*%(GOO#O*H
M>3O2P!DA5ODC#B%+*L$^W,N"J1IC16SEC<#N,Y+4\>9SC@I0+DK6^.\3RNB(
M+4'JEZP**B@^ET9=RDJ]%OEB;UF!#R/'TEB/: 3H*UA$]2:7C3ED7-(^Y(S.
M<]<X,LZWH'C6$1.9F;ZD0QF<1:$&M_7,8TEO+1XFR3[Z/HO1-W6\R2S[6"-C
M1H7&D5.A<:-T?/(V >1U\1_\V8W32J7<AKK=*/DH;LN29 " $  #@,E#@),)
M79&B(-7+L[:O;7OH>GBHWU\@20MF9B2MNC9E9/<=8$FQEIG!RLX<+2_AW"8A
M6*RV;')$$ARC"E[J>OT:,/]S&E/=IFA=5W>8!U?DVW<.W&$N3'9'&$&RAJ9N
MHP$QG=&VI8\M[BB7@32/*B$ :B6N59*R_&"U(GU74 "$VA&-L&8,6F4/E%8X
M"[0<GXY1Y?>63[T9YR; ]?"Z&=:IU-2,7PX8-1URU!4JMQCRD=2JN6=^ VGY
M\+#1P[7KS33PS'HR9UEHEG[W[B6'D<[!O8N1#UDBCD#/5#(F>)HMCV).9-K+
MYJ5 XRRH;S.8DK./TGJ!Z3J9@.5]X"Z1ENGL&9_K^ES.QSW;WJ>2<9'5*T#M
MRF4Y(1@ .;GK9%-08VN:2JODYG!$4%48NULV+3,Y"EOJ>BFE2F!<D\PV$F]]
M).QRI*$-]YRAQ&[+I92F I\RQU+3ESO"HSUSM> RV?*[NH+ZN52;V\Z25(0Q
M^&8(K!6TQ,3AQ%)<;MGT>!WL>)CYP?Q['!T>V).5EI<<85LP*WGEL.9Q(E*!
MG;@<K02=1JHWL.^TY=_:N%JH-5I?PE_MK*5'$BR#20!)'</K.X1QZ KRYX\!
M=>"\/,7F#AX0; *357WT+19F=@HCT3MVUF'UJ<JRPEA2^)>STD)YS]$PMR:7
MF)@>F)/1H:YLAASTW,!%N0L.S3J09,9FEP1AW"@(UXT:4AV0$UM-Y/(X=TRE
MG'BU\)60@13U"6G%&LA94,2P/TU>L8>7C]L]!GM],?28*"TO-(9929/]-'+Z
M+7;H4Q6CK?+SL_IBV7B["3(!CJWC7*/1I2 /8:IP.4AKP36/8;_TST6;SN5Z
M&X4$\%ASETR9H>FVV2O>_- YCJ(W@=MSZG-CV.K+R9=2S1O"FEW*8YL!]6@#
MF!KHN76O8$(@>U?+='O%56$$*?*Z$\Z5$=H,9$E0%EB]#M37;<BW=8]XV*Y^
MJI'3J*_J+N:]\$89LH4BY;6>J[0$#[&US>!N ?5R%+C.#.(N'!05H1]4VSZU
M_<AZ-D5N3'Q02)9S-$^EJY?F0B!")A5\%-3^=V47_ZNE$"38URP5+_R24[!-
MD1X/KFX9FL[7.PL)3VD+_A6N6EV68;9H,N>$.4_&L]';:JG2HAB(E*;(I/MR
MXWIPJ*B@W!=UY3&GH')H0S4^S3@%P_=EJLTDKS'*2*Z!.CG8VQ+,ZI6NW\N=
M<C=%ZR*T-HDB%0X'G+J>IV!XWB7WO8/W'N=Y6P;WE*>):U:9M83#98J4D_N:
MX+U,/!_*(%[R9V+KJ6<M.4E98[U# =Y_T&R=C"2*<W]%3OXTS9-$=H7B0QJ,
M)(><'1M( Z;U#M*:=7WHNKM%]\RG,%& P05+0) B&K-=?][9\>L.R<WK:>(7
MEL19))R]@6"$<EFF61V$]")6VA8\0PRF<F!S6D_VH$ZF?+-G=>D3#6&< ]@M
MJVR<);0:6G_%( 5#\>%)W?$888_ DQ^4N-[>CO;BBD:>*II,(OLSM+GJ@1>6
MZI/<-_AJ*R6LAY)D,L>I&\J^]-'XOWB6V])%'/HI\</8UCCVMT*33^]E!IO6
M*'A2@C[]2UE%E<^L:3+?O!NBJ1C [ -L<H-3T51_V:2*FG0_?M@TD*<>V&U<
MD]D')M(@K.>8,O*TEF[)73.-(S^)-:7YD*BQ0/36>LR3M)@&AWN4'J@G^3]-
M+_R&-)N05+D/:.\#\R7+212W?LL0NN'Y.Y"BOV4&_0;ZRF?S.Q@;9LV_*9GF
M#Z"OV2<T]@$3MEW(/G!>K/COP4?^+4-(W^W7?2K ^F^R2"#E/V<'A?UIMPHH
M_YOVQ;Z[5T;EL:=\BVV;-B7LVPT&89!8X=]B$YI6MH/?7<_X"7B7Y,BDU*KY
MO *;>D,6ZXG7/1_IB!Q1+4[=$4Z[V?IEGU77?7="9#\/N4O+[LF3/;!L/-O<
MIO],^R DY*V$O!C1HU&ET0KJJ&N]<7!K?"%OTL4O[<%IR4'V /RI2D-I:,M9
MQD_)<W3C"4)MW/=239^%81Q%&_(Z:L3M+&YF$,#13FNY@2Y=8:L4C&Y0Y-'X
MYR<RFCJ46V^F(!^GWG@>_UQ4S2I%LTN0V'+LG+,0LJ:1$)%N4EM0@8)\B5ED
M^[ /7(I_=P+)=V*7_&"6[-E\>0*)8LKW-5\*5]UT35IQ>EFI[,Y_\+9AR7\8
M&X;4X<G;+U,*P"S]=%$;5P!+=0.=]>F20"' :&D1P'.XO&/E+='EIL#P]"#4
M@&D_'M+C_S2O<++XB69X%UP+%/XA$H#SJ.JG3M2LVSW<6Y\OG<@WW#;#>J^$
MKX+B_]'[,GAS8&L,!]<.NC2IK*OU<MC@3N#5#X[B;.,\I,59CX/C69-??C3Z
MHGG_Y#(:ZE*TB'9*"(FP015S$C<F_6LCYA3W@<IMML6D(VX:FNV$3V:VUMVN
M#EAL%(Y6X<""4Z_ZVRCL+7P]7V#KC=H'?%91P[+'9Q([=TG-,LL>ZVJ636N^
M,(]6XN)04X)'>\D49^]ELFU472#2__H[0#[5BM8J>ZP/G4%CZ(R/1NN.XLP)
M7(2DD2+>]/5G_E_V:#;5O_T*%)NY28;7<#E;D.G2F6G>R!6M>#XI6I5KV<^Z
M<<B6ZV[O74U.2I@YDCEHZ(U'5"EI=P$+G^K.5=3"K9!='F)GQ,Y@\CY  8A1
M"4I?L'Q<7I%Y7'X4*S)A/80E2-.P?K+/^DYW(.N&MSSZW(D;3<L;YGL#?858
M0CZRWF]Z0/-7@=^&"\-=7FQ09&4.5:+/IHR*K .;N[3?5]8JD@\6OAUV/J,1
M02%$IBK->^;;J*9^:QK)VS\[[1^O+#:IQ-Y_2*8;[;C,,]%*!M"8"DEJ+_QE
M1(S/4!F<7WH?Q7N6^_U-9D"$1UM2!X@&8$$=H85[\6Q/UP>J*I=W*S^C/-QG
MS1 SS4Z)WG]]NZ0[@BC)N7)_G[$MGQ>WYN=ZZIVZ<029M>M_6;'_^OZN]^Z>
MZYC352PXS8GR>]H=%:[5$[09<:NXRL.FQ*JU023ZM#:4DR.8O&$B3?ZOOU:V
MMGEUMZ!>*"I#"PH'H8'&B;03?ZEMR*CZ2XLI>6Y!K=N$G(#WD6AC-,P[\"W=
M+)K&>^K:G6MJ=P$M " #2#$ "Y"U#WQ[DPJ_C)W:H=??T2S[T,R_MLX@Y7L:
M<7PR*_&'T/^_A'[SU;^I& -+?1IS-H]4K'1$>COFV+>4"FUTO'?D:6T$<E4F
M,.\_LJ,_A/Z_% K6_YD5P^93>K_)AL)RSISVVBDU^M&@A)#6SJ[M(L6LM#(*
M23;5-,"J3;/JU<E?K-;=JI\7T2*M,[_<I^Y</_.SZ9]C4/YV3^RY_\L*52Y_
M]=</J%_$8 1_B/Q[118?6M@NV0?<JF(O[!6>^,F,,'1E'TOEL;\4B9#&']B1
MN@,'O.4K)4M'SA76/8'6;!S+VU5XP2J#S__'W?HA\I^*_"V;(KNJC\[_ZYS7
MBSMWC[Z%DRVVQ'1HXV8K1.X_HR<_1/X3D13ZORLMFEC(/ZH7+8_BG6NLF?V<
MB_K/ZLH/D7\0^=NNC(;_3?F?UW/UKC/MPR3)C?TTYR6_<IFZ_N=V[X?(WXG\
M8WZ6S:NT3(6S-T.=50Y>\ASZ2:8"I0W6$>W#IC$GR]3YOZOG/T3^S2*9?ZOB
MTC(RN!IN]8A^%.<ND]H;"A#FOY,,0U*X*P<9B%E$??#7[\EP$""VWI%6F$;2
M U;=QJ[*TQ5L=>E3H:TZ>08[)*I:NRT'T4@ /(MHN<LCF?Q0_S1B;F(? &8N
M= 1U<WS[@E@=\\E?E$A/LW/A)SZW0AKE-Z6#LX>E=5:^QB+@A.RMQ,4D$Y.?
M^=UF2]J^\ZU,U=X@G@CJ.?$\/D_AST]FZ_Z%#$[BQ6J]]]@^4,"U9O+A:_C3
M<]0[?]R_-B '__7)).<<2E03DI],5>\#,Q23,Z*7VZ^\/'&=!F:6B'_<D33T
M /?$[R\U5P9OCE8NFPL19"Q]5WL95Q<>U^:J4OGC:[\> AR3969ZDSFN$E=^
M:[00-Y&OTK.QEJW?E<Z*:^*0;:?#(]@I]YQP"?TK+0QA&?L ?G$?R#N(P;A3
MZU$S\<2RB+W#&:27%O$Y?45#UR)9%4<9H)Q2YFQ-.(+8D^'<T_;G5-G?I\LU
M-L(2('#25]0NVD6HS=4GQ%[_29+XVA->.AC'0<]C#:.@CG"<Q\19D,/.M709
MPTA4G"I7II0[M_L^8/+<%O*62;&CWVXGHJ'EIAM;"%NB]Z#>@K+=9T;8[EO<
MK;"$6[%!(\QE%M=@-7*7"99OI%O2"Y.H(_0Z-2Z?M"M_2C0NE52 XU@GEG;Y
MX J%Y\/\G5;\1D#U-)GXRS'5,)?-ZZI,^T 3:I.-V*2<^F):_*,U3F("MC,/
M2;^\Z$U,P4"67%V.1K"J;4>JEKQ'HXQY3>BS<E^#=Y+C&9&,O4X?S?/OI N4
M -2WKM>QI4OM\1F\$[HKT"[<IB?;8DP?"A0MXZF*G"^?X\TR=72^1$@>6E1=
MF=/*E9)G?7ZKY:0IBA3.N6VZ;59Y1>:QVQ%= H22@;Q%M3S<4_K>KJWH=_$E
M25%:[1^+OEP*9PRK0DM1JYKA91[E80-2,A13+6_4CR01 K QP;OE+ILC,_HI
MC8XOTD]*5]) K!OG-CW6\L*W1ZX?5S;-R0'5F;-Z0:(1ZS-[ (^1'M4-$:)>
MN,4:8TM2(RD[@750I>!7^N[B[R":9GB*CW)*668#"KL0))NQ_P59V)Q; F]B
M@Z=YO7LA8IM![.D^0(XK7W=ZB?+G3,\3Q>UX;^#%4-B\"R_0$AE<!ZI>&+!&
M6*,'%?KE^L71E_8]W?%L%BYSZ69XM \([0,K7W/"?U?6AQIG(_I/I $7DJT+
M\="*AQ9H1VIA/'0B$XZA\:\['O]NBN^FZQ:U'-=$T'3I;KTJX7+;9S?F&T7-
M+"[A?AND'<\]I?W5-4\NYGSHTP7*QEZ0X_-$$]-G0H'D3&58LSXW;WKAVD+U
MI'09,2C_\9"U>OJ#)ZG$4X:6 ,W#(9>HP8"%C\[G],WZE-9= O&,O9X3Z<]1
ML%M:;5.O="1L^7VE%*"CE)9YHBV019FWBZ"6F1-T+1Q6.C:K!(S3($M5X[1-
MV,W-+.YPAQ@H[Q&SSIAM EM+I=F?3@9D&$KTQGCK.*\1KQ?^ :_G.;$I8J<J
M<Q]@0KT@$!>F_>MSVV09OMU'S)8>&(_MQ*4\E&S7FIT]N.*N/CC&G?1>D&^.
MY@0X/+6KB%]*P<-"0M]&^.2]ASDNYP=?"Q31WD8VP"-% _%WKHI8D2;]Y0DO
M=RUSW]RSYAZ54\:_!-7PK4AD-I-+T^1:_I8,!;BR?7;:!SS64 2%=4/_@3W5
MS6XQ&FQZ^P!'Y[!N[.<'JLSC)ZMWRV /P!YF":.@<H=KWVEUMMN]K!D':P_;
M&\GNAEM]]R".RZU">,1,-SN1'I2\%\^VX:]!/.MO@=\;[-P'P@RRM@,>H+_(
M:@C*F A%/EJ3E$.P.$JL-DP#T+_\[_5-'8.R\H3QYEGY-WWOQVEW5!^F56$G
MGDM2[]FF)5$D_KGUGU[SD*3_<M_VBS0Q^U @\Z^M2,'P_OKAUU'0GOPA](?0
M?RBTTX/IIE5.M3/]ADRB?M7O2@V;VV>CW?CKX#+IK5HMW^9%1I%JZ4_Y 7<
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MPKU;;+9!T&/O#PU\$*8_\U#V6J<"GCU#VGMB$9@_^\3C53 B3?*98JNH.:Y
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MJ&E(.]RJR/1M[4^51?C<H:#>, ;!&;5),\5*9%FA!!JPS7&UO;SY:R)HV7U
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M&@<+F@R#5N&0VB-_?[&K/?^^2'KSO>OIA-""ERV"KK7&H*UEB=X&.E#K@7A
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MI_\1B+%F$J.&:EZ^H>#(('WO7*37ONBM9DW%3?LV4".(%+</=X$-K+8''(8
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M^[CY"&C[Y--^KA8XHO,QX<SR-CW@(N@;Z-YOW0V5Z4T<,6K3-OIZ9=.VS2>
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M>\8'J=W?.ECO,]TF,8XZD<="-6(P@JIMW_^H+%N",[M%;A5?H95;F//(:*<
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MHTQWF9"9'[WH%-3' R6='^6?($U0X#1*KF\UZ/WIQ<&[0>][!C:-WO.L_CF
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M2\79*29\$LK<M:,_^:,<S"?[RUM&#Z]%C/ 00R6PP9MB1D&>;,T6_/L7 J3
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M]$;S+]YS E\2:HKX.8CT"B:>M\UD$10S5;"N)Z3/:QO+ !I])<U]<^?Q*I4
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M(J8WZ<!I6IQ79T 5+#-+GQ[8-=7@4D[_DGEJ+]_]WUE%\Y)()VY1Q9GZ%^(
M7IW!XED]MT2U7#Y!Y@5V4#9V(.)D.N4''6XI*_9@$=X8L5J! ZJ/D[;23F[#
MUK&9IU; 3YF?,C]E?LK\?R43CE8+&WS#]" 1U;^D!C='G4T/X( P.:>/K2%=
MX&LJ+DM[R:3'!LN2&3HSF-YCTLJS3\P'=?>P-"J*GQ4&BLF0QTE2VK#/:.S&
M,KP50;$FCP.^'#-OIIVHP3;\@D_9L9T1)W6??A1Q_RGS4^:GS'\-&8[E\D]\
MB$P(PZY$T,?RP5093>ZV1R/'SS@9M=JOJ6H8Q81G]@Z)24#ZR\)ZNHG\'GL?
MK"G)=)JQW6 <_0:WDSG;Z#T/69C'*>$^N[!9?1QP"GG_]  ';(V>KS6'"G>G
M-W  ^O.YB/;G) N5DF!7UU]EY?:;#:?.* [_M)W@YH>S\U/=#3?3L%1*0B<X
MX'"U;E;N_!2F/L9OO?\[]V'J>/;.1]Y#3NJLZ)<?J]/EOYY\[F%O1EO73>,
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M[+YL">LL^ *86?_M1B##K=L%UQ\8RW+F1%0Y*K *MV'J'J)#A^3&FJF."@,
MNRPV,6\&=UAG:&+I-X4;^24$T8(H !37L($2HUP77D*Z)I.Q#=]TW5:DRA3N
M4:.PVT,=HC/LK.!;2T(_-@SW$DIERUC;,L<EB26\%!8[@#CYAR=U"F=:#2LP
MYF9U@1@/"1#*JN1O\&R;^(^N;"N$KEE C]D%8C-L^8XZXR"B@)0P,^_NVEK$
M]Q:];_G1HH\?O2,2W20!D,F,7/1*CM&M* 2CLXIR*D+05\[N1F68")B87&2[
MV7(E9&+@+J8"CS6F4W,U+:F+$E6. _08,"&WG\=PM=;/@CE= F@3T[X\L<VQ
MM[KSWET^+:;QS%%9EL^3$:X+#);WT\KV/L :.<S[-DG,(]%9NZ=%[8M70T84
MOF!7R*A$S0*3^D]W<[SS2C,^VX?&Q11I]12H'SB*@\4E2O6DMH4H84XO>B8Q
M@4A7B>#D^;T6P'YJO OT]>G-7=\M9%3/9E)/?X1ZR#Q70=#<11K:UI.=T-LS
M7J<B/DE/&RM)__["_S_=.5O2WSIZ"-&KYZO8N;HU3-UX+=VW]MZ@J^]N2%2K
MD/Q\1Q-I)5VKURE8#6^QY!F30CJVMP:5%$")UR&=F1TXV;-5!Z^J>-2#]!6-
M<A4,V=]RN;RL1O?JALFU";Y+G@8H-HGX5<.GGWO!'%N*6*E^'# ..[L:FX,#
MB!.23D^:<(#?N>U[E5OPFTW7N3Y[ [FW34JC-U]F$MR:M@A^&M].&:E"X+^-
M/&V> ;4#5X8:F<F7'65L\"\T?_@:RCLF>'%QUF4;N?[H%-JF*IP_5W17Y4(^
M<F%9SBN?[D%)-.^BO$EVX'?-"3XB:#=_R&O4$U9L?8G7\)FI;Q0.J!EM6)3K
MP'/PA**\@>\"],%5"35RM),TR-=7$21WJ#8>S]/.%NJ_,6IPS'1$)\D'F<??
M2R'4^9,C(D7@1E3!?:?E6"DL=>FC_;>7'4+K"_3EEEXGZ6'-,0UH,:W@)O%G
M;L17!P1WK,9!]EQ5$KZ9K41\1+S1?OHQ,9)7F22JXOI:K>T[26AD22G>7:SG
M97JGC]Q?B0H=Y(8UZ+JG614UAGRK<F('?5TY*$=?\U^F *W'HCH-[)VTJVA0
M00;KN[T%H-,^/88] K.6\.>A6VL(^N^:P/1F:\C8K0LVVR75_$%&1&!S4 Q"
MQ"S)C@PO\V[JC=LN+PB0^*@(23S("5[,6+955;-W,X<'N;L\'Q^/+ D!Y3(Q
M:W]OU-<GR:3'?BE,:5<GI!O2G"+ECF;"GS-)S>RH?>5KS)A 9)- D  8$NV-
MIY_OS[?X-GJ)P)\AK0=AF6QR/\J_'N"YE9WV8D+AJVAK.=S.RM7,OL!]6AA,
M=EWR\59HI,[%G$B-T_I>L%SF],>4JSUT-QC,%;3TPU%D> UK*-:H%M-E/XFB
M?H:F6QT,;J1TFU(L :H\!)1M8A$/>K:R2UJ'99\?6;MV,:1<>)FJ^A@@=8KT
M7&OMWXXQN!V?(9.1'$2@(34JR^=(I+"L#+0+LU4FDQV>6EO>NNC]^5.(F ,+
MK_G$N*PZ?9#*PW#OW86RE:]8KD.MN_ZEQ$!8 [Y!';N;!Z,DK<5TR3RZ4OB:
M4Z_GF$4USQ+[@P_#1EWDO RFO@C*TX<\1%($5.3L^*V9Z!5&WBZ^KA24:DH2
M 17Q#1 @Q1#8MIM3!7ME7^K_P4NSFV2,G %P5+@7!))(ZQ_0#.-_\%I1BHPX
M*_!SJ-D,6<P $B_:6<7E\8ZGR)!"W^G-]JARA] W$\JKZQ<0SGJ0/7$2KDA)
MP96D@=-GIA^%@QZ_@2Y?YI\)D")(-B)FC?1BBC5L[1<8#5:0UIBJ)C)R>HFF
MGP<BYHP1?,0LD4YZ51:Q5^(":"D?@<UIV^OIV#Y!09#YQ 4$U^(_H%70Q+9;
M[J^=:*_5*J_.%A>+"EFN8PY=#HI0DZE/P;KM(H;/1_D$U[Y%?W@UF=#@2*YH
MEIB9<L.9''[:"E]GQ@&EBZ#DBD'6LFA12SL%B;-  HQ1IS,1$?@3T^#K?T *
M 6LVX"BUS:'7-*DU1O*"K4=++R <O3BBVAJZ*>CR.X8?A Q=LWJ9RI+A;LH5
M.," $>X1[G9V0?82OK1X_$;DDB:")3!2:OZ2G*I-;69V2T;*>P\-J<EP/D=E
M8%D9[[S+A?GP1N9%#Z'WWO#L(/E)\('OWNT.H)Z4^$@21"?\U7G[,*A[^]BK
M5(C>?C(UZ*9V%-%T[$26='H1@UFT"'-5$$)DQ?#5U6?]Q$-N!)B-G-1-_DX1
M!(QZ;:A*=ZX4QF1]-976,LJ PB)$/3" C[PK,,!1EGC5>OIBJ17F<>Y<[,?P
MR>%.#WV_M6'.FIGH=)YY<MY0,@!O]%]=&/&?#SIKU%&)')5]>QQBG_0A]I0D
M7TZ+G\NR9+$8):;5*L%:=/T*/LJ<I3@YCIBDQ'$PV+>A.?U5R4*IR"]0#@LG
M4UBEUL0\'-HSO-IZW3_N1I@3I)+CRV?B)G8(@^DU1Y%Y1$>I86,M=\VWIT'Q
M[FO72VKUP)V,7U_(:OD*]CD^$XR6G@\!5K'LMCN+<>T"Q78N?)]$-2O8,;1&
M<JI<H85#;FO2E%XDW)1D4A>(E/ND&M%.PN!0L_W\"+3AJ1?J/%2Z@ .2%?3?
M!DMP"0;;E"D06T@>.I^:Q[^C2O$FVYW@7V8'51T^VR+P?'.7*NMQ[Y5K4B.=
MD7Q\YSX] ?6ZZ(OOODY;^#MR=='$9DP:%GR74B\YAS13AXU $F>.*7692<08
M)=[WP*$<E:2</-=ZNDA,**2VS\W.2GVK%YQ)!P=8V5ZT3ZBUB[SIA'20;W6*
M0EH.(<3?2@YIZP:(ELS(5YX[-4VWY>D:""P9T*PA.V<NK1[N59]'(.\07_'7
M1H*#22K,\KW:-W9SX7@K7V<O5-[M3+TBZ,MKTJ")$-4W>S:,AOA'E;X"G'NH
M<$";%WQE;OA(3I)I^ E\2[%UV\K/H+38/K;6'0J^T 8B2V=$B9/+3GOODFYQ
ML4P)#IXVWI..J(Z*W4Z%L8]ATK:BEIO7SH?CRZ'EW- 6 =E-X<0K30QXD:.<
M(Z3 >@7=2:6X;6'!Y4VSB%ENU:5MH;:U[T@,6*QY1$T2$C4L>N^24SO3L"3A
M92U8J !>YF@/KTGZ_08=RVOO[!]2MHF^Q)3K CN*L"LV4]?B+ I-3.0@^(4<
MFB;C>!/"4*;,3-V5&IJS/(S0?L1QP2WTF<K41 4.T.YY>.(7NR!!N<4]'<P:
M-S?%\DU8<GUQ%9'O*,0!,"?59148;1J&L6[=MUO.@(0B%I57';K[Z$$L,_L$
MESQ;28#)ZBJ]^];I4/F!8@9J1!IDQJ6OPC!X2KQBZW*?]%9!7/4'3P@-8?@
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M(VW%EQ3?9?BNM0$T1A5@\>)H9T_:W0@&3\(:M<6%I]RL:OA'QI6F.X(>'/,
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MMI->.D';8-2O0+3#* 58CXUQOQ1X#X59:(<0URI'V K/ZPUZB6KL[\O/'B^
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M^%B W#1>UB;]J?R#R/KVCBBI$'%M2K7;$:-3?EUZ'-SQ,7\ZEG^RH3J^J_[
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MF-_('SV+BKCLY;QT(R+-2Q#S2QN5MZ]C%C!7T[)$!O*90H^-=<2%HV))(R,
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M+/E]3?BDS:C!^,A%RIRP%LB!JLPS,IS%(M0)N<V5G:?:4+-.V0=?'L0"4O3
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MT@3I-*"^FB2])'U%7%"RTDFVXG-:?*WA?G07Q.,3/9'1%L$AY3B"X8OC:UA
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MKDK3M9GV2;>FJ<A$Z"2\+SG7[L64XVU!J_,S9L:!,C@1.0E>@&;355WFH6O
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M=GWK6, 3TR3><VV89+S^ E>U18[%4_A$;Q?]A5MC[,^SAXC&-^N"$J2?9@_
M$7@+&[W7@C[/N/<]U^9PG7YLDF\I;"AV^%W/>DL[]$^_5,^Z/6MPAJH<PFK/
MK]"&-H@*56K)M]02*C;B3!Y#)K,>+L? D50NJU2/MU*F/=*IT+GL8I0Z,)J]
M,/^ 1&7VN],?SX7>:GG)W\D6F#/M_$%R)"!1G:K,&L_>M6!4^=6AQ4KCNQP
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M@KK] "3MK7WES-KN\*'LV.XI.W+##WVOP2<HWTO'5-?$,T[TI?K?9WJ!MR0
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MXY/W7I@M9)0QL==E/$8E@K<[.BZ]86]]#ADRCKA<,[JG-VVZ2"G?+20M >9
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M:T<SF$1C"0!*_UB@7N>^V$<?]\\[L>&=C0-' ;)?(N^.(:V5*@>XPE\\[B<
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M^< '?^ZQYHXWBZ&H4KVP3+Z?RSPW6<@KRA),NTZ.'_H,#ZJ-4(GY5I8!8RR
M)&9RDL5Q+[P6X]9*'V.O3MN"WFO@R?LV$W3VJ5+)^-V%:Y.K9^C$V-:Y9]'\
MBGA^<3)LYO:9!U8YC8^O!HY)"#T-*.M9U7_J'DEM"+.01'Q\NVD#^EP5=9'O
MGG1EWQEY10B159^XM2T#\Z9W'Z4:3X<P,[\DCW[T=UEF9&AFF6;]D2-.:5G5
M=]_@FRHU[MGP@:]\&3U4D&$9_<_Z7@-K]HF_8U)4<<7/0>A&'CZ',6.'F' I
M<);Z+;HFMW_)?_Q_NQD,5IVO</C8O\L<<[AJ5TJ+XKC@\6[0=G)]C7]D[>9C
M;^GD/6%A"V^XLKV:I7](ZSH6T-PX:4SL]=.RXI(5*>G[+#+\&3>*E[+_S(SH
MU5D?'4K/FAZ=*RUJ'Y0>[<("^%B@_Q'@\ <I7'A/"[% >0P&A-O'+HZ7&*N>
M^L,W64])1H;_F*,0*5\H=RU.YTZB;$=^]H-?Q\O_@QS[A'P6IYJ!K#WJ.5B@
MR!1QF"K\6U\X_IJ"B^BS/*1YIFI+;HD3E=$L27B@Z@X6D!I&1I:O<G;#O0KS
M+@9^LKM\QE[D/;724'#&2=H\BF7LI-WFP!?MFQRSN245CIN_D^6\C+=\6FPJ
MZ2KK^5M%>Z,A7/[-6X6PZ/<L#0('@71SYBL#+\4U(\OV,D[A'W<DR9ZC-82>
M&KB+%Z&K;,].9M.M-6UT+7OO;.R4OE@I?_,R\/1#0R,RS\KF_,+8*]@>.D,5
M@@4R#7:VB=?RR<67-Z[>=)U+@EBI[TP,C850D3UD!@HYLQMHGVLH6R34UV=X
M?+G+O;I\/LO8K'/T"G@^?SWH3D)'H'],$L<KH9%ZGM.[[CP6+J[M[W.-5R\0
MOGC4J=[$B\B7S<ART\-<P@+/HC.Q@)/I$:>6*0U^B<[6;2%:KV=O4S2Z:1;)
M%8%O?9+;T3M-_@++OI^>G+17:N!I43W)19=M'<O + &AT+!Y+5'Q*708@\%.
MR<C#-=N<&V^XH*WB^+J.*C-)U11>YTK'1BBC\Z(E&$/Y10[O$,D'6K2XA/9M
M7?-C\>ZP ?E6GLBYCR0.]C*T(L@C\X'9(FH*2F;;C+^OS$>+/ ]'I"-/_7JQ
M0)8PX%K'4E%P\.JZ-X/9$VW0G:\7E9BX*+2EUJ<F/?<DU6Q[6?*S"S-[#-N!
M1#GZ,!7Q!USO:/H4P5!ZD[NFF[P571:.]SIFN&2;$#W0P&MBTQ2J;DBQ7B<U
M0N8+>C%ZC_CG^KJ(Y.5)FME")&4)?'VIQ<H\9XSJOTFA+*K/F+61SANO'ZS'
MII%;GE/VA)D'@X1:U9Y&2:M=X]I:3%QMH2.9S .,BX,1] !%#K,\3]X_) A8
M&4\LUT&/;_34V&6M/\FF$@-B:BO%'EB7SY8X<R."/?:_T0KUZ >)4I=8VQ%I
MC><179,%2^Z[C5ZJJT-)T2LS51B]AVZE[MU+9I3_1.-(1$0D81$!#&]&5UQ>
M=2#LD!IT7+C<U.&R;T11;^Q##-"D 9S?/"LN/[<G_" UZ#QWJ;-/:#\MNE[=
MAX, %!G"'99S;D"89,-GJUPF3$6%(.=4TX+C<M#G:X")$BRM4OGABF]D38\;
M7:+Y8_+@1:KCD6;''(G =7JJF/I48,7\1@1M7!M "NU"N 41J;X&]>M>_7:A
MS=4[D+[L'NYI?D@./4RR/V_TS"7- X3C?P&&TT'XX7OG:K# 6 $^(MS]^+3E
MRY[+-OX=THN$&KZ40HGL"OGP+V92=ML'(2B]1&5E0FT]0\LDZA M4?8$&E:A
MJT;Q-9%4(;F['H@3+K)$GG.,EM%*Y]6TBHG)52ADNLBT_-S7@H##MU,ZS7<J
MC!2</TO7)U*=V^VT--]V"2(]TP6)U"D++BM_S";(9I-V7D%#RGN20J'GFF(G
M&,R2(P:Z]PX+D!#ZK=W0"P,+WJ@ETU;.?OW,G8$]6K7,;08"4FX1;TNJ>'N!
M_OAN_?,D$ -BREE\S6.>"5!Q!G+:Q]L2U4O.'QS?;7WX% Q%3KN*K]V:3SM'
M(4A2=#%2[N80N '=W8#/( :EQHFHR+1$D%D3G@]DR[67GZ9T67!&H$='/XQ-
MD#A98<.0L"YR[?B=F;S4N@U(V?0;U<!Y3JJ+?D^B/_>;*SMT+-X_4R5#S!'I
M1]A%VUA1)9$Y+?GE)J+HEF-9*)/S)V:$I(I?'#%]05D(HJ3M$V7C_8\,W(K3
M9?I!T"9VH4R+:)3D(\!G&!VQL=/EL'.<E:W$S\[R0(9^/O+D#66R\Q@8"BK'
MDS_C\(-G51O#KDR?V$P!&_2C,A$;)YGI@S+PQ&9X[WQ!/&Z<!^=C@8E13 0M
M7N:W>]U>57%6+QZ0580]_:CY[C!T<6;(@XE2U7<BQ=']J<23RYF]">"$X9.J
M.^:".3:=4#!LMX\[O_WJ(;'J7XY<VNF4/\5!-32F81&W*5X,.LNAA07DHO<\
ML4"2>^P$ZRJ1Q2-6S2"ID->\ZU6L.)R2V[)B^\!M85$ 4@9M%:P!6!2;63?9
MPXHP[(_R^I]S0DY3/\^2;W[0Y_@*0(XH[-;RPYVJKR8$?C 9J+$JD?!$+710
M"$0GHVCQ:,?;-QXE2V[S[D5^%KKD$"=X(TC_0E1M)XIC1D)MXZ#8$--6E;C-
M(%#>+1!;^U@;"8Z,S7"+1*6V#,$$ JX[T(X';<TS4CAD&VT<>J*=Y]$@IOEO
MO>X6\OIK[0F(#=V/6JZ''\\!DSX0:GFWM-!.L<4@ <+$0IN;&'?-\U93I#$?
M;Y'+K[TAKYCH=R3FB0_Y3%Q<=JYT)B2D4K'2]FMG?@]]XN7[W"3@#<+NH_@!
M;07AJ7X"T;^OM\1C'P#_HDW3I/.)J$O>G;H'!:/.)RMJ0M=VSB:P#<<\>?VV
MSGU.EH/$F<A;GS9^!Z .(!;NM_V$X%7<1'5;:GP7*D23Y.3DG@A:O&Z3Z666
MBZ92]PWK/<2>E00:+><7DN6;:S=)O4^;DY_SZS X-EC:@-M]OGS/TB%K<_W]
M7+BS7\Q(C0>#102'3\4"MX!_5*L-L:<\A;R$1>JVDKG->XDP B90B$"K40AE
M?PC)+E,_L:R52X%W0N P;<@G?+@[N3(D.O_@A4M+]$IT5D:./>,X2Z%DVLQ8
M34\YF >F43#.+&=6: 1 U$-NS#NL#/(-R)&UO#P'% $ .4 , .)X1HV_>2*'
M!W[ 0?^"W_O_1?LAW;D]68T_,Z:V<24%]Q(D!DE<Y,P.@JKBV5Q;=A9>&^<=
MU>C\8BJFG:)/7W WUS^9'MH$BVZ6Z=_,?YB[N;K]>"P0P<]PKE*HF-RZH$,\
M<KX"3]#[NEW@Q<06MT+;8[G&HZ]Z:THR79U0=DNDW" ').:%9VG-DWMU;\53
M'05(QKY%BM!(A)%VR!)X=/@RN<F<%[[K>);+:U*QX)KB9!--31FQCE03S>!(
MI3N256_9D3W"BM^7B#P%$@3PTU(KS5*HYED?2-_$?-(>WD@P671*$12L>"4;
MI645U"$*"FIUZ>I36O*0Y.93)Q?*KF/I$0H-$:14<U8A:6:. @S+-.6Q@-+0
M!B30@&0-)3=(MFQICC"J$1.3#$;0B0;QI\S:ZTI$I7V2K0<<J2QLFY::00R2
M@DI7BKPI+95]O#T?QFUY4C,1V@QM3AS1$7N)-:&G@X3=)91%$_WJK4RO=PYT
M-UV3B&<,AWDT7_:VZ((,-UB;AMXR%5R\)>-KG0@+<LZ!H,!08F95.L2!M2&F
M8Z#Q+<D4^[9>G*"!?$*L?K0L#,4AUG2D,_/PY JOP@0_W,>/'P=#\+L5.]H[
M;CPB=OHX>CH)X/&GH%:8[[8)W,E#RC3'0YX!A"TA2C"\KIVB5-$CE7P?\%:_
M@M-%EF1=33"%^$)M5]<J!;0TRJ_UF7U%LK6:-YL(T6Z?F,ZJ-PN"GBV:)_/
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M[]L,G2?P_^H;'SD_ZYQ#]U(D%%[*%;)G@WH8PN  <G3VNQ O(=/TE6)647C
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MPEV&!P8;-R;K_#O->6^WNI9H@UQ=+J5/^5(D0])J.%Y_3]46<\9XI5Y7+86
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MT+@\%6)B!C:J7E]FRX/05G7[HF+^!9O/@DH,$Y?.R7974PA%PT%#^(!@XQR
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MU*DL"2,ZJ4@2Z5(%PZ3IR\</3#2S>/WV6!Y2U*[,;!-$)+7LD8;5Q^<&2*!
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MG2^F3OXJ2;R5D\FK#*T(QO6"XB5+>B7=T%&U>(<C=_*G)Y<^JK>4Y"+RHR+
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MQ19RH5B.I[.%:<<Y=_!S\E>V*LW7D33RTNY9H'1K%'<[($AG2$. N*8# ):
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M"NO'G0?'HV FY%MCC"'7VD:NYZ2OI5EUI5.0 Q#D=H@L;Q1@'V%2\?:X0DX
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MITO33 1]%74[[S_S;4+''BFO7P(U?Y+__7[UKB?GV=IE%XWVY$K>+%O1XY>
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MA1(T5XUY2#=I%+^A:FH/NBW%W!##20DA?O/2(H:69_*(LCQT%!"&1G:0+N,
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M5D$1^D/0.':$8^L3=A<^(?MI$KN'')'=MXK<N\O2W!;ZI<E%UD+:#FD;N;>
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M5<+_D'M PYWY:R13U,K6?BD.^"@U@@/N)E#D_#;.*6K[!0Y@G<4!"_'8D.O
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M[CLS@0/(6\9:S/3,[A9$^;EB'J^VX0 ^'<KE'"^UN$G3/-;<E[7\[Q,[?+)
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M.'HK/-JN ^PR[Q<A3(-O&W][ @L4;8>8D]7G&<=@KPLH'\0N4QJZAJ_=)\=
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MV!,LO@C'5OJAO8VCJY,/P[+$6"Z"R-8Y,/@U?PM3=L;K^?#BI-BT[+^V:04
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M4*>5.(RI+DH:^82^"1AM3!<Z;KE4XKJ [Q*+XC<,-13?+!M@2PNY3\+B]NQ
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M[7:2@>=N5Y,86'BG]/LDIR^YX3D0>MC5\^%;5>.A%7]?,+1^GQFW+=I%[V2
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ML$%*V4Q_;:]NV56J*JZRF)64?[=YK1[7BV1<BM8>P?+K!N"GKL$X.K4PB'.
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M?TU;Y[5-$?;\L2/)[!8(4LS^%AA]-V/__@HU/SJ3:9K9I.4#B23#U-1>7OC
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MTKGB^QNF8))-TVK1UFXRQ_12HI*^0^^<9]%HC)PI.?SD;5RPET=HZ:?N-):
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MU4A?TR/WO4\@GPA(OP*["S/YM++VG)^B-PO71%/;"+7>OGWMK0388M).VY1
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MNO4/%S@@\6006L%JG?20VOEN;,-EO'L2='0 5)X)BJOS\)#T52:3KMI&^-I
M5&U(@5;Q-_9%'K)!U&T\Z[&L%RB)).ZE?)[^P'*3<0Z#-YS![YI"\8*EU2YL
M;]Z?I;;11-J0/*3S(VP$^Z$9-]W(S=V\B;LCM.^7:P.T+=]C2('1+-(>!79'
M,:!"(I'4_%Z%,@0'I.E,O=B=L+DV-H05[[^]BL^2XS",;K' \@I$;:OSPX>Q
MZS$RAKY7;DN_(+H*MI34<=X5C)K-3A]<?RKSIBWEJON'QU6^-N? \1>-PY S
MD=M5/HN[EN<NT7A4F0R 5H(UM^7;&2.0<89Q#HQ/SC/=00MII5@$&O&$ A9)
MU\L!R,7R,X&Q?O4]^*%?@_KH\>P,R$(/.H/6T0_0#[>QJYCS4]I$!8[>NFBV
M75PEX*]'"#$"1WB+&"98D  @H:+\^N3\&/MKB>("[<Q24)5PV[ X<'!Z8,#]
MK6=Y96&6URKHVK9S?8*="B",P3_W;P^),J"-LEL.]/QCV"[GG:9??$>A9).C
MN5LGEK 1-%863^Z[O"PN[_\\93VH6)B6H;"U#I/1<J3-W0QH_[."AT&.4QX>
M4:P[8@Z&. S\NP;NQ"(OR@BSJM;F-&@)UO3D)_K8LA(,0"M+&MG(+4G_*XI/
MLX;/^YL[&+1EOYV3WN'GSX-A_(:@<_K/W72IU'35B=:C::-H"DA7*6$ZQYDM
M$IC$1)(C#WMC1AR@SQ\BZO(X2>>TR?N*C6I%:_V"7SWJDK7&S=]UX]35!:B?
M/59^]EY1YNYZAE\5H^%T'*@_#NS-KZROLSI%D?* _[W[E[?G[ON2A68LN%P/
M:).#03&Y@&-)0I:YZ9>["JP6RJQ!FH :'PNGV,(/% CP&?=1LQ0SMW3;E+MX
MY40ADIMSFC92@/"2/P02#)O>9>UGH<C5<J?3XCMI*6U)):=[9$%;(*;W!A+6
MK3_H+:+%Q? /C#I<9G]:YRTNAMKRJ?6$^:>_K-%Z<RW^RJ73_=LJ+35H)E[H
MJ_:9X5C-O7:>RG"1F7#>G\S";I!F'@G)U2&0%/G'-E#=RX\<@![<G"(X(<VN
MYFK/^O7!#S,&H<T+8TPSM%^HY2*J:.OJN].<62C6F-<;3)+5G25>T(!>0<,4
MZAAW$TGMI^,3:,O"5TQV'J4).X_2,%@7M+:B7PCTP*.'>-2'=-2DO:T2K5*W
MYYE")%(C3LOS,#.7/_.\24EM:4$YL8I$08?]H*RVS?8O_DW-@-7I'Y9RVQWO
MD)7DEE0?MBHT^GHR,?F+Z)U+I&AE]U_E'JRYO=0[-7KM'G*50_7>37A0L( W
M&6/?Z9V9(L_4VPDV.<@5UJO]_D]_%''3'"E#((S&BR;@E_7GQD?EKB<3!$N7
M9[#/%/F?__2!%6FX#V8T^-;>5+O-_/+XL 2K,EC64&ZUJS#9YF*DF=K=H5+*
M_<5UXG.Y'E%+URP5A.9EDPA34V7O^"U5VF\G\&]LU UOMYWAM+2PW40B+_9%
M2A>[>4=WU2?R1^Q"\I'K''ZGM_AM6T[JILFYJ5?>YRWW3')%42I;;L?;:!B$
MQ6-8I[?"AAWRK0>+7?;>ONBU6 W5FYY&DDM#^LG)TC/8 K=XV.JCW8Q..3<K
M-->OM2<+R'E/KY,0\@6[HD2G?3G!(Q[/<G& @5:[*_+CT#QMRW@3UT(82KX;
MAK+M=+W3J&O0]_B#XLD2PLV.RJZJ5#O:[IXP1Z)H4;NA'7?:82,3*FE>2YHZ
M[WVT0=@'G;,!!F\.5JL6C*_(_F!O#=6(#"7[UD8DY^2DH??E#20-+<2G#HIR
M[01<%]Z7E+/6Z#Y5"N5C%[B4]]&VT=#R479P.7NX-K0EW^B3CHJ)([6J1@O_
M&S%*(6L@+(YY @?08TZU-[^.K7;MVT;%$,XW5EF-#=@H&H;%Z8&K&#&"UC-\
M\1=?%9<'W^>3>-J!3!P]G:8$L0O->O+#5@'>VAE7'-!7AI7% 6N.2QJCQ2)>
M8D>4XB/HC\L5* %D6)SAL\JY&K9#\6]RP';APCV%1W&&%#L<.N=LB#C*45+L
M/6 Q[6DB#TWUU8=M6*W71J-;4:T6&%\[VFE_<-+Q=@*)X(A#56G/#]'0NX'E
M<]SH\&$.@IM '#R/E%!;T&'"_?EW R%N<,'CMIR>JJ_!WMQDD3ZG,!)1NW*:
MJLV#F=5CAP75:K:.1DO=Y@1[2KH8GWIVXRIC)R6B1-(4] LV;%VQZ] 9W",,
M/W='ZA?EVD!6+E"TV[P$B8M]2] >QTGO/-79@"3?](%^L*SL)%3P2C,+V8L5
M#?(<TX^$_>HLO)>N'L5X,T22D,2K :1V\OGR?3D?&MC+'D6]HY$6MTD$Q<'C
M.<$!AXVS5_H2M>51$GWE H:^-$)S) AWJ'AAF%\\?E(1FZF+Z :ACA"]>?IA
M0A_'YFGULFAOLO#5<T 7B1CL/,UU-TM*J\O6;M:V3Y3],$*M&J^'+8H,B>9Y
M\!<&3AK[@W_D*#TEXV:J5QJ_A.80+^P$['# >4'YM=0/(V.4RD5Z];!A=IX6
M6EKF5'<-_5DR_T+S:$7W6\%J< ?#>?DGO%DNG +A$_810>FQ/VHH7%02PQ4_
M?=1E#S&.--10_L8H :H3@V= ]]/-+U?F^^=IS0ZWVH*I2C2_U1&V$C\I],B3
MV%Q!*7>H>_/6W'!1E211I-Y_$ZH03DT5:;*_31NW$^HIS<A(#BDT<<Y%6%]J
MG+Y;R$8N8A1)A5P(-F^KG6'L][ 5Z7;YPOG$6P;,3*AA<]^RLSS8F<)7]L(T
M:/4?/C>"_S,<\=V_-1=PC)T:_TDL8AZ1SP+# =$(R9[=K]UEVV?W CGS&7<#
MY*XB_9FD6TZYM;:'S8R[W@8U76J/MT?GSP_;:NZJ]R]G-#=GIY^9&(LXFRF,
MI+SH;5PEN?$)N&WS[3)'*01SZ%5R(P 6[QR* R@CAL31+&\,U(,#G$KSGG>!
M5$6HQMTT9)F_/9-_X%ZH=%S;N0C7BJQ@/XA0[XE%R^O-ZH3PX&'GM$^W4LJ4
M."RK3*/^QT[=-"_;E)5D/%<4#3([[P%MMKG7<6R6<DQKU1+<Z_BFE7:G3SL;
M_(T%W ?%+U';]37?+^DBFQ4KPMU)7&XHV"R76KV)*]K)M'JO;QT'^'*IZ=PJ
M_KH]M"%XJH@M0)1+QB0O8,7A., #!ZP.A#V &52DJZH?1E4+X:.7[)L4HJD9
M9^*A"KSOU\0!4Y(G@H8JSWNS6]*^+$^%I3WT.*U1^E'=?>J&QA[A04GF,<FL
M];BD 9U7XEPP(KW:X+L6^C)&5:"T]4;5HO$M$1O;FO6#5?-)?,[<@P,\)?>U
MO++3%,5REBL@3.A$IDZ#[S)-J(</%59N6[+D1ZP3OTZ>[1O1MCZ\4=QUZYH)
MB%!.+&H58N"^N[2.8(SES,D:V \R-8P*OYNN'":1N]P0R)GS_C^\Y[H6GA8S
MD";&Y2M7 3YRP[Y4< ABG?B\T4 VA -REQ&@M1[=#,UA4D#F-+N_?1L'F)I%
MC"5OX'.):10<)MZR,;#/]=>Z]/_J=6F[EU1^,F9E;V57%&8CS_'3^H^"ZAD]
M1D[YIMARLV)+0O9?\VL;6W]B^&(;9Z4J@$1B)(I!W8=RV!M/)\R,HUS%,D(F
MF77$+LMA5\K82?E%(I0/?2[*$)M1^!H61;'_[+8H:OBX,4HUG:>>]H6LB(4)
M/?]B@9Q)W-LANH5PUU?U''3L<<;(:5OUO#7U-7HZ0M4'7(WLAKSU=#\1'[P>
ME'_C6[\"PZL$ TN6F_*@!S8CHG[&=(R&C&Z$9E?8E =FPI4H9P>295M0>Q&N
M$ YQ7D@F*^GAQ.:D?R7--R>SYM=ZIVCDA^OOT/@T"%:W[M:W-T',8\=F"6TK
MNR>Q'=]!9B!YC&8-E;K+';)5W5(>W]8,BYQ@+R>P"3,LA,&6XFR[>B%LA"\/
M'^3K';'6VM(N7O>')?3_D/%U[8).ZSGE7@(WJ)AT['"+A;<&]3X:FZL#SD_X
MH%E"Z+H( 0$<\ -_X.'R6;[6'VD<) MJ^R2+RQ#MM5%%UB?N!U;=,T@O06OU
M0FR/OZ+%V@[<H4L@J$T6GX<9#WI#/1T[:S[I.TG?M-BWD^#[G/5QFI+?3@I=
M^^6Q&\'?4R \5>H=')RX-46:28FR@^IE4<\KN4C$#5XYO:JJZ5'IV5Y/M\+
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M@.^$Y[NVG>/]],.'4CW?7,9E*#7Z:0!2EP7(<>_M;(O.^;<7K%PH;KNLH$S
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MIDZA,B/K6[X,P42PA73J,J%<"R<HZPG>0\E5_UR&'AX<!*DCOIVU6A@C=^O
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M6,7/DN7SA._?65]Y=XV-I=@D""1QE8SJXU$QLQ6S$>DW^UKB-,;*L"Y2U&;
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MS\0V,FGH!K&LBQ-2G?'H%E1G1J^H_T%=#=PT"'2%]U@[57&CIAP>ZX?!L/U
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MWL9GE#5WK3+.T(2^/)#+\T9TKG\X2=$K5WW$!UL*KWZH E?@EH2G8>K<_6+
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M\#HF@,7VH^^(RR]+1'&)^^'Q8CJM]L93+*.I!4CY"23Y0=+K \O(TD:GJ0&
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MXDED?O2:D\6Z[<5\EW5R^,#95.\+VOQ#4"PT ;613,4#*OY4UOAI"C^$Z:X
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MGF:=CPC5.Q_?W>3W:(NP./QRN_R$^0Y+)Q5?YOI.GKZ!/&4P-5@HCS(X*)N
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M#^@&&!WVI(Y=$8,B)T"& . ABO<"79Z)'P2\<G<_$MO $#(>9L%K8^D[]0R
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M)\;L)K6S)H)'];K_5G__LY7MOX^5]D^O7Y@EA?Z"U7(("T/VJ'ZZ_,[\DU_
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M]/AE.B77T\A/@5_FI/[K?#K?_F'[_U[;M ]BM(V2I2$K2P&KUHH<%>>%W^)
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M3P$#&;K^X!F$MHXYN82#DCCS1)@/ZP7#)BZ%O5&O$$O/_'*B)O,78#&RZ^2
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M+ 'Y9A$&)2NV6.B'83=>5P"0P3+*\RNV;Q1^'.X+3QXKHE%RN2"#H0%P=CJ
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M1^GR5RWV@]AOELRGQ5N: 00Q2AHH< &2Y7Q)RU.O4T!4Y/ZXH<A[?9R/8Y1
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MXT^UY6<2W3F0.1G,;C#>_ 502P,$%     @ XT!95$R?C&NBTP$ M9 " !0
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M_9_@[)FU*56-5CH)Y1(K?VQR#%]_WO*U5-X\?'C@P[&&^-^B?95:\6J+VS#
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MD?&VO>  "F&8@_WRA*3(0BU7!JGW:&"?,O(CYVC-W/(OMRA6KKXCWW/#QB1
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MAK5D<BV<?$F3,!=KJ?^2X?YUD"-;"PIZTU" UM=>'62_!1_S0F8\7@?07?#
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M/N0.HTR_JN&#(R]Z&D[JEK"/J0WI>_<IUL?<&$*,^S9_75]D&T!A=+1SE]X
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M%%/L_%H]+D<)M ESSD*@%4[HQFW#+A$ 321'0H]%8"3VU\(YCDQ3\K=!!Z9
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MM>7&5"Y1>ZKSNDHD?3"B+B%KR";AA.C*!4LF4@!:KPC(66CB+-KQ[[-^G-N
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M;^!^[YK/ "$\)2SG+FX<3J57B"TJ XDLGT]T9=[9C\F_F7_RVWOE.T;@LKB
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M\S2>SB#C-(3=//YX1"M*+8NE#G<'Z_S$XC7D3WTI&W7OW2+O&1ECQ?N"8$7
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M N$TB6 ;,XHT_D. K+_)L?],:M#^,5\%HS8*UJH]%)E4W0.]^W93+[Y!I".
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M)QQ@,K#- SD0LLI?>XVTAKA_@-@U<LSQI6BE4GU6_/9*)>"#%B2P+4>1GS_
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M&P,)SI\^G83?N;V3#";U:7F,KR):NBYM>I;GW"H8+'&:"-[()/N+8_Q!"71
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MC?1C$U%2"6,6W(_TV!Q^9-51Q ((F3;]5BG/\F"?LMQ2WBUM":[X&5W*VA=
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M2 <\.$^O!/#[7"E#Q"DKBNKT;S^/B%'Z('4-'CJ^+:0P5(MA#(KW'\.F:^E
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M-+1F+IO50A+"ZS>#JE!M8II8\S8_10<O]!VX6G*4TE#7:I\"T[IQ5]I=+@
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MZGF=-,*PTP"@B64B2JR39!MW=VHZN142BEL"JUXFRCN/[3,W[AYUB*>6 K#
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M$9U)G&K\3P0GN:L'=*$#,"\[SSG32,C\\^CHJ7Q'L/G'R+TP&I%B191K:-*
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MZ<FU[X<62J))&TWV$_TZ0FP=6[*=_6\1%XU5W'L?[H$>5 ()W:3'A]P)U0_
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M'[ ' @5$3\^^[T,AWZ+@?;W41ME<B7.WB-QZT@S*)]K:FUET9A!1+[V*^[6
M&R&2#2@_\+LY>K"%]\G'T+]/6'L1%Y/96I.N/8#=75 7Z>0FPM;$1:<&&0$M
MQB0Q)VC"%^4N-WJX)--)M\1L!A1MJLAM>B6/"U(=SHQO&6F:;YTM5$38 \5&
MO*8^CLXN!K=T!9R/']L5UI066*>Y*4N/+2FKS6:!%2&XJ?NGRHKQMW$C2S2N
M=?*7RWR(8\4EV):PVA&?G3I*+6;)]V.3@"_6GDO^#^4Y?FWKM.[U3GB?*I'6
MZ;=*:+''T_=/*E3P(:^:^YLB,Z=Y8]Q4Q3$GFLO#D?KM;+8*EC(1X^N4^#,+
MZA,;^S(^9:N?*K0(8^L$0IN/)46KH0\&QHT23<N#IE:6R=I?-<QK#\5U0 2G
M(C9W=(F?5COIMQ*F>2(TA&A@MD='-ZCG7'O,3M4)C9450]Y/FYF-W*.:SLZL
MC;GCJA<RVW5,393S7V7(6UH&S"2F#8V>CBOM]_0/_5[O"GVCMKS?R=UY'S/8
M32OM"_[!X*?^UWU-X3OP3ZX=J-$_0[@R0G=V#6#4L3XE=V'&(#L(4F;/"@>>
M@$E&;0T,FQI&.(743A!W E3:@WG9=P)8/K ;[$/MVREFR\+_A;WWCFJRV_I%
M@XA4 >E%B%)%2E2:TB(J340$*5(C M+! M)"HBC2B8" HA(0%) 2Z5(DTE5$
M>B\A :4&$L3P8-H-^XQSQG?VN^^Y^^[[?>>>/S9C3&"L/&.NE;76G/,WYS/7
M7)L.N_>//M8_L(W)WPL)O$)SR$FB.UN5GNST$3^ B\!C'Q&'2"RM\D&?S4"=
MKUD@X><+M(Y2W.$+HR..:CZV+_Q5LU=5+\SD$?-\#OF<P0D1%MSK3]6IFIAE
MI_K7WEB?;DX]4_2CXL7<%_4,J&:ET0'$L*ZK)=5K51ZUZX/WS62"C)_9\Z(G
M"RD)S?TOJ'X1]WV@J[4]UO0#BXZK,=AU=A*/\'-QYYPI*W,!.@>'>P,]CB47
MIV__C'"G!'K2;U:<Z*=OM;<24K9F=$FGUA6@'0\[(/1.>,6EYPX,#55AB*O#
M429HX^J6/<LX6*?F7+I<2/4!ZNVA[:_Q9HRL]#]7K=>-":J875[$L*SZA]_T
M-53Q7%;9[Y\XB@8]-Z@'?/ AVDG;I;Y_2>,X';N.INJ[W 6W]QDP0>-F62PG
M1EE[9:B?/ *-X]F309Y#M-+"-%?EC!&&7"F$[% !^5X(E<'B<:U"34S0DX8N
MG)BK#^:/G:<\8W_%Y7@&=Q_)V.5;$QF2I.RYDXS[= K)I?EG?+T"NXXG28T?
M@#[*Y>ZA;0^S-,;V$7\BM@W\4.<95;?=FJ] 9OQ<0_]2=;-']TL;*^<\Q2YD
MF"DTPTQ_/E@XLX64GE.629N&2E6P5A0-K5F7WTE?NXL<M[JT-X>P!OHCZ,T)
M@4VX8J0N=&O8\25R64V58HO#]W3T6@._2;+)XO2[0WC88AT"U_'G8,&!\0LU
MR9PHC4GQ79[O<,^NJSAIQQ\Z6*4@?CZ\7O1U/SA>?+=P2P"/6\>0'/']2>IP
MV#P89-A:YO/!95:=_NU;W&!A2-:B]P^G^,N_Y[YH90H.&:V'8H9A4LMZF 0:
MN"0BI.,/:2@8HR[%%<91_\NJ%1_;QJYQF;M'GI.S7O7G)G OA^Z H35 J6];
M?<!<-QN+[JKYV]\^B5+P[Y\K*2C[<35KL3#28JLX)'*ES"B9_6*VXX-L7@[1
MBREHS4?B:H=K7;^?K [^HEH7(^X%KXLA418(]<EA^  LIS7F&C:'TJM0[3>
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MD*;) 3&DI.XE*R"ZP @=$GDLFR <8_#U^P%=-M7ZX33^DR_YMD6'KG#V[,5
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MH@==@_F$3L8>5!J%VXLR"BJ<5T^]S4?!;US+2EN.53-&6#T#U5MXP_.>_9[
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M"1)0H9=C5U@P0(1EP-606X9@TA9ZJI>1#B7O)03V,$'R8T"@@RJ'DT-'7WN
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MXDGNT/0/K7")?XFXE:D^J5:6>"%]Y+7[^9,4@M/AY\(?$( *EB4%9=QAI^]
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M'8(0[XX.&55?<M3L??B^* ,XU$(]PC3Y11#$!D>%70&6R/)(&(#$08'$;]^
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MA*9ZU@_,A7N9CZZ#@?=ZQD*B((XZ%GB_Y5B*:@0E6>;YM=GN]K2CWZH>*J6
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MHU&3O90X'YP5?5\13YR3X_#O,KL!]"4^7H7*'D$J$0O2-W(/CN:  "Z"O\F
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M'O>*D$:OO"RTQRVTJ?U>^S4+65WTDQMUKDDO9K61C+1JE?*?2Q)<_W8+4+0
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M)ABF8'AP,XVQ78K80'@:@1;,7F>)33'2 +<P6AO%-ZYZ;H4C/?[7+M*NLZZ
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M(IE2=R&@(FCXF2R$LNYI"3X+MLZS,C-U5_>>+S-C9LA9&)B";CZ^>C<#'05
M9PIF^VC/]F:D4#,R [<DU]%<%SWDUK9/7UR=&D'60HQJ#?6%:-\LZGV?'J=O
MOXJ\%%^;-RS"(<8!QI"RU%>[-1E"Q9 !3--4!'X:2\J-O,\'=YX:U=6R61P?
M[<!D<*C65_F!&:86J\_YV0X %J=F?8$8Z:S,%!"[D[)C2I\]']NY8+Q3L6-R
M[IR%'?U /_/LC92"E=F3>+=DRN;[0KY^4@3W26@YLT56;_C*MT+=D2P^JWE?
M*X"?=SX\CRGV<>C[,&5(\1-BBIH21"$5B*8D5D:+G>?9@4Q38[9&6%"TTH*2
M? 6YDM3..G,Q768&V\B3,###;K0!M81 B0BTC&!7HQD@)6@G:Z/5_D7*GA-*
M,)>'<0[A=FK:N9!K5&O/(9#[!J#+6_>P"=4S5ZR6M<WY\Z</-Z]TLD/^*V$L
M6XKB-E_Q-2O;71F.4AKX(8,)XVKO'/D($A1A&,1^A(* 1F%*C&U&FY&GQKRW
MKW[580J5A!:&E178!I;G4! .S)M=L8&6&]2"@U9RT(K>QWJU MG"NAT*[)&L
M7Y>@VUG(?8 [:T%;W7 \"[N/GCL6>*\;]+302;[,EG>%&O+S/<E%'=JK0\"K
M"/!Y*HBOJ#Z!::I/3#SL0^I3 47H4QRG/&0^L[*^SX\W-7YOQ6U=HH_J/:GD
MMC2L+Z!L:#2[PVYH@[B%[;;%:YPL T.$W-JP%\8<USXU ^# ]C2\K(==6=WO
M)U((_FKU\"B616W(YKEZ7JI3X)^>MQ^Y)<_Z5S=_D)Q77WX51:D$J[/S/JPU
MX7V4[W0J[F*A/UG,O9!XC*4IE#@(($I1 %./$!CA6'K(3P5.S=V7 PL[-7:K
M900K";*.E!8FUM"3:V#Z3FC*!B;52@U8Z0&ZNH*.LN"G9]#]7*,PJ)2=U?^
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M-=KMU&1\5<^*PFU]U;>K7->[W=Y>EV+=_M3(,?<C%$9<F<$!D4+OLA4O>T)
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M$BC\,%%T1PA,$QK"($E9(FB*N6\5M7M^N*F16R4M(+S* B1?=4I@([ =H5T
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M!J[#E*^K[M:S9[H:ZJ/\),CBC3+*2M&>(LY]DD:ACV*8^+HO+TL]2 CAD.'
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MCPU=(K5\[A1TKCP_7^[)\F-5>+WXL*JZ#@O>V+181I0',851$L<0>3Z!&,D
M8IE@)GTN@EC.'RN/==7/VXSO1I/?YCW?UV) 7^EV$S(#R]42UB(#4@(J[K*E
MWBM6'3XKB<#WV;)V9Q26_HSQ'I/0%S&.)8)I&GE0+8X8IK[Z,:&>B#SL)6D2
M-8_)FZ5A\O2$'Y)6AQ=Y1)1!_VT]'&9+]R2G>\13Z)ZE,6OM=WHWU$<QI0(
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MS((TLO$6.I5N:B[%UVL!B!8<K)8"/"MY-ST3I6Z=I7]CZ=9U.YMF-O:+S='
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M]DEU^%SU@ZJ:G1AY@JJW4-G4,2,Y33B/89XG%*(T3R&1LH#Z BY1)I/43D/
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MFBE8D)AR(GB$.',)W8:;,K6(KO;$D2ZOF H[QAP'X,"DV71[Z]+5+NM@:F?
MP9L@M'D]J'[%M(:;,Z[LUM6PG0AT77_'813Z[N'G8O4D94G1GW^:6]?M6#DC
M:8(E@1&)]>*6*<V5F2"0946<9 @IPH5;3'EQK.E%C54/@%5IH^.J]C*B(E-,
M,5G A"2FL7(>0UQ$"#(=OE/]!Z1BIS8<7O <I5NH7QSM7AA>T G\/F@?$WVI
M.C>!V_5:?Z3L &Z:#E7MX_L:+3LS?R\Z7HG]\FBC\G:OT\>TW'_!@-;K9=;Y
M\USTW^ERIS29[TP]\2S&/.4*Z^5[R;PT0Q"K1"_N"YQG"4TCS*WZ-%B--C6N
M>+OZ<[GO8F96D@]M:\&C7(K5VJ4]>R_<W73B'<3 E%+5H1Q5J)C>XRUS?:+G
MT+7=)XHC]6Z_"DVW3NZVZ'3V<^^]R7A=W6W]>=;;W?JB@=%NV6IGO_+,*(_C
MB$NHHI3I$!<C2)! ,(YSEHHD2O/<J57R\]M/C5GK!E86ZT@;["R#L,&(!*9)
M>S#<0ZNS/ON-IYX/,6X0==:]D\CI_*<&)I_0^?I_Z&(G7S_M?_SON5X)K_G]
MTT?YJ/TUU6!")9(5B8(B0@E$>K4%*6*:)O6CG(E4,,H+IRH[JV&G]I@;4T%I
M*]@;6V:G?;K]GV'%=W;HVQ&"?TP#$\4U<+JGD#BAXS=WQ&[H<9-&G. XR19Q
MNWK@$<3JX>=:WAM5KD=9;=]5(HW5?P]]_W.J2)2A&%)%I5[4B10RG"<P13F/
M(L2B'#GU@+ =>&KT],SNYR>(CB<.MLA;GB\$P#/T:<(9*,<1<74%R^\I@>W@
MXYX).$)R<@+@>OU C:M]%VO]Q+VAZ_636JW_I&M1B3+,4D&+*(LBR+E1=8TD
M@RR-<HA$GJ4DI23.G&*HGO&FQDZM)N]&K.29P<.Z./<!;L=.'F$,O?]T#8+N
M<E9VN/@5LNH9<UP)*SL 3L2K+"\;6FS&M@?1ZGTZR/O5VG0$K$\S5[O-<XF8
M1N349,A_OZ?+./E=?_)^,\.YRBF.$LB)"9WB0D**L2GJCVD2J8C%*!I03>#7
M2JM'</QR@]_6YBG<'428%BM34W@#%B8%?JL= '$"'DH77$O0O$ZR'0^^P)R-
M57;&MN#@V<TAFP[J)Q-NM'?[Q!#MWXFL5N/B#?C8GMC?NR=V0,%9"/P]EYIY
M-7'D(K,0\)Z6EP499? "NLD0K(_WF4R2&#$%B3!5Q<I4%6NJAZ)(::PP2POE
M%(*>C#"UH+.=*^N\!CX"SWJQ.QR2\*O:/1H!$A\NNNY[C7HTRMB+T?-.GEEU
M7OC@\*JI2N2O6L)^J&L:9S&*99X@ C.>$?U0JP+2/*5&B@(CFK!<<NI:*G5N
MH*D]VXU=8%Z:Z5X@=19-NZ?<!T:!'_:#B?O]JP]]9;"#:I^Z</!>\'1VL-&K
MG+I</E?:U/GY:X1H3/30M#HY3F-]+75X*_=YKW*CHQ YOUO..%<X$U3 @A5&
MLTQJPN"D@ 67,E&$FX,^=[&:(:9,C5)JLX:(UPR:"5NR&0/?X'34+FC:MV4Z
M3<9GI2^M/'ZS9.N;F(%R.==@&D!29Y Y+R"[<PULYZ5YKKKC]6TW_J;O=[^5
MXO91#WHGO\H'.E\V>I3?Y?HAGF5$113'"C*2"8AX@2"-$PPQHQ&**.-)AMS[
M#-L./SFBK-M!E,JX^OE<-R;76KG:AH?AS38LIL...<.!')@MC]IM-+:#VGBP
MM[[Z!/C>A?=5[3;L80O6;\/"A!=KN&$/3U?'#8>[7'DV>:#;&2\PR21+H,A%
M!I'(8LAX)F&L,B0PC6E!<I>&OF?&<**M$5KY-D'(XA"$K/;OF8&'CRU$'0\<
MA^$TVB&C70+)\'/%4_?#G"6VQGF9\\-31R^>&9[YZ$!Q0GXOQ<YHA'U9FZ_X
M]NF+GN;M[5*8]-&?9CE:'9+G&>,R2ACDE*<0$11#'!<49FE$4!;'F%"G1CNV
M T\MHFFLO0&EO64>XM[B@2K3MG-@QQLAD U,)M>!ZBX[Z(B07\5!V\''%1MT
MA.1$9]#U^FMSIYXU(-OK3+$"TXRE,(\*#%$A%:2,$1ACA#.9%P073HNO[N&F
M1DV'5W*UN!HL1-"#LF/X<C5VHT4RITT+O2L3V*$2*%GJ[) OE"O5Y?[E5*G.
MJZZ-@(Z/X0\']!_G2_EA*Q\V,T6EB&ADFGMQ"A$U>^(TEI 6@A981)B3@6&0
MQ>A3(QR+C!GPA[$>E.8/#HML)L8U-O(,=V".\H;T%;&2 V*! B8;"UXH:G(
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M/3>/W-N9LWG>S&Q/Q(?UDUK:[6&IGM1\-7U1M?_(GKWKS.0,8DJ*5 "!RA)
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M!:0YE0 5QE*&.=6 TK0 W.QFF?FAR+579;?]P<=F(F]E\VW9L8<73946&G%
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M^893D.:$ B@R"!@W=ATM5,9YFG%$N=\!\OJD8Z/)K<PV,WTK==**[?)J]E\
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MSDYEVO>S^T/]#B^?U7K:7#>9)?NPF<OI_-&:'9M5X[PDD)54,0*$LD5LA4:
M<4@!4["0J2XSI;S.+5=G'-NK_$[IZ=Q8T4VR6>5!ODL:P9-:\I[.X^OHNQU8
M@F(:F0S"P.E]5'&&*.@IY?JL@QY0G$$X/INX/^AO*;QK;+Z5S>Y<?ELL[9GG
MS8_/]C2DC%H[YR0L<B%0*@'5R)Q8M*2 TU0 A7#*J=292'-7"\)YUM'142MX
MLB^Y;7*RE=W=TG#'_KH%$@71V&1T'<SDCZ!^X%Y(]39GW&<:S,SQ5G[?_/%_
MN&=TW[F:EWN-CC_./R]F,UL?TQ8=MOFT'Z8O:E)@+/-"0L!P:7L48V((2I=
ML)PQ!LV_<J_NHOW$&!MC?7TRBU/5^?8,]>NW"&XF4WQH(U/7I4JX=VT>R.HN
M,7K8,/-&DZ;6>I7];94)&!1X$YAA(P3[B3)LN.!-<)W$#MXV6I\JZ;94^U^7
M;+YNNC8W'D)8*%)JR$!:V(M\2!&@.;/%>S&7J5!9 9FS1_G")&,CM[HE0B5G
MVUO<I[KW!20=',X!\(G,4&>@Z>.%OH213]WSV[$:JMJYQ]?)L[1Y-P;=!<TO
M/#M@&?-NZ0^+EU_Y;#^3L&ZG9U/O%G/S/6C\,UG&M: %!!)R:BP^90ZG*1;
M&($TPTBQ7#@=23MG&1OG-2TSMU+V]'Z=1]3-?+L9I]@N;V^(O(VN3@B"VE3G
M9QK49.I4]M@BZOYPWTK<B^7ZJUH^5W;6V\5J/4$EA"5A.2@+Q "DD@+*;4=X
M1,N"LBS+E%\$X\D48WOQ*PD3,]-S,JMR)X41TC<@\11(MU?^-G@BO^^5<*!"
MICF060%#EKF^I'S@*M8GTPQ<I/J2FJ<UJ"]^,GR)Z2KR9C7)B-2LM/Z<-(4
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M *H9!)S)DD/$M(!>/5CBBSRV_:35N'**J5WEX+ERK.LRX&J;E<8*L@)@FB(
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M8:.>NJ<<-G+)2?V3Z".WI_H13&?'N+TRO1+1U)CZ&(C4V*$PDP7@-.> F3.
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MC=H?[%VWCA6FDOO1X?9YL5S;L^S;Q6K]AJVFJTE1JB(OF 8IT1S '"K *.=
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M-O6P%.<%QPF-^3WM'S7T=O.\F55'Y/=:*[&N.Z,\Z'NYJ#QMC:\&<\-*)%<
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M;9I?&1)KF[M/4I5#C#(.1(D9@*HL 2$I!UI( ?,<99BAR5P]LK627]V9)YK
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MV+:31BQ;BT?: *6:K#RYZA*F"DJ$&(* "6P#_^WV(64.B*"IDI2GFE&_[2,
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MRK?_ZGDDOF4Q'8_  RU1["-OHX9=%]=2_LD?E3I)G*#^ +B&/=+>(M"P1]@
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M00DSJ("#$FP,:(\).<H<?4W"U?I!_W6QD#MAU.K+8B8G>9ZE0A %.*\N,80
M)+-%!@M<IF56PA)+/X/PTE1C(U<KJ;VP7OEW?>_ T]7:"X%2=%NO!J@2LPKU
M:05-K*0A+;UK: 2V\RY.-["5=TWM4QOOZA/]"**I([W:5@+61:H*:$^'I-0
M0J$!XYH!GI:4Y9ED)?3J3'H\P=C(H)'/L\#R"6QN;_\M8$1^YUO1HI0\OJ1W
MT+?[9))!W^E+*AZ_R1<_UR-BK0V$>+=862OB;TP82T.]M4<_R=9J4@HD9$$%
M8"CC  ID7F-)2P!+F:908D*5D\_'9;*QO=>[N#1I!;8_O-0B)Z*5V2.$ZAK4
MW>]_:  C<\$N_JF2U?[02)N\C8"=1\190 P'"C*["4N_H#)'<#KCR*Z-,5SH
MF*,V!]%BKL_<5'W$'.:^6/<:6\K5[]_LN'F:P90VX4@P)9!JF=FFJM20;D8
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MI"A+P;UBY:Y/.;8]_/UJ/7VNVJ?]OE)Z,TM^,<M0%2MK=:GL]:TBGJEJUY>
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M #0_ \8T!C@O-=6LI+3PLKTO3_7_5?>MO8WCVI;?YU<(&,Q,-Q#.U8.2R#O
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M?%PG2KW8[]CY44V!.)$6U?C58;1SL@+,N2P0#VJ@Q(R)A.>YS$ BB$YTRA)
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M@&$T(UO/@^.99S?2:]SWY-=_T++?Z(H#^H>@T6*4P+L!8'H)MK.1XTT"[ 8
M=2ZH;DA3 SFU<^7NXOAN%W7F_5(\ZCQ37:KIKN+$+"&0$8D0X RI#;,0&2!$
M1B"G.(UR2F1L9WA:]C\U+MV(W\S9';F[J%F#8AU.!L:0(?W![9L=72!M3X+#
M\')+@)8RC$M^PP Z(KZ!S0QV5Q>5LE/UXMFE;$O3"*6*SP!6) 8@CU- = PQ
MT6D<LBQ+0F)U;7NBCZF15SMO5EK2X+D1U=H)_0A(,R*Z$A[/9%-+%[3B><A[
MUZ.]:X?RHW[&=B(_I^@)Q_&SCPZ;YK=JE[JJVK8V"R4/4XI9*@#"*%4[0I8!
MG!$"!,]3*9CZ1.0V$_UD+U.;ZET%2U(+^^]VL_PTCF;S_&IT/,_T1K[-%/=B
M1/1BX'2^G^YIU!G?J^SAG.]_>'!FV[IDM[(@WF^+Q^]4$-/U<G0_#\M[4<IE
M^?1Q6=;%PJKME51(64A#P0'B2!^RQUB1A#(.2$H32D(2P]S( ]NE4%/CE$U-
M>GTJM*/5;HG$FZ!3+%@M@U:U^J2I4>Z*NT4GXVQ&8F./GF?.&V_@AB0$=H:T
MZ_S!UPLV=KIA9U">R$[LKNVK77'?D>=B1>9-0(X6K7P1.NO4Q_5J70H=H:.=
M2V:1S!/,$@8@@3K%,4H (DD$).2A"/.0"&E4?F*P!%,C\%K<@'3>./7LEK7$
M=5Q@[8DU.#+0?GS,N-@KZIZ)=]^5MQ6_"Q#L%*B'H5$AZ'3PXMAK!Y\O-U]#
M*=[*Z=<.I!X78,N&AOJ3D$I4FRT:I2Q#.$< $T@!9!(!BA$%BNX@DIQF:6AU
MIK7?_-3HK)%N\('[ 7:F[AU#$?'NM&$*Q@ 'C%,Z.W:KV.MB9&>)4^H=NT"<
M?&IHN=4V:^;]<EZPU^VU=YS *.,H C&2(8 BD@"Q6 "9H22&J9K>PJ@JPZ6.
MIC:5AV?]/0NEV7QV 9#GF;V;C;>1,OBC_:\7/X!+D#@NJ'JFLY%+J?:K?%Q$
M]<+S VGAZ9D497TK5KXOJN=E1>9W\O-R\?USH8R'YO#L\'N..$,T2R2(B [O
MR7FFZPUP0!F+)<DRGF7"BC(&"#$Y.MGHH"^/M>R@%CYHI+=DF"&C8L@^GK'V
MS4P[,)=!I\!)R$>BKBOP=$MK0P09E_*N@.J(#J]IRU'UT?J?3;5QM<_Z95W,
MN?KTOES^IV"K!U$^S5*&H8P0!B*-%5>2F /"<P&B%&,9PYBKWZXJ2&HBQ=3(
MLI8Y()M"[?HX@K9BZW3B6NXKBVL:#4X_98X&N?=]VCGG^GH8-HK4M3$Z58)6
MEYM :S/&8%Q9_-3UH+QU/50'@W-]F50;4*TKIQHU_K;%5&WTOUA?U:JQ@>XH
M3'UIUW.=!*"^"CGAWZ;C7K>7DU+*+,GC$+ \XP#B% ),1 0B"$5,(RY09.>I
M8BG U%:F'?F;6\C3?J _:25^ON)FV7J@S*Q[G_![7J4\(&_O13,0/K<.-K9"
MC.M[,Q"B([><H>W8$2,7Q:P.1GJ]Y5P7][A?5BLR_[_%\[LE%[.4RC1%N8[:
MHHK^9"( 90D'"4U2C"*$XM3HOK:_FZF17"-IT(JJ]\E:V$!)&VAQS9CL K+]
M?.4.+\^L-!0J8^HQ0Z(G\Z)JH.:6?T'](VA^K GE0M.CT(:9>ATY&#X]U&FO
M#C#4-?\ZUY%_%JO'=^MJI<BF/#Q."]-8QJ', ,U@KB\V(T!"Q@&5+..49@Q"
MRSKU-MU/C3*ZZ,RO@BV_+XK>Q,(NT#<S=_QAZIE6.CCU1-EZP?VE9 \ZX?T>
M6PY#SK&[FY4((SNV#8'GV(5M4"M#HRQ5&TVJZ/?K4N\JFR)<M3-(_>'=LYZV
MU8<?HF1%)?@LCR)!4A8"#BE3%)=R0* ( <5)&@M**9=65[_V(DR-YCK!](7"
MLI%5^Z8^J_8?]7',7F+[X1GM[8<*APE+:1X#754 0((B@+2S..0R@VD,.4O@
M;"&^:WOZX<U'##<C=B2/_X&[ILZ _:B8K5)^IX7GE:J6$E"BH=5[-+5!:_(%
M['CBZI0!N\^UZ3F"VZ9Z2JO=3=#I5]55,&L07(;1#D79<22MM1@C!],.A>DX
MGG9P2\-6N/N6A>_HO/A>?PGK_"^_J@7TX2\Q?Q%?U"+[J+./8B9@EH$\U+5Y
M<Y("%.4I8#!2VWJ:8BZM+'?#?J>VEG5B!\N-W'HMHR)X)D5=)41]A6,[CC0=
M C-B] "L9S;<8+H5^:8%]5Z!>M/DHKI;./2FM@3)*9F9]CTJ@UD"<DA;MJ\/
MM,8U"]:KX>ZBN;-F_O*Z?:1=+^OE4A?,6[U^JNL2USFNZM/1AT>R:-GT]OOW
MLK:K/JD=1;&H"E:G>_Y=5,K4FHE,<9S$"(0HQMJD1P#KS,N91"+)&4ZI3*Q,
M^K?18VI<NI&QS3*ODR5]^ZVI:7JO?WBIQ;8T.-_H.V)HM4Y_Y*=O^C98!#M@
MM'=;=?ZSC6&\0238?M%J3&Z"W_N_6/9F\ML.JUM;^XUT&==@?]L!.[+ZWUB<
M8<OQ/T7Q_5$U<_LB2O)==/75WA?SM?IKLV6Y6Z^JE2)TM9.9143 1$0QP&G"
M :0A!@2J+42$",I2##.UR-HLHY;]3VWY:^4<?K9BBW^2I B%RGC)"51F#(P3
M0$7( (98RBBF@L/(ILJZ3_Q'J*O>X?]7JP8@C1Z;\\BV\N96@_&&RLR:\#@
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MVF'F3OY6B3K=XDY]Q>:I@LSOEU6=*^##CY7.[$+GXG-1K68Y29)<, AH)"6
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M"RB.SLQMWAW&20W7B<]-?D\UN46U:D_?[Q;;4K%9G KMS@)BFDD ,\0!SKD
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MOH3@5>4<>G#Q5L?A5)]O5L"A!X"^R@U]KPVL.KJL5G?R&YEO4G>E>1HED:0
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M<,%_>?VM$OS3XD[MKXG.0'/+5L5+<TA)J]K3=Q9%>98*$8%(<@$@#0F@ J4
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M=81R0G(B",U!QM((0!BG@"12@(R&42IX$D?0ZISS3#]3FZ]'_OI:4*M [TO
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M-@*V]E!&!["Z=!QQYY9O9%;<&T$PH%A<Z^Q9K 7^X)U)/"NO>!N_; ?BQDZ
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MT!Q"2:[)\AZ$_$.MX$%$?%_,'TBESV:;\]42,;IDF<PR,!W(__4>+"NA0+&
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M;+<KYO;,L]3>*(>2R5![X@>>&5@RPVB+Y* =R:U1-YP=*=P-;D_M:*")?CK
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M*UE1X$A0M:B&0V0Q!<4C#V@<WPDF=[Q@G"DSC7 QA!#[J#2\6D\GG1$!%$G
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MG$^K<)[FA\N$6AF0T9&55\'4?D,&HF'9*LFD3&W*"%^B;"LTFE\>C8,JL -
MWKQ2_/;SYLO_FN"\ME#]^4=MH+JZE_ L&1>SKS)2H'3D$!SG4+3@ IW(&-J$
M+]O1-VXDT_P.<G@=]82\N^]CC_F[[DE85.%9,M#<)E",:XB%>8@I<,&9+Z91
MNXF=R!SY4K$!3C9!<7"E]83(=]/OE\O%2F)\;=8ED9N$H*U+,1@H<BP@:)7
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M1A>=CI\7Q]-".$,L6CB> $U@9!!JTK4S!40M?;<V.8EC.$I/4SONA)9>@#V
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ME64M%C"N\DT.9\$ 63L>%8])/+QOW R%.Y\[SE/6:%C85Z(=@.'S[))(7[-
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MIK\E#O\OIN47G%^<98FIB& !35*U$4X QSDQ69@M*9?BA=[JW-N7@A[MU&'
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M%]#I>DF=!)\P@9&N"%M(/:RSYI>]^.S\]!@8Q4,947M(_34,[J9WP7&IN6=
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MCJ 9GL_:"^R07Q5FD469P&'=Z5+OBIPN'B33R@KNA0PGVV8YC <XY7O\,_
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M&G"E/C]-4(3%[)ED\?$L^Q?VFP]&4K]1[CYH'5%=)^*17]K#E'"YO'N"=3O
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M1Y.91Q/W.W-?^,9QRXS'/E*'$'MW6/IA.@NS])0IA3XK;B.PG$AV]6U+8+&
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M!I]Y!I<LY<%.IMQHT'(K+_-K^HSYZA(_E,??\%U83E/=Y36]O*IUU2KM.R-
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M;V]D;&5A<V5A;2YH=&U02P$"% ,4    " #C0%E4HJ_7_J 6  #2;0  '@
M            @ '-/P  97AH:6)I=#$P,38M;&5G;V9F8V]R:6YN96\N:'1M
M4$L! A0#%     @ XT!95"??M0J?/0  3( ! !X              ( !J58
M &5X:&EB:70Q,#$W+65X96-U=&EV97-E<&%R+FAT;5!+ 0(4 Q0    ( .-
M652^Z@#5T",  '[?   >              "  824  !E>&AI8FET,3 Q."UC
M;VYS=6QT:6YG86=R92YH=&U02P$"% ,4    " #C0%E4S1B!TEP;  #>BP
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M<F4N:'1M4$L! A0#%     @ XT!95*INVO#A$@   F(  !X
M ( !MP<! &5X:&EB:70Q,#(W+6YQ<V]A9W)E96UE;G1F+FAT;5!+ 0(4 Q0
M   ( .- 652PI4+[2Q8  &'-   >              "  =0: 0!E>&AI8FET
M,3 S-"UB87)D86%M96YM9&5N="YH=&U02P$"% ,4    " #C0%E4,#R#V(+A
M  !U/ < '0              @ %;,0$ 97AH:6)I=#$P-# M9&]D86UE;F1M
M96YT<RYH=&U02P$"% ,4    " #C0%E41+OM(5X$  !K,@  &@
M    @ $8$P( 97AH:6)I=#(Q,7-U8G-I9&EA<FEE<RYH=&U02P$"% ,4
M" #C0%E4+*_12?<#  " %   %@              @ &N%P( 97AH:6)I=#(S
M,3$R,S$R,#(Q+FAT;5!+ 0(4 Q0    ( .- 652=WNPL8 @  $PE   6
M          "  =D; @!E>&AI8FET,S$Q,3(S,3(P,C$N:'1M4$L! A0#%
M  @ XT!95':P?,]<"   FR0  !8              ( !;20" &5X:&EB:70S
M,3(Q,C,Q,C R,2YH=&U02P$"% ,4    " #C0%E4\=;\3PX%  "3&0  %@
M            @ ']+ ( 97AH:6)I=#,R,3$R,S$R,#(Q+FAT;5!+ 0(4 Q0
M   ( .- 6507#Y;-"04  (L9   6              "  3\R @!E>&AI8FET
M,S(R,3(S,3(P,C$N:'1M4$L! A0#%     @ XT!95,Y;JIPMGP4 64PR !$
M             ( !?#<" &UR;F$M,C R,3$R,S$N:'1M4$L! A0#%     @
MXT!95/-Y;_%*&@  O",! !$              ( !V-8' &UR;F$M,C R,3$R
M,S$N>'-D4$L! A0#%     @ XT!95$JO1''1+P  @_,! !4
M ( !4?$' &UR;F$M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( .- 653]
M.5?+,W8  -U$!0 5              "  54A" !M<FYA+3(P,C$Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    " #C0%E4 F/ )Q",  "U^0  %
M@ &[EP@ ;7)N82TR,#(Q,3(S,5]G,2YJ<&=02P$"% ,4    " #C0%E4^1+S
M:]S/   J)@$ %               @ '](PD ;7)N82TR,#(Q,3(S,5]G,BYJ
M<&=02P$"% ,4    " #C0%E4VAV08?.* 0"0U@$ %               @ $+
M] D ;7)N82TR,#(Q,3(S,5]G,RYJ<&=02P$"% ,4    " #C0%E4^@>#(5A-
M 0!D?0$ %               @ $P?PL ;7)N82TR,#(Q,3(S,5]G-"YJ<&=0
M2P$"% ,4    " #C0%E4MVNE+<$V" "!X \ %               @ &ZS P
M;7)N82TR,#(Q,3(S,5]G-2YJ<&=02P$"% ,4    " #C0%E43)^,:Z+3 0"U
MD ( %               @ &M Q4 ;7)N82TR,#(Q,3(S,5]G-BYJ<&=02P$"
M% ,4    " #C0%E40$PQQRA@ 0 >W X %0              @ &!UQ8 ;7)N
M82TR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ XT!95"AO:AA\U@  J0 *
M !4              ( !W#<8 &UR;F$M,C R,3$R,S%?<')E+GAM;%!+!08
1    '0 = /4'  "+#AD    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
